N@@	B-Chemical	D009270	227508
al@@	I-Chemical	-1	227508
ox@@	I-Chemical	-1	227508
one	I-Chemical	-1	227508
rever@@	O	-1	227508
ses	O	-1	227508
the	O	-1	227508
anti@@	O	-1	227508
hypertensive	O	-1	227508
effect	O	-1	227508
of	O	-1	227508
clonidine	B-Chemical	D003000	227508
.	O	-1	227508
In	O	-1	227508
un@@	O	-1	227508
anesthe@@	O	-1	227508
tiz@@	O	-1	227508
ed,	O	-1	227508
spont@@	O	-1	227508
ane@@	O	-1	227508
ously	O	-1	227508
hypertensive	B-Disease	D006973	227508
rats	O	-1	227508
the	O	-1	227508
decrease	O	-1	227508
in	O	-1	227508
blood	O	-1	227508
pressure	O	-1	227508
and	O	-1	227508
heart	O	-1	227508
rate	O	-1	227508
produced	O	-1	227508
by	O	-1	227508
intravenous	O	-1	227508
clonidine	B-Chemical	D003000	227508
,	O	-1	227508
5	O	-1	227508
to	O	-1	227508
20	O	-1	227508
microgram@@	O	-1	227508
s/@@	O	-1	227508
kg@@	O	-1	227508
,	O	-1	227508
was	O	-1	227508
inhibited	O	-1	227508
or	O	-1	227508
reversed	O	-1	227508
by	O	-1	227508
n@@	B-Chemical	-1	227508
alo@@	I-Chemical	-1	227508
z@@	I-Chemical	-1	227508
one	I-Chemical	-1	227508
,	O	-1	227508
0.@@	O	-1	227508
2	O	-1	227508
to	O	-1	227508
2	O	-1	227508
mg/kg@@	O	-1	227508
.	O	-1	227508
The	O	-1	227508
hypoten@@	B-Disease	D007022	227508
sive	I-Disease	-1	227508
effect	O	-1	227508
of	O	-1	227508
100	O	-1	227508
mg/kg	O	-1	227508
alpha-@@	B-Chemical	D008750	227508
methyl@@	I-Chemical	-1	227508
dopa	I-Chemical	-1	227508
was	O	-1	227508
also	O	-1	227508
par@@	O	-1	227508
ti@@	O	-1	227508
ally	O	-1	227508
reversed	O	-1	227508
by	O	-1	227508
n@@	B-Chemical	D009270	227508
al@@	I-Chemical	-1	227508
ox@@	I-Chemical	-1	227508
one	I-Chemical	-1	227508
.	O	-1	227508
N@@	B-Chemical	D009270	227508
al@@	I-Chemical	-1	227508
ox@@	I-Chemical	-1	227508
one	I-Chemical	-1	227508
alone	O	-1	227508
did	O	-1	227508
not	O	-1	227508
aff@@	O	-1	227508
ect	O	-1	227508
either	O	-1	227508
blood	O	-1	227508
pressure	O	-1	227508
or	O	-1	227508
heart	O	-1	227508
rat@@	O	-1	227508
e.	O	-1	227508
In	O	-1	227508
brain	O	-1	227508
membran@@	O	-1	227508
es	O	-1	227508
from	O	-1	227508
spont@@	O	-1	227508
ane@@	O	-1	227508
ously	O	-1	227508
hypertensive	B-Disease	D006973	227508
rats	O	-1	227508
clonidine	B-Chemical	D003000	227508
,	O	-1	227508
10@@	O	-1	227508
(-@@	O	-1	227508
8@@	O	-1	227508
)	O	-1	227508
to	O	-1	227508
10@@	O	-1	227508
(-@@	O	-1	227508
5@@	O	-1	227508
)	O	-1	227508
M@@	O	-1	227508
,	O	-1	227508
did	O	-1	227508
not	O	-1	227508
influence	O	-1	227508
ste@@	O	-1	227508
re@@	O	-1	227508
o@@	O	-1	227508
selective	O	-1	227508
b@@	O	-1	227508
ind@@	O	-1	227508
ing	O	-1	227508
of	O	-1	227508
[@@	B-Chemical	-1	227508
3@@	I-Chemical	-1	227508
H@@	I-Chemical	-1	227508
]@@	I-Chemical	-1	227508
-@@	I-Chemical	-1	227508
n@@	I-Chemical	-1	227508
al@@	I-Chemical	-1	227508
ox@@	I-Chemical	-1	227508
one	I-Chemical	-1	227508
(@@	O	-1	227508
8	O	-1	227508
n@@	O	-1	227508
M@@	O	-1	227508
),	O	-1	227508
and	O	-1	227508
n@@	B-Chemical	D009270	227508
al@@	I-Chemical	-1	227508
ox@@	I-Chemical	-1	227508
one	I-Chemical	-1	227508
,	O	-1	227508
10@@	O	-1	227508
(-@@	O	-1	227508
8@@	O	-1	227508
)	O	-1	227508
to	O	-1	227508
10@@	O	-1	227508
(-@@	O	-1	227508
4@@	O	-1	227508
)	O	-1	227508
M@@	O	-1	227508
,	O	-1	227508
did	O	-1	227508
not	O	-1	227508
influence	O	-1	227508
clonidine	B-Chemical	D003000	227508
-@@	O	-1	227508
sup@@	O	-1	227508
pres@@	O	-1	227508
sible	O	-1	227508
b@@	O	-1	227508
ind@@	O	-1	227508
ing	O	-1	227508
of	O	-1	227508
[@@	B-Chemical	-1	227508
3@@	I-Chemical	-1	227508
H@@	I-Chemical	-1	227508
]@@	I-Chemical	-1	227508
-@@	I-Chemical	-1	227508
di@@	I-Chemical	-1	227508
hydro@@	I-Chemical	-1	227508
erg@@	I-Chemical	-1	227508
oc@@	I-Chemical	-1	227508
r@@	I-Chemical	-1	227508
y@@	I-Chemical	-1	227508
pt@@	I-Chemical	-1	227508
ine	I-Chemical	-1	227508
(@@	O	-1	227508
1	O	-1	227508
n@@	O	-1	227508
M@@	O	-1	227508
).	O	-1	227508
These	O	-1	227508
findings	O	-1	227508
indicate	O	-1	227508
that	O	-1	227508
in	O	-1	227508
spont@@	O	-1	227508
ane@@	O	-1	227508
ously	O	-1	227508
hypertensive	B-Disease	D006973	227508
rats	O	-1	227508
the	O	-1	227508
effects	O	-1	227508
of	O	-1	227508
central	O	-1	227508
alpha-@@	O	-1	227508
adren@@	O	-1	227508
oc@@	O	-1	227508
e@@	O	-1	227508
pt@@	O	-1	227508
or	O	-1	227508
stimulation	O	-1	227508
invol@@	O	-1	227508
ve	O	-1	227508
activation	O	-1	227508
of	O	-1	227508
o@@	O	-1	227508
pi@@	O	-1	227508
ate	O	-1	227508
receptor@@	O	-1	227508
s.	O	-1	227508
A@@	O	-1	227508
s	O	-1	227508
n@@	B-Chemical	D009270	227508
al@@	I-Chemical	-1	227508
ox@@	I-Chemical	-1	227508
one	I-Chemical	-1	227508
and	O	-1	227508
clonidine	B-Chemical	D003000	227508
d@@	O	-1	227508
o	O	-1	227508
not	O	-1	227508
appe@@	O	-1	227508
ar	O	-1	227508
to	O	-1	227508
inter@@	O	-1	227508
ac@@	O	-1	227508
t	O	-1	227508
with	O	-1	227508
the	O	-1	227508
same	O	-1	227508
receptor	O	-1	227508
sit@@	O	-1	227508
e,	O	-1	227508
the	O	-1	227508
observed	O	-1	227508
functional	O	-1	227508
antagon@@	O	-1	227508
ism	O	-1	227508
suggests	O	-1	227508
the	O	-1	227508
release	O	-1	227508
of	O	-1	227508
an	O	-1	227508
endo@@	O	-1	227508
gen@@	O	-1	227508
ous	O	-1	227508
o@@	O	-1	227508
pi@@	O	-1	227508
ate	O	-1	227508
by	O	-1	227508
clonidine	B-Chemical	D003000	227508
or	O	-1	227508
alpha-@@	B-Chemical	D008750	227508
methyl@@	I-Chemical	-1	227508
dopa	I-Chemical	-1	227508
and	O	-1	227508
the	O	-1	227508
possible	O	-1	227508
role	O	-1	227508
of	O	-1	227508
the	O	-1	227508
o@@	O	-1	227508
pi@@	O	-1	227508
ate	O	-1	227508
in	O	-1	227508
the	O	-1	227508
central	O	-1	227508
control	O	-1	227508
of	O	-1	227508
sym@@	O	-1	227508
pa@@	O	-1	227508
thetic	O	-1	227508
t@@	O	-1	227508
one.	O	-1	227508

L@@	B-Chemical	D008012	354896
idoc@@	I-Chemical	-1	354896
aine	I-Chemical	-1	354896
-induced	O	-1	354896
cardiac	B-Disease	D006323	354896
as@@	I-Disease	-1	354896
y@@	I-Disease	-1	354896
st@@	I-Disease	-1	354896
ole	I-Disease	-1	354896
.	O	-1	354896
In@@	O	-1	354896
tra@@	O	-1	354896
venous	O	-1	354896
administration	O	-1	354896
of	O	-1	354896
a	O	-1	354896
single	O	-1	354896
50@@	O	-1	354896
-@@	O	-1	354896
mg	O	-1	354896
b@@	O	-1	354896
ol@@	O	-1	354896
us	O	-1	354896
of	O	-1	354896
lidocaine	B-Chemical	D008012	354896
in	O	-1	354896
a	O	-1	354896
6@@	O	-1	354896
7-@@	O	-1	354896
year-old	O	-1	354896
man	O	-1	354896
resulted	O	-1	354896
in	O	-1	354896
pro@@	O	-1	354896
found	O	-1	354896
de@@	B-Disease	D003866	354896
pression	I-Disease	-1	354896
of	O	-1	354896
the	O	-1	354896
activity	O	-1	354896
of	O	-1	354896
the	O	-1	354896
s@@	O	-1	354896
ino@@	O	-1	354896
atrial	O	-1	354896
and	O	-1	354896
atri@@	O	-1	354896
o@@	O	-1	354896
ventricular	O	-1	354896
no@@	O	-1	354896
d@@	O	-1	354896
al	O	-1	354896
pac@@	O	-1	354896
em@@	O	-1	354896
ak@@	O	-1	354896
ers.	O	-1	354896
The	O	-1	354896
patient	O	-1	354896
had	O	-1	354896
no	O	-1	354896
appa@@	O	-1	354896
rent	O	-1	354896
associated	O	-1	354896
condi@@	O	-1	354896
tions	O	-1	354896
which	O	-1	354896
might	O	-1	354896
have	O	-1	354896
pre@@	O	-1	354896
dis@@	O	-1	354896
pos@@	O	-1	354896
ed	O	-1	354896
hi@@	O	-1	354896
m	O	-1	354896
to	O	-1	354896
the	O	-1	354896
development	O	-1	354896
of	O	-1	354896
brady@@	B-Disease	D001919	354896
arrhyth@@	I-Disease	-1	354896
mi@@	I-Disease	-1	354896
as	I-Disease	-1	354896
;	O	-1	354896
and@@	O	-1	354896
,	O	-1	354896
th@@	O	-1	354896
us,	O	-1	354896
this	O	-1	354896
prob@@	O	-1	354896
ably	O	-1	354896
re@@	O	-1	354896
presented	O	-1	354896
a	O	-1	354896
t@@	O	-1	354896
ru@@	O	-1	354896
e	O	-1	354896
i@@	O	-1	354896
di@@	O	-1	354896
os@@	O	-1	354896
yn@@	O	-1	354896
c@@	O	-1	354896
r@@	O	-1	354896
as@@	O	-1	354896
y	O	-1	354896
to	O	-1	354896
lidocaine	B-Chemical	D008012	354896
.	O	-1	354896

S@@	B-Chemical	D013390	435349
u@@	I-Chemical	-1	435349
xameth@@	I-Chemical	-1	435349
oni@@	I-Chemical	-1	435349
um	I-Chemical	-1	435349
infusion	O	-1	435349
rate	O	-1	435349
and	O	-1	435349
observed	O	-1	435349
f@@	B-Disease	D005207	435349
as@@	I-Disease	-1	435349
c@@	I-Disease	-1	435349
ic@@	I-Disease	-1	435349
ul@@	I-Disease	-1	435349
ations	I-Disease	-1	435349
.	O	-1	435349
A	O	-1	435349
dose-@@	O	-1	435349
response	O	-1	435349
study.	O	-1	435349
S@@	B-Chemical	D013390	435349
u@@	I-Chemical	-1	435349
xameth@@	I-Chemical	-1	435349
oni@@	I-Chemical	-1	435349
um	I-Chemical	-1	435349
chlor@@	I-Chemical	-1	435349
ide	I-Chemical	-1	435349
(	O	-1	435349
S@@	B-Chemical	D013390	435349
ch	I-Chemical	-1	435349
)	O	-1	435349
was	O	-1	435349
administered	O	-1	435349
i.v@@	O	-1	435349
.	O	-1	435349
to	O	-1	435349
3@@	O	-1	435349
6	O	-1	435349
ad@@	O	-1	435349
ult	O	-1	435349
mal@@	O	-1	435349
es	O	-1	435349
at	O	-1	435349
six	O	-1	435349
rat@@	O	-1	435349
es@@	O	-1	435349
:	O	-1	435349
0.@@	O	-1	435349
25	O	-1	435349
mg	O	-1	435349
s@@	O	-1	435349
-1	O	-1	435349
to	O	-1	435349
20	O	-1	435349
mg	O	-1	435349
s@@	O	-1	435349
-1@@	O	-1	435349
.	O	-1	435349
The	O	-1	435349
infusion	O	-1	435349
was	O	-1	435349
discontinu@@	O	-1	435349
ed	O	-1	435349
either	O	-1	435349
when	O	-1	435349
there	O	-1	435349
was	O	-1	435349
no	O	-1	435349
mus@@	O	-1	435349
cular	O	-1	435349
response	O	-1	435349
to	O	-1	435349
te@@	B-Disease	D013746	435349
t@@	I-Disease	-1	435349
anic	I-Disease	-1	435349
stimulation	O	-1	435349
of	O	-1	435349
the	O	-1	435349
ul@@	O	-1	435349
n@@	O	-1	435349
ar	O	-1	435349
nerve	O	-1	435349
or	O	-1	435349
when	O	-1	435349
S@@	B-Chemical	D013390	435349
ch	I-Chemical	-1	435349
1@@	O	-1	435349
20	O	-1	435349
mg	O	-1	435349
was	O	-1	435349
ex@@	O	-1	435349
ce@@	O	-1	435349
e@@	O	-1	435349
de@@	O	-1	435349
d.	O	-1	435349
Si@@	O	-1	435349
x	O	-1	435349
addi@@	O	-1	435349
tional	O	-1	435349
patients	O	-1	435349
received	O	-1	435349
a	O	-1	435349
3@@	O	-1	435349
0-@@	O	-1	435349
mg	O	-1	435349
i.v@@	O	-1	435349
.	O	-1	435349
b@@	O	-1	435349
ol@@	O	-1	435349
us	O	-1	435349
dose.	O	-1	435349
F@@	B-Disease	D005207	435349
as@@	I-Disease	-1	435349
c@@	I-Disease	-1	435349
ic@@	I-Disease	-1	435349
ul@@	I-Disease	-1	435349
ations	I-Disease	-1	435349
in	O	-1	435349
six	O	-1	435349
a@@	O	-1	435349
reas	O	-1	435349
of	O	-1	435349
the	O	-1	435349
body	O	-1	435349
were	O	-1	435349
sco@@	O	-1	435349
red	O	-1	435349
from	O	-1	435349
0	O	-1	435349
to	O	-1	435349
3	O	-1	435349
and	O	-1	435349
su@@	O	-1	435349
mm@@	O	-1	435349
ated	O	-1	435349
as	O	-1	435349
a	O	-1	435349
total	O	-1	435349
f@@	B-Disease	D005207	435349
as@@	I-Disease	-1	435349
c@@	I-Disease	-1	435349
ic@@	I-Disease	-1	435349
ulation	I-Disease	-1	435349
sco@@	O	-1	435349
re.	O	-1	435349
The	O	-1	435349
times	O	-1	435349
to	O	-1	435349
first	O	-1	435349
f@@	B-Disease	D005207	435349
as@@	I-Disease	-1	435349
c@@	I-Disease	-1	435349
ic@@	I-Disease	-1	435349
ulation	I-Disease	-1	435349
,	O	-1	435349
t@@	B-Disease	D013746	435349
wit@@	I-Disease	-1	435349
ch	I-Disease	-1	435349
sup@@	O	-1	435349
pression	O	-1	435349
and	O	-1	435349
te@@	B-Disease	D013746	435349
t@@	I-Disease	-1	435349
an@@	I-Disease	-1	435349
us	I-Disease	-1	435349
sup@@	O	-1	435349
pression	O	-1	435349
were	O	-1	435349
in@@	O	-1	435349
ver@@	O	-1	435349
se@@	O	-1	435349
ly	O	-1	435349
related	O	-1	435349
to	O	-1	435349
the	O	-1	435349
infusion	O	-1	435349
rat@@	O	-1	435349
es.	O	-1	435349
F@@	B-Disease	D005207	435349
as@@	I-Disease	-1	435349
c@@	I-Disease	-1	435349
ic@@	I-Disease	-1	435349
ul@@	I-Disease	-1	435349
ations	I-Disease	-1	435349
in	O	-1	435349
the	O	-1	435349
six	O	-1	435349
a@@	O	-1	435349
reas	O	-1	435349
and	O	-1	435349
the	O	-1	435349
total	O	-1	435349
f@@	B-Disease	D005207	435349
as@@	I-Disease	-1	435349
c@@	I-Disease	-1	435349
ic@@	I-Disease	-1	435349
ulation	I-Disease	-1	435349
scor@@	O	-1	435349
e	O	-1	435349
were	O	-1	435349
related	O	-1	435349
direc@@	O	-1	435349
tly	O	-1	435349
to	O	-1	435349
the	O	-1	435349
rate	O	-1	435349
of	O	-1	435349
infu@@	O	-1	435349
sion.	O	-1	435349
T@@	O	-1	435349
ot@@	O	-1	435349
al	O	-1	435349
f@@	B-Disease	D005207	435349
as@@	I-Disease	-1	435349
c@@	I-Disease	-1	435349
ic@@	I-Disease	-1	435349
ulation	I-Disease	-1	435349
sco@@	O	-1	435349
res	O	-1	435349
in	O	-1	435349
the	O	-1	435349
3@@	O	-1	435349
0-@@	O	-1	435349
mg	O	-1	435349
b@@	O	-1	435349
ol@@	O	-1	435349
us	O	-1	435349
group	O	-1	435349
and	O	-1	435349
the	O	-1	435349
5-@@	O	-1	435349
mg	O	-1	435349
s@@	O	-1	435349
-1	O	-1	435349
and	O	-1	435349
20@@	O	-1	435349
-@@	O	-1	435349
mg	O	-1	435349
s@@	O	-1	435349
-1	O	-1	435349
infusion	O	-1	435349
groups	O	-1	435349
were	O	-1	435349
not	O	-1	435349
significantly	O	-1	435349
differen@@	O	-1	435349
t.	O	-1	435349

G@@	B-Chemical	D005702	603022
al@@	I-Chemical	-1	603022
an@@	I-Chemical	-1	603022
th@@	I-Chemical	-1	603022
amine	I-Chemical	-1	603022
hydro@@	I-Chemical	-1	603022
brom@@	I-Chemical	-1	603022
ide	I-Chemical	-1	603022
,	O	-1	603022
a	O	-1	603022
long@@	O	-1	603022
er	O	-1	603022
act@@	O	-1	603022
ing	O	-1	603022
anti@@	O	-1	603022
chol@@	O	-1	603022
ine@@	O	-1	603022
ster@@	O	-1	603022
ase	O	-1	603022
drug@@	O	-1	603022
,	O	-1	603022
in	O	-1	603022
the	O	-1	603022
treatment	O	-1	603022
of	O	-1	603022
the	O	-1	603022
central	O	-1	603022
effects	O	-1	603022
of	O	-1	603022
scopol@@	B-Chemical	D012601	603022
amine	I-Chemical	-1	603022
(	O	-1	603022
H@@	B-Chemical	D012601	603022
y@@	I-Chemical	-1	603022
os@@	I-Chemical	-1	603022
c@@	I-Chemical	-1	603022
ine	I-Chemical	-1	603022
).	O	-1	603022
G@@	B-Chemical	D005702	603022
al@@	I-Chemical	-1	603022
an@@	I-Chemical	-1	603022
th@@	I-Chemical	-1	603022
amine	I-Chemical	-1	603022
hydro@@	I-Chemical	-1	603022
brom@@	I-Chemical	-1	603022
ide	I-Chemical	-1	603022
,	O	-1	603022
an	O	-1	603022
anti@@	O	-1	603022
chol@@	O	-1	603022
ine@@	O	-1	603022
ster@@	O	-1	603022
ase	O	-1	603022
drug	O	-1	603022
cap@@	O	-1	603022
able	O	-1	603022
of	O	-1	603022
pen@@	O	-1	603022
et@@	O	-1	603022
rat@@	O	-1	603022
ing	O	-1	603022
the	O	-1	603022
blo@@	O	-1	603022
o@@	O	-1	603022
d-@@	O	-1	603022
brain	O	-1	603022
bar@@	O	-1	603022
ri@@	O	-1	603022
er,	O	-1	603022
was	O	-1	603022
used	O	-1	603022
in	O	-1	603022
a	O	-1	603022
patient	O	-1	603022
demon@@	O	-1	603022
strat@@	O	-1	603022
ing	O	-1	603022
central	O	-1	603022
effects	O	-1	603022
of	O	-1	603022
scopol@@	B-Chemical	D012601	603022
amine	I-Chemical	-1	603022
(	O	-1	603022
hy@@	B-Chemical	D012601	603022
os@@	I-Chemical	-1	603022
c@@	I-Chemical	-1	603022
ine	I-Chemical	-1	603022
)	O	-1	603022
over@@	B-Disease	D062787	603022
dos@@	I-Disease	-1	603022
age	I-Disease	-1	603022
.	O	-1	603022
It	O	-1	603022
is	O	-1	603022
long@@	O	-1	603022
er	O	-1	603022
act@@	O	-1	603022
ing	O	-1	603022
than	O	-1	603022
ph@@	B-Chemical	D010830	603022
ys@@	I-Chemical	-1	603022
os@@	I-Chemical	-1	603022
tig@@	I-Chemical	-1	603022
mine	I-Chemical	-1	603022
and	O	-1	603022
is	O	-1	603022
used	O	-1	603022
in	O	-1	603022
anaesthe@@	O	-1	603022
sia	O	-1	603022
to	O	-1	603022
re@@	O	-1	603022
verse	O	-1	603022
the	O	-1	603022
non-@@	O	-1	603022
de@@	O	-1	603022
pol@@	O	-1	603022
ar@@	O	-1	603022
iz@@	O	-1	603022
ing	O	-1	603022
neuro@@	O	-1	603022
mus@@	O	-1	603022
cular	O	-1	603022
block@@	O	-1	603022
.	O	-1	603022
However,	O	-1	603022
studies	O	-1	603022
into	O	-1	603022
the	O	-1	603022
dose	O	-1	603022
nec@@	O	-1	603022
ess@@	O	-1	603022
ary	O	-1	603022
to	O	-1	603022
com@@	O	-1	603022
b@@	O	-1	603022
ating	O	-1	603022
scopol@@	B-Chemical	D012601	603022
amine	I-Chemical	-1	603022
in@@	O	-1	603022
toxic@@	O	-1	603022
ation	O	-1	603022
are	O	-1	603022
indic@@	O	-1	603022
ated.	O	-1	603022

Eff@@	O	-1	1378968
ects	O	-1	1378968
of	O	-1	1378968
un@@	O	-1	1378968
ine@@	O	-1	1378968
ph@@	O	-1	1378968
rec@@	O	-1	1378968
to@@	O	-1	1378968
m@@	O	-1	1378968
y	O	-1	1378968
and	O	-1	1378968
high	O	-1	1378968
protein	O	-1	1378968
fe@@	O	-1	1378968
ed@@	O	-1	1378968
ing	O	-1	1378968
on	O	-1	1378968
lithium	B-Chemical	D008094	1378968
-induced	O	-1	1378968
chronic	B-Disease	D007676	1378968
renal	I-Disease	-1	1378968
failure	I-Disease	-1	1378968
in	O	-1	1378968
rats.	O	-1	1378968
R@@	O	-1	1378968
at@@	O	-1	1378968
s	O	-1	1378968
with	O	-1	1378968
lithium	B-Chemical	D008094	1378968
-induced	O	-1	1378968
nephro@@	B-Disease	D007674	1378968
pathy	I-Disease	-1	1378968
were	O	-1	1378968
subj@@	O	-1	1378968
ected	O	-1	1378968
to	O	-1	1378968
high	O	-1	1378968
protein	O	-1	1378968
(@@	O	-1	1378968
H@@	O	-1	1378968
P)	O	-1	1378968
fe@@	O	-1	1378968
ed@@	O	-1	1378968
ing,	O	-1	1378968
un@@	O	-1	1378968
ine@@	O	-1	1378968
ph@@	O	-1	1378968
rec@@	O	-1	1378968
to@@	O	-1	1378968
m@@	O	-1	1378968
y	O	-1	1378968
(N@@	O	-1	1378968
X@@	O	-1	1378968
)	O	-1	1378968
or	O	-1	1378968
a	O	-1	1378968
combination	O	-1	1378968
of	O	-1	1378968
th@@	O	-1	1378968
es@@	O	-1	1378968
e,	O	-1	1378968
in	O	-1	1378968
an	O	-1	1378968
at@@	O	-1	1378968
tem@@	O	-1	1378968
p@@	O	-1	1378968
t	O	-1	1378968
to	O	-1	1378968
induce	O	-1	1378968
glomerular	O	-1	1378968
hyper@@	O	-1	1378968
f@@	O	-1	1378968
iltration	O	-1	1378968
and	O	-1	1378968
further	O	-1	1378968
progres@@	O	-1	1378968
sion	O	-1	1378968
of	O	-1	1378968
renal	B-Disease	D051437	1378968
failure	I-Disease	-1	1378968
.	O	-1	1378968
Ne@@	O	-1	1378968
w@@	O	-1	1378968
b@@	O	-1	1378968
or@@	O	-1	1378968
n	O	-1	1378968
female	O	-1	1378968
Wistar	O	-1	1378968
rats	O	-1	1378968
were	O	-1	1378968
f@@	O	-1	1378968
ed	O	-1	1378968
a	O	-1	1378968
lithium	B-Chemical	D008094	1378968
-@@	O	-1	1378968
containing	O	-1	1378968
diet	O	-1	1378968
(@@	O	-1	1378968
50	O	-1	1378968
m@@	O	-1	1378968
mol@@	O	-1	1378968
/@@	O	-1	1378968
kg@@	O	-1	1378968
)	O	-1	1378968
for	O	-1	1378968
8	O	-1	1378968
weeks	O	-1	1378968
and	O	-1	1378968
then	O	-1	1378968
randomized	O	-1	1378968
to	O	-1	1378968
normal	O	-1	1378968
di@@	O	-1	1378968
et@@	O	-1	1378968
,	O	-1	1378968
H@@	O	-1	1378968
P	O	-1	1378968
diet	O	-1	1378968
(@@	O	-1	1378968
40	O	-1	1378968
vs.	O	-1	1378968
19@@	O	-1	1378968
%),	O	-1	1378968
N@@	O	-1	1378968
X	O	-1	1378968
or	O	-1	1378968
H@@	O	-1	1378968
P@@	O	-1	1378968
+@@	O	-1	1378968
N@@	O	-1	1378968
X	O	-1	1378968
for	O	-1	1378968
an@@	O	-1	1378968
other	O	-1	1378968
8	O	-1	1378968
week@@	O	-1	1378968
s.	O	-1	1378968
C@@	O	-1	1378968
or@@	O	-1	1378968
respon@@	O	-1	1378968
ding	O	-1	1378968
non@@	O	-1	1378968
-	O	-1	1378968
lithium	B-Chemical	D008094	1378968
pre@@	O	-1	1378968
treated	O	-1	1378968
groups	O	-1	1378968
were	O	-1	1378968
gener@@	O	-1	1378968
ated.	O	-1	1378968
Whe@@	O	-1	1378968
n	O	-1	1378968
compar@@	O	-1	1378968
ing	O	-1	1378968
all	O	-1	1378968
lithium	B-Chemical	D008094	1378968
treated	O	-1	1378968
versus	O	-1	1378968
non@@	O	-1	1378968
-	O	-1	1378968
lithium	B-Chemical	D008094	1378968
-treated	O	-1	1378968
group@@	O	-1	1378968
s,	O	-1	1378968
lithium	B-Chemical	D008094	1378968
caused	O	-1	1378968
a	O	-1	1378968
reduction	O	-1	1378968
in	O	-1	1378968
glomerular	O	-1	1378968
f@@	O	-1	1378968
iltration	O	-1	1378968
rate	O	-1	1378968
(@@	O	-1	1378968
GF@@	O	-1	1378968
R@@	O	-1	1378968
)	O	-1	1378968
without	O	-1	1378968
significant	O	-1	1378968
changes	O	-1	1378968
in	O	-1	1378968
effective	O	-1	1378968
renal	O	-1	1378968
plasma	O	-1	1378968
flow	O	-1	1378968
(@@	O	-1	1378968
as	O	-1	1378968
determined	O	-1	1378968
by	O	-1	1378968
a	O	-1	1378968
mark@@	O	-1	1378968
er	O	-1	1378968
secre@@	O	-1	1378968
ted	O	-1	1378968
into	O	-1	1378968
the	O	-1	1378968
pro@@	O	-1	1378968
xim@@	O	-1	1378968
al	O	-1	1378968
tub@@	O	-1	1378968
ul@@	O	-1	1378968
es@@	O	-1	1378968
)	O	-1	1378968
or	O	-1	1378968
lithium	B-Chemical	D008094	1378968
clear@@	O	-1	1378968
ance@@	O	-1	1378968
.	O	-1	1378968
Con@@	O	-1	1378968
sequ@@	O	-1	1378968
ent@@	O	-1	1378968
ly,	O	-1	1378968
lithium	B-Chemical	D008094	1378968
pretreatment	O	-1	1378968
caused	O	-1	1378968
a	O	-1	1378968
f@@	O	-1	1378968
all	O	-1	1378968
in	O	-1	1378968
f@@	O	-1	1378968
iltration	O	-1	1378968
frac@@	O	-1	1378968
tion	O	-1	1378968
and	O	-1	1378968
an	O	-1	1378968
increase	O	-1	1378968
in	O	-1	1378968
frac@@	O	-1	1378968
tional	O	-1	1378968
L@@	B-Chemical	D008094	1378968
i	I-Chemical	-1	1378968
ex@@	O	-1	1378968
cre@@	O	-1	1378968
tion.	O	-1	1378968
L@@	B-Chemical	D008094	1378968
i@@	I-Chemical	-1	1378968
thi@@	I-Chemical	-1	1378968
um	I-Chemical	-1	1378968
also	O	-1	1378968
caused	O	-1	1378968
proteinuria	B-Disease	D011507	1378968
and	O	-1	1378968
systolic	O	-1	1378968
hypertension	B-Disease	D006973	1378968
in	O	-1	1378968
absence	O	-1	1378968
of	O	-1	1378968
glomer@@	B-Disease	D005921	1378968
u@@	I-Disease	-1	1378968
los@@	I-Disease	-1	1378968
clero@@	I-Disease	-1	1378968
sis	I-Disease	-1	1378968
.	O	-1	1378968
H@@	O	-1	1378968
P	O	-1	1378968
fail@@	O	-1	1378968
ed	O	-1	1378968
to	O	-1	1378968
ac@@	O	-1	1378968
c@@	O	-1	1378968
ent@@	O	-1	1378968
u@@	O	-1	1378968
ant@@	O	-1	1378968
e	O	-1	1378968
progres@@	O	-1	1378968
sion	O	-1	1378968
of	O	-1	1378968
renal	B-Disease	D051437	1378968
failure	I-Disease	-1	1378968
and	O	-1	1378968
in	O	-1	1378968
fac@@	O	-1	1378968
t	O	-1	1378968
ten@@	O	-1	1378968
ded	O	-1	1378968
to	O	-1	1378968
increase	O	-1	1378968
GF@@	O	-1	1378968
R	O	-1	1378968
and	O	-1	1378968
decrease	O	-1	1378968
plasma	O	-1	1378968
creatinine	B-Chemical	D003404	1378968
levels	O	-1	1378968
in	O	-1	1378968
lithium	B-Chemical	D008094	1378968
pre@@	O	-1	1378968
treated	O	-1	1378968
rats.	O	-1	1378968
N@@	O	-1	1378968
X	O	-1	1378968
caused	O	-1	1378968
an	O	-1	1378968
addi@@	O	-1	1378968
tive	O	-1	1378968
deter@@	O	-1	1378968
i@@	O	-1	1378968
or@@	O	-1	1378968
ation	O	-1	1378968
in	O	-1	1378968
GF@@	O	-1	1378968
R	O	-1	1378968
wh@@	O	-1	1378968
ic@@	O	-1	1378968
h@@	O	-1	1378968
,	O	-1	1378968
however,	O	-1	1378968
was	O	-1	1378968
ame@@	O	-1	1378968
li@@	O	-1	1378968
or@@	O	-1	1378968
ated	O	-1	1378968
by	O	-1	1378968
H@@	O	-1	1378968
P@@	O	-1	1378968
.	O	-1	1378968
N@@	O	-1	1378968
X@@	O	-1	1378968
+@@	O	-1	1378968
H@@	O	-1	1378968
P	O	-1	1378968
caused	O	-1	1378968
a	O	-1	1378968
further	O	-1	1378968
ri@@	O	-1	1378968
se	O	-1	1378968
in	O	-1	1378968
blood	O	-1	1378968
pressure	O	-1	1378968
in	O	-1	1378968
L@@	B-Chemical	D008094	1378968
i	I-Chemical	-1	1378968
-@@	O	-1	1378968
pre@@	O	-1	1378968
treated	O	-1	1378968
rats.	O	-1	1378968
The	O	-1	1378968
results	O	-1	1378968
indicate	O	-1	1378968
that	O	-1	1378968
L@@	B-Chemical	D008094	1378968
i	I-Chemical	-1	1378968
-induced	O	-1	1378968
nephro@@	B-Disease	D007674	1378968
pathy	I-Disease	-1	1378968
,	O	-1	1378968
even	O	-1	1378968
when	O	-1	1378968
the	O	-1	1378968
GF@@	O	-1	1378968
R	O	-1	1378968
is	O	-1	1378968
only	O	-1	1378968
mode@@	O	-1	1378968
st@@	O	-1	1378968
ly	O	-1	1378968
reduc@@	O	-1	1378968
ed,	O	-1	1378968
is	O	-1	1378968
associated	O	-1	1378968
with	O	-1	1378968
proteinuria	B-Disease	D011507	1378968
and	O	-1	1378968
arterial	O	-1	1378968
systolic	O	-1	1378968
hypertension	B-Disease	D006973	1378968
.	O	-1	1378968
In	O	-1	1378968
this	O	-1	1378968
model	O	-1	1378968
of	O	-1	1378968
chronic	B-Disease	D007676	1378968
renal	I-Disease	-1	1378968
failure	I-Disease	-1	1378968
the	O	-1	1378968
dec@@	O	-1	1378968
line	O	-1	1378968
in	O	-1	1378968
GF@@	O	-1	1378968
R	O	-1	1378968
is	O	-1	1378968
not	O	-1	1378968
ac@@	O	-1	1378968
comp@@	O	-1	1378968
an@@	O	-1	1378968
ied	O	-1	1378968
by	O	-1	1378968
a	O	-1	1378968
cor@@	O	-1	1378968
respon@@	O	-1	1378968
ding	O	-1	1378968
f@@	O	-1	1378968
all	O	-1	1378968
in	O	-1	1378968
effective	O	-1	1378968
renal	O	-1	1378968
plasma	O	-1	1378968
f@@	O	-1	1378968
low@@	O	-1	1378968
,	O	-1	1378968
which	O	-1	1378968
may	O	-1	1378968
be	O	-1	1378968
the	O	-1	1378968
functional	O	-1	1378968
expression	O	-1	1378968
of	O	-1	1378968
the	O	-1	1378968
formation	O	-1	1378968
of	O	-1	1378968
non@@	O	-1	1378968
f@@	O	-1	1378968
ilt@@	O	-1	1378968
rat@@	O	-1	1378968
ing	O	-1	1378968
at@@	O	-1	1378968
ub@@	O	-1	1378968
ular	O	-1	1378968
glomerul@@	O	-1	1378968
i@@	O	-1	1378968
.	O	-1	1378968
The	O	-1	1378968
frac@@	O	-1	1378968
tional	O	-1	1378968
re@@	O	-1	1378968
abs@@	O	-1	1378968
or@@	O	-1	1378968
ption	O	-1	1378968
of	O	-1	1378968
tub@@	O	-1	1378968
ular	O	-1	1378968
flu@@	O	-1	1378968
id	O	-1	1378968
by	O	-1	1378968
the	O	-1	1378968
pro@@	O	-1	1378968
xim@@	O	-1	1378968
al	O	-1	1378968
tub@@	O	-1	1378968
ul@@	O	-1	1378968
es	O	-1	1378968
is	O	-1	1378968
reduc@@	O	-1	1378968
ed,	O	-1	1378968
le@@	O	-1	1378968
a@@	O	-1	1378968
ving	O	-1	1378968
the	O	-1	1378968
dist@@	O	-1	1378968
al	O	-1	1378968
de@@	O	-1	1378968
li@@	O	-1	1378968
very	O	-1	1378968
un@@	O	-1	1378968
chang@@	O	-1	1378968
ed@@	O	-1	1378968
.@@	O	-1	1378968
(A@@	O	-1	1378968
B@@	O	-1	1378968
S@@	O	-1	1378968
TR@@	O	-1	1378968
AC@@	O	-1	1378968
T	O	-1	1378968
TR@@	O	-1	1378968
UN@@	O	-1	1378968
C@@	O	-1	1378968
AT@@	O	-1	1378968
E@@	O	-1	1378968
D	O	-1	1378968
A@@	O	-1	1378968
T	O	-1	1378968
2@@	O	-1	1378968
50	O	-1	1378968
W@@	O	-1	1378968
O@@	O	-1	1378968
RD@@	O	-1	1378968
S)	O	-1	1378968

Treat@@	O	-1	1420741
ment	O	-1	1420741
of	O	-1	1420741
C@@	B-Disease	D003424	1420741
ro@@	I-Disease	-1	1420741
h@@	I-Disease	-1	1420741
n@@	I-Disease	-1	1420741
's	I-Disease	-1	1420741
disease	I-Disease	-1	1420741
with	O	-1	1420741
fu@@	B-Chemical	D005672	1420741
si@@	I-Chemical	-1	1420741
di@@	I-Chemical	-1	1420741
c	I-Chemical	-1	1420741
acid	I-Chemical	-1	1420741
:	O	-1	1420741
an	O	-1	1420741
anti@@	O	-1	1420741
bio@@	O	-1	1420741
tic	O	-1	1420741
with	O	-1	1420741
immunosup@@	O	-1	1420741
pressive	O	-1	1420741
pro@@	O	-1	1420741
per@@	O	-1	1420741
ties	O	-1	1420741
similar	O	-1	1420741
to	O	-1	1420741
cyclospor@@	B-Chemical	D016572	1420741
in	I-Chemical	-1	1420741
.	O	-1	1420741
F@@	O	-1	1420741
u@@	O	-1	1420741
si@@	O	-1	1420741
di@@	O	-1	1420741
c	O	-1	1420741
acid	O	-1	1420741
is	O	-1	1420741
an	O	-1	1420741
anti@@	O	-1	1420741
bio@@	O	-1	1420741
tic	O	-1	1420741
with	O	-1	1420741
T@@	O	-1	1420741
-@@	O	-1	1420741
cell	O	-1	1420741
specific	O	-1	1420741
immunosup@@	O	-1	1420741
pressive	O	-1	1420741
effects	O	-1	1420741
similar	O	-1	1420741
to	O	-1	1420741
those	O	-1	1420741
of	O	-1	1420741
cyclospor@@	B-Chemical	D016572	1420741
in	I-Chemical	-1	1420741
.	O	-1	1420741
B@@	O	-1	1420741
ecause	O	-1	1420741
of	O	-1	1420741
the	O	-1	1420741
need	O	-1	1420741
for	O	-1	1420741
the	O	-1	1420741
development	O	-1	1420741
of	O	-1	1420741
new	O	-1	1420741
treat@@	O	-1	1420741
ments	O	-1	1420741
for	O	-1	1420741
C@@	B-Disease	D003424	1420741
ro@@	I-Disease	-1	1420741
h@@	I-Disease	-1	1420741
n@@	I-Disease	-1	1420741
's	I-Disease	-1	1420741
disease	I-Disease	-1	1420741
,	O	-1	1420741
a	O	-1	1420741
pilo@@	O	-1	1420741
t	O	-1	1420741
study	O	-1	1420741
was	O	-1	1420741
under@@	O	-1	1420741
tak@@	O	-1	1420741
en	O	-1	1420741
to	O	-1	1420741
estim@@	O	-1	1420741
ate	O	-1	1420741
the	O	-1	1420741
pharmac@@	O	-1	1420741
o@@	O	-1	1420741
dynam@@	O	-1	1420741
ic@@	O	-1	1420741
s	O	-1	1420741
and	O	-1	1420741
toler@@	O	-1	1420741
ability	O	-1	1420741
of	O	-1	1420741
fu@@	B-Chemical	D005672	1420741
si@@	I-Chemical	-1	1420741
di@@	I-Chemical	-1	1420741
c	I-Chemical	-1	1420741
acid	I-Chemical	-1	1420741
treatment	O	-1	1420741
in	O	-1	1420741
chronic	O	-1	1420741
ac@@	O	-1	1420741
ti@@	O	-1	1420741
ve,	O	-1	1420741
therap@@	O	-1	1420741
y-@@	O	-1	1420741
resist@@	O	-1	1420741
ant	O	-1	1420741
patients.	O	-1	1420741
E@@	O	-1	1420741
ight	O	-1	1420741
C@@	B-Disease	D003424	1420741
ro@@	I-Disease	-1	1420741
h@@	I-Disease	-1	1420741
n@@	I-Disease	-1	1420741
's	I-Disease	-1	1420741
disease	I-Disease	-1	1420741
patients	O	-1	1420741
were	O	-1	1420741
inc@@	O	-1	1420741
lu@@	O	-1	1420741
de@@	O	-1	1420741
d.	O	-1	1420741
F@@	B-Chemical	D005672	1420741
u@@	I-Chemical	-1	1420741
si@@	I-Chemical	-1	1420741
di@@	I-Chemical	-1	1420741
c	I-Chemical	-1	1420741
acid	I-Chemical	-1	1420741
was	O	-1	1420741
administered	O	-1	1420741
or@@	O	-1	1420741
ally	O	-1	1420741
in	O	-1	1420741
a	O	-1	1420741
dose	O	-1	1420741
of	O	-1	1420741
5@@	O	-1	1420741
00	O	-1	1420741
mg	O	-1	1420741
t@@	O	-1	1420741
.@@	O	-1	1420741
d@@	O	-1	1420741
.@@	O	-1	1420741
s.	O	-1	1420741
and	O	-1	1420741
the	O	-1	1420741
treatment	O	-1	1420741
was	O	-1	1420741
pl@@	O	-1	1420741
an@@	O	-1	1420741
n@@	O	-1	1420741
ed	O	-1	1420741
to	O	-1	1420741
las@@	O	-1	1420741
t	O	-1	1420741
8	O	-1	1420741
week@@	O	-1	1420741
s.	O	-1	1420741
The	O	-1	1420741
disease	O	-1	1420741
activity	O	-1	1420741
was	O	-1	1420741
prim@@	O	-1	1420741
ari@@	O	-1	1420741
ly	O	-1	1420741
measured	O	-1	1420741
by	O	-1	1420741
a	O	-1	1420741
mo@@	O	-1	1420741
di@@	O	-1	1420741
fied	O	-1	1420741
individ@@	O	-1	1420741
ual	O	-1	1420741
gra@@	O	-1	1420741
ding	O	-1	1420741
sco@@	O	-1	1420741
re.	O	-1	1420741
F@@	O	-1	1420741
i@@	O	-1	1420741
ve	O	-1	1420741
of	O	-1	1420741
8	O	-1	1420741
patients	O	-1	1420741
(6@@	O	-1	1420741
3@@	O	-1	1420741
%)	O	-1	1420741
improved	O	-1	1420741
during	O	-1	1420741
fu@@	B-Chemical	D005672	1420741
si@@	I-Chemical	-1	1420741
di@@	I-Chemical	-1	1420741
c	I-Chemical	-1	1420741
acid	I-Chemical	-1	1420741
treatment@@	O	-1	1420741
:	O	-1	1420741
3	O	-1	1420741
at	O	-1	1420741
two	O	-1	1420741
weeks	O	-1	1420741
and	O	-1	1420741
2	O	-1	1420741
after	O	-1	1420741
four	O	-1	1420741
week@@	O	-1	1420741
s.	O	-1	1420741
There	O	-1	1420741
were	O	-1	1420741
no	O	-1	1420741
seri@@	O	-1	1420741
ous	O	-1	1420741
clinical	O	-1	1420741
side	O	-1	1420741
effect@@	O	-1	1420741
s,	O	-1	1420741
but	O	-1	1420741
dose	O	-1	1420741
reduction	O	-1	1420741
was	O	-1	1420741
requ@@	O	-1	1420741
ired	O	-1	1420741
in	O	-1	1420741
two	O	-1	1420741
patients	O	-1	1420741
because	O	-1	1420741
of	O	-1	1420741
nausea	B-Disease	D009325	1420741
.	O	-1	1420741
B@@	O	-1	1420741
io@@	O	-1	1420741
chem@@	O	-1	1420741
ic@@	O	-1	1420741
ally,	O	-1	1420741
an	O	-1	1420741
increase	O	-1	1420741
in	O	-1	1420741
al@@	O	-1	1420741
k@@	O	-1	1420741
aline	O	-1	1420741
phosph@@	O	-1	1420741
at@@	O	-1	1420741
as@@	O	-1	1420741
es	O	-1	1420741
was	O	-1	1420741
not@@	O	-1	1420741
ed	O	-1	1420741
in	O	-1	1420741
5	O	-1	1420741
of	O	-1	1420741
8	O	-1	1420741
cases	O	-1	1420741
(6@@	O	-1	1420741
3@@	O	-1	1420741
%),	O	-1	1420741
and	O	-1	1420741
the	O	-1	1420741
great@@	O	-1	1420741
est	O	-1	1420741
increases	O	-1	1420741
were	O	-1	1420741
seen	O	-1	1420741
in	O	-1	1420741
those	O	-1	1420741
who	O	-1	1420741
had	O	-1	1420741
elevated	O	-1	1420741
levels	O	-1	1420741
prior	O	-1	1420741
to	O	-1	1420741
treatment.	O	-1	1420741
All	O	-1	1420741
reversed	O	-1	1420741
to	O	-1	1420741
pre-@@	O	-1	1420741
treatment	O	-1	1420741
levels	O	-1	1420741
after	O	-1	1420741
cess@@	O	-1	1420741
ation	O	-1	1420741
of	O	-1	1420741
treatment.	O	-1	1420741
The	O	-1	1420741
results	O	-1	1420741
of	O	-1	1420741
this	O	-1	1420741
pilo@@	O	-1	1420741
t	O	-1	1420741
study	O	-1	1420741
suggest	O	-1	1420741
that	O	-1	1420741
fu@@	B-Chemical	D005672	1420741
si@@	I-Chemical	-1	1420741
di@@	I-Chemical	-1	1420741
c	I-Chemical	-1	1420741
acid	I-Chemical	-1	1420741
may	O	-1	1420741
be	O	-1	1420741
of	O	-1	1420741
ben@@	O	-1	1420741
e@@	O	-1	1420741
fi@@	O	-1	1420741
t	O	-1	1420741
in	O	-1	1420741
sel@@	O	-1	1420741
ected	O	-1	1420741
chronic	O	-1	1420741
active	O	-1	1420741
C@@	B-Disease	D003424	1420741
ro@@	I-Disease	-1	1420741
h@@	I-Disease	-1	1420741
n@@	I-Disease	-1	1420741
's	I-Disease	-1	1420741
disease	I-Disease	-1	1420741
patients	O	-1	1420741
in	O	-1	1420741
whom	O	-1	1420741
con@@	O	-1	1420741
ven@@	O	-1	1420741
tional	O	-1	1420741
treatment	O	-1	1420741
is	O	-1	1420741
ine@@	O	-1	1420741
ff@@	O	-1	1420741
ecti@@	O	-1	1420741
ve.	O	-1	1420741
B@@	O	-1	1420741
ecause	O	-1	1420741
there	O	-1	1420741
se@@	O	-1	1420741
em@@	O	-1	1420741
s	O	-1	1420741
to	O	-1	1420741
ex@@	O	-1	1420741
ist	O	-1	1420741
a	O	-1	1420741
s@@	O	-1	1420741
ci@@	O	-1	1420741
enti@@	O	-1	1420741
f@@	O	-1	1420741
ic	O	-1	1420741
r@@	O	-1	1420741
ation@@	O	-1	1420741
al@@	O	-1	1420741
e	O	-1	1420741
for	O	-1	1420741
the	O	-1	1420741
use	O	-1	1420741
of	O	-1	1420741
fu@@	B-Chemical	D005672	1420741
si@@	I-Chemical	-1	1420741
di@@	I-Chemical	-1	1420741
c	I-Chemical	-1	1420741
acid	I-Chemical	-1	1420741
at	O	-1	1420741
the	O	-1	1420741
cyto@@	O	-1	1420741
k@@	O	-1	1420741
ine	O	-1	1420741
level	O	-1	1420741
in	O	-1	1420741
inflam@@	B-Disease	D015212	1420741
mat@@	I-Disease	-1	1420741
ory	I-Disease	-1	1420741
bo@@	I-Disease	-1	1420741
we@@	I-Disease	-1	1420741
l	I-Disease	-1	1420741
disease	I-Disease	-1	1420741
,	O	-1	1420741
we	O	-1	1420741
suggest	O	-1	1420741
that	O	-1	1420741
the	O	-1	1420741
role	O	-1	1420741
of	O	-1	1420741
this	O	-1	1420741
treatment	O	-1	1420741
should	O	-1	1420741
be	O	-1	1420741
further	O	-1	1420741
investig@@	O	-1	1420741
ated.	O	-1	1420741

E@@	O	-1	1601297
l@@	O	-1	1601297
ect@@	O	-1	1601297
ro@@	O	-1	1601297
cardio@@	O	-1	1601297
graph@@	O	-1	1601297
ic	O	-1	1601297
evidence	O	-1	1601297
of	O	-1	1601297
myocardial	B-Disease	D009202	1601297
injury	I-Disease	-1	1601297
in	O	-1	1601297
psych@@	O	-1	1601297
i@@	O	-1	1601297
at@@	O	-1	1601297
r@@	O	-1	1601297
ically	O	-1	1601297
hospit@@	O	-1	1601297
al@@	O	-1	1601297
ized	O	-1	1601297
cocaine	B-Chemical	D003042	1601297
ab@@	O	-1	1601297
us@@	O	-1	1601297
ers.	O	-1	1601297
The	O	-1	1601297
electro@@	O	-1	1601297
cardio@@	O	-1	1601297
gram@@	O	-1	1601297
s	O	-1	1601297
(@@	O	-1	1601297
EC@@	O	-1	1601297
G@@	O	-1	1601297
)	O	-1	1601297
of	O	-1	1601297
9@@	O	-1	1601297
9	O	-1	1601297
cocaine	B-Chemical	D003042	1601297
-@@	O	-1	1601297
ab@@	O	-1	1601297
using	O	-1	1601297
patients	O	-1	1601297
were	O	-1	1601297
compared	O	-1	1601297
with	O	-1	1601297
the	O	-1	1601297
EC@@	O	-1	1601297
G@@	O	-1	1601297
s	O	-1	1601297
of	O	-1	1601297
50	O	-1	1601297
sch@@	B-Disease	D012559	1601297
iz@@	I-Disease	-1	1601297
oph@@	I-Disease	-1	1601297
ren@@	I-Disease	-1	1601297
ic	I-Disease	-1	1601297
controls.	O	-1	1601297
E@@	O	-1	1601297
le@@	O	-1	1601297
ven	O	-1	1601297
of	O	-1	1601297
the	O	-1	1601297
cocaine	B-Chemical	D003042	1601297
ab@@	O	-1	1601297
users	O	-1	1601297
and	O	-1	1601297
n@@	O	-1	1601297
one	O	-1	1601297
of	O	-1	1601297
the	O	-1	1601297
controls	O	-1	1601297
had	O	-1	1601297
EC@@	O	-1	1601297
G	O	-1	1601297
evidence	O	-1	1601297
of	O	-1	1601297
significant	O	-1	1601297
myocardial	B-Disease	D009202	1601297
injury	I-Disease	-1	1601297
def@@	O	-1	1601297
in@@	O	-1	1601297
ed	O	-1	1601297
as	O	-1	1601297
myocardial	B-Disease	D009203	1601297
infarction	I-Disease	-1	1601297
,	O	-1	1601297
ischem@@	B-Disease	D007511	1601297
ia	I-Disease	-1	1601297
,	O	-1	1601297
and	O	-1	1601297
b@@	B-Disease	D002037	1601297
und@@	I-Disease	-1	1601297
le	I-Disease	-1	1601297
b@@	I-Disease	-1	1601297
ran@@	I-Disease	-1	1601297
ch	I-Disease	-1	1601297
bloc@@	I-Disease	-1	1601297
k	I-Disease	-1	1601297
.	O	-1	1601297

S@@	B-Chemical	D013469	1967484
ul@@	I-Chemical	-1	1967484
pi@@	I-Chemical	-1	1967484
ri@@	I-Chemical	-1	1967484
de	I-Chemical	-1	1967484
-induced	O	-1	1967484
t@@	B-Disease	D004421	1967484
ardi@@	I-Disease	-1	1967484
ve	I-Disease	-1	1967484
dy@@	I-Disease	-1	1967484
ston@@	I-Disease	-1	1967484
ia	I-Disease	-1	1967484
.	O	-1	1967484
S@@	B-Chemical	D013469	1967484
ul@@	I-Chemical	-1	1967484
pi@@	I-Chemical	-1	1967484
ri@@	I-Chemical	-1	1967484
de	I-Chemical	-1	1967484
is	O	-1	1967484
a	O	-1	1967484
selective	O	-1	1967484
D@@	O	-1	1967484
2-@@	O	-1	1967484
receptor	O	-1	1967484
antagonist	O	-1	1967484
with	O	-1	1967484
anti@@	O	-1	1967484
psycho@@	O	-1	1967484
tic	O	-1	1967484
and	O	-1	1967484
antidepress@@	B-Chemical	D000928	1967484
ant	I-Chemical	-1	1967484
pro@@	O	-1	1967484
per@@	O	-1	1967484
ti@@	O	-1	1967484
es.	O	-1	1967484
Although	O	-1	1967484
initi@@	O	-1	1967484
ally	O	-1	1967484
thou@@	O	-1	1967484
ght	O	-1	1967484
to	O	-1	1967484
be	O	-1	1967484
free	O	-1	1967484
of	O	-1	1967484
ext@@	O	-1	1967484
ra@@	O	-1	1967484
py@@	O	-1	1967484
ram@@	O	-1	1967484
idal	O	-1	1967484
side	O	-1	1967484
effect@@	O	-1	1967484
s,	O	-1	1967484
sul@@	B-Chemical	D013469	1967484
pi@@	I-Chemical	-1	1967484
ri@@	I-Chemical	-1	1967484
de	I-Chemical	-1	1967484
-induced	O	-1	1967484
t@@	B-Disease	D004409	1967484
ardi@@	I-Disease	-1	1967484
ve	I-Disease	-1	1967484
dyskine@@	I-Disease	-1	1967484
sia	I-Disease	-1	1967484
and	O	-1	1967484
par@@	B-Disease	D010302	1967484
k@@	I-Disease	-1	1967484
inson@@	I-Disease	-1	1967484
ism	I-Disease	-1	1967484
have	O	-1	1967484
been	O	-1	1967484
reported	O	-1	1967484
oc@@	O	-1	1967484
ca@@	O	-1	1967484
sion@@	O	-1	1967484
all@@	O	-1	1967484
y.	O	-1	1967484
We	O	-1	1967484
studied	O	-1	1967484
a	O	-1	1967484
3@@	O	-1	1967484
7-@@	O	-1	1967484
year-old	O	-1	1967484
man	O	-1	1967484
who	O	-1	1967484
developed	O	-1	1967484
per@@	O	-1	1967484
sist@@	O	-1	1967484
ent	O	-1	1967484
seg@@	O	-1	1967484
mental	O	-1	1967484
dy@@	B-Disease	D004421	1967484
ston@@	I-Disease	-1	1967484
ia	I-Disease	-1	1967484
within	O	-1	1967484
2	O	-1	1967484
months	O	-1	1967484
after	O	-1	1967484
star@@	O	-1	1967484
ting	O	-1	1967484
sul@@	B-Chemical	D013469	1967484
pi@@	I-Chemical	-1	1967484
ri@@	I-Chemical	-1	1967484
de	I-Chemical	-1	1967484
therapy.	O	-1	1967484
We	O	-1	1967484
could	O	-1	1967484
not	O	-1	1967484
f@@	O	-1	1967484
ind	O	-1	1967484
any	O	-1	1967484
previ@@	O	-1	1967484
ous	O	-1	1967484
reports	O	-1	1967484
of	O	-1	1967484
sul@@	B-Chemical	D013469	1967484
pi@@	I-Chemical	-1	1967484
ri@@	I-Chemical	-1	1967484
de	I-Chemical	-1	1967484
-induced	O	-1	1967484
t@@	B-Disease	D004421	1967484
ardi@@	I-Disease	-1	1967484
ve	I-Disease	-1	1967484
dy@@	I-Disease	-1	1967484
ston@@	I-Disease	-1	1967484
ia	I-Disease	-1	1967484
.	O	-1	1967484

O@@	B-Disease	D014786	2234245
cular	I-Disease	-1	2234245
and	I-Disease	-1	2234245
a@@	I-Disease	-1	2234245
ud@@	I-Disease	-1	2234245
it@@	I-Disease	-1	2234245
ory	I-Disease	-1	2234245
toxicity	I-Disease	-1	2234245
O@@	B-Disease	D006311	2234245
cular	I-Disease	-1	2234245
and	I-Disease	-1	2234245
a@@	I-Disease	-1	2234245
ud@@	I-Disease	-1	2234245
it@@	I-Disease	-1	2234245
ory	I-Disease	-1	2234245
toxicity	I-Disease	-1	2234245
in	O	-1	2234245
hemo@@	O	-1	2234245
dialy@@	O	-1	2234245
zed	O	-1	2234245
patients	O	-1	2234245
receiving	O	-1	2234245
des@@	B-Chemical	D003676	2234245
fer@@	I-Chemical	-1	2234245
ri@@	I-Chemical	-1	2234245
ox@@	I-Chemical	-1	2234245
amine	I-Chemical	-1	2234245
.	O	-1	2234245
D@@	O	-1	2234245
uring	O	-1	2234245
an	O	-1	2234245
18@@	O	-1	2234245
-@@	O	-1	2234245
mon@@	O	-1	2234245
th	O	-1	2234245
period	O	-1	2234245
of	O	-1	2234245
study	O	-1	2234245
4@@	O	-1	2234245
1	O	-1	2234245
hemo@@	O	-1	2234245
dialy@@	O	-1	2234245
zed	O	-1	2234245
patients	O	-1	2234245
receiving	O	-1	2234245
des@@	B-Chemical	D003676	2234245
fer@@	I-Chemical	-1	2234245
ri@@	I-Chemical	-1	2234245
ox@@	I-Chemical	-1	2234245
amine	I-Chemical	-1	2234245
(@@	O	-1	2234245
10-@@	O	-1	2234245
40	O	-1	2234245
mg/kg	O	-1	2234245
B@@	O	-1	2234245
W@@	O	-1	2234245
/@@	O	-1	2234245
3	O	-1	2234245
times	O	-1	2234245
week@@	O	-1	2234245
ly@@	O	-1	2234245
)	O	-1	2234245
for	O	-1	2234245
the	O	-1	2234245
first	O	-1	2234245
time	O	-1	2234245
were	O	-1	2234245
monit@@	O	-1	2234245
o@@	O	-1	2234245
red	O	-1	2234245
for	O	-1	2234245
det@@	O	-1	2234245
ection	O	-1	2234245
of	O	-1	2234245
a@@	B-Disease	D014786	2234245
udi@@	I-Disease	-1	2234245
o@@	I-Disease	-1	2234245
visual	I-Disease	-1	2234245
toxicity	I-Disease	-1	2234245
a@@	B-Disease	D006311	2234245
udi@@	I-Disease	-1	2234245
o@@	I-Disease	-1	2234245
visual	I-Disease	-1	2234245
toxicity	I-Disease	-1	2234245
.	O	-1	2234245
6	O	-1	2234245
patients	O	-1	2234245
presented	O	-1	2234245
clinical	O	-1	2234245
symptoms	O	-1	2234245
of	O	-1	2234245
visual	B-Disease	D014786	2234245
or	I-Disease	-1	2234245
a@@	I-Disease	-1	2234245
ud@@	I-Disease	-1	2234245
it@@	I-Disease	-1	2234245
ory	I-Disease	-1	2234245
toxicity	I-Disease	-1	2234245
visual	B-Disease	D006311	2234245
or	I-Disease	-1	2234245
a@@	I-Disease	-1	2234245
ud@@	I-Disease	-1	2234245
it@@	I-Disease	-1	2234245
ory	I-Disease	-1	2234245
toxicity	I-Disease	-1	2234245
.	O	-1	2234245
M@@	O	-1	2234245
ore@@	O	-1	2234245
o@@	O	-1	2234245
ver,	O	-1	2234245
det@@	O	-1	2234245
ail@@	O	-1	2234245
ed	O	-1	2234245
oph@@	O	-1	2234245
thal@@	O	-1	2234245
mo@@	O	-1	2234245
log@@	O	-1	2234245
ic	O	-1	2234245
and	O	-1	2234245
a@@	O	-1	2234245
udi@@	O	-1	2234245
ologic	O	-1	2234245
studies	O	-1	2234245
disc@@	O	-1	2234245
los@@	O	-1	2234245
ed	O	-1	2234245
abnormal@@	O	-1	2234245
ities	O	-1	2234245
in	O	-1	2234245
7	O	-1	2234245
more	O	-1	2234245
as@@	O	-1	2234245
ym@@	O	-1	2234245
pto@@	O	-1	2234245
m@@	O	-1	2234245
atic	O	-1	2234245
patients.	O	-1	2234245
V@@	B-Disease	D014786	2234245
i@@	I-Disease	-1	2234245
sual	I-Disease	-1	2234245
toxicity	I-Disease	-1	2234245
was	O	-1	2234245
of	O	-1	2234245
ret@@	O	-1	2234245
inal	O	-1	2234245
or@@	O	-1	2234245
ig@@	O	-1	2234245
in	O	-1	2234245
and	O	-1	2234245
was	O	-1	2234245
character@@	O	-1	2234245
ized	O	-1	2234245
by	O	-1	2234245
a	O	-1	2234245
t@@	O	-1	2234245
rit@@	O	-1	2234245
an@@	O	-1	2234245
-@@	O	-1	2234245
type	O	-1	2234245
dys@@	B-Disease	-1	2234245
ch@@	I-Disease	-1	2234245
rom@@	I-Disease	-1	2234245
at@@	I-Disease	-1	2234245
op@@	I-Disease	-1	2234245
sy	I-Disease	-1	2234245
,	O	-1	2234245
so@@	O	-1	2234245
me@@	O	-1	2234245
times	O	-1	2234245
associated	O	-1	2234245
with	O	-1	2234245
a	B-Disease	D014786	2234245
loss	I-Disease	-1	2234245
of	I-Disease	-1	2234245
visual	I-Disease	-1	2234245
ac@@	I-Disease	-1	2234245
u@@	I-Disease	-1	2234245
ity	I-Disease	-1	2234245
and	O	-1	2234245
pi@@	B-Disease	D012164	2234245
g@@	I-Disease	-1	2234245
ment@@	I-Disease	-1	2234245
ary	I-Disease	-1	2234245
ret@@	I-Disease	-1	2234245
inal	I-Disease	-1	2234245
de@@	I-Disease	-1	2234245
pos@@	I-Disease	-1	2234245
its	I-Disease	-1	2234245
.	O	-1	2234245
A@@	B-Disease	D006311	2234245
ud@@	I-Disease	-1	2234245
it@@	I-Disease	-1	2234245
ory	I-Disease	-1	2234245
toxicity	I-Disease	-1	2234245
was	O	-1	2234245
character@@	O	-1	2234245
ized	O	-1	2234245
by	O	-1	2234245
a	O	-1	2234245
mid@@	O	-1	2234245
-	O	-1	2234245
to	O	-1	2234245
high-@@	O	-1	2234245
frequency	O	-1	2234245
neuro@@	B-Disease	D006319	2234245
sens@@	I-Disease	-1	2234245
or@@	I-Disease	-1	2234245
ial	I-Disease	-1	2234245
hearing	I-Disease	-1	2234245
loss	I-Disease	-1	2234245
and	O	-1	2234245
the	O	-1	2234245
le@@	O	-1	2234245
sion	O	-1	2234245
was	O	-1	2234245
of	O	-1	2234245
the	O	-1	2234245
co@@	O	-1	2234245
ch@@	O	-1	2234245
le@@	O	-1	2234245
ar	O	-1	2234245
typ@@	O	-1	2234245
e.	O	-1	2234245
D@@	B-Chemical	D003676	2234245
es@@	I-Chemical	-1	2234245
fer@@	I-Chemical	-1	2234245
ri@@	I-Chemical	-1	2234245
ox@@	I-Chemical	-1	2234245
amine	I-Chemical	-1	2234245
withdrawal	O	-1	2234245
resulted	O	-1	2234245
in	O	-1	2234245
a	O	-1	2234245
complete	O	-1	2234245
recovery	O	-1	2234245
of	O	-1	2234245
visual	O	-1	2234245
function	O	-1	2234245
in	O	-1	2234245
1	O	-1	2234245
patient	O	-1	2234245
and	O	-1	2234245
partial	O	-1	2234245
recovery	O	-1	2234245
in	O	-1	2234245
3,	O	-1	2234245
and	O	-1	2234245
a	O	-1	2234245
complete	O	-1	2234245
rever@@	O	-1	2234245
s@@	O	-1	2234245
al	O	-1	2234245
of	O	-1	2234245
hearing	B-Disease	D034381	2234245
loss	I-Disease	-1	2234245
in	O	-1	2234245
3	O	-1	2234245
patients	O	-1	2234245
and	O	-1	2234245
partial	O	-1	2234245
recovery	O	-1	2234245
in	O	-1	2234245
3@@	O	-1	2234245
.	O	-1	2234245
This	O	-1	2234245
toxicity	B-Disease	D064420	2234245
appe@@	O	-1	2234245
a@@	O	-1	2234245
red	O	-1	2234245
in	O	-1	2234245
patients	O	-1	2234245
receiving	O	-1	2234245
the	O	-1	2234245
higher	O	-1	2234245
doses	O	-1	2234245
of	O	-1	2234245
des@@	B-Chemical	D003676	2234245
fer@@	I-Chemical	-1	2234245
ri@@	I-Chemical	-1	2234245
ox@@	I-Chemical	-1	2234245
amine	I-Chemical	-1	2234245
or	O	-1	2234245
co@@	O	-1	2234245
inc@@	O	-1	2234245
id@@	O	-1	2234245
ed	O	-1	2234245
with	O	-1	2234245
the	O	-1	2234245
normal@@	O	-1	2234245
ization	O	-1	2234245
of	O	-1	2234245
fer@@	O	-1	2234245
ri@@	O	-1	2234245
tin	O	-1	2234245
or	O	-1	2234245
alu@@	B-Chemical	-1	2234245
min@@	I-Chemical	-1	2234245
i@@	I-Chemical	-1	2234245
um	I-Chemical	-1	2234245
serum	O	-1	2234245
level@@	O	-1	2234245
s.	O	-1	2234245
The	O	-1	2234245
data	O	-1	2234245
indicate	O	-1	2234245
that	O	-1	2234245
a@@	B-Disease	D014786	2234245
udi@@	I-Disease	-1	2234245
o@@	I-Disease	-1	2234245
visual	I-Disease	-1	2234245
toxicity	I-Disease	-1	2234245
a@@	B-Disease	D006311	2234245
udi@@	I-Disease	-1	2234245
o@@	I-Disease	-1	2234245
visual	I-Disease	-1	2234245
toxicity	I-Disease	-1	2234245
is	O	-1	2234245
not	O	-1	2234245
an	O	-1	2234245
inf@@	O	-1	2234245
requ@@	O	-1	2234245
ent	O	-1	2234245
complication	O	-1	2234245
in	O	-1	2234245
hemo@@	O	-1	2234245
dialy@@	O	-1	2234245
zed	O	-1	2234245
patients	O	-1	2234245
receiving	O	-1	2234245
des@@	B-Chemical	D003676	2234245
fer@@	I-Chemical	-1	2234245
ri@@	I-Chemical	-1	2234245
ox@@	I-Chemical	-1	2234245
amine	I-Chemical	-1	2234245
.	O	-1	2234245
P@@	O	-1	2234245
er@@	O	-1	2234245
iod@@	O	-1	2234245
ical	O	-1	2234245
a@@	O	-1	2234245
udi@@	O	-1	2234245
o@@	O	-1	2234245
visual	O	-1	2234245
monit@@	O	-1	2234245
or@@	O	-1	2234245
ing	O	-1	2234245
should	O	-1	2234245
be	O	-1	2234245
performed	O	-1	2234245
on	O	-1	2234245
hemo@@	O	-1	2234245
dialy@@	O	-1	2234245
zed	O	-1	2234245
patients	O	-1	2234245
receiving	O	-1	2234245
the	O	-1	2234245
drug	O	-1	2234245
in	O	-1	2234245
or@@	O	-1	2234245
der	O	-1	2234245
to	O	-1	2234245
det@@	O	-1	2234245
ect	O	-1	2234245
adverse	O	-1	2234245
effects	O	-1	2234245
as	O	-1	2234245
early	O	-1	2234245
as	O	-1	2234245
possib@@	O	-1	2234245
le@@	O	-1	2234245
.	O	-1	2234245

M@@	B-Disease	D009157	2385256
y@@	I-Disease	-1	2385256
as@@	I-Disease	-1	2385256
th@@	I-Disease	-1	2385256
en@@	I-Disease	-1	2385256
ia	I-Disease	-1	2385256
gra@@	I-Disease	-1	2385256
v@@	I-Disease	-1	2385256
is	I-Disease	-1	2385256
present@@	O	-1	2385256
ing	O	-1	2385256
as	O	-1	2385256
we@@	O	-1	2385256
ak@@	O	-1	2385256
ness	O	-1	2385256
after	O	-1	2385256
mag@@	B-Chemical	D008274	2385256
ne@@	I-Chemical	-1	2385256
si@@	I-Chemical	-1	2385256
um	I-Chemical	-1	2385256
administr@@	O	-1	2385256
ation.	O	-1	2385256
We	O	-1	2385256
studied	O	-1	2385256
a	O	-1	2385256
patient	O	-1	2385256
with	O	-1	2385256
no	O	-1	2385256
prior	O	-1	2385256
hist@@	O	-1	2385256
ory	O	-1	2385256
of	O	-1	2385256
neuro@@	B-Disease	D009468	2385256
mus@@	I-Disease	-1	2385256
cular	I-Disease	-1	2385256
disease	I-Disease	-1	2385256
who	O	-1	2385256
b@@	O	-1	2385256
ec@@	O	-1	2385256
am@@	O	-1	2385256
e	O	-1	2385256
vi@@	O	-1	2385256
r@@	O	-1	2385256
tu@@	O	-1	2385256
ally	O	-1	2385256
qu@@	B-Disease	D011782	2385256
ad@@	I-Disease	-1	2385256
ri@@	I-Disease	-1	2385256
ple@@	I-Disease	-1	2385256
g@@	I-Disease	-1	2385256
ic	I-Disease	-1	2385256
after	O	-1	2385256
pa@@	O	-1	2385256
ren@@	O	-1	2385256
ter@@	O	-1	2385256
al	O	-1	2385256
mag@@	B-Chemical	D008274	2385256
ne@@	I-Chemical	-1	2385256
si@@	I-Chemical	-1	2385256
um	I-Chemical	-1	2385256
administration	O	-1	2385256
for	O	-1	2385256
pre@@	B-Disease	D011225	2385256
ec@@	I-Disease	-1	2385256
l@@	I-Disease	-1	2385256
amp@@	I-Disease	-1	2385256
sia	I-Disease	-1	2385256
.	O	-1	2385256
The	O	-1	2385256
serum	O	-1	2385256
mag@@	B-Chemical	D008274	2385256
ne@@	I-Chemical	-1	2385256
si@@	I-Chemical	-1	2385256
um	I-Chemical	-1	2385256
concentration	O	-1	2385256
was	O	-1	2385256
3.@@	O	-1	2385256
0	O	-1	2385256
m@@	O	-1	2385256
E@@	O	-1	2385256
q@@	O	-1	2385256
/@@	O	-1	2385256
L@@	O	-1	2385256
,	O	-1	2385256
which	O	-1	2385256
is	O	-1	2385256
us@@	O	-1	2385256
ually	O	-1	2385256
well	O	-1	2385256
toler@@	O	-1	2385256
ated.	O	-1	2385256
The	O	-1	2385256
mag@@	B-Chemical	D008274	2385256
ne@@	I-Chemical	-1	2385256
si@@	I-Chemical	-1	2385256
um	I-Chemical	-1	2385256
was	O	-1	2385256
sto@@	O	-1	2385256
pp@@	O	-1	2385256
ed	O	-1	2385256
and	O	-1	2385256
sh@@	O	-1	2385256
e	O	-1	2385256
reco@@	O	-1	2385256
vered	O	-1	2385256
over	O	-1	2385256
a	O	-1	2385256
fe@@	O	-1	2385256
w	O	-1	2385256
days.	O	-1	2385256
W@@	O	-1	2385256
h@@	O	-1	2385256
ile	O	-1	2385256
sh@@	O	-1	2385256
e	O	-1	2385256
was	O	-1	2385256
we@@	O	-1	2385256
ak@@	O	-1	2385256
,	O	-1	2385256
2-@@	O	-1	2385256
H@@	O	-1	2385256
z	O	-1	2385256
repe@@	O	-1	2385256
ti@@	O	-1	2385256
tive	O	-1	2385256
stimulation	O	-1	2385256
revealed	O	-1	2385256
a	O	-1	2385256
dec@@	O	-1	2385256
re@@	O	-1	2385256
ment	O	-1	2385256
without	O	-1	2385256
significant	O	-1	2385256
fac@@	O	-1	2385256
il@@	O	-1	2385256
it@@	O	-1	2385256
ation	O	-1	2385256
at	O	-1	2385256
ra@@	O	-1	2385256
pid	O	-1	2385256
rat@@	O	-1	2385256
es	O	-1	2385256
or	O	-1	2385256
after	O	-1	2385256
ex@@	O	-1	2385256
er@@	O	-1	2385256
ci@@	O	-1	2385256
se@@	O	-1	2385256
,	O	-1	2385256
suggesting	O	-1	2385256
post@@	B-Disease	D009468	2385256
syn@@	I-Disease	-1	2385256
ap@@	I-Disease	-1	2385256
tic	I-Disease	-1	2385256
neuro@@	I-Disease	-1	2385256
mus@@	I-Disease	-1	2385256
cular	I-Disease	-1	2385256
block@@	I-Disease	-1	2385256
ade	I-Disease	-1	2385256
.	O	-1	2385256
After	O	-1	2385256
h@@	O	-1	2385256
er	O	-1	2385256
st@@	O	-1	2385256
ren@@	O	-1	2385256
g@@	O	-1	2385256
th	O	-1	2385256
retur@@	O	-1	2385256
ne@@	O	-1	2385256
d,	O	-1	2385256
repe@@	O	-1	2385256
ti@@	O	-1	2385256
tive	O	-1	2385256
stimulation	O	-1	2385256
was	O	-1	2385256
normal@@	O	-1	2385256
,	O	-1	2385256
but	O	-1	2385256
single	O	-1	2385256
fib@@	O	-1	2385256
er	O	-1	2385256
E@@	O	-1	2385256
M@@	O	-1	2385256
G	O	-1	2385256
revealed	O	-1	2385256
increased	O	-1	2385256
j@@	O	-1	2385256
it@@	O	-1	2385256
ter	O	-1	2385256
and	O	-1	2385256
block@@	O	-1	2385256
ing.	O	-1	2385256
H@@	O	-1	2385256
er	O	-1	2385256
acet@@	B-Chemical	D000109	2385256
ylcholine	I-Chemical	-1	2385256
receptor	O	-1	2385256
anti@@	O	-1	2385256
body	O	-1	2385256
level	O	-1	2385256
was	O	-1	2385256
mark@@	O	-1	2385256
ed@@	O	-1	2385256
ly	O	-1	2385256
elev@@	O	-1	2385256
ated.	O	-1	2385256
Although	O	-1	2385256
par@@	B-Disease	D010243	2385256
aly@@	I-Disease	-1	2385256
sis	I-Disease	-1	2385256
after	O	-1	2385256
mag@@	B-Chemical	D008274	2385256
ne@@	I-Chemical	-1	2385256
si@@	I-Chemical	-1	2385256
um	I-Chemical	-1	2385256
administration	O	-1	2385256
has	O	-1	2385256
been	O	-1	2385256
descri@@	O	-1	2385256
bed	O	-1	2385256
in	O	-1	2385256
patients	O	-1	2385256
with	O	-1	2385256
known	O	-1	2385256
my@@	B-Disease	D009157	2385256
as@@	I-Disease	-1	2385256
th@@	I-Disease	-1	2385256
en@@	I-Disease	-1	2385256
ia	I-Disease	-1	2385256
gra@@	I-Disease	-1	2385256
v@@	I-Disease	-1	2385256
is	I-Disease	-1	2385256
,	O	-1	2385256
it	O	-1	2385256
has	O	-1	2385256
not	O	-1	2385256
previously	O	-1	2385256
been	O	-1	2385256
reported	O	-1	2385256
to	O	-1	2385256
be	O	-1	2385256
the	O	-1	2385256
initial	O	-1	2385256
or	O	-1	2385256
only	O	-1	2385256
man@@	O	-1	2385256
if@@	O	-1	2385256
est@@	O	-1	2385256
ation	O	-1	2385256
of	O	-1	2385256
the	O	-1	2385256
disease.	O	-1	2385256
Patients	O	-1	2385256
who	O	-1	2385256
are	O	-1	2385256
un@@	O	-1	2385256
us@@	O	-1	2385256
ually	O	-1	2385256
sensitive	O	-1	2385256
to	O	-1	2385256
the	O	-1	2385256
neuro@@	O	-1	2385256
mus@@	O	-1	2385256
cular	O	-1	2385256
effects	O	-1	2385256
of	O	-1	2385256
mag@@	B-Chemical	D008274	2385256
ne@@	I-Chemical	-1	2385256
si@@	I-Chemical	-1	2385256
um	I-Chemical	-1	2385256
should	O	-1	2385256
be	O	-1	2385256
sus@@	O	-1	2385256
p@@	O	-1	2385256
ected	O	-1	2385256
of	O	-1	2385256
ha@@	O	-1	2385256
ving	O	-1	2385256
an	O	-1	2385256
underlying	O	-1	2385256
disor@@	B-Disease	D020511	2385256
der	I-Disease	-1	2385256
of	I-Disease	-1	2385256
neuro@@	I-Disease	-1	2385256
mus@@	I-Disease	-1	2385256
cular	I-Disease	-1	2385256
trans@@	I-Disease	-1	2385256
mission	I-Disease	-1	2385256
.	O	-1	2385256

Ch@@	B-Chemical	C004656	2505783
loro@@	I-Chemical	-1	2505783
acet@@	I-Chemical	-1	2505783
al@@	I-Chemical	-1	2505783
de@@	I-Chemical	-1	2505783
hy@@	I-Chemical	-1	2505783
de	I-Chemical	-1	2505783
and	O	-1	2505783
its	O	-1	2505783
cont@@	O	-1	2505783
ri@@	O	-1	2505783
bu@@	O	-1	2505783
tion	O	-1	2505783
to	O	-1	2505783
uro@@	O	-1	2505783
toxicity	O	-1	2505783
during	O	-1	2505783
treatment	O	-1	2505783
with	O	-1	2505783
cyclophosph@@	B-Chemical	D003520	2505783
amide	I-Chemical	-1	2505783
or	O	-1	2505783
if@@	B-Chemical	D007069	2505783
os@@	I-Chemical	-1	2505783
f@@	I-Chemical	-1	2505783
amide	I-Chemical	-1	2505783
.	O	-1	2505783
An	O	-1	2505783
experimental	O	-1	2505783
stud@@	O	-1	2505783
y@@	O	-1	2505783
/@@	O	-1	2505783
sh@@	O	-1	2505783
ort	O	-1	2505783
com@@	O	-1	2505783
mun@@	O	-1	2505783
ic@@	O	-1	2505783
ation.	O	-1	2505783
B@@	O	-1	2505783
as@@	O	-1	2505783
ed	O	-1	2505783
on	O	-1	2505783
clinical	O	-1	2505783
dat@@	O	-1	2505783
a,	O	-1	2505783
indicating	O	-1	2505783
that	O	-1	2505783
ch@@	B-Chemical	C004656	2505783
loro@@	I-Chemical	-1	2505783
acet@@	I-Chemical	-1	2505783
al@@	I-Chemical	-1	2505783
de@@	I-Chemical	-1	2505783
hy@@	I-Chemical	-1	2505783
de	I-Chemical	-1	2505783
(	O	-1	2505783
CA@@	B-Chemical	C004656	2505783
A	I-Chemical	-1	2505783
)	O	-1	2505783
is	O	-1	2505783
an	O	-1	2505783
important	O	-1	2505783
metabol@@	O	-1	2505783
ite	O	-1	2505783
of	O	-1	2505783
ox@@	O	-1	2505783
az@@	O	-1	2505783
a@@	O	-1	2505783
phosph@@	O	-1	2505783
or@@	O	-1	2505783
ine	O	-1	2505783
cyto@@	O	-1	2505783
st@@	O	-1	2505783
ati@@	O	-1	2505783
c@@	O	-1	2505783
s,	O	-1	2505783
an	O	-1	2505783
experimental	O	-1	2505783
study	O	-1	2505783
was	O	-1	2505783
car@@	O	-1	2505783
ri@@	O	-1	2505783
ed	O	-1	2505783
out	O	-1	2505783
in	O	-1	2505783
or@@	O	-1	2505783
der	O	-1	2505783
to	O	-1	2505783
el@@	O	-1	2505783
uc@@	O	-1	2505783
id@@	O	-1	2505783
ate	O	-1	2505783
the	O	-1	2505783
role	O	-1	2505783
of	O	-1	2505783
CA@@	B-Chemical	C004656	2505783
A	I-Chemical	-1	2505783
in	O	-1	2505783
the	O	-1	2505783
development	O	-1	2505783
of	O	-1	2505783
hemorrh@@	B-Disease	D006470	2505783
ag@@	I-Disease	-1	2505783
ic	I-Disease	-1	2505783
cys@@	I-Disease	-1	2505783
ti@@	I-Disease	-1	2505783
tis	I-Disease	-1	2505783
hemorrh@@	B-Disease	D003556	2505783
ag@@	I-Disease	-1	2505783
ic	I-Disease	-1	2505783
cys@@	I-Disease	-1	2505783
ti@@	I-Disease	-1	2505783
tis	I-Disease	-1	2505783
.	O	-1	2505783
The	O	-1	2505783
data	O	-1	2505783
demon@@	O	-1	2505783
st@@	O	-1	2505783
rate	O	-1	2505783
that	O	-1	2505783
CA@@	B-Chemical	C004656	2505783
A	I-Chemical	-1	2505783
after	O	-1	2505783
i.v@@	O	-1	2505783
.	O	-1	2505783
administration	O	-1	2505783
does	O	-1	2505783
not	O	-1	2505783
cont@@	O	-1	2505783
rib@@	O	-1	2505783
ute	O	-1	2505783
to	O	-1	2505783
bladder	B-Disease	D001745	2505783
damage	I-Disease	-1	2505783
.	O	-1	2505783
Whe@@	O	-1	2505783
n	O	-1	2505783
insti@@	O	-1	2505783
lled	O	-1	2505783
direc@@	O	-1	2505783
tly	O	-1	2505783
into	O	-1	2505783
the	O	-1	2505783
blad@@	O	-1	2505783
der@@	O	-1	2505783
,	O	-1	2505783
CA@@	B-Chemical	C004656	2505783
A	I-Chemical	-1	2505783
ex@@	O	-1	2505783
er@@	O	-1	2505783
ts	O	-1	2505783
uro@@	O	-1	2505783
toxic	O	-1	2505783
effect@@	O	-1	2505783
s,	O	-1	2505783
it	O	-1	2505783
is@@	O	-1	2505783
,	O	-1	2505783
however,	O	-1	2505783
sus@@	O	-1	2505783
cep@@	O	-1	2505783
ti@@	O	-1	2505783
ble	O	-1	2505783
to	O	-1	2505783
de@@	O	-1	2505783
tox@@	O	-1	2505783
ification	O	-1	2505783
with	O	-1	2505783
m@@	B-Chemical	D015080	2505783
es@@	I-Chemical	-1	2505783
n@@	I-Chemical	-1	2505783
a	I-Chemical	-1	2505783
.	O	-1	2505783

S@@	O	-1	2515254
o@@	O	-1	2515254
ur@@	O	-1	2515254
ce	O	-1	2515254
of	O	-1	2515254
pain	B-Disease	D010146	2515254
and	O	-1	2515254
pri@@	O	-1	2515254
mi@@	O	-1	2515254
tive	O	-1	2515254
dysfunction	O	-1	2515254
in	O	-1	2515254
migra@@	B-Disease	D008881	2515254
ine	I-Disease	-1	2515254
:	O	-1	2515254
an	O	-1	2515254
id@@	O	-1	2515254
en@@	O	-1	2515254
tical	O	-1	2515254
sit@@	O	-1	2515254
e@@	O	-1	2515254
?	O	-1	2515254
Tw@@	O	-1	2515254
ent@@	O	-1	2515254
y	O	-1	2515254
common	O	-1	2515254
migra@@	B-Disease	D008881	2515254
ine	I-Disease	-1	2515254
patients	O	-1	2515254
received	O	-1	2515254
a	O	-1	2515254
one	O	-1	2515254
si@@	O	-1	2515254
ded	O	-1	2515254
fron@@	O	-1	2515254
tot@@	O	-1	2515254
em@@	O	-1	2515254
por@@	O	-1	2515254
al	O	-1	2515254
ap@@	O	-1	2515254
plic@@	O	-1	2515254
ation	O	-1	2515254
of	O	-1	2515254
nitro@@	B-Chemical	D005996	2515254
glycer@@	I-Chemical	-1	2515254
in	I-Chemical	-1	2515254
(10	O	-1	2515254
patient@@	O	-1	2515254
s)	O	-1	2515254
or	O	-1	2515254
placebo	O	-1	2515254
o@@	O	-1	2515254
int@@	O	-1	2515254
ment	O	-1	2515254
(10	O	-1	2515254
patient@@	O	-1	2515254
s)	O	-1	2515254
in	O	-1	2515254
a	O	-1	2515254
dou@@	O	-1	2515254
ble	O	-1	2515254
bl@@	O	-1	2515254
ind	O	-1	2515254
study.	O	-1	2515254
E@@	O	-1	2515254
arly	O	-1	2515254
onset	O	-1	2515254
migra@@	B-Disease	D008881	2515254
ine	I-Disease	-1	2515254
at@@	O	-1	2515254
tac@@	O	-1	2515254
k@@	O	-1	2515254
s	O	-1	2515254
were	O	-1	2515254
induced	O	-1	2515254
by	O	-1	2515254
nitro@@	B-Chemical	D005996	2515254
glycer@@	I-Chemical	-1	2515254
in	I-Chemical	-1	2515254
in	O	-1	2515254
seven	O	-1	2515254
out	O	-1	2515254
of	O	-1	2515254
10	O	-1	2515254
patients	O	-1	2515254
versus	O	-1	2515254
no	O	-1	2515254
patient	O	-1	2515254
in	O	-1	2515254
the	O	-1	2515254
placebo	O	-1	2515254
group.	O	-1	2515254
S@@	O	-1	2515254
ub@@	O	-1	2515254
sequ@@	O	-1	2515254
ently	O	-1	2515254
20	O	-1	2515254
migra@@	B-Disease	D008881	2515254
ine	I-Disease	-1	2515254
patients,	O	-1	2515254
who	O	-1	2515254
developed	O	-1	2515254
an	O	-1	2515254
early	O	-1	2515254
onset	O	-1	2515254
at@@	O	-1	2515254
tac@@	O	-1	2515254
k	O	-1	2515254
with	O	-1	2515254
fron@@	O	-1	2515254
tot@@	O	-1	2515254
em@@	O	-1	2515254
por@@	O	-1	2515254
al	O	-1	2515254
nitro@@	B-Chemical	D005996	2515254
glycer@@	I-Chemical	-1	2515254
in	I-Chemical	-1	2515254
,	O	-1	2515254
received	O	-1	2515254
the	O	-1	2515254
drug	O	-1	2515254
in	O	-1	2515254
a	O	-1	2515254
second	O	-1	2515254
induction	O	-1	2515254
test	O	-1	2515254
at	O	-1	2515254
other	O	-1	2515254
body	O	-1	2515254
a@@	O	-1	2515254
reas@@	O	-1	2515254
.	O	-1	2515254
No	O	-1	2515254
early	O	-1	2515254
onset	O	-1	2515254
migra@@	B-Disease	D008881	2515254
ine	I-Disease	-1	2515254
was	O	-1	2515254
obser@@	O	-1	2515254
ved.	O	-1	2515254
Th@@	O	-1	2515254
us	O	-1	2515254
the	O	-1	2515254
migra@@	B-Disease	D008881	2515254
ine	I-Disease	-1	2515254
-@@	O	-1	2515254
induc@@	O	-1	2515254
ing	O	-1	2515254
effect	O	-1	2515254
of	O	-1	2515254
nitro@@	B-Chemical	D005996	2515254
glycer@@	I-Chemical	-1	2515254
in	I-Chemical	-1	2515254
se@@	O	-1	2515254
em@@	O	-1	2515254
s	O	-1	2515254
to	O	-1	2515254
depen@@	O	-1	2515254
d	O	-1	2515254
on	O	-1	2515254
direct	O	-1	2515254
stimulation	O	-1	2515254
of	O	-1	2515254
the	O	-1	2515254
h@@	O	-1	2515254
ab@@	O	-1	2515254
it@@	O	-1	2515254
ual	O	-1	2515254
sit@@	O	-1	2515254
e	O	-1	2515254
of	O	-1	2515254
pain	B-Disease	D010146	2515254
,	O	-1	2515254
suggesting	O	-1	2515254
that	O	-1	2515254
the	O	-1	2515254
fron@@	O	-1	2515254
tot@@	O	-1	2515254
em@@	O	-1	2515254
por@@	O	-1	2515254
al	O	-1	2515254
regi@@	O	-1	2515254
on	O	-1	2515254
is	O	-1	2515254
of	O	-1	2515254
c@@	O	-1	2515254
r@@	O	-1	2515254
uc@@	O	-1	2515254
ial	O	-1	2515254
import@@	O	-1	2515254
ance	O	-1	2515254
in	O	-1	2515254
the	O	-1	2515254
development	O	-1	2515254
of	O	-1	2515254
a	O	-1	2515254
migra@@	B-Disease	D008881	2515254
ine	I-Disease	-1	2515254
cri@@	O	-1	2515254
sis.	O	-1	2515254
This	O	-1	2515254
is	O	-1	2515254
not	O	-1	2515254
consist@@	O	-1	2515254
ent	O	-1	2515254
with	O	-1	2515254
a	O	-1	2515254
C@@	O	-1	2515254
N@@	O	-1	2515254
S	O	-1	2515254
or@@	O	-1	2515254
ig@@	O	-1	2515254
in	O	-1	2515254
of	O	-1	2515254
migra@@	B-Disease	D008881	2515254
ine	I-Disease	-1	2515254
at@@	O	-1	2515254
tac@@	O	-1	2515254
k@@	O	-1	2515254
.	O	-1	2515254

C@@	B-Chemical	C084599	2572625
lo@@	I-Chemical	-1	2572625
ti@@	I-Chemical	-1	2572625
az@@	I-Chemical	-1	2572625
epam	I-Chemical	-1	2572625
-induced	O	-1	2572625
acute	O	-1	2572625
hepatitis	B-Disease	D056486	2572625
.	O	-1	2572625
We	O	-1	2572625
report	O	-1	2572625
the	O	-1	2572625
case	O	-1	2572625
of	O	-1	2572625
a	O	-1	2572625
patient	O	-1	2572625
who	O	-1	2572625
developed	O	-1	2572625
acute	O	-1	2572625
hepatitis	B-Disease	D056486	2572625
with	O	-1	2572625
exten@@	B-Disease	D047508	2572625
sive	I-Disease	-1	2572625
hepat@@	I-Disease	-1	2572625
oc@@	I-Disease	-1	2572625
ell@@	I-Disease	-1	2572625
ular	I-Disease	-1	2572625
necro@@	I-Disease	-1	2572625
sis	I-Disease	-1	2572625
,	O	-1	2572625
7	O	-1	2572625
months	O	-1	2572625
after	O	-1	2572625
the	O	-1	2572625
onset	O	-1	2572625
of	O	-1	2572625
administration	O	-1	2572625
of	O	-1	2572625
clo@@	B-Chemical	C084599	2572625
ti@@	I-Chemical	-1	2572625
az@@	I-Chemical	-1	2572625
epam	I-Chemical	-1	2572625
,	O	-1	2572625
a	O	-1	2572625
thi@@	B-Chemical	C013295	2572625
en@@	I-Chemical	-1	2572625
odi@@	I-Chemical	-1	2572625
azepine	I-Chemical	-1	2572625
der@@	O	-1	2572625
i@@	O	-1	2572625
v@@	O	-1	2572625
ati@@	O	-1	2572625
ve.	O	-1	2572625
C@@	B-Chemical	C084599	2572625
lo@@	I-Chemical	-1	2572625
ti@@	I-Chemical	-1	2572625
az@@	I-Chemical	-1	2572625
epam	I-Chemical	-1	2572625
withdrawal	O	-1	2572625
was	O	-1	2572625
followed	O	-1	2572625
by	O	-1	2572625
pro@@	O	-1	2572625
m@@	O	-1	2572625
p@@	O	-1	2572625
t	O	-1	2572625
reco@@	O	-1	2572625
ver@@	O	-1	2572625
y.	O	-1	2572625
The	O	-1	2572625
administration	O	-1	2572625
of	O	-1	2572625
several	O	-1	2572625
b@@	B-Chemical	D001569	2572625
enz@@	I-Chemical	-1	2572625
odi@@	I-Chemical	-1	2572625
azep@@	I-Chemical	-1	2572625
in@@	I-Chemical	-1	2572625
es	I-Chemical	-1	2572625
,	O	-1	2572625
chem@@	O	-1	2572625
ically	O	-1	2572625
related	O	-1	2572625
to	O	-1	2572625
clo@@	B-Chemical	C084599	2572625
ti@@	I-Chemical	-1	2572625
az@@	I-Chemical	-1	2572625
epam	I-Chemical	-1	2572625
,	O	-1	2572625
did	O	-1	2572625
not	O	-1	2572625
inter@@	O	-1	2572625
f@@	O	-1	2572625
ere	O	-1	2572625
with	O	-1	2572625
recovery	O	-1	2572625
and	O	-1	2572625
did	O	-1	2572625
not	O	-1	2572625
induce	O	-1	2572625
any	O	-1	2572625
rel@@	O	-1	2572625
ap@@	O	-1	2572625
se	O	-1	2572625
of	O	-1	2572625
hepatitis	B-Disease	D056486	2572625
.	O	-1	2572625
This	O	-1	2572625
observ@@	O	-1	2572625
ation	O	-1	2572625
show@@	O	-1	2572625
s	O	-1	2572625
that	O	-1	2572625
clo@@	B-Chemical	C084599	2572625
ti@@	I-Chemical	-1	2572625
az@@	I-Chemical	-1	2572625
epam	I-Chemical	-1	2572625
can	O	-1	2572625
induce	O	-1	2572625
acute	O	-1	2572625
hepatitis	B-Disease	D056486	2572625
and	O	-1	2572625
suggests	O	-1	2572625
that	O	-1	2572625
there	O	-1	2572625
is	O	-1	2572625
no	O	-1	2572625
cros@@	O	-1	2572625
s	O	-1	2572625
hepat@@	B-Disease	D056486	2572625
otoxicity	I-Disease	-1	2572625
between	O	-1	2572625
clo@@	B-Chemical	C084599	2572625
ti@@	I-Chemical	-1	2572625
az@@	I-Chemical	-1	2572625
epam	I-Chemical	-1	2572625
and	O	-1	2572625
several	O	-1	2572625
b@@	B-Chemical	D001569	2572625
enz@@	I-Chemical	-1	2572625
odi@@	I-Chemical	-1	2572625
azep@@	I-Chemical	-1	2572625
in@@	I-Chemical	-1	2572625
es	I-Chemical	-1	2572625
.	O	-1	2572625

A@@	O	-1	2632720
r@@	O	-1	2632720
ter@@	O	-1	2632720
ial	O	-1	2632720
hypertension	B-Disease	D006973	2632720
as	O	-1	2632720
a	O	-1	2632720
complication	O	-1	2632720
of	O	-1	2632720
prolonged	O	-1	2632720
ke@@	B-Chemical	D007654	2632720
to@@	I-Chemical	-1	2632720
con@@	I-Chemical	-1	2632720
azole	I-Chemical	-1	2632720
treatment.	O	-1	2632720
Two	O	-1	2632720
of	O	-1	2632720
14	O	-1	2632720
patients	O	-1	2632720
with	O	-1	2632720
C@@	B-Disease	D003480	2632720
us@@	I-Disease	-1	2632720
h@@	I-Disease	-1	2632720
ing@@	I-Disease	-1	2632720
's	I-Disease	-1	2632720
syndrome	I-Disease	-1	2632720
treated	O	-1	2632720
on	O	-1	2632720
a	O	-1	2632720
long-term	O	-1	2632720
b@@	O	-1	2632720
asis	O	-1	2632720
with	O	-1	2632720
ke@@	B-Chemical	D007654	2632720
to@@	I-Chemical	-1	2632720
con@@	I-Chemical	-1	2632720
azole	I-Chemical	-1	2632720
developed	O	-1	2632720
su@@	O	-1	2632720
st@@	O	-1	2632720
ained	O	-1	2632720
hypertension	B-Disease	D006973	2632720
.	O	-1	2632720
In	O	-1	2632720
both	O	-1	2632720
cases	O	-1	2632720
normal	O	-1	2632720
plasma	O	-1	2632720
and	O	-1	2632720
urinary	O	-1	2632720
free	O	-1	2632720
cor@@	B-Chemical	D006854	2632720
tis@@	I-Chemical	-1	2632720
ol	I-Chemical	-1	2632720
levels	O	-1	2632720
had	O	-1	2632720
been	O	-1	2632720
achi@@	O	-1	2632720
ev@@	O	-1	2632720
ed	O	-1	2632720
following	O	-1	2632720
ke@@	B-Chemical	D007654	2632720
to@@	I-Chemical	-1	2632720
con@@	I-Chemical	-1	2632720
azole	I-Chemical	-1	2632720
therapy,	O	-1	2632720
y@@	O	-1	2632720
et	O	-1	2632720
continu@@	O	-1	2632720
ous	O	-1	2632720
blood	O	-1	2632720
pressure	O	-1	2632720
monit@@	O	-1	2632720
or@@	O	-1	2632720
ing	O	-1	2632720
demonstrated	O	-1	2632720
hypertension	B-Disease	D006973	2632720
3@@	O	-1	2632720
1	O	-1	2632720
(@@	O	-1	2632720
patient	O	-1	2632720
1)	O	-1	2632720
and	O	-1	2632720
5@@	O	-1	2632720
2	O	-1	2632720
weeks	O	-1	2632720
(@@	O	-1	2632720
patient	O	-1	2632720
2)	O	-1	2632720
after	O	-1	2632720
treatment.	O	-1	2632720
In	O	-1	2632720
patient	O	-1	2632720
1,	O	-1	2632720
plasma	O	-1	2632720
levels	O	-1	2632720
of	O	-1	2632720
de@@	B-Chemical	D003900	2632720
oxy@@	I-Chemical	-1	2632720
cortico@@	I-Chemical	-1	2632720
sterone	I-Chemical	-1	2632720
and	O	-1	2632720
1@@	B-Chemical	D003350	2632720
1-@@	I-Chemical	-1	2632720
de@@	I-Chemical	-1	2632720
oxy@@	I-Chemical	-1	2632720
cor@@	I-Chemical	-1	2632720
tis@@	I-Chemical	-1	2632720
ol	I-Chemical	-1	2632720
were	O	-1	2632720
elev@@	O	-1	2632720
ated.	O	-1	2632720
In	O	-1	2632720
patient	O	-1	2632720
2,	O	-1	2632720
in	O	-1	2632720
addition	O	-1	2632720
to	O	-1	2632720
an	O	-1	2632720
increase	O	-1	2632720
in	O	-1	2632720
both	O	-1	2632720
de@@	B-Chemical	D003900	2632720
oxy@@	I-Chemical	-1	2632720
cortico@@	I-Chemical	-1	2632720
sterone	I-Chemical	-1	2632720
and	O	-1	2632720
1@@	B-Chemical	D003350	2632720
1-@@	I-Chemical	-1	2632720
de@@	I-Chemical	-1	2632720
oxy@@	I-Chemical	-1	2632720
cor@@	I-Chemical	-1	2632720
tis@@	I-Chemical	-1	2632720
ol	I-Chemical	-1	2632720
level@@	O	-1	2632720
s,	O	-1	2632720
plasma	O	-1	2632720
al@@	B-Chemical	D000450	2632720
do@@	I-Chemical	-1	2632720
sterone	I-Chemical	-1	2632720
values	O	-1	2632720
were	O	-1	2632720
ra@@	O	-1	2632720
i@@	O	-1	2632720
se@@	O	-1	2632720
d,	O	-1	2632720
with	O	-1	2632720
a	O	-1	2632720
concomit@@	O	-1	2632720
ant	O	-1	2632720
sup@@	O	-1	2632720
pression	O	-1	2632720
of	O	-1	2632720
ren@@	O	-1	2632720
in	O	-1	2632720
level@@	O	-1	2632720
s.	O	-1	2632720
Our	O	-1	2632720
findings	O	-1	2632720
show	O	-1	2632720
that	O	-1	2632720
long-term	O	-1	2632720
treatment	O	-1	2632720
with	O	-1	2632720
high	O	-1	2632720
doses	O	-1	2632720
of	O	-1	2632720
ke@@	B-Chemical	D007654	2632720
to@@	I-Chemical	-1	2632720
con@@	I-Chemical	-1	2632720
azole	I-Chemical	-1	2632720
may	O	-1	2632720
induce	O	-1	2632720
enzyme	O	-1	2632720
block@@	O	-1	2632720
ade	O	-1	2632720
lead@@	O	-1	2632720
ing	O	-1	2632720
to	O	-1	2632720
min@@	O	-1	2632720
er@@	O	-1	2632720
al@@	O	-1	2632720
oc@@	O	-1	2632720
or@@	O	-1	2632720
tico@@	O	-1	2632720
id@@	O	-1	2632720
-@@	O	-1	2632720
related	O	-1	2632720
hypertension	B-Disease	D006973	2632720
.	O	-1	2632720

Eff@@	O	-1	2670794
ects	O	-1	2670794
of	O	-1	2670794
an	O	-1	2670794
inhibitor	O	-1	2670794
of	O	-1	2670794
angiotens@@	B-Chemical	D000809	2670794
in	I-Chemical	-1	2670794
conver@@	O	-1	2670794
ting	O	-1	2670794
enzyme	O	-1	2670794
(	O	-1	2670794
C@@	B-Chemical	D002216	2670794
ap@@	I-Chemical	-1	2670794
to@@	I-Chemical	-1	2670794
pri@@	I-Chemical	-1	2670794
l	I-Chemical	-1	2670794
)	O	-1	2670794
on	O	-1	2670794
pulmonary	B-Disease	D011665	2670794
and	I-Disease	-1	2670794
renal	I-Disease	-1	2670794
in@@	I-Disease	-1	2670794
suffici@@	I-Disease	-1	2670794
ency	I-Disease	-1	2670794
pulmonary	B-Disease	D051437	2670794
and	I-Disease	-1	2670794
renal	I-Disease	-1	2670794
in@@	I-Disease	-1	2670794
suffici@@	I-Disease	-1	2670794
ency	I-Disease	-1	2670794
due	O	-1	2670794
to	O	-1	2670794
intra@@	B-Disease	D004211	2670794
vascular	I-Disease	-1	2670794
co@@	I-Disease	-1	2670794
ag@@	I-Disease	-1	2670794
ulation	I-Disease	-1	2670794
in	O	-1	2670794
the	O	-1	2670794
rat@@	O	-1	2670794
.	O	-1	2670794
In@@	O	-1	2670794
duction	O	-1	2670794
of	O	-1	2670794
intra@@	B-Disease	D004211	2670794
vascular	I-Disease	-1	2670794
co@@	I-Disease	-1	2670794
ag@@	I-Disease	-1	2670794
ulation	I-Disease	-1	2670794
and	O	-1	2670794
inhibition	O	-1	2670794
of	O	-1	2670794
fib@@	O	-1	2670794
r@@	O	-1	2670794
in@@	O	-1	2670794
oly@@	O	-1	2670794
sis	O	-1	2670794
by	O	-1	2670794
injection	O	-1	2670794
of	O	-1	2670794
throm@@	O	-1	2670794
bin	O	-1	2670794
and	O	-1	2670794
tran@@	B-Chemical	D014148	2670794
ex@@	I-Chemical	-1	2670794
am@@	I-Chemical	-1	2670794
ic	I-Chemical	-1	2670794
acid	I-Chemical	-1	2670794
(	O	-1	2670794
AM@@	B-Chemical	D014148	2670794
C@@	I-Chemical	-1	2670794
A	I-Chemical	-1	2670794
)	O	-1	2670794
in	O	-1	2670794
the	O	-1	2670794
rat	O	-1	2670794
gi@@	O	-1	2670794
v@@	O	-1	2670794
es	O	-1	2670794
ri@@	O	-1	2670794
se	O	-1	2670794
to	O	-1	2670794
pulmonary	B-Disease	D011665	2670794
and	I-Disease	-1	2670794
renal	I-Disease	-1	2670794
in@@	I-Disease	-1	2670794
suffici@@	I-Disease	-1	2670794
ency	I-Disease	-1	2670794
pulmonary	B-Disease	D051437	2670794
and	I-Disease	-1	2670794
renal	I-Disease	-1	2670794
in@@	I-Disease	-1	2670794
suffici@@	I-Disease	-1	2670794
ency	I-Disease	-1	2670794
re@@	O	-1	2670794
se@@	O	-1	2670794
m@@	O	-1	2670794
bl@@	O	-1	2670794
ing	O	-1	2670794
that	O	-1	2670794
occur@@	O	-1	2670794
r@@	O	-1	2670794
ing	O	-1	2670794
after	O	-1	2670794
tra@@	B-Disease	D014947	2670794
um@@	I-Disease	-1	2670794
a	I-Disease	-1	2670794
or	O	-1	2670794
se@@	B-Disease	D018805	2670794
p@@	I-Disease	-1	2670794
sis	I-Disease	-1	2670794
in	O	-1	2670794
man@@	O	-1	2670794
.	O	-1	2670794
In@@	O	-1	2670794
j@@	O	-1	2670794
ection	O	-1	2670794
of	O	-1	2670794
C@@	B-Chemical	D002216	2670794
ap@@	I-Chemical	-1	2670794
to@@	I-Chemical	-1	2670794
pri@@	I-Chemical	-1	2670794
l	I-Chemical	-1	2670794
(@@	O	-1	2670794
1	O	-1	2670794
mg/kg@@	O	-1	2670794
),	O	-1	2670794
an	O	-1	2670794
inhibitor	O	-1	2670794
of	O	-1	2670794
angiotens@@	B-Chemical	D000809	2670794
in	I-Chemical	-1	2670794
conver@@	O	-1	2670794
ting	O	-1	2670794
enzyme	O	-1	2670794
(@@	O	-1	2670794
AC@@	O	-1	2670794
E@@	O	-1	2670794
),	O	-1	2670794
reduced	O	-1	2670794
both	O	-1	2670794
pulmonary	B-Disease	D011665	2670794
and	I-Disease	-1	2670794
renal	I-Disease	-1	2670794
in@@	I-Disease	-1	2670794
suffici@@	I-Disease	-1	2670794
ency	I-Disease	-1	2670794
pulmonary	B-Disease	D051437	2670794
and	I-Disease	-1	2670794
renal	I-Disease	-1	2670794
in@@	I-Disease	-1	2670794
suffici@@	I-Disease	-1	2670794
ency	I-Disease	-1	2670794
in	O	-1	2670794
this	O	-1	2670794
rat	O	-1	2670794
model@@	O	-1	2670794
.	O	-1	2670794
The	O	-1	2670794
l@@	O	-1	2670794
un@@	O	-1	2670794
g	O	-1	2670794
weigh@@	O	-1	2670794
ts	O	-1	2670794
were	O	-1	2670794
lower	O	-1	2670794
and	O	-1	2670794
P@@	O	-1	2670794
a@@	O	-1	2670794
O@@	O	-1	2670794
2	O	-1	2670794
was	O	-1	2670794
improved	O	-1	2670794
in	O	-1	2670794
rats	O	-1	2670794
given	O	-1	2670794
this	O	-1	2670794
enz@@	O	-1	2670794
y@@	O	-1	2670794
me@@	O	-1	2670794
-@@	O	-1	2670794
block@@	O	-1	2670794
ing	O	-1	2670794
agent@@	O	-1	2670794
.	O	-1	2670794
The	O	-1	2670794
cont@@	O	-1	2670794
ents	O	-1	2670794
of	O	-1	2670794
al@@	O	-1	2670794
b@@	O	-1	2670794
um@@	O	-1	2670794
in	O	-1	2670794
in	O	-1	2670794
the	O	-1	2670794
l@@	O	-1	2670794
un@@	O	-1	2670794
g@@	O	-1	2670794
s	O	-1	2670794
were	O	-1	2670794
not	O	-1	2670794
chang@@	O	-1	2670794
ed,	O	-1	2670794
indicating	O	-1	2670794
that	O	-1	2670794
C@@	B-Chemical	D002216	2670794
ap@@	I-Chemical	-1	2670794
to@@	I-Chemical	-1	2670794
pri@@	I-Chemical	-1	2670794
l	I-Chemical	-1	2670794
did	O	-1	2670794
not	O	-1	2670794
influence	O	-1	2670794
the	O	-1	2670794
ext@@	O	-1	2670794
ra@@	O	-1	2670794
vas@@	O	-1	2670794
ation	O	-1	2670794
of	O	-1	2670794
protein@@	O	-1	2670794
.	O	-1	2670794
R@@	B-Disease	D007674	2670794
en@@	I-Disease	-1	2670794
al	I-Disease	-1	2670794
damage	I-Disease	-1	2670794
as	O	-1	2670794
ref@@	O	-1	2670794
l@@	O	-1	2670794
ected	O	-1	2670794
by	O	-1	2670794
an	O	-1	2670794
increase	O	-1	2670794
in	O	-1	2670794
serum	O	-1	2670794
ure@@	B-Chemical	D014508	2670794
a	I-Chemical	-1	2670794
and	O	-1	2670794
in	O	-1	2670794
kidney	O	-1	2670794
weight	O	-1	2670794
was	O	-1	2670794
prevent@@	O	-1	2670794
ed	O	-1	2670794
by	O	-1	2670794
C@@	B-Chemical	D002216	2670794
ap@@	I-Chemical	-1	2670794
to@@	I-Chemical	-1	2670794
pri@@	I-Chemical	-1	2670794
l	I-Chemical	-1	2670794
.	O	-1	2670794
The	O	-1	2670794
amoun@@	O	-1	2670794
t	O	-1	2670794
of	O	-1	2670794
fib@@	O	-1	2670794
rin	O	-1	2670794
in	O	-1	2670794
the	O	-1	2670794
kidne@@	O	-1	2670794
ys	O	-1	2670794
was	O	-1	2670794
also	O	-1	2670794
con@@	O	-1	2670794
si@@	O	-1	2670794
der@@	O	-1	2670794
ably	O	-1	2670794
lower	O	-1	2670794
than	O	-1	2670794
in	O	-1	2670794
animals	O	-1	2670794
which	O	-1	2670794
received	O	-1	2670794
throm@@	O	-1	2670794
bin	O	-1	2670794
and	O	-1	2670794
AM@@	B-Chemical	D014148	2670794
C@@	I-Chemical	-1	2670794
A	I-Chemical	-1	2670794
al@@	O	-1	2670794
one.	O	-1	2670794
It	O	-1	2670794
is	O	-1	2670794
suggested	O	-1	2670794
that	O	-1	2670794
the	O	-1	2670794
effects	O	-1	2670794
of	O	-1	2670794
C@@	B-Chemical	D002216	2670794
ap@@	I-Chemical	-1	2670794
to@@	I-Chemical	-1	2670794
pri@@	I-Chemical	-1	2670794
l	I-Chemical	-1	2670794
on	O	-1	2670794
the	O	-1	2670794
l@@	O	-1	2670794
un@@	O	-1	2670794
g@@	O	-1	2670794
s	O	-1	2670794
may	O	-1	2670794
be	O	-1	2670794
at@@	O	-1	2670794
tri@@	O	-1	2670794
but@@	O	-1	2670794
able	O	-1	2670794
to	O	-1	2670794
a	O	-1	2670794
vas@@	O	-1	2670794
odi@@	O	-1	2670794
lat@@	O	-1	2670794
ory	O	-1	2670794
effect	O	-1	2670794
due	O	-1	2670794
to	O	-1	2670794
a	O	-1	2670794
reduction	O	-1	2670794
in	O	-1	2670794
the	O	-1	2670794
cir@@	O	-1	2670794
cul@@	O	-1	2670794
ating	O	-1	2670794
level	O	-1	2670794
of	O	-1	2670794
An@@	B-Chemical	D000804	2670794
gi@@	I-Chemical	-1	2670794
oten@@	I-Chemical	-1	2670794
sion	I-Chemical	-1	2670794
II	I-Chemical	-1	2670794
and	O	-1	2670794
an	O	-1	2670794
increase	O	-1	2670794
in	O	-1	2670794
pro@@	B-Chemical	D011464	2670794
st@@	I-Chemical	-1	2670794
ac@@	I-Chemical	-1	2670794
y@@	I-Chemical	-1	2670794
cl@@	I-Chemical	-1	2670794
in	I-Chemical	-1	2670794
(@@	O	-1	2670794
secondary	O	-1	2670794
to	O	-1	2670794
an	O	-1	2670794
increase	O	-1	2670794
in	O	-1	2670794
brady@@	B-Chemical	D001920	2670794
kin@@	I-Chemical	-1	2670794
in	I-Chemical	-1	2670794
).	O	-1	2670794
C@@	B-Chemical	D002216	2670794
ap@@	I-Chemical	-1	2670794
to@@	I-Chemical	-1	2670794
pri@@	I-Chemical	-1	2670794
l	I-Chemical	-1	2670794
ma@@	O	-1	2670794
y,	O	-1	2670794
by	O	-1	2670794
the	O	-1	2670794
same	O	-1	2670794
mechanis@@	O	-1	2670794
m@@	O	-1	2670794
,	O	-1	2670794
re@@	O	-1	2670794
duce	O	-1	2670794
the	O	-1	2670794
increase	O	-1	2670794
in	O	-1	2670794
glomerular	O	-1	2670794
f@@	O	-1	2670794
iltration	O	-1	2670794
that	O	-1	2670794
is	O	-1	2670794
known	O	-1	2670794
to	O	-1	2670794
occ@@	O	-1	2670794
ur	O	-1	2670794
after	O	-1	2670794
an	O	-1	2670794
injection	O	-1	2670794
of	O	-1	2670794
throm@@	O	-1	2670794
bin@@	O	-1	2670794
,	O	-1	2670794
the@@	O	-1	2670794
re@@	O	-1	2670794
by	O	-1	2670794
di@@	O	-1	2670794
min@@	O	-1	2670794
ish@@	O	-1	2670794
ing	O	-1	2670794
the	O	-1	2670794
ag@@	O	-1	2670794
g@@	O	-1	2670794
reg@@	O	-1	2670794
ation	O	-1	2670794
of	O	-1	2670794
fib@@	O	-1	2670794
rin	O	-1	2670794
mon@@	O	-1	2670794
om@@	O	-1	2670794
ers	O	-1	2670794
in	O	-1	2670794
the	O	-1	2670794
glomerul@@	O	-1	2670794
i@@	O	-1	2670794
,	O	-1	2670794
with	O	-1	2670794
the	O	-1	2670794
result	O	-1	2670794
that	O	-1	2670794
less	O	-1	2670794
fib@@	O	-1	2670794
rin	O	-1	2670794
wil@@	O	-1	2670794
l	O	-1	2670794
be	O	-1	2670794
de@@	O	-1	2670794
pos@@	O	-1	2670794
ited	O	-1	2670794
and	O	-1	2670794
th@@	O	-1	2670794
us	O	-1	2670794
less	O	-1	2670794
kidney	B-Disease	D007674	2670794
damage	I-Disease	-1	2670794
wil@@	O	-1	2670794
l	O	-1	2670794
be	O	-1	2670794
produc@@	O	-1	2670794
ed.	O	-1	2670794

A	O	-1	2696505
randomized	O	-1	2696505
compar@@	O	-1	2696505
ison	O	-1	2696505
of	O	-1	2696505
l@@	B-Chemical	D007741	2696505
a@@	I-Chemical	-1	2696505
bet@@	I-Chemical	-1	2696505
al@@	I-Chemical	-1	2696505
ol	I-Chemical	-1	2696505
and	O	-1	2696505
nitro@@	B-Chemical	D009599	2696505
pr@@	I-Chemical	-1	2696505
us@@	I-Chemical	-1	2696505
side	I-Chemical	-1	2696505
for	O	-1	2696505
induced	O	-1	2696505
hypotension	B-Disease	D007022	2696505
.	O	-1	2696505
In	O	-1	2696505
a	O	-1	2696505
randomized	O	-1	2696505
study,	O	-1	2696505
l@@	B-Chemical	D007741	2696505
a@@	I-Chemical	-1	2696505
bet@@	I-Chemical	-1	2696505
al@@	I-Chemical	-1	2696505
ol	I-Chemical	-1	2696505
-induced	O	-1	2696505
hypotension	B-Disease	D007022	2696505
and	O	-1	2696505
nitro@@	B-Chemical	D009599	2696505
pr@@	I-Chemical	-1	2696505
us@@	I-Chemical	-1	2696505
side	I-Chemical	-1	2696505
-induced	O	-1	2696505
hypotension	B-Disease	D007022	2696505
were	O	-1	2696505
compared	O	-1	2696505
in	O	-1	2696505
20	O	-1	2696505
patients	O	-1	2696505
(10	O	-1	2696505
in	O	-1	2696505
each	O	-1	2696505
group@@	O	-1	2696505
)	O	-1	2696505
sch@@	O	-1	2696505
ed@@	O	-1	2696505
ul@@	O	-1	2696505
ed	O	-1	2696505
for	O	-1	2696505
major	O	-1	2696505
or@@	O	-1	2696505
th@@	O	-1	2696505
o@@	O	-1	2696505
pe@@	O	-1	2696505
di@@	O	-1	2696505
c	O	-1	2696505
proce@@	O	-1	2696505
du@@	O	-1	2696505
res@@	O	-1	2696505
.	O	-1	2696505
E@@	O	-1	2696505
ach	O	-1	2696505
patient	O	-1	2696505
was	O	-1	2696505
subj@@	O	-1	2696505
ected	O	-1	2696505
to	O	-1	2696505
an	O	-1	2696505
id@@	O	-1	2696505
en@@	O	-1	2696505
tical	O	-1	2696505
anesthe@@	O	-1	2696505
tic	O	-1	2696505
pro@@	O	-1	2696505
to@@	O	-1	2696505
co@@	O	-1	2696505
l	O	-1	2696505
and	O	-1	2696505
similar	O	-1	2696505
drug@@	O	-1	2696505
-induced	O	-1	2696505
reduc@@	B-Disease	D007022	2696505
tions	I-Disease	-1	2696505
in	I-Disease	-1	2696505
mean	I-Disease	-1	2696505
arterial	I-Disease	-1	2696505
blood	I-Disease	-1	2696505
pressure	I-Disease	-1	2696505
(B@@	O	-1	2696505
P)	O	-1	2696505
(@@	O	-1	2696505
50	O	-1	2696505
to	O	-1	2696505
5@@	O	-1	2696505
5	O	-1	2696505
mm@@	O	-1	2696505
H@@	O	-1	2696505
g@@	O	-1	2696505
).	O	-1	2696505
N@@	O	-1	2696505
it@@	O	-1	2696505
ro@@	O	-1	2696505
pr@@	O	-1	2696505
us@@	O	-1	2696505
side	O	-1	2696505
infusion	O	-1	2696505
was	O	-1	2696505
associated	O	-1	2696505
with	O	-1	2696505
a	O	-1	2696505
significant	O	-1	2696505
(p	O	-1	2696505
less	O	-1	2696505
than	O	-1	2696505
0.05@@	O	-1	2696505
)	O	-1	2696505
increase	B-Disease	D016534	2696505
in	I-Disease	-1	2696505
heart	I-Disease	-1	2696505
rate	I-Disease	-1	2696505
and	I-Disease	-1	2696505
cardiac	I-Disease	-1	2696505
out@@	I-Disease	-1	2696505
pu@@	I-Disease	-1	2696505
t	I-Disease	-1	2696505
;	O	-1	2696505
reb@@	O	-1	2696505
ound	O	-1	2696505
hypertension	B-Disease	D006973	2696505
was	O	-1	2696505
observed	O	-1	2696505
in	O	-1	2696505
three	O	-1	2696505
patients	O	-1	2696505
after	O	-1	2696505
discontinu@@	O	-1	2696505
ation	O	-1	2696505
of	O	-1	2696505
nitro@@	B-Chemical	D009599	2696505
pr@@	I-Chemical	-1	2696505
us@@	I-Chemical	-1	2696505
side	I-Chemical	-1	2696505
.	O	-1	2696505
L@@	B-Chemical	D007741	2696505
a@@	I-Chemical	-1	2696505
bet@@	I-Chemical	-1	2696505
al@@	I-Chemical	-1	2696505
ol	I-Chemical	-1	2696505
administration	O	-1	2696505
was	O	-1	2696505
not	O	-1	2696505
associated	O	-1	2696505
with	O	-1	2696505
any	O	-1	2696505
of	O	-1	2696505
these	O	-1	2696505
find@@	O	-1	2696505
ing@@	O	-1	2696505
s.	O	-1	2696505
A@@	O	-1	2696505
r@@	O	-1	2696505
ter@@	O	-1	2696505
ial	O	-1	2696505
P@@	B-Chemical	C093415	2696505
O@@	I-Chemical	-1	2696505
2	I-Chemical	-1	2696505
decreased	O	-1	2696505
in	O	-1	2696505
both	O	-1	2696505
groups.	O	-1	2696505
It	O	-1	2696505
was	O	-1	2696505
concl@@	O	-1	2696505
uded	O	-1	2696505
that	O	-1	2696505
l@@	B-Chemical	D007741	2696505
a@@	I-Chemical	-1	2696505
bet@@	I-Chemical	-1	2696505
al@@	I-Chemical	-1	2696505
ol	I-Chemical	-1	2696505
o@@	O	-1	2696505
ff@@	O	-1	2696505
ers	O	-1	2696505
adv@@	O	-1	2696505
ant@@	O	-1	2696505
ages	O	-1	2696505
over	O	-1	2696505
nitro@@	B-Chemical	D009599	2696505
pr@@	I-Chemical	-1	2696505
us@@	I-Chemical	-1	2696505
side	I-Chemical	-1	2696505
.	O	-1	2696505

Ch@@	O	-1	2924746
ron@@	O	-1	2924746
ic	O	-1	2924746
carbamazepine	B-Chemical	D002220	2924746
treatment	O	-1	2924746
in	O	-1	2924746
the	O	-1	2924746
rat@@	O	-1	2924746
:	O	-1	2924746
efficac@@	O	-1	2924746
y,	O	-1	2924746
toxicity	B-Disease	D064420	2924746
,	O	-1	2924746
and	O	-1	2924746
effect	O	-1	2924746
on	O	-1	2924746
plasma	O	-1	2924746
and	O	-1	2924746
tissue	O	-1	2924746
fol@@	B-Chemical	D005492	2924746
ate	I-Chemical	-1	2924746
concentr@@	O	-1	2924746
ations.	O	-1	2924746
F@@	B-Chemical	D005492	2924746
ol@@	I-Chemical	-1	2924746
ate	I-Chemical	-1	2924746
deple@@	O	-1	2924746
tion	O	-1	2924746
has	O	-1	2924746
often	O	-1	2924746
been	O	-1	2924746
a	O	-1	2924746
pro@@	O	-1	2924746
ble@@	O	-1	2924746
m	O	-1	2924746
in	O	-1	2924746
chronic	O	-1	2924746
anti@@	O	-1	2924746
epileptic	O	-1	2924746
drug	O	-1	2924746
(A@@	O	-1	2924746
E@@	O	-1	2924746
D)	O	-1	2924746
therapy.	O	-1	2924746
C@@	B-Chemical	D002220	2924746
arb@@	I-Chemical	-1	2924746
am@@	I-Chemical	-1	2924746
azepine	I-Chemical	-1	2924746
(	O	-1	2924746
C@@	B-Chemical	D002220	2924746
B@@	I-Chemical	-1	2924746
Z	I-Chemical	-1	2924746
),	O	-1	2924746
a	O	-1	2924746
common@@	O	-1	2924746
ly	O	-1	2924746
used	O	-1	2924746
A@@	O	-1	2924746
E@@	O	-1	2924746
D@@	O	-1	2924746
,	O	-1	2924746
has	O	-1	2924746
been	O	-1	2924746
implic@@	O	-1	2924746
ated	O	-1	2924746
in	O	-1	2924746
some	O	-1	2924746
clinical	O	-1	2924746
studi@@	O	-1	2924746
es.	O	-1	2924746
A	O	-1	2924746
rat	O	-1	2924746
model	O	-1	2924746
was	O	-1	2924746
developed	O	-1	2924746
to	O	-1	2924746
ex@@	O	-1	2924746
amine	O	-1	2924746
the	O	-1	2924746
effects	O	-1	2924746
of	O	-1	2924746
chronic	O	-1	2924746
C@@	B-Chemical	D002220	2924746
B@@	I-Chemical	-1	2924746
Z	I-Chemical	-1	2924746
treatment	O	-1	2924746
on	O	-1	2924746
fol@@	B-Chemical	D005492	2924746
ate	I-Chemical	-1	2924746
concentrations	O	-1	2924746
in	O	-1	2924746
the	O	-1	2924746
rat@@	O	-1	2924746
.	O	-1	2924746
In	O	-1	2924746
the	O	-1	2924746
course	O	-1	2924746
of	O	-1	2924746
develop@@	O	-1	2924746
ing	O	-1	2924746
this	O	-1	2924746
model@@	O	-1	2924746
,	O	-1	2924746
a	O	-1	2924746
common	O	-1	2924746
ve@@	O	-1	2924746
h@@	O	-1	2924746
ic@@	O	-1	2924746
le@@	O	-1	2924746
,	O	-1	2924746
prop@@	B-Chemical	D019946	2924746
yl@@	I-Chemical	-1	2924746
ene	I-Chemical	-1	2924746
gly@@	I-Chemical	-1	2924746
co@@	I-Chemical	-1	2924746
l	I-Chemical	-1	2924746
,	O	-1	2924746
by	O	-1	2924746
it@@	O	-1	2924746
sel@@	O	-1	2924746
f	O	-1	2924746
in	O	-1	2924746
high	O	-1	2924746
dos@@	O	-1	2924746
es,	O	-1	2924746
was	O	-1	2924746
found	O	-1	2924746
to	O	-1	2924746
ex@@	O	-1	2924746
hib@@	O	-1	2924746
it	O	-1	2924746
protective	O	-1	2924746
pro@@	O	-1	2924746
per@@	O	-1	2924746
ties	O	-1	2924746
against	O	-1	2924746
induced	O	-1	2924746
seizures	B-Disease	D012640	2924746
and	O	-1	2924746
inhibited	O	-1	2924746
weight	B-Disease	D015430	2924746
g@@	I-Disease	-1	2924746
ain	I-Disease	-1	2924746
.	O	-1	2924746
S@@	B-Disease	D012640	2924746
e@@	I-Disease	-1	2924746
iz@@	I-Disease	-1	2924746
ures	I-Disease	-1	2924746
induced	O	-1	2924746
by	O	-1	2924746
he@@	B-Chemical	D005481	2924746
x@@	I-Chemical	-1	2924746
af@@	I-Chemical	-1	2924746
lu@@	I-Chemical	-1	2924746
o@@	I-Chemical	-1	2924746
ro@@	I-Chemical	-1	2924746
di@@	I-Chemical	-1	2924746
eth@@	I-Chemical	-1	2924746
yl	I-Chemical	-1	2924746
e@@	I-Chemical	-1	2924746
ther	I-Chemical	-1	2924746
(	O	-1	2924746
H@@	B-Chemical	D005481	2924746
F@@	I-Chemical	-1	2924746
D@@	I-Chemical	-1	2924746
E	I-Chemical	-1	2924746
)	O	-1	2924746
were	O	-1	2924746
also	O	-1	2924746
found	O	-1	2924746
to	O	-1	2924746
be	O	-1	2924746
a	O	-1	2924746
more	O	-1	2924746
sensitive	O	-1	2924746
meas@@	O	-1	2924746
ure	O	-1	2924746
of	O	-1	2924746
prot@@	O	-1	2924746
ection	O	-1	2924746
by	O	-1	2924746
C@@	B-Chemical	D002220	2924746
B@@	I-Chemical	-1	2924746
Z	I-Chemical	-1	2924746
than	O	-1	2924746
seizures	B-Disease	D012640	2924746
induced	O	-1	2924746
by	O	-1	2924746
maxim@@	O	-1	2924746
al	O	-1	2924746
electro@@	O	-1	2924746
sh@@	O	-1	2924746
oc@@	O	-1	2924746
k	O	-1	2924746
(@@	O	-1	2924746
M@@	O	-1	2924746
ES@@	O	-1	2924746
).	O	-1	2924746
O@@	O	-1	2924746
ral	O	-1	2924746
administration	O	-1	2924746
of	O	-1	2924746
C@@	B-Chemical	D002220	2924746
B@@	I-Chemical	-1	2924746
Z	I-Chemical	-1	2924746
as	O	-1	2924746
an	O	-1	2924746
a@@	O	-1	2924746
qu@@	O	-1	2924746
e@@	O	-1	2924746
ous	O	-1	2924746
sus@@	O	-1	2924746
pen@@	O	-1	2924746
sion	O	-1	2924746
every	O	-1	2924746
8	O	-1	2924746
h	O	-1	2924746
at	O	-1	2924746
a	O	-1	2924746
dose	O	-1	2924746
of	O	-1	2924746
2@@	O	-1	2924746
50	O	-1	2924746
mg/kg	O	-1	2924746
was	O	-1	2924746
continu@@	O	-1	2924746
ously	O	-1	2924746
protective	O	-1	2924746
against	O	-1	2924746
H@@	B-Chemical	D005481	2924746
F@@	I-Chemical	-1	2924746
D@@	I-Chemical	-1	2924746
E	I-Chemical	-1	2924746
-induced	O	-1	2924746
seizures	B-Disease	D012640	2924746
and	O	-1	2924746
was	O	-1	2924746
minim@@	O	-1	2924746
ally	O	-1	2924746
toxic	O	-1	2924746
as	O	-1	2924746
measured	O	-1	2924746
by	O	-1	2924746
weight	B-Disease	D015430	2924746
g@@	I-Disease	-1	2924746
ain	I-Disease	-1	2924746
over	O	-1	2924746
8	O	-1	2924746
weeks	O	-1	2924746
of	O	-1	2924746
treatment.	O	-1	2924746
The	O	-1	2924746
C@@	B-Chemical	D002220	2924746
B@@	I-Chemical	-1	2924746
Z	I-Chemical	-1	2924746
levels	O	-1	2924746
measured	O	-1	2924746
in	O	-1	2924746
plasma	O	-1	2924746
and	O	-1	2924746
brain	O	-1	2924746
of	O	-1	2924746
these	O	-1	2924746
anim@@	O	-1	2924746
al@@	O	-1	2924746
s,	O	-1	2924746
however,	O	-1	2924746
were	O	-1	2924746
be@@	O	-1	2924746
low	O	-1	2924746
those	O	-1	2924746
norm@@	O	-1	2924746
ally	O	-1	2924746
considered	O	-1	2924746
prot@@	O	-1	2924746
ecti@@	O	-1	2924746
ve.	O	-1	2924746
This	O	-1	2924746
treatment	O	-1	2924746
with	O	-1	2924746
C@@	B-Chemical	D002220	2924746
B@@	I-Chemical	-1	2924746
Z	I-Chemical	-1	2924746
had	O	-1	2924746
no	O	-1	2924746
appa@@	O	-1	2924746
rent	O	-1	2924746
adverse	O	-1	2924746
effect	O	-1	2924746
on	O	-1	2924746
fol@@	B-Chemical	D005492	2924746
ate	I-Chemical	-1	2924746
concentrations	O	-1	2924746
in	O	-1	2924746
the	O	-1	2924746
rat@@	O	-1	2924746
,	O	-1	2924746
and@@	O	-1	2924746
,	O	-1	2924746
in@@	O	-1	2924746
de@@	O	-1	2924746
ed,	O	-1	2924746
the	O	-1	2924746
fol@@	B-Chemical	D005492	2924746
ate	I-Chemical	-1	2924746
concentration	O	-1	2924746
increased	O	-1	2924746
in	O	-1	2924746
liver	O	-1	2924746
after	O	-1	2924746
6	O	-1	2924746
weeks	O	-1	2924746
of	O	-1	2924746
treatment	O	-1	2924746
and	O	-1	2924746
in	O	-1	2924746
plasma	O	-1	2924746
at	O	-1	2924746
8	O	-1	2924746
weeks	O	-1	2924746
of	O	-1	2924746
treatment.	O	-1	2924746

In@@	O	-1	2951327
hib@@	O	-1	2951327
ition	O	-1	2951327
of	O	-1	2951327
sym@@	O	-1	2951327
path@@	O	-1	2951327
o@@	O	-1	2951327
ad@@	O	-1	2951327
renal	O	-1	2951327
activity	O	-1	2951327
by	O	-1	2951327
atrial	O	-1	2951327
n@@	O	-1	2951327
atri@@	O	-1	2951327
ure@@	O	-1	2951327
tic	O	-1	2951327
factor	O	-1	2951327
in	O	-1	2951327
dog@@	O	-1	2951327
s.	O	-1	2951327
In	O	-1	2951327
six	O	-1	2951327
con@@	O	-1	2951327
s@@	O	-1	2951327
ci@@	O	-1	2951327
ou@@	O	-1	2951327
s,	O	-1	2951327
tra@@	O	-1	2951327
in@@	O	-1	2951327
ed	O	-1	2951327
dog@@	O	-1	2951327
s,	O	-1	2951327
maint@@	O	-1	2951327
ained	O	-1	2951327
on	O	-1	2951327
a	O	-1	2951327
normal	O	-1	2951327
sodium	B-Chemical	D012964	2951327
int@@	O	-1	2951327
ake	O	-1	2951327
of	O	-1	2951327
2	O	-1	2951327
to	O	-1	2951327
4	O	-1	2951327
m@@	O	-1	2951327
E@@	O	-1	2951327
q@@	O	-1	2951327
/@@	O	-1	2951327
k@@	O	-1	2951327
g/@@	O	-1	2951327
da@@	O	-1	2951327
y,	O	-1	2951327
sym@@	O	-1	2951327
pa@@	O	-1	2951327
thetic	O	-1	2951327
activity	O	-1	2951327
was	O	-1	2951327
assessed	O	-1	2951327
as	O	-1	2951327
the	O	-1	2951327
release	O	-1	2951327
rate	O	-1	2951327
of	O	-1	2951327
no@@	B-Chemical	D009638	2951327
re@@	I-Chemical	-1	2951327
p@@	I-Chemical	-1	2951327
ine@@	I-Chemical	-1	2951327
phrine	I-Chemical	-1	2951327
and	O	-1	2951327
ep@@	B-Chemical	D004837	2951327
ine@@	I-Chemical	-1	2951327
phrine	I-Chemical	-1	2951327
during	O	-1	2951327
1@@	O	-1	2951327
5-@@	O	-1	2951327
min@@	O	-1	2951327
ute	O	-1	2951327
i.v@@	O	-1	2951327
.	O	-1	2951327
infu@@	O	-1	2951327
sions	O	-1	2951327
of	O	-1	2951327
human	O	-1	2951327
alpha-@@	O	-1	2951327
atrial	O	-1	2951327
n@@	O	-1	2951327
atri@@	O	-1	2951327
ure@@	O	-1	2951327
tic	O	-1	2951327
fact@@	O	-1	2951327
or@@	O	-1	2951327
.	O	-1	2951327
M@@	O	-1	2951327
e@@	O	-1	2951327
an	O	-1	2951327
arterial	O	-1	2951327
pressure	O	-1	2951327
(@@	O	-1	2951327
as	O	-1	2951327
a	O	-1	2951327
perc@@	O	-1	2951327
ent@@	O	-1	2951327
age	O	-1	2951327
of	O	-1	2951327
control	O	-1	2951327
+/-	O	-1	2951327
S@@	O	-1	2951327
E@@	O	-1	2951327
M@@	O	-1	2951327
)	O	-1	2951327
during	O	-1	2951327
randomized	O	-1	2951327
infu@@	O	-1	2951327
sions	O	-1	2951327
of	O	-1	2951327
0.0@@	O	-1	2951327
3,	O	-1	2951327
0.@@	O	-1	2951327
1,	O	-1	2951327
0.@@	O	-1	2951327
3,	O	-1	2951327
or	O	-1	2951327
1.@@	O	-1	2951327
0	O	-1	2951327
microgram@@	O	-1	2951327
/@@	O	-1	2951327
k@@	O	-1	2951327
g/@@	O	-1	2951327
min	O	-1	2951327
was	O	-1	2951327
9@@	O	-1	2951327
9	O	-1	2951327
+/-	O	-1	2951327
1,	O	-1	2951327
9@@	O	-1	2951327
5	O	-1	2951327
+/-	O	-1	2951327
1	O	-1	2951327
(p	O	-1	2951327
less	O	-1	2951327
than	O	-1	2951327
0.05@@	O	-1	2951327
),	O	-1	2951327
9@@	O	-1	2951327
3	O	-1	2951327
+/-	O	-1	2951327
1	O	-1	2951327
(p	O	-1	2951327
less	O	-1	2951327
than	O	-1	2951327
0.0@@	O	-1	2951327
1),	O	-1	2951327
or	O	-1	2951327
7@@	O	-1	2951327
9	O	-1	2951327
+/-	O	-1	2951327
6%	O	-1	2951327
(p	O	-1	2951327
less	O	-1	2951327
than	O	-1	2951327
0.00@@	O	-1	2951327
1),	O	-1	2951327
respectivel@@	O	-1	2951327
y,	O	-1	2951327
but	O	-1	2951327
no	O	-1	2951327
tachycardia	B-Disease	D013610	2951327
and	O	-1	2951327
no	O	-1	2951327
au@@	O	-1	2951327
g@@	O	-1	2951327
ment@@	O	-1	2951327
ation	O	-1	2951327
of	O	-1	2951327
the	O	-1	2951327
no@@	B-Chemical	D009638	2951327
re@@	I-Chemical	-1	2951327
p@@	I-Chemical	-1	2951327
ine@@	I-Chemical	-1	2951327
phrine	I-Chemical	-1	2951327
release	O	-1	2951327
rate	O	-1	2951327
(@@	O	-1	2951327
up	O	-1	2951327
to	O	-1	2951327
0.@@	O	-1	2951327
3	O	-1	2951327
microgram@@	O	-1	2951327
/@@	O	-1	2951327
k@@	O	-1	2951327
g/@@	O	-1	2951327
min@@	O	-1	2951327
)	O	-1	2951327
were	O	-1	2951327
obser@@	O	-1	2951327
ve@@	O	-1	2951327
d,	O	-1	2951327
which	O	-1	2951327
is	O	-1	2951327
in	O	-1	2951327
contr@@	O	-1	2951327
ast	O	-1	2951327
to	O	-1	2951327
compar@@	O	-1	2951327
able	O	-1	2951327
hypotension	B-Disease	D007022	2951327
induced	O	-1	2951327
by	O	-1	2951327
hy@@	B-Chemical	D006830	2951327
d@@	I-Chemical	-1	2951327
r@@	I-Chemical	-1	2951327
al@@	I-Chemical	-1	2951327
az@@	I-Chemical	-1	2951327
ine	I-Chemical	-1	2951327
or	O	-1	2951327
nitro@@	B-Chemical	D005996	2951327
glycer@@	I-Chemical	-1	2951327
in	I-Chemical	-1	2951327
.	O	-1	2951327
The	O	-1	2951327
release	O	-1	2951327
rate	O	-1	2951327
of	O	-1	2951327
ep@@	B-Chemical	D004837	2951327
ine@@	I-Chemical	-1	2951327
phrine	I-Chemical	-1	2951327
(@@	O	-1	2951327
control@@	O	-1	2951327
,	O	-1	2951327
6.@@	O	-1	2951327
7	O	-1	2951327
+/-	O	-1	2951327
0.@@	O	-1	2951327
6	O	-1	2951327
n@@	O	-1	2951327
g/@@	O	-1	2951327
k@@	O	-1	2951327
g/@@	O	-1	2951327
min@@	O	-1	2951327
)	O	-1	2951327
dec@@	O	-1	2951327
lin@@	O	-1	2951327
ed	O	-1	2951327
immedi@@	O	-1	2951327
ately	O	-1	2951327
during	O	-1	2951327
infu@@	O	-1	2951327
sions	O	-1	2951327
of	O	-1	2951327
atrial	O	-1	2951327
n@@	O	-1	2951327
atri@@	O	-1	2951327
ure@@	O	-1	2951327
tic	O	-1	2951327
factor	O	-1	2951327
to	O	-1	2951327
a	O	-1	2951327
minim@@	O	-1	2951327
um	O	-1	2951327
of	O	-1	2951327
4@@	O	-1	2951327
9	O	-1	2951327
+/-	O	-1	2951327
5%	O	-1	2951327
of	O	-1	2951327
control	O	-1	2951327
(p	O	-1	2951327
less	O	-1	2951327
than	O	-1	2951327
0.00@@	O	-1	2951327
1)	O	-1	2951327
during	O	-1	2951327
0.@@	O	-1	2951327
1	O	-1	2951327
microgram@@	O	-1	2951327
/@@	O	-1	2951327
k@@	O	-1	2951327
g/@@	O	-1	2951327
min	O	-1	2951327
and	O	-1	2951327
to	O	-1	2951327
6@@	O	-1	2951327
3	O	-1	2951327
+/-	O	-1	2951327
5%	O	-1	2951327
(0.@@	O	-1	2951327
1	O	-1	2951327
greater	O	-1	2951327
than	O	-1	2951327
p	O	-1	2951327
greater	O	-1	2951327
than	O	-1	2951327
0.05@@	O	-1	2951327
)	O	-1	2951327
or	O	-1	2951327
9@@	O	-1	2951327
5	O	-1	2951327
+/-	O	-1	2951327
13@@	O	-1	2951327
%	O	-1	2951327
(@@	O	-1	2951327
not	O	-1	2951327
significant@@	O	-1	2951327
)	O	-1	2951327
during	O	-1	2951327
0.@@	O	-1	2951327
3	O	-1	2951327
or	O	-1	2951327
1.@@	O	-1	2951327
0	O	-1	2951327
microgram@@	O	-1	2951327
/@@	O	-1	2951327
k@@	O	-1	2951327
g/@@	O	-1	2951327
min@@	O	-1	2951327
.	O	-1	2951327
S@@	O	-1	2951327
te@@	O	-1	2951327
ad@@	O	-1	2951327
y	O	-1	2951327
state	O	-1	2951327
arterial	O	-1	2951327
plasma	O	-1	2951327
concentrations	O	-1	2951327
of	O	-1	2951327
atrial	O	-1	2951327
n@@	O	-1	2951327
atri@@	O	-1	2951327
ure@@	O	-1	2951327
tic	O	-1	2951327
factor	O	-1	2951327
were	O	-1	2951327
3@@	O	-1	2951327
9	O	-1	2951327
+/-	O	-1	2951327
10	O	-1	2951327
p@@	O	-1	2951327
g/@@	O	-1	2951327
m@@	O	-1	2951327
l	O	-1	2951327
(n	O	-1	2951327
=	O	-1	2951327
6@@	O	-1	2951327
)	O	-1	2951327
during	O	-1	2951327
infu@@	O	-1	2951327
sions	O	-1	2951327
of	O	-1	2951327
saline	O	-1	2951327
and	O	-1	2951327
2@@	O	-1	2951327
8@@	O	-1	2951327
4	O	-1	2951327
+/-	O	-1	2951327
24	O	-1	2951327
p@@	O	-1	2951327
g/@@	O	-1	2951327
m@@	O	-1	2951327
l	O	-1	2951327
(n	O	-1	2951327
=	O	-1	2951327
6@@	O	-1	2951327
)	O	-1	2951327
and	O	-1	2951327
1@@	O	-1	2951327
5@@	O	-1	2951327
20	O	-1	2951327
+/-	O	-1	2951327
3@@	O	-1	2951327
00	O	-1	2951327
p@@	O	-1	2951327
g/@@	O	-1	2951327
m@@	O	-1	2951327
l	O	-1	2951327
(n	O	-1	2951327
=	O	-1	2951327
9@@	O	-1	2951327
)	O	-1	2951327
during	O	-1	2951327
0.0@@	O	-1	2951327
3	O	-1	2951327
and	O	-1	2951327
0.@@	O	-1	2951327
1	O	-1	2951327
microgram@@	O	-1	2951327
/@@	O	-1	2951327
k@@	O	-1	2951327
g/@@	O	-1	2951327
min	O	-1	2951327
infu@@	O	-1	2951327
sions	O	-1	2951327
of	O	-1	2951327
the	O	-1	2951327
fact@@	O	-1	2951327
or@@	O	-1	2951327
.@@	O	-1	2951327
(A@@	O	-1	2951327
B@@	O	-1	2951327
S@@	O	-1	2951327
TR@@	O	-1	2951327
AC@@	O	-1	2951327
T	O	-1	2951327
TR@@	O	-1	2951327
UN@@	O	-1	2951327
C@@	O	-1	2951327
AT@@	O	-1	2951327
E@@	O	-1	2951327
D	O	-1	2951327
A@@	O	-1	2951327
T	O	-1	2951327
2@@	O	-1	2951327
50	O	-1	2951327
W@@	O	-1	2951327
O@@	O	-1	2951327
RD@@	O	-1	2951327
S)	O	-1	2951327

De@@	B-Disease	D003643	3192036
ath	I-Disease	-1	3192036
from	O	-1	3192036
chemotherapy	O	-1	3192036
in	O	-1	3192036
g@@	B-Disease	D031901	3192036
est@@	I-Disease	-1	3192036
ation@@	I-Disease	-1	3192036
al	I-Disease	-1	3192036
tro@@	I-Disease	-1	3192036
ph@@	I-Disease	-1	3192036
ob@@	I-Disease	-1	3192036
las@@	I-Disease	-1	3192036
tic	I-Disease	-1	3192036
disease	I-Disease	-1	3192036
.	O	-1	3192036
M@@	O	-1	3192036
ul@@	O	-1	3192036
ti@@	O	-1	3192036
ple	O	-1	3192036
cy@@	O	-1	3192036
tot@@	O	-1	3192036
ox@@	O	-1	3192036
ic	O	-1	3192036
drug	O	-1	3192036
administration	O	-1	3192036
is	O	-1	3192036
the	O	-1	3192036
gener@@	O	-1	3192036
ally	O	-1	3192036
ac@@	O	-1	3192036
ce@@	O	-1	3192036
pt@@	O	-1	3192036
ed	O	-1	3192036
treatment	O	-1	3192036
of	O	-1	3192036
patients	O	-1	3192036
with	O	-1	3192036
a	O	-1	3192036
high-@@	O	-1	3192036
risk	O	-1	3192036
st@@	O	-1	3192036
age	O	-1	3192036
of	O	-1	3192036
ch@@	B-Disease	D002822	3192036
or@@	I-Disease	-1	3192036
i@@	I-Disease	-1	3192036
oc@@	I-Disease	-1	3192036
arc@@	I-Disease	-1	3192036
in@@	I-Disease	-1	3192036
oma	I-Disease	-1	3192036
.	O	-1	3192036
B@@	O	-1	3192036
as@@	O	-1	3192036
ed	O	-1	3192036
on	O	-1	3192036
this	O	-1	3192036
pr@@	O	-1	3192036
inc@@	O	-1	3192036
i@@	O	-1	3192036
ple	O	-1	3192036
a	O	-1	3192036
27@@	O	-1	3192036
-@@	O	-1	3192036
year	O	-1	3192036
old	O	-1	3192036
wom@@	O	-1	3192036
an@@	O	-1	3192036
,	O	-1	3192036
cl@@	O	-1	3192036
assi@@	O	-1	3192036
fied	O	-1	3192036
as	O	-1	3192036
being	O	-1	3192036
in	O	-1	3192036
the	O	-1	3192036
high-@@	O	-1	3192036
risk	O	-1	3192036
group	O	-1	3192036
(@@	O	-1	3192036
G@@	O	-1	3192036
ol@@	O	-1	3192036
d@@	O	-1	3192036
ste@@	O	-1	3192036
in	O	-1	3192036
and	O	-1	3192036
B@@	O	-1	3192036
er@@	O	-1	3192036
k@@	O	-1	3192036
o@@	O	-1	3192036
wit@@	O	-1	3192036
z	O	-1	3192036
sco@@	O	-1	3192036
re@@	O	-1	3192036
:	O	-1	3192036
1@@	O	-1	3192036
1),	O	-1	3192036
was	O	-1	3192036
treated	O	-1	3192036
with	O	-1	3192036
multiple	O	-1	3192036
cy@@	O	-1	3192036
tot@@	O	-1	3192036
ox@@	O	-1	3192036
ic	O	-1	3192036
drug@@	O	-1	3192036
s.	O	-1	3192036
The	O	-1	3192036
multiple	O	-1	3192036
drug	O	-1	3192036
s@@	O	-1	3192036
chem@@	O	-1	3192036
a	O	-1	3192036
consist@@	O	-1	3192036
ed	O	-1	3192036
of@@	O	-1	3192036
:	O	-1	3192036
E@@	B-Chemical	D005047	3192036
to@@	I-Chemical	-1	3192036
po@@	I-Chemical	-1	3192036
side	I-Chemical	-1	3192036
1@@	O	-1	3192036
6.@@	O	-1	3192036
2@@	O	-1	3192036
13@@	O	-1	3192036
,	O	-1	3192036
M@@	B-Chemical	D008727	3192036
eth@@	I-Chemical	-1	3192036
ot@@	I-Chemical	-1	3192036
re@@	I-Chemical	-1	3192036
x@@	I-Chemical	-1	3192036
ate	I-Chemical	-1	3192036
,	O	-1	3192036
C@@	B-Chemical	D003520	3192036
yc@@	I-Chemical	-1	3192036
lo@@	I-Chemical	-1	3192036
phosph@@	I-Chemical	-1	3192036
amide	I-Chemical	-1	3192036
,	O	-1	3192036
Ac@@	B-Chemical	D003609	3192036
to@@	I-Chemical	-1	3192036
m@@	I-Chemical	-1	3192036
yc@@	I-Chemical	-1	3192036
in-@@	I-Chemical	-1	3192036
D	I-Chemical	-1	3192036
,	O	-1	3192036
and	O	-1	3192036
C@@	B-Chemical	D002945	3192036
is@@	I-Chemical	-1	3192036
pl@@	I-Chemical	-1	3192036
atin	I-Chemical	-1	3192036
.	O	-1	3192036
O@@	O	-1	3192036
n	O	-1	3192036
the	O	-1	3192036
first	O	-1	3192036
day	O	-1	3192036
of	O	-1	3192036
the	O	-1	3192036
sch@@	O	-1	3192036
ed@@	O	-1	3192036
ul@@	O	-1	3192036
e,	O	-1	3192036
moder@@	O	-1	3192036
ate	O	-1	3192036
high	O	-1	3192036
doses	O	-1	3192036
of	O	-1	3192036
M@@	B-Chemical	D008727	3192036
eth@@	I-Chemical	-1	3192036
ot@@	I-Chemical	-1	3192036
re@@	I-Chemical	-1	3192036
x@@	I-Chemical	-1	3192036
ate	I-Chemical	-1	3192036
,	O	-1	3192036
E@@	B-Chemical	D005047	3192036
to@@	I-Chemical	-1	3192036
po@@	I-Chemical	-1	3192036
side	I-Chemical	-1	3192036
and	O	-1	3192036
C@@	B-Chemical	D003520	3192036
yc@@	I-Chemical	-1	3192036
lo@@	I-Chemical	-1	3192036
phosph@@	I-Chemical	-1	3192036
amide	I-Chemical	-1	3192036
were	O	-1	3192036
administ@@	O	-1	3192036
e@@	O	-1	3192036
red.	O	-1	3192036
W@@	O	-1	3192036
i@@	O	-1	3192036
th@@	O	-1	3192036
in	O	-1	3192036
8	O	-1	3192036
hours	O	-1	3192036
after	O	-1	3192036
initi@@	O	-1	3192036
ation	O	-1	3192036
of	O	-1	3192036
therapy	O	-1	3192036
the	O	-1	3192036
patient	O	-1	3192036
di@@	O	-1	3192036
ed	O	-1	3192036
with	O	-1	3192036
a	O	-1	3192036
clinical	O	-1	3192036
p@@	O	-1	3192036
ic@@	O	-1	3192036
t@@	O	-1	3192036
ure	O	-1	3192036
re@@	O	-1	3192036
se@@	O	-1	3192036
m@@	O	-1	3192036
bl@@	O	-1	3192036
ing	O	-1	3192036
mas@@	O	-1	3192036
sive	O	-1	3192036
pulmonary	B-Disease	D011655	3192036
ob@@	I-Disease	-1	3192036
struc@@	I-Disease	-1	3192036
tion	I-Disease	-1	3192036
due	O	-1	3192036
to	O	-1	3192036
ch@@	O	-1	3192036
or@@	O	-1	3192036
i@@	O	-1	3192036
oc@@	O	-1	3192036
arc@@	O	-1	3192036
in@@	O	-1	3192036
om@@	O	-1	3192036
ic	O	-1	3192036
tissue	O	-1	3192036
pl@@	O	-1	3192036
u@@	O	-1	3192036
g@@	O	-1	3192036
s,	O	-1	3192036
prob@@	O	-1	3192036
ably	O	-1	3192036
or@@	O	-1	3192036
ig@@	O	-1	3192036
in@@	O	-1	3192036
ating	O	-1	3192036
from	O	-1	3192036
the	O	-1	3192036
u@@	O	-1	3192036
ter@@	O	-1	3192036
us.	O	-1	3192036
F@@	O	-1	3192036
orm@@	O	-1	3192036
ation	O	-1	3192036
of	O	-1	3192036
these	O	-1	3192036
pl@@	O	-1	3192036
u@@	O	-1	3192036
g@@	O	-1	3192036
s	O	-1	3192036
was	O	-1	3192036
prob@@	O	-1	3192036
ably	O	-1	3192036
due	O	-1	3192036
to	O	-1	3192036
exten@@	O	-1	3192036
sive	O	-1	3192036
tumor	B-Disease	D009369	3192036
necro@@	B-Disease	D009336	3192036
sis	I-Disease	-1	3192036
at	O	-1	3192036
the	O	-1	3192036
level	O	-1	3192036
of	O	-1	3192036
the	O	-1	3192036
w@@	O	-1	3192036
all@@	O	-1	3192036
s	O	-1	3192036
of	O	-1	3192036
the	O	-1	3192036
major	O	-1	3192036
u@@	O	-1	3192036
ter@@	O	-1	3192036
ine	O	-1	3192036
ve@@	O	-1	3192036
in@@	O	-1	3192036
s,	O	-1	3192036
which	O	-1	3192036
resulted	O	-1	3192036
in	O	-1	3192036
an	O	-1	3192036
op@@	O	-1	3192036
en	O	-1	3192036
ex@@	O	-1	3192036
change	O	-1	3192036
of	O	-1	3192036
tumor	B-Disease	D009369	3192036
pl@@	O	-1	3192036
u@@	O	-1	3192036
g@@	O	-1	3192036
s	O	-1	3192036
to	O	-1	3192036
the	O	-1	3192036
vascular	O	-1	3192036
sp@@	O	-1	3192036
ac@@	O	-1	3192036
es@@	O	-1	3192036
;	O	-1	3192036
decrease	O	-1	3192036
in	O	-1	3192036
tumor	B-Disease	D009369	3192036
tissue	O	-1	3192036
co@@	O	-1	3192036
he@@	O	-1	3192036
rence	O	-1	3192036
secondary	O	-1	3192036
to	O	-1	3192036
chemotherapy	O	-1	3192036
may	O	-1	3192036
have	O	-1	3192036
further	O	-1	3192036
cont@@	O	-1	3192036
ri@@	O	-1	3192036
but@@	O	-1	3192036
ed	O	-1	3192036
to	O	-1	3192036
the	O	-1	3192036
formation	O	-1	3192036
of	O	-1	3192036
tumor	B-Disease	D009369	3192036
emb@@	O	-1	3192036
ol@@	O	-1	3192036
i@@	O	-1	3192036
.	O	-1	3192036
In	O	-1	3192036
vie@@	O	-1	3192036
w	O	-1	3192036
of	O	-1	3192036
the	O	-1	3192036
clo@@	O	-1	3192036
se	O	-1	3192036
time	O	-1	3192036
association	O	-1	3192036
between	O	-1	3192036
the	O	-1	3192036
star@@	O	-1	3192036
t	O	-1	3192036
of	O	-1	3192036
chemotherapy	O	-1	3192036
and	O	-1	3192036
the	O	-1	3192036
acute	O	-1	3192036
onset	O	-1	3192036
of	O	-1	3192036
mas@@	O	-1	3192036
sive	O	-1	3192036
emb@@	B-Disease	D004617	3192036
ol@@	I-Disease	-1	3192036
ism	I-Disease	-1	3192036
other	O	-1	3192036
expl@@	O	-1	3192036
an@@	O	-1	3192036
ation@@	O	-1	3192036
s,	O	-1	3192036
such	O	-1	3192036
as	O	-1	3192036
spont@@	O	-1	3192036
aneous	O	-1	3192036
necro@@	B-Disease	D009336	3192036
sis	I-Disease	-1	3192036
,	O	-1	3192036
mus@@	O	-1	3192036
t	O	-1	3192036
be	O	-1	3192036
considered	O	-1	3192036
less	O	-1	3192036
lik@@	O	-1	3192036
el@@	O	-1	3192036
y.	O	-1	3192036
Patients	O	-1	3192036
with	O	-1	3192036
larg@@	O	-1	3192036
e	O	-1	3192036
p@@	B-Disease	D010386	3192036
el@@	I-Disease	-1	3192036
v@@	I-Disease	-1	3192036
ic	I-Disease	-1	3192036
tumor	I-Disease	-1	3192036
lo@@	O	-1	3192036
ad@@	O	-1	3192036
s	O	-1	3192036
a@@	O	-1	3192036
re,	O	-1	3192036
ac@@	O	-1	3192036
cor@@	O	-1	3192036
ding	O	-1	3192036
to	O	-1	3192036
ex@@	O	-1	3192036
ist@@	O	-1	3192036
ing	O	-1	3192036
cl@@	O	-1	3192036
assi@@	O	-1	3192036
fic@@	O	-1	3192036
ation@@	O	-1	3192036
s,	O	-1	3192036
at	O	-1	3192036
high	O	-1	3192036
risk	O	-1	3192036
to	O	-1	3192036
di@@	O	-1	3192036
e	O	-1	3192036
and	O	-1	3192036
to	O	-1	3192036
deve@@	O	-1	3192036
lo@@	O	-1	3192036
p	O	-1	3192036
drug	O	-1	3192036
resist@@	O	-1	3192036
ance@@	O	-1	3192036
.	O	-1	3192036
N@@	O	-1	3192036
ot@@	O	-1	3192036
with@@	O	-1	3192036
stand@@	O	-1	3192036
ing	O	-1	3192036
these	O	-1	3192036
fact@@	O	-1	3192036
s	O	-1	3192036
our	O	-1	3192036
findings	O	-1	3192036
suggest	O	-1	3192036
that	O	-1	3192036
these	O	-1	3192036
patients	O	-1	3192036
might	O	-1	3192036
ben@@	O	-1	3192036
e@@	O	-1	3192036
fi@@	O	-1	3192036
t	O	-1	3192036
from	O	-1	3192036
rel@@	O	-1	3192036
atively	O	-1	3192036
mil@@	O	-1	3192036
d	O	-1	3192036
initial	O	-1	3192036
treatment,	O	-1	3192036
es@@	O	-1	3192036
p@@	O	-1	3192036
ec@@	O	-1	3192036
i@@	O	-1	3192036
ally	O	-1	3192036
t@@	O	-1	3192036
ru@@	O	-1	3192036
e	O	-1	3192036
for	O	-1	3192036
patients	O	-1	3192036
not	O	-1	3192036
previously	O	-1	3192036
exposed	O	-1	3192036
to	O	-1	3192036
this	O	-1	3192036
drug.	O	-1	3192036
C@@	O	-1	3192036
lo@@	O	-1	3192036
se	O	-1	3192036
observ@@	O	-1	3192036
ation	O	-1	3192036
of	O	-1	3192036
the	O	-1	3192036
response	O	-1	3192036
status	O	-1	3192036
both	O	-1	3192036
clin@@	O	-1	3192036
ically	O	-1	3192036
and	O	-1	3192036
with	O	-1	3192036
beta-@@	O	-1	3192036
h@@	O	-1	3192036
C@@	O	-1	3192036
G	O	-1	3192036
values	O	-1	3192036
may	O	-1	3192036
indicate	O	-1	3192036
whether	O	-1	3192036
and	O	-1	3192036
when	O	-1	3192036
more	O	-1	3192036
ag@@	O	-1	3192036
res@@	O	-1	3192036
sive	O	-1	3192036
combination	O	-1	3192036
chemotherapy	O	-1	3192036
should	O	-1	3192036
be	O	-1	3192036
star@@	O	-1	3192036
te@@	O	-1	3192036
d@@	O	-1	3192036
.@@	O	-1	3192036
(A@@	O	-1	3192036
B@@	O	-1	3192036
S@@	O	-1	3192036
TR@@	O	-1	3192036
AC@@	O	-1	3192036
T	O	-1	3192036
TR@@	O	-1	3192036
UN@@	O	-1	3192036
C@@	O	-1	3192036
AT@@	O	-1	3192036
E@@	O	-1	3192036
D	O	-1	3192036
A@@	O	-1	3192036
T	O	-1	3192036
2@@	O	-1	3192036
50	O	-1	3192036
W@@	O	-1	3192036
O@@	O	-1	3192036
RD@@	O	-1	3192036
S)	O	-1	3192036

S@@	B-Disease	D012735	3409645
ex@@	I-Disease	-1	3409645
ual	I-Disease	-1	3409645
dysfunction	I-Disease	-1	3409645
among	O	-1	3409645
patients	O	-1	3409645
with	O	-1	3409645
arth@@	B-Disease	D001168	3409645
ritis	I-Disease	-1	3409645
.	O	-1	3409645
The	O	-1	3409645
rel@@	O	-1	3409645
ationship	O	-1	3409645
of	O	-1	3409645
arth@@	B-Disease	D001168	3409645
ritis	I-Disease	-1	3409645
and	O	-1	3409645
sex@@	B-Disease	D012735	3409645
ual	I-Disease	-1	3409645
dysfunction	I-Disease	-1	3409645
was	O	-1	3409645
investigated	O	-1	3409645
among	O	-1	3409645
1@@	O	-1	3409645
6@@	O	-1	3409645
9	O	-1	3409645
patients	O	-1	3409645
with	O	-1	3409645
r@@	B-Disease	D001172	3409645
he@@	I-Disease	-1	3409645
um@@	I-Disease	-1	3409645
at@@	I-Disease	-1	3409645
oid	I-Disease	-1	3409645
arth@@	I-Disease	-1	3409645
ritis	I-Disease	-1	3409645
,	O	-1	3409645
ost@@	B-Disease	D010003	3409645
e@@	I-Disease	-1	3409645
o@@	I-Disease	-1	3409645
arth@@	I-Disease	-1	3409645
ritis	I-Disease	-1	3409645
and	O	-1	3409645
sp@@	B-Disease	D025242	3409645
on@@	I-Disease	-1	3409645
dy@@	I-Disease	-1	3409645
lo@@	I-Disease	-1	3409645
arth@@	I-Disease	-1	3409645
ro@@	I-Disease	-1	3409645
pathy	I-Disease	-1	3409645
,	O	-1	3409645
1@@	O	-1	3409645
30	O	-1	3409645
of	O	-1	3409645
whom	O	-1	3409645
were	O	-1	3409645
pa@@	O	-1	3409645
ir@@	O	-1	3409645
-@@	O	-1	3409645
mat@@	O	-1	3409645
ch@@	O	-1	3409645
ed	O	-1	3409645
to	O	-1	3409645
controls.	O	-1	3409645
A@@	O	-1	3409645
s@@	O	-1	3409645
s@@	O	-1	3409645
ess@@	O	-1	3409645
ments	O	-1	3409645
of	O	-1	3409645
m@@	O	-1	3409645
ar@@	O	-1	3409645
it@@	O	-1	3409645
al	O	-1	3409645
h@@	O	-1	3409645
app@@	O	-1	3409645
in@@	O	-1	3409645
ess	O	-1	3409645
and	O	-1	3409645
depress@@	B-Disease	D003866	3409645
ed	I-Disease	-1	3409645
mo@@	I-Disease	-1	3409645
od	I-Disease	-1	3409645
were	O	-1	3409645
also	O	-1	3409645
m@@	O	-1	3409645
ade	O	-1	3409645
using	O	-1	3409645
the	O	-1	3409645
C@@	O	-1	3409645
ES@@	O	-1	3409645
-@@	O	-1	3409645
D	O	-1	3409645
and	O	-1	3409645
the	O	-1	3409645
A@@	O	-1	3409645
z@@	O	-1	3409645
rin	O	-1	3409645
M@@	O	-1	3409645
ar@@	O	-1	3409645
it@@	O	-1	3409645
al	O	-1	3409645
H@@	O	-1	3409645
app@@	O	-1	3409645
in@@	O	-1	3409645
ess	O	-1	3409645
S@@	O	-1	3409645
cal@@	O	-1	3409645
e	O	-1	3409645
(A@@	O	-1	3409645
M@@	O	-1	3409645
H@@	O	-1	3409645
S@@	O	-1	3409645
).	O	-1	3409645
S@@	B-Disease	D012735	3409645
ex@@	I-Disease	-1	3409645
ual	I-Disease	-1	3409645
dysfunc@@	I-Disease	-1	3409645
tions	I-Disease	-1	3409645
were	O	-1	3409645
found	O	-1	3409645
to	O	-1	3409645
be	O	-1	3409645
common	O	-1	3409645
among	O	-1	3409645
patients	O	-1	3409645
and	O	-1	3409645
control@@	O	-1	3409645
s,	O	-1	3409645
the	O	-1	3409645
maj@@	O	-1	3409645
or@@	O	-1	3409645
ity	O	-1	3409645
in	O	-1	3409645
both	O	-1	3409645
groups	O	-1	3409645
repor@@	O	-1	3409645
ting	O	-1	3409645
one	O	-1	3409645
or	O	-1	3409645
more	O	-1	3409645
dysfunc@@	O	-1	3409645
tions.	O	-1	3409645
Im@@	B-Disease	D007172	3409645
pot@@	I-Disease	-1	3409645
ence	I-Disease	-1	3409645
was	O	-1	3409645
more	O	-1	3409645
common	O	-1	3409645
among	O	-1	3409645
male	O	-1	3409645
patients	O	-1	3409645
than	O	-1	3409645
controls	O	-1	3409645
and	O	-1	3409645
was	O	-1	3409645
found	O	-1	3409645
to	O	-1	3409645
be	O	-1	3409645
associated	O	-1	3409645
with	O	-1	3409645
co-@@	O	-1	3409645
mor@@	O	-1	3409645
b@@	O	-1	3409645
idity	O	-1	3409645
and	O	-1	3409645
the	O	-1	3409645
taking	O	-1	3409645
of	O	-1	3409645
meth@@	B-Chemical	D008727	3409645
ot@@	I-Chemical	-1	3409645
re@@	I-Chemical	-1	3409645
x@@	I-Chemical	-1	3409645
ate	I-Chemical	-1	3409645
.	O	-1	3409645
De@@	B-Disease	D003866	3409645
press@@	I-Disease	-1	3409645
ed	I-Disease	-1	3409645
mo@@	I-Disease	-1	3409645
od	I-Disease	-1	3409645
was	O	-1	3409645
more	O	-1	3409645
common	O	-1	3409645
among	O	-1	3409645
patients	O	-1	3409645
and	O	-1	3409645
was	O	-1	3409645
associated	O	-1	3409645
with	O	-1	3409645
cer@@	O	-1	3409645
t@@	O	-1	3409645
ain	O	-1	3409645
sex@@	O	-1	3409645
ual	O	-1	3409645
diff@@	O	-1	3409645
ic@@	O	-1	3409645
ul@@	O	-1	3409645
ti@@	O	-1	3409645
es,	O	-1	3409645
but	O	-1	3409645
not	O	-1	3409645
with	O	-1	3409645
im@@	B-Disease	D007172	3409645
pot@@	I-Disease	-1	3409645
ence	I-Disease	-1	3409645
.	O	-1	3409645
M@@	O	-1	3409645
ar@@	O	-1	3409645
it@@	O	-1	3409645
al	O	-1	3409645
un@@	O	-1	3409645
h@@	O	-1	3409645
app@@	O	-1	3409645
in@@	O	-1	3409645
es@@	O	-1	3409645
s,	O	-1	3409645
as	O	-1	3409645
indic@@	O	-1	3409645
ated	O	-1	3409645
by	O	-1	3409645
AM@@	O	-1	3409645
H@@	O	-1	3409645
S	O	-1	3409645
sco@@	O	-1	3409645
res@@	O	-1	3409645
,	O	-1	3409645
was	O	-1	3409645
not	O	-1	3409645
associated	O	-1	3409645
with	O	-1	3409645
arth@@	B-Disease	D001168	3409645
ritis	I-Disease	-1	3409645
but	O	-1	3409645
was	O	-1	3409645
associated	O	-1	3409645
with	O	-1	3409645
sex@@	B-Disease	D012735	3409645
ual	I-Disease	-1	3409645
dysfunction	I-Disease	-1	3409645
,	O	-1	3409645
sex@@	O	-1	3409645
ual	O	-1	3409645
dis@@	O	-1	3409645
s@@	O	-1	3409645
atis@@	O	-1	3409645
f@@	O	-1	3409645
action	O	-1	3409645
and	O	-1	3409645
being	O	-1	3409645
femal@@	O	-1	3409645
e.	O	-1	3409645

D@@	O	-1	3412544
o@@	O	-1	3412544
es	O	-1	3412544
par@@	B-Chemical	D000082	3412544
acet@@	I-Chemical	-1	3412544
am@@	I-Chemical	-1	3412544
ol	I-Chemical	-1	3412544
cause	O	-1	3412544
uro@@	B-Disease	D014523	3412544
thelial	I-Disease	-1	3412544
cancer	I-Disease	-1	3412544
or	O	-1	3412544
renal	B-Disease	D007681	3412544
pap@@	I-Disease	-1	3412544
ill@@	I-Disease	-1	3412544
ary	I-Disease	-1	3412544
necro@@	I-Disease	-1	3412544
sis	I-Disease	-1	3412544
?	O	-1	3412544
The	O	-1	3412544
risk	O	-1	3412544
of	O	-1	3412544
develop@@	O	-1	3412544
ing	O	-1	3412544
renal	B-Disease	D007681	3412544
pap@@	I-Disease	-1	3412544
ill@@	I-Disease	-1	3412544
ary	I-Disease	-1	3412544
necro@@	I-Disease	-1	3412544
sis	I-Disease	-1	3412544
or	O	-1	3412544
cancer	B-Disease	D007680	3412544
of	I-Disease	-1	3412544
the	I-Disease	-1	3412544
renal	I-Disease	-1	3412544
p@@	I-Disease	-1	3412544
el@@	I-Disease	-1	3412544
v@@	I-Disease	-1	3412544
is@@	I-Disease	-1	3412544
,	I-Disease	-1	3412544
ure@@	I-Disease	-1	3412544
ter	I-Disease	-1	3412544
or	I-Disease	-1	3412544
bladder	I-Disease	-1	3412544
cancer	B-Disease	D014516	3412544
of	I-Disease	-1	3412544
the	I-Disease	-1	3412544
renal	I-Disease	-1	3412544
p@@	I-Disease	-1	3412544
el@@	I-Disease	-1	3412544
v@@	I-Disease	-1	3412544
is@@	I-Disease	-1	3412544
,	I-Disease	-1	3412544
ure@@	I-Disease	-1	3412544
ter	I-Disease	-1	3412544
or	I-Disease	-1	3412544
bladder	I-Disease	-1	3412544
cancer	B-Disease	D001749	3412544
of	I-Disease	-1	3412544
the	I-Disease	-1	3412544
renal	I-Disease	-1	3412544
p@@	I-Disease	-1	3412544
el@@	I-Disease	-1	3412544
v@@	I-Disease	-1	3412544
is@@	I-Disease	-1	3412544
,	I-Disease	-1	3412544
ure@@	I-Disease	-1	3412544
ter	I-Disease	-1	3412544
or	I-Disease	-1	3412544
bladder	I-Disease	-1	3412544
associated	O	-1	3412544
with	O	-1	3412544
consum@@	O	-1	3412544
ption	O	-1	3412544
of	O	-1	3412544
either	O	-1	3412544
phen@@	B-Chemical	D010615	3412544
ace@@	I-Chemical	-1	3412544
tin	I-Chemical	-1	3412544
or	O	-1	3412544
par@@	B-Chemical	D000082	3412544
acet@@	I-Chemical	-1	3412544
am@@	I-Chemical	-1	3412544
ol	I-Chemical	-1	3412544
was	O	-1	3412544
calc@@	O	-1	3412544
ul@@	O	-1	3412544
ated	O	-1	3412544
from	O	-1	3412544
data	O	-1	3412544
ac@@	O	-1	3412544
qu@@	O	-1	3412544
ired	O	-1	3412544
by	O	-1	3412544
qu@@	O	-1	3412544
es@@	O	-1	3412544
tion@@	O	-1	3412544
na@@	O	-1	3412544
ir@@	O	-1	3412544
e	O	-1	3412544
from	O	-1	3412544
3@@	O	-1	3412544
8@@	O	-1	3412544
1	O	-1	3412544
cases	O	-1	3412544
and	O	-1	3412544
80@@	O	-1	3412544
8	O	-1	3412544
controls.	O	-1	3412544
The	O	-1	3412544
risk	O	-1	3412544
of	O	-1	3412544
renal	B-Disease	D007681	3412544
pap@@	I-Disease	-1	3412544
ill@@	I-Disease	-1	3412544
ary	I-Disease	-1	3412544
necro@@	I-Disease	-1	3412544
sis	I-Disease	-1	3412544
was	O	-1	3412544
increased	O	-1	3412544
ne@@	O	-1	3412544
arly	O	-1	3412544
20@@	O	-1	3412544
-@@	O	-1	3412544
fol@@	O	-1	3412544
d	O	-1	3412544
by	O	-1	3412544
consum@@	O	-1	3412544
ption	O	-1	3412544
of	O	-1	3412544
phen@@	B-Chemical	D010615	3412544
ace@@	I-Chemical	-1	3412544
tin	I-Chemical	-1	3412544
,	O	-1	3412544
which	O	-1	3412544
also	O	-1	3412544
increased	O	-1	3412544
the	O	-1	3412544
risk	O	-1	3412544
for	O	-1	3412544
cancer	B-Disease	D007680	3412544
of	I-Disease	-1	3412544
the	I-Disease	-1	3412544
renal	I-Disease	-1	3412544
p@@	I-Disease	-1	3412544
el@@	I-Disease	-1	3412544
v@@	I-Disease	-1	3412544
is	I-Disease	-1	3412544
and	I-Disease	-1	3412544
bladder	I-Disease	-1	3412544
cancer	B-Disease	D001749	3412544
of	I-Disease	-1	3412544
the	I-Disease	-1	3412544
renal	I-Disease	-1	3412544
p@@	I-Disease	-1	3412544
el@@	I-Disease	-1	3412544
v@@	I-Disease	-1	3412544
is	I-Disease	-1	3412544
and	I-Disease	-1	3412544
bladder	I-Disease	-1	3412544
but	O	-1	3412544
not	O	-1	3412544
for	O	-1	3412544
ure@@	B-Disease	D014516	3412544
ter@@	I-Disease	-1	3412544
ic	I-Disease	-1	3412544
cancer	I-Disease	-1	3412544
.	O	-1	3412544
B@@	O	-1	3412544
y	O	-1	3412544
contrast@@	O	-1	3412544
,	O	-1	3412544
we	O	-1	3412544
were	O	-1	3412544
un@@	O	-1	3412544
able	O	-1	3412544
to	O	-1	3412544
subst@@	O	-1	3412544
anti@@	O	-1	3412544
ate	O	-1	3412544
an	O	-1	3412544
increased	O	-1	3412544
risk	O	-1	3412544
from	O	-1	3412544
par@@	B-Chemical	D000082	3412544
acet@@	I-Chemical	-1	3412544
am@@	I-Chemical	-1	3412544
ol	I-Chemical	-1	3412544
consum@@	O	-1	3412544
ption	O	-1	3412544
for	O	-1	3412544
renal	B-Disease	D007681	3412544
pap@@	I-Disease	-1	3412544
ill@@	I-Disease	-1	3412544
ary	I-Disease	-1	3412544
necro@@	I-Disease	-1	3412544
sis	I-Disease	-1	3412544
or	O	-1	3412544
any	O	-1	3412544
of	O	-1	3412544
these	O	-1	3412544
canc@@	B-Disease	D009369	3412544
ers	I-Disease	-1	3412544
although	O	-1	3412544
there	O	-1	3412544
was	O	-1	3412544
a	O	-1	3412544
sugg@@	O	-1	3412544
es@@	O	-1	3412544
tion	O	-1	3412544
of	O	-1	3412544
an	O	-1	3412544
association	O	-1	3412544
with	O	-1	3412544
cancer	B-Disease	D014516	3412544
of	I-Disease	-1	3412544
the	I-Disease	-1	3412544
ure@@	I-Disease	-1	3412544
ter	I-Disease	-1	3412544
.	O	-1	3412544

D@@	B-Chemical	D003622	3425586
ap@@	I-Chemical	-1	3425586
s@@	I-Chemical	-1	3425586
one	I-Chemical	-1	3425586
-@@	O	-1	3425586
associated	O	-1	3425586
He@@	O	-1	3425586
in@@	O	-1	3425586
z	O	-1	3425586
body	O	-1	3425586
hemolytic	B-Disease	D000743	3425586
anemia	I-Disease	-1	3425586
in	O	-1	3425586
a	O	-1	3425586
C@@	O	-1	3425586
am@@	O	-1	3425586
bo@@	O	-1	3425586
di@@	O	-1	3425586
an	O	-1	3425586
woman	O	-1	3425586
with	O	-1	3425586
hemo@@	O	-1	3425586
globin	O	-1	3425586
E	O	-1	3425586
tra@@	O	-1	3425586
it@@	O	-1	3425586
.	O	-1	3425586
A	O	-1	3425586
C@@	O	-1	3425586
am@@	O	-1	3425586
bo@@	O	-1	3425586
di@@	O	-1	3425586
an	O	-1	3425586
woman	O	-1	3425586
with	O	-1	3425586
hemo@@	O	-1	3425586
globin	O	-1	3425586
E	O	-1	3425586
tra@@	O	-1	3425586
it	O	-1	3425586
(A@@	O	-1	3425586
E@@	O	-1	3425586
)	O	-1	3425586
and	O	-1	3425586
le@@	B-Disease	D007918	3425586
pro@@	I-Disease	-1	3425586
sy	I-Disease	-1	3425586
developed	O	-1	3425586
a	O	-1	3425586
He@@	O	-1	3425586
in@@	O	-1	3425586
z	O	-1	3425586
body	O	-1	3425586
hemolytic	B-Disease	D000743	3425586
anemia	I-Disease	-1	3425586
while	O	-1	3425586
taking	O	-1	3425586
a	O	-1	3425586
dose	O	-1	3425586
of	O	-1	3425586
d@@	B-Chemical	D003622	3425586
ap@@	I-Chemical	-1	3425586
s@@	I-Chemical	-1	3425586
one	I-Chemical	-1	3425586
(@@	O	-1	3425586
50	O	-1	3425586
mg/@@	O	-1	3425586
day@@	O	-1	3425586
)	O	-1	3425586
not	O	-1	3425586
us@@	O	-1	3425586
ually	O	-1	3425586
associated	O	-1	3425586
with	O	-1	3425586
clinical	O	-1	3425586
hemoly@@	B-Disease	D006461	3425586
sis	I-Disease	-1	3425586
.	O	-1	3425586
H@@	O	-1	3425586
er	O	-1	3425586
red	O	-1	3425586
blood	O	-1	3425586
cells	O	-1	3425586
(@@	O	-1	3425586
R@@	O	-1	3425586
BC@@	O	-1	3425586
s)	O	-1	3425586
had	O	-1	3425586
increased	O	-1	3425586
inc@@	O	-1	3425586
ub@@	O	-1	3425586
ated	O	-1	3425586
He@@	O	-1	3425586
in@@	O	-1	3425586
z	O	-1	3425586
body	O	-1	3425586
form@@	O	-1	3425586
ation,	O	-1	3425586
decreased	O	-1	3425586
reduced	O	-1	3425586
glut@@	B-Chemical	D005978	3425586
athi@@	I-Chemical	-1	3425586
one	I-Chemical	-1	3425586
(	O	-1	3425586
G@@	B-Chemical	D005978	3425586
S@@	I-Chemical	-1	3425586
H	I-Chemical	-1	3425586
),	O	-1	3425586
and	O	-1	3425586
decreased	O	-1	3425586
G@@	B-Chemical	D005978	3425586
S@@	I-Chemical	-1	3425586
H	I-Chemical	-1	3425586
st@@	O	-1	3425586
abil@@	O	-1	3425586
ity.	O	-1	3425586
The	O	-1	3425586
pent@@	B-Chemical	D010428	3425586
ose	I-Chemical	-1	3425586
phosph@@	I-Chemical	-1	3425586
ate	I-Chemical	-1	3425586
sh@@	O	-1	3425586
un@@	O	-1	3425586
t	O	-1	3425586
activity	O	-1	3425586
of	O	-1	3425586
the	O	-1	3425586
d@@	B-Chemical	D003622	3425586
ap@@	I-Chemical	-1	3425586
s@@	I-Chemical	-1	3425586
one	I-Chemical	-1	3425586
-@@	O	-1	3425586
exposed	O	-1	3425586
A@@	O	-1	3425586
E	O	-1	3425586
R@@	O	-1	3425586
BC@@	O	-1	3425586
s	O	-1	3425586
was	O	-1	3425586
increased	O	-1	3425586
compared	O	-1	3425586
to	O	-1	3425586
normal	O	-1	3425586
R@@	O	-1	3425586
BC@@	O	-1	3425586
s.	O	-1	3425586
Although	O	-1	3425586
the	O	-1	3425586
A@@	O	-1	3425586
E	O	-1	3425586
R@@	O	-1	3425586
BC@@	O	-1	3425586
s	O	-1	3425586
from	O	-1	3425586
an	O	-1	3425586
individ@@	O	-1	3425586
ual	O	-1	3425586
not	O	-1	3425586
taking	O	-1	3425586
d@@	B-Chemical	D003622	3425586
ap@@	I-Chemical	-1	3425586
s@@	I-Chemical	-1	3425586
one	I-Chemical	-1	3425586
had	O	-1	3425586
increased	O	-1	3425586
inc@@	O	-1	3425586
ub@@	O	-1	3425586
ated	O	-1	3425586
He@@	O	-1	3425586
in@@	O	-1	3425586
z	O	-1	3425586
body	O	-1	3425586
form@@	O	-1	3425586
ation,	O	-1	3425586
the	O	-1	3425586
G@@	B-Chemical	D005978	3425586
S@@	I-Chemical	-1	3425586
H	I-Chemical	-1	3425586
cont@@	O	-1	3425586
ent	O	-1	3425586
and	O	-1	3425586
G@@	B-Chemical	D005978	3425586
S@@	I-Chemical	-1	3425586
H	I-Chemical	-1	3425586
st@@	O	-1	3425586
ability	O	-1	3425586
were	O	-1	3425586
normal@@	O	-1	3425586
.	O	-1	3425586
The	O	-1	3425586
pent@@	B-Chemical	D010428	3425586
ose	I-Chemical	-1	3425586
phosph@@	I-Chemical	-1	3425586
ate	I-Chemical	-1	3425586
sh@@	O	-1	3425586
un@@	O	-1	3425586
t	O	-1	3425586
activity	O	-1	3425586
of	O	-1	3425586
the	O	-1	3425586
non@@	O	-1	3425586
-	O	-1	3425586
d@@	B-Chemical	D003622	3425586
ap@@	I-Chemical	-1	3425586
s@@	I-Chemical	-1	3425586
one	I-Chemical	-1	3425586
-@@	O	-1	3425586
exposed	O	-1	3425586
A@@	O	-1	3425586
E	O	-1	3425586
R@@	O	-1	3425586
BC@@	O	-1	3425586
s	O	-1	3425586
was	O	-1	3425586
decreased	O	-1	3425586
compared	O	-1	3425586
to	O	-1	3425586
normal	O	-1	3425586
R@@	O	-1	3425586
BC@@	O	-1	3425586
s.	O	-1	3425586
Th@@	O	-1	3425586
us,	O	-1	3425586
A@@	O	-1	3425586
E	O	-1	3425586
R@@	O	-1	3425586
BC@@	O	-1	3425586
s	O	-1	3425586
appe@@	O	-1	3425586
ar	O	-1	3425586
to	O	-1	3425586
have	O	-1	3425586
an	O	-1	3425586
increased	O	-1	3425586
sensitivity	O	-1	3425586
to	O	-1	3425586
oxid@@	O	-1	3425586
ant	O	-1	3425586
stres@@	O	-1	3425586
s	O	-1	3425586
both	O	-1	3425586
in	O	-1	3425586
vit@@	O	-1	3425586
r@@	O	-1	3425586
o	O	-1	3425586
and	O	-1	3425586
in	O	-1	3425586
viv@@	O	-1	3425586
o@@	O	-1	3425586
,	O	-1	3425586
s@@	O	-1	3425586
inc@@	O	-1	3425586
e	O	-1	3425586
d@@	B-Chemical	D003622	3425586
ap@@	I-Chemical	-1	3425586
s@@	I-Chemical	-1	3425586
one	I-Chemical	-1	3425586
does	O	-1	3425586
not	O	-1	3425586
cause	O	-1	3425586
hemolytic	B-Disease	D000743	3425586
anemia	I-Disease	-1	3425586
at	O	-1	3425586
this	O	-1	3425586
dose	O	-1	3425586
in	O	-1	3425586
hemat@@	O	-1	3425586
olog@@	O	-1	3425586
ically	O	-1	3425586
normal	O	-1	3425586
individ@@	O	-1	3425586
u@@	O	-1	3425586
al@@	O	-1	3425586
s.	O	-1	3425586
G@@	O	-1	3425586
i@@	O	-1	3425586
ven	O	-1	3425586
the	O	-1	3425586
influ@@	O	-1	3425586
x	O	-1	3425586
of	O	-1	3425586
S@@	O	-1	3425586
ou@@	O	-1	3425586
the@@	O	-1	3425586
ast	O	-1	3425586
A@@	O	-1	3425586
si@@	O	-1	3425586
ans	O	-1	3425586
into	O	-1	3425586
the	O	-1	3425586
U@@	O	-1	3425586
nit@@	O	-1	3425586
ed	O	-1	3425586
S@@	O	-1	3425586
t@@	O	-1	3425586
at@@	O	-1	3425586
es,	O	-1	3425586
oxid@@	O	-1	3425586
ant	O	-1	3425586
medic@@	O	-1	3425586
ations	O	-1	3425586
should	O	-1	3425586
be	O	-1	3425586
used	O	-1	3425586
with	O	-1	3425586
cau@@	O	-1	3425586
tion,	O	-1	3425586
es@@	O	-1	3425586
p@@	O	-1	3425586
ec@@	O	-1	3425586
i@@	O	-1	3425586
ally	O	-1	3425586
if	O	-1	3425586
an	O	-1	3425586
inf@@	B-Disease	D007239	3425586
ection	I-Disease	-1	3425586
is	O	-1	3425586
present@@	O	-1	3425586
,	O	-1	3425586
in	O	-1	3425586
individ@@	O	-1	3425586
u@@	O	-1	3425586
als	O	-1	3425586
of	O	-1	3425586
eth@@	O	-1	3425586
n@@	O	-1	3425586
ic	O	-1	3425586
bac@@	O	-1	3425586
kg@@	O	-1	3425586
ro@@	O	-1	3425586
un@@	O	-1	3425586
ds	O	-1	3425586
that	O	-1	3425586
have	O	-1	3425586
an	O	-1	3425586
increased	O	-1	3425586
prev@@	O	-1	3425586
al@@	O	-1	3425586
ence	O	-1	3425586
of	O	-1	3425586
hemo@@	O	-1	3425586
globin	O	-1	3425586
E@@	O	-1	3425586
.	O	-1	3425586

S@@	O	-1	3437726
ev@@	O	-1	3437726
ere	O	-1	3437726
complications	O	-1	3437726
of	O	-1	3437726
anti@@	O	-1	3437726
ang@@	O	-1	3437726
inal	O	-1	3437726
drug	O	-1	3437726
therapy	O	-1	3437726
in	O	-1	3437726
a	O	-1	3437726
patient	O	-1	3437726
identi@@	O	-1	3437726
fied	O	-1	3437726
as	O	-1	3437726
a	O	-1	3437726
po@@	O	-1	3437726
or	O	-1	3437726
metabol@@	O	-1	3437726
iz@@	O	-1	3437726
er	O	-1	3437726
of	O	-1	3437726
me@@	B-Chemical	D008790	3437726
to@@	I-Chemical	-1	3437726
pro@@	I-Chemical	-1	3437726
lol	I-Chemical	-1	3437726
,	O	-1	3437726
pro@@	B-Chemical	D011405	3437726
pa@@	I-Chemical	-1	3437726
f@@	I-Chemical	-1	3437726
en@@	I-Chemical	-1	3437726
one	I-Chemical	-1	3437726
,	O	-1	3437726
di@@	B-Chemical	D004110	3437726
l@@	I-Chemical	-1	3437726
ti@@	I-Chemical	-1	3437726
az@@	I-Chemical	-1	3437726
em	I-Chemical	-1	3437726
,	O	-1	3437726
and	O	-1	3437726
s@@	B-Chemical	D013034	3437726
par@@	I-Chemical	-1	3437726
te@@	I-Chemical	-1	3437726
ine	I-Chemical	-1	3437726
.	O	-1	3437726
A	O	-1	3437726
4@@	O	-1	3437726
7-@@	O	-1	3437726
year-old	O	-1	3437726
patient	O	-1	3437726
suff@@	O	-1	3437726
ering	O	-1	3437726
from	O	-1	3437726
coronary	B-Disease	D003324	3437726
artery	I-Disease	-1	3437726
disease	I-Disease	-1	3437726
was	O	-1	3437726
ad@@	O	-1	3437726
mit@@	O	-1	3437726
ted	O	-1	3437726
to	O	-1	3437726
the	O	-1	3437726
C@@	O	-1	3437726
C@@	O	-1	3437726
U	O	-1	3437726
in	O	-1	3437726
sh@@	B-Disease	D012769	3437726
oc@@	I-Disease	-1	3437726
k	I-Disease	-1	3437726
with	O	-1	3437726
II@@	O	-1	3437726
I@@	O	-1	3437726
.	O	-1	3437726
A@@	B-Disease	D054537	3437726
V	I-Disease	-1	3437726
bloc@@	I-Disease	-1	3437726
k	I-Disease	-1	3437726
,	O	-1	3437726
severe	O	-1	3437726
hypotension	B-Disease	D007022	3437726
,	O	-1	3437726
and	O	-1	3437726
impair@@	B-Disease	D018754	3437726
ment	I-Disease	-1	3437726
of	I-Disease	-1	3437726
ventricular	I-Disease	-1	3437726
function	I-Disease	-1	3437726
.	O	-1	3437726
One	O	-1	3437726
week	O	-1	3437726
prior	O	-1	3437726
to	O	-1	3437726
ad@@	O	-1	3437726
mission	O	-1	3437726
a	O	-1	3437726
therapy	O	-1	3437726
with	O	-1	3437726
standard	O	-1	3437726
doses	O	-1	3437726
of	O	-1	3437726
me@@	B-Chemical	D008790	3437726
to@@	I-Chemical	-1	3437726
pro@@	I-Chemical	-1	3437726
lol	I-Chemical	-1	3437726
(@@	O	-1	3437726
100	O	-1	3437726
mg	O	-1	3437726
t@@	O	-1	3437726
.@@	O	-1	3437726
i.@@	O	-1	3437726
d.	O	-1	3437726
and	O	-1	3437726
then	O	-1	3437726
100	O	-1	3437726
mg	O	-1	3437726
b@@	O	-1	3437726
.@@	O	-1	3437726
i.@@	O	-1	3437726
d@@	O	-1	3437726
.)	O	-1	3437726
had	O	-1	3437726
been	O	-1	3437726
initi@@	O	-1	3437726
ated.	O	-1	3437726
Two	O	-1	3437726
days	O	-1	3437726
before	O	-1	3437726
ad@@	O	-1	3437726
mission	O	-1	3437726
di@@	B-Chemical	D004110	3437726
l@@	I-Chemical	-1	3437726
ti@@	I-Chemical	-1	3437726
az@@	I-Chemical	-1	3437726
em	I-Chemical	-1	3437726
(@@	O	-1	3437726
60	O	-1	3437726
mg	O	-1	3437726
b@@	O	-1	3437726
.@@	O	-1	3437726
i.@@	O	-1	3437726
d@@	O	-1	3437726
.)	O	-1	3437726
was	O	-1	3437726
prescri@@	O	-1	3437726
bed	O	-1	3437726
in	O	-1	3437726
addi@@	O	-1	3437726
tion.	O	-1	3437726
An@@	O	-1	3437726
aly@@	O	-1	3437726
ses	O	-1	3437726
of	O	-1	3437726
a	O	-1	3437726
blood	O	-1	3437726
sam@@	O	-1	3437726
ple	O	-1	3437726
revealed	O	-1	3437726
un@@	O	-1	3437726
us@@	O	-1	3437726
ually	O	-1	3437726
high	O	-1	3437726
plasma	O	-1	3437726
concentrations	O	-1	3437726
of	O	-1	3437726
me@@	B-Chemical	D008790	3437726
to@@	I-Chemical	-1	3437726
pro@@	I-Chemical	-1	3437726
lol	I-Chemical	-1	3437726
(@@	O	-1	3437726
greater	O	-1	3437726
than	O	-1	3437726
3@@	O	-1	3437726
0@@	O	-1	3437726
00	O	-1	3437726
n@@	O	-1	3437726
g/@@	O	-1	3437726
ml@@	O	-1	3437726
)	O	-1	3437726
and	O	-1	3437726
di@@	B-Chemical	D004110	3437726
l@@	I-Chemical	-1	3437726
ti@@	I-Chemical	-1	3437726
az@@	I-Chemical	-1	3437726
em	I-Chemical	-1	3437726
(5@@	O	-1	3437726
2@@	O	-1	3437726
6	O	-1	3437726
n@@	O	-1	3437726
g/@@	O	-1	3437726
ml@@	O	-1	3437726
).	O	-1	3437726
The	O	-1	3437726
patient	O	-1	3437726
reco@@	O	-1	3437726
vered	O	-1	3437726
within	O	-1	3437726
1	O	-1	3437726
week	O	-1	3437726
following	O	-1	3437726
discontinu@@	O	-1	3437726
ation	O	-1	3437726
of	O	-1	3437726
anti@@	O	-1	3437726
ang@@	O	-1	3437726
inal	O	-1	3437726
therapy.	O	-1	3437726
Th@@	O	-1	3437726
ree	O	-1	3437726
months	O	-1	3437726
lat@@	O	-1	3437726
er	O	-1	3437726
the	O	-1	3437726
patient	O	-1	3437726
was	O	-1	3437726
exposed	O	-1	3437726
to	O	-1	3437726
a	O	-1	3437726
single	O	-1	3437726
dose	O	-1	3437726
of	O	-1	3437726
me@@	B-Chemical	D008790	3437726
to@@	I-Chemical	-1	3437726
pro@@	I-Chemical	-1	3437726
lol	I-Chemical	-1	3437726
,	O	-1	3437726
di@@	B-Chemical	D004110	3437726
l@@	I-Chemical	-1	3437726
ti@@	I-Chemical	-1	3437726
az@@	I-Chemical	-1	3437726
em	I-Chemical	-1	3437726
,	O	-1	3437726
pro@@	B-Chemical	D011405	3437726
pa@@	I-Chemical	-1	3437726
f@@	I-Chemical	-1	3437726
en@@	I-Chemical	-1	3437726
one	I-Chemical	-1	3437726
(@@	O	-1	3437726
s@@	O	-1	3437726
inc@@	O	-1	3437726
e	O	-1	3437726
he	O	-1	3437726
had	O	-1	3437726
received	O	-1	3437726
this	O	-1	3437726
drug	O	-1	3437726
in	O	-1	3437726
the	O	-1	3437726
pa@@	O	-1	3437726
st@@	O	-1	3437726
),	O	-1	3437726
and	O	-1	3437726
s@@	B-Chemical	D013034	3437726
par@@	I-Chemical	-1	3437726
te@@	I-Chemical	-1	3437726
ine	I-Chemical	-1	3437726
(@@	O	-1	3437726
as	O	-1	3437726
a	O	-1	3437726
pro@@	O	-1	3437726
be	O	-1	3437726
for	O	-1	3437726
the	O	-1	3437726
de@@	B-Chemical	D003647	3437726
b@@	I-Chemical	-1	3437726
ris@@	I-Chemical	-1	3437726
o@@	I-Chemical	-1	3437726
qu@@	I-Chemical	-1	3437726
ine	I-Chemical	-1	3437726
/	O	-1	3437726
s@@	B-Chemical	D013034	3437726
par@@	I-Chemical	-1	3437726
te@@	I-Chemical	-1	3437726
ine	I-Chemical	-1	3437726
type	O	-1	3437726
poly@@	O	-1	3437726
morph@@	O	-1	3437726
ism	O	-1	3437726
of	O	-1	3437726
oxid@@	O	-1	3437726
ative	O	-1	3437726
drug	O	-1	3437726
metabol@@	O	-1	3437726
is@@	O	-1	3437726
m@@	O	-1	3437726
).	O	-1	3437726
It	O	-1	3437726
was	O	-1	3437726
found	O	-1	3437726
that	O	-1	3437726
he	O	-1	3437726
was	O	-1	3437726
a	O	-1	3437726
po@@	O	-1	3437726
or	O	-1	3437726
metabol@@	O	-1	3437726
iz@@	O	-1	3437726
er	O	-1	3437726
of	O	-1	3437726
all	O	-1	3437726
four	O	-1	3437726
drug@@	O	-1	3437726
s,	O	-1	3437726
indicating	O	-1	3437726
that	O	-1	3437726
their	O	-1	3437726
metabol@@	O	-1	3437726
ism	O	-1	3437726
is	O	-1	3437726
under	O	-1	3437726
the	O	-1	3437726
same	O	-1	3437726
gene@@	O	-1	3437726
tic	O	-1	3437726
control@@	O	-1	3437726
.	O	-1	3437726
The@@	O	-1	3437726
refore,	O	-1	3437726
patients	O	-1	3437726
be@@	O	-1	3437726
long@@	O	-1	3437726
ing	O	-1	3437726
to	O	-1	3437726
the	O	-1	3437726
po@@	O	-1	3437726
or@@	O	-1	3437726
-@@	O	-1	3437726
metabol@@	O	-1	3437726
iz@@	O	-1	3437726
er	O	-1	3437726
phen@@	O	-1	3437726
ot@@	O	-1	3437726
yp@@	O	-1	3437726
e	O	-1	3437726
of	O	-1	3437726
s@@	B-Chemical	D013034	3437726
par@@	I-Chemical	-1	3437726
te@@	I-Chemical	-1	3437726
ine	I-Chemical	-1	3437726
/	O	-1	3437726
de@@	B-Chemical	D003647	3437726
b@@	I-Chemical	-1	3437726
ris@@	I-Chemical	-1	3437726
o@@	I-Chemical	-1	3437726
qu@@	I-Chemical	-1	3437726
ine	I-Chemical	-1	3437726
poly@@	O	-1	3437726
morph@@	O	-1	3437726
ism	O	-1	3437726
in	O	-1	3437726
drug	O	-1	3437726
metabol@@	O	-1	3437726
is@@	O	-1	3437726
m@@	O	-1	3437726
,	O	-1	3437726
which	O	-1	3437726
con@@	O	-1	3437726
sti@@	O	-1	3437726
t@@	O	-1	3437726
ut@@	O	-1	3437726
es	O	-1	3437726
6.@@	O	-1	3437726
4@@	O	-1	3437726
%	O	-1	3437726
of	O	-1	3437726
the	O	-1	3437726
G@@	O	-1	3437726
er@@	O	-1	3437726
man	O	-1	3437726
po@@	O	-1	3437726
pul@@	O	-1	3437726
ation,	O	-1	3437726
may	O	-1	3437726
experi@@	O	-1	3437726
ence	O	-1	3437726
adverse	B-Disease	D064420	3437726
drug	I-Disease	-1	3437726
reactions	I-Disease	-1	3437726
when	O	-1	3437726
treated	O	-1	3437726
with	O	-1	3437726
standard	O	-1	3437726
doses	O	-1	3437726
of	O	-1	3437726
one	O	-1	3437726
of	O	-1	3437726
these	O	-1	3437726
drugs	O	-1	3437726
al@@	O	-1	3437726
one.	O	-1	3437726
M@@	O	-1	3437726
ore@@	O	-1	3437726
o@@	O	-1	3437726
ver,	O	-1	3437726
the	O	-1	3437726
co@@	O	-1	3437726
administration	O	-1	3437726
of	O	-1	3437726
these	O	-1	3437726
frequ@@	O	-1	3437726
ently	O	-1	3437726
used	O	-1	3437726
drugs	O	-1	3437726
is	O	-1	3437726
ex@@	O	-1	3437726
p@@	O	-1	3437726
ected	O	-1	3437726
to	O	-1	3437726
be	O	-1	3437726
es@@	O	-1	3437726
p@@	O	-1	3437726
ec@@	O	-1	3437726
i@@	O	-1	3437726
ally	O	-1	3437726
h@@	O	-1	3437726
ar@@	O	-1	3437726
m@@	O	-1	3437726
ful	O	-1	3437726
in	O	-1	3437726
this	O	-1	3437726
sub@@	O	-1	3437726
group	O	-1	3437726
of	O	-1	3437726
patients.	O	-1	3437726

T@@	B-Chemical	D014229	3693336
ri@@	I-Chemical	-1	3693336
azol@@	I-Chemical	-1	3693336
am	I-Chemical	-1	3693336
-induced	O	-1	3693336
b@@	O	-1	3693336
ri@@	O	-1	3693336
e@@	O	-1	3693336
f	O	-1	3693336
episo@@	O	-1	3693336
des	O	-1	3693336
of	O	-1	3693336
secondary	O	-1	3693336
man@@	B-Disease	D001714	3693336
ia	I-Disease	-1	3693336
in	O	-1	3693336
a	O	-1	3693336
depress@@	B-Disease	D003866	3693336
ed	I-Disease	-1	3693336
patient@@	O	-1	3693336
.	O	-1	3693336
L@@	O	-1	3693336
arg@@	O	-1	3693336
e	O	-1	3693336
doses	O	-1	3693336
of	O	-1	3693336
tri@@	B-Chemical	D014229	3693336
azol@@	I-Chemical	-1	3693336
am	I-Chemical	-1	3693336
repe@@	O	-1	3693336
ated@@	O	-1	3693336
ly	O	-1	3693336
induced	O	-1	3693336
b@@	O	-1	3693336
ri@@	O	-1	3693336
e@@	O	-1	3693336
f	O	-1	3693336
episo@@	O	-1	3693336
des	O	-1	3693336
of	O	-1	3693336
man@@	B-Disease	D001714	3693336
ia	I-Disease	-1	3693336
in	O	-1	3693336
a	O	-1	3693336
depress@@	B-Disease	D003866	3693336
ed	I-Disease	-1	3693336
el@@	O	-1	3693336
der@@	O	-1	3693336
ly	O	-1	3693336
wom@@	O	-1	3693336
an@@	O	-1	3693336
.	O	-1	3693336
F@@	O	-1	3693336
e@@	O	-1	3693336
at@@	O	-1	3693336
ures	O	-1	3693336
of	O	-1	3693336
org@@	B-Disease	D019965	3693336
anic	I-Disease	-1	3693336
mental	I-Disease	-1	3693336
disor@@	I-Disease	-1	3693336
der	I-Disease	-1	3693336
(	O	-1	3693336
de@@	B-Disease	D003693	3693336
li@@	I-Disease	-1	3693336
ri@@	I-Disease	-1	3693336
um	I-Disease	-1	3693336
)	O	-1	3693336
were	O	-1	3693336
not	O	-1	3693336
present@@	O	-1	3693336
.	O	-1	3693336
M@@	B-Disease	D001714	3693336
anic	I-Disease	-1	3693336
ex@@	O	-1	3693336
cit@@	O	-1	3693336
ement	O	-1	3693336
was	O	-1	3693336
co@@	O	-1	3693336
inc@@	O	-1	3693336
id@@	O	-1	3693336
ent	O	-1	3693336
with	O	-1	3693336
the	O	-1	3693336
duration	O	-1	3693336
of	O	-1	3693336
action	O	-1	3693336
of	O	-1	3693336
tri@@	B-Chemical	D014229	3693336
azol@@	I-Chemical	-1	3693336
am	I-Chemical	-1	3693336
.	O	-1	3693336
The	O	-1	3693336
possible	O	-1	3693336
cont@@	O	-1	3693336
ri@@	O	-1	3693336
bu@@	O	-1	3693336
tion	O	-1	3693336
of	O	-1	3693336
the	O	-1	3693336
tri@@	B-Chemical	D014229	3693336
azol@@	I-Chemical	-1	3693336
o	I-Chemical	-1	3693336
group	O	-1	3693336
to	O	-1	3693336
changes	O	-1	3693336
in	O	-1	3693336
aff@@	O	-1	3693336
ective	O	-1	3693336
status	O	-1	3693336
is	O	-1	3693336
discus@@	O	-1	3693336
sed.	O	-1	3693336

O@@	O	-1	3780846
n	O	-1	3780846
the	O	-1	3780846
mechanisms	O	-1	3780846
of	O	-1	3780846
the	O	-1	3780846
development	O	-1	3780846
of	O	-1	3780846
toler@@	O	-1	3780846
ance	O	-1	3780846
to	O	-1	3780846
the	O	-1	3780846
mus@@	B-Disease	D009127	3780846
cular	I-Disease	-1	3780846
rig@@	I-Disease	-1	3780846
idity	I-Disease	-1	3780846
produced	O	-1	3780846
by	O	-1	3780846
morphine	B-Chemical	D009020	3780846
in	O	-1	3780846
rats.	O	-1	3780846
The	O	-1	3780846
development	O	-1	3780846
of	O	-1	3780846
toler@@	O	-1	3780846
ance	O	-1	3780846
to	O	-1	3780846
the	O	-1	3780846
mus@@	B-Disease	D009127	3780846
cular	I-Disease	-1	3780846
rig@@	I-Disease	-1	3780846
idity	I-Disease	-1	3780846
produced	O	-1	3780846
by	O	-1	3780846
morphine	B-Chemical	D009020	3780846
was	O	-1	3780846
studied	O	-1	3780846
in	O	-1	3780846
rats.	O	-1	3780846
S@@	O	-1	3780846
al@@	O	-1	3780846
ine-@@	O	-1	3780846
pre@@	O	-1	3780846
treated	O	-1	3780846
controls	O	-1	3780846
given	O	-1	3780846
a	O	-1	3780846
test	O	-1	3780846
dose	O	-1	3780846
of	O	-1	3780846
morphine	B-Chemical	D009020	3780846
(2@@	O	-1	3780846
0	O	-1	3780846
mg/kg	O	-1	3780846
i.p.@@	O	-1	3780846
)	O	-1	3780846
showed	O	-1	3780846
a	O	-1	3780846
p@@	O	-1	3780846
ron@@	O	-1	3780846
oun@@	O	-1	3780846
c@@	O	-1	3780846
ed	O	-1	3780846
rig@@	B-Disease	D009127	3780846
idity	I-Disease	-1	3780846
recor@@	O	-1	3780846
ded	O	-1	3780846
as	O	-1	3780846
t@@	O	-1	3780846
onic	O	-1	3780846
activity	O	-1	3780846
in	O	-1	3780846
the	O	-1	3780846
elect@@	O	-1	3780846
rom@@	O	-1	3780846
yo@@	O	-1	3780846
gram@@	O	-1	3780846
.	O	-1	3780846
R@@	O	-1	3780846
at@@	O	-1	3780846
s	O	-1	3780846
treated	O	-1	3780846
for	O	-1	3780846
11	O	-1	3780846
days	O	-1	3780846
with	O	-1	3780846
morphine	B-Chemical	D009020	3780846
and	O	-1	3780846
withdraw@@	O	-1	3780846
n	O	-1	3780846
for	O	-1	3780846
3@@	O	-1	3780846
6-@@	O	-1	3780846
40	O	-1	3780846
h	O	-1	3780846
showed	O	-1	3780846
differences	O	-1	3780846
in	O	-1	3780846
the	O	-1	3780846
development	O	-1	3780846
of	O	-1	3780846
toler@@	O	-1	3780846
ance@@	O	-1	3780846
:	O	-1	3780846
about	O	-1	3780846
h@@	O	-1	3780846
al@@	O	-1	3780846
f	O	-1	3780846
of	O	-1	3780846
the	O	-1	3780846
animals	O	-1	3780846
showed	O	-1	3780846
a	O	-1	3780846
rig@@	B-Disease	D009127	3780846
idity	I-Disease	-1	3780846
after	O	-1	3780846
the	O	-1	3780846
test	O	-1	3780846
dose	O	-1	3780846
of	O	-1	3780846
morphine	B-Chemical	D009020	3780846
that	O	-1	3780846
was	O	-1	3780846
not	O	-1	3780846
significantly	O	-1	3780846
less	O	-1	3780846
than	O	-1	3780846
in	O	-1	3780846
the	O	-1	3780846
controls	O	-1	3780846
and	O	-1	3780846
were	O	-1	3780846
ak@@	B-Disease	D018476	3780846
ine@@	I-Disease	-1	3780846
tic	I-Disease	-1	3780846
(@@	O	-1	3780846
A	O	-1	3780846
group@@	O	-1	3780846
).	O	-1	3780846
The	O	-1	3780846
other	O	-1	3780846
rats	O	-1	3780846
showed	O	-1	3780846
a	O	-1	3780846
st@@	O	-1	3780846
ron@@	O	-1	3780846
g	O	-1	3780846
decrease	O	-1	3780846
in	O	-1	3780846
the	O	-1	3780846
rig@@	B-Disease	D009127	3780846
idity	I-Disease	-1	3780846
and	O	-1	3780846
the	O	-1	3780846
occur@@	O	-1	3780846
rence	O	-1	3780846
of	O	-1	3780846
ste@@	O	-1	3780846
re@@	O	-1	3780846
ot@@	O	-1	3780846
yp@@	O	-1	3780846
ed	O	-1	3780846
(S@@	O	-1	3780846
)	O	-1	3780846
l@@	O	-1	3780846
ic@@	O	-1	3780846
king	O	-1	3780846
and/or	O	-1	3780846
gn@@	O	-1	3780846
aw@@	O	-1	3780846
ing	O	-1	3780846
in	O	-1	3780846
presence	O	-1	3780846
of	O	-1	3780846
ak@@	B-Disease	D018476	3780846
ine@@	I-Disease	-1	3780846
tic	I-Disease	-1	3780846
or	O	-1	3780846
hyper@@	B-Disease	D006948	3780846
kine@@	I-Disease	-1	3780846
tic	I-Disease	-1	3780846
(@@	O	-1	3780846
K@@	O	-1	3780846
)	O	-1	3780846
behavi@@	O	-1	3780846
our	O	-1	3780846
(A@@	O	-1	3780846
S@@	O	-1	3780846
/@@	O	-1	3780846
K@@	O	-1	3780846
S	O	-1	3780846
group@@	O	-1	3780846
),	O	-1	3780846
suggesting	O	-1	3780846
signs	O	-1	3780846
of	O	-1	3780846
dop@@	O	-1	3780846
aminergic	O	-1	3780846
activ@@	O	-1	3780846
ation.	O	-1	3780846
The	O	-1	3780846
rig@@	B-Disease	D009127	3780846
idity	I-Disease	-1	3780846
was	O	-1	3780846
con@@	O	-1	3780846
si@@	O	-1	3780846
der@@	O	-1	3780846
ably	O	-1	3780846
decreased	O	-1	3780846
in	O	-1	3780846
both	O	-1	3780846
groups	O	-1	3780846
after	O	-1	3780846
20	O	-1	3780846
da@@	O	-1	3780846
ys@@	O	-1	3780846
'	O	-1	3780846
treatment.	O	-1	3780846
In	O	-1	3780846
a	O	-1	3780846
further	O	-1	3780846
seri@@	O	-1	3780846
es	O	-1	3780846
of	O	-1	3780846
experim@@	O	-1	3780846
ent@@	O	-1	3780846
s,	O	-1	3780846
haloperidol	B-Chemical	D006220	3780846
(0.@@	O	-1	3780846
2	O	-1	3780846
mg/kg	O	-1	3780846
i.p.@@	O	-1	3780846
)	O	-1	3780846
was	O	-1	3780846
used	O	-1	3780846
in	O	-1	3780846
or@@	O	-1	3780846
der	O	-1	3780846
to	O	-1	3780846
bloc@@	O	-1	3780846
k	O	-1	3780846
the	O	-1	3780846
dop@@	O	-1	3780846
aminergic	O	-1	3780846
activation	O	-1	3780846
and	O	-1	3780846
to	O	-1	3780846
estim@@	O	-1	3780846
ate	O	-1	3780846
the	O	-1	3780846
re@@	O	-1	3780846
al	O	-1	3780846
de@@	O	-1	3780846
g@@	O	-1	3780846
ree	O	-1	3780846
of	O	-1	3780846
the	O	-1	3780846
toler@@	O	-1	3780846
ance	O	-1	3780846
to	O	-1	3780846
the	O	-1	3780846
rig@@	B-Disease	D009127	3780846
idity	I-Disease	-1	3780846
without	O	-1	3780846
any	O	-1	3780846
dop@@	O	-1	3780846
aminergic	O	-1	3780846
inter@@	O	-1	3780846
fe@@	O	-1	3780846
ren@@	O	-1	3780846
ce@@	O	-1	3780846
.	O	-1	3780846
H@@	B-Chemical	D006220	3780846
alo@@	I-Chemical	-1	3780846
perid@@	I-Chemical	-1	3780846
ol	I-Chemical	-1	3780846
enhanced	O	-1	3780846
the	O	-1	3780846
rig@@	B-Disease	D009127	3780846
idity	I-Disease	-1	3780846
in	O	-1	3780846
the	O	-1	3780846
A	O	-1	3780846
group.	O	-1	3780846
However,	O	-1	3780846
the	O	-1	3780846
level	O	-1	3780846
in	O	-1	3780846
the	O	-1	3780846
A@@	O	-1	3780846
S@@	O	-1	3780846
/@@	O	-1	3780846
K@@	O	-1	3780846
S	O	-1	3780846
group	O	-1	3780846
remained	O	-1	3780846
con@@	O	-1	3780846
si@@	O	-1	3780846
der@@	O	-1	3780846
ably	O	-1	3780846
lower	O	-1	3780846
than	O	-1	3780846
in	O	-1	3780846
the	O	-1	3780846
A	O	-1	3780846
group.	O	-1	3780846
The	O	-1	3780846
results	O	-1	3780846
suggest	O	-1	3780846
that	O	-1	3780846
rig@@	B-Disease	D009127	3780846
idity	I-Disease	-1	3780846
,	O	-1	3780846
which	O	-1	3780846
is	O	-1	3780846
as@@	O	-1	3780846
sum@@	O	-1	3780846
ed	O	-1	3780846
to	O	-1	3780846
be	O	-1	3780846
due	O	-1	3780846
to	O	-1	3780846
an	O	-1	3780846
action	O	-1	3780846
of	O	-1	3780846
morphine	B-Chemical	D009020	3780846
in	O	-1	3780846
the	O	-1	3780846
striat@@	O	-1	3780846
um,	O	-1	3780846
can	O	-1	3780846
be	O	-1	3780846
antagon@@	O	-1	3780846
ized	O	-1	3780846
by	O	-1	3780846
an@@	O	-1	3780846
other	O	-1	3780846
pro@@	O	-1	3780846
cess	O	-1	3780846
lead@@	O	-1	3780846
ing	O	-1	3780846
to	O	-1	3780846
dop@@	O	-1	3780846
aminergic	O	-1	3780846
activation	O	-1	3780846
in	O	-1	3780846
the	O	-1	3780846
striat@@	O	-1	3780846
um@@	O	-1	3780846
.	O	-1	3780846
Ne@@	O	-1	3780846
ver@@	O	-1	3780846
the@@	O	-1	3780846
l@@	O	-1	3780846
es@@	O	-1	3780846
s,	O	-1	3780846
there	O	-1	3780846
occur@@	O	-1	3780846
s	O	-1	3780846
some	O	-1	3780846
re@@	O	-1	3780846
al	O	-1	3780846
toler@@	O	-1	3780846
ance	O	-1	3780846
to	O	-1	3780846
this	O	-1	3780846
effect@@	O	-1	3780846
.	O	-1	3780846
The	O	-1	3780846
ra@@	O	-1	3780846
pid	O	-1	3780846
al@@	O	-1	3780846
tern@@	O	-1	3780846
ations	O	-1	3780846
of	O	-1	3780846
rig@@	B-Disease	D009127	3780846
idity	I-Disease	-1	3780846
and	O	-1	3780846
the	O	-1	3780846
signs	O	-1	3780846
of	O	-1	3780846
dop@@	O	-1	3780846
aminergic	O	-1	3780846
activation	O	-1	3780846
observed	O	-1	3780846
in	O	-1	3780846
the	O	-1	3780846
animals	O	-1	3780846
of	O	-1	3780846
the	O	-1	3780846
A@@	O	-1	3780846
S@@	O	-1	3780846
/@@	O	-1	3780846
K@@	O	-1	3780846
S	O	-1	3780846
group	O	-1	3780846
might	O	-1	3780846
be	O	-1	3780846
due	O	-1	3780846
to	O	-1	3780846
ra@@	O	-1	3780846
pid	O	-1	3780846
shi@@	O	-1	3780846
f@@	O	-1	3780846
ts	O	-1	3780846
in	O	-1	3780846
the	O	-1	3780846
pre@@	O	-1	3780846
domin@@	O	-1	3780846
ance	O	-1	3780846
of	O	-1	3780846
various	O	-1	3780846
D@@	O	-1	3780846
A@@	O	-1	3780846
-@@	O	-1	3780846
in@@	O	-1	3780846
ner@@	O	-1	3780846
v@@	O	-1	3780846
ated	O	-1	3780846
struc@@	O	-1	3780846
tu@@	O	-1	3780846
res@@	O	-1	3780846
.	O	-1	3780846

Com@@	B-Disease	D009408	3800626
pression	I-Disease	-1	3800626
neuropathy	I-Disease	-1	3800626
of	I-Disease	-1	3800626
the	I-Disease	-1	3800626
radi@@	I-Disease	-1	3800626
al	I-Disease	-1	3800626
nerve	I-Disease	-1	3800626
Com@@	B-Disease	D020425	3800626
pression	I-Disease	-1	3800626
neuropathy	I-Disease	-1	3800626
of	I-Disease	-1	3800626
the	I-Disease	-1	3800626
radi@@	I-Disease	-1	3800626
al	I-Disease	-1	3800626
nerve	I-Disease	-1	3800626
due	O	-1	3800626
to	O	-1	3800626
pent@@	B-Chemical	D010423	3800626
az@@	I-Chemical	-1	3800626
oc@@	I-Chemical	-1	3800626
ine	I-Chemical	-1	3800626
-induced	O	-1	3800626
fib@@	B-Disease	D005355	3800626
rou@@	I-Disease	-1	3800626
s	I-Disease	-1	3800626
my@@	I-Disease	-1	3800626
o@@	I-Disease	-1	3800626
pathy	I-Disease	-1	3800626
fib@@	B-Disease	D009135	3800626
rou@@	I-Disease	-1	3800626
s	I-Disease	-1	3800626
my@@	I-Disease	-1	3800626
o@@	I-Disease	-1	3800626
pathy	I-Disease	-1	3800626
.	O	-1	3800626
F@@	B-Disease	D005355	3800626
i@@	I-Disease	-1	3800626
b@@	I-Disease	-1	3800626
rou@@	I-Disease	-1	3800626
s	I-Disease	-1	3800626
my@@	I-Disease	-1	3800626
o@@	I-Disease	-1	3800626
pathy	I-Disease	-1	3800626
F@@	B-Disease	D009135	3800626
i@@	I-Disease	-1	3800626
b@@	I-Disease	-1	3800626
rou@@	I-Disease	-1	3800626
s	I-Disease	-1	3800626
my@@	I-Disease	-1	3800626
o@@	I-Disease	-1	3800626
pathy	I-Disease	-1	3800626
is	O	-1	3800626
a	O	-1	3800626
common@@	O	-1	3800626
,	O	-1	3800626
we@@	O	-1	3800626
ll@@	O	-1	3800626
-@@	O	-1	3800626
known	O	-1	3800626
side	O	-1	3800626
effect	O	-1	3800626
of	O	-1	3800626
repe@@	O	-1	3800626
ated	O	-1	3800626
pent@@	B-Chemical	D010423	3800626
az@@	I-Chemical	-1	3800626
oc@@	I-Chemical	-1	3800626
ine	I-Chemical	-1	3800626
injec@@	O	-1	3800626
tion.	O	-1	3800626
However,	O	-1	3800626
com@@	B-Disease	D009408	3800626
pression	I-Disease	-1	3800626
neuropathy	I-Disease	-1	3800626
due	O	-1	3800626
to	O	-1	3800626
fib@@	O	-1	3800626
ro@@	O	-1	3800626
tic	O	-1	3800626
musc@@	O	-1	3800626
le	O	-1	3800626
affected	O	-1	3800626
by	O	-1	3800626
pent@@	B-Chemical	D010423	3800626
az@@	I-Chemical	-1	3800626
oc@@	I-Chemical	-1	3800626
ine	I-Chemical	-1	3800626
-induced	O	-1	3800626
my@@	B-Disease	D009135	3800626
o@@	I-Disease	-1	3800626
pathy	I-Disease	-1	3800626
has	O	-1	3800626
not	O	-1	3800626
previously	O	-1	3800626
been	O	-1	3800626
repor@@	O	-1	3800626
ted.	O	-1	3800626
In	O	-1	3800626
a	O	-1	3800626
3@@	O	-1	3800626
7-@@	O	-1	3800626
year-old	O	-1	3800626
woman	O	-1	3800626
with	O	-1	3800626
doc@@	O	-1	3800626
um@@	O	-1	3800626
ent@@	O	-1	3800626
ed	O	-1	3800626
pent@@	B-Chemical	D010423	3800626
az@@	I-Chemical	-1	3800626
oc@@	I-Chemical	-1	3800626
ine	I-Chemical	-1	3800626
-induced	O	-1	3800626
fib@@	B-Disease	D005355	3800626
rou@@	I-Disease	-1	3800626
s	I-Disease	-1	3800626
my@@	I-Disease	-1	3800626
o@@	I-Disease	-1	3800626
pathy	I-Disease	-1	3800626
fib@@	B-Disease	D009135	3800626
rou@@	I-Disease	-1	3800626
s	I-Disease	-1	3800626
my@@	I-Disease	-1	3800626
o@@	I-Disease	-1	3800626
pathy	I-Disease	-1	3800626
of	O	-1	3800626
tr@@	O	-1	3800626
icep@@	O	-1	3800626
s	O	-1	3800626
and	O	-1	3800626
del@@	O	-1	3800626
to@@	O	-1	3800626
id	O	-1	3800626
musc@@	O	-1	3800626
le@@	O	-1	3800626
s	O	-1	3800626
bil@@	O	-1	3800626
at@@	O	-1	3800626
er@@	O	-1	3800626
ally	O	-1	3800626
and	O	-1	3800626
a	O	-1	3800626
th@@	O	-1	3800626
re@@	O	-1	3800626
e-@@	O	-1	3800626
week	O	-1	3800626
hist@@	O	-1	3800626
ory	O	-1	3800626
of	O	-1	3800626
right	O	-1	3800626
w@@	O	-1	3800626
ris@@	O	-1	3800626
t	O	-1	3800626
dro@@	O	-1	3800626
p@@	O	-1	3800626
,	O	-1	3800626
electro@@	O	-1	3800626
diagnos@@	O	-1	3800626
tic	O	-1	3800626
examin@@	O	-1	3800626
ation	O	-1	3800626
showed	O	-1	3800626
a	O	-1	3800626
severe	O	-1	3800626
but	O	-1	3800626
partial	O	-1	3800626
le@@	O	-1	3800626
sion	O	-1	3800626
of	O	-1	3800626
the	O	-1	3800626
right	O	-1	3800626
radi@@	O	-1	3800626
al	O	-1	3800626
nerve	O	-1	3800626
dist@@	O	-1	3800626
al	O	-1	3800626
to	O	-1	3800626
the	O	-1	3800626
b@@	O	-1	3800626
ran@@	O	-1	3800626
ch@@	O	-1	3800626
es	O	-1	3800626
to	O	-1	3800626
the	O	-1	3800626
tr@@	O	-1	3800626
icep@@	O	-1	3800626
s,	O	-1	3800626
in	O	-1	3800626
addition	O	-1	3800626
to	O	-1	3800626
the	O	-1	3800626
fib@@	B-Disease	D005355	3800626
rou@@	I-Disease	-1	3800626
s	I-Disease	-1	3800626
my@@	I-Disease	-1	3800626
o@@	I-Disease	-1	3800626
pathy	I-Disease	-1	3800626
fib@@	B-Disease	D009135	3800626
rou@@	I-Disease	-1	3800626
s	I-Disease	-1	3800626
my@@	I-Disease	-1	3800626
o@@	I-Disease	-1	3800626
pathy	I-Disease	-1	3800626
.	O	-1	3800626
S@@	O	-1	3800626
ur@@	O	-1	3800626
g@@	O	-1	3800626
er@@	O	-1	3800626
y	O	-1	3800626
revealed	O	-1	3800626
the	O	-1	3800626
right	O	-1	3800626
radi@@	O	-1	3800626
al	O	-1	3800626
nerve	O	-1	3800626
to	O	-1	3800626
be	O	-1	3800626
se@@	O	-1	3800626
ve@@	O	-1	3800626
re@@	O	-1	3800626
ly	O	-1	3800626
com@@	O	-1	3800626
press@@	O	-1	3800626
ed	O	-1	3800626
by	O	-1	3800626
the	O	-1	3800626
d@@	O	-1	3800626
en@@	O	-1	3800626
se@@	O	-1	3800626
ly	O	-1	3800626
fib@@	O	-1	3800626
ro@@	O	-1	3800626
tic	O	-1	3800626
lat@@	O	-1	3800626
eral	O	-1	3800626
he@@	O	-1	3800626
ad	O	-1	3800626
of	O	-1	3800626
the	O	-1	3800626
tr@@	O	-1	3800626
icep@@	O	-1	3800626
s.	O	-1	3800626
D@@	O	-1	3800626
ec@@	O	-1	3800626
om@@	O	-1	3800626
pression	O	-1	3800626
and	O	-1	3800626
neuro@@	O	-1	3800626
ly@@	O	-1	3800626
sis	O	-1	3800626
were	O	-1	3800626
performed	O	-1	3800626
with	O	-1	3800626
go@@	O	-1	3800626
od	O	-1	3800626
subsequ@@	O	-1	3800626
ent	O	-1	3800626
recovery	O	-1	3800626
of	O	-1	3800626
func@@	O	-1	3800626
tion.	O	-1	3800626

Rec@@	O	-1	3827439
ur@@	O	-1	3827439
rent	O	-1	3827439
reversible	O	-1	3827439
acute	B-Disease	D058186	3827439
renal	I-Disease	-1	3827439
failure	I-Disease	-1	3827439
from	O	-1	3827439
amph@@	B-Chemical	D000666	3827439
ot@@	I-Chemical	-1	3827439
er@@	I-Chemical	-1	3827439
icin	I-Chemical	-1	3827439
.	O	-1	3827439
A	O	-1	3827439
patient	O	-1	3827439
with	O	-1	3827439
c@@	O	-1	3827439
r@@	O	-1	3827439
y@@	O	-1	3827439
pto@@	O	-1	3827439
genic	O	-1	3827439
cir@@	B-Disease	D005355	3827439
r@@	I-Disease	-1	3827439
ho@@	I-Disease	-1	3827439
sis	I-Disease	-1	3827439
and	O	-1	3827439
dis@@	O	-1	3827439
se@@	O	-1	3827439
min@@	O	-1	3827439
ated	O	-1	3827439
s@@	B-Disease	D013174	3827439
po@@	I-Disease	-1	3827439
ro@@	I-Disease	-1	3827439
tr@@	I-Disease	-1	3827439
ic@@	I-Disease	-1	3827439
ho@@	I-Disease	-1	3827439
sis	I-Disease	-1	3827439
developed	O	-1	3827439
acute	B-Disease	D058186	3827439
renal	I-Disease	-1	3827439
failure	I-Disease	-1	3827439
immedi@@	O	-1	3827439
ately	O	-1	3827439
following	O	-1	3827439
the	O	-1	3827439
administration	O	-1	3827439
of	O	-1	3827439
amph@@	B-Chemical	D000666	3827439
ot@@	I-Chemical	-1	3827439
er@@	I-Chemical	-1	3827439
icin	I-Chemical	-1	3827439
B	I-Chemical	-1	3827439
on	O	-1	3827439
four	O	-1	3827439
se@@	O	-1	3827439
par@@	O	-1	3827439
ate	O	-1	3827439
oc@@	O	-1	3827439
ca@@	O	-1	3827439
sion@@	O	-1	3827439
s.	O	-1	3827439
The	O	-1	3827439
ab@@	O	-1	3827439
ru@@	O	-1	3827439
pt@@	O	-1	3827439
ness	O	-1	3827439
of	O	-1	3827439
the	O	-1	3827439
renal	B-Disease	D051437	3827439
failure	I-Disease	-1	3827439
and	O	-1	3827439
its	O	-1	3827439
rever@@	O	-1	3827439
sib@@	O	-1	3827439
ility	O	-1	3827439
within	O	-1	3827439
days	O	-1	3827439
suggests	O	-1	3827439
that	O	-1	3827439
there	O	-1	3827439
was	O	-1	3827439
a	O	-1	3827439
functional	O	-1	3827439
comp@@	O	-1	3827439
on@@	O	-1	3827439
ent	O	-1	3827439
to	O	-1	3827439
the	O	-1	3827439
renal	B-Disease	D007674	3827439
dysfunction	I-Disease	-1	3827439
.	O	-1	3827439
We	O	-1	3827439
prop@@	O	-1	3827439
ose	O	-1	3827439
that	O	-1	3827439
amph@@	B-Chemical	D000666	3827439
ot@@	I-Chemical	-1	3827439
er@@	I-Chemical	-1	3827439
icin	I-Chemical	-1	3827439
,	O	-1	3827439
in	O	-1	3827439
the	O	-1	3827439
se@@	O	-1	3827439
t@@	O	-1	3827439
ting	O	-1	3827439
of	O	-1	3827439
reduced	O	-1	3827439
effective	O	-1	3827439
arterial	O	-1	3827439
vol@@	O	-1	3827439
u@@	O	-1	3827439
me,	O	-1	3827439
may	O	-1	3827439
activ@@	O	-1	3827439
ate	O	-1	3827439
tu@@	O	-1	3827439
bu@@	O	-1	3827439
log@@	O	-1	3827439
lo@@	O	-1	3827439
mer@@	O	-1	3827439
ular	O	-1	3827439
fe@@	O	-1	3827439
ed@@	O	-1	3827439
bac@@	O	-1	3827439
k@@	O	-1	3827439
,	O	-1	3827439
the@@	O	-1	3827439
re@@	O	-1	3827439
by	O	-1	3827439
cont@@	O	-1	3827439
ri@@	O	-1	3827439
but@@	O	-1	3827439
ing	O	-1	3827439
to	O	-1	3827439
acute	B-Disease	D058186	3827439
renal	I-Disease	-1	3827439
failure	I-Disease	-1	3827439
.	O	-1	3827439

P@@	O	-1	3997294
ne@@	O	-1	3997294
um@@	O	-1	3997294
on@@	O	-1	3997294
iti@@	O	-1	3997294
s	O	-1	3997294
with	O	-1	3997294
ple@@	B-Disease	D010996	3997294
ural	I-Disease	-1	3997294
and	I-Disease	-1	3997294
per@@	I-Disease	-1	3997294
ic@@	I-Disease	-1	3997294
ardi@@	I-Disease	-1	3997294
al	I-Disease	-1	3997294
eff@@	I-Disease	-1	3997294
usion	I-Disease	-1	3997294
ple@@	B-Disease	D010490	3997294
ural	I-Disease	-1	3997294
and	I-Disease	-1	3997294
per@@	I-Disease	-1	3997294
ic@@	I-Disease	-1	3997294
ardi@@	I-Disease	-1	3997294
al	I-Disease	-1	3997294
eff@@	I-Disease	-1	3997294
usion	I-Disease	-1	3997294
and	O	-1	3997294
neuropathy	B-Disease	D009422	3997294
during	O	-1	3997294
am@@	B-Chemical	D000638	3997294
iodar@@	I-Chemical	-1	3997294
one	I-Chemical	-1	3997294
therapy.	O	-1	3997294
A	O	-1	3997294
patient	O	-1	3997294
with	O	-1	3997294
s@@	B-Disease	D002318	3997294
in@@	I-Disease	-1	3997294
u@@	I-Disease	-1	3997294
atrial	I-Disease	-1	3997294
disease	I-Disease	-1	3997294
and	O	-1	3997294
im@@	O	-1	3997294
pl@@	O	-1	3997294
ant@@	O	-1	3997294
ed	O	-1	3997294
pac@@	O	-1	3997294
em@@	O	-1	3997294
ak@@	O	-1	3997294
er	O	-1	3997294
was	O	-1	3997294
treated	O	-1	3997294
with	O	-1	3997294
am@@	B-Chemical	D000638	3997294
iodar@@	I-Chemical	-1	3997294
one	I-Chemical	-1	3997294
(@@	O	-1	3997294
maxim@@	O	-1	3997294
um	O	-1	3997294
dose	O	-1	3997294
10@@	O	-1	3997294
00	O	-1	3997294
mg@@	O	-1	3997294
,	O	-1	3997294
maint@@	O	-1	3997294
en@@	O	-1	3997294
ance	O	-1	3997294
dose	O	-1	3997294
8@@	O	-1	3997294
00	O	-1	3997294
mg	O	-1	3997294
da@@	O	-1	3997294
il@@	O	-1	3997294
y@@	O	-1	3997294
)	O	-1	3997294
for	O	-1	3997294
10	O	-1	3997294
month@@	O	-1	3997294
s,	O	-1	3997294
for	O	-1	3997294
control	O	-1	3997294
of	O	-1	3997294
sup@@	B-Disease	D013617	3997294
ra@@	I-Disease	-1	3997294
ventricular	I-Disease	-1	3997294
tachy@@	I-Disease	-1	3997294
arrhyth@@	I-Disease	-1	3997294
mi@@	I-Disease	-1	3997294
as	I-Disease	-1	3997294
.	O	-1	3997294
H@@	O	-1	3997294
e	O	-1	3997294
developed	O	-1	3997294
p@@	B-Disease	D011014	3997294
ne@@	I-Disease	-1	3997294
um@@	I-Disease	-1	3997294
on@@	I-Disease	-1	3997294
iti@@	I-Disease	-1	3997294
s	I-Disease	-1	3997294
,	O	-1	3997294
ple@@	B-Disease	D010996	3997294
ural	I-Disease	-1	3997294
and	I-Disease	-1	3997294
per@@	I-Disease	-1	3997294
ic@@	I-Disease	-1	3997294
ardi@@	I-Disease	-1	3997294
al	I-Disease	-1	3997294
eff@@	I-Disease	-1	3997294
u@@	I-Disease	-1	3997294
sions	I-Disease	-1	3997294
ple@@	B-Disease	D010490	3997294
ural	I-Disease	-1	3997294
and	I-Disease	-1	3997294
per@@	I-Disease	-1	3997294
ic@@	I-Disease	-1	3997294
ardi@@	I-Disease	-1	3997294
al	I-Disease	-1	3997294
eff@@	I-Disease	-1	3997294
u@@	I-Disease	-1	3997294
sions	I-Disease	-1	3997294
,	O	-1	3997294
and	O	-1	3997294
a	O	-1	3997294
pre@@	O	-1	3997294
domin@@	O	-1	3997294
ant@@	O	-1	3997294
ly	O	-1	3997294
pro@@	B-Disease	D009468	3997294
xim@@	I-Disease	-1	3997294
al	I-Disease	-1	3997294
motor	I-Disease	-1	3997294
neuropathy	I-Disease	-1	3997294
.	O	-1	3997294
Im@@	O	-1	3997294
medi@@	O	-1	3997294
ate	O	-1	3997294
but	O	-1	3997294
gra@@	O	-1	3997294
du@@	O	-1	3997294
al	O	-1	3997294
impro@@	O	-1	3997294
vement	O	-1	3997294
followed	O	-1	3997294
withdrawal	O	-1	3997294
of	O	-1	3997294
am@@	B-Chemical	D000638	3997294
iodar@@	I-Chemical	-1	3997294
one	I-Chemical	-1	3997294
and	O	-1	3997294
treatment	O	-1	3997294
with	O	-1	3997294
pre@@	B-Chemical	D011239	3997294
d@@	I-Chemical	-1	3997294
n@@	I-Chemical	-1	3997294
isol@@	I-Chemical	-1	3997294
one	I-Chemical	-1	3997294
.	O	-1	3997294
Re@@	O	-1	3997294
vie@@	O	-1	3997294
w	O	-1	3997294
of	O	-1	3997294
this	O	-1	3997294
and	O	-1	3997294
previously	O	-1	3997294
reported	O	-1	3997294
cases	O	-1	3997294
indic@@	O	-1	3997294
ates	O	-1	3997294
the	O	-1	3997294
need	O	-1	3997294
for	O	-1	3997294
early	O	-1	3997294
diagnosis	O	-1	3997294
of	O	-1	3997294
am@@	B-Chemical	D000638	3997294
iodar@@	I-Chemical	-1	3997294
one	I-Chemical	-1	3997294
p@@	B-Disease	D011014	3997294
ne@@	I-Disease	-1	3997294
um@@	I-Disease	-1	3997294
on@@	I-Disease	-1	3997294
iti@@	I-Disease	-1	3997294
s	I-Disease	-1	3997294
,	O	-1	3997294
immedi@@	O	-1	3997294
ate	O	-1	3997294
withdrawal	O	-1	3997294
of	O	-1	3997294
am@@	B-Chemical	D000638	3997294
iodar@@	I-Chemical	-1	3997294
one	I-Chemical	-1	3997294
,	O	-1	3997294
and	O	-1	3997294
pro@@	O	-1	3997294
m@@	O	-1	3997294
p@@	O	-1	3997294
t	O	-1	3997294
but	O	-1	3997294
continu@@	O	-1	3997294
ed	O	-1	3997294
ster@@	B-Chemical	D013256	3997294
oid	I-Chemical	-1	3997294
therapy	O	-1	3997294
to	O	-1	3997294
ens@@	O	-1	3997294
ure	O	-1	3997294
ful@@	O	-1	3997294
l	O	-1	3997294
reco@@	O	-1	3997294
ver@@	O	-1	3997294
y.	O	-1	3997294

In@@	B-Chemical	D007213	4071154
do@@	I-Chemical	-1	4071154
meth@@	I-Chemical	-1	4071154
ac@@	I-Chemical	-1	4071154
in	I-Chemical	-1	4071154
-induced	O	-1	4071154
renal	B-Disease	D051437	4071154
in@@	I-Disease	-1	4071154
suffici@@	I-Disease	-1	4071154
ency	I-Disease	-1	4071154
:	O	-1	4071154
recur@@	O	-1	4071154
rence	O	-1	4071154
on	O	-1	4071154
re@@	O	-1	4071154
ch@@	O	-1	4071154
all@@	O	-1	4071154
en@@	O	-1	4071154
g@@	O	-1	4071154
e.	O	-1	4071154
We	O	-1	4071154
have	O	-1	4071154
reported	O	-1	4071154
a	O	-1	4071154
case	O	-1	4071154
of	O	-1	4071154
acute	O	-1	4071154
ol@@	O	-1	4071154
ig@@	O	-1	4071154
ur@@	O	-1	4071154
ic	O	-1	4071154
renal	B-Disease	D051437	4071154
failure	I-Disease	-1	4071154
with	O	-1	4071154
hyper@@	B-Disease	D006947	4071154
k@@	I-Disease	-1	4071154
al@@	I-Disease	-1	4071154
emia	I-Disease	-1	4071154
in	O	-1	4071154
a	O	-1	4071154
patient	O	-1	4071154
with	O	-1	4071154
cir@@	B-Disease	D005355	4071154
r@@	I-Disease	-1	4071154
ho@@	I-Disease	-1	4071154
sis	I-Disease	-1	4071154
,	O	-1	4071154
as@@	B-Disease	D001201	4071154
cit@@	I-Disease	-1	4071154
es	I-Disease	-1	4071154
,	O	-1	4071154
and	O	-1	4071154
c@@	B-Disease	D011660	4071154
or	I-Disease	-1	4071154
pul@@	I-Disease	-1	4071154
mon@@	I-Disease	-1	4071154
al@@	I-Disease	-1	4071154
e	I-Disease	-1	4071154
after	O	-1	4071154
in@@	B-Chemical	D007213	4071154
do@@	I-Chemical	-1	4071154
meth@@	I-Chemical	-1	4071154
ac@@	I-Chemical	-1	4071154
in	I-Chemical	-1	4071154
therapy.	O	-1	4071154
P@@	O	-1	4071154
rom@@	O	-1	4071154
p@@	O	-1	4071154
t	O	-1	4071154
rest@@	O	-1	4071154
or@@	O	-1	4071154
ation	O	-1	4071154
of	O	-1	4071154
renal	O	-1	4071154
function	O	-1	4071154
followed	O	-1	4071154
drug	O	-1	4071154
withdraw@@	O	-1	4071154
al,	O	-1	4071154
while	O	-1	4071154
re@@	O	-1	4071154
-@@	O	-1	4071154
exposure	O	-1	4071154
to	O	-1	4071154
a	O	-1	4071154
single	O	-1	4071154
dose	O	-1	4071154
of	O	-1	4071154
in@@	B-Chemical	D007213	4071154
do@@	I-Chemical	-1	4071154
meth@@	I-Chemical	-1	4071154
ac@@	I-Chemical	-1	4071154
in	I-Chemical	-1	4071154
caused	O	-1	4071154
recur@@	O	-1	4071154
rence	O	-1	4071154
of	O	-1	4071154
acute	O	-1	4071154
reversible	O	-1	4071154
ol@@	B-Disease	D009846	4071154
ig@@	I-Disease	-1	4071154
uria	I-Disease	-1	4071154
.	O	-1	4071154
Our	O	-1	4071154
case	O	-1	4071154
suppor@@	O	-1	4071154
ts	O	-1	4071154
the	O	-1	4071154
hypo@@	O	-1	4071154
thesis	O	-1	4071154
that	O	-1	4071154
endo@@	O	-1	4071154
gen@@	O	-1	4071154
ous	O	-1	4071154
renal	O	-1	4071154
pro@@	B-Chemical	D011453	4071154
st@@	I-Chemical	-1	4071154
ag@@	I-Chemical	-1	4071154
l@@	I-Chemical	-1	4071154
and@@	I-Chemical	-1	4071154
ins	I-Chemical	-1	4071154
pl@@	O	-1	4071154
ay	O	-1	4071154
a	O	-1	4071154
role	O	-1	4071154
in	O	-1	4071154
the	O	-1	4071154
maint@@	O	-1	4071154
en@@	O	-1	4071154
ance	O	-1	4071154
of	O	-1	4071154
renal	O	-1	4071154
blood	O	-1	4071154
flow	O	-1	4071154
when	O	-1	4071154
cir@@	O	-1	4071154
cul@@	O	-1	4071154
ating	O	-1	4071154
plasma	O	-1	4071154
volume	O	-1	4071154
is	O	-1	4071154
di@@	O	-1	4071154
min@@	O	-1	4071154
is@@	O	-1	4071154
he@@	O	-1	4071154
d.	O	-1	4071154
S@@	O	-1	4071154
inc@@	O	-1	4071154
e	O	-1	4071154
non@@	O	-1	4071154
steroid@@	O	-1	4071154
al	O	-1	4071154
anti@@	O	-1	4071154
-@@	O	-1	4071154
inflam@@	O	-1	4071154
mat@@	O	-1	4071154
ory	O	-1	4071154
agents	O	-1	4071154
inter@@	O	-1	4071154
f@@	O	-1	4071154
ere	O	-1	4071154
with	O	-1	4071154
this	O	-1	4071154
com@@	O	-1	4071154
pen@@	O	-1	4071154
s@@	O	-1	4071154
atory	O	-1	4071154
mechanism	O	-1	4071154
and	O	-1	4071154
may	O	-1	4071154
cause	O	-1	4071154
acute	B-Disease	D058186	4071154
renal	I-Disease	-1	4071154
failure	I-Disease	-1	4071154
,	O	-1	4071154
they	O	-1	4071154
should	O	-1	4071154
be	O	-1	4071154
used	O	-1	4071154
with	O	-1	4071154
cau@@	O	-1	4071154
tion	O	-1	4071154
in	O	-1	4071154
such	O	-1	4071154
patients.	O	-1	4071154

Com@@	O	-1	6103707
par@@	O	-1	6103707
ison	O	-1	6103707
of	O	-1	6103707
the	O	-1	6103707
subj@@	O	-1	6103707
ective	O	-1	6103707
effects	O	-1	6103707
and	O	-1	6103707
plasma	O	-1	6103707
concentrations	O	-1	6103707
following	O	-1	6103707
oral	O	-1	6103707
and	O	-1	6103707
i.@@	O	-1	6103707
m.	O	-1	6103707
administration	O	-1	6103707
of	O	-1	6103707
f@@	B-Chemical	D005445	6103707
l@@	I-Chemical	-1	6103707
un@@	I-Chemical	-1	6103707
it@@	I-Chemical	-1	6103707
ra@@	I-Chemical	-1	6103707
z@@	I-Chemical	-1	6103707
epam	I-Chemical	-1	6103707
in	O	-1	6103707
vol@@	O	-1	6103707
un@@	O	-1	6103707
te@@	O	-1	6103707
ers.	O	-1	6103707
F@@	B-Chemical	D005445	6103707
l@@	I-Chemical	-1	6103707
un@@	I-Chemical	-1	6103707
it@@	I-Chemical	-1	6103707
ra@@	I-Chemical	-1	6103707
z@@	I-Chemical	-1	6103707
epam	I-Chemical	-1	6103707
0.@@	O	-1	6103707
5,	O	-1	6103707
1.@@	O	-1	6103707
0	O	-1	6103707
or	O	-1	6103707
2.@@	O	-1	6103707
0	O	-1	6103707
mg	O	-1	6103707
was	O	-1	6103707
given	O	-1	6103707
by	O	-1	6103707
the	O	-1	6103707
oral	O	-1	6103707
or	O	-1	6103707
i.@@	O	-1	6103707
m.	O	-1	6103707
ro@@	O	-1	6103707
ut@@	O	-1	6103707
es	O	-1	6103707
to	O	-1	6103707
groups	O	-1	6103707
of	O	-1	6103707
vol@@	O	-1	6103707
un@@	O	-1	6103707
te@@	O	-1	6103707
ers	O	-1	6103707
and	O	-1	6103707
its	O	-1	6103707
effects	O	-1	6103707
com@@	O	-1	6103707
pa@@	O	-1	6103707
red.	O	-1	6103707
P@@	O	-1	6103707
las@@	O	-1	6103707
ma	O	-1	6103707
concentrations	O	-1	6103707
of	O	-1	6103707
the	O	-1	6103707
drug	O	-1	6103707
were	O	-1	6103707
estim@@	O	-1	6103707
ated	O	-1	6103707
by	O	-1	6103707
g@@	O	-1	6103707
as@@	O	-1	6103707
-@@	O	-1	6103707
li@@	O	-1	6103707
qu@@	O	-1	6103707
id	O	-1	6103707
ch@@	O	-1	6103707
rom@@	O	-1	6103707
at@@	O	-1	6103707
ograph@@	O	-1	6103707
y,	O	-1	6103707
in	O	-1	6103707
a	O	-1	6103707
sm@@	O	-1	6103707
all@@	O	-1	6103707
er	O	-1	6103707
number	O	-1	6103707
of	O	-1	6103707
the	O	-1	6103707
subj@@	O	-1	6103707
ect@@	O	-1	6103707
s.	O	-1	6103707
The	O	-1	6103707
most	O	-1	6103707
stri@@	O	-1	6103707
king	O	-1	6103707
effect	O	-1	6103707
was	O	-1	6103707
sed@@	O	-1	6103707
ation	O	-1	6103707
which	O	-1	6103707
increased	O	-1	6103707
with	O	-1	6103707
the	O	-1	6103707
dose@@	O	-1	6103707
,	O	-1	6103707
2	O	-1	6103707
mg	O	-1	6103707
produc@@	O	-1	6103707
ing	O	-1	6103707
de@@	O	-1	6103707
ep	O	-1	6103707
sleep	O	-1	6103707
although	O	-1	6103707
the	O	-1	6103707
subjects	O	-1	6103707
could	O	-1	6103707
sti@@	O	-1	6103707
ll	O	-1	6103707
be	O	-1	6103707
a@@	O	-1	6103707
rou@@	O	-1	6103707
sed.	O	-1	6103707
The	O	-1	6103707
effects	O	-1	6103707
of	O	-1	6103707
i.@@	O	-1	6103707
m.	O	-1	6103707
administration	O	-1	6103707
were	O	-1	6103707
appa@@	O	-1	6103707
rent	O	-1	6103707
ear@@	O	-1	6103707
li@@	O	-1	6103707
er	O	-1	6103707
and	O	-1	6103707
so@@	O	-1	6103707
me@@	O	-1	6103707
times	O	-1	6103707
l@@	O	-1	6103707
ast@@	O	-1	6103707
ed	O	-1	6103707
long@@	O	-1	6103707
er	O	-1	6103707
than	O	-1	6103707
those	O	-1	6103707
following	O	-1	6103707
oral	O	-1	6103707
administr@@	O	-1	6103707
ation.	O	-1	6103707
D@@	B-Disease	D004244	6103707
iz@@	I-Disease	-1	6103707
z@@	I-Disease	-1	6103707
in@@	I-Disease	-1	6103707
ess	I-Disease	-1	6103707
was	O	-1	6103707
less	O	-1	6103707
mark@@	O	-1	6103707
ed	O	-1	6103707
than	O	-1	6103707
sed@@	O	-1	6103707
ation,	O	-1	6103707
but	O	-1	6103707
increased	O	-1	6103707
with	O	-1	6103707
the	O	-1	6103707
dose.	O	-1	6103707
There	O	-1	6103707
was	O	-1	6103707
pain	B-Disease	D010146	6103707
on	O	-1	6103707
i.@@	O	-1	6103707
m.	O	-1	6103707
injection	O	-1	6103707
of	O	-1	6103707
f@@	B-Chemical	D005445	6103707
l@@	I-Chemical	-1	6103707
un@@	I-Chemical	-1	6103707
it@@	I-Chemical	-1	6103707
ra@@	I-Chemical	-1	6103707
z@@	I-Chemical	-1	6103707
epam	I-Chemical	-1	6103707
significantly	O	-1	6103707
more	O	-1	6103707
often	O	-1	6103707
than	O	-1	6103707
with	O	-1	6103707
is@@	O	-1	6103707
oton@@	O	-1	6103707
ic	O	-1	6103707
sal@@	O	-1	6103707
ine.	O	-1	6103707
P@@	O	-1	6103707
las@@	O	-1	6103707
ma	O	-1	6103707
concentrations	O	-1	6103707
vari@@	O	-1	6103707
ed	O	-1	6103707
with	O	-1	6103707
dose	O	-1	6103707
and	O	-1	6103707
ro@@	O	-1	6103707
ute	O	-1	6103707
and	O	-1	6103707
cor@@	O	-1	6103707
respon@@	O	-1	6103707
ded	O	-1	6103707
qu@@	O	-1	6103707
al@@	O	-1	6103707
it@@	O	-1	6103707
atively	O	-1	6103707
with	O	-1	6103707
the	O	-1	6103707
subj@@	O	-1	6103707
ective	O	-1	6103707
effects.	O	-1	6103707
The	O	-1	6103707
drug	O	-1	6103707
was	O	-1	6103707
sti@@	O	-1	6103707
ll	O	-1	6103707
present	O	-1	6103707
in	O	-1	6103707
meas@@	O	-1	6103707
ur@@	O	-1	6103707
able	O	-1	6103707
qu@@	O	-1	6103707
anti@@	O	-1	6103707
ties	O	-1	6103707
after	O	-1	6103707
24	O	-1	6103707
h	O	-1	6103707
even	O	-1	6103707
with	O	-1	6103707
the	O	-1	6103707
sm@@	O	-1	6103707
all@@	O	-1	6103707
est	O	-1	6103707
dose.	O	-1	6103707

Ch@@	O	-1	6229975
ang@@	O	-1	6229975
es	O	-1	6229975
in	O	-1	6229975
heart	O	-1	6229975
size	O	-1	6229975
during	O	-1	6229975
long-term	O	-1	6229975
ti@@	B-Chemical	D013999	6229975
mo@@	I-Chemical	-1	6229975
lol	I-Chemical	-1	6229975
treatment	O	-1	6229975
after	O	-1	6229975
myocardial	B-Disease	D009203	6229975
infarction	I-Disease	-1	6229975
.	O	-1	6229975
The	O	-1	6229975
effect	O	-1	6229975
of	O	-1	6229975
long-term	O	-1	6229975
ti@@	B-Chemical	D013999	6229975
mo@@	I-Chemical	-1	6229975
lol	I-Chemical	-1	6229975
treatment	O	-1	6229975
on	O	-1	6229975
heart	O	-1	6229975
size	O	-1	6229975
after	O	-1	6229975
myocardial	B-Disease	D009203	6229975
infarction	I-Disease	-1	6229975
was	O	-1	6229975
evaluated	O	-1	6229975
by	O	-1	6229975
X@@	O	-1	6229975
-@@	O	-1	6229975
ra@@	O	-1	6229975
y	O	-1	6229975
in	O	-1	6229975
a	O	-1	6229975
double-bl@@	O	-1	6229975
ind	O	-1	6229975
study	O	-1	6229975
including	O	-1	6229975
2@@	O	-1	6229975
4@@	O	-1	6229975
1	O	-1	6229975
patients	O	-1	6229975
(@@	O	-1	6229975
placebo	O	-1	6229975
12@@	O	-1	6229975
6,	O	-1	6229975
ti@@	B-Chemical	D013999	6229975
mo@@	I-Chemical	-1	6229975
lol	I-Chemical	-1	6229975
1@@	O	-1	6229975
1@@	O	-1	6229975
5@@	O	-1	6229975
).	O	-1	6229975
The	O	-1	6229975
follow-up	O	-1	6229975
period	O	-1	6229975
was	O	-1	6229975
12	O	-1	6229975
months.	O	-1	6229975
The	O	-1	6229975
ti@@	B-Chemical	D013999	6229975
mo@@	I-Chemical	-1	6229975
lol	I-Chemical	-1	6229975
-treated	O	-1	6229975
patients	O	-1	6229975
showed	O	-1	6229975
a	O	-1	6229975
sm@@	O	-1	6229975
all	O	-1	6229975
but	O	-1	6229975
significant	O	-1	6229975
increase	O	-1	6229975
in	O	-1	6229975
heart	O	-1	6229975
size	O	-1	6229975
from	O	-1	6229975
baseline	O	-1	6229975
in	O	-1	6229975
contr@@	O	-1	6229975
ast	O	-1	6229975
to	O	-1	6229975
a	O	-1	6229975
decrease	O	-1	6229975
in	O	-1	6229975
the	O	-1	6229975
placebo	O	-1	6229975
group.	O	-1	6229975
These	O	-1	6229975
differences	O	-1	6229975
may	O	-1	6229975
be	O	-1	6229975
caused	O	-1	6229975
by	O	-1	6229975
ti@@	B-Chemical	D013999	6229975
mo@@	I-Chemical	-1	6229975
lol	I-Chemical	-1	6229975
-induced	O	-1	6229975
brady@@	B-Disease	D001919	6229975
cardia	I-Disease	-1	6229975
and	O	-1	6229975
a	O	-1	6229975
com@@	O	-1	6229975
pen@@	O	-1	6229975
s@@	O	-1	6229975
atory	O	-1	6229975
increase	O	-1	6229975
in	O	-1	6229975
en@@	O	-1	6229975
d-@@	O	-1	6229975
di@@	O	-1	6229975
ast@@	O	-1	6229975
olic	O	-1	6229975
vol@@	O	-1	6229975
u@@	O	-1	6229975
me.	O	-1	6229975
The	O	-1	6229975
ti@@	B-Chemical	D013999	6229975
mo@@	I-Chemical	-1	6229975
lol	I-Chemical	-1	6229975
-@@	O	-1	6229975
related	O	-1	6229975
increase	O	-1	6229975
in	O	-1	6229975
heart	O	-1	6229975
size	O	-1	6229975
was	O	-1	6229975
observed	O	-1	6229975
only	O	-1	6229975
in	O	-1	6229975
patients	O	-1	6229975
with	O	-1	6229975
normal	O	-1	6229975
and	O	-1	6229975
b@@	O	-1	6229975
or@@	O	-1	6229975
der@@	O	-1	6229975
line	O	-1	6229975
heart	O	-1	6229975
si@@	O	-1	6229975
z@@	O	-1	6229975
e.	O	-1	6229975
In	O	-1	6229975
patients	O	-1	6229975
with	O	-1	6229975
cardio@@	B-Disease	D006332	6229975
me@@	I-Disease	-1	6229975
g@@	I-Disease	-1	6229975
al@@	I-Disease	-1	6229975
y	I-Disease	-1	6229975
,	O	-1	6229975
the	O	-1	6229975
increase	O	-1	6229975
in	O	-1	6229975
heart	O	-1	6229975
size	O	-1	6229975
was	O	-1	6229975
similar	O	-1	6229975
in	O	-1	6229975
both	O	-1	6229975
groups.	O	-1	6229975
After	O	-1	6229975
re@@	O	-1	6229975
-	O	-1	6229975
infarction	B-Disease	D007238	6229975
,	O	-1	6229975
heart	O	-1	6229975
size	O	-1	6229975
increased	O	-1	6229975
in	O	-1	6229975
the	O	-1	6229975
placebo	O	-1	6229975
group	O	-1	6229975
and	O	-1	6229975
remained	O	-1	6229975
un@@	O	-1	6229975
chang@@	O	-1	6229975
ed	O	-1	6229975
in	O	-1	6229975
the	O	-1	6229975
ti@@	B-Chemical	D013999	6229975
mo@@	I-Chemical	-1	6229975
lol	I-Chemical	-1	6229975
group.	O	-1	6229975

V@@	B-Chemical	D002762	6286738
it@@	I-Chemical	-1	6286738
amin	I-Chemical	-1	6286738
D@@	I-Chemical	-1	6286738
3	I-Chemical	-1	6286738
toxicity	B-Disease	D064420	6286738
in	O	-1	6286738
da@@	O	-1	6286738
ir@@	O	-1	6286738
y	O	-1	6286738
co@@	O	-1	6286738
w@@	O	-1	6286738
s.	O	-1	6286738
L@@	O	-1	6286738
arg@@	O	-1	6286738
e	O	-1	6286738
pa@@	O	-1	6286738
ren@@	O	-1	6286738
ter@@	O	-1	6286738
al	O	-1	6286738
doses	O	-1	6286738
of	O	-1	6286738
vitamin	B-Chemical	D002762	6286738
D@@	I-Chemical	-1	6286738
3	I-Chemical	-1	6286738
(1@@	O	-1	6286738
5	O	-1	6286738
to	O	-1	6286738
1@@	O	-1	6286738
7.@@	O	-1	6286738
5	O	-1	6286738
x	O	-1	6286738
10@@	O	-1	6286738
(6@@	O	-1	6286738
)	O	-1	6286738
I@@	O	-1	6286738
U	O	-1	6286738
vitamin	B-Chemical	D002762	6286738
D@@	I-Chemical	-1	6286738
3	I-Chemical	-1	6286738
)	O	-1	6286738
were	O	-1	6286738
associated	O	-1	6286738
with	O	-1	6286738
prolonged	O	-1	6286738
hyper@@	B-Disease	D006934	6286738
cal@@	I-Disease	-1	6286738
ce@@	I-Disease	-1	6286738
mia	I-Disease	-1	6286738
,	O	-1	6286738
hyper@@	B-Disease	D054559	6286738
phosph@@	I-Disease	-1	6286738
at@@	I-Disease	-1	6286738
emia	I-Disease	-1	6286738
,	O	-1	6286738
and	O	-1	6286738
larg@@	O	-1	6286738
e	O	-1	6286738
increases	O	-1	6286738
of	O	-1	6286738
vitamin	B-Chemical	D002762	6286738
D@@	I-Chemical	-1	6286738
3	I-Chemical	-1	6286738
and	O	-1	6286738
its	O	-1	6286738
metabol@@	O	-1	6286738
it@@	O	-1	6286738
es	O	-1	6286738
in	O	-1	6286738
the	O	-1	6286738
blood	O	-1	6286738
plasma	O	-1	6286738
of	O	-1	6286738
non@@	O	-1	6286738
l@@	O	-1	6286738
act@@	O	-1	6286738
ating	O	-1	6286738
non@@	O	-1	6286738
pregn@@	O	-1	6286738
ant	O	-1	6286738
and	O	-1	6286738
pregn@@	O	-1	6286738
ant	O	-1	6286738
J@@	O	-1	6286738
er@@	O	-1	6286738
se@@	O	-1	6286738
y	O	-1	6286738
co@@	O	-1	6286738
w@@	O	-1	6286738
s.	O	-1	6286738
C@@	B-Chemical	D002118	6286738
al@@	I-Chemical	-1	6286738
ci@@	I-Chemical	-1	6286738
um	I-Chemical	-1	6286738
concentrations	O	-1	6286738
1	O	-1	6286738
day	O	-1	6286738
post@@	O	-1	6286738
part@@	O	-1	6286738
um	O	-1	6286738
were	O	-1	6286738
higher	O	-1	6286738
in	O	-1	6286738
co@@	O	-1	6286738
w@@	O	-1	6286738
s	O	-1	6286738
treated	O	-1	6286738
with	O	-1	6286738
vitamin	B-Chemical	D002762	6286738
D@@	I-Chemical	-1	6286738
3	I-Chemical	-1	6286738
about	O	-1	6286738
3@@	O	-1	6286738
2	O	-1	6286738
days	O	-1	6286738
pre@@	O	-1	6286738
part@@	O	-1	6286738
um	O	-1	6286738
(@@	O	-1	6286738
8.@@	O	-1	6286738
8	O	-1	6286738
mg/@@	O	-1	6286738
100	O	-1	6286738
ml@@	O	-1	6286738
)	O	-1	6286738
than	O	-1	6286738
in	O	-1	6286738
control	O	-1	6286738
co@@	O	-1	6286738
w@@	O	-1	6286738
s	O	-1	6286738
(@@	O	-1	6286738
5.@@	O	-1	6286738
5	O	-1	6286738
mg/@@	O	-1	6286738
100	O	-1	6286738
ml@@	O	-1	6286738
).	O	-1	6286738
N@@	O	-1	6286738
one	O	-1	6286738
of	O	-1	6286738
the	O	-1	6286738
co@@	O	-1	6286738
w@@	O	-1	6286738
s	O	-1	6286738
treated	O	-1	6286738
with	O	-1	6286738
vitamin	B-Chemical	D002762	6286738
D@@	I-Chemical	-1	6286738
3	I-Chemical	-1	6286738
showed	O	-1	6286738
signs	O	-1	6286738
of	O	-1	6286738
mil@@	B-Disease	D010319	6286738
k	I-Disease	-1	6286738
f@@	I-Disease	-1	6286738
ev@@	I-Disease	-1	6286738
er	I-Disease	-1	6286738
during	O	-1	6286738
the	O	-1	6286738
peri@@	O	-1	6286738
part@@	O	-1	6286738
al	O	-1	6286738
perio@@	O	-1	6286738
d@@	O	-1	6286738
;	O	-1	6286738
however,	O	-1	6286738
2@@	O	-1	6286738
2@@	O	-1	6286738
%	O	-1	6286738
of	O	-1	6286738
the	O	-1	6286738
control	O	-1	6286738
co@@	O	-1	6286738
w@@	O	-1	6286738
s	O	-1	6286738
developed	O	-1	6286738
clinical	O	-1	6286738
signs	O	-1	6286738
of	O	-1	6286738
mil@@	B-Disease	D010319	6286738
k	I-Disease	-1	6286738
f@@	I-Disease	-1	6286738
ev@@	I-Disease	-1	6286738
er	I-Disease	-1	6286738
during	O	-1	6286738
this	O	-1	6286738
perio@@	O	-1	6286738
d.	O	-1	6286738
Si@@	O	-1	6286738
gn@@	O	-1	6286738
s	O	-1	6286738
of	O	-1	6286738
vitamin	B-Chemical	D002762	6286738
D@@	I-Chemical	-1	6286738
3	I-Chemical	-1	6286738
toxicity	B-Disease	D064420	6286738
were	O	-1	6286738
not	O	-1	6286738
observed	O	-1	6286738
in	O	-1	6286738
non@@	O	-1	6286738
l@@	O	-1	6286738
act@@	O	-1	6286738
ating	O	-1	6286738
non@@	O	-1	6286738
pregn@@	O	-1	6286738
ant	O	-1	6286738
co@@	O	-1	6286738
w@@	O	-1	6286738
s;	O	-1	6286738
however,	O	-1	6286738
pregn@@	O	-1	6286738
ant	O	-1	6286738
co@@	O	-1	6286738
w@@	O	-1	6286738
s	O	-1	6286738
common@@	O	-1	6286738
ly	O	-1	6286738
developed	O	-1	6286738
severe	O	-1	6286738
signs	O	-1	6286738
of	O	-1	6286738
vitamin	B-Chemical	D002762	6286738
D@@	I-Chemical	-1	6286738
3	I-Chemical	-1	6286738
toxicity	B-Disease	D064420	6286738
and	O	-1	6286738
10	O	-1	6286738
of	O	-1	6286738
17	O	-1	6286738
co@@	O	-1	6286738
w@@	O	-1	6286738
s	O	-1	6286738
di@@	O	-1	6286738
ed.	O	-1	6286738
There	O	-1	6286738
was	O	-1	6286738
w@@	O	-1	6286738
id@@	O	-1	6286738
es@@	O	-1	6286738
pre@@	O	-1	6286738
ad	O	-1	6286738
met@@	O	-1	6286738
ast@@	O	-1	6286738
atic	O	-1	6286738
calcification	O	-1	6286738
in	O	-1	6286738
the	O	-1	6286738
co@@	O	-1	6286738
w@@	O	-1	6286738
s	O	-1	6286738
that	O	-1	6286738
di@@	O	-1	6286738
ed.	O	-1	6286738
B@@	O	-1	6286738
ecause	O	-1	6286738
of	O	-1	6286738
the	O	-1	6286738
ex@@	O	-1	6286738
trem@@	O	-1	6286738
e	O	-1	6286738
toxicity	B-Disease	D064420	6286738
of	O	-1	6286738
vitamin	B-Chemical	D002762	6286738
D@@	I-Chemical	-1	6286738
3	I-Chemical	-1	6286738
in	O	-1	6286738
pregn@@	O	-1	6286738
ant	O	-1	6286738
J@@	O	-1	6286738
er@@	O	-1	6286738
se@@	O	-1	6286738
y	O	-1	6286738
co@@	O	-1	6286738
w@@	O	-1	6286738
s	O	-1	6286738
and	O	-1	6286738
the	O	-1	6286738
low	O	-1	6286738
m@@	O	-1	6286738
arg@@	O	-1	6286738
in	O	-1	6286738
of	O	-1	6286738
safety	O	-1	6286738
between	O	-1	6286738
doses	O	-1	6286738
of	O	-1	6286738
vitamin	B-Chemical	D002762	6286738
D@@	I-Chemical	-1	6286738
3	I-Chemical	-1	6286738
that	O	-1	6286738
prev@@	O	-1	6286738
ent	O	-1	6286738
mil@@	B-Disease	D010319	6286738
k	I-Disease	-1	6286738
f@@	I-Disease	-1	6286738
ev@@	I-Disease	-1	6286738
er	I-Disease	-1	6286738
and	O	-1	6286738
doses	O	-1	6286738
that	O	-1	6286738
induce	O	-1	6286738
mil@@	B-Disease	D010319	6286738
k	I-Disease	-1	6286738
f@@	I-Disease	-1	6286738
ev@@	I-Disease	-1	6286738
er	I-Disease	-1	6286738
,	O	-1	6286738
we	O	-1	6286738
concl@@	O	-1	6286738
uded	O	-1	6286738
that	O	-1	6286738
vitamin	B-Chemical	D002762	6286738
D@@	I-Chemical	-1	6286738
3	I-Chemical	-1	6286738
can@@	O	-1	6286738
not	O	-1	6286738
be	O	-1	6286738
used	O	-1	6286738
p@@	O	-1	6286738
rac@@	O	-1	6286738
tically	O	-1	6286738
to	O	-1	6286738
prev@@	O	-1	6286738
ent	O	-1	6286738
mil@@	B-Disease	D010319	6286738
k	I-Disease	-1	6286738
f@@	I-Disease	-1	6286738
ev@@	I-Disease	-1	6286738
er	I-Disease	-1	6286738
when	O	-1	6286738
injected	O	-1	6286738
several	O	-1	6286738
weeks	O	-1	6286738
pre@@	O	-1	6286738
part@@	O	-1	6286738
um@@	O	-1	6286738
.	O	-1	6286738

Di@@	B-Disease	D010523	6287825
se@@	I-Disease	-1	6287825
as@@	I-Disease	-1	6287825
es	I-Disease	-1	6287825
of	I-Disease	-1	6287825
peripheral	I-Disease	-1	6287825
ner@@	I-Disease	-1	6287825
v@@	I-Disease	-1	6287825
es	I-Disease	-1	6287825
as	O	-1	6287825
seen	O	-1	6287825
in	O	-1	6287825
the	O	-1	6287825
N@@	O	-1	6287825
ig@@	O	-1	6287825
er@@	O	-1	6287825
i@@	O	-1	6287825
an	O	-1	6287825
Af@@	O	-1	6287825
r@@	O	-1	6287825
ic@@	O	-1	6287825
an@@	O	-1	6287825
.	O	-1	6287825
The	O	-1	6287825
an@@	O	-1	6287825
at@@	O	-1	6287825
om@@	O	-1	6287825
ical	O	-1	6287825
and	O	-1	6287825
a@@	O	-1	6287825
e@@	O	-1	6287825
ti@@	O	-1	6287825
ological	O	-1	6287825
diagno@@	O	-1	6287825
ses	O	-1	6287825
of	O	-1	6287825
peripheral	B-Disease	D010523	6287825
nerve	I-Disease	-1	6287825
disease	I-Disease	-1	6287825
ex@@	O	-1	6287825
cl@@	O	-1	6287825
ud@@	O	-1	6287825
ing	O	-1	6287825
its	O	-1	6287825
prim@@	O	-1	6287825
ary	O	-1	6287825
ben@@	O	-1	6287825
ig@@	O	-1	6287825
n	O	-1	6287825
and	O	-1	6287825
mal@@	O	-1	6287825
i@@	O	-1	6287825
gn@@	O	-1	6287825
ant	O	-1	6287825
disorder@@	O	-1	6287825
s,	O	-1	6287825
as	O	-1	6287825
seen	O	-1	6287825
in	O	-1	6287825
3@@	O	-1	6287825
5@@	O	-1	6287825
8	O	-1	6287825
N@@	O	-1	6287825
ig@@	O	-1	6287825
er@@	O	-1	6287825
i@@	O	-1	6287825
ans	O	-1	6287825
are	O	-1	6287825
present@@	O	-1	6287825
ed.	O	-1	6287825
There	O	-1	6287825
is	O	-1	6287825
a	O	-1	6287825
male	O	-1	6287825
pre@@	O	-1	6287825
p@@	O	-1	6287825
on@@	O	-1	6287825
der@@	O	-1	6287825
ance	O	-1	6287825
and	O	-1	6287825
the	O	-1	6287825
pe@@	O	-1	6287825
a@@	O	-1	6287825
k	O	-1	6287825
incidence	O	-1	6287825
is	O	-1	6287825
in	O	-1	6287825
the	O	-1	6287825
fo@@	O	-1	6287825
ur@@	O	-1	6287825
th	O	-1	6287825
dec@@	O	-1	6287825
ade@@	O	-1	6287825
.	O	-1	6287825
S@@	B-Disease	D010523	6287825
ens@@	I-Disease	-1	6287825
or@@	I-Disease	-1	6287825
i@@	I-Disease	-1	6287825
-@@	I-Disease	-1	6287825
motor	I-Disease	-1	6287825
neuropathy	I-Disease	-1	6287825
was	O	-1	6287825
the	O	-1	6287825
common@@	O	-1	6287825
est	O	-1	6287825
present@@	O	-1	6287825
ation	O	-1	6287825
(@@	O	-1	6287825
50@@	O	-1	6287825
%).	O	-1	6287825
G@@	B-Disease	D020275	6287825
u@@	I-Disease	-1	6287825
ill@@	I-Disease	-1	6287825
ain@@	I-Disease	-1	6287825
-@@	I-Disease	-1	6287825
B@@	I-Disease	-1	6287825
ar@@	I-Disease	-1	6287825
r	I-Disease	-1	6287825
syndrome	I-Disease	-1	6287825
was	O	-1	6287825
the	O	-1	6287825
common@@	O	-1	6287825
est	O	-1	6287825
identi@@	O	-1	6287825
fi@@	O	-1	6287825
able	O	-1	6287825
cause	O	-1	6287825
(1@@	O	-1	6287825
5.@@	O	-1	6287825
6@@	O	-1	6287825
%),	O	-1	6287825
ac@@	O	-1	6287825
coun@@	O	-1	6287825
ting	O	-1	6287825
for	O	-1	6287825
h@@	O	-1	6287825
al@@	O	-1	6287825
f	O	-1	6287825
of	O	-1	6287825
the	O	-1	6287825
cases	O	-1	6287825
with	O	-1	6287825
motor	B-Disease	D010523	6287825
neuropathy	I-Disease	-1	6287825
.	O	-1	6287825
P@@	B-Disease	D010523	6287825
er@@	I-Disease	-1	6287825
i@@	I-Disease	-1	6287825
pheral	I-Disease	-1	6287825
neuropathy	I-Disease	-1	6287825
due	O	-1	6287825
to	O	-1	6287825
n@@	B-Disease	D044342	6287825
ut@@	I-Disease	-1	6287825
ri@@	I-Disease	-1	6287825
tional	I-Disease	-1	6287825
defici@@	I-Disease	-1	6287825
ency	I-Disease	-1	6287825
of	O	-1	6287825
thi@@	B-Chemical	D013831	6287825
amine	I-Chemical	-1	6287825
and	O	-1	6287825
ri@@	B-Chemical	D012256	6287825
bo@@	I-Chemical	-1	6287825
f@@	I-Chemical	-1	6287825
l@@	I-Chemical	-1	6287825
av@@	I-Chemical	-1	6287825
in	I-Chemical	-1	6287825
was	O	-1	6287825
common	O	-1	6287825
(1@@	O	-1	6287825
0.@@	O	-1	6287825
1@@	O	-1	6287825
%)	O	-1	6287825
and	O	-1	6287825
presented	O	-1	6287825
main@@	O	-1	6287825
ly	O	-1	6287825
as	O	-1	6287825
sens@@	O	-1	6287825
ory	O	-1	6287825
and	O	-1	6287825
sens@@	B-Disease	D010523	6287825
or@@	I-Disease	-1	6287825
i@@	I-Disease	-1	6287825
-@@	I-Disease	-1	6287825
motor	I-Disease	-1	6287825
neuropathy	I-Disease	-1	6287825
.	O	-1	6287825
D@@	B-Disease	D003920	6287825
ia@@	I-Disease	-1	6287825
bet@@	I-Disease	-1	6287825
es	I-Disease	-1	6287825
me@@	I-Disease	-1	6287825
ll@@	I-Disease	-1	6287825
it@@	I-Disease	-1	6287825
us	I-Disease	-1	6287825
was	O	-1	6287825
the	O	-1	6287825
major	O	-1	6287825
cause	O	-1	6287825
of	O	-1	6287825
a@@	B-Disease	D009422	6287825
ut@@	I-Disease	-1	6287825
on@@	I-Disease	-1	6287825
om@@	I-Disease	-1	6287825
ic	I-Disease	-1	6287825
neuropathy	I-Disease	-1	6287825
.	O	-1	6287825
I@@	B-Chemical	D007538	6287825
son@@	I-Chemical	-1	6287825
i@@	I-Chemical	-1	6287825
az@@	I-Chemical	-1	6287825
id	I-Chemical	-1	6287825
was	O	-1	6287825
the	O	-1	6287825
most	O	-1	6287825
frequent	O	-1	6287825
agent	O	-1	6287825
in	O	-1	6287825
drug@@	O	-1	6287825
-induced	O	-1	6287825
neuropathy	B-Disease	D009422	6287825
.	O	-1	6287825
M@@	B-Disease	D008881	6287825
i@@	I-Disease	-1	6287825
gra@@	I-Disease	-1	6287825
ine	I-Disease	-1	6287825
(2@@	O	-1	6287825
0@@	O	-1	6287825
%)	O	-1	6287825
was	O	-1	6287825
not	O	-1	6287825
an	O	-1	6287825
un@@	O	-1	6287825
common	O	-1	6287825
cause	O	-1	6287825
of	O	-1	6287825
c@@	B-Disease	D003389	6287825
ranial	I-Disease	-1	6287825
neuropathy	I-Disease	-1	6287825
although	O	-1	6287825
mal@@	B-Disease	D009369	6287825
i@@	I-Disease	-1	6287825
gn@@	I-Disease	-1	6287825
an@@	I-Disease	-1	6287825
ci@@	I-Disease	-1	6287825
es	I-Disease	-1	6287825
ar@@	O	-1	6287825
is@@	O	-1	6287825
ing	O	-1	6287825
from	O	-1	6287825
the	O	-1	6287825
re@@	O	-1	6287825
tic@@	O	-1	6287825
ulo@@	O	-1	6287825
endothelial	O	-1	6287825
system	O	-1	6287825
or	O	-1	6287825
related	O	-1	6287825
struct@@	O	-1	6287825
ures	O	-1	6287825
of	O	-1	6287825
the	O	-1	6287825
he@@	O	-1	6287825
ad	O	-1	6287825
and	O	-1	6287825
nec@@	O	-1	6287825
k	O	-1	6287825
were	O	-1	6287825
more	O	-1	6287825
frequent	O	-1	6287825
(2@@	O	-1	6287825
6@@	O	-1	6287825
%).	O	-1	6287825
In	O	-1	6287825
2@@	O	-1	6287825
6.@@	O	-1	6287825
5%	O	-1	6287825
of	O	-1	6287825
all	O	-1	6287825
the	O	-1	6287825
cas@@	O	-1	6287825
es,	O	-1	6287825
the	O	-1	6287825
a@@	O	-1	6287825
e@@	O	-1	6287825
ti@@	O	-1	6287825
ology	O	-1	6287825
of	O	-1	6287825
the	O	-1	6287825
neuropathy	B-Disease	D009422	6287825
was	O	-1	6287825
un@@	O	-1	6287825
deter@@	O	-1	6287825
m@@	O	-1	6287825
ine@@	O	-1	6287825
d.	O	-1	6287825
He@@	O	-1	6287825
re@@	O	-1	6287825
do@@	O	-1	6287825
f@@	O	-1	6287825
am@@	O	-1	6287825
il@@	O	-1	6287825
ial	O	-1	6287825
and	O	-1	6287825
con@@	B-Disease	D003240	6287825
n@@	I-Disease	-1	6287825
ective	I-Disease	-1	6287825
tissue	I-Disease	-1	6287825
disorder@@	I-Disease	-1	6287825
s	I-Disease	-1	6287825
were	O	-1	6287825
ra@@	O	-1	6287825
re.	O	-1	6287825
S@@	O	-1	6287825
ome	O	-1	6287825
of	O	-1	6287825
the	O	-1	6287825
factors	O	-1	6287825
related	O	-1	6287825
to	O	-1	6287825
the	O	-1	6287825
clinical	O	-1	6287825
present@@	O	-1	6287825
ation	O	-1	6287825
and	O	-1	6287825
path@@	O	-1	6287825
o@@	O	-1	6287825
genesis	O	-1	6287825
of	O	-1	6287825
the	O	-1	6287825
neuro@@	B-Disease	D009422	6287825
path@@	I-Disease	-1	6287825
i@@	I-Disease	-1	6287825
es	I-Disease	-1	6287825
are	O	-1	6287825
b@@	O	-1	6287825
ri@@	O	-1	6287825
e@@	O	-1	6287825
f@@	O	-1	6287825
ly	O	-1	6287825
discus@@	O	-1	6287825
sed.	O	-1	6287825

A	O	-1	6386793
double-bl@@	O	-1	6386793
ind	O	-1	6386793
study	O	-1	6386793
of	O	-1	6386793
the	O	-1	6386793
efficacy	O	-1	6386793
and	O	-1	6386793
safety	O	-1	6386793
of	O	-1	6386793
do@@	B-Chemical	D004308	6386793
thi@@	I-Chemical	-1	6386793
ep@@	I-Chemical	-1	6386793
in	I-Chemical	-1	6386793
hydro@@	I-Chemical	-1	6386793
chlor@@	I-Chemical	-1	6386793
ide	I-Chemical	-1	6386793
in	O	-1	6386793
the	O	-1	6386793
treatment	O	-1	6386793
of	O	-1	6386793
major	O	-1	6386793
de@@	B-Disease	D003866	6386793
pressive	I-Disease	-1	6386793
disor@@	I-Disease	-1	6386793
der	I-Disease	-1	6386793
.	O	-1	6386793
In	O	-1	6386793
a	O	-1	6386793
6-@@	O	-1	6386793
week	O	-1	6386793
double-bl@@	O	-1	6386793
ind	O	-1	6386793
par@@	O	-1	6386793
al@@	O	-1	6386793
le@@	O	-1	6386793
l	O	-1	6386793
treatment	O	-1	6386793
study,	O	-1	6386793
do@@	B-Chemical	D004308	6386793
thi@@	I-Chemical	-1	6386793
ep@@	I-Chemical	-1	6386793
in	I-Chemical	-1	6386793
and	O	-1	6386793
am@@	B-Chemical	D000639	6386793
it@@	I-Chemical	-1	6386793
ript@@	I-Chemical	-1	6386793
yl@@	I-Chemical	-1	6386793
ine	I-Chemical	-1	6386793
were	O	-1	6386793
compared	O	-1	6386793
to	O	-1	6386793
placebo	O	-1	6386793
in	O	-1	6386793
the	O	-1	6386793
treatment	O	-1	6386793
of	O	-1	6386793
3@@	O	-1	6386793
3	O	-1	6386793
depress@@	B-Disease	D003866	6386793
ed	I-Disease	-1	6386793
out@@	O	-1	6386793
patients.	O	-1	6386793
D@@	B-Chemical	D004308	6386793
o@@	I-Chemical	-1	6386793
thi@@	I-Chemical	-1	6386793
ep@@	I-Chemical	-1	6386793
in	I-Chemical	-1	6386793
and	O	-1	6386793
am@@	B-Chemical	D000639	6386793
it@@	I-Chemical	-1	6386793
ript@@	I-Chemical	-1	6386793
yl@@	I-Chemical	-1	6386793
ine	I-Chemical	-1	6386793
were	O	-1	6386793
equ@@	O	-1	6386793
ally	O	-1	6386793
effective	O	-1	6386793
in	O	-1	6386793
al@@	O	-1	6386793
le@@	O	-1	6386793
vi@@	O	-1	6386793
ating	O	-1	6386793
the	O	-1	6386793
symptoms	O	-1	6386793
of	O	-1	6386793
de@@	B-Disease	D003866	6386793
pressive	I-Disease	-1	6386793
ill@@	I-Disease	-1	6386793
ness	I-Disease	-1	6386793
,	O	-1	6386793
and	O	-1	6386793
both	O	-1	6386793
were	O	-1	6386793
significantly	O	-1	6386793
su@@	O	-1	6386793
peri@@	O	-1	6386793
or	O	-1	6386793
to	O	-1	6386793
placebo@@	O	-1	6386793
.	O	-1	6386793
The	O	-1	6386793
over@@	O	-1	6386793
all	O	-1	6386793
incidence	O	-1	6386793
of	O	-1	6386793
side	O	-1	6386793
effects	O	-1	6386793
and	O	-1	6386793
the	O	-1	6386793
frequency	O	-1	6386793
and	O	-1	6386793
severity	O	-1	6386793
of	O	-1	6386793
bl@@	B-Disease	D014786	6386793
ur@@	I-Disease	-1	6386793
red	I-Disease	-1	6386793
vi@@	I-Disease	-1	6386793
sion	I-Disease	-1	6386793
,	O	-1	6386793
d@@	B-Disease	D014987	6386793
r@@	I-Disease	-1	6386793
y	I-Disease	-1	6386793
mou@@	I-Disease	-1	6386793
th	I-Disease	-1	6386793
,	O	-1	6386793
and	O	-1	6386793
dro@@	O	-1	6386793
w@@	O	-1	6386793
s@@	O	-1	6386793
in@@	O	-1	6386793
ess	O	-1	6386793
were	O	-1	6386793
significantly	O	-1	6386793
less	O	-1	6386793
with	O	-1	6386793
do@@	B-Chemical	D004308	6386793
thi@@	I-Chemical	-1	6386793
ep@@	I-Chemical	-1	6386793
in	I-Chemical	-1	6386793
than	O	-1	6386793
with	O	-1	6386793
am@@	B-Chemical	D000639	6386793
it@@	I-Chemical	-1	6386793
ript@@	I-Chemical	-1	6386793
yl@@	I-Chemical	-1	6386793
ine	I-Chemical	-1	6386793
.	O	-1	6386793
D@@	B-Chemical	D004308	6386793
o@@	I-Chemical	-1	6386793
thi@@	I-Chemical	-1	6386793
ep@@	I-Chemical	-1	6386793
in	I-Chemical	-1	6386793
also	O	-1	6386793
produced	O	-1	6386793
fe@@	O	-1	6386793
w@@	O	-1	6386793
er	O	-1	6386793
C@@	O	-1	6386793
N@@	O	-1	6386793
S	O	-1	6386793
and	O	-1	6386793
cardiovascular	O	-1	6386793
effects.	O	-1	6386793
There	O	-1	6386793
were	O	-1	6386793
no	O	-1	6386793
clin@@	O	-1	6386793
ically	O	-1	6386793
important	O	-1	6386793
changes	O	-1	6386793
in	O	-1	6386793
labor@@	O	-1	6386793
atory	O	-1	6386793
par@@	O	-1	6386793
ame@@	O	-1	6386793
ter@@	O	-1	6386793
s.	O	-1	6386793
D@@	B-Chemical	D004308	6386793
o@@	I-Chemical	-1	6386793
thi@@	I-Chemical	-1	6386793
ep@@	I-Chemical	-1	6386793
in	I-Chemical	-1	6386793
th@@	O	-1	6386793
us	O	-1	6386793
was	O	-1	6386793
found	O	-1	6386793
to	O	-1	6386793
be	O	-1	6386793
an	O	-1	6386793
effective	O	-1	6386793
antidepress@@	B-Chemical	D000928	6386793
ant	I-Chemical	-1	6386793
drug	O	-1	6386793
associated	O	-1	6386793
with	O	-1	6386793
fe@@	O	-1	6386793
w@@	O	-1	6386793
er	O	-1	6386793
side	O	-1	6386793
effects	O	-1	6386793
than	O	-1	6386793
am@@	B-Chemical	D000639	6386793
it@@	I-Chemical	-1	6386793
ript@@	I-Chemical	-1	6386793
yl@@	I-Chemical	-1	6386793
ine	I-Chemical	-1	6386793
in	O	-1	6386793
the	O	-1	6386793
treatment	O	-1	6386793
of	O	-1	6386793
depress@@	B-Disease	D003866	6386793
ed	I-Disease	-1	6386793
out@@	O	-1	6386793
patients.	O	-1	6386793

B@@	O	-1	6387529
e@@	O	-1	6387529
havi@@	O	-1	6387529
oral	O	-1	6387529
effects	O	-1	6387529
of	O	-1	6387529
di@@	B-Chemical	D003975	6387529
az@@	I-Chemical	-1	6387529
epam	I-Chemical	-1	6387529
and	O	-1	6387529
prop@@	B-Chemical	D011433	6387529
ran@@	I-Chemical	-1	6387529
o@@	I-Chemical	-1	6387529
lol	I-Chemical	-1	6387529
in	O	-1	6387529
patients	O	-1	6387529
with	O	-1	6387529
p@@	B-Disease	D016584	6387529
anic	I-Disease	-1	6387529
disor@@	I-Disease	-1	6387529
der	I-Disease	-1	6387529
and	O	-1	6387529
ag@@	B-Disease	D000379	6387529
or@@	I-Disease	-1	6387529
a@@	I-Disease	-1	6387529
ph@@	I-Disease	-1	6387529
ob@@	I-Disease	-1	6387529
ia	I-Disease	-1	6387529
.	O	-1	6387529
The	O	-1	6387529
effects	O	-1	6387529
of	O	-1	6387529
oral	O	-1	6387529
doses	O	-1	6387529
of	O	-1	6387529
di@@	B-Chemical	D003975	6387529
az@@	I-Chemical	-1	6387529
epam	I-Chemical	-1	6387529
(@@	O	-1	6387529
single	O	-1	6387529
dose	O	-1	6387529
of	O	-1	6387529
10	O	-1	6387529
mg	O	-1	6387529
and	O	-1	6387529
a	O	-1	6387529
median	O	-1	6387529
dose	O	-1	6387529
of	O	-1	6387529
30	O	-1	6387529
mg/@@	O	-1	6387529
day	O	-1	6387529
for	O	-1	6387529
2	O	-1	6387529
week@@	O	-1	6387529
s)	O	-1	6387529
and	O	-1	6387529
prop@@	B-Chemical	D011433	6387529
ran@@	I-Chemical	-1	6387529
o@@	I-Chemical	-1	6387529
lol	I-Chemical	-1	6387529
(@@	O	-1	6387529
single	O	-1	6387529
dose	O	-1	6387529
of	O	-1	6387529
8@@	O	-1	6387529
0	O	-1	6387529
mg	O	-1	6387529
and	O	-1	6387529
a	O	-1	6387529
median	O	-1	6387529
dose	O	-1	6387529
of	O	-1	6387529
2@@	O	-1	6387529
40	O	-1	6387529
mg/@@	O	-1	6387529
day	O	-1	6387529
for	O	-1	6387529
2	O	-1	6387529
week@@	O	-1	6387529
s)	O	-1	6387529
on	O	-1	6387529
psych@@	O	-1	6387529
ological	O	-1	6387529
perform@@	O	-1	6387529
ance	O	-1	6387529
of	O	-1	6387529
patients	O	-1	6387529
with	O	-1	6387529
p@@	B-Disease	D016584	6387529
anic	I-Disease	-1	6387529
disorder@@	I-Disease	-1	6387529
s	I-Disease	-1	6387529
and	O	-1	6387529
ag@@	B-Disease	D000379	6387529
or@@	I-Disease	-1	6387529
a@@	I-Disease	-1	6387529
ph@@	I-Disease	-1	6387529
ob@@	I-Disease	-1	6387529
ia	I-Disease	-1	6387529
were	O	-1	6387529
investigated	O	-1	6387529
in	O	-1	6387529
a	O	-1	6387529
double-bl@@	O	-1	6387529
ind@@	O	-1	6387529
,	O	-1	6387529
randomized	O	-1	6387529
and	O	-1	6387529
cros@@	O	-1	6387529
s@@	O	-1	6387529
over	O	-1	6387529
de@@	O	-1	6387529
sign@@	O	-1	6387529
.	O	-1	6387529
B@@	O	-1	6387529
oth	O	-1	6387529
drugs	O	-1	6387529
impaired	B-Disease	D008569	6387529
immedi@@	I-Disease	-1	6387529
ate	I-Disease	-1	6387529
free	I-Disease	-1	6387529
rec@@	I-Disease	-1	6387529
all	I-Disease	-1	6387529
but	O	-1	6387529
the	O	-1	6387529
decrease	O	-1	6387529
was	O	-1	6387529
greater	O	-1	6387529
for	O	-1	6387529
di@@	B-Chemical	D003975	6387529
az@@	I-Chemical	-1	6387529
epam	I-Chemical	-1	6387529
than	O	-1	6387529
prop@@	B-Chemical	D011433	6387529
ran@@	I-Chemical	-1	6387529
o@@	I-Chemical	-1	6387529
lol	I-Chemical	-1	6387529
.	O	-1	6387529
D@@	B-Disease	D008569	6387529
el@@	I-Disease	-1	6387529
ayed	I-Disease	-1	6387529
free	I-Disease	-1	6387529
rec@@	I-Disease	-1	6387529
all	I-Disease	-1	6387529
was	I-Disease	-1	6387529
also	I-Disease	-1	6387529
impaired	I-Disease	-1	6387529
but	O	-1	6387529
the	O	-1	6387529
two	O	-1	6387529
drugs	O	-1	6387529
did	O	-1	6387529
not	O	-1	6387529
diff@@	O	-1	6387529
er.	O	-1	6387529
Patients	O	-1	6387529
t@@	O	-1	6387529
app@@	O	-1	6387529
ed	O	-1	6387529
f@@	O	-1	6387529
ast@@	O	-1	6387529
er	O	-1	6387529
after	O	-1	6387529
prop@@	B-Chemical	D011433	6387529
ran@@	I-Chemical	-1	6387529
o@@	I-Chemical	-1	6387529
lol	I-Chemical	-1	6387529
than	O	-1	6387529
di@@	B-Chemical	D003975	6387529
az@@	I-Chemical	-1	6387529
epam	I-Chemical	-1	6387529
and	O	-1	6387529
they	O	-1	6387529
were	O	-1	6387529
more	O	-1	6387529
sed@@	O	-1	6387529
ated	O	-1	6387529
after	O	-1	6387529
di@@	B-Chemical	D003975	6387529
az@@	I-Chemical	-1	6387529
epam	I-Chemical	-1	6387529
than	O	-1	6387529
prop@@	B-Chemical	D011433	6387529
ran@@	I-Chemical	-1	6387529
o@@	I-Chemical	-1	6387529
lol	I-Chemical	-1	6387529
.	O	-1	6387529
After	O	-1	6387529
2	O	-1	6387529
weeks	O	-1	6387529
of	O	-1	6387529
treatment,	O	-1	6387529
patients	O	-1	6387529
tested	O	-1	6387529
5-@@	O	-1	6387529
8	O	-1	6387529
h	O	-1	6387529
after	O	-1	6387529
the	O	-1	6387529
las@@	O	-1	6387529
t	O	-1	6387529
dose	O	-1	6387529
of	O	-1	6387529
medic@@	O	-1	6387529
ation	O	-1	6387529
did	O	-1	6387529
not	O	-1	6387529
show	O	-1	6387529
any	O	-1	6387529
dec@@	O	-1	6387529
re@@	O	-1	6387529
ment	O	-1	6387529
of	O	-1	6387529
perform@@	O	-1	6387529
ance@@	O	-1	6387529
.	O	-1	6387529
These	O	-1	6387529
results	O	-1	6387529
are	O	-1	6387529
similar	O	-1	6387529
to	O	-1	6387529
those	O	-1	6387529
previously	O	-1	6387529
found	O	-1	6387529
in	O	-1	6387529
healthy	O	-1	6387529
subj@@	O	-1	6387529
ect@@	O	-1	6387529
s.	O	-1	6387529
Ac@@	O	-1	6387529
cum@@	O	-1	6387529
ulation	O	-1	6387529
of	O	-1	6387529
drugs	O	-1	6387529
was	O	-1	6387529
not	O	-1	6387529
ref@@	O	-1	6387529
l@@	O	-1	6387529
ected	O	-1	6387529
in	O	-1	6387529
prolonged	O	-1	6387529
behavioral	B-Disease	D001523	6387529
impair@@	I-Disease	-1	6387529
ment	I-Disease	-1	6387529
.	O	-1	6387529

Eff@@	O	-1	6692345
ect	O	-1	6692345
of	O	-1	6692345
as@@	B-Chemical	D001241	6692345
pi@@	I-Chemical	-1	6692345
rin	I-Chemical	-1	6692345
on	O	-1	6692345
N@@	B-Chemical	D005200	6692345
-@@	I-Chemical	-1	6692345
[@@	I-Chemical	-1	6692345
4-@@	I-Chemical	-1	6692345
(@@	I-Chemical	-1	6692345
5-@@	I-Chemical	-1	6692345
nitro@@	I-Chemical	-1	6692345
-@@	I-Chemical	-1	6692345
2-@@	I-Chemical	-1	6692345
f@@	I-Chemical	-1	6692345
ur@@	I-Chemical	-1	6692345
yl@@	I-Chemical	-1	6692345
)-@@	I-Chemical	-1	6692345
2-@@	I-Chemical	-1	6692345
thi@@	I-Chemical	-1	6692345
azol@@	I-Chemical	-1	6692345
yl@@	I-Chemical	-1	6692345
]@@	I-Chemical	-1	6692345
-@@	I-Chemical	-1	6692345
form@@	I-Chemical	-1	6692345
amide	I-Chemical	-1	6692345
-induced	O	-1	6692345
epi@@	O	-1	6692345
thelial	O	-1	6692345
pro@@	O	-1	6692345
li@@	O	-1	6692345
fer@@	O	-1	6692345
ation	O	-1	6692345
in	O	-1	6692345
the	O	-1	6692345
urinary	O	-1	6692345
bladder	O	-1	6692345
and	O	-1	6692345
fo@@	O	-1	6692345
rest@@	O	-1	6692345
om@@	O	-1	6692345
ach	O	-1	6692345
of	O	-1	6692345
the	O	-1	6692345
rat@@	O	-1	6692345
.	O	-1	6692345
The	O	-1	6692345
co-@@	O	-1	6692345
administration	O	-1	6692345
of	O	-1	6692345
as@@	B-Chemical	D001241	6692345
pi@@	I-Chemical	-1	6692345
rin	I-Chemical	-1	6692345
with	O	-1	6692345
N@@	B-Chemical	D005200	6692345
-@@	I-Chemical	-1	6692345
[@@	I-Chemical	-1	6692345
4-@@	I-Chemical	-1	6692345
(@@	I-Chemical	-1	6692345
5-@@	I-Chemical	-1	6692345
nitro@@	I-Chemical	-1	6692345
-@@	I-Chemical	-1	6692345
2-@@	I-Chemical	-1	6692345
f@@	I-Chemical	-1	6692345
ur@@	I-Chemical	-1	6692345
yl@@	I-Chemical	-1	6692345
)-@@	I-Chemical	-1	6692345
2-@@	I-Chemical	-1	6692345
thi@@	I-Chemical	-1	6692345
azol@@	I-Chemical	-1	6692345
yl@@	I-Chemical	-1	6692345
]@@	I-Chemical	-1	6692345
-@@	I-Chemical	-1	6692345
form@@	I-Chemical	-1	6692345
amide	I-Chemical	-1	6692345
(	O	-1	6692345
F@@	B-Chemical	D005200	6692345
AN@@	I-Chemical	-1	6692345
F@@	I-Chemical	-1	6692345
T	I-Chemical	-1	6692345
)	O	-1	6692345
to	O	-1	6692345
rats	O	-1	6692345
resulted	O	-1	6692345
in	O	-1	6692345
a	O	-1	6692345
reduced	O	-1	6692345
incidence	O	-1	6692345
of	O	-1	6692345
F@@	B-Chemical	D005200	6692345
AN@@	I-Chemical	-1	6692345
F@@	I-Chemical	-1	6692345
T	I-Chemical	-1	6692345
-induced	O	-1	6692345
bladder	B-Disease	D001749	6692345
carcin@@	I-Disease	-1	6692345
om@@	I-Disease	-1	6692345
as	I-Disease	-1	6692345
but	O	-1	6692345
a	O	-1	6692345
concomit@@	O	-1	6692345
ant	O	-1	6692345
induction	O	-1	6692345
of	O	-1	6692345
fo@@	B-Disease	D013274	6692345
rest@@	I-Disease	-1	6692345
om@@	I-Disease	-1	6692345
ach	I-Disease	-1	6692345
tu@@	I-Disease	-1	6692345
mor@@	I-Disease	-1	6692345
s	I-Disease	-1	6692345
.	O	-1	6692345
An	O	-1	6692345
a@@	O	-1	6692345
ut@@	O	-1	6692345
or@@	O	-1	6692345
a@@	O	-1	6692345
di@@	O	-1	6692345
ograph@@	O	-1	6692345
ic	O	-1	6692345
study	O	-1	6692345
was	O	-1	6692345
performed	O	-1	6692345
on	O	-1	6692345
male	O	-1	6692345
F@@	O	-1	6692345
-@@	O	-1	6692345
34@@	O	-1	6692345
4	O	-1	6692345
rats	O	-1	6692345
f@@	O	-1	6692345
ed	O	-1	6692345
diet	O	-1	6692345
containing	O	-1	6692345
F@@	B-Chemical	D005200	6692345
AN@@	I-Chemical	-1	6692345
F@@	I-Chemical	-1	6692345
T	I-Chemical	-1	6692345
at	O	-1	6692345
a	O	-1	6692345
level	O	-1	6692345
of	O	-1	6692345
0.@@	O	-1	6692345
2@@	O	-1	6692345
%	O	-1	6692345
and/or	O	-1	6692345
as@@	B-Chemical	D001241	6692345
pi@@	I-Chemical	-1	6692345
rin	I-Chemical	-1	6692345
at	O	-1	6692345
a	O	-1	6692345
level	O	-1	6692345
of	O	-1	6692345
0.@@	O	-1	6692345
5%	O	-1	6692345
to	O	-1	6692345
evalu@@	O	-1	6692345
ate	O	-1	6692345
the	O	-1	6692345
effect	O	-1	6692345
of	O	-1	6692345
as@@	B-Chemical	D001241	6692345
pi@@	I-Chemical	-1	6692345
rin	I-Chemical	-1	6692345
on	O	-1	6692345
the	O	-1	6692345
increased	O	-1	6692345
cell	O	-1	6692345
pro@@	O	-1	6692345
li@@	O	-1	6692345
fer@@	O	-1	6692345
ation	O	-1	6692345
induced	O	-1	6692345
by	O	-1	6692345
F@@	B-Chemical	D005200	6692345
AN@@	I-Chemical	-1	6692345
F@@	I-Chemical	-1	6692345
T	I-Chemical	-1	6692345
in	O	-1	6692345
the	O	-1	6692345
fo@@	O	-1	6692345
rest@@	O	-1	6692345
om@@	O	-1	6692345
ach	O	-1	6692345
and	O	-1	6692345
blad@@	O	-1	6692345
der@@	O	-1	6692345
.	O	-1	6692345
F@@	B-Chemical	D005200	6692345
AN@@	I-Chemical	-1	6692345
F@@	I-Chemical	-1	6692345
T	I-Chemical	-1	6692345
-induced	O	-1	6692345
cell	O	-1	6692345
pro@@	O	-1	6692345
li@@	O	-1	6692345
fer@@	O	-1	6692345
ation	O	-1	6692345
in	O	-1	6692345
the	O	-1	6692345
bladder	O	-1	6692345
was	O	-1	6692345
significantly	O	-1	6692345
sup@@	O	-1	6692345
press@@	O	-1	6692345
ed	O	-1	6692345
by	O	-1	6692345
as@@	B-Chemical	D001241	6692345
pi@@	I-Chemical	-1	6692345
rin	I-Chemical	-1	6692345
co-@@	O	-1	6692345
administration	O	-1	6692345
after	O	-1	6692345
4	O	-1	6692345
weeks	O	-1	6692345
but	O	-1	6692345
not	O	-1	6692345
after	O	-1	6692345
12	O	-1	6692345
week@@	O	-1	6692345
s.	O	-1	6692345
In	O	-1	6692345
the	O	-1	6692345
fo@@	O	-1	6692345
rest@@	O	-1	6692345
om@@	O	-1	6692345
ac@@	O	-1	6692345
h@@	O	-1	6692345
,	O	-1	6692345
and	O	-1	6692345
also	O	-1	6692345
in	O	-1	6692345
the	O	-1	6692345
li@@	O	-1	6692345
ver,	O	-1	6692345
as@@	B-Chemical	D001241	6692345
pi@@	I-Chemical	-1	6692345
rin	I-Chemical	-1	6692345
did	O	-1	6692345
not	O	-1	6692345
aff@@	O	-1	6692345
ect	O	-1	6692345
the	O	-1	6692345
F@@	B-Chemical	D005200	6692345
AN@@	I-Chemical	-1	6692345
F@@	I-Chemical	-1	6692345
T	I-Chemical	-1	6692345
-induced	O	-1	6692345
increase	O	-1	6692345
in	O	-1	6692345
l@@	O	-1	6692345
a@@	O	-1	6692345
be@@	O	-1	6692345
l@@	O	-1	6692345
ing	O	-1	6692345
in@@	O	-1	6692345
de@@	O	-1	6692345
x@@	O	-1	6692345
.	O	-1	6692345
The	O	-1	6692345
present	O	-1	6692345
results	O	-1	6692345
are	O	-1	6692345
consist@@	O	-1	6692345
ent	O	-1	6692345
with	O	-1	6692345
the	O	-1	6692345
carcino@@	O	-1	6692345
gen@@	O	-1	6692345
ic@@	O	-1	6692345
ity	O	-1	6692345
experim@@	O	-1	6692345
ent	O	-1	6692345
suggesting	O	-1	6692345
that	O	-1	6692345
different	O	-1	6692345
mechanisms	O	-1	6692345
are	O	-1	6692345
involved	O	-1	6692345
in	O	-1	6692345
F@@	B-Chemical	D005200	6692345
AN@@	I-Chemical	-1	6692345
F@@	I-Chemical	-1	6692345
T	I-Chemical	-1	6692345
carcino@@	B-Disease	D063646	6692345
genesis	I-Disease	-1	6692345
in	O	-1	6692345
the	O	-1	6692345
bladder	O	-1	6692345
and	O	-1	6692345
fo@@	O	-1	6692345
rest@@	O	-1	6692345
om@@	O	-1	6692345
ac@@	O	-1	6692345
h@@	O	-1	6692345
,	O	-1	6692345
and	O	-1	6692345
that	O	-1	6692345
as@@	B-Chemical	D001241	6692345
pi@@	I-Chemical	-1	6692345
rin	I-Chemical	-1	6692345
's	O	-1	6692345
effect	O	-1	6692345
on	O	-1	6692345
F@@	B-Chemical	D005200	6692345
AN@@	I-Chemical	-1	6692345
F@@	I-Chemical	-1	6692345
T	I-Chemical	-1	6692345
in	O	-1	6692345
the	O	-1	6692345
fo@@	O	-1	6692345
rest@@	O	-1	6692345
om@@	O	-1	6692345
ach	O	-1	6692345
is	O	-1	6692345
not	O	-1	6692345
due	O	-1	6692345
to	O	-1	6692345
an	O	-1	6692345
ir@@	O	-1	6692345
rit@@	O	-1	6692345
ant	O	-1	6692345
effect	O	-1	6692345
associated	O	-1	6692345
with	O	-1	6692345
increased	O	-1	6692345
cell	O	-1	6692345
pro@@	O	-1	6692345
li@@	O	-1	6692345
fer@@	O	-1	6692345
ation.	O	-1	6692345
Al@@	O	-1	6692345
so@@	O	-1	6692345
,	O	-1	6692345
there	O	-1	6692345
appear@@	O	-1	6692345
s	O	-1	6692345
to	O	-1	6692345
be	O	-1	6692345
an	O	-1	6692345
ad@@	O	-1	6692345
ap@@	O	-1	6692345
t@@	O	-1	6692345
ation	O	-1	6692345
by	O	-1	6692345
the	O	-1	6692345
rats	O	-1	6692345
to	O	-1	6692345
the	O	-1	6692345
chronic	O	-1	6692345
ing@@	O	-1	6692345
es@@	O	-1	6692345
tion	O	-1	6692345
of	O	-1	6692345
as@@	B-Chemical	D001241	6692345
pi@@	I-Chemical	-1	6692345
rin	I-Chemical	-1	6692345
.	O	-1	6692345

Pro@@	O	-1	6773726
v@@	O	-1	6773726
oc@@	O	-1	6773726
ation	O	-1	6773726
of	O	-1	6773726
post@@	O	-1	6773726
ural	O	-1	6773726
hypotension	B-Disease	D007022	6773726
by	O	-1	6773726
nitro@@	B-Chemical	D005996	6773726
glycer@@	I-Chemical	-1	6773726
in	I-Chemical	-1	6773726
in	O	-1	6773726
dia@@	B-Disease	D003929	6773726
be@@	I-Disease	-1	6773726
tic	I-Disease	-1	6773726
a@@	I-Disease	-1	6773726
ut@@	I-Disease	-1	6773726
on@@	I-Disease	-1	6773726
om@@	I-Disease	-1	6773726
ic	I-Disease	-1	6773726
neuropathy	I-Disease	-1	6773726
?	O	-1	6773726
The	O	-1	6773726
effect	O	-1	6773726
of	O	-1	6773726
nitro@@	B-Chemical	D005996	6773726
glycer@@	I-Chemical	-1	6773726
in	I-Chemical	-1	6773726
on	O	-1	6773726
heart	O	-1	6773726
rate	O	-1	6773726
and	O	-1	6773726
systolic	O	-1	6773726
blood	O	-1	6773726
pressure	O	-1	6773726
was	O	-1	6773726
compared	O	-1	6773726
in	O	-1	6773726
5	O	-1	6773726
normal	O	-1	6773726
subj@@	O	-1	6773726
ect@@	O	-1	6773726
s,	O	-1	6773726
12	O	-1	6773726
dia@@	B-Disease	D003920	6773726
be@@	I-Disease	-1	6773726
tic	I-Disease	-1	6773726
subjects	O	-1	6773726
without	O	-1	6773726
a@@	B-Disease	D009422	6773726
ut@@	I-Disease	-1	6773726
on@@	I-Disease	-1	6773726
om@@	I-Disease	-1	6773726
ic	I-Disease	-1	6773726
neuropathy	I-Disease	-1	6773726
,	O	-1	6773726
and	O	-1	6773726
5	O	-1	6773726
dia@@	B-Disease	D003920	6773726
be@@	I-Disease	-1	6773726
tic	I-Disease	-1	6773726
subjects	O	-1	6773726
with	O	-1	6773726
a@@	B-Disease	D009422	6773726
ut@@	I-Disease	-1	6773726
on@@	I-Disease	-1	6773726
om@@	I-Disease	-1	6773726
ic	I-Disease	-1	6773726
neuropathy	I-Disease	-1	6773726
.	O	-1	6773726
The	O	-1	6773726
mag@@	O	-1	6773726
nit@@	O	-1	6773726
ude	O	-1	6773726
and	O	-1	6773726
time	O	-1	6773726
course	O	-1	6773726
of	O	-1	6773726
the	O	-1	6773726
increase	O	-1	6773726
in	O	-1	6773726
heart	O	-1	6773726
rate	O	-1	6773726
and	O	-1	6773726
the	O	-1	6773726
decrease	O	-1	6773726
in	O	-1	6773726
systolic	O	-1	6773726
blood	O	-1	6773726
pressure	O	-1	6773726
after	O	-1	6773726
nitro@@	B-Chemical	D005996	6773726
glycer@@	I-Chemical	-1	6773726
in	I-Chemical	-1	6773726
were	O	-1	6773726
similar	O	-1	6773726
in	O	-1	6773726
the	O	-1	6773726
normal	O	-1	6773726
and	O	-1	6773726
dia@@	B-Disease	D003920	6773726
be@@	I-Disease	-1	6773726
tic	I-Disease	-1	6773726
subjects	O	-1	6773726
without	O	-1	6773726
a@@	B-Disease	D009422	6773726
ut@@	I-Disease	-1	6773726
on@@	I-Disease	-1	6773726
om@@	I-Disease	-1	6773726
ic	I-Disease	-1	6773726
neuropathy	I-Disease	-1	6773726
,	O	-1	6773726
whereas	O	-1	6773726
a	O	-1	6773726
l@@	O	-1	6773726
ess@@	O	-1	6773726
er	O	-1	6773726
increase	O	-1	6773726
in	O	-1	6773726
heart	O	-1	6773726
rate	O	-1	6773726
and	O	-1	6773726
a	O	-1	6773726
greater	O	-1	6773726
decrease	O	-1	6773726
in	O	-1	6773726
systolic	O	-1	6773726
blood	O	-1	6773726
pressure	O	-1	6773726
occurred	O	-1	6773726
in	O	-1	6773726
the	O	-1	6773726
dia@@	B-Disease	D003920	6773726
be@@	I-Disease	-1	6773726
tic	I-Disease	-1	6773726
subjects	O	-1	6773726
with	O	-1	6773726
a@@	B-Disease	D009422	6773726
ut@@	I-Disease	-1	6773726
on@@	I-Disease	-1	6773726
om@@	I-Disease	-1	6773726
ic	I-Disease	-1	6773726
neuropathy	I-Disease	-1	6773726
.	O	-1	6773726
It	O	-1	6773726
is	O	-1	6773726
the@@	O	-1	6773726
re@@	O	-1	6773726
fore	O	-1	6773726
suggested	O	-1	6773726
that	O	-1	6773726
cau@@	O	-1	6773726
tion	O	-1	6773726
should	O	-1	6773726
be	O	-1	6773726
ex@@	O	-1	6773726
er@@	O	-1	6773726
cis@@	O	-1	6773726
ed	O	-1	6773726
when	O	-1	6773726
prescri@@	O	-1	6773726
b@@	O	-1	6773726
ing	O	-1	6773726
vas@@	O	-1	6773726
odi@@	O	-1	6773726
lat@@	O	-1	6773726
or	O	-1	6773726
drugs	O	-1	6773726
in	O	-1	6773726
dia@@	B-Disease	D003920	6773726
be@@	I-Disease	-1	6773726
tic	I-Disease	-1	6773726
patients,	O	-1	6773726
partic@@	O	-1	6773726
ul@@	O	-1	6773726
arly	O	-1	6773726
those	O	-1	6773726
with	O	-1	6773726
a@@	B-Disease	D009422	6773726
ut@@	I-Disease	-1	6773726
on@@	I-Disease	-1	6773726
om@@	I-Disease	-1	6773726
ic	I-Disease	-1	6773726
neuropathy	I-Disease	-1	6773726
.	O	-1	6773726

Ch@@	O	-1	6888657
aracter@@	O	-1	6888657
ization	O	-1	6888657
of	O	-1	6888657
est@@	B-Chemical	D004967	6888657
ro@@	I-Chemical	-1	6888657
gen	I-Chemical	-1	6888657
-induced	O	-1	6888657
aden@@	B-Disease	D010911	6888657
o@@	I-Disease	-1	6888657
hypo@@	I-Disease	-1	6888657
ph@@	I-Disease	-1	6888657
y@@	I-Disease	-1	6888657
se@@	I-Disease	-1	6888657
al	I-Disease	-1	6888657
tu@@	I-Disease	-1	6888657
mor@@	I-Disease	-1	6888657
s	I-Disease	-1	6888657
in	O	-1	6888657
the	O	-1	6888657
F@@	O	-1	6888657
is@@	O	-1	6888657
ch@@	O	-1	6888657
er	O	-1	6888657
34@@	O	-1	6888657
4	O	-1	6888657
rat@@	O	-1	6888657
.	O	-1	6888657
P@@	B-Disease	D010911	6888657
it@@	I-Disease	-1	6888657
u@@	I-Disease	-1	6888657
it@@	I-Disease	-1	6888657
ary	I-Disease	-1	6888657
tu@@	I-Disease	-1	6888657
mor@@	I-Disease	-1	6888657
s	I-Disease	-1	6888657
were	O	-1	6888657
induced	O	-1	6888657
in	O	-1	6888657
F@@	O	-1	6888657
34@@	O	-1	6888657
4	O	-1	6888657
female	O	-1	6888657
rats	O	-1	6888657
by	O	-1	6888657
chronic	O	-1	6888657
treatment	O	-1	6888657
with	O	-1	6888657
di@@	B-Chemical	D004054	6888657
eth@@	I-Chemical	-1	6888657
yl@@	I-Chemical	-1	6888657
sti@@	I-Chemical	-1	6888657
l@@	I-Chemical	-1	6888657
be@@	I-Chemical	-1	6888657
stro@@	I-Chemical	-1	6888657
l	I-Chemical	-1	6888657
(	O	-1	6888657
D@@	B-Chemical	D004054	6888657
E@@	I-Chemical	-1	6888657
S	I-Chemical	-1	6888657
,	O	-1	6888657
8@@	O	-1	6888657
-@@	O	-1	6888657
10	O	-1	6888657
mg@@	O	-1	6888657
)	O	-1	6888657
im@@	O	-1	6888657
pl@@	O	-1	6888657
ant@@	O	-1	6888657
ed	O	-1	6888657
sub@@	O	-1	6888657
c@@	O	-1	6888657
ut@@	O	-1	6888657
ane@@	O	-1	6888657
ously	O	-1	6888657
in	O	-1	6888657
si@@	O	-1	6888657
las@@	O	-1	6888657
tic	O	-1	6888657
cap@@	O	-1	6888657
sul@@	O	-1	6888657
es.	O	-1	6888657
O@@	O	-1	6888657
ver	O	-1	6888657
a	O	-1	6888657
range	O	-1	6888657
of	O	-1	6888657
1@@	O	-1	6888657
-1@@	O	-1	6888657
50	O	-1	6888657
days	O	-1	6888657
of	O	-1	6888657
D@@	B-Chemical	D004054	6888657
E@@	I-Chemical	-1	6888657
S	I-Chemical	-1	6888657
treatment,	O	-1	6888657
pa@@	O	-1	6888657
ir@@	O	-1	6888657
s	O	-1	6888657
of	O	-1	6888657
control	O	-1	6888657
and	O	-1	6888657
D@@	B-Chemical	D004054	6888657
E@@	I-Chemical	-1	6888657
S	I-Chemical	-1	6888657
-treated	O	-1	6888657
rats	O	-1	6888657
were	O	-1	6888657
s@@	O	-1	6888657
ac@@	O	-1	6888657
ri@@	O	-1	6888657
fic@@	O	-1	6888657
ed,	O	-1	6888657
and	O	-1	6888657
their	O	-1	6888657
pit@@	O	-1	6888657
u@@	O	-1	6888657
it@@	O	-1	6888657
ari@@	O	-1	6888657
es	O	-1	6888657
dis@@	O	-1	6888657
s@@	O	-1	6888657
oci@@	O	-1	6888657
ated	O	-1	6888657
enzym@@	O	-1	6888657
ati@@	O	-1	6888657
c@@	O	-1	6888657
ally	O	-1	6888657
into	O	-1	6888657
sing@@	O	-1	6888657
le@@	O	-1	6888657
-@@	O	-1	6888657
cell	O	-1	6888657
pre@@	O	-1	6888657
par@@	O	-1	6888657
ations.	O	-1	6888657
The	O	-1	6888657
cell	O	-1	6888657
po@@	O	-1	6888657
pul@@	O	-1	6888657
ations	O	-1	6888657
were	O	-1	6888657
examined	O	-1	6888657
reg@@	O	-1	6888657
ar@@	O	-1	6888657
ding	O	-1	6888657
total	O	-1	6888657
cell	O	-1	6888657
recovery	O	-1	6888657
cor@@	O	-1	6888657
related	O	-1	6888657
with	O	-1	6888657
gl@@	O	-1	6888657
and	O	-1	6888657
weigh@@	O	-1	6888657
t,	O	-1	6888657
intrac@@	O	-1	6888657
ell@@	O	-1	6888657
ular	O	-1	6888657
prolactin	O	-1	6888657
(P@@	O	-1	6888657
R@@	O	-1	6888657
L@@	O	-1	6888657
)	O	-1	6888657
cont@@	O	-1	6888657
ent	O	-1	6888657
and	O	-1	6888657
subsequ@@	O	-1	6888657
ent	O	-1	6888657
release	O	-1	6888657
in	O	-1	6888657
prim@@	O	-1	6888657
ary	O	-1	6888657
c@@	O	-1	6888657
ult@@	O	-1	6888657
ure,	O	-1	6888657
immun@@	O	-1	6888657
ocyto@@	O	-1	6888657
chemical	O	-1	6888657
P@@	O	-1	6888657
R@@	O	-1	6888657
L	O	-1	6888657
st@@	O	-1	6888657
ain@@	O	-1	6888657
ing,	O	-1	6888657
d@@	O	-1	6888657
ensity	O	-1	6888657
and/or	O	-1	6888657
size	O	-1	6888657
al@@	O	-1	6888657
ter@@	O	-1	6888657
ations	O	-1	6888657
vi@@	O	-1	6888657
a	O	-1	6888657
se@@	O	-1	6888657
par@@	O	-1	6888657
ation	O	-1	6888657
on	O	-1	6888657
F@@	O	-1	6888657
ic@@	O	-1	6888657
ol@@	O	-1	6888657
l@@	O	-1	6888657
-H@@	O	-1	6888657
y@@	O	-1	6888657
pa@@	O	-1	6888657
qu@@	O	-1	6888657
e	O	-1	6888657
and	O	-1	6888657
by	O	-1	6888657
un@@	O	-1	6888657
it	O	-1	6888657
gra@@	O	-1	6888657
v@@	O	-1	6888657
ity	O	-1	6888657
se@@	O	-1	6888657
di@@	O	-1	6888657
ment@@	O	-1	6888657
ation,	O	-1	6888657
and	O	-1	6888657
cell	O	-1	6888657
cyc@@	O	-1	6888657
le	O	-1	6888657
analy@@	O	-1	6888657
sis,	O	-1	6888657
after	O	-1	6888657
ac@@	B-Chemical	D000167	6888657
ri@@	I-Chemical	-1	6888657
f@@	I-Chemical	-1	6888657
l@@	I-Chemical	-1	6888657
av@@	I-Chemical	-1	6888657
ine	I-Chemical	-1	6888657
D@@	O	-1	6888657
NA	O	-1	6888657
st@@	O	-1	6888657
ain@@	O	-1	6888657
ing,	O	-1	6888657
by	O	-1	6888657
las@@	O	-1	6888657
er	O	-1	6888657
flow	O	-1	6888657
cyto@@	O	-1	6888657
met@@	O	-1	6888657
r@@	O	-1	6888657
y.	O	-1	6888657
T@@	O	-1	6888657
ot@@	O	-1	6888657
al	O	-1	6888657
cell	O	-1	6888657
y@@	O	-1	6888657
i@@	O	-1	6888657
el@@	O	-1	6888657
ds	O	-1	6888657
from	O	-1	6888657
D@@	B-Chemical	D004054	6888657
E@@	I-Chemical	-1	6888657
S	I-Chemical	-1	6888657
-treated	O	-1	6888657
pit@@	O	-1	6888657
u@@	O	-1	6888657
it@@	O	-1	6888657
ari@@	O	-1	6888657
es	O	-1	6888657
increased	O	-1	6888657
from	O	-1	6888657
1.@@	O	-1	6888657
3	O	-1	6888657
times	O	-1	6888657
control	O	-1	6888657
y@@	O	-1	6888657
i@@	O	-1	6888657
el@@	O	-1	6888657
ds	O	-1	6888657
at	O	-1	6888657
8	O	-1	6888657
days	O	-1	6888657
of	O	-1	6888657
treatment	O	-1	6888657
to	O	-1	6888657
5@@	O	-1	6888657
8.@@	O	-1	6888657
9	O	-1	6888657
times	O	-1	6888657
control	O	-1	6888657
values	O	-1	6888657
by	O	-1	6888657
day	O	-1	6888657
1@@	O	-1	6888657
50@@	O	-1	6888657
.	O	-1	6888657
In@@	O	-1	6888657
trac@@	O	-1	6888657
ell@@	O	-1	6888657
ular	O	-1	6888657
P@@	O	-1	6888657
R@@	O	-1	6888657
L	O	-1	6888657
cont@@	O	-1	6888657
ent	O	-1	6888657
rang@@	O	-1	6888657
ed	O	-1	6888657
from	O	-1	6888657
1.@@	O	-1	6888657
9	O	-1	6888657
to	O	-1	6888657
9.@@	O	-1	6888657
4	O	-1	6888657
times	O	-1	6888657
control	O	-1	6888657
level@@	O	-1	6888657
s,	O	-1	6888657
and	O	-1	6888657
P@@	O	-1	6888657
R@@	O	-1	6888657
L	O	-1	6888657
release	O	-1	6888657
in	O	-1	6888657
vit@@	O	-1	6888657
r@@	O	-1	6888657
o	O	-1	6888657
was	O	-1	6888657
significantly	O	-1	6888657
and	O	-1	6888657
consist@@	O	-1	6888657
ently	O	-1	6888657
higher	O	-1	6888657
than	O	-1	6888657
control@@	O	-1	6888657
s,	O	-1	6888657
after	O	-1	6888657
at	O	-1	6888657
le@@	O	-1	6888657
ast	O	-1	6888657
8	O	-1	6888657
days	O	-1	6888657
of	O	-1	6888657
D@@	B-Chemical	D004054	6888657
E@@	I-Chemical	-1	6888657
S	I-Chemical	-1	6888657
expos@@	O	-1	6888657
ure.	O	-1	6888657
B@@	O	-1	6888657
e@@	O	-1	6888657
y@@	O	-1	6888657
on@@	O	-1	6888657
d	O	-1	6888657
8	O	-1	6888657
days	O	-1	6888657
of	O	-1	6888657
D@@	B-Chemical	D004054	6888657
E@@	I-Chemical	-1	6888657
S	I-Chemical	-1	6888657
expos@@	O	-1	6888657
ure,	O	-1	6888657
the	O	-1	6888657
immuno@@	O	-1	6888657
chem@@	O	-1	6888657
ically	O	-1	6888657
P@@	O	-1	6888657
R@@	O	-1	6888657
L-@@	O	-1	6888657
positive	O	-1	6888657
pro@@	O	-1	6888657
por@@	O	-1	6888657
tion	O	-1	6888657
of	O	-1	6888657
cells	O	-1	6888657
increased	O	-1	6888657
to	O	-1	6888657
over	O	-1	6888657
50@@	O	-1	6888657
%	O	-1	6888657
of	O	-1	6888657
the	O	-1	6888657
total	O	-1	6888657
po@@	O	-1	6888657
pul@@	O	-1	6888657
ation.	O	-1	6888657
In@@	O	-1	6888657
c@@	O	-1	6888657
reas@@	O	-1	6888657
ed	O	-1	6888657
d@@	O	-1	6888657
ensity	O	-1	6888657
and/or	O	-1	6888657
size	O	-1	6888657
and	O	-1	6888657
P@@	O	-1	6888657
R@@	O	-1	6888657
L	O	-1	6888657
cont@@	O	-1	6888657
ent	O	-1	6888657
were	O	-1	6888657
indic@@	O	-1	6888657
ated	O	-1	6888657
for	O	-1	6888657
the	O	-1	6888657
maj@@	O	-1	6888657
or@@	O	-1	6888657
ity	O	-1	6888657
of	O	-1	6888657
the	O	-1	6888657
P@@	O	-1	6888657
R@@	O	-1	6888657
L	O	-1	6888657
cell	O	-1	6888657
po@@	O	-1	6888657
p@@	O	-1	6888657
ulation	O	-1	6888657
in	O	-1	6888657
both	O	-1	6888657
typ@@	O	-1	6888657
es	O	-1	6888657
of	O	-1	6888657
se@@	O	-1	6888657
par@@	O	-1	6888657
ation	O	-1	6888657
pro@@	O	-1	6888657
to@@	O	-1	6888657
co@@	O	-1	6888657
l@@	O	-1	6888657
s.	O	-1	6888657
All	O	-1	6888657
these	O	-1	6888657
effects	O	-1	6888657
of	O	-1	6888657
D@@	B-Chemical	D004054	6888657
E@@	I-Chemical	-1	6888657
S	I-Chemical	-1	6888657
were	O	-1	6888657
more	O	-1	6888657
p@@	O	-1	6888657
ron@@	O	-1	6888657
oun@@	O	-1	6888657
c@@	O	-1	6888657
ed	O	-1	6888657
among	O	-1	6888657
previously	O	-1	6888657
o@@	O	-1	6888657
vari@@	O	-1	6888657
ect@@	O	-1	6888657
om@@	O	-1	6888657
ized	O	-1	6888657
anim@@	O	-1	6888657
al@@	O	-1	6888657
s.	O	-1	6888657
The	O	-1	6888657
data	O	-1	6888657
exten@@	O	-1	6888657
d	O	-1	6888657
the	O	-1	6888657
findings	O	-1	6888657
of	O	-1	6888657
other	O	-1	6888657
investig@@	O	-1	6888657
at@@	O	-1	6888657
or@@	O	-1	6888657
s,	O	-1	6888657
further	O	-1	6888657
est@@	O	-1	6888657
abl@@	O	-1	6888657
ish@@	O	-1	6888657
ing	O	-1	6888657
the	O	-1	6888657
D@@	B-Chemical	D004054	6888657
E@@	I-Chemical	-1	6888657
S	I-Chemical	-1	6888657
-induced	O	-1	6888657
tumor	B-Disease	D009369	6888657
as	O	-1	6888657
a	O	-1	6888657
model	O	-1	6888657
for	O	-1	6888657
study	O	-1	6888657
of	O	-1	6888657
P@@	O	-1	6888657
R@@	O	-1	6888657
L	O	-1	6888657
cell@@	O	-1	6888657
ular	O	-1	6888657
control	O	-1	6888657
mechanis@@	O	-1	6888657
m@@	O	-1	6888657
s.	O	-1	6888657

T@@	B-Chemical	D014223	7265370
riam@@	I-Chemical	-1	7265370
te@@	I-Chemical	-1	7265370
ren@@	I-Chemical	-1	7265370
e	I-Chemical	-1	7265370
nephro@@	B-Disease	D053040	7265370
li@@	I-Disease	-1	7265370
th@@	I-Disease	-1	7265370
ia@@	I-Disease	-1	7265370
sis	I-Disease	-1	7265370
complic@@	O	-1	7265370
ating	O	-1	7265370
dy@@	B-Chemical	C020743	7265370
az@@	I-Chemical	-1	7265370
ide	I-Chemical	-1	7265370
therapy.	O	-1	7265370
A	O	-1	7265370
case	O	-1	7265370
of	O	-1	7265370
tri@@	B-Chemical	D014223	7265370
am@@	I-Chemical	-1	7265370
te@@	I-Chemical	-1	7265370
ren@@	I-Chemical	-1	7265370
e	I-Chemical	-1	7265370
nephro@@	B-Disease	D053040	7265370
li@@	I-Disease	-1	7265370
th@@	I-Disease	-1	7265370
ia@@	I-Disease	-1	7265370
sis	I-Disease	-1	7265370
is	O	-1	7265370
reported	O	-1	7265370
in	O	-1	7265370
a	O	-1	7265370
man	O	-1	7265370
after	O	-1	7265370
4	O	-1	7265370
years	O	-1	7265370
of	O	-1	7265370
hydro@@	B-Chemical	C020743	7265370
ch@@	I-Chemical	-1	7265370
loro@@	I-Chemical	-1	7265370
thi@@	I-Chemical	-1	7265370
az@@	I-Chemical	-1	7265370
ide@@	I-Chemical	-1	7265370
-@@	I-Chemical	-1	7265370
tri@@	I-Chemical	-1	7265370
am@@	I-Chemical	-1	7265370
te@@	I-Chemical	-1	7265370
ren@@	I-Chemical	-1	7265370
e	I-Chemical	-1	7265370
therapy	O	-1	7265370
for	O	-1	7265370
hypertension	B-Disease	D006973	7265370
.	O	-1	7265370
The	O	-1	7265370
st@@	O	-1	7265370
one	O	-1	7265370
p@@	O	-1	7265370
ass@@	O	-1	7265370
ed	O	-1	7265370
spont@@	O	-1	7265370
ane@@	O	-1	7265370
ously	O	-1	7265370
and	O	-1	7265370
was	O	-1	7265370
found	O	-1	7265370
to	O	-1	7265370
cont@@	O	-1	7265370
ain	O	-1	7265370
a	O	-1	7265370
tri@@	B-Chemical	D014223	7265370
am@@	I-Chemical	-1	7265370
te@@	I-Chemical	-1	7265370
ren@@	I-Chemical	-1	7265370
e	I-Chemical	-1	7265370
metabol@@	O	-1	7265370
ite	O	-1	7265370
ad@@	O	-1	7265370
mi@@	O	-1	7265370
x@@	O	-1	7265370
ed	O	-1	7265370
with	O	-1	7265370
ur@@	B-Chemical	D014527	7265370
ic	I-Chemical	-1	7265370
acid	I-Chemical	-1	7265370
sal@@	I-Chemical	-1	7265370
ts	I-Chemical	-1	7265370
ur@@	B-Chemical	D012492	7265370
ic	I-Chemical	-1	7265370
acid	I-Chemical	-1	7265370
sal@@	I-Chemical	-1	7265370
ts	I-Chemical	-1	7265370
.	O	-1	7265370
F@@	O	-1	7265370
act@@	O	-1	7265370
ors	O	-1	7265370
aff@@	O	-1	7265370
ect@@	O	-1	7265370
ing	O	-1	7265370
tri@@	B-Chemical	D014223	7265370
am@@	I-Chemical	-1	7265370
te@@	I-Chemical	-1	7265370
ren@@	I-Chemical	-1	7265370
e	I-Chemical	-1	7265370
nephro@@	B-Disease	D053040	7265370
li@@	I-Disease	-1	7265370
th@@	I-Disease	-1	7265370
ia@@	I-Disease	-1	7265370
sis	I-Disease	-1	7265370
are	O	-1	7265370
discus@@	O	-1	7265370
sed	O	-1	7265370
and	O	-1	7265370
2	O	-1	7265370
previously	O	-1	7265370
reported	O	-1	7265370
cases	O	-1	7265370
are	O	-1	7265370
revie@@	O	-1	7265370
we@@	O	-1	7265370
d.	O	-1	7265370

M@@	O	-1	7423039
et@@	O	-1	7423039
ab@@	O	-1	7423039
olic	O	-1	7423039
invol@@	O	-1	7423039
vement	O	-1	7423039
in	O	-1	7423039
adriam@@	B-Chemical	D004317	7423039
ycin	I-Chemical	-1	7423039
cardi@@	B-Disease	D066126	7423039
otoxicity	I-Disease	-1	7423039
.	O	-1	7423039
The	O	-1	7423039
cardi@@	B-Disease	D066126	7423039
ot@@	I-Disease	-1	7423039
ox@@	I-Disease	-1	7423039
ic	I-Disease	-1	7423039
effects	O	-1	7423039
of	O	-1	7423039
adriam@@	B-Chemical	D004317	7423039
ycin	I-Chemical	-1	7423039
were	O	-1	7423039
studied	O	-1	7423039
in	O	-1	7423039
m@@	O	-1	7423039
am@@	O	-1	7423039
mal@@	O	-1	7423039
i@@	O	-1	7423039
an	O	-1	7423039
myocardial	O	-1	7423039
cells	O	-1	7423039
in	O	-1	7423039
c@@	O	-1	7423039
ult@@	O	-1	7423039
ure	O	-1	7423039
as	O	-1	7423039
a	O	-1	7423039
model	O	-1	7423039
system@@	O	-1	7423039
.	O	-1	7423039
Ad@@	B-Chemical	D004317	7423039
riam@@	I-Chemical	-1	7423039
ycin	I-Chemical	-1	7423039
inhibited	O	-1	7423039
cell	O	-1	7423039
growth	O	-1	7423039
and	O	-1	7423039
the	O	-1	7423039
rhyth@@	O	-1	7423039
mic	O	-1	7423039
contrac@@	O	-1	7423039
tions	O	-1	7423039
character@@	O	-1	7423039
istic	O	-1	7423039
of	O	-1	7423039
myocardial	O	-1	7423039
cells	O	-1	7423039
in	O	-1	7423039
c@@	O	-1	7423039
ult@@	O	-1	7423039
ure.	O	-1	7423039
A	O	-1	7423039
possible	O	-1	7423039
invol@@	O	-1	7423039
vement	O	-1	7423039
of	O	-1	7423039
en@@	O	-1	7423039
erg@@	O	-1	7423039
y	O	-1	7423039
metabol@@	O	-1	7423039
ism	O	-1	7423039
was	O	-1	7423039
suggested	O	-1	7423039
previ@@	O	-1	7423039
ous@@	O	-1	7423039
ly,	O	-1	7423039
and	O	-1	7423039
in	O	-1	7423039
this	O	-1	7423039
study	O	-1	7423039
the	O	-1	7423039
aden@@	O	-1	7423039
yl@@	O	-1	7423039
ate	O	-1	7423039
en@@	O	-1	7423039
erg@@	O	-1	7423039
y	O	-1	7423039
ch@@	O	-1	7423039
arg@@	O	-1	7423039
e	O	-1	7423039
and	O	-1	7423039
phosph@@	B-Chemical	D010725	7423039
or@@	I-Chemical	-1	7423039
yl@@	I-Chemical	-1	7423039
creat@@	I-Chemical	-1	7423039
ine	I-Chemical	-1	7423039
mol@@	O	-1	7423039
e	O	-1	7423039
frac@@	O	-1	7423039
tion	O	-1	7423039
were	O	-1	7423039
determined	O	-1	7423039
in	O	-1	7423039
the	O	-1	7423039
adriam@@	B-Chemical	D004317	7423039
ycin	I-Chemical	-1	7423039
-treated	O	-1	7423039
cell@@	O	-1	7423039
s.	O	-1	7423039
The	O	-1	7423039
aden@@	O	-1	7423039
yl@@	O	-1	7423039
ate	O	-1	7423039
en@@	O	-1	7423039
erg@@	O	-1	7423039
y	O	-1	7423039
ch@@	O	-1	7423039
arg@@	O	-1	7423039
e	O	-1	7423039
was	O	-1	7423039
found	O	-1	7423039
to	O	-1	7423039
be	O	-1	7423039
significantly	O	-1	7423039
decreas@@	O	-1	7423039
ed,	O	-1	7423039
while	O	-1	7423039
the	O	-1	7423039
ph@@	B-Chemical	D010725	7423039
oph@@	I-Chemical	-1	7423039
or@@	I-Chemical	-1	7423039
yl@@	I-Chemical	-1	7423039
creat@@	I-Chemical	-1	7423039
ine	I-Chemical	-1	7423039
mol@@	O	-1	7423039
e	O	-1	7423039
frac@@	O	-1	7423039
tion	O	-1	7423039
was	O	-1	7423039
un@@	O	-1	7423039
chang@@	O	-1	7423039
ed.	O	-1	7423039
S@@	O	-1	7423039
uc@@	O	-1	7423039
h	O	-1	7423039
dis@@	O	-1	7423039
par@@	O	-1	7423039
ity	O	-1	7423039
suggests	O	-1	7423039
an	O	-1	7423039
inhibition	O	-1	7423039
of	O	-1	7423039
creat@@	B-Chemical	D003401	7423039
ine	I-Chemical	-1	7423039
phosph@@	O	-1	7423039
o@@	O	-1	7423039
kin@@	O	-1	7423039
as@@	O	-1	7423039
e.	O	-1	7423039
The	O	-1	7423039
addition	O	-1	7423039
of	O	-1	7423039
1	O	-1	7423039
m@@	O	-1	7423039
M	O	-1	7423039
aden@@	B-Chemical	D000241	7423039
os@@	I-Chemical	-1	7423039
ine	I-Chemical	-1	7423039
to	O	-1	7423039
the	O	-1	7423039
myocardial	O	-1	7423039
cell	O	-1	7423039
c@@	O	-1	7423039
ult@@	O	-1	7423039
ures	O	-1	7423039
mark@@	O	-1	7423039
ed@@	O	-1	7423039
ly	O	-1	7423039
increases	O	-1	7423039
the	O	-1	7423039
AT@@	B-Chemical	D000255	7423039
P	I-Chemical	-1	7423039
concentration	O	-1	7423039
through	O	-1	7423039
a	O	-1	7423039
path@@	O	-1	7423039
w@@	O	-1	7423039
ay	O	-1	7423039
repor@@	O	-1	7423039
te@@	O	-1	7423039
d@@	O	-1	7423039
ly	O	-1	7423039
lead@@	O	-1	7423039
ing	O	-1	7423039
to	O	-1	7423039
a	O	-1	7423039
compar@@	O	-1	7423039
t@@	O	-1	7423039
ment@@	O	-1	7423039
al@@	O	-1	7423039
ized	O	-1	7423039
AT@@	B-Chemical	D000255	7423039
P	I-Chemical	-1	7423039
po@@	O	-1	7423039
ol@@	O	-1	7423039
.	O	-1	7423039
In	O	-1	7423039
the	O	-1	7423039
adriam@@	B-Chemical	D004317	7423039
ycin	I-Chemical	-1	7423039
-treated	O	-1	7423039
cell@@	O	-1	7423039
s,	O	-1	7423039
the	O	-1	7423039
addition	O	-1	7423039
of	O	-1	7423039
aden@@	B-Chemical	D000241	7423039
os@@	I-Chemical	-1	7423039
ine	I-Chemical	-1	7423039
increased	O	-1	7423039
the	O	-1	7423039
aden@@	O	-1	7423039
yl@@	O	-1	7423039
ate	O	-1	7423039
ch@@	O	-1	7423039
arg@@	O	-1	7423039
e	O	-1	7423039
and@@	O	-1	7423039
,	O	-1	7423039
concomit@@	O	-1	7423039
ant	O	-1	7423039
with	O	-1	7423039
this	O	-1	7423039
in@@	O	-1	7423039
r@@	O	-1	7423039
ce@@	O	-1	7423039
ase,	O	-1	7423039
the	O	-1	7423039
cell@@	O	-1	7423039
s@@	O	-1	7423039
'	O	-1	7423039
functional	O	-1	7423039
in@@	O	-1	7423039
te@@	O	-1	7423039
g@@	O	-1	7423039
r@@	O	-1	7423039
ity,	O	-1	7423039
in	O	-1	7423039
ter@@	O	-1	7423039
ms	O	-1	7423039
of	O	-1	7423039
perc@@	O	-1	7423039
ent@@	O	-1	7423039
age	O	-1	7423039
of	O	-1	7423039
be@@	O	-1	7423039
ating	O	-1	7423039
cells	O	-1	7423039
and	O	-1	7423039
rate	O	-1	7423039
of	O	-1	7423039
contrac@@	O	-1	7423039
tion@@	O	-1	7423039
s,	O	-1	7423039
was	O	-1	7423039
maint@@	O	-1	7423039
a@@	O	-1	7423039
ine@@	O	-1	7423039
d.	O	-1	7423039

A@@	O	-1	7444978
g@@	O	-1	7444978
e-@@	O	-1	7444978
dependent	O	-1	7444978
sensitivity	O	-1	7444978
of	O	-1	7444978
the	O	-1	7444978
rat	O	-1	7444978
to	O	-1	7444978
neuro@@	B-Disease	D020258	7444978
toxic	I-Disease	-1	7444978
effects	O	-1	7444978
of	O	-1	7444978
st@@	B-Chemical	D013307	7444978
re@@	I-Chemical	-1	7444978
pto@@	I-Chemical	-1	7444978
m@@	I-Chemical	-1	7444978
ycin	I-Chemical	-1	7444978
.	O	-1	7444978
S@@	B-Chemical	D013307	7444978
tre@@	I-Chemical	-1	7444978
pto@@	I-Chemical	-1	7444978
m@@	I-Chemical	-1	7444978
ycin	I-Chemical	-1	7444978
sulf@@	O	-1	7444978
ate	O	-1	7444978
(3@@	O	-1	7444978
00	O	-1	7444978
mg/kg	O	-1	7444978
s@@	O	-1	7444978
.@@	O	-1	7444978
c@@	O	-1	7444978
.)	O	-1	7444978
was	O	-1	7444978
injected	O	-1	7444978
for	O	-1	7444978
various	O	-1	7444978
perio@@	O	-1	7444978
ds	O	-1	7444978
into	O	-1	7444978
pre@@	O	-1	7444978
we@@	O	-1	7444978
an@@	O	-1	7444978
l@@	O	-1	7444978
ing	O	-1	7444978
rats	O	-1	7444978
and	O	-1	7444978
for	O	-1	7444978
3	O	-1	7444978
weeks	O	-1	7444978
into	O	-1	7444978
we@@	O	-1	7444978
an@@	O	-1	7444978
l@@	O	-1	7444978
ing	O	-1	7444978
rats.	O	-1	7444978
B@@	O	-1	7444978
e@@	O	-1	7444978
g@@	O	-1	7444978
in@@	O	-1	7444978
ning	O	-1	7444978
at	O	-1	7444978
8	O	-1	7444978
days	O	-1	7444978
of	O	-1	7444978
age,	O	-1	7444978
body	O	-1	7444978
mo@@	O	-1	7444978
vement	O	-1	7444978
and	O	-1	7444978
hearing	O	-1	7444978
were	O	-1	7444978
examined	O	-1	7444978
for	O	-1	7444978
6	O	-1	7444978
and	O	-1	7444978
up	O	-1	7444978
to	O	-1	7444978
17	O	-1	7444978
week@@	O	-1	7444978
s,	O	-1	7444978
respectively.	O	-1	7444978
A@@	B-Disease	D004409	7444978
b@@	I-Disease	-1	7444978
normal	I-Disease	-1	7444978
mo@@	I-Disease	-1	7444978
ve@@	I-Disease	-1	7444978
ments	I-Disease	-1	7444978
and	O	-1	7444978
de@@	B-Disease	D003638	7444978
af@@	I-Disease	-1	7444978
ness	I-Disease	-1	7444978
occurred	O	-1	7444978
only	O	-1	7444978
in	O	-1	7444978
rats	O	-1	7444978
treated	O	-1	7444978
during	O	-1	7444978
the	O	-1	7444978
pre@@	O	-1	7444978
we@@	O	-1	7444978
an@@	O	-1	7444978
ing	O	-1	7444978
perio@@	O	-1	7444978
d@@	O	-1	7444978
;	O	-1	7444978
within	O	-1	7444978
this	O	-1	7444978
period	O	-1	7444978
the	O	-1	7444978
great@@	O	-1	7444978
est	O	-1	7444978
sensi@@	O	-1	7444978
ti@@	O	-1	7444978
vi@@	O	-1	7444978
ties	O	-1	7444978
for	O	-1	7444978
these	O	-1	7444978
abnormal@@	O	-1	7444978
ities	O	-1	7444978
occurred	O	-1	7444978
from	O	-1	7444978
2	O	-1	7444978
to	O	-1	7444978
1@@	O	-1	7444978
1@@	O	-1	7444978
-1@@	O	-1	7444978
7	O	-1	7444978
and	O	-1	7444978
5	O	-1	7444978
to	O	-1	7444978
11	O	-1	7444978
days	O	-1	7444978
of	O	-1	7444978
age,	O	-1	7444978
respectivel@@	O	-1	7444978
y,	O	-1	7444978
indicating	O	-1	7444978
that	O	-1	7444978
the	O	-1	7444978
co@@	O	-1	7444978
ch@@	O	-1	7444978
le@@	O	-1	7444978
a	O	-1	7444978
is	O	-1	7444978
more	O	-1	7444978
sensitive	O	-1	7444978
to	O	-1	7444978
st@@	B-Chemical	D013307	7444978
re@@	I-Chemical	-1	7444978
pto@@	I-Chemical	-1	7444978
m@@	I-Chemical	-1	7444978
ycin	I-Chemical	-1	7444978
than	O	-1	7444978
the	O	-1	7444978
sit@@	O	-1	7444978
e	O	-1	7444978
(@@	O	-1	7444978
v@@	O	-1	7444978
es@@	O	-1	7444978
ti@@	O	-1	7444978
b@@	O	-1	7444978
ular	O	-1	7444978
or	O	-1	7444978
centr@@	O	-1	7444978
al@@	O	-1	7444978
)	O	-1	7444978
respon@@	O	-1	7444978
sible	O	-1	7444978
for	O	-1	7444978
the	O	-1	7444978
dyskine@@	B-Disease	D004409	7444978
si@@	I-Disease	-1	7444978
as	I-Disease	-1	7444978
.	O	-1	7444978

C@@	O	-1	7834920
res@@	O	-1	7834920
c@@	O	-1	7834920
en@@	O	-1	7834920
tic	O	-1	7834920
fibrill@@	O	-1	7834920
ary	O	-1	7834920
glomerul@@	B-Disease	D005921	7834920
one@@	I-Disease	-1	7834920
ph@@	I-Disease	-1	7834920
ritis	I-Disease	-1	7834920
associated	O	-1	7834920
with	O	-1	7834920
inter@@	O	-1	7834920
mit@@	O	-1	7834920
t@@	O	-1	7834920
ent	O	-1	7834920
ri@@	B-Chemical	D012293	7834920
f@@	I-Chemical	-1	7834920
amp@@	I-Chemical	-1	7834920
in	I-Chemical	-1	7834920
therapy	O	-1	7834920
for	O	-1	7834920
pulmonary	B-Disease	D014397	7834920
tub@@	I-Disease	-1	7834920
er@@	I-Disease	-1	7834920
c@@	I-Disease	-1	7834920
ulo@@	I-Disease	-1	7834920
sis	I-Disease	-1	7834920
.	O	-1	7834920
This	O	-1	7834920
case	O	-1	7834920
study	O	-1	7834920
reve@@	O	-1	7834920
als	O	-1	7834920
an	O	-1	7834920
un@@	O	-1	7834920
us@@	O	-1	7834920
ual	O	-1	7834920
find@@	O	-1	7834920
ing	O	-1	7834920
of	O	-1	7834920
ra@@	O	-1	7834920
pid@@	O	-1	7834920
ly	O	-1	7834920
pro@@	O	-1	7834920
li@@	O	-1	7834920
fer@@	O	-1	7834920
ative	O	-1	7834920
c@@	O	-1	7834920
res@@	O	-1	7834920
c@@	O	-1	7834920
en@@	O	-1	7834920
tic	O	-1	7834920
glomerul@@	B-Disease	D005921	7834920
one@@	I-Disease	-1	7834920
ph@@	I-Disease	-1	7834920
ritis	I-Disease	-1	7834920
in	O	-1	7834920
a	O	-1	7834920
patient	O	-1	7834920
treated	O	-1	7834920
with	O	-1	7834920
ri@@	B-Chemical	D012293	7834920
f@@	I-Chemical	-1	7834920
amp@@	I-Chemical	-1	7834920
in	I-Chemical	-1	7834920
who	O	-1	7834920
had	O	-1	7834920
no	O	-1	7834920
other	O	-1	7834920
identi@@	O	-1	7834920
fi@@	O	-1	7834920
able	O	-1	7834920
causes	O	-1	7834920
for	O	-1	7834920
develop@@	O	-1	7834920
ing	O	-1	7834920
this	O	-1	7834920
disease.	O	-1	7834920
This	O	-1	7834920
patient	O	-1	7834920
under@@	O	-1	7834920
w@@	O	-1	7834920
ent	O	-1	7834920
a	O	-1	7834920
10-@@	O	-1	7834920
mon@@	O	-1	7834920
th	O	-1	7834920
regi@@	O	-1	7834920
men	O	-1	7834920
of	O	-1	7834920
ri@@	B-Chemical	D012293	7834920
f@@	I-Chemical	-1	7834920
amp@@	I-Chemical	-1	7834920
in	I-Chemical	-1	7834920
and	O	-1	7834920
is@@	B-Chemical	D007538	7834920
oni@@	I-Chemical	-1	7834920
az@@	I-Chemical	-1	7834920
id	I-Chemical	-1	7834920
for	O	-1	7834920
pulmonary	B-Disease	D014397	7834920
tub@@	I-Disease	-1	7834920
er@@	I-Disease	-1	7834920
c@@	I-Disease	-1	7834920
ulo@@	I-Disease	-1	7834920
sis	I-Disease	-1	7834920
and	O	-1	7834920
was	O	-1	7834920
dis@@	O	-1	7834920
co@@	O	-1	7834920
vered	O	-1	7834920
to	O	-1	7834920
have	O	-1	7834920
developed	O	-1	7834920
signs	O	-1	7834920
of	O	-1	7834920
severe	O	-1	7834920
renal	B-Disease	D051437	7834920
failure	I-Disease	-1	7834920
five	O	-1	7834920
weeks	O	-1	7834920
after	O	-1	7834920
comple@@	O	-1	7834920
tion	O	-1	7834920
of	O	-1	7834920
therapy.	O	-1	7834920
R@@	O	-1	7834920
en@@	O	-1	7834920
al	O	-1	7834920
biop@@	O	-1	7834920
sy	O	-1	7834920
revealed	O	-1	7834920
severe	O	-1	7834920
glomerul@@	B-Disease	D005921	7834920
one@@	I-Disease	-1	7834920
ph@@	I-Disease	-1	7834920
ritis	I-Disease	-1	7834920
with	O	-1	7834920
c@@	O	-1	7834920
res@@	O	-1	7834920
c@@	O	-1	7834920
ent@@	O	-1	7834920
s,	O	-1	7834920
electro@@	O	-1	7834920
n	O	-1	7834920
d@@	O	-1	7834920
en@@	O	-1	7834920
se	O	-1	7834920
fibrill@@	O	-1	7834920
ar	O	-1	7834920
de@@	O	-1	7834920
pos@@	O	-1	7834920
its	O	-1	7834920
and	O	-1	7834920
moder@@	O	-1	7834920
ate	O	-1	7834920
lymph@@	O	-1	7834920
ocy@@	O	-1	7834920
tic	O	-1	7834920
interstitial	O	-1	7834920
inf@@	O	-1	7834920
ilt@@	O	-1	7834920
rat@@	O	-1	7834920
e.	O	-1	7834920
O@@	O	-1	7834920
ther	O	-1	7834920
possible	O	-1	7834920
causes	O	-1	7834920
of	O	-1	7834920
ra@@	O	-1	7834920
pid@@	O	-1	7834920
ly	O	-1	7834920
progressive	O	-1	7834920
glomerul@@	B-Disease	D005921	7834920
one@@	I-Disease	-1	7834920
ph@@	I-Disease	-1	7834920
ritis	I-Disease	-1	7834920
were	O	-1	7834920
investigated	O	-1	7834920
and	O	-1	7834920
r@@	O	-1	7834920
ul@@	O	-1	7834920
ed	O	-1	7834920
out@@	O	-1	7834920
.	O	-1	7834920
This	O	-1	7834920
report	O	-1	7834920
doc@@	O	-1	7834920
um@@	O	-1	7834920
ents	O	-1	7834920
the	O	-1	7834920
un@@	O	-1	7834920
us@@	O	-1	7834920
ual	O	-1	7834920
occur@@	O	-1	7834920
rence	O	-1	7834920
of	O	-1	7834920
ra@@	O	-1	7834920
pid@@	O	-1	7834920
ly	O	-1	7834920
progressive	O	-1	7834920
glomerul@@	B-Disease	D005921	7834920
one@@	I-Disease	-1	7834920
ph@@	I-Disease	-1	7834920
ritis	I-Disease	-1	7834920
with	O	-1	7834920
c@@	O	-1	7834920
res@@	O	-1	7834920
c@@	O	-1	7834920
ents	O	-1	7834920
and	O	-1	7834920
fibrill@@	O	-1	7834920
ar	O	-1	7834920
glomerul@@	B-Disease	D005921	7834920
one@@	I-Disease	-1	7834920
ph@@	I-Disease	-1	7834920
ritis	I-Disease	-1	7834920
in	O	-1	7834920
a	O	-1	7834920
patient	O	-1	7834920
treated	O	-1	7834920
with	O	-1	7834920
ri@@	B-Chemical	D012293	7834920
f@@	I-Chemical	-1	7834920
amp@@	I-Chemical	-1	7834920
in	I-Chemical	-1	7834920
.	O	-1	7834920

T@@	O	-1	7881871
im@@	O	-1	7881871
e	O	-1	7881871
course	O	-1	7881871
of	O	-1	7881871
li@@	O	-1	7881871
pid	O	-1	7881871
per@@	O	-1	7881871
oxid@@	O	-1	7881871
ation	O	-1	7881871
in	O	-1	7881871
p@@	B-Chemical	D011692	7881871
uro@@	I-Chemical	-1	7881871
m@@	I-Chemical	-1	7881871
ycin	I-Chemical	-1	7881871
amin@@	I-Chemical	-1	7881871
on@@	I-Chemical	-1	7881871
ucle@@	I-Chemical	-1	7881871
o@@	I-Chemical	-1	7881871
side	I-Chemical	-1	7881871
-induced	O	-1	7881871
nephro@@	B-Disease	D007674	7881871
pathy	I-Disease	-1	7881871
.	O	-1	7881871
Re@@	O	-1	7881871
active	O	-1	7881871
oxy@@	B-Chemical	D010100	7881871
gen	I-Chemical	-1	7881871
spec@@	O	-1	7881871
i@@	O	-1	7881871
es	O	-1	7881871
have	O	-1	7881871
been	O	-1	7881871
implic@@	O	-1	7881871
ated	O	-1	7881871
in	O	-1	7881871
the	O	-1	7881871
path@@	O	-1	7881871
o@@	O	-1	7881871
genesis	O	-1	7881871
of	O	-1	7881871
acute	O	-1	7881871
p@@	B-Chemical	D011692	7881871
uro@@	I-Chemical	-1	7881871
m@@	I-Chemical	-1	7881871
ycin	I-Chemical	-1	7881871
amin@@	I-Chemical	-1	7881871
on@@	I-Chemical	-1	7881871
ucle@@	I-Chemical	-1	7881871
o@@	I-Chemical	-1	7881871
side	I-Chemical	-1	7881871
(	O	-1	7881871
PA@@	B-Chemical	D011692	7881871
N	I-Chemical	-1	7881871
)@@	O	-1	7881871
-induced	O	-1	7881871
nephro@@	B-Disease	D007674	7881871
pathy	I-Disease	-1	7881871
,	O	-1	7881871
with	O	-1	7881871
anti@@	O	-1	7881871
oxid@@	O	-1	7881871
ants	O	-1	7881871
significantly	O	-1	7881871
reduc@@	O	-1	7881871
ing	O	-1	7881871
the	O	-1	7881871
proteinuria	B-Disease	D011507	7881871
.	O	-1	7881871
The	O	-1	7881871
tempor@@	O	-1	7881871
al	O	-1	7881871
rel@@	O	-1	7881871
ationship	O	-1	7881871
between	O	-1	7881871
li@@	O	-1	7881871
pid	O	-1	7881871
per@@	O	-1	7881871
oxid@@	O	-1	7881871
ation	O	-1	7881871
in	O	-1	7881871
the	O	-1	7881871
kidney	O	-1	7881871
and	O	-1	7881871
proteinuria	B-Disease	D011507	7881871
was	O	-1	7881871
examined	O	-1	7881871
in	O	-1	7881871
this	O	-1	7881871
study.	O	-1	7881871
R@@	O	-1	7881871
at@@	O	-1	7881871
s	O	-1	7881871
were	O	-1	7881871
treated	O	-1	7881871
with	O	-1	7881871
a	O	-1	7881871
single	O	-1	7881871
IV	O	-1	7881871
injection	O	-1	7881871
of	O	-1	7881871
p@@	B-Chemical	D011692	7881871
uro@@	I-Chemical	-1	7881871
m@@	I-Chemical	-1	7881871
ycin	I-Chemical	-1	7881871
amin@@	I-Chemical	-1	7881871
on@@	I-Chemical	-1	7881871
ucle@@	I-Chemical	-1	7881871
o@@	I-Chemical	-1	7881871
side	I-Chemical	-1	7881871
,	O	-1	7881871
(	O	-1	7881871
PA@@	B-Chemical	D011692	7881871
N	I-Chemical	-1	7881871
,	O	-1	7881871
7.@@	O	-1	7881871
5	O	-1	7881871
mg/kg)	O	-1	7881871
and	O	-1	7881871
24	O	-1	7881871
h@@	O	-1	7881871
our	O	-1	7881871
urine	O	-1	7881871
sam@@	O	-1	7881871
ple@@	O	-1	7881871
s	O	-1	7881871
were	O	-1	7881871
obtained	O	-1	7881871
prior	O	-1	7881871
to	O	-1	7881871
s@@	O	-1	7881871
ac@@	O	-1	7881871
ri@@	O	-1	7881871
fic@@	O	-1	7881871
e	O	-1	7881871
on	O	-1	7881871
days	O	-1	7881871
3@@	O	-1	7881871
,@@	O	-1	7881871
5@@	O	-1	7881871
,@@	O	-1	7881871
7@@	O	-1	7881871
,@@	O	-1	7881871
10@@	O	-1	7881871
,@@	O	-1	7881871
17@@	O	-1	7881871
,@@	O	-1	7881871
27@@	O	-1	7881871
,@@	O	-1	7881871
4@@	O	-1	7881871
1	O	-1	7881871
(@@	O	-1	7881871
N	O	-1	7881871
=	O	-1	7881871
5-@@	O	-1	7881871
10	O	-1	7881871
per	O	-1	7881871
group@@	O	-1	7881871
).	O	-1	7881871
The	O	-1	7881871
kidne@@	O	-1	7881871
ys	O	-1	7881871
were	O	-1	7881871
re@@	O	-1	7881871
mo@@	O	-1	7881871
ve@@	O	-1	7881871
d,	O	-1	7881871
f@@	O	-1	7881871
l@@	O	-1	7881871
us@@	O	-1	7881871
h@@	O	-1	7881871
ed	O	-1	7881871
with	O	-1	7881871
ic@@	O	-1	7881871
e	O	-1	7881871
co@@	O	-1	7881871
l@@	O	-1	7881871
d	O	-1	7881871
TR@@	O	-1	7881871
I@@	O	-1	7881871
S	O	-1	7881871
bu@@	O	-1	7881871
ff@@	O	-1	7881871
er.	O	-1	7881871
K@@	O	-1	7881871
idne@@	O	-1	7881871
y	O	-1	7881871
cor@@	O	-1	7881871
tic@@	O	-1	7881871
es	O	-1	7881871
from	O	-1	7881871
each	O	-1	7881871
anim@@	O	-1	7881871
al	O	-1	7881871
were	O	-1	7881871
used	O	-1	7881871
to	O	-1	7881871
pre@@	O	-1	7881871
par@@	O	-1	7881871
e	O	-1	7881871
ho@@	O	-1	7881871
mo@@	O	-1	7881871
gen@@	O	-1	7881871
at@@	O	-1	7881871
es.	O	-1	7881871
T@@	O	-1	7881871
is@@	O	-1	7881871
su@@	O	-1	7881871
e	O	-1	7881871
li@@	O	-1	7881871
pid	O	-1	7881871
per@@	O	-1	7881871
oxid@@	O	-1	7881871
ation	O	-1	7881871
was	O	-1	7881871
measured	O	-1	7881871
in	O	-1	7881871
wh@@	O	-1	7881871
ole	O	-1	7881871
ho@@	O	-1	7881871
mo@@	O	-1	7881871
gen@@	O	-1	7881871
ates	O	-1	7881871
as	O	-1	7881871
well	O	-1	7881871
as	O	-1	7881871
in	O	-1	7881871
li@@	O	-1	7881871
pid	O	-1	7881871
extrac@@	O	-1	7881871
ts	O	-1	7881871
from	O	-1	7881871
ho@@	O	-1	7881871
mo@@	O	-1	7881871
gen@@	O	-1	7881871
ates	O	-1	7881871
as	O	-1	7881871
th@@	B-Chemical	C029684	7881871
io@@	I-Chemical	-1	7881871
b@@	I-Chemical	-1	7881871
arbit@@	I-Chemical	-1	7881871
ur@@	I-Chemical	-1	7881871
ic	I-Chemical	-1	7881871
acid	I-Chemical	-1	7881871
reac@@	O	-1	7881871
tive	O	-1	7881871
subst@@	O	-1	7881871
anc@@	O	-1	7881871
es.	O	-1	7881871
Pro@@	B-Disease	D011507	7881871
te@@	I-Disease	-1	7881871
in@@	I-Disease	-1	7881871
uria	I-Disease	-1	7881871
was	O	-1	7881871
ev@@	O	-1	7881871
id@@	O	-1	7881871
ent	O	-1	7881871
at	O	-1	7881871
day	O	-1	7881871
5,	O	-1	7881871
pe@@	O	-1	7881871
ak@@	O	-1	7881871
ed	O	-1	7881871
at	O	-1	7881871
day	O	-1	7881871
7	O	-1	7881871
and	O	-1	7881871
per@@	O	-1	7881871
sist@@	O	-1	7881871
ed	O	-1	7881871
to	O	-1	7881871
day	O	-1	7881871
27@@	O	-1	7881871
.	O	-1	7881871
L@@	O	-1	7881871
i@@	O	-1	7881871
pid	O	-1	7881871
per@@	O	-1	7881871
oxid@@	O	-1	7881871
ation	O	-1	7881871
in	O	-1	7881871
ho@@	O	-1	7881871
mo@@	O	-1	7881871
gen@@	O	-1	7881871
ates	O	-1	7881871
was	O	-1	7881871
maxim@@	O	-1	7881871
al	O	-1	7881871
at	O	-1	7881871
day	O	-1	7881871
3	O	-1	7881871
and	O	-1	7881871
dec@@	O	-1	7881871
lin@@	O	-1	7881871
ed	O	-1	7881871
ra@@	O	-1	7881871
pid@@	O	-1	7881871
ly	O	-1	7881871
to	O	-1	7881871
control	O	-1	7881871
levels	O	-1	7881871
by	O	-1	7881871
day	O	-1	7881871
17@@	O	-1	7881871
.	O	-1	7881871
This	O	-1	7881871
study	O	-1	7881871
suppor@@	O	-1	7881871
ts	O	-1	7881871
the	O	-1	7881871
role	O	-1	7881871
of	O	-1	7881871
li@@	O	-1	7881871
pid	O	-1	7881871
per@@	O	-1	7881871
oxid@@	O	-1	7881871
ation	O	-1	7881871
in	O	-1	7881871
medi@@	O	-1	7881871
ating	O	-1	7881871
the	O	-1	7881871
protein@@	B-Disease	D011507	7881871
ur@@	I-Disease	-1	7881871
ic	I-Disease	-1	7881871
injury	I-Disease	-1	7881871
in	O	-1	7881871
PA@@	B-Chemical	D011692	7881871
N	I-Chemical	-1	7881871
nephro@@	B-Disease	D007674	7881871
pathy	I-Disease	-1	7881871
.	O	-1	7881871

C@@	B-Chemical	D002997	7930386
lo@@	I-Chemical	-1	7930386
mi@@	I-Chemical	-1	7930386
pramine	I-Chemical	-1	7930386
-induced	O	-1	7930386
sleep	B-Disease	D012893	7930386
dist@@	I-Disease	-1	7930386
urb@@	I-Disease	-1	7930386
ance	I-Disease	-1	7930386
does	O	-1	7930386
not	O	-1	7930386
impa@@	O	-1	7930386
ir	O	-1	7930386
its	O	-1	7930386
prol@@	O	-1	7930386
act@@	O	-1	7930386
in-@@	O	-1	7930386
rele@@	O	-1	7930386
as@@	O	-1	7930386
ing	O	-1	7930386
ac@@	O	-1	7930386
tion.	O	-1	7930386
The	O	-1	7930386
present	O	-1	7930386
study	O	-1	7930386
was	O	-1	7930386
under@@	O	-1	7930386
tak@@	O	-1	7930386
en	O	-1	7930386
to	O	-1	7930386
ex@@	O	-1	7930386
amine	O	-1	7930386
the	O	-1	7930386
role	O	-1	7930386
of	O	-1	7930386
sleep	B-Disease	D012893	7930386
dist@@	I-Disease	-1	7930386
urb@@	I-Disease	-1	7930386
ance	I-Disease	-1	7930386
,	O	-1	7930386
induced	O	-1	7930386
by	O	-1	7930386
clo@@	B-Chemical	D002997	7930386
mi@@	I-Chemical	-1	7930386
pramine	I-Chemical	-1	7930386
administr@@	O	-1	7930386
ation,	O	-1	7930386
on	O	-1	7930386
the	O	-1	7930386
sec@@	O	-1	7930386
ret@@	O	-1	7930386
ory	O	-1	7930386
rate	O	-1	7930386
of	O	-1	7930386
prolactin	O	-1	7930386
(P@@	O	-1	7930386
R@@	O	-1	7930386
L@@	O	-1	7930386
)	O	-1	7930386
in	O	-1	7930386
addition	O	-1	7930386
to	O	-1	7930386
the	O	-1	7930386
direct	O	-1	7930386
drug	O	-1	7930386
effect@@	O	-1	7930386
.	O	-1	7930386
Two	O	-1	7930386
groups	O	-1	7930386
of	O	-1	7930386
sup@@	O	-1	7930386
ine	O	-1	7930386
subjects	O	-1	7930386
were	O	-1	7930386
studied	O	-1	7930386
under	O	-1	7930386
placebo@@	O	-1	7930386
-@@	O	-1	7930386
controlled	O	-1	7930386
condi@@	O	-1	7930386
tion@@	O	-1	7930386
s,	O	-1	7930386
one	O	-1	7930386
during	O	-1	7930386
the	O	-1	7930386
n@@	O	-1	7930386
igh@@	O	-1	7930386
t,	O	-1	7930386
when	O	-1	7930386
sle@@	O	-1	7930386
ep@@	O	-1	7930386
ing	O	-1	7930386
(n	O	-1	7930386
=	O	-1	7930386
7@@	O	-1	7930386
)	O	-1	7930386
and	O	-1	7930386
the	O	-1	7930386
other	O	-1	7930386
at	O	-1	7930386
day@@	O	-1	7930386
ti@@	O	-1	7930386
me,	O	-1	7930386
when	O	-1	7930386
aw@@	O	-1	7930386
ake	O	-1	7930386
(n	O	-1	7930386
=	O	-1	7930386
6@@	O	-1	7930386
).	O	-1	7930386
E@@	O	-1	7930386
ach	O	-1	7930386
subj@@	O	-1	7930386
ect	O	-1	7930386
received	O	-1	7930386
a	O	-1	7930386
single	O	-1	7930386
50	O	-1	7930386
mg	O	-1	7930386
dose	O	-1	7930386
of	O	-1	7930386
clo@@	B-Chemical	D002997	7930386
mi@@	I-Chemical	-1	7930386
pramine	I-Chemical	-1	7930386
given	O	-1	7930386
or@@	O	-1	7930386
ally	O	-1	7930386
2	O	-1	7930386
hours	O	-1	7930386
before	O	-1	7930386
blood	O	-1	7930386
coll@@	O	-1	7930386
ec@@	O	-1	7930386
tion.	O	-1	7930386
P@@	O	-1	7930386
las@@	O	-1	7930386
ma	O	-1	7930386
P@@	O	-1	7930386
R@@	O	-1	7930386
L	O	-1	7930386
concentrations	O	-1	7930386
were	O	-1	7930386
an@@	O	-1	7930386
al@@	O	-1	7930386
ys@@	O	-1	7930386
ed	O	-1	7930386
at	O	-1	7930386
10	O	-1	7930386
min	O	-1	7930386
interv@@	O	-1	7930386
als	O	-1	7930386
and	O	-1	7930386
underlying	O	-1	7930386
sec@@	O	-1	7930386
ret@@	O	-1	7930386
ory	O	-1	7930386
rat@@	O	-1	7930386
es	O	-1	7930386
calc@@	O	-1	7930386
ul@@	O	-1	7930386
ated	O	-1	7930386
by	O	-1	7930386
a	O	-1	7930386
dec@@	O	-1	7930386
on@@	O	-1	7930386
vol@@	O	-1	7930386
u@@	O	-1	7930386
tion	O	-1	7930386
proce@@	O	-1	7930386
d@@	O	-1	7930386
ure.	O	-1	7930386
F@@	O	-1	7930386
or	O	-1	7930386
both	O	-1	7930386
experim@@	O	-1	7930386
ents	O	-1	7930386
the	O	-1	7930386
drug	O	-1	7930386
int@@	O	-1	7930386
ake	O	-1	7930386
l@@	O	-1	7930386
ed	O	-1	7930386
to	O	-1	7930386
significant	O	-1	7930386
increases	O	-1	7930386
in	O	-1	7930386
P@@	O	-1	7930386
R@@	O	-1	7930386
L	O	-1	7930386
secre@@	O	-1	7930386
tion,	O	-1	7930386
act@@	O	-1	7930386
ing	O	-1	7930386
pre@@	O	-1	7930386
fe@@	O	-1	7930386
ren@@	O	-1	7930386
ti@@	O	-1	7930386
ally	O	-1	7930386
on	O	-1	7930386
t@@	O	-1	7930386
onic	O	-1	7930386
secre@@	O	-1	7930386
tion	O	-1	7930386
as	O	-1	7930386
pul@@	O	-1	7930386
se	O	-1	7930386
am@@	O	-1	7930386
pl@@	O	-1	7930386
it@@	O	-1	7930386
ude	O	-1	7930386
and	O	-1	7930386
frequency	O	-1	7930386
did	O	-1	7930386
not	O	-1	7930386
diff@@	O	-1	7930386
er	O	-1	7930386
significantly	O	-1	7930386
from	O	-1	7930386
cor@@	O	-1	7930386
respon@@	O	-1	7930386
ding	O	-1	7930386
control	O	-1	7930386
valu@@	O	-1	7930386
es.	O	-1	7930386
D@@	O	-1	7930386
uring	O	-1	7930386
the	O	-1	7930386
n@@	O	-1	7930386
ight	O	-1	7930386
clo@@	B-Chemical	D002997	7930386
mi@@	I-Chemical	-1	7930386
pramine	I-Chemical	-1	7930386
ing@@	O	-1	7930386
es@@	O	-1	7930386
tion	O	-1	7930386
al@@	O	-1	7930386
te@@	O	-1	7930386
red	O	-1	7930386
the	O	-1	7930386
complete	O	-1	7930386
sleep	O	-1	7930386
ar@@	O	-1	7930386
ch@@	O	-1	7930386
it@@	O	-1	7930386
ect@@	O	-1	7930386
ure	O	-1	7930386
in	O	-1	7930386
that	O	-1	7930386
it	O	-1	7930386
sup@@	O	-1	7930386
press@@	O	-1	7930386
ed	O	-1	7930386
R@@	O	-1	7930386
E@@	O	-1	7930386
M	O	-1	7930386
sleep	O	-1	7930386
and	O	-1	7930386
the	O	-1	7930386
sleep	O	-1	7930386
cyc@@	O	-1	7930386
le@@	O	-1	7930386
s	O	-1	7930386
and	O	-1	7930386
induced	O	-1	7930386
increased	O	-1	7930386
w@@	O	-1	7930386
ak@@	O	-1	7930386
e@@	O	-1	7930386
ful@@	O	-1	7930386
n@@	O	-1	7930386
es@@	O	-1	7930386
s.	O	-1	7930386
A@@	O	-1	7930386
s	O	-1	7930386
the	O	-1	7930386
rel@@	O	-1	7930386
ative	O	-1	7930386
increase	O	-1	7930386
in	O	-1	7930386
P@@	O	-1	7930386
R@@	O	-1	7930386
L	O	-1	7930386
secre@@	O	-1	7930386
tion	O	-1	7930386
ex@@	O	-1	7930386
press@@	O	-1	7930386
ed	O	-1	7930386
as	O	-1	7930386
a	O	-1	7930386
perc@@	O	-1	7930386
ent@@	O	-1	7930386
age	O	-1	7930386
of	O	-1	7930386
the	O	-1	7930386
mean	O	-1	7930386
did	O	-1	7930386
not	O	-1	7930386
significantly	O	-1	7930386
diff@@	O	-1	7930386
er	O	-1	7930386
between	O	-1	7930386
the	O	-1	7930386
n@@	O	-1	7930386
ight	O	-1	7930386
and	O	-1	7930386
day	O	-1	7930386
time	O	-1	7930386
studies	O	-1	7930386
(4@@	O	-1	7930386
6	O	-1	7930386
+/-	O	-1	7930386
19@@	O	-1	7930386
%	O	-1	7930386
v@@	O	-1	7930386
s	O	-1	7930386
3@@	O	-1	7930386
4	O	-1	7930386
+/-	O	-1	7930386
10@@	O	-1	7930386
%),	O	-1	7930386
it	O	-1	7930386
can	O	-1	7930386
be	O	-1	7930386
concl@@	O	-1	7930386
uded	O	-1	7930386
that	O	-1	7930386
the	O	-1	7930386
observed	O	-1	7930386
sleep	B-Disease	D012893	7930386
dist@@	I-Disease	-1	7930386
urb@@	I-Disease	-1	7930386
ance	I-Disease	-1	7930386
did	O	-1	7930386
not	O	-1	7930386
inter@@	O	-1	7930386
f@@	O	-1	7930386
ere	O	-1	7930386
with	O	-1	7930386
the	O	-1	7930386
drug	O	-1	7930386
action	O	-1	7930386
per	O	-1	7930386
se.	O	-1	7930386
The	O	-1	7930386
presence	O	-1	7930386
of	O	-1	7930386
R@@	O	-1	7930386
E@@	O	-1	7930386
M	O	-1	7930386
sleep	O	-1	7930386
was	O	-1	7930386
shown	O	-1	7930386
not	O	-1	7930386
to	O	-1	7930386
be	O	-1	7930386
a	O	-1	7930386
determin@@	O	-1	7930386
ing	O	-1	7930386
factor	O	-1	7930386
either	O	-1	7930386
for	O	-1	7930386
sec@@	O	-1	7930386
ret@@	O	-1	7930386
ory	O	-1	7930386
pul@@	O	-1	7930386
se	O	-1	7930386
am@@	O	-1	7930386
pl@@	O	-1	7930386
it@@	O	-1	7930386
ude	O	-1	7930386
and	O	-1	7930386
frequ@@	O	-1	7930386
enc@@	O	-1	7930386
y,	O	-1	7930386
as@@	O	-1	7930386
,	O	-1	7930386
for	O	-1	7930386
bo@@	O	-1	7930386
th@@	O	-1	7930386
,	O	-1	7930386
mean	O	-1	7930386
n@@	O	-1	7930386
oc@@	O	-1	7930386
t@@	O	-1	7930386
ur@@	O	-1	7930386
n@@	O	-1	7930386
al	O	-1	7930386
values	O	-1	7930386
were	O	-1	7930386
similar	O	-1	7930386
with	O	-1	7930386
and	O	-1	7930386
without	O	-1	7930386
prior	O	-1	7930386
clo@@	B-Chemical	D002997	7930386
mi@@	I-Chemical	-1	7930386
pramine	I-Chemical	-1	7930386
ing@@	O	-1	7930386
es@@	O	-1	7930386
tion.	O	-1	7930386

An@@	B-Disease	D000799	7988234
g@@	I-Disease	-1	7988234
io@@	I-Disease	-1	7988234
e@@	I-Disease	-1	7988234
de@@	I-Disease	-1	7988234
ma	I-Disease	-1	7988234
following	O	-1	7988234
the	O	-1	7988234
intravenous	O	-1	7988234
administration	O	-1	7988234
of	O	-1	7988234
me@@	B-Chemical	D008790	7988234
to@@	I-Chemical	-1	7988234
pro@@	I-Chemical	-1	7988234
lol	I-Chemical	-1	7988234
.	O	-1	7988234
A	O	-1	7988234
7@@	O	-1	7988234
2-@@	O	-1	7988234
year-old	O	-1	7988234
woman	O	-1	7988234
was	O	-1	7988234
ad@@	O	-1	7988234
mit@@	O	-1	7988234
ted	O	-1	7988234
to	O	-1	7988234
the	O	-1	7988234
hospit@@	O	-1	7988234
al	O	-1	7988234
with	O	-1	7988234
"@@	O	-1	7988234
f@@	O	-1	7988234
las@@	O	-1	7988234
h@@	O	-1	7988234
"	O	-1	7988234
pulmonary	B-Disease	D011654	7988234
e@@	I-Disease	-1	7988234
de@@	I-Disease	-1	7988234
ma	I-Disease	-1	7988234
,	O	-1	7988234
pre@@	O	-1	7988234
ce@@	O	-1	7988234
ded	O	-1	7988234
by	O	-1	7988234
ch@@	B-Disease	D002637	7988234
est	I-Disease	-1	7988234
pain	I-Disease	-1	7988234
,	O	-1	7988234
requ@@	O	-1	7988234
ir@@	O	-1	7988234
ing	O	-1	7988234
int@@	O	-1	7988234
ub@@	O	-1	7988234
ation.	O	-1	7988234
H@@	O	-1	7988234
er	O	-1	7988234
med@@	O	-1	7988234
ical	O	-1	7988234
hist@@	O	-1	7988234
ory	O	-1	7988234
included	O	-1	7988234
coronary	B-Disease	D003324	7988234
artery	I-Disease	-1	7988234
disease	I-Disease	-1	7988234
with	O	-1	7988234
previ@@	O	-1	7988234
ous	O	-1	7988234
myocardial	B-Disease	D009203	7988234
infarc@@	I-Disease	-1	7988234
tions	I-Disease	-1	7988234
,	O	-1	7988234
hypertension	B-Disease	D006973	7988234
,	O	-1	7988234
and	O	-1	7988234
dia@@	B-Disease	D003920	7988234
bet@@	I-Disease	-1	7988234
es	I-Disease	-1	7988234
me@@	I-Disease	-1	7988234
ll@@	I-Disease	-1	7988234
it@@	I-Disease	-1	7988234
us	I-Disease	-1	7988234
.	O	-1	7988234
A	O	-1	7988234
hist@@	O	-1	7988234
ory	O	-1	7988234
of	O	-1	7988234
angio@@	B-Disease	D000799	7988234
e@@	I-Disease	-1	7988234
de@@	I-Disease	-1	7988234
ma	I-Disease	-1	7988234
secondary	O	-1	7988234
to	O	-1	7988234
l@@	B-Chemical	D017706	7988234
is@@	I-Chemical	-1	7988234
ino@@	I-Chemical	-1	7988234
pri@@	I-Chemical	-1	7988234
l	I-Chemical	-1	7988234
therapy	O	-1	7988234
was	O	-1	7988234
el@@	O	-1	7988234
ic@@	O	-1	7988234
it@@	O	-1	7988234
ed.	O	-1	7988234
C@@	O	-1	7988234
ur@@	O	-1	7988234
rent	O	-1	7988234
medic@@	O	-1	7988234
ations	O	-1	7988234
did	O	-1	7988234
not	O	-1	7988234
includ@@	O	-1	7988234
e	O	-1	7988234
angiotens@@	B-Chemical	D000809	7988234
in	I-Chemical	-1	7988234
-@@	O	-1	7988234
conver@@	O	-1	7988234
ting	O	-1	7988234
enzyme	O	-1	7988234
inhibitors	O	-1	7988234
or	O	-1	7988234
beta-@@	O	-1	7988234
block@@	O	-1	7988234
ers.	O	-1	7988234
S@@	O	-1	7988234
he	O	-1	7988234
had	O	-1	7988234
no	O	-1	7988234
previ@@	O	-1	7988234
ous	O	-1	7988234
beta-@@	O	-1	7988234
block@@	O	-1	7988234
ing	O	-1	7988234
drug	O	-1	7988234
expos@@	O	-1	7988234
ure.	O	-1	7988234
D@@	O	-1	7988234
uring	O	-1	7988234
the	O	-1	7988234
first	O	-1	7988234
day	O	-1	7988234
of	O	-1	7988234
hospit@@	O	-1	7988234
al@@	O	-1	7988234
ization	O	-1	7988234
(@@	O	-1	7988234
while	O	-1	7988234
int@@	O	-1	7988234
ub@@	O	-1	7988234
ated@@	O	-1	7988234
),	O	-1	7988234
intravenous	O	-1	7988234
me@@	B-Chemical	D008790	7988234
to@@	I-Chemical	-1	7988234
pro@@	I-Chemical	-1	7988234
lol	I-Chemical	-1	7988234
was	O	-1	7988234
gi@@	O	-1	7988234
ven@@	O	-1	7988234
,	O	-1	7988234
result@@	O	-1	7988234
ing	O	-1	7988234
in	O	-1	7988234
severe	O	-1	7988234
angio@@	B-Disease	D000799	7988234
e@@	I-Disease	-1	7988234
de@@	I-Disease	-1	7988234
ma	I-Disease	-1	7988234
.	O	-1	7988234
The	O	-1	7988234
angio@@	B-Disease	D000799	7988234
e@@	I-Disease	-1	7988234
de@@	I-Disease	-1	7988234
ma	I-Disease	-1	7988234
resol@@	O	-1	7988234
ved	O	-1	7988234
after	O	-1	7988234
therapy	O	-1	7988234
with	O	-1	7988234
intravenous	O	-1	7988234
steroid@@	B-Chemical	D013256	7988234
s	I-Chemical	-1	7988234
and	O	-1	7988234
di@@	B-Chemical	D004155	7988234
phen@@	I-Chemical	-1	7988234
hy@@	I-Chemical	-1	7988234
d@@	I-Chemical	-1	7988234
r@@	I-Chemical	-1	7988234
amine	I-Chemical	-1	7988234
hydro@@	O	-1	7988234
chlor@@	O	-1	7988234
ide@@	O	-1	7988234
.	O	-1	7988234

Eff@@	O	-1	8073369
ect	O	-1	8073369
of	O	-1	8073369
con@@	B-Chemical	C007112	8073369
i@@	I-Chemical	-1	8073369
ine	I-Chemical	-1	8073369
on	O	-1	8073369
the	O	-1	8073369
develop@@	O	-1	8073369
ing	O	-1	8073369
ch@@	O	-1	8073369
ic@@	O	-1	8073369
k	O	-1	8073369
emb@@	O	-1	8073369
r@@	O	-1	8073369
yo@@	O	-1	8073369
.	O	-1	8073369
Con@@	B-Chemical	C007112	8073369
i@@	I-Chemical	-1	8073369
ine	I-Chemical	-1	8073369
,	O	-1	8073369
an	O	-1	8073369
al@@	O	-1	8073369
k@@	O	-1	8073369
alo@@	O	-1	8073369
id	O	-1	8073369
from	O	-1	8073369
Con@@	O	-1	8073369
i@@	O	-1	8073369
um	O	-1	8073369
mac@@	O	-1	8073369
ul@@	O	-1	8073369
at@@	O	-1	8073369
um	O	-1	8073369
(@@	O	-1	8073369
po@@	O	-1	8073369
ison	O	-1	8073369
hem@@	O	-1	8073369
loc@@	O	-1	8073369
k@@	O	-1	8073369
),	O	-1	8073369
has	O	-1	8073369
been	O	-1	8073369
shown	O	-1	8073369
to	O	-1	8073369
be	O	-1	8073369
ter@@	O	-1	8073369
at@@	O	-1	8073369
o@@	O	-1	8073369
genic	O	-1	8073369
in	O	-1	8073369
li@@	O	-1	8073369
ve@@	O	-1	8073369
st@@	O	-1	8073369
oc@@	O	-1	8073369
k@@	O	-1	8073369
.	O	-1	8073369
The	O	-1	8073369
major	O	-1	8073369
ter@@	O	-1	8073369
at@@	O	-1	8073369
o@@	O	-1	8073369
genic	O	-1	8073369
outcom@@	O	-1	8073369
e	O	-1	8073369
is	O	-1	8073369
arth@@	B-Disease	D001176	8073369
ro@@	I-Disease	-1	8073369
g@@	I-Disease	-1	8073369
r@@	I-Disease	-1	8073369
y@@	I-Disease	-1	8073369
po@@	I-Disease	-1	8073369
sis	I-Disease	-1	8073369
,	O	-1	8073369
pres@@	O	-1	8073369
um@@	O	-1	8073369
ably	O	-1	8073369
due	O	-1	8073369
to	O	-1	8073369
nicot@@	O	-1	8073369
inic	O	-1	8073369
receptor	O	-1	8073369
block@@	O	-1	8073369
ade@@	O	-1	8073369
.	O	-1	8073369
However,	O	-1	8073369
con@@	B-Chemical	C007112	8073369
i@@	I-Chemical	-1	8073369
ine	I-Chemical	-1	8073369
has	O	-1	8073369
fail@@	O	-1	8073369
ed	O	-1	8073369
to	O	-1	8073369
produce	O	-1	8073369
arth@@	B-Disease	D001176	8073369
ro@@	I-Disease	-1	8073369
g@@	I-Disease	-1	8073369
r@@	I-Disease	-1	8073369
y@@	I-Disease	-1	8073369
po@@	I-Disease	-1	8073369
sis	I-Disease	-1	8073369
in	O	-1	8073369
rats	O	-1	8073369
or	O	-1	8073369
mice	O	-1	8073369
and	O	-1	8073369
is	O	-1	8073369
only	O	-1	8073369
we@@	O	-1	8073369
ak@@	O	-1	8073369
ly	O	-1	8073369
ter@@	O	-1	8073369
at@@	O	-1	8073369
o@@	O	-1	8073369
genic	O	-1	8073369
in	O	-1	8073369
ra@@	O	-1	8073369
b@@	O	-1	8073369
b@@	O	-1	8073369
it@@	O	-1	8073369
s.	O	-1	8073369
The	O	-1	8073369
pur@@	O	-1	8073369
p@@	O	-1	8073369
ose	O	-1	8073369
of	O	-1	8073369
this	O	-1	8073369
study	O	-1	8073369
was	O	-1	8073369
to	O	-1	8073369
evalu@@	O	-1	8073369
ate	O	-1	8073369
and	O	-1	8073369
compar@@	O	-1	8073369
e	O	-1	8073369
the	O	-1	8073369
effects	O	-1	8073369
of	O	-1	8073369
con@@	B-Chemical	C007112	8073369
i@@	I-Chemical	-1	8073369
ine	I-Chemical	-1	8073369
and	O	-1	8073369
nicotine	B-Chemical	D009538	8073369
in	O	-1	8073369
the	O	-1	8073369
develop@@	O	-1	8073369
ing	O	-1	8073369
ch@@	O	-1	8073369
ic@@	O	-1	8073369
k@@	O	-1	8073369
.	O	-1	8073369
Con@@	O	-1	8073369
centr@@	O	-1	8073369
ations	O	-1	8073369
of	O	-1	8073369
con@@	B-Chemical	C007112	8073369
i@@	I-Chemical	-1	8073369
ine	I-Chemical	-1	8073369
and	O	-1	8073369
nicotine	B-Chemical	D009538	8073369
sulf@@	O	-1	8073369
ate	O	-1	8073369
were	O	-1	8073369
0.0@@	O	-1	8073369
1@@	O	-1	8073369
5@@	O	-1	8073369
%,	O	-1	8073369
0.0@@	O	-1	8073369
3@@	O	-1	8073369
%,	O	-1	8073369
0.0@@	O	-1	8073369
7@@	O	-1	8073369
5@@	O	-1	8073369
%,	O	-1	8073369
0.@@	O	-1	8073369
1@@	O	-1	8073369
5@@	O	-1	8073369
%,	O	-1	8073369
0.@@	O	-1	8073369
7@@	O	-1	8073369
5@@	O	-1	8073369
%,	O	-1	8073369
1.@@	O	-1	8073369
5@@	O	-1	8073369
%,	O	-1	8073369
3@@	O	-1	8073369
%,	O	-1	8073369
and	O	-1	8073369
6%	O	-1	8073369
and	O	-1	8073369
1@@	O	-1	8073369
%,	O	-1	8073369
5@@	O	-1	8073369
%,	O	-1	8073369
and	O	-1	8073369
10@@	O	-1	8073369
%,	O	-1	8073369
respectively.	O	-1	8073369
B@@	O	-1	8073369
oth	O	-1	8073369
comp@@	O	-1	8073369
oun@@	O	-1	8073369
ds	O	-1	8073369
caused	O	-1	8073369
de@@	B-Disease	D009140	8073369
form@@	I-Disease	-1	8073369
ations	I-Disease	-1	8073369
and	O	-1	8073369
le@@	O	-1	8073369
thal@@	O	-1	8073369
ity	O	-1	8073369
in	O	-1	8073369
a	O	-1	8073369
dose-@@	O	-1	8073369
dependent	O	-1	8073369
man@@	O	-1	8073369
ner@@	O	-1	8073369
.	O	-1	8073369
All	O	-1	8073369
concentrations	O	-1	8073369
of	O	-1	8073369
nicotine	B-Chemical	D009538	8073369
sulf@@	O	-1	8073369
ate	O	-1	8073369
caused	O	-1	8073369
some	O	-1	8073369
le@@	O	-1	8073369
thal@@	O	-1	8073369
ity	O	-1	8073369
but	O	-1	8073369
a	O	-1	8073369
no	O	-1	8073369
effect	O	-1	8073369
level	O	-1	8073369
for	O	-1	8073369
con@@	B-Chemical	C007112	8073369
i@@	I-Chemical	-1	8073369
ine	I-Chemical	-1	8073369
le@@	O	-1	8073369
thal@@	O	-1	8073369
ity	O	-1	8073369
was	O	-1	8073369
0.@@	O	-1	8073369
7@@	O	-1	8073369
5@@	O	-1	8073369
%.	O	-1	8073369
The	O	-1	8073369
de@@	B-Disease	D009140	8073369
form@@	I-Disease	-1	8073369
ations	I-Disease	-1	8073369
caused	O	-1	8073369
by	O	-1	8073369
both	O	-1	8073369
con@@	B-Chemical	C007112	8073369
i@@	I-Chemical	-1	8073369
ine	I-Chemical	-1	8073369
and	O	-1	8073369
nicotine	B-Chemical	D009538	8073369
sulf@@	O	-1	8073369
ate	O	-1	8073369
were	O	-1	8073369
ex@@	B-Disease	D009140	8073369
ces@@	I-Disease	-1	8073369
sive	I-Disease	-1	8073369
f@@	I-Disease	-1	8073369
le@@	I-Disease	-1	8073369
xi@@	I-Disease	-1	8073369
on	I-Disease	-1	8073369
or	I-Disease	-1	8073369
exten@@	I-Disease	-1	8073369
sion	I-Disease	-1	8073369
of	I-Disease	-1	8073369
one	I-Disease	-1	8073369
or	I-Disease	-1	8073369
more	I-Disease	-1	8073369
to@@	I-Disease	-1	8073369
es	I-Disease	-1	8073369
.	O	-1	8073369
No	O	-1	8073369
histo@@	O	-1	8073369
path@@	O	-1	8073369
ological	O	-1	8073369
al@@	O	-1	8073369
ter@@	O	-1	8073369
ations	O	-1	8073369
or	O	-1	8073369
differences	O	-1	8073369
in	O	-1	8073369
b@@	O	-1	8073369
one	O	-1	8073369
formation	O	-1	8073369
were	O	-1	8073369
seen	O	-1	8073369
in	O	-1	8073369
the	O	-1	8073369
lim@@	O	-1	8073369
b@@	O	-1	8073369
s	O	-1	8073369
or	O	-1	8073369
to@@	O	-1	8073369
es	O	-1	8073369
of	O	-1	8073369
any	O	-1	8073369
ch@@	O	-1	8073369
ic@@	O	-1	8073369
k@@	O	-1	8073369
s	O	-1	8073369
from	O	-1	8073369
any	O	-1	8073369
group@@	O	-1	8073369
;	O	-1	8073369
however,	O	-1	8073369
exten@@	O	-1	8073369
sive	O	-1	8073369
c@@	B-Disease	D002543	8073369
ranial	I-Disease	-1	8073369
hemorrh@@	I-Disease	-1	8073369
age	I-Disease	-1	8073369
occurred	O	-1	8073369
in	O	-1	8073369
all	O	-1	8073369
nicotine	B-Chemical	D009538	8073369
sulf@@	O	-1	8073369
at@@	O	-1	8073369
e-@@	O	-1	8073369
treated	O	-1	8073369
ch@@	O	-1	8073369
ic@@	O	-1	8073369
k@@	O	-1	8073369
s.	O	-1	8073369
There	O	-1	8073369
was	O	-1	8073369
a	O	-1	8073369
statis@@	O	-1	8073369
tically	O	-1	8073369
significant	O	-1	8073369
(P	O	-1	8073369
<	O	-1	8073369
or	O	-1	8073369
=	O	-1	8073369
0.0@@	O	-1	8073369
1)	O	-1	8073369
decrease	O	-1	8073369
in	O	-1	8073369
mo@@	O	-1	8073369
vement	O	-1	8073369
in	O	-1	8073369
con@@	B-Chemical	C007112	8073369
i@@	I-Chemical	-1	8073369
ine	I-Chemical	-1	8073369
and	O	-1	8073369
nicotine	B-Chemical	D009538	8073369
sulf@@	O	-1	8073369
ate	O	-1	8073369
treated	O	-1	8073369
ch@@	O	-1	8073369
ic@@	O	-1	8073369
k@@	O	-1	8073369
s	O	-1	8073369
as	O	-1	8073369
determined	O	-1	8073369
by	O	-1	8073369
ult@@	O	-1	8073369
r@@	O	-1	8073369
as@@	O	-1	8073369
oun@@	O	-1	8073369
d.	O	-1	8073369
C@@	O	-1	8073369
ont@@	O	-1	8073369
ro@@	O	-1	8073369
l	O	-1	8073369
ch@@	O	-1	8073369
ic@@	O	-1	8073369
k@@	O	-1	8073369
s	O	-1	8073369
were	O	-1	8073369
in	O	-1	8073369
mo@@	O	-1	8073369
tion	O	-1	8073369
an	O	-1	8073369
average	O	-1	8073369
of	O	-1	8073369
3@@	O	-1	8073369
3.@@	O	-1	8073369
6@@	O	-1	8073369
7@@	O	-1	8073369
%	O	-1	8073369
of	O	-1	8073369
the	O	-1	8073369
ti@@	O	-1	8073369
me,	O	-1	8073369
while	O	-1	8073369
con@@	B-Chemical	C007112	8073369
i@@	I-Chemical	-1	8073369
ine	I-Chemical	-1	8073369
-treated	O	-1	8073369
ch@@	O	-1	8073369
ic@@	O	-1	8073369
k@@	O	-1	8073369
s	O	-1	8073369
were	O	-1	8073369
only	O	-1	8073369
mo@@	O	-1	8073369
ving	O	-1	8073369
8.@@	O	-1	8073369
95%	O	-1	8073369
of	O	-1	8073369
a	O	-1	8073369
5-@@	O	-1	8073369
min	O	-1	8073369
inter@@	O	-1	8073369
val@@	O	-1	8073369
,	O	-1	8073369
and	O	-1	8073369
no	O	-1	8073369
mo@@	O	-1	8073369
vement	O	-1	8073369
was	O	-1	8073369
observed	O	-1	8073369
for	O	-1	8073369
nicotine	B-Chemical	D009538	8073369
sulf@@	O	-1	8073369
ate	O	-1	8073369
treated	O	-1	8073369
ch@@	O	-1	8073369
ic@@	O	-1	8073369
k@@	O	-1	8073369
s.	O	-1	8073369
In	O	-1	8073369
su@@	O	-1	8073369
mm@@	O	-1	8073369
ar@@	O	-1	8073369
y,	O	-1	8073369
the	O	-1	8073369
ch@@	O	-1	8073369
ic@@	O	-1	8073369
k	O	-1	8073369
emb@@	O	-1	8073369
r@@	O	-1	8073369
y@@	O	-1	8073369
o	O	-1	8073369
pro@@	O	-1	8073369
vi@@	O	-1	8073369
des	O	-1	8073369
a	O	-1	8073369
re@@	O	-1	8073369
li@@	O	-1	8073369
able	O	-1	8073369
and	O	-1	8073369
sim@@	O	-1	8073369
ple	O	-1	8073369
experimental	O	-1	8073369
anim@@	O	-1	8073369
al	O	-1	8073369
model	O	-1	8073369
of	O	-1	8073369
con@@	B-Chemical	C007112	8073369
i@@	I-Chemical	-1	8073369
ine	I-Chemical	-1	8073369
-induced	O	-1	8073369
arth@@	B-Disease	D001176	8073369
ro@@	I-Disease	-1	8073369
g@@	I-Disease	-1	8073369
r@@	I-Disease	-1	8073369
y@@	I-Disease	-1	8073369
po@@	I-Disease	-1	8073369
sis	I-Disease	-1	8073369
.	O	-1	8073369
D@@	O	-1	8073369
at@@	O	-1	8073369
a	O	-1	8073369
from	O	-1	8073369
this	O	-1	8073369
model	O	-1	8073369
suppor@@	O	-1	8073369
t	O	-1	8073369
a	O	-1	8073369
mechanism	O	-1	8073369
invol@@	O	-1	8073369
ving	O	-1	8073369
nicot@@	O	-1	8073369
inic	O	-1	8073369
receptor	O	-1	8073369
block@@	O	-1	8073369
ade	O	-1	8073369
with	O	-1	8073369
subsequ@@	O	-1	8073369
ent	O	-1	8073369
decreased	O	-1	8073369
f@@	O	-1	8073369
et@@	O	-1	8073369
al	O	-1	8073369
mo@@	O	-1	8073369
ve@@	O	-1	8073369
ment.	O	-1	8073369

E@@	O	-1	8302922
pid@@	O	-1	8302922
ural	O	-1	8302922
blood	O	-1	8302922
flow	O	-1	8302922
during	O	-1	8302922
pro@@	B-Chemical	D000527	8302922
st@@	I-Chemical	-1	8302922
ag@@	I-Chemical	-1	8302922
l@@	I-Chemical	-1	8302922
and@@	I-Chemical	-1	8302922
in	I-Chemical	-1	8302922
E@@	I-Chemical	-1	8302922
1	I-Chemical	-1	8302922
or	O	-1	8302922
tri@@	B-Chemical	D014294	8302922
meth@@	I-Chemical	-1	8302922
a@@	I-Chemical	-1	8302922
ph@@	I-Chemical	-1	8302922
an	I-Chemical	-1	8302922
induced	O	-1	8302922
hypotension	B-Disease	D007022	8302922
.	O	-1	8302922
To	O	-1	8302922
evalu@@	O	-1	8302922
ate	O	-1	8302922
the	O	-1	8302922
effect	O	-1	8302922
of	O	-1	8302922
pro@@	B-Chemical	D000527	8302922
st@@	I-Chemical	-1	8302922
ag@@	I-Chemical	-1	8302922
l@@	I-Chemical	-1	8302922
and@@	I-Chemical	-1	8302922
in	I-Chemical	-1	8302922
E@@	I-Chemical	-1	8302922
1	I-Chemical	-1	8302922
(	O	-1	8302922
PG@@	B-Chemical	D000527	8302922
E@@	I-Chemical	-1	8302922
1	I-Chemical	-1	8302922
)	O	-1	8302922
or	O	-1	8302922
tri@@	B-Chemical	D014294	8302922
meth@@	I-Chemical	-1	8302922
a@@	I-Chemical	-1	8302922
ph@@	I-Chemical	-1	8302922
an	I-Chemical	-1	8302922
(	O	-1	8302922
T@@	B-Chemical	D014294	8302922
M@@	I-Chemical	-1	8302922
P	I-Chemical	-1	8302922
)	O	-1	8302922
induced	O	-1	8302922
hypotension	B-Disease	D007022	8302922
on	O	-1	8302922
ep@@	O	-1	8302922
id@@	O	-1	8302922
ural	O	-1	8302922
blood	O	-1	8302922
flow	O	-1	8302922
(@@	O	-1	8302922
E@@	O	-1	8302922
B@@	O	-1	8302922
F@@	O	-1	8302922
)	O	-1	8302922
during	O	-1	8302922
spinal	O	-1	8302922
surger@@	O	-1	8302922
y,	O	-1	8302922
E@@	O	-1	8302922
B@@	O	-1	8302922
F	O	-1	8302922
was	O	-1	8302922
measured	O	-1	8302922
using	O	-1	8302922
the	O	-1	8302922
he@@	O	-1	8302922
at	O	-1	8302922
clear@@	O	-1	8302922
ance	O	-1	8302922
meth@@	O	-1	8302922
od	O	-1	8302922
in	O	-1	8302922
30	O	-1	8302922
patients	O	-1	8302922
who	O	-1	8302922
under@@	O	-1	8302922
w@@	O	-1	8302922
ent	O	-1	8302922
po@@	O	-1	8302922
ster@@	O	-1	8302922
o@@	O	-1	8302922
-@@	O	-1	8302922
lat@@	O	-1	8302922
eral	O	-1	8302922
inter@@	O	-1	8302922
body	O	-1	8302922
f@@	O	-1	8302922
usion	O	-1	8302922
under	O	-1	8302922
iso@@	B-Chemical	D007530	8302922
f@@	I-Chemical	-1	8302922
lur@@	I-Chemical	-1	8302922
ane	I-Chemical	-1	8302922
anaesthe@@	O	-1	8302922
sia.	O	-1	8302922
An	O	-1	8302922
initial	O	-1	8302922
dose	O	-1	8302922
of	O	-1	8302922
0.@@	O	-1	8302922
1	O	-1	8302922
microgram@@	O	-1	8302922
.@@	O	-1	8302922
kg@@	O	-1	8302922
-@@	O	-1	8302922
1.@@	O	-1	8302922
min@@	O	-1	8302922
-1	O	-1	8302922
of	O	-1	8302922
PG@@	B-Chemical	D000527	8302922
E@@	I-Chemical	-1	8302922
1	I-Chemical	-1	8302922
(1@@	O	-1	8302922
5	O	-1	8302922
patient@@	O	-1	8302922
s),	O	-1	8302922
or	O	-1	8302922
10	O	-1	8302922
microgram@@	O	-1	8302922
s@@	O	-1	8302922
.@@	O	-1	8302922
kg@@	O	-1	8302922
-@@	O	-1	8302922
1.@@	O	-1	8302922
min@@	O	-1	8302922
-1	O	-1	8302922
of	O	-1	8302922
T@@	B-Chemical	D014294	8302922
M@@	I-Chemical	-1	8302922
P	I-Chemical	-1	8302922
(1@@	O	-1	8302922
5	O	-1	8302922
patient@@	O	-1	8302922
s)	O	-1	8302922
was	O	-1	8302922
administered	O	-1	8302922
intra@@	O	-1	8302922
ven@@	O	-1	8302922
ously	O	-1	8302922
after	O	-1	8302922
the	O	-1	8302922
dur@@	O	-1	8302922
al	O	-1	8302922
o@@	O	-1	8302922
pen@@	O	-1	8302922
ing	O	-1	8302922
and	O	-1	8302922
the	O	-1	8302922
dose	O	-1	8302922
was	O	-1	8302922
adjust@@	O	-1	8302922
ed	O	-1	8302922
to	O	-1	8302922
maint@@	O	-1	8302922
ain	O	-1	8302922
the	O	-1	8302922
mean	O	-1	8302922
arterial	O	-1	8302922
blood	O	-1	8302922
pressure	O	-1	8302922
(@@	O	-1	8302922
MA@@	O	-1	8302922
P)	O	-1	8302922
at	O	-1	8302922
about	O	-1	8302922
60	O	-1	8302922
mm@@	O	-1	8302922
H@@	O	-1	8302922
g@@	O	-1	8302922
.	O	-1	8302922
The	O	-1	8302922
hypoten@@	B-Disease	D007022	8302922
sive	I-Disease	-1	8302922
drug	O	-1	8302922
was	O	-1	8302922
discontinu@@	O	-1	8302922
ed	O	-1	8302922
at	O	-1	8302922
the	O	-1	8302922
comple@@	O	-1	8302922
tion	O	-1	8302922
of	O	-1	8302922
the	O	-1	8302922
o@@	O	-1	8302922
perative	O	-1	8302922
proce@@	O	-1	8302922
d@@	O	-1	8302922
ure.	O	-1	8302922
After	O	-1	8302922
star@@	O	-1	8302922
ting	O	-1	8302922
PG@@	B-Chemical	D000527	8302922
E@@	I-Chemical	-1	8302922
1	I-Chemical	-1	8302922
or	O	-1	8302922
T@@	B-Chemical	D014294	8302922
M@@	I-Chemical	-1	8302922
P	I-Chemical	-1	8302922
,	O	-1	8302922
MA@@	O	-1	8302922
P	O	-1	8302922
and	O	-1	8302922
rate	O	-1	8302922
pressure	O	-1	8302922
produc@@	O	-1	8302922
t	O	-1	8302922
(@@	O	-1	8302922
R@@	O	-1	8302922
P@@	O	-1	8302922
P)	O	-1	8302922
decreased	O	-1	8302922
significantly	O	-1	8302922
compared	O	-1	8302922
with	O	-1	8302922
pre@@	O	-1	8302922
infusion	O	-1	8302922
values	O	-1	8302922
(P	O	-1	8302922
<	O	-1	8302922
0.0@@	O	-1	8302922
1),	O	-1	8302922
and	O	-1	8302922
the	O	-1	8302922
de@@	O	-1	8302922
g@@	O	-1	8302922
ree	O	-1	8302922
of	O	-1	8302922
hypotension	B-Disease	D007022	8302922
due	O	-1	8302922
to	O	-1	8302922
PG@@	B-Chemical	D000527	8302922
E@@	I-Chemical	-1	8302922
1	I-Chemical	-1	8302922
remained	O	-1	8302922
con@@	O	-1	8302922
st@@	O	-1	8302922
ant	O	-1	8302922
un@@	O	-1	8302922
ti@@	O	-1	8302922
l	O	-1	8302922
60	O	-1	8302922
min	O	-1	8302922
after	O	-1	8302922
its	O	-1	8302922
discontinu@@	O	-1	8302922
ation.	O	-1	8302922
H@@	O	-1	8302922
ear@@	O	-1	8302922
t	O	-1	8302922
rate	O	-1	8302922
(@@	O	-1	8302922
H@@	O	-1	8302922
R@@	O	-1	8302922
)	O	-1	8302922
did	O	-1	8302922
not	O	-1	8302922
change	O	-1	8302922
in	O	-1	8302922
either	O	-1	8302922
group.	O	-1	8302922
E@@	O	-1	8302922
B@@	O	-1	8302922
F@@	O	-1	8302922
F	O	-1	8302922
did	O	-1	8302922
not	O	-1	8302922
change	O	-1	8302922
during	O	-1	8302922
PG@@	B-Chemical	D000527	8302922
E@@	I-Chemical	-1	8302922
1	I-Chemical	-1	8302922
infusion	O	-1	8302922
whereas	O	-1	8302922
in	O	-1	8302922
the	O	-1	8302922
T@@	B-Chemical	D014294	8302922
M@@	I-Chemical	-1	8302922
P	I-Chemical	-1	8302922
group@@	O	-1	8302922
,	O	-1	8302922
E@@	O	-1	8302922
B@@	O	-1	8302922
F	O	-1	8302922
decreased	O	-1	8302922
significantly	O	-1	8302922
at	O	-1	8302922
30	O	-1	8302922
and	O	-1	8302922
60	O	-1	8302922
min	O	-1	8302922
after	O	-1	8302922
the	O	-1	8302922
star@@	O	-1	8302922
t	O	-1	8302922
of	O	-1	8302922
T@@	B-Chemical	D014294	8302922
M@@	I-Chemical	-1	8302922
P	I-Chemical	-1	8302922
(@@	O	-1	8302922
pre@@	O	-1	8302922
infu@@	O	-1	8302922
sion@@	O	-1	8302922
:	O	-1	8302922
4@@	O	-1	8302922
5.@@	O	-1	8302922
9	O	-1	8302922
+/-	O	-1	8302922
1@@	O	-1	8302922
3.@@	O	-1	8302922
9	O	-1	8302922
ml@@	O	-1	8302922
/@@	O	-1	8302922
10@@	O	-1	8302922
0@@	O	-1	8302922
g/@@	O	-1	8302922
min@@	O	-1	8302922
.	O	-1	8302922
30	O	-1	8302922
min@@	O	-1	8302922
:	O	-1	8302922
3@@	O	-1	8302922
2.@@	O	-1	8302922
3	O	-1	8302922
+/-	O	-1	8302922
9.@@	O	-1	8302922
9	O	-1	8302922
ml@@	O	-1	8302922
/@@	O	-1	8302922
100	O	-1	8302922
g/@@	O	-1	8302922
min	O	-1	8302922
(P	O	-1	8302922
<	O	-1	8302922
0.05@@	O	-1	8302922
).	O	-1	8302922
60	O	-1	8302922
min@@	O	-1	8302922
:	O	-1	8302922
30	O	-1	8302922
+/-	O	-1	8302922
7.@@	O	-1	8302922
5	O	-1	8302922
ml@@	O	-1	8302922
/@@	O	-1	8302922
100	O	-1	8302922
g/@@	O	-1	8302922
min	O	-1	8302922
(P	O	-1	8302922
<	O	-1	8302922
0.05@@	O	-1	8302922
)@@	O	-1	8302922
).	O	-1	8302922
These	O	-1	8302922
results	O	-1	8302922
suggest	O	-1	8302922
that	O	-1	8302922
PG@@	B-Chemical	D000527	8302922
E@@	I-Chemical	-1	8302922
1	I-Chemical	-1	8302922
may	O	-1	8302922
be	O	-1	8302922
pre@@	O	-1	8302922
fer@@	O	-1	8302922
able	O	-1	8302922
to	O	-1	8302922
T@@	B-Chemical	D014294	8302922
M@@	I-Chemical	-1	8302922
P	I-Chemical	-1	8302922
for	O	-1	8302922
hypoten@@	B-Disease	D007022	8302922
sive	I-Disease	-1	8302922
anaesthe@@	O	-1	8302922
sia	O	-1	8302922
in	O	-1	8302922
spinal	O	-1	8302922
surger@@	O	-1	8302922
y	O	-1	8302922
because	O	-1	8302922
T@@	B-Chemical	D014294	8302922
M@@	I-Chemical	-1	8302922
P	I-Chemical	-1	8302922
decreased	O	-1	8302922
E@@	O	-1	8302922
B@@	O	-1	8302922
F@@	O	-1	8302922
.	O	-1	8302922

Im@@	O	-1	8410052
mun@@	O	-1	8410052
o@@	O	-1	8410052
histo@@	O	-1	8410052
chemical	O	-1	8410052
studies	O	-1	8410052
with	O	-1	8410052
anti@@	O	-1	8410052
bo@@	O	-1	8410052
di@@	O	-1	8410052
es	O	-1	8410052
to	O	-1	8410052
neuro@@	O	-1	8410052
f@@	O	-1	8410052
il@@	O	-1	8410052
am@@	O	-1	8410052
ent	O	-1	8410052
protein@@	O	-1	8410052
s	O	-1	8410052
on	O	-1	8410052
ax@@	B-Disease	D001480	8410052
on@@	I-Disease	-1	8410052
al	I-Disease	-1	8410052
damage	I-Disease	-1	8410052
in	O	-1	8410052
experimental	O	-1	8410052
foc@@	O	-1	8410052
al	O	-1	8410052
lesions	O	-1	8410052
in	O	-1	8410052
rat@@	O	-1	8410052
.	O	-1	8410052
Im@@	O	-1	8410052
mun@@	O	-1	8410052
o@@	O	-1	8410052
histo@@	O	-1	8410052
chem@@	O	-1	8410052
ist@@	O	-1	8410052
r@@	O	-1	8410052
y	O	-1	8410052
with	O	-1	8410052
mon@@	O	-1	8410052
oc@@	O	-1	8410052
lon@@	O	-1	8410052
al	O	-1	8410052
anti@@	O	-1	8410052
bo@@	O	-1	8410052
di@@	O	-1	8410052
es	O	-1	8410052
against	O	-1	8410052
neuro@@	O	-1	8410052
f@@	O	-1	8410052
il@@	O	-1	8410052
am@@	O	-1	8410052
ent	O	-1	8410052
(N@@	O	-1	8410052
F@@	O	-1	8410052
)	O	-1	8410052
protein@@	O	-1	8410052
s	O	-1	8410052
of	O	-1	8410052
mid@@	O	-1	8410052
d@@	O	-1	8410052
le	O	-1	8410052
and	O	-1	8410052
high	O	-1	8410052
mol@@	O	-1	8410052
ec@@	O	-1	8410052
ular	O	-1	8410052
weight	O	-1	8410052
cl@@	O	-1	8410052
as@@	O	-1	8410052
s,	O	-1	8410052
N@@	O	-1	8410052
F@@	O	-1	8410052
-@@	O	-1	8410052
M	O	-1	8410052
and	O	-1	8410052
N@@	O	-1	8410052
F@@	O	-1	8410052
-H@@	O	-1	8410052
,	O	-1	8410052
was	O	-1	8410052
used	O	-1	8410052
to	O	-1	8410052
study	O	-1	8410052
ax@@	B-Disease	D001480	8410052
on@@	I-Disease	-1	8410052
al	I-Disease	-1	8410052
injury	I-Disease	-1	8410052
in	O	-1	8410052
the	O	-1	8410052
b@@	O	-1	8410052
or@@	O	-1	8410052
der@@	O	-1	8410052
z@@	O	-1	8410052
one	O	-1	8410052
of	O	-1	8410052
foc@@	O	-1	8410052
al	O	-1	8410052
lesions	O	-1	8410052
in	O	-1	8410052
rats.	O	-1	8410052
F@@	O	-1	8410052
oc@@	O	-1	8410052
al	O	-1	8410052
injury	B-Disease	D001480	8410052
in	I-Disease	-1	8410052
the	I-Disease	-1	8410052
cor@@	I-Disease	-1	8410052
te@@	I-Disease	-1	8410052
x	I-Disease	-1	8410052
was	O	-1	8410052
produced	O	-1	8410052
by	O	-1	8410052
infusion	O	-1	8410052
of	O	-1	8410052
l@@	B-Chemical	D019344	8410052
act@@	I-Chemical	-1	8410052
ate	I-Chemical	-1	8410052
at	O	-1	8410052
acid	O	-1	8410052
p@@	O	-1	8410052
H	O	-1	8410052
or	O	-1	8410052
by	O	-1	8410052
st@@	O	-1	8410052
a@@	O	-1	8410052
b	O	-1	8410052
caused	O	-1	8410052
by	O	-1	8410052
ne@@	O	-1	8410052
ed@@	O	-1	8410052
le	O	-1	8410052
in@@	O	-1	8410052
ser@@	O	-1	8410052
tion.	O	-1	8410052
In@@	B-Disease	D002544	8410052
f@@	I-Disease	-1	8410052
arc@@	I-Disease	-1	8410052
ts	I-Disease	-1	8410052
in	I-Disease	-1	8410052
subst@@	I-Disease	-1	8410052
anti@@	I-Disease	-1	8410052
a	I-Disease	-1	8410052
n@@	I-Disease	-1	8410052
ig@@	I-Disease	-1	8410052
r@@	I-Disease	-1	8410052
a	I-Disease	-1	8410052
par@@	I-Disease	-1	8410052
s	I-Disease	-1	8410052
re@@	I-Disease	-1	8410052
tic@@	I-Disease	-1	8410052
ul@@	I-Disease	-1	8410052
at@@	I-Disease	-1	8410052
a	I-Disease	-1	8410052
were	O	-1	8410052
evoked	O	-1	8410052
by	O	-1	8410052
prolonged	O	-1	8410052
pilocar@@	B-Chemical	D010862	8410052
pine	I-Chemical	-1	8410052
-induced	O	-1	8410052
status	B-Disease	D013226	8410052
epilep@@	I-Disease	-1	8410052
tic@@	I-Disease	-1	8410052
us	I-Disease	-1	8410052
.	O	-1	8410052
Im@@	O	-1	8410052
mun@@	O	-1	8410052
o@@	O	-1	8410052
histo@@	O	-1	8410052
chemical	O	-1	8410052
st@@	O	-1	8410052
aining	O	-1	8410052
for	O	-1	8410052
N@@	O	-1	8410052
F@@	O	-1	8410052
s	O	-1	8410052
showed	O	-1	8410052
character@@	O	-1	8410052
istic	O	-1	8410052
ter@@	O	-1	8410052
min@@	O	-1	8410052
al	O	-1	8410052
cl@@	O	-1	8410052
ub@@	O	-1	8410052
s	O	-1	8410052
of	O	-1	8410052
ax@@	O	-1	8410052
ons	O	-1	8410052
in	O	-1	8410052
the	O	-1	8410052
b@@	O	-1	8410052
or@@	O	-1	8410052
der@@	O	-1	8410052
z@@	O	-1	8410052
one	O	-1	8410052
of	O	-1	8410052
le@@	O	-1	8410052
sion@@	O	-1	8410052
s.	O	-1	8410052
Di@@	O	-1	8410052
fferen@@	O	-1	8410052
ces	O	-1	8410052
in	O	-1	8410052
the	O	-1	8410052
l@@	O	-1	8410052
a@@	O	-1	8410052
bell@@	O	-1	8410052
ing	O	-1	8410052
pat@@	O	-1	8410052
ter@@	O	-1	8410052
n	O	-1	8410052
occurred	O	-1	8410052
with	O	-1	8410052
different	O	-1	8410052
anti@@	O	-1	8410052
bo@@	O	-1	8410052
di@@	O	-1	8410052
es	O	-1	8410052
which	O	-1	8410052
appa@@	O	-1	8410052
ren@@	O	-1	8410052
tly	O	-1	8410052
depend@@	O	-1	8410052
ed	O	-1	8410052
on	O	-1	8410052
mol@@	O	-1	8410052
ec@@	O	-1	8410052
ular	O	-1	8410052
weight	O	-1	8410052
cl@@	O	-1	8410052
as@@	O	-1	8410052
s	O	-1	8410052
of	O	-1	8410052
N@@	O	-1	8410052
F@@	O	-1	8410052
s	O	-1	8410052
and	O	-1	8410052
phosph@@	O	-1	8410052
or@@	O	-1	8410052
yl@@	O	-1	8410052
ation	O	-1	8410052
stat@@	O	-1	8410052
e.	O	-1	8410052
These	O	-1	8410052
immuno@@	O	-1	8410052
histo@@	O	-1	8410052
chemical	O	-1	8410052
changes	O	-1	8410052
of	O	-1	8410052
N@@	O	-1	8410052
F@@	O	-1	8410052
s	O	-1	8410052
can	O	-1	8410052
ser@@	O	-1	8410052
ve	O	-1	8410052
as	O	-1	8410052
a	O	-1	8410052
mark@@	O	-1	8410052
er	O	-1	8410052
for	O	-1	8410052
ax@@	B-Disease	D001480	8410052
on@@	I-Disease	-1	8410052
al	I-Disease	-1	8410052
damage	I-Disease	-1	8410052
in	O	-1	8410052
various	O	-1	8410052
experimental	O	-1	8410052
tra@@	B-Disease	D014947	8410052
um@@	I-Disease	-1	8410052
atic	I-Disease	-1	8410052
or	O	-1	8410052
ischem@@	O	-1	8410052
ic	O	-1	8410052
le@@	O	-1	8410052
sion@@	O	-1	8410052
s.	O	-1	8410052

In@@	O	-1	8423889
c@@	O	-1	8423889
reas@@	O	-1	8423889
e	O	-1	8423889
of	O	-1	8423889
Park@@	B-Disease	D009069	8423889
in@@	I-Disease	-1	8423889
s@@	I-Disease	-1	8423889
on	I-Disease	-1	8423889
dis@@	I-Disease	-1	8423889
ability	I-Disease	-1	8423889
after	O	-1	8423889
flu@@	B-Chemical	D005473	8423889
ox@@	I-Chemical	-1	8423889
et@@	I-Chemical	-1	8423889
ine	I-Chemical	-1	8423889
medic@@	O	-1	8423889
ation.	O	-1	8423889
De@@	B-Disease	D003866	8423889
pression	I-Disease	-1	8423889
is	O	-1	8423889
a	O	-1	8423889
major	O	-1	8423889
clinical	O	-1	8423889
feat@@	O	-1	8423889
ure	O	-1	8423889
of	O	-1	8423889
Parkinson's	B-Disease	D010300	8423889
disease	I-Disease	-1	8423889
.	O	-1	8423889
We	O	-1	8423889
report	O	-1	8423889
the	O	-1	8423889
increased	O	-1	8423889
amoun@@	O	-1	8423889
t	O	-1	8423889
of	O	-1	8423889
motor	B-Disease	D009069	8423889
dis@@	I-Disease	-1	8423889
ability	I-Disease	-1	8423889
in	O	-1	8423889
four	O	-1	8423889
patients	O	-1	8423889
with	O	-1	8423889
i@@	B-Disease	D010300	8423889
di@@	I-Disease	-1	8423889
o@@	I-Disease	-1	8423889
path@@	I-Disease	-1	8423889
ic	I-Disease	-1	8423889
Parkinson's	I-Disease	-1	8423889
disease	I-Disease	-1	8423889
after	O	-1	8423889
exposure	O	-1	8423889
to	O	-1	8423889
the	O	-1	8423889
antidepress@@	B-Chemical	D000928	8423889
ant	I-Chemical	-1	8423889
flu@@	B-Chemical	D005473	8423889
ox@@	I-Chemical	-1	8423889
et@@	I-Chemical	-1	8423889
ine	I-Chemical	-1	8423889
.	O	-1	8423889
The	O	-1	8423889
possib@@	O	-1	8423889
ility	O	-1	8423889
of	O	-1	8423889
a	O	-1	8423889
clin@@	O	-1	8423889
ically	O	-1	8423889
re@@	O	-1	8423889
lev@@	O	-1	8423889
ant	O	-1	8423889
dopamine	B-Chemical	D004298	8423889
-@@	O	-1	8423889
antagon@@	O	-1	8423889
istic	O	-1	8423889
cap@@	O	-1	8423889
ac@@	O	-1	8423889
ity	O	-1	8423889
of	O	-1	8423889
flu@@	B-Chemical	D005473	8423889
ox@@	I-Chemical	-1	8423889
et@@	I-Chemical	-1	8423889
ine	I-Chemical	-1	8423889
in	O	-1	8423889
Parkinson's	B-Disease	D010300	8423889
disease	I-Disease	-1	8423889
patients	O	-1	8423889
mus@@	O	-1	8423889
t	O	-1	8423889
be	O	-1	8423889
conside@@	O	-1	8423889
red.	O	-1	8423889

A@@	B-Chemical	D000082	8682684
ce@@	I-Chemical	-1	8682684
t@@	I-Chemical	-1	8682684
aminoph@@	I-Chemical	-1	8682684
en	I-Chemical	-1	8682684
-induced	O	-1	8682684
hypotension	B-Disease	D007022	8682684
.	O	-1	8682684
Th@@	O	-1	8682684
rou@@	O	-1	8682684
gh	O	-1	8682684
30	O	-1	8682684
years	O	-1	8682684
of	O	-1	8682684
w@@	O	-1	8682684
id@@	O	-1	8682684
es@@	O	-1	8682684
pre@@	O	-1	8682684
ad	O	-1	8682684
use@@	O	-1	8682684
,	O	-1	8682684
acet@@	B-Chemical	D000082	8682684
aminoph@@	I-Chemical	-1	8682684
en	I-Chemical	-1	8682684
has	O	-1	8682684
been	O	-1	8682684
shown	O	-1	8682684
to	O	-1	8682684
be	O	-1	8682684
a	O	-1	8682684
re@@	O	-1	8682684
mark@@	O	-1	8682684
ably	O	-1	8682684
saf@@	O	-1	8682684
e	O	-1	8682684
medic@@	O	-1	8682684
ation	O	-1	8682684
in	O	-1	8682684
therapeutic	O	-1	8682684
dos@@	O	-1	8682684
ag@@	O	-1	8682684
es.	O	-1	8682684
The	O	-1	8682684
potential	O	-1	8682684
for	O	-1	8682684
acet@@	B-Chemical	D000082	8682684
aminoph@@	I-Chemical	-1	8682684
en	I-Chemical	-1	8682684
to	O	-1	8682684
produce	O	-1	8682684
cardiovascular	B-Disease	D002318	8682684
toxic@@	I-Disease	-1	8682684
ities	I-Disease	-1	8682684
is	O	-1	8682684
very	O	-1	8682684
low@@	O	-1	8682684
.	O	-1	8682684
However,	O	-1	8682684
acet@@	B-Chemical	D000082	8682684
aminoph@@	I-Chemical	-1	8682684
en	I-Chemical	-1	8682684
has	O	-1	8682684
been	O	-1	8682684
demonstrated	O	-1	8682684
to	O	-1	8682684
produce	O	-1	8682684
symptoms	O	-1	8682684
of	O	-1	8682684
ana@@	B-Disease	D000707	8682684
phyl@@	I-Disease	-1	8682684
ax@@	I-Disease	-1	8682684
is	I-Disease	-1	8682684
,	O	-1	8682684
including	O	-1	8682684
hypotension	B-Disease	D007022	8682684
,	O	-1	8682684
in	O	-1	8682684
sensitive	O	-1	8682684
individ@@	O	-1	8682684
u@@	O	-1	8682684
al@@	O	-1	8682684
s.	O	-1	8682684
This	O	-1	8682684
ar@@	O	-1	8682684
tic@@	O	-1	8682684
le	O	-1	8682684
descri@@	O	-1	8682684
b@@	O	-1	8682684
es	O	-1	8682684
two	O	-1	8682684
cri@@	B-Disease	D016638	8682684
tically	I-Disease	-1	8682684
il@@	I-Disease	-1	8682684
l	I-Disease	-1	8682684
patients	O	-1	8682684
in	O	-1	8682684
whom	O	-1	8682684
transi@@	O	-1	8682684
ent	O	-1	8682684
episo@@	O	-1	8682684
des	O	-1	8682684
of	O	-1	8682684
hypotension	B-Disease	D007022	8682684
re@@	O	-1	8682684
produc@@	O	-1	8682684
i@@	O	-1	8682684
b@@	O	-1	8682684
ly	O	-1	8682684
developed	O	-1	8682684
after	O	-1	8682684
administration	O	-1	8682684
of	O	-1	8682684
acet@@	B-Chemical	D000082	8682684
aminoph@@	I-Chemical	-1	8682684
en	I-Chemical	-1	8682684
.	O	-1	8682684
O@@	O	-1	8682684
ther	O	-1	8682684
symptoms	O	-1	8682684
of	O	-1	8682684
all@@	B-Disease	D004342	8682684
ergic	I-Disease	-1	8682684
reactions	I-Disease	-1	8682684
were	O	-1	8682684
not	O	-1	8682684
clin@@	O	-1	8682684
ically	O	-1	8682684
det@@	O	-1	8682684
ect@@	O	-1	8682684
able@@	O	-1	8682684
.	O	-1	8682684
The	O	-1	8682684
hypoten@@	B-Disease	D007022	8682684
sive	I-Disease	-1	8682684
episo@@	O	-1	8682684
des	O	-1	8682684
were	O	-1	8682684
severe	O	-1	8682684
en@@	O	-1	8682684
ou@@	O	-1	8682684
gh	O	-1	8682684
to	O	-1	8682684
requ@@	O	-1	8682684
ir@@	O	-1	8682684
e	O	-1	8682684
vas@@	O	-1	8682684
o@@	O	-1	8682684
press@@	O	-1	8682684
or	O	-1	8682684
administr@@	O	-1	8682684
ation.	O	-1	8682684
The	O	-1	8682684
reports	O	-1	8682684
il@@	O	-1	8682684
lu@@	O	-1	8682684
st@@	O	-1	8682684
rate	O	-1	8682684
the	O	-1	8682684
need	O	-1	8682684
for	O	-1	8682684
clin@@	O	-1	8682684
ici@@	O	-1	8682684
ans	O	-1	8682684
to	O	-1	8682684
con@@	O	-1	8682684
si@@	O	-1	8682684
der	O	-1	8682684
acet@@	B-Chemical	D000082	8682684
aminoph@@	I-Chemical	-1	8682684
en	I-Chemical	-1	8682684
in	O	-1	8682684
patients	O	-1	8682684
with	O	-1	8682684
hypotension	B-Disease	D007022	8682684
of	O	-1	8682684
un@@	O	-1	8682684
known	O	-1	8682684
or@@	O	-1	8682684
ig@@	O	-1	8682684
in.	O	-1	8682684

Ac@@	O	-1	9625142
ute	O	-1	9625142
hepatitis	B-Disease	D056486	9625142
,	O	-1	9625142
auto@@	B-Disease	D000744	9625142
immun@@	I-Disease	-1	9625142
e	I-Disease	-1	9625142
hemolytic	I-Disease	-1	9625142
anemia	I-Disease	-1	9625142
,	O	-1	9625142
and	O	-1	9625142
erythro@@	B-Disease	-1	9625142
bl@@	I-Disease	-1	9625142
ast@@	I-Disease	-1	9625142
ocyto@@	I-Disease	-1	9625142
pen@@	I-Disease	-1	9625142
ia	I-Disease	-1	9625142
induced	O	-1	9625142
by	O	-1	9625142
ce@@	B-Chemical	D002443	9625142
f@@	I-Chemical	-1	9625142
tri@@	I-Chemical	-1	9625142
ax@@	I-Chemical	-1	9625142
one	I-Chemical	-1	9625142
.	O	-1	9625142
An	O	-1	9625142
8@@	O	-1	9625142
0-@@	O	-1	9625142
y@@	O	-1	9625142
r@@	O	-1	9625142
-old	O	-1	9625142
man	O	-1	9625142
developed	O	-1	9625142
acute	O	-1	9625142
hepatitis	B-Disease	D056486	9625142
sh@@	O	-1	9625142
ort@@	O	-1	9625142
ly	O	-1	9625142
after	O	-1	9625142
ing@@	O	-1	9625142
est@@	O	-1	9625142
ing	O	-1	9625142
oral	O	-1	9625142
ce@@	B-Chemical	D002443	9625142
f@@	I-Chemical	-1	9625142
tri@@	I-Chemical	-1	9625142
ax@@	I-Chemical	-1	9625142
one	I-Chemical	-1	9625142
.	O	-1	9625142
Although	O	-1	9625142
the	O	-1	9625142
trans@@	O	-1	9625142
amin@@	O	-1	9625142
as@@	O	-1	9625142
es	O	-1	9625142
gra@@	O	-1	9625142
du@@	O	-1	9625142
ally	O	-1	9625142
retur@@	O	-1	9625142
n@@	O	-1	9625142
ed	O	-1	9625142
to	O	-1	9625142
baseline	O	-1	9625142
after	O	-1	9625142
with@@	O	-1	9625142
h@@	O	-1	9625142
ol@@	O	-1	9625142
ding	O	-1	9625142
the	O	-1	9625142
bet@@	B-Chemical	D047090	9625142
a	I-Chemical	-1	9625142
l@@	I-Chemical	-1	9625142
act@@	I-Chemical	-1	9625142
am	I-Chemical	-1	9625142
anti@@	O	-1	9625142
bio@@	O	-1	9625142
tic@@	O	-1	9625142
,	O	-1	9625142
there	O	-1	9625142
was	O	-1	9625142
a	O	-1	9625142
gra@@	O	-1	9625142
du@@	O	-1	9625142
al	O	-1	9625142
increase	O	-1	9625142
in	O	-1	9625142
serum	O	-1	9625142
bil@@	B-Chemical	D001663	9625142
i@@	I-Chemical	-1	9625142
ru@@	I-Chemical	-1	9625142
bin	I-Chemical	-1	9625142
and	O	-1	9625142
a	O	-1	9625142
decrease	O	-1	9625142
in	O	-1	9625142
hemo@@	O	-1	9625142
globin	O	-1	9625142
concentration	O	-1	9625142
caused	O	-1	9625142
by	O	-1	9625142
an	O	-1	9625142
auto@@	B-Disease	D000744	9625142
immun@@	I-Disease	-1	9625142
e	I-Disease	-1	9625142
hemolytic	I-Disease	-1	9625142
anemia	I-Disease	-1	9625142
and	O	-1	9625142
erythro@@	B-Disease	-1	9625142
bl@@	I-Disease	-1	9625142
ast@@	I-Disease	-1	9625142
ocyto@@	I-Disease	-1	9625142
pen@@	I-Disease	-1	9625142
ia	I-Disease	-1	9625142
.	O	-1	9625142
These	O	-1	9625142
respon@@	O	-1	9625142
ded	O	-1	9625142
to	O	-1	9625142
systemic	O	-1	9625142
steroid@@	B-Chemical	D013256	9625142
s	I-Chemical	-1	9625142
and	O	-1	9625142
immuno@@	O	-1	9625142
glo@@	O	-1	9625142
b@@	O	-1	9625142
ul@@	O	-1	9625142
in@@	O	-1	9625142
s.	O	-1	9625142
D@@	O	-1	9625142
es@@	O	-1	9625142
pit@@	O	-1	9625142
e	O	-1	9625142
the	O	-1	9625142
w@@	O	-1	9625142
id@@	O	-1	9625142
es@@	O	-1	9625142
pre@@	O	-1	9625142
ad	O	-1	9625142
use	O	-1	9625142
of	O	-1	9625142
these	O	-1	9625142
agents	O	-1	9625142
this	O	-1	9625142
tri@@	O	-1	9625142
ad	O	-1	9625142
of	O	-1	9625142
side	O	-1	9625142
effects	O	-1	9625142
has	O	-1	9625142
not	O	-1	9625142
previously	O	-1	9625142
been	O	-1	9625142
reported	O	-1	9625142
in	O	-1	9625142
con@@	O	-1	9625142
n@@	O	-1	9625142
ection	O	-1	9625142
with	O	-1	9625142
bet@@	B-Chemical	D047090	9625142
a	I-Chemical	-1	9625142
l@@	I-Chemical	-1	9625142
act@@	I-Chemical	-1	9625142
am	I-Chemical	-1	9625142
anti@@	O	-1	9625142
bio@@	O	-1	9625142
tic@@	O	-1	9625142
s.	O	-1	9625142

Ad@@	O	-1	9766615
verse	O	-1	9766615
effects	O	-1	9766615
of	O	-1	9766615
the	O	-1	9766615
at@@	O	-1	9766615
yp@@	O	-1	9766615
ical	O	-1	9766615
anti@@	O	-1	9766615
psycho@@	O	-1	9766615
tic@@	O	-1	9766615
s.	O	-1	9766615
C@@	O	-1	9766615
ol@@	O	-1	9766615
labor@@	O	-1	9766615
ative	O	-1	9766615
W@@	O	-1	9766615
or@@	O	-1	9766615
king	O	-1	9766615
Group	O	-1	9766615
on	O	-1	9766615
Clin@@	O	-1	9766615
ical	O	-1	9766615
T@@	O	-1	9766615
rial	O	-1	9766615
E@@	O	-1	9766615
valu@@	O	-1	9766615
ations.	O	-1	9766615
Ad@@	O	-1	9766615
verse	O	-1	9766615
effects	O	-1	9766615
of	O	-1	9766615
anti@@	O	-1	9766615
psycho@@	O	-1	9766615
tics	O	-1	9766615
often	O	-1	9766615
le@@	O	-1	9766615
ad	O	-1	9766615
to	O	-1	9766615
non@@	O	-1	9766615
com@@	O	-1	9766615
pl@@	O	-1	9766615
i@@	O	-1	9766615
ance@@	O	-1	9766615
.	O	-1	9766615
Th@@	O	-1	9766615
us,	O	-1	9766615
clin@@	O	-1	9766615
ici@@	O	-1	9766615
ans	O	-1	9766615
should	O	-1	9766615
ad@@	O	-1	9766615
d@@	O	-1	9766615
res@@	O	-1	9766615
s	O	-1	9766615
patient@@	O	-1	9766615
s@@	O	-1	9766615
'	O	-1	9766615
con@@	O	-1	9766615
cer@@	O	-1	9766615
n@@	O	-1	9766615
s	O	-1	9766615
about	O	-1	9766615
adverse	O	-1	9766615
effects	O	-1	9766615
and	O	-1	9766615
at@@	O	-1	9766615
tem@@	O	-1	9766615
p@@	O	-1	9766615
t	O	-1	9766615
to	O	-1	9766615
ch@@	O	-1	9766615
o@@	O	-1	9766615
ose	O	-1	9766615
medic@@	O	-1	9766615
ations	O	-1	9766615
that	O	-1	9766615
wil@@	O	-1	9766615
l	O	-1	9766615
impro@@	O	-1	9766615
ve	O	-1	9766615
their	O	-1	9766615
patient@@	O	-1	9766615
s@@	O	-1	9766615
'	O	-1	9766615
qu@@	O	-1	9766615
ality	O	-1	9766615
of	O	-1	9766615
lif@@	O	-1	9766615
e	O	-1	9766615
as	O	-1	9766615
well	O	-1	9766615
as	O	-1	9766615
over@@	O	-1	9766615
all	O	-1	9766615
health@@	O	-1	9766615
.	O	-1	9766615
The	O	-1	9766615
side	O	-1	9766615
effect	O	-1	9766615
pro@@	O	-1	9766615
fi@@	O	-1	9766615
le@@	O	-1	9766615
s	O	-1	9766615
of	O	-1	9766615
the	O	-1	9766615
at@@	O	-1	9766615
yp@@	O	-1	9766615
ical	O	-1	9766615
anti@@	O	-1	9766615
psycho@@	O	-1	9766615
tics	O	-1	9766615
are	O	-1	9766615
more	O	-1	9766615
adv@@	O	-1	9766615
ant@@	O	-1	9766615
ag@@	O	-1	9766615
e@@	O	-1	9766615
ous	O	-1	9766615
than	O	-1	9766615
those	O	-1	9766615
of	O	-1	9766615
the	O	-1	9766615
con@@	O	-1	9766615
ven@@	O	-1	9766615
tional	O	-1	9766615
neuro@@	O	-1	9766615
le@@	O	-1	9766615
p@@	O	-1	9766615
tic@@	O	-1	9766615
s.	O	-1	9766615
Con@@	O	-1	9766615
ven@@	O	-1	9766615
tional	O	-1	9766615
agents	O	-1	9766615
are	O	-1	9766615
associated	O	-1	9766615
with	O	-1	9766615
un@@	O	-1	9766615
w@@	O	-1	9766615
ant@@	O	-1	9766615
ed	O	-1	9766615
central	O	-1	9766615
ner@@	O	-1	9766615
v@@	O	-1	9766615
ous	O	-1	9766615
system	O	-1	9766615
effect@@	O	-1	9766615
s,	O	-1	9766615
including	O	-1	9766615
ext@@	B-Disease	D001480	9766615
ra@@	I-Disease	-1	9766615
py@@	I-Disease	-1	9766615
ram@@	I-Disease	-1	9766615
idal	I-Disease	-1	9766615
symptoms	I-Disease	-1	9766615
(	O	-1	9766615
EP@@	B-Disease	D001480	9766615
S	I-Disease	-1	9766615
),	O	-1	9766615
t@@	B-Disease	D004409	9766615
ardi@@	I-Disease	-1	9766615
ve	I-Disease	-1	9766615
dyskine@@	I-Disease	-1	9766615
sia	I-Disease	-1	9766615
,	O	-1	9766615
sed@@	O	-1	9766615
ation,	O	-1	9766615
and	O	-1	9766615
possible	O	-1	9766615
impair@@	O	-1	9766615
ment	O	-1	9766615
of	O	-1	9766615
some	O	-1	9766615
cognitive	O	-1	9766615
meas@@	O	-1	9766615
ures@@	O	-1	9766615
,	O	-1	9766615
as	O	-1	9766615
well	O	-1	9766615
as	O	-1	9766615
cardiac	O	-1	9766615
effect@@	O	-1	9766615
s,	O	-1	9766615
or@@	B-Disease	D007024	9766615
th@@	I-Disease	-1	9766615
ost@@	I-Disease	-1	9766615
atic	I-Disease	-1	9766615
hypotension	I-Disease	-1	9766615
,	O	-1	9766615
hepatic	O	-1	9766615
chang@@	O	-1	9766615
es,	O	-1	9766615
anti@@	O	-1	9766615
cholinergic	O	-1	9766615
side	O	-1	9766615
effect@@	O	-1	9766615
s,	O	-1	9766615
sex@@	B-Disease	D012735	9766615
ual	I-Disease	-1	9766615
dysfunction	I-Disease	-1	9766615
,	O	-1	9766615
and	O	-1	9766615
weight	B-Disease	D015430	9766615
g@@	I-Disease	-1	9766615
ain	I-Disease	-1	9766615
.	O	-1	9766615
The	O	-1	9766615
ne@@	O	-1	9766615
w@@	O	-1	9766615
er	O	-1	9766615
at@@	O	-1	9766615
yp@@	O	-1	9766615
ical	O	-1	9766615
agents	O	-1	9766615
have	O	-1	9766615
a	O	-1	9766615
lower	O	-1	9766615
risk	O	-1	9766615
of	O	-1	9766615
EP@@	B-Disease	D001480	9766615
S	I-Disease	-1	9766615
,	O	-1	9766615
but	O	-1	9766615
are	O	-1	9766615
associated	O	-1	9766615
in	O	-1	9766615
v@@	O	-1	9766615
ar@@	O	-1	9766615
y@@	O	-1	9766615
ing	O	-1	9766615
de@@	O	-1	9766615
gre@@	O	-1	9766615
es	O	-1	9766615
with	O	-1	9766615
sed@@	O	-1	9766615
ation,	O	-1	9766615
cardiovascular	O	-1	9766615
effect@@	O	-1	9766615
s,	O	-1	9766615
anti@@	O	-1	9766615
cholinergic	O	-1	9766615
effect@@	O	-1	9766615
s,	O	-1	9766615
weight	B-Disease	D015430	9766615
g@@	I-Disease	-1	9766615
ain	I-Disease	-1	9766615
,	O	-1	9766615
sex@@	B-Disease	D012735	9766615
ual	I-Disease	-1	9766615
dysfunction	I-Disease	-1	9766615
,	O	-1	9766615
hepatic	O	-1	9766615
effect@@	O	-1	9766615
s,	O	-1	9766615
lo@@	O	-1	9766615
we@@	O	-1	9766615
red	O	-1	9766615
seizure	B-Disease	D012640	9766615
th@@	O	-1	9766615
res@@	O	-1	9766615
h@@	O	-1	9766615
old	O	-1	9766615
(@@	O	-1	9766615
prim@@	O	-1	9766615
ari@@	O	-1	9766615
ly	O	-1	9766615
cloz@@	B-Chemical	D003024	9766615
apine	I-Chemical	-1	9766615
),	O	-1	9766615
and	O	-1	9766615
ag@@	B-Disease	D000380	9766615
ran@@	I-Disease	-1	9766615
ulo@@	I-Disease	-1	9766615
cyto@@	I-Disease	-1	9766615
sis	I-Disease	-1	9766615
(	O	-1	9766615
cloz@@	B-Chemical	D003024	9766615
apine	I-Chemical	-1	9766615
on@@	O	-1	9766615
ly@@	O	-1	9766615
).	O	-1	9766615
S@@	O	-1	9766615
inc@@	O	-1	9766615
e	O	-1	9766615
the	O	-1	9766615
incidence	O	-1	9766615
and	O	-1	9766615
severity	O	-1	9766615
of	O	-1	9766615
specific	O	-1	9766615
adverse	O	-1	9766615
effects	O	-1	9766615
diff@@	O	-1	9766615
er	O	-1	9766615
among	O	-1	9766615
the	O	-1	9766615
various	O	-1	9766615
at@@	O	-1	9766615
yp@@	O	-1	9766615
ic@@	O	-1	9766615
al@@	O	-1	9766615
s,	O	-1	9766615
the	O	-1	9766615
clin@@	O	-1	9766615
ici@@	O	-1	9766615
an	O	-1	9766615
should	O	-1	9766615
ca@@	O	-1	9766615
ref@@	O	-1	9766615
ul@@	O	-1	9766615
ly	O	-1	9766615
con@@	O	-1	9766615
si@@	O	-1	9766615
der	O	-1	9766615
which	O	-1	9766615
side	O	-1	9766615
effects	O	-1	9766615
are	O	-1	9766615
most	O	-1	9766615
likely	O	-1	9766615
to	O	-1	9766615
le@@	O	-1	9766615
ad	O	-1	9766615
to	O	-1	9766615
the	O	-1	9766615
individ@@	O	-1	9766615
u@@	O	-1	9766615
al@@	O	-1	9766615
's	O	-1	9766615
dis@@	O	-1	9766615
s@@	O	-1	9766615
atis@@	O	-1	9766615
f@@	O	-1	9766615
action	O	-1	9766615
and	O	-1	9766615
non@@	O	-1	9766615
com@@	O	-1	9766615
pl@@	O	-1	9766615
i@@	O	-1	9766615
ance	O	-1	9766615
before	O	-1	9766615
ch@@	O	-1	9766615
o@@	O	-1	9766615
os@@	O	-1	9766615
ing	O	-1	9766615
an	O	-1	9766615
anti@@	O	-1	9766615
psycho@@	O	-1	9766615
tic	O	-1	9766615
for	O	-1	9766615
a	O	-1	9766615
partic@@	O	-1	9766615
ular	O	-1	9766615
patient@@	O	-1	9766615
.	O	-1	9766615

Eff@@	O	-1	10193204
ects	O	-1	10193204
of	O	-1	10193204
te@@	B-Chemical	C009438	10193204
tran@@	I-Chemical	-1	10193204
d@@	I-Chemical	-1	10193204
rine	I-Chemical	-1	10193204
and	O	-1	10193204
f@@	B-Chemical	C060802	10193204
ang@@	I-Chemical	-1	10193204
ch@@	I-Chemical	-1	10193204
in@@	I-Chemical	-1	10193204
ol@@	I-Chemical	-1	10193204
ine	I-Chemical	-1	10193204
on	O	-1	10193204
experimental	O	-1	10193204
thrombo@@	B-Disease	D013927	10193204
sis	I-Disease	-1	10193204
in	O	-1	10193204
mice	O	-1	10193204
and	O	-1	10193204
human	O	-1	10193204
platele@@	B-Disease	D001791	10193204
t	I-Disease	-1	10193204
ag@@	I-Disease	-1	10193204
g@@	I-Disease	-1	10193204
reg@@	I-Disease	-1	10193204
ation	I-Disease	-1	10193204
.	O	-1	10193204
T@@	B-Chemical	C009438	10193204
et@@	I-Chemical	-1	10193204
ran@@	I-Chemical	-1	10193204
d@@	I-Chemical	-1	10193204
rine	I-Chemical	-1	10193204
(	O	-1	10193204
TE@@	B-Chemical	C009438	10193204
T	I-Chemical	-1	10193204
)	O	-1	10193204
and	O	-1	10193204
f@@	B-Chemical	C060802	10193204
ang@@	I-Chemical	-1	10193204
ch@@	I-Chemical	-1	10193204
in@@	I-Chemical	-1	10193204
ol@@	I-Chemical	-1	10193204
ine	I-Chemical	-1	10193204
(	O	-1	10193204
F@@	B-Chemical	C060802	10193204
A@@	I-Chemical	-1	10193204
N	I-Chemical	-1	10193204
)	O	-1	10193204
are	O	-1	10193204
two	O	-1	10193204
n@@	O	-1	10193204
at@@	O	-1	10193204
ur@@	O	-1	10193204
ally	O	-1	10193204
occur@@	O	-1	10193204
r@@	O	-1	10193204
ing	O	-1	10193204
an@@	O	-1	10193204
alo@@	O	-1	10193204
gu@@	O	-1	10193204
es	O	-1	10193204
with	O	-1	10193204
a	O	-1	10193204
b@@	B-Chemical	D044182	10193204
is@@	I-Chemical	-1	10193204
b@@	I-Chemical	-1	10193204
enz@@	I-Chemical	-1	10193204
yl@@	I-Chemical	-1	10193204
iso@@	I-Chemical	-1	10193204
qu@@	I-Chemical	-1	10193204
in@@	I-Chemical	-1	10193204
ol@@	I-Chemical	-1	10193204
ine	I-Chemical	-1	10193204
struct@@	O	-1	10193204
ure.	O	-1	10193204
The	O	-1	10193204
present	O	-1	10193204
study	O	-1	10193204
was	O	-1	10193204
under@@	O	-1	10193204
tak@@	O	-1	10193204
en	O	-1	10193204
to	O	-1	10193204
investigate	O	-1	10193204
the	O	-1	10193204
effects	O	-1	10193204
of	O	-1	10193204
TE@@	B-Chemical	C009438	10193204
T	I-Chemical	-1	10193204
and	O	-1	10193204
F@@	B-Chemical	C060802	10193204
A@@	I-Chemical	-1	10193204
N	I-Chemical	-1	10193204
on	O	-1	10193204
the	O	-1	10193204
experimental	O	-1	10193204
thrombo@@	B-Disease	D013927	10193204
sis	I-Disease	-1	10193204
induced	O	-1	10193204
by	O	-1	10193204
coll@@	O	-1	10193204
ag@@	O	-1	10193204
en	O	-1	10193204
plus	O	-1	10193204
ep@@	B-Chemical	D004837	10193204
ine@@	I-Chemical	-1	10193204
phrine	I-Chemical	-1	10193204
(	O	-1	10193204
E@@	B-Chemical	D004837	10193204
P	I-Chemical	-1	10193204
)	O	-1	10193204
in	O	-1	10193204
mic@@	O	-1	10193204
e,	O	-1	10193204
and	O	-1	10193204
platele@@	B-Disease	D001791	10193204
t	I-Disease	-1	10193204
ag@@	I-Disease	-1	10193204
g@@	I-Disease	-1	10193204
reg@@	I-Disease	-1	10193204
ation	I-Disease	-1	10193204
and	O	-1	10193204
blood	B-Disease	D001778	10193204
co@@	I-Disease	-1	10193204
ag@@	I-Disease	-1	10193204
ulation	I-Disease	-1	10193204
in	O	-1	10193204
vit@@	O	-1	10193204
ro@@	O	-1	10193204
.	O	-1	10193204
In	O	-1	10193204
the	O	-1	10193204
in	O	-1	10193204
viv@@	O	-1	10193204
o	O	-1	10193204
study,	O	-1	10193204
the	O	-1	10193204
administration	O	-1	10193204
(@@	O	-1	10193204
50	O	-1	10193204
mg/kg@@	O	-1	10193204
,	O	-1	10193204
i.p.@@	O	-1	10193204
)	O	-1	10193204
of	O	-1	10193204
TE@@	B-Chemical	C009438	10193204
T	I-Chemical	-1	10193204
and	O	-1	10193204
F@@	B-Chemical	C060802	10193204
A@@	I-Chemical	-1	10193204
N	I-Chemical	-1	10193204
in	O	-1	10193204
mice	O	-1	10193204
showed	O	-1	10193204
the	O	-1	10193204
inhibition	O	-1	10193204
of	O	-1	10193204
thrombo@@	B-Disease	D013927	10193204
sis	I-Disease	-1	10193204
by	O	-1	10193204
5@@	O	-1	10193204
5%	O	-1	10193204
and	O	-1	10193204
3@@	O	-1	10193204
5@@	O	-1	10193204
%,	O	-1	10193204
respectivel@@	O	-1	10193204
y,	O	-1	10193204
while	O	-1	10193204
acet@@	B-Chemical	D001241	10193204
yl@@	I-Chemical	-1	10193204
sal@@	I-Chemical	-1	10193204
ic@@	I-Chemical	-1	10193204
yl@@	I-Chemical	-1	10193204
ic	I-Chemical	-1	10193204
acid	I-Chemical	-1	10193204
(	O	-1	10193204
A@@	B-Chemical	D001241	10193204
S@@	I-Chemical	-1	10193204
A	I-Chemical	-1	10193204
,	O	-1	10193204
50	O	-1	10193204
mg/kg@@	O	-1	10193204
,	O	-1	10193204
i.p.@@	O	-1	10193204
),	O	-1	10193204
a	O	-1	10193204
positive	O	-1	10193204
control@@	O	-1	10193204
,	O	-1	10193204
showed	O	-1	10193204
only	O	-1	10193204
3@@	O	-1	10193204
0%	O	-1	10193204
inhib@@	O	-1	10193204
i@@	O	-1	10193204
tion.	O	-1	10193204
In	O	-1	10193204
the	O	-1	10193204
vit@@	O	-1	10193204
r@@	O	-1	10193204
o	O	-1	10193204
human	O	-1	10193204
platele@@	B-Disease	D001791	10193204
t	I-Disease	-1	10193204
ag@@	I-Disease	-1	10193204
g@@	I-Disease	-1	10193204
reg@@	I-Disease	-1	10193204
ations	I-Disease	-1	10193204
induced	O	-1	10193204
by	O	-1	10193204
the	O	-1	10193204
agon@@	O	-1	10193204
ist@@	O	-1	10193204
s	O	-1	10193204
used	O	-1	10193204
in	O	-1	10193204
test@@	O	-1	10193204
s,	O	-1	10193204
TE@@	B-Chemical	C009438	10193204
T	I-Chemical	-1	10193204
and	O	-1	10193204
F@@	B-Chemical	C060802	10193204
A@@	I-Chemical	-1	10193204
N	I-Chemical	-1	10193204
showed	O	-1	10193204
the	O	-1	10193204
inhib@@	O	-1	10193204
i@@	O	-1	10193204
tions	O	-1	10193204
dose	O	-1	10193204
depend@@	O	-1	10193204
ent@@	O	-1	10193204
ly.	O	-1	10193204
In	O	-1	10193204
addi@@	O	-1	10193204
tion,	O	-1	10193204
ne@@	O	-1	10193204
ither	O	-1	10193204
TE@@	B-Chemical	C009438	10193204
T	I-Chemical	-1	10193204
n@@	O	-1	10193204
or	O	-1	10193204
F@@	B-Chemical	C060802	10193204
A@@	I-Chemical	-1	10193204
N	I-Chemical	-1	10193204
showed	O	-1	10193204
any	O	-1	10193204
anti@@	O	-1	10193204
co@@	O	-1	10193204
ag@@	O	-1	10193204
ulation	O	-1	10193204
ac@@	O	-1	10193204
ti@@	O	-1	10193204
vi@@	O	-1	10193204
ties	O	-1	10193204
in	O	-1	10193204
the	O	-1	10193204
meas@@	O	-1	10193204
ure@@	O	-1	10193204
ment	O	-1	10193204
of	O	-1	10193204
the	O	-1	10193204
activ@@	O	-1	10193204
ated	O	-1	10193204
partial	O	-1	10193204
thrombo@@	O	-1	10193204
plas@@	O	-1	10193204
tin	O	-1	10193204
time	O	-1	10193204
(A@@	O	-1	10193204
P@@	O	-1	10193204
T@@	O	-1	10193204
T@@	O	-1	10193204
),	O	-1	10193204
pro@@	O	-1	10193204
throm@@	O	-1	10193204
bin	O	-1	10193204
time	O	-1	10193204
(P@@	O	-1	10193204
T)	O	-1	10193204
and	O	-1	10193204
throm@@	O	-1	10193204
bin	O	-1	10193204
time	O	-1	10193204
(T@@	O	-1	10193204
T)	O	-1	10193204
using	O	-1	10193204
hum@@	O	-1	10193204
an@@	O	-1	10193204
-@@	O	-1	10193204
cit@@	O	-1	10193204
r@@	O	-1	10193204
ated	O	-1	10193204
plas@@	O	-1	10193204
ma.	O	-1	10193204
These	O	-1	10193204
results	O	-1	10193204
suggest	O	-1	10193204
that	O	-1	10193204
anti@@	O	-1	10193204
thrombo@@	O	-1	10193204
sis	O	-1	10193204
of	O	-1	10193204
TE@@	B-Chemical	C009438	10193204
T	I-Chemical	-1	10193204
and	O	-1	10193204
F@@	B-Chemical	C060802	10193204
A@@	I-Chemical	-1	10193204
N	I-Chemical	-1	10193204
in	O	-1	10193204
mice	O	-1	10193204
may	O	-1	10193204
be	O	-1	10193204
main@@	O	-1	10193204
ly	O	-1	10193204
related	O	-1	10193204
to	O	-1	10193204
the	O	-1	10193204
anti@@	O	-1	10193204
platele@@	O	-1	10193204
t	O	-1	10193204
ag@@	O	-1	10193204
g@@	O	-1	10193204
reg@@	O	-1	10193204
ation	O	-1	10193204
ac@@	O	-1	10193204
ti@@	O	-1	10193204
vi@@	O	-1	10193204
ti@@	O	-1	10193204
es.	O	-1	10193204

G@@	B-Chemical	C056507	10526274
em@@	I-Chemical	-1	10526274
cit@@	I-Chemical	-1	10526274
ab@@	I-Chemical	-1	10526274
ine	I-Chemical	-1	10526274
plus	O	-1	10526274
v@@	B-Chemical	C030852	10526274
ino@@	I-Chemical	-1	10526274
rel@@	I-Chemical	-1	10526274
b@@	I-Chemical	-1	10526274
ine	I-Chemical	-1	10526274
in	O	-1	10526274
non@@	B-Disease	D002289	10526274
sm@@	I-Disease	-1	10526274
all	I-Disease	-1	10526274
cell	I-Disease	-1	10526274
l@@	I-Disease	-1	10526274
un@@	I-Disease	-1	10526274
g	I-Disease	-1	10526274
carcin@@	I-Disease	-1	10526274
oma	I-Disease	-1	10526274
patients	O	-1	10526274
age	O	-1	10526274
7@@	O	-1	10526274
0	O	-1	10526274
years	O	-1	10526274
or	O	-1	10526274
ol@@	O	-1	10526274
der	O	-1	10526274
or	O	-1	10526274
patients	O	-1	10526274
who	O	-1	10526274
can@@	O	-1	10526274
not	O	-1	10526274
recei@@	O	-1	10526274
ve	O	-1	10526274
cisplatin	B-Chemical	D002945	10526274
.	O	-1	10526274
On@@	O	-1	10526274
co@@	O	-1	10526274
pa@@	O	-1	10526274
z	O	-1	10526274
C@@	O	-1	10526274
o@@	O	-1	10526274
o@@	O	-1	10526274
perative	O	-1	10526274
Grou@@	O	-1	10526274
p@@	O	-1	10526274
.	O	-1	10526274
BACKGROUND:	O	-1	10526274
Although	O	-1	10526274
the	O	-1	10526274
prev@@	O	-1	10526274
al@@	O	-1	10526274
ence	O	-1	10526274
of	O	-1	10526274
non@@	B-Disease	D002289	10526274
sm@@	I-Disease	-1	10526274
all	I-Disease	-1	10526274
cell	I-Disease	-1	10526274
l@@	I-Disease	-1	10526274
un@@	I-Disease	-1	10526274
g	I-Disease	-1	10526274
carcin@@	I-Disease	-1	10526274
oma	I-Disease	-1	10526274
(	O	-1	10526274
N@@	B-Disease	D002289	10526274
S@@	I-Disease	-1	10526274
CL@@	I-Disease	-1	10526274
C	I-Disease	-1	10526274
)	O	-1	10526274
is	O	-1	10526274
high	O	-1	10526274
among	O	-1	10526274
el@@	O	-1	10526274
der@@	O	-1	10526274
ly	O	-1	10526274
patients,	O	-1	10526274
fe@@	O	-1	10526274
w	O	-1	10526274
data	O	-1	10526274
are	O	-1	10526274
av@@	O	-1	10526274
ail@@	O	-1	10526274
able	O	-1	10526274
reg@@	O	-1	10526274
ar@@	O	-1	10526274
ding	O	-1	10526274
the	O	-1	10526274
efficacy	O	-1	10526274
and	O	-1	10526274
toxicity	B-Disease	D064420	10526274
of	O	-1	10526274
chemotherapy	O	-1	10526274
in	O	-1	10526274
this	O	-1	10526274
group	O	-1	10526274
of	O	-1	10526274
patients.	O	-1	10526274
Rec@@	O	-1	10526274
ent	O	-1	10526274
reports	O	-1	10526274
indicate	O	-1	10526274
that	O	-1	10526274
single	O	-1	10526274
agent	O	-1	10526274
therapy	O	-1	10526274
with	O	-1	10526274
v@@	B-Chemical	C030852	10526274
ino@@	I-Chemical	-1	10526274
rel@@	I-Chemical	-1	10526274
b@@	I-Chemical	-1	10526274
ine	I-Chemical	-1	10526274
(	O	-1	10526274
V@@	B-Chemical	C030852	10526274
N@@	I-Chemical	-1	10526274
B	I-Chemical	-1	10526274
)	O	-1	10526274
or	O	-1	10526274
g@@	B-Chemical	C056507	10526274
em@@	I-Chemical	-1	10526274
cit@@	I-Chemical	-1	10526274
ab@@	I-Chemical	-1	10526274
ine	I-Chemical	-1	10526274
(	O	-1	10526274
G@@	B-Chemical	C056507	10526274
E@@	I-Chemical	-1	10526274
M	I-Chemical	-1	10526274
)	O	-1	10526274
may	O	-1	10526274
obt@@	O	-1	10526274
ain	O	-1	10526274
a	O	-1	10526274
response	O	-1	10526274
rate	O	-1	10526274
of	O	-1	10526274
20@@	O	-1	10526274
-@@	O	-1	10526274
3@@	O	-1	10526274
0%	O	-1	10526274
in	O	-1	10526274
el@@	O	-1	10526274
der@@	O	-1	10526274
ly	O	-1	10526274
patients,	O	-1	10526274
with	O	-1	10526274
ac@@	O	-1	10526274
ce@@	O	-1	10526274
pt@@	O	-1	10526274
able	O	-1	10526274
toxicity	B-Disease	D064420	10526274
and	O	-1	10526274
impro@@	O	-1	10526274
vement	O	-1	10526274
in	O	-1	10526274
symptoms	O	-1	10526274
and	O	-1	10526274
qu@@	O	-1	10526274
ality	O	-1	10526274
of	O	-1	10526274
lif@@	O	-1	10526274
e.	O	-1	10526274
In	O	-1	10526274
the	O	-1	10526274
current	O	-1	10526274
study	O	-1	10526274
the	O	-1	10526274
efficacy	O	-1	10526274
and	O	-1	10526274
toxicity	B-Disease	D064420	10526274
of	O	-1	10526274
the	O	-1	10526274
combination	O	-1	10526274
of	O	-1	10526274
G@@	B-Chemical	C056507	10526274
E@@	I-Chemical	-1	10526274
M	I-Chemical	-1	10526274
and	O	-1	10526274
V@@	B-Chemical	C030852	10526274
N@@	I-Chemical	-1	10526274
B	I-Chemical	-1	10526274
in	O	-1	10526274
el@@	O	-1	10526274
der@@	O	-1	10526274
ly	O	-1	10526274
patients	O	-1	10526274
with	O	-1	10526274
adv@@	O	-1	10526274
anced	O	-1	10526274
N@@	B-Disease	D002289	10526274
S@@	I-Disease	-1	10526274
CL@@	I-Disease	-1	10526274
C	I-Disease	-1	10526274
or	O	-1	10526274
those	O	-1	10526274
with	O	-1	10526274
some	O	-1	10526274
contra@@	O	-1	10526274
indic@@	O	-1	10526274
ation	O	-1	10526274
to	O	-1	10526274
receiving	O	-1	10526274
cisplatin	B-Chemical	D002945	10526274
were	O	-1	10526274
ass@@	O	-1	10526274
es@@	O	-1	10526274
sed.	O	-1	10526274
METHODS:	O	-1	10526274
F@@	O	-1	10526274
or@@	O	-1	10526274
ty-@@	O	-1	10526274
n@@	O	-1	10526274
ine	O	-1	10526274
patients	O	-1	10526274
with	O	-1	10526274
adv@@	O	-1	10526274
anced	O	-1	10526274
N@@	B-Disease	D002289	10526274
S@@	I-Disease	-1	10526274
CL@@	I-Disease	-1	10526274
C	I-Disease	-1	10526274
were	O	-1	10526274
inc@@	O	-1	10526274
lu@@	O	-1	10526274
de@@	O	-1	10526274
d,	O	-1	10526274
3@@	O	-1	10526274
8	O	-1	10526274
of	O	-1	10526274
whom	O	-1	10526274
were	O	-1	10526274
age	O	-1	10526274
>@@	O	-1	10526274
/@@	O	-1	10526274
=	O	-1	10526274
7@@	O	-1	10526274
0	O	-1	10526274
years	O	-1	10526274
and	O	-1	10526274
11	O	-1	10526274
were	O	-1	10526274
age	O	-1	10526274
<	O	-1	10526274
7@@	O	-1	10526274
0	O	-1	10526274
years	O	-1	10526274
but	O	-1	10526274
who	O	-1	10526274
had	O	-1	10526274
some	O	-1	10526274
contra@@	O	-1	10526274
indic@@	O	-1	10526274
ation	O	-1	10526274
to	O	-1	10526274
receiving	O	-1	10526274
cisplatin	B-Chemical	D002945	10526274
.	O	-1	10526274
All	O	-1	10526274
patients	O	-1	10526274
were	O	-1	10526274
evalu@@	O	-1	10526274
able	O	-1	10526274
for	O	-1	10526274
response	O	-1	10526274
and	O	-1	10526274
toxicity	B-Disease	D064420	10526274
.	O	-1	10526274
Treat@@	O	-1	10526274
ment	O	-1	10526274
was	O	-1	10526274
comp@@	O	-1	10526274
ris@@	O	-1	10526274
ed	O	-1	10526274
of	O	-1	10526274
V@@	B-Chemical	C030852	10526274
N@@	I-Chemical	-1	10526274
B	I-Chemical	-1	10526274
,	O	-1	10526274
25	O	-1	10526274
mg/m@@	O	-1	10526274
(2@@	O	-1	10526274
),	O	-1	10526274
plus	O	-1	10526274
G@@	B-Chemical	C056507	10526274
E@@	I-Chemical	-1	10526274
M	I-Chemical	-1	10526274
,	O	-1	10526274
10@@	O	-1	10526274
00	O	-1	10526274
mg/m@@	O	-1	10526274
(2@@	O	-1	10526274
),	O	-1	10526274
both	O	-1	10526274
on	O	-1	10526274
D@@	O	-1	10526274
ays	O	-1	10526274
1,	O	-1	10526274
8@@	O	-1	10526274
,	O	-1	10526274
and	O	-1	10526274
15	O	-1	10526274
every	O	-1	10526274
2@@	O	-1	10526274
8	O	-1	10526274
days.	O	-1	10526274
Patients	O	-1	10526274
received	O	-1	10526274
a	O	-1	10526274
minim@@	O	-1	10526274
um	O	-1	10526274
of	O	-1	10526274
three	O	-1	10526274
cour@@	O	-1	10526274
ses	O	-1	10526274
un@@	O	-1	10526274
less	O	-1	10526274
progressive	O	-1	10526274
disease	O	-1	10526274
was	O	-1	10526274
det@@	O	-1	10526274
ect@@	O	-1	10526274
ed.	O	-1	10526274
RESULTS:	O	-1	10526274
One	O	-1	10526274
h@@	O	-1	10526274
und@@	O	-1	10526274
red	O	-1	10526274
si@@	O	-1	10526274
x@@	O	-1	10526274
ty-@@	O	-1	10526274
five	O	-1	10526274
cour@@	O	-1	10526274
ses	O	-1	10526274
were	O	-1	10526274
administ@@	O	-1	10526274
e@@	O	-1	10526274
re@@	O	-1	10526274
d,	O	-1	10526274
with	O	-1	10526274
a	O	-1	10526274
median	O	-1	10526274
of	O	-1	10526274
3@@	O	-1	10526274
.	O	-1	10526274
6	O	-1	10526274
cour@@	O	-1	10526274
ses	O	-1	10526274
per	O	-1	10526274
patient@@	O	-1	10526274
.	O	-1	10526274
The	O	-1	10526274
over@@	O	-1	10526274
all	O	-1	10526274
response	O	-1	10526274
rate	O	-1	10526274
was	O	-1	10526274
2@@	O	-1	10526274
6%	O	-1	10526274
(@@	O	-1	10526274
95%	O	-1	10526274
conf@@	O	-1	10526274
idence	O	-1	10526274
inter@@	O	-1	10526274
val@@	O	-1	10526274
,	O	-1	10526274
1@@	O	-1	10526274
5-@@	O	-1	10526274
4@@	O	-1	10526274
1@@	O	-1	10526274
%).	O	-1	10526274
Two	O	-1	10526274
patients	O	-1	10526274
at@@	O	-1	10526274
t@@	O	-1	10526274
ained	O	-1	10526274
a	O	-1	10526274
complete	O	-1	10526274
response	O	-1	10526274
(4@@	O	-1	10526274
%)	O	-1	10526274
and	O	-1	10526274
11	O	-1	10526274
patients	O	-1	10526274
(2@@	O	-1	10526274
2@@	O	-1	10526274
%)	O	-1	10526274
achi@@	O	-1	10526274
ev@@	O	-1	10526274
ed	O	-1	10526274
a	O	-1	10526274
partial	O	-1	10526274
respon@@	O	-1	10526274
se.	O	-1	10526274
E@@	O	-1	10526274
ast@@	O	-1	10526274
er@@	O	-1	10526274
n	O	-1	10526274
C@@	O	-1	10526274
o@@	O	-1	10526274
o@@	O	-1	10526274
perative	O	-1	10526274
On@@	O	-1	10526274
co@@	O	-1	10526274
log@@	O	-1	10526274
y	O	-1	10526274
Group	O	-1	10526274
perform@@	O	-1	10526274
ance	O	-1	10526274
status	O	-1	10526274
improved	O	-1	10526274
in	O	-1	10526274
3@@	O	-1	10526274
5%	O	-1	10526274
of	O	-1	10526274
those	O	-1	10526274
patients	O	-1	10526274
with	O	-1	10526274
an	O	-1	10526274
initial	O	-1	10526274
valu@@	O	-1	10526274
e	O	-1	10526274
>	O	-1	10526274
0@@	O	-1	10526274
,	O	-1	10526274
whereas	O	-1	10526274
re@@	O	-1	10526274
li@@	O	-1	10526274
e@@	O	-1	10526274
f	O	-1	10526274
of	O	-1	10526274
at	O	-1	10526274
le@@	O	-1	10526274
ast	O	-1	10526274
1	O	-1	10526274
sympto@@	O	-1	10526274
m	O	-1	10526274
without	O	-1	10526274
wor@@	O	-1	10526274
sen@@	O	-1	10526274
ing	O	-1	10526274
of	O	-1	10526274
other	O	-1	10526274
symptoms	O	-1	10526274
was	O	-1	10526274
not@@	O	-1	10526274
ed	O	-1	10526274
in	O	-1	10526274
2@@	O	-1	10526274
7	O	-1	10526274
patients	O	-1	10526274
(5@@	O	-1	10526274
5@@	O	-1	10526274
%).	O	-1	10526274
The	O	-1	10526274
median	O	-1	10526274
time	O	-1	10526274
to	O	-1	10526274
progres@@	O	-1	10526274
sion	O	-1	10526274
was	O	-1	10526274
16	O	-1	10526274
weeks	O	-1	10526274
and	O	-1	10526274
the	O	-1	10526274
1-@@	O	-1	10526274
year	O	-1	10526274
sur@@	O	-1	10526274
viv@@	O	-1	10526274
al	O	-1	10526274
rate	O	-1	10526274
was	O	-1	10526274
3@@	O	-1	10526274
3@@	O	-1	10526274
%.	O	-1	10526274
T@@	B-Disease	D064420	10526274
oxic@@	I-Disease	-1	10526274
ity	I-Disease	-1	10526274
was	O	-1	10526274
mil@@	O	-1	10526274
d.	O	-1	10526274
Si@@	O	-1	10526274
x	O	-1	10526274
patients	O	-1	10526274
(1@@	O	-1	10526274
2@@	O	-1	10526274
%)	O	-1	10526274
had	O	-1	10526274
W@@	O	-1	10526274
or@@	O	-1	10526274
l@@	O	-1	10526274
d	O	-1	10526274
He@@	O	-1	10526274
al@@	O	-1	10526274
th	O	-1	10526274
O@@	O	-1	10526274
r@@	O	-1	10526274
g@@	O	-1	10526274
an@@	O	-1	10526274
ization	O	-1	10526274
G@@	O	-1	10526274
ra@@	O	-1	10526274
de	O	-1	10526274
3-@@	O	-1	10526274
4	O	-1	10526274
ne@@	B-Disease	D009503	10526274
ut@@	I-Disease	-1	10526274
ro@@	I-Disease	-1	10526274
pen@@	I-Disease	-1	10526274
ia	I-Disease	-1	10526274
,	O	-1	10526274
2	O	-1	10526274
patients	O	-1	10526274
(4@@	O	-1	10526274
%)	O	-1	10526274
had	O	-1	10526274
G@@	O	-1	10526274
ra@@	O	-1	10526274
de	O	-1	10526274
3-@@	O	-1	10526274
4	O	-1	10526274
throm@@	B-Disease	D013921	10526274
b@@	I-Disease	-1	10526274
ocyto@@	I-Disease	-1	10526274
pen@@	I-Disease	-1	10526274
ia	I-Disease	-1	10526274
,	O	-1	10526274
and	O	-1	10526274
2	O	-1	10526274
patients	O	-1	10526274
(4@@	O	-1	10526274
%)	O	-1	10526274
had	O	-1	10526274
G@@	O	-1	10526274
ra@@	O	-1	10526274
de	O	-1	10526274
3	O	-1	10526274
neuro@@	B-Disease	D020258	10526274
toxicity	I-Disease	-1	10526274
.	O	-1	10526274
Th@@	O	-1	10526274
ree	O	-1	10526274
patients	O	-1	10526274
with	O	-1	10526274
severe	O	-1	10526274
ne@@	B-Disease	D009503	10526274
ut@@	I-Disease	-1	10526274
ro@@	I-Disease	-1	10526274
pen@@	I-Disease	-1	10526274
ia	I-Disease	-1	10526274
(6@@	O	-1	10526274
%)	O	-1	10526274
di@@	O	-1	10526274
ed	O	-1	10526274
of	O	-1	10526274
se@@	B-Disease	D018805	10526274
p@@	I-Disease	-1	10526274
sis	I-Disease	-1	10526274
.	O	-1	10526274
The	O	-1	10526274
median	O	-1	10526274
age	O	-1	10526274
of	O	-1	10526274
those	O	-1	10526274
patients	O	-1	10526274
develop@@	O	-1	10526274
ing	O	-1	10526274
G@@	O	-1	10526274
ra@@	O	-1	10526274
de	O	-1	10526274
3-@@	O	-1	10526274
4	O	-1	10526274
ne@@	B-Disease	D009503	10526274
ut@@	I-Disease	-1	10526274
ro@@	I-Disease	-1	10526274
pen@@	I-Disease	-1	10526274
ia	I-Disease	-1	10526274
was	O	-1	10526274
significantly	O	-1	10526274
higher	O	-1	10526274
than	O	-1	10526274
that	O	-1	10526274
of	O	-1	10526274
the	O	-1	10526274
remain@@	O	-1	10526274
ing	O	-1	10526274
patients	O	-1	10526274
(@@	O	-1	10526274
7@@	O	-1	10526274
5	O	-1	10526274
years	O	-1	10526274
vs.	O	-1	10526274
7@@	O	-1	10526274
2	O	-1	10526274
year@@	O	-1	10526274
s;	O	-1	10526274
P	O	-1	10526274
=	O	-1	10526274
0.0@@	O	-1	10526274
4@@	O	-1	10526274
7@@	O	-1	10526274
).	O	-1	10526274
CONCLUSIONS:	O	-1	10526274
The	O	-1	10526274
combination	O	-1	10526274
of	O	-1	10526274
G@@	B-Chemical	C056507	10526274
E@@	I-Chemical	-1	10526274
M	I-Chemical	-1	10526274
and	O	-1	10526274
V@@	B-Chemical	C030852	10526274
N@@	I-Chemical	-1	10526274
B	I-Chemical	-1	10526274
is	O	-1	10526274
moder@@	O	-1	10526274
ately	O	-1	10526274
active	O	-1	10526274
and	O	-1	10526274
well	O	-1	10526274
toler@@	O	-1	10526274
ated	O	-1	10526274
ex@@	O	-1	10526274
cep@@	O	-1	10526274
t	O	-1	10526274
in	O	-1	10526274
patients	O	-1	10526274
age	O	-1	10526274
>@@	O	-1	10526274
/@@	O	-1	10526274
=	O	-1	10526274
7@@	O	-1	10526274
5	O	-1	10526274
year@@	O	-1	10526274
s.	O	-1	10526274
This	O	-1	10526274
age	O	-1	10526274
group	O	-1	10526274
had	O	-1	10526274
an	O	-1	10526274
increased	O	-1	10526274
risk	O	-1	10526274
of	O	-1	10526274
my@@	B-Disease	D001855	10526274
e@@	I-Disease	-1	10526274
lo@@	I-Disease	-1	10526274
sup@@	I-Disease	-1	10526274
pression	I-Disease	-1	10526274
.	O	-1	10526274
The@@	O	-1	10526274
re@@	O	-1	10526274
fore	O	-1	10526274
the	O	-1	10526274
pro@@	O	-1	10526274
phyl@@	O	-1	10526274
ac@@	O	-1	10526274
tic	O	-1	10526274
use	O	-1	10526274
of	O	-1	10526274
gran@@	O	-1	10526274
ulo@@	O	-1	10526274
cy@@	O	-1	10526274
te@@	O	-1	10526274
-@@	O	-1	10526274
co@@	O	-1	10526274
lon@@	O	-1	10526274
y	O	-1	10526274
stimul@@	O	-1	10526274
ating	O	-1	10526274
factor	O	-1	10526274
should	O	-1	10526274
be	O	-1	10526274
considered	O	-1	10526274
with	O	-1	10526274
this	O	-1	10526274
treatment.	O	-1	10526274
Ne@@	O	-1	10526274
w	O	-1	10526274
chemotherapy	O	-1	10526274
combin@@	O	-1	10526274
ations	O	-1	10526274
with	O	-1	10526274
higher	O	-1	10526274
activity	O	-1	10526274
and	O	-1	10526274
lower	O	-1	10526274
toxicity	B-Disease	D064420	10526274
are	O	-1	10526274
ne@@	O	-1	10526274
ed@@	O	-1	10526274
ed	O	-1	10526274
for	O	-1	10526274
el@@	O	-1	10526274
der@@	O	-1	10526274
ly	O	-1	10526274
patients	O	-1	10526274
with	O	-1	10526274
adv@@	O	-1	10526274
anced	O	-1	10526274
N@@	B-Disease	D002289	10526274
S@@	I-Disease	-1	10526274
CL@@	I-Disease	-1	10526274
C	I-Disease	-1	10526274
.	O	-1	10526274

W@@	B-Chemical	D014859	10669626
ar@@	I-Chemical	-1	10669626
farin	I-Chemical	-1	10669626
-induced	O	-1	10669626
artery	B-Disease	D061205	10669626
calcification	I-Disease	-1	10669626
is	O	-1	10669626
ac@@	O	-1	10669626
ce@@	O	-1	10669626
l@@	O	-1	10669626
er@@	O	-1	10669626
ated	O	-1	10669626
by	O	-1	10669626
growth	O	-1	10669626
and	O	-1	10669626
vitamin	B-Chemical	D014807	10669626
D	I-Chemical	-1	10669626
.	O	-1	10669626
The	O	-1	10669626
present	O	-1	10669626
studies	O	-1	10669626
demon@@	O	-1	10669626
st@@	O	-1	10669626
rate	O	-1	10669626
that	O	-1	10669626
growth	O	-1	10669626
and	O	-1	10669626
vitamin	B-Chemical	D014807	10669626
D	I-Chemical	-1	10669626
treatment	O	-1	10669626
enh@@	O	-1	10669626
ance	O	-1	10669626
the	O	-1	10669626
ext@@	O	-1	10669626
ent	O	-1	10669626
of	O	-1	10669626
artery	B-Disease	D061205	10669626
calcification	I-Disease	-1	10669626
in	O	-1	10669626
rats	O	-1	10669626
given	O	-1	10669626
suffici@@	O	-1	10669626
ent	O	-1	10669626
doses	O	-1	10669626
of	O	-1	10669626
W@@	B-Chemical	D014859	10669626
ar@@	I-Chemical	-1	10669626
farin	I-Chemical	-1	10669626
to	O	-1	10669626
inhib@@	O	-1	10669626
it	O	-1	10669626
gamma@@	O	-1	10669626
-@@	O	-1	10669626
carb@@	O	-1	10669626
ox@@	O	-1	10669626
yl@@	O	-1	10669626
ation	O	-1	10669626
of	O	-1	10669626
mat@@	O	-1	10669626
ri@@	O	-1	10669626
x	O	-1	10669626
G@@	O	-1	10669626
l@@	O	-1	10669626
a	O	-1	10669626
protein@@	O	-1	10669626
,	O	-1	10669626
a	O	-1	10669626
calcification	B-Disease	D002114	10669626
inhibitor	O	-1	10669626
known	O	-1	10669626
to	O	-1	10669626
be	O	-1	10669626
ex@@	O	-1	10669626
press@@	O	-1	10669626
ed	O	-1	10669626
by	O	-1	10669626
smo@@	O	-1	10669626
oth	O	-1	10669626
musc@@	O	-1	10669626
le	O	-1	10669626
cells	O	-1	10669626
and	O	-1	10669626
mac@@	O	-1	10669626
ro@@	O	-1	10669626
ph@@	O	-1	10669626
ages	O	-1	10669626
in	O	-1	10669626
the	O	-1	10669626
artery	O	-1	10669626
w@@	O	-1	10669626
all@@	O	-1	10669626
.	O	-1	10669626
The	O	-1	10669626
first	O	-1	10669626
seri@@	O	-1	10669626
es	O	-1	10669626
of	O	-1	10669626
experim@@	O	-1	10669626
ents	O	-1	10669626
examined	O	-1	10669626
the	O	-1	10669626
influence	O	-1	10669626
of	O	-1	10669626
age	O	-1	10669626
and	O	-1	10669626
growth	O	-1	10669626
status	O	-1	10669626
on	O	-1	10669626
artery	B-Disease	D061205	10669626
calcification	I-Disease	-1	10669626
in	O	-1	10669626
W@@	B-Chemical	D014859	10669626
ar@@	I-Chemical	-1	10669626
farin	I-Chemical	-1	10669626
-treated	O	-1	10669626
rats.	O	-1	10669626
Treat@@	O	-1	10669626
ment	O	-1	10669626
for	O	-1	10669626
2	O	-1	10669626
weeks	O	-1	10669626
with	O	-1	10669626
W@@	B-Chemical	D014859	10669626
ar@@	I-Chemical	-1	10669626
farin	I-Chemical	-1	10669626
caused	O	-1	10669626
mas@@	O	-1	10669626
sive	O	-1	10669626
foc@@	O	-1	10669626
al	O	-1	10669626
calcification	B-Disease	D061205	10669626
of	I-Disease	-1	10669626
the	I-Disease	-1	10669626
artery	I-Disease	-1	10669626
medi@@	O	-1	10669626
a	O	-1	10669626
in	O	-1	10669626
20@@	O	-1	10669626
-@@	O	-1	10669626
day@@	O	-1	10669626
-old	O	-1	10669626
rats	O	-1	10669626
and	O	-1	10669626
less	O	-1	10669626
exten@@	O	-1	10669626
sive	O	-1	10669626
foc@@	O	-1	10669626
al	O	-1	10669626
calcification	B-Disease	D002114	10669626
in	O	-1	10669626
4@@	O	-1	10669626
2-@@	O	-1	10669626
day@@	O	-1	10669626
-old	O	-1	10669626
rats.	O	-1	10669626
In	O	-1	10669626
contrast@@	O	-1	10669626
,	O	-1	10669626
no	O	-1	10669626
artery	B-Disease	D061205	10669626
calcification	I-Disease	-1	10669626
could	O	-1	10669626
be	O	-1	10669626
det@@	O	-1	10669626
ected	O	-1	10669626
in	O	-1	10669626
10-@@	O	-1	10669626
month@@	O	-1	10669626
-old	O	-1	10669626
ad@@	O	-1	10669626
ult	O	-1	10669626
rats	O	-1	10669626
even	O	-1	10669626
after	O	-1	10669626
4	O	-1	10669626
weeks	O	-1	10669626
of	O	-1	10669626
W@@	B-Chemical	D014859	10669626
ar@@	I-Chemical	-1	10669626
farin	I-Chemical	-1	10669626
treatment.	O	-1	10669626
To	O	-1	10669626
direc@@	O	-1	10669626
tly	O	-1	10669626
ex@@	O	-1	10669626
amine	O	-1	10669626
the	O	-1	10669626
import@@	O	-1	10669626
ance	O	-1	10669626
of	O	-1	10669626
growth	O	-1	10669626
to	O	-1	10669626
W@@	B-Chemical	D014859	10669626
ar@@	I-Chemical	-1	10669626
farin	I-Chemical	-1	10669626
-induced	O	-1	10669626
artery	B-Disease	D061205	10669626
calcification	I-Disease	-1	10669626
in	O	-1	10669626
animals	O	-1	10669626
of	O	-1	10669626
the	O	-1	10669626
same	O	-1	10669626
age,	O	-1	10669626
20@@	O	-1	10669626
-@@	O	-1	10669626
day@@	O	-1	10669626
-old	O	-1	10669626
rats	O	-1	10669626
were	O	-1	10669626
f@@	O	-1	10669626
ed	O	-1	10669626
for	O	-1	10669626
2	O	-1	10669626
weeks	O	-1	10669626
either	O	-1	10669626
an	O	-1	10669626
ad	O	-1	10669626
li@@	O	-1	10669626
b@@	O	-1	10669626
it@@	O	-1	10669626
um	O	-1	10669626
diet	O	-1	10669626
or	O	-1	10669626
a	O	-1	10669626
6-@@	O	-1	10669626
g/@@	O	-1	10669626
d	O	-1	10669626
re@@	O	-1	10669626
stric@@	O	-1	10669626
ted	O	-1	10669626
diet	O	-1	10669626
that	O	-1	10669626
maint@@	O	-1	10669626
ain@@	O	-1	10669626
s	O	-1	10669626
weight	O	-1	10669626
but	O	-1	10669626
prev@@	O	-1	10669626
ents	O	-1	10669626
grow@@	O	-1	10669626
th@@	O	-1	10669626
.	O	-1	10669626
Con@@	O	-1	10669626
current	O	-1	10669626
treatment	O	-1	10669626
of	O	-1	10669626
both	O	-1	10669626
di@@	O	-1	10669626
et@@	O	-1	10669626
ary	O	-1	10669626
groups	O	-1	10669626
with	O	-1	10669626
W@@	B-Chemical	D014859	10669626
ar@@	I-Chemical	-1	10669626
farin	I-Chemical	-1	10669626
produced	O	-1	10669626
mas@@	O	-1	10669626
sive	O	-1	10669626
foc@@	O	-1	10669626
al	O	-1	10669626
calcification	B-Disease	D061205	10669626
of	I-Disease	-1	10669626
the	I-Disease	-1	10669626
artery	I-Disease	-1	10669626
medi@@	O	-1	10669626
a	O	-1	10669626
in	O	-1	10669626
the	O	-1	10669626
ad	O	-1	10669626
li@@	O	-1	10669626
b@@	O	-1	10669626
it@@	O	-1	10669626
um@@	O	-1	10669626
-@@	O	-1	10669626
f@@	O	-1	10669626
ed	O	-1	10669626
rats	O	-1	10669626
but	O	-1	10669626
no	O	-1	10669626
det@@	O	-1	10669626
ect@@	O	-1	10669626
able	O	-1	10669626
artery	B-Disease	D061205	10669626
calcification	I-Disease	-1	10669626
in	O	-1	10669626
the	O	-1	10669626
re@@	O	-1	10669626
stric@@	O	-1	10669626
te@@	O	-1	10669626
d-@@	O	-1	10669626
di@@	O	-1	10669626
et@@	O	-1	10669626
,	O	-1	10669626
grow@@	O	-1	10669626
th@@	O	-1	10669626
-@@	O	-1	10669626
inhibited	O	-1	10669626
group.	O	-1	10669626
Although	O	-1	10669626
the	O	-1	10669626
expl@@	O	-1	10669626
an@@	O	-1	10669626
ation	O	-1	10669626
for	O	-1	10669626
the	O	-1	10669626
association	O	-1	10669626
between	O	-1	10669626
artery	B-Disease	D061205	10669626
calcification	I-Disease	-1	10669626
and	O	-1	10669626
growth	O	-1	10669626
status	O	-1	10669626
can@@	O	-1	10669626
not	O	-1	10669626
be	O	-1	10669626
determined	O	-1	10669626
from	O	-1	10669626
the	O	-1	10669626
present	O	-1	10669626
study,	O	-1	10669626
there	O	-1	10669626
was	O	-1	10669626
a	O	-1	10669626
rel@@	O	-1	10669626
ationship	O	-1	10669626
between	O	-1	10669626
higher	O	-1	10669626
serum	O	-1	10669626
phosph@@	B-Chemical	D010710	10669626
ate	I-Chemical	-1	10669626
and	O	-1	10669626
sus@@	O	-1	10669626
cep@@	O	-1	10669626
ti@@	O	-1	10669626
b@@	O	-1	10669626
ility	O	-1	10669626
to	O	-1	10669626
artery	B-Disease	D061205	10669626
calcification	I-Disease	-1	10669626
,	O	-1	10669626
with	O	-1	10669626
3@@	O	-1	10669626
0%	O	-1	10669626
higher	O	-1	10669626
levels	O	-1	10669626
of	O	-1	10669626
serum	O	-1	10669626
phosph@@	B-Chemical	D010710	10669626
ate	I-Chemical	-1	10669626
in	O	-1	10669626
youn@@	O	-1	10669626
g@@	O	-1	10669626
,	O	-1	10669626
ad	O	-1	10669626
li@@	O	-1	10669626
b@@	O	-1	10669626
it@@	O	-1	10669626
um@@	O	-1	10669626
-@@	O	-1	10669626
f@@	O	-1	10669626
ed	O	-1	10669626
rats	O	-1	10669626
compared	O	-1	10669626
with	O	-1	10669626
either	O	-1	10669626
of	O	-1	10669626
the	O	-1	10669626
groups	O	-1	10669626
that	O	-1	10669626
was	O	-1	10669626
resist@@	O	-1	10669626
ant	O	-1	10669626
to	O	-1	10669626
W@@	B-Chemical	D014859	10669626
ar@@	I-Chemical	-1	10669626
farin	I-Chemical	-1	10669626
-induced	O	-1	10669626
artery	B-Disease	D061205	10669626
calcification	I-Disease	-1	10669626
,	O	-1	10669626
i@@	O	-1	10669626
e,	O	-1	10669626
the	O	-1	10669626
10-@@	O	-1	10669626
month@@	O	-1	10669626
-old	O	-1	10669626
rats	O	-1	10669626
and	O	-1	10669626
the	O	-1	10669626
re@@	O	-1	10669626
stric@@	O	-1	10669626
te@@	O	-1	10669626
d-@@	O	-1	10669626
di@@	O	-1	10669626
et@@	O	-1	10669626
,	O	-1	10669626
grow@@	O	-1	10669626
th@@	O	-1	10669626
-@@	O	-1	10669626
inhibited	O	-1	10669626
youn@@	O	-1	10669626
g	O	-1	10669626
rats.	O	-1	10669626
This	O	-1	10669626
observ@@	O	-1	10669626
ation	O	-1	10669626
suggests	O	-1	10669626
that	O	-1	10669626
increased	O	-1	10669626
sus@@	O	-1	10669626
cep@@	O	-1	10669626
ti@@	O	-1	10669626
b@@	O	-1	10669626
ility	O	-1	10669626
to	O	-1	10669626
W@@	B-Chemical	D014859	10669626
ar@@	I-Chemical	-1	10669626
farin	I-Chemical	-1	10669626
-induced	O	-1	10669626
artery	B-Disease	D061205	10669626
calcification	I-Disease	-1	10669626
could	O	-1	10669626
be	O	-1	10669626
related	O	-1	10669626
to	O	-1	10669626
higher	O	-1	10669626
serum	O	-1	10669626
phosph@@	B-Chemical	D010710	10669626
ate	I-Chemical	-1	10669626
level@@	O	-1	10669626
s.	O	-1	10669626
The	O	-1	10669626
second	O	-1	10669626
set	O	-1	10669626
of	O	-1	10669626
experim@@	O	-1	10669626
ents	O	-1	10669626
examined	O	-1	10669626
the	O	-1	10669626
possible	O	-1	10669626
syn@@	O	-1	10669626
erg@@	O	-1	10669626
y	O	-1	10669626
between	O	-1	10669626
vitamin	B-Chemical	D014807	10669626
D	I-Chemical	-1	10669626
and	O	-1	10669626
W@@	B-Chemical	D014859	10669626
ar@@	I-Chemical	-1	10669626
farin	I-Chemical	-1	10669626
in	O	-1	10669626
artery	B-Disease	D061205	10669626
calcification	I-Disease	-1	10669626
.	O	-1	10669626
H@@	O	-1	10669626
i@@	O	-1	10669626
gh	O	-1	10669626
doses	O	-1	10669626
of	O	-1	10669626
vitamin	B-Chemical	D014807	10669626
D	I-Chemical	-1	10669626
are	O	-1	10669626
known	O	-1	10669626
to	O	-1	10669626
cause	O	-1	10669626
calcification	B-Disease	D061205	10669626
of	I-Disease	-1	10669626
the	I-Disease	-1	10669626
artery	I-Disease	-1	10669626
medi@@	O	-1	10669626
a	O	-1	10669626
in	O	-1	10669626
as	O	-1	10669626
lit@@	O	-1	10669626
t@@	O	-1	10669626
le	O	-1	10669626
as	O	-1	10669626
3	O	-1	10669626
to	O	-1	10669626
4	O	-1	10669626
days.	O	-1	10669626
H@@	O	-1	10669626
i@@	O	-1	10669626
gh	O	-1	10669626
doses	O	-1	10669626
of	O	-1	10669626
the	O	-1	10669626
vitamin	B-Chemical	D014812	10669626
K	I-Chemical	-1	10669626
antagonist	O	-1	10669626
W@@	B-Chemical	D014859	10669626
ar@@	I-Chemical	-1	10669626
farin	I-Chemical	-1	10669626
are	O	-1	10669626
also	O	-1	10669626
known	O	-1	10669626
to	O	-1	10669626
cause	O	-1	10669626
calcification	B-Disease	D061205	10669626
of	I-Disease	-1	10669626
the	I-Disease	-1	10669626
artery	I-Disease	-1	10669626
medi@@	O	-1	10669626
a,	O	-1	10669626
but	O	-1	10669626
at	O	-1	10669626
treatment	O	-1	10669626
times	O	-1	10669626
of	O	-1	10669626
2	O	-1	10669626
weeks	O	-1	10669626
or	O	-1	10669626
long@@	O	-1	10669626
er	O	-1	10669626
y@@	O	-1	10669626
et	O	-1	10669626
not	O	-1	10669626
at	O	-1	10669626
1	O	-1	10669626
week@@	O	-1	10669626
.	O	-1	10669626
In	O	-1	10669626
the	O	-1	10669626
current	O	-1	10669626
study,	O	-1	10669626
we	O	-1	10669626
investigated	O	-1	10669626
the	O	-1	10669626
syn@@	O	-1	10669626
erg@@	O	-1	10669626
y	O	-1	10669626
between	O	-1	10669626
these	O	-1	10669626
2	O	-1	10669626
treat@@	O	-1	10669626
ments	O	-1	10669626
and	O	-1	10669626
found	O	-1	10669626
that	O	-1	10669626
con@@	O	-1	10669626
current	O	-1	10669626
W@@	B-Chemical	D014859	10669626
ar@@	I-Chemical	-1	10669626
farin	I-Chemical	-1	10669626
administration	O	-1	10669626
d@@	O	-1	10669626
ram@@	O	-1	10669626
ati@@	O	-1	10669626
c@@	O	-1	10669626
ally	O	-1	10669626
increased	O	-1	10669626
the	O	-1	10669626
ext@@	O	-1	10669626
ent	O	-1	10669626
of	O	-1	10669626
calcification	B-Disease	D002114	10669626
in	O	-1	10669626
the	O	-1	10669626
medi@@	O	-1	10669626
a	O	-1	10669626
of	O	-1	10669626
vitamin	B-Chemical	D014807	10669626
D	I-Chemical	-1	10669626
-treated	O	-1	10669626
rats	O	-1	10669626
at	O	-1	10669626
3	O	-1	10669626
and	O	-1	10669626
4	O	-1	10669626
days.	O	-1	10669626
There	O	-1	10669626
was	O	-1	10669626
a	O	-1	10669626
clo@@	O	-1	10669626
se	O	-1	10669626
par@@	O	-1	10669626
al@@	O	-1	10669626
le@@	O	-1	10669626
l	O	-1	10669626
between	O	-1	10669626
the	O	-1	10669626
effect	O	-1	10669626
of	O	-1	10669626
vitamin	B-Chemical	D014807	10669626
D	I-Chemical	-1	10669626
dose	O	-1	10669626
on	O	-1	10669626
artery	B-Disease	D061205	10669626
calcification	I-Disease	-1	10669626
and	O	-1	10669626
the	O	-1	10669626
effect	O	-1	10669626
of	O	-1	10669626
vitamin	B-Chemical	D014807	10669626
D	I-Chemical	-1	10669626
dose	O	-1	10669626
on	O	-1	10669626
the	O	-1	10669626
elev@@	O	-1	10669626
ation	O	-1	10669626
of	O	-1	10669626
serum	O	-1	10669626
calcium	B-Chemical	D002118	10669626
,	O	-1	10669626
which	O	-1	10669626
suggests	O	-1	10669626
that	O	-1	10669626
vitamin	B-Chemical	D014807	10669626
D	I-Chemical	-1	10669626
may	O	-1	10669626
induce	O	-1	10669626
artery	B-Disease	D061205	10669626
calcification	I-Disease	-1	10669626
through	O	-1	10669626
its	O	-1	10669626
effect	O	-1	10669626
on	O	-1	10669626
serum	O	-1	10669626
calcium	B-Chemical	D002118	10669626
.	O	-1	10669626
B@@	O	-1	10669626
ecause	O	-1	10669626
W@@	B-Chemical	D014859	10669626
ar@@	I-Chemical	-1	10669626
farin	I-Chemical	-1	10669626
treatment	O	-1	10669626
had	O	-1	10669626
no	O	-1	10669626
effect	O	-1	10669626
on	O	-1	10669626
the	O	-1	10669626
elev@@	O	-1	10669626
ation	O	-1	10669626
in	O	-1	10669626
serum	O	-1	10669626
calcium	B-Chemical	D002118	10669626
produced	O	-1	10669626
by	O	-1	10669626
vitamin	B-Chemical	D014807	10669626
D	I-Chemical	-1	10669626
,	O	-1	10669626
the	O	-1	10669626
syn@@	O	-1	10669626
erg@@	O	-1	10669626
y	O	-1	10669626
between	O	-1	10669626
W@@	B-Chemical	D014859	10669626
ar@@	I-Chemical	-1	10669626
farin	I-Chemical	-1	10669626
and	O	-1	10669626
vitamin	B-Chemical	D014807	10669626
D	I-Chemical	-1	10669626
is	O	-1	10669626
prob@@	O	-1	10669626
ably	O	-1	10669626
b@@	O	-1	10669626
est	O	-1	10669626
expl@@	O	-1	10669626
ained	O	-1	10669626
by	O	-1	10669626
the	O	-1	10669626
hypo@@	O	-1	10669626
thesis	O	-1	10669626
that	O	-1	10669626
W@@	B-Chemical	D014859	10669626
ar@@	I-Chemical	-1	10669626
farin	I-Chemical	-1	10669626
inhibit@@	O	-1	10669626
s	O	-1	10669626
the	O	-1	10669626
activity	O	-1	10669626
of	O	-1	10669626
mat@@	O	-1	10669626
ri@@	O	-1	10669626
x	O	-1	10669626
G@@	O	-1	10669626
l@@	O	-1	10669626
a	O	-1	10669626
protein	O	-1	10669626
as	O	-1	10669626
a	O	-1	10669626
calcification	B-Disease	D002114	10669626
inhibitor@@	O	-1	10669626
.	O	-1	10669626
H@@	O	-1	10669626
i@@	O	-1	10669626
gh	O	-1	10669626
levels	O	-1	10669626
of	O	-1	10669626
mat@@	O	-1	10669626
ri@@	O	-1	10669626
x	O	-1	10669626
G@@	O	-1	10669626
l@@	O	-1	10669626
a	O	-1	10669626
protein	O	-1	10669626
are	O	-1	10669626
found	O	-1	10669626
at	O	-1	10669626
sit@@	O	-1	10669626
es	O	-1	10669626
of	O	-1	10669626
artery	B-Disease	D061205	10669626
calcification	I-Disease	-1	10669626
in	O	-1	10669626
rats	O	-1	10669626
treated	O	-1	10669626
with	O	-1	10669626
vitamin	B-Chemical	D014807	10669626
D	I-Chemical	-1	10669626
plus	O	-1	10669626
W@@	B-Chemical	D014859	10669626
ar@@	I-Chemical	-1	10669626
farin	I-Chemical	-1	10669626
,	O	-1	10669626
and	O	-1	10669626
chemical	O	-1	10669626
analysis	O	-1	10669626
showed	O	-1	10669626
that	O	-1	10669626
the	O	-1	10669626
protein	O	-1	10669626
that	O	-1	10669626
accum@@	O	-1	10669626
ul@@	O	-1	10669626
ated	O	-1	10669626
was	O	-1	10669626
in@@	O	-1	10669626
de@@	O	-1	10669626
ed	O	-1	10669626
not	O	-1	10669626
gamma@@	B-Chemical	D015055	10669626
-@@	I-Chemical	-1	10669626
carb@@	I-Chemical	-1	10669626
ox@@	I-Chemical	-1	10669626
yl@@	I-Chemical	-1	10669626
ated	I-Chemical	-1	10669626
.	O	-1	10669626
These	O	-1	10669626
observ@@	O	-1	10669626
ations	O	-1	10669626
indicate	O	-1	10669626
that	O	-1	10669626
although	O	-1	10669626
the	O	-1	10669626
gamma@@	B-Chemical	D015055	10669626
-@@	I-Chemical	-1	10669626
carb@@	I-Chemical	-1	10669626
oxy@@	I-Chemical	-1	10669626
glutamate	I-Chemical	-1	10669626
re@@	O	-1	10669626
si@@	O	-1	10669626
du@@	O	-1	10669626
es	O	-1	10669626
of	O	-1	10669626
mat@@	O	-1	10669626
ri@@	O	-1	10669626
x	O	-1	10669626
G@@	O	-1	10669626
l@@	O	-1	10669626
a	O	-1	10669626
protein	O	-1	10669626
are	O	-1	10669626
appa@@	O	-1	10669626
ren@@	O	-1	10669626
tly	O	-1	10669626
requ@@	O	-1	10669626
ired	O	-1	10669626
for	O	-1	10669626
its	O	-1	10669626
function	O	-1	10669626
as	O	-1	10669626
a	O	-1	10669626
calcification	B-Disease	D002114	10669626
inhibitor@@	O	-1	10669626
,	O	-1	10669626
they	O	-1	10669626
are	O	-1	10669626
not	O	-1	10669626
requ@@	O	-1	10669626
ired	O	-1	10669626
for	O	-1	10669626
its	O	-1	10669626
accum@@	O	-1	10669626
ulation	O	-1	10669626
at	O	-1	10669626
calcification	B-Disease	D002114	10669626
sit@@	O	-1	10669626
es.	O	-1	10669626

An@@	B-Chemical	D000928	11379838
ti@@	I-Chemical	-1	11379838
depress@@	I-Chemical	-1	11379838
ant	I-Chemical	-1	11379838
-induced	O	-1	11379838
man@@	B-Disease	D001714	11379838
ia	I-Disease	-1	11379838
in	O	-1	11379838
b@@	B-Disease	D001714	11379838
ip@@	I-Disease	-1	11379838
ol@@	I-Disease	-1	11379838
ar	I-Disease	-1	11379838
patient@@	O	-1	11379838
s:	O	-1	11379838
identi@@	O	-1	11379838
fic@@	O	-1	11379838
ation	O	-1	11379838
of	O	-1	11379838
risk	O	-1	11379838
fact@@	O	-1	11379838
or@@	O	-1	11379838
s.	O	-1	11379838
BACKGROUND:	O	-1	11379838
Con@@	O	-1	11379838
cer@@	O	-1	11379838
n@@	O	-1	11379838
s	O	-1	11379838
about	O	-1	11379838
possible	O	-1	11379838
ris@@	O	-1	11379838
k@@	O	-1	11379838
s	O	-1	11379838
of	O	-1	11379838
switch@@	O	-1	11379838
ing	O	-1	11379838
to	O	-1	11379838
man@@	B-Disease	D001714	11379838
ia	I-Disease	-1	11379838
associated	O	-1	11379838
with	O	-1	11379838
antidepress@@	B-Chemical	D000928	11379838
ants	I-Chemical	-1	11379838
continu@@	O	-1	11379838
e	O	-1	11379838
to	O	-1	11379838
inter@@	O	-1	11379838
f@@	O	-1	11379838
ere	O	-1	11379838
with	O	-1	11379838
the	O	-1	11379838
est@@	O	-1	11379838
abl@@	O	-1	11379838
ish@@	O	-1	11379838
ment	O	-1	11379838
of	O	-1	11379838
an	O	-1	11379838
op@@	O	-1	11379838
tim@@	O	-1	11379838
al	O	-1	11379838
treatment	O	-1	11379838
par@@	O	-1	11379838
a@@	O	-1	11379838
di@@	O	-1	11379838
g@@	O	-1	11379838
m	O	-1	11379838
for	O	-1	11379838
b@@	B-Disease	D001714	11379838
ip@@	I-Disease	-1	11379838
ol@@	I-Disease	-1	11379838
ar	I-Disease	-1	11379838
de@@	I-Disease	-1	11379838
pression	I-Disease	-1	11379838
.	O	-1	11379838
METHOD@@	O	-1	11379838
:	O	-1	11379838
The	O	-1	11379838
response	O	-1	11379838
of	O	-1	11379838
4@@	O	-1	11379838
4	O	-1	11379838
patients	O	-1	11379838
me@@	O	-1	11379838
et@@	O	-1	11379838
ing	O	-1	11379838
D@@	O	-1	11379838
S@@	O	-1	11379838
M@@	O	-1	11379838
-@@	O	-1	11379838
IV	O	-1	11379838
c@@	O	-1	11379838
rit@@	O	-1	11379838
er@@	O	-1	11379838
ia	O	-1	11379838
for	O	-1	11379838
b@@	B-Disease	D001714	11379838
ip@@	I-Disease	-1	11379838
ol@@	I-Disease	-1	11379838
ar	I-Disease	-1	11379838
disor@@	I-Disease	-1	11379838
der	I-Disease	-1	11379838
to	O	-1	11379838
n@@	O	-1	11379838
at@@	O	-1	11379838
ur@@	O	-1	11379838
al@@	O	-1	11379838
istic	O	-1	11379838
treatment	O	-1	11379838
was	O	-1	11379838
assessed	O	-1	11379838
for	O	-1	11379838
at	O	-1	11379838
le@@	O	-1	11379838
ast	O	-1	11379838
6	O	-1	11379838
weeks	O	-1	11379838
using	O	-1	11379838
the	O	-1	11379838
M@@	O	-1	11379838
ont@@	O	-1	11379838
g@@	O	-1	11379838
om@@	O	-1	11379838
er@@	O	-1	11379838
y-@@	O	-1	11379838
A@@	O	-1	11379838
s@@	O	-1	11379838
b@@	O	-1	11379838
er@@	O	-1	11379838
g	O	-1	11379838
De@@	O	-1	11379838
pression	O	-1	11379838
R@@	O	-1	11379838
ating	O	-1	11379838
S@@	O	-1	11379838
cal@@	O	-1	11379838
e	O	-1	11379838
and	O	-1	11379838
the	O	-1	11379838
B@@	O	-1	11379838
ech@@	O	-1	11379838
-@@	O	-1	11379838
R@@	O	-1	11379838
af@@	O	-1	11379838
a@@	O	-1	11379838
el@@	O	-1	11379838
s@@	O	-1	11379838
on	O	-1	11379838
M@@	O	-1	11379838
an@@	O	-1	11379838
ia	O	-1	11379838
R@@	O	-1	11379838
ating	O	-1	11379838
S@@	O	-1	11379838
cal@@	O	-1	11379838
e.	O	-1	11379838
Patients	O	-1	11379838
who	O	-1	11379838
experienced	O	-1	11379838
a	O	-1	11379838
man@@	B-Disease	D001714	11379838
ic	I-Disease	-1	11379838
or	O	-1	11379838
hypo@@	B-Disease	D001714	11379838
man@@	I-Disease	-1	11379838
ic	I-Disease	-1	11379838
s@@	O	-1	11379838
wit@@	O	-1	11379838
ch	O	-1	11379838
were	O	-1	11379838
compared	O	-1	11379838
with	O	-1	11379838
those	O	-1	11379838
who	O	-1	11379838
did	O	-1	11379838
not	O	-1	11379838
on	O	-1	11379838
several	O	-1	11379838
vari@@	O	-1	11379838
able@@	O	-1	11379838
s	O	-1	11379838
including	O	-1	11379838
age,	O	-1	11379838
sex@@	O	-1	11379838
,	O	-1	11379838
diagnosis	O	-1	11379838
(	O	-1	11379838
D@@	B-Disease	D001714	11379838
S@@	I-Disease	-1	11379838
M@@	I-Disease	-1	11379838
-@@	I-Disease	-1	11379838
IV	I-Disease	-1	11379838
b@@	I-Disease	-1	11379838
ip@@	I-Disease	-1	11379838
ol@@	I-Disease	-1	11379838
ar	I-Disease	-1	11379838
I	I-Disease	-1	11379838
vs.	O	-1	11379838
b@@	B-Disease	D001714	11379838
ip@@	I-Disease	-1	11379838
ol@@	I-Disease	-1	11379838
ar	I-Disease	-1	11379838
II	I-Disease	-1	11379838
),	O	-1	11379838
number	O	-1	11379838
of	O	-1	11379838
previ@@	O	-1	11379838
ous	O	-1	11379838
man@@	B-Disease	D001714	11379838
ic	I-Disease	-1	11379838
episo@@	O	-1	11379838
d@@	O	-1	11379838
es,	O	-1	11379838
type	O	-1	11379838
of	O	-1	11379838
antidepress@@	B-Chemical	D000928	11379838
ant	I-Chemical	-1	11379838
therapy	O	-1	11379838
used	O	-1	11379838
(@@	O	-1	11379838
electro@@	O	-1	11379838
convul@@	O	-1	11379838
sive	O	-1	11379838
therapy	O	-1	11379838
vs.	O	-1	11379838
antidepress@@	B-Chemical	D000928	11379838
ant	I-Chemical	-1	11379838
drugs	O	-1	11379838
and@@	O	-1	11379838
,	O	-1	11379838
more	O	-1	11379838
partic@@	O	-1	11379838
ul@@	O	-1	11379838
ar@@	O	-1	11379838
ly,	O	-1	11379838
selective	O	-1	11379838
seroton@@	B-Chemical	D017367	11379838
in	I-Chemical	-1	11379838
re@@	I-Chemical	-1	11379838
u@@	I-Chemical	-1	11379838
pt@@	I-Chemical	-1	11379838
ake	I-Chemical	-1	11379838
inhibitors	I-Chemical	-1	11379838
[	O	-1	11379838
S@@	B-Chemical	D017367	11379838
SR@@	I-Chemical	-1	11379838
I@@	I-Chemical	-1	11379838
s	I-Chemical	-1	11379838
]@@	O	-1	11379838
),	O	-1	11379838
use	O	-1	11379838
and	O	-1	11379838
type	O	-1	11379838
of	O	-1	11379838
mo@@	O	-1	11379838
od	O	-1	11379838
st@@	O	-1	11379838
abil@@	O	-1	11379838
iz@@	O	-1	11379838
ers	O	-1	11379838
(	O	-1	11379838
lithium	B-Chemical	D008094	11379838
vs.	O	-1	11379838
anti@@	O	-1	11379838
convul@@	O	-1	11379838
s@@	O	-1	11379838
ant@@	O	-1	11379838
s),	O	-1	11379838
and	O	-1	11379838
tem@@	O	-1	11379838
per@@	O	-1	11379838
am@@	O	-1	11379838
ent	O	-1	11379838
of	O	-1	11379838
the	O	-1	11379838
patient@@	O	-1	11379838
,	O	-1	11379838
assessed	O	-1	11379838
during	O	-1	11379838
a	O	-1	11379838
nor@@	O	-1	11379838
mo@@	O	-1	11379838
th@@	O	-1	11379838
ym@@	O	-1	11379838
ic	O	-1	11379838
period	O	-1	11379838
using	O	-1	11379838
the	O	-1	11379838
hyper@@	O	-1	11379838
th@@	O	-1	11379838
ym@@	O	-1	11379838
ia	O	-1	11379838
comp@@	O	-1	11379838
on@@	O	-1	11379838
ent	O	-1	11379838
of	O	-1	11379838
the	O	-1	11379838
S@@	O	-1	11379838
em@@	O	-1	11379838
i@@	O	-1	11379838
-@@	O	-1	11379838
struct@@	O	-1	11379838
ured	O	-1	11379838
A@@	O	-1	11379838
ff@@	O	-1	11379838
ective	O	-1	11379838
T@@	O	-1	11379838
em@@	O	-1	11379838
per@@	O	-1	11379838
am@@	O	-1	11379838
ent	O	-1	11379838
In@@	O	-1	11379838
ter@@	O	-1	11379838
vie@@	O	-1	11379838
w@@	O	-1	11379838
.	O	-1	11379838
RESULTS:	O	-1	11379838
S@@	O	-1	11379838
witch@@	O	-1	11379838
es	O	-1	11379838
to	O	-1	11379838
hypo@@	B-Disease	D001714	11379838
man@@	I-Disease	-1	11379838
ia	I-Disease	-1	11379838
or	O	-1	11379838
man@@	B-Disease	D001714	11379838
ia	I-Disease	-1	11379838
occurred	O	-1	11379838
in	O	-1	11379838
27@@	O	-1	11379838
%	O	-1	11379838
of	O	-1	11379838
all	O	-1	11379838
patients	O	-1	11379838
(@@	O	-1	11379838
N	O	-1	11379838
=	O	-1	11379838
12@@	O	-1	11379838
)	O	-1	11379838
(@@	O	-1	11379838
and	O	-1	11379838
in	O	-1	11379838
2@@	O	-1	11379838
4@@	O	-1	11379838
%	O	-1	11379838
of	O	-1	11379838
the	O	-1	11379838
sub@@	O	-1	11379838
group	O	-1	11379838
of	O	-1	11379838
patients	O	-1	11379838
treated	O	-1	11379838
with	O	-1	11379838
S@@	B-Chemical	D017367	11379838
SR@@	I-Chemical	-1	11379838
I@@	I-Chemical	-1	11379838
s	I-Chemical	-1	11379838
[@@	O	-1	11379838
8@@	O	-1	11379838
/@@	O	-1	11379838
3@@	O	-1	11379838
3@@	O	-1	11379838
]@@	O	-1	11379838
);	O	-1	11379838
1@@	O	-1	11379838
6%	O	-1	11379838
(@@	O	-1	11379838
N	O	-1	11379838
=	O	-1	11379838
7@@	O	-1	11379838
)	O	-1	11379838
experienced	O	-1	11379838
man@@	B-Disease	D001714	11379838
ic	I-Disease	-1	11379838
episo@@	O	-1	11379838
d@@	O	-1	11379838
es,	O	-1	11379838
and	O	-1	11379838
1@@	O	-1	11379838
1@@	O	-1	11379838
%	O	-1	11379838
(@@	O	-1	11379838
N	O	-1	11379838
=	O	-1	11379838
5@@	O	-1	11379838
)	O	-1	11379838
experienced	O	-1	11379838
hypo@@	B-Disease	D001714	11379838
man@@	I-Disease	-1	11379838
ic	I-Disease	-1	11379838
episo@@	O	-1	11379838
d@@	O	-1	11379838
es.	O	-1	11379838
S@@	O	-1	11379838
ex@@	O	-1	11379838
,	O	-1	11379838
age,	O	-1	11379838
diagnosis	O	-1	11379838
(	O	-1	11379838
b@@	B-Disease	D001714	11379838
ip@@	I-Disease	-1	11379838
ol@@	I-Disease	-1	11379838
ar	I-Disease	-1	11379838
I	I-Disease	-1	11379838
vs.	O	-1	11379838
b@@	B-Disease	D001714	11379838
ip@@	I-Disease	-1	11379838
ol@@	I-Disease	-1	11379838
ar	I-Disease	-1	11379838
II	I-Disease	-1	11379838
),	O	-1	11379838
and	O	-1	11379838
addi@@	O	-1	11379838
tional	O	-1	11379838
treatment	O	-1	11379838
did	O	-1	11379838
not	O	-1	11379838
aff@@	O	-1	11379838
ect	O	-1	11379838
the	O	-1	11379838
risk	O	-1	11379838
of	O	-1	11379838
switch@@	O	-1	11379838
ing.	O	-1	11379838
The	O	-1	11379838
incidence	O	-1	11379838
of	O	-1	11379838
mo@@	O	-1	11379838
od	O	-1	11379838
switch@@	O	-1	11379838
es	O	-1	11379838
se@@	O	-1	11379838
em@@	O	-1	11379838
ed	O	-1	11379838
not	O	-1	11379838
to	O	-1	11379838
diff@@	O	-1	11379838
er	O	-1	11379838
between	O	-1	11379838
patients	O	-1	11379838
receiving	O	-1	11379838
an	O	-1	11379838
anti@@	O	-1	11379838
convul@@	O	-1	11379838
s@@	O	-1	11379838
ant	O	-1	11379838
and	O	-1	11379838
those	O	-1	11379838
receiving	O	-1	11379838
no	O	-1	11379838
mo@@	O	-1	11379838
od	O	-1	11379838
st@@	O	-1	11379838
abil@@	O	-1	11379838
iz@@	O	-1	11379838
er.	O	-1	11379838
In	O	-1	11379838
contrast@@	O	-1	11379838
,	O	-1	11379838
mo@@	O	-1	11379838
od	O	-1	11379838
switch@@	O	-1	11379838
es	O	-1	11379838
were	O	-1	11379838
less	O	-1	11379838
frequent	O	-1	11379838
in	O	-1	11379838
patients	O	-1	11379838
receiving	O	-1	11379838
lithium	B-Chemical	D008094	11379838
(1@@	O	-1	11379838
5@@	O	-1	11379838
%,	O	-1	11379838
4@@	O	-1	11379838
/@@	O	-1	11379838
2@@	O	-1	11379838
6@@	O	-1	11379838
)	O	-1	11379838
than	O	-1	11379838
in	O	-1	11379838
patients	O	-1	11379838
not	O	-1	11379838
treated	O	-1	11379838
with	O	-1	11379838
lithium	B-Chemical	D008094	11379838
(4@@	O	-1	11379838
4@@	O	-1	11379838
%,	O	-1	11379838
8@@	O	-1	11379838
/@@	O	-1	11379838
18@@	O	-1	11379838
;	O	-1	11379838
p	O	-1	11379838
=	O	-1	11379838
.@@	O	-1	11379838
0@@	O	-1	11379838
4@@	O	-1	11379838
).	O	-1	11379838
The	O	-1	11379838
number	O	-1	11379838
of	O	-1	11379838
previ@@	O	-1	11379838
ous	O	-1	11379838
man@@	B-Disease	D001714	11379838
ic	I-Disease	-1	11379838
episo@@	O	-1	11379838
des	O	-1	11379838
did	O	-1	11379838
not	O	-1	11379838
aff@@	O	-1	11379838
ect	O	-1	11379838
the	O	-1	11379838
prob@@	O	-1	11379838
ability	O	-1	11379838
of	O	-1	11379838
switch@@	O	-1	11379838
ing,	O	-1	11379838
whereas	O	-1	11379838
a	O	-1	11379838
high	O	-1	11379838
scor@@	O	-1	11379838
e	O	-1	11379838
on	O	-1	11379838
the	O	-1	11379838
hyper@@	O	-1	11379838
th@@	O	-1	11379838
ym@@	O	-1	11379838
ia	O	-1	11379838
comp@@	O	-1	11379838
on@@	O	-1	11379838
ent	O	-1	11379838
of	O	-1	11379838
the	O	-1	11379838
S@@	O	-1	11379838
em@@	O	-1	11379838
ist@@	O	-1	11379838
r@@	O	-1	11379838
uc@@	O	-1	11379838
t@@	O	-1	11379838
ured	O	-1	11379838
A@@	O	-1	11379838
ff@@	O	-1	11379838
ective	O	-1	11379838
T@@	O	-1	11379838
em@@	O	-1	11379838
per@@	O	-1	11379838
am@@	O	-1	11379838
ent	O	-1	11379838
In@@	O	-1	11379838
ter@@	O	-1	11379838
vie@@	O	-1	11379838
w	O	-1	11379838
was	O	-1	11379838
associated	O	-1	11379838
with	O	-1	11379838
a	O	-1	11379838
greater	O	-1	11379838
risk	O	-1	11379838
of	O	-1	11379838
switch@@	O	-1	11379838
ing	O	-1	11379838
(p	O	-1	11379838
=	O	-1	11379838
.@@	O	-1	11379838
0@@	O	-1	11379838
0@@	O	-1	11379838
8@@	O	-1	11379838
).	O	-1	11379838
CONCLUSION:	O	-1	11379838
The	O	-1	11379838
frequency	O	-1	11379838
of	O	-1	11379838
mo@@	O	-1	11379838
od	O	-1	11379838
switch@@	O	-1	11379838
ing	O	-1	11379838
associated	O	-1	11379838
with	O	-1	11379838
acute	O	-1	11379838
antidepress@@	B-Chemical	D000928	11379838
ant	I-Chemical	-1	11379838
therapy	O	-1	11379838
may	O	-1	11379838
be	O	-1	11379838
reduced	O	-1	11379838
by	O	-1	11379838
lithium	B-Chemical	D008094	11379838
treatment.	O	-1	11379838
P@@	O	-1	11379838
ar@@	O	-1	11379838
tic@@	O	-1	11379838
ular	O	-1	11379838
atten@@	O	-1	11379838
tion	O	-1	11379838
should	O	-1	11379838
be	O	-1	11379838
pa@@	O	-1	11379838
id	O	-1	11379838
to	O	-1	11379838
patients	O	-1	11379838
with	O	-1	11379838
a	O	-1	11379838
hyper@@	O	-1	11379838
th@@	O	-1	11379838
ym@@	O	-1	11379838
ic	O	-1	11379838
tem@@	O	-1	11379838
per@@	O	-1	11379838
am@@	O	-1	11379838
ent@@	O	-1	11379838
,	O	-1	11379838
who	O	-1	11379838
have	O	-1	11379838
a	O	-1	11379838
greater	O	-1	11379838
risk	O	-1	11379838
of	O	-1	11379838
mo@@	O	-1	11379838
od	O	-1	11379838
switch@@	O	-1	11379838
es.	O	-1	11379838

Ca@@	B-Chemical	D002110	11419773
ffe@@	I-Chemical	-1	11419773
ine	I-Chemical	-1	11419773
-induced	O	-1	11419773
cardiac	B-Disease	D001145	11419773
arrhyth@@	I-Disease	-1	11419773
mia	I-Disease	-1	11419773
:	O	-1	11419773
an	O	-1	11419773
un@@	O	-1	11419773
reco@@	O	-1	11419773
gn@@	O	-1	11419773
is@@	O	-1	11419773
ed	O	-1	11419773
d@@	O	-1	11419773
ang@@	O	-1	11419773
er	O	-1	11419773
of	O	-1	11419773
health@@	O	-1	11419773
fo@@	O	-1	11419773
od	O	-1	11419773
produc@@	O	-1	11419773
t@@	O	-1	11419773
s.	O	-1	11419773
We	O	-1	11419773
describe	O	-1	11419773
a	O	-1	11419773
2@@	O	-1	11419773
5-@@	O	-1	11419773
year-old	O	-1	11419773
woman	O	-1	11419773
with	O	-1	11419773
pre-@@	O	-1	11419773
ex@@	O	-1	11419773
ist@@	O	-1	11419773
ing	O	-1	11419773
mit@@	B-Disease	D008945	11419773
ral	I-Disease	-1	11419773
val@@	I-Disease	-1	11419773
ve	I-Disease	-1	11419773
prol@@	I-Disease	-1	11419773
ap@@	I-Disease	-1	11419773
se	I-Disease	-1	11419773
who	O	-1	11419773
developed	O	-1	11419773
intrac@@	O	-1	11419773
t@@	O	-1	11419773
able	O	-1	11419773
ventricular	B-Disease	D014693	11419773
fibrill@@	I-Disease	-1	11419773
ation	I-Disease	-1	11419773
after	O	-1	11419773
consum@@	O	-1	11419773
ing	O	-1	11419773
a	O	-1	11419773
"@@	O	-1	11419773
n@@	O	-1	11419773
at@@	O	-1	11419773
ural	O	-1	11419773
en@@	O	-1	11419773
erg@@	O	-1	11419773
y@@	O	-1	11419773
"	O	-1	11419773
gu@@	O	-1	11419773
ar@@	O	-1	11419773
an@@	O	-1	11419773
a	O	-1	11419773
heal@@	O	-1	11419773
th	O	-1	11419773
d@@	O	-1	11419773
r@@	O	-1	11419773
in@@	O	-1	11419773
k	O	-1	11419773
containing	O	-1	11419773
a	O	-1	11419773
high	O	-1	11419773
concentration	O	-1	11419773
of	O	-1	11419773
caffe@@	B-Chemical	D002110	11419773
ine	I-Chemical	-1	11419773
.	O	-1	11419773
This	O	-1	11419773
case	O	-1	11419773
high@@	O	-1	11419773
li@@	O	-1	11419773
gh@@	O	-1	11419773
ts	O	-1	11419773
the	O	-1	11419773
need	O	-1	11419773
for	O	-1	11419773
ade@@	O	-1	11419773
qu@@	O	-1	11419773
ate	O	-1	11419773
l@@	O	-1	11419773
a@@	O	-1	11419773
bell@@	O	-1	11419773
ing	O	-1	11419773
and	O	-1	11419773
reg@@	O	-1	11419773
ulation	O	-1	11419773
of	O	-1	11419773
such	O	-1	11419773
produc@@	O	-1	11419773
t@@	O	-1	11419773
s.	O	-1	11419773

B@@	O	-1	11581460
l@@	O	-1	11581460
ad@@	O	-1	11581460
der	O	-1	11581460
re@@	B-Disease	D016055	11581460
ten@@	I-Disease	-1	11581460
tion	I-Disease	-1	11581460
of	I-Disease	-1	11581460
urine	I-Disease	-1	11581460
as	O	-1	11581460
a	O	-1	11581460
result	O	-1	11581460
of	O	-1	11581460
continu@@	O	-1	11581460
ous	O	-1	11581460
intravenous	O	-1	11581460
infusion	O	-1	11581460
of	O	-1	11581460
f@@	B-Chemical	D005283	11581460
entan@@	I-Chemical	-1	11581460
yl	I-Chemical	-1	11581460
:	O	-1	11581460
2	O	-1	11581460
case	O	-1	11581460
repor@@	O	-1	11581460
t@@	O	-1	11581460
s.	O	-1	11581460
S@@	O	-1	11581460
ed@@	O	-1	11581460
ation	O	-1	11581460
has	O	-1	11581460
been	O	-1	11581460
common@@	O	-1	11581460
ly	O	-1	11581460
used	O	-1	11581460
in	O	-1	11581460
the	O	-1	11581460
ne@@	O	-1	11581460
on@@	O	-1	11581460
ate	O	-1	11581460
to	O	-1	11581460
decrease	O	-1	11581460
the	O	-1	11581460
stres@@	O	-1	11581460
s	O	-1	11581460
and	O	-1	11581460
pain	B-Disease	D010146	11581460
from	O	-1	11581460
the	O	-1	11581460
no@@	O	-1	11581460
xi@@	O	-1	11581460
ous	O	-1	11581460
stimul@@	O	-1	11581460
i	O	-1	11581460
and	O	-1	11581460
inv@@	O	-1	11581460
a@@	O	-1	11581460
sive	O	-1	11581460
proce@@	O	-1	11581460
d@@	O	-1	11581460
ures	O	-1	11581460
in	O	-1	11581460
the	O	-1	11581460
ne@@	O	-1	11581460
on@@	O	-1	11581460
atal	O	-1	11581460
int@@	O	-1	11581460
en@@	O	-1	11581460
sive	O	-1	11581460
car@@	O	-1	11581460
e	O	-1	11581460
un@@	O	-1	11581460
it@@	O	-1	11581460
,	O	-1	11581460
as	O	-1	11581460
well	O	-1	11581460
as	O	-1	11581460
to	O	-1	11581460
fac@@	O	-1	11581460
il@@	O	-1	11581460
it@@	O	-1	11581460
ate	O	-1	11581460
syn@@	O	-1	11581460
chron@@	O	-1	11581460
y	O	-1	11581460
between	O	-1	11581460
ven@@	O	-1	11581460
ti@@	O	-1	11581460
lat@@	O	-1	11581460
or	O	-1	11581460
and	O	-1	11581460
spont@@	O	-1	11581460
aneous	O	-1	11581460
b@@	O	-1	11581460
re@@	O	-1	11581460
ath@@	O	-1	11581460
s.	O	-1	11581460
F@@	B-Chemical	D005283	11581460
entan@@	I-Chemical	-1	11581460
yl	I-Chemical	-1	11581460
,	O	-1	11581460
an	O	-1	11581460
o@@	O	-1	11581460
pi@@	O	-1	11581460
oid	O	-1	11581460
analge@@	O	-1	11581460
si@@	O	-1	11581460
c@@	O	-1	11581460
,	O	-1	11581460
is	O	-1	11581460
frequ@@	O	-1	11581460
ently	O	-1	11581460
used	O	-1	11581460
in	O	-1	11581460
the	O	-1	11581460
ne@@	O	-1	11581460
on@@	O	-1	11581460
atal	O	-1	11581460
int@@	O	-1	11581460
en@@	O	-1	11581460
sive	O	-1	11581460
car@@	O	-1	11581460
e	O	-1	11581460
un@@	O	-1	11581460
it	O	-1	11581460
se@@	O	-1	11581460
t@@	O	-1	11581460
ting	O	-1	11581460
for	O	-1	11581460
these	O	-1	11581460
very	O	-1	11581460
pur@@	O	-1	11581460
pos@@	O	-1	11581460
es.	O	-1	11581460
V@@	O	-1	11581460
ari@@	O	-1	11581460
ous	O	-1	11581460
reported	O	-1	11581460
side	O	-1	11581460
effects	O	-1	11581460
of	O	-1	11581460
f@@	B-Chemical	D005283	11581460
entan@@	I-Chemical	-1	11581460
yl	I-Chemical	-1	11581460
administration	O	-1	11581460
includ@@	O	-1	11581460
e	O	-1	11581460
ch@@	B-Disease	D009127	11581460
est	I-Disease	-1	11581460
w@@	I-Disease	-1	11581460
all	I-Disease	-1	11581460
rig@@	I-Disease	-1	11581460
idity	I-Disease	-1	11581460
,	O	-1	11581460
hypotension	B-Disease	D007022	11581460
,	O	-1	11581460
respiratory	B-Disease	D012131	11581460
de@@	I-Disease	-1	11581460
pression	I-Disease	-1	11581460
,	O	-1	11581460
and	O	-1	11581460
brady@@	B-Disease	D001919	11581460
cardia	I-Disease	-1	11581460
.	O	-1	11581460
He@@	O	-1	11581460
re,	O	-1	11581460
2	O	-1	11581460
cases	O	-1	11581460
of	O	-1	11581460
urinary	B-Disease	D001745	11581460
bladder	I-Disease	-1	11581460
re@@	I-Disease	-1	11581460
ten@@	I-Disease	-1	11581460
tion	I-Disease	-1	11581460
lead@@	O	-1	11581460
ing	O	-1	11581460
to	O	-1	11581460
renal	O	-1	11581460
p@@	O	-1	11581460
el@@	O	-1	11581460
v@@	O	-1	11581460
oc@@	O	-1	11581460
aly@@	O	-1	11581460
ce@@	O	-1	11581460
al	O	-1	11581460
di@@	O	-1	11581460
lat@@	O	-1	11581460
ation	O	-1	11581460
m@@	O	-1	11581460
im@@	O	-1	11581460
ic@@	O	-1	11581460
king	O	-1	11581460
hy@@	B-Disease	D006869	11581460
d@@	I-Disease	-1	11581460
ron@@	I-Disease	-1	11581460
e@@	I-Disease	-1	11581460
ph@@	I-Disease	-1	11581460
ro@@	I-Disease	-1	11581460
sis	I-Disease	-1	11581460
as	O	-1	11581460
a	O	-1	11581460
result	O	-1	11581460
of	O	-1	11581460
continu@@	O	-1	11581460
ous	O	-1	11581460
infusion	O	-1	11581460
of	O	-1	11581460
f@@	B-Chemical	D005283	11581460
entan@@	I-Chemical	-1	11581460
yl	I-Chemical	-1	11581460
are	O	-1	11581460
repor@@	O	-1	11581460
ted.	O	-1	11581460

Com@@	O	-1	11706060
bin@@	O	-1	11706060
ed	O	-1	11706060
anti@@	O	-1	11706060
ret@@	O	-1	11706060
ro@@	O	-1	11706060
viral	O	-1	11706060
therapy	O	-1	11706060
causes	O	-1	11706060
cardi@@	B-Disease	D009202	11706060
om@@	I-Disease	-1	11706060
yo@@	I-Disease	-1	11706060
pathy	I-Disease	-1	11706060
and	O	-1	11706060
elev@@	O	-1	11706060
ates	O	-1	11706060
plasma	O	-1	11706060
l@@	B-Chemical	D019344	11706060
act@@	I-Chemical	-1	11706060
ate	I-Chemical	-1	11706060
in	O	-1	11706060
trans@@	O	-1	11706060
genic	O	-1	11706060
A@@	B-Disease	D000163	11706060
I@@	I-Disease	-1	11706060
D@@	I-Disease	-1	11706060
S	I-Disease	-1	11706060
mice.	O	-1	11706060
H@@	O	-1	11706060
igh@@	O	-1	11706060
ly	O	-1	11706060
active	O	-1	11706060
anti@@	O	-1	11706060
ret@@	O	-1	11706060
ro@@	O	-1	11706060
viral	O	-1	11706060
therapy	O	-1	11706060
(@@	O	-1	11706060
H@@	O	-1	11706060
A@@	O	-1	11706060
A@@	O	-1	11706060
R@@	O	-1	11706060
T)	O	-1	11706060
is	O	-1	11706060
implic@@	O	-1	11706060
ated	O	-1	11706060
in	O	-1	11706060
cardi@@	B-Disease	D009202	11706060
om@@	I-Disease	-1	11706060
yo@@	I-Disease	-1	11706060
pathy	I-Disease	-1	11706060
(	O	-1	11706060
C@@	B-Disease	D009202	11706060
M	I-Disease	-1	11706060
)	O	-1	11706060
and	O	-1	11706060
in	O	-1	11706060
elevated	O	-1	11706060
plasma	O	-1	11706060
l@@	B-Chemical	D019344	11706060
act@@	I-Chemical	-1	11706060
ate	I-Chemical	-1	11706060
(	O	-1	11706060
L@@	B-Chemical	D019344	11706060
A	I-Chemical	-1	11706060
)	O	-1	11706060
in	O	-1	11706060
A@@	B-Disease	D000163	11706060
I@@	I-Disease	-1	11706060
D@@	I-Disease	-1	11706060
S	I-Disease	-1	11706060
through	O	-1	11706060
mechanisms	O	-1	11706060
of	O	-1	11706060
mitochondrial	B-Disease	D028361	11706060
dysfunction	I-Disease	-1	11706060
.	O	-1	11706060
To	O	-1	11706060
determine	O	-1	11706060
mitochondrial	O	-1	11706060
events	O	-1	11706060
from	O	-1	11706060
H@@	O	-1	11706060
A@@	O	-1	11706060
A@@	O	-1	11706060
R@@	O	-1	11706060
T	O	-1	11706060
in	O	-1	11706060
viv@@	O	-1	11706060
o@@	O	-1	11706060
,	O	-1	11706060
8@@	O	-1	11706060
-@@	O	-1	11706060
week@@	O	-1	11706060
-old	O	-1	11706060
hem@@	O	-1	11706060
iz@@	O	-1	11706060
y@@	O	-1	11706060
g@@	O	-1	11706060
ous	O	-1	11706060
trans@@	O	-1	11706060
genic	O	-1	11706060
A@@	B-Disease	D000163	11706060
I@@	I-Disease	-1	11706060
D@@	I-Disease	-1	11706060
S	I-Disease	-1	11706060
mice	O	-1	11706060
(N@@	O	-1	11706060
L@@	O	-1	11706060
4-@@	O	-1	11706060
3@@	O	-1	11706060
D@@	O	-1	11706060
el@@	O	-1	11706060
t@@	O	-1	11706060
a	O	-1	11706060
g@@	O	-1	11706060
ag@@	O	-1	11706060
/@@	O	-1	11706060
pol@@	O	-1	11706060
;	O	-1	11706060
T@@	O	-1	11706060
G@@	O	-1	11706060
)	O	-1	11706060
and	O	-1	11706060
wil@@	O	-1	11706060
d-@@	O	-1	11706060
type	O	-1	11706060
F@@	O	-1	11706060
V@@	O	-1	11706060
B@@	O	-1	11706060
/@@	O	-1	11706060
n	O	-1	11706060
lit@@	O	-1	11706060
ter@@	O	-1	11706060
mat@@	O	-1	11706060
es	O	-1	11706060
were	O	-1	11706060
treated	O	-1	11706060
with	O	-1	11706060
the	O	-1	11706060
H@@	O	-1	11706060
A@@	O	-1	11706060
A@@	O	-1	11706060
R@@	O	-1	11706060
T	O	-1	11706060
combination	O	-1	11706060
of	O	-1	11706060
z@@	B-Chemical	D015215	11706060
id@@	I-Chemical	-1	11706060
o@@	I-Chemical	-1	11706060
vud@@	I-Chemical	-1	11706060
ine	I-Chemical	-1	11706060
,	O	-1	11706060
lamivud@@	B-Chemical	D019259	11706060
ine	I-Chemical	-1	11706060
,	O	-1	11706060
and	O	-1	11706060
ind@@	B-Chemical	D019469	11706060
in@@	I-Chemical	-1	11706060
avi@@	I-Chemical	-1	11706060
r	I-Chemical	-1	11706060
or	O	-1	11706060
ve@@	O	-1	11706060
h@@	O	-1	11706060
ic@@	O	-1	11706060
le	O	-1	11706060
control	O	-1	11706060
for	O	-1	11706060
10	O	-1	11706060
days	O	-1	11706060
or	O	-1	11706060
3@@	O	-1	11706060
5	O	-1	11706060
days.	O	-1	11706060
A@@	O	-1	11706060
t	O	-1	11706060
ter@@	O	-1	11706060
min@@	O	-1	11706060
ation	O	-1	11706060
of	O	-1	11706060
the	O	-1	11706060
experim@@	O	-1	11706060
ent@@	O	-1	11706060
s,	O	-1	11706060
mice	O	-1	11706060
under@@	O	-1	11706060
w@@	O	-1	11706060
ent	O	-1	11706060
echocardiograph@@	O	-1	11706060
y,	O	-1	11706060
qu@@	O	-1	11706060
anti@@	O	-1	11706060
t@@	O	-1	11706060
ation	O	-1	11706060
of	O	-1	11706060
ab@@	O	-1	11706060
und@@	O	-1	11706060
ance	O	-1	11706060
of	O	-1	11706060
mol@@	O	-1	11706060
ec@@	O	-1	11706060
ular	O	-1	11706060
mark@@	O	-1	11706060
ers	O	-1	11706060
of	O	-1	11706060
C@@	B-Disease	D009202	11706060
M	I-Disease	-1	11706060
(@@	O	-1	11706060
ventricular	O	-1	11706060
mRNA	O	-1	11706060
en@@	O	-1	11706060
co@@	O	-1	11706060
ding	O	-1	11706060
atrial	O	-1	11706060
n@@	O	-1	11706060
atri@@	O	-1	11706060
ure@@	O	-1	11706060
tic	O	-1	11706060
factor	O	-1	11706060
[@@	O	-1	11706060
AN@@	O	-1	11706060
F@@	O	-1	11706060
]	O	-1	11706060
and	O	-1	11706060
s@@	O	-1	11706060
ar@@	O	-1	11706060
co@@	O	-1	11706060
plas@@	O	-1	11706060
mic	O	-1	11706060
calcium	B-Chemical	D002118	11706060
AT@@	O	-1	11706060
P@@	O	-1	11706060
ase	O	-1	11706060
[@@	O	-1	11706060
S@@	O	-1	11706060
E@@	O	-1	11706060
R@@	O	-1	11706060
CA@@	O	-1	11706060
2@@	O	-1	11706060
]@@	O	-1	11706060
),	O	-1	11706060
and	O	-1	11706060
determin@@	O	-1	11706060
ation	O	-1	11706060
of	O	-1	11706060
plasma	O	-1	11706060
L@@	B-Chemical	D019344	11706060
A	I-Chemical	-1	11706060
.	O	-1	11706060
M@@	O	-1	11706060
y@@	O	-1	11706060
ocardi@@	O	-1	11706060
al	O	-1	11706060
hist@@	O	-1	11706060
ologic	O	-1	11706060
feat@@	O	-1	11706060
ures	O	-1	11706060
were	O	-1	11706060
analy@@	O	-1	11706060
zed	O	-1	11706060
se@@	O	-1	11706060
mi@@	O	-1	11706060
qu@@	O	-1	11706060
anti@@	O	-1	11706060
t@@	O	-1	11706060
atively	O	-1	11706060
and	O	-1	11706060
results	O	-1	11706060
were	O	-1	11706060
con@@	O	-1	11706060
fir@@	O	-1	11706060
m@@	O	-1	11706060
ed	O	-1	11706060
by	O	-1	11706060
trans@@	O	-1	11706060
mission	O	-1	11706060
electro@@	O	-1	11706060
n	O	-1	11706060
micro@@	O	-1	11706060
sco@@	O	-1	11706060
p@@	O	-1	11706060
y.	O	-1	11706060
After	O	-1	11706060
3@@	O	-1	11706060
5	O	-1	11706060
days	O	-1	11706060
in	O	-1	11706060
the	O	-1	11706060
T@@	O	-1	11706060
G	O	-1	11706060
+	O	-1	11706060
H@@	O	-1	11706060
A@@	O	-1	11706060
A@@	O	-1	11706060
R@@	O	-1	11706060
T	O	-1	11706060
co@@	O	-1	11706060
h@@	O	-1	11706060
ort@@	O	-1	11706060
,	O	-1	11706060
left	O	-1	11706060
ventricular	O	-1	11706060
mas@@	O	-1	11706060
s	O	-1	11706060
increased	O	-1	11706060
1@@	O	-1	11706060
6@@	O	-1	11706060
0%	O	-1	11706060
by	O	-1	11706060
echocardiograph@@	O	-1	11706060
y.	O	-1	11706060
M@@	O	-1	11706060
ol@@	O	-1	11706060
ec@@	O	-1	11706060
ul@@	O	-1	11706060
ar@@	O	-1	11706060
ly,	O	-1	11706060
AN@@	O	-1	11706060
F	O	-1	11706060
mRNA	O	-1	11706060
increased	O	-1	11706060
2@@	O	-1	11706060
50@@	O	-1	11706060
%	O	-1	11706060
and	O	-1	11706060
S@@	O	-1	11706060
E@@	O	-1	11706060
R@@	O	-1	11706060
CA@@	O	-1	11706060
2	O	-1	11706060
mRNA	O	-1	11706060
decreased	O	-1	11706060
5@@	O	-1	11706060
7@@	O	-1	11706060
%.	O	-1	11706060
B@@	O	-1	11706060
io@@	O	-1	11706060
chem@@	O	-1	11706060
ic@@	O	-1	11706060
ally,	O	-1	11706060
L@@	B-Chemical	D019344	11706060
A	I-Chemical	-1	11706060
was	O	-1	11706060
elevated	O	-1	11706060
(@@	O	-1	11706060
8.@@	O	-1	11706060
5	O	-1	11706060
+/-	O	-1	11706060
2.@@	O	-1	11706060
0	O	-1	11706060
m@@	O	-1	11706060
M@@	O	-1	11706060
).	O	-1	11706060
P@@	O	-1	11706060
ath@@	O	-1	11706060
olog@@	O	-1	11706060
ic@@	O	-1	11706060
ally,	O	-1	11706060
gran@@	O	-1	11706060
ular	O	-1	11706060
cyto@@	O	-1	11706060
plas@@	O	-1	11706060
mic	O	-1	11706060
changes	O	-1	11706060
were	O	-1	11706060
found	O	-1	11706060
in	O	-1	11706060
cardiac	O	-1	11706060
my@@	O	-1	11706060
ocy@@	O	-1	11706060
t@@	O	-1	11706060
es,	O	-1	11706060
indicating	O	-1	11706060
en@@	O	-1	11706060
larg@@	O	-1	11706060
ed,	O	-1	11706060
dam@@	O	-1	11706060
aged	O	-1	11706060
mitochond@@	O	-1	11706060
ri@@	O	-1	11706060
a.	O	-1	11706060
F@@	O	-1	11706060
ind@@	O	-1	11706060
ings	O	-1	11706060
were	O	-1	11706060
con@@	O	-1	11706060
fir@@	O	-1	11706060
m@@	O	-1	11706060
ed	O	-1	11706060
ult@@	O	-1	11706060
ra@@	O	-1	11706060
struct@@	O	-1	11706060
ur@@	O	-1	11706060
all@@	O	-1	11706060
y.	O	-1	11706060
No	O	-1	11706060
changes	O	-1	11706060
were	O	-1	11706060
found	O	-1	11706060
in	O	-1	11706060
other	O	-1	11706060
co@@	O	-1	11706060
h@@	O	-1	11706060
ort@@	O	-1	11706060
s.	O	-1	11706060
After	O	-1	11706060
10	O	-1	11706060
day@@	O	-1	11706060
s,	O	-1	11706060
only	O	-1	11706060
AN@@	O	-1	11706060
F	O	-1	11706060
was	O	-1	11706060
elev@@	O	-1	11706060
at@@	O	-1	11706060
ed,	O	-1	11706060
and	O	-1	11706060
only	O	-1	11706060
in	O	-1	11706060
the	O	-1	11706060
T@@	O	-1	11706060
G	O	-1	11706060
+	O	-1	11706060
H@@	O	-1	11706060
A@@	O	-1	11706060
A@@	O	-1	11706060
R@@	O	-1	11706060
T	O	-1	11706060
co@@	O	-1	11706060
h@@	O	-1	11706060
ort@@	O	-1	11706060
.	O	-1	11706060
R@@	O	-1	11706060
es@@	O	-1	11706060
ult@@	O	-1	11706060
s	O	-1	11706060
show	O	-1	11706060
that	O	-1	11706060
cum@@	O	-1	11706060
ul@@	O	-1	11706060
ative	O	-1	11706060
H@@	O	-1	11706060
A@@	O	-1	11706060
A@@	O	-1	11706060
R@@	O	-1	11706060
T	O	-1	11706060
caused	O	-1	11706060
mitochondrial	O	-1	11706060
C@@	B-Disease	D009202	11706060
M	I-Disease	-1	11706060
with	O	-1	11706060
elevated	O	-1	11706060
L@@	B-Chemical	D019344	11706060
A	I-Chemical	-1	11706060
in	O	-1	11706060
A@@	B-Disease	D000163	11706060
I@@	I-Disease	-1	11706060
D@@	I-Disease	-1	11706060
S	I-Disease	-1	11706060
trans@@	O	-1	11706060
genic	O	-1	11706060
mice.	O	-1	11706060

O@@	B-Chemical	D003276	11752354
ral	I-Chemical	-1	11752354
contrac@@	I-Chemical	-1	11752354
ep@@	I-Chemical	-1	11752354
tiv@@	I-Chemical	-1	11752354
es	I-Chemical	-1	11752354
and	O	-1	11752354
the	O	-1	11752354
risk	O	-1	11752354
of	O	-1	11752354
myocardial	B-Disease	D009203	11752354
infarction	I-Disease	-1	11752354
.	O	-1	11752354
BACKGROUND:	O	-1	11752354
An	O	-1	11752354
association	O	-1	11752354
between	O	-1	11752354
the	O	-1	11752354
use	O	-1	11752354
of	O	-1	11752354
oral	B-Chemical	D003276	11752354
contrac@@	I-Chemical	-1	11752354
ep@@	I-Chemical	-1	11752354
tiv@@	I-Chemical	-1	11752354
es	I-Chemical	-1	11752354
and	O	-1	11752354
the	O	-1	11752354
risk	O	-1	11752354
of	O	-1	11752354
myocardial	B-Disease	D009203	11752354
infarction	I-Disease	-1	11752354
has	O	-1	11752354
been	O	-1	11752354
found	O	-1	11752354
in	O	-1	11752354
so@@	O	-1	11752354
me,	O	-1	11752354
but	O	-1	11752354
not	O	-1	11752354
all@@	O	-1	11752354
,	O	-1	11752354
studi@@	O	-1	11752354
es.	O	-1	11752354
We	O	-1	11752354
investigated	O	-1	11752354
this	O	-1	11752354
associ@@	O	-1	11752354
ation,	O	-1	11752354
ac@@	O	-1	11752354
cor@@	O	-1	11752354
ding	O	-1	11752354
to	O	-1	11752354
the	O	-1	11752354
type	O	-1	11752354
of	O	-1	11752354
pro@@	B-Chemical	D011372	11752354
g@@	I-Chemical	-1	11752354
est@@	I-Chemical	-1	11752354
ag@@	I-Chemical	-1	11752354
en	I-Chemical	-1	11752354
included	O	-1	11752354
in	O	-1	11752354
thir@@	O	-1	11752354
d-@@	O	-1	11752354
generation	O	-1	11752354
(@@	O	-1	11752354
i.@@	O	-1	11752354
e@@	O	-1	11752354
.,	O	-1	11752354
des@@	B-Chemical	D017135	11752354
o@@	I-Chemical	-1	11752354
g@@	I-Chemical	-1	11752354
est@@	I-Chemical	-1	11752354
re@@	I-Chemical	-1	11752354
l	I-Chemical	-1	11752354
or	O	-1	11752354
g@@	B-Chemical	C033273	11752354
est@@	I-Chemical	-1	11752354
o@@	I-Chemical	-1	11752354
d@@	I-Chemical	-1	11752354
ene	I-Chemical	-1	11752354
)	O	-1	11752354
and	O	-1	11752354
secon@@	O	-1	11752354
d-@@	O	-1	11752354
generation	O	-1	11752354
(@@	O	-1	11752354
i.@@	O	-1	11752354
e@@	O	-1	11752354
.,	O	-1	11752354
lev@@	B-Chemical	D016912	11752354
on@@	I-Chemical	-1	11752354
org@@	I-Chemical	-1	11752354
est@@	I-Chemical	-1	11752354
re@@	I-Chemical	-1	11752354
l	I-Chemical	-1	11752354
)	O	-1	11752354
oral	B-Chemical	D003276	11752354
contrac@@	I-Chemical	-1	11752354
ep@@	I-Chemical	-1	11752354
tiv@@	I-Chemical	-1	11752354
es	I-Chemical	-1	11752354
,	O	-1	11752354
the	O	-1	11752354
dose	O	-1	11752354
of	O	-1	11752354
est@@	B-Chemical	D004967	11752354
ro@@	I-Chemical	-1	11752354
gen	I-Chemical	-1	11752354
,	O	-1	11752354
and	O	-1	11752354
the	O	-1	11752354
presence	O	-1	11752354
or	O	-1	11752354
absence	O	-1	11752354
of	O	-1	11752354
pro@@	O	-1	11752354
thrombotic	O	-1	11752354
mut@@	O	-1	11752354
ations	O	-1	11752354
METHODS:	O	-1	11752354
In	O	-1	11752354
a	O	-1	11752354
n@@	O	-1	11752354
ation@@	O	-1	11752354
wi@@	O	-1	11752354
de@@	O	-1	11752354
,	O	-1	11752354
po@@	O	-1	11752354
pul@@	O	-1	11752354
ation@@	O	-1	11752354
-@@	O	-1	11752354
bas@@	O	-1	11752354
ed,	O	-1	11752354
cas@@	O	-1	11752354
e-@@	O	-1	11752354
control	O	-1	11752354
study,	O	-1	11752354
we	O	-1	11752354
identi@@	O	-1	11752354
fied	O	-1	11752354
and	O	-1	11752354
en@@	O	-1	11752354
ro@@	O	-1	11752354
lled	O	-1	11752354
2@@	O	-1	11752354
4@@	O	-1	11752354
8	O	-1	11752354
women	O	-1	11752354
1@@	O	-1	11752354
8	O	-1	11752354
through	O	-1	11752354
4@@	O	-1	11752354
9	O	-1	11752354
years	O	-1	11752354
of	O	-1	11752354
age	O	-1	11752354
who	O	-1	11752354
had	O	-1	11752354
had	O	-1	11752354
a	O	-1	11752354
first	O	-1	11752354
myocardial	B-Disease	D009203	11752354
infarction	I-Disease	-1	11752354
between	O	-1	11752354
19@@	O	-1	11752354
9@@	O	-1	11752354
0	O	-1	11752354
and	O	-1	11752354
19@@	O	-1	11752354
9@@	O	-1	11752354
5	O	-1	11752354
and	O	-1	11752354
9@@	O	-1	11752354
25	O	-1	11752354
control	O	-1	11752354
women	O	-1	11752354
who	O	-1	11752354
had	O	-1	11752354
not	O	-1	11752354
had	O	-1	11752354
a	O	-1	11752354
myocardial	B-Disease	D009203	11752354
infarction	I-Disease	-1	11752354
and	O	-1	11752354
who	O	-1	11752354
were	O	-1	11752354
mat@@	O	-1	11752354
ch@@	O	-1	11752354
ed	O	-1	11752354
for	O	-1	11752354
age,	O	-1	11752354
cal@@	O	-1	11752354
en@@	O	-1	11752354
d@@	O	-1	11752354
ar	O	-1	11752354
year	O	-1	11752354
of	O	-1	11752354
the	O	-1	11752354
in@@	O	-1	11752354
de@@	O	-1	11752354
x	O	-1	11752354
event@@	O	-1	11752354
,	O	-1	11752354
and	O	-1	11752354
a@@	O	-1	11752354
re@@	O	-1	11752354
a	O	-1	11752354
of	O	-1	11752354
re@@	O	-1	11752354
si@@	O	-1	11752354
d@@	O	-1	11752354
ence@@	O	-1	11752354
.	O	-1	11752354
S@@	O	-1	11752354
ub@@	O	-1	11752354
j@@	O	-1	11752354
ects	O	-1	11752354
sup@@	O	-1	11752354
pl@@	O	-1	11752354
ied	O	-1	11752354
inf@@	O	-1	11752354
orm@@	O	-1	11752354
ation	O	-1	11752354
on	O	-1	11752354
or@@	B-Chemical	D003276	11752354
al@@	I-Chemical	-1	11752354
-@@	I-Chemical	-1	11752354
contrac@@	I-Chemical	-1	11752354
ep@@	I-Chemical	-1	11752354
tive	I-Chemical	-1	11752354
use	O	-1	11752354
and	O	-1	11752354
major	O	-1	11752354
cardiovascular	O	-1	11752354
risk	O	-1	11752354
fact@@	O	-1	11752354
or@@	O	-1	11752354
s.	O	-1	11752354
An	O	-1	11752354
analysis	O	-1	11752354
for	O	-1	11752354
factor	O	-1	11752354
V	O	-1	11752354
L@@	O	-1	11752354
e@@	O	-1	11752354
ide@@	O	-1	11752354
n	O	-1	11752354
and	O	-1	11752354
the	O	-1	11752354
G@@	O	-1	11752354
20@@	O	-1	11752354
2@@	O	-1	11752354
10@@	O	-1	11752354
A	O	-1	11752354
mut@@	O	-1	11752354
ation	O	-1	11752354
in	O	-1	11752354
the	O	-1	11752354
pro@@	O	-1	11752354
throm@@	O	-1	11752354
bin	O	-1	11752354
gen@@	O	-1	11752354
e	O	-1	11752354
was	O	-1	11752354
con@@	O	-1	11752354
duc@@	O	-1	11752354
ted	O	-1	11752354
in	O	-1	11752354
2@@	O	-1	11752354
17	O	-1	11752354
patients	O	-1	11752354
and	O	-1	11752354
7@@	O	-1	11752354
6@@	O	-1	11752354
3	O	-1	11752354
controls	O	-1	11752354
RESULTS:	O	-1	11752354
The	O	-1	11752354
o@@	O	-1	11752354
d@@	O	-1	11752354
ds	O	-1	11752354
rati@@	O	-1	11752354
o	O	-1	11752354
for	O	-1	11752354
myocardial	B-Disease	D009203	11752354
infarction	I-Disease	-1	11752354
among	O	-1	11752354
women	O	-1	11752354
who	O	-1	11752354
used	O	-1	11752354
any	O	-1	11752354
type	O	-1	11752354
of	O	-1	11752354
combined	O	-1	11752354
oral	B-Chemical	D003276	11752354
contrac@@	I-Chemical	-1	11752354
ep@@	I-Chemical	-1	11752354
tive	I-Chemical	-1	11752354
,	O	-1	11752354
as	O	-1	11752354
compared	O	-1	11752354
with	O	-1	11752354
non@@	O	-1	11752354
us@@	O	-1	11752354
er@@	O	-1	11752354
s,	O	-1	11752354
was	O	-1	11752354
2.@@	O	-1	11752354
0	O	-1	11752354
(@@	O	-1	11752354
9@@	O	-1	11752354
5	O	-1	11752354
perc@@	O	-1	11752354
ent	O	-1	11752354
conf@@	O	-1	11752354
idence	O	-1	11752354
inter@@	O	-1	11752354
val@@	O	-1	11752354
,	O	-1	11752354
1.@@	O	-1	11752354
5	O	-1	11752354
to	O	-1	11752354
2.@@	O	-1	11752354
8@@	O	-1	11752354
).	O	-1	11752354
The	O	-1	11752354
adjust@@	O	-1	11752354
ed	O	-1	11752354
o@@	O	-1	11752354
d@@	O	-1	11752354
ds	O	-1	11752354
rati@@	O	-1	11752354
o	O	-1	11752354
was	O	-1	11752354
2.@@	O	-1	11752354
5	O	-1	11752354
(@@	O	-1	11752354
9@@	O	-1	11752354
5	O	-1	11752354
perc@@	O	-1	11752354
ent	O	-1	11752354
conf@@	O	-1	11752354
idence	O	-1	11752354
inter@@	O	-1	11752354
val@@	O	-1	11752354
,	O	-1	11752354
1.@@	O	-1	11752354
5	O	-1	11752354
to	O	-1	11752354
4.@@	O	-1	11752354
1)	O	-1	11752354
among	O	-1	11752354
women	O	-1	11752354
who	O	-1	11752354
used	O	-1	11752354
secon@@	O	-1	11752354
d-@@	O	-1	11752354
generation	O	-1	11752354
oral	B-Chemical	D003276	11752354
contrac@@	I-Chemical	-1	11752354
ep@@	I-Chemical	-1	11752354
tiv@@	I-Chemical	-1	11752354
es	I-Chemical	-1	11752354
and	O	-1	11752354
1.@@	O	-1	11752354
3	O	-1	11752354
(@@	O	-1	11752354
9@@	O	-1	11752354
5	O	-1	11752354
perc@@	O	-1	11752354
ent	O	-1	11752354
conf@@	O	-1	11752354
idence	O	-1	11752354
inter@@	O	-1	11752354
val@@	O	-1	11752354
,	O	-1	11752354
0.@@	O	-1	11752354
7	O	-1	11752354
to	O	-1	11752354
2.@@	O	-1	11752354
5@@	O	-1	11752354
)	O	-1	11752354
among	O	-1	11752354
those	O	-1	11752354
who	O	-1	11752354
used	O	-1	11752354
thir@@	O	-1	11752354
d-@@	O	-1	11752354
generation	O	-1	11752354
oral	B-Chemical	D003276	11752354
contrac@@	I-Chemical	-1	11752354
ep@@	I-Chemical	-1	11752354
tiv@@	I-Chemical	-1	11752354
es	I-Chemical	-1	11752354
.	O	-1	11752354
A@@	O	-1	11752354
mon@@	O	-1	11752354
g	O	-1	11752354
women	O	-1	11752354
who	O	-1	11752354
used	O	-1	11752354
oral	B-Chemical	D003276	11752354
contrac@@	I-Chemical	-1	11752354
ep@@	I-Chemical	-1	11752354
tiv@@	I-Chemical	-1	11752354
es	I-Chemical	-1	11752354
,	O	-1	11752354
the	O	-1	11752354
o@@	O	-1	11752354
d@@	O	-1	11752354
ds	O	-1	11752354
rati@@	O	-1	11752354
o	O	-1	11752354
was	O	-1	11752354
2.@@	O	-1	11752354
1	O	-1	11752354
(@@	O	-1	11752354
9@@	O	-1	11752354
5	O	-1	11752354
perc@@	O	-1	11752354
ent	O	-1	11752354
conf@@	O	-1	11752354
idence	O	-1	11752354
inter@@	O	-1	11752354
val@@	O	-1	11752354
,	O	-1	11752354
1.@@	O	-1	11752354
5	O	-1	11752354
to	O	-1	11752354
3.@@	O	-1	11752354
0@@	O	-1	11752354
)	O	-1	11752354
for	O	-1	11752354
those	O	-1	11752354
without	O	-1	11752354
a	O	-1	11752354
pro@@	O	-1	11752354
thrombotic	O	-1	11752354
mut@@	O	-1	11752354
ation	O	-1	11752354
and	O	-1	11752354
1.@@	O	-1	11752354
9	O	-1	11752354
(@@	O	-1	11752354
9@@	O	-1	11752354
5	O	-1	11752354
perc@@	O	-1	11752354
ent	O	-1	11752354
conf@@	O	-1	11752354
idence	O	-1	11752354
inter@@	O	-1	11752354
val@@	O	-1	11752354
,	O	-1	11752354
0.@@	O	-1	11752354
6	O	-1	11752354
to	O	-1	11752354
5.@@	O	-1	11752354
5@@	O	-1	11752354
)	O	-1	11752354
for	O	-1	11752354
those	O	-1	11752354
with	O	-1	11752354
a	O	-1	11752354
mut@@	O	-1	11752354
ation	O	-1	11752354
CONCLUSIONS:	O	-1	11752354
The	O	-1	11752354
risk	O	-1	11752354
of	O	-1	11752354
myocardial	B-Disease	D009203	11752354
infarction	I-Disease	-1	11752354
was	O	-1	11752354
increased	O	-1	11752354
among	O	-1	11752354
women	O	-1	11752354
who	O	-1	11752354
used	O	-1	11752354
secon@@	O	-1	11752354
d-@@	O	-1	11752354
generation	O	-1	11752354
oral	B-Chemical	D003276	11752354
contrac@@	I-Chemical	-1	11752354
ep@@	I-Chemical	-1	11752354
tiv@@	I-Chemical	-1	11752354
es	I-Chemical	-1	11752354
.	O	-1	11752354
The	O	-1	11752354
results	O	-1	11752354
with	O	-1	11752354
resp@@	O	-1	11752354
ect	O	-1	11752354
to	O	-1	11752354
the	O	-1	11752354
use	O	-1	11752354
of	O	-1	11752354
thir@@	O	-1	11752354
d-@@	O	-1	11752354
generation	O	-1	11752354
oral	B-Chemical	D003276	11752354
contrac@@	I-Chemical	-1	11752354
ep@@	I-Chemical	-1	11752354
tiv@@	I-Chemical	-1	11752354
es	I-Chemical	-1	11752354
were	O	-1	11752354
in@@	O	-1	11752354
concl@@	O	-1	11752354
u@@	O	-1	11752354
sive	O	-1	11752354
but	O	-1	11752354
suggested	O	-1	11752354
that	O	-1	11752354
the	O	-1	11752354
risk	O	-1	11752354
was	O	-1	11752354
lower	O	-1	11752354
than	O	-1	11752354
the	O	-1	11752354
risk	O	-1	11752354
associated	O	-1	11752354
with	O	-1	11752354
secon@@	O	-1	11752354
d-@@	O	-1	11752354
generation	O	-1	11752354
oral	B-Chemical	D003276	11752354
contrac@@	I-Chemical	-1	11752354
ep@@	I-Chemical	-1	11752354
tiv@@	I-Chemical	-1	11752354
es	I-Chemical	-1	11752354
.	O	-1	11752354
The	O	-1	11752354
risk	O	-1	11752354
of	O	-1	11752354
myocardial	B-Disease	D009203	11752354
infarction	I-Disease	-1	11752354
was	O	-1	11752354
similar	O	-1	11752354
among	O	-1	11752354
women	O	-1	11752354
who	O	-1	11752354
used	O	-1	11752354
oral	B-Chemical	D003276	11752354
contrac@@	I-Chemical	-1	11752354
ep@@	I-Chemical	-1	11752354
tiv@@	I-Chemical	-1	11752354
es	I-Chemical	-1	11752354
whether	O	-1	11752354
or	O	-1	11752354
not	O	-1	11752354
they	O	-1	11752354
had	O	-1	11752354
a	O	-1	11752354
pro@@	O	-1	11752354
thrombotic	O	-1	11752354
mut@@	O	-1	11752354
ation.	O	-1	11752354

Eff@@	O	-1	12369736
ects	O	-1	12369736
of	O	-1	12369736
5-@@	O	-1	12369736
H@@	O	-1	12369736
T@@	O	-1	12369736
1@@	O	-1	12369736
B	O	-1	12369736
receptor	O	-1	12369736
li@@	O	-1	12369736
g@@	O	-1	12369736
and@@	O	-1	12369736
s	O	-1	12369736
micro@@	O	-1	12369736
injected	O	-1	12369736
into	O	-1	12369736
the	O	-1	12369736
accum@@	O	-1	12369736
b@@	O	-1	12369736
al	O	-1	12369736
s@@	O	-1	12369736
he@@	O	-1	12369736
ll	O	-1	12369736
or	O	-1	12369736
cor@@	O	-1	12369736
e	O	-1	12369736
on	O	-1	12369736
the	O	-1	12369736
cocaine	B-Chemical	D003042	12369736
-induced	O	-1	12369736
locomotor	B-Disease	D009069	12369736
hyperactivity	I-Disease	-1	12369736
in	O	-1	12369736
rats.	O	-1	12369736
The	O	-1	12369736
present	O	-1	12369736
study	O	-1	12369736
was	O	-1	12369736
de@@	O	-1	12369736
signed	O	-1	12369736
to	O	-1	12369736
ex@@	O	-1	12369736
amine	O	-1	12369736
the	O	-1	12369736
effect	O	-1	12369736
of	O	-1	12369736
5-@@	O	-1	12369736
H@@	O	-1	12369736
T@@	O	-1	12369736
1@@	O	-1	12369736
B	O	-1	12369736
receptor	O	-1	12369736
li@@	O	-1	12369736
g@@	O	-1	12369736
and@@	O	-1	12369736
s	O	-1	12369736
micro@@	O	-1	12369736
injected	O	-1	12369736
into	O	-1	12369736
the	O	-1	12369736
sub@@	O	-1	12369736
regi@@	O	-1	12369736
ons	O	-1	12369736
of	O	-1	12369736
the	O	-1	12369736
nucle@@	O	-1	12369736
us	O	-1	12369736
accum@@	O	-1	12369736
ben@@	O	-1	12369736
s	O	-1	12369736
(@@	O	-1	12369736
the	O	-1	12369736
s@@	O	-1	12369736
he@@	O	-1	12369736
ll	O	-1	12369736
and	O	-1	12369736
the	O	-1	12369736
co@@	O	-1	12369736
re@@	O	-1	12369736
)	O	-1	12369736
on	O	-1	12369736
the	O	-1	12369736
locomotor	B-Disease	D009069	12369736
hyperactivity	I-Disease	-1	12369736
induced	O	-1	12369736
by	O	-1	12369736
cocaine	B-Chemical	D003042	12369736
in	O	-1	12369736
rats.	O	-1	12369736
M@@	O	-1	12369736
al@@	O	-1	12369736
e	O	-1	12369736
Wistar	O	-1	12369736
rats	O	-1	12369736
were	O	-1	12369736
im@@	O	-1	12369736
pl@@	O	-1	12369736
ant@@	O	-1	12369736
ed	O	-1	12369736
bil@@	O	-1	12369736
at@@	O	-1	12369736
er@@	O	-1	12369736
ally	O	-1	12369736
with	O	-1	12369736
can@@	O	-1	12369736
n@@	O	-1	12369736
ul@@	O	-1	12369736
a@@	O	-1	12369736
e	O	-1	12369736
into	O	-1	12369736
the	O	-1	12369736
accum@@	O	-1	12369736
ben@@	O	-1	12369736
s	O	-1	12369736
s@@	O	-1	12369736
he@@	O	-1	12369736
ll	O	-1	12369736
or	O	-1	12369736
co@@	O	-1	12369736
re,	O	-1	12369736
and	O	-1	12369736
then	O	-1	12369736
were	O	-1	12369736
loc@@	O	-1	12369736
ally	O	-1	12369736
injected	O	-1	12369736
with	O	-1	12369736
G@@	B-Chemical	C103477	12369736
R	I-Chemical	-1	12369736
55@@	I-Chemical	-1	12369736
5@@	I-Chemical	-1	12369736
6@@	I-Chemical	-1	12369736
2	I-Chemical	-1	12369736
(@@	O	-1	12369736
an	O	-1	12369736
antagonist	O	-1	12369736
of	O	-1	12369736
5-@@	O	-1	12369736
H@@	O	-1	12369736
T@@	O	-1	12369736
1@@	O	-1	12369736
B	O	-1	12369736
receptor@@	O	-1	12369736
s)	O	-1	12369736
or	O	-1	12369736
C@@	B-Chemical	C065046	12369736
P	I-Chemical	-1	12369736
9@@	I-Chemical	-1	12369736
3@@	I-Chemical	-1	12369736
12@@	I-Chemical	-1	12369736
9	I-Chemical	-1	12369736
(@@	O	-1	12369736
an	O	-1	12369736
agon@@	O	-1	12369736
ist	O	-1	12369736
of	O	-1	12369736
5-@@	O	-1	12369736
H@@	O	-1	12369736
T@@	O	-1	12369736
1@@	O	-1	12369736
B	O	-1	12369736
receptor@@	O	-1	12369736
s@@	O	-1	12369736
).	O	-1	12369736
G@@	O	-1	12369736
i@@	O	-1	12369736
ven	O	-1	12369736
alone	O	-1	12369736
to	O	-1	12369736
any	O	-1	12369736
accum@@	O	-1	12369736
b@@	O	-1	12369736
al	O	-1	12369736
sub@@	O	-1	12369736
regi@@	O	-1	12369736
on@@	O	-1	12369736
,	O	-1	12369736
G@@	B-Chemical	C103477	12369736
R	I-Chemical	-1	12369736
55@@	I-Chemical	-1	12369736
5@@	I-Chemical	-1	12369736
6@@	I-Chemical	-1	12369736
2	I-Chemical	-1	12369736
(0.@@	O	-1	12369736
1-@@	O	-1	12369736
10	O	-1	12369736
micro@@	O	-1	12369736
g/@@	O	-1	12369736
side@@	O	-1	12369736
)	O	-1	12369736
or	O	-1	12369736
C@@	B-Chemical	C065046	12369736
P	I-Chemical	-1	12369736
9@@	I-Chemical	-1	12369736
3@@	I-Chemical	-1	12369736
12@@	I-Chemical	-1	12369736
9	I-Chemical	-1	12369736
(0.@@	O	-1	12369736
1-@@	O	-1	12369736
10	O	-1	12369736
micro@@	O	-1	12369736
g/@@	O	-1	12369736
side@@	O	-1	12369736
)	O	-1	12369736
did	O	-1	12369736
not	O	-1	12369736
change	O	-1	12369736
bas@@	O	-1	12369736
al	O	-1	12369736
locomotor	O	-1	12369736
activ@@	O	-1	12369736
ity.	O	-1	12369736
S@@	O	-1	12369736
y@@	O	-1	12369736
st@@	O	-1	12369736
em@@	O	-1	12369736
ic	O	-1	12369736
cocaine	B-Chemical	D003042	12369736
(10	O	-1	12369736
mg/kg)	O	-1	12369736
significantly	O	-1	12369736
increased	O	-1	12369736
the	O	-1	12369736
locomotor	O	-1	12369736
activity	O	-1	12369736
of	O	-1	12369736
rats.	O	-1	12369736
G@@	B-Chemical	C103477	12369736
R	I-Chemical	-1	12369736
55@@	I-Chemical	-1	12369736
5@@	I-Chemical	-1	12369736
6@@	I-Chemical	-1	12369736
2	I-Chemical	-1	12369736
(0.@@	O	-1	12369736
1-@@	O	-1	12369736
10	O	-1	12369736
micro@@	O	-1	12369736
g/@@	O	-1	12369736
side@@	O	-1	12369736
),	O	-1	12369736
administered	O	-1	12369736
intra@@	O	-1	12369736
-@@	O	-1	12369736
accum@@	O	-1	12369736
ben@@	O	-1	12369736
s	O	-1	12369736
s@@	O	-1	12369736
he@@	O	-1	12369736
ll	O	-1	12369736
prior	O	-1	12369736
to	O	-1	12369736
cocaine	B-Chemical	D003042	12369736
,	O	-1	12369736
dose-@@	O	-1	12369736
depend@@	O	-1	12369736
ently	O	-1	12369736
attenu@@	O	-1	12369736
ated	O	-1	12369736
the	O	-1	12369736
psych@@	O	-1	12369736
os@@	O	-1	12369736
tim@@	O	-1	12369736
ul@@	O	-1	12369736
ant@@	O	-1	12369736
-induced	O	-1	12369736
locomotor	B-Disease	D009069	12369736
hyperactivity	I-Disease	-1	12369736
.	O	-1	12369736
S@@	O	-1	12369736
uc@@	O	-1	12369736
h	O	-1	12369736
attenu@@	O	-1	12369736
ation	O	-1	12369736
was	O	-1	12369736
not	O	-1	12369736
found	O	-1	12369736
in	O	-1	12369736
animals	O	-1	12369736
which	O	-1	12369736
had	O	-1	12369736
been	O	-1	12369736
injected	O	-1	12369736
with	O	-1	12369736
G@@	B-Chemical	C103477	12369736
R	I-Chemical	-1	12369736
55@@	I-Chemical	-1	12369736
5@@	I-Chemical	-1	12369736
6@@	I-Chemical	-1	12369736
2	I-Chemical	-1	12369736
into	O	-1	12369736
the	O	-1	12369736
accum@@	O	-1	12369736
ben@@	O	-1	12369736
s	O	-1	12369736
co@@	O	-1	12369736
re.	O	-1	12369736
Whe@@	O	-1	12369736
n	O	-1	12369736
injected	O	-1	12369736
into	O	-1	12369736
the	O	-1	12369736
accum@@	O	-1	12369736
ben@@	O	-1	12369736
s	O	-1	12369736
s@@	O	-1	12369736
he@@	O	-1	12369736
ll	O	-1	12369736
(@@	O	-1	12369736
but	O	-1	12369736
not	O	-1	12369736
the	O	-1	12369736
co@@	O	-1	12369736
re@@	O	-1	12369736
)	O	-1	12369736
before	O	-1	12369736
cocaine	B-Chemical	D003042	12369736
,	O	-1	12369736
C@@	B-Chemical	C065046	12369736
P	I-Chemical	-1	12369736
9@@	I-Chemical	-1	12369736
3@@	I-Chemical	-1	12369736
12@@	I-Chemical	-1	12369736
9	I-Chemical	-1	12369736
(0.@@	O	-1	12369736
1-@@	O	-1	12369736
10	O	-1	12369736
micro@@	O	-1	12369736
g/@@	O	-1	12369736
side@@	O	-1	12369736
)	O	-1	12369736
enhanced	O	-1	12369736
the	O	-1	12369736
locomotor	O	-1	12369736
response	O	-1	12369736
to	O	-1	12369736
cocaine	B-Chemical	D003042	12369736
;	O	-1	12369736
the	O	-1	12369736
maxim@@	O	-1	12369736
um	O	-1	12369736
effect	O	-1	12369736
being	O	-1	12369736
observed	O	-1	12369736
after	O	-1	12369736
10	O	-1	12369736
micro@@	O	-1	12369736
g/@@	O	-1	12369736
side	O	-1	12369736
of	O	-1	12369736
the	O	-1	12369736
agon@@	O	-1	12369736
ist@@	O	-1	12369736
.	O	-1	12369736
The	O	-1	12369736
lat@@	O	-1	12369736
er	O	-1	12369736
enh@@	O	-1	12369736
ance@@	O	-1	12369736
ment	O	-1	12369736
was	O	-1	12369736
attenu@@	O	-1	12369736
ated	O	-1	12369736
after	O	-1	12369736
intra@@	O	-1	12369736
-@@	O	-1	12369736
accum@@	O	-1	12369736
ben@@	O	-1	12369736
s	O	-1	12369736
s@@	O	-1	12369736
he@@	O	-1	12369736
ll	O	-1	12369736
treatment	O	-1	12369736
with	O	-1	12369736
G@@	B-Chemical	C103477	12369736
R	I-Chemical	-1	12369736
55@@	I-Chemical	-1	12369736
5@@	I-Chemical	-1	12369736
6@@	I-Chemical	-1	12369736
2	I-Chemical	-1	12369736
(@@	O	-1	12369736
1	O	-1	12369736
micro@@	O	-1	12369736
g/@@	O	-1	12369736
side@@	O	-1	12369736
).	O	-1	12369736
Our	O	-1	12369736
findings	O	-1	12369736
indicate	O	-1	12369736
that	O	-1	12369736
cocaine	B-Chemical	D003042	12369736
induced	O	-1	12369736
hyper@@	B-Disease	D009069	12369736
locom@@	I-Disease	-1	12369736
o@@	I-Disease	-1	12369736
tion	I-Disease	-1	12369736
is	O	-1	12369736
mo@@	O	-1	12369736
di@@	O	-1	12369736
fied	O	-1	12369736
by	O	-1	12369736
5-@@	O	-1	12369736
H@@	O	-1	12369736
T@@	O	-1	12369736
1@@	O	-1	12369736
B	O	-1	12369736
receptor	O	-1	12369736
li@@	O	-1	12369736
g@@	O	-1	12369736
and@@	O	-1	12369736
s	O	-1	12369736
micro@@	O	-1	12369736
injected	O	-1	12369736
into	O	-1	12369736
the	O	-1	12369736
accum@@	O	-1	12369736
ben@@	O	-1	12369736
s	O	-1	12369736
s@@	O	-1	12369736
he@@	O	-1	12369736
ll@@	O	-1	12369736
,	O	-1	12369736
but	O	-1	12369736
not	O	-1	12369736
co@@	O	-1	12369736
re,	O	-1	12369736
this	O	-1	12369736
mo@@	O	-1	12369736
di@@	O	-1	12369736
fic@@	O	-1	12369736
ation	O	-1	12369736
consist@@	O	-1	12369736
ing	O	-1	12369736
in	O	-1	12369736
inhibit@@	O	-1	12369736
ory	O	-1	12369736
and	O	-1	12369736
fac@@	O	-1	12369736
il@@	O	-1	12369736
it@@	O	-1	12369736
atory	O	-1	12369736
effects	O	-1	12369736
of	O	-1	12369736
the	O	-1	12369736
5-@@	O	-1	12369736
H@@	O	-1	12369736
T@@	O	-1	12369736
1@@	O	-1	12369736
B	O	-1	12369736
receptor	O	-1	12369736
antagonist	O	-1	12369736
(	O	-1	12369736
G@@	B-Chemical	C103477	12369736
R	I-Chemical	-1	12369736
55@@	I-Chemical	-1	12369736
5@@	I-Chemical	-1	12369736
6@@	I-Chemical	-1	12369736
2	I-Chemical	-1	12369736
)	O	-1	12369736
and	O	-1	12369736
agon@@	O	-1	12369736
ist	O	-1	12369736
(	O	-1	12369736
C@@	B-Chemical	C065046	12369736
P	I-Chemical	-1	12369736
9@@	I-Chemical	-1	12369736
3@@	I-Chemical	-1	12369736
12@@	I-Chemical	-1	12369736
9	I-Chemical	-1	12369736
),	O	-1	12369736
respectively.	O	-1	12369736
In	O	-1	12369736
other	O	-1	12369736
wor@@	O	-1	12369736
d@@	O	-1	12369736
s,	O	-1	12369736
the	O	-1	12369736
present	O	-1	12369736
results	O	-1	12369736
suggest	O	-1	12369736
that	O	-1	12369736
the	O	-1	12369736
accum@@	O	-1	12369736
b@@	O	-1	12369736
al	O	-1	12369736
s@@	O	-1	12369736
he@@	O	-1	12369736
ll	O	-1	12369736
5-@@	O	-1	12369736
H@@	O	-1	12369736
T@@	O	-1	12369736
1@@	O	-1	12369736
B	O	-1	12369736
receptors	O	-1	12369736
pl@@	O	-1	12369736
ay	O	-1	12369736
a	O	-1	12369736
per@@	O	-1	12369736
mis@@	O	-1	12369736
sive	O	-1	12369736
role	O	-1	12369736
in	O	-1	12369736
the	O	-1	12369736
behavi@@	O	-1	12369736
o@@	O	-1	12369736
ural	O	-1	12369736
response	O	-1	12369736
to	O	-1	12369736
the	O	-1	12369736
psych@@	O	-1	12369736
os@@	O	-1	12369736
tim@@	O	-1	12369736
ul@@	O	-1	12369736
ant@@	O	-1	12369736
.	O	-1	12369736

T@@	B-Chemical	D013988	12639165
ic@@	I-Chemical	-1	12639165
lop@@	I-Chemical	-1	12639165
idine	I-Chemical	-1	12639165
-induced	O	-1	12639165
cholest@@	B-Disease	D002779	12639165
atic	I-Disease	-1	12639165
hepatitis	I-Disease	-1	12639165
cholest@@	B-Disease	D056486	12639165
atic	I-Disease	-1	12639165
hepatitis	I-Disease	-1	12639165
.	O	-1	12639165
OBJECTIVE:	O	-1	12639165
To	O	-1	12639165
report	O	-1	12639165
2	O	-1	12639165
cases	O	-1	12639165
of	O	-1	12639165
tic@@	B-Chemical	D013988	12639165
lop@@	I-Chemical	-1	12639165
idine	I-Chemical	-1	12639165
-induced	O	-1	12639165
cholest@@	B-Disease	D002779	12639165
atic	I-Disease	-1	12639165
hepatitis	I-Disease	-1	12639165
cholest@@	B-Disease	D056486	12639165
atic	I-Disease	-1	12639165
hepatitis	I-Disease	-1	12639165
,	O	-1	12639165
investigate	O	-1	12639165
its	O	-1	12639165
mechanis@@	O	-1	12639165
m@@	O	-1	12639165
,	O	-1	12639165
and	O	-1	12639165
compar@@	O	-1	12639165
e	O	-1	12639165
the	O	-1	12639165
observed	O	-1	12639165
ma@@	O	-1	12639165
in	O	-1	12639165
character@@	O	-1	12639165
is@@	O	-1	12639165
tics	O	-1	12639165
with	O	-1	12639165
those	O	-1	12639165
of	O	-1	12639165
the	O	-1	12639165
pu@@	O	-1	12639165
bl@@	O	-1	12639165
ished	O	-1	12639165
cas@@	O	-1	12639165
es.	O	-1	12639165
CA@@	O	-1	12639165
S@@	O	-1	12639165
E	O	-1	12639165
S@@	O	-1	12639165
U@@	O	-1	12639165
M@@	O	-1	12639165
MA@@	O	-1	12639165
R@@	O	-1	12639165
I@@	O	-1	12639165
E@@	O	-1	12639165
S:	O	-1	12639165
Two	O	-1	12639165
patients	O	-1	12639165
developed	O	-1	12639165
prolonged	O	-1	12639165
cholest@@	B-Disease	D002779	12639165
atic	I-Disease	-1	12639165
hepatitis	I-Disease	-1	12639165
cholest@@	B-Disease	D056486	12639165
atic	I-Disease	-1	12639165
hepatitis	I-Disease	-1	12639165
after	O	-1	12639165
receiving	O	-1	12639165
tic@@	B-Chemical	D013988	12639165
lop@@	I-Chemical	-1	12639165
idine	I-Chemical	-1	12639165
following	O	-1	12639165
perc@@	O	-1	12639165
utaneous	O	-1	12639165
coronary	O	-1	12639165
angio@@	O	-1	12639165
pl@@	O	-1	12639165
ast@@	O	-1	12639165
y,	O	-1	12639165
with	O	-1	12639165
complete	O	-1	12639165
re@@	O	-1	12639165
mission	O	-1	12639165
during	O	-1	12639165
the	O	-1	12639165
follow-up	O	-1	12639165
perio@@	O	-1	12639165
d.	O	-1	12639165
T@@	O	-1	12639165
-@@	O	-1	12639165
cell	O	-1	12639165
stimulation	O	-1	12639165
by	O	-1	12639165
therapeutic	O	-1	12639165
concentration	O	-1	12639165
of	O	-1	12639165
tic@@	B-Chemical	D013988	12639165
lop@@	I-Chemical	-1	12639165
idine	I-Chemical	-1	12639165
was	O	-1	12639165
demonstrated	O	-1	12639165
in	O	-1	12639165
vit@@	O	-1	12639165
r@@	O	-1	12639165
o	O	-1	12639165
in	O	-1	12639165
the	O	-1	12639165
patients,	O	-1	12639165
but	O	-1	12639165
not	O	-1	12639165
in	O	-1	12639165
healthy	O	-1	12639165
controls.	O	-1	12639165
D@@	O	-1	12639165
I@@	O	-1	12639165
S@@	O	-1	12639165
C@@	O	-1	12639165
US@@	O	-1	12639165
S@@	O	-1	12639165
ION@@	O	-1	12639165
:	O	-1	12639165
Ch@@	B-Disease	D002779	12639165
ol@@	I-Disease	-1	12639165
est@@	I-Disease	-1	12639165
atic	I-Disease	-1	12639165
hepatitis	I-Disease	-1	12639165
Ch@@	B-Disease	D056486	12639165
ol@@	I-Disease	-1	12639165
est@@	I-Disease	-1	12639165
atic	I-Disease	-1	12639165
hepatitis	I-Disease	-1	12639165
is	O	-1	12639165
a	O	-1	12639165
r@@	O	-1	12639165
are	O	-1	12639165
complication	O	-1	12639165
of	O	-1	12639165
the	O	-1	12639165
anti@@	O	-1	12639165
platele@@	O	-1	12639165
t	O	-1	12639165
agent	O	-1	12639165
tic@@	B-Chemical	D013988	12639165
lop@@	I-Chemical	-1	12639165
idine	I-Chemical	-1	12639165
;	O	-1	12639165
several	O	-1	12639165
cases	O	-1	12639165
have	O	-1	12639165
been	O	-1	12639165
reported	O	-1	12639165
but	O	-1	12639165
fe@@	O	-1	12639165
w	O	-1	12639165
in	O	-1	12639165
the	O	-1	12639165
E@@	O	-1	12639165
n@@	O	-1	12639165
gl@@	O	-1	12639165
is@@	O	-1	12639165
h	O	-1	12639165
literat@@	O	-1	12639165
ure.	O	-1	12639165
Our	O	-1	12639165
patients	O	-1	12639165
developed	O	-1	12639165
j@@	B-Disease	D007565	12639165
a@@	I-Disease	-1	12639165
un@@	I-Disease	-1	12639165
dic@@	I-Disease	-1	12639165
e	I-Disease	-1	12639165
following	O	-1	12639165
treatment	O	-1	12639165
with	O	-1	12639165
tic@@	B-Chemical	D013988	12639165
lop@@	I-Chemical	-1	12639165
idine	I-Chemical	-1	12639165
and	O	-1	12639165
showed	O	-1	12639165
the	O	-1	12639165
clinical	O	-1	12639165
and	O	-1	12639165
labor@@	O	-1	12639165
atory	O	-1	12639165
character@@	O	-1	12639165
is@@	O	-1	12639165
tics	O	-1	12639165
of	O	-1	12639165
cholest@@	B-Disease	D002779	12639165
atic	I-Disease	-1	12639165
hepatitis	I-Disease	-1	12639165
cholest@@	B-Disease	D056486	12639165
atic	I-Disease	-1	12639165
hepatitis	I-Disease	-1	12639165
,	O	-1	12639165
which	O	-1	12639165
resol@@	O	-1	12639165
ved	O	-1	12639165
after	O	-1	12639165
discontinu@@	O	-1	12639165
ation	O	-1	12639165
of	O	-1	12639165
the	O	-1	12639165
drug.	O	-1	12639165
He@@	B-Disease	D056486	12639165
pati@@	I-Disease	-1	12639165
tis	I-Disease	-1	12639165
may	O	-1	12639165
deve@@	O	-1	12639165
lo@@	O	-1	12639165
p	O	-1	12639165
weeks	O	-1	12639165
after	O	-1	12639165
discontinu@@	O	-1	12639165
ation	O	-1	12639165
of	O	-1	12639165
the	O	-1	12639165
drug	O	-1	12639165
and	O	-1	12639165
may	O	-1	12639165
ru@@	O	-1	12639165
n	O	-1	12639165
a	O	-1	12639165
prolonged	O	-1	12639165
cour@@	O	-1	12639165
se@@	O	-1	12639165
,	O	-1	12639165
but	O	-1	12639165
complete	O	-1	12639165
re@@	O	-1	12639165
mission	O	-1	12639165
was	O	-1	12639165
observed	O	-1	12639165
in	O	-1	12639165
all	O	-1	12639165
reported	O	-1	12639165
cas@@	O	-1	12639165
es.	O	-1	12639165
An	O	-1	12639165
ob@@	O	-1	12639165
j@@	O	-1	12639165
ective	O	-1	12639165
ca@@	O	-1	12639165
us@@	O	-1	12639165
ality	O	-1	12639165
assess@@	O	-1	12639165
ment	O	-1	12639165
revealed	O	-1	12639165
that	O	-1	12639165
the	O	-1	12639165
adverse	O	-1	12639165
drug	O	-1	12639165
ev@@	O	-1	12639165
ent	O	-1	12639165
was	O	-1	12639165
prob@@	O	-1	12639165
ably	O	-1	12639165
related	O	-1	12639165
to	O	-1	12639165
the	O	-1	12639165
use	O	-1	12639165
of	O	-1	12639165
tic@@	B-Chemical	D013988	12639165
lop@@	I-Chemical	-1	12639165
idine	I-Chemical	-1	12639165
.	O	-1	12639165
The	O	-1	12639165
mechanisms	O	-1	12639165
of	O	-1	12639165
this	O	-1	12639165
tic@@	B-Chemical	D013988	12639165
lop@@	I-Chemical	-1	12639165
idine	I-Chemical	-1	12639165
-induced	O	-1	12639165
cholest@@	B-Disease	D002779	12639165
asis	I-Disease	-1	12639165
are	O	-1	12639165
unc@@	O	-1	12639165
lear@@	O	-1	12639165
.	O	-1	12639165
Im@@	O	-1	12639165
mun@@	O	-1	12639165
e	O	-1	12639165
mechanisms	O	-1	12639165
may	O	-1	12639165
be	O	-1	12639165
involved	O	-1	12639165
in	O	-1	12639165
the	O	-1	12639165
drug@@	O	-1	12639165
's	O	-1	12639165
hepat@@	B-Disease	D056486	12639165
otoxicity	I-Disease	-1	12639165
,	O	-1	12639165
as	O	-1	12639165
suggested	O	-1	12639165
by	O	-1	12639165
the	O	-1	12639165
T@@	O	-1	12639165
-@@	O	-1	12639165
cell	O	-1	12639165
stimulation	O	-1	12639165
study	O	-1	12639165
reported	O	-1	12639165
he@@	O	-1	12639165
re.	O	-1	12639165
CONCLUSIONS:	O	-1	12639165
Ch@@	B-Disease	D002779	12639165
ol@@	I-Disease	-1	12639165
est@@	I-Disease	-1	12639165
atic	I-Disease	-1	12639165
hepatitis	I-Disease	-1	12639165
Ch@@	B-Disease	D056486	12639165
ol@@	I-Disease	-1	12639165
est@@	I-Disease	-1	12639165
atic	I-Disease	-1	12639165
hepatitis	I-Disease	-1	12639165
is	O	-1	12639165
a	O	-1	12639165
r@@	O	-1	12639165
are	O	-1	12639165
adverse	O	-1	12639165
effect	O	-1	12639165
of	O	-1	12639165
tic@@	B-Chemical	D013988	12639165
lop@@	I-Chemical	-1	12639165
idine	I-Chemical	-1	12639165
that	O	-1	12639165
may	O	-1	12639165
be	O	-1	12639165
immun@@	O	-1	12639165
e	O	-1	12639165
medi@@	O	-1	12639165
ated.	O	-1	12639165
Patients	O	-1	12639165
receiving	O	-1	12639165
the	O	-1	12639165
drug	O	-1	12639165
should	O	-1	12639165
be	O	-1	12639165
monit@@	O	-1	12639165
o@@	O	-1	12639165
red	O	-1	12639165
with	O	-1	12639165
liver	O	-1	12639165
function	O	-1	12639165
tests	O	-1	12639165
al@@	O	-1	12639165
ong	O	-1	12639165
with	O	-1	12639165
complete	O	-1	12639165
blood	O	-1	12639165
cell	O	-1	12639165
coun@@	O	-1	12639165
t@@	O	-1	12639165
s.	O	-1	12639165
This	O	-1	12639165
complication	O	-1	12639165
wil@@	O	-1	12639165
l	O	-1	12639165
be	O	-1	12639165
observed	O	-1	12639165
even	O	-1	12639165
less	O	-1	12639165
often	O	-1	12639165
in	O	-1	12639165
the	O	-1	12639165
f@@	O	-1	12639165
ut@@	O	-1	12639165
ure	O	-1	12639165
as	O	-1	12639165
tic@@	B-Chemical	D013988	12639165
lop@@	I-Chemical	-1	12639165
idine	I-Chemical	-1	12639165
is	O	-1	12639165
being	O	-1	12639165
re@@	O	-1	12639165
pl@@	O	-1	12639165
ac@@	O	-1	12639165
ed	O	-1	12639165
by	O	-1	12639165
the	O	-1	12639165
ne@@	O	-1	12639165
w@@	O	-1	12639165
er	O	-1	12639165
anti@@	O	-1	12639165
platele@@	O	-1	12639165
t	O	-1	12639165
agent	O	-1	12639165
c@@	B-Chemical	C055162	12639165
lop@@	I-Chemical	-1	12639165
id@@	I-Chemical	-1	12639165
o@@	I-Chemical	-1	12639165
gre@@	I-Chemical	-1	12639165
l	I-Chemical	-1	12639165
.	O	-1	12639165

E@@	O	-1	12653683
pi@@	O	-1	12653683
thelial	O	-1	12653683
sodium	B-Chemical	D012964	12653683
channel	O	-1	12653683
(@@	O	-1	12653683
E@@	O	-1	12653683
Na@@	O	-1	12653683
C@@	O	-1	12653683
)	O	-1	12653683
sub@@	O	-1	12653683
un@@	O	-1	12653683
it	O	-1	12653683
mRNA	O	-1	12653683
and	O	-1	12653683
protein	O	-1	12653683
expression	O	-1	12653683
in	O	-1	12653683
rats	O	-1	12653683
with	O	-1	12653683
p@@	B-Chemical	D011692	12653683
uro@@	I-Chemical	-1	12653683
m@@	I-Chemical	-1	12653683
ycin	I-Chemical	-1	12653683
amin@@	I-Chemical	-1	12653683
on@@	I-Chemical	-1	12653683
ucle@@	I-Chemical	-1	12653683
o@@	I-Chemical	-1	12653683
side	I-Chemical	-1	12653683
-induced	O	-1	12653683
nephro@@	B-Disease	D009404	12653683
tic	I-Disease	-1	12653683
syndrome	I-Disease	-1	12653683
.	O	-1	12653683
In	O	-1	12653683
experimental	O	-1	12653683
nephro@@	B-Disease	D009404	12653683
tic	I-Disease	-1	12653683
syndrome	I-Disease	-1	12653683
,	O	-1	12653683
urinary	O	-1	12653683
sodium	B-Chemical	D012964	12653683
ex@@	O	-1	12653683
cre@@	O	-1	12653683
tion	O	-1	12653683
is	O	-1	12653683
decreased	O	-1	12653683
during	O	-1	12653683
the	O	-1	12653683
early	O	-1	12653683
phase	O	-1	12653683
of	O	-1	12653683
the	O	-1	12653683
disease.	O	-1	12653683
The	O	-1	12653683
mol@@	O	-1	12653683
ec@@	O	-1	12653683
ular	O	-1	12653683
mechanis@@	O	-1	12653683
m@@	O	-1	12653683
(@@	O	-1	12653683
s)	O	-1	12653683
lead@@	O	-1	12653683
ing	O	-1	12653683
to	O	-1	12653683
sal@@	O	-1	12653683
t	O	-1	12653683
re@@	O	-1	12653683
ten@@	O	-1	12653683
tion	O	-1	12653683
has	O	-1	12653683
not	O	-1	12653683
been	O	-1	12653683
complete@@	O	-1	12653683
ly	O	-1	12653683
el@@	O	-1	12653683
uc@@	O	-1	12653683
id@@	O	-1	12653683
ated.	O	-1	12653683
The	O	-1	12653683
rat@@	O	-1	12653683
e-@@	O	-1	12653683
lim@@	O	-1	12653683
it@@	O	-1	12653683
ing	O	-1	12653683
con@@	O	-1	12653683
sti@@	O	-1	12653683
tu@@	O	-1	12653683
ent	O	-1	12653683
of	O	-1	12653683
coll@@	O	-1	12653683
ect@@	O	-1	12653683
ing	O	-1	12653683
duc@@	O	-1	12653683
t	O	-1	12653683
sodium	B-Chemical	D012964	12653683
trans@@	O	-1	12653683
por@@	O	-1	12653683
t	O	-1	12653683
is	O	-1	12653683
the	O	-1	12653683
epi@@	O	-1	12653683
thelial	O	-1	12653683
sodium	B-Chemical	D012964	12653683
channel	O	-1	12653683
(@@	O	-1	12653683
E@@	O	-1	12653683
Na@@	O	-1	12653683
C@@	O	-1	12653683
).	O	-1	12653683
We	O	-1	12653683
examined	O	-1	12653683
the	O	-1	12653683
ab@@	O	-1	12653683
und@@	O	-1	12653683
ance	O	-1	12653683
of	O	-1	12653683
E@@	O	-1	12653683
Na@@	O	-1	12653683
C	O	-1	12653683
sub@@	O	-1	12653683
un@@	O	-1	12653683
it	O	-1	12653683
mR@@	O	-1	12653683
N@@	O	-1	12653683
A@@	O	-1	12653683
s	O	-1	12653683
and	O	-1	12653683
protein@@	O	-1	12653683
s	O	-1	12653683
in	O	-1	12653683
p@@	B-Chemical	D011692	12653683
uro@@	I-Chemical	-1	12653683
m@@	I-Chemical	-1	12653683
ycin	I-Chemical	-1	12653683
amin@@	I-Chemical	-1	12653683
on@@	I-Chemical	-1	12653683
ucle@@	I-Chemical	-1	12653683
o@@	I-Chemical	-1	12653683
side	I-Chemical	-1	12653683
(	O	-1	12653683
PA@@	B-Chemical	D011692	12653683
N	I-Chemical	-1	12653683
)@@	O	-1	12653683
-induced	O	-1	12653683
nephro@@	B-Disease	D009404	12653683
tic	I-Disease	-1	12653683
syndrome	I-Disease	-1	12653683
.	O	-1	12653683
The	O	-1	12653683
time	O	-1	12653683
cour@@	O	-1	12653683
ses	O	-1	12653683
of	O	-1	12653683
urinary	O	-1	12653683
sodium	B-Chemical	D012964	12653683
ex@@	O	-1	12653683
cre@@	O	-1	12653683
tion,	O	-1	12653683
plasma	O	-1	12653683
al@@	B-Chemical	D000450	12653683
do@@	I-Chemical	-1	12653683
sterone	I-Chemical	-1	12653683
concentration	O	-1	12653683
and	O	-1	12653683
proteinuria	B-Disease	D011507	12653683
were	O	-1	12653683
studied	O	-1	12653683
in	O	-1	12653683
male	O	-1	12653683
S@@	O	-1	12653683
pra@@	O	-1	12653683
gu@@	O	-1	12653683
e-@@	O	-1	12653683
D@@	O	-1	12653683
aw@@	O	-1	12653683
le@@	O	-1	12653683
y	O	-1	12653683
rats	O	-1	12653683
treated	O	-1	12653683
with	O	-1	12653683
a	O	-1	12653683
single	O	-1	12653683
dose	O	-1	12653683
of	O	-1	12653683
either	O	-1	12653683
PA@@	B-Chemical	D011692	12653683
N	I-Chemical	-1	12653683
or	O	-1	12653683
ve@@	O	-1	12653683
h@@	O	-1	12653683
ic@@	O	-1	12653683
le@@	O	-1	12653683
.	O	-1	12653683
The	O	-1	12653683
rel@@	O	-1	12653683
ative	O	-1	12653683
amoun@@	O	-1	12653683
ts	O	-1	12653683
of	O	-1	12653683
alpha@@	O	-1	12653683
E@@	O	-1	12653683
Na@@	O	-1	12653683
C@@	O	-1	12653683
,	O	-1	12653683
beta@@	O	-1	12653683
E@@	O	-1	12653683
Na@@	O	-1	12653683
C	O	-1	12653683
and	O	-1	12653683
gamma@@	O	-1	12653683
E@@	O	-1	12653683
Na@@	O	-1	12653683
C	O	-1	12653683
mR@@	O	-1	12653683
N@@	O	-1	12653683
A@@	O	-1	12653683
s	O	-1	12653683
were	O	-1	12653683
determined	O	-1	12653683
in	O	-1	12653683
kidne@@	O	-1	12653683
ys	O	-1	12653683
from	O	-1	12653683
these	O	-1	12653683
rats	O	-1	12653683
by	O	-1	12653683
re@@	O	-1	12653683
al@@	O	-1	12653683
-@@	O	-1	12653683
time	O	-1	12653683
qu@@	O	-1	12653683
anti@@	O	-1	12653683
t@@	O	-1	12653683
ative	O	-1	12653683
T@@	O	-1	12653683
a@@	O	-1	12653683
q@@	O	-1	12653683
M@@	O	-1	12653683
an	O	-1	12653683
P@@	O	-1	12653683
CR@@	O	-1	12653683
,	O	-1	12653683
and	O	-1	12653683
the	O	-1	12653683
amoun@@	O	-1	12653683
ts	O	-1	12653683
of	O	-1	12653683
protein@@	O	-1	12653683
s	O	-1	12653683
by	O	-1	12653683
W@@	O	-1	12653683
est@@	O	-1	12653683
er@@	O	-1	12653683
n	O	-1	12653683
blo@@	O	-1	12653683
t.	O	-1	12653683
The	O	-1	12653683
kine@@	O	-1	12653683
tics	O	-1	12653683
of	O	-1	12653683
urinary	O	-1	12653683
sodium	B-Chemical	D012964	12653683
ex@@	O	-1	12653683
cre@@	O	-1	12653683
tion	O	-1	12653683
and	O	-1	12653683
the	O	-1	12653683
appear@@	O	-1	12653683
ance	O	-1	12653683
of	O	-1	12653683
proteinuria	B-Disease	D011507	12653683
were	O	-1	12653683
compar@@	O	-1	12653683
able	O	-1	12653683
with	O	-1	12653683
those	O	-1	12653683
reported	O	-1	12653683
previ@@	O	-1	12653683
ous@@	O	-1	12653683
ly.	O	-1	12653683
S@@	B-Chemical	D012964	12653683
odium	I-Chemical	-1	12653683
re@@	O	-1	12653683
ten@@	O	-1	12653683
tion	O	-1	12653683
occurred	O	-1	12653683
on	O	-1	12653683
days	O	-1	12653683
2,	O	-1	12653683
3	O	-1	12653683
and	O	-1	12653683
6	O	-1	12653683
after	O	-1	12653683
PA@@	B-Chemical	D011692	12653683
N	I-Chemical	-1	12653683
injec@@	O	-1	12653683
tion.	O	-1	12653683
A	O	-1	12653683
significant	O	-1	12653683
up@@	O	-1	12653683
-@@	O	-1	12653683
reg@@	O	-1	12653683
ulation	O	-1	12653683
of	O	-1	12653683
alpha@@	O	-1	12653683
E@@	O	-1	12653683
Na@@	O	-1	12653683
C	O	-1	12653683
and	O	-1	12653683
beta@@	O	-1	12653683
E@@	O	-1	12653683
Na@@	O	-1	12653683
C	O	-1	12653683
mRNA	O	-1	12653683
ab@@	O	-1	12653683
und@@	O	-1	12653683
ance	O	-1	12653683
on	O	-1	12653683
days	O	-1	12653683
1	O	-1	12653683
and	O	-1	12653683
2	O	-1	12653683
pre@@	O	-1	12653683
ce@@	O	-1	12653683
ded	O	-1	12653683
sodium	B-Chemical	D012964	12653683
re@@	O	-1	12653683
ten@@	O	-1	12653683
tion	O	-1	12653683
on	O	-1	12653683
days	O	-1	12653683
2	O	-1	12653683
and	O	-1	12653683
3@@	O	-1	12653683
.	O	-1	12653683
Con@@	O	-1	12653683
ver@@	O	-1	12653683
sel@@	O	-1	12653683
y,	O	-1	12653683
do@@	O	-1	12653683
w@@	O	-1	12653683
n@@	O	-1	12653683
-@@	O	-1	12653683
reg@@	O	-1	12653683
ulation	O	-1	12653683
of	O	-1	12653683
alpha@@	O	-1	12653683
E@@	O	-1	12653683
Na@@	O	-1	12653683
C@@	O	-1	12653683
,	O	-1	12653683
beta@@	O	-1	12653683
E@@	O	-1	12653683
Na@@	O	-1	12653683
C	O	-1	12653683
and	O	-1	12653683
gamma@@	O	-1	12653683
E@@	O	-1	12653683
Na@@	O	-1	12653683
C	O	-1	12653683
mRNA	O	-1	12653683
expression	O	-1	12653683
on	O	-1	12653683
day	O	-1	12653683
3	O	-1	12653683
occurred	O	-1	12653683
in	O	-1	12653683
the	O	-1	12653683
presence	O	-1	12653683
of	O	-1	12653683
high	O	-1	12653683
al@@	B-Chemical	D000450	12653683
do@@	I-Chemical	-1	12653683
sterone	I-Chemical	-1	12653683
concentr@@	O	-1	12653683
ation@@	O	-1	12653683
s,	O	-1	12653683
and	O	-1	12653683
was	O	-1	12653683
followed	O	-1	12653683
by	O	-1	12653683
a	O	-1	12653683
retur@@	O	-1	12653683
n	O	-1	12653683
of	O	-1	12653683
sodium	B-Chemical	D012964	12653683
ex@@	O	-1	12653683
cre@@	O	-1	12653683
tion	O	-1	12653683
to	O	-1	12653683
control	O	-1	12653683
valu@@	O	-1	12653683
es.	O	-1	12653683
The	O	-1	12653683
amoun@@	O	-1	12653683
ts	O	-1	12653683
of	O	-1	12653683
alpha@@	O	-1	12653683
E@@	O	-1	12653683
Na@@	O	-1	12653683
C@@	O	-1	12653683
,	O	-1	12653683
beta@@	O	-1	12653683
E@@	O	-1	12653683
Na@@	O	-1	12653683
C	O	-1	12653683
and	O	-1	12653683
gamma@@	O	-1	12653683
E@@	O	-1	12653683
Na@@	O	-1	12653683
C	O	-1	12653683
protein@@	O	-1	12653683
s	O	-1	12653683
were	O	-1	12653683
not	O	-1	12653683
increased	O	-1	12653683
during	O	-1	12653683
PA@@	B-Chemical	D011692	12653683
N	I-Chemical	-1	12653683
-induced	O	-1	12653683
sodium	B-Chemical	D012964	12653683
re@@	O	-1	12653683
ten@@	O	-1	12653683
tion.	O	-1	12653683
In	O	-1	12653683
concl@@	O	-1	12653683
u@@	O	-1	12653683
sion,	O	-1	12653683
E@@	O	-1	12653683
Na@@	O	-1	12653683
C	O	-1	12653683
mRNA	O	-1	12653683
ex@@	O	-1	12653683
pres@@	O	-1	12653683
sion,	O	-1	12653683
es@@	O	-1	12653683
p@@	O	-1	12653683
ec@@	O	-1	12653683
i@@	O	-1	12653683
ally	O	-1	12653683
alpha@@	O	-1	12653683
E@@	O	-1	12653683
Na@@	O	-1	12653683
C@@	O	-1	12653683
,	O	-1	12653683
is	O	-1	12653683
increased	O	-1	12653683
in	O	-1	12653683
the	O	-1	12653683
very	O	-1	12653683
early	O	-1	12653683
phase	O	-1	12653683
of	O	-1	12653683
the	O	-1	12653683
experimental	O	-1	12653683
model	O	-1	12653683
of	O	-1	12653683
PA@@	B-Chemical	D011692	12653683
N	I-Chemical	-1	12653683
-induced	O	-1	12653683
nephro@@	B-Disease	D009404	12653683
tic	I-Disease	-1	12653683
syndrome	I-Disease	-1	12653683
in	O	-1	12653683
rats,	O	-1	12653683
but	O	-1	12653683
appear@@	O	-1	12653683
s	O	-1	12653683
to	O	-1	12653683
es@@	O	-1	12653683
cap@@	O	-1	12653683
e	O	-1	12653683
from	O	-1	12653683
the	O	-1	12653683
reg@@	O	-1	12653683
ulation	O	-1	12653683
by	O	-1	12653683
al@@	B-Chemical	D000450	12653683
do@@	I-Chemical	-1	12653683
sterone	I-Chemical	-1	12653683
after	O	-1	12653683
day	O	-1	12653683
3@@	O	-1	12653683
.	O	-1	12653683

N@@	B-Chemical	D009569	14659530
O	I-Chemical	-1	14659530
-induced	O	-1	14659530
migra@@	B-Disease	D008881	14659530
ine	I-Disease	-1	14659530
at@@	O	-1	14659530
tac@@	O	-1	14659530
k@@	O	-1	14659530
:	O	-1	14659530
st@@	O	-1	14659530
ron@@	O	-1	14659530
g	O	-1	14659530
increase	O	-1	14659530
in	O	-1	14659530
plasma	O	-1	14659530
calc@@	B-Chemical	D015740	14659530
it@@	I-Chemical	-1	14659530
on@@	I-Chemical	-1	14659530
in	I-Chemical	-1	14659530
gen@@	I-Chemical	-1	14659530
e-@@	I-Chemical	-1	14659530
related	I-Chemical	-1	14659530
p@@	I-Chemical	-1	14659530
ep@@	I-Chemical	-1	14659530
ti@@	I-Chemical	-1	14659530
de	I-Chemical	-1	14659530
(	O	-1	14659530
C@@	B-Chemical	D015740	14659530
G@@	I-Chemical	-1	14659530
R@@	I-Chemical	-1	14659530
P	I-Chemical	-1	14659530
)	O	-1	14659530
concentration	O	-1	14659530
and	O	-1	14659530
negative	O	-1	14659530
correl@@	O	-1	14659530
ation	O	-1	14659530
with	O	-1	14659530
platele@@	O	-1	14659530
t	O	-1	14659530
seroton@@	B-Chemical	D012701	14659530
in	I-Chemical	-1	14659530
rele@@	O	-1	14659530
as@@	O	-1	14659530
e.	O	-1	14659530
The	O	-1	14659530
a@@	O	-1	14659530
im	O	-1	14659530
of	O	-1	14659530
the	O	-1	14659530
present	O	-1	14659530
study	O	-1	14659530
was	O	-1	14659530
to	O	-1	14659530
investigate	O	-1	14659530
changes	O	-1	14659530
in	O	-1	14659530
the	O	-1	14659530
plasma	O	-1	14659530
calc@@	B-Chemical	D015740	14659530
it@@	I-Chemical	-1	14659530
on@@	I-Chemical	-1	14659530
in	I-Chemical	-1	14659530
gen@@	I-Chemical	-1	14659530
e-@@	I-Chemical	-1	14659530
related	I-Chemical	-1	14659530
p@@	I-Chemical	-1	14659530
ep@@	I-Chemical	-1	14659530
ti@@	I-Chemical	-1	14659530
de	I-Chemical	-1	14659530
(	O	-1	14659530
C@@	B-Chemical	D015740	14659530
G@@	I-Chemical	-1	14659530
R@@	I-Chemical	-1	14659530
P	I-Chemical	-1	14659530
)	O	-1	14659530
concentration	O	-1	14659530
and	O	-1	14659530
platele@@	O	-1	14659530
t	O	-1	14659530
seroton@@	B-Chemical	D012701	14659530
in	I-Chemical	-1	14659530
(	O	-1	14659530
5-@@	B-Chemical	D012701	14659530
hydrox@@	I-Chemical	-1	14659530
y@@	I-Chemical	-1	14659530
tri@@	I-Chemical	-1	14659530
pt@@	I-Chemical	-1	14659530
amine	I-Chemical	-1	14659530
,	O	-1	14659530
5-@@	B-Chemical	D012701	14659530
H@@	I-Chemical	-1	14659530
T	I-Chemical	-1	14659530
)	O	-1	14659530
cont@@	O	-1	14659530
ent	O	-1	14659530
during	O	-1	14659530
the	O	-1	14659530
immedi@@	O	-1	14659530
ate	O	-1	14659530
headac@@	B-Disease	D006261	14659530
he	I-Disease	-1	14659530
and	O	-1	14659530
the	O	-1	14659530
del@@	O	-1	14659530
ayed	O	-1	14659530
gen@@	O	-1	14659530
u@@	O	-1	14659530
ine	O	-1	14659530
migra@@	B-Disease	D008881	14659530
ine	I-Disease	-1	14659530
at@@	O	-1	14659530
tac@@	O	-1	14659530
k	O	-1	14659530
prov@@	O	-1	14659530
o@@	O	-1	14659530
ked	O	-1	14659530
by	O	-1	14659530
nitro@@	B-Chemical	D005996	14659530
glycer@@	I-Chemical	-1	14659530
in	I-Chemical	-1	14659530
.	O	-1	14659530
F@@	O	-1	14659530
if@@	O	-1	14659530
te@@	O	-1	14659530
en	O	-1	14659530
female	O	-1	14659530
migra@@	B-Disease	D020326	14659530
ine@@	I-Disease	-1	14659530
ur@@	I-Disease	-1	14659530
s	I-Disease	-1	14659530
(@@	I-Disease	-1	14659530
without	I-Disease	-1	14659530
a@@	I-Disease	-1	14659530
ur@@	I-Disease	-1	14659530
a@@	I-Disease	-1	14659530
)	I-Disease	-1	14659530
and	O	-1	14659530
e@@	O	-1	14659530
ight	O	-1	14659530
controls	O	-1	14659530
partic@@	O	-1	14659530
ip@@	O	-1	14659530
ated	O	-1	14659530
in	O	-1	14659530
the	O	-1	14659530
study.	O	-1	14659530
S@@	O	-1	14659530
u@@	O	-1	14659530
bl@@	O	-1	14659530
ing@@	O	-1	14659530
ual	O	-1	14659530
nitro@@	B-Chemical	D005996	14659530
glycer@@	I-Chemical	-1	14659530
in	I-Chemical	-1	14659530
(0.@@	O	-1	14659530
5	O	-1	14659530
mg@@	O	-1	14659530
)	O	-1	14659530
was	O	-1	14659530
administ@@	O	-1	14659530
e@@	O	-1	14659530
red.	O	-1	14659530
B@@	O	-1	14659530
lo@@	O	-1	14659530
od	O	-1	14659530
was	O	-1	14659530
coll@@	O	-1	14659530
ected	O	-1	14659530
from	O	-1	14659530
the	O	-1	14659530
ant@@	O	-1	14659530
ec@@	O	-1	14659530
ub@@	O	-1	14659530
it@@	O	-1	14659530
al	O	-1	14659530
ve@@	O	-1	14659530
in	O	-1	14659530
four	O	-1	14659530
tim@@	O	-1	14659530
es@@	O	-1	14659530
:	O	-1	14659530
60	O	-1	14659530
min	O	-1	14659530
before	O	-1	14659530
and	O	-1	14659530
after	O	-1	14659530
the	O	-1	14659530
nitro@@	B-Chemical	D005996	14659530
glycer@@	I-Chemical	-1	14659530
in	I-Chemical	-1	14659530
ap@@	O	-1	14659530
plic@@	O	-1	14659530
ation,	O	-1	14659530
and	O	-1	14659530
60	O	-1	14659530
and	O	-1	14659530
1@@	O	-1	14659530
20	O	-1	14659530
min	O	-1	14659530
after	O	-1	14659530
the	O	-1	14659530
be@@	O	-1	14659530
g@@	O	-1	14659530
in@@	O	-1	14659530
ning	O	-1	14659530
of	O	-1	14659530
the	O	-1	14659530
migra@@	B-Disease	D008881	14659530
ine	I-Disease	-1	14659530
at@@	O	-1	14659530
tac@@	O	-1	14659530
k	O	-1	14659530
(@@	O	-1	14659530
mean	O	-1	14659530
34@@	O	-1	14659530
4	O	-1	14659530
and	O	-1	14659530
4@@	O	-1	14659530
0@@	O	-1	14659530
4	O	-1	14659530
min@@	O	-1	14659530
;	O	-1	14659530
12	O	-1	14659530
subj@@	O	-1	14659530
ect@@	O	-1	14659530
s@@	O	-1	14659530
).	O	-1	14659530
In	O	-1	14659530
those	O	-1	14659530
subjects	O	-1	14659530
who	O	-1	14659530
had	O	-1	14659530
no	O	-1	14659530
migra@@	B-Disease	D008881	14659530
ine	I-Disease	-1	14659530
at@@	O	-1	14659530
tac@@	O	-1	14659530
k	O	-1	14659530
(1@@	O	-1	14659530
1	O	-1	14659530
subj@@	O	-1	14659530
ect@@	O	-1	14659530
s)	O	-1	14659530
a	O	-1	14659530
similar	O	-1	14659530
time	O	-1	14659530
sch@@	O	-1	14659530
ed@@	O	-1	14659530
ul@@	O	-1	14659530
e	O	-1	14659530
was	O	-1	14659530
use@@	O	-1	14659530
d.	O	-1	14659530
P@@	O	-1	14659530
las@@	O	-1	14659530
ma	O	-1	14659530
C@@	B-Chemical	D015740	14659530
G@@	I-Chemical	-1	14659530
R@@	I-Chemical	-1	14659530
P	I-Chemical	-1	14659530
concentration	O	-1	14659530
increased	O	-1	14659530
significantly	O	-1	14659530
(P@@	O	-1	14659530
<@@	O	-1	14659530
0.0@@	O	-1	14659530
1)	O	-1	14659530
during	O	-1	14659530
the	O	-1	14659530
migra@@	B-Disease	D008881	14659530
ine	I-Disease	-1	14659530
at@@	O	-1	14659530
tac@@	O	-1	14659530
k	O	-1	14659530
and	O	-1	14659530
retur@@	O	-1	14659530
n@@	O	-1	14659530
ed	O	-1	14659530
to	O	-1	14659530
baseline	O	-1	14659530
after	O	-1	14659530
the	O	-1	14659530
cess@@	O	-1	14659530
ation	O	-1	14659530
of	O	-1	14659530
the	O	-1	14659530
migra@@	B-Disease	D008881	14659530
ine	I-Disease	-1	14659530
.	O	-1	14659530
In	O	-1	14659530
addi@@	O	-1	14659530
tion,	O	-1	14659530
both	O	-1	14659530
change	O	-1	14659530
and	O	-1	14659530
pe@@	O	-1	14659530
ak@@	O	-1	14659530
,	O	-1	14659530
showed	O	-1	14659530
significant	O	-1	14659530
positive	O	-1	14659530
correl@@	O	-1	14659530
ations	O	-1	14659530
with	O	-1	14659530
migra@@	B-Disease	D008881	14659530
ine	I-Disease	-1	14659530
headac@@	B-Disease	D006261	14659530
he	I-Disease	-1	14659530
int@@	O	-1	14659530
ensity	O	-1	14659530
(P@@	O	-1	14659530
<@@	O	-1	14659530
0.00@@	O	-1	14659530
1).	O	-1	14659530
However,	O	-1	14659530
plasma	O	-1	14659530
C@@	B-Chemical	D015740	14659530
G@@	I-Chemical	-1	14659530
R@@	I-Chemical	-1	14659530
P	I-Chemical	-1	14659530
concentrations	O	-1	14659530
fail@@	O	-1	14659530
ed	O	-1	14659530
to	O	-1	14659530
change	O	-1	14659530
during	O	-1	14659530
immedi@@	O	-1	14659530
ate	O	-1	14659530
headac@@	B-Disease	D006261	14659530
he	I-Disease	-1	14659530
and	O	-1	14659530
in	O	-1	14659530
the	O	-1	14659530
subjects	O	-1	14659530
with	O	-1	14659530
no	O	-1	14659530
migra@@	B-Disease	D008881	14659530
ine	I-Disease	-1	14659530
at@@	O	-1	14659530
tac@@	O	-1	14659530
k@@	O	-1	14659530
.	O	-1	14659530
B@@	O	-1	14659530
as@@	O	-1	14659530
al	O	-1	14659530
C@@	B-Chemical	D015740	14659530
G@@	I-Chemical	-1	14659530
R@@	I-Chemical	-1	14659530
P	I-Chemical	-1	14659530
concentration	O	-1	14659530
was	O	-1	14659530
significantly	O	-1	14659530
higher	O	-1	14659530
and	O	-1	14659530
platele@@	O	-1	14659530
t	O	-1	14659530
5-@@	B-Chemical	D012701	14659530
H@@	I-Chemical	-1	14659530
T	I-Chemical	-1	14659530
cont@@	O	-1	14659530
ent	O	-1	14659530
ten@@	O	-1	14659530
ded	O	-1	14659530
to	O	-1	14659530
be	O	-1	14659530
lower	O	-1	14659530
in	O	-1	14659530
subjects	O	-1	14659530
who	O	-1	14659530
experienced	O	-1	14659530
a	O	-1	14659530
migra@@	B-Disease	D008881	14659530
ine	I-Disease	-1	14659530
at@@	O	-1	14659530
tac@@	O	-1	14659530
k@@	O	-1	14659530
.	O	-1	14659530
P@@	O	-1	14659530
lat@@	O	-1	14659530
e@@	O	-1	14659530
le@@	O	-1	14659530
t	O	-1	14659530
seroton@@	B-Chemical	D012701	14659530
in	I-Chemical	-1	14659530
cont@@	O	-1	14659530
ent	O	-1	14659530
decreased	O	-1	14659530
significantly	O	-1	14659530
(P@@	O	-1	14659530
<@@	O	-1	14659530
0.0@@	O	-1	14659530
1)	O	-1	14659530
after	O	-1	14659530
nitro@@	B-Chemical	D005996	14659530
glycer@@	I-Chemical	-1	14659530
in	I-Chemical	-1	14659530
in	O	-1	14659530
subjects	O	-1	14659530
with	O	-1	14659530
no	O	-1	14659530
migra@@	B-Disease	D008881	14659530
ine	I-Disease	-1	14659530
at@@	O	-1	14659530
tac@@	O	-1	14659530
k	O	-1	14659530
but	O	-1	14659530
no	O	-1	14659530
consist@@	O	-1	14659530
ent	O	-1	14659530
change	O	-1	14659530
was	O	-1	14659530
observed	O	-1	14659530
in	O	-1	14659530
patients	O	-1	14659530
with	O	-1	14659530
migra@@	B-Disease	D008881	14659530
ine	I-Disease	-1	14659530
at@@	O	-1	14659530
tac@@	O	-1	14659530
k@@	O	-1	14659530
.	O	-1	14659530
In	O	-1	14659530
concl@@	O	-1	14659530
u@@	O	-1	14659530
sion,	O	-1	14659530
the	O	-1	14659530
fac@@	O	-1	14659530
t	O	-1	14659530
that	O	-1	14659530
plasma	O	-1	14659530
C@@	B-Chemical	D015740	14659530
G@@	I-Chemical	-1	14659530
R@@	I-Chemical	-1	14659530
P	I-Chemical	-1	14659530
concentration	O	-1	14659530
correl@@	O	-1	14659530
ates	O	-1	14659530
with	O	-1	14659530
the	O	-1	14659530
tim@@	O	-1	14659530
ing	O	-1	14659530
and	O	-1	14659530
severity	O	-1	14659530
of	O	-1	14659530
a	O	-1	14659530
migra@@	B-Disease	D008881	14659530
ine	I-Disease	-1	14659530
headac@@	B-Disease	D006261	14659530
he	I-Disease	-1	14659530
suggests	O	-1	14659530
a	O	-1	14659530
direct	O	-1	14659530
rel@@	O	-1	14659530
ationship	O	-1	14659530
between	O	-1	14659530
C@@	B-Chemical	D015740	14659530
G@@	I-Chemical	-1	14659530
R@@	I-Chemical	-1	14659530
P	I-Chemical	-1	14659530
and	O	-1	14659530
migra@@	B-Disease	D008881	14659530
ine	I-Disease	-1	14659530
.	O	-1	14659530
In	O	-1	14659530
contrast@@	O	-1	14659530
,	O	-1	14659530
seroton@@	B-Chemical	D012701	14659530
in	I-Chemical	-1	14659530
release	O	-1	14659530
from	O	-1	14659530
platele@@	O	-1	14659530
ts	O	-1	14659530
does	O	-1	14659530
not	O	-1	14659530
prov@@	O	-1	14659530
o@@	O	-1	14659530
k@@	O	-1	14659530
e	O	-1	14659530
migra@@	B-Disease	D008881	14659530
ine	I-Disease	-1	14659530
,	O	-1	14659530
it	O	-1	14659530
may	O	-1	14659530
even	O	-1	14659530
coun@@	O	-1	14659530
ter@@	O	-1	14659530
ac@@	O	-1	14659530
t	O	-1	14659530
the	O	-1	14659530
headac@@	B-Disease	D006261	14659530
he	I-Disease	-1	14659530
and	O	-1	14659530
the	O	-1	14659530
concomit@@	O	-1	14659530
ant	O	-1	14659530
C@@	B-Chemical	D015740	14659530
G@@	I-Chemical	-1	14659530
R@@	I-Chemical	-1	14659530
P	I-Chemical	-1	14659530
release	O	-1	14659530
in	O	-1	14659530
this	O	-1	14659530
model@@	O	-1	14659530
.	O	-1	14659530

C@@	B-Disease	D003323	15804801
or@@	I-Disease	-1	15804801
onary	I-Disease	-1	15804801
aneurys@@	I-Disease	-1	15804801
m	I-Disease	-1	15804801
after	O	-1	15804801
im@@	O	-1	15804801
pl@@	O	-1	15804801
ant@@	O	-1	15804801
ation	O	-1	15804801
of	O	-1	15804801
a	O	-1	15804801
paclitax@@	B-Chemical	D017239	15804801
el	I-Chemical	-1	15804801
-@@	O	-1	15804801
el@@	O	-1	15804801
ut@@	O	-1	15804801
ing	O	-1	15804801
st@@	O	-1	15804801
ent@@	O	-1	15804801
.	O	-1	15804801
F@@	O	-1	15804801
orm@@	O	-1	15804801
ation	O	-1	15804801
of	O	-1	15804801
coronary	B-Disease	D003323	15804801
aneurys@@	I-Disease	-1	15804801
m	I-Disease	-1	15804801
is	O	-1	15804801
a	O	-1	15804801
r@@	O	-1	15804801
are	O	-1	15804801
complication	O	-1	15804801
of	O	-1	15804801
st@@	O	-1	15804801
ent@@	O	-1	15804801
ing	O	-1	15804801
with	O	-1	15804801
b@@	O	-1	15804801
are	O	-1	15804801
met@@	O	-1	15804801
al	O	-1	15804801
st@@	O	-1	15804801
ent@@	O	-1	15804801
s,	O	-1	15804801
but	O	-1	15804801
bas@@	O	-1	15804801
ed	O	-1	15804801
on	O	-1	15804801
experimental	O	-1	15804801
studies	O	-1	15804801
drug@@	O	-1	15804801
-@@	O	-1	15804801
el@@	O	-1	15804801
ut@@	O	-1	15804801
ing	O	-1	15804801
st@@	O	-1	15804801
ents	O	-1	15804801
may	O	-1	15804801
induce	O	-1	15804801
toxic	O	-1	15804801
effects	O	-1	15804801
on	O	-1	15804801
the	O	-1	15804801
v@@	O	-1	15804801
es@@	O	-1	15804801
se@@	O	-1	15804801
l	O	-1	15804801
w@@	O	-1	15804801
all	O	-1	15804801
with	O	-1	15804801
in@@	O	-1	15804801
complete	O	-1	15804801
st@@	O	-1	15804801
ent	O	-1	15804801
ap@@	O	-1	15804801
posi@@	O	-1	15804801
tion,	O	-1	15804801
aneurys@@	B-Disease	D000783	15804801
m	I-Disease	-1	15804801
formation	O	-1	15804801
and	O	-1	15804801
with	O	-1	15804801
the	O	-1	15804801
potential	O	-1	15804801
of	O	-1	15804801
st@@	O	-1	15804801
ent	O	-1	15804801
thrombo@@	B-Disease	D013927	15804801
sis	I-Disease	-1	15804801
or	O	-1	15804801
v@@	B-Disease	-1	15804801
es@@	I-Disease	-1	15804801
se@@	I-Disease	-1	15804801
l	I-Disease	-1	15804801
ru@@	I-Disease	-1	15804801
pt@@	I-Disease	-1	15804801
ure	I-Disease	-1	15804801
.	O	-1	15804801
We	O	-1	15804801
present	O	-1	15804801
a	O	-1	15804801
4@@	O	-1	15804801
3-@@	O	-1	15804801
year-old	O	-1	15804801
man	O	-1	15804801
who	O	-1	15804801
developed	O	-1	15804801
a	O	-1	15804801
coronary	B-Disease	D003323	15804801
aneurys@@	I-Disease	-1	15804801
m	I-Disease	-1	15804801
in	O	-1	15804801
the	O	-1	15804801
right	O	-1	15804801
coronary	O	-1	15804801
artery	O	-1	15804801
6	O	-1	15804801
months	O	-1	15804801
after	O	-1	15804801
receiving	O	-1	15804801
a	O	-1	15804801
paclitax@@	B-Chemical	D017239	15804801
el	I-Chemical	-1	15804801
-@@	O	-1	15804801
el@@	O	-1	15804801
ut@@	O	-1	15804801
ing	O	-1	15804801
st@@	O	-1	15804801
ent@@	O	-1	15804801
.	O	-1	15804801
The	O	-1	15804801
patient	O	-1	15804801
was	O	-1	15804801
as@@	O	-1	15804801
ym@@	O	-1	15804801
pto@@	O	-1	15804801
m@@	O	-1	15804801
atic	O	-1	15804801
and	O	-1	15804801
the	O	-1	15804801
aneurys@@	B-Disease	D000783	15804801
m	I-Disease	-1	15804801
was	O	-1	15804801
det@@	O	-1	15804801
ected	O	-1	15804801
in	O	-1	15804801
a	O	-1	15804801
ro@@	O	-1	15804801
ut@@	O	-1	15804801
ine	O	-1	15804801
control@@	O	-1	15804801
.	O	-1	15804801
An@@	O	-1	15804801
g@@	O	-1	15804801
io@@	O	-1	15804801
graph@@	O	-1	15804801
y	O	-1	15804801
and	O	-1	15804801
intrac@@	O	-1	15804801
or@@	O	-1	15804801
onary	O	-1	15804801
ult@@	O	-1	15804801
r@@	O	-1	15804801
as@@	O	-1	15804801
ound	O	-1	15804801
demonstrated	O	-1	15804801
l@@	O	-1	15804801
ac@@	O	-1	15804801
k	O	-1	15804801
of	O	-1	15804801
cont@@	O	-1	15804801
ac@@	O	-1	15804801
t	O	-1	15804801
between	O	-1	15804801
st@@	O	-1	15804801
ent	O	-1	15804801
and	O	-1	15804801
v@@	O	-1	15804801
es@@	O	-1	15804801
se@@	O	-1	15804801
l	O	-1	15804801
w@@	O	-1	15804801
all	O	-1	15804801
in	O	-1	15804801
a	O	-1	15804801
1@@	O	-1	15804801
5-@@	O	-1	15804801
mm	O	-1	15804801
lon@@	O	-1	15804801
g	O	-1	15804801
seg@@	O	-1	15804801
ment	O	-1	15804801
with	O	-1	15804801
maxim@@	O	-1	15804801
al	O	-1	15804801
aneurys@@	B-Disease	D000783	15804801
m	I-Disease	-1	15804801
di@@	O	-1	15804801
ame@@	O	-1	15804801
ter	O	-1	15804801
of	O	-1	15804801
6.@@	O	-1	15804801
0	O	-1	15804801
mm@@	O	-1	15804801
.	O	-1	15804801
The	O	-1	15804801
patient	O	-1	15804801
was	O	-1	15804801
suc@@	O	-1	15804801
cess@@	O	-1	15804801
ful@@	O	-1	15804801
ly	O	-1	15804801
treated	O	-1	15804801
with	O	-1	15804801
a	O	-1	15804801
gra@@	O	-1	15804801
ft	O	-1	15804801
st@@	O	-1	15804801
ent@@	O	-1	15804801
.	O	-1	15804801

B@@	O	-1	16160878
e@@	O	-1	16160878
havi@@	O	-1	16160878
oral	O	-1	16160878
effects	O	-1	16160878
of	O	-1	16160878
uro@@	B-Chemical	D014579	16160878
ten@@	I-Chemical	-1	16160878
s@@	I-Chemical	-1	16160878
in-@@	I-Chemical	-1	16160878
II	I-Chemical	-1	16160878
centr@@	O	-1	16160878
ally	O	-1	16160878
administered	O	-1	16160878
in	O	-1	16160878
mice.	O	-1	16160878
U@@	B-Chemical	D014579	16160878
ro@@	I-Chemical	-1	16160878
ten@@	I-Chemical	-1	16160878
s@@	I-Chemical	-1	16160878
in-@@	I-Chemical	-1	16160878
II	I-Chemical	-1	16160878
(	O	-1	16160878
U@@	B-Chemical	D014579	16160878
-@@	I-Chemical	-1	16160878
II	I-Chemical	-1	16160878
)	O	-1	16160878
receptors	O	-1	16160878
are	O	-1	16160878
wi@@	O	-1	16160878
de@@	O	-1	16160878
ly	O	-1	16160878
di@@	O	-1	16160878
stri@@	O	-1	16160878
but@@	O	-1	16160878
ed	O	-1	16160878
in	O	-1	16160878
the	O	-1	16160878
central	O	-1	16160878
ner@@	O	-1	16160878
v@@	O	-1	16160878
ous	O	-1	16160878
system@@	O	-1	16160878
.	O	-1	16160878
In@@	O	-1	16160878
trac@@	O	-1	16160878
e@@	O	-1	16160878
reb@@	O	-1	16160878
ro@@	O	-1	16160878
ventricular	O	-1	16160878
(@@	O	-1	16160878
i.@@	O	-1	16160878
c@@	O	-1	16160878
.@@	O	-1	16160878
v@@	O	-1	16160878
.)	O	-1	16160878
injection	O	-1	16160878
of	O	-1	16160878
U@@	B-Chemical	D014579	16160878
-@@	I-Chemical	-1	16160878
II	I-Chemical	-1	16160878
causes	O	-1	16160878
hypertension	B-Disease	D006973	16160878
and	O	-1	16160878
brady@@	B-Disease	D001919	16160878
cardia	I-Disease	-1	16160878
and	O	-1	16160878
stimul@@	O	-1	16160878
ates	O	-1	16160878
prolactin	O	-1	16160878
and	O	-1	16160878
th@@	O	-1	16160878
yro@@	O	-1	16160878
tro@@	O	-1	16160878
p@@	O	-1	16160878
in	O	-1	16160878
secre@@	O	-1	16160878
tion.	O	-1	16160878
However,	O	-1	16160878
the	O	-1	16160878
behavioral	O	-1	16160878
effects	O	-1	16160878
of	O	-1	16160878
centr@@	O	-1	16160878
ally	O	-1	16160878
administered	O	-1	16160878
U@@	B-Chemical	D014579	16160878
-@@	I-Chemical	-1	16160878
II	I-Chemical	-1	16160878
have	O	-1	16160878
received	O	-1	16160878
lit@@	O	-1	16160878
t@@	O	-1	16160878
le	O	-1	16160878
atten@@	O	-1	16160878
tion.	O	-1	16160878
In	O	-1	16160878
the	O	-1	16160878
present	O	-1	16160878
study,	O	-1	16160878
we	O	-1	16160878
tested	O	-1	16160878
the	O	-1	16160878
effects	O	-1	16160878
of	O	-1	16160878
i.@@	O	-1	16160878
c@@	O	-1	16160878
.@@	O	-1	16160878
v@@	O	-1	16160878
.	O	-1	16160878
injec@@	O	-1	16160878
tions	O	-1	16160878
of	O	-1	16160878
U@@	B-Chemical	D014579	16160878
-@@	I-Chemical	-1	16160878
II	I-Chemical	-1	16160878
on	O	-1	16160878
behavi@@	O	-1	16160878
or@@	O	-1	16160878
al,	O	-1	16160878
metabol@@	O	-1	16160878
ic@@	O	-1	16160878
,	O	-1	16160878
and	O	-1	16160878
en@@	O	-1	16160878
doc@@	O	-1	16160878
rine	O	-1	16160878
responses	O	-1	16160878
in	O	-1	16160878
mice.	O	-1	16160878
Ad@@	O	-1	16160878
minist@@	O	-1	16160878
ration	O	-1	16160878
of	O	-1	16160878
gra@@	O	-1	16160878
ded	O	-1	16160878
doses	O	-1	16160878
of	O	-1	16160878
U@@	B-Chemical	D014579	16160878
-@@	I-Chemical	-1	16160878
II	I-Chemical	-1	16160878
(1@@	O	-1	16160878
-@@	O	-1	16160878
10@@	O	-1	16160878
,@@	O	-1	16160878
0@@	O	-1	16160878
00	O	-1	16160878
n@@	O	-1	16160878
g/@@	O	-1	16160878
mou@@	O	-1	16160878
se@@	O	-1	16160878
)	O	-1	16160878
prov@@	O	-1	16160878
o@@	O	-1	16160878
k@@	O	-1	16160878
ed@@	O	-1	16160878
:	O	-1	16160878
(1@@	O	-1	16160878
)	O	-1	16160878
a	O	-1	16160878
dose-@@	O	-1	16160878
dependent	O	-1	16160878
reduction	O	-1	16160878
in	O	-1	16160878
the	O	-1	16160878
number	O	-1	16160878
of	O	-1	16160878
he@@	O	-1	16160878
ad	O	-1	16160878
di@@	O	-1	16160878
p@@	O	-1	16160878
s	O	-1	16160878
in	O	-1	16160878
the	O	-1	16160878
h@@	O	-1	16160878
ol@@	O	-1	16160878
e-@@	O	-1	16160878
bo@@	O	-1	16160878
ard	O	-1	16160878
test@@	O	-1	16160878
;	O	-1	16160878
(2@@	O	-1	16160878
)	O	-1	16160878
a	O	-1	16160878
dose-@@	O	-1	16160878
dependent	O	-1	16160878
reduction	O	-1	16160878
in	O	-1	16160878
the	O	-1	16160878
number	O	-1	16160878
of	O	-1	16160878
ent@@	O	-1	16160878
ri@@	O	-1	16160878
es	O	-1	16160878
in	O	-1	16160878
the	O	-1	16160878
wh@@	O	-1	16160878
ite	O	-1	16160878
ch@@	O	-1	16160878
am@@	O	-1	16160878
b@@	O	-1	16160878
er	O	-1	16160878
in	O	-1	16160878
the	O	-1	16160878
bl@@	O	-1	16160878
ac@@	O	-1	16160878
k@@	O	-1	16160878
-@@	O	-1	16160878
and@@	O	-1	16160878
-@@	O	-1	16160878
wh@@	O	-1	16160878
ite	O	-1	16160878
compar@@	O	-1	16160878
t@@	O	-1	16160878
ment	O	-1	16160878
test@@	O	-1	16160878
,	O	-1	16160878
and	O	-1	16160878
in	O	-1	16160878
the	O	-1	16160878
number	O	-1	16160878
of	O	-1	16160878
ent@@	O	-1	16160878
ri@@	O	-1	16160878
es	O	-1	16160878
in	O	-1	16160878
the	O	-1	16160878
central	O	-1	16160878
pl@@	O	-1	16160878
at@@	O	-1	16160878
form	O	-1	16160878
and	O	-1	16160878
op@@	O	-1	16160878
en	O	-1	16160878
ar@@	O	-1	16160878
ms	O	-1	16160878
in	O	-1	16160878
the	O	-1	16160878
pl@@	O	-1	16160878
us@@	O	-1	16160878
-@@	O	-1	16160878
ma@@	O	-1	16160878
ze	O	-1	16160878
test@@	O	-1	16160878
;	O	-1	16160878
and	O	-1	16160878
(3@@	O	-1	16160878
)	O	-1	16160878
a	O	-1	16160878
dose-@@	O	-1	16160878
dependent	O	-1	16160878
increase	O	-1	16160878
in	O	-1	16160878
the	O	-1	16160878
duration	O	-1	16160878
of	O	-1	16160878
im@@	O	-1	16160878
mo@@	O	-1	16160878
b@@	O	-1	16160878
ility	O	-1	16160878
in	O	-1	16160878
the	O	-1	16160878
for@@	O	-1	16160878
ce@@	O	-1	16160878
d-@@	O	-1	16160878
s@@	O	-1	16160878
w@@	O	-1	16160878
im@@	O	-1	16160878
m@@	O	-1	16160878
ing	O	-1	16160878
test	O	-1	16160878
and	O	-1	16160878
t@@	O	-1	16160878
a@@	O	-1	16160878
il	O	-1	16160878
sus@@	O	-1	16160878
pen@@	O	-1	16160878
sion	O	-1	16160878
test@@	O	-1	16160878
.	O	-1	16160878
In@@	O	-1	16160878
trac@@	O	-1	16160878
e@@	O	-1	16160878
reb@@	O	-1	16160878
ro@@	O	-1	16160878
ventricular	O	-1	16160878
injection	O	-1	16160878
of	O	-1	16160878
U@@	B-Chemical	D014579	16160878
-@@	I-Chemical	-1	16160878
II	I-Chemical	-1	16160878
also	O	-1	16160878
caused	O	-1	16160878
an	O	-1	16160878
increase	O	-1	16160878
in@@	O	-1	16160878
:	O	-1	16160878
fo@@	O	-1	16160878
od	O	-1	16160878
int@@	O	-1	16160878
ake	O	-1	16160878
at	O	-1	16160878
doses	O	-1	16160878
of	O	-1	16160878
100	O	-1	16160878
and	O	-1	16160878
1@@	O	-1	16160878
,@@	O	-1	16160878
0@@	O	-1	16160878
00	O	-1	16160878
n@@	O	-1	16160878
g/@@	O	-1	16160878
mou@@	O	-1	16160878
se@@	O	-1	16160878
,	O	-1	16160878
w@@	O	-1	16160878
at@@	O	-1	16160878
er	O	-1	16160878
int@@	O	-1	16160878
ake	O	-1	16160878
at	O	-1	16160878
doses	O	-1	16160878
of	O	-1	16160878
10@@	O	-1	16160878
0-@@	O	-1	16160878
10@@	O	-1	16160878
,@@	O	-1	16160878
0@@	O	-1	16160878
00	O	-1	16160878
n@@	O	-1	16160878
g/@@	O	-1	16160878
mou@@	O	-1	16160878
se@@	O	-1	16160878
,	O	-1	16160878
and	O	-1	16160878
h@@	O	-1	16160878
or@@	O	-1	16160878
iz@@	O	-1	16160878
ont@@	O	-1	16160878
al	O	-1	16160878
locom@@	O	-1	16160878
o@@	O	-1	16160878
tion	O	-1	16160878
activity	O	-1	16160878
at	O	-1	16160878
a	O	-1	16160878
dose	O	-1	16160878
of	O	-1	16160878
10@@	O	-1	16160878
,@@	O	-1	16160878
0@@	O	-1	16160878
00	O	-1	16160878
n@@	O	-1	16160878
g/@@	O	-1	16160878
mou@@	O	-1	16160878
se.	O	-1	16160878
W@@	O	-1	16160878
h@@	O	-1	16160878
at@@	O	-1	16160878
ev@@	O	-1	16160878
er	O	-1	16160878
was	O	-1	16160878
the	O	-1	16160878
dose@@	O	-1	16160878
,	O	-1	16160878
the	O	-1	16160878
central	O	-1	16160878
administration	O	-1	16160878
of	O	-1	16160878
U@@	B-Chemical	D014579	16160878
-@@	I-Chemical	-1	16160878
II	I-Chemical	-1	16160878
had	O	-1	16160878
no	O	-1	16160878
effect	O	-1	16160878
on	O	-1	16160878
body	O	-1	16160878
tem@@	O	-1	16160878
per@@	O	-1	16160878
at@@	O	-1	16160878
ure,	O	-1	16160878
n@@	O	-1	16160878
ocicep@@	O	-1	16160878
tion,	O	-1	16160878
apo@@	B-Chemical	D001058	16160878
morphine	I-Chemical	-1	16160878
-induced	O	-1	16160878
pen@@	B-Disease	D010409	16160878
ile	I-Disease	-1	16160878
e@@	I-Disease	-1	16160878
rec@@	I-Disease	-1	16160878
tion	I-Disease	-1	16160878
and	O	-1	16160878
cl@@	O	-1	16160878
im@@	O	-1	16160878
b@@	O	-1	16160878
ing	O	-1	16160878
behavi@@	O	-1	16160878
or@@	O	-1	16160878
,	O	-1	16160878
and	O	-1	16160878
stres@@	O	-1	16160878
s@@	O	-1	16160878
-induced	O	-1	16160878
plasma	O	-1	16160878
cortico@@	B-Chemical	D003345	16160878
sterone	I-Chemical	-1	16160878
level@@	O	-1	16160878
.	O	-1	16160878
T@@	O	-1	16160878
ak@@	O	-1	16160878
en	O	-1	16160878
to@@	O	-1	16160878
ge@@	O	-1	16160878
ther@@	O	-1	16160878
,	O	-1	16160878
the	O	-1	16160878
present	O	-1	16160878
study	O	-1	16160878
demon@@	O	-1	16160878
strat@@	O	-1	16160878
es	O	-1	16160878
that	O	-1	16160878
the	O	-1	16160878
central	O	-1	16160878
injection	O	-1	16160878
of	O	-1	16160878
U@@	B-Chemical	D014579	16160878
-@@	I-Chemical	-1	16160878
II	I-Chemical	-1	16160878
at	O	-1	16160878
doses	O	-1	16160878
of	O	-1	16160878
1-@@	O	-1	16160878
10@@	O	-1	16160878
,@@	O	-1	16160878
0@@	O	-1	16160878
00	O	-1	16160878
n@@	O	-1	16160878
g/@@	O	-1	16160878
mouse	O	-1	16160878
induc@@	O	-1	16160878
es	O	-1	16160878
an@@	O	-1	16160878
x@@	O	-1	16160878
io@@	O	-1	16160878
gen@@	O	-1	16160878
ic@@	O	-1	16160878
-	O	-1	16160878
and	O	-1	16160878
depress@@	O	-1	16160878
ant@@	O	-1	16160878
-@@	O	-1	16160878
like	O	-1	16160878
effects	O	-1	16160878
in	O	-1	16160878
mou@@	O	-1	16160878
se.	O	-1	16160878
These	O	-1	16160878
data	O	-1	16160878
suggest	O	-1	16160878
that	O	-1	16160878
U@@	B-Chemical	D014579	16160878
-@@	I-Chemical	-1	16160878
II	I-Chemical	-1	16160878
may	O	-1	16160878
be	O	-1	16160878
involved	O	-1	16160878
in	O	-1	16160878
some	O	-1	16160878
as@@	O	-1	16160878
p@@	O	-1	16160878
ects	O	-1	16160878
of	O	-1	16160878
psych@@	B-Disease	D001523	16160878
i@@	I-Disease	-1	16160878
atric	I-Disease	-1	16160878
disorder@@	I-Disease	-1	16160878
s	I-Disease	-1	16160878
.	O	-1	16160878

Rec@@	O	-1	16274958
ur@@	O	-1	16274958
rent	O	-1	16274958
dys@@	B-Disease	D055154	16274958
ph@@	I-Disease	-1	16274958
on@@	I-Disease	-1	16274958
ia	I-Disease	-1	16274958
and	O	-1	16274958
ac@@	B-Chemical	D017255	16274958
it@@	I-Chemical	-1	16274958
re@@	I-Chemical	-1	16274958
tin	I-Chemical	-1	16274958
.	O	-1	16274958
We	O	-1	16274958
report	O	-1	16274958
the	O	-1	16274958
case	O	-1	16274958
of	O	-1	16274958
a	O	-1	16274958
woman	O	-1	16274958
com@@	O	-1	16274958
pl@@	O	-1	16274958
aining	O	-1	16274958
of	O	-1	16274958
dys@@	B-Disease	D055154	16274958
ph@@	I-Disease	-1	16274958
on@@	I-Disease	-1	16274958
ia	I-Disease	-1	16274958
while	O	-1	16274958
sh@@	O	-1	16274958
e	O	-1	16274958
was	O	-1	16274958
treated	O	-1	16274958
by	O	-1	16274958
ac@@	B-Chemical	D017255	16274958
it@@	I-Chemical	-1	16274958
re@@	I-Chemical	-1	16274958
tin	I-Chemical	-1	16274958
.	O	-1	16274958
H@@	O	-1	16274958
er	O	-1	16274958
symptoms	O	-1	16274958
tot@@	O	-1	16274958
ally	O	-1	16274958
reg@@	O	-1	16274958
res@@	O	-1	16274958
sed	O	-1	16274958
after	O	-1	16274958
drug	O	-1	16274958
withdrawal	O	-1	16274958
and	O	-1	16274958
re@@	O	-1	16274958
appe@@	O	-1	16274958
a@@	O	-1	16274958
red	O	-1	16274958
when	O	-1	16274958
ac@@	B-Chemical	D017255	16274958
it@@	I-Chemical	-1	16274958
re@@	I-Chemical	-1	16274958
tin	I-Chemical	-1	16274958
was	O	-1	16274958
re@@	O	-1	16274958
int@@	O	-1	16274958
ro@@	O	-1	16274958
duc@@	O	-1	16274958
ed.	O	-1	16274958
To	O	-1	16274958
our	O	-1	16274958
know@@	O	-1	16274958
le@@	O	-1	16274958
d@@	O	-1	16274958
g@@	O	-1	16274958
e,	O	-1	16274958
this	O	-1	16274958
is	O	-1	16274958
the	O	-1	16274958
first	O	-1	16274958
case	O	-1	16274958
of	O	-1	16274958
ac@@	B-Chemical	D017255	16274958
it@@	I-Chemical	-1	16274958
re@@	I-Chemical	-1	16274958
tin	I-Chemical	-1	16274958
-induced	O	-1	16274958
dys@@	B-Disease	D055154	16274958
ph@@	I-Disease	-1	16274958
on@@	I-Disease	-1	16274958
ia	I-Disease	-1	16274958
.	O	-1	16274958
This	O	-1	16274958
effect	O	-1	16274958
may	O	-1	16274958
be	O	-1	16274958
related	O	-1	16274958
to	O	-1	16274958
the	O	-1	16274958
pharmac@@	O	-1	16274958
ological	O	-1	16274958
effect	O	-1	16274958
of	O	-1	16274958
this	O	-1	16274958
drug	O	-1	16274958
on	O	-1	16274958
m@@	O	-1	16274958
u@@	O	-1	16274958
co@@	O	-1	16274958
us	O	-1	16274958
membran@@	O	-1	16274958
es.	O	-1	16274958

Ph@@	O	-1	16330766
armac@@	O	-1	16330766
ological	O	-1	16330766
mod@@	O	-1	16330766
ulation	O	-1	16330766
of	O	-1	16330766
pain	B-Disease	D010146	16330766
-@@	O	-1	16330766
related	O	-1	16330766
brain	O	-1	16330766
activity	O	-1	16330766
during	O	-1	16330766
normal	O	-1	16330766
and	O	-1	16330766
central	O	-1	16330766
sensi@@	O	-1	16330766
tiz@@	O	-1	16330766
ation	O	-1	16330766
st@@	O	-1	16330766
ates	O	-1	16330766
in	O	-1	16330766
hum@@	O	-1	16330766
an@@	O	-1	16330766
s.	O	-1	16330766
A@@	O	-1	16330766
b@@	O	-1	16330766
normal	O	-1	16330766
pro@@	O	-1	16330766
cess@@	O	-1	16330766
ing	O	-1	16330766
of	O	-1	16330766
s@@	O	-1	16330766
om@@	O	-1	16330766
at@@	O	-1	16330766
os@@	O	-1	16330766
ens@@	O	-1	16330766
ory	O	-1	16330766
in@@	O	-1	16330766
p@@	O	-1	16330766
ut@@	O	-1	16330766
s	O	-1	16330766
in	O	-1	16330766
the	O	-1	16330766
central	O	-1	16330766
ner@@	O	-1	16330766
v@@	O	-1	16330766
ous	O	-1	16330766
system	O	-1	16330766
(@@	O	-1	16330766
central	O	-1	16330766
sensi@@	O	-1	16330766
tiz@@	O	-1	16330766
ation@@	O	-1	16330766
)	O	-1	16330766
is	O	-1	16330766
the	O	-1	16330766
mechanism	O	-1	16330766
ac@@	O	-1	16330766
coun@@	O	-1	16330766
ting	O	-1	16330766
for	O	-1	16330766
the	O	-1	16330766
enhanced	O	-1	16330766
pain	B-Disease	D010146	16330766
sensitivity	O	-1	16330766
in	O	-1	16330766
the	O	-1	16330766
s@@	O	-1	16330766
k@@	O	-1	16330766
in	O	-1	16330766
sur@@	O	-1	16330766
ro@@	O	-1	16330766
un@@	O	-1	16330766
ding	O	-1	16330766
tissue	B-Disease	D017695	16330766
injury	I-Disease	-1	16330766
(	O	-1	16330766
secondary	B-Disease	D006930	16330766
hyperalge@@	I-Disease	-1	16330766
sia	I-Disease	-1	16330766
).	O	-1	16330766
S@@	B-Disease	D006930	16330766
ec@@	I-Disease	-1	16330766
ond@@	I-Disease	-1	16330766
ary	I-Disease	-1	16330766
hyperalge@@	I-Disease	-1	16330766
sia	I-Disease	-1	16330766
s@@	O	-1	16330766
ha@@	O	-1	16330766
res	O	-1	16330766
clinical	O	-1	16330766
character@@	O	-1	16330766
is@@	O	-1	16330766
tics	O	-1	16330766
with	O	-1	16330766
neuro@@	B-Disease	D006930	16330766
genic	I-Disease	-1	16330766
hyperalge@@	I-Disease	-1	16330766
sia	I-Disease	-1	16330766
in	O	-1	16330766
patients	O	-1	16330766
with	O	-1	16330766
neuro@@	B-Disease	D009437	16330766
path@@	I-Disease	-1	16330766
ic	I-Disease	-1	16330766
pain	I-Disease	-1	16330766
.	O	-1	16330766
A@@	O	-1	16330766
b@@	O	-1	16330766
normal	O	-1	16330766
brain	O	-1	16330766
responses	O	-1	16330766
to	O	-1	16330766
s@@	O	-1	16330766
om@@	O	-1	16330766
at@@	O	-1	16330766
os@@	O	-1	16330766
ens@@	O	-1	16330766
ory	O	-1	16330766
stimul@@	O	-1	16330766
i	O	-1	16330766
have	O	-1	16330766
been	O	-1	16330766
found	O	-1	16330766
in	O	-1	16330766
patients	O	-1	16330766
with	O	-1	16330766
hyperalge@@	B-Disease	D006930	16330766
sia	I-Disease	-1	16330766
as	O	-1	16330766
well	O	-1	16330766
as	O	-1	16330766
in	O	-1	16330766
normal	O	-1	16330766
subjects	O	-1	16330766
during	O	-1	16330766
experimental	O	-1	16330766
central	O	-1	16330766
sensi@@	O	-1	16330766
tiz@@	O	-1	16330766
ation.	O	-1	16330766
The	O	-1	16330766
a@@	O	-1	16330766
im	O	-1	16330766
of	O	-1	16330766
this	O	-1	16330766
study	O	-1	16330766
was	O	-1	16330766
to	O	-1	16330766
ass@@	O	-1	16330766
ess	O	-1	16330766
the	O	-1	16330766
effects	O	-1	16330766
of	O	-1	16330766
g@@	B-Chemical	C040029	16330766
ab@@	I-Chemical	-1	16330766
ap@@	I-Chemical	-1	16330766
enti@@	I-Chemical	-1	16330766
n	I-Chemical	-1	16330766
,	O	-1	16330766
a	O	-1	16330766
drug	O	-1	16330766
effective	O	-1	16330766
in	O	-1	16330766
neuro@@	B-Disease	D009437	16330766
path@@	I-Disease	-1	16330766
ic	I-Disease	-1	16330766
pain	I-Disease	-1	16330766
patients,	O	-1	16330766
on	O	-1	16330766
brain	O	-1	16330766
pro@@	O	-1	16330766
cess@@	O	-1	16330766
ing	O	-1	16330766
of	O	-1	16330766
n@@	O	-1	16330766
ocicep@@	O	-1	16330766
tive	O	-1	16330766
inf@@	O	-1	16330766
orm@@	O	-1	16330766
ation	O	-1	16330766
in	O	-1	16330766
normal	O	-1	16330766
and	O	-1	16330766
central	O	-1	16330766
sensi@@	O	-1	16330766
tiz@@	O	-1	16330766
ation	O	-1	16330766
stat@@	O	-1	16330766
es.	O	-1	16330766
U@@	O	-1	16330766
s@@	O	-1	16330766
ing	O	-1	16330766
functional	O	-1	16330766
mag@@	O	-1	16330766
ne@@	O	-1	16330766
tic	O	-1	16330766
res@@	O	-1	16330766
on@@	O	-1	16330766
ance	O	-1	16330766
imaging	O	-1	16330766
(@@	O	-1	16330766
f@@	O	-1	16330766
MR@@	O	-1	16330766
I@@	O	-1	16330766
)	O	-1	16330766
in	O	-1	16330766
normal	O	-1	16330766
vol@@	O	-1	16330766
un@@	O	-1	16330766
te@@	O	-1	16330766
er@@	O	-1	16330766
s,	O	-1	16330766
we	O	-1	16330766
studied	O	-1	16330766
the	O	-1	16330766
g@@	B-Chemical	C040029	16330766
ab@@	I-Chemical	-1	16330766
ap@@	I-Chemical	-1	16330766
enti@@	I-Chemical	-1	16330766
n	I-Chemical	-1	16330766
-induced	O	-1	16330766
mod@@	O	-1	16330766
ulation	O	-1	16330766
of	O	-1	16330766
brain	O	-1	16330766
activity	O	-1	16330766
in	O	-1	16330766
response	O	-1	16330766
to	O	-1	16330766
n@@	O	-1	16330766
ocicep@@	O	-1	16330766
tive	O	-1	16330766
mechan@@	O	-1	16330766
ical	O	-1	16330766
stimulation	O	-1	16330766
of	O	-1	16330766
normal	O	-1	16330766
s@@	O	-1	16330766
k@@	O	-1	16330766
in	O	-1	16330766
and	O	-1	16330766
cap@@	B-Chemical	D002211	16330766
sa@@	I-Chemical	-1	16330766
icin	I-Chemical	-1	16330766
-induced	O	-1	16330766
secondary	B-Disease	D006930	16330766
hyperalge@@	I-Disease	-1	16330766
sia	I-Disease	-1	16330766
.	O	-1	16330766
The	O	-1	16330766
dose	O	-1	16330766
of	O	-1	16330766
g@@	B-Chemical	C040029	16330766
ab@@	I-Chemical	-1	16330766
ap@@	I-Chemical	-1	16330766
enti@@	I-Chemical	-1	16330766
n	I-Chemical	-1	16330766
was	O	-1	16330766
1@@	O	-1	16330766
,@@	O	-1	16330766
8@@	O	-1	16330766
00	O	-1	16330766
mg	O	-1	16330766
per	O	-1	16330766
os@@	O	-1	16330766
,	O	-1	16330766
in	O	-1	16330766
a	O	-1	16330766
single	O	-1	16330766
administr@@	O	-1	16330766
ation.	O	-1	16330766
We	O	-1	16330766
found	O	-1	16330766
that	O	-1	16330766
(@@	O	-1	16330766
i@@	O	-1	16330766
)	O	-1	16330766
g@@	B-Chemical	C040029	16330766
ab@@	I-Chemical	-1	16330766
ap@@	I-Chemical	-1	16330766
enti@@	I-Chemical	-1	16330766
n	I-Chemical	-1	16330766
reduced	O	-1	16330766
the	O	-1	16330766
activ@@	O	-1	16330766
ations	O	-1	16330766
in	O	-1	16330766
the	O	-1	16330766
bil@@	O	-1	16330766
ateral	O	-1	16330766
o@@	O	-1	16330766
perc@@	O	-1	16330766
ulo@@	O	-1	16330766
in@@	O	-1	16330766
s@@	O	-1	16330766
ular	O	-1	16330766
cor@@	O	-1	16330766
t@@	O	-1	16330766
ex@@	O	-1	16330766
,	O	-1	16330766
in@@	O	-1	16330766
depend@@	O	-1	16330766
ently	O	-1	16330766
of	O	-1	16330766
the	O	-1	16330766
presence	O	-1	16330766
of	O	-1	16330766
central	O	-1	16330766
sensi@@	O	-1	16330766
tiz@@	O	-1	16330766
ation@@	O	-1	16330766
;	O	-1	16330766
(@@	O	-1	16330766
i@@	O	-1	16330766
i@@	O	-1	16330766
)	O	-1	16330766
g@@	B-Chemical	C040029	16330766
ab@@	I-Chemical	-1	16330766
ap@@	I-Chemical	-1	16330766
enti@@	I-Chemical	-1	16330766
n	I-Chemical	-1	16330766
reduced	O	-1	16330766
the	O	-1	16330766
activation	O	-1	16330766
in	O	-1	16330766
the	O	-1	16330766
bra@@	O	-1	16330766
in@@	O	-1	16330766
st@@	O	-1	16330766
em@@	O	-1	16330766
,	O	-1	16330766
only	O	-1	16330766
during	O	-1	16330766
central	O	-1	16330766
sensi@@	O	-1	16330766
tiz@@	O	-1	16330766
ation@@	O	-1	16330766
;	O	-1	16330766
(@@	O	-1	16330766
i@@	O	-1	16330766
i@@	O	-1	16330766
i@@	O	-1	16330766
)	O	-1	16330766
g@@	B-Chemical	C040029	16330766
ab@@	I-Chemical	-1	16330766
ap@@	I-Chemical	-1	16330766
enti@@	I-Chemical	-1	16330766
n	I-Chemical	-1	16330766
sup@@	O	-1	16330766
press@@	O	-1	16330766
ed	O	-1	16330766
stimul@@	O	-1	16330766
us@@	O	-1	16330766
-induced	O	-1	16330766
de@@	O	-1	16330766
activ@@	O	-1	16330766
ation@@	O	-1	16330766
s,	O	-1	16330766
only	O	-1	16330766
during	O	-1	16330766
central	O	-1	16330766
sensi@@	O	-1	16330766
tiz@@	O	-1	16330766
ation@@	O	-1	16330766
;	O	-1	16330766
this	O	-1	16330766
effect	O	-1	16330766
was	O	-1	16330766
more	O	-1	16330766
ro@@	O	-1	16330766
b@@	O	-1	16330766
us@@	O	-1	16330766
t	O	-1	16330766
than	O	-1	16330766
the	O	-1	16330766
effect	O	-1	16330766
on	O	-1	16330766
brain	O	-1	16330766
activ@@	O	-1	16330766
ation.	O	-1	16330766
The	O	-1	16330766
observed	O	-1	16330766
drug@@	O	-1	16330766
-induced	O	-1	16330766
effects	O	-1	16330766
were	O	-1	16330766
not	O	-1	16330766
due	O	-1	16330766
to	O	-1	16330766
changes	O	-1	16330766
in	O	-1	16330766
the	O	-1	16330766
baseline	O	-1	16330766
f@@	O	-1	16330766
MR@@	O	-1	16330766
I	O	-1	16330766
sign@@	O	-1	16330766
al.	O	-1	16330766
These	O	-1	16330766
findings	O	-1	16330766
indicate	O	-1	16330766
that	O	-1	16330766
g@@	B-Chemical	C040029	16330766
ab@@	I-Chemical	-1	16330766
ap@@	I-Chemical	-1	16330766
enti@@	I-Chemical	-1	16330766
n	I-Chemical	-1	16330766
has	O	-1	16330766
a	O	-1	16330766
meas@@	O	-1	16330766
ur@@	O	-1	16330766
able	O	-1	16330766
ant@@	O	-1	16330766
in@@	O	-1	16330766
ocicep@@	O	-1	16330766
tive	O	-1	16330766
effect	O	-1	16330766
and	O	-1	16330766
a	O	-1	16330766
st@@	O	-1	16330766
ron@@	O	-1	16330766
g@@	O	-1	16330766
er	O	-1	16330766
anti@@	O	-1	16330766
hyperalge@@	O	-1	16330766
sic	O	-1	16330766
effect	O	-1	16330766
most	O	-1	16330766
ev@@	O	-1	16330766
id@@	O	-1	16330766
ent	O	-1	16330766
in	O	-1	16330766
the	O	-1	16330766
brain	O	-1	16330766
a@@	O	-1	16330766
reas	O	-1	16330766
under@@	O	-1	16330766
go@@	O	-1	16330766
ing	O	-1	16330766
de@@	O	-1	16330766
activ@@	O	-1	16330766
ation,	O	-1	16330766
th@@	O	-1	16330766
us	O	-1	16330766
sup@@	O	-1	16330766
port@@	O	-1	16330766
ing	O	-1	16330766
the	O	-1	16330766
con@@	O	-1	16330766
cep@@	O	-1	16330766
t	O	-1	16330766
that	O	-1	16330766
g@@	B-Chemical	C040029	16330766
ab@@	I-Chemical	-1	16330766
ap@@	I-Chemical	-1	16330766
enti@@	I-Chemical	-1	16330766
n	I-Chemical	-1	16330766
is	O	-1	16330766
more	O	-1	16330766
effective	O	-1	16330766
in	O	-1	16330766
mod@@	O	-1	16330766
ul@@	O	-1	16330766
ating	O	-1	16330766
n@@	O	-1	16330766
ocicep@@	O	-1	16330766
tive	O	-1	16330766
trans@@	O	-1	16330766
mission	O	-1	16330766
when	O	-1	16330766
central	O	-1	16330766
sensi@@	O	-1	16330766
tiz@@	O	-1	16330766
ation	O	-1	16330766
is	O	-1	16330766
present@@	O	-1	16330766
.	O	-1	16330766

MD@@	B-Chemical	D018817	16574712
M@@	I-Chemical	-1	16574712
A	I-Chemical	-1	16574712
poly@@	O	-1	16574712
drug	O	-1	16574712
users	O	-1	16574712
show	O	-1	16574712
pro@@	O	-1	16574712
cess@@	O	-1	16574712
-@@	O	-1	16574712
specific	O	-1	16574712
central	O	-1	16574712
ex@@	O	-1	16574712
ec@@	O	-1	16574712
utive	O	-1	16574712
impair@@	O	-1	16574712
ments	O	-1	16574712
co@@	O	-1	16574712
u@@	O	-1	16574712
pl@@	O	-1	16574712
ed	O	-1	16574712
with	O	-1	16574712
impaired	B-Disease	D003072	16574712
s@@	I-Disease	-1	16574712
oci@@	I-Disease	-1	16574712
al	I-Disease	-1	16574712
and	I-Disease	-1	16574712
em@@	I-Disease	-1	16574712
o@@	I-Disease	-1	16574712
tional	I-Disease	-1	16574712
j@@	I-Disease	-1	16574712
ud@@	I-Disease	-1	16574712
g@@	I-Disease	-1	16574712
ement	I-Disease	-1	16574712
pro@@	I-Disease	-1	16574712
ces@@	I-Disease	-1	16574712
ses	I-Disease	-1	16574712
.	O	-1	16574712
In	O	-1	16574712
rec@@	O	-1	16574712
ent	O	-1	16574712
years	O	-1	16574712
wor@@	O	-1	16574712
king	O	-1	16574712
memory	B-Disease	D008569	16574712
defic@@	I-Disease	-1	16574712
its	I-Disease	-1	16574712
have	O	-1	16574712
been	O	-1	16574712
reported	O	-1	16574712
in	O	-1	16574712
users	O	-1	16574712
of	O	-1	16574712
MD@@	B-Chemical	D018817	16574712
M@@	I-Chemical	-1	16574712
A	I-Chemical	-1	16574712
(	O	-1	16574712
3@@	B-Chemical	D018817	16574712
,@@	I-Chemical	-1	16574712
4-@@	I-Chemical	-1	16574712
methyl@@	I-Chemical	-1	16574712
en@@	I-Chemical	-1	16574712
edi@@	I-Chemical	-1	16574712
oxy@@	I-Chemical	-1	16574712
meth@@	I-Chemical	-1	16574712
amphetamine	I-Chemical	-1	16574712
,	O	-1	16574712
ec@@	B-Chemical	D018817	16574712
st@@	I-Chemical	-1	16574712
as@@	I-Chemical	-1	16574712
y	I-Chemical	-1	16574712
).	O	-1	16574712
The	O	-1	16574712
current	O	-1	16574712
study	O	-1	16574712
a@@	O	-1	16574712
im@@	O	-1	16574712
ed	O	-1	16574712
to	O	-1	16574712
ass@@	O	-1	16574712
ess	O	-1	16574712
the	O	-1	16574712
im@@	O	-1	16574712
pac@@	O	-1	16574712
t	O	-1	16574712
of	O	-1	16574712
MD@@	B-Chemical	D018817	16574712
M@@	I-Chemical	-1	16574712
A	I-Chemical	-1	16574712
use	O	-1	16574712
on	O	-1	16574712
three	O	-1	16574712
se@@	O	-1	16574712
par@@	O	-1	16574712
ate	O	-1	16574712
central	O	-1	16574712
ex@@	O	-1	16574712
ec@@	O	-1	16574712
utive	O	-1	16574712
pro@@	O	-1	16574712
ces@@	O	-1	16574712
ses	O	-1	16574712
(@@	O	-1	16574712
set	O	-1	16574712
shi@@	O	-1	16574712
f@@	O	-1	16574712
t@@	O	-1	16574712
ing,	O	-1	16574712
inhibition	O	-1	16574712
and	O	-1	16574712
memory	O	-1	16574712
up@@	O	-1	16574712
dat@@	O	-1	16574712
ing@@	O	-1	16574712
)	O	-1	16574712
and	O	-1	16574712
also	O	-1	16574712
on	O	-1	16574712
"@@	O	-1	16574712
pre@@	O	-1	16574712
fron@@	O	-1	16574712
t@@	O	-1	16574712
al@@	O	-1	16574712
"	O	-1	16574712
mediated	O	-1	16574712
s@@	O	-1	16574712
oci@@	O	-1	16574712
al	O	-1	16574712
and	O	-1	16574712
em@@	O	-1	16574712
o@@	O	-1	16574712
tional	O	-1	16574712
j@@	O	-1	16574712
ud@@	O	-1	16574712
g@@	O	-1	16574712
ement	O	-1	16574712
pro@@	O	-1	16574712
cess@@	O	-1	16574712
es.	O	-1	16574712
F@@	O	-1	16574712
if@@	O	-1	16574712
te@@	O	-1	16574712
en	O	-1	16574712
poly@@	O	-1	16574712
drug	O	-1	16574712
ec@@	B-Chemical	D018817	16574712
st@@	I-Chemical	-1	16574712
as@@	I-Chemical	-1	16574712
y	I-Chemical	-1	16574712
users	O	-1	16574712
and	O	-1	16574712
15	O	-1	16574712
poly@@	O	-1	16574712
drug	O	-1	16574712
non@@	O	-1	16574712
-	O	-1	16574712
ec@@	B-Chemical	D018817	16574712
st@@	I-Chemical	-1	16574712
as@@	I-Chemical	-1	16574712
y	I-Chemical	-1	16574712
us@@	O	-1	16574712
er	O	-1	16574712
controls	O	-1	16574712
comple@@	O	-1	16574712
ted	O	-1	16574712
a	O	-1	16574712
gener@@	O	-1	16574712
al	O	-1	16574712
drug	O	-1	16574712
use	O	-1	16574712
qu@@	O	-1	16574712
es@@	O	-1	16574712
tion@@	O	-1	16574712
na@@	O	-1	16574712
i@@	O	-1	16574712
re,	O	-1	16574712
the	O	-1	16574712
B@@	O	-1	16574712
ri@@	O	-1	16574712
x@@	O	-1	16574712
t@@	O	-1	16574712
on	O	-1	16574712
S@@	O	-1	16574712
pati@@	O	-1	16574712
al	O	-1	16574712
An@@	O	-1	16574712
tic@@	O	-1	16574712
ip@@	O	-1	16574712
ation	O	-1	16574712
t@@	O	-1	16574712
as@@	O	-1	16574712
k	O	-1	16574712
(@@	O	-1	16574712
set	O	-1	16574712
shi@@	O	-1	16574712
f@@	O	-1	16574712
t@@	O	-1	16574712
ing@@	O	-1	16574712
),	O	-1	16574712
B@@	O	-1	16574712
ac@@	O	-1	16574712
k@@	O	-1	16574712
war@@	O	-1	16574712
d	O	-1	16574712
Di@@	O	-1	16574712
gi@@	O	-1	16574712
t	O	-1	16574712
S@@	O	-1	16574712
p@@	O	-1	16574712
an	O	-1	16574712
proce@@	O	-1	16574712
d@@	O	-1	16574712
ure	O	-1	16574712
(@@	O	-1	16574712
memory	O	-1	16574712
up@@	O	-1	16574712
dat@@	O	-1	16574712
ing@@	O	-1	16574712
),	O	-1	16574712
In@@	O	-1	16574712
hib@@	O	-1	16574712
ition	O	-1	16574712
of	O	-1	16574712
R@@	O	-1	16574712
et@@	O	-1	16574712
ur@@	O	-1	16574712
n	O	-1	16574712
(@@	O	-1	16574712
inhib@@	O	-1	16574712
i@@	O	-1	16574712
tion@@	O	-1	16574712
),	O	-1	16574712
an	O	-1	16574712
em@@	O	-1	16574712
o@@	O	-1	16574712
tional	O	-1	16574712
in@@	O	-1	16574712
te@@	O	-1	16574712
l@@	O	-1	16574712
li@@	O	-1	16574712
gen@@	O	-1	16574712
ce	O	-1	16574712
s@@	O	-1	16574712
cal@@	O	-1	16574712
e,	O	-1	16574712
the	O	-1	16574712
T@@	O	-1	16574712
rom@@	O	-1	16574712
so	O	-1	16574712
S@@	O	-1	16574712
oci@@	O	-1	16574712
al	O	-1	16574712
In@@	O	-1	16574712
te@@	O	-1	16574712
l@@	O	-1	16574712
li@@	O	-1	16574712
gen@@	O	-1	16574712
ce	O	-1	16574712
S@@	O	-1	16574712
cal@@	O	-1	16574712
e	O	-1	16574712
and	O	-1	16574712
the	O	-1	16574712
D@@	O	-1	16574712
y@@	O	-1	16574712
sex@@	O	-1	16574712
ec@@	O	-1	16574712
utive	O	-1	16574712
Q@@	O	-1	16574712
u@@	O	-1	16574712
es@@	O	-1	16574712
tion@@	O	-1	16574712
na@@	O	-1	16574712
ir@@	O	-1	16574712
e	O	-1	16574712
(D@@	O	-1	16574712
E@@	O	-1	16574712
X@@	O	-1	16574712
).	O	-1	16574712
Com@@	O	-1	16574712
pared	O	-1	16574712
with	O	-1	16574712
MD@@	B-Chemical	D018817	16574712
M@@	I-Chemical	-1	16574712
A	I-Chemical	-1	16574712
-@@	O	-1	16574712
free	O	-1	16574712
poly@@	O	-1	16574712
drug	O	-1	16574712
control@@	O	-1	16574712
s,	O	-1	16574712
MD@@	B-Chemical	D018817	16574712
M@@	I-Chemical	-1	16574712
A	I-Chemical	-1	16574712
poly@@	O	-1	16574712
drug	O	-1	16574712
users	O	-1	16574712
showed	O	-1	16574712
impair@@	O	-1	16574712
ments	O	-1	16574712
in	O	-1	16574712
set	O	-1	16574712
shi@@	O	-1	16574712
f@@	O	-1	16574712
ting	O	-1	16574712
and	O	-1	16574712
memory	O	-1	16574712
up@@	O	-1	16574712
dat@@	O	-1	16574712
ing,	O	-1	16574712
and	O	-1	16574712
also	O	-1	16574712
in	O	-1	16574712
s@@	O	-1	16574712
oci@@	O	-1	16574712
al	O	-1	16574712
and	O	-1	16574712
em@@	O	-1	16574712
o@@	O	-1	16574712
tional	O	-1	16574712
j@@	O	-1	16574712
ud@@	O	-1	16574712
g@@	O	-1	16574712
ement	O	-1	16574712
pro@@	O	-1	16574712
cess@@	O	-1	16574712
es.	O	-1	16574712
The	O	-1	16574712
lat@@	O	-1	16574712
ter	O	-1	16574712
two	O	-1	16574712
defic@@	O	-1	16574712
its	O	-1	16574712
remained	O	-1	16574712
significant	O	-1	16574712
after	O	-1	16574712
contro@@	O	-1	16574712
ll@@	O	-1	16574712
ing	O	-1	16574712
for	O	-1	16574712
other	O	-1	16574712
drug	O	-1	16574712
use.	O	-1	16574712
These	O	-1	16574712
data	O	-1	16574712
l@@	O	-1	16574712
end	O	-1	16574712
further	O	-1	16574712
suppor@@	O	-1	16574712
t	O	-1	16574712
to	O	-1	16574712
the	O	-1	16574712
pro@@	O	-1	16574712
pos@@	O	-1	16574712
al	O	-1	16574712
that	O	-1	16574712
cognitive	O	-1	16574712
pro@@	O	-1	16574712
ces@@	O	-1	16574712
ses	O	-1	16574712
mediated	O	-1	16574712
by	O	-1	16574712
the	O	-1	16574712
pre@@	O	-1	16574712
fron@@	O	-1	16574712
t@@	O	-1	16574712
al	O	-1	16574712
cor@@	O	-1	16574712
te@@	O	-1	16574712
x	O	-1	16574712
may	O	-1	16574712
be	O	-1	16574712
impaired	O	-1	16574712
by	O	-1	16574712
rec@@	O	-1	16574712
re@@	O	-1	16574712
ation@@	O	-1	16574712
al	O	-1	16574712
ec@@	B-Chemical	D018817	16574712
st@@	I-Chemical	-1	16574712
as@@	I-Chemical	-1	16574712
y	I-Chemical	-1	16574712
use.	O	-1	16574712

S@@	O	-1	17111419
ev@@	O	-1	17111419
ere	O	-1	17111419
cit@@	B-Chemical	C102006	17111419
rate	I-Chemical	-1	17111419
toxicity	B-Disease	D064420	17111419
complic@@	O	-1	17111419
ating	O	-1	17111419
vol@@	O	-1	17111419
un@@	O	-1	17111419
te@@	O	-1	17111419
er	O	-1	17111419
a@@	O	-1	17111419
ph@@	O	-1	17111419
e@@	O	-1	17111419
re@@	O	-1	17111419
sis	O	-1	17111419
platele@@	O	-1	17111419
t	O	-1	17111419
d@@	O	-1	17111419
on@@	O	-1	17111419
ation.	O	-1	17111419
We	O	-1	17111419
report	O	-1	17111419
a	O	-1	17111419
case	O	-1	17111419
of	O	-1	17111419
severe	O	-1	17111419
cit@@	B-Chemical	C102006	17111419
rate	I-Chemical	-1	17111419
toxicity	B-Disease	D064420	17111419
during	O	-1	17111419
vol@@	O	-1	17111419
un@@	O	-1	17111419
te@@	O	-1	17111419
er	O	-1	17111419
d@@	O	-1	17111419
on@@	O	-1	17111419
or	O	-1	17111419
a@@	O	-1	17111419
ph@@	O	-1	17111419
e@@	O	-1	17111419
re@@	O	-1	17111419
sis	O	-1	17111419
platele@@	O	-1	17111419
t	O	-1	17111419
coll@@	O	-1	17111419
ec@@	O	-1	17111419
tion.	O	-1	17111419
The	O	-1	17111419
d@@	O	-1	17111419
on@@	O	-1	17111419
or	O	-1	17111419
was	O	-1	17111419
a	O	-1	17111419
4@@	O	-1	17111419
0-@@	O	-1	17111419
year-old	O	-1	17111419
femal@@	O	-1	17111419
e,	O	-1	17111419
fir@@	O	-1	17111419
st@@	O	-1	17111419
-@@	O	-1	17111419
time	O	-1	17111419
a@@	O	-1	17111419
ph@@	O	-1	17111419
e@@	O	-1	17111419
re@@	O	-1	17111419
sis	O	-1	17111419
platele@@	O	-1	17111419
t	O	-1	17111419
d@@	O	-1	17111419
on@@	O	-1	17111419
or@@	O	-1	17111419
.	O	-1	17111419
P@@	O	-1	17111419
ast	O	-1	17111419
med@@	O	-1	17111419
ical	O	-1	17111419
hist@@	O	-1	17111419
ory	O	-1	17111419
was	O	-1	17111419
re@@	O	-1	17111419
mark@@	O	-1	17111419
able	O	-1	17111419
for	O	-1	17111419
hypertension	B-Disease	D006973	17111419
,	O	-1	17111419
hyper@@	B-Disease	D006949	17111419
li@@	I-Disease	-1	17111419
pi@@	I-Disease	-1	17111419
de@@	I-Disease	-1	17111419
mia	I-Disease	-1	17111419
,	O	-1	17111419
and	O	-1	17111419
de@@	B-Disease	D003866	17111419
pression	I-Disease	-1	17111419
.	O	-1	17111419
Re@@	O	-1	17111419
por@@	O	-1	17111419
ted	O	-1	17111419
medic@@	O	-1	17111419
ations	O	-1	17111419
included	O	-1	17111419
bu@@	B-Chemical	D002034	17111419
met@@	I-Chemical	-1	17111419
an@@	I-Chemical	-1	17111419
ide	I-Chemical	-1	17111419
,	O	-1	17111419
pra@@	B-Chemical	D017035	17111419
vastatin	I-Chemical	-1	17111419
,	O	-1	17111419
and	O	-1	17111419
pa@@	B-Chemical	D017374	17111419
ro@@	I-Chemical	-1	17111419
x@@	I-Chemical	-1	17111419
et@@	I-Chemical	-1	17111419
ine	I-Chemical	-1	17111419
.	O	-1	17111419
Th@@	O	-1	17111419
ir@@	O	-1	17111419
t@@	O	-1	17111419
y	O	-1	17111419
minutes	O	-1	17111419
from	O	-1	17111419
the	O	-1	17111419
star@@	O	-1	17111419
t	O	-1	17111419
of	O	-1	17111419
the	O	-1	17111419
proce@@	O	-1	17111419
d@@	O	-1	17111419
ure,	O	-1	17111419
the	O	-1	17111419
d@@	O	-1	17111419
on@@	O	-1	17111419
or	O	-1	17111419
not@@	O	-1	17111419
ed	O	-1	17111419
t@@	O	-1	17111419
ing@@	O	-1	17111419
l@@	O	-1	17111419
ing	O	-1	17111419
a@@	O	-1	17111419
ro@@	O	-1	17111419
un@@	O	-1	17111419
d	O	-1	17111419
the	O	-1	17111419
mou@@	O	-1	17111419
th@@	O	-1	17111419
,	O	-1	17111419
h@@	O	-1	17111419
and@@	O	-1	17111419
s,	O	-1	17111419
and	O	-1	17111419
fe@@	O	-1	17111419
et@@	O	-1	17111419
.	O	-1	17111419
S@@	O	-1	17111419
he	O	-1	17111419
then	O	-1	17111419
very	O	-1	17111419
ra@@	O	-1	17111419
pid@@	O	-1	17111419
ly	O	-1	17111419
developed	O	-1	17111419
acute	O	-1	17111419
onset	O	-1	17111419
of	O	-1	17111419
severe	O	-1	17111419
fac@@	O	-1	17111419
ial	O	-1	17111419
and	O	-1	17111419
ex@@	O	-1	17111419
trem@@	O	-1	17111419
ity	O	-1	17111419
te@@	B-Disease	D013746	17111419
t@@	I-Disease	-1	17111419
any	I-Disease	-1	17111419
.	O	-1	17111419
E@@	O	-1	17111419
m@@	O	-1	17111419
pi@@	O	-1	17111419
r@@	O	-1	17111419
ical	O	-1	17111419
treatment	O	-1	17111419
with	O	-1	17111419
intravenous	O	-1	17111419
calcium	B-Chemical	D002125	17111419
gl@@	I-Chemical	-1	17111419
uc@@	I-Chemical	-1	17111419
on@@	I-Chemical	-1	17111419
ate	I-Chemical	-1	17111419
was	O	-1	17111419
initi@@	O	-1	17111419
at@@	O	-1	17111419
ed,	O	-1	17111419
and	O	-1	17111419
musc@@	B-Disease	C536214	17111419
le	I-Disease	-1	17111419
contrac@@	I-Disease	-1	17111419
tions	I-Disease	-1	17111419
s@@	O	-1	17111419
low@@	O	-1	17111419
ly	O	-1	17111419
sub@@	O	-1	17111419
si@@	O	-1	17111419
ded	O	-1	17111419
over	O	-1	17111419
appro@@	O	-1	17111419
xim@@	O	-1	17111419
ately	O	-1	17111419
10	O	-1	17111419
to	O	-1	17111419
15	O	-1	17111419
minut@@	O	-1	17111419
es.	O	-1	17111419
The	O	-1	17111419
events	O	-1	17111419
are	O	-1	17111419
consist@@	O	-1	17111419
ent	O	-1	17111419
with	O	-1	17111419
a	O	-1	17111419
severe	O	-1	17111419
reaction	O	-1	17111419
to	O	-1	17111419
calcium	B-Chemical	D002118	17111419
ch@@	O	-1	17111419
el@@	O	-1	17111419
ation	O	-1	17111419
by	O	-1	17111419
sodium	B-Chemical	C102006	17111419
cit@@	I-Chemical	-1	17111419
rate	I-Chemical	-1	17111419
anti@@	O	-1	17111419
co@@	O	-1	17111419
ag@@	O	-1	17111419
ul@@	O	-1	17111419
ant	O	-1	17111419
result@@	O	-1	17111419
ing	O	-1	17111419
in	O	-1	17111419
symptom@@	O	-1	17111419
atic	O	-1	17111419
systemic	O	-1	17111419
hy@@	B-Disease	D006996	17111419
p@@	I-Disease	-1	17111419
oc@@	I-Disease	-1	17111419
al@@	I-Disease	-1	17111419
ce@@	I-Disease	-1	17111419
mia	I-Disease	-1	17111419
.	O	-1	17111419
U@@	O	-1	17111419
p@@	O	-1	17111419
on	O	-1	17111419
addi@@	O	-1	17111419
tional	O	-1	17111419
ret@@	O	-1	17111419
ro@@	O	-1	17111419
sp@@	O	-1	17111419
ective	O	-1	17111419
analy@@	O	-1	17111419
sis,	O	-1	17111419
it	O	-1	17111419
was	O	-1	17111419
not@@	O	-1	17111419
ed	O	-1	17111419
that	O	-1	17111419
bu@@	B-Chemical	D002034	17111419
met@@	I-Chemical	-1	17111419
an@@	I-Chemical	-1	17111419
ide	I-Chemical	-1	17111419
is	O	-1	17111419
a	O	-1	17111419
lo@@	B-Chemical	D049994	17111419
o@@	I-Chemical	-1	17111419
p	I-Chemical	-1	17111419
di@@	I-Chemical	-1	17111419
ure@@	I-Chemical	-1	17111419
tic	I-Chemical	-1	17111419
that	O	-1	17111419
may	O	-1	17111419
cause	O	-1	17111419
significant	O	-1	17111419
hy@@	B-Disease	D006996	17111419
p@@	I-Disease	-1	17111419
oc@@	I-Disease	-1	17111419
al@@	I-Disease	-1	17111419
ce@@	I-Disease	-1	17111419
mia	I-Disease	-1	17111419
.	O	-1	17111419
We	O	-1	17111419
concl@@	O	-1	17111419
ude	O	-1	17111419
that	O	-1	17111419
ca@@	O	-1	17111419
ref@@	O	-1	17111419
u@@	O	-1	17111419
l	O	-1	17111419
s@@	O	-1	17111419
cre@@	O	-1	17111419
en@@	O	-1	17111419
ing	O	-1	17111419
for	O	-1	17111419
medic@@	O	-1	17111419
ations	O	-1	17111419
and	O	-1	17111419
underlying	O	-1	17111419
condi@@	O	-1	17111419
tions	O	-1	17111419
pre@@	O	-1	17111419
dis@@	O	-1	17111419
pos@@	O	-1	17111419
ing	O	-1	17111419
to	O	-1	17111419
hy@@	B-Disease	D006996	17111419
p@@	I-Disease	-1	17111419
oc@@	I-Disease	-1	17111419
al@@	I-Disease	-1	17111419
ce@@	I-Disease	-1	17111419
mia	I-Disease	-1	17111419
is	O	-1	17111419
recomm@@	O	-1	17111419
en@@	O	-1	17111419
ded	O	-1	17111419
to	O	-1	17111419
he@@	O	-1	17111419
l@@	O	-1	17111419
p	O	-1	17111419
prev@@	O	-1	17111419
ent	O	-1	17111419
severe	O	-1	17111419
reactions	O	-1	17111419
due	O	-1	17111419
to	O	-1	17111419
cit@@	B-Chemical	C102006	17111419
rate	I-Chemical	-1	17111419
toxicity	B-Disease	D064420	17111419
.	O	-1	17111419
L@@	O	-1	17111419
abor@@	O	-1	17111419
atory	O	-1	17111419
meas@@	O	-1	17111419
ure@@	O	-1	17111419
ment	O	-1	17111419
of	O	-1	17111419
pre-@@	O	-1	17111419
proce@@	O	-1	17111419
d@@	O	-1	17111419
ure	O	-1	17111419
serum	O	-1	17111419
calcium	B-Chemical	D002118	17111419
levels	O	-1	17111419
in	O	-1	17111419
sel@@	O	-1	17111419
ected	O	-1	17111419
d@@	O	-1	17111419
on@@	O	-1	17111419
ors	O	-1	17111419
may	O	-1	17111419
identi@@	O	-1	17111419
f@@	O	-1	17111419
y	O	-1	17111419
cases	O	-1	17111419
requ@@	O	-1	17111419
ir@@	O	-1	17111419
ing	O	-1	17111419
he@@	O	-1	17111419
igh@@	O	-1	17111419
ten@@	O	-1	17111419
ed	O	-1	17111419
vi@@	O	-1	17111419
g@@	O	-1	17111419
il@@	O	-1	17111419
ance@@	O	-1	17111419
.	O	-1	17111419
The	O	-1	17111419
case	O	-1	17111419
also	O	-1	17111419
il@@	O	-1	17111419
lu@@	O	-1	17111419
strat@@	O	-1	17111419
es	O	-1	17111419
the	O	-1	17111419
import@@	O	-1	17111419
ance	O	-1	17111419
of	O	-1	17111419
maint@@	O	-1	17111419
aining	O	-1	17111419
pre@@	O	-1	17111419
pa@@	O	-1	17111419
re@@	O	-1	17111419
d@@	O	-1	17111419
ness	O	-1	17111419
for	O	-1	17111419
man@@	O	-1	17111419
ag@@	O	-1	17111419
ing	O	-1	17111419
r@@	O	-1	17111419
are	O	-1	17111419
but	O	-1	17111419
seri@@	O	-1	17111419
ous	O	-1	17111419
reactions	O	-1	17111419
in	O	-1	17111419
vol@@	O	-1	17111419
un@@	O	-1	17111419
te@@	O	-1	17111419
er	O	-1	17111419
a@@	O	-1	17111419
ph@@	O	-1	17111419
e@@	O	-1	17111419
re@@	O	-1	17111419
sis	O	-1	17111419
blood	O	-1	17111419
d@@	O	-1	17111419
on@@	O	-1	17111419
or@@	O	-1	17111419
s.	O	-1	17111419

Pro@@	B-Disease	D011507	17175308
te@@	I-Disease	-1	17175308
in@@	I-Disease	-1	17175308
uria	I-Disease	-1	17175308
after	O	-1	17175308
conver@@	O	-1	17175308
sion	O	-1	17175308
to	O	-1	17175308
sirolimus	B-Chemical	D020123	17175308
in	O	-1	17175308
renal	O	-1	17175308
transplant	O	-1	17175308
re@@	O	-1	17175308
ci@@	O	-1	17175308
pi@@	O	-1	17175308
ent@@	O	-1	17175308
s.	O	-1	17175308
Si@@	B-Chemical	D020123	17175308
rolimus	I-Chemical	-1	17175308
(	O	-1	17175308
SR@@	B-Chemical	D020123	17175308
L	I-Chemical	-1	17175308
)	O	-1	17175308
is	O	-1	17175308
a	O	-1	17175308
ne@@	O	-1	17175308
w@@	O	-1	17175308
,	O	-1	17175308
pot@@	O	-1	17175308
ent	O	-1	17175308
immunosup@@	O	-1	17175308
pressive	O	-1	17175308
agent@@	O	-1	17175308
.	O	-1	17175308
M@@	O	-1	17175308
or@@	O	-1	17175308
e	O	-1	17175308
rec@@	O	-1	17175308
ent@@	O	-1	17175308
ly,	O	-1	17175308
proteinuria	B-Disease	D011507	17175308
has	O	-1	17175308
been	O	-1	17175308
reported	O	-1	17175308
as	O	-1	17175308
a	O	-1	17175308
con@@	O	-1	17175308
sequ@@	O	-1	17175308
ence	O	-1	17175308
of	O	-1	17175308
sirolimus	B-Chemical	D020123	17175308
therapy,	O	-1	17175308
although	O	-1	17175308
the	O	-1	17175308
mechanism	O	-1	17175308
has	O	-1	17175308
remained	O	-1	17175308
unc@@	O	-1	17175308
lear@@	O	-1	17175308
.	O	-1	17175308
We	O	-1	17175308
ret@@	O	-1	17175308
ro@@	O	-1	17175308
sp@@	O	-1	17175308
ectively	O	-1	17175308
examined	O	-1	17175308
the	O	-1	17175308
recor@@	O	-1	17175308
ds	O	-1	17175308
of	O	-1	17175308
25	O	-1	17175308
renal	O	-1	17175308
transplant	O	-1	17175308
patients,	O	-1	17175308
who	O	-1	17175308
developed	O	-1	17175308
or	O	-1	17175308
dis@@	O	-1	17175308
pl@@	O	-1	17175308
ayed	O	-1	17175308
increased	O	-1	17175308
proteinuria	B-Disease	D011507	17175308
after	O	-1	17175308
SR@@	B-Chemical	D020123	17175308
L	I-Chemical	-1	17175308
conver@@	O	-1	17175308
sion.	O	-1	17175308
The	O	-1	17175308
patient	O	-1	17175308
co@@	O	-1	17175308
h@@	O	-1	17175308
ort	O	-1	17175308
(1@@	O	-1	17175308
4	O	-1	17175308
men@@	O	-1	17175308
,	O	-1	17175308
11	O	-1	17175308
wom@@	O	-1	17175308
en@@	O	-1	17175308
)	O	-1	17175308
was	O	-1	17175308
treated	O	-1	17175308
with	O	-1	17175308
SR@@	B-Chemical	D020123	17175308
L	I-Chemical	-1	17175308
as	O	-1	17175308
conver@@	O	-1	17175308
sion	O	-1	17175308
therapy,	O	-1	17175308
due	O	-1	17175308
to	O	-1	17175308
chronic	B-Disease	D051436	17175308
allogra@@	I-Disease	-1	17175308
ft	I-Disease	-1	17175308
nephro@@	I-Disease	-1	17175308
pathy	I-Disease	-1	17175308
(	O	-1	17175308
CA@@	B-Disease	D007674	17175308
N	I-Disease	-1	17175308
)	O	-1	17175308
(n	O	-1	17175308
=	O	-1	17175308
1@@	O	-1	17175308
5@@	O	-1	17175308
)	O	-1	17175308
ne@@	B-Disease	D009369	17175308
o@@	I-Disease	-1	17175308
pl@@	I-Disease	-1	17175308
a@@	I-Disease	-1	17175308
sia	I-Disease	-1	17175308
(n	O	-1	17175308
=	O	-1	17175308
8@@	O	-1	17175308
);	O	-1	17175308
K@@	B-Disease	D012514	17175308
apo@@	I-Disease	-1	17175308
si@@	I-Disease	-1	17175308
's	I-Disease	-1	17175308
s@@	I-Disease	-1	17175308
ar@@	I-Disease	-1	17175308
com@@	I-Disease	-1	17175308
a	I-Disease	-1	17175308
,	O	-1	17175308
F@@	O	-1	17175308
our	O	-1	17175308
s@@	B-Disease	D012878	17175308
k@@	I-Disease	-1	17175308
in	I-Disease	-1	17175308
canc@@	I-Disease	-1	17175308
ers	I-Disease	-1	17175308
,	O	-1	17175308
One	O	-1	17175308
in@@	B-Disease	D007414	17175308
test@@	I-Disease	-1	17175308
inal	I-Disease	-1	17175308
tu@@	I-Disease	-1	17175308
mor@@	I-Disease	-1	17175308
s	I-Disease	-1	17175308
,	O	-1	17175308
One	O	-1	17175308
renal	B-Disease	D002292	17175308
cell	I-Disease	-1	17175308
car@@	I-Disease	-1	17175308
s@@	I-Disease	-1	17175308
ino@@	I-Disease	-1	17175308
m	I-Disease	-1	17175308
)	O	-1	17175308
or	O	-1	17175308
B@@	O	-1	17175308
K	O	-1	17175308
vi@@	O	-1	17175308
ru@@	O	-1	17175308
s	O	-1	17175308
nephro@@	B-Disease	D007674	17175308
pathy	I-Disease	-1	17175308
(n	O	-1	17175308
=	O	-1	17175308
2@@	O	-1	17175308
).	O	-1	17175308
SR@@	B-Chemical	D020123	17175308
L	I-Chemical	-1	17175308
was	O	-1	17175308
star@@	O	-1	17175308
ted	O	-1	17175308
at	O	-1	17175308
a	O	-1	17175308
mean	O	-1	17175308
of	O	-1	17175308
7@@	O	-1	17175308
8	O	-1	17175308
+/-	O	-1	17175308
4@@	O	-1	17175308
2	O	-1	17175308
(1@@	O	-1	17175308
5	O	-1	17175308
to	O	-1	17175308
1@@	O	-1	17175308
6@@	O	-1	17175308
3@@	O	-1	17175308
)	O	-1	17175308
months	O	-1	17175308
after	O	-1	17175308
transplant@@	O	-1	17175308
ation.	O	-1	17175308
M@@	O	-1	17175308
e@@	O	-1	17175308
an	O	-1	17175308
follow-up	O	-1	17175308
on	O	-1	17175308
SR@@	B-Chemical	D020123	17175308
L	I-Chemical	-1	17175308
therapy	O	-1	17175308
was	O	-1	17175308
20	O	-1	17175308
+/-	O	-1	17175308
12	O	-1	17175308
(@@	O	-1	17175308
6	O	-1	17175308
to	O	-1	17175308
4@@	O	-1	17175308
3@@	O	-1	17175308
)	O	-1	17175308
months.	O	-1	17175308
Pro@@	B-Disease	D011507	17175308
te@@	I-Disease	-1	17175308
in@@	I-Disease	-1	17175308
uria	I-Disease	-1	17175308
increased	O	-1	17175308
from	O	-1	17175308
0.@@	O	-1	17175308
4@@	O	-1	17175308
4@@	O	-1	17175308
5	O	-1	17175308
(@@	O	-1	17175308
0	O	-1	17175308
to	O	-1	17175308
1.@@	O	-1	17175308
5@@	O	-1	17175308
)	O	-1	17175308
g/@@	O	-1	17175308
d	O	-1	17175308
before	O	-1	17175308
conver@@	O	-1	17175308
sion	O	-1	17175308
to	O	-1	17175308
3.@@	O	-1	17175308
2	O	-1	17175308
g/@@	O	-1	17175308
d@@	O	-1	17175308
L	O	-1	17175308
(0.@@	O	-1	17175308
2	O	-1	17175308
to	O	-1	17175308
12@@	O	-1	17175308
)	O	-1	17175308
after	O	-1	17175308
conver@@	O	-1	17175308
sion	O	-1	17175308
(P	O	-1	17175308
=	O	-1	17175308
0.00@@	O	-1	17175308
1).	O	-1	17175308
B@@	O	-1	17175308
e@@	O	-1	17175308
fore	O	-1	17175308
conver@@	O	-1	17175308
sion	O	-1	17175308
8	O	-1	17175308
(3@@	O	-1	17175308
2@@	O	-1	17175308
%)	O	-1	17175308
patients	O	-1	17175308
had	O	-1	17175308
no	O	-1	17175308
proteinuria	B-Disease	D011507	17175308
,	O	-1	17175308
whereas	O	-1	17175308
af@@	O	-1	17175308
ter@@	O	-1	17175308
war@@	O	-1	17175308
ds	O	-1	17175308
all	O	-1	17175308
patients	O	-1	17175308
had	O	-1	17175308
proteinuria	B-Disease	D011507	17175308
.	O	-1	17175308
In	O	-1	17175308
2@@	O	-1	17175308
8@@	O	-1	17175308
%	O	-1	17175308
of	O	-1	17175308
patients	O	-1	17175308
proteinuria	B-Disease	D011507	17175308
remained	O	-1	17175308
un@@	O	-1	17175308
chang@@	O	-1	17175308
ed,	O	-1	17175308
whereas	O	-1	17175308
it	O	-1	17175308
increased	O	-1	17175308
in	O	-1	17175308
6@@	O	-1	17175308
8@@	O	-1	17175308
%	O	-1	17175308
of	O	-1	17175308
patients.	O	-1	17175308
In	O	-1	17175308
4@@	O	-1	17175308
0%	O	-1	17175308
it	O	-1	17175308
increased	O	-1	17175308
by	O	-1	17175308
more	O	-1	17175308
than	O	-1	17175308
10@@	O	-1	17175308
0@@	O	-1	17175308
%.	O	-1	17175308
Tw@@	O	-1	17175308
ent@@	O	-1	17175308
y-@@	O	-1	17175308
e@@	O	-1	17175308
ight	O	-1	17175308
perc@@	O	-1	17175308
ent	O	-1	17175308
of	O	-1	17175308
patients	O	-1	17175308
showed	O	-1	17175308
increased	O	-1	17175308
proteinuria	B-Disease	D011507	17175308
to	O	-1	17175308
the	O	-1	17175308
nephro@@	B-Disease	D009404	17175308
tic	I-Disease	-1	17175308
rang@@	O	-1	17175308
e.	O	-1	17175308
B@@	O	-1	17175308
io@@	O	-1	17175308
p@@	O	-1	17175308
si@@	O	-1	17175308
es	O	-1	17175308
performed	O	-1	17175308
in	O	-1	17175308
five	O	-1	17175308
patients	O	-1	17175308
revealed	O	-1	17175308
new	O	-1	17175308
path@@	O	-1	17175308
ological	O	-1	17175308
chang@@	O	-1	17175308
es@@	O	-1	17175308
:	O	-1	17175308
One	O	-1	17175308
membran@@	B-Disease	D015433	17175308
o@@	I-Disease	-1	17175308
pro@@	I-Disease	-1	17175308
li@@	I-Disease	-1	17175308
fer@@	I-Disease	-1	17175308
ative	I-Disease	-1	17175308
glomer@@	I-Disease	-1	17175308
ulo@@	I-Disease	-1	17175308
pathy	I-Disease	-1	17175308
and	O	-1	17175308
interstitial	B-Disease	D009395	17175308
neph@@	I-Disease	-1	17175308
ritis	I-Disease	-1	17175308
.	O	-1	17175308
These	O	-1	17175308
patients	O	-1	17175308
showed	O	-1	17175308
per@@	O	-1	17175308
sist@@	O	-1	17175308
ently	O	-1	17175308
go@@	O	-1	17175308
od	O	-1	17175308
gra@@	O	-1	17175308
ft	O	-1	17175308
func@@	O	-1	17175308
tion.	O	-1	17175308
S@@	O	-1	17175308
er@@	O	-1	17175308
um	O	-1	17175308
creatinine	B-Chemical	D003404	17175308
values	O	-1	17175308
did	O	-1	17175308
not	O	-1	17175308
change	O	-1	17175308
significant@@	O	-1	17175308
ly@@	O	-1	17175308
:	O	-1	17175308
1.@@	O	-1	17175308
9@@	O	-1	17175308
8	O	-1	17175308
+/-	O	-1	17175308
0.@@	O	-1	17175308
8	O	-1	17175308
mg/d@@	O	-1	17175308
L	O	-1	17175308
before	O	-1	17175308
SR@@	B-Chemical	D020123	17175308
L	I-Chemical	-1	17175308
therapy	O	-1	17175308
and	O	-1	17175308
2.@@	O	-1	17175308
5@@	O	-1	17175308
3	O	-1	17175308
+/-	O	-1	17175308
1.@@	O	-1	17175308
9	O	-1	17175308
mg/d@@	O	-1	17175308
L	O	-1	17175308
at	O	-1	17175308
las@@	O	-1	17175308
t	O	-1	17175308
follow-up	O	-1	17175308
(P	O	-1	17175308
=	O	-1	17175308
.@@	O	-1	17175308
14@@	O	-1	17175308
).	O	-1	17175308
F@@	O	-1	17175308
i@@	O	-1	17175308
ve	O	-1	17175308
gra@@	O	-1	17175308
f@@	O	-1	17175308
ts	O	-1	17175308
were	O	-1	17175308
lo@@	O	-1	17175308
st	O	-1	17175308
and	O	-1	17175308
the	O	-1	17175308
patients	O	-1	17175308
retur@@	O	-1	17175308
n@@	O	-1	17175308
ed	O	-1	17175308
to	O	-1	17175308
dialy@@	O	-1	17175308
sis.	O	-1	17175308
F@@	O	-1	17175308
i@@	O	-1	17175308
ve	O	-1	17175308
patients	O	-1	17175308
dis@@	O	-1	17175308
pl@@	O	-1	17175308
ayed	O	-1	17175308
CA@@	B-Disease	D007674	17175308
N	I-Disease	-1	17175308
and	O	-1	17175308
K@@	B-Disease	D012514	17175308
apo@@	I-Disease	-1	17175308
si@@	I-Disease	-1	17175308
's	I-Disease	-1	17175308
s@@	I-Disease	-1	17175308
ar@@	I-Disease	-1	17175308
com@@	I-Disease	-1	17175308
a	I-Disease	-1	17175308
.	O	-1	17175308
M@@	O	-1	17175308
e@@	O	-1	17175308
an	O	-1	17175308
urinary	O	-1	17175308
protein	O	-1	17175308
of	O	-1	17175308
patients	O	-1	17175308
who	O	-1	17175308
retur@@	O	-1	17175308
n@@	O	-1	17175308
ed	O	-1	17175308
to	O	-1	17175308
dialy@@	O	-1	17175308
sis	O	-1	17175308
was	O	-1	17175308
1.@@	O	-1	17175308
2@@	O	-1	17175308
6	O	-1	17175308
(0.@@	O	-1	17175308
5	O	-1	17175308
to	O	-1	17175308
3.@@	O	-1	17175308
5@@	O	-1	17175308
)	O	-1	17175308
g/@@	O	-1	17175308
d	O	-1	17175308
before	O	-1	17175308
and	O	-1	17175308
4.@@	O	-1	17175308
7	O	-1	17175308
(@@	O	-1	17175308
3	O	-1	17175308
to	O	-1	17175308
12@@	O	-1	17175308
)	O	-1	17175308
g/@@	O	-1	17175308
d	O	-1	17175308
after	O	-1	17175308
conver@@	O	-1	17175308
sion	O	-1	17175308
(P	O	-1	17175308
=	O	-1	17175308
.@@	O	-1	17175308
0@@	O	-1	17175308
1).	O	-1	17175308
M@@	O	-1	17175308
e@@	O	-1	17175308
an	O	-1	17175308
serum	O	-1	17175308
creatinine	B-Chemical	D003404	17175308
level	O	-1	17175308
before	O	-1	17175308
conver@@	O	-1	17175308
sion	O	-1	17175308
was	O	-1	17175308
2.@@	O	-1	17175308
21	O	-1	17175308
mg/d@@	O	-1	17175308
L	O	-1	17175308
and	O	-1	17175308
the@@	O	-1	17175308
re@@	O	-1	17175308
af@@	O	-1	17175308
ter@@	O	-1	17175308
,	O	-1	17175308
4.@@	O	-1	17175308
9@@	O	-1	17175308
3	O	-1	17175308
mg/d@@	O	-1	17175308
L	O	-1	17175308
(P	O	-1	17175308
=	O	-1	17175308
.@@	O	-1	17175308
0@@	O	-1	17175308
2@@	O	-1	17175308
).	O	-1	17175308
He@@	O	-1	17175308
av@@	O	-1	17175308
y	O	-1	17175308
proteinuria	B-Disease	D011507	17175308
was	O	-1	17175308
common	O	-1	17175308
after	O	-1	17175308
the	O	-1	17175308
use	O	-1	17175308
of	O	-1	17175308
SR@@	B-Chemical	D020123	17175308
L	I-Chemical	-1	17175308
as	O	-1	17175308
res@@	O	-1	17175308
c@@	O	-1	17175308
u@@	O	-1	17175308
e	O	-1	17175308
therapy	O	-1	17175308
for	O	-1	17175308
renal	O	-1	17175308
transplant@@	O	-1	17175308
ation.	O	-1	17175308
The@@	O	-1	17175308
refore,	O	-1	17175308
conver@@	O	-1	17175308
sion	O	-1	17175308
should	O	-1	17175308
be	O	-1	17175308
considered	O	-1	17175308
for	O	-1	17175308
patients	O	-1	17175308
who	O	-1	17175308
have	O	-1	17175308
not	O	-1	17175308
developed	O	-1	17175308
adv@@	O	-1	17175308
anced	O	-1	17175308
CA@@	B-Disease	D007674	17175308
N	I-Disease	-1	17175308
and	O	-1	17175308
proteinuria	B-Disease	D011507	17175308
.	O	-1	17175308
The	O	-1	17175308
possib@@	O	-1	17175308
ility	O	-1	17175308
of	O	-1	17175308
de	O	-1	17175308
no@@	O	-1	17175308
v@@	O	-1	17175308
o	O	-1	17175308
glomerular	O	-1	17175308
path@@	O	-1	17175308
ology	O	-1	17175308
under	O	-1	17175308
SR@@	B-Chemical	D020123	17175308
L	I-Chemical	-1	17175308
treatment	O	-1	17175308
requ@@	O	-1	17175308
i@@	O	-1	17175308
res	O	-1	17175308
further	O	-1	17175308
investig@@	O	-1	17175308
ation	O	-1	17175308
by	O	-1	17175308
renal	O	-1	17175308
bio@@	O	-1	17175308
psy@@	O	-1	17175308
.	O	-1	17175308

In	O	-1	17244258
vit@@	O	-1	17244258
r@@	O	-1	17244258
o	O	-1	17244258
character@@	O	-1	17244258
ization	O	-1	17244258
of	O	-1	17244258
par@@	O	-1	17244258
as@@	O	-1	17244258
ym@@	O	-1	17244258
pa@@	O	-1	17244258
thetic	O	-1	17244258
and	O	-1	17244258
sym@@	O	-1	17244258
pa@@	O	-1	17244258
thetic	O	-1	17244258
responses	O	-1	17244258
in	O	-1	17244258
cyclophosph@@	B-Chemical	D003520	17244258
amide	I-Chemical	-1	17244258
-induced	O	-1	17244258
cys@@	B-Disease	D003556	17244258
ti@@	I-Disease	-1	17244258
tis	I-Disease	-1	17244258
in	O	-1	17244258
the	O	-1	17244258
rat@@	O	-1	17244258
.	O	-1	17244258
In	O	-1	17244258
cyclophosph@@	B-Chemical	D003520	17244258
amide	I-Chemical	-1	17244258
-induced	O	-1	17244258
cys@@	B-Disease	D003556	17244258
ti@@	I-Disease	-1	17244258
tis	I-Disease	-1	17244258
in	O	-1	17244258
the	O	-1	17244258
rat@@	O	-1	17244258
,	O	-1	17244258
det@@	O	-1	17244258
r@@	O	-1	17244258
us@@	O	-1	17244258
or	O	-1	17244258
function	O	-1	17244258
is	O	-1	17244258
impaired	O	-1	17244258
and	O	-1	17244258
the	O	-1	17244258
expression	O	-1	17244258
and	O	-1	17244258
effects	O	-1	17244258
of	O	-1	17244258
mus@@	O	-1	17244258
car@@	O	-1	17244258
inic	O	-1	17244258
receptors	O	-1	17244258
al@@	O	-1	17244258
te@@	O	-1	17244258
red.	O	-1	17244258
Whe@@	O	-1	17244258
ther	O	-1	17244258
or	O	-1	17244258
not	O	-1	17244258
the	O	-1	17244258
neuron@@	O	-1	17244258
al	O	-1	17244258
trans@@	O	-1	17244258
mission	O	-1	17244258
may	O	-1	17244258
be	O	-1	17244258
affected	O	-1	17244258
by	O	-1	17244258
cys@@	B-Disease	D003556	17244258
ti@@	I-Disease	-1	17244258
tis	I-Disease	-1	17244258
was	O	-1	17244258
present@@	O	-1	17244258
ly	O	-1	17244258
investig@@	O	-1	17244258
ated.	O	-1	17244258
R@@	O	-1	17244258
es@@	O	-1	17244258
p@@	O	-1	17244258
on@@	O	-1	17244258
ses	O	-1	17244258
of	O	-1	17244258
urinary	O	-1	17244258
stri@@	O	-1	17244258
p	O	-1	17244258
pre@@	O	-1	17244258
par@@	O	-1	17244258
ations	O	-1	17244258
from	O	-1	17244258
control	O	-1	17244258
and	O	-1	17244258
cyclophosph@@	B-Chemical	D003520	17244258
amide	I-Chemical	-1	17244258
-@@	O	-1	17244258
pre@@	O	-1	17244258
treated	O	-1	17244258
rats	O	-1	17244258
to	O	-1	17244258
elect@@	O	-1	17244258
r@@	O	-1	17244258
ical	O	-1	17244258
fi@@	O	-1	17244258
el@@	O	-1	17244258
d	O	-1	17244258
stimulation	O	-1	17244258
and	O	-1	17244258
to	O	-1	17244258
agon@@	O	-1	17244258
ist@@	O	-1	17244258
s	O	-1	17244258
were	O	-1	17244258
assessed	O	-1	17244258
in	O	-1	17244258
the	O	-1	17244258
absence	O	-1	17244258
and	O	-1	17244258
presence	O	-1	17244258
of	O	-1	17244258
mus@@	O	-1	17244258
car@@	O	-1	17244258
in@@	O	-1	17244258
ic@@	O	-1	17244258
,	O	-1	17244258
adrenergic	O	-1	17244258
and	O	-1	17244258
pur@@	O	-1	17244258
inergic	O	-1	17244258
receptor	O	-1	17244258
antagonist@@	O	-1	17244258
s.	O	-1	17244258
G@@	O	-1	17244258
en@@	O	-1	17244258
er@@	O	-1	17244258
ally,	O	-1	17244258
atro@@	B-Chemical	D001285	17244258
pine	I-Chemical	-1	17244258
reduced	O	-1	17244258
contrac@@	O	-1	17244258
tion@@	O	-1	17244258
s,	O	-1	17244258
but	O	-1	17244258
in	O	-1	17244258
contr@@	O	-1	17244258
ast	O	-1	17244258
to	O	-1	17244258
control@@	O	-1	17244258
s,	O	-1	17244258
it	O	-1	17244258
also	O	-1	17244258
reduced	O	-1	17244258
responses	O	-1	17244258
to	O	-1	17244258
low	O	-1	17244258
elect@@	O	-1	17244258
r@@	O	-1	17244258
ical	O	-1	17244258
fi@@	O	-1	17244258
el@@	O	-1	17244258
d	O	-1	17244258
stimulation	O	-1	17244258
int@@	O	-1	17244258
ensity	O	-1	17244258
(1@@	O	-1	17244258
-@@	O	-1	17244258
5	O	-1	17244258
H@@	O	-1	17244258
z@@	O	-1	17244258
)	O	-1	17244258
in	O	-1	17244258
inflam@@	O	-1	17244258
ed	O	-1	17244258
pre@@	O	-1	17244258
par@@	O	-1	17244258
ations.	O	-1	17244258
In	O	-1	17244258
both	O	-1	17244258
typ@@	O	-1	17244258
es,	O	-1	17244258
pur@@	O	-1	17244258
in@@	O	-1	17244258
oc@@	O	-1	17244258
e@@	O	-1	17244258
pt@@	O	-1	17244258
or	O	-1	17244258
des@@	O	-1	17244258
en@@	O	-1	17244258
si@@	O	-1	17244258
tiz@@	O	-1	17244258
ation	O	-1	17244258
with	O	-1	17244258
alpha@@	B-Chemical	C002630	17244258
,@@	I-Chemical	-1	17244258
beta-@@	I-Chemical	-1	17244258
methyl@@	I-Chemical	-1	17244258
ene	I-Chemical	-1	17244258
aden@@	I-Chemical	-1	17244258
os@@	I-Chemical	-1	17244258
ine-@@	I-Chemical	-1	17244258
5@@	I-Chemical	-1	17244258
'@@	I-Chemical	-1	17244258
-@@	I-Chemical	-1	17244258
tri@@	I-Chemical	-1	17244258
phosph@@	I-Chemical	-1	17244258
ate	I-Chemical	-1	17244258
(	O	-1	17244258
alpha@@	B-Chemical	C002630	17244258
,@@	I-Chemical	-1	17244258
beta-@@	I-Chemical	-1	17244258
me@@	I-Chemical	-1	17244258
AT@@	I-Chemical	-1	17244258
P	I-Chemical	-1	17244258
)	O	-1	17244258
caused	O	-1	17244258
further	O	-1	17244258
reduc@@	O	-1	17244258
tions	O	-1	17244258
at	O	-1	17244258
low	O	-1	17244258
frequ@@	O	-1	17244258
en@@	O	-1	17244258
ci@@	O	-1	17244258
es	O	-1	17244258
(@@	O	-1	17244258
<@@	O	-1	17244258
10	O	-1	17244258
H@@	O	-1	17244258
z@@	O	-1	17244258
).	O	-1	17244258
The	O	-1	17244258
mus@@	O	-1	17244258
car@@	O	-1	17244258
inic	O	-1	17244258
receptor	O	-1	17244258
antagonist@@	O	-1	17244258
s	O	-1	17244258
atro@@	B-Chemical	D001285	17244258
pine	I-Chemical	-1	17244258
,	O	-1	17244258
4-@@	B-Chemical	C042375	17244258
di@@	I-Chemical	-1	17244258
phenyl@@	I-Chemical	-1	17244258
ace@@	I-Chemical	-1	17244258
tox@@	I-Chemical	-1	17244258
y-@@	I-Chemical	-1	17244258
N@@	I-Chemical	-1	17244258
-@@	I-Chemical	-1	17244258
methyl@@	I-Chemical	-1	17244258
pi@@	I-Chemical	-1	17244258
perid@@	I-Chemical	-1	17244258
ine	I-Chemical	-1	17244258
(	O	-1	17244258
4-@@	B-Chemical	C042375	17244258
D@@	I-Chemical	-1	17244258
AM@@	I-Chemical	-1	17244258
P	I-Chemical	-1	17244258
)	O	-1	17244258
(@@	O	-1	17244258
'@@	O	-1	17244258
M@@	O	-1	17244258
(1@@	O	-1	17244258
)@@	O	-1	17244258
/@@	O	-1	17244258
M@@	O	-1	17244258
(3@@	O	-1	17244258
)@@	O	-1	17244258
/@@	O	-1	17244258
M@@	O	-1	17244258
(5@@	O	-1	17244258
)-@@	O	-1	17244258
sel@@	O	-1	17244258
ecti@@	O	-1	17244258
ve@@	O	-1	17244258
'@@	O	-1	17244258
),	O	-1	17244258
meth@@	B-Chemical	C054938	17244258
oc@@	I-Chemical	-1	17244258
tr@@	I-Chemical	-1	17244258
amine	I-Chemical	-1	17244258
(@@	O	-1	17244258
'@@	O	-1	17244258
M@@	O	-1	17244258
(2@@	O	-1	17244258
)-@@	O	-1	17244258
sel@@	O	-1	17244258
ecti@@	O	-1	17244258
ve@@	O	-1	17244258
'@@	O	-1	17244258
)	O	-1	17244258
and	O	-1	17244258
pi@@	B-Chemical	D010890	17244258
ren@@	I-Chemical	-1	17244258
z@@	I-Chemical	-1	17244258
ep@@	I-Chemical	-1	17244258
ine	I-Chemical	-1	17244258
(@@	O	-1	17244258
'@@	O	-1	17244258
M@@	O	-1	17244258
(1@@	O	-1	17244258
)-@@	O	-1	17244258
sel@@	O	-1	17244258
ecti@@	O	-1	17244258
ve@@	O	-1	17244258
'@@	O	-1	17244258
)	O	-1	17244258
antagon@@	O	-1	17244258
ized	O	-1	17244258
the	O	-1	17244258
t@@	O	-1	17244258
onic	O	-1	17244258
comp@@	O	-1	17244258
on@@	O	-1	17244258
ent	O	-1	17244258
of	O	-1	17244258
the	O	-1	17244258
elect@@	O	-1	17244258
r@@	O	-1	17244258
ical	O	-1	17244258
fi@@	O	-1	17244258
el@@	O	-1	17244258
d	O	-1	17244258
stimul@@	O	-1	17244258
ation@@	O	-1	17244258
-@@	O	-1	17244258
evoked	O	-1	17244258
contrac@@	O	-1	17244258
ti@@	O	-1	17244258
le	O	-1	17244258
response	O	-1	17244258
more	O	-1	17244258
pot@@	O	-1	17244258
ently	O	-1	17244258
than	O	-1	17244258
the	O	-1	17244258
pha@@	O	-1	17244258
sic	O	-1	17244258
comp@@	O	-1	17244258
on@@	O	-1	17244258
ent@@	O	-1	17244258
.	O	-1	17244258
4-@@	B-Chemical	C042375	17244258
D@@	I-Chemical	-1	17244258
AM@@	I-Chemical	-1	17244258
P	I-Chemical	-1	17244258
inhibited	O	-1	17244258
the	O	-1	17244258
t@@	O	-1	17244258
onic	O	-1	17244258
contrac@@	O	-1	17244258
tions	O	-1	17244258
in	O	-1	17244258
controls	O	-1	17244258
more	O	-1	17244258
pot@@	O	-1	17244258
ently	O	-1	17244258
than	O	-1	17244258
meth@@	B-Chemical	C054938	17244258
oc@@	I-Chemical	-1	17244258
tr@@	I-Chemical	-1	17244258
amine	I-Chemical	-1	17244258
and	O	-1	17244258
pi@@	B-Chemical	D010890	17244258
ren@@	I-Chemical	-1	17244258
z@@	I-Chemical	-1	17244258
ep@@	I-Chemical	-1	17244258
ine	I-Chemical	-1	17244258
.	O	-1	17244258
In	O	-1	17244258
inflam@@	O	-1	17244258
ed	O	-1	17244258
pre@@	O	-1	17244258
par@@	O	-1	17244258
ation@@	O	-1	17244258
s,	O	-1	17244258
the	O	-1	17244258
mus@@	O	-1	17244258
car@@	O	-1	17244258
inic	O	-1	17244258
receptor	O	-1	17244258
antagon@@	O	-1	17244258
ism	O	-1	17244258
on	O	-1	17244258
the	O	-1	17244258
pha@@	O	-1	17244258
sic	O	-1	17244258
comp@@	O	-1	17244258
on@@	O	-1	17244258
ent	O	-1	17244258
of	O	-1	17244258
the	O	-1	17244258
elect@@	O	-1	17244258
r@@	O	-1	17244258
ical	O	-1	17244258
fi@@	O	-1	17244258
el@@	O	-1	17244258
d	O	-1	17244258
stimul@@	O	-1	17244258
ation@@	O	-1	17244258
-@@	O	-1	17244258
evoked	O	-1	17244258
contrac@@	O	-1	17244258
tion	O	-1	17244258
was	O	-1	17244258
decreased	O	-1	17244258
and	O	-1	17244258
the	O	-1	17244258
pi@@	B-Chemical	D010890	17244258
ren@@	I-Chemical	-1	17244258
z@@	I-Chemical	-1	17244258
ep@@	I-Chemical	-1	17244258
ine	I-Chemical	-1	17244258
and	O	-1	17244258
4-@@	B-Chemical	C042375	17244258
D@@	I-Chemical	-1	17244258
AM@@	I-Chemical	-1	17244258
P	I-Chemical	-1	17244258
antagon@@	O	-1	17244258
ism	O	-1	17244258
on	O	-1	17244258
the	O	-1	17244258
t@@	O	-1	17244258
onic	O	-1	17244258
comp@@	O	-1	17244258
on@@	O	-1	17244258
ent	O	-1	17244258
was	O	-1	17244258
m@@	O	-1	17244258
uc@@	O	-1	17244258
h	O	-1	17244258
less	O	-1	17244258
eff@@	O	-1	17244258
ici@@	O	-1	17244258
ent	O	-1	17244258
than	O	-1	17244258
in	O	-1	17244258
controls.	O	-1	17244258
In	O	-1	17244258
contr@@	O	-1	17244258
ast	O	-1	17244258
to	O	-1	17244258
control@@	O	-1	17244258
s,	O	-1	17244258
meth@@	B-Chemical	C054938	17244258
oc@@	I-Chemical	-1	17244258
tr@@	I-Chemical	-1	17244258
amine	I-Chemical	-1	17244258
increased	O	-1	17244258
-@@	O	-1	17244258
-	O	-1	17244258
in@@	O	-1	17244258
ste@@	O	-1	17244258
ad	O	-1	17244258
of	O	-1	17244258
decreased	O	-1	17244258
-@@	O	-1	17244258
-	O	-1	17244258
the	O	-1	17244258
t@@	O	-1	17244258
onic	O	-1	17244258
responses	O	-1	17244258
at	O	-1	17244258
high	O	-1	17244258
frequ@@	O	-1	17244258
en@@	O	-1	17244258
ci@@	O	-1	17244258
es.	O	-1	17244258
W@@	O	-1	17244258
h@@	O	-1	17244258
ile	O	-1	17244258
contrac@@	O	-1	17244258
tions	O	-1	17244258
to	O	-1	17244258
carb@@	B-Chemical	D002217	17244258
ac@@	I-Chemical	-1	17244258
hol	I-Chemical	-1	17244258
and	O	-1	17244258
AT@@	B-Chemical	D000255	17244258
P	I-Chemical	-1	17244258
were	O	-1	17244258
the	O	-1	17244258
same	O	-1	17244258
in	O	-1	17244258
inflam@@	O	-1	17244258
ed	O	-1	17244258
and	O	-1	17244258
in	O	-1	17244258
control	O	-1	17244258
stri@@	O	-1	17244258
p@@	O	-1	17244258
s	O	-1	17244258
when	O	-1	17244258
related	O	-1	17244258
to	O	-1	17244258
a	O	-1	17244258
ref@@	O	-1	17244258
e@@	O	-1	17244258
rence	O	-1	17244258
pot@@	B-Chemical	D011188	17244258
assi@@	I-Chemical	-1	17244258
um	I-Chemical	-1	17244258
respon@@	O	-1	17244258
se@@	O	-1	17244258
,	O	-1	17244258
iso@@	B-Chemical	D007545	17244258
p@@	I-Chemical	-1	17244258
ren@@	I-Chemical	-1	17244258
aline	I-Chemical	-1	17244258
-induced	O	-1	17244258
rel@@	O	-1	17244258
ax@@	O	-1	17244258
ations	O	-1	17244258
were	O	-1	17244258
sm@@	O	-1	17244258
all@@	O	-1	17244258
er	O	-1	17244258
in	O	-1	17244258
inflam@@	O	-1	17244258
ed	O	-1	17244258
stri@@	O	-1	17244258
p@@	O	-1	17244258
s.	O	-1	17244258
Th@@	O	-1	17244258
us,	O	-1	17244258
in	O	-1	17244258
cys@@	B-Disease	D003556	17244258
ti@@	I-Disease	-1	17244258
tis	I-Disease	-1	17244258
subst@@	O	-1	17244258
anti@@	O	-1	17244258
al	O	-1	17244258
changes	O	-1	17244258
of	O	-1	17244258
the	O	-1	17244258
eff@@	O	-1	17244258
e@@	O	-1	17244258
rent	O	-1	17244258
functional	O	-1	17244258
responses	O	-1	17244258
occur@@	O	-1	17244258
.	O	-1	17244258
W@@	O	-1	17244258
h@@	O	-1	17244258
ile	O	-1	17244258
post@@	O	-1	17244258
j@@	O	-1	17244258
unc@@	O	-1	17244258
tional	O	-1	17244258
beta-@@	O	-1	17244258
adren@@	O	-1	17244258
oc@@	O	-1	17244258
e@@	O	-1	17244258
pt@@	O	-1	17244258
or@@	O	-1	17244258
-@@	O	-1	17244258
mediated	O	-1	17244258
rel@@	O	-1	17244258
ax@@	O	-1	17244258
ations	O	-1	17244258
are	O	-1	17244258
reduc@@	O	-1	17244258
ed,	O	-1	17244258
effects	O	-1	17244258
by	O	-1	17244258
pre@@	O	-1	17244258
j@@	O	-1	17244258
unc@@	O	-1	17244258
tional	O	-1	17244258
inhibit@@	O	-1	17244258
ory	O	-1	17244258
mus@@	O	-1	17244258
car@@	O	-1	17244258
inic	O	-1	17244258
receptors	O	-1	17244258
may	O	-1	17244258
be	O	-1	17244258
increas@@	O	-1	17244258
ed.	O	-1	17244258

A@@	O	-1	18020536
s@@	O	-1	18020536
s@@	O	-1	18020536
oci@@	O	-1	18020536
ations	O	-1	18020536
between	O	-1	18020536
use	O	-1	18020536
of	O	-1	18020536
b@@	B-Chemical	D001569	18020536
enz@@	I-Chemical	-1	18020536
odi@@	I-Chemical	-1	18020536
azep@@	I-Chemical	-1	18020536
in@@	I-Chemical	-1	18020536
es	I-Chemical	-1	18020536
or	O	-1	18020536
related	O	-1	18020536
drugs	O	-1	18020536
and	O	-1	18020536
health@@	O	-1	18020536
,	O	-1	18020536
physi@@	O	-1	18020536
c@@	O	-1	18020536
al	O	-1	18020536
abil@@	O	-1	18020536
ities	O	-1	18020536
and	O	-1	18020536
cognitive	O	-1	18020536
func@@	O	-1	18020536
tion@@	O	-1	18020536
:	O	-1	18020536
a	O	-1	18020536
non-@@	O	-1	18020536
random@@	O	-1	18020536
is@@	O	-1	18020536
ed	O	-1	18020536
clinical	O	-1	18020536
study	O	-1	18020536
in	O	-1	18020536
the	O	-1	18020536
el@@	O	-1	18020536
der@@	O	-1	18020536
ly.	O	-1	18020536
OBJECTIVE:	O	-1	18020536
To	O	-1	18020536
describe	O	-1	18020536
associ@@	O	-1	18020536
ations	O	-1	18020536
between	O	-1	18020536
the	O	-1	18020536
use	O	-1	18020536
of	O	-1	18020536
b@@	B-Chemical	D001569	18020536
enz@@	I-Chemical	-1	18020536
odi@@	I-Chemical	-1	18020536
azep@@	I-Chemical	-1	18020536
in@@	I-Chemical	-1	18020536
es	I-Chemical	-1	18020536
or	O	-1	18020536
related	O	-1	18020536
drugs	O	-1	18020536
(	O	-1	18020536
B@@	B-Chemical	D001569	18020536
Z@@	I-Chemical	-1	18020536
D@@	I-Chemical	-1	18020536
s	I-Chemical	-1	18020536
/@@	O	-1	18020536
RD@@	O	-1	18020536
s)	O	-1	18020536
and	O	-1	18020536
health@@	O	-1	18020536
,	O	-1	18020536
functional	O	-1	18020536
abil@@	O	-1	18020536
ities	O	-1	18020536
and	O	-1	18020536
cognitive	O	-1	18020536
function	O	-1	18020536
in	O	-1	18020536
the	O	-1	18020536
el@@	O	-1	18020536
der@@	O	-1	18020536
ly.	O	-1	18020536
METHODS:	O	-1	18020536
A	O	-1	18020536
non-@@	O	-1	18020536
random@@	O	-1	18020536
is@@	O	-1	18020536
ed	O	-1	18020536
clinical	O	-1	18020536
study	O	-1	18020536
of	O	-1	18020536
patients	O	-1	18020536
aged	O	-1	18020536
>	O	-1	18020536
or	O	-1	18020536
=@@	O	-1	18020536
6@@	O	-1	18020536
5	O	-1	18020536
years	O	-1	18020536
ad@@	O	-1	18020536
mit@@	O	-1	18020536
ted	O	-1	18020536
to	O	-1	18020536
acute	O	-1	18020536
hospit@@	O	-1	18020536
al	O	-1	18020536
war@@	O	-1	18020536
ds	O	-1	18020536
during	O	-1	18020536
1	O	-1	18020536
month@@	O	-1	18020536
.	O	-1	18020536
1@@	O	-1	18020536
6@@	O	-1	18020536
4	O	-1	18020536
patients	O	-1	18020536
(@@	O	-1	18020536
mean	O	-1	18020536
age	O	-1	18020536
+/-	O	-1	18020536
standard	O	-1	18020536
de@@	O	-1	18020536
vi@@	O	-1	18020536
ation	O	-1	18020536
[@@	O	-1	18020536
S@@	O	-1	18020536
D@@	O	-1	18020536
]	O	-1	18020536
8@@	O	-1	18020536
1.@@	O	-1	18020536
6	O	-1	18020536
+/-	O	-1	18020536
6.@@	O	-1	18020536
8	O	-1	18020536
year@@	O	-1	18020536
s)	O	-1	18020536
were	O	-1	18020536
ad@@	O	-1	18020536
mit@@	O	-1	18020536
ted.	O	-1	18020536
Of	O	-1	18020536
th@@	O	-1	18020536
es@@	O	-1	18020536
e,	O	-1	18020536
ne@@	O	-1	18020536
arly	O	-1	18020536
h@@	O	-1	18020536
al@@	O	-1	18020536
f	O	-1	18020536
(n	O	-1	18020536
=	O	-1	18020536
7@@	O	-1	18020536
8@@	O	-1	18020536
)	O	-1	18020536
had	O	-1	18020536
used	O	-1	18020536
B@@	B-Chemical	D001569	18020536
Z@@	I-Chemical	-1	18020536
D@@	I-Chemical	-1	18020536
s	I-Chemical	-1	18020536
/@@	O	-1	18020536
RD@@	O	-1	18020536
s	O	-1	18020536
before	O	-1	18020536
ad@@	O	-1	18020536
mis@@	O	-1	18020536
sion,	O	-1	18020536
and	O	-1	18020536
the	O	-1	18020536
re@@	O	-1	18020536
ma@@	O	-1	18020536
ind@@	O	-1	18020536
er	O	-1	18020536
(n	O	-1	18020536
=	O	-1	18020536
8@@	O	-1	18020536
6@@	O	-1	18020536
)	O	-1	18020536
were	O	-1	18020536
non-@@	O	-1	18020536
us@@	O	-1	18020536
ers.	O	-1	18020536
C@@	O	-1	18020536
o@@	O	-1	18020536
gn@@	O	-1	18020536
itive	O	-1	18020536
ability	O	-1	18020536
was	O	-1	18020536
assessed	O	-1	18020536
by	O	-1	18020536
the	O	-1	18020536
M@@	O	-1	18020536
in@@	O	-1	18020536
i@@	O	-1	18020536
-@@	O	-1	18020536
M@@	O	-1	18020536
ental	O	-1	18020536
S@@	O	-1	18020536
t@@	O	-1	18020536
ate	O	-1	18020536
E@@	O	-1	18020536
x@@	O	-1	18020536
amin@@	O	-1	18020536
ation	O	-1	18020536
(@@	O	-1	18020536
M@@	O	-1	18020536
M@@	O	-1	18020536
S@@	O	-1	18020536
E@@	O	-1	18020536
).	O	-1	18020536
Patients	O	-1	18020536
scor@@	O	-1	18020536
ing	O	-1	18020536
>	O	-1	18020536
or	O	-1	18020536
=@@	O	-1	18020536
20	O	-1	18020536
M@@	O	-1	18020536
M@@	O	-1	18020536
S@@	O	-1	18020536
E	O	-1	18020536
su@@	O	-1	18020536
m	O	-1	18020536
po@@	O	-1	18020536
int@@	O	-1	18020536
s	O	-1	18020536
were	O	-1	18020536
inter@@	O	-1	18020536
vie@@	O	-1	18020536
w@@	O	-1	18020536
ed	O	-1	18020536
(n	O	-1	18020536
=	O	-1	18020536
7@@	O	-1	18020536
9@@	O	-1	18020536
)	O	-1	18020536
and	O	-1	18020536
qu@@	O	-1	18020536
es@@	O	-1	18020536
tion@@	O	-1	18020536
ed	O	-1	18020536
reg@@	O	-1	18020536
ar@@	O	-1	18020536
ding	O	-1	18020536
symptoms	O	-1	18020536
and	O	-1	18020536
functional	O	-1	18020536
abil@@	O	-1	18020536
ities	O	-1	18020536
during	O	-1	18020536
the	O	-1	18020536
week	O	-1	18020536
prior	O	-1	18020536
to	O	-1	18020536
ad@@	O	-1	18020536
mis@@	O	-1	18020536
sion.	O	-1	18020536
D@@	O	-1	18020536
at@@	O	-1	18020536
a	O	-1	18020536
on	O	-1	18020536
use	O	-1	18020536
of	O	-1	18020536
B@@	B-Chemical	D001569	18020536
Z@@	I-Chemical	-1	18020536
D@@	I-Chemical	-1	18020536
s	I-Chemical	-1	18020536
/@@	O	-1	18020536
RD@@	O	-1	18020536
s	O	-1	18020536
before	O	-1	18020536
ad@@	O	-1	18020536
mis@@	O	-1	18020536
sion,	O	-1	18020536
current	O	-1	18020536
medic@@	O	-1	18020536
ations	O	-1	18020536
and	O	-1	18020536
dis@@	O	-1	18020536
ch@@	O	-1	18020536
arg@@	O	-1	18020536
e	O	-1	18020536
diagno@@	O	-1	18020536
ses	O	-1	18020536
were	O	-1	18020536
coll@@	O	-1	18020536
ected	O	-1	18020536
from	O	-1	18020536
med@@	O	-1	18020536
ical	O	-1	18020536
recor@@	O	-1	18020536
d@@	O	-1	18020536
s.	O	-1	18020536
He@@	O	-1	18020536
al@@	O	-1	18020536
th@@	O	-1	18020536
,	O	-1	18020536
physi@@	O	-1	18020536
c@@	O	-1	18020536
al	O	-1	18020536
abil@@	O	-1	18020536
ities	O	-1	18020536
and	O	-1	18020536
cognitive	O	-1	18020536
function	O	-1	18020536
were	O	-1	18020536
compared	O	-1	18020536
between	O	-1	18020536
B@@	O	-1	18020536
Z@@	O	-1	18020536
D@@	O	-1	18020536
/@@	O	-1	18020536
R@@	O	-1	18020536
D	O	-1	18020536
users	O	-1	18020536
and	O	-1	18020536
non-@@	O	-1	18020536
us@@	O	-1	18020536
er@@	O	-1	18020536
s,	O	-1	18020536
and	O	-1	18020536
adjust@@	O	-1	18020536
ments	O	-1	18020536
were	O	-1	18020536
m@@	O	-1	18020536
ade	O	-1	18020536
for	O	-1	18020536
conf@@	O	-1	18020536
oun@@	O	-1	18020536
ding	O	-1	18020536
vari@@	O	-1	18020536
abl@@	O	-1	18020536
es.	O	-1	18020536
The	O	-1	18020536
re@@	O	-1	18020536
si@@	O	-1	18020536
du@@	O	-1	18020536
al	O	-1	18020536
serum	O	-1	18020536
concentrations	O	-1	18020536
of	O	-1	18020536
ox@@	B-Chemical	D010076	18020536
az@@	I-Chemical	-1	18020536
epam	I-Chemical	-1	18020536
,	O	-1	18020536
tem@@	B-Chemical	D013693	18020536
az@@	I-Chemical	-1	18020536
epam	I-Chemical	-1	18020536
and	O	-1	18020536
z@@	B-Chemical	C515050	18020536
op@@	I-Chemical	-1	18020536
ic@@	I-Chemical	-1	18020536
l@@	I-Chemical	-1	18020536
one	I-Chemical	-1	18020536
were	O	-1	18020536
analy@@	O	-1	18020536
sed.	O	-1	18020536
RESULTS:	O	-1	18020536
The	O	-1	18020536
mean	O	-1	18020536
+/-	O	-1	18020536
S@@	O	-1	18020536
D	O	-1	18020536
duration	O	-1	18020536
of	O	-1	18020536
B@@	O	-1	18020536
Z@@	O	-1	18020536
D@@	O	-1	18020536
/@@	O	-1	18020536
R@@	O	-1	18020536
D	O	-1	18020536
use	O	-1	18020536
was	O	-1	18020536
7	O	-1	18020536
+/-	O	-1	18020536
7	O	-1	18020536
years	O	-1	18020536
(@@	O	-1	18020536
range	O	-1	18020536
1-@@	O	-1	18020536
3@@	O	-1	18020536
1).	O	-1	18020536
Two	O	-1	18020536
or	O	-1	18020536
three	O	-1	18020536
B@@	B-Chemical	D001569	18020536
Z@@	I-Chemical	-1	18020536
D@@	I-Chemical	-1	18020536
s	I-Chemical	-1	18020536
/@@	O	-1	18020536
RD@@	O	-1	18020536
s	O	-1	18020536
were	O	-1	18020536
concomit@@	O	-1	18020536
ant@@	O	-1	18020536
ly	O	-1	18020536
tak@@	O	-1	18020536
en	O	-1	18020536
by	O	-1	18020536
2@@	O	-1	18020536
6%	O	-1	18020536
of	O	-1	18020536
users	O	-1	18020536
(n	O	-1	18020536
=	O	-1	18020536
20@@	O	-1	18020536
).	O	-1	18020536
L@@	O	-1	18020536
on@@	O	-1	18020536
g@@	O	-1	18020536
-term	O	-1	18020536
use	O	-1	18020536
of	O	-1	18020536
these	O	-1	18020536
drugs	O	-1	18020536
was	O	-1	18020536
associated	O	-1	18020536
with	O	-1	18020536
female	O	-1	18020536
se@@	O	-1	18020536
x	O	-1	18020536
and	O	-1	18020536
use	O	-1	18020536
of	O	-1	18020536
a	O	-1	18020536
higher	O	-1	18020536
number	O	-1	18020536
of	O	-1	18020536
drugs	O	-1	18020536
with	O	-1	18020536
effects	O	-1	18020536
on	O	-1	18020536
the	O	-1	18020536
C@@	O	-1	18020536
N@@	O	-1	18020536
S@@	O	-1	18020536
,	O	-1	18020536
which	O	-1	18020536
ten@@	O	-1	18020536
ded	O	-1	18020536
to	O	-1	18020536
be	O	-1	18020536
related	O	-1	18020536
to	O	-1	18020536
diagnos@@	O	-1	18020536
ed	O	-1	18020536
de@@	B-Disease	D003704	18020536
m@@	I-Disease	-1	18020536
enti@@	I-Disease	-1	18020536
a	I-Disease	-1	18020536
.	O	-1	18020536
After	O	-1	18020536
adjust@@	O	-1	18020536
ment	O	-1	18020536
for	O	-1	18020536
these	O	-1	18020536
vari@@	O	-1	18020536
able@@	O	-1	18020536
s	O	-1	18020536
as	O	-1	18020536
conf@@	O	-1	18020536
oun@@	O	-1	18020536
der@@	O	-1	18020536
s,	O	-1	18020536
use	O	-1	18020536
of	O	-1	18020536
B@@	B-Chemical	D001569	18020536
Z@@	I-Chemical	-1	18020536
D@@	I-Chemical	-1	18020536
s	I-Chemical	-1	18020536
/@@	O	-1	18020536
RD@@	O	-1	18020536
s	O	-1	18020536
was	O	-1	18020536
not	O	-1	18020536
associated	O	-1	18020536
with	O	-1	18020536
cognitive	O	-1	18020536
function	O	-1	18020536
as	O	-1	18020536
measured	O	-1	18020536
by	O	-1	18020536
the	O	-1	18020536
M@@	O	-1	18020536
M@@	O	-1	18020536
S@@	O	-1	18020536
E@@	O	-1	18020536
.	O	-1	18020536
However,	O	-1	18020536
use	O	-1	18020536
of	O	-1	18020536
B@@	B-Chemical	D001569	18020536
Z@@	I-Chemical	-1	18020536
D@@	I-Chemical	-1	18020536
s	I-Chemical	-1	18020536
/@@	O	-1	18020536
RD@@	O	-1	18020536
s	O	-1	18020536
was	O	-1	18020536
associated	O	-1	18020536
with	O	-1	18020536
di@@	B-Disease	D004244	18020536
z@@	I-Disease	-1	18020536
z@@	I-Disease	-1	18020536
in@@	I-Disease	-1	18020536
ess	I-Disease	-1	18020536
,	O	-1	18020536
in@@	B-Disease	D007319	18020536
ability	I-Disease	-1	18020536
to	I-Disease	-1	18020536
sleep	I-Disease	-1	18020536
after	O	-1	18020536
aw@@	O	-1	18020536
ak@@	O	-1	18020536
ing	O	-1	18020536
at	O	-1	18020536
n@@	O	-1	18020536
ight	O	-1	18020536
and	O	-1	18020536
ti@@	B-Disease	D005221	18020536
re@@	I-Disease	-1	18020536
d@@	I-Disease	-1	18020536
ness	I-Disease	-1	18020536
in	O	-1	18020536
the	O	-1	18020536
mor@@	O	-1	18020536
n@@	O	-1	18020536
ings	O	-1	18020536
during	O	-1	18020536
the	O	-1	18020536
week	O	-1	18020536
prior	O	-1	18020536
to	O	-1	18020536
ad@@	O	-1	18020536
mission	O	-1	18020536
and	O	-1	18020536
with	O	-1	18020536
st@@	O	-1	18020536
ron@@	O	-1	18020536
g@@	O	-1	18020536
er	O	-1	18020536
de@@	B-Disease	D003866	18020536
pressive	I-Disease	-1	18020536
symptoms	I-Disease	-1	18020536
measured	O	-1	18020536
at	O	-1	18020536
the	O	-1	18020536
be@@	O	-1	18020536
g@@	O	-1	18020536
in@@	O	-1	18020536
ning	O	-1	18020536
of	O	-1	18020536
the	O	-1	18020536
hospit@@	O	-1	18020536
al	O	-1	18020536
st@@	O	-1	18020536
a@@	O	-1	18020536
y.	O	-1	18020536
U@@	O	-1	18020536
se	O	-1	18020536
of	O	-1	18020536
B@@	B-Chemical	D001569	18020536
Z@@	I-Chemical	-1	18020536
D@@	I-Chemical	-1	18020536
s	I-Chemical	-1	18020536
/@@	O	-1	18020536
RD@@	O	-1	18020536
s	O	-1	18020536
ten@@	O	-1	18020536
ded	O	-1	18020536
to	O	-1	18020536
be	O	-1	18020536
associated	O	-1	18020536
with	O	-1	18020536
a	O	-1	18020536
reduced	O	-1	18020536
ability	O	-1	18020536
to	O	-1	18020536
w@@	O	-1	18020536
al@@	O	-1	18020536
k	O	-1	18020536
and	O	-1	18020536
sh@@	O	-1	18020536
or@@	O	-1	18020536
ter	O	-1	18020536
n@@	O	-1	18020536
igh@@	O	-1	18020536
t-@@	O	-1	18020536
time	O	-1	18020536
sleep	O	-1	18020536
during	O	-1	18020536
the	O	-1	18020536
week	O	-1	18020536
prior	O	-1	18020536
to	O	-1	18020536
ad@@	O	-1	18020536
mis@@	O	-1	18020536
sion.	O	-1	18020536
A	O	-1	18020536
higher	O	-1	18020536
re@@	O	-1	18020536
si@@	O	-1	18020536
du@@	O	-1	18020536
al	O	-1	18020536
serum	O	-1	18020536
concentration	O	-1	18020536
of	O	-1	18020536
tem@@	B-Chemical	D013693	18020536
az@@	I-Chemical	-1	18020536
epam	I-Chemical	-1	18020536
cor@@	O	-1	18020536
related	O	-1	18020536
with	O	-1	18020536
a	O	-1	18020536
lower	O	-1	18020536
M@@	O	-1	18020536
M@@	O	-1	18020536
S@@	O	-1	18020536
E	O	-1	18020536
su@@	O	-1	18020536
m	O	-1	18020536
scor@@	O	-1	18020536
e	O	-1	18020536
after	O	-1	18020536
adjust@@	O	-1	18020536
ment	O	-1	18020536
for	O	-1	18020536
conf@@	O	-1	18020536
oun@@	O	-1	18020536
ding	O	-1	18020536
vari@@	O	-1	18020536
abl@@	O	-1	18020536
es.	O	-1	18020536
CONCLUSIONS:	O	-1	18020536
L@@	O	-1	18020536
on@@	O	-1	18020536
g@@	O	-1	18020536
-term	O	-1	18020536
use	O	-1	18020536
and	O	-1	18020536
concomit@@	O	-1	18020536
ant	O	-1	18020536
use	O	-1	18020536
of	O	-1	18020536
more	O	-1	18020536
than	O	-1	18020536
one	O	-1	18020536
B@@	O	-1	18020536
Z@@	O	-1	18020536
D@@	O	-1	18020536
/@@	O	-1	18020536
R@@	O	-1	18020536
D	O	-1	18020536
were	O	-1	18020536
common	O	-1	18020536
in	O	-1	18020536
el@@	O	-1	18020536
der@@	O	-1	18020536
ly	O	-1	18020536
patients	O	-1	18020536
hospit@@	O	-1	18020536
al@@	O	-1	18020536
is@@	O	-1	18020536
ed	O	-1	18020536
because	O	-1	18020536
of	O	-1	18020536
acute	O	-1	18020536
ill@@	O	-1	18020536
n@@	O	-1	18020536
ess@@	O	-1	18020536
es.	O	-1	18020536
L@@	O	-1	18020536
on@@	O	-1	18020536
g@@	O	-1	18020536
-term	O	-1	18020536
use	O	-1	18020536
was	O	-1	18020536
associated	O	-1	18020536
with	O	-1	18020536
day@@	O	-1	18020536
time	O	-1	18020536
and	O	-1	18020536
n@@	O	-1	18020536
igh@@	O	-1	18020536
t-@@	O	-1	18020536
time	O	-1	18020536
symptoms	O	-1	18020536
indic@@	O	-1	18020536
ative	O	-1	18020536
of	O	-1	18020536
po@@	O	-1	18020536
ore@@	O	-1	18020536
r	O	-1	18020536
heal@@	O	-1	18020536
th	O	-1	18020536
and	O	-1	18020536
potenti@@	O	-1	18020536
ally	O	-1	18020536
caused	O	-1	18020536
by	O	-1	18020536
the	O	-1	18020536
adverse	O	-1	18020536
effects	O	-1	18020536
of	O	-1	18020536
these	O	-1	18020536
drug@@	O	-1	18020536
s.	O	-1	18020536

Ac@@	O	-1	18023325
ute	O	-1	18023325
v@@	B-Disease	D014826	18023325
oc@@	I-Disease	-1	18023325
al	I-Disease	-1	18023325
fol@@	I-Disease	-1	18023325
d	I-Disease	-1	18023325
p@@	I-Disease	-1	18023325
al@@	I-Disease	-1	18023325
sy	I-Disease	-1	18023325
after	O	-1	18023325
acute	O	-1	18023325
dis@@	B-Chemical	D004221	18023325
ul@@	I-Chemical	-1	18023325
fi@@	I-Chemical	-1	18023325
ra@@	I-Chemical	-1	18023325
m	I-Chemical	-1	18023325
in@@	O	-1	18023325
toxic@@	O	-1	18023325
ation.	O	-1	18023325
Ac@@	O	-1	18023325
ute	O	-1	18023325
peripheral	B-Disease	D010523	18023325
neuropathy	I-Disease	-1	18023325
caused	O	-1	18023325
by	O	-1	18023325
a	O	-1	18023325
dis@@	B-Chemical	D004221	18023325
ul@@	I-Chemical	-1	18023325
fi@@	I-Chemical	-1	18023325
ra@@	I-Chemical	-1	18023325
m	I-Chemical	-1	18023325
over@@	B-Disease	D062787	18023325
dose	I-Disease	-1	18023325
is	O	-1	18023325
very	O	-1	18023325
r@@	O	-1	18023325
are	O	-1	18023325
and	O	-1	18023325
there	O	-1	18023325
is	O	-1	18023325
no	O	-1	18023325
report	O	-1	18023325
of	O	-1	18023325
it	O	-1	18023325
lead@@	O	-1	18023325
ing	O	-1	18023325
to	O	-1	18023325
v@@	B-Disease	D014826	18023325
oc@@	I-Disease	-1	18023325
al	I-Disease	-1	18023325
fol@@	I-Disease	-1	18023325
d	I-Disease	-1	18023325
p@@	I-Disease	-1	18023325
al@@	I-Disease	-1	18023325
sy	I-Disease	-1	18023325
.	O	-1	18023325
A	O	-1	18023325
4@@	O	-1	18023325
9@@	O	-1	18023325
-@@	O	-1	18023325
year-old	O	-1	18023325
woman	O	-1	18023325
was	O	-1	18023325
trans@@	O	-1	18023325
fer@@	O	-1	18023325
red	O	-1	18023325
to	O	-1	18023325
our	O	-1	18023325
de@@	O	-1	18023325
part@@	O	-1	18023325
ment	O	-1	18023325
because	O	-1	18023325
of	O	-1	18023325
qu@@	B-Disease	D011782	18023325
ad@@	I-Disease	-1	18023325
ri@@	I-Disease	-1	18023325
pa@@	I-Disease	-1	18023325
re@@	I-Disease	-1	18023325
sis	I-Disease	-1	18023325
,	O	-1	18023325
l@@	O	-1	18023325
anc@@	O	-1	18023325
in@@	O	-1	18023325
ating	O	-1	18023325
pain	B-Disease	D010146	18023325
,	O	-1	18023325
sens@@	B-Disease	C580162	18023325
ory	I-Disease	-1	18023325
loss	I-Disease	-1	18023325
,	O	-1	18023325
and	O	-1	18023325
pa@@	B-Disease	D010292	18023325
res@@	I-Disease	-1	18023325
the@@	I-Disease	-1	18023325
sia	I-Disease	-1	18023325
of	O	-1	18023325
the	O	-1	18023325
dist@@	O	-1	18023325
al	O	-1	18023325
lim@@	O	-1	18023325
b@@	O	-1	18023325
s.	O	-1	18023325
One	O	-1	18023325
mon@@	O	-1	18023325
th	O	-1	18023325
previ@@	O	-1	18023325
ous@@	O	-1	18023325
ly,	O	-1	18023325
sh@@	O	-1	18023325
e	O	-1	18023325
had	O	-1	18023325
tak@@	O	-1	18023325
en	O	-1	18023325
a	O	-1	18023325
single	O	-1	18023325
high	O	-1	18023325
dose	O	-1	18023325
of	O	-1	18023325
dis@@	B-Chemical	D004221	18023325
ul@@	I-Chemical	-1	18023325
fi@@	I-Chemical	-1	18023325
ra@@	I-Chemical	-1	18023325
m	I-Chemical	-1	18023325
(1@@	O	-1	18023325
30	O	-1	18023325
t@@	O	-1	18023325
able@@	O	-1	18023325
ts	O	-1	18023325
of	O	-1	18023325
AL@@	B-Chemical	D000431	18023325
CO@@	I-Chemical	-1	18023325
HO@@	I-Chemical	-1	18023325
L	I-Chemical	-1	18023325
S@@	O	-1	18023325
T@@	O	-1	18023325
O@@	O	-1	18023325
P	O	-1	18023325
TA@@	O	-1	18023325
B@@	O	-1	18023325
,	O	-1	18023325
S@@	O	-1	18023325
h@@	O	-1	18023325
in-@@	O	-1	18023325
P@@	O	-1	18023325
o@@	O	-1	18023325
ong	O	-1	18023325
Ph@@	O	-1	18023325
ar@@	O	-1	18023325
m.	O	-1	18023325
C@@	O	-1	18023325
o@@	O	-1	18023325
.,	O	-1	18023325
An@@	O	-1	18023325
s@@	O	-1	18023325
an@@	O	-1	18023325
,	O	-1	18023325
K@@	O	-1	18023325
ore@@	O	-1	18023325
a@@	O	-1	18023325
)	O	-1	18023325
in	O	-1	18023325
a	O	-1	18023325
su@@	O	-1	18023325
ic@@	O	-1	18023325
ide	O	-1	18023325
at@@	O	-1	18023325
tem@@	O	-1	18023325
pt@@	O	-1	18023325
.	O	-1	18023325
S@@	O	-1	18023325
he	O	-1	18023325
was	O	-1	18023325
not	O	-1	18023325
an	O	-1	18023325
alco@@	O	-1	18023325
h@@	O	-1	18023325
ol@@	O	-1	18023325
ic@@	O	-1	18023325
.	O	-1	18023325
F@@	O	-1	18023325
or	O	-1	18023325
the	O	-1	18023325
first	O	-1	18023325
fe@@	O	-1	18023325
w	O	-1	18023325
days	O	-1	18023325
after	O	-1	18023325
ing@@	O	-1	18023325
es@@	O	-1	18023325
tion,	O	-1	18023325
sh@@	O	-1	18023325
e	O	-1	18023325
was	O	-1	18023325
in	O	-1	18023325
a	O	-1	18023325
conf@@	O	-1	18023325
used	O	-1	18023325
state	O	-1	18023325
and	O	-1	18023325
had	O	-1	18023325
mil@@	O	-1	18023325
d	O	-1	18023325
to	O	-1	18023325
moder@@	O	-1	18023325
ate	O	-1	18023325
at@@	B-Disease	D001259	18023325
ax@@	I-Disease	-1	18023325
ia	I-Disease	-1	18023325
and	O	-1	18023325
g@@	B-Disease	D004244	18023325
id@@	I-Disease	-1	18023325
d@@	I-Disease	-1	18023325
in@@	I-Disease	-1	18023325
ess	I-Disease	-1	18023325
.	O	-1	18023325
S@@	O	-1	18023325
he	O	-1	18023325
no@@	O	-1	18023325
tic@@	O	-1	18023325
ed	O	-1	18023325
ho@@	B-Disease	D006685	18023325
ar@@	I-Disease	-1	18023325
sen@@	I-Disease	-1	18023325
ess	I-Disease	-1	18023325
and	O	-1	18023325
dist@@	O	-1	18023325
ally	O	-1	18023325
ac@@	O	-1	18023325
c@@	O	-1	18023325
ent@@	O	-1	18023325
u@@	O	-1	18023325
ated	O	-1	18023325
motor	O	-1	18023325
and	O	-1	18023325
sens@@	O	-1	18023325
ory	O	-1	18023325
dysfunction	O	-1	18023325
after	O	-1	18023325
sh@@	O	-1	18023325
e	O	-1	18023325
had	O	-1	18023325
reco@@	O	-1	18023325
vered	O	-1	18023325
from	O	-1	18023325
this	O	-1	18023325
stat@@	O	-1	18023325
e.	O	-1	18023325
A	O	-1	18023325
nerve	O	-1	18023325
con@@	O	-1	18023325
duction	O	-1	18023325
study	O	-1	18023325
was	O	-1	18023325
consist@@	O	-1	18023325
ent	O	-1	18023325
with	O	-1	18023325
severe	O	-1	18023325
sens@@	O	-1	18023325
or@@	O	-1	18023325
im@@	O	-1	18023325
otor	O	-1	18023325
ax@@	O	-1	18023325
on@@	O	-1	18023325
al	O	-1	18023325
poly@@	B-Disease	D011115	18023325
neuropathy	I-Disease	-1	18023325
.	O	-1	18023325
L@@	O	-1	18023325
ar@@	O	-1	18023325
yn@@	O	-1	18023325
ge@@	O	-1	18023325
al	O	-1	18023325
elect@@	O	-1	18023325
rom@@	O	-1	18023325
y@@	O	-1	18023325
ograph@@	O	-1	18023325
y	O	-1	18023325
(@@	O	-1	18023325
th@@	O	-1	18023325
yro@@	O	-1	18023325
ar@@	O	-1	18023325
y@@	O	-1	18023325
ten@@	O	-1	18023325
oid	O	-1	18023325
musc@@	O	-1	18023325
le@@	O	-1	18023325
)	O	-1	18023325
showed	O	-1	18023325
am@@	O	-1	18023325
ple	O	-1	18023325
d@@	O	-1	18023325
en@@	O	-1	18023325
er@@	O	-1	18023325
v@@	O	-1	18023325
ation	O	-1	18023325
potenti@@	O	-1	18023325
al@@	O	-1	18023325
s.	O	-1	18023325
L@@	O	-1	18023325
ar@@	O	-1	18023325
yn@@	O	-1	18023325
g@@	O	-1	18023325
os@@	O	-1	18023325
co@@	O	-1	18023325
p@@	O	-1	18023325
y	O	-1	18023325
revealed	O	-1	18023325
as@@	O	-1	18023325
ym@@	O	-1	18023325
me@@	O	-1	18023325
tri@@	O	-1	18023325
c	O	-1	18023325
v@@	O	-1	18023325
oc@@	O	-1	18023325
al	O	-1	18023325
fol@@	O	-1	18023325
d	O	-1	18023325
mo@@	O	-1	18023325
ve@@	O	-1	18023325
ments	O	-1	18023325
during	O	-1	18023325
ph@@	O	-1	18023325
on@@	O	-1	18023325
ation.	O	-1	18023325
H@@	O	-1	18023325
er	O	-1	18023325
v@@	O	-1	18023325
oc@@	O	-1	18023325
al	O	-1	18023325
change	O	-1	18023325
and	O	-1	18023325
we@@	O	-1	18023325
ak@@	O	-1	18023325
ness	O	-1	18023325
be@@	O	-1	18023325
g@@	O	-1	18023325
an	O	-1	18023325
to	O	-1	18023325
impro@@	O	-1	18023325
ve	O	-1	18023325
spont@@	O	-1	18023325
ane@@	O	-1	18023325
ously	O	-1	18023325
about	O	-1	18023325
3	O	-1	18023325
weeks	O	-1	18023325
after	O	-1	18023325
trans@@	O	-1	18023325
fer@@	O	-1	18023325
.	O	-1	18023325
This	O	-1	18023325
was	O	-1	18023325
a	O	-1	18023325
case	O	-1	18023325
of	O	-1	18023325
acute	O	-1	18023325
p@@	B-Disease	D010243	18023325
al@@	I-Disease	-1	18023325
sy	I-Disease	-1	18023325
of	O	-1	18023325
the	O	-1	18023325
recur@@	O	-1	18023325
rent	O	-1	18023325
l@@	O	-1	18023325
ar@@	O	-1	18023325
yn@@	O	-1	18023325
ge@@	O	-1	18023325
al	O	-1	18023325
nerve	O	-1	18023325
and	O	-1	18023325
su@@	O	-1	18023325
per@@	O	-1	18023325
im@@	O	-1	18023325
pos@@	O	-1	18023325
ed	O	-1	18023325
severe	O	-1	18023325
acute	O	-1	18023325
sens@@	O	-1	18023325
or@@	O	-1	18023325
im@@	O	-1	18023325
otor	O	-1	18023325
ax@@	O	-1	18023325
on@@	O	-1	18023325
al	O	-1	18023325
poly@@	B-Disease	D011115	18023325
neuropathy	I-Disease	-1	18023325
caused	O	-1	18023325
by	O	-1	18023325
high-dose	O	-1	18023325
dis@@	B-Chemical	D004221	18023325
ul@@	I-Chemical	-1	18023325
fi@@	I-Chemical	-1	18023325
ra@@	I-Chemical	-1	18023325
m	I-Chemical	-1	18023325
in@@	O	-1	18023325
toxic@@	O	-1	18023325
ation.	O	-1	18023325

H@@	O	-1	18208574
igh@@	O	-1	18208574
er	O	-1	18208574
op@@	O	-1	18208574
tical	O	-1	18208574
d@@	O	-1	18208574
ensity	O	-1	18208574
of	O	-1	18208574
an	O	-1	18208574
anti@@	O	-1	18208574
gen	O	-1	18208574
ass@@	O	-1	18208574
ay	O	-1	18208574
predic@@	O	-1	18208574
ts	O	-1	18208574
thrombo@@	B-Disease	D013927	18208574
sis	I-Disease	-1	18208574
in	O	-1	18208574
patients	O	-1	18208574
with	O	-1	18208574
hepar@@	B-Chemical	D006493	18208574
in	I-Chemical	-1	18208574
-induced	O	-1	18208574
throm@@	B-Disease	D013921	18208574
b@@	I-Disease	-1	18208574
ocyto@@	I-Disease	-1	18208574
pen@@	I-Disease	-1	18208574
ia	I-Disease	-1	18208574
.	O	-1	18208574
OBJECTIV@@	O	-1	18208574
E@@	O	-1	18208574
S:	O	-1	18208574
To	O	-1	18208574
correl@@	O	-1	18208574
ate	O	-1	18208574
op@@	O	-1	18208574
tical	O	-1	18208574
d@@	O	-1	18208574
ensity	O	-1	18208574
and	O	-1	18208574
perc@@	O	-1	18208574
ent	O	-1	18208574
inhibition	O	-1	18208574
of	O	-1	18208574
a	O	-1	18208574
tw@@	O	-1	18208574
o@@	O	-1	18208574
-@@	O	-1	18208574
st@@	O	-1	18208574
ep	O	-1	18208574
hepar@@	B-Chemical	D006493	18208574
in	I-Chemical	-1	18208574
-induced	O	-1	18208574
throm@@	B-Disease	D013921	18208574
b@@	I-Disease	-1	18208574
ocyto@@	I-Disease	-1	18208574
pen@@	I-Disease	-1	18208574
ia	I-Disease	-1	18208574
(	O	-1	18208574
H@@	B-Disease	D013921	18208574
I@@	I-Disease	-1	18208574
T	I-Disease	-1	18208574
)	O	-1	18208574
anti@@	O	-1	18208574
gen	O	-1	18208574
ass@@	O	-1	18208574
ay	O	-1	18208574
with	O	-1	18208574
thrombo@@	B-Disease	D013927	18208574
sis	I-Disease	-1	18208574
;	O	-1	18208574
the	O	-1	18208574
ass@@	O	-1	18208574
ay	O	-1	18208574
u@@	O	-1	18208574
ti@@	O	-1	18208574
li@@	O	-1	18208574
z@@	O	-1	18208574
es	O	-1	18208574
reaction	O	-1	18208574
inhibition	O	-1	18208574
character@@	O	-1	18208574
is@@	O	-1	18208574
tics	O	-1	18208574
of	O	-1	18208574
a	O	-1	18208574
high	O	-1	18208574
hepar@@	B-Chemical	D006493	18208574
in	I-Chemical	-1	18208574
concentr@@	O	-1	18208574
ation.	O	-1	18208574
PA@@	O	-1	18208574
TI@@	O	-1	18208574
E@@	O	-1	18208574
N@@	O	-1	18208574
T@@	O	-1	18208574
S	O	-1	18208574
AN@@	O	-1	18208574
D	O	-1	18208574
METHODS:	O	-1	18208574
Patients	O	-1	18208574
with	O	-1	18208574
more	O	-1	18208574
than	O	-1	18208574
50@@	O	-1	18208574
%	O	-1	18208574
decrease	O	-1	18208574
in	O	-1	18208574
platele@@	O	-1	18208574
t	O	-1	18208574
coun@@	O	-1	18208574
t	O	-1	18208574
or	O	-1	18208574
throm@@	B-Disease	D013921	18208574
b@@	I-Disease	-1	18208574
ocyto@@	I-Disease	-1	18208574
pen@@	I-Disease	-1	18208574
ia	I-Disease	-1	18208574
(@@	O	-1	18208574
<@@	O	-1	18208574
1@@	O	-1	18208574
50	O	-1	18208574
x	O	-1	18208574
10@@	O	-1	18208574
(@@	O	-1	18208574
9@@	O	-1	18208574
)@@	O	-1	18208574
/@@	O	-1	18208574
L@@	O	-1	18208574
)	O	-1	18208574
after	O	-1	18208574
exposure	O	-1	18208574
to	O	-1	18208574
hepar@@	B-Chemical	D006493	18208574
in	I-Chemical	-1	18208574
,	O	-1	18208574
who	O	-1	18208574
had	O	-1	18208574
a	O	-1	18208574
positive	O	-1	18208574
tw@@	O	-1	18208574
o@@	O	-1	18208574
-@@	O	-1	18208574
st@@	O	-1	18208574
ep	O	-1	18208574
anti@@	O	-1	18208574
gen	O	-1	18208574
ass@@	O	-1	18208574
ay	O	-1	18208574
[@@	O	-1	18208574
op@@	O	-1	18208574
tical	O	-1	18208574
d@@	O	-1	18208574
ensity	O	-1	18208574
(@@	O	-1	18208574
O@@	O	-1	18208574
D)	O	-1	18208574
>@@	O	-1	18208574
0.@@	O	-1	18208574
4	O	-1	18208574
and	O	-1	18208574
>@@	O	-1	18208574
50	O	-1	18208574
inhibition	O	-1	18208574
with	O	-1	18208574
high	O	-1	18208574
concentration	O	-1	18208574
of	O	-1	18208574
hepar@@	B-Chemical	D006493	18208574
in	I-Chemical	-1	18208574
]	O	-1	18208574
were	O	-1	18208574
included	O	-1	18208574
in	O	-1	18208574
the	O	-1	18208574
study.	O	-1	18208574
RESULTS:	O	-1	18208574
F@@	O	-1	18208574
ort@@	O	-1	18208574
y	O	-1	18208574
of	O	-1	18208574
9@@	O	-1	18208574
4	O	-1	18208574
H@@	B-Disease	D013921	18208574
I@@	I-Disease	-1	18208574
T	I-Disease	-1	18208574
patients	O	-1	18208574
had	O	-1	18208574
thrombo@@	B-Disease	D013927	18208574
sis	I-Disease	-1	18208574
at	O	-1	18208574
diagno@@	O	-1	18208574
si@@	O	-1	18208574
s;	O	-1	18208574
5@@	O	-1	18208574
4@@	O	-1	18208574
/@@	O	-1	18208574
9@@	O	-1	18208574
4	O	-1	18208574
had	O	-1	18208574
isol@@	O	-1	18208574
ated@@	O	-1	18208574
-	O	-1	18208574
H@@	B-Disease	D013921	18208574
I@@	I-Disease	-1	18208574
T	I-Disease	-1	18208574
without	O	-1	18208574
thrombo@@	B-Disease	D013927	18208574
sis	I-Disease	-1	18208574
.	O	-1	18208574
E@@	O	-1	18208574
ight	O	-1	18208574
of	O	-1	18208574
the	O	-1	18208574
isol@@	O	-1	18208574
ated@@	O	-1	18208574
-	O	-1	18208574
H@@	B-Disease	D013921	18208574
I@@	I-Disease	-1	18208574
T	I-Disease	-1	18208574
patients	O	-1	18208574
developed	O	-1	18208574
thrombo@@	B-Disease	D013927	18208574
sis	I-Disease	-1	18208574
within	O	-1	18208574
the	O	-1	18208574
ne@@	O	-1	18208574
x@@	O	-1	18208574
t	O	-1	18208574
30	O	-1	18208574
d@@	O	-1	18208574
;	O	-1	18208574
th@@	O	-1	18208574
us,	O	-1	18208574
a	O	-1	18208574
total	O	-1	18208574
of	O	-1	18208574
4@@	O	-1	18208574
8	O	-1	18208574
patients	O	-1	18208574
had	O	-1	18208574
thrombo@@	B-Disease	D013927	18208574
sis	I-Disease	-1	18208574
at	O	-1	18208574
day	O	-1	18208574
3@@	O	-1	18208574
0@@	O	-1	18208574
.	O	-1	18208574
A@@	O	-1	18208574
t	O	-1	18208574
diagnosis	O	-1	18208574
there	O	-1	18208574
was	O	-1	18208574
no	O	-1	18208574
significant	O	-1	18208574
difference	O	-1	18208574
in	O	-1	18208574
O@@	O	-1	18208574
D	O	-1	18208574
between	O	-1	18208574
H@@	B-Disease	D013921	18208574
I@@	I-Disease	-1	18208574
T	I-Disease	-1	18208574
patients	O	-1	18208574
with	O	-1	18208574
thrombo@@	B-Disease	D013927	18208574
sis	I-Disease	-1	18208574
and	O	-1	18208574
those	O	-1	18208574
with	O	-1	18208574
isol@@	O	-1	18208574
ated@@	O	-1	18208574
-	O	-1	18208574
H@@	B-Disease	D013921	18208574
I@@	I-Disease	-1	18208574
T	I-Disease	-1	18208574
.	O	-1	18208574
However,	O	-1	18208574
O@@	O	-1	18208574
D	O	-1	18208574
was	O	-1	18208574
significantly	O	-1	18208574
higher	O	-1	18208574
in	O	-1	18208574
all	O	-1	18208574
patients	O	-1	18208574
with	O	-1	18208574
thrombo@@	B-Disease	D013927	18208574
sis	I-Disease	-1	18208574
(n	O	-1	18208574
=	O	-1	18208574
4@@	O	-1	18208574
8@@	O	-1	18208574
,	O	-1	18208574
1.@@	O	-1	18208574
3@@	O	-1	18208574
4	O	-1	18208574
+/-	O	-1	18208574
0.@@	O	-1	18208574
8@@	O	-1	18208574
9@@	O	-1	18208574
),	O	-1	18208574
including	O	-1	18208574
isol@@	O	-1	18208574
ated@@	O	-1	18208574
-	O	-1	18208574
H@@	B-Disease	D013921	18208574
I@@	I-Disease	-1	18208574
T	I-Disease	-1	18208574
patients	O	-1	18208574
who	O	-1	18208574
lat@@	O	-1	18208574
er	O	-1	18208574
developed	O	-1	18208574
thrombo@@	B-Disease	D013927	18208574
sis	I-Disease	-1	18208574
within	O	-1	18208574
30	O	-1	18208574
d	O	-1	18208574
(n	O	-1	18208574
=	O	-1	18208574
8@@	O	-1	18208574
,	O	-1	18208574
1.@@	O	-1	18208574
8@@	O	-1	18208574
4	O	-1	18208574
+/-	O	-1	18208574
0.@@	O	-1	18208574
6@@	O	-1	18208574
4@@	O	-1	18208574
)	O	-1	18208574
as	O	-1	18208574
compared	O	-1	18208574
to	O	-1	18208574
isol@@	O	-1	18208574
ated@@	O	-1	18208574
-	O	-1	18208574
H@@	B-Disease	D013921	18208574
I@@	I-Disease	-1	18208574
T	I-Disease	-1	18208574
patients	O	-1	18208574
who	O	-1	18208574
did	O	-1	18208574
not	O	-1	18208574
deve@@	O	-1	18208574
lo@@	O	-1	18208574
p	O	-1	18208574
thrombo@@	B-Disease	D013927	18208574
sis	I-Disease	-1	18208574
(0.@@	O	-1	18208574
9@@	O	-1	18208574
6	O	-1	18208574
+/-	O	-1	18208574
0.@@	O	-1	18208574
7@@	O	-1	18208574
5@@	O	-1	18208574
;	O	-1	18208574
P	O	-1	18208574
=	O	-1	18208574
0.0@@	O	-1	18208574
11	O	-1	18208574
and	O	-1	18208574
P	O	-1	18208574
=	O	-1	18208574
0.00@@	O	-1	18208574
8@@	O	-1	18208574
).	O	-1	18208574
The	O	-1	18208574
Rec@@	O	-1	18208574
e@@	O	-1	18208574
i@@	O	-1	18208574
ver	O	-1	18208574
O@@	O	-1	18208574
perative	O	-1	18208574
Ch@@	O	-1	18208574
aracter@@	O	-1	18208574
istic	O	-1	18208574
C@@	O	-1	18208574
ur@@	O	-1	18208574
ve	O	-1	18208574
showed	O	-1	18208574
that	O	-1	18208574
O@@	O	-1	18208574
D	O	-1	18208574
>@@	O	-1	18208574
1.@@	O	-1	18208574
2@@	O	-1	18208574
7	O	-1	18208574
in	O	-1	18208574
the	O	-1	18208574
isol@@	O	-1	18208574
ated@@	O	-1	18208574
-	O	-1	18208574
H@@	B-Disease	D013921	18208574
I@@	I-Disease	-1	18208574
T	I-Disease	-1	18208574
group	O	-1	18208574
had	O	-1	18208574
a	O	-1	18208574
significantly	O	-1	18208574
higher	O	-1	18208574
ch@@	O	-1	18208574
ance	O	-1	18208574
of	O	-1	18208574
develop@@	O	-1	18208574
ing	O	-1	18208574
thrombo@@	B-Disease	D013927	18208574
sis	I-Disease	-1	18208574
by	O	-1	18208574
day	O	-1	18208574
3@@	O	-1	18208574
0@@	O	-1	18208574
.	O	-1	18208574
N@@	O	-1	18208574
one	O	-1	18208574
of	O	-1	18208574
these	O	-1	18208574
groups	O	-1	18208574
showed	O	-1	18208574
significant	O	-1	18208574
difference	O	-1	18208574
in	O	-1	18208574
perc@@	O	-1	18208574
ent	O	-1	18208574
inhib@@	O	-1	18208574
i@@	O	-1	18208574
tion.	O	-1	18208574
M@@	O	-1	18208574
ul@@	O	-1	18208574
tiv@@	O	-1	18208574
ari@@	O	-1	18208574
ate	O	-1	18208574
analysis	O	-1	18208574
showed	O	-1	18208574
a	O	-1	18208574
2.@@	O	-1	18208574
8@@	O	-1	18208574
-@@	O	-1	18208574
fol@@	O	-1	18208574
d	O	-1	18208574
increased	O	-1	18208574
risk	O	-1	18208574
of	O	-1	18208574
thrombo@@	B-Disease	D013927	18208574
sis	I-Disease	-1	18208574
in	O	-1	18208574
femal@@	O	-1	18208574
es.	O	-1	18208574
S@@	O	-1	18208574
im@@	O	-1	18208574
il@@	O	-1	18208574
ar@@	O	-1	18208574
ly,	O	-1	18208574
thrombotic	B-Disease	D013927	18208574
risk	O	-1	18208574
increased	O	-1	18208574
with	O	-1	18208574
age	O	-1	18208574
and	O	-1	18208574
O@@	O	-1	18208574
D	O	-1	18208574
valu@@	O	-1	18208574
es.	O	-1	18208574
CONCLUSION:	O	-1	18208574
H@@	O	-1	18208574
igh@@	O	-1	18208574
er	O	-1	18208574
O@@	O	-1	18208574
D	O	-1	18208574
is	O	-1	18208574
associated	O	-1	18208574
with	O	-1	18208574
significant	O	-1	18208574
risk	O	-1	18208574
of	O	-1	18208574
subsequ@@	O	-1	18208574
ent	O	-1	18208574
thrombo@@	B-Disease	D013927	18208574
sis	I-Disease	-1	18208574
in	O	-1	18208574
patients	O	-1	18208574
with	O	-1	18208574
isol@@	O	-1	18208574
ated@@	O	-1	18208574
-	O	-1	18208574
H@@	B-Disease	D013921	18208574
I@@	I-Disease	-1	18208574
T	I-Disease	-1	18208574
;	O	-1	18208574
perc@@	O	-1	18208574
ent	O	-1	18208574
inhib@@	O	-1	18208574
i@@	O	-1	18208574
tion,	O	-1	18208574
however,	O	-1	18208574
was	O	-1	18208574
not	O	-1	18208574
predic@@	O	-1	18208574
ti@@	O	-1	18208574
ve.	O	-1	18208574

C@@	O	-1	18343374
entr@@	O	-1	18343374
al	O	-1	18343374
ret@@	B-Disease	D012170	18343374
inal	I-Disease	-1	18343374
ve@@	I-Disease	-1	18343374
in	I-Disease	-1	18343374
oc@@	I-Disease	-1	18343374
cl@@	I-Disease	-1	18343374
usion	I-Disease	-1	18343374
associated	O	-1	18343374
with	O	-1	18343374
clo@@	B-Chemical	D002996	18343374
mi@@	I-Chemical	-1	18343374
phen@@	I-Chemical	-1	18343374
e	I-Chemical	-1	18343374
-induced	O	-1	18343374
o@@	O	-1	18343374
vul@@	O	-1	18343374
ation.	O	-1	18343374
OBJECTIVE:	O	-1	18343374
To	O	-1	18343374
report	O	-1	18343374
a	O	-1	18343374
case	O	-1	18343374
of	O	-1	18343374
central	O	-1	18343374
ret@@	B-Disease	D012170	18343374
inal	I-Disease	-1	18343374
ve@@	I-Disease	-1	18343374
in	I-Disease	-1	18343374
oc@@	I-Disease	-1	18343374
cl@@	I-Disease	-1	18343374
usion	I-Disease	-1	18343374
associated	O	-1	18343374
with	O	-1	18343374
clo@@	B-Chemical	D002996	18343374
mi@@	I-Chemical	-1	18343374
phen@@	I-Chemical	-1	18343374
e	I-Chemical	-1	18343374
cit@@	I-Chemical	-1	18343374
rate	I-Chemical	-1	18343374
(	O	-1	18343374
C@@	B-Chemical	D002996	18343374
C	I-Chemical	-1	18343374
).	O	-1	18343374
D@@	O	-1	18343374
ES@@	O	-1	18343374
I@@	O	-1	18343374
G@@	O	-1	18343374
N@@	O	-1	18343374
:	O	-1	18343374
C@@	O	-1	18343374
ase	O	-1	18343374
study.	O	-1	18343374
S@@	O	-1	18343374
ET@@	O	-1	18343374
TI@@	O	-1	18343374
N@@	O	-1	18343374
G@@	O	-1	18343374
:	O	-1	18343374
O@@	O	-1	18343374
ph@@	O	-1	18343374
thal@@	O	-1	18343374
mo@@	O	-1	18343374
log@@	O	-1	18343374
y	O	-1	18343374
clin@@	O	-1	18343374
ic	O	-1	18343374
of	O	-1	18343374
an	O	-1	18343374
ac@@	O	-1	18343374
ade@@	O	-1	18343374
mic	O	-1	18343374
hospit@@	O	-1	18343374
al.	O	-1	18343374
PA@@	O	-1	18343374
TI@@	O	-1	18343374
E@@	O	-1	18343374
N@@	O	-1	18343374
T@@	O	-1	18343374
(S@@	O	-1	18343374
)@@	O	-1	18343374
:	O	-1	18343374
A	O	-1	18343374
3@@	O	-1	18343374
6-@@	O	-1	18343374
year-old	O	-1	18343374
woman	O	-1	18343374
ref@@	O	-1	18343374
er@@	O	-1	18343374
red	O	-1	18343374
from	O	-1	18343374
the	O	-1	18343374
inf@@	B-Disease	D007247	18343374
er@@	I-Disease	-1	18343374
til@@	I-Disease	-1	18343374
ity	I-Disease	-1	18343374
clin@@	O	-1	18343374
ic	O	-1	18343374
for	O	-1	18343374
bl@@	B-Disease	D014786	18343374
ur@@	I-Disease	-1	18343374
red	I-Disease	-1	18343374
vi@@	I-Disease	-1	18343374
sion	I-Disease	-1	18343374
.	O	-1	18343374
IN@@	O	-1	18343374
TE@@	O	-1	18343374
R@@	O	-1	18343374
V@@	O	-1	18343374
E@@	O	-1	18343374
N@@	O	-1	18343374
T@@	O	-1	18343374
ION@@	O	-1	18343374
(S@@	O	-1	18343374
)@@	O	-1	18343374
:	O	-1	18343374
O@@	O	-1	18343374
ph@@	O	-1	18343374
thal@@	O	-1	18343374
mic	O	-1	18343374
examin@@	O	-1	18343374
ation	O	-1	18343374
after	O	-1	18343374
C@@	B-Chemical	D002996	18343374
C	I-Chemical	-1	18343374
therapy.	O	-1	18343374
MA@@	O	-1	18343374
I@@	O	-1	18343374
N	O	-1	18343374
O@@	O	-1	18343374
U@@	O	-1	18343374
T@@	O	-1	18343374
CO@@	O	-1	18343374
M@@	O	-1	18343374
E	O	-1	18343374
M@@	O	-1	18343374
E@@	O	-1	18343374
A@@	O	-1	18343374
S@@	O	-1	18343374
U@@	O	-1	18343374
R@@	O	-1	18343374
E@@	O	-1	18343374
(S@@	O	-1	18343374
)@@	O	-1	18343374
:	O	-1	18343374
C@@	O	-1	18343374
entr@@	O	-1	18343374
al	O	-1	18343374
ret@@	B-Disease	D012170	18343374
inal	I-Disease	-1	18343374
ve@@	I-Disease	-1	18343374
in	I-Disease	-1	18343374
oc@@	I-Disease	-1	18343374
cl@@	I-Disease	-1	18343374
usion	I-Disease	-1	18343374
after	O	-1	18343374
o@@	O	-1	18343374
v@@	O	-1	18343374
ulation	O	-1	18343374
induction	O	-1	18343374
with	O	-1	18343374
C@@	B-Chemical	D002996	18343374
C	I-Chemical	-1	18343374
.	O	-1	18343374
RESULT@@	O	-1	18343374
(S@@	O	-1	18343374
)@@	O	-1	18343374
:	O	-1	18343374
A	O	-1	18343374
3@@	O	-1	18343374
6-@@	O	-1	18343374
year-old	O	-1	18343374
Ch@@	O	-1	18343374
in@@	O	-1	18343374
ese	O	-1	18343374
woman	O	-1	18343374
developed	O	-1	18343374
central	O	-1	18343374
ret@@	B-Disease	D012170	18343374
inal	I-Disease	-1	18343374
ve@@	I-Disease	-1	18343374
in	I-Disease	-1	18343374
oc@@	I-Disease	-1	18343374
cl@@	I-Disease	-1	18343374
usion	I-Disease	-1	18343374
after	O	-1	18343374
e@@	O	-1	18343374
ight	O	-1	18343374
cour@@	O	-1	18343374
ses	O	-1	18343374
of	O	-1	18343374
C@@	B-Chemical	D002996	18343374
C	I-Chemical	-1	18343374
.	O	-1	18343374
A	O	-1	18343374
se@@	O	-1	18343374
arc@@	O	-1	18343374
h	O	-1	18343374
of	O	-1	18343374
the	O	-1	18343374
literat@@	O	-1	18343374
ure	O	-1	18343374
on	O	-1	18343374
the	O	-1	18343374
thrombo@@	B-Disease	D013923	18343374
emb@@	I-Disease	-1	18343374
olic	I-Disease	-1	18343374
complications	O	-1	18343374
of	O	-1	18343374
C@@	B-Chemical	D002996	18343374
C	I-Chemical	-1	18343374
does	O	-1	18343374
not	O	-1	18343374
includ@@	O	-1	18343374
e	O	-1	18343374
this	O	-1	18343374
severe	O	-1	18343374
oph@@	O	-1	18343374
thal@@	O	-1	18343374
mic	O	-1	18343374
complic@@	O	-1	18343374
ation,	O	-1	18343374
although	O	-1	18343374
mil@@	O	-1	18343374
d	O	-1	18343374
visual	B-Disease	D014786	18343374
dist@@	I-Disease	-1	18343374
urb@@	I-Disease	-1	18343374
ance	I-Disease	-1	18343374
after	O	-1	18343374
C@@	B-Chemical	D002996	18343374
C	I-Chemical	-1	18343374
int@@	O	-1	18343374
ake	O	-1	18343374
is	O	-1	18343374
not	O	-1	18343374
un@@	O	-1	18343374
common@@	O	-1	18343374
.	O	-1	18343374
CONCLUSION@@	O	-1	18343374
(S@@	O	-1	18343374
)@@	O	-1	18343374
:	O	-1	18343374
This	O	-1	18343374
is	O	-1	18343374
the	O	-1	18343374
first	O	-1	18343374
reported	O	-1	18343374
case	O	-1	18343374
of	O	-1	18343374
central	O	-1	18343374
ret@@	B-Disease	D012170	18343374
inal	I-Disease	-1	18343374
ve@@	I-Disease	-1	18343374
in	I-Disease	-1	18343374
oc@@	I-Disease	-1	18343374
cl@@	I-Disease	-1	18343374
usion	I-Disease	-1	18343374
after	O	-1	18343374
treatment	O	-1	18343374
with	O	-1	18343374
C@@	B-Chemical	D002996	18343374
C	I-Chemical	-1	18343374
.	O	-1	18343374
E@@	O	-1	18343374
x@@	O	-1	18343374
tr@@	O	-1	18343374
a	O	-1	18343374
cau@@	O	-1	18343374
tion	O	-1	18343374
is	O	-1	18343374
war@@	O	-1	18343374
ran@@	O	-1	18343374
ted	O	-1	18343374
in	O	-1	18343374
treat@@	O	-1	18343374
ing	O	-1	18343374
inf@@	B-Disease	D007247	18343374
er@@	I-Disease	-1	18343374
til@@	I-Disease	-1	18343374
ity	I-Disease	-1	18343374
patients	O	-1	18343374
with	O	-1	18343374
C@@	B-Chemical	D002996	18343374
C	I-Chemical	-1	18343374
,	O	-1	18343374
and	O	-1	18343374
patients	O	-1	18343374
should	O	-1	18343374
be	O	-1	18343374
well	O	-1	18343374
inf@@	O	-1	18343374
orm@@	O	-1	18343374
ed	O	-1	18343374
of	O	-1	18343374
this	O	-1	18343374
side	O	-1	18343374
effect	O	-1	18343374
before	O	-1	18343374
comm@@	O	-1	18343374
ence@@	O	-1	18343374
ment	O	-1	18343374
of	O	-1	18343374
therapy.	O	-1	18343374

N@@	B-Chemical	D009538	18417364
icot@@	I-Chemical	-1	18417364
ine	I-Chemical	-1	18417364
-induced	O	-1	18417364
n@@	B-Disease	D009759	18417364
y@@	I-Disease	-1	18417364
st@@	I-Disease	-1	18417364
ag@@	I-Disease	-1	18417364
m@@	I-Disease	-1	18417364
us	I-Disease	-1	18417364
correl@@	O	-1	18417364
ates	O	-1	18417364
with	O	-1	18417364
mid@@	O	-1	18417364
p@@	O	-1	18417364
ont@@	O	-1	18417364
ine	O	-1	18417364
activ@@	O	-1	18417364
ation.	O	-1	18417364
The	O	-1	18417364
path@@	O	-1	18417364
om@@	O	-1	18417364
echan@@	O	-1	18417364
ism	O	-1	18417364
of	O	-1	18417364
nicotine	B-Chemical	D009538	18417364
-induced	O	-1	18417364
n@@	B-Disease	D009759	18417364
y@@	I-Disease	-1	18417364
st@@	I-Disease	-1	18417364
ag@@	I-Disease	-1	18417364
m@@	I-Disease	-1	18417364
us	I-Disease	-1	18417364
(	O	-1	18417364
N@@	B-Disease	D009759	18417364
I@@	I-Disease	-1	18417364
N	I-Disease	-1	18417364
)	O	-1	18417364
is	O	-1	18417364
un@@	O	-1	18417364
know@@	O	-1	18417364
n@@	O	-1	18417364
.	O	-1	18417364
The	O	-1	18417364
a@@	O	-1	18417364
im	O	-1	18417364
of	O	-1	18417364
this	O	-1	18417364
study	O	-1	18417364
was	O	-1	18417364
to	O	-1	18417364
del@@	O	-1	18417364
ine@@	O	-1	18417364
ate	O	-1	18417364
brain	O	-1	18417364
struct@@	O	-1	18417364
ures	O	-1	18417364
that	O	-1	18417364
are	O	-1	18417364
involved	O	-1	18417364
in	O	-1	18417364
N@@	B-Disease	D009759	18417364
I@@	I-Disease	-1	18417364
N	I-Disease	-1	18417364
gener@@	O	-1	18417364
ation.	O	-1	18417364
E@@	O	-1	18417364
ight	O	-1	18417364
healthy	O	-1	18417364
vol@@	O	-1	18417364
un@@	O	-1	18417364
te@@	O	-1	18417364
ers	O	-1	18417364
in@@	O	-1	18417364
h@@	O	-1	18417364
al@@	O	-1	18417364
ed	O	-1	18417364
nicotine	B-Chemical	D009538	18417364
in	O	-1	18417364
d@@	O	-1	18417364
ark@@	O	-1	18417364
ness	O	-1	18417364
during	O	-1	18417364
a	O	-1	18417364
functional	O	-1	18417364
mag@@	O	-1	18417364
ne@@	O	-1	18417364
tic	O	-1	18417364
res@@	O	-1	18417364
on@@	O	-1	18417364
ance	O	-1	18417364
imaging	O	-1	18417364
(@@	O	-1	18417364
f@@	O	-1	18417364
MR@@	O	-1	18417364
I@@	O	-1	18417364
)	O	-1	18417364
experim@@	O	-1	18417364
ent@@	O	-1	18417364
;	O	-1	18417364
e@@	O	-1	18417364
y@@	O	-1	18417364
e	O	-1	18417364
mo@@	O	-1	18417364
ve@@	O	-1	18417364
ments	O	-1	18417364
were	O	-1	18417364
reg@@	O	-1	18417364
ist@@	O	-1	18417364
ered	O	-1	18417364
using	O	-1	18417364
vi@@	O	-1	18417364
de@@	O	-1	18417364
o@@	O	-1	18417364
-@@	O	-1	18417364
oc@@	O	-1	18417364
u@@	O	-1	18417364
logra@@	O	-1	18417364
ph@@	O	-1	18417364
y.	O	-1	18417364
N@@	B-Disease	D009759	18417364
I@@	I-Disease	-1	18417364
N	I-Disease	-1	18417364
cor@@	O	-1	18417364
related	O	-1	18417364
with	O	-1	18417364
blood	O	-1	18417364
oxy@@	B-Chemical	D010100	18417364
gen	I-Chemical	-1	18417364
level@@	O	-1	18417364
-@@	O	-1	18417364
dependent	O	-1	18417364
(B@@	O	-1	18417364
O@@	O	-1	18417364
L@@	O	-1	18417364
D)	O	-1	18417364
activity	O	-1	18417364
levels	O	-1	18417364
in	O	-1	18417364
a	O	-1	18417364
mid@@	O	-1	18417364
p@@	O	-1	18417364
ont@@	O	-1	18417364
ine	O	-1	18417364
sit@@	O	-1	18417364
e	O	-1	18417364
in	O	-1	18417364
the	O	-1	18417364
po@@	O	-1	18417364
ster@@	O	-1	18417364
ior	O	-1	18417364
b@@	O	-1	18417364
asis	O	-1	18417364
p@@	O	-1	18417364
on@@	O	-1	18417364
tis.	O	-1	18417364
N@@	B-Disease	D009759	18417364
I@@	I-Disease	-1	18417364
N	I-Disease	-1	18417364
-induced	O	-1	18417364
mid@@	O	-1	18417364
p@@	O	-1	18417364
ont@@	O	-1	18417364
ine	O	-1	18417364
activation	O	-1	18417364
may	O	-1	18417364
cor@@	O	-1	18417364
respon@@	O	-1	18417364
d	O	-1	18417364
to	O	-1	18417364
activation	O	-1	18417364
of	O	-1	18417364
the	O	-1	18417364
d@@	O	-1	18417364
or@@	O	-1	18417364
so@@	O	-1	18417364
medi@@	O	-1	18417364
al	O	-1	18417364
p@@	O	-1	18417364
ont@@	O	-1	18417364
ine	O	-1	18417364
nucle@@	O	-1	18417364
i	O	-1	18417364
and	O	-1	18417364
the	O	-1	18417364
nucle@@	O	-1	18417364
us	O	-1	18417364
re@@	O	-1	18417364
tic@@	O	-1	18417364
ul@@	O	-1	18417364
ar@@	O	-1	18417364
is	O	-1	18417364
te@@	O	-1	18417364
g@@	O	-1	18417364
ment@@	O	-1	18417364
i	O	-1	18417364
p@@	O	-1	18417364
on@@	O	-1	18417364
tis,	O	-1	18417364
struct@@	O	-1	18417364
ures	O	-1	18417364
known	O	-1	18417364
to	O	-1	18417364
partic@@	O	-1	18417364
ip@@	O	-1	18417364
ate	O	-1	18417364
in	O	-1	18417364
the	O	-1	18417364
generation	O	-1	18417364
of	O	-1	18417364
multi@@	O	-1	18417364
direc@@	O	-1	18417364
tional	O	-1	18417364
s@@	O	-1	18417364
ac@@	O	-1	18417364
ca@@	O	-1	18417364
des	O	-1	18417364
and	O	-1	18417364
smo@@	O	-1	18417364
oth	O	-1	18417364
pur@@	O	-1	18417364
su@@	O	-1	18417364
it	O	-1	18417364
e@@	O	-1	18417364
y@@	O	-1	18417364
e	O	-1	18417364
mo@@	O	-1	18417364
ve@@	O	-1	18417364
ment@@	O	-1	18417364
s.	O	-1	18417364

Pro@@	O	-1	18442015
t@@	O	-1	18442015
ective	O	-1	18442015
effect	O	-1	18442015
of	O	-1	18442015
verap@@	B-Chemical	D014700	18442015
ami@@	I-Chemical	-1	18442015
l	I-Chemical	-1	18442015
on	O	-1	18442015
gast@@	B-Disease	D006471	18442015
ric	I-Disease	-1	18442015
hemorrh@@	I-Disease	-1	18442015
ag@@	I-Disease	-1	18442015
ic	I-Disease	-1	18442015
ul@@	B-Disease	D014456	18442015
c@@	I-Disease	-1	18442015
ers	I-Disease	-1	18442015
in	O	-1	18442015
severe	O	-1	18442015
a@@	B-Disease	D050197	18442015
therosclero@@	I-Disease	-1	18442015
tic	I-Disease	-1	18442015
rats.	O	-1	18442015
S@@	O	-1	18442015
t@@	O	-1	18442015
udi@@	O	-1	18442015
es	O	-1	18442015
con@@	O	-1	18442015
cer@@	O	-1	18442015
ning	O	-1	18442015
with	O	-1	18442015
path@@	O	-1	18442015
o@@	O	-1	18442015
genesis	O	-1	18442015
of	O	-1	18442015
gast@@	B-Disease	D006471	18442015
ric	I-Disease	-1	18442015
hemorrh@@	I-Disease	-1	18442015
age	I-Disease	-1	18442015
and	O	-1	18442015
m@@	O	-1	18442015
u@@	O	-1	18442015
co@@	O	-1	18442015
s@@	O	-1	18442015
al	O	-1	18442015
ul@@	O	-1	18442015
cer@@	O	-1	18442015
ation	O	-1	18442015
produced	O	-1	18442015
in	O	-1	18442015
a@@	B-Disease	D050197	18442015
therosclero@@	I-Disease	-1	18442015
tic	I-Disease	-1	18442015
rats	O	-1	18442015
are	O	-1	18442015
l@@	O	-1	18442015
ac@@	O	-1	18442015
k@@	O	-1	18442015
ing.	O	-1	18442015
The	O	-1	18442015
a@@	O	-1	18442015
im	O	-1	18442015
of	O	-1	18442015
this	O	-1	18442015
study	O	-1	18442015
is	O	-1	18442015
to	O	-1	18442015
ex@@	O	-1	18442015
amine	O	-1	18442015
the	O	-1	18442015
role	O	-1	18442015
of	O	-1	18442015
gast@@	O	-1	18442015
ric	O	-1	18442015
acid	O	-1	18442015
bac@@	O	-1	18442015
k@@	O	-1	18442015
-@@	O	-1	18442015
diff@@	O	-1	18442015
u@@	O	-1	18442015
sion,	O	-1	18442015
m@@	O	-1	18442015
ast	O	-1	18442015
cell	O	-1	18442015
hist@@	B-Chemical	D006632	18442015
amine	I-Chemical	-1	18442015
rele@@	O	-1	18442015
ase,	O	-1	18442015
li@@	O	-1	18442015
pid	O	-1	18442015
per@@	O	-1	18442015
ox@@	O	-1	18442015
ide	O	-1	18442015
(@@	O	-1	18442015
L@@	O	-1	18442015
P@@	O	-1	18442015
O@@	O	-1	18442015
)	O	-1	18442015
generation	O	-1	18442015
and	O	-1	18442015
m@@	O	-1	18442015
u@@	O	-1	18442015
co@@	O	-1	18442015
s@@	O	-1	18442015
al	O	-1	18442015
micro@@	O	-1	18442015
vascular	O	-1	18442015
per@@	O	-1	18442015
me@@	O	-1	18442015
ability	O	-1	18442015
in	O	-1	18442015
mod@@	O	-1	18442015
ul@@	O	-1	18442015
ating	O	-1	18442015
gast@@	B-Disease	D006471	18442015
ric	I-Disease	-1	18442015
hemorrh@@	I-Disease	-1	18442015
age	I-Disease	-1	18442015
and	O	-1	18442015
ul@@	B-Disease	D014456	18442015
c@@	I-Disease	-1	18442015
er	I-Disease	-1	18442015
in	O	-1	18442015
rats	O	-1	18442015
with	O	-1	18442015
a@@	B-Disease	D050197	18442015
therosclero@@	I-Disease	-1	18442015
sis	I-Disease	-1	18442015
induced	O	-1	18442015
by	O	-1	18442015
co@@	O	-1	18442015
administration	O	-1	18442015
of	O	-1	18442015
vitamin	B-Chemical	D004872	18442015
D2	I-Chemical	-1	18442015
and	O	-1	18442015
cholester@@	B-Chemical	D002784	18442015
ol	I-Chemical	-1	18442015
.	O	-1	18442015
Ad@@	O	-1	18442015
di@@	O	-1	18442015
tion@@	O	-1	18442015
ally,	O	-1	18442015
the	O	-1	18442015
protective	O	-1	18442015
effect	O	-1	18442015
of	O	-1	18442015
verap@@	B-Chemical	D014700	18442015
ami@@	I-Chemical	-1	18442015
l	I-Chemical	-1	18442015
on	O	-1	18442015
this	O	-1	18442015
ul@@	B-Disease	D014456	18442015
c@@	I-Disease	-1	18442015
er	I-Disease	-1	18442015
model	O	-1	18442015
was	O	-1	18442015
evalu@@	O	-1	18442015
ated.	O	-1	18442015
M@@	O	-1	18442015
al@@	O	-1	18442015
e	O	-1	18442015
Wistar	O	-1	18442015
rats	O	-1	18442015
were	O	-1	18442015
ch@@	O	-1	18442015
all@@	O	-1	18442015
en@@	O	-1	18442015
g@@	O	-1	18442015
ed	O	-1	18442015
intra@@	O	-1	18442015
gast@@	O	-1	18442015
r@@	O	-1	18442015
ically	O	-1	18442015
on@@	O	-1	18442015
ce	O	-1	18442015
daily	O	-1	18442015
for	O	-1	18442015
9	O	-1	18442015
days	O	-1	18442015
with	O	-1	18442015
1.@@	O	-1	18442015
0	O	-1	18442015
ml@@	O	-1	18442015
/@@	O	-1	18442015
k@@	O	-1	18442015
g	O	-1	18442015
of	O	-1	18442015
cor@@	O	-1	18442015
n	O	-1	18442015
o@@	O	-1	18442015
il	O	-1	18442015
containing	O	-1	18442015
vitamin	B-Chemical	D004872	18442015
D2	I-Chemical	-1	18442015
and	O	-1	18442015
cholester@@	B-Chemical	D002784	18442015
ol	I-Chemical	-1	18442015
to	O	-1	18442015
induce	O	-1	18442015
a@@	B-Disease	D050197	18442015
therosclero@@	I-Disease	-1	18442015
sis	I-Disease	-1	18442015
.	O	-1	18442015
C@@	O	-1	18442015
ont@@	O	-1	18442015
ro@@	O	-1	18442015
l	O	-1	18442015
rats	O	-1	18442015
received	O	-1	18442015
cor@@	O	-1	18442015
n	O	-1	18442015
o@@	O	-1	18442015
il	O	-1	18442015
on@@	O	-1	18442015
ly.	O	-1	18442015
After	O	-1	18442015
gast@@	O	-1	18442015
ric	O	-1	18442015
surger@@	O	-1	18442015
y,	O	-1	18442015
rat	O	-1	18442015
st@@	O	-1	18442015
om@@	O	-1	18442015
ac@@	O	-1	18442015
h@@	O	-1	18442015
s	O	-1	18442015
were	O	-1	18442015
ir@@	O	-1	18442015
rig@@	O	-1	18442015
ated	O	-1	18442015
for	O	-1	18442015
3	O	-1	18442015
h	O	-1	18442015
with	O	-1	18442015
either	O	-1	18442015
si@@	O	-1	18442015
mul@@	O	-1	18442015
ated	O	-1	18442015
gast@@	O	-1	18442015
ric	O	-1	18442015
j@@	O	-1	18442015
u@@	O	-1	18442015
ic@@	O	-1	18442015
e	O	-1	18442015
or	O	-1	18442015
normal	O	-1	18442015
sal@@	O	-1	18442015
ine.	O	-1	18442015
G@@	O	-1	18442015
ast@@	O	-1	18442015
ric	O	-1	18442015
acid	O	-1	18442015
bac@@	O	-1	18442015
k@@	O	-1	18442015
-@@	O	-1	18442015
diff@@	O	-1	18442015
u@@	O	-1	18442015
sion,	O	-1	18442015
m@@	O	-1	18442015
u@@	O	-1	18442015
co@@	O	-1	18442015
s@@	O	-1	18442015
al	O	-1	18442015
L@@	O	-1	18442015
P@@	O	-1	18442015
O	O	-1	18442015
gener@@	O	-1	18442015
ation,	O	-1	18442015
hist@@	B-Chemical	D006632	18442015
amine	I-Chemical	-1	18442015
concentr@@	O	-1	18442015
ation,	O	-1	18442015
micro@@	O	-1	18442015
vascular	O	-1	18442015
per@@	O	-1	18442015
me@@	O	-1	18442015
abil@@	O	-1	18442015
ity,	O	-1	18442015
lu@@	B-Chemical	D010634	18442015
min@@	I-Chemical	-1	18442015
al	I-Chemical	-1	18442015
hemo@@	O	-1	18442015
globin	O	-1	18442015
cont@@	O	-1	18442015
ent	O	-1	18442015
and	O	-1	18442015
ul@@	B-Disease	D014456	18442015
c@@	I-Disease	-1	18442015
er	I-Disease	-1	18442015
a@@	O	-1	18442015
reas	O	-1	18442015
were	O	-1	18442015
deter@@	O	-1	18442015
m@@	O	-1	18442015
ine@@	O	-1	18442015
d.	O	-1	18442015
E@@	O	-1	18442015
lev@@	O	-1	18442015
ated	O	-1	18442015
a@@	B-Disease	D050197	18442015
therosclero@@	I-Disease	-1	18442015
tic	I-Disease	-1	18442015
par@@	O	-1	18442015
ame@@	O	-1	18442015
ter@@	O	-1	18442015
s,	O	-1	18442015
such	O	-1	18442015
as	O	-1	18442015
serum	O	-1	18442015
calcium	B-Chemical	D002118	18442015
,	O	-1	18442015
total	O	-1	18442015
cholester@@	B-Chemical	D002784	18442015
ol	I-Chemical	-1	18442015
and	O	-1	18442015
low@@	O	-1	18442015
-@@	O	-1	18442015
d@@	O	-1	18442015
ensity	O	-1	18442015
li@@	O	-1	18442015
po@@	O	-1	18442015
protein	O	-1	18442015
concentration	O	-1	18442015
were	O	-1	18442015
obtained	O	-1	18442015
in	O	-1	18442015
a@@	B-Disease	D050197	18442015
therosclero@@	I-Disease	-1	18442015
tic	I-Disease	-1	18442015
rats.	O	-1	18442015
S@@	O	-1	18442015
ev@@	O	-1	18442015
ere	O	-1	18442015
gast@@	O	-1	18442015
ric	O	-1	18442015
ul@@	B-Disease	D014456	18442015
c@@	I-Disease	-1	18442015
ers	I-Disease	-1	18442015
ac@@	O	-1	18442015
comp@@	O	-1	18442015
an@@	O	-1	18442015
ied	O	-1	18442015
with	O	-1	18442015
increased	O	-1	18442015
ul@@	O	-1	18442015
c@@	O	-1	18442015
ero@@	O	-1	18442015
genic	O	-1	18442015
fact@@	O	-1	18442015
or@@	O	-1	18442015
s,	O	-1	18442015
including	O	-1	18442015
gast@@	O	-1	18442015
ric	O	-1	18442015
acid	O	-1	18442015
bac@@	O	-1	18442015
k@@	O	-1	18442015
-@@	O	-1	18442015
diff@@	O	-1	18442015
u@@	O	-1	18442015
sion,	O	-1	18442015
hist@@	B-Chemical	D006632	18442015
amine	I-Chemical	-1	18442015
rele@@	O	-1	18442015
ase,	O	-1	18442015
L@@	O	-1	18442015
P@@	O	-1	18442015
O	O	-1	18442015
generation	O	-1	18442015
and	O	-1	18442015
lu@@	B-Chemical	D010634	18442015
min@@	I-Chemical	-1	18442015
al	I-Chemical	-1	18442015
hemo@@	O	-1	18442015
globin	O	-1	18442015
cont@@	O	-1	18442015
ent	O	-1	18442015
were	O	-1	18442015
also	O	-1	18442015
observed	O	-1	18442015
in	O	-1	18442015
these	O	-1	18442015
rats.	O	-1	18442015
M@@	O	-1	18442015
ore@@	O	-1	18442015
o@@	O	-1	18442015
ver,	O	-1	18442015
a	O	-1	18442015
positive	O	-1	18442015
correl@@	O	-1	18442015
ation	O	-1	18442015
of	O	-1	18442015
hist@@	B-Chemical	D006632	18442015
amine	I-Chemical	-1	18442015
to	O	-1	18442015
gast@@	B-Disease	D006471	18442015
ric	I-Disease	-1	18442015
hemorrh@@	I-Disease	-1	18442015
age	I-Disease	-1	18442015
and	O	-1	18442015
to	O	-1	18442015
ul@@	B-Disease	D014456	18442015
c@@	I-Disease	-1	18442015
er	I-Disease	-1	18442015
was	O	-1	18442015
found	O	-1	18442015
in	O	-1	18442015
those	O	-1	18442015
a@@	B-Disease	D050197	18442015
therosclero@@	I-Disease	-1	18442015
tic	I-Disease	-1	18442015
rats.	O	-1	18442015
This	O	-1	18442015
hemorrh@@	B-Disease	D006471	18442015
ag@@	I-Disease	-1	18442015
ic	I-Disease	-1	18442015
ul@@	B-Disease	D014456	18442015
c@@	I-Disease	-1	18442015
er	I-Disease	-1	18442015
and	O	-1	18442015
various	O	-1	18442015
ul@@	O	-1	18442015
c@@	O	-1	18442015
ero@@	O	-1	18442015
genic	O	-1	18442015
par@@	O	-1	18442015
ame@@	O	-1	18442015
ters	O	-1	18442015
were	O	-1	18442015
dose-@@	O	-1	18442015
depend@@	O	-1	18442015
ently	O	-1	18442015
ame@@	O	-1	18442015
li@@	O	-1	18442015
or@@	O	-1	18442015
ated	O	-1	18442015
by	O	-1	18442015
daily	O	-1	18442015
intra@@	O	-1	18442015
gast@@	O	-1	18442015
ric	O	-1	18442015
verap@@	B-Chemical	D014700	18442015
ami@@	I-Chemical	-1	18442015
l	I-Chemical	-1	18442015
.	O	-1	18442015
A@@	B-Disease	D050197	18442015
therosclero@@	I-Disease	-1	18442015
sis	I-Disease	-1	18442015
could	O	-1	18442015
produce	O	-1	18442015
gast@@	B-Disease	D006471	18442015
ric	I-Disease	-1	18442015
hemorrh@@	I-Disease	-1	18442015
ag@@	I-Disease	-1	18442015
ic	I-Disease	-1	18442015
ul@@	B-Disease	D014456	18442015
c@@	I-Disease	-1	18442015
er	I-Disease	-1	18442015
vi@@	O	-1	18442015
a	O	-1	18442015
ag@@	O	-1	18442015
gra@@	O	-1	18442015
v@@	O	-1	18442015
ation	O	-1	18442015
of	O	-1	18442015
gast@@	O	-1	18442015
ric	O	-1	18442015
acid	O	-1	18442015
bac@@	O	-1	18442015
k@@	O	-1	18442015
-@@	O	-1	18442015
diff@@	O	-1	18442015
u@@	O	-1	18442015
sion,	O	-1	18442015
L@@	O	-1	18442015
P@@	O	-1	18442015
O	O	-1	18442015
gener@@	O	-1	18442015
ation,	O	-1	18442015
hist@@	B-Chemical	D006632	18442015
amine	I-Chemical	-1	18442015
release	O	-1	18442015
and	O	-1	18442015
micro@@	O	-1	18442015
vascular	O	-1	18442015
per@@	O	-1	18442015
me@@	O	-1	18442015
ability	O	-1	18442015
that	O	-1	18442015
could	O	-1	18442015
be	O	-1	18442015
ame@@	O	-1	18442015
li@@	O	-1	18442015
or@@	O	-1	18442015
ated	O	-1	18442015
by	O	-1	18442015
verap@@	B-Chemical	D014700	18442015
ami@@	I-Chemical	-1	18442015
l	I-Chemical	-1	18442015
in	O	-1	18442015
rats.	O	-1	18442015

Ad@@	B-Chemical	D004317	18619688
riam@@	I-Chemical	-1	18619688
ycin	I-Chemical	-1	18619688
-induced	O	-1	18619688
auto@@	O	-1	18619688
ph@@	O	-1	18619688
ag@@	O	-1	18619688
ic	O	-1	18619688
cardi@@	O	-1	18619688
om@@	O	-1	18619688
y@@	O	-1	18619688
ocyte	O	-1	18619688
death	B-Disease	D003643	18619688
pl@@	O	-1	18619688
ays	O	-1	18619688
a	O	-1	18619688
path@@	O	-1	18619688
o@@	O	-1	18619688
genic	O	-1	18619688
role	O	-1	18619688
in	O	-1	18619688
a	O	-1	18619688
rat	O	-1	18619688
model	O	-1	18619688
of	O	-1	18619688
heart	B-Disease	D006333	18619688
failure	I-Disease	-1	18619688
.	O	-1	18619688
BACKGROUND:	O	-1	18619688
The	O	-1	18619688
mechanisms	O	-1	18619688
underlying	O	-1	18619688
heart	B-Disease	D006333	18619688
failure	I-Disease	-1	18619688
induced	O	-1	18619688
by	O	-1	18619688
adriam@@	B-Chemical	D004317	18619688
ycin	I-Chemical	-1	18619688
are	O	-1	18619688
very	O	-1	18619688
complic@@	O	-1	18619688
ated	O	-1	18619688
and	O	-1	18619688
sti@@	O	-1	18619688
ll	O	-1	18619688
unc@@	O	-1	18619688
lear@@	O	-1	18619688
.	O	-1	18619688
The	O	-1	18619688
a@@	O	-1	18619688
im	O	-1	18619688
of	O	-1	18619688
this	O	-1	18619688
study	O	-1	18619688
was	O	-1	18619688
to	O	-1	18619688
investigate	O	-1	18619688
whether	O	-1	18619688
auto@@	O	-1	18619688
ph@@	O	-1	18619688
ag@@	O	-1	18619688
y	O	-1	18619688
was	O	-1	18619688
involved	O	-1	18619688
in	O	-1	18619688
the	O	-1	18619688
progres@@	O	-1	18619688
sion	O	-1	18619688
of	O	-1	18619688
heart	B-Disease	D006333	18619688
failure	I-Disease	-1	18619688
induced	O	-1	18619688
by	O	-1	18619688
adriam@@	B-Chemical	D004317	18619688
ycin	I-Chemical	-1	18619688
,	O	-1	18619688
so	O	-1	18619688
that	O	-1	18619688
we	O	-1	18619688
can	O	-1	18619688
deve@@	O	-1	18619688
lo@@	O	-1	18619688
p	O	-1	18619688
a	O	-1	18619688
novel	O	-1	18619688
treatment	O	-1	18619688
strat@@	O	-1	18619688
e@@	O	-1	18619688
g@@	O	-1	18619688
y	O	-1	18619688
for	O	-1	18619688
heart	B-Disease	D006333	18619688
failure	I-Disease	-1	18619688
.	O	-1	18619688
METHODS:	O	-1	18619688
3-@@	B-Chemical	C025946	18619688
methyl@@	I-Chemical	-1	18619688
aden@@	I-Chemical	-1	18619688
ine	I-Chemical	-1	18619688
(	O	-1	18619688
3@@	B-Chemical	C025946	18619688
M@@	I-Chemical	-1	18619688
A	I-Chemical	-1	18619688
),	O	-1	18619688
a	O	-1	18619688
specific	O	-1	18619688
inhibitor	O	-1	18619688
on	O	-1	18619688
auto@@	O	-1	18619688
ph@@	O	-1	18619688
ag@@	O	-1	18619688
y	O	-1	18619688
was	O	-1	18619688
used	O	-1	18619688
in	O	-1	18619688
a	O	-1	18619688
heart	B-Disease	D006333	18619688
failure	I-Disease	-1	18619688
model	O	-1	18619688
of	O	-1	18619688
rats	O	-1	18619688
induced	O	-1	18619688
by	O	-1	18619688
adriam@@	B-Chemical	D004317	18619688
ycin	I-Chemical	-1	18619688
.	O	-1	18619688
Ne@@	O	-1	18619688
on@@	O	-1	18619688
atal	O	-1	18619688
cardi@@	O	-1	18619688
om@@	O	-1	18619688
y@@	O	-1	18619688
ocy@@	O	-1	18619688
tes	O	-1	18619688
were	O	-1	18619688
isol@@	O	-1	18619688
ated	O	-1	18619688
from	O	-1	18619688
S@@	O	-1	18619688
pra@@	O	-1	18619688
gu@@	O	-1	18619688
e-@@	O	-1	18619688
D@@	O	-1	18619688
aw@@	O	-1	18619688
le@@	O	-1	18619688
y	O	-1	18619688
rat	O	-1	18619688
hear@@	O	-1	18619688
ts	O	-1	18619688
and	O	-1	18619688
random@@	O	-1	18619688
ly	O	-1	18619688
divid@@	O	-1	18619688
ed	O	-1	18619688
into	O	-1	18619688
control@@	O	-1	18619688
s,	O	-1	18619688
an	O	-1	18619688
adriam@@	B-Chemical	D004317	18619688
ycin	I-Chemical	-1	18619688
-treated	O	-1	18619688
group@@	O	-1	18619688
,	O	-1	18619688
and	O	-1	18619688
a	O	-1	18619688
3@@	B-Chemical	C025946	18619688
M@@	I-Chemical	-1	18619688
A	I-Chemical	-1	18619688
plus	O	-1	18619688
adriam@@	B-Chemical	D004317	18619688
ycin	I-Chemical	-1	18619688
-treated	O	-1	18619688
group.	O	-1	18619688
We	O	-1	18619688
then	O	-1	18619688
examined	O	-1	18619688
the	O	-1	18619688
morph@@	O	-1	18619688
olog@@	O	-1	18619688
y,	O	-1	18619688
expression	O	-1	18619688
of	O	-1	18619688
b@@	O	-1	18619688
ec@@	O	-1	18619688
l@@	O	-1	18619688
in	O	-1	18619688
1	O	-1	18619688
gen@@	O	-1	18619688
e,	O	-1	18619688
mitochondrial	O	-1	18619688
per@@	O	-1	18619688
me@@	O	-1	18619688
ability	O	-1	18619688
transi@@	O	-1	18619688
tion	O	-1	18619688
(@@	O	-1	18619688
MP@@	O	-1	18619688
T@@	O	-1	18619688
),	O	-1	18619688
and	O	-1	18619688
Na@@	O	-1	18619688
+@@	O	-1	18619688
-	O	-1	18619688
K	B-Chemical	D011188	18619688
+	O	-1	18619688
AT@@	O	-1	18619688
P@@	O	-1	18619688
ase	O	-1	18619688
activity	O	-1	18619688
in	O	-1	18619688
viv@@	O	-1	18619688
o@@	O	-1	18619688
.	O	-1	18619688
We	O	-1	18619688
also	O	-1	18619688
assessed	O	-1	18619688
cell	O	-1	18619688
vi@@	O	-1	18619688
abil@@	O	-1	18619688
ity,	O	-1	18619688
mitochondrial	O	-1	18619688
membran@@	O	-1	18619688
e	O	-1	18619688
potential	O	-1	18619688
changes	O	-1	18619688
and	O	-1	18619688
coun@@	O	-1	18619688
ted	O	-1	18619688
auto@@	O	-1	18619688
ph@@	O	-1	18619688
ag@@	O	-1	18619688
ic	O	-1	18619688
vac@@	O	-1	18619688
u@@	O	-1	18619688
ol@@	O	-1	18619688
es	O	-1	18619688
in	O	-1	18619688
c@@	O	-1	18619688
ult@@	O	-1	18619688
ured	O	-1	18619688
cardi@@	O	-1	18619688
om@@	O	-1	18619688
y@@	O	-1	18619688
ocy@@	O	-1	18619688
t@@	O	-1	18619688
es.	O	-1	18619688
In	O	-1	18619688
addi@@	O	-1	18619688
tion,	O	-1	18619688
we	O	-1	18619688
analy@@	O	-1	18619688
zed	O	-1	18619688
the	O	-1	18619688
expression	O	-1	18619688
of	O	-1	18619688
auto@@	O	-1	18619688
ph@@	O	-1	18619688
ag@@	O	-1	18619688
y	O	-1	18619688
associated	O	-1	18619688
gen@@	O	-1	18619688
e,	O	-1	18619688
b@@	O	-1	18619688
ec@@	O	-1	18619688
l@@	O	-1	18619688
in	O	-1	18619688
1	O	-1	18619688
using	O	-1	18619688
R@@	O	-1	18619688
T@@	O	-1	18619688
-@@	O	-1	18619688
P@@	O	-1	18619688
C@@	O	-1	18619688
R	O	-1	18619688
and	O	-1	18619688
W@@	O	-1	18619688
est@@	O	-1	18619688
er@@	O	-1	18619688
n	O	-1	18619688
blo@@	O	-1	18619688
t@@	O	-1	18619688
ting	O	-1	18619688
in	O	-1	18619688
an	O	-1	18619688
anim@@	O	-1	18619688
al	O	-1	18619688
model@@	O	-1	18619688
.	O	-1	18619688
RESULTS:	O	-1	18619688
3@@	B-Chemical	C025946	18619688
M@@	I-Chemical	-1	18619688
A	I-Chemical	-1	18619688
significantly	O	-1	18619688
improved	O	-1	18619688
cardiac	O	-1	18619688
function	O	-1	18619688
and	O	-1	18619688
reduced	O	-1	18619688
mitochondrial	O	-1	18619688
injur@@	O	-1	18619688
y.	O	-1	18619688
F@@	O	-1	18619688
ur@@	O	-1	18619688
ther@@	O	-1	18619688
mo@@	O	-1	18619688
re,	O	-1	18619688
adriam@@	B-Chemical	D004317	18619688
ycin	I-Chemical	-1	18619688
induced	O	-1	18619688
the	O	-1	18619688
formation	O	-1	18619688
of	O	-1	18619688
auto@@	O	-1	18619688
ph@@	O	-1	18619688
ag@@	O	-1	18619688
ic	O	-1	18619688
vac@@	O	-1	18619688
u@@	O	-1	18619688
ol@@	O	-1	18619688
es,	O	-1	18619688
and	O	-1	18619688
3@@	B-Chemical	C025946	18619688
M@@	I-Chemical	-1	18619688
A	I-Chemical	-1	18619688
st@@	O	-1	18619688
ron@@	O	-1	18619688
g@@	O	-1	18619688
ly	O	-1	18619688
do@@	O	-1	18619688
w@@	O	-1	18619688
n@@	O	-1	18619688
reg@@	O	-1	18619688
ul@@	O	-1	18619688
ated	O	-1	18619688
the	O	-1	18619688
expression	O	-1	18619688
of	O	-1	18619688
b@@	O	-1	18619688
ec@@	O	-1	18619688
l@@	O	-1	18619688
in	O	-1	18619688
1	O	-1	18619688
in	O	-1	18619688
adriam@@	B-Chemical	D004317	18619688
ycin	I-Chemical	-1	18619688
-induced	O	-1	18619688
fail@@	O	-1	18619688
ing	O	-1	18619688
heart	O	-1	18619688
and	O	-1	18619688
inhibited	O	-1	18619688
the	O	-1	18619688
formation	O	-1	18619688
of	O	-1	18619688
auto@@	O	-1	18619688
ph@@	O	-1	18619688
ag@@	O	-1	18619688
ic	O	-1	18619688
vac@@	O	-1	18619688
u@@	O	-1	18619688
ol@@	O	-1	18619688
es.	O	-1	18619688
CONCLUSION:	O	-1	18619688
A@@	O	-1	18619688
u@@	O	-1	18619688
to@@	O	-1	18619688
ph@@	O	-1	18619688
ag@@	O	-1	18619688
ic	O	-1	18619688
cardi@@	O	-1	18619688
om@@	O	-1	18619688
y@@	O	-1	18619688
ocyte	O	-1	18619688
death	B-Disease	D003643	18619688
pl@@	O	-1	18619688
ays	O	-1	18619688
an	O	-1	18619688
important	O	-1	18619688
role	O	-1	18619688
in	O	-1	18619688
the	O	-1	18619688
path@@	O	-1	18619688
o@@	O	-1	18619688
genesis	O	-1	18619688
of	O	-1	18619688
heart	B-Disease	D006333	18619688
failure	I-Disease	-1	18619688
in	O	-1	18619688
rats	O	-1	18619688
induced	O	-1	18619688
by	O	-1	18619688
adriam@@	B-Chemical	D004317	18619688
ycin	I-Chemical	-1	18619688
.	O	-1	18619688
M@@	O	-1	18619688
it@@	O	-1	18619688
ochond@@	O	-1	18619688
rial	O	-1	18619688
injury	O	-1	18619688
may	O	-1	18619688
be	O	-1	18619688
involved	O	-1	18619688
in	O	-1	18619688
the	O	-1	18619688
progres@@	O	-1	18619688
sion	O	-1	18619688
of	O	-1	18619688
heart	B-Disease	D006333	18619688
failure	I-Disease	-1	18619688
caused	O	-1	18619688
by	O	-1	18619688
adriam@@	B-Chemical	D004317	18619688
ycin	I-Chemical	-1	18619688
vi@@	O	-1	18619688
a	O	-1	18619688
the	O	-1	18619688
auto@@	O	-1	18619688
ph@@	O	-1	18619688
ag@@	O	-1	18619688
y	O	-1	18619688
path@@	O	-1	18619688
w@@	O	-1	18619688
a@@	O	-1	18619688
y.	O	-1	18619688

Con@@	B-Disease	D003221	19308880
f@@	I-Disease	-1	19308880
usion	I-Disease	-1	19308880
,	O	-1	19308880
a	O	-1	19308880
ra@@	O	-1	19308880
ther	O	-1	19308880
seri@@	O	-1	19308880
ous	O	-1	19308880
adverse	O	-1	19308880
drug	O	-1	19308880
reaction	O	-1	19308880
with	O	-1	19308880
valpro@@	B-Chemical	D014635	19308880
ic	I-Chemical	-1	19308880
acid	I-Chemical	-1	19308880
:	O	-1	19308880
a	O	-1	19308880
revie@@	O	-1	19308880
w	O	-1	19308880
of	O	-1	19308880
the	O	-1	19308880
F@@	O	-1	19308880
ren@@	O	-1	19308880
ch	O	-1	19308880
Ph@@	O	-1	19308880
armac@@	O	-1	19308880
o@@	O	-1	19308880
vi@@	O	-1	19308880
g@@	O	-1	19308880
il@@	O	-1	19308880
ance	O	-1	19308880
dat@@	O	-1	19308880
ab@@	O	-1	19308880
as@@	O	-1	19308880
e.	O	-1	19308880
IN@@	O	-1	19308880
T@@	O	-1	19308880
RO@@	O	-1	19308880
D@@	O	-1	19308880
U@@	O	-1	19308880
C@@	O	-1	19308880
T@@	O	-1	19308880
ION@@	O	-1	19308880
:	O	-1	19308880
Con@@	B-Disease	D003221	19308880
f@@	I-Disease	-1	19308880
usion	I-Disease	-1	19308880
is	O	-1	19308880
an	O	-1	19308880
adverse	O	-1	19308880
drug	O	-1	19308880
reaction	O	-1	19308880
frequ@@	O	-1	19308880
ently	O	-1	19308880
observed	O	-1	19308880
with	O	-1	19308880
valpro@@	B-Chemical	D014635	19308880
ic	I-Chemical	-1	19308880
acid	I-Chemical	-1	19308880
.	O	-1	19308880
S@@	O	-1	19308880
ome	O	-1	19308880
case	O	-1	19308880
reports	O	-1	19308880
are	O	-1	19308880
pu@@	O	-1	19308880
bl@@	O	-1	19308880
ished	O	-1	19308880
in	O	-1	19308880
the	O	-1	19308880
literat@@	O	-1	19308880
ure	O	-1	19308880
but	O	-1	19308880
no	O	-1	19308880
system@@	O	-1	19308880
atic	O	-1	19308880
study	O	-1	19308880
from	O	-1	19308880
a	O	-1	19308880
sam@@	O	-1	19308880
ple	O	-1	19308880
of	O	-1	19308880
patients	O	-1	19308880
has	O	-1	19308880
been	O	-1	19308880
pu@@	O	-1	19308880
bl@@	O	-1	19308880
is@@	O	-1	19308880
he@@	O	-1	19308880
d.	O	-1	19308880
We	O	-1	19308880
performed	O	-1	19308880
this	O	-1	19308880
study	O	-1	19308880
in	O	-1	19308880
or@@	O	-1	19308880
der	O	-1	19308880
to	O	-1	19308880
describe	O	-1	19308880
the	O	-1	19308880
ma@@	O	-1	19308880
in	O	-1	19308880
character@@	O	-1	19308880
is@@	O	-1	19308880
tics	O	-1	19308880
of	O	-1	19308880
this	O	-1	19308880
adverse	O	-1	19308880
drug	O	-1	19308880
reac@@	O	-1	19308880
tion.	O	-1	19308880
METHODS:	O	-1	19308880
U@@	O	-1	19308880
s@@	O	-1	19308880
ing	O	-1	19308880
the	O	-1	19308880
F@@	O	-1	19308880
ren@@	O	-1	19308880
ch	O	-1	19308880
Ph@@	O	-1	19308880
armac@@	O	-1	19308880
o@@	O	-1	19308880
vi@@	O	-1	19308880
g@@	O	-1	19308880
il@@	O	-1	19308880
ance	O	-1	19308880
dat@@	O	-1	19308880
ab@@	O	-1	19308880
ase,	O	-1	19308880
we	O	-1	19308880
sel@@	O	-1	19308880
ected	O	-1	19308880
the	O	-1	19308880
cases	O	-1	19308880
of	O	-1	19308880
conf@@	B-Disease	D003221	19308880
usion	I-Disease	-1	19308880
reported	O	-1	19308880
s@@	O	-1	19308880
inc@@	O	-1	19308880
e	O	-1	19308880
19@@	O	-1	19308880
8@@	O	-1	19308880
5	O	-1	19308880
with	O	-1	19308880
valpro@@	B-Chemical	D014635	19308880
ic	I-Chemical	-1	19308880
acid	I-Chemical	-1	19308880
.	O	-1	19308880
RESULTS:	O	-1	19308880
27@@	O	-1	19308880
2	O	-1	19308880
cases	O	-1	19308880
of	O	-1	19308880
conf@@	B-Disease	D003221	19308880
usion	I-Disease	-1	19308880
were	O	-1	19308880
reported	O	-1	19308880
with	O	-1	19308880
valpro@@	B-Chemical	D014635	19308880
ic	I-Chemical	-1	19308880
acid	I-Chemical	-1	19308880
:	O	-1	19308880
1@@	O	-1	19308880
5@@	O	-1	19308880
3	O	-1	19308880
women	O	-1	19308880
and	O	-1	19308880
1@@	O	-1	19308880
1@@	O	-1	19308880
9	O	-1	19308880
men@@	O	-1	19308880
.	O	-1	19308880
Con@@	B-Disease	D003221	19308880
f@@	I-Disease	-1	19308880
usion	I-Disease	-1	19308880
mo@@	O	-1	19308880
st@@	O	-1	19308880
ly	O	-1	19308880
occurred	O	-1	19308880
during	O	-1	19308880
the	O	-1	19308880
two	O	-1	19308880
first	O	-1	19308880
weeks	O	-1	19308880
following	O	-1	19308880
valpro@@	B-Chemical	D014635	19308880
ic	I-Chemical	-1	19308880
acid	I-Chemical	-1	19308880
exposure	O	-1	19308880
(3@@	O	-1	19308880
9.@@	O	-1	19308880
7@@	O	-1	19308880
%).	O	-1	19308880
It	O	-1	19308880
was	O	-1	19308880
"@@	O	-1	19308880
seri@@	O	-1	19308880
ous@@	O	-1	19308880
"	O	-1	19308880
for	O	-1	19308880
al@@	O	-1	19308880
most	O	-1	19308880
2@@	O	-1	19308880
/@@	O	-1	19308880
3	O	-1	19308880
of	O	-1	19308880
the	O	-1	19308880
patients	O	-1	19308880
(6@@	O	-1	19308880
2.@@	O	-1	19308880
5@@	O	-1	19308880
%)	O	-1	19308880
and	O	-1	19308880
its	O	-1	19308880
outcom@@	O	-1	19308880
e	O	-1	19308880
f@@	O	-1	19308880
av@@	O	-1	19308880
o@@	O	-1	19308880
ur@@	O	-1	19308880
able	O	-1	19308880
in	O	-1	19308880
most	O	-1	19308880
of	O	-1	19308880
the	O	-1	19308880
cases	O	-1	19308880
(@@	O	-1	19308880
8@@	O	-1	19308880
2@@	O	-1	19308880
%).	O	-1	19308880
The	O	-1	19308880
occur@@	O	-1	19308880
rence	O	-1	19308880
of	O	-1	19308880
this	O	-1	19308880
AD@@	O	-1	19308880
R	O	-1	19308880
was	O	-1	19308880
more	O	-1	19308880
frequent	O	-1	19308880
in	O	-1	19308880
patients	O	-1	19308880
aged	O	-1	19308880
between	O	-1	19308880
6@@	O	-1	19308880
1	O	-1	19308880
and	O	-1	19308880
8@@	O	-1	19308880
0	O	-1	19308880
year@@	O	-1	19308880
s.	O	-1	19308880
CONCLUSION:	O	-1	19308880
This	O	-1	19308880
wor@@	O	-1	19308880
k	O	-1	19308880
show@@	O	-1	19308880
s	O	-1	19308880
that	O	-1	19308880
conf@@	B-Disease	D003221	19308880
usion	I-Disease	-1	19308880
with	O	-1	19308880
valpro@@	B-Chemical	D014635	19308880
ic	I-Chemical	-1	19308880
acid	I-Chemical	-1	19308880
is	O	-1	19308880
a	O	-1	19308880
seri@@	O	-1	19308880
ou@@	O	-1	19308880
s,	O	-1	19308880
ra@@	O	-1	19308880
ther	O	-1	19308880
frequent	O	-1	19308880
but	O	-1	19308880
reversible	O	-1	19308880
adverse	O	-1	19308880
drug	O	-1	19308880
reac@@	O	-1	19308880
tion.	O	-1	19308880
It	O	-1	19308880
occur@@	O	-1	19308880
s	O	-1	19308880
es@@	O	-1	19308880
p@@	O	-1	19308880
ec@@	O	-1	19308880
i@@	O	-1	19308880
ally	O	-1	19308880
in	O	-1	19308880
ol@@	O	-1	19308880
der	O	-1	19308880
patients	O	-1	19308880
and	O	-1	19308880
during	O	-1	19308880
the	O	-1	19308880
first	O	-1	19308880
two	O	-1	19308880
weeks	O	-1	19308880
of	O	-1	19308880
treatment.	O	-1	19308880

L@@	B-Disease	D007859	19631624
ear@@	I-Disease	-1	19631624
ning	I-Disease	-1	19631624
and	I-Disease	-1	19631624
memory	I-Disease	-1	19631624
defic@@	I-Disease	-1	19631624
its	I-Disease	-1	19631624
L@@	B-Disease	D008569	19631624
ear@@	I-Disease	-1	19631624
ning	I-Disease	-1	19631624
and	I-Disease	-1	19631624
memory	I-Disease	-1	19631624
defic@@	I-Disease	-1	19631624
its	I-Disease	-1	19631624
in	O	-1	19631624
ec@@	B-Chemical	D018817	19631624
st@@	I-Chemical	-1	19631624
as@@	I-Chemical	-1	19631624
y	I-Chemical	-1	19631624
users	O	-1	19631624
and	O	-1	19631624
their	O	-1	19631624
ne@@	O	-1	19631624
ural	O	-1	19631624
correl@@	O	-1	19631624
ates	O	-1	19631624
during	O	-1	19631624
a	O	-1	19631624
fac@@	O	-1	19631624
e-@@	O	-1	19631624
lear@@	O	-1	19631624
ning	O	-1	19631624
t@@	O	-1	19631624
as@@	O	-1	19631624
k@@	O	-1	19631624
.	O	-1	19631624
It	O	-1	19631624
has	O	-1	19631624
been	O	-1	19631624
consist@@	O	-1	19631624
ently	O	-1	19631624
shown	O	-1	19631624
that	O	-1	19631624
ec@@	B-Chemical	D018817	19631624
st@@	I-Chemical	-1	19631624
as@@	I-Chemical	-1	19631624
y	I-Chemical	-1	19631624
users	O	-1	19631624
dis@@	O	-1	19631624
pl@@	O	-1	19631624
ay	O	-1	19631624
impair@@	B-Disease	D007859	19631624
ments	I-Disease	-1	19631624
in	I-Disease	-1	19631624
lear@@	I-Disease	-1	19631624
ning	I-Disease	-1	19631624
and	I-Disease	-1	19631624
memory	I-Disease	-1	19631624
impair@@	B-Disease	D008569	19631624
ments	I-Disease	-1	19631624
in	I-Disease	-1	19631624
lear@@	I-Disease	-1	19631624
ning	I-Disease	-1	19631624
and	I-Disease	-1	19631624
memory	I-Disease	-1	19631624
perform@@	O	-1	19631624
ance@@	O	-1	19631624
.	O	-1	19631624
In	O	-1	19631624
addi@@	O	-1	19631624
tion,	O	-1	19631624
wor@@	O	-1	19631624
king	O	-1	19631624
memory	O	-1	19631624
pro@@	O	-1	19631624
cess@@	O	-1	19631624
ing	O	-1	19631624
in	O	-1	19631624
ec@@	B-Chemical	D018817	19631624
st@@	I-Chemical	-1	19631624
as@@	I-Chemical	-1	19631624
y	I-Chemical	-1	19631624
users	O	-1	19631624
has	O	-1	19631624
been	O	-1	19631624
shown	O	-1	19631624
to	O	-1	19631624
be	O	-1	19631624
associated	O	-1	19631624
with	O	-1	19631624
ne@@	O	-1	19631624
ural	O	-1	19631624
al@@	O	-1	19631624
ter@@	O	-1	19631624
ations	O	-1	19631624
in	O	-1	19631624
hippocamp@@	O	-1	19631624
al	O	-1	19631624
and/or	O	-1	19631624
cor@@	O	-1	19631624
tical	O	-1	19631624
regi@@	O	-1	19631624
ons	O	-1	19631624
as	O	-1	19631624
measured	O	-1	19631624
by	O	-1	19631624
functional	O	-1	19631624
mag@@	O	-1	19631624
ne@@	O	-1	19631624
tic	O	-1	19631624
res@@	O	-1	19631624
on@@	O	-1	19631624
ance	O	-1	19631624
imaging	O	-1	19631624
(@@	O	-1	19631624
f@@	O	-1	19631624
MR@@	O	-1	19631624
I@@	O	-1	19631624
).	O	-1	19631624
U@@	O	-1	19631624
s@@	O	-1	19631624
ing	O	-1	19631624
functional	O	-1	19631624
imaging	O	-1	19631624
and	O	-1	19631624
a	O	-1	19631624
fac@@	O	-1	19631624
e-@@	O	-1	19631624
lear@@	O	-1	19631624
ning	O	-1	19631624
t@@	O	-1	19631624
as@@	O	-1	19631624
k@@	O	-1	19631624
,	O	-1	19631624
we	O	-1	19631624
investigated	O	-1	19631624
ne@@	O	-1	19631624
ural	O	-1	19631624
correl@@	O	-1	19631624
ates	O	-1	19631624
of	O	-1	19631624
en@@	O	-1	19631624
co@@	O	-1	19631624
ding	O	-1	19631624
and	O	-1	19631624
rec@@	O	-1	19631624
all@@	O	-1	19631624
ing	O	-1	19631624
fac@@	O	-1	19631624
e-@@	O	-1	19631624
nam@@	O	-1	19631624
e	O	-1	19631624
associ@@	O	-1	19631624
ations	O	-1	19631624
in	O	-1	19631624
20	O	-1	19631624
rec@@	O	-1	19631624
re@@	O	-1	19631624
ation@@	O	-1	19631624
al	O	-1	19631624
drug	O	-1	19631624
users	O	-1	19631624
wh@@	O	-1	19631624
ose	O	-1	19631624
pre@@	O	-1	19631624
domin@@	O	-1	19631624
ant	O	-1	19631624
drug	O	-1	19631624
use	O	-1	19631624
was	O	-1	19631624
ec@@	B-Chemical	D018817	19631624
st@@	I-Chemical	-1	19631624
as@@	I-Chemical	-1	19631624
y	I-Chemical	-1	19631624
and	O	-1	19631624
20	O	-1	19631624
controls.	O	-1	19631624
To	O	-1	19631624
ad@@	O	-1	19631624
d@@	O	-1	19631624
res@@	O	-1	19631624
s	O	-1	19631624
the	O	-1	19631624
potential	O	-1	19631624
conf@@	O	-1	19631624
oun@@	O	-1	19631624
ding	O	-1	19631624
effects	O	-1	19631624
of	O	-1	19631624
the	O	-1	19631624
can@@	B-Chemical	D002188	19631624
n@@	I-Chemical	-1	19631624
ab@@	I-Chemical	-1	19631624
is	I-Chemical	-1	19631624
use	O	-1	19631624
of	O	-1	19631624
the	O	-1	19631624
ec@@	B-Chemical	D018817	19631624
st@@	I-Chemical	-1	19631624
as@@	I-Chemical	-1	19631624
y	I-Chemical	-1	19631624
using	O	-1	19631624
group@@	O	-1	19631624
,	O	-1	19631624
a	O	-1	19631624
second	O	-1	19631624
analysis	O	-1	19631624
included	O	-1	19631624
14	O	-1	19631624
previously	O	-1	19631624
tested	O	-1	19631624
can@@	B-Chemical	D002188	19631624
n@@	I-Chemical	-1	19631624
ab@@	I-Chemical	-1	19631624
is	I-Chemical	-1	19631624
users	O	-1	19631624
(N@@	O	-1	19631624
est@@	O	-1	19631624
or@@	O	-1	19631624
,	O	-1	19631624
L@@	O	-1	19631624
.,	O	-1	19631624
R@@	O	-1	19631624
ob@@	O	-1	19631624
er@@	O	-1	19631624
t@@	O	-1	19631624
s,	O	-1	19631624
G@@	O	-1	19631624
.,	O	-1	19631624
G@@	O	-1	19631624
ar@@	O	-1	19631624
av@@	O	-1	19631624
an@@	O	-1	19631624
,	O	-1	19631624
H@@	O	-1	19631624
.,	O	-1	19631624
H@@	O	-1	19631624
est@@	O	-1	19631624
er,	O	-1	19631624
R@@	O	-1	19631624
.,	O	-1	19631624
20@@	O	-1	19631624
0@@	O	-1	19631624
8@@	O	-1	19631624
.	O	-1	19631624
De@@	B-Disease	D007859	19631624
fic@@	I-Disease	-1	19631624
its	I-Disease	-1	19631624
in	I-Disease	-1	19631624
lear@@	I-Disease	-1	19631624
ning	I-Disease	-1	19631624
and	I-Disease	-1	19631624
memory	I-Disease	-1	19631624
De@@	B-Disease	D008569	19631624
fic@@	I-Disease	-1	19631624
its	I-Disease	-1	19631624
in	I-Disease	-1	19631624
lear@@	I-Disease	-1	19631624
ning	I-Disease	-1	19631624
and	I-Disease	-1	19631624
memory	I-Disease	-1	19631624
:	O	-1	19631624
par@@	O	-1	19631624
a@@	O	-1	19631624
hippocamp@@	O	-1	19631624
al	O	-1	19631624
hyperactivity	B-Disease	D006948	19631624
and	O	-1	19631624
fron@@	O	-1	19631624
t@@	O	-1	19631624
oc@@	O	-1	19631624
or@@	O	-1	19631624
tical	O	-1	19631624
hypo@@	O	-1	19631624
activity	O	-1	19631624
in	O	-1	19631624
can@@	B-Chemical	D002188	19631624
n@@	I-Chemical	-1	19631624
ab@@	I-Chemical	-1	19631624
is	I-Chemical	-1	19631624
us@@	O	-1	19631624
ers.	O	-1	19631624
Ne@@	O	-1	19631624
uro@@	O	-1	19631624
im@@	O	-1	19631624
age	O	-1	19631624
4@@	O	-1	19631624
0@@	O	-1	19631624
,	O	-1	19631624
13@@	O	-1	19631624
2@@	O	-1	19631624
8@@	O	-1	19631624
-1@@	O	-1	19631624
3@@	O	-1	19631624
3@@	O	-1	19631624
9@@	O	-1	19631624
).	O	-1	19631624
E@@	B-Chemical	D018817	19631624
c@@	I-Chemical	-1	19631624
st@@	I-Chemical	-1	19631624
as@@	I-Chemical	-1	19631624
y	I-Chemical	-1	19631624
users	O	-1	19631624
performed	O	-1	19631624
significantly	O	-1	19631624
wor@@	O	-1	19631624
se	O	-1	19631624
in	O	-1	19631624
lear@@	O	-1	19631624
ning	O	-1	19631624
and	O	-1	19631624
memory	O	-1	19631624
compared	O	-1	19631624
to	O	-1	19631624
controls	O	-1	19631624
and	O	-1	19631624
can@@	B-Chemical	D002188	19631624
n@@	I-Chemical	-1	19631624
ab@@	I-Chemical	-1	19631624
is	I-Chemical	-1	19631624
us@@	O	-1	19631624
ers.	O	-1	19631624
A	O	-1	19631624
con@@	O	-1	19631624
j@@	O	-1	19631624
unc@@	O	-1	19631624
tion	O	-1	19631624
analysis	O	-1	19631624
of	O	-1	19631624
the	O	-1	19631624
en@@	O	-1	19631624
co@@	O	-1	19631624
de	O	-1	19631624
and	O	-1	19631624
rec@@	O	-1	19631624
all	O	-1	19631624
ph@@	O	-1	19631624
as@@	O	-1	19631624
es	O	-1	19631624
of	O	-1	19631624
the	O	-1	19631624
t@@	O	-1	19631624
as@@	O	-1	19631624
k	O	-1	19631624
revealed	O	-1	19631624
ec@@	B-Chemical	D018817	19631624
st@@	I-Chemical	-1	19631624
as@@	I-Chemical	-1	19631624
y	I-Chemical	-1	19631624
-@@	O	-1	19631624
specific	O	-1	19631624
hyperactivity	B-Disease	D006948	19631624
in	O	-1	19631624
bil@@	O	-1	19631624
ateral	O	-1	19631624
fron@@	O	-1	19631624
t@@	O	-1	19631624
al	O	-1	19631624
regi@@	O	-1	19631624
on@@	O	-1	19631624
s,	O	-1	19631624
left	O	-1	19631624
tempor@@	O	-1	19631624
al,	O	-1	19631624
right	O	-1	19631624
par@@	O	-1	19631624
i@@	O	-1	19631624
et@@	O	-1	19631624
al,	O	-1	19631624
bil@@	O	-1	19631624
ateral	O	-1	19631624
tempor@@	O	-1	19631624
al,	O	-1	19631624
and	O	-1	19631624
bil@@	O	-1	19631624
ateral	O	-1	19631624
oc@@	O	-1	19631624
ci@@	O	-1	19631624
pit@@	O	-1	19631624
al	O	-1	19631624
brain	O	-1	19631624
regi@@	O	-1	19631624
on@@	O	-1	19631624
s.	O	-1	19631624
E@@	B-Chemical	D018817	19631624
c@@	I-Chemical	-1	19631624
st@@	I-Chemical	-1	19631624
as@@	I-Chemical	-1	19631624
y	I-Chemical	-1	19631624
-@@	O	-1	19631624
specific	O	-1	19631624
hypo@@	O	-1	19631624
activity	O	-1	19631624
was	O	-1	19631624
ev@@	O	-1	19631624
id@@	O	-1	19631624
ent	O	-1	19631624
in	O	-1	19631624
the	O	-1	19631624
right	O	-1	19631624
d@@	O	-1	19631624
or@@	O	-1	19631624
s@@	O	-1	19631624
al	O	-1	19631624
an@@	O	-1	19631624
ter@@	O	-1	19631624
ior	O	-1	19631624
c@@	O	-1	19631624
ing@@	O	-1	19631624
ul@@	O	-1	19631624
ated	O	-1	19631624
cor@@	O	-1	19631624
te@@	O	-1	19631624
x	O	-1	19631624
(@@	O	-1	19631624
AC@@	O	-1	19631624
C@@	O	-1	19631624
)	O	-1	19631624
and	O	-1	19631624
left	O	-1	19631624
po@@	O	-1	19631624
ster@@	O	-1	19631624
ior	O	-1	19631624
c@@	O	-1	19631624
ing@@	O	-1	19631624
ul@@	O	-1	19631624
ated	O	-1	19631624
cor@@	O	-1	19631624
t@@	O	-1	19631624
ex@@	O	-1	19631624
.	O	-1	19631624
In	O	-1	19631624
both	O	-1	19631624
ec@@	B-Chemical	D018817	19631624
st@@	I-Chemical	-1	19631624
as@@	I-Chemical	-1	19631624
y	I-Chemical	-1	19631624
and	O	-1	19631624
can@@	B-Chemical	D002188	19631624
n@@	I-Chemical	-1	19631624
ab@@	I-Chemical	-1	19631624
is	I-Chemical	-1	19631624
groups	O	-1	19631624
brain	O	-1	19631624
activation	O	-1	19631624
was	O	-1	19631624
decreased	O	-1	19631624
in	O	-1	19631624
the	O	-1	19631624
right	O	-1	19631624
medi@@	O	-1	19631624
al	O	-1	19631624
fron@@	O	-1	19631624
t@@	O	-1	19631624
al	O	-1	19631624
g@@	O	-1	19631624
y@@	O	-1	19631624
r@@	O	-1	19631624
us,	O	-1	19631624
left	O	-1	19631624
par@@	O	-1	19631624
a@@	O	-1	19631624
hippocamp@@	O	-1	19631624
al	O	-1	19631624
g@@	O	-1	19631624
y@@	O	-1	19631624
r@@	O	-1	19631624
us,	O	-1	19631624
left	O	-1	19631624
d@@	O	-1	19631624
or@@	O	-1	19631624
s@@	O	-1	19631624
al	O	-1	19631624
c@@	O	-1	19631624
ing@@	O	-1	19631624
ul@@	O	-1	19631624
ate	O	-1	19631624
g@@	O	-1	19631624
y@@	O	-1	19631624
r@@	O	-1	19631624
us,	O	-1	19631624
and	O	-1	19631624
left	O	-1	19631624
ca@@	O	-1	19631624
ud@@	O	-1	19631624
at@@	O	-1	19631624
e.	O	-1	19631624
These	O	-1	19631624
results	O	-1	19631624
el@@	O	-1	19631624
uc@@	O	-1	19631624
id@@	O	-1	19631624
ated	O	-1	19631624
ec@@	B-Chemical	D018817	19631624
st@@	I-Chemical	-1	19631624
as@@	I-Chemical	-1	19631624
y	I-Chemical	-1	19631624
-@@	O	-1	19631624
related	O	-1	19631624
defic@@	O	-1	19631624
it@@	O	-1	19631624
s,	O	-1	19631624
only	O	-1	19631624
some	O	-1	19631624
of	O	-1	19631624
which	O	-1	19631624
might	O	-1	19631624
be	O	-1	19631624
at@@	O	-1	19631624
tri@@	O	-1	19631624
but@@	O	-1	19631624
ed	O	-1	19631624
to	O	-1	19631624
can@@	B-Chemical	D002188	19631624
n@@	I-Chemical	-1	19631624
ab@@	I-Chemical	-1	19631624
is	I-Chemical	-1	19631624
use.	O	-1	19631624
These	O	-1	19631624
ec@@	B-Chemical	D018817	19631624
st@@	I-Chemical	-1	19631624
as@@	I-Chemical	-1	19631624
y	I-Chemical	-1	19631624
-@@	O	-1	19631624
specific	O	-1	19631624
effects	O	-1	19631624
may	O	-1	19631624
be	O	-1	19631624
related	O	-1	19631624
to	O	-1	19631624
the	O	-1	19631624
vul@@	O	-1	19631624
ner@@	O	-1	19631624
ability	O	-1	19631624
of	O	-1	19631624
is@@	O	-1	19631624
oc@@	O	-1	19631624
or@@	O	-1	19631624
tical	O	-1	19631624
and	O	-1	19631624
al@@	O	-1	19631624
lo@@	O	-1	19631624
cor@@	O	-1	19631624
tical	O	-1	19631624
regi@@	O	-1	19631624
ons	O	-1	19631624
to	O	-1	19631624
the	O	-1	19631624
neuro@@	B-Disease	D020258	19631624
toxic	I-Disease	-1	19631624
effects	O	-1	19631624
of	O	-1	19631624
ec@@	B-Chemical	D018817	19631624
st@@	I-Chemical	-1	19631624
as@@	I-Chemical	-1	19631624
y	I-Chemical	-1	19631624
.	O	-1	19631624

Pro@@	O	-1	20003049
long@@	O	-1	20003049
ed	O	-1	20003049
elev@@	O	-1	20003049
ation	O	-1	20003049
of	O	-1	20003049
plasma	O	-1	20003049
arg@@	B-Chemical	C031942	20003049
atro@@	I-Chemical	-1	20003049
b@@	I-Chemical	-1	20003049
an	I-Chemical	-1	20003049
in	O	-1	20003049
a	O	-1	20003049
cardiac	O	-1	20003049
transplant	O	-1	20003049
patient	O	-1	20003049
with	O	-1	20003049
a	O	-1	20003049
sus@@	O	-1	20003049
p@@	O	-1	20003049
ected	O	-1	20003049
hist@@	O	-1	20003049
ory	O	-1	20003049
of	O	-1	20003049
hepar@@	B-Chemical	D006493	20003049
in	I-Chemical	-1	20003049
-induced	O	-1	20003049
throm@@	B-Disease	D013921	20003049
b@@	I-Disease	-1	20003049
ocyto@@	I-Disease	-1	20003049
pen@@	I-Disease	-1	20003049
ia	I-Disease	-1	20003049
with	O	-1	20003049
thrombo@@	B-Disease	D013927	20003049
sis	I-Disease	-1	20003049
.	O	-1	20003049
BACKGROUND:	O	-1	20003049
Di@@	O	-1	20003049
rec@@	O	-1	20003049
t	O	-1	20003049
throm@@	O	-1	20003049
bin	O	-1	20003049
inhibitors	O	-1	20003049
(D@@	O	-1	20003049
TI@@	O	-1	20003049
s)	O	-1	20003049
prov@@	O	-1	20003049
ide	O	-1	20003049
an	O	-1	20003049
al@@	O	-1	20003049
tern@@	O	-1	20003049
ative	O	-1	20003049
meth@@	O	-1	20003049
od	O	-1	20003049
of	O	-1	20003049
anti@@	O	-1	20003049
co@@	O	-1	20003049
ag@@	O	-1	20003049
ulation	O	-1	20003049
for	O	-1	20003049
patients	O	-1	20003049
with	O	-1	20003049
a	O	-1	20003049
hist@@	O	-1	20003049
ory	O	-1	20003049
of	O	-1	20003049
hepar@@	B-Chemical	D006493	20003049
in	I-Chemical	-1	20003049
-induced	O	-1	20003049
throm@@	B-Disease	D013921	20003049
b@@	I-Disease	-1	20003049
ocyto@@	I-Disease	-1	20003049
pen@@	I-Disease	-1	20003049
ia	I-Disease	-1	20003049
(	O	-1	20003049
H@@	B-Disease	D013921	20003049
I@@	I-Disease	-1	20003049
T	I-Disease	-1	20003049
)	O	-1	20003049
or	O	-1	20003049
H@@	B-Disease	D013921	20003049
I@@	I-Disease	-1	20003049
T	I-Disease	-1	20003049
with	O	-1	20003049
thrombo@@	B-Disease	D013927	20003049
sis	I-Disease	-1	20003049
(	O	-1	20003049
H@@	B-Disease	D013921	20003049
I@@	I-Disease	-1	20003049
T@@	I-Disease	-1	20003049
T	I-Disease	-1	20003049
H@@	B-Disease	D013927	20003049
I@@	I-Disease	-1	20003049
T@@	I-Disease	-1	20003049
T	I-Disease	-1	20003049
)	O	-1	20003049
under@@	O	-1	20003049
go@@	O	-1	20003049
ing	O	-1	20003049
cardio@@	O	-1	20003049
pulmonary	O	-1	20003049
b@@	O	-1	20003049
yp@@	O	-1	20003049
as@@	O	-1	20003049
s	O	-1	20003049
(C@@	O	-1	20003049
P@@	O	-1	20003049
B@@	O	-1	20003049
).	O	-1	20003049
In	O	-1	20003049
the	O	-1	20003049
following	O	-1	20003049
repor@@	O	-1	20003049
t,	O	-1	20003049
a	O	-1	20003049
6@@	O	-1	20003049
5-@@	O	-1	20003049
year-old	O	-1	20003049
cri@@	B-Disease	D016638	20003049
tically	I-Disease	-1	20003049
il@@	I-Disease	-1	20003049
l	I-Disease	-1	20003049
patient	O	-1	20003049
with	O	-1	20003049
a	O	-1	20003049
sus@@	O	-1	20003049
p@@	O	-1	20003049
ected	O	-1	20003049
hist@@	O	-1	20003049
ory	O	-1	20003049
of	O	-1	20003049
H@@	B-Disease	D013921	20003049
I@@	I-Disease	-1	20003049
T@@	I-Disease	-1	20003049
T	I-Disease	-1	20003049
H@@	B-Disease	D013927	20003049
I@@	I-Disease	-1	20003049
T@@	I-Disease	-1	20003049
T	I-Disease	-1	20003049
was	O	-1	20003049
administered	O	-1	20003049
arg@@	B-Chemical	C031942	20003049
atro@@	I-Chemical	-1	20003049
b@@	I-Chemical	-1	20003049
an	I-Chemical	-1	20003049
for	O	-1	20003049
anti@@	O	-1	20003049
co@@	O	-1	20003049
ag@@	O	-1	20003049
ulation	O	-1	20003049
on	O	-1	20003049
b@@	O	-1	20003049
yp@@	O	-1	20003049
as@@	O	-1	20003049
s	O	-1	20003049
during	O	-1	20003049
heart	O	-1	20003049
transplant@@	O	-1	20003049
ation.	O	-1	20003049
The	O	-1	20003049
patient	O	-1	20003049
requ@@	O	-1	20003049
ired	O	-1	20003049
mas@@	O	-1	20003049
sive	O	-1	20003049
trans@@	O	-1	20003049
f@@	O	-1	20003049
usion	O	-1	20003049
suppor@@	O	-1	20003049
t	O	-1	20003049
(5@@	O	-1	20003049
5	O	-1	20003049
un@@	O	-1	20003049
its	O	-1	20003049
of	O	-1	20003049
red	O	-1	20003049
blood	O	-1	20003049
cell@@	O	-1	20003049
s,	O	-1	20003049
4@@	O	-1	20003049
2	O	-1	20003049
un@@	O	-1	20003049
its	O	-1	20003049
of	O	-1	20003049
f@@	O	-1	20003049
res@@	O	-1	20003049
h@@	O	-1	20003049
-@@	O	-1	20003049
f@@	O	-1	20003049
ro@@	O	-1	20003049
z@@	O	-1	20003049
en	O	-1	20003049
plas@@	O	-1	20003049
ma@@	O	-1	20003049
,	O	-1	20003049
40	O	-1	20003049
un@@	O	-1	20003049
its	O	-1	20003049
of	O	-1	20003049
c@@	O	-1	20003049
r@@	O	-1	20003049
yo@@	O	-1	20003049
pre@@	O	-1	20003049
ci@@	O	-1	20003049
pit@@	O	-1	20003049
ate,	O	-1	20003049
40	O	-1	20003049
un@@	O	-1	20003049
its	O	-1	20003049
of	O	-1	20003049
platele@@	O	-1	20003049
t@@	O	-1	20003049
s,	O	-1	20003049
and	O	-1	20003049
three	O	-1	20003049
doses	O	-1	20003049
of	O	-1	20003049
re@@	O	-1	20003049
combin@@	O	-1	20003049
ant	O	-1	20003049
F@@	O	-1	20003049
act@@	O	-1	20003049
or	O	-1	20003049
V@@	O	-1	20003049
II@@	O	-1	20003049
a@@	O	-1	20003049
)	O	-1	20003049
for	O	-1	20003049
severe	O	-1	20003049
intra@@	B-Disease	D016063	20003049
o@@	I-Disease	-1	20003049
perative	I-Disease	-1	20003049
and	I-Disease	-1	20003049
postoperative	I-Disease	-1	20003049
ble@@	I-Disease	-1	20003049
ed@@	I-Disease	-1	20003049
ing	I-Disease	-1	20003049
intra@@	B-Disease	D019106	20003049
o@@	I-Disease	-1	20003049
perative	I-Disease	-1	20003049
and	I-Disease	-1	20003049
postoperative	I-Disease	-1	20003049
ble@@	I-Disease	-1	20003049
ed@@	I-Disease	-1	20003049
ing	I-Disease	-1	20003049
.	O	-1	20003049
S@@	O	-1	20003049
T@@	O	-1	20003049
U@@	O	-1	20003049
D@@	O	-1	20003049
Y	O	-1	20003049
D@@	O	-1	20003049
ES@@	O	-1	20003049
I@@	O	-1	20003049
G@@	O	-1	20003049
N	O	-1	20003049
AN@@	O	-1	20003049
D	O	-1	20003049
METHODS:	O	-1	20003049
P@@	O	-1	20003049
las@@	O	-1	20003049
ma	O	-1	20003049
sam@@	O	-1	20003049
ple@@	O	-1	20003049
s	O	-1	20003049
from	O	-1	20003049
before	O	-1	20003049
and	O	-1	20003049
after	O	-1	20003049
C@@	O	-1	20003049
P@@	O	-1	20003049
B	O	-1	20003049
were	O	-1	20003049
analy@@	O	-1	20003049
zed	O	-1	20003049
posto@@	O	-1	20003049
per@@	O	-1	20003049
atively	O	-1	20003049
for	O	-1	20003049
arg@@	B-Chemical	C031942	20003049
atro@@	I-Chemical	-1	20003049
b@@	I-Chemical	-1	20003049
an	I-Chemical	-1	20003049
concentration	O	-1	20003049
using	O	-1	20003049
a	O	-1	20003049
mo@@	O	-1	20003049
di@@	O	-1	20003049
fied	O	-1	20003049
ec@@	O	-1	20003049
ar@@	O	-1	20003049
in	O	-1	20003049
clo@@	O	-1	20003049
t@@	O	-1	20003049
ting	O	-1	20003049
time	O	-1	20003049
(@@	O	-1	20003049
EC@@	O	-1	20003049
T)	O	-1	20003049
ass@@	O	-1	20003049
a@@	O	-1	20003049
y.	O	-1	20003049
RESULTS:	O	-1	20003049
U@@	O	-1	20003049
ne@@	O	-1	20003049
x@@	O	-1	20003049
p@@	O	-1	20003049
ect@@	O	-1	20003049
ed@@	O	-1	20003049
ly	O	-1	20003049
high	O	-1	20003049
concentrations	O	-1	20003049
of	O	-1	20003049
arg@@	B-Chemical	C031942	20003049
atro@@	I-Chemical	-1	20003049
b@@	I-Chemical	-1	20003049
an	I-Chemical	-1	20003049
were	O	-1	20003049
measured	O	-1	20003049
in	O	-1	20003049
these	O	-1	20003049
sam@@	O	-1	20003049
ple@@	O	-1	20003049
s	O	-1	20003049
(@@	O	-1	20003049
rang@@	O	-1	20003049
e,	O	-1	20003049
0-@@	O	-1	20003049
3@@	O	-1	20003049
2	O	-1	20003049
micro@@	O	-1	20003049
g/@@	O	-1	20003049
m@@	O	-1	20003049
L@@	O	-1	20003049
),	O	-1	20003049
and	O	-1	20003049
a	O	-1	20003049
prolonged	O	-1	20003049
plasma	O	-1	20003049
arg@@	B-Chemical	C031942	20003049
atro@@	I-Chemical	-1	20003049
b@@	I-Chemical	-1	20003049
an	I-Chemical	-1	20003049
h@@	O	-1	20003049
al@@	O	-1	20003049
f	O	-1	20003049
lif@@	O	-1	20003049
e	O	-1	20003049
(@@	O	-1	20003049
t@@	O	-1	20003049
(1@@	O	-1	20003049
/@@	O	-1	20003049
2@@	O	-1	20003049
)@@	O	-1	20003049
)	O	-1	20003049
of	O	-1	20003049
5@@	O	-1	20003049
14	O	-1	20003049
minutes	O	-1	20003049
was	O	-1	20003049
observed	O	-1	20003049
(@@	O	-1	20003049
pu@@	O	-1	20003049
bl@@	O	-1	20003049
ished	O	-1	20003049
el@@	O	-1	20003049
im@@	O	-1	20003049
in@@	O	-1	20003049
ation	O	-1	20003049
t@@	O	-1	20003049
(1@@	O	-1	20003049
/@@	O	-1	20003049
2)	O	-1	20003049
is	O	-1	20003049
3@@	O	-1	20003049
9@@	O	-1	20003049
-@@	O	-1	20003049
5@@	O	-1	20003049
1	O	-1	20003049
minutes	O	-1	20003049
[@@	O	-1	20003049
<	O	-1	20003049
or	O	-1	20003049
=	O	-1	20003049
18@@	O	-1	20003049
1	O	-1	20003049
minutes	O	-1	20003049
with	O	-1	20003049
hepatic	B-Disease	D008107	20003049
impair@@	I-Disease	-1	20003049
ment	I-Disease	-1	20003049
]@@	O	-1	20003049
).	O	-1	20003049
CONCLUSIONS:	O	-1	20003049
C@@	O	-1	20003049
or@@	O	-1	20003049
rel@@	O	-1	20003049
ation	O	-1	20003049
of	O	-1	20003049
plasma	O	-1	20003049
arg@@	B-Chemical	C031942	20003049
atro@@	I-Chemical	-1	20003049
b@@	I-Chemical	-1	20003049
an	I-Chemical	-1	20003049
concentration	O	-1	20003049
versus	O	-1	20003049
the	O	-1	20003049
patient@@	O	-1	20003049
's	O	-1	20003049
co@@	O	-1	20003049
ag@@	O	-1	20003049
ulation	O	-1	20003049
vari@@	O	-1	20003049
able@@	O	-1	20003049
s	O	-1	20003049
and	O	-1	20003049
clinical	O	-1	20003049
course	O	-1	20003049
suggest	O	-1	20003049
that	O	-1	20003049
prolonged	O	-1	20003049
elevated	O	-1	20003049
levels	O	-1	20003049
of	O	-1	20003049
plasma	O	-1	20003049
arg@@	B-Chemical	C031942	20003049
atro@@	I-Chemical	-1	20003049
b@@	I-Chemical	-1	20003049
an	I-Chemical	-1	20003049
may	O	-1	20003049
have	O	-1	20003049
cont@@	O	-1	20003049
ri@@	O	-1	20003049
but@@	O	-1	20003049
ed	O	-1	20003049
to	O	-1	20003049
the	O	-1	20003049
patient@@	O	-1	20003049
's	O	-1	20003049
exten@@	O	-1	20003049
ded	O	-1	20003049
co@@	B-Disease	D001778	20003049
ag@@	I-Disease	-1	20003049
ulo@@	I-Disease	-1	20003049
pathy	I-Disease	-1	20003049
.	O	-1	20003049
B@@	O	-1	20003049
ecause	O	-1	20003049
D@@	O	-1	20003049
TI@@	O	-1	20003049
s	O	-1	20003049
d@@	O	-1	20003049
o	O	-1	20003049
not	O	-1	20003049
have	O	-1	20003049
rever@@	O	-1	20003049
s@@	O	-1	20003049
al	O	-1	20003049
agent@@	O	-1	20003049
s,	O	-1	20003049
surg@@	O	-1	20003049
ical	O	-1	20003049
te@@	O	-1	20003049
am@@	O	-1	20003049
s	O	-1	20003049
and	O	-1	20003049
trans@@	O	-1	20003049
f@@	O	-1	20003049
usion	O	-1	20003049
ser@@	O	-1	20003049
v@@	O	-1	20003049
ic@@	O	-1	20003049
es	O	-1	20003049
should	O	-1	20003049
re@@	O	-1	20003049
ma@@	O	-1	20003049
in	O	-1	20003049
aw@@	O	-1	20003049
are	O	-1	20003049
of	O	-1	20003049
the	O	-1	20003049
possib@@	O	-1	20003049
ility	O	-1	20003049
of	O	-1	20003049
mas@@	O	-1	20003049
sive	O	-1	20003049
trans@@	O	-1	20003049
f@@	O	-1	20003049
usion	O	-1	20003049
events	O	-1	20003049
during	O	-1	20003049
anti@@	O	-1	20003049
co@@	O	-1	20003049
ag@@	O	-1	20003049
ulation	O	-1	20003049
with	O	-1	20003049
these	O	-1	20003049
agent@@	O	-1	20003049
s.	O	-1	20003049
This	O	-1	20003049
is	O	-1	20003049
the	O	-1	20003049
first	O	-1	20003049
report	O	-1	20003049
to	O	-1	20003049
meas@@	O	-1	20003049
ure	O	-1	20003049
plasma	O	-1	20003049
arg@@	B-Chemical	C031942	20003049
atro@@	I-Chemical	-1	20003049
b@@	I-Chemical	-1	20003049
an	I-Chemical	-1	20003049
concentration	O	-1	20003049
in	O	-1	20003049
the	O	-1	20003049
cont@@	O	-1	20003049
ex@@	O	-1	20003049
t	O	-1	20003049
of	O	-1	20003049
C@@	O	-1	20003049
P@@	O	-1	20003049
B	O	-1	20003049
and	O	-1	20003049
exten@@	O	-1	20003049
ded	O	-1	20003049
co@@	B-Disease	D001778	20003049
ag@@	I-Disease	-1	20003049
ulo@@	I-Disease	-1	20003049
pathy	I-Disease	-1	20003049
.	O	-1	20003049

An@@	B-Chemical	D000995	20196116
ti@@	I-Chemical	-1	20196116
tub@@	I-Chemical	-1	20196116
er@@	I-Chemical	-1	20196116
c@@	I-Chemical	-1	20196116
ulo@@	I-Chemical	-1	20196116
sis	I-Chemical	-1	20196116
therap@@	O	-1	20196116
y@@	O	-1	20196116
-induced	O	-1	20196116
acute	B-Disease	D017114	20196116
liver	I-Disease	-1	20196116
failure	I-Disease	-1	20196116
:	O	-1	20196116
mag@@	O	-1	20196116
nit@@	O	-1	20196116
u@@	O	-1	20196116
de@@	O	-1	20196116
,	O	-1	20196116
pro@@	O	-1	20196116
fi@@	O	-1	20196116
le@@	O	-1	20196116
,	O	-1	20196116
pro@@	O	-1	20196116
g@@	O	-1	20196116
no@@	O	-1	20196116
sis,	O	-1	20196116
and	O	-1	20196116
predic@@	O	-1	20196116
t@@	O	-1	20196116
ors	O	-1	20196116
of	O	-1	20196116
out@@	O	-1	20196116
co@@	O	-1	20196116
me.	O	-1	20196116
An@@	B-Chemical	D000995	20196116
ti@@	I-Chemical	-1	20196116
tub@@	I-Chemical	-1	20196116
er@@	I-Chemical	-1	20196116
c@@	I-Chemical	-1	20196116
ulo@@	I-Chemical	-1	20196116
sis	I-Chemical	-1	20196116
therapy	O	-1	20196116
(A@@	O	-1	20196116
T@@	O	-1	20196116
T@@	O	-1	20196116
)-@@	O	-1	20196116
associated	O	-1	20196116
acute	B-Disease	D017114	20196116
liver	I-Disease	-1	20196116
failure	I-Disease	-1	20196116
(A@@	O	-1	20196116
T@@	O	-1	20196116
T@@	O	-1	20196116
-	O	-1	20196116
AL@@	B-Disease	D017114	20196116
F	I-Disease	-1	20196116
)	O	-1	20196116
is	O	-1	20196116
the	O	-1	20196116
common@@	O	-1	20196116
est	O	-1	20196116
drug@@	O	-1	20196116
-induced	O	-1	20196116
AL@@	B-Disease	D017114	20196116
F	I-Disease	-1	20196116
in	O	-1	20196116
S@@	O	-1	20196116
ou@@	O	-1	20196116
th	O	-1	20196116
A@@	O	-1	20196116
sia.	O	-1	20196116
Pro@@	O	-1	20196116
sp@@	O	-1	20196116
ective	O	-1	20196116
studies	O	-1	20196116
on	O	-1	20196116
AT@@	O	-1	20196116
T@@	O	-1	20196116
-	O	-1	20196116
AL@@	B-Disease	D017114	20196116
F	I-Disease	-1	20196116
are	O	-1	20196116
l@@	O	-1	20196116
ac@@	O	-1	20196116
k@@	O	-1	20196116
ing.	O	-1	20196116
The	O	-1	20196116
current	O	-1	20196116
study	O	-1	20196116
pro@@	O	-1	20196116
sp@@	O	-1	20196116
ectively	O	-1	20196116
evaluated	O	-1	20196116
the	O	-1	20196116
mag@@	O	-1	20196116
nit@@	O	-1	20196116
u@@	O	-1	20196116
de@@	O	-1	20196116
,	O	-1	20196116
clinical	O	-1	20196116
cour@@	O	-1	20196116
se@@	O	-1	20196116
,	O	-1	20196116
out@@	O	-1	20196116
co@@	O	-1	20196116
me,	O	-1	20196116
and	O	-1	20196116
pro@@	O	-1	20196116
gn@@	O	-1	20196116
os@@	O	-1	20196116
tic	O	-1	20196116
factors	O	-1	20196116
in	O	-1	20196116
AT@@	O	-1	20196116
T@@	O	-1	20196116
-	O	-1	20196116
AL@@	B-Disease	D017114	20196116
F	I-Disease	-1	20196116
.	O	-1	20196116
F@@	O	-1	20196116
rom	O	-1	20196116
J@@	O	-1	20196116
an@@	O	-1	20196116
u@@	O	-1	20196116
ary	O	-1	20196116
19@@	O	-1	20196116
8@@	O	-1	20196116
6	O	-1	20196116
to	O	-1	20196116
J@@	O	-1	20196116
an@@	O	-1	20196116
u@@	O	-1	20196116
ary	O	-1	20196116
20@@	O	-1	20196116
0@@	O	-1	20196116
9@@	O	-1	20196116
,	O	-1	20196116
12@@	O	-1	20196116
2@@	O	-1	20196116
3	O	-1	20196116
con@@	O	-1	20196116
sec@@	O	-1	20196116
utive	O	-1	20196116
AL@@	B-Disease	D017114	20196116
F	I-Disease	-1	20196116
patients	O	-1	20196116
were	O	-1	20196116
evalu@@	O	-1	20196116
ated@@	O	-1	20196116
:	O	-1	20196116
AT@@	O	-1	20196116
T	O	-1	20196116
alone	O	-1	20196116
was	O	-1	20196116
the	O	-1	20196116
cause	O	-1	20196116
in	O	-1	20196116
7@@	O	-1	20196116
0	O	-1	20196116
(@@	O	-1	20196116
5.@@	O	-1	20196116
7@@	O	-1	20196116
%)	O	-1	20196116
patients.	O	-1	20196116
A@@	O	-1	20196116
no@@	O	-1	20196116
ther	O	-1	20196116
15	O	-1	20196116
(1@@	O	-1	20196116
.@@	O	-1	20196116
2@@	O	-1	20196116
%)	O	-1	20196116
had	O	-1	20196116
AT@@	O	-1	20196116
T	O	-1	20196116
and	O	-1	20196116
sim@@	O	-1	20196116
ult@@	O	-1	20196116
aneous	O	-1	20196116
hepatitis	B-Disease	D006525	20196116
vi@@	I-Disease	-1	20196116
ru@@	I-Disease	-1	20196116
s	I-Disease	-1	20196116
inf@@	I-Disease	-1	20196116
ection	I-Disease	-1	20196116
.	O	-1	20196116
In	O	-1	20196116
4@@	O	-1	20196116
4	O	-1	20196116
(6@@	O	-1	20196116
2.@@	O	-1	20196116
8@@	O	-1	20196116
%)	O	-1	20196116
patients,	O	-1	20196116
AT@@	O	-1	20196116
T	O	-1	20196116
was	O	-1	20196116
prescri@@	O	-1	20196116
bed	O	-1	20196116
em@@	O	-1	20196116
pi@@	O	-1	20196116
r@@	O	-1	20196116
ically	O	-1	20196116
without	O	-1	20196116
def@@	O	-1	20196116
in@@	O	-1	20196116
itive	O	-1	20196116
evidence	O	-1	20196116
of	O	-1	20196116
tub@@	B-Disease	D014376	20196116
er@@	I-Disease	-1	20196116
c@@	I-Disease	-1	20196116
ulo@@	I-Disease	-1	20196116
sis	I-Disease	-1	20196116
.	O	-1	20196116
AT@@	O	-1	20196116
T@@	O	-1	20196116
-	O	-1	20196116
AL@@	B-Disease	D017114	20196116
F	I-Disease	-1	20196116
patients	O	-1	20196116
were	O	-1	20196116
youn@@	O	-1	20196116
g@@	O	-1	20196116
er	O	-1	20196116
(3@@	O	-1	20196116
2.@@	O	-1	20196116
8@@	O	-1	20196116
7	O	-1	20196116
[@@	O	-1	20196116
+/@@	O	-1	20196116
-1@@	O	-1	20196116
5.@@	O	-1	20196116
8@@	O	-1	20196116
]	O	-1	20196116
year@@	O	-1	20196116
s),	O	-1	20196116
and	O	-1	20196116
4@@	O	-1	20196116
9	O	-1	20196116
(@@	O	-1	20196116
7@@	O	-1	20196116
0@@	O	-1	20196116
%)	O	-1	20196116
of	O	-1	20196116
the@@	O	-1	20196116
m	O	-1	20196116
were	O	-1	20196116
wom@@	O	-1	20196116
en@@	O	-1	20196116
.	O	-1	20196116
M@@	O	-1	20196116
ost	O	-1	20196116
had	O	-1	20196116
hyper@@	O	-1	20196116
acute	O	-1	20196116
present@@	O	-1	20196116
ation@@	O	-1	20196116
;	O	-1	20196116
the	O	-1	20196116
median	O	-1	20196116
ic@@	B-Disease	D007565	20196116
ter@@	I-Disease	-1	20196116
us	I-Disease	-1	20196116
encephalo@@	B-Disease	D001927	20196116
pathy	I-Disease	-1	20196116
interv@@	O	-1	20196116
al	O	-1	20196116
was	O	-1	20196116
4.@@	O	-1	20196116
5	O	-1	20196116
(@@	O	-1	20196116
0-@@	O	-1	20196116
3@@	O	-1	20196116
0@@	O	-1	20196116
)	O	-1	20196116
days.	O	-1	20196116
The	O	-1	20196116
median	O	-1	20196116
duration	O	-1	20196116
of	O	-1	20196116
AT@@	O	-1	20196116
T	O	-1	20196116
before	O	-1	20196116
AL@@	B-Disease	D017114	20196116
F	I-Disease	-1	20196116
was	O	-1	20196116
30	O	-1	20196116
(@@	O	-1	20196116
7-@@	O	-1	20196116
3@@	O	-1	20196116
50@@	O	-1	20196116
)	O	-1	20196116
days.	O	-1	20196116
A@@	O	-1	20196116
t	O	-1	20196116
present@@	O	-1	20196116
ation,	O	-1	20196116
adv@@	O	-1	20196116
anced	O	-1	20196116
encephalo@@	B-Disease	D001927	20196116
pathy	I-Disease	-1	20196116
and	O	-1	20196116
cerebral	B-Disease	D001929	20196116
e@@	I-Disease	-1	20196116
de@@	I-Disease	-1	20196116
ma	I-Disease	-1	20196116
were	O	-1	20196116
present	O	-1	20196116
in	O	-1	20196116
5@@	O	-1	20196116
1	O	-1	20196116
(@@	O	-1	20196116
7@@	O	-1	20196116
6@@	O	-1	20196116
%)	O	-1	20196116
and	O	-1	20196116
2@@	O	-1	20196116
9	O	-1	20196116
(4@@	O	-1	20196116
1.@@	O	-1	20196116
4@@	O	-1	20196116
%)	O	-1	20196116
patients,	O	-1	20196116
respectively.	O	-1	20196116
G@@	B-Disease	D006471	20196116
ast@@	I-Disease	-1	20196116
ro@@	I-Disease	-1	20196116
in@@	I-Disease	-1	20196116
test@@	I-Disease	-1	20196116
inal	I-Disease	-1	20196116
ble@@	I-Disease	-1	20196116
ed	I-Disease	-1	20196116
,	O	-1	20196116
seizures	B-Disease	D012640	20196116
,	O	-1	20196116
inf@@	B-Disease	D007239	20196116
ection	I-Disease	-1	20196116
,	O	-1	20196116
and	O	-1	20196116
acute	B-Disease	D058186	20196116
renal	I-Disease	-1	20196116
failure	I-Disease	-1	20196116
were	O	-1	20196116
doc@@	O	-1	20196116
um@@	O	-1	20196116
ent@@	O	-1	20196116
ed	O	-1	20196116
in	O	-1	20196116
seven	O	-1	20196116
(@@	O	-1	20196116
10@@	O	-1	20196116
%),	O	-1	20196116
five	O	-1	20196116
(@@	O	-1	20196116
7.@@	O	-1	20196116
1@@	O	-1	20196116
%),	O	-1	20196116
2@@	O	-1	20196116
6	O	-1	20196116
(3@@	O	-1	20196116
7.@@	O	-1	20196116
1@@	O	-1	20196116
%),	O	-1	20196116
and	O	-1	20196116
seven	O	-1	20196116
(@@	O	-1	20196116
10@@	O	-1	20196116
%)	O	-1	20196116
patients,	O	-1	20196116
respectively.	O	-1	20196116
Com@@	O	-1	20196116
pared	O	-1	20196116
with	O	-1	20196116
hepatitis	B-Disease	D016751	20196116
E	I-Disease	-1	20196116
vi@@	O	-1	20196116
ru@@	O	-1	20196116
s	O	-1	20196116
(@@	O	-1	20196116
H@@	O	-1	20196116
E@@	O	-1	20196116
V@@	O	-1	20196116
)	O	-1	20196116
and	O	-1	20196116
non-@@	O	-1	20196116
A	O	-1	20196116
non-@@	O	-1	20196116
E@@	O	-1	20196116
-induced	O	-1	20196116
AL@@	B-Disease	D017114	20196116
F	I-Disease	-1	20196116
,	O	-1	20196116
AT@@	O	-1	20196116
T@@	O	-1	20196116
-	O	-1	20196116
AL@@	B-Disease	D017114	20196116
F	I-Disease	-1	20196116
patients	O	-1	20196116
had	O	-1	20196116
ne@@	O	-1	20196116
arly	O	-1	20196116
similar	O	-1	20196116
present@@	O	-1	20196116
ations	O	-1	20196116
ex@@	O	-1	20196116
cep@@	O	-1	20196116
t	O	-1	20196116
for	O	-1	20196116
ol@@	O	-1	20196116
der	O	-1	20196116
age	O	-1	20196116
and	O	-1	20196116
less	O	-1	20196116
elev@@	O	-1	20196116
ation	O	-1	20196116
of	O	-1	20196116
liver	O	-1	20196116
enzym@@	O	-1	20196116
es.	O	-1	20196116
The	O	-1	20196116
mor@@	O	-1	20196116
t@@	O	-1	20196116
ality	O	-1	20196116
rate	O	-1	20196116
among	O	-1	20196116
patients	O	-1	20196116
with	O	-1	20196116
AT@@	O	-1	20196116
T@@	O	-1	20196116
-	O	-1	20196116
AL@@	B-Disease	D017114	20196116
F	I-Disease	-1	20196116
was	O	-1	20196116
high	O	-1	20196116
(6@@	O	-1	20196116
7.@@	O	-1	20196116
1@@	O	-1	20196116
%,	O	-1	20196116
n	O	-1	20196116
=	O	-1	20196116
4@@	O	-1	20196116
7@@	O	-1	20196116
),	O	-1	20196116
and	O	-1	20196116
only	O	-1	20196116
2@@	O	-1	20196116
3	O	-1	20196116
(3@@	O	-1	20196116
2.@@	O	-1	20196116
9@@	O	-1	20196116
%)	O	-1	20196116
patients	O	-1	20196116
reco@@	O	-1	20196116
vered	O	-1	20196116
with	O	-1	20196116
med@@	O	-1	20196116
ical	O	-1	20196116
treatment.	O	-1	20196116
In	O	-1	20196116
mul@@	O	-1	20196116
tiv@@	O	-1	20196116
ari@@	O	-1	20196116
ate	O	-1	20196116
analy@@	O	-1	20196116
sis,	O	-1	20196116
three	O	-1	20196116
factors	O	-1	20196116
in@@	O	-1	20196116
depend@@	O	-1	20196116
ently	O	-1	20196116
predic@@	O	-1	20196116
ted	O	-1	20196116
mor@@	O	-1	20196116
t@@	O	-1	20196116
al@@	O	-1	20196116
it@@	O	-1	20196116
y@@	O	-1	20196116
:	O	-1	20196116
serum	O	-1	20196116
bil@@	B-Chemical	D001663	20196116
i@@	I-Chemical	-1	20196116
ru@@	I-Chemical	-1	20196116
bin	I-Chemical	-1	20196116
(@@	O	-1	20196116
>@@	O	-1	20196116
or@@	O	-1	20196116
=@@	O	-1	20196116
1@@	O	-1	20196116
0.@@	O	-1	20196116
8	O	-1	20196116
mg/d@@	O	-1	20196116
L@@	O	-1	20196116
),	O	-1	20196116
pro@@	O	-1	20196116
throm@@	O	-1	20196116
bin	O	-1	20196116
time	O	-1	20196116
(P@@	O	-1	20196116
T)	O	-1	20196116
prolong@@	O	-1	20196116
ation	O	-1	20196116
(@@	O	-1	20196116
>@@	O	-1	20196116
or@@	O	-1	20196116
=@@	O	-1	20196116
2@@	O	-1	20196116
6	O	-1	20196116
second@@	O	-1	20196116
s),	O	-1	20196116
and	O	-1	20196116
gra@@	O	-1	20196116
de	O	-1	20196116
II@@	O	-1	20196116
I@@	O	-1	20196116
/@@	O	-1	20196116
IV	O	-1	20196116
encephalo@@	B-Disease	D001927	20196116
pathy	I-Disease	-1	20196116
at	O	-1	20196116
present@@	O	-1	20196116
ation.	O	-1	20196116
CONCLUSION:	O	-1	20196116
AT@@	O	-1	20196116
T@@	O	-1	20196116
-	O	-1	20196116
AL@@	B-Disease	D017114	20196116
F	I-Disease	-1	20196116
con@@	O	-1	20196116
sti@@	O	-1	20196116
t@@	O	-1	20196116
ut@@	O	-1	20196116
ed	O	-1	20196116
5.@@	O	-1	20196116
7@@	O	-1	20196116
%	O	-1	20196116
of	O	-1	20196116
AL@@	B-Disease	D017114	20196116
F	I-Disease	-1	20196116
at	O	-1	20196116
our	O	-1	20196116
c@@	O	-1	20196116
ent@@	O	-1	20196116
er	O	-1	20196116
and	O	-1	20196116
had	O	-1	20196116
a	O	-1	20196116
high	O	-1	20196116
mor@@	O	-1	20196116
t@@	O	-1	20196116
ality	O	-1	20196116
rat@@	O	-1	20196116
e.	O	-1	20196116
B@@	O	-1	20196116
ecause	O	-1	20196116
the	O	-1	20196116
mor@@	O	-1	20196116
t@@	O	-1	20196116
ality	O	-1	20196116
rate	O	-1	20196116
is	O	-1	20196116
so	O	-1	20196116
high@@	O	-1	20196116
,	O	-1	20196116
determin@@	O	-1	20196116
ing	O	-1	20196116
which	O	-1	20196116
factors	O	-1	20196116
are	O	-1	20196116
predic@@	O	-1	20196116
t@@	O	-1	20196116
ors	O	-1	20196116
is	O	-1	20196116
less	O	-1	20196116
import@@	O	-1	20196116
ant@@	O	-1	20196116
.	O	-1	20196116
A	O	-1	20196116
high	O	-1	20196116
pro@@	O	-1	20196116
por@@	O	-1	20196116
tion	O	-1	20196116
of	O	-1	20196116
patients	O	-1	20196116
had	O	-1	20196116
consum@@	O	-1	20196116
ed	O	-1	20196116
AT@@	O	-1	20196116
T	O	-1	20196116
em@@	O	-1	20196116
pi@@	O	-1	20196116
r@@	O	-1	20196116
ic@@	O	-1	20196116
ally,	O	-1	20196116
which	O	-1	20196116
could	O	-1	20196116
have	O	-1	20196116
been	O	-1	20196116
prevent@@	O	-1	20196116
ed.	O	-1	20196116

C@@	B-Disease	D002493	20470218
entr@@	I-Disease	-1	20470218
al	I-Disease	-1	20470218
ner@@	I-Disease	-1	20470218
v@@	I-Disease	-1	20470218
ous	I-Disease	-1	20470218
system	I-Disease	-1	20470218
complications	I-Disease	-1	20470218
during	O	-1	20470218
treatment	O	-1	20470218
of	O	-1	20470218
acute	B-Disease	D054198	20470218
lymph@@	I-Disease	-1	20470218
ob@@	I-Disease	-1	20470218
las@@	I-Disease	-1	20470218
tic	I-Disease	-1	20470218
leuk@@	I-Disease	-1	20470218
emia	I-Disease	-1	20470218
in	O	-1	20470218
a	O	-1	20470218
single	O	-1	20470218
pe@@	O	-1	20470218
di@@	O	-1	20470218
atric	O	-1	20470218
insti@@	O	-1	20470218
tu@@	O	-1	20470218
tion.	O	-1	20470218
C@@	B-Disease	D002493	20470218
entr@@	I-Disease	-1	20470218
al	I-Disease	-1	20470218
ner@@	I-Disease	-1	20470218
v@@	I-Disease	-1	20470218
ous	I-Disease	-1	20470218
system	I-Disease	-1	20470218
(C@@	I-Disease	-1	20470218
N@@	I-Disease	-1	20470218
S)	I-Disease	-1	20470218
complications	I-Disease	-1	20470218
during	O	-1	20470218
treatment	O	-1	20470218
of	O	-1	20470218
child@@	O	-1	20470218
ho@@	O	-1	20470218
od	O	-1	20470218
acute	B-Disease	D054198	20470218
lymph@@	I-Disease	-1	20470218
ob@@	I-Disease	-1	20470218
las@@	I-Disease	-1	20470218
tic	I-Disease	-1	20470218
leuk@@	I-Disease	-1	20470218
emia	I-Disease	-1	20470218
(	O	-1	20470218
AL@@	B-Disease	D054198	20470218
L	I-Disease	-1	20470218
)	O	-1	20470218
re@@	O	-1	20470218
ma@@	O	-1	20470218
in	O	-1	20470218
a	O	-1	20470218
ch@@	O	-1	20470218
all@@	O	-1	20470218
en@@	O	-1	20470218
g@@	O	-1	20470218
ing	O	-1	20470218
clinical	O	-1	20470218
pro@@	O	-1	20470218
ble@@	O	-1	20470218
m.	O	-1	20470218
O@@	O	-1	20470218
ut@@	O	-1	20470218
com@@	O	-1	20470218
e	O	-1	20470218
impro@@	O	-1	20470218
vement	O	-1	20470218
with	O	-1	20470218
more	O	-1	20470218
int@@	O	-1	20470218
en@@	O	-1	20470218
sive	O	-1	20470218
chemotherapy	O	-1	20470218
has	O	-1	20470218
significantly	O	-1	20470218
increased	O	-1	20470218
the	O	-1	20470218
incidence	O	-1	20470218
and	O	-1	20470218
severity	O	-1	20470218
of	O	-1	20470218
adverse	O	-1	20470218
event@@	O	-1	20470218
s.	O	-1	20470218
This	O	-1	20470218
study	O	-1	20470218
analy@@	O	-1	20470218
zed	O	-1	20470218
the	O	-1	20470218
incidence	O	-1	20470218
of	O	-1	20470218
neurolog@@	B-Disease	D002493	20470218
ical	I-Disease	-1	20470218
complications	I-Disease	-1	20470218
during	O	-1	20470218
AL@@	B-Disease	D054198	20470218
L	I-Disease	-1	20470218
treatment	O	-1	20470218
in	O	-1	20470218
a	O	-1	20470218
single	O	-1	20470218
pe@@	O	-1	20470218
di@@	O	-1	20470218
atric	O	-1	20470218
insti@@	O	-1	20470218
tu@@	O	-1	20470218
tion,	O	-1	20470218
foc@@	O	-1	20470218
using	O	-1	20470218
on	O	-1	20470218
clin@@	O	-1	20470218
ic@@	O	-1	20470218
al,	O	-1	20470218
radi@@	O	-1	20470218
olog@@	O	-1	20470218
ic@@	O	-1	20470218
al,	O	-1	20470218
and	O	-1	20470218
electro@@	O	-1	20470218
physi@@	O	-1	20470218
ological	O	-1	20470218
find@@	O	-1	20470218
ing@@	O	-1	20470218
s.	O	-1	20470218
E@@	O	-1	20470218
x@@	O	-1	20470218
cl@@	O	-1	20470218
usion	O	-1	20470218
c@@	O	-1	20470218
rit@@	O	-1	20470218
er@@	O	-1	20470218
ia	O	-1	20470218
included	O	-1	20470218
C@@	O	-1	20470218
N@@	O	-1	20470218
S	O	-1	20470218
leuk@@	B-Disease	D017254	20470218
em@@	I-Disease	-1	20470218
ic	I-Disease	-1	20470218
inf@@	I-Disease	-1	20470218
iltration	I-Disease	-1	20470218
at	O	-1	20470218
diagno@@	O	-1	20470218
sis,	O	-1	20470218
therap@@	O	-1	20470218
y-@@	O	-1	20470218
related	O	-1	20470218
peripheral	B-Disease	D010523	20470218
neuropathy	I-Disease	-1	20470218
,	O	-1	20470218
lat@@	O	-1	20470218
e-@@	O	-1	20470218
onset	O	-1	20470218
encephalo@@	B-Disease	D001927	20470218
pathy	I-Disease	-1	20470218
,	O	-1	20470218
or	O	-1	20470218
long-term	O	-1	20470218
neuro@@	B-Disease	D002493	20470218
cognitive	I-Disease	-1	20470218
def@@	I-Disease	-1	20470218
ects	I-Disease	-1	20470218
.	O	-1	20470218
D@@	O	-1	20470218
uring	O	-1	20470218
a	O	-1	20470218
9@@	O	-1	20470218
-@@	O	-1	20470218
year	O	-1	20470218
perio@@	O	-1	20470218
d,	O	-1	20470218
we	O	-1	20470218
ret@@	O	-1	20470218
ro@@	O	-1	20470218
sp@@	O	-1	20470218
ectively	O	-1	20470218
coll@@	O	-1	20470218
ected	O	-1	20470218
2@@	O	-1	20470218
7	O	-1	20470218
neurolog@@	O	-1	20470218
ical	O	-1	20470218
events	O	-1	20470218
(1@@	O	-1	20470218
1@@	O	-1	20470218
%)	O	-1	20470218
in	O	-1	20470218
as	O	-1	20470218
man@@	O	-1	20470218
y	O	-1	20470218
patients,	O	-1	20470218
from	O	-1	20470218
25@@	O	-1	20470218
3	O	-1	20470218
children	O	-1	20470218
en@@	O	-1	20470218
ro@@	O	-1	20470218
lled	O	-1	20470218
in	O	-1	20470218
the	O	-1	20470218
AL@@	B-Disease	D054198	20470218
L	I-Disease	-1	20470218
fron@@	O	-1	20470218
t-@@	O	-1	20470218
line	O	-1	20470218
pro@@	O	-1	20470218
to@@	O	-1	20470218
co@@	O	-1	20470218
l@@	O	-1	20470218
.	O	-1	20470218
C@@	O	-1	20470218
N@@	O	-1	20470218
S	O	-1	20470218
complications	O	-1	20470218
included	O	-1	20470218
po@@	O	-1	20470218
ster@@	O	-1	20470218
ior	O	-1	20470218
reversible	O	-1	20470218
leuk@@	B-Disease	D056784	20470218
o@@	I-Disease	-1	20470218
encephalo@@	I-Disease	-1	20470218
pathy	I-Disease	-1	20470218
syndrome	O	-1	20470218
(n	O	-1	20470218
=	O	-1	20470218
10@@	O	-1	20470218
),	O	-1	20470218
strok@@	B-Disease	D020521	20470218
e	I-Disease	-1	20470218
(n	O	-1	20470218
=	O	-1	20470218
5@@	O	-1	20470218
),	O	-1	20470218
tempor@@	B-Disease	D004833	20470218
al	I-Disease	-1	20470218
lo@@	I-Disease	-1	20470218
be	I-Disease	-1	20470218
epilep@@	I-Disease	-1	20470218
sy	I-Disease	-1	20470218
(n	O	-1	20470218
=	O	-1	20470218
2@@	O	-1	20470218
),	O	-1	20470218
high-dose	O	-1	20470218
meth@@	B-Chemical	D008727	20470218
ot@@	I-Chemical	-1	20470218
re@@	I-Chemical	-1	20470218
x@@	I-Chemical	-1	20470218
ate	I-Chemical	-1	20470218
toxicity	B-Disease	D064420	20470218
(n	O	-1	20470218
=	O	-1	20470218
2@@	O	-1	20470218
),	O	-1	20470218
syndrome	O	-1	20470218
of	O	-1	20470218
in@@	B-Disease	D007177	20470218
appro@@	I-Disease	-1	20470218
pri@@	I-Disease	-1	20470218
ate	I-Disease	-1	20470218
anti@@	I-Disease	-1	20470218
di@@	I-Disease	-1	20470218
ure@@	I-Disease	-1	20470218
tic	I-Disease	-1	20470218
h@@	I-Disease	-1	20470218
orm@@	I-Disease	-1	20470218
one	I-Disease	-1	20470218
secre@@	I-Disease	-1	20470218
tion	I-Disease	-1	20470218
(n	O	-1	20470218
=	O	-1	20470218
1),	O	-1	20470218
and	O	-1	20470218
other	O	-1	20470218
un@@	O	-1	20470218
cl@@	O	-1	20470218
assi@@	O	-1	20470218
fied	O	-1	20470218
events	O	-1	20470218
(n	O	-1	20470218
=	O	-1	20470218
7@@	O	-1	20470218
).	O	-1	20470218
In	O	-1	20470218
concl@@	O	-1	20470218
u@@	O	-1	20470218
sion,	O	-1	20470218
C@@	O	-1	20470218
N@@	O	-1	20470218
S	O	-1	20470218
complications	O	-1	20470218
are	O	-1	20470218
frequent	O	-1	20470218
events	O	-1	20470218
during	O	-1	20470218
AL@@	B-Disease	D054198	20470218
L	I-Disease	-1	20470218
therapy,	O	-1	20470218
and	O	-1	20470218
requ@@	O	-1	20470218
ir@@	O	-1	20470218
e	O	-1	20470218
ra@@	O	-1	20470218
pid	O	-1	20470218
det@@	O	-1	20470218
ection	O	-1	20470218
and	O	-1	20470218
pro@@	O	-1	20470218
m@@	O	-1	20470218
p@@	O	-1	20470218
t	O	-1	20470218
treatment	O	-1	20470218
to	O	-1	20470218
lim@@	O	-1	20470218
it	O	-1	20470218
per@@	O	-1	20470218
man@@	O	-1	20470218
ent	O	-1	20470218
dam@@	O	-1	20470218
age.	O	-1	20470218

S@@	O	-1	20722491
af@@	O	-1	20722491
ety	O	-1	20722491
of	O	-1	20722491
cap@@	B-Chemical	C110904	20722491
ec@@	I-Chemical	-1	20722491
it@@	I-Chemical	-1	20722491
ab@@	I-Chemical	-1	20722491
ine	I-Chemical	-1	20722491
:	O	-1	20722491
a	O	-1	20722491
revie@@	O	-1	20722491
w@@	O	-1	20722491
.	O	-1	20722491
I@@	O	-1	20722491
MP@@	O	-1	20722491
O@@	O	-1	20722491
R@@	O	-1	20722491
T@@	O	-1	20722491
AN@@	O	-1	20722491
C@@	O	-1	20722491
E	O	-1	20722491
O@@	O	-1	20722491
F	O	-1	20722491
T@@	O	-1	20722491
H@@	O	-1	20722491
E	O	-1	20722491
F@@	O	-1	20722491
I@@	O	-1	20722491
E@@	O	-1	20722491
L@@	O	-1	20722491
D@@	O	-1	20722491
:	O	-1	20722491
F@@	B-Chemical	-1	20722491
lu@@	I-Chemical	-1	20722491
o@@	I-Chemical	-1	20722491
ro@@	I-Chemical	-1	20722491
pyri@@	I-Chemical	-1	20722491
mid@@	I-Chemical	-1	20722491
in@@	I-Chemical	-1	20722491
es	I-Chemical	-1	20722491
,	O	-1	20722491
in	O	-1	20722491
partic@@	O	-1	20722491
ular	O	-1	20722491
5-@@	B-Chemical	D005472	20722491
fluoro@@	I-Chemical	-1	20722491
urac@@	I-Chemical	-1	20722491
il	I-Chemical	-1	20722491
(	O	-1	20722491
5-@@	B-Chemical	D005472	20722491
F@@	I-Chemical	-1	20722491
U	I-Chemical	-1	20722491
),	O	-1	20722491
have	O	-1	20722491
been	O	-1	20722491
the	O	-1	20722491
main@@	O	-1	20722491
st@@	O	-1	20722491
ay	O	-1	20722491
of	O	-1	20722491
treatment	O	-1	20722491
for	O	-1	20722491
several	O	-1	20722491
sol@@	O	-1	20722491
id	O	-1	20722491
tu@@	B-Disease	D009369	20722491
mor@@	I-Disease	-1	20722491
s	I-Disease	-1	20722491
,	O	-1	20722491
including	O	-1	20722491
co@@	B-Disease	D015179	20722491
lo@@	I-Disease	-1	20722491
rec@@	I-Disease	-1	20722491
t@@	I-Disease	-1	20722491
al,	I-Disease	-1	20722491
b@@	I-Disease	-1	20722491
reas@@	I-Disease	-1	20722491
t	I-Disease	-1	20722491
and	I-Disease	-1	20722491
he@@	I-Disease	-1	20722491
ad	I-Disease	-1	20722491
and	I-Disease	-1	20722491
nec@@	I-Disease	-1	20722491
k	I-Disease	-1	20722491
canc@@	I-Disease	-1	20722491
ers	I-Disease	-1	20722491
co@@	B-Disease	D001943	20722491
lo@@	I-Disease	-1	20722491
rec@@	I-Disease	-1	20722491
t@@	I-Disease	-1	20722491
al,	I-Disease	-1	20722491
b@@	I-Disease	-1	20722491
reas@@	I-Disease	-1	20722491
t	I-Disease	-1	20722491
and	I-Disease	-1	20722491
he@@	I-Disease	-1	20722491
ad	I-Disease	-1	20722491
and	I-Disease	-1	20722491
nec@@	I-Disease	-1	20722491
k	I-Disease	-1	20722491
canc@@	I-Disease	-1	20722491
ers	I-Disease	-1	20722491
co@@	B-Disease	D006258	20722491
lo@@	I-Disease	-1	20722491
rec@@	I-Disease	-1	20722491
t@@	I-Disease	-1	20722491
al,	I-Disease	-1	20722491
b@@	I-Disease	-1	20722491
reas@@	I-Disease	-1	20722491
t	I-Disease	-1	20722491
and	I-Disease	-1	20722491
he@@	I-Disease	-1	20722491
ad	I-Disease	-1	20722491
and	I-Disease	-1	20722491
nec@@	I-Disease	-1	20722491
k	I-Disease	-1	20722491
canc@@	I-Disease	-1	20722491
ers	I-Disease	-1	20722491
,	O	-1	20722491
for	O	-1	20722491
>	O	-1	20722491
40	O	-1	20722491
year@@	O	-1	20722491
s.	O	-1	20722491
A@@	O	-1	20722491
R@@	O	-1	20722491
E@@	O	-1	20722491
A@@	O	-1	20722491
S	O	-1	20722491
CO@@	O	-1	20722491
V@@	O	-1	20722491
E@@	O	-1	20722491
R@@	O	-1	20722491
E@@	O	-1	20722491
D	O	-1	20722491
I@@	O	-1	20722491
N	O	-1	20722491
T@@	O	-1	20722491
H@@	O	-1	20722491
I@@	O	-1	20722491
S	O	-1	20722491
R@@	O	-1	20722491
E@@	O	-1	20722491
V@@	O	-1	20722491
I@@	O	-1	20722491
E@@	O	-1	20722491
W@@	O	-1	20722491
:	O	-1	20722491
This	O	-1	20722491
ar@@	O	-1	20722491
tic@@	O	-1	20722491
le	O	-1	20722491
revie@@	O	-1	20722491
w@@	O	-1	20722491
s	O	-1	20722491
the	O	-1	20722491
pharmac@@	O	-1	20722491
ology	O	-1	20722491
and	O	-1	20722491
efficacy	O	-1	20722491
of	O	-1	20722491
cap@@	B-Chemical	C110904	20722491
ec@@	I-Chemical	-1	20722491
it@@	I-Chemical	-1	20722491
ab@@	I-Chemical	-1	20722491
ine	I-Chemical	-1	20722491
with	O	-1	20722491
a	O	-1	20722491
spec@@	O	-1	20722491
ial	O	-1	20722491
em@@	O	-1	20722491
pha@@	O	-1	20722491
sis	O	-1	20722491
on	O	-1	20722491
its	O	-1	20722491
saf@@	O	-1	20722491
et@@	O	-1	20722491
y.	O	-1	20722491
W@@	O	-1	20722491
H@@	O	-1	20722491
A@@	O	-1	20722491
T	O	-1	20722491
T@@	O	-1	20722491
H@@	O	-1	20722491
E	O	-1	20722491
R@@	O	-1	20722491
E@@	O	-1	20722491
AD@@	O	-1	20722491
E@@	O	-1	20722491
R	O	-1	20722491
W@@	O	-1	20722491
I@@	O	-1	20722491
L@@	O	-1	20722491
L	O	-1	20722491
G@@	O	-1	20722491
A@@	O	-1	20722491
IN@@	O	-1	20722491
:	O	-1	20722491
The	O	-1	20722491
re@@	O	-1	20722491
ad@@	O	-1	20722491
er	O	-1	20722491
wil@@	O	-1	20722491
l	O	-1	20722491
g@@	O	-1	20722491
ain	O	-1	20722491
bet@@	O	-1	20722491
ter	O	-1	20722491
in@@	O	-1	20722491
si@@	O	-1	20722491
ght	O	-1	20722491
into	O	-1	20722491
the	O	-1	20722491
safety	O	-1	20722491
of	O	-1	20722491
cap@@	B-Chemical	C110904	20722491
ec@@	I-Chemical	-1	20722491
it@@	I-Chemical	-1	20722491
ab@@	I-Chemical	-1	20722491
ine	I-Chemical	-1	20722491
in	O	-1	20722491
spec@@	O	-1	20722491
ial	O	-1	20722491
po@@	O	-1	20722491
pul@@	O	-1	20722491
ations	O	-1	20722491
such	O	-1	20722491
as	O	-1	20722491
patients	O	-1	20722491
with	O	-1	20722491
adv@@	O	-1	20722491
anced	O	-1	20722491
age,	O	-1	20722491
renal	B-Disease	D007674	20722491
and	I-Disease	-1	20722491
kidney	I-Disease	-1	20722491
disease	I-Disease	-1	20722491
.	O	-1	20722491
We	O	-1	20722491
also	O	-1	20722491
expl@@	O	-1	20722491
or@@	O	-1	20722491
e	O	-1	20722491
different	O	-1	20722491
dos@@	O	-1	20722491
ing	O	-1	20722491
and	O	-1	20722491
sch@@	O	-1	20722491
ed@@	O	-1	20722491
ul@@	O	-1	20722491
es	O	-1	20722491
of	O	-1	20722491
cap@@	B-Chemical	C110904	20722491
ec@@	I-Chemical	-1	20722491
it@@	I-Chemical	-1	20722491
ab@@	I-Chemical	-1	20722491
ine	I-Chemical	-1	20722491
administr@@	O	-1	20722491
ation.	O	-1	20722491
TA@@	O	-1	20722491
K@@	O	-1	20722491
E	O	-1	20722491
HO@@	O	-1	20722491
M@@	O	-1	20722491
E	O	-1	20722491
M@@	O	-1	20722491
ES@@	O	-1	20722491
S@@	O	-1	20722491
A@@	O	-1	20722491
G@@	O	-1	20722491
E:	O	-1	20722491
C@@	B-Chemical	C110904	20722491
ap@@	I-Chemical	-1	20722491
ec@@	I-Chemical	-1	20722491
it@@	I-Chemical	-1	20722491
ab@@	I-Chemical	-1	20722491
ine	I-Chemical	-1	20722491
is	O	-1	20722491
an	O	-1	20722491
oral	O	-1	20722491
pro@@	O	-1	20722491
drug	O	-1	20722491
of	O	-1	20722491
5-@@	B-Chemical	D005472	20722491
F@@	I-Chemical	-1	20722491
U	I-Chemical	-1	20722491
and	O	-1	20722491
was	O	-1	20722491
developed	O	-1	20722491
to	O	-1	20722491
ful@@	O	-1	20722491
f@@	O	-1	20722491
il@@	O	-1	20722491
l	O	-1	20722491
the	O	-1	20722491
need	O	-1	20722491
for	O	-1	20722491
a	O	-1	20722491
more	O	-1	20722491
con@@	O	-1	20722491
ven@@	O	-1	20722491
i@@	O	-1	20722491
ent	O	-1	20722491
therapy	O	-1	20722491
and	O	-1	20722491
prov@@	O	-1	20722491
ide	O	-1	20722491
an	O	-1	20722491
improved	O	-1	20722491
saf@@	O	-1	20722491
et@@	O	-1	20722491
y@@	O	-1	20722491
/@@	O	-1	20722491
efficacy	O	-1	20722491
pro@@	O	-1	20722491
fi@@	O	-1	20722491
le@@	O	-1	20722491
.	O	-1	20722491
It	O	-1	20722491
has	O	-1	20722491
shown	O	-1	20722491
pro@@	O	-1	20722491
mis@@	O	-1	20722491
ing	O	-1	20722491
results	O	-1	20722491
alone	O	-1	20722491
or	O	-1	20722491
in	O	-1	20722491
combination	O	-1	20722491
with	O	-1	20722491
other	O	-1	20722491
chemo@@	O	-1	20722491
therapeutic	O	-1	20722491
agents	O	-1	20722491
in	O	-1	20722491
co@@	B-Disease	D015179	20722491
lo@@	I-Disease	-1	20722491
rec@@	I-Disease	-1	20722491
t@@	I-Disease	-1	20722491
al,	I-Disease	-1	20722491
b@@	I-Disease	-1	20722491
re@@	I-Disease	-1	20722491
ast@@	I-Disease	-1	20722491
,	I-Disease	-1	20722491
p@@	I-Disease	-1	20722491
anc@@	I-Disease	-1	20722491
re@@	I-Disease	-1	20722491
ati@@	I-Disease	-1	20722491
co@@	I-Disease	-1	20722491
bil@@	I-Disease	-1	20722491
i@@	I-Disease	-1	20722491
ar@@	I-Disease	-1	20722491
y,	I-Disease	-1	20722491
gast@@	I-Disease	-1	20722491
r@@	I-Disease	-1	20722491
ic@@	I-Disease	-1	20722491
,	I-Disease	-1	20722491
renal	I-Disease	-1	20722491
cell	I-Disease	-1	20722491
and	I-Disease	-1	20722491
he@@	I-Disease	-1	20722491
ad	I-Disease	-1	20722491
and	I-Disease	-1	20722491
nec@@	I-Disease	-1	20722491
k	I-Disease	-1	20722491
canc@@	I-Disease	-1	20722491
ers	I-Disease	-1	20722491
co@@	B-Disease	D001943	20722491
lo@@	I-Disease	-1	20722491
rec@@	I-Disease	-1	20722491
t@@	I-Disease	-1	20722491
al,	I-Disease	-1	20722491
b@@	I-Disease	-1	20722491
re@@	I-Disease	-1	20722491
ast@@	I-Disease	-1	20722491
,	I-Disease	-1	20722491
p@@	I-Disease	-1	20722491
anc@@	I-Disease	-1	20722491
re@@	I-Disease	-1	20722491
ati@@	I-Disease	-1	20722491
co@@	I-Disease	-1	20722491
bil@@	I-Disease	-1	20722491
i@@	I-Disease	-1	20722491
ar@@	I-Disease	-1	20722491
y,	I-Disease	-1	20722491
gast@@	I-Disease	-1	20722491
r@@	I-Disease	-1	20722491
ic@@	I-Disease	-1	20722491
,	I-Disease	-1	20722491
renal	I-Disease	-1	20722491
cell	I-Disease	-1	20722491
and	I-Disease	-1	20722491
he@@	I-Disease	-1	20722491
ad	I-Disease	-1	20722491
and	I-Disease	-1	20722491
nec@@	I-Disease	-1	20722491
k	I-Disease	-1	20722491
canc@@	I-Disease	-1	20722491
ers	I-Disease	-1	20722491
co@@	B-Disease	D010190	20722491
lo@@	I-Disease	-1	20722491
rec@@	I-Disease	-1	20722491
t@@	I-Disease	-1	20722491
al,	I-Disease	-1	20722491
b@@	I-Disease	-1	20722491
re@@	I-Disease	-1	20722491
ast@@	I-Disease	-1	20722491
,	I-Disease	-1	20722491
p@@	I-Disease	-1	20722491
anc@@	I-Disease	-1	20722491
re@@	I-Disease	-1	20722491
ati@@	I-Disease	-1	20722491
co@@	I-Disease	-1	20722491
bil@@	I-Disease	-1	20722491
i@@	I-Disease	-1	20722491
ar@@	I-Disease	-1	20722491
y,	I-Disease	-1	20722491
gast@@	I-Disease	-1	20722491
r@@	I-Disease	-1	20722491
ic@@	I-Disease	-1	20722491
,	I-Disease	-1	20722491
renal	I-Disease	-1	20722491
cell	I-Disease	-1	20722491
and	I-Disease	-1	20722491
he@@	I-Disease	-1	20722491
ad	I-Disease	-1	20722491
and	I-Disease	-1	20722491
nec@@	I-Disease	-1	20722491
k	I-Disease	-1	20722491
canc@@	I-Disease	-1	20722491
ers	I-Disease	-1	20722491
co@@	B-Disease	D013274	20722491
lo@@	I-Disease	-1	20722491
rec@@	I-Disease	-1	20722491
t@@	I-Disease	-1	20722491
al,	I-Disease	-1	20722491
b@@	I-Disease	-1	20722491
re@@	I-Disease	-1	20722491
ast@@	I-Disease	-1	20722491
,	I-Disease	-1	20722491
p@@	I-Disease	-1	20722491
anc@@	I-Disease	-1	20722491
re@@	I-Disease	-1	20722491
ati@@	I-Disease	-1	20722491
co@@	I-Disease	-1	20722491
bil@@	I-Disease	-1	20722491
i@@	I-Disease	-1	20722491
ar@@	I-Disease	-1	20722491
y,	I-Disease	-1	20722491
gast@@	I-Disease	-1	20722491
r@@	I-Disease	-1	20722491
ic@@	I-Disease	-1	20722491
,	I-Disease	-1	20722491
renal	I-Disease	-1	20722491
cell	I-Disease	-1	20722491
and	I-Disease	-1	20722491
he@@	I-Disease	-1	20722491
ad	I-Disease	-1	20722491
and	I-Disease	-1	20722491
nec@@	I-Disease	-1	20722491
k	I-Disease	-1	20722491
canc@@	I-Disease	-1	20722491
ers	I-Disease	-1	20722491
co@@	B-Disease	D002292	20722491
lo@@	I-Disease	-1	20722491
rec@@	I-Disease	-1	20722491
t@@	I-Disease	-1	20722491
al,	I-Disease	-1	20722491
b@@	I-Disease	-1	20722491
re@@	I-Disease	-1	20722491
ast@@	I-Disease	-1	20722491
,	I-Disease	-1	20722491
p@@	I-Disease	-1	20722491
anc@@	I-Disease	-1	20722491
re@@	I-Disease	-1	20722491
ati@@	I-Disease	-1	20722491
co@@	I-Disease	-1	20722491
bil@@	I-Disease	-1	20722491
i@@	I-Disease	-1	20722491
ar@@	I-Disease	-1	20722491
y,	I-Disease	-1	20722491
gast@@	I-Disease	-1	20722491
r@@	I-Disease	-1	20722491
ic@@	I-Disease	-1	20722491
,	I-Disease	-1	20722491
renal	I-Disease	-1	20722491
cell	I-Disease	-1	20722491
and	I-Disease	-1	20722491
he@@	I-Disease	-1	20722491
ad	I-Disease	-1	20722491
and	I-Disease	-1	20722491
nec@@	I-Disease	-1	20722491
k	I-Disease	-1	20722491
canc@@	I-Disease	-1	20722491
ers	I-Disease	-1	20722491
co@@	B-Disease	D006258	20722491
lo@@	I-Disease	-1	20722491
rec@@	I-Disease	-1	20722491
t@@	I-Disease	-1	20722491
al,	I-Disease	-1	20722491
b@@	I-Disease	-1	20722491
re@@	I-Disease	-1	20722491
ast@@	I-Disease	-1	20722491
,	I-Disease	-1	20722491
p@@	I-Disease	-1	20722491
anc@@	I-Disease	-1	20722491
re@@	I-Disease	-1	20722491
ati@@	I-Disease	-1	20722491
co@@	I-Disease	-1	20722491
bil@@	I-Disease	-1	20722491
i@@	I-Disease	-1	20722491
ar@@	I-Disease	-1	20722491
y,	I-Disease	-1	20722491
gast@@	I-Disease	-1	20722491
r@@	I-Disease	-1	20722491
ic@@	I-Disease	-1	20722491
,	I-Disease	-1	20722491
renal	I-Disease	-1	20722491
cell	I-Disease	-1	20722491
and	I-Disease	-1	20722491
he@@	I-Disease	-1	20722491
ad	I-Disease	-1	20722491
and	I-Disease	-1	20722491
nec@@	I-Disease	-1	20722491
k	I-Disease	-1	20722491
canc@@	I-Disease	-1	20722491
ers	I-Disease	-1	20722491
.	O	-1	20722491
The	O	-1	20722491
most	O	-1	20722491
common@@	O	-1	20722491
ly	O	-1	20722491
reported	O	-1	20722491
toxic	O	-1	20722491
effects	O	-1	20722491
of	O	-1	20722491
cap@@	B-Chemical	C110904	20722491
ec@@	I-Chemical	-1	20722491
it@@	I-Chemical	-1	20722491
ab@@	I-Chemical	-1	20722491
ine	I-Chemical	-1	20722491
are	O	-1	20722491
di@@	B-Disease	D003967	20722491
ar@@	I-Disease	-1	20722491
r@@	I-Disease	-1	20722491
he@@	I-Disease	-1	20722491
a	I-Disease	-1	20722491
,	O	-1	20722491
nausea	B-Disease	D009325	20722491
,	O	-1	20722491
v@@	B-Disease	D014839	20722491
om@@	I-Disease	-1	20722491
it@@	I-Disease	-1	20722491
ing	I-Disease	-1	20722491
,	O	-1	20722491
st@@	B-Disease	D013280	20722491
om@@	I-Disease	-1	20722491
ati@@	I-Disease	-1	20722491
tis	I-Disease	-1	20722491
and	O	-1	20722491
h@@	B-Disease	D060831	20722491
and@@	I-Disease	-1	20722491
-@@	I-Disease	-1	20722491
fo@@	I-Disease	-1	20722491
o@@	I-Disease	-1	20722491
t	I-Disease	-1	20722491
syndrome	I-Disease	-1	20722491
.	O	-1	20722491
C@@	B-Chemical	C110904	20722491
ap@@	I-Chemical	-1	20722491
ec@@	I-Chemical	-1	20722491
it@@	I-Chemical	-1	20722491
ab@@	I-Chemical	-1	20722491
ine	I-Chemical	-1	20722491
has	O	-1	20722491
a	O	-1	20722491
we@@	O	-1	20722491
ll@@	O	-1	20722491
-@@	O	-1	20722491
est@@	O	-1	20722491
abl@@	O	-1	20722491
ished	O	-1	20722491
safety	O	-1	20722491
prof@@	O	-1	20722491
ile	O	-1	20722491
and	O	-1	20722491
can	O	-1	20722491
be	O	-1	20722491
given	O	-1	20722491
saf@@	O	-1	20722491
ely	O	-1	20722491
to	O	-1	20722491
patients	O	-1	20722491
with	O	-1	20722491
adv@@	O	-1	20722491
anced	O	-1	20722491
age,	O	-1	20722491
hepatic	B-Disease	D008107	20722491
and	I-Disease	-1	20722491
renal	I-Disease	-1	20722491
dysfunc@@	I-Disease	-1	20722491
tions	I-Disease	-1	20722491
hepatic	B-Disease	D007674	20722491
and	I-Disease	-1	20722491
renal	I-Disease	-1	20722491
dysfunc@@	I-Disease	-1	20722491
tions	I-Disease	-1	20722491
.	O	-1	20722491

Eff@@	O	-1	20882060
ects	O	-1	20882060
of	O	-1	20882060
p@@	O	-1	20882060
all@@	O	-1	20882060
idal	O	-1	20882060
neuro@@	B-Chemical	D009496	20882060
ten@@	I-Chemical	-1	20882060
s@@	I-Chemical	-1	20882060
in	I-Chemical	-1	20882060
on	O	-1	20882060
haloperidol	B-Chemical	D006220	20882060
-induced	O	-1	20882060
par@@	B-Disease	D002375	20882060
k@@	I-Disease	-1	20882060
inson@@	I-Disease	-1	20882060
i@@	I-Disease	-1	20882060
an	I-Disease	-1	20882060
cat@@	I-Disease	-1	20882060
al@@	I-Disease	-1	20882060
ep@@	I-Disease	-1	20882060
sy	I-Disease	-1	20882060
:	O	-1	20882060
behavioral	O	-1	20882060
and	O	-1	20882060
electro@@	O	-1	20882060
physi@@	O	-1	20882060
ological	O	-1	20882060
studi@@	O	-1	20882060
es.	O	-1	20882060
OBJECTIVE:	O	-1	20882060
The	O	-1	20882060
glo@@	O	-1	20882060
bu@@	O	-1	20882060
s	O	-1	20882060
p@@	O	-1	20882060
all@@	O	-1	20882060
id@@	O	-1	20882060
us	O	-1	20882060
pl@@	O	-1	20882060
ays	O	-1	20882060
a	O	-1	20882060
cri@@	O	-1	20882060
tical	O	-1	20882060
role	O	-1	20882060
in	O	-1	20882060
mo@@	O	-1	20882060
vement	O	-1	20882060
reg@@	O	-1	20882060
ul@@	O	-1	20882060
ation.	O	-1	20882060
Pre@@	O	-1	20882060
vi@@	O	-1	20882060
ous	O	-1	20882060
studies	O	-1	20882060
have	O	-1	20882060
indic@@	O	-1	20882060
ated	O	-1	20882060
that	O	-1	20882060
the	O	-1	20882060
glo@@	O	-1	20882060
bu@@	O	-1	20882060
s	O	-1	20882060
p@@	O	-1	20882060
all@@	O	-1	20882060
id@@	O	-1	20882060
us	O	-1	20882060
recei@@	O	-1	20882060
v@@	O	-1	20882060
es	O	-1	20882060
neuro@@	O	-1	20882060
ten@@	O	-1	20882060
s@@	O	-1	20882060
inergic	O	-1	20882060
in@@	O	-1	20882060
ner@@	O	-1	20882060
v@@	O	-1	20882060
ation	O	-1	20882060
from	O	-1	20882060
the	O	-1	20882060
striat@@	O	-1	20882060
um,	O	-1	20882060
and	O	-1	20882060
systemic	O	-1	20882060
administration	O	-1	20882060
of	O	-1	20882060
a	O	-1	20882060
neuro@@	B-Chemical	D009496	20882060
ten@@	I-Chemical	-1	20882060
s@@	I-Chemical	-1	20882060
in	I-Chemical	-1	20882060
an@@	O	-1	20882060
alo@@	O	-1	20882060
g	O	-1	20882060
could	O	-1	20882060
produce	O	-1	20882060
anti@@	O	-1	20882060
par@@	O	-1	20882060
k@@	O	-1	20882060
inson@@	O	-1	20882060
i@@	O	-1	20882060
an	O	-1	20882060
effects.	O	-1	20882060
The	O	-1	20882060
present	O	-1	20882060
study	O	-1	20882060
a@@	O	-1	20882060
im@@	O	-1	20882060
ed	O	-1	20882060
to	O	-1	20882060
investigate	O	-1	20882060
the	O	-1	20882060
effects	O	-1	20882060
of	O	-1	20882060
p@@	O	-1	20882060
all@@	O	-1	20882060
idal	O	-1	20882060
neuro@@	B-Chemical	D009496	20882060
ten@@	I-Chemical	-1	20882060
s@@	I-Chemical	-1	20882060
in	I-Chemical	-1	20882060
on	O	-1	20882060
haloperidol	B-Chemical	D006220	20882060
-induced	O	-1	20882060
par@@	B-Disease	D010302	20882060
k@@	I-Disease	-1	20882060
inson@@	I-Disease	-1	20882060
i@@	I-Disease	-1	20882060
an	I-Disease	-1	20882060
symptoms	I-Disease	-1	20882060
.	O	-1	20882060
METHODS:	O	-1	20882060
B@@	O	-1	20882060
e@@	O	-1	20882060
havi@@	O	-1	20882060
oral	O	-1	20882060
experim@@	O	-1	20882060
ents	O	-1	20882060
and	O	-1	20882060
electro@@	O	-1	20882060
physi@@	O	-1	20882060
ological	O	-1	20882060
recor@@	O	-1	20882060
d@@	O	-1	20882060
ings	O	-1	20882060
were	O	-1	20882060
performed	O	-1	20882060
in	O	-1	20882060
the	O	-1	20882060
present	O	-1	20882060
study.	O	-1	20882060
RESULTS:	O	-1	20882060
B@@	O	-1	20882060
il@@	O	-1	20882060
ateral	O	-1	20882060
infu@@	O	-1	20882060
sions	O	-1	20882060
of	O	-1	20882060
neuro@@	B-Chemical	D009496	20882060
ten@@	I-Chemical	-1	20882060
s@@	I-Chemical	-1	20882060
in	I-Chemical	-1	20882060
into	O	-1	20882060
the	O	-1	20882060
glo@@	O	-1	20882060
bu@@	O	-1	20882060
s	O	-1	20882060
p@@	O	-1	20882060
all@@	O	-1	20882060
id@@	O	-1	20882060
us	O	-1	20882060
reversed	O	-1	20882060
haloperidol	B-Chemical	D006220	20882060
-induced	O	-1	20882060
par@@	B-Disease	D002375	20882060
k@@	I-Disease	-1	20882060
inson@@	I-Disease	-1	20882060
i@@	I-Disease	-1	20882060
an	I-Disease	-1	20882060
cat@@	I-Disease	-1	20882060
al@@	I-Disease	-1	20882060
ep@@	I-Disease	-1	20882060
sy	I-Disease	-1	20882060
in	O	-1	20882060
rats.	O	-1	20882060
E@@	O	-1	20882060
l@@	O	-1	20882060
ect@@	O	-1	20882060
ro@@	O	-1	20882060
physi@@	O	-1	20882060
ological	O	-1	20882060
recor@@	O	-1	20882060
d@@	O	-1	20882060
ings	O	-1	20882060
showed	O	-1	20882060
that	O	-1	20882060
micro@@	O	-1	20882060
injection	O	-1	20882060
of	O	-1	20882060
neuro@@	B-Chemical	D009496	20882060
ten@@	I-Chemical	-1	20882060
s@@	I-Chemical	-1	20882060
in	I-Chemical	-1	20882060
induced	O	-1	20882060
ex@@	O	-1	20882060
cit@@	O	-1	20882060
ation	O	-1	20882060
of	O	-1	20882060
p@@	O	-1	20882060
all@@	O	-1	20882060
idal	O	-1	20882060
neuron@@	O	-1	20882060
s	O	-1	20882060
in	O	-1	20882060
the	O	-1	20882060
presence	O	-1	20882060
of	O	-1	20882060
systemic	O	-1	20882060
haloperidol	B-Chemical	D006220	20882060
administr@@	O	-1	20882060
ation.	O	-1	20882060
The	O	-1	20882060
neuro@@	B-Chemical	C079087	20882060
ten@@	I-Chemical	-1	20882060
s@@	I-Chemical	-1	20882060
in	I-Chemical	-1	20882060
ty@@	I-Chemical	-1	20882060
pe@@	I-Chemical	-1	20882060
-1	I-Chemical	-1	20882060
receptor	I-Chemical	-1	20882060
antagonist	I-Chemical	-1	20882060
SR@@	B-Chemical	C079087	20882060
4@@	I-Chemical	-1	20882060
8@@	I-Chemical	-1	20882060
6@@	I-Chemical	-1	20882060
9@@	I-Chemical	-1	20882060
2	I-Chemical	-1	20882060
block@@	O	-1	20882060
ed	O	-1	20882060
both	O	-1	20882060
the	O	-1	20882060
behavioral	O	-1	20882060
and	O	-1	20882060
the	O	-1	20882060
electro@@	O	-1	20882060
physi@@	O	-1	20882060
ological	O	-1	20882060
effects	O	-1	20882060
induced	O	-1	20882060
by	O	-1	20882060
neuro@@	B-Chemical	D009496	20882060
ten@@	I-Chemical	-1	20882060
s@@	I-Chemical	-1	20882060
in	I-Chemical	-1	20882060
.	O	-1	20882060
CONCLUSION:	O	-1	20882060
Ac@@	O	-1	20882060
tiv@@	O	-1	20882060
ation	O	-1	20882060
of	O	-1	20882060
p@@	O	-1	20882060
all@@	O	-1	20882060
idal	O	-1	20882060
neuro@@	B-Chemical	D009496	20882060
ten@@	I-Chemical	-1	20882060
s@@	I-Chemical	-1	20882060
in	I-Chemical	-1	20882060
receptors	O	-1	20882060
may	O	-1	20882060
be	O	-1	20882060
involved	O	-1	20882060
in	O	-1	20882060
neuro@@	B-Chemical	D009496	20882060
ten@@	I-Chemical	-1	20882060
s@@	I-Chemical	-1	20882060
in	I-Chemical	-1	20882060
-induced	O	-1	20882060
anti@@	O	-1	20882060
par@@	O	-1	20882060
k@@	O	-1	20882060
inson@@	O	-1	20882060
i@@	O	-1	20882060
an	O	-1	20882060
effects.	O	-1	20882060

An@@	O	-1	26094
ti@@	O	-1	26094
hypertensive	O	-1	26094
drugs	O	-1	26094
and	O	-1	26094
de@@	B-Disease	D003866	26094
pression	I-Disease	-1	26094
:	O	-1	26094
a	O	-1	26094
re@@	O	-1	26094
ap@@	O	-1	26094
pra@@	O	-1	26094
is@@	O	-1	26094
al.	O	-1	26094
E@@	O	-1	26094
igh@@	O	-1	26094
ty-@@	O	-1	26094
n@@	O	-1	26094
ine	O	-1	26094
new	O	-1	26094
ref@@	O	-1	26094
er@@	O	-1	26094
ral	O	-1	26094
hypertensive	B-Disease	D006973	26094
out@@	O	-1	26094
-@@	O	-1	26094
patients	O	-1	26094
and	O	-1	26094
4@@	O	-1	26094
6	O	-1	26094
new	O	-1	26094
ref@@	O	-1	26094
er@@	O	-1	26094
ral	O	-1	26094
non@@	O	-1	26094
-	O	-1	26094
hypertensive	B-Disease	D006973	26094
chron@@	O	-1	26094
ically	O	-1	26094
physi@@	O	-1	26094
c@@	O	-1	26094
ally	O	-1	26094
il@@	O	-1	26094
l	O	-1	26094
out@@	O	-1	26094
-@@	O	-1	26094
patients	O	-1	26094
comple@@	O	-1	26094
ted	O	-1	26094
a	O	-1	26094
mo@@	O	-1	26094
od	O	-1	26094
rat@@	O	-1	26094
ing	O	-1	26094
s@@	O	-1	26094
cal@@	O	-1	26094
e	O	-1	26094
at	O	-1	26094
reg@@	O	-1	26094
ular	O	-1	26094
interv@@	O	-1	26094
als	O	-1	26094
for	O	-1	26094
one	O	-1	26094
year@@	O	-1	26094
.	O	-1	26094
The	O	-1	26094
results	O	-1	26094
showed	O	-1	26094
a	O	-1	26094
high	O	-1	26094
prev@@	O	-1	26094
al@@	O	-1	26094
ence	O	-1	26094
of	O	-1	26094
de@@	B-Disease	D003866	26094
pression	I-Disease	-1	26094
in	O	-1	26094
both	O	-1	26094
groups	O	-1	26094
of	O	-1	26094
patients,	O	-1	26094
with	O	-1	26094
no	O	-1	26094
pre@@	O	-1	26094
p@@	O	-1	26094
on@@	O	-1	26094
der@@	O	-1	26094
ance	O	-1	26094
in	O	-1	26094
the	O	-1	26094
hypertensive	B-Disease	D006973	26094
group.	O	-1	26094
H@@	B-Disease	D006973	26094
y@@	I-Disease	-1	26094
per@@	I-Disease	-1	26094
ten@@	I-Disease	-1	26094
sive	I-Disease	-1	26094
patients	O	-1	26094
with	O	-1	26094
psych@@	B-Disease	D001523	26094
i@@	I-Disease	-1	26094
atric	I-Disease	-1	26094
hist@@	O	-1	26094
or@@	O	-1	26094
i@@	O	-1	26094
es	O	-1	26094
had	O	-1	26094
a	O	-1	26094
higher	O	-1	26094
prev@@	O	-1	26094
al@@	O	-1	26094
ence	O	-1	26094
of	O	-1	26094
de@@	B-Disease	D003866	26094
pression	I-Disease	-1	26094
than	O	-1	26094
the	O	-1	26094
compar@@	O	-1	26094
ison	O	-1	26094
patients.	O	-1	26094
This	O	-1	26094
was	O	-1	26094
ac@@	O	-1	26094
coun@@	O	-1	26094
ted	O	-1	26094
for	O	-1	26094
by	O	-1	26094
a	O	-1	26094
significant	O	-1	26094
number	O	-1	26094
of	O	-1	26094
de@@	B-Disease	D003866	26094
pres@@	I-Disease	-1	26094
sions	I-Disease	-1	26094
occur@@	O	-1	26094
r@@	O	-1	26094
ing	O	-1	26094
in	O	-1	26094
meth@@	B-Chemical	D008750	26094
yl	I-Chemical	-1	26094
dopa	I-Chemical	-1	26094
treated	O	-1	26094
patients	O	-1	26094
with	O	-1	26094
psych@@	B-Disease	D001523	26094
i@@	I-Disease	-1	26094
atric	I-Disease	-1	26094
hist@@	O	-1	26094
or@@	O	-1	26094
i@@	O	-1	26094
es.	O	-1	26094

P@@	O	-1	322550
ul@@	O	-1	322550
monary	O	-1	322550
sh@@	O	-1	322550
un@@	O	-1	322550
t	O	-1	322550
and	O	-1	322550
cardiovascular	O	-1	322550
responses	O	-1	322550
to	O	-1	322550
C@@	O	-1	322550
PA@@	O	-1	322550
P	O	-1	322550
during	O	-1	322550
nitro@@	B-Chemical	D009599	322550
pr@@	I-Chemical	-1	322550
us@@	I-Chemical	-1	322550
side	I-Chemical	-1	322550
-induced	O	-1	322550
hypotension	B-Disease	D007022	322550
.	O	-1	322550
The	O	-1	322550
effects	O	-1	322550
of	O	-1	322550
continu@@	O	-1	322550
ous	O	-1	322550
positive	O	-1	322550
a@@	O	-1	322550
ir@@	O	-1	322550
w@@	O	-1	322550
ay	O	-1	322550
pressure	O	-1	322550
(C@@	O	-1	322550
PA@@	O	-1	322550
P)	O	-1	322550
on	O	-1	322550
cardiovascular	O	-1	322550
dynam@@	O	-1	322550
ic@@	O	-1	322550
s	O	-1	322550
and	O	-1	322550
pulmonary	O	-1	322550
sh@@	O	-1	322550
un@@	O	-1	322550
t	O	-1	322550
(@@	O	-1	322550
Q@@	O	-1	322550
S@@	O	-1	322550
/@@	O	-1	322550
Q@@	O	-1	322550
T)	O	-1	322550
were	O	-1	322550
investigated	O	-1	322550
in	O	-1	322550
12	O	-1	322550
dog@@	O	-1	322550
s	O	-1	322550
before	O	-1	322550
and	O	-1	322550
during	O	-1	322550
sodium	B-Chemical	D009599	322550
nitro@@	I-Chemical	-1	322550
pr@@	I-Chemical	-1	322550
us@@	I-Chemical	-1	322550
side	I-Chemical	-1	322550
infusion	O	-1	322550
that	O	-1	322550
decreased	O	-1	322550
mean	O	-1	322550
arterial	O	-1	322550
blood	O	-1	322550
pressure	O	-1	322550
4@@	O	-1	322550
0-@@	O	-1	322550
50	O	-1	322550
per	O	-1	322550
c@@	O	-1	322550
ent@@	O	-1	322550
.	O	-1	322550
B@@	O	-1	322550
e@@	O	-1	322550
fore	O	-1	322550
nitro@@	B-Chemical	D009599	322550
pr@@	I-Chemical	-1	322550
us@@	I-Chemical	-1	322550
side	I-Chemical	-1	322550
infu@@	O	-1	322550
sion,	O	-1	322550
5	O	-1	322550
c@@	O	-1	322550
m	O	-1	322550
H@@	B-Chemical	D014867	322550
2@@	I-Chemical	-1	322550
O	I-Chemical	-1	322550
C@@	O	-1	322550
PA@@	O	-1	322550
P	O	-1	322550
significant@@	O	-1	322550
ly,	O	-1	322550
P	O	-1	322550
less	O	-1	322550
than	O	-1	322550
.@@	O	-1	322550
0@@	O	-1	322550
5,	O	-1	322550
decreased	O	-1	322550
arterial	O	-1	322550
blood	O	-1	322550
pressu@@	O	-1	322550
re,	O	-1	322550
but	O	-1	322550
did	O	-1	322550
not	O	-1	322550
significantly	O	-1	322550
al@@	O	-1	322550
ter	O	-1	322550
heart	O	-1	322550
rat@@	O	-1	322550
e,	O	-1	322550
cardiac	O	-1	322550
out@@	O	-1	322550
p@@	O	-1	322550
ut@@	O	-1	322550
,	O	-1	322550
systemic	O	-1	322550
vascular	O	-1	322550
resist@@	O	-1	322550
ance@@	O	-1	322550
,	O	-1	322550
or	O	-1	322550
Q@@	O	-1	322550
S@@	O	-1	322550
/@@	O	-1	322550
Q@@	O	-1	322550
T@@	O	-1	322550
.	O	-1	322550
T@@	O	-1	322550
en	O	-1	322550
c@@	O	-1	322550
m	O	-1	322550
H@@	B-Chemical	D014867	322550
2@@	I-Chemical	-1	322550
O	I-Chemical	-1	322550
C@@	O	-1	322550
PA@@	O	-1	322550
P	O	-1	322550
before	O	-1	322550
nitro@@	B-Chemical	D009599	322550
pr@@	I-Chemical	-1	322550
us@@	I-Chemical	-1	322550
side	I-Chemical	-1	322550
infusion	O	-1	322550
produced	O	-1	322550
a	O	-1	322550
further	O	-1	322550
decrease	B-Disease	D007022	322550
in	I-Disease	-1	322550
arterial	I-Disease	-1	322550
blood	I-Disease	-1	322550
pressure	I-Disease	-1	322550
and	O	-1	322550
significantly	O	-1	322550
increased	O	-1	322550
heart	O	-1	322550
rate	O	-1	322550
and	O	-1	322550
decreased	B-Disease	D002303	322550
cardiac	I-Disease	-1	322550
out@@	I-Disease	-1	322550
pu@@	I-Disease	-1	322550
t	I-Disease	-1	322550
and	O	-1	322550
Q@@	O	-1	322550
S@@	O	-1	322550
/@@	O	-1	322550
Q@@	O	-1	322550
T@@	O	-1	322550
.	O	-1	322550
N@@	B-Chemical	D009599	322550
it@@	I-Chemical	-1	322550
ro@@	I-Chemical	-1	322550
pr@@	I-Chemical	-1	322550
us@@	I-Chemical	-1	322550
side	I-Chemical	-1	322550
caused	O	-1	322550
significant	O	-1	322550
decreas@@	B-Disease	D007022	322550
es	I-Disease	-1	322550
in	I-Disease	-1	322550
arterial	I-Disease	-1	322550
blood	I-Disease	-1	322550
pressure	I-Disease	-1	322550
and	O	-1	322550
systemic	O	-1	322550
vascular	O	-1	322550
resist@@	O	-1	322550
ance	O	-1	322550
and	O	-1	322550
increases	O	-1	322550
in	O	-1	322550
heart	O	-1	322550
rat@@	O	-1	322550
e,	O	-1	322550
but	O	-1	322550
did	O	-1	322550
not	O	-1	322550
change	O	-1	322550
cardiac	O	-1	322550
out@@	O	-1	322550
pu@@	O	-1	322550
t	O	-1	322550
or	O	-1	322550
Q@@	O	-1	322550
S@@	O	-1	322550
/@@	O	-1	322550
Q@@	O	-1	322550
T@@	O	-1	322550
.	O	-1	322550
F@@	O	-1	322550
i@@	O	-1	322550
ve	O	-1	322550
c@@	O	-1	322550
m	O	-1	322550
H@@	B-Chemical	D014867	322550
2@@	I-Chemical	-1	322550
O	I-Chemical	-1	322550
C@@	O	-1	322550
PA@@	O	-1	322550
P	O	-1	322550
during	O	-1	322550
nitro@@	B-Chemical	D009599	322550
pr@@	I-Chemical	-1	322550
us@@	I-Chemical	-1	322550
side	I-Chemical	-1	322550
did	O	-1	322550
not	O	-1	322550
further	O	-1	322550
al@@	O	-1	322550
ter	O	-1	322550
any	O	-1	322550
of	O	-1	322550
the	O	-1	322550
ab@@	O	-1	322550
o@@	O	-1	322550
ve@@	O	-1	322550
-@@	O	-1	322550
men@@	O	-1	322550
tion@@	O	-1	322550
ed	O	-1	322550
vari@@	O	-1	322550
abl@@	O	-1	322550
es.	O	-1	322550
However,	O	-1	322550
10	O	-1	322550
c@@	O	-1	322550
m	O	-1	322550
H@@	B-Chemical	D014867	322550
2@@	I-Chemical	-1	322550
O	I-Chemical	-1	322550
C@@	O	-1	322550
PA@@	O	-1	322550
P	O	-1	322550
decreased	O	-1	322550
arterial	O	-1	322550
blood	O	-1	322550
pressu@@	O	-1	322550
re,	O	-1	322550
cardiac	O	-1	322550
out@@	O	-1	322550
p@@	O	-1	322550
ut@@	O	-1	322550
,	O	-1	322550
and	O	-1	322550
Q@@	O	-1	322550
S@@	O	-1	322550
/@@	O	-1	322550
Q@@	O	-1	322550
T@@	O	-1	322550
.	O	-1	322550
These	O	-1	322550
data	O	-1	322550
indicate	O	-1	322550
that	O	-1	322550
nitro@@	B-Chemical	D009599	322550
pr@@	I-Chemical	-1	322550
us@@	I-Chemical	-1	322550
side	I-Chemical	-1	322550
infusion	O	-1	322550
rat@@	O	-1	322550
es	O	-1	322550
that	O	-1	322550
decrease	O	-1	322550
mean	O	-1	322550
arterial	O	-1	322550
blood	O	-1	322550
pressure	O	-1	322550
by	O	-1	322550
4@@	O	-1	322550
0-@@	O	-1	322550
50	O	-1	322550
per	O	-1	322550
c@@	O	-1	322550
ent	O	-1	322550
d@@	O	-1	322550
o	O	-1	322550
not	O	-1	322550
change	O	-1	322550
cardiac	O	-1	322550
out@@	O	-1	322550
pu@@	O	-1	322550
t	O	-1	322550
or	O	-1	322550
Q@@	O	-1	322550
S@@	O	-1	322550
/@@	O	-1	322550
Q@@	O	-1	322550
T@@	O	-1	322550
.	O	-1	322550
D@@	O	-1	322550
uring	O	-1	322550
nitro@@	B-Chemical	D009599	322550
pr@@	I-Chemical	-1	322550
us@@	I-Chemical	-1	322550
side	I-Chemical	-1	322550
infusion	O	-1	322550
low	O	-1	322550
levels	O	-1	322550
of	O	-1	322550
C@@	O	-1	322550
PA@@	O	-1	322550
P	O	-1	322550
d@@	O	-1	322550
o	O	-1	322550
not	O	-1	322550
mark@@	O	-1	322550
ed@@	O	-1	322550
ly	O	-1	322550
al@@	O	-1	322550
ter	O	-1	322550
cardiovascular	O	-1	322550
dynam@@	O	-1	322550
ic@@	O	-1	322550
s,	O	-1	322550
but	O	-1	322550
high	O	-1	322550
levels	O	-1	322550
of	O	-1	322550
C@@	O	-1	322550
PA@@	O	-1	322550
P	O	-1	322550
(10	O	-1	322550
c@@	O	-1	322550
m	O	-1	322550
H@@	B-Chemical	D014867	322550
2@@	I-Chemical	-1	322550
O	I-Chemical	-1	322550
),	O	-1	322550
while	O	-1	322550
decreas@@	O	-1	322550
ing	O	-1	322550
Q@@	O	-1	322550
S@@	O	-1	322550
/@@	O	-1	322550
Q@@	O	-1	322550
T@@	O	-1	322550
,	O	-1	322550
produce	O	-1	322550
mark@@	O	-1	322550
ed	O	-1	322550
decreas@@	B-Disease	D007022	322550
es	I-Disease	-1	322550
in	I-Disease	-1	322550
arterial	I-Disease	-1	322550
blood	I-Disease	-1	322550
pressure	I-Disease	-1	322550
and	I-Disease	-1	322550
cardiac	I-Disease	-1	322550
out@@	I-Disease	-1	322550
pu@@	I-Disease	-1	322550
t	I-Disease	-1	322550
decreas@@	B-Disease	D002303	322550
es	I-Disease	-1	322550
in	I-Disease	-1	322550
arterial	I-Disease	-1	322550
blood	I-Disease	-1	322550
pressure	I-Disease	-1	322550
and	I-Disease	-1	322550
cardiac	I-Disease	-1	322550
out@@	I-Disease	-1	322550
pu@@	I-Disease	-1	322550
t	I-Disease	-1	322550
.	O	-1	322550

M@@	O	-1	869641
edi@@	O	-1	869641
ation	O	-1	869641
of	O	-1	869641
enhanced	O	-1	869641
ref@@	O	-1	869641
le@@	O	-1	869641
x	O	-1	869641
v@@	O	-1	869641
ag@@	O	-1	869641
al	O	-1	869641
brady@@	B-Disease	D001919	869641
cardia	I-Disease	-1	869641
by	O	-1	869641
L-@@	B-Chemical	D007980	869641
dopa	I-Chemical	-1	869641
vi@@	O	-1	869641
a	O	-1	869641
central	O	-1	869641
dopamine	B-Chemical	D004298	869641
formation	O	-1	869641
in	O	-1	869641
dog@@	O	-1	869641
s.	O	-1	869641
L-@@	B-Chemical	D007980	869641
D@@	I-Chemical	-1	869641
op@@	I-Chemical	-1	869641
a	I-Chemical	-1	869641
(@@	O	-1	869641
5	O	-1	869641
mg/kg	O	-1	869641
i.v@@	O	-1	869641
.)	O	-1	869641
decreased	O	-1	869641
blood	O	-1	869641
pressure	O	-1	869641
and	O	-1	869641
heart	O	-1	869641
rate	O	-1	869641
after	O	-1	869641
extrac@@	O	-1	869641
e@@	O	-1	869641
rebral	O	-1	869641
dec@@	O	-1	869641
arb@@	O	-1	869641
ox@@	O	-1	869641
yl@@	O	-1	869641
ase	O	-1	869641
inhibition	O	-1	869641
with	O	-1	869641
M@@	B-Chemical	D002230	869641
K@@	I-Chemical	-1	869641
-@@	I-Chemical	-1	869641
4@@	I-Chemical	-1	869641
8@@	I-Chemical	-1	869641
6	I-Chemical	-1	869641
(2@@	O	-1	869641
5	O	-1	869641
mg/kg	O	-1	869641
i.v@@	O	-1	869641
.)	O	-1	869641
in	O	-1	869641
anesthe@@	O	-1	869641
ti@@	O	-1	869641
ze	O	-1	869641
MA@@	B-Chemical	D008995	869641
O	I-Chemical	-1	869641
-@@	O	-1	869641
inhibited	O	-1	869641
dog@@	O	-1	869641
s.	O	-1	869641
In	O	-1	869641
addi@@	O	-1	869641
tion,	O	-1	869641
ref@@	O	-1	869641
le@@	O	-1	869641
x	O	-1	869641
brady@@	B-Disease	D001919	869641
cardia	I-Disease	-1	869641
caused	O	-1	869641
by	O	-1	869641
injected	O	-1	869641
no@@	B-Chemical	D009638	869641
re@@	I-Chemical	-1	869641
p@@	I-Chemical	-1	869641
ine@@	I-Chemical	-1	869641
phrine	I-Chemical	-1	869641
was	O	-1	869641
significantly	O	-1	869641
enhanced	O	-1	869641
by	O	-1	869641
L-@@	B-Chemical	D007980	869641
dopa	I-Chemical	-1	869641
,	O	-1	869641
D@@	B-Chemical	D015103	869641
L-@@	I-Chemical	-1	869641
Th@@	I-Chemical	-1	869641
re@@	I-Chemical	-1	869641
o@@	I-Chemical	-1	869641
-@@	I-Chemical	-1	869641
di@@	I-Chemical	-1	869641
hydrox@@	I-Chemical	-1	869641
y@@	I-Chemical	-1	869641
phenyl@@	I-Chemical	-1	869641
ser@@	I-Chemical	-1	869641
ine	I-Chemical	-1	869641
had	O	-1	869641
no	O	-1	869641
effect	O	-1	869641
on	O	-1	869641
blood	O	-1	869641
pressu@@	O	-1	869641
re,	O	-1	869641
heart	O	-1	869641
rate	O	-1	869641
or	O	-1	869641
ref@@	O	-1	869641
le@@	O	-1	869641
x	O	-1	869641
responses	O	-1	869641
to	O	-1	869641
no@@	B-Chemical	D009638	869641
re@@	I-Chemical	-1	869641
p@@	I-Chemical	-1	869641
ine@@	I-Chemical	-1	869641
phrine	I-Chemical	-1	869641
.	O	-1	869641
F@@	B-Chemical	D005406	869641
L@@	I-Chemical	-1	869641
A@@	I-Chemical	-1	869641
-@@	I-Chemical	-1	869641
6@@	I-Chemical	-1	869641
3	I-Chemical	-1	869641
,	O	-1	869641
a	O	-1	869641
dopamine	B-Chemical	D004298	869641
-@@	O	-1	869641
beta-@@	O	-1	869641
oxid@@	O	-1	869641
ase	O	-1	869641
inhibitor@@	O	-1	869641
,	O	-1	869641
did	O	-1	869641
not	O	-1	869641
have	O	-1	869641
any	O	-1	869641
effect	O	-1	869641
on	O	-1	869641
the	O	-1	869641
hypotension	B-Disease	D007022	869641
,	O	-1	869641
brady@@	B-Disease	D001919	869641
cardia	I-Disease	-1	869641
or	O	-1	869641
ref@@	O	-1	869641
le@@	O	-1	869641
x@@	O	-1	869641
-@@	O	-1	869641
enh@@	O	-1	869641
anc@@	O	-1	869641
ing	O	-1	869641
effect	O	-1	869641
of	O	-1	869641
L-@@	B-Chemical	D007980	869641
dopa	I-Chemical	-1	869641
.	O	-1	869641
P@@	B-Chemical	D010868	869641
im@@	I-Chemical	-1	869641
o@@	I-Chemical	-1	869641
z@@	I-Chemical	-1	869641
ide	I-Chemical	-1	869641
did	O	-1	869641
not	O	-1	869641
aff@@	O	-1	869641
ect	O	-1	869641
the	O	-1	869641
ac@@	O	-1	869641
tions	O	-1	869641
of	O	-1	869641
L-@@	B-Chemical	D007980	869641
dopa	I-Chemical	-1	869641
on	O	-1	869641
blood	O	-1	869641
pressure	O	-1	869641
and	O	-1	869641
heart	O	-1	869641
rate	O	-1	869641
but	O	-1	869641
complete@@	O	-1	869641
ly	O	-1	869641
block@@	O	-1	869641
ed	O	-1	869641
the	O	-1	869641
enh@@	O	-1	869641
ance@@	O	-1	869641
ment	O	-1	869641
of	O	-1	869641
ref@@	O	-1	869641
le@@	O	-1	869641
x@@	O	-1	869641
es.	O	-1	869641
R@@	O	-1	869641
em@@	O	-1	869641
o@@	O	-1	869641
v@@	O	-1	869641
al	O	-1	869641
of	O	-1	869641
the	O	-1	869641
ca@@	O	-1	869641
ro@@	O	-1	869641
ti@@	O	-1	869641
d	O	-1	869641
s@@	O	-1	869641
in@@	O	-1	869641
u@@	O	-1	869641
ses	O	-1	869641
caused	O	-1	869641
an	O	-1	869641
elev@@	O	-1	869641
ation	O	-1	869641
blood	O	-1	869641
pressure	O	-1	869641
and	O	-1	869641
heart	O	-1	869641
rate	O	-1	869641
and	O	-1	869641
abol@@	O	-1	869641
ished	O	-1	869641
the	O	-1	869641
negative	O	-1	869641
chron@@	O	-1	869641
ot@@	O	-1	869641
ro@@	O	-1	869641
p@@	O	-1	869641
ic	O	-1	869641
effect	O	-1	869641
of	O	-1	869641
no@@	B-Chemical	D009638	869641
re@@	I-Chemical	-1	869641
p@@	I-Chemical	-1	869641
ine@@	I-Chemical	-1	869641
phrine	I-Chemical	-1	869641
.	O	-1	869641
However,	O	-1	869641
L-@@	B-Chemical	D007980	869641
dopa	I-Chemical	-1	869641
re@@	O	-1	869641
sto@@	O	-1	869641
red	O	-1	869641
the	O	-1	869641
brady@@	B-Disease	D001919	869641
cardia	I-Disease	-1	869641
caused	O	-1	869641
by	O	-1	869641
no@@	B-Chemical	D009638	869641
re@@	I-Chemical	-1	869641
p@@	I-Chemical	-1	869641
ine@@	I-Chemical	-1	869641
phrine	I-Chemical	-1	869641
in	O	-1	869641
addition	O	-1	869641
to	O	-1	869641
decreas@@	O	-1	869641
ing	O	-1	869641
blood	O	-1	869641
pressure	O	-1	869641
and	O	-1	869641
heart	O	-1	869641
rat@@	O	-1	869641
e.	O	-1	869641
5-@@	B-Chemical	D006916	869641
H@@	I-Chemical	-1	869641
T@@	I-Chemical	-1	869641
P	I-Chemical	-1	869641
(@@	O	-1	869641
5	O	-1	869641
mg/kg	O	-1	869641
i.v@@	O	-1	869641
.)	O	-1	869641
decreased	O	-1	869641
blood	O	-1	869641
pressure	O	-1	869641
and	O	-1	869641
heart	O	-1	869641
rate	O	-1	869641
and	O	-1	869641
decreased	O	-1	869641
the	O	-1	869641
ref@@	O	-1	869641
le@@	O	-1	869641
x	O	-1	869641
brady@@	B-Disease	D001919	869641
cardia	I-Disease	-1	869641
to	O	-1	869641
no@@	B-Chemical	D009638	869641
re@@	I-Chemical	-1	869641
p@@	I-Chemical	-1	869641
ine@@	I-Chemical	-1	869641
phrine	I-Chemical	-1	869641
.	O	-1	869641
It	O	-1	869641
is	O	-1	869641
concl@@	O	-1	869641
uded	O	-1	869641
that	O	-1	869641
L-@@	B-Chemical	D007980	869641
dopa	I-Chemical	-1	869641
enh@@	O	-1	869641
anc@@	O	-1	869641
es	O	-1	869641
ref@@	O	-1	869641
le@@	O	-1	869641
x	O	-1	869641
brady@@	B-Disease	D001919	869641
cardia	I-Disease	-1	869641
through	O	-1	869641
central	O	-1	869641
alpha-@@	O	-1	869641
receptor	O	-1	869641
stimul@@	O	-1	869641
ation.	O	-1	869641
F@@	O	-1	869641
ur@@	O	-1	869641
ther@@	O	-1	869641
mo@@	O	-1	869641
re,	O	-1	869641
the	O	-1	869641
effects	O	-1	869641
are	O	-1	869641
mediated	O	-1	869641
through	O	-1	869641
dopamine	B-Chemical	D004298	869641
ra@@	O	-1	869641
ther	O	-1	869641
than	O	-1	869641
no@@	B-Chemical	D009638	869641
re@@	I-Chemical	-1	869641
p@@	I-Chemical	-1	869641
ine@@	I-Chemical	-1	869641
phrine	I-Chemical	-1	869641
and	O	-1	869641
d@@	O	-1	869641
o	O	-1	869641
not	O	-1	869641
requ@@	O	-1	869641
ir@@	O	-1	869641
e	O	-1	869641
the	O	-1	869641
ca@@	O	-1	869641
ro@@	O	-1	869641
ti@@	O	-1	869641
d	O	-1	869641
s@@	O	-1	869641
in@@	O	-1	869641
us	O	-1	869641
b@@	O	-1	869641
a@@	O	-1	869641
ro@@	O	-1	869641
receptor@@	O	-1	869641
s.	O	-1	869641

C@@	B-Chemical	D003042	1749407
oc@@	I-Chemical	-1	1749407
aine	I-Chemical	-1	1749407
-induced	O	-1	1749407
myocardial	B-Disease	D009203	1749407
infarction	I-Disease	-1	1749407
:	O	-1	1749407
clinical	O	-1	1749407
observ@@	O	-1	1749407
ations	O	-1	1749407
and	O	-1	1749407
path@@	O	-1	1749407
o@@	O	-1	1749407
gene@@	O	-1	1749407
tic	O	-1	1749407
con@@	O	-1	1749407
si@@	O	-1	1749407
der@@	O	-1	1749407
ations.	O	-1	1749407
Clin@@	O	-1	1749407
ical	O	-1	1749407
and	O	-1	1749407
experimental	O	-1	1749407
data	O	-1	1749407
pu@@	O	-1	1749407
bl@@	O	-1	1749407
ished	O	-1	1749407
to	O	-1	1749407
d@@	O	-1	1749407
ate	O	-1	1749407
suggest	O	-1	1749407
several	O	-1	1749407
possible	O	-1	1749407
mechanisms	O	-1	1749407
by	O	-1	1749407
which	O	-1	1749407
cocaine	B-Chemical	D003042	1749407
may	O	-1	1749407
result	O	-1	1749407
in	O	-1	1749407
acute	B-Disease	D009203	1749407
myocardial	I-Disease	-1	1749407
infarction	I-Disease	-1	1749407
.	O	-1	1749407
In	O	-1	1749407
individ@@	O	-1	1749407
u@@	O	-1	1749407
als	O	-1	1749407
with	O	-1	1749407
pre@@	O	-1	1749407
ex@@	O	-1	1749407
ist@@	O	-1	1749407
ing,	O	-1	1749407
high-@@	O	-1	1749407
gra@@	O	-1	1749407
de	O	-1	1749407
coronary	O	-1	1749407
arterial	O	-1	1749407
n@@	O	-1	1749407
ar@@	O	-1	1749407
row@@	O	-1	1749407
ing,	O	-1	1749407
acute	B-Disease	D009203	1749407
myocardial	I-Disease	-1	1749407
infarction	I-Disease	-1	1749407
may	O	-1	1749407
result	O	-1	1749407
from	O	-1	1749407
an	O	-1	1749407
increase	O	-1	1749407
in	O	-1	1749407
myocardial	O	-1	1749407
oxy@@	B-Chemical	D010100	1749407
gen	I-Chemical	-1	1749407
de@@	O	-1	1749407
m@@	O	-1	1749407
and	O	-1	1749407
associated	O	-1	1749407
with	O	-1	1749407
cocaine	B-Chemical	D003042	1749407
-induced	O	-1	1749407
increase	O	-1	1749407
in	O	-1	1749407
rat@@	O	-1	1749407
e-@@	O	-1	1749407
pressure	O	-1	1749407
produc@@	O	-1	1749407
t.	O	-1	1749407
In	O	-1	1749407
other	O	-1	1749407
individ@@	O	-1	1749407
u@@	O	-1	1749407
als	O	-1	1749407
with	O	-1	1749407
no	O	-1	1749407
underlying	O	-1	1749407
a@@	B-Disease	D050197	1749407
therosclero@@	I-Disease	-1	1749407
tic	I-Disease	-1	1749407
ob@@	I-Disease	-1	1749407
struc@@	I-Disease	-1	1749407
tion	I-Disease	-1	1749407
,	O	-1	1749407
coronary	B-Disease	D054059	1749407
oc@@	I-Disease	-1	1749407
cl@@	I-Disease	-1	1749407
usion	I-Disease	-1	1749407
may	O	-1	1749407
be	O	-1	1749407
due	O	-1	1749407
to	O	-1	1749407
sp@@	B-Disease	D013035	1749407
as@@	I-Disease	-1	1749407
m	I-Disease	-1	1749407
,	O	-1	1749407
throm@@	B-Disease	D013927	1749407
bu@@	I-Disease	-1	1749407
s	I-Disease	-1	1749407
,	O	-1	1749407
or	O	-1	1749407
bo@@	O	-1	1749407
th@@	O	-1	1749407
.	O	-1	1749407
W@@	O	-1	1749407
it@@	O	-1	1749407
h	O	-1	1749407
reg@@	O	-1	1749407
ard	O	-1	1749407
to	O	-1	1749407
sp@@	B-Disease	D013035	1749407
as@@	I-Disease	-1	1749407
m	I-Disease	-1	1749407
,	O	-1	1749407
the	O	-1	1749407
clinical	O	-1	1749407
findings	O	-1	1749407
are	O	-1	1749407
larg@@	O	-1	1749407
ely	O	-1	1749407
cir@@	O	-1	1749407
cum@@	O	-1	1749407
st@@	O	-1	1749407
anti@@	O	-1	1749407
al,	O	-1	1749407
and	O	-1	1749407
the	O	-1	1749407
loc@@	O	-1	1749407
us	O	-1	1749407
of	O	-1	1749407
cocaine	B-Chemical	D003042	1749407
-induced	O	-1	1749407
vas@@	O	-1	1749407
o@@	O	-1	1749407
con@@	O	-1	1749407
stric@@	O	-1	1749407
tion	O	-1	1749407
remain@@	O	-1	1749407
s	O	-1	1749407
spec@@	O	-1	1749407
ul@@	O	-1	1749407
ati@@	O	-1	1749407
ve.	O	-1	1749407
Although	O	-1	1749407
cer@@	O	-1	1749407
t@@	O	-1	1749407
ain	O	-1	1749407
clinical	O	-1	1749407
and	O	-1	1749407
experimental	O	-1	1749407
findings	O	-1	1749407
suppor@@	O	-1	1749407
t	O	-1	1749407
the	O	-1	1749407
hypo@@	O	-1	1749407
thesis	O	-1	1749407
that	O	-1	1749407
sp@@	B-Disease	D013035	1749407
as@@	I-Disease	-1	1749407
m	I-Disease	-1	1749407
invol@@	O	-1	1749407
v@@	O	-1	1749407
es	O	-1	1749407
the	O	-1	1749407
ep@@	O	-1	1749407
ic@@	O	-1	1749407
ardi@@	O	-1	1749407
al,	O	-1	1749407
medi@@	O	-1	1749407
um@@	O	-1	1749407
-@@	O	-1	1749407
size	O	-1	1749407
v@@	O	-1	1749407
es@@	O	-1	1749407
sel@@	O	-1	1749407
s,	O	-1	1749407
other	O	-1	1749407
data	O	-1	1749407
suggest	O	-1	1749407
int@@	O	-1	1749407
ram@@	O	-1	1749407
ural	O	-1	1749407
vas@@	O	-1	1749407
o@@	O	-1	1749407
con@@	O	-1	1749407
stric@@	O	-1	1749407
tion.	O	-1	1749407
Di@@	O	-1	1749407
ff@@	O	-1	1749407
use	O	-1	1749407
int@@	O	-1	1749407
ram@@	O	-1	1749407
ural	O	-1	1749407
vas@@	O	-1	1749407
o@@	O	-1	1749407
con@@	O	-1	1749407
stric@@	O	-1	1749407
tion	O	-1	1749407
is	O	-1	1749407
not	O	-1	1749407
consist@@	O	-1	1749407
ent	O	-1	1749407
with	O	-1	1749407
reports	O	-1	1749407
of	O	-1	1749407
seg@@	O	-1	1749407
ment@@	O	-1	1749407
al,	O	-1	1749407
disc@@	O	-1	1749407
ret@@	O	-1	1749407
e	O	-1	1749407
infarction	B-Disease	D007238	1749407
.	O	-1	1749407
Whe@@	O	-1	1749407
reas	O	-1	1749407
cer@@	O	-1	1749407
t@@	O	-1	1749407
ain	O	-1	1749407
in	O	-1	1749407
viv@@	O	-1	1749407
o	O	-1	1749407
data	O	-1	1749407
suggest	O	-1	1749407
that	O	-1	1749407
these	O	-1	1749407
effects	O	-1	1749407
are	O	-1	1749407
alpha-@@	O	-1	1749407
medi@@	O	-1	1749407
at@@	O	-1	1749407
ed,	O	-1	1749407
other	O	-1	1749407
in	O	-1	1749407
vit@@	O	-1	1749407
r@@	O	-1	1749407
o	O	-1	1749407
data	O	-1	1749407
suggest	O	-1	1749407
the	O	-1	1749407
op@@	O	-1	1749407
pos@@	O	-1	1749407
it@@	O	-1	1749407
e.	O	-1	1749407
The	O	-1	1749407
find@@	O	-1	1749407
ing	O	-1	1749407
of	O	-1	1749407
cocaine	B-Chemical	D003042	1749407
-induced	O	-1	1749407
vas@@	O	-1	1749407
o@@	O	-1	1749407
con@@	O	-1	1749407
stric@@	O	-1	1749407
tion	O	-1	1749407
in	O	-1	1749407
seg@@	O	-1	1749407
ments	O	-1	1749407
of	O	-1	1749407
(@@	O	-1	1749407
non@@	O	-1	1749407
in@@	O	-1	1749407
ner@@	O	-1	1749407
v@@	O	-1	1749407
ated@@	O	-1	1749407
)	O	-1	1749407
human	O	-1	1749407
um@@	O	-1	1749407
bil@@	O	-1	1749407
ical	O	-1	1749407
artery	O	-1	1749407
suggests	O	-1	1749407
that	O	-1	1749407
the	O	-1	1749407
presence	O	-1	1749407
or	O	-1	1749407
absence	O	-1	1749407
of	O	-1	1749407
int@@	O	-1	1749407
ac@@	O	-1	1749407
t	O	-1	1749407
in@@	O	-1	1749407
ner@@	O	-1	1749407
v@@	O	-1	1749407
ation	O	-1	1749407
is	O	-1	1749407
not	O	-1	1749407
suffici@@	O	-1	1749407
ent	O	-1	1749407
to	O	-1	1749407
expl@@	O	-1	1749407
ain	O	-1	1749407
the	O	-1	1749407
disc@@	O	-1	1749407
re@@	O	-1	1749407
p@@	O	-1	1749407
ant	O	-1	1749407
data	O	-1	1749407
invol@@	O	-1	1749407
ving	O	-1	1749407
the	O	-1	1749407
possib@@	O	-1	1749407
ility	O	-1	1749407
of	O	-1	1749407
alpha-@@	O	-1	1749407
mediated	O	-1	1749407
effects.	O	-1	1749407
F@@	O	-1	1749407
in@@	O	-1	1749407
ally,	O	-1	1749407
the	O	-1	1749407
cont@@	O	-1	1749407
ri@@	O	-1	1749407
bu@@	O	-1	1749407
tion	O	-1	1749407
of	O	-1	1749407
a	O	-1	1749407
prim@@	O	-1	1749407
ar@@	O	-1	1749407
y,	O	-1	1749407
thrombotic	B-Disease	D013927	1749407
effect	O	-1	1749407
of	O	-1	1749407
cocaine	B-Chemical	D003042	1749407
has	O	-1	1749407
not	O	-1	1749407
been	O	-1	1749407
ex@@	O	-1	1749407
cl@@	O	-1	1749407
u@@	O	-1	1749407
de@@	O	-1	1749407
d.	O	-1	1749407

R@@	B-Disease	D001480	1786266
ab@@	I-Disease	-1	1786266
b@@	I-Disease	-1	1786266
it	I-Disease	-1	1786266
syndrome	I-Disease	-1	1786266
,	O	-1	1786266
antidepress@@	B-Chemical	D000928	1786266
ant	I-Chemical	-1	1786266
use@@	O	-1	1786266
,	O	-1	1786266
and	O	-1	1786266
cerebral	O	-1	1786266
per@@	O	-1	1786266
f@@	O	-1	1786266
usion	O	-1	1786266
S@@	O	-1	1786266
P@@	O	-1	1786266
EC@@	O	-1	1786266
T	O	-1	1786266
s@@	O	-1	1786266
can	O	-1	1786266
find@@	O	-1	1786266
ing@@	O	-1	1786266
s.	O	-1	1786266
The	O	-1	1786266
ra@@	B-Disease	D001480	1786266
b@@	I-Disease	-1	1786266
b@@	I-Disease	-1	1786266
it	I-Disease	-1	1786266
syndrome	I-Disease	-1	1786266
is	O	-1	1786266
an	O	-1	1786266
ext@@	O	-1	1786266
ra@@	O	-1	1786266
py@@	O	-1	1786266
ram@@	O	-1	1786266
idal	O	-1	1786266
side	O	-1	1786266
effect	O	-1	1786266
associated	O	-1	1786266
with	O	-1	1786266
chronic	O	-1	1786266
neuro@@	O	-1	1786266
le@@	O	-1	1786266
p@@	O	-1	1786266
tic	O	-1	1786266
therapy.	O	-1	1786266
I@@	O	-1	1786266
ts	O	-1	1786266
occur@@	O	-1	1786266
rence	O	-1	1786266
in	O	-1	1786266
a	O	-1	1786266
patient	O	-1	1786266
being	O	-1	1786266
treated	O	-1	1786266
with	O	-1	1786266
im@@	B-Chemical	D007099	1786266
ip@@	I-Chemical	-1	1786266
r@@	I-Chemical	-1	1786266
amine	I-Chemical	-1	1786266
is	O	-1	1786266
descri@@	O	-1	1786266
be@@	O	-1	1786266
d,	O	-1	1786266
re@@	O	-1	1786266
present@@	O	-1	1786266
ing	O	-1	1786266
the	O	-1	1786266
first	O	-1	1786266
reported	O	-1	1786266
case	O	-1	1786266
of	O	-1	1786266
this	O	-1	1786266
syndrome	O	-1	1786266
in	O	-1	1786266
con@@	O	-1	1786266
j@@	O	-1	1786266
unc@@	O	-1	1786266
tion	O	-1	1786266
with	O	-1	1786266
antidepress@@	B-Chemical	D000928	1786266
ants	I-Chemical	-1	1786266
.	O	-1	1786266
R@@	O	-1	1786266
ep@@	O	-1	1786266
e@@	O	-1	1786266
ated	O	-1	1786266
cerebral	O	-1	1786266
per@@	O	-1	1786266
f@@	O	-1	1786266
usion	O	-1	1786266
S@@	O	-1	1786266
P@@	O	-1	1786266
EC@@	O	-1	1786266
T	O	-1	1786266
s@@	O	-1	1786266
c@@	O	-1	1786266
ans	O	-1	1786266
revealed	O	-1	1786266
decreased	B-Disease	D001480	1786266
bas@@	I-Disease	-1	1786266
al	I-Disease	-1	1786266
g@@	I-Disease	-1	1786266
ang@@	I-Disease	-1	1786266
li@@	I-Disease	-1	1786266
a	I-Disease	-1	1786266
per@@	I-Disease	-1	1786266
f@@	I-Disease	-1	1786266
usion	I-Disease	-1	1786266
while	O	-1	1786266
the	O	-1	1786266
mo@@	B-Disease	D009069	1786266
vement	I-Disease	-1	1786266
disor@@	I-Disease	-1	1786266
der	I-Disease	-1	1786266
was	O	-1	1786266
present@@	O	-1	1786266
,	O	-1	1786266
and	O	-1	1786266
a	O	-1	1786266
retur@@	O	-1	1786266
n	O	-1	1786266
to	O	-1	1786266
normal	O	-1	1786266
per@@	O	-1	1786266
f@@	O	-1	1786266
usion	O	-1	1786266
when	O	-1	1786266
the	O	-1	1786266
ra@@	B-Disease	D001480	1786266
b@@	I-Disease	-1	1786266
b@@	I-Disease	-1	1786266
it	I-Disease	-1	1786266
syndrome	I-Disease	-1	1786266
resol@@	O	-1	1786266
ved.	O	-1	1786266

Ac@@	O	-1	1835291
ute	O	-1	1835291
b@@	O	-1	1835291
ron@@	O	-1	1835291
ch@@	O	-1	1835291
odi@@	O	-1	1835291
l@@	O	-1	1835291
ating	O	-1	1835291
effects	O	-1	1835291
of	O	-1	1835291
ip@@	B-Chemical	D009241	1835291
rat@@	I-Chemical	-1	1835291
ro@@	I-Chemical	-1	1835291
pi@@	I-Chemical	-1	1835291
um	I-Chemical	-1	1835291
brom@@	I-Chemical	-1	1835291
ide	I-Chemical	-1	1835291
and	O	-1	1835291
the@@	B-Chemical	D013806	1835291
oph@@	I-Chemical	-1	1835291
yl@@	I-Chemical	-1	1835291
line	I-Chemical	-1	1835291
in	O	-1	1835291
chronic	B-Disease	D029424	1835291
ob@@	I-Disease	-1	1835291
struc@@	I-Disease	-1	1835291
tive	I-Disease	-1	1835291
pulmonary	I-Disease	-1	1835291
disease	I-Disease	-1	1835291
.	O	-1	1835291
The	O	-1	1835291
b@@	O	-1	1835291
ron@@	O	-1	1835291
ch@@	O	-1	1835291
odi@@	O	-1	1835291
lat@@	O	-1	1835291
or	O	-1	1835291
effects	O	-1	1835291
of	O	-1	1835291
a	O	-1	1835291
single	O	-1	1835291
dose	O	-1	1835291
of	O	-1	1835291
ip@@	B-Chemical	D009241	1835291
rat@@	I-Chemical	-1	1835291
ro@@	I-Chemical	-1	1835291
pi@@	I-Chemical	-1	1835291
um	I-Chemical	-1	1835291
brom@@	I-Chemical	-1	1835291
ide	I-Chemical	-1	1835291
a@@	O	-1	1835291
er@@	O	-1	1835291
os@@	O	-1	1835291
ol	O	-1	1835291
(3@@	O	-1	1835291
6	O	-1	1835291
microgram@@	O	-1	1835291
s)	O	-1	1835291
and	O	-1	1835291
sh@@	O	-1	1835291
ort@@	O	-1	1835291
-@@	O	-1	1835291
act@@	O	-1	1835291
ing	O	-1	1835291
the@@	B-Chemical	D013806	1835291
oph@@	I-Chemical	-1	1835291
yl@@	I-Chemical	-1	1835291
line	I-Chemical	-1	1835291
t@@	O	-1	1835291
able@@	O	-1	1835291
ts	O	-1	1835291
(@@	O	-1	1835291
dose	O	-1	1835291
ti@@	O	-1	1835291
tr@@	O	-1	1835291
ated	O	-1	1835291
to	O	-1	1835291
produce	O	-1	1835291
serum	O	-1	1835291
levels	O	-1	1835291
of	O	-1	1835291
10-@@	O	-1	1835291
20	O	-1	1835291
microgram@@	O	-1	1835291
s/@@	O	-1	1835291
m@@	O	-1	1835291
L@@	O	-1	1835291
)	O	-1	1835291
were	O	-1	1835291
compared	O	-1	1835291
in	O	-1	1835291
a	O	-1	1835291
double-bl@@	O	-1	1835291
ind@@	O	-1	1835291
,	O	-1	1835291
placebo@@	O	-1	1835291
-@@	O	-1	1835291
controlled	O	-1	1835291
cros@@	O	-1	1835291
s@@	O	-1	1835291
over	O	-1	1835291
study	O	-1	1835291
in	O	-1	1835291
21	O	-1	1835291
patients	O	-1	1835291
with	O	-1	1835291
st@@	O	-1	1835291
able@@	O	-1	1835291
,	O	-1	1835291
chronic	B-Disease	D029424	1835291
ob@@	I-Disease	-1	1835291
struc@@	I-Disease	-1	1835291
tive	I-Disease	-1	1835291
pulmonary	I-Disease	-1	1835291
disease	I-Disease	-1	1835291
.	O	-1	1835291
M@@	O	-1	1835291
e@@	O	-1	1835291
an	O	-1	1835291
pe@@	O	-1	1835291
a@@	O	-1	1835291
k	O	-1	1835291
for@@	O	-1	1835291
c@@	O	-1	1835291
ed	O	-1	1835291
ex@@	O	-1	1835291
piratory	O	-1	1835291
volume	O	-1	1835291
in	O	-1	1835291
1	O	-1	1835291
second	O	-1	1835291
(@@	O	-1	1835291
F@@	O	-1	1835291
E@@	O	-1	1835291
V@@	O	-1	1835291
1)	O	-1	1835291
increases	O	-1	1835291
over	O	-1	1835291
baseline	O	-1	1835291
and	O	-1	1835291
the	O	-1	1835291
pro@@	O	-1	1835291
por@@	O	-1	1835291
tion	O	-1	1835291
of	O	-1	1835291
patients	O	-1	1835291
at@@	O	-1	1835291
t@@	O	-1	1835291
aining	O	-1	1835291
at	O	-1	1835291
le@@	O	-1	1835291
ast	O	-1	1835291
a	O	-1	1835291
1@@	O	-1	1835291
5%	O	-1	1835291
increase	O	-1	1835291
in	O	-1	1835291
the	O	-1	1835291
F@@	O	-1	1835291
E@@	O	-1	1835291
V@@	O	-1	1835291
1	O	-1	1835291
(@@	O	-1	1835291
respon@@	O	-1	1835291
der@@	O	-1	1835291
s)	O	-1	1835291
were	O	-1	1835291
3@@	O	-1	1835291
1@@	O	-1	1835291
%	O	-1	1835291
and	O	-1	1835291
9@@	O	-1	1835291
0@@	O	-1	1835291
%,	O	-1	1835291
respectivel@@	O	-1	1835291
y,	O	-1	1835291
for	O	-1	1835291
ip@@	B-Chemical	D009241	1835291
rat@@	I-Chemical	-1	1835291
ro@@	I-Chemical	-1	1835291
pi@@	I-Chemical	-1	1835291
um	I-Chemical	-1	1835291
and	O	-1	1835291
17@@	O	-1	1835291
%	O	-1	1835291
and	O	-1	1835291
50@@	O	-1	1835291
%,	O	-1	1835291
respectivel@@	O	-1	1835291
y,	O	-1	1835291
for	O	-1	1835291
the@@	B-Chemical	D013806	1835291
oph@@	I-Chemical	-1	1835291
yl@@	I-Chemical	-1	1835291
line	I-Chemical	-1	1835291
.	O	-1	1835291
The	O	-1	1835291
average	O	-1	1835291
F@@	O	-1	1835291
E@@	O	-1	1835291
V@@	O	-1	1835291
1	O	-1	1835291
increases	O	-1	1835291
during	O	-1	1835291
the	O	-1	1835291
6-@@	O	-1	1835291
h@@	O	-1	1835291
our	O	-1	1835291
observ@@	O	-1	1835291
ation	O	-1	1835291
period	O	-1	1835291
were	O	-1	1835291
18@@	O	-1	1835291
%	O	-1	1835291
for	O	-1	1835291
ip@@	B-Chemical	D009241	1835291
rat@@	I-Chemical	-1	1835291
ro@@	I-Chemical	-1	1835291
pi@@	I-Chemical	-1	1835291
um	I-Chemical	-1	1835291
and	O	-1	1835291
8@@	O	-1	1835291
%	O	-1	1835291
for	O	-1	1835291
the@@	B-Chemical	D013806	1835291
oph@@	I-Chemical	-1	1835291
yl@@	I-Chemical	-1	1835291
line	I-Chemical	-1	1835291
.	O	-1	1835291
The	O	-1	1835291
mean	O	-1	1835291
duration	O	-1	1835291
of	O	-1	1835291
action	O	-1	1835291
was	O	-1	1835291
3.@@	O	-1	1835291
8	O	-1	1835291
hours	O	-1	1835291
with	O	-1	1835291
ip@@	B-Chemical	D009241	1835291
rat@@	I-Chemical	-1	1835291
ro@@	I-Chemical	-1	1835291
pi@@	I-Chemical	-1	1835291
um	I-Chemical	-1	1835291
and	O	-1	1835291
2.@@	O	-1	1835291
4	O	-1	1835291
hours	O	-1	1835291
with	O	-1	1835291
the@@	B-Chemical	D013806	1835291
oph@@	I-Chemical	-1	1835291
yl@@	I-Chemical	-1	1835291
line	I-Chemical	-1	1835291
.	O	-1	1835291
W@@	O	-1	1835291
h@@	O	-1	1835291
ile	O	-1	1835291
side	O	-1	1835291
effects	O	-1	1835291
were	O	-1	1835291
ra@@	O	-1	1835291
re,	O	-1	1835291
those	O	-1	1835291
experienced	O	-1	1835291
after	O	-1	1835291
the@@	B-Chemical	D013806	1835291
oph@@	I-Chemical	-1	1835291
yl@@	I-Chemical	-1	1835291
line	I-Chemical	-1	1835291
use	O	-1	1835291
did	O	-1	1835291
invol@@	O	-1	1835291
ve	O	-1	1835291
the	O	-1	1835291
cardiovascular	B-Disease	D002318	1835291
and	I-Disease	-1	1835291
gast@@	I-Disease	-1	1835291
ro@@	I-Disease	-1	1835291
in@@	I-Disease	-1	1835291
test@@	I-Disease	-1	1835291
inal	I-Disease	-1	1835291
system@@	I-Disease	-1	1835291
s	I-Disease	-1	1835291
cardiovascular	B-Disease	D005767	1835291
and	I-Disease	-1	1835291
gast@@	I-Disease	-1	1835291
ro@@	I-Disease	-1	1835291
in@@	I-Disease	-1	1835291
test@@	I-Disease	-1	1835291
inal	I-Disease	-1	1835291
system@@	I-Disease	-1	1835291
s	I-Disease	-1	1835291
.	O	-1	1835291
These	O	-1	1835291
results	O	-1	1835291
show	O	-1	1835291
that	O	-1	1835291
ip@@	B-Chemical	D009241	1835291
rat@@	I-Chemical	-1	1835291
ro@@	I-Chemical	-1	1835291
pi@@	I-Chemical	-1	1835291
um	I-Chemical	-1	1835291
is	O	-1	1835291
a	O	-1	1835291
more	O	-1	1835291
pot@@	O	-1	1835291
ent	O	-1	1835291
b@@	O	-1	1835291
ron@@	O	-1	1835291
ch@@	O	-1	1835291
odi@@	O	-1	1835291
lat@@	O	-1	1835291
or	O	-1	1835291
than	O	-1	1835291
oral	O	-1	1835291
the@@	B-Chemical	D013806	1835291
oph@@	I-Chemical	-1	1835291
yl@@	I-Chemical	-1	1835291
line	I-Chemical	-1	1835291
in	O	-1	1835291
patients	O	-1	1835291
with	O	-1	1835291
chronic	B-Disease	D029424	1835291
a@@	I-Disease	-1	1835291
ir@@	I-Disease	-1	1835291
flow	I-Disease	-1	1835291
ob@@	I-Disease	-1	1835291
struc@@	I-Disease	-1	1835291
tion	I-Disease	-1	1835291
.	O	-1	1835291

I@@	O	-1	1919871
r@@	O	-1	1919871
reversible	O	-1	1919871
damage	O	-1	1919871
to	O	-1	1919871
the	O	-1	1919871
med@@	O	-1	1919871
ul@@	O	-1	1919871
l@@	O	-1	1919871
ary	O	-1	1919871
intersti@@	O	-1	1919871
ti@@	O	-1	1919871
um	O	-1	1919871
in	O	-1	1919871
experimental	O	-1	1919871
analge@@	O	-1	1919871
sic	O	-1	1919871
nephro@@	B-Disease	D007674	1919871
pathy	I-Disease	-1	1919871
in	O	-1	1919871
F@@	O	-1	1919871
34@@	O	-1	1919871
4	O	-1	1919871
rats.	O	-1	1919871
R@@	B-Disease	D007681	1919871
en@@	I-Disease	-1	1919871
al	I-Disease	-1	1919871
pap@@	I-Disease	-1	1919871
ill@@	I-Disease	-1	1919871
ary	I-Disease	-1	1919871
necro@@	I-Disease	-1	1919871
sis	I-Disease	-1	1919871
(	O	-1	1919871
R@@	B-Disease	D007681	1919871
P@@	I-Disease	-1	1919871
N	I-Disease	-1	1919871
)	O	-1	1919871
and	O	-1	1919871
a	O	-1	1919871
decreased	O	-1	1919871
urinary	O	-1	1919871
con@@	O	-1	1919871
c@@	O	-1	1919871
ent@@	O	-1	1919871
rat@@	O	-1	1919871
ing	O	-1	1919871
ability	O	-1	1919871
developed	O	-1	1919871
during	O	-1	1919871
continu@@	O	-1	1919871
ous	O	-1	1919871
long-term	O	-1	1919871
treatment	O	-1	1919871
with	O	-1	1919871
as@@	B-Chemical	D001241	1919871
pi@@	I-Chemical	-1	1919871
rin	I-Chemical	-1	1919871
and	O	-1	1919871
par@@	B-Chemical	D000082	1919871
acet@@	I-Chemical	-1	1919871
am@@	I-Chemical	-1	1919871
ol	I-Chemical	-1	1919871
in	O	-1	1919871
female	O	-1	1919871
F@@	O	-1	1919871
is@@	O	-1	1919871
ch@@	O	-1	1919871
er	O	-1	1919871
34@@	O	-1	1919871
4	O	-1	1919871
rats.	O	-1	1919871
R@@	O	-1	1919871
en@@	O	-1	1919871
al	O	-1	1919871
struct@@	O	-1	1919871
ure	O	-1	1919871
and	O	-1	1919871
con@@	O	-1	1919871
c@@	O	-1	1919871
ent@@	O	-1	1919871
rat@@	O	-1	1919871
ing	O	-1	1919871
ability	O	-1	1919871
were	O	-1	1919871
examined	O	-1	1919871
after	O	-1	1919871
a	O	-1	1919871
recovery	O	-1	1919871
period	O	-1	1919871
of	O	-1	1919871
up	O	-1	1919871
to	O	-1	1919871
1@@	O	-1	1919871
8	O	-1	1919871
week@@	O	-1	1919871
s,	O	-1	1919871
when	O	-1	1919871
no	O	-1	1919871
analge@@	O	-1	1919871
si@@	O	-1	1919871
c@@	O	-1	1919871
s	O	-1	1919871
were	O	-1	1919871
gi@@	O	-1	1919871
ven@@	O	-1	1919871
,	O	-1	1919871
to	O	-1	1919871
investigate	O	-1	1919871
whether	O	-1	1919871
the	O	-1	1919871
analge@@	O	-1	1919871
si@@	O	-1	1919871
c@@	O	-1	1919871
-induced	O	-1	1919871
changes	O	-1	1919871
were	O	-1	1919871
rever@@	O	-1	1919871
sib@@	O	-1	1919871
le@@	O	-1	1919871
.	O	-1	1919871
There	O	-1	1919871
was	O	-1	1919871
no	O	-1	1919871
evidence	O	-1	1919871
of	O	-1	1919871
re@@	O	-1	1919871
pa@@	O	-1	1919871
ir	O	-1	1919871
to	O	-1	1919871
the	O	-1	1919871
dam@@	O	-1	1919871
aged	O	-1	1919871
med@@	O	-1	1919871
ul@@	O	-1	1919871
l@@	O	-1	1919871
ary	O	-1	1919871
interstitial	O	-1	1919871
mat@@	O	-1	1919871
ri@@	O	-1	1919871
x@@	O	-1	1919871
,	O	-1	1919871
or	O	-1	1919871
pro@@	O	-1	1919871
li@@	O	-1	1919871
fer@@	O	-1	1919871
ation	O	-1	1919871
of	O	-1	1919871
remain@@	O	-1	1919871
ing	O	-1	1919871
un@@	O	-1	1919871
dam@@	O	-1	1919871
aged	O	-1	1919871
type	O	-1	1919871
1	O	-1	1919871
med@@	O	-1	1919871
ul@@	O	-1	1919871
l@@	O	-1	1919871
ary	O	-1	1919871
interstitial	O	-1	1919871
cells	O	-1	1919871
after	O	-1	1919871
the	O	-1	1919871
recovery	O	-1	1919871
period	O	-1	1919871
following	O	-1	1919871
analge@@	O	-1	1919871
sic	O	-1	1919871
treatment.	O	-1	1919871
The	O	-1	1919871
recovery	O	-1	1919871
of	O	-1	1919871
urinary	O	-1	1919871
con@@	O	-1	1919871
c@@	O	-1	1919871
ent@@	O	-1	1919871
rat@@	O	-1	1919871
ing	O	-1	1919871
ability	O	-1	1919871
was	O	-1	1919871
related	O	-1	1919871
to	O	-1	1919871
the	O	-1	1919871
l@@	O	-1	1919871
en@@	O	-1	1919871
g@@	O	-1	1919871
th	O	-1	1919871
of	O	-1	1919871
analge@@	O	-1	1919871
sic	O	-1	1919871
treatment	O	-1	1919871
and	O	-1	1919871
the	O	-1	1919871
ext@@	O	-1	1919871
ent	O	-1	1919871
of	O	-1	1919871
the	O	-1	1919871
result@@	O	-1	1919871
ing	O	-1	1919871
in@@	O	-1	1919871
n@@	O	-1	1919871
er	O	-1	1919871
med@@	O	-1	1919871
ul@@	O	-1	1919871
l@@	O	-1	1919871
ary	O	-1	1919871
struct@@	O	-1	1919871
ural	O	-1	1919871
dam@@	O	-1	1919871
age.	O	-1	1919871
D@@	O	-1	1919871
uring	O	-1	1919871
the	O	-1	1919871
early	O	-1	1919871
st@@	O	-1	1919871
ages	O	-1	1919871
of	O	-1	1919871
analge@@	O	-1	1919871
sic	O	-1	1919871
treatment,	O	-1	1919871
the	O	-1	1919871
changes	O	-1	1919871
in	O	-1	1919871
urinary	O	-1	1919871
con@@	O	-1	1919871
c@@	O	-1	1919871
ent@@	O	-1	1919871
rat@@	O	-1	1919871
ing	O	-1	1919871
ability	O	-1	1919871
were	O	-1	1919871
rever@@	O	-1	1919871
sib@@	O	-1	1919871
le@@	O	-1	1919871
,	O	-1	1919871
but	O	-1	1919871
after	O	-1	1919871
prolonged	O	-1	1919871
analge@@	O	-1	1919871
sic	O	-1	1919871
treatment,	O	-1	1919871
maxim@@	O	-1	1919871
um	O	-1	1919871
urinary	O	-1	1919871
con@@	O	-1	1919871
c@@	O	-1	1919871
ent@@	O	-1	1919871
rat@@	O	-1	1919871
ing	O	-1	1919871
ability	O	-1	1919871
fail@@	O	-1	1919871
ed	O	-1	1919871
to	O	-1	1919871
reco@@	O	-1	1919871
ver@@	O	-1	1919871
.	O	-1	1919871
This	O	-1	1919871
study	O	-1	1919871
show@@	O	-1	1919871
s	O	-1	1919871
that	O	-1	1919871
prolonged	O	-1	1919871
analge@@	O	-1	1919871
sic	O	-1	1919871
treatment	O	-1	1919871
in	O	-1	1919871
F@@	O	-1	1919871
is@@	O	-1	1919871
ch@@	O	-1	1919871
er	O	-1	1919871
34@@	O	-1	1919871
4	O	-1	1919871
rats	O	-1	1919871
causes	O	-1	1919871
progressive	O	-1	1919871
and	O	-1	1919871
ir@@	O	-1	1919871
reversible	O	-1	1919871
damage	O	-1	1919871
to	O	-1	1919871
the	O	-1	1919871
interstitial	O	-1	1919871
mat@@	O	-1	1919871
ri@@	O	-1	1919871
x	O	-1	1919871
and	O	-1	1919871
type	O	-1	1919871
1	O	-1	1919871
interstitial	O	-1	1919871
cells	O	-1	1919871
lead@@	O	-1	1919871
ing	O	-1	1919871
to	O	-1	1919871
R@@	B-Disease	D007681	1919871
P@@	I-Disease	-1	1919871
N	I-Disease	-1	1919871
.	O	-1	1919871
The	O	-1	1919871
associated	O	-1	1919871
urinary	O	-1	1919871
con@@	O	-1	1919871
c@@	O	-1	1919871
ent@@	O	-1	1919871
rat@@	O	-1	1919871
ing	O	-1	1919871
def@@	O	-1	1919871
ect	O	-1	1919871
is	O	-1	1919871
reversible	O	-1	1919871
only	O	-1	1919871
during	O	-1	1919871
the	O	-1	1919871
early	O	-1	1919871
st@@	O	-1	1919871
ages	O	-1	1919871
of	O	-1	1919871
struct@@	O	-1	1919871
ural	O	-1	1919871
damage	O	-1	1919871
to	O	-1	1919871
the	O	-1	1919871
in@@	O	-1	1919871
n@@	O	-1	1919871
er	O	-1	1919871
med@@	O	-1	1919871
ul@@	O	-1	1919871
l@@	O	-1	1919871
a.	O	-1	1919871

L@@	O	-1	1987816
ess	O	-1	1987816
frequent	O	-1	1987816
lithium	B-Chemical	D008094	1987816
administration	O	-1	1987816
and	O	-1	1987816
lower	O	-1	1987816
urine	O	-1	1987816
vol@@	O	-1	1987816
u@@	O	-1	1987816
me.	O	-1	1987816
OBJECTIVE:	O	-1	1987816
This	O	-1	1987816
study	O	-1	1987816
was	O	-1	1987816
de@@	O	-1	1987816
signed	O	-1	1987816
to	O	-1	1987816
determine	O	-1	1987816
whether	O	-1	1987816
patients	O	-1	1987816
maint@@	O	-1	1987816
ained	O	-1	1987816
on	O	-1	1987816
a	O	-1	1987816
regi@@	O	-1	1987816
men	O	-1	1987816
of	O	-1	1987816
lithium	B-Chemical	D008094	1987816
on	O	-1	1987816
a	O	-1	1987816
on@@	O	-1	1987816
ce@@	O	-1	1987816
-@@	O	-1	1987816
per@@	O	-1	1987816
-@@	O	-1	1987816
day	O	-1	1987816
sch@@	O	-1	1987816
ed@@	O	-1	1987816
ul@@	O	-1	1987816
e	O	-1	1987816
have	O	-1	1987816
lower	O	-1	1987816
urine	O	-1	1987816
volum@@	O	-1	1987816
es	O	-1	1987816
than	O	-1	1987816
d@@	O	-1	1987816
o	O	-1	1987816
patients	O	-1	1987816
receiving	O	-1	1987816
multiple	O	-1	1987816
doses	O	-1	1987816
per	O	-1	1987816
da@@	O	-1	1987816
y.	O	-1	1987816
METHOD@@	O	-1	1987816
:	O	-1	1987816
This	O	-1	1987816
was	O	-1	1987816
a	O	-1	1987816
cros@@	O	-1	1987816
s-@@	O	-1	1987816
sec@@	O	-1	1987816
tional	O	-1	1987816
study	O	-1	1987816
of	O	-1	1987816
8@@	O	-1	1987816
5	O	-1	1987816
patients	O	-1	1987816
from	O	-1	1987816
a	O	-1	1987816
lithium	B-Chemical	D008094	1987816
clin@@	O	-1	1987816
ic	O	-1	1987816
who	O	-1	1987816
received	O	-1	1987816
different	O	-1	1987816
dose	O	-1	1987816
sch@@	O	-1	1987816
ed@@	O	-1	1987816
ul@@	O	-1	1987816
es.	O	-1	1987816
Patients	O	-1	1987816
were	O	-1	1987816
ad@@	O	-1	1987816
mit@@	O	-1	1987816
ted	O	-1	1987816
to	O	-1	1987816
the	O	-1	1987816
hospit@@	O	-1	1987816
al	O	-1	1987816
for	O	-1	1987816
meas@@	O	-1	1987816
ure@@	O	-1	1987816
ment	O	-1	1987816
of	O	-1	1987816
lithium	B-Chemical	D008094	1987816
level@@	O	-1	1987816
,	O	-1	1987816
creatinine	B-Chemical	D003404	1987816
clear@@	O	-1	1987816
ance@@	O	-1	1987816
,	O	-1	1987816
urine	O	-1	1987816
vol@@	O	-1	1987816
u@@	O	-1	1987816
me,	O	-1	1987816
and	O	-1	1987816
maxim@@	O	-1	1987816
um	O	-1	1987816
os@@	O	-1	1987816
mol@@	O	-1	1987816
al@@	O	-1	1987816
ity.	O	-1	1987816
RESULTS:	O	-1	1987816
M@@	O	-1	1987816
ul@@	O	-1	1987816
ti@@	O	-1	1987816
ple	O	-1	1987816
daily	O	-1	1987816
doses	O	-1	1987816
of	O	-1	1987816
lithium	B-Chemical	D008094	1987816
were	O	-1	1987816
associated	O	-1	1987816
with	O	-1	1987816
higher	O	-1	1987816
urine	O	-1	1987816
volum@@	O	-1	1987816
es.	O	-1	1987816
The	O	-1	1987816
dos@@	O	-1	1987816
ing	O	-1	1987816
sch@@	O	-1	1987816
ed@@	O	-1	1987816
ul@@	O	-1	1987816
e,	O	-1	1987816
duration	O	-1	1987816
of	O	-1	1987816
lithium	B-Chemical	D008094	1987816
treatment,	O	-1	1987816
and	O	-1	1987816
daily	O	-1	1987816
dose	O	-1	1987816
of	O	-1	1987816
lithium	B-Chemical	D008094	1987816
did	O	-1	1987816
not	O	-1	1987816
aff@@	O	-1	1987816
ect	O	-1	1987816
maxim@@	O	-1	1987816
um	O	-1	1987816
os@@	O	-1	1987816
mol@@	O	-1	1987816
ality	O	-1	1987816
or	O	-1	1987816
creatinine	B-Chemical	D003404	1987816
clear@@	O	-1	1987816
ance@@	O	-1	1987816
.	O	-1	1987816
CONCLUSIONS:	O	-1	1987816
U@@	O	-1	1987816
rine	O	-1	1987816
volume	O	-1	1987816
can	O	-1	1987816
be	O	-1	1987816
reduced	O	-1	1987816
by	O	-1	1987816
gi@@	O	-1	1987816
ving	O	-1	1987816
lithium	B-Chemical	D008094	1987816
on@@	O	-1	1987816
ce	O	-1	1987816
daily	O	-1	1987816
and/or	O	-1	1987816
by	O	-1	1987816
low@@	O	-1	1987816
ering	O	-1	1987816
the	O	-1	1987816
total	O	-1	1987816
daily	O	-1	1987816
dose.	O	-1	1987816
L@@	B-Chemical	D008094	1987816
i@@	I-Chemical	-1	1987816
thi@@	I-Chemical	-1	1987816
um	I-Chemical	-1	1987816
-induced	O	-1	1987816
poly@@	B-Disease	D011141	1987816
uria	I-Disease	-1	1987816
se@@	O	-1	1987816
em@@	O	-1	1987816
s	O	-1	1987816
to	O	-1	1987816
be	O	-1	1987816
related	O	-1	1987816
to	O	-1	1987816
ext@@	O	-1	1987816
ra@@	O	-1	1987816
renal	O	-1	1987816
as	O	-1	1987816
well	O	-1	1987816
as	O	-1	1987816
to	O	-1	1987816
renal	O	-1	1987816
effects.	O	-1	1987816

Eff@@	O	-1	2054792
ect	O	-1	2054792
of	O	-1	2054792
adriam@@	B-Chemical	D004317	2054792
ycin	I-Chemical	-1	2054792
combined	O	-1	2054792
with	O	-1	2054792
wh@@	O	-1	2054792
ole	O	-1	2054792
body	O	-1	2054792
hyper@@	B-Disease	D005334	2054792
ther@@	I-Disease	-1	2054792
mia	I-Disease	-1	2054792
on	O	-1	2054792
tumor	B-Disease	D009369	2054792
and	O	-1	2054792
normal	O	-1	2054792
tissu@@	O	-1	2054792
es.	O	-1	2054792
Th@@	O	-1	2054792
er@@	O	-1	2054792
m@@	O	-1	2054792
al	O	-1	2054792
enh@@	O	-1	2054792
ance@@	O	-1	2054792
ment	O	-1	2054792
of	O	-1	2054792
Ad@@	B-Chemical	D004317	2054792
riam@@	I-Chemical	-1	2054792
ycin	I-Chemical	-1	2054792
-@@	O	-1	2054792
mediated	O	-1	2054792
anti@@	O	-1	2054792
tumor	O	-1	2054792
activity	O	-1	2054792
and	O	-1	2054792
normal	O	-1	2054792
tissue	O	-1	2054792
toxic@@	B-Disease	D064420	2054792
ities	I-Disease	-1	2054792
by	O	-1	2054792
wh@@	O	-1	2054792
ole	O	-1	2054792
body	O	-1	2054792
hyper@@	B-Disease	D005334	2054792
ther@@	I-Disease	-1	2054792
mia	I-Disease	-1	2054792
were	O	-1	2054792
compared	O	-1	2054792
using	O	-1	2054792
a	O	-1	2054792
F@@	O	-1	2054792
34@@	O	-1	2054792
4	O	-1	2054792
rat	O	-1	2054792
model@@	O	-1	2054792
.	O	-1	2054792
An@@	O	-1	2054792
ti@@	O	-1	2054792
tumor	O	-1	2054792
activity	O	-1	2054792
was	O	-1	2054792
studied	O	-1	2054792
using	O	-1	2054792
a	O	-1	2054792
tumor	B-Disease	D009369	2054792
growth	O	-1	2054792
del@@	O	-1	2054792
ay	O	-1	2054792
ass@@	O	-1	2054792
a@@	O	-1	2054792
y.	O	-1	2054792
Ac@@	O	-1	2054792
ute	O	-1	2054792
normal	O	-1	2054792
tissue	O	-1	2054792
toxic@@	B-Disease	D064420	2054792
ities	I-Disease	-1	2054792
(@@	O	-1	2054792
i.@@	O	-1	2054792
e@@	O	-1	2054792
.,	O	-1	2054792
leuk@@	B-Disease	D007970	2054792
o@@	I-Disease	-1	2054792
pen@@	I-Disease	-1	2054792
ia	I-Disease	-1	2054792
and	O	-1	2054792
throm@@	B-Disease	D013921	2054792
b@@	I-Disease	-1	2054792
ocyto@@	I-Disease	-1	2054792
pen@@	I-Disease	-1	2054792
ia	I-Disease	-1	2054792
)	O	-1	2054792
and	O	-1	2054792
l@@	O	-1	2054792
ate	O	-1	2054792
normal	O	-1	2054792
tissue	O	-1	2054792
toxic@@	B-Disease	D064420	2054792
ities	I-Disease	-1	2054792
(@@	O	-1	2054792
i.@@	O	-1	2054792
e@@	O	-1	2054792
.,	O	-1	2054792
myocardial	B-Disease	D006331	2054792
and	I-Disease	-1	2054792
kidney	I-Disease	-1	2054792
injury	I-Disease	-1	2054792
myocardial	B-Disease	D007674	2054792
and	I-Disease	-1	2054792
kidney	I-Disease	-1	2054792
injury	I-Disease	-1	2054792
)	O	-1	2054792
were	O	-1	2054792
evaluated	O	-1	2054792
by	O	-1	2054792
func@@	O	-1	2054792
tion@@	O	-1	2054792
al@@	O	-1	2054792
/@@	O	-1	2054792
physi@@	O	-1	2054792
ological	O	-1	2054792
ass@@	O	-1	2054792
ays	O	-1	2054792
and	O	-1	2054792
by	O	-1	2054792
morph@@	O	-1	2054792
ological	O	-1	2054792
t@@	O	-1	2054792
ech@@	O	-1	2054792
n@@	O	-1	2054792
i@@	O	-1	2054792
qu@@	O	-1	2054792
es.	O	-1	2054792
W@@	O	-1	2054792
h@@	O	-1	2054792
ole	O	-1	2054792
body	O	-1	2054792
hyper@@	B-Disease	D005334	2054792
ther@@	I-Disease	-1	2054792
mia	I-Disease	-1	2054792
(1@@	O	-1	2054792
20	O	-1	2054792
min	O	-1	2054792
at	O	-1	2054792
4@@	O	-1	2054792
1.@@	O	-1	2054792
5	O	-1	2054792
de@@	O	-1	2054792
gre@@	O	-1	2054792
es	O	-1	2054792
C@@	O	-1	2054792
)	O	-1	2054792
enhanced	O	-1	2054792
both	O	-1	2054792
Ad@@	B-Chemical	D004317	2054792
riam@@	I-Chemical	-1	2054792
ycin	I-Chemical	-1	2054792
-@@	O	-1	2054792
mediated	O	-1	2054792
anti@@	O	-1	2054792
tumor	O	-1	2054792
activity	O	-1	2054792
and	O	-1	2054792
toxic	O	-1	2054792
side	O	-1	2054792
effects.	O	-1	2054792
The	O	-1	2054792
ther@@	O	-1	2054792
m@@	O	-1	2054792
al	O	-1	2054792
enh@@	O	-1	2054792
ance@@	O	-1	2054792
ment	O	-1	2054792
rati@@	O	-1	2054792
o	O	-1	2054792
calc@@	O	-1	2054792
ul@@	O	-1	2054792
ated	O	-1	2054792
for	O	-1	2054792
anti@@	O	-1	2054792
tumor	O	-1	2054792
activity	O	-1	2054792
was	O	-1	2054792
1.@@	O	-1	2054792
6@@	O	-1	2054792
.	O	-1	2054792
Th@@	O	-1	2054792
er@@	O	-1	2054792
m@@	O	-1	2054792
al	O	-1	2054792
enh@@	O	-1	2054792
ance@@	O	-1	2054792
ment	O	-1	2054792
rati@@	O	-1	2054792
o@@	O	-1	2054792
s	O	-1	2054792
estim@@	O	-1	2054792
ated	O	-1	2054792
for	O	-1	2054792
"@@	O	-1	2054792
ac@@	O	-1	2054792
u@@	O	-1	2054792
te@@	O	-1	2054792
"	O	-1	2054792
hemat@@	O	-1	2054792
ological	O	-1	2054792
changes	O	-1	2054792
were	O	-1	2054792
1.@@	O	-1	2054792
3,	O	-1	2054792
whereas	O	-1	2054792
those	O	-1	2054792
estim@@	O	-1	2054792
ated	O	-1	2054792
for	O	-1	2054792
"@@	O	-1	2054792
lat@@	O	-1	2054792
e@@	O	-1	2054792
"	O	-1	2054792
damage	O	-1	2054792
(@@	O	-1	2054792
bas@@	O	-1	2054792
ed	O	-1	2054792
on	O	-1	2054792
morph@@	O	-1	2054792
ological	O	-1	2054792
cardiac	B-Disease	D006331	2054792
and	I-Disease	-1	2054792
renal	I-Disease	-1	2054792
lesions	I-Disease	-1	2054792
cardiac	B-Disease	D007674	2054792
and	I-Disease	-1	2054792
renal	I-Disease	-1	2054792
lesions	I-Disease	-1	2054792
)	O	-1	2054792
vari@@	O	-1	2054792
ed	O	-1	2054792
between	O	-1	2054792
2.@@	O	-1	2054792
4	O	-1	2054792
and	O	-1	2054792
4.@@	O	-1	2054792
3@@	O	-1	2054792
.	O	-1	2054792
Th@@	O	-1	2054792
us,	O	-1	2054792
while	O	-1	2054792
wh@@	O	-1	2054792
ole	O	-1	2054792
body	O	-1	2054792
hyper@@	B-Disease	D005334	2054792
ther@@	I-Disease	-1	2054792
mia	I-Disease	-1	2054792
enh@@	O	-1	2054792
anc@@	O	-1	2054792
es	O	-1	2054792
Ad@@	B-Chemical	D004317	2054792
riam@@	I-Chemical	-1	2054792
ycin	I-Chemical	-1	2054792
-@@	O	-1	2054792
mediated	O	-1	2054792
anti@@	O	-1	2054792
tumor	O	-1	2054792
effect@@	O	-1	2054792
,	O	-1	2054792
normal	O	-1	2054792
tissue	O	-1	2054792
toxicity	B-Disease	D064420	2054792
is	O	-1	2054792
also	O	-1	2054792
increas@@	O	-1	2054792
ed,	O	-1	2054792
and	O	-1	2054792
the	O	-1	2054792
potential	O	-1	2054792
therapeutic	O	-1	2054792
g@@	O	-1	2054792
ain	O	-1	2054792
of	O	-1	2054792
the	O	-1	2054792
combined	O	-1	2054792
mod@@	O	-1	2054792
ality	O	-1	2054792
treatment	O	-1	2054792
is	O	-1	2054792
ero@@	O	-1	2054792
de@@	O	-1	2054792
d.	O	-1	2054792

P@@	B-Chemical	D011224	2304736
ra@@	I-Chemical	-1	2304736
z@@	I-Chemical	-1	2304736
os@@	I-Chemical	-1	2304736
in	I-Chemical	-1	2304736
-induced	O	-1	2304736
stres@@	B-Disease	D014550	2304736
s	I-Disease	-1	2304736
in@@	I-Disease	-1	2304736
contin@@	I-Disease	-1	2304736
ence	I-Disease	-1	2304736
.	O	-1	2304736
A	O	-1	2304736
case	O	-1	2304736
of	O	-1	2304736
gen@@	O	-1	2304736
u@@	O	-1	2304736
ine	O	-1	2304736
stres@@	B-Disease	D014550	2304736
s	I-Disease	-1	2304736
in@@	I-Disease	-1	2304736
contin@@	I-Disease	-1	2304736
ence	I-Disease	-1	2304736
due	O	-1	2304736
to	O	-1	2304736
praz@@	B-Chemical	D011224	2304736
os@@	I-Chemical	-1	2304736
in	I-Chemical	-1	2304736
,	O	-1	2304736
a	O	-1	2304736
common	O	-1	2304736
anti@@	O	-1	2304736
hypertensive	O	-1	2304736
drug@@	O	-1	2304736
,	O	-1	2304736
is	O	-1	2304736
present@@	O	-1	2304736
ed.	O	-1	2304736
P@@	B-Chemical	D011224	2304736
ra@@	I-Chemical	-1	2304736
z@@	I-Chemical	-1	2304736
os@@	I-Chemical	-1	2304736
in	I-Chemical	-1	2304736
ex@@	O	-1	2304736
er@@	O	-1	2304736
ts	O	-1	2304736
its	O	-1	2304736
anti@@	O	-1	2304736
hypertensive	O	-1	2304736
effects	O	-1	2304736
through	O	-1	2304736
vas@@	O	-1	2304736
odi@@	O	-1	2304736
lat@@	O	-1	2304736
ation	O	-1	2304736
caused	O	-1	2304736
by	O	-1	2304736
selective	O	-1	2304736
block@@	O	-1	2304736
ade	O	-1	2304736
of	O	-1	2304736
post@@	O	-1	2304736
syn@@	O	-1	2304736
ap@@	O	-1	2304736
tic	O	-1	2304736
alpha-@@	O	-1	2304736
1	O	-1	2304736
adrenergic	O	-1	2304736
receptor@@	O	-1	2304736
s.	O	-1	2304736
A@@	O	-1	2304736
s	O	-1	2304736
an	O	-1	2304736
alpha-@@	O	-1	2304736
block@@	O	-1	2304736
er,	O	-1	2304736
it	O	-1	2304736
also	O	-1	2304736
ex@@	O	-1	2304736
er@@	O	-1	2304736
ts	O	-1	2304736
a	O	-1	2304736
significant	O	-1	2304736
rel@@	O	-1	2304736
ax@@	O	-1	2304736
ant	O	-1	2304736
effect	O	-1	2304736
on	O	-1	2304736
the	O	-1	2304736
bladder	O	-1	2304736
nec@@	O	-1	2304736
k	O	-1	2304736
and	O	-1	2304736
ure@@	O	-1	2304736
th@@	O	-1	2304736
ra@@	O	-1	2304736
.	O	-1	2304736
The	O	-1	2304736
patient@@	O	-1	2304736
's	O	-1	2304736
clinical	O	-1	2304736
course	O	-1	2304736
is	O	-1	2304736
descri@@	O	-1	2304736
bed	O	-1	2304736
and	O	-1	2304736
cor@@	O	-1	2304736
related	O	-1	2304736
with	O	-1	2304736
initial	O	-1	2304736
uro@@	O	-1	2304736
dynam@@	O	-1	2304736
ic	O	-1	2304736
studies	O	-1	2304736
while	O	-1	2304736
on	O	-1	2304736
praz@@	B-Chemical	D011224	2304736
os@@	I-Chemical	-1	2304736
in	I-Chemical	-1	2304736
and	O	-1	2304736
subsequ@@	O	-1	2304736
ent	O	-1	2304736
studies	O	-1	2304736
while	O	-1	2304736
taking	O	-1	2304736
verap@@	B-Chemical	D014700	2304736
ami@@	I-Chemical	-1	2304736
l	I-Chemical	-1	2304736
.	O	-1	2304736
H@@	O	-1	2304736
er	O	-1	2304736
in@@	B-Disease	D014549	2304736
contin@@	I-Disease	-1	2304736
ence	I-Disease	-1	2304736
resol@@	O	-1	2304736
ved	O	-1	2304736
with	O	-1	2304736
the	O	-1	2304736
change	O	-1	2304736
of	O	-1	2304736
medic@@	O	-1	2304736
ation.	O	-1	2304736
The	O	-1	2304736
rest@@	O	-1	2304736
or@@	O	-1	2304736
ation	O	-1	2304736
of	O	-1	2304736
contin@@	O	-1	2304736
ence	O	-1	2304736
was	O	-1	2304736
ac@@	O	-1	2304736
comp@@	O	-1	2304736
an@@	O	-1	2304736
ied	O	-1	2304736
by	O	-1	2304736
a	O	-1	2304736
subst@@	O	-1	2304736
anti@@	O	-1	2304736
al	O	-1	2304736
ri@@	O	-1	2304736
se	O	-1	2304736
in	O	-1	2304736
maxim@@	O	-1	2304736
um	O	-1	2304736
ure@@	O	-1	2304736
th@@	O	-1	2304736
ral	O	-1	2304736
pressu@@	O	-1	2304736
re,	O	-1	2304736
maxim@@	O	-1	2304736
um	O	-1	2304736
ure@@	O	-1	2304736
th@@	O	-1	2304736
ral	O	-1	2304736
c@@	O	-1	2304736
los@@	O	-1	2304736
ure	O	-1	2304736
pressu@@	O	-1	2304736
re,	O	-1	2304736
and	O	-1	2304736
functional	O	-1	2304736
ure@@	O	-1	2304736
th@@	O	-1	2304736
ral	O	-1	2304736
l@@	O	-1	2304736
en@@	O	-1	2304736
g@@	O	-1	2304736
th@@	O	-1	2304736
.	O	-1	2304736
Patients	O	-1	2304736
who	O	-1	2304736
present	O	-1	2304736
with	O	-1	2304736
stres@@	B-Disease	D014550	2304736
s	I-Disease	-1	2304736
in@@	I-Disease	-1	2304736
contin@@	I-Disease	-1	2304736
ence	I-Disease	-1	2304736
while	O	-1	2304736
taking	O	-1	2304736
praz@@	B-Chemical	D011224	2304736
os@@	I-Chemical	-1	2304736
in	I-Chemical	-1	2304736
should	O	-1	2304736
change	O	-1	2304736
their	O	-1	2304736
anti@@	O	-1	2304736
hypertensive	O	-1	2304736
medic@@	O	-1	2304736
ation	O	-1	2304736
before	O	-1	2304736
con@@	O	-1	2304736
si@@	O	-1	2304736
der@@	O	-1	2304736
ing	O	-1	2304736
surger@@	O	-1	2304736
y,	O	-1	2304736
because	O	-1	2304736
their	O	-1	2304736
in@@	B-Disease	D014549	2304736
contin@@	I-Disease	-1	2304736
ence	I-Disease	-1	2304736
may	O	-1	2304736
resol@@	O	-1	2304736
ve	O	-1	2304736
spont@@	O	-1	2304736
ane@@	O	-1	2304736
ously	O	-1	2304736
with	O	-1	2304736
a	O	-1	2304736
change	O	-1	2304736
in	O	-1	2304736
drug	O	-1	2304736
therapy.	O	-1	2304736

M@@	B-Disease	D009203	2312209
y@@	I-Disease	-1	2312209
ocardi@@	I-Disease	-1	2312209
al	I-Disease	-1	2312209
infarction	I-Disease	-1	2312209
following	O	-1	2312209
sub@@	O	-1	2312209
l@@	O	-1	2312209
ing@@	O	-1	2312209
ual	O	-1	2312209
administration	O	-1	2312209
of	O	-1	2312209
is@@	B-Chemical	D007548	2312209
os@@	I-Chemical	-1	2312209
or@@	I-Chemical	-1	2312209
b@@	I-Chemical	-1	2312209
ide	I-Chemical	-1	2312209
d@@	I-Chemical	-1	2312209
in@@	I-Chemical	-1	2312209
it@@	I-Chemical	-1	2312209
rate	I-Chemical	-1	2312209
.	O	-1	2312209
A	O	-1	2312209
7@@	O	-1	2312209
8@@	O	-1	2312209
-@@	O	-1	2312209
year-old	O	-1	2312209
with	O	-1	2312209
heal@@	O	-1	2312209
ed	O	-1	2312209
se@@	O	-1	2312209
pt@@	O	-1	2312209
al	O	-1	2312209
necro@@	B-Disease	D009336	2312209
sis	I-Disease	-1	2312209
su@@	O	-1	2312209
ffe@@	O	-1	2312209
red	O	-1	2312209
a	O	-1	2312209
recur@@	O	-1	2312209
rent	O	-1	2312209
myocardial	B-Disease	D009203	2312209
infarction	I-Disease	-1	2312209
of	O	-1	2312209
the	O	-1	2312209
an@@	O	-1	2312209
ter@@	O	-1	2312209
ior	O	-1	2312209
w@@	O	-1	2312209
all	O	-1	2312209
following	O	-1	2312209
the	O	-1	2312209
administration	O	-1	2312209
of	O	-1	2312209
is@@	B-Chemical	D007548	2312209
os@@	I-Chemical	-1	2312209
or@@	I-Chemical	-1	2312209
b@@	I-Chemical	-1	2312209
ide	I-Chemical	-1	2312209
d@@	I-Chemical	-1	2312209
in@@	I-Chemical	-1	2312209
it@@	I-Chemical	-1	2312209
rate	I-Chemical	-1	2312209
5	O	-1	2312209
mg	O	-1	2312209
sub@@	O	-1	2312209
l@@	O	-1	2312209
ing@@	O	-1	2312209
u@@	O	-1	2312209
all@@	O	-1	2312209
y.	O	-1	2312209
After	O	-1	2312209
det@@	O	-1	2312209
ail@@	O	-1	2312209
ing	O	-1	2312209
the	O	-1	2312209
course	O	-1	2312209
of	O	-1	2312209
event@@	O	-1	2312209
s,	O	-1	2312209
we	O	-1	2312209
discus@@	O	-1	2312209
s	O	-1	2312209
the	O	-1	2312209
role	O	-1	2312209
of	O	-1	2312209
par@@	O	-1	2312209
ad@@	O	-1	2312209
ox@@	O	-1	2312209
ical	O	-1	2312209
coronary	O	-1	2312209
sp@@	B-Disease	D013035	2312209
as@@	I-Disease	-1	2312209
m	I-Disease	-1	2312209
and	O	-1	2312209
hypotension	B-Disease	D007022	2312209
-@@	O	-1	2312209
mediated	O	-1	2312209
myocardial	B-Disease	D017202	2312209
ischem@@	I-Disease	-1	2312209
ia	I-Disease	-1	2312209
occur@@	O	-1	2312209
r@@	O	-1	2312209
ing	O	-1	2312209
do@@	O	-1	2312209
w@@	O	-1	2312209
n@@	O	-1	2312209
st@@	O	-1	2312209
re@@	O	-1	2312209
am	O	-1	2312209
to	O	-1	2312209
significant	O	-1	2312209
coronary	B-Disease	D023921	2312209
arterial	I-Disease	-1	2312209
st@@	I-Disease	-1	2312209
en@@	I-Disease	-1	2312209
o@@	I-Disease	-1	2312209
sis	I-Disease	-1	2312209
in	O	-1	2312209
the	O	-1	2312209
path@@	O	-1	2312209
oph@@	O	-1	2312209
ysi@@	O	-1	2312209
ology	O	-1	2312209
of	O	-1	2312209
acute	B-Disease	D054058	2312209
coronary	I-Disease	-1	2312209
in@@	I-Disease	-1	2312209
suffici@@	I-Disease	-1	2312209
ency	I-Disease	-1	2312209
.	O	-1	2312209

F@@	B-Chemical	D005473	2549018
lu@@	I-Chemical	-1	2549018
ox@@	I-Chemical	-1	2549018
et@@	I-Chemical	-1	2549018
ine	I-Chemical	-1	2549018
-induced	O	-1	2549018
ak@@	B-Disease	D017109	2549018
athi@@	I-Disease	-1	2549018
sia	I-Disease	-1	2549018
:	O	-1	2549018
clinical	O	-1	2549018
and	O	-1	2549018
the@@	O	-1	2549018
ore@@	O	-1	2549018
tical	O	-1	2549018
implic@@	O	-1	2549018
ations.	O	-1	2549018
F@@	O	-1	2549018
i@@	O	-1	2549018
ve	O	-1	2549018
patients	O	-1	2549018
receiving	O	-1	2549018
flu@@	B-Chemical	D005473	2549018
ox@@	I-Chemical	-1	2549018
et@@	I-Chemical	-1	2549018
ine	I-Chemical	-1	2549018
for	O	-1	2549018
the	O	-1	2549018
treatment	O	-1	2549018
of	O	-1	2549018
ob@@	B-Disease	D009771	2549018
s@@	I-Disease	-1	2549018
es@@	I-Disease	-1	2549018
sive	I-Disease	-1	2549018
comp@@	I-Disease	-1	2549018
ul@@	I-Disease	-1	2549018
sive	I-Disease	-1	2549018
disor@@	I-Disease	-1	2549018
der	I-Disease	-1	2549018
or	O	-1	2549018
major	B-Disease	D003865	2549018
de@@	I-Disease	-1	2549018
pression	I-Disease	-1	2549018
developed	O	-1	2549018
ak@@	B-Disease	D017109	2549018
athi@@	I-Disease	-1	2549018
sia	I-Disease	-1	2549018
.	O	-1	2549018
The	O	-1	2549018
typ@@	O	-1	2549018
ical	O	-1	2549018
flu@@	B-Chemical	D005473	2549018
ox@@	I-Chemical	-1	2549018
et@@	I-Chemical	-1	2549018
ine	I-Chemical	-1	2549018
-induced	O	-1	2549018
symptoms	O	-1	2549018
of	O	-1	2549018
rest@@	O	-1	2549018
l@@	O	-1	2549018
ess@@	O	-1	2549018
n@@	O	-1	2549018
es@@	O	-1	2549018
s,	O	-1	2549018
con@@	O	-1	2549018
st@@	O	-1	2549018
ant	O	-1	2549018
pac@@	O	-1	2549018
ing,	O	-1	2549018
pur@@	O	-1	2549018
po@@	O	-1	2549018
sel@@	O	-1	2549018
ess	O	-1	2549018
mo@@	O	-1	2549018
ve@@	O	-1	2549018
ments	O	-1	2549018
of	O	-1	2549018
the	O	-1	2549018
fe@@	O	-1	2549018
et	O	-1	2549018
and	O	-1	2549018
le@@	O	-1	2549018
g@@	O	-1	2549018
s,	O	-1	2549018
and	O	-1	2549018
mark@@	O	-1	2549018
ed	O	-1	2549018
an@@	B-Disease	D001008	2549018
xi@@	I-Disease	-1	2549018
ety	I-Disease	-1	2549018
were	O	-1	2549018
in@@	O	-1	2549018
dist@@	O	-1	2549018
ing@@	O	-1	2549018
u@@	O	-1	2549018
ish@@	O	-1	2549018
able	O	-1	2549018
from	O	-1	2549018
those	O	-1	2549018
of	O	-1	2549018
neuro@@	O	-1	2549018
le@@	O	-1	2549018
p@@	O	-1	2549018
tic@@	O	-1	2549018
-induced	O	-1	2549018
ak@@	B-Disease	D017109	2549018
athi@@	I-Disease	-1	2549018
sia	I-Disease	-1	2549018
.	O	-1	2549018
Th@@	O	-1	2549018
ree	O	-1	2549018
patients	O	-1	2549018
who	O	-1	2549018
had	O	-1	2549018
experienced	O	-1	2549018
neuro@@	O	-1	2549018
le@@	O	-1	2549018
p@@	O	-1	2549018
tic@@	O	-1	2549018
-induced	O	-1	2549018
ak@@	B-Disease	D017109	2549018
athi@@	I-Disease	-1	2549018
sia	I-Disease	-1	2549018
in	O	-1	2549018
the	O	-1	2549018
p@@	O	-1	2549018
ast	O	-1	2549018
reported	O	-1	2549018
that	O	-1	2549018
the	O	-1	2549018
symptoms	O	-1	2549018
of	O	-1	2549018
flu@@	B-Chemical	D005473	2549018
ox@@	I-Chemical	-1	2549018
et@@	I-Chemical	-1	2549018
ine	I-Chemical	-1	2549018
-induced	O	-1	2549018
ak@@	B-Disease	D017109	2549018
athi@@	I-Disease	-1	2549018
sia	I-Disease	-1	2549018
were	O	-1	2549018
id@@	O	-1	2549018
en@@	O	-1	2549018
tic@@	O	-1	2549018
al,	O	-1	2549018
although	O	-1	2549018
so@@	O	-1	2549018
me@@	O	-1	2549018
wh@@	O	-1	2549018
at	O	-1	2549018
mil@@	O	-1	2549018
der@@	O	-1	2549018
.	O	-1	2549018
A@@	B-Disease	D017109	2549018
k@@	I-Disease	-1	2549018
athi@@	I-Disease	-1	2549018
sia	I-Disease	-1	2549018
appe@@	O	-1	2549018
a@@	O	-1	2549018
red	O	-1	2549018
to	O	-1	2549018
be	O	-1	2549018
a	O	-1	2549018
common	O	-1	2549018
side	O	-1	2549018
effect	O	-1	2549018
of	O	-1	2549018
flu@@	B-Chemical	D005473	2549018
ox@@	I-Chemical	-1	2549018
et@@	I-Chemical	-1	2549018
ine	I-Chemical	-1	2549018
and	O	-1	2549018
gener@@	O	-1	2549018
ally	O	-1	2549018
respon@@	O	-1	2549018
ded	O	-1	2549018
well	O	-1	2549018
to	O	-1	2549018
treatment	O	-1	2549018
with	O	-1	2549018
the	O	-1	2549018
beta-@@	O	-1	2549018
adrenergic	O	-1	2549018
antagonist	O	-1	2549018
prop@@	B-Chemical	D011433	2549018
ran@@	I-Chemical	-1	2549018
o@@	I-Chemical	-1	2549018
lol	I-Chemical	-1	2549018
,	O	-1	2549018
dose	O	-1	2549018
reduc@@	O	-1	2549018
tion,	O	-1	2549018
or	O	-1	2549018
bo@@	O	-1	2549018
th@@	O	-1	2549018
.	O	-1	2549018
The	O	-1	2549018
au@@	O	-1	2549018
th@@	O	-1	2549018
ors	O	-1	2549018
suggest	O	-1	2549018
that	O	-1	2549018
flu@@	B-Chemical	D005473	2549018
ox@@	I-Chemical	-1	2549018
et@@	I-Chemical	-1	2549018
ine	I-Chemical	-1	2549018
-induced	O	-1	2549018
ak@@	B-Disease	D017109	2549018
athi@@	I-Disease	-1	2549018
sia	I-Disease	-1	2549018
may	O	-1	2549018
be	O	-1	2549018
caused	O	-1	2549018
by	O	-1	2549018
seroton@@	O	-1	2549018
erg@@	O	-1	2549018
ically	O	-1	2549018
mediated	O	-1	2549018
inhibition	O	-1	2549018
of	O	-1	2549018
dop@@	O	-1	2549018
aminergic	O	-1	2549018
neuro@@	O	-1	2549018
trans@@	O	-1	2549018
mission	O	-1	2549018
and	O	-1	2549018
that	O	-1	2549018
the	O	-1	2549018
path@@	O	-1	2549018
oph@@	O	-1	2549018
ysi@@	O	-1	2549018
ology	O	-1	2549018
of	O	-1	2549018
flu@@	B-Chemical	D005473	2549018
ox@@	I-Chemical	-1	2549018
et@@	I-Chemical	-1	2549018
ine	I-Chemical	-1	2549018
-induced	O	-1	2549018
ak@@	B-Disease	D017109	2549018
athi@@	I-Disease	-1	2549018
sia	I-Disease	-1	2549018
and	O	-1	2549018
tr@@	O	-1	2549018
ic@@	O	-1	2549018
y@@	O	-1	2549018
cl@@	O	-1	2549018
ic	O	-1	2549018
antidepress@@	B-Chemical	D000928	2549018
ant	I-Chemical	-1	2549018
-induced	O	-1	2549018
"@@	O	-1	2549018
j@@	O	-1	2549018
it@@	O	-1	2549018
ter@@	O	-1	2549018
in@@	O	-1	2549018
ess@@	O	-1	2549018
"	O	-1	2549018
may	O	-1	2549018
be	O	-1	2549018
id@@	O	-1	2549018
en@@	O	-1	2549018
tic@@	O	-1	2549018
al.	O	-1	2549018

Ch@@	B-Disease	D006521	2611118
ron@@	I-Disease	-1	2611118
ic	I-Disease	-1	2611118
active	I-Disease	-1	2611118
hepatitis	I-Disease	-1	2611118
associated	O	-1	2611118
with	O	-1	2611118
dic@@	B-Chemical	D004008	2611118
lo@@	I-Chemical	-1	2611118
f@@	I-Chemical	-1	2611118
en@@	I-Chemical	-1	2611118
a@@	I-Chemical	-1	2611118
c	I-Chemical	-1	2611118
sodium	I-Chemical	-1	2611118
therapy.	O	-1	2611118
D@@	B-Chemical	D004008	2611118
ic@@	I-Chemical	-1	2611118
lo@@	I-Chemical	-1	2611118
f@@	I-Chemical	-1	2611118
en@@	I-Chemical	-1	2611118
a@@	I-Chemical	-1	2611118
c	I-Chemical	-1	2611118
sodium	I-Chemical	-1	2611118
(	O	-1	2611118
V@@	B-Chemical	D004008	2611118
ol@@	I-Chemical	-1	2611118
t@@	I-Chemical	-1	2611118
a@@	I-Chemical	-1	2611118
ro@@	I-Chemical	-1	2611118
l	I-Chemical	-1	2611118
,	O	-1	2611118
G@@	O	-1	2611118
e@@	O	-1	2611118
ig@@	O	-1	2611118
y	O	-1	2611118
Ph@@	O	-1	2611118
ar@@	O	-1	2611118
m@@	O	-1	2611118
ace@@	O	-1	2611118
u@@	O	-1	2611118
tic@@	O	-1	2611118
al@@	O	-1	2611118
s)	O	-1	2611118
is	O	-1	2611118
a	O	-1	2611118
non-@@	O	-1	2611118
steroid@@	O	-1	2611118
al	O	-1	2611118
anti@@	O	-1	2611118
-@@	O	-1	2611118
inflam@@	O	-1	2611118
mat@@	O	-1	2611118
ory	O	-1	2611118
der@@	O	-1	2611118
i@@	O	-1	2611118
v@@	O	-1	2611118
ative	O	-1	2611118
of	O	-1	2611118
phenyl@@	B-Chemical	C025136	2611118
ace@@	I-Chemical	-1	2611118
tic	I-Chemical	-1	2611118
acid	I-Chemical	-1	2611118
.	O	-1	2611118
Although	O	-1	2611118
gener@@	O	-1	2611118
ally	O	-1	2611118
we@@	O	-1	2611118
ll@@	O	-1	2611118
-@@	O	-1	2611118
toler@@	O	-1	2611118
at@@	O	-1	2611118
ed,	O	-1	2611118
as@@	O	-1	2611118
ym@@	O	-1	2611118
pto@@	O	-1	2611118
m@@	O	-1	2611118
atic	O	-1	2611118
abnormal@@	B-Disease	D056486	2611118
ities	I-Disease	-1	2611118
of	I-Disease	-1	2611118
liver	I-Disease	-1	2611118
function	I-Disease	-1	2611118
have	O	-1	2611118
been	O	-1	2611118
recor@@	O	-1	2611118
ded	O	-1	2611118
and@@	O	-1	2611118
,	O	-1	2611118
less	O	-1	2611118
common@@	O	-1	2611118
ly,	O	-1	2611118
severe	O	-1	2611118
hepatitis	B-Disease	D056486	2611118
induced	O	-1	2611118
by	O	-1	2611118
dic@@	B-Chemical	D004008	2611118
lo@@	I-Chemical	-1	2611118
f@@	I-Chemical	-1	2611118
en@@	I-Chemical	-1	2611118
a@@	I-Chemical	-1	2611118
c	I-Chemical	-1	2611118
.	O	-1	2611118
The	O	-1	2611118
patient	O	-1	2611118
descri@@	O	-1	2611118
bed	O	-1	2611118
developed	O	-1	2611118
chronic	B-Disease	D006521	2611118
active	I-Disease	-1	2611118
hepatitis	I-Disease	-1	2611118
after	O	-1	2611118
six	O	-1	2611118
months	O	-1	2611118
therapy	O	-1	2611118
with	O	-1	2611118
dic@@	B-Chemical	D004008	2611118
lo@@	I-Chemical	-1	2611118
f@@	I-Chemical	-1	2611118
en@@	I-Chemical	-1	2611118
a@@	I-Chemical	-1	2611118
c	I-Chemical	-1	2611118
sodium	I-Chemical	-1	2611118
which	O	-1	2611118
progres@@	O	-1	2611118
sed	O	-1	2611118
des@@	O	-1	2611118
pit@@	O	-1	2611118
e	O	-1	2611118
the	O	-1	2611118
withdrawal	O	-1	2611118
of	O	-1	2611118
the	O	-1	2611118
drug@@	O	-1	2611118
,	O	-1	2611118
a	O	-1	2611118
find@@	O	-1	2611118
ing	O	-1	2611118
not	O	-1	2611118
previously	O	-1	2611118
repor@@	O	-1	2611118
ted.	O	-1	2611118

S@@	B-Disease	D020521	2673163
tro@@	I-Disease	-1	2673163
k@@	I-Disease	-1	2673163
e	I-Disease	-1	2673163
associated	O	-1	2673163
with	O	-1	2673163
cocaine	B-Chemical	D003042	2673163
use.	O	-1	2673163
We	O	-1	2673163
describe	O	-1	2673163
e@@	O	-1	2673163
ight	O	-1	2673163
patients	O	-1	2673163
in	O	-1	2673163
whom	O	-1	2673163
cocaine	B-Chemical	D003042	2673163
use	O	-1	2673163
was	O	-1	2673163
related	O	-1	2673163
to	O	-1	2673163
strok@@	B-Disease	D020521	2673163
e	I-Disease	-1	2673163
and	O	-1	2673163
revie@@	O	-1	2673163
w	O	-1	2673163
3@@	O	-1	2673163
9	O	-1	2673163
cases	O	-1	2673163
from	O	-1	2673163
the	O	-1	2673163
literat@@	O	-1	2673163
ure.	O	-1	2673163
A@@	O	-1	2673163
mon@@	O	-1	2673163
g	O	-1	2673163
these	O	-1	2673163
4@@	O	-1	2673163
7	O	-1	2673163
patients	O	-1	2673163
the	O	-1	2673163
mean	O	-1	2673163
(@@	O	-1	2673163
+/-	O	-1	2673163
S@@	O	-1	2673163
D)	O	-1	2673163
age	O	-1	2673163
was	O	-1	2673163
3@@	O	-1	2673163
2.@@	O	-1	2673163
5	O	-1	2673163
+/-	O	-1	2673163
1@@	O	-1	2673163
2.@@	O	-1	2673163
1	O	-1	2673163
year@@	O	-1	2673163
s;	O	-1	2673163
7@@	O	-1	2673163
6%	O	-1	2673163
(3@@	O	-1	2673163
4@@	O	-1	2673163
/@@	O	-1	2673163
4@@	O	-1	2673163
5@@	O	-1	2673163
)	O	-1	2673163
were	O	-1	2673163
men@@	O	-1	2673163
.	O	-1	2673163
S@@	B-Disease	D020521	2673163
tro@@	I-Disease	-1	2673163
k@@	I-Disease	-1	2673163
e	I-Disease	-1	2673163
followed	O	-1	2673163
cocaine	B-Chemical	D003042	2673163
use	O	-1	2673163
by	O	-1	2673163
in@@	O	-1	2673163
h@@	O	-1	2673163
al@@	O	-1	2673163
ation,	O	-1	2673163
int@@	O	-1	2673163
ran@@	O	-1	2673163
as@@	O	-1	2673163
al,	O	-1	2673163
intra@@	O	-1	2673163
ven@@	O	-1	2673163
ou@@	O	-1	2673163
s,	O	-1	2673163
and	O	-1	2673163
int@@	O	-1	2673163
ram@@	O	-1	2673163
us@@	O	-1	2673163
cular	O	-1	2673163
ro@@	O	-1	2673163
ut@@	O	-1	2673163
es.	O	-1	2673163
In@@	B-Disease	D002532	2673163
trac@@	I-Disease	-1	2673163
ranial	I-Disease	-1	2673163
aneurys@@	I-Disease	-1	2673163
ms	I-Disease	-1	2673163
or	O	-1	2673163
arter@@	B-Disease	D001165	2673163
io@@	I-Disease	-1	2673163
venous	I-Disease	-1	2673163
mal@@	I-Disease	-1	2673163
form@@	I-Disease	-1	2673163
ations	I-Disease	-1	2673163
were	O	-1	2673163
present	O	-1	2673163
in	O	-1	2673163
17	O	-1	2673163
of	O	-1	2673163
3@@	O	-1	2673163
2	O	-1	2673163
patients	O	-1	2673163
studied	O	-1	2673163
angio@@	O	-1	2673163
graph@@	O	-1	2673163
ically	O	-1	2673163
or	O	-1	2673163
at	O	-1	2673163
auto@@	O	-1	2673163
psy@@	O	-1	2673163
;	O	-1	2673163
cerebral	B-Disease	D020293	2673163
vas@@	I-Disease	-1	2673163
cul@@	I-Disease	-1	2673163
iti@@	I-Disease	-1	2673163
s	I-Disease	-1	2673163
was	O	-1	2673163
present	O	-1	2673163
in	O	-1	2673163
two	O	-1	2673163
patients.	O	-1	2673163
C@@	B-Disease	D002544	2673163
e@@	I-Disease	-1	2673163
rebral	I-Disease	-1	2673163
infarction	I-Disease	-1	2673163
occurred	O	-1	2673163
in	O	-1	2673163
10	O	-1	2673163
patients	O	-1	2673163
(2@@	O	-1	2673163
2@@	O	-1	2673163
%),	O	-1	2673163
intrac@@	B-Disease	D002543	2673163
e@@	I-Disease	-1	2673163
rebral	I-Disease	-1	2673163
hemorrh@@	I-Disease	-1	2673163
age	I-Disease	-1	2673163
in	O	-1	2673163
2@@	O	-1	2673163
2	O	-1	2673163
(4@@	O	-1	2673163
9@@	O	-1	2673163
%),	O	-1	2673163
and	O	-1	2673163
sub@@	B-Disease	D013345	2673163
arac@@	I-Disease	-1	2673163
h@@	I-Disease	-1	2673163
no@@	I-Disease	-1	2673163
id	I-Disease	-1	2673163
hemorrh@@	I-Disease	-1	2673163
age	I-Disease	-1	2673163
in	O	-1	2673163
13	O	-1	2673163
(2@@	O	-1	2673163
9@@	O	-1	2673163
%).	O	-1	2673163
These	O	-1	2673163
data	O	-1	2673163
indicate	O	-1	2673163
that	O	-1	2673163
(1@@	O	-1	2673163
)	O	-1	2673163
the	O	-1	2673163
appa@@	O	-1	2673163
rent	O	-1	2673163
incidence	O	-1	2673163
of	O	-1	2673163
strok@@	B-Disease	D020521	2673163
e	I-Disease	-1	2673163
related	O	-1	2673163
to	O	-1	2673163
cocaine	B-Chemical	D003042	2673163
use	O	-1	2673163
is	O	-1	2673163
increas@@	O	-1	2673163
ing@@	O	-1	2673163
;	O	-1	2673163
(2@@	O	-1	2673163
)	O	-1	2673163
cocaine	B-Chemical	D003042	2673163
-@@	O	-1	2673163
associated	O	-1	2673163
strok@@	B-Disease	D020521	2673163
e	I-Disease	-1	2673163
occur@@	O	-1	2673163
s	O	-1	2673163
prim@@	O	-1	2673163
ari@@	O	-1	2673163
ly	O	-1	2673163
in	O	-1	2673163
youn@@	O	-1	2673163
g	O	-1	2673163
ad@@	O	-1	2673163
ult@@	O	-1	2673163
s;	O	-1	2673163
(3@@	O	-1	2673163
)	O	-1	2673163
strok@@	B-Disease	D020521	2673163
e	I-Disease	-1	2673163
may	O	-1	2673163
fol@@	O	-1	2673163
low	O	-1	2673163
any	O	-1	2673163
ro@@	O	-1	2673163
ute	O	-1	2673163
of	O	-1	2673163
cocaine	B-Chemical	D003042	2673163
administr@@	O	-1	2673163
ation@@	O	-1	2673163
;	O	-1	2673163
(4@@	O	-1	2673163
)	O	-1	2673163
strok@@	B-Disease	D020521	2673163
e	I-Disease	-1	2673163
after	O	-1	2673163
cocaine	B-Chemical	D003042	2673163
use	O	-1	2673163
is	O	-1	2673163
frequ@@	O	-1	2673163
ently	O	-1	2673163
associated	O	-1	2673163
with	O	-1	2673163
intrac@@	B-Disease	D002532	2673163
ranial	I-Disease	-1	2673163
aneurys@@	I-Disease	-1	2673163
ms	I-Disease	-1	2673163
and	O	-1	2673163
arter@@	B-Disease	D001165	2673163
io@@	I-Disease	-1	2673163
venous	I-Disease	-1	2673163
mal@@	I-Disease	-1	2673163
form@@	I-Disease	-1	2673163
ations	I-Disease	-1	2673163
;	O	-1	2673163
and	O	-1	2673163
(5@@	O	-1	2673163
)	O	-1	2673163
in	O	-1	2673163
cocaine	B-Chemical	D003042	2673163
-@@	O	-1	2673163
associated	O	-1	2673163
strok@@	B-Disease	D020521	2673163
e	I-Disease	-1	2673163
,	O	-1	2673163
the	O	-1	2673163
frequency	O	-1	2673163
of	O	-1	2673163
intrac@@	B-Disease	D020300	2673163
ranial	I-Disease	-1	2673163
hemorrh@@	I-Disease	-1	2673163
age	I-Disease	-1	2673163
ex@@	O	-1	2673163
ce@@	O	-1	2673163
ed@@	O	-1	2673163
s	O	-1	2673163
that	O	-1	2673163
of	O	-1	2673163
cerebral	B-Disease	D002544	2673163
infarction	I-Disease	-1	2673163
.	O	-1	2673163

G@@	B-Chemical	D005905	3107448
ly@@	I-Chemical	-1	3107448
b@@	I-Chemical	-1	3107448
ur@@	I-Chemical	-1	3107448
ide	I-Chemical	-1	3107448
-induced	O	-1	3107448
hepatitis	B-Disease	D056486	3107448
.	O	-1	3107448
D@@	O	-1	3107448
ru@@	O	-1	3107448
g@@	O	-1	3107448
-induced	O	-1	3107448
hepat@@	B-Disease	D056486	3107448
otoxicity	I-Disease	-1	3107448
,	O	-1	3107448
although	O	-1	3107448
common@@	O	-1	3107448
,	O	-1	3107448
has	O	-1	3107448
been	O	-1	3107448
reported	O	-1	3107448
only	O	-1	3107448
inf@@	O	-1	3107448
requ@@	O	-1	3107448
ently	O	-1	3107448
with	O	-1	3107448
sulf@@	B-Chemical	D013453	3107448
on@@	I-Chemical	-1	3107448
yl@@	I-Chemical	-1	3107448
ure@@	I-Chemical	-1	3107448
as	I-Chemical	-1	3107448
.	O	-1	3107448
F@@	O	-1	3107448
or	O	-1	3107448
gly@@	B-Chemical	D005905	3107448
b@@	I-Chemical	-1	3107448
ur@@	I-Chemical	-1	3107448
ide	I-Chemical	-1	3107448
,	O	-1	3107448
a	O	-1	3107448
secon@@	O	-1	3107448
d-@@	O	-1	3107448
generation	O	-1	3107448
sulf@@	B-Chemical	D013453	3107448
on@@	I-Chemical	-1	3107448
yl@@	I-Chemical	-1	3107448
ure@@	I-Chemical	-1	3107448
a	I-Chemical	-1	3107448
,	O	-1	3107448
only	O	-1	3107448
two	O	-1	3107448
b@@	O	-1	3107448
ri@@	O	-1	3107448
e@@	O	-1	3107448
f	O	-1	3107448
reports	O	-1	3107448
of	O	-1	3107448
hepat@@	B-Disease	D056486	3107448
otoxicity	I-Disease	-1	3107448
ex@@	O	-1	3107448
ist@@	O	-1	3107448
.	O	-1	3107448
Two	O	-1	3107448
patients	O	-1	3107448
with	O	-1	3107448
type	B-Disease	D003924	3107448
II	I-Disease	-1	3107448
dia@@	I-Disease	-1	3107448
bet@@	I-Disease	-1	3107448
es	I-Disease	-1	3107448
me@@	I-Disease	-1	3107448
ll@@	I-Disease	-1	3107448
it@@	I-Disease	-1	3107448
us	I-Disease	-1	3107448
developed	O	-1	3107448
an	O	-1	3107448
acute	B-Disease	D056486	3107448
hepati@@	I-Disease	-1	3107448
tis@@	I-Disease	-1	3107448
-@@	I-Disease	-1	3107448
like	I-Disease	-1	3107448
syndrome	I-Disease	-1	3107448
so@@	O	-1	3107448
on	O	-1	3107448
after	O	-1	3107448
initi@@	O	-1	3107448
ation	O	-1	3107448
of	O	-1	3107448
gly@@	B-Chemical	D005905	3107448
b@@	I-Chemical	-1	3107448
ur@@	I-Chemical	-1	3107448
ide	I-Chemical	-1	3107448
therapy.	O	-1	3107448
There	O	-1	3107448
was	O	-1	3107448
no	O	-1	3107448
ser@@	O	-1	3107448
ologic	O	-1	3107448
evidence	O	-1	3107448
of	O	-1	3107448
viral	B-Disease	D014777	3107448
inf@@	I-Disease	-1	3107448
ection	I-Disease	-1	3107448
,	O	-1	3107448
and	O	-1	3107448
a	O	-1	3107448
liver	O	-1	3107448
biop@@	O	-1	3107448
sy	O	-1	3107448
sam@@	O	-1	3107448
ple	O	-1	3107448
showed	O	-1	3107448
a	O	-1	3107448
hist@@	O	-1	3107448
ologic	O	-1	3107448
pat@@	O	-1	3107448
ter@@	O	-1	3107448
n	O	-1	3107448
consist@@	O	-1	3107448
ent	O	-1	3107448
with	O	-1	3107448
drug@@	B-Disease	D056486	3107448
-induced	I-Disease	-1	3107448
hepatitis	I-Disease	-1	3107448
.	O	-1	3107448
B@@	O	-1	3107448
oth	O	-1	3107448
patients	O	-1	3107448
reco@@	O	-1	3107448
vered	O	-1	3107448
qu@@	O	-1	3107448
ic@@	O	-1	3107448
k@@	O	-1	3107448
ly	O	-1	3107448
after	O	-1	3107448
sto@@	O	-1	3107448
pp@@	O	-1	3107448
ing	O	-1	3107448
gly@@	B-Chemical	D005905	3107448
b@@	I-Chemical	-1	3107448
ur@@	I-Chemical	-1	3107448
ide	I-Chemical	-1	3107448
therapy	O	-1	3107448
and	O	-1	3107448
have	O	-1	3107448
remained	O	-1	3107448
well	O	-1	3107448
for	O	-1	3107448
a	O	-1	3107448
follow-up	O	-1	3107448
period	O	-1	3107448
of	O	-1	3107448
1	O	-1	3107448
year@@	O	-1	3107448
.	O	-1	3107448
G@@	B-Chemical	D005905	3107448
ly@@	I-Chemical	-1	3107448
b@@	I-Chemical	-1	3107448
ur@@	I-Chemical	-1	3107448
ide	I-Chemical	-1	3107448
can	O	-1	3107448
produce	O	-1	3107448
an	O	-1	3107448
acute	B-Disease	D056486	3107448
hepati@@	I-Disease	-1	3107448
tis@@	I-Disease	-1	3107448
-@@	I-Disease	-1	3107448
like	I-Disease	-1	3107448
ill@@	I-Disease	-1	3107448
ness	I-Disease	-1	3107448
in	O	-1	3107448
some	O	-1	3107448
per@@	O	-1	3107448
son@@	O	-1	3107448
s.	O	-1	3107448

S@@	O	-1	3341566
y@@	O	-1	3341566
st@@	O	-1	3341566
olic	O	-1	3341566
pressure	O	-1	3341566
vari@@	O	-1	3341566
ation	O	-1	3341566
is	O	-1	3341566
greater	O	-1	3341566
during	O	-1	3341566
hemorrh@@	B-Disease	D006470	3341566
age	I-Disease	-1	3341566
than	O	-1	3341566
during	O	-1	3341566
sodium	B-Chemical	D009599	3341566
nitro@@	I-Chemical	-1	3341566
pr@@	I-Chemical	-1	3341566
us@@	I-Chemical	-1	3341566
side	I-Chemical	-1	3341566
-induced	O	-1	3341566
hypotension	B-Disease	D007022	3341566
in	O	-1	3341566
ven@@	O	-1	3341566
til@@	O	-1	3341566
ated	O	-1	3341566
dog@@	O	-1	3341566
s.	O	-1	3341566
The	O	-1	3341566
systolic	O	-1	3341566
pressure	O	-1	3341566
vari@@	O	-1	3341566
ation	O	-1	3341566
(S@@	O	-1	3341566
P@@	O	-1	3341566
V@@	O	-1	3341566
),	O	-1	3341566
which	O	-1	3341566
is	O	-1	3341566
the	O	-1	3341566
difference	O	-1	3341566
between	O	-1	3341566
the	O	-1	3341566
maxim@@	O	-1	3341566
al	O	-1	3341566
and	O	-1	3341566
minim@@	O	-1	3341566
al	O	-1	3341566
values	O	-1	3341566
of	O	-1	3341566
the	O	-1	3341566
systolic	O	-1	3341566
blood	O	-1	3341566
pressure	O	-1	3341566
(S@@	O	-1	3341566
B@@	O	-1	3341566
P)	O	-1	3341566
after	O	-1	3341566
one	O	-1	3341566
posi@@	O	-1	3341566
ti@@	O	-1	3341566
ve@@	O	-1	3341566
-@@	O	-1	3341566
pressure	O	-1	3341566
b@@	O	-1	3341566
re@@	O	-1	3341566
ath@@	O	-1	3341566
,	O	-1	3341566
was	O	-1	3341566
studied	O	-1	3341566
in	O	-1	3341566
ven@@	O	-1	3341566
til@@	O	-1	3341566
ated	O	-1	3341566
dog@@	O	-1	3341566
s	O	-1	3341566
subj@@	O	-1	3341566
ected	O	-1	3341566
to	O	-1	3341566
hypotension	B-Disease	D007022	3341566
.	O	-1	3341566
M@@	O	-1	3341566
e@@	O	-1	3341566
an	O	-1	3341566
arterial	O	-1	3341566
pressure	O	-1	3341566
was	O	-1	3341566
decreased	O	-1	3341566
to	O	-1	3341566
50	O	-1	3341566
mm	O	-1	3341566
H@@	O	-1	3341566
g	O	-1	3341566
for	O	-1	3341566
30	O	-1	3341566
minutes	O	-1	3341566
either	O	-1	3341566
by	O	-1	3341566
hemorrh@@	B-Disease	D006470	3341566
age	I-Disease	-1	3341566
(	O	-1	3341566
H@@	B-Disease	D006470	3341566
E@@	I-Disease	-1	3341566
M	I-Disease	-1	3341566
,	O	-1	3341566
n	O	-1	3341566
=	O	-1	3341566
7@@	O	-1	3341566
)	O	-1	3341566
or	O	-1	3341566
by	O	-1	3341566
continu@@	O	-1	3341566
ous	O	-1	3341566
infusion	O	-1	3341566
of	O	-1	3341566
sodium	B-Chemical	D009599	3341566
nitro@@	I-Chemical	-1	3341566
pr@@	I-Chemical	-1	3341566
us@@	I-Chemical	-1	3341566
side	I-Chemical	-1	3341566
(	O	-1	3341566
S@@	B-Chemical	D009599	3341566
N@@	I-Chemical	-1	3341566
P	I-Chemical	-1	3341566
,	O	-1	3341566
n	O	-1	3341566
=	O	-1	3341566
7@@	O	-1	3341566
).	O	-1	3341566
D@@	O	-1	3341566
uring	O	-1	3341566
H@@	B-Disease	D006470	3341566
E@@	I-Disease	-1	3341566
M	I-Disease	-1	3341566
-induced	O	-1	3341566
hypotension	B-Disease	D007022	3341566
the	O	-1	3341566
cardiac	O	-1	3341566
out@@	O	-1	3341566
pu@@	O	-1	3341566
t	O	-1	3341566
was	O	-1	3341566
significantly	O	-1	3341566
lower	O	-1	3341566
and	O	-1	3341566
systemic	O	-1	3341566
vascular	O	-1	3341566
resist@@	O	-1	3341566
ance	O	-1	3341566
higher	O	-1	3341566
compared	O	-1	3341566
with	O	-1	3341566
that	O	-1	3341566
in	O	-1	3341566
the	O	-1	3341566
S@@	B-Chemical	D009599	3341566
N@@	I-Chemical	-1	3341566
P	I-Chemical	-1	3341566
group.	O	-1	3341566
The	O	-1	3341566
system@@	O	-1	3341566
ic@@	O	-1	3341566
,	O	-1	3341566
central	O	-1	3341566
ven@@	O	-1	3341566
ou@@	O	-1	3341566
s,	O	-1	3341566
pulmonary	O	-1	3341566
cap@@	O	-1	3341566
ill@@	O	-1	3341566
ary	O	-1	3341566
we@@	O	-1	3341566
d@@	O	-1	3341566
ge	O	-1	3341566
pressu@@	O	-1	3341566
res@@	O	-1	3341566
,	O	-1	3341566
and	O	-1	3341566
heart	O	-1	3341566
rat@@	O	-1	3341566
es,	O	-1	3341566
were	O	-1	3341566
similar	O	-1	3341566
in	O	-1	3341566
the	O	-1	3341566
two	O	-1	3341566
groups.	O	-1	3341566
An@@	O	-1	3341566
aly@@	O	-1	3341566
sis	O	-1	3341566
of	O	-1	3341566
the	O	-1	3341566
respiratory	O	-1	3341566
changes	O	-1	3341566
in	O	-1	3341566
the	O	-1	3341566
arterial	O	-1	3341566
pressure	O	-1	3341566
w@@	O	-1	3341566
a@@	O	-1	3341566
ve@@	O	-1	3341566
form	O	-1	3341566
en@@	O	-1	3341566
abl@@	O	-1	3341566
ed	O	-1	3341566
differen@@	O	-1	3341566
ti@@	O	-1	3341566
ation	O	-1	3341566
between	O	-1	3341566
the	O	-1	3341566
two	O	-1	3341566
groups.	O	-1	3341566
The	O	-1	3341566
S@@	O	-1	3341566
P@@	O	-1	3341566
V	O	-1	3341566
during	O	-1	3341566
hypotension	B-Disease	D007022	3341566
was	O	-1	3341566
1@@	O	-1	3341566
5.@@	O	-1	3341566
7	O	-1	3341566
+/-	O	-1	3341566
6.@@	O	-1	3341566
7	O	-1	3341566
mm	O	-1	3341566
H@@	O	-1	3341566
g	O	-1	3341566
in	O	-1	3341566
the	O	-1	3341566
H@@	B-Disease	D006470	3341566
E@@	I-Disease	-1	3341566
M	I-Disease	-1	3341566
group@@	O	-1	3341566
,	O	-1	3341566
compared	O	-1	3341566
with	O	-1	3341566
9.@@	O	-1	3341566
1	O	-1	3341566
+/-	O	-1	3341566
2.@@	O	-1	3341566
0	O	-1	3341566
mm	O	-1	3341566
H@@	O	-1	3341566
g	O	-1	3341566
in	O	-1	3341566
the	O	-1	3341566
S@@	B-Chemical	D009599	3341566
N@@	I-Chemical	-1	3341566
P	I-Chemical	-1	3341566
group	O	-1	3341566
(P	O	-1	3341566
less	O	-1	3341566
than	O	-1	3341566
0.0@@	O	-1	3341566
2@@	O	-1	3341566
).	O	-1	3341566
The	O	-1	3341566
del@@	O	-1	3341566
t@@	O	-1	3341566
a	O	-1	3341566
do@@	O	-1	3341566
w@@	O	-1	3341566
n@@	O	-1	3341566
,	O	-1	3341566
which	O	-1	3341566
is	O	-1	3341566
the	O	-1	3341566
meas@@	O	-1	3341566
ure	O	-1	3341566
of	O	-1	3341566
decrease	O	-1	3341566
of	O	-1	3341566
S@@	O	-1	3341566
B@@	O	-1	3341566
P	O	-1	3341566
after	O	-1	3341566
a	O	-1	3341566
mechan@@	O	-1	3341566
ical	O	-1	3341566
b@@	O	-1	3341566
re@@	O	-1	3341566
ath@@	O	-1	3341566
,	O	-1	3341566
was	O	-1	3341566
2@@	O	-1	3341566
0.@@	O	-1	3341566
3	O	-1	3341566
+/-	O	-1	3341566
8.@@	O	-1	3341566
4	O	-1	3341566
and	O	-1	3341566
1@@	O	-1	3341566
0.@@	O	-1	3341566
1	O	-1	3341566
+/-	O	-1	3341566
3.@@	O	-1	3341566
8	O	-1	3341566
mm	O	-1	3341566
H@@	O	-1	3341566
g	O	-1	3341566
in	O	-1	3341566
the	O	-1	3341566
H@@	B-Disease	D006470	3341566
E@@	I-Disease	-1	3341566
M	I-Disease	-1	3341566
and	O	-1	3341566
S@@	B-Chemical	D009599	3341566
N@@	I-Chemical	-1	3341566
P	I-Chemical	-1	3341566
group@@	O	-1	3341566
s,	O	-1	3341566
respectivel@@	O	-1	3341566
y,	O	-1	3341566
during	O	-1	3341566
hypotension	B-Disease	D007022	3341566
(P	O	-1	3341566
less	O	-1	3341566
than	O	-1	3341566
0.0@@	O	-1	3341566
2@@	O	-1	3341566
).	O	-1	3341566
It	O	-1	3341566
is	O	-1	3341566
concl@@	O	-1	3341566
uded	O	-1	3341566
that	O	-1	3341566
increases	O	-1	3341566
in	O	-1	3341566
the	O	-1	3341566
S@@	O	-1	3341566
P@@	O	-1	3341566
V	O	-1	3341566
and	O	-1	3341566
the	O	-1	3341566
del@@	O	-1	3341566
t@@	O	-1	3341566
a	O	-1	3341566
do@@	O	-1	3341566
w@@	O	-1	3341566
n	O	-1	3341566
are	O	-1	3341566
character@@	O	-1	3341566
istic	O	-1	3341566
of	O	-1	3341566
a	O	-1	3341566
hypoten@@	B-Disease	D007022	3341566
sive	I-Disease	-1	3341566
state	O	-1	3341566
due	O	-1	3341566
to	O	-1	3341566
a	O	-1	3341566
pre@@	O	-1	3341566
domin@@	O	-1	3341566
ant	O	-1	3341566
decrease	O	-1	3341566
in	O	-1	3341566
pre@@	O	-1	3341566
lo@@	O	-1	3341566
ad@@	O	-1	3341566
.	O	-1	3341566
The@@	O	-1	3341566
y	O	-1	3341566
are	O	-1	3341566
th@@	O	-1	3341566
us	O	-1	3341566
more	O	-1	3341566
important	O	-1	3341566
during	O	-1	3341566
abs@@	O	-1	3341566
ol@@	O	-1	3341566
ute	O	-1	3341566
hypo@@	B-Disease	D020896	3341566
vol@@	I-Disease	-1	3341566
emia	I-Disease	-1	3341566
than	O	-1	3341566
during	O	-1	3341566
de@@	O	-1	3341566
li@@	O	-1	3341566
b@@	O	-1	3341566
er@@	O	-1	3341566
ate	O	-1	3341566
hypotension	B-Disease	D007022	3341566
.	O	-1	3341566

D@@	O	-1	3564823
ru@@	O	-1	3564823
g@@	O	-1	3564823
-induced	O	-1	3564823
arterial	O	-1	3564823
sp@@	B-Disease	D013035	3564823
as@@	I-Disease	-1	3564823
m	I-Disease	-1	3564823
re@@	O	-1	3564823
li@@	O	-1	3564823
ev@@	O	-1	3564823
ed	O	-1	3564823
by	O	-1	3564823
lidocaine	B-Chemical	D008012	3564823
.	O	-1	3564823
C@@	O	-1	3564823
ase	O	-1	3564823
repor@@	O	-1	3564823
t.	O	-1	3564823
F@@	O	-1	3564823
ol@@	O	-1	3564823
low@@	O	-1	3564823
ing	O	-1	3564823
major	O	-1	3564823
intrac@@	O	-1	3564823
ranial	O	-1	3564823
surger@@	O	-1	3564823
y	O	-1	3564823
in	O	-1	3564823
a	O	-1	3564823
3@@	O	-1	3564823
5-@@	O	-1	3564823
year-old	O	-1	3564823
man@@	O	-1	3564823
,	O	-1	3564823
sodium	B-Chemical	D013874	3564823
pent@@	I-Chemical	-1	3564823
o@@	I-Chemical	-1	3564823
th@@	I-Chemical	-1	3564823
al	I-Chemical	-1	3564823
was	O	-1	3564823
intra@@	O	-1	3564823
ven@@	O	-1	3564823
ously	O	-1	3564823
inf@@	O	-1	3564823
used	O	-1	3564823
to	O	-1	3564823
minim@@	O	-1	3564823
iz@@	O	-1	3564823
e	O	-1	3564823
cerebral	B-Disease	D002545	3564823
is@@	I-Disease	-1	3564823
ch@@	I-Disease	-1	3564823
a@@	I-Disease	-1	3564823
emia	I-Disease	-1	3564823
.	O	-1	3564823
In@@	O	-1	3564823
ten@@	O	-1	3564823
se	O	-1	3564823
vas@@	B-Disease	D020301	3564823
os@@	I-Disease	-1	3564823
p@@	I-Disease	-1	3564823
as@@	I-Disease	-1	3564823
m	I-Disease	-1	3564823
with	O	-1	3564823
th@@	O	-1	3564823
reat@@	O	-1	3564823
en@@	O	-1	3564823
ed	O	-1	3564823
g@@	B-Disease	D005734	3564823
ang@@	I-Disease	-1	3564823
ren@@	I-Disease	-1	3564823
e	I-Disease	-1	3564823
a@@	O	-1	3564823
ro@@	O	-1	3564823
se	O	-1	3564823
in	O	-1	3564823
the	O	-1	3564823
ar@@	O	-1	3564823
m	O	-1	3564823
used	O	-1	3564823
for	O	-1	3564823
the	O	-1	3564823
infu@@	O	-1	3564823
sion.	O	-1	3564823
S@@	O	-1	3564823
inc@@	O	-1	3564823
e	O	-1	3564823
the	O	-1	3564823
c@@	O	-1	3564823
ranial	O	-1	3564823
condi@@	O	-1	3564823
tion	O	-1	3564823
pre@@	O	-1	3564823
cl@@	O	-1	3564823
uded	O	-1	3564823
use	O	-1	3564823
of	O	-1	3564823
more	O	-1	3564823
us@@	O	-1	3564823
ual	O	-1	3564823
meth@@	O	-1	3564823
o@@	O	-1	3564823
d@@	O	-1	3564823
s,	O	-1	3564823
lidocaine	B-Chemical	D008012	3564823
was	O	-1	3564823
given	O	-1	3564823
intra@@	O	-1	3564823
-@@	O	-1	3564823
arter@@	O	-1	3564823
i@@	O	-1	3564823
ally,	O	-1	3564823
with	O	-1	3564823
ca@@	O	-1	3564823
ref@@	O	-1	3564823
u@@	O	-1	3564823
l	O	-1	3564823
cardiovascular	O	-1	3564823
monit@@	O	-1	3564823
or@@	O	-1	3564823
ing,	O	-1	3564823
to	O	-1	3564823
coun@@	O	-1	3564823
ter@@	O	-1	3564823
ac@@	O	-1	3564823
t	O	-1	3564823
the	O	-1	3564823
vas@@	B-Disease	D020301	3564823
os@@	I-Disease	-1	3564823
p@@	I-Disease	-1	3564823
as@@	I-Disease	-1	3564823
m	I-Disease	-1	3564823
.	O	-1	3564823
The	O	-1	3564823
treatment	O	-1	3564823
was	O	-1	3564823
ra@@	O	-1	3564823
pid@@	O	-1	3564823
ly	O	-1	3564823
suc@@	O	-1	3564823
cess@@	O	-1	3564823
ful@@	O	-1	3564823
.	O	-1	3564823

C@@	O	-1	3676049
e@@	O	-1	3676049
rebral	O	-1	3676049
blood	O	-1	3676049
flow	O	-1	3676049
and	O	-1	3676049
metabol@@	O	-1	3676049
ism	O	-1	3676049
during	O	-1	3676049
iso@@	B-Chemical	D007530	3676049
f@@	I-Chemical	-1	3676049
lur@@	I-Chemical	-1	3676049
ane	I-Chemical	-1	3676049
-induced	O	-1	3676049
hypotension	B-Disease	D007022	3676049
in	O	-1	3676049
patients	O	-1	3676049
subj@@	O	-1	3676049
ected	O	-1	3676049
to	O	-1	3676049
surger@@	O	-1	3676049
y	O	-1	3676049
for	O	-1	3676049
cerebral	B-Disease	D002532	3676049
aneurys@@	I-Disease	-1	3676049
ms	I-Disease	-1	3676049
.	O	-1	3676049
C@@	O	-1	3676049
e@@	O	-1	3676049
rebral	O	-1	3676049
blood	O	-1	3676049
flow	O	-1	3676049
and	O	-1	3676049
cerebral	O	-1	3676049
met@@	O	-1	3676049
ab@@	O	-1	3676049
olic	O	-1	3676049
rate	O	-1	3676049
for	O	-1	3676049
oxy@@	B-Chemical	D010100	3676049
gen	I-Chemical	-1	3676049
were	O	-1	3676049
measured	O	-1	3676049
during	O	-1	3676049
iso@@	B-Chemical	D007530	3676049
f@@	I-Chemical	-1	3676049
lur@@	I-Chemical	-1	3676049
ane	I-Chemical	-1	3676049
-induced	O	-1	3676049
hypotension	B-Disease	D007022	3676049
in	O	-1	3676049
10	O	-1	3676049
patients	O	-1	3676049
subj@@	O	-1	3676049
ected	O	-1	3676049
to	O	-1	3676049
c@@	O	-1	3676049
ran@@	O	-1	3676049
i@@	O	-1	3676049
ot@@	O	-1	3676049
om@@	O	-1	3676049
y	O	-1	3676049
for	O	-1	3676049
c@@	O	-1	3676049
li@@	O	-1	3676049
pp@@	O	-1	3676049
ing	O	-1	3676049
of	O	-1	3676049
a	O	-1	3676049
cerebral	B-Disease	D002532	3676049
aneurys@@	I-Disease	-1	3676049
m	I-Disease	-1	3676049
.	O	-1	3676049
F@@	O	-1	3676049
low	O	-1	3676049
and	O	-1	3676049
metabol@@	O	-1	3676049
ism	O	-1	3676049
were	O	-1	3676049
measured	O	-1	3676049
5-@@	O	-1	3676049
13	O	-1	3676049
days	O	-1	3676049
after	O	-1	3676049
the	O	-1	3676049
sub@@	B-Disease	D013345	3676049
arac@@	I-Disease	-1	3676049
h@@	I-Disease	-1	3676049
no@@	I-Disease	-1	3676049
id	I-Disease	-1	3676049
haem@@	I-Disease	-1	3676049
or@@	I-Disease	-1	3676049
rh@@	I-Disease	-1	3676049
age	I-Disease	-1	3676049
by	O	-1	3676049
a	O	-1	3676049
mo@@	O	-1	3676049
di@@	O	-1	3676049
fic@@	O	-1	3676049
ation	O	-1	3676049
of	O	-1	3676049
the	O	-1	3676049
cl@@	O	-1	3676049
assi@@	O	-1	3676049
c@@	O	-1	3676049
al	O	-1	3676049
K@@	O	-1	3676049
et@@	O	-1	3676049
y-@@	O	-1	3676049
S@@	O	-1	3676049
ch@@	O	-1	3676049
mid@@	O	-1	3676049
t	O	-1	3676049
t@@	O	-1	3676049
ech@@	O	-1	3676049
n@@	O	-1	3676049
i@@	O	-1	3676049
qu@@	O	-1	3676049
e	O	-1	3676049
using	O	-1	3676049
x@@	B-Chemical	D014978	3676049
en@@	I-Chemical	-1	3676049
on	I-Chemical	-1	3676049
-1@@	O	-1	3676049
3@@	O	-1	3676049
3	O	-1	3676049
i.v@@	O	-1	3676049
.	O	-1	3676049
An@@	O	-1	3676049
a@@	O	-1	3676049
esthe@@	O	-1	3676049
sia	O	-1	3676049
was	O	-1	3676049
maint@@	O	-1	3676049
ained	O	-1	3676049
with	O	-1	3676049
an	O	-1	3676049
in@@	O	-1	3676049
s@@	O	-1	3676049
pi@@	O	-1	3676049
red	O	-1	3676049
iso@@	B-Chemical	D007530	3676049
f@@	I-Chemical	-1	3676049
lur@@	I-Chemical	-1	3676049
ane	I-Chemical	-1	3676049
concentration	O	-1	3676049
of	O	-1	3676049
0.@@	O	-1	3676049
7@@	O	-1	3676049
5%	O	-1	3676049
(@@	O	-1	3676049
plus	O	-1	3676049
6@@	O	-1	3676049
7@@	O	-1	3676049
%	O	-1	3676049
nit@@	B-Chemical	D009609	3676049
rou@@	I-Chemical	-1	3676049
s	I-Chemical	-1	3676049
ox@@	I-Chemical	-1	3676049
ide	I-Chemical	-1	3676049
in	O	-1	3676049
oxy@@	B-Chemical	D010100	3676049
gen	I-Chemical	-1	3676049
),	O	-1	3676049
during	O	-1	3676049
which	O	-1	3676049
C@@	O	-1	3676049
B@@	O	-1	3676049
F	O	-1	3676049
and	O	-1	3676049
C@@	O	-1	3676049
M@@	O	-1	3676049
RO@@	O	-1	3676049
2	O	-1	3676049
were	O	-1	3676049
3@@	O	-1	3676049
4.@@	O	-1	3676049
3	O	-1	3676049
+/-	O	-1	3676049
2.@@	O	-1	3676049
1	O	-1	3676049
ml@@	O	-1	3676049
/@@	O	-1	3676049
100	O	-1	3676049
g	O	-1	3676049
min@@	O	-1	3676049
-1	O	-1	3676049
and	O	-1	3676049
2.@@	O	-1	3676049
3@@	O	-1	3676049
2	O	-1	3676049
+/-	O	-1	3676049
0.@@	O	-1	3676049
16	O	-1	3676049
ml@@	O	-1	3676049
/@@	O	-1	3676049
100	O	-1	3676049
g	O	-1	3676049
min@@	O	-1	3676049
-1	O	-1	3676049
at	O	-1	3676049
P@@	O	-1	3676049
a@@	O	-1	3676049
CO@@	O	-1	3676049
2	O	-1	3676049
4.@@	O	-1	3676049
1	O	-1	3676049
+/-	O	-1	3676049
0.@@	O	-1	3676049
1	O	-1	3676049
k@@	O	-1	3676049
P@@	O	-1	3676049
a	O	-1	3676049
(@@	O	-1	3676049
mean	O	-1	3676049
+/-	O	-1	3676049
S@@	O	-1	3676049
E@@	O	-1	3676049
M@@	O	-1	3676049
).	O	-1	3676049
C@@	O	-1	3676049
ont@@	O	-1	3676049
ro@@	O	-1	3676049
lled	O	-1	3676049
hypotension	B-Disease	D007022	3676049
to	O	-1	3676049
an	O	-1	3676049
average	O	-1	3676049
MA@@	O	-1	3676049
P	O	-1	3676049
of	O	-1	3676049
50@@	O	-1	3676049
-@@	O	-1	3676049
5@@	O	-1	3676049
5	O	-1	3676049
mm	O	-1	3676049
H@@	B-Chemical	D008628	3676049
g	I-Chemical	-1	3676049
was	O	-1	3676049
induced	O	-1	3676049
by	O	-1	3676049
increas@@	O	-1	3676049
ing	O	-1	3676049
the	O	-1	3676049
dose	O	-1	3676049
of	O	-1	3676049
iso@@	B-Chemical	D007530	3676049
f@@	I-Chemical	-1	3676049
lur@@	I-Chemical	-1	3676049
ane	I-Chemical	-1	3676049
,	O	-1	3676049
and	O	-1	3676049
maint@@	O	-1	3676049
ained	O	-1	3676049
at	O	-1	3676049
an	O	-1	3676049
in@@	O	-1	3676049
s@@	O	-1	3676049
pi@@	O	-1	3676049
red	O	-1	3676049
concentration	O	-1	3676049
of	O	-1	3676049
2.@@	O	-1	3676049
2	O	-1	3676049
+/-	O	-1	3676049
0.@@	O	-1	3676049
2@@	O	-1	3676049
%.	O	-1	3676049
This	O	-1	3676049
resulted	O	-1	3676049
in	O	-1	3676049
a	O	-1	3676049
significant	O	-1	3676049
decrease	O	-1	3676049
in	O	-1	3676049
C@@	O	-1	3676049
M@@	O	-1	3676049
RO@@	O	-1	3676049
2	O	-1	3676049
(@@	O	-1	3676049
to	O	-1	3676049
1.@@	O	-1	3676049
7@@	O	-1	3676049
3	O	-1	3676049
+/-	O	-1	3676049
0.@@	O	-1	3676049
16	O	-1	3676049
ml@@	O	-1	3676049
/@@	O	-1	3676049
100	O	-1	3676049
g	O	-1	3676049
min@@	O	-1	3676049
-1@@	O	-1	3676049
),	O	-1	3676049
while	O	-1	3676049
C@@	O	-1	3676049
B@@	O	-1	3676049
F	O	-1	3676049
was	O	-1	3676049
un@@	O	-1	3676049
chang@@	O	-1	3676049
ed.	O	-1	3676049
After	O	-1	3676049
the	O	-1	3676049
c@@	O	-1	3676049
li@@	O	-1	3676049
pp@@	O	-1	3676049
ing	O	-1	3676049
of	O	-1	3676049
the	O	-1	3676049
aneurys@@	B-Disease	D000783	3676049
m	I-Disease	-1	3676049
the	O	-1	3676049
iso@@	B-Chemical	D007530	3676049
f@@	I-Chemical	-1	3676049
lur@@	I-Chemical	-1	3676049
ane	I-Chemical	-1	3676049
concentration	O	-1	3676049
was	O	-1	3676049
reduced	O	-1	3676049
to	O	-1	3676049
0.@@	O	-1	3676049
7@@	O	-1	3676049
5@@	O	-1	3676049
%.	O	-1	3676049
There	O	-1	3676049
was	O	-1	3676049
a	O	-1	3676049
significant	O	-1	3676049
increase	O	-1	3676049
in	O	-1	3676049
C@@	O	-1	3676049
B@@	O	-1	3676049
F@@	O	-1	3676049
,	O	-1	3676049
although	O	-1	3676049
C@@	O	-1	3676049
M@@	O	-1	3676049
RO@@	O	-1	3676049
2	O	-1	3676049
was	O	-1	3676049
un@@	O	-1	3676049
chang@@	O	-1	3676049
ed,	O	-1	3676049
compared	O	-1	3676049
with	O	-1	3676049
pre@@	O	-1	3676049
-	O	-1	3676049
hypoten@@	B-Disease	D007022	3676049
sive	I-Disease	-1	3676049
valu@@	O	-1	3676049
es.	O	-1	3676049
These	O	-1	3676049
changes	O	-1	3676049
might	O	-1	3676049
o@@	O	-1	3676049
ff@@	O	-1	3676049
er	O	-1	3676049
prot@@	O	-1	3676049
ection	O	-1	3676049
to	O	-1	3676049
brain	O	-1	3676049
tissue	O	-1	3676049
during	O	-1	3676049
perio@@	O	-1	3676049
ds	O	-1	3676049
of	O	-1	3676049
induced	O	-1	3676049
hypotension	B-Disease	D007022	3676049
.	O	-1	3676049

A@@	B-Disease	D004342	3719553
ll@@	I-Disease	-1	3719553
ergic	I-Disease	-1	3719553
reaction	I-Disease	-1	3719553
to	O	-1	3719553
5-@@	B-Chemical	D005472	3719553
fluoro@@	I-Chemical	-1	3719553
urac@@	I-Chemical	-1	3719553
il	I-Chemical	-1	3719553
infu@@	O	-1	3719553
sion.	O	-1	3719553
An	O	-1	3719553
all@@	B-Disease	D004342	3719553
ergic	I-Disease	-1	3719553
reaction	I-Disease	-1	3719553
consist@@	O	-1	3719553
ing	O	-1	3719553
of	O	-1	3719553
angi@@	B-Disease	D000799	3719553
one@@	I-Disease	-1	3719553
uro@@	I-Disease	-1	3719553
tic	I-Disease	-1	3719553
e@@	I-Disease	-1	3719553
de@@	I-Disease	-1	3719553
ma	I-Disease	-1	3719553
secondary	O	-1	3719553
to	O	-1	3719553
continu@@	O	-1	3719553
ous	O	-1	3719553
infusion	O	-1	3719553
5-@@	B-Chemical	D005472	3719553
fluoro@@	I-Chemical	-1	3719553
urac@@	I-Chemical	-1	3719553
il	I-Chemical	-1	3719553
occurred	O	-1	3719553
in	O	-1	3719553
a	O	-1	3719553
patient	O	-1	3719553
with	O	-1	3719553
recur@@	O	-1	3719553
rent	O	-1	3719553
carcin@@	B-Disease	D009062	3719553
oma	I-Disease	-1	3719553
of	I-Disease	-1	3719553
the	I-Disease	-1	3719553
oral	I-Disease	-1	3719553
ca@@	I-Disease	-1	3719553
v@@	I-Disease	-1	3719553
ity	I-Disease	-1	3719553
,	O	-1	3719553
cir@@	B-Disease	D005355	3719553
r@@	I-Disease	-1	3719553
ho@@	I-Disease	-1	3719553
sis	I-Disease	-1	3719553
,	O	-1	3719553
and	O	-1	3719553
cisplatin	B-Chemical	D002945	3719553
-induced	O	-1	3719553
impaired	B-Disease	D007674	3719553
renal	I-Disease	-1	3719553
function	I-Disease	-1	3719553
.	O	-1	3719553
This	O	-1	3719553
reaction	O	-1	3719553
occurred	O	-1	3719553
during	O	-1	3719553
the	O	-1	3719553
si@@	O	-1	3719553
x@@	O	-1	3719553
th	O	-1	3719553
and	O	-1	3719553
sev@@	O	-1	3719553
ent@@	O	-1	3719553
h	O	-1	3719553
cour@@	O	-1	3719553
ses	O	-1	3719553
of	O	-1	3719553
infu@@	O	-1	3719553
sion@@	O	-1	3719553
al	O	-1	3719553
chemo@@	O	-1	3719553
therapy.	O	-1	3719553
O@@	O	-1	3719553
ral	O	-1	3719553
di@@	B-Chemical	D004155	3719553
phen@@	I-Chemical	-1	3719553
hy@@	I-Chemical	-1	3719553
d@@	I-Chemical	-1	3719553
r@@	I-Chemical	-1	3719553
amine	I-Chemical	-1	3719553
and	O	-1	3719553
pre@@	B-Chemical	D011241	3719553
d@@	I-Chemical	-1	3719553
n@@	I-Chemical	-1	3719553
is@@	I-Chemical	-1	3719553
one	I-Chemical	-1	3719553
were	O	-1	3719553
ine@@	O	-1	3719553
ff@@	O	-1	3719553
ective	O	-1	3719553
in	O	-1	3719553
prevent@@	O	-1	3719553
ing	O	-1	3719553
the	O	-1	3719553
recur@@	O	-1	3719553
rence	O	-1	3719553
of	O	-1	3719553
the	O	-1	3719553
all@@	B-Disease	D004342	3719553
ergic	I-Disease	-1	3719553
reaction	I-Disease	-1	3719553
.	O	-1	3719553
D@@	O	-1	3719553
is@@	O	-1	3719553
continu@@	O	-1	3719553
ance	O	-1	3719553
of	O	-1	3719553
effective	O	-1	3719553
chemotherapy	O	-1	3719553
in	O	-1	3719553
this	O	-1	3719553
patient	O	-1	3719553
during	O	-1	3719553
partial	O	-1	3719553
re@@	O	-1	3719553
mission	O	-1	3719553
resulted	O	-1	3719553
in	O	-1	3719553
f@@	O	-1	3719553
atal	O	-1	3719553
disease	O	-1	3719553
progres@@	O	-1	3719553
sion.	O	-1	3719553

A@@	B-Chemical	D000638	4008111
m@@	I-Chemical	-1	4008111
iodar@@	I-Chemical	-1	4008111
one	I-Chemical	-1	4008111
-induced	O	-1	4008111
s@@	B-Disease	D012848	4008111
ino@@	I-Disease	-1	4008111
atrial	I-Disease	-1	4008111
bloc@@	I-Disease	-1	4008111
k	I-Disease	-1	4008111
.	O	-1	4008111
We	O	-1	4008111
observed	O	-1	4008111
s@@	B-Disease	D012848	4008111
ino@@	I-Disease	-1	4008111
atrial	I-Disease	-1	4008111
bloc@@	I-Disease	-1	4008111
k	I-Disease	-1	4008111
due	O	-1	4008111
to	O	-1	4008111
chronic	O	-1	4008111
am@@	B-Chemical	D000638	4008111
iodar@@	I-Chemical	-1	4008111
one	I-Chemical	-1	4008111
administration	O	-1	4008111
in	O	-1	4008111
a	O	-1	4008111
5-@@	O	-1	4008111
year-old	O	-1	4008111
bo@@	O	-1	4008111
y	O	-1	4008111
with	O	-1	4008111
prim@@	B-Disease	D009202	4008111
ary	I-Disease	-1	4008111
cardi@@	I-Disease	-1	4008111
om@@	I-Disease	-1	4008111
yo@@	I-Disease	-1	4008111
pathy	I-Disease	-1	4008111
,	O	-1	4008111
W@@	B-Disease	D014927	4008111
ol@@	I-Disease	-1	4008111
ff@@	I-Disease	-1	4008111
-@@	I-Disease	-1	4008111
Parkinson@@	I-Disease	-1	4008111
-@@	I-Disease	-1	4008111
W@@	I-Disease	-1	4008111
h@@	I-Disease	-1	4008111
ite	I-Disease	-1	4008111
syndrome	I-Disease	-1	4008111
and	O	-1	4008111
sup@@	B-Disease	D013617	4008111
ra@@	I-Disease	-1	4008111
ventricular	I-Disease	-1	4008111
tachycardia	I-Disease	-1	4008111
.	O	-1	4008111
Re@@	O	-1	4008111
duction	O	-1	4008111
in	O	-1	4008111
the	O	-1	4008111
dos@@	O	-1	4008111
age	O	-1	4008111
of	O	-1	4008111
am@@	B-Chemical	D000638	4008111
iodar@@	I-Chemical	-1	4008111
one	I-Chemical	-1	4008111
resulted	O	-1	4008111
in	O	-1	4008111
the	O	-1	4008111
dis@@	O	-1	4008111
appear@@	O	-1	4008111
ance	O	-1	4008111
of	O	-1	4008111
the	O	-1	4008111
s@@	B-Disease	D012848	4008111
ino@@	I-Disease	-1	4008111
atrial	I-Disease	-1	4008111
bloc@@	I-Disease	-1	4008111
k	I-Disease	-1	4008111
and	O	-1	4008111
the	O	-1	4008111
per@@	O	-1	4008111
sist@@	O	-1	4008111
ence	O	-1	4008111
of	O	-1	4008111
as@@	O	-1	4008111
ym@@	O	-1	4008111
pto@@	O	-1	4008111
m@@	O	-1	4008111
atic	O	-1	4008111
s@@	B-Disease	D012804	4008111
in@@	I-Disease	-1	4008111
us	I-Disease	-1	4008111
brady@@	I-Disease	-1	4008111
cardia	I-Disease	-1	4008111
.	O	-1	4008111

P@@	O	-1	6133211
os@@	O	-1	6133211
sible	O	-1	6133211
ter@@	O	-1	6133211
at@@	O	-1	6133211
o@@	O	-1	6133211
gen@@	O	-1	6133211
ic@@	O	-1	6133211
ity	O	-1	6133211
of	O	-1	6133211
sul@@	B-Chemical	D012460	6133211
ph@@	I-Chemical	-1	6133211
as@@	I-Chemical	-1	6133211
al@@	I-Chemical	-1	6133211
az@@	I-Chemical	-1	6133211
ine	I-Chemical	-1	6133211
.	O	-1	6133211
Th@@	O	-1	6133211
ree	O	-1	6133211
inf@@	O	-1	6133211
ant@@	O	-1	6133211
s,	O	-1	6133211
b@@	O	-1	6133211
or@@	O	-1	6133211
n	O	-1	6133211
of	O	-1	6133211
two	O	-1	6133211
mo@@	O	-1	6133211
ther@@	O	-1	6133211
s	O	-1	6133211
with	O	-1	6133211
inflam@@	B-Disease	D015212	6133211
mat@@	I-Disease	-1	6133211
ory	I-Disease	-1	6133211
bo@@	I-Disease	-1	6133211
we@@	I-Disease	-1	6133211
l	I-Disease	-1	6133211
disease	I-Disease	-1	6133211
who	O	-1	6133211
received	O	-1	6133211
treatment	O	-1	6133211
with	O	-1	6133211
sul@@	B-Chemical	D012460	6133211
ph@@	I-Chemical	-1	6133211
as@@	I-Chemical	-1	6133211
al@@	I-Chemical	-1	6133211
az@@	I-Chemical	-1	6133211
ine	I-Chemical	-1	6133211
throu@@	O	-1	6133211
gh@@	O	-1	6133211
out	O	-1	6133211
pregn@@	O	-1	6133211
anc@@	O	-1	6133211
y,	O	-1	6133211
were	O	-1	6133211
found	O	-1	6133211
to	O	-1	6133211
have	O	-1	6133211
major	O	-1	6133211
con@@	B-Disease	D000013	6133211
gen@@	I-Disease	-1	6133211
it@@	I-Disease	-1	6133211
al	I-Disease	-1	6133211
an@@	I-Disease	-1	6133211
om@@	I-Disease	-1	6133211
al@@	I-Disease	-1	6133211
i@@	I-Disease	-1	6133211
es	I-Disease	-1	6133211
.	O	-1	6133211
In	O	-1	6133211
the	O	-1	6133211
sing@@	O	-1	6133211
le@@	O	-1	6133211
t@@	O	-1	6133211
on	O	-1	6133211
pregn@@	O	-1	6133211
anc@@	O	-1	6133211
y,	O	-1	6133211
the	O	-1	6133211
mo@@	O	-1	6133211
ther	O	-1	6133211
had	O	-1	6133211
ul@@	B-Disease	D003093	6133211
cer@@	I-Disease	-1	6133211
ative	I-Disease	-1	6133211
co@@	I-Disease	-1	6133211
li@@	I-Disease	-1	6133211
tis	I-Disease	-1	6133211
,	O	-1	6133211
and	O	-1	6133211
the	O	-1	6133211
inf@@	O	-1	6133211
ant@@	O	-1	6133211
,	O	-1	6133211
a	O	-1	6133211
mal@@	O	-1	6133211
e,	O	-1	6133211
had	O	-1	6133211
co@@	B-Disease	D001017	6133211
arc@@	I-Disease	-1	6133211
t@@	I-Disease	-1	6133211
ation	I-Disease	-1	6133211
of	I-Disease	-1	6133211
the	I-Disease	-1	6133211
a@@	I-Disease	-1	6133211
ort@@	I-Disease	-1	6133211
a	I-Disease	-1	6133211
and	O	-1	6133211
a	O	-1	6133211
ventricular	B-Disease	D006345	6133211
se@@	I-Disease	-1	6133211
pt@@	I-Disease	-1	6133211
al	I-Disease	-1	6133211
def@@	I-Disease	-1	6133211
ect	I-Disease	-1	6133211
.	O	-1	6133211
In	O	-1	6133211
the	O	-1	6133211
tw@@	O	-1	6133211
in	O	-1	6133211
pregn@@	O	-1	6133211
anc@@	O	-1	6133211
y,	O	-1	6133211
the	O	-1	6133211
mo@@	O	-1	6133211
ther	O	-1	6133211
had	O	-1	6133211
C@@	B-Disease	D003424	6133211
ro@@	I-Disease	-1	6133211
h@@	I-Disease	-1	6133211
n@@	I-Disease	-1	6133211
's	I-Disease	-1	6133211
disease	I-Disease	-1	6133211
.	O	-1	6133211
The	O	-1	6133211
first	O	-1	6133211
tw@@	O	-1	6133211
in,	O	-1	6133211
a	O	-1	6133211
femal@@	O	-1	6133211
e,	O	-1	6133211
had	O	-1	6133211
a	O	-1	6133211
left	O	-1	6133211
P@@	B-Disease	D007690	6133211
ot@@	I-Disease	-1	6133211
ter@@	I-Disease	-1	6133211
-@@	I-Disease	-1	6133211
type	I-Disease	-1	6133211
II@@	I-Disease	-1	6133211
a	I-Disease	-1	6133211
pol@@	I-Disease	-1	6133211
yc@@	I-Disease	-1	6133211
ys@@	I-Disease	-1	6133211
tic	I-Disease	-1	6133211
kidney	I-Disease	-1	6133211
and	O	-1	6133211
a	O	-1	6133211
ru@@	B-Disease	-1	6133211
di@@	I-Disease	-1	6133211
ment@@	I-Disease	-1	6133211
ary	I-Disease	-1	6133211
left	I-Disease	-1	6133211
u@@	I-Disease	-1	6133211
ter@@	I-Disease	-1	6133211
ine	I-Disease	-1	6133211
cor@@	I-Disease	-1	6133211
n@@	I-Disease	-1	6133211
u	I-Disease	-1	6133211
.	O	-1	6133211
The	O	-1	6133211
second	O	-1	6133211
tw@@	O	-1	6133211
in,	O	-1	6133211
a	O	-1	6133211
mal@@	O	-1	6133211
e,	O	-1	6133211
had	O	-1	6133211
some	O	-1	6133211
feat@@	O	-1	6133211
ures	O	-1	6133211
of	O	-1	6133211
P@@	B-Disease	-1	6133211
ot@@	I-Disease	-1	6133211
ter@@	I-Disease	-1	6133211
's	I-Disease	-1	6133211
fac@@	I-Disease	-1	6133211
i@@	I-Disease	-1	6133211
es	I-Disease	-1	6133211
,	O	-1	6133211
hypo@@	B-Disease	-1	6133211
plas@@	I-Disease	-1	6133211
tic	I-Disease	-1	6133211
l@@	I-Disease	-1	6133211
un@@	I-Disease	-1	6133211
g@@	I-Disease	-1	6133211
s	I-Disease	-1	6133211
,	O	-1	6133211
abs@@	B-Disease	-1	6133211
ent	I-Disease	-1	6133211
kidne@@	I-Disease	-1	6133211
ys	I-Disease	-1	6133211
and	I-Disease	-1	6133211
ure@@	I-Disease	-1	6133211
ters	I-Disease	-1	6133211
,	O	-1	6133211
and	O	-1	6133211
t@@	B-Disease	D003025	6133211
al@@	I-Disease	-1	6133211
ip@@	I-Disease	-1	6133211
es	I-Disease	-1	6133211
equ@@	I-Disease	-1	6133211
ino@@	I-Disease	-1	6133211
v@@	I-Disease	-1	6133211
ar@@	I-Disease	-1	6133211
us	I-Disease	-1	6133211
.	O	-1	6133211
D@@	O	-1	6133211
es@@	O	-1	6133211
pit@@	O	-1	6133211
e	O	-1	6133211
reports	O	-1	6133211
to	O	-1	6133211
the	O	-1	6133211
contr@@	O	-1	6133211
ar@@	O	-1	6133211
y,	O	-1	6133211
it	O	-1	6133211
is	O	-1	6133211
suggested	O	-1	6133211
that	O	-1	6133211
sul@@	B-Chemical	D012460	6133211
ph@@	I-Chemical	-1	6133211
as@@	I-Chemical	-1	6133211
al@@	I-Chemical	-1	6133211
az@@	I-Chemical	-1	6133211
ine	I-Chemical	-1	6133211
may	O	-1	6133211
be	O	-1	6133211
ter@@	O	-1	6133211
at@@	O	-1	6133211
o@@	O	-1	6133211
gen@@	O	-1	6133211
ic@@	O	-1	6133211
.	O	-1	6133211

V@@	B-Disease	D006504	6503301
en@@	I-Disease	-1	6503301
o@@	I-Disease	-1	6503301
-@@	I-Disease	-1	6503301
oc@@	I-Disease	-1	6503301
cl@@	I-Disease	-1	6503301
u@@	I-Disease	-1	6503301
sive	I-Disease	-1	6503301
liver	I-Disease	-1	6503301
disease	I-Disease	-1	6503301
after	O	-1	6503301
d@@	B-Chemical	D003606	6503301
ac@@	I-Chemical	-1	6503301
arb@@	I-Chemical	-1	6503301
az@@	I-Chemical	-1	6503301
ine	I-Chemical	-1	6503301
therapy	O	-1	6503301
(	O	-1	6503301
D@@	B-Chemical	D003606	6503301
TI@@	I-Chemical	-1	6503301
C	I-Chemical	-1	6503301
)	O	-1	6503301
for	O	-1	6503301
me@@	B-Disease	D008545	6503301
l@@	I-Disease	-1	6503301
an@@	I-Disease	-1	6503301
oma	I-Disease	-1	6503301
.	O	-1	6503301
A	O	-1	6503301
case	O	-1	6503301
of	O	-1	6503301
ven@@	B-Disease	D006504	6503301
o@@	I-Disease	-1	6503301
-@@	I-Disease	-1	6503301
oc@@	I-Disease	-1	6503301
cl@@	I-Disease	-1	6503301
u@@	I-Disease	-1	6503301
sive	I-Disease	-1	6503301
disease	I-Disease	-1	6503301
of	I-Disease	-1	6503301
the	I-Disease	-1	6503301
liver	I-Disease	-1	6503301
with	O	-1	6503301
f@@	O	-1	6503301
atal	O	-1	6503301
outcom@@	O	-1	6503301
e	O	-1	6503301
after	O	-1	6503301
d@@	B-Chemical	D003606	6503301
ac@@	I-Chemical	-1	6503301
arb@@	I-Chemical	-1	6503301
az@@	I-Chemical	-1	6503301
ine	I-Chemical	-1	6503301
(	O	-1	6503301
D@@	B-Chemical	D003606	6503301
TI@@	I-Chemical	-1	6503301
C	I-Chemical	-1	6503301
)	O	-1	6503301
therapy	O	-1	6503301
for	O	-1	6503301
me@@	B-Disease	D008545	6503301
l@@	I-Disease	-1	6503301
an@@	I-Disease	-1	6503301
oma	I-Disease	-1	6503301
is	O	-1	6503301
repor@@	O	-1	6503301
ted.	O	-1	6503301
There	O	-1	6503301
was	O	-1	6503301
a	O	-1	6503301
ful@@	O	-1	6503301
min@@	O	-1	6503301
ant	O	-1	6503301
clinical	O	-1	6503301
course	O	-1	6503301
from	O	-1	6503301
star@@	O	-1	6503301
t	O	-1	6503301
of	O	-1	6503301
symptoms	O	-1	6503301
un@@	O	-1	6503301
ti@@	O	-1	6503301
l	O	-1	6503301
death	B-Disease	D003643	6503301
.	O	-1	6503301
A@@	O	-1	6503301
t	O	-1	6503301
auto@@	O	-1	6503301
p@@	O	-1	6503301
sy	O	-1	6503301
the	O	-1	6503301
liver	O	-1	6503301
was	O	-1	6503301
en@@	O	-1	6503301
larg@@	O	-1	6503301
ed	O	-1	6503301
and	O	-1	6503301
fir@@	O	-1	6503301
m	O	-1	6503301
with	O	-1	6503301
signs	O	-1	6503301
of	O	-1	6503301
venous	B-Disease	D006940	6503301
con@@	I-Disease	-1	6503301
g@@	I-Disease	-1	6503301
es@@	I-Disease	-1	6503301
tion	I-Disease	-1	6503301
.	O	-1	6503301
S@@	O	-1	6503301
m@@	O	-1	6503301
all@@	O	-1	6503301
-	O	-1	6503301
and	O	-1	6503301
medi@@	O	-1	6503301
um@@	O	-1	6503301
-@@	O	-1	6503301
si@@	O	-1	6503301
zed	O	-1	6503301
hepatic	O	-1	6503301
ve@@	O	-1	6503301
ins	O	-1	6503301
were	O	-1	6503301
block@@	O	-1	6503301
ed	O	-1	6503301
by	O	-1	6503301
thrombo@@	B-Disease	D013927	6503301
sis	I-Disease	-1	6503301
.	O	-1	6503301
E@@	O	-1	6503301
os@@	O	-1	6503301
in@@	O	-1	6503301
oph@@	O	-1	6503301
il@@	O	-1	6503301
ic	O	-1	6503301
inf@@	O	-1	6503301
il@@	O	-1	6503301
tr@@	O	-1	6503301
ations	O	-1	6503301
were	O	-1	6503301
found	O	-1	6503301
a@@	O	-1	6503301
ro@@	O	-1	6503301
un@@	O	-1	6503301
d	O	-1	6503301
the	O	-1	6503301
v@@	O	-1	6503301
es@@	O	-1	6503301
sel@@	O	-1	6503301
s.	O	-1	6503301
P@@	O	-1	6503301
u@@	O	-1	6503301
bl@@	O	-1	6503301
ished	O	-1	6503301
cases	O	-1	6503301
from	O	-1	6503301
the	O	-1	6503301
literat@@	O	-1	6503301
ure	O	-1	6503301
are	O	-1	6503301
revie@@	O	-1	6503301
w@@	O	-1	6503301
ed	O	-1	6503301
and	O	-1	6503301
per@@	O	-1	6503301
t@@	O	-1	6503301
in@@	O	-1	6503301
ent	O	-1	6503301
feat@@	O	-1	6503301
ures	O	-1	6503301
discus@@	O	-1	6503301
sed.	O	-1	6503301

A	O	-1	6727060
case	O	-1	6727060
of	O	-1	6727060
t@@	B-Disease	D004409	6727060
ardi@@	I-Disease	-1	6727060
ve	I-Disease	-1	6727060
dyskine@@	I-Disease	-1	6727060
sia	I-Disease	-1	6727060
caused	O	-1	6727060
by	O	-1	6727060
met@@	B-Chemical	D008787	6727060
oc@@	I-Chemical	-1	6727060
lop@@	I-Chemical	-1	6727060
ram@@	I-Chemical	-1	6727060
ide	I-Chemical	-1	6727060
.	O	-1	6727060
A@@	B-Disease	D004409	6727060
b@@	I-Disease	-1	6727060
normal	I-Disease	-1	6727060
invol@@	I-Disease	-1	6727060
un@@	I-Disease	-1	6727060
t@@	I-Disease	-1	6727060
ary	I-Disease	-1	6727060
mo@@	I-Disease	-1	6727060
ve@@	I-Disease	-1	6727060
ments	I-Disease	-1	6727060
appe@@	O	-1	6727060
a@@	O	-1	6727060
red	O	-1	6727060
in	O	-1	6727060
the	O	-1	6727060
mou@@	O	-1	6727060
th@@	O	-1	6727060
,	O	-1	6727060
t@@	O	-1	6727060
on@@	O	-1	6727060
gu@@	O	-1	6727060
e,	O	-1	6727060
nec@@	O	-1	6727060
k	O	-1	6727060
and	O	-1	6727060
ab@@	O	-1	6727060
do@@	O	-1	6727060
men	O	-1	6727060
of	O	-1	6727060
a	O	-1	6727060
6@@	O	-1	6727060
4-@@	O	-1	6727060
year-old	O	-1	6727060
male	O	-1	6727060
patient	O	-1	6727060
after	O	-1	6727060
he	O	-1	6727060
to@@	O	-1	6727060
o@@	O	-1	6727060
k	O	-1	6727060
met@@	B-Chemical	D008787	6727060
oc@@	I-Chemical	-1	6727060
lop@@	I-Chemical	-1	6727060
ram@@	I-Chemical	-1	6727060
ide	I-Chemical	-1	6727060
for	O	-1	6727060
gast@@	B-Disease	D005767	6727060
ro@@	I-Disease	-1	6727060
in@@	I-Disease	-1	6727060
test@@	I-Disease	-1	6727060
inal	I-Disease	-1	6727060
disor@@	I-Disease	-1	6727060
der	I-Disease	-1	6727060
in	O	-1	6727060
a	O	-1	6727060
regi@@	O	-1	6727060
men	O	-1	6727060
of	O	-1	6727060
30	O	-1	6727060
mg	O	-1	6727060
per	O	-1	6727060
day	O	-1	6727060
for	O	-1	6727060
a	O	-1	6727060
total	O	-1	6727060
of	O	-1	6727060
about	O	-1	6727060
2@@	O	-1	6727060
60	O	-1	6727060
days.	O	-1	6727060
The	O	-1	6727060
symptoms	O	-1	6727060
ex@@	O	-1	6727060
ac@@	O	-1	6727060
er@@	O	-1	6727060
b@@	O	-1	6727060
ated	O	-1	6727060
to	O	-1	6727060
a	O	-1	6727060
maxim@@	O	-1	6727060
um	O	-1	6727060
in	O	-1	6727060
a	O	-1	6727060
month@@	O	-1	6727060
.	O	-1	6727060
Whe@@	O	-1	6727060
n	O	-1	6727060
the	O	-1	6727060
met@@	B-Chemical	D008787	6727060
oc@@	I-Chemical	-1	6727060
lop@@	I-Chemical	-1	6727060
ram@@	I-Chemical	-1	6727060
ide	I-Chemical	-1	6727060
administration	O	-1	6727060
was	O	-1	6727060
discontinu@@	O	-1	6727060
ed,	O	-1	6727060
the	O	-1	6727060
ab@@	B-Disease	D004409	6727060
normal	I-Disease	-1	6727060
mo@@	I-Disease	-1	6727060
ve@@	I-Disease	-1	6727060
ments	I-Disease	-1	6727060
gra@@	O	-1	6727060
du@@	O	-1	6727060
ally	O	-1	6727060
improved	O	-1	6727060
to	O	-1	6727060
a	O	-1	6727060
con@@	O	-1	6727060
si@@	O	-1	6727060
der@@	O	-1	6727060
able	O	-1	6727060
ext@@	O	-1	6727060
ent@@	O	-1	6727060
.	O	-1	6727060
A@@	O	-1	6727060
t@@	O	-1	6727060
ten@@	O	-1	6727060
tion	O	-1	6727060
to	O	-1	6727060
the	O	-1	6727060
possible	O	-1	6727060
induction	O	-1	6727060
of	O	-1	6727060
specific	O	-1	6727060
t@@	B-Disease	D004409	6727060
ardi@@	I-Disease	-1	6727060
ve	I-Disease	-1	6727060
dyskine@@	I-Disease	-1	6727060
sia	I-Disease	-1	6727060
is	O	-1	6727060
c@@	O	-1	6727060
all@@	O	-1	6727060
ed	O	-1	6727060
for	O	-1	6727060
in	O	-1	6727060
the	O	-1	6727060
use	O	-1	6727060
of	O	-1	6727060
this	O	-1	6727060
drug.	O	-1	6727060

F@@	O	-1	7083920
urther	O	-1	7083920
observ@@	O	-1	7083920
ations	O	-1	7083920
on	O	-1	7083920
the	O	-1	7083920
electro@@	O	-1	7083920
physi@@	O	-1	7083920
ologic	O	-1	7083920
effects	O	-1	7083920
of	O	-1	7083920
oral	O	-1	7083920
am@@	B-Chemical	D000638	7083920
iodar@@	I-Chemical	-1	7083920
one	I-Chemical	-1	7083920
therapy.	O	-1	7083920
A	O	-1	7083920
case	O	-1	7083920
is	O	-1	7083920
presented	O	-1	7083920
of	O	-1	7083920
a	O	-1	7083920
reversible	O	-1	7083920
intra@@	B-Disease	D006327	7083920
-H@@	I-Disease	-1	7083920
i@@	I-Disease	-1	7083920
si@@	I-Disease	-1	7083920
an	I-Disease	-1	7083920
bloc@@	I-Disease	-1	7083920
k	I-Disease	-1	7083920
occur@@	O	-1	7083920
r@@	O	-1	7083920
ing	O	-1	7083920
under	O	-1	7083920
am@@	B-Chemical	D000638	7083920
iodar@@	I-Chemical	-1	7083920
one	I-Chemical	-1	7083920
treatment	O	-1	7083920
for	O	-1	7083920
atrial	B-Disease	D013617	7083920
tachycardia	I-Disease	-1	7083920
in	O	-1	7083920
a	O	-1	7083920
patient	O	-1	7083920
without	O	-1	7083920
c@@	O	-1	7083920
le@@	O	-1	7083920
ar	O	-1	7083920
intra@@	B-Disease	D006345	7083920
ventricular	I-Disease	-1	7083920
con@@	I-Disease	-1	7083920
duction	I-Disease	-1	7083920
abnormal@@	I-Disease	-1	7083920
ities	I-Disease	-1	7083920
.	O	-1	7083920
H@@	O	-1	7083920
is	O	-1	7083920
b@@	O	-1	7083920
und@@	O	-1	7083920
le	O	-1	7083920
recor@@	O	-1	7083920
d@@	O	-1	7083920
ings	O	-1	7083920
showed	O	-1	7083920
an	O	-1	7083920
atrial	B-Disease	D013617	7083920
tachycardia	I-Disease	-1	7083920
with	O	-1	7083920
inter@@	O	-1	7083920
mit@@	O	-1	7083920
t@@	O	-1	7083920
ent	O	-1	7083920
ex@@	O	-1	7083920
it	O	-1	7083920
bloc@@	O	-1	7083920
k	O	-1	7083920
and	O	-1	7083920
great@@	O	-1	7083920
ly	O	-1	7083920
prolonged	O	-1	7083920
B@@	O	-1	7083920
H	O	-1	7083920
and	O	-1	7083920
H@@	O	-1	7083920
V	O	-1	7083920
interv@@	O	-1	7083920
als	O	-1	7083920
(@@	O	-1	7083920
40	O	-1	7083920
and	O	-1	7083920
100	O	-1	7083920
m@@	O	-1	7083920
sec@@	O	-1	7083920
,	O	-1	7083920
respectivel@@	O	-1	7083920
y@@	O	-1	7083920
).	O	-1	7083920
Th@@	O	-1	7083920
ir@@	O	-1	7083920
t@@	O	-1	7083920
y	O	-1	7083920
days	O	-1	7083920
after	O	-1	7083920
am@@	B-Chemical	D000638	7083920
iodar@@	I-Chemical	-1	7083920
one	I-Chemical	-1	7083920
discontinu@@	O	-1	7083920
ation,	O	-1	7083920
H@@	O	-1	7083920
is	O	-1	7083920
b@@	O	-1	7083920
und@@	O	-1	7083920
le	O	-1	7083920
electro@@	O	-1	7083920
gram@@	O	-1	7083920
s	O	-1	7083920
showed	O	-1	7083920
atrial	B-Disease	D001282	7083920
f@@	I-Disease	-1	7083920
l@@	I-Disease	-1	7083920
ut@@	I-Disease	-1	7083920
ter	I-Disease	-1	7083920
without	O	-1	7083920
intra@@	O	-1	7083920
-H@@	O	-1	7083920
i@@	O	-1	7083920
si@@	O	-1	7083920
an	O	-1	7083920
or	O	-1	7083920
inf@@	O	-1	7083920
ra@@	O	-1	7083920
-H@@	O	-1	7083920
i@@	O	-1	7083920
si@@	O	-1	7083920
an	O	-1	7083920
del@@	O	-1	7083920
a@@	O	-1	7083920
y.	O	-1	7083920
A@@	B-Chemical	D000638	7083920
m@@	I-Chemical	-1	7083920
iodar@@	I-Chemical	-1	7083920
one	I-Chemical	-1	7083920
should	O	-1	7083920
be	O	-1	7083920
used	O	-1	7083920
with	O	-1	7083920
cau@@	O	-1	7083920
tion	O	-1	7083920
during	O	-1	7083920
long-term	O	-1	7083920
oral	O	-1	7083920
therapy	O	-1	7083920
in	O	-1	7083920
patients	O	-1	7083920
with	O	-1	7083920
or	O	-1	7083920
without	O	-1	7083920
c@@	O	-1	7083920
le@@	O	-1	7083920
ar	O	-1	7083920
intra@@	O	-1	7083920
ventricular	O	-1	7083920
con@@	O	-1	7083920
duction	O	-1	7083920
def@@	O	-1	7083920
ect@@	O	-1	7083920
s.	O	-1	7083920

B@@	B-Chemical	D002066	7269015
us@@	I-Chemical	-1	7269015
ul@@	I-Chemical	-1	7269015
f@@	I-Chemical	-1	7269015
an	I-Chemical	-1	7269015
-induced	O	-1	7269015
hemorrh@@	B-Disease	D006470	7269015
ag@@	I-Disease	-1	7269015
ic	I-Disease	-1	7269015
cys@@	I-Disease	-1	7269015
ti@@	I-Disease	-1	7269015
tis	I-Disease	-1	7269015
hemorrh@@	B-Disease	D003556	7269015
ag@@	I-Disease	-1	7269015
ic	I-Disease	-1	7269015
cys@@	I-Disease	-1	7269015
ti@@	I-Disease	-1	7269015
tis	I-Disease	-1	7269015
.	O	-1	7269015
A	O	-1	7269015
case	O	-1	7269015
of	O	-1	7269015
a	O	-1	7269015
b@@	B-Chemical	D002066	7269015
us@@	I-Chemical	-1	7269015
ul@@	I-Chemical	-1	7269015
f@@	I-Chemical	-1	7269015
an	I-Chemical	-1	7269015
-induced	O	-1	7269015
hemorrh@@	B-Disease	D006470	7269015
age	I-Disease	-1	7269015
cys@@	I-Disease	-1	7269015
ti@@	I-Disease	-1	7269015
tis	I-Disease	-1	7269015
hemorrh@@	B-Disease	D003556	7269015
age	I-Disease	-1	7269015
cys@@	I-Disease	-1	7269015
ti@@	I-Disease	-1	7269015
tis	I-Disease	-1	7269015
is	O	-1	7269015
repor@@	O	-1	7269015
ted.	O	-1	7269015
S@@	O	-1	7269015
p@@	O	-1	7269015
ont@@	O	-1	7269015
aneous	O	-1	7269015
resol@@	O	-1	7269015
u@@	O	-1	7269015
tion	O	-1	7269015
occurred	O	-1	7269015
following	O	-1	7269015
cess@@	O	-1	7269015
ation	O	-1	7269015
of	O	-1	7269015
the	O	-1	7269015
drug.	O	-1	7269015
The	O	-1	7269015
simil@@	O	-1	7269015
ar@@	O	-1	7269015
ity	O	-1	7269015
between	O	-1	7269015
the	O	-1	7269015
hist@@	O	-1	7269015
ologic	O	-1	7269015
appear@@	O	-1	7269015
anc@@	O	-1	7269015
es	O	-1	7269015
of	O	-1	7269015
b@@	B-Chemical	D002066	7269015
us@@	I-Chemical	-1	7269015
ul@@	I-Chemical	-1	7269015
f@@	I-Chemical	-1	7269015
an	I-Chemical	-1	7269015
cys@@	B-Disease	D003556	7269015
ti@@	I-Disease	-1	7269015
tis	I-Disease	-1	7269015
and	O	-1	7269015
both	O	-1	7269015
radi@@	O	-1	7269015
ation	O	-1	7269015
and	O	-1	7269015
cyclophosph@@	B-Chemical	D003520	7269015
amide	I-Chemical	-1	7269015
-induced	O	-1	7269015
cys@@	B-Disease	D003556	7269015
ti@@	I-Disease	-1	7269015
tis	I-Disease	-1	7269015
is	O	-1	7269015
discus@@	O	-1	7269015
sed	O	-1	7269015
and	O	-1	7269015
the	O	-1	7269015
wor@@	O	-1	7269015
l@@	O	-1	7269015
d	O	-1	7269015
literat@@	O	-1	7269015
ure	O	-1	7269015
revie@@	O	-1	7269015
we@@	O	-1	7269015
d.	O	-1	7269015
In	O	-1	7269015
vie@@	O	-1	7269015
w	O	-1	7269015
of	O	-1	7269015
the	O	-1	7269015
known	O	-1	7269015
ten@@	O	-1	7269015
d@@	O	-1	7269015
ency	O	-1	7269015
of	O	-1	7269015
b@@	B-Chemical	D002066	7269015
us@@	I-Chemical	-1	7269015
ul@@	I-Chemical	-1	7269015
f@@	I-Chemical	-1	7269015
an	I-Chemical	-1	7269015
to	O	-1	7269015
induce	O	-1	7269015
cell@@	O	-1	7269015
ular	O	-1	7269015
at@@	O	-1	7269015
y@@	O	-1	7269015
pi@@	O	-1	7269015
a	O	-1	7269015
and	O	-1	7269015
carcin@@	B-Disease	D002277	7269015
oma	I-Disease	-1	7269015
in	O	-1	7269015
other	O	-1	7269015
sit@@	O	-1	7269015
es,	O	-1	7269015
perio@@	O	-1	7269015
di@@	O	-1	7269015
c	O	-1	7269015
urinary	O	-1	7269015
cyto@@	O	-1	7269015
log@@	O	-1	7269015
y	O	-1	7269015
is	O	-1	7269015
suggested	O	-1	7269015
in	O	-1	7269015
patients	O	-1	7269015
on	O	-1	7269015
long-term	O	-1	7269015
therapy.	O	-1	7269015

Re@@	O	-1	7352670
b@@	O	-1	7352670
ound	O	-1	7352670
hypertensive	B-Disease	D006973	7352670
after	O	-1	7352670
sodium	B-Chemical	D009599	7352670
nitro@@	I-Chemical	-1	7352670
pr@@	I-Chemical	-1	7352670
us@@	I-Chemical	-1	7352670
side	I-Chemical	-1	7352670
prevent@@	O	-1	7352670
ed	O	-1	7352670
by	O	-1	7352670
s@@	B-Chemical	D012504	7352670
ar@@	I-Chemical	-1	7352670
al@@	I-Chemical	-1	7352670
as@@	I-Chemical	-1	7352670
in	I-Chemical	-1	7352670
in	O	-1	7352670
rats.	O	-1	7352670
The	O	-1	7352670
role	O	-1	7352670
of	O	-1	7352670
the	O	-1	7352670
ren@@	O	-1	7352670
in-@@	O	-1	7352670
-	O	-1	7352670
angiotens@@	B-Chemical	D000809	7352670
in	I-Chemical	-1	7352670
system	O	-1	7352670
in	O	-1	7352670
the	O	-1	7352670
maint@@	O	-1	7352670
en@@	O	-1	7352670
ance	O	-1	7352670
of	O	-1	7352670
blood	O	-1	7352670
pressure	O	-1	7352670
during	O	-1	7352670
halo@@	B-Chemical	D006221	7352670
th@@	I-Chemical	-1	7352670
ane	I-Chemical	-1	7352670
anesthe@@	O	-1	7352670
sia	O	-1	7352670
and	O	-1	7352670
sodium	B-Chemical	D009599	7352670
nitro@@	I-Chemical	-1	7352670
pr@@	I-Chemical	-1	7352670
us@@	I-Chemical	-1	7352670
side	I-Chemical	-1	7352670
(	O	-1	7352670
S@@	B-Chemical	D009599	7352670
N@@	I-Chemical	-1	7352670
P	I-Chemical	-1	7352670
)@@	O	-1	7352670
-induced	O	-1	7352670
hypotension	B-Disease	D007022	7352670
was	O	-1	7352670
evalu@@	O	-1	7352670
ated.	O	-1	7352670
C@@	O	-1	7352670
ont@@	O	-1	7352670
ro@@	O	-1	7352670
l	O	-1	7352670
rats	O	-1	7352670
received	O	-1	7352670
halo@@	B-Chemical	D006221	7352670
th@@	I-Chemical	-1	7352670
ane	I-Chemical	-1	7352670
anesthe@@	O	-1	7352670
sia	O	-1	7352670
(@@	O	-1	7352670
1	O	-1	7352670
M@@	O	-1	7352670
AC@@	O	-1	7352670
)	O	-1	7352670
for	O	-1	7352670
one	O	-1	7352670
hour@@	O	-1	7352670
,	O	-1	7352670
followed	O	-1	7352670
by	O	-1	7352670
S@@	B-Chemical	D009599	7352670
N@@	I-Chemical	-1	7352670
P	I-Chemical	-1	7352670
infu@@	O	-1	7352670
sion,	O	-1	7352670
40	O	-1	7352670
microgram@@	O	-1	7352670
/@@	O	-1	7352670
k@@	O	-1	7352670
g/@@	O	-1	7352670
min@@	O	-1	7352670
,	O	-1	7352670
for	O	-1	7352670
30	O	-1	7352670
min@@	O	-1	7352670
,	O	-1	7352670
followed	O	-1	7352670
by	O	-1	7352670
a	O	-1	7352670
3@@	O	-1	7352670
0-@@	O	-1	7352670
min	O	-1	7352670
recovery	O	-1	7352670
perio@@	O	-1	7352670
d.	O	-1	7352670
A	O	-1	7352670
second	O	-1	7352670
group	O	-1	7352670
of	O	-1	7352670
rats	O	-1	7352670
was	O	-1	7352670
treated	O	-1	7352670
id@@	O	-1	7352670
en@@	O	-1	7352670
tically	O	-1	7352670
and@@	O	-1	7352670
,	O	-1	7352670
in	O	-1	7352670
addi@@	O	-1	7352670
tion,	O	-1	7352670
received	O	-1	7352670
an	O	-1	7352670
infusion	O	-1	7352670
of	O	-1	7352670
s@@	B-Chemical	D012504	7352670
ar@@	I-Chemical	-1	7352670
al@@	I-Chemical	-1	7352670
as@@	I-Chemical	-1	7352670
in	I-Chemical	-1	7352670
(@@	O	-1	7352670
a	O	-1	7352670
comp@@	O	-1	7352670
e@@	O	-1	7352670
ti@@	O	-1	7352670
tive	O	-1	7352670
inhibitor	O	-1	7352670
of	O	-1	7352670
angiotens@@	B-Chemical	D000804	7352670
in	I-Chemical	-1	7352670
II	I-Chemical	-1	7352670
)	O	-1	7352670
throu@@	O	-1	7352670
gh@@	O	-1	7352670
out	O	-1	7352670
the	O	-1	7352670
experimental	O	-1	7352670
perio@@	O	-1	7352670
d.	O	-1	7352670
In	O	-1	7352670
each	O	-1	7352670
group@@	O	-1	7352670
,	O	-1	7352670
S@@	B-Chemical	D009599	7352670
N@@	I-Chemical	-1	7352670
P	I-Chemical	-1	7352670
infusion	O	-1	7352670
resulted	O	-1	7352670
in	O	-1	7352670
an	O	-1	7352670
initial	O	-1	7352670
decrease	O	-1	7352670
in	O	-1	7352670
blood	O	-1	7352670
pressure	O	-1	7352670
from	O	-1	7352670
8@@	O	-1	7352670
6	O	-1	7352670
t@@	O	-1	7352670
or@@	O	-1	7352670
r	O	-1	7352670
and	O	-1	7352670
8@@	O	-1	7352670
3	O	-1	7352670
t@@	O	-1	7352670
or@@	O	-1	7352670
r@@	O	-1	7352670
,	O	-1	7352670
respectivel@@	O	-1	7352670
y,	O	-1	7352670
to	O	-1	7352670
4@@	O	-1	7352670
8	O	-1	7352670
t@@	O	-1	7352670
or@@	O	-1	7352670
r@@	O	-1	7352670
.	O	-1	7352670
D@@	O	-1	7352670
uring	O	-1	7352670
the	O	-1	7352670
S@@	B-Chemical	D009599	7352670
N@@	I-Chemical	-1	7352670
P	I-Chemical	-1	7352670
infusion	O	-1	7352670
the	O	-1	7352670
control	O	-1	7352670
animals	O	-1	7352670
demonstrated	O	-1	7352670
a	O	-1	7352670
progressive	O	-1	7352670
increase	B-Disease	D006973	7352670
in	I-Disease	-1	7352670
blood	I-Disease	-1	7352670
pressure	I-Disease	-1	7352670
to	O	-1	7352670
6@@	O	-1	7352670
1	O	-1	7352670
t@@	O	-1	7352670
or@@	O	-1	7352670
r@@	O	-1	7352670
,	O	-1	7352670
whereas	O	-1	7352670
the	O	-1	7352670
s@@	B-Chemical	D012504	7352670
ar@@	I-Chemical	-1	7352670
al@@	I-Chemical	-1	7352670
as@@	I-Chemical	-1	7352670
in	I-Chemical	-1	7352670
-treated	O	-1	7352670
animals	O	-1	7352670
showed	O	-1	7352670
no	O	-1	7352670
chang@@	O	-1	7352670
e.	O	-1	7352670
F@@	O	-1	7352670
ol@@	O	-1	7352670
low@@	O	-1	7352670
ing	O	-1	7352670
discontinu@@	O	-1	7352670
ation	O	-1	7352670
of	O	-1	7352670
S@@	B-Chemical	D009599	7352670
N@@	I-Chemical	-1	7352670
P	I-Chemical	-1	7352670
,	O	-1	7352670
blood	O	-1	7352670
pressure	O	-1	7352670
in	O	-1	7352670
the	O	-1	7352670
control	O	-1	7352670
animals	O	-1	7352670
reb@@	O	-1	7352670
oun@@	O	-1	7352670
ded	O	-1	7352670
to	O	-1	7352670
9@@	O	-1	7352670
4	O	-1	7352670
t@@	O	-1	7352670
or@@	O	-1	7352670
r@@	O	-1	7352670
,	O	-1	7352670
as	O	-1	7352670
compared	O	-1	7352670
with	O	-1	7352670
7@@	O	-1	7352670
8	O	-1	7352670
t@@	O	-1	7352670
or@@	O	-1	7352670
r	O	-1	7352670
in	O	-1	7352670
the	O	-1	7352670
s@@	B-Chemical	D012504	7352670
ar@@	I-Chemical	-1	7352670
al@@	I-Chemical	-1	7352670
as@@	I-Chemical	-1	7352670
in	I-Chemical	-1	7352670
-treated	O	-1	7352670
rats.	O	-1	7352670
This	O	-1	7352670
study	O	-1	7352670
indic@@	O	-1	7352670
ates	O	-1	7352670
that	O	-1	7352670
with	O	-1	7352670
st@@	O	-1	7352670
able	O	-1	7352670
halo@@	B-Chemical	D006221	7352670
th@@	I-Chemical	-1	7352670
ane	I-Chemical	-1	7352670
anesthe@@	O	-1	7352670
si@@	O	-1	7352670
a,	O	-1	7352670
the	O	-1	7352670
partial	O	-1	7352670
recovery	O	-1	7352670
of	O	-1	7352670
blood	O	-1	7352670
pressure	O	-1	7352670
during	O	-1	7352670
S@@	B-Chemical	D009599	7352670
N@@	I-Chemical	-1	7352670
P	I-Chemical	-1	7352670
infusion	O	-1	7352670
and	O	-1	7352670
the	O	-1	7352670
post@@	O	-1	7352670
-	O	-1	7352670
S@@	B-Chemical	D009599	7352670
N@@	I-Chemical	-1	7352670
P	I-Chemical	-1	7352670
reb@@	O	-1	7352670
ound	O	-1	7352670
of	O	-1	7352670
blood	O	-1	7352670
pressure	O	-1	7352670
can	O	-1	7352670
be	O	-1	7352670
complete@@	O	-1	7352670
ly	O	-1	7352670
block@@	O	-1	7352670
ed	O	-1	7352670
by	O	-1	7352670
s@@	B-Chemical	D012504	7352670
ar@@	I-Chemical	-1	7352670
al@@	I-Chemical	-1	7352670
as@@	I-Chemical	-1	7352670
in	I-Chemical	-1	7352670
.	O	-1	7352670
This	O	-1	7352670
demon@@	O	-1	7352670
strat@@	O	-1	7352670
es	O	-1	7352670
the	O	-1	7352670
partic@@	O	-1	7352670
ip@@	O	-1	7352670
ation	O	-1	7352670
of	O	-1	7352670
the	O	-1	7352670
ren@@	O	-1	7352670
in-@@	O	-1	7352670
-	O	-1	7352670
angiotens@@	B-Chemical	D000809	7352670
in	I-Chemical	-1	7352670
system	O	-1	7352670
in	O	-1	7352670
antagon@@	O	-1	7352670
iz@@	O	-1	7352670
ing	O	-1	7352670
the	O	-1	7352670
combined	O	-1	7352670
hypoten@@	B-Disease	D007022	7352670
sive	I-Disease	-1	7352670
effects	O	-1	7352670
of	O	-1	7352670
halo@@	B-Chemical	D006221	7352670
th@@	I-Chemical	-1	7352670
ane	I-Chemical	-1	7352670
and	O	-1	7352670
S@@	B-Chemical	D009599	7352670
N@@	I-Chemical	-1	7352670
P	I-Chemical	-1	7352670
.	O	-1	7352670

T@@	B-Disease	D056486	7504976
ox@@	I-Disease	-1	7504976
ic	I-Disease	-1	7504976
hepatitis	I-Disease	-1	7504976
induced	O	-1	7504976
by	O	-1	7504976
anti@@	O	-1	7504976
th@@	O	-1	7504976
yro@@	O	-1	7504976
id	O	-1	7504976
drug@@	O	-1	7504976
s:	O	-1	7504976
four	O	-1	7504976
cases	O	-1	7504976
including	O	-1	7504976
one	O	-1	7504976
with	O	-1	7504976
cros@@	O	-1	7504976
s-@@	O	-1	7504976
re@@	O	-1	7504976
activity	O	-1	7504976
between	O	-1	7504976
carb@@	B-Chemical	D002231	7504976
im@@	I-Chemical	-1	7504976
azole	I-Chemical	-1	7504976
and	O	-1	7504976
b@@	B-Chemical	C019269	7504976
enz@@	I-Chemical	-1	7504976
yl@@	I-Chemical	-1	7504976
th@@	I-Chemical	-1	7504976
io@@	I-Chemical	-1	7504976
urac@@	I-Chemical	-1	7504976
il	I-Chemical	-1	7504976
.	O	-1	7504976
OBJECTIVE:	O	-1	7504976
This	O	-1	7504976
study	O	-1	7504976
was	O	-1	7504976
con@@	O	-1	7504976
duc@@	O	-1	7504976
ted	O	-1	7504976
to	O	-1	7504976
ass@@	O	-1	7504976
ess	O	-1	7504976
the	O	-1	7504976
occur@@	O	-1	7504976
rence	O	-1	7504976
of	O	-1	7504976
hepatic	B-Disease	D056486	7504976
adverse	I-Disease	-1	7504976
effects	I-Disease	-1	7504976
en@@	O	-1	7504976
coun@@	O	-1	7504976
te@@	O	-1	7504976
red	O	-1	7504976
with	O	-1	7504976
anti@@	O	-1	7504976
th@@	O	-1	7504976
yro@@	O	-1	7504976
id	O	-1	7504976
drug@@	O	-1	7504976
s.	O	-1	7504976
METHODS:	O	-1	7504976
R@@	O	-1	7504976
et@@	O	-1	7504976
ro@@	O	-1	7504976
sp@@	O	-1	7504976
ective	O	-1	7504976
revie@@	O	-1	7504976
w	O	-1	7504976
of	O	-1	7504976
med@@	O	-1	7504976
ical	O	-1	7504976
recor@@	O	-1	7504976
ds	O	-1	7504976
of	O	-1	7504976
2@@	O	-1	7504976
3@@	O	-1	7504976
6	O	-1	7504976
patients	O	-1	7504976
with	O	-1	7504976
hyper@@	B-Disease	D006980	7504976
th@@	I-Disease	-1	7504976
yro@@	I-Disease	-1	7504976
i@@	I-Disease	-1	7504976
dis@@	I-Disease	-1	7504976
m	I-Disease	-1	7504976
ad@@	O	-1	7504976
mit@@	O	-1	7504976
ted	O	-1	7504976
in	O	-1	7504976
our	O	-1	7504976
de@@	O	-1	7504976
part@@	O	-1	7504976
ment	O	-1	7504976
(@@	O	-1	7504976
in@@	O	-1	7504976
-	O	-1	7504976
or	O	-1	7504976
out@@	O	-1	7504976
-@@	O	-1	7504976
patient@@	O	-1	7504976
s)	O	-1	7504976
from	O	-1	7504976
19@@	O	-1	7504976
8@@	O	-1	7504976
6	O	-1	7504976
to	O	-1	7504976
19@@	O	-1	7504976
9@@	O	-1	7504976
2@@	O	-1	7504976
.	O	-1	7504976
RESULTS:	O	-1	7504976
F@@	O	-1	7504976
our	O	-1	7504976
patients	O	-1	7504976
(1@@	O	-1	7504976
.@@	O	-1	7504976
7@@	O	-1	7504976
%)	O	-1	7504976
were	O	-1	7504976
identi@@	O	-1	7504976
fied	O	-1	7504976
with	O	-1	7504976
toxic	B-Disease	D056486	7504976
hepatitis	I-Disease	-1	7504976
which	O	-1	7504976
could	O	-1	7504976
reas@@	O	-1	7504976
on@@	O	-1	7504976
ably	O	-1	7504976
be	O	-1	7504976
at@@	O	-1	7504976
tri@@	O	-1	7504976
but@@	O	-1	7504976
ed	O	-1	7504976
to	O	-1	7504976
the	O	-1	7504976
use	O	-1	7504976
of	O	-1	7504976
anti@@	O	-1	7504976
th@@	O	-1	7504976
yro@@	O	-1	7504976
id	O	-1	7504976
agent@@	O	-1	7504976
.	O	-1	7504976
Two	O	-1	7504976
patients	O	-1	7504976
had	O	-1	7504976
a	O	-1	7504976
cholest@@	B-Disease	D002779	7504976
atic	I-Disease	-1	7504976
hepatitis	I-Disease	-1	7504976
cholest@@	B-Disease	D056486	7504976
atic	I-Disease	-1	7504976
hepatitis	I-Disease	-1	7504976
induced	O	-1	7504976
by	O	-1	7504976
carb@@	B-Chemical	D002231	7504976
im@@	I-Chemical	-1	7504976
azole	I-Chemical	-1	7504976
(	O	-1	7504976
N	B-Chemical	D002231	7504976
om@@	I-Chemical	-1	7504976
er@@	I-Chemical	-1	7504976
ca@@	I-Chemical	-1	7504976
z@@	I-Chemical	-1	7504976
ole	I-Chemical	-1	7504976
).	O	-1	7504976
Two	O	-1	7504976
o@@	O	-1	7504976
ther@@	O	-1	7504976
s	O	-1	7504976
had	O	-1	7504976
a	O	-1	7504976
mi@@	O	-1	7504976
x@@	O	-1	7504976
ed	O	-1	7504976
(	O	-1	7504976
cholest@@	B-Disease	D002779	7504976
atic	I-Disease	-1	7504976
and	O	-1	7504976
cy@@	O	-1	7504976
t@@	O	-1	7504976
oly@@	O	-1	7504976
tic@@	O	-1	7504976
)	O	-1	7504976
hepatitis	B-Disease	D056486	7504976
following	O	-1	7504976
carb@@	B-Chemical	D002231	7504976
im@@	I-Chemical	-1	7504976
azole	I-Chemical	-1	7504976
.	O	-1	7504976
One	O	-1	7504976
of	O	-1	7504976
the	O	-1	7504976
lat@@	O	-1	7504976
ter	O	-1	7504976
two	O	-1	7504976
patients	O	-1	7504976
further	O	-1	7504976
experienced	O	-1	7504976
a	O	-1	7504976
cy@@	O	-1	7504976
t@@	O	-1	7504976
oly@@	O	-1	7504976
tic	O	-1	7504976
hepatitis	B-Disease	D056486	7504976
which	O	-1	7504976
appe@@	O	-1	7504976
a@@	O	-1	7504976
red	O	-1	7504976
after	O	-1	7504976
B@@	B-Chemical	C019269	7504976
enz@@	I-Chemical	-1	7504976
yl@@	I-Chemical	-1	7504976
th@@	I-Chemical	-1	7504976
io@@	I-Chemical	-1	7504976
urac@@	I-Chemical	-1	7504976
il	I-Chemical	-1	7504976
(	O	-1	7504976
B@@	B-Chemical	C019269	7504976
as@@	I-Chemical	-1	7504976
d	I-Chemical	-1	7504976
n@@	I-Chemical	-1	7504976
e	I-Chemical	-1	7504976
)	O	-1	7504976
had	O	-1	7504976
re@@	O	-1	7504976
pl@@	O	-1	7504976
ac@@	O	-1	7504976
ed	O	-1	7504976
carb@@	B-Chemical	D002231	7504976
im@@	I-Chemical	-1	7504976
azole	I-Chemical	-1	7504976
.	O	-1	7504976
B@@	O	-1	7504976
io@@	O	-1	7504976
log@@	O	-1	7504976
ical	O	-1	7504976
feat@@	O	-1	7504976
ures	O	-1	7504976
of	O	-1	7504976
hepatitis	B-Disease	D056486	7504976
dis@@	O	-1	7504976
appe@@	O	-1	7504976
a@@	O	-1	7504976
red	O	-1	7504976
in	O	-1	7504976
all	O	-1	7504976
cases	O	-1	7504976
after	O	-1	7504976
cess@@	O	-1	7504976
ation	O	-1	7504976
of	O	-1	7504976
the	O	-1	7504976
inc@@	O	-1	7504976
ri@@	O	-1	7504976
min@@	O	-1	7504976
ated	O	-1	7504976
drug@@	O	-1	7504976
,	O	-1	7504976
while	O	-1	7504976
bil@@	O	-1	7504976
i@@	O	-1	7504976
ar@@	O	-1	7504976
y,	O	-1	7504976
viral	O	-1	7504976
and	O	-1	7504976
immun@@	O	-1	7504976
ological	O	-1	7504976
se@@	O	-1	7504976
ar@@	O	-1	7504976
ch@@	O	-1	7504976
es	O	-1	7504976
were	O	-1	7504976
neg@@	O	-1	7504976
ati@@	O	-1	7504976
ve.	O	-1	7504976
On@@	O	-1	7504976
ly	O	-1	7504976
2	O	-1	7504976
patients	O	-1	7504976
of	O	-1	7504976
our	O	-1	7504976
ret@@	O	-1	7504976
ro@@	O	-1	7504976
sp@@	O	-1	7504976
ective	O	-1	7504976
study	O	-1	7504976
experienced	O	-1	7504976
a	O	-1	7504976
mil@@	O	-1	7504976
d	O	-1	7504976
or	O	-1	7504976
severe	O	-1	7504976
ne@@	B-Disease	D009503	7504976
ut@@	I-Disease	-1	7504976
ro@@	I-Disease	-1	7504976
pen@@	I-Disease	-1	7504976
ia	I-Disease	-1	7504976
.	O	-1	7504976
CONCLUSION:	O	-1	7504976
T@@	B-Disease	D056486	7504976
ox@@	I-Disease	-1	7504976
ic	I-Disease	-1	7504976
hepatitis	I-Disease	-1	7504976
is	O	-1	7504976
a	O	-1	7504976
potential	O	-1	7504976
adverse	O	-1	7504976
effect	O	-1	7504976
of	O	-1	7504976
anti@@	O	-1	7504976
th@@	O	-1	7504976
yro@@	O	-1	7504976
id	O	-1	7504976
drugs	O	-1	7504976
which	O	-1	7504976
war@@	O	-1	7504976
ran@@	O	-1	7504976
t@@	O	-1	7504976
s,	O	-1	7504976
as	O	-1	7504976
for	O	-1	7504976
haem@@	O	-1	7504976
at@@	O	-1	7504976
ological	O	-1	7504976
dist@@	O	-1	7504976
urb@@	O	-1	7504976
anc@@	O	-1	7504976
es,	O	-1	7504976
a	O	-1	7504976
pre-@@	O	-1	7504976
therapeutic	O	-1	7504976
determin@@	O	-1	7504976
ation	O	-1	7504976
and	O	-1	7504976
a	O	-1	7504976
ca@@	O	-1	7504976
ref@@	O	-1	7504976
u@@	O	-1	7504976
l	O	-1	7504976
follow-up	O	-1	7504976
of	O	-1	7504976
re@@	O	-1	7504976
lev@@	O	-1	7504976
ant	O	-1	7504976
bio@@	O	-1	7504976
log@@	O	-1	7504976
ical	O	-1	7504976
mark@@	O	-1	7504976
ers.	O	-1	7504976
M@@	O	-1	7504976
ore@@	O	-1	7504976
o@@	O	-1	7504976
ver,	O	-1	7504976
hepat@@	B-Disease	D056486	7504976
otoxicity	I-Disease	-1	7504976
may	O	-1	7504976
not	O	-1	7504976
be	O	-1	7504976
re@@	O	-1	7504976
stric@@	O	-1	7504976
ted	O	-1	7504976
to	O	-1	7504976
one	O	-1	7504976
cl@@	O	-1	7504976
as@@	O	-1	7504976
s	O	-1	7504976
of	O	-1	7504976
anti@@	O	-1	7504976
th@@	O	-1	7504976
yro@@	O	-1	7504976
id	O	-1	7504976
agent@@	O	-1	7504976
s.	O	-1	7504976

S@@	O	-1	7628595
t@@	O	-1	7628595
ud@@	O	-1	7628595
y	O	-1	7628595
of	O	-1	7628595
the	O	-1	7628595
role	O	-1	7628595
of	O	-1	7628595
vitamin	B-Chemical	D014805	7628595
B@@	I-Chemical	-1	7628595
12	I-Chemical	-1	7628595
and	O	-1	7628595
fol@@	B-Chemical	D002955	7628595
inic	I-Chemical	-1	7628595
acid	I-Chemical	-1	7628595
sup@@	O	-1	7628595
ple@@	O	-1	7628595
ment@@	O	-1	7628595
ation	O	-1	7628595
in	O	-1	7628595
prevent@@	O	-1	7628595
ing	O	-1	7628595
hemat@@	O	-1	7628595
ologic	O	-1	7628595
toxicity	B-Disease	D064420	7628595
of	O	-1	7628595
z@@	B-Chemical	D015215	7628595
id@@	I-Chemical	-1	7628595
o@@	I-Chemical	-1	7628595
vud@@	I-Chemical	-1	7628595
ine	I-Chemical	-1	7628595
.	O	-1	7628595
A	O	-1	7628595
pro@@	O	-1	7628595
sp@@	O	-1	7628595
ecti@@	O	-1	7628595
ve,	O	-1	7628595
randomized	O	-1	7628595
study	O	-1	7628595
was	O	-1	7628595
con@@	O	-1	7628595
duc@@	O	-1	7628595
ted	O	-1	7628595
to	O	-1	7628595
evalu@@	O	-1	7628595
ate	O	-1	7628595
the	O	-1	7628595
role	O	-1	7628595
of	O	-1	7628595
vitamin	B-Chemical	D014805	7628595
B@@	I-Chemical	-1	7628595
12	I-Chemical	-1	7628595
and	O	-1	7628595
fol@@	B-Chemical	D002955	7628595
inic	I-Chemical	-1	7628595
acid	I-Chemical	-1	7628595
sup@@	O	-1	7628595
ple@@	O	-1	7628595
ment@@	O	-1	7628595
ation	O	-1	7628595
in	O	-1	7628595
prevent@@	O	-1	7628595
ing	O	-1	7628595
z@@	B-Chemical	D015215	7628595
id@@	I-Chemical	-1	7628595
o@@	I-Chemical	-1	7628595
vud@@	I-Chemical	-1	7628595
ine	I-Chemical	-1	7628595
(	O	-1	7628595
Z@@	B-Chemical	D015215	7628595
D@@	I-Chemical	-1	7628595
V	I-Chemical	-1	7628595
)@@	O	-1	7628595
-induced	O	-1	7628595
b@@	B-Disease	D001855	7628595
one	I-Disease	-1	7628595
m@@	I-Disease	-1	7628595
ar@@	I-Disease	-1	7628595
ro@@	I-Disease	-1	7628595
w	I-Disease	-1	7628595
sup@@	I-Disease	-1	7628595
pression	I-Disease	-1	7628595
.	O	-1	7628595
S@@	O	-1	7628595
event@@	O	-1	7628595
y-@@	O	-1	7628595
five	O	-1	7628595
human	B-Disease	D015658	7628595
immuno@@	I-Disease	-1	7628595
defici@@	I-Disease	-1	7628595
ency	I-Disease	-1	7628595
vi@@	I-Disease	-1	7628595
ru@@	I-Disease	-1	7628595
s	I-Disease	-1	7628595
(@@	I-Disease	-1	7628595
H@@	I-Disease	-1	7628595
I@@	I-Disease	-1	7628595
V@@	I-Disease	-1	7628595
)-@@	I-Disease	-1	7628595
inf@@	I-Disease	-1	7628595
ected	I-Disease	-1	7628595
patients	O	-1	7628595
with	O	-1	7628595
C@@	O	-1	7628595
D@@	O	-1	7628595
4@@	O	-1	7628595
+	O	-1	7628595
cell	O	-1	7628595
coun@@	O	-1	7628595
ts	O	-1	7628595
<	O	-1	7628595
50@@	O	-1	7628595
0@@	O	-1	7628595
/@@	O	-1	7628595
mm@@	O	-1	7628595
3	O	-1	7628595
were	O	-1	7628595
randomized	O	-1	7628595
to	O	-1	7628595
recei@@	O	-1	7628595
ve	O	-1	7628595
either	O	-1	7628595
Z@@	B-Chemical	D015215	7628595
D@@	I-Chemical	-1	7628595
V	I-Chemical	-1	7628595
(5@@	O	-1	7628595
00	O	-1	7628595
mg	O	-1	7628595
da@@	O	-1	7628595
il@@	O	-1	7628595
y@@	O	-1	7628595
)	O	-1	7628595
alone	O	-1	7628595
(@@	O	-1	7628595
group	O	-1	7628595
I@@	O	-1	7628595
,	O	-1	7628595
n	O	-1	7628595
=	O	-1	7628595
3@@	O	-1	7628595
8@@	O	-1	7628595
)	O	-1	7628595
or	O	-1	7628595
in	O	-1	7628595
combination	O	-1	7628595
with	O	-1	7628595
fol@@	B-Chemical	D002955	7628595
inic	I-Chemical	-1	7628595
acid	I-Chemical	-1	7628595
(1@@	O	-1	7628595
5	O	-1	7628595
mg	O	-1	7628595
da@@	O	-1	7628595
il@@	O	-1	7628595
y@@	O	-1	7628595
)	O	-1	7628595
and	O	-1	7628595
int@@	O	-1	7628595
ram@@	O	-1	7628595
as@@	O	-1	7628595
cular	O	-1	7628595
vitamin	B-Chemical	D014805	7628595
B@@	I-Chemical	-1	7628595
12	I-Chemical	-1	7628595
(@@	O	-1	7628595
10@@	O	-1	7628595
00	O	-1	7628595
microgram@@	O	-1	7628595
s	O	-1	7628595
month@@	O	-1	7628595
ly@@	O	-1	7628595
)	O	-1	7628595
(@@	O	-1	7628595
group	O	-1	7628595
II@@	O	-1	7628595
,	O	-1	7628595
n	O	-1	7628595
=	O	-1	7628595
3@@	O	-1	7628595
7@@	O	-1	7628595
).	O	-1	7628595
F@@	O	-1	7628595
in@@	O	-1	7628595
ally,	O	-1	7628595
15	O	-1	7628595
patients	O	-1	7628595
were	O	-1	7628595
ex@@	O	-1	7628595
cl@@	O	-1	7628595
uded	O	-1	7628595
from	O	-1	7628595
the	O	-1	7628595
study	O	-1	7628595
(@@	O	-1	7628595
non@@	O	-1	7628595
com@@	O	-1	7628595
pl@@	O	-1	7628595
i@@	O	-1	7628595
ance	O	-1	7628595
14@@	O	-1	7628595
,	O	-1	7628595
death	B-Disease	D003643	7628595
1@@	O	-1	7628595
);	O	-1	7628595
th@@	O	-1	7628595
us,	O	-1	7628595
60	O	-1	7628595
patients	O	-1	7628595
(3@@	O	-1	7628595
1	O	-1	7628595
in	O	-1	7628595
group	O	-1	7628595
I	O	-1	7628595
and	O	-1	7628595
2@@	O	-1	7628595
9	O	-1	7628595
in	O	-1	7628595
group	O	-1	7628595
II@@	O	-1	7628595
)	O	-1	7628595
were	O	-1	7628595
e@@	O	-1	7628595
li@@	O	-1	7628595
gi@@	O	-1	7628595
ble	O	-1	7628595
for	O	-1	7628595
analy@@	O	-1	7628595
sis.	O	-1	7628595
No	O	-1	7628595
significant	O	-1	7628595
differences	O	-1	7628595
between	O	-1	7628595
groups	O	-1	7628595
were	O	-1	7628595
found	O	-1	7628595
at	O	-1	7628595
en@@	O	-1	7628595
ro@@	O	-1	7628595
ll@@	O	-1	7628595
ment.	O	-1	7628595
D@@	O	-1	7628595
uring	O	-1	7628595
the	O	-1	7628595
study,	O	-1	7628595
vitamin	B-Chemical	D014805	7628595
B@@	I-Chemical	-1	7628595
12	I-Chemical	-1	7628595
and	O	-1	7628595
fol@@	B-Chemical	D005492	7628595
ate	I-Chemical	-1	7628595
levels	O	-1	7628595
were	O	-1	7628595
significantly	O	-1	7628595
higher	O	-1	7628595
in	O	-1	7628595
group	O	-1	7628595
II	O	-1	7628595
patient@@	O	-1	7628595
s;	O	-1	7628595
however,	O	-1	7628595
no	O	-1	7628595
differences	O	-1	7628595
in	O	-1	7628595
hemo@@	O	-1	7628595
glo@@	O	-1	7628595
bin@@	O	-1	7628595
,	O	-1	7628595
hemat@@	O	-1	7628595
oc@@	O	-1	7628595
rit@@	O	-1	7628595
,	O	-1	7628595
mean	O	-1	7628595
cor@@	O	-1	7628595
p@@	O	-1	7628595
us@@	O	-1	7628595
cular	O	-1	7628595
vol@@	O	-1	7628595
u@@	O	-1	7628595
me,	O	-1	7628595
and	O	-1	7628595
wh@@	O	-1	7628595
it@@	O	-1	7628595
e-@@	O	-1	7628595
cell@@	O	-1	7628595
,	O	-1	7628595
ne@@	O	-1	7628595
ut@@	O	-1	7628595
ro@@	O	-1	7628595
ph@@	O	-1	7628595
il	O	-1	7628595
and	O	-1	7628595
platele@@	O	-1	7628595
t	O	-1	7628595
coun@@	O	-1	7628595
ts	O	-1	7628595
were	O	-1	7628595
observed	O	-1	7628595
between	O	-1	7628595
groups	O	-1	7628595
at	O	-1	7628595
3,	O	-1	7628595
6,	O	-1	7628595
9	O	-1	7628595
and	O	-1	7628595
12	O	-1	7628595
months.	O	-1	7628595
S@@	O	-1	7628595
ev@@	O	-1	7628595
ere	O	-1	7628595
hemat@@	O	-1	7628595
ologic	O	-1	7628595
toxicity	B-Disease	D064420	7628595
(@@	O	-1	7628595
ne@@	O	-1	7628595
ut@@	O	-1	7628595
ro@@	O	-1	7628595
ph@@	O	-1	7628595
il	O	-1	7628595
coun@@	O	-1	7628595
t	O	-1	7628595
<	O	-1	7628595
10@@	O	-1	7628595
0@@	O	-1	7628595
0@@	O	-1	7628595
/@@	O	-1	7628595
mm@@	O	-1	7628595
3	O	-1	7628595
and/or	O	-1	7628595
hemo@@	O	-1	7628595
globin	O	-1	7628595
<	O	-1	7628595
8	O	-1	7628595
g/@@	O	-1	7628595
d@@	O	-1	7628595
l@@	O	-1	7628595
)	O	-1	7628595
occurred	O	-1	7628595
in	O	-1	7628595
4	O	-1	7628595
patients	O	-1	7628595
as@@	O	-1	7628595
signed	O	-1	7628595
to	O	-1	7628595
group	O	-1	7628595
I	O	-1	7628595
and	O	-1	7628595
7	O	-1	7628595
as@@	O	-1	7628595
signed	O	-1	7628595
to	O	-1	7628595
group	O	-1	7628595
II@@	O	-1	7628595
.	O	-1	7628595
There	O	-1	7628595
was	O	-1	7628595
no	O	-1	7628595
correl@@	O	-1	7628595
ation	O	-1	7628595
between	O	-1	7628595
vitamin	B-Chemical	D014805	7628595
B@@	I-Chemical	-1	7628595
12	I-Chemical	-1	7628595
or	O	-1	7628595
fol@@	B-Chemical	D005492	7628595
ate	I-Chemical	-1	7628595
levels	O	-1	7628595
and	O	-1	7628595
development	O	-1	7628595
of	O	-1	7628595
my@@	B-Disease	D001855	7628595
e@@	I-Disease	-1	7628595
lo@@	I-Disease	-1	7628595
sup@@	I-Disease	-1	7628595
pression	I-Disease	-1	7628595
.	O	-1	7628595
V@@	B-Chemical	D014805	7628595
it@@	I-Chemical	-1	7628595
amin	I-Chemical	-1	7628595
B@@	I-Chemical	-1	7628595
12	I-Chemical	-1	7628595
and	O	-1	7628595
fol@@	B-Chemical	D002955	7628595
inic	I-Chemical	-1	7628595
acid	I-Chemical	-1	7628595
sup@@	O	-1	7628595
ple@@	O	-1	7628595
ment@@	O	-1	7628595
ation	O	-1	7628595
of	O	-1	7628595
Z@@	B-Chemical	D015215	7628595
D@@	I-Chemical	-1	7628595
V	I-Chemical	-1	7628595
therapy	O	-1	7628595
does	O	-1	7628595
not	O	-1	7628595
se@@	O	-1	7628595
em	O	-1	7628595
use@@	O	-1	7628595
ful	O	-1	7628595
in	O	-1	7628595
prevent@@	O	-1	7628595
ing	O	-1	7628595
or	O	-1	7628595
reduc@@	O	-1	7628595
ing	O	-1	7628595
Z@@	B-Chemical	D015215	7628595
D@@	I-Chemical	-1	7628595
V	I-Chemical	-1	7628595
-induced	O	-1	7628595
my@@	B-Disease	D001855	7628595
e@@	I-Disease	-1	7628595
lo@@	I-Disease	-1	7628595
toxicity	I-Disease	-1	7628595
in	O	-1	7628595
the	O	-1	7628595
over@@	O	-1	7628595
all	O	-1	7628595
treated	O	-1	7628595
po@@	O	-1	7628595
pul@@	O	-1	7628595
ation,	O	-1	7628595
although	O	-1	7628595
a	O	-1	7628595
ben@@	O	-1	7628595
e@@	O	-1	7628595
fic@@	O	-1	7628595
ial	O	-1	7628595
effect	O	-1	7628595
in	O	-1	7628595
cer@@	O	-1	7628595
t@@	O	-1	7628595
ain	O	-1	7628595
sub@@	O	-1	7628595
groups	O	-1	7628595
of	O	-1	7628595
patients	O	-1	7628595
can@@	O	-1	7628595
not	O	-1	7628595
be	O	-1	7628595
ex@@	O	-1	7628595
cl@@	O	-1	7628595
u@@	O	-1	7628595
de@@	O	-1	7628595
d.	O	-1	7628595

Ac@@	O	-1	7858459
ute	O	-1	7858459
conf@@	B-Disease	D003221	7858459
usion	I-Disease	-1	7858459
induced	O	-1	7858459
by	O	-1	7858459
a	O	-1	7858459
high-dose	O	-1	7858459
infusion	O	-1	7858459
of	O	-1	7858459
5-@@	B-Chemical	D005472	7858459
fluoro@@	I-Chemical	-1	7858459
urac@@	I-Chemical	-1	7858459
il	I-Chemical	-1	7858459
and	O	-1	7858459
fol@@	B-Chemical	D002955	7858459
inic	I-Chemical	-1	7858459
acid	I-Chemical	-1	7858459
.	O	-1	7858459
A	O	-1	7858459
6@@	O	-1	7858459
1-@@	O	-1	7858459
year-old	O	-1	7858459
man	O	-1	7858459
was	O	-1	7858459
treated	O	-1	7858459
with	O	-1	7858459
combination	O	-1	7858459
chemotherapy	O	-1	7858459
inc@@	O	-1	7858459
or@@	O	-1	7858459
por@@	O	-1	7858459
ating	O	-1	7858459
cispl@@	B-Chemical	D002945	7858459
at@@	I-Chemical	-1	7858459
in@@	I-Chemical	-1	7858459
um	I-Chemical	-1	7858459
,	O	-1	7858459
e@@	B-Chemical	D005047	7858459
to@@	I-Chemical	-1	7858459
po@@	I-Chemical	-1	7858459
side	I-Chemical	-1	7858459
,	O	-1	7858459
high-dose	O	-1	7858459
5-@@	B-Chemical	D005472	7858459
fluoro@@	I-Chemical	-1	7858459
urac@@	I-Chemical	-1	7858459
il	I-Chemical	-1	7858459
(2@@	O	-1	7858459
,@@	O	-1	7858459
2@@	O	-1	7858459
50	O	-1	7858459
mg/m@@	O	-1	7858459
2@@	O	-1	7858459
/@@	O	-1	7858459
24	O	-1	7858459
hour@@	O	-1	7858459
s)	O	-1	7858459
and	O	-1	7858459
fol@@	B-Chemical	D002955	7858459
inic	I-Chemical	-1	7858459
acid	I-Chemical	-1	7858459
for	O	-1	7858459
an	O	-1	7858459
ino@@	O	-1	7858459
per@@	O	-1	7858459
able	O	-1	7858459
gast@@	B-Disease	D013274	7858459
ric	I-Disease	-1	7858459
aden@@	I-Disease	-1	7858459
oc@@	I-Disease	-1	7858459
arc@@	I-Disease	-1	7858459
in@@	I-Disease	-1	7858459
oma	I-Disease	-1	7858459
.	O	-1	7858459
H@@	O	-1	7858459
e	O	-1	7858459
developed	O	-1	7858459
acute	O	-1	7858459
neurolog@@	O	-1	7858459
ic	O	-1	7858459
symptoms	O	-1	7858459
of	O	-1	7858459
mental	O	-1	7858459
conf@@	B-Disease	D003221	7858459
usion	I-Disease	-1	7858459
,	O	-1	7858459
disor@@	B-Disease	D003221	7858459
i@@	I-Disease	-1	7858459
ent@@	I-Disease	-1	7858459
ation	I-Disease	-1	7858459
and	O	-1	7858459
ir@@	B-Disease	D001523	7858459
rit@@	I-Disease	-1	7858459
ability	I-Disease	-1	7858459
,	O	-1	7858459
and	O	-1	7858459
then	O	-1	7858459
l@@	O	-1	7858459
ap@@	O	-1	7858459
sed	O	-1	7858459
into	O	-1	7858459
a	O	-1	7858459
de@@	O	-1	7858459
ep	O	-1	7858459
com@@	B-Disease	D003128	7858459
a	I-Disease	-1	7858459
,	O	-1	7858459
l@@	O	-1	7858459
ast@@	O	-1	7858459
ing	O	-1	7858459
for	O	-1	7858459
appro@@	O	-1	7858459
xim@@	O	-1	7858459
ately	O	-1	7858459
40	O	-1	7858459
hours	O	-1	7858459
during	O	-1	7858459
the	O	-1	7858459
first	O	-1	7858459
dose	O	-1	7858459
(@@	O	-1	7858459
day	O	-1	7858459
2)	O	-1	7858459
of	O	-1	7858459
5-@@	B-Chemical	D005472	7858459
fluoro@@	I-Chemical	-1	7858459
urac@@	I-Chemical	-1	7858459
il	I-Chemical	-1	7858459
and	O	-1	7858459
fol@@	B-Chemical	D002955	7858459
inic	I-Chemical	-1	7858459
acid	I-Chemical	-1	7858459
infu@@	O	-1	7858459
sion.	O	-1	7858459
This	O	-1	7858459
complication	O	-1	7858459
re@@	O	-1	7858459
appe@@	O	-1	7858459
a@@	O	-1	7858459
red	O	-1	7858459
on	O	-1	7858459
day	O	-1	7858459
25	O	-1	7858459
during	O	-1	7858459
the	O	-1	7858459
second	O	-1	7858459
dose	O	-1	7858459
of	O	-1	7858459
5-@@	B-Chemical	D005472	7858459
fluoro@@	I-Chemical	-1	7858459
urac@@	I-Chemical	-1	7858459
il	I-Chemical	-1	7858459
and	O	-1	7858459
fol@@	B-Chemical	D002955	7858459
inic	I-Chemical	-1	7858459
acid	I-Chemical	-1	7858459
,	O	-1	7858459
which	O	-1	7858459
were	O	-1	7858459
then	O	-1	7858459
the	O	-1	7858459
only	O	-1	7858459
drugs	O	-1	7858459
gi@@	O	-1	7858459
ven@@	O	-1	7858459
.	O	-1	7858459
B@@	O	-1	7858459
ecause	O	-1	7858459
fol@@	B-Chemical	D002955	7858459
inic	I-Chemical	-1	7858459
acid	I-Chemical	-1	7858459
was	O	-1	7858459
un@@	O	-1	7858459
likely	O	-1	7858459
to	O	-1	7858459
be	O	-1	7858459
associated	O	-1	7858459
with	O	-1	7858459
this	O	-1	7858459
condi@@	O	-1	7858459
tion,	O	-1	7858459
neuro@@	B-Disease	D020258	7858459
toxicity	I-Disease	-1	7858459
due	O	-1	7858459
to	O	-1	7858459
high-dose	O	-1	7858459
5-@@	B-Chemical	D005472	7858459
fluoro@@	I-Chemical	-1	7858459
urac@@	I-Chemical	-1	7858459
il	I-Chemical	-1	7858459
was	O	-1	7858459
high@@	O	-1	7858459
ly	O	-1	7858459
sus@@	O	-1	7858459
p@@	O	-1	7858459
ect@@	O	-1	7858459
ed.	O	-1	7858459
The	O	-1	7858459
path@@	O	-1	7858459
o@@	O	-1	7858459
genesis	O	-1	7858459
of	O	-1	7858459
5-@@	B-Chemical	D005472	7858459
fluoro@@	I-Chemical	-1	7858459
urac@@	I-Chemical	-1	7858459
il	I-Chemical	-1	7858459
neuro@@	B-Disease	D020258	7858459
toxicity	I-Disease	-1	7858459
may	O	-1	7858459
be	O	-1	7858459
due	O	-1	7858459
to	O	-1	7858459
a	O	-1	7858459
K@@	O	-1	7858459
reb@@	O	-1	7858459
s	O	-1	7858459
cyc@@	O	-1	7858459
le	O	-1	7858459
block@@	O	-1	7858459
ade	O	-1	7858459
by	O	-1	7858459
fluoro@@	B-Chemical	D005463	7858459
acet@@	I-Chemical	-1	7858459
ate	I-Chemical	-1	7858459
and	O	-1	7858459
fluoro@@	B-Chemical	C007744	7858459
cit@@	I-Chemical	-1	7858459
rate	I-Chemical	-1	7858459
,	O	-1	7858459
thi@@	B-Chemical	D013831	7858459
amine	I-Chemical	-1	7858459
defici@@	O	-1	7858459
enc@@	O	-1	7858459
y,	O	-1	7858459
or	O	-1	7858459
di@@	B-Chemical	C007419	7858459
hydro@@	I-Chemical	-1	7858459
urac@@	I-Chemical	-1	7858459
il	I-Chemical	-1	7858459
de@@	O	-1	7858459
hydro@@	O	-1	7858459
gen@@	O	-1	7858459
ase	O	-1	7858459
defici@@	O	-1	7858459
enc@@	O	-1	7858459
y.	O	-1	7858459
H@@	O	-1	7858459
igh@@	O	-1	7858459
-@@	O	-1	7858459
dose	O	-1	7858459
5-@@	B-Chemical	D005472	7858459
fluoro@@	I-Chemical	-1	7858459
urac@@	I-Chemical	-1	7858459
il	I-Chemical	-1	7858459
/	O	-1	7858459
fol@@	B-Chemical	D002955	7858459
inic	I-Chemical	-1	7858459
acid	I-Chemical	-1	7858459
infusion	O	-1	7858459
therapy	O	-1	7858459
has	O	-1	7858459
rec@@	O	-1	7858459
ently	O	-1	7858459
b@@	O	-1	7858459
ec@@	O	-1	7858459
ome	O	-1	7858459
a	O	-1	7858459
po@@	O	-1	7858459
p@@	O	-1	7858459
ular	O	-1	7858459
regi@@	O	-1	7858459
men	O	-1	7858459
for	O	-1	7858459
various	O	-1	7858459
canc@@	B-Disease	D009369	7858459
ers	I-Disease	-1	7858459
.	O	-1	7858459
It	O	-1	7858459
is	O	-1	7858459
nec@@	O	-1	7858459
ess@@	O	-1	7858459
ary	O	-1	7858459
that	O	-1	7858459
both	O	-1	7858459
on@@	O	-1	7858459
co@@	O	-1	7858459
log@@	O	-1	7858459
ist@@	O	-1	7858459
s	O	-1	7858459
and	O	-1	7858459
neurolog@@	O	-1	7858459
ist@@	O	-1	7858459
s	O	-1	7858459
be	O	-1	7858459
ful@@	O	-1	7858459
ly	O	-1	7858459
aw@@	O	-1	7858459
are	O	-1	7858459
of	O	-1	7858459
this	O	-1	7858459
un@@	O	-1	7858459
us@@	O	-1	7858459
ual	O	-1	7858459
complic@@	O	-1	7858459
ation.	O	-1	7858459

Eff@@	O	-1	7862923
ect	O	-1	7862923
of	O	-1	7862923
switch@@	O	-1	7862923
ing	O	-1	7862923
carbamazepine	B-Chemical	D002220	7862923
to	O	-1	7862923
ox@@	B-Chemical	C036006	7862923
carb@@	I-Chemical	-1	7862923
azepine	I-Chemical	-1	7862923
on	O	-1	7862923
the	O	-1	7862923
plasma	O	-1	7862923
levels	O	-1	7862923
of	O	-1	7862923
neuro@@	O	-1	7862923
le@@	O	-1	7862923
p@@	O	-1	7862923
tic@@	O	-1	7862923
s.	O	-1	7862923
A	O	-1	7862923
case	O	-1	7862923
repor@@	O	-1	7862923
t.	O	-1	7862923
C@@	B-Chemical	D002220	7862923
arb@@	I-Chemical	-1	7862923
am@@	I-Chemical	-1	7862923
azepine	I-Chemical	-1	7862923
was	O	-1	7862923
switch@@	O	-1	7862923
ed	O	-1	7862923
to	O	-1	7862923
its	O	-1	7862923
10-@@	O	-1	7862923
ke@@	O	-1	7862923
to	O	-1	7862923
an@@	O	-1	7862923
alo@@	O	-1	7862923
gu@@	O	-1	7862923
e	O	-1	7862923
ox@@	B-Chemical	C036006	7862923
carb@@	I-Chemical	-1	7862923
azepine	I-Chemical	-1	7862923
among	O	-1	7862923
six	O	-1	7862923
diff@@	O	-1	7862923
ic@@	O	-1	7862923
ult@@	O	-1	7862923
-@@	O	-1	7862923
to@@	O	-1	7862923
-@@	O	-1	7862923
tre@@	O	-1	7862923
at	O	-1	7862923
sch@@	B-Disease	D012559	7862923
iz@@	I-Disease	-1	7862923
oph@@	I-Disease	-1	7862923
ren@@	I-Disease	-1	7862923
ic	I-Disease	-1	7862923
or	O	-1	7862923
org@@	B-Disease	D019965	7862923
anic	I-Disease	-1	7862923
psycho@@	I-Disease	-1	7862923
tic	I-Disease	-1	7862923
patients	O	-1	7862923
using	O	-1	7862923
concomit@@	O	-1	7862923
ant@@	O	-1	7862923
ly	O	-1	7862923
haloperidol	B-Chemical	D006220	7862923
,	O	-1	7862923
chlor@@	B-Chemical	D002746	7862923
pro@@	I-Chemical	-1	7862923
ma@@	I-Chemical	-1	7862923
z@@	I-Chemical	-1	7862923
ine	I-Chemical	-1	7862923
or	O	-1	7862923
cloz@@	B-Chemical	D003024	7862923
apine	I-Chemical	-1	7862923
.	O	-1	7862923
This	O	-1	7862923
change	O	-1	7862923
resulted	O	-1	7862923
within	O	-1	7862923
2-@@	O	-1	7862923
4	O	-1	7862923
weeks	O	-1	7862923
in	O	-1	7862923
the	O	-1	7862923
50@@	O	-1	7862923
-@@	O	-1	7862923
20@@	O	-1	7862923
0%	O	-1	7862923
increase	O	-1	7862923
in	O	-1	7862923
the	O	-1	7862923
plasma	O	-1	7862923
levels	O	-1	7862923
of	O	-1	7862923
these	O	-1	7862923
neuro@@	O	-1	7862923
le@@	O	-1	7862923
p@@	O	-1	7862923
tics	O	-1	7862923
and	O	-1	7862923
the	O	-1	7862923
appear@@	O	-1	7862923
ance	O	-1	7862923
of	O	-1	7862923
ext@@	B-Disease	D001480	7862923
ra@@	I-Disease	-1	7862923
py@@	I-Disease	-1	7862923
ram@@	I-Disease	-1	7862923
idal	I-Disease	-1	7862923
symptoms	I-Disease	-1	7862923
.	O	-1	7862923
N@@	O	-1	7862923
one	O	-1	7862923
of	O	-1	7862923
the	O	-1	7862923
patients	O	-1	7862923
showed	O	-1	7862923
any	O	-1	7862923
clinical	O	-1	7862923
deter@@	O	-1	7862923
i@@	O	-1	7862923
ot@@	O	-1	7862923
ation	O	-1	7862923
during	O	-1	7862923
the	O	-1	7862923
following	O	-1	7862923
3-@@	O	-1	7862923
6	O	-1	7862923
months.	O	-1	7862923
The	O	-1	7862923
results	O	-1	7862923
of	O	-1	7862923
this	O	-1	7862923
case	O	-1	7862923
report	O	-1	7862923
suppor@@	O	-1	7862923
t	O	-1	7862923
the	O	-1	7862923
ide@@	O	-1	7862923
a	O	-1	7862923
that	O	-1	7862923
in	O	-1	7862923
contr@@	O	-1	7862923
ast	O	-1	7862923
with	O	-1	7862923
carbamazepine	B-Chemical	D002220	7862923
ox@@	B-Chemical	C036006	7862923
carb@@	I-Chemical	-1	7862923
azepine	I-Chemical	-1	7862923
does	O	-1	7862923
not	O	-1	7862923
induce	O	-1	7862923
the	O	-1	7862923
hepatic	O	-1	7862923
micro@@	O	-1	7862923
s@@	O	-1	7862923
om@@	O	-1	7862923
al	O	-1	7862923
enzyme	O	-1	7862923
system@@	O	-1	7862923
s	O	-1	7862923
reg@@	O	-1	7862923
ul@@	O	-1	7862923
ating	O	-1	7862923
the	O	-1	7862923
in@@	O	-1	7862923
activation	O	-1	7862923
of	O	-1	7862923
anti@@	O	-1	7862923
psycho@@	O	-1	7862923
tic	O	-1	7862923
drug@@	O	-1	7862923
s.	O	-1	7862923

E@@	B-Disease	D004892	7919560
r@@	I-Disease	-1	7919560
y@@	I-Disease	-1	7919560
th@@	I-Disease	-1	7919560
em@@	I-Disease	-1	7919560
a	I-Disease	-1	7919560
multi@@	I-Disease	-1	7919560
form@@	I-Disease	-1	7919560
e	I-Disease	-1	7919560
and	O	-1	7919560
hyper@@	B-Disease	D009205	7919560
sensitivity	I-Disease	-1	7919560
myocardi@@	I-Disease	-1	7919560
tis	I-Disease	-1	7919560
caused	O	-1	7919560
by	O	-1	7919560
amp@@	B-Chemical	D000667	7919560
icill@@	I-Chemical	-1	7919560
in	I-Chemical	-1	7919560
.	O	-1	7919560
OBJECTIVE:	O	-1	7919560
To	O	-1	7919560
report	O	-1	7919560
a	O	-1	7919560
case	O	-1	7919560
of	O	-1	7919560
eryth@@	B-Disease	D004892	7919560
em@@	I-Disease	-1	7919560
a	I-Disease	-1	7919560
multi@@	I-Disease	-1	7919560
form@@	I-Disease	-1	7919560
e	I-Disease	-1	7919560
and	O	-1	7919560
hyper@@	B-Disease	D009205	7919560
sensitivity	I-Disease	-1	7919560
myocardi@@	I-Disease	-1	7919560
tis	I-Disease	-1	7919560
caused	O	-1	7919560
by	O	-1	7919560
amp@@	B-Chemical	D000667	7919560
icill@@	I-Chemical	-1	7919560
in	I-Chemical	-1	7919560
.	O	-1	7919560
CA@@	O	-1	7919560
S@@	O	-1	7919560
E	O	-1	7919560
S@@	O	-1	7919560
U@@	O	-1	7919560
M@@	O	-1	7919560
MA@@	O	-1	7919560
R@@	O	-1	7919560
Y@@	O	-1	7919560
:	O	-1	7919560
A	O	-1	7919560
1@@	O	-1	7919560
3-@@	O	-1	7919560
year-old	O	-1	7919560
bo@@	O	-1	7919560
y	O	-1	7919560
was	O	-1	7919560
treated	O	-1	7919560
with	O	-1	7919560
amp@@	B-Chemical	D000667	7919560
icill@@	I-Chemical	-1	7919560
in	I-Chemical	-1	7919560
and	O	-1	7919560
g@@	B-Chemical	D005839	7919560
ent@@	I-Chemical	-1	7919560
am@@	I-Chemical	-1	7919560
icin	I-Chemical	-1	7919560
because	O	-1	7919560
of	O	-1	7919560
sus@@	O	-1	7919560
p@@	O	-1	7919560
ected	O	-1	7919560
se@@	B-Disease	D018805	7919560
p@@	I-Disease	-1	7919560
ti@@	I-Disease	-1	7919560
ce@@	I-Disease	-1	7919560
mia	I-Disease	-1	7919560
.	O	-1	7919560
M@@	O	-1	7919560
ed@@	O	-1	7919560
ic@@	O	-1	7919560
ations	O	-1	7919560
were	O	-1	7919560
discontinu@@	O	-1	7919560
ed	O	-1	7919560
when	O	-1	7919560
eryth@@	B-Disease	D004892	7919560
em@@	I-Disease	-1	7919560
a	I-Disease	-1	7919560
multi@@	I-Disease	-1	7919560
form@@	I-Disease	-1	7919560
e	I-Disease	-1	7919560
and	O	-1	7919560
con@@	B-Disease	D006333	7919560
g@@	I-Disease	-1	7919560
es@@	I-Disease	-1	7919560
tive	I-Disease	-1	7919560
heart	I-Disease	-1	7919560
failure	I-Disease	-1	7919560
caused	O	-1	7919560
by	O	-1	7919560
myocardi@@	B-Disease	D009205	7919560
tis	I-Disease	-1	7919560
occur@@	O	-1	7919560
red.	O	-1	7919560
The	O	-1	7919560
patient	O	-1	7919560
was	O	-1	7919560
treated	O	-1	7919560
with	O	-1	7919560
methyl@@	B-Chemical	D008775	7919560
pre@@	I-Chemical	-1	7919560
d@@	I-Chemical	-1	7919560
n@@	I-Chemical	-1	7919560
isol@@	I-Chemical	-1	7919560
one	I-Chemical	-1	7919560
and	O	-1	7919560
gra@@	O	-1	7919560
du@@	O	-1	7919560
ally	O	-1	7919560
impro@@	O	-1	7919560
ved.	O	-1	7919560
M@@	O	-1	7919560
ac@@	O	-1	7919560
ro@@	O	-1	7919560
ph@@	O	-1	7919560
ag@@	O	-1	7919560
e-@@	O	-1	7919560
mi@@	O	-1	7919560
g@@	O	-1	7919560
ration	O	-1	7919560
inhibition	O	-1	7919560
(@@	O	-1	7919560
M@@	O	-1	7919560
I@@	O	-1	7919560
F@@	O	-1	7919560
)	O	-1	7919560
test	O	-1	7919560
with	O	-1	7919560
amp@@	B-Chemical	D000667	7919560
icill@@	I-Chemical	-1	7919560
in	I-Chemical	-1	7919560
was	O	-1	7919560
posi@@	O	-1	7919560
ti@@	O	-1	7919560
ve.	O	-1	7919560
D@@	O	-1	7919560
I@@	O	-1	7919560
S@@	O	-1	7919560
C@@	O	-1	7919560
US@@	O	-1	7919560
S@@	O	-1	7919560
ION@@	O	-1	7919560
:	O	-1	7919560
After	O	-1	7919560
most	O	-1	7919560
inf@@	B-Disease	D007239	7919560
ec@@	I-Disease	-1	7919560
tions	I-Disease	-1	7919560
ca@@	O	-1	7919560
using	O	-1	7919560
eryth@@	B-Disease	D004892	7919560
em@@	I-Disease	-1	7919560
a	I-Disease	-1	7919560
multi@@	I-Disease	-1	7919560
form@@	I-Disease	-1	7919560
e	I-Disease	-1	7919560
and	O	-1	7919560
myocardi@@	B-Disease	D009205	7919560
tis	I-Disease	-1	7919560
were	O	-1	7919560
r@@	O	-1	7919560
ul@@	O	-1	7919560
ed	O	-1	7919560
out@@	O	-1	7919560
,	O	-1	7919560
a	O	-1	7919560
drug@@	B-Disease	D004342	7919560
-induced	I-Disease	-1	7919560
all@@	I-Disease	-1	7919560
ergic	I-Disease	-1	7919560
reaction	I-Disease	-1	7919560
was	O	-1	7919560
sus@@	O	-1	7919560
p@@	O	-1	7919560
ect@@	O	-1	7919560
ed.	O	-1	7919560
P@@	O	-1	7919560
o@@	O	-1	7919560
si@@	O	-1	7919560
tive	O	-1	7919560
M@@	O	-1	7919560
I@@	O	-1	7919560
F	O	-1	7919560
test	O	-1	7919560
for	O	-1	7919560
amp@@	B-Chemical	D000667	7919560
icill@@	I-Chemical	-1	7919560
in	I-Chemical	-1	7919560
showed	O	-1	7919560
sensi@@	O	-1	7919560
tiz@@	O	-1	7919560
ation	O	-1	7919560
of	O	-1	7919560
the	O	-1	7919560
patient@@	O	-1	7919560
's	O	-1	7919560
lymph@@	O	-1	7919560
ocy@@	O	-1	7919560
tes	O	-1	7919560
to	O	-1	7919560
amp@@	B-Chemical	D000667	7919560
icill@@	I-Chemical	-1	7919560
in	I-Chemical	-1	7919560
.	O	-1	7919560
CONCLUSIONS:	O	-1	7919560
H@@	B-Disease	D009205	7919560
y@@	I-Disease	-1	7919560
per@@	I-Disease	-1	7919560
sensitivity	I-Disease	-1	7919560
myocardi@@	I-Disease	-1	7919560
tis	I-Disease	-1	7919560
is	O	-1	7919560
a	O	-1	7919560
r@@	O	-1	7919560
are	O	-1	7919560
and	O	-1	7919560
d@@	O	-1	7919560
ang@@	O	-1	7919560
er@@	O	-1	7919560
ous	O	-1	7919560
man@@	O	-1	7919560
if@@	O	-1	7919560
est@@	O	-1	7919560
ation	O	-1	7919560
of	O	-1	7919560
all@@	B-Disease	D004342	7919560
erg@@	I-Disease	-1	7919560
y	I-Disease	-1	7919560
to	O	-1	7919560
pen@@	B-Chemical	D010406	7919560
icill@@	I-Chemical	-1	7919560
ins	I-Chemical	-1	7919560
.	O	-1	7919560

Im@@	O	-1	8092427
medi@@	O	-1	8092427
ate	O	-1	8092427
all@@	B-Disease	D004342	8092427
ergic	I-Disease	-1	8092427
reactions	I-Disease	-1	8092427
to	O	-1	8092427
am@@	B-Chemical	D000658	8092427
oxic@@	I-Chemical	-1	8092427
ill@@	I-Chemical	-1	8092427
in	I-Chemical	-1	8092427
.	O	-1	8092427
A	O	-1	8092427
larg@@	O	-1	8092427
e	O	-1	8092427
group	O	-1	8092427
of	O	-1	8092427
patients	O	-1	8092427
with	O	-1	8092427
sus@@	O	-1	8092427
p@@	O	-1	8092427
ected	O	-1	8092427
all@@	B-Disease	D004342	8092427
ergic	I-Disease	-1	8092427
reactions	I-Disease	-1	8092427
to	O	-1	8092427
beta-@@	B-Chemical	D047090	8092427
l@@	I-Chemical	-1	8092427
act@@	I-Chemical	-1	8092427
am	I-Chemical	-1	8092427
anti@@	O	-1	8092427
bio@@	O	-1	8092427
tics	O	-1	8092427
was	O	-1	8092427
evalu@@	O	-1	8092427
ated.	O	-1	8092427
A	O	-1	8092427
det@@	O	-1	8092427
ail@@	O	-1	8092427
ed	O	-1	8092427
clinical	O	-1	8092427
hist@@	O	-1	8092427
or@@	O	-1	8092427
y,	O	-1	8092427
to@@	O	-1	8092427
ge@@	O	-1	8092427
ther	O	-1	8092427
with	O	-1	8092427
s@@	O	-1	8092427
k@@	O	-1	8092427
in	O	-1	8092427
test@@	O	-1	8092427
s,	O	-1	8092427
R@@	O	-1	8092427
A@@	O	-1	8092427
S@@	O	-1	8092427
T	O	-1	8092427
(@@	O	-1	8092427
radi@@	O	-1	8092427
o@@	O	-1	8092427
all@@	O	-1	8092427
erg@@	O	-1	8092427
os@@	O	-1	8092427
or@@	O	-1	8092427
b@@	O	-1	8092427
ent	O	-1	8092427
test@@	O	-1	8092427
),	O	-1	8092427
and	O	-1	8092427
controlled	O	-1	8092427
ch@@	O	-1	8092427
all@@	O	-1	8092427
enge	O	-1	8092427
test@@	O	-1	8092427
s,	O	-1	8092427
was	O	-1	8092427
used	O	-1	8092427
to	O	-1	8092427
est@@	O	-1	8092427
abl@@	O	-1	8092427
is@@	O	-1	8092427
h	O	-1	8092427
whether	O	-1	8092427
patients	O	-1	8092427
all@@	B-Disease	D004342	8092427
ergic	I-Disease	-1	8092427
to	O	-1	8092427
beta-@@	B-Chemical	D047090	8092427
l@@	I-Chemical	-1	8092427
act@@	I-Chemical	-1	8092427
am	I-Chemical	-1	8092427
anti@@	O	-1	8092427
bio@@	O	-1	8092427
tics	O	-1	8092427
had	O	-1	8092427
selective	O	-1	8092427
immedi@@	O	-1	8092427
ate	O	-1	8092427
all@@	B-Disease	D004342	8092427
ergic	I-Disease	-1	8092427
responses	O	-1	8092427
to	O	-1	8092427
am@@	B-Chemical	D000658	8092427
oxic@@	I-Chemical	-1	8092427
ill@@	I-Chemical	-1	8092427
in	I-Chemical	-1	8092427
(	O	-1	8092427
A@@	B-Chemical	D000658	8092427
X	I-Chemical	-1	8092427
)	O	-1	8092427
or	O	-1	8092427
were	O	-1	8092427
cros@@	O	-1	8092427
s-@@	O	-1	8092427
re@@	O	-1	8092427
act@@	O	-1	8092427
ing	O	-1	8092427
with	O	-1	8092427
other	O	-1	8092427
pen@@	B-Chemical	D010406	8092427
icill@@	I-Chemical	-1	8092427
in	I-Chemical	-1	8092427
der@@	O	-1	8092427
i@@	O	-1	8092427
v@@	O	-1	8092427
ati@@	O	-1	8092427
v@@	O	-1	8092427
es.	O	-1	8092427
S@@	O	-1	8092427
k@@	O	-1	8092427
in	O	-1	8092427
tests	O	-1	8092427
were	O	-1	8092427
performed	O	-1	8092427
with	O	-1	8092427
b@@	B-Chemical	-1	8092427
enz@@	I-Chemical	-1	8092427
yl@@	I-Chemical	-1	8092427
pen@@	I-Chemical	-1	8092427
ic@@	I-Chemical	-1	8092427
il@@	I-Chemical	-1	8092427
lo@@	I-Chemical	-1	8092427
yl@@	I-Chemical	-1	8092427
-@@	I-Chemical	-1	8092427
poly@@	I-Chemical	-1	8092427
-@@	I-Chemical	-1	8092427
L-@@	I-Chemical	-1	8092427
l@@	I-Chemical	-1	8092427
ys@@	I-Chemical	-1	8092427
ine	I-Chemical	-1	8092427
(	O	-1	8092427
B@@	B-Chemical	-1	8092427
P@@	I-Chemical	-1	8092427
O@@	I-Chemical	-1	8092427
-@@	I-Chemical	-1	8092427
P@@	I-Chemical	-1	8092427
L@@	I-Chemical	-1	8092427
L	I-Chemical	-1	8092427
),	O	-1	8092427
b@@	B-Chemical	-1	8092427
enz@@	I-Chemical	-1	8092427
yl@@	I-Chemical	-1	8092427
pen@@	I-Chemical	-1	8092427
ic@@	I-Chemical	-1	8092427
il@@	I-Chemical	-1	8092427
lo@@	I-Chemical	-1	8092427
ate	I-Chemical	-1	8092427
,	O	-1	8092427
b@@	B-Chemical	D010400	8092427
enz@@	I-Chemical	-1	8092427
yl@@	I-Chemical	-1	8092427
pen@@	I-Chemical	-1	8092427
icill@@	I-Chemical	-1	8092427
in	I-Chemical	-1	8092427
(	O	-1	8092427
P@@	B-Chemical	D010400	8092427
G	I-Chemical	-1	8092427
),	O	-1	8092427
amp@@	B-Chemical	D000667	8092427
icill@@	I-Chemical	-1	8092427
in	I-Chemical	-1	8092427
(	O	-1	8092427
AM@@	B-Chemical	D000667	8092427
P	I-Chemical	-1	8092427
),	O	-1	8092427
and	O	-1	8092427
A@@	B-Chemical	D000658	8092427
X	I-Chemical	-1	8092427
.	O	-1	8092427
R@@	O	-1	8092427
A@@	O	-1	8092427
S@@	O	-1	8092427
T	O	-1	8092427
for	O	-1	8092427
B@@	B-Chemical	-1	8092427
P@@	I-Chemical	-1	8092427
O@@	I-Chemical	-1	8092427
-@@	I-Chemical	-1	8092427
P@@	I-Chemical	-1	8092427
L@@	I-Chemical	-1	8092427
L	I-Chemical	-1	8092427
and	O	-1	8092427
A@@	B-Chemical	D000658	8092427
X	I-Chemical	-1	8092427
-@@	O	-1	8092427
P@@	O	-1	8092427
L@@	O	-1	8092427
L	O	-1	8092427
was	O	-1	8092427
d@@	O	-1	8092427
one.	O	-1	8092427
Whe@@	O	-1	8092427
n	O	-1	8092427
both	O	-1	8092427
s@@	O	-1	8092427
k@@	O	-1	8092427
in	O	-1	8092427
test	O	-1	8092427
and	O	-1	8092427
R@@	O	-1	8092427
A@@	O	-1	8092427
S@@	O	-1	8092427
T	O	-1	8092427
for	O	-1	8092427
B@@	B-Chemical	-1	8092427
P@@	I-Chemical	-1	8092427
O	I-Chemical	-1	8092427
were	O	-1	8092427
neg@@	O	-1	8092427
ati@@	O	-1	8092427
ve,	O	-1	8092427
sing@@	O	-1	8092427
le@@	O	-1	8092427
-@@	O	-1	8092427
bl@@	O	-1	8092427
ind@@	O	-1	8092427
,	O	-1	8092427
placebo@@	O	-1	8092427
-@@	O	-1	8092427
controlled	O	-1	8092427
ch@@	O	-1	8092427
all@@	O	-1	8092427
enge	O	-1	8092427
tests	O	-1	8092427
were	O	-1	8092427
d@@	O	-1	8092427
one	O	-1	8092427
to	O	-1	8092427
ens@@	O	-1	8092427
ure	O	-1	8092427
toler@@	O	-1	8092427
ance	O	-1	8092427
of	O	-1	8092427
P@@	B-Chemical	D010400	8092427
G	I-Chemical	-1	8092427
or	O	-1	8092427
sensitivity	O	-1	8092427
to	O	-1	8092427
A@@	B-Chemical	D000658	8092427
X	I-Chemical	-1	8092427
.	O	-1	8092427
A	O	-1	8092427
total	O	-1	8092427
of	O	-1	8092427
17@@	O	-1	8092427
7	O	-1	8092427
patients	O	-1	8092427
were	O	-1	8092427
diagnos@@	O	-1	8092427
ed	O	-1	8092427
as	O	-1	8092427
all@@	B-Disease	D004342	8092427
ergic	I-Disease	-1	8092427
to	O	-1	8092427
beta-@@	B-Chemical	D047090	8092427
l@@	I-Chemical	-1	8092427
act@@	I-Chemical	-1	8092427
am	I-Chemical	-1	8092427
anti@@	O	-1	8092427
bio@@	O	-1	8092427
tic@@	O	-1	8092427
s.	O	-1	8092427
We	O	-1	8092427
sel@@	O	-1	8092427
ected	O	-1	8092427
the	O	-1	8092427
5@@	O	-1	8092427
4	O	-1	8092427
(3@@	O	-1	8092427
0.@@	O	-1	8092427
5@@	O	-1	8092427
%)	O	-1	8092427
cases	O	-1	8092427
of	O	-1	8092427
immedi@@	O	-1	8092427
ate	O	-1	8092427
A@@	B-Chemical	D000658	8092427
X	I-Chemical	-1	8092427
all@@	B-Disease	D004342	8092427
erg@@	I-Disease	-1	8092427
y	I-Disease	-1	8092427
with	O	-1	8092427
go@@	O	-1	8092427
od	O	-1	8092427
toler@@	O	-1	8092427
ance	O	-1	8092427
of	O	-1	8092427
P@@	B-Chemical	D010400	8092427
G	I-Chemical	-1	8092427
.	O	-1	8092427
An@@	B-Disease	D000707	8092427
a@@	I-Disease	-1	8092427
phyl@@	I-Disease	-1	8092427
ax@@	I-Disease	-1	8092427
is	I-Disease	-1	8092427
was	O	-1	8092427
seen	O	-1	8092427
in	O	-1	8092427
3@@	O	-1	8092427
7	O	-1	8092427
patients	O	-1	8092427
(6@@	O	-1	8092427
9@@	O	-1	8092427
%),	O	-1	8092427
the	O	-1	8092427
other	O	-1	8092427
17	O	-1	8092427
(3@@	O	-1	8092427
1@@	O	-1	8092427
%)	O	-1	8092427
ha@@	O	-1	8092427
ving	O	-1	8092427
ur@@	B-Disease	D014581	8092427
ti@@	I-Disease	-1	8092427
car@@	I-Disease	-1	8092427
ia	I-Disease	-1	8092427
and/or	O	-1	8092427
angio@@	B-Disease	D000799	8092427
e@@	I-Disease	-1	8092427
de@@	I-Disease	-1	8092427
ma	I-Disease	-1	8092427
.	O	-1	8092427
All	O	-1	8092427
the	O	-1	8092427
patients	O	-1	8092427
were	O	-1	8092427
s@@	O	-1	8092427
k@@	O	-1	8092427
in	O	-1	8092427
test	O	-1	8092427
negative	O	-1	8092427
to	O	-1	8092427
B@@	B-Chemical	-1	8092427
P@@	I-Chemical	-1	8092427
O	I-Chemical	-1	8092427
;	O	-1	8092427
4@@	O	-1	8092427
9	O	-1	8092427
of	O	-1	8092427
5@@	O	-1	8092427
1	O	-1	8092427
(@@	O	-1	8092427
9@@	O	-1	8092427
6@@	O	-1	8092427
%)	O	-1	8092427
were	O	-1	8092427
also	O	-1	8092427
negative	O	-1	8092427
to	O	-1	8092427
MD@@	B-Disease	D007645	8092427
M	I-Disease	-1	8092427
,	O	-1	8092427
and	O	-1	8092427
4@@	O	-1	8092427
4	O	-1	8092427
of	O	-1	8092427
4@@	O	-1	8092427
6	O	-1	8092427
(@@	O	-1	8092427
9@@	O	-1	8092427
6@@	O	-1	8092427
%)	O	-1	8092427
to	O	-1	8092427
P@@	B-Chemical	D010400	8092427
G	I-Chemical	-1	8092427
.	O	-1	8092427
S@@	O	-1	8092427
k@@	O	-1	8092427
in	O	-1	8092427
tests	O	-1	8092427
with	O	-1	8092427
A@@	B-Chemical	D000658	8092427
X	I-Chemical	-1	8092427
were	O	-1	8092427
positive	O	-1	8092427
in	O	-1	8092427
3@@	O	-1	8092427
4	O	-1	8092427
(6@@	O	-1	8092427
3@@	O	-1	8092427
%)	O	-1	8092427
patients.	O	-1	8092427
R@@	O	-1	8092427
A@@	O	-1	8092427
S@@	O	-1	8092427
T	O	-1	8092427
was	O	-1	8092427
positive	O	-1	8092427
for	O	-1	8092427
A@@	B-Chemical	D000658	8092427
X	I-Chemical	-1	8092427
in	O	-1	8092427
2@@	O	-1	8092427
2	O	-1	8092427
patients	O	-1	8092427
(4@@	O	-1	8092427
1@@	O	-1	8092427
%)	O	-1	8092427
and	O	-1	8092427
to	O	-1	8092427
B@@	B-Chemical	-1	8092427
P@@	I-Chemical	-1	8092427
O	I-Chemical	-1	8092427
in	O	-1	8092427
j@@	O	-1	8092427
us@@	O	-1	8092427
t	O	-1	8092427
5	O	-1	8092427
(@@	O	-1	8092427
9@@	O	-1	8092427
%).	O	-1	8092427
N@@	O	-1	8092427
one	O	-1	8092427
of	O	-1	8092427
the	O	-1	8092427
ser@@	O	-1	8092427
a	O	-1	8092427
with	O	-1	8092427
negative	O	-1	8092427
R@@	O	-1	8092427
A@@	O	-1	8092427
S@@	O	-1	8092427
T	O	-1	8092427
for	O	-1	8092427
A@@	B-Chemical	D000658	8092427
X	I-Chemical	-1	8092427
were	O	-1	8092427
positive	O	-1	8092427
to	O	-1	8092427
B@@	B-Chemical	-1	8092427
P@@	I-Chemical	-1	8092427
O	I-Chemical	-1	8092427
.	O	-1	8092427
Ch@@	O	-1	8092427
all@@	O	-1	8092427
enge	O	-1	8092427
tests	O	-1	8092427
with	O	-1	8092427
A@@	B-Chemical	D000658	8092427
X	I-Chemical	-1	8092427
were	O	-1	8092427
performed	O	-1	8092427
in	O	-1	8092427
2@@	O	-1	8092427
3	O	-1	8092427
subjects	O	-1	8092427
(4@@	O	-1	8092427
3@@	O	-1	8092427
%)	O	-1	8092427
to	O	-1	8092427
est@@	O	-1	8092427
abl@@	O	-1	8092427
is@@	O	-1	8092427
h	O	-1	8092427
the	O	-1	8092427
diagnosis	O	-1	8092427
of	O	-1	8092427
immedi@@	O	-1	8092427
ate	O	-1	8092427
all@@	B-Disease	D004342	8092427
ergic	I-Disease	-1	8092427
reaction	I-Disease	-1	8092427
to	O	-1	8092427
A@@	B-Chemical	D000658	8092427
X	I-Chemical	-1	8092427
,	O	-1	8092427
and	O	-1	8092427
in	O	-1	8092427
15	O	-1	8092427
cases	O	-1	8092427
(2@@	O	-1	8092427
8@@	O	-1	8092427
%)	O	-1	8092427
both	O	-1	8092427
s@@	O	-1	8092427
k@@	O	-1	8092427
in	O	-1	8092427
test	O	-1	8092427
and	O	-1	8092427
R@@	O	-1	8092427
A@@	O	-1	8092427
S@@	O	-1	8092427
T	O	-1	8092427
for	O	-1	8092427
A@@	B-Chemical	D000658	8092427
X	I-Chemical	-1	8092427
were	O	-1	8092427
neg@@	O	-1	8092427
ati@@	O	-1	8092427
ve.	O	-1	8092427
P@@	B-Chemical	D010400	8092427
G	I-Chemical	-1	8092427
was	O	-1	8092427
well	O	-1	8092427
toler@@	O	-1	8092427
ated	O	-1	8092427
by	O	-1	8092427
all	O	-1	8092427
5@@	O	-1	8092427
4	O	-1	8092427
patients.	O	-1	8092427
We	O	-1	8092427
describe	O	-1	8092427
the	O	-1	8092427
larg@@	O	-1	8092427
est	O	-1	8092427
group	O	-1	8092427
of	O	-1	8092427
A@@	B-Chemical	D000658	8092427
X	I-Chemical	-1	8092427
-	O	-1	8092427
all@@	B-Disease	D004342	8092427
ergic	I-Disease	-1	8092427
patients	O	-1	8092427
who	O	-1	8092427
have	O	-1	8092427
toler@@	O	-1	8092427
ated	O	-1	8092427
P@@	B-Chemical	D010400	8092427
G	I-Chemical	-1	8092427
reported	O	-1	8092427
so	O	-1	8092427
far@@	O	-1	8092427
.	O	-1	8092427
Di@@	O	-1	8092427
ag@@	O	-1	8092427
no@@	O	-1	8092427
sis	O	-1	8092427
of	O	-1	8092427
these	O	-1	8092427
patients	O	-1	8092427
can	O	-1	8092427
be	O	-1	8092427
achi@@	O	-1	8092427
ev@@	O	-1	8092427
ed	O	-1	8092427
only	O	-1	8092427
if	O	-1	8092427
specific	O	-1	8092427
A@@	B-Chemical	D000658	8092427
X	I-Chemical	-1	8092427
-@@	O	-1	8092427
related	O	-1	8092427
re@@	O	-1	8092427
agents	O	-1	8092427
are	O	-1	8092427
em@@	O	-1	8092427
p@@	O	-1	8092427
lo@@	O	-1	8092427
y@@	O	-1	8092427
ed.	O	-1	8092427
F@@	O	-1	8092427
urther	O	-1	8092427
studies	O	-1	8092427
are	O	-1	8092427
nec@@	O	-1	8092427
ess@@	O	-1	8092427
ary	O	-1	8092427
to	O	-1	8092427
determine	O	-1	8092427
the	O	-1	8092427
ex@@	O	-1	8092427
ac@@	O	-1	8092427
t	O	-1	8092427
ext@@	O	-1	8092427
ent	O	-1	8092427
of	O	-1	8092427
this	O	-1	8092427
pro@@	O	-1	8092427
ble@@	O	-1	8092427
m	O	-1	8092427
and	O	-1	8092427
to	O	-1	8092427
impro@@	O	-1	8092427
ve	O	-1	8092427
the	O	-1	8092427
efficacy	O	-1	8092427
of	O	-1	8092427
diagnos@@	O	-1	8092427
tic	O	-1	8092427
meth@@	O	-1	8092427
o@@	O	-1	8092427
d@@	O	-1	8092427
s.	O	-1	8092427

P@@	O	-1	8638206
er@@	O	-1	8638206
sist@@	O	-1	8638206
ent	O	-1	8638206
par@@	B-Disease	D010243	8638206
aly@@	I-Disease	-1	8638206
sis	I-Disease	-1	8638206
after	O	-1	8638206
prolonged	O	-1	8638206
use	O	-1	8638206
of	O	-1	8638206
at@@	B-Chemical	D001279	8638206
rac@@	I-Chemical	-1	8638206
ur@@	I-Chemical	-1	8638206
i@@	I-Chemical	-1	8638206
um	I-Chemical	-1	8638206
in	O	-1	8638206
the	O	-1	8638206
absence	O	-1	8638206
of	O	-1	8638206
cortico@@	O	-1	8638206
steroid@@	O	-1	8638206
s.	O	-1	8638206
Ne@@	O	-1	8638206
uro@@	O	-1	8638206
mus@@	O	-1	8638206
cular	O	-1	8638206
block@@	O	-1	8638206
ing	O	-1	8638206
agents	O	-1	8638206
(N@@	O	-1	8638206
M@@	O	-1	8638206
BA@@	O	-1	8638206
s)	O	-1	8638206
are	O	-1	8638206
often	O	-1	8638206
used	O	-1	8638206
for	O	-1	8638206
patients	O	-1	8638206
requ@@	O	-1	8638206
ir@@	O	-1	8638206
ing	O	-1	8638206
prolonged	O	-1	8638206
mechan@@	O	-1	8638206
ical	O	-1	8638206
ven@@	O	-1	8638206
til@@	O	-1	8638206
ation.	O	-1	8638206
Re@@	O	-1	8638206
por@@	O	-1	8638206
ts	O	-1	8638206
of	O	-1	8638206
per@@	O	-1	8638206
sist@@	O	-1	8638206
ent	O	-1	8638206
par@@	B-Disease	D010243	8638206
aly@@	I-Disease	-1	8638206
sis	I-Disease	-1	8638206
after	O	-1	8638206
the	O	-1	8638206
discontinu@@	O	-1	8638206
ance	O	-1	8638206
of	O	-1	8638206
these	O	-1	8638206
drugs	O	-1	8638206
have	O	-1	8638206
most	O	-1	8638206
often	O	-1	8638206
involved	O	-1	8638206
amino@@	O	-1	8638206
steroid@@	O	-1	8638206
-@@	O	-1	8638206
bas@@	O	-1	8638206
ed	O	-1	8638206
N@@	O	-1	8638206
M@@	O	-1	8638206
BA@@	O	-1	8638206
s	O	-1	8638206
such	O	-1	8638206
as	O	-1	8638206
v@@	B-Chemical	D014673	8638206
ec@@	I-Chemical	-1	8638206
uron@@	I-Chemical	-1	8638206
i@@	I-Chemical	-1	8638206
um	I-Chemical	-1	8638206
brom@@	I-Chemical	-1	8638206
ide	I-Chemical	-1	8638206
,	O	-1	8638206
es@@	O	-1	8638206
p@@	O	-1	8638206
ec@@	O	-1	8638206
i@@	O	-1	8638206
ally	O	-1	8638206
when	O	-1	8638206
used	O	-1	8638206
in	O	-1	8638206
con@@	O	-1	8638206
j@@	O	-1	8638206
unc@@	O	-1	8638206
tion	O	-1	8638206
with	O	-1	8638206
cortico@@	O	-1	8638206
steroid@@	O	-1	8638206
s.	O	-1	8638206
A@@	B-Chemical	D001279	8638206
trac@@	I-Chemical	-1	8638206
ur@@	I-Chemical	-1	8638206
i@@	I-Chemical	-1	8638206
um	I-Chemical	-1	8638206
b@@	I-Chemical	-1	8638206
es@@	I-Chemical	-1	8638206
yl@@	I-Chemical	-1	8638206
ate	I-Chemical	-1	8638206
,	O	-1	8638206
a	O	-1	8638206
sh@@	O	-1	8638206
ort@@	O	-1	8638206
-@@	O	-1	8638206
act@@	O	-1	8638206
ing	O	-1	8638206
b@@	B-Chemical	-1	8638206
enz@@	I-Chemical	-1	8638206
yl@@	I-Chemical	-1	8638206
iso@@	I-Chemical	-1	8638206
qu@@	I-Chemical	-1	8638206
in@@	I-Chemical	-1	8638206
ol@@	I-Chemical	-1	8638206
in@@	I-Chemical	-1	8638206
i@@	I-Chemical	-1	8638206
um	I-Chemical	-1	8638206
N@@	O	-1	8638206
M@@	O	-1	8638206
B@@	O	-1	8638206
A	O	-1	8638206
that	O	-1	8638206
is	O	-1	8638206
el@@	O	-1	8638206
im@@	O	-1	8638206
in@@	O	-1	8638206
ated	O	-1	8638206
in@@	O	-1	8638206
depend@@	O	-1	8638206
ently	O	-1	8638206
of	O	-1	8638206
renal	O	-1	8638206
or	O	-1	8638206
hepatic	O	-1	8638206
func@@	O	-1	8638206
tion,	O	-1	8638206
has	O	-1	8638206
also	O	-1	8638206
been	O	-1	8638206
associated	O	-1	8638206
with	O	-1	8638206
per@@	O	-1	8638206
sist@@	O	-1	8638206
ent	O	-1	8638206
par@@	B-Disease	D010243	8638206
aly@@	I-Disease	-1	8638206
sis	I-Disease	-1	8638206
,	O	-1	8638206
but	O	-1	8638206
only	O	-1	8638206
when	O	-1	8638206
used	O	-1	8638206
with	O	-1	8638206
cortico@@	O	-1	8638206
steroid@@	O	-1	8638206
s.	O	-1	8638206
We	O	-1	8638206
report	O	-1	8638206
a	O	-1	8638206
case	O	-1	8638206
of	O	-1	8638206
at@@	B-Chemical	D001279	8638206
rac@@	I-Chemical	-1	8638206
ur@@	I-Chemical	-1	8638206
i@@	I-Chemical	-1	8638206
um	I-Chemical	-1	8638206
-@@	O	-1	8638206
related	O	-1	8638206
par@@	B-Disease	D010243	8638206
aly@@	I-Disease	-1	8638206
sis	I-Disease	-1	8638206
per@@	O	-1	8638206
sist@@	O	-1	8638206
ing	O	-1	8638206
for	O	-1	8638206
appro@@	O	-1	8638206
xim@@	O	-1	8638206
ately	O	-1	8638206
50	O	-1	8638206
hours	O	-1	8638206
in	O	-1	8638206
a	O	-1	8638206
patient	O	-1	8638206
who	O	-1	8638206
was	O	-1	8638206
not	O	-1	8638206
treated	O	-1	8638206
with	O	-1	8638206
cortico@@	O	-1	8638206
steroid@@	O	-1	8638206
s.	O	-1	8638206

H@@	O	-1	8669433
ab@@	O	-1	8669433
it@@	O	-1	8669433
ual	O	-1	8669433
use	O	-1	8669433
of	O	-1	8669433
acet@@	B-Chemical	D000082	8669433
aminoph@@	I-Chemical	-1	8669433
en	I-Chemical	-1	8669433
as	O	-1	8669433
a	O	-1	8669433
risk	O	-1	8669433
factor	O	-1	8669433
for	O	-1	8669433
chronic	B-Disease	D007676	8669433
renal	I-Disease	-1	8669433
failure	I-Disease	-1	8669433
:	O	-1	8669433
a	O	-1	8669433
compar@@	O	-1	8669433
ison	O	-1	8669433
with	O	-1	8669433
phen@@	B-Chemical	D010615	8669433
ace@@	I-Chemical	-1	8669433
tin	I-Chemical	-1	8669433
.	O	-1	8669433
Si@@	O	-1	8669433
x	O	-1	8669433
epi@@	O	-1	8669433
de@@	O	-1	8669433
m@@	O	-1	8669433
io@@	O	-1	8669433
log@@	O	-1	8669433
ic	O	-1	8669433
studies	O	-1	8669433
in	O	-1	8669433
the	O	-1	8669433
U@@	O	-1	8669433
nit@@	O	-1	8669433
ed	O	-1	8669433
S@@	O	-1	8669433
t@@	O	-1	8669433
ates	O	-1	8669433
and	O	-1	8669433
E@@	O	-1	8669433
uro@@	O	-1	8669433
p@@	O	-1	8669433
e	O	-1	8669433
indicate	O	-1	8669433
that	O	-1	8669433
h@@	O	-1	8669433
ab@@	O	-1	8669433
it@@	O	-1	8669433
ual	O	-1	8669433
use	O	-1	8669433
of	O	-1	8669433
phen@@	B-Chemical	D010615	8669433
ace@@	I-Chemical	-1	8669433
tin	I-Chemical	-1	8669433
is	O	-1	8669433
associated	O	-1	8669433
with	O	-1	8669433
the	O	-1	8669433
development	O	-1	8669433
of	O	-1	8669433
chronic	B-Disease	D007676	8669433
renal	I-Disease	-1	8669433
failure	I-Disease	-1	8669433
and	O	-1	8669433
en@@	B-Disease	D007676	8669433
d-@@	I-Disease	-1	8669433
st@@	I-Disease	-1	8669433
age	I-Disease	-1	8669433
renal	I-Disease	-1	8669433
disease	I-Disease	-1	8669433
(	O	-1	8669433
ES@@	B-Disease	D007676	8669433
R@@	I-Disease	-1	8669433
D	I-Disease	-1	8669433
),	O	-1	8669433
with	O	-1	8669433
a	O	-1	8669433
rel@@	O	-1	8669433
ative	O	-1	8669433
risk	O	-1	8669433
in	O	-1	8669433
the	O	-1	8669433
range	O	-1	8669433
of	O	-1	8669433
4	O	-1	8669433
to	O	-1	8669433
19@@	O	-1	8669433
.	O	-1	8669433
A@@	O	-1	8669433
s	O	-1	8669433
a	O	-1	8669433
result	O	-1	8669433
of	O	-1	8669433
these	O	-1	8669433
and	O	-1	8669433
other	O	-1	8669433
studi@@	O	-1	8669433
es,	O	-1	8669433
phen@@	B-Chemical	D010615	8669433
ace@@	I-Chemical	-1	8669433
tin	I-Chemical	-1	8669433
has	O	-1	8669433
no@@	O	-1	8669433
w	O	-1	8669433
been	O	-1	8669433
withdraw@@	O	-1	8669433
n	O	-1	8669433
from	O	-1	8669433
the	O	-1	8669433
mark@@	O	-1	8669433
et	O	-1	8669433
in	O	-1	8669433
most	O	-1	8669433
coun@@	O	-1	8669433
tri@@	O	-1	8669433
es.	O	-1	8669433
However,	O	-1	8669433
three	O	-1	8669433
case	O	-1	8669433
control	O	-1	8669433
studi@@	O	-1	8669433
es,	O	-1	8669433
one	O	-1	8669433
each	O	-1	8669433
in	O	-1	8669433
N@@	O	-1	8669433
or@@	O	-1	8669433
th	O	-1	8669433
Ca@@	O	-1	8669433
ro@@	O	-1	8669433
lin@@	O	-1	8669433
a,	O	-1	8669433
nor@@	O	-1	8669433
ther@@	O	-1	8669433
n	O	-1	8669433
M@@	O	-1	8669433
ar@@	O	-1	8669433
yl@@	O	-1	8669433
and@@	O	-1	8669433
,	O	-1	8669433
and	O	-1	8669433
W@@	O	-1	8669433
est	O	-1	8669433
B@@	O	-1	8669433
er@@	O	-1	8669433
l@@	O	-1	8669433
in,	O	-1	8669433
G@@	O	-1	8669433
er@@	O	-1	8669433
man@@	O	-1	8669433
y,	O	-1	8669433
showed	O	-1	8669433
that	O	-1	8669433
h@@	O	-1	8669433
ab@@	O	-1	8669433
it@@	O	-1	8669433
ual	O	-1	8669433
use	O	-1	8669433
of	O	-1	8669433
acet@@	B-Chemical	D000082	8669433
aminoph@@	I-Chemical	-1	8669433
en	I-Chemical	-1	8669433
is	O	-1	8669433
also	O	-1	8669433
associated	O	-1	8669433
with	O	-1	8669433
chronic	B-Disease	D007676	8669433
renal	I-Disease	-1	8669433
failure	I-Disease	-1	8669433
and	O	-1	8669433
ES@@	B-Disease	D007676	8669433
R@@	I-Disease	-1	8669433
D	I-Disease	-1	8669433
,	O	-1	8669433
with	O	-1	8669433
a	O	-1	8669433
rel@@	O	-1	8669433
ative	O	-1	8669433
risk	O	-1	8669433
in	O	-1	8669433
the	O	-1	8669433
range	O	-1	8669433
of	O	-1	8669433
2	O	-1	8669433
to	O	-1	8669433
4@@	O	-1	8669433
.	O	-1	8669433
These	O	-1	8669433
studies	O	-1	8669433
suggest	O	-1	8669433
that	O	-1	8669433
both	O	-1	8669433
phen@@	B-Chemical	D010615	8669433
ace@@	I-Chemical	-1	8669433
tin	I-Chemical	-1	8669433
and	O	-1	8669433
acet@@	B-Chemical	D000082	8669433
aminoph@@	I-Chemical	-1	8669433
en	I-Chemical	-1	8669433
may	O	-1	8669433
cont@@	O	-1	8669433
rib@@	O	-1	8669433
ute	O	-1	8669433
to	O	-1	8669433
the	O	-1	8669433
b@@	O	-1	8669433
ur@@	O	-1	8669433
de@@	O	-1	8669433
n	O	-1	8669433
of	O	-1	8669433
ES@@	B-Disease	D007676	8669433
R@@	I-Disease	-1	8669433
D	I-Disease	-1	8669433
,	O	-1	8669433
with	O	-1	8669433
the	O	-1	8669433
risk	O	-1	8669433
of	O	-1	8669433
the	O	-1	8669433
lat@@	O	-1	8669433
ter	O	-1	8669433
being	O	-1	8669433
so@@	O	-1	8669433
me@@	O	-1	8669433
wh@@	O	-1	8669433
at	O	-1	8669433
less	O	-1	8669433
than	O	-1	8669433
that	O	-1	8669433
of	O	-1	8669433
the	O	-1	8669433
form@@	O	-1	8669433
er.	O	-1	8669433
This	O	-1	8669433
appa@@	O	-1	8669433
rent	O	-1	8669433
difference	O	-1	8669433
in	O	-1	8669433
risk	O	-1	8669433
may	O	-1	8669433
not	O	-1	8669433
be	O	-1	8669433
due	O	-1	8669433
to	O	-1	8669433
differences	O	-1	8669433
in	O	-1	8669433
nephro@@	B-Disease	D007674	8669433
toxic	I-Disease	-1	8669433
potential	O	-1	8669433
of	O	-1	8669433
the	O	-1	8669433
drugs	O	-1	8669433
th@@	O	-1	8669433
em@@	O	-1	8669433
sel@@	O	-1	8669433
v@@	O	-1	8669433
es.	O	-1	8669433
A	O	-1	8669433
lower	O	-1	8669433
rel@@	O	-1	8669433
ative	O	-1	8669433
risk	O	-1	8669433
wo@@	O	-1	8669433
uld	O	-1	8669433
be	O	-1	8669433
ex@@	O	-1	8669433
p@@	O	-1	8669433
ected	O	-1	8669433
for	O	-1	8669433
acet@@	B-Chemical	D000082	8669433
aminoph@@	I-Chemical	-1	8669433
en	I-Chemical	-1	8669433
if	O	-1	8669433
the	O	-1	8669433
risk	O	-1	8669433
of	O	-1	8669433
both	O	-1	8669433
drugs	O	-1	8669433
in	O	-1	8669433
combination	O	-1	8669433
with	O	-1	8669433
other	O	-1	8669433
analge@@	O	-1	8669433
si@@	O	-1	8669433
c@@	O	-1	8669433
s	O	-1	8669433
was	O	-1	8669433
higher	O	-1	8669433
than	O	-1	8669433
the	O	-1	8669433
risk	O	-1	8669433
of	O	-1	8669433
either	O	-1	8669433
agent	O	-1	8669433
al@@	O	-1	8669433
one.	O	-1	8669433
Th@@	O	-1	8669433
us,	O	-1	8669433
acet@@	B-Chemical	D000082	8669433
aminoph@@	I-Chemical	-1	8669433
en	I-Chemical	-1	8669433
has	O	-1	8669433
been	O	-1	8669433
used	O	-1	8669433
both	O	-1	8669433
as	O	-1	8669433
a	O	-1	8669433
single	O	-1	8669433
agent	O	-1	8669433
and	O	-1	8669433
in	O	-1	8669433
combination	O	-1	8669433
with	O	-1	8669433
other	O	-1	8669433
analge@@	O	-1	8669433
si@@	O	-1	8669433
c@@	O	-1	8669433
s,	O	-1	8669433
whereas	O	-1	8669433
phen@@	B-Chemical	D010615	8669433
ace@@	I-Chemical	-1	8669433
tin	I-Chemical	-1	8669433
was	O	-1	8669433
av@@	O	-1	8669433
ail@@	O	-1	8669433
able	O	-1	8669433
only	O	-1	8669433
in	O	-1	8669433
combin@@	O	-1	8669433
ations.	O	-1	8669433
The	O	-1	8669433
possib@@	O	-1	8669433
ility	O	-1	8669433
that	O	-1	8669433
h@@	O	-1	8669433
ab@@	O	-1	8669433
it@@	O	-1	8669433
ual	O	-1	8669433
use	O	-1	8669433
of	O	-1	8669433
acet@@	B-Chemical	D000082	8669433
aminoph@@	I-Chemical	-1	8669433
en	I-Chemical	-1	8669433
alone	O	-1	8669433
increases	O	-1	8669433
the	O	-1	8669433
risk	O	-1	8669433
of	O	-1	8669433
ES@@	B-Disease	D007676	8669433
R@@	I-Disease	-1	8669433
D	I-Disease	-1	8669433
has	O	-1	8669433
not	O	-1	8669433
been	O	-1	8669433
clear@@	O	-1	8669433
ly	O	-1	8669433
demon@@	O	-1	8669433
strat@@	O	-1	8669433
ed,	O	-1	8669433
but	O	-1	8669433
can@@	O	-1	8669433
not	O	-1	8669433
be	O	-1	8669433
dis@@	O	-1	8669433
mis@@	O	-1	8669433
sed.	O	-1	8669433

Re@@	O	-1	8690168
duction	O	-1	8690168
of	O	-1	8690168
hepar@@	B-Chemical	D006497	8690168
an	I-Chemical	-1	8690168
sul@@	I-Chemical	-1	8690168
ph@@	I-Chemical	-1	8690168
ate	I-Chemical	-1	8690168
-@@	O	-1	8690168
associated	O	-1	8690168
an@@	O	-1	8690168
i@@	O	-1	8690168
onic	O	-1	8690168
sit@@	O	-1	8690168
es	O	-1	8690168
in	O	-1	8690168
the	O	-1	8690168
glomerular	O	-1	8690168
bas@@	O	-1	8690168
ement	O	-1	8690168
membran@@	O	-1	8690168
e	O	-1	8690168
of	O	-1	8690168
rats	O	-1	8690168
with	O	-1	8690168
st@@	B-Chemical	D013311	8690168
re@@	I-Chemical	-1	8690168
pto@@	I-Chemical	-1	8690168
z@@	I-Chemical	-1	8690168
ot@@	I-Chemical	-1	8690168
oc@@	I-Chemical	-1	8690168
in	I-Chemical	-1	8690168
-induced	O	-1	8690168
dia@@	B-Disease	D003928	8690168
be@@	I-Disease	-1	8690168
tic	I-Disease	-1	8690168
nephro@@	I-Disease	-1	8690168
pathy	I-Disease	-1	8690168
.	O	-1	8690168
He@@	B-Chemical	D006497	8690168
par@@	I-Chemical	-1	8690168
an	I-Chemical	-1	8690168
sul@@	I-Chemical	-1	8690168
ph@@	I-Chemical	-1	8690168
ate	I-Chemical	-1	8690168
-@@	O	-1	8690168
associated	O	-1	8690168
an@@	O	-1	8690168
i@@	O	-1	8690168
onic	O	-1	8690168
sit@@	O	-1	8690168
es	O	-1	8690168
in	O	-1	8690168
the	O	-1	8690168
glomerular	O	-1	8690168
bas@@	O	-1	8690168
ement	O	-1	8690168
membran@@	O	-1	8690168
e	O	-1	8690168
were	O	-1	8690168
studied	O	-1	8690168
in	O	-1	8690168
rats	O	-1	8690168
8	O	-1	8690168
months	O	-1	8690168
after	O	-1	8690168
induction	O	-1	8690168
of	O	-1	8690168
dia@@	B-Disease	D003920	8690168
bet@@	I-Disease	-1	8690168
es	I-Disease	-1	8690168
by	O	-1	8690168
st@@	B-Chemical	D013311	8690168
re@@	I-Chemical	-1	8690168
pto@@	I-Chemical	-1	8690168
z@@	I-Chemical	-1	8690168
ot@@	I-Chemical	-1	8690168
oc@@	I-Chemical	-1	8690168
in	I-Chemical	-1	8690168
and	O	-1	8690168
in	O	-1	8690168
ag@@	O	-1	8690168
e@@	O	-1	8690168
-	O	-1	8690168
ad@@	O	-1	8690168
n	O	-1	8690168
sex@@	O	-1	8690168
-@@	O	-1	8690168
mat@@	O	-1	8690168
ch@@	O	-1	8690168
ed	O	-1	8690168
control	O	-1	8690168
rats,	O	-1	8690168
em@@	O	-1	8690168
p@@	O	-1	8690168
lo@@	O	-1	8690168
y@@	O	-1	8690168
ing	O	-1	8690168
the	O	-1	8690168
c@@	O	-1	8690168
ation@@	O	-1	8690168
ic	O	-1	8690168
dy@@	O	-1	8690168
e	O	-1	8690168
c@@	B-Chemical	C015445	8690168
u@@	I-Chemical	-1	8690168
pro@@	I-Chemical	-1	8690168
lin@@	I-Chemical	-1	8690168
ic	I-Chemical	-1	8690168
b@@	I-Chemical	-1	8690168
lu@@	I-Chemical	-1	8690168
e	I-Chemical	-1	8690168
.	O	-1	8690168
M@@	O	-1	8690168
or@@	O	-1	8690168
ph@@	O	-1	8690168
o@@	O	-1	8690168
me@@	O	-1	8690168
tri@@	O	-1	8690168
c	O	-1	8690168
analysis	O	-1	8690168
at	O	-1	8690168
the	O	-1	8690168
ult@@	O	-1	8690168
ra@@	O	-1	8690168
struct@@	O	-1	8690168
ural	O	-1	8690168
level	O	-1	8690168
was	O	-1	8690168
performed	O	-1	8690168
using	O	-1	8690168
a	O	-1	8690168
comp@@	O	-1	8690168
u@@	O	-1	8690168
ter@@	O	-1	8690168
ized	O	-1	8690168
im@@	O	-1	8690168
age	O	-1	8690168
pro@@	O	-1	8690168
cess@@	O	-1	8690168
or@@	O	-1	8690168
.	O	-1	8690168
The	O	-1	8690168
hepar@@	B-Chemical	D006497	8690168
an	I-Chemical	-1	8690168
sul@@	I-Chemical	-1	8690168
ph@@	I-Chemical	-1	8690168
ate	I-Chemical	-1	8690168
spec@@	O	-1	8690168
ific@@	O	-1	8690168
ity	O	-1	8690168
of	O	-1	8690168
the	O	-1	8690168
c@@	B-Chemical	C015445	8690168
u@@	I-Chemical	-1	8690168
pro@@	I-Chemical	-1	8690168
lin@@	I-Chemical	-1	8690168
ic	I-Chemical	-1	8690168
b@@	I-Chemical	-1	8690168
lu@@	I-Chemical	-1	8690168
e	I-Chemical	-1	8690168
st@@	O	-1	8690168
aining	O	-1	8690168
was	O	-1	8690168
demonstrated	O	-1	8690168
by	O	-1	8690168
gly@@	B-Chemical	D006025	8690168
co@@	I-Chemical	-1	8690168
s@@	I-Chemical	-1	8690168
amino@@	I-Chemical	-1	8690168
glyc@@	I-Chemical	-1	8690168
an	I-Chemical	-1	8690168
-@@	O	-1	8690168
de@@	O	-1	8690168
gra@@	O	-1	8690168
ding	O	-1	8690168
enzym@@	O	-1	8690168
es,	O	-1	8690168
show@@	O	-1	8690168
ing	O	-1	8690168
that	O	-1	8690168
pretreatment	O	-1	8690168
of	O	-1	8690168
the	O	-1	8690168
sec@@	O	-1	8690168
tions	O	-1	8690168
with	O	-1	8690168
hepar@@	O	-1	8690168
it@@	O	-1	8690168
in@@	O	-1	8690168
ase	O	-1	8690168
abol@@	O	-1	8690168
ished	O	-1	8690168
all	O	-1	8690168
st@@	O	-1	8690168
ain@@	O	-1	8690168
ing,	O	-1	8690168
whereas	O	-1	8690168
ch@@	O	-1	8690168
on@@	O	-1	8690168
dro@@	O	-1	8690168
it@@	O	-1	8690168
in@@	O	-1	8690168
ase	O	-1	8690168
A@@	O	-1	8690168
B@@	O	-1	8690168
C	O	-1	8690168
had	O	-1	8690168
no	O	-1	8690168
effect@@	O	-1	8690168
.	O	-1	8690168
The	O	-1	8690168
maj@@	O	-1	8690168
or@@	O	-1	8690168
ity	O	-1	8690168
of	O	-1	8690168
an@@	O	-1	8690168
i@@	O	-1	8690168
onic	O	-1	8690168
sit@@	O	-1	8690168
es	O	-1	8690168
(@@	O	-1	8690168
7@@	O	-1	8690168
4@@	O	-1	8690168
%	O	-1	8690168
in	O	-1	8690168
dia@@	B-Disease	D003920	8690168
be@@	I-Disease	-1	8690168
tic	I-Disease	-1	8690168
and	O	-1	8690168
8@@	O	-1	8690168
1@@	O	-1	8690168
%	O	-1	8690168
in	O	-1	8690168
control	O	-1	8690168
rat@@	O	-1	8690168
s)	O	-1	8690168
were	O	-1	8690168
found	O	-1	8690168
within	O	-1	8690168
the	O	-1	8690168
l@@	O	-1	8690168
amin@@	O	-1	8690168
a	O	-1	8690168
r@@	O	-1	8690168
ar@@	O	-1	8690168
a	O	-1	8690168
ex@@	O	-1	8690168
tern@@	O	-1	8690168
a	O	-1	8690168
of	O	-1	8690168
the	O	-1	8690168
glomerular	O	-1	8690168
bas@@	O	-1	8690168
ement	O	-1	8690168
membran@@	O	-1	8690168
e.	O	-1	8690168
A	O	-1	8690168
min@@	O	-1	8690168
or@@	O	-1	8690168
ity	O	-1	8690168
of	O	-1	8690168
an@@	O	-1	8690168
i@@	O	-1	8690168
onic	O	-1	8690168
sit@@	O	-1	8690168
es	O	-1	8690168
were	O	-1	8690168
s@@	O	-1	8690168
cat@@	O	-1	8690168
te@@	O	-1	8690168
red	O	-1	8690168
throu@@	O	-1	8690168
gh@@	O	-1	8690168
out	O	-1	8690168
the	O	-1	8690168
l@@	O	-1	8690168
amin@@	O	-1	8690168
a	O	-1	8690168
d@@	O	-1	8690168
ens@@	O	-1	8690168
a	O	-1	8690168
and	O	-1	8690168
l@@	O	-1	8690168
amin@@	O	-1	8690168
a	O	-1	8690168
r@@	O	-1	8690168
ar@@	O	-1	8690168
a	O	-1	8690168
inter@@	O	-1	8690168
n@@	O	-1	8690168
a,	O	-1	8690168
and	O	-1	8690168
were	O	-1	8690168
significantly	O	-1	8690168
sm@@	O	-1	8690168
all@@	O	-1	8690168
er	O	-1	8690168
than	O	-1	8690168
those	O	-1	8690168
in	O	-1	8690168
the	O	-1	8690168
l@@	O	-1	8690168
amin@@	O	-1	8690168
a	O	-1	8690168
r@@	O	-1	8690168
ar@@	O	-1	8690168
a	O	-1	8690168
ex@@	O	-1	8690168
tern@@	O	-1	8690168
a	O	-1	8690168
of	O	-1	8690168
the	O	-1	8690168
glomerular	O	-1	8690168
bas@@	O	-1	8690168
ement	O	-1	8690168
membran@@	O	-1	8690168
e	O	-1	8690168
(p@@	O	-1	8690168
<@@	O	-1	8690168
0.00@@	O	-1	8690168
1	O	-1	8690168
and	O	-1	8690168
p@@	O	-1	8690168
<@@	O	-1	8690168
0.0@@	O	-1	8690168
1	O	-1	8690168
for	O	-1	8690168
dia@@	B-Disease	D003920	8690168
be@@	I-Disease	-1	8690168
tic	I-Disease	-1	8690168
and	O	-1	8690168
control	O	-1	8690168
rats,	O	-1	8690168
respectivel@@	O	-1	8690168
y@@	O	-1	8690168
).	O	-1	8690168
D@@	B-Disease	D003920	8690168
ia@@	I-Disease	-1	8690168
be@@	I-Disease	-1	8690168
tic	I-Disease	-1	8690168
rats	O	-1	8690168
progres@@	O	-1	8690168
si@@	O	-1	8690168
vely	O	-1	8690168
developed	O	-1	8690168
al@@	B-Disease	D000419	8690168
bu@@	I-Disease	-1	8690168
min@@	I-Disease	-1	8690168
uria	I-Disease	-1	8690168
reac@@	O	-1	8690168
h@@	O	-1	8690168
ing	O	-1	8690168
4@@	O	-1	8690168
0.@@	O	-1	8690168
3	O	-1	8690168
(3@@	O	-1	8690168
2.@@	O	-1	8690168
2-@@	O	-1	8690168
6@@	O	-1	8690168
2.@@	O	-1	8690168
0@@	O	-1	8690168
)	O	-1	8690168
mg/@@	O	-1	8690168
24	O	-1	8690168
h	O	-1	8690168
after	O	-1	8690168
8	O	-1	8690168
months	O	-1	8690168
in	O	-1	8690168
contr@@	O	-1	8690168
ast	O	-1	8690168
to	O	-1	8690168
the	O	-1	8690168
control	O	-1	8690168
animals	O	-1	8690168
(0.@@	O	-1	8690168
8	O	-1	8690168
(0.@@	O	-1	8690168
2-@@	O	-1	8690168
0.@@	O	-1	8690168
9@@	O	-1	8690168
)	O	-1	8690168
mg/@@	O	-1	8690168
24	O	-1	8690168
h@@	O	-1	8690168
,	O	-1	8690168
p@@	O	-1	8690168
<@@	O	-1	8690168
0.00@@	O	-1	8690168
2@@	O	-1	8690168
).	O	-1	8690168
A@@	O	-1	8690168
t	O	-1	8690168
the	O	-1	8690168
same	O	-1	8690168
ti@@	O	-1	8690168
me,	O	-1	8690168
the	O	-1	8690168
number	O	-1	8690168
of	O	-1	8690168
hepar@@	B-Chemical	D006497	8690168
an	I-Chemical	-1	8690168
sul@@	I-Chemical	-1	8690168
ph@@	I-Chemical	-1	8690168
ate	I-Chemical	-1	8690168
an@@	O	-1	8690168
i@@	O	-1	8690168
onic	O	-1	8690168
sit@@	O	-1	8690168
es	O	-1	8690168
and	O	-1	8690168
the	O	-1	8690168
total	O	-1	8690168
an@@	O	-1	8690168
i@@	O	-1	8690168
onic	O	-1	8690168
sit@@	O	-1	8690168
e	O	-1	8690168
sur@@	O	-1	8690168
fac@@	O	-1	8690168
e	O	-1	8690168
(@@	O	-1	8690168
number	O	-1	8690168
of	O	-1	8690168
an@@	O	-1	8690168
i@@	O	-1	8690168
onic	O	-1	8690168
sit@@	O	-1	8690168
es	O	-1	8690168
x	O	-1	8690168
mean	O	-1	8690168
an@@	O	-1	8690168
i@@	O	-1	8690168
onic	O	-1	8690168
sit@@	O	-1	8690168
e	O	-1	8690168
sur@@	O	-1	8690168
f@@	O	-1	8690168
ace@@	O	-1	8690168
)	O	-1	8690168
in	O	-1	8690168
the	O	-1	8690168
l@@	O	-1	8690168
amin@@	O	-1	8690168
a	O	-1	8690168
r@@	O	-1	8690168
ar@@	O	-1	8690168
a	O	-1	8690168
ex@@	O	-1	8690168
tern@@	O	-1	8690168
a	O	-1	8690168
of	O	-1	8690168
the	O	-1	8690168
glomerular	O	-1	8690168
bas@@	O	-1	8690168
ement	O	-1	8690168
membran@@	O	-1	8690168
e	O	-1	8690168
was	O	-1	8690168
reduced	O	-1	8690168
by	O	-1	8690168
19@@	O	-1	8690168
%	O	-1	8690168
(p@@	O	-1	8690168
<@@	O	-1	8690168
0.0@@	O	-1	8690168
2@@	O	-1	8690168
1)	O	-1	8690168
and	O	-1	8690168
by	O	-1	8690168
2@@	O	-1	8690168
6%	O	-1	8690168
(p@@	O	-1	8690168
<@@	O	-1	8690168
0.0@@	O	-1	8690168
2@@	O	-1	8690168
),	O	-1	8690168
respectively.	O	-1	8690168
N@@	O	-1	8690168
umb@@	O	-1	8690168
er	O	-1	8690168
and	O	-1	8690168
total	O	-1	8690168
an@@	O	-1	8690168
i@@	O	-1	8690168
onic	O	-1	8690168
sit@@	O	-1	8690168
e	O	-1	8690168
sur@@	O	-1	8690168
fac@@	O	-1	8690168
e	O	-1	8690168
in	O	-1	8690168
the	O	-1	8690168
remain@@	O	-1	8690168
ing	O	-1	8690168
par@@	O	-1	8690168
t	O	-1	8690168
of	O	-1	8690168
the	O	-1	8690168
glomerular	O	-1	8690168
bas@@	O	-1	8690168
ement	O	-1	8690168
membran@@	O	-1	8690168
e	O	-1	8690168
(@@	O	-1	8690168
l@@	O	-1	8690168
amin@@	O	-1	8690168
a	O	-1	8690168
d@@	O	-1	8690168
ens@@	O	-1	8690168
a	O	-1	8690168
and	O	-1	8690168
l@@	O	-1	8690168
amin@@	O	-1	8690168
a	O	-1	8690168
r@@	O	-1	8690168
ar@@	O	-1	8690168
a	O	-1	8690168
inter@@	O	-1	8690168
na@@	O	-1	8690168
)	O	-1	8690168
were	O	-1	8690168
not	O	-1	8690168
significantly	O	-1	8690168
chang@@	O	-1	8690168
ed.	O	-1	8690168
We	O	-1	8690168
concl@@	O	-1	8690168
ude	O	-1	8690168
that	O	-1	8690168
in	O	-1	8690168
st@@	B-Chemical	D013311	8690168
re@@	I-Chemical	-1	8690168
pto@@	I-Chemical	-1	8690168
z@@	I-Chemical	-1	8690168
ot@@	I-Chemical	-1	8690168
oc@@	I-Chemical	-1	8690168
in	I-Chemical	-1	8690168
-	O	-1	8690168
dia@@	B-Disease	D003920	8690168
be@@	I-Disease	-1	8690168
tic	I-Disease	-1	8690168
rats	O	-1	8690168
with	O	-1	8690168
an	O	-1	8690168
increased	O	-1	8690168
urinary	O	-1	8690168
al@@	O	-1	8690168
b@@	O	-1	8690168
um@@	O	-1	8690168
in	O	-1	8690168
ex@@	O	-1	8690168
cre@@	O	-1	8690168
tion,	O	-1	8690168
a	O	-1	8690168
reduced	O	-1	8690168
hepar@@	B-Chemical	D006497	8690168
an	I-Chemical	-1	8690168
sul@@	I-Chemical	-1	8690168
ph@@	I-Chemical	-1	8690168
ate	I-Chemical	-1	8690168
ch@@	O	-1	8690168
arg@@	O	-1	8690168
e	O	-1	8690168
bar@@	O	-1	8690168
ri@@	O	-1	8690168
er@@	O	-1	8690168
/@@	O	-1	8690168
d@@	O	-1	8690168
ensity	O	-1	8690168
is	O	-1	8690168
found	O	-1	8690168
at	O	-1	8690168
the	O	-1	8690168
l@@	O	-1	8690168
amin@@	O	-1	8690168
a	O	-1	8690168
r@@	O	-1	8690168
ar@@	O	-1	8690168
a	O	-1	8690168
ex@@	O	-1	8690168
tern@@	O	-1	8690168
a	O	-1	8690168
of	O	-1	8690168
the	O	-1	8690168
glomerular	O	-1	8690168
bas@@	O	-1	8690168
ement	O	-1	8690168
membran@@	O	-1	8690168
e.	O	-1	8690168

Eff@@	O	-1	8739323
ect	O	-1	8739323
of	O	-1	8739323
some	O	-1	8739323
anti@@	O	-1	8739323
cancer	O	-1	8739323
drugs	O	-1	8739323
and	O	-1	8739323
combined	O	-1	8739323
chemotherapy	O	-1	8739323
on	O	-1	8739323
renal	B-Disease	D007674	8739323
toxicity	I-Disease	-1	8739323
.	O	-1	8739323
The	O	-1	8739323
nephro@@	B-Disease	D007674	8739323
toxic	I-Disease	-1	8739323
action	O	-1	8739323
of	O	-1	8739323
anti@@	O	-1	8739323
cancer	O	-1	8739323
drugs	O	-1	8739323
such	O	-1	8739323
as	O	-1	8739323
nitro@@	B-Chemical	D008466	8739323
gran@@	I-Chemical	-1	8739323
u@@	I-Chemical	-1	8739323
log@@	I-Chemical	-1	8739323
en	I-Chemical	-1	8739323
(	O	-1	8739323
N@@	B-Chemical	D008466	8739323
G	I-Chemical	-1	8739323
),	O	-1	8739323
meth@@	B-Chemical	D008727	8739323
ot@@	I-Chemical	-1	8739323
re@@	I-Chemical	-1	8739323
x@@	I-Chemical	-1	8739323
ate	I-Chemical	-1	8739323
(	O	-1	8739323
M@@	B-Chemical	D008727	8739323
T@@	I-Chemical	-1	8739323
X	I-Chemical	-1	8739323
),	O	-1	8739323
5-@@	B-Chemical	D005472	8739323
fluoro@@	I-Chemical	-1	8739323
urac@@	I-Chemical	-1	8739323
il	I-Chemical	-1	8739323
(	O	-1	8739323
5-@@	B-Chemical	D005472	8739323
F@@	I-Chemical	-1	8739323
U	I-Chemical	-1	8739323
)	O	-1	8739323
and	O	-1	8739323
cyclophosph@@	B-Chemical	D003520	8739323
amide	I-Chemical	-1	8739323
(	O	-1	8739323
C@@	B-Chemical	D003520	8739323
Y	I-Chemical	-1	8739323
)	O	-1	8739323
administered	O	-1	8739323
alone	O	-1	8739323
or	O	-1	8739323
in	O	-1	8739323
combination	O	-1	8739323
[	O	-1	8739323
M@@	B-Chemical	D008727	8739323
T@@	I-Chemical	-1	8739323
X	I-Chemical	-1	8739323
+	O	-1	8739323
5-@@	B-Chemical	D005472	8739323
F@@	I-Chemical	-1	8739323
U	I-Chemical	-1	8739323
+	O	-1	8739323
C@@	B-Chemical	D003520	8739323
Y	I-Chemical	-1	8739323
(C@@	O	-1	8739323
M@@	O	-1	8739323
F@@	O	-1	8739323
)@@	O	-1	8739323
]	O	-1	8739323
was	O	-1	8739323
evaluated	O	-1	8739323
in	O	-1	8739323
experim@@	O	-1	8739323
ents	O	-1	8739323
on	O	-1	8739323
Wistar	O	-1	8739323
rats.	O	-1	8739323
After	O	-1	8739323
drug	O	-1	8739323
administr@@	O	-1	8739323
ation,	O	-1	8739323
creatinine	B-Chemical	D003404	8739323
concentrations	O	-1	8739323
in	O	-1	8739323
the	O	-1	8739323
plasma	O	-1	8739323
and	O	-1	8739323
in	O	-1	8739323
the	O	-1	8739323
urine	O	-1	8739323
of	O	-1	8739323
the	O	-1	8739323
rats	O	-1	8739323
were	O	-1	8739323
deter@@	O	-1	8739323
m@@	O	-1	8739323
ine@@	O	-1	8739323
d,	O	-1	8739323
as	O	-1	8739323
well	O	-1	8739323
as	O	-1	8739323
creatinine	B-Chemical	D003404	8739323
clear@@	O	-1	8739323
ance@@	O	-1	8739323
.	O	-1	8739323
H@@	O	-1	8739323
ist@@	O	-1	8739323
o@@	O	-1	8739323
path@@	O	-1	8739323
ologic	O	-1	8739323
evalu@@	O	-1	8739323
ation	O	-1	8739323
of	O	-1	8739323
the	O	-1	8739323
kidne@@	O	-1	8739323
ys	O	-1	8739323
was	O	-1	8739323
also	O	-1	8739323
per@@	O	-1	8739323
for@@	O	-1	8739323
me@@	O	-1	8739323
d.	O	-1	8739323
After	O	-1	8739323
M@@	B-Chemical	D008727	8739323
T@@	I-Chemical	-1	8739323
X	I-Chemical	-1	8739323
administration	O	-1	8739323
a	O	-1	8739323
significant	O	-1	8739323
increase	O	-1	8739323
(p	O	-1	8739323
=	O	-1	8739323
0.0@@	O	-1	8739323
2@@	O	-1	8739323
2@@	O	-1	8739323
8@@	O	-1	8739323
)	O	-1	8739323
in	O	-1	8739323
the	O	-1	8739323
plasma	O	-1	8739323
creatinine	B-Chemical	D003404	8739323
concentration	O	-1	8739323
and	O	-1	8739323
a	O	-1	8739323
significant	O	-1	8739323
(p	O	-1	8739323
=	O	-1	8739323
0.00@@	O	-1	8739323
0@@	O	-1	8739323
1)	O	-1	8739323
decrease	O	-1	8739323
in	O	-1	8739323
creatinine	B-Chemical	D003404	8739323
clear@@	O	-1	8739323
ance	O	-1	8739323
was	O	-1	8739323
not@@	O	-1	8739323
ed	O	-1	8739323
compared	O	-1	8739323
to	O	-1	8739323
controls.	O	-1	8739323
After	O	-1	8739323
the	O	-1	8739323
administration	O	-1	8739323
of	O	-1	8739323
N@@	B-Chemical	D008466	8739323
G	I-Chemical	-1	8739323
,	O	-1	8739323
5-@@	B-Chemical	D005472	8739323
F@@	I-Chemical	-1	8739323
U	I-Chemical	-1	8739323
and	O	-1	8739323
C@@	B-Chemical	D003520	8739323
Y	I-Chemical	-1	8739323
ne@@	O	-1	8739323
ither	O	-1	8739323
a	O	-1	8739323
statis@@	O	-1	8739323
tically	O	-1	8739323
significant	O	-1	8739323
increase	O	-1	8739323
in	O	-1	8739323
creatinine	B-Chemical	D003404	8739323
concentration	O	-1	8739323
n@@	O	-1	8739323
or	O	-1	8739323
an	O	-1	8739323
increase	O	-1	8739323
in	O	-1	8739323
creatinine	B-Chemical	D003404	8739323
clear@@	O	-1	8739323
ance	O	-1	8739323
was	O	-1	8739323
observed	O	-1	8739323
compared	O	-1	8739323
to	O	-1	8739323
the	O	-1	8739323
group	O	-1	8739323
receiving	O	-1	8739323
no	O	-1	8739323
cyto@@	O	-1	8739323
st@@	O	-1	8739323
ati@@	O	-1	8739323
c@@	O	-1	8739323
s.	O	-1	8739323
F@@	O	-1	8739323
ol@@	O	-1	8739323
low@@	O	-1	8739323
ing	O	-1	8739323
poly@@	O	-1	8739323
therapy	O	-1	8739323
ac@@	O	-1	8739323
cor@@	O	-1	8739323
ding	O	-1	8739323
to	O	-1	8739323
the	O	-1	8739323
C@@	O	-1	8739323
M@@	O	-1	8739323
F	O	-1	8739323
regimen@@	O	-1	8739323
,	O	-1	8739323
a	O	-1	8739323
statis@@	O	-1	8739323
tically	O	-1	8739323
significant	O	-1	8739323
decrease	O	-1	8739323
(p	O	-1	8739323
=	O	-1	8739323
0.0@@	O	-1	8739323
34@@	O	-1	8739323
3@@	O	-1	8739323
)	O	-1	8739323
in	O	-1	8739323
creatinine	B-Chemical	D003404	8739323
clear@@	O	-1	8739323
ance	O	-1	8739323
was	O	-1	8739323
f@@	O	-1	8739323
oun@@	O	-1	8739323
d,	O	-1	8739323
but	O	-1	8739323
creatinine	B-Chemical	D003404	8739323
concentration	O	-1	8739323
did	O	-1	8739323
not	O	-1	8739323
increase	O	-1	8739323
significantly	O	-1	8739323
compared	O	-1	8739323
to	O	-1	8739323
controls.	O	-1	8739323
C@@	B-Chemical	D003520	8739323
Y	I-Chemical	-1	8739323
caused	O	-1	8739323
hemorrh@@	B-Disease	D006470	8739323
ag@@	I-Disease	-1	8739323
ic	I-Disease	-1	8739323
cys@@	I-Disease	-1	8739323
ti@@	I-Disease	-1	8739323
tis	I-Disease	-1	8739323
hemorrh@@	B-Disease	D003556	8739323
ag@@	I-Disease	-1	8739323
ic	I-Disease	-1	8739323
cys@@	I-Disease	-1	8739323
ti@@	I-Disease	-1	8739323
tis	I-Disease	-1	8739323
in	O	-1	8739323
4@@	O	-1	8739323
0%	O	-1	8739323
of	O	-1	8739323
rats,	O	-1	8739323
but	O	-1	8739323
it	O	-1	8739323
did	O	-1	8739323
not	O	-1	8739323
cause	O	-1	8739323
this	O	-1	8739323
complication	O	-1	8739323
when	O	-1	8739323
combined	O	-1	8739323
with	O	-1	8739323
5-@@	B-Chemical	D005472	8739323
F@@	I-Chemical	-1	8739323
U	I-Chemical	-1	8739323
and	O	-1	8739323
M@@	B-Chemical	D008727	8739323
T@@	I-Chemical	-1	8739323
X	I-Chemical	-1	8739323
.	O	-1	8739323
H@@	O	-1	8739323
ist@@	O	-1	8739323
ologic	O	-1	8739323
changes	O	-1	8739323
were	O	-1	8739323
found	O	-1	8739323
in	O	-1	8739323
rat	O	-1	8739323
kidne@@	O	-1	8739323
ys	O	-1	8739323
after	O	-1	8739323
administration	O	-1	8739323
of	O	-1	8739323
M@@	B-Chemical	D008727	8739323
T@@	I-Chemical	-1	8739323
X	I-Chemical	-1	8739323
,	O	-1	8739323
C@@	B-Chemical	D003520	8739323
Y	I-Chemical	-1	8739323
and	O	-1	8739323
N@@	B-Chemical	D008466	8739323
G	I-Chemical	-1	8739323
,	O	-1	8739323
while	O	-1	8739323
no	O	-1	8739323
such	O	-1	8739323
change	O	-1	8739323
was	O	-1	8739323
observed	O	-1	8739323
after	O	-1	8739323
5-@@	B-Chemical	D005472	8739323
F@@	I-Chemical	-1	8739323
U	I-Chemical	-1	8739323
and	O	-1	8739323
j@@	O	-1	8739323
o@@	O	-1	8739323
in@@	O	-1	8739323
t	O	-1	8739323
administration	O	-1	8739323
of	O	-1	8739323
M@@	B-Chemical	D008727	8739323
T@@	I-Chemical	-1	8739323
X	I-Chemical	-1	8739323
+	O	-1	8739323
5-@@	B-Chemical	D005472	8739323
F@@	I-Chemical	-1	8739323
U	I-Chemical	-1	8739323
+	O	-1	8739323
C@@	B-Chemical	D003520	8739323
Y	I-Chemical	-1	8739323
compared	O	-1	8739323
to	O	-1	8739323
controls.	O	-1	8739323
Our	O	-1	8739323
studies	O	-1	8739323
indicate	O	-1	8739323
that	O	-1	8739323
nephro@@	B-Disease	D007674	8739323
toxicity	I-Disease	-1	8739323
of	O	-1	8739323
M@@	B-Chemical	D008727	8739323
T@@	I-Chemical	-1	8739323
X	I-Chemical	-1	8739323
+	O	-1	8739323
5-@@	B-Chemical	D005472	8739323
F@@	I-Chemical	-1	8739323
U	I-Chemical	-1	8739323
+	O	-1	8739323
C@@	B-Chemical	D003520	8739323
Y	I-Chemical	-1	8739323
administered	O	-1	8739323
j@@	O	-1	8739323
o@@	O	-1	8739323
int@@	O	-1	8739323
ly	O	-1	8739323
is	O	-1	8739323
lower	O	-1	8739323
than	O	-1	8739323
in	O	-1	8739323
mon@@	O	-1	8739323
o@@	O	-1	8739323
therapy.	O	-1	8739323

L@@	B-Chemical	D008094	8752018
i@@	I-Chemical	-1	8752018
thi@@	I-Chemical	-1	8752018
um	I-Chemical	-1	8752018
-@@	O	-1	8752018
associated	O	-1	8752018
cognitive	B-Disease	D003072	8752018
and	I-Disease	-1	8752018
functional	I-Disease	-1	8752018
defic@@	I-Disease	-1	8752018
its	I-Disease	-1	8752018
reduced	O	-1	8752018
by	O	-1	8752018
a	O	-1	8752018
s@@	O	-1	8752018
wit@@	O	-1	8752018
ch	O	-1	8752018
to	O	-1	8752018
di@@	B-Chemical	D014635	8752018
valpro@@	I-Chemical	-1	8752018
e@@	I-Chemical	-1	8752018
x	I-Chemical	-1	8752018
sodium	I-Chemical	-1	8752018
:	O	-1	8752018
a	O	-1	8752018
case	O	-1	8752018
seri@@	O	-1	8752018
es.	O	-1	8752018
BACKGROUND:	O	-1	8752018
L@@	B-Chemical	D008094	8752018
i@@	I-Chemical	-1	8752018
thi@@	I-Chemical	-1	8752018
um	I-Chemical	-1	8752018
remain@@	O	-1	8752018
s	O	-1	8752018
a	O	-1	8752018
fir@@	O	-1	8752018
st@@	O	-1	8752018
-@@	O	-1	8752018
line	O	-1	8752018
treatment	O	-1	8752018
for	O	-1	8752018
the	O	-1	8752018
acute	O	-1	8752018
and	O	-1	8752018
maint@@	O	-1	8752018
en@@	O	-1	8752018
ance	O	-1	8752018
treatment	O	-1	8752018
of	O	-1	8752018
b@@	B-Disease	D001714	8752018
ip@@	I-Disease	-1	8752018
ol@@	I-Disease	-1	8752018
ar	I-Disease	-1	8752018
disor@@	I-Disease	-1	8752018
der	I-Disease	-1	8752018
.	O	-1	8752018
Although	O	-1	8752018
m@@	O	-1	8752018
uc@@	O	-1	8752018
h	O	-1	8752018
has	O	-1	8752018
been	O	-1	8752018
w@@	O	-1	8752018
rit@@	O	-1	8752018
ten	O	-1	8752018
about	O	-1	8752018
the	O	-1	8752018
man@@	O	-1	8752018
ag@@	O	-1	8752018
ement	O	-1	8752018
of	O	-1	8752018
the	O	-1	8752018
more	O	-1	8752018
common	O	-1	8752018
adverse	O	-1	8752018
effects	O	-1	8752018
of	O	-1	8752018
lithium	B-Chemical	D008094	8752018
,	O	-1	8752018
such	O	-1	8752018
as	O	-1	8752018
poly@@	B-Disease	D011141	8752018
uria	I-Disease	-1	8752018
and	O	-1	8752018
trem@@	B-Disease	D014202	8752018
or	I-Disease	-1	8752018
,	O	-1	8752018
more	O	-1	8752018
sub@@	O	-1	8752018
t@@	O	-1	8752018
le	O	-1	8752018
lithium	B-Chemical	D008094	8752018
side	O	-1	8752018
effects	O	-1	8752018
such	O	-1	8752018
as	O	-1	8752018
cognitive	B-Disease	D003072	8752018
defic@@	I-Disease	-1	8752018
its	I-Disease	-1	8752018
,	O	-1	8752018
loss	B-Disease	D003072	8752018
of	I-Disease	-1	8752018
cre@@	I-Disease	-1	8752018
ati@@	I-Disease	-1	8752018
v@@	I-Disease	-1	8752018
ity	I-Disease	-1	8752018
,	O	-1	8752018
and	O	-1	8752018
functional	B-Disease	D003072	8752018
impair@@	I-Disease	-1	8752018
ments	I-Disease	-1	8752018
re@@	O	-1	8752018
ma@@	O	-1	8752018
in	O	-1	8752018
under@@	O	-1	8752018
studi@@	O	-1	8752018
ed.	O	-1	8752018
This	O	-1	8752018
report	O	-1	8752018
su@@	O	-1	8752018
mm@@	O	-1	8752018
ar@@	O	-1	8752018
iz@@	O	-1	8752018
es	O	-1	8752018
our	O	-1	8752018
experi@@	O	-1	8752018
ence	O	-1	8752018
in	O	-1	8752018
switch@@	O	-1	8752018
ing	O	-1	8752018
b@@	B-Disease	D001714	8752018
ip@@	I-Disease	-1	8752018
ol@@	I-Disease	-1	8752018
ar	I-Disease	-1	8752018
patients	O	-1	8752018
from	O	-1	8752018
lithium	B-Chemical	D008094	8752018
to	O	-1	8752018
di@@	B-Chemical	D014635	8752018
valpro@@	I-Chemical	-1	8752018
e@@	I-Chemical	-1	8752018
x	I-Chemical	-1	8752018
sodium	I-Chemical	-1	8752018
to	O	-1	8752018
al@@	O	-1	8752018
le@@	O	-1	8752018
vi@@	O	-1	8752018
ate	O	-1	8752018
such	O	-1	8752018
cognitive	B-Disease	D003072	8752018
and	I-Disease	-1	8752018
functional	I-Disease	-1	8752018
impair@@	I-Disease	-1	8752018
ments	I-Disease	-1	8752018
.	O	-1	8752018
METHOD@@	O	-1	8752018
:	O	-1	8752018
O@@	O	-1	8752018
pen@@	O	-1	8752018
,	O	-1	8752018
case	O	-1	8752018
seri@@	O	-1	8752018
es	O	-1	8752018
de@@	O	-1	8752018
sign@@	O	-1	8752018
.	O	-1	8752018
RESULTS:	O	-1	8752018
We	O	-1	8752018
report	O	-1	8752018
seven	O	-1	8752018
cases	O	-1	8752018
wh@@	O	-1	8752018
ere	O	-1	8752018
sub@@	O	-1	8752018
sti@@	O	-1	8752018
tu@@	O	-1	8752018
tion	O	-1	8752018
of	O	-1	8752018
lithium	B-Chemical	D008094	8752018
,	O	-1	8752018
either	O	-1	8752018
ful@@	O	-1	8752018
ly	O	-1	8752018
or	O	-1	8752018
par@@	O	-1	8752018
ti@@	O	-1	8752018
ally,	O	-1	8752018
with	O	-1	8752018
di@@	B-Chemical	D014635	8752018
valpro@@	I-Chemical	-1	8752018
e@@	I-Chemical	-1	8752018
x	I-Chemical	-1	8752018
sodium	I-Chemical	-1	8752018
was	O	-1	8752018
ex@@	O	-1	8752018
tre@@	O	-1	8752018
me@@	O	-1	8752018
ly	O	-1	8752018
he@@	O	-1	8752018
l@@	O	-1	8752018
p@@	O	-1	8752018
ful	O	-1	8752018
in	O	-1	8752018
reduc@@	O	-1	8752018
ing	O	-1	8752018
the	O	-1	8752018
cogn@@	B-Disease	D003072	8752018
iti@@	I-Disease	-1	8752018
ve,	I-Disease	-1	8752018
mo@@	I-Disease	-1	8752018
tiv@@	I-Disease	-1	8752018
ation@@	I-Disease	-1	8752018
al,	I-Disease	-1	8752018
or	I-Disease	-1	8752018
cre@@	I-Disease	-1	8752018
ative	I-Disease	-1	8752018
defic@@	I-Disease	-1	8752018
its	I-Disease	-1	8752018
at@@	O	-1	8752018
tri@@	O	-1	8752018
but@@	O	-1	8752018
ed	O	-1	8752018
to	O	-1	8752018
lithium	B-Chemical	D008094	8752018
in	O	-1	8752018
our	O	-1	8752018
b@@	B-Disease	D001714	8752018
ip@@	I-Disease	-1	8752018
ol@@	I-Disease	-1	8752018
ar	I-Disease	-1	8752018
patients.	O	-1	8752018
CONCLUSION:	O	-1	8752018
In	O	-1	8752018
this	O	-1	8752018
pre@@	O	-1	8752018
lim@@	O	-1	8752018
inary	O	-1	8752018
repor@@	O	-1	8752018
t,	O	-1	8752018
di@@	B-Chemical	D014635	8752018
valpro@@	I-Chemical	-1	8752018
e@@	I-Chemical	-1	8752018
x	I-Chemical	-1	8752018
sodium	I-Chemical	-1	8752018
was	O	-1	8752018
a	O	-1	8752018
su@@	O	-1	8752018
peri@@	O	-1	8752018
or	O	-1	8752018
al@@	O	-1	8752018
tern@@	O	-1	8752018
ative	O	-1	8752018
to	O	-1	8752018
lithium	B-Chemical	D008094	8752018
in	O	-1	8752018
b@@	B-Disease	D001714	8752018
ip@@	I-Disease	-1	8752018
ol@@	I-Disease	-1	8752018
ar	I-Disease	-1	8752018
patients	O	-1	8752018
experienc@@	O	-1	8752018
ing	O	-1	8752018
cognitive	B-Disease	D003072	8752018
defic@@	I-Disease	-1	8752018
its	I-Disease	-1	8752018
,	O	-1	8752018
loss	B-Disease	D003072	8752018
of	I-Disease	-1	8752018
cre@@	I-Disease	-1	8752018
ati@@	I-Disease	-1	8752018
v@@	I-Disease	-1	8752018
ity	I-Disease	-1	8752018
,	O	-1	8752018
and	O	-1	8752018
functional	B-Disease	D003072	8752018
impair@@	I-Disease	-1	8752018
ments	I-Disease	-1	8752018
.	O	-1	8752018

Treat@@	O	-1	9390208
ment	O	-1	9390208
of	O	-1	9390208
previously	O	-1	9390208
treated	O	-1	9390208
met@@	O	-1	9390208
ast@@	O	-1	9390208
atic	O	-1	9390208
b@@	B-Disease	D001943	9390208
reas@@	I-Disease	-1	9390208
t	I-Disease	-1	9390208
cancer	I-Disease	-1	9390208
by	O	-1	9390208
mit@@	B-Chemical	D008942	9390208
ox@@	I-Chemical	-1	9390208
ant@@	I-Chemical	-1	9390208
r@@	I-Chemical	-1	9390208
one	I-Chemical	-1	9390208
and	O	-1	9390208
4@@	O	-1	9390208
8@@	O	-1	9390208
-@@	O	-1	9390208
h@@	O	-1	9390208
our	O	-1	9390208
continu@@	O	-1	9390208
ous	O	-1	9390208
infusion	O	-1	9390208
of	O	-1	9390208
high-dose	O	-1	9390208
5-@@	B-Chemical	D005472	9390208
F@@	I-Chemical	-1	9390208
U	I-Chemical	-1	9390208
and	O	-1	9390208
leu@@	B-Chemical	D002955	9390208
co@@	I-Chemical	-1	9390208
v@@	I-Chemical	-1	9390208
or@@	I-Chemical	-1	9390208
in	I-Chemical	-1	9390208
(	O	-1	9390208
M@@	B-Chemical	C085788	9390208
F@@	I-Chemical	-1	9390208
L	I-Chemical	-1	9390208
)@@	O	-1	9390208
:	O	-1	9390208
low	O	-1	9390208
p@@	O	-1	9390208
al@@	O	-1	9390208
li@@	O	-1	9390208
ative	O	-1	9390208
ben@@	O	-1	9390208
e@@	O	-1	9390208
fi@@	O	-1	9390208
t	O	-1	9390208
and	O	-1	9390208
high	O	-1	9390208
treatment@@	O	-1	9390208
-@@	O	-1	9390208
related	O	-1	9390208
toxicity	B-Disease	D064420	9390208
.	O	-1	9390208
F@@	O	-1	9390208
or	O	-1	9390208
previously	O	-1	9390208
treated	O	-1	9390208
adv@@	O	-1	9390208
anced	O	-1	9390208
b@@	B-Disease	D001943	9390208
reas@@	I-Disease	-1	9390208
t	I-Disease	-1	9390208
cancer	I-Disease	-1	9390208
,	O	-1	9390208
there	O	-1	9390208
is	O	-1	9390208
no	O	-1	9390208
standard	O	-1	9390208
secon@@	O	-1	9390208
d-@@	O	-1	9390208
line	O	-1	9390208
therapy.	O	-1	9390208
Com@@	O	-1	9390208
bin@@	O	-1	9390208
ation	O	-1	9390208
chemotherapy	O	-1	9390208
with	O	-1	9390208
mit@@	B-Chemical	D008942	9390208
ox@@	I-Chemical	-1	9390208
ant@@	I-Chemical	-1	9390208
r@@	I-Chemical	-1	9390208
one	I-Chemical	-1	9390208
,	O	-1	9390208
high-dose	O	-1	9390208
5-@@	B-Chemical	D005472	9390208
fluoro@@	I-Chemical	-1	9390208
urac@@	I-Chemical	-1	9390208
il	I-Chemical	-1	9390208
(	O	-1	9390208
5-@@	B-Chemical	D005472	9390208
F@@	I-Chemical	-1	9390208
U	I-Chemical	-1	9390208
)	O	-1	9390208
and	O	-1	9390208
leu@@	B-Chemical	D002955	9390208
co@@	I-Chemical	-1	9390208
v@@	I-Chemical	-1	9390208
or@@	I-Chemical	-1	9390208
in	I-Chemical	-1	9390208
(	O	-1	9390208
M@@	B-Chemical	C085788	9390208
F@@	I-Chemical	-1	9390208
L	I-Chemical	-1	9390208
regi@@	I-Chemical	-1	9390208
men	I-Chemical	-1	9390208
)	O	-1	9390208
had	O	-1	9390208
been	O	-1	9390208
reported	O	-1	9390208
as	O	-1	9390208
an	O	-1	9390208
effective	O	-1	9390208
and	O	-1	9390208
well	O	-1	9390208
toler@@	O	-1	9390208
ated	O	-1	9390208
regimen@@	O	-1	9390208
.	O	-1	9390208
F@@	O	-1	9390208
rom	O	-1	9390208
O@@	O	-1	9390208
c@@	O	-1	9390208
to@@	O	-1	9390208
b@@	O	-1	9390208
er	O	-1	9390208
19@@	O	-1	9390208
9@@	O	-1	9390208
3	O	-1	9390208
to	O	-1	9390208
N@@	O	-1	9390208
o@@	O	-1	9390208
ve@@	O	-1	9390208
mb@@	O	-1	9390208
er	O	-1	9390208
19@@	O	-1	9390208
9@@	O	-1	9390208
5,	O	-1	9390208
we	O	-1	9390208
treated	O	-1	9390208
13	O	-1	9390208
patients	O	-1	9390208
with	O	-1	9390208
previously	O	-1	9390208
chemo@@	O	-1	9390208
therap@@	O	-1	9390208
y-@@	O	-1	9390208
treated	O	-1	9390208
met@@	O	-1	9390208
ast@@	O	-1	9390208
atic	O	-1	9390208
b@@	B-Disease	D001943	9390208
reas@@	I-Disease	-1	9390208
t	I-Disease	-1	9390208
cancer	I-Disease	-1	9390208
by	O	-1	9390208
mit@@	B-Chemical	D008942	9390208
ox@@	I-Chemical	-1	9390208
ant@@	I-Chemical	-1	9390208
r@@	I-Chemical	-1	9390208
one	I-Chemical	-1	9390208
,	O	-1	9390208
12	O	-1	9390208
mg/m@@	O	-1	9390208
2,	O	-1	9390208
on	O	-1	9390208
day	O	-1	9390208
1	O	-1	9390208
and	O	-1	9390208
continu@@	O	-1	9390208
ous	O	-1	9390208
infusion	O	-1	9390208
of	O	-1	9390208
5-@@	B-Chemical	D005472	9390208
F@@	I-Chemical	-1	9390208
U	I-Chemical	-1	9390208
,	O	-1	9390208
3@@	O	-1	9390208
0@@	O	-1	9390208
00	O	-1	9390208
mg/m@@	O	-1	9390208
2,	O	-1	9390208
to@@	O	-1	9390208
ge@@	O	-1	9390208
ther	O	-1	9390208
with	O	-1	9390208
leu@@	B-Chemical	D002955	9390208
co@@	I-Chemical	-1	9390208
v@@	I-Chemical	-1	9390208
or@@	I-Chemical	-1	9390208
in	I-Chemical	-1	9390208
,	O	-1	9390208
3@@	O	-1	9390208
00	O	-1	9390208
mg/m@@	O	-1	9390208
2,	O	-1	9390208
for	O	-1	9390208
4@@	O	-1	9390208
8	O	-1	9390208
h	O	-1	9390208
from	O	-1	9390208
day	O	-1	9390208
1	O	-1	9390208
to	O	-1	9390208
2@@	O	-1	9390208
.	O	-1	9390208
E@@	O	-1	9390208
ach	O	-1	9390208
course	O	-1	9390208
of	O	-1	9390208
chemotherapy	O	-1	9390208
was	O	-1	9390208
given	O	-1	9390208
every	O	-1	9390208
4	O	-1	9390208
week@@	O	-1	9390208
s.	O	-1	9390208
M@@	O	-1	9390208
ost	O	-1	9390208
of	O	-1	9390208
these	O	-1	9390208
patients	O	-1	9390208
had	O	-1	9390208
more	O	-1	9390208
than	O	-1	9390208
two	O	-1	9390208
met@@	O	-1	9390208
ast@@	O	-1	9390208
atic	O	-1	9390208
sit@@	O	-1	9390208
es,	O	-1	9390208
with	O	-1	9390208
l@@	O	-1	9390208
un@@	O	-1	9390208
g	O	-1	9390208
met@@	O	-1	9390208
ast@@	O	-1	9390208
asis	O	-1	9390208
pre@@	O	-1	9390208
domin@@	O	-1	9390208
ant@@	O	-1	9390208
.	O	-1	9390208
S@@	O	-1	9390208
even	O	-1	9390208
patients	O	-1	9390208
had	O	-1	9390208
been	O	-1	9390208
treated	O	-1	9390208
with	O	-1	9390208
an@@	B-Chemical	D018943	9390208
th@@	I-Chemical	-1	9390208
rac@@	I-Chemical	-1	9390208
y@@	I-Chemical	-1	9390208
cl@@	I-Chemical	-1	9390208
ine	I-Chemical	-1	9390208
.	O	-1	9390208
S@@	O	-1	9390208
even	O	-1	9390208
patients	O	-1	9390208
had	O	-1	9390208
previously	O	-1	9390208
received	O	-1	9390208
radi@@	O	-1	9390208
o@@	O	-1	9390208
therapy	O	-1	9390208
and	O	-1	9390208
seven	O	-1	9390208
had	O	-1	9390208
received	O	-1	9390208
h@@	O	-1	9390208
orm@@	O	-1	9390208
one	O	-1	9390208
therapy.	O	-1	9390208
M@@	O	-1	9390208
edi@@	O	-1	9390208
an	O	-1	9390208
number	O	-1	9390208
of	O	-1	9390208
cour@@	O	-1	9390208
ses	O	-1	9390208
of	O	-1	9390208
M@@	B-Chemical	C085788	9390208
F@@	I-Chemical	-1	9390208
L	I-Chemical	-1	9390208
regi@@	I-Chemical	-1	9390208
men	I-Chemical	-1	9390208
given	O	-1	9390208
was	O	-1	9390208
six	O	-1	9390208
and	O	-1	9390208
the	O	-1	9390208
median	O	-1	9390208
cum@@	O	-1	9390208
ul@@	O	-1	9390208
ative	O	-1	9390208
dose	O	-1	9390208
of	O	-1	9390208
mit@@	B-Chemical	D008942	9390208
ox@@	I-Chemical	-1	9390208
ant@@	I-Chemical	-1	9390208
r@@	I-Chemical	-1	9390208
one	I-Chemical	-1	9390208
was	O	-1	9390208
6@@	O	-1	9390208
8.@@	O	-1	9390208
3@@	O	-1	9390208
5	O	-1	9390208
mg/m@@	O	-1	9390208
2@@	O	-1	9390208
.	O	-1	9390208
One	O	-1	9390208
patient	O	-1	9390208
had	O	-1	9390208
complete	O	-1	9390208
respon@@	O	-1	9390208
se@@	O	-1	9390208
,	O	-1	9390208
seven	O	-1	9390208
had	O	-1	9390208
st@@	O	-1	9390208
able	O	-1	9390208
diseas@@	O	-1	9390208
e,	O	-1	9390208
n@@	O	-1	9390208
one	O	-1	9390208
had	O	-1	9390208
partial	O	-1	9390208
response	O	-1	9390208
and	O	-1	9390208
five	O	-1	9390208
had	O	-1	9390208
progressive	O	-1	9390208
disease.	O	-1	9390208
The	O	-1	9390208
over@@	O	-1	9390208
all	O	-1	9390208
ob@@	O	-1	9390208
j@@	O	-1	9390208
ective	O	-1	9390208
response	O	-1	9390208
rate	O	-1	9390208
was	O	-1	9390208
7.@@	O	-1	9390208
6@@	O	-1	9390208
%.	O	-1	9390208
The	O	-1	9390208
median	O	-1	9390208
follow-up	O	-1	9390208
period	O	-1	9390208
was	O	-1	9390208
14	O	-1	9390208
months.	O	-1	9390208
M@@	O	-1	9390208
edi@@	O	-1	9390208
an	O	-1	9390208
sur@@	O	-1	9390208
viv@@	O	-1	9390208
al	O	-1	9390208
was	O	-1	9390208
16	O	-1	9390208
months.	O	-1	9390208
M@@	O	-1	9390208
edi@@	O	-1	9390208
an	O	-1	9390208
progres@@	O	-1	9390208
sion@@	O	-1	9390208
-@@	O	-1	9390208
free	O	-1	9390208
sur@@	O	-1	9390208
viv@@	O	-1	9390208
al	O	-1	9390208
was	O	-1	9390208
5	O	-1	9390208
months.	O	-1	9390208
A	O	-1	9390208
complete	O	-1	9390208
respon@@	O	-1	9390208
der	O	-1	9390208
had	O	-1	9390208
rel@@	O	-1	9390208
ap@@	O	-1	9390208
se@@	O	-1	9390208
-@@	O	-1	9390208
free	O	-1	9390208
sur@@	O	-1	9390208
viv@@	O	-1	9390208
al	O	-1	9390208
up	O	-1	9390208
to	O	-1	9390208
17	O	-1	9390208
months.	O	-1	9390208
M@@	O	-1	9390208
a@@	O	-1	9390208
j@@	O	-1	9390208
or	O	-1	9390208
toxic@@	B-Disease	D064420	9390208
ities	I-Disease	-1	9390208
were	O	-1	9390208
cardi@@	B-Disease	D066126	9390208
otoxicity	I-Disease	-1	9390208
and	O	-1	9390208
leuk@@	B-Disease	D007970	9390208
o@@	I-Disease	-1	9390208
pen@@	I-Disease	-1	9390208
ia	I-Disease	-1	9390208
.	O	-1	9390208
E@@	O	-1	9390208
ight	O	-1	9390208
patients	O	-1	9390208
were	O	-1	9390208
de@@	O	-1	9390208
ad	O	-1	9390208
in	O	-1	9390208
the	O	-1	9390208
las@@	O	-1	9390208
t	O	-1	9390208
follow-@@	O	-1	9390208
up@@	O	-1	9390208
;	O	-1	9390208
two	O	-1	9390208
of	O	-1	9390208
the@@	O	-1	9390208
m	O	-1	9390208
di@@	O	-1	9390208
ed	O	-1	9390208
of	O	-1	9390208
treatment@@	O	-1	9390208
-@@	O	-1	9390208
related	O	-1	9390208
toxicity	B-Disease	D064420	9390208
.	O	-1	9390208
The	O	-1	9390208
M@@	B-Chemical	C085788	9390208
F@@	I-Chemical	-1	9390208
L	I-Chemical	-1	9390208
regi@@	I-Chemical	-1	9390208
men	I-Chemical	-1	9390208
achi@@	O	-1	9390208
ev@@	O	-1	9390208
es	O	-1	9390208
lit@@	O	-1	9390208
t@@	O	-1	9390208
le	O	-1	9390208
p@@	O	-1	9390208
al@@	O	-1	9390208
li@@	O	-1	9390208
ative	O	-1	9390208
ben@@	O	-1	9390208
e@@	O	-1	9390208
fi@@	O	-1	9390208
t	O	-1	9390208
and	O	-1	9390208
induc@@	O	-1	9390208
es	O	-1	9390208
severe	O	-1	9390208
toxicity	B-Disease	D064420	9390208
at	O	-1	9390208
a	O	-1	9390208
f@@	O	-1	9390208
a@@	O	-1	9390208
ir@@	O	-1	9390208
ly	O	-1	9390208
high	O	-1	9390208
rat@@	O	-1	9390208
e.	O	-1	9390208
Ad@@	O	-1	9390208
minist@@	O	-1	9390208
ration	O	-1	9390208
of	O	-1	9390208
this	O	-1	9390208
regi@@	O	-1	9390208
men	O	-1	9390208
to	O	-1	9390208
b@@	B-Disease	D001943	9390208
reas@@	I-Disease	-1	9390208
t	I-Disease	-1	9390208
cancer	I-Disease	-1	9390208
patients	O	-1	9390208
who	O	-1	9390208
have	O	-1	9390208
been	O	-1	9390208
treated	O	-1	9390208
by	O	-1	9390208
chemotherapy	O	-1	9390208
and	O	-1	9390208
those	O	-1	9390208
with	O	-1	9390208
impaired	B-Disease	D006331	9390208
heart	I-Disease	-1	9390208
function	I-Disease	-1	9390208
requ@@	O	-1	9390208
i@@	O	-1	9390208
res	O	-1	9390208
ca@@	O	-1	9390208
ref@@	O	-1	9390208
u@@	O	-1	9390208
l	O	-1	9390208
atten@@	O	-1	9390208
tion.	O	-1	9390208

U@@	O	-1	9406968
pre@@	O	-1	9406968
g@@	O	-1	9406968
ulation	O	-1	9406968
of	O	-1	9406968
the	O	-1	9406968
expression	O	-1	9406968
of	O	-1	9406968
vas@@	B-Chemical	D014667	9406968
o@@	I-Chemical	-1	9406968
press@@	I-Chemical	-1	9406968
in	I-Chemical	-1	9406968
gen@@	O	-1	9406968
e	O	-1	9406968
in	O	-1	9406968
the	O	-1	9406968
par@@	O	-1	9406968
a@@	O	-1	9406968
ventricular	O	-1	9406968
and	O	-1	9406968
sup@@	O	-1	9406968
ra@@	O	-1	9406968
op@@	O	-1	9406968
tic	O	-1	9406968
nucle@@	O	-1	9406968
i	O	-1	9406968
of	O	-1	9406968
the	O	-1	9406968
lithium	B-Chemical	D008094	9406968
-induced	O	-1	9406968
dia@@	B-Disease	D003919	9406968
bet@@	I-Disease	-1	9406968
es	I-Disease	-1	9406968
in@@	I-Disease	-1	9406968
si@@	I-Disease	-1	9406968
pid@@	I-Disease	-1	9406968
us	I-Disease	-1	9406968
rat@@	O	-1	9406968
.	O	-1	9406968
The	O	-1	9406968
expression	O	-1	9406968
of	O	-1	9406968
arg@@	B-Chemical	D001127	9406968
inine	I-Chemical	-1	9406968
vas@@	I-Chemical	-1	9406968
o@@	I-Chemical	-1	9406968
press@@	I-Chemical	-1	9406968
in	I-Chemical	-1	9406968
(	O	-1	9406968
A@@	B-Chemical	D001127	9406968
V@@	I-Chemical	-1	9406968
P	I-Chemical	-1	9406968
)	O	-1	9406968
gen@@	O	-1	9406968
e	O	-1	9406968
in	O	-1	9406968
the	O	-1	9406968
par@@	O	-1	9406968
a@@	O	-1	9406968
ventricular	O	-1	9406968
(P@@	O	-1	9406968
V@@	O	-1	9406968
N@@	O	-1	9406968
)	O	-1	9406968
and	O	-1	9406968
sup@@	O	-1	9406968
ra@@	O	-1	9406968
op@@	O	-1	9406968
tic	O	-1	9406968
nucle@@	O	-1	9406968
i	O	-1	9406968
(S@@	O	-1	9406968
ON@@	O	-1	9406968
)	O	-1	9406968
was	O	-1	9406968
investigated	O	-1	9406968
in	O	-1	9406968
rats	O	-1	9406968
with	O	-1	9406968
lithium	B-Chemical	D008094	9406968
(	O	-1	9406968
L@@	B-Chemical	D008094	9406968
i	I-Chemical	-1	9406968
)@@	O	-1	9406968
-induced	O	-1	9406968
poly@@	B-Disease	D011141	9406968
uria	I-Disease	-1	9406968
,	O	-1	9406968
using	O	-1	9406968
in	O	-1	9406968
sit@@	O	-1	9406968
u	O	-1	9406968
hy@@	O	-1	9406968
b@@	O	-1	9406968
ri@@	O	-1	9406968
di@@	O	-1	9406968
z@@	O	-1	9406968
ation	O	-1	9406968
histo@@	O	-1	9406968
chem@@	O	-1	9406968
ist@@	O	-1	9406968
r@@	O	-1	9406968
y	O	-1	9406968
and	O	-1	9406968
radi@@	O	-1	9406968
o@@	O	-1	9406968
immuno@@	O	-1	9406968
ass@@	O	-1	9406968
a@@	O	-1	9406968
y.	O	-1	9406968
The	O	-1	9406968
male	O	-1	9406968
Wistar	O	-1	9406968
rats	O	-1	9406968
consum@@	O	-1	9406968
ing	O	-1	9406968
a	O	-1	9406968
diet	O	-1	9406968
that	O	-1	9406968
cont@@	O	-1	9406968
ained	O	-1	9406968
L@@	B-Chemical	D018021	9406968
i@@	I-Chemical	-1	9406968
C@@	I-Chemical	-1	9406968
l	I-Chemical	-1	9406968
(@@	O	-1	9406968
60	O	-1	9406968
m@@	O	-1	9406968
mol@@	O	-1	9406968
/@@	O	-1	9406968
kg@@	O	-1	9406968
)	O	-1	9406968
for	O	-1	9406968
4	O	-1	9406968
weeks	O	-1	9406968
developed	O	-1	9406968
mark@@	O	-1	9406968
ed	O	-1	9406968
poly@@	B-Disease	D011141	9406968
uria	I-Disease	-1	9406968
.	O	-1	9406968
The	O	-1	9406968
L@@	B-Chemical	D008094	9406968
i	I-Chemical	-1	9406968
-treated	O	-1	9406968
rats	O	-1	9406968
produced	O	-1	9406968
a	O	-1	9406968
larg@@	O	-1	9406968
e	O	-1	9406968
volume	O	-1	9406968
of	O	-1	9406968
hy@@	O	-1	9406968
pot@@	O	-1	9406968
onic	O	-1	9406968
urine	O	-1	9406968
with	O	-1	9406968
low	O	-1	9406968
i@@	O	-1	9406968
onic	O	-1	9406968
concentr@@	O	-1	9406968
ations.	O	-1	9406968
P@@	O	-1	9406968
las@@	O	-1	9406968
ma	O	-1	9406968
sodium	B-Chemical	D012964	9406968
concentrations	O	-1	9406968
were	O	-1	9406968
found	O	-1	9406968
to	O	-1	9406968
be	O	-1	9406968
s@@	O	-1	9406968
li@@	O	-1	9406968
gh@@	O	-1	9406968
tly	O	-1	9406968
increased	O	-1	9406968
in	O	-1	9406968
the	O	-1	9406968
L@@	B-Chemical	D008094	9406968
i	I-Chemical	-1	9406968
-treated	O	-1	9406968
rats	O	-1	9406968
compared	O	-1	9406968
with	O	-1	9406968
those	O	-1	9406968
in	O	-1	9406968
controls.	O	-1	9406968
P@@	O	-1	9406968
las@@	O	-1	9406968
ma	O	-1	9406968
concentration	O	-1	9406968
of	O	-1	9406968
A@@	B-Chemical	D001127	9406968
V@@	I-Chemical	-1	9406968
P	I-Chemical	-1	9406968
and	O	-1	9406968
trans@@	O	-1	9406968
cri@@	O	-1	9406968
pt@@	O	-1	9406968
s	O	-1	9406968
of	O	-1	9406968
A@@	B-Chemical	D001127	9406968
V@@	I-Chemical	-1	9406968
P	I-Chemical	-1	9406968
gen@@	O	-1	9406968
e	O	-1	9406968
in	O	-1	9406968
the	O	-1	9406968
P@@	O	-1	9406968
V@@	O	-1	9406968
N	O	-1	9406968
and	O	-1	9406968
S@@	O	-1	9406968
O@@	O	-1	9406968
N	O	-1	9406968
were	O	-1	9406968
significantly	O	-1	9406968
increased	O	-1	9406968
in	O	-1	9406968
the	O	-1	9406968
L@@	B-Chemical	D008094	9406968
i	I-Chemical	-1	9406968
-treated	O	-1	9406968
rats	O	-1	9406968
compared	O	-1	9406968
with	O	-1	9406968
controls.	O	-1	9406968
These	O	-1	9406968
results	O	-1	9406968
suggest	O	-1	9406968
that	O	-1	9406968
de@@	B-Disease	D003681	9406968
hy@@	I-Disease	-1	9406968
d@@	I-Disease	-1	9406968
ration	I-Disease	-1	9406968
and/or	O	-1	9406968
the	O	-1	9406968
activation	O	-1	9406968
of	O	-1	9406968
v@@	O	-1	9406968
is@@	O	-1	9406968
c@@	O	-1	9406968
eral	O	-1	9406968
a@@	O	-1	9406968
fferen@@	O	-1	9406968
t	O	-1	9406968
in@@	O	-1	9406968
p@@	O	-1	9406968
ut@@	O	-1	9406968
s	O	-1	9406968
may	O	-1	9406968
cont@@	O	-1	9406968
rib@@	O	-1	9406968
ute	O	-1	9406968
to	O	-1	9406968
the	O	-1	9406968
elev@@	O	-1	9406968
ation	O	-1	9406968
of	O	-1	9406968
plasma	O	-1	9406968
A@@	B-Chemical	D001127	9406968
V@@	I-Chemical	-1	9406968
P	I-Chemical	-1	9406968
and	O	-1	9406968
the	O	-1	9406968
u@@	O	-1	9406968
pre@@	O	-1	9406968
g@@	O	-1	9406968
ulation	O	-1	9406968
of	O	-1	9406968
A@@	B-Chemical	D001127	9406968
V@@	I-Chemical	-1	9406968
P	I-Chemical	-1	9406968
gen@@	O	-1	9406968
e	O	-1	9406968
expression	O	-1	9406968
in	O	-1	9406968
the	O	-1	9406968
P@@	O	-1	9406968
V@@	O	-1	9406968
N	O	-1	9406968
and	O	-1	9406968
the	O	-1	9406968
S@@	O	-1	9406968
O@@	O	-1	9406968
N	O	-1	9406968
of	O	-1	9406968
the	O	-1	9406968
L@@	B-Chemical	D008094	9406968
i	I-Chemical	-1	9406968
-induced	O	-1	9406968
dia@@	B-Disease	D003919	9406968
bet@@	I-Disease	-1	9406968
es	I-Disease	-1	9406968
in@@	I-Disease	-1	9406968
si@@	I-Disease	-1	9406968
pid@@	I-Disease	-1	9406968
us	I-Disease	-1	9406968
rat@@	O	-1	9406968
.	O	-1	9406968

S@@	B-Chemical	D013390	9587734
u@@	I-Chemical	-1	9587734
xameth@@	I-Chemical	-1	9587734
oni@@	I-Chemical	-1	9587734
um	I-Chemical	-1	9587734
-induced	O	-1	9587734
cardiac	B-Disease	D006323	9587734
ar@@	I-Disease	-1	9587734
res@@	I-Disease	-1	9587734
t	I-Disease	-1	9587734
and	O	-1	9587734
death	B-Disease	D003643	9587734
following	O	-1	9587734
5	O	-1	9587734
days	O	-1	9587734
of	O	-1	9587734
im@@	O	-1	9587734
mo@@	O	-1	9587734
bil@@	O	-1	9587734
iz@@	O	-1	9587734
ation.	O	-1	9587734
The	O	-1	9587734
present	O	-1	9587734
report	O	-1	9587734
descri@@	O	-1	9587734
b@@	O	-1	9587734
es	O	-1	9587734
a	O	-1	9587734
case	O	-1	9587734
of	O	-1	9587734
cardiac	B-Disease	D006323	9587734
ar@@	I-Disease	-1	9587734
res@@	I-Disease	-1	9587734
t	I-Disease	-1	9587734
and	O	-1	9587734
subsequ@@	O	-1	9587734
ent	O	-1	9587734
death	B-Disease	D003643	9587734
as	O	-1	9587734
a	O	-1	9587734
result	O	-1	9587734
of	O	-1	9587734
hyper@@	B-Disease	D006947	9587734
k@@	I-Disease	-1	9587734
al@@	I-Disease	-1	9587734
a@@	I-Disease	-1	9587734
emia	I-Disease	-1	9587734
following	O	-1	9587734
the	O	-1	9587734
use	O	-1	9587734
of	O	-1	9587734
su@@	B-Chemical	D013390	9587734
xameth@@	I-Chemical	-1	9587734
oni@@	I-Chemical	-1	9587734
um	I-Chemical	-1	9587734
in	O	-1	9587734
a	O	-1	9587734
2@@	O	-1	9587734
3-@@	O	-1	9587734
year-old	O	-1	9587734
M@@	O	-1	9587734
al@@	O	-1	9587734
a@@	O	-1	9587734
wi@@	O	-1	9587734
an	O	-1	9587734
wom@@	O	-1	9587734
an@@	O	-1	9587734
.	O	-1	9587734
F@@	O	-1	9587734
i@@	O	-1	9587734
ve	O	-1	9587734
days	O	-1	9587734
after	O	-1	9587734
the	O	-1	9587734
onset	O	-1	9587734
of	O	-1	9587734
the	O	-1	9587734
symptoms	O	-1	9587734
of	O	-1	9587734
men@@	B-Disease	D008581	9587734
ing@@	I-Disease	-1	9587734
iti@@	I-Disease	-1	9587734
s	I-Disease	-1	9587734
,	O	-1	9587734
the	O	-1	9587734
patient	O	-1	9587734
as@@	O	-1	9587734
pi@@	O	-1	9587734
r@@	O	-1	9587734
ated	O	-1	9587734
st@@	O	-1	9587734
om@@	O	-1	9587734
ach	O	-1	9587734
cont@@	O	-1	9587734
ents	O	-1	9587734
and	O	-1	9587734
ne@@	O	-1	9587734
ed@@	O	-1	9587734
ed	O	-1	9587734
en@@	O	-1	9587734
d@@	O	-1	9587734
ot@@	O	-1	9587734
rac@@	O	-1	9587734
he@@	O	-1	9587734
al	O	-1	9587734
int@@	O	-1	9587734
ub@@	O	-1	9587734
ation.	O	-1	9587734
F@@	O	-1	9587734
ort@@	O	-1	9587734
y	O	-1	9587734
secon@@	O	-1	9587734
ds	O	-1	9587734
after	O	-1	9587734
injection	O	-1	9587734
of	O	-1	9587734
su@@	B-Chemical	D013390	9587734
xameth@@	I-Chemical	-1	9587734
oni@@	I-Chemical	-1	9587734
um	I-Chemical	-1	9587734
,	O	-1	9587734
brady@@	B-Disease	D001919	9587734
cardia	I-Disease	-1	9587734
and	O	-1	9587734
cardiac	B-Disease	D006323	9587734
ar@@	I-Disease	-1	9587734
res@@	I-Disease	-1	9587734
t	I-Disease	-1	9587734
occur@@	O	-1	9587734
red.	O	-1	9587734
A@@	O	-1	9587734
t@@	O	-1	9587734
tem@@	O	-1	9587734
pt@@	O	-1	9587734
s	O	-1	9587734
to	O	-1	9587734
res@@	O	-1	9587734
us@@	O	-1	9587734
cit@@	O	-1	9587734
ate	O	-1	9587734
the	O	-1	9587734
patient	O	-1	9587734
were	O	-1	9587734
not	O	-1	9587734
suc@@	O	-1	9587734
cess@@	O	-1	9587734
ful@@	O	-1	9587734
.	O	-1	9587734
The	O	-1	9587734
serum	O	-1	9587734
level	O	-1	9587734
of	O	-1	9587734
pot@@	B-Chemical	D011188	9587734
assi@@	I-Chemical	-1	9587734
um	I-Chemical	-1	9587734
was	O	-1	9587734
observed	O	-1	9587734
to	O	-1	9587734
be	O	-1	9587734
8.@@	O	-1	9587734
4	O	-1	9587734
me@@	O	-1	9587734
qu@@	O	-1	9587734
i@@	O	-1	9587734
v	O	-1	9587734
L-@@	O	-1	9587734
1@@	O	-1	9587734
.	O	-1	9587734
A@@	O	-1	9587734
par@@	O	-1	9587734
t	O	-1	9587734
from	O	-1	9587734
the	O	-1	9587734
reduction	O	-1	9587734
in	O	-1	9587734
the	O	-1	9587734
patient@@	O	-1	9587734
's	O	-1	9587734
level	O	-1	9587734
of	O	-1	9587734
con@@	O	-1	9587734
s@@	O	-1	9587734
ci@@	O	-1	9587734
ous@@	O	-1	9587734
n@@	O	-1	9587734
es@@	O	-1	9587734
s,	O	-1	9587734
there	O	-1	9587734
were	O	-1	9587734
no	O	-1	9587734
signs	O	-1	9587734
of	O	-1	9587734
motor	O	-1	9587734
ne@@	O	-1	9587734
ur@@	O	-1	9587734
one	O	-1	9587734
damage	O	-1	9587734
or	O	-1	9587734
of	O	-1	9587734
any	O	-1	9587734
of	O	-1	9587734
the	O	-1	9587734
other	O	-1	9587734
known	O	-1	9587734
pre@@	O	-1	9587734
dis@@	O	-1	9587734
pos@@	O	-1	9587734
ing	O	-1	9587734
condi@@	O	-1	9587734
tions	O	-1	9587734
for	O	-1	9587734
hyper@@	B-Disease	D006947	9587734
k@@	I-Disease	-1	9587734
al@@	I-Disease	-1	9587734
a@@	I-Disease	-1	9587734
emia	I-Disease	-1	9587734
following	O	-1	9587734
the	O	-1	9587734
administration	O	-1	9587734
of	O	-1	9587734
su@@	B-Chemical	D013390	9587734
xameth@@	I-Chemical	-1	9587734
oni@@	I-Chemical	-1	9587734
um	I-Chemical	-1	9587734
.	O	-1	9587734
It	O	-1	9587734
is	O	-1	9587734
post@@	O	-1	9587734
ul@@	O	-1	9587734
ated	O	-1	9587734
that	O	-1	9587734
h@@	O	-1	9587734
er	O	-1	9587734
death	B-Disease	D003643	9587734
was	O	-1	9587734
caused	O	-1	9587734
by	O	-1	9587734
hyper@@	B-Disease	D004342	9587734
sensitivity	I-Disease	-1	9587734
to	O	-1	9587734
su@@	B-Chemical	D013390	9587734
xameth@@	I-Chemical	-1	9587734
oni@@	I-Chemical	-1	9587734
um	I-Chemical	-1	9587734
,	O	-1	9587734
associated	O	-1	9587734
with	O	-1	9587734
h@@	O	-1	9587734
er	O	-1	9587734
5-@@	O	-1	9587734
day	O	-1	9587734
im@@	O	-1	9587734
mo@@	O	-1	9587734
bil@@	O	-1	9587734
iz@@	O	-1	9587734
ation.	O	-1	9587734

An	O	-1	9698967
un@@	O	-1	9698967
us@@	O	-1	9698967
ual	O	-1	9698967
toxic	O	-1	9698967
reaction	O	-1	9698967
to	O	-1	9698967
ax@@	O	-1	9698967
ill@@	O	-1	9698967
ary	O	-1	9698967
bloc@@	O	-1	9698967
k	O	-1	9698967
by	O	-1	9698967
me@@	B-Chemical	D008619	9698967
pivac@@	I-Chemical	-1	9698967
aine	I-Chemical	-1	9698967
with	O	-1	9698967
adren@@	B-Chemical	D004837	9698967
aline	I-Chemical	-1	9698967
.	O	-1	9698967
An	O	-1	9698967
increase	B-Disease	D006973	9698967
in	I-Disease	-1	9698967
blood	I-Disease	-1	9698967
pressure	I-Disease	-1	9698967
,	O	-1	9698967
ac@@	O	-1	9698967
comp@@	O	-1	9698967
an@@	O	-1	9698967
ied	O	-1	9698967
by	O	-1	9698967
atrial	B-Disease	D001281	9698967
fibrill@@	I-Disease	-1	9698967
ation	I-Disease	-1	9698967
,	O	-1	9698967
ag@@	B-Disease	D011595	9698967
it@@	I-Disease	-1	9698967
ation	I-Disease	-1	9698967
,	O	-1	9698967
in@@	B-Disease	D019954	9698967
com@@	I-Disease	-1	9698967
pre@@	I-Disease	-1	9698967
h@@	I-Disease	-1	9698967
en@@	I-Disease	-1	9698967
sible	I-Disease	-1	9698967
sh@@	I-Disease	-1	9698967
ou@@	I-Disease	-1	9698967
ts	I-Disease	-1	9698967
and	O	-1	9698967
loss	B-Disease	D014474	9698967
of	I-Disease	-1	9698967
con@@	I-Disease	-1	9698967
s@@	I-Disease	-1	9698967
ci@@	I-Disease	-1	9698967
ous@@	I-Disease	-1	9698967
ness	I-Disease	-1	9698967
,	O	-1	9698967
was	O	-1	9698967
observed	O	-1	9698967
in	O	-1	9698967
an	O	-1	9698967
el@@	O	-1	9698967
der@@	O	-1	9698967
ly,	O	-1	9698967
A@@	O	-1	9698967
S@@	O	-1	9698967
A	O	-1	9698967
cl@@	O	-1	9698967
assi@@	O	-1	9698967
fic@@	O	-1	9698967
ation	O	-1	9698967
group	O	-1	9698967
II@@	O	-1	9698967
,	O	-1	9698967
cardio@@	O	-1	9698967
vas@@	O	-1	9698967
cul@@	O	-1	9698967
arly	O	-1	9698967
medic@@	O	-1	9698967
ated	O	-1	9698967
mal@@	O	-1	9698967
e,	O	-1	9698967
12	O	-1	9698967
min	O	-1	9698967
after	O	-1	9698967
perform@@	O	-1	9698967
ance	O	-1	9698967
of	O	-1	9698967
ax@@	O	-1	9698967
ill@@	O	-1	9698967
ary	O	-1	9698967
bloc@@	O	-1	9698967
k	O	-1	9698967
with	O	-1	9698967
me@@	B-Chemical	D008619	9698967
pivac@@	I-Chemical	-1	9698967
aine	I-Chemical	-1	9698967
8@@	O	-1	9698967
50	O	-1	9698967
mg	O	-1	9698967
containing	O	-1	9698967
adren@@	B-Chemical	D004837	9698967
aline	I-Chemical	-1	9698967
0.@@	O	-1	9698967
2@@	O	-1	9698967
25	O	-1	9698967
mg@@	O	-1	9698967
,	O	-1	9698967
for	O	-1	9698967
cor@@	O	-1	9698967
rec@@	O	-1	9698967
tion	O	-1	9698967
of	O	-1	9698967
D@@	B-Disease	D004387	9698967
up@@	I-Disease	-1	9698967
u@@	I-Disease	-1	9698967
y@@	I-Disease	-1	9698967
tre@@	I-Disease	-1	9698967
n@@	I-Disease	-1	9698967
's	I-Disease	-1	9698967
contrac@@	I-Disease	-1	9698967
t@@	I-Disease	-1	9698967
ure	I-Disease	-1	9698967
.	O	-1	9698967
After	O	-1	9698967
intravenous	O	-1	9698967
administration	O	-1	9698967
of	O	-1	9698967
l@@	B-Chemical	D007741	9698967
a@@	I-Chemical	-1	9698967
bet@@	I-Chemical	-1	9698967
al@@	I-Chemical	-1	9698967
ol	I-Chemical	-1	9698967
,	O	-1	9698967
me@@	B-Chemical	D008790	9698967
to@@	I-Chemical	-1	9698967
pro@@	I-Chemical	-1	9698967
lol	I-Chemical	-1	9698967
and	O	-1	9698967
mid@@	B-Chemical	D008874	9698967
azol@@	I-Chemical	-1	9698967
am	I-Chemical	-1	9698967
the	O	-1	9698967
patient@@	O	-1	9698967
's	O	-1	9698967
condi@@	O	-1	9698967
tion	O	-1	9698967
impro@@	O	-1	9698967
ve@@	O	-1	9698967
d,	O	-1	9698967
and	O	-1	9698967
15	O	-1	9698967
min	O	-1	9698967
lat@@	O	-1	9698967
er	O	-1	9698967
he	O	-1	9698967
wo@@	O	-1	9698967
k@@	O	-1	9698967
e	O	-1	9698967
up@@	O	-1	9698967
.	O	-1	9698967
The	O	-1	9698967
bloc@@	O	-1	9698967
k	O	-1	9698967
was	O	-1	9698967
suc@@	O	-1	9698967
cess@@	O	-1	9698967
ful	O	-1	9698967
and	O	-1	9698967
surger@@	O	-1	9698967
y	O	-1	9698967
was	O	-1	9698967
con@@	O	-1	9698967
duc@@	O	-1	9698967
ted	O	-1	9698967
as	O	-1	9698967
sch@@	O	-1	9698967
ed@@	O	-1	9698967
ul@@	O	-1	9698967
ed	O	-1	9698967
des@@	O	-1	9698967
pit@@	O	-1	9698967
e	O	-1	9698967
per@@	O	-1	9698967
sist@@	O	-1	9698967
ing	O	-1	9698967
atrial	B-Disease	D001281	9698967
fibrill@@	I-Disease	-1	9698967
ation	I-Disease	-1	9698967
.	O	-1	9698967
P@@	O	-1	9698967
o@@	O	-1	9698967
sto@@	O	-1	9698967
per@@	O	-1	9698967
ati@@	O	-1	9698967
vel@@	O	-1	9698967
y,	O	-1	9698967
the	O	-1	9698967
patient	O	-1	9698967
ref@@	O	-1	9698967
used	O	-1	9698967
D@@	O	-1	9698967
C	O	-1	9698967
cardio@@	O	-1	9698967
ver@@	O	-1	9698967
sion	O	-1	9698967
and	O	-1	9698967
was	O	-1	9698967
treated	O	-1	9698967
medic@@	O	-1	9698967
all@@	O	-1	9698967
y.	O	-1	9698967
B@@	O	-1	9698967
oth	O	-1	9698967
the	O	-1	9698967
tempor@@	O	-1	9698967
al	O	-1	9698967
rel@@	O	-1	9698967
ationship	O	-1	9698967
of	O	-1	9698967
events	O	-1	9698967
and	O	-1	9698967
the	O	-1	9698967
response	O	-1	9698967
to	O	-1	9698967
treatment	O	-1	9698967
suggest	O	-1	9698967
that	O	-1	9698967
a	O	-1	9698967
ra@@	O	-1	9698967
pid	O	-1	9698967
systemic	O	-1	9698967
abs@@	O	-1	9698967
or@@	O	-1	9698967
ption	O	-1	9698967
of	O	-1	9698967
me@@	B-Chemical	D008619	9698967
pivac@@	I-Chemical	-1	9698967
aine	I-Chemical	-1	9698967
with	O	-1	9698967
adren@@	B-Chemical	D004837	9698967
aline	I-Chemical	-1	9698967
and/or	O	-1	9698967
inter@@	O	-1	9698967
action	O	-1	9698967
of	O	-1	9698967
these	O	-1	9698967
drugs	O	-1	9698967
with	O	-1	9698967
the	O	-1	9698967
patient@@	O	-1	9698967
's	O	-1	9698967
cardiovascular	O	-1	9698967
medic@@	O	-1	9698967
ations	O	-1	9698967
were	O	-1	9698967
respon@@	O	-1	9698967
sible	O	-1	9698967
for	O	-1	9698967
the	O	-1	9698967
perio@@	O	-1	9698967
perative	O	-1	9698967
complic@@	O	-1	9698967
ations.	O	-1	9698967

Clin@@	O	-1	9855119
ical	O	-1	9855119
and	O	-1	9855119
histo@@	O	-1	9855119
path@@	O	-1	9855119
ologic	O	-1	9855119
examin@@	O	-1	9855119
ation	O	-1	9855119
of	O	-1	9855119
renal	O	-1	9855119
allogra@@	O	-1	9855119
f@@	O	-1	9855119
ts	O	-1	9855119
treated	O	-1	9855119
with	O	-1	9855119
tacrolimus	B-Chemical	D016559	9855119
(	O	-1	9855119
FK50@@	B-Chemical	D016559	9855119
6	I-Chemical	-1	9855119
)	O	-1	9855119
for	O	-1	9855119
at	O	-1	9855119
le@@	O	-1	9855119
ast	O	-1	9855119
one	O	-1	9855119
year@@	O	-1	9855119
.	O	-1	9855119
BACKGROUND:	O	-1	9855119
We	O	-1	9855119
clin@@	O	-1	9855119
ically	O	-1	9855119
and	O	-1	9855119
path@@	O	-1	9855119
olog@@	O	-1	9855119
ically	O	-1	9855119
analy@@	O	-1	9855119
zed	O	-1	9855119
renal	O	-1	9855119
allogra@@	O	-1	9855119
f@@	O	-1	9855119
ts	O	-1	9855119
from	O	-1	9855119
1	O	-1	9855119
9	O	-1	9855119
renal	O	-1	9855119
transplant	O	-1	9855119
patients	O	-1	9855119
treated	O	-1	9855119
with	O	-1	9855119
tacrolimus	B-Chemical	D016559	9855119
(	O	-1	9855119
FK50@@	B-Chemical	D016559	9855119
6	I-Chemical	-1	9855119
)	O	-1	9855119
for	O	-1	9855119
more	O	-1	9855119
than	O	-1	9855119
1	O	-1	9855119
year@@	O	-1	9855119
.	O	-1	9855119
METHODS:	O	-1	9855119
Tw@@	O	-1	9855119
ent@@	O	-1	9855119
y-@@	O	-1	9855119
six	O	-1	9855119
renal	O	-1	9855119
allogra@@	O	-1	9855119
ft	O	-1	9855119
biop@@	O	-1	9855119
sy	O	-1	9855119
spec@@	O	-1	9855119
imen@@	O	-1	9855119
s	O	-1	9855119
from	O	-1	9855119
1	O	-1	9855119
9	O	-1	9855119
renal	O	-1	9855119
transplant	O	-1	9855119
patients	O	-1	9855119
who	O	-1	9855119
under@@	O	-1	9855119
w@@	O	-1	9855119
ent	O	-1	9855119
transplant@@	O	-1	9855119
ations	O	-1	9855119
between	O	-1	9855119
19@@	O	-1	9855119
9@@	O	-1	9855119
1	O	-1	9855119
and	O	-1	9855119
19@@	O	-1	9855119
9@@	O	-1	9855119
3	O	-1	9855119
were	O	-1	9855119
evalu@@	O	-1	9855119
ated.	O	-1	9855119
Th@@	O	-1	9855119
ir@@	O	-1	9855119
te@@	O	-1	9855119
en	O	-1	9855119
biop@@	O	-1	9855119
si@@	O	-1	9855119
es	O	-1	9855119
were	O	-1	9855119
performed	O	-1	9855119
from	O	-1	9855119
st@@	O	-1	9855119
able	O	-1	9855119
func@@	O	-1	9855119
tion@@	O	-1	9855119
ing	O	-1	9855119
renal	O	-1	9855119
allogra@@	O	-1	9855119
f@@	O	-1	9855119
ts	O	-1	9855119
with	O	-1	9855119
inf@@	O	-1	9855119
orm@@	O	-1	9855119
ed	O	-1	9855119
con@@	O	-1	9855119
s@@	O	-1	9855119
ent	O	-1	9855119
(@@	O	-1	9855119
non@@	O	-1	9855119
episo@@	O	-1	9855119
de	O	-1	9855119
bio@@	O	-1	9855119
psy@@	O	-1	9855119
)	O	-1	9855119
and	O	-1	9855119
the	O	-1	9855119
other	O	-1	9855119
13	O	-1	9855119
were	O	-1	9855119
from	O	-1	9855119
dysfunc@@	O	-1	9855119
tional	O	-1	9855119
renal	O	-1	9855119
allogra@@	O	-1	9855119
f@@	O	-1	9855119
ts	O	-1	9855119
with	O	-1	9855119
a	O	-1	9855119
clinical	O	-1	9855119
indic@@	O	-1	9855119
ation	O	-1	9855119
for	O	-1	9855119
biop@@	O	-1	9855119
sy	O	-1	9855119
(@@	O	-1	9855119
episo@@	O	-1	9855119
de	O	-1	9855119
bio@@	O	-1	9855119
psy@@	O	-1	9855119
).	O	-1	9855119
RESULTS:	O	-1	9855119
The	O	-1	9855119
ma@@	O	-1	9855119
in	O	-1	9855119
path@@	O	-1	9855119
ologic	O	-1	9855119
diagno@@	O	-1	9855119
ses	O	-1	9855119
(@@	O	-1	9855119
some	O	-1	9855119
over@@	O	-1	9855119
l@@	O	-1	9855119
ap@@	O	-1	9855119
)	O	-1	9855119
were	O	-1	9855119
acute	O	-1	9855119
re@@	O	-1	9855119
j@@	O	-1	9855119
ection	O	-1	9855119
(A@@	O	-1	9855119
R@@	O	-1	9855119
;	O	-1	9855119
n	O	-1	9855119
=	O	-1	9855119
4@@	O	-1	9855119
),	O	-1	9855119
chronic	O	-1	9855119
re@@	O	-1	9855119
j@@	O	-1	9855119
ection	O	-1	9855119
(C@@	O	-1	9855119
R@@	O	-1	9855119
;	O	-1	9855119
n@@	O	-1	9855119
=@@	O	-1	9855119
5@@	O	-1	9855119
),	O	-1	9855119
A@@	O	-1	9855119
R@@	O	-1	9855119
+@@	O	-1	9855119
C@@	O	-1	9855119
R	O	-1	9855119
(n	O	-1	9855119
=@@	O	-1	9855119
4@@	O	-1	9855119
),	O	-1	9855119
recur@@	O	-1	9855119
rent	O	-1	9855119
I@@	B-Disease	D005922	9855119
g@@	I-Disease	-1	9855119
A	I-Disease	-1	9855119
nephro@@	I-Disease	-1	9855119
pathy	I-Disease	-1	9855119
(n	O	-1	9855119
=@@	O	-1	9855119
5@@	O	-1	9855119
),	O	-1	9855119
normal	O	-1	9855119
findings	O	-1	9855119
(n	O	-1	9855119
=@@	O	-1	9855119
2@@	O	-1	9855119
),	O	-1	9855119
minim@@	O	-1	9855119
al@@	O	-1	9855119
-@@	O	-1	9855119
type	O	-1	9855119
chronic	O	-1	9855119
FK50@@	B-Chemical	D016559	9855119
6	I-Chemical	-1	9855119
nephro@@	B-Disease	D007674	9855119
pathy	I-Disease	-1	9855119
(n	O	-1	9855119
=	O	-1	9855119
9@@	O	-1	9855119
),	O	-1	9855119
and	O	-1	9855119
mil@@	O	-1	9855119
d-@@	O	-1	9855119
type	O	-1	9855119
FK50@@	B-Chemical	D016559	9855119
6	I-Chemical	-1	9855119
nephro@@	B-Disease	D007674	9855119
pathy	I-Disease	-1	9855119
(n	O	-1	9855119
=	O	-1	9855119
1@@	O	-1	9855119
1).	O	-1	9855119
Of	O	-1	9855119
the	O	-1	9855119
non@@	O	-1	9855119
episo@@	O	-1	9855119
de	O	-1	9855119
biop@@	O	-1	9855119
si@@	O	-1	9855119
es,	O	-1	9855119
7	O	-1	9855119
and	O	-1	9855119
4	O	-1	9855119
biop@@	O	-1	9855119
si@@	O	-1	9855119
es	O	-1	9855119
showed	O	-1	9855119
minim@@	O	-1	9855119
al@@	O	-1	9855119
-@@	O	-1	9855119
type	O	-1	9855119
and	O	-1	9855119
mil@@	O	-1	9855119
d-@@	O	-1	9855119
type	O	-1	9855119
chronic	O	-1	9855119
FK50@@	B-Chemical	D016559	9855119
6	I-Chemical	-1	9855119
nephro@@	B-Disease	D007674	9855119
pathy	I-Disease	-1	9855119
,	O	-1	9855119
respectively.	O	-1	9855119
Ch@@	O	-1	9855119
ron@@	O	-1	9855119
ic	O	-1	9855119
FK50@@	B-Chemical	D016559	9855119
6	I-Chemical	-1	9855119
nephro@@	B-Disease	D007674	9855119
pathy	I-Disease	-1	9855119
consist@@	O	-1	9855119
ed	O	-1	9855119
of	O	-1	9855119
rou@@	O	-1	9855119
gh	O	-1	9855119
and	O	-1	9855119
fo@@	O	-1	9855119
am@@	O	-1	9855119
y	O	-1	9855119
tub@@	O	-1	9855119
ular	O	-1	9855119
vac@@	O	-1	9855119
u@@	O	-1	9855119
ol@@	O	-1	9855119
ization	O	-1	9855119
(@@	O	-1	9855119
5	O	-1	9855119
biop@@	O	-1	9855119
si@@	O	-1	9855119
es@@	O	-1	9855119
),	O	-1	9855119
arter@@	O	-1	9855119
io@@	O	-1	9855119
lo@@	O	-1	9855119
pathy	O	-1	9855119
(@@	O	-1	9855119
angio@@	O	-1	9855119
de@@	O	-1	9855119
generation	O	-1	9855119
of	O	-1	9855119
the	O	-1	9855119
arter@@	O	-1	9855119
i@@	O	-1	9855119
ol@@	O	-1	9855119
ar	O	-1	9855119
w@@	O	-1	9855119
all@@	O	-1	9855119
;	O	-1	9855119
20	O	-1	9855119
biop@@	O	-1	9855119
si@@	O	-1	9855119
es@@	O	-1	9855119
),	O	-1	9855119
foc@@	B-Disease	D005923	9855119
al	I-Disease	-1	9855119
seg@@	I-Disease	-1	9855119
mental	I-Disease	-1	9855119
glomer@@	I-Disease	-1	9855119
u@@	I-Disease	-1	9855119
los@@	I-Disease	-1	9855119
clero@@	I-Disease	-1	9855119
sis	I-Disease	-1	9855119
(@@	O	-1	9855119
4	O	-1	9855119
biop@@	O	-1	9855119
si@@	O	-1	9855119
es@@	O	-1	9855119
)	O	-1	9855119
and	O	-1	9855119
the	O	-1	9855119
stri@@	O	-1	9855119
p@@	O	-1	9855119
ed	O	-1	9855119
form	O	-1	9855119
of	O	-1	9855119
interstitial	B-Disease	D005355	9855119
fib@@	I-Disease	-1	9855119
ro@@	I-Disease	-1	9855119
sis	I-Disease	-1	9855119
(1@@	O	-1	9855119
1	O	-1	9855119
biop@@	O	-1	9855119
si@@	O	-1	9855119
es@@	O	-1	9855119
).	O	-1	9855119
The	O	-1	9855119
serum	O	-1	9855119
creatinine	B-Chemical	D003404	9855119
levels	O	-1	9855119
of	O	-1	9855119
patients	O	-1	9855119
in	O	-1	9855119
the	O	-1	9855119
mil@@	O	-1	9855119
d-@@	O	-1	9855119
type	O	-1	9855119
chronic	O	-1	9855119
FK50@@	B-Chemical	D016559	9855119
6	I-Chemical	-1	9855119
nephro@@	B-Disease	D007674	9855119
pathy	I-Disease	-1	9855119
group@@	O	-1	9855119
,	O	-1	9855119
which	O	-1	9855119
included	O	-1	9855119
7	O	-1	9855119
episo@@	O	-1	9855119
de	O	-1	9855119
biop@@	O	-1	9855119
si@@	O	-1	9855119
es,	O	-1	9855119
were	O	-1	9855119
statis@@	O	-1	9855119
tically	O	-1	9855119
higher	O	-1	9855119
than	O	-1	9855119
those	O	-1	9855119
in	O	-1	9855119
the	O	-1	9855119
minim@@	O	-1	9855119
um@@	O	-1	9855119
-@@	O	-1	9855119
type	O	-1	9855119
chronic	O	-1	9855119
FK50@@	B-Chemical	D016559	9855119
6	I-Chemical	-1	9855119
-	O	-1	9855119
nephro@@	B-Disease	D007674	9855119
pathy	I-Disease	-1	9855119
group	O	-1	9855119
(P@@	O	-1	9855119
<	O	-1	9855119
0.00@@	O	-1	9855119
1).	O	-1	9855119
CONCLUSIONS:	O	-1	9855119
This	O	-1	9855119
study	O	-1	9855119
demon@@	O	-1	9855119
strat@@	O	-1	9855119
es	O	-1	9855119
that	O	-1	9855119
chronic	O	-1	9855119
FK50@@	B-Chemical	D016559	9855119
6	I-Chemical	-1	9855119
nephro@@	B-Disease	D007674	9855119
pathy	I-Disease	-1	9855119
consist@@	O	-1	9855119
s	O	-1	9855119
prim@@	O	-1	9855119
ari@@	O	-1	9855119
ly	O	-1	9855119
of	O	-1	9855119
arter@@	O	-1	9855119
io@@	O	-1	9855119
lo@@	O	-1	9855119
pathy	O	-1	9855119
man@@	O	-1	9855119
if@@	O	-1	9855119
est@@	O	-1	9855119
ing	O	-1	9855119
as	O	-1	9855119
in@@	O	-1	9855119
su@@	O	-1	9855119
d@@	O	-1	9855119
ative	O	-1	9855119
hy@@	O	-1	9855119
al@@	O	-1	9855119
ino@@	O	-1	9855119
sis	O	-1	9855119
of	O	-1	9855119
the	O	-1	9855119
arter@@	O	-1	9855119
i@@	O	-1	9855119
ol@@	O	-1	9855119
ar	O	-1	9855119
w@@	O	-1	9855119
all@@	O	-1	9855119
,	O	-1	9855119
and	O	-1	9855119
suggests	O	-1	9855119
that	O	-1	9855119
mil@@	O	-1	9855119
d-@@	O	-1	9855119
type	O	-1	9855119
chronic	O	-1	9855119
FK50@@	B-Chemical	D016559	9855119
6	I-Chemical	-1	9855119
nephro@@	B-Disease	D007674	9855119
pathy	I-Disease	-1	9855119
is	O	-1	9855119
a	O	-1	9855119
condi@@	O	-1	9855119
tion	O	-1	9855119
which	O	-1	9855119
may	O	-1	9855119
le@@	O	-1	9855119
ad	O	-1	9855119
to	O	-1	9855119
deter@@	O	-1	9855119
i@@	O	-1	9855119
or@@	O	-1	9855119
ation	O	-1	9855119
of	O	-1	9855119
renal	O	-1	9855119
allogra@@	O	-1	9855119
ft	O	-1	9855119
func@@	O	-1	9855119
tion.	O	-1	9855119

M@@	O	-1	9869257
em@@	O	-1	9869257
ory	O	-1	9869257
fac@@	O	-1	9869257
il@@	O	-1	9869257
it@@	O	-1	9869257
ation	O	-1	9869257
and	O	-1	9869257
stimulation	O	-1	9869257
of	O	-1	9869257
endo@@	O	-1	9869257
gen@@	O	-1	9869257
ous	O	-1	9869257
nerve	O	-1	9869257
growth	O	-1	9869257
factor	O	-1	9869257
syn@@	O	-1	9869257
thesis	O	-1	9869257
by	O	-1	9869257
the	O	-1	9869257
acet@@	B-Chemical	D000109	9869257
ylcholine	I-Chemical	-1	9869257
rele@@	O	-1	9869257
as@@	O	-1	9869257
er	O	-1	9869257
PG@@	B-Chemical	C087567	9869257
-@@	I-Chemical	-1	9869257
9	I-Chemical	-1	9869257
.	O	-1	9869257
The	O	-1	9869257
effects	O	-1	9869257
of	O	-1	9869257
PG@@	B-Chemical	C087567	9869257
-@@	I-Chemical	-1	9869257
9	I-Chemical	-1	9869257
(	O	-1	9869257
3@@	B-Chemical	C087567	9869257
alpha-@@	I-Chemical	-1	9869257
tro@@	I-Chemical	-1	9869257
py@@	I-Chemical	-1	9869257
l	I-Chemical	-1	9869257
2-@@	I-Chemical	-1	9869257
(p@@	I-Chemical	-1	9869257
-@@	I-Chemical	-1	9869257
b@@	I-Chemical	-1	9869257
ro@@	I-Chemical	-1	9869257
mo@@	I-Chemical	-1	9869257
phenyl@@	I-Chemical	-1	9869257
)@@	I-Chemical	-1	9869257
pro@@	I-Chemical	-1	9869257
pi@@	I-Chemical	-1	9869257
on@@	I-Chemical	-1	9869257
ate	I-Chemical	-1	9869257
),	O	-1	9869257
the	O	-1	9869257
acet@@	B-Chemical	D000109	9869257
ylcholine	I-Chemical	-1	9869257
rele@@	O	-1	9869257
as@@	O	-1	9869257
er,	O	-1	9869257
on	O	-1	9869257
memory	O	-1	9869257
pro@@	O	-1	9869257
ces@@	O	-1	9869257
ses	O	-1	9869257
and	O	-1	9869257
nerve	O	-1	9869257
growth	O	-1	9869257
factor	O	-1	9869257
(N@@	O	-1	9869257
GF@@	O	-1	9869257
)	O	-1	9869257
syn@@	O	-1	9869257
thesis	O	-1	9869257
were	O	-1	9869257
evalu@@	O	-1	9869257
ated.	O	-1	9869257
In	O	-1	9869257
the	O	-1	9869257
mouse	O	-1	9869257
p@@	O	-1	9869257
assi@@	O	-1	9869257
ve@@	O	-1	9869257
-@@	O	-1	9869257
avoid@@	O	-1	9869257
ance	O	-1	9869257
test@@	O	-1	9869257
,	O	-1	9869257
PG@@	B-Chemical	C087567	9869257
-@@	I-Chemical	-1	9869257
9	I-Chemical	-1	9869257
(@@	O	-1	9869257
10-@@	O	-1	9869257
30	O	-1	9869257
mg/kg@@	O	-1	9869257
,	O	-1	9869257
i.p.@@	O	-1	9869257
),	O	-1	9869257
administered	O	-1	9869257
20	O	-1	9869257
min	O	-1	9869257
before	O	-1	9869257
the	O	-1	9869257
tra@@	O	-1	9869257
in@@	O	-1	9869257
ing	O	-1	9869257
s@@	O	-1	9869257
es@@	O	-1	9869257
sion,	O	-1	9869257
prevent@@	O	-1	9869257
ed	O	-1	9869257
am@@	B-Disease	D000647	9869257
ne@@	I-Disease	-1	9869257
sia	I-Disease	-1	9869257
induced	O	-1	9869257
by	O	-1	9869257
both	O	-1	9869257
the	O	-1	9869257
n@@	O	-1	9869257
on	O	-1	9869257
selective	O	-1	9869257
anti@@	O	-1	9869257
mus@@	O	-1	9869257
car@@	O	-1	9869257
inic	O	-1	9869257
drug	O	-1	9869257
scopol@@	B-Chemical	D012601	9869257
amine	I-Chemical	-1	9869257
and	O	-1	9869257
the	O	-1	9869257
M@@	O	-1	9869257
1-@@	O	-1	9869257
selective	O	-1	9869257
antagonist	O	-1	9869257
S@@	B-Chemical	C098725	9869257
-@@	I-Chemical	-1	9869257
(-@@	I-Chemical	-1	9869257
)-@@	I-Chemical	-1	9869257
ET@@	I-Chemical	-1	9869257
-1@@	I-Chemical	-1	9869257
2@@	I-Chemical	-1	9869257
6	I-Chemical	-1	9869257
.	O	-1	9869257
In	O	-1	9869257
the	O	-1	9869257
same	O	-1	9869257
experimental	O	-1	9869257
condi@@	O	-1	9869257
tion@@	O	-1	9869257
s,	O	-1	9869257
PG@@	B-Chemical	C087567	9869257
-@@	I-Chemical	-1	9869257
9	I-Chemical	-1	9869257
(@@	O	-1	9869257
5-@@	O	-1	9869257
20	O	-1	9869257
micro@@	O	-1	9869257
g	O	-1	9869257
per	O	-1	9869257
mou@@	O	-1	9869257
se@@	O	-1	9869257
,	O	-1	9869257
i.@@	O	-1	9869257
c@@	O	-1	9869257
.@@	O	-1	9869257
v@@	O	-1	9869257
.)	O	-1	9869257
was	O	-1	9869257
also	O	-1	9869257
able	O	-1	9869257
to	O	-1	9869257
prev@@	O	-1	9869257
ent	O	-1	9869257
anti@@	O	-1	9869257
mus@@	O	-1	9869257
car@@	O	-1	9869257
ine-induced	O	-1	9869257
am@@	B-Disease	D000647	9869257
ne@@	I-Disease	-1	9869257
sia	I-Disease	-1	9869257
,	O	-1	9869257
demon@@	O	-1	9869257
strat@@	O	-1	9869257
ing	O	-1	9869257
a	O	-1	9869257
central	O	-1	9869257
lo@@	O	-1	9869257
cal@@	O	-1	9869257
ization	O	-1	9869257
of	O	-1	9869257
the	O	-1	9869257
activ@@	O	-1	9869257
ity.	O	-1	9869257
A@@	O	-1	9869257
t	O	-1	9869257
the	O	-1	9869257
high@@	O	-1	9869257
est	O	-1	9869257
effective	O	-1	9869257
dos@@	O	-1	9869257
es,	O	-1	9869257
PG@@	B-Chemical	C087567	9869257
-@@	I-Chemical	-1	9869257
9	I-Chemical	-1	9869257
did	O	-1	9869257
not	O	-1	9869257
produce	O	-1	9869257
any	O	-1	9869257
coll@@	O	-1	9869257
ateral	O	-1	9869257
symptoms	O	-1	9869257
as	O	-1	9869257
revealed	O	-1	9869257
by	O	-1	9869257
the	O	-1	9869257
I@@	O	-1	9869257
r@@	O	-1	9869257
w@@	O	-1	9869257
in	O	-1	9869257
test@@	O	-1	9869257
,	O	-1	9869257
and	O	-1	9869257
it	O	-1	9869257
did	O	-1	9869257
not	O	-1	9869257
mo@@	O	-1	9869257
di@@	O	-1	9869257
f@@	O	-1	9869257
y	O	-1	9869257
spont@@	O	-1	9869257
aneous	O	-1	9869257
mo@@	O	-1	9869257
til@@	O	-1	9869257
ity	O	-1	9869257
and	O	-1	9869257
in@@	O	-1	9869257
sp@@	O	-1	9869257
ection	O	-1	9869257
activ@@	O	-1	9869257
ity,	O	-1	9869257
as	O	-1	9869257
revealed	O	-1	9869257
by	O	-1	9869257
the	O	-1	9869257
h@@	O	-1	9869257
ol@@	O	-1	9869257
e-@@	O	-1	9869257
bo@@	O	-1	9869257
ard	O	-1	9869257
test@@	O	-1	9869257
.	O	-1	9869257
PG@@	B-Chemical	C087567	9869257
-@@	I-Chemical	-1	9869257
9	I-Chemical	-1	9869257
was	O	-1	9869257
also	O	-1	9869257
able	O	-1	9869257
to	O	-1	9869257
increase	O	-1	9869257
the	O	-1	9869257
amoun@@	O	-1	9869257
t	O	-1	9869257
of	O	-1	9869257
N@@	O	-1	9869257
G@@	O	-1	9869257
F	O	-1	9869257
secre@@	O	-1	9869257
ted	O	-1	9869257
in	O	-1	9869257
vit@@	O	-1	9869257
r@@	O	-1	9869257
o	O	-1	9869257
by	O	-1	9869257
ast@@	O	-1	9869257
ro@@	O	-1	9869257
cy@@	O	-1	9869257
tes	O	-1	9869257
in	O	-1	9869257
a	O	-1	9869257
dose-@@	O	-1	9869257
dependent	O	-1	9869257
man@@	O	-1	9869257
ner@@	O	-1	9869257
.	O	-1	9869257
The	O	-1	9869257
maxim@@	O	-1	9869257
al	O	-1	9869257
N@@	O	-1	9869257
G@@	O	-1	9869257
F	O	-1	9869257
cont@@	O	-1	9869257
ents	O	-1	9869257
obtained	O	-1	9869257
by	O	-1	9869257
PG@@	B-Chemical	C087567	9869257
-@@	I-Chemical	-1	9869257
9	I-Chemical	-1	9869257
were	O	-1	9869257
1@@	O	-1	9869257
7.@@	O	-1	9869257
6-@@	O	-1	9869257
fol@@	O	-1	9869257
d	O	-1	9869257
of	O	-1	9869257
the	O	-1	9869257
control	O	-1	9869257
valu@@	O	-1	9869257
e.	O	-1	9869257
D@@	O	-1	9869257
uring	O	-1	9869257
c@@	O	-1	9869257
ult@@	O	-1	9869257
ure,	O	-1	9869257
no	O	-1	9869257
morph@@	O	-1	9869257
ological	O	-1	9869257
changes	O	-1	9869257
were	O	-1	9869257
found	O	-1	9869257
at	O	-1	9869257
effective	O	-1	9869257
concentrations	O	-1	9869257
of	O	-1	9869257
PG@@	B-Chemical	C087567	9869257
-@@	I-Chemical	-1	9869257
9	I-Chemical	-1	9869257
.	O	-1	9869257
The	O	-1	9869257
current	O	-1	9869257
wor@@	O	-1	9869257
k	O	-1	9869257
indic@@	O	-1	9869257
ates	O	-1	9869257
the	O	-1	9869257
ability	O	-1	9869257
of	O	-1	9869257
PG@@	B-Chemical	C087567	9869257
-@@	I-Chemical	-1	9869257
9	I-Chemical	-1	9869257
to	O	-1	9869257
induce	O	-1	9869257
ben@@	O	-1	9869257
e@@	O	-1	9869257
fic@@	O	-1	9869257
ial	O	-1	9869257
effects	O	-1	9869257
on	O	-1	9869257
cognitive	O	-1	9869257
pro@@	O	-1	9869257
ces@@	O	-1	9869257
ses	O	-1	9869257
and	O	-1	9869257
stimul@@	O	-1	9869257
ate	O	-1	9869257
activity	O	-1	9869257
of	O	-1	9869257
N@@	O	-1	9869257
G@@	O	-1	9869257
F	O	-1	9869257
syn@@	O	-1	9869257
thesis	O	-1	9869257
in	O	-1	9869257
ast@@	O	-1	9869257
ro@@	O	-1	9869257
g@@	O	-1	9869257
lial	O	-1	9869257
cell@@	O	-1	9869257
s.	O	-1	9869257
The@@	O	-1	9869257
refore,	O	-1	9869257
PG@@	B-Chemical	C087567	9869257
-@@	I-Chemical	-1	9869257
9	I-Chemical	-1	9869257
could	O	-1	9869257
re@@	O	-1	9869257
present	O	-1	9869257
a	O	-1	9869257
potential	O	-1	9869257
use@@	O	-1	9869257
ful	O	-1	9869257
drug	O	-1	9869257
able	O	-1	9869257
to	O	-1	9869257
impro@@	O	-1	9869257
ve	O	-1	9869257
the	O	-1	9869257
function	O	-1	9869257
of	O	-1	9869257
impaired	O	-1	9869257
cognitive	O	-1	9869257
pro@@	O	-1	9869257
cess@@	O	-1	9869257
es.	O	-1	9869257

An@@	B-Disease	D000799	10342929
g@@	I-Disease	-1	10342929
io@@	I-Disease	-1	10342929
e@@	I-Disease	-1	10342929
de@@	I-Disease	-1	10342929
ma	I-Disease	-1	10342929
due	O	-1	10342929
to	O	-1	10342929
AC@@	B-Chemical	D000806	10342929
E	I-Chemical	-1	10342929
inhibitors	I-Chemical	-1	10342929
:	O	-1	10342929
common	O	-1	10342929
and	O	-1	10342929
in@@	O	-1	10342929
ade@@	O	-1	10342929
qu@@	O	-1	10342929
ately	O	-1	10342929
diagno@@	O	-1	10342929
sed.	O	-1	10342929
The	O	-1	10342929
estim@@	O	-1	10342929
ated	O	-1	10342929
incidence	O	-1	10342929
of	O	-1	10342929
angio@@	B-Disease	D000799	10342929
e@@	I-Disease	-1	10342929
de@@	I-Disease	-1	10342929
ma	I-Disease	-1	10342929
during	O	-1	10342929
angiotens@@	B-Chemical	D000806	10342929
in-@@	I-Chemical	-1	10342929
conver@@	I-Chemical	-1	10342929
ting	I-Chemical	-1	10342929
enzyme	I-Chemical	-1	10342929
(@@	I-Chemical	-1	10342929
AC@@	I-Chemical	-1	10342929
E@@	I-Chemical	-1	10342929
)	I-Chemical	-1	10342929
inhibitor	I-Chemical	-1	10342929
treatment	O	-1	10342929
is	O	-1	10342929
between	O	-1	10342929
1	O	-1	10342929
and	O	-1	10342929
7	O	-1	10342929
per	O	-1	10342929
th@@	O	-1	10342929
ous@@	O	-1	10342929
and	O	-1	10342929
patients.	O	-1	10342929
This	O	-1	10342929
potenti@@	O	-1	10342929
ally	O	-1	10342929
seri@@	O	-1	10342929
ous	O	-1	10342929
adverse	O	-1	10342929
effect	O	-1	10342929
is	O	-1	10342929
often	O	-1	10342929
pre@@	O	-1	10342929
ce@@	O	-1	10342929
ded	O	-1	10342929
by	O	-1	10342929
min@@	O	-1	10342929
or	O	-1	10342929
man@@	O	-1	10342929
if@@	O	-1	10342929
est@@	O	-1	10342929
ations	O	-1	10342929
that	O	-1	10342929
may	O	-1	10342929
ser@@	O	-1	10342929
ve	O	-1	10342929
as	O	-1	10342929
a	O	-1	10342929
war@@	O	-1	10342929
n@@	O	-1	10342929
ing.	O	-1	10342929

Rec@@	O	-1	10457883
ur@@	O	-1	10457883
ar@@	O	-1	10457883
ization	O	-1	10457883
in	O	-1	10457883
the	O	-1	10457883
recovery	O	-1	10457883
ro@@	O	-1	10457883
om@@	O	-1	10457883
.	O	-1	10457883
A	O	-1	10457883
case	O	-1	10457883
of	O	-1	10457883
recur@@	O	-1	10457883
ar@@	O	-1	10457883
ization	O	-1	10457883
in	O	-1	10457883
the	O	-1	10457883
recovery	O	-1	10457883
ro@@	O	-1	10457883
o@@	O	-1	10457883
m	O	-1	10457883
is	O	-1	10457883
repor@@	O	-1	10457883
ted.	O	-1	10457883
Ac@@	O	-1	10457883
cum@@	O	-1	10457883
ulation	O	-1	10457883
of	O	-1	10457883
at@@	B-Chemical	D001279	10457883
rac@@	I-Chemical	-1	10457883
ur@@	I-Chemical	-1	10457883
i@@	I-Chemical	-1	10457883
um	I-Chemical	-1	10457883
in	O	-1	10457883
the	O	-1	10457883
intravenous	O	-1	10457883
line	O	-1	10457883
l@@	O	-1	10457883
ed	O	-1	10457883
to	O	-1	10457883
recur@@	O	-1	10457883
ar@@	O	-1	10457883
ization	O	-1	10457883
after	O	-1	10457883
f@@	O	-1	10457883
l@@	O	-1	10457883
us@@	O	-1	10457883
h@@	O	-1	10457883
ing	O	-1	10457883
the	O	-1	10457883
line	O	-1	10457883
in	O	-1	10457883
the	O	-1	10457883
recovery	O	-1	10457883
ro@@	O	-1	10457883
om@@	O	-1	10457883
.	O	-1	10457883
A	O	-1	10457883
respiratory	B-Disease	D012131	10457883
ar@@	I-Disease	-1	10457883
res@@	I-Disease	-1	10457883
t	I-Disease	-1	10457883
with	O	-1	10457883
severe	O	-1	10457883
des@@	B-Disease	D001049	10457883
at@@	I-Disease	-1	10457883
ur@@	I-Disease	-1	10457883
ation	I-Disease	-1	10457883
and	O	-1	10457883
brady@@	B-Disease	D001919	10457883
cardia	I-Disease	-1	10457883
occur@@	O	-1	10457883
red.	O	-1	10457883
C@@	O	-1	10457883
ir@@	O	-1	10457883
cum@@	O	-1	10457883
st@@	O	-1	10457883
anc@@	O	-1	10457883
es	O	-1	10457883
lead@@	O	-1	10457883
ing	O	-1	10457883
to	O	-1	10457883
this	O	-1	10457883
ev@@	O	-1	10457883
ent	O	-1	10457883
and	O	-1	10457883
the	O	-1	10457883
mechanisms	O	-1	10457883
en@@	O	-1	10457883
abl@@	O	-1	10457883
ing	O	-1	10457883
a	O	-1	10457883
neuro@@	B-Disease	D020879	10457883
mus@@	I-Disease	-1	10457883
cular	I-Disease	-1	10457883
block@@	I-Disease	-1	10457883
ade	I-Disease	-1	10457883
to	O	-1	10457883
occur@@	O	-1	10457883
,	O	-1	10457883
following	O	-1	10457883
the	O	-1	10457883
administration	O	-1	10457883
of	O	-1	10457883
a	O	-1	10457883
sm@@	O	-1	10457883
all	O	-1	10457883
dose	O	-1	10457883
of	O	-1	10457883
rel@@	O	-1	10457883
ax@@	O	-1	10457883
ant@@	O	-1	10457883
,	O	-1	10457883
are	O	-1	10457883
discus@@	O	-1	10457883
sed.	O	-1	10457883

Rec@@	O	-1	10739826
ur@@	O	-1	10739826
rent	O	-1	10739826
use	O	-1	10739826
of	O	-1	10739826
ne@@	O	-1	10739826
w@@	O	-1	10739826
er	O	-1	10739826
oral	B-Chemical	D003276	10739826
contrac@@	I-Chemical	-1	10739826
ep@@	I-Chemical	-1	10739826
tiv@@	I-Chemical	-1	10739826
es	I-Chemical	-1	10739826
and	O	-1	10739826
the	O	-1	10739826
risk	O	-1	10739826
of	O	-1	10739826
venous	B-Disease	D054556	10739826
thrombo@@	I-Disease	-1	10739826
emb@@	I-Disease	-1	10739826
ol@@	I-Disease	-1	10739826
ism	I-Disease	-1	10739826
.	O	-1	10739826
The	O	-1	10739826
epi@@	O	-1	10739826
de@@	O	-1	10739826
m@@	O	-1	10739826
io@@	O	-1	10739826
log@@	O	-1	10739826
ical	O	-1	10739826
studies	O	-1	10739826
that	O	-1	10739826
assessed	O	-1	10739826
the	O	-1	10739826
risk	O	-1	10739826
of	O	-1	10739826
venous	B-Disease	D054556	10739826
thrombo@@	I-Disease	-1	10739826
emb@@	I-Disease	-1	10739826
ol@@	I-Disease	-1	10739826
ism	I-Disease	-1	10739826
(	O	-1	10739826
V@@	B-Disease	D054556	10739826
T@@	I-Disease	-1	10739826
E	I-Disease	-1	10739826
)	O	-1	10739826
associated	O	-1	10739826
with	O	-1	10739826
ne@@	O	-1	10739826
w@@	O	-1	10739826
er	O	-1	10739826
oral	B-Chemical	D003276	10739826
contrac@@	I-Chemical	-1	10739826
ep@@	I-Chemical	-1	10739826
tiv@@	I-Chemical	-1	10739826
es	I-Chemical	-1	10739826
(	O	-1	10739826
O@@	B-Chemical	D003276	10739826
C	I-Chemical	-1	10739826
)	O	-1	10739826
did	O	-1	10739826
not	O	-1	10739826
dist@@	O	-1	10739826
ing@@	O	-1	10739826
u@@	O	-1	10739826
is@@	O	-1	10739826
h	O	-1	10739826
between	O	-1	10739826
pat@@	O	-1	10739826
tern@@	O	-1	10739826
s	O	-1	10739826
of	O	-1	10739826
O@@	B-Chemical	D003276	10739826
C	I-Chemical	-1	10739826
use@@	O	-1	10739826
,	O	-1	10739826
n@@	O	-1	10739826
ame@@	O	-1	10739826
ly	O	-1	10739826
fir@@	O	-1	10739826
st@@	O	-1	10739826
-@@	O	-1	10739826
time	O	-1	10739826
us@@	O	-1	10739826
er@@	O	-1	10739826
s,	O	-1	10739826
repe@@	O	-1	10739826
at@@	O	-1	10739826
ers	O	-1	10739826
and	O	-1	10739826
switch@@	O	-1	10739826
ers.	O	-1	10739826
D@@	O	-1	10739826
at@@	O	-1	10739826
a	O	-1	10739826
from	O	-1	10739826
a	O	-1	10739826
T@@	O	-1	10739826
ran@@	O	-1	10739826
s@@	O	-1	10739826
n@@	O	-1	10739826
ation@@	O	-1	10739826
al	O	-1	10739826
cas@@	O	-1	10739826
e-@@	O	-1	10739826
control	O	-1	10739826
study	O	-1	10739826
were	O	-1	10739826
used	O	-1	10739826
to	O	-1	10739826
ass@@	O	-1	10739826
ess	O	-1	10739826
the	O	-1	10739826
risk	O	-1	10739826
of	O	-1	10739826
V@@	B-Disease	D054556	10739826
T@@	I-Disease	-1	10739826
E	I-Disease	-1	10739826
for	O	-1	10739826
the	O	-1	10739826
lat@@	O	-1	10739826
ter	O	-1	10739826
pat@@	O	-1	10739826
tern@@	O	-1	10739826
s	O	-1	10739826
of	O	-1	10739826
use@@	O	-1	10739826
,	O	-1	10739826
while	O	-1	10739826
ac@@	O	-1	10739826
coun@@	O	-1	10739826
ting	O	-1	10739826
for	O	-1	10739826
duration	O	-1	10739826
of	O	-1	10739826
use.	O	-1	10739826
O@@	O	-1	10739826
ver	O	-1	10739826
the	O	-1	10739826
period	O	-1	10739826
19@@	O	-1	10739826
9@@	O	-1	10739826
3@@	O	-1	10739826
-1@@	O	-1	10739826
9@@	O	-1	10739826
9@@	O	-1	10739826
6,	O	-1	10739826
55@@	O	-1	10739826
1	O	-1	10739826
cases	O	-1	10739826
of	O	-1	10739826
V@@	B-Disease	D054556	10739826
T@@	I-Disease	-1	10739826
E	I-Disease	-1	10739826
were	O	-1	10739826
identi@@	O	-1	10739826
fied	O	-1	10739826
in	O	-1	10739826
G@@	O	-1	10739826
er@@	O	-1	10739826
man@@	O	-1	10739826
y	O	-1	10739826
and	O	-1	10739826
the	O	-1	10739826
U@@	O	-1	10739826
K	O	-1	10739826
al@@	O	-1	10739826
ong	O	-1	10739826
with	O	-1	10739826
20@@	O	-1	10739826
6@@	O	-1	10739826
6	O	-1	10739826
controls.	O	-1	10739826
T@@	O	-1	10739826
ot@@	O	-1	10739826
als	O	-1	10739826
of	O	-1	10739826
12@@	O	-1	10739826
8	O	-1	10739826
cases	O	-1	10739826
and	O	-1	10739826
6@@	O	-1	10739826
50	O	-1	10739826
controls	O	-1	10739826
were	O	-1	10739826
an@@	O	-1	10739826
al@@	O	-1	10739826
ys@@	O	-1	10739826
ed	O	-1	10739826
for	O	-1	10739826
repe@@	O	-1	10739826
at	O	-1	10739826
use	O	-1	10739826
and	O	-1	10739826
13@@	O	-1	10739826
5	O	-1	10739826
cases	O	-1	10739826
and	O	-1	10739826
6@@	O	-1	10739826
2@@	O	-1	10739826
2	O	-1	10739826
controls	O	-1	10739826
for	O	-1	10739826
switch@@	O	-1	10739826
ing	O	-1	10739826
pat@@	O	-1	10739826
tern@@	O	-1	10739826
s.	O	-1	10739826
The	O	-1	10739826
adjust@@	O	-1	10739826
ed	O	-1	10739826
rate	O	-1	10739826
rati@@	O	-1	10739826
o	O	-1	10739826
of	O	-1	10739826
V@@	B-Disease	D054556	10739826
T@@	I-Disease	-1	10739826
E	I-Disease	-1	10739826
for	O	-1	10739826
repe@@	O	-1	10739826
at	O	-1	10739826
users	O	-1	10739826
of	O	-1	10739826
thir@@	O	-1	10739826
d	O	-1	10739826
generation	O	-1	10739826
O@@	B-Chemical	D003276	10739826
C	I-Chemical	-1	10739826
was	O	-1	10739826
0.@@	O	-1	10739826
6	O	-1	10739826
(@@	O	-1	10739826
95%	O	-1	10739826
CI@@	O	-1	10739826
:@@	O	-1	10739826
0.@@	O	-1	10739826
3-@@	O	-1	10739826
1.@@	O	-1	10739826
2)	O	-1	10739826
rel@@	O	-1	10739826
ative	O	-1	10739826
to	O	-1	10739826
repe@@	O	-1	10739826
at	O	-1	10739826
users	O	-1	10739826
of	O	-1	10739826
second	O	-1	10739826
generation	O	-1	10739826
p@@	O	-1	10739826
ill@@	O	-1	10739826
s,	O	-1	10739826
whereas	O	-1	10739826
it	O	-1	10739826
was	O	-1	10739826
1.@@	O	-1	10739826
3	O	-1	10739826
(@@	O	-1	10739826
95%	O	-1	10739826
CI@@	O	-1	10739826
:@@	O	-1	10739826
0.@@	O	-1	10739826
7-@@	O	-1	10739826
2.@@	O	-1	10739826
4@@	O	-1	10739826
)	O	-1	10739826
for	O	-1	10739826
switch@@	O	-1	10739826
ers	O	-1	10739826
from	O	-1	10739826
second	O	-1	10739826
to	O	-1	10739826
thir@@	O	-1	10739826
d	O	-1	10739826
generation	O	-1	10739826
p@@	O	-1	10739826
ill@@	O	-1	10739826
s	O	-1	10739826
rel@@	O	-1	10739826
ative	O	-1	10739826
to	O	-1	10739826
switch@@	O	-1	10739826
ers	O	-1	10739826
from	O	-1	10739826
thir@@	O	-1	10739826
d	O	-1	10739826
to	O	-1	10739826
second	O	-1	10739826
generation	O	-1	10739826
p@@	O	-1	10739826
ill@@	O	-1	10739826
s.	O	-1	10739826
We	O	-1	10739826
concl@@	O	-1	10739826
ude	O	-1	10739826
that	O	-1	10739826
second	O	-1	10739826
and	O	-1	10739826
thir@@	O	-1	10739826
d	O	-1	10739826
generation	O	-1	10739826
agents	O	-1	10739826
are	O	-1	10739826
associated	O	-1	10739826
with	O	-1	10739826
equ@@	O	-1	10739826
i@@	O	-1	10739826
val@@	O	-1	10739826
ent	O	-1	10739826
ris@@	O	-1	10739826
k@@	O	-1	10739826
s	O	-1	10739826
of	O	-1	10739826
V@@	B-Disease	D054556	10739826
T@@	I-Disease	-1	10739826
E	I-Disease	-1	10739826
when	O	-1	10739826
the	O	-1	10739826
same	O	-1	10739826
agent	O	-1	10739826
is	O	-1	10739826
used	O	-1	10739826
repe@@	O	-1	10739826
ated@@	O	-1	10739826
ly	O	-1	10739826
after	O	-1	10739826
inter@@	O	-1	10739826
ru@@	O	-1	10739826
ption	O	-1	10739826
perio@@	O	-1	10739826
ds	O	-1	10739826
or	O	-1	10739826
when	O	-1	10739826
users	O	-1	10739826
are	O	-1	10739826
switch@@	O	-1	10739826
ed	O	-1	10739826
between	O	-1	10739826
the	O	-1	10739826
two	O	-1	10739826
gener@@	O	-1	10739826
ations	O	-1	10739826
of	O	-1	10739826
p@@	O	-1	10739826
ill@@	O	-1	10739826
s.	O	-1	10739826
These	O	-1	10739826
analy@@	O	-1	10739826
ses	O	-1	10739826
suggest	O	-1	10739826
that	O	-1	10739826
the	O	-1	10739826
higher	O	-1	10739826
risk	O	-1	10739826
observed	O	-1	10739826
for	O	-1	10739826
the	O	-1	10739826
ne@@	O	-1	10739826
w@@	O	-1	10739826
er	O	-1	10739826
O@@	B-Chemical	D003276	10739826
C	I-Chemical	-1	10739826
in	O	-1	10739826
other	O	-1	10739826
studies	O	-1	10739826
may	O	-1	10739826
be	O	-1	10739826
the	O	-1	10739826
result	O	-1	10739826
of	O	-1	10739826
in@@	O	-1	10739826
ade@@	O	-1	10739826
qu@@	O	-1	10739826
ate	O	-1	10739826
compar@@	O	-1	10739826
is@@	O	-1	10739826
ons	O	-1	10739826
of	O	-1	10739826
p@@	O	-1	10739826
il@@	O	-1	10739826
l	O	-1	10739826
users	O	-1	10739826
with	O	-1	10739826
different	O	-1	10739826
pat@@	O	-1	10739826
tern@@	O	-1	10739826
s	O	-1	10739826
of	O	-1	10739826
p@@	O	-1	10739826
il@@	O	-1	10739826
l	O	-1	10739826
use.	O	-1	10739826

De@@	O	-1	10791295
ve@@	O	-1	10791295
lop@@	O	-1	10791295
ment	O	-1	10791295
of	O	-1	10791295
apo@@	B-Chemical	D001058	10791295
morphine	I-Chemical	-1	10791295
-induced	O	-1	10791295
ag@@	B-Disease	D010554	10791295
gres@@	I-Disease	-1	10791295
sive	I-Disease	-1	10791295
behavi@@	I-Disease	-1	10791295
or	I-Disease	-1	10791295
:	O	-1	10791295
compar@@	O	-1	10791295
ison	O	-1	10791295
of	O	-1	10791295
ad@@	O	-1	10791295
ult	O	-1	10791295
male	O	-1	10791295
and	O	-1	10791295
female	O	-1	10791295
Wistar	O	-1	10791295
rats.	O	-1	10791295
The	O	-1	10791295
development	O	-1	10791295
of	O	-1	10791295
apo@@	B-Chemical	D001058	10791295
morphine	I-Chemical	-1	10791295
-induced	O	-1	10791295
(1@@	O	-1	10791295
.@@	O	-1	10791295
0	O	-1	10791295
mg/kg	O	-1	10791295
s@@	O	-1	10791295
.@@	O	-1	10791295
c@@	O	-1	10791295
.	O	-1	10791295
on@@	O	-1	10791295
ce	O	-1	10791295
da@@	O	-1	10791295
il@@	O	-1	10791295
y@@	O	-1	10791295
)	O	-1	10791295
ag@@	B-Disease	D010554	10791295
gres@@	I-Disease	-1	10791295
sive	I-Disease	-1	10791295
behavi@@	I-Disease	-1	10791295
or	I-Disease	-1	10791295
of	O	-1	10791295
ad@@	O	-1	10791295
ult	O	-1	10791295
male	O	-1	10791295
and	O	-1	10791295
female	O	-1	10791295
Wistar	O	-1	10791295
rats	O	-1	10791295
obtained	O	-1	10791295
from	O	-1	10791295
the	O	-1	10791295
same	O	-1	10791295
b@@	O	-1	10791295
re@@	O	-1	10791295
ed@@	O	-1	10791295
er	O	-1	10791295
was	O	-1	10791295
studied	O	-1	10791295
in	O	-1	10791295
two	O	-1	10791295
con@@	O	-1	10791295
sec@@	O	-1	10791295
utive	O	-1	10791295
se@@	O	-1	10791295
t@@	O	-1	10791295
s.	O	-1	10791295
In	O	-1	10791295
male	O	-1	10791295
anim@@	O	-1	10791295
al@@	O	-1	10791295
s,	O	-1	10791295
repe@@	O	-1	10791295
ated	O	-1	10791295
apo@@	B-Chemical	D001058	10791295
morphine	I-Chemical	-1	10791295
treatment	O	-1	10791295
induced	O	-1	10791295
a	O	-1	10791295
gra@@	O	-1	10791295
du@@	O	-1	10791295
al	O	-1	10791295
development	O	-1	10791295
of	O	-1	10791295
ag@@	B-Disease	D010554	10791295
gres@@	I-Disease	-1	10791295
sive	I-Disease	-1	10791295
behavi@@	I-Disease	-1	10791295
or	I-Disease	-1	10791295
as	O	-1	10791295
ev@@	O	-1	10791295
id@@	O	-1	10791295
enc@@	O	-1	10791295
ed	O	-1	10791295
by	O	-1	10791295
the	O	-1	10791295
increased	O	-1	10791295
int@@	O	-1	10791295
ensity	O	-1	10791295
of	O	-1	10791295
ag@@	B-Disease	D010554	10791295
gres@@	I-Disease	-1	10791295
si@@	I-Disease	-1	10791295
ven@@	I-Disease	-1	10791295
ess	I-Disease	-1	10791295
and	O	-1	10791295
sh@@	O	-1	10791295
or@@	O	-1	10791295
ten@@	O	-1	10791295
ed	O	-1	10791295
lat@@	O	-1	10791295
ency	O	-1	10791295
before	O	-1	10791295
the	O	-1	10791295
first	O	-1	10791295
at@@	O	-1	10791295
tac@@	O	-1	10791295
k	O	-1	10791295
to@@	O	-1	10791295
war@@	O	-1	10791295
d	O	-1	10791295
the	O	-1	10791295
op@@	O	-1	10791295
p@@	O	-1	10791295
on@@	O	-1	10791295
ent@@	O	-1	10791295
.	O	-1	10791295
In	O	-1	10791295
female	O	-1	10791295
rats,	O	-1	10791295
only	O	-1	10791295
a	O	-1	10791295
we@@	O	-1	10791295
a@@	O	-1	10791295
k	O	-1	10791295
ten@@	O	-1	10791295
d@@	O	-1	10791295
ency	O	-1	10791295
to@@	O	-1	10791295
war@@	O	-1	10791295
d	O	-1	10791295
ag@@	B-Disease	D010554	10791295
gres@@	I-Disease	-1	10791295
si@@	I-Disease	-1	10791295
ven@@	I-Disease	-1	10791295
ess	I-Disease	-1	10791295
was	O	-1	10791295
f@@	O	-1	10791295
oun@@	O	-1	10791295
d.	O	-1	10791295
In	O	-1	10791295
concl@@	O	-1	10791295
u@@	O	-1	10791295
sion,	O	-1	10791295
the	O	-1	10791295
present	O	-1	10791295
study	O	-1	10791295
demon@@	O	-1	10791295
strat@@	O	-1	10791295
es	O	-1	10791295
gen@@	O	-1	10791295
der	O	-1	10791295
differences	O	-1	10791295
in	O	-1	10791295
the	O	-1	10791295
development	O	-1	10791295
of	O	-1	10791295
the	O	-1	10791295
apo@@	B-Chemical	D001058	10791295
morphine	I-Chemical	-1	10791295
-induced	O	-1	10791295
ag@@	B-Disease	D010554	10791295
gres@@	I-Disease	-1	10791295
sive	I-Disease	-1	10791295
behavi@@	I-Disease	-1	10791295
or	I-Disease	-1	10791295
and	O	-1	10791295
indic@@	O	-1	10791295
ates	O	-1	10791295
that	O	-1	10791295
the	O	-1	10791295
female	O	-1	10791295
rats	O	-1	10791295
d@@	O	-1	10791295
o	O	-1	10791295
not	O	-1	10791295
f@@	O	-1	10791295
il@@	O	-1	10791295
l	O	-1	10791295
the	O	-1	10791295
val@@	O	-1	10791295
id@@	O	-1	10791295
ation	O	-1	10791295
c@@	O	-1	10791295
rit@@	O	-1	10791295
er@@	O	-1	10791295
ia	O	-1	10791295
for	O	-1	10791295
use	O	-1	10791295
in	O	-1	10791295
this	O	-1	10791295
meth@@	O	-1	10791295
o@@	O	-1	10791295
d.	O	-1	10791295

S@@	B-Chemical	D018490	11147747
er@@	I-Chemical	-1	11147747
oton@@	I-Chemical	-1	11147747
ergic	I-Chemical	-1	11147747
antidepress@@	I-Chemical	-1	11147747
ants	I-Chemical	-1	11147747
and	O	-1	11147747
urinary	B-Disease	D014549	11147747
in@@	I-Disease	-1	11147747
contin@@	I-Disease	-1	11147747
ence	I-Disease	-1	11147747
.	O	-1	11147747
M@@	O	-1	11147747
any	O	-1	11147747
new	O	-1	11147747
seroton@@	B-Chemical	D018490	11147747
ergic	I-Chemical	-1	11147747
antidepress@@	I-Chemical	-1	11147747
ants	I-Chemical	-1	11147747
have	O	-1	11147747
been	O	-1	11147747
int@@	O	-1	11147747
ro@@	O	-1	11147747
duced	O	-1	11147747
over	O	-1	11147747
the	O	-1	11147747
p@@	O	-1	11147747
ast	O	-1	11147747
dec@@	O	-1	11147747
ade@@	O	-1	11147747
.	O	-1	11147747
Although	O	-1	11147747
urinary	B-Disease	D014549	11147747
in@@	I-Disease	-1	11147747
contin@@	I-Disease	-1	11147747
ence	I-Disease	-1	11147747
is	O	-1	11147747
li@@	O	-1	11147747
st@@	O	-1	11147747
ed	O	-1	11147747
as	O	-1	11147747
one	O	-1	11147747
side	O	-1	11147747
effect	O	-1	11147747
of	O	-1	11147747
these	O	-1	11147747
drugs	O	-1	11147747
in	O	-1	11147747
their	O	-1	11147747
pac@@	O	-1	11147747
k@@	O	-1	11147747
age	O	-1	11147747
in@@	O	-1	11147747
ser@@	O	-1	11147747
ts	O	-1	11147747
there	O	-1	11147747
is	O	-1	11147747
only	O	-1	11147747
one	O	-1	11147747
report	O	-1	11147747
in	O	-1	11147747
the	O	-1	11147747
literat@@	O	-1	11147747
ure.	O	-1	11147747
This	O	-1	11147747
con@@	O	-1	11147747
cer@@	O	-1	11147747
n@@	O	-1	11147747
s	O	-1	11147747
2	O	-1	11147747
male	O	-1	11147747
patients	O	-1	11147747
who	O	-1	11147747
experienced	O	-1	11147747
in@@	B-Disease	D014549	11147747
contin@@	I-Disease	-1	11147747
ence	I-Disease	-1	11147747
while	O	-1	11147747
taking	O	-1	11147747
ven@@	B-Chemical	C047426	11147747
l@@	I-Chemical	-1	11147747
af@@	I-Chemical	-1	11147747
ax@@	I-Chemical	-1	11147747
ine	I-Chemical	-1	11147747
.	O	-1	11147747
In	O	-1	11147747
the	O	-1	11147747
present	O	-1	11147747
pap@@	O	-1	11147747
er	O	-1	11147747
the	O	-1	11147747
au@@	O	-1	11147747
th@@	O	-1	11147747
ors	O	-1	11147747
describe	O	-1	11147747
2	O	-1	11147747
female	O	-1	11147747
patients	O	-1	11147747
who	O	-1	11147747
developed	O	-1	11147747
in@@	B-Disease	D014549	11147747
contin@@	I-Disease	-1	11147747
ence	I-Disease	-1	11147747
secondary	O	-1	11147747
to	O	-1	11147747
the	O	-1	11147747
selective	O	-1	11147747
seroton@@	B-Chemical	D012701	11147747
in	I-Chemical	-1	11147747
re@@	O	-1	11147747
u@@	O	-1	11147747
pt@@	O	-1	11147747
ake	O	-1	11147747
inhibitors	O	-1	11147747
pa@@	B-Chemical	D017374	11147747
ro@@	I-Chemical	-1	11147747
x@@	I-Chemical	-1	11147747
et@@	I-Chemical	-1	11147747
ine	I-Chemical	-1	11147747
and	O	-1	11147747
ser@@	B-Chemical	D020280	11147747
tr@@	I-Chemical	-1	11147747
aline	I-Chemical	-1	11147747
,	O	-1	11147747
as	O	-1	11147747
well	O	-1	11147747
as	O	-1	11147747
a	O	-1	11147747
thir@@	O	-1	11147747
d	O	-1	11147747
who	O	-1	11147747
developed	O	-1	11147747
this	O	-1	11147747
side	O	-1	11147747
effect	O	-1	11147747
on	O	-1	11147747
ven@@	B-Chemical	C047426	11147747
l@@	I-Chemical	-1	11147747
af@@	I-Chemical	-1	11147747
ax@@	I-Chemical	-1	11147747
ine	I-Chemical	-1	11147747
.	O	-1	11147747
In	O	-1	11147747
2	O	-1	11147747
of	O	-1	11147747
the	O	-1	11147747
3	O	-1	11147747
cases	O	-1	11147747
the	O	-1	11147747
patients	O	-1	11147747
were	O	-1	11147747
also	O	-1	11147747
taking	O	-1	11147747
lithium	B-Chemical	D016651	11147747
carb@@	I-Chemical	-1	11147747
on@@	I-Chemical	-1	11147747
ate	I-Chemical	-1	11147747
and	O	-1	11147747
beta-@@	O	-1	11147747
block@@	O	-1	11147747
er@@	O	-1	11147747
s,	O	-1	11147747
both	O	-1	11147747
of	O	-1	11147747
which	O	-1	11147747
could	O	-1	11147747
have	O	-1	11147747
cont@@	O	-1	11147747
ri@@	O	-1	11147747
but@@	O	-1	11147747
ed	O	-1	11147747
to	O	-1	11147747
the	O	-1	11147747
in@@	B-Disease	D014549	11147747
contin@@	I-Disease	-1	11147747
ence	I-Disease	-1	11147747
.	O	-1	11147747
An@@	O	-1	11147747
im@@	O	-1	11147747
al	O	-1	11147747
studies	O	-1	11147747
suggest	O	-1	11147747
that	O	-1	11147747
in@@	B-Disease	D014549	11147747
contin@@	I-Disease	-1	11147747
ence	I-Disease	-1	11147747
secondary	O	-1	11147747
to	O	-1	11147747
seroton@@	B-Chemical	D018490	11147747
ergic	I-Chemical	-1	11147747
antidepress@@	I-Chemical	-1	11147747
ants	I-Chemical	-1	11147747
could	O	-1	11147747
be	O	-1	11147747
mediated	O	-1	11147747
by	O	-1	11147747
the	O	-1	11147747
5@@	O	-1	11147747
H@@	O	-1	11147747
T@@	O	-1	11147747
4	O	-1	11147747
receptors	O	-1	11147747
found	O	-1	11147747
on	O	-1	11147747
the	O	-1	11147747
blad@@	O	-1	11147747
der@@	O	-1	11147747
.	O	-1	11147747
F@@	O	-1	11147747
urther	O	-1	11147747
re@@	O	-1	11147747
se@@	O	-1	11147747
arc@@	O	-1	11147747
h	O	-1	11147747
is	O	-1	11147747
ne@@	O	-1	11147747
ed@@	O	-1	11147747
ed	O	-1	11147747
to	O	-1	11147747
del@@	O	-1	11147747
ine@@	O	-1	11147747
ate	O	-1	11147747
the	O	-1	11147747
frequency	O	-1	11147747
of	O	-1	11147747
this	O	-1	11147747
t@@	O	-1	11147747
rou@@	O	-1	11147747
bl@@	O	-1	11147747
ing	O	-1	11147747
side	O	-1	11147747
effect	O	-1	11147747
and	O	-1	11147747
ho@@	O	-1	11147747
w	O	-1	11147747
b@@	O	-1	11147747
est	O	-1	11147747
to	O	-1	11147747
tre@@	O	-1	11147747
at	O	-1	11147747
it@@	O	-1	11147747
.	O	-1	11147747

H@@	B-Disease	D007022	11198499
y@@	I-Disease	-1	11198499
poten@@	I-Disease	-1	11198499
sion	I-Disease	-1	11198499
following	O	-1	11198499
the	O	-1	11198499
initi@@	O	-1	11198499
ation	O	-1	11198499
of	O	-1	11198499
tiz@@	B-Chemical	C023754	11198499
an@@	I-Chemical	-1	11198499
idine	I-Chemical	-1	11198499
in	O	-1	11198499
a	O	-1	11198499
patient	O	-1	11198499
treated	O	-1	11198499
with	O	-1	11198499
an	O	-1	11198499
angiotens@@	B-Chemical	D000809	11198499
in	I-Chemical	-1	11198499
conver@@	O	-1	11198499
ting	O	-1	11198499
enzyme	O	-1	11198499
inhibitor	O	-1	11198499
for	O	-1	11198499
chronic	O	-1	11198499
hypertension	B-Disease	D006973	11198499
.	O	-1	11198499
C@@	O	-1	11198499
entr@@	O	-1	11198499
ally	O	-1	11198499
act@@	O	-1	11198499
ing	O	-1	11198499
alpha-@@	O	-1	11198499
2	O	-1	11198499
adrenergic	O	-1	11198499
agon@@	O	-1	11198499
ist@@	O	-1	11198499
s	O	-1	11198499
are	O	-1	11198499
one	O	-1	11198499
of	O	-1	11198499
several	O	-1	11198499
pharmac@@	O	-1	11198499
ologic	O	-1	11198499
agents	O	-1	11198499
used	O	-1	11198499
in	O	-1	11198499
the	O	-1	11198499
treatment	O	-1	11198499
of	O	-1	11198499
sp@@	B-Disease	D009128	11198499
as@@	I-Disease	-1	11198499
tic@@	I-Disease	-1	11198499
ity	I-Disease	-1	11198499
related	O	-1	11198499
to	O	-1	11198499
disorder@@	B-Disease	D002493	11198499
s	I-Disease	-1	11198499
of	I-Disease	-1	11198499
the	I-Disease	-1	11198499
central	I-Disease	-1	11198499
ner@@	I-Disease	-1	11198499
v@@	I-Disease	-1	11198499
ous	I-Disease	-1	11198499
system	I-Disease	-1	11198499
.	O	-1	11198499
In	O	-1	11198499
addition	O	-1	11198499
to	O	-1	11198499
their	O	-1	11198499
effects	O	-1	11198499
on	O	-1	11198499
sp@@	B-Disease	D009128	11198499
as@@	I-Disease	-1	11198499
tic@@	I-Disease	-1	11198499
ity	I-Disease	-1	11198499
,	O	-1	11198499
cer@@	O	-1	11198499
t@@	O	-1	11198499
ain	O	-1	11198499
adverse	O	-1	11198499
cardio@@	O	-1	11198499
respiratory	O	-1	11198499
effects	O	-1	11198499
have	O	-1	11198499
been	O	-1	11198499
repor@@	O	-1	11198499
ted.	O	-1	11198499
Ad@@	O	-1	11198499
ult@@	O	-1	11198499
s	O	-1	11198499
chron@@	O	-1	11198499
ically	O	-1	11198499
treated	O	-1	11198499
with	O	-1	11198499
angiotens@@	B-Chemical	D000809	11198499
in	I-Chemical	-1	11198499
conver@@	O	-1	11198499
ting	O	-1	11198499
enzyme	O	-1	11198499
inhibitors	O	-1	11198499
may	O	-1	11198499
have	O	-1	11198499
a	O	-1	11198499
lim@@	O	-1	11198499
ited	O	-1	11198499
ability	O	-1	11198499
to	O	-1	11198499
respon@@	O	-1	11198499
d	O	-1	11198499
to	O	-1	11198499
hypotension	B-Disease	D007022	11198499
when	O	-1	11198499
the	O	-1	11198499
sym@@	O	-1	11198499
pa@@	O	-1	11198499
thetic	O	-1	11198499
response	O	-1	11198499
is	O	-1	11198499
sim@@	O	-1	11198499
ult@@	O	-1	11198499
ane@@	O	-1	11198499
ously	O	-1	11198499
block@@	O	-1	11198499
ed.	O	-1	11198499
The	O	-1	11198499
au@@	O	-1	11198499
th@@	O	-1	11198499
ors	O	-1	11198499
present	O	-1	11198499
a	O	-1	11198499
10-@@	O	-1	11198499
year-old	O	-1	11198499
bo@@	O	-1	11198499
y	O	-1	11198499
chron@@	O	-1	11198499
ically	O	-1	11198499
treated	O	-1	11198499
with	O	-1	11198499
l@@	B-Chemical	D017706	11198499
is@@	I-Chemical	-1	11198499
ino@@	I-Chemical	-1	11198499
pri@@	I-Chemical	-1	11198499
l	I-Chemical	-1	11198499
,	O	-1	11198499
an	O	-1	11198499
angiotens@@	B-Chemical	D000809	11198499
in	I-Chemical	-1	11198499
conver@@	O	-1	11198499
ting	O	-1	11198499
enzyme	O	-1	11198499
inhibitor@@	O	-1	11198499
,	O	-1	11198499
to	O	-1	11198499
control	O	-1	11198499
hypertension	B-Disease	D006973	11198499
who	O	-1	11198499
developed	O	-1	11198499
hypotension	B-Disease	D007022	11198499
following	O	-1	11198499
the	O	-1	11198499
addition	O	-1	11198499
of	O	-1	11198499
tiz@@	B-Chemical	C023754	11198499
an@@	I-Chemical	-1	11198499
idine	I-Chemical	-1	11198499
,	O	-1	11198499
an	O	-1	11198499
alpha-@@	O	-1	11198499
2	O	-1	11198499
agon@@	O	-1	11198499
ist@@	O	-1	11198499
,	O	-1	11198499
for	O	-1	11198499
the	O	-1	11198499
treatment	O	-1	11198499
of	O	-1	11198499
sp@@	B-Disease	D009128	11198499
as@@	I-Disease	-1	11198499
tic@@	I-Disease	-1	11198499
ity	I-Disease	-1	11198499
.	O	-1	11198499
The	O	-1	11198499
possible	O	-1	11198499
inter@@	O	-1	11198499
action	O	-1	11198499
of	O	-1	11198499
tiz@@	B-Chemical	C023754	11198499
an@@	I-Chemical	-1	11198499
idine	I-Chemical	-1	11198499
and	O	-1	11198499
other	O	-1	11198499
anti@@	O	-1	11198499
hypertensive	O	-1	11198499
agents	O	-1	11198499
should	O	-1	11198499
be	O	-1	11198499
k@@	O	-1	11198499
ep@@	O	-1	11198499
t	O	-1	11198499
in	O	-1	11198499
min@@	O	-1	11198499
d	O	-1	11198499
when	O	-1	11198499
prescri@@	O	-1	11198499
b@@	O	-1	11198499
ing	O	-1	11198499
therapy	O	-1	11198499
to	O	-1	11198499
tre@@	O	-1	11198499
at	O	-1	11198499
either	O	-1	11198499
hypertension	B-Disease	D006973	11198499
or	O	-1	11198499
sp@@	B-Disease	D009128	11198499
as@@	I-Disease	-1	11198499
tic@@	I-Disease	-1	11198499
ity	I-Disease	-1	11198499
in	O	-1	11198499
such	O	-1	11198499
patients.	O	-1	11198499

P@@	O	-1	11391224
er@@	O	-1	11391224
it@@	O	-1	11391224
ub@@	O	-1	11391224
ular	O	-1	11391224
cap@@	O	-1	11391224
ill@@	O	-1	11391224
ary	O	-1	11391224
bas@@	O	-1	11391224
ement	O	-1	11391224
membran@@	O	-1	11391224
e	O	-1	11391224
re@@	O	-1	11391224
du@@	O	-1	11391224
plic@@	O	-1	11391224
ation	O	-1	11391224
in	O	-1	11391224
allogra@@	O	-1	11391224
f@@	O	-1	11391224
ts	O	-1	11391224
and	O	-1	11391224
n@@	O	-1	11391224
ative	O	-1	11391224
kidney	B-Disease	D007674	11391224
disease	I-Disease	-1	11391224
:	O	-1	11391224
a	O	-1	11391224
clin@@	O	-1	11391224
ic@@	O	-1	11391224
o@@	O	-1	11391224
path@@	O	-1	11391224
ologic	O	-1	11391224
study	O	-1	11391224
of	O	-1	11391224
27@@	O	-1	11391224
8	O	-1	11391224
con@@	O	-1	11391224
sec@@	O	-1	11391224
utive	O	-1	11391224
renal	O	-1	11391224
spec@@	O	-1	11391224
imen@@	O	-1	11391224
s.	O	-1	11391224
BACKGROUND:	O	-1	11391224
An	O	-1	11391224
association	O	-1	11391224
has	O	-1	11391224
been	O	-1	11391224
found	O	-1	11391224
between	O	-1	11391224
transplant	B-Disease	D007674	11391224
glomer@@	I-Disease	-1	11391224
ulo@@	I-Disease	-1	11391224
pathy	I-Disease	-1	11391224
(	O	-1	11391224
T@@	B-Disease	D007674	11391224
G	I-Disease	-1	11391224
)	O	-1	11391224
and	O	-1	11391224
re@@	O	-1	11391224
du@@	O	-1	11391224
plic@@	O	-1	11391224
ation	O	-1	11391224
of	O	-1	11391224
per@@	O	-1	11391224
it@@	O	-1	11391224
ub@@	O	-1	11391224
ular	O	-1	11391224
cap@@	O	-1	11391224
ill@@	O	-1	11391224
ary	O	-1	11391224
bas@@	O	-1	11391224
ement	O	-1	11391224
membran@@	O	-1	11391224
es	O	-1	11391224
(P@@	O	-1	11391224
T@@	O	-1	11391224
CR@@	O	-1	11391224
).	O	-1	11391224
Although	O	-1	11391224
such	O	-1	11391224
an	O	-1	11391224
association	O	-1	11391224
is	O	-1	11391224
of	O	-1	11391224
p@@	O	-1	11391224
rac@@	O	-1	11391224
tical	O	-1	11391224
and	O	-1	11391224
the@@	O	-1	11391224
ore@@	O	-1	11391224
tical	O	-1	11391224
import@@	O	-1	11391224
ance@@	O	-1	11391224
,	O	-1	11391224
only	O	-1	11391224
one	O	-1	11391224
pro@@	O	-1	11391224
sp@@	O	-1	11391224
ective	O	-1	11391224
study	O	-1	11391224
has	O	-1	11391224
tri@@	O	-1	11391224
ed	O	-1	11391224
to	O	-1	11391224
con@@	O	-1	11391224
fir@@	O	-1	11391224
m	O	-1	11391224
it@@	O	-1	11391224
.	O	-1	11391224
METHODS:	O	-1	11391224
We	O	-1	11391224
examined	O	-1	11391224
27@@	O	-1	11391224
8	O	-1	11391224
con@@	O	-1	11391224
sec@@	O	-1	11391224
utive	O	-1	11391224
renal	O	-1	11391224
spec@@	O	-1	11391224
imen@@	O	-1	11391224
s	O	-1	11391224
(@@	O	-1	11391224
from	O	-1	11391224
13@@	O	-1	11391224
5	O	-1	11391224
transplant@@	O	-1	11391224
s	O	-1	11391224
and	O	-1	11391224
14@@	O	-1	11391224
3	O	-1	11391224
n@@	O	-1	11391224
ative	O	-1	11391224
kidne@@	O	-1	11391224
ys@@	O	-1	11391224
)	O	-1	11391224
for	O	-1	11391224
ult@@	O	-1	11391224
ra@@	O	-1	11391224
struct@@	O	-1	11391224
ural	O	-1	11391224
evidence	O	-1	11391224
of	O	-1	11391224
P@@	O	-1	11391224
T@@	O	-1	11391224
CR@@	O	-1	11391224
.	O	-1	11391224
In	O	-1	11391224
addition	O	-1	11391224
to	O	-1	11391224
renal	O	-1	11391224
allogra@@	O	-1	11391224
f@@	O	-1	11391224
ts	O	-1	11391224
with	O	-1	11391224
T@@	B-Disease	D007674	11391224
G	I-Disease	-1	11391224
,	O	-1	11391224
we	O	-1	11391224
also	O	-1	11391224
examined	O	-1	11391224
gra@@	O	-1	11391224
f@@	O	-1	11391224
ts	O	-1	11391224
with	O	-1	11391224
acute	O	-1	11391224
re@@	O	-1	11391224
j@@	O	-1	11391224
ec@@	O	-1	11391224
tion,	O	-1	11391224
recur@@	O	-1	11391224
rent	O	-1	11391224
glomerul@@	B-Disease	D005921	11391224
one@@	I-Disease	-1	11391224
ph@@	I-Disease	-1	11391224
ritis	I-Disease	-1	11391224
,	O	-1	11391224
chronic	B-Disease	D051436	11391224
allogra@@	I-Disease	-1	11391224
ft	I-Disease	-1	11391224
nephro@@	I-Disease	-1	11391224
pathy	I-Disease	-1	11391224
and	O	-1	11391224
st@@	O	-1	11391224
able	O	-1	11391224
gra@@	O	-1	11391224
f@@	O	-1	11391224
ts	O	-1	11391224
(@@	O	-1	11391224
"@@	O	-1	11391224
pro@@	O	-1	11391224
to@@	O	-1	11391224
co@@	O	-1	11391224
l	O	-1	11391224
biop@@	O	-1	11391224
si@@	O	-1	11391224
es@@	O	-1	11391224
"@@	O	-1	11391224
).	O	-1	11391224
N@@	O	-1	11391224
ative	O	-1	11391224
kidney	O	-1	11391224
spec@@	O	-1	11391224
imen@@	O	-1	11391224
s	O	-1	11391224
included	O	-1	11391224
a	O	-1	11391224
w@@	O	-1	11391224
ide	O	-1	11391224
range	O	-1	11391224
of	O	-1	11391224
glomer@@	B-Disease	D007674	11391224
ulo@@	I-Disease	-1	11391224
path@@	I-Disease	-1	11391224
i@@	I-Disease	-1	11391224
es	I-Disease	-1	11391224
as	O	-1	11391224
well	O	-1	11391224
as	O	-1	11391224
cases	O	-1	11391224
of	O	-1	11391224
thrombotic	B-Disease	D057049	11391224
microangio@@	I-Disease	-1	11391224
pathy	I-Disease	-1	11391224
,	O	-1	11391224
mal@@	B-Disease	D006974	11391224
i@@	I-Disease	-1	11391224
gn@@	I-Disease	-1	11391224
ant	I-Disease	-1	11391224
hypertension	I-Disease	-1	11391224
,	O	-1	11391224
acute	O	-1	11391224
interstitial	B-Disease	D009395	11391224
neph@@	I-Disease	-1	11391224
ritis	I-Disease	-1	11391224
,	O	-1	11391224
and	O	-1	11391224
acute	B-Disease	D007683	11391224
tub@@	I-Disease	-1	11391224
ular	I-Disease	-1	11391224
necro@@	I-Disease	-1	11391224
sis	I-Disease	-1	11391224
.	O	-1	11391224
RESULTS:	O	-1	11391224
We	O	-1	11391224
found	O	-1	11391224
P@@	O	-1	11391224
T@@	O	-1	11391224
C@@	O	-1	11391224
R	O	-1	11391224
in	O	-1	11391224
14	O	-1	11391224
of	O	-1	11391224
15	O	-1	11391224
cases	O	-1	11391224
of	O	-1	11391224
T@@	B-Disease	D007674	11391224
G	I-Disease	-1	11391224
,	O	-1	11391224
in	O	-1	11391224
7	O	-1	11391224
transplant	O	-1	11391224
biop@@	O	-1	11391224
sy	O	-1	11391224
spec@@	O	-1	11391224
imen@@	O	-1	11391224
s	O	-1	11391224
without	O	-1	11391224
T@@	B-Disease	D007674	11391224
G	I-Disease	-1	11391224
,	O	-1	11391224
and	O	-1	11391224
in	O	-1	11391224
13	O	-1	11391224
of	O	-1	11391224
14@@	O	-1	11391224
3	O	-1	11391224
n@@	O	-1	11391224
ative	O	-1	11391224
kidney	O	-1	11391224
biop@@	O	-1	11391224
sy	O	-1	11391224
spec@@	O	-1	11391224
imen@@	O	-1	11391224
s.	O	-1	11391224
These	O	-1	11391224
13	O	-1	11391224
included	O	-1	11391224
cases	O	-1	11391224
of	O	-1	11391224
mal@@	B-Disease	D006974	11391224
i@@	I-Disease	-1	11391224
gn@@	I-Disease	-1	11391224
ant	I-Disease	-1	11391224
hypertension	I-Disease	-1	11391224
,	O	-1	11391224
thrombotic	B-Disease	D057049	11391224
microangio@@	I-Disease	-1	11391224
pathy	I-Disease	-1	11391224
,	O	-1	11391224
lu@@	B-Disease	D008181	11391224
p@@	I-Disease	-1	11391224
us	I-Disease	-1	11391224
neph@@	I-Disease	-1	11391224
ritis	I-Disease	-1	11391224
,	O	-1	11391224
H@@	B-Disease	D011695	11391224
en@@	I-Disease	-1	11391224
och@@	I-Disease	-1	11391224
-@@	I-Disease	-1	11391224
S@@	I-Disease	-1	11391224
ch@@	I-Disease	-1	11391224
on@@	I-Disease	-1	11391224
le@@	I-Disease	-1	11391224
in	I-Disease	-1	11391224
neph@@	I-Disease	-1	11391224
ritis	I-Disease	-1	11391224
,	O	-1	11391224
c@@	O	-1	11391224
res@@	O	-1	11391224
c@@	O	-1	11391224
en@@	O	-1	11391224
tic	O	-1	11391224
glomerul@@	B-Disease	D005921	11391224
one@@	I-Disease	-1	11391224
ph@@	I-Disease	-1	11391224
ritis	I-Disease	-1	11391224
,	O	-1	11391224
and	O	-1	11391224
cocaine	B-Chemical	D003042	11391224
-@@	O	-1	11391224
related	O	-1	11391224
acute	B-Disease	D058186	11391224
renal	I-Disease	-1	11391224
failure	I-Disease	-1	11391224
.	O	-1	11391224
M@@	O	-1	11391224
il@@	O	-1	11391224
d	O	-1	11391224
P@@	O	-1	11391224
T@@	O	-1	11391224
C@@	O	-1	11391224
R	O	-1	11391224
in	O	-1	11391224
allogra@@	O	-1	11391224
f@@	O	-1	11391224
ts	O	-1	11391224
without	O	-1	11391224
T@@	B-Disease	D007674	11391224
G	I-Disease	-1	11391224
did	O	-1	11391224
not	O	-1	11391224
predic@@	O	-1	11391224
t	O	-1	11391224
renal	B-Disease	D051437	11391224
failure	I-Disease	-1	11391224
or	O	-1	11391224
significant	O	-1	11391224
proteinuria	B-Disease	D011507	11391224
after	O	-1	11391224
follow-up	O	-1	11391224
perio@@	O	-1	11391224
ds	O	-1	11391224
of	O	-1	11391224
between	O	-1	11391224
3	O	-1	11391224
months	O	-1	11391224
and	O	-1	11391224
1	O	-1	11391224
year@@	O	-1	11391224
.	O	-1	11391224
CONCLUSIONS:	O	-1	11391224
We	O	-1	11391224
concl@@	O	-1	11391224
ude	O	-1	11391224
that	O	-1	11391224
in	O	-1	11391224
transplant@@	O	-1	11391224
s,	O	-1	11391224
there	O	-1	11391224
is	O	-1	11391224
a	O	-1	11391224
st@@	O	-1	11391224
ron@@	O	-1	11391224
g	O	-1	11391224
association	O	-1	11391224
between	O	-1	11391224
we@@	O	-1	11391224
ll@@	O	-1	11391224
-@@	O	-1	11391224
developed	O	-1	11391224
P@@	O	-1	11391224
T@@	O	-1	11391224
C@@	O	-1	11391224
R	O	-1	11391224
and	O	-1	11391224
T@@	B-Disease	D007674	11391224
G	I-Disease	-1	11391224
,	O	-1	11391224
while	O	-1	11391224
the	O	-1	11391224
signific@@	O	-1	11391224
ance	O	-1	11391224
of	O	-1	11391224
mil@@	O	-1	11391224
d	O	-1	11391224
P@@	O	-1	11391224
T@@	O	-1	11391224
C@@	O	-1	11391224
R	O	-1	11391224
and	O	-1	11391224
its	O	-1	11391224
predic@@	O	-1	11391224
tive	O	-1	11391224
valu@@	O	-1	11391224
e	O	-1	11391224
in	O	-1	11391224
the	O	-1	11391224
absence	O	-1	11391224
of	O	-1	11391224
T@@	B-Disease	D007674	11391224
G	I-Disease	-1	11391224
is	O	-1	11391224
unc@@	O	-1	11391224
lear@@	O	-1	11391224
.	O	-1	11391224
P@@	O	-1	11391224
T@@	O	-1	11391224
C@@	O	-1	11391224
R	O	-1	11391224
also	O	-1	11391224
occur@@	O	-1	11391224
s	O	-1	11391224
in	O	-1	11391224
cer@@	O	-1	11391224
t@@	O	-1	11391224
ain	O	-1	11391224
n@@	O	-1	11391224
ative	O	-1	11391224
kidney	B-Disease	D007674	11391224
diseas@@	I-Disease	-1	11391224
es	I-Disease	-1	11391224
,	O	-1	11391224
though	O	-1	11391224
the	O	-1	11391224
association	O	-1	11391224
is	O	-1	11391224
not	O	-1	11391224
as	O	-1	11391224
st@@	O	-1	11391224
ron@@	O	-1	11391224
g	O	-1	11391224
as	O	-1	11391224
that	O	-1	11391224
for	O	-1	11391224
T@@	B-Disease	D007674	11391224
G	I-Disease	-1	11391224
.	O	-1	11391224
We	O	-1	11391224
suggest	O	-1	11391224
that	O	-1	11391224
repe@@	O	-1	11391224
ated	O	-1	11391224
endothelial	B-Disease	D014947	11391224
injury	I-Disease	-1	11391224
,	O	-1	11391224
including	O	-1	11391224
immun@@	B-Disease	D007154	11391224
ologic	I-Disease	-1	11391224
injury	I-Disease	-1	11391224
,	O	-1	11391224
may	O	-1	11391224
be	O	-1	11391224
the	O	-1	11391224
cause	O	-1	11391224
of	O	-1	11391224
this	O	-1	11391224
le@@	O	-1	11391224
sion	O	-1	11391224
both	O	-1	11391224
in	O	-1	11391224
allogra@@	O	-1	11391224
f@@	O	-1	11391224
ts	O	-1	11391224
and	O	-1	11391224
n@@	O	-1	11391224
ative	O	-1	11391224
kidne@@	O	-1	11391224
y@@	O	-1	11391224
s.	O	-1	11391224

Con@@	O	-1	11426838
form@@	O	-1	11426838
ation@@	O	-1	11426838
ally	O	-1	11426838
re@@	O	-1	11426838
stric@@	O	-1	11426838
ted	O	-1	11426838
an@@	O	-1	11426838
alo@@	O	-1	11426838
g@@	O	-1	11426838
s	O	-1	11426838
of	O	-1	11426838
B@@	B-Chemical	C085527	11426838
D@@	I-Chemical	-1	11426838
10@@	I-Chemical	-1	11426838
0@@	I-Chemical	-1	11426838
8	I-Chemical	-1	11426838
and	O	-1	11426838
an	O	-1	11426838
anti@@	O	-1	11426838
sen@@	O	-1	11426838
se	O	-1	11426838
ol@@	B-Chemical	D009838	11426838
i@@	I-Chemical	-1	11426838
go@@	I-Chemical	-1	11426838
de@@	I-Chemical	-1	11426838
oxy@@	I-Chemical	-1	11426838
nucle@@	I-Chemical	-1	11426838
o@@	I-Chemical	-1	11426838
ti@@	I-Chemical	-1	11426838
de	I-Chemical	-1	11426838
t@@	O	-1	11426838
arg@@	O	-1	11426838
et@@	O	-1	11426838
ing	O	-1	11426838
si@@	O	-1	11426838
g@@	O	-1	11426838
ma@@	O	-1	11426838
1	O	-1	11426838
receptors	O	-1	11426838
produce	O	-1	11426838
anti@@	O	-1	11426838
-	O	-1	11426838
cocaine	B-Chemical	D003042	11426838
effects	O	-1	11426838
in	O	-1	11426838
mice.	O	-1	11426838
C@@	B-Chemical	D003042	11426838
oc@@	I-Chemical	-1	11426838
aine	I-Chemical	-1	11426838
's	O	-1	11426838
ability	O	-1	11426838
to	O	-1	11426838
inter@@	O	-1	11426838
ac@@	O	-1	11426838
t	O	-1	11426838
with	O	-1	11426838
si@@	O	-1	11426838
g@@	O	-1	11426838
ma	O	-1	11426838
receptors	O	-1	11426838
suggests	O	-1	11426838
that	O	-1	11426838
these	O	-1	11426838
protein@@	O	-1	11426838
s	O	-1	11426838
medi@@	O	-1	11426838
ate	O	-1	11426838
some	O	-1	11426838
of	O	-1	11426838
its	O	-1	11426838
behavioral	O	-1	11426838
effects.	O	-1	11426838
The@@	O	-1	11426838
refore,	O	-1	11426838
three	O	-1	11426838
novel	O	-1	11426838
si@@	O	-1	11426838
g@@	O	-1	11426838
ma	O	-1	11426838
receptor	O	-1	11426838
li@@	O	-1	11426838
g@@	O	-1	11426838
and@@	O	-1	11426838
s	O	-1	11426838
with	O	-1	11426838
antagonist	O	-1	11426838
activity	O	-1	11426838
were	O	-1	11426838
evaluated	O	-1	11426838
in	O	-1	11426838
S@@	O	-1	11426838
w@@	O	-1	11426838
is@@	O	-1	11426838
s	O	-1	11426838
W@@	O	-1	11426838
e@@	O	-1	11426838
b@@	O	-1	11426838
st@@	O	-1	11426838
er	O	-1	11426838
mic@@	O	-1	11426838
e@@	O	-1	11426838
:	O	-1	11426838
B@@	B-Chemical	-1	11426838
D@@	I-Chemical	-1	11426838
10@@	I-Chemical	-1	11426838
1@@	I-Chemical	-1	11426838
8	I-Chemical	-1	11426838
(	O	-1	11426838
3@@	B-Chemical	-1	11426838
S@@	I-Chemical	-1	11426838
-1@@	I-Chemical	-1	11426838
-@@	I-Chemical	-1	11426838
[@@	I-Chemical	-1	11426838
2-@@	I-Chemical	-1	11426838
(3@@	I-Chemical	-1	11426838
,@@	I-Chemical	-1	11426838
4-@@	I-Chemical	-1	11426838
dic@@	I-Chemical	-1	11426838
h@@	I-Chemical	-1	11426838
loro@@	I-Chemical	-1	11426838
phenyl@@	I-Chemical	-1	11426838
)@@	I-Chemical	-1	11426838
eth@@	I-Chemical	-1	11426838
yl@@	I-Chemical	-1	11426838
]@@	I-Chemical	-1	11426838
-1@@	I-Chemical	-1	11426838
,@@	I-Chemical	-1	11426838
4-@@	I-Chemical	-1	11426838
di@@	I-Chemical	-1	11426838
az@@	I-Chemical	-1	11426838
ab@@	I-Chemical	-1	11426838
ic@@	I-Chemical	-1	11426838
yc@@	I-Chemical	-1	11426838
lo@@	I-Chemical	-1	11426838
[@@	I-Chemical	-1	11426838
4.@@	I-Chemical	-1	11426838
3.@@	I-Chemical	-1	11426838
0@@	I-Chemical	-1	11426838
]@@	I-Chemical	-1	11426838
non@@	I-Chemical	-1	11426838
ane	I-Chemical	-1	11426838
),	O	-1	11426838
B@@	B-Chemical	C093337	11426838
D@@	I-Chemical	-1	11426838
10@@	I-Chemical	-1	11426838
6@@	I-Chemical	-1	11426838
3	I-Chemical	-1	11426838
(	O	-1	11426838
1-@@	B-Chemical	C093337	11426838
[@@	I-Chemical	-1	11426838
2-@@	I-Chemical	-1	11426838
(3@@	I-Chemical	-1	11426838
,@@	I-Chemical	-1	11426838
4-@@	I-Chemical	-1	11426838
dic@@	I-Chemical	-1	11426838
h@@	I-Chemical	-1	11426838
loro@@	I-Chemical	-1	11426838
phenyl@@	I-Chemical	-1	11426838
)@@	I-Chemical	-1	11426838
eth@@	I-Chemical	-1	11426838
yl@@	I-Chemical	-1	11426838
]@@	I-Chemical	-1	11426838
-@@	I-Chemical	-1	11426838
4-@@	I-Chemical	-1	11426838
methyl@@	I-Chemical	-1	11426838
pi@@	I-Chemical	-1	11426838
per@@	I-Chemical	-1	11426838
az@@	I-Chemical	-1	11426838
ine	I-Chemical	-1	11426838
),	O	-1	11426838
and	O	-1	11426838
L@@	B-Chemical	-1	11426838
R@@	I-Chemical	-1	11426838
13@@	I-Chemical	-1	11426838
2	I-Chemical	-1	11426838
(1@@	O	-1	11426838
R@@	O	-1	11426838
,@@	O	-1	11426838
2@@	O	-1	11426838
S@@	O	-1	11426838
-@@	O	-1	11426838
(@@	O	-1	11426838
+@@	O	-1	11426838
)-@@	O	-1	11426838
cis@@	O	-1	11426838
-@@	O	-1	11426838
N@@	O	-1	11426838
-@@	O	-1	11426838
[@@	O	-1	11426838
2-@@	O	-1	11426838
(3@@	O	-1	11426838
,@@	O	-1	11426838
4-@@	O	-1	11426838
dic@@	O	-1	11426838
h@@	O	-1	11426838
loro@@	O	-1	11426838
phenyl@@	O	-1	11426838
)@@	O	-1	11426838
eth@@	O	-1	11426838
yl@@	O	-1	11426838
]@@	O	-1	11426838
-@@	O	-1	11426838
2-@@	O	-1	11426838
(1@@	O	-1	11426838
-@@	O	-1	11426838
py@@	O	-1	11426838
r@@	O	-1	11426838
ro@@	O	-1	11426838
l@@	O	-1	11426838
id@@	O	-1	11426838
in@@	O	-1	11426838
yl@@	O	-1	11426838
)@@	O	-1	11426838
cyclo@@	O	-1	11426838
he@@	O	-1	11426838
x@@	O	-1	11426838
yl@@	O	-1	11426838
am@@	O	-1	11426838
ine@@	O	-1	11426838
).	O	-1	11426838
Com@@	O	-1	11426838
pe@@	O	-1	11426838
ti@@	O	-1	11426838
tion	O	-1	11426838
b@@	O	-1	11426838
ind@@	O	-1	11426838
ing	O	-1	11426838
ass@@	O	-1	11426838
ays	O	-1	11426838
demonstrated	O	-1	11426838
that	O	-1	11426838
all	O	-1	11426838
three	O	-1	11426838
comp@@	O	-1	11426838
oun@@	O	-1	11426838
ds	O	-1	11426838
have	O	-1	11426838
high	O	-1	11426838
aff@@	O	-1	11426838
initi@@	O	-1	11426838
es	O	-1	11426838
for	O	-1	11426838
si@@	O	-1	11426838
g@@	O	-1	11426838
ma@@	O	-1	11426838
1	O	-1	11426838
receptor@@	O	-1	11426838
s.	O	-1	11426838
The	O	-1	11426838
three	O	-1	11426838
comp@@	O	-1	11426838
oun@@	O	-1	11426838
ds	O	-1	11426838
v@@	O	-1	11426838
ary	O	-1	11426838
in	O	-1	11426838
their	O	-1	11426838
aff@@	O	-1	11426838
initi@@	O	-1	11426838
es	O	-1	11426838
for	O	-1	11426838
si@@	O	-1	11426838
g@@	O	-1	11426838
ma@@	O	-1	11426838
2	O	-1	11426838
receptors	O	-1	11426838
and	O	-1	11426838
ex@@	O	-1	11426838
hib@@	O	-1	11426838
it	O	-1	11426838
neg@@	O	-1	11426838
li@@	O	-1	11426838
gi@@	O	-1	11426838
ble	O	-1	11426838
aff@@	O	-1	11426838
initi@@	O	-1	11426838
es	O	-1	11426838
for	O	-1	11426838
dopamine	B-Chemical	D004298	11426838
,	O	-1	11426838
o@@	O	-1	11426838
pi@@	O	-1	11426838
oid@@	O	-1	11426838
,	O	-1	11426838
G@@	B-Chemical	D005680	11426838
A@@	I-Chemical	-1	11426838
B@@	I-Chemical	-1	11426838
A	I-Chemical	-1	11426838
(A@@	O	-1	11426838
)	O	-1	11426838
and	O	-1	11426838
N@@	B-Chemical	D016202	11426838
MD@@	I-Chemical	-1	11426838
A	I-Chemical	-1	11426838
receptor@@	O	-1	11426838
s.	O	-1	11426838
In	O	-1	11426838
behavioral	O	-1	11426838
studi@@	O	-1	11426838
es,	O	-1	11426838
pre-@@	O	-1	11426838
treatment	O	-1	11426838
of	O	-1	11426838
mice	O	-1	11426838
with	O	-1	11426838
B@@	B-Chemical	-1	11426838
D@@	I-Chemical	-1	11426838
10@@	I-Chemical	-1	11426838
1@@	I-Chemical	-1	11426838
8	I-Chemical	-1	11426838
,	O	-1	11426838
B@@	B-Chemical	C093337	11426838
D@@	I-Chemical	-1	11426838
10@@	I-Chemical	-1	11426838
6@@	I-Chemical	-1	11426838
3	I-Chemical	-1	11426838
,	O	-1	11426838
or	O	-1	11426838
L@@	B-Chemical	-1	11426838
R@@	I-Chemical	-1	11426838
13@@	I-Chemical	-1	11426838
2	I-Chemical	-1	11426838
significantly	O	-1	11426838
attenu@@	O	-1	11426838
ated	O	-1	11426838
cocaine	B-Chemical	D003042	11426838
-induced	O	-1	11426838
convul@@	B-Disease	D012640	11426838
sions	I-Disease	-1	11426838
and	O	-1	11426838
le@@	O	-1	11426838
thal@@	O	-1	11426838
ity.	O	-1	11426838
M@@	O	-1	11426838
ore@@	O	-1	11426838
o@@	O	-1	11426838
ver,	O	-1	11426838
post@@	O	-1	11426838
-@@	O	-1	11426838
treatment	O	-1	11426838
with	O	-1	11426838
L@@	B-Chemical	-1	11426838
R@@	I-Chemical	-1	11426838
13@@	I-Chemical	-1	11426838
2	I-Chemical	-1	11426838
prevent@@	O	-1	11426838
ed	O	-1	11426838
cocaine	B-Chemical	D003042	11426838
-induced	O	-1	11426838
le@@	O	-1	11426838
thal@@	O	-1	11426838
ity	O	-1	11426838
in	O	-1	11426838
a	O	-1	11426838
significant	O	-1	11426838
pro@@	O	-1	11426838
por@@	O	-1	11426838
tion	O	-1	11426838
of	O	-1	11426838
anim@@	O	-1	11426838
al@@	O	-1	11426838
s.	O	-1	11426838
In	O	-1	11426838
contr@@	O	-1	11426838
ast	O	-1	11426838
to	O	-1	11426838
the	O	-1	11426838
prot@@	O	-1	11426838
ection	O	-1	11426838
pro@@	O	-1	11426838
vid@@	O	-1	11426838
ed	O	-1	11426838
by	O	-1	11426838
the	O	-1	11426838
p@@	O	-1	11426838
ut@@	O	-1	11426838
ative	O	-1	11426838
antagonist@@	O	-1	11426838
s,	O	-1	11426838
the	O	-1	11426838
we@@	O	-1	11426838
ll@@	O	-1	11426838
-@@	O	-1	11426838
character@@	O	-1	11426838
ized	O	-1	11426838
si@@	O	-1	11426838
g@@	O	-1	11426838
ma	O	-1	11426838
receptor	O	-1	11426838
agon@@	O	-1	11426838
ist	O	-1	11426838
di@@	B-Chemical	C050232	11426838
-@@	I-Chemical	-1	11426838
o@@	I-Chemical	-1	11426838
-@@	I-Chemical	-1	11426838
t@@	I-Chemical	-1	11426838
ol@@	I-Chemical	-1	11426838
yl@@	I-Chemical	-1	11426838
gu@@	I-Chemical	-1	11426838
an@@	I-Chemical	-1	11426838
idine	I-Chemical	-1	11426838
(	O	-1	11426838
D@@	B-Chemical	C050232	11426838
T@@	I-Chemical	-1	11426838
G	I-Chemical	-1	11426838
)	O	-1	11426838
and	O	-1	11426838
the	O	-1	11426838
novel	O	-1	11426838
si@@	O	-1	11426838
g@@	O	-1	11426838
ma	O	-1	11426838
receptor	O	-1	11426838
agon@@	O	-1	11426838
ist	O	-1	11426838
B@@	B-Chemical	-1	11426838
D@@	I-Chemical	-1	11426838
10@@	I-Chemical	-1	11426838
3@@	I-Chemical	-1	11426838
1	I-Chemical	-1	11426838
(	O	-1	11426838
3@@	B-Chemical	-1	11426838
R@@	I-Chemical	-1	11426838
-1@@	I-Chemical	-1	11426838
-@@	I-Chemical	-1	11426838
[@@	I-Chemical	-1	11426838
2-@@	I-Chemical	-1	11426838
(3@@	I-Chemical	-1	11426838
,@@	I-Chemical	-1	11426838
4-@@	I-Chemical	-1	11426838
dic@@	I-Chemical	-1	11426838
h@@	I-Chemical	-1	11426838
loro@@	I-Chemical	-1	11426838
phenyl@@	I-Chemical	-1	11426838
)@@	I-Chemical	-1	11426838
eth@@	I-Chemical	-1	11426838
yl@@	I-Chemical	-1	11426838
]@@	I-Chemical	-1	11426838
-1@@	I-Chemical	-1	11426838
,@@	I-Chemical	-1	11426838
4-@@	I-Chemical	-1	11426838
di@@	I-Chemical	-1	11426838
az@@	I-Chemical	-1	11426838
ab@@	I-Chemical	-1	11426838
ic@@	I-Chemical	-1	11426838
yc@@	I-Chemical	-1	11426838
lo@@	I-Chemical	-1	11426838
[@@	I-Chemical	-1	11426838
4.@@	I-Chemical	-1	11426838
3.@@	I-Chemical	-1	11426838
0@@	I-Chemical	-1	11426838
]@@	I-Chemical	-1	11426838
non@@	I-Chemical	-1	11426838
ane	I-Chemical	-1	11426838
)	O	-1	11426838
each	O	-1	11426838
wor@@	O	-1	11426838
sen@@	O	-1	11426838
ed	O	-1	11426838
the	O	-1	11426838
behavioral	O	-1	11426838
toxicity	B-Disease	D064420	11426838
of	O	-1	11426838
cocaine	B-Chemical	D003042	11426838
.	O	-1	11426838
A@@	O	-1	11426838
t	O	-1	11426838
doses	O	-1	11426838
wh@@	O	-1	11426838
ere	O	-1	11426838
al@@	O	-1	11426838
one,	O	-1	11426838
they	O	-1	11426838
produced	O	-1	11426838
no	O	-1	11426838
significant	O	-1	11426838
effects	O	-1	11426838
on	O	-1	11426838
locom@@	O	-1	11426838
o@@	O	-1	11426838
tion,	O	-1	11426838
B@@	B-Chemical	-1	11426838
D@@	I-Chemical	-1	11426838
10@@	I-Chemical	-1	11426838
1@@	I-Chemical	-1	11426838
8	I-Chemical	-1	11426838
,	O	-1	11426838
B@@	B-Chemical	C093337	11426838
D@@	I-Chemical	-1	11426838
10@@	I-Chemical	-1	11426838
6@@	I-Chemical	-1	11426838
3	I-Chemical	-1	11426838
and	O	-1	11426838
L@@	B-Chemical	-1	11426838
R@@	I-Chemical	-1	11426838
13@@	I-Chemical	-1	11426838
2	I-Chemical	-1	11426838
significantly	O	-1	11426838
attenu@@	O	-1	11426838
ated	O	-1	11426838
the	O	-1	11426838
locomotor	O	-1	11426838
stimul@@	O	-1	11426838
atory	O	-1	11426838
effects	O	-1	11426838
of	O	-1	11426838
cocaine	B-Chemical	D003042	11426838
.	O	-1	11426838
To	O	-1	11426838
further	O	-1	11426838
val@@	O	-1	11426838
id@@	O	-1	11426838
ate	O	-1	11426838
the	O	-1	11426838
hypo@@	O	-1	11426838
thesis	O	-1	11426838
that	O	-1	11426838
the	O	-1	11426838
anti@@	O	-1	11426838
-	O	-1	11426838
cocaine	B-Chemical	D003042	11426838
effects	O	-1	11426838
of	O	-1	11426838
the	O	-1	11426838
novel	O	-1	11426838
li@@	O	-1	11426838
g@@	O	-1	11426838
and@@	O	-1	11426838
s	O	-1	11426838
involved	O	-1	11426838
antagon@@	O	-1	11426838
ism	O	-1	11426838
of	O	-1	11426838
si@@	O	-1	11426838
g@@	O	-1	11426838
ma	O	-1	11426838
receptor@@	O	-1	11426838
s,	O	-1	11426838
an	O	-1	11426838
anti@@	O	-1	11426838
sen@@	O	-1	11426838
se	O	-1	11426838
ol@@	B-Chemical	D009838	11426838
i@@	I-Chemical	-1	11426838
go@@	I-Chemical	-1	11426838
de@@	I-Chemical	-1	11426838
oxy@@	I-Chemical	-1	11426838
nucle@@	I-Chemical	-1	11426838
o@@	I-Chemical	-1	11426838
ti@@	I-Chemical	-1	11426838
de	I-Chemical	-1	11426838
against	O	-1	11426838
si@@	O	-1	11426838
g@@	O	-1	11426838
ma@@	O	-1	11426838
1	O	-1	11426838
receptors	O	-1	11426838
was	O	-1	11426838
also	O	-1	11426838
shown	O	-1	11426838
to	O	-1	11426838
significantly	O	-1	11426838
attenu@@	O	-1	11426838
ate	O	-1	11426838
the	O	-1	11426838
convul@@	B-Disease	D012640	11426838
sive	I-Disease	-1	11426838
and	O	-1	11426838
locomotor	O	-1	11426838
stimul@@	O	-1	11426838
atory	O	-1	11426838
effects	O	-1	11426838
of	O	-1	11426838
cocaine	B-Chemical	D003042	11426838
.	O	-1	11426838
T@@	O	-1	11426838
o@@	O	-1	11426838
ge@@	O	-1	11426838
ther@@	O	-1	11426838
,	O	-1	11426838
the	O	-1	11426838
data	O	-1	11426838
suggests	O	-1	11426838
that	O	-1	11426838
functional	O	-1	11426838
antagon@@	O	-1	11426838
ism	O	-1	11426838
of	O	-1	11426838
si@@	O	-1	11426838
g@@	O	-1	11426838
ma	O	-1	11426838
receptors	O	-1	11426838
is	O	-1	11426838
cap@@	O	-1	11426838
able	O	-1	11426838
of	O	-1	11426838
attenu@@	O	-1	11426838
ating	O	-1	11426838
a	O	-1	11426838
number	O	-1	11426838
of	O	-1	11426838
cocaine	B-Chemical	D003042	11426838
-induced	O	-1	11426838
behavi@@	O	-1	11426838
or@@	O	-1	11426838
s.	O	-1	11426838

Ph@@	O	-1	11569530
armac@@	O	-1	11569530
o@@	O	-1	11569530
kine@@	O	-1	11569530
tic@@	O	-1	11569530
/@@	O	-1	11569530
pharmac@@	O	-1	11569530
o@@	O	-1	11569530
dynam@@	O	-1	11569530
ic	O	-1	11569530
assess@@	O	-1	11569530
ment	O	-1	11569530
of	O	-1	11569530
the	O	-1	11569530
effects	O	-1	11569530
of	O	-1	11569530
E@@	B-Chemical	C063968	11569530
4@@	I-Chemical	-1	11569530
0@@	I-Chemical	-1	11569530
3@@	I-Chemical	-1	11569530
1	I-Chemical	-1	11569530
,	O	-1	11569530
cis@@	B-Chemical	D020117	11569530
apri@@	I-Chemical	-1	11569530
de	I-Chemical	-1	11569530
,	O	-1	11569530
ter@@	B-Chemical	D016593	11569530
f@@	I-Chemical	-1	11569530
en@@	I-Chemical	-1	11569530
ad@@	I-Chemical	-1	11569530
ine	I-Chemical	-1	11569530
and	O	-1	11569530
ter@@	B-Chemical	C010637	11569530
odi@@	I-Chemical	-1	11569530
line	I-Chemical	-1	11569530
on	O	-1	11569530
mon@@	O	-1	11569530
o@@	O	-1	11569530
pha@@	O	-1	11569530
sic	O	-1	11569530
action	O	-1	11569530
potential	O	-1	11569530
duration	O	-1	11569530
in	O	-1	11569530
dog@@	O	-1	11569530
.	O	-1	11569530
1@@	O	-1	11569530
.	O	-1	11569530
T@@	B-Disease	D016171	11569530
or@@	I-Disease	-1	11569530
sa@@	I-Disease	-1	11569530
des	I-Disease	-1	11569530
de	I-Disease	-1	11569530
po@@	I-Disease	-1	11569530
int@@	I-Disease	-1	11569530
es	I-Disease	-1	11569530
(	O	-1	11569530
T@@	B-Disease	D016171	11569530
D@@	I-Disease	-1	11569530
P	I-Disease	-1	11569530
)	O	-1	11569530
is	O	-1	11569530
a	O	-1	11569530
potenti@@	O	-1	11569530
ally	O	-1	11569530
f@@	O	-1	11569530
atal	O	-1	11569530
ventricular	B-Disease	D017180	11569530
tachycardia	I-Disease	-1	11569530
associated	O	-1	11569530
with	O	-1	11569530
increases	O	-1	11569530
in	O	-1	11569530
Q@@	O	-1	11569530
T	O	-1	11569530
interv@@	O	-1	11569530
al	O	-1	11569530
and	O	-1	11569530
mon@@	O	-1	11569530
o@@	O	-1	11569530
pha@@	O	-1	11569530
sic	O	-1	11569530
action	O	-1	11569530
potential	O	-1	11569530
duration	O	-1	11569530
(@@	O	-1	11569530
MA@@	O	-1	11569530
P@@	O	-1	11569530
D@@	O	-1	11569530
).	O	-1	11569530
T@@	B-Disease	D016171	11569530
D@@	I-Disease	-1	11569530
P	I-Disease	-1	11569530
is	O	-1	11569530
a	O	-1	11569530
side@@	O	-1	11569530
-@@	O	-1	11569530
effect	O	-1	11569530
that	O	-1	11569530
has	O	-1	11569530
l@@	O	-1	11569530
ed	O	-1	11569530
to	O	-1	11569530
withdrawal	O	-1	11569530
of	O	-1	11569530
several	O	-1	11569530
drugs	O	-1	11569530
from	O	-1	11569530
the	O	-1	11569530
mark@@	O	-1	11569530
et	O	-1	11569530
(@@	O	-1	11569530
e@@	O	-1	11569530
.@@	O	-1	11569530
g@@	O	-1	11569530
.	O	-1	11569530
ter@@	B-Chemical	D016593	11569530
f@@	I-Chemical	-1	11569530
en@@	I-Chemical	-1	11569530
ad@@	I-Chemical	-1	11569530
ine	I-Chemical	-1	11569530
and	O	-1	11569530
ter@@	B-Chemical	C010637	11569530
odi@@	I-Chemical	-1	11569530
line	I-Chemical	-1	11569530
).	O	-1	11569530
2@@	O	-1	11569530
.	O	-1	11569530
The	O	-1	11569530
potential	O	-1	11569530
of	O	-1	11569530
comp@@	O	-1	11569530
oun@@	O	-1	11569530
ds	O	-1	11569530
to	O	-1	11569530
cause	O	-1	11569530
T@@	B-Disease	D016171	11569530
D@@	I-Disease	-1	11569530
P	I-Disease	-1	11569530
was	O	-1	11569530
evaluated	O	-1	11569530
by	O	-1	11569530
monit@@	O	-1	11569530
or@@	O	-1	11569530
ing	O	-1	11569530
their	O	-1	11569530
effects	O	-1	11569530
on	O	-1	11569530
MA@@	O	-1	11569530
P@@	O	-1	11569530
D	O	-1	11569530
in	O	-1	11569530
dog@@	O	-1	11569530
.	O	-1	11569530
F@@	O	-1	11569530
our	O	-1	11569530
comp@@	O	-1	11569530
oun@@	O	-1	11569530
ds	O	-1	11569530
known	O	-1	11569530
to	O	-1	11569530
increase	O	-1	11569530
Q@@	O	-1	11569530
T	O	-1	11569530
interv@@	O	-1	11569530
al	O	-1	11569530
and	O	-1	11569530
cause	O	-1	11569530
T@@	B-Disease	D016171	11569530
D@@	I-Disease	-1	11569530
P	I-Disease	-1	11569530
were	O	-1	11569530
investig@@	O	-1	11569530
ated@@	O	-1	11569530
:	O	-1	11569530
ter@@	B-Chemical	D016593	11569530
f@@	I-Chemical	-1	11569530
en@@	I-Chemical	-1	11569530
ad@@	I-Chemical	-1	11569530
ine	I-Chemical	-1	11569530
,	O	-1	11569530
ter@@	B-Chemical	C010637	11569530
odi@@	I-Chemical	-1	11569530
line	I-Chemical	-1	11569530
,	O	-1	11569530
cis@@	B-Chemical	D020117	11569530
apri@@	I-Chemical	-1	11569530
de	I-Chemical	-1	11569530
and	O	-1	11569530
E@@	B-Chemical	C063968	11569530
4@@	I-Chemical	-1	11569530
0@@	I-Chemical	-1	11569530
3@@	I-Chemical	-1	11569530
1	I-Chemical	-1	11569530
.	O	-1	11569530
O@@	O	-1	11569530
n	O	-1	11569530
the	O	-1	11569530
b@@	O	-1	11569530
asis	O	-1	11569530
that	O	-1	11569530
only	O	-1	11569530
free	O	-1	11569530
drug	O	-1	11569530
in	O	-1	11569530
the	O	-1	11569530
systemic	O	-1	11569530
cir@@	O	-1	11569530
c@@	O	-1	11569530
ulation	O	-1	11569530
wil@@	O	-1	11569530
l	O	-1	11569530
el@@	O	-1	11569530
ic@@	O	-1	11569530
it	O	-1	11569530
a	O	-1	11569530
pharmac@@	O	-1	11569530
ological	O	-1	11569530
response	O	-1	11569530
t@@	O	-1	11569530
arg@@	O	-1	11569530
et@@	O	-1	11569530
,	O	-1	11569530
free	O	-1	11569530
concentrations	O	-1	11569530
in	O	-1	11569530
plasma	O	-1	11569530
were	O	-1	11569530
sel@@	O	-1	11569530
ected	O	-1	11569530
to	O	-1	11569530
m@@	O	-1	11569530
im@@	O	-1	11569530
ic	O	-1	11569530
the	O	-1	11569530
free	O	-1	11569530
drug	O	-1	11569530
expos@@	O	-1	11569530
ures	O	-1	11569530
in	O	-1	11569530
man@@	O	-1	11569530
.	O	-1	11569530
In@@	O	-1	11569530
f@@	O	-1	11569530
usion	O	-1	11569530
regimen@@	O	-1	11569530
s	O	-1	11569530
were	O	-1	11569530
de@@	O	-1	11569530
signed	O	-1	11569530
that	O	-1	11569530
ra@@	O	-1	11569530
pid@@	O	-1	11569530
ly	O	-1	11569530
achi@@	O	-1	11569530
ev@@	O	-1	11569530
ed	O	-1	11569530
and	O	-1	11569530
maint@@	O	-1	11569530
ained	O	-1	11569530
t@@	O	-1	11569530
arg@@	O	-1	11569530
et@@	O	-1	11569530
-@@	O	-1	11569530
free	O	-1	11569530
concentrations	O	-1	11569530
of	O	-1	11569530
these	O	-1	11569530
drugs	O	-1	11569530
in	O	-1	11569530
plasma	O	-1	11569530
and	O	-1	11569530
data	O	-1	11569530
on	O	-1	11569530
the	O	-1	11569530
rel@@	O	-1	11569530
ationship	O	-1	11569530
between	O	-1	11569530
free	O	-1	11569530
concentration	O	-1	11569530
and	O	-1	11569530
changes	O	-1	11569530
in	O	-1	11569530
MA@@	O	-1	11569530
P@@	O	-1	11569530
D	O	-1	11569530
were	O	-1	11569530
obtained	O	-1	11569530
for	O	-1	11569530
these	O	-1	11569530
comp@@	O	-1	11569530
oun@@	O	-1	11569530
d@@	O	-1	11569530
s.	O	-1	11569530
3@@	O	-1	11569530
.	O	-1	11569530
These	O	-1	11569530
data	O	-1	11569530
indicate	O	-1	11569530
that	O	-1	11569530
the	O	-1	11569530
free	O	-1	11569530
E@@	O	-1	11569530
D@@	O	-1	11569530
50	O	-1	11569530
in	O	-1	11569530
plasma	O	-1	11569530
for	O	-1	11569530
ter@@	B-Chemical	D016593	11569530
f@@	I-Chemical	-1	11569530
en@@	I-Chemical	-1	11569530
ad@@	I-Chemical	-1	11569530
ine	I-Chemical	-1	11569530
(1@@	O	-1	11569530
.@@	O	-1	11569530
9	O	-1	11569530
n@@	O	-1	11569530
M@@	O	-1	11569530
),	O	-1	11569530
ter@@	B-Chemical	C010637	11569530
odi@@	I-Chemical	-1	11569530
line	I-Chemical	-1	11569530
(@@	O	-1	11569530
7@@	O	-1	11569530
6	O	-1	11569530
n@@	O	-1	11569530
M@@	O	-1	11569530
),	O	-1	11569530
cis@@	B-Chemical	D020117	11569530
apri@@	I-Chemical	-1	11569530
de	I-Chemical	-1	11569530
(1@@	O	-1	11569530
1	O	-1	11569530
n@@	O	-1	11569530
M@@	O	-1	11569530
)	O	-1	11569530
and	O	-1	11569530
E@@	B-Chemical	C063968	11569530
4@@	I-Chemical	-1	11569530
0@@	I-Chemical	-1	11569530
3@@	I-Chemical	-1	11569530
1	I-Chemical	-1	11569530
(1@@	O	-1	11569530
.@@	O	-1	11569530
9	O	-1	11569530
n@@	O	-1	11569530
M@@	O	-1	11569530
)	O	-1	11569530
clo@@	O	-1	11569530
se@@	O	-1	11569530
ly	O	-1	11569530
correl@@	O	-1	11569530
ate	O	-1	11569530
with	O	-1	11569530
the	O	-1	11569530
free	O	-1	11569530
concentration	O	-1	11569530
in	O	-1	11569530
man	O	-1	11569530
ca@@	O	-1	11569530
using	O	-1	11569530
Q@@	O	-1	11569530
T	O	-1	11569530
effects.	O	-1	11569530
F@@	O	-1	11569530
or	O	-1	11569530
comp@@	O	-1	11569530
oun@@	O	-1	11569530
ds	O	-1	11569530
that	O	-1	11569530
have	O	-1	11569530
shown	O	-1	11569530
T@@	B-Disease	D016171	11569530
D@@	I-Disease	-1	11569530
P	I-Disease	-1	11569530
in	O	-1	11569530
the	O	-1	11569530
clin@@	O	-1	11569530
ic	O	-1	11569530
(	O	-1	11569530
ter@@	B-Chemical	D016593	11569530
f@@	I-Chemical	-1	11569530
en@@	I-Chemical	-1	11569530
ad@@	I-Chemical	-1	11569530
ine	I-Chemical	-1	11569530
,	O	-1	11569530
ter@@	B-Chemical	C010637	11569530
odi@@	I-Chemical	-1	11569530
line	I-Chemical	-1	11569530
,	O	-1	11569530
cis@@	B-Chemical	D020117	11569530
apri@@	I-Chemical	-1	11569530
de	I-Chemical	-1	11569530
)	O	-1	11569530
there	O	-1	11569530
is	O	-1	11569530
lit@@	O	-1	11569530
t@@	O	-1	11569530
le	O	-1	11569530
differen@@	O	-1	11569530
ti@@	O	-1	11569530
ation	O	-1	11569530
between	O	-1	11569530
the	O	-1	11569530
do@@	O	-1	11569530
g	O	-1	11569530
E@@	O	-1	11569530
D@@	O	-1	11569530
50	O	-1	11569530
and	O	-1	11569530
the	O	-1	11569530
efficac@@	O	-1	11569530
i@@	O	-1	11569530
ous	O	-1	11569530
free	O	-1	11569530
plasma	O	-1	11569530
concentrations	O	-1	11569530
in	O	-1	11569530
man	O	-1	11569530
(@@	O	-1	11569530
<	O	-1	11569530
10-@@	O	-1	11569530
fol@@	O	-1	11569530
d@@	O	-1	11569530
)	O	-1	11569530
ref@@	O	-1	11569530
l@@	O	-1	11569530
ect@@	O	-1	11569530
ing	O	-1	11569530
their	O	-1	11569530
lim@@	O	-1	11569530
ited	O	-1	11569530
safety	O	-1	11569530
m@@	O	-1	11569530
arg@@	O	-1	11569530
in@@	O	-1	11569530
s.	O	-1	11569530
These	O	-1	11569530
data	O	-1	11569530
under@@	O	-1	11569530
line	O	-1	11569530
the	O	-1	11569530
need	O	-1	11569530
to	O	-1	11569530
maxim@@	O	-1	11569530
iz@@	O	-1	11569530
e	O	-1	11569530
the	O	-1	11569530
therapeutic	O	-1	11569530
rati@@	O	-1	11569530
o	O	-1	11569530
with	O	-1	11569530
resp@@	O	-1	11569530
ect	O	-1	11569530
to	O	-1	11569530
T@@	B-Disease	D016171	11569530
D@@	I-Disease	-1	11569530
P	I-Disease	-1	11569530
in	O	-1	11569530
potential	O	-1	11569530
development	O	-1	11569530
can@@	O	-1	11569530
di@@	O	-1	11569530
dat@@	O	-1	11569530
es	O	-1	11569530
and	O	-1	11569530
the	O	-1	11569530
import@@	O	-1	11569530
ance	O	-1	11569530
of	O	-1	11569530
using	O	-1	11569530
free	O	-1	11569530
drug	O	-1	11569530
concentrations	O	-1	11569530
in	O	-1	11569530
pharmac@@	O	-1	11569530
o@@	O	-1	11569530
kine@@	O	-1	11569530
tic@@	O	-1	11569530
/@@	O	-1	11569530
pharmac@@	O	-1	11569530
o@@	O	-1	11569530
dynam@@	O	-1	11569530
ic	O	-1	11569530
studi@@	O	-1	11569530
es.	O	-1	11569530

F@@	O	-1	11587867
atal	O	-1	11587867
my@@	B-Disease	D001927	11587867
e@@	I-Disease	-1	11587867
lo@@	I-Disease	-1	11587867
encephalo@@	I-Disease	-1	11587867
pathy	I-Disease	-1	11587867
due	O	-1	11587867
to	O	-1	11587867
ac@@	O	-1	11587867
c@@	O	-1	11587867
id@@	O	-1	11587867
ental	O	-1	11587867
intra@@	O	-1	11587867
th@@	O	-1	11587867
ec@@	O	-1	11587867
al	O	-1	11587867
v@@	B-Chemical	D014750	11587867
inc@@	I-Chemical	-1	11587867
ris@@	I-Chemical	-1	11587867
tin	I-Chemical	-1	11587867
administr@@	O	-1	11587867
ation@@	O	-1	11587867
:	O	-1	11587867
a	O	-1	11587867
report	O	-1	11587867
of	O	-1	11587867
two	O	-1	11587867
cas@@	O	-1	11587867
es.	O	-1	11587867
We	O	-1	11587867
report	O	-1	11587867
on	O	-1	11587867
two	O	-1	11587867
f@@	O	-1	11587867
atal	O	-1	11587867
cases	O	-1	11587867
of	O	-1	11587867
ac@@	O	-1	11587867
c@@	O	-1	11587867
id@@	O	-1	11587867
ental	O	-1	11587867
intra@@	O	-1	11587867
th@@	O	-1	11587867
ec@@	O	-1	11587867
al	O	-1	11587867
v@@	B-Chemical	D014750	11587867
inc@@	I-Chemical	-1	11587867
ri@@	I-Chemical	-1	11587867
st@@	I-Chemical	-1	11587867
ine	I-Chemical	-1	11587867
insti@@	O	-1	11587867
ll@@	O	-1	11587867
ation	O	-1	11587867
in	O	-1	11587867
a	O	-1	11587867
5-@@	O	-1	11587867
year	O	-1	11587867
old	O	-1	11587867
gi@@	O	-1	11587867
r@@	O	-1	11587867
l	O	-1	11587867
with	O	-1	11587867
recur@@	O	-1	11587867
rent	O	-1	11587867
acute	B-Disease	D054198	11587867
lymph@@	I-Disease	-1	11587867
ob@@	I-Disease	-1	11587867
las@@	I-Disease	-1	11587867
tic	I-Disease	-1	11587867
le@@	I-Disease	-1	11587867
uc@@	I-Disease	-1	11587867
emia	I-Disease	-1	11587867
and	O	-1	11587867
a	O	-1	11587867
5@@	O	-1	11587867
7-@@	O	-1	11587867
year	O	-1	11587867
old	O	-1	11587867
man	O	-1	11587867
with	O	-1	11587867
lymph@@	B-Disease	D054198	11587867
ob@@	I-Disease	-1	11587867
las@@	I-Disease	-1	11587867
tic	I-Disease	-1	11587867
lymph@@	I-Disease	-1	11587867
oma	I-Disease	-1	11587867
.	O	-1	11587867
The	O	-1	11587867
gi@@	O	-1	11587867
r@@	O	-1	11587867
l	O	-1	11587867
di@@	O	-1	11587867
ed	O	-1	11587867
seven	O	-1	11587867
day@@	O	-1	11587867
s,	O	-1	11587867
the	O	-1	11587867
man	O	-1	11587867
four	O	-1	11587867
weeks	O	-1	11587867
after	O	-1	11587867
intra@@	O	-1	11587867
th@@	O	-1	11587867
ec@@	O	-1	11587867
al	O	-1	11587867
injection	O	-1	11587867
of	O	-1	11587867
v@@	B-Chemical	D014750	11587867
inc@@	I-Chemical	-1	11587867
ri@@	I-Chemical	-1	11587867
st@@	I-Chemical	-1	11587867
ine	I-Chemical	-1	11587867
.	O	-1	11587867
Clin@@	O	-1	11587867
ic@@	O	-1	11587867
ally,	O	-1	11587867
the	O	-1	11587867
onset	O	-1	11587867
was	O	-1	11587867
character@@	O	-1	11587867
ized	O	-1	11587867
by	O	-1	11587867
the	O	-1	11587867
signs	O	-1	11587867
of	O	-1	11587867
op@@	B-Disease	D020258	11587867
ist@@	I-Disease	-1	11587867
o@@	I-Disease	-1	11587867
th@@	I-Disease	-1	11587867
on@@	I-Disease	-1	11587867
us,	I-Disease	-1	11587867
sens@@	I-Disease	-1	11587867
ory	I-Disease	-1	11587867
and	I-Disease	-1	11587867
motor	I-Disease	-1	11587867
dysfunction	I-Disease	-1	11587867
op@@	B-Disease	D020258	11587867
ist@@	I-Disease	-1	11587867
o@@	I-Disease	-1	11587867
th@@	I-Disease	-1	11587867
on@@	I-Disease	-1	11587867
us,	I-Disease	-1	11587867
sens@@	I-Disease	-1	11587867
ory	I-Disease	-1	11587867
and	I-Disease	-1	11587867
motor	I-Disease	-1	11587867
dysfunction	I-Disease	-1	11587867
op@@	B-Disease	D020258	11587867
ist@@	I-Disease	-1	11587867
o@@	I-Disease	-1	11587867
th@@	I-Disease	-1	11587867
on@@	I-Disease	-1	11587867
us,	I-Disease	-1	11587867
sens@@	I-Disease	-1	11587867
ory	I-Disease	-1	11587867
and	I-Disease	-1	11587867
motor	I-Disease	-1	11587867
dysfunction	I-Disease	-1	11587867
and	O	-1	11587867
as@@	O	-1	11587867
c@@	O	-1	11587867
en@@	O	-1	11587867
ding	O	-1	11587867
par@@	B-Disease	D010243	11587867
aly@@	I-Disease	-1	11587867
sis	I-Disease	-1	11587867
.	O	-1	11587867
H@@	O	-1	11587867
ist@@	O	-1	11587867
ological	O	-1	11587867
and	O	-1	11587867
immuno@@	O	-1	11587867
histo@@	O	-1	11587867
chemical	O	-1	11587867
investig@@	O	-1	11587867
ations	O	-1	11587867
(@@	O	-1	11587867
H@@	O	-1	11587867
E@@	O	-1	11587867
-@@	O	-1	11587867
L@@	O	-1	11587867
F@@	O	-1	11587867
B@@	O	-1	11587867
,	O	-1	11587867
C@@	O	-1	11587867
D-@@	O	-1	11587867
6@@	O	-1	11587867
8@@	O	-1	11587867
,	O	-1	11587867
Ne@@	O	-1	11587867
uro@@	O	-1	11587867
f@@	O	-1	11587867
il@@	O	-1	11587867
am@@	O	-1	11587867
ent@@	O	-1	11587867
)	O	-1	11587867
revealed	O	-1	11587867
de@@	B-Disease	D003711	11587867
generation	I-Disease	-1	11587867
of	I-Disease	-1	11587867
my@@	I-Disease	-1	11587867
el@@	I-Disease	-1	11587867
in	I-Disease	-1	11587867
and	I-Disease	-1	11587867
ax@@	I-Disease	-1	11587867
ons	I-Disease	-1	11587867
de@@	B-Disease	D009410	11587867
generation	I-Disease	-1	11587867
of	I-Disease	-1	11587867
my@@	I-Disease	-1	11587867
el@@	I-Disease	-1	11587867
in	I-Disease	-1	11587867
and	I-Disease	-1	11587867
ax@@	I-Disease	-1	11587867
ons	I-Disease	-1	11587867
as	O	-1	11587867
well	O	-1	11587867
as	O	-1	11587867
p@@	B-Disease	-1	11587867
se@@	I-Disease	-1	11587867
ud@@	I-Disease	-1	11587867
oc@@	I-Disease	-1	11587867
ys@@	I-Disease	-1	11587867
tic	I-Disease	-1	11587867
trans@@	I-Disease	-1	11587867
formation	I-Disease	-1	11587867
in	O	-1	11587867
a@@	O	-1	11587867
reas	O	-1	11587867
exposed	O	-1	11587867
to	O	-1	11587867
v@@	B-Chemical	D014750	11587867
inc@@	I-Chemical	-1	11587867
ri@@	I-Chemical	-1	11587867
st@@	I-Chemical	-1	11587867
ine	I-Chemical	-1	11587867
,	O	-1	11587867
ac@@	O	-1	11587867
comp@@	O	-1	11587867
an@@	O	-1	11587867
ied	O	-1	11587867
by	O	-1	11587867
secondary	O	-1	11587867
changes	O	-1	11587867
with	O	-1	11587867
n@@	O	-1	11587867
um@@	O	-1	11587867
er@@	O	-1	11587867
ous	O	-1	11587867
pro@@	O	-1	11587867
min@@	O	-1	11587867
ent	O	-1	11587867
mac@@	O	-1	11587867
ro@@	O	-1	11587867
ph@@	O	-1	11587867
ag@@	O	-1	11587867
es.	O	-1	11587867
The	O	-1	11587867
clinical	O	-1	11587867
course	O	-1	11587867
and	O	-1	11587867
histo@@	O	-1	11587867
path@@	O	-1	11587867
ological	O	-1	11587867
results	O	-1	11587867
of	O	-1	11587867
the	O	-1	11587867
two	O	-1	11587867
cases	O	-1	11587867
are	O	-1	11587867
present@@	O	-1	11587867
ed.	O	-1	11587867
A	O	-1	11587867
revie@@	O	-1	11587867
w	O	-1	11587867
of	O	-1	11587867
all	O	-1	11587867
reported	O	-1	11587867
cases	O	-1	11587867
in	O	-1	11587867
the	O	-1	11587867
literat@@	O	-1	11587867
ure	O	-1	11587867
is	O	-1	11587867
gi@@	O	-1	11587867
ven@@	O	-1	11587867
.	O	-1	11587867
A	O	-1	11587867
bet@@	O	-1	11587867
ter	O	-1	11587867
controlled	O	-1	11587867
regi@@	O	-1	11587867
men	O	-1	11587867
for	O	-1	11587867
administ@@	O	-1	11587867
ering	O	-1	11587867
v@@	B-Chemical	D014750	11587867
inc@@	I-Chemical	-1	11587867
ri@@	I-Chemical	-1	11587867
st@@	I-Chemical	-1	11587867
ine	I-Chemical	-1	11587867
and	O	-1	11587867
intra@@	O	-1	11587867
th@@	O	-1	11587867
ec@@	O	-1	11587867
al	O	-1	11587867
chemotherapy	O	-1	11587867
is	O	-1	11587867
recomm@@	O	-1	11587867
en@@	O	-1	11587867
de@@	O	-1	11587867
d.	O	-1	11587867

In@@	O	-1	11679859
tra@@	O	-1	11679859
venous	O	-1	11679859
administration	O	-1	11679859
of	O	-1	11679859
pro@@	B-Chemical	D011346	11679859
chlor@@	I-Chemical	-1	11679859
per@@	I-Chemical	-1	11679859
az@@	I-Chemical	-1	11679859
ine	I-Chemical	-1	11679859
by	O	-1	11679859
1@@	O	-1	11679859
5-@@	O	-1	11679859
min@@	O	-1	11679859
ute	O	-1	11679859
infusion	O	-1	11679859
versus	O	-1	11679859
2-@@	O	-1	11679859
min@@	O	-1	11679859
ute	O	-1	11679859
b@@	O	-1	11679859
ol@@	O	-1	11679859
us	O	-1	11679859
does	O	-1	11679859
not	O	-1	11679859
aff@@	O	-1	11679859
ect	O	-1	11679859
the	O	-1	11679859
incidence	O	-1	11679859
of	O	-1	11679859
ak@@	B-Disease	D017109	11679859
athi@@	I-Disease	-1	11679859
sia	I-Disease	-1	11679859
:	O	-1	11679859
a	O	-1	11679859
pro@@	O	-1	11679859
sp@@	O	-1	11679859
ecti@@	O	-1	11679859
ve,	O	-1	11679859
random@@	O	-1	11679859
iz@@	O	-1	11679859
ed,	O	-1	11679859
controlled	O	-1	11679859
tri@@	O	-1	11679859
al.	O	-1	11679859
S@@	O	-1	11679859
T@@	O	-1	11679859
U@@	O	-1	11679859
D@@	O	-1	11679859
Y	O	-1	11679859
OBJECTIVE:	O	-1	11679859
We	O	-1	11679859
s@@	O	-1	11679859
ou@@	O	-1	11679859
ght	O	-1	11679859
to	O	-1	11679859
compar@@	O	-1	11679859
e	O	-1	11679859
the	O	-1	11679859
rate	O	-1	11679859
of	O	-1	11679859
ak@@	B-Disease	D017109	11679859
athi@@	I-Disease	-1	11679859
sia	I-Disease	-1	11679859
after	O	-1	11679859
administration	O	-1	11679859
of	O	-1	11679859
intravenous	O	-1	11679859
pro@@	B-Chemical	D011346	11679859
chlor@@	I-Chemical	-1	11679859
per@@	I-Chemical	-1	11679859
az@@	I-Chemical	-1	11679859
ine	I-Chemical	-1	11679859
as	O	-1	11679859
a	O	-1	11679859
2-@@	O	-1	11679859
min@@	O	-1	11679859
ute	O	-1	11679859
b@@	O	-1	11679859
ol@@	O	-1	11679859
us	O	-1	11679859
or	O	-1	11679859
1@@	O	-1	11679859
5-@@	O	-1	11679859
min@@	O	-1	11679859
ute	O	-1	11679859
infu@@	O	-1	11679859
sion.	O	-1	11679859
METHODS:	O	-1	11679859
We	O	-1	11679859
con@@	O	-1	11679859
duc@@	O	-1	11679859
ted	O	-1	11679859
a	O	-1	11679859
pro@@	O	-1	11679859
sp@@	O	-1	11679859
ecti@@	O	-1	11679859
ve,	O	-1	11679859
random@@	O	-1	11679859
iz@@	O	-1	11679859
ed,	O	-1	11679859
double-bl@@	O	-1	11679859
ind	O	-1	11679859
study	O	-1	11679859
in	O	-1	11679859
the	O	-1	11679859
em@@	O	-1	11679859
er@@	O	-1	11679859
gen@@	O	-1	11679859
c@@	O	-1	11679859
y	O	-1	11679859
de@@	O	-1	11679859
part@@	O	-1	11679859
ment	O	-1	11679859
of	O	-1	11679859
a	O	-1	11679859
centr@@	O	-1	11679859
al@@	O	-1	11679859
-@@	O	-1	11679859
c@@	O	-1	11679859
ity	O	-1	11679859
te@@	O	-1	11679859
ac@@	O	-1	11679859
h@@	O	-1	11679859
ing	O	-1	11679859
hospit@@	O	-1	11679859
al.	O	-1	11679859
Patients	O	-1	11679859
aged	O	-1	11679859
1@@	O	-1	11679859
8	O	-1	11679859
years	O	-1	11679859
or	O	-1	11679859
ol@@	O	-1	11679859
der	O	-1	11679859
treated	O	-1	11679859
with	O	-1	11679859
pro@@	B-Chemical	D011346	11679859
chlor@@	I-Chemical	-1	11679859
per@@	I-Chemical	-1	11679859
az@@	I-Chemical	-1	11679859
ine	I-Chemical	-1	11679859
for	O	-1	11679859
headac@@	B-Disease	D006261	11679859
he	I-Disease	-1	11679859
,	O	-1	11679859
nausea	B-Disease	D009325	11679859
,	O	-1	11679859
or	O	-1	11679859
v@@	B-Disease	D014839	11679859
om@@	I-Disease	-1	11679859
it@@	I-Disease	-1	11679859
ing	I-Disease	-1	11679859
were	O	-1	11679859
e@@	O	-1	11679859
li@@	O	-1	11679859
gi@@	O	-1	11679859
ble	O	-1	11679859
for	O	-1	11679859
inc@@	O	-1	11679859
lu@@	O	-1	11679859
sion.	O	-1	11679859
S@@	O	-1	11679859
t@@	O	-1	11679859
ud@@	O	-1	11679859
y	O	-1	11679859
partic@@	O	-1	11679859
ip@@	O	-1	11679859
ants	O	-1	11679859
were	O	-1	11679859
randomized	O	-1	11679859
to	O	-1	11679859
recei@@	O	-1	11679859
ve	O	-1	11679859
10	O	-1	11679859
mg	O	-1	11679859
of	O	-1	11679859
pro@@	B-Chemical	D011346	11679859
chlor@@	I-Chemical	-1	11679859
per@@	I-Chemical	-1	11679859
az@@	I-Chemical	-1	11679859
ine	I-Chemical	-1	11679859
administered	O	-1	11679859
intra@@	O	-1	11679859
ven@@	O	-1	11679859
ously	O	-1	11679859
by	O	-1	11679859
me@@	O	-1	11679859
ans	O	-1	11679859
of	O	-1	11679859
2-@@	O	-1	11679859
min@@	O	-1	11679859
ute	O	-1	11679859
p@@	O	-1	11679859
us@@	O	-1	11679859
h	O	-1	11679859
(@@	O	-1	11679859
b@@	O	-1	11679859
ol@@	O	-1	11679859
us	O	-1	11679859
group@@	O	-1	11679859
)	O	-1	11679859
or	O	-1	11679859
10	O	-1	11679859
mg	O	-1	11679859
di@@	O	-1	11679859
l@@	O	-1	11679859
ut@@	O	-1	11679859
ed	O	-1	11679859
in	O	-1	11679859
50	O	-1	11679859
m@@	O	-1	11679859
L	O	-1	11679859
of	O	-1	11679859
normal	O	-1	11679859
saline	O	-1	11679859
sol@@	O	-1	11679859
u@@	O	-1	11679859
tion	O	-1	11679859
administered	O	-1	11679859
by	O	-1	11679859
me@@	O	-1	11679859
ans	O	-1	11679859
of	O	-1	11679859
intravenous	O	-1	11679859
infusion	O	-1	11679859
during	O	-1	11679859
a	O	-1	11679859
1@@	O	-1	11679859
5-@@	O	-1	11679859
min@@	O	-1	11679859
ute	O	-1	11679859
period	O	-1	11679859
(@@	O	-1	11679859
infusion	O	-1	11679859
group@@	O	-1	11679859
).	O	-1	11679859
The	O	-1	11679859
ma@@	O	-1	11679859
in	O	-1	11679859
outcom@@	O	-1	11679859
e	O	-1	11679859
was	O	-1	11679859
the	O	-1	11679859
number	O	-1	11679859
of	O	-1	11679859
study	O	-1	11679859
partic@@	O	-1	11679859
ip@@	O	-1	11679859
ants	O	-1	11679859
experienc@@	O	-1	11679859
ing	O	-1	11679859
ak@@	B-Disease	D017109	11679859
athi@@	I-Disease	-1	11679859
sia	I-Disease	-1	11679859
within	O	-1	11679859
60	O	-1	11679859
minutes	O	-1	11679859
of	O	-1	11679859
administr@@	O	-1	11679859
ation.	O	-1	11679859
A@@	O	-1	11679859
k@@	O	-1	11679859
athi@@	O	-1	11679859
sia	O	-1	11679859
was	O	-1	11679859
def@@	O	-1	11679859
in@@	O	-1	11679859
ed	O	-1	11679859
as	O	-1	11679859
either	O	-1	11679859
a	O	-1	11679859
spont@@	O	-1	11679859
aneous	O	-1	11679859
report	O	-1	11679859
of	O	-1	11679859
rest@@	O	-1	11679859
l@@	O	-1	11679859
ess@@	O	-1	11679859
ness	O	-1	11679859
or	O	-1	11679859
ag@@	B-Disease	D011595	11679859
it@@	I-Disease	-1	11679859
ation	I-Disease	-1	11679859
or	O	-1	11679859
a	O	-1	11679859
change	O	-1	11679859
of	O	-1	11679859
2	O	-1	11679859
or	O	-1	11679859
more	O	-1	11679859
in	O	-1	11679859
the	O	-1	11679859
patient@@	O	-1	11679859
-@@	O	-1	11679859
reported	O	-1	11679859
ak@@	B-Disease	D017109	11679859
athi@@	I-Disease	-1	11679859
sia	I-Disease	-1	11679859
rat@@	O	-1	11679859
ing	O	-1	11679859
s@@	O	-1	11679859
cal@@	O	-1	11679859
e	O	-1	11679859
and	O	-1	11679859
a	O	-1	11679859
change	O	-1	11679859
of	O	-1	11679859
at	O	-1	11679859
le@@	O	-1	11679859
ast	O	-1	11679859
1	O	-1	11679859
in	O	-1	11679859
the	O	-1	11679859
investig@@	O	-1	11679859
at@@	O	-1	11679859
or@@	O	-1	11679859
-@@	O	-1	11679859
observed	O	-1	11679859
ak@@	B-Disease	D017109	11679859
athi@@	I-Disease	-1	11679859
sia	I-Disease	-1	11679859
rat@@	O	-1	11679859
ing	O	-1	11679859
s@@	O	-1	11679859
cal@@	O	-1	11679859
e.	O	-1	11679859
The	O	-1	11679859
int@@	O	-1	11679859
ensity	O	-1	11679859
of	O	-1	11679859
headac@@	B-Disease	D006261	11679859
he	I-Disease	-1	11679859
and	O	-1	11679859
nausea	B-Disease	D009325	11679859
was	O	-1	11679859
measured	O	-1	11679859
with	O	-1	11679859
a	O	-1	11679859
10@@	O	-1	11679859
0-@@	O	-1	11679859
mm	O	-1	11679859
visual	O	-1	11679859
an@@	O	-1	11679859
alo@@	O	-1	11679859
g	O	-1	11679859
s@@	O	-1	11679859
cal@@	O	-1	11679859
e.	O	-1	11679859
RESULTS:	O	-1	11679859
One	O	-1	11679859
h@@	O	-1	11679859
und@@	O	-1	11679859
red	O	-1	11679859
patients	O	-1	11679859
were	O	-1	11679859
en@@	O	-1	11679859
ro@@	O	-1	11679859
l@@	O	-1	11679859
le@@	O	-1	11679859
d.	O	-1	11679859
One	O	-1	11679859
study	O	-1	11679859
partic@@	O	-1	11679859
ip@@	O	-1	11679859
ant	O	-1	11679859
was	O	-1	11679859
ex@@	O	-1	11679859
cl@@	O	-1	11679859
uded	O	-1	11679859
after	O	-1	11679859
pro@@	O	-1	11679859
to@@	O	-1	11679859
co@@	O	-1	11679859
l	O	-1	11679859
vi@@	O	-1	11679859
ol@@	O	-1	11679859
ation.	O	-1	11679859
S@@	O	-1	11679859
event@@	O	-1	11679859
y-@@	O	-1	11679859
three	O	-1	11679859
perc@@	O	-1	11679859
ent	O	-1	11679859
(@@	O	-1	11679859
7@@	O	-1	11679859
3@@	O	-1	11679859
/@@	O	-1	11679859
9@@	O	-1	11679859
9@@	O	-1	11679859
)	O	-1	11679859
of	O	-1	11679859
the	O	-1	11679859
study	O	-1	11679859
partic@@	O	-1	11679859
ip@@	O	-1	11679859
ants	O	-1	11679859
were	O	-1	11679859
treated	O	-1	11679859
for	O	-1	11679859
headac@@	B-Disease	D006261	11679859
he	I-Disease	-1	11679859
and	O	-1	11679859
7@@	O	-1	11679859
0%	O	-1	11679859
(@@	O	-1	11679859
7@@	O	-1	11679859
0@@	O	-1	11679859
/@@	O	-1	11679859
9@@	O	-1	11679859
9@@	O	-1	11679859
)	O	-1	11679859
for	O	-1	11679859
nausea	B-Disease	D009325	11679859
.	O	-1	11679859
In	O	-1	11679859
the	O	-1	11679859
b@@	O	-1	11679859
ol@@	O	-1	11679859
us	O	-1	11679859
group@@	O	-1	11679859
,	O	-1	11679859
2@@	O	-1	11679859
6.@@	O	-1	11679859
0%	O	-1	11679859
(1@@	O	-1	11679859
3@@	O	-1	11679859
/@@	O	-1	11679859
50@@	O	-1	11679859
)	O	-1	11679859
had	O	-1	11679859
ak@@	B-Disease	D017109	11679859
athi@@	I-Disease	-1	11679859
sia	I-Disease	-1	11679859
compared	O	-1	11679859
with	O	-1	11679859
3@@	O	-1	11679859
2.@@	O	-1	11679859
7@@	O	-1	11679859
%	O	-1	11679859
(1@@	O	-1	11679859
6@@	O	-1	11679859
/@@	O	-1	11679859
4@@	O	-1	11679859
9@@	O	-1	11679859
)	O	-1	11679859
in	O	-1	11679859
the	O	-1	11679859
infusion	O	-1	11679859
group	O	-1	11679859
(D@@	O	-1	11679859
el@@	O	-1	11679859
t@@	O	-1	11679859
a@@	O	-1	11679859
=@@	O	-1	11679859
-@@	O	-1	11679859
6.@@	O	-1	11679859
7@@	O	-1	11679859
%@@	O	-1	11679859
;	O	-1	11679859
95%	O	-1	11679859
conf@@	O	-1	11679859
idence	O	-1	11679859
interv@@	O	-1	11679859
al	O	-1	11679859
[@@	O	-1	11679859
CI@@	O	-1	11679859
]	O	-1	11679859
-@@	O	-1	11679859
2@@	O	-1	11679859
4.@@	O	-1	11679859
6%	O	-1	11679859
to	O	-1	11679859
1@@	O	-1	11679859
1.@@	O	-1	11679859
2@@	O	-1	11679859
%).	O	-1	11679859
The	O	-1	11679859
difference	O	-1	11679859
between	O	-1	11679859
the	O	-1	11679859
b@@	O	-1	11679859
ol@@	O	-1	11679859
us	O	-1	11679859
and	O	-1	11679859
infusion	O	-1	11679859
groups	O	-1	11679859
in	O	-1	11679859
the	O	-1	11679859
perc@@	O	-1	11679859
ent@@	O	-1	11679859
age	O	-1	11679859
of	O	-1	11679859
partic@@	O	-1	11679859
ip@@	O	-1	11679859
ants	O	-1	11679859
who	O	-1	11679859
sa@@	O	-1	11679859
w	O	-1	11679859
a	O	-1	11679859
50@@	O	-1	11679859
%	O	-1	11679859
reduction	O	-1	11679859
in	O	-1	11679859
their	O	-1	11679859
headac@@	B-Disease	D006261	11679859
he	I-Disease	-1	11679859
int@@	O	-1	11679859
ensity	O	-1	11679859
within	O	-1	11679859
30	O	-1	11679859
minutes	O	-1	11679859
was	O	-1	11679859
1@@	O	-1	11679859
1.@@	O	-1	11679859
8@@	O	-1	11679859
%	O	-1	11679859
(@@	O	-1	11679859
95%	O	-1	11679859
C@@	O	-1	11679859
I	O	-1	11679859
-@@	O	-1	11679859
9.@@	O	-1	11679859
6%	O	-1	11679859
to	O	-1	11679859
3@@	O	-1	11679859
3.@@	O	-1	11679859
3@@	O	-1	11679859
%).	O	-1	11679859
The	O	-1	11679859
difference	O	-1	11679859
in	O	-1	11679859
the	O	-1	11679859
perc@@	O	-1	11679859
ent@@	O	-1	11679859
age	O	-1	11679859
of	O	-1	11679859
patients	O	-1	11679859
with	O	-1	11679859
a	O	-1	11679859
50@@	O	-1	11679859
%	O	-1	11679859
reduction	O	-1	11679859
in	O	-1	11679859
their	O	-1	11679859
nausea	B-Disease	D009325	11679859
was	O	-1	11679859
1@@	O	-1	11679859
2.@@	O	-1	11679859
6%	O	-1	11679859
(@@	O	-1	11679859
95%	O	-1	11679859
C@@	O	-1	11679859
I	O	-1	11679859
-@@	O	-1	11679859
4.@@	O	-1	11679859
6%	O	-1	11679859
to	O	-1	11679859
2@@	O	-1	11679859
9.@@	O	-1	11679859
8@@	O	-1	11679859
%).	O	-1	11679859
CONCLUSION:	O	-1	11679859
A	O	-1	11679859
50@@	O	-1	11679859
%	O	-1	11679859
reduction	O	-1	11679859
in	O	-1	11679859
the	O	-1	11679859
incidence	O	-1	11679859
of	O	-1	11679859
ak@@	B-Disease	D017109	11679859
athi@@	I-Disease	-1	11679859
sia	I-Disease	-1	11679859
when	O	-1	11679859
pro@@	B-Chemical	D011346	11679859
chlor@@	I-Chemical	-1	11679859
per@@	I-Chemical	-1	11679859
az@@	I-Chemical	-1	11679859
ine	I-Chemical	-1	11679859
was	O	-1	11679859
administered	O	-1	11679859
by	O	-1	11679859
me@@	O	-1	11679859
ans	O	-1	11679859
of	O	-1	11679859
1@@	O	-1	11679859
5-@@	O	-1	11679859
min@@	O	-1	11679859
ute	O	-1	11679859
intravenous	O	-1	11679859
infusion	O	-1	11679859
versus	O	-1	11679859
a	O	-1	11679859
2-@@	O	-1	11679859
min@@	O	-1	11679859
ute	O	-1	11679859
intravenous	O	-1	11679859
p@@	O	-1	11679859
us@@	O	-1	11679859
h	O	-1	11679859
was	O	-1	11679859
not	O	-1	11679859
det@@	O	-1	11679859
ect@@	O	-1	11679859
ed.	O	-1	11679859
The	O	-1	11679859
efficacy	O	-1	11679859
of	O	-1	11679859
pro@@	B-Chemical	D011346	11679859
chlor@@	I-Chemical	-1	11679859
per@@	I-Chemical	-1	11679859
az@@	I-Chemical	-1	11679859
ine	I-Chemical	-1	11679859
in	O	-1	11679859
the	O	-1	11679859
treatment	O	-1	11679859
of	O	-1	11679859
headac@@	B-Disease	D006261	11679859
he	I-Disease	-1	11679859
and	O	-1	11679859
nausea	B-Disease	D009325	11679859
lik@@	O	-1	11679859
e@@	O	-1	11679859
w@@	O	-1	11679859
is@@	O	-1	11679859
e	O	-1	11679859
did	O	-1	11679859
not	O	-1	11679859
appe@@	O	-1	11679859
ar	O	-1	11679859
to	O	-1	11679859
be	O	-1	11679859
affected	O	-1	11679859
by	O	-1	11679859
the	O	-1	11679859
rate	O	-1	11679859
of	O	-1	11679859
administr@@	O	-1	11679859
ation,	O	-1	11679859
although	O	-1	11679859
no	O	-1	11679859
form@@	O	-1	11679859
al	O	-1	11679859
statis@@	O	-1	11679859
tical	O	-1	11679859
compar@@	O	-1	11679859
is@@	O	-1	11679859
ons	O	-1	11679859
were	O	-1	11679859
ma@@	O	-1	11679859
de@@	O	-1	11679859
.	O	-1	11679859

An@@	B-Chemical	D000961	12041669
ti@@	I-Chemical	-1	12041669
th@@	I-Chemical	-1	12041669
ym@@	I-Chemical	-1	12041669
ocyte	I-Chemical	-1	12041669
glo@@	I-Chemical	-1	12041669
b@@	I-Chemical	-1	12041669
ul@@	I-Chemical	-1	12041669
in	I-Chemical	-1	12041669
in	O	-1	12041669
the	O	-1	12041669
treatment	O	-1	12041669
of	O	-1	12041669
D-@@	B-Chemical	D010396	12041669
pen@@	I-Chemical	-1	12041669
icill@@	I-Chemical	-1	12041669
amine	I-Chemical	-1	12041669
-induced	O	-1	12041669
ap@@	B-Disease	D000741	12041669
las@@	I-Disease	-1	12041669
tic	I-Disease	-1	12041669
anemia	I-Disease	-1	12041669
.	O	-1	12041669
A	O	-1	12041669
patient	O	-1	12041669
who	O	-1	12041669
received	O	-1	12041669
anti@@	B-Chemical	D000961	12041669
th@@	I-Chemical	-1	12041669
ym@@	I-Chemical	-1	12041669
ocyte	I-Chemical	-1	12041669
glo@@	I-Chemical	-1	12041669
b@@	I-Chemical	-1	12041669
ul@@	I-Chemical	-1	12041669
in	I-Chemical	-1	12041669
therapy	O	-1	12041669
for	O	-1	12041669
ap@@	B-Disease	D000741	12041669
las@@	I-Disease	-1	12041669
tic	I-Disease	-1	12041669
anemia	I-Disease	-1	12041669
due	O	-1	12041669
to	O	-1	12041669
D-@@	B-Chemical	D010396	12041669
pen@@	I-Chemical	-1	12041669
icill@@	I-Chemical	-1	12041669
amine	I-Chemical	-1	12041669
therapy	O	-1	12041669
is	O	-1	12041669
descri@@	O	-1	12041669
be@@	O	-1	12041669
d.	O	-1	12041669
B@@	O	-1	12041669
one	O	-1	12041669
m@@	O	-1	12041669
ar@@	O	-1	12041669
ro@@	O	-1	12041669
w	O	-1	12041669
recovery	O	-1	12041669
and	O	-1	12041669
peripheral	O	-1	12041669
blood	O	-1	12041669
recovery	O	-1	12041669
were	O	-1	12041669
complete	O	-1	12041669
1	O	-1	12041669
mon@@	O	-1	12041669
th	O	-1	12041669
and	O	-1	12041669
3	O	-1	12041669
month@@	O	-1	12041669
s,	O	-1	12041669
respectivel@@	O	-1	12041669
y,	O	-1	12041669
after	O	-1	12041669
treatment,	O	-1	12041669
and	O	-1	12041669
blood	O	-1	12041669
trans@@	O	-1	12041669
f@@	O	-1	12041669
usion	O	-1	12041669
or	O	-1	12041669
other	O	-1	12041669
therap@@	O	-1	12041669
i@@	O	-1	12041669
es	O	-1	12041669
were	O	-1	12041669
not	O	-1	12041669
nec@@	O	-1	12041669
ess@@	O	-1	12041669
ary	O	-1	12041669
in	O	-1	12041669
a	O	-1	12041669
follow-up	O	-1	12041669
period	O	-1	12041669
of	O	-1	12041669
more	O	-1	12041669
than	O	-1	12041669
2	O	-1	12041669
year@@	O	-1	12041669
s.	O	-1	12041669
U@@	O	-1	12041669
se	O	-1	12041669
of	O	-1	12041669
anti@@	B-Chemical	D000961	12041669
th@@	I-Chemical	-1	12041669
ym@@	I-Chemical	-1	12041669
ocyte	I-Chemical	-1	12041669
glo@@	I-Chemical	-1	12041669
b@@	I-Chemical	-1	12041669
ul@@	I-Chemical	-1	12041669
in	I-Chemical	-1	12041669
may	O	-1	12041669
be	O	-1	12041669
the	O	-1	12041669
op@@	O	-1	12041669
tim@@	O	-1	12041669
al	O	-1	12041669
treatment	O	-1	12041669
of	O	-1	12041669
D-@@	B-Chemical	D010396	12041669
pen@@	I-Chemical	-1	12041669
icill@@	I-Chemical	-1	12041669
amine	I-Chemical	-1	12041669
-induced	O	-1	12041669
ap@@	B-Disease	D000741	12041669
las@@	I-Disease	-1	12041669
tic	I-Disease	-1	12041669
anemia	I-Disease	-1	12041669
.	O	-1	12041669

The	O	-1	12198388
rel@@	O	-1	12198388
ationship	O	-1	12198388
between	O	-1	12198388
hippocamp@@	O	-1	12198388
al	O	-1	12198388
acet@@	B-Chemical	D000109	12198388
ylcholine	I-Chemical	-1	12198388
release	O	-1	12198388
and	O	-1	12198388
cholinergic	O	-1	12198388
convul@@	O	-1	12198388
s@@	O	-1	12198388
ant	O	-1	12198388
sensitivity	O	-1	12198388
in	O	-1	12198388
withdrawal	O	-1	12198388
seizure	B-Disease	D012640	12198388
-@@	O	-1	12198388
pr@@	O	-1	12198388
one	O	-1	12198388
and	O	-1	12198388
withdrawal	O	-1	12198388
seizure	B-Disease	D012640	12198388
-@@	O	-1	12198388
resist@@	O	-1	12198388
ant	O	-1	12198388
sel@@	O	-1	12198388
ected	O	-1	12198388
mouse	O	-1	12198388
lin@@	O	-1	12198388
es.	O	-1	12198388
BACKGROUND:	O	-1	12198388
The	O	-1	12198388
se@@	O	-1	12198388
pto@@	O	-1	12198388
-@@	O	-1	12198388
hippocamp@@	O	-1	12198388
al	O	-1	12198388
cholinergic	O	-1	12198388
path@@	O	-1	12198388
w@@	O	-1	12198388
ay	O	-1	12198388
has	O	-1	12198388
been	O	-1	12198388
implic@@	O	-1	12198388
ated	O	-1	12198388
in	O	-1	12198388
epile@@	O	-1	12198388
pto@@	O	-1	12198388
gene@@	O	-1	12198388
sis,	O	-1	12198388
and	O	-1	12198388
gene@@	O	-1	12198388
tic	O	-1	12198388
factors	O	-1	12198388
influence	O	-1	12198388
the	O	-1	12198388
response	O	-1	12198388
to	O	-1	12198388
cholinergic	O	-1	12198388
agent@@	O	-1	12198388
s,	O	-1	12198388
but	O	-1	12198388
lim@@	O	-1	12198388
ited	O	-1	12198388
data	O	-1	12198388
are	O	-1	12198388
av@@	O	-1	12198388
ail@@	O	-1	12198388
able	O	-1	12198388
on	O	-1	12198388
cholinergic	O	-1	12198388
invol@@	O	-1	12198388
vement	O	-1	12198388
in	O	-1	12198388
alco@@	B-Chemical	D000431	12198388
hol	I-Chemical	-1	12198388
withdrawal	O	-1	12198388
sever@@	O	-1	12198388
ity.	O	-1	12198388
Th@@	O	-1	12198388
us,	O	-1	12198388
the	O	-1	12198388
rel@@	O	-1	12198388
ationship	O	-1	12198388
between	O	-1	12198388
cholinergic	O	-1	12198388
activity	O	-1	12198388
and	O	-1	12198388
respon@@	O	-1	12198388
si@@	O	-1	12198388
ven@@	O	-1	12198388
ess	O	-1	12198388
and	O	-1	12198388
alco@@	B-Chemical	D000431	12198388
hol	I-Chemical	-1	12198388
withdrawal	O	-1	12198388
was	O	-1	12198388
investigated	O	-1	12198388
in	O	-1	12198388
a	O	-1	12198388
gene@@	O	-1	12198388
tic	O	-1	12198388
anim@@	O	-1	12198388
al	O	-1	12198388
model	O	-1	12198388
of	O	-1	12198388
eth@@	B-Chemical	D000431	12198388
an@@	I-Chemical	-1	12198388
ol	I-Chemical	-1	12198388
withdrawal	O	-1	12198388
sever@@	O	-1	12198388
ity.	O	-1	12198388
METHODS:	O	-1	12198388
Ch@@	O	-1	12198388
ol@@	O	-1	12198388
inergic	O	-1	12198388
convul@@	O	-1	12198388
s@@	O	-1	12198388
ant	O	-1	12198388
sensitivity	O	-1	12198388
was	O	-1	12198388
examined	O	-1	12198388
in	O	-1	12198388
alco@@	B-Chemical	D000431	12198388
hol	I-Chemical	-1	12198388
-@@	O	-1	12198388
n@@	O	-1	12198388
a	O	-1	12198388
ve	O	-1	12198388
W@@	O	-1	12198388
i@@	O	-1	12198388
th@@	O	-1	12198388
draw@@	O	-1	12198388
al	O	-1	12198388
S@@	B-Disease	D012640	12198388
e@@	I-Disease	-1	12198388
iz@@	I-Disease	-1	12198388
ure	I-Disease	-1	12198388
-@@	O	-1	12198388
P@@	O	-1	12198388
r@@	O	-1	12198388
one	O	-1	12198388
(@@	O	-1	12198388
W@@	O	-1	12198388
S@@	O	-1	12198388
P)	O	-1	12198388
and@@	O	-1	12198388
-@@	O	-1	12198388
Re@@	O	-1	12198388
sist@@	O	-1	12198388
ant	O	-1	12198388
(@@	O	-1	12198388
W@@	O	-1	12198388
SR@@	O	-1	12198388
)	O	-1	12198388
mice.	O	-1	12198388
An@@	O	-1	12198388
im@@	O	-1	12198388
als	O	-1	12198388
were	O	-1	12198388
administered	O	-1	12198388
nicotine	B-Chemical	D009538	12198388
,	O	-1	12198388
carb@@	B-Chemical	D002217	12198388
ac@@	I-Chemical	-1	12198388
hol	I-Chemical	-1	12198388
,	O	-1	12198388
or	O	-1	12198388
ne@@	B-Chemical	D009388	12198388
os@@	I-Chemical	-1	12198388
tig@@	I-Chemical	-1	12198388
mine	I-Chemical	-1	12198388
vi@@	O	-1	12198388
a	O	-1	12198388
tim@@	O	-1	12198388
ed	O	-1	12198388
t@@	O	-1	12198388
a@@	O	-1	12198388
il	O	-1	12198388
ve@@	O	-1	12198388
in	O	-1	12198388
infu@@	O	-1	12198388
sion,	O	-1	12198388
and	O	-1	12198388
the	O	-1	12198388
lat@@	O	-1	12198388
en@@	O	-1	12198388
ci@@	O	-1	12198388
es	O	-1	12198388
to	O	-1	12198388
onset	O	-1	12198388
of	O	-1	12198388
trem@@	B-Disease	D014202	12198388
or	I-Disease	-1	12198388
and	O	-1	12198388
clon@@	O	-1	12198388
us	O	-1	12198388
were	O	-1	12198388
recor@@	O	-1	12198388
ded	O	-1	12198388
and	O	-1	12198388
conver@@	O	-1	12198388
ted	O	-1	12198388
to	O	-1	12198388
th@@	O	-1	12198388
res@@	O	-1	12198388
h@@	O	-1	12198388
old	O	-1	12198388
dose.	O	-1	12198388
We	O	-1	12198388
also	O	-1	12198388
used	O	-1	12198388
micro@@	O	-1	12198388
dialy@@	O	-1	12198388
sis	O	-1	12198388
to	O	-1	12198388
meas@@	O	-1	12198388
ure	O	-1	12198388
bas@@	O	-1	12198388
al	O	-1	12198388
and	O	-1	12198388
pot@@	B-Chemical	D011188	12198388
assi@@	I-Chemical	-1	12198388
um	I-Chemical	-1	12198388
-@@	O	-1	12198388
stimul@@	O	-1	12198388
ated	O	-1	12198388
acet@@	B-Chemical	D000109	12198388
ylcholine	I-Chemical	-1	12198388
(	O	-1	12198388
AC@@	B-Chemical	D000109	12198388
h	I-Chemical	-1	12198388
)	O	-1	12198388
release	O	-1	12198388
in	O	-1	12198388
the	O	-1	12198388
CA@@	O	-1	12198388
1	O	-1	12198388
regi@@	O	-1	12198388
on	O	-1	12198388
of	O	-1	12198388
the	O	-1	12198388
hippocamp@@	O	-1	12198388
us.	O	-1	12198388
P@@	B-Chemical	D011188	12198388
ot@@	I-Chemical	-1	12198388
assi@@	I-Chemical	-1	12198388
um	I-Chemical	-1	12198388
was	O	-1	12198388
ap@@	O	-1	12198388
pl@@	O	-1	12198388
ied	O	-1	12198388
by	O	-1	12198388
re@@	O	-1	12198388
verse	O	-1	12198388
dialy@@	O	-1	12198388
sis	O	-1	12198388
tw@@	O	-1	12198388
ic@@	O	-1	12198388
e,	O	-1	12198388
se@@	O	-1	12198388
par@@	O	-1	12198388
ated	O	-1	12198388
by	O	-1	12198388
7@@	O	-1	12198388
5	O	-1	12198388
min@@	O	-1	12198388
.	O	-1	12198388
H@@	O	-1	12198388
ip@@	O	-1	12198388
p@@	O	-1	12198388
ocamp@@	O	-1	12198388
al	O	-1	12198388
AC@@	B-Chemical	D000109	12198388
h	I-Chemical	-1	12198388
also	O	-1	12198388
was	O	-1	12198388
measured	O	-1	12198388
during	O	-1	12198388
test@@	O	-1	12198388
ing	O	-1	12198388
for	O	-1	12198388
h@@	O	-1	12198388
and@@	O	-1	12198388
l@@	O	-1	12198388
ing@@	O	-1	12198388
-induced	O	-1	12198388
convul@@	B-Disease	D012640	12198388
sions	I-Disease	-1	12198388
.	O	-1	12198388
RESULTS:	O	-1	12198388
S@@	O	-1	12198388
en@@	O	-1	12198388
si@@	O	-1	12198388
tivity	O	-1	12198388
to	O	-1	12198388
several	O	-1	12198388
convul@@	B-Disease	D012640	12198388
sion	I-Disease	-1	12198388
en@@	O	-1	12198388
d@@	O	-1	12198388
po@@	O	-1	12198388
int@@	O	-1	12198388
s	O	-1	12198388
induced	O	-1	12198388
by	O	-1	12198388
nicotine	B-Chemical	D009538	12198388
,	O	-1	12198388
carb@@	B-Chemical	D002217	12198388
ac@@	I-Chemical	-1	12198388
hol	I-Chemical	-1	12198388
,	O	-1	12198388
and	O	-1	12198388
ne@@	B-Chemical	D009388	12198388
os@@	I-Chemical	-1	12198388
tig@@	I-Chemical	-1	12198388
mine	I-Chemical	-1	12198388
were	O	-1	12198388
significantly	O	-1	12198388
greater	O	-1	12198388
in	O	-1	12198388
W@@	O	-1	12198388
S@@	O	-1	12198388
R	O	-1	12198388
versus	O	-1	12198388
W@@	O	-1	12198388
S@@	O	-1	12198388
P	O	-1	12198388
mice.	O	-1	12198388
In	O	-1	12198388
micro@@	O	-1	12198388
dialy@@	O	-1	12198388
sis	O	-1	12198388
experim@@	O	-1	12198388
ent@@	O	-1	12198388
s,	O	-1	12198388
the	O	-1	12198388
lin@@	O	-1	12198388
es	O	-1	12198388
did	O	-1	12198388
not	O	-1	12198388
diff@@	O	-1	12198388
er	O	-1	12198388
in	O	-1	12198388
bas@@	O	-1	12198388
al	O	-1	12198388
release	O	-1	12198388
of	O	-1	12198388
AC@@	B-Chemical	D000109	12198388
h	I-Chemical	-1	12198388
,	O	-1	12198388
and	O	-1	12198388
50	O	-1	12198388
m@@	O	-1	12198388
M	O	-1	12198388
K@@	B-Chemical	C522374	12198388
C@@	I-Chemical	-1	12198388
l	I-Chemical	-1	12198388
increased	O	-1	12198388
AC@@	B-Chemical	D000109	12198388
h	I-Chemical	-1	12198388
out@@	O	-1	12198388
pu@@	O	-1	12198388
t	O	-1	12198388
in	O	-1	12198388
both	O	-1	12198388
lin@@	O	-1	12198388
es	O	-1	12198388
of	O	-1	12198388
mice.	O	-1	12198388
However,	O	-1	12198388
the	O	-1	12198388
increase	O	-1	12198388
in	O	-1	12198388
release	O	-1	12198388
of	O	-1	12198388
AC@@	B-Chemical	D000109	12198388
h	I-Chemical	-1	12198388
produced	O	-1	12198388
by	O	-1	12198388
the	O	-1	12198388
first	O	-1	12198388
ap@@	O	-1	12198388
plic@@	O	-1	12198388
ation	O	-1	12198388
of	O	-1	12198388
K@@	B-Chemical	C522374	12198388
C@@	I-Chemical	-1	12198388
l	I-Chemical	-1	12198388
was	O	-1	12198388
2-@@	O	-1	12198388
fol@@	O	-1	12198388
d	O	-1	12198388
higher	O	-1	12198388
in	O	-1	12198388
W@@	O	-1	12198388
S@@	O	-1	12198388
P	O	-1	12198388
versus	O	-1	12198388
W@@	O	-1	12198388
S@@	O	-1	12198388
R	O	-1	12198388
mice.	O	-1	12198388
Whe@@	O	-1	12198388
n	O	-1	12198388
hippocamp@@	O	-1	12198388
al	O	-1	12198388
AC@@	B-Chemical	D000109	12198388
h	I-Chemical	-1	12198388
was	O	-1	12198388
measured	O	-1	12198388
during	O	-1	12198388
test@@	O	-1	12198388
ing	O	-1	12198388
for	O	-1	12198388
h@@	O	-1	12198388
and@@	O	-1	12198388
l@@	O	-1	12198388
ing@@	O	-1	12198388
-induced	O	-1	12198388
convul@@	B-Disease	D012640	12198388
sions	I-Disease	-1	12198388
,	O	-1	12198388
extrac@@	O	-1	12198388
ell@@	O	-1	12198388
ular	O	-1	12198388
AC@@	B-Chemical	D000109	12198388
h	I-Chemical	-1	12198388
was	O	-1	12198388
significantly	O	-1	12198388
elevated	O	-1	12198388
(1@@	O	-1	12198388
9@@	O	-1	12198388
2@@	O	-1	12198388
%)	O	-1	12198388
in	O	-1	12198388
W@@	O	-1	12198388
S@@	O	-1	12198388
P	O	-1	12198388
mic@@	O	-1	12198388
e,	O	-1	12198388
but	O	-1	12198388
was	O	-1	12198388
non@@	O	-1	12198388
significantly	O	-1	12198388
elevated	O	-1	12198388
(5@@	O	-1	12198388
9@@	O	-1	12198388
%)	O	-1	12198388
in	O	-1	12198388
W@@	O	-1	12198388
S@@	O	-1	12198388
R	O	-1	12198388
mice.	O	-1	12198388
CONCLUSIONS:	O	-1	12198388
These	O	-1	12198388
results	O	-1	12198388
suggest	O	-1	12198388
that	O	-1	12198388
differences	O	-1	12198388
in	O	-1	12198388
cholinergic	O	-1	12198388
activity	O	-1	12198388
and	O	-1	12198388
post@@	O	-1	12198388
syn@@	O	-1	12198388
ap@@	O	-1	12198388
tic	O	-1	12198388
sensitivity	O	-1	12198388
to	O	-1	12198388
cholinergic	O	-1	12198388
convul@@	B-Disease	D012640	12198388
s@@	I-Disease	-1	12198388
ants	I-Disease	-1	12198388
may	O	-1	12198388
be	O	-1	12198388
associated	O	-1	12198388
with	O	-1	12198388
eth@@	B-Chemical	D000431	12198388
an@@	I-Chemical	-1	12198388
ol	I-Chemical	-1	12198388
withdrawal	O	-1	12198388
severity	O	-1	12198388
and	O	-1	12198388
implic@@	O	-1	12198388
ate	O	-1	12198388
cholinergic	O	-1	12198388
mechanisms	O	-1	12198388
in	O	-1	12198388
alco@@	B-Chemical	D000431	12198388
hol	I-Chemical	-1	12198388
withdraw@@	O	-1	12198388
al.	O	-1	12198388
S@@	O	-1	12198388
p@@	O	-1	12198388
ec@@	O	-1	12198388
ific@@	O	-1	12198388
ally,	O	-1	12198388
W@@	O	-1	12198388
S@@	O	-1	12198388
P	O	-1	12198388
mice	O	-1	12198388
may	O	-1	12198388
have	O	-1	12198388
lower	O	-1	12198388
sensitivity	O	-1	12198388
to	O	-1	12198388
cholinergic	O	-1	12198388
convul@@	B-Disease	D012640	12198388
s@@	I-Disease	-1	12198388
ants	I-Disease	-1	12198388
compared	O	-1	12198388
with	O	-1	12198388
W@@	O	-1	12198388
S@@	O	-1	12198388
R	O	-1	12198388
because	O	-1	12198388
of	O	-1	12198388
post@@	O	-1	12198388
syn@@	O	-1	12198388
ap@@	O	-1	12198388
tic	O	-1	12198388
receptor	O	-1	12198388
des@@	O	-1	12198388
en@@	O	-1	12198388
si@@	O	-1	12198388
tiz@@	O	-1	12198388
ation	O	-1	12198388
b@@	O	-1	12198388
rou@@	O	-1	12198388
ght	O	-1	12198388
on	O	-1	12198388
by	O	-1	12198388
higher	O	-1	12198388
activity	O	-1	12198388
of	O	-1	12198388
cholinergic	O	-1	12198388
neuron@@	O	-1	12198388
s.	O	-1	12198388

P@@	O	-1	12574103
ren@@	O	-1	12574103
atal	O	-1	12574103
de@@	B-Chemical	D003907	12574103
xameth@@	I-Chemical	-1	12574103
as@@	I-Chemical	-1	12574103
one	I-Chemical	-1	12574103
pro@@	O	-1	12574103
gram@@	O	-1	12574103
s	O	-1	12574103
hypertension	B-Disease	D006973	12574103
and	O	-1	12574103
renal	B-Disease	D007674	12574103
injury	I-Disease	-1	12574103
in	O	-1	12574103
the	O	-1	12574103
rat@@	O	-1	12574103
.	O	-1	12574103
D@@	O	-1	12574103
ex@@	O	-1	12574103
ameth@@	O	-1	12574103
as@@	O	-1	12574103
one	O	-1	12574103
is	O	-1	12574103
frequ@@	O	-1	12574103
ently	O	-1	12574103
administered	O	-1	12574103
to	O	-1	12574103
the	O	-1	12574103
develop@@	O	-1	12574103
ing	O	-1	12574103
f@@	O	-1	12574103
et@@	O	-1	12574103
us	O	-1	12574103
to	O	-1	12574103
ac@@	O	-1	12574103
ce@@	O	-1	12574103
l@@	O	-1	12574103
er@@	O	-1	12574103
ate	O	-1	12574103
pulmonary	O	-1	12574103
develop@@	O	-1	12574103
ment.	O	-1	12574103
The	O	-1	12574103
pur@@	O	-1	12574103
p@@	O	-1	12574103
ose	O	-1	12574103
of	O	-1	12574103
the	O	-1	12574103
present	O	-1	12574103
study	O	-1	12574103
was	O	-1	12574103
to	O	-1	12574103
determine	O	-1	12574103
if	O	-1	12574103
p@@	O	-1	12574103
ren@@	O	-1	12574103
atal	O	-1	12574103
de@@	B-Chemical	D003907	12574103
xameth@@	I-Chemical	-1	12574103
as@@	I-Chemical	-1	12574103
one	I-Chemical	-1	12574103
pro@@	O	-1	12574103
gram@@	O	-1	12574103
m@@	O	-1	12574103
ed	O	-1	12574103
a	O	-1	12574103
progressive	O	-1	12574103
increase	B-Disease	D006973	12574103
in	I-Disease	-1	12574103
blood	I-Disease	-1	12574103
pressure	I-Disease	-1	12574103
and	O	-1	12574103
renal	B-Disease	D007674	12574103
injury	I-Disease	-1	12574103
in	O	-1	12574103
rats.	O	-1	12574103
Pre@@	O	-1	12574103
gn@@	O	-1	12574103
ant	O	-1	12574103
rats	O	-1	12574103
were	O	-1	12574103
given	O	-1	12574103
either	O	-1	12574103
ve@@	O	-1	12574103
h@@	O	-1	12574103
ic@@	O	-1	12574103
le	O	-1	12574103
or	O	-1	12574103
2	O	-1	12574103
daily	O	-1	12574103
intra@@	O	-1	12574103
per@@	O	-1	12574103
it@@	O	-1	12574103
one@@	O	-1	12574103
al	O	-1	12574103
injec@@	O	-1	12574103
tions	O	-1	12574103
of	O	-1	12574103
de@@	B-Chemical	D003907	12574103
xameth@@	I-Chemical	-1	12574103
as@@	I-Chemical	-1	12574103
one	I-Chemical	-1	12574103
(0.@@	O	-1	12574103
2	O	-1	12574103
mg/kg	O	-1	12574103
body	O	-1	12574103
weigh@@	O	-1	12574103
t@@	O	-1	12574103
)	O	-1	12574103
on	O	-1	12574103
g@@	O	-1	12574103
est@@	O	-1	12574103
ation@@	O	-1	12574103
al	O	-1	12574103
days	O	-1	12574103
11	O	-1	12574103
and	O	-1	12574103
12@@	O	-1	12574103
,	O	-1	12574103
13	O	-1	12574103
and	O	-1	12574103
14@@	O	-1	12574103
,	O	-1	12574103
15	O	-1	12574103
and	O	-1	12574103
1@@	O	-1	12574103
6,	O	-1	12574103
17	O	-1	12574103
and	O	-1	12574103
18@@	O	-1	12574103
,	O	-1	12574103
or	O	-1	12574103
1@@	O	-1	12574103
9	O	-1	12574103
and	O	-1	12574103
20@@	O	-1	12574103
.	O	-1	12574103
O@@	O	-1	12574103
ff@@	O	-1	12574103
sp@@	O	-1	12574103
r@@	O	-1	12574103
ing	O	-1	12574103
of	O	-1	12574103
rats	O	-1	12574103
administered	O	-1	12574103
de@@	B-Chemical	D003907	12574103
xameth@@	I-Chemical	-1	12574103
as@@	I-Chemical	-1	12574103
one	I-Chemical	-1	12574103
on	O	-1	12574103
days	O	-1	12574103
15	O	-1	12574103
and	O	-1	12574103
16	O	-1	12574103
g@@	O	-1	12574103
est@@	O	-1	12574103
ation	O	-1	12574103
had	O	-1	12574103
a	O	-1	12574103
20@@	O	-1	12574103
%	O	-1	12574103
reduction	B-Disease	D007674	12574103
in	I-Disease	-1	12574103
glomerular	I-Disease	-1	12574103
number	I-Disease	-1	12574103
compared	O	-1	12574103
with	O	-1	12574103
control	O	-1	12574103
at	O	-1	12574103
6	O	-1	12574103
to	O	-1	12574103
9	O	-1	12574103
months	O	-1	12574103
of	O	-1	12574103
age	O	-1	12574103
(2@@	O	-1	12574103
2	O	-1	12574103
5@@	O	-1	12574103
27@@	O	-1	12574103
+/-@@	O	-1	12574103
50@@	O	-1	12574103
9	O	-1	12574103
versus	O	-1	12574103
2@@	O	-1	12574103
8	O	-1	12574103
0@@	O	-1	12574103
50@@	O	-1	12574103
+/-@@	O	-1	12574103
5@@	O	-1	12574103
6@@	O	-1	12574103
1,	O	-1	12574103
P@@	O	-1	12574103
<@@	O	-1	12574103
0.05@@	O	-1	12574103
),	O	-1	12574103
which	O	-1	12574103
was	O	-1	12574103
compar@@	O	-1	12574103
able	O	-1	12574103
to	O	-1	12574103
the	O	-1	12574103
perc@@	O	-1	12574103
ent	O	-1	12574103
reduction	O	-1	12574103
in	O	-1	12574103
glomerul@@	O	-1	12574103
i	O	-1	12574103
measured	O	-1	12574103
at	O	-1	12574103
3	O	-1	12574103
weeks	O	-1	12574103
of	O	-1	12574103
age.	O	-1	12574103
Si@@	O	-1	12574103
x@@	O	-1	12574103
-	O	-1	12574103
to	O	-1	12574103
9@@	O	-1	12574103
-@@	O	-1	12574103
mon@@	O	-1	12574103
th	O	-1	12574103
old	O	-1	12574103
rats	O	-1	12574103
receiving	O	-1	12574103
p@@	O	-1	12574103
ren@@	O	-1	12574103
atal	O	-1	12574103
de@@	B-Chemical	D003907	12574103
xameth@@	I-Chemical	-1	12574103
as@@	I-Chemical	-1	12574103
one	I-Chemical	-1	12574103
on	O	-1	12574103
days	O	-1	12574103
17	O	-1	12574103
and	O	-1	12574103
1@@	O	-1	12574103
8	O	-1	12574103
of	O	-1	12574103
g@@	O	-1	12574103
est@@	O	-1	12574103
ation	O	-1	12574103
had	O	-1	12574103
a	O	-1	12574103
17@@	O	-1	12574103
%	O	-1	12574103
reduction	O	-1	12574103
in	O	-1	12574103
glomerul@@	O	-1	12574103
i	O	-1	12574103
(2@@	O	-1	12574103
3	O	-1	12574103
3@@	O	-1	12574103
80@@	O	-1	12574103
+/-@@	O	-1	12574103
5@@	O	-1	12574103
8@@	O	-1	12574103
7@@	O	-1	12574103
)	O	-1	12574103
compared	O	-1	12574103
with	O	-1	12574103
control	O	-1	12574103
rats	O	-1	12574103
(P@@	O	-1	12574103
<@@	O	-1	12574103
0.05@@	O	-1	12574103
).	O	-1	12574103
M@@	O	-1	12574103
al@@	O	-1	12574103
e	O	-1	12574103
rats	O	-1	12574103
that	O	-1	12574103
received	O	-1	12574103
p@@	O	-1	12574103
ren@@	O	-1	12574103
atal	O	-1	12574103
de@@	B-Chemical	D003907	12574103
xameth@@	I-Chemical	-1	12574103
as@@	I-Chemical	-1	12574103
one	I-Chemical	-1	12574103
on	O	-1	12574103
days	O	-1	12574103
15	O	-1	12574103
and	O	-1	12574103
1@@	O	-1	12574103
6,	O	-1	12574103
17	O	-1	12574103
and	O	-1	12574103
18@@	O	-1	12574103
,	O	-1	12574103
and	O	-1	12574103
13	O	-1	12574103
and	O	-1	12574103
14	O	-1	12574103
of	O	-1	12574103
g@@	O	-1	12574103
est@@	O	-1	12574103
ation	O	-1	12574103
had	O	-1	12574103
elevated	B-Disease	D006973	12574103
blood	I-Disease	-1	12574103
pressu@@	I-Disease	-1	12574103
res	I-Disease	-1	12574103
at	O	-1	12574103
6	O	-1	12574103
months	O	-1	12574103
of	O	-1	12574103
ag@@	O	-1	12574103
e@@	O	-1	12574103
;	O	-1	12574103
the	O	-1	12574103
lat@@	O	-1	12574103
ter	O	-1	12574103
group	O	-1	12574103
did	O	-1	12574103
not	O	-1	12574103
have	O	-1	12574103
a	O	-1	12574103
reduction	B-Disease	D007674	12574103
in	I-Disease	-1	12574103
glomerular	I-Disease	-1	12574103
number	I-Disease	-1	12574103
.	O	-1	12574103
Ad@@	O	-1	12574103
ult	O	-1	12574103
rats	O	-1	12574103
given	O	-1	12574103
de@@	B-Chemical	D003907	12574103
xameth@@	I-Chemical	-1	12574103
as@@	I-Chemical	-1	12574103
one	I-Chemical	-1	12574103
on	O	-1	12574103
days	O	-1	12574103
15	O	-1	12574103
and	O	-1	12574103
16	O	-1	12574103
of	O	-1	12574103
g@@	O	-1	12574103
est@@	O	-1	12574103
ation	O	-1	12574103
had	O	-1	12574103
more	O	-1	12574103
glomerul@@	O	-1	12574103
i	O	-1	12574103
with	O	-1	12574103
glomer@@	B-Disease	D005921	12574103
u@@	I-Disease	-1	12574103
los@@	I-Disease	-1	12574103
clero@@	I-Disease	-1	12574103
sis	I-Disease	-1	12574103
than	O	-1	12574103
control	O	-1	12574103
rats.	O	-1	12574103
This	O	-1	12574103
study	O	-1	12574103
show@@	O	-1	12574103
s	O	-1	12574103
that	O	-1	12574103
p@@	O	-1	12574103
ren@@	O	-1	12574103
atal	O	-1	12574103
de@@	B-Chemical	D003907	12574103
xameth@@	I-Chemical	-1	12574103
as@@	I-Chemical	-1	12574103
one	I-Chemical	-1	12574103
in	O	-1	12574103
rats	O	-1	12574103
results	O	-1	12574103
in	O	-1	12574103
a	O	-1	12574103
reduction	B-Disease	D007674	12574103
in	I-Disease	-1	12574103
glomerular	I-Disease	-1	12574103
number	I-Disease	-1	12574103
,	O	-1	12574103
glomer@@	B-Disease	D005921	12574103
u@@	I-Disease	-1	12574103
los@@	I-Disease	-1	12574103
clero@@	I-Disease	-1	12574103
sis	I-Disease	-1	12574103
,	O	-1	12574103
and	O	-1	12574103
hypertension	B-Disease	D006973	12574103
when	O	-1	12574103
administered	O	-1	12574103
at	O	-1	12574103
specific	O	-1	12574103
po@@	O	-1	12574103
int@@	O	-1	12574103
s	O	-1	12574103
during	O	-1	12574103
g@@	O	-1	12574103
est@@	O	-1	12574103
ation.	O	-1	12574103
H@@	B-Disease	D006973	12574103
y@@	I-Disease	-1	12574103
per@@	I-Disease	-1	12574103
ten@@	I-Disease	-1	12574103
sion	I-Disease	-1	12574103
was	O	-1	12574103
observed	O	-1	12574103
in	O	-1	12574103
animals	O	-1	12574103
that	O	-1	12574103
had	O	-1	12574103
a	O	-1	12574103
reduction	O	-1	12574103
in	O	-1	12574103
glomerul@@	O	-1	12574103
i	O	-1	12574103
as	O	-1	12574103
well	O	-1	12574103
as	O	-1	12574103
in	O	-1	12574103
a	O	-1	12574103
group	O	-1	12574103
that	O	-1	12574103
did	O	-1	12574103
not	O	-1	12574103
have	O	-1	12574103
a	O	-1	12574103
reduction	B-Disease	D007674	12574103
in	I-Disease	-1	12574103
glomerular	I-Disease	-1	12574103
number	I-Disease	-1	12574103
,	O	-1	12574103
suggesting	O	-1	12574103
that	O	-1	12574103
a	O	-1	12574103
reduction	B-Disease	D007674	12574103
in	I-Disease	-1	12574103
glomerular	I-Disease	-1	12574103
number	I-Disease	-1	12574103
is	O	-1	12574103
not	O	-1	12574103
the	O	-1	12574103
sol@@	O	-1	12574103
e	O	-1	12574103
cause	O	-1	12574103
for	O	-1	12574103
the	O	-1	12574103
development	O	-1	12574103
of	O	-1	12574103
hypertension	B-Disease	D006973	12574103
.	O	-1	12574103

The	O	-1	12615818
risk	O	-1	12615818
of	O	-1	12615818
venous	B-Disease	D054556	12615818
thrombo@@	I-Disease	-1	12615818
emb@@	I-Disease	-1	12615818
ol@@	I-Disease	-1	12615818
ism	I-Disease	-1	12615818
in	O	-1	12615818
women	O	-1	12615818
prescri@@	O	-1	12615818
bed	O	-1	12615818
cy@@	B-Chemical	D017373	12615818
pro@@	I-Chemical	-1	12615818
ter@@	I-Chemical	-1	12615818
one	I-Chemical	-1	12615818
acet@@	I-Chemical	-1	12615818
ate	I-Chemical	-1	12615818
in	O	-1	12615818
combination	O	-1	12615818
with	O	-1	12615818
eth@@	B-Chemical	D004997	12615818
in@@	I-Chemical	-1	12615818
yl	I-Chemical	-1	12615818
est@@	I-Chemical	-1	12615818
radi@@	I-Chemical	-1	12615818
ol	I-Chemical	-1	12615818
:	O	-1	12615818
a	O	-1	12615818
ne@@	O	-1	12615818
st@@	O	-1	12615818
ed	O	-1	12615818
co@@	O	-1	12615818
h@@	O	-1	12615818
ort	O	-1	12615818
analysis	O	-1	12615818
and	O	-1	12615818
cas@@	O	-1	12615818
e-@@	O	-1	12615818
control	O	-1	12615818
study.	O	-1	12615818
BACKGROUND:	O	-1	12615818
C@@	B-Chemical	D017373	12615818
y@@	I-Chemical	-1	12615818
pro@@	I-Chemical	-1	12615818
ter@@	I-Chemical	-1	12615818
one	I-Chemical	-1	12615818
acet@@	I-Chemical	-1	12615818
ate	I-Chemical	-1	12615818
combined	O	-1	12615818
with	O	-1	12615818
eth@@	B-Chemical	D004997	12615818
in@@	I-Chemical	-1	12615818
yl	I-Chemical	-1	12615818
est@@	I-Chemical	-1	12615818
radi@@	I-Chemical	-1	12615818
ol	I-Chemical	-1	12615818
(	O	-1	12615818
C@@	B-Chemical	D017373	12615818
P@@	I-Chemical	-1	12615818
A	I-Chemical	-1	12615818
/	O	-1	12615818
E@@	B-Chemical	D004997	12615818
E	I-Chemical	-1	12615818
)	O	-1	12615818
is	O	-1	12615818
l@@	O	-1	12615818
ic@@	O	-1	12615818
en@@	O	-1	12615818
sed	O	-1	12615818
in	O	-1	12615818
the	O	-1	12615818
U@@	O	-1	12615818
K	O	-1	12615818
for	O	-1	12615818
the	O	-1	12615818
treatment	O	-1	12615818
of	O	-1	12615818
women	O	-1	12615818
with	O	-1	12615818
ac@@	B-Disease	D000152	12615818
n@@	I-Disease	-1	12615818
e	I-Disease	-1	12615818
and	O	-1	12615818
hi@@	B-Disease	D006628	12615818
r@@	I-Disease	-1	12615818
su@@	I-Disease	-1	12615818
tis@@	I-Disease	-1	12615818
m	I-Disease	-1	12615818
and	O	-1	12615818
is	O	-1	12615818
also	O	-1	12615818
a	O	-1	12615818
treatment	O	-1	12615818
op@@	O	-1	12615818
tion	O	-1	12615818
for	O	-1	12615818
pol@@	B-Disease	D011085	12615818
yc@@	I-Disease	-1	12615818
ys@@	I-Disease	-1	12615818
tic	I-Disease	-1	12615818
o@@	I-Disease	-1	12615818
v@@	I-Disease	-1	12615818
ary	I-Disease	-1	12615818
syndrome	I-Disease	-1	12615818
(	O	-1	12615818
P@@	B-Disease	D011085	12615818
CO@@	I-Disease	-1	12615818
S	I-Disease	-1	12615818
).	O	-1	12615818
Pre@@	O	-1	12615818
vi@@	O	-1	12615818
ous	O	-1	12615818
studies	O	-1	12615818
have	O	-1	12615818
demonstrated	O	-1	12615818
an	O	-1	12615818
increased	O	-1	12615818
risk	O	-1	12615818
of	O	-1	12615818
venous	B-Disease	D054556	12615818
thrombo@@	I-Disease	-1	12615818
emb@@	I-Disease	-1	12615818
ol@@	I-Disease	-1	12615818
ism	I-Disease	-1	12615818
(	O	-1	12615818
V@@	B-Disease	D054556	12615818
T@@	I-Disease	-1	12615818
E	I-Disease	-1	12615818
)	O	-1	12615818
associated	O	-1	12615818
with	O	-1	12615818
C@@	B-Chemical	D017373	12615818
P@@	I-Chemical	-1	12615818
A	I-Chemical	-1	12615818
/	O	-1	12615818
E@@	B-Chemical	D004997	12615818
E	I-Chemical	-1	12615818
compared	O	-1	12615818
with	O	-1	12615818
con@@	O	-1	12615818
ven@@	O	-1	12615818
tional	O	-1	12615818
combined	O	-1	12615818
oral	B-Chemical	D003276	12615818
contrac@@	I-Chemical	-1	12615818
ep@@	I-Chemical	-1	12615818
tiv@@	I-Chemical	-1	12615818
es	I-Chemical	-1	12615818
(C@@	O	-1	12615818
O@@	O	-1	12615818
C@@	O	-1	12615818
s@@	O	-1	12615818
).	O	-1	12615818
We	O	-1	12615818
be@@	O	-1	12615818
li@@	O	-1	12615818
e@@	O	-1	12615818
ve	O	-1	12615818
the	O	-1	12615818
results	O	-1	12615818
of	O	-1	12615818
those	O	-1	12615818
studies	O	-1	12615818
may	O	-1	12615818
have	O	-1	12615818
been	O	-1	12615818
affected	O	-1	12615818
by	O	-1	12615818
re@@	O	-1	12615818
si@@	O	-1	12615818
du@@	O	-1	12615818
al	O	-1	12615818
conf@@	O	-1	12615818
oun@@	O	-1	12615818
d@@	O	-1	12615818
ing.	O	-1	12615818
METHODS:	O	-1	12615818
U@@	O	-1	12615818
s@@	O	-1	12615818
ing	O	-1	12615818
the	O	-1	12615818
G@@	O	-1	12615818
en@@	O	-1	12615818
eral	O	-1	12615818
P@@	O	-1	12615818
rac@@	O	-1	12615818
ti@@	O	-1	12615818
ce	O	-1	12615818
R@@	O	-1	12615818
es@@	O	-1	12615818
ear@@	O	-1	12615818
ch	O	-1	12615818
D@@	O	-1	12615818
at@@	O	-1	12615818
ab@@	O	-1	12615818
ase	O	-1	12615818
we	O	-1	12615818
con@@	O	-1	12615818
duc@@	O	-1	12615818
ted	O	-1	12615818
a	O	-1	12615818
co@@	O	-1	12615818
h@@	O	-1	12615818
ort	O	-1	12615818
analysis	O	-1	12615818
and	O	-1	12615818
cas@@	O	-1	12615818
e-@@	O	-1	12615818
control	O	-1	12615818
study	O	-1	12615818
ne@@	O	-1	12615818
st@@	O	-1	12615818
ed	O	-1	12615818
within	O	-1	12615818
a	O	-1	12615818
po@@	O	-1	12615818
p@@	O	-1	12615818
ulation	O	-1	12615818
of	O	-1	12615818
women	O	-1	12615818
aged	O	-1	12615818
between	O	-1	12615818
15	O	-1	12615818
and	O	-1	12615818
3@@	O	-1	12615818
9	O	-1	12615818
years	O	-1	12615818
with	O	-1	12615818
ac@@	B-Disease	D000152	12615818
n@@	I-Disease	-1	12615818
e	I-Disease	-1	12615818
,	O	-1	12615818
hi@@	B-Disease	D006628	12615818
r@@	I-Disease	-1	12615818
su@@	I-Disease	-1	12615818
tis@@	I-Disease	-1	12615818
m	I-Disease	-1	12615818
or	O	-1	12615818
P@@	B-Disease	D011085	12615818
CO@@	I-Disease	-1	12615818
S	I-Disease	-1	12615818
to	O	-1	12615818
estim@@	O	-1	12615818
ate	O	-1	12615818
the	O	-1	12615818
risk	O	-1	12615818
of	O	-1	12615818
V@@	B-Disease	D054556	12615818
T@@	I-Disease	-1	12615818
E	I-Disease	-1	12615818
associated	O	-1	12615818
with	O	-1	12615818
C@@	B-Chemical	D017373	12615818
P@@	I-Chemical	-1	12615818
A	I-Chemical	-1	12615818
/	O	-1	12615818
E@@	B-Chemical	D004997	12615818
E	I-Chemical	-1	12615818
.	O	-1	12615818
RESULTS:	O	-1	12615818
The	O	-1	12615818
ag@@	O	-1	12615818
e-@@	O	-1	12615818
adjust@@	O	-1	12615818
ed	O	-1	12615818
incidence	O	-1	12615818
rate	O	-1	12615818
rati@@	O	-1	12615818
o	O	-1	12615818
for	O	-1	12615818
C@@	B-Chemical	D017373	12615818
P@@	I-Chemical	-1	12615818
A	I-Chemical	-1	12615818
/	O	-1	12615818
E@@	B-Chemical	D004997	12615818
E	I-Chemical	-1	12615818
versus	O	-1	12615818
con@@	O	-1	12615818
ven@@	O	-1	12615818
tional	O	-1	12615818
CO@@	O	-1	12615818
C@@	O	-1	12615818
s	O	-1	12615818
was	O	-1	12615818
2.@@	O	-1	12615818
20	O	-1	12615818
[@@	O	-1	12615818
95%	O	-1	12615818
conf@@	O	-1	12615818
idence	O	-1	12615818
interv@@	O	-1	12615818
al	O	-1	12615818
(C@@	O	-1	12615818
I@@	O	-1	12615818
)	O	-1	12615818
1.@@	O	-1	12615818
3@@	O	-1	12615818
5-@@	O	-1	12615818
3.@@	O	-1	12615818
5@@	O	-1	12615818
8@@	O	-1	12615818
]@@	O	-1	12615818
.	O	-1	12615818
U@@	O	-1	12615818
s@@	O	-1	12615818
ing	O	-1	12615818
as	O	-1	12615818
the	O	-1	12615818
ref@@	O	-1	12615818
e@@	O	-1	12615818
rence	O	-1	12615818
group	O	-1	12615818
women	O	-1	12615818
who	O	-1	12615818
were	O	-1	12615818
not	O	-1	12615818
using	O	-1	12615818
oral	O	-1	12615818
contrac@@	O	-1	12615818
ep@@	O	-1	12615818
tion,	O	-1	12615818
had	O	-1	12615818
no	O	-1	12615818
rec@@	O	-1	12615818
ent	O	-1	12615818
pregn@@	O	-1	12615818
anc@@	O	-1	12615818
y	O	-1	12615818
or	O	-1	12615818
men@@	O	-1	12615818
o@@	O	-1	12615818
pa@@	O	-1	12615818
us@@	O	-1	12615818
al	O	-1	12615818
symptom@@	O	-1	12615818
s,	O	-1	12615818
the	O	-1	12615818
cas@@	O	-1	12615818
e-@@	O	-1	12615818
control	O	-1	12615818
analysis	O	-1	12615818
g@@	O	-1	12615818
a@@	O	-1	12615818
ve	O	-1	12615818
an	O	-1	12615818
adjust@@	O	-1	12615818
ed	O	-1	12615818
o@@	O	-1	12615818
d@@	O	-1	12615818
ds	O	-1	12615818
rati@@	O	-1	12615818
o	O	-1	12615818
(@@	O	-1	12615818
O@@	O	-1	12615818
R@@	O	-1	12615818
(@@	O	-1	12615818
adj@@	O	-1	12615818
)@@	O	-1	12615818
)	O	-1	12615818
of	O	-1	12615818
7.@@	O	-1	12615818
4@@	O	-1	12615818
4	O	-1	12615818
(@@	O	-1	12615818
95%	O	-1	12615818
C@@	O	-1	12615818
I	O	-1	12615818
3.@@	O	-1	12615818
6@@	O	-1	12615818
7@@	O	-1	12615818
-1@@	O	-1	12615818
5.@@	O	-1	12615818
0@@	O	-1	12615818
8@@	O	-1	12615818
)	O	-1	12615818
for	O	-1	12615818
C@@	B-Chemical	D017373	12615818
P@@	I-Chemical	-1	12615818
A	I-Chemical	-1	12615818
/	O	-1	12615818
E@@	B-Chemical	D004997	12615818
E	I-Chemical	-1	12615818
use	O	-1	12615818
compared	O	-1	12615818
with	O	-1	12615818
an	O	-1	12615818
O@@	O	-1	12615818
R@@	O	-1	12615818
(@@	O	-1	12615818
adj@@	O	-1	12615818
)	O	-1	12615818
of	O	-1	12615818
2.@@	O	-1	12615818
5@@	O	-1	12615818
8	O	-1	12615818
(@@	O	-1	12615818
95%	O	-1	12615818
C@@	O	-1	12615818
I	O	-1	12615818
1.@@	O	-1	12615818
6@@	O	-1	12615818
0-@@	O	-1	12615818
4.@@	O	-1	12615818
18@@	O	-1	12615818
)	O	-1	12615818
for	O	-1	12615818
use	O	-1	12615818
of	O	-1	12615818
con@@	O	-1	12615818
ven@@	O	-1	12615818
tional	O	-1	12615818
CO@@	O	-1	12615818
C@@	O	-1	12615818
s.	O	-1	12615818
CONCLUSIONS:	O	-1	12615818
We	O	-1	12615818
have	O	-1	12615818
demonstrated	O	-1	12615818
an	O	-1	12615818
increased	O	-1	12615818
risk	O	-1	12615818
of	O	-1	12615818
V@@	B-Disease	D054556	12615818
T@@	I-Disease	-1	12615818
E	I-Disease	-1	12615818
associated	O	-1	12615818
with	O	-1	12615818
the	O	-1	12615818
use	O	-1	12615818
of	O	-1	12615818
C@@	B-Chemical	D017373	12615818
P@@	I-Chemical	-1	12615818
A	I-Chemical	-1	12615818
/	O	-1	12615818
E@@	B-Chemical	D004997	12615818
E	I-Chemical	-1	12615818
in	O	-1	12615818
women	O	-1	12615818
with	O	-1	12615818
ac@@	B-Disease	D000152	12615818
n@@	I-Disease	-1	12615818
e	I-Disease	-1	12615818
,	O	-1	12615818
hi@@	B-Disease	D006628	12615818
r@@	I-Disease	-1	12615818
su@@	I-Disease	-1	12615818
tis@@	I-Disease	-1	12615818
m	I-Disease	-1	12615818
or	O	-1	12615818
P@@	B-Disease	D011085	12615818
CO@@	I-Disease	-1	12615818
S	I-Disease	-1	12615818
although	O	-1	12615818
re@@	O	-1	12615818
si@@	O	-1	12615818
du@@	O	-1	12615818
al	O	-1	12615818
conf@@	O	-1	12615818
oun@@	O	-1	12615818
ding	O	-1	12615818
by	O	-1	12615818
indic@@	O	-1	12615818
ation	O	-1	12615818
can@@	O	-1	12615818
not	O	-1	12615818
be	O	-1	12615818
ex@@	O	-1	12615818
cl@@	O	-1	12615818
u@@	O	-1	12615818
de@@	O	-1	12615818
d.	O	-1	12615818

P@@	B-Disease	D004194	12789195
se@@	I-Disease	-1	12789195
u@@	I-Disease	-1	12789195
do@@	I-Disease	-1	12789195
ac@@	I-Disease	-1	12789195
ro@@	I-Disease	-1	12789195
me@@	I-Disease	-1	12789195
g@@	I-Disease	-1	12789195
al@@	I-Disease	-1	12789195
y	I-Disease	-1	12789195
induced	O	-1	12789195
by	O	-1	12789195
the	O	-1	12789195
long-term	O	-1	12789195
use	O	-1	12789195
of	O	-1	12789195
min@@	B-Chemical	D008914	12789195
ox@@	I-Chemical	-1	12789195
i@@	I-Chemical	-1	12789195
di@@	I-Chemical	-1	12789195
l	I-Chemical	-1	12789195
.	O	-1	12789195
Ac@@	B-Disease	D000172	12789195
ro@@	I-Disease	-1	12789195
me@@	I-Disease	-1	12789195
g@@	I-Disease	-1	12789195
al@@	I-Disease	-1	12789195
y	I-Disease	-1	12789195
is	O	-1	12789195
an	O	-1	12789195
en@@	B-Disease	D004700	12789195
doc@@	I-Disease	-1	12789195
rine	I-Disease	-1	12789195
disor@@	I-Disease	-1	12789195
der	I-Disease	-1	12789195
caused	O	-1	12789195
by	O	-1	12789195
chronic	O	-1	12789195
ex@@	O	-1	12789195
ces@@	O	-1	12789195
sive	O	-1	12789195
growth	O	-1	12789195
h@@	O	-1	12789195
orm@@	O	-1	12789195
one	O	-1	12789195
secre@@	O	-1	12789195
tion	O	-1	12789195
from	O	-1	12789195
the	O	-1	12789195
an@@	O	-1	12789195
ter@@	O	-1	12789195
ior	O	-1	12789195
pit@@	O	-1	12789195
u@@	O	-1	12789195
it@@	O	-1	12789195
ary	O	-1	12789195
gl@@	O	-1	12789195
an@@	O	-1	12789195
d.	O	-1	12789195
Si@@	O	-1	12789195
gn@@	O	-1	12789195
ific@@	O	-1	12789195
ant	O	-1	12789195
dis@@	O	-1	12789195
fi@@	O	-1	12789195
g@@	O	-1	12789195
uring	O	-1	12789195
changes	O	-1	12789195
occ@@	O	-1	12789195
ur	O	-1	12789195
as	O	-1	12789195
a	O	-1	12789195
result	O	-1	12789195
of	O	-1	12789195
b@@	O	-1	12789195
one,	O	-1	12789195
car@@	O	-1	12789195
til@@	O	-1	12789195
age,	O	-1	12789195
and	O	-1	12789195
so@@	O	-1	12789195
ft	O	-1	12789195
tissue	O	-1	12789195
hyper@@	B-Disease	D006984	12789195
tro@@	I-Disease	-1	12789195
ph@@	I-Disease	-1	12789195
y	I-Disease	-1	12789195
,	O	-1	12789195
including	O	-1	12789195
the	O	-1	12789195
th@@	O	-1	12789195
ic@@	O	-1	12789195
k@@	O	-1	12789195
en@@	O	-1	12789195
ing	O	-1	12789195
of	O	-1	12789195
the	O	-1	12789195
s@@	O	-1	12789195
k@@	O	-1	12789195
in,	O	-1	12789195
co@@	O	-1	12789195
ar@@	O	-1	12789195
sen@@	O	-1	12789195
ing	O	-1	12789195
of	O	-1	12789195
fac@@	O	-1	12789195
ial	O	-1	12789195
feat@@	O	-1	12789195
ures@@	O	-1	12789195
,	O	-1	12789195
and	O	-1	12789195
c@@	B-Disease	C535610	12789195
u@@	I-Disease	-1	12789195
tis	I-Disease	-1	12789195
ver@@	I-Disease	-1	12789195
tic@@	I-Disease	-1	12789195
is	I-Disease	-1	12789195
g@@	I-Disease	-1	12789195
y@@	I-Disease	-1	12789195
rat@@	I-Disease	-1	12789195
a	I-Disease	-1	12789195
.	O	-1	12789195
P@@	B-Disease	D004194	12789195
se@@	I-Disease	-1	12789195
u@@	I-Disease	-1	12789195
do@@	I-Disease	-1	12789195
ac@@	I-Disease	-1	12789195
ro@@	I-Disease	-1	12789195
me@@	I-Disease	-1	12789195
g@@	I-Disease	-1	12789195
al@@	I-Disease	-1	12789195
y	I-Disease	-1	12789195
,	O	-1	12789195
on	O	-1	12789195
the	O	-1	12789195
other	O	-1	12789195
h@@	O	-1	12789195
and@@	O	-1	12789195
,	O	-1	12789195
is	O	-1	12789195
the	O	-1	12789195
presence	O	-1	12789195
of	O	-1	12789195
similar	O	-1	12789195
ac@@	O	-1	12789195
ro@@	O	-1	12789195
me@@	O	-1	12789195
g@@	O	-1	12789195
alo@@	O	-1	12789195
id	O	-1	12789195
feat@@	O	-1	12789195
ures	O	-1	12789195
in	O	-1	12789195
the	O	-1	12789195
absence	O	-1	12789195
of	O	-1	12789195
elevated	O	-1	12789195
growth	O	-1	12789195
h@@	O	-1	12789195
orm@@	O	-1	12789195
one	O	-1	12789195
or	O	-1	12789195
in@@	O	-1	12789195
sul@@	O	-1	12789195
in-@@	O	-1	12789195
like	O	-1	12789195
growth	O	-1	12789195
factor	O	-1	12789195
level@@	O	-1	12789195
s.	O	-1	12789195
We	O	-1	12789195
present	O	-1	12789195
a	O	-1	12789195
patient	O	-1	12789195
with	O	-1	12789195
p@@	B-Disease	D004194	12789195
se@@	I-Disease	-1	12789195
u@@	I-Disease	-1	12789195
do@@	I-Disease	-1	12789195
ac@@	I-Disease	-1	12789195
ro@@	I-Disease	-1	12789195
me@@	I-Disease	-1	12789195
g@@	I-Disease	-1	12789195
al@@	I-Disease	-1	12789195
y	I-Disease	-1	12789195
that	O	-1	12789195
resulted	O	-1	12789195
from	O	-1	12789195
the	O	-1	12789195
long-term	O	-1	12789195
use	O	-1	12789195
of	O	-1	12789195
min@@	B-Chemical	D008914	12789195
ox@@	I-Chemical	-1	12789195
i@@	I-Chemical	-1	12789195
di@@	I-Chemical	-1	12789195
l	I-Chemical	-1	12789195
at	O	-1	12789195
an	O	-1	12789195
un@@	O	-1	12789195
us@@	O	-1	12789195
ually	O	-1	12789195
high	O	-1	12789195
dose.	O	-1	12789195
This	O	-1	12789195
is	O	-1	12789195
the	O	-1	12789195
first	O	-1	12789195
case	O	-1	12789195
report	O	-1	12789195
of	O	-1	12789195
p@@	B-Disease	D004194	12789195
se@@	I-Disease	-1	12789195
u@@	I-Disease	-1	12789195
do@@	I-Disease	-1	12789195
ac@@	I-Disease	-1	12789195
ro@@	I-Disease	-1	12789195
me@@	I-Disease	-1	12789195
g@@	I-Disease	-1	12789195
al@@	I-Disease	-1	12789195
y	I-Disease	-1	12789195
as	O	-1	12789195
a	O	-1	12789195
side	O	-1	12789195
effect	O	-1	12789195
of	O	-1	12789195
min@@	B-Chemical	D008914	12789195
ox@@	I-Chemical	-1	12789195
i@@	I-Chemical	-1	12789195
di@@	I-Chemical	-1	12789195
l	I-Chemical	-1	12789195
use.	O	-1	12789195

Com@@	O	-1	12820454
bin@@	O	-1	12820454
ed	O	-1	12820454
and@@	O	-1	12820454
ro@@	O	-1	12820454
gen	O	-1	12820454
block@@	O	-1	12820454
ade@@	O	-1	12820454
-induced	O	-1	12820454
anemia	B-Disease	D000740	12820454
in	O	-1	12820454
pro@@	B-Disease	D011471	12820454
state	I-Disease	-1	12820454
cancer	I-Disease	-1	12820454
patients	O	-1	12820454
without	O	-1	12820454
b@@	O	-1	12820454
one	O	-1	12820454
invol@@	O	-1	12820454
ve@@	O	-1	12820454
ment.	O	-1	12820454
BACKGROUND:	O	-1	12820454
To	O	-1	12820454
determine	O	-1	12820454
the	O	-1	12820454
onset	O	-1	12820454
and	O	-1	12820454
ext@@	O	-1	12820454
ent	O	-1	12820454
of	O	-1	12820454
combined	O	-1	12820454
and@@	O	-1	12820454
ro@@	O	-1	12820454
gen	O	-1	12820454
block@@	O	-1	12820454
ade	O	-1	12820454
(C@@	O	-1	12820454
A@@	O	-1	12820454
B@@	O	-1	12820454
)@@	O	-1	12820454
-induced	O	-1	12820454
anemia	B-Disease	D000740	12820454
in	O	-1	12820454
pro@@	B-Disease	D011471	12820454
state	I-Disease	-1	12820454
cancer	I-Disease	-1	12820454
patients	O	-1	12820454
without	O	-1	12820454
b@@	O	-1	12820454
one	O	-1	12820454
invol@@	O	-1	12820454
ve@@	O	-1	12820454
ment.	O	-1	12820454
PA@@	O	-1	12820454
TI@@	O	-1	12820454
E@@	O	-1	12820454
N@@	O	-1	12820454
T@@	O	-1	12820454
S	O	-1	12820454
AN@@	O	-1	12820454
D	O	-1	12820454
METHODS:	O	-1	12820454
F@@	O	-1	12820454
or@@	O	-1	12820454
ty-@@	O	-1	12820454
two	O	-1	12820454
patients	O	-1	12820454
with	O	-1	12820454
bio@@	O	-1	12820454
psy@@	O	-1	12820454
-@@	O	-1	12820454
pro@@	O	-1	12820454
ven	O	-1	12820454
pro@@	B-Disease	D000230	12820454
st@@	I-Disease	-1	12820454
atic	I-Disease	-1	12820454
aden@@	I-Disease	-1	12820454
oc@@	I-Disease	-1	12820454
arc@@	I-Disease	-1	12820454
in@@	I-Disease	-1	12820454
oma	I-Disease	-1	12820454
[@@	O	-1	12820454
2@@	O	-1	12820454
6	O	-1	12820454
with	O	-1	12820454
st@@	O	-1	12820454
age	O	-1	12820454
C	O	-1	12820454
(T@@	O	-1	12820454
3@@	O	-1	12820454
N@@	O	-1	12820454
0@@	O	-1	12820454
M@@	O	-1	12820454
0@@	O	-1	12820454
)	O	-1	12820454
and	O	-1	12820454
16	O	-1	12820454
with	O	-1	12820454
st@@	O	-1	12820454
age	O	-1	12820454
D@@	O	-1	12820454
1	O	-1	12820454
(T@@	O	-1	12820454
3@@	O	-1	12820454
N@@	O	-1	12820454
1@@	O	-1	12820454
M@@	O	-1	12820454
0@@	O	-1	12820454
)@@	O	-1	12820454
]	O	-1	12820454
were	O	-1	12820454
included	O	-1	12820454
in	O	-1	12820454
this	O	-1	12820454
study.	O	-1	12820454
All	O	-1	12820454
patients	O	-1	12820454
received	O	-1	12820454
CA@@	O	-1	12820454
B	O	-1	12820454
[	O	-1	12820454
leu@@	B-Chemical	D016729	12820454
prol@@	I-Chemical	-1	12820454
ide	I-Chemical	-1	12820454
acet@@	I-Chemical	-1	12820454
ate	I-Chemical	-1	12820454
(	O	-1	12820454
L@@	B-Chemical	D016729	12820454
H@@	I-Chemical	-1	12820454
R@@	I-Chemical	-1	12820454
H@@	I-Chemical	-1	12820454
-@@	I-Chemical	-1	12820454
A	I-Chemical	-1	12820454
)	O	-1	12820454
3.@@	O	-1	12820454
7@@	O	-1	12820454
5	O	-1	12820454
mg@@	O	-1	12820454
,	O	-1	12820454
int@@	O	-1	12820454
ram@@	O	-1	12820454
us@@	O	-1	12820454
cul@@	O	-1	12820454
ar@@	O	-1	12820454
ly,	O	-1	12820454
every	O	-1	12820454
2@@	O	-1	12820454
8	O	-1	12820454
days	O	-1	12820454
plus	O	-1	12820454
2@@	O	-1	12820454
50	O	-1	12820454
mg	O	-1	12820454
f@@	B-Chemical	D005485	12820454
l@@	I-Chemical	-1	12820454
ut@@	I-Chemical	-1	12820454
amide	I-Chemical	-1	12820454
,	O	-1	12820454
ti@@	O	-1	12820454
d,	O	-1	12820454
per	O	-1	12820454
O@@	O	-1	12820454
s@@	O	-1	12820454
]	O	-1	12820454
and	O	-1	12820454
were	O	-1	12820454
evaluated	O	-1	12820454
for	O	-1	12820454
anemia	B-Disease	D000740	12820454
by	O	-1	12820454
physi@@	O	-1	12820454
c@@	O	-1	12820454
al	O	-1	12820454
examin@@	O	-1	12820454
ation	O	-1	12820454
and	O	-1	12820454
labor@@	O	-1	12820454
atory	O	-1	12820454
tests	O	-1	12820454
at	O	-1	12820454
baseline	O	-1	12820454
and	O	-1	12820454
4	O	-1	12820454
subsequ@@	O	-1	12820454
ent	O	-1	12820454
interv@@	O	-1	12820454
als	O	-1	12820454
(1@@	O	-1	12820454
,	O	-1	12820454
2,	O	-1	12820454
3	O	-1	12820454
and	O	-1	12820454
6	O	-1	12820454
months	O	-1	12820454
post@@	O	-1	12820454
-@@	O	-1	12820454
CA@@	O	-1	12820454
B@@	O	-1	12820454
).	O	-1	12820454
H@@	O	-1	12820454
b@@	O	-1	12820454
,	O	-1	12820454
P@@	O	-1	12820454
S@@	O	-1	12820454
A	O	-1	12820454
and	O	-1	12820454
T@@	B-Chemical	D013739	12820454
est@@	I-Chemical	-1	12820454
osterone	I-Chemical	-1	12820454
meas@@	O	-1	12820454
ure@@	O	-1	12820454
ments	O	-1	12820454
were	O	-1	12820454
recor@@	O	-1	12820454
de@@	O	-1	12820454
d.	O	-1	12820454
Patients	O	-1	12820454
with	O	-1	12820454
st@@	O	-1	12820454
age	O	-1	12820454
D@@	O	-1	12820454
2-@@	O	-1	12820454
3	O	-1	12820454
diseas@@	O	-1	12820454
e,	O	-1	12820454
ab@@	O	-1	12820454
normal	O	-1	12820454
hemo@@	O	-1	12820454
globin	O	-1	12820454
level	O	-1	12820454
or	O	-1	12820454
renal	O	-1	12820454
and	O	-1	12820454
liver	O	-1	12820454
function	O	-1	12820454
tests	O	-1	12820454
that	O	-1	12820454
were	O	-1	12820454
higher	O	-1	12820454
than	O	-1	12820454
the	O	-1	12820454
up@@	O	-1	12820454
per	O	-1	12820454
lim@@	O	-1	12820454
its	O	-1	12820454
were	O	-1	12820454
ex@@	O	-1	12820454
cl@@	O	-1	12820454
uded	O	-1	12820454
from	O	-1	12820454
the	O	-1	12820454
study.	O	-1	12820454
The	O	-1	12820454
duration	O	-1	12820454
of	O	-1	12820454
the	O	-1	12820454
study	O	-1	12820454
was	O	-1	12820454
six	O	-1	12820454
months.	O	-1	12820454
RESULTS:	O	-1	12820454
The	O	-1	12820454
mean	O	-1	12820454
hemo@@	O	-1	12820454
globin	O	-1	12820454
(@@	O	-1	12820454
H@@	O	-1	12820454
b@@	O	-1	12820454
)	O	-1	12820454
levels	O	-1	12820454
were	O	-1	12820454
significantly	O	-1	12820454
dec@@	O	-1	12820454
lin@@	O	-1	12820454
ed	O	-1	12820454
in	O	-1	12820454
all	O	-1	12820454
patients	O	-1	12820454
from	O	-1	12820454
baseline	O	-1	12820454
of	O	-1	12820454
1@@	O	-1	12820454
4.@@	O	-1	12820454
2	O	-1	12820454
g/@@	O	-1	12820454
d@@	O	-1	12820454
l	O	-1	12820454
to	O	-1	12820454
1@@	O	-1	12820454
4.@@	O	-1	12820454
0	O	-1	12820454
g/@@	O	-1	12820454
d@@	O	-1	12820454
l@@	O	-1	12820454
,	O	-1	12820454
1@@	O	-1	12820454
3.@@	O	-1	12820454
5	O	-1	12820454
g/@@	O	-1	12820454
d@@	O	-1	12820454
l@@	O	-1	12820454
,	O	-1	12820454
1@@	O	-1	12820454
3.@@	O	-1	12820454
2	O	-1	12820454
g/@@	O	-1	12820454
d@@	O	-1	12820454
l	O	-1	12820454
and	O	-1	12820454
1@@	O	-1	12820454
2.@@	O	-1	12820454
7	O	-1	12820454
g/@@	O	-1	12820454
d@@	O	-1	12820454
l	O	-1	12820454
at	O	-1	12820454
1,	O	-1	12820454
2,	O	-1	12820454
3	O	-1	12820454
and	O	-1	12820454
6	O	-1	12820454
months	O	-1	12820454
post@@	O	-1	12820454
-@@	O	-1	12820454
CA@@	O	-1	12820454
B@@	O	-1	12820454
,	O	-1	12820454
respectively.	O	-1	12820454
S@@	O	-1	12820454
ev@@	O	-1	12820454
ere	O	-1	12820454
and	O	-1	12820454
clin@@	O	-1	12820454
ically	O	-1	12820454
ev@@	O	-1	12820454
id@@	O	-1	12820454
ent	O	-1	12820454
anemia	B-Disease	D000740	12820454
of	O	-1	12820454
H@@	O	-1	12820454
b	O	-1	12820454
<	O	-1	12820454
11	O	-1	12820454
g/@@	O	-1	12820454
d@@	O	-1	12820454
l	O	-1	12820454
with	O	-1	12820454
clinical	O	-1	12820454
symptoms	O	-1	12820454
was	O	-1	12820454
det@@	O	-1	12820454
ected	O	-1	12820454
in	O	-1	12820454
6	O	-1	12820454
patients	O	-1	12820454
(1@@	O	-1	12820454
4.@@	O	-1	12820454
3@@	O	-1	12820454
%).	O	-1	12820454
This	O	-1	12820454
CA@@	O	-1	12820454
B@@	O	-1	12820454
-induced	O	-1	12820454
anemia	B-Disease	D000740	12820454
was	O	-1	12820454
nor@@	O	-1	12820454
mo@@	O	-1	12820454
ch@@	O	-1	12820454
rom@@	O	-1	12820454
ic	O	-1	12820454
and	O	-1	12820454
norm@@	O	-1	12820454
ocy@@	O	-1	12820454
tic@@	O	-1	12820454
.	O	-1	12820454
A@@	O	-1	12820454
t	O	-1	12820454
six	O	-1	12820454
months	O	-1	12820454
post@@	O	-1	12820454
-@@	O	-1	12820454
CA@@	O	-1	12820454
B@@	O	-1	12820454
,	O	-1	12820454
patients	O	-1	12820454
with	O	-1	12820454
severe	O	-1	12820454
anemia	B-Disease	D000740	12820454
had	O	-1	12820454
a	O	-1	12820454
H@@	O	-1	12820454
b	O	-1	12820454
mean	O	-1	12820454
valu@@	O	-1	12820454
e	O	-1	12820454
of	O	-1	12820454
1@@	O	-1	12820454
0.@@	O	-1	12820454
2	O	-1	12820454
+/-	O	-1	12820454
0.@@	O	-1	12820454
1	O	-1	12820454
g/@@	O	-1	12820454
d@@	O	-1	12820454
l	O	-1	12820454
(@@	O	-1	12820454
X	O	-1	12820454
+/-	O	-1	12820454
S@@	O	-1	12820454
E@@	O	-1	12820454
),	O	-1	12820454
whereas	O	-1	12820454
the	O	-1	12820454
other	O	-1	12820454
patients	O	-1	12820454
had	O	-1	12820454
mil@@	O	-1	12820454
d	O	-1	12820454
anemia	B-Disease	D000740	12820454
with	O	-1	12820454
H@@	O	-1	12820454
b	O	-1	12820454
mean	O	-1	12820454
valu@@	O	-1	12820454
e	O	-1	12820454
of	O	-1	12820454
1@@	O	-1	12820454
3.@@	O	-1	12820454
2	O	-1	12820454
+/-	O	-1	12820454
0.@@	O	-1	12820454
17	O	-1	12820454
(@@	O	-1	12820454
X	O	-1	12820454
+/-	O	-1	12820454
S@@	O	-1	12820454
E@@	O	-1	12820454
).	O	-1	12820454
The	O	-1	12820454
development	O	-1	12820454
of	O	-1	12820454
severe	O	-1	12820454
anemia	B-Disease	D000740	12820454
at	O	-1	12820454
6	O	-1	12820454
months	O	-1	12820454
post@@	O	-1	12820454
-@@	O	-1	12820454
CA@@	O	-1	12820454
B	O	-1	12820454
was	O	-1	12820454
predic@@	O	-1	12820454
t@@	O	-1	12820454
able	O	-1	12820454
by	O	-1	12820454
the	O	-1	12820454
reduction	O	-1	12820454
of	O	-1	12820454
H@@	O	-1	12820454
b	O	-1	12820454
baseline	O	-1	12820454
valu@@	O	-1	12820454
e	O	-1	12820454
of	O	-1	12820454
more	O	-1	12820454
than	O	-1	12820454
2.@@	O	-1	12820454
5	O	-1	12820454
g/@@	O	-1	12820454
d@@	O	-1	12820454
l	O	-1	12820454
after	O	-1	12820454
3	O	-1	12820454
months	O	-1	12820454
of	O	-1	12820454
CA@@	O	-1	12820454
B	O	-1	12820454
(p	O	-1	12820454
=	O	-1	12820454
0.0@@	O	-1	12820454
1).	O	-1	12820454
The	O	-1	12820454
development	O	-1	12820454
of	O	-1	12820454
severe	O	-1	12820454
CA@@	O	-1	12820454
B@@	O	-1	12820454
-induced	O	-1	12820454
anemia	B-Disease	D000740	12820454
in	O	-1	12820454
pro@@	B-Disease	D011471	12820454
state	I-Disease	-1	12820454
cancer	I-Disease	-1	12820454
patients	O	-1	12820454
did	O	-1	12820454
not	O	-1	12820454
correl@@	O	-1	12820454
ate	O	-1	12820454
with	O	-1	12820454
T	O	-1	12820454
baseline	O	-1	12820454
values	O	-1	12820454
(@@	O	-1	12820454
T	O	-1	12820454
<	O	-1	12820454
3	O	-1	12820454
n@@	O	-1	12820454
g/@@	O	-1	12820454
m@@	O	-1	12820454
l	O	-1	12820454
versus	O	-1	12820454
T	O	-1	12820454
>	O	-1	12820454
or	O	-1	12820454
=	O	-1	12820454
3	O	-1	12820454
n@@	O	-1	12820454
g/@@	O	-1	12820454
ml@@	O	-1	12820454
),	O	-1	12820454
with	O	-1	12820454
age	O	-1	12820454
(@@	O	-1	12820454
<	O	-1	12820454
7@@	O	-1	12820454
6	O	-1	12820454
y@@	O	-1	12820454
r@@	O	-1	12820454
s	O	-1	12820454
versus	O	-1	12820454
>	O	-1	12820454
or	O	-1	12820454
=	O	-1	12820454
7@@	O	-1	12820454
6	O	-1	12820454
y@@	O	-1	12820454
r@@	O	-1	12820454
s),	O	-1	12820454
and	O	-1	12820454
clinical	O	-1	12820454
st@@	O	-1	12820454
age	O	-1	12820454
(@@	O	-1	12820454
st@@	O	-1	12820454
age	O	-1	12820454
C	O	-1	12820454
versus	O	-1	12820454
st@@	O	-1	12820454
age	O	-1	12820454
D@@	O	-1	12820454
1).	O	-1	12820454
S@@	O	-1	12820454
ev@@	O	-1	12820454
ere	O	-1	12820454
and	O	-1	12820454
clin@@	O	-1	12820454
ically	O	-1	12820454
ev@@	O	-1	12820454
id@@	O	-1	12820454
ent	O	-1	12820454
anemia	B-Disease	D000740	12820454
was	O	-1	12820454
e@@	O	-1	12820454
a@@	O	-1	12820454
si@@	O	-1	12820454
ly	O	-1	12820454
cor@@	O	-1	12820454
rec@@	O	-1	12820454
ted	O	-1	12820454
by	O	-1	12820454
sub@@	O	-1	12820454
c@@	O	-1	12820454
utaneous	O	-1	12820454
injec@@	O	-1	12820454
tions	O	-1	12820454
(@@	O	-1	12820454
3	O	-1	12820454
tim@@	O	-1	12820454
es@@	O	-1	12820454
/@@	O	-1	12820454
week	O	-1	12820454
for	O	-1	12820454
1	O	-1	12820454
month@@	O	-1	12820454
)	O	-1	12820454
of	O	-1	12820454
re@@	O	-1	12820454
combin@@	O	-1	12820454
ant	O	-1	12820454
erythro@@	O	-1	12820454
po@@	O	-1	12820454
i@@	O	-1	12820454
e@@	O	-1	12820454
tin	O	-1	12820454
(@@	O	-1	12820454
r@@	O	-1	12820454
H@@	O	-1	12820454
u@@	O	-1	12820454
EP@@	O	-1	12820454
O@@	O	-1	12820454
-@@	O	-1	12820454
beta@@	O	-1	12820454
).	O	-1	12820454
CONCLUSION:	O	-1	12820454
Our	O	-1	12820454
data	O	-1	12820454
suggest	O	-1	12820454
that	O	-1	12820454
r@@	O	-1	12820454
H@@	O	-1	12820454
u@@	O	-1	12820454
EP@@	O	-1	12820454
O@@	O	-1	12820454
-@@	O	-1	12820454
bet@@	O	-1	12820454
a	O	-1	12820454
cor@@	O	-1	12820454
rec@@	O	-1	12820454
t@@	O	-1	12820454
able	O	-1	12820454
CA@@	O	-1	12820454
B@@	O	-1	12820454
-induced	O	-1	12820454
anemia	B-Disease	D000740	12820454
occur@@	O	-1	12820454
s	O	-1	12820454
in	O	-1	12820454
1@@	O	-1	12820454
4.@@	O	-1	12820454
3@@	O	-1	12820454
%	O	-1	12820454
of	O	-1	12820454
pro@@	B-Disease	D011471	12820454
state	I-Disease	-1	12820454
cancer	I-Disease	-1	12820454
patients	O	-1	12820454
after	O	-1	12820454
6	O	-1	12820454
months	O	-1	12820454
of	O	-1	12820454
therapy.	O	-1	12820454

Re@@	O	-1	14657095
ver@@	O	-1	14657095
sible	O	-1	14657095
di@@	B-Disease	D002311	14657095
l@@	I-Disease	-1	14657095
ated	I-Disease	-1	14657095
cardi@@	I-Disease	-1	14657095
om@@	I-Disease	-1	14657095
yo@@	I-Disease	-1	14657095
pathy	I-Disease	-1	14657095
related	O	-1	14657095
to	O	-1	14657095
amph@@	B-Chemical	D000666	14657095
ot@@	I-Chemical	-1	14657095
er@@	I-Chemical	-1	14657095
icin	I-Chemical	-1	14657095
B	I-Chemical	-1	14657095
therapy.	O	-1	14657095
We	O	-1	14657095
describe	O	-1	14657095
a	O	-1	14657095
patient	O	-1	14657095
who	O	-1	14657095
developed	O	-1	14657095
di@@	B-Disease	D002311	14657095
l@@	I-Disease	-1	14657095
ated	I-Disease	-1	14657095
cardi@@	I-Disease	-1	14657095
om@@	I-Disease	-1	14657095
yo@@	I-Disease	-1	14657095
pathy	I-Disease	-1	14657095
and	O	-1	14657095
clinical	O	-1	14657095
con@@	O	-1	14657095
g@@	O	-1	14657095
es@@	O	-1	14657095
tive	O	-1	14657095
heart	B-Disease	D006333	14657095
failure	I-Disease	-1	14657095
after	O	-1	14657095
2	O	-1	14657095
months	O	-1	14657095
of	O	-1	14657095
therapy	O	-1	14657095
with	O	-1	14657095
amph@@	B-Chemical	D000666	14657095
ot@@	I-Chemical	-1	14657095
er@@	I-Chemical	-1	14657095
icin	I-Chemical	-1	14657095
B	I-Chemical	-1	14657095
(	O	-1	14657095
A@@	B-Chemical	D000666	14657095
m@@	I-Chemical	-1	14657095
B	I-Chemical	-1	14657095
)	O	-1	14657095
for	O	-1	14657095
dis@@	O	-1	14657095
se@@	O	-1	14657095
min@@	O	-1	14657095
ated	O	-1	14657095
co@@	B-Disease	D003047	14657095
c@@	I-Disease	-1	14657095
ci@@	I-Disease	-1	14657095
di@@	I-Disease	-1	14657095
oid@@	I-Disease	-1	14657095
om@@	I-Disease	-1	14657095
y@@	I-Disease	-1	14657095
co@@	I-Disease	-1	14657095
sis	I-Disease	-1	14657095
.	O	-1	14657095
H@@	O	-1	14657095
is	O	-1	14657095
echocardiograph@@	O	-1	14657095
ic	O	-1	14657095
abnormal@@	O	-1	14657095
ities	O	-1	14657095
and	O	-1	14657095
heart	B-Disease	D006333	14657095
failure	I-Disease	-1	14657095
resol@@	O	-1	14657095
ved	O	-1	14657095
after	O	-1	14657095
pos@@	B-Chemical	C101425	14657095
ac@@	I-Chemical	-1	14657095
on@@	I-Chemical	-1	14657095
azole	I-Chemical	-1	14657095
was	O	-1	14657095
sub@@	O	-1	14657095
sti@@	O	-1	14657095
t@@	O	-1	14657095
ut@@	O	-1	14657095
ed	O	-1	14657095
for	O	-1	14657095
A@@	B-Chemical	D000666	14657095
m@@	I-Chemical	-1	14657095
B	I-Chemical	-1	14657095
.	O	-1	14657095
It	O	-1	14657095
is	O	-1	14657095
important	O	-1	14657095
to	O	-1	14657095
reco@@	O	-1	14657095
gn@@	O	-1	14657095
iz@@	O	-1	14657095
e	O	-1	14657095
the	O	-1	14657095
r@@	O	-1	14657095
are	O	-1	14657095
and	O	-1	14657095
potenti@@	O	-1	14657095
ally	O	-1	14657095
reversible	O	-1	14657095
toxicity	B-Disease	D064420	14657095
of	O	-1	14657095
A@@	B-Chemical	D000666	14657095
m@@	I-Chemical	-1	14657095
B	I-Chemical	-1	14657095
.	O	-1	14657095

R@@	O	-1	14765563
is@@	O	-1	14765563
k@@	O	-1	14765563
s	O	-1	14765563
of	O	-1	14765563
the	O	-1	14765563
consum@@	O	-1	14765563
ption	O	-1	14765563
of	O	-1	14765563
be@@	O	-1	14765563
ver@@	O	-1	14765563
ages	O	-1	14765563
containing	O	-1	14765563
qu@@	B-Chemical	D011803	14765563
inine	I-Chemical	-1	14765563
.	O	-1	14765563
Although	O	-1	14765563
the	O	-1	14765563
U@@	O	-1	14765563
nit@@	O	-1	14765563
ed	O	-1	14765563
S@@	O	-1	14765563
t@@	O	-1	14765563
ates	O	-1	14765563
F@@	O	-1	14765563
o@@	O	-1	14765563
od	O	-1	14765563
and	O	-1	14765563
D@@	O	-1	14765563
ru@@	O	-1	14765563
g	O	-1	14765563
Ad@@	O	-1	14765563
minist@@	O	-1	14765563
ration	O	-1	14765563
b@@	O	-1	14765563
an@@	O	-1	14765563
n@@	O	-1	14765563
ed	O	-1	14765563
its	O	-1	14765563
use	O	-1	14765563
for	O	-1	14765563
n@@	B-Disease	D020922	14765563
oc@@	I-Disease	-1	14765563
t@@	I-Disease	-1	14765563
ur@@	I-Disease	-1	14765563
n@@	I-Disease	-1	14765563
al	I-Disease	-1	14765563
le@@	I-Disease	-1	14765563
g	I-Disease	-1	14765563
c@@	I-Disease	-1	14765563
ram@@	I-Disease	-1	14765563
p@@	I-Disease	-1	14765563
s	I-Disease	-1	14765563
due	O	-1	14765563
to	O	-1	14765563
l@@	O	-1	14765563
ac@@	O	-1	14765563
k	O	-1	14765563
of	O	-1	14765563
safety	O	-1	14765563
and	O	-1	14765563
efficac@@	O	-1	14765563
y,	O	-1	14765563
qu@@	B-Chemical	D011803	14765563
inine	I-Chemical	-1	14765563
is	O	-1	14765563
wi@@	O	-1	14765563
de@@	O	-1	14765563
ly	O	-1	14765563
av@@	O	-1	14765563
ail@@	O	-1	14765563
able	O	-1	14765563
in	O	-1	14765563
be@@	O	-1	14765563
ver@@	O	-1	14765563
ages	O	-1	14765563
including	O	-1	14765563
t@@	O	-1	14765563
onic	O	-1	14765563
w@@	O	-1	14765563
at@@	O	-1	14765563
er	O	-1	14765563
and	O	-1	14765563
b@@	O	-1	14765563
it@@	O	-1	14765563
ter	O	-1	14765563
le@@	O	-1	14765563
mon@@	O	-1	14765563
.	O	-1	14765563
N@@	O	-1	14765563
um@@	O	-1	14765563
er@@	O	-1	14765563
ous	O	-1	14765563
an@@	O	-1	14765563
ec@@	O	-1	14765563
d@@	O	-1	14765563
ot@@	O	-1	14765563
al	O	-1	14765563
reports	O	-1	14765563
suggest	O	-1	14765563
that	O	-1	14765563
produc@@	O	-1	14765563
ts	O	-1	14765563
containing	O	-1	14765563
qu@@	B-Chemical	D011803	14765563
inine	I-Chemical	-1	14765563
may	O	-1	14765563
produce	O	-1	14765563
neurolog@@	B-Disease	D002493	14765563
ical	I-Disease	-1	14765563
complications	I-Disease	-1	14765563
,	O	-1	14765563
including	O	-1	14765563
conf@@	B-Disease	D003221	14765563
usion	I-Disease	-1	14765563
,	O	-1	14765563
al@@	O	-1	14765563
te@@	O	-1	14765563
red	O	-1	14765563
mental	O	-1	14765563
stat@@	O	-1	14765563
us,	O	-1	14765563
seizures	B-Disease	D012640	14765563
,	O	-1	14765563
and	O	-1	14765563
com@@	B-Disease	D003128	14765563
a	I-Disease	-1	14765563
,	O	-1	14765563
partic@@	O	-1	14765563
ul@@	O	-1	14765563
arly	O	-1	14765563
in	O	-1	14765563
ol@@	O	-1	14765563
der	O	-1	14765563
wom@@	O	-1	14765563
en@@	O	-1	14765563
.	O	-1	14765563
P@@	O	-1	14765563
sy@@	O	-1	14765563
ch@@	O	-1	14765563
olog@@	O	-1	14765563
ist@@	O	-1	14765563
s	O	-1	14765563
need	O	-1	14765563
to	O	-1	14765563
in@@	O	-1	14765563
qu@@	O	-1	14765563
ir@@	O	-1	14765563
e	O	-1	14765563
about	O	-1	14765563
consum@@	O	-1	14765563
ption	O	-1	14765563
of	O	-1	14765563
qu@@	B-Chemical	D011803	14765563
inine	I-Chemical	-1	14765563
-@@	O	-1	14765563
containing	O	-1	14765563
be@@	O	-1	14765563
ver@@	O	-1	14765563
ages	O	-1	14765563
as	O	-1	14765563
par@@	O	-1	14765563
t	O	-1	14765563
of	O	-1	14765563
an	O	-1	14765563
evalu@@	O	-1	14765563
ation	O	-1	14765563
pro@@	O	-1	14765563
ces@@	O	-1	14765563
s.	O	-1	14765563

O@@	B-Chemical	D010755	15036754
r@@	I-Chemical	-1	15036754
g@@	I-Chemical	-1	15036754
an@@	I-Chemical	-1	15036754
oph@@	I-Chemical	-1	15036754
osph@@	I-Chemical	-1	15036754
ate	I-Chemical	-1	15036754
-induced	O	-1	15036754
convul@@	B-Disease	D012640	15036754
sions	I-Disease	-1	15036754
and	O	-1	15036754
pre@@	O	-1	15036754
ven@@	O	-1	15036754
tion	O	-1	15036754
of	O	-1	15036754
neuro@@	B-Disease	D004194	15036754
path@@	I-Disease	-1	15036754
ological	I-Disease	-1	15036754
dam@@	I-Disease	-1	15036754
ages	I-Disease	-1	15036754
.	O	-1	15036754
S@@	O	-1	15036754
uc@@	O	-1	15036754
h	O	-1	15036754
org@@	B-Chemical	D010755	15036754
an@@	I-Chemical	-1	15036754
oph@@	I-Chemical	-1	15036754
osph@@	I-Chemical	-1	15036754
or@@	I-Chemical	-1	15036754
us	I-Chemical	-1	15036754
(	O	-1	15036754
O@@	B-Chemical	D010755	15036754
P	I-Chemical	-1	15036754
)	O	-1	15036754
comp@@	O	-1	15036754
oun@@	O	-1	15036754
ds	O	-1	15036754
as	O	-1	15036754
di@@	B-Chemical	D007531	15036754
iso@@	I-Chemical	-1	15036754
prop@@	I-Chemical	-1	15036754
yl@@	I-Chemical	-1	15036754
fluoro@@	I-Chemical	-1	15036754
phosph@@	I-Chemical	-1	15036754
ate	I-Chemical	-1	15036754
(	O	-1	15036754
DF@@	B-Chemical	D007531	15036754
P	I-Chemical	-1	15036754
),	O	-1	15036754
s@@	B-Chemical	D012524	15036754
ar@@	I-Chemical	-1	15036754
in	I-Chemical	-1	15036754
and	O	-1	15036754
s@@	B-Chemical	D012999	15036754
om@@	I-Chemical	-1	15036754
an	I-Chemical	-1	15036754
are	O	-1	15036754
pot@@	O	-1	15036754
ent	O	-1	15036754
inhibitors	O	-1	15036754
of	O	-1	15036754
acet@@	O	-1	15036754
ylchol@@	O	-1	15036754
ine@@	O	-1	15036754
ster@@	O	-1	15036754
as@@	O	-1	15036754
es	O	-1	15036754
(@@	O	-1	15036754
AC@@	O	-1	15036754
h@@	O	-1	15036754
E@@	O	-1	15036754
s)	O	-1	15036754
and	O	-1	15036754
but@@	O	-1	15036754
y@@	O	-1	15036754
r@@	O	-1	15036754
ylchol@@	O	-1	15036754
ine@@	O	-1	15036754
ster@@	O	-1	15036754
as@@	O	-1	15036754
es	O	-1	15036754
(B@@	O	-1	15036754
Ch@@	O	-1	15036754
E@@	O	-1	15036754
s@@	O	-1	15036754
).	O	-1	15036754
The	O	-1	15036754
acute	O	-1	15036754
toxicity	B-Disease	D064420	15036754
of	O	-1	15036754
O@@	B-Chemical	D010755	15036754
P@@	I-Chemical	-1	15036754
s	I-Chemical	-1	15036754
is	O	-1	15036754
the	O	-1	15036754
result	O	-1	15036754
of	O	-1	15036754
their	O	-1	15036754
ir@@	O	-1	15036754
reversible	O	-1	15036754
b@@	O	-1	15036754
ind@@	O	-1	15036754
ing	O	-1	15036754
with	O	-1	15036754
AC@@	O	-1	15036754
h@@	O	-1	15036754
E@@	O	-1	15036754
s	O	-1	15036754
in	O	-1	15036754
the	O	-1	15036754
central	O	-1	15036754
ner@@	O	-1	15036754
v@@	O	-1	15036754
ous	O	-1	15036754
system	O	-1	15036754
(C@@	O	-1	15036754
N@@	O	-1	15036754
S@@	O	-1	15036754
),	O	-1	15036754
which	O	-1	15036754
elev@@	O	-1	15036754
ates	O	-1	15036754
acet@@	B-Chemical	D000109	15036754
ylcholine	I-Chemical	-1	15036754
(	O	-1	15036754
AC@@	B-Chemical	D000109	15036754
h	I-Chemical	-1	15036754
)	O	-1	15036754
level@@	O	-1	15036754
s.	O	-1	15036754
The	O	-1	15036754
protective	O	-1	15036754
action	O	-1	15036754
of	O	-1	15036754
sub@@	O	-1	15036754
c@@	O	-1	15036754
ut@@	O	-1	15036754
ane@@	O	-1	15036754
ously	O	-1	15036754
(S@@	O	-1	15036754
C@@	O	-1	15036754
)	O	-1	15036754
administered	O	-1	15036754
anti@@	O	-1	15036754
d@@	O	-1	15036754
ot@@	O	-1	15036754
es	O	-1	15036754
or	O	-1	15036754
their	O	-1	15036754
combin@@	O	-1	15036754
ations	O	-1	15036754
in	O	-1	15036754
DF@@	B-Chemical	D007531	15036754
P	I-Chemical	-1	15036754
(2@@	O	-1	15036754
.@@	O	-1	15036754
0	O	-1	15036754
mg/kg	O	-1	15036754
B@@	O	-1	15036754
W@@	O	-1	15036754
)	O	-1	15036754
in@@	O	-1	15036754
toxic@@	O	-1	15036754
ation	O	-1	15036754
was	O	-1	15036754
studied	O	-1	15036754
in	O	-1	15036754
9@@	O	-1	15036754
-@@	O	-1	15036754
10-@@	O	-1	15036754
week@@	O	-1	15036754
s@@	O	-1	15036754
-old	O	-1	15036754
H@@	O	-1	15036754
an@@	O	-1	15036754
-@@	O	-1	15036754
Wistar	O	-1	15036754
male	O	-1	15036754
rats.	O	-1	15036754
The	O	-1	15036754
rats	O	-1	15036754
received	O	-1	15036754
AC@@	O	-1	15036754
h@@	O	-1	15036754
E	O	-1	15036754
re@@	O	-1	15036754
activ@@	O	-1	15036754
at@@	O	-1	15036754
or	O	-1	15036754
pr@@	B-Chemical	D011220	15036754
al@@	I-Chemical	-1	15036754
id@@	I-Chemical	-1	15036754
ox@@	I-Chemical	-1	15036754
i@@	I-Chemical	-1	15036754
me@@	I-Chemical	-1	15036754
-@@	I-Chemical	-1	15036754
2-@@	I-Chemical	-1	15036754
chlor@@	I-Chemical	-1	15036754
ide	I-Chemical	-1	15036754
(	O	-1	15036754
2@@	B-Chemical	D011220	15036754
PA@@	I-Chemical	-1	15036754
M	I-Chemical	-1	15036754
)	O	-1	15036754
(3@@	O	-1	15036754
0.@@	O	-1	15036754
0	O	-1	15036754
mg/kg	O	-1	15036754
B@@	O	-1	15036754
W@@	O	-1	15036754
),	O	-1	15036754
anti@@	O	-1	15036754
convul@@	O	-1	15036754
s@@	O	-1	15036754
ant	O	-1	15036754
di@@	B-Chemical	D003975	15036754
az@@	I-Chemical	-1	15036754
epam	I-Chemical	-1	15036754
(2@@	O	-1	15036754
.@@	O	-1	15036754
0	O	-1	15036754
mg/kg	O	-1	15036754
B@@	O	-1	15036754
W@@	O	-1	15036754
),	O	-1	15036754
A@@	O	-1	15036754
(1@@	O	-1	15036754
)@@	O	-1	15036754
-	O	-1	15036754
aden@@	B-Chemical	D000241	15036754
os@@	I-Chemical	-1	15036754
ine	I-Chemical	-1	15036754
receptor	O	-1	15036754
agon@@	O	-1	15036754
ist	O	-1	15036754
N@@	B-Chemical	C048599	15036754
(6@@	I-Chemical	-1	15036754
)-@@	I-Chemical	-1	15036754
cyc@@	I-Chemical	-1	15036754
lop@@	I-Chemical	-1	15036754
ent@@	I-Chemical	-1	15036754
yl	I-Chemical	-1	15036754
aden@@	I-Chemical	-1	15036754
os@@	I-Chemical	-1	15036754
ine	I-Chemical	-1	15036754
(	O	-1	15036754
C@@	B-Chemical	C048599	15036754
P@@	I-Chemical	-1	15036754
A	I-Chemical	-1	15036754
)	O	-1	15036754
(2@@	O	-1	15036754
.@@	O	-1	15036754
0	O	-1	15036754
mg/kg	O	-1	15036754
B@@	O	-1	15036754
W@@	O	-1	15036754
),	O	-1	15036754
N@@	B-Chemical	D016202	15036754
MD@@	I-Chemical	-1	15036754
A	I-Chemical	-1	15036754
-@@	O	-1	15036754
receptor	O	-1	15036754
antagonist	O	-1	15036754
di@@	B-Chemical	D016291	15036754
z@@	I-Chemical	-1	15036754
oc@@	I-Chemical	-1	15036754
il@@	I-Chemical	-1	15036754
pine	I-Chemical	-1	15036754
mal@@	I-Chemical	-1	15036754
e@@	I-Chemical	-1	15036754
ate	I-Chemical	-1	15036754
(@@	O	-1	15036754
+@@	O	-1	15036754
-@@	O	-1	15036754
M@@	O	-1	15036754
K@@	O	-1	15036754
80@@	O	-1	15036754
1	O	-1	15036754
hydro@@	O	-1	15036754
gen	O	-1	15036754
mal@@	O	-1	15036754
e@@	O	-1	15036754
ate@@	O	-1	15036754
)	O	-1	15036754
(2@@	O	-1	15036754
.@@	O	-1	15036754
0	O	-1	15036754
mg/kg	O	-1	15036754
B@@	O	-1	15036754
W@@	O	-1	15036754
)	O	-1	15036754
or	O	-1	15036754
their	O	-1	15036754
combin@@	O	-1	15036754
ations	O	-1	15036754
with	O	-1	15036754
chol@@	O	-1	15036754
in@@	O	-1	15036754
oly@@	O	-1	15036754
tic	O	-1	15036754
drug	O	-1	15036754
atro@@	B-Chemical	D001285	15036754
pine	I-Chemical	-1	15036754
sulf@@	I-Chemical	-1	15036754
ate	I-Chemical	-1	15036754
(5@@	O	-1	15036754
0.@@	O	-1	15036754
0	O	-1	15036754
mg/kg	O	-1	15036754
B@@	O	-1	15036754
W@@	O	-1	15036754
)	O	-1	15036754
immedi@@	O	-1	15036754
ately	O	-1	15036754
or	O	-1	15036754
30	O	-1	15036754
min	O	-1	15036754
after	O	-1	15036754
the	O	-1	15036754
single	O	-1	15036754
S@@	O	-1	15036754
C	O	-1	15036754
injection	O	-1	15036754
of	O	-1	15036754
DF@@	B-Chemical	D007531	15036754
P	I-Chemical	-1	15036754
.	O	-1	15036754
The	O	-1	15036754
control	O	-1	15036754
rats	O	-1	15036754
received	O	-1	15036754
atro@@	B-Chemical	D001285	15036754
pine	I-Chemical	-1	15036754
sulf@@	I-Chemical	-1	15036754
ate	I-Chemical	-1	15036754
,	O	-1	15036754
but	O	-1	15036754
also	O	-1	15036754
saline	O	-1	15036754
and	O	-1	15036754
ol@@	O	-1	15036754
i@@	O	-1	15036754
ve	O	-1	15036754
o@@	O	-1	15036754
il	O	-1	15036754
in@@	O	-1	15036754
ste@@	O	-1	15036754
ad	O	-1	15036754
of	O	-1	15036754
other	O	-1	15036754
anti@@	O	-1	15036754
d@@	O	-1	15036754
ot@@	O	-1	15036754
es	O	-1	15036754
and	O	-1	15036754
DF@@	B-Chemical	D007531	15036754
P	I-Chemical	-1	15036754
,	O	-1	15036754
respectively.	O	-1	15036754
All	O	-1	15036754
rats	O	-1	15036754
were	O	-1	15036754
ter@@	O	-1	15036754
min@@	O	-1	15036754
ated	O	-1	15036754
either	O	-1	15036754
24	O	-1	15036754
h	O	-1	15036754
or	O	-1	15036754
3	O	-1	15036754
weeks	O	-1	15036754
after	O	-1	15036754
the	O	-1	15036754
DF@@	B-Chemical	D007531	15036754
P	I-Chemical	-1	15036754
injec@@	O	-1	15036754
tion.	O	-1	15036754
The	O	-1	15036754
rats	O	-1	15036754
treated	O	-1	15036754
with	O	-1	15036754
DF@@	B-Chemical	D007531	15036754
P	I-Chemical	-1	15036754
-	O	-1	15036754
atro@@	B-Chemical	D001285	15036754
pine	I-Chemical	-1	15036754
showed	O	-1	15036754
severe	O	-1	15036754
typ@@	O	-1	15036754
ical	O	-1	15036754
O@@	B-Chemical	D010755	15036754
P	I-Chemical	-1	15036754
-induced	O	-1	15036754
toxicity	B-Disease	D064420	15036754
sign@@	O	-1	15036754
s.	O	-1	15036754
Whe@@	O	-1	15036754
n	O	-1	15036754
C@@	B-Chemical	C048599	15036754
P@@	I-Chemical	-1	15036754
A	I-Chemical	-1	15036754
,	O	-1	15036754
di@@	B-Chemical	D003975	15036754
az@@	I-Chemical	-1	15036754
epam	I-Chemical	-1	15036754
or	O	-1	15036754
2@@	B-Chemical	D011220	15036754
PA@@	I-Chemical	-1	15036754
M	I-Chemical	-1	15036754
was	O	-1	15036754
given	O	-1	15036754
immedi@@	O	-1	15036754
ately	O	-1	15036754
after	O	-1	15036754
DF@@	B-Chemical	D007531	15036754
P	I-Chemical	-1	15036754
-	O	-1	15036754
atro@@	B-Chemical	D001285	15036754
pine	I-Chemical	-1	15036754
,	O	-1	15036754
these	O	-1	15036754
treat@@	O	-1	15036754
ments	O	-1	15036754
prevent@@	O	-1	15036754
ed,	O	-1	15036754
del@@	O	-1	15036754
ayed	O	-1	15036754
or	O	-1	15036754
sh@@	O	-1	15036754
or@@	O	-1	15036754
ten@@	O	-1	15036754
ed	O	-1	15036754
the	O	-1	15036754
occur@@	O	-1	15036754
rence	O	-1	15036754
of	O	-1	15036754
seri@@	O	-1	15036754
ous	O	-1	15036754
signs	O	-1	15036754
of	O	-1	15036754
po@@	B-Disease	D011041	15036754
is@@	I-Disease	-1	15036754
on@@	I-Disease	-1	15036754
ing	I-Disease	-1	15036754
.	O	-1	15036754
A@@	B-Chemical	D001285	15036754
tro@@	I-Chemical	-1	15036754
pine	I-Chemical	-1	15036754
-	O	-1	15036754
M@@	B-Chemical	D016291	15036754
K@@	I-Chemical	-1	15036754
80@@	I-Chemical	-1	15036754
1	I-Chemical	-1	15036754
did	O	-1	15036754
not	O	-1	15036754
o@@	O	-1	15036754
ff@@	O	-1	15036754
er	O	-1	15036754
any	O	-1	15036754
addi@@	O	-1	15036754
tional	O	-1	15036754
prot@@	O	-1	15036754
ection	O	-1	15036754
against	O	-1	15036754
DF@@	B-Chemical	D007531	15036754
P	I-Chemical	-1	15036754
toxicity	B-Disease	D064420	15036754
.	O	-1	15036754
In	O	-1	15036754
concl@@	O	-1	15036754
u@@	O	-1	15036754
sion,	O	-1	15036754
C@@	B-Chemical	C048599	15036754
P@@	I-Chemical	-1	15036754
A	I-Chemical	-1	15036754
,	O	-1	15036754
di@@	B-Chemical	D003975	15036754
az@@	I-Chemical	-1	15036754
epam	I-Chemical	-1	15036754
and	O	-1	15036754
2@@	B-Chemical	D011220	15036754
PA@@	I-Chemical	-1	15036754
M	I-Chemical	-1	15036754
in	O	-1	15036754
combination	O	-1	15036754
with	O	-1	15036754
atro@@	B-Chemical	D001285	15036754
pine	I-Chemical	-1	15036754
prevent@@	O	-1	15036754
ed	O	-1	15036754
the	O	-1	15036754
occur@@	O	-1	15036754
rence	O	-1	15036754
of	O	-1	15036754
seri@@	O	-1	15036754
ous	O	-1	15036754
signs	O	-1	15036754
of	O	-1	15036754
po@@	B-Disease	D011041	15036754
is@@	I-Disease	-1	15036754
on@@	I-Disease	-1	15036754
ing	I-Disease	-1	15036754
and	O	-1	15036754
th@@	O	-1	15036754
us	O	-1	15036754
reduced	O	-1	15036754
the	O	-1	15036754
toxicity	B-Disease	D064420	15036754
of	O	-1	15036754
DF@@	B-Chemical	D007531	15036754
P	I-Chemical	-1	15036754
in	O	-1	15036754
rat@@	O	-1	15036754
.	O	-1	15036754

Di@@	O	-1	15145918
fferen@@	O	-1	15145918
tial	O	-1	15145918
mod@@	O	-1	15145918
ulation	O	-1	15145918
by	O	-1	15145918
est@@	B-Chemical	D004967	15145918
ro@@	I-Chemical	-1	15145918
gen	I-Chemical	-1	15145918
of	O	-1	15145918
alpha@@	O	-1	15145918
2-@@	O	-1	15145918
adrenergic	O	-1	15145918
and	O	-1	15145918
I@@	O	-1	15145918
1@@	O	-1	15145918
-	O	-1	15145918
im@@	B-Chemical	D048288	15145918
id@@	I-Chemical	-1	15145918
azol@@	I-Chemical	-1	15145918
ine	I-Chemical	-1	15145918
receptor@@	O	-1	15145918
-@@	O	-1	15145918
mediated	O	-1	15145918
hypotension	B-Disease	D007022	15145918
in	O	-1	15145918
female	O	-1	15145918
rats.	O	-1	15145918
We	O	-1	15145918
have	O	-1	15145918
rec@@	O	-1	15145918
ently	O	-1	15145918
shown	O	-1	15145918
that	O	-1	15145918
est@@	B-Chemical	D004967	15145918
ro@@	I-Chemical	-1	15145918
gen	I-Chemical	-1	15145918
neg@@	O	-1	15145918
atively	O	-1	15145918
mod@@	O	-1	15145918
ul@@	O	-1	15145918
ates	O	-1	15145918
the	O	-1	15145918
hypoten@@	B-Disease	D007022	15145918
sive	I-Disease	-1	15145918
effect	O	-1	15145918
of	O	-1	15145918
clonidine	B-Chemical	D003000	15145918
(@@	O	-1	15145918
mi@@	O	-1	15145918
x@@	O	-1	15145918
ed	O	-1	15145918
alpha@@	O	-1	15145918
2-@@	O	-1	15145918
/@@	O	-1	15145918
I@@	O	-1	15145918
1-@@	O	-1	15145918
receptor	O	-1	15145918
agon@@	O	-1	15145918
ist@@	O	-1	15145918
)	O	-1	15145918
in	O	-1	15145918
female	O	-1	15145918
rats	O	-1	15145918
and	O	-1	15145918
implic@@	O	-1	15145918
ates	O	-1	15145918
the	O	-1	15145918
cardiovascular	O	-1	15145918
a@@	O	-1	15145918
ut@@	O	-1	15145918
on@@	O	-1	15145918
om@@	O	-1	15145918
ic	O	-1	15145918
control	O	-1	15145918
in	O	-1	15145918
this	O	-1	15145918
inter@@	O	-1	15145918
ac@@	O	-1	15145918
tion.	O	-1	15145918
The	O	-1	15145918
present	O	-1	15145918
study	O	-1	15145918
investigated	O	-1	15145918
whether	O	-1	15145918
this	O	-1	15145918
effect	O	-1	15145918
of	O	-1	15145918
est@@	B-Chemical	D004967	15145918
ro@@	I-Chemical	-1	15145918
gen	I-Chemical	-1	15145918
invol@@	O	-1	15145918
v@@	O	-1	15145918
es	O	-1	15145918
inter@@	O	-1	15145918
action	O	-1	15145918
with	O	-1	15145918
alpha@@	O	-1	15145918
2@@	O	-1	15145918
-	O	-1	15145918
and/or	O	-1	15145918
I@@	O	-1	15145918
1-@@	O	-1	15145918
receptor@@	O	-1	15145918
s.	O	-1	15145918
Ch@@	O	-1	15145918
ang@@	O	-1	15145918
es	O	-1	15145918
evoked	O	-1	15145918
by	O	-1	15145918
a	O	-1	15145918
single	O	-1	15145918
intra@@	O	-1	15145918
per@@	O	-1	15145918
it@@	O	-1	15145918
one@@	O	-1	15145918
al	O	-1	15145918
injection	O	-1	15145918
of	O	-1	15145918
ri@@	B-Chemical	C032302	15145918
l@@	I-Chemical	-1	15145918
men@@	I-Chemical	-1	15145918
idine	I-Chemical	-1	15145918
(6@@	O	-1	15145918
00	O	-1	15145918
micro@@	O	-1	15145918
g/@@	O	-1	15145918
kg@@	O	-1	15145918
)	O	-1	15145918
or	O	-1	15145918
alpha-@@	B-Chemical	D008750	15145918
methyl@@	I-Chemical	-1	15145918
dopa	I-Chemical	-1	15145918
(@@	O	-1	15145918
100	O	-1	15145918
mg/kg@@	O	-1	15145918
),	O	-1	15145918
selective	O	-1	15145918
I@@	O	-1	15145918
1@@	O	-1	15145918
-	O	-1	15145918
and	O	-1	15145918
alpha@@	O	-1	15145918
2-@@	O	-1	15145918
receptor	O	-1	15145918
agon@@	O	-1	15145918
ist@@	O	-1	15145918
s,	O	-1	15145918
respectivel@@	O	-1	15145918
y,	O	-1	15145918
in	O	-1	15145918
blood	O	-1	15145918
pressu@@	O	-1	15145918
re,	O	-1	15145918
hemo@@	O	-1	15145918
dynam@@	O	-1	15145918
ic	O	-1	15145918
vari@@	O	-1	15145918
abil@@	O	-1	15145918
ity,	O	-1	15145918
and	O	-1	15145918
locomotor	O	-1	15145918
activity	O	-1	15145918
were	O	-1	15145918
assessed	O	-1	15145918
in	O	-1	15145918
radi@@	O	-1	15145918
ot@@	O	-1	15145918
e@@	O	-1	15145918
le@@	O	-1	15145918
me@@	O	-1	15145918
te@@	O	-1	15145918
red	O	-1	15145918
sh@@	O	-1	15145918
am@@	O	-1	15145918
-@@	O	-1	15145918
o@@	O	-1	15145918
per@@	O	-1	15145918
ated	O	-1	15145918
and	O	-1	15145918
o@@	O	-1	15145918
vari@@	O	-1	15145918
ect@@	O	-1	15145918
om@@	O	-1	15145918
ized	O	-1	15145918
(@@	O	-1	15145918
O@@	O	-1	15145918
v@@	O	-1	15145918
x@@	O	-1	15145918
)	O	-1	15145918
S@@	O	-1	15145918
pra@@	O	-1	15145918
gu@@	O	-1	15145918
e-@@	O	-1	15145918
D@@	O	-1	15145918
aw@@	O	-1	15145918
le@@	O	-1	15145918
y	O	-1	15145918
female	O	-1	15145918
rats	O	-1	15145918
with	O	-1	15145918
or	O	-1	15145918
without	O	-1	15145918
1@@	O	-1	15145918
2-@@	O	-1	15145918
w@@	O	-1	15145918
k	O	-1	15145918
est@@	B-Chemical	D004967	15145918
ro@@	I-Chemical	-1	15145918
gen	I-Chemical	-1	15145918
re@@	O	-1	15145918
pl@@	O	-1	15145918
ac@@	O	-1	15145918
em@@	O	-1	15145918
ent@@	O	-1	15145918
.	O	-1	15145918
Th@@	O	-1	15145918
ree	O	-1	15145918
time	O	-1	15145918
do@@	O	-1	15145918
ma@@	O	-1	15145918
in	O	-1	15145918
in@@	O	-1	15145918
de@@	O	-1	15145918
x@@	O	-1	15145918
es	O	-1	15145918
of	O	-1	15145918
hemo@@	O	-1	15145918
dynam@@	O	-1	15145918
ic	O	-1	15145918
vari@@	O	-1	15145918
ability	O	-1	15145918
were	O	-1	15145918
em@@	O	-1	15145918
p@@	O	-1	15145918
lo@@	O	-1	15145918
y@@	O	-1	15145918
ed@@	O	-1	15145918
:	O	-1	15145918
the	O	-1	15145918
standard	O	-1	15145918
de@@	O	-1	15145918
vi@@	O	-1	15145918
ation	O	-1	15145918
of	O	-1	15145918
mean	O	-1	15145918
arterial	O	-1	15145918
pressure	O	-1	15145918
as	O	-1	15145918
a	O	-1	15145918
meas@@	O	-1	15145918
ure	O	-1	15145918
of	O	-1	15145918
blood	O	-1	15145918
pressure	O	-1	15145918
vari@@	O	-1	15145918
ability	O	-1	15145918
and	O	-1	15145918
the	O	-1	15145918
standard	O	-1	15145918
de@@	O	-1	15145918
vi@@	O	-1	15145918
ation	O	-1	15145918
of	O	-1	15145918
be@@	O	-1	15145918
at@@	O	-1	15145918
-@@	O	-1	15145918
to@@	O	-1	15145918
-@@	O	-1	15145918
be@@	O	-1	15145918
at	O	-1	15145918
interv@@	O	-1	15145918
als	O	-1	15145918
(S@@	O	-1	15145918
D@@	O	-1	15145918
R@@	O	-1	15145918
R@@	O	-1	15145918
)	O	-1	15145918
and	O	-1	15145918
the	O	-1	15145918
ro@@	O	-1	15145918
o@@	O	-1	15145918
t	O	-1	15145918
mean	O	-1	15145918
s@@	O	-1	15145918
qu@@	O	-1	15145918
are	O	-1	15145918
of	O	-1	15145918
suc@@	O	-1	15145918
ces@@	O	-1	15145918
sive	O	-1	15145918
differences	O	-1	15145918
in	O	-1	15145918
R@@	O	-1	15145918
-@@	O	-1	15145918
w@@	O	-1	15145918
a@@	O	-1	15145918
ve@@	O	-1	15145918
-@@	O	-1	15145918
to@@	O	-1	15145918
-@@	O	-1	15145918
R@@	O	-1	15145918
-@@	O	-1	15145918
w@@	O	-1	15145918
a@@	O	-1	15145918
ve	O	-1	15145918
interv@@	O	-1	15145918
als	O	-1	15145918
as	O	-1	15145918
meas@@	O	-1	15145918
ures	O	-1	15145918
of	O	-1	15145918
heart	O	-1	15145918
rate	O	-1	15145918
vari@@	O	-1	15145918
abil@@	O	-1	15145918
ity.	O	-1	15145918
In	O	-1	15145918
sh@@	O	-1	15145918
am@@	O	-1	15145918
-@@	O	-1	15145918
o@@	O	-1	15145918
per@@	O	-1	15145918
ated	O	-1	15145918
rats,	O	-1	15145918
ri@@	B-Chemical	C032302	15145918
l@@	I-Chemical	-1	15145918
men@@	I-Chemical	-1	15145918
idine	I-Chemical	-1	15145918
or	O	-1	15145918
alpha-@@	B-Chemical	D008750	15145918
methyl@@	I-Chemical	-1	15145918
dopa	I-Chemical	-1	15145918
el@@	O	-1	15145918
ic@@	O	-1	15145918
ited	O	-1	15145918
similar	O	-1	15145918
hypotension	B-Disease	D007022	15145918
that	O	-1	15145918
l@@	O	-1	15145918
ast@@	O	-1	15145918
ed	O	-1	15145918
at	O	-1	15145918
le@@	O	-1	15145918
ast	O	-1	15145918
5	O	-1	15145918
h	O	-1	15145918
and	O	-1	15145918
was	O	-1	15145918
associated	O	-1	15145918
with	O	-1	15145918
reduc@@	O	-1	15145918
tions	O	-1	15145918
in	O	-1	15145918
standard	O	-1	15145918
de@@	O	-1	15145918
vi@@	O	-1	15145918
ation	O	-1	15145918
of	O	-1	15145918
mean	O	-1	15145918
arterial	O	-1	15145918
pressu@@	O	-1	15145918
re.	O	-1	15145918
S@@	O	-1	15145918
D@@	O	-1	15145918
R@@	O	-1	15145918
R	O	-1	15145918
was	O	-1	15145918
reduced	O	-1	15145918
only	O	-1	15145918
by	O	-1	15145918
alpha-@@	B-Chemical	D008750	15145918
methyl@@	I-Chemical	-1	15145918
dopa	I-Chemical	-1	15145918
.	O	-1	15145918
O@@	O	-1	15145918
v@@	O	-1	15145918
x	O	-1	15145918
significantly	O	-1	15145918
enhanced	O	-1	15145918
the	O	-1	15145918
hypoten@@	B-Disease	D007022	15145918
sive	I-Disease	-1	15145918
response	O	-1	15145918
to	O	-1	15145918
alpha-@@	B-Chemical	D008750	15145918
methyl@@	I-Chemical	-1	15145918
dopa	I-Chemical	-1	15145918
,	O	-1	15145918
in	O	-1	15145918
contr@@	O	-1	15145918
ast	O	-1	15145918
to	O	-1	15145918
no	O	-1	15145918
effect	O	-1	15145918
on	O	-1	15145918
ri@@	B-Chemical	C032302	15145918
l@@	I-Chemical	-1	15145918
men@@	I-Chemical	-1	15145918
idine	I-Chemical	-1	15145918
hypotension	B-Disease	D007022	15145918
.	O	-1	15145918
The	O	-1	15145918
enhanced	O	-1	15145918
alpha-@@	B-Chemical	D008750	15145918
methyl@@	I-Chemical	-1	15145918
dopa	I-Chemical	-1	15145918
hypotension	B-Disease	D007022	15145918
in	O	-1	15145918
O@@	O	-1	15145918
v@@	O	-1	15145918
x	O	-1	15145918
rats	O	-1	15145918
was	O	-1	15145918
par@@	O	-1	15145918
al@@	O	-1	15145918
le@@	O	-1	15145918
l@@	O	-1	15145918
ed	O	-1	15145918
with	O	-1	15145918
further	O	-1	15145918
reduction	O	-1	15145918
in	O	-1	15145918
S@@	O	-1	15145918
D@@	O	-1	15145918
R@@	O	-1	15145918
R	O	-1	15145918
and	O	-1	15145918
a	B-Disease	D001523	15145918
reduced	I-Disease	-1	15145918
locomotor	I-Disease	-1	15145918
activity	I-Disease	-1	15145918
.	O	-1	15145918
E@@	O	-1	15145918
stro@@	O	-1	15145918
gen	O	-1	15145918
re@@	O	-1	15145918
pl@@	O	-1	15145918
ac@@	O	-1	15145918
ement	O	-1	15145918
(	O	-1	15145918
17@@	B-Chemical	D004958	15145918
beta-@@	I-Chemical	-1	15145918
est@@	I-Chemical	-1	15145918
radi@@	I-Chemical	-1	15145918
ol	I-Chemical	-1	15145918
sub@@	O	-1	15145918
c@@	O	-1	15145918
utaneous	O	-1	15145918
p@@	O	-1	15145918
el@@	O	-1	15145918
le@@	O	-1	15145918
t,	O	-1	15145918
1@@	O	-1	15145918
4.@@	O	-1	15145918
2	O	-1	15145918
micro@@	O	-1	15145918
g/@@	O	-1	15145918
da@@	O	-1	15145918
y,	O	-1	15145918
12	O	-1	15145918
w@@	O	-1	15145918
k@@	O	-1	15145918
)	O	-1	15145918
of	O	-1	15145918
O@@	O	-1	15145918
v@@	O	-1	15145918
x	O	-1	15145918
rats	O	-1	15145918
re@@	O	-1	15145918
sto@@	O	-1	15145918
red	O	-1	15145918
the	O	-1	15145918
hemo@@	O	-1	15145918
dynam@@	O	-1	15145918
ic	O	-1	15145918
and	O	-1	15145918
locomotor	O	-1	15145918
effects	O	-1	15145918
of	O	-1	15145918
alpha-@@	B-Chemical	D008750	15145918
methyl@@	I-Chemical	-1	15145918
dopa	I-Chemical	-1	15145918
to	O	-1	15145918
sh@@	O	-1	15145918
am@@	O	-1	15145918
-@@	O	-1	15145918
o@@	O	-1	15145918
per@@	O	-1	15145918
ated	O	-1	15145918
level@@	O	-1	15145918
s.	O	-1	15145918
These	O	-1	15145918
findings	O	-1	15145918
suggest	O	-1	15145918
that	O	-1	15145918
est@@	B-Chemical	D004967	15145918
ro@@	I-Chemical	-1	15145918
gen	I-Chemical	-1	15145918
do@@	O	-1	15145918
w@@	O	-1	15145918
n@@	O	-1	15145918
reg@@	O	-1	15145918
ul@@	O	-1	15145918
ates	O	-1	15145918
alpha@@	O	-1	15145918
2@@	O	-1	15145918
-	O	-1	15145918
but	O	-1	15145918
not	O	-1	15145918
I@@	O	-1	15145918
1-@@	O	-1	15145918
receptor@@	O	-1	15145918
-@@	O	-1	15145918
mediated	O	-1	15145918
hypotension	B-Disease	D007022	15145918
and	O	-1	15145918
high@@	O	-1	15145918
li@@	O	-1	15145918
ght	O	-1	15145918
a	O	-1	15145918
role	O	-1	15145918
for	O	-1	15145918
the	O	-1	15145918
cardiac	O	-1	15145918
a@@	O	-1	15145918
ut@@	O	-1	15145918
on@@	O	-1	15145918
om@@	O	-1	15145918
ic	O	-1	15145918
control	O	-1	15145918
in	O	-1	15145918
alpha-@@	B-Chemical	D008750	15145918
methyl@@	I-Chemical	-1	15145918
dopa	I-Chemical	-1	15145918
-	O	-1	15145918
est@@	B-Chemical	D004967	15145918
ro@@	I-Chemical	-1	15145918
gen	I-Chemical	-1	15145918
inter@@	O	-1	15145918
ac@@	O	-1	15145918
tion.	O	-1	15145918

C@@	O	-1	15233872
ardi@@	O	-1	15233872
o@@	O	-1	15233872
protective	O	-1	15233872
effect	O	-1	15233872
of	O	-1	15233872
t@@	B-Chemical	C007145	15233872
inc@@	I-Chemical	-1	15233872
t@@	I-Chemical	-1	15233872
ure	I-Chemical	-1	15233872
of	I-Chemical	-1	15233872
C@@	I-Chemical	-1	15233872
rat@@	I-Chemical	-1	15233872
a@@	I-Chemical	-1	15233872
e@@	I-Chemical	-1	15233872
g@@	I-Chemical	-1	15233872
us	I-Chemical	-1	15233872
on	O	-1	15233872
isoproteren@@	B-Chemical	D007545	15233872
ol	I-Chemical	-1	15233872
-induced	O	-1	15233872
myocardial	B-Disease	D009203	15233872
infarction	I-Disease	-1	15233872
in	O	-1	15233872
rats.	O	-1	15233872
T@@	B-Chemical	C007145	15233872
inc@@	I-Chemical	-1	15233872
t@@	I-Chemical	-1	15233872
ure	I-Chemical	-1	15233872
of	I-Chemical	-1	15233872
C@@	I-Chemical	-1	15233872
rat@@	I-Chemical	-1	15233872
a@@	I-Chemical	-1	15233872
e@@	I-Chemical	-1	15233872
g@@	I-Chemical	-1	15233872
us	I-Chemical	-1	15233872
(	O	-1	15233872
T@@	B-Chemical	C007145	15233872
C@@	I-Chemical	-1	15233872
R	I-Chemical	-1	15233872
),	O	-1	15233872
an	O	-1	15233872
alco@@	B-Chemical	C007145	15233872
h@@	I-Chemical	-1	15233872
olic	I-Chemical	-1	15233872
extrac@@	I-Chemical	-1	15233872
t	I-Chemical	-1	15233872
of	I-Chemical	-1	15233872
the	I-Chemical	-1	15233872
b@@	I-Chemical	-1	15233872
er@@	I-Chemical	-1	15233872
ri@@	I-Chemical	-1	15233872
es	I-Chemical	-1	15233872
of	I-Chemical	-1	15233872
ha@@	I-Chemical	-1	15233872
w@@	I-Chemical	-1	15233872
th@@	I-Chemical	-1	15233872
or@@	I-Chemical	-1	15233872
n	I-Chemical	-1	15233872
(	O	-1	15233872
C@@	B-Chemical	C007145	15233872
rat@@	I-Chemical	-1	15233872
a@@	I-Chemical	-1	15233872
e@@	I-Chemical	-1	15233872
g@@	I-Chemical	-1	15233872
us	I-Chemical	-1	15233872
ox@@	I-Chemical	-1	15233872
yc@@	I-Chemical	-1	15233872
an@@	I-Chemical	-1	15233872
th@@	I-Chemical	-1	15233872
a	I-Chemical	-1	15233872
),	O	-1	15233872
is	O	-1	15233872
used	O	-1	15233872
in	O	-1	15233872
h@@	O	-1	15233872
er@@	O	-1	15233872
b@@	O	-1	15233872
al	O	-1	15233872
and	O	-1	15233872
ho@@	O	-1	15233872
me@@	O	-1	15233872
o@@	O	-1	15233872
path@@	O	-1	15233872
ic	O	-1	15233872
medic@@	O	-1	15233872
ine.	O	-1	15233872
The	O	-1	15233872
present	O	-1	15233872
study	O	-1	15233872
was	O	-1	15233872
d@@	O	-1	15233872
one	O	-1	15233872
to	O	-1	15233872
investigate	O	-1	15233872
the	O	-1	15233872
protective	O	-1	15233872
effect	O	-1	15233872
of	O	-1	15233872
T@@	B-Chemical	C007145	15233872
C@@	I-Chemical	-1	15233872
R	I-Chemical	-1	15233872
on	O	-1	15233872
experim@@	O	-1	15233872
ent@@	O	-1	15233872
ally	O	-1	15233872
induced	O	-1	15233872
myocardial	B-Disease	D009203	15233872
infarction	I-Disease	-1	15233872
in	O	-1	15233872
rats.	O	-1	15233872
Pre@@	O	-1	15233872
treatment	O	-1	15233872
of	O	-1	15233872
T@@	B-Chemical	C007145	15233872
C@@	I-Chemical	-1	15233872
R	I-Chemical	-1	15233872
,	O	-1	15233872
at	O	-1	15233872
a	O	-1	15233872
dose	O	-1	15233872
of	O	-1	15233872
0.@@	O	-1	15233872
5	O	-1	15233872
m@@	O	-1	15233872
L@@	O	-1	15233872
/@@	O	-1	15233872
100	O	-1	15233872
g	O	-1	15233872
bo@@	O	-1	15233872
dy@@	O	-1	15233872
weight	O	-1	15233872
per	O	-1	15233872
da@@	O	-1	15233872
y,	O	-1	15233872
or@@	O	-1	15233872
ally	O	-1	15233872
for	O	-1	15233872
30	O	-1	15233872
day@@	O	-1	15233872
s,	O	-1	15233872
prevent@@	O	-1	15233872
ed	O	-1	15233872
the	O	-1	15233872
increase	O	-1	15233872
in	O	-1	15233872
li@@	O	-1	15233872
pid	O	-1	15233872
per@@	O	-1	15233872
oxid@@	O	-1	15233872
ation	O	-1	15233872
and	O	-1	15233872
activity	O	-1	15233872
of	O	-1	15233872
mark@@	O	-1	15233872
er	O	-1	15233872
enzym@@	O	-1	15233872
es	O	-1	15233872
observed	O	-1	15233872
in	O	-1	15233872
isoproteren@@	B-Chemical	D007545	15233872
ol	I-Chemical	-1	15233872
-induced	O	-1	15233872
rats	O	-1	15233872
(@@	O	-1	15233872
8@@	O	-1	15233872
5	O	-1	15233872
mg	O	-1	15233872
kg@@	O	-1	15233872
(@@	O	-1	15233872
-1@@	O	-1	15233872
)	O	-1	15233872
s.	O	-1	15233872
c@@	O	-1	15233872
.	O	-1	15233872
for	O	-1	15233872
2	O	-1	15233872
days	O	-1	15233872
at	O	-1	15233872
an	O	-1	15233872
interv@@	O	-1	15233872
al	O	-1	15233872
of	O	-1	15233872
24	O	-1	15233872
h@@	O	-1	15233872
).	O	-1	15233872
T@@	B-Chemical	C007145	15233872
C@@	I-Chemical	-1	15233872
R	I-Chemical	-1	15233872
prevent@@	O	-1	15233872
ed	O	-1	15233872
the	O	-1	15233872
isoproteren@@	B-Chemical	D007545	15233872
ol	I-Chemical	-1	15233872
-induced	O	-1	15233872
decrease	O	-1	15233872
in	O	-1	15233872
anti@@	O	-1	15233872
oxid@@	O	-1	15233872
ant	O	-1	15233872
enzym@@	O	-1	15233872
es	O	-1	15233872
in	O	-1	15233872
the	O	-1	15233872
heart	O	-1	15233872
and	O	-1	15233872
increased	O	-1	15233872
the	O	-1	15233872
rate	O	-1	15233872
of	O	-1	15233872
AD@@	B-Chemical	D000244	15233872
P	I-Chemical	-1	15233872
-@@	O	-1	15233872
stimul@@	O	-1	15233872
ated	O	-1	15233872
oxy@@	B-Chemical	D010100	15233872
gen	I-Chemical	-1	15233872
u@@	O	-1	15233872
pt@@	O	-1	15233872
ake	O	-1	15233872
and	O	-1	15233872
respiratory	O	-1	15233872
co@@	O	-1	15233872
u@@	O	-1	15233872
pl@@	O	-1	15233872
ing	O	-1	15233872
rati@@	O	-1	15233872
o@@	O	-1	15233872
.	O	-1	15233872
T@@	B-Chemical	C007145	15233872
C@@	I-Chemical	-1	15233872
R	I-Chemical	-1	15233872
prot@@	O	-1	15233872
ected	O	-1	15233872
against	O	-1	15233872
path@@	O	-1	15233872
ological	O	-1	15233872
changes	O	-1	15233872
induced	O	-1	15233872
by	O	-1	15233872
isoproteren@@	B-Chemical	D007545	15233872
ol	I-Chemical	-1	15233872
in	O	-1	15233872
rat	O	-1	15233872
hear@@	O	-1	15233872
t.	O	-1	15233872
The	O	-1	15233872
results	O	-1	15233872
show	O	-1	15233872
that	O	-1	15233872
pretreatment	O	-1	15233872
with	O	-1	15233872
T@@	B-Chemical	C007145	15233872
C@@	I-Chemical	-1	15233872
R	I-Chemical	-1	15233872
may	O	-1	15233872
be	O	-1	15233872
use@@	O	-1	15233872
ful	O	-1	15233872
in	O	-1	15233872
prevent@@	O	-1	15233872
ing	O	-1	15233872
the	O	-1	15233872
damage	O	-1	15233872
induced	O	-1	15233872
by	O	-1	15233872
isoproteren@@	B-Chemical	D007545	15233872
ol	I-Chemical	-1	15233872
in	O	-1	15233872
rat	O	-1	15233872
hear@@	O	-1	15233872
t.	O	-1	15233872

S@@	O	-1	15458908
af@@	O	-1	15458908
ety	O	-1	15458908
and	O	-1	15458908
adverse	O	-1	15458908
effects	O	-1	15458908
associated	O	-1	15458908
with	O	-1	15458908
r@@	B-Chemical	D020849	15458908
al@@	I-Chemical	-1	15458908
oxif@@	I-Chemical	-1	15458908
ene	I-Chemical	-1	15458908
:	O	-1	15458908
multiple	O	-1	15458908
outcom@@	O	-1	15458908
es	O	-1	15458908
of	O	-1	15458908
r@@	B-Chemical	D020849	15458908
al@@	I-Chemical	-1	15458908
oxif@@	I-Chemical	-1	15458908
ene	I-Chemical	-1	15458908
evalu@@	O	-1	15458908
ation.	O	-1	15458908
OBJECTIVE:	O	-1	15458908
To	O	-1	15458908
ex@@	O	-1	15458908
amine	O	-1	15458908
the	O	-1	15458908
effect	O	-1	15458908
of	O	-1	15458908
r@@	B-Chemical	D020849	15458908
al@@	I-Chemical	-1	15458908
oxif@@	I-Chemical	-1	15458908
ene	I-Chemical	-1	15458908
on	O	-1	15458908
major	O	-1	15458908
adverse	O	-1	15458908
events	O	-1	15458908
that	O	-1	15458908
occ@@	O	-1	15458908
ur	O	-1	15458908
with	O	-1	15458908
post@@	O	-1	15458908
men@@	O	-1	15458908
o@@	O	-1	15458908
pa@@	O	-1	15458908
us@@	O	-1	15458908
al	O	-1	15458908
est@@	B-Chemical	D004967	15458908
ro@@	I-Chemical	-1	15458908
gen	I-Chemical	-1	15458908
therapy	O	-1	15458908
or	O	-1	15458908
t@@	B-Chemical	D013629	15458908
am@@	I-Chemical	-1	15458908
oxif@@	I-Chemical	-1	15458908
en	I-Chemical	-1	15458908
.	O	-1	15458908
METHODS:	O	-1	15458908
The	O	-1	15458908
M@@	O	-1	15458908
ul@@	O	-1	15458908
ti@@	O	-1	15458908
ple	O	-1	15458908
O@@	O	-1	15458908
ut@@	O	-1	15458908
com@@	O	-1	15458908
es	O	-1	15458908
of	O	-1	15458908
R@@	B-Chemical	D020849	15458908
al@@	I-Chemical	-1	15458908
oxif@@	I-Chemical	-1	15458908
ene	I-Chemical	-1	15458908
E@@	O	-1	15458908
valu@@	O	-1	15458908
ation,	O	-1	15458908
a	O	-1	15458908
mul@@	O	-1	15458908
tic@@	O	-1	15458908
ent@@	O	-1	15458908
er,	O	-1	15458908
random@@	O	-1	15458908
iz@@	O	-1	15458908
ed,	O	-1	15458908
double-bl@@	O	-1	15458908
ind	O	-1	15458908
tri@@	O	-1	15458908
al,	O	-1	15458908
en@@	O	-1	15458908
ro@@	O	-1	15458908
lled	O	-1	15458908
7@@	O	-1	15458908
,@@	O	-1	15458908
7@@	O	-1	15458908
0@@	O	-1	15458908
5	O	-1	15458908
post@@	O	-1	15458908
men@@	O	-1	15458908
o@@	O	-1	15458908
pa@@	O	-1	15458908
us@@	O	-1	15458908
al	O	-1	15458908
women	O	-1	15458908
with	O	-1	15458908
ost@@	B-Disease	D010024	15458908
e@@	I-Disease	-1	15458908
o@@	I-Disease	-1	15458908
po@@	I-Disease	-1	15458908
ro@@	I-Disease	-1	15458908
sis	I-Disease	-1	15458908
.	O	-1	15458908
W@@	O	-1	15458908
o@@	O	-1	15458908
men	O	-1	15458908
were	O	-1	15458908
random@@	O	-1	15458908
ly	O	-1	15458908
as@@	O	-1	15458908
signed	O	-1	15458908
to	O	-1	15458908
r@@	B-Chemical	D020849	15458908
al@@	I-Chemical	-1	15458908
oxif@@	I-Chemical	-1	15458908
ene	I-Chemical	-1	15458908
60	O	-1	15458908
mg/@@	O	-1	15458908
d	O	-1	15458908
or	O	-1	15458908
1@@	O	-1	15458908
20	O	-1	15458908
mg/@@	O	-1	15458908
d	O	-1	15458908
or	O	-1	15458908
placebo@@	O	-1	15458908
.	O	-1	15458908
O@@	O	-1	15458908
ut@@	O	-1	15458908
com@@	O	-1	15458908
es	O	-1	15458908
included	O	-1	15458908
venous	B-Disease	D054556	15458908
thrombo@@	I-Disease	-1	15458908
emb@@	I-Disease	-1	15458908
ol@@	I-Disease	-1	15458908
ism	I-Disease	-1	15458908
,	O	-1	15458908
cat@@	B-Disease	D002386	15458908
ar@@	I-Disease	-1	15458908
act@@	I-Disease	-1	15458908
s	I-Disease	-1	15458908
,	O	-1	15458908
g@@	B-Disease	D005705	15458908
all@@	I-Disease	-1	15458908
bladder	I-Disease	-1	15458908
disease	I-Disease	-1	15458908
,	O	-1	15458908
and	O	-1	15458908
endo@@	B-Disease	D004714	15458908
me@@	I-Disease	-1	15458908
trial	I-Disease	-1	15458908
hyper@@	I-Disease	-1	15458908
pl@@	I-Disease	-1	15458908
a@@	I-Disease	-1	15458908
sia	I-Disease	-1	15458908
or	I-Disease	-1	15458908
cancer	I-Disease	-1	15458908
endo@@	B-Disease	D016889	15458908
me@@	I-Disease	-1	15458908
trial	I-Disease	-1	15458908
hyper@@	I-Disease	-1	15458908
pl@@	I-Disease	-1	15458908
a@@	I-Disease	-1	15458908
sia	I-Disease	-1	15458908
or	I-Disease	-1	15458908
cancer	I-Disease	-1	15458908
.	O	-1	15458908
RESULTS:	O	-1	15458908
D@@	O	-1	15458908
uring	O	-1	15458908
a	O	-1	15458908
mean	O	-1	15458908
follow-up	O	-1	15458908
of	O	-1	15458908
3.@@	O	-1	15458908
3	O	-1	15458908
year@@	O	-1	15458908
s,	O	-1	15458908
r@@	B-Chemical	D020849	15458908
al@@	I-Chemical	-1	15458908
oxif@@	I-Chemical	-1	15458908
ene	I-Chemical	-1	15458908
was	O	-1	15458908
associated	O	-1	15458908
with	O	-1	15458908
an	O	-1	15458908
increased	O	-1	15458908
risk	O	-1	15458908
for	O	-1	15458908
venous	B-Disease	D054556	15458908
thrombo@@	I-Disease	-1	15458908
emb@@	I-Disease	-1	15458908
ol@@	I-Disease	-1	15458908
ism	I-Disease	-1	15458908
(@@	O	-1	15458908
rel@@	O	-1	15458908
ative	O	-1	15458908
risk	O	-1	15458908
[@@	O	-1	15458908
R@@	O	-1	15458908
R@@	O	-1	15458908
]	O	-1	15458908
2.@@	O	-1	15458908
1@@	O	-1	15458908
;	O	-1	15458908
95%	O	-1	15458908
conf@@	O	-1	15458908
idence	O	-1	15458908
interv@@	O	-1	15458908
al	O	-1	15458908
[@@	O	-1	15458908
CI@@	O	-1	15458908
]	O	-1	15458908
1.@@	O	-1	15458908
2-@@	O	-1	15458908
3.@@	O	-1	15458908
8@@	O	-1	15458908
).	O	-1	15458908
The	O	-1	15458908
ex@@	O	-1	15458908
cess	O	-1	15458908
ev@@	O	-1	15458908
ent	O	-1	15458908
rate	O	-1	15458908
was	O	-1	15458908
1.@@	O	-1	15458908
8	O	-1	15458908
per	O	-1	15458908
1@@	O	-1	15458908
,@@	O	-1	15458908
0@@	O	-1	15458908
00	O	-1	15458908
wom@@	O	-1	15458908
an@@	O	-1	15458908
-@@	O	-1	15458908
years	O	-1	15458908
(@@	O	-1	15458908
95%	O	-1	15458908
C@@	O	-1	15458908
I	O	-1	15458908
-@@	O	-1	15458908
0.@@	O	-1	15458908
5-@@	O	-1	15458908
4.@@	O	-1	15458908
1),	O	-1	15458908
and	O	-1	15458908
the	O	-1	15458908
number	O	-1	15458908
ne@@	O	-1	15458908
ed@@	O	-1	15458908
ed	O	-1	15458908
to	O	-1	15458908
tre@@	O	-1	15458908
at	O	-1	15458908
to	O	-1	15458908
cause	O	-1	15458908
1	O	-1	15458908
ev@@	O	-1	15458908
ent	O	-1	15458908
was	O	-1	15458908
17@@	O	-1	15458908
0	O	-1	15458908
(@@	O	-1	15458908
95%	O	-1	15458908
C@@	O	-1	15458908
I	O	-1	15458908
10@@	O	-1	15458908
0-@@	O	-1	15458908
5@@	O	-1	15458908
8@@	O	-1	15458908
2)	O	-1	15458908
over	O	-1	15458908
3.@@	O	-1	15458908
3	O	-1	15458908
year@@	O	-1	15458908
s.	O	-1	15458908
R@@	O	-1	15458908
is@@	O	-1	15458908
k	O	-1	15458908
in	O	-1	15458908
the	O	-1	15458908
r@@	B-Chemical	D020849	15458908
al@@	I-Chemical	-1	15458908
oxif@@	I-Chemical	-1	15458908
ene	I-Chemical	-1	15458908
group	O	-1	15458908
was	O	-1	15458908
higher	O	-1	15458908
than	O	-1	15458908
in	O	-1	15458908
the	O	-1	15458908
placebo	O	-1	15458908
group	O	-1	15458908
for	O	-1	15458908
the	O	-1	15458908
first	O	-1	15458908
2	O	-1	15458908
year@@	O	-1	15458908
s,	O	-1	15458908
but	O	-1	15458908
decreased	O	-1	15458908
to	O	-1	15458908
about	O	-1	15458908
the	O	-1	15458908
same	O	-1	15458908
rate	O	-1	15458908
as	O	-1	15458908
in	O	-1	15458908
the	O	-1	15458908
placebo	O	-1	15458908
group	O	-1	15458908
the@@	O	-1	15458908
re@@	O	-1	15458908
af@@	O	-1	15458908
ter@@	O	-1	15458908
.	O	-1	15458908
R@@	B-Chemical	D020849	15458908
al@@	I-Chemical	-1	15458908
oxif@@	I-Chemical	-1	15458908
ene	I-Chemical	-1	15458908
did	O	-1	15458908
not	O	-1	15458908
increase	O	-1	15458908
risk	O	-1	15458908
for	O	-1	15458908
cat@@	B-Disease	D002386	15458908
ar@@	I-Disease	-1	15458908
act@@	I-Disease	-1	15458908
s	I-Disease	-1	15458908
(@@	O	-1	15458908
R@@	O	-1	15458908
R	O	-1	15458908
0.@@	O	-1	15458908
9@@	O	-1	15458908
;	O	-1	15458908
95%	O	-1	15458908
C@@	O	-1	15458908
I	O	-1	15458908
0.@@	O	-1	15458908
8@@	O	-1	15458908
-@@	O	-1	15458908
1.@@	O	-1	15458908
1),	O	-1	15458908
g@@	B-Disease	D005705	15458908
all@@	I-Disease	-1	15458908
bladder	I-Disease	-1	15458908
disease	I-Disease	-1	15458908
(@@	O	-1	15458908
R@@	O	-1	15458908
R	O	-1	15458908
1.@@	O	-1	15458908
0@@	O	-1	15458908
;	O	-1	15458908
95%	O	-1	15458908
C@@	O	-1	15458908
I	O	-1	15458908
0.@@	O	-1	15458908
7-@@	O	-1	15458908
1.@@	O	-1	15458908
3@@	O	-1	15458908
),	O	-1	15458908
endo@@	B-Disease	D004714	15458908
me@@	I-Disease	-1	15458908
trial	I-Disease	-1	15458908
hyper@@	I-Disease	-1	15458908
pl@@	I-Disease	-1	15458908
a@@	I-Disease	-1	15458908
sia	I-Disease	-1	15458908
(@@	O	-1	15458908
R@@	O	-1	15458908
R	O	-1	15458908
1.@@	O	-1	15458908
3@@	O	-1	15458908
;	O	-1	15458908
95%	O	-1	15458908
C@@	O	-1	15458908
I	O	-1	15458908
0.@@	O	-1	15458908
4-@@	O	-1	15458908
5.@@	O	-1	15458908
1),	O	-1	15458908
or	O	-1	15458908
endo@@	B-Disease	D016889	15458908
me@@	I-Disease	-1	15458908
trial	I-Disease	-1	15458908
cancer	I-Disease	-1	15458908
(@@	O	-1	15458908
R@@	O	-1	15458908
R	O	-1	15458908
0.@@	O	-1	15458908
9@@	O	-1	15458908
;	O	-1	15458908
95%	O	-1	15458908
C@@	O	-1	15458908
I	O	-1	15458908
0.@@	O	-1	15458908
3-@@	O	-1	15458908
2.@@	O	-1	15458908
7@@	O	-1	15458908
).	O	-1	15458908
CONCLUSION:	O	-1	15458908
R@@	B-Chemical	D020849	15458908
al@@	I-Chemical	-1	15458908
oxif@@	I-Chemical	-1	15458908
ene	I-Chemical	-1	15458908
was	O	-1	15458908
associated	O	-1	15458908
with	O	-1	15458908
an	O	-1	15458908
increased	O	-1	15458908
risk	O	-1	15458908
for	O	-1	15458908
venous	B-Disease	D054556	15458908
thrombo@@	I-Disease	-1	15458908
emb@@	I-Disease	-1	15458908
ol@@	I-Disease	-1	15458908
ism	I-Disease	-1	15458908
,	O	-1	15458908
but	O	-1	15458908
there	O	-1	15458908
was	O	-1	15458908
no	O	-1	15458908
increased	O	-1	15458908
risk	O	-1	15458908
for	O	-1	15458908
cat@@	B-Disease	D002386	15458908
ar@@	I-Disease	-1	15458908
act@@	I-Disease	-1	15458908
s	I-Disease	-1	15458908
,	O	-1	15458908
g@@	B-Disease	D005705	15458908
all@@	I-Disease	-1	15458908
bladder	I-Disease	-1	15458908
disease	I-Disease	-1	15458908
,	O	-1	15458908
endo@@	B-Disease	D004714	15458908
me@@	I-Disease	-1	15458908
trial	I-Disease	-1	15458908
hyper@@	I-Disease	-1	15458908
pl@@	I-Disease	-1	15458908
a@@	I-Disease	-1	15458908
sia	I-Disease	-1	15458908
,	O	-1	15458908
or	O	-1	15458908
endo@@	B-Disease	D016889	15458908
me@@	I-Disease	-1	15458908
trial	I-Disease	-1	15458908
cancer	I-Disease	-1	15458908
.	O	-1	15458908
L@@	O	-1	15458908
E@@	O	-1	15458908
V@@	O	-1	15458908
E@@	O	-1	15458908
L	O	-1	15458908
O@@	O	-1	15458908
F	O	-1	15458908
E@@	O	-1	15458908
V@@	O	-1	15458908
I@@	O	-1	15458908
D@@	O	-1	15458908
E@@	O	-1	15458908
N@@	O	-1	15458908
C@@	O	-1	15458908
E:	O	-1	15458908
I	O	-1	15458908

C@@	B-Chemical	D002443	15737522
e@@	I-Chemical	-1	15737522
f@@	I-Chemical	-1	15737522
tri@@	I-Chemical	-1	15737522
ax@@	I-Chemical	-1	15737522
one	I-Chemical	-1	15737522
-@@	O	-1	15737522
associated	O	-1	15737522
bil@@	B-Disease	D001660	15737522
i@@	I-Disease	-1	15737522
ary	I-Disease	-1	15737522
p@@	I-Disease	-1	15737522
se@@	I-Disease	-1	15737522
ud@@	I-Disease	-1	15737522
ol@@	I-Disease	-1	15737522
i@@	I-Disease	-1	15737522
th@@	I-Disease	-1	15737522
ia@@	I-Disease	-1	15737522
sis	I-Disease	-1	15737522
in	O	-1	15737522
pa@@	O	-1	15737522
edi@@	O	-1	15737522
atric	O	-1	15737522
surg@@	O	-1	15737522
ical	O	-1	15737522
patients.	O	-1	15737522
It	O	-1	15737522
is	O	-1	15737522
well	O	-1	15737522
known	O	-1	15737522
that	O	-1	15737522
ce@@	B-Chemical	D002443	15737522
f@@	I-Chemical	-1	15737522
tri@@	I-Chemical	-1	15737522
ax@@	I-Chemical	-1	15737522
one	I-Chemical	-1	15737522
lead@@	O	-1	15737522
s	O	-1	15737522
to	O	-1	15737522
p@@	B-Disease	D001660	15737522
se@@	I-Disease	-1	15737522
ud@@	I-Disease	-1	15737522
ol@@	I-Disease	-1	15737522
i@@	I-Disease	-1	15737522
th@@	I-Disease	-1	15737522
ia@@	I-Disease	-1	15737522
sis	I-Disease	-1	15737522
in	O	-1	15737522
some	O	-1	15737522
patients.	O	-1	15737522
Clin@@	O	-1	15737522
ical	O	-1	15737522
and	O	-1	15737522
experimental	O	-1	15737522
studies	O	-1	15737522
also	O	-1	15737522
suggest	O	-1	15737522
that	O	-1	15737522
sit@@	O	-1	15737522
u@@	O	-1	15737522
ations	O	-1	15737522
ca@@	O	-1	15737522
using	O	-1	15737522
g@@	B-Disease	D005705	15737522
all@@	I-Disease	-1	15737522
bladder	I-Disease	-1	15737522
dysfunction	I-Disease	-1	15737522
,	O	-1	15737522
such	O	-1	15737522
as	O	-1	15737522
f@@	O	-1	15737522
ast@@	O	-1	15737522
ing,	O	-1	15737522
may	O	-1	15737522
have	O	-1	15737522
a	O	-1	15737522
role	O	-1	15737522
for	O	-1	15737522
the	O	-1	15737522
development	O	-1	15737522
of	O	-1	15737522
p@@	B-Disease	D001660	15737522
se@@	I-Disease	-1	15737522
ud@@	I-Disease	-1	15737522
ol@@	I-Disease	-1	15737522
i@@	I-Disease	-1	15737522
th@@	I-Disease	-1	15737522
ia@@	I-Disease	-1	15737522
sis	I-Disease	-1	15737522
.	O	-1	15737522
In	O	-1	15737522
this	O	-1	15737522
study,	O	-1	15737522
we	O	-1	15737522
pro@@	O	-1	15737522
sp@@	O	-1	15737522
ectively	O	-1	15737522
evaluated	O	-1	15737522
the	O	-1	15737522
incidence	O	-1	15737522
and	O	-1	15737522
clinical	O	-1	15737522
import@@	O	-1	15737522
ance	O	-1	15737522
of	O	-1	15737522
p@@	B-Disease	D001660	15737522
se@@	I-Disease	-1	15737522
ud@@	I-Disease	-1	15737522
ol@@	I-Disease	-1	15737522
i@@	I-Disease	-1	15737522
th@@	I-Disease	-1	15737522
ia@@	I-Disease	-1	15737522
sis	I-Disease	-1	15737522
in	O	-1	15737522
pa@@	O	-1	15737522
edi@@	O	-1	15737522
atric	O	-1	15737522
surg@@	O	-1	15737522
ical	O	-1	15737522
patients	O	-1	15737522
receiving	O	-1	15737522
ce@@	B-Chemical	D002443	15737522
f@@	I-Chemical	-1	15737522
tri@@	I-Chemical	-1	15737522
ax@@	I-Chemical	-1	15737522
one	I-Chemical	-1	15737522
treatment,	O	-1	15737522
who	O	-1	15737522
often	O	-1	15737522
had	O	-1	15737522
to	O	-1	15737522
f@@	O	-1	15737522
ast	O	-1	15737522
in	O	-1	15737522
the	O	-1	15737522
post@@	O	-1	15737522
-@@	O	-1	15737522
o@@	O	-1	15737522
perative	O	-1	15737522
perio@@	O	-1	15737522
d.	O	-1	15737522
F@@	O	-1	15737522
if@@	O	-1	15737522
t@@	O	-1	15737522
y	O	-1	15737522
children	O	-1	15737522
who	O	-1	15737522
were	O	-1	15737522
given	O	-1	15737522
ce@@	B-Chemical	D002443	15737522
f@@	I-Chemical	-1	15737522
tri@@	I-Chemical	-1	15737522
ax@@	I-Chemical	-1	15737522
one	I-Chemical	-1	15737522
were	O	-1	15737522
evaluated	O	-1	15737522
by	O	-1	15737522
ser@@	O	-1	15737522
ial	O	-1	15737522
ab@@	O	-1	15737522
domin@@	O	-1	15737522
al	O	-1	15737522
son@@	O	-1	15737522
o@@	O	-1	15737522
gram@@	O	-1	15737522
s.	O	-1	15737522
Of	O	-1	15737522
th@@	O	-1	15737522
o@@	O	-1	15737522
se@@	O	-1	15737522
,	O	-1	15737522
13	O	-1	15737522
(2@@	O	-1	15737522
6@@	O	-1	15737522
%)	O	-1	15737522
developed	O	-1	15737522
bil@@	O	-1	15737522
i@@	O	-1	15737522
ary	O	-1	15737522
path@@	O	-1	15737522
olog@@	O	-1	15737522
y.	O	-1	15737522
Com@@	O	-1	15737522
par@@	O	-1	15737522
ison	O	-1	15737522
of	O	-1	15737522
the	O	-1	15737522
patients	O	-1	15737522
with	O	-1	15737522
or	O	-1	15737522
without	O	-1	15737522
p@@	B-Disease	D001660	15737522
se@@	I-Disease	-1	15737522
ud@@	I-Disease	-1	15737522
ol@@	I-Disease	-1	15737522
i@@	I-Disease	-1	15737522
th@@	I-Disease	-1	15737522
ia@@	I-Disease	-1	15737522
sis	I-Disease	-1	15737522
revealed	O	-1	15737522
no	O	-1	15737522
significant	O	-1	15737522
difference	O	-1	15737522
with	O	-1	15737522
resp@@	O	-1	15737522
ect	O	-1	15737522
to	O	-1	15737522
age,	O	-1	15737522
sex@@	O	-1	15737522
,	O	-1	15737522
duration	O	-1	15737522
of	O	-1	15737522
the	O	-1	15737522
treatment	O	-1	15737522
and	O	-1	15737522
star@@	O	-1	15737522
v@@	O	-1	15737522
ation	O	-1	15737522
vari@@	O	-1	15737522
abl@@	O	-1	15737522
es.	O	-1	15737522
After	O	-1	15737522
cess@@	O	-1	15737522
ation	O	-1	15737522
of	O	-1	15737522
the	O	-1	15737522
treatment,	O	-1	15737522
p@@	B-Disease	D001660	15737522
se@@	I-Disease	-1	15737522
ud@@	I-Disease	-1	15737522
ol@@	I-Disease	-1	15737522
i@@	I-Disease	-1	15737522
th@@	I-Disease	-1	15737522
ia@@	I-Disease	-1	15737522
sis	I-Disease	-1	15737522
resol@@	O	-1	15737522
ved	O	-1	15737522
spont@@	O	-1	15737522
ane@@	O	-1	15737522
ously	O	-1	15737522
within	O	-1	15737522
a	O	-1	15737522
sh@@	O	-1	15737522
ort	O	-1	15737522
perio@@	O	-1	15737522
d.	O	-1	15737522
The	O	-1	15737522
incidence	O	-1	15737522
of	O	-1	15737522
p@@	B-Disease	D001660	15737522
se@@	I-Disease	-1	15737522
ud@@	I-Disease	-1	15737522
ol@@	I-Disease	-1	15737522
i@@	I-Disease	-1	15737522
th@@	I-Disease	-1	15737522
ia@@	I-Disease	-1	15737522
sis	I-Disease	-1	15737522
is	O	-1	15737522
not	O	-1	15737522
affected	O	-1	15737522
by	O	-1	15737522
f@@	O	-1	15737522
ast@@	O	-1	15737522
ing.	O	-1	15737522

E@@	O	-1	16005948
valu@@	O	-1	16005948
ation	O	-1	16005948
of	O	-1	16005948
the	O	-1	16005948
anti@@	O	-1	16005948
cocaine	O	-1	16005948
mon@@	O	-1	16005948
oc@@	O	-1	16005948
lon@@	O	-1	16005948
al	O	-1	16005948
anti@@	O	-1	16005948
body	O	-1	16005948
G@@	B-Chemical	-1	16005948
N@@	I-Chemical	-1	16005948
C@@	I-Chemical	-1	16005948
9@@	I-Chemical	-1	16005948
2@@	I-Chemical	-1	16005948
H@@	I-Chemical	-1	16005948
2	I-Chemical	-1	16005948
as	O	-1	16005948
an	O	-1	16005948
immuno@@	O	-1	16005948
therapy	O	-1	16005948
for	O	-1	16005948
cocaine	B-Disease	D062787	16005948
over@@	I-Disease	-1	16005948
dose	I-Disease	-1	16005948
.	O	-1	16005948
The	O	-1	16005948
ill@@	O	-1	16005948
ic@@	O	-1	16005948
it	O	-1	16005948
use	O	-1	16005948
of	O	-1	16005948
cocaine	B-Chemical	D003042	16005948
continu@@	O	-1	16005948
es	O	-1	16005948
in	O	-1	16005948
epi@@	O	-1	16005948
de@@	O	-1	16005948
mic	O	-1	16005948
pro@@	O	-1	16005948
por@@	O	-1	16005948
tions	O	-1	16005948
and	O	-1	16005948
treatment	O	-1	16005948
for	O	-1	16005948
cocaine	B-Disease	D062787	16005948
over@@	I-Disease	-1	16005948
dose	I-Disease	-1	16005948
remain@@	O	-1	16005948
s	O	-1	16005948
el@@	O	-1	16005948
u@@	O	-1	16005948
si@@	O	-1	16005948
ve.	O	-1	16005948
C@@	O	-1	16005948
ur@@	O	-1	16005948
rent	O	-1	16005948
protein@@	O	-1	16005948
-@@	O	-1	16005948
bas@@	O	-1	16005948
ed	O	-1	16005948
t@@	O	-1	16005948
ech@@	O	-1	16005948
no@@	O	-1	16005948
log@@	O	-1	16005948
y	O	-1	16005948
o@@	O	-1	16005948
ff@@	O	-1	16005948
ers	O	-1	16005948
a	O	-1	16005948
new	O	-1	16005948
therapeutic	O	-1	16005948
ven@@	O	-1	16005948
u@@	O	-1	16005948
e	O	-1	16005948
by	O	-1	16005948
which	O	-1	16005948
anti@@	O	-1	16005948
bo@@	O	-1	16005948
di@@	O	-1	16005948
es	O	-1	16005948
bin@@	O	-1	16005948
d	O	-1	16005948
the	O	-1	16005948
drug	O	-1	16005948
in	O	-1	16005948
the	O	-1	16005948
blood	O	-1	16005948
st@@	O	-1	16005948
re@@	O	-1	16005948
am@@	O	-1	16005948
,	O	-1	16005948
in@@	O	-1	16005948
activ@@	O	-1	16005948
ating	O	-1	16005948
its	O	-1	16005948
toxic	O	-1	16005948
effects.	O	-1	16005948
The	O	-1	16005948
therapeutic	O	-1	16005948
potential	O	-1	16005948
of	O	-1	16005948
the	O	-1	16005948
anti@@	O	-1	16005948
cocaine	O	-1	16005948
anti@@	O	-1	16005948
body	O	-1	16005948
G@@	B-Chemical	-1	16005948
N@@	I-Chemical	-1	16005948
C@@	I-Chemical	-1	16005948
9@@	I-Chemical	-1	16005948
2@@	I-Chemical	-1	16005948
H@@	I-Chemical	-1	16005948
2	I-Chemical	-1	16005948
was	O	-1	16005948
examined	O	-1	16005948
using	O	-1	16005948
a	O	-1	16005948
model	O	-1	16005948
of	O	-1	16005948
cocaine	B-Disease	D062787	16005948
over@@	I-Disease	-1	16005948
dose	I-Disease	-1	16005948
.	O	-1	16005948
S@@	O	-1	16005948
w@@	O	-1	16005948
is@@	O	-1	16005948
s	O	-1	16005948
al@@	O	-1	16005948
bin@@	O	-1	16005948
o	O	-1	16005948
mice	O	-1	16005948
pre@@	O	-1	16005948
pared	O	-1	16005948
with	O	-1	16005948
intra@@	O	-1	16005948
j@@	O	-1	16005948
u@@	O	-1	16005948
g@@	O	-1	16005948
ular	O	-1	16005948
ca@@	O	-1	16005948
the@@	O	-1	16005948
ters	O	-1	16005948
were	O	-1	16005948
tested	O	-1	16005948
in	O	-1	16005948
ph@@	O	-1	16005948
ot@@	O	-1	16005948
oc@@	O	-1	16005948
el@@	O	-1	16005948
l	O	-1	16005948
c@@	O	-1	16005948
ages	O	-1	16005948
after	O	-1	16005948
administration	O	-1	16005948
of	O	-1	16005948
9@@	O	-1	16005948
3	O	-1	16005948
mg/kg	O	-1	16005948
(@@	O	-1	16005948
L@@	O	-1	16005948
D@@	O	-1	16005948
50@@	O	-1	16005948
)	O	-1	16005948
of	O	-1	16005948
cocaine	B-Chemical	D003042	16005948
and	O	-1	16005948
G@@	B-Chemical	-1	16005948
N@@	I-Chemical	-1	16005948
C@@	I-Chemical	-1	16005948
9@@	I-Chemical	-1	16005948
2@@	I-Chemical	-1	16005948
H@@	I-Chemical	-1	16005948
2	I-Chemical	-1	16005948
infu@@	O	-1	16005948
sions	O	-1	16005948
rang@@	O	-1	16005948
ing	O	-1	16005948
from	O	-1	16005948
30	O	-1	16005948
to	O	-1	16005948
19@@	O	-1	16005948
0	O	-1	16005948
mg/kg@@	O	-1	16005948
.	O	-1	16005948
G@@	B-Chemical	-1	16005948
N@@	I-Chemical	-1	16005948
C@@	I-Chemical	-1	16005948
9@@	I-Chemical	-1	16005948
2@@	I-Chemical	-1	16005948
H@@	I-Chemical	-1	16005948
2	I-Chemical	-1	16005948
was	O	-1	16005948
de@@	O	-1	16005948
li@@	O	-1	16005948
vered	O	-1	16005948
30	O	-1	16005948
min	O	-1	16005948
be@@	O	-1	16005948
fo@@	O	-1	16005948
re,	O	-1	16005948
concomit@@	O	-1	16005948
ant@@	O	-1	16005948
ly	O	-1	16005948
or	O	-1	16005948
3	O	-1	16005948
min	O	-1	16005948
after	O	-1	16005948
cocaine	B-Chemical	D003042	16005948
treatment.	O	-1	16005948
Si@@	O	-1	16005948
gn@@	O	-1	16005948
ific@@	O	-1	16005948
ant	O	-1	16005948
block@@	O	-1	16005948
ade	O	-1	16005948
of	O	-1	16005948
cocaine	B-Chemical	D003042	16005948
toxicity	B-Disease	D064420	16005948
was	O	-1	16005948
observed	O	-1	16005948
with	O	-1	16005948
the	O	-1	16005948
higher	O	-1	16005948
dose	O	-1	16005948
of	O	-1	16005948
G@@	B-Chemical	-1	16005948
N@@	I-Chemical	-1	16005948
C@@	I-Chemical	-1	16005948
9@@	I-Chemical	-1	16005948
2@@	I-Chemical	-1	16005948
H@@	I-Chemical	-1	16005948
2	I-Chemical	-1	16005948
(1@@	O	-1	16005948
9@@	O	-1	16005948
0	O	-1	16005948
mg/kg@@	O	-1	16005948
),	O	-1	16005948
wh@@	O	-1	16005948
ere	O	-1	16005948
pre@@	O	-1	16005948
mor@@	O	-1	16005948
b@@	O	-1	16005948
id	O	-1	16005948
behavi@@	O	-1	16005948
ors	O	-1	16005948
were	O	-1	16005948
reduced	O	-1	16005948
up	O	-1	16005948
to	O	-1	16005948
4@@	O	-1	16005948
0@@	O	-1	16005948
%,	O	-1	16005948
seizures	B-Disease	D012640	16005948
up	O	-1	16005948
to	O	-1	16005948
7@@	O	-1	16005948
7@@	O	-1	16005948
%	O	-1	16005948
and	O	-1	16005948
death	B-Disease	D003643	16005948
by	O	-1	16005948
7@@	O	-1	16005948
2@@	O	-1	16005948
%.	O	-1	16005948
Im@@	O	-1	16005948
port@@	O	-1	16005948
ant@@	O	-1	16005948
ly,	O	-1	16005948
G@@	B-Chemical	-1	16005948
N@@	I-Chemical	-1	16005948
C@@	I-Chemical	-1	16005948
9@@	I-Chemical	-1	16005948
2@@	I-Chemical	-1	16005948
H@@	I-Chemical	-1	16005948
2	I-Chemical	-1	16005948
prevent@@	O	-1	16005948
ed	O	-1	16005948
death	B-Disease	D003643	16005948
even	O	-1	16005948
post@@	O	-1	16005948
-	O	-1	16005948
cocaine	B-Chemical	D003042	16005948
injec@@	O	-1	16005948
tion.	O	-1	16005948
The	O	-1	16005948
results	O	-1	16005948
suppor@@	O	-1	16005948
t	O	-1	16005948
the	O	-1	16005948
important	O	-1	16005948
potential	O	-1	16005948
of	O	-1	16005948
G@@	B-Chemical	-1	16005948
N@@	I-Chemical	-1	16005948
C@@	I-Chemical	-1	16005948
9@@	I-Chemical	-1	16005948
2@@	I-Chemical	-1	16005948
H@@	I-Chemical	-1	16005948
2	I-Chemical	-1	16005948
as	O	-1	16005948
a	O	-1	16005948
therapeutic	O	-1	16005948
to@@	O	-1	16005948
ol	O	-1	16005948
against	O	-1	16005948
cocaine	B-Disease	D062787	16005948
over@@	I-Disease	-1	16005948
dose	I-Disease	-1	16005948
.	O	-1	16005948

The	O	-1	16167916
effects	O	-1	16167916
of	O	-1	16167916
sh@@	O	-1	16167916
ort@@	O	-1	16167916
-term	O	-1	16167916
r@@	B-Chemical	D020849	16167916
al@@	I-Chemical	-1	16167916
oxif@@	I-Chemical	-1	16167916
ene	I-Chemical	-1	16167916
therapy	O	-1	16167916
on	O	-1	16167916
fib@@	O	-1	16167916
r@@	O	-1	16167916
in@@	O	-1	16167916
oly@@	O	-1	16167916
sis	O	-1	16167916
mark@@	O	-1	16167916
er@@	O	-1	16167916
s:	O	-1	16167916
TA@@	O	-1	16167916
F@@	O	-1	16167916
I@@	O	-1	16167916
,	O	-1	16167916
t@@	O	-1	16167916
PA@@	O	-1	16167916
,	O	-1	16167916
and	O	-1	16167916
PA@@	O	-1	16167916
I@@	O	-1	16167916
-1@@	O	-1	16167916
.	O	-1	16167916
BACKGROUND:	O	-1	16167916
M@@	O	-1	16167916
ark@@	O	-1	16167916
ers	O	-1	16167916
of	O	-1	16167916
fib@@	O	-1	16167916
r@@	O	-1	16167916
in@@	O	-1	16167916
oly@@	O	-1	16167916
sis,	O	-1	16167916
throm@@	O	-1	16167916
bin@@	O	-1	16167916
-@@	O	-1	16167916
activ@@	O	-1	16167916
at@@	O	-1	16167916
able	O	-1	16167916
fib@@	O	-1	16167916
r@@	O	-1	16167916
in@@	O	-1	16167916
oly@@	O	-1	16167916
sis	O	-1	16167916
inhibitor	O	-1	16167916
(T@@	O	-1	16167916
A@@	O	-1	16167916
F@@	O	-1	16167916
I@@	O	-1	16167916
),	O	-1	16167916
tissu@@	O	-1	16167916
e-@@	O	-1	16167916
type	O	-1	16167916
plas@@	O	-1	16167916
min@@	O	-1	16167916
o@@	O	-1	16167916
gen	O	-1	16167916
activ@@	O	-1	16167916
at@@	O	-1	16167916
or	O	-1	16167916
(@@	O	-1	16167916
t@@	O	-1	16167916
PA@@	O	-1	16167916
),	O	-1	16167916
and	O	-1	16167916
plas@@	O	-1	16167916
min@@	O	-1	16167916
o@@	O	-1	16167916
gen	O	-1	16167916
activ@@	O	-1	16167916
at@@	O	-1	16167916
or	O	-1	16167916
inhibitor@@	O	-1	16167916
-1	O	-1	16167916
(@@	O	-1	16167916
PA@@	O	-1	16167916
I@@	O	-1	16167916
-1@@	O	-1	16167916
)	O	-1	16167916
levels	O	-1	16167916
were	O	-1	16167916
studied	O	-1	16167916
for	O	-1	16167916
the	O	-1	16167916
evalu@@	O	-1	16167916
ation	O	-1	16167916
of	O	-1	16167916
sh@@	O	-1	16167916
ort@@	O	-1	16167916
-term	O	-1	16167916
effects	O	-1	16167916
of	O	-1	16167916
r@@	B-Chemical	D020849	16167916
al@@	I-Chemical	-1	16167916
oxif@@	I-Chemical	-1	16167916
ene	I-Chemical	-1	16167916
administration	O	-1	16167916
in	O	-1	16167916
post@@	O	-1	16167916
men@@	O	-1	16167916
o@@	O	-1	16167916
pa@@	O	-1	16167916
us@@	O	-1	16167916
al	O	-1	16167916
wom@@	O	-1	16167916
en@@	O	-1	16167916
.	O	-1	16167916
METHODS:	O	-1	16167916
Th@@	O	-1	16167916
ir@@	O	-1	16167916
ty-@@	O	-1	16167916
n@@	O	-1	16167916
ine	O	-1	16167916
post@@	O	-1	16167916
men@@	O	-1	16167916
o@@	O	-1	16167916
pa@@	O	-1	16167916
us@@	O	-1	16167916
al	O	-1	16167916
women	O	-1	16167916
with	O	-1	16167916
ost@@	B-Disease	D001851	16167916
e@@	I-Disease	-1	16167916
o@@	I-Disease	-1	16167916
pen@@	I-Disease	-1	16167916
ia	I-Disease	-1	16167916
or	O	-1	16167916
ost@@	B-Disease	D010024	16167916
e@@	I-Disease	-1	16167916
o@@	I-Disease	-1	16167916
po@@	I-Disease	-1	16167916
ro@@	I-Disease	-1	16167916
sis	I-Disease	-1	16167916
were	O	-1	16167916
included	O	-1	16167916
in	O	-1	16167916
this	O	-1	16167916
pro@@	O	-1	16167916
sp@@	O	-1	16167916
ecti@@	O	-1	16167916
ve,	O	-1	16167916
controlled	O	-1	16167916
clinical	O	-1	16167916
study.	O	-1	16167916
Tw@@	O	-1	16167916
ent@@	O	-1	16167916
y-@@	O	-1	16167916
five	O	-1	16167916
women	O	-1	16167916
were	O	-1	16167916
given	O	-1	16167916
r@@	B-Chemical	D020849	16167916
al@@	I-Chemical	-1	16167916
oxif@@	I-Chemical	-1	16167916
ene	I-Chemical	-1	16167916
hydro@@	I-Chemical	-1	16167916
chlor@@	I-Chemical	-1	16167916
ide	I-Chemical	-1	16167916
(@@	O	-1	16167916
60	O	-1	16167916
mg/@@	O	-1	16167916
day@@	O	-1	16167916
)	O	-1	16167916
plus	O	-1	16167916
calcium	B-Chemical	D002118	16167916
(5@@	O	-1	16167916
00	O	-1	16167916
mg/@@	O	-1	16167916
day@@	O	-1	16167916
).	O	-1	16167916
A@@	O	-1	16167916
g@@	O	-1	16167916
e-@@	O	-1	16167916
mat@@	O	-1	16167916
ch@@	O	-1	16167916
ed	O	-1	16167916
controls	O	-1	16167916
(n	O	-1	16167916
=	O	-1	16167916
14@@	O	-1	16167916
)	O	-1	16167916
were	O	-1	16167916
given	O	-1	16167916
only	O	-1	16167916
calcium	B-Chemical	D002118	16167916
.	O	-1	16167916
P@@	O	-1	16167916
las@@	O	-1	16167916
ma	O	-1	16167916
TA@@	O	-1	16167916
F@@	O	-1	16167916
I@@	O	-1	16167916
,	O	-1	16167916
t@@	O	-1	16167916
PA@@	O	-1	16167916
,	O	-1	16167916
and	O	-1	16167916
PA@@	O	-1	16167916
I@@	O	-1	16167916
-1	O	-1	16167916
anti@@	O	-1	16167916
gen	O	-1	16167916
levels	O	-1	16167916
were	O	-1	16167916
measured	O	-1	16167916
at	O	-1	16167916
baseline	O	-1	16167916
and	O	-1	16167916
after	O	-1	16167916
3	O	-1	16167916
months	O	-1	16167916
of	O	-1	16167916
treatment	O	-1	16167916
by	O	-1	16167916
com@@	O	-1	16167916
mer@@	O	-1	16167916
ci@@	O	-1	16167916
ally	O	-1	16167916
av@@	O	-1	16167916
ail@@	O	-1	16167916
able	O	-1	16167916
E@@	O	-1	16167916
L@@	O	-1	16167916
I@@	O	-1	16167916
S@@	O	-1	16167916
A	O	-1	16167916
k@@	O	-1	16167916
it@@	O	-1	16167916
s.	O	-1	16167916
V@@	O	-1	16167916
ari@@	O	-1	16167916
ations	O	-1	16167916
of	O	-1	16167916
individ@@	O	-1	16167916
u@@	O	-1	16167916
als	O	-1	16167916
were	O	-1	16167916
assessed	O	-1	16167916
by	O	-1	16167916
W@@	O	-1	16167916
il@@	O	-1	16167916
co@@	O	-1	16167916
x@@	O	-1	16167916
on@@	O	-1	16167916
's	O	-1	16167916
test@@	O	-1	16167916
.	O	-1	16167916
R@@	O	-1	16167916
el@@	O	-1	16167916
ationship	O	-1	16167916
between	O	-1	16167916
those	O	-1	16167916
mark@@	O	-1	16167916
ers	O	-1	16167916
and	O	-1	16167916
de@@	O	-1	16167916
mo@@	O	-1	16167916
graph@@	O	-1	16167916
ic	O	-1	16167916
character@@	O	-1	16167916
is@@	O	-1	16167916
tics	O	-1	16167916
were	O	-1	16167916
investig@@	O	-1	16167916
ated.	O	-1	16167916
RESULTS:	O	-1	16167916
Th@@	O	-1	16167916
ree	O	-1	16167916
months	O	-1	16167916
of	O	-1	16167916
r@@	B-Chemical	D020849	16167916
al@@	I-Chemical	-1	16167916
oxif@@	I-Chemical	-1	16167916
ene	I-Chemical	-1	16167916
treatment	O	-1	16167916
was	O	-1	16167916
associated	O	-1	16167916
with	O	-1	16167916
a	O	-1	16167916
significant	O	-1	16167916
decrease	O	-1	16167916
in	O	-1	16167916
the	O	-1	16167916
plasma	O	-1	16167916
TA@@	O	-1	16167916
F@@	O	-1	16167916
I	O	-1	16167916
anti@@	O	-1	16167916
gen	O	-1	16167916
concentrations	O	-1	16167916
(1@@	O	-1	16167916
6%	O	-1	16167916
chang@@	O	-1	16167916
e,	O	-1	16167916
P	O	-1	16167916
<	O	-1	16167916
0.0@@	O	-1	16167916
1),	O	-1	16167916
and	O	-1	16167916
a	O	-1	16167916
significant	O	-1	16167916
increase	O	-1	16167916
in	O	-1	16167916
t@@	O	-1	16167916
P@@	O	-1	16167916
A	O	-1	16167916
anti@@	O	-1	16167916
gen	O	-1	16167916
concentrations	O	-1	16167916
(2@@	O	-1	16167916
5%	O	-1	16167916
chang@@	O	-1	16167916
e,	O	-1	16167916
P	O	-1	16167916
<	O	-1	16167916
0.05@@	O	-1	16167916
).	O	-1	16167916
A	O	-1	16167916
significant	O	-1	16167916
correl@@	O	-1	16167916
ation	O	-1	16167916
was	O	-1	16167916
found	O	-1	16167916
between	O	-1	16167916
baseline	O	-1	16167916
TA@@	O	-1	16167916
F@@	O	-1	16167916
I	O	-1	16167916
anti@@	O	-1	16167916
gen	O	-1	16167916
concentrations	O	-1	16167916
and	O	-1	16167916
the	O	-1	16167916
duration	O	-1	16167916
of	O	-1	16167916
am@@	B-Disease	D000568	16167916
en@@	I-Disease	-1	16167916
or@@	I-Disease	-1	16167916
r@@	I-Disease	-1	16167916
he@@	I-Disease	-1	16167916
a	I-Disease	-1	16167916
(P	O	-1	16167916
<	O	-1	16167916
0.05@@	O	-1	16167916
;	O	-1	16167916
r	O	-1	16167916
=	O	-1	16167916
0.@@	O	-1	16167916
3@@	O	-1	16167916
3@@	O	-1	16167916
).	O	-1	16167916
CONCLUSION:	O	-1	16167916
We	O	-1	16167916
suggest	O	-1	16167916
that	O	-1	16167916
the	O	-1	16167916
increased	O	-1	16167916
risk	O	-1	16167916
of	O	-1	16167916
venous	B-Disease	D054556	16167916
thrombo@@	I-Disease	-1	16167916
emb@@	I-Disease	-1	16167916
ol@@	I-Disease	-1	16167916
ism	I-Disease	-1	16167916
due	O	-1	16167916
to	O	-1	16167916
r@@	B-Chemical	D020849	16167916
al@@	I-Chemical	-1	16167916
oxif@@	I-Chemical	-1	16167916
ene	I-Chemical	-1	16167916
treatment	O	-1	16167916
may	O	-1	16167916
be	O	-1	16167916
related	O	-1	16167916
to	O	-1	16167916
increased	O	-1	16167916
t@@	O	-1	16167916
P@@	O	-1	16167916
A	O	-1	16167916
level@@	O	-1	16167916
s,	O	-1	16167916
but	O	-1	16167916
not	O	-1	16167916
TA@@	O	-1	16167916
F@@	O	-1	16167916
I	O	-1	16167916
level@@	O	-1	16167916
s.	O	-1	16167916

K@@	B-Chemical	D007654	16403073
e@@	I-Chemical	-1	16403073
to@@	I-Chemical	-1	16403073
con@@	I-Chemical	-1	16403073
azole	I-Chemical	-1	16403073
induced	O	-1	16403073
t@@	B-Disease	D016171	16403073
or@@	I-Disease	-1	16403073
sa@@	I-Disease	-1	16403073
des	I-Disease	-1	16403073
de	I-Disease	-1	16403073
po@@	I-Disease	-1	16403073
int@@	I-Disease	-1	16403073
es	I-Disease	-1	16403073
without	O	-1	16403073
concomit@@	O	-1	16403073
ant	O	-1	16403073
use	O	-1	16403073
of	O	-1	16403073
Q@@	O	-1	16403073
T	O	-1	16403073
inter@@	O	-1	16403073
val@@	O	-1	16403073
-@@	O	-1	16403073
prolong@@	O	-1	16403073
ing	O	-1	16403073
drug.	O	-1	16403073
K@@	B-Chemical	D007654	16403073
e@@	I-Chemical	-1	16403073
to@@	I-Chemical	-1	16403073
con@@	I-Chemical	-1	16403073
azole	I-Chemical	-1	16403073
is	O	-1	16403073
not	O	-1	16403073
known	O	-1	16403073
to	O	-1	16403073
be	O	-1	16403073
pro@@	O	-1	16403073
arrhyth@@	O	-1	16403073
mic	O	-1	16403073
without	O	-1	16403073
concomit@@	O	-1	16403073
ant	O	-1	16403073
use	O	-1	16403073
of	O	-1	16403073
Q@@	O	-1	16403073
T	O	-1	16403073
inter@@	O	-1	16403073
val@@	O	-1	16403073
-@@	O	-1	16403073
prolong@@	O	-1	16403073
ing	O	-1	16403073
drug@@	O	-1	16403073
s.	O	-1	16403073
We	O	-1	16403073
report	O	-1	16403073
a	O	-1	16403073
woman	O	-1	16403073
with	O	-1	16403073
coronary	B-Disease	D003324	16403073
artery	I-Disease	-1	16403073
disease	I-Disease	-1	16403073
who	O	-1	16403073
developed	O	-1	16403073
a	O	-1	16403073
mark@@	O	-1	16403073
ed@@	O	-1	16403073
ly	O	-1	16403073
prolonged	B-Disease	D008133	16403073
Q@@	I-Disease	-1	16403073
T	I-Disease	-1	16403073
interv@@	I-Disease	-1	16403073
al	I-Disease	-1	16403073
and	O	-1	16403073
t@@	B-Disease	D016171	16403073
or@@	I-Disease	-1	16403073
sa@@	I-Disease	-1	16403073
des	I-Disease	-1	16403073
de	I-Disease	-1	16403073
po@@	I-Disease	-1	16403073
int@@	I-Disease	-1	16403073
es	I-Disease	-1	16403073
(	O	-1	16403073
T@@	B-Disease	D016171	16403073
d@@	I-Disease	-1	16403073
P	I-Disease	-1	16403073
)	O	-1	16403073
after	O	-1	16403073
taking	O	-1	16403073
ke@@	B-Chemical	D007654	16403073
to@@	I-Chemical	-1	16403073
con@@	I-Chemical	-1	16403073
azole	I-Chemical	-1	16403073
for	O	-1	16403073
treatment	O	-1	16403073
of	O	-1	16403073
f@@	B-Disease	D009181	16403073
un@@	I-Disease	-1	16403073
g@@	I-Disease	-1	16403073
al	I-Disease	-1	16403073
inf@@	I-Disease	-1	16403073
ection	I-Disease	-1	16403073
.	O	-1	16403073
H@@	O	-1	16403073
er	O	-1	16403073
Q@@	O	-1	16403073
T	O	-1	16403073
interv@@	O	-1	16403073
al	O	-1	16403073
retur@@	O	-1	16403073
n@@	O	-1	16403073
ed	O	-1	16403073
to	O	-1	16403073
normal	O	-1	16403073
up@@	O	-1	16403073
on	O	-1	16403073
withdrawal	O	-1	16403073
of	O	-1	16403073
ke@@	B-Chemical	D007654	16403073
to@@	I-Chemical	-1	16403073
con@@	I-Chemical	-1	16403073
azole	I-Chemical	-1	16403073
.	O	-1	16403073
G@@	O	-1	16403073
en@@	O	-1	16403073
e@@	O	-1	16403073
tic	O	-1	16403073
study	O	-1	16403073
did	O	-1	16403073
not	O	-1	16403073
f@@	O	-1	16403073
ind	O	-1	16403073
any	O	-1	16403073
mut@@	O	-1	16403073
ation	O	-1	16403073
in	O	-1	16403073
h@@	O	-1	16403073
er	O	-1	16403073
gen@@	O	-1	16403073
es	O	-1	16403073
that	O	-1	16403073
en@@	O	-1	16403073
co@@	O	-1	16403073
de	O	-1	16403073
cardiac	O	-1	16403073
I@@	O	-1	16403073
K@@	O	-1	16403073
r	O	-1	16403073
channel	O	-1	16403073
protein@@	O	-1	16403073
s.	O	-1	16403073
We	O	-1	16403073
post@@	O	-1	16403073
ul@@	O	-1	16403073
ate	O	-1	16403073
that	O	-1	16403073
by	O	-1	16403073
vi@@	O	-1	16403073
r@@	O	-1	16403073
tu@@	O	-1	16403073
e	O	-1	16403073
of	O	-1	16403073
its	O	-1	16403073
direct	O	-1	16403073
block@@	O	-1	16403073
ing	O	-1	16403073
action	O	-1	16403073
on	O	-1	16403073
I@@	O	-1	16403073
K@@	O	-1	16403073
r@@	O	-1	16403073
,	O	-1	16403073
ke@@	B-Chemical	D007654	16403073
to@@	I-Chemical	-1	16403073
con@@	I-Chemical	-1	16403073
azole	I-Chemical	-1	16403073
alone	O	-1	16403073
may	O	-1	16403073
pro@@	O	-1	16403073
lon@@	O	-1	16403073
g	O	-1	16403073
Q@@	O	-1	16403073
T	O	-1	16403073
interv@@	O	-1	16403073
al	O	-1	16403073
and	O	-1	16403073
induce	O	-1	16403073
T@@	B-Disease	D016171	16403073
d@@	I-Disease	-1	16403073
P	I-Disease	-1	16403073
.	O	-1	16403073
This	O	-1	16403073
c@@	O	-1	16403073
all@@	O	-1	16403073
s	O	-1	16403073
for	O	-1	16403073
atten@@	O	-1	16403073
tion	O	-1	16403073
when	O	-1	16403073
ke@@	B-Chemical	D007654	16403073
to@@	I-Chemical	-1	16403073
con@@	I-Chemical	-1	16403073
azole	I-Chemical	-1	16403073
is	O	-1	16403073
administered	O	-1	16403073
to	O	-1	16403073
patients	O	-1	16403073
with	O	-1	16403073
risk	O	-1	16403073
factors	O	-1	16403073
for	O	-1	16403073
ac@@	O	-1	16403073
qu@@	O	-1	16403073
ired	O	-1	16403073
lon@@	B-Disease	D008133	16403073
g	I-Disease	-1	16403073
Q@@	I-Disease	-1	16403073
T	I-Disease	-1	16403073
syndrome	I-Disease	-1	16403073
.	O	-1	16403073

Ph@@	O	-1	16755009
armac@@	O	-1	16755009
ological	O	-1	16755009
evidence	O	-1	16755009
for	O	-1	16755009
the	O	-1	16755009
potential	O	-1	16755009
of	O	-1	16755009
D@@	O	-1	16755009
a@@	O	-1	16755009
uc@@	O	-1	16755009
us	O	-1	16755009
ca@@	O	-1	16755009
ro@@	O	-1	16755009
t@@	O	-1	16755009
a	O	-1	16755009
in	O	-1	16755009
the	O	-1	16755009
man@@	O	-1	16755009
ag@@	O	-1	16755009
ement	O	-1	16755009
of	O	-1	16755009
cognitive	B-Disease	D003072	16755009
dysfunc@@	I-Disease	-1	16755009
tions	I-Disease	-1	16755009
.	O	-1	16755009
The	O	-1	16755009
present	O	-1	16755009
study	O	-1	16755009
was	O	-1	16755009
a@@	O	-1	16755009
im@@	O	-1	16755009
ed	O	-1	16755009
at	O	-1	16755009
investig@@	O	-1	16755009
ating	O	-1	16755009
the	O	-1	16755009
effects	O	-1	16755009
of	O	-1	16755009
D@@	O	-1	16755009
a@@	O	-1	16755009
uc@@	O	-1	16755009
us	O	-1	16755009
ca@@	O	-1	16755009
ro@@	O	-1	16755009
t@@	O	-1	16755009
a	O	-1	16755009
se@@	O	-1	16755009
ed@@	O	-1	16755009
s	O	-1	16755009
on	O	-1	16755009
cognitive	O	-1	16755009
func@@	O	-1	16755009
tion@@	O	-1	16755009
s,	O	-1	16755009
total	O	-1	16755009
serum	O	-1	16755009
cholester@@	B-Chemical	D002784	16755009
ol	I-Chemical	-1	16755009
levels	O	-1	16755009
and	O	-1	16755009
brain	O	-1	16755009
chol@@	O	-1	16755009
ine@@	O	-1	16755009
ster@@	O	-1	16755009
ase	O	-1	16755009
activity	O	-1	16755009
in	O	-1	16755009
mice.	O	-1	16755009
The	O	-1	16755009
eth@@	O	-1	16755009
an@@	O	-1	16755009
olic	O	-1	16755009
extrac@@	B-Chemical	D010936	16755009
t	I-Chemical	-1	16755009
of	I-Chemical	-1	16755009
D@@	I-Chemical	-1	16755009
a@@	I-Chemical	-1	16755009
uc@@	I-Chemical	-1	16755009
us	I-Chemical	-1	16755009
ca@@	I-Chemical	-1	16755009
ro@@	I-Chemical	-1	16755009
t@@	I-Chemical	-1	16755009
a	I-Chemical	-1	16755009
se@@	I-Chemical	-1	16755009
ed@@	I-Chemical	-1	16755009
s	I-Chemical	-1	16755009
(	O	-1	16755009
D@@	B-Chemical	D010936	16755009
C@@	I-Chemical	-1	16755009
E	I-Chemical	-1	16755009
)	O	-1	16755009
was	O	-1	16755009
administered	O	-1	16755009
or@@	O	-1	16755009
ally	O	-1	16755009
in	O	-1	16755009
three	O	-1	16755009
doses	O	-1	16755009
(@@	O	-1	16755009
10@@	O	-1	16755009
0@@	O	-1	16755009
,	O	-1	16755009
20@@	O	-1	16755009
0@@	O	-1	16755009
,	O	-1	16755009
4@@	O	-1	16755009
00	O	-1	16755009
mg/kg)	O	-1	16755009
for	O	-1	16755009
seven	O	-1	16755009
suc@@	O	-1	16755009
ces@@	O	-1	16755009
sive	O	-1	16755009
days	O	-1	16755009
to	O	-1	16755009
different	O	-1	16755009
groups	O	-1	16755009
of	O	-1	16755009
youn@@	O	-1	16755009
g	O	-1	16755009
and	O	-1	16755009
aged	O	-1	16755009
mice.	O	-1	16755009
E@@	O	-1	16755009
lev@@	O	-1	16755009
ated	O	-1	16755009
plus	O	-1	16755009
ma@@	O	-1	16755009
ze	O	-1	16755009
and	O	-1	16755009
p@@	O	-1	16755009
as@@	O	-1	16755009
sive	O	-1	16755009
avoid@@	O	-1	16755009
ance	O	-1	16755009
ap@@	O	-1	16755009
par@@	O	-1	16755009
at@@	O	-1	16755009
us	O	-1	16755009
ser@@	O	-1	16755009
ved	O	-1	16755009
as	O	-1	16755009
the	O	-1	16755009
ex@@	O	-1	16755009
ter@@	O	-1	16755009
oc@@	O	-1	16755009
ep@@	O	-1	16755009
tive	O	-1	16755009
behavioral	O	-1	16755009
models	O	-1	16755009
for	O	-1	16755009
test@@	O	-1	16755009
ing	O	-1	16755009
memor@@	O	-1	16755009
y.	O	-1	16755009
Di@@	B-Chemical	D003975	16755009
az@@	I-Chemical	-1	16755009
epam	I-Chemical	-1	16755009
-@@	O	-1	16755009
,	O	-1	16755009
scopol@@	B-Chemical	D012601	16755009
amine	I-Chemical	-1	16755009
-	O	-1	16755009
and	O	-1	16755009
ag@@	O	-1	16755009
e@@	O	-1	16755009
ing@@	O	-1	16755009
-induced	O	-1	16755009
am@@	B-Disease	D000647	16755009
ne@@	I-Disease	-1	16755009
sia	I-Disease	-1	16755009
ser@@	O	-1	16755009
ved	O	-1	16755009
as	O	-1	16755009
the	O	-1	16755009
inter@@	O	-1	16755009
oc@@	O	-1	16755009
ep@@	O	-1	16755009
tive	O	-1	16755009
behavioral	O	-1	16755009
model@@	O	-1	16755009
s.	O	-1	16755009
D@@	B-Chemical	D010936	16755009
C@@	I-Chemical	-1	16755009
E	I-Chemical	-1	16755009
(2@@	O	-1	16755009
0@@	O	-1	16755009
0@@	O	-1	16755009
,	O	-1	16755009
4@@	O	-1	16755009
00	O	-1	16755009
mg/kg@@	O	-1	16755009
,	O	-1	16755009
p.@@	O	-1	16755009
o@@	O	-1	16755009
.)	O	-1	16755009
showed	O	-1	16755009
significant	O	-1	16755009
impro@@	O	-1	16755009
vement	O	-1	16755009
in	O	-1	16755009
memory	O	-1	16755009
sco@@	O	-1	16755009
res	O	-1	16755009
of	O	-1	16755009
youn@@	O	-1	16755009
g	O	-1	16755009
and	O	-1	16755009
aged	O	-1	16755009
mice.	O	-1	16755009
The	O	-1	16755009
ext@@	O	-1	16755009
ent	O	-1	16755009
of	O	-1	16755009
memory	O	-1	16755009
impro@@	O	-1	16755009
vement	O	-1	16755009
evoked	O	-1	16755009
by	O	-1	16755009
D@@	B-Chemical	D010936	16755009
C@@	I-Chemical	-1	16755009
E	I-Chemical	-1	16755009
was	O	-1	16755009
2@@	O	-1	16755009
3@@	O	-1	16755009
%	O	-1	16755009
at	O	-1	16755009
the	O	-1	16755009
dose	O	-1	16755009
of	O	-1	16755009
2@@	O	-1	16755009
00	O	-1	16755009
mg/kg	O	-1	16755009
and	O	-1	16755009
3@@	O	-1	16755009
5%	O	-1	16755009
at	O	-1	16755009
the	O	-1	16755009
dose	O	-1	16755009
of	O	-1	16755009
4@@	O	-1	16755009
00	O	-1	16755009
mg/kg	O	-1	16755009
in	O	-1	16755009
youn@@	O	-1	16755009
g	O	-1	16755009
mice	O	-1	16755009
using	O	-1	16755009
elevated	O	-1	16755009
plus	O	-1	16755009
ma@@	O	-1	16755009
z@@	O	-1	16755009
e.	O	-1	16755009
S@@	O	-1	16755009
im@@	O	-1	16755009
il@@	O	-1	16755009
ar@@	O	-1	16755009
ly,	O	-1	16755009
significant	O	-1	16755009
impro@@	O	-1	16755009
ve@@	O	-1	16755009
ments	O	-1	16755009
in	O	-1	16755009
memory	O	-1	16755009
sco@@	O	-1	16755009
res	O	-1	16755009
were	O	-1	16755009
observed	O	-1	16755009
using	O	-1	16755009
p@@	O	-1	16755009
as@@	O	-1	16755009
sive	O	-1	16755009
avoid@@	O	-1	16755009
ance	O	-1	16755009
ap@@	O	-1	16755009
par@@	O	-1	16755009
at@@	O	-1	16755009
us	O	-1	16755009
and	O	-1	16755009
aged	O	-1	16755009
mice.	O	-1	16755009
F@@	O	-1	16755009
ur@@	O	-1	16755009
ther@@	O	-1	16755009
mo@@	O	-1	16755009
re,	O	-1	16755009
D@@	B-Chemical	D010936	16755009
C@@	I-Chemical	-1	16755009
E	I-Chemical	-1	16755009
reversed	O	-1	16755009
the	O	-1	16755009
am@@	B-Disease	D000647	16755009
ne@@	I-Disease	-1	16755009
sia	I-Disease	-1	16755009
induced	O	-1	16755009
by	O	-1	16755009
scopol@@	B-Chemical	D012601	16755009
amine	I-Chemical	-1	16755009
(0.@@	O	-1	16755009
4	O	-1	16755009
mg/kg@@	O	-1	16755009
,	O	-1	16755009
i.p.@@	O	-1	16755009
)	O	-1	16755009
and	O	-1	16755009
di@@	B-Chemical	D003975	16755009
az@@	I-Chemical	-1	16755009
epam	I-Chemical	-1	16755009
(@@	O	-1	16755009
1	O	-1	16755009
mg/kg@@	O	-1	16755009
,	O	-1	16755009
i.p.@@	O	-1	16755009
).	O	-1	16755009
D@@	B-Chemical	D010936	16755009
a@@	I-Chemical	-1	16755009
uc@@	I-Chemical	-1	16755009
us	I-Chemical	-1	16755009
ca@@	I-Chemical	-1	16755009
ro@@	I-Chemical	-1	16755009
t@@	I-Chemical	-1	16755009
a	I-Chemical	-1	16755009
extrac@@	I-Chemical	-1	16755009
t	I-Chemical	-1	16755009
(2@@	O	-1	16755009
0@@	O	-1	16755009
0@@	O	-1	16755009
,	O	-1	16755009
4@@	O	-1	16755009
00	O	-1	16755009
mg/kg@@	O	-1	16755009
,	O	-1	16755009
p.@@	O	-1	16755009
o@@	O	-1	16755009
.)	O	-1	16755009
reduced	O	-1	16755009
significantly	O	-1	16755009
the	O	-1	16755009
brain	O	-1	16755009
acet@@	O	-1	16755009
ylchol@@	O	-1	16755009
ine@@	O	-1	16755009
ster@@	O	-1	16755009
ase	O	-1	16755009
activity	O	-1	16755009
and	O	-1	16755009
cholester@@	B-Chemical	D002784	16755009
ol	I-Chemical	-1	16755009
levels	O	-1	16755009
in	O	-1	16755009
youn@@	O	-1	16755009
g	O	-1	16755009
and	O	-1	16755009
aged	O	-1	16755009
mice.	O	-1	16755009
The	O	-1	16755009
ext@@	O	-1	16755009
ent	O	-1	16755009
of	O	-1	16755009
inhibition	O	-1	16755009
of	O	-1	16755009
brain	O	-1	16755009
chol@@	O	-1	16755009
ine@@	O	-1	16755009
ster@@	O	-1	16755009
ase	O	-1	16755009
activity	O	-1	16755009
evoked	O	-1	16755009
by	O	-1	16755009
D@@	B-Chemical	D010936	16755009
C@@	I-Chemical	-1	16755009
E	I-Chemical	-1	16755009
at	O	-1	16755009
the	O	-1	16755009
dose	O	-1	16755009
of	O	-1	16755009
4@@	O	-1	16755009
00	O	-1	16755009
mg/kg	O	-1	16755009
was	O	-1	16755009
2@@	O	-1	16755009
2@@	O	-1	16755009
%	O	-1	16755009
in	O	-1	16755009
youn@@	O	-1	16755009
g	O	-1	16755009
and	O	-1	16755009
19@@	O	-1	16755009
%	O	-1	16755009
in	O	-1	16755009
aged	O	-1	16755009
mice.	O	-1	16755009
There	O	-1	16755009
was	O	-1	16755009
a	O	-1	16755009
re@@	O	-1	16755009
mark@@	O	-1	16755009
able	O	-1	16755009
reduction	O	-1	16755009
in	O	-1	16755009
total	O	-1	16755009
cholester@@	B-Chemical	D002784	16755009
ol	I-Chemical	-1	16755009
level	O	-1	16755009
as	O	-1	16755009
we@@	O	-1	16755009
ll@@	O	-1	16755009
,	O	-1	16755009
to	O	-1	16755009
the	O	-1	16755009
ext@@	O	-1	16755009
ent	O	-1	16755009
of	O	-1	16755009
2@@	O	-1	16755009
3@@	O	-1	16755009
%	O	-1	16755009
in	O	-1	16755009
youn@@	O	-1	16755009
g	O	-1	16755009
and	O	-1	16755009
2@@	O	-1	16755009
1@@	O	-1	16755009
%	O	-1	16755009
in	O	-1	16755009
aged	O	-1	16755009
animals	O	-1	16755009
with	O	-1	16755009
this	O	-1	16755009
dose	O	-1	16755009
of	O	-1	16755009
D@@	B-Chemical	D010936	16755009
C@@	I-Chemical	-1	16755009
E	I-Chemical	-1	16755009
.	O	-1	16755009
The@@	O	-1	16755009
refore,	O	-1	16755009
D@@	B-Chemical	D010936	16755009
C@@	I-Chemical	-1	16755009
E	I-Chemical	-1	16755009
may	O	-1	16755009
pro@@	O	-1	16755009
ve	O	-1	16755009
to	O	-1	16755009
be	O	-1	16755009
a	O	-1	16755009
use@@	O	-1	16755009
ful	O	-1	16755009
re@@	O	-1	16755009
me@@	O	-1	16755009
dy	O	-1	16755009
for	O	-1	16755009
the	O	-1	16755009
man@@	O	-1	16755009
ag@@	O	-1	16755009
ement	O	-1	16755009
of	O	-1	16755009
cognitive	B-Disease	D003072	16755009
dysfunc@@	I-Disease	-1	16755009
tions	I-Disease	-1	16755009
on	O	-1	16755009
ac@@	O	-1	16755009
coun@@	O	-1	16755009
t	O	-1	16755009
of	O	-1	16755009
its	O	-1	16755009
multi@@	O	-1	16755009
f@@	O	-1	16755009
ari@@	O	-1	16755009
ous	O	-1	16755009
ben@@	O	-1	16755009
e@@	O	-1	16755009
fic@@	O	-1	16755009
ial	O	-1	16755009
effects	O	-1	16755009
such	O	-1	16755009
as@@	O	-1	16755009
,	O	-1	16755009
memory	O	-1	16755009
impro@@	O	-1	16755009
ving	O	-1	16755009
pro@@	O	-1	16755009
per@@	O	-1	16755009
t@@	O	-1	16755009
y,	O	-1	16755009
cholester@@	B-Chemical	D002784	16755009
ol	I-Chemical	-1	16755009
low@@	O	-1	16755009
ering	O	-1	16755009
pro@@	O	-1	16755009
per@@	O	-1	16755009
t@@	O	-1	16755009
y	O	-1	16755009
and	O	-1	16755009
anti@@	O	-1	16755009
chol@@	O	-1	16755009
ine@@	O	-1	16755009
ster@@	O	-1	16755009
ase	O	-1	16755009
activ@@	O	-1	16755009
ity.	O	-1	16755009

Ca@@	B-Disease	D011128	16904497
ud@@	I-Disease	-1	16904497
a	I-Disease	-1	16904497
equ@@	I-Disease	-1	16904497
in@@	I-Disease	-1	16904497
a	I-Disease	-1	16904497
syndrome	I-Disease	-1	16904497
after	O	-1	16904497
ep@@	O	-1	16904497
id@@	O	-1	16904497
ural	O	-1	16904497
ster@@	B-Chemical	D013256	16904497
oid	I-Chemical	-1	16904497
injec@@	O	-1	16904497
tion@@	O	-1	16904497
:	O	-1	16904497
a	O	-1	16904497
case	O	-1	16904497
repor@@	O	-1	16904497
t.	O	-1	16904497
OBJECTIVE:	O	-1	16904497
Con@@	O	-1	16904497
ven@@	O	-1	16904497
tional	O	-1	16904497
treatment	O	-1	16904497
meth@@	O	-1	16904497
o@@	O	-1	16904497
ds	O	-1	16904497
of	O	-1	16904497
l@@	O	-1	16904497
umb@@	O	-1	16904497
us@@	O	-1	16904497
ac@@	O	-1	16904497
ral	O	-1	16904497
ra@@	B-Disease	D011843	16904497
dic@@	I-Disease	-1	16904497
ulo@@	I-Disease	-1	16904497
pathy	I-Disease	-1	16904497
are	O	-1	16904497
physi@@	O	-1	16904497
c@@	O	-1	16904497
al	O	-1	16904497
therapy,	O	-1	16904497
ep@@	O	-1	16904497
id@@	O	-1	16904497
ural	O	-1	16904497
ster@@	B-Chemical	D013256	16904497
oid	I-Chemical	-1	16904497
injec@@	O	-1	16904497
tion@@	O	-1	16904497
s,	O	-1	16904497
oral	O	-1	16904497
medic@@	O	-1	16904497
ation@@	O	-1	16904497
s,	O	-1	16904497
and	O	-1	16904497
spinal	O	-1	16904497
man@@	O	-1	16904497
ip@@	O	-1	16904497
ul@@	O	-1	16904497
ative	O	-1	16904497
therapy.	O	-1	16904497
Ca@@	B-Disease	D011128	16904497
ud@@	I-Disease	-1	16904497
a	I-Disease	-1	16904497
equ@@	I-Disease	-1	16904497
in@@	I-Disease	-1	16904497
a	I-Disease	-1	16904497
syndrome	I-Disease	-1	16904497
is	O	-1	16904497
a	O	-1	16904497
r@@	O	-1	16904497
are	O	-1	16904497
complication	O	-1	16904497
of	O	-1	16904497
ep@@	O	-1	16904497
id@@	O	-1	16904497
ural	O	-1	16904497
anesthe@@	O	-1	16904497
sia.	O	-1	16904497
The	O	-1	16904497
following	O	-1	16904497
case	O	-1	16904497
is	O	-1	16904497
a	O	-1	16904497
report	O	-1	16904497
of	O	-1	16904497
ca@@	B-Disease	D011128	16904497
ud@@	I-Disease	-1	16904497
a	I-Disease	-1	16904497
equ@@	I-Disease	-1	16904497
in@@	I-Disease	-1	16904497
a	I-Disease	-1	16904497
syndrome	I-Disease	-1	16904497
possib@@	O	-1	16904497
ly	O	-1	16904497
caused	O	-1	16904497
by	O	-1	16904497
ep@@	O	-1	16904497
id@@	O	-1	16904497
ural	O	-1	16904497
injection	O	-1	16904497
of	O	-1	16904497
tri@@	B-Chemical	D014221	16904497
am@@	I-Chemical	-1	16904497
cin@@	I-Chemical	-1	16904497
ol@@	I-Chemical	-1	16904497
one	I-Chemical	-1	16904497
and	O	-1	16904497
bupivac@@	B-Chemical	D002045	16904497
aine	I-Chemical	-1	16904497
.	O	-1	16904497
CL@@	O	-1	16904497
IN@@	O	-1	16904497
I@@	O	-1	16904497
CA@@	O	-1	16904497
L	O	-1	16904497
F@@	O	-1	16904497
E@@	O	-1	16904497
AT@@	O	-1	16904497
U@@	O	-1	16904497
R@@	O	-1	16904497
E@@	O	-1	16904497
S:	O	-1	16904497
A	O	-1	16904497
50@@	O	-1	16904497
-@@	O	-1	16904497
year-old	O	-1	16904497
woman	O	-1	16904497
with	O	-1	16904497
low	B-Disease	D017116	16904497
bac@@	I-Disease	-1	16904497
k	I-Disease	-1	16904497
and	I-Disease	-1	16904497
right	I-Disease	-1	16904497
le@@	I-Disease	-1	16904497
g	I-Disease	-1	16904497
pain	I-Disease	-1	16904497
low	B-Disease	D010146	16904497
bac@@	I-Disease	-1	16904497
k	I-Disease	-1	16904497
and	I-Disease	-1	16904497
right	I-Disease	-1	16904497
le@@	I-Disease	-1	16904497
g	I-Disease	-1	16904497
pain	I-Disease	-1	16904497
was	O	-1	16904497
sch@@	O	-1	16904497
ed@@	O	-1	16904497
ul@@	O	-1	16904497
ed	O	-1	16904497
for	O	-1	16904497
ep@@	O	-1	16904497
id@@	O	-1	16904497
ural	O	-1	16904497
ster@@	B-Chemical	D013256	16904497
oid	I-Chemical	-1	16904497
injec@@	O	-1	16904497
tion.	O	-1	16904497
IN@@	O	-1	16904497
TE@@	O	-1	16904497
R@@	O	-1	16904497
V@@	O	-1	16904497
E@@	O	-1	16904497
N@@	O	-1	16904497
TI@@	O	-1	16904497
O@@	O	-1	16904497
N	O	-1	16904497
AN@@	O	-1	16904497
D	O	-1	16904497
O@@	O	-1	16904497
U@@	O	-1	16904497
T@@	O	-1	16904497
CO@@	O	-1	16904497
M@@	O	-1	16904497
E:	O	-1	16904497
An	O	-1	16904497
18@@	O	-1	16904497
-@@	O	-1	16904497
g@@	O	-1	16904497
au@@	O	-1	16904497
ge	O	-1	16904497
T@@	O	-1	16904497
ou@@	O	-1	16904497
h@@	O	-1	16904497
y	O	-1	16904497
ne@@	O	-1	16904497
ed@@	O	-1	16904497
le	O	-1	16904497
was	O	-1	16904497
in@@	O	-1	16904497
ser@@	O	-1	16904497
ted	O	-1	16904497
un@@	O	-1	16904497
ti@@	O	-1	16904497
l	O	-1	16904497
loss	O	-1	16904497
of	O	-1	16904497
resist@@	O	-1	16904497
ance	O	-1	16904497
occurred	O	-1	16904497
at	O	-1	16904497
the	O	-1	16904497
L@@	O	-1	16904497
4-@@	O	-1	16904497
5	O	-1	16904497
level@@	O	-1	16904497
.	O	-1	16904497
S@@	O	-1	16904497
pre@@	O	-1	16904497
ad	O	-1	16904497
of	O	-1	16904497
the	O	-1	16904497
contr@@	O	-1	16904497
ast	O	-1	16904497
medi@@	O	-1	16904497
um	O	-1	16904497
within	O	-1	16904497
the	O	-1	16904497
ep@@	O	-1	16904497
id@@	O	-1	16904497
ural	O	-1	16904497
sp@@	O	-1	16904497
ac@@	O	-1	16904497
e	O	-1	16904497
was	O	-1	16904497
determined	O	-1	16904497
by	O	-1	16904497
radi@@	O	-1	16904497
ograph@@	O	-1	16904497
ic	O	-1	16904497
imag@@	O	-1	16904497
ing.	O	-1	16904497
After	O	-1	16904497
ver@@	O	-1	16904497
if@@	O	-1	16904497
y@@	O	-1	16904497
ing	O	-1	16904497
the	O	-1	16904497
ep@@	O	-1	16904497
id@@	O	-1	16904497
ural	O	-1	16904497
sp@@	O	-1	16904497
ac@@	O	-1	16904497
e,	O	-1	16904497
bupivac@@	B-Chemical	D002045	16904497
aine	I-Chemical	-1	16904497
and	O	-1	16904497
tri@@	B-Chemical	C030262	16904497
am@@	I-Chemical	-1	16904497
cin@@	I-Chemical	-1	16904497
ol@@	I-Chemical	-1	16904497
one	I-Chemical	-1	16904497
di@@	I-Chemical	-1	16904497
acet@@	I-Chemical	-1	16904497
ate	I-Chemical	-1	16904497
were	O	-1	16904497
inj@@	O	-1	16904497
ect@@	O	-1	16904497
ed.	O	-1	16904497
After	O	-1	16904497
the	O	-1	16904497
injec@@	O	-1	16904497
tion,	O	-1	16904497
there	O	-1	16904497
was	O	-1	16904497
a	O	-1	16904497
reduction	O	-1	16904497
in	O	-1	16904497
ra@@	O	-1	16904497
dic@@	O	-1	16904497
ular	O	-1	16904497
symptom@@	O	-1	16904497
s.	O	-1	16904497
Th@@	O	-1	16904497
ree	O	-1	16904497
hours	O	-1	16904497
lat@@	O	-1	16904497
er,	O	-1	16904497
sh@@	O	-1	16904497
e	O	-1	16904497
com@@	O	-1	16904497
pl@@	O	-1	16904497
ained	O	-1	16904497
of	O	-1	16904497
per@@	O	-1	16904497
ine@@	O	-1	16904497
al	O	-1	16904497
numb@@	B-Disease	D006987	16904497
ness	I-Disease	-1	16904497
and	O	-1	16904497
lower	B-Disease	D020335	16904497
ex@@	I-Disease	-1	16904497
trem@@	I-Disease	-1	16904497
ity	I-Disease	-1	16904497
we@@	I-Disease	-1	16904497
ak@@	I-Disease	-1	16904497
ness	I-Disease	-1	16904497
.	O	-1	16904497
The	O	-1	16904497
neurolog@@	O	-1	16904497
ic	O	-1	16904497
evalu@@	O	-1	16904497
ation	O	-1	16904497
revealed	O	-1	16904497
loss	B-Disease	D006987	16904497
of	I-Disease	-1	16904497
sens@@	I-Disease	-1	16904497
ation	I-Disease	-1	16904497
in	O	-1	16904497
the	O	-1	16904497
s@@	O	-1	16904497
ad@@	O	-1	16904497
d@@	O	-1	16904497
le	O	-1	16904497
a@@	O	-1	16904497
re@@	O	-1	16904497
a	O	-1	16904497
and	O	-1	16904497
medi@@	O	-1	16904497
al	O	-1	16904497
as@@	O	-1	16904497
p@@	O	-1	16904497
ect	O	-1	16904497
of	O	-1	16904497
h@@	O	-1	16904497
er	O	-1	16904497
right	O	-1	16904497
le@@	O	-1	16904497
g@@	O	-1	16904497
.	O	-1	16904497
There	O	-1	16904497
was	O	-1	16904497
a	O	-1	16904497
decrease	O	-1	16904497
in	O	-1	16904497
the	O	-1	16904497
per@@	O	-1	16904497
ce@@	O	-1	16904497
ption	O	-1	16904497
of	O	-1	16904497
p@@	O	-1	16904497
in@@	O	-1	16904497
pr@@	O	-1	16904497
ic@@	O	-1	16904497
k	O	-1	16904497
test@@	O	-1	16904497
.	O	-1	16904497
De@@	O	-1	16904497
ep@@	O	-1	16904497
-@@	O	-1	16904497
ten@@	O	-1	16904497
d@@	O	-1	16904497
on	O	-1	16904497
ref@@	O	-1	16904497
le@@	O	-1	16904497
x@@	O	-1	16904497
es	O	-1	16904497
were	O	-1	16904497
decreased	O	-1	16904497
es@@	O	-1	16904497
p@@	O	-1	16904497
ec@@	O	-1	16904497
i@@	O	-1	16904497
ally	O	-1	16904497
in	O	-1	16904497
the	O	-1	16904497
right	O	-1	16904497
le@@	O	-1	16904497
g@@	O	-1	16904497
.	O	-1	16904497
S@@	O	-1	16904497
he	O	-1	16904497
was	O	-1	16904497
un@@	O	-1	16904497
able	O	-1	16904497
to	O	-1	16904497
ur@@	O	-1	16904497
in@@	O	-1	16904497
at@@	O	-1	16904497
e.	O	-1	16904497
The	O	-1	16904497
patient@@	O	-1	16904497
's	O	-1	16904497
symptoms	O	-1	16904497
improved	O	-1	16904497
s@@	O	-1	16904497
li@@	O	-1	16904497
gh@@	O	-1	16904497
tly	O	-1	16904497
over	O	-1	16904497
the	O	-1	16904497
ne@@	O	-1	16904497
x@@	O	-1	16904497
t	O	-1	16904497
fe@@	O	-1	16904497
w	O	-1	16904497
hour@@	O	-1	16904497
s.	O	-1	16904497
S@@	O	-1	16904497
he	O	-1	16904497
had	O	-1	16904497
a	O	-1	16904497
gra@@	O	-1	16904497
du@@	O	-1	16904497
al	O	-1	16904497
retur@@	O	-1	16904497
n	O	-1	16904497
of	O	-1	16904497
motor	O	-1	16904497
function	O	-1	16904497
and	O	-1	16904497
ability	O	-1	16904497
of	O	-1	16904497
fe@@	O	-1	16904497
el@@	O	-1	16904497
ing	O	-1	16904497
F@@	O	-1	16904497
ol@@	O	-1	16904497
e@@	O	-1	16904497
y	O	-1	16904497
ca@@	O	-1	16904497
the@@	O	-1	16904497
ter@@	O	-1	16904497
.	O	-1	16904497
All	O	-1	16904497
of	O	-1	16904497
the	O	-1	16904497
symptoms	O	-1	16904497
were	O	-1	16904497
complete@@	O	-1	16904497
ly	O	-1	16904497
resol@@	O	-1	16904497
ved	O	-1	16904497
over	O	-1	16904497
the	O	-1	16904497
ne@@	O	-1	16904497
x@@	O	-1	16904497
t	O	-1	16904497
8	O	-1	16904497
hour@@	O	-1	16904497
s.	O	-1	16904497
CONCLUSION:	O	-1	16904497
Com@@	O	-1	16904497
plic@@	O	-1	16904497
ations	O	-1	16904497
associated	O	-1	16904497
with	O	-1	16904497
ep@@	O	-1	16904497
id@@	O	-1	16904497
ural	O	-1	16904497
ster@@	B-Chemical	D013256	16904497
oid	I-Chemical	-1	16904497
injec@@	O	-1	16904497
tions	O	-1	16904497
are	O	-1	16904497
ra@@	O	-1	16904497
re.	O	-1	16904497
Clin@@	O	-1	16904497
ical	O	-1	16904497
examin@@	O	-1	16904497
ation	O	-1	16904497
and	O	-1	16904497
continu@@	O	-1	16904497
ed	O	-1	16904497
vi@@	O	-1	16904497
g@@	O	-1	16904497
il@@	O	-1	16904497
ance	O	-1	16904497
for	O	-1	16904497
neurolog@@	B-Disease	D009422	16904497
ic	I-Disease	-1	16904497
deter@@	I-Disease	-1	16904497
i@@	I-Disease	-1	16904497
or@@	I-Disease	-1	16904497
ation	I-Disease	-1	16904497
after	O	-1	16904497
ep@@	O	-1	16904497
id@@	O	-1	16904497
ural	O	-1	16904497
ster@@	B-Chemical	D013256	16904497
oid	I-Chemical	-1	16904497
injec@@	O	-1	16904497
tions	O	-1	16904497
is	O	-1	16904497
import@@	O	-1	16904497
ant@@	O	-1	16904497
.	O	-1	16904497

H@@	O	-1	16938416
igh@@	O	-1	16938416
-@@	O	-1	16938416
dose	O	-1	16938416
test@@	B-Chemical	D013739	16938416
osterone	I-Chemical	-1	16938416
is	O	-1	16938416
associated	O	-1	16938416
with	O	-1	16938416
a@@	B-Disease	D050197	16938416
therosclero@@	I-Disease	-1	16938416
sis	I-Disease	-1	16938416
in	O	-1	16938416
post@@	O	-1	16938416
men@@	O	-1	16938416
o@@	O	-1	16938416
pa@@	O	-1	16938416
us@@	O	-1	16938416
al	O	-1	16938416
wom@@	O	-1	16938416
en@@	O	-1	16938416
.	O	-1	16938416
OBJECTIV@@	O	-1	16938416
E@@	O	-1	16938416
S:	O	-1	16938416
To	O	-1	16938416
study	O	-1	16938416
the	O	-1	16938416
long-term	O	-1	16938416
effects	O	-1	16938416
of	O	-1	16938416
and@@	O	-1	16938416
ro@@	O	-1	16938416
gen	O	-1	16938416
treatment	O	-1	16938416
on	O	-1	16938416
a@@	B-Disease	D050197	16938416
therosclero@@	I-Disease	-1	16938416
sis	I-Disease	-1	16938416
in	O	-1	16938416
post@@	O	-1	16938416
men@@	O	-1	16938416
o@@	O	-1	16938416
pa@@	O	-1	16938416
us@@	O	-1	16938416
al	O	-1	16938416
wom@@	O	-1	16938416
en@@	O	-1	16938416
.	O	-1	16938416
METHODS:	O	-1	16938416
In	O	-1	16938416
a	O	-1	16938416
po@@	O	-1	16938416
pul@@	O	-1	16938416
ation@@	O	-1	16938416
-@@	O	-1	16938416
bas@@	O	-1	16938416
ed	O	-1	16938416
study	O	-1	16938416
in	O	-1	16938416
5@@	O	-1	16938416
13	O	-1	16938416
n@@	O	-1	16938416
at@@	O	-1	16938416
ur@@	O	-1	16938416
ally	O	-1	16938416
post@@	O	-1	16938416
men@@	O	-1	16938416
o@@	O	-1	16938416
pa@@	O	-1	16938416
us@@	O	-1	16938416
al	O	-1	16938416
women	O	-1	16938416
aged	O	-1	16938416
5@@	O	-1	16938416
4-@@	O	-1	16938416
6@@	O	-1	16938416
7	O	-1	16938416
year@@	O	-1	16938416
s,	O	-1	16938416
we	O	-1	16938416
studied	O	-1	16938416
the	O	-1	16938416
association	O	-1	16938416
between	O	-1	16938416
sel@@	O	-1	16938416
f@@	O	-1	16938416
-@@	O	-1	16938416
reported	O	-1	16938416
int@@	O	-1	16938416
ram@@	O	-1	16938416
us@@	O	-1	16938416
cul@@	O	-1	16938416
arly	O	-1	16938416
administered	O	-1	16938416
high-dose	O	-1	16938416
est@@	B-Chemical	D004967	16938416
ro@@	I-Chemical	-1	16938416
gen	I-Chemical	-1	16938416
-	O	-1	16938416
test@@	B-Chemical	D013739	16938416
osterone	I-Chemical	-1	16938416
therapy	O	-1	16938416
(	O	-1	16938416
est@@	B-Chemical	C032109	16938416
radi@@	I-Chemical	-1	16938416
ol@@	I-Chemical	-1	16938416
-	I-Chemical	-1	16938416
and	I-Chemical	-1	16938416
test@@	I-Chemical	-1	16938416
osterone	I-Chemical	-1	16938416
est@@	I-Chemical	-1	16938416
ers	I-Chemical	-1	16938416
)	O	-1	16938416
and	O	-1	16938416
a@@	O	-1	16938416
or@@	O	-1	16938416
tic	O	-1	16938416
a@@	B-Disease	D050197	16938416
therosclero@@	I-Disease	-1	16938416
sis	I-Disease	-1	16938416
.	O	-1	16938416
A@@	O	-1	16938416
or@@	O	-1	16938416
tic	O	-1	16938416
a@@	B-Disease	D050197	16938416
therosclero@@	I-Disease	-1	16938416
sis	I-Disease	-1	16938416
was	O	-1	16938416
diagnos@@	O	-1	16938416
ed	O	-1	16938416
by	O	-1	16938416
radi@@	O	-1	16938416
ograph@@	O	-1	16938416
ic	O	-1	16938416
det@@	O	-1	16938416
ection	O	-1	16938416
of	O	-1	16938416
calc@@	O	-1	16938416
if@@	O	-1	16938416
ied	O	-1	16938416
de@@	O	-1	16938416
pos@@	O	-1	16938416
its	O	-1	16938416
in	O	-1	16938416
the	O	-1	16938416
ab@@	O	-1	16938416
domin@@	O	-1	16938416
al	O	-1	16938416
a@@	O	-1	16938416
ort@@	O	-1	16938416
a,	O	-1	16938416
which	O	-1	16938416
have	O	-1	16938416
been	O	-1	16938416
shown	O	-1	16938416
to	O	-1	16938416
ref@@	O	-1	16938416
l@@	O	-1	16938416
ect	O	-1	16938416
in@@	O	-1	16938416
tim@@	O	-1	16938416
a	O	-1	16938416
a@@	B-Disease	D050197	16938416
therosclero@@	I-Disease	-1	16938416
sis	I-Disease	-1	16938416
.	O	-1	16938416
H@@	O	-1	16938416
orm@@	O	-1	16938416
one	O	-1	16938416
therapy	O	-1	16938416
users	O	-1	16938416
were	O	-1	16938416
compared	O	-1	16938416
with	O	-1	16938416
ne@@	O	-1	16938416
ver	O	-1	16938416
us@@	O	-1	16938416
ers.	O	-1	16938416
RESULTS:	O	-1	16938416
In@@	O	-1	16938416
t@@	O	-1	16938416
ram@@	O	-1	16938416
us@@	O	-1	16938416
cular	O	-1	16938416
h@@	O	-1	16938416
orm@@	O	-1	16938416
one	O	-1	16938416
therapy	O	-1	16938416
use	O	-1	16938416
for	O	-1	16938416
1	O	-1	16938416
year	O	-1	16938416
or	O	-1	16938416
long@@	O	-1	16938416
er	O	-1	16938416
was	O	-1	16938416
reported	O	-1	16938416
by	O	-1	16938416
25	O	-1	16938416
wom@@	O	-1	16938416
en@@	O	-1	16938416
.	O	-1	16938416
In	O	-1	16938416
al@@	O	-1	16938416
most	O	-1	16938416
h@@	O	-1	16938416
al@@	O	-1	16938416
f	O	-1	16938416
of	O	-1	16938416
these	O	-1	16938416
women	O	-1	16938416
severe	O	-1	16938416
a@@	B-Disease	D050197	16938416
therosclero@@	I-Disease	-1	16938416
sis	I-Disease	-1	16938416
of	O	-1	16938416
the	O	-1	16938416
a@@	O	-1	16938416
ort@@	O	-1	16938416
a	O	-1	16938416
was	O	-1	16938416
present	O	-1	16938416
(n@@	O	-1	16938416
=@@	O	-1	16938416
1@@	O	-1	16938416
1),	O	-1	16938416
while	O	-1	16938416
in	O	-1	16938416
women	O	-1	16938416
without	O	-1	16938416
h@@	O	-1	16938416
orm@@	O	-1	16938416
one	O	-1	16938416
use	O	-1	16938416
severe	O	-1	16938416
a@@	B-Disease	D050197	16938416
therosclero@@	I-Disease	-1	16938416
sis	I-Disease	-1	16938416
of	O	-1	16938416
the	O	-1	16938416
a@@	O	-1	16938416
ort@@	O	-1	16938416
a	O	-1	16938416
was	O	-1	16938416
present	O	-1	16938416
in	O	-1	16938416
less	O	-1	16938416
than	O	-1	16938416
20@@	O	-1	16938416
%	O	-1	16938416
(@@	O	-1	16938416
O@@	O	-1	16938416
R	O	-1	16938416
3.@@	O	-1	16938416
1@@	O	-1	16938416
;	O	-1	16938416
95%	O	-1	16938416
CI@@	O	-1	16938416
,	O	-1	16938416
1.@@	O	-1	16938416
1-@@	O	-1	16938416
8.@@	O	-1	16938416
5,	O	-1	16938416
adjust@@	O	-1	16938416
ed	O	-1	16938416
for	O	-1	16938416
age,	O	-1	16938416
years	O	-1	16938416
s@@	O	-1	16938416
inc@@	O	-1	16938416
e	O	-1	16938416
men@@	O	-1	16938416
o@@	O	-1	16938416
pa@@	O	-1	16938416
use@@	O	-1	16938416
,	O	-1	16938416
smo@@	O	-1	16938416
k@@	O	-1	16938416
ing,	O	-1	16938416
and	O	-1	16938416
body	O	-1	16938416
mas@@	O	-1	16938416
s	O	-1	16938416
in@@	O	-1	16938416
de@@	O	-1	16938416
x@@	O	-1	16938416
).	O	-1	16938416
The	O	-1	16938416
association	O	-1	16938416
remained	O	-1	16938416
after	O	-1	16938416
addi@@	O	-1	16938416
tional	O	-1	16938416
adjust@@	O	-1	16938416
ment	O	-1	16938416
for	O	-1	16938416
dia@@	B-Disease	D003920	16938416
bet@@	I-Disease	-1	16938416
es	I-Disease	-1	16938416
,	O	-1	16938416
cholester@@	B-Chemical	D002784	16938416
ol	I-Chemical	-1	16938416
level@@	O	-1	16938416
,	O	-1	16938416
systolic	O	-1	16938416
blood	O	-1	16938416
pressu@@	O	-1	16938416
re,	O	-1	16938416
or	O	-1	16938416
alco@@	B-Chemical	D000431	16938416
hol	I-Chemical	-1	16938416
use.	O	-1	16938416
No	O	-1	16938416
association	O	-1	16938416
was	O	-1	16938416
found	O	-1	16938416
for	O	-1	16938416
h@@	O	-1	16938416
orm@@	O	-1	16938416
one	O	-1	16938416
use	O	-1	16938416
less	O	-1	16938416
than	O	-1	16938416
1	O	-1	16938416
year@@	O	-1	16938416
.	O	-1	16938416
CONCLUSION:	O	-1	16938416
Our	O	-1	16938416
results	O	-1	16938416
suggest	O	-1	16938416
that	O	-1	16938416
high-dose	O	-1	16938416
test@@	B-Chemical	D013739	16938416
osterone	I-Chemical	-1	16938416
therapy	O	-1	16938416
may	O	-1	16938416
ad@@	O	-1	16938416
ver@@	O	-1	16938416
se@@	O	-1	16938416
ly	O	-1	16938416
aff@@	O	-1	16938416
ect	O	-1	16938416
a@@	B-Disease	D050197	16938416
therosclero@@	I-Disease	-1	16938416
sis	I-Disease	-1	16938416
in	O	-1	16938416
post@@	O	-1	16938416
men@@	O	-1	16938416
o@@	O	-1	16938416
pa@@	O	-1	16938416
us@@	O	-1	16938416
al	O	-1	16938416
women	O	-1	16938416
and	O	-1	16938416
indicate	O	-1	16938416
that	O	-1	16938416
and@@	O	-1	16938416
ro@@	O	-1	16938416
gen	O	-1	16938416
re@@	O	-1	16938416
pl@@	O	-1	16938416
ac@@	O	-1	16938416
ement	O	-1	16938416
in	O	-1	16938416
these	O	-1	16938416
women	O	-1	16938416
may	O	-1	16938416
not	O	-1	16938416
be	O	-1	16938416
h@@	O	-1	16938416
ar@@	O	-1	16938416
ml@@	O	-1	16938416
es@@	O	-1	16938416
s.	O	-1	16938416

Si@@	B-Chemical	D020123	17147461
rolimus	I-Chemical	-1	17147461
-@@	O	-1	17147461
associated	O	-1	17147461
proteinuria	B-Disease	D011507	17147461
and	O	-1	17147461
renal	B-Disease	D007674	17147461
dysfunction	I-Disease	-1	17147461
.	O	-1	17147461
Si@@	B-Chemical	D020123	17147461
rolimus	I-Chemical	-1	17147461
is	O	-1	17147461
a	O	-1	17147461
novel	O	-1	17147461
immunosup@@	O	-1	17147461
press@@	O	-1	17147461
ant	O	-1	17147461
with	O	-1	17147461
pot@@	O	-1	17147461
ent	O	-1	17147461
anti@@	O	-1	17147461
pro@@	O	-1	17147461
li@@	O	-1	17147461
fer@@	O	-1	17147461
ative	O	-1	17147461
ac@@	O	-1	17147461
tions	O	-1	17147461
through	O	-1	17147461
its	O	-1	17147461
ability	O	-1	17147461
to	O	-1	17147461
inhib@@	O	-1	17147461
it	O	-1	17147461
the	O	-1	17147461
ra@@	O	-1	17147461
pt@@	O	-1	17147461
or@@	O	-1	17147461
-@@	O	-1	17147461
containing	O	-1	17147461
m@@	O	-1	17147461
am@@	O	-1	17147461
mal@@	O	-1	17147461
i@@	O	-1	17147461
an	O	-1	17147461
t@@	O	-1	17147461
arg@@	O	-1	17147461
et	O	-1	17147461
of	O	-1	17147461
ra@@	B-Chemical	D020123	17147461
p@@	I-Chemical	-1	17147461
am@@	I-Chemical	-1	17147461
ycin	I-Chemical	-1	17147461
protein	O	-1	17147461
kin@@	O	-1	17147461
as@@	O	-1	17147461
e.	O	-1	17147461
Si@@	B-Chemical	D020123	17147461
rolimus	I-Chemical	-1	17147461
re@@	O	-1	17147461
pres@@	O	-1	17147461
ents	O	-1	17147461
a	O	-1	17147461
major	O	-1	17147461
therapeutic	O	-1	17147461
adv@@	O	-1	17147461
ance	O	-1	17147461
in	O	-1	17147461
the	O	-1	17147461
pre@@	O	-1	17147461
ven@@	O	-1	17147461
tion	O	-1	17147461
of	O	-1	17147461
acute	O	-1	17147461
renal	O	-1	17147461
allogra@@	O	-1	17147461
ft	O	-1	17147461
re@@	O	-1	17147461
j@@	O	-1	17147461
ection	O	-1	17147461
and	O	-1	17147461
chronic	O	-1	17147461
allogra@@	O	-1	17147461
ft	O	-1	17147461
nephro@@	B-Disease	D007674	17147461
pathy	I-Disease	-1	17147461
.	O	-1	17147461
I@@	O	-1	17147461
ts	O	-1	17147461
role	O	-1	17147461
in	O	-1	17147461
the	O	-1	17147461
therapy	O	-1	17147461
of	O	-1	17147461
glomerul@@	B-Disease	D005921	17147461
one@@	I-Disease	-1	17147461
ph@@	I-Disease	-1	17147461
ritis	I-Disease	-1	17147461
,	O	-1	17147461
auto@@	B-Disease	D001327	17147461
immun@@	I-Disease	-1	17147461
ity	I-Disease	-1	17147461
,	O	-1	17147461
cys@@	B-Disease	D052177	17147461
tic	I-Disease	-1	17147461
renal	I-Disease	-1	17147461
diseas@@	I-Disease	-1	17147461
es	I-Disease	-1	17147461
and	O	-1	17147461
renal	B-Disease	D007680	17147461
cancer	I-Disease	-1	17147461
is	O	-1	17147461
under	O	-1	17147461
investig@@	O	-1	17147461
ation.	O	-1	17147461
B@@	O	-1	17147461
ecause	O	-1	17147461
sirolimus	B-Chemical	D020123	17147461
does	O	-1	17147461
not	O	-1	17147461
sh@@	O	-1	17147461
are	O	-1	17147461
the	O	-1	17147461
vas@@	O	-1	17147461
om@@	O	-1	17147461
otor	O	-1	17147461
renal	O	-1	17147461
adverse	O	-1	17147461
effects	O	-1	17147461
ex@@	O	-1	17147461
hib@@	O	-1	17147461
ited	O	-1	17147461
by	O	-1	17147461
calc@@	O	-1	17147461
ine@@	O	-1	17147461
ur@@	O	-1	17147461
in	O	-1	17147461
inhibitor@@	O	-1	17147461
s,	O	-1	17147461
it	O	-1	17147461
has	O	-1	17147461
been	O	-1	17147461
de@@	O	-1	17147461
sign@@	O	-1	17147461
ated	O	-1	17147461
a	O	-1	17147461
'@@	O	-1	17147461
non@@	O	-1	17147461
-	O	-1	17147461
nephro@@	B-Disease	D007674	17147461
toxic	I-Disease	-1	17147461
drug@@	O	-1	17147461
'@@	O	-1	17147461
.	O	-1	17147461
However,	O	-1	17147461
clinical	O	-1	17147461
reports	O	-1	17147461
suggest	O	-1	17147461
th@@	O	-1	17147461
at@@	O	-1	17147461
,	O	-1	17147461
under	O	-1	17147461
some	O	-1	17147461
cir@@	O	-1	17147461
cum@@	O	-1	17147461
st@@	O	-1	17147461
anc@@	O	-1	17147461
es,	O	-1	17147461
sirolimus	B-Chemical	D020123	17147461
is	O	-1	17147461
associated	O	-1	17147461
with	O	-1	17147461
proteinuria	B-Disease	D011507	17147461
and	O	-1	17147461
acute	B-Disease	D058186	17147461
renal	I-Disease	-1	17147461
dysfunction	I-Disease	-1	17147461
.	O	-1	17147461
A	O	-1	17147461
common	O	-1	17147461
risk	O	-1	17147461
factor	O	-1	17147461
appear@@	O	-1	17147461
s	O	-1	17147461
to	O	-1	17147461
be	O	-1	17147461
presence	O	-1	17147461
of	O	-1	17147461
pre-@@	O	-1	17147461
ex@@	O	-1	17147461
ist@@	O	-1	17147461
ing	O	-1	17147461
chronic	B-Disease	D051436	17147461
renal	I-Disease	-1	17147461
damage	I-Disease	-1	17147461
.	O	-1	17147461
The	O	-1	17147461
mechanisms	O	-1	17147461
of	O	-1	17147461
sirolimus	B-Chemical	D020123	17147461
-@@	O	-1	17147461
associated	O	-1	17147461
proteinuria	B-Disease	D011507	17147461
are	O	-1	17147461
multi@@	O	-1	17147461
fact@@	O	-1	17147461
or@@	O	-1	17147461
ial	O	-1	17147461
and	O	-1	17147461
may	O	-1	17147461
be	O	-1	17147461
due	O	-1	17147461
to	O	-1	17147461
an	O	-1	17147461
increase	O	-1	17147461
in	O	-1	17147461
glomerular	O	-1	17147461
cap@@	O	-1	17147461
ill@@	O	-1	17147461
ary	O	-1	17147461
pressure	O	-1	17147461
following	O	-1	17147461
calc@@	O	-1	17147461
ine@@	O	-1	17147461
ur@@	O	-1	17147461
in	O	-1	17147461
inhibitor	O	-1	17147461
withdraw@@	O	-1	17147461
al.	O	-1	17147461
It	O	-1	17147461
has	O	-1	17147461
also	O	-1	17147461
been	O	-1	17147461
suggested	O	-1	17147461
that	O	-1	17147461
sirolimus	B-Chemical	D020123	17147461
direc@@	O	-1	17147461
tly	O	-1	17147461
causes	O	-1	17147461
increased	O	-1	17147461
glomerular	O	-1	17147461
per@@	O	-1	17147461
me@@	O	-1	17147461
abil@@	O	-1	17147461
it@@	O	-1	17147461
y@@	O	-1	17147461
/@@	O	-1	17147461
injur@@	O	-1	17147461
y,	O	-1	17147461
but	O	-1	17147461
evidence	O	-1	17147461
for	O	-1	17147461
this	O	-1	17147461
mechanism	O	-1	17147461
is	O	-1	17147461
cur@@	O	-1	17147461
ren@@	O	-1	17147461
tly	O	-1	17147461
in@@	O	-1	17147461
concl@@	O	-1	17147461
u@@	O	-1	17147461
si@@	O	-1	17147461
ve.	O	-1	17147461
The	O	-1	17147461
acute	B-Disease	D058186	17147461
renal	I-Disease	-1	17147461
dysfunction	I-Disease	-1	17147461
associated	O	-1	17147461
with	O	-1	17147461
sirolimus	B-Chemical	D020123	17147461
(@@	O	-1	17147461
such	O	-1	17147461
as	O	-1	17147461
in	O	-1	17147461
del@@	O	-1	17147461
ayed	O	-1	17147461
gra@@	O	-1	17147461
ft	O	-1	17147461
func@@	O	-1	17147461
tion@@	O	-1	17147461
)	O	-1	17147461
may	O	-1	17147461
be	O	-1	17147461
due	O	-1	17147461
to	O	-1	17147461
sup@@	O	-1	17147461
pression	O	-1	17147461
of	O	-1	17147461
com@@	O	-1	17147461
pen@@	O	-1	17147461
s@@	O	-1	17147461
atory	O	-1	17147461
renal	O	-1	17147461
cell	O	-1	17147461
pro@@	O	-1	17147461
li@@	O	-1	17147461
fer@@	O	-1	17147461
ation	O	-1	17147461
and	O	-1	17147461
sur@@	O	-1	17147461
vi@@	O	-1	17147461
val@@	O	-1	17147461
/@@	O	-1	17147461
re@@	O	-1	17147461
pa@@	O	-1	17147461
ir	O	-1	17147461
pro@@	O	-1	17147461
cess@@	O	-1	17147461
es.	O	-1	17147461
Although	O	-1	17147461
these	O	-1	17147461
adverse	O	-1	17147461
effects	O	-1	17147461
occ@@	O	-1	17147461
ur	O	-1	17147461
in	O	-1	17147461
some	O	-1	17147461
patients,	O	-1	17147461
their	O	-1	17147461
occur@@	O	-1	17147461
rence	O	-1	17147461
could	O	-1	17147461
be	O	-1	17147461
minim@@	O	-1	17147461
is@@	O	-1	17147461
ed	O	-1	17147461
by	O	-1	17147461
know@@	O	-1	17147461
le@@	O	-1	17147461
d@@	O	-1	17147461
ge	O	-1	17147461
of	O	-1	17147461
the	O	-1	17147461
mol@@	O	-1	17147461
ec@@	O	-1	17147461
ular	O	-1	17147461
effects	O	-1	17147461
of	O	-1	17147461
sirolimus	B-Chemical	D020123	17147461
on	O	-1	17147461
the	O	-1	17147461
kidne@@	O	-1	17147461
y,	O	-1	17147461
the	O	-1	17147461
use	O	-1	17147461
of	O	-1	17147461
sirolimus	B-Chemical	D020123	17147461
in	O	-1	17147461
appro@@	O	-1	17147461
pri@@	O	-1	17147461
ate	O	-1	17147461
patient	O	-1	17147461
po@@	O	-1	17147461
pul@@	O	-1	17147461
ation@@	O	-1	17147461
s,	O	-1	17147461
clo@@	O	-1	17147461
se	O	-1	17147461
monit@@	O	-1	17147461
or@@	O	-1	17147461
ing	O	-1	17147461
of	O	-1	17147461
proteinuria	B-Disease	D011507	17147461
and	O	-1	17147461
renal	O	-1	17147461
func@@	O	-1	17147461
tion,	O	-1	17147461
use	O	-1	17147461
of	O	-1	17147461
angiotens@@	B-Chemical	D000809	17147461
in	I-Chemical	-1	17147461
-@@	O	-1	17147461
conver@@	O	-1	17147461
ting	O	-1	17147461
enzyme	O	-1	17147461
inhibitors	O	-1	17147461
or	O	-1	17147461
angiotens@@	B-Chemical	D000804	17147461
in	I-Chemical	-1	17147461
II	I-Chemical	-1	17147461
receptor	O	-1	17147461
block@@	O	-1	17147461
ers	O	-1	17147461
if	O	-1	17147461
proteinuria	B-Disease	D011507	17147461
occur@@	O	-1	17147461
s	O	-1	17147461
and	O	-1	17147461
withdrawal	O	-1	17147461
if	O	-1	17147461
ne@@	O	-1	17147461
e@@	O	-1	17147461
de@@	O	-1	17147461
d.	O	-1	17147461
F@@	O	-1	17147461
urther	O	-1	17147461
long-term	O	-1	17147461
analysis	O	-1	17147461
of	O	-1	17147461
renal	O	-1	17147461
allogra@@	O	-1	17147461
ft	O	-1	17147461
studies	O	-1	17147461
using	O	-1	17147461
sirolimus	B-Chemical	D020123	17147461
as	O	-1	17147461
de	O	-1	17147461
no@@	O	-1	17147461
v@@	O	-1	17147461
o	O	-1	17147461
immunosup@@	O	-1	17147461
pression	O	-1	17147461
al@@	O	-1	17147461
ong	O	-1	17147461
with	O	-1	17147461
clinical	O	-1	17147461
and	O	-1	17147461
labor@@	O	-1	17147461
atory	O	-1	17147461
studies	O	-1	17147461
wil@@	O	-1	17147461
l	O	-1	17147461
ref@@	O	-1	17147461
ine	O	-1	17147461
these	O	-1	17147461
is@@	O	-1	17147461
su@@	O	-1	17147461
es	O	-1	17147461
in	O	-1	17147461
the	O	-1	17147461
f@@	O	-1	17147461
ut@@	O	-1	17147461
ure.	O	-1	17147461

Pro@@	O	-1	17241784
gres@@	O	-1	17241784
sive	O	-1	17241784
my@@	B-Disease	D009135	17241784
o@@	I-Disease	-1	17241784
pathy	I-Disease	-1	17241784
with	O	-1	17241784
up@@	O	-1	17241784
-@@	O	-1	17241784
reg@@	O	-1	17241784
ulation	O	-1	17241784
of	O	-1	17241784
M@@	O	-1	17241784
HC@@	O	-1	17241784
-@@	O	-1	17241784
I	O	-1	17241784
associated	O	-1	17241784
with	O	-1	17241784
st@@	B-Chemical	D019821	17241784
atin	I-Chemical	-1	17241784
therapy.	O	-1	17241784
S@@	B-Chemical	D019821	17241784
t@@	I-Chemical	-1	17241784
at@@	I-Chemical	-1	17241784
ins	I-Chemical	-1	17241784
can	O	-1	17241784
cause	O	-1	17241784
a	O	-1	17241784
necro@@	O	-1	17241784
tiz@@	O	-1	17241784
ing	O	-1	17241784
my@@	B-Disease	D009135	17241784
o@@	I-Disease	-1	17241784
pathy	I-Disease	-1	17241784
and	O	-1	17241784
hyper@@	B-Disease	-1	17241784
C@@	I-Disease	-1	17241784
K@@	I-Disease	-1	17241784
a@@	I-Disease	-1	17241784
emia	I-Disease	-1	17241784
which	O	-1	17241784
is	O	-1	17241784
reversible	O	-1	17241784
on	O	-1	17241784
cess@@	O	-1	17241784
ation	O	-1	17241784
of	O	-1	17241784
the	O	-1	17241784
drug.	O	-1	17241784
W@@	O	-1	17241784
h@@	O	-1	17241784
at	O	-1	17241784
is	O	-1	17241784
less	O	-1	17241784
well	O	-1	17241784
known	O	-1	17241784
is	O	-1	17241784
a	O	-1	17241784
phen@@	O	-1	17241784
om@@	O	-1	17241784
en@@	O	-1	17241784
on	O	-1	17241784
whe@@	O	-1	17241784
re@@	O	-1	17241784
by	O	-1	17241784
stat@@	B-Chemical	D019821	17241784
ins	I-Chemical	-1	17241784
may	O	-1	17241784
induce	O	-1	17241784
a	O	-1	17241784
my@@	B-Disease	D009135	17241784
o@@	I-Disease	-1	17241784
pathy	I-Disease	-1	17241784
,	O	-1	17241784
which	O	-1	17241784
per@@	O	-1	17241784
sist@@	O	-1	17241784
s	O	-1	17241784
or	O	-1	17241784
may	O	-1	17241784
progres@@	O	-1	17241784
s	O	-1	17241784
after	O	-1	17241784
sto@@	O	-1	17241784
pp@@	O	-1	17241784
ing	O	-1	17241784
the	O	-1	17241784
drug.	O	-1	17241784
We	O	-1	17241784
investigated	O	-1	17241784
the	O	-1	17241784
musc@@	O	-1	17241784
le	O	-1	17241784
path@@	O	-1	17241784
ology	O	-1	17241784
in	O	-1	17241784
8	O	-1	17241784
such	O	-1	17241784
cas@@	O	-1	17241784
es.	O	-1	17241784
All	O	-1	17241784
had	O	-1	17241784
my@@	O	-1	17241784
o@@	O	-1	17241784
fib@@	O	-1	17241784
r@@	O	-1	17241784
e	O	-1	17241784
necro@@	B-Disease	D009336	17241784
sis	I-Disease	-1	17241784
but	O	-1	17241784
only	O	-1	17241784
3	O	-1	17241784
had	O	-1	17241784
an	O	-1	17241784
inflam@@	O	-1	17241784
mat@@	O	-1	17241784
ory	O	-1	17241784
inf@@	O	-1	17241784
ilt@@	O	-1	17241784
rat@@	O	-1	17241784
e.	O	-1	17241784
In	O	-1	17241784
all	O	-1	17241784
cases	O	-1	17241784
there	O	-1	17241784
was	O	-1	17241784
diff@@	O	-1	17241784
use	O	-1	17241784
or	O	-1	17241784
multi@@	O	-1	17241784
foc@@	O	-1	17241784
al	O	-1	17241784
up@@	O	-1	17241784
-@@	O	-1	17241784
reg@@	O	-1	17241784
ulation	O	-1	17241784
of	O	-1	17241784
M@@	O	-1	17241784
HC@@	O	-1	17241784
-@@	O	-1	17241784
I	O	-1	17241784
expression	O	-1	17241784
even	O	-1	17241784
in	O	-1	17241784
non@@	O	-1	17241784
-	O	-1	17241784
necro@@	B-Disease	D009336	17241784
tic	I-Disease	-1	17241784
fib@@	O	-1	17241784
res@@	O	-1	17241784
.	O	-1	17241784
Pro@@	O	-1	17241784
gres@@	O	-1	17241784
sive	O	-1	17241784
impro@@	O	-1	17241784
vement	O	-1	17241784
occurred	O	-1	17241784
in	O	-1	17241784
7	O	-1	17241784
cases	O	-1	17241784
after	O	-1	17241784
comm@@	O	-1	17241784
ence@@	O	-1	17241784
ment	O	-1	17241784
of	O	-1	17241784
pre@@	B-Chemical	D011239	17241784
d@@	I-Chemical	-1	17241784
n@@	I-Chemical	-1	17241784
isol@@	I-Chemical	-1	17241784
one	I-Chemical	-1	17241784
and	O	-1	17241784
meth@@	B-Chemical	D008727	17241784
ot@@	I-Chemical	-1	17241784
re@@	I-Chemical	-1	17241784
x@@	I-Chemical	-1	17241784
ate	I-Chemical	-1	17241784
,	O	-1	17241784
and	O	-1	17241784
in	O	-1	17241784
one	O	-1	17241784
case	O	-1	17241784
spont@@	O	-1	17241784
ane@@	O	-1	17241784
ous@@	O	-1	17241784
ly.	O	-1	17241784
These	O	-1	17241784
observ@@	O	-1	17241784
ations	O	-1	17241784
suggest	O	-1	17241784
that	O	-1	17241784
stat@@	B-Chemical	D019821	17241784
ins	I-Chemical	-1	17241784
may	O	-1	17241784
initi@@	O	-1	17241784
ate	O	-1	17241784
an	O	-1	17241784
immun@@	O	-1	17241784
e-@@	O	-1	17241784
mediated	O	-1	17241784
my@@	B-Disease	D009135	17241784
o@@	I-Disease	-1	17241784
pathy	I-Disease	-1	17241784
that	O	-1	17241784
per@@	O	-1	17241784
sist@@	O	-1	17241784
s	O	-1	17241784
after	O	-1	17241784
withdrawal	O	-1	17241784
of	O	-1	17241784
the	O	-1	17241784
drug	O	-1	17241784
and	O	-1	17241784
respon@@	O	-1	17241784
ds	O	-1	17241784
to	O	-1	17241784
immunosup@@	O	-1	17241784
pressive	O	-1	17241784
therapy.	O	-1	17241784
The	O	-1	17241784
mechanism	O	-1	17241784
of	O	-1	17241784
this	O	-1	17241784
my@@	B-Disease	D009135	17241784
o@@	I-Disease	-1	17241784
pathy	I-Disease	-1	17241784
is	O	-1	17241784
unc@@	O	-1	17241784
er@@	O	-1	17241784
t@@	O	-1	17241784
ain	O	-1	17241784
but	O	-1	17241784
may	O	-1	17241784
invol@@	O	-1	17241784
ve	O	-1	17241784
the	O	-1	17241784
induction	O	-1	17241784
by	O	-1	17241784
stat@@	B-Chemical	D019821	17241784
ins	I-Chemical	-1	17241784
of	O	-1	17241784
an	O	-1	17241784
endo@@	O	-1	17241784
plas@@	O	-1	17241784
mic	O	-1	17241784
re@@	O	-1	17241784
tic@@	O	-1	17241784
ul@@	O	-1	17241784
um	O	-1	17241784
stres@@	O	-1	17241784
s	O	-1	17241784
response	O	-1	17241784
with	O	-1	17241784
associated	O	-1	17241784
up@@	O	-1	17241784
-@@	O	-1	17241784
reg@@	O	-1	17241784
ulation	O	-1	17241784
of	O	-1	17241784
M@@	O	-1	17241784
HC@@	O	-1	17241784
-@@	O	-1	17241784
I	O	-1	17241784
expression	O	-1	17241784
and	O	-1	17241784
anti@@	O	-1	17241784
gen	O	-1	17241784
present@@	O	-1	17241784
ation	O	-1	17241784
by	O	-1	17241784
musc@@	O	-1	17241784
le	O	-1	17241784
fib@@	O	-1	17241784
res@@	O	-1	17241784
.	O	-1	17241784

Di@@	O	-1	17261653
rec@@	O	-1	17261653
t	O	-1	17261653
inhibition	O	-1	17261653
of	O	-1	17261653
cardiac	O	-1	17261653
hyper@@	O	-1	17261653
pol@@	O	-1	17261653
ar@@	O	-1	17261653
iz@@	O	-1	17261653
ation@@	O	-1	17261653
-@@	O	-1	17261653
activ@@	O	-1	17261653
ated	O	-1	17261653
cy@@	B-Chemical	D009712	17261653
cl@@	I-Chemical	-1	17261653
ic	I-Chemical	-1	17261653
nucle@@	I-Chemical	-1	17261653
o@@	I-Chemical	-1	17261653
ti@@	I-Chemical	-1	17261653
de	I-Chemical	-1	17261653
-@@	O	-1	17261653
g@@	O	-1	17261653
ated	O	-1	17261653
pac@@	O	-1	17261653
em@@	O	-1	17261653
ak@@	O	-1	17261653
er	O	-1	17261653
channe@@	O	-1	17261653
l@@	O	-1	17261653
s	O	-1	17261653
by	O	-1	17261653
clonidine	B-Chemical	D003000	17261653
.	O	-1	17261653
BACKGROUND:	O	-1	17261653
In@@	O	-1	17261653
hib@@	O	-1	17261653
ition	O	-1	17261653
of	O	-1	17261653
cardiac	O	-1	17261653
sym@@	O	-1	17261653
pa@@	O	-1	17261653
thetic	O	-1	17261653
t@@	O	-1	17261653
one	O	-1	17261653
re@@	O	-1	17261653
pres@@	O	-1	17261653
ents	O	-1	17261653
an	O	-1	17261653
important	O	-1	17261653
strat@@	O	-1	17261653
e@@	O	-1	17261653
g@@	O	-1	17261653
y	O	-1	17261653
for	O	-1	17261653
treatment	O	-1	17261653
of	O	-1	17261653
cardiovascular	B-Disease	D002318	17261653
disease	I-Disease	-1	17261653
,	O	-1	17261653
including	O	-1	17261653
arrhyth@@	B-Disease	D001145	17261653
mia	I-Disease	-1	17261653
,	O	-1	17261653
coronary	B-Disease	D003327	17261653
heart	I-Disease	-1	17261653
disease	I-Disease	-1	17261653
,	O	-1	17261653
and	O	-1	17261653
chronic	O	-1	17261653
heart	B-Disease	D006333	17261653
failure	I-Disease	-1	17261653
.	O	-1	17261653
Ac@@	O	-1	17261653
tiv@@	O	-1	17261653
ation	O	-1	17261653
of	O	-1	17261653
pres@@	O	-1	17261653
yn@@	O	-1	17261653
ap@@	O	-1	17261653
tic	O	-1	17261653
alpha@@	O	-1	17261653
2-@@	O	-1	17261653
adren@@	O	-1	17261653
oc@@	O	-1	17261653
e@@	O	-1	17261653
pt@@	O	-1	17261653
ors	O	-1	17261653
is	O	-1	17261653
the	O	-1	17261653
most	O	-1	17261653
wi@@	O	-1	17261653
de@@	O	-1	17261653
ly	O	-1	17261653
ac@@	O	-1	17261653
ce@@	O	-1	17261653
pt@@	O	-1	17261653
ed	O	-1	17261653
mechanism	O	-1	17261653
of	O	-1	17261653
action	O	-1	17261653
of	O	-1	17261653
the	O	-1	17261653
anti@@	O	-1	17261653
sym@@	O	-1	17261653
pa@@	O	-1	17261653
thetic	O	-1	17261653
drug	O	-1	17261653
clonidine	B-Chemical	D003000	17261653
;	O	-1	17261653
however,	O	-1	17261653
other	O	-1	17261653
t@@	O	-1	17261653
arg@@	O	-1	17261653
et	O	-1	17261653
protein@@	O	-1	17261653
s	O	-1	17261653
have	O	-1	17261653
been	O	-1	17261653
post@@	O	-1	17261653
ul@@	O	-1	17261653
ated	O	-1	17261653
to	O	-1	17261653
cont@@	O	-1	17261653
rib@@	O	-1	17261653
ute	O	-1	17261653
to	O	-1	17261653
the	O	-1	17261653
in	O	-1	17261653
viv@@	O	-1	17261653
o	O	-1	17261653
ac@@	O	-1	17261653
tions	O	-1	17261653
of	O	-1	17261653
clonidine	B-Chemical	D003000	17261653
.	O	-1	17261653
METHOD@@	O	-1	17261653
S	O	-1	17261653
AN@@	O	-1	17261653
D	O	-1	17261653
RESULTS:	O	-1	17261653
To	O	-1	17261653
test	O	-1	17261653
whether	O	-1	17261653
clonidine	B-Chemical	D003000	17261653
el@@	O	-1	17261653
ic@@	O	-1	17261653
its	O	-1	17261653
pharmac@@	O	-1	17261653
ological	O	-1	17261653
effects	O	-1	17261653
in@@	O	-1	17261653
dependent	O	-1	17261653
of	O	-1	17261653
alpha@@	O	-1	17261653
2-@@	O	-1	17261653
adren@@	O	-1	17261653
oc@@	O	-1	17261653
e@@	O	-1	17261653
pt@@	O	-1	17261653
or@@	O	-1	17261653
s,	O	-1	17261653
we	O	-1	17261653
have	O	-1	17261653
gener@@	O	-1	17261653
ated	O	-1	17261653
mice	O	-1	17261653
with	O	-1	17261653
a	O	-1	17261653
t@@	O	-1	17261653
arg@@	O	-1	17261653
et@@	O	-1	17261653
ed	O	-1	17261653
de@@	O	-1	17261653
le@@	O	-1	17261653
tion	O	-1	17261653
of	O	-1	17261653
all	O	-1	17261653
3	O	-1	17261653
alpha@@	O	-1	17261653
2-@@	O	-1	17261653
adren@@	O	-1	17261653
oc@@	O	-1	17261653
e@@	O	-1	17261653
pt@@	O	-1	17261653
or	O	-1	17261653
sub@@	O	-1	17261653
typ@@	O	-1	17261653
es	O	-1	17261653
(@@	O	-1	17261653
alpha@@	O	-1	17261653
2@@	O	-1	17261653
A@@	O	-1	17261653
BC@@	O	-1	17261653
-@@	O	-1	17261653
/@@	O	-1	17261653
-@@	O	-1	17261653
).	O	-1	17261653
Al@@	O	-1	17261653
pha@@	O	-1	17261653
2@@	O	-1	17261653
A@@	O	-1	17261653
BC@@	O	-1	17261653
-@@	O	-1	17261653
/@@	O	-1	17261653
-	O	-1	17261653
mice	O	-1	17261653
were	O	-1	17261653
complete@@	O	-1	17261653
ly	O	-1	17261653
un@@	O	-1	17261653
respon@@	O	-1	17261653
sive	O	-1	17261653
to	O	-1	17261653
the	O	-1	17261653
analge@@	O	-1	17261653
sic	O	-1	17261653
and	O	-1	17261653
hy@@	O	-1	17261653
p@@	O	-1	17261653
no@@	O	-1	17261653
tic	O	-1	17261653
effects	O	-1	17261653
of	O	-1	17261653
clonidine	B-Chemical	D003000	17261653
;	O	-1	17261653
however,	O	-1	17261653
clonidine	B-Chemical	D003000	17261653
significantly	O	-1	17261653
lo@@	O	-1	17261653
we@@	O	-1	17261653
red	O	-1	17261653
heart	O	-1	17261653
rate	O	-1	17261653
in	O	-1	17261653
alpha@@	O	-1	17261653
2@@	O	-1	17261653
A@@	O	-1	17261653
BC@@	O	-1	17261653
-@@	O	-1	17261653
/@@	O	-1	17261653
-	O	-1	17261653
mice	O	-1	17261653
by	O	-1	17261653
up	O	-1	17261653
to	O	-1	17261653
1@@	O	-1	17261653
50	O	-1	17261653
b@@	O	-1	17261653
p@@	O	-1	17261653
m.	O	-1	17261653
C@@	B-Chemical	D003000	17261653
lon@@	I-Chemical	-1	17261653
idine	I-Chemical	-1	17261653
-induced	O	-1	17261653
brady@@	B-Disease	D001919	17261653
cardia	I-Disease	-1	17261653
in	O	-1	17261653
con@@	O	-1	17261653
s@@	O	-1	17261653
ci@@	O	-1	17261653
ous	O	-1	17261653
alpha@@	O	-1	17261653
2@@	O	-1	17261653
A@@	O	-1	17261653
BC@@	O	-1	17261653
-@@	O	-1	17261653
/@@	O	-1	17261653
-	O	-1	17261653
mice	O	-1	17261653
was	O	-1	17261653
3@@	O	-1	17261653
2.@@	O	-1	17261653
3@@	O	-1	17261653
%	O	-1	17261653
(10	O	-1	17261653
micro@@	O	-1	17261653
g/@@	O	-1	17261653
kg@@	O	-1	17261653
)	O	-1	17261653
and	O	-1	17261653
2@@	O	-1	17261653
6.@@	O	-1	17261653
6%	O	-1	17261653
(@@	O	-1	17261653
100	O	-1	17261653
micro@@	O	-1	17261653
g/@@	O	-1	17261653
kg@@	O	-1	17261653
)	O	-1	17261653
of	O	-1	17261653
the	O	-1	17261653
effect	O	-1	17261653
in	O	-1	17261653
wil@@	O	-1	17261653
d-@@	O	-1	17261653
type	O	-1	17261653
mice.	O	-1	17261653
A	O	-1	17261653
similar	O	-1	17261653
brady@@	O	-1	17261653
cardi@@	O	-1	17261653
c	O	-1	17261653
effect	O	-1	17261653
of	O	-1	17261653
clonidine	B-Chemical	D003000	17261653
was	O	-1	17261653
observed	O	-1	17261653
in	O	-1	17261653
isol@@	O	-1	17261653
ated	O	-1	17261653
spont@@	O	-1	17261653
ane@@	O	-1	17261653
ously	O	-1	17261653
be@@	O	-1	17261653
ating	O	-1	17261653
right	O	-1	17261653
atri@@	O	-1	17261653
a	O	-1	17261653
from	O	-1	17261653
alpha@@	O	-1	17261653
2@@	O	-1	17261653
A@@	O	-1	17261653
BC@@	O	-1	17261653
-@@	O	-1	17261653
k@@	O	-1	17261653
n@@	O	-1	17261653
oc@@	O	-1	17261653
k@@	O	-1	17261653
out	O	-1	17261653
and	O	-1	17261653
wil@@	O	-1	17261653
d-@@	O	-1	17261653
type	O	-1	17261653
mice.	O	-1	17261653
C@@	B-Chemical	D003000	17261653
lon@@	I-Chemical	-1	17261653
idine	I-Chemical	-1	17261653
inhibited	O	-1	17261653
the	O	-1	17261653
n@@	O	-1	17261653
ative	O	-1	17261653
pac@@	O	-1	17261653
em@@	O	-1	17261653
ak@@	O	-1	17261653
er	O	-1	17261653
current	O	-1	17261653
(@@	O	-1	17261653
I@@	O	-1	17261653
(@@	O	-1	17261653
f@@	O	-1	17261653
)@@	O	-1	17261653
)	O	-1	17261653
in	O	-1	17261653
isol@@	O	-1	17261653
ated	O	-1	17261653
s@@	O	-1	17261653
ino@@	O	-1	17261653
atrial	O	-1	17261653
no@@	O	-1	17261653
de	O	-1	17261653
pac@@	O	-1	17261653
em@@	O	-1	17261653
ak@@	O	-1	17261653
er	O	-1	17261653
cells	O	-1	17261653
and	O	-1	17261653
the	O	-1	17261653
I@@	O	-1	17261653
(@@	O	-1	17261653
f@@	O	-1	17261653
)-@@	O	-1	17261653
gener@@	O	-1	17261653
ating	O	-1	17261653
hyper@@	O	-1	17261653
pol@@	O	-1	17261653
ar@@	O	-1	17261653
iz@@	O	-1	17261653
ation@@	O	-1	17261653
-@@	O	-1	17261653
activ@@	O	-1	17261653
ated	O	-1	17261653
cy@@	B-Chemical	D009712	17261653
cl@@	I-Chemical	-1	17261653
ic	I-Chemical	-1	17261653
nucle@@	I-Chemical	-1	17261653
o@@	I-Chemical	-1	17261653
ti@@	I-Chemical	-1	17261653
de	I-Chemical	-1	17261653
-@@	O	-1	17261653
g@@	O	-1	17261653
ated	O	-1	17261653
(@@	O	-1	17261653
HC@@	O	-1	17261653
N@@	O	-1	17261653
)	O	-1	17261653
2	O	-1	17261653
and	O	-1	17261653
HC@@	O	-1	17261653
N@@	O	-1	17261653
4	O	-1	17261653
channe@@	O	-1	17261653
l@@	O	-1	17261653
s	O	-1	17261653
in	O	-1	17261653
trans@@	O	-1	17261653
f@@	O	-1	17261653
ected	O	-1	17261653
H@@	O	-1	17261653
E@@	O	-1	17261653
K@@	O	-1	17261653
2@@	O	-1	17261653
9@@	O	-1	17261653
3	O	-1	17261653
cell@@	O	-1	17261653
s.	O	-1	17261653
A@@	O	-1	17261653
s	O	-1	17261653
a	O	-1	17261653
con@@	O	-1	17261653
sequ@@	O	-1	17261653
ence	O	-1	17261653
of	O	-1	17261653
block@@	O	-1	17261653
ing	O	-1	17261653
I@@	O	-1	17261653
(@@	O	-1	17261653
f@@	O	-1	17261653
),	O	-1	17261653
clonidine	B-Chemical	D003000	17261653
reduced	O	-1	17261653
the	O	-1	17261653
s@@	O	-1	17261653
lop@@	O	-1	17261653
e	O	-1	17261653
of	O	-1	17261653
the	O	-1	17261653
di@@	O	-1	17261653
ast@@	O	-1	17261653
olic	O	-1	17261653
de@@	O	-1	17261653
pol@@	O	-1	17261653
ar@@	O	-1	17261653
ization	O	-1	17261653
and	O	-1	17261653
the	O	-1	17261653
frequency	O	-1	17261653
of	O	-1	17261653
pac@@	O	-1	17261653
em@@	O	-1	17261653
ak@@	O	-1	17261653
er	O	-1	17261653
potenti@@	O	-1	17261653
als	O	-1	17261653
in	O	-1	17261653
s@@	O	-1	17261653
ino@@	O	-1	17261653
atrial	O	-1	17261653
no@@	O	-1	17261653
de	O	-1	17261653
cells	O	-1	17261653
from	O	-1	17261653
wil@@	O	-1	17261653
d-@@	O	-1	17261653
type	O	-1	17261653
and	O	-1	17261653
alpha@@	O	-1	17261653
2@@	O	-1	17261653
A@@	O	-1	17261653
BC@@	O	-1	17261653
-@@	O	-1	17261653
k@@	O	-1	17261653
n@@	O	-1	17261653
oc@@	O	-1	17261653
k@@	O	-1	17261653
out	O	-1	17261653
mice.	O	-1	17261653
CONCLUSIONS:	O	-1	17261653
Di@@	O	-1	17261653
rec@@	O	-1	17261653
t	O	-1	17261653
inhibition	O	-1	17261653
of	O	-1	17261653
cardiac	O	-1	17261653
HC@@	O	-1	17261653
N	O	-1	17261653
pac@@	O	-1	17261653
em@@	O	-1	17261653
ak@@	O	-1	17261653
er	O	-1	17261653
channe@@	O	-1	17261653
l@@	O	-1	17261653
s	O	-1	17261653
cont@@	O	-1	17261653
ri@@	O	-1	17261653
but@@	O	-1	17261653
es	O	-1	17261653
to	O	-1	17261653
the	O	-1	17261653
brady@@	O	-1	17261653
cardi@@	O	-1	17261653
c	O	-1	17261653
effects	O	-1	17261653
of	O	-1	17261653
clonidine	B-Chemical	D003000	17261653
gen@@	O	-1	17261653
e-@@	O	-1	17261653
t@@	O	-1	17261653
arg@@	O	-1	17261653
et@@	O	-1	17261653
ed	O	-1	17261653
mice	O	-1	17261653
in	O	-1	17261653
viv@@	O	-1	17261653
o@@	O	-1	17261653
,	O	-1	17261653
and	O	-1	17261653
th@@	O	-1	17261653
us,	O	-1	17261653
clonidine	B-Chemical	D003000	17261653
-@@	O	-1	17261653
like	O	-1	17261653
drugs	O	-1	17261653
re@@	O	-1	17261653
present	O	-1	17261653
novel	O	-1	17261653
struct@@	O	-1	17261653
ures	O	-1	17261653
for	O	-1	17261653
f@@	O	-1	17261653
ut@@	O	-1	17261653
ure	O	-1	17261653
HC@@	O	-1	17261653
N	O	-1	17261653
channel	O	-1	17261653
inhibitor@@	O	-1	17261653
s.	O	-1	17261653

In@@	O	-1	17343925
flu@@	O	-1	17343925
ence	O	-1	17343925
of	O	-1	17343925
smo@@	B-Chemical	D012906	17343925
king	I-Chemical	-1	17343925
on	O	-1	17343925
develop@@	O	-1	17343925
ing	O	-1	17343925
co@@	O	-1	17343925
ch@@	O	-1	17343925
le@@	O	-1	17343925
a.	O	-1	17343925
D@@	O	-1	17343925
o@@	O	-1	17343925
es	O	-1	17343925
smo@@	B-Chemical	D012906	17343925
king	I-Chemical	-1	17343925
during	O	-1	17343925
pregn@@	O	-1	17343925
anc@@	O	-1	17343925
y	O	-1	17343925
aff@@	O	-1	17343925
ect	O	-1	17343925
the	O	-1	17343925
am@@	O	-1	17343925
pl@@	O	-1	17343925
it@@	O	-1	17343925
u@@	O	-1	17343925
des	O	-1	17343925
of	O	-1	17343925
transi@@	O	-1	17343925
ent	O	-1	17343925
evoked	O	-1	17343925
ot@@	O	-1	17343925
o@@	O	-1	17343925
ac@@	O	-1	17343925
ous@@	O	-1	17343925
tic	O	-1	17343925
em@@	O	-1	17343925
is@@	O	-1	17343925
sions	O	-1	17343925
in	O	-1	17343925
ne@@	O	-1	17343925
w@@	O	-1	17343925
b@@	O	-1	17343925
or@@	O	-1	17343925
n@@	O	-1	17343925
s@@	O	-1	17343925
?	O	-1	17343925
OBJECTIVE:	O	-1	17343925
M@@	O	-1	17343925
at@@	O	-1	17343925
er@@	O	-1	17343925
n@@	O	-1	17343925
al	O	-1	17343925
to@@	O	-1	17343925
bac@@	O	-1	17343925
c@@	O	-1	17343925
o	O	-1	17343925
smo@@	B-Chemical	D012906	17343925
king	I-Chemical	-1	17343925
has	O	-1	17343925
negative	O	-1	17343925
effects	O	-1	17343925
on	O	-1	17343925
f@@	O	-1	17343925
et@@	O	-1	17343925
al	O	-1	17343925
grow@@	O	-1	17343925
th@@	O	-1	17343925
.	O	-1	17343925
The	O	-1	17343925
influence	O	-1	17343925
of	O	-1	17343925
smo@@	B-Chemical	D012906	17343925
king	I-Chemical	-1	17343925
during	O	-1	17343925
pregn@@	O	-1	17343925
anc@@	O	-1	17343925
y	O	-1	17343925
on	O	-1	17343925
the	O	-1	17343925
develop@@	O	-1	17343925
ing	O	-1	17343925
co@@	O	-1	17343925
ch@@	O	-1	17343925
le@@	O	-1	17343925
a	O	-1	17343925
has	O	-1	17343925
not	O	-1	17343925
been	O	-1	17343925
estim@@	O	-1	17343925
at@@	O	-1	17343925
ed,	O	-1	17343925
although	O	-1	17343925
smo@@	B-Chemical	D012906	17343925
king	I-Chemical	-1	17343925
has	O	-1	17343925
been	O	-1	17343925
posi@@	O	-1	17343925
ti@@	O	-1	17343925
vely	O	-1	17343925
associated	O	-1	17343925
with	O	-1	17343925
hearing	B-Disease	D034381	17343925
loss	I-Disease	-1	17343925
in	O	-1	17343925
ad@@	O	-1	17343925
ult@@	O	-1	17343925
s.	O	-1	17343925
The	O	-1	17343925
ob@@	O	-1	17343925
j@@	O	-1	17343925
ective	O	-1	17343925
of	O	-1	17343925
this	O	-1	17343925
study	O	-1	17343925
was	O	-1	17343925
to	O	-1	17343925
determine	O	-1	17343925
the	O	-1	17343925
effects	O	-1	17343925
of	O	-1	17343925
mat@@	O	-1	17343925
er@@	O	-1	17343925
n@@	O	-1	17343925
al	O	-1	17343925
smo@@	B-Chemical	D012906	17343925
king	I-Chemical	-1	17343925
on	O	-1	17343925
transi@@	O	-1	17343925
ent	O	-1	17343925
evoked	O	-1	17343925
ot@@	O	-1	17343925
o@@	O	-1	17343925
ac@@	O	-1	17343925
ous@@	O	-1	17343925
tic	O	-1	17343925
em@@	O	-1	17343925
is@@	O	-1	17343925
sions	O	-1	17343925
(T@@	O	-1	17343925
E@@	O	-1	17343925
O@@	O	-1	17343925
A@@	O	-1	17343925
E@@	O	-1	17343925
s)	O	-1	17343925
of	O	-1	17343925
healthy	O	-1	17343925
ne@@	O	-1	17343925
on@@	O	-1	17343925
at@@	O	-1	17343925
es.	O	-1	17343925
METHODS:	O	-1	17343925
This	O	-1	17343925
study	O	-1	17343925
was	O	-1	17343925
under@@	O	-1	17343925
tak@@	O	-1	17343925
en	O	-1	17343925
as	O	-1	17343925
par@@	O	-1	17343925
t	O	-1	17343925
of	O	-1	17343925
ne@@	O	-1	17343925
on@@	O	-1	17343925
atal	O	-1	17343925
s@@	O	-1	17343925
cre@@	O	-1	17343925
en@@	O	-1	17343925
ing	O	-1	17343925
for	O	-1	17343925
hearing	B-Disease	D034381	17343925
impair@@	I-Disease	-1	17343925
ment	I-Disease	-1	17343925
and	O	-1	17343925
involved	O	-1	17343925
both	O	-1	17343925
ear@@	O	-1	17343925
s	O	-1	17343925
of	O	-1	17343925
2@@	O	-1	17343925
00	O	-1	17343925
ne@@	O	-1	17343925
w@@	O	-1	17343925
b@@	O	-1	17343925
or@@	O	-1	17343925
n@@	O	-1	17343925
s.	O	-1	17343925
Ne@@	O	-1	17343925
w@@	O	-1	17343925
b@@	O	-1	17343925
or@@	O	-1	17343925
n@@	O	-1	17343925
s	O	-1	17343925
wh@@	O	-1	17343925
ose	O	-1	17343925
mo@@	O	-1	17343925
ther@@	O	-1	17343925
s	O	-1	17343925
reported	O	-1	17343925
smo@@	B-Chemical	D012906	17343925
king	I-Chemical	-1	17343925
during	O	-1	17343925
pregn@@	O	-1	17343925
anc@@	O	-1	17343925
y	O	-1	17343925
(n@@	O	-1	17343925
=@@	O	-1	17343925
2@@	O	-1	17343925
00	O	-1	17343925
ear@@	O	-1	17343925
s)	O	-1	17343925
were	O	-1	17343925
compared	O	-1	17343925
to	O	-1	17343925
a	O	-1	17343925
control	O	-1	17343925
group	O	-1	17343925
of	O	-1	17343925
ne@@	O	-1	17343925
w@@	O	-1	17343925
b@@	O	-1	17343925
or@@	O	-1	17343925
n@@	O	-1	17343925
s	O	-1	17343925
(n@@	O	-1	17343925
=@@	O	-1	17343925
2@@	O	-1	17343925
00	O	-1	17343925
ear@@	O	-1	17343925
s),	O	-1	17343925
wh@@	O	-1	17343925
ose	O	-1	17343925
mo@@	O	-1	17343925
ther@@	O	-1	17343925
s	O	-1	17343925
were	O	-1	17343925
non-@@	O	-1	17343925
smo@@	O	-1	17343925
k@@	O	-1	17343925
ers.	O	-1	17343925
E@@	O	-1	17343925
x@@	O	-1	17343925
pos@@	O	-1	17343925
ure	O	-1	17343925
to	O	-1	17343925
to@@	O	-1	17343925
bac@@	O	-1	17343925
c@@	O	-1	17343925
o	O	-1	17343925
was	O	-1	17343925
character@@	O	-1	17343925
ized	O	-1	17343925
as	O	-1	17343925
low	O	-1	17343925
(@@	O	-1	17343925
<@@	O	-1	17343925
5	O	-1	17343925
ci@@	O	-1	17343925
g@@	O	-1	17343925
a@@	O	-1	17343925
ret@@	O	-1	17343925
tes	O	-1	17343925
per	O	-1	17343925
da@@	O	-1	17343925
y,	O	-1	17343925
n@@	O	-1	17343925
=@@	O	-1	17343925
8@@	O	-1	17343925
8	O	-1	17343925
ear@@	O	-1	17343925
s),	O	-1	17343925
moder@@	O	-1	17343925
ate	O	-1	17343925
(5@@	O	-1	17343925
<	O	-1	17343925
or	O	-1	17343925
=@@	O	-1	17343925
ci@@	O	-1	17343925
g@@	O	-1	17343925
a@@	O	-1	17343925
ret@@	O	-1	17343925
tes	O	-1	17343925
per	O	-1	17343925
day@@	O	-1	17343925
<@@	O	-1	17343925
10@@	O	-1	17343925
,	O	-1	17343925
n@@	O	-1	17343925
=@@	O	-1	17343925
7@@	O	-1	17343925
6@@	O	-1	17343925
)	O	-1	17343925
or	O	-1	17343925
high	O	-1	17343925
(@@	O	-1	17343925
>	O	-1	17343925
or	O	-1	17343925
=@@	O	-1	17343925
10	O	-1	17343925
ci@@	O	-1	17343925
g@@	O	-1	17343925
a@@	O	-1	17343925
ret@@	O	-1	17343925
tes	O	-1	17343925
per	O	-1	17343925
da@@	O	-1	17343925
y,	O	-1	17343925
n@@	O	-1	17343925
=@@	O	-1	17343925
3@@	O	-1	17343925
6@@	O	-1	17343925
).	O	-1	17343925
RESULTS:	O	-1	17343925
In	O	-1	17343925
exposed	O	-1	17343925
ne@@	O	-1	17343925
on@@	O	-1	17343925
at@@	O	-1	17343925
es,	O	-1	17343925
TE@@	O	-1	17343925
O@@	O	-1	17343925
A@@	O	-1	17343925
E@@	O	-1	17343925
s	O	-1	17343925
mean	O	-1	17343925
response	O	-1	17343925
(@@	O	-1	17343925
ac@@	O	-1	17343925
ros@@	O	-1	17343925
s	O	-1	17343925
frequ@@	O	-1	17343925
enc@@	O	-1	17343925
y@@	O	-1	17343925
)	O	-1	17343925
and	O	-1	17343925
mean	O	-1	17343925
am@@	O	-1	17343925
pl@@	O	-1	17343925
it@@	O	-1	17343925
ude	O	-1	17343925
at	O	-1	17343925
4@@	O	-1	17343925
0@@	O	-1	17343925
0@@	O	-1	17343925
0@@	O	-1	17343925
H@@	O	-1	17343925
z	O	-1	17343925
was	O	-1	17343925
significantly	O	-1	17343925
lower	O	-1	17343925
than	O	-1	17343925
in	O	-1	17343925
non-@@	O	-1	17343925
exposed	O	-1	17343925
ne@@	O	-1	17343925
on@@	O	-1	17343925
at@@	O	-1	17343925
es.	O	-1	17343925
Com@@	O	-1	17343925
par@@	O	-1	17343925
is@@	O	-1	17343925
ons	O	-1	17343925
between	O	-1	17343925
exposed	O	-1	17343925
ne@@	O	-1	17343925
w@@	O	-1	17343925
b@@	O	-1	17343925
or@@	O	-1	17343925
n@@	O	-1	17343925
s@@	O	-1	17343925
'	O	-1	17343925
sub@@	O	-1	17343925
groups	O	-1	17343925
revealed	O	-1	17343925
no	O	-1	17343925
significant	O	-1	17343925
differen@@	O	-1	17343925
c@@	O	-1	17343925
es.	O	-1	17343925
However,	O	-1	17343925
by	O	-1	17343925
compar@@	O	-1	17343925
ing	O	-1	17343925
each	O	-1	17343925
sub@@	O	-1	17343925
group	O	-1	17343925
to	O	-1	17343925
control	O	-1	17343925
group@@	O	-1	17343925
,	O	-1	17343925
we	O	-1	17343925
found	O	-1	17343925
statis@@	O	-1	17343925
tically	O	-1	17343925
significant	O	-1	17343925
decreas@@	B-Disease	-1	17343925
es	I-Disease	-1	17343925
of	I-Disease	-1	17343925
TE@@	I-Disease	-1	17343925
O@@	I-Disease	-1	17343925
A@@	I-Disease	-1	17343925
E@@	I-Disease	-1	17343925
s	I-Disease	-1	17343925
am@@	I-Disease	-1	17343925
pl@@	I-Disease	-1	17343925
it@@	I-Disease	-1	17343925
u@@	I-Disease	-1	17343925
des	I-Disease	-1	17343925
at	O	-1	17343925
4@@	O	-1	17343925
0@@	O	-1	17343925
0@@	O	-1	17343925
0@@	O	-1	17343925
H@@	O	-1	17343925
z	O	-1	17343925
for	O	-1	17343925
all	O	-1	17343925
three	O	-1	17343925
groups.	O	-1	17343925
M@@	O	-1	17343925
e@@	O	-1	17343925
an	O	-1	17343925
TE@@	O	-1	17343925
O@@	O	-1	17343925
A@@	O	-1	17343925
E@@	O	-1	17343925
s	O	-1	17343925
responses	O	-1	17343925
of	O	-1	17343925
high@@	O	-1	17343925
ly	O	-1	17343925
exposed	O	-1	17343925
ne@@	O	-1	17343925
w@@	O	-1	17343925
b@@	O	-1	17343925
or@@	O	-1	17343925
n@@	O	-1	17343925
s	O	-1	17343925
were	O	-1	17343925
also	O	-1	17343925
significantly	O	-1	17343925
lower	O	-1	17343925
in	O	-1	17343925
compar@@	O	-1	17343925
ison	O	-1	17343925
to	O	-1	17343925
our	O	-1	17343925
control	O	-1	17343925
group.	O	-1	17343925
CONCLUSION:	O	-1	17343925
In	O	-1	17343925
u@@	O	-1	17343925
ter@@	O	-1	17343925
o@@	O	-1	17343925
,	O	-1	17343925
exposure	O	-1	17343925
to	O	-1	17343925
to@@	O	-1	17343925
bac@@	O	-1	17343925
c@@	O	-1	17343925
o	O	-1	17343925
smo@@	B-Chemical	D012906	17343925
king	I-Chemical	-1	17343925
se@@	O	-1	17343925
em@@	O	-1	17343925
s	O	-1	17343925
to	O	-1	17343925
have	O	-1	17343925
a	O	-1	17343925
sm@@	O	-1	17343925
all	O	-1	17343925
im@@	O	-1	17343925
pac@@	O	-1	17343925
t	O	-1	17343925
on	O	-1	17343925
ou@@	O	-1	17343925
ter	O	-1	17343925
ha@@	O	-1	17343925
ir	O	-1	17343925
cell@@	O	-1	17343925
s.	O	-1	17343925
These	O	-1	17343925
effects	O	-1	17343925
se@@	O	-1	17343925
em	O	-1	17343925
to	O	-1	17343925
be	O	-1	17343925
equ@@	O	-1	17343925
ally	O	-1	17343925
t@@	O	-1	17343925
ru@@	O	-1	17343925
e	O	-1	17343925
for	O	-1	17343925
all	O	-1	17343925
exposed	O	-1	17343925
ne@@	O	-1	17343925
w@@	O	-1	17343925
b@@	O	-1	17343925
or@@	O	-1	17343925
n@@	O	-1	17343925
s,	O	-1	17343925
reg@@	O	-1	17343925
ar@@	O	-1	17343925
d@@	O	-1	17343925
less	O	-1	17343925
of	O	-1	17343925
the	O	-1	17343925
de@@	O	-1	17343925
g@@	O	-1	17343925
ree	O	-1	17343925
of	O	-1	17343925
expos@@	O	-1	17343925
ure.	O	-1	17343925
F@@	O	-1	17343925
urther	O	-1	17343925
studies	O	-1	17343925
are	O	-1	17343925
ne@@	O	-1	17343925
ed@@	O	-1	17343925
ed	O	-1	17343925
in	O	-1	17343925
or@@	O	-1	17343925
der	O	-1	17343925
to	O	-1	17343925
est@@	O	-1	17343925
abl@@	O	-1	17343925
is@@	O	-1	17343925
h	O	-1	17343925
a	O	-1	17343925
potential	O	-1	17343925
negative	O	-1	17343925
effect	O	-1	17343925
of	O	-1	17343925
mat@@	O	-1	17343925
er@@	O	-1	17343925
n@@	O	-1	17343925
al	O	-1	17343925
smo@@	B-Chemical	D012906	17343925
king	I-Chemical	-1	17343925
on	O	-1	17343925
the	O	-1	17343925
ne@@	O	-1	17343925
on@@	O	-1	17343925
ate@@	O	-1	17343925
's	O	-1	17343925
hearing	O	-1	17343925
ac@@	O	-1	17343925
u@@	O	-1	17343925
ity.	O	-1	17343925

Ne@@	B-Disease	D020078	17400887
uro@@	I-Disease	-1	17400887
inflam@@	I-Disease	-1	17400887
m@@	I-Disease	-1	17400887
ation	I-Disease	-1	17400887
and	O	-1	17400887
behavioral	B-Disease	D001523	17400887
abnormal@@	I-Disease	-1	17400887
ities	I-Disease	-1	17400887
after	O	-1	17400887
ne@@	O	-1	17400887
on@@	O	-1	17400887
atal	O	-1	17400887
ter@@	B-Chemical	D013726	17400887
but@@	I-Chemical	-1	17400887
aline	I-Chemical	-1	17400887
treatment	O	-1	17400887
in	O	-1	17400887
rat@@	O	-1	17400887
s:	O	-1	17400887
implic@@	O	-1	17400887
ations	O	-1	17400887
for	O	-1	17400887
au@@	B-Disease	D001321	17400887
tis@@	I-Disease	-1	17400887
m	I-Disease	-1	17400887
.	O	-1	17400887
A@@	B-Disease	D001321	17400887
u@@	I-Disease	-1	17400887
tis@@	I-Disease	-1	17400887
m	I-Disease	-1	17400887
is	O	-1	17400887
a	O	-1	17400887
neuro@@	B-Disease	D002658	17400887
develop@@	I-Disease	-1	17400887
mental	I-Disease	-1	17400887
disor@@	I-Disease	-1	17400887
der	I-Disease	-1	17400887
present@@	O	-1	17400887
ing	O	-1	17400887
before	O	-1	17400887
3	O	-1	17400887
years	O	-1	17400887
of	O	-1	17400887
age	O	-1	17400887
with	O	-1	17400887
defic@@	B-Disease	D003147	17400887
its	I-Disease	-1	17400887
in	I-Disease	-1	17400887
com@@	I-Disease	-1	17400887
mun@@	I-Disease	-1	17400887
ic@@	I-Disease	-1	17400887
ation	I-Disease	-1	17400887
and	I-Disease	-1	17400887
s@@	I-Disease	-1	17400887
oci@@	I-Disease	-1	17400887
al	I-Disease	-1	17400887
s@@	I-Disease	-1	17400887
k@@	I-Disease	-1	17400887
ill@@	I-Disease	-1	17400887
s	I-Disease	-1	17400887
and	O	-1	17400887
repe@@	B-Disease	D001523	17400887
ti@@	I-Disease	-1	17400887
tive	I-Disease	-1	17400887
behavi@@	I-Disease	-1	17400887
ors	I-Disease	-1	17400887
.	O	-1	17400887
In	O	-1	17400887
addition	O	-1	17400887
to	O	-1	17400887
gene@@	O	-1	17400887
tic	O	-1	17400887
influ@@	O	-1	17400887
enc@@	O	-1	17400887
es,	O	-1	17400887
rec@@	O	-1	17400887
ent	O	-1	17400887
studies	O	-1	17400887
suggest	O	-1	17400887
that	O	-1	17400887
p@@	O	-1	17400887
ren@@	O	-1	17400887
atal	O	-1	17400887
drug	O	-1	17400887
or	O	-1	17400887
chemical	O	-1	17400887
expos@@	O	-1	17400887
ures	O	-1	17400887
are	O	-1	17400887
risk	O	-1	17400887
factors	O	-1	17400887
for	O	-1	17400887
au@@	B-Disease	D001321	17400887
tis@@	I-Disease	-1	17400887
m	I-Disease	-1	17400887
.	O	-1	17400887
T@@	B-Chemical	D013726	17400887
er@@	I-Chemical	-1	17400887
but@@	I-Chemical	-1	17400887
aline	I-Chemical	-1	17400887
,	O	-1	17400887
a	O	-1	17400887
beta@@	O	-1	17400887
2-@@	O	-1	17400887
adren@@	O	-1	17400887
oc@@	O	-1	17400887
e@@	O	-1	17400887
pt@@	O	-1	17400887
or	O	-1	17400887
agon@@	O	-1	17400887
ist	O	-1	17400887
used	O	-1	17400887
to	O	-1	17400887
ar@@	O	-1	17400887
res@@	O	-1	17400887
t	O	-1	17400887
pre@@	B-Disease	D007752	17400887
term	I-Disease	-1	17400887
l@@	I-Disease	-1	17400887
ab@@	I-Disease	-1	17400887
or	I-Disease	-1	17400887
,	O	-1	17400887
has	O	-1	17400887
been	O	-1	17400887
associated	O	-1	17400887
with	O	-1	17400887
increased	O	-1	17400887
con@@	O	-1	17400887
cor@@	O	-1	17400887
d@@	O	-1	17400887
ance	O	-1	17400887
for	O	-1	17400887
au@@	B-Disease	D001321	17400887
tis@@	I-Disease	-1	17400887
m	I-Disease	-1	17400887
in	O	-1	17400887
di@@	O	-1	17400887
z@@	O	-1	17400887
y@@	O	-1	17400887
go@@	O	-1	17400887
tic	O	-1	17400887
tw@@	O	-1	17400887
in@@	O	-1	17400887
s.	O	-1	17400887
We	O	-1	17400887
studied	O	-1	17400887
the	O	-1	17400887
effects	O	-1	17400887
of	O	-1	17400887
ter@@	B-Chemical	D013726	17400887
but@@	I-Chemical	-1	17400887
aline	I-Chemical	-1	17400887
on	O	-1	17400887
micro@@	O	-1	17400887
g@@	O	-1	17400887
lial	O	-1	17400887
activation	O	-1	17400887
in	O	-1	17400887
different	O	-1	17400887
brain	O	-1	17400887
regi@@	O	-1	17400887
ons	O	-1	17400887
and	O	-1	17400887
behavioral	O	-1	17400887
outcom@@	O	-1	17400887
es	O	-1	17400887
in	O	-1	17400887
develop@@	O	-1	17400887
ing	O	-1	17400887
rats.	O	-1	17400887
Ne@@	O	-1	17400887
w@@	O	-1	17400887
b@@	O	-1	17400887
or@@	O	-1	17400887
n	O	-1	17400887
rats	O	-1	17400887
were	O	-1	17400887
given	O	-1	17400887
ter@@	B-Chemical	D013726	17400887
but@@	I-Chemical	-1	17400887
aline	I-Chemical	-1	17400887
(10	O	-1	17400887
mg/kg)	O	-1	17400887
daily	O	-1	17400887
on	O	-1	17400887
post@@	O	-1	17400887
n@@	O	-1	17400887
atal	O	-1	17400887
days	O	-1	17400887
(P@@	O	-1	17400887
N@@	O	-1	17400887
)	O	-1	17400887
2	O	-1	17400887
to	O	-1	17400887
5	O	-1	17400887
or	O	-1	17400887
P@@	O	-1	17400887
N	O	-1	17400887
11	O	-1	17400887
to	O	-1	17400887
14	O	-1	17400887
and	O	-1	17400887
examined	O	-1	17400887
24	O	-1	17400887
h	O	-1	17400887
after	O	-1	17400887
the	O	-1	17400887
las@@	O	-1	17400887
t	O	-1	17400887
dose	O	-1	17400887
and	O	-1	17400887
at	O	-1	17400887
P@@	O	-1	17400887
N	O	-1	17400887
3@@	O	-1	17400887
0@@	O	-1	17400887
.	O	-1	17400887
Im@@	O	-1	17400887
mun@@	O	-1	17400887
o@@	O	-1	17400887
histo@@	O	-1	17400887
chemical	O	-1	17400887
studies	O	-1	17400887
showed	O	-1	17400887
that	O	-1	17400887
administration	O	-1	17400887
of	O	-1	17400887
ter@@	B-Chemical	D013726	17400887
but@@	I-Chemical	-1	17400887
aline	I-Chemical	-1	17400887
on	O	-1	17400887
P@@	O	-1	17400887
N	O	-1	17400887
2	O	-1	17400887
to	O	-1	17400887
5	O	-1	17400887
produced	O	-1	17400887
a	O	-1	17400887
ro@@	O	-1	17400887
b@@	O	-1	17400887
us@@	O	-1	17400887
t	O	-1	17400887
increase	O	-1	17400887
in	O	-1	17400887
micro@@	O	-1	17400887
g@@	O	-1	17400887
lial	O	-1	17400887
activation	O	-1	17400887
on	O	-1	17400887
P@@	O	-1	17400887
N	O	-1	17400887
30	O	-1	17400887
in	O	-1	17400887
the	O	-1	17400887
cerebral	O	-1	17400887
cor@@	O	-1	17400887
t@@	O	-1	17400887
ex@@	O	-1	17400887
,	O	-1	17400887
as	O	-1	17400887
well	O	-1	17400887
as	O	-1	17400887
in	O	-1	17400887
ce@@	O	-1	17400887
re@@	O	-1	17400887
bell@@	O	-1	17400887
ar	O	-1	17400887
and	O	-1	17400887
ce@@	O	-1	17400887
reb@@	O	-1	17400887
ro@@	O	-1	17400887
cor@@	O	-1	17400887
tical	O	-1	17400887
wh@@	O	-1	17400887
ite	O	-1	17400887
mat@@	O	-1	17400887
ter@@	O	-1	17400887
.	O	-1	17400887
N@@	O	-1	17400887
one	O	-1	17400887
of	O	-1	17400887
these	O	-1	17400887
effects	O	-1	17400887
occurred	O	-1	17400887
in	O	-1	17400887
animals	O	-1	17400887
given	O	-1	17400887
ter@@	B-Chemical	D013726	17400887
but@@	I-Chemical	-1	17400887
aline	I-Chemical	-1	17400887
on	O	-1	17400887
P@@	O	-1	17400887
N	O	-1	17400887
11	O	-1	17400887
to	O	-1	17400887
14@@	O	-1	17400887
.	O	-1	17400887
In	O	-1	17400887
behavioral	O	-1	17400887
test@@	O	-1	17400887
s,	O	-1	17400887
animals	O	-1	17400887
treated	O	-1	17400887
with	O	-1	17400887
ter@@	B-Chemical	D013726	17400887
but@@	I-Chemical	-1	17400887
aline	I-Chemical	-1	17400887
on	O	-1	17400887
P@@	O	-1	17400887
N	O	-1	17400887
2	O	-1	17400887
to	O	-1	17400887
5	O	-1	17400887
showed	O	-1	17400887
consist@@	O	-1	17400887
ent	O	-1	17400887
pat@@	O	-1	17400887
tern@@	O	-1	17400887
s	O	-1	17400887
of	O	-1	17400887
hyper@@	O	-1	17400887
-@@	O	-1	17400887
re@@	O	-1	17400887
activity	O	-1	17400887
to	O	-1	17400887
no@@	O	-1	17400887
vel@@	O	-1	17400887
t@@	O	-1	17400887
y	O	-1	17400887
and	O	-1	17400887
aver@@	O	-1	17400887
sive	O	-1	17400887
stimul@@	O	-1	17400887
i	O	-1	17400887
when	O	-1	17400887
assessed	O	-1	17400887
in	O	-1	17400887
a	O	-1	17400887
novel	O	-1	17400887
op@@	O	-1	17400887
en	O	-1	17400887
fi@@	O	-1	17400887
el@@	O	-1	17400887
d,	O	-1	17400887
as	O	-1	17400887
well	O	-1	17400887
as	O	-1	17400887
in	O	-1	17400887
the	O	-1	17400887
ac@@	O	-1	17400887
ous@@	O	-1	17400887
tic	O	-1	17400887
star@@	O	-1	17400887
t@@	O	-1	17400887
le	O	-1	17400887
response	O	-1	17400887
test@@	O	-1	17400887
.	O	-1	17400887
Our	O	-1	17400887
findings	O	-1	17400887
indicate	O	-1	17400887
that	O	-1	17400887
beta@@	O	-1	17400887
2-@@	O	-1	17400887
adren@@	O	-1	17400887
oc@@	O	-1	17400887
e@@	O	-1	17400887
pt@@	O	-1	17400887
or	O	-1	17400887
over@@	O	-1	17400887
stimulation	O	-1	17400887
during	O	-1	17400887
an	O	-1	17400887
early	O	-1	17400887
cri@@	O	-1	17400887
tical	O	-1	17400887
period	O	-1	17400887
results	O	-1	17400887
in	O	-1	17400887
micro@@	O	-1	17400887
g@@	O	-1	17400887
lial	O	-1	17400887
activation	O	-1	17400887
associated	O	-1	17400887
with	O	-1	17400887
in@@	O	-1	17400887
n@@	O	-1	17400887
ate	O	-1	17400887
neuro@@	O	-1	17400887
inflam@@	O	-1	17400887
mat@@	O	-1	17400887
ory	O	-1	17400887
path@@	O	-1	17400887
w@@	O	-1	17400887
ays	O	-1	17400887
and	O	-1	17400887
behavioral	B-Disease	D001523	17400887
abnormal@@	I-Disease	-1	17400887
ities	I-Disease	-1	17400887
,	O	-1	17400887
similar	O	-1	17400887
to	O	-1	17400887
those	O	-1	17400887
descri@@	O	-1	17400887
bed	O	-1	17400887
in	O	-1	17400887
au@@	B-Disease	D001321	17400887
tis@@	I-Disease	-1	17400887
m	I-Disease	-1	17400887
.	O	-1	17400887
This	O	-1	17400887
study	O	-1	17400887
pro@@	O	-1	17400887
vi@@	O	-1	17400887
des	O	-1	17400887
a	O	-1	17400887
use@@	O	-1	17400887
ful	O	-1	17400887
anim@@	O	-1	17400887
al	O	-1	17400887
model	O	-1	17400887
for	O	-1	17400887
under@@	O	-1	17400887
stand@@	O	-1	17400887
ing	O	-1	17400887
the	O	-1	17400887
neuro@@	O	-1	17400887
path@@	O	-1	17400887
ological	O	-1	17400887
pro@@	O	-1	17400887
ces@@	O	-1	17400887
ses	O	-1	17400887
underlying	O	-1	17400887
au@@	B-Disease	D002659	17400887
tis@@	I-Disease	-1	17400887
m	I-Disease	-1	17400887
sp@@	I-Disease	-1	17400887
ect@@	I-Disease	-1	17400887
ru@@	I-Disease	-1	17400887
m	I-Disease	-1	17400887
disorder@@	I-Disease	-1	17400887
s	I-Disease	-1	17400887
.	O	-1	17400887

Ac@@	O	-1	17612891
ute	O	-1	17612891
myocardi@@	B-Disease	D009205	17612891
tis	I-Disease	-1	17612891
associated	O	-1	17612891
with	O	-1	17612891
cloz@@	B-Chemical	D003024	17612891
apine	I-Chemical	-1	17612891
.	O	-1	17612891
OBJECTIVE:	O	-1	17612891
A	O	-1	17612891
case	O	-1	17612891
of	O	-1	17612891
acute	O	-1	17612891
myocardi@@	B-Disease	D009205	17612891
tis	I-Disease	-1	17612891
associated	O	-1	17612891
with	O	-1	17612891
the	O	-1	17612891
comm@@	O	-1	17612891
ence@@	O	-1	17612891
ment	O	-1	17612891
of	O	-1	17612891
cloz@@	B-Chemical	D003024	17612891
apine	I-Chemical	-1	17612891
is	O	-1	17612891
descri@@	O	-1	17612891
be@@	O	-1	17612891
d,	O	-1	17612891
high@@	O	-1	17612891
li@@	O	-1	17612891
gh@@	O	-1	17612891
ting	O	-1	17612891
the	O	-1	17612891
on@@	O	-1	17612891
se@@	O	-1	17612891
t,	O	-1	17612891
course	O	-1	17612891
and	O	-1	17612891
possible	O	-1	17612891
cont@@	O	-1	17612891
ri@@	O	-1	17612891
but@@	O	-1	17612891
ing	O	-1	17612891
fact@@	O	-1	17612891
or@@	O	-1	17612891
s.	O	-1	17612891
There	O	-1	17612891
is	O	-1	17612891
an	O	-1	17612891
ur@@	O	-1	17612891
g@@	O	-1	17612891
ent	O	-1	17612891
need	O	-1	17612891
to	O	-1	17612891
ra@@	O	-1	17612891
is@@	O	-1	17612891
e	O	-1	17612891
aw@@	O	-1	17612891
a@@	O	-1	17612891
ren@@	O	-1	17612891
ess	O	-1	17612891
about	O	-1	17612891
this	O	-1	17612891
potenti@@	O	-1	17612891
ally	O	-1	17612891
f@@	O	-1	17612891
atal	O	-1	17612891
complication	O	-1	17612891
of	O	-1	17612891
cloz@@	B-Chemical	D003024	17612891
apine	I-Chemical	-1	17612891
use.	O	-1	17612891
RESULTS:	O	-1	17612891
A	O	-1	17612891
20@@	O	-1	17612891
-@@	O	-1	17612891
year-old	O	-1	17612891
male	O	-1	17612891
with	O	-1	17612891
sch@@	B-Disease	D012559	17612891
iz@@	I-Disease	-1	17612891
oph@@	I-Disease	-1	17612891
ren@@	I-Disease	-1	17612891
ia	I-Disease	-1	17612891
developed	O	-1	17612891
a	O	-1	17612891
su@@	O	-1	17612891
d@@	O	-1	17612891
de@@	O	-1	17612891
n	O	-1	17612891
onset	O	-1	17612891
of	O	-1	17612891
myocardi@@	B-Disease	D009205	17612891
tis	I-Disease	-1	17612891
after	O	-1	17612891
comm@@	O	-1	17612891
ence@@	O	-1	17612891
ment	O	-1	17612891
of	O	-1	17612891
cloz@@	B-Chemical	D003024	17612891
apine	I-Chemical	-1	17612891
.	O	-1	17612891
The	O	-1	17612891
patient	O	-1	17612891
reco@@	O	-1	17612891
vered	O	-1	17612891
with	O	-1	17612891
int@@	O	-1	17612891
en@@	O	-1	17612891
sive	O	-1	17612891
med@@	O	-1	17612891
ical	O	-1	17612891
sup@@	O	-1	17612891
port@@	O	-1	17612891
.	O	-1	17612891
The	O	-1	17612891
symptoms	O	-1	17612891
occurred	O	-1	17612891
a@@	O	-1	17612891
ro@@	O	-1	17612891
un@@	O	-1	17612891
d	O	-1	17612891
2	O	-1	17612891
weeks	O	-1	17612891
after	O	-1	17612891
star@@	O	-1	17612891
ting	O	-1	17612891
cloz@@	B-Chemical	D003024	17612891
apine	I-Chemical	-1	17612891
in	O	-1	17612891
an	O	-1	17612891
in@@	O	-1	17612891
patient	O	-1	17612891
se@@	O	-1	17612891
t@@	O	-1	17612891
t@@	O	-1	17612891
ing.	O	-1	17612891
P@@	O	-1	17612891
os@@	O	-1	17612891
sible	O	-1	17612891
cont@@	O	-1	17612891
ri@@	O	-1	17612891
but@@	O	-1	17612891
ing	O	-1	17612891
factors	O	-1	17612891
may	O	-1	17612891
have	O	-1	17612891
been	O	-1	17612891
concomit@@	O	-1	17612891
ant	O	-1	17612891
antidepress@@	B-Chemical	D000928	17612891
ant	I-Chemical	-1	17612891
use	O	-1	17612891
and	O	-1	17612891
un@@	O	-1	17612891
ac@@	O	-1	17612891
c@@	O	-1	17612891
ust@@	O	-1	17612891
om@@	O	-1	17612891
ed	O	-1	17612891
physi@@	O	-1	17612891
c@@	O	-1	17612891
al	O	-1	17612891
activ@@	O	-1	17612891
ity.	O	-1	17612891
CONCLUSIONS:	O	-1	17612891
M@@	B-Disease	D009205	17612891
y@@	I-Disease	-1	17612891
ocardi@@	I-Disease	-1	17612891
tis	I-Disease	-1	17612891
is	O	-1	17612891
an	O	-1	17612891
increas@@	O	-1	17612891
ing@@	O	-1	17612891
ly	O	-1	17612891
reco@@	O	-1	17612891
gn@@	O	-1	17612891
ized	O	-1	17612891
complication	O	-1	17612891
associated	O	-1	17612891
with	O	-1	17612891
the	O	-1	17612891
use	O	-1	17612891
of	O	-1	17612891
cloz@@	B-Chemical	D003024	17612891
apine	I-Chemical	-1	17612891
.	O	-1	17612891
It	O	-1	17612891
can	O	-1	17612891
be	O	-1	17612891
f@@	O	-1	17612891
atal	O	-1	17612891
if	O	-1	17612891
not	O	-1	17612891
reco@@	O	-1	17612891
gn@@	O	-1	17612891
ized	O	-1	17612891
and	O	-1	17612891
treated	O	-1	17612891
ear@@	O	-1	17612891
ly.	O	-1	17612891
Con@@	O	-1	17612891
si@@	O	-1	17612891
der@@	O	-1	17612891
ing	O	-1	17612891
that	O	-1	17612891
cloz@@	B-Chemical	D003024	17612891
apine	I-Chemical	-1	17612891
remain@@	O	-1	17612891
s	O	-1	17612891
the	O	-1	17612891
g@@	O	-1	17612891
old	O	-1	17612891
standard	O	-1	17612891
in	O	-1	17612891
treatment	O	-1	17612891
of	O	-1	17612891
resist@@	O	-1	17612891
ant	O	-1	17612891
psycho@@	B-Disease	D011618	17612891
sis	I-Disease	-1	17612891
,	O	-1	17612891
there	O	-1	17612891
is	O	-1	17612891
an	O	-1	17612891
ur@@	O	-1	17612891
g@@	O	-1	17612891
ent	O	-1	17612891
need	O	-1	17612891
to	O	-1	17612891
ra@@	O	-1	17612891
is@@	O	-1	17612891
e	O	-1	17612891
aw@@	O	-1	17612891
a@@	O	-1	17612891
ren@@	O	-1	17612891
ess	O	-1	17612891
among	O	-1	17612891
med@@	O	-1	17612891
ical	O	-1	17612891
and	O	-1	17612891
par@@	O	-1	17612891
am@@	O	-1	17612891
ed@@	O	-1	17612891
ical	O	-1	17612891
st@@	O	-1	17612891
af@@	O	-1	17612891
f	O	-1	17612891
involved	O	-1	17612891
in	O	-1	17612891
the	O	-1	17612891
car@@	O	-1	17612891
e	O	-1	17612891
of	O	-1	17612891
these	O	-1	17612891
patients.	O	-1	17612891
There	O	-1	17612891
are	O	-1	17612891
also	O	-1	17612891
implic@@	O	-1	17612891
ations	O	-1	17612891
for	O	-1	17612891
recomm@@	O	-1	17612891
en@@	O	-1	17612891
d@@	O	-1	17612891
ations	O	-1	17612891
and	O	-1	17612891
reg@@	O	-1	17612891
ul@@	O	-1	17612891
ations	O	-1	17612891
reg@@	O	-1	17612891
ar@@	O	-1	17612891
ding	O	-1	17612891
the	O	-1	17612891
use	O	-1	17612891
of	O	-1	17612891
cloz@@	B-Chemical	D003024	17612891
apine	I-Chemical	-1	17612891
.	O	-1	17612891

E@@	B-Disease	D001927	18081909
n@@	I-Disease	-1	18081909
ce@@	I-Disease	-1	18081909
ph@@	I-Disease	-1	18081909
alo@@	I-Disease	-1	18081909
pathy	I-Disease	-1	18081909
induced	O	-1	18081909
by	O	-1	18081909
le@@	B-Chemical	C026098	18081909
ve@@	I-Chemical	-1	18081909
ti@@	I-Chemical	-1	18081909
rac@@	I-Chemical	-1	18081909
et@@	I-Chemical	-1	18081909
am	I-Chemical	-1	18081909
ad@@	O	-1	18081909
ded	O	-1	18081909
to	O	-1	18081909
valpro@@	B-Chemical	D014635	18081909
ate	I-Chemical	-1	18081909
.	O	-1	18081909
BACKGROUND:	O	-1	18081909
We	O	-1	18081909
report	O	-1	18081909
on	O	-1	18081909
the	O	-1	18081909
man@@	O	-1	18081909
if@@	O	-1	18081909
est@@	O	-1	18081909
ation	O	-1	18081909
of	O	-1	18081909
a	O	-1	18081909
le@@	B-Chemical	C026098	18081909
ve@@	I-Chemical	-1	18081909
ti@@	I-Chemical	-1	18081909
rac@@	I-Chemical	-1	18081909
et@@	I-Chemical	-1	18081909
am	I-Chemical	-1	18081909
(	O	-1	18081909
L@@	B-Chemical	C026098	18081909
E@@	I-Chemical	-1	18081909
V	I-Chemical	-1	18081909
)@@	O	-1	18081909
-induced	O	-1	18081909
encephalo@@	B-Disease	D001927	18081909
pathy	I-Disease	-1	18081909
.	O	-1	18081909
F@@	O	-1	18081909
IN@@	O	-1	18081909
D@@	O	-1	18081909
IN@@	O	-1	18081909
G@@	O	-1	18081909
S:	O	-1	18081909
A	O	-1	18081909
2@@	O	-1	18081909
8@@	O	-1	18081909
-@@	O	-1	18081909
year-old	O	-1	18081909
man	O	-1	18081909
suff@@	O	-1	18081909
ering	O	-1	18081909
from	O	-1	18081909
i@@	B-Disease	C562694	18081909
di@@	I-Disease	-1	18081909
o@@	I-Disease	-1	18081909
path@@	I-Disease	-1	18081909
ic	I-Disease	-1	18081909
epilep@@	I-Disease	-1	18081909
sy	I-Disease	-1	18081909
with	O	-1	18081909
gener@@	O	-1	18081909
al@@	O	-1	18081909
ized	O	-1	18081909
seizures	B-Disease	D012640	18081909
was	O	-1	18081909
treated	O	-1	18081909
with	O	-1	18081909
L@@	B-Chemical	C026098	18081909
E@@	I-Chemical	-1	18081909
V	I-Chemical	-1	18081909
(3@@	O	-1	18081909
0@@	O	-1	18081909
00	O	-1	18081909
mg@@	O	-1	18081909
)	O	-1	18081909
ad@@	O	-1	18081909
ded	O	-1	18081909
to	O	-1	18081909
valpro@@	B-Chemical	D014635	18081909
ate	I-Chemical	-1	18081909
(	O	-1	18081909
V@@	B-Chemical	D014635	18081909
P@@	I-Chemical	-1	18081909
A	I-Chemical	-1	18081909
)	O	-1	18081909
(2@@	O	-1	18081909
0@@	O	-1	18081909
00	O	-1	18081909
mg@@	O	-1	18081909
).	O	-1	18081909
F@@	O	-1	18081909
requ@@	O	-1	18081909
ency	O	-1	18081909
of	O	-1	18081909
gener@@	O	-1	18081909
al@@	O	-1	18081909
ized	O	-1	18081909
t@@	B-Disease	D004830	18081909
on@@	I-Disease	-1	18081909
ic@@	I-Disease	-1	18081909
-@@	I-Disease	-1	18081909
clon@@	I-Disease	-1	18081909
ic	I-Disease	-1	18081909
seizures	I-Disease	-1	18081909
increased	O	-1	18081909
from	O	-1	18081909
one	O	-1	18081909
per	O	-1	18081909
6	O	-1	18081909
months	O	-1	18081909
to	O	-1	18081909
two	O	-1	18081909
per	O	-1	18081909
month@@	O	-1	18081909
.	O	-1	18081909
Ne@@	O	-1	18081909
uro@@	O	-1	18081909
psych@@	O	-1	18081909
ological	O	-1	18081909
test@@	O	-1	18081909
ing	O	-1	18081909
showed	O	-1	18081909
impaired	B-Disease	D008569	18081909
wor@@	I-Disease	-1	18081909
d	I-Disease	-1	18081909
flu@@	I-Disease	-1	18081909
enc@@	I-Disease	-1	18081909
y,	I-Disease	-1	18081909
psych@@	I-Disease	-1	18081909
om@@	I-Disease	-1	18081909
otor	I-Disease	-1	18081909
sp@@	I-Disease	-1	18081909
e@@	I-Disease	-1	18081909
ed	I-Disease	-1	18081909
and	I-Disease	-1	18081909
wor@@	I-Disease	-1	18081909
king	I-Disease	-1	18081909
memory	I-Disease	-1	18081909
.	O	-1	18081909
The	O	-1	18081909
inter@@	O	-1	18081909
ic@@	O	-1	18081909
t@@	O	-1	18081909
al	O	-1	18081909
electro@@	O	-1	18081909
encephalo@@	O	-1	18081909
gra@@	O	-1	18081909
m	O	-1	18081909
(@@	O	-1	18081909
E@@	O	-1	18081909
E@@	O	-1	18081909
G@@	O	-1	18081909
)	O	-1	18081909
showed	O	-1	18081909
a	O	-1	18081909
gener@@	O	-1	18081909
al@@	O	-1	18081909
ized	O	-1	18081909
s@@	O	-1	18081909
low@@	O	-1	18081909
ing	O	-1	18081909
to	O	-1	18081909
5	O	-1	18081909
per	O	-1	18081909
second	O	-1	18081909
the@@	O	-1	18081909
t@@	O	-1	18081909
a	O	-1	18081909
rhyth@@	O	-1	18081909
ms	O	-1	18081909
with	O	-1	18081909
bil@@	O	-1	18081909
ateral	O	-1	18081909
gener@@	O	-1	18081909
al@@	O	-1	18081909
ized	O	-1	18081909
high-@@	O	-1	18081909
am@@	O	-1	18081909
pl@@	O	-1	18081909
it@@	O	-1	18081909
ude	O	-1	18081909
dis@@	O	-1	18081909
ch@@	O	-1	18081909
arg@@	O	-1	18081909
es.	O	-1	18081909
O@@	O	-1	18081909
U@@	O	-1	18081909
T@@	O	-1	18081909
CO@@	O	-1	18081909
M@@	O	-1	18081909
E:	O	-1	18081909
F@@	O	-1	18081909
ol@@	O	-1	18081909
low@@	O	-1	18081909
ing	O	-1	18081909
discontinu@@	O	-1	18081909
ation	O	-1	18081909
of	O	-1	18081909
L@@	B-Chemical	C026098	18081909
E@@	I-Chemical	-1	18081909
V	I-Chemical	-1	18081909
,	O	-1	18081909
E@@	O	-1	18081909
E@@	O	-1	18081909
G	O	-1	18081909
and	O	-1	18081909
neuro@@	O	-1	18081909
psych@@	O	-1	18081909
ological	O	-1	18081909
findings	O	-1	18081909
improved	O	-1	18081909
and	O	-1	18081909
seizure	B-Disease	D012640	18081909
frequency	O	-1	18081909
decreas@@	O	-1	18081909
ed.	O	-1	18081909

N@@	B-Chemical	D009638	18083142
ore@@	I-Chemical	-1	18083142
p@@	I-Chemical	-1	18083142
ine@@	I-Chemical	-1	18083142
phrine	I-Chemical	-1	18083142
sign@@	O	-1	18083142
al@@	O	-1	18083142
ing	O	-1	18083142
through	O	-1	18083142
beta-@@	O	-1	18083142
adrenergic	O	-1	18083142
receptors	O	-1	18083142
is	O	-1	18083142
cri@@	O	-1	18083142
tical	O	-1	18083142
for	O	-1	18083142
expression	O	-1	18083142
of	O	-1	18083142
cocaine	B-Chemical	D003042	18083142
-induced	O	-1	18083142
an@@	B-Disease	D001008	18083142
xi@@	I-Disease	-1	18083142
ety	I-Disease	-1	18083142
.	O	-1	18083142
BACKGROUND:	O	-1	18083142
C@@	B-Chemical	D003042	18083142
oc@@	I-Chemical	-1	18083142
aine	I-Chemical	-1	18083142
is	O	-1	18083142
a	O	-1	18083142
wi@@	O	-1	18083142
de@@	O	-1	18083142
ly	O	-1	18083142
ab@@	O	-1	18083142
used	O	-1	18083142
psych@@	O	-1	18083142
os@@	O	-1	18083142
tim@@	O	-1	18083142
ul@@	O	-1	18083142
ant	O	-1	18083142
that	O	-1	18083142
has	O	-1	18083142
both	O	-1	18083142
re@@	O	-1	18083142
war@@	O	-1	18083142
ding	O	-1	18083142
and	O	-1	18083142
aver@@	O	-1	18083142
sive	O	-1	18083142
pro@@	O	-1	18083142
per@@	O	-1	18083142
ti@@	O	-1	18083142
es.	O	-1	18083142
W@@	O	-1	18083142
h@@	O	-1	18083142
ile	O	-1	18083142
the	O	-1	18083142
mechanisms	O	-1	18083142
underlying	O	-1	18083142
cocaine	B-Chemical	D003042	18083142
's	O	-1	18083142
re@@	O	-1	18083142
war@@	O	-1	18083142
ding	O	-1	18083142
effects	O	-1	18083142
have	O	-1	18083142
been	O	-1	18083142
studied	O	-1	18083142
exten@@	O	-1	18083142
si@@	O	-1	18083142
vel@@	O	-1	18083142
y,	O	-1	18083142
less	O	-1	18083142
atten@@	O	-1	18083142
tion	O	-1	18083142
has	O	-1	18083142
been	O	-1	18083142
pa@@	O	-1	18083142
id	O	-1	18083142
to	O	-1	18083142
the	O	-1	18083142
un@@	O	-1	18083142
ple@@	O	-1	18083142
as@@	O	-1	18083142
ant	O	-1	18083142
behavioral	O	-1	18083142
st@@	O	-1	18083142
ates	O	-1	18083142
induced	O	-1	18083142
by	O	-1	18083142
cocaine	B-Chemical	D003042	18083142
,	O	-1	18083142
such	O	-1	18083142
as	O	-1	18083142
an@@	B-Disease	D001008	18083142
xi@@	I-Disease	-1	18083142
ety	I-Disease	-1	18083142
.	O	-1	18083142
METHODS:	O	-1	18083142
In	O	-1	18083142
this	O	-1	18083142
study,	O	-1	18083142
we	O	-1	18083142
evaluated	O	-1	18083142
the	O	-1	18083142
perform@@	O	-1	18083142
ance	O	-1	18083142
of	O	-1	18083142
dopamine	B-Chemical	D004298	18083142
beta-@@	O	-1	18083142
hydrox@@	O	-1	18083142
yl@@	O	-1	18083142
ase	O	-1	18083142
k@@	O	-1	18083142
n@@	O	-1	18083142
oc@@	O	-1	18083142
k@@	O	-1	18083142
out	O	-1	18083142
(D@@	O	-1	18083142
b@@	O	-1	18083142
h	O	-1	18083142
-@@	O	-1	18083142
/@@	O	-1	18083142
-@@	O	-1	18083142
)	O	-1	18083142
mic@@	O	-1	18083142
e,	O	-1	18083142
which	O	-1	18083142
l@@	O	-1	18083142
ac@@	O	-1	18083142
k	O	-1	18083142
no@@	B-Chemical	D009638	18083142
re@@	I-Chemical	-1	18083142
p@@	I-Chemical	-1	18083142
ine@@	I-Chemical	-1	18083142
phrine	I-Chemical	-1	18083142
(	O	-1	18083142
N@@	B-Chemical	D009638	18083142
E	I-Chemical	-1	18083142
),	O	-1	18083142
in	O	-1	18083142
the	O	-1	18083142
elevated	O	-1	18083142
plus	O	-1	18083142
ma@@	O	-1	18083142
ze	O	-1	18083142
(@@	O	-1	18083142
EP@@	O	-1	18083142
M@@	O	-1	18083142
)	O	-1	18083142
to	O	-1	18083142
ex@@	O	-1	18083142
amine	O	-1	18083142
the	O	-1	18083142
cont@@	O	-1	18083142
ri@@	O	-1	18083142
bu@@	O	-1	18083142
tion	O	-1	18083142
of	O	-1	18083142
nor@@	O	-1	18083142
adrenergic	O	-1	18083142
sign@@	O	-1	18083142
al@@	O	-1	18083142
ing	O	-1	18083142
to	O	-1	18083142
cocaine	B-Chemical	D003042	18083142
-induced	O	-1	18083142
an@@	B-Disease	D001008	18083142
xi@@	I-Disease	-1	18083142
ety	I-Disease	-1	18083142
.	O	-1	18083142
RESULTS:	O	-1	18083142
We	O	-1	18083142
found	O	-1	18083142
that	O	-1	18083142
cocaine	B-Chemical	D003042	18083142
dose-@@	O	-1	18083142
depend@@	O	-1	18083142
ently	O	-1	18083142
increased	O	-1	18083142
an@@	B-Disease	D001008	18083142
xi@@	I-Disease	-1	18083142
ety	I-Disease	-1	18083142
-@@	O	-1	18083142
like	O	-1	18083142
behavi@@	O	-1	18083142
or	O	-1	18083142
in	O	-1	18083142
control	O	-1	18083142
(D@@	O	-1	18083142
b@@	O	-1	18083142
h	O	-1	18083142
+/-@@	O	-1	18083142
)	O	-1	18083142
mic@@	O	-1	18083142
e,	O	-1	18083142
as	O	-1	18083142
measured	O	-1	18083142
by	O	-1	18083142
a	O	-1	18083142
decrease	O	-1	18083142
in	O	-1	18083142
op@@	O	-1	18083142
en	O	-1	18083142
ar@@	O	-1	18083142
m	O	-1	18083142
expl@@	O	-1	18083142
or@@	O	-1	18083142
ation.	O	-1	18083142
The	O	-1	18083142
D@@	O	-1	18083142
b@@	O	-1	18083142
h	O	-1	18083142
-@@	O	-1	18083142
/@@	O	-1	18083142
-	O	-1	18083142
mice	O	-1	18083142
had	O	-1	18083142
normal	O	-1	18083142
baseline	O	-1	18083142
perform@@	O	-1	18083142
ance	O	-1	18083142
in	O	-1	18083142
the	O	-1	18083142
EP@@	O	-1	18083142
M	O	-1	18083142
but	O	-1	18083142
were	O	-1	18083142
complete@@	O	-1	18083142
ly	O	-1	18083142
resist@@	O	-1	18083142
ant	O	-1	18083142
to	O	-1	18083142
the	O	-1	18083142
an@@	O	-1	18083142
x@@	O	-1	18083142
io@@	O	-1	18083142
genic	O	-1	18083142
effects	O	-1	18083142
of	O	-1	18083142
cocaine	B-Chemical	D003042	18083142
.	O	-1	18083142
C@@	B-Chemical	D003042	18083142
oc@@	I-Chemical	-1	18083142
aine	I-Chemical	-1	18083142
-induced	O	-1	18083142
an@@	B-Disease	D001008	18083142
xi@@	I-Disease	-1	18083142
ety	I-Disease	-1	18083142
was	O	-1	18083142
also	O	-1	18083142
attenu@@	O	-1	18083142
ated	O	-1	18083142
in	O	-1	18083142
D@@	O	-1	18083142
b@@	O	-1	18083142
h	O	-1	18083142
+/-	O	-1	18083142
mice	O	-1	18083142
following	O	-1	18083142
administration	O	-1	18083142
of	O	-1	18083142
dis@@	B-Chemical	D004221	18083142
ul@@	I-Chemical	-1	18083142
fi@@	I-Chemical	-1	18083142
ra@@	I-Chemical	-1	18083142
m	I-Chemical	-1	18083142
,	O	-1	18083142
a	O	-1	18083142
dopamine	B-Chemical	D004298	18083142
beta-@@	O	-1	18083142
hydrox@@	O	-1	18083142
yl@@	O	-1	18083142
ase	O	-1	18083142
(D@@	O	-1	18083142
B@@	O	-1	18083142
H@@	O	-1	18083142
)	O	-1	18083142
inhibitor@@	O	-1	18083142
.	O	-1	18083142
In	O	-1	18083142
experim@@	O	-1	18083142
ents	O	-1	18083142
using	O	-1	18083142
specific	O	-1	18083142
adrenergic	O	-1	18083142
antagonist@@	O	-1	18083142
s,	O	-1	18083142
we	O	-1	18083142
found	O	-1	18083142
that	O	-1	18083142
pretreatment	O	-1	18083142
with	O	-1	18083142
the	O	-1	18083142
beta-@@	O	-1	18083142
adrenergic	O	-1	18083142
receptor	O	-1	18083142
antagonist	O	-1	18083142
prop@@	B-Chemical	D011433	18083142
ran@@	I-Chemical	-1	18083142
o@@	I-Chemical	-1	18083142
lol	I-Chemical	-1	18083142
block@@	O	-1	18083142
ed	O	-1	18083142
cocaine	B-Chemical	D003042	18083142
-induced	O	-1	18083142
an@@	B-Disease	D001008	18083142
xi@@	I-Disease	-1	18083142
ety	I-Disease	-1	18083142
-@@	O	-1	18083142
like	O	-1	18083142
behavi@@	O	-1	18083142
or	O	-1	18083142
in	O	-1	18083142
D@@	O	-1	18083142
b@@	O	-1	18083142
h	O	-1	18083142
+/-	O	-1	18083142
and	O	-1	18083142
wil@@	O	-1	18083142
d-@@	O	-1	18083142
type	O	-1	18083142
C@@	O	-1	18083142
5@@	O	-1	18083142
7@@	O	-1	18083142
B@@	O	-1	18083142
L@@	O	-1	18083142
6@@	O	-1	18083142
/@@	O	-1	18083142
J	O	-1	18083142
mic@@	O	-1	18083142
e,	O	-1	18083142
while	O	-1	18083142
the	O	-1	18083142
alpha@@	O	-1	18083142
(1@@	O	-1	18083142
)	O	-1	18083142
antagonist	O	-1	18083142
praz@@	B-Chemical	D011224	18083142
os@@	I-Chemical	-1	18083142
in	I-Chemical	-1	18083142
and	O	-1	18083142
the	O	-1	18083142
alpha@@	O	-1	18083142
(2@@	O	-1	18083142
)	O	-1	18083142
antagonist	O	-1	18083142
yo@@	B-Chemical	D015016	18083142
h@@	I-Chemical	-1	18083142
im@@	I-Chemical	-1	18083142
b@@	I-Chemical	-1	18083142
ine	I-Chemical	-1	18083142
had	O	-1	18083142
no	O	-1	18083142
effect@@	O	-1	18083142
.	O	-1	18083142
CONCLUSIONS:	O	-1	18083142
These	O	-1	18083142
results	O	-1	18083142
indicate	O	-1	18083142
that	O	-1	18083142
nor@@	O	-1	18083142
adrenergic	O	-1	18083142
sign@@	O	-1	18083142
al@@	O	-1	18083142
ing	O	-1	18083142
vi@@	O	-1	18083142
a	O	-1	18083142
beta-@@	O	-1	18083142
adrenergic	O	-1	18083142
receptors	O	-1	18083142
is	O	-1	18083142
requ@@	O	-1	18083142
ired	O	-1	18083142
for	O	-1	18083142
cocaine	B-Chemical	D003042	18083142
-induced	O	-1	18083142
an@@	B-Disease	D001008	18083142
xi@@	I-Disease	-1	18083142
ety	I-Disease	-1	18083142
in	O	-1	18083142
mice.	O	-1	18083142

C@@	B-Chemical	D003000	18182964
lon@@	I-Chemical	-1	18182964
idine	I-Chemical	-1	18182964
for	O	-1	18182964
atten@@	B-Disease	D001289	18182964
tion@@	I-Disease	-1	18182964
-@@	I-Disease	-1	18182964
defic@@	I-Disease	-1	18182964
it@@	I-Disease	-1	18182964
/@@	I-Disease	-1	18182964
hyperactivity	I-Disease	-1	18182964
disor@@	I-Disease	-1	18182964
der	I-Disease	-1	18182964
:	O	-1	18182964
II@@	O	-1	18182964
.	O	-1	18182964
EC@@	O	-1	18182964
G	O	-1	18182964
changes	O	-1	18182964
and	O	-1	18182964
adverse	O	-1	18182964
events	O	-1	18182964
analy@@	O	-1	18182964
sis.	O	-1	18182964
OBJECTIVE:	O	-1	18182964
To	O	-1	18182964
ex@@	O	-1	18182964
amine	O	-1	18182964
the	O	-1	18182964
safety	O	-1	18182964
and	O	-1	18182964
toler@@	O	-1	18182964
ability	O	-1	18182964
of	O	-1	18182964
clonidine	B-Chemical	D003000	18182964
used	O	-1	18182964
alone	O	-1	18182964
or	O	-1	18182964
with	O	-1	18182964
methyl@@	B-Chemical	D008774	18182964
phen@@	I-Chemical	-1	18182964
id@@	I-Chemical	-1	18182964
ate	I-Chemical	-1	18182964
in	O	-1	18182964
children	O	-1	18182964
with	O	-1	18182964
atten@@	B-Disease	D001289	18182964
tion@@	I-Disease	-1	18182964
-@@	I-Disease	-1	18182964
defic@@	I-Disease	-1	18182964
it@@	I-Disease	-1	18182964
/@@	I-Disease	-1	18182964
hyperactivity	I-Disease	-1	18182964
disor@@	I-Disease	-1	18182964
der	I-Disease	-1	18182964
(	O	-1	18182964
AD@@	B-Disease	D001289	18182964
H@@	I-Disease	-1	18182964
D	I-Disease	-1	18182964
).	O	-1	18182964
METHOD@@	O	-1	18182964
:	O	-1	18182964
In	O	-1	18182964
a	O	-1	18182964
1@@	O	-1	18182964
6-@@	O	-1	18182964
week	O	-1	18182964
mul@@	O	-1	18182964
tic@@	O	-1	18182964
ent@@	O	-1	18182964
er,	O	-1	18182964
double-bl@@	O	-1	18182964
ind	O	-1	18182964
tri@@	O	-1	18182964
al,	O	-1	18182964
12@@	O	-1	18182964
2	O	-1	18182964
children	O	-1	18182964
with	O	-1	18182964
AD@@	B-Disease	D001289	18182964
H@@	I-Disease	-1	18182964
D	I-Disease	-1	18182964
were	O	-1	18182964
random@@	O	-1	18182964
ly	O	-1	18182964
as@@	O	-1	18182964
signed	O	-1	18182964
to	O	-1	18182964
clonidine	B-Chemical	D003000	18182964
(n	O	-1	18182964
=	O	-1	18182964
3@@	O	-1	18182964
1),	O	-1	18182964
methyl@@	B-Chemical	D008774	18182964
phen@@	I-Chemical	-1	18182964
id@@	I-Chemical	-1	18182964
ate	I-Chemical	-1	18182964
(n	O	-1	18182964
=	O	-1	18182964
2@@	O	-1	18182964
9@@	O	-1	18182964
),	O	-1	18182964
clonidine	B-Chemical	D003000	18182964
and	O	-1	18182964
methyl@@	B-Chemical	D008774	18182964
phen@@	I-Chemical	-1	18182964
id@@	I-Chemical	-1	18182964
ate	I-Chemical	-1	18182964
(n	O	-1	18182964
=	O	-1	18182964
3@@	O	-1	18182964
2@@	O	-1	18182964
),	O	-1	18182964
or	O	-1	18182964
placebo	O	-1	18182964
(n	O	-1	18182964
=	O	-1	18182964
3@@	O	-1	18182964
0@@	O	-1	18182964
).	O	-1	18182964
D@@	O	-1	18182964
o@@	O	-1	18182964
ses	O	-1	18182964
were	O	-1	18182964
f@@	O	-1	18182964
le@@	O	-1	18182964
xi@@	O	-1	18182964
b@@	O	-1	18182964
ly	O	-1	18182964
ti@@	O	-1	18182964
tr@@	O	-1	18182964
ated	O	-1	18182964
up	O	-1	18182964
to	O	-1	18182964
0.@@	O	-1	18182964
6	O	-1	18182964
mg/@@	O	-1	18182964
day	O	-1	18182964
for	O	-1	18182964
clonidine	B-Chemical	D003000	18182964
and	O	-1	18182964
60	O	-1	18182964
mg/@@	O	-1	18182964
day	O	-1	18182964
for	O	-1	18182964
methyl@@	B-Chemical	D008774	18182964
phen@@	I-Chemical	-1	18182964
id@@	I-Chemical	-1	18182964
ate	I-Chemical	-1	18182964
(@@	O	-1	18182964
both	O	-1	18182964
with	O	-1	18182964
divid@@	O	-1	18182964
ed	O	-1	18182964
dos@@	O	-1	18182964
ing@@	O	-1	18182964
).	O	-1	18182964
Grou@@	O	-1	18182964
p@@	O	-1	18182964
s	O	-1	18182964
were	O	-1	18182964
compared	O	-1	18182964
reg@@	O	-1	18182964
ar@@	O	-1	18182964
ding	O	-1	18182964
adverse	O	-1	18182964
events	O	-1	18182964
and	O	-1	18182964
changes	O	-1	18182964
from	O	-1	18182964
baseline	O	-1	18182964
to	O	-1	18182964
week	O	-1	18182964
16	O	-1	18182964
in	O	-1	18182964
electro@@	O	-1	18182964
cardio@@	O	-1	18182964
gram@@	O	-1	18182964
s	O	-1	18182964
and	O	-1	18182964
vit@@	O	-1	18182964
al	O	-1	18182964
sign@@	O	-1	18182964
s.	O	-1	18182964
RESULTS:	O	-1	18182964
There	O	-1	18182964
were	O	-1	18182964
more	O	-1	18182964
inc@@	O	-1	18182964
id@@	O	-1	18182964
ents	O	-1	18182964
of	O	-1	18182964
brady@@	B-Disease	D001919	18182964
cardia	I-Disease	-1	18182964
in	O	-1	18182964
subjects	O	-1	18182964
treated	O	-1	18182964
with	O	-1	18182964
clonidine	B-Chemical	D003000	18182964
compared	O	-1	18182964
with	O	-1	18182964
those	O	-1	18182964
not	O	-1	18182964
treated	O	-1	18182964
with	O	-1	18182964
clonidine	B-Chemical	D003000	18182964
(1@@	O	-1	18182964
7.@@	O	-1	18182964
5%	O	-1	18182964
versus	O	-1	18182964
3.@@	O	-1	18182964
4@@	O	-1	18182964
%@@	O	-1	18182964
;	O	-1	18182964
p	O	-1	18182964
=@@	O	-1	18182964
.@@	O	-1	18182964
0@@	O	-1	18182964
2@@	O	-1	18182964
),	O	-1	18182964
but	O	-1	18182964
no	O	-1	18182964
other	O	-1	18182964
significant	O	-1	18182964
group	O	-1	18182964
differences	O	-1	18182964
reg@@	O	-1	18182964
ar@@	O	-1	18182964
ding	O	-1	18182964
electro@@	O	-1	18182964
cardio@@	O	-1	18182964
gra@@	O	-1	18182964
m	O	-1	18182964
and	O	-1	18182964
other	O	-1	18182964
cardiovascular	O	-1	18182964
outcom@@	O	-1	18182964
es.	O	-1	18182964
There	O	-1	18182964
were	O	-1	18182964
no	O	-1	18182964
sugg@@	O	-1	18182964
es@@	O	-1	18182964
tions	O	-1	18182964
of	O	-1	18182964
inter@@	O	-1	18182964
ac@@	O	-1	18182964
tions	O	-1	18182964
between	O	-1	18182964
clonidine	B-Chemical	D003000	18182964
and	O	-1	18182964
methyl@@	B-Chemical	D008774	18182964
phen@@	I-Chemical	-1	18182964
id@@	I-Chemical	-1	18182964
ate	I-Chemical	-1	18182964
reg@@	O	-1	18182964
ar@@	O	-1	18182964
ding	O	-1	18182964
cardiovascular	O	-1	18182964
outcom@@	O	-1	18182964
es.	O	-1	18182964
M@@	O	-1	18182964
o@@	O	-1	18182964
der@@	O	-1	18182964
ate	O	-1	18182964
or	O	-1	18182964
severe	O	-1	18182964
adverse	O	-1	18182964
events	O	-1	18182964
were	O	-1	18182964
more	O	-1	18182964
common	O	-1	18182964
in	O	-1	18182964
subjects	O	-1	18182964
on	O	-1	18182964
clonidine	B-Chemical	D003000	18182964
(@@	O	-1	18182964
7@@	O	-1	18182964
9.@@	O	-1	18182964
4@@	O	-1	18182964
%	O	-1	18182964
versus	O	-1	18182964
4@@	O	-1	18182964
9.@@	O	-1	18182964
2@@	O	-1	18182964
%@@	O	-1	18182964
;	O	-1	18182964
p	O	-1	18182964
=@@	O	-1	18182964
.@@	O	-1	18182964
0@@	O	-1	18182964
0@@	O	-1	18182964
0@@	O	-1	18182964
6@@	O	-1	18182964
)	O	-1	18182964
but	O	-1	18182964
not	O	-1	18182964
associated	O	-1	18182964
with	O	-1	18182964
higher	O	-1	18182964
rat@@	O	-1	18182964
es	O	-1	18182964
of	O	-1	18182964
early	O	-1	18182964
study	O	-1	18182964
withdraw@@	O	-1	18182964
al.	O	-1	18182964
D@@	B-Disease	D006970	18182964
row@@	I-Disease	-1	18182964
s@@	I-Disease	-1	18182964
in@@	I-Disease	-1	18182964
ess	I-Disease	-1	18182964
was	O	-1	18182964
common	O	-1	18182964
on	O	-1	18182964
clonidine	B-Chemical	D003000	18182964
,	O	-1	18182964
but	O	-1	18182964
gener@@	O	-1	18182964
ally	O	-1	18182964
resol@@	O	-1	18182964
ved	O	-1	18182964
by	O	-1	18182964
6	O	-1	18182964
to	O	-1	18182964
8	O	-1	18182964
week@@	O	-1	18182964
s.	O	-1	18182964
CONCLUSIONS:	O	-1	18182964
C@@	B-Chemical	D003000	18182964
lon@@	I-Chemical	-1	18182964
idine	I-Chemical	-1	18182964
,	O	-1	18182964
used	O	-1	18182964
alone	O	-1	18182964
or	O	-1	18182964
with	O	-1	18182964
methyl@@	B-Chemical	D008774	18182964
phen@@	I-Chemical	-1	18182964
id@@	I-Chemical	-1	18182964
ate	I-Chemical	-1	18182964
,	O	-1	18182964
appear@@	O	-1	18182964
s	O	-1	18182964
saf@@	O	-1	18182964
e	O	-1	18182964
and	O	-1	18182964
well	O	-1	18182964
toler@@	O	-1	18182964
ated	O	-1	18182964
in	O	-1	18182964
child@@	O	-1	18182964
ho@@	O	-1	18182964
od	O	-1	18182964
AD@@	B-Disease	D001289	18182964
H@@	I-Disease	-1	18182964
D	I-Disease	-1	18182964
.	O	-1	18182964
P@@	O	-1	18182964
hy@@	O	-1	18182964
si@@	O	-1	18182964
ci@@	O	-1	18182964
ans	O	-1	18182964
prescri@@	O	-1	18182964
b@@	O	-1	18182964
ing	O	-1	18182964
clonidine	B-Chemical	D003000	18182964
should	O	-1	18182964
monit@@	O	-1	18182964
or	O	-1	18182964
for	O	-1	18182964
brady@@	B-Disease	D001919	18182964
cardia	I-Disease	-1	18182964
and	O	-1	18182964
adv@@	O	-1	18182964
is@@	O	-1	18182964
e	O	-1	18182964
patients	O	-1	18182964
about	O	-1	18182964
the	O	-1	18182964
high	O	-1	18182964
lik@@	O	-1	18182964
e@@	O	-1	18182964
li@@	O	-1	18182964
ho@@	O	-1	18182964
od	O	-1	18182964
of	O	-1	18182964
initial	O	-1	18182964
dro@@	B-Disease	D006970	18182964
w@@	I-Disease	-1	18182964
s@@	I-Disease	-1	18182964
in@@	I-Disease	-1	18182964
ess	I-Disease	-1	18182964
.	O	-1	18182964

Th@@	B-Chemical	D013792	18217897
al@@	I-Chemical	-1	18217897
id@@	I-Chemical	-1	18217897
om@@	I-Chemical	-1	18217897
ide	I-Chemical	-1	18217897
has	O	-1	18217897
lim@@	O	-1	18217897
ited	O	-1	18217897
sing@@	O	-1	18217897
le@@	O	-1	18217897
-@@	O	-1	18217897
agent	O	-1	18217897
activity	O	-1	18217897
in	O	-1	18217897
rel@@	O	-1	18217897
ap@@	O	-1	18217897
sed	O	-1	18217897
or	O	-1	18217897
ref@@	O	-1	18217897
rac@@	O	-1	18217897
t@@	O	-1	18217897
ory	O	-1	18217897
ind@@	O	-1	18217897
ol@@	O	-1	18217897
ent	O	-1	18217897
non-@@	B-Disease	D008228	18217897
Ho@@	I-Disease	-1	18217897
d@@	I-Disease	-1	18217897
g@@	I-Disease	-1	18217897
k@@	I-Disease	-1	18217897
in	I-Disease	-1	18217897
lymph@@	I-Disease	-1	18217897
om@@	I-Disease	-1	18217897
as	I-Disease	-1	18217897
:	O	-1	18217897
a	O	-1	18217897
phase	O	-1	18217897
II	O	-1	18217897
trial	O	-1	18217897
of	O	-1	18217897
the	O	-1	18217897
C@@	B-Disease	D009369	18217897
anc@@	I-Disease	-1	18217897
er	I-Disease	-1	18217897
and	O	-1	18217897
L@@	B-Disease	D007938	18217897
eu@@	I-Disease	-1	18217897
k@@	I-Disease	-1	18217897
emia	I-Disease	-1	18217897
Group	O	-1	18217897
B@@	O	-1	18217897
.	O	-1	18217897
Th@@	B-Chemical	D013792	18217897
al@@	I-Chemical	-1	18217897
id@@	I-Chemical	-1	18217897
om@@	I-Chemical	-1	18217897
ide	I-Chemical	-1	18217897
is	O	-1	18217897
an	O	-1	18217897
immuno@@	O	-1	18217897
mod@@	O	-1	18217897
ul@@	O	-1	18217897
atory	O	-1	18217897
agent	O	-1	18217897
with	O	-1	18217897
demonstrated	O	-1	18217897
activity	O	-1	18217897
in	O	-1	18217897
multiple	B-Disease	D009101	18217897
my@@	I-Disease	-1	18217897
e@@	I-Disease	-1	18217897
lo@@	I-Disease	-1	18217897
ma	I-Disease	-1	18217897
,	O	-1	18217897
m@@	B-Disease	D020522	18217897
ant@@	I-Disease	-1	18217897
le	I-Disease	-1	18217897
cell	I-Disease	-1	18217897
lymph@@	I-Disease	-1	18217897
oma	I-Disease	-1	18217897
and	O	-1	18217897
lymph@@	B-Disease	D008223	18217897
o@@	I-Disease	-1	18217897
plas@@	I-Disease	-1	18217897
mac@@	I-Disease	-1	18217897
y@@	I-Disease	-1	18217897
tic	I-Disease	-1	18217897
lymph@@	I-Disease	-1	18217897
oma	I-Disease	-1	18217897
.	O	-1	18217897
I@@	O	-1	18217897
ts	O	-1	18217897
activity	O	-1	18217897
is	O	-1	18217897
be@@	O	-1	18217897
li@@	O	-1	18217897
ev@@	O	-1	18217897
ed	O	-1	18217897
to	O	-1	18217897
be	O	-1	18217897
due	O	-1	18217897
mod@@	O	-1	18217897
ulation	O	-1	18217897
of	O	-1	18217897
the	O	-1	18217897
tum@@	B-Disease	D009369	18217897
our	I-Disease	-1	18217897
mil@@	O	-1	18217897
i@@	O	-1	18217897
eu@@	O	-1	18217897
,	O	-1	18217897
including	O	-1	18217897
do@@	O	-1	18217897
w@@	O	-1	18217897
n@@	O	-1	18217897
reg@@	O	-1	18217897
ulation	O	-1	18217897
of	O	-1	18217897
angio@@	O	-1	18217897
genesis	O	-1	18217897
and	O	-1	18217897
inflam@@	O	-1	18217897
mat@@	O	-1	18217897
ory	O	-1	18217897
cyto@@	O	-1	18217897
kin@@	O	-1	18217897
es.	O	-1	18217897
B@@	O	-1	18217897
et@@	O	-1	18217897
ween	O	-1	18217897
J@@	O	-1	18217897
ul@@	O	-1	18217897
y	O	-1	18217897
20@@	O	-1	18217897
0@@	O	-1	18217897
1	O	-1	18217897
and	O	-1	18217897
A@@	O	-1	18217897
pri@@	O	-1	18217897
l	O	-1	18217897
20@@	O	-1	18217897
0@@	O	-1	18217897
4@@	O	-1	18217897
,	O	-1	18217897
24	O	-1	18217897
patients	O	-1	18217897
with	O	-1	18217897
rel@@	O	-1	18217897
ap@@	O	-1	18217897
sed@@	O	-1	18217897
/@@	O	-1	18217897
ref@@	O	-1	18217897
rac@@	O	-1	18217897
t@@	O	-1	18217897
ory	O	-1	18217897
ind@@	O	-1	18217897
ol@@	O	-1	18217897
ent	O	-1	18217897
lymph@@	B-Disease	D008223	18217897
om@@	I-Disease	-1	18217897
as	I-Disease	-1	18217897
received	O	-1	18217897
thal@@	B-Chemical	D013792	18217897
id@@	I-Chemical	-1	18217897
om@@	I-Chemical	-1	18217897
ide	I-Chemical	-1	18217897
2@@	O	-1	18217897
00	O	-1	18217897
mg	O	-1	18217897
daily	O	-1	18217897
with	O	-1	18217897
es@@	O	-1	18217897
cal@@	O	-1	18217897
ation	O	-1	18217897
by	O	-1	18217897
100	O	-1	18217897
mg	O	-1	18217897
daily	O	-1	18217897
every	O	-1	18217897
1-@@	O	-1	18217897
2	O	-1	18217897
weeks	O	-1	18217897
as	O	-1	18217897
toler@@	O	-1	18217897
at@@	O	-1	18217897
ed,	O	-1	18217897
up	O	-1	18217897
to	O	-1	18217897
a	O	-1	18217897
maxim@@	O	-1	18217897
um	O	-1	18217897
of	O	-1	18217897
8@@	O	-1	18217897
00	O	-1	18217897
mg	O	-1	18217897
da@@	O	-1	18217897
il@@	O	-1	18217897
y.	O	-1	18217897
Patients	O	-1	18217897
had	O	-1	18217897
received	O	-1	18217897
a	O	-1	18217897
median	O	-1	18217897
of	O	-1	18217897
2	O	-1	18217897
(@@	O	-1	18217897
rang@@	O	-1	18217897
e,	O	-1	18217897
1-@@	O	-1	18217897
4@@	O	-1	18217897
)	O	-1	18217897
prior	O	-1	18217897
regimen@@	O	-1	18217897
s.	O	-1	18217897
Of	O	-1	18217897
24	O	-1	18217897
evalu@@	O	-1	18217897
able	O	-1	18217897
patients,	O	-1	18217897
two	O	-1	18217897
achi@@	O	-1	18217897
ev@@	O	-1	18217897
ed	O	-1	18217897
a	O	-1	18217897
complete	O	-1	18217897
re@@	O	-1	18217897
mission	O	-1	18217897
and	O	-1	18217897
one	O	-1	18217897
achi@@	O	-1	18217897
ev@@	O	-1	18217897
ed	O	-1	18217897
a	O	-1	18217897
partial	O	-1	18217897
re@@	O	-1	18217897
mission	O	-1	18217897
for	O	-1	18217897
an	O	-1	18217897
over@@	O	-1	18217897
all	O	-1	18217897
response	O	-1	18217897
rate	O	-1	18217897
of	O	-1	18217897
1@@	O	-1	18217897
2.@@	O	-1	18217897
5%	O	-1	18217897
(@@	O	-1	18217897
95%	O	-1	18217897
conf@@	O	-1	18217897
idence	O	-1	18217897
inter@@	O	-1	18217897
val@@	O	-1	18217897
:	O	-1	18217897
2.@@	O	-1	18217897
6-@@	O	-1	18217897
3@@	O	-1	18217897
2.@@	O	-1	18217897
4@@	O	-1	18217897
%).	O	-1	18217897
E@@	O	-1	18217897
le@@	O	-1	18217897
ven	O	-1	18217897
patients	O	-1	18217897
progres@@	O	-1	18217897
sed	O	-1	18217897
during	O	-1	18217897
therapy.	O	-1	18217897
G@@	O	-1	18217897
ra@@	O	-1	18217897
de	O	-1	18217897
3-@@	O	-1	18217897
4	O	-1	18217897
adverse	O	-1	18217897
effects	O	-1	18217897
included	O	-1	18217897
my@@	B-Disease	D001855	18217897
e@@	I-Disease	-1	18217897
lo@@	I-Disease	-1	18217897
sup@@	I-Disease	-1	18217897
pression	I-Disease	-1	18217897
,	O	-1	18217897
f@@	B-Disease	D005221	18217897
ati@@	I-Disease	-1	18217897
gu@@	I-Disease	-1	18217897
e	I-Disease	-1	18217897
,	O	-1	18217897
s@@	B-Disease	D006970	18217897
om@@	I-Disease	-1	18217897
n@@	I-Disease	-1	18217897
ol@@	I-Disease	-1	18217897
ence	I-Disease	-1	18217897
/	O	-1	18217897
depress@@	B-Disease	D003866	18217897
ed	I-Disease	-1	18217897
mo@@	I-Disease	-1	18217897
od	I-Disease	-1	18217897
,	O	-1	18217897
neuropathy	B-Disease	D009422	18217897
and	O	-1	18217897
dys@@	B-Disease	D004417	18217897
p@@	I-Disease	-1	18217897
ne@@	I-Disease	-1	18217897
a	I-Disease	-1	18217897
.	O	-1	18217897
Of	O	-1	18217897
con@@	O	-1	18217897
cer@@	O	-1	18217897
n	O	-1	18217897
was	O	-1	18217897
the	O	-1	18217897
occur@@	O	-1	18217897
rence	O	-1	18217897
of	O	-1	18217897
four	O	-1	18217897
thrombo@@	B-Disease	D013923	18217897
emb@@	I-Disease	-1	18217897
olic	I-Disease	-1	18217897
event@@	O	-1	18217897
s.	O	-1	18217897
Our	O	-1	18217897
results	O	-1	18217897
fail@@	O	-1	18217897
ed	O	-1	18217897
to	O	-1	18217897
demon@@	O	-1	18217897
st@@	O	-1	18217897
rate	O	-1	18217897
an	O	-1	18217897
important	O	-1	18217897
response	O	-1	18217897
rate	O	-1	18217897
to	O	-1	18217897
single	O	-1	18217897
agent	O	-1	18217897
thal@@	B-Chemical	D013792	18217897
id@@	I-Chemical	-1	18217897
om@@	I-Chemical	-1	18217897
ide	I-Chemical	-1	18217897
in	O	-1	18217897
ind@@	O	-1	18217897
ol@@	O	-1	18217897
ent	O	-1	18217897
lymph@@	B-Disease	D008223	18217897
om@@	I-Disease	-1	18217897
as	I-Disease	-1	18217897
and	O	-1	18217897
contr@@	O	-1	18217897
ast	O	-1	18217897
with	O	-1	18217897
the	O	-1	18217897
higher	O	-1	18217897
activity	O	-1	18217897
level	O	-1	18217897
reported	O	-1	18217897
with	O	-1	18217897
the	O	-1	18217897
second	O	-1	18217897
generation	O	-1	18217897
immuno@@	O	-1	18217897
mod@@	O	-1	18217897
ul@@	O	-1	18217897
atory	O	-1	18217897
agent@@	O	-1	18217897
,	O	-1	18217897
l@@	B-Chemical	C467567	18217897
en@@	I-Chemical	-1	18217897
al@@	I-Chemical	-1	18217897
id@@	I-Chemical	-1	18217897
om@@	I-Chemical	-1	18217897
ide	I-Chemical	-1	18217897
.	O	-1	18217897

In@@	O	-1	18996674
trac@@	O	-1	18996674
aver@@	O	-1	18996674
n@@	O	-1	18996674
ous	O	-1	18996674
ep@@	B-Chemical	D004837	18996674
ine@@	I-Chemical	-1	18996674
phrine	I-Chemical	-1	18996674
:	O	-1	18996674
a	O	-1	18996674
minim@@	O	-1	18996674
ally	O	-1	18996674
inv@@	O	-1	18996674
a@@	O	-1	18996674
sive	O	-1	18996674
treatment	O	-1	18996674
for	O	-1	18996674
pri@@	B-Disease	D011317	18996674
ap@@	I-Disease	-1	18996674
ism	I-Disease	-1	18996674
in	O	-1	18996674
the	O	-1	18996674
em@@	O	-1	18996674
er@@	O	-1	18996674
gen@@	O	-1	18996674
c@@	O	-1	18996674
y	O	-1	18996674
de@@	O	-1	18996674
part@@	O	-1	18996674
ment.	O	-1	18996674
P@@	B-Disease	D011317	18996674
ri@@	I-Disease	-1	18996674
ap@@	I-Disease	-1	18996674
ism	I-Disease	-1	18996674
is	O	-1	18996674
the	O	-1	18996674
prolonged	O	-1	18996674
e@@	O	-1	18996674
rec@@	O	-1	18996674
tion	O	-1	18996674
of	O	-1	18996674
the	O	-1	18996674
pen@@	O	-1	18996674
is	O	-1	18996674
in	O	-1	18996674
the	O	-1	18996674
absence	O	-1	18996674
of	O	-1	18996674
sex@@	O	-1	18996674
ual	O	-1	18996674
a@@	O	-1	18996674
ro@@	O	-1	18996674
us@@	O	-1	18996674
al.	O	-1	18996674
A	O	-1	18996674
4@@	O	-1	18996674
5-@@	O	-1	18996674
year-old	O	-1	18996674
man@@	O	-1	18996674
,	O	-1	18996674
an	O	-1	18996674
ad@@	O	-1	18996674
mit@@	O	-1	18996674
ted	O	-1	18996674
frequent	O	-1	18996674
cocaine	B-Chemical	D003042	18996674
us@@	O	-1	18996674
er,	O	-1	18996674
presented	O	-1	18996674
to	O	-1	18996674
the	O	-1	18996674
E@@	O	-1	18996674
mer@@	O	-1	18996674
gen@@	O	-1	18996674
c@@	O	-1	18996674
y	O	-1	18996674
De@@	O	-1	18996674
part@@	O	-1	18996674
ment	O	-1	18996674
(@@	O	-1	18996674
E@@	O	-1	18996674
D)	O	-1	18996674
on	O	-1	18996674
two	O	-1	18996674
se@@	O	-1	18996674
par@@	O	-1	18996674
ate	O	-1	18996674
oc@@	O	-1	18996674
ca@@	O	-1	18996674
sions	O	-1	18996674
with	O	-1	18996674
a	O	-1	18996674
hist@@	O	-1	18996674
ory	O	-1	18996674
of	O	-1	18996674
pri@@	B-Disease	D011317	18996674
ap@@	I-Disease	-1	18996674
ism	I-Disease	-1	18996674
after	O	-1	18996674
cocaine	B-Chemical	D003042	18996674
use.	O	-1	18996674
The	O	-1	18996674
man@@	O	-1	18996674
ag@@	O	-1	18996674
ement	O	-1	18996674
op@@	O	-1	18996674
tions	O	-1	18996674
in	O	-1	18996674
the	O	-1	18996674
E@@	O	-1	18996674
D@@	O	-1	18996674
,	O	-1	18996674
as	O	-1	18996674
ex@@	O	-1	18996674
em@@	O	-1	18996674
pl@@	O	-1	18996674
if@@	O	-1	18996674
ied	O	-1	18996674
by	O	-1	18996674
four	O	-1	18996674
individ@@	O	-1	18996674
ual	O	-1	18996674
case	O	-1	18996674
repor@@	O	-1	18996674
t@@	O	-1	18996674
s,	O	-1	18996674
in	O	-1	18996674
partic@@	O	-1	18996674
ular	O	-1	18996674
the	O	-1	18996674
use	O	-1	18996674
of	O	-1	18996674
a	O	-1	18996674
minim@@	O	-1	18996674
ally	O	-1	18996674
inv@@	O	-1	18996674
a@@	O	-1	18996674
sive	O	-1	18996674
meth@@	O	-1	18996674
od	O	-1	18996674
of	O	-1	18996674
intrac@@	O	-1	18996674
or@@	O	-1	18996674
por@@	O	-1	18996674
al	O	-1	18996674
ep@@	B-Chemical	D004837	18996674
ine@@	I-Chemical	-1	18996674
phrine	I-Chemical	-1	18996674
insti@@	O	-1	18996674
ll@@	O	-1	18996674
ation,	O	-1	18996674
are	O	-1	18996674
discus@@	O	-1	18996674
sed.	O	-1	18996674

Eff@@	O	-1	19058010
ect	O	-1	19058010
of	O	-1	19058010
gre@@	B-Chemical	D010936	19058010
en	I-Chemical	-1	19058010
te@@	I-Chemical	-1	19058010
a	I-Chemical	-1	19058010
and	O	-1	19058010
vitamin	B-Chemical	D014810	19058010
E	I-Chemical	-1	19058010
combination	O	-1	19058010
in	O	-1	19058010
isoproteren@@	B-Chemical	D007545	19058010
ol	I-Chemical	-1	19058010
induced	O	-1	19058010
myocardial	B-Disease	D009203	19058010
infarction	I-Disease	-1	19058010
in	O	-1	19058010
rats.	O	-1	19058010
The	O	-1	19058010
present	O	-1	19058010
study	O	-1	19058010
was	O	-1	19058010
a@@	O	-1	19058010
im@@	O	-1	19058010
ed	O	-1	19058010
to	O	-1	19058010
investigate	O	-1	19058010
the	O	-1	19058010
combined	O	-1	19058010
effects	O	-1	19058010
of	O	-1	19058010
gre@@	B-Chemical	D010936	19058010
en	I-Chemical	-1	19058010
te@@	I-Chemical	-1	19058010
a	I-Chemical	-1	19058010
and	O	-1	19058010
vitamin	B-Chemical	D014810	19058010
E	I-Chemical	-1	19058010
on	O	-1	19058010
heart	O	-1	19058010
weigh@@	O	-1	19058010
t,	O	-1	19058010
body	O	-1	19058010
weigh@@	O	-1	19058010
t,	O	-1	19058010
serum	O	-1	19058010
mark@@	O	-1	19058010
er	O	-1	19058010
enzym@@	O	-1	19058010
es,	O	-1	19058010
li@@	O	-1	19058010
pid	O	-1	19058010
per@@	O	-1	19058010
oxid@@	O	-1	19058010
ation,	O	-1	19058010
endo@@	O	-1	19058010
gen@@	O	-1	19058010
ous	O	-1	19058010
anti@@	O	-1	19058010
oxid@@	O	-1	19058010
ants	O	-1	19058010
and	O	-1	19058010
membran@@	O	-1	19058010
e	O	-1	19058010
b@@	O	-1	19058010
ound	O	-1	19058010
AT@@	O	-1	19058010
P@@	O	-1	19058010
as@@	O	-1	19058010
es	O	-1	19058010
in	O	-1	19058010
isoproteren@@	B-Chemical	D007545	19058010
ol	I-Chemical	-1	19058010
(	O	-1	19058010
I@@	B-Chemical	D007545	19058010
S@@	I-Chemical	-1	19058010
O	I-Chemical	-1	19058010
)@@	O	-1	19058010
-induced	O	-1	19058010
myocardial	B-Disease	D009203	19058010
infarction	I-Disease	-1	19058010
in	O	-1	19058010
rats.	O	-1	19058010
Ad@@	O	-1	19058010
ult	O	-1	19058010
male	O	-1	19058010
al@@	O	-1	19058010
bin@@	O	-1	19058010
o	O	-1	19058010
rats,	O	-1	19058010
treated	O	-1	19058010
with	O	-1	19058010
I@@	B-Chemical	D007545	19058010
S@@	I-Chemical	-1	19058010
O	I-Chemical	-1	19058010
(2@@	O	-1	19058010
00	O	-1	19058010
mg/kg@@	O	-1	19058010
,	O	-1	19058010
s@@	O	-1	19058010
.@@	O	-1	19058010
c@@	O	-1	19058010
.)	O	-1	19058010
for	O	-1	19058010
2	O	-1	19058010
days	O	-1	19058010
at	O	-1	19058010
an	O	-1	19058010
interv@@	O	-1	19058010
al	O	-1	19058010
of	O	-1	19058010
24	O	-1	19058010
h	O	-1	19058010
caused	O	-1	19058010
a	O	-1	19058010
significant	O	-1	19058010
(P@@	O	-1	19058010
<@@	O	-1	19058010
0.05@@	O	-1	19058010
)	O	-1	19058010
elev@@	O	-1	19058010
ation	O	-1	19058010
of	O	-1	19058010
heart	O	-1	19058010
weigh@@	O	-1	19058010
t,	O	-1	19058010
serum	O	-1	19058010
mark@@	O	-1	19058010
er	O	-1	19058010
enzym@@	O	-1	19058010
es,	O	-1	19058010
li@@	O	-1	19058010
pid	O	-1	19058010
per@@	O	-1	19058010
oxid@@	O	-1	19058010
ation	O	-1	19058010
and	O	-1	19058010
C@@	B-Chemical	D002118	19058010
a	I-Chemical	-1	19058010
+@@	O	-1	19058010
2	O	-1	19058010
AT@@	O	-1	19058010
P@@	O	-1	19058010
ase	O	-1	19058010
level	O	-1	19058010
whereas	O	-1	19058010
there	O	-1	19058010
was	O	-1	19058010
a	O	-1	19058010
significant	O	-1	19058010
(P@@	O	-1	19058010
<@@	O	-1	19058010
0.05@@	O	-1	19058010
)	O	-1	19058010
decrease	O	-1	19058010
in	O	-1	19058010
body	O	-1	19058010
weigh@@	O	-1	19058010
t,	O	-1	19058010
endo@@	O	-1	19058010
gen@@	O	-1	19058010
ous	O	-1	19058010
anti@@	O	-1	19058010
oxid@@	O	-1	19058010
ant@@	O	-1	19058010
s,	O	-1	19058010
N@@	B-Chemical	D012964	19058010
a	I-Chemical	-1	19058010
+@@	O	-1	19058010
/	O	-1	19058010
K	B-Chemical	D011188	19058010
+	O	-1	19058010
AT@@	O	-1	19058010
P@@	O	-1	19058010
ase	O	-1	19058010
and	O	-1	19058010
M@@	B-Chemical	D008274	19058010
g	I-Chemical	-1	19058010
+@@	O	-1	19058010
2	O	-1	19058010
AT@@	O	-1	19058010
P@@	O	-1	19058010
ase	O	-1	19058010
level@@	O	-1	19058010
s.	O	-1	19058010
Ad@@	O	-1	19058010
minist@@	O	-1	19058010
ration	O	-1	19058010
of	O	-1	19058010
gre@@	B-Chemical	D010936	19058010
en	I-Chemical	-1	19058010
te@@	I-Chemical	-1	19058010
a	I-Chemical	-1	19058010
(@@	O	-1	19058010
100	O	-1	19058010
mg/k@@	O	-1	19058010
g/@@	O	-1	19058010
da@@	O	-1	19058010
y,	O	-1	19058010
p.@@	O	-1	19058010
o@@	O	-1	19058010
.)	O	-1	19058010
and	O	-1	19058010
vitamin	B-Chemical	D014810	19058010
E	I-Chemical	-1	19058010
(@@	O	-1	19058010
100	O	-1	19058010
mg/k@@	O	-1	19058010
g/@@	O	-1	19058010
da@@	O	-1	19058010
y,	O	-1	19058010
p.@@	O	-1	19058010
o@@	O	-1	19058010
.)	O	-1	19058010
to@@	O	-1	19058010
ge@@	O	-1	19058010
ther	O	-1	19058010
for	O	-1	19058010
30	O	-1	19058010
con@@	O	-1	19058010
sec@@	O	-1	19058010
utive	O	-1	19058010
days	O	-1	19058010
and	O	-1	19058010
ch@@	O	-1	19058010
all@@	O	-1	19058010
en@@	O	-1	19058010
g@@	O	-1	19058010
ed	O	-1	19058010
with	O	-1	19058010
I@@	B-Chemical	D007545	19058010
S@@	I-Chemical	-1	19058010
O	I-Chemical	-1	19058010
on	O	-1	19058010
the	O	-1	19058010
day	O	-1	19058010
2@@	O	-1	19058010
9@@	O	-1	19058010
th	O	-1	19058010
and	O	-1	19058010
3@@	O	-1	19058010
0@@	O	-1	19058010
th@@	O	-1	19058010
,	O	-1	19058010
showed	O	-1	19058010
a	O	-1	19058010
significant	O	-1	19058010
(P@@	O	-1	19058010
<@@	O	-1	19058010
0.05@@	O	-1	19058010
)	O	-1	19058010
decrease	O	-1	19058010
in	O	-1	19058010
heart	O	-1	19058010
weigh@@	O	-1	19058010
t,	O	-1	19058010
serum	O	-1	19058010
mark@@	O	-1	19058010
er	O	-1	19058010
enzym@@	O	-1	19058010
es,	O	-1	19058010
li@@	O	-1	19058010
pid	O	-1	19058010
per@@	O	-1	19058010
oxid@@	O	-1	19058010
ation,	O	-1	19058010
C@@	B-Chemical	D002118	19058010
a	I-Chemical	-1	19058010
+@@	O	-1	19058010
2	O	-1	19058010
AT@@	O	-1	19058010
P@@	O	-1	19058010
ase	O	-1	19058010
and	O	-1	19058010
a	O	-1	19058010
significant	O	-1	19058010
increase	O	-1	19058010
in	O	-1	19058010
the	O	-1	19058010
body	O	-1	19058010
weigh@@	O	-1	19058010
t,	O	-1	19058010
endo@@	O	-1	19058010
gen@@	O	-1	19058010
ous	O	-1	19058010
anti@@	O	-1	19058010
oxid@@	O	-1	19058010
ant@@	O	-1	19058010
s,	O	-1	19058010
N@@	B-Chemical	D012964	19058010
a	I-Chemical	-1	19058010
+@@	O	-1	19058010
/	O	-1	19058010
K	B-Chemical	D011188	19058010
+	O	-1	19058010
AT@@	O	-1	19058010
P@@	O	-1	19058010
ase	O	-1	19058010
and	O	-1	19058010
M@@	B-Chemical	D008274	19058010
g	I-Chemical	-1	19058010
+@@	O	-1	19058010
2	O	-1	19058010
AT@@	O	-1	19058010
P@@	O	-1	19058010
ase	O	-1	19058010
when	O	-1	19058010
compared	O	-1	19058010
with	O	-1	19058010
I@@	B-Chemical	D007545	19058010
S@@	I-Chemical	-1	19058010
O	I-Chemical	-1	19058010
treated	O	-1	19058010
group	O	-1	19058010
and	O	-1	19058010
gre@@	B-Chemical	D010936	19058010
en	I-Chemical	-1	19058010
te@@	I-Chemical	-1	19058010
a	I-Chemical	-1	19058010
or	O	-1	19058010
vitamin	B-Chemical	D014810	19058010
E	I-Chemical	-1	19058010
alone	O	-1	19058010
treated	O	-1	19058010
groups.	O	-1	19058010
These	O	-1	19058010
findings	O	-1	19058010
indicate	O	-1	19058010
the	O	-1	19058010
syn@@	O	-1	19058010
erg@@	O	-1	19058010
istic	O	-1	19058010
protective	O	-1	19058010
effect	O	-1	19058010
of	O	-1	19058010
gre@@	B-Chemical	D010936	19058010
en	I-Chemical	-1	19058010
te@@	I-Chemical	-1	19058010
a	I-Chemical	-1	19058010
and	O	-1	19058010
vitamin	B-Chemical	D014810	19058010
E	I-Chemical	-1	19058010
during	O	-1	19058010
I@@	B-Chemical	D007545	19058010
S@@	I-Chemical	-1	19058010
O	I-Chemical	-1	19058010
induced	O	-1	19058010
myocardial	B-Disease	D009203	19058010
infarction	I-Disease	-1	19058010
in	O	-1	19058010
rats.	O	-1	19058010

De@@	O	-1	19581773
ve@@	O	-1	19581773
lop@@	O	-1	19581773
ment	O	-1	19581773
of	O	-1	19581773
oc@@	B-Disease	D009157	19581773
ular	I-Disease	-1	19581773
my@@	I-Disease	-1	19581773
as@@	I-Disease	-1	19581773
th@@	I-Disease	-1	19581773
en@@	I-Disease	-1	19581773
ia	I-Disease	-1	19581773
during	O	-1	19581773
pe@@	B-Chemical	C417083	19581773
g@@	I-Chemical	-1	19581773
yl@@	I-Chemical	-1	19581773
ated	I-Chemical	-1	19581773
inter@@	I-Chemical	-1	19581773
fer@@	I-Chemical	-1	19581773
on	I-Chemical	-1	19581773
and	O	-1	19581773
rib@@	B-Chemical	D012254	19581773
avi@@	I-Chemical	-1	19581773
rin	I-Chemical	-1	19581773
treatment	O	-1	19581773
for	O	-1	19581773
chronic	B-Disease	D019698	19581773
hepatitis	I-Disease	-1	19581773
C	I-Disease	-1	19581773
.	O	-1	19581773
A	O	-1	19581773
6@@	O	-1	19581773
3-@@	O	-1	19581773
year-old	O	-1	19581773
male	O	-1	19581773
experienced	O	-1	19581773
su@@	O	-1	19581773
d@@	O	-1	19581773
de@@	O	-1	19581773
n	O	-1	19581773
di@@	B-Disease	D004172	19581773
p@@	I-Disease	-1	19581773
lo@@	I-Disease	-1	19581773
pi@@	I-Disease	-1	19581773
a	I-Disease	-1	19581773
after	O	-1	19581773
9	O	-1	19581773
weeks	O	-1	19581773
of	O	-1	19581773
administration	O	-1	19581773
of	O	-1	19581773
pe@@	B-Chemical	C417083	19581773
g@@	I-Chemical	-1	19581773
yl@@	I-Chemical	-1	19581773
ated	I-Chemical	-1	19581773
inter@@	I-Chemical	-1	19581773
fer@@	I-Chemical	-1	19581773
on	I-Chemical	-1	19581773
(@@	I-Chemical	-1	19581773
I@@	I-Chemical	-1	19581773
F@@	I-Chemical	-1	19581773
N@@	I-Chemical	-1	19581773
)	I-Chemical	-1	19581773
alpha-@@	I-Chemical	-1	19581773
2@@	I-Chemical	-1	19581773
b	I-Chemical	-1	19581773
and	O	-1	19581773
rib@@	B-Chemical	D012254	19581773
avi@@	I-Chemical	-1	19581773
rin	I-Chemical	-1	19581773
for	O	-1	19581773
chronic	B-Disease	D019698	19581773
hepatitis	I-Disease	-1	19581773
C	I-Disease	-1	19581773
(	O	-1	19581773
C@@	B-Disease	D019698	19581773
H@@	I-Disease	-1	19581773
C	I-Disease	-1	19581773
).	O	-1	19581773
O@@	O	-1	19581773
ph@@	O	-1	19581773
thal@@	O	-1	19581773
mo@@	O	-1	19581773
log@@	O	-1	19581773
ic	O	-1	19581773
examin@@	O	-1	19581773
ations	O	-1	19581773
showed	O	-1	19581773
pto@@	B-Disease	D001763	19581773
sis	I-Disease	-1	19581773
on	I-Disease	-1	19581773
the	I-Disease	-1	19581773
right	I-Disease	-1	19581773
up@@	I-Disease	-1	19581773
per	I-Disease	-1	19581773
li@@	I-Disease	-1	19581773
d	I-Disease	-1	19581773
and	O	-1	19581773
re@@	B-Disease	D015835	19581773
stric@@	I-Disease	-1	19581773
ted	I-Disease	-1	19581773
right	I-Disease	-1	19581773
e@@	I-Disease	-1	19581773
y@@	I-Disease	-1	19581773
e	I-Disease	-1	19581773
mo@@	I-Disease	-1	19581773
vement	I-Disease	-1	19581773
without	O	-1	19581773
any	O	-1	19581773
other	O	-1	19581773
neurolog@@	O	-1	19581773
ical	O	-1	19581773
sign@@	O	-1	19581773
s.	O	-1	19581773
A	O	-1	19581773
brain	O	-1	19581773
imaging	O	-1	19581773
study	O	-1	19581773
and	O	-1	19581773
repe@@	O	-1	19581773
ti@@	O	-1	19581773
tive	O	-1	19581773
nerve	O	-1	19581773
stimulation	O	-1	19581773
test	O	-1	19581773
indic@@	O	-1	19581773
ated	O	-1	19581773
no	O	-1	19581773
abnormal@@	O	-1	19581773
ity.	O	-1	19581773
The	O	-1	19581773
acet@@	B-Chemical	D000109	19581773
ylcholine	I-Chemical	-1	19581773
receptor	O	-1	19581773
anti@@	O	-1	19581773
body	O	-1	19581773
ti@@	O	-1	19581773
ter	O	-1	19581773
and	O	-1	19581773
response	O	-1	19581773
to	O	-1	19581773
acet@@	O	-1	19581773
ylchol@@	O	-1	19581773
ine@@	O	-1	19581773
ster@@	O	-1	19581773
ase	O	-1	19581773
inhibitors	O	-1	19581773
were	O	-1	19581773
neg@@	O	-1	19581773
ati@@	O	-1	19581773
ve,	O	-1	19581773
and	O	-1	19581773
the	O	-1	19581773
results	O	-1	19581773
of	O	-1	19581773
th@@	O	-1	19581773
yro@@	O	-1	19581773
id	O	-1	19581773
function	O	-1	19581773
tests	O	-1	19581773
were	O	-1	19581773
normal@@	O	-1	19581773
.	O	-1	19581773
The	O	-1	19581773
patient@@	O	-1	19581773
's	O	-1	19581773
oph@@	O	-1	19581773
thal@@	O	-1	19581773
mo@@	O	-1	19581773
log@@	O	-1	19581773
ical	O	-1	19581773
symptoms	O	-1	19581773
improved	O	-1	19581773
ra@@	O	-1	19581773
pid@@	O	-1	19581773
ly	O	-1	19581773
3	O	-1	19581773
weeks	O	-1	19581773
after	O	-1	19581773
discontinu@@	O	-1	19581773
ation	O	-1	19581773
of	O	-1	19581773
pe@@	B-Chemical	C417083	19581773
g@@	I-Chemical	-1	19581773
yl@@	I-Chemical	-1	19581773
ated	I-Chemical	-1	19581773
I@@	I-Chemical	-1	19581773
F@@	I-Chemical	-1	19581773
N	I-Chemical	-1	19581773
alpha-@@	I-Chemical	-1	19581773
2@@	I-Chemical	-1	19581773
b	I-Chemical	-1	19581773
and	O	-1	19581773
rib@@	B-Chemical	D012254	19581773
avi@@	I-Chemical	-1	19581773
rin	I-Chemical	-1	19581773
.	O	-1	19581773
The	O	-1	19581773
oc@@	B-Disease	D009157	19581773
ular	I-Disease	-1	19581773
my@@	I-Disease	-1	19581773
as@@	I-Disease	-1	19581773
th@@	I-Disease	-1	19581773
en@@	I-Disease	-1	19581773
ia	I-Disease	-1	19581773
associated	O	-1	19581773
with	O	-1	19581773
combination	O	-1	19581773
therapy	O	-1	19581773
of	O	-1	19581773
pe@@	B-Chemical	C417083	19581773
g@@	I-Chemical	-1	19581773
yl@@	I-Chemical	-1	19581773
ated	I-Chemical	-1	19581773
I@@	I-Chemical	-1	19581773
F@@	I-Chemical	-1	19581773
N	I-Chemical	-1	19581773
alpha-@@	I-Chemical	-1	19581773
2@@	I-Chemical	-1	19581773
b	I-Chemical	-1	19581773
and	O	-1	19581773
rib@@	B-Chemical	D012254	19581773
avi@@	I-Chemical	-1	19581773
rin	I-Chemical	-1	19581773
for	O	-1	19581773
C@@	B-Disease	D019698	19581773
H@@	I-Disease	-1	19581773
C	I-Disease	-1	19581773
is	O	-1	19581773
very	O	-1	19581773
ra@@	O	-1	19581773
re@@	O	-1	19581773
ly	O	-1	19581773
repor@@	O	-1	19581773
te@@	O	-1	19581773
d@@	O	-1	19581773
;	O	-1	19581773
the@@	O	-1	19581773
refore,	O	-1	19581773
we	O	-1	19581773
present	O	-1	19581773
this	O	-1	19581773
case	O	-1	19581773
with	O	-1	19581773
a	O	-1	19581773
revie@@	O	-1	19581773
w	O	-1	19581773
of	O	-1	19581773
the	O	-1	19581773
various	O	-1	19581773
e@@	O	-1	19581773
y@@	O	-1	19581773
e	O	-1	19581773
complications	O	-1	19581773
of	O	-1	19581773
I@@	B-Chemical	C417083	19581773
F@@	I-Chemical	-1	19581773
N	I-Chemical	-1	19581773
therapy.	O	-1	19581773

The	O	-1	19759529
glyc@@	B-Chemical	D005998	19759529
ine	I-Chemical	-1	19759529
trans@@	O	-1	19759529
por@@	O	-1	19759529
ter@@	O	-1	19759529
-1	O	-1	19759529
inhibitor	O	-1	19759529
S@@	B-Chemical	-1	19759529
SR@@	I-Chemical	-1	19759529
10@@	I-Chemical	-1	19759529
3@@	I-Chemical	-1	19759529
8@@	I-Chemical	-1	19759529
00	I-Chemical	-1	19759529
dis@@	O	-1	19759529
pl@@	O	-1	19759529
ays	O	-1	19759529
a	O	-1	19759529
selective	O	-1	19759529
and	O	-1	19759529
specific	O	-1	19759529
anti@@	O	-1	19759529
psycho@@	O	-1	19759529
tic@@	O	-1	19759529
-@@	O	-1	19759529
like	O	-1	19759529
prof@@	O	-1	19759529
ile	O	-1	19759529
in	O	-1	19759529
normal	O	-1	19759529
and	O	-1	19759529
trans@@	O	-1	19759529
genic	O	-1	19759529
mice.	O	-1	19759529
S@@	B-Disease	D012559	19759529
ch@@	I-Disease	-1	19759529
iz@@	I-Disease	-1	19759529
oph@@	I-Disease	-1	19759529
ren@@	I-Disease	-1	19759529
ia	I-Disease	-1	19759529
has	O	-1	19759529
been	O	-1	19759529
initi@@	O	-1	19759529
ally	O	-1	19759529
associated	O	-1	19759529
with	O	-1	19759529
dysfunction	O	-1	19759529
in	O	-1	19759529
dopamine	B-Chemical	D004298	19759529
neuro@@	O	-1	19759529
trans@@	O	-1	19759529
mis@@	O	-1	19759529
sion.	O	-1	19759529
However,	O	-1	19759529
the	O	-1	19759529
observ@@	O	-1	19759529
ation	O	-1	19759529
that	O	-1	19759529
antagonist@@	O	-1	19759529
s	O	-1	19759529
of	O	-1	19759529
the	O	-1	19759529
glutamate	B-Chemical	D018698	19759529
N@@	B-Chemical	D016202	19759529
-@@	I-Chemical	-1	19759529
methyl@@	I-Chemical	-1	19759529
-@@	I-Chemical	-1	19759529
D-@@	I-Chemical	-1	19759529
as@@	I-Chemical	-1	19759529
part@@	I-Chemical	-1	19759529
ate	I-Chemical	-1	19759529
(	O	-1	19759529
N@@	B-Chemical	D016202	19759529
MD@@	I-Chemical	-1	19759529
A	I-Chemical	-1	19759529
)	O	-1	19759529
receptor	O	-1	19759529
produce	O	-1	19759529
sch@@	B-Disease	D012559	19759529
iz@@	I-Disease	-1	19759529
oph@@	I-Disease	-1	19759529
ren@@	I-Disease	-1	19759529
ic	I-Disease	-1	19759529
-@@	O	-1	19759529
like	O	-1	19759529
symptoms	O	-1	19759529
in	O	-1	19759529
hum@@	O	-1	19759529
ans	O	-1	19759529
has	O	-1	19759529
l@@	O	-1	19759529
ed	O	-1	19759529
to	O	-1	19759529
the	O	-1	19759529
ide@@	O	-1	19759529
a	O	-1	19759529
of	O	-1	19759529
a	O	-1	19759529
dysfunc@@	O	-1	19759529
tion@@	O	-1	19759529
ing	O	-1	19759529
of	O	-1	19759529
the	O	-1	19759529
glutam@@	O	-1	19759529
at@@	O	-1	19759529
ergic	O	-1	19759529
system	O	-1	19759529
vi@@	O	-1	19759529
a	O	-1	19759529
its	O	-1	19759529
N@@	B-Chemical	D016202	19759529
MD@@	I-Chemical	-1	19759529
A	I-Chemical	-1	19759529
receptor@@	O	-1	19759529
.	O	-1	19759529
A@@	O	-1	19759529
s	O	-1	19759529
a	O	-1	19759529
result@@	O	-1	19759529
,	O	-1	19759529
there	O	-1	19759529
is	O	-1	19759529
a	O	-1	19759529
grow@@	O	-1	19759529
ing	O	-1	19759529
in@@	O	-1	19759529
te@@	O	-1	19759529
res@@	O	-1	19759529
t	O	-1	19759529
in	O	-1	19759529
the	O	-1	19759529
development	O	-1	19759529
of	O	-1	19759529
pharmac@@	O	-1	19759529
ological	O	-1	19759529
agents	O	-1	19759529
with	O	-1	19759529
potential	O	-1	19759529
anti@@	O	-1	19759529
psycho@@	O	-1	19759529
tic	O	-1	19759529
pro@@	O	-1	19759529
per@@	O	-1	19759529
ties	O	-1	19759529
that	O	-1	19759529
enh@@	O	-1	19759529
ance	O	-1	19759529
the	O	-1	19759529
activity	O	-1	19759529
of	O	-1	19759529
the	O	-1	19759529
glutam@@	O	-1	19759529
at@@	O	-1	19759529
ergic	O	-1	19759529
system	O	-1	19759529
vi@@	O	-1	19759529
a	O	-1	19759529
a	O	-1	19759529
mod@@	O	-1	19759529
ulation	O	-1	19759529
of	O	-1	19759529
the	O	-1	19759529
N@@	B-Chemical	D016202	19759529
MD@@	I-Chemical	-1	19759529
A	I-Chemical	-1	19759529
receptor@@	O	-1	19759529
.	O	-1	19759529
A@@	O	-1	19759529
mon@@	O	-1	19759529
g	O	-1	19759529
the@@	O	-1	19759529
m	O	-1	19759529
are	O	-1	19759529
glyc@@	B-Chemical	D005998	19759529
ine	I-Chemical	-1	19759529
trans@@	O	-1	19759529
por@@	O	-1	19759529
ter@@	O	-1	19759529
-1	O	-1	19759529
(@@	O	-1	19759529
G@@	O	-1	19759529
ly@@	O	-1	19759529
T@@	O	-1	19759529
1)	O	-1	19759529
inhibitors	O	-1	19759529
such	O	-1	19759529
as	O	-1	19759529
S@@	B-Chemical	-1	19759529
SR@@	I-Chemical	-1	19759529
10@@	I-Chemical	-1	19759529
3@@	I-Chemical	-1	19759529
8@@	I-Chemical	-1	19759529
00	I-Chemical	-1	19759529
,	O	-1	19759529
which	O	-1	19759529
in@@	O	-1	19759529
direc@@	O	-1	19759529
tly	O	-1	19759529
enh@@	O	-1	19759529
ance	O	-1	19759529
N@@	B-Chemical	D016202	19759529
MD@@	I-Chemical	-1	19759529
A	I-Chemical	-1	19759529
receptor	O	-1	19759529
function	O	-1	19759529
by	O	-1	19759529
increas@@	O	-1	19759529
ing	O	-1	19759529
the	O	-1	19759529
glyc@@	B-Chemical	D005998	19759529
ine	I-Chemical	-1	19759529
(@@	O	-1	19759529
a	O	-1	19759529
co-@@	O	-1	19759529
agon@@	O	-1	19759529
ist	O	-1	19759529
for	O	-1	19759529
the	O	-1	19759529
N@@	B-Chemical	D016202	19759529
MD@@	I-Chemical	-1	19759529
A	I-Chemical	-1	19759529
receptor@@	O	-1	19759529
)	O	-1	19759529
levels	O	-1	19759529
in	O	-1	19759529
the	O	-1	19759529
syn@@	O	-1	19759529
ap@@	O	-1	19759529
se.	O	-1	19759529
This	O	-1	19759529
study	O	-1	19759529
a@@	O	-1	19759529
im@@	O	-1	19759529
ed	O	-1	19759529
at	O	-1	19759529
investig@@	O	-1	19759529
ating	O	-1	19759529
the	O	-1	19759529
potential	O	-1	19759529
anti@@	O	-1	19759529
psycho@@	O	-1	19759529
tic@@	O	-1	19759529
-@@	O	-1	19759529
like	O	-1	19759529
pro@@	O	-1	19759529
per@@	O	-1	19759529
ties	O	-1	19759529
of	O	-1	19759529
S@@	B-Chemical	-1	19759529
SR@@	I-Chemical	-1	19759529
10@@	I-Chemical	-1	19759529
3@@	I-Chemical	-1	19759529
8@@	I-Chemical	-1	19759529
00	I-Chemical	-1	19759529
,	O	-1	19759529
with	O	-1	19759529
a	O	-1	19759529
partic@@	O	-1	19759529
ular	O	-1	19759529
foc@@	O	-1	19759529
us	O	-1	19759529
on	O	-1	19759529
models	O	-1	19759529
of	O	-1	19759529
hyperactivity	B-Disease	D006948	19759529
,	O	-1	19759529
invol@@	O	-1	19759529
ving	O	-1	19759529
either	O	-1	19759529
drug	O	-1	19759529
ch@@	O	-1	19759529
all@@	O	-1	19759529
enge	O	-1	19759529
(@@	O	-1	19759529
i@@	O	-1	19759529
e,	O	-1	19759529
amphetamine	B-Chemical	D000661	19759529
and	O	-1	19759529
M@@	B-Chemical	D016291	19759529
K@@	I-Chemical	-1	19759529
-@@	I-Chemical	-1	19759529
80@@	I-Chemical	-1	19759529
1	I-Chemical	-1	19759529
)	O	-1	19759529
or	O	-1	19759529
trans@@	O	-1	19759529
genic	O	-1	19759529
mice	O	-1	19759529
(@@	O	-1	19759529
i@@	O	-1	19759529
e,	O	-1	19759529
N@@	B-Chemical	D016202	19759529
MD@@	I-Chemical	-1	19759529
A	I-Chemical	-1	19759529
N@@	O	-1	19759529
r@@	O	-1	19759529
1@@	O	-1	19759529
(@@	O	-1	19759529
ne@@	O	-1	19759529
o@@	O	-1	19759529
-@@	O	-1	19759529
/@@	O	-1	19759529
-@@	O	-1	19759529
)	O	-1	19759529
and	O	-1	19759529
D@@	O	-1	19759529
AT@@	O	-1	19759529
(-@@	O	-1	19759529
/@@	O	-1	19759529
-@@	O	-1	19759529
)@@	O	-1	19759529
).	O	-1	19759529
R@@	O	-1	19759529
es@@	O	-1	19759529
ult@@	O	-1	19759529
s	O	-1	19759529
showed	O	-1	19759529
that	O	-1	19759529
S@@	B-Chemical	-1	19759529
SR@@	I-Chemical	-1	19759529
10@@	I-Chemical	-1	19759529
3@@	I-Chemical	-1	19759529
8@@	I-Chemical	-1	19759529
00	I-Chemical	-1	19759529
(@@	O	-1	19759529
10-@@	O	-1	19759529
30	O	-1	19759529
mg/kg	O	-1	19759529
p.@@	O	-1	19759529
o@@	O	-1	19759529
.)	O	-1	19759529
block@@	O	-1	19759529
ed	O	-1	19759529
hyperactivity	B-Disease	D006948	19759529
induced	O	-1	19759529
by	O	-1	19759529
the	O	-1	19759529
non-@@	O	-1	19759529
comp@@	O	-1	19759529
e@@	O	-1	19759529
ti@@	O	-1	19759529
tive	O	-1	19759529
N@@	B-Chemical	D016202	19759529
MD@@	I-Chemical	-1	19759529
A	I-Chemical	-1	19759529
receptor	O	-1	19759529
antagonist@@	O	-1	19759529
,	O	-1	19759529
M@@	B-Chemical	D016291	19759529
K@@	I-Chemical	-1	19759529
-@@	I-Chemical	-1	19759529
80@@	I-Chemical	-1	19759529
1	I-Chemical	-1	19759529
and	O	-1	19759529
par@@	O	-1	19759529
ti@@	O	-1	19759529
ally	O	-1	19759529
reversed	O	-1	19759529
spont@@	O	-1	19759529
aneous	O	-1	19759529
hyperactivity	B-Disease	D006948	19759529
of	O	-1	19759529
N@@	B-Chemical	D016202	19759529
MD@@	I-Chemical	-1	19759529
A	I-Chemical	-1	19759529
N@@	O	-1	19759529
r@@	O	-1	19759529
1@@	O	-1	19759529
(@@	O	-1	19759529
ne@@	O	-1	19759529
o@@	O	-1	19759529
-@@	O	-1	19759529
/@@	O	-1	19759529
-@@	O	-1	19759529
)	O	-1	19759529
mice.	O	-1	19759529
In	O	-1	19759529
contrast@@	O	-1	19759529
,	O	-1	19759529
S@@	B-Chemical	-1	19759529
SR@@	I-Chemical	-1	19759529
10@@	I-Chemical	-1	19759529
3@@	I-Chemical	-1	19759529
8@@	I-Chemical	-1	19759529
00	I-Chemical	-1	19759529
fail@@	O	-1	19759529
ed	O	-1	19759529
to	O	-1	19759529
aff@@	O	-1	19759529
ect	O	-1	19759529
hyperactivity	B-Disease	D006948	19759529
induced	O	-1	19759529
by	O	-1	19759529
amphetamine	B-Chemical	D000661	19759529
or	O	-1	19759529
n@@	O	-1	19759529
at@@	O	-1	19759529
ur@@	O	-1	19759529
ally	O	-1	19759529
observed	O	-1	19759529
in	O	-1	19759529
dopamine	B-Chemical	D004298	19759529
trans@@	O	-1	19759529
por@@	O	-1	19759529
ter	O	-1	19759529
(D@@	O	-1	19759529
AT@@	O	-1	19759529
(-@@	O	-1	19759529
/@@	O	-1	19759529
-@@	O	-1	19759529
)@@	O	-1	19759529
)	O	-1	19759529
k@@	O	-1	19759529
n@@	O	-1	19759529
oc@@	O	-1	19759529
k@@	O	-1	19759529
out	O	-1	19759529
mice	O	-1	19759529
(@@	O	-1	19759529
10-@@	O	-1	19759529
30	O	-1	19759529
mg/kg	O	-1	19759529
p.@@	O	-1	19759529
o@@	O	-1	19759529
.@@	O	-1	19759529
).	O	-1	19759529
Im@@	O	-1	19759529
port@@	O	-1	19759529
ant@@	O	-1	19759529
ly,	O	-1	19759529
both	O	-1	19759529
cl@@	O	-1	19759529
assi@@	O	-1	19759529
c@@	O	-1	19759529
al	O	-1	19759529
(	O	-1	19759529
haloperidol	B-Chemical	D006220	19759529
)	O	-1	19759529
and	O	-1	19759529
at@@	O	-1	19759529
yp@@	O	-1	19759529
ical	O	-1	19759529
(	O	-1	19759529
ol@@	B-Chemical	C076029	19759529
an@@	I-Chemical	-1	19759529
z@@	I-Chemical	-1	19759529
apine	I-Chemical	-1	19759529
,	O	-1	19759529
cloz@@	B-Chemical	D003024	19759529
apine	I-Chemical	-1	19759529
and	O	-1	19759529
ari@@	B-Chemical	C094645	19759529
pi@@	I-Chemical	-1	19759529
praz@@	I-Chemical	-1	19759529
ole	I-Chemical	-1	19759529
)	O	-1	19759529
anti@@	O	-1	19759529
psycho@@	O	-1	19759529
tics	O	-1	19759529
were	O	-1	19759529
effective	O	-1	19759529
in	O	-1	19759529
all	O	-1	19759529
these	O	-1	19759529
models	O	-1	19759529
of	O	-1	19759529
hyperactivity	B-Disease	D006948	19759529
.	O	-1	19759529
However,	O	-1	19759529
un@@	O	-1	19759529
like	O	-1	19759529
these	O	-1	19759529
lat@@	O	-1	19759529
ter@@	O	-1	19759529
,	O	-1	19759529
S@@	B-Chemical	-1	19759529
SR@@	I-Chemical	-1	19759529
10@@	I-Chemical	-1	19759529
3@@	I-Chemical	-1	19759529
8@@	I-Chemical	-1	19759529
00	I-Chemical	-1	19759529
did	O	-1	19759529
not	O	-1	19759529
produce	O	-1	19759529
cat@@	B-Disease	D002375	19759529
al@@	I-Disease	-1	19759529
ep@@	I-Disease	-1	19759529
sy	I-Disease	-1	19759529
(@@	O	-1	19759529
re@@	O	-1	19759529
ten@@	O	-1	19759529
tion	O	-1	19759529
on	O	-1	19759529
the	O	-1	19759529
b@@	O	-1	19759529
ar	O	-1	19759529
test@@	O	-1	19759529
)	O	-1	19759529
up	O	-1	19759529
to	O	-1	19759529
30	O	-1	19759529
mg/kg	O	-1	19759529
p.@@	O	-1	19759529
o@@	O	-1	19759529
.	O	-1	19759529
T@@	O	-1	19759529
o@@	O	-1	19759529
ge@@	O	-1	19759529
ther	O	-1	19759529
these	O	-1	19759529
findings	O	-1	19759529
show	O	-1	19759529
that	O	-1	19759529
the	O	-1	19759529
G@@	O	-1	19759529
ly@@	O	-1	19759529
T@@	O	-1	19759529
1	O	-1	19759529
inhibitor@@	O	-1	19759529
,	O	-1	19759529
S@@	B-Chemical	-1	19759529
SR@@	I-Chemical	-1	19759529
10@@	I-Chemical	-1	19759529
3@@	I-Chemical	-1	19759529
8@@	I-Chemical	-1	19759529
00	I-Chemical	-1	19759529
,	O	-1	19759529
produc@@	O	-1	19759529
es	O	-1	19759529
anti@@	O	-1	19759529
psycho@@	O	-1	19759529
tic@@	O	-1	19759529
-@@	O	-1	19759529
like	O	-1	19759529
effect@@	O	-1	19759529
s,	O	-1	19759529
which	O	-1	19759529
diff@@	O	-1	19759529
er	O	-1	19759529
from	O	-1	19759529
those	O	-1	19759529
observed	O	-1	19759529
with	O	-1	19759529
comp@@	O	-1	19759529
oun@@	O	-1	19759529
ds	O	-1	19759529
prim@@	O	-1	19759529
ari@@	O	-1	19759529
ly	O	-1	19759529
t@@	O	-1	19759529
arg@@	O	-1	19759529
et@@	O	-1	19759529
ing	O	-1	19759529
the	O	-1	19759529
dop@@	O	-1	19759529
aminergic	O	-1	19759529
system@@	O	-1	19759529
,	O	-1	19759529
and	O	-1	19759529
has	O	-1	19759529
a	O	-1	19759529
reduced	O	-1	19759529
side@@	O	-1	19759529
-@@	O	-1	19759529
effect	O	-1	19759529
potential	O	-1	19759529
as	O	-1	19759529
compared	O	-1	19759529
with	O	-1	19759529
these	O	-1	19759529
lat@@	O	-1	19759529
ter	O	-1	19759529
drug@@	O	-1	19759529
s.	O	-1	19759529

Ph@@	B-Chemical	D010656	19957053
en@@	I-Chemical	-1	19957053
y@@	I-Chemical	-1	19957053
le@@	I-Chemical	-1	19957053
phrine	I-Chemical	-1	19957053
but	O	-1	19957053
not	O	-1	19957053
e@@	B-Chemical	D004809	19957053
ph@@	I-Chemical	-1	19957053
ed@@	I-Chemical	-1	19957053
rine	I-Chemical	-1	19957053
reduc@@	B-Disease	D002534	19957053
es	I-Disease	-1	19957053
fron@@	I-Disease	-1	19957053
t@@	I-Disease	-1	19957053
al	I-Disease	-1	19957053
lo@@	I-Disease	-1	19957053
be	I-Disease	-1	19957053
oxy@@	I-Disease	-1	19957053
gen@@	I-Disease	-1	19957053
ation	I-Disease	-1	19957053
following	O	-1	19957053
anesthe@@	O	-1	19957053
si@@	O	-1	19957053
a@@	O	-1	19957053
-induced	O	-1	19957053
hypotension	B-Disease	D007022	19957053
.	O	-1	19957053
BACKGROUND:	O	-1	19957053
V@@	O	-1	19957053
as@@	O	-1	19957053
o@@	O	-1	19957053
press@@	O	-1	19957053
or	O	-1	19957053
agents	O	-1	19957053
are	O	-1	19957053
used	O	-1	19957053
to	O	-1	19957053
cor@@	O	-1	19957053
rec@@	O	-1	19957053
t	O	-1	19957053
anesthe@@	O	-1	19957053
si@@	O	-1	19957053
a@@	O	-1	19957053
-induced	O	-1	19957053
hypotension	B-Disease	D007022	19957053
.	O	-1	19957053
We	O	-1	19957053
describe	O	-1	19957053
the	O	-1	19957053
effect	O	-1	19957053
of	O	-1	19957053
pheny@@	B-Chemical	D010656	19957053
le@@	I-Chemical	-1	19957053
phrine	I-Chemical	-1	19957053
and	O	-1	19957053
e@@	B-Chemical	D004809	19957053
ph@@	I-Chemical	-1	19957053
ed@@	I-Chemical	-1	19957053
rine	I-Chemical	-1	19957053
on	O	-1	19957053
fron@@	O	-1	19957053
t@@	O	-1	19957053
al	O	-1	19957053
lo@@	O	-1	19957053
be	O	-1	19957053
oxy@@	O	-1	19957053
gen@@	O	-1	19957053
ation	O	-1	19957053
(S@@	O	-1	19957053
(@@	O	-1	19957053
c@@	O	-1	19957053
)@@	O	-1	19957053
O@@	O	-1	19957053
(2@@	O	-1	19957053
)@@	O	-1	19957053
)	O	-1	19957053
following	O	-1	19957053
anesthe@@	O	-1	19957053
si@@	O	-1	19957053
a@@	O	-1	19957053
-induced	O	-1	19957053
hypotension	B-Disease	D007022	19957053
.	O	-1	19957053
METHODS:	O	-1	19957053
F@@	O	-1	19957053
ol@@	O	-1	19957053
low@@	O	-1	19957053
ing	O	-1	19957053
induction	O	-1	19957053
of	O	-1	19957053
anesthe@@	O	-1	19957053
sia	O	-1	19957053
by	O	-1	19957053
f@@	B-Chemical	D005283	19957053
entan@@	I-Chemical	-1	19957053
yl	I-Chemical	-1	19957053
(0.@@	O	-1	19957053
15	O	-1	19957053
mg	O	-1	19957053
kg@@	O	-1	19957053
(@@	O	-1	19957053
-1@@	O	-1	19957053
)@@	O	-1	19957053
)	O	-1	19957053
and	O	-1	19957053
pro@@	B-Chemical	D015742	19957053
po@@	I-Chemical	-1	19957053
f@@	I-Chemical	-1	19957053
ol	I-Chemical	-1	19957053
(2@@	O	-1	19957053
.@@	O	-1	19957053
0	O	-1	19957053
mg	O	-1	19957053
kg@@	O	-1	19957053
(@@	O	-1	19957053
-1@@	O	-1	19957053
)@@	O	-1	19957053
),	O	-1	19957053
13	O	-1	19957053
patients	O	-1	19957053
received	O	-1	19957053
pheny@@	B-Chemical	D010656	19957053
le@@	I-Chemical	-1	19957053
phrine	I-Chemical	-1	19957053
(0.@@	O	-1	19957053
1	O	-1	19957053
mg	O	-1	19957053
i@@	O	-1	19957053
v@@	O	-1	19957053
)	O	-1	19957053
and	O	-1	19957053
12	O	-1	19957053
patients	O	-1	19957053
received	O	-1	19957053
e@@	B-Chemical	D004809	19957053
ph@@	I-Chemical	-1	19957053
ed@@	I-Chemical	-1	19957053
rine	I-Chemical	-1	19957053
(10	O	-1	19957053
mg	O	-1	19957053
i@@	O	-1	19957053
v@@	O	-1	19957053
)	O	-1	19957053
to	O	-1	19957053
rest@@	O	-1	19957053
or@@	O	-1	19957053
e	O	-1	19957053
mean	O	-1	19957053
arterial	O	-1	19957053
pressure	O	-1	19957053
(@@	O	-1	19957053
MA@@	O	-1	19957053
P@@	O	-1	19957053
).	O	-1	19957053
H@@	O	-1	19957053
ear@@	O	-1	19957053
t	O	-1	19957053
rate	O	-1	19957053
(@@	O	-1	19957053
H@@	O	-1	19957053
R@@	O	-1	19957053
),	O	-1	19957053
MA@@	O	-1	19957053
P@@	O	-1	19957053
,	O	-1	19957053
strok@@	B-Disease	D020521	19957053
e	I-Disease	-1	19957053
volume	O	-1	19957053
(S@@	O	-1	19957053
V@@	O	-1	19957053
),	O	-1	19957053
cardiac	O	-1	19957053
out@@	O	-1	19957053
pu@@	O	-1	19957053
t	O	-1	19957053
(C@@	O	-1	19957053
O@@	O	-1	19957053
),	O	-1	19957053
and	O	-1	19957053
fron@@	O	-1	19957053
t@@	O	-1	19957053
al	O	-1	19957053
lo@@	O	-1	19957053
be	O	-1	19957053
oxy@@	O	-1	19957053
gen@@	O	-1	19957053
ation	O	-1	19957053
(S@@	O	-1	19957053
(@@	O	-1	19957053
c@@	O	-1	19957053
)@@	O	-1	19957053
O@@	O	-1	19957053
(2@@	O	-1	19957053
)@@	O	-1	19957053
)	O	-1	19957053
were	O	-1	19957053
reg@@	O	-1	19957053
ist@@	O	-1	19957053
e@@	O	-1	19957053
red.	O	-1	19957053
RESULTS:	O	-1	19957053
In@@	O	-1	19957053
duction	O	-1	19957053
of	O	-1	19957053
anesthe@@	O	-1	19957053
sia	O	-1	19957053
was	O	-1	19957053
followed	O	-1	19957053
by	O	-1	19957053
a	B-Disease	D007022	19957053
decrease	I-Disease	-1	19957053
in	I-Disease	-1	19957053
MA@@	I-Disease	-1	19957053
P@@	I-Disease	-1	19957053
,	I-Disease	-1	19957053
H@@	I-Disease	-1	19957053
R@@	I-Disease	-1	19957053
,	I-Disease	-1	19957053
S@@	I-Disease	-1	19957053
V@@	I-Disease	-1	19957053
,	I-Disease	-1	19957053
and	I-Disease	-1	19957053
C@@	I-Disease	-1	19957053
O	I-Disease	-1	19957053
a	B-Disease	D002303	19957053
decrease	I-Disease	-1	19957053
in	I-Disease	-1	19957053
MA@@	I-Disease	-1	19957053
P@@	I-Disease	-1	19957053
,	I-Disease	-1	19957053
H@@	I-Disease	-1	19957053
R@@	I-Disease	-1	19957053
,	I-Disease	-1	19957053
S@@	I-Disease	-1	19957053
V@@	I-Disease	-1	19957053
,	I-Disease	-1	19957053
and	I-Disease	-1	19957053
C@@	I-Disease	-1	19957053
O	I-Disease	-1	19957053
concomit@@	O	-1	19957053
ant	O	-1	19957053
with	O	-1	19957053
an	O	-1	19957053
elev@@	O	-1	19957053
ation	O	-1	19957053
in	O	-1	19957053
S@@	O	-1	19957053
(@@	O	-1	19957053
c@@	O	-1	19957053
)@@	O	-1	19957053
O@@	O	-1	19957053
(2@@	O	-1	19957053
).	O	-1	19957053
After	O	-1	19957053
administration	O	-1	19957053
of	O	-1	19957053
pheny@@	B-Chemical	D010656	19957053
le@@	I-Chemical	-1	19957053
phrine	I-Chemical	-1	19957053
,	O	-1	19957053
MA@@	O	-1	19957053
P	O	-1	19957053
increased	O	-1	19957053
(5@@	O	-1	19957053
1	O	-1	19957053
+/-	O	-1	19957053
12	O	-1	19957053
to	O	-1	19957053
8@@	O	-1	19957053
1	O	-1	19957053
+/-	O	-1	19957053
13	O	-1	19957053
mm@@	O	-1	19957053
H@@	O	-1	19957053
g@@	O	-1	19957053
;	O	-1	19957053
P	O	-1	19957053
<	O	-1	19957053
0.00@@	O	-1	19957053
1@@	O	-1	19957053
;	O	-1	19957053
mean	O	-1	19957053
+/-	O	-1	19957053
S@@	O	-1	19957053
D@@	O	-1	19957053
).	O	-1	19957053
However,	O	-1	19957053
a	O	-1	19957053
14@@	O	-1	19957053
%	O	-1	19957053
(@@	O	-1	19957053
from	O	-1	19957053
7@@	O	-1	19957053
0	O	-1	19957053
+/-	O	-1	19957053
8@@	O	-1	19957053
%	O	-1	19957053
to	O	-1	19957053
60	O	-1	19957053
+/-	O	-1	19957053
7@@	O	-1	19957053
%)	O	-1	19957053
reduction	O	-1	19957053
in	O	-1	19957053
S@@	O	-1	19957053
(@@	O	-1	19957053
c@@	O	-1	19957053
)@@	O	-1	19957053
O@@	O	-1	19957053
(2@@	O	-1	19957053
)	O	-1	19957053
(P	O	-1	19957053
<	O	-1	19957053
0.05@@	O	-1	19957053
)	O	-1	19957053
followed	O	-1	19957053
with	O	-1	19957053
no	O	-1	19957053
change	O	-1	19957053
in	O	-1	19957053
C@@	O	-1	19957053
O	O	-1	19957053
(@@	O	-1	19957053
3.@@	O	-1	19957053
7	O	-1	19957053
+/-	O	-1	19957053
1.@@	O	-1	19957053
1	O	-1	19957053
to	O	-1	19957053
3.@@	O	-1	19957053
4	O	-1	19957053
+/-	O	-1	19957053
0.@@	O	-1	19957053
9	O	-1	19957053
l	O	-1	19957053
min@@	O	-1	19957053
(@@	O	-1	19957053
-1@@	O	-1	19957053
)@@	O	-1	19957053
).	O	-1	19957053
The	O	-1	19957053
administration	O	-1	19957053
of	O	-1	19957053
e@@	B-Chemical	D004809	19957053
ph@@	I-Chemical	-1	19957053
ed@@	I-Chemical	-1	19957053
rine	I-Chemical	-1	19957053
l@@	O	-1	19957053
ed	O	-1	19957053
to	O	-1	19957053
a	O	-1	19957053
similar	O	-1	19957053
increase	O	-1	19957053
in	O	-1	19957053
MA@@	O	-1	19957053
P	O	-1	19957053
(5@@	O	-1	19957053
3	O	-1	19957053
+/-	O	-1	19957053
9	O	-1	19957053
to	O	-1	19957053
7@@	O	-1	19957053
9	O	-1	19957053
+/-	O	-1	19957053
8	O	-1	19957053
mm@@	O	-1	19957053
H@@	O	-1	19957053
g@@	O	-1	19957053
;	O	-1	19957053
P	O	-1	19957053
<	O	-1	19957053
0.00@@	O	-1	19957053
1),	O	-1	19957053
re@@	O	-1	19957053
sto@@	O	-1	19957053
red	O	-1	19957053
C@@	O	-1	19957053
O	O	-1	19957053
(@@	O	-1	19957053
3.@@	O	-1	19957053
2	O	-1	19957053
+/-	O	-1	19957053
1.@@	O	-1	19957053
2	O	-1	19957053
to	O	-1	19957053
5.@@	O	-1	19957053
0	O	-1	19957053
+/-	O	-1	19957053
1.@@	O	-1	19957053
3	O	-1	19957053
l	O	-1	19957053
min@@	O	-1	19957053
(@@	O	-1	19957053
-1@@	O	-1	19957053
)@@	O	-1	19957053
),	O	-1	19957053
and	O	-1	19957053
pres@@	O	-1	19957053
er@@	O	-1	19957053
ved	O	-1	19957053
S@@	O	-1	19957053
(@@	O	-1	19957053
c@@	O	-1	19957053
)@@	O	-1	19957053
O@@	O	-1	19957053
(2@@	O	-1	19957053
).	O	-1	19957053
CONCLUSIONS:	O	-1	19957053
The	O	-1	19957053
u@@	O	-1	19957053
ti@@	O	-1	19957053
li@@	O	-1	19957053
z@@	O	-1	19957053
ation	O	-1	19957053
of	O	-1	19957053
pheny@@	B-Chemical	D010656	19957053
le@@	I-Chemical	-1	19957053
phrine	I-Chemical	-1	19957053
to	O	-1	19957053
cor@@	O	-1	19957053
rec@@	O	-1	19957053
t	O	-1	19957053
hypotension	B-Disease	D007022	19957053
induced	O	-1	19957053
by	O	-1	19957053
anesthe@@	O	-1	19957053
sia	O	-1	19957053
has	O	-1	19957053
a	O	-1	19957053
negative	O	-1	19957053
im@@	O	-1	19957053
pac@@	O	-1	19957053
t	O	-1	19957053
on	O	-1	19957053
S@@	O	-1	19957053
(@@	O	-1	19957053
c@@	O	-1	19957053
)@@	O	-1	19957053
O@@	O	-1	19957053
(2@@	O	-1	19957053
)	O	-1	19957053
while	O	-1	19957053
e@@	B-Chemical	D004809	19957053
ph@@	I-Chemical	-1	19957053
ed@@	I-Chemical	-1	19957053
rine	I-Chemical	-1	19957053
maint@@	O	-1	19957053
ain@@	O	-1	19957053
s	O	-1	19957053
fron@@	O	-1	19957053
t@@	O	-1	19957053
al	O	-1	19957053
lo@@	O	-1	19957053
be	O	-1	19957053
oxy@@	O	-1	19957053
gen@@	O	-1	19957053
ation	O	-1	19957053
potenti@@	O	-1	19957053
ally	O	-1	19957053
related	O	-1	19957053
to	O	-1	19957053
an	O	-1	19957053
increase	O	-1	19957053
in	O	-1	19957053
CO@@	O	-1	19957053
.	O	-1	19957053

A	O	-1	20619828
no@@	O	-1	20619828
vel@@	O	-1	20619828
,	O	-1	20619828
multiple	O	-1	20619828
sympto@@	O	-1	20619828
m	O	-1	20619828
model	O	-1	20619828
of	O	-1	20619828
ob@@	B-Disease	D009771	20619828
s@@	I-Disease	-1	20619828
es@@	I-Disease	-1	20619828
si@@	I-Disease	-1	20619828
ve@@	I-Disease	-1	20619828
-@@	I-Disease	-1	20619828
comp@@	I-Disease	-1	20619828
ul@@	I-Disease	-1	20619828
si@@	I-Disease	-1	20619828
ve@@	I-Disease	-1	20619828
-@@	I-Disease	-1	20619828
like	I-Disease	-1	20619828
behavi@@	I-Disease	-1	20619828
ors	I-Disease	-1	20619828
in	O	-1	20619828
anim@@	O	-1	20619828
al@@	O	-1	20619828
s.	O	-1	20619828
BACKGROUND:	O	-1	20619828
C@@	O	-1	20619828
ur@@	O	-1	20619828
rent	O	-1	20619828
anim@@	O	-1	20619828
al	O	-1	20619828
models	O	-1	20619828
of	O	-1	20619828
ob@@	B-Disease	D009771	20619828
s@@	I-Disease	-1	20619828
es@@	I-Disease	-1	20619828
si@@	I-Disease	-1	20619828
ve@@	I-Disease	-1	20619828
-@@	I-Disease	-1	20619828
comp@@	I-Disease	-1	20619828
ul@@	I-Disease	-1	20619828
sive	I-Disease	-1	20619828
disor@@	I-Disease	-1	20619828
der	I-Disease	-1	20619828
(	O	-1	20619828
O@@	B-Disease	D009771	20619828
C@@	I-Disease	-1	20619828
D	I-Disease	-1	20619828
)	O	-1	20619828
typ@@	O	-1	20619828
ically	O	-1	20619828
invol@@	O	-1	20619828
ve	O	-1	20619828
ac@@	O	-1	20619828
u@@	O	-1	20619828
te@@	O	-1	20619828
,	O	-1	20619828
drug@@	O	-1	20619828
-induced	O	-1	20619828
sympto@@	O	-1	20619828
m	O	-1	20619828
prov@@	O	-1	20619828
oc@@	O	-1	20619828
ation	O	-1	20619828
or	O	-1	20619828
a	O	-1	20619828
gene@@	O	-1	20619828
tic	O	-1	20619828
association	O	-1	20619828
with	O	-1	20619828
ste@@	O	-1	20619828
re@@	O	-1	20619828
ot@@	O	-1	20619828
y@@	O	-1	20619828
pi@@	O	-1	20619828
es	O	-1	20619828
or	O	-1	20619828
an@@	B-Disease	D001008	20619828
xi@@	I-Disease	-1	20619828
ety	I-Disease	-1	20619828
.	O	-1	20619828
N@@	O	-1	20619828
one	O	-1	20619828
of	O	-1	20619828
these	O	-1	20619828
current	O	-1	20619828
models	O	-1	20619828
demon@@	O	-1	20619828
st@@	O	-1	20619828
rate	O	-1	20619828
multiple	O	-1	20619828
O@@	B-Disease	D009771	20619828
C@@	I-Disease	-1	20619828
D	I-Disease	-1	20619828
-@@	O	-1	20619828
like	O	-1	20619828
behavi@@	O	-1	20619828
or@@	O	-1	20619828
s.	O	-1	20619828
METHODS:	O	-1	20619828
Ne@@	O	-1	20619828
on@@	O	-1	20619828
atal	O	-1	20619828
rats	O	-1	20619828
were	O	-1	20619828
treated	O	-1	20619828
with	O	-1	20619828
the	O	-1	20619828
tr@@	O	-1	20619828
ic@@	O	-1	20619828
y@@	O	-1	20619828
cl@@	O	-1	20619828
ic	O	-1	20619828
antidepress@@	B-Chemical	D000928	20619828
ant	I-Chemical	-1	20619828
clo@@	B-Chemical	D002997	20619828
mi@@	I-Chemical	-1	20619828
pramine	I-Chemical	-1	20619828
or	O	-1	20619828
ve@@	O	-1	20619828
h@@	O	-1	20619828
ic@@	O	-1	20619828
le	O	-1	20619828
between	O	-1	20619828
days	O	-1	20619828
9	O	-1	20619828
and	O	-1	20619828
16	O	-1	20619828
tw@@	O	-1	20619828
ic@@	O	-1	20619828
e	O	-1	20619828
daily	O	-1	20619828
and	O	-1	20619828
behavi@@	O	-1	20619828
or@@	O	-1	20619828
ally	O	-1	20619828
tested	O	-1	20619828
in	O	-1	20619828
ad@@	O	-1	20619828
ul@@	O	-1	20619828
th@@	O	-1	20619828
o@@	O	-1	20619828
o@@	O	-1	20619828
d.	O	-1	20619828
RESULTS:	O	-1	20619828
C@@	B-Chemical	D002997	20619828
lo@@	I-Chemical	-1	20619828
mi@@	I-Chemical	-1	20619828
pramine	I-Chemical	-1	20619828
exposure	O	-1	20619828
in	O	-1	20619828
im@@	O	-1	20619828
mat@@	O	-1	20619828
ure	O	-1	20619828
rats	O	-1	20619828
produced	O	-1	20619828
significant	O	-1	20619828
behavioral	O	-1	20619828
and	O	-1	20619828
bio@@	O	-1	20619828
chemical	O	-1	20619828
changes	O	-1	20619828
that	O	-1	20619828
includ@@	O	-1	20619828
e	O	-1	20619828
enhanced	O	-1	20619828
an@@	B-Disease	D001008	20619828
xi@@	I-Disease	-1	20619828
ety	I-Disease	-1	20619828
(@@	O	-1	20619828
elevated	O	-1	20619828
plus	O	-1	20619828
ma@@	O	-1	20619828
ze	O	-1	20619828
and	O	-1	20619828
m@@	O	-1	20619828
arb@@	O	-1	20619828
le	O	-1	20619828
b@@	O	-1	20619828
ur@@	O	-1	20619828
y@@	O	-1	20619828
ing@@	O	-1	20619828
),	O	-1	20619828
behavioral	B-Disease	-1	20619828
inf@@	I-Disease	-1	20619828
le@@	I-Disease	-1	20619828
xi@@	I-Disease	-1	20619828
b@@	I-Disease	-1	20619828
ility	I-Disease	-1	20619828
(@@	O	-1	20619828
per@@	O	-1	20619828
sever@@	O	-1	20619828
ation	O	-1	20619828
in	O	-1	20619828
the	O	-1	20619828
spont@@	O	-1	20619828
aneous	O	-1	20619828
al@@	O	-1	20619828
tern@@	O	-1	20619828
ation	O	-1	20619828
t@@	O	-1	20619828
as@@	O	-1	20619828
k	O	-1	20619828
and	O	-1	20619828
impaired	O	-1	20619828
rever@@	O	-1	20619828
s@@	O	-1	20619828
al	O	-1	20619828
lear@@	O	-1	20619828
n@@	O	-1	20619828
ing@@	O	-1	20619828
),	O	-1	20619828
wor@@	O	-1	20619828
king	O	-1	20619828
memory	B-Disease	D008569	20619828
impair@@	I-Disease	-1	20619828
ment	I-Disease	-1	20619828
(@@	O	-1	20619828
e@@	O	-1	20619828
.@@	O	-1	20619828
g@@	O	-1	20619828
.,	O	-1	20619828
w@@	O	-1	20619828
in-@@	O	-1	20619828
shi@@	O	-1	20619828
ft	O	-1	20619828
par@@	O	-1	20619828
a@@	O	-1	20619828
di@@	O	-1	20619828
g@@	O	-1	20619828
m@@	O	-1	20619828
),	O	-1	20619828
ho@@	B-Disease	D060845	20619828
ar@@	I-Disease	-1	20619828
ding	I-Disease	-1	20619828
,	O	-1	20619828
and	O	-1	20619828
cortico@@	B-Disease	-1	20619828
stri@@	I-Disease	-1	20619828
atal	I-Disease	-1	20619828
dysfunction	I-Disease	-1	20619828
.	O	-1	20619828
D@@	B-Chemical	D004298	20619828
op@@	I-Chemical	-1	20619828
amine	I-Chemical	-1	20619828
D2	O	-1	20619828
receptors	O	-1	20619828
were	O	-1	20619828
elevated	O	-1	20619828
in	O	-1	20619828
the	O	-1	20619828
striat@@	O	-1	20619828
um,	O	-1	20619828
whereas	O	-1	20619828
seroton@@	B-Chemical	D012701	20619828
in	I-Chemical	-1	20619828
2@@	O	-1	20619828
C@@	O	-1	20619828
,	O	-1	20619828
but	O	-1	20619828
not	O	-1	20619828
seroton@@	B-Chemical	D012701	20619828
in	I-Chemical	-1	20619828
1@@	O	-1	20619828
A@@	O	-1	20619828
,	O	-1	20619828
receptors	O	-1	20619828
were	O	-1	20619828
elevated	O	-1	20619828
in	O	-1	20619828
the	O	-1	20619828
or@@	O	-1	20619828
b@@	O	-1	20619828
it@@	O	-1	20619828
al	O	-1	20619828
fron@@	O	-1	20619828
t@@	O	-1	20619828
al	O	-1	20619828
cor@@	O	-1	20619828
t@@	O	-1	20619828
ex@@	O	-1	20619828
.	O	-1	20619828
CONCLUSIONS:	O	-1	20619828
This	O	-1	20619828
is	O	-1	20619828
the	O	-1	20619828
first	O	-1	20619828
demon@@	O	-1	20619828
st@@	O	-1	20619828
ration	O	-1	20619828
of	O	-1	20619828
multiple	O	-1	20619828
symptoms	O	-1	20619828
consist@@	O	-1	20619828
ent	O	-1	20619828
with	O	-1	20619828
an	O	-1	20619828
O@@	B-Disease	D009771	20619828
C@@	I-Disease	-1	20619828
D	I-Disease	-1	20619828
-@@	O	-1	20619828
like	O	-1	20619828
prof@@	O	-1	20619828
ile	O	-1	20619828
in	O	-1	20619828
anim@@	O	-1	20619828
al@@	O	-1	20619828
s.	O	-1	20619828
M@@	O	-1	20619828
ore@@	O	-1	20619828
o@@	O	-1	20619828
ver,	O	-1	20619828
these	O	-1	20619828
behavi@@	O	-1	20619828
ors	O	-1	20619828
are	O	-1	20619828
ac@@	O	-1	20619828
comp@@	O	-1	20619828
an@@	O	-1	20619828
ied	O	-1	20619828
by	O	-1	20619828
bio@@	O	-1	20619828
chemical	O	-1	20619828
changes	O	-1	20619828
in	O	-1	20619828
brain	O	-1	20619828
regi@@	O	-1	20619828
ons	O	-1	20619828
previously	O	-1	20619828
identi@@	O	-1	20619828
fied	O	-1	20619828
as	O	-1	20619828
re@@	O	-1	20619828
lev@@	O	-1	20619828
ant	O	-1	20619828
to	O	-1	20619828
O@@	B-Disease	D009771	20619828
C@@	I-Disease	-1	20619828
D	I-Disease	-1	20619828
.	O	-1	20619828
This	O	-1	20619828
novel	O	-1	20619828
model	O	-1	20619828
of	O	-1	20619828
O@@	B-Disease	D009771	20619828
C@@	I-Disease	-1	20619828
D	I-Disease	-1	20619828
demon@@	O	-1	20619828
strat@@	O	-1	20619828
es	O	-1	20619828
that	O	-1	20619828
drug	O	-1	20619828
exposure	O	-1	20619828
during	O	-1	20619828
a	O	-1	20619828
sensitive	O	-1	20619828
period	O	-1	20619828
can	O	-1	20619828
pro@@	O	-1	20619828
gra@@	O	-1	20619828
m	O	-1	20619828
diseas@@	O	-1	20619828
e-@@	O	-1	20619828
like	O	-1	20619828
system@@	O	-1	20619828
s	O	-1	20619828
per@@	O	-1	20619828
man@@	O	-1	20619828
ent@@	O	-1	20619828
ly,	O	-1	20619828
which	O	-1	20619828
could	O	-1	20619828
have	O	-1	20619828
implic@@	O	-1	20619828
ations	O	-1	20619828
for	O	-1	20619828
current	O	-1	20619828
and	O	-1	20619828
f@@	O	-1	20619828
ut@@	O	-1	20619828
ure	O	-1	20619828
therapeutic	O	-1	20619828
strat@@	O	-1	20619828
e@@	O	-1	20619828
gi@@	O	-1	20619828
es	O	-1	20619828
for	O	-1	20619828
this	O	-1	20619828
and	O	-1	20619828
other	O	-1	20619828
psych@@	B-Disease	D001523	20619828
i@@	I-Disease	-1	20619828
atric	I-Disease	-1	20619828
disorder@@	I-Disease	-1	20619828
s	I-Disease	-1	20619828
.	O	-1	20619828

L@@	O	-1	891050
ate	O	-1	891050
recovery	O	-1	891050
of	O	-1	891050
renal	O	-1	891050
function	O	-1	891050
in	O	-1	891050
a	O	-1	891050
woman	O	-1	891050
with	O	-1	891050
the	O	-1	891050
hemolytic	B-Disease	D006463	891050
ure@@	I-Disease	-1	891050
mic	I-Disease	-1	891050
syndrome	I-Disease	-1	891050
.	O	-1	891050
A	O	-1	891050
case	O	-1	891050
is	O	-1	891050
reported	O	-1	891050
of	O	-1	891050
the	O	-1	891050
hemolytic	B-Disease	D006463	891050
ure@@	I-Disease	-1	891050
mic	I-Disease	-1	891050
syndrome	I-Disease	-1	891050
(	O	-1	891050
H@@	B-Disease	D006463	891050
U@@	I-Disease	-1	891050
S	I-Disease	-1	891050
)	O	-1	891050
in	O	-1	891050
a	O	-1	891050
woman	O	-1	891050
taking	O	-1	891050
oral	B-Chemical	D003276	891050
contrac@@	I-Chemical	-1	891050
ep@@	I-Chemical	-1	891050
tiv@@	I-Chemical	-1	891050
es	I-Chemical	-1	891050
.	O	-1	891050
S@@	O	-1	891050
he	O	-1	891050
was	O	-1	891050
treated	O	-1	891050
with	O	-1	891050
hepar@@	B-Chemical	D006493	891050
in	I-Chemical	-1	891050
,	O	-1	891050
di@@	B-Chemical	D004176	891050
pyri@@	I-Chemical	-1	891050
dam@@	I-Chemical	-1	891050
ole	I-Chemical	-1	891050
and	O	-1	891050
hemo@@	O	-1	891050
dialy@@	O	-1	891050
si@@	O	-1	891050
s;	O	-1	891050
and	O	-1	891050
after	O	-1	891050
more	O	-1	891050
than	O	-1	891050
three	O	-1	891050
month@@	O	-1	891050
s,	O	-1	891050
h@@	O	-1	891050
er	O	-1	891050
urinary	O	-1	891050
out@@	O	-1	891050
pu@@	O	-1	891050
t	O	-1	891050
ro@@	O	-1	891050
se	O	-1	891050
ab@@	O	-1	891050
o@@	O	-1	891050
ve	O	-1	891050
5@@	O	-1	891050
00	O	-1	891050
ml@@	O	-1	891050
;	O	-1	891050
and	O	-1	891050
six	O	-1	891050
months	O	-1	891050
after	O	-1	891050
the	O	-1	891050
onset	O	-1	891050
of	O	-1	891050
an@@	B-Disease	D001002	891050
uria	I-Disease	-1	891050
,	O	-1	891050
dialy@@	O	-1	891050
sis	O	-1	891050
treatment	O	-1	891050
was	O	-1	891050
sto@@	O	-1	891050
pp@@	O	-1	891050
ed.	O	-1	891050
This	O	-1	891050
case	O	-1	891050
em@@	O	-1	891050
pha@@	O	-1	891050
si@@	O	-1	891050
z@@	O	-1	891050
es	O	-1	891050
the	O	-1	891050
possib@@	O	-1	891050
ility	O	-1	891050
that	O	-1	891050
H@@	B-Disease	D006463	891050
U@@	I-Disease	-1	891050
S	I-Disease	-1	891050
in	O	-1	891050
ad@@	O	-1	891050
ult@@	O	-1	891050
s	O	-1	891050
is	O	-1	891050
not	O	-1	891050
inv@@	O	-1	891050
ari@@	O	-1	891050
ably	O	-1	891050
ir@@	O	-1	891050
reversible	O	-1	891050
and	O	-1	891050
th@@	O	-1	891050
at@@	O	-1	891050
,	O	-1	891050
des@@	O	-1	891050
pit@@	O	-1	891050
e	O	-1	891050
prolonged	O	-1	891050
ol@@	B-Disease	D009846	891050
ig@@	I-Disease	-1	891050
uria	I-Disease	-1	891050
,	O	-1	891050
recovery	O	-1	891050
of	O	-1	891050
renal	O	-1	891050
function	O	-1	891050
can	O	-1	891050
be	O	-1	891050
obt@@	O	-1	891050
a@@	O	-1	891050
ine@@	O	-1	891050
d.	O	-1	891050
The@@	O	-1	891050
refore,	O	-1	891050
in	O	-1	891050
ad@@	O	-1	891050
ult	O	-1	891050
patients	O	-1	891050
affected	O	-1	891050
by	O	-1	891050
H@@	B-Disease	D006463	891050
U@@	I-Disease	-1	891050
S	I-Disease	-1	891050
,	O	-1	891050
dialy@@	O	-1	891050
sis	O	-1	891050
should	O	-1	891050
not	O	-1	891050
be	O	-1	891050
discontinu@@	O	-1	891050
ed	O	-1	891050
pre@@	O	-1	891050
mat@@	O	-1	891050
ure@@	O	-1	891050
ly@@	O	-1	891050
;	O	-1	891050
mo@@	O	-1	891050
re@@	O	-1	891050
o@@	O	-1	891050
ver,	O	-1	891050
bil@@	O	-1	891050
ateral	O	-1	891050
neph@@	O	-1	891050
rec@@	O	-1	891050
to@@	O	-1	891050
m@@	O	-1	891050
y,	O	-1	891050
for	O	-1	891050
treatment	O	-1	891050
of	O	-1	891050
severe	O	-1	891050
hypertension	B-Disease	D006973	891050
and	O	-1	891050
microangio@@	B-Disease	D000743	891050
path@@	I-Disease	-1	891050
ic	I-Disease	-1	891050
hemolytic	I-Disease	-1	891050
anemia	I-Disease	-1	891050
,	O	-1	891050
should	O	-1	891050
be	O	-1	891050
performed	O	-1	891050
with	O	-1	891050
cau@@	O	-1	891050
tion.	O	-1	891050

Eff@@	O	-1	983936
ects	O	-1	983936
of	O	-1	983936
acet@@	B-Chemical	D001241	983936
yl@@	I-Chemical	-1	983936
sal@@	I-Chemical	-1	983936
ic@@	I-Chemical	-1	983936
yl@@	I-Chemical	-1	983936
ic	I-Chemical	-1	983936
acid	I-Chemical	-1	983936
,	O	-1	983936
di@@	B-Chemical	D004176	983936
pyri@@	I-Chemical	-1	983936
dam@@	I-Chemical	-1	983936
ole	I-Chemical	-1	983936
,	O	-1	983936
and	O	-1	983936
hydro@@	B-Chemical	D006854	983936
cor@@	I-Chemical	-1	983936
tis@@	I-Chemical	-1	983936
one	I-Chemical	-1	983936
on	O	-1	983936
ep@@	B-Chemical	D004837	983936
ine@@	I-Chemical	-1	983936
phrine	I-Chemical	-1	983936
-induced	O	-1	983936
myocardial	B-Disease	D009202	983936
injury	I-Disease	-1	983936
in	O	-1	983936
dog@@	O	-1	983936
s.	O	-1	983936
A	O	-1	983936
re@@	O	-1	983936
produc@@	O	-1	983936
i@@	O	-1	983936
ble	O	-1	983936
model	O	-1	983936
for	O	-1	983936
produc@@	O	-1	983936
ing	O	-1	983936
diff@@	O	-1	983936
use	O	-1	983936
myocardial	B-Disease	D009202	983936
injury	I-Disease	-1	983936
(	O	-1	983936
ep@@	B-Chemical	D004837	983936
ine@@	I-Chemical	-1	983936
phrine	I-Chemical	-1	983936
infu@@	O	-1	983936
sion@@	O	-1	983936
)	O	-1	983936
has	O	-1	983936
been	O	-1	983936
developed	O	-1	983936
to	O	-1	983936
study	O	-1	983936
the	O	-1	983936
cardio@@	O	-1	983936
protective	O	-1	983936
effects	O	-1	983936
of	O	-1	983936
agents	O	-1	983936
or	O	-1	983936
man@@	O	-1	983936
eu@@	O	-1	983936
ver@@	O	-1	983936
s	O	-1	983936
which	O	-1	983936
might	O	-1	983936
al@@	O	-1	983936
ter	O	-1	983936
the	O	-1	983936
ev@@	O	-1	983936
ol@@	O	-1	983936
u@@	O	-1	983936
tion	O	-1	983936
of	O	-1	983936
acute	O	-1	983936
myocardial	B-Disease	D009203	983936
infarction	I-Disease	-1	983936
.	O	-1	983936
In@@	O	-1	983936
fu@@	O	-1	983936
sions	O	-1	983936
of	O	-1	983936
ep@@	B-Chemical	D004837	983936
ine@@	I-Chemical	-1	983936
phrine	I-Chemical	-1	983936
(@@	O	-1	983936
4	O	-1	983936
m@@	O	-1	983936
u@@	O	-1	983936
g	O	-1	983936
per	O	-1	983936
k@@	O	-1	983936
i@@	O	-1	983936
logra@@	O	-1	983936
m	O	-1	983936
per	O	-1	983936
min@@	O	-1	983936
ute	O	-1	983936
for	O	-1	983936
6	O	-1	983936
hour@@	O	-1	983936
s)	O	-1	983936
increased	O	-1	983936
radi@@	B-Chemical	D002132	983936
oc@@	I-Chemical	-1	983936
al@@	I-Chemical	-1	983936
ci@@	I-Chemical	-1	983936
um	I-Chemical	-1	983936
u@@	O	-1	983936
pt@@	O	-1	983936
ak@@	O	-1	983936
es	O	-1	983936
into	O	-1	983936
int@@	O	-1	983936
ac@@	O	-1	983936
t	O	-1	983936
myocardi@@	O	-1	983936
um	O	-1	983936
and	O	-1	983936
each	O	-1	983936
of	O	-1	983936
its	O	-1	983936
sub@@	O	-1	983936
cell@@	O	-1	983936
ular	O	-1	983936
comp@@	O	-1	983936
on@@	O	-1	983936
ents	O	-1	983936
with	O	-1	983936
the	O	-1	983936
mitochondrial	O	-1	983936
frac@@	O	-1	983936
tion	O	-1	983936
show@@	O	-1	983936
ing	O	-1	983936
the	O	-1	983936
most	O	-1	983936
consist@@	O	-1	983936
ent	O	-1	983936
changes	O	-1	983936
when	O	-1	983936
compared	O	-1	983936
to	O	-1	983936
sal@@	O	-1	983936
ine-@@	O	-1	983936
inf@@	O	-1	983936
used	O	-1	983936
control	O	-1	983936
animals	O	-1	983936
(4@@	O	-1	983936
,@@	O	-1	983936
9@@	O	-1	983936
5@@	O	-1	983936
7	O	-1	983936
vs.	O	-1	983936
8@@	O	-1	983936
2@@	O	-1	983936
7	O	-1	983936
coun@@	O	-1	983936
ts	O	-1	983936
per	O	-1	983936
min@@	O	-1	983936
ute	O	-1	983936
per	O	-1	983936
gra@@	O	-1	983936
m	O	-1	983936
of	O	-1	983936
d@@	O	-1	983936
ri@@	O	-1	983936
ed	O	-1	983936
tissue	O	-1	983936
or	O	-1	983936
frac@@	O	-1	983936
tion@@	O	-1	983936
).	O	-1	983936
M@@	O	-1	983936
y@@	O	-1	983936
ocardi@@	O	-1	983936
al	O	-1	983936
concentrations	O	-1	983936
of	O	-1	983936
calcium	B-Chemical	D002118	983936
also	O	-1	983936
increased	O	-1	983936
significantly	O	-1	983936
(1@@	O	-1	983936
2.@@	O	-1	983936
0	O	-1	983936
vs.	O	-1	983936
5.@@	O	-1	983936
0	O	-1	983936
mg@@	O	-1	983936
.@@	O	-1	983936
per	O	-1	983936
100	O	-1	983936
G@@	O	-1	983936
m.	O	-1	983936
of	O	-1	983936
f@@	O	-1	983936
at@@	O	-1	983936
-@@	O	-1	983936
free	O	-1	983936
d@@	O	-1	983936
r@@	O	-1	983936
y	O	-1	983936
weigh@@	O	-1	983936
t@@	O	-1	983936
).	O	-1	983936
In@@	O	-1	983936
fu@@	O	-1	983936
sions	O	-1	983936
of	O	-1	983936
calcium	B-Chemical	D002122	983936
chlor@@	I-Chemical	-1	983936
ide	I-Chemical	-1	983936
suffici@@	O	-1	983936
ent	O	-1	983936
to	O	-1	983936
ra@@	O	-1	983936
is@@	O	-1	983936
e	O	-1	983936
serum	O	-1	983936
calcium	B-Chemical	D002118	983936
concentrations	O	-1	983936
2	O	-1	983936
m@@	O	-1	983936
E@@	O	-1	983936
q@@	O	-1	983936
.	O	-1	983936
per	O	-1	983936
lit@@	O	-1	983936
er	O	-1	983936
fail@@	O	-1	983936
ed	O	-1	983936
to	O	-1	983936
increase	O	-1	983936
calcium	B-Chemical	D002118	983936
influ@@	O	-1	983936
x	O	-1	983936
into	O	-1	983936
the	O	-1	983936
myocardial	O	-1	983936
cell@@	O	-1	983936
.	O	-1	983936
M@@	O	-1	983936
it@@	O	-1	983936
ochond@@	O	-1	983936
rial	O	-1	983936
radi@@	B-Chemical	D002132	983936
oc@@	I-Chemical	-1	983936
al@@	I-Chemical	-1	983936
ci@@	I-Chemical	-1	983936
um	I-Chemical	-1	983936
u@@	O	-1	983936
pt@@	O	-1	983936
ak@@	O	-1	983936
es	O	-1	983936
were	O	-1	983936
significantly	O	-1	983936
decreased	O	-1	983936
in	O	-1	983936
animals	O	-1	983936
pre@@	O	-1	983936
treated	O	-1	983936
with	O	-1	983936
acet@@	B-Chemical	D001241	983936
yl@@	I-Chemical	-1	983936
sal@@	I-Chemical	-1	983936
ic@@	I-Chemical	-1	983936
yl@@	I-Chemical	-1	983936
ic	I-Chemical	-1	983936
acid	I-Chemical	-1	983936
or	O	-1	983936
di@@	B-Chemical	D004176	983936
pyri@@	I-Chemical	-1	983936
dam@@	I-Chemical	-1	983936
ole	I-Chemical	-1	983936
or	O	-1	983936
when	O	-1	983936
hydro@@	B-Chemical	D006854	983936
cor@@	I-Chemical	-1	983936
tis@@	I-Chemical	-1	983936
one	I-Chemical	-1	983936
was	O	-1	983936
ad@@	O	-1	983936
ded	O	-1	983936
to	O	-1	983936
the	O	-1	983936
ep@@	B-Chemical	D004837	983936
ine@@	I-Chemical	-1	983936
phrine	I-Chemical	-1	983936
infusion	O	-1	983936
(2@@	O	-1	983936
,@@	O	-1	983936
6@@	O	-1	983936
8@@	O	-1	983936
2@@	O	-1	983936
,@@	O	-1	983936
2@@	O	-1	983936
,@@	O	-1	983936
80@@	O	-1	983936
3,	O	-1	983936
and	O	-1	983936
3@@	O	-1	983936
,@@	O	-1	983936
4@@	O	-1	983936
24	O	-1	983936
coun@@	O	-1	983936
ts	O	-1	983936
per	O	-1	983936
min@@	O	-1	983936
ute	O	-1	983936
per	O	-1	983936
gra@@	O	-1	983936
m	O	-1	983936
of	O	-1	983936
d@@	O	-1	983936
ri@@	O	-1	983936
ed	O	-1	983936
frac@@	O	-1	983936
tion,	O	-1	983936
respectivel@@	O	-1	983936
y@@	O	-1	983936
).	O	-1	983936
M@@	O	-1	983936
y@@	O	-1	983936
ocardi@@	O	-1	983936
al	O	-1	983936
calcium	B-Chemical	D002118	983936
concentrations	O	-1	983936
also	O	-1	983936
were	O	-1	983936
decreased	O	-1	983936
(1@@	O	-1	983936
1.@@	O	-1	983936
2,	O	-1	983936
8.@@	O	-1	983936
3,	O	-1	983936
and	O	-1	983936
8.@@	O	-1	983936
9	O	-1	983936
mg@@	O	-1	983936
.	O	-1	983936
per	O	-1	983936
100	O	-1	983936
G@@	O	-1	983936
m.	O	-1	983936
of	O	-1	983936
f@@	O	-1	983936
at@@	O	-1	983936
-@@	O	-1	983936
free	O	-1	983936
d@@	O	-1	983936
r@@	O	-1	983936
y	O	-1	983936
weigh@@	O	-1	983936
t,	O	-1	983936
respectivel@@	O	-1	983936
y@@	O	-1	983936
)	O	-1	983936
in	O	-1	983936
the	O	-1	983936
three	O	-1	983936
treatment	O	-1	983936
group@@	O	-1	983936
s,	O	-1	983936
being	O	-1	983936
significantly	O	-1	983936
decreased	O	-1	983936
only	O	-1	983936
in	O	-1	983936
the	O	-1	983936
las@@	O	-1	983936
t	O	-1	983936
tw@@	O	-1	983936
o@@	O	-1	983936
.	O	-1	983936
E@@	O	-1	983936
v@@	O	-1	983936
idence	O	-1	983936
of	O	-1	983936
micro@@	O	-1	983936
sco@@	O	-1	983936
p@@	O	-1	983936
ic	O	-1	983936
damage	O	-1	983936
was	O	-1	983936
gra@@	O	-1	983936
ded	O	-1	983936
as	O	-1	983936
less	O	-1	983936
severe	O	-1	983936
in	O	-1	983936
the	O	-1	983936
three	O	-1	983936
treatment	O	-1	983936
groups.	O	-1	983936
A@@	B-Chemical	D001241	983936
ce@@	I-Chemical	-1	983936
t@@	I-Chemical	-1	983936
yl@@	I-Chemical	-1	983936
sal@@	I-Chemical	-1	983936
ic@@	I-Chemical	-1	983936
yl@@	I-Chemical	-1	983936
ic	I-Chemical	-1	983936
acid	I-Chemical	-1	983936
,	O	-1	983936
di@@	B-Chemical	D004176	983936
pyri@@	I-Chemical	-1	983936
dam@@	I-Chemical	-1	983936
ole	I-Chemical	-1	983936
,	O	-1	983936
and	O	-1	983936
hydro@@	B-Chemical	D006854	983936
cor@@	I-Chemical	-1	983936
tis@@	I-Chemical	-1	983936
one	I-Chemical	-1	983936
all	O	-1	983936
appe@@	O	-1	983936
ar	O	-1	983936
to	O	-1	983936
have	O	-1	983936
cardio@@	O	-1	983936
protective	O	-1	983936
effects	O	-1	983936
when	O	-1	983936
tested	O	-1	983936
in	O	-1	983936
this	O	-1	983936
model@@	O	-1	983936
.	O	-1	983936

Ch@@	O	-1	1428568
ang@@	O	-1	1428568
es	O	-1	1428568
in	O	-1	1428568
de@@	B-Disease	D003866	1428568
pressive	I-Disease	-1	1428568
status	O	-1	1428568
associated	O	-1	1428568
with	O	-1	1428568
to@@	O	-1	1428568
p@@	O	-1	1428568
ical	O	-1	1428568
beta-@@	O	-1	1428568
block@@	O	-1	1428568
ers.	O	-1	1428568
De@@	B-Disease	D003866	1428568
pression	I-Disease	-1	1428568
and	O	-1	1428568
sex@@	B-Disease	D012735	1428568
ual	I-Disease	-1	1428568
dysfunction	I-Disease	-1	1428568
have	O	-1	1428568
been	O	-1	1428568
related	O	-1	1428568
to	O	-1	1428568
side	O	-1	1428568
effects	O	-1	1428568
of	O	-1	1428568
to@@	O	-1	1428568
p@@	O	-1	1428568
ical	O	-1	1428568
beta-@@	O	-1	1428568
block@@	O	-1	1428568
ers.	O	-1	1428568
We	O	-1	1428568
performed	O	-1	1428568
a	O	-1	1428568
pre@@	O	-1	1428568
lim@@	O	-1	1428568
inary	O	-1	1428568
study	O	-1	1428568
in	O	-1	1428568
or@@	O	-1	1428568
der	O	-1	1428568
to	O	-1	1428568
determine	O	-1	1428568
any	O	-1	1428568
difference	O	-1	1428568
between	O	-1	1428568
a	O	-1	1428568
n@@	O	-1	1428568
on	O	-1	1428568
selective	O	-1	1428568
beta-@@	O	-1	1428568
block@@	O	-1	1428568
er	O	-1	1428568
(	O	-1	1428568
ti@@	B-Chemical	D013999	1428568
mo@@	I-Chemical	-1	1428568
lol	I-Chemical	-1	1428568
)	O	-1	1428568
and	O	-1	1428568
a	O	-1	1428568
selective	O	-1	1428568
beta-@@	O	-1	1428568
block@@	O	-1	1428568
er	O	-1	1428568
(	O	-1	1428568
bet@@	B-Chemical	D015784	1428568
ax@@	I-Chemical	-1	1428568
o@@	I-Chemical	-1	1428568
lol	I-Chemical	-1	1428568
)	O	-1	1428568
reg@@	O	-1	1428568
ar@@	O	-1	1428568
ding	O	-1	1428568
C@@	O	-1	1428568
N@@	O	-1	1428568
S	O	-1	1428568
side	O	-1	1428568
effects.	O	-1	1428568
E@@	O	-1	1428568
ight	O	-1	1428568
gl@@	B-Disease	D005901	1428568
au@@	I-Disease	-1	1428568
com@@	I-Disease	-1	1428568
at@@	I-Disease	-1	1428568
ous	I-Disease	-1	1428568
patients	O	-1	1428568
chron@@	O	-1	1428568
ically	O	-1	1428568
treated	O	-1	1428568
with	O	-1	1428568
ti@@	B-Chemical	D013999	1428568
mo@@	I-Chemical	-1	1428568
lol	I-Chemical	-1	1428568
0.@@	O	-1	1428568
5@@	O	-1	1428568
%@@	O	-1	1428568
/@@	O	-1	1428568
12@@	O	-1	1428568
h@@	O	-1	1428568
,	O	-1	1428568
suff@@	O	-1	1428568
ering	O	-1	1428568
from	O	-1	1428568
de@@	B-Disease	D003866	1428568
pression	I-Disease	-1	1428568
diagnos@@	O	-1	1428568
ed	O	-1	1428568
through	O	-1	1428568
D@@	O	-1	1428568
M@@	O	-1	1428568
S@@	O	-1	1428568
-@@	O	-1	1428568
II@@	O	-1	1428568
I@@	O	-1	1428568
-@@	O	-1	1428568
R	O	-1	1428568
c@@	O	-1	1428568
rit@@	O	-1	1428568
er@@	O	-1	1428568
ia,	O	-1	1428568
were	O	-1	1428568
included	O	-1	1428568
in	O	-1	1428568
the	O	-1	1428568
study.	O	-1	1428568
D@@	O	-1	1428568
uring	O	-1	1428568
the	O	-1	1428568
si@@	O	-1	1428568
x@@	O	-1	1428568
-@@	O	-1	1428568
mon@@	O	-1	1428568
th	O	-1	1428568
fol@@	O	-1	1428568
low	O	-1	1428568
up@@	O	-1	1428568
,	O	-1	1428568
de@@	B-Disease	D003866	1428568
pression	I-Disease	-1	1428568
was	O	-1	1428568
qu@@	O	-1	1428568
anti@@	O	-1	1428568
fied	O	-1	1428568
through	O	-1	1428568
the	O	-1	1428568
B@@	O	-1	1428568
ec@@	O	-1	1428568
k	O	-1	1428568
and	O	-1	1428568
Z@@	O	-1	1428568
un@@	O	-1	1428568
g@@	O	-1	1428568
-@@	O	-1	1428568
Con@@	O	-1	1428568
de	O	-1	1428568
s@@	O	-1	1428568
cal@@	O	-1	1428568
es	O	-1	1428568
every	O	-1	1428568
two	O	-1	1428568
months.	O	-1	1428568
In	O	-1	1428568
a	O	-1	1428568
dou@@	O	-1	1428568
ble	O	-1	1428568
bl@@	O	-1	1428568
ind	O	-1	1428568
cros@@	O	-1	1428568
s-@@	O	-1	1428568
over	O	-1	1428568
study	O	-1	1428568
with	O	-1	1428568
control	O	-1	1428568
group@@	O	-1	1428568
,	O	-1	1428568
the	O	-1	1428568
patients	O	-1	1428568
under	O	-1	1428568
ti@@	B-Chemical	D013999	1428568
mo@@	I-Chemical	-1	1428568
lol	I-Chemical	-1	1428568
treatment	O	-1	1428568
presented	O	-1	1428568
higher	O	-1	1428568
de@@	B-Disease	D003866	1428568
pression	I-Disease	-1	1428568
values	O	-1	1428568
measured	O	-1	1428568
through	O	-1	1428568
the	O	-1	1428568
B@@	O	-1	1428568
ec@@	O	-1	1428568
k	O	-1	1428568
and	O	-1	1428568
the	O	-1	1428568
Z@@	O	-1	1428568
un@@	O	-1	1428568
g@@	O	-1	1428568
-@@	O	-1	1428568
Con@@	O	-1	1428568
de	O	-1	1428568
s@@	O	-1	1428568
cal@@	O	-1	1428568
es	O	-1	1428568
(p	O	-1	1428568
<	O	-1	1428568
0.00@@	O	-1	1428568
1	O	-1	1428568
v@@	O	-1	1428568
s	O	-1	1428568
control@@	O	-1	1428568
).	O	-1	1428568
These	O	-1	1428568
results	O	-1	1428568
suggest	O	-1	1428568
that	O	-1	1428568
bet@@	B-Chemical	D015784	1428568
ax@@	I-Chemical	-1	1428568
o@@	I-Chemical	-1	1428568
lol	I-Chemical	-1	1428568
could	O	-1	1428568
be	O	-1	1428568
less	O	-1	1428568
of	O	-1	1428568
a	O	-1	1428568
de@@	B-Disease	D003866	1428568
pression	I-Disease	-1	1428568
-@@	O	-1	1428568
induc@@	O	-1	1428568
er	O	-1	1428568
than	O	-1	1428568
ti@@	B-Chemical	D013999	1428568
mo@@	I-Chemical	-1	1428568
lol	I-Chemical	-1	1428568
in	O	-1	1428568
pre@@	O	-1	1428568
dis@@	O	-1	1428568
pos@@	O	-1	1428568
ed	O	-1	1428568
patients.	O	-1	1428568

L@@	O	-1	1720453
on@@	O	-1	1720453
g@@	O	-1	1720453
-term	O	-1	1720453
follow-up	O	-1	1720453
of	O	-1	1720453
if@@	B-Chemical	D007069	1720453
os@@	I-Chemical	-1	1720453
f@@	I-Chemical	-1	1720453
amide	I-Chemical	-1	1720453
renal	B-Disease	D007674	1720453
toxicity	I-Disease	-1	1720453
in	O	-1	1720453
children	O	-1	1720453
treated	O	-1	1720453
for	O	-1	1720453
mal@@	B-Disease	C535700	1720453
i@@	I-Disease	-1	1720453
gn@@	I-Disease	-1	1720453
ant	I-Disease	-1	1720453
m@@	I-Disease	-1	1720453
es@@	I-Disease	-1	1720453
en@@	I-Disease	-1	1720453
ch@@	I-Disease	-1	1720453
ym@@	I-Disease	-1	1720453
al	I-Disease	-1	1720453
tu@@	I-Disease	-1	1720453
mor@@	I-Disease	-1	1720453
s	I-Disease	-1	1720453
:	O	-1	1720453
an	O	-1	1720453
In@@	O	-1	1720453
tern@@	O	-1	1720453
ation@@	O	-1	1720453
al	O	-1	1720453
S@@	O	-1	1720453
oci@@	O	-1	1720453
ety	O	-1	1720453
of	O	-1	1720453
P@@	O	-1	1720453
edi@@	O	-1	1720453
atric	O	-1	1720453
On@@	O	-1	1720453
co@@	O	-1	1720453
log@@	O	-1	1720453
y	O	-1	1720453
repor@@	O	-1	1720453
t.	O	-1	1720453
The	O	-1	1720453
renal	O	-1	1720453
function	O	-1	1720453
of	O	-1	1720453
7@@	O	-1	1720453
4	O	-1	1720453
children	O	-1	1720453
with	O	-1	1720453
mal@@	B-Disease	C535700	1720453
i@@	I-Disease	-1	1720453
gn@@	I-Disease	-1	1720453
ant	I-Disease	-1	1720453
m@@	I-Disease	-1	1720453
es@@	I-Disease	-1	1720453
en@@	I-Disease	-1	1720453
ch@@	I-Disease	-1	1720453
ym@@	I-Disease	-1	1720453
al	I-Disease	-1	1720453
tu@@	I-Disease	-1	1720453
mor@@	I-Disease	-1	1720453
s	I-Disease	-1	1720453
in	O	-1	1720453
complete	O	-1	1720453
re@@	O	-1	1720453
mission	O	-1	1720453
and	O	-1	1720453
who	O	-1	1720453
have	O	-1	1720453
received	O	-1	1720453
the	O	-1	1720453
same	O	-1	1720453
if@@	B-Chemical	D007069	1720453
os@@	I-Chemical	-1	1720453
f@@	I-Chemical	-1	1720453
amide	I-Chemical	-1	1720453
chemotherapy	O	-1	1720453
pro@@	O	-1	1720453
to@@	O	-1	1720453
co@@	O	-1	1720453
l	O	-1	1720453
(@@	O	-1	1720453
In@@	O	-1	1720453
tern@@	O	-1	1720453
ation@@	O	-1	1720453
al	O	-1	1720453
S@@	O	-1	1720453
oci@@	O	-1	1720453
ety	O	-1	1720453
of	O	-1	1720453
P@@	O	-1	1720453
edi@@	O	-1	1720453
atric	O	-1	1720453
On@@	O	-1	1720453
co@@	O	-1	1720453
log@@	O	-1	1720453
y	O	-1	1720453
M@@	B-Disease	C535700	1720453
al@@	I-Disease	-1	1720453
i@@	I-Disease	-1	1720453
gn@@	I-Disease	-1	1720453
ant	I-Disease	-1	1720453
M@@	I-Disease	-1	1720453
es@@	I-Disease	-1	1720453
en@@	I-Disease	-1	1720453
ch@@	I-Disease	-1	1720453
ym@@	I-Disease	-1	1720453
al	I-Disease	-1	1720453
T@@	I-Disease	-1	1720453
um@@	I-Disease	-1	1720453
or	I-Disease	-1	1720453
S@@	O	-1	1720453
t@@	O	-1	1720453
ud@@	O	-1	1720453
y	O	-1	1720453
8@@	O	-1	1720453
4	O	-1	1720453
[@@	O	-1	1720453
S@@	O	-1	1720453
I@@	O	-1	1720453
O@@	O	-1	1720453
P	O	-1	1720453
M@@	O	-1	1720453
M@@	O	-1	1720453
T	O	-1	1720453
8@@	O	-1	1720453
4@@	O	-1	1720453
]@@	O	-1	1720453
)	O	-1	1720453
were	O	-1	1720453
studied	O	-1	1720453
1	O	-1	1720453
year	O	-1	1720453
after	O	-1	1720453
the	O	-1	1720453
comple@@	O	-1	1720453
tion	O	-1	1720453
of	O	-1	1720453
treatment.	O	-1	1720453
T@@	O	-1	1720453
ot@@	O	-1	1720453
al	O	-1	1720453
cum@@	O	-1	1720453
ul@@	O	-1	1720453
ative	O	-1	1720453
doses	O	-1	1720453
were	O	-1	1720453
3@@	O	-1	1720453
6	O	-1	1720453
or	O	-1	1720453
60	O	-1	1720453
g/@@	O	-1	1720453
m@@	O	-1	1720453
2	O	-1	1720453
of	O	-1	1720453
if@@	B-Chemical	D007069	1720453
os@@	I-Chemical	-1	1720453
f@@	I-Chemical	-1	1720453
amide	I-Chemical	-1	1720453
(@@	O	-1	1720453
six	O	-1	1720453
or	O	-1	1720453
10	O	-1	1720453
cyc@@	O	-1	1720453
le@@	O	-1	1720453
s	O	-1	1720453
of	O	-1	1720453
if@@	B-Chemical	C064227	1720453
os@@	I-Chemical	-1	1720453
f@@	I-Chemical	-1	1720453
amide@@	I-Chemical	-1	1720453
,	I-Chemical	-1	1720453
v@@	I-Chemical	-1	1720453
inc@@	I-Chemical	-1	1720453
ri@@	I-Chemical	-1	1720453
st@@	I-Chemical	-1	1720453
ine,	I-Chemical	-1	1720453
and	I-Chemical	-1	1720453
d@@	I-Chemical	-1	1720453
act@@	I-Chemical	-1	1720453
in@@	I-Chemical	-1	1720453
om@@	I-Chemical	-1	1720453
ycin	I-Chemical	-1	1720453
[	O	-1	1720453
I@@	B-Chemical	C064227	1720453
V@@	I-Chemical	-1	1720453
A	I-Chemical	-1	1720453
]@@	O	-1	1720453
).	O	-1	1720453
N@@	O	-1	1720453
one	O	-1	1720453
of	O	-1	1720453
the@@	O	-1	1720453
m	O	-1	1720453
had	O	-1	1720453
received	O	-1	1720453
cisplatin	B-Chemical	D002945	1720453
chemo@@	O	-1	1720453
therapy.	O	-1	1720453
A@@	O	-1	1720453
g@@	O	-1	1720453
es	O	-1	1720453
rang@@	O	-1	1720453
ed	O	-1	1720453
from	O	-1	1720453
4	O	-1	1720453
months	O	-1	1720453
to	O	-1	1720453
17	O	-1	1720453
year@@	O	-1	1720453
s;	O	-1	1720453
5@@	O	-1	1720453
8	O	-1	1720453
patients	O	-1	1720453
were	O	-1	1720453
mal@@	O	-1	1720453
es	O	-1	1720453
and	O	-1	1720453
4@@	O	-1	1720453
2	O	-1	1720453
femal@@	O	-1	1720453
es.	O	-1	1720453
The	O	-1	1720453
most	O	-1	1720453
common	O	-1	1720453
prim@@	O	-1	1720453
ary	O	-1	1720453
tumor	B-Disease	D009369	1720453
sit@@	O	-1	1720453
e	O	-1	1720453
was	O	-1	1720453
the	O	-1	1720453
he@@	O	-1	1720453
ad	O	-1	1720453
and	O	-1	1720453
nec@@	O	-1	1720453
k@@	O	-1	1720453
.	O	-1	1720453
R@@	O	-1	1720453
en@@	O	-1	1720453
al	O	-1	1720453
function	O	-1	1720453
was	O	-1	1720453
investigated	O	-1	1720453
by	O	-1	1720453
meas@@	O	-1	1720453
uring	O	-1	1720453
plasma	O	-1	1720453
and	O	-1	1720453
urinary	O	-1	1720453
electro@@	O	-1	1720453
ly@@	O	-1	1720453
t@@	O	-1	1720453
es,	O	-1	1720453
g@@	B-Disease	D006030	1720453
lu@@	I-Disease	-1	1720453
co@@	I-Disease	-1	1720453
sur@@	I-Disease	-1	1720453
ia	I-Disease	-1	1720453
,	O	-1	1720453
proteinuria	B-Disease	D011507	1720453
,	O	-1	1720453
amino@@	B-Disease	D000608	1720453
acid@@	I-Disease	-1	1720453
uria	I-Disease	-1	1720453
,	O	-1	1720453
urinary	O	-1	1720453
p@@	O	-1	1720453
H@@	O	-1	1720453
,	O	-1	1720453
os@@	O	-1	1720453
mol@@	O	-1	1720453
ar@@	O	-1	1720453
ity,	O	-1	1720453
creatinine	B-Chemical	D003404	1720453
clear@@	O	-1	1720453
ance@@	O	-1	1720453
,	O	-1	1720453
phosph@@	B-Chemical	D010710	1720453
ate	I-Chemical	-1	1720453
tub@@	O	-1	1720453
ular	O	-1	1720453
re@@	O	-1	1720453
abs@@	O	-1	1720453
or@@	O	-1	1720453
p@@	O	-1	1720453
tion,	O	-1	1720453
bet@@	O	-1	1720453
a	O	-1	1720453
2	O	-1	1720453
micro@@	O	-1	1720453
glo@@	O	-1	1720453
b@@	O	-1	1720453
ul@@	O	-1	1720453
in@@	O	-1	1720453
ur@@	O	-1	1720453
ia,	O	-1	1720453
and	O	-1	1720453
l@@	O	-1	1720453
ys@@	O	-1	1720453
o@@	O	-1	1720453
z@@	O	-1	1720453
ym@@	O	-1	1720453
ur@@	O	-1	1720453
ia.	O	-1	1720453
F@@	O	-1	1720453
if@@	O	-1	1720453
ty-@@	O	-1	1720453
e@@	O	-1	1720453
ight	O	-1	1720453
patients	O	-1	1720453
(@@	O	-1	1720453
7@@	O	-1	1720453
8@@	O	-1	1720453
%)	O	-1	1720453
had	O	-1	1720453
normal	O	-1	1720453
renal	O	-1	1720453
test@@	O	-1	1720453
s,	O	-1	1720453
whereas	O	-1	1720453
16	O	-1	1720453
patients	O	-1	1720453
(2@@	O	-1	1720453
2@@	O	-1	1720453
%)	O	-1	1720453
had	O	-1	1720453
renal	B-Disease	D007674	1720453
abnormal@@	I-Disease	-1	1720453
ities	I-Disease	-1	1720453
.	O	-1	1720453
Two	O	-1	1720453
sub@@	O	-1	1720453
se@@	O	-1	1720453
ts	O	-1	1720453
of	O	-1	1720453
patients	O	-1	1720453
were	O	-1	1720453
identi@@	O	-1	1720453
fied	O	-1	1720453
from	O	-1	1720453
this	O	-1	1720453
lat@@	O	-1	1720453
ter	O	-1	1720453
group@@	O	-1	1720453
:	O	-1	1720453
the	O	-1	1720453
first	O	-1	1720453
included	O	-1	1720453
four	O	-1	1720453
patients	O	-1	1720453
(@@	O	-1	1720453
5%	O	-1	1720453
of	O	-1	1720453
the	O	-1	1720453
total	O	-1	1720453
po@@	O	-1	1720453
pul@@	O	-1	1720453
ation@@	O	-1	1720453
)	O	-1	1720453
who	O	-1	1720453
developed	O	-1	1720453
major	O	-1	1720453
toxicity	B-Disease	D064420	1720453
result@@	O	-1	1720453
ing	O	-1	1720453
in	O	-1	1720453
F@@	B-Disease	D005198	1720453
an@@	I-Disease	-1	1720453
con@@	I-Disease	-1	1720453
i@@	I-Disease	-1	1720453
's	I-Disease	-1	1720453
syndrome	I-Disease	-1	1720453
(	O	-1	1720453
T@@	B-Disease	D005198	1720453
DF@@	I-Disease	-1	1720453
S	I-Disease	-1	1720453
);	O	-1	1720453
and	O	-1	1720453
the	O	-1	1720453
second	O	-1	1720453
group	O	-1	1720453
included	O	-1	1720453
five	O	-1	1720453
patients	O	-1	1720453
with	O	-1	1720453
elevated	O	-1	1720453
bet@@	O	-1	1720453
a	O	-1	1720453
2	O	-1	1720453
micro@@	O	-1	1720453
glo@@	O	-1	1720453
b@@	O	-1	1720453
ul@@	O	-1	1720453
in@@	O	-1	1720453
uria	O	-1	1720453
and	O	-1	1720453
low	O	-1	1720453
phosph@@	B-Chemical	D010710	1720453
ate	I-Chemical	-1	1720453
re@@	O	-1	1720453
abs@@	O	-1	1720453
or@@	O	-1	1720453
p@@	O	-1	1720453
tion.	O	-1	1720453
The	O	-1	1720453
remain@@	O	-1	1720453
ing	O	-1	1720453
seven	O	-1	1720453
patients	O	-1	1720453
had	O	-1	1720453
isol@@	O	-1	1720453
ated	O	-1	1720453
bet@@	O	-1	1720453
a	O	-1	1720453
2	O	-1	1720453
micro@@	O	-1	1720453
glo@@	O	-1	1720453
b@@	O	-1	1720453
ul@@	O	-1	1720453
in@@	O	-1	1720453
ur@@	O	-1	1720453
ia.	O	-1	1720453
S@@	O	-1	1720453
ev@@	O	-1	1720453
ere	O	-1	1720453
toxicity	B-Disease	D064420	1720453
was	O	-1	1720453
cor@@	O	-1	1720453
related	O	-1	1720453
with	O	-1	1720453
the	O	-1	1720453
higher	O	-1	1720453
cum@@	O	-1	1720453
ul@@	O	-1	1720453
ative	O	-1	1720453
dose	O	-1	1720453
of	O	-1	1720453
60	O	-1	1720453
g/@@	O	-1	1720453
m@@	O	-1	1720453
2	O	-1	1720453
of	O	-1	1720453
if@@	B-Chemical	D007069	1720453
os@@	I-Chemical	-1	1720453
f@@	I-Chemical	-1	1720453
amide	I-Chemical	-1	1720453
,	O	-1	1720453
a	O	-1	1720453
youn@@	O	-1	1720453
g@@	O	-1	1720453
er	O	-1	1720453
age	O	-1	1720453
(@@	O	-1	1720453
less	O	-1	1720453
than	O	-1	1720453
2	O	-1	1720453
1@@	O	-1	1720453
/@@	O	-1	1720453
2	O	-1	1720453
years	O	-1	1720453
ol@@	O	-1	1720453
d@@	O	-1	1720453
),	O	-1	1720453
and	O	-1	1720453
a	O	-1	1720453
pre@@	O	-1	1720453
domin@@	O	-1	1720453
ance	O	-1	1720453
of	O	-1	1720453
ve@@	O	-1	1720453
si@@	O	-1	1720453
co@@	O	-1	1720453
pro@@	O	-1	1720453
st@@	O	-1	1720453
atic	O	-1	1720453
tumor	B-Disease	D009369	1720453
invol@@	O	-1	1720453
ve@@	O	-1	1720453
ment.	O	-1	1720453
This	O	-1	1720453
low	O	-1	1720453
perc@@	O	-1	1720453
ent@@	O	-1	1720453
age	O	-1	1720453
(5@@	O	-1	1720453
%)	O	-1	1720453
of	O	-1	1720453
T@@	O	-1	1720453
DF@@	O	-1	1720453
S	O	-1	1720453
mus@@	O	-1	1720453
t	O	-1	1720453
be	O	-1	1720453
evaluated	O	-1	1720453
with	O	-1	1720453
resp@@	O	-1	1720453
ect	O	-1	1720453
to	O	-1	1720453
the	O	-1	1720453
efficacy	O	-1	1720453
of	O	-1	1720453
if@@	B-Chemical	D007069	1720453
os@@	I-Chemical	-1	1720453
f@@	I-Chemical	-1	1720453
amide	I-Chemical	-1	1720453
in	O	-1	1720453
the	O	-1	1720453
treatment	O	-1	1720453
of	O	-1	1720453
m@@	B-Disease	C535700	1720453
es@@	I-Disease	-1	1720453
en@@	I-Disease	-1	1720453
ch@@	I-Disease	-1	1720453
ym@@	I-Disease	-1	1720453
al	I-Disease	-1	1720453
tu@@	I-Disease	-1	1720453
mor@@	I-Disease	-1	1720453
s	I-Disease	-1	1720453
in	O	-1	1720453
child@@	O	-1	1720453
ren@@	O	-1	1720453
.	O	-1	1720453

E@@	O	-1	1833784
v@@	O	-1	1833784
idence	O	-1	1833784
for	O	-1	1833784
an	O	-1	1833784
invol@@	O	-1	1833784
vement	O	-1	1833784
of	O	-1	1833784
D@@	O	-1	1833784
1	O	-1	1833784
and	O	-1	1833784
D2	O	-1	1833784
dopamine	B-Chemical	D004298	1833784
receptors	O	-1	1833784
in	O	-1	1833784
medi@@	O	-1	1833784
ating	O	-1	1833784
nicotine	B-Chemical	D009538	1833784
-induced	O	-1	1833784
hyperactivity	B-Disease	D006948	1833784
in	O	-1	1833784
rats.	O	-1	1833784
Pre@@	O	-1	1833784
vi@@	O	-1	1833784
ous	O	-1	1833784
studies	O	-1	1833784
have	O	-1	1833784
suggested	O	-1	1833784
that	O	-1	1833784
repe@@	O	-1	1833784
ated	O	-1	1833784
exposure	O	-1	1833784
of	O	-1	1833784
rats	O	-1	1833784
to	O	-1	1833784
the	O	-1	1833784
drug	O	-1	1833784
or	O	-1	1833784
to	O	-1	1833784
the	O	-1	1833784
experimental	O	-1	1833784
en@@	O	-1	1833784
vi@@	O	-1	1833784
ron@@	O	-1	1833784
ment	O	-1	1833784
is	O	-1	1833784
nec@@	O	-1	1833784
ess@@	O	-1	1833784
ary	O	-1	1833784
to	O	-1	1833784
obser@@	O	-1	1833784
ve	O	-1	1833784
nicotine	B-Chemical	D009538	1833784
-induced	O	-1	1833784
locomotor	O	-1	1833784
stimul@@	O	-1	1833784
ation.	O	-1	1833784
In	O	-1	1833784
the	O	-1	1833784
present	O	-1	1833784
study	O	-1	1833784
the	O	-1	1833784
role	O	-1	1833784
of	O	-1	1833784
h@@	O	-1	1833784
ab@@	O	-1	1833784
it@@	O	-1	1833784
u@@	O	-1	1833784
ation	O	-1	1833784
to	O	-1	1833784
the	O	-1	1833784
experimental	O	-1	1833784
en@@	O	-1	1833784
vi@@	O	-1	1833784
ron@@	O	-1	1833784
ment	O	-1	1833784
on	O	-1	1833784
the	O	-1	1833784
stimul@@	O	-1	1833784
ant	O	-1	1833784
effect	O	-1	1833784
of	O	-1	1833784
nicotine	B-Chemical	D009538	1833784
in	O	-1	1833784
rats	O	-1	1833784
was	O	-1	1833784
ex@@	O	-1	1833784
am@@	O	-1	1833784
ine@@	O	-1	1833784
d.	O	-1	1833784
In	O	-1	1833784
addi@@	O	-1	1833784
tion,	O	-1	1833784
the	O	-1	1833784
role	O	-1	1833784
of	O	-1	1833784
dopamine	B-Chemical	D004298	1833784
receptors	O	-1	1833784
in	O	-1	1833784
medi@@	O	-1	1833784
ating	O	-1	1833784
nicotine	B-Chemical	D009538	1833784
-induced	O	-1	1833784
locomotor	O	-1	1833784
stimulation	O	-1	1833784
was	O	-1	1833784
investigated	O	-1	1833784
by	O	-1	1833784
examin@@	O	-1	1833784
ing	O	-1	1833784
the	O	-1	1833784
effects	O	-1	1833784
of	O	-1	1833784
selective	O	-1	1833784
D@@	O	-1	1833784
1	O	-1	1833784
and	O	-1	1833784
D2	O	-1	1833784
dopamine	B-Chemical	D004298	1833784
receptor	O	-1	1833784
antagonist@@	O	-1	1833784
s	O	-1	1833784
on	O	-1	1833784
activity	O	-1	1833784
induced	O	-1	1833784
by	O	-1	1833784
nicotine	B-Chemical	D009538	1833784
.	O	-1	1833784
L@@	O	-1	1833784
o@@	O	-1	1833784
com@@	O	-1	1833784
otor	O	-1	1833784
activity	O	-1	1833784
was	O	-1	1833784
assessed	O	-1	1833784
in	O	-1	1833784
male	O	-1	1833784
S@@	O	-1	1833784
pra@@	O	-1	1833784
gu@@	O	-1	1833784
e-@@	O	-1	1833784
D@@	O	-1	1833784
aw@@	O	-1	1833784
le@@	O	-1	1833784
y	O	-1	1833784
rats	O	-1	1833784
tested	O	-1	1833784
in	O	-1	1833784
ph@@	O	-1	1833784
ot@@	O	-1	1833784
oc@@	O	-1	1833784
el@@	O	-1	1833784
l	O	-1	1833784
c@@	O	-1	1833784
ag@@	O	-1	1833784
es.	O	-1	1833784
N@@	B-Chemical	D009538	1833784
icot@@	I-Chemical	-1	1833784
ine	I-Chemical	-1	1833784
(1@@	O	-1	1833784
.@@	O	-1	1833784
0	O	-1	1833784
mg/kg)	O	-1	1833784
caused	O	-1	1833784
a	O	-1	1833784
significant	O	-1	1833784
increase	B-Disease	D006948	1833784
in	I-Disease	-1	1833784
locomotor	I-Disease	-1	1833784
activity	I-Disease	-1	1833784
in	O	-1	1833784
rats	O	-1	1833784
that	O	-1	1833784
were	O	-1	1833784
h@@	O	-1	1833784
ab@@	O	-1	1833784
it@@	O	-1	1833784
u@@	O	-1	1833784
ated	O	-1	1833784
to	O	-1	1833784
the	O	-1	1833784
test	O	-1	1833784
en@@	O	-1	1833784
vi@@	O	-1	1833784
ron@@	O	-1	1833784
ment@@	O	-1	1833784
,	O	-1	1833784
but	O	-1	1833784
had	O	-1	1833784
only	O	-1	1833784
a	O	-1	1833784
we@@	O	-1	1833784
a@@	O	-1	1833784
k	O	-1	1833784
and	O	-1	1833784
del@@	O	-1	1833784
ayed	O	-1	1833784
stimul@@	O	-1	1833784
ant	O	-1	1833784
action	O	-1	1833784
in	O	-1	1833784
rats	O	-1	1833784
that	O	-1	1833784
were	O	-1	1833784
un@@	O	-1	1833784
f@@	O	-1	1833784
am@@	O	-1	1833784
il@@	O	-1	1833784
i@@	O	-1	1833784
ar	O	-1	1833784
with	O	-1	1833784
the	O	-1	1833784
test	O	-1	1833784
en@@	O	-1	1833784
vi@@	O	-1	1833784
ron@@	O	-1	1833784
ment.	O	-1	1833784
The	O	-1	1833784
stimul@@	O	-1	1833784
ant	O	-1	1833784
action	O	-1	1833784
of	O	-1	1833784
nicotine	B-Chemical	D009538	1833784
was	O	-1	1833784
block@@	O	-1	1833784
ed	O	-1	1833784
by	O	-1	1833784
the	O	-1	1833784
central	O	-1	1833784
nicot@@	O	-1	1833784
inic	O	-1	1833784
antagonist	O	-1	1833784
m@@	B-Chemical	D008464	1833784
ec@@	I-Chemical	-1	1833784
am@@	I-Chemical	-1	1833784
yl@@	I-Chemical	-1	1833784
amine	I-Chemical	-1	1833784
but	O	-1	1833784
not	O	-1	1833784
by	O	-1	1833784
the	O	-1	1833784
peripheral	O	-1	1833784
nicot@@	O	-1	1833784
inic	O	-1	1833784
block@@	O	-1	1833784
er	O	-1	1833784
he@@	B-Chemical	D018738	1833784
xameth@@	I-Chemical	-1	1833784
oni@@	I-Chemical	-1	1833784
um	I-Chemical	-1	1833784
,	O	-1	1833784
indicating	O	-1	1833784
that	O	-1	1833784
the	O	-1	1833784
response	O	-1	1833784
is	O	-1	1833784
prob@@	O	-1	1833784
ably	O	-1	1833784
mediated	O	-1	1833784
by	O	-1	1833784
central	O	-1	1833784
nicot@@	O	-1	1833784
inic	O	-1	1833784
receptor@@	O	-1	1833784
s.	O	-1	1833784
N@@	B-Chemical	D009538	1833784
icot@@	I-Chemical	-1	1833784
ine	I-Chemical	-1	1833784
-induced	O	-1	1833784
hyperactivity	B-Disease	D006948	1833784
was	O	-1	1833784
block@@	O	-1	1833784
ed	O	-1	1833784
by	O	-1	1833784
the	O	-1	1833784
selective	O	-1	1833784
D@@	O	-1	1833784
1	O	-1	1833784
antagonist	O	-1	1833784
S@@	B-Chemical	C534628	1833784
C@@	I-Chemical	-1	1833784
H	I-Chemical	-1	1833784
2@@	I-Chemical	-1	1833784
3@@	I-Chemical	-1	1833784
3@@	I-Chemical	-1	1833784
9@@	I-Chemical	-1	1833784
0	I-Chemical	-1	1833784
,	O	-1	1833784
the	O	-1	1833784
selective	O	-1	1833784
D2	O	-1	1833784
antagonist	O	-1	1833784
rac@@	B-Chemical	D020891	1833784
lop@@	I-Chemical	-1	1833784
ri@@	I-Chemical	-1	1833784
de	I-Chemical	-1	1833784
and	O	-1	1833784
the	O	-1	1833784
D@@	O	-1	1833784
1@@	O	-1	1833784
/@@	O	-1	1833784
D2	O	-1	1833784
antagonist	O	-1	1833784
flu@@	B-Chemical	D005476	1833784
phen@@	I-Chemical	-1	1833784
az@@	I-Chemical	-1	1833784
ine	I-Chemical	-1	1833784
.	O	-1	1833784
Pre@@	O	-1	1833784
treatment	O	-1	1833784
with	O	-1	1833784
the	O	-1	1833784
D2	O	-1	1833784
agon@@	O	-1	1833784
ist	O	-1	1833784
P@@	B-Chemical	-1	1833784
H@@	I-Chemical	-1	1833784
N@@	I-Chemical	-1	1833784
O	I-Chemical	-1	1833784
enhanced	O	-1	1833784
nicotine	B-Chemical	D009538	1833784
-induced	O	-1	1833784
hyperactivity	B-Disease	D006948	1833784
,	O	-1	1833784
whereas	O	-1	1833784
the	O	-1	1833784
D@@	O	-1	1833784
1	O	-1	1833784
agon@@	O	-1	1833784
ist	O	-1	1833784
S@@	B-Chemical	D015647	1833784
K@@	I-Chemical	-1	1833784
F	I-Chemical	-1	1833784
3@@	I-Chemical	-1	1833784
8@@	I-Chemical	-1	1833784
3@@	I-Chemical	-1	1833784
9@@	I-Chemical	-1	1833784
3	I-Chemical	-1	1833784
had	O	-1	1833784
no	O	-1	1833784
effect@@	O	-1	1833784
.	O	-1	1833784
The	O	-1	1833784
results	O	-1	1833784
indicate	O	-1	1833784
that	O	-1	1833784
acute	O	-1	1833784
nicotine	B-Chemical	D009538	1833784
injection	O	-1	1833784
induc@@	O	-1	1833784
es	O	-1	1833784
a	O	-1	1833784
p@@	O	-1	1833784
ron@@	O	-1	1833784
oun@@	O	-1	1833784
c@@	O	-1	1833784
ed	O	-1	1833784
hyperactivity	B-Disease	D006948	1833784
in	O	-1	1833784
rats	O	-1	1833784
h@@	O	-1	1833784
ab@@	O	-1	1833784
it@@	O	-1	1833784
u@@	O	-1	1833784
ated	O	-1	1833784
to	O	-1	1833784
the	O	-1	1833784
test	O	-1	1833784
en@@	O	-1	1833784
vi@@	O	-1	1833784
ron@@	O	-1	1833784
ment.	O	-1	1833784
The	O	-1	1833784
effect	O	-1	1833784
appear@@	O	-1	1833784
s	O	-1	1833784
to	O	-1	1833784
be	O	-1	1833784
mediated	O	-1	1833784
by	O	-1	1833784
central	O	-1	1833784
nicotine	B-Chemical	D009538	1833784
receptor@@	O	-1	1833784
s,	O	-1	1833784
possib@@	O	-1	1833784
ly	O	-1	1833784
loc@@	O	-1	1833784
ated	O	-1	1833784
on	O	-1	1833784
dop@@	O	-1	1833784
aminergic	O	-1	1833784
neuron@@	O	-1	1833784
s,	O	-1	1833784
and	O	-1	1833784
also	O	-1	1833784
requ@@	O	-1	1833784
i@@	O	-1	1833784
res	O	-1	1833784
the	O	-1	1833784
activation	O	-1	1833784
of	O	-1	1833784
both	O	-1	1833784
D@@	O	-1	1833784
1	O	-1	1833784
and	O	-1	1833784
D2	O	-1	1833784
dopamine	B-Chemical	D004298	1833784
receptor@@	O	-1	1833784
s.	O	-1	1833784

Ne@@	O	-1	1867351
uro@@	O	-1	1867351
psych@@	O	-1	1867351
i@@	O	-1	1867351
atric	O	-1	1867351
side	O	-1	1867351
effects	O	-1	1867351
after	O	-1	1867351
the	O	-1	1867351
use	O	-1	1867351
of	O	-1	1867351
me@@	B-Chemical	D015767	1867351
f@@	I-Chemical	-1	1867351
lo@@	I-Chemical	-1	1867351
qu@@	I-Chemical	-1	1867351
ine	I-Chemical	-1	1867351
.	O	-1	1867351
This	O	-1	1867351
study	O	-1	1867351
descri@@	O	-1	1867351
b@@	O	-1	1867351
es	O	-1	1867351
neuro@@	O	-1	1867351
psych@@	O	-1	1867351
i@@	O	-1	1867351
atric	O	-1	1867351
side	O	-1	1867351
effects	O	-1	1867351
in	O	-1	1867351
patients	O	-1	1867351
after	O	-1	1867351
treatment	O	-1	1867351
with	O	-1	1867351
me@@	B-Chemical	D015767	1867351
f@@	I-Chemical	-1	1867351
lo@@	I-Chemical	-1	1867351
qu@@	I-Chemical	-1	1867351
ine	I-Chemical	-1	1867351
.	O	-1	1867351
Re@@	O	-1	1867351
ac@@	O	-1	1867351
tions	O	-1	1867351
consist@@	O	-1	1867351
ed	O	-1	1867351
main@@	O	-1	1867351
ly	O	-1	1867351
of	O	-1	1867351
seizures	B-Disease	D012640	1867351
,	O	-1	1867351
acute	O	-1	1867351
psycho@@	B-Disease	D011605	1867351
ses	I-Disease	-1	1867351
,	O	-1	1867351
an@@	B-Disease	D001008	1867351
xi@@	I-Disease	-1	1867351
ety	I-Disease	-1	1867351
neuro@@	I-Disease	-1	1867351
sis	I-Disease	-1	1867351
,	O	-1	1867351
and	O	-1	1867351
major	O	-1	1867351
dist@@	B-Disease	D012893	1867351
urb@@	I-Disease	-1	1867351
anc@@	I-Disease	-1	1867351
es	I-Disease	-1	1867351
of	I-Disease	-1	1867351
sle@@	I-Disease	-1	1867351
ep@@	I-Disease	-1	1867351
-@@	I-Disease	-1	1867351
w@@	I-Disease	-1	1867351
ake	I-Disease	-1	1867351
rhyth@@	I-Disease	-1	1867351
m	I-Disease	-1	1867351
.	O	-1	1867351
S@@	O	-1	1867351
ide	O	-1	1867351
effects	O	-1	1867351
occurred	O	-1	1867351
after	O	-1	1867351
both	O	-1	1867351
therapeutic	O	-1	1867351
and	O	-1	1867351
pro@@	O	-1	1867351
phyl@@	O	-1	1867351
ac@@	O	-1	1867351
tic	O	-1	1867351
int@@	O	-1	1867351
ake	O	-1	1867351
and	O	-1	1867351
were	O	-1	1867351
gra@@	O	-1	1867351
ded	O	-1	1867351
from	O	-1	1867351
moder@@	O	-1	1867351
ate	O	-1	1867351
to	O	-1	1867351
se@@	O	-1	1867351
ve@@	O	-1	1867351
re.	O	-1	1867351
In	O	-1	1867351
a	O	-1	1867351
risk	O	-1	1867351
analysis	O	-1	1867351
of	O	-1	1867351
neuro@@	O	-1	1867351
psych@@	O	-1	1867351
i@@	O	-1	1867351
atric	O	-1	1867351
side	O	-1	1867351
effects	O	-1	1867351
in	O	-1	1867351
G@@	O	-1	1867351
er@@	O	-1	1867351
man@@	O	-1	1867351
y,	O	-1	1867351
it	O	-1	1867351
is	O	-1	1867351
estim@@	O	-1	1867351
ated	O	-1	1867351
that	O	-1	1867351
one	O	-1	1867351
of	O	-1	1867351
8@@	O	-1	1867351
,@@	O	-1	1867351
0@@	O	-1	1867351
00	O	-1	1867351
me@@	B-Chemical	D015767	1867351
f@@	I-Chemical	-1	1867351
lo@@	I-Chemical	-1	1867351
qu@@	I-Chemical	-1	1867351
ine	I-Chemical	-1	1867351
users	O	-1	1867351
suff@@	O	-1	1867351
ers	O	-1	1867351
from	O	-1	1867351
such	O	-1	1867351
reac@@	O	-1	1867351
tions.	O	-1	1867351
The	O	-1	1867351
incidence	O	-1	1867351
calc@@	O	-1	1867351
ulation	O	-1	1867351
revealed	O	-1	1867351
that	O	-1	1867351
one	O	-1	1867351
of	O	-1	1867351
2@@	O	-1	1867351
15	O	-1	1867351
therapeutic	O	-1	1867351
users	O	-1	1867351
had	O	-1	1867351
reac@@	O	-1	1867351
tion@@	O	-1	1867351
s,	O	-1	1867351
compared	O	-1	1867351
with	O	-1	1867351
one	O	-1	1867351
of	O	-1	1867351
13@@	O	-1	1867351
,@@	O	-1	1867351
0@@	O	-1	1867351
00	O	-1	1867351
in	O	-1	1867351
the	O	-1	1867351
pro@@	O	-1	1867351
phyl@@	O	-1	1867351
ax@@	O	-1	1867351
is	O	-1	1867351
group@@	O	-1	1867351
,	O	-1	1867351
ma@@	O	-1	1867351
king	O	-1	1867351
the	O	-1	1867351
risk	O	-1	1867351
of	O	-1	1867351
neuro@@	O	-1	1867351
psych@@	O	-1	1867351
i@@	O	-1	1867351
atric	O	-1	1867351
reactions	O	-1	1867351
after	O	-1	1867351
me@@	B-Chemical	D015767	1867351
f@@	I-Chemical	-1	1867351
lo@@	I-Chemical	-1	1867351
qu@@	I-Chemical	-1	1867351
ine	I-Chemical	-1	1867351
treatment	O	-1	1867351
60	O	-1	1867351
times	O	-1	1867351
higher	O	-1	1867351
than	O	-1	1867351
after	O	-1	1867351
pro@@	O	-1	1867351
phyl@@	O	-1	1867351
ax@@	O	-1	1867351
i@@	O	-1	1867351
s.	O	-1	1867351
The@@	O	-1	1867351
refore,	O	-1	1867351
cer@@	O	-1	1867351
t@@	O	-1	1867351
ain	O	-1	1867351
lim@@	O	-1	1867351
it@@	O	-1	1867351
ations	O	-1	1867351
for	O	-1	1867351
mal@@	B-Disease	D008288	1867351
ar@@	I-Disease	-1	1867351
ia	I-Disease	-1	1867351
pro@@	O	-1	1867351
phyl@@	O	-1	1867351
ax@@	O	-1	1867351
is	O	-1	1867351
and	O	-1	1867351
treatment	O	-1	1867351
with	O	-1	1867351
me@@	B-Chemical	D015767	1867351
f@@	I-Chemical	-1	1867351
lo@@	I-Chemical	-1	1867351
qu@@	I-Chemical	-1	1867351
ine	I-Chemical	-1	1867351
are	O	-1	1867351
recomm@@	O	-1	1867351
en@@	O	-1	1867351
de@@	O	-1	1867351
d.	O	-1	1867351

Re@@	O	-1	2070391
duction	O	-1	2070391
in	O	-1	2070391
injection	O	-1	2070391
pain	B-Disease	D010146	2070391
using	O	-1	2070391
bu@@	O	-1	2070391
ffe@@	O	-1	2070391
red	O	-1	2070391
lidocaine	B-Chemical	D008012	2070391
as	O	-1	2070391
a	O	-1	2070391
loc@@	O	-1	2070391
al	O	-1	2070391
anesthe@@	O	-1	2070391
tic	O	-1	2070391
before	O	-1	2070391
cardiac	O	-1	2070391
ca@@	O	-1	2070391
the@@	O	-1	2070391
ter@@	O	-1	2070391
iz@@	O	-1	2070391
ation.	O	-1	2070391
Pre@@	O	-1	2070391
vi@@	O	-1	2070391
ous	O	-1	2070391
reports	O	-1	2070391
have	O	-1	2070391
suggested	O	-1	2070391
that	O	-1	2070391
pain	B-Disease	D010146	2070391
associated	O	-1	2070391
with	O	-1	2070391
the	O	-1	2070391
injection	O	-1	2070391
of	O	-1	2070391
lidocaine	B-Chemical	D008012	2070391
is	O	-1	2070391
related	O	-1	2070391
to	O	-1	2070391
the	O	-1	2070391
ac@@	O	-1	2070391
i@@	O	-1	2070391
di@@	O	-1	2070391
c	O	-1	2070391
p@@	O	-1	2070391
H	O	-1	2070391
of	O	-1	2070391
the	O	-1	2070391
sol@@	O	-1	2070391
u@@	O	-1	2070391
tion.	O	-1	2070391
To	O	-1	2070391
determine	O	-1	2070391
if	O	-1	2070391
the	O	-1	2070391
addition	O	-1	2070391
of	O	-1	2070391
a	O	-1	2070391
bu@@	O	-1	2070391
ff@@	O	-1	2070391
ering	O	-1	2070391
sol@@	O	-1	2070391
u@@	O	-1	2070391
tion	O	-1	2070391
to	O	-1	2070391
adj@@	O	-1	2070391
us@@	O	-1	2070391
t	O	-1	2070391
the	O	-1	2070391
p@@	O	-1	2070391
H	O	-1	2070391
of	O	-1	2070391
lidocaine	B-Chemical	D008012	2070391
into	O	-1	2070391
the	O	-1	2070391
physi@@	O	-1	2070391
ologic	O	-1	2070391
range	O	-1	2070391
wo@@	O	-1	2070391
uld	O	-1	2070391
re@@	O	-1	2070391
duce	O	-1	2070391
pain	B-Disease	D010146	2070391
during	O	-1	2070391
injec@@	O	-1	2070391
tion,	O	-1	2070391
we	O	-1	2070391
performed	O	-1	2070391
a	O	-1	2070391
bl@@	O	-1	2070391
ind@@	O	-1	2070391
ed	O	-1	2070391
randomized	O	-1	2070391
study	O	-1	2070391
in	O	-1	2070391
patients	O	-1	2070391
under@@	O	-1	2070391
go@@	O	-1	2070391
ing	O	-1	2070391
cardiac	O	-1	2070391
ca@@	O	-1	2070391
the@@	O	-1	2070391
ter@@	O	-1	2070391
iz@@	O	-1	2070391
ation.	O	-1	2070391
Tw@@	O	-1	2070391
ent@@	O	-1	2070391
y	O	-1	2070391
patients	O	-1	2070391
were	O	-1	2070391
as@@	O	-1	2070391
ked	O	-1	2070391
to	O	-1	2070391
qu@@	O	-1	2070391
anti@@	O	-1	2070391
f@@	O	-1	2070391
y	O	-1	2070391
the	O	-1	2070391
severity	O	-1	2070391
of	O	-1	2070391
pain	B-Disease	D010146	2070391
after	O	-1	2070391
receiving	O	-1	2070391
standard	O	-1	2070391
lidocaine	B-Chemical	D008012	2070391
in	O	-1	2070391
one	O	-1	2070391
fem@@	O	-1	2070391
oral	O	-1	2070391
a@@	O	-1	2070391
re@@	O	-1	2070391
a	O	-1	2070391
and	O	-1	2070391
bu@@	O	-1	2070391
ffe@@	O	-1	2070391
red	O	-1	2070391
lidocaine	B-Chemical	D008012	2070391
in	O	-1	2070391
the	O	-1	2070391
op@@	O	-1	2070391
pos@@	O	-1	2070391
ite	O	-1	2070391
fem@@	O	-1	2070391
oral	O	-1	2070391
a@@	O	-1	2070391
re@@	O	-1	2070391
a.	O	-1	2070391
The	O	-1	2070391
mean	O	-1	2070391
pain	B-Disease	D010146	2070391
scor@@	O	-1	2070391
e	O	-1	2070391
for	O	-1	2070391
bu@@	O	-1	2070391
ffe@@	O	-1	2070391
red	O	-1	2070391
lidocaine	B-Chemical	D008012	2070391
was	O	-1	2070391
significantly	O	-1	2070391
lower	O	-1	2070391
than	O	-1	2070391
the	O	-1	2070391
mean	O	-1	2070391
scor@@	O	-1	2070391
e	O	-1	2070391
for	O	-1	2070391
standard	O	-1	2070391
lidocaine	B-Chemical	D008012	2070391
(2@@	O	-1	2070391
.@@	O	-1	2070391
7	O	-1	2070391
+/-	O	-1	2070391
1.@@	O	-1	2070391
9	O	-1	2070391
vs.	O	-1	2070391
3.@@	O	-1	2070391
8	O	-1	2070391
+/-	O	-1	2070391
2.@@	O	-1	2070391
2,	O	-1	2070391
P	O	-1	2070391
=	O	-1	2070391
0.0@@	O	-1	2070391
3@@	O	-1	2070391
).	O	-1	2070391
The	O	-1	2070391
p@@	O	-1	2070391
H	O	-1	2070391
adjust@@	O	-1	2070391
ment	O	-1	2070391
of	O	-1	2070391
standard	O	-1	2070391
lidocaine	B-Chemical	D008012	2070391
can	O	-1	2070391
be	O	-1	2070391
ac@@	O	-1	2070391
com@@	O	-1	2070391
pl@@	O	-1	2070391
ished	O	-1	2070391
e@@	O	-1	2070391
a@@	O	-1	2070391
si@@	O	-1	2070391
ly	O	-1	2070391
in	O	-1	2070391
the	O	-1	2070391
ca@@	O	-1	2070391
the@@	O	-1	2070391
ter@@	O	-1	2070391
ization	O	-1	2070391
labor@@	O	-1	2070391
atory	O	-1	2070391
before	O	-1	2070391
injection	O	-1	2070391
and	O	-1	2070391
results	O	-1	2070391
in	O	-1	2070391
a	O	-1	2070391
reduction	O	-1	2070391
of	O	-1	2070391
the	O	-1	2070391
pain	B-Disease	D010146	2070391
occur@@	O	-1	2070391
r@@	O	-1	2070391
ing	O	-1	2070391
during	O	-1	2070391
the	O	-1	2070391
inf@@	O	-1	2070391
iltration	O	-1	2070391
of	O	-1	2070391
tissu@@	O	-1	2070391
es.	O	-1	2070391

R@@	O	-1	2266990
an@@	O	-1	2266990
dom@@	O	-1	2266990
iz@@	O	-1	2266990
ed,	O	-1	2266990
double-bl@@	O	-1	2266990
ind	O	-1	2266990
trial	O	-1	2266990
of	O	-1	2266990
ma@@	B-Chemical	D008454	2266990
z@@	I-Chemical	-1	2266990
in@@	I-Chemical	-1	2266990
do@@	I-Chemical	-1	2266990
l	I-Chemical	-1	2266990
in	O	-1	2266990
D@@	B-Disease	D020388	2266990
uc@@	I-Disease	-1	2266990
h@@	I-Disease	-1	2266990
en@@	I-Disease	-1	2266990
n@@	I-Disease	-1	2266990
e	I-Disease	-1	2266990
dy@@	I-Disease	-1	2266990
stro@@	I-Disease	-1	2266990
ph@@	I-Disease	-1	2266990
y	I-Disease	-1	2266990
.	O	-1	2266990
There	O	-1	2266990
is	O	-1	2266990
evidence	O	-1	2266990
that	O	-1	2266990
growth	O	-1	2266990
h@@	O	-1	2266990
orm@@	O	-1	2266990
one	O	-1	2266990
may	O	-1	2266990
be	O	-1	2266990
related	O	-1	2266990
to	O	-1	2266990
the	O	-1	2266990
progres@@	O	-1	2266990
sion	O	-1	2266990
of	O	-1	2266990
we@@	B-Disease	D018908	2266990
ak@@	I-Disease	-1	2266990
ness	I-Disease	-1	2266990
in	O	-1	2266990
D@@	B-Disease	D020388	2266990
uc@@	I-Disease	-1	2266990
h@@	I-Disease	-1	2266990
en@@	I-Disease	-1	2266990
n@@	I-Disease	-1	2266990
e	I-Disease	-1	2266990
dy@@	I-Disease	-1	2266990
stro@@	I-Disease	-1	2266990
ph@@	I-Disease	-1	2266990
y	I-Disease	-1	2266990
.	O	-1	2266990
We	O	-1	2266990
con@@	O	-1	2266990
duc@@	O	-1	2266990
ted	O	-1	2266990
a	O	-1	2266990
1@@	O	-1	2266990
2-@@	O	-1	2266990
mon@@	O	-1	2266990
th	O	-1	2266990
controlled	O	-1	2266990
trial	O	-1	2266990
of	O	-1	2266990
ma@@	B-Chemical	D008454	2266990
z@@	I-Chemical	-1	2266990
in@@	I-Chemical	-1	2266990
do@@	I-Chemical	-1	2266990
l	I-Chemical	-1	2266990
,	O	-1	2266990
a	O	-1	2266990
p@@	O	-1	2266990
ut@@	O	-1	2266990
ative	O	-1	2266990
growth	O	-1	2266990
h@@	O	-1	2266990
orm@@	O	-1	2266990
one	O	-1	2266990
secre@@	O	-1	2266990
tion	O	-1	2266990
inhibitor@@	O	-1	2266990
,	O	-1	2266990
in	O	-1	2266990
8@@	O	-1	2266990
3	O	-1	2266990
bo@@	O	-1	2266990
ys	O	-1	2266990
with	O	-1	2266990
D@@	B-Disease	D020388	2266990
uc@@	I-Disease	-1	2266990
h@@	I-Disease	-1	2266990
en@@	I-Disease	-1	2266990
n@@	I-Disease	-1	2266990
e	I-Disease	-1	2266990
dy@@	I-Disease	-1	2266990
stro@@	I-Disease	-1	2266990
ph@@	I-Disease	-1	2266990
y	I-Disease	-1	2266990
.	O	-1	2266990
M@@	O	-1	2266990
us@@	O	-1	2266990
c@@	O	-1	2266990
le	O	-1	2266990
st@@	O	-1	2266990
ren@@	O	-1	2266990
g@@	O	-1	2266990
th@@	O	-1	2266990
,	O	-1	2266990
contrac@@	O	-1	2266990
tu@@	O	-1	2266990
res@@	O	-1	2266990
,	O	-1	2266990
functional	O	-1	2266990
ability	O	-1	2266990
and	O	-1	2266990
pulmonary	O	-1	2266990
function	O	-1	2266990
were	O	-1	2266990
tested	O	-1	2266990
at	O	-1	2266990
basel@@	O	-1	2266990
ine,	O	-1	2266990
and	O	-1	2266990
6	O	-1	2266990
and	O	-1	2266990
12	O	-1	2266990
months	O	-1	2266990
after	O	-1	2266990
treatment	O	-1	2266990
with	O	-1	2266990
ma@@	B-Chemical	D008454	2266990
z@@	I-Chemical	-1	2266990
in@@	I-Chemical	-1	2266990
do@@	I-Chemical	-1	2266990
l	I-Chemical	-1	2266990
(@@	O	-1	2266990
3	O	-1	2266990
mg/d@@	O	-1	2266990
)	O	-1	2266990
or	O	-1	2266990
placebo@@	O	-1	2266990
.	O	-1	2266990
The	O	-1	2266990
study	O	-1	2266990
was	O	-1	2266990
de@@	O	-1	2266990
signed	O	-1	2266990
to	O	-1	2266990
have	O	-1	2266990
a	O	-1	2266990
po@@	O	-1	2266990
w@@	O	-1	2266990
er	O	-1	2266990
of	O	-1	2266990
greater	O	-1	2266990
than	O	-1	2266990
0.@@	O	-1	2266990
9@@	O	-1	2266990
0	O	-1	2266990
to	O	-1	2266990
det@@	O	-1	2266990
ect	O	-1	2266990
a	O	-1	2266990
s@@	O	-1	2266990
low@@	O	-1	2266990
ing	O	-1	2266990
to	O	-1	2266990
2@@	O	-1	2266990
5%	O	-1	2266990
of	O	-1	2266990
the	O	-1	2266990
ex@@	O	-1	2266990
p@@	O	-1	2266990
ected	O	-1	2266990
rate	O	-1	2266990
of	O	-1	2266990
progres@@	O	-1	2266990
sion	O	-1	2266990
of	O	-1	2266990
we@@	B-Disease	D018908	2266990
ak@@	I-Disease	-1	2266990
ness	I-Disease	-1	2266990
at	O	-1	2266990
P	O	-1	2266990
less	O	-1	2266990
than	O	-1	2266990
0.05@@	O	-1	2266990
.	O	-1	2266990
M@@	B-Chemical	D008454	2266990
az@@	I-Chemical	-1	2266990
in@@	I-Chemical	-1	2266990
do@@	I-Chemical	-1	2266990
l	I-Chemical	-1	2266990
did	O	-1	2266990
not	O	-1	2266990
ben@@	O	-1	2266990
e@@	O	-1	2266990
fi@@	O	-1	2266990
t	O	-1	2266990
st@@	O	-1	2266990
ren@@	O	-1	2266990
g@@	O	-1	2266990
th	O	-1	2266990
at	O	-1	2266990
any	O	-1	2266990
po@@	O	-1	2266990
in@@	O	-1	2266990
t	O	-1	2266990
in	O	-1	2266990
the	O	-1	2266990
study.	O	-1	2266990
S@@	O	-1	2266990
ide	O	-1	2266990
effects	O	-1	2266990
at@@	O	-1	2266990
tri@@	O	-1	2266990
but@@	O	-1	2266990
able	O	-1	2266990
to	O	-1	2266990
ma@@	B-Chemical	D008454	2266990
z@@	I-Chemical	-1	2266990
in@@	I-Chemical	-1	2266990
do@@	I-Chemical	-1	2266990
l	I-Chemical	-1	2266990
included	O	-1	2266990
decreased	B-Disease	D001068	2266990
appe@@	I-Disease	-1	2266990
ti@@	I-Disease	-1	2266990
te	I-Disease	-1	2266990
(3@@	O	-1	2266990
6@@	O	-1	2266990
%),	O	-1	2266990
d@@	B-Disease	D014987	2266990
r@@	I-Disease	-1	2266990
y	I-Disease	-1	2266990
mou@@	I-Disease	-1	2266990
th	I-Disease	-1	2266990
(@@	O	-1	2266990
10@@	O	-1	2266990
%),	O	-1	2266990
behavioral	O	-1	2266990
change	O	-1	2266990
(2@@	O	-1	2266990
2@@	O	-1	2266990
%),	O	-1	2266990
and	O	-1	2266990
gast@@	B-Disease	D012817	2266990
ro@@	I-Disease	-1	2266990
in@@	I-Disease	-1	2266990
test@@	I-Disease	-1	2266990
inal	I-Disease	-1	2266990
symptoms	I-Disease	-1	2266990
(1@@	O	-1	2266990
8@@	O	-1	2266990
%@@	O	-1	2266990
);	O	-1	2266990
ma@@	B-Chemical	D008454	2266990
z@@	I-Chemical	-1	2266990
in@@	I-Chemical	-1	2266990
do@@	I-Chemical	-1	2266990
l	I-Chemical	-1	2266990
dos@@	O	-1	2266990
age	O	-1	2266990
was	O	-1	2266990
reduced	O	-1	2266990
in	O	-1	2266990
4@@	O	-1	2266990
3@@	O	-1	2266990
%	O	-1	2266990
of	O	-1	2266990
patients.	O	-1	2266990
The	O	-1	2266990
effect	O	-1	2266990
of	O	-1	2266990
ma@@	B-Chemical	D008454	2266990
z@@	I-Chemical	-1	2266990
in@@	I-Chemical	-1	2266990
do@@	I-Chemical	-1	2266990
l	I-Chemical	-1	2266990
on	O	-1	2266990
G@@	O	-1	2266990
H	O	-1	2266990
secre@@	O	-1	2266990
tion	O	-1	2266990
was	O	-1	2266990
estim@@	O	-1	2266990
ated	O	-1	2266990
in@@	O	-1	2266990
direc@@	O	-1	2266990
tly	O	-1	2266990
by	O	-1	2266990
compar@@	O	-1	2266990
ing	O	-1	2266990
the	O	-1	2266990
post@@	O	-1	2266990
abs@@	O	-1	2266990
or@@	O	-1	2266990
p@@	O	-1	2266990
tive	O	-1	2266990
I@@	O	-1	2266990
GF@@	O	-1	2266990
-@@	O	-1	2266990
I	O	-1	2266990
levels	O	-1	2266990
obtained	O	-1	2266990
following	O	-1	2266990
3,	O	-1	2266990
6,	O	-1	2266990
9@@	O	-1	2266990
,	O	-1	2266990
and	O	-1	2266990
12	O	-1	2266990
months	O	-1	2266990
in	O	-1	2266990
the	O	-1	2266990
ma@@	B-Chemical	D008454	2266990
z@@	I-Chemical	-1	2266990
in@@	I-Chemical	-1	2266990
do@@	I-Chemical	-1	2266990
l	I-Chemical	-1	2266990
treated	O	-1	2266990
to	O	-1	2266990
those	O	-1	2266990
in	O	-1	2266990
the	O	-1	2266990
placebo	O	-1	2266990
groups.	O	-1	2266990
Although	O	-1	2266990
ma@@	B-Chemical	D008454	2266990
z@@	I-Chemical	-1	2266990
in@@	I-Chemical	-1	2266990
do@@	I-Chemical	-1	2266990
l	I-Chemical	-1	2266990
-treated	O	-1	2266990
patients	O	-1	2266990
g@@	O	-1	2266990
ained	O	-1	2266990
less	O	-1	2266990
weight	O	-1	2266990
and	O	-1	2266990
he@@	O	-1	2266990
ight	O	-1	2266990
than	O	-1	2266990
placebo@@	O	-1	2266990
-treated	O	-1	2266990
patients,	O	-1	2266990
no	O	-1	2266990
significant	O	-1	2266990
effect	O	-1	2266990
on	O	-1	2266990
I@@	O	-1	2266990
GF@@	O	-1	2266990
-@@	O	-1	2266990
I	O	-1	2266990
levels	O	-1	2266990
was	O	-1	2266990
obser@@	O	-1	2266990
ved.	O	-1	2266990
M@@	B-Chemical	D008454	2266990
az@@	I-Chemical	-1	2266990
in@@	I-Chemical	-1	2266990
do@@	I-Chemical	-1	2266990
l	I-Chemical	-1	2266990
doses	O	-1	2266990
not	O	-1	2266990
s@@	O	-1	2266990
low	O	-1	2266990
the	O	-1	2266990
progres@@	O	-1	2266990
sion	O	-1	2266990
of	O	-1	2266990
we@@	B-Disease	D018908	2266990
ak@@	I-Disease	-1	2266990
ness	I-Disease	-1	2266990
in	O	-1	2266990
D@@	B-Disease	D020388	2266990
uc@@	I-Disease	-1	2266990
h@@	I-Disease	-1	2266990
en@@	I-Disease	-1	2266990
n@@	I-Disease	-1	2266990
e	I-Disease	-1	2266990
dy@@	I-Disease	-1	2266990
stro@@	I-Disease	-1	2266990
ph@@	I-Disease	-1	2266990
y	I-Disease	-1	2266990
.	O	-1	2266990

P@@	B-Chemical	D010431	2348231
ent@@	I-Chemical	-1	2348231
oxif@@	I-Chemical	-1	2348231
yl@@	I-Chemical	-1	2348231
line	I-Chemical	-1	2348231
(	O	-1	2348231
T@@	B-Chemical	D010431	2348231
ren@@	I-Chemical	-1	2348231
t@@	I-Chemical	-1	2348231
al	I-Chemical	-1	2348231
)	O	-1	2348231
does	O	-1	2348231
not	O	-1	2348231
inhib@@	O	-1	2348231
it	O	-1	2348231
di@@	B-Chemical	D004176	2348231
pyri@@	I-Chemical	-1	2348231
dam@@	I-Chemical	-1	2348231
ole	I-Chemical	-1	2348231
-induced	O	-1	2348231
coronary	O	-1	2348231
hy@@	B-Disease	D006940	2348231
pe@@	I-Disease	-1	2348231
re@@	I-Disease	-1	2348231
mia	I-Disease	-1	2348231
:	O	-1	2348231
implic@@	O	-1	2348231
ations	O	-1	2348231
for	O	-1	2348231
di@@	B-Chemical	D004176	2348231
pyri@@	I-Chemical	-1	2348231
dam@@	I-Chemical	-1	2348231
ole	I-Chemical	-1	2348231
-	O	-1	2348231
thal@@	B-Chemical	D013793	2348231
li@@	I-Chemical	-1	2348231
um	I-Chemical	-1	2348231
-@@	O	-1	2348231
20@@	O	-1	2348231
1	O	-1	2348231
myocardial	O	-1	2348231
imag@@	O	-1	2348231
ing.	O	-1	2348231
D@@	B-Chemical	D004176	2348231
ip@@	I-Chemical	-1	2348231
y@@	I-Chemical	-1	2348231
ri@@	I-Chemical	-1	2348231
dam@@	I-Chemical	-1	2348231
ole	I-Chemical	-1	2348231
-	O	-1	2348231
thal@@	B-Chemical	D013793	2348231
li@@	I-Chemical	-1	2348231
um	I-Chemical	-1	2348231
-@@	O	-1	2348231
20@@	O	-1	2348231
1	O	-1	2348231
imaging	O	-1	2348231
is	O	-1	2348231
often	O	-1	2348231
performed	O	-1	2348231
in	O	-1	2348231
patients	O	-1	2348231
un@@	O	-1	2348231
able	O	-1	2348231
to	O	-1	2348231
ex@@	O	-1	2348231
er@@	O	-1	2348231
cis@@	O	-1	2348231
e	O	-1	2348231
because	O	-1	2348231
of	O	-1	2348231
peripheral	B-Disease	D016491	2348231
vascular	I-Disease	-1	2348231
disease	I-Disease	-1	2348231
.	O	-1	2348231
M@@	O	-1	2348231
any	O	-1	2348231
of	O	-1	2348231
these	O	-1	2348231
patients	O	-1	2348231
are	O	-1	2348231
taking	O	-1	2348231
pent@@	B-Chemical	D010431	2348231
oxif@@	I-Chemical	-1	2348231
yl@@	I-Chemical	-1	2348231
line	I-Chemical	-1	2348231
(	O	-1	2348231
T@@	B-Chemical	D010431	2348231
ren@@	I-Chemical	-1	2348231
t@@	I-Chemical	-1	2348231
al	I-Chemical	-1	2348231
),	O	-1	2348231
a	O	-1	2348231
methyl@@	B-Chemical	C008514	2348231
x@@	I-Chemical	-1	2348231
an@@	I-Chemical	-1	2348231
th@@	I-Chemical	-1	2348231
ine	I-Chemical	-1	2348231
der@@	O	-1	2348231
i@@	O	-1	2348231
v@@	O	-1	2348231
ative	O	-1	2348231
which	O	-1	2348231
may	O	-1	2348231
impro@@	O	-1	2348231
ve	O	-1	2348231
inter@@	B-Disease	D007383	2348231
mit@@	I-Disease	-1	2348231
t@@	I-Disease	-1	2348231
ent	I-Disease	-1	2348231
cl@@	I-Disease	-1	2348231
a@@	I-Disease	-1	2348231
ud@@	I-Disease	-1	2348231
ic@@	I-Disease	-1	2348231
ation	I-Disease	-1	2348231
.	O	-1	2348231
Whe@@	O	-1	2348231
ther	O	-1	2348231
pent@@	B-Chemical	D010431	2348231
oxif@@	I-Chemical	-1	2348231
yl@@	I-Chemical	-1	2348231
line	I-Chemical	-1	2348231
inhibit@@	O	-1	2348231
s	O	-1	2348231
di@@	B-Chemical	D004176	2348231
pyri@@	I-Chemical	-1	2348231
dam@@	I-Chemical	-1	2348231
ole	I-Chemical	-1	2348231
-induced	O	-1	2348231
coronary	O	-1	2348231
hy@@	B-Disease	D006940	2348231
pe@@	I-Disease	-1	2348231
re@@	I-Disease	-1	2348231
mia	I-Disease	-1	2348231
like	O	-1	2348231
other	O	-1	2348231
methyl@@	B-Chemical	C008514	2348231
x@@	I-Chemical	-1	2348231
an@@	I-Chemical	-1	2348231
th@@	I-Chemical	-1	2348231
in@@	I-Chemical	-1	2348231
es	I-Chemical	-1	2348231
such	O	-1	2348231
as	O	-1	2348231
the@@	B-Chemical	D013806	2348231
oph@@	I-Chemical	-1	2348231
yl@@	I-Chemical	-1	2348231
line	I-Chemical	-1	2348231
and	O	-1	2348231
should	O	-1	2348231
be	O	-1	2348231
sto@@	O	-1	2348231
pp@@	O	-1	2348231
ed	O	-1	2348231
prior	O	-1	2348231
to	O	-1	2348231
di@@	B-Chemical	D004176	2348231
pyri@@	I-Chemical	-1	2348231
dam@@	I-Chemical	-1	2348231
ole	I-Chemical	-1	2348231
-	O	-1	2348231
thal@@	B-Chemical	D013793	2348231
li@@	I-Chemical	-1	2348231
um	I-Chemical	-1	2348231
-@@	O	-1	2348231
20@@	O	-1	2348231
1	O	-1	2348231
imaging	O	-1	2348231
is	O	-1	2348231
un@@	O	-1	2348231
know@@	O	-1	2348231
n@@	O	-1	2348231
.	O	-1	2348231
The@@	O	-1	2348231
refore,	O	-1	2348231
we	O	-1	2348231
studied	O	-1	2348231
the	O	-1	2348231
hy@@	O	-1	2348231
pe@@	O	-1	2348231
re@@	O	-1	2348231
mic	O	-1	2348231
response	O	-1	2348231
to	O	-1	2348231
di@@	B-Chemical	D004176	2348231
pyri@@	I-Chemical	-1	2348231
dam@@	I-Chemical	-1	2348231
ole	I-Chemical	-1	2348231
in	O	-1	2348231
seven	O	-1	2348231
o@@	O	-1	2348231
pen@@	O	-1	2348231
-@@	O	-1	2348231
ch@@	O	-1	2348231
est	O	-1	2348231
anesthe@@	O	-1	2348231
tiz@@	O	-1	2348231
ed	O	-1	2348231
dog@@	O	-1	2348231
s	O	-1	2348231
after	O	-1	2348231
pretreatment	O	-1	2348231
with	O	-1	2348231
either	O	-1	2348231
pent@@	B-Chemical	D010431	2348231
oxif@@	I-Chemical	-1	2348231
yl@@	I-Chemical	-1	2348231
line	I-Chemical	-1	2348231
(@@	O	-1	2348231
0@@	O	-1	2348231
,	O	-1	2348231
7.@@	O	-1	2348231
5,	O	-1	2348231
or	O	-1	2348231
15	O	-1	2348231
mg/kg	O	-1	2348231
i.v@@	O	-1	2348231
.)	O	-1	2348231
or	O	-1	2348231
the@@	B-Chemical	D013806	2348231
oph@@	I-Chemical	-1	2348231
yl@@	I-Chemical	-1	2348231
line	I-Chemical	-1	2348231
(@@	O	-1	2348231
3	O	-1	2348231
mg/kg	O	-1	2348231
i.v@@	O	-1	2348231
.@@	O	-1	2348231
).	O	-1	2348231
B@@	O	-1	2348231
as@@	O	-1	2348231
el@@	O	-1	2348231
ine	O	-1	2348231
cir@@	O	-1	2348231
cum@@	O	-1	2348231
f@@	O	-1	2348231
le@@	O	-1	2348231
x	O	-1	2348231
coronary	O	-1	2348231
blood	O	-1	2348231
f@@	O	-1	2348231
low@@	O	-1	2348231
s	O	-1	2348231
did	O	-1	2348231
not	O	-1	2348231
diff@@	O	-1	2348231
er	O	-1	2348231
significantly	O	-1	2348231
among	O	-1	2348231
treatment	O	-1	2348231
groups.	O	-1	2348231
D@@	B-Chemical	D004176	2348231
ip@@	I-Chemical	-1	2348231
y@@	I-Chemical	-1	2348231
ri@@	I-Chemical	-1	2348231
dam@@	I-Chemical	-1	2348231
ole	I-Chemical	-1	2348231
significantly	O	-1	2348231
increased	O	-1	2348231
coronary	O	-1	2348231
blood	O	-1	2348231
flow	O	-1	2348231
before	O	-1	2348231
and	O	-1	2348231
after	O	-1	2348231
7.@@	O	-1	2348231
5	O	-1	2348231
or	O	-1	2348231
15	O	-1	2348231
mm@@	O	-1	2348231
/@@	O	-1	2348231
k@@	O	-1	2348231
g	O	-1	2348231
i.v@@	O	-1	2348231
.	O	-1	2348231
pent@@	B-Chemical	D010431	2348231
oxif@@	I-Chemical	-1	2348231
yl@@	I-Chemical	-1	2348231
line	I-Chemical	-1	2348231
(p	O	-1	2348231
less	O	-1	2348231
than	O	-1	2348231
0.00@@	O	-1	2348231
2@@	O	-1	2348231
).	O	-1	2348231
N@@	O	-1	2348231
either	O	-1	2348231
dose	O	-1	2348231
of	O	-1	2348231
pent@@	B-Chemical	D010431	2348231
oxif@@	I-Chemical	-1	2348231
yl@@	I-Chemical	-1	2348231
line	I-Chemical	-1	2348231
significantly	O	-1	2348231
decreased	O	-1	2348231
the	O	-1	2348231
di@@	B-Chemical	D004176	2348231
pyri@@	I-Chemical	-1	2348231
dam@@	I-Chemical	-1	2348231
ole	I-Chemical	-1	2348231
-induced	O	-1	2348231
hy@@	B-Disease	D006940	2348231
pe@@	I-Disease	-1	2348231
re@@	I-Disease	-1	2348231
mia	I-Disease	-1	2348231
,	O	-1	2348231
while	O	-1	2348231
pe@@	O	-1	2348231
a@@	O	-1	2348231
k	O	-1	2348231
coronary	O	-1	2348231
blood	O	-1	2348231
flow	O	-1	2348231
was	O	-1	2348231
significantly	O	-1	2348231
lower	O	-1	2348231
after	O	-1	2348231
the@@	B-Chemical	D013806	2348231
oph@@	I-Chemical	-1	2348231
yl@@	I-Chemical	-1	2348231
line	I-Chemical	-1	2348231
(p	O	-1	2348231
less	O	-1	2348231
than	O	-1	2348231
0.0@@	O	-1	2348231
1).	O	-1	2348231
We	O	-1	2348231
concl@@	O	-1	2348231
ude	O	-1	2348231
that	O	-1	2348231
pent@@	B-Chemical	D010431	2348231
oxy@@	I-Chemical	-1	2348231
if@@	I-Chemical	-1	2348231
yl@@	I-Chemical	-1	2348231
line	I-Chemical	-1	2348231
does	O	-1	2348231
not	O	-1	2348231
inhib@@	O	-1	2348231
it	O	-1	2348231
di@@	B-Chemical	D004176	2348231
pyri@@	I-Chemical	-1	2348231
dam@@	I-Chemical	-1	2348231
ole	I-Chemical	-1	2348231
-induced	O	-1	2348231
coronary	O	-1	2348231
hy@@	B-Disease	D006940	2348231
pe@@	I-Disease	-1	2348231
re@@	I-Disease	-1	2348231
mia	I-Disease	-1	2348231
even	O	-1	2348231
at	O	-1	2348231
high	O	-1	2348231
dos@@	O	-1	2348231
es.	O	-1	2348231

C@@	O	-1	2355241
ause	O	-1	2355241
of	O	-1	2355241
death	B-Disease	D003643	2355241
among	O	-1	2355241
patients	O	-1	2355241
with	O	-1	2355241
Parkinson's	B-Disease	D010300	2355241
disease	I-Disease	-1	2355241
:	O	-1	2355241
a	O	-1	2355241
r@@	O	-1	2355241
are	O	-1	2355241
mor@@	O	-1	2355241
t@@	O	-1	2355241
ality	O	-1	2355241
due	O	-1	2355241
to	O	-1	2355241
cerebral	B-Disease	D002543	2355241
haem@@	I-Disease	-1	2355241
or@@	I-Disease	-1	2355241
rh@@	I-Disease	-1	2355241
age	I-Disease	-1	2355241
.	O	-1	2355241
C@@	O	-1	2355241
au@@	O	-1	2355241
ses	O	-1	2355241
of	O	-1	2355241
death	B-Disease	D003643	2355241
,	O	-1	2355241
with	O	-1	2355241
spec@@	O	-1	2355241
ial	O	-1	2355241
ref@@	O	-1	2355241
e@@	O	-1	2355241
rence	O	-1	2355241
to	O	-1	2355241
cerebral	B-Disease	D002543	2355241
haem@@	I-Disease	-1	2355241
or@@	I-Disease	-1	2355241
rh@@	I-Disease	-1	2355241
age	I-Disease	-1	2355241
,	O	-1	2355241
among	O	-1	2355241
2@@	O	-1	2355241
40	O	-1	2355241
patients	O	-1	2355241
with	O	-1	2355241
path@@	O	-1	2355241
olog@@	O	-1	2355241
ically	O	-1	2355241
ver@@	O	-1	2355241
if@@	O	-1	2355241
ied	O	-1	2355241
Parkinson's	B-Disease	D010300	2355241
disease	I-Disease	-1	2355241
were	O	-1	2355241
investigated	O	-1	2355241
using	O	-1	2355241
the	O	-1	2355241
An@@	O	-1	2355241
n@@	O	-1	2355241
u@@	O	-1	2355241
als	O	-1	2355241
of	O	-1	2355241
the	O	-1	2355241
P@@	O	-1	2355241
ath@@	O	-1	2355241
ological	O	-1	2355241
A@@	O	-1	2355241
u@@	O	-1	2355241
to@@	O	-1	2355241
p@@	O	-1	2355241
sy	O	-1	2355241
C@@	O	-1	2355241
as@@	O	-1	2355241
es	O	-1	2355241
in	O	-1	2355241
J@@	O	-1	2355241
ap@@	O	-1	2355241
an	O	-1	2355241
from	O	-1	2355241
19@@	O	-1	2355241
8@@	O	-1	2355241
1	O	-1	2355241
to	O	-1	2355241
19@@	O	-1	2355241
8@@	O	-1	2355241
5@@	O	-1	2355241
.	O	-1	2355241
The	O	-1	2355241
lead@@	O	-1	2355241
ing	O	-1	2355241
causes	O	-1	2355241
of	O	-1	2355241
death	B-Disease	D003643	2355241
were	O	-1	2355241
p@@	B-Disease	D011014	2355241
ne@@	I-Disease	-1	2355241
um@@	I-Disease	-1	2355241
on@@	I-Disease	-1	2355241
ia	I-Disease	-1	2355241
and	O	-1	2355241
b@@	B-Disease	D001991	2355241
ron@@	I-Disease	-1	2355241
ch@@	I-Disease	-1	2355241
iti@@	I-Disease	-1	2355241
s	I-Disease	-1	2355241
(4@@	O	-1	2355241
4.@@	O	-1	2355241
1@@	O	-1	2355241
%),	O	-1	2355241
mal@@	O	-1	2355241
i@@	O	-1	2355241
gn@@	O	-1	2355241
ant	O	-1	2355241
ne@@	B-Disease	D009369	2355241
o@@	I-Disease	-1	2355241
plas@@	I-Disease	-1	2355241
ms	I-Disease	-1	2355241
(1@@	O	-1	2355241
1.@@	O	-1	2355241
6@@	O	-1	2355241
%),	O	-1	2355241
heart	B-Disease	D006331	2355241
diseas@@	I-Disease	-1	2355241
es	I-Disease	-1	2355241
(@@	O	-1	2355241
4.@@	O	-1	2355241
1@@	O	-1	2355241
%),	O	-1	2355241
cerebral	B-Disease	D002544	2355241
infarction	I-Disease	-1	2355241
(@@	O	-1	2355241
3.@@	O	-1	2355241
7@@	O	-1	2355241
%)	O	-1	2355241
and	O	-1	2355241
se@@	B-Disease	D018805	2355241
p@@	I-Disease	-1	2355241
ti@@	I-Disease	-1	2355241
ca@@	I-Disease	-1	2355241
emia	I-Disease	-1	2355241
(@@	O	-1	2355241
3.@@	O	-1	2355241
3@@	O	-1	2355241
%).	O	-1	2355241
C@@	B-Disease	D002543	2355241
e@@	I-Disease	-1	2355241
rebral	I-Disease	-1	2355241
haem@@	I-Disease	-1	2355241
or@@	I-Disease	-1	2355241
rh@@	I-Disease	-1	2355241
age	I-Disease	-1	2355241
was	O	-1	2355241
the	O	-1	2355241
1@@	O	-1	2355241
1@@	O	-1	2355241
th	O	-1	2355241
most	O	-1	2355241
frequent	O	-1	2355241
cause	O	-1	2355241
of	O	-1	2355241
death	B-Disease	D003643	2355241
,	O	-1	2355241
ac@@	O	-1	2355241
coun@@	O	-1	2355241
ting	O	-1	2355241
for	O	-1	2355241
only	O	-1	2355241
0.@@	O	-1	2355241
8@@	O	-1	2355241
%	O	-1	2355241
of	O	-1	2355241
de@@	B-Disease	D003643	2355241
ath@@	I-Disease	-1	2355241
s	I-Disease	-1	2355241
among	O	-1	2355241
the	O	-1	2355241
patients,	O	-1	2355241
whereas	O	-1	2355241
it	O	-1	2355241
was	O	-1	2355241
the	O	-1	2355241
5@@	O	-1	2355241
th	O	-1	2355241
most	O	-1	2355241
common	O	-1	2355241
cause	O	-1	2355241
of	O	-1	2355241
death	B-Disease	D003643	2355241
among	O	-1	2355241
the	O	-1	2355241
J@@	O	-1	2355241
ap@@	O	-1	2355241
an@@	O	-1	2355241
ese	O	-1	2355241
gener@@	O	-1	2355241
al	O	-1	2355241
po@@	O	-1	2355241
p@@	O	-1	2355241
ulation	O	-1	2355241
in	O	-1	2355241
19@@	O	-1	2355241
8@@	O	-1	2355241
5@@	O	-1	2355241
.	O	-1	2355241
The	O	-1	2355241
low	O	-1	2355241
incidence	O	-1	2355241
of	O	-1	2355241
cerebral	B-Disease	D002543	2355241
haem@@	I-Disease	-1	2355241
or@@	I-Disease	-1	2355241
rh@@	I-Disease	-1	2355241
age	I-Disease	-1	2355241
as	O	-1	2355241
a	O	-1	2355241
cause	O	-1	2355241
of	O	-1	2355241
death	B-Disease	D003643	2355241
in	O	-1	2355241
patients	O	-1	2355241
with	O	-1	2355241
Parkinson's	B-Disease	D010300	2355241
disease	I-Disease	-1	2355241
may	O	-1	2355241
ref@@	O	-1	2355241
l@@	O	-1	2355241
ect	O	-1	2355241
the	O	-1	2355241
hypoten@@	B-Disease	D007022	2355241
sive	I-Disease	-1	2355241
effect	O	-1	2355241
of	O	-1	2355241
levo@@	B-Chemical	D007980	2355241
dopa	I-Chemical	-1	2355241
and	O	-1	2355241
a	O	-1	2355241
hypoten@@	B-Disease	D007022	2355241
sive	I-Disease	-1	2355241
mechanism	O	-1	2355241
due	O	-1	2355241
to	O	-1	2355241
reduced	O	-1	2355241
nor@@	B-Chemical	D009638	2355241
adren@@	I-Chemical	-1	2355241
aline	I-Chemical	-1	2355241
levels	O	-1	2355241
in	O	-1	2355241
the	O	-1	2355241
par@@	B-Disease	D010300	2355241
k@@	I-Disease	-1	2355241
inson@@	I-Disease	-1	2355241
i@@	I-Disease	-1	2355241
an	I-Disease	-1	2355241
bra@@	O	-1	2355241
in.	O	-1	2355241

T@@	O	-1	2445283
oler@@	O	-1	2445283
ance	O	-1	2445283
and	O	-1	2445283
anti@@	O	-1	2445283
viral	O	-1	2445283
effect	O	-1	2445283
of	O	-1	2445283
rib@@	B-Chemical	D012254	2445283
avi@@	I-Chemical	-1	2445283
rin	I-Chemical	-1	2445283
in	O	-1	2445283
patients	O	-1	2445283
with	O	-1	2445283
A@@	B-Disease	D006478	2445283
r@@	I-Disease	-1	2445283
g@@	I-Disease	-1	2445283
ent@@	I-Disease	-1	2445283
ine	I-Disease	-1	2445283
hemorrh@@	I-Disease	-1	2445283
ag@@	I-Disease	-1	2445283
ic	I-Disease	-1	2445283
f@@	I-Disease	-1	2445283
ev@@	I-Disease	-1	2445283
er	I-Disease	-1	2445283
.	O	-1	2445283
T@@	O	-1	2445283
oler@@	O	-1	2445283
ance	O	-1	2445283
and	O	-1	2445283
anti@@	O	-1	2445283
viral	O	-1	2445283
effect	O	-1	2445283
of	O	-1	2445283
rib@@	B-Chemical	D012254	2445283
avi@@	I-Chemical	-1	2445283
rin	I-Chemical	-1	2445283
was	O	-1	2445283
studied	O	-1	2445283
in	O	-1	2445283
6	O	-1	2445283
patients	O	-1	2445283
with	O	-1	2445283
A@@	B-Disease	D006478	2445283
r@@	I-Disease	-1	2445283
g@@	I-Disease	-1	2445283
ent@@	I-Disease	-1	2445283
ine	I-Disease	-1	2445283
hemorrh@@	I-Disease	-1	2445283
ag@@	I-Disease	-1	2445283
ic	I-Disease	-1	2445283
f@@	I-Disease	-1	2445283
ev@@	I-Disease	-1	2445283
er	I-Disease	-1	2445283
(	O	-1	2445283
A@@	B-Disease	D006478	2445283
H@@	I-Disease	-1	2445283
F	I-Disease	-1	2445283
)	O	-1	2445283
of	O	-1	2445283
more	O	-1	2445283
than	O	-1	2445283
8	O	-1	2445283
days	O	-1	2445283
of	O	-1	2445283
ev@@	O	-1	2445283
ol@@	O	-1	2445283
u@@	O	-1	2445283
tion.	O	-1	2445283
Ad@@	O	-1	2445283
minist@@	O	-1	2445283
ration	O	-1	2445283
of	O	-1	2445283
rib@@	B-Chemical	D012254	2445283
avi@@	I-Chemical	-1	2445283
rin	I-Chemical	-1	2445283
resulted	O	-1	2445283
in	O	-1	2445283
a	O	-1	2445283
ne@@	O	-1	2445283
ut@@	O	-1	2445283
r@@	O	-1	2445283
al@@	O	-1	2445283
ization	O	-1	2445283
of	O	-1	2445283
vi@@	B-Disease	D014766	2445283
re@@	I-Disease	-1	2445283
mia	I-Disease	-1	2445283
and	O	-1	2445283
a	O	-1	2445283
dro@@	O	-1	2445283
p	O	-1	2445283
of	O	-1	2445283
endo@@	O	-1	2445283
gen@@	O	-1	2445283
ous	O	-1	2445283
inter@@	O	-1	2445283
fer@@	O	-1	2445283
on	O	-1	2445283
ti@@	O	-1	2445283
ter@@	O	-1	2445283
s.	O	-1	2445283
The	O	-1	2445283
average	O	-1	2445283
time	O	-1	2445283
of	O	-1	2445283
death	B-Disease	D003643	2445283
was	O	-1	2445283
del@@	O	-1	2445283
ay@@	O	-1	2445283
ed.	O	-1	2445283
A	O	-1	2445283
reversible	O	-1	2445283
anemia	B-Disease	D000740	2445283
was	O	-1	2445283
the	O	-1	2445283
only	O	-1	2445283
adverse	O	-1	2445283
effect	O	-1	2445283
obser@@	O	-1	2445283
ved.	O	-1	2445283
F@@	O	-1	2445283
rom	O	-1	2445283
these	O	-1	2445283
result@@	O	-1	2445283
s,	O	-1	2445283
we	O	-1	2445283
concl@@	O	-1	2445283
ude	O	-1	2445283
that	O	-1	2445283
rib@@	B-Chemical	D012254	2445283
avi@@	I-Chemical	-1	2445283
rin	I-Chemical	-1	2445283
has	O	-1	2445283
an	O	-1	2445283
anti@@	O	-1	2445283
viral	O	-1	2445283
effect	O	-1	2445283
in	O	-1	2445283
adv@@	O	-1	2445283
anced	O	-1	2445283
cases	O	-1	2445283
of	O	-1	2445283
A@@	B-Disease	D006478	2445283
H@@	I-Disease	-1	2445283
F	I-Disease	-1	2445283
,	O	-1	2445283
and	O	-1	2445283
that	O	-1	2445283
anemia	B-Disease	D000740	2445283
,	O	-1	2445283
the	O	-1	2445283
only	O	-1	2445283
secondary	O	-1	2445283
reaction	O	-1	2445283
obser@@	O	-1	2445283
ve@@	O	-1	2445283
d,	O	-1	2445283
can	O	-1	2445283
be	O	-1	2445283
e@@	O	-1	2445283
a@@	O	-1	2445283
si@@	O	-1	2445283
ly	O	-1	2445283
man@@	O	-1	2445283
ag@@	O	-1	2445283
ed.	O	-1	2445283
The	O	-1	2445283
possible	O	-1	2445283
ben@@	O	-1	2445283
e@@	O	-1	2445283
fic@@	O	-1	2445283
ial	O	-1	2445283
effect	O	-1	2445283
of	O	-1	2445283
rib@@	B-Chemical	D012254	2445283
avi@@	I-Chemical	-1	2445283
rin	I-Chemical	-1	2445283
during	O	-1	2445283
the	O	-1	2445283
initial	O	-1	2445283
days	O	-1	2445283
of	O	-1	2445283
A@@	B-Disease	D006478	2445283
H@@	I-Disease	-1	2445283
F	I-Disease	-1	2445283
is	O	-1	2445283
discus@@	O	-1	2445283
sed.	O	-1	2445283

D@@	B-Chemical	D004176	2950248
ip@@	I-Chemical	-1	2950248
y@@	I-Chemical	-1	2950248
ri@@	I-Chemical	-1	2950248
dam@@	I-Chemical	-1	2950248
ole	I-Chemical	-1	2950248
-induced	O	-1	2950248
myocardial	B-Disease	D017202	2950248
ischem@@	I-Disease	-1	2950248
ia	I-Disease	-1	2950248
.	O	-1	2950248
An@@	B-Disease	D000787	2950248
g@@	I-Disease	-1	2950248
in@@	I-Disease	-1	2950248
a	I-Disease	-1	2950248
and	O	-1	2950248
ischem@@	O	-1	2950248
ic	O	-1	2950248
electro@@	O	-1	2950248
cardio@@	O	-1	2950248
graph@@	O	-1	2950248
ic	O	-1	2950248
changes	O	-1	2950248
occurred	O	-1	2950248
after	O	-1	2950248
administration	O	-1	2950248
of	O	-1	2950248
oral	O	-1	2950248
di@@	B-Chemical	D004176	2950248
pyri@@	I-Chemical	-1	2950248
dam@@	I-Chemical	-1	2950248
ole	I-Chemical	-1	2950248
in	O	-1	2950248
four	O	-1	2950248
patients	O	-1	2950248
aw@@	O	-1	2950248
a@@	O	-1	2950248
it@@	O	-1	2950248
ing	O	-1	2950248
ur@@	O	-1	2950248
g@@	O	-1	2950248
ent	O	-1	2950248
myocardial	O	-1	2950248
re@@	O	-1	2950248
vas@@	O	-1	2950248
cul@@	O	-1	2950248
ar@@	O	-1	2950248
ization	O	-1	2950248
proce@@	O	-1	2950248
du@@	O	-1	2950248
res@@	O	-1	2950248
.	O	-1	2950248
To	O	-1	2950248
our	O	-1	2950248
know@@	O	-1	2950248
le@@	O	-1	2950248
d@@	O	-1	2950248
g@@	O	-1	2950248
e,	O	-1	2950248
this	O	-1	2950248
has	O	-1	2950248
not	O	-1	2950248
previously	O	-1	2950248
been	O	-1	2950248
reported	O	-1	2950248
as	O	-1	2950248
a	O	-1	2950248
side	O	-1	2950248
effect	O	-1	2950248
of	O	-1	2950248
pre@@	O	-1	2950248
o@@	O	-1	2950248
perative	O	-1	2950248
di@@	B-Chemical	D004176	2950248
pyri@@	I-Chemical	-1	2950248
dam@@	I-Chemical	-1	2950248
ole	I-Chemical	-1	2950248
therapy,	O	-1	2950248
although	O	-1	2950248
di@@	B-Chemical	D004176	2950248
pyri@@	I-Chemical	-1	2950248
dam@@	I-Chemical	-1	2950248
ole	I-Chemical	-1	2950248
-induced	O	-1	2950248
myocardial	B-Disease	D017202	2950248
ischem@@	I-Disease	-1	2950248
ia	I-Disease	-1	2950248
has	O	-1	2950248
been	O	-1	2950248
demonstrated	O	-1	2950248
to	O	-1	2950248
occ@@	O	-1	2950248
ur	O	-1	2950248
in	O	-1	2950248
animals	O	-1	2950248
and	O	-1	2950248
hum@@	O	-1	2950248
ans	O	-1	2950248
with	O	-1	2950248
coronary	B-Disease	D003324	2950248
artery	I-Disease	-1	2950248
disease	I-Disease	-1	2950248
.	O	-1	2950248
E@@	O	-1	2950248
p@@	O	-1	2950248
ic@@	O	-1	2950248
ardi@@	O	-1	2950248
al	O	-1	2950248
coronary	O	-1	2950248
coll@@	O	-1	2950248
ateral	O	-1	2950248
v@@	O	-1	2950248
es@@	O	-1	2950248
sel@@	O	-1	2950248
s	O	-1	2950248
were	O	-1	2950248
demonstrated	O	-1	2950248
in	O	-1	2950248
all	O	-1	2950248
four	O	-1	2950248
patient@@	O	-1	2950248
s;	O	-1	2950248
a	O	-1	2950248
coronary	O	-1	2950248
"@@	O	-1	2950248
ste@@	O	-1	2950248
al@@	O	-1	2950248
"	O	-1	2950248
phen@@	O	-1	2950248
om@@	O	-1	2950248
en@@	O	-1	2950248
on	O	-1	2950248
may	O	-1	2950248
be	O	-1	2950248
the	O	-1	2950248
mechanism	O	-1	2950248
of	O	-1	2950248
the	O	-1	2950248
di@@	B-Chemical	D004176	2950248
pyri@@	I-Chemical	-1	2950248
dam@@	I-Chemical	-1	2950248
ole	I-Chemical	-1	2950248
-induced	O	-1	2950248
ischem@@	B-Disease	D007511	2950248
ia	I-Disease	-1	2950248
obser@@	O	-1	2950248
ved.	O	-1	2950248

In@@	O	-1	3015567
hib@@	O	-1	3015567
ition	O	-1	3015567
of	O	-1	3015567
immuno@@	O	-1	3015567
reac@@	O	-1	3015567
tive	O	-1	3015567
cortico@@	O	-1	3015567
tro@@	O	-1	3015567
p@@	O	-1	3015567
in-@@	O	-1	3015567
rele@@	O	-1	3015567
as@@	O	-1	3015567
ing	O	-1	3015567
factor	O	-1	3015567
secre@@	O	-1	3015567
tion	O	-1	3015567
into	O	-1	3015567
the	O	-1	3015567
hypo@@	O	-1	3015567
physi@@	O	-1	3015567
al@@	O	-1	3015567
-@@	O	-1	3015567
port@@	O	-1	3015567
al	O	-1	3015567
cir@@	O	-1	3015567
c@@	O	-1	3015567
ulation	O	-1	3015567
by	O	-1	3015567
del@@	O	-1	3015567
ayed	O	-1	3015567
g@@	O	-1	3015567
lu@@	O	-1	3015567
co@@	O	-1	3015567
cortico@@	O	-1	3015567
id	O	-1	3015567
fe@@	O	-1	3015567
ed@@	O	-1	3015567
bac@@	O	-1	3015567
k@@	O	-1	3015567
.	O	-1	3015567
N@@	B-Chemical	D009599	3015567
it@@	I-Chemical	-1	3015567
ro@@	I-Chemical	-1	3015567
pr@@	I-Chemical	-1	3015567
us@@	I-Chemical	-1	3015567
side	I-Chemical	-1	3015567
-induced	O	-1	3015567
hypotension	B-Disease	D007022	3015567
evo@@	O	-1	3015567
k@@	O	-1	3015567
es	O	-1	3015567
AC@@	O	-1	3015567
T@@	O	-1	3015567
H	O	-1	3015567
secre@@	O	-1	3015567
tion	O	-1	3015567
which	O	-1	3015567
is	O	-1	3015567
prim@@	O	-1	3015567
ari@@	O	-1	3015567
ly	O	-1	3015567
mediated	O	-1	3015567
by	O	-1	3015567
enhanced	O	-1	3015567
secre@@	O	-1	3015567
tion	O	-1	3015567
of	O	-1	3015567
immuno@@	O	-1	3015567
reac@@	O	-1	3015567
tive	O	-1	3015567
cortico@@	O	-1	3015567
tro@@	O	-1	3015567
p@@	O	-1	3015567
in-@@	O	-1	3015567
rele@@	O	-1	3015567
as@@	O	-1	3015567
ing	O	-1	3015567
factor	O	-1	3015567
(@@	O	-1	3015567
ir@@	O	-1	3015567
CR@@	O	-1	3015567
F@@	O	-1	3015567
)	O	-1	3015567
into	O	-1	3015567
the	O	-1	3015567
hypo@@	O	-1	3015567
physi@@	O	-1	3015567
al@@	O	-1	3015567
-@@	O	-1	3015567
port@@	O	-1	3015567
al	O	-1	3015567
cir@@	O	-1	3015567
cul@@	O	-1	3015567
ation.	O	-1	3015567
P@@	O	-1	3015567
ort@@	O	-1	3015567
al	O	-1	3015567
plasma	O	-1	3015567
concentrations	O	-1	3015567
of	O	-1	3015567
ne@@	O	-1	3015567
ither	O	-1	3015567
arg@@	B-Chemical	D001127	3015567
inine	I-Chemical	-1	3015567
vas@@	I-Chemical	-1	3015567
o@@	I-Chemical	-1	3015567
press@@	I-Chemical	-1	3015567
in	I-Chemical	-1	3015567
n@@	O	-1	3015567
or	O	-1	3015567
oxy@@	B-Chemical	D010121	3015567
t@@	I-Chemical	-1	3015567
oc@@	I-Chemical	-1	3015567
in	I-Chemical	-1	3015567
are	O	-1	3015567
significantly	O	-1	3015567
al@@	O	-1	3015567
te@@	O	-1	3015567
red	O	-1	3015567
in	O	-1	3015567
this	O	-1	3015567
par@@	O	-1	3015567
a@@	O	-1	3015567
di@@	O	-1	3015567
g@@	O	-1	3015567
m.	O	-1	3015567
A@@	O	-1	3015567
p@@	O	-1	3015567
plic@@	O	-1	3015567
ation	O	-1	3015567
of	O	-1	3015567
a	O	-1	3015567
del@@	O	-1	3015567
ayed	O	-1	3015567
fe@@	O	-1	3015567
ed@@	O	-1	3015567
bac@@	O	-1	3015567
k	O	-1	3015567
sign@@	O	-1	3015567
al,	O	-1	3015567
in	O	-1	3015567
the	O	-1	3015567
form	O	-1	3015567
of	O	-1	3015567
a	O	-1	3015567
2-@@	O	-1	3015567
h	O	-1	3015567
systemic	O	-1	3015567
cortico@@	B-Chemical	D003345	3015567
sterone	I-Chemical	-1	3015567
infusion	O	-1	3015567
in	O	-1	3015567
ure@@	B-Chemical	D014520	3015567
th@@	I-Chemical	-1	3015567
ane	I-Chemical	-1	3015567
-@@	O	-1	3015567
anesthe@@	O	-1	3015567
tiz@@	O	-1	3015567
ed	O	-1	3015567
rats	O	-1	3015567
with	O	-1	3015567
pharmac@@	O	-1	3015567
ological	O	-1	3015567
block@@	O	-1	3015567
ade	O	-1	3015567
of	O	-1	3015567
g@@	O	-1	3015567
lu@@	O	-1	3015567
co@@	O	-1	3015567
cortico@@	O	-1	3015567
id	O	-1	3015567
syn@@	O	-1	3015567
the@@	O	-1	3015567
sis,	O	-1	3015567
is	O	-1	3015567
without	O	-1	3015567
effect	O	-1	3015567
on	O	-1	3015567
the	O	-1	3015567
rest@@	O	-1	3015567
ing	O	-1	3015567
secre@@	O	-1	3015567
tion	O	-1	3015567
of	O	-1	3015567
arg@@	B-Chemical	D001127	3015567
inine	I-Chemical	-1	3015567
vas@@	I-Chemical	-1	3015567
o@@	I-Chemical	-1	3015567
press@@	I-Chemical	-1	3015567
in	I-Chemical	-1	3015567
and	O	-1	3015567
oxy@@	B-Chemical	D010121	3015567
t@@	I-Chemical	-1	3015567
oc@@	I-Chemical	-1	3015567
in	I-Chemical	-1	3015567
at	O	-1	3015567
any	O	-1	3015567
cortico@@	B-Chemical	D003345	3015567
sterone	I-Chemical	-1	3015567
fe@@	O	-1	3015567
ed@@	O	-1	3015567
bac@@	O	-1	3015567
k	O	-1	3015567
dose	O	-1	3015567
test@@	O	-1	3015567
ed.	O	-1	3015567
R@@	O	-1	3015567
est@@	O	-1	3015567
ing	O	-1	3015567
ir@@	O	-1	3015567
CR@@	O	-1	3015567
F	O	-1	3015567
levels	O	-1	3015567
are	O	-1	3015567
sup@@	O	-1	3015567
press@@	O	-1	3015567
ed	O	-1	3015567
only	O	-1	3015567
at	O	-1	3015567
the	O	-1	3015567
high@@	O	-1	3015567
est	O	-1	3015567
cortico@@	B-Chemical	D003345	3015567
sterone	I-Chemical	-1	3015567
infusion	O	-1	3015567
rat@@	O	-1	3015567
e,	O	-1	3015567
which	O	-1	3015567
resulted	O	-1	3015567
in	O	-1	3015567
systemic	O	-1	3015567
cortico@@	B-Chemical	D003345	3015567
sterone	I-Chemical	-1	3015567
levels	O	-1	3015567
of	O	-1	3015567
40	O	-1	3015567
microgram@@	O	-1	3015567
s/@@	O	-1	3015567
d@@	O	-1	3015567
l@@	O	-1	3015567
.	O	-1	3015567
S@@	O	-1	3015567
up@@	O	-1	3015567
pression	O	-1	3015567
of	O	-1	3015567
ir@@	O	-1	3015567
CR@@	O	-1	3015567
F	O	-1	3015567
secre@@	O	-1	3015567
tion	O	-1	3015567
in	O	-1	3015567
response	O	-1	3015567
to	O	-1	3015567
nitro@@	B-Chemical	D009599	3015567
pr@@	I-Chemical	-1	3015567
us@@	I-Chemical	-1	3015567
side	I-Chemical	-1	3015567
-induced	O	-1	3015567
hypotension	B-Disease	D007022	3015567
is	O	-1	3015567
observed	O	-1	3015567
and	O	-1	3015567
occur@@	O	-1	3015567
s	O	-1	3015567
at	O	-1	3015567
a	O	-1	3015567
plasma	O	-1	3015567
cortico@@	B-Chemical	D003345	3015567
sterone	I-Chemical	-1	3015567
level	O	-1	3015567
between	O	-1	3015567
8@@	O	-1	3015567
-1@@	O	-1	3015567
2	O	-1	3015567
microgram@@	O	-1	3015567
s/@@	O	-1	3015567
d@@	O	-1	3015567
l@@	O	-1	3015567
.	O	-1	3015567
These	O	-1	3015567
studies	O	-1	3015567
prov@@	O	-1	3015567
ide	O	-1	3015567
further	O	-1	3015567
evidence	O	-1	3015567
for	O	-1	3015567
a	O	-1	3015567
st@@	O	-1	3015567
ron@@	O	-1	3015567
g	O	-1	3015567
central	O	-1	3015567
comp@@	O	-1	3015567
on@@	O	-1	3015567
ent	O	-1	3015567
of	O	-1	3015567
the	O	-1	3015567
del@@	O	-1	3015567
ayed	O	-1	3015567
fe@@	O	-1	3015567
ed@@	O	-1	3015567
bac@@	O	-1	3015567
k	O	-1	3015567
pro@@	O	-1	3015567
cess	O	-1	3015567
which	O	-1	3015567
is	O	-1	3015567
mediated	O	-1	3015567
by	O	-1	3015567
mod@@	O	-1	3015567
ulation	O	-1	3015567
of	O	-1	3015567
ir@@	O	-1	3015567
CR@@	O	-1	3015567
F	O	-1	3015567
rele@@	O	-1	3015567
as@@	O	-1	3015567
e.	O	-1	3015567

N@@	O	-1	3031535
or@@	O	-1	3031535
adrenergic	O	-1	3031535
invol@@	O	-1	3031535
vement	O	-1	3031535
in	O	-1	3031535
cat@@	B-Disease	D002375	3031535
al@@	I-Disease	-1	3031535
ep@@	I-Disease	-1	3031535
sy	I-Disease	-1	3031535
induced	O	-1	3031535
by	O	-1	3031535
del@@	B-Chemical	D013759	3031535
t@@	I-Chemical	-1	3031535
a	I-Chemical	-1	3031535
9@@	I-Chemical	-1	3031535
-@@	I-Chemical	-1	3031535
te@@	I-Chemical	-1	3031535
tra@@	I-Chemical	-1	3031535
hydro@@	I-Chemical	-1	3031535
can@@	I-Chemical	-1	3031535
n@@	I-Chemical	-1	3031535
ab@@	I-Chemical	-1	3031535
in@@	I-Chemical	-1	3031535
ol	I-Chemical	-1	3031535
.	O	-1	3031535
In	O	-1	3031535
or@@	O	-1	3031535
der	O	-1	3031535
to	O	-1	3031535
el@@	O	-1	3031535
uc@@	O	-1	3031535
id@@	O	-1	3031535
ate	O	-1	3031535
the	O	-1	3031535
role	O	-1	3031535
of	O	-1	3031535
the	O	-1	3031535
cat@@	O	-1	3031535
ech@@	O	-1	3031535
ol@@	O	-1	3031535
aminergic	O	-1	3031535
system	O	-1	3031535
in	O	-1	3031535
the	O	-1	3031535
cat@@	O	-1	3031535
al@@	O	-1	3031535
ep@@	O	-1	3031535
to@@	O	-1	3031535
genic	O	-1	3031535
effect	O	-1	3031535
of	O	-1	3031535
del@@	B-Chemical	D013759	3031535
t@@	I-Chemical	-1	3031535
a	I-Chemical	-1	3031535
9@@	I-Chemical	-1	3031535
-@@	I-Chemical	-1	3031535
te@@	I-Chemical	-1	3031535
tra@@	I-Chemical	-1	3031535
hydro@@	I-Chemical	-1	3031535
can@@	I-Chemical	-1	3031535
n@@	I-Chemical	-1	3031535
ab@@	I-Chemical	-1	3031535
in@@	I-Chemical	-1	3031535
ol	I-Chemical	-1	3031535
(	O	-1	3031535
T@@	B-Chemical	D013759	3031535
H@@	I-Chemical	-1	3031535
C	I-Chemical	-1	3031535
),	O	-1	3031535
the	O	-1	3031535
effect	O	-1	3031535
of	O	-1	3031535
pretreatment	O	-1	3031535
with	O	-1	3031535
6-@@	B-Chemical	D016627	3031535
hydrox@@	I-Chemical	-1	3031535
y@@	I-Chemical	-1	3031535
dopamine	I-Chemical	-1	3031535
(	O	-1	3031535
6-@@	B-Chemical	D016627	3031535
O@@	I-Chemical	-1	3031535
H@@	I-Chemical	-1	3031535
D@@	I-Chemical	-1	3031535
A	I-Chemical	-1	3031535
)	O	-1	3031535
or	O	-1	3031535
with	O	-1	3031535
desi@@	B-Chemical	D003891	3031535
pramine	I-Chemical	-1	3031535
and	O	-1	3031535
6-@@	B-Chemical	D016627	3031535
O@@	I-Chemical	-1	3031535
H@@	I-Chemical	-1	3031535
D@@	I-Chemical	-1	3031535
A	I-Chemical	-1	3031535
and	O	-1	3031535
lesions	O	-1	3031535
of	O	-1	3031535
the	O	-1	3031535
loc@@	O	-1	3031535
us	O	-1	3031535
co@@	O	-1	3031535
er@@	O	-1	3031535
ul@@	O	-1	3031535
e@@	O	-1	3031535
us	O	-1	3031535
were	O	-1	3031535
investigated	O	-1	3031535
in	O	-1	3031535
rats.	O	-1	3031535
The	O	-1	3031535
cat@@	O	-1	3031535
al@@	O	-1	3031535
ep@@	O	-1	3031535
to@@	O	-1	3031535
genic	O	-1	3031535
effect	O	-1	3031535
of	O	-1	3031535
T@@	B-Chemical	D013759	3031535
H@@	I-Chemical	-1	3031535
C	I-Chemical	-1	3031535
was	O	-1	3031535
significantly	O	-1	3031535
reduced	O	-1	3031535
in	O	-1	3031535
rats	O	-1	3031535
treated	O	-1	3031535
with	O	-1	3031535
6-@@	B-Chemical	D016627	3031535
O@@	I-Chemical	-1	3031535
H@@	I-Chemical	-1	3031535
D@@	I-Chemical	-1	3031535
A	I-Chemical	-1	3031535
and	O	-1	3031535
in	O	-1	3031535
rats	O	-1	3031535
with	O	-1	3031535
lesions	O	-1	3031535
of	O	-1	3031535
the	O	-1	3031535
loc@@	O	-1	3031535
us	O	-1	3031535
co@@	O	-1	3031535
er@@	O	-1	3031535
ul@@	O	-1	3031535
e@@	O	-1	3031535
us	O	-1	3031535
but	O	-1	3031535
not	O	-1	3031535
in	O	-1	3031535
rats	O	-1	3031535
treated	O	-1	3031535
with	O	-1	3031535
desi@@	B-Chemical	D003891	3031535
pramine	I-Chemical	-1	3031535
and	O	-1	3031535
6-@@	B-Chemical	D016627	3031535
O@@	I-Chemical	-1	3031535
H@@	I-Chemical	-1	3031535
D@@	I-Chemical	-1	3031535
A	I-Chemical	-1	3031535
,	O	-1	3031535
as	O	-1	3031535
compared	O	-1	3031535
with	O	-1	3031535
control	O	-1	3031535
rats.	O	-1	3031535
O@@	O	-1	3031535
n	O	-1	3031535
the	O	-1	3031535
contr@@	O	-1	3031535
ar@@	O	-1	3031535
y,	O	-1	3031535
the	O	-1	3031535
cat@@	O	-1	3031535
al@@	O	-1	3031535
ep@@	O	-1	3031535
to@@	O	-1	3031535
genic	O	-1	3031535
effect	O	-1	3031535
of	O	-1	3031535
haloperidol	B-Chemical	D006220	3031535
was	O	-1	3031535
significantly	O	-1	3031535
reduced	O	-1	3031535
in	O	-1	3031535
rats	O	-1	3031535
treated	O	-1	3031535
with	O	-1	3031535
desi@@	B-Chemical	D003891	3031535
pramine	I-Chemical	-1	3031535
and	O	-1	3031535
6-@@	B-Chemical	D016627	3031535
O@@	I-Chemical	-1	3031535
H@@	I-Chemical	-1	3031535
D@@	I-Chemical	-1	3031535
A	I-Chemical	-1	3031535
but	O	-1	3031535
not	O	-1	3031535
in	O	-1	3031535
rats	O	-1	3031535
treated	O	-1	3031535
with	O	-1	3031535
6-@@	B-Chemical	D016627	3031535
O@@	I-Chemical	-1	3031535
H@@	I-Chemical	-1	3031535
D@@	I-Chemical	-1	3031535
A	I-Chemical	-1	3031535
or	O	-1	3031535
in	O	-1	3031535
rats	O	-1	3031535
with	O	-1	3031535
lesions	O	-1	3031535
of	O	-1	3031535
the	O	-1	3031535
loc@@	O	-1	3031535
us	O	-1	3031535
co@@	O	-1	3031535
er@@	O	-1	3031535
ul@@	O	-1	3031535
eu@@	O	-1	3031535
s.	O	-1	3031535
These	O	-1	3031535
results	O	-1	3031535
indicate	O	-1	3031535
that	O	-1	3031535
nor@@	O	-1	3031535
adrenergic	O	-1	3031535
neuron@@	O	-1	3031535
s	O	-1	3031535
have	O	-1	3031535
an	O	-1	3031535
important	O	-1	3031535
role	O	-1	3031535
in	O	-1	3031535
the	O	-1	3031535
man@@	O	-1	3031535
if@@	O	-1	3031535
est@@	O	-1	3031535
ation	O	-1	3031535
of	O	-1	3031535
cat@@	B-Disease	D002375	3031535
al@@	I-Disease	-1	3031535
ep@@	I-Disease	-1	3031535
sy	I-Disease	-1	3031535
induced	O	-1	3031535
by	O	-1	3031535
T@@	B-Chemical	D013759	3031535
H@@	I-Chemical	-1	3031535
C	I-Chemical	-1	3031535
,	O	-1	3031535
whereas	O	-1	3031535
dop@@	O	-1	3031535
aminergic	O	-1	3031535
neuron@@	O	-1	3031535
s	O	-1	3031535
are	O	-1	3031535
important	O	-1	3031535
in	O	-1	3031535
cat@@	B-Disease	D002375	3031535
al@@	I-Disease	-1	3031535
ep@@	I-Disease	-1	3031535
sy	I-Disease	-1	3031535
induced	O	-1	3031535
by	O	-1	3031535
haloperidol	B-Chemical	D006220	3031535
.	O	-1	3031535

In@@	O	-1	3125768
trac@@	O	-1	3125768
ranial	O	-1	3125768
pressure	O	-1	3125768
increases	O	-1	3125768
during	O	-1	3125768
al@@	B-Chemical	D015760	3125768
f@@	I-Chemical	-1	3125768
entan@@	I-Chemical	-1	3125768
il	I-Chemical	-1	3125768
-induced	O	-1	3125768
rig@@	B-Disease	D009127	3125768
idity	I-Disease	-1	3125768
.	O	-1	3125768
In@@	O	-1	3125768
trac@@	O	-1	3125768
ranial	O	-1	3125768
pressure	O	-1	3125768
(@@	O	-1	3125768
IC@@	O	-1	3125768
P)	O	-1	3125768
was	O	-1	3125768
measured	O	-1	3125768
during	O	-1	3125768
al@@	B-Chemical	D015760	3125768
f@@	I-Chemical	-1	3125768
entan@@	I-Chemical	-1	3125768
il	I-Chemical	-1	3125768
-induced	O	-1	3125768
rig@@	B-Disease	D009127	3125768
idity	I-Disease	-1	3125768
in	O	-1	3125768
rats.	O	-1	3125768
T@@	O	-1	3125768
en	O	-1	3125768
rats	O	-1	3125768
had	O	-1	3125768
arter@@	O	-1	3125768
i@@	O	-1	3125768
al,	O	-1	3125768
central	O	-1	3125768
venous	O	-1	3125768
(C@@	O	-1	3125768
V@@	O	-1	3125768
P@@	O	-1	3125768
),	O	-1	3125768
and	O	-1	3125768
sub@@	O	-1	3125768
dur@@	O	-1	3125768
al	O	-1	3125768
can@@	O	-1	3125768
n@@	O	-1	3125768
ul@@	O	-1	3125768
a@@	O	-1	3125768
e	O	-1	3125768
in@@	O	-1	3125768
ser@@	O	-1	3125768
ted	O	-1	3125768
under	O	-1	3125768
halo@@	B-Chemical	D006221	3125768
th@@	I-Chemical	-1	3125768
ane	I-Chemical	-1	3125768
anesthe@@	O	-1	3125768
sia.	O	-1	3125768
The	O	-1	3125768
animals	O	-1	3125768
were	O	-1	3125768
mechan@@	O	-1	3125768
ically	O	-1	3125768
ven@@	O	-1	3125768
til@@	O	-1	3125768
ated	O	-1	3125768
to	O	-1	3125768
achi@@	O	-1	3125768
e@@	O	-1	3125768
ve	O	-1	3125768
norm@@	O	-1	3125768
oc@@	O	-1	3125768
arb@@	O	-1	3125768
ia	O	-1	3125768
(P@@	O	-1	3125768
CO@@	O	-1	3125768
2	O	-1	3125768
=	O	-1	3125768
4@@	O	-1	3125768
2	O	-1	3125768
+/-	O	-1	3125768
1	O	-1	3125768
mm@@	O	-1	3125768
H@@	O	-1	3125768
g@@	O	-1	3125768
,	O	-1	3125768
mean	O	-1	3125768
+/-	O	-1	3125768
S@@	O	-1	3125768
E@@	O	-1	3125768
).	O	-1	3125768
F@@	O	-1	3125768
ol@@	O	-1	3125768
low@@	O	-1	3125768
ing	O	-1	3125768
in@@	O	-1	3125768
st@@	O	-1	3125768
ru@@	O	-1	3125768
ment@@	O	-1	3125768
ation,	O	-1	3125768
halo@@	B-Chemical	D006221	3125768
th@@	I-Chemical	-1	3125768
ane	I-Chemical	-1	3125768
was	O	-1	3125768
discontinu@@	O	-1	3125768
ed	O	-1	3125768
and	O	-1	3125768
al@@	B-Chemical	D015760	3125768
f@@	I-Chemical	-1	3125768
entan@@	I-Chemical	-1	3125768
il	I-Chemical	-1	3125768
(1@@	O	-1	3125768
25	O	-1	3125768
m@@	O	-1	3125768
u@@	O	-1	3125768
/@@	O	-1	3125768
kg@@	O	-1	3125768
)	O	-1	3125768
administered	O	-1	3125768
i@@	O	-1	3125768
v	O	-1	3125768
during	O	-1	3125768
em@@	O	-1	3125768
er@@	O	-1	3125768
gen@@	O	-1	3125768
ce	O	-1	3125768
from	O	-1	3125768
halo@@	B-Chemical	D006221	3125768
th@@	I-Chemical	-1	3125768
ane	I-Chemical	-1	3125768
anesthe@@	O	-1	3125768
sia.	O	-1	3125768
In	O	-1	3125768
the	O	-1	3125768
five	O	-1	3125768
rats	O	-1	3125768
that	O	-1	3125768
developed	O	-1	3125768
s@@	B-Disease	D009127	3125768
om@@	I-Disease	-1	3125768
atic	I-Disease	-1	3125768
rig@@	I-Disease	-1	3125768
idity	I-Disease	-1	3125768
,	O	-1	3125768
IC@@	O	-1	3125768
P	O	-1	3125768
and	O	-1	3125768
C@@	O	-1	3125768
V@@	O	-1	3125768
P	O	-1	3125768
increased	O	-1	3125768
significantly	O	-1	3125768
ab@@	O	-1	3125768
o@@	O	-1	3125768
ve	O	-1	3125768
baseline	O	-1	3125768
(@@	O	-1	3125768
del@@	O	-1	3125768
t@@	O	-1	3125768
a	O	-1	3125768
IC@@	O	-1	3125768
P	O	-1	3125768
7.@@	O	-1	3125768
5	O	-1	3125768
+/-	O	-1	3125768
1.@@	O	-1	3125768
0	O	-1	3125768
mm@@	O	-1	3125768
H@@	O	-1	3125768
g@@	O	-1	3125768
,	O	-1	3125768
del@@	O	-1	3125768
t@@	O	-1	3125768
a	O	-1	3125768
C@@	O	-1	3125768
V@@	O	-1	3125768
P	O	-1	3125768
5.@@	O	-1	3125768
9	O	-1	3125768
+/-	O	-1	3125768
1.@@	O	-1	3125768
3	O	-1	3125768
mm@@	O	-1	3125768
H@@	O	-1	3125768
g@@	O	-1	3125768
).	O	-1	3125768
These	O	-1	3125768
vari@@	O	-1	3125768
able@@	O	-1	3125768
s	O	-1	3125768
retur@@	O	-1	3125768
n@@	O	-1	3125768
ed	O	-1	3125768
to	O	-1	3125768
baseline	O	-1	3125768
when	O	-1	3125768
rig@@	B-Disease	D009127	3125768
idity	I-Disease	-1	3125768
was	O	-1	3125768
abol@@	O	-1	3125768
ished	O	-1	3125768
with	O	-1	3125768
met@@	B-Chemical	C032943	3125768
oc@@	I-Chemical	-1	3125768
urine	I-Chemical	-1	3125768
.	O	-1	3125768
In	O	-1	3125768
five	O	-1	3125768
rats	O	-1	3125768
that	O	-1	3125768
did	O	-1	3125768
not	O	-1	3125768
b@@	O	-1	3125768
ec@@	O	-1	3125768
ome	O	-1	3125768
rig@@	O	-1	3125768
id@@	O	-1	3125768
,	O	-1	3125768
IC@@	O	-1	3125768
P	O	-1	3125768
and	O	-1	3125768
C@@	O	-1	3125768
V@@	O	-1	3125768
P	O	-1	3125768
did	O	-1	3125768
not	O	-1	3125768
change	O	-1	3125768
following	O	-1	3125768
al@@	B-Chemical	D015760	3125768
f@@	I-Chemical	-1	3125768
entan@@	I-Chemical	-1	3125768
il	I-Chemical	-1	3125768
.	O	-1	3125768
These	O	-1	3125768
observ@@	O	-1	3125768
ations	O	-1	3125768
suggest	O	-1	3125768
that	O	-1	3125768
rig@@	B-Disease	D009127	3125768
idity	I-Disease	-1	3125768
should	O	-1	3125768
be	O	-1	3125768
prevent@@	O	-1	3125768
ed	O	-1	3125768
when	O	-1	3125768
al@@	B-Chemical	D015760	3125768
f@@	I-Chemical	-1	3125768
entan@@	I-Chemical	-1	3125768
il	I-Chemical	-1	3125768
,	O	-1	3125768
and@@	O	-1	3125768
,	O	-1	3125768
pres@@	O	-1	3125768
um@@	O	-1	3125768
ab@@	O	-1	3125768
ly,	O	-1	3125768
other	O	-1	3125768
o@@	O	-1	3125768
pi@@	O	-1	3125768
at@@	O	-1	3125768
es,	O	-1	3125768
are	O	-1	3125768
used	O	-1	3125768
in	O	-1	3125768
the	O	-1	3125768
anesthe@@	O	-1	3125768
tic	O	-1	3125768
man@@	O	-1	3125768
ag@@	O	-1	3125768
ement	O	-1	3125768
of	O	-1	3125768
patients	O	-1	3125768
with	O	-1	3125768
IC@@	O	-1	3125768
P	O	-1	3125768
pro@@	O	-1	3125768
ble@@	O	-1	3125768
m@@	O	-1	3125768
s.	O	-1	3125768

Ad@@	O	-1	3187073
verse	O	-1	3187073
cardiac	O	-1	3187073
effects	O	-1	3187073
during	O	-1	3187073
induction	O	-1	3187073
chemotherapy	O	-1	3187073
treatment	O	-1	3187073
with	O	-1	3187073
cis@@	B-Chemical	D002945	3187073
-@@	I-Chemical	-1	3187073
pl@@	I-Chemical	-1	3187073
atin	I-Chemical	-1	3187073
and	O	-1	3187073
5-@@	B-Chemical	D005472	3187073
fluoro@@	I-Chemical	-1	3187073
urac@@	I-Chemical	-1	3187073
il	I-Chemical	-1	3187073
.	O	-1	3187073
S@@	O	-1	3187073
ur@@	O	-1	3187073
viv@@	O	-1	3187073
al	O	-1	3187073
for	O	-1	3187073
patients	O	-1	3187073
with	O	-1	3187073
adv@@	O	-1	3187073
anced	O	-1	3187073
he@@	B-Disease	D006258	3187073
ad	I-Disease	-1	3187073
and	I-Disease	-1	3187073
nec@@	I-Disease	-1	3187073
k	I-Disease	-1	3187073
carcin@@	I-Disease	-1	3187073
oma	I-Disease	-1	3187073
and	O	-1	3187073
es@@	B-Disease	D004938	3187073
oph@@	I-Disease	-1	3187073
ag@@	I-Disease	-1	3187073
e@@	I-Disease	-1	3187073
al	I-Disease	-1	3187073
carcin@@	I-Disease	-1	3187073
oma	I-Disease	-1	3187073
is	O	-1	3187073
po@@	O	-1	3187073
or	O	-1	3187073
with	O	-1	3187073
radi@@	O	-1	3187073
o@@	O	-1	3187073
therapy	O	-1	3187073
and/or	O	-1	3187073
surger@@	O	-1	3187073
y.	O	-1	3187073
O@@	O	-1	3187073
b@@	O	-1	3187073
vi@@	O	-1	3187073
ous@@	O	-1	3187073
ly,	O	-1	3187073
there	O	-1	3187073
is	O	-1	3187073
a	O	-1	3187073
need	O	-1	3187073
for	O	-1	3187073
effective	O	-1	3187073
chemo@@	O	-1	3187073
therapy.	O	-1	3187073
In	O	-1	3187073
the	O	-1	3187073
present	O	-1	3187073
study,	O	-1	3187073
cis@@	B-Chemical	D002945	3187073
-@@	I-Chemical	-1	3187073
pl@@	I-Chemical	-1	3187073
atin	I-Chemical	-1	3187073
(@@	O	-1	3187073
80@@	O	-1	3187073
-1@@	O	-1	3187073
20	O	-1	3187073
mg/m@@	O	-1	3187073
2@@	O	-1	3187073
B@@	O	-1	3187073
S@@	O	-1	3187073
A@@	O	-1	3187073
)	O	-1	3187073
and	O	-1	3187073
5-@@	B-Chemical	D005472	3187073
F@@	I-Chemical	-1	3187073
U	I-Chemical	-1	3187073
(@@	O	-1	3187073
10@@	O	-1	3187073
00	O	-1	3187073
mg/m@@	O	-1	3187073
2@@	O	-1	3187073
B@@	O	-1	3187073
S@@	O	-1	3187073
A	O	-1	3187073
daily	O	-1	3187073
as	O	-1	3187073
a	O	-1	3187073
continu@@	O	-1	3187073
ous	O	-1	3187073
infusion	O	-1	3187073
during	O	-1	3187073
5	O	-1	3187073
da@@	O	-1	3187073
ys@@	O	-1	3187073
)	O	-1	3187073
were	O	-1	3187073
given	O	-1	3187073
to	O	-1	3187073
7@@	O	-1	3187073
6	O	-1	3187073
patients	O	-1	3187073
before	O	-1	3187073
radi@@	O	-1	3187073
o@@	O	-1	3187073
therapy	O	-1	3187073
and	O	-1	3187073
surger@@	O	-1	3187073
y.	O	-1	3187073
The	O	-1	3187073
a@@	O	-1	3187073
im	O	-1	3187073
of	O	-1	3187073
the	O	-1	3187073
study	O	-1	3187073
was	O	-1	3187073
to	O	-1	3187073
cl@@	O	-1	3187073
ar@@	O	-1	3187073
if@@	O	-1	3187073
y	O	-1	3187073
the	O	-1	3187073
incidence	O	-1	3187073
and	O	-1	3187073
severity	O	-1	3187073
of	O	-1	3187073
adverse	O	-1	3187073
cardiac	O	-1	3187073
effects	O	-1	3187073
to	O	-1	3187073
this	O	-1	3187073
treatment.	O	-1	3187073
B@@	O	-1	3187073
e@@	O	-1	3187073
fore	O	-1	3187073
treatment	O	-1	3187073
all	O	-1	3187073
patients	O	-1	3187073
had	O	-1	3187073
a	O	-1	3187073
cardiac	O	-1	3187073
evalu@@	O	-1	3187073
ation	O	-1	3187073
and	O	-1	3187073
during	O	-1	3187073
treatment	O	-1	3187073
ser@@	O	-1	3187073
ial	O	-1	3187073
EC@@	O	-1	3187073
G	O	-1	3187073
recor@@	O	-1	3187073
d@@	O	-1	3187073
ings	O	-1	3187073
were	O	-1	3187073
per@@	O	-1	3187073
for@@	O	-1	3187073
me@@	O	-1	3187073
d.	O	-1	3187073
In	O	-1	3187073
the	O	-1	3187073
pre-@@	O	-1	3187073
treatment	O	-1	3187073
evalu@@	O	-1	3187073
ation,	O	-1	3187073
signs	O	-1	3187073
of	O	-1	3187073
cardiovascular	B-Disease	D002318	3187073
disease	I-Disease	-1	3187073
were	O	-1	3187073
found	O	-1	3187073
in	O	-1	3187073
3@@	O	-1	3187073
3	O	-1	3187073
patients	O	-1	3187073
(4@@	O	-1	3187073
3@@	O	-1	3187073
%).	O	-1	3187073
D@@	O	-1	3187073
uring	O	-1	3187073
treatment,	O	-1	3187073
adverse	O	-1	3187073
cardiac	O	-1	3187073
effects	O	-1	3187073
were	O	-1	3187073
observed	O	-1	3187073
in	O	-1	3187073
14	O	-1	3187073
patients	O	-1	3187073
(1@@	O	-1	3187073
8@@	O	-1	3187073
%).	O	-1	3187073
The	O	-1	3187073
mean	O	-1	3187073
age	O	-1	3187073
of	O	-1	3187073
these	O	-1	3187073
patients	O	-1	3187073
was	O	-1	3187073
the	O	-1	3187073
same	O	-1	3187073
as	O	-1	3187073
for	O	-1	3187073
the	O	-1	3187073
enti@@	O	-1	3187073
r@@	O	-1	3187073
e	O	-1	3187073
group@@	O	-1	3187073
,	O	-1	3187073
6@@	O	-1	3187073
4	O	-1	3187073
year@@	O	-1	3187073
s.	O	-1	3187073
The	O	-1	3187073
incidence	O	-1	3187073
of	O	-1	3187073
cardi@@	B-Disease	D066126	3187073
otoxicity	I-Disease	-1	3187073
was	O	-1	3187073
not	O	-1	3187073
higher	O	-1	3187073
in	O	-1	3187073
patients	O	-1	3187073
with	O	-1	3187073
signs	O	-1	3187073
of	O	-1	3187073
cardiovascular	B-Disease	D002318	3187073
disease	I-Disease	-1	3187073
than	O	-1	3187073
in	O	-1	3187073
those	O	-1	3187073
without	O	-1	3187073
in	O	-1	3187073
the	O	-1	3187073
pre-@@	O	-1	3187073
treatment	O	-1	3187073
evalu@@	O	-1	3187073
ation.	O	-1	3187073
The	O	-1	3187073
most	O	-1	3187073
common	O	-1	3187073
signs	O	-1	3187073
of	O	-1	3187073
cardi@@	B-Disease	D066126	3187073
otoxicity	I-Disease	-1	3187073
were	O	-1	3187073
ch@@	B-Disease	D002637	3187073
est	I-Disease	-1	3187073
pain	I-Disease	-1	3187073
,	O	-1	3187073
S@@	O	-1	3187073
T@@	O	-1	3187073
-@@	O	-1	3187073
T	O	-1	3187073
w@@	O	-1	3187073
a@@	O	-1	3187073
ve	O	-1	3187073
changes	O	-1	3187073
and	O	-1	3187073
atrial	B-Disease	D001281	3187073
fibrill@@	I-Disease	-1	3187073
ation	I-Disease	-1	3187073
.	O	-1	3187073
This	O	-1	3187073
was	O	-1	3187073
followed	O	-1	3187073
by	O	-1	3187073
ventricular	B-Disease	D014693	3187073
fibrill@@	I-Disease	-1	3187073
ation	I-Disease	-1	3187073
in	O	-1	3187073
one	O	-1	3187073
patient	O	-1	3187073
and	O	-1	3187073
su@@	B-Disease	D003645	3187073
d@@	I-Disease	-1	3187073
de@@	I-Disease	-1	3187073
n	I-Disease	-1	3187073
death	I-Disease	-1	3187073
in	O	-1	3187073
an@@	O	-1	3187073
o@@	O	-1	3187073
ther@@	O	-1	3187073
.	O	-1	3187073
It	O	-1	3187073
is	O	-1	3187073
concl@@	O	-1	3187073
uded	O	-1	3187073
that	O	-1	3187073
patients	O	-1	3187073
on	O	-1	3187073
5-@@	B-Chemical	D005472	3187073
F@@	I-Chemical	-1	3187073
U	I-Chemical	-1	3187073
treatment	O	-1	3187073
should	O	-1	3187073
be	O	-1	3187073
under	O	-1	3187073
clo@@	O	-1	3187073
se	O	-1	3187073
su@@	O	-1	3187073
per@@	O	-1	3187073
vi@@	O	-1	3187073
sion	O	-1	3187073
and	O	-1	3187073
that	O	-1	3187073
the	O	-1	3187073
treatment	O	-1	3187073
should	O	-1	3187073
be	O	-1	3187073
discontinu@@	O	-1	3187073
ed	O	-1	3187073
if	O	-1	3187073
ch@@	B-Disease	D002637	3187073
est	I-Disease	-1	3187073
pain	I-Disease	-1	3187073
or	O	-1	3187073
tachy@@	B-Disease	D013610	3187073
arrhyth@@	I-Disease	-1	3187073
mia	I-Disease	-1	3187073
is	O	-1	3187073
obser@@	O	-1	3187073
ved.	O	-1	3187073

V@@	B-Chemical	D014700	3371379
er@@	I-Chemical	-1	3371379
ap@@	I-Chemical	-1	3371379
ami@@	I-Chemical	-1	3371379
l	I-Chemical	-1	3371379
-induced	O	-1	3371379
carbamazepine	B-Chemical	D002220	3371379
neuro@@	B-Disease	D020258	3371379
toxicity	I-Disease	-1	3371379
.	O	-1	3371379
A	O	-1	3371379
report	O	-1	3371379
of	O	-1	3371379
two	O	-1	3371379
cas@@	O	-1	3371379
es.	O	-1	3371379
Two	O	-1	3371379
patients	O	-1	3371379
with	O	-1	3371379
signs	O	-1	3371379
of	O	-1	3371379
carbamazepine	B-Chemical	D002220	3371379
neuro@@	B-Disease	D020258	3371379
toxicity	I-Disease	-1	3371379
after	O	-1	3371379
combined	O	-1	3371379
treatment	O	-1	3371379
with	O	-1	3371379
verap@@	B-Chemical	D014700	3371379
ami@@	I-Chemical	-1	3371379
l	I-Chemical	-1	3371379
showed	O	-1	3371379
complete	O	-1	3371379
recovery	O	-1	3371379
after	O	-1	3371379
discontinu@@	O	-1	3371379
ation	O	-1	3371379
of	O	-1	3371379
the	O	-1	3371379
calcium	B-Chemical	D002118	3371379
entr@@	O	-1	3371379
y	O	-1	3371379
block@@	O	-1	3371379
er.	O	-1	3371379
U@@	O	-1	3371379
se	O	-1	3371379
of	O	-1	3371379
verap@@	B-Chemical	D014700	3371379
ami@@	I-Chemical	-1	3371379
l	I-Chemical	-1	3371379
in	O	-1	3371379
combination	O	-1	3371379
with	O	-1	3371379
carbamazepine	B-Chemical	D002220	3371379
should	O	-1	3371379
either	O	-1	3371379
be	O	-1	3371379
avoid@@	O	-1	3371379
ed	O	-1	3371379
or	O	-1	3371379
prescri@@	O	-1	3371379
bed	O	-1	3371379
only	O	-1	3371379
with	O	-1	3371379
appro@@	O	-1	3371379
pri@@	O	-1	3371379
ate	O	-1	3371379
adjust@@	O	-1	3371379
ment	O	-1	3371379
of	O	-1	3371379
the	O	-1	3371379
carbamazepine	B-Chemical	D002220	3371379
dose	O	-1	3371379
(@@	O	-1	3371379
us@@	O	-1	3371379
ually	O	-1	3371379
reduction	O	-1	3371379
of	O	-1	3371379
the	O	-1	3371379
carbamazepine	B-Chemical	D002220	3371379
dose	O	-1	3371379
by	O	-1	3371379
one	O	-1	3371379
h@@	O	-1	3371379
al@@	O	-1	3371379
f@@	O	-1	3371379
).	O	-1	3371379

S@@	O	-1	3503576
er@@	O	-1	3503576
ial	O	-1	3503576
studies	O	-1	3503576
of	O	-1	3503576
a@@	B-Disease	D006311	3503576
ud@@	I-Disease	-1	3503576
it@@	I-Disease	-1	3503576
ory	I-Disease	-1	3503576
neuro@@	I-Disease	-1	3503576
toxicity	I-Disease	-1	3503576
in	O	-1	3503576
patients	O	-1	3503576
receiving	O	-1	3503576
def@@	B-Chemical	D003676	3503576
er@@	I-Chemical	-1	3503576
ox@@	I-Chemical	-1	3503576
amine	I-Chemical	-1	3503576
therapy.	O	-1	3503576
V@@	B-Disease	D014786	3503576
i@@	I-Disease	-1	3503576
sual	I-Disease	-1	3503576
and	I-Disease	-1	3503576
a@@	I-Disease	-1	3503576
ud@@	I-Disease	-1	3503576
it@@	I-Disease	-1	3503576
ory	I-Disease	-1	3503576
neuro@@	I-Disease	-1	3503576
toxicity	I-Disease	-1	3503576
V@@	B-Disease	D006311	3503576
i@@	I-Disease	-1	3503576
sual	I-Disease	-1	3503576
and	I-Disease	-1	3503576
a@@	I-Disease	-1	3503576
ud@@	I-Disease	-1	3503576
it@@	I-Disease	-1	3503576
ory	I-Disease	-1	3503576
neuro@@	I-Disease	-1	3503576
toxicity	I-Disease	-1	3503576
was	O	-1	3503576
previously	O	-1	3503576
doc@@	O	-1	3503576
um@@	O	-1	3503576
ent@@	O	-1	3503576
ed	O	-1	3503576
in	O	-1	3503576
4@@	O	-1	3503576
2	O	-1	3503576
of	O	-1	3503576
8@@	O	-1	3503576
9	O	-1	3503576
patients	O	-1	3503576
with	O	-1	3503576
trans@@	O	-1	3503576
fu@@	O	-1	3503576
sion@@	O	-1	3503576
-@@	O	-1	3503576
dependent	O	-1	3503576
anemia	B-Disease	D000740	3503576
who	O	-1	3503576
were	O	-1	3503576
receiving	O	-1	3503576
i@@	B-Chemical	D007501	3503576
ro@@	I-Chemical	-1	3503576
n	I-Chemical	-1	3503576
ch@@	O	-1	3503576
el@@	O	-1	3503576
ation	O	-1	3503576
therapy	O	-1	3503576
with	O	-1	3503576
daily	O	-1	3503576
sub@@	O	-1	3503576
c@@	O	-1	3503576
utaneous	O	-1	3503576
def@@	B-Chemical	D003676	3503576
er@@	I-Chemical	-1	3503576
ox@@	I-Chemical	-1	3503576
amine	I-Chemical	-1	3503576
.	O	-1	3503576
Tw@@	O	-1	3503576
ent@@	O	-1	3503576
y-@@	O	-1	3503576
two	O	-1	3503576
patients	O	-1	3503576
in	O	-1	3503576
the	O	-1	3503576
affected	O	-1	3503576
group	O	-1	3503576
had	O	-1	3503576
ab@@	B-Disease	D006316	3503576
normal	I-Disease	-1	3503576
a@@	I-Disease	-1	3503576
udi@@	I-Disease	-1	3503576
o@@	I-Disease	-1	3503576
gram@@	I-Disease	-1	3503576
s	I-Disease	-1	3503576
with	I-Disease	-1	3503576
defic@@	I-Disease	-1	3503576
its	I-Disease	-1	3503576
mo@@	I-Disease	-1	3503576
st@@	I-Disease	-1	3503576
ly	I-Disease	-1	3503576
in	I-Disease	-1	3503576
the	I-Disease	-1	3503576
high	I-Disease	-1	3503576
frequency	I-Disease	-1	3503576
range	I-Disease	-1	3503576
of	I-Disease	-1	3503576
4@@	I-Disease	-1	3503576
,@@	I-Disease	-1	3503576
0@@	I-Disease	-1	3503576
00	I-Disease	-1	3503576
to	I-Disease	-1	3503576
8@@	I-Disease	-1	3503576
,@@	I-Disease	-1	3503576
0@@	I-Disease	-1	3503576
00	I-Disease	-1	3503576
H@@	I-Disease	-1	3503576
z	I-Disease	-1	3503576
and	O	-1	3503576
in	O	-1	3503576
the	O	-1	3503576
hearing	O	-1	3503576
th@@	O	-1	3503576
res@@	O	-1	3503576
h@@	O	-1	3503576
old	O	-1	3503576
levels	O	-1	3503576
of	O	-1	3503576
30	O	-1	3503576
to	O	-1	3503576
100	O	-1	3503576
dec@@	O	-1	3503576
i@@	O	-1	3503576
be@@	O	-1	3503576
l@@	O	-1	3503576
s.	O	-1	3503576
Whe@@	O	-1	3503576
n	O	-1	3503576
def@@	B-Chemical	D003676	3503576
er@@	I-Chemical	-1	3503576
ox@@	I-Chemical	-1	3503576
amine	I-Chemical	-1	3503576
therapy	O	-1	3503576
was	O	-1	3503576
discontinu@@	O	-1	3503576
ed	O	-1	3503576
and	O	-1	3503576
ser@@	O	-1	3503576
ial	O	-1	3503576
studies	O	-1	3503576
were	O	-1	3503576
per@@	O	-1	3503576
for@@	O	-1	3503576
me@@	O	-1	3503576
d,	O	-1	3503576
a@@	O	-1	3503576
udi@@	O	-1	3503576
o@@	O	-1	3503576
gram@@	O	-1	3503576
s	O	-1	3503576
in	O	-1	3503576
seven	O	-1	3503576
cases	O	-1	3503576
rever@@	O	-1	3503576
ted	O	-1	3503576
to	O	-1	3503576
normal	O	-1	3503576
or	O	-1	3503576
ne@@	O	-1	3503576
ar	O	-1	3503576
normal	O	-1	3503576
within	O	-1	3503576
two	O	-1	3503576
to	O	-1	3503576
three	O	-1	3503576
week@@	O	-1	3503576
s,	O	-1	3503576
and	O	-1	3503576
n@@	O	-1	3503576
ine	O	-1	3503576
of	O	-1	3503576
13	O	-1	3503576
patients	O	-1	3503576
with	O	-1	3503576
symptoms	O	-1	3503576
b@@	O	-1	3503576
ec@@	O	-1	3503576
am@@	O	-1	3503576
e	O	-1	3503576
as@@	O	-1	3503576
ym@@	O	-1	3503576
pto@@	O	-1	3503576
m@@	O	-1	3503576
ati@@	O	-1	3503576
c@@	O	-1	3503576
.	O	-1	3503576
A@@	O	-1	3503576
udi@@	O	-1	3503576
o@@	O	-1	3503576
gram@@	O	-1	3503576
s	O	-1	3503576
from	O	-1	3503576
15	O	-1	3503576
patients	O	-1	3503576
remained	O	-1	3503576
ab@@	O	-1	3503576
normal	O	-1	3503576
and	O	-1	3503576
four	O	-1	3503576
patients	O	-1	3503576
requ@@	O	-1	3503576
ired	O	-1	3503576
hearing	O	-1	3503576
a@@	O	-1	3503576
id@@	O	-1	3503576
s	O	-1	3503576
because	O	-1	3503576
of	O	-1	3503576
per@@	B-Disease	D003638	3503576
man@@	I-Disease	-1	3503576
ent	I-Disease	-1	3503576
dis@@	I-Disease	-1	3503576
ability	I-Disease	-1	3503576
.	O	-1	3503576
S@@	O	-1	3503576
inc@@	O	-1	3503576
e	O	-1	3503576
1@@	O	-1	3503576
8	O	-1	3503576
of	O	-1	3503576
the	O	-1	3503576
2@@	O	-1	3503576
2	O	-1	3503576
patients	O	-1	3503576
were	O	-1	3503576
initi@@	O	-1	3503576
ally	O	-1	3503576
receiving	O	-1	3503576
def@@	B-Chemical	D003676	3503576
er@@	I-Chemical	-1	3503576
ox@@	I-Chemical	-1	3503576
amine	I-Chemical	-1	3503576
doses	O	-1	3503576
in	O	-1	3503576
ex@@	O	-1	3503576
cess	O	-1	3503576
of	O	-1	3503576
the	O	-1	3503576
common@@	O	-1	3503576
ly	O	-1	3503576
recomm@@	O	-1	3503576
en@@	O	-1	3503576
ded	O	-1	3503576
50	O	-1	3503576
mg/kg	O	-1	3503576
per	O	-1	3503576
dose@@	O	-1	3503576
,	O	-1	3503576
therapy	O	-1	3503576
was	O	-1	3503576
re@@	O	-1	3503576
star@@	O	-1	3503576
ted	O	-1	3503576
with	O	-1	3503576
lower	O	-1	3503576
dos@@	O	-1	3503576
es,	O	-1	3503576
us@@	O	-1	3503576
ually	O	-1	3503576
50	O	-1	3503576
mg/kg	O	-1	3503576
per	O	-1	3503576
dose	O	-1	3503576
or	O	-1	3503576
less	O	-1	3503576
depend@@	O	-1	3503576
ing	O	-1	3503576
on	O	-1	3503576
the	O	-1	3503576
de@@	O	-1	3503576
g@@	O	-1	3503576
ree	O	-1	3503576
of	O	-1	3503576
a@@	B-Disease	D006311	3503576
ud@@	I-Disease	-1	3503576
it@@	I-Disease	-1	3503576
ory	I-Disease	-1	3503576
abnormal@@	I-Disease	-1	3503576
ity	I-Disease	-1	3503576
,	O	-1	3503576
and	O	-1	3503576
with	O	-1	3503576
the	O	-1	3503576
ex@@	O	-1	3503576
ce@@	O	-1	3503576
ption	O	-1	3503576
of	O	-1	3503576
two	O	-1	3503576
cases	O	-1	3503576
no	O	-1	3503576
further	O	-1	3503576
toxicity	B-Disease	D064420	3503576
was	O	-1	3503576
demon@@	O	-1	3503576
strat@@	O	-1	3503576
ed.	O	-1	3503576
A@@	O	-1	3503576
ud@@	O	-1	3503576
it@@	O	-1	3503576
ory	O	-1	3503576
deter@@	O	-1	3503576
i@@	O	-1	3503576
or@@	O	-1	3503576
ation	O	-1	3503576
and	O	-1	3503576
impro@@	O	-1	3503576
ve@@	O	-1	3503576
ment@@	O	-1	3503576
,	O	-1	3503576
demonstrated	O	-1	3503576
seri@@	O	-1	3503576
ally	O	-1	3503576
in	O	-1	3503576
individ@@	O	-1	3503576
ual	O	-1	3503576
patients	O	-1	3503576
receiving	O	-1	3503576
and	O	-1	3503576
not	O	-1	3503576
receiving	O	-1	3503576
def@@	B-Chemical	D003676	3503576
er@@	I-Chemical	-1	3503576
ox@@	I-Chemical	-1	3503576
amine	I-Chemical	-1	3503576
,	O	-1	3503576
respectivel@@	O	-1	3503576
y,	O	-1	3503576
pro@@	O	-1	3503576
vid@@	O	-1	3503576
ed	O	-1	3503576
con@@	O	-1	3503576
v@@	O	-1	3503576
inc@@	O	-1	3503576
ing	O	-1	3503576
evidence	O	-1	3503576
for	O	-1	3503576
a	O	-1	3503576
ca@@	O	-1	3503576
use@@	O	-1	3503576
-@@	O	-1	3503576
and@@	O	-1	3503576
-@@	O	-1	3503576
effect	O	-1	3503576
rel@@	O	-1	3503576
ation	O	-1	3503576
between	O	-1	3503576
def@@	B-Chemical	D003676	3503576
er@@	I-Chemical	-1	3503576
ox@@	I-Chemical	-1	3503576
amine	I-Chemical	-1	3503576
administration	O	-1	3503576
and	O	-1	3503576
ot@@	B-Disease	D006311	3503576
otoxicity	I-Disease	-1	3503576
.	O	-1	3503576
B@@	O	-1	3503576
as@@	O	-1	3503576
ed	O	-1	3503576
on	O	-1	3503576
these	O	-1	3503576
dat@@	O	-1	3503576
a,	O	-1	3503576
a	O	-1	3503576
pl@@	O	-1	3503576
an	O	-1	3503576
of	O	-1	3503576
man@@	O	-1	3503576
ag@@	O	-1	3503576
ement	O	-1	3503576
was	O	-1	3503576
developed	O	-1	3503576
that	O	-1	3503576
al@@	O	-1	3503576
low@@	O	-1	3503576
s	O	-1	3503576
effective	O	-1	3503576
y@@	O	-1	3503576
et	O	-1	3503576
saf@@	O	-1	3503576
e	O	-1	3503576
administration	O	-1	3503576
of	O	-1	3503576
def@@	B-Chemical	D003676	3503576
er@@	I-Chemical	-1	3503576
ox@@	I-Chemical	-1	3503576
amine	I-Chemical	-1	3503576
.	O	-1	3503576
A	O	-1	3503576
dose	O	-1	3503576
of	O	-1	3503576
50	O	-1	3503576
mg/kg	O	-1	3503576
is	O	-1	3503576
recomm@@	O	-1	3503576
en@@	O	-1	3503576
ded	O	-1	3503576
in	O	-1	3503576
those	O	-1	3503576
without	O	-1	3503576
a@@	O	-1	3503576
udi@@	O	-1	3503576
o@@	O	-1	3503576
gra@@	O	-1	3503576
m	O	-1	3503576
abnormal@@	O	-1	3503576
iti@@	O	-1	3503576
es.	O	-1	3503576
W@@	O	-1	3503576
it@@	O	-1	3503576
h	O	-1	3503576
mil@@	O	-1	3503576
d	O	-1	3503576
toxicity	B-Disease	D064420	3503576
,	O	-1	3503576
a	O	-1	3503576
reduction	O	-1	3503576
to	O	-1	3503576
30	O	-1	3503576
or	O	-1	3503576
40	O	-1	3503576
mg/kg	O	-1	3503576
per	O	-1	3503576
dose	O	-1	3503576
should	O	-1	3503576
result	O	-1	3503576
in	O	-1	3503576
a	O	-1	3503576
rever@@	O	-1	3503576
s@@	O	-1	3503576
al	O	-1	3503576
of	O	-1	3503576
the	O	-1	3503576
ab@@	O	-1	3503576
normal	O	-1	3503576
results	O	-1	3503576
to	O	-1	3503576
normal	O	-1	3503576
within	O	-1	3503576
four	O	-1	3503576
week@@	O	-1	3503576
s.	O	-1	3503576
M@@	O	-1	3503576
o@@	O	-1	3503576
der@@	O	-1	3503576
ate	O	-1	3503576
abnormal@@	O	-1	3503576
ities	O	-1	3503576
requ@@	O	-1	3503576
ir@@	O	-1	3503576
e	O	-1	3503576
a	O	-1	3503576
reduction	O	-1	3503576
of	O	-1	3503576
def@@	B-Chemical	D003676	3503576
er@@	I-Chemical	-1	3503576
ox@@	I-Chemical	-1	3503576
amine	I-Chemical	-1	3503576
to	O	-1	3503576
25	O	-1	3503576
mg/kg	O	-1	3503576
per	O	-1	3503576
dose	O	-1	3503576
with	O	-1	3503576
ca@@	O	-1	3503576
ref@@	O	-1	3503576
u@@	O	-1	3503576
l	O	-1	3503576
monit@@	O	-1	3503576
or@@	O	-1	3503576
ing.	O	-1	3503576
In	O	-1	3503576
those	O	-1	3503576
with	O	-1	3503576
symptoms	O	-1	3503576
of	O	-1	3503576
hearing	B-Disease	D034381	3503576
loss	I-Disease	-1	3503576
,	O	-1	3503576
the	O	-1	3503576
drug	O	-1	3503576
should	O	-1	3503576
be	O	-1	3503576
sto@@	O	-1	3503576
pp@@	O	-1	3503576
ed	O	-1	3503576
for	O	-1	3503576
four	O	-1	3503576
week@@	O	-1	3503576
s,	O	-1	3503576
and	O	-1	3503576
when	O	-1	3503576
the	O	-1	3503576
a@@	O	-1	3503576
udi@@	O	-1	3503576
o@@	O	-1	3503576
gra@@	O	-1	3503576
m	O	-1	3503576
is	O	-1	3503576
st@@	O	-1	3503576
able	O	-1	3503576
or	O	-1	3503576
impro@@	O	-1	3503576
ve@@	O	-1	3503576
d,	O	-1	3503576
therapy	O	-1	3503576
should	O	-1	3503576
be	O	-1	3503576
re@@	O	-1	3503576
star@@	O	-1	3503576
ted	O	-1	3503576
at	O	-1	3503576
10	O	-1	3503576
to	O	-1	3503576
25	O	-1	3503576
mg/kg	O	-1	3503576
per	O	-1	3503576
dose.	O	-1	3503576
S@@	O	-1	3503576
er@@	O	-1	3503576
ial	O	-1	3503576
a@@	O	-1	3503576
udi@@	O	-1	3503576
o@@	O	-1	3503576
gram@@	O	-1	3503576
s	O	-1	3503576
should	O	-1	3503576
be	O	-1	3503576
performed	O	-1	3503576
every	O	-1	3503576
six	O	-1	3503576
months	O	-1	3503576
in	O	-1	3503576
those	O	-1	3503576
without	O	-1	3503576
pro@@	O	-1	3503576
ble@@	O	-1	3503576
ms	O	-1	3503576
and	O	-1	3503576
more	O	-1	3503576
frequ@@	O	-1	3503576
ently	O	-1	3503576
in	O	-1	3503576
youn@@	O	-1	3503576
g	O	-1	3503576
patients	O	-1	3503576
with	O	-1	3503576
normal	O	-1	3503576
serum	O	-1	3503576
fer@@	O	-1	3503576
ri@@	O	-1	3503576
tin	O	-1	3503576
values	O	-1	3503576
and	O	-1	3503576
in	O	-1	3503576
those	O	-1	3503576
with	O	-1	3503576
a@@	B-Disease	D006311	3503576
ud@@	I-Disease	-1	3503576
it@@	I-Disease	-1	3503576
ory	I-Disease	-1	3503576
dysfunction	I-Disease	-1	3503576
.	O	-1	3503576

F@@	B-Chemical	D005480	3560095
lur@@	I-Chemical	-1	3560095
b@@	I-Chemical	-1	3560095
i@@	I-Chemical	-1	3560095
prof@@	I-Chemical	-1	3560095
en	I-Chemical	-1	3560095
in	O	-1	3560095
the	O	-1	3560095
treatment	O	-1	3560095
of	O	-1	3560095
j@@	B-Disease	D001171	3560095
u@@	I-Disease	-1	3560095
ven@@	I-Disease	-1	3560095
ile	I-Disease	-1	3560095
r@@	I-Disease	-1	3560095
he@@	I-Disease	-1	3560095
um@@	I-Disease	-1	3560095
at@@	I-Disease	-1	3560095
oid	I-Disease	-1	3560095
arth@@	I-Disease	-1	3560095
ritis	I-Disease	-1	3560095
.	O	-1	3560095
Th@@	O	-1	3560095
ir@@	O	-1	3560095
ty-@@	O	-1	3560095
four	O	-1	3560095
patients	O	-1	3560095
with	O	-1	3560095
j@@	B-Disease	D001171	3560095
u@@	I-Disease	-1	3560095
ven@@	I-Disease	-1	3560095
ile	I-Disease	-1	3560095
r@@	I-Disease	-1	3560095
he@@	I-Disease	-1	3560095
um@@	I-Disease	-1	3560095
at@@	I-Disease	-1	3560095
oid	I-Disease	-1	3560095
arth@@	I-Disease	-1	3560095
ritis	I-Disease	-1	3560095
,	O	-1	3560095
who	O	-1	3560095
were	O	-1	3560095
treated	O	-1	3560095
with	O	-1	3560095
f@@	B-Chemical	D005480	3560095
lur@@	I-Chemical	-1	3560095
b@@	I-Chemical	-1	3560095
i@@	I-Chemical	-1	3560095
prof@@	I-Chemical	-1	3560095
en	I-Chemical	-1	3560095
at	O	-1	3560095
a	O	-1	3560095
maxim@@	O	-1	3560095
um	O	-1	3560095
dose	O	-1	3560095
of	O	-1	3560095
4	O	-1	3560095
mg/k@@	O	-1	3560095
g/@@	O	-1	3560095
da@@	O	-1	3560095
y,	O	-1	3560095
had	O	-1	3560095
statis@@	O	-1	3560095
tically	O	-1	3560095
significant	O	-1	3560095
decreas@@	O	-1	3560095
es	O	-1	3560095
from	O	-1	3560095
baseline	O	-1	3560095
in	O	-1	3560095
6	O	-1	3560095
arth@@	B-Disease	D001168	3560095
ritis	I-Disease	-1	3560095
indic@@	O	-1	3560095
es	O	-1	3560095
after	O	-1	3560095
12	O	-1	3560095
weeks	O	-1	3560095
of	O	-1	3560095
treatment.	O	-1	3560095
Im@@	O	-1	3560095
pro@@	O	-1	3560095
ve@@	O	-1	3560095
ments	O	-1	3560095
were	O	-1	3560095
seen	O	-1	3560095
in	O	-1	3560095
the	O	-1	3560095
number	O	-1	3560095
of	O	-1	3560095
ten@@	B-Disease	-1	3560095
der	I-Disease	-1	3560095
j@@	I-Disease	-1	3560095
o@@	I-Disease	-1	3560095
int@@	I-Disease	-1	3560095
s	I-Disease	-1	3560095
,	O	-1	3560095
the	O	-1	3560095
severity	O	-1	3560095
of	O	-1	3560095
s@@	B-Disease	D004487	3560095
we@@	I-Disease	-1	3560095
ll@@	I-Disease	-1	3560095
ing	I-Disease	-1	3560095
and	O	-1	3560095
ten@@	B-Disease	-1	3560095
der@@	I-Disease	-1	3560095
ness	I-Disease	-1	3560095
,	O	-1	3560095
the	O	-1	3560095
time	O	-1	3560095
of	O	-1	3560095
w@@	O	-1	3560095
al@@	O	-1	3560095
k	O	-1	3560095
50	O	-1	3560095
fe@@	O	-1	3560095
et@@	O	-1	3560095
,	O	-1	3560095
the	O	-1	3560095
duration	O	-1	3560095
of	O	-1	3560095
mor@@	B-Disease	-1	3560095
ning	I-Disease	-1	3560095
sti@@	I-Disease	-1	3560095
ff@@	I-Disease	-1	3560095
ness	I-Disease	-1	3560095
and	O	-1	3560095
the	O	-1	3560095
cir@@	O	-1	3560095
cum@@	O	-1	3560095
fe@@	O	-1	3560095
rence	O	-1	3560095
of	O	-1	3560095
the	O	-1	3560095
left	O	-1	3560095
k@@	O	-1	3560095
ne@@	O	-1	3560095
e.	O	-1	3560095
The	O	-1	3560095
most	O	-1	3560095
frequ@@	O	-1	3560095
ently	O	-1	3560095
observed	O	-1	3560095
side	O	-1	3560095
effect	O	-1	3560095
was	O	-1	3560095
f@@	B-Disease	-1	3560095
ec@@	I-Disease	-1	3560095
al	I-Disease	-1	3560095
occ@@	I-Disease	-1	3560095
ult	I-Disease	-1	3560095
blood	I-Disease	-1	3560095
(2@@	O	-1	3560095
5%	O	-1	3560095
of	O	-1	3560095
patient@@	O	-1	3560095
s@@	O	-1	3560095
);	O	-1	3560095
however,	O	-1	3560095
there	O	-1	3560095
was	O	-1	3560095
no	O	-1	3560095
other	O	-1	3560095
evidence	O	-1	3560095
of	O	-1	3560095
gast@@	B-Disease	D006471	3560095
ro@@	I-Disease	-1	3560095
in@@	I-Disease	-1	3560095
test@@	I-Disease	-1	3560095
inal	I-Disease	-1	3560095
(@@	I-Disease	-1	3560095
G@@	I-Disease	-1	3560095
I@@	I-Disease	-1	3560095
)	I-Disease	-1	3560095
ble@@	I-Disease	-1	3560095
ed@@	I-Disease	-1	3560095
ing	I-Disease	-1	3560095
in	O	-1	3560095
these	O	-1	3560095
patients.	O	-1	3560095
One	O	-1	3560095
patient	O	-1	3560095
was	O	-1	3560095
pre@@	O	-1	3560095
mat@@	O	-1	3560095
ure@@	O	-1	3560095
ly	O	-1	3560095
discontinu@@	O	-1	3560095
ed	O	-1	3560095
from	O	-1	3560095
the	O	-1	3560095
study	O	-1	3560095
for	O	-1	3560095
severe	O	-1	3560095
headac@@	B-Disease	D006261	3560095
he	I-Disease	-1	3560095
and	O	-1	3560095
ab@@	B-Disease	D015746	3560095
domin@@	I-Disease	-1	3560095
al	I-Disease	-1	3560095
pain	I-Disease	-1	3560095
.	O	-1	3560095
M@@	O	-1	3560095
ost	O	-1	3560095
side	O	-1	3560095
effects	O	-1	3560095
were	O	-1	3560095
mil@@	O	-1	3560095
d	O	-1	3560095
and	O	-1	3560095
related	O	-1	3560095
to	O	-1	3560095
the	O	-1	3560095
G@@	O	-1	3560095
I	O	-1	3560095
trac@@	O	-1	3560095
t.	O	-1	3560095

The	O	-1	3714122
correl@@	O	-1	3714122
ation	O	-1	3714122
between	O	-1	3714122
neuro@@	B-Disease	D020258	3714122
toxic	I-Disease	-1	3714122
est@@	O	-1	3714122
er@@	O	-1	3714122
ase	O	-1	3714122
inhibition	O	-1	3714122
and	O	-1	3714122
mi@@	B-Chemical	C005238	3714122
pa@@	I-Chemical	-1	3714122
fo@@	I-Chemical	-1	3714122
x	I-Chemical	-1	3714122
-induced	O	-1	3714122
neuro@@	B-Disease	D009422	3714122
path@@	I-Disease	-1	3714122
ic	I-Disease	-1	3714122
damage	I-Disease	-1	3714122
in	O	-1	3714122
rats.	O	-1	3714122
The	O	-1	3714122
correl@@	O	-1	3714122
ation	O	-1	3714122
between	O	-1	3714122
neuro@@	B-Disease	D009422	3714122
path@@	I-Disease	-1	3714122
ic	I-Disease	-1	3714122
damage	I-Disease	-1	3714122
and	O	-1	3714122
inhibition	O	-1	3714122
of	O	-1	3714122
neuro@@	B-Disease	D020258	3714122
toxic	I-Disease	-1	3714122
est@@	O	-1	3714122
er@@	O	-1	3714122
ase	O	-1	3714122
or	O	-1	3714122
neuropathy	B-Disease	D009422	3714122
t@@	O	-1	3714122
arg@@	O	-1	3714122
et	O	-1	3714122
enzyme	O	-1	3714122
(N@@	O	-1	3714122
TE@@	O	-1	3714122
)	O	-1	3714122
was	O	-1	3714122
examined	O	-1	3714122
in	O	-1	3714122
rats	O	-1	3714122
ac@@	O	-1	3714122
u@@	O	-1	3714122
te@@	O	-1	3714122
ly	O	-1	3714122
exposed	O	-1	3714122
to	O	-1	3714122
M@@	B-Chemical	C005238	3714122
i@@	I-Chemical	-1	3714122
pa@@	I-Chemical	-1	3714122
fo@@	I-Chemical	-1	3714122
x	I-Chemical	-1	3714122
(	O	-1	3714122
N@@	B-Chemical	C005238	3714122
,	I-Chemical	-1	3714122
N@@	I-Chemical	-1	3714122
'@@	I-Chemical	-1	3714122
-@@	I-Chemical	-1	3714122
di@@	I-Chemical	-1	3714122
iso@@	I-Chemical	-1	3714122
prop@@	I-Chemical	-1	3714122
yl@@	I-Chemical	-1	3714122
phosph@@	I-Chemical	-1	3714122
o@@	I-Chemical	-1	3714122
ro@@	I-Chemical	-1	3714122
di@@	I-Chemical	-1	3714122
am@@	I-Chemical	-1	3714122
id@@	I-Chemical	-1	3714122
o@@	I-Chemical	-1	3714122
flu@@	I-Chemical	-1	3714122
or@@	I-Chemical	-1	3714122
id@@	I-Chemical	-1	3714122
ate	I-Chemical	-1	3714122
),	O	-1	3714122
a	O	-1	3714122
neuro@@	B-Disease	D020258	3714122
toxic	I-Disease	-1	3714122
org@@	B-Chemical	D010755	3714122
an@@	I-Chemical	-1	3714122
oph@@	I-Chemical	-1	3714122
osph@@	I-Chemical	-1	3714122
ate	I-Chemical	-1	3714122
.	O	-1	3714122
B@@	O	-1	3714122
ra@@	O	-1	3714122
in	O	-1	3714122
and	O	-1	3714122
spinal	O	-1	3714122
cor@@	O	-1	3714122
d	O	-1	3714122
N@@	O	-1	3714122
T@@	O	-1	3714122
E	O	-1	3714122
ac@@	O	-1	3714122
ti@@	O	-1	3714122
vi@@	O	-1	3714122
ties	O	-1	3714122
were	O	-1	3714122
measured	O	-1	3714122
in	O	-1	3714122
L@@	O	-1	3714122
on@@	O	-1	3714122
g@@	O	-1	3714122
-@@	O	-1	3714122
E@@	O	-1	3714122
v@@	O	-1	3714122
ans	O	-1	3714122
male	O	-1	3714122
rats	O	-1	3714122
1	O	-1	3714122
h@@	O	-1	3714122
r	O	-1	3714122
post@@	O	-1	3714122
-@@	O	-1	3714122
exposure	O	-1	3714122
to	O	-1	3714122
various	O	-1	3714122
dos@@	O	-1	3714122
ages	O	-1	3714122
of	O	-1	3714122
M@@	B-Chemical	C005238	3714122
i@@	I-Chemical	-1	3714122
pa@@	I-Chemical	-1	3714122
fo@@	I-Chemical	-1	3714122
x	I-Chemical	-1	3714122
(@@	O	-1	3714122
ip@@	O	-1	3714122
,	O	-1	3714122
1@@	O	-1	3714122
-1@@	O	-1	3714122
5	O	-1	3714122
mg/kg@@	O	-1	3714122
).	O	-1	3714122
These	O	-1	3714122
data	O	-1	3714122
were	O	-1	3714122
cor@@	O	-1	3714122
related	O	-1	3714122
with	O	-1	3714122
hist@@	O	-1	3714122
olog@@	O	-1	3714122
ically	O	-1	3714122
sco@@	O	-1	3714122
red	O	-1	3714122
cer@@	O	-1	3714122
v@@	O	-1	3714122
ical	O	-1	3714122
cor@@	B-Disease	D013118	3714122
d	I-Disease	-1	3714122
damage	I-Disease	-1	3714122
in	O	-1	3714122
a	O	-1	3714122
se@@	O	-1	3714122
par@@	O	-1	3714122
ate	O	-1	3714122
group	O	-1	3714122
of	O	-1	3714122
simil@@	O	-1	3714122
arly	O	-1	3714122
dos@@	O	-1	3714122
ed	O	-1	3714122
rats	O	-1	3714122
sam@@	O	-1	3714122
pl@@	O	-1	3714122
ed	O	-1	3714122
1@@	O	-1	3714122
4-@@	O	-1	3714122
21	O	-1	3714122
days	O	-1	3714122
post@@	O	-1	3714122
-@@	O	-1	3714122
expos@@	O	-1	3714122
ure.	O	-1	3714122
Th@@	O	-1	3714122
ose	O	-1	3714122
dos@@	O	-1	3714122
ages	O	-1	3714122
(@@	O	-1	3714122
greater	O	-1	3714122
than	O	-1	3714122
or	O	-1	3714122
equ@@	O	-1	3714122
al	O	-1	3714122
to	O	-1	3714122
10	O	-1	3714122
mg/kg)	O	-1	3714122
that	O	-1	3714122
inhibited	O	-1	3714122
mean	O	-1	3714122
N@@	O	-1	3714122
T@@	O	-1	3714122
E	O	-1	3714122
activity	O	-1	3714122
in	O	-1	3714122
the	O	-1	3714122
spinal	O	-1	3714122
cor@@	O	-1	3714122
d	O	-1	3714122
greater	O	-1	3714122
than	O	-1	3714122
or	O	-1	3714122
equ@@	O	-1	3714122
al	O	-1	3714122
to	O	-1	3714122
7@@	O	-1	3714122
3@@	O	-1	3714122
%	O	-1	3714122
and	O	-1	3714122
brain	O	-1	3714122
greater	O	-1	3714122
than	O	-1	3714122
or	O	-1	3714122
equ@@	O	-1	3714122
al	O	-1	3714122
to	O	-1	3714122
6@@	O	-1	3714122
7@@	O	-1	3714122
%	O	-1	3714122
of	O	-1	3714122
control	O	-1	3714122
values	O	-1	3714122
produced	O	-1	3714122
severe	O	-1	3714122
(@@	O	-1	3714122
greater	O	-1	3714122
than	O	-1	3714122
or	O	-1	3714122
equ@@	O	-1	3714122
al	O	-1	3714122
to	O	-1	3714122
3@@	O	-1	3714122
)	O	-1	3714122
cer@@	O	-1	3714122
v@@	O	-1	3714122
ical	O	-1	3714122
cor@@	O	-1	3714122
d	O	-1	3714122
path@@	O	-1	3714122
ology	O	-1	3714122
in	O	-1	3714122
8@@	O	-1	3714122
5%	O	-1	3714122
of	O	-1	3714122
the	O	-1	3714122
rats.	O	-1	3714122
In	O	-1	3714122
contrast@@	O	-1	3714122
,	O	-1	3714122
dos@@	O	-1	3714122
ages	O	-1	3714122
of	O	-1	3714122
M@@	B-Chemical	C005238	3714122
i@@	I-Chemical	-1	3714122
pa@@	I-Chemical	-1	3714122
fo@@	I-Chemical	-1	3714122
x	I-Chemical	-1	3714122
(@@	O	-1	3714122
less	O	-1	3714122
than	O	-1	3714122
or	O	-1	3714122
equ@@	O	-1	3714122
al	O	-1	3714122
to	O	-1	3714122
5	O	-1	3714122
mg/kg)	O	-1	3714122
which	O	-1	3714122
inhibited	O	-1	3714122
mean	O	-1	3714122
N@@	O	-1	3714122
T@@	O	-1	3714122
E	O	-1	3714122
activity	O	-1	3714122
in	O	-1	3714122
spinal	O	-1	3714122
cor@@	O	-1	3714122
d	O	-1	3714122
less	O	-1	3714122
than	O	-1	3714122
or	O	-1	3714122
equ@@	O	-1	3714122
al	O	-1	3714122
to	O	-1	3714122
6@@	O	-1	3714122
1@@	O	-1	3714122
%	O	-1	3714122
and	O	-1	3714122
brain	O	-1	3714122
less	O	-1	3714122
than	O	-1	3714122
or	O	-1	3714122
equ@@	O	-1	3714122
al	O	-1	3714122
to	O	-1	3714122
6@@	O	-1	3714122
0%	O	-1	3714122
produced	O	-1	3714122
this	O	-1	3714122
de@@	O	-1	3714122
g@@	O	-1	3714122
ree	O	-1	3714122
of	O	-1	3714122
cor@@	B-Disease	D013118	3714122
d	I-Disease	-1	3714122
damage	I-Disease	-1	3714122
in	O	-1	3714122
only	O	-1	3714122
9@@	O	-1	3714122
%	O	-1	3714122
of	O	-1	3714122
the	O	-1	3714122
anim@@	O	-1	3714122
al@@	O	-1	3714122
s.	O	-1	3714122
These	O	-1	3714122
data	O	-1	3714122
indicate	O	-1	3714122
that	O	-1	3714122
a	O	-1	3714122
cri@@	O	-1	3714122
tical	O	-1	3714122
perc@@	O	-1	3714122
ent@@	O	-1	3714122
age	O	-1	3714122
of	O	-1	3714122
N@@	O	-1	3714122
T@@	O	-1	3714122
E	O	-1	3714122
inhibition	O	-1	3714122
in	O	-1	3714122
brain	O	-1	3714122
and	O	-1	3714122
spinal	O	-1	3714122
cor@@	O	-1	3714122
d	O	-1	3714122
sam@@	O	-1	3714122
pl@@	O	-1	3714122
ed	O	-1	3714122
sh@@	O	-1	3714122
ort@@	O	-1	3714122
ly	O	-1	3714122
after	O	-1	3714122
M@@	B-Chemical	C005238	3714122
i@@	I-Chemical	-1	3714122
pa@@	I-Chemical	-1	3714122
fo@@	I-Chemical	-1	3714122
x	I-Chemical	-1	3714122
exposure	O	-1	3714122
can	O	-1	3714122
predic@@	O	-1	3714122
t	O	-1	3714122
neuro@@	B-Disease	D009422	3714122
path@@	I-Disease	-1	3714122
ic	I-Disease	-1	3714122
damage	I-Disease	-1	3714122
in	O	-1	3714122
rats	O	-1	3714122
several	O	-1	3714122
weeks	O	-1	3714122
lat@@	O	-1	3714122
er.	O	-1	3714122

C@@	B-Disease	D002544	3828020
e@@	I-Disease	-1	3828020
rebral	I-Disease	-1	3828020
infarction	I-Disease	-1	3828020
with	O	-1	3828020
a	O	-1	3828020
single	O	-1	3828020
oral	O	-1	3828020
dose	O	-1	3828020
of	O	-1	3828020
phenyl@@	B-Chemical	D010665	3828020
prop@@	I-Chemical	-1	3828020
an@@	I-Chemical	-1	3828020
ol@@	I-Chemical	-1	3828020
amine	I-Chemical	-1	3828020
.	O	-1	3828020
Ph@@	B-Chemical	D010665	3828020
en@@	I-Chemical	-1	3828020
yl@@	I-Chemical	-1	3828020
prop@@	I-Chemical	-1	3828020
an@@	I-Chemical	-1	3828020
ol@@	I-Chemical	-1	3828020
amine	I-Chemical	-1	3828020
(	O	-1	3828020
P@@	B-Chemical	D010665	3828020
P@@	I-Chemical	-1	3828020
A	I-Chemical	-1	3828020
),	O	-1	3828020
a	O	-1	3828020
syn@@	O	-1	3828020
thetic	O	-1	3828020
sym@@	O	-1	3828020
path@@	O	-1	3828020
om@@	O	-1	3828020
i@@	O	-1	3828020
me@@	O	-1	3828020
tic	O	-1	3828020
that	O	-1	3828020
is	O	-1	3828020
struct@@	O	-1	3828020
ur@@	O	-1	3828020
ally	O	-1	3828020
similar	O	-1	3828020
to	O	-1	3828020
amphetamine	B-Chemical	D000661	3828020
,	O	-1	3828020
is	O	-1	3828020
av@@	O	-1	3828020
ail@@	O	-1	3828020
able	O	-1	3828020
over	O	-1	3828020
the	O	-1	3828020
coun@@	O	-1	3828020
ter	O	-1	3828020
in	O	-1	3828020
an@@	O	-1	3828020
o@@	O	-1	3828020
rec@@	O	-1	3828020
tic@@	O	-1	3828020
s,	O	-1	3828020
n@@	O	-1	3828020
as@@	O	-1	3828020
al	O	-1	3828020
con@@	O	-1	3828020
g@@	O	-1	3828020
est@@	O	-1	3828020
ant@@	O	-1	3828020
s,	O	-1	3828020
and	O	-1	3828020
co@@	O	-1	3828020
l@@	O	-1	3828020
d	O	-1	3828020
pre@@	O	-1	3828020
par@@	O	-1	3828020
ations.	O	-1	3828020
I@@	O	-1	3828020
ts	O	-1	3828020
prolonged	O	-1	3828020
use	O	-1	3828020
or	O	-1	3828020
over@@	O	-1	3828020
use	O	-1	3828020
has	O	-1	3828020
been	O	-1	3828020
associated	O	-1	3828020
with	O	-1	3828020
seizures	B-Disease	D012640	3828020
,	O	-1	3828020
intrac@@	B-Disease	D002543	3828020
e@@	I-Disease	-1	3828020
rebral	I-Disease	-1	3828020
hemorrh@@	I-Disease	-1	3828020
age	I-Disease	-1	3828020
,	O	-1	3828020
neuro@@	B-Disease	D001523	3828020
psych@@	I-Disease	-1	3828020
i@@	I-Disease	-1	3828020
atric	I-Disease	-1	3828020
symptoms	I-Disease	-1	3828020
,	O	-1	3828020
and	O	-1	3828020
non@@	O	-1	3828020
hemorrh@@	O	-1	3828020
ag@@	O	-1	3828020
ic	O	-1	3828020
cerebral	B-Disease	D002544	3828020
infarction	I-Disease	-1	3828020
.	O	-1	3828020
We	O	-1	3828020
report	O	-1	3828020
the	O	-1	3828020
case	O	-1	3828020
of	O	-1	3828020
a	O	-1	3828020
youn@@	O	-1	3828020
g	O	-1	3828020
woman	O	-1	3828020
who	O	-1	3828020
su@@	O	-1	3828020
ffe@@	O	-1	3828020
red	O	-1	3828020
a	O	-1	3828020
cerebral	B-Disease	D002544	3828020
infarction	I-Disease	-1	3828020
after	O	-1	3828020
taking	O	-1	3828020
a	O	-1	3828020
single	O	-1	3828020
oral	O	-1	3828020
dose	O	-1	3828020
of	O	-1	3828020
P@@	B-Chemical	D010665	3828020
P@@	I-Chemical	-1	3828020
A	I-Chemical	-1	3828020
.	O	-1	3828020

Treat@@	O	-1	4812392
ment	O	-1	4812392
of	O	-1	4812392
p@@	B-Disease	D011565	4812392
s@@	I-Disease	-1	4812392
or@@	I-Disease	-1	4812392
ia@@	I-Disease	-1	4812392
sis	I-Disease	-1	4812392
with	O	-1	4812392
az@@	B-Chemical	D001379	4812392
ath@@	I-Chemical	-1	4812392
io@@	I-Chemical	-1	4812392
p@@	I-Chemical	-1	4812392
rine	I-Chemical	-1	4812392
.	O	-1	4812392
A@@	B-Chemical	D001379	4812392
z@@	I-Chemical	-1	4812392
ath@@	I-Chemical	-1	4812392
io@@	I-Chemical	-1	4812392
p@@	I-Chemical	-1	4812392
rine	I-Chemical	-1	4812392
treatment	O	-1	4812392
ben@@	O	-1	4812392
e@@	O	-1	4812392
f@@	O	-1	4812392
ited	O	-1	4812392
1@@	O	-1	4812392
9	O	-1	4812392
(6@@	O	-1	4812392
6@@	O	-1	4812392
%)	O	-1	4812392
out	O	-1	4812392
of	O	-1	4812392
2@@	O	-1	4812392
9	O	-1	4812392
patients	O	-1	4812392
suff@@	O	-1	4812392
ering	O	-1	4812392
from	O	-1	4812392
severe	O	-1	4812392
p@@	B-Disease	D011565	4812392
s@@	I-Disease	-1	4812392
or@@	I-Disease	-1	4812392
ia@@	I-Disease	-1	4812392
sis	I-Disease	-1	4812392
.	O	-1	4812392
H@@	O	-1	4812392
a@@	O	-1	4812392
em@@	O	-1	4812392
at@@	O	-1	4812392
ological	O	-1	4812392
complications	O	-1	4812392
were	O	-1	4812392
not	O	-1	4812392
t@@	O	-1	4812392
rou@@	O	-1	4812392
bl@@	O	-1	4812392
es@@	O	-1	4812392
ome	O	-1	4812392
and	O	-1	4812392
results	O	-1	4812392
of	O	-1	4812392
bio@@	O	-1	4812392
chemical	O	-1	4812392
liver	O	-1	4812392
function	O	-1	4812392
tests	O	-1	4812392
remained	O	-1	4812392
normal@@	O	-1	4812392
.	O	-1	4812392
M@@	O	-1	4812392
in@@	O	-1	4812392
im@@	O	-1	4812392
al	O	-1	4812392
cholest@@	B-Disease	D002779	4812392
asis	I-Disease	-1	4812392
was	O	-1	4812392
seen	O	-1	4812392
in	O	-1	4812392
two	O	-1	4812392
cases	O	-1	4812392
and	O	-1	4812392
port@@	O	-1	4812392
al	O	-1	4812392
fib@@	B-Disease	D005355	4812392
ro@@	I-Disease	-1	4812392
sis	I-Disease	-1	4812392
of	O	-1	4812392
a	O	-1	4812392
reversible	O	-1	4812392
de@@	O	-1	4812392
g@@	O	-1	4812392
ree	O	-1	4812392
in	O	-1	4812392
e@@	O	-1	4812392
igh@@	O	-1	4812392
t.	O	-1	4812392
L@@	O	-1	4812392
i@@	O	-1	4812392
ver	O	-1	4812392
biop@@	O	-1	4812392
si@@	O	-1	4812392
es	O	-1	4812392
should	O	-1	4812392
be	O	-1	4812392
under@@	O	-1	4812392
tak@@	O	-1	4812392
en	O	-1	4812392
at	O	-1	4812392
reg@@	O	-1	4812392
ular	O	-1	4812392
interv@@	O	-1	4812392
als	O	-1	4812392
if	O	-1	4812392
az@@	B-Chemical	D001379	4812392
ath@@	I-Chemical	-1	4812392
io@@	I-Chemical	-1	4812392
p@@	I-Chemical	-1	4812392
rine	I-Chemical	-1	4812392
therapy	O	-1	4812392
is	O	-1	4812392
continu@@	O	-1	4812392
ed	O	-1	4812392
so	O	-1	4812392
that	O	-1	4812392
struct@@	O	-1	4812392
ural	O	-1	4812392
liver	B-Disease	D056486	4812392
damage	I-Disease	-1	4812392
may	O	-1	4812392
be	O	-1	4812392
det@@	O	-1	4812392
ected	O	-1	4812392
at	O	-1	4812392
an	O	-1	4812392
early	O	-1	4812392
and	O	-1	4812392
reversible	O	-1	4812392
st@@	O	-1	4812392
age.	O	-1	4812392

M@@	O	-1	6518066
at@@	O	-1	6518066
er@@	O	-1	6518066
n@@	O	-1	6518066
al	O	-1	6518066
lithium	B-Chemical	D008094	6518066
and	O	-1	6518066
ne@@	O	-1	6518066
on@@	O	-1	6518066
atal	O	-1	6518066
E@@	B-Disease	D004437	6518066
b@@	I-Disease	-1	6518066
ste@@	I-Disease	-1	6518066
in@@	I-Disease	-1	6518066
's	I-Disease	-1	6518066
an@@	I-Disease	-1	6518066
om@@	I-Disease	-1	6518066
al@@	I-Disease	-1	6518066
y	I-Disease	-1	6518066
:	O	-1	6518066
evalu@@	O	-1	6518066
ation	O	-1	6518066
with	O	-1	6518066
cros@@	O	-1	6518066
s-@@	O	-1	6518066
sec@@	O	-1	6518066
tional	O	-1	6518066
echocardiograph@@	O	-1	6518066
y.	O	-1	6518066
C@@	O	-1	6518066
ros@@	O	-1	6518066
s-@@	O	-1	6518066
sec@@	O	-1	6518066
tional	O	-1	6518066
echocardiograph@@	O	-1	6518066
y	O	-1	6518066
was	O	-1	6518066
used	O	-1	6518066
to	O	-1	6518066
evalu@@	O	-1	6518066
ate	O	-1	6518066
two	O	-1	6518066
ne@@	O	-1	6518066
on@@	O	-1	6518066
ates	O	-1	6518066
wh@@	O	-1	6518066
ose	O	-1	6518066
mo@@	O	-1	6518066
ther@@	O	-1	6518066
s	O	-1	6518066
ing@@	O	-1	6518066
est@@	O	-1	6518066
ed	O	-1	6518066
lithium	B-Chemical	D008094	6518066
during	O	-1	6518066
pregn@@	O	-1	6518066
anc@@	O	-1	6518066
y.	O	-1	6518066
In	O	-1	6518066
one	O	-1	6518066
inf@@	O	-1	6518066
ant@@	O	-1	6518066
,	O	-1	6518066
E@@	B-Disease	D004437	6518066
b@@	I-Disease	-1	6518066
ste@@	I-Disease	-1	6518066
in@@	I-Disease	-1	6518066
's	I-Disease	-1	6518066
an@@	I-Disease	-1	6518066
om@@	I-Disease	-1	6518066
al@@	I-Disease	-1	6518066
y	I-Disease	-1	6518066
of	O	-1	6518066
the	O	-1	6518066
tr@@	O	-1	6518066
ic@@	O	-1	6518066
us@@	O	-1	6518066
pid	O	-1	6518066
val@@	O	-1	6518066
ve	O	-1	6518066
was	O	-1	6518066
identi@@	O	-1	6518066
fi@@	O	-1	6518066
ed.	O	-1	6518066
In	O	-1	6518066
the	O	-1	6518066
other	O	-1	6518066
inf@@	O	-1	6518066
ant	O	-1	6518066
cros@@	O	-1	6518066
s-@@	O	-1	6518066
sec@@	O	-1	6518066
tional	O	-1	6518066
echocardiograph@@	O	-1	6518066
y	O	-1	6518066
pro@@	O	-1	6518066
vid@@	O	-1	6518066
ed	O	-1	6518066
reas@@	O	-1	6518066
sur@@	O	-1	6518066
ance	O	-1	6518066
that	O	-1	6518066
the	O	-1	6518066
inf@@	O	-1	6518066
ant	O	-1	6518066
did	O	-1	6518066
not	O	-1	6518066
have	O	-1	6518066
E@@	B-Disease	D004437	6518066
b@@	I-Disease	-1	6518066
ste@@	I-Disease	-1	6518066
in@@	I-Disease	-1	6518066
's	I-Disease	-1	6518066
an@@	I-Disease	-1	6518066
om@@	I-Disease	-1	6518066
al@@	I-Disease	-1	6518066
y	I-Disease	-1	6518066
.	O	-1	6518066
C@@	O	-1	6518066
ros@@	O	-1	6518066
s-@@	O	-1	6518066
sec@@	O	-1	6518066
tional	O	-1	6518066
echocardiograph@@	O	-1	6518066
ic	O	-1	6518066
s@@	O	-1	6518066
cre@@	O	-1	6518066
en@@	O	-1	6518066
ing	O	-1	6518066
of	O	-1	6518066
ne@@	O	-1	6518066
w@@	O	-1	6518066
b@@	O	-1	6518066
or@@	O	-1	6518066
n@@	O	-1	6518066
s	O	-1	6518066
exposed	O	-1	6518066
to	O	-1	6518066
lithium	B-Chemical	D008094	6518066
during	O	-1	6518066
g@@	O	-1	6518066
est@@	O	-1	6518066
ation	O	-1	6518066
can	O	-1	6518066
prov@@	O	-1	6518066
ide	O	-1	6518066
high@@	O	-1	6518066
ly	O	-1	6518066
ac@@	O	-1	6518066
cur@@	O	-1	6518066
ate,	O	-1	6518066
non@@	O	-1	6518066
inv@@	O	-1	6518066
a@@	O	-1	6518066
sive	O	-1	6518066
assess@@	O	-1	6518066
ment	O	-1	6518066
of	O	-1	6518066
the	O	-1	6518066
presence	O	-1	6518066
or	O	-1	6518066
absence	O	-1	6518066
of	O	-1	6518066
lithium	B-Chemical	D008094	6518066
-induced	O	-1	6518066
cardiac	B-Disease	D006331	6518066
mal@@	I-Disease	-1	6518066
form@@	I-Disease	-1	6518066
ations	I-Disease	-1	6518066
.	O	-1	6518066

Eff@@	O	-1	6534871
ects	O	-1	6534871
of	O	-1	6534871
tra@@	O	-1	6534871
in@@	O	-1	6534871
ing	O	-1	6534871
on	O	-1	6534871
the	O	-1	6534871
ext@@	O	-1	6534871
ent	O	-1	6534871
of	O	-1	6534871
experimental	O	-1	6534871
myocardial	B-Disease	D009203	6534871
infarction	I-Disease	-1	6534871
in	O	-1	6534871
ag@@	O	-1	6534871
ing	O	-1	6534871
rats.	O	-1	6534871
The	O	-1	6534871
effects	O	-1	6534871
of	O	-1	6534871
ex@@	O	-1	6534871
er@@	O	-1	6534871
cis@@	O	-1	6534871
e	O	-1	6534871
on	O	-1	6534871
the	O	-1	6534871
severity	O	-1	6534871
of	O	-1	6534871
isoproteren@@	B-Chemical	D007545	6534871
ol	I-Chemical	-1	6534871
-induced	O	-1	6534871
myocardial	B-Disease	D009203	6534871
infarction	I-Disease	-1	6534871
were	O	-1	6534871
studied	O	-1	6534871
in	O	-1	6534871
female	O	-1	6534871
al@@	O	-1	6534871
bin@@	O	-1	6534871
o	O	-1	6534871
rats	O	-1	6534871
of	O	-1	6534871
20@@	O	-1	6534871
,@@	O	-1	6534871
4@@	O	-1	6534871
0@@	O	-1	6534871
,@@	O	-1	6534871
60	O	-1	6534871
and	O	-1	6534871
8@@	O	-1	6534871
0	O	-1	6534871
weeks	O	-1	6534871
of	O	-1	6534871
age.	O	-1	6534871
The	O	-1	6534871
rats	O	-1	6534871
were	O	-1	6534871
tra@@	O	-1	6534871
in@@	O	-1	6534871
ed	O	-1	6534871
to	O	-1	6534871
s@@	O	-1	6534871
wi@@	O	-1	6534871
m	O	-1	6534871
for	O	-1	6534871
a	O	-1	6534871
specific	O	-1	6534871
duration	O	-1	6534871
and	O	-1	6534871
for	O	-1	6534871
a	O	-1	6534871
partic@@	O	-1	6534871
ular	O	-1	6534871
perio@@	O	-1	6534871
d.	O	-1	6534871
The	O	-1	6534871
occur@@	O	-1	6534871
rence	O	-1	6534871
of	O	-1	6534871
infarc@@	B-Disease	D007238	6534871
ts	I-Disease	-1	6534871
were	O	-1	6534871
con@@	O	-1	6534871
fir@@	O	-1	6534871
m@@	O	-1	6534871
ed	O	-1	6534871
by	O	-1	6534871
hist@@	O	-1	6534871
ological	O	-1	6534871
meth@@	O	-1	6534871
o@@	O	-1	6534871
d@@	O	-1	6534871
s.	O	-1	6534871
E@@	O	-1	6534871
lev@@	O	-1	6534871
ations	O	-1	6534871
in	O	-1	6534871
the	O	-1	6534871
serum	O	-1	6534871
G@@	O	-1	6534871
O@@	O	-1	6534871
T	O	-1	6534871
and	O	-1	6534871
G@@	O	-1	6534871
P@@	O	-1	6534871
T	O	-1	6534871
were	O	-1	6534871
maxim@@	O	-1	6534871
um	O	-1	6534871
in	O	-1	6534871
the	O	-1	6534871
sed@@	O	-1	6534871
ent@@	O	-1	6534871
ar@@	O	-1	6534871
y@@	O	-1	6534871
-	O	-1	6534871
isoproteren@@	B-Chemical	D007545	6534871
ol@@	I-Chemical	-1	6534871
s	I-Chemical	-1	6534871
and	O	-1	6534871
minim@@	O	-1	6534871
um	O	-1	6534871
in	O	-1	6534871
the	O	-1	6534871
ex@@	O	-1	6534871
er@@	O	-1	6534871
ci@@	O	-1	6534871
se@@	O	-1	6534871
-@@	O	-1	6534871
controls.	O	-1	6534871
These	O	-1	6534871
changes	O	-1	6534871
in	O	-1	6534871
the	O	-1	6534871
serum	O	-1	6534871
trans@@	O	-1	6534871
amin@@	O	-1	6534871
as@@	O	-1	6534871
es	O	-1	6534871
were	O	-1	6534871
associated	O	-1	6534871
with	O	-1	6534871
cor@@	O	-1	6534871
respon@@	O	-1	6534871
ding	O	-1	6534871
deple@@	O	-1	6534871
tions	O	-1	6534871
in	O	-1	6534871
the	O	-1	6534871
cardiac	O	-1	6534871
G@@	O	-1	6534871
O@@	O	-1	6534871
T	O	-1	6534871
and	O	-1	6534871
G@@	O	-1	6534871
P@@	O	-1	6534871
T@@	O	-1	6534871
.	O	-1	6534871
However,	O	-1	6534871
age	O	-1	6534871
was	O	-1	6534871
seen	O	-1	6534871
to	O	-1	6534871
inter@@	O	-1	6534871
f@@	O	-1	6534871
ere	O	-1	6534871
with	O	-1	6534871
the	O	-1	6534871
responses	O	-1	6534871
ex@@	O	-1	6534871
hib@@	O	-1	6534871
ited	O	-1	6534871
by	O	-1	6534871
the	O	-1	6534871
youn@@	O	-1	6534871
g	O	-1	6534871
and	O	-1	6534871
old	O	-1	6534871
rats.	O	-1	6534871
S@@	O	-1	6534871
t@@	O	-1	6534871
udi@@	O	-1	6534871
es	O	-1	6534871
de@@	O	-1	6534871
al@@	O	-1	6534871
ing	O	-1	6534871
with	O	-1	6534871
myocardial	B-Disease	D009203	6534871
infarction	I-Disease	-1	6534871
are	O	-1	6534871
more	O	-1	6534871
inf@@	O	-1	6534871
orm@@	O	-1	6534871
ative	O	-1	6534871
when	O	-1	6534871
de@@	O	-1	6534871
al@@	O	-1	6534871
t	O	-1	6534871
with	O	-1	6534871
age.	O	-1	6534871

Eff@@	O	-1	6538499
ect	O	-1	6538499
of	O	-1	6538499
poly@@	B-Chemical	D011092	6538499
eth@@	I-Chemical	-1	6538499
yl@@	I-Chemical	-1	6538499
ene	I-Chemical	-1	6538499
gly@@	I-Chemical	-1	6538499
co@@	I-Chemical	-1	6538499
l	I-Chemical	-1	6538499
4@@	I-Chemical	-1	6538499
00	I-Chemical	-1	6538499
on	O	-1	6538499
adriam@@	B-Chemical	D004317	6538499
ycin	I-Chemical	-1	6538499
toxicity	B-Disease	D064420	6538499
in	O	-1	6538499
mice.	O	-1	6538499
The	O	-1	6538499
effect	O	-1	6538499
of	O	-1	6538499
a	O	-1	6538499
wi@@	O	-1	6538499
de@@	O	-1	6538499
ly	O	-1	6538499
used	O	-1	6538499
org@@	O	-1	6538499
anic	O	-1	6538499
sol@@	O	-1	6538499
v@@	O	-1	6538499
ent@@	O	-1	6538499
,	O	-1	6538499
poly@@	B-Chemical	D011092	6538499
eth@@	I-Chemical	-1	6538499
yl@@	I-Chemical	-1	6538499
ene	I-Chemical	-1	6538499
gly@@	I-Chemical	-1	6538499
co@@	I-Chemical	-1	6538499
l	I-Chemical	-1	6538499
4@@	I-Chemical	-1	6538499
00	I-Chemical	-1	6538499
(	O	-1	6538499
P@@	B-Chemical	D011092	6538499
E@@	I-Chemical	-1	6538499
G	I-Chemical	-1	6538499
4@@	I-Chemical	-1	6538499
00	I-Chemical	-1	6538499
),	O	-1	6538499
on	O	-1	6538499
the	O	-1	6538499
toxic	O	-1	6538499
action	O	-1	6538499
of	O	-1	6538499
an	O	-1	6538499
acute	O	-1	6538499
or	O	-1	6538499
chronic	O	-1	6538499
treatment	O	-1	6538499
with	O	-1	6538499
adriam@@	B-Chemical	D004317	6538499
ycin	I-Chemical	-1	6538499
(	O	-1	6538499
AD@@	B-Chemical	D004317	6538499
R	I-Chemical	-1	6538499
)	O	-1	6538499
was	O	-1	6538499
evaluated	O	-1	6538499
in	O	-1	6538499
mice.	O	-1	6538499
P@@	B-Chemical	D011092	6538499
E@@	I-Chemical	-1	6538499
G	I-Chemical	-1	6538499
4@@	I-Chemical	-1	6538499
00	I-Chemical	-1	6538499
im@@	O	-1	6538499
pres@@	O	-1	6538499
si@@	O	-1	6538499
vely	O	-1	6538499
decreased	O	-1	6538499
both	O	-1	6538499
acute	O	-1	6538499
high-dose	O	-1	6538499
and	O	-1	6538499
chronic	O	-1	6538499
low@@	O	-1	6538499
-@@	O	-1	6538499
dose@@	O	-1	6538499
-	O	-1	6538499
AD@@	B-Chemical	D004317	6538499
R	I-Chemical	-1	6538499
-@@	O	-1	6538499
associated	O	-1	6538499
le@@	O	-1	6538499
thal@@	O	-1	6538499
ity.	O	-1	6538499
L@@	O	-1	6538499
ight	O	-1	6538499
micro@@	O	-1	6538499
sco@@	O	-1	6538499
p@@	O	-1	6538499
ic	O	-1	6538499
analysis	O	-1	6538499
showed	O	-1	6538499
a	O	-1	6538499
significant	O	-1	6538499
prot@@	O	-1	6538499
ection	O	-1	6538499
against	O	-1	6538499
AD@@	B-Chemical	D004317	6538499
R	I-Chemical	-1	6538499
-induced	O	-1	6538499
cardiac	B-Disease	D009202	6538499
morph@@	I-Disease	-1	6538499
ological	I-Disease	-1	6538499
al@@	I-Disease	-1	6538499
ter@@	I-Disease	-1	6538499
ations	I-Disease	-1	6538499
.	O	-1	6538499
S@@	O	-1	6538499
uc@@	O	-1	6538499
h	O	-1	6538499
treatment	O	-1	6538499
did	O	-1	6538499
not	O	-1	6538499
di@@	O	-1	6538499
min@@	O	-1	6538499
is@@	O	-1	6538499
h	O	-1	6538499
the	O	-1	6538499
AD@@	B-Chemical	D004317	6538499
R	I-Chemical	-1	6538499
anti@@	O	-1	6538499
tumor	O	-1	6538499
activity	O	-1	6538499
in	O	-1	6538499
L@@	B-Disease	D007939	6538499
12@@	I-Disease	-1	6538499
10	I-Disease	-1	6538499
leuk@@	I-Disease	-1	6538499
emia	I-Disease	-1	6538499
and	O	-1	6538499
in	O	-1	6538499
E@@	B-Disease	D002286	6538499
h@@	I-Disease	-1	6538499
r@@	I-Disease	-1	6538499
l@@	I-Disease	-1	6538499
ich	I-Disease	-1	6538499
as@@	I-Disease	-1	6538499
cit@@	I-Disease	-1	6538499
es	I-Disease	-1	6538499
tumor	I-Disease	-1	6538499
.	O	-1	6538499

In@@	O	-1	6747681
tra@@	O	-1	6747681
-@@	O	-1	6747681
arterial	O	-1	6747681
BC@@	B-Chemical	D002330	6747681
N@@	I-Chemical	-1	6747681
U	I-Chemical	-1	6747681
chemotherapy	O	-1	6747681
for	O	-1	6747681
treatment	O	-1	6747681
of	O	-1	6747681
mal@@	B-Disease	D005910	6747681
i@@	I-Disease	-1	6747681
gn@@	I-Disease	-1	6747681
ant	I-Disease	-1	6747681
g@@	I-Disease	-1	6747681
li@@	I-Disease	-1	6747681
om@@	I-Disease	-1	6747681
as	I-Disease	-1	6747681
of	O	-1	6747681
the	O	-1	6747681
central	O	-1	6747681
ner@@	O	-1	6747681
v@@	O	-1	6747681
ous	O	-1	6747681
system@@	O	-1	6747681
.	O	-1	6747681
B@@	O	-1	6747681
ecause	O	-1	6747681
of	O	-1	6747681
the	O	-1	6747681
ra@@	O	-1	6747681
pid	O	-1	6747681
systemic	O	-1	6747681
clear@@	O	-1	6747681
ance	O	-1	6747681
of	O	-1	6747681
BC@@	B-Chemical	D002330	6747681
N@@	I-Chemical	-1	6747681
U	I-Chemical	-1	6747681
(	O	-1	6747681
1@@	B-Chemical	D002330	6747681
,@@	I-Chemical	-1	6747681
3-@@	I-Chemical	-1	6747681
b@@	I-Chemical	-1	6747681
is@@	I-Chemical	-1	6747681
-@@	I-Chemical	-1	6747681
(2@@	I-Chemical	-1	6747681
-@@	I-Chemical	-1	6747681
ch@@	I-Chemical	-1	6747681
loro@@	I-Chemical	-1	6747681
eth@@	I-Chemical	-1	6747681
yl@@	I-Chemical	-1	6747681
)@@	I-Chemical	-1	6747681
-1@@	I-Chemical	-1	6747681
-@@	I-Chemical	-1	6747681
nit@@	I-Chemical	-1	6747681
ros@@	I-Chemical	-1	6747681
ou@@	I-Chemical	-1	6747681
re@@	I-Chemical	-1	6747681
a	I-Chemical	-1	6747681
),	O	-1	6747681
intra@@	O	-1	6747681
-@@	O	-1	6747681
arterial	O	-1	6747681
administration	O	-1	6747681
should	O	-1	6747681
prov@@	O	-1	6747681
ide	O	-1	6747681
a	O	-1	6747681
subst@@	O	-1	6747681
anti@@	O	-1	6747681
al	O	-1	6747681
adv@@	O	-1	6747681
ant@@	O	-1	6747681
age	O	-1	6747681
over	O	-1	6747681
intravenous	O	-1	6747681
administration	O	-1	6747681
for	O	-1	6747681
the	O	-1	6747681
treatment	O	-1	6747681
of	O	-1	6747681
mal@@	B-Disease	D005910	6747681
i@@	I-Disease	-1	6747681
gn@@	I-Disease	-1	6747681
ant	I-Disease	-1	6747681
g@@	I-Disease	-1	6747681
li@@	I-Disease	-1	6747681
om@@	I-Disease	-1	6747681
as	I-Disease	-1	6747681
.	O	-1	6747681
Th@@	O	-1	6747681
ir@@	O	-1	6747681
ty-@@	O	-1	6747681
six	O	-1	6747681
patients	O	-1	6747681
were	O	-1	6747681
treated	O	-1	6747681
with	O	-1	6747681
BC@@	B-Chemical	D002330	6747681
N@@	I-Chemical	-1	6747681
U	I-Chemical	-1	6747681
every	O	-1	6747681
6	O	-1	6747681
to	O	-1	6747681
8	O	-1	6747681
week@@	O	-1	6747681
s,	O	-1	6747681
either	O	-1	6747681
by	O	-1	6747681
trans@@	O	-1	6747681
fem@@	O	-1	6747681
oral	O	-1	6747681
ca@@	O	-1	6747681
the@@	O	-1	6747681
ter@@	O	-1	6747681
ization	O	-1	6747681
of	O	-1	6747681
the	O	-1	6747681
inter@@	O	-1	6747681
n@@	O	-1	6747681
al	O	-1	6747681
ca@@	O	-1	6747681
ro@@	O	-1	6747681
ti@@	O	-1	6747681
d	O	-1	6747681
or	O	-1	6747681
ver@@	O	-1	6747681
te@@	O	-1	6747681
b@@	O	-1	6747681
ral	O	-1	6747681
artery	O	-1	6747681
or	O	-1	6747681
through	O	-1	6747681
a	O	-1	6747681
ful@@	O	-1	6747681
ly	O	-1	6747681
im@@	O	-1	6747681
pl@@	O	-1	6747681
ant@@	O	-1	6747681
able	O	-1	6747681
intrac@@	O	-1	6747681
a@@	O	-1	6747681
ro@@	O	-1	6747681
ti@@	O	-1	6747681
d	O	-1	6747681
drug	O	-1	6747681
de@@	O	-1	6747681
li@@	O	-1	6747681
very	O	-1	6747681
system@@	O	-1	6747681
,	O	-1	6747681
be@@	O	-1	6747681
g@@	O	-1	6747681
in@@	O	-1	6747681
ning	O	-1	6747681
with	O	-1	6747681
a	O	-1	6747681
dose	O	-1	6747681
of	O	-1	6747681
2@@	O	-1	6747681
00	O	-1	6747681
mg/@@	O	-1	6747681
s@@	O	-1	6747681
q	O	-1	6747681
m	O	-1	6747681
body	O	-1	6747681
sur@@	O	-1	6747681
fac@@	O	-1	6747681
e	O	-1	6747681
a@@	O	-1	6747681
re@@	O	-1	6747681
a.	O	-1	6747681
T@@	O	-1	6747681
we@@	O	-1	6747681
l@@	O	-1	6747681
ve	O	-1	6747681
patients	O	-1	6747681
with	O	-1	6747681
G@@	O	-1	6747681
ra@@	O	-1	6747681
de	O	-1	6747681
I@@	O	-1	6747681
II	O	-1	6747681
or	O	-1	6747681
IV	O	-1	6747681
ast@@	B-Disease	D001254	6747681
ro@@	I-Disease	-1	6747681
cyto@@	I-Disease	-1	6747681
m@@	I-Disease	-1	6747681
as	I-Disease	-1	6747681
were	O	-1	6747681
treated	O	-1	6747681
after	O	-1	6747681
partial	O	-1	6747681
res@@	O	-1	6747681
ection	O	-1	6747681
of	O	-1	6747681
the	O	-1	6747681
tumor	B-Disease	D009369	6747681
without	O	-1	6747681
prior	O	-1	6747681
radi@@	O	-1	6747681
ation	O	-1	6747681
therapy.	O	-1	6747681
After	O	-1	6747681
two	O	-1	6747681
to	O	-1	6747681
seven	O	-1	6747681
cyc@@	O	-1	6747681
le@@	O	-1	6747681
s	O	-1	6747681
of	O	-1	6747681
chemo@@	O	-1	6747681
therapy,	O	-1	6747681
n@@	O	-1	6747681
ine	O	-1	6747681
patients	O	-1	6747681
showed	O	-1	6747681
a	O	-1	6747681
decrease	O	-1	6747681
in	O	-1	6747681
tumor	B-Disease	D009369	6747681
size	O	-1	6747681
and	O	-1	6747681
sur@@	O	-1	6747681
ro@@	O	-1	6747681
un@@	O	-1	6747681
ding	O	-1	6747681
e@@	B-Disease	D004487	6747681
de@@	I-Disease	-1	6747681
ma	I-Disease	-1	6747681
on	O	-1	6747681
contrast@@	O	-1	6747681
-@@	O	-1	6747681
enhanced	O	-1	6747681
comp@@	O	-1	6747681
u@@	O	-1	6747681
ter@@	O	-1	6747681
ized	O	-1	6747681
to@@	O	-1	6747681
mo@@	O	-1	6747681
graph@@	O	-1	6747681
y	O	-1	6747681
s@@	O	-1	6747681
can@@	O	-1	6747681
s.	O	-1	6747681
In	O	-1	6747681
the	O	-1	6747681
n@@	O	-1	6747681
ine	O	-1	6747681
respon@@	O	-1	6747681
der@@	O	-1	6747681
s,	O	-1	6747681
median	O	-1	6747681
duration	O	-1	6747681
of	O	-1	6747681
chemotherapy	O	-1	6747681
response	O	-1	6747681
from	O	-1	6747681
the	O	-1	6747681
time	O	-1	6747681
of	O	-1	6747681
o@@	O	-1	6747681
per@@	O	-1	6747681
ation	O	-1	6747681
was	O	-1	6747681
25	O	-1	6747681
weeks	O	-1	6747681
(@@	O	-1	6747681
range	O	-1	6747681
12	O	-1	6747681
to	O	-1	6747681
more	O	-1	6747681
than	O	-1	6747681
9@@	O	-1	6747681
1	O	-1	6747681
week@@	O	-1	6747681
s@@	O	-1	6747681
).	O	-1	6747681
The	O	-1	6747681
median	O	-1	6747681
duration	O	-1	6747681
of	O	-1	6747681
sur@@	O	-1	6747681
viv@@	O	-1	6747681
al	O	-1	6747681
in	O	-1	6747681
the	O	-1	6747681
12	O	-1	6747681
patients	O	-1	6747681
was	O	-1	6747681
5@@	O	-1	6747681
4	O	-1	6747681
weeks	O	-1	6747681
(@@	O	-1	6747681
range	O	-1	6747681
21	O	-1	6747681
to	O	-1	6747681
more	O	-1	6747681
than	O	-1	6747681
1@@	O	-1	6747681
5@@	O	-1	6747681
6	O	-1	6747681
week@@	O	-1	6747681
s),	O	-1	6747681
with	O	-1	6747681
an	O	-1	6747681
18@@	O	-1	6747681
-@@	O	-1	6747681
mon@@	O	-1	6747681
th	O	-1	6747681
sur@@	O	-1	6747681
viv@@	O	-1	6747681
al	O	-1	6747681
rate	O	-1	6747681
of	O	-1	6747681
4@@	O	-1	6747681
2@@	O	-1	6747681
%.	O	-1	6747681
Tw@@	O	-1	6747681
ent@@	O	-1	6747681
y-@@	O	-1	6747681
four	O	-1	6747681
patients	O	-1	6747681
with	O	-1	6747681
recur@@	O	-1	6747681
rent	O	-1	6747681
G@@	O	-1	6747681
ra@@	O	-1	6747681
de	O	-1	6747681
I	O	-1	6747681
to	O	-1	6747681
IV	O	-1	6747681
ast@@	B-Disease	D001254	6747681
ro@@	I-Disease	-1	6747681
cyto@@	I-Disease	-1	6747681
m@@	I-Disease	-1	6747681
as	I-Disease	-1	6747681
,	O	-1	6747681
wh@@	O	-1	6747681
ose	O	-1	6747681
res@@	O	-1	6747681
ection	O	-1	6747681
and	O	-1	6747681
ir@@	O	-1	6747681
radi@@	O	-1	6747681
ation	O	-1	6747681
therapy	O	-1	6747681
had	O	-1	6747681
f@@	O	-1	6747681
a@@	O	-1	6747681
i@@	O	-1	6747681
le@@	O	-1	6747681
d,	O	-1	6747681
received	O	-1	6747681
two	O	-1	6747681
to	O	-1	6747681
e@@	O	-1	6747681
ight	O	-1	6747681
cour@@	O	-1	6747681
ses	O	-1	6747681
of	O	-1	6747681
intra@@	O	-1	6747681
-@@	O	-1	6747681
arterial	O	-1	6747681
BC@@	B-Chemical	D002330	6747681
N@@	I-Chemical	-1	6747681
U	I-Chemical	-1	6747681
therapy.	O	-1	6747681
S@@	O	-1	6747681
event@@	O	-1	6747681
e@@	O	-1	6747681
en	O	-1	6747681
of	O	-1	6747681
these	O	-1	6747681
had	O	-1	6747681
a	O	-1	6747681
response	O	-1	6747681
or	O	-1	6747681
were	O	-1	6747681
st@@	O	-1	6747681
able	O	-1	6747681
for	O	-1	6747681
a	O	-1	6747681
median	O	-1	6747681
of	O	-1	6747681
20	O	-1	6747681
weeks	O	-1	6747681
(@@	O	-1	6747681
range	O	-1	6747681
6	O	-1	6747681
to	O	-1	6747681
more	O	-1	6747681
than	O	-1	6747681
6@@	O	-1	6747681
6	O	-1	6747681
week@@	O	-1	6747681
s@@	O	-1	6747681
).	O	-1	6747681
The	O	-1	6747681
ca@@	O	-1	6747681
the@@	O	-1	6747681
ter@@	O	-1	6747681
ization	O	-1	6747681
proce@@	O	-1	6747681
d@@	O	-1	6747681
ure	O	-1	6747681
is	O	-1	6747681
saf@@	O	-1	6747681
e,	O	-1	6747681
with	O	-1	6747681
no	O	-1	6747681
immedi@@	O	-1	6747681
ate	O	-1	6747681
complication	O	-1	6747681
in	O	-1	6747681
1@@	O	-1	6747681
11	O	-1	6747681
infu@@	O	-1	6747681
sions	O	-1	6747681
of	O	-1	6747681
BC@@	B-Chemical	D002330	6747681
N@@	I-Chemical	-1	6747681
U	I-Chemical	-1	6747681
.	O	-1	6747681
A	O	-1	6747681
del@@	O	-1	6747681
ayed	O	-1	6747681
complication	O	-1	6747681
in	O	-1	6747681
n@@	O	-1	6747681
ine	O	-1	6747681
patients	O	-1	6747681
has	O	-1	6747681
been	O	-1	6747681
un@@	O	-1	6747681
il@@	O	-1	6747681
ateral	O	-1	6747681
loss	B-Disease	D014786	6747681
of	I-Disease	-1	6747681
vi@@	I-Disease	-1	6747681
sion	I-Disease	-1	6747681
secondary	O	-1	6747681
to	O	-1	6747681
a	O	-1	6747681
ret@@	B-Disease	D031300	6747681
inal	I-Disease	-1	6747681
vas@@	I-Disease	-1	6747681
cul@@	I-Disease	-1	6747681
iti@@	I-Disease	-1	6747681
s	I-Disease	-1	6747681
.	O	-1	6747681
The	O	-1	6747681
frequency	O	-1	6747681
of	O	-1	6747681
visual	B-Disease	D014786	6747681
loss	I-Disease	-1	6747681
decreased	O	-1	6747681
after	O	-1	6747681
the	O	-1	6747681
concentration	O	-1	6747681
of	O	-1	6747681
the	O	-1	6747681
eth@@	B-Chemical	D000431	6747681
an@@	I-Chemical	-1	6747681
ol	I-Chemical	-1	6747681
di@@	O	-1	6747681
lu@@	O	-1	6747681
ent	O	-1	6747681
was	O	-1	6747681
lo@@	O	-1	6747681
we@@	O	-1	6747681
red.	O	-1	6747681

B@@	O	-1	6861444
lo@@	O	-1	6861444
od	O	-1	6861444
pressure	O	-1	6861444
response	O	-1	6861444
to	O	-1	6861444
chronic	O	-1	6861444
low@@	O	-1	6861444
-@@	O	-1	6861444
dose	O	-1	6861444
intra@@	O	-1	6861444
renal	O	-1	6861444
nor@@	B-Chemical	D009638	6861444
adren@@	I-Chemical	-1	6861444
aline	I-Chemical	-1	6861444
infusion	O	-1	6861444
in	O	-1	6861444
con@@	O	-1	6861444
s@@	O	-1	6861444
ci@@	O	-1	6861444
ous	O	-1	6861444
rats.	O	-1	6861444
S@@	B-Chemical	D012965	6861444
odium	I-Chemical	-1	6861444
chlor@@	I-Chemical	-1	6861444
ide	I-Chemical	-1	6861444
sol@@	O	-1	6861444
u@@	O	-1	6861444
tion	O	-1	6861444
(0.@@	O	-1	6861444
9@@	O	-1	6861444
%)	O	-1	6861444
or	O	-1	6861444
nor@@	B-Chemical	D009638	6861444
adren@@	I-Chemical	-1	6861444
aline	I-Chemical	-1	6861444
in	O	-1	6861444
doses	O	-1	6861444
of	O	-1	6861444
4@@	O	-1	6861444
,	O	-1	6861444
12	O	-1	6861444
and	O	-1	6861444
3@@	O	-1	6861444
6	O	-1	6861444
microgram@@	O	-1	6861444
s	O	-1	6861444
h@@	O	-1	6861444
-1	O	-1	6861444
kg@@	O	-1	6861444
-1	O	-1	6861444
was	O	-1	6861444
inf@@	O	-1	6861444
used	O	-1	6861444
for	O	-1	6861444
five	O	-1	6861444
con@@	O	-1	6861444
sec@@	O	-1	6861444
utive	O	-1	6861444
day@@	O	-1	6861444
s,	O	-1	6861444
either	O	-1	6861444
intra@@	O	-1	6861444
ren@@	O	-1	6861444
ally	O	-1	6861444
(@@	O	-1	6861444
by	O	-1	6861444
a	O	-1	6861444
new	O	-1	6861444
t@@	O	-1	6861444
ech@@	O	-1	6861444
n@@	O	-1	6861444
i@@	O	-1	6861444
qu@@	O	-1	6861444
e@@	O	-1	6861444
)	O	-1	6861444
or	O	-1	6861444
intra@@	O	-1	6861444
ven@@	O	-1	6861444
ously	O	-1	6861444
into	O	-1	6861444
rats	O	-1	6861444
with	O	-1	6861444
one	O	-1	6861444
kidney	O	-1	6861444
re@@	O	-1	6861444
mo@@	O	-1	6861444
ved.	O	-1	6861444
In@@	O	-1	6861444
tra@@	O	-1	6861444
renal	O	-1	6861444
infusion	O	-1	6861444
of	O	-1	6861444
nor@@	B-Chemical	D009638	6861444
adren@@	I-Chemical	-1	6861444
aline	I-Chemical	-1	6861444
caused	O	-1	6861444
hypertension	B-Disease	D006973	6861444
at	O	-1	6861444
doses	O	-1	6861444
which	O	-1	6861444
did	O	-1	6861444
not	O	-1	6861444
d@@	O	-1	6861444
o	O	-1	6861444
so	O	-1	6861444
when	O	-1	6861444
inf@@	O	-1	6861444
used	O	-1	6861444
intra@@	O	-1	6861444
ven@@	O	-1	6861444
ous@@	O	-1	6861444
ly.	O	-1	6861444
In@@	O	-1	6861444
tra@@	O	-1	6861444
renal	O	-1	6861444
compared	O	-1	6861444
with	O	-1	6861444
intravenous	O	-1	6861444
infusion	O	-1	6861444
of	O	-1	6861444
nor@@	B-Chemical	D009638	6861444
adren@@	I-Chemical	-1	6861444
aline	I-Chemical	-1	6861444
caused	O	-1	6861444
higher	O	-1	6861444
plasma	O	-1	6861444
nor@@	B-Chemical	D009638	6861444
adren@@	I-Chemical	-1	6861444
aline	I-Chemical	-1	6861444
concentrations	O	-1	6861444
and	O	-1	6861444
a	O	-1	6861444
shi@@	O	-1	6861444
ft	O	-1	6861444
of	O	-1	6861444
the	O	-1	6861444
plasma	O	-1	6861444
nor@@	B-Chemical	D009638	6861444
adren@@	I-Chemical	-1	6861444
aline	I-Chemical	-1	6861444
concentr@@	O	-1	6861444
ation@@	O	-1	6861444
-@@	O	-1	6861444
blood	O	-1	6861444
pressure	O	-1	6861444
effect	O	-1	6861444
cur@@	O	-1	6861444
ve	O	-1	6861444
to@@	O	-1	6861444
war@@	O	-1	6861444
ds	O	-1	6861444
lower	O	-1	6861444
plasma	O	-1	6861444
nor@@	B-Chemical	D009638	6861444
adren@@	I-Chemical	-1	6861444
aline	I-Chemical	-1	6861444
level@@	O	-1	6861444
s.	O	-1	6861444
These	O	-1	6861444
results	O	-1	6861444
suggest	O	-1	6861444
that	O	-1	6861444
hypertension	B-Disease	D006973	6861444
after	O	-1	6861444
chronic	O	-1	6861444
intra@@	O	-1	6861444
renal	O	-1	6861444
nor@@	B-Chemical	D009638	6861444
adren@@	I-Chemical	-1	6861444
aline	I-Chemical	-1	6861444
infusion	O	-1	6861444
is	O	-1	6861444
produced	O	-1	6861444
by	O	-1	6861444
rel@@	O	-1	6861444
atively	O	-1	6861444
higher	O	-1	6861444
levels	O	-1	6861444
of	O	-1	6861444
cir@@	O	-1	6861444
cul@@	O	-1	6861444
ating	O	-1	6861444
nor@@	B-Chemical	D009638	6861444
adren@@	I-Chemical	-1	6861444
aline	I-Chemical	-1	6861444
and	O	-1	6861444
by	O	-1	6861444
tri@@	O	-1	6861444
g@@	O	-1	6861444
g@@	O	-1	6861444
ering	O	-1	6861444
of	O	-1	6861444
an	O	-1	6861444
addi@@	O	-1	6861444
tional	O	-1	6861444
intra@@	O	-1	6861444
renal	O	-1	6861444
press@@	O	-1	6861444
or	O	-1	6861444
mechanis@@	O	-1	6861444
m.	O	-1	6861444

A@@	O	-1	7053303
ge	O	-1	7053303
and	O	-1	7053303
renal	O	-1	7053303
clear@@	O	-1	7053303
ance	O	-1	7053303
of	O	-1	7053303
cimetid@@	B-Chemical	D002927	7053303
ine	I-Chemical	-1	7053303
.	O	-1	7053303
In	O	-1	7053303
3@@	O	-1	7053303
5	O	-1	7053303
patients	O	-1	7053303
(@@	O	-1	7053303
ages	O	-1	7053303
20	O	-1	7053303
to	O	-1	7053303
8@@	O	-1	7053303
6	O	-1	7053303
y@@	O	-1	7053303
r@@	O	-1	7053303
)	O	-1	7053303
receiving	O	-1	7053303
cimetid@@	B-Chemical	D002927	7053303
ine	I-Chemical	-1	7053303
therapeu@@	O	-1	7053303
tically	O	-1	7053303
two	O	-1	7053303
serum	O	-1	7053303
sam@@	O	-1	7053303
ple@@	O	-1	7053303
s	O	-1	7053303
and	O	-1	7053303
all	O	-1	7053303
urine	O	-1	7053303
form@@	O	-1	7053303
ed	O	-1	7053303
in	O	-1	7053303
the	O	-1	7053303
inter@@	O	-1	7053303
im	O	-1	7053303
were	O	-1	7053303
coll@@	O	-1	7053303
ected	O	-1	7053303
for	O	-1	7053303
analysis	O	-1	7053303
of	O	-1	7053303
cimetid@@	B-Chemical	D002927	7053303
ine	I-Chemical	-1	7053303
by	O	-1	7053303
high-@@	O	-1	7053303
pressure	O	-1	7053303
li@@	O	-1	7053303
qu@@	O	-1	7053303
id	O	-1	7053303
ch@@	O	-1	7053303
rom@@	O	-1	7053303
at@@	O	-1	7053303
ograph@@	O	-1	7053303
y	O	-1	7053303
and	O	-1	7053303
for	O	-1	7053303
creatinine	B-Chemical	D003404	7053303
.	O	-1	7053303
C@@	B-Chemical	D002927	7053303
i@@	I-Chemical	-1	7053303
metid@@	I-Chemical	-1	7053303
ine	I-Chemical	-1	7053303
clear@@	O	-1	7053303
ance	O	-1	7053303
decreased	O	-1	7053303
with	O	-1	7053303
age.	O	-1	7053303
The	O	-1	7053303
ext@@	O	-1	7053303
ra@@	O	-1	7053303
pol@@	O	-1	7053303
ated	O	-1	7053303
6-@@	O	-1	7053303
h@@	O	-1	7053303
r	O	-1	7053303
serum	O	-1	7053303
concentration	O	-1	7053303
of	O	-1	7053303
cimetid@@	B-Chemical	D002927	7053303
ine	I-Chemical	-1	7053303
per	O	-1	7053303
un@@	O	-1	7053303
it	O	-1	7053303
dose@@	O	-1	7053303
,	O	-1	7053303
after	O	-1	7053303
intravenous	O	-1	7053303
cimetid@@	B-Chemical	D002927	7053303
ine	I-Chemical	-1	7053303
,	O	-1	7053303
increased	O	-1	7053303
with	O	-1	7053303
age	O	-1	7053303
of	O	-1	7053303
the	O	-1	7053303
patients.	O	-1	7053303
The	O	-1	7053303
rati@@	O	-1	7053303
o	O	-1	7053303
of	O	-1	7053303
cimetid@@	B-Chemical	D002927	7053303
ine	I-Chemical	-1	7053303
clear@@	O	-1	7053303
ance	O	-1	7053303
to	O	-1	7053303
creatinine	B-Chemical	D003404	7053303
clear@@	O	-1	7053303
ance	O	-1	7053303
(@@	O	-1	7053303
R@@	O	-1	7053303
c@@	O	-1	7053303
)	O	-1	7053303
aver@@	O	-1	7053303
aged	O	-1	7053303
4.@@	O	-1	7053303
8	O	-1	7053303
+/-	O	-1	7053303
2.@@	O	-1	7053303
0@@	O	-1	7053303
,	O	-1	7053303
indicating	O	-1	7053303
ne@@	O	-1	7053303
t	O	-1	7053303
tub@@	O	-1	7053303
ular	O	-1	7053303
secre@@	O	-1	7053303
tion	O	-1	7053303
for	O	-1	7053303
cimetid@@	B-Chemical	D002927	7053303
ine	I-Chemical	-1	7053303
.	O	-1	7053303
R@@	O	-1	7053303
c	O	-1	7053303
se@@	O	-1	7053303
em@@	O	-1	7053303
ed	O	-1	7053303
to	O	-1	7053303
be	O	-1	7053303
in@@	O	-1	7053303
dependent	O	-1	7053303
of	O	-1	7053303
age	O	-1	7053303
and	O	-1	7053303
decreased	O	-1	7053303
with	O	-1	7053303
increas@@	O	-1	7053303
ing	O	-1	7053303
serum	O	-1	7053303
concentration	O	-1	7053303
of	O	-1	7053303
cimetid@@	B-Chemical	D002927	7053303
ine	I-Chemical	-1	7053303
,	O	-1	7053303
suggesting	O	-1	7053303
that	O	-1	7053303
secre@@	O	-1	7053303
tion	O	-1	7053303
of	O	-1	7053303
cimetid@@	B-Chemical	D002927	7053303
ine	I-Chemical	-1	7053303
is	O	-1	7053303
a	O	-1	7053303
s@@	O	-1	7053303
at@@	O	-1	7053303
ur@@	O	-1	7053303
able	O	-1	7053303
pro@@	O	-1	7053303
ces@@	O	-1	7053303
s.	O	-1	7053303
There	O	-1	7053303
was	O	-1	7053303
only	O	-1	7053303
one	O	-1	7053303
case	O	-1	7053303
of	O	-1	7053303
de@@	B-Disease	D003704	7053303
m@@	I-Disease	-1	7053303
enti@@	I-Disease	-1	7053303
a	I-Disease	-1	7053303
possib@@	O	-1	7053303
ly	O	-1	7053303
due	O	-1	7053303
to	O	-1	7053303
cimetid@@	B-Chemical	D002927	7053303
ine	I-Chemical	-1	7053303
(@@	O	-1	7053303
with	O	-1	7053303
a	O	-1	7053303
drug	O	-1	7053303
level	O	-1	7053303
of	O	-1	7053303
1.@@	O	-1	7053303
9	O	-1	7053303
microgram@@	O	-1	7053303
/@@	O	-1	7053303
m@@	O	-1	7053303
l	O	-1	7053303
6	O	-1	7053303
h@@	O	-1	7053303
r	O	-1	7053303
after	O	-1	7053303
a	O	-1	7053303
dose@@	O	-1	7053303
)	O	-1	7053303
in	O	-1	7053303
a	O	-1	7053303
group	O	-1	7053303
of	O	-1	7053303
13	O	-1	7053303
patients	O	-1	7053303
without	O	-1	7053303
liver	B-Disease	D008107	7053303
or	I-Disease	-1	7053303
kidney	I-Disease	-1	7053303
disease	I-Disease	-1	7053303
liver	B-Disease	D007674	7053303
or	I-Disease	-1	7053303
kidney	I-Disease	-1	7053303
disease	I-Disease	-1	7053303
who	O	-1	7053303
had	O	-1	7053303
cimetid@@	B-Chemical	D002927	7053303
ine	I-Chemical	-1	7053303
levels	O	-1	7053303
ab@@	O	-1	7053303
o@@	O	-1	7053303
ve	O	-1	7053303
1.@@	O	-1	7053303
25	O	-1	7053303
microgram@@	O	-1	7053303
/@@	O	-1	7053303
ml@@	O	-1	7053303
.	O	-1	7053303
Th@@	O	-1	7053303
us,	O	-1	7053303
high	O	-1	7053303
cimetid@@	B-Chemical	D002927	7053303
ine	I-Chemical	-1	7053303
levels	O	-1	7053303
alone	O	-1	7053303
d@@	O	-1	7053303
o	O	-1	7053303
not	O	-1	7053303
al@@	O	-1	7053303
w@@	O	-1	7053303
ays	O	-1	7053303
induce	O	-1	7053303
de@@	B-Disease	D003704	7053303
m@@	I-Disease	-1	7053303
enti@@	I-Disease	-1	7053303
a	I-Disease	-1	7053303
.	O	-1	7053303

De@@	O	-1	7088431
ve@@	O	-1	7088431
lop@@	O	-1	7088431
ment	O	-1	7088431
of	O	-1	7088431
c@@	B-Disease	D018262	7088431
le@@	I-Disease	-1	7088431
ar	I-Disease	-1	7088431
cell	I-Disease	-1	7088431
aden@@	I-Disease	-1	7088431
oc@@	I-Disease	-1	7088431
arc@@	I-Disease	-1	7088431
in@@	I-Disease	-1	7088431
oma	I-Disease	-1	7088431
in	O	-1	7088431
D@@	B-Chemical	D004054	7088431
E@@	I-Chemical	-1	7088431
S	I-Chemical	-1	7088431
-@@	O	-1	7088431
exposed	O	-1	7088431
o@@	O	-1	7088431
ff@@	O	-1	7088431
sp@@	O	-1	7088431
r@@	O	-1	7088431
ing	O	-1	7088431
under	O	-1	7088431
observ@@	O	-1	7088431
ation.	O	-1	7088431
Two	O	-1	7088431
cases	O	-1	7088431
of	O	-1	7088431
c@@	B-Disease	D018262	7088431
le@@	I-Disease	-1	7088431
ar	I-Disease	-1	7088431
cell	I-Disease	-1	7088431
aden@@	I-Disease	-1	7088431
oc@@	I-Disease	-1	7088431
arc@@	I-Disease	-1	7088431
in@@	I-Disease	-1	7088431
oma	I-Disease	-1	7088431
of	I-Disease	-1	7088431
the	I-Disease	-1	7088431
v@@	I-Disease	-1	7088431
ag@@	I-Disease	-1	7088431
in@@	I-Disease	-1	7088431
a	I-Disease	-1	7088431
c@@	B-Disease	D014625	7088431
le@@	I-Disease	-1	7088431
ar	I-Disease	-1	7088431
cell	I-Disease	-1	7088431
aden@@	I-Disease	-1	7088431
oc@@	I-Disease	-1	7088431
arc@@	I-Disease	-1	7088431
in@@	I-Disease	-1	7088431
oma	I-Disease	-1	7088431
of	I-Disease	-1	7088431
the	I-Disease	-1	7088431
v@@	I-Disease	-1	7088431
ag@@	I-Disease	-1	7088431
in@@	I-Disease	-1	7088431
a	I-Disease	-1	7088431
det@@	O	-1	7088431
ected	O	-1	7088431
at	O	-1	7088431
follow-up	O	-1	7088431
in	O	-1	7088431
youn@@	O	-1	7088431
g	O	-1	7088431
women	O	-1	7088431
exposed	O	-1	7088431
in	O	-1	7088431
u@@	O	-1	7088431
ter@@	O	-1	7088431
o	O	-1	7088431
to	O	-1	7088431
di@@	B-Chemical	D004054	7088431
eth@@	I-Chemical	-1	7088431
yl@@	I-Chemical	-1	7088431
sti@@	I-Chemical	-1	7088431
l@@	I-Chemical	-1	7088431
be@@	I-Chemical	-1	7088431
stro@@	I-Chemical	-1	7088431
l	I-Chemical	-1	7088431
are	O	-1	7088431
repor@@	O	-1	7088431
ted.	O	-1	7088431
One	O	-1	7088431
patient@@	O	-1	7088431
,	O	-1	7088431
aged	O	-1	7088431
2@@	O	-1	7088431
3,	O	-1	7088431
had	O	-1	7088431
been	O	-1	7088431
followed	O	-1	7088431
for	O	-1	7088431
2	O	-1	7088431
years	O	-1	7088431
before	O	-1	7088431
carcin@@	B-Disease	D002277	7088431
oma	I-Disease	-1	7088431
was	O	-1	7088431
diagno@@	O	-1	7088431
sed@@	O	-1	7088431
;	O	-1	7088431
the	O	-1	7088431
second	O	-1	7088431
patient@@	O	-1	7088431
,	O	-1	7088431
aged	O	-1	7088431
2@@	O	-1	7088431
2,	O	-1	7088431
had	O	-1	7088431
been	O	-1	7088431
seen	O	-1	7088431
on	O	-1	7088431
a	O	-1	7088431
reg@@	O	-1	7088431
ular	O	-1	7088431
b@@	O	-1	7088431
asis	O	-1	7088431
for	O	-1	7088431
5	O	-1	7088431
year@@	O	-1	7088431
s,	O	-1	7088431
8	O	-1	7088431
months.	O	-1	7088431
In	O	-1	7088431
both	O	-1	7088431
in@@	O	-1	7088431
st@@	O	-1	7088431
anc@@	O	-1	7088431
es,	O	-1	7088431
sus@@	O	-1	7088431
p@@	O	-1	7088431
ici@@	O	-1	7088431
on	O	-1	7088431
of	O	-1	7088431
the	O	-1	7088431
presence	O	-1	7088431
of	O	-1	7088431
carcin@@	B-Disease	D002277	7088431
oma	I-Disease	-1	7088431
was	O	-1	7088431
a@@	O	-1	7088431
ro@@	O	-1	7088431
used	O	-1	7088431
by	O	-1	7088431
the	O	-1	7088431
p@@	O	-1	7088431
al@@	O	-1	7088431
p@@	O	-1	7088431
ation	O	-1	7088431
of	O	-1	7088431
a	O	-1	7088431
sm@@	O	-1	7088431
all	O	-1	7088431
no@@	O	-1	7088431
d@@	O	-1	7088431
ul@@	O	-1	7088431
e	O	-1	7088431
in	O	-1	7088431
the	O	-1	7088431
v@@	O	-1	7088431
ag@@	O	-1	7088431
inal	O	-1	7088431
for@@	O	-1	7088431
n@@	O	-1	7088431
i@@	O	-1	7088431
x@@	O	-1	7088431
.	O	-1	7088431
H@@	O	-1	7088431
y@@	O	-1	7088431
ster@@	O	-1	7088431
os@@	O	-1	7088431
al@@	O	-1	7088431
p@@	O	-1	7088431
ing@@	O	-1	7088431
ograph@@	O	-1	7088431
y	O	-1	7088431
was	O	-1	7088431
performed	O	-1	7088431
on	O	-1	7088431
both	O	-1	7088431
patients	O	-1	7088431
and@@	O	-1	7088431
,	O	-1	7088431
in	O	-1	7088431
1	O	-1	7088431
in@@	O	-1	7088431
st@@	O	-1	7088431
ance@@	O	-1	7088431
,	O	-1	7088431
an	O	-1	7088431
ab@@	O	-1	7088431
normal	O	-1	7088431
x@@	O	-1	7088431
-@@	O	-1	7088431
ra@@	O	-1	7088431
y	O	-1	7088431
f@@	O	-1	7088431
il@@	O	-1	7088431
m	O	-1	7088431
was	O	-1	7088431
ref@@	O	-1	7088431
l@@	O	-1	7088431
ected	O	-1	7088431
by	O	-1	7088431
the	O	-1	7088431
g@@	O	-1	7088431
ros@@	O	-1	7088431
s	O	-1	7088431
appear@@	O	-1	7088431
ance	O	-1	7088431
of	O	-1	7088431
the	O	-1	7088431
u@@	O	-1	7088431
ter@@	O	-1	7088431
ine	O	-1	7088431
ca@@	O	-1	7088431
v@@	O	-1	7088431
ity	O	-1	7088431
found	O	-1	7088431
in	O	-1	7088431
the	O	-1	7088431
surg@@	O	-1	7088431
ical	O	-1	7088431
spec@@	O	-1	7088431
imen@@	O	-1	7088431
.	O	-1	7088431

Ph@@	B-Chemical	D010634	7248170
en@@	I-Chemical	-1	7248170
obarbit@@	I-Chemical	-1	7248170
one	I-Chemical	-1	7248170
-induced	O	-1	7248170
en@@	B-Disease	D006529	7248170
larg@@	I-Disease	-1	7248170
ement	I-Disease	-1	7248170
of	I-Disease	-1	7248170
the	I-Disease	-1	7248170
liver	I-Disease	-1	7248170
in	O	-1	7248170
the	O	-1	7248170
rat@@	O	-1	7248170
:	O	-1	7248170
its	O	-1	7248170
rel@@	O	-1	7248170
ationship	O	-1	7248170
to	O	-1	7248170
carb@@	B-Chemical	D002251	7248170
on	I-Chemical	-1	7248170
te@@	I-Chemical	-1	7248170
trac@@	I-Chemical	-1	7248170
h@@	I-Chemical	-1	7248170
lor@@	I-Chemical	-1	7248170
ide	I-Chemical	-1	7248170
-induced	O	-1	7248170
cir@@	B-Disease	D005355	7248170
r@@	I-Disease	-1	7248170
ho@@	I-Disease	-1	7248170
sis	I-Disease	-1	7248170
.	O	-1	7248170
The	O	-1	7248170
y@@	O	-1	7248170
i@@	O	-1	7248170
el@@	O	-1	7248170
d	O	-1	7248170
of	O	-1	7248170
severe	O	-1	7248170
cir@@	B-Disease	D008103	7248170
r@@	I-Disease	-1	7248170
ho@@	I-Disease	-1	7248170
sis	I-Disease	-1	7248170
of	I-Disease	-1	7248170
the	I-Disease	-1	7248170
liver	I-Disease	-1	7248170
(@@	O	-1	7248170
def@@	O	-1	7248170
in@@	O	-1	7248170
ed	O	-1	7248170
as	O	-1	7248170
a	O	-1	7248170
sh@@	O	-1	7248170
r@@	O	-1	7248170
un@@	O	-1	7248170
k@@	O	-1	7248170
en	O	-1	7248170
f@@	O	-1	7248170
ine@@	O	-1	7248170
ly	O	-1	7248170
no@@	O	-1	7248170
d@@	O	-1	7248170
ular	O	-1	7248170
liver	O	-1	7248170
with	O	-1	7248170
mic@@	O	-1	7248170
ron@@	O	-1	7248170
o@@	O	-1	7248170
d@@	O	-1	7248170
ular	O	-1	7248170
hist@@	O	-1	7248170
olog@@	O	-1	7248170
y,	O	-1	7248170
as@@	B-Disease	D001201	7248170
cit@@	I-Disease	-1	7248170
es	I-Disease	-1	7248170
greater	O	-1	7248170
than	O	-1	7248170
30	O	-1	7248170
ml@@	O	-1	7248170
,	O	-1	7248170
plasma	O	-1	7248170
al@@	O	-1	7248170
b@@	O	-1	7248170
um@@	O	-1	7248170
in	O	-1	7248170
less	O	-1	7248170
than	O	-1	7248170
2.@@	O	-1	7248170
2	O	-1	7248170
g/@@	O	-1	7248170
d@@	O	-1	7248170
l@@	O	-1	7248170
,	O	-1	7248170
s@@	B-Disease	D013163	7248170
pl@@	I-Disease	-1	7248170
en@@	I-Disease	-1	7248170
o@@	I-Disease	-1	7248170
me@@	I-Disease	-1	7248170
g@@	I-Disease	-1	7248170
al@@	I-Disease	-1	7248170
y	I-Disease	-1	7248170
2-@@	O	-1	7248170
3	O	-1	7248170
times	O	-1	7248170
normal@@	O	-1	7248170
,	O	-1	7248170
and	O	-1	7248170
t@@	O	-1	7248170
es@@	O	-1	7248170
tic@@	O	-1	7248170
ular	O	-1	7248170
atro@@	B-Disease	D001284	7248170
ph@@	I-Disease	-1	7248170
y	I-Disease	-1	7248170
appro@@	O	-1	7248170
xim@@	O	-1	7248170
ately	O	-1	7248170
h@@	O	-1	7248170
al@@	O	-1	7248170
f	O	-1	7248170
normal	O	-1	7248170
weigh@@	O	-1	7248170
t@@	O	-1	7248170
)	O	-1	7248170
after	O	-1	7248170
12	O	-1	7248170
doses	O	-1	7248170
of	O	-1	7248170
carb@@	B-Chemical	D002251	7248170
on	I-Chemical	-1	7248170
te@@	I-Chemical	-1	7248170
trac@@	I-Chemical	-1	7248170
h@@	I-Chemical	-1	7248170
lor@@	I-Chemical	-1	7248170
ide	I-Chemical	-1	7248170
given	O	-1	7248170
intra@@	O	-1	7248170
gast@@	O	-1	7248170
r@@	O	-1	7248170
ically	O	-1	7248170
in	O	-1	7248170
the	O	-1	7248170
phenobarbit@@	B-Chemical	D010634	7248170
one	I-Chemical	-1	7248170
-@@	O	-1	7248170
prim@@	O	-1	7248170
ed	O	-1	7248170
rat	O	-1	7248170
was	O	-1	7248170
increased	O	-1	7248170
from	O	-1	7248170
2@@	O	-1	7248170
5%	O	-1	7248170
to	O	-1	7248170
5@@	O	-1	7248170
6%	O	-1	7248170
by	O	-1	7248170
gi@@	O	-1	7248170
ving	O	-1	7248170
the	O	-1	7248170
initial	O	-1	7248170
"@@	O	-1	7248170
cal@@	O	-1	7248170
i@@	O	-1	7248170
b@@	O	-1	7248170
rat@@	O	-1	7248170
ing@@	O	-1	7248170
"	O	-1	7248170
dose	O	-1	7248170
of	O	-1	7248170
carb@@	B-Chemical	D002251	7248170
on	I-Chemical	-1	7248170
te@@	I-Chemical	-1	7248170
trac@@	I-Chemical	-1	7248170
h@@	I-Chemical	-1	7248170
lor@@	I-Chemical	-1	7248170
ide	I-Chemical	-1	7248170
at	O	-1	7248170
the	O	-1	7248170
pe@@	O	-1	7248170
a@@	O	-1	7248170
k	O	-1	7248170
of	O	-1	7248170
the	O	-1	7248170
phenobarbit@@	B-Chemical	D010634	7248170
one	I-Chemical	-1	7248170
-induced	O	-1	7248170
en@@	B-Disease	D006529	7248170
larg@@	I-Disease	-1	7248170
ement	I-Disease	-1	7248170
of	I-Disease	-1	7248170
the	I-Disease	-1	7248170
liver	I-Disease	-1	7248170
.	O	-1	7248170
A@@	O	-1	7248170
t	O	-1	7248170
this	O	-1	7248170
po@@	O	-1	7248170
in@@	O	-1	7248170
t	O	-1	7248170
it	O	-1	7248170
was	O	-1	7248170
as@@	O	-1	7248170
sum@@	O	-1	7248170
ed	O	-1	7248170
that	O	-1	7248170
the	O	-1	7248170
cyto@@	O	-1	7248170
ch@@	O	-1	7248170
rom@@	O	-1	7248170
e	O	-1	7248170
P@@	O	-1	7248170
4@@	O	-1	7248170
50@@	O	-1	7248170
/	O	-1	7248170
C@@	B-Chemical	D002251	7248170
Cl@@	I-Chemical	-1	7248170
4	I-Chemical	-1	7248170
toxic	O	-1	7248170
state	O	-1	7248170
was	O	-1	7248170
both	O	-1	7248170
maxim@@	O	-1	7248170
al	O	-1	7248170
and	O	-1	7248170
st@@	O	-1	7248170
able@@	O	-1	7248170
.	O	-1	7248170
The	O	-1	7248170
op@@	O	-1	7248170
tim@@	O	-1	7248170
al	O	-1	7248170
rat	O	-1	7248170
size	O	-1	7248170
to	O	-1	7248170
be@@	O	-1	7248170
g@@	O	-1	7248170
in	O	-1	7248170
phenobarbit@@	B-Chemical	D010634	7248170
one	I-Chemical	-1	7248170
was	O	-1	7248170
determined	O	-1	7248170
as	O	-1	7248170
100	O	-1	7248170
g@@	O	-1	7248170
,	O	-1	7248170
and	O	-1	7248170
this	O	-1	7248170
size	O	-1	7248170
as	O	-1	7248170
a	O	-1	7248170
group	O	-1	7248170
had	O	-1	7248170
a	O	-1	7248170
mean	O	-1	7248170
maxim@@	O	-1	7248170
um	O	-1	7248170
rel@@	O	-1	7248170
ative	O	-1	7248170
liver	O	-1	7248170
weight	O	-1	7248170
increase	O	-1	7248170
4@@	O	-1	7248170
7@@	O	-1	7248170
%	O	-1	7248170
greater	O	-1	7248170
than	O	-1	7248170
normal	O	-1	7248170
rats	O	-1	7248170
of	O	-1	7248170
the	O	-1	7248170
same	O	-1	7248170
body	O	-1	7248170
weigh@@	O	-1	7248170
t.	O	-1	7248170
The	O	-1	7248170
op@@	O	-1	7248170
tim@@	O	-1	7248170
al	O	-1	7248170
time	O	-1	7248170
for	O	-1	7248170
the	O	-1	7248170
initial	O	-1	7248170
dose	O	-1	7248170
of	O	-1	7248170
carb@@	B-Chemical	D002251	7248170
on	I-Chemical	-1	7248170
te@@	I-Chemical	-1	7248170
trac@@	I-Chemical	-1	7248170
h@@	I-Chemical	-1	7248170
lor@@	I-Chemical	-1	7248170
ide	I-Chemical	-1	7248170
was	O	-1	7248170
after	O	-1	7248170
14	O	-1	7248170
days	O	-1	7248170
on	O	-1	7248170
phenobarbit@@	B-Chemical	D010634	7248170
one	I-Chemical	-1	7248170
.	O	-1	7248170

A@@	O	-1	7453952
t@@	O	-1	7453952
ten@@	O	-1	7453952
u@@	O	-1	7453952
ation	O	-1	7453952
of	O	-1	7453952
the	O	-1	7453952
lithium	B-Chemical	D008094	7453952
-induced	O	-1	7453952
dia@@	B-Disease	D003919	7453952
bet@@	I-Disease	-1	7453952
es@@	I-Disease	-1	7453952
-@@	I-Disease	-1	7453952
in@@	I-Disease	-1	7453952
si@@	I-Disease	-1	7453952
pid@@	I-Disease	-1	7453952
us@@	I-Disease	-1	7453952
-@@	I-Disease	-1	7453952
like	I-Disease	-1	7453952
syndrome	I-Disease	-1	7453952
by	O	-1	7453952
am@@	B-Chemical	D000584	7453952
il@@	I-Chemical	-1	7453952
or@@	I-Chemical	-1	7453952
ide	I-Chemical	-1	7453952
in	O	-1	7453952
rats.	O	-1	7453952
The	O	-1	7453952
effect	O	-1	7453952
of	O	-1	7453952
am@@	B-Chemical	D000584	7453952
il@@	I-Chemical	-1	7453952
or@@	I-Chemical	-1	7453952
ide	I-Chemical	-1	7453952
on	O	-1	7453952
lithium	B-Chemical	D008094	7453952
-induced	O	-1	7453952
poly@@	B-Disease	D059606	7453952
di@@	I-Disease	-1	7453952
p@@	I-Disease	-1	7453952
sia	I-Disease	-1	7453952
and	O	-1	7453952
poly@@	B-Disease	D011141	7453952
uria	I-Disease	-1	7453952
and	O	-1	7453952
on	O	-1	7453952
the	O	-1	7453952
lithium	B-Chemical	D008094	7453952
concentration	O	-1	7453952
in	O	-1	7453952
the	O	-1	7453952
plas@@	O	-1	7453952
ma@@	O	-1	7453952
,	O	-1	7453952
bra@@	O	-1	7453952
in,	O	-1	7453952
kidne@@	O	-1	7453952
y,	O	-1	7453952
th@@	O	-1	7453952
yro@@	O	-1	7453952
id	O	-1	7453952
and	O	-1	7453952
red	O	-1	7453952
blood	O	-1	7453952
cells	O	-1	7453952
was	O	-1	7453952
investigated	O	-1	7453952
in	O	-1	7453952
rats,	O	-1	7453952
chron@@	O	-1	7453952
ically	O	-1	7453952
treated	O	-1	7453952
with	O	-1	7453952
L@@	B-Chemical	D018021	7453952
i@@	I-Chemical	-1	7453952
C@@	I-Chemical	-1	7453952
l	I-Chemical	-1	7453952
.	O	-1	7453952
A@@	B-Chemical	D000584	7453952
mil@@	I-Chemical	-1	7453952
or@@	I-Chemical	-1	7453952
ide	I-Chemical	-1	7453952
reduced	O	-1	7453952
the	O	-1	7453952
d@@	O	-1	7453952
r@@	O	-1	7453952
in@@	O	-1	7453952
king	O	-1	7453952
and	O	-1	7453952
urine	O	-1	7453952
volume	O	-1	7453952
of	O	-1	7453952
rats	O	-1	7453952
in	O	-1	7453952
an	O	-1	7453952
acute	O	-1	7453952
(@@	O	-1	7453952
6	O	-1	7453952
or	O	-1	7453952
12	O	-1	7453952
h@@	O	-1	7453952
)	O	-1	7453952
and	O	-1	7453952
a	O	-1	7453952
sub@@	O	-1	7453952
acute	O	-1	7453952
(@@	O	-1	7453952
3	O	-1	7453952
da@@	O	-1	7453952
ys@@	O	-1	7453952
)	O	-1	7453952
experim@@	O	-1	7453952
ent@@	O	-1	7453952
.	O	-1	7453952
6	O	-1	7453952
h	O	-1	7453952
after	O	-1	7453952
the	O	-1	7453952
administration	O	-1	7453952
of	O	-1	7453952
am@@	B-Chemical	D000584	7453952
il@@	I-Chemical	-1	7453952
or@@	I-Chemical	-1	7453952
ide	I-Chemical	-1	7453952
,	O	-1	7453952
a	O	-1	7453952
reduction	O	-1	7453952
was	O	-1	7453952
observed	O	-1	7453952
in	O	-1	7453952
the	O	-1	7453952
lithium	B-Chemical	D008094	7453952
cont@@	O	-1	7453952
ent	O	-1	7453952
of	O	-1	7453952
the	O	-1	7453952
renal	O	-1	7453952
med@@	O	-1	7453952
ul@@	O	-1	7453952
l@@	O	-1	7453952
a	O	-1	7453952
but	O	-1	7453952
not	O	-1	7453952
in	O	-1	7453952
the	O	-1	7453952
other	O	-1	7453952
org@@	O	-1	7453952
ans	O	-1	7453952
studi@@	O	-1	7453952
ed.	O	-1	7453952
A@@	O	-1	7453952
t	O	-1	7453952
12	O	-1	7453952
h@@	O	-1	7453952
,	O	-1	7453952
all	O	-1	7453952
the	O	-1	7453952
tissu@@	O	-1	7453952
es	O	-1	7453952
showed	O	-1	7453952
a	O	-1	7453952
s@@	O	-1	7453952
li@@	O	-1	7453952
ght	O	-1	7453952
increase	O	-1	7453952
in	O	-1	7453952
lithium	B-Chemical	D008094	7453952
level@@	O	-1	7453952
s.	O	-1	7453952
After	O	-1	7453952
3	O	-1	7453952
days	O	-1	7453952
of	O	-1	7453952
combined	O	-1	7453952
treatment,	O	-1	7453952
a	O	-1	7453952
mark@@	O	-1	7453952
ed	O	-1	7453952
elev@@	O	-1	7453952
ation	O	-1	7453952
in	O	-1	7453952
plasma	O	-1	7453952
and	O	-1	7453952
tissue	O	-1	7453952
lithium	B-Chemical	D008094	7453952
levels	O	-1	7453952
ac@@	O	-1	7453952
comp@@	O	-1	7453952
an@@	O	-1	7453952
ied	O	-1	7453952
a	O	-1	7453952
reduction	O	-1	7453952
in	O	-1	7453952
w@@	O	-1	7453952
at@@	O	-1	7453952
er	O	-1	7453952
int@@	O	-1	7453952
ak@@	O	-1	7453952
e.	O	-1	7453952
In	O	-1	7453952
all	O	-1	7453952
the	O	-1	7453952
experim@@	O	-1	7453952
ent@@	O	-1	7453952
s,	O	-1	7453952
the	O	-1	7453952
attenu@@	O	-1	7453952
ation	O	-1	7453952
of	O	-1	7453952
the	O	-1	7453952
lithium	B-Chemical	D008094	7453952
-induced	O	-1	7453952
dia@@	B-Disease	D003919	7453952
bet@@	I-Disease	-1	7453952
es@@	I-Disease	-1	7453952
-@@	I-Disease	-1	7453952
in@@	I-Disease	-1	7453952
si@@	I-Disease	-1	7453952
pid@@	I-Disease	-1	7453952
us@@	I-Disease	-1	7453952
-@@	I-Disease	-1	7453952
like	I-Disease	-1	7453952
syndrome	I-Disease	-1	7453952
by	O	-1	7453952
am@@	B-Chemical	D000584	7453952
il@@	I-Chemical	-1	7453952
or@@	I-Chemical	-1	7453952
ide	I-Chemical	-1	7453952
was	O	-1	7453952
ac@@	O	-1	7453952
comp@@	O	-1	7453952
an@@	O	-1	7453952
ied	O	-1	7453952
by	O	-1	7453952
a	O	-1	7453952
reduction	O	-1	7453952
of	O	-1	7453952
the	O	-1	7453952
rati@@	O	-1	7453952
o	O	-1	7453952
between	O	-1	7453952
the	O	-1	7453952
lithium	B-Chemical	D008094	7453952
concentration	O	-1	7453952
in	O	-1	7453952
the	O	-1	7453952
renal	O	-1	7453952
med@@	O	-1	7453952
ul@@	O	-1	7453952
l@@	O	-1	7453952
a	O	-1	7453952
and	O	-1	7453952
its	O	-1	7453952
levels	O	-1	7453952
in	O	-1	7453952
the	O	-1	7453952
blood	O	-1	7453952
and	O	-1	7453952
an	O	-1	7453952
elev@@	O	-1	7453952
ation	O	-1	7453952
in	O	-1	7453952
the	O	-1	7453952
plasma	O	-1	7453952
pot@@	B-Chemical	D011188	7453952
assi@@	I-Chemical	-1	7453952
um	I-Chemical	-1	7453952
level@@	O	-1	7453952
.	O	-1	7453952
It	O	-1	7453952
is	O	-1	7453952
concl@@	O	-1	7453952
uded	O	-1	7453952
that	O	-1	7453952
acute	O	-1	7453952
am@@	B-Chemical	D000584	7453952
il@@	I-Chemical	-1	7453952
or@@	I-Chemical	-1	7453952
ide	I-Chemical	-1	7453952
administration	O	-1	7453952
to	O	-1	7453952
lithium	B-Chemical	D008094	7453952
-treated	O	-1	7453952
patients	O	-1	7453952
suff@@	O	-1	7453952
ering	O	-1	7453952
from	O	-1	7453952
poly@@	B-Disease	D059606	7453952
di@@	I-Disease	-1	7453952
p@@	I-Disease	-1	7453952
sia	I-Disease	-1	7453952
and	O	-1	7453952
poly@@	B-Disease	D011141	7453952
uria	I-Disease	-1	7453952
might	O	-1	7453952
re@@	O	-1	7453952
li@@	O	-1	7453952
e@@	O	-1	7453952
ve	O	-1	7453952
these	O	-1	7453952
patients	O	-1	7453952
but	O	-1	7453952
prolonged	O	-1	7453952
am@@	B-Chemical	D000584	7453952
il@@	I-Chemical	-1	7453952
or@@	I-Chemical	-1	7453952
ide	I-Chemical	-1	7453952
sup@@	O	-1	7453952
ple@@	O	-1	7453952
ment@@	O	-1	7453952
ation	O	-1	7453952
wo@@	O	-1	7453952
uld	O	-1	7453952
result	O	-1	7453952
in	O	-1	7453952
elevated	O	-1	7453952
lithium	B-Chemical	D008094	7453952
levels	O	-1	7453952
and	O	-1	7453952
might	O	-1	7453952
be	O	-1	7453952
ha@@	O	-1	7453952
z@@	O	-1	7453952
ar@@	O	-1	7453952
dou@@	O	-1	7453952
s.	O	-1	7453952

S@@	O	-1	7802851
af@@	O	-1	7802851
ety	O	-1	7802851
and	O	-1	7802851
side@@	O	-1	7802851
-@@	O	-1	7802851
effects	O	-1	7802851
of	O	-1	7802851
al@@	B-Chemical	D000525	7802851
praz@@	I-Chemical	-1	7802851
ol@@	I-Chemical	-1	7802851
am	I-Chemical	-1	7802851
.	O	-1	7802851
C@@	O	-1	7802851
ont@@	O	-1	7802851
ro@@	O	-1	7802851
lled	O	-1	7802851
study	O	-1	7802851
in	O	-1	7802851
ag@@	B-Disease	D000379	7802851
or@@	I-Disease	-1	7802851
a@@	I-Disease	-1	7802851
ph@@	I-Disease	-1	7802851
ob@@	I-Disease	-1	7802851
ia	I-Disease	-1	7802851
with	O	-1	7802851
p@@	B-Disease	D016584	7802851
anic	I-Disease	-1	7802851
disor@@	I-Disease	-1	7802851
der	I-Disease	-1	7802851
.	O	-1	7802851
BACKGROUND:	O	-1	7802851
The	O	-1	7802851
w@@	O	-1	7802851
id@@	O	-1	7802851
es@@	O	-1	7802851
pre@@	O	-1	7802851
ad	O	-1	7802851
use	O	-1	7802851
of	O	-1	7802851
b@@	B-Chemical	D001569	7802851
enz@@	I-Chemical	-1	7802851
odi@@	I-Chemical	-1	7802851
azep@@	I-Chemical	-1	7802851
in@@	I-Chemical	-1	7802851
es	I-Chemical	-1	7802851
has	O	-1	7802851
l@@	O	-1	7802851
ed	O	-1	7802851
to	O	-1	7802851
increas@@	O	-1	7802851
ing	O	-1	7802851
reco@@	O	-1	7802851
gn@@	O	-1	7802851
ition	O	-1	7802851
of	O	-1	7802851
their	O	-1	7802851
un@@	O	-1	7802851
w@@	O	-1	7802851
ant@@	O	-1	7802851
ed	O	-1	7802851
effects.	O	-1	7802851
The	O	-1	7802851
efficacy	O	-1	7802851
of	O	-1	7802851
al@@	B-Chemical	D000525	7802851
praz@@	I-Chemical	-1	7802851
ol@@	I-Chemical	-1	7802851
am	I-Chemical	-1	7802851
and	O	-1	7802851
placebo	O	-1	7802851
in	O	-1	7802851
p@@	B-Disease	D016584	7802851
anic	I-Disease	-1	7802851
disor@@	I-Disease	-1	7802851
der	I-Disease	-1	7802851
with	O	-1	7802851
ag@@	B-Disease	D000379	7802851
or@@	I-Disease	-1	7802851
a@@	I-Disease	-1	7802851
ph@@	I-Disease	-1	7802851
ob@@	I-Disease	-1	7802851
ia	I-Disease	-1	7802851
,	O	-1	7802851
and	O	-1	7802851
the	O	-1	7802851
side@@	O	-1	7802851
-@@	O	-1	7802851
effect	O	-1	7802851
and	O	-1	7802851
adverse	O	-1	7802851
effect	O	-1	7802851
pro@@	O	-1	7802851
fi@@	O	-1	7802851
le@@	O	-1	7802851
s	O	-1	7802851
of	O	-1	7802851
both	O	-1	7802851
drug	O	-1	7802851
groups	O	-1	7802851
were	O	-1	7802851
meas@@	O	-1	7802851
ure@@	O	-1	7802851
d.	O	-1	7802851
METHOD@@	O	-1	7802851
:	O	-1	7802851
In	O	-1	7802851
L@@	O	-1	7802851
ond@@	O	-1	7802851
on	O	-1	7802851
and	O	-1	7802851
T@@	O	-1	7802851
or@@	O	-1	7802851
on@@	O	-1	7802851
to	O	-1	7802851
1@@	O	-1	7802851
5@@	O	-1	7802851
4	O	-1	7802851
patients	O	-1	7802851
who	O	-1	7802851
me@@	O	-1	7802851
t	O	-1	7802851
D@@	O	-1	7802851
S@@	O	-1	7802851
M@@	O	-1	7802851
-@@	O	-1	7802851
I@@	O	-1	7802851
II	O	-1	7802851
c@@	O	-1	7802851
rit@@	O	-1	7802851
er@@	O	-1	7802851
ia	O	-1	7802851
for	O	-1	7802851
p@@	B-Disease	D016584	7802851
anic	I-Disease	-1	7802851
disor@@	I-Disease	-1	7802851
der	I-Disease	-1	7802851
with	O	-1	7802851
ag@@	B-Disease	D000379	7802851
or@@	I-Disease	-1	7802851
a@@	I-Disease	-1	7802851
ph@@	I-Disease	-1	7802851
ob@@	I-Disease	-1	7802851
ia	I-Disease	-1	7802851
were	O	-1	7802851
random@@	O	-1	7802851
is@@	O	-1	7802851
ed	O	-1	7802851
to	O	-1	7802851
al@@	B-Chemical	D000525	7802851
praz@@	I-Chemical	-1	7802851
ol@@	I-Chemical	-1	7802851
am	I-Chemical	-1	7802851
or	O	-1	7802851
placebo@@	O	-1	7802851
.	O	-1	7802851
S@@	O	-1	7802851
ub@@	O	-1	7802851
j@@	O	-1	7802851
ects	O	-1	7802851
in	O	-1	7802851
each	O	-1	7802851
drug	O	-1	7802851
group	O	-1	7802851
also	O	-1	7802851
received	O	-1	7802851
either	O	-1	7802851
exposure	O	-1	7802851
or	O	-1	7802851
rel@@	O	-1	7802851
ax@@	O	-1	7802851
ation.	O	-1	7802851
Treat@@	O	-1	7802851
ment	O	-1	7802851
was	O	-1	7802851
from	O	-1	7802851
weeks	O	-1	7802851
0	O	-1	7802851
to	O	-1	7802851
8	O	-1	7802851
and	O	-1	7802851
was	O	-1	7802851
then	O	-1	7802851
t@@	O	-1	7802851
ap@@	O	-1	7802851
ered	O	-1	7802851
from	O	-1	7802851
weeks	O	-1	7802851
8	O	-1	7802851
to	O	-1	7802851
1@@	O	-1	7802851
6@@	O	-1	7802851
.	O	-1	7802851
RESULTS:	O	-1	7802851
M@@	O	-1	7802851
e@@	O	-1	7802851
an	O	-1	7802851
al@@	B-Chemical	D000525	7802851
praz@@	I-Chemical	-1	7802851
ol@@	I-Chemical	-1	7802851
am	I-Chemical	-1	7802851
dose	O	-1	7802851
was	O	-1	7802851
5	O	-1	7802851
mg	O	-1	7802851
da@@	O	-1	7802851
il@@	O	-1	7802851
y.	O	-1	7802851
Com@@	O	-1	7802851
pared	O	-1	7802851
with	O	-1	7802851
placebo	O	-1	7802851
subj@@	O	-1	7802851
ect@@	O	-1	7802851
s,	O	-1	7802851
al@@	B-Chemical	D000525	7802851
praz@@	I-Chemical	-1	7802851
ol@@	I-Chemical	-1	7802851
am	I-Chemical	-1	7802851
patients	O	-1	7802851
developed	O	-1	7802851
more	O	-1	7802851
adverse	O	-1	7802851
reactions	O	-1	7802851
(2@@	O	-1	7802851
1@@	O	-1	7802851
%	O	-1	7802851
v@@	O	-1	7802851
.	O	-1	7802851
0@@	O	-1	7802851
%)	O	-1	7802851
of	O	-1	7802851
de@@	B-Disease	D003866	7802851
pression	I-Disease	-1	7802851
,	O	-1	7802851
en@@	B-Disease	D004775	7802851
ure@@	I-Disease	-1	7802851
sis	I-Disease	-1	7802851
,	O	-1	7802851
dis@@	O	-1	7802851
inhibition	O	-1	7802851
and	O	-1	7802851
ag@@	B-Disease	D001523	7802851
gres@@	I-Disease	-1	7802851
sion	I-Disease	-1	7802851
;	O	-1	7802851
and	O	-1	7802851
more	O	-1	7802851
side@@	O	-1	7802851
-@@	O	-1	7802851
effect@@	O	-1	7802851
s,	O	-1	7802851
partic@@	O	-1	7802851
ul@@	O	-1	7802851
arly	O	-1	7802851
sed@@	O	-1	7802851
ation,	O	-1	7802851
ir@@	B-Disease	D001523	7802851
rit@@	I-Disease	-1	7802851
ability	I-Disease	-1	7802851
,	O	-1	7802851
impaired	B-Disease	D008569	7802851
memory	I-Disease	-1	7802851
,	O	-1	7802851
weight	B-Disease	D015431	7802851
loss	I-Disease	-1	7802851
and	O	-1	7802851
at@@	B-Disease	D001259	7802851
ax@@	I-Disease	-1	7802851
ia	I-Disease	-1	7802851
.	O	-1	7802851
S@@	O	-1	7802851
ide@@	O	-1	7802851
-@@	O	-1	7802851
effects	O	-1	7802851
ten@@	O	-1	7802851
ded	O	-1	7802851
to	O	-1	7802851
di@@	O	-1	7802851
min@@	O	-1	7802851
is@@	O	-1	7802851
h	O	-1	7802851
during	O	-1	7802851
treatment	O	-1	7802851
but	O	-1	7802851
remained	O	-1	7802851
significant	O	-1	7802851
at	O	-1	7802851
week	O	-1	7802851
8@@	O	-1	7802851
.	O	-1	7802851
D@@	O	-1	7802851
es@@	O	-1	7802851
pit@@	O	-1	7802851
e	O	-1	7802851
th@@	O	-1	7802851
is@@	O	-1	7802851
,	O	-1	7802851
the	O	-1	7802851
dro@@	O	-1	7802851
p@@	O	-1	7802851
-@@	O	-1	7802851
out	O	-1	7802851
rate	O	-1	7802851
was	O	-1	7802851
low@@	O	-1	7802851
.	O	-1	7802851
CONCLUSIONS:	O	-1	7802851
Al@@	B-Chemical	D000525	7802851
praz@@	I-Chemical	-1	7802851
ol@@	I-Chemical	-1	7802851
am	I-Chemical	-1	7802851
caused	O	-1	7802851
side@@	O	-1	7802851
-@@	O	-1	7802851
effects	O	-1	7802851
and	O	-1	7802851
adverse	O	-1	7802851
effects	O	-1	7802851
during	O	-1	7802851
treatment	O	-1	7802851
but	O	-1	7802851
man@@	O	-1	7802851
y	O	-1	7802851
patients	O	-1	7802851
were	O	-1	7802851
w@@	O	-1	7802851
ill@@	O	-1	7802851
ing	O	-1	7802851
to	O	-1	7802851
ac@@	O	-1	7802851
cep@@	O	-1	7802851
t	O	-1	7802851
th@@	O	-1	7802851
es@@	O	-1	7802851
e.	O	-1	7802851

D@@	B-Chemical	D019808	8319760
up	I-Chemical	-1	8319760
7@@	I-Chemical	-1	8319760
5@@	I-Chemical	-1	8319760
3	I-Chemical	-1	8319760
prev@@	O	-1	8319760
ents	O	-1	8319760
the	O	-1	8319760
development	O	-1	8319760
of	O	-1	8319760
p@@	B-Chemical	D011692	8319760
uro@@	I-Chemical	-1	8319760
m@@	I-Chemical	-1	8319760
ycin	I-Chemical	-1	8319760
amin@@	I-Chemical	-1	8319760
on@@	I-Chemical	-1	8319760
ucle@@	I-Chemical	-1	8319760
o@@	I-Chemical	-1	8319760
side	I-Chemical	-1	8319760
-induced	O	-1	8319760
nephro@@	B-Disease	D009401	8319760
sis	I-Disease	-1	8319760
.	O	-1	8319760
The	O	-1	8319760
appear@@	O	-1	8319760
ance	O	-1	8319760
of	O	-1	8319760
nephro@@	B-Disease	D009404	8319760
tic	I-Disease	-1	8319760
syndrom@@	I-Disease	-1	8319760
es	I-Disease	-1	8319760
such	O	-1	8319760
as	O	-1	8319760
proteinuria	B-Disease	D011507	8319760
,	O	-1	8319760
hypo@@	B-Disease	D034141	8319760
al@@	I-Disease	-1	8319760
b@@	I-Disease	-1	8319760
um@@	I-Disease	-1	8319760
ine@@	I-Disease	-1	8319760
mia	I-Disease	-1	8319760
,	O	-1	8319760
hyper@@	B-Disease	D006937	8319760
cholester@@	I-Disease	-1	8319760
ol@@	I-Disease	-1	8319760
emia	I-Disease	-1	8319760
and	O	-1	8319760
increase	O	-1	8319760
in	O	-1	8319760
blood	B-Chemical	D001806	8319760
nitro@@	I-Chemical	-1	8319760
gen	I-Chemical	-1	8319760
ure@@	I-Chemical	-1	8319760
a	I-Chemical	-1	8319760
,	O	-1	8319760
induced	O	-1	8319760
in	O	-1	8319760
rats	O	-1	8319760
by	O	-1	8319760
injection	O	-1	8319760
of	O	-1	8319760
p@@	B-Chemical	D011692	8319760
uro@@	I-Chemical	-1	8319760
m@@	I-Chemical	-1	8319760
ycin	I-Chemical	-1	8319760
amin@@	I-Chemical	-1	8319760
on@@	I-Chemical	-1	8319760
ucle@@	I-Chemical	-1	8319760
o@@	I-Chemical	-1	8319760
side	I-Chemical	-1	8319760
was	O	-1	8319760
mark@@	O	-1	8319760
ed@@	O	-1	8319760
ly	O	-1	8319760
inhibited	O	-1	8319760
by	O	-1	8319760
oral	O	-1	8319760
administration	O	-1	8319760
of	O	-1	8319760
D@@	B-Chemical	D019808	8319760
up	I-Chemical	-1	8319760
7@@	I-Chemical	-1	8319760
5@@	I-Chemical	-1	8319760
3	I-Chemical	-1	8319760
(	O	-1	8319760
los@@	B-Chemical	D019808	8319760
ar@@	I-Chemical	-1	8319760
t@@	I-Chemical	-1	8319760
an	I-Chemical	-1	8319760
),	O	-1	8319760
a	O	-1	8319760
novel	O	-1	8319760
angiotens@@	B-Chemical	D000804	8319760
in	I-Chemical	-1	8319760
II	I-Chemical	-1	8319760
receptor	O	-1	8319760
antagonist@@	O	-1	8319760
,	O	-1	8319760
at	O	-1	8319760
a	O	-1	8319760
dose	O	-1	8319760
of	O	-1	8319760
1	O	-1	8319760
or	O	-1	8319760
2	O	-1	8319760
mg/kg	O	-1	8319760
per	O	-1	8319760
da@@	O	-1	8319760
y.	O	-1	8319760
The	O	-1	8319760
results	O	-1	8319760
suggest	O	-1	8319760
a	O	-1	8319760
possible	O	-1	8319760
invol@@	O	-1	8319760
vement	O	-1	8319760
of	O	-1	8319760
the	O	-1	8319760
ren@@	O	-1	8319760
in@@	O	-1	8319760
-	O	-1	8319760
angiotens@@	B-Chemical	D000809	8319760
in	I-Chemical	-1	8319760
system	O	-1	8319760
in	O	-1	8319760
the	O	-1	8319760
development	O	-1	8319760
of	O	-1	8319760
p@@	B-Chemical	D011692	8319760
uro@@	I-Chemical	-1	8319760
m@@	I-Chemical	-1	8319760
ycin	I-Chemical	-1	8319760
amin@@	I-Chemical	-1	8319760
on@@	I-Chemical	-1	8319760
ucle@@	I-Chemical	-1	8319760
o@@	I-Chemical	-1	8319760
side	I-Chemical	-1	8319760
-induced	O	-1	8319760
nephro@@	B-Disease	D009401	8319760
sis	I-Disease	-1	8319760
.	O	-1	8319760

S@@	B-Chemical	D017693	8386779
odium	I-Chemical	-1	8386779
b@@	I-Chemical	-1	8386779
ic@@	I-Chemical	-1	8386779
arb@@	I-Chemical	-1	8386779
on@@	I-Chemical	-1	8386779
ate	I-Chemical	-1	8386779
al@@	O	-1	8386779
le@@	O	-1	8386779
vi@@	O	-1	8386779
ates	O	-1	8386779
pen@@	B-Disease	D004414	8386779
ile	I-Disease	-1	8386779
pain	I-Disease	-1	8386779
induced	O	-1	8386779
by	O	-1	8386779
intrac@@	O	-1	8386779
aver@@	O	-1	8386779
n@@	O	-1	8386779
ous	O	-1	8386779
injec@@	O	-1	8386779
tions	O	-1	8386779
for	O	-1	8386779
e@@	B-Disease	D007172	8386779
rec@@	I-Disease	-1	8386779
ti@@	I-Disease	-1	8386779
le	I-Disease	-1	8386779
dysfunction	I-Disease	-1	8386779
.	O	-1	8386779
In	O	-1	8386779
an	O	-1	8386779
at@@	O	-1	8386779
tem@@	O	-1	8386779
p@@	O	-1	8386779
t	O	-1	8386779
to	O	-1	8386779
determine	O	-1	8386779
whether	O	-1	8386779
pen@@	B-Disease	D004414	8386779
ile	I-Disease	-1	8386779
pain	I-Disease	-1	8386779
associated	O	-1	8386779
with	O	-1	8386779
intrac@@	O	-1	8386779
or@@	O	-1	8386779
po@@	O	-1	8386779
re@@	O	-1	8386779
al	O	-1	8386779
injec@@	O	-1	8386779
tions	O	-1	8386779
could	O	-1	8386779
be	O	-1	8386779
due	O	-1	8386779
to	O	-1	8386779
the	O	-1	8386779
acid@@	O	-1	8386779
ity	O	-1	8386779
of	O	-1	8386779
the	O	-1	8386779
medic@@	O	-1	8386779
ation,	O	-1	8386779
we	O	-1	8386779
performed	O	-1	8386779
a	O	-1	8386779
randomized	O	-1	8386779
study	O	-1	8386779
compar@@	O	-1	8386779
ing	O	-1	8386779
the	O	-1	8386779
incidence	O	-1	8386779
of	O	-1	8386779
pen@@	B-Disease	D004414	8386779
ile	I-Disease	-1	8386779
pain	I-Disease	-1	8386779
following	O	-1	8386779
intrac@@	O	-1	8386779
or@@	O	-1	8386779
po@@	O	-1	8386779
re@@	O	-1	8386779
al	O	-1	8386779
injec@@	O	-1	8386779
tions	O	-1	8386779
with	O	-1	8386779
or	O	-1	8386779
without	O	-1	8386779
the	O	-1	8386779
addition	O	-1	8386779
of	O	-1	8386779
sodium	B-Chemical	D017693	8386779
b@@	I-Chemical	-1	8386779
ic@@	I-Chemical	-1	8386779
arb@@	I-Chemical	-1	8386779
on@@	I-Chemical	-1	8386779
ate	I-Chemical	-1	8386779
to	O	-1	8386779
the	O	-1	8386779
intrac@@	O	-1	8386779
or@@	O	-1	8386779
po@@	O	-1	8386779
re@@	O	-1	8386779
al	O	-1	8386779
medic@@	O	-1	8386779
ations.	O	-1	8386779
A	O	-1	8386779
total	O	-1	8386779
of	O	-1	8386779
3@@	O	-1	8386779
8	O	-1	8386779
con@@	O	-1	8386779
sec@@	O	-1	8386779
utive	O	-1	8386779
patients	O	-1	8386779
who	O	-1	8386779
presented	O	-1	8386779
to	O	-1	8386779
our	O	-1	8386779
clin@@	O	-1	8386779
ic	O	-1	8386779
with	O	-1	8386779
im@@	B-Disease	D007172	8386779
pot@@	I-Disease	-1	8386779
ence	I-Disease	-1	8386779
received	O	-1	8386779
0.@@	O	-1	8386779
2	O	-1	8386779
ml@@	O	-1	8386779
.	O	-1	8386779
of	O	-1	8386779
a	O	-1	8386779
combination	O	-1	8386779
of	O	-1	8386779
3	O	-1	8386779
drug@@	O	-1	8386779
s:	O	-1	8386779
6	O	-1	8386779
mg@@	O	-1	8386779
.	O	-1	8386779
pap@@	B-Chemical	D010208	8386779
aver@@	I-Chemical	-1	8386779
ine	I-Chemical	-1	8386779
,	O	-1	8386779
100	O	-1	8386779
microgram@@	O	-1	8386779
s.	O	-1	8386779
ph@@	B-Chemical	D010646	8386779
ent@@	I-Chemical	-1	8386779
ol@@	I-Chemical	-1	8386779
amine	I-Chemical	-1	8386779
and	O	-1	8386779
10	O	-1	8386779
microgram@@	O	-1	8386779
s.	O	-1	8386779
pro@@	B-Chemical	D000527	8386779
st@@	I-Chemical	-1	8386779
ag@@	I-Chemical	-1	8386779
l@@	I-Chemical	-1	8386779
and@@	I-Chemical	-1	8386779
in	I-Chemical	-1	8386779
E@@	I-Chemical	-1	8386779
1	I-Chemical	-1	8386779
with	O	-1	8386779
(p@@	O	-1	8386779
H	O	-1	8386779
7.@@	O	-1	8386779
0@@	O	-1	8386779
5@@	O	-1	8386779
)	O	-1	8386779
or	O	-1	8386779
without	O	-1	8386779
(p@@	O	-1	8386779
H	O	-1	8386779
4.@@	O	-1	8386779
17@@	O	-1	8386779
)	O	-1	8386779
the	O	-1	8386779
addition	O	-1	8386779
of	O	-1	8386779
sodium	B-Chemical	D017693	8386779
b@@	I-Chemical	-1	8386779
ic@@	I-Chemical	-1	8386779
arb@@	I-Chemical	-1	8386779
on@@	I-Chemical	-1	8386779
ate	I-Chemical	-1	8386779
(@@	O	-1	8386779
0.0@@	O	-1	8386779
3	O	-1	8386779
m@@	O	-1	8386779
E@@	O	-1	8386779
q@@	O	-1	8386779
.@@	O	-1	8386779
).	O	-1	8386779
Of	O	-1	8386779
the	O	-1	8386779
1@@	O	-1	8386779
9	O	-1	8386779
patients	O	-1	8386779
without	O	-1	8386779
sodium	B-Chemical	D017693	8386779
b@@	I-Chemical	-1	8386779
ic@@	I-Chemical	-1	8386779
arb@@	I-Chemical	-1	8386779
on@@	I-Chemical	-1	8386779
ate	I-Chemical	-1	8386779
ad@@	O	-1	8386779
ded	O	-1	8386779
to	O	-1	8386779
the	O	-1	8386779
medic@@	O	-1	8386779
ation	O	-1	8386779
11	O	-1	8386779
(5@@	O	-1	8386779
8@@	O	-1	8386779
%)	O	-1	8386779
com@@	O	-1	8386779
pl@@	O	-1	8386779
ained	O	-1	8386779
of	O	-1	8386779
pen@@	B-Disease	D004414	8386779
ile	I-Disease	-1	8386779
pain	I-Disease	-1	8386779
due	O	-1	8386779
to	O	-1	8386779
the	O	-1	8386779
medic@@	O	-1	8386779
ation,	O	-1	8386779
while	O	-1	8386779
only	O	-1	8386779
1	O	-1	8386779
of	O	-1	8386779
the	O	-1	8386779
1@@	O	-1	8386779
9	O	-1	8386779
men	O	-1	8386779
(5@@	O	-1	8386779
%)	O	-1	8386779
who	O	-1	8386779
received	O	-1	8386779
sodium	B-Chemical	D017693	8386779
b@@	I-Chemical	-1	8386779
ic@@	I-Chemical	-1	8386779
arb@@	I-Chemical	-1	8386779
on@@	I-Chemical	-1	8386779
ate	I-Chemical	-1	8386779
com@@	O	-1	8386779
pl@@	O	-1	8386779
ained	O	-1	8386779
of	O	-1	8386779
pen@@	B-Disease	D004414	8386779
ile	I-Disease	-1	8386779
pain	I-Disease	-1	8386779
.	O	-1	8386779
F@@	O	-1	8386779
rom	O	-1	8386779
these	O	-1	8386779
data	O	-1	8386779
we	O	-1	8386779
concl@@	O	-1	8386779
ude	O	-1	8386779
that	O	-1	8386779
the	O	-1	8386779
pen@@	B-Disease	D004414	8386779
ile	I-Disease	-1	8386779
pain	I-Disease	-1	8386779
following	O	-1	8386779
intrac@@	O	-1	8386779
or@@	O	-1	8386779
po@@	O	-1	8386779
re@@	O	-1	8386779
al	O	-1	8386779
injec@@	O	-1	8386779
tions	O	-1	8386779
is	O	-1	8386779
most	O	-1	8386779
likely	O	-1	8386779
due	O	-1	8386779
to	O	-1	8386779
the	O	-1	8386779
acid@@	O	-1	8386779
ity	O	-1	8386779
of	O	-1	8386779
the	O	-1	8386779
medic@@	O	-1	8386779
ation,	O	-1	8386779
which	O	-1	8386779
can	O	-1	8386779
be	O	-1	8386779
over@@	O	-1	8386779
com@@	O	-1	8386779
e	O	-1	8386779
by	O	-1	8386779
elev@@	O	-1	8386779
ating	O	-1	8386779
the	O	-1	8386779
p@@	O	-1	8386779
H	O	-1	8386779
to	O	-1	8386779
a	O	-1	8386779
ne@@	O	-1	8386779
ut@@	O	-1	8386779
ral	O	-1	8386779
level@@	O	-1	8386779
.	O	-1	8386779

Pro@@	O	-1	8421099
sp@@	O	-1	8421099
ective	O	-1	8421099
study	O	-1	8421099
of	O	-1	8421099
the	O	-1	8421099
long-term	O	-1	8421099
effects	O	-1	8421099
of	O	-1	8421099
s@@	O	-1	8421099
om@@	O	-1	8421099
at@@	O	-1	8421099
ost@@	O	-1	8421099
atin	O	-1	8421099
an@@	O	-1	8421099
alo@@	O	-1	8421099
g	O	-1	8421099
(	O	-1	8421099
oc@@	B-Chemical	D015282	8421099
tre@@	I-Chemical	-1	8421099
o@@	I-Chemical	-1	8421099
ti@@	I-Chemical	-1	8421099
de	I-Chemical	-1	8421099
)	O	-1	8421099
on	O	-1	8421099
g@@	O	-1	8421099
all@@	O	-1	8421099
bladder	O	-1	8421099
function	O	-1	8421099
and	O	-1	8421099
g@@	B-Disease	D042882	8421099
all@@	I-Disease	-1	8421099
st@@	I-Disease	-1	8421099
one	I-Disease	-1	8421099
formation	O	-1	8421099
in	O	-1	8421099
Ch@@	O	-1	8421099
in@@	O	-1	8421099
ese	O	-1	8421099
ac@@	B-Disease	D000172	8421099
ro@@	I-Disease	-1	8421099
me@@	I-Disease	-1	8421099
g@@	I-Disease	-1	8421099
al@@	I-Disease	-1	8421099
ic	I-Disease	-1	8421099
patients.	O	-1	8421099
This	O	-1	8421099
ar@@	O	-1	8421099
tic@@	O	-1	8421099
le	O	-1	8421099
reports	O	-1	8421099
the	O	-1	8421099
changes	O	-1	8421099
in	O	-1	8421099
g@@	O	-1	8421099
all@@	O	-1	8421099
bladder	O	-1	8421099
function	O	-1	8421099
examined	O	-1	8421099
by	O	-1	8421099
ult@@	O	-1	8421099
r@@	O	-1	8421099
as@@	O	-1	8421099
on@@	O	-1	8421099
ograph@@	O	-1	8421099
y	O	-1	8421099
in	O	-1	8421099
20	O	-1	8421099
Ch@@	O	-1	8421099
in@@	O	-1	8421099
ese	O	-1	8421099
patients	O	-1	8421099
with	O	-1	8421099
active	O	-1	8421099
ac@@	B-Disease	D000172	8421099
ro@@	I-Disease	-1	8421099
me@@	I-Disease	-1	8421099
g@@	I-Disease	-1	8421099
al@@	I-Disease	-1	8421099
y	I-Disease	-1	8421099
treated	O	-1	8421099
with	O	-1	8421099
s@@	O	-1	8421099
c	O	-1	8421099
injection	O	-1	8421099
of	O	-1	8421099
the	O	-1	8421099
s@@	O	-1	8421099
om@@	O	-1	8421099
at@@	O	-1	8421099
ost@@	O	-1	8421099
atin	O	-1	8421099
an@@	O	-1	8421099
alo@@	O	-1	8421099
g	O	-1	8421099
oc@@	B-Chemical	D015282	8421099
tre@@	I-Chemical	-1	8421099
o@@	I-Chemical	-1	8421099
ti@@	I-Chemical	-1	8421099
de	I-Chemical	-1	8421099
in	O	-1	8421099
dos@@	O	-1	8421099
ages	O	-1	8421099
of	O	-1	8421099
3@@	O	-1	8421099
0@@	O	-1	8421099
0@@	O	-1	8421099
-1@@	O	-1	8421099
5@@	O	-1	8421099
00	O	-1	8421099
microgram@@	O	-1	8421099
s/@@	O	-1	8421099
day	O	-1	8421099
for	O	-1	8421099
a	O	-1	8421099
mean	O	-1	8421099
of	O	-1	8421099
2@@	O	-1	8421099
4.@@	O	-1	8421099
2	O	-1	8421099
+/-	O	-1	8421099
1@@	O	-1	8421099
3.@@	O	-1	8421099
9	O	-1	8421099
months.	O	-1	8421099
D@@	O	-1	8421099
uring	O	-1	8421099
treatment	O	-1	8421099
with	O	-1	8421099
oc@@	B-Chemical	D015282	8421099
tre@@	I-Chemical	-1	8421099
o@@	I-Chemical	-1	8421099
ti@@	I-Chemical	-1	8421099
de	I-Chemical	-1	8421099
,	O	-1	8421099
17	O	-1	8421099
patients	O	-1	8421099
developed	O	-1	8421099
s@@	O	-1	8421099
lud@@	O	-1	8421099
g@@	O	-1	8421099
e,	O	-1	8421099
10	O	-1	8421099
had	O	-1	8421099
g@@	B-Disease	D042882	8421099
all@@	I-Disease	-1	8421099
ston@@	I-Disease	-1	8421099
es	I-Disease	-1	8421099
,	O	-1	8421099
and	O	-1	8421099
1	O	-1	8421099
developed	O	-1	8421099
acute	B-Disease	D041881	8421099
chol@@	I-Disease	-1	8421099
ec@@	I-Disease	-1	8421099
ys@@	I-Disease	-1	8421099
ti@@	I-Disease	-1	8421099
tis	I-Disease	-1	8421099
requ@@	O	-1	8421099
ir@@	O	-1	8421099
ing	O	-1	8421099
surger@@	O	-1	8421099
y.	O	-1	8421099
In	O	-1	8421099
all	O	-1	8421099
of	O	-1	8421099
7	O	-1	8421099
patients	O	-1	8421099
examined	O	-1	8421099
ac@@	O	-1	8421099
u@@	O	-1	8421099
te@@	O	-1	8421099
ly,	O	-1	8421099
g@@	O	-1	8421099
all@@	O	-1	8421099
bladder	O	-1	8421099
contrac@@	O	-1	8421099
til@@	O	-1	8421099
ity	O	-1	8421099
was	O	-1	8421099
inhibited	O	-1	8421099
after	O	-1	8421099
a	O	-1	8421099
single	O	-1	8421099
10@@	O	-1	8421099
0-@@	O	-1	8421099
microgram@@	O	-1	8421099
s	O	-1	8421099
injec@@	O	-1	8421099
tion.	O	-1	8421099
In	O	-1	8421099
8	O	-1	8421099
patients	O	-1	8421099
followed	O	-1	8421099
for	O	-1	8421099
24	O	-1	8421099
week@@	O	-1	8421099
s,	O	-1	8421099
g@@	O	-1	8421099
all@@	O	-1	8421099
bladder	O	-1	8421099
contrac@@	O	-1	8421099
til@@	O	-1	8421099
ity	O	-1	8421099
remained	O	-1	8421099
depress@@	B-Disease	D003866	8421099
ed	I-Disease	-1	8421099
throu@@	O	-1	8421099
gh@@	O	-1	8421099
out	O	-1	8421099
therapy.	O	-1	8421099
After	O	-1	8421099
withdrawal	O	-1	8421099
of	O	-1	8421099
oc@@	B-Chemical	D015282	8421099
tre@@	I-Chemical	-1	8421099
o@@	I-Chemical	-1	8421099
ti@@	I-Chemical	-1	8421099
de	I-Chemical	-1	8421099
in	O	-1	8421099
10	O	-1	8421099
patients	O	-1	8421099
without	O	-1	8421099
g@@	B-Disease	D042882	8421099
all@@	I-Disease	-1	8421099
ston@@	I-Disease	-1	8421099
es	I-Disease	-1	8421099
,	O	-1	8421099
8	O	-1	8421099
patients	O	-1	8421099
assessed	O	-1	8421099
had	O	-1	8421099
retur@@	O	-1	8421099
n	O	-1	8421099
of	O	-1	8421099
normal	O	-1	8421099
g@@	O	-1	8421099
all@@	O	-1	8421099
bladder	O	-1	8421099
contrac@@	O	-1	8421099
til@@	O	-1	8421099
ity	O	-1	8421099
within	O	-1	8421099
1	O	-1	8421099
month@@	O	-1	8421099
.	O	-1	8421099
In	O	-1	8421099
8	O	-1	8421099
of	O	-1	8421099
the	O	-1	8421099
remain@@	O	-1	8421099
ing	O	-1	8421099
10	O	-1	8421099
patients	O	-1	8421099
who	O	-1	8421099
developed	O	-1	8421099
g@@	B-Disease	D042882	8421099
all@@	I-Disease	-1	8421099
ston@@	I-Disease	-1	8421099
es	I-Disease	-1	8421099
during	O	-1	8421099
treatment,	O	-1	8421099
g@@	O	-1	8421099
all@@	O	-1	8421099
bladder	O	-1	8421099
contrac@@	O	-1	8421099
til@@	O	-1	8421099
ity	O	-1	8421099
normal@@	O	-1	8421099
ized	O	-1	8421099
in	O	-1	8421099
5	O	-1	8421099
patients	O	-1	8421099
(@@	O	-1	8421099
3	O	-1	8421099
of	O	-1	8421099
whom	O	-1	8421099
has	O	-1	8421099
dis@@	O	-1	8421099
appear@@	O	-1	8421099
ance	O	-1	8421099
of	O	-1	8421099
their	O	-1	8421099
ston@@	O	-1	8421099
es	O	-1	8421099
within	O	-1	8421099
3	O	-1	8421099
week@@	O	-1	8421099
s),	O	-1	8421099
and	O	-1	8421099
remained	O	-1	8421099
depress@@	B-Disease	D003866	8421099
ed	I-Disease	-1	8421099
in	O	-1	8421099
3	O	-1	8421099
(@@	O	-1	8421099
2	O	-1	8421099
of	O	-1	8421099
whom	O	-1	8421099
had	O	-1	8421099
ston@@	O	-1	8421099
es	O	-1	8421099
present	O	-1	8421099
at	O	-1	8421099
6	O	-1	8421099
month@@	O	-1	8421099
s@@	O	-1	8421099
).	O	-1	8421099
Our	O	-1	8421099
results	O	-1	8421099
suggest	O	-1	8421099
that	O	-1	8421099
the	O	-1	8421099
sup@@	O	-1	8421099
pression	O	-1	8421099
of	O	-1	8421099
g@@	O	-1	8421099
all@@	O	-1	8421099
bladder	O	-1	8421099
contrac@@	O	-1	8421099
til@@	O	-1	8421099
ity	O	-1	8421099
is	O	-1	8421099
the	O	-1	8421099
cause	O	-1	8421099
of	O	-1	8421099
the	O	-1	8421099
suc@@	O	-1	8421099
ces@@	O	-1	8421099
sive	O	-1	8421099
formation	O	-1	8421099
of	O	-1	8421099
b@@	O	-1	8421099
ile	O	-1	8421099
s@@	O	-1	8421099
lud@@	O	-1	8421099
g@@	O	-1	8421099
e,	O	-1	8421099
g@@	B-Disease	D042882	8421099
all@@	I-Disease	-1	8421099
ston@@	I-Disease	-1	8421099
es	I-Disease	-1	8421099
,	O	-1	8421099
and	O	-1	8421099
chol@@	B-Disease	D002764	8421099
ec@@	I-Disease	-1	8421099
ys@@	I-Disease	-1	8421099
ti@@	I-Disease	-1	8421099
tis	I-Disease	-1	8421099
during	O	-1	8421099
oc@@	B-Chemical	D015282	8421099
tre@@	I-Chemical	-1	8421099
o@@	I-Chemical	-1	8421099
ti@@	I-Chemical	-1	8421099
de	I-Chemical	-1	8421099
therapy	O	-1	8421099
in	O	-1	8421099
Ch@@	O	-1	8421099
in@@	O	-1	8421099
ese	O	-1	8421099
ac@@	B-Disease	D000172	8421099
ro@@	I-Disease	-1	8421099
me@@	I-Disease	-1	8421099
g@@	I-Disease	-1	8421099
al@@	I-Disease	-1	8421099
ic	I-Disease	-1	8421099
patients.	O	-1	8421099
It	O	-1	8421099
is	O	-1	8421099
the@@	O	-1	8421099
re@@	O	-1	8421099
fore	O	-1	8421099
very	O	-1	8421099
important	O	-1	8421099
to	O	-1	8421099
fol@@	O	-1	8421099
low	O	-1	8421099
the	O	-1	8421099
changes	O	-1	8421099
of	O	-1	8421099
g@@	O	-1	8421099
all@@	O	-1	8421099
bladder	O	-1	8421099
function	O	-1	8421099
during	O	-1	8421099
long-term	O	-1	8421099
oc@@	B-Chemical	D015282	8421099
tre@@	I-Chemical	-1	8421099
o@@	I-Chemical	-1	8421099
ti@@	I-Chemical	-1	8421099
de	I-Chemical	-1	8421099
therapy	O	-1	8421099
of	O	-1	8421099
ac@@	B-Disease	D000172	8421099
ro@@	I-Disease	-1	8421099
me@@	I-Disease	-1	8421099
g@@	I-Disease	-1	8421099
al@@	I-Disease	-1	8421099
ic	I-Disease	-1	8421099
patients.	O	-1	8421099

Im@@	O	-1	8649546
pro@@	O	-1	8649546
vement	O	-1	8649546
of	O	-1	8649546
levo@@	B-Chemical	D007980	8649546
dopa	I-Chemical	-1	8649546
-induced	O	-1	8649546
dyskine@@	B-Disease	D004409	8649546
sia	I-Disease	-1	8649546
by	O	-1	8649546
prop@@	B-Chemical	D011433	8649546
ran@@	I-Chemical	-1	8649546
o@@	I-Chemical	-1	8649546
lol	I-Chemical	-1	8649546
in	O	-1	8649546
Parkinson's	B-Disease	D010300	8649546
disease	I-Disease	-1	8649546
.	O	-1	8649546
S@@	O	-1	8649546
even	O	-1	8649546
patients	O	-1	8649546
suff@@	O	-1	8649546
ering	O	-1	8649546
from	O	-1	8649546
Parkinson's	B-Disease	D010300	8649546
disease	I-Disease	-1	8649546
(	O	-1	8649546
P@@	B-Disease	D010300	8649546
D	I-Disease	-1	8649546
)	O	-1	8649546
with	O	-1	8649546
se@@	O	-1	8649546
ve@@	O	-1	8649546
re@@	O	-1	8649546
ly	O	-1	8649546
dis@@	O	-1	8649546
abl@@	O	-1	8649546
ing	O	-1	8649546
dyskine@@	B-Disease	D004409	8649546
sia	I-Disease	-1	8649546
received	O	-1	8649546
low@@	O	-1	8649546
-@@	O	-1	8649546
dose	O	-1	8649546
prop@@	B-Chemical	D011433	8649546
ran@@	I-Chemical	-1	8649546
o@@	I-Chemical	-1	8649546
lol	I-Chemical	-1	8649546
as	O	-1	8649546
an	O	-1	8649546
adj@@	O	-1	8649546
unc@@	O	-1	8649546
t	O	-1	8649546
to	O	-1	8649546
the	O	-1	8649546
cur@@	O	-1	8649546
ren@@	O	-1	8649546
tly	O	-1	8649546
used	O	-1	8649546
med@@	O	-1	8649546
ical	O	-1	8649546
treatment.	O	-1	8649546
There	O	-1	8649546
was	O	-1	8649546
a	O	-1	8649546
significant	O	-1	8649546
4@@	O	-1	8649546
0%	O	-1	8649546
impro@@	O	-1	8649546
vement	O	-1	8649546
in	O	-1	8649546
the	O	-1	8649546
dyskine@@	B-Disease	D004409	8649546
sia	I-Disease	-1	8649546
scor@@	O	-1	8649546
e	O	-1	8649546
without	O	-1	8649546
increase	O	-1	8649546
of	O	-1	8649546
par@@	B-Disease	D010300	8649546
k@@	I-Disease	-1	8649546
inson@@	I-Disease	-1	8649546
i@@	I-Disease	-1	8649546
an	I-Disease	-1	8649546
motor	B-Disease	D009069	8649546
dis@@	I-Disease	-1	8649546
ability	I-Disease	-1	8649546
.	O	-1	8649546
B@@	O	-1	8649546
all@@	O	-1	8649546
istic	O	-1	8649546
and	O	-1	8649546
ch@@	O	-1	8649546
ore@@	O	-1	8649546
ic	O	-1	8649546
dyskine@@	B-Disease	D004409	8649546
sia	I-Disease	-1	8649546
were	O	-1	8649546
mark@@	O	-1	8649546
ed@@	O	-1	8649546
ly	O	-1	8649546
ame@@	O	-1	8649546
li@@	O	-1	8649546
or@@	O	-1	8649546
at@@	O	-1	8649546
ed,	O	-1	8649546
whereas	O	-1	8649546
dy@@	B-Disease	D004421	8649546
ston@@	I-Disease	-1	8649546
ia	I-Disease	-1	8649546
was	O	-1	8649546
not@@	O	-1	8649546
.	O	-1	8649546
This	O	-1	8649546
study	O	-1	8649546
suggests	O	-1	8649546
that	O	-1	8649546
administration	O	-1	8649546
of	O	-1	8649546
low	O	-1	8649546
doses	O	-1	8649546
of	O	-1	8649546
beta-@@	O	-1	8649546
block@@	O	-1	8649546
ers	O	-1	8649546
may	O	-1	8649546
impro@@	O	-1	8649546
ve	O	-1	8649546
levo@@	B-Chemical	D007980	8649546
dopa	I-Chemical	-1	8649546
-induced	O	-1	8649546
b@@	O	-1	8649546
all@@	O	-1	8649546
istic	O	-1	8649546
and	O	-1	8649546
ch@@	O	-1	8649546
ore@@	O	-1	8649546
ic	O	-1	8649546
dyskine@@	B-Disease	D004409	8649546
sia	I-Disease	-1	8649546
in	O	-1	8649546
P@@	B-Disease	D010300	8649546
D	I-Disease	-1	8649546
.	O	-1	8649546

M@@	O	-1	8919272
or@@	O	-1	8919272
ph@@	O	-1	8919272
ological	O	-1	8919272
feat@@	O	-1	8919272
ures	O	-1	8919272
of	O	-1	8919272
encephalo@@	B-Disease	D001927	8919272
pathy	I-Disease	-1	8919272
after	O	-1	8919272
chronic	O	-1	8919272
administration	O	-1	8919272
of	O	-1	8919272
the	O	-1	8919272
anti@@	O	-1	8919272
epileptic	O	-1	8919272
drug	O	-1	8919272
valpro@@	B-Chemical	D014635	8919272
ate	I-Chemical	-1	8919272
to	O	-1	8919272
rats.	O	-1	8919272
A	O	-1	8919272
trans@@	O	-1	8919272
mission	O	-1	8919272
electro@@	O	-1	8919272
n	O	-1	8919272
micro@@	O	-1	8919272
sco@@	O	-1	8919272
p@@	O	-1	8919272
ic	O	-1	8919272
study	O	-1	8919272
of	O	-1	8919272
cap@@	O	-1	8919272
ill@@	O	-1	8919272
ari@@	O	-1	8919272
es	O	-1	8919272
in	O	-1	8919272
the	O	-1	8919272
ce@@	O	-1	8919272
re@@	O	-1	8919272
bell@@	O	-1	8919272
ar	O	-1	8919272
cor@@	O	-1	8919272
t@@	O	-1	8919272
ex@@	O	-1	8919272
.	O	-1	8919272
L@@	O	-1	8919272
on@@	O	-1	8919272
g@@	O	-1	8919272
-term	O	-1	8919272
intra@@	O	-1	8919272
gast@@	O	-1	8919272
ric	O	-1	8919272
ap@@	O	-1	8919272
plic@@	O	-1	8919272
ation	O	-1	8919272
of	O	-1	8919272
the	O	-1	8919272
anti@@	O	-1	8919272
epileptic	O	-1	8919272
drug	O	-1	8919272
sodium	B-Chemical	D014635	8919272
valpro@@	I-Chemical	-1	8919272
ate	I-Chemical	-1	8919272
(V@@	O	-1	8919272
up@@	O	-1	8919272
ral	O	-1	8919272
"@@	O	-1	8919272
P@@	O	-1	8919272
ol@@	O	-1	8919272
f@@	O	-1	8919272
a@@	O	-1	8919272
"@@	O	-1	8919272
)	O	-1	8919272
at	O	-1	8919272
the	O	-1	8919272
effective	O	-1	8919272
dose	O	-1	8919272
of	O	-1	8919272
2@@	O	-1	8919272
00	O	-1	8919272
mg/kg	O	-1	8919272
b@@	O	-1	8919272
.	O	-1	8919272
w@@	O	-1	8919272
.	O	-1	8919272
on@@	O	-1	8919272
ce	O	-1	8919272
daily	O	-1	8919272
to	O	-1	8919272
rats	O	-1	8919272
for	O	-1	8919272
1,	O	-1	8919272
3,	O	-1	8919272
6,	O	-1	8919272
9	O	-1	8919272
and	O	-1	8919272
12	O	-1	8919272
months	O	-1	8919272
revealed	O	-1	8919272
neurolog@@	B-Disease	D009422	8919272
ical	I-Disease	-1	8919272
disorder@@	I-Disease	-1	8919272
s	I-Disease	-1	8919272
indicating	O	-1	8919272
ce@@	B-Disease	D002526	8919272
re@@	I-Disease	-1	8919272
bell@@	I-Disease	-1	8919272
um	I-Disease	-1	8919272
damage	I-Disease	-1	8919272
(@@	O	-1	8919272
"	O	-1	8919272
valpro@@	B-Chemical	D014635	8919272
ate	I-Chemical	-1	8919272
encephalo@@	B-Disease	D001927	8919272
pathy	I-Disease	-1	8919272
"@@	O	-1	8919272
).	O	-1	8919272
The	O	-1	8919272
first	O	-1	8919272
ult@@	O	-1	8919272
ra@@	O	-1	8919272
struct@@	O	-1	8919272
ural	O	-1	8919272
changes	O	-1	8919272
in	O	-1	8919272
struct@@	O	-1	8919272
ural	O	-1	8919272
e@@	O	-1	8919272
le@@	O	-1	8919272
ments	O	-1	8919272
of	O	-1	8919272
the	O	-1	8919272
blo@@	O	-1	8919272
o@@	O	-1	8919272
d-@@	O	-1	8919272
bra@@	O	-1	8919272
in-@@	O	-1	8919272
bar@@	O	-1	8919272
ri@@	O	-1	8919272
er	O	-1	8919272
(B@@	O	-1	8919272
B@@	O	-1	8919272
B@@	O	-1	8919272
)	O	-1	8919272
in	O	-1	8919272
the	O	-1	8919272
ce@@	O	-1	8919272
re@@	O	-1	8919272
bell@@	O	-1	8919272
ar	O	-1	8919272
cor@@	O	-1	8919272
te@@	O	-1	8919272
x	O	-1	8919272
were	O	-1	8919272
det@@	O	-1	8919272
ect@@	O	-1	8919272
able	O	-1	8919272
after	O	-1	8919272
3	O	-1	8919272
months	O	-1	8919272
of	O	-1	8919272
the	O	-1	8919272
experim@@	O	-1	8919272
ent@@	O	-1	8919272
.	O	-1	8919272
The@@	O	-1	8919272
y	O	-1	8919272
b@@	O	-1	8919272
ec@@	O	-1	8919272
am@@	O	-1	8919272
e	O	-1	8919272
more	O	-1	8919272
severe	O	-1	8919272
in	O	-1	8919272
the	O	-1	8919272
lat@@	O	-1	8919272
er	O	-1	8919272
months	O	-1	8919272
of	O	-1	8919272
the	O	-1	8919272
experim@@	O	-1	8919272
ent@@	O	-1	8919272
,	O	-1	8919272
and	O	-1	8919272
were	O	-1	8919272
most	O	-1	8919272
severe	O	-1	8919272
after	O	-1	8919272
12	O	-1	8919272
month@@	O	-1	8919272
s,	O	-1	8919272
loc@@	O	-1	8919272
ated	O	-1	8919272
main@@	O	-1	8919272
ly	O	-1	8919272
in	O	-1	8919272
the	O	-1	8919272
mol@@	O	-1	8919272
ec@@	O	-1	8919272
ular	O	-1	8919272
l@@	O	-1	8919272
ay@@	O	-1	8919272
er	O	-1	8919272
of	O	-1	8919272
the	O	-1	8919272
ce@@	O	-1	8919272
re@@	O	-1	8919272
bell@@	O	-1	8919272
ar	O	-1	8919272
cor@@	O	-1	8919272
t@@	O	-1	8919272
ex@@	O	-1	8919272
.	O	-1	8919272
L@@	O	-1	8919272
e@@	O	-1	8919272
sions	O	-1	8919272
of	O	-1	8919272
the	O	-1	8919272
cap@@	O	-1	8919272
ill@@	O	-1	8919272
ary	O	-1	8919272
included	O	-1	8919272
necro@@	B-Disease	D009336	8919272
sis	I-Disease	-1	8919272
of	O	-1	8919272
endothelial	O	-1	8919272
cell@@	O	-1	8919272
s.	O	-1	8919272
O@@	O	-1	8919272
r@@	O	-1	8919272
g@@	O	-1	8919272
an@@	O	-1	8919272
el@@	O	-1	8919272
le@@	O	-1	8919272
s	O	-1	8919272
of	O	-1	8919272
these	O	-1	8919272
cell@@	O	-1	8919272
s,	O	-1	8919272
in	O	-1	8919272
partic@@	O	-1	8919272
ular	O	-1	8919272
the	O	-1	8919272
mitochond@@	O	-1	8919272
ri@@	O	-1	8919272
a	O	-1	8919272
(@@	O	-1	8919272
increased	O	-1	8919272
number	O	-1	8919272
and	O	-1	8919272
si@@	O	-1	8919272
z@@	O	-1	8919272
e,	O	-1	8919272
dist@@	O	-1	8919272
inc@@	O	-1	8919272
t	O	-1	8919272
de@@	O	-1	8919272
generation	O	-1	8919272
of	O	-1	8919272
their	O	-1	8919272
mat@@	O	-1	8919272
ri@@	O	-1	8919272
x	O	-1	8919272
and	O	-1	8919272
cri@@	O	-1	8919272
st@@	O	-1	8919272
a@@	O	-1	8919272
e@@	O	-1	8919272
)	O	-1	8919272
and	O	-1	8919272
G@@	O	-1	8919272
ol@@	O	-1	8919272
g@@	O	-1	8919272
i	O	-1	8919272
ap@@	O	-1	8919272
par@@	O	-1	8919272
at@@	O	-1	8919272
us	O	-1	8919272
were	O	-1	8919272
al@@	O	-1	8919272
te@@	O	-1	8919272
red.	O	-1	8919272
Re@@	O	-1	8919272
duced	O	-1	8919272
size	O	-1	8919272
of	O	-1	8919272
cap@@	O	-1	8919272
ill@@	O	-1	8919272
ary	O	-1	8919272
lu@@	O	-1	8919272
men	O	-1	8919272
and	O	-1	8919272
oc@@	O	-1	8919272
cl@@	O	-1	8919272
usion	O	-1	8919272
were	O	-1	8919272
caused	O	-1	8919272
by	O	-1	8919272
s@@	O	-1	8919272
w@@	O	-1	8919272
ol@@	O	-1	8919272
le@@	O	-1	8919272
n	O	-1	8919272
endothelial	O	-1	8919272
cells	O	-1	8919272
which	O	-1	8919272
had	O	-1	8919272
lu@@	B-Chemical	D010634	8919272
min@@	I-Chemical	-1	8919272
al	I-Chemical	-1	8919272
prot@@	O	-1	8919272
ru@@	O	-1	8919272
sions	O	-1	8919272
and	O	-1	8919272
s@@	O	-1	8919272
w@@	O	-1	8919272
ol@@	O	-1	8919272
le@@	O	-1	8919272
n	O	-1	8919272
micro@@	O	-1	8919272
v@@	O	-1	8919272
il@@	O	-1	8919272
li@@	O	-1	8919272
.	O	-1	8919272
P@@	O	-1	8919272
res@@	O	-1	8919272
s@@	O	-1	8919272
ure	O	-1	8919272
on	O	-1	8919272
the	O	-1	8919272
v@@	O	-1	8919272
es@@	O	-1	8919272
se@@	O	-1	8919272
l	O	-1	8919272
w@@	O	-1	8919272
all	O	-1	8919272
was	O	-1	8919272
produced	O	-1	8919272
by	O	-1	8919272
en@@	O	-1	8919272
larg@@	O	-1	8919272
ed	O	-1	8919272
peri@@	O	-1	8919272
vascular	O	-1	8919272
ast@@	O	-1	8919272
ro@@	O	-1	8919272
cy@@	O	-1	8919272
tic	O	-1	8919272
pro@@	O	-1	8919272
cess@@	O	-1	8919272
es.	O	-1	8919272
F@@	O	-1	8919272
ra@@	O	-1	8919272
g@@	O	-1	8919272
ments	O	-1	8919272
of	O	-1	8919272
necro@@	B-Disease	D009336	8919272
tic	I-Disease	-1	8919272
endothelial	O	-1	8919272
cells	O	-1	8919272
were	O	-1	8919272
in	O	-1	8919272
the	O	-1	8919272
vascular	O	-1	8919272
l@@	O	-1	8919272
um@@	O	-1	8919272
en@@	O	-1	8919272
s	O	-1	8919272
and	O	-1	8919272
in	O	-1	8919272
these	O	-1	8919272
there	O	-1	8919272
was	O	-1	8919272
lo@@	O	-1	8919272
os@@	O	-1	8919272
en@@	O	-1	8919272
ing	O	-1	8919272
and	O	-1	8919272
b@@	O	-1	8919272
re@@	O	-1	8919272
ak@@	O	-1	8919272
ing	O	-1	8919272
of	O	-1	8919272
ti@@	O	-1	8919272
ght	O	-1	8919272
cell@@	O	-1	8919272
ular	O	-1	8919272
j@@	O	-1	8919272
unc@@	O	-1	8919272
tions.	O	-1	8919272
D@@	O	-1	8919272
am@@	O	-1	8919272
age	O	-1	8919272
to	O	-1	8919272
the	O	-1	8919272
vascular	O	-1	8919272
bas@@	O	-1	8919272
ement	O	-1	8919272
l@@	O	-1	8919272
amin@@	O	-1	8919272
a	O	-1	8919272
was	O	-1	8919272
also	O	-1	8919272
obser@@	O	-1	8919272
ved.	O	-1	8919272
D@@	O	-1	8919272
am@@	O	-1	8919272
age	O	-1	8919272
to	O	-1	8919272
the	O	-1	8919272
cap@@	O	-1	8919272
ill@@	O	-1	8919272
ary	O	-1	8919272
was	O	-1	8919272
ac@@	O	-1	8919272
comp@@	O	-1	8919272
an@@	O	-1	8919272
ied	O	-1	8919272
by	O	-1	8919272
mark@@	O	-1	8919272
ed	O	-1	8919272
damage	O	-1	8919272
to	O	-1	8919272
neuro@@	O	-1	8919272
g@@	O	-1	8919272
lial	O	-1	8919272
cell@@	O	-1	8919272
s,	O	-1	8919272
main@@	O	-1	8919272
ly	O	-1	8919272
to	O	-1	8919272
peri@@	O	-1	8919272
vascular	O	-1	8919272
pro@@	O	-1	8919272
ces@@	O	-1	8919272
ses	O	-1	8919272
of	O	-1	8919272
ast@@	O	-1	8919272
ro@@	O	-1	8919272
cy@@	O	-1	8919272
t@@	O	-1	8919272
es.	O	-1	8919272
The	O	-1	8919272
pro@@	O	-1	8919272
li@@	O	-1	8919272
fer@@	O	-1	8919272
ation	O	-1	8919272
of	O	-1	8919272
ast@@	O	-1	8919272
ro@@	O	-1	8919272
cy@@	O	-1	8919272
tes	O	-1	8919272
(B@@	O	-1	8919272
erg@@	O	-1	8919272
man@@	O	-1	8919272
n@@	O	-1	8919272
's	O	-1	8919272
in	O	-1	8919272
partic@@	O	-1	8919272
ul@@	O	-1	8919272
ar@@	O	-1	8919272
)	O	-1	8919272
and	O	-1	8919272
oc@@	O	-1	8919272
ca@@	O	-1	8919272
sion@@	O	-1	8919272
ally	O	-1	8919272
of	O	-1	8919272
ol@@	O	-1	8919272
i@@	O	-1	8919272
go@@	O	-1	8919272
d@@	O	-1	8919272
en@@	O	-1	8919272
dro@@	O	-1	8919272
cy@@	O	-1	8919272
tes	O	-1	8919272
was	O	-1	8919272
f@@	O	-1	8919272
oun@@	O	-1	8919272
d.	O	-1	8919272
Al@@	O	-1	8919272
ter@@	O	-1	8919272
ations	O	-1	8919272
in	O	-1	8919272
the	O	-1	8919272
struct@@	O	-1	8919272
ural	O	-1	8919272
e@@	O	-1	8919272
le@@	O	-1	8919272
ments	O	-1	8919272
of	O	-1	8919272
the	O	-1	8919272
B@@	O	-1	8919272
B@@	O	-1	8919272
B	O	-1	8919272
co@@	O	-1	8919272
ex@@	O	-1	8919272
ist@@	O	-1	8919272
ed	O	-1	8919272
with	O	-1	8919272
mark@@	O	-1	8919272
ed	O	-1	8919272
lesions	O	-1	8919272
of	O	-1	8919272
neuron@@	O	-1	8919272
s	O	-1	8919272
of	O	-1	8919272
the	O	-1	8919272
ce@@	O	-1	8919272
re@@	O	-1	8919272
bell@@	O	-1	8919272
um	O	-1	8919272
(P@@	O	-1	8919272
ur@@	O	-1	8919272
k@@	O	-1	8919272
inj@@	O	-1	8919272
e	O	-1	8919272
cells	O	-1	8919272
are	O	-1	8919272
ear@@	O	-1	8919272
li@@	O	-1	8919272
est@@	O	-1	8919272
).	O	-1	8919272
In	O	-1	8919272
electro@@	O	-1	8919272
n	O	-1	8919272
micro@@	O	-1	8919272
graph@@	O	-1	8919272
s	O	-1	8919272
both	O	-1	8919272
lu@@	B-Chemical	D010634	8919272
min@@	I-Chemical	-1	8919272
al	I-Chemical	-1	8919272
and	O	-1	8919272
anti@@	O	-1	8919272
lu@@	O	-1	8919272
min@@	O	-1	8919272
al	O	-1	8919272
side@@	O	-1	8919272
s	O	-1	8919272
of	O	-1	8919272
the	O	-1	8919272
B@@	O	-1	8919272
B@@	O	-1	8919272
B	O	-1	8919272
of	O	-1	8919272
the	O	-1	8919272
ce@@	O	-1	8919272
re@@	O	-1	8919272
bell@@	O	-1	8919272
ar	O	-1	8919272
cor@@	O	-1	8919272
te@@	O	-1	8919272
x	O	-1	8919272
had	O	-1	8919272
similar	O	-1	8919272
le@@	O	-1	8919272
sion@@	O	-1	8919272
s.	O	-1	8919272
The	O	-1	8919272
possible	O	-1	8919272
influence	O	-1	8919272
of	O	-1	8919272
the	O	-1	8919272
hepatic	B-Disease	D056486	8919272
damage	I-Disease	-1	8919272
,	O	-1	8919272
main@@	O	-1	8919272
ly	O	-1	8919272
hyper@@	B-Disease	D022124	8919272
am@@	I-Disease	-1	8919272
mon@@	I-Disease	-1	8919272
emia	I-Disease	-1	8919272
,	O	-1	8919272
up@@	O	-1	8919272
on	O	-1	8919272
the	O	-1	8919272
development	O	-1	8919272
of	O	-1	8919272
valpro@@	B-Chemical	D014635	8919272
ate	I-Chemical	-1	8919272
encephalo@@	B-Disease	D001927	8919272
pathy	I-Disease	-1	8919272
is	O	-1	8919272
discus@@	O	-1	8919272
sed.	O	-1	8919272

M@@	O	-1	9199746
ac@@	O	-1	9199746
ul@@	O	-1	9199746
a	O	-1	9199746
toxicity	B-Disease	D064420	9199746
after	O	-1	9199746
intra@@	O	-1	9199746
vit@@	O	-1	9199746
re@@	O	-1	9199746
al	O	-1	9199746
ami@@	B-Chemical	D000583	9199746
k@@	I-Chemical	-1	9199746
ac@@	I-Chemical	-1	9199746
in	I-Chemical	-1	9199746
.	O	-1	9199746
BACKGROUND:	O	-1	9199746
Although	O	-1	9199746
intra@@	O	-1	9199746
vit@@	O	-1	9199746
re@@	O	-1	9199746
al	O	-1	9199746
amino@@	B-Chemical	D000617	9199746
gly@@	I-Chemical	-1	9199746
co@@	I-Chemical	-1	9199746
side@@	I-Chemical	-1	9199746
s	I-Chemical	-1	9199746
have	O	-1	9199746
subst@@	O	-1	9199746
anti@@	O	-1	9199746
ally	O	-1	9199746
improved	O	-1	9199746
visual	O	-1	9199746
pro@@	O	-1	9199746
g@@	O	-1	9199746
no@@	O	-1	9199746
sis	O	-1	9199746
in	O	-1	9199746
endo@@	B-Disease	D009877	9199746
ph@@	I-Disease	-1	9199746
thal@@	I-Disease	-1	9199746
m@@	I-Disease	-1	9199746
iti@@	I-Disease	-1	9199746
s	I-Disease	-1	9199746
,	O	-1	9199746
mac@@	O	-1	9199746
ular	O	-1	9199746
infarction	B-Disease	D007238	9199746
may	O	-1	9199746
impa@@	O	-1	9199746
ir	O	-1	9199746
ful@@	O	-1	9199746
l	O	-1	9199746
visual	O	-1	9199746
reco@@	O	-1	9199746
ver@@	O	-1	9199746
y.	O	-1	9199746
METHODS:	O	-1	9199746
We	O	-1	9199746
present	O	-1	9199746
a	O	-1	9199746
case	O	-1	9199746
of	O	-1	9199746
pres@@	O	-1	9199746
um@@	O	-1	9199746
ed	O	-1	9199746
ami@@	B-Chemical	D000583	9199746
k@@	I-Chemical	-1	9199746
ac@@	I-Chemical	-1	9199746
in	I-Chemical	-1	9199746
ret@@	B-Disease	D012164	9199746
inal	I-Disease	-1	9199746
toxicity	I-Disease	-1	9199746
following	O	-1	9199746
treatment	O	-1	9199746
with	O	-1	9199746
ami@@	B-Chemical	D000583	9199746
k@@	I-Chemical	-1	9199746
ac@@	I-Chemical	-1	9199746
in	I-Chemical	-1	9199746
and	O	-1	9199746
v@@	B-Chemical	D014640	9199746
an@@	I-Chemical	-1	9199746
com@@	I-Chemical	-1	9199746
ycin	I-Chemical	-1	9199746
for	O	-1	9199746
alpha-@@	O	-1	9199746
haem@@	O	-1	9199746
oly@@	O	-1	9199746
tic	O	-1	9199746
st@@	B-Disease	D013290	9199746
re@@	I-Disease	-1	9199746
pto@@	I-Disease	-1	9199746
co@@	I-Disease	-1	9199746
c@@	I-Disease	-1	9199746
c@@	I-Disease	-1	9199746
al	I-Disease	-1	9199746
endo@@	I-Disease	-1	9199746
ph@@	I-Disease	-1	9199746
thal@@	I-Disease	-1	9199746
m@@	I-Disease	-1	9199746
iti@@	I-Disease	-1	9199746
s	I-Disease	-1	9199746
.	O	-1	9199746
RESULTS:	O	-1	9199746
E@@	B-Disease	D009877	9199746
n@@	I-Disease	-1	9199746
do@@	I-Disease	-1	9199746
ph@@	I-Disease	-1	9199746
thal@@	I-Disease	-1	9199746
m@@	I-Disease	-1	9199746
iti@@	I-Disease	-1	9199746
s	I-Disease	-1	9199746
resol@@	O	-1	9199746
ved	O	-1	9199746
with	O	-1	9199746
impro@@	O	-1	9199746
vement	O	-1	9199746
in	O	-1	9199746
visual	O	-1	9199746
ac@@	O	-1	9199746
u@@	O	-1	9199746
ity	O	-1	9199746
to	O	-1	9199746
6@@	O	-1	9199746
/@@	O	-1	9199746
24	O	-1	9199746
at	O	-1	9199746
three	O	-1	9199746
months.	O	-1	9199746
F@@	O	-1	9199746
und@@	O	-1	9199746
us	O	-1	9199746
fluo@@	B-Chemical	D019793	9199746
res@@	I-Chemical	-1	9199746
ce@@	I-Chemical	-1	9199746
in	I-Chemical	-1	9199746
angio@@	O	-1	9199746
graph@@	O	-1	9199746
y	O	-1	9199746
con@@	O	-1	9199746
fir@@	O	-1	9199746
m@@	O	-1	9199746
ed	O	-1	9199746
mac@@	O	-1	9199746
ular	O	-1	9199746
cap@@	O	-1	9199746
ill@@	O	-1	9199746
ary	O	-1	9199746
c@@	O	-1	9199746
los@@	O	-1	9199746
ure	O	-1	9199746
and	O	-1	9199746
te@@	B-Disease	D013684	9199746
l@@	I-Disease	-1	9199746
angi@@	I-Disease	-1	9199746
ect@@	I-Disease	-1	9199746
asis	I-Disease	-1	9199746
.	O	-1	9199746
CONCLUSIONS:	O	-1	9199746
C@@	O	-1	9199746
ur@@	O	-1	9199746
ren@@	O	-1	9199746
tly	O	-1	9199746
ac@@	O	-1	9199746
ce@@	O	-1	9199746
pt@@	O	-1	9199746
ed	O	-1	9199746
intra@@	O	-1	9199746
vit@@	O	-1	9199746
re@@	O	-1	9199746
al	O	-1	9199746
anti@@	O	-1	9199746
bio@@	O	-1	9199746
tic	O	-1	9199746
regimen@@	O	-1	9199746
s	O	-1	9199746
may	O	-1	9199746
cause	O	-1	9199746
ret@@	B-Disease	D012164	9199746
inal	I-Disease	-1	9199746
toxicity	I-Disease	-1	9199746
and	O	-1	9199746
mac@@	O	-1	9199746
ular	O	-1	9199746
is@@	B-Disease	D007511	9199746
ch@@	I-Disease	-1	9199746
a@@	I-Disease	-1	9199746
emia	I-Disease	-1	9199746
.	O	-1	9199746
Treat@@	O	-1	9199746
ment	O	-1	9199746
strat@@	O	-1	9199746
e@@	O	-1	9199746
gi@@	O	-1	9199746
es	O	-1	9199746
a@@	O	-1	9199746
im@@	O	-1	9199746
ed	O	-1	9199746
at	O	-1	9199746
avoid@@	O	-1	9199746
ing	O	-1	9199746
ret@@	B-Disease	D012164	9199746
inal	I-Disease	-1	9199746
toxicity	I-Disease	-1	9199746
are	O	-1	9199746
discus@@	O	-1	9199746
sed.	O	-1	9199746

I@@	O	-1	9249847
atro@@	O	-1	9249847
gen@@	O	-1	9249847
ically	O	-1	9249847
induced	O	-1	9249847
intrac@@	O	-1	9249847
t@@	O	-1	9249847
able	O	-1	9249847
atri@@	B-Disease	D013611	9249847
o@@	I-Disease	-1	9249847
ventricular	I-Disease	-1	9249847
re@@	I-Disease	-1	9249847
ent@@	I-Disease	-1	9249847
ran@@	I-Disease	-1	9249847
t	I-Disease	-1	9249847
tachycardia	I-Disease	-1	9249847
after	O	-1	9249847
verap@@	B-Chemical	D014700	9249847
ami@@	I-Chemical	-1	9249847
l	I-Chemical	-1	9249847
and	O	-1	9249847
ca@@	O	-1	9249847
the@@	O	-1	9249847
ter	O	-1	9249847
abl@@	O	-1	9249847
ation	O	-1	9249847
in	O	-1	9249847
a	O	-1	9249847
patient	O	-1	9249847
with	O	-1	9249847
W@@	B-Disease	D014927	9249847
ol@@	I-Disease	-1	9249847
ff@@	I-Disease	-1	9249847
-@@	I-Disease	-1	9249847
Parkinson@@	I-Disease	-1	9249847
-@@	I-Disease	-1	9249847
W@@	I-Disease	-1	9249847
h@@	I-Disease	-1	9249847
ite	I-Disease	-1	9249847
syndrome	I-Disease	-1	9249847
and	O	-1	9249847
i@@	B-Disease	D002311	9249847
di@@	I-Disease	-1	9249847
o@@	I-Disease	-1	9249847
path@@	I-Disease	-1	9249847
ic	I-Disease	-1	9249847
di@@	I-Disease	-1	9249847
l@@	I-Disease	-1	9249847
ated	I-Disease	-1	9249847
cardi@@	I-Disease	-1	9249847
om@@	I-Disease	-1	9249847
yo@@	I-Disease	-1	9249847
pathy	I-Disease	-1	9249847
.	O	-1	9249847
In	O	-1	9249847
a	O	-1	9249847
patient	O	-1	9249847
with	O	-1	9249847
W@@	B-Disease	D014927	9249847
P@@	I-Disease	-1	9249847
W	I-Disease	-1	9249847
syndrome	I-Disease	-1	9249847
and	O	-1	9249847
i@@	B-Disease	D002311	9249847
di@@	I-Disease	-1	9249847
o@@	I-Disease	-1	9249847
path@@	I-Disease	-1	9249847
ic	I-Disease	-1	9249847
di@@	I-Disease	-1	9249847
l@@	I-Disease	-1	9249847
ated	I-Disease	-1	9249847
cardi@@	I-Disease	-1	9249847
om@@	I-Disease	-1	9249847
yo@@	I-Disease	-1	9249847
pathy	I-Disease	-1	9249847
,	O	-1	9249847
intrac@@	O	-1	9249847
t@@	O	-1	9249847
able	O	-1	9249847
atri@@	B-Disease	D013611	9249847
o@@	I-Disease	-1	9249847
ventricular	I-Disease	-1	9249847
re@@	I-Disease	-1	9249847
ent@@	I-Disease	-1	9249847
ran@@	I-Disease	-1	9249847
t	I-Disease	-1	9249847
tachycardia	I-Disease	-1	9249847
(	O	-1	9249847
A@@	B-Disease	D013611	9249847
V@@	I-Disease	-1	9249847
R@@	I-Disease	-1	9249847
T	I-Disease	-1	9249847
)	O	-1	9249847
was	O	-1	9249847
i@@	O	-1	9249847
atro@@	O	-1	9249847
gen@@	O	-1	9249847
ically	O	-1	9249847
induc@@	O	-1	9249847
ed.	O	-1	9249847
Q@@	O	-1	9249847
R@@	O	-1	9249847
S	O	-1	9249847
without	O	-1	9249847
pre@@	O	-1	9249847
ex@@	O	-1	9249847
cit@@	O	-1	9249847
ation,	O	-1	9249847
caused	O	-1	9249847
by	O	-1	9249847
j@@	O	-1	9249847
unc@@	O	-1	9249847
tional	O	-1	9249847
es@@	O	-1	9249847
cap@@	O	-1	9249847
e	O	-1	9249847
be@@	O	-1	9249847
at@@	O	-1	9249847
s	O	-1	9249847
after	O	-1	9249847
verap@@	B-Chemical	D014700	9249847
ami@@	I-Chemical	-1	9249847
l	I-Chemical	-1	9249847
or	O	-1	9249847
un@@	O	-1	9249847
i@@	O	-1	9249847
direc@@	O	-1	9249847
tional	O	-1	9249847
an@@	O	-1	9249847
te@@	O	-1	9249847
gra@@	O	-1	9249847
de	O	-1	9249847
bloc@@	O	-1	9249847
k	O	-1	9249847
of	O	-1	9249847
ac@@	O	-1	9249847
cess@@	O	-1	9249847
ory	O	-1	9249847
path@@	O	-1	9249847
w@@	O	-1	9249847
ay	O	-1	9249847
after	O	-1	9249847
ca@@	O	-1	9249847
the@@	O	-1	9249847
ter	O	-1	9249847
abl@@	O	-1	9249847
ation,	O	-1	9249847
est@@	O	-1	9249847
abl@@	O	-1	9249847
ished	O	-1	9249847
frequent	O	-1	9249847
A@@	B-Disease	D013611	9249847
V@@	I-Disease	-1	9249847
R@@	I-Disease	-1	9249847
T	I-Disease	-1	9249847
at@@	O	-1	9249847
tac@@	O	-1	9249847
k@@	O	-1	9249847
.	O	-1	9249847

E@@	O	-1	9284778
pi@@	O	-1	9284778
de@@	O	-1	9284778
mic	O	-1	9284778
of	O	-1	9284778
liver	B-Disease	D008107	9284778
disease	I-Disease	-1	9284778
caused	O	-1	9284778
by	O	-1	9284778
hydro@@	B-Chemical	-1	9284778
ch@@	I-Chemical	-1	9284778
loro@@	I-Chemical	-1	9284778
fluoro@@	I-Chemical	-1	9284778
carb@@	I-Chemical	-1	9284778
ons	I-Chemical	-1	9284778
used	O	-1	9284778
as	O	-1	9284778
o@@	B-Chemical	D010126	9284778
z@@	I-Chemical	-1	9284778
one	I-Chemical	-1	9284778
-@@	O	-1	9284778
s@@	O	-1	9284778
par@@	O	-1	9284778
ing	O	-1	9284778
sub@@	O	-1	9284778
sti@@	O	-1	9284778
t@@	O	-1	9284778
ut@@	O	-1	9284778
es	O	-1	9284778
of	O	-1	9284778
ch@@	B-Chemical	D017402	9284778
loro@@	I-Chemical	-1	9284778
fluoro@@	I-Chemical	-1	9284778
carb@@	I-Chemical	-1	9284778
ons	I-Chemical	-1	9284778
.	O	-1	9284778
BACKGROUND:	O	-1	9284778
H@@	B-Chemical	-1	9284778
y@@	I-Chemical	-1	9284778
dro@@	I-Chemical	-1	9284778
ch@@	I-Chemical	-1	9284778
loro@@	I-Chemical	-1	9284778
fluoro@@	I-Chemical	-1	9284778
carb@@	I-Chemical	-1	9284778
ons	I-Chemical	-1	9284778
(	O	-1	9284778
HC@@	B-Chemical	-1	9284778
F@@	I-Chemical	-1	9284778
C@@	I-Chemical	-1	9284778
s	I-Chemical	-1	9284778
)	O	-1	9284778
are	O	-1	9284778
used	O	-1	9284778
increas@@	O	-1	9284778
ing@@	O	-1	9284778
ly	O	-1	9284778
in	O	-1	9284778
ind@@	O	-1	9284778
u@@	O	-1	9284778
str@@	O	-1	9284778
y	O	-1	9284778
as	O	-1	9284778
sub@@	O	-1	9284778
sti@@	O	-1	9284778
t@@	O	-1	9284778
ut@@	O	-1	9284778
es	O	-1	9284778
for	O	-1	9284778
o@@	B-Chemical	D010126	9284778
z@@	I-Chemical	-1	9284778
one	I-Chemical	-1	9284778
-@@	O	-1	9284778
deple@@	O	-1	9284778
ting	O	-1	9284778
ch@@	B-Chemical	D017402	9284778
loro@@	I-Chemical	-1	9284778
fluoro@@	I-Chemical	-1	9284778
carb@@	I-Chemical	-1	9284778
ons	I-Chemical	-1	9284778
(	O	-1	9284778
C@@	B-Chemical	D017402	9284778
F@@	I-Chemical	-1	9284778
C@@	I-Chemical	-1	9284778
s	I-Chemical	-1	9284778
).	O	-1	9284778
L@@	O	-1	9284778
im@@	O	-1	9284778
ited	O	-1	9284778
studies	O	-1	9284778
in	O	-1	9284778
animals	O	-1	9284778
indicate	O	-1	9284778
potential	O	-1	9284778
hepat@@	B-Disease	D056486	9284778
otoxicity	I-Disease	-1	9284778
of	O	-1	9284778
some	O	-1	9284778
of	O	-1	9284778
these	O	-1	9284778
comp@@	O	-1	9284778
oun@@	O	-1	9284778
d@@	O	-1	9284778
s.	O	-1	9284778
We	O	-1	9284778
investigated	O	-1	9284778
an	O	-1	9284778
epi@@	O	-1	9284778
de@@	O	-1	9284778
mic	O	-1	9284778
of	O	-1	9284778
liver	B-Disease	D008107	9284778
disease	I-Disease	-1	9284778
in	O	-1	9284778
n@@	O	-1	9284778
ine	O	-1	9284778
ind@@	O	-1	9284778
u@@	O	-1	9284778
stri@@	O	-1	9284778
al	O	-1	9284778
wor@@	O	-1	9284778
k@@	O	-1	9284778
ers	O	-1	9284778
who	O	-1	9284778
had	O	-1	9284778
had	O	-1	9284778
repe@@	O	-1	9284778
ated	O	-1	9284778
ac@@	O	-1	9284778
c@@	O	-1	9284778
id@@	O	-1	9284778
ental	O	-1	9284778
exposure	O	-1	9284778
to	O	-1	9284778
a	O	-1	9284778
mi@@	O	-1	9284778
x@@	O	-1	9284778
t@@	O	-1	9284778
ure	O	-1	9284778
of	O	-1	9284778
1@@	B-Chemical	C067411	9284778
,@@	I-Chemical	-1	9284778
1-@@	I-Chemical	-1	9284778
dic@@	I-Chemical	-1	9284778
h@@	I-Chemical	-1	9284778
loro@@	I-Chemical	-1	9284778
-@@	I-Chemical	-1	9284778
2@@	I-Chemical	-1	9284778
,@@	I-Chemical	-1	9284778
2@@	I-Chemical	-1	9284778
,@@	I-Chemical	-1	9284778
2-@@	I-Chemical	-1	9284778
tri@@	I-Chemical	-1	9284778
fluoro@@	I-Chemical	-1	9284778
eth@@	I-Chemical	-1	9284778
ane	I-Chemical	-1	9284778
(	O	-1	9284778
HC@@	B-Chemical	C067411	9284778
F@@	I-Chemical	-1	9284778
C	I-Chemical	-1	9284778
12@@	I-Chemical	-1	9284778
3	I-Chemical	-1	9284778
)	O	-1	9284778
and	O	-1	9284778
1-@@	B-Chemical	C072959	9284778
ch@@	I-Chemical	-1	9284778
loro@@	I-Chemical	-1	9284778
-1@@	I-Chemical	-1	9284778
,@@	I-Chemical	-1	9284778
2@@	I-Chemical	-1	9284778
,@@	I-Chemical	-1	9284778
2@@	I-Chemical	-1	9284778
,@@	I-Chemical	-1	9284778
2-@@	I-Chemical	-1	9284778
te@@	I-Chemical	-1	9284778
tra@@	I-Chemical	-1	9284778
fluoro@@	I-Chemical	-1	9284778
eth@@	I-Chemical	-1	9284778
ane	I-Chemical	-1	9284778
(	O	-1	9284778
HC@@	B-Chemical	C072959	9284778
F@@	I-Chemical	-1	9284778
C	I-Chemical	-1	9284778
1@@	I-Chemical	-1	9284778
24	I-Chemical	-1	9284778
).	O	-1	9284778
All	O	-1	9284778
n@@	O	-1	9284778
ine	O	-1	9284778
exposed	O	-1	9284778
wor@@	O	-1	9284778
k@@	O	-1	9284778
ers	O	-1	9284778
were	O	-1	9284778
affected	O	-1	9284778
to	O	-1	9284778
various	O	-1	9284778
de@@	O	-1	9284778
gre@@	O	-1	9284778
es.	O	-1	9284778
B@@	O	-1	9284778
oth	O	-1	9284778
comp@@	O	-1	9284778
oun@@	O	-1	9284778
ds	O	-1	9284778
are	O	-1	9284778
metabol@@	O	-1	9284778
is@@	O	-1	9284778
ed	O	-1	9284778
in	O	-1	9284778
the	O	-1	9284778
same	O	-1	9284778
w@@	O	-1	9284778
ay	O	-1	9284778
as	O	-1	9284778
1-@@	B-Chemical	D006221	9284778
b@@	I-Chemical	-1	9284778
ro@@	I-Chemical	-1	9284778
mo@@	I-Chemical	-1	9284778
-1@@	I-Chemical	-1	9284778
-@@	I-Chemical	-1	9284778
ch@@	I-Chemical	-1	9284778
loro@@	I-Chemical	-1	9284778
-@@	I-Chemical	-1	9284778
2@@	I-Chemical	-1	9284778
,@@	I-Chemical	-1	9284778
2@@	I-Chemical	-1	9284778
,@@	I-Chemical	-1	9284778
2-@@	I-Chemical	-1	9284778
tri@@	I-Chemical	-1	9284778
fluoro@@	I-Chemical	-1	9284778
eth@@	I-Chemical	-1	9284778
ane	I-Chemical	-1	9284778
(	O	-1	9284778
halo@@	B-Chemical	D006221	9284778
th@@	I-Chemical	-1	9284778
ane	I-Chemical	-1	9284778
)	O	-1	9284778
to	O	-1	9284778
form	O	-1	9284778
reac@@	O	-1	9284778
tive	O	-1	9284778
tri@@	B-Chemical	D014269	9284778
fluoro@@	I-Chemical	-1	9284778
acet@@	I-Chemical	-1	9284778
yl	I-Chemical	-1	9284778
h@@	O	-1	9284778
al@@	O	-1	9284778
ide	O	-1	9284778
inter@@	O	-1	9284778
medi@@	O	-1	9284778
at@@	O	-1	9284778
es,	O	-1	9284778
which	O	-1	9284778
have	O	-1	9284778
been	O	-1	9284778
implic@@	O	-1	9284778
ated	O	-1	9284778
in	O	-1	9284778
the	O	-1	9284778
hepat@@	B-Disease	D056486	9284778
otoxicity	I-Disease	-1	9284778
of	O	-1	9284778
halo@@	B-Chemical	D006221	9284778
th@@	I-Chemical	-1	9284778
ane	I-Chemical	-1	9284778
.	O	-1	9284778
We	O	-1	9284778
a@@	O	-1	9284778
im@@	O	-1	9284778
ed	O	-1	9284778
to	O	-1	9284778
test	O	-1	9284778
whether	O	-1	9284778
HC@@	B-Chemical	C067411	9284778
F@@	I-Chemical	-1	9284778
C@@	I-Chemical	-1	9284778
s	I-Chemical	-1	9284778
12@@	I-Chemical	-1	9284778
3	I-Chemical	-1	9284778
and	I-Chemical	-1	9284778
1@@	I-Chemical	-1	9284778
24	I-Chemical	-1	9284778
HC@@	B-Chemical	C072959	9284778
F@@	I-Chemical	-1	9284778
C@@	I-Chemical	-1	9284778
s	I-Chemical	-1	9284778
12@@	I-Chemical	-1	9284778
3	I-Chemical	-1	9284778
and	I-Chemical	-1	9284778
1@@	I-Chemical	-1	9284778
24	I-Chemical	-1	9284778
can	O	-1	9284778
result	O	-1	9284778
in	O	-1	9284778
seri@@	O	-1	9284778
ous	O	-1	9284778
liver	B-Disease	D008107	9284778
disease	I-Disease	-1	9284778
.	O	-1	9284778
METHODS:	O	-1	9284778
F@@	O	-1	9284778
or	O	-1	9284778
one	O	-1	9284778
se@@	O	-1	9284778
ve@@	O	-1	9284778
re@@	O	-1	9284778
ly	O	-1	9284778
affected	O	-1	9284778
wor@@	O	-1	9284778
k@@	O	-1	9284778
er	O	-1	9284778
liver	O	-1	9284778
biop@@	O	-1	9284778
sy	O	-1	9284778
and	O	-1	9284778
immuno@@	O	-1	9284778
histo@@	O	-1	9284778
chemical	O	-1	9284778
st@@	O	-1	9284778
ain@@	O	-1	9284778
ings	O	-1	9284778
for	O	-1	9284778
the	O	-1	9284778
presence	O	-1	9284778
of	O	-1	9284778
tri@@	B-Chemical	D014269	9284778
fluoro@@	I-Chemical	-1	9284778
acet@@	I-Chemical	-1	9284778
yl	I-Chemical	-1	9284778
protein	O	-1	9284778
ad@@	O	-1	9284778
duc@@	O	-1	9284778
ts	O	-1	9284778
were	O	-1	9284778
d@@	O	-1	9284778
one.	O	-1	9284778
The	O	-1	9284778
serum	O	-1	9284778
of	O	-1	9284778
six	O	-1	9284778
affected	O	-1	9284778
wor@@	O	-1	9284778
k@@	O	-1	9284778
ers	O	-1	9284778
and	O	-1	9284778
five	O	-1	9284778
controls	O	-1	9284778
was	O	-1	9284778
tested	O	-1	9284778
for	O	-1	9284778
auto@@	O	-1	9284778
anti@@	O	-1	9284778
bo@@	O	-1	9284778
di@@	O	-1	9284778
es	O	-1	9284778
that	O	-1	9284778
reac@@	O	-1	9284778
t	O	-1	9284778
with	O	-1	9284778
human	O	-1	9284778
liver	O	-1	9284778
cyto@@	O	-1	9284778
ch@@	O	-1	9284778
ro@@	O	-1	9284778
me@@	O	-1	9284778
-@@	O	-1	9284778
P@@	O	-1	9284778
4@@	O	-1	9284778
50	O	-1	9284778
2@@	O	-1	9284778
E@@	O	-1	9284778
1	O	-1	9284778
(P@@	O	-1	9284778
4@@	O	-1	9284778
50	O	-1	9284778
2@@	O	-1	9284778
E@@	O	-1	9284778
1)	O	-1	9284778
and	O	-1	9284778
P@@	O	-1	9284778
5@@	O	-1	9284778
8	O	-1	9284778
protein	O	-1	9284778
dis@@	O	-1	9284778
ul@@	O	-1	9284778
ph@@	O	-1	9284778
ide	O	-1	9284778
is@@	O	-1	9284778
om@@	O	-1	9284778
er@@	O	-1	9284778
ase	O	-1	9284778
iso@@	O	-1	9284778
form	O	-1	9284778
(P@@	O	-1	9284778
5@@	O	-1	9284778
8@@	O	-1	9284778
).	O	-1	9284778
F@@	O	-1	9284778
IN@@	O	-1	9284778
D@@	O	-1	9284778
IN@@	O	-1	9284778
G@@	O	-1	9284778
S:	O	-1	9284778
The	O	-1	9284778
liver	O	-1	9284778
biop@@	O	-1	9284778
sy	O	-1	9284778
sam@@	O	-1	9284778
ple	O	-1	9284778
showed	O	-1	9284778
hepat@@	O	-1	9284778
oc@@	O	-1	9284778
ell@@	O	-1	9284778
ular	O	-1	9284778
necro@@	B-Disease	D009336	9284778
sis	I-Disease	-1	9284778
which	O	-1	9284778
was	O	-1	9284778
pro@@	O	-1	9284778
min@@	O	-1	9284778
ent	O	-1	9284778
in	O	-1	9284778
peri@@	O	-1	9284778
ven@@	O	-1	9284778
ular	O	-1	9284778
z@@	O	-1	9284778
one	O	-1	9284778
three	O	-1	9284778
and	O	-1	9284778
exten@@	O	-1	9284778
ded	O	-1	9284778
foc@@	O	-1	9284778
ally	O	-1	9284778
from	O	-1	9284778
port@@	O	-1	9284778
al	O	-1	9284778
trac@@	O	-1	9284778
ts	O	-1	9284778
to	O	-1	9284778
port@@	O	-1	9284778
al	O	-1	9284778
trac@@	O	-1	9284778
ts	O	-1	9284778
and	O	-1	9284778
c@@	O	-1	9284778
ent@@	O	-1	9284778
ri@@	O	-1	9284778
lo@@	O	-1	9284778
b@@	O	-1	9284778
ular	O	-1	9284778
a@@	O	-1	9284778
reas	O	-1	9284778
(@@	O	-1	9284778
b@@	O	-1	9284778
ri@@	O	-1	9284778
d@@	O	-1	9284778
g@@	O	-1	9284778
ing	O	-1	9284778
necro@@	B-Disease	D009336	9284778
sis	I-Disease	-1	9284778
).	O	-1	9284778
T@@	B-Chemical	D014269	9284778
ri@@	I-Chemical	-1	9284778
fluoro@@	I-Chemical	-1	9284778
acet@@	I-Chemical	-1	9284778
yl	I-Chemical	-1	9284778
-@@	O	-1	9284778
ad@@	O	-1	9284778
duc@@	O	-1	9284778
ted	O	-1	9284778
protein@@	O	-1	9284778
s	O	-1	9284778
were	O	-1	9284778
det@@	O	-1	9284778
ected	O	-1	9284778
in	O	-1	9284778
sur@@	O	-1	9284778
vi@@	O	-1	9284778
ving	O	-1	9284778
hepat@@	O	-1	9284778
ocy@@	O	-1	9284778
t@@	O	-1	9284778
es.	O	-1	9284778
A@@	O	-1	9284778
u@@	O	-1	9284778
to@@	O	-1	9284778
anti@@	O	-1	9284778
bo@@	O	-1	9284778
di@@	O	-1	9284778
es	O	-1	9284778
against	O	-1	9284778
P@@	O	-1	9284778
4@@	O	-1	9284778
50	O	-1	9284778
2@@	O	-1	9284778
E@@	O	-1	9284778
1	O	-1	9284778
or	O	-1	9284778
P@@	O	-1	9284778
5@@	O	-1	9284778
8@@	O	-1	9284778
,	O	-1	9284778
previously	O	-1	9284778
associated	O	-1	9284778
with	O	-1	9284778
halo@@	B-Disease	C562477	9284778
th@@	I-Disease	-1	9284778
ane	I-Disease	-1	9284778
hepatitis	I-Disease	-1	9284778
,	O	-1	9284778
were	O	-1	9284778
det@@	O	-1	9284778
ected	O	-1	9284778
in	O	-1	9284778
the	O	-1	9284778
serum	O	-1	9284778
of	O	-1	9284778
five	O	-1	9284778
affected	O	-1	9284778
wor@@	O	-1	9284778
k@@	O	-1	9284778
ers.	O	-1	9284778
IN@@	O	-1	9284778
TE@@	O	-1	9284778
R@@	O	-1	9284778
P@@	O	-1	9284778
R@@	O	-1	9284778
ET@@	O	-1	9284778
AT@@	O	-1	9284778
ION@@	O	-1	9284778
:	O	-1	9284778
R@@	O	-1	9284778
ep@@	O	-1	9284778
e@@	O	-1	9284778
ated	O	-1	9284778
exposure	O	-1	9284778
of	O	-1	9284778
human	O	-1	9284778
be@@	O	-1	9284778
ings	O	-1	9284778
to	O	-1	9284778
HC@@	B-Chemical	C067411	9284778
F@@	I-Chemical	-1	9284778
C@@	I-Chemical	-1	9284778
s	I-Chemical	-1	9284778
12@@	I-Chemical	-1	9284778
3	I-Chemical	-1	9284778
and	I-Chemical	-1	9284778
1@@	I-Chemical	-1	9284778
24	I-Chemical	-1	9284778
HC@@	B-Chemical	C072959	9284778
F@@	I-Chemical	-1	9284778
C@@	I-Chemical	-1	9284778
s	I-Chemical	-1	9284778
12@@	I-Chemical	-1	9284778
3	I-Chemical	-1	9284778
and	I-Chemical	-1	9284778
1@@	I-Chemical	-1	9284778
24	I-Chemical	-1	9284778
can	O	-1	9284778
result	O	-1	9284778
in	O	-1	9284778
seri@@	O	-1	9284778
ous	O	-1	9284778
liver	B-Disease	D056486	9284778
injury	I-Disease	-1	9284778
in	O	-1	9284778
a	O	-1	9284778
larg@@	O	-1	9284778
e	O	-1	9284778
pro@@	O	-1	9284778
por@@	O	-1	9284778
tion	O	-1	9284778
of	O	-1	9284778
the	O	-1	9284778
exposed	O	-1	9284778
po@@	O	-1	9284778
pul@@	O	-1	9284778
ation.	O	-1	9284778
Although	O	-1	9284778
the	O	-1	9284778
ex@@	O	-1	9284778
ac@@	O	-1	9284778
t	O	-1	9284778
mechanism	O	-1	9284778
of	O	-1	9284778
hepat@@	B-Disease	D056486	9284778
otoxicity	I-Disease	-1	9284778
of	O	-1	9284778
these	O	-1	9284778
agents	O	-1	9284778
is	O	-1	9284778
not	O	-1	9284778
know@@	O	-1	9284778
n@@	O	-1	9284778
,	O	-1	9284778
the	O	-1	9284778
results	O	-1	9284778
suggest	O	-1	9284778
that	O	-1	9284778
tri@@	B-Chemical	D014269	9284778
fluoro@@	I-Chemical	-1	9284778
acet@@	I-Chemical	-1	9284778
yl	I-Chemical	-1	9284778
-@@	O	-1	9284778
al@@	O	-1	9284778
te@@	O	-1	9284778
red	O	-1	9284778
liver	O	-1	9284778
protein@@	O	-1	9284778
s	O	-1	9284778
are	O	-1	9284778
invol@@	O	-1	9284778
ved.	O	-1	9284778
In	O	-1	9284778
vie@@	O	-1	9284778
w	O	-1	9284778
of	O	-1	9284778
the	O	-1	9284778
potenti@@	O	-1	9284778
ally	O	-1	9284778
w@@	O	-1	9284778
id@@	O	-1	9284778
es@@	O	-1	9284778
pre@@	O	-1	9284778
ad	O	-1	9284778
use	O	-1	9284778
of	O	-1	9284778
these	O	-1	9284778
comp@@	O	-1	9284778
oun@@	O	-1	9284778
d@@	O	-1	9284778
s,	O	-1	9284778
there	O	-1	9284778
is	O	-1	9284778
an	O	-1	9284778
ur@@	O	-1	9284778
g@@	O	-1	9284778
ent	O	-1	9284778
need	O	-1	9284778
to	O	-1	9284778
deve@@	O	-1	9284778
lo@@	O	-1	9284778
p	O	-1	9284778
saf@@	O	-1	9284778
er	O	-1	9284778
al@@	O	-1	9284778
tern@@	O	-1	9284778
ati@@	O	-1	9284778
v@@	O	-1	9284778
es.	O	-1	9284778

The	O	-1	9522143
effect	O	-1	9522143
of	O	-1	9522143
different	O	-1	9522143
anaesthe@@	O	-1	9522143
tic	O	-1	9522143
agents	O	-1	9522143
in	O	-1	9522143
hearing	B-Disease	D034381	9522143
loss	I-Disease	-1	9522143
following	O	-1	9522143
spinal	O	-1	9522143
anaesthe@@	O	-1	9522143
sia.	O	-1	9522143
The	O	-1	9522143
cause	O	-1	9522143
of	O	-1	9522143
hearing	B-Disease	D034381	9522143
loss	I-Disease	-1	9522143
after	O	-1	9522143
spinal	O	-1	9522143
anaesthe@@	O	-1	9522143
sia	O	-1	9522143
is	O	-1	9522143
un@@	O	-1	9522143
know@@	O	-1	9522143
n@@	O	-1	9522143
.	O	-1	9522143
U@@	O	-1	9522143
p	O	-1	9522143
un@@	O	-1	9522143
ti@@	O	-1	9522143
l	O	-1	9522143
now@@	O	-1	9522143
,	O	-1	9522143
the	O	-1	9522143
only	O	-1	9522143
factor	O	-1	9522143
studied	O	-1	9522143
has	O	-1	9522143
been	O	-1	9522143
the	O	-1	9522143
effect	O	-1	9522143
of	O	-1	9522143
the	O	-1	9522143
di@@	O	-1	9522143
ame@@	O	-1	9522143
ter	O	-1	9522143
of	O	-1	9522143
the	O	-1	9522143
spinal	O	-1	9522143
ne@@	O	-1	9522143
ed@@	O	-1	9522143
le	O	-1	9522143
on	O	-1	9522143
post@@	O	-1	9522143
-@@	O	-1	9522143
o@@	O	-1	9522143
perative	O	-1	9522143
sens@@	B-Disease	D006319	9522143
or@@	I-Disease	-1	9522143
ine@@	I-Disease	-1	9522143
ural	I-Disease	-1	9522143
hearing	I-Disease	-1	9522143
loss	I-Disease	-1	9522143
.	O	-1	9522143
The	O	-1	9522143
a@@	O	-1	9522143
im	O	-1	9522143
of	O	-1	9522143
this	O	-1	9522143
study	O	-1	9522143
was	O	-1	9522143
to	O	-1	9522143
describe	O	-1	9522143
this	O	-1	9522143
hearing	B-Disease	D034381	9522143
loss	I-Disease	-1	9522143
and	O	-1	9522143
to	O	-1	9522143
investigate	O	-1	9522143
other	O	-1	9522143
factors	O	-1	9522143
influ@@	O	-1	9522143
enc@@	O	-1	9522143
ing	O	-1	9522143
the	O	-1	9522143
de@@	O	-1	9522143
g@@	O	-1	9522143
ree	O	-1	9522143
of	O	-1	9522143
hearing	B-Disease	D034381	9522143
loss	I-Disease	-1	9522143
.	O	-1	9522143
Two	O	-1	9522143
groups	O	-1	9522143
of	O	-1	9522143
2@@	O	-1	9522143
2	O	-1	9522143
similar	O	-1	9522143
patients	O	-1	9522143
were	O	-1	9522143
studi@@	O	-1	9522143
ed@@	O	-1	9522143
:	O	-1	9522143
one	O	-1	9522143
group	O	-1	9522143
received	O	-1	9522143
6	O	-1	9522143
m@@	O	-1	9522143
L	O	-1	9522143
pri@@	B-Chemical	D011318	9522143
lo@@	I-Chemical	-1	9522143
ca@@	I-Chemical	-1	9522143
ine	I-Chemical	-1	9522143
2@@	O	-1	9522143
%@@	O	-1	9522143
;	O	-1	9522143
and	O	-1	9522143
the	O	-1	9522143
other	O	-1	9522143
received	O	-1	9522143
3	O	-1	9522143
m@@	O	-1	9522143
L	O	-1	9522143
bupivac@@	B-Chemical	D002045	9522143
aine	I-Chemical	-1	9522143
0.@@	O	-1	9522143
5@@	O	-1	9522143
%.	O	-1	9522143
Patients	O	-1	9522143
given	O	-1	9522143
pri@@	B-Chemical	D011318	9522143
lo@@	I-Chemical	-1	9522143
ca@@	I-Chemical	-1	9522143
ine	I-Chemical	-1	9522143
were	O	-1	9522143
more	O	-1	9522143
likely	O	-1	9522143
to	O	-1	9522143
deve@@	O	-1	9522143
lo@@	O	-1	9522143
p	O	-1	9522143
hearing	B-Disease	D034381	9522143
loss	I-Disease	-1	9522143
(10	O	-1	9522143
out	O	-1	9522143
of	O	-1	9522143
2@@	O	-1	9522143
2)	O	-1	9522143
than	O	-1	9522143
those	O	-1	9522143
given	O	-1	9522143
bupivac@@	B-Chemical	D002045	9522143
aine	I-Chemical	-1	9522143
(@@	O	-1	9522143
4	O	-1	9522143
out	O	-1	9522143
of	O	-1	9522143
2@@	O	-1	9522143
2)	O	-1	9522143
(P	O	-1	9522143
<	O	-1	9522143
0.05@@	O	-1	9522143
).	O	-1	9522143
The	O	-1	9522143
average	O	-1	9522143
hearing	B-Disease	D034381	9522143
loss	I-Disease	-1	9522143
for	O	-1	9522143
sp@@	O	-1	9522143
e@@	O	-1	9522143
ec@@	O	-1	9522143
h	O	-1	9522143
frequ@@	O	-1	9522143
en@@	O	-1	9522143
ci@@	O	-1	9522143
es	O	-1	9522143
was	O	-1	9522143
about	O	-1	9522143
10	O	-1	9522143
d@@	O	-1	9522143
B	O	-1	9522143
after	O	-1	9522143
pri@@	B-Chemical	D011318	9522143
lo@@	I-Chemical	-1	9522143
ca@@	I-Chemical	-1	9522143
ine	I-Chemical	-1	9522143
and	O	-1	9522143
15	O	-1	9522143
d@@	O	-1	9522143
B	O	-1	9522143
after	O	-1	9522143
bupivac@@	B-Chemical	D002045	9522143
aine	I-Chemical	-1	9522143
.	O	-1	9522143
N@@	O	-1	9522143
one	O	-1	9522143
of	O	-1	9522143
the	O	-1	9522143
patients	O	-1	9522143
com@@	O	-1	9522143
pl@@	O	-1	9522143
ained	O	-1	9522143
of	O	-1	9522143
subj@@	O	-1	9522143
ective	O	-1	9522143
hearing	B-Disease	D034381	9522143
loss	I-Disease	-1	9522143
.	O	-1	9522143
L@@	O	-1	9522143
on@@	O	-1	9522143
g@@	O	-1	9522143
-term	O	-1	9522143
follow-up	O	-1	9522143
of	O	-1	9522143
the	O	-1	9522143
patients	O	-1	9522143
was	O	-1	9522143
not	O	-1	9522143
possib@@	O	-1	9522143
le@@	O	-1	9522143
.	O	-1	9522143

A	O	-1	9522152
transi@@	O	-1	9522152
ent	O	-1	9522152
neurolog@@	B-Disease	D009461	9522152
ical	I-Disease	-1	9522152
defic@@	I-Disease	-1	9522152
it	I-Disease	-1	9522152
following	O	-1	9522152
intra@@	O	-1	9522152
th@@	O	-1	9522152
ec@@	O	-1	9522152
al	O	-1	9522152
injection	O	-1	9522152
of	O	-1	9522152
1@@	O	-1	9522152
%	O	-1	9522152
hyper@@	O	-1	9522152
bar@@	O	-1	9522152
ic	O	-1	9522152
bupivac@@	B-Chemical	D002045	9522152
aine	I-Chemical	-1	9522152
for	O	-1	9522152
un@@	O	-1	9522152
il@@	O	-1	9522152
ateral	O	-1	9522152
spinal	O	-1	9522152
anaesthe@@	O	-1	9522152
sia.	O	-1	9522152
We	O	-1	9522152
describe	O	-1	9522152
a	O	-1	9522152
case	O	-1	9522152
of	O	-1	9522152
transi@@	O	-1	9522152
ent	O	-1	9522152
neurolog@@	B-Disease	D009461	9522152
ical	I-Disease	-1	9522152
defic@@	I-Disease	-1	9522152
it	I-Disease	-1	9522152
that	O	-1	9522152
occurred	O	-1	9522152
after	O	-1	9522152
un@@	O	-1	9522152
il@@	O	-1	9522152
ateral	O	-1	9522152
spinal	O	-1	9522152
anaesthe@@	O	-1	9522152
sia	O	-1	9522152
with	O	-1	9522152
8	O	-1	9522152
mg	O	-1	9522152
of	O	-1	9522152
1@@	O	-1	9522152
%	O	-1	9522152
hyper@@	O	-1	9522152
bar@@	O	-1	9522152
ic	O	-1	9522152
bupivac@@	B-Chemical	D002045	9522152
aine	I-Chemical	-1	9522152
s@@	O	-1	9522152
low@@	O	-1	9522152
ly	O	-1	9522152
injected	O	-1	9522152
through	O	-1	9522152
a	O	-1	9522152
2@@	O	-1	9522152
5-@@	O	-1	9522152
g@@	O	-1	9522152
au@@	O	-1	9522152
ge	O	-1	9522152
pen@@	O	-1	9522152
c@@	O	-1	9522152
il@@	O	-1	9522152
-@@	O	-1	9522152
po@@	O	-1	9522152
in@@	O	-1	9522152
t	O	-1	9522152
spinal	O	-1	9522152
ne@@	O	-1	9522152
ed@@	O	-1	9522152
le@@	O	-1	9522152
.	O	-1	9522152
The	O	-1	9522152
surger@@	O	-1	9522152
y	O	-1	9522152
and	O	-1	9522152
anaesthe@@	O	-1	9522152
sia	O	-1	9522152
were	O	-1	9522152
un@@	O	-1	9522152
event@@	O	-1	9522152
ful@@	O	-1	9522152
,	O	-1	9522152
but	O	-1	9522152
3	O	-1	9522152
days	O	-1	9522152
after	O	-1	9522152
surger@@	O	-1	9522152
y,	O	-1	9522152
the	O	-1	9522152
patient	O	-1	9522152
reported	O	-1	9522152
an	O	-1	9522152
a@@	O	-1	9522152
re@@	O	-1	9522152
a	O	-1	9522152
of	O	-1	9522152
hypo@@	O	-1	9522152
a@@	O	-1	9522152
esthe@@	O	-1	9522152
sia	O	-1	9522152
over	O	-1	9522152
L@@	O	-1	9522152
3-@@	O	-1	9522152
L@@	O	-1	9522152
4	O	-1	9522152
der@@	O	-1	9522152
mat@@	O	-1	9522152
om@@	O	-1	9522152
es	O	-1	9522152
of	O	-1	9522152
the	O	-1	9522152
le@@	O	-1	9522152
g	O	-1	9522152
which	O	-1	9522152
had	O	-1	9522152
been	O	-1	9522152
o@@	O	-1	9522152
per@@	O	-1	9522152
ated	O	-1	9522152
on	O	-1	9522152
(	O	-1	9522152
loss	B-Disease	D012678	9522152
of	I-Disease	-1	9522152
p@@	I-Disease	-1	9522152
in@@	I-Disease	-1	9522152
pr@@	I-Disease	-1	9522152
ic@@	I-Disease	-1	9522152
k	I-Disease	-1	9522152
sens@@	I-Disease	-1	9522152
ation	I-Disease	-1	9522152
)	O	-1	9522152
without	O	-1	9522152
reduction	O	-1	9522152
in	O	-1	9522152
mus@@	O	-1	9522152
cular	O	-1	9522152
st@@	O	-1	9522152
ren@@	O	-1	9522152
g@@	O	-1	9522152
th@@	O	-1	9522152
.	O	-1	9522152
S@@	O	-1	9522152
ens@@	O	-1	9522152
ation	O	-1	9522152
in	O	-1	9522152
this	O	-1	9522152
a@@	O	-1	9522152
re@@	O	-1	9522152
a	O	-1	9522152
retur@@	O	-1	9522152
n@@	O	-1	9522152
ed	O	-1	9522152
to	O	-1	9522152
normal	O	-1	9522152
over	O	-1	9522152
the	O	-1	9522152
following	O	-1	9522152
2	O	-1	9522152
week@@	O	-1	9522152
s.	O	-1	9522152
Pro@@	O	-1	9522152
sp@@	O	-1	9522152
ective	O	-1	9522152
mul@@	O	-1	9522152
tic@@	O	-1	9522152
entr@@	O	-1	9522152
e	O	-1	9522152
studies	O	-1	9522152
with	O	-1	9522152
a	O	-1	9522152
larg@@	O	-1	9522152
e	O	-1	9522152
po@@	O	-1	9522152
p@@	O	-1	9522152
ulation	O	-1	9522152
and	O	-1	9522152
a	O	-1	9522152
lon@@	O	-1	9522152
g	O	-1	9522152
follow-up	O	-1	9522152
should	O	-1	9522152
be	O	-1	9522152
performed	O	-1	9522152
in	O	-1	9522152
or@@	O	-1	9522152
der	O	-1	9522152
to	O	-1	9522152
evalu@@	O	-1	9522152
ate	O	-1	9522152
the	O	-1	9522152
incidence	O	-1	9522152
of	O	-1	9522152
this	O	-1	9522152
un@@	O	-1	9522152
us@@	O	-1	9522152
ual	O	-1	9522152
side	O	-1	9522152
effect@@	O	-1	9522152
.	O	-1	9522152
However,	O	-1	9522152
we	O	-1	9522152
suggest	O	-1	9522152
that	O	-1	9522152
a	O	-1	9522152
low	O	-1	9522152
sol@@	O	-1	9522152
u@@	O	-1	9522152
tion	O	-1	9522152
concentration	O	-1	9522152
should	O	-1	9522152
be	O	-1	9522152
pre@@	O	-1	9522152
fer@@	O	-1	9522152
red	O	-1	9522152
for	O	-1	9522152
un@@	O	-1	9522152
il@@	O	-1	9522152
ateral	O	-1	9522152
spinal	O	-1	9522152
anaesthe@@	O	-1	9522152
sia	O	-1	9522152
with	O	-1	9522152
a	O	-1	9522152
hyper@@	O	-1	9522152
bar@@	O	-1	9522152
ic	O	-1	9522152
anaesthe@@	O	-1	9522152
tic	O	-1	9522152
sol@@	O	-1	9522152
u@@	O	-1	9522152
tion	O	-1	9522152
(@@	O	-1	9522152
if	O	-1	9522152
pen@@	O	-1	9522152
c@@	O	-1	9522152
il@@	O	-1	9522152
-@@	O	-1	9522152
po@@	O	-1	9522152
in@@	O	-1	9522152
t	O	-1	9522152
ne@@	O	-1	9522152
ed@@	O	-1	9522152
le	O	-1	9522152
and	O	-1	9522152
s@@	O	-1	9522152
low	O	-1	9522152
injection	O	-1	9522152
rate	O	-1	9522152
are	O	-1	9522152
em@@	O	-1	9522152
p@@	O	-1	9522152
lo@@	O	-1	9522152
y@@	O	-1	9522152
ed@@	O	-1	9522152
),	O	-1	9522152
in	O	-1	9522152
or@@	O	-1	9522152
der	O	-1	9522152
to	O	-1	9522152
minim@@	O	-1	9522152
iz@@	O	-1	9522152
e	O	-1	9522152
the	O	-1	9522152
risk	O	-1	9522152
of	O	-1	9522152
a	O	-1	9522152
lo@@	O	-1	9522152
cal@@	O	-1	9522152
ized	O	-1	9522152
high	O	-1	9522152
pe@@	O	-1	9522152
a@@	O	-1	9522152
k	O	-1	9522152
anaesthe@@	O	-1	9522152
tic	O	-1	9522152
concentr@@	O	-1	9522152
ation,	O	-1	9522152
which	O	-1	9522152
might	O	-1	9522152
le@@	O	-1	9522152
ad	O	-1	9522152
to	O	-1	9522152
a	O	-1	9522152
transi@@	O	-1	9522152
ent	O	-1	9522152
neurolog@@	B-Disease	D009461	9522152
ical	I-Disease	-1	9522152
defic@@	I-Disease	-1	9522152
it	I-Disease	-1	9522152
.	O	-1	9522152

P@@	B-Chemical	D008614	9672936
eth@@	I-Chemical	-1	9672936
idine	I-Chemical	-1	9672936
-@@	O	-1	9672936
associated	O	-1	9672936
seizure	B-Disease	D012640	9672936
in	O	-1	9672936
a	O	-1	9672936
healthy	O	-1	9672936
ad@@	O	-1	9672936
ol@@	O	-1	9672936
es@@	O	-1	9672936
c@@	O	-1	9672936
ent	O	-1	9672936
receiving	O	-1	9672936
pe@@	B-Chemical	D008614	9672936
th@@	I-Chemical	-1	9672936
idine	I-Chemical	-1	9672936
for	O	-1	9672936
postoperative	B-Disease	D010149	9672936
pain	I-Disease	-1	9672936
control@@	O	-1	9672936
.	O	-1	9672936
A	O	-1	9672936
healthy	O	-1	9672936
17@@	O	-1	9672936
-@@	O	-1	9672936
year-old	O	-1	9672936
male	O	-1	9672936
received	O	-1	9672936
standard	O	-1	9672936
inter@@	O	-1	9672936
mit@@	O	-1	9672936
t@@	O	-1	9672936
ent	O	-1	9672936
doses	O	-1	9672936
of	O	-1	9672936
pe@@	B-Chemical	D008614	9672936
th@@	I-Chemical	-1	9672936
idine	I-Chemical	-1	9672936
vi@@	O	-1	9672936
a	O	-1	9672936
a	O	-1	9672936
patient@@	O	-1	9672936
-@@	O	-1	9672936
controlled	O	-1	9672936
analge@@	O	-1	9672936
sia	O	-1	9672936
(P@@	O	-1	9672936
CA@@	O	-1	9672936
)	O	-1	9672936
p@@	O	-1	9672936
um@@	O	-1	9672936
p	O	-1	9672936
for	O	-1	9672936
man@@	O	-1	9672936
ag@@	O	-1	9672936
ement	O	-1	9672936
of	O	-1	9672936
postoperative	B-Disease	D010149	9672936
pain	I-Disease	-1	9672936
control@@	O	-1	9672936
.	O	-1	9672936
Tw@@	O	-1	9672936
ent@@	O	-1	9672936
y-@@	O	-1	9672936
three	O	-1	9672936
h	O	-1	9672936
posto@@	O	-1	9672936
per@@	O	-1	9672936
atively	O	-1	9672936
he	O	-1	9672936
developed	O	-1	9672936
a	O	-1	9672936
b@@	O	-1	9672936
ri@@	O	-1	9672936
e@@	O	-1	9672936
f	O	-1	9672936
sel@@	O	-1	9672936
f@@	O	-1	9672936
-@@	O	-1	9672936
lim@@	O	-1	9672936
ited	O	-1	9672936
seizure	B-Disease	D012640	9672936
.	O	-1	9672936
B@@	O	-1	9672936
oth	O	-1	9672936
plasma	O	-1	9672936
pe@@	B-Chemical	D008614	9672936
th@@	I-Chemical	-1	9672936
idine	I-Chemical	-1	9672936
and	O	-1	9672936
nor@@	B-Chemical	C002752	9672936
pe@@	I-Chemical	-1	9672936
th@@	I-Chemical	-1	9672936
idine	I-Chemical	-1	9672936
were	O	-1	9672936
elevated	O	-1	9672936
in	O	-1	9672936
the	O	-1	9672936
range	O	-1	9672936
associated	O	-1	9672936
with	O	-1	9672936
clinical	O	-1	9672936
man@@	O	-1	9672936
if@@	O	-1	9672936
est@@	O	-1	9672936
ations	O	-1	9672936
of	O	-1	9672936
central	O	-1	9672936
ner@@	O	-1	9672936
v@@	O	-1	9672936
ous	O	-1	9672936
system	O	-1	9672936
ex@@	O	-1	9672936
cit@@	O	-1	9672936
ation.	O	-1	9672936
No	O	-1	9672936
other	O	-1	9672936
risk	O	-1	9672936
factors	O	-1	9672936
for	O	-1	9672936
C@@	O	-1	9672936
N@@	O	-1	9672936
S	O	-1	9672936
toxicity	B-Disease	D064420	9672936
were	O	-1	9672936
identi@@	O	-1	9672936
fi@@	O	-1	9672936
ed.	O	-1	9672936
This	O	-1	9672936
meth@@	O	-1	9672936
od	O	-1	9672936
al@@	O	-1	9672936
low@@	O	-1	9672936
ed	O	-1	9672936
frequent	O	-1	9672936
sel@@	O	-1	9672936
f@@	O	-1	9672936
-@@	O	-1	9672936
dos@@	O	-1	9672936
ing	O	-1	9672936
of	O	-1	9672936
pe@@	B-Chemical	D008614	9672936
th@@	I-Chemical	-1	9672936
idine	I-Chemical	-1	9672936
at	O	-1	9672936
sh@@	O	-1	9672936
ort	O	-1	9672936
time	O	-1	9672936
interv@@	O	-1	9672936
als	O	-1	9672936
and	O	-1	9672936
ra@@	O	-1	9672936
pid	O	-1	9672936
accum@@	O	-1	9672936
ulation	O	-1	9672936
of	O	-1	9672936
pe@@	B-Chemical	D008614	9672936
th@@	I-Chemical	-1	9672936
idine	I-Chemical	-1	9672936
and	O	-1	9672936
nor@@	B-Chemical	C002752	9672936
pe@@	I-Chemical	-1	9672936
th@@	I-Chemical	-1	9672936
idine	I-Chemical	-1	9672936
.	O	-1	9672936
The	O	-1	9672936
ro@@	O	-1	9672936
ut@@	O	-1	9672936
ine	O	-1	9672936
use	O	-1	9672936
of	O	-1	9672936
pe@@	B-Chemical	D008614	9672936
th@@	I-Chemical	-1	9672936
idine	I-Chemical	-1	9672936
vi@@	O	-1	9672936
a	O	-1	9672936
P@@	O	-1	9672936
C@@	O	-1	9672936
A	O	-1	9672936
even	O	-1	9672936
for	O	-1	9672936
a	O	-1	9672936
b@@	O	-1	9672936
ri@@	O	-1	9672936
e@@	O	-1	9672936
f	O	-1	9672936
postoperative	O	-1	9672936
analge@@	O	-1	9672936
sia	O	-1	9672936
should	O	-1	9672936
be	O	-1	9672936
re@@	O	-1	9672936
conside@@	O	-1	9672936
red.	O	-1	9672936

D@@	O	-1	9721172
ru@@	O	-1	9721172
g@@	O	-1	9721172
-@@	O	-1	9721172
associated	O	-1	9721172
ac@@	O	-1	9721172
u@@	O	-1	9721172
te@@	O	-1	9721172
-@@	O	-1	9721172
onset	O	-1	9721172
v@@	B-Disease	D001649	9721172
an@@	I-Disease	-1	9721172
ish@@	I-Disease	-1	9721172
ing	I-Disease	-1	9721172
b@@	I-Disease	-1	9721172
ile	I-Disease	-1	9721172
duc@@	I-Disease	-1	9721172
t	I-Disease	-1	9721172
and	O	-1	9721172
S@@	B-Disease	D013262	9721172
te@@	I-Disease	-1	9721172
ven@@	I-Disease	-1	9721172
s-@@	I-Disease	-1	9721172
J@@	I-Disease	-1	9721172
o@@	I-Disease	-1	9721172
h@@	I-Disease	-1	9721172
n@@	I-Disease	-1	9721172
s@@	I-Disease	-1	9721172
on	I-Disease	-1	9721172
syndrom@@	I-Disease	-1	9721172
es	I-Disease	-1	9721172
in	O	-1	9721172
a	O	-1	9721172
ch@@	O	-1	9721172
il@@	O	-1	9721172
d.	O	-1	9721172
Ac@@	O	-1	9721172
ute	O	-1	9721172
v@@	B-Disease	D001649	9721172
an@@	I-Disease	-1	9721172
ish@@	I-Disease	-1	9721172
ing	I-Disease	-1	9721172
b@@	I-Disease	-1	9721172
ile	I-Disease	-1	9721172
duc@@	I-Disease	-1	9721172
t	I-Disease	-1	9721172
syndrome	O	-1	9721172
is	O	-1	9721172
a	O	-1	9721172
r@@	O	-1	9721172
are	O	-1	9721172
but	O	-1	9721172
est@@	O	-1	9721172
abl@@	O	-1	9721172
ished	O	-1	9721172
cause	O	-1	9721172
of	O	-1	9721172
progressive	O	-1	9721172
cholest@@	B-Disease	D002779	9721172
asis	I-Disease	-1	9721172
in	O	-1	9721172
ad@@	O	-1	9721172
ult@@	O	-1	9721172
s,	O	-1	9721172
is	O	-1	9721172
most	O	-1	9721172
often	O	-1	9721172
drug	O	-1	9721172
or	O	-1	9721172
tox@@	O	-1	9721172
in	O	-1	9721172
rel@@	O	-1	9721172
at@@	O	-1	9721172
ed,	O	-1	9721172
and	O	-1	9721172
is	O	-1	9721172
of	O	-1	9721172
un@@	O	-1	9721172
known	O	-1	9721172
path@@	O	-1	9721172
o@@	O	-1	9721172
gene@@	O	-1	9721172
sis.	O	-1	9721172
It	O	-1	9721172
has	O	-1	9721172
not	O	-1	9721172
been	O	-1	9721172
reported	O	-1	9721172
previously	O	-1	9721172
in	O	-1	9721172
child@@	O	-1	9721172
ren@@	O	-1	9721172
.	O	-1	9721172
S@@	B-Disease	D013262	9721172
te@@	I-Disease	-1	9721172
ven@@	I-Disease	-1	9721172
s-@@	I-Disease	-1	9721172
J@@	I-Disease	-1	9721172
o@@	I-Disease	-1	9721172
h@@	I-Disease	-1	9721172
n@@	I-Disease	-1	9721172
s@@	I-Disease	-1	9721172
on	I-Disease	-1	9721172
syndrome	I-Disease	-1	9721172
is	O	-1	9721172
a	O	-1	9721172
we@@	O	-1	9721172
ll@@	O	-1	9721172
-@@	O	-1	9721172
reco@@	O	-1	9721172
gn@@	O	-1	9721172
ized	O	-1	9721172
immun@@	O	-1	9721172
e	O	-1	9721172
comple@@	O	-1	9721172
x@@	O	-1	9721172
-@@	O	-1	9721172
mediated	O	-1	9721172
hyper@@	B-Disease	D004342	9721172
sensitivity	I-Disease	-1	9721172
reaction	O	-1	9721172
that	O	-1	9721172
aff@@	O	-1	9721172
ects	O	-1	9721172
all	O	-1	9721172
age	O	-1	9721172
group@@	O	-1	9721172
s,	O	-1	9721172
is	O	-1	9721172
drug	O	-1	9721172
or	O	-1	9721172
inf@@	B-Disease	D007239	9721172
ection	I-Disease	-1	9721172
induc@@	O	-1	9721172
ed,	O	-1	9721172
and	O	-1	9721172
has	O	-1	9721172
cl@@	O	-1	9721172
as@@	O	-1	9721172
sic	O	-1	9721172
system@@	O	-1	9721172
ic@@	O	-1	9721172
,	O	-1	9721172
m@@	O	-1	9721172
u@@	O	-1	9721172
co@@	O	-1	9721172
sal@@	O	-1	9721172
,	O	-1	9721172
and	O	-1	9721172
der@@	O	-1	9721172
mat@@	O	-1	9721172
ologic	O	-1	9721172
man@@	O	-1	9721172
if@@	O	-1	9721172
est@@	O	-1	9721172
ations.	O	-1	9721172
A	O	-1	9721172
previously	O	-1	9721172
healthy	O	-1	9721172
ch@@	O	-1	9721172
il@@	O	-1	9721172
d	O	-1	9721172
who	O	-1	9721172
developed	O	-1	9721172
ac@@	O	-1	9721172
u@@	O	-1	9721172
te@@	O	-1	9721172
,	O	-1	9721172
se@@	O	-1	9721172
ve@@	O	-1	9721172
re,	O	-1	9721172
ra@@	O	-1	9721172
pid@@	O	-1	9721172
ly	O	-1	9721172
progressive	O	-1	9721172
v@@	B-Disease	D001649	9721172
an@@	I-Disease	-1	9721172
ish@@	I-Disease	-1	9721172
ing	I-Disease	-1	9721172
b@@	I-Disease	-1	9721172
ile	I-Disease	-1	9721172
duc@@	I-Disease	-1	9721172
t	I-Disease	-1	9721172
syndrome	I-Disease	-1	9721172
sh@@	O	-1	9721172
ort@@	O	-1	9721172
ly	O	-1	9721172
after	O	-1	9721172
S@@	B-Disease	D013262	9721172
te@@	I-Disease	-1	9721172
ven@@	I-Disease	-1	9721172
s-@@	I-Disease	-1	9721172
J@@	I-Disease	-1	9721172
o@@	I-Disease	-1	9721172
h@@	I-Disease	-1	9721172
n@@	I-Disease	-1	9721172
s@@	I-Disease	-1	9721172
on	I-Disease	-1	9721172
syndrome	I-Disease	-1	9721172
is	O	-1	9721172
descri@@	O	-1	9721172
be@@	O	-1	9721172
d@@	O	-1	9721172
;	O	-1	9721172
this	O	-1	9721172
was	O	-1	9721172
tempor@@	O	-1	9721172
ally	O	-1	9721172
associated	O	-1	9721172
with	O	-1	9721172
i@@	B-Chemical	D007052	9721172
bu@@	I-Chemical	-1	9721172
prof@@	I-Chemical	-1	9721172
en	I-Chemical	-1	9721172
use.	O	-1	9721172
D@@	O	-1	9721172
es@@	O	-1	9721172
pit@@	O	-1	9721172
e	O	-1	9721172
therapy	O	-1	9721172
with	O	-1	9721172
ur@@	B-Chemical	D014580	9721172
so@@	I-Chemical	-1	9721172
de@@	I-Chemical	-1	9721172
oxy@@	I-Chemical	-1	9721172
chol@@	I-Chemical	-1	9721172
ic	I-Chemical	-1	9721172
acid	I-Chemical	-1	9721172
,	O	-1	9721172
pre@@	B-Chemical	D011241	9721172
d@@	I-Chemical	-1	9721172
n@@	I-Chemical	-1	9721172
is@@	I-Chemical	-1	9721172
one	I-Chemical	-1	9721172
,	O	-1	9721172
and	O	-1	9721172
then	O	-1	9721172
tacrolimus	B-Chemical	D016559	9721172
,	O	-1	9721172
h@@	O	-1	9721172
er	O	-1	9721172
cholest@@	B-Disease	D002779	9721172
atic	I-Disease	-1	9721172
disease	I-Disease	-1	9721172
was	O	-1	9721172
un@@	O	-1	9721172
rel@@	O	-1	9721172
ent@@	O	-1	9721172
ing,	O	-1	9721172
with	O	-1	9721172
cir@@	B-Disease	D005355	9721172
r@@	I-Disease	-1	9721172
ho@@	I-Disease	-1	9721172
sis	I-Disease	-1	9721172
shown	O	-1	9721172
by	O	-1	9721172
biop@@	O	-1	9721172
sy	O	-1	9721172
6	O	-1	9721172
months	O	-1	9721172
after	O	-1	9721172
present@@	O	-1	9721172
ation.	O	-1	9721172
This	O	-1	9721172
case	O	-1	9721172
doc@@	O	-1	9721172
um@@	O	-1	9721172
ents	O	-1	9721172
acute	O	-1	9721172
drug@@	O	-1	9721172
-@@	O	-1	9721172
related	O	-1	9721172
v@@	B-Disease	D001649	9721172
an@@	I-Disease	-1	9721172
ish@@	I-Disease	-1	9721172
ing	I-Disease	-1	9721172
b@@	I-Disease	-1	9721172
ile	I-Disease	-1	9721172
duc@@	I-Disease	-1	9721172
t	I-Disease	-1	9721172
syndrome	I-Disease	-1	9721172
in	O	-1	9721172
the	O	-1	9721172
pe@@	O	-1	9721172
di@@	O	-1	9721172
atric	O	-1	9721172
age	O	-1	9721172
group	O	-1	9721172
and	O	-1	9721172
suggests	O	-1	9721172
s@@	O	-1	9721172
ha@@	O	-1	9721172
red	O	-1	9721172
immun@@	O	-1	9721172
e	O	-1	9721172
mechanisms	O	-1	9721172
in	O	-1	9721172
the	O	-1	9721172
path@@	O	-1	9721172
o@@	O	-1	9721172
genesis	O	-1	9721172
of	O	-1	9721172
both	O	-1	9721172
S@@	B-Disease	D013262	9721172
te@@	I-Disease	-1	9721172
ven@@	I-Disease	-1	9721172
s-@@	I-Disease	-1	9721172
J@@	I-Disease	-1	9721172
o@@	I-Disease	-1	9721172
h@@	I-Disease	-1	9721172
n@@	I-Disease	-1	9721172
s@@	I-Disease	-1	9721172
on	I-Disease	-1	9721172
syndrome	I-Disease	-1	9721172
and	O	-1	9721172
v@@	B-Disease	D001649	9721172
an@@	I-Disease	-1	9721172
ish@@	I-Disease	-1	9721172
ing	I-Disease	-1	9721172
b@@	I-Disease	-1	9721172
ile	I-Disease	-1	9721172
duc@@	I-Disease	-1	9721172
t	I-Disease	-1	9721172
syndrome	I-Disease	-1	9721172
.	O	-1	9721172

H@@	O	-1	9727773
i@@	O	-1	9727773
gh	O	-1	9727773
incidence	O	-1	9727773
of	O	-1	9727773
prim@@	B-Disease	D006976	9727773
ary	I-Disease	-1	9727773
pulmonary	I-Disease	-1	9727773
hypertension	I-Disease	-1	9727773
associated	O	-1	9727773
with	O	-1	9727773
appe@@	B-Chemical	D001067	9727773
ti@@	I-Chemical	-1	9727773
te	I-Chemical	-1	9727773
sup@@	I-Chemical	-1	9727773
press@@	I-Chemical	-1	9727773
ants	I-Chemical	-1	9727773
in	O	-1	9727773
B@@	O	-1	9727773
el@@	O	-1	9727773
gi@@	O	-1	9727773
um@@	O	-1	9727773
.	O	-1	9727773
P@@	B-Disease	D006976	9727773
ri@@	I-Disease	-1	9727773
m@@	I-Disease	-1	9727773
ary	I-Disease	-1	9727773
pulmonary	I-Disease	-1	9727773
hypertension	I-Disease	-1	9727773
is	O	-1	9727773
a	O	-1	9727773
ra@@	O	-1	9727773
re,	O	-1	9727773
progressive	O	-1	9727773
and	O	-1	9727773
inc@@	O	-1	9727773
ur@@	O	-1	9727773
able	O	-1	9727773
diseas@@	O	-1	9727773
e,	O	-1	9727773
which	O	-1	9727773
has	O	-1	9727773
been	O	-1	9727773
associated	O	-1	9727773
with	O	-1	9727773
the	O	-1	9727773
int@@	O	-1	9727773
ake	O	-1	9727773
of	O	-1	9727773
appe@@	B-Chemical	D001067	9727773
ti@@	I-Chemical	-1	9727773
te	I-Chemical	-1	9727773
sup@@	I-Chemical	-1	9727773
press@@	I-Chemical	-1	9727773
ant	I-Chemical	-1	9727773
drug@@	O	-1	9727773
s.	O	-1	9727773
The	O	-1	9727773
import@@	O	-1	9727773
ance	O	-1	9727773
of	O	-1	9727773
this	O	-1	9727773
association	O	-1	9727773
was	O	-1	9727773
evaluated	O	-1	9727773
in	O	-1	9727773
B@@	O	-1	9727773
el@@	O	-1	9727773
gi@@	O	-1	9727773
um	O	-1	9727773
while	O	-1	9727773
this	O	-1	9727773
coun@@	O	-1	9727773
tr@@	O	-1	9727773
y	O	-1	9727773
sti@@	O	-1	9727773
ll	O	-1	9727773
had	O	-1	9727773
no	O	-1	9727773
re@@	O	-1	9727773
stric@@	O	-1	9727773
tion	O	-1	9727773
on	O	-1	9727773
the	O	-1	9727773
prescri@@	O	-1	9727773
ption	O	-1	9727773
of	O	-1	9727773
appe@@	B-Chemical	D001067	9727773
ti@@	I-Chemical	-1	9727773
te	I-Chemical	-1	9727773
sup@@	I-Chemical	-1	9727773
press@@	I-Chemical	-1	9727773
ants	I-Chemical	-1	9727773
.	O	-1	9727773
Th@@	O	-1	9727773
ir@@	O	-1	9727773
ty-@@	O	-1	9727773
five	O	-1	9727773
patients	O	-1	9727773
with	O	-1	9727773
prim@@	B-Disease	D006976	9727773
ary	I-Disease	-1	9727773
pulmonary	I-Disease	-1	9727773
hypertension	I-Disease	-1	9727773
and	O	-1	9727773
8@@	O	-1	9727773
5	O	-1	9727773
mat@@	O	-1	9727773
ch@@	O	-1	9727773
ed	O	-1	9727773
controls	O	-1	9727773
were	O	-1	9727773
rec@@	O	-1	9727773
ru@@	O	-1	9727773
ited	O	-1	9727773
over	O	-1	9727773
3@@	O	-1	9727773
2	O	-1	9727773
months	O	-1	9727773
(1@@	O	-1	9727773
9@@	O	-1	9727773
9@@	O	-1	9727773
2-@@	O	-1	9727773
19@@	O	-1	9727773
9@@	O	-1	9727773
4@@	O	-1	9727773
)	O	-1	9727773
in	O	-1	9727773
B@@	O	-1	9727773
el@@	O	-1	9727773
gi@@	O	-1	9727773
um@@	O	-1	9727773
.	O	-1	9727773
E@@	O	-1	9727773
x@@	O	-1	9727773
pos@@	O	-1	9727773
ure	O	-1	9727773
to	O	-1	9727773
appe@@	B-Chemical	D001067	9727773
ti@@	I-Chemical	-1	9727773
te@@	I-Chemical	-1	9727773
-@@	I-Chemical	-1	9727773
sup@@	I-Chemical	-1	9727773
press@@	I-Chemical	-1	9727773
ants	I-Chemical	-1	9727773
was	O	-1	9727773
assessed	O	-1	9727773
on	O	-1	9727773
the	O	-1	9727773
b@@	O	-1	9727773
asis	O	-1	9727773
of	O	-1	9727773
hospit@@	O	-1	9727773
al	O	-1	9727773
recor@@	O	-1	9727773
ds	O	-1	9727773
and	O	-1	9727773
stand@@	O	-1	9727773
ardi@@	O	-1	9727773
zed	O	-1	9727773
inter@@	O	-1	9727773
vie@@	O	-1	9727773
w@@	O	-1	9727773
.	O	-1	9727773
Tw@@	O	-1	9727773
ent@@	O	-1	9727773
y-@@	O	-1	9727773
three	O	-1	9727773
of	O	-1	9727773
the	O	-1	9727773
patients	O	-1	9727773
had	O	-1	9727773
previously	O	-1	9727773
tak@@	O	-1	9727773
en	O	-1	9727773
appe@@	B-Chemical	D001067	9727773
ti@@	I-Chemical	-1	9727773
te	I-Chemical	-1	9727773
sup@@	I-Chemical	-1	9727773
press@@	I-Chemical	-1	9727773
ants	I-Chemical	-1	9727773
,	O	-1	9727773
main@@	O	-1	9727773
ly	O	-1	9727773
f@@	B-Chemical	D005277	9727773
en@@	I-Chemical	-1	9727773
f@@	I-Chemical	-1	9727773
lur@@	I-Chemical	-1	9727773
amin@@	I-Chemical	-1	9727773
es	I-Chemical	-1	9727773
,	O	-1	9727773
as	O	-1	9727773
compared	O	-1	9727773
with	O	-1	9727773
only	O	-1	9727773
5	O	-1	9727773
of	O	-1	9727773
the	O	-1	9727773
controls	O	-1	9727773
(6@@	O	-1	9727773
6	O	-1	9727773
versus	O	-1	9727773
6@@	O	-1	9727773
%,	O	-1	9727773
p@@	O	-1	9727773
<@@	O	-1	9727773
0.00@@	O	-1	9727773
0@@	O	-1	9727773
1).	O	-1	9727773
F@@	O	-1	9727773
i@@	O	-1	9727773
ve	O	-1	9727773
patients	O	-1	9727773
di@@	O	-1	9727773
ed	O	-1	9727773
before	O	-1	9727773
the	O	-1	9727773
inter@@	O	-1	9727773
vie@@	O	-1	9727773
w@@	O	-1	9727773
,	O	-1	9727773
all	O	-1	9727773
of	O	-1	9727773
the@@	O	-1	9727773
m	O	-1	9727773
had	O	-1	9727773
tak@@	O	-1	9727773
en	O	-1	9727773
appe@@	B-Chemical	D001067	9727773
ti@@	I-Chemical	-1	9727773
te	I-Chemical	-1	9727773
sup@@	I-Chemical	-1	9727773
press@@	I-Chemical	-1	9727773
ants	I-Chemical	-1	9727773
.	O	-1	9727773
In	O	-1	9727773
8	O	-1	9727773
patients	O	-1	9727773
the	O	-1	9727773
diagnosis	O	-1	9727773
of	O	-1	9727773
prim@@	B-Disease	D006976	9727773
ary	I-Disease	-1	9727773
pulmonary	I-Disease	-1	9727773
hypertension	I-Disease	-1	9727773
was	O	-1	9727773
unc@@	O	-1	9727773
er@@	O	-1	9727773
t@@	O	-1	9727773
ain@@	O	-1	9727773
,	O	-1	9727773
5	O	-1	9727773
of	O	-1	9727773
the@@	O	-1	9727773
m	O	-1	9727773
had	O	-1	9727773
tak@@	O	-1	9727773
en	O	-1	9727773
appe@@	B-Chemical	D001067	9727773
ti@@	I-Chemical	-1	9727773
te	I-Chemical	-1	9727773
sup@@	I-Chemical	-1	9727773
press@@	I-Chemical	-1	9727773
ants	I-Chemical	-1	9727773
.	O	-1	9727773
The	O	-1	9727773
patients	O	-1	9727773
who	O	-1	9727773
had	O	-1	9727773
been	O	-1	9727773
exposed	O	-1	9727773
to	O	-1	9727773
appe@@	B-Chemical	D001067	9727773
ti@@	I-Chemical	-1	9727773
te	I-Chemical	-1	9727773
sup@@	I-Chemical	-1	9727773
press@@	I-Chemical	-1	9727773
ants	I-Chemical	-1	9727773
ten@@	O	-1	9727773
ded	O	-1	9727773
to	O	-1	9727773
be	O	-1	9727773
on	O	-1	9727773
average	O	-1	9727773
more	O	-1	9727773
se@@	O	-1	9727773
ve@@	O	-1	9727773
re@@	O	-1	9727773
ly	O	-1	9727773
ill@@	O	-1	9727773
,	O	-1	9727773
and	O	-1	9727773
to	O	-1	9727773
have	O	-1	9727773
a	O	-1	9727773
sh@@	O	-1	9727773
or@@	O	-1	9727773
ter	O	-1	9727773
median	O	-1	9727773
del@@	O	-1	9727773
ay	O	-1	9727773
between	O	-1	9727773
onset	O	-1	9727773
of	O	-1	9727773
symptoms	O	-1	9727773
and	O	-1	9727773
diagno@@	O	-1	9727773
sis.	O	-1	9727773
A	O	-1	9727773
pol@@	O	-1	9727773
ic@@	O	-1	9727773
y	O	-1	9727773
of	O	-1	9727773
un@@	O	-1	9727773
re@@	O	-1	9727773
stric@@	O	-1	9727773
ted	O	-1	9727773
prescri@@	O	-1	9727773
ption	O	-1	9727773
of	O	-1	9727773
appe@@	B-Chemical	D001067	9727773
ti@@	I-Chemical	-1	9727773
te	I-Chemical	-1	9727773
sup@@	I-Chemical	-1	9727773
press@@	I-Chemical	-1	9727773
ants	I-Chemical	-1	9727773
may	O	-1	9727773
le@@	O	-1	9727773
ad	O	-1	9727773
to	O	-1	9727773
a	O	-1	9727773
high	O	-1	9727773
incidence	O	-1	9727773
of	O	-1	9727773
associated	O	-1	9727773
prim@@	B-Disease	D006976	9727773
ary	I-Disease	-1	9727773
pulmonary	I-Disease	-1	9727773
hypertension	I-Disease	-1	9727773
.	O	-1	9727773
In@@	O	-1	9727773
tak@@	O	-1	9727773
e	O	-1	9727773
of	O	-1	9727773
appe@@	B-Chemical	D001067	9727773
ti@@	I-Chemical	-1	9727773
te	I-Chemical	-1	9727773
sup@@	I-Chemical	-1	9727773
press@@	I-Chemical	-1	9727773
ants	I-Chemical	-1	9727773
may	O	-1	9727773
ac@@	O	-1	9727773
ce@@	O	-1	9727773
l@@	O	-1	9727773
er@@	O	-1	9727773
ate	O	-1	9727773
the	O	-1	9727773
progres@@	O	-1	9727773
sion	O	-1	9727773
of	O	-1	9727773
the	O	-1	9727773
disease.	O	-1	9727773

C@@	B-Disease	D002819	9754849
ho@@	I-Disease	-1	9754849
re@@	I-Disease	-1	9754849
o@@	I-Disease	-1	9754849
a@@	I-Disease	-1	9754849
the@@	I-Disease	-1	9754849
to@@	I-Disease	-1	9754849
id	I-Disease	-1	9754849
mo@@	I-Disease	-1	9754849
ve@@	I-Disease	-1	9754849
ments	I-Disease	-1	9754849
associated	O	-1	9754849
with	O	-1	9754849
ra@@	O	-1	9754849
pid	O	-1	9754849
adjust@@	O	-1	9754849
ment	O	-1	9754849
to	O	-1	9754849
meth@@	B-Chemical	D008691	9754849
ad@@	I-Chemical	-1	9754849
one	I-Chemical	-1	9754849
.	O	-1	9754849
C@@	B-Disease	D002819	9754849
ho@@	I-Disease	-1	9754849
re@@	I-Disease	-1	9754849
ati@@	I-Disease	-1	9754849
form	I-Disease	-1	9754849
hyper@@	I-Disease	-1	9754849
kine@@	I-Disease	-1	9754849
si@@	I-Disease	-1	9754849
as	I-Disease	-1	9754849
C@@	B-Disease	D006948	9754849
ho@@	I-Disease	-1	9754849
re@@	I-Disease	-1	9754849
ati@@	I-Disease	-1	9754849
form	I-Disease	-1	9754849
hyper@@	I-Disease	-1	9754849
kine@@	I-Disease	-1	9754849
si@@	I-Disease	-1	9754849
as	I-Disease	-1	9754849
are	O	-1	9754849
known	O	-1	9754849
to	O	-1	9754849
be	O	-1	9754849
oc@@	O	-1	9754849
ca@@	O	-1	9754849
sion@@	O	-1	9754849
al	O	-1	9754849
mo@@	B-Disease	D020820	9754849
vement	I-Disease	-1	9754849
abnormal@@	I-Disease	-1	9754849
ities	I-Disease	-1	9754849
during	O	-1	9754849
in@@	O	-1	9754849
toxic@@	O	-1	9754849
ations	O	-1	9754849
with	O	-1	9754849
cocaine	B-Chemical	D003042	9754849
but	O	-1	9754849
not	O	-1	9754849
o@@	O	-1	9754849
pi@@	O	-1	9754849
at@@	O	-1	9754849
es.	O	-1	9754849
This	O	-1	9754849
is	O	-1	9754849
a	O	-1	9754849
case	O	-1	9754849
report	O	-1	9754849
of	O	-1	9754849
eu@@	O	-1	9754849
ph@@	O	-1	9754849
or@@	O	-1	9754849
ia	O	-1	9754849
and	O	-1	9754849
ch@@	B-Disease	D002819	9754849
ore@@	I-Disease	-1	9754849
o@@	I-Disease	-1	9754849
a@@	I-Disease	-1	9754849
the@@	I-Disease	-1	9754849
to@@	I-Disease	-1	9754849
id	I-Disease	-1	9754849
mo@@	I-Disease	-1	9754849
ve@@	I-Disease	-1	9754849
ments	I-Disease	-1	9754849
both	O	-1	9754849
transi@@	O	-1	9754849
ently	O	-1	9754849
induced	O	-1	9754849
by	O	-1	9754849
ra@@	O	-1	9754849
pid	O	-1	9754849
adjust@@	O	-1	9754849
ment	O	-1	9754849
to	O	-1	9754849
the	O	-1	9754849
selective	O	-1	9754849
m@@	O	-1	9754849
u@@	O	-1	9754849
-@@	O	-1	9754849
o@@	O	-1	9754849
pi@@	O	-1	9754849
oid	O	-1	9754849
receptor	O	-1	9754849
agon@@	O	-1	9754849
ist	O	-1	9754849
meth@@	B-Chemical	D008691	9754849
ad@@	I-Chemical	-1	9754849
one	I-Chemical	-1	9754849
in	O	-1	9754849
an	O	-1	9754849
in@@	O	-1	9754849
patient	O	-1	9754849
previously	O	-1	9754849
ab@@	O	-1	9754849
using	O	-1	9754849
h@@	B-Chemical	D003932	9754849
ero@@	I-Chemical	-1	9754849
ine	I-Chemical	-1	9754849
and	O	-1	9754849
cocaine	B-Chemical	D003042	9754849
.	O	-1	9754849
In	O	-1	9754849
addi@@	O	-1	9754849
tion,	O	-1	9754849
min@@	O	-1	9754849
or	O	-1	9754849
E@@	O	-1	9754849
E@@	O	-1	9754849
G	O	-1	9754849
abnormal@@	O	-1	9754849
ities	O	-1	9754849
occur@@	O	-1	9754849
red.	O	-1	9754849
P@@	O	-1	9754849
os@@	O	-1	9754849
sible	O	-1	9754849
underlying	O	-1	9754849
neuro@@	O	-1	9754849
bio@@	O	-1	9754849
log@@	O	-1	9754849
ical	O	-1	9754849
phen@@	O	-1	9754849
om@@	O	-1	9754849
en@@	O	-1	9754849
a	O	-1	9754849
are	O	-1	9754849
discus@@	O	-1	9754849
sed.	O	-1	9754849

C@@	B-Chemical	D003042	10365197
oc@@	I-Chemical	-1	10365197
aine	I-Chemical	-1	10365197
-induced	O	-1	10365197
mo@@	B-Disease	D019964	10365197
od	I-Disease	-1	10365197
disor@@	I-Disease	-1	10365197
der	I-Disease	-1	10365197
:	O	-1	10365197
prev@@	O	-1	10365197
al@@	O	-1	10365197
ence	O	-1	10365197
rat@@	O	-1	10365197
es	O	-1	10365197
and	O	-1	10365197
psych@@	B-Disease	D001523	10365197
i@@	I-Disease	-1	10365197
atric	I-Disease	-1	10365197
symptoms	O	-1	10365197
in	O	-1	10365197
an	O	-1	10365197
out@@	O	-1	10365197
patient	O	-1	10365197
cocaine	B-Chemical	D003042	10365197
-@@	O	-1	10365197
dependent	O	-1	10365197
sam@@	O	-1	10365197
ple@@	O	-1	10365197
.	O	-1	10365197
This	O	-1	10365197
pap@@	O	-1	10365197
er	O	-1	10365197
at@@	O	-1	10365197
tem@@	O	-1	10365197
pt@@	O	-1	10365197
s	O	-1	10365197
to	O	-1	10365197
ex@@	O	-1	10365197
amine	O	-1	10365197
and	O	-1	10365197
compar@@	O	-1	10365197
e	O	-1	10365197
prev@@	O	-1	10365197
al@@	O	-1	10365197
ence	O	-1	10365197
rat@@	O	-1	10365197
es	O	-1	10365197
and	O	-1	10365197
sympto@@	O	-1	10365197
m	O	-1	10365197
pat@@	O	-1	10365197
tern@@	O	-1	10365197
s	O	-1	10365197
of	O	-1	10365197
D@@	O	-1	10365197
S@@	O	-1	10365197
M	O	-1	10365197
subst@@	O	-1	10365197
ance@@	O	-1	10365197
-induced	O	-1	10365197
and	O	-1	10365197
other	O	-1	10365197
mo@@	B-Disease	D019964	10365197
od	I-Disease	-1	10365197
disorder@@	I-Disease	-1	10365197
s	I-Disease	-1	10365197
.	O	-1	10365197
2@@	O	-1	10365197
4@@	O	-1	10365197
3	O	-1	10365197
cocaine	B-Chemical	D003042	10365197
-@@	O	-1	10365197
dependent	O	-1	10365197
out@@	O	-1	10365197
patients	O	-1	10365197
with	O	-1	10365197
cocaine	B-Chemical	D003042	10365197
-induced	O	-1	10365197
mo@@	B-Disease	D019964	10365197
od	I-Disease	-1	10365197
disor@@	I-Disease	-1	10365197
der	I-Disease	-1	10365197
(	O	-1	10365197
CI@@	B-Disease	D019970	10365197
M@@	I-Disease	-1	10365197
D	I-Disease	-1	10365197
),	O	-1	10365197
other	O	-1	10365197
mo@@	B-Disease	D019964	10365197
od	I-Disease	-1	10365197
disorder@@	I-Disease	-1	10365197
s	I-Disease	-1	10365197
,	O	-1	10365197
or	O	-1	10365197
no	O	-1	10365197
mo@@	B-Disease	D019964	10365197
od	I-Disease	-1	10365197
disor@@	I-Disease	-1	10365197
der	I-Disease	-1	10365197
were	O	-1	10365197
compared	O	-1	10365197
on	O	-1	10365197
meas@@	O	-1	10365197
ures	O	-1	10365197
of	O	-1	10365197
psych@@	B-Disease	D001523	10365197
i@@	I-Disease	-1	10365197
atric	I-Disease	-1	10365197
symptom@@	O	-1	10365197
s.	O	-1	10365197
The	O	-1	10365197
prev@@	O	-1	10365197
al@@	O	-1	10365197
ence	O	-1	10365197
rate	O	-1	10365197
for	O	-1	10365197
CI@@	B-Disease	D019970	10365197
M@@	I-Disease	-1	10365197
D	I-Disease	-1	10365197
was	O	-1	10365197
12@@	O	-1	10365197
%	O	-1	10365197
at	O	-1	10365197
basel@@	O	-1	10365197
ine.	O	-1	10365197
In@@	O	-1	10365197
tro@@	O	-1	10365197
duction	O	-1	10365197
of	O	-1	10365197
the	O	-1	10365197
D@@	O	-1	10365197
S@@	O	-1	10365197
M@@	O	-1	10365197
-@@	O	-1	10365197
IV	O	-1	10365197
diagnosis	O	-1	10365197
of	O	-1	10365197
CI@@	B-Disease	D019970	10365197
M@@	I-Disease	-1	10365197
D	I-Disease	-1	10365197
did	O	-1	10365197
not	O	-1	10365197
subst@@	O	-1	10365197
anti@@	O	-1	10365197
ally	O	-1	10365197
aff@@	O	-1	10365197
ect	O	-1	10365197
rat@@	O	-1	10365197
es	O	-1	10365197
of	O	-1	10365197
the	O	-1	10365197
other	O	-1	10365197
de@@	B-Disease	D003866	10365197
pressive	I-Disease	-1	10365197
disorder@@	I-Disease	-1	10365197
s	I-Disease	-1	10365197
.	O	-1	10365197
Patients	O	-1	10365197
with	O	-1	10365197
CI@@	B-Disease	D019970	10365197
M@@	I-Disease	-1	10365197
D	I-Disease	-1	10365197
had	O	-1	10365197
sympto@@	O	-1	10365197
m	O	-1	10365197
severity	O	-1	10365197
levels	O	-1	10365197
between	O	-1	10365197
those	O	-1	10365197
of	O	-1	10365197
patients	O	-1	10365197
with	O	-1	10365197
and	O	-1	10365197
without	O	-1	10365197
a	O	-1	10365197
mo@@	B-Disease	D019964	10365197
od	I-Disease	-1	10365197
disor@@	I-Disease	-1	10365197
der	I-Disease	-1	10365197
.	O	-1	10365197
These	O	-1	10365197
findings	O	-1	10365197
suggest	O	-1	10365197
some	O	-1	10365197
val@@	O	-1	10365197
idity	O	-1	10365197
for	O	-1	10365197
the	O	-1	10365197
new	O	-1	10365197
D@@	O	-1	10365197
S@@	O	-1	10365197
M@@	O	-1	10365197
-@@	O	-1	10365197
IV	O	-1	10365197
diagnosis	O	-1	10365197
of	O	-1	10365197
CI@@	B-Disease	D019970	10365197
M@@	I-Disease	-1	10365197
D	I-Disease	-1	10365197
,	O	-1	10365197
but	O	-1	10365197
also	O	-1	10365197
suggest	O	-1	10365197
that	O	-1	10365197
it	O	-1	10365197
requ@@	O	-1	10365197
i@@	O	-1	10365197
res	O	-1	10365197
further	O	-1	10365197
spec@@	O	-1	10365197
ification	O	-1	10365197
and	O	-1	10365197
re@@	O	-1	10365197
plic@@	O	-1	10365197
ation.	O	-1	10365197

H@@	B-Disease	D006461	10704919
em@@	I-Disease	-1	10704919
oly@@	I-Disease	-1	10704919
sis	I-Disease	-1	10704919
of	O	-1	10704919
human	O	-1	10704919
erythro@@	O	-1	10704919
cy@@	O	-1	10704919
tes	O	-1	10704919
induced	O	-1	10704919
by	O	-1	10704919
t@@	B-Chemical	D013629	10704919
am@@	I-Chemical	-1	10704919
oxif@@	I-Chemical	-1	10704919
en	I-Chemical	-1	10704919
is	O	-1	10704919
related	O	-1	10704919
to	O	-1	10704919
dis@@	O	-1	10704919
ru@@	O	-1	10704919
ption	O	-1	10704919
of	O	-1	10704919
membran@@	O	-1	10704919
e	O	-1	10704919
struct@@	O	-1	10704919
ure.	O	-1	10704919
T@@	B-Chemical	D013629	10704919
am@@	I-Chemical	-1	10704919
oxif@@	I-Chemical	-1	10704919
en	I-Chemical	-1	10704919
(	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
),	O	-1	10704919
the	O	-1	10704919
anti@@	O	-1	10704919
est@@	O	-1	10704919
ro@@	O	-1	10704919
genic	O	-1	10704919
drug	O	-1	10704919
most	O	-1	10704919
wi@@	O	-1	10704919
de@@	O	-1	10704919
ly	O	-1	10704919
prescri@@	O	-1	10704919
bed	O	-1	10704919
in	O	-1	10704919
the	O	-1	10704919
chemotherapy	O	-1	10704919
of	O	-1	10704919
b@@	B-Disease	D001943	10704919
reas@@	I-Disease	-1	10704919
t	I-Disease	-1	10704919
cancer	I-Disease	-1	10704919
,	O	-1	10704919
induc@@	O	-1	10704919
es	O	-1	10704919
changes	O	-1	10704919
in	O	-1	10704919
normal	O	-1	10704919
dis@@	O	-1	10704919
co@@	O	-1	10704919
id	O	-1	10704919
sh@@	O	-1	10704919
ap@@	O	-1	10704919
e	O	-1	10704919
of	O	-1	10704919
erythro@@	O	-1	10704919
cy@@	O	-1	10704919
tes	O	-1	10704919
and	O	-1	10704919
hemolytic	B-Disease	D000743	10704919
anemia	I-Disease	-1	10704919
.	O	-1	10704919
This	O	-1	10704919
wor@@	O	-1	10704919
k	O	-1	10704919
evalu@@	O	-1	10704919
ates	O	-1	10704919
the	O	-1	10704919
effects	O	-1	10704919
of	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
on	O	-1	10704919
isol@@	O	-1	10704919
ated	O	-1	10704919
human	O	-1	10704919
erythro@@	O	-1	10704919
cy@@	O	-1	10704919
t@@	O	-1	10704919
es,	O	-1	10704919
at@@	O	-1	10704919
tem@@	O	-1	10704919
pt@@	O	-1	10704919
ing	O	-1	10704919
to	O	-1	10704919
identi@@	O	-1	10704919
f@@	O	-1	10704919
y	O	-1	10704919
the	O	-1	10704919
underlying	O	-1	10704919
mechanisms	O	-1	10704919
on	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
-induced	O	-1	10704919
hemolytic	B-Disease	D000743	10704919
anemia	I-Disease	-1	10704919
and	O	-1	10704919
the	O	-1	10704919
invol@@	O	-1	10704919
vement	O	-1	10704919
of	O	-1	10704919
bio@@	O	-1	10704919
membran@@	O	-1	10704919
es	O	-1	10704919
in	O	-1	10704919
its	O	-1	10704919
cyto@@	O	-1	10704919
st@@	O	-1	10704919
atic	O	-1	10704919
action	O	-1	10704919
mechanis@@	O	-1	10704919
m@@	O	-1	10704919
s.	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
induc@@	O	-1	10704919
es	O	-1	10704919
hemoly@@	B-Disease	D006461	10704919
sis	I-Disease	-1	10704919
of	O	-1	10704919
erythro@@	O	-1	10704919
cy@@	O	-1	10704919
tes	O	-1	10704919
as	O	-1	10704919
a	O	-1	10704919
function	O	-1	10704919
of	O	-1	10704919
concentr@@	O	-1	10704919
ation.	O	-1	10704919
The	O	-1	10704919
exten@@	O	-1	10704919
sion	O	-1	10704919
of	O	-1	10704919
hemoly@@	B-Disease	D006461	10704919
sis	I-Disease	-1	10704919
is	O	-1	10704919
vari@@	O	-1	10704919
able	O	-1	10704919
with	O	-1	10704919
erythro@@	O	-1	10704919
cy@@	O	-1	10704919
te	O	-1	10704919
sam@@	O	-1	10704919
pl@@	O	-1	10704919
es,	O	-1	10704919
but	O	-1	10704919
1@@	O	-1	10704919
2.@@	O	-1	10704919
5	O	-1	10704919
micro@@	O	-1	10704919
M	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
induc@@	O	-1	10704919
es	O	-1	10704919
total	O	-1	10704919
hemoly@@	B-Disease	D006461	10704919
sis	I-Disease	-1	10704919
of	O	-1	10704919
all	O	-1	10704919
tested	O	-1	10704919
sus@@	O	-1	10704919
pen@@	O	-1	10704919
sion@@	O	-1	10704919
s.	O	-1	10704919
D@@	O	-1	10704919
es@@	O	-1	10704919
pit@@	O	-1	10704919
e	O	-1	10704919
induc@@	O	-1	10704919
ing	O	-1	10704919
exten@@	O	-1	10704919
sive	O	-1	10704919
erythro@@	O	-1	10704919
cy@@	O	-1	10704919
te	O	-1	10704919
l@@	O	-1	10704919
ysi@@	O	-1	10704919
s,	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
does	O	-1	10704919
not	O	-1	10704919
shi@@	O	-1	10704919
ft	O	-1	10704919
the	O	-1	10704919
os@@	O	-1	10704919
mo@@	O	-1	10704919
tic	O	-1	10704919
f@@	O	-1	10704919
ra@@	O	-1	10704919
g@@	O	-1	10704919
ility	O	-1	10704919
cur@@	O	-1	10704919
v@@	O	-1	10704919
es	O	-1	10704919
of	O	-1	10704919
erythro@@	O	-1	10704919
cy@@	O	-1	10704919
t@@	O	-1	10704919
es.	O	-1	10704919
The	O	-1	10704919
hemolytic	B-Disease	D006461	10704919
effect	O	-1	10704919
of	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
is	O	-1	10704919
prevent@@	O	-1	10704919
ed	O	-1	10704919
by	O	-1	10704919
low	O	-1	10704919
concentrations	O	-1	10704919
of	O	-1	10704919
alpha-@@	B-Chemical	D024502	10704919
to@@	I-Chemical	-1	10704919
co@@	I-Chemical	-1	10704919
ph@@	I-Chemical	-1	10704919
er@@	I-Chemical	-1	10704919
ol	I-Chemical	-1	10704919
(	O	-1	10704919
alpha-@@	B-Chemical	D024502	10704919
T	I-Chemical	-1	10704919
)	O	-1	10704919
and	O	-1	10704919
alpha-@@	B-Chemical	D024502	10704919
to@@	I-Chemical	-1	10704919
co@@	I-Chemical	-1	10704919
ph@@	I-Chemical	-1	10704919
er@@	I-Chemical	-1	10704919
ol	I-Chemical	-1	10704919
acet@@	I-Chemical	-1	10704919
ate	I-Chemical	-1	10704919
(	O	-1	10704919
alpha-@@	B-Chemical	D024502	10704919
TA@@	I-Chemical	-1	10704919
c	I-Chemical	-1	10704919
)	O	-1	10704919
(@@	O	-1	10704919
in@@	O	-1	10704919
activ@@	O	-1	10704919
ated	O	-1	10704919
functional	O	-1	10704919
hydrox@@	B-Chemical	D017665	10704919
yl	I-Chemical	-1	10704919
)	O	-1	10704919
indicating	O	-1	10704919
that	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
-induced	O	-1	10704919
hemoly@@	B-Disease	D006461	10704919
sis	I-Disease	-1	10704919
is	O	-1	10704919
not	O	-1	10704919
related	O	-1	10704919
to	O	-1	10704919
oxid@@	O	-1	10704919
ative	O	-1	10704919
membran@@	O	-1	10704919
e	O	-1	10704919
dam@@	O	-1	10704919
age.	O	-1	10704919
This	O	-1	10704919
was	O	-1	10704919
further	O	-1	10704919
ev@@	O	-1	10704919
id@@	O	-1	10704919
enc@@	O	-1	10704919
ed	O	-1	10704919
by	O	-1	10704919
absence	O	-1	10704919
of	O	-1	10704919
oxy@@	B-Chemical	D010100	10704919
gen	I-Chemical	-1	10704919
consum@@	O	-1	10704919
ption	O	-1	10704919
and	O	-1	10704919
hemo@@	O	-1	10704919
globin	O	-1	10704919
oxid@@	O	-1	10704919
ation	O	-1	10704919
both	O	-1	10704919
determined	O	-1	10704919
in	O	-1	10704919
par@@	O	-1	10704919
al@@	O	-1	10704919
le@@	O	-1	10704919
l	O	-1	10704919
with	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
-induced	O	-1	10704919
hemoly@@	B-Disease	D006461	10704919
sis	I-Disease	-1	10704919
.	O	-1	10704919
F@@	O	-1	10704919
ur@@	O	-1	10704919
ther@@	O	-1	10704919
mo@@	O	-1	10704919
re,	O	-1	10704919
it	O	-1	10704919
was	O	-1	10704919
observed	O	-1	10704919
that	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
inhibit@@	O	-1	10704919
s	O	-1	10704919
the	O	-1	10704919
per@@	O	-1	10704919
oxid@@	O	-1	10704919
ation	O	-1	10704919
of	O	-1	10704919
human	O	-1	10704919
erythro@@	O	-1	10704919
cy@@	O	-1	10704919
tes	O	-1	10704919
induced	O	-1	10704919
by	O	-1	10704919
A@@	B-Chemical	C046728	10704919
A@@	I-Chemical	-1	10704919
P@@	I-Chemical	-1	10704919
H	I-Chemical	-1	10704919
,	O	-1	10704919
th@@	O	-1	10704919
us	O	-1	10704919
r@@	O	-1	10704919
ul@@	O	-1	10704919
ing	O	-1	10704919
out	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
-induced	O	-1	10704919
cell	O	-1	10704919
oxid@@	O	-1	10704919
ative	O	-1	10704919
stres@@	O	-1	10704919
s.	O	-1	10704919
H@@	B-Disease	D006461	10704919
em@@	I-Disease	-1	10704919
oly@@	I-Disease	-1	10704919
sis	I-Disease	-1	10704919
caused	O	-1	10704919
by	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
was	O	-1	10704919
not	O	-1	10704919
pre@@	O	-1	10704919
ce@@	O	-1	10704919
ded	O	-1	10704919
by	O	-1	10704919
the	O	-1	10704919
le@@	O	-1	10704919
ak@@	O	-1	10704919
age	O	-1	10704919
of	O	-1	10704919
K	B-Chemical	D011188	10704919
(@@	O	-1	10704919
+@@	O	-1	10704919
)	O	-1	10704919
from	O	-1	10704919
the	O	-1	10704919
cell@@	O	-1	10704919
s,	O	-1	10704919
also	O	-1	10704919
ex@@	O	-1	10704919
cl@@	O	-1	10704919
ud@@	O	-1	10704919
ing	O	-1	10704919
a	O	-1	10704919
co@@	O	-1	10704919
l@@	O	-1	10704919
lo@@	O	-1	10704919
id@@	O	-1	10704919
-@@	O	-1	10704919
os@@	O	-1	10704919
mo@@	O	-1	10704919
tic	O	-1	10704919
type	O	-1	10704919
mechanism	O	-1	10704919
of	O	-1	10704919
hemoly@@	B-Disease	D006461	10704919
sis	I-Disease	-1	10704919
,	O	-1	10704919
ac@@	O	-1	10704919
cor@@	O	-1	10704919
ding	O	-1	10704919
to	O	-1	10704919
the	O	-1	10704919
effects	O	-1	10704919
on	O	-1	10704919
os@@	O	-1	10704919
mo@@	O	-1	10704919
tic	O	-1	10704919
f@@	O	-1	10704919
ra@@	O	-1	10704919
g@@	O	-1	10704919
ility	O	-1	10704919
cur@@	O	-1	10704919
v@@	O	-1	10704919
es.	O	-1	10704919
However,	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
induc@@	O	-1	10704919
es	O	-1	10704919
release	O	-1	10704919
of	O	-1	10704919
peripheral	O	-1	10704919
protein@@	O	-1	10704919
s	O	-1	10704919
of	O	-1	10704919
membran@@	O	-1	10704919
e-@@	O	-1	10704919
cy@@	O	-1	10704919
t@@	O	-1	10704919
os@@	O	-1	10704919
ke@@	O	-1	10704919
le@@	O	-1	10704919
t@@	O	-1	10704919
on	O	-1	10704919
and	O	-1	10704919
cy@@	O	-1	10704919
t@@	O	-1	10704919
os@@	O	-1	10704919
ol	O	-1	10704919
protein@@	O	-1	10704919
s	O	-1	10704919
es@@	O	-1	10704919
sen@@	O	-1	10704919
ti@@	O	-1	10704919
ally	O	-1	10704919
b@@	O	-1	10704919
ound	O	-1	10704919
to	O	-1	10704919
b@@	O	-1	10704919
and	O	-1	10704919
3@@	O	-1	10704919
.	O	-1	10704919
E@@	O	-1	10704919
ither	O	-1	10704919
alpha-@@	B-Chemical	D024502	10704919
T	I-Chemical	-1	10704919
or	O	-1	10704919
alpha-@@	B-Chemical	D024502	10704919
TA@@	I-Chemical	-1	10704919
c	I-Chemical	-1	10704919
increases	O	-1	10704919
membran@@	O	-1	10704919
e	O	-1	10704919
pac@@	O	-1	10704919
king	O	-1	10704919
and	O	-1	10704919
prev@@	O	-1	10704919
ents	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
par@@	O	-1	10704919
ti@@	O	-1	10704919
tion	O	-1	10704919
into	O	-1	10704919
model	O	-1	10704919
membran@@	O	-1	10704919
es.	O	-1	10704919
These	O	-1	10704919
effects	O	-1	10704919
suggest	O	-1	10704919
that	O	-1	10704919
the	O	-1	10704919
prot@@	O	-1	10704919
ection	O	-1	10704919
from	O	-1	10704919
hemoly@@	B-Disease	D006461	10704919
sis	I-Disease	-1	10704919
by	O	-1	10704919
to@@	B-Chemical	D024505	10704919
co@@	I-Chemical	-1	10704919
ph@@	I-Chemical	-1	10704919
er@@	I-Chemical	-1	10704919
ol@@	I-Chemical	-1	10704919
s	I-Chemical	-1	10704919
is	O	-1	10704919
related	O	-1	10704919
to	O	-1	10704919
a	O	-1	10704919
decreased	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
inc@@	O	-1	10704919
or@@	O	-1	10704919
por@@	O	-1	10704919
ation	O	-1	10704919
in	O	-1	10704919
con@@	O	-1	10704919
d@@	O	-1	10704919
en@@	O	-1	10704919
sed	O	-1	10704919
membran@@	O	-1	10704919
es	O	-1	10704919
and	O	-1	10704919
the	O	-1	10704919
struct@@	O	-1	10704919
ural	O	-1	10704919
damage	O	-1	10704919
of	O	-1	10704919
the	O	-1	10704919
erythro@@	O	-1	10704919
cy@@	O	-1	10704919
te	O	-1	10704919
membran@@	O	-1	10704919
e	O	-1	10704919
is	O	-1	10704919
con@@	O	-1	10704919
sequ@@	O	-1	10704919
ently	O	-1	10704919
av@@	O	-1	10704919
o@@	O	-1	10704919
ide@@	O	-1	10704919
d.	O	-1	10704919
The@@	O	-1	10704919
refore,	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
-induced	O	-1	10704919
hemoly@@	B-Disease	D006461	10704919
sis	I-Disease	-1	10704919
results	O	-1	10704919
from	O	-1	10704919
a	O	-1	10704919
struct@@	O	-1	10704919
ural	O	-1	10704919
per@@	O	-1	10704919
t@@	O	-1	10704919
urb@@	O	-1	10704919
ation	O	-1	10704919
of	O	-1	10704919
red	O	-1	10704919
cell	O	-1	10704919
membran@@	O	-1	10704919
e,	O	-1	10704919
lead@@	O	-1	10704919
ing	O	-1	10704919
to	O	-1	10704919
changes	O	-1	10704919
in	O	-1	10704919
the	O	-1	10704919
f@@	O	-1	10704919
ram@@	O	-1	10704919
e@@	O	-1	10704919
wor@@	O	-1	10704919
k	O	-1	10704919
of	O	-1	10704919
the	O	-1	10704919
erythro@@	O	-1	10704919
cy@@	O	-1	10704919
te	O	-1	10704919
membran@@	O	-1	10704919
e	O	-1	10704919
and	O	-1	10704919
its	O	-1	10704919
cy@@	O	-1	10704919
t@@	O	-1	10704919
os@@	O	-1	10704919
ke@@	O	-1	10704919
le@@	O	-1	10704919
t@@	O	-1	10704919
on	O	-1	10704919
caused	O	-1	10704919
by	O	-1	10704919
its	O	-1	10704919
high	O	-1	10704919
par@@	O	-1	10704919
ti@@	O	-1	10704919
tion	O	-1	10704919
in	O	-1	10704919
the	O	-1	10704919
membran@@	O	-1	10704919
e.	O	-1	10704919
These	O	-1	10704919
def@@	O	-1	10704919
ects	O	-1	10704919
expl@@	O	-1	10704919
ain	O	-1	10704919
the	O	-1	10704919
ab@@	O	-1	10704919
normal	O	-1	10704919
erythro@@	O	-1	10704919
cy@@	O	-1	10704919
te	O	-1	10704919
sh@@	O	-1	10704919
ap@@	O	-1	10704919
e	O	-1	10704919
and	O	-1	10704919
decreased	O	-1	10704919
mechan@@	O	-1	10704919
ical	O	-1	10704919
st@@	O	-1	10704919
ability	O	-1	10704919
pro@@	O	-1	10704919
m@@	O	-1	10704919
ot@@	O	-1	10704919
ed	O	-1	10704919
by	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
,	O	-1	10704919
result@@	O	-1	10704919
ing	O	-1	10704919
in	O	-1	10704919
hemolytic	B-Disease	D000743	10704919
anemia	I-Disease	-1	10704919
.	O	-1	10704919
Ad@@	O	-1	10704919
di@@	O	-1	10704919
tion@@	O	-1	10704919
ally,	O	-1	10704919
s@@	O	-1	10704919
inc@@	O	-1	10704919
e	O	-1	10704919
membran@@	O	-1	10704919
e	O	-1	10704919
le@@	O	-1	10704919
ak@@	O	-1	10704919
age	O	-1	10704919
is	O	-1	10704919
a	O	-1	10704919
f@@	O	-1	10704919
inal	O	-1	10704919
st@@	O	-1	10704919
age	O	-1	10704919
of	O	-1	10704919
cy@@	O	-1	10704919
tot@@	O	-1	10704919
oxic@@	O	-1	10704919
ity,	O	-1	10704919
the	O	-1	10704919
dis@@	O	-1	10704919
ru@@	O	-1	10704919
ption	O	-1	10704919
of	O	-1	10704919
the	O	-1	10704919
struct@@	O	-1	10704919
ural	O	-1	10704919
character@@	O	-1	10704919
is@@	O	-1	10704919
tics	O	-1	10704919
of	O	-1	10704919
bio@@	O	-1	10704919
membran@@	O	-1	10704919
es	O	-1	10704919
by	O	-1	10704919
TA@@	B-Chemical	D013629	10704919
M	I-Chemical	-1	10704919
may	O	-1	10704919
cont@@	O	-1	10704919
rib@@	O	-1	10704919
ute	O	-1	10704919
to	O	-1	10704919
the	O	-1	10704919
multiple	O	-1	10704919
mechanisms	O	-1	10704919
of	O	-1	10704919
its	O	-1	10704919
anti@@	O	-1	10704919
cancer	O	-1	10704919
ac@@	O	-1	10704919
tion.	O	-1	10704919

Ch@@	O	-1	10706004
ang@@	O	-1	10706004
es	O	-1	10706004
of	O	-1	10706004
sodium	B-Chemical	D012964	10706004
and	O	-1	10706004
AT@@	B-Chemical	D000255	10706004
P	I-Chemical	-1	10706004
aff@@	O	-1	10706004
initi@@	O	-1	10706004
es	O	-1	10706004
of	O	-1	10706004
the	O	-1	10706004
cardiac	O	-1	10706004
(	O	-1	10706004
N@@	B-Chemical	D012964	10706004
a	I-Chemical	-1	10706004
,	O	-1	10706004
K	B-Chemical	D011188	10706004
)-@@	O	-1	10706004
AT@@	O	-1	10706004
P@@	O	-1	10706004
ase	O	-1	10706004
during	O	-1	10706004
and	O	-1	10706004
after	O	-1	10706004
nit@@	B-Chemical	D009569	10706004
ric	I-Chemical	-1	10706004
ox@@	I-Chemical	-1	10706004
ide	I-Chemical	-1	10706004
defici@@	O	-1	10706004
ent	O	-1	10706004
hypertension	B-Disease	D006973	10706004
.	O	-1	10706004
In	O	-1	10706004
the	O	-1	10706004
cardiovascular	O	-1	10706004
system@@	O	-1	10706004
,	O	-1	10706004
N@@	B-Chemical	D009569	10706004
O	I-Chemical	-1	10706004
is	O	-1	10706004
involved	O	-1	10706004
in	O	-1	10706004
the	O	-1	10706004
reg@@	O	-1	10706004
ulation	O	-1	10706004
of	O	-1	10706004
a	O	-1	10706004
vari@@	O	-1	10706004
ety	O	-1	10706004
of	O	-1	10706004
func@@	O	-1	10706004
tions.	O	-1	10706004
In@@	O	-1	10706004
hib@@	O	-1	10706004
ition	O	-1	10706004
of	O	-1	10706004
N@@	B-Chemical	D009569	10706004
O	I-Chemical	-1	10706004
syn@@	O	-1	10706004
thesis	O	-1	10706004
induc@@	O	-1	10706004
es	O	-1	10706004
su@@	O	-1	10706004
st@@	O	-1	10706004
ained	O	-1	10706004
hypertension	B-Disease	D006973	10706004
.	O	-1	10706004
In	O	-1	10706004
several	O	-1	10706004
models	O	-1	10706004
of	O	-1	10706004
hypertension	B-Disease	D006973	10706004
,	O	-1	10706004
elev@@	O	-1	10706004
ation	O	-1	10706004
of	O	-1	10706004
intrac@@	O	-1	10706004
ell@@	O	-1	10706004
ular	O	-1	10706004
sodium	B-Chemical	D012964	10706004
level	O	-1	10706004
was	O	-1	10706004
doc@@	O	-1	10706004
um@@	O	-1	10706004
ent@@	O	-1	10706004
ed	O	-1	10706004
in	O	-1	10706004
cardiac	O	-1	10706004
tissu@@	O	-1	10706004
e.	O	-1	10706004
To	O	-1	10706004
ass@@	O	-1	10706004
ess	O	-1	10706004
the	O	-1	10706004
mol@@	O	-1	10706004
ec@@	O	-1	10706004
ular	O	-1	10706004
b@@	O	-1	10706004
asis	O	-1	10706004
of	O	-1	10706004
dist@@	O	-1	10706004
urb@@	O	-1	10706004
anc@@	O	-1	10706004
es	O	-1	10706004
in	O	-1	10706004
trans@@	O	-1	10706004
membran@@	O	-1	10706004
e@@	O	-1	10706004
ous	O	-1	10706004
trans@@	O	-1	10706004
por@@	O	-1	10706004
t	O	-1	10706004
of	O	-1	10706004
N@@	B-Chemical	D012964	10706004
a	I-Chemical	-1	10706004
+@@	O	-1	10706004
,	O	-1	10706004
we	O	-1	10706004
studied	O	-1	10706004
the	O	-1	10706004
response	O	-1	10706004
of	O	-1	10706004
cardiac	O	-1	10706004
(	O	-1	10706004
N@@	B-Chemical	D012964	10706004
a	I-Chemical	-1	10706004
,	O	-1	10706004
K	B-Chemical	D011188	10706004
)-@@	O	-1	10706004
AT@@	O	-1	10706004
P@@	O	-1	10706004
ase	O	-1	10706004
to	O	-1	10706004
N@@	B-Chemical	D009569	10706004
O	I-Chemical	-1	10706004
-@@	O	-1	10706004
defici@@	O	-1	10706004
ent	O	-1	10706004
hypertension	B-Disease	D006973	10706004
induced	O	-1	10706004
in	O	-1	10706004
rats	O	-1	10706004
by	O	-1	10706004
N@@	B-Chemical	D009569	10706004
O	I-Chemical	-1	10706004
-@@	O	-1	10706004
syn@@	O	-1	10706004
th@@	O	-1	10706004
ase	O	-1	10706004
inhibition	O	-1	10706004
with	O	-1	10706004
40	O	-1	10706004
mg/k@@	O	-1	10706004
g/@@	O	-1	10706004
day	O	-1	10706004
N@@	B-Chemical	D019331	10706004
(@@	I-Chemical	-1	10706004
G@@	I-Chemical	-1	10706004
)-@@	I-Chemical	-1	10706004
nitro@@	I-Chemical	-1	10706004
-@@	I-Chemical	-1	10706004
L-@@	I-Chemical	-1	10706004
arg@@	I-Chemical	-1	10706004
inine	I-Chemical	-1	10706004
meth@@	I-Chemical	-1	10706004
yl	I-Chemical	-1	10706004
est@@	I-Chemical	-1	10706004
er	I-Chemical	-1	10706004
(	O	-1	10706004
L-@@	B-Chemical	D019331	10706004
N@@	I-Chemical	-1	10706004
AM@@	I-Chemical	-1	10706004
E	I-Chemical	-1	10706004
)	O	-1	10706004
for	O	-1	10706004
4	O	-1	10706004
four	O	-1	10706004
week@@	O	-1	10706004
s.	O	-1	10706004
After	O	-1	10706004
4-@@	O	-1	10706004
week	O	-1	10706004
administration	O	-1	10706004
of	O	-1	10706004
L-@@	B-Chemical	D019331	10706004
N@@	I-Chemical	-1	10706004
AM@@	I-Chemical	-1	10706004
E	I-Chemical	-1	10706004
,	O	-1	10706004
the	O	-1	10706004
systolic	O	-1	10706004
blood	O	-1	10706004
pressure	O	-1	10706004
(S@@	O	-1	10706004
B@@	O	-1	10706004
P)	O	-1	10706004
increased	O	-1	10706004
by	O	-1	10706004
3@@	O	-1	10706004
6@@	O	-1	10706004
%.	O	-1	10706004
Two	O	-1	10706004
weeks	O	-1	10706004
after	O	-1	10706004
ter@@	O	-1	10706004
min@@	O	-1	10706004
ating	O	-1	10706004
the	O	-1	10706004
treatment,	O	-1	10706004
the	O	-1	10706004
S@@	O	-1	10706004
B@@	O	-1	10706004
P	O	-1	10706004
reco@@	O	-1	10706004
vered	O	-1	10706004
to	O	-1	10706004
control	O	-1	10706004
valu@@	O	-1	10706004
e.	O	-1	10706004
Whe@@	O	-1	10706004
n	O	-1	10706004
activ@@	O	-1	10706004
ating	O	-1	10706004
the	O	-1	10706004
(	O	-1	10706004
N@@	B-Chemical	D012964	10706004
a	I-Chemical	-1	10706004
,	O	-1	10706004
K	B-Chemical	D011188	10706004
)-@@	O	-1	10706004
AT@@	O	-1	10706004
P@@	O	-1	10706004
ase	O	-1	10706004
with	O	-1	10706004
its	O	-1	10706004
subst@@	O	-1	10706004
rate	O	-1	10706004
AT@@	B-Chemical	D000255	10706004
P	I-Chemical	-1	10706004
,	O	-1	10706004
no	O	-1	10706004
changes	O	-1	10706004
in	O	-1	10706004
K@@	O	-1	10706004
m	O	-1	10706004
and	O	-1	10706004
V@@	O	-1	10706004
ma@@	O	-1	10706004
x	O	-1	10706004
values	O	-1	10706004
were	O	-1	10706004
observed	O	-1	10706004
in	O	-1	10706004
N@@	B-Chemical	D009569	10706004
O	I-Chemical	-1	10706004
-@@	O	-1	10706004
defici@@	O	-1	10706004
ent	O	-1	10706004
rats.	O	-1	10706004
D@@	O	-1	10706004
uring	O	-1	10706004
activation	O	-1	10706004
with	O	-1	10706004
N@@	B-Chemical	D012964	10706004
a	I-Chemical	-1	10706004
+@@	O	-1	10706004
,	O	-1	10706004
the	O	-1	10706004
V@@	O	-1	10706004
ma@@	O	-1	10706004
x	O	-1	10706004
remained	O	-1	10706004
un@@	O	-1	10706004
chang@@	O	-1	10706004
ed,	O	-1	10706004
ho@@	O	-1	10706004
we@@	O	-1	10706004
ver	O	-1	10706004
the	O	-1	10706004
K	B-Chemical	D011188	10706004
(	O	-1	10706004
N@@	B-Chemical	D012964	10706004
a	I-Chemical	-1	10706004
)	O	-1	10706004
increased	O	-1	10706004
by	O	-1	10706004
50@@	O	-1	10706004
%,	O	-1	10706004
indicating	O	-1	10706004
a	O	-1	10706004
pro@@	O	-1	10706004
found	O	-1	10706004
decrease	O	-1	10706004
in	O	-1	10706004
the	O	-1	10706004
aff@@	O	-1	10706004
in@@	O	-1	10706004
ity	O	-1	10706004
of	O	-1	10706004
the	O	-1	10706004
N@@	B-Chemical	D012964	10706004
a	I-Chemical	-1	10706004
+@@	O	-1	10706004
-@@	O	-1	10706004
b@@	O	-1	10706004
ind@@	O	-1	10706004
ing	O	-1	10706004
sit@@	O	-1	10706004
e	O	-1	10706004
in	O	-1	10706004
N@@	B-Chemical	D009569	10706004
O	I-Chemical	-1	10706004
-@@	O	-1	10706004
defici@@	O	-1	10706004
ent	O	-1	10706004
rats.	O	-1	10706004
After	O	-1	10706004
recovery	O	-1	10706004
from	O	-1	10706004
hypertension	B-Disease	D006973	10706004
,	O	-1	10706004
the	O	-1	10706004
activity	O	-1	10706004
of	O	-1	10706004
(	O	-1	10706004
N@@	B-Chemical	D012964	10706004
a	I-Chemical	-1	10706004
,	O	-1	10706004
K	B-Chemical	D011188	10706004
)-@@	O	-1	10706004
AT@@	O	-1	10706004
P@@	O	-1	10706004
ase	O	-1	10706004
increas@@	O	-1	10706004
ed,	O	-1	10706004
due	O	-1	10706004
to	O	-1	10706004
higher	O	-1	10706004
aff@@	O	-1	10706004
in@@	O	-1	10706004
ity	O	-1	10706004
of	O	-1	10706004
the	O	-1	10706004
AT@@	B-Chemical	D000255	10706004
P	I-Chemical	-1	10706004
-@@	O	-1	10706004
b@@	O	-1	10706004
ind@@	O	-1	10706004
ing	O	-1	10706004
sit@@	O	-1	10706004
e,	O	-1	10706004
as	O	-1	10706004
revealed	O	-1	10706004
from	O	-1	10706004
the	O	-1	10706004
lo@@	O	-1	10706004
we@@	O	-1	10706004
red	O	-1	10706004
K@@	O	-1	10706004
m	O	-1	10706004
valu@@	O	-1	10706004
e	O	-1	10706004
for	O	-1	10706004
AT@@	B-Chemical	D000255	10706004
P	I-Chemical	-1	10706004
.	O	-1	10706004
The	O	-1	10706004
K	B-Chemical	D011188	10706004
(	O	-1	10706004
N@@	B-Chemical	D012964	10706004
a	I-Chemical	-1	10706004
)	O	-1	10706004
valu@@	O	-1	10706004
e	O	-1	10706004
for	O	-1	10706004
N@@	B-Chemical	D012964	10706004
a	I-Chemical	-1	10706004
+	O	-1	10706004
retur@@	O	-1	10706004
n@@	O	-1	10706004
ed	O	-1	10706004
to	O	-1	10706004
control	O	-1	10706004
valu@@	O	-1	10706004
e.	O	-1	10706004
In@@	O	-1	10706004
hib@@	O	-1	10706004
ition	O	-1	10706004
of	O	-1	10706004
N@@	B-Chemical	D009569	10706004
O	I-Chemical	-1	10706004
-@@	O	-1	10706004
syn@@	O	-1	10706004
th@@	O	-1	10706004
ase	O	-1	10706004
induced	O	-1	10706004
a	O	-1	10706004
reversible	O	-1	10706004
hypertension	B-Disease	D006973	10706004
ac@@	O	-1	10706004
comp@@	O	-1	10706004
an@@	O	-1	10706004
ied	O	-1	10706004
by	O	-1	10706004
depress@@	B-Disease	D003866	10706004
ed	I-Disease	-1	10706004
N@@	B-Chemical	D012964	10706004
a	I-Chemical	-1	10706004
+@@	O	-1	10706004
-@@	O	-1	10706004
ext@@	O	-1	10706004
ru@@	O	-1	10706004
sion	O	-1	10706004
from	O	-1	10706004
cardiac	O	-1	10706004
cells	O	-1	10706004
as	O	-1	10706004
a	O	-1	10706004
con@@	O	-1	10706004
sequ@@	O	-1	10706004
ence	O	-1	10706004
of	O	-1	10706004
deter@@	O	-1	10706004
i@@	O	-1	10706004
or@@	O	-1	10706004
ated	O	-1	10706004
N@@	B-Chemical	D012964	10706004
a	I-Chemical	-1	10706004
+@@	O	-1	10706004
-@@	O	-1	10706004
b@@	O	-1	10706004
ind@@	O	-1	10706004
ing	O	-1	10706004
pro@@	O	-1	10706004
per@@	O	-1	10706004
ties	O	-1	10706004
of	O	-1	10706004
the	O	-1	10706004
(	O	-1	10706004
N@@	B-Chemical	D012964	10706004
a	I-Chemical	-1	10706004
,	O	-1	10706004
K	B-Chemical	D011188	10706004
)-@@	O	-1	10706004
AT@@	O	-1	10706004
P@@	O	-1	10706004
as@@	O	-1	10706004
e.	O	-1	10706004
After	O	-1	10706004
recovery	O	-1	10706004
of	O	-1	10706004
blood	O	-1	10706004
pressure	O	-1	10706004
to	O	-1	10706004
control	O	-1	10706004
valu@@	O	-1	10706004
es,	O	-1	10706004
the	O	-1	10706004
ext@@	O	-1	10706004
ru@@	O	-1	10706004
sion	O	-1	10706004
of	O	-1	10706004
N@@	B-Chemical	D012964	10706004
a	I-Chemical	-1	10706004
+	O	-1	10706004
from	O	-1	10706004
cardiac	O	-1	10706004
cells	O	-1	10706004
was	O	-1	10706004
normal@@	O	-1	10706004
iz@@	O	-1	10706004
ed,	O	-1	10706004
as	O	-1	10706004
revealed	O	-1	10706004
by	O	-1	10706004
rest@@	O	-1	10706004
or@@	O	-1	10706004
ation	O	-1	10706004
of	O	-1	10706004
the	O	-1	10706004
(	O	-1	10706004
N@@	B-Chemical	D012964	10706004
a	I-Chemical	-1	10706004
,	O	-1	10706004
K	B-Chemical	D011188	10706004
)-@@	O	-1	10706004
AT@@	O	-1	10706004
P@@	O	-1	10706004
ase	O	-1	10706004
activ@@	O	-1	10706004
ity.	O	-1	10706004

Eff@@	O	-1	10721819
ects	O	-1	10721819
of	O	-1	10721819
long-term	O	-1	10721819
pretreatment	O	-1	10721819
with	O	-1	10721819
isoproteren@@	B-Chemical	D007545	10721819
ol	I-Chemical	-1	10721819
on	O	-1	10721819
brom@@	B-Chemical	D001971	10721819
oc@@	I-Chemical	-1	10721819
ript@@	I-Chemical	-1	10721819
ine	I-Chemical	-1	10721819
-induced	O	-1	10721819
tachycardia	B-Disease	D013610	10721819
in	O	-1	10721819
con@@	O	-1	10721819
s@@	O	-1	10721819
ci@@	O	-1	10721819
ous	O	-1	10721819
rats.	O	-1	10721819
It	O	-1	10721819
has	O	-1	10721819
been	O	-1	10721819
shown	O	-1	10721819
that	O	-1	10721819
brom@@	B-Chemical	D001971	10721819
oc@@	I-Chemical	-1	10721819
ript@@	I-Chemical	-1	10721819
ine	I-Chemical	-1	10721819
-induced	O	-1	10721819
tachycardia	B-Disease	D013610	10721819
,	O	-1	10721819
which	O	-1	10721819
per@@	O	-1	10721819
sist@@	O	-1	10721819
ed	O	-1	10721819
after	O	-1	10721819
adren@@	O	-1	10721819
al@@	O	-1	10721819
ect@@	O	-1	10721819
om@@	O	-1	10721819
y,	O	-1	10721819
is	O	-1	10721819
(@@	O	-1	10721819
i@@	O	-1	10721819
)	O	-1	10721819
mediated	O	-1	10721819
by	O	-1	10721819
central	O	-1	10721819
dopamine	B-Chemical	D004298	10721819
D2	O	-1	10721819
receptor	O	-1	10721819
activation	O	-1	10721819
and	O	-1	10721819
(@@	O	-1	10721819
i@@	O	-1	10721819
i@@	O	-1	10721819
)	O	-1	10721819
reduced	O	-1	10721819
by	O	-1	10721819
5-@@	O	-1	10721819
day	O	-1	10721819
isoproteren@@	B-Chemical	D007545	10721819
ol	I-Chemical	-1	10721819
pre@@	O	-1	10721819
treatment,	O	-1	10721819
sup@@	O	-1	10721819
port@@	O	-1	10721819
ing	O	-1	10721819
the@@	O	-1	10721819
re@@	O	-1	10721819
fore	O	-1	10721819
the	O	-1	10721819
hypo@@	O	-1	10721819
thesis	O	-1	10721819
that	O	-1	10721819
this	O	-1	10721819
effect	O	-1	10721819
is	O	-1	10721819
dependent	O	-1	10721819
on	O	-1	10721819
sym@@	O	-1	10721819
pa@@	O	-1	10721819
thetic	O	-1	10721819
out@@	O	-1	10721819
flow	O	-1	10721819
to	O	-1	10721819
the	O	-1	10721819
hear@@	O	-1	10721819
t.	O	-1	10721819
This	O	-1	10721819
study	O	-1	10721819
was	O	-1	10721819
con@@	O	-1	10721819
duc@@	O	-1	10721819
ted	O	-1	10721819
to	O	-1	10721819
ex@@	O	-1	10721819
amine	O	-1	10721819
whether	O	-1	10721819
prolonged	O	-1	10721819
pretreatment	O	-1	10721819
with	O	-1	10721819
isoproteren@@	B-Chemical	D007545	10721819
ol	I-Chemical	-1	10721819
could	O	-1	10721819
abol@@	O	-1	10721819
is@@	O	-1	10721819
h	O	-1	10721819
brom@@	B-Chemical	D001971	10721819
oc@@	I-Chemical	-1	10721819
ript@@	I-Chemical	-1	10721819
ine	I-Chemical	-1	10721819
-induced	O	-1	10721819
tachycardia	B-Disease	D013610	10721819
in	O	-1	10721819
con@@	O	-1	10721819
s@@	O	-1	10721819
ci@@	O	-1	10721819
ous	O	-1	10721819
rats.	O	-1	10721819
I@@	B-Chemical	D007545	10721819
so@@	I-Chemical	-1	10721819
proteren@@	I-Chemical	-1	10721819
ol	I-Chemical	-1	10721819
pretreatment	O	-1	10721819
for	O	-1	10721819
15	O	-1	10721819
days	O	-1	10721819
caused	O	-1	10721819
cardiac	B-Disease	D006332	10721819
hyper@@	I-Disease	-1	10721819
tro@@	I-Disease	-1	10721819
ph@@	I-Disease	-1	10721819
y	I-Disease	-1	10721819
without	O	-1	10721819
aff@@	O	-1	10721819
ect@@	O	-1	10721819
ing	O	-1	10721819
baseline	O	-1	10721819
blood	O	-1	10721819
pressure	O	-1	10721819
and	O	-1	10721819
heart	O	-1	10721819
rat@@	O	-1	10721819
e.	O	-1	10721819
In	O	-1	10721819
control	O	-1	10721819
rats,	O	-1	10721819
intravenous	O	-1	10721819
brom@@	B-Chemical	D001971	10721819
oc@@	I-Chemical	-1	10721819
ript@@	I-Chemical	-1	10721819
ine	I-Chemical	-1	10721819
(1@@	O	-1	10721819
50	O	-1	10721819
micro@@	O	-1	10721819
g/@@	O	-1	10721819
kg@@	O	-1	10721819
)	O	-1	10721819
induced	O	-1	10721819
significant	O	-1	10721819
hypotension	B-Disease	D007022	10721819
and	O	-1	10721819
tachycardia	B-Disease	D013610	10721819
.	O	-1	10721819
B@@	B-Chemical	D001971	10721819
rom@@	I-Chemical	-1	10721819
oc@@	I-Chemical	-1	10721819
ript@@	I-Chemical	-1	10721819
ine	I-Chemical	-1	10721819
-induced	O	-1	10721819
hypotension	B-Disease	D007022	10721819
was	O	-1	10721819
un@@	O	-1	10721819
affected	O	-1	10721819
by	O	-1	10721819
isoproteren@@	B-Chemical	D007545	10721819
ol	I-Chemical	-1	10721819
pre@@	O	-1	10721819
treatment,	O	-1	10721819
while	O	-1	10721819
tachycardia	B-Disease	D013610	10721819
was	O	-1	10721819
reversed	O	-1	10721819
to	O	-1	10721819
significant	O	-1	10721819
brady@@	B-Disease	D001919	10721819
cardia	I-Disease	-1	10721819
,	O	-1	10721819
an	O	-1	10721819
effect	O	-1	10721819
that	O	-1	10721819
was	O	-1	10721819
part@@	O	-1	10721819
ly	O	-1	10721819
reduced	O	-1	10721819
by	O	-1	10721819
i.v@@	O	-1	10721819
.	O	-1	10721819
dom@@	B-Chemical	D004294	10721819
perid@@	I-Chemical	-1	10721819
one	I-Chemical	-1	10721819
(0.@@	O	-1	10721819
5	O	-1	10721819
mg/kg@@	O	-1	10721819
).	O	-1	10721819
N@@	O	-1	10721819
either	O	-1	10721819
cardiac	O	-1	10721819
v@@	O	-1	10721819
ag@@	O	-1	10721819
al	O	-1	10721819
n@@	O	-1	10721819
or	O	-1	10721819
sym@@	O	-1	10721819
pa@@	O	-1	10721819
thetic	O	-1	10721819
t@@	O	-1	10721819
one	O	-1	10721819
was	O	-1	10721819
al@@	O	-1	10721819
te@@	O	-1	10721819
red	O	-1	10721819
by	O	-1	10721819
isoproteren@@	B-Chemical	D007545	10721819
ol	I-Chemical	-1	10721819
pre@@	O	-1	10721819
treatment.	O	-1	10721819
In	O	-1	10721819
isol@@	O	-1	10721819
ated	O	-1	10721819
per@@	O	-1	10721819
f@@	O	-1	10721819
used	O	-1	10721819
heart	O	-1	10721819
pre@@	O	-1	10721819
par@@	O	-1	10721819
ations	O	-1	10721819
from	O	-1	10721819
isoproteren@@	B-Chemical	D007545	10721819
ol	I-Chemical	-1	10721819
-@@	O	-1	10721819
pre@@	O	-1	10721819
treated	O	-1	10721819
rats,	O	-1	10721819
the	O	-1	10721819
isoproteren@@	B-Chemical	D007545	10721819
ol	I-Chemical	-1	10721819
-induced	O	-1	10721819
maxim@@	O	-1	10721819
al	O	-1	10721819
increase	O	-1	10721819
in	O	-1	10721819
left	O	-1	10721819
ventricular	O	-1	10721819
systolic	O	-1	10721819
pressure	O	-1	10721819
was	O	-1	10721819
significantly	O	-1	10721819
reduc@@	O	-1	10721819
ed,	O	-1	10721819
compared	O	-1	10721819
with	O	-1	10721819
sal@@	O	-1	10721819
ine-@@	O	-1	10721819
pre@@	O	-1	10721819
treated	O	-1	10721819
rats	O	-1	10721819
(@@	O	-1	10721819
the	O	-1	10721819
EC@@	O	-1	10721819
50	O	-1	10721819
of	O	-1	10721819
the	O	-1	10721819
isoproteren@@	B-Chemical	D007545	10721819
ol	I-Chemical	-1	10721819
-induced	O	-1	10721819
increase	O	-1	10721819
in	O	-1	10721819
left	O	-1	10721819
ventricular	O	-1	10721819
systolic	O	-1	10721819
pressure	O	-1	10721819
was	O	-1	10721819
enhanced	O	-1	10721819
appro@@	O	-1	10721819
xim@@	O	-1	10721819
ately	O	-1	10721819
2@@	O	-1	10721819
2-@@	O	-1	10721819
fol@@	O	-1	10721819
d@@	O	-1	10721819
).	O	-1	10721819
These	O	-1	10721819
results	O	-1	10721819
show	O	-1	10721819
that	O	-1	10721819
1@@	O	-1	10721819
5-@@	O	-1	10721819
day	O	-1	10721819
isoproteren@@	B-Chemical	D007545	10721819
ol	I-Chemical	-1	10721819
pretreatment	O	-1	10721819
not	O	-1	10721819
only	O	-1	10721819
abol@@	O	-1	10721819
ished	O	-1	10721819
but	O	-1	10721819
reversed	O	-1	10721819
brom@@	B-Chemical	D001971	10721819
oc@@	I-Chemical	-1	10721819
ript@@	I-Chemical	-1	10721819
ine	I-Chemical	-1	10721819
-induced	O	-1	10721819
tachycardia	B-Disease	D013610	10721819
to	O	-1	10721819
brady@@	B-Disease	D001919	10721819
cardia	I-Disease	-1	10721819
,	O	-1	10721819
an	O	-1	10721819
effect	O	-1	10721819
that	O	-1	10721819
is	O	-1	10721819
main@@	O	-1	10721819
ly	O	-1	10721819
related	O	-1	10721819
to	O	-1	10721819
further	O	-1	10721819
cardiac	O	-1	10721819
beta-@@	O	-1	10721819
adren@@	O	-1	10721819
oc@@	O	-1	10721819
e@@	O	-1	10721819
pt@@	O	-1	10721819
or	O	-1	10721819
des@@	O	-1	10721819
en@@	O	-1	10721819
si@@	O	-1	10721819
tiz@@	O	-1	10721819
ation	O	-1	10721819
ra@@	O	-1	10721819
ther	O	-1	10721819
than	O	-1	10721819
to	O	-1	10721819
impair@@	O	-1	10721819
ment	O	-1	10721819
of	O	-1	10721819
a@@	O	-1	10721819
ut@@	O	-1	10721819
on@@	O	-1	10721819
om@@	O	-1	10721819
ic	O	-1	10721819
reg@@	O	-1	10721819
ulation	O	-1	10721819
of	O	-1	10721819
the	O	-1	10721819
hear@@	O	-1	10721819
t.	O	-1	10721819
The@@	O	-1	10721819
y	O	-1	10721819
suggest	O	-1	10721819
th@@	O	-1	10721819
at@@	O	-1	10721819
,	O	-1	10721819
in	O	-1	10721819
normal	O	-1	10721819
con@@	O	-1	10721819
s@@	O	-1	10721819
ci@@	O	-1	10721819
ous	O	-1	10721819
rats,	O	-1	10721819
the	O	-1	10721819
central	O	-1	10721819
tachycardia	B-Disease	D013610	10721819
of	O	-1	10721819
brom@@	B-Chemical	D001971	10721819
oc@@	I-Chemical	-1	10721819
ript@@	I-Chemical	-1	10721819
ine	I-Chemical	-1	10721819
appear@@	O	-1	10721819
s	O	-1	10721819
to	O	-1	10721819
pre@@	O	-1	10721819
domin@@	O	-1	10721819
ate	O	-1	10721819
and	O	-1	10721819
to	O	-1	10721819
mas@@	O	-1	10721819
k	O	-1	10721819
the	O	-1	10721819
brady@@	B-Disease	D001919	10721819
cardia	I-Disease	-1	10721819
of	O	-1	10721819
this	O	-1	10721819
agon@@	O	-1	10721819
ist	O	-1	10721819
at	O	-1	10721819
peripheral	O	-1	10721819
dopamine	B-Chemical	D004298	10721819
D2	O	-1	10721819
receptor@@	O	-1	10721819
s.	O	-1	10721819

A	O	-1	10737864
develop@@	O	-1	10737864
mental	O	-1	10737864
analysis	O	-1	10737864
of	O	-1	10737864
clonidine	B-Chemical	D003000	10737864
's	O	-1	10737864
effects	O	-1	10737864
on	O	-1	10737864
cardiac	O	-1	10737864
rate	O	-1	10737864
and	O	-1	10737864
ult@@	O	-1	10737864
r@@	O	-1	10737864
as@@	O	-1	10737864
ound	O	-1	10737864
pro@@	O	-1	10737864
duction	O	-1	10737864
in	O	-1	10737864
inf@@	O	-1	10737864
ant	O	-1	10737864
rats.	O	-1	10737864
U@@	O	-1	10737864
n@@	O	-1	10737864
der	O	-1	10737864
controlled	O	-1	10737864
condi@@	O	-1	10737864
tion@@	O	-1	10737864
s,	O	-1	10737864
inf@@	O	-1	10737864
ant	O	-1	10737864
rats	O	-1	10737864
em@@	O	-1	10737864
it	O	-1	10737864
ult@@	O	-1	10737864
r@@	O	-1	10737864
as@@	O	-1	10737864
onic	O	-1	10737864
v@@	O	-1	10737864
oc@@	O	-1	10737864
al@@	O	-1	10737864
iz@@	O	-1	10737864
ations	O	-1	10737864
during	O	-1	10737864
ex@@	O	-1	10737864
trem@@	O	-1	10737864
e	O	-1	10737864
co@@	O	-1	10737864
l@@	O	-1	10737864
d	O	-1	10737864
exposure	O	-1	10737864
and	O	-1	10737864
after	O	-1	10737864
administration	O	-1	10737864
of	O	-1	10737864
the	O	-1	10737864
alpha@@	O	-1	10737864
(2@@	O	-1	10737864
)	O	-1	10737864
adren@@	O	-1	10737864
oc@@	O	-1	10737864
e@@	O	-1	10737864
pt@@	O	-1	10737864
or	O	-1	10737864
agon@@	O	-1	10737864
ist@@	O	-1	10737864
,	O	-1	10737864
clonidine	B-Chemical	D003000	10737864
.	O	-1	10737864
Pre@@	O	-1	10737864
vi@@	O	-1	10737864
ous	O	-1	10737864
investig@@	O	-1	10737864
ations	O	-1	10737864
have	O	-1	10737864
determined	O	-1	10737864
th@@	O	-1	10737864
at@@	O	-1	10737864
,	O	-1	10737864
in	O	-1	10737864
response	O	-1	10737864
to	O	-1	10737864
clonidine	B-Chemical	D003000	10737864
,	O	-1	10737864
ult@@	O	-1	10737864
r@@	O	-1	10737864
as@@	O	-1	10737864
ound	O	-1	10737864
pro@@	O	-1	10737864
duction	O	-1	10737864
increases	O	-1	10737864
through	O	-1	10737864
the	O	-1	10737864
2@@	O	-1	10737864
n@@	O	-1	10737864
d-@@	O	-1	10737864
week	O	-1	10737864
post@@	O	-1	10737864
part@@	O	-1	10737864
um	O	-1	10737864
and	O	-1	10737864
decreas@@	O	-1	10737864
es	O	-1	10737864
the@@	O	-1	10737864
re@@	O	-1	10737864
af@@	O	-1	10737864
ter@@	O	-1	10737864
.	O	-1	10737864
G@@	O	-1	10737864
i@@	O	-1	10737864
ven	O	-1	10737864
that	O	-1	10737864
sym@@	O	-1	10737864
pa@@	O	-1	10737864
thetic	O	-1	10737864
ne@@	O	-1	10737864
ural	O	-1	10737864
domin@@	O	-1	10737864
ance	O	-1	10737864
ex@@	O	-1	10737864
hib@@	O	-1	10737864
its	O	-1	10737864
a	O	-1	10737864
similar	O	-1	10737864
develop@@	O	-1	10737864
mental	O	-1	10737864
pat@@	O	-1	10737864
tern@@	O	-1	10737864
,	O	-1	10737864
and	O	-1	10737864
given	O	-1	10737864
that	O	-1	10737864
clonidine	B-Chemical	D003000	10737864
induc@@	O	-1	10737864
es	O	-1	10737864
sym@@	O	-1	10737864
pa@@	O	-1	10737864
thetic	O	-1	10737864
withdrawal	O	-1	10737864
and	O	-1	10737864
brady@@	B-Disease	D001919	10737864
cardia	I-Disease	-1	10737864
,	O	-1	10737864
we	O	-1	10737864
hypo@@	O	-1	10737864
the@@	O	-1	10737864
si@@	O	-1	10737864
zed	O	-1	10737864
that	O	-1	10737864
clonidine	B-Chemical	D003000	10737864
's	O	-1	10737864
develop@@	O	-1	10737864
mental	O	-1	10737864
effects	O	-1	10737864
on	O	-1	10737864
cardiac	O	-1	10737864
rate	O	-1	10737864
and	O	-1	10737864
ult@@	O	-1	10737864
r@@	O	-1	10737864
as@@	O	-1	10737864
ound	O	-1	10737864
pro@@	O	-1	10737864
duction	O	-1	10737864
wo@@	O	-1	10737864
uld	O	-1	10737864
m@@	O	-1	10737864
ir@@	O	-1	10737864
ro@@	O	-1	10737864
r	O	-1	10737864
each	O	-1	10737864
o@@	O	-1	10737864
ther@@	O	-1	10737864
.	O	-1	10737864
The@@	O	-1	10737864
refore,	O	-1	10737864
in	O	-1	10737864
the	O	-1	10737864
present	O	-1	10737864
experim@@	O	-1	10737864
ent@@	O	-1	10737864
,	O	-1	10737864
the	O	-1	10737864
effects	O	-1	10737864
of	O	-1	10737864
clonidine	B-Chemical	D003000	10737864
administration	O	-1	10737864
(0.@@	O	-1	10737864
5	O	-1	10737864
mg/kg)	O	-1	10737864
on	O	-1	10737864
cardiac	O	-1	10737864
rate	O	-1	10737864
and	O	-1	10737864
ult@@	O	-1	10737864
r@@	O	-1	10737864
as@@	O	-1	10737864
ound	O	-1	10737864
pro@@	O	-1	10737864
duction	O	-1	10737864
were	O	-1	10737864
examined	O	-1	10737864
in	O	-1	10737864
2-@@	O	-1	10737864
,	O	-1	10737864
8@@	O	-1	10737864
-@@	O	-1	10737864
,	O	-1	10737864
1@@	O	-1	10737864
5-@@	O	-1	10737864
,	O	-1	10737864
and	O	-1	10737864
20@@	O	-1	10737864
-@@	O	-1	10737864
day@@	O	-1	10737864
-old	O	-1	10737864
rats.	O	-1	10737864
A@@	O	-1	10737864
g@@	O	-1	10737864
e-@@	O	-1	10737864
related	O	-1	10737864
changes	O	-1	10737864
in	O	-1	10737864
ult@@	O	-1	10737864
r@@	O	-1	10737864
as@@	O	-1	10737864
ound	O	-1	10737864
pro@@	O	-1	10737864
duction	O	-1	10737864
cor@@	O	-1	10737864
respon@@	O	-1	10737864
ded	O	-1	10737864
with	O	-1	10737864
changes	O	-1	10737864
in	O	-1	10737864
cardiovascular	O	-1	10737864
vari@@	O	-1	10737864
abl@@	O	-1	10737864
es,	O	-1	10737864
including	O	-1	10737864
baseline	O	-1	10737864
cardiac	O	-1	10737864
rate	O	-1	10737864
and	O	-1	10737864
clonidine	B-Chemical	D003000	10737864
-induced	O	-1	10737864
brady@@	B-Disease	D001919	10737864
cardia	I-Disease	-1	10737864
.	O	-1	10737864
This	O	-1	10737864
experim@@	O	-1	10737864
ent	O	-1	10737864
is	O	-1	10737864
discus@@	O	-1	10737864
sed	O	-1	10737864
with	O	-1	10737864
reg@@	O	-1	10737864
ard	O	-1	10737864
to	O	-1	10737864
the	O	-1	10737864
hypo@@	O	-1	10737864
thesis	O	-1	10737864
that	O	-1	10737864
ult@@	O	-1	10737864
r@@	O	-1	10737864
as@@	O	-1	10737864
ound	O	-1	10737864
pro@@	O	-1	10737864
duction	O	-1	10737864
is	O	-1	10737864
the	O	-1	10737864
ac@@	O	-1	10737864
ous@@	O	-1	10737864
tic	O	-1	10737864
b@@	O	-1	10737864
y-@@	O	-1	10737864
produc@@	O	-1	10737864
t	O	-1	10737864
of	O	-1	10737864
a	O	-1	10737864
physi@@	O	-1	10737864
ological	O	-1	10737864
man@@	O	-1	10737864
eu@@	O	-1	10737864
ver	O	-1	10737864
that	O	-1	10737864
com@@	O	-1	10737864
pen@@	O	-1	10737864
s@@	O	-1	10737864
ates	O	-1	10737864
for	O	-1	10737864
clonidine	B-Chemical	D003000	10737864
's	O	-1	10737864
de@@	O	-1	10737864
tri@@	O	-1	10737864
mental	O	-1	10737864
effects	O	-1	10737864
on	O	-1	10737864
cardiovascular	O	-1	10737864
func@@	O	-1	10737864
tion.	O	-1	10737864

Di@@	O	-1	10743446
fferen@@	O	-1	10743446
tial	O	-1	10743446
effects	O	-1	10743446
of	O	-1	10743446
system@@	O	-1	10743446
ically	O	-1	10743446
administered	O	-1	10743446
k@@	B-Chemical	D007649	10743446
et@@	I-Chemical	-1	10743446
amine	I-Chemical	-1	10743446
and	O	-1	10743446
lidocaine	B-Chemical	D008012	10743446
on	O	-1	10743446
dynam@@	O	-1	10743446
ic	O	-1	10743446
and	O	-1	10743446
st@@	O	-1	10743446
atic	O	-1	10743446
hyperalge@@	B-Disease	D006930	10743446
sia	I-Disease	-1	10743446
induced	O	-1	10743446
by	O	-1	10743446
intra@@	O	-1	10743446
der@@	O	-1	10743446
m@@	O	-1	10743446
al	O	-1	10743446
cap@@	B-Chemical	D002211	10743446
sa@@	I-Chemical	-1	10743446
icin	I-Chemical	-1	10743446
in	O	-1	10743446
hum@@	O	-1	10743446
an@@	O	-1	10743446
s.	O	-1	10743446
We	O	-1	10743446
have	O	-1	10743446
examined	O	-1	10743446
the	O	-1	10743446
effect	O	-1	10743446
of	O	-1	10743446
systemic	O	-1	10743446
administration	O	-1	10743446
of	O	-1	10743446
k@@	B-Chemical	D007649	10743446
et@@	I-Chemical	-1	10743446
amine	I-Chemical	-1	10743446
and	O	-1	10743446
lidocaine	B-Chemical	D008012	10743446
on	O	-1	10743446
b@@	O	-1	10743446
r@@	O	-1	10743446
us@@	O	-1	10743446
h@@	O	-1	10743446
-@@	O	-1	10743446
evoked	O	-1	10743446
(@@	O	-1	10743446
dynam@@	O	-1	10743446
ic@@	O	-1	10743446
)	O	-1	10743446
pain	B-Disease	D010146	10743446
and	O	-1	10743446
p@@	O	-1	10743446
unc@@	O	-1	10743446
t@@	O	-1	10743446
at@@	O	-1	10743446
e-@@	O	-1	10743446
evoked	O	-1	10743446
(@@	O	-1	10743446
st@@	O	-1	10743446
ati@@	O	-1	10743446
c@@	O	-1	10743446
)	O	-1	10743446
hyperalge@@	B-Disease	D006930	10743446
sia	I-Disease	-1	10743446
induced	O	-1	10743446
by	O	-1	10743446
cap@@	B-Chemical	D002211	10743446
sa@@	I-Chemical	-1	10743446
icin	I-Chemical	-1	10743446
.	O	-1	10743446
In	O	-1	10743446
a	O	-1	10743446
random@@	O	-1	10743446
iz@@	O	-1	10743446
ed,	O	-1	10743446
double-bl@@	O	-1	10743446
ind@@	O	-1	10743446
,	O	-1	10743446
placebo@@	O	-1	10743446
-@@	O	-1	10743446
control@@	O	-1	10743446
le@@	O	-1	10743446
d,	O	-1	10743446
cros@@	O	-1	10743446
s@@	O	-1	10743446
over	O	-1	10743446
study,	O	-1	10743446
we	O	-1	10743446
studied	O	-1	10743446
12	O	-1	10743446
vol@@	O	-1	10743446
un@@	O	-1	10743446
te@@	O	-1	10743446
ers	O	-1	10743446
in	O	-1	10743446
three	O	-1	10743446
experim@@	O	-1	10743446
ent@@	O	-1	10743446
s.	O	-1	10743446
C@@	B-Chemical	D002211	10743446
ap@@	I-Chemical	-1	10743446
sa@@	I-Chemical	-1	10743446
icin	I-Chemical	-1	10743446
100	O	-1	10743446
microgram@@	O	-1	10743446
s	O	-1	10743446
was	O	-1	10743446
injected	O	-1	10743446
intra@@	O	-1	10743446
der@@	O	-1	10743446
m@@	O	-1	10743446
ally	O	-1	10743446
on	O	-1	10743446
the	O	-1	10743446
vol@@	O	-1	10743446
ar	O	-1	10743446
fo@@	O	-1	10743446
re@@	O	-1	10743446
ar@@	O	-1	10743446
m	O	-1	10743446
followed	O	-1	10743446
by	O	-1	10743446
an	O	-1	10743446
i.v@@	O	-1	10743446
.	O	-1	10743446
infusion	O	-1	10743446
of	O	-1	10743446
k@@	B-Chemical	D007649	10743446
et@@	I-Chemical	-1	10743446
amine	I-Chemical	-1	10743446
(@@	O	-1	10743446
b@@	O	-1	10743446
ol@@	O	-1	10743446
us	O	-1	10743446
0.@@	O	-1	10743446
1	O	-1	10743446
mg	O	-1	10743446
kg@@	O	-1	10743446
-1	O	-1	10743446
over	O	-1	10743446
10	O	-1	10743446
min	O	-1	10743446
followed	O	-1	10743446
by	O	-1	10743446
infusion	O	-1	10743446
of	O	-1	10743446
7	O	-1	10743446
microgram@@	O	-1	10743446
s	O	-1	10743446
kg@@	O	-1	10743446
-1	O	-1	10743446
min@@	O	-1	10743446
-1@@	O	-1	10743446
),	O	-1	10743446
lidocaine	B-Chemical	D008012	10743446
5	O	-1	10743446
mg	O	-1	10743446
kg@@	O	-1	10743446
-1	O	-1	10743446
or	O	-1	10743446
saline	O	-1	10743446
for	O	-1	10743446
50	O	-1	10743446
min@@	O	-1	10743446
.	O	-1	10743446
In@@	O	-1	10743446
f@@	O	-1	10743446
usion	O	-1	10743446
star@@	O	-1	10743446
ted	O	-1	10743446
15	O	-1	10743446
min	O	-1	10743446
after	O	-1	10743446
injection	O	-1	10743446
of	O	-1	10743446
cap@@	B-Chemical	D002211	10743446
sa@@	I-Chemical	-1	10743446
icin	I-Chemical	-1	10743446
.	O	-1	10743446
The	O	-1	10743446
following	O	-1	10743446
were	O	-1	10743446
meas@@	O	-1	10743446
ure@@	O	-1	10743446
d@@	O	-1	10743446
:	O	-1	10743446
spont@@	O	-1	10743446
aneous	O	-1	10743446
pain	B-Disease	D010146	10743446
,	O	-1	10743446
pain	B-Disease	D010146	10743446
evoked	O	-1	10743446
by	O	-1	10743446
p@@	O	-1	10743446
unc@@	O	-1	10743446
t@@	O	-1	10743446
ate	O	-1	10743446
and	O	-1	10743446
b@@	O	-1	10743446
r@@	O	-1	10743446
us@@	O	-1	10743446
h	O	-1	10743446
stimul@@	O	-1	10743446
i	O	-1	10743446
(V@@	O	-1	10743446
A@@	O	-1	10743446
S@@	O	-1	10743446
),	O	-1	10743446
and	O	-1	10743446
a@@	O	-1	10743446
reas	O	-1	10743446
of	O	-1	10743446
b@@	O	-1	10743446
r@@	O	-1	10743446
us@@	O	-1	10743446
h@@	O	-1	10743446
-@@	O	-1	10743446
evoked	O	-1	10743446
and	O	-1	10743446
p@@	O	-1	10743446
unc@@	O	-1	10743446
t@@	O	-1	10743446
at@@	O	-1	10743446
e-@@	O	-1	10743446
evoked	O	-1	10743446
hyperalge@@	B-Disease	D006930	10743446
sia	I-Disease	-1	10743446
.	O	-1	10743446
K@@	B-Chemical	D007649	10743446
et@@	I-Chemical	-1	10743446
amine	I-Chemical	-1	10743446
reduced	O	-1	10743446
both	O	-1	10743446
the	O	-1	10743446
a@@	O	-1	10743446
re@@	O	-1	10743446
a	O	-1	10743446
of	O	-1	10743446
b@@	O	-1	10743446
r@@	O	-1	10743446
us@@	O	-1	10743446
h@@	O	-1	10743446
-@@	O	-1	10743446
evoked	O	-1	10743446
and	O	-1	10743446
p@@	O	-1	10743446
unc@@	O	-1	10743446
t@@	O	-1	10743446
at@@	O	-1	10743446
e-@@	O	-1	10743446
evoked	O	-1	10743446
hyperalge@@	B-Disease	D006930	10743446
sia	I-Disease	-1	10743446
significantly	O	-1	10743446
and	O	-1	10743446
it	O	-1	10743446
ten@@	O	-1	10743446
ded	O	-1	10743446
to	O	-1	10743446
re@@	O	-1	10743446
duce	O	-1	10743446
b@@	O	-1	10743446
r@@	O	-1	10743446
us@@	O	-1	10743446
h@@	O	-1	10743446
-@@	O	-1	10743446
evoked	O	-1	10743446
pain	B-Disease	D010146	10743446
.	O	-1	10743446
L@@	B-Chemical	D008012	10743446
idoc@@	I-Chemical	-1	10743446
aine	I-Chemical	-1	10743446
reduced	O	-1	10743446
the	O	-1	10743446
a@@	O	-1	10743446
re@@	O	-1	10743446
a	O	-1	10743446
of	O	-1	10743446
p@@	O	-1	10743446
unc@@	O	-1	10743446
t@@	O	-1	10743446
at@@	O	-1	10743446
e-@@	O	-1	10743446
evoked	O	-1	10743446
hyperalge@@	B-Disease	D006930	10743446
sia	I-Disease	-1	10743446
significant@@	O	-1	10743446
ly.	O	-1	10743446
It	O	-1	10743446
ten@@	O	-1	10743446
ded	O	-1	10743446
to	O	-1	10743446
re@@	O	-1	10743446
duce	O	-1	10743446
V@@	O	-1	10743446
A@@	O	-1	10743446
S	O	-1	10743446
sco@@	O	-1	10743446
res	O	-1	10743446
of	O	-1	10743446
spont@@	O	-1	10743446
aneous	O	-1	10743446
pain	B-Disease	D010146	10743446
but	O	-1	10743446
had	O	-1	10743446
no	O	-1	10743446
effect	O	-1	10743446
on	O	-1	10743446
evoked	O	-1	10743446
pain	B-Disease	D010146	10743446
.	O	-1	10743446
The	O	-1	10743446
differen@@	O	-1	10743446
tial	O	-1	10743446
effects	O	-1	10743446
of	O	-1	10743446
k@@	B-Chemical	D007649	10743446
et@@	I-Chemical	-1	10743446
amine	I-Chemical	-1	10743446
and	O	-1	10743446
lidocaine	B-Chemical	D008012	10743446
on	O	-1	10743446
st@@	O	-1	10743446
atic	O	-1	10743446
and	O	-1	10743446
dynam@@	O	-1	10743446
ic	O	-1	10743446
hyperalge@@	B-Disease	D006930	10743446
sia	I-Disease	-1	10743446
suggest	O	-1	10743446
that	O	-1	10743446
the	O	-1	10743446
two	O	-1	10743446
typ@@	O	-1	10743446
es	O	-1	10743446
of	O	-1	10743446
hyperalge@@	B-Disease	D006930	10743446
sia	I-Disease	-1	10743446
are	O	-1	10743446
mediated	O	-1	10743446
by	O	-1	10743446
se@@	O	-1	10743446
par@@	O	-1	10743446
ate	O	-1	10743446
mechanisms	O	-1	10743446
and	O	-1	10743446
have	O	-1	10743446
a	O	-1	10743446
dist@@	O	-1	10743446
inc@@	O	-1	10743446
t	O	-1	10743446
pharmac@@	O	-1	10743446
olog@@	O	-1	10743446
y.	O	-1	10743446

C@@	B-Chemical	D016572	11007689
yc@@	I-Chemical	-1	11007689
lospor@@	I-Chemical	-1	11007689
ine	I-Chemical	-1	11007689
and	O	-1	11007689
tacrolimus	B-Chemical	D016559	11007689
-@@	O	-1	11007689
associated	O	-1	11007689
thrombotic	B-Disease	D057049	11007689
microangio@@	I-Disease	-1	11007689
pathy	I-Disease	-1	11007689
.	O	-1	11007689
The	O	-1	11007689
development	O	-1	11007689
of	O	-1	11007689
thrombotic	B-Disease	D057049	11007689
microangio@@	I-Disease	-1	11007689
pathy	I-Disease	-1	11007689
(	O	-1	11007689
T@@	B-Disease	D057049	11007689
M@@	I-Disease	-1	11007689
A	I-Disease	-1	11007689
)	O	-1	11007689
associated	O	-1	11007689
with	O	-1	11007689
the	O	-1	11007689
use	O	-1	11007689
of	O	-1	11007689
cyclospor@@	B-Chemical	D016572	11007689
ine	I-Chemical	-1	11007689
has	O	-1	11007689
been	O	-1	11007689
well	O	-1	11007689
doc@@	O	-1	11007689
um@@	O	-1	11007689
ent@@	O	-1	11007689
ed.	O	-1	11007689
Treat@@	O	-1	11007689
ments	O	-1	11007689
have	O	-1	11007689
included	O	-1	11007689
discontinu@@	O	-1	11007689
ation	O	-1	11007689
or	O	-1	11007689
reduction	O	-1	11007689
of	O	-1	11007689
cyclospor@@	B-Chemical	D016572	11007689
ine	I-Chemical	-1	11007689
dose	O	-1	11007689
with	O	-1	11007689
or	O	-1	11007689
without	O	-1	11007689
con@@	O	-1	11007689
current	O	-1	11007689
plasma	O	-1	11007689
ex@@	O	-1	11007689
chang@@	O	-1	11007689
e,	O	-1	11007689
plasma	O	-1	11007689
infu@@	O	-1	11007689
sion,	O	-1	11007689
anti@@	O	-1	11007689
co@@	O	-1	11007689
ag@@	O	-1	11007689
ul@@	O	-1	11007689
ation,	O	-1	11007689
and	O	-1	11007689
intravenous	O	-1	11007689
immuno@@	O	-1	11007689
glo@@	O	-1	11007689
b@@	O	-1	11007689
ul@@	O	-1	11007689
in	O	-1	11007689
G	O	-1	11007689
infu@@	O	-1	11007689
sion.	O	-1	11007689
However,	O	-1	11007689
for	O	-1	11007689
re@@	O	-1	11007689
ci@@	O	-1	11007689
pi@@	O	-1	11007689
ents	O	-1	11007689
of	O	-1	11007689
org@@	O	-1	11007689
an	O	-1	11007689
transplant@@	O	-1	11007689
ation,	O	-1	11007689
re@@	O	-1	11007689
mo@@	O	-1	11007689
ving	O	-1	11007689
the	O	-1	11007689
inc@@	O	-1	11007689
it@@	O	-1	11007689
ing	O	-1	11007689
agent	O	-1	11007689
is	O	-1	11007689
not	O	-1	11007689
without	O	-1	11007689
the	O	-1	11007689
atten@@	O	-1	11007689
d@@	O	-1	11007689
ant	O	-1	11007689
risk	O	-1	11007689
of	O	-1	11007689
pre@@	O	-1	11007689
ci@@	O	-1	11007689
pit@@	O	-1	11007689
ating	O	-1	11007689
acute	O	-1	11007689
re@@	O	-1	11007689
j@@	O	-1	11007689
ection	O	-1	11007689
and	O	-1	11007689
gra@@	O	-1	11007689
ft	O	-1	11007689
los@@	O	-1	11007689
s.	O	-1	11007689
The	O	-1	11007689
las@@	O	-1	11007689
t	O	-1	11007689
dec@@	O	-1	11007689
ade	O	-1	11007689
has	O	-1	11007689
seen	O	-1	11007689
the	O	-1	11007689
em@@	O	-1	11007689
er@@	O	-1	11007689
gen@@	O	-1	11007689
ce	O	-1	11007689
of	O	-1	11007689
tacrolimus	B-Chemical	D016559	11007689
as	O	-1	11007689
a	O	-1	11007689
pot@@	O	-1	11007689
ent	O	-1	11007689
immunosup@@	O	-1	11007689
pressive	O	-1	11007689
agent	O	-1	11007689
with	O	-1	11007689
mechanisms	O	-1	11007689
of	O	-1	11007689
action	O	-1	11007689
vi@@	O	-1	11007689
r@@	O	-1	11007689
tu@@	O	-1	11007689
ally	O	-1	11007689
id@@	O	-1	11007689
en@@	O	-1	11007689
tical	O	-1	11007689
to	O	-1	11007689
those	O	-1	11007689
of	O	-1	11007689
cyclospor@@	B-Chemical	D016572	11007689
ine	I-Chemical	-1	11007689
.	O	-1	11007689
A@@	O	-1	11007689
s	O	-1	11007689
a	O	-1	11007689
result@@	O	-1	11007689
,	O	-1	11007689
switch@@	O	-1	11007689
ing	O	-1	11007689
to	O	-1	11007689
tacrolimus	B-Chemical	D016559	11007689
has	O	-1	11007689
been	O	-1	11007689
reported	O	-1	11007689
to	O	-1	11007689
be	O	-1	11007689
a	O	-1	11007689
vi@@	O	-1	11007689
able	O	-1	11007689
therapeutic	O	-1	11007689
op@@	O	-1	11007689
tion	O	-1	11007689
in	O	-1	11007689
the	O	-1	11007689
se@@	O	-1	11007689
t@@	O	-1	11007689
ting	O	-1	11007689
of	O	-1	11007689
cyclospor@@	B-Chemical	D016572	11007689
ine	I-Chemical	-1	11007689
-induced	O	-1	11007689
T@@	B-Disease	D057049	11007689
M@@	I-Disease	-1	11007689
A	I-Disease	-1	11007689
.	O	-1	11007689
W@@	O	-1	11007689
it@@	O	-1	11007689
h	O	-1	11007689
the	O	-1	11007689
more	O	-1	11007689
w@@	O	-1	11007689
id@@	O	-1	11007689
es@@	O	-1	11007689
pre@@	O	-1	11007689
ad	O	-1	11007689
ap@@	O	-1	11007689
plic@@	O	-1	11007689
ation	O	-1	11007689
of	O	-1	11007689
tacrolimus	B-Chemical	D016559	11007689
in	O	-1	11007689
org@@	O	-1	11007689
an	O	-1	11007689
transplant@@	O	-1	11007689
ation,	O	-1	11007689
tacrolimus	B-Chemical	D016559	11007689
-@@	O	-1	11007689
associated	O	-1	11007689
T@@	B-Disease	D057049	11007689
M@@	I-Disease	-1	11007689
A	I-Disease	-1	11007689
has	O	-1	11007689
also	O	-1	11007689
been	O	-1	11007689
reco@@	O	-1	11007689
gn@@	O	-1	11007689
iz@@	O	-1	11007689
ed.	O	-1	11007689
However,	O	-1	11007689
literat@@	O	-1	11007689
ure	O	-1	11007689
reg@@	O	-1	11007689
ar@@	O	-1	11007689
ding	O	-1	11007689
the	O	-1	11007689
incidence	O	-1	11007689
of	O	-1	11007689
the	O	-1	11007689
recur@@	O	-1	11007689
rence	O	-1	11007689
of	O	-1	11007689
T@@	B-Disease	D057049	11007689
M@@	I-Disease	-1	11007689
A	I-Disease	-1	11007689
in	O	-1	11007689
patients	O	-1	11007689
exposed	O	-1	11007689
sequ@@	O	-1	11007689
enti@@	O	-1	11007689
ally	O	-1	11007689
to	O	-1	11007689
cyclospor@@	B-Chemical	D016572	11007689
ine	I-Chemical	-1	11007689
and	O	-1	11007689
tacrolimus	B-Chemical	D016559	11007689
is	O	-1	11007689
lim@@	O	-1	11007689
it@@	O	-1	11007689
ed.	O	-1	11007689
We	O	-1	11007689
report	O	-1	11007689
a	O	-1	11007689
case	O	-1	11007689
of	O	-1	11007689
a	O	-1	11007689
li@@	O	-1	11007689
ving	O	-1	11007689
d@@	O	-1	11007689
on@@	O	-1	11007689
or	O	-1	11007689
renal	O	-1	11007689
transplant	O	-1	11007689
re@@	O	-1	11007689
ci@@	O	-1	11007689
pi@@	O	-1	11007689
ent	O	-1	11007689
who	O	-1	11007689
developed	O	-1	11007689
cyclospor@@	B-Chemical	D016572	11007689
ine	I-Chemical	-1	11007689
-induced	O	-1	11007689
T@@	B-Disease	D057049	11007689
M@@	I-Disease	-1	11007689
A	I-Disease	-1	11007689
that	O	-1	11007689
respon@@	O	-1	11007689
ded	O	-1	11007689
to	O	-1	11007689
the	O	-1	11007689
withdrawal	O	-1	11007689
of	O	-1	11007689
cyclospor@@	B-Chemical	D016572	11007689
ine	I-Chemical	-1	11007689
in	O	-1	11007689
con@@	O	-1	11007689
j@@	O	-1	11007689
unc@@	O	-1	11007689
tion	O	-1	11007689
with	O	-1	11007689
plas@@	O	-1	11007689
ma@@	O	-1	11007689
ph@@	O	-1	11007689
e@@	O	-1	11007689
re@@	O	-1	11007689
sis	O	-1	11007689
and	O	-1	11007689
f@@	O	-1	11007689
res@@	O	-1	11007689
h	O	-1	11007689
f@@	O	-1	11007689
ro@@	O	-1	11007689
z@@	O	-1	11007689
en	O	-1	11007689
plasma	O	-1	11007689
re@@	O	-1	11007689
pl@@	O	-1	11007689
ac@@	O	-1	11007689
ement	O	-1	11007689
therapy.	O	-1	11007689
In@@	O	-1	11007689
tro@@	O	-1	11007689
duction	O	-1	11007689
of	O	-1	11007689
tacrolimus	B-Chemical	D016559	11007689
as	O	-1	11007689
an	O	-1	11007689
al@@	O	-1	11007689
tern@@	O	-1	11007689
ative	O	-1	11007689
immunosup@@	O	-1	11007689
pressive	O	-1	11007689
agent	O	-1	11007689
resulted	O	-1	11007689
in	O	-1	11007689
the	O	-1	11007689
recur@@	O	-1	11007689
rence	O	-1	11007689
of	O	-1	11007689
T@@	B-Disease	D057049	11007689
M@@	I-Disease	-1	11007689
A	I-Disease	-1	11007689
and	O	-1	11007689
the	O	-1	11007689
subsequ@@	O	-1	11007689
ent	O	-1	11007689
loss	O	-1	11007689
of	O	-1	11007689
the	O	-1	11007689
renal	O	-1	11007689
allogra@@	O	-1	11007689
f@@	O	-1	11007689
t.	O	-1	11007689
Patients	O	-1	11007689
who	O	-1	11007689
are	O	-1	11007689
switch@@	O	-1	11007689
ed	O	-1	11007689
from	O	-1	11007689
cyclospor@@	B-Chemical	D016572	11007689
ine	I-Chemical	-1	11007689
to	O	-1	11007689
tacrolimus	B-Chemical	D016559	11007689
or	O	-1	11007689
v@@	O	-1	11007689
ic@@	O	-1	11007689
e	O	-1	11007689
ver@@	O	-1	11007689
s@@	O	-1	11007689
a	O	-1	11007689
should	O	-1	11007689
be	O	-1	11007689
clo@@	O	-1	11007689
se@@	O	-1	11007689
ly	O	-1	11007689
monit@@	O	-1	11007689
o@@	O	-1	11007689
red	O	-1	11007689
for	O	-1	11007689
the	O	-1	11007689
signs	O	-1	11007689
and	O	-1	11007689
symptoms	O	-1	11007689
of	O	-1	11007689
recur@@	O	-1	11007689
rent	O	-1	11007689
T@@	B-Disease	D057049	11007689
M@@	I-Disease	-1	11007689
A	I-Disease	-1	11007689
.	O	-1	11007689

R@@	O	-1	11256525
ep@@	O	-1	11256525
e@@	O	-1	11256525
ated	O	-1	11256525
transi@@	O	-1	11256525
ent	O	-1	11256525
an@@	B-Disease	D001002	11256525
uria	I-Disease	-1	11256525
following	O	-1	11256525
los@@	B-Chemical	D019808	11256525
ar@@	I-Chemical	-1	11256525
t@@	I-Chemical	-1	11256525
an	I-Chemical	-1	11256525
administration	O	-1	11256525
in	O	-1	11256525
a	O	-1	11256525
patient	O	-1	11256525
with	O	-1	11256525
a	O	-1	11256525
sol@@	O	-1	11256525
it@@	O	-1	11256525
ary	O	-1	11256525
kidne@@	O	-1	11256525
y.	O	-1	11256525
We	O	-1	11256525
report	O	-1	11256525
the	O	-1	11256525
case	O	-1	11256525
of	O	-1	11256525
a	O	-1	11256525
7@@	O	-1	11256525
0-@@	O	-1	11256525
year-old	O	-1	11256525
hypertensive	B-Disease	D006973	11256525
man	O	-1	11256525
with	O	-1	11256525
a	O	-1	11256525
sol@@	O	-1	11256525
it@@	O	-1	11256525
ary	O	-1	11256525
kidney	O	-1	11256525
and	O	-1	11256525
chronic	B-Disease	D051436	11256525
renal	I-Disease	-1	11256525
in@@	I-Disease	-1	11256525
suffici@@	I-Disease	-1	11256525
ency	I-Disease	-1	11256525
who	O	-1	11256525
developed	O	-1	11256525
two	O	-1	11256525
episo@@	O	-1	11256525
des	O	-1	11256525
of	O	-1	11256525
transi@@	O	-1	11256525
ent	O	-1	11256525
an@@	B-Disease	D001002	11256525
uria	I-Disease	-1	11256525
after	O	-1	11256525
los@@	B-Chemical	D019808	11256525
ar@@	I-Chemical	-1	11256525
t@@	I-Chemical	-1	11256525
an	I-Chemical	-1	11256525
administr@@	O	-1	11256525
ation.	O	-1	11256525
H@@	O	-1	11256525
e	O	-1	11256525
was	O	-1	11256525
hospit@@	O	-1	11256525
al@@	O	-1	11256525
ized	O	-1	11256525
for	O	-1	11256525
a	O	-1	11256525
myocardial	B-Disease	D009203	11256525
infarction	I-Disease	-1	11256525
with	O	-1	11256525
pulmonary	B-Disease	D011654	11256525
e@@	I-Disease	-1	11256525
de@@	I-Disease	-1	11256525
ma	I-Disease	-1	11256525
,	O	-1	11256525
treated	O	-1	11256525
with	O	-1	11256525
high-dose	O	-1	11256525
di@@	O	-1	11256525
ure@@	O	-1	11256525
tic@@	O	-1	11256525
s.	O	-1	11256525
D@@	O	-1	11256525
u@@	O	-1	11256525
e	O	-1	11256525
to	O	-1	11256525
severe	O	-1	11256525
systolic	B-Disease	D006331	11256525
dysfunction	I-Disease	-1	11256525
los@@	B-Chemical	D019808	11256525
ar@@	I-Chemical	-1	11256525
t@@	I-Chemical	-1	11256525
an	I-Chemical	-1	11256525
was	O	-1	11256525
prescri@@	O	-1	11256525
be@@	O	-1	11256525
d.	O	-1	11256525
S@@	O	-1	11256525
ur@@	O	-1	11256525
p@@	O	-1	11256525
ris@@	O	-1	11256525
ing@@	O	-1	11256525
ly,	O	-1	11256525
the	O	-1	11256525
first	O	-1	11256525
dose	O	-1	11256525
of	O	-1	11256525
50	O	-1	11256525
mg	O	-1	11256525
of	O	-1	11256525
los@@	B-Chemical	D019808	11256525
ar@@	I-Chemical	-1	11256525
t@@	I-Chemical	-1	11256525
an	I-Chemical	-1	11256525
resulted	O	-1	11256525
in	O	-1	11256525
a	O	-1	11256525
su@@	O	-1	11256525
d@@	O	-1	11256525
de@@	O	-1	11256525
n	O	-1	11256525
an@@	B-Disease	D001002	11256525
uria	I-Disease	-1	11256525
,	O	-1	11256525
which	O	-1	11256525
l@@	O	-1	11256525
ast@@	O	-1	11256525
ed	O	-1	11256525
e@@	O	-1	11256525
ight	O	-1	11256525
hours	O	-1	11256525
des@@	O	-1	11256525
pit@@	O	-1	11256525
e	O	-1	11256525
high-dose	O	-1	11256525
f@@	B-Chemical	D005665	11256525
uro@@	I-Chemical	-1	11256525
se@@	I-Chemical	-1	11256525
m@@	I-Chemical	-1	11256525
ide	I-Chemical	-1	11256525
and	O	-1	11256525
amine	B-Chemical	D000588	11256525
infu@@	O	-1	11256525
sion.	O	-1	11256525
One	O	-1	11256525
week	O	-1	11256525
lat@@	O	-1	11256525
er,	O	-1	11256525
by	O	-1	11256525
m@@	O	-1	11256525
ist@@	O	-1	11256525
ak@@	O	-1	11256525
e,	O	-1	11256525
los@@	B-Chemical	D019808	11256525
ar@@	I-Chemical	-1	11256525
t@@	I-Chemical	-1	11256525
an	I-Chemical	-1	11256525
was	O	-1	11256525
prescri@@	O	-1	11256525
bed	O	-1	11256525
ag@@	O	-1	11256525
ain	O	-1	11256525
and	O	-1	11256525
after	O	-1	11256525
the	O	-1	11256525
second	O	-1	11256525
dose	O	-1	11256525
of	O	-1	11256525
50	O	-1	11256525
mg@@	O	-1	11256525
,	O	-1	11256525
the	O	-1	11256525
patient	O	-1	11256525
developed	O	-1	11256525
a	O	-1	11256525
second	O	-1	11256525
episo@@	O	-1	11256525
de	O	-1	11256525
of	O	-1	11256525
transi@@	O	-1	11256525
ent	O	-1	11256525
an@@	B-Disease	D001002	11256525
uria	I-Disease	-1	11256525
l@@	O	-1	11256525
ast@@	O	-1	11256525
ing	O	-1	11256525
10	O	-1	11256525
hour@@	O	-1	11256525
s.	O	-1	11256525
D@@	O	-1	11256525
uring	O	-1	11256525
these	O	-1	11256525
two	O	-1	11256525
episo@@	O	-1	11256525
d@@	O	-1	11256525
es,	O	-1	11256525
h@@	O	-1	11256525
is	O	-1	11256525
blood	O	-1	11256525
pressure	O	-1	11256525
di@@	O	-1	11256525
min@@	O	-1	11256525
ished	O	-1	11256525
but	O	-1	11256525
no	O	-1	11256525
severe	O	-1	11256525
hypotension	B-Disease	D007022	11256525
was	O	-1	11256525
not@@	O	-1	11256525
ed.	O	-1	11256525
U@@	O	-1	11256525
l@@	O	-1	11256525
tim@@	O	-1	11256525
at@@	O	-1	11256525
el@@	O	-1	11256525
y,	O	-1	11256525
an	O	-1	11256525
arter@@	O	-1	11256525
io@@	O	-1	11256525
graph@@	O	-1	11256525
y	O	-1	11256525
showed	O	-1	11256525
a	O	-1	11256525
7@@	O	-1	11256525
0-@@	O	-1	11256525
8@@	O	-1	11256525
0%	O	-1	11256525
renal	B-Disease	D012078	11256525
artery	I-Disease	-1	11256525
st@@	I-Disease	-1	11256525
en@@	I-Disease	-1	11256525
o@@	I-Disease	-1	11256525
sis	I-Disease	-1	11256525
.	O	-1	11256525
In	O	-1	11256525
this	O	-1	11256525
patient@@	O	-1	11256525
,	O	-1	11256525
renal	B-Disease	D012078	11256525
artery	I-Disease	-1	11256525
st@@	I-Disease	-1	11256525
en@@	I-Disease	-1	11256525
o@@	I-Disease	-1	11256525
sis	I-Disease	-1	11256525
combined	O	-1	11256525
with	O	-1	11256525
heart	B-Disease	D006333	11256525
failure	I-Disease	-1	11256525
and	O	-1	11256525
di@@	O	-1	11256525
ure@@	O	-1	11256525
tic	O	-1	11256525
therapy	O	-1	11256525
cer@@	O	-1	11256525
t@@	O	-1	11256525
ain@@	O	-1	11256525
ly	O	-1	11256525
resulted	O	-1	11256525
in	O	-1	11256525
a	O	-1	11256525
st@@	O	-1	11256525
ron@@	O	-1	11256525
g	O	-1	11256525
activation	O	-1	11256525
of	O	-1	11256525
the	O	-1	11256525
ren@@	O	-1	11256525
in@@	O	-1	11256525
-	O	-1	11256525
angiotens@@	B-Chemical	D000809	11256525
in	I-Chemical	-1	11256525
system	O	-1	11256525
(@@	O	-1	11256525
R@@	O	-1	11256525
A@@	O	-1	11256525
S@@	O	-1	11256525
).	O	-1	11256525
U@@	O	-1	11256525
n@@	O	-1	11256525
der	O	-1	11256525
such	O	-1	11256525
condi@@	O	-1	11256525
tion@@	O	-1	11256525
s,	O	-1	11256525
angiotens@@	B-Chemical	D000804	11256525
in	I-Chemical	-1	11256525
II	I-Chemical	-1	11256525
receptor	O	-1	11256525
block@@	O	-1	11256525
ade	O	-1	11256525
by	O	-1	11256525
los@@	B-Chemical	D019808	11256525
ar@@	I-Chemical	-1	11256525
t@@	I-Chemical	-1	11256525
an	I-Chemical	-1	11256525
prob@@	O	-1	11256525
ably	O	-1	11256525
induced	O	-1	11256525
a	O	-1	11256525
cri@@	O	-1	11256525
tical	O	-1	11256525
f@@	O	-1	11256525
all	O	-1	11256525
in	O	-1	11256525
glomerular	O	-1	11256525
f@@	O	-1	11256525
iltration	O	-1	11256525
pressu@@	O	-1	11256525
re.	O	-1	11256525
This	O	-1	11256525
case	O	-1	11256525
report	O	-1	11256525
high@@	O	-1	11256525
li@@	O	-1	11256525
gh@@	O	-1	11256525
ts	O	-1	11256525
the	O	-1	11256525
fac@@	O	-1	11256525
t	O	-1	11256525
that	O	-1	11256525
the	O	-1	11256525
angiotens@@	B-Chemical	D000804	11256525
in	I-Chemical	-1	11256525
II	I-Chemical	-1	11256525
receptor	O	-1	11256525
antagonist	O	-1	11256525
los@@	B-Chemical	D019808	11256525
ar@@	I-Chemical	-1	11256525
t@@	I-Chemical	-1	11256525
an	I-Chemical	-1	11256525
can	O	-1	11256525
cause	O	-1	11256525
seri@@	O	-1	11256525
ous	O	-1	11256525
un@@	O	-1	11256525
ex@@	O	-1	11256525
p@@	O	-1	11256525
ected	O	-1	11256525
complications	O	-1	11256525
in	O	-1	11256525
patients	O	-1	11256525
with	O	-1	11256525
ren@@	B-Disease	D014652	11256525
o@@	I-Disease	-1	11256525
vascular	I-Disease	-1	11256525
disease	I-Disease	-1	11256525
and	O	-1	11256525
should	O	-1	11256525
be	O	-1	11256525
used	O	-1	11256525
with	O	-1	11256525
ex@@	O	-1	11256525
trem@@	O	-1	11256525
e	O	-1	11256525
cau@@	O	-1	11256525
tion	O	-1	11256525
in	O	-1	11256525
this	O	-1	11256525
se@@	O	-1	11256525
t@@	O	-1	11256525
t@@	O	-1	11256525
ing.	O	-1	11256525

In	O	-1	11334364
viv@@	O	-1	11334364
o	O	-1	11334364
prot@@	O	-1	11334364
ection	O	-1	11334364
of	O	-1	11334364
d@@	O	-1	11334364
n@@	O	-1	11334364
a	O	-1	11334364
damage	O	-1	11334364
associated	O	-1	11334364
apo@@	O	-1	11334364
pto@@	O	-1	11334364
tic	O	-1	11334364
and	O	-1	11334364
necro@@	B-Disease	D009336	11334364
tic	I-Disease	-1	11334364
cell	O	-1	11334364
de@@	O	-1	11334364
ath@@	O	-1	11334364
s	O	-1	11334364
during	O	-1	11334364
acet@@	B-Chemical	D000082	11334364
aminoph@@	I-Chemical	-1	11334364
en	I-Chemical	-1	11334364
-induced	O	-1	11334364
nephro@@	B-Disease	D007674	11334364
toxicity	I-Disease	-1	11334364
,	O	-1	11334364
am@@	B-Chemical	D000638	11334364
iodar@@	I-Chemical	-1	11334364
one	I-Chemical	-1	11334364
-induced	O	-1	11334364
l@@	B-Disease	D008171	11334364
un@@	I-Disease	-1	11334364
g	I-Disease	-1	11334364
toxicity	I-Disease	-1	11334364
and	O	-1	11334364
dox@@	B-Chemical	D004317	11334364
orub@@	I-Chemical	-1	11334364
icin	I-Chemical	-1	11334364
-induced	O	-1	11334364
cardi@@	B-Disease	D066126	11334364
otoxicity	I-Disease	-1	11334364
by	O	-1	11334364
a	O	-1	11334364
novel	O	-1	11334364
I@@	B-Chemical	C511402	11334364
H@@	I-Chemical	-1	11334364
6@@	I-Chemical	-1	11334364
3@@	I-Chemical	-1	11334364
6	I-Chemical	-1	11334364
gra@@	I-Chemical	-1	11334364
p@@	I-Chemical	-1	11334364
e	I-Chemical	-1	11334364
se@@	I-Chemical	-1	11334364
ed	I-Chemical	-1	11334364
pro@@	I-Chemical	-1	11334364
an@@	I-Chemical	-1	11334364
th@@	I-Chemical	-1	11334364
ocy@@	I-Chemical	-1	11334364
an@@	I-Chemical	-1	11334364
id@@	I-Chemical	-1	11334364
in	I-Chemical	-1	11334364
extrac@@	I-Chemical	-1	11334364
t	I-Chemical	-1	11334364
.	O	-1	11334364
G@@	B-Chemical	C511402	11334364
ra@@	I-Chemical	-1	11334364
p@@	I-Chemical	-1	11334364
e	I-Chemical	-1	11334364
se@@	I-Chemical	-1	11334364
ed	I-Chemical	-1	11334364
extrac@@	I-Chemical	-1	11334364
t	I-Chemical	-1	11334364
,	O	-1	11334364
prim@@	O	-1	11334364
ari@@	O	-1	11334364
ly	O	-1	11334364
a	O	-1	11334364
mi@@	O	-1	11334364
x@@	O	-1	11334364
t@@	O	-1	11334364
ure	O	-1	11334364
of	O	-1	11334364
pro@@	B-Chemical	D044945	11334364
an@@	I-Chemical	-1	11334364
th@@	I-Chemical	-1	11334364
ocy@@	I-Chemical	-1	11334364
an@@	I-Chemical	-1	11334364
id@@	I-Chemical	-1	11334364
ins	I-Chemical	-1	11334364
,	O	-1	11334364
has	O	-1	11334364
been	O	-1	11334364
shown	O	-1	11334364
to	O	-1	11334364
mod@@	O	-1	11334364
ul@@	O	-1	11334364
ate	O	-1	11334364
a	O	-1	11334364
wi@@	O	-1	11334364
de@@	O	-1	11334364
-@@	O	-1	11334364
range	O	-1	11334364
of	O	-1	11334364
bio@@	O	-1	11334364
log@@	O	-1	11334364
ic@@	O	-1	11334364
al,	O	-1	11334364
pharmac@@	O	-1	11334364
ological	O	-1	11334364
and	O	-1	11334364
toxic@@	O	-1	11334364
ological	O	-1	11334364
effects	O	-1	11334364
which	O	-1	11334364
are	O	-1	11334364
main@@	O	-1	11334364
ly	O	-1	11334364
cyto@@	O	-1	11334364
prot@@	O	-1	11334364
ecti@@	O	-1	11334364
ve.	O	-1	11334364
This	O	-1	11334364
study	O	-1	11334364
assessed	O	-1	11334364
the	O	-1	11334364
ability	O	-1	11334364
of	O	-1	11334364
I@@	B-Chemical	C511402	11334364
H@@	I-Chemical	-1	11334364
6@@	I-Chemical	-1	11334364
3@@	I-Chemical	-1	11334364
6	I-Chemical	-1	11334364
gra@@	I-Chemical	-1	11334364
p@@	I-Chemical	-1	11334364
e	I-Chemical	-1	11334364
se@@	I-Chemical	-1	11334364
ed	I-Chemical	-1	11334364
pro@@	I-Chemical	-1	11334364
an@@	I-Chemical	-1	11334364
th@@	I-Chemical	-1	11334364
ocy@@	I-Chemical	-1	11334364
an@@	I-Chemical	-1	11334364
id@@	I-Chemical	-1	11334364
in	I-Chemical	-1	11334364
extrac@@	I-Chemical	-1	11334364
t	I-Chemical	-1	11334364
(	O	-1	11334364
G@@	B-Chemical	C511402	11334364
S@@	I-Chemical	-1	11334364
P@@	I-Chemical	-1	11334364
E	I-Chemical	-1	11334364
)	O	-1	11334364
to	O	-1	11334364
prev@@	O	-1	11334364
ent	O	-1	11334364
acet@@	B-Chemical	D000082	11334364
aminoph@@	I-Chemical	-1	11334364
en	I-Chemical	-1	11334364
(	O	-1	11334364
A@@	B-Chemical	D000082	11334364
A@@	I-Chemical	-1	11334364
P	I-Chemical	-1	11334364
)@@	O	-1	11334364
-induced	O	-1	11334364
nephro@@	B-Disease	D007674	11334364
toxicity	I-Disease	-1	11334364
,	O	-1	11334364
am@@	B-Chemical	D000638	11334364
iodar@@	I-Chemical	-1	11334364
one	I-Chemical	-1	11334364
(	O	-1	11334364
AM@@	B-Chemical	D000638	11334364
I	I-Chemical	-1	11334364
)@@	O	-1	11334364
-induced	O	-1	11334364
l@@	B-Disease	D008171	11334364
un@@	I-Disease	-1	11334364
g	I-Disease	-1	11334364
toxicity	I-Disease	-1	11334364
,	O	-1	11334364
and	O	-1	11334364
dox@@	B-Chemical	D004317	11334364
orub@@	I-Chemical	-1	11334364
icin	I-Chemical	-1	11334364
(	O	-1	11334364
DO@@	B-Chemical	D004317	11334364
X	I-Chemical	-1	11334364
)@@	O	-1	11334364
-induced	O	-1	11334364
cardi@@	B-Disease	D066126	11334364
otoxicity	I-Disease	-1	11334364
in	O	-1	11334364
mice.	O	-1	11334364
E@@	O	-1	11334364
x@@	O	-1	11334364
per@@	O	-1	11334364
im@@	O	-1	11334364
ental	O	-1	11334364
desi@@	O	-1	11334364
g@@	O	-1	11334364
n	O	-1	11334364
consist@@	O	-1	11334364
ed	O	-1	11334364
of	O	-1	11334364
four	O	-1	11334364
group@@	O	-1	11334364
s:	O	-1	11334364
control	O	-1	11334364
(@@	O	-1	11334364
ve@@	O	-1	11334364
h@@	O	-1	11334364
ic@@	O	-1	11334364
le	O	-1	11334364
al@@	O	-1	11334364
one@@	O	-1	11334364
),	O	-1	11334364
G@@	B-Chemical	C511402	11334364
S@@	I-Chemical	-1	11334364
P@@	I-Chemical	-1	11334364
E	I-Chemical	-1	11334364
al@@	O	-1	11334364
one,	O	-1	11334364
drug	O	-1	11334364
alone	O	-1	11334364
and	O	-1	11334364
G@@	B-Chemical	C511402	11334364
S@@	I-Chemical	-1	11334364
P@@	I-Chemical	-1	11334364
E	I-Chemical	-1	11334364
+@@	O	-1	11334364
drug.	O	-1	11334364
F@@	O	-1	11334364
or	O	-1	11334364
the	O	-1	11334364
cyto@@	O	-1	11334364
prot@@	O	-1	11334364
ection	O	-1	11334364
study,	O	-1	11334364
animals	O	-1	11334364
were	O	-1	11334364
or@@	O	-1	11334364
ally	O	-1	11334364
g@@	O	-1	11334364
av@@	O	-1	11334364
aged	O	-1	11334364
100	O	-1	11334364
mg/@@	O	-1	11334364
K@@	O	-1	11334364
g	O	-1	11334364
G@@	B-Chemical	C511402	11334364
S@@	I-Chemical	-1	11334364
P@@	I-Chemical	-1	11334364
E	I-Chemical	-1	11334364
for	O	-1	11334364
7-@@	O	-1	11334364
10	O	-1	11334364
days	O	-1	11334364
followed	O	-1	11334364
by	O	-1	11334364
i.@@	O	-1	11334364
p@@	O	-1	11334364
.	O	-1	11334364
injec@@	O	-1	11334364
tions	O	-1	11334364
of	O	-1	11334364
org@@	O	-1	11334364
an	O	-1	11334364
specific	O	-1	11334364
three	O	-1	11334364
drugs	O	-1	11334364
(	O	-1	11334364
A@@	B-Chemical	D000082	11334364
A@@	I-Chemical	-1	11334364
P	I-Chemical	-1	11334364
:	O	-1	11334364
5@@	O	-1	11334364
00	O	-1	11334364
mg/@@	O	-1	11334364
K@@	O	-1	11334364
g	O	-1	11334364
for	O	-1	11334364
24	O	-1	11334364
h@@	O	-1	11334364
;	O	-1	11334364
AM@@	B-Chemical	D000638	11334364
I	I-Chemical	-1	11334364
:	O	-1	11334364
50	O	-1	11334364
mg/@@	O	-1	11334364
K@@	O	-1	11334364
g/@@	O	-1	11334364
day	O	-1	11334364
for	O	-1	11334364
four	O	-1	11334364
da@@	O	-1	11334364
ys@@	O	-1	11334364
;	O	-1	11334364
DO@@	B-Chemical	D004317	11334364
X	I-Chemical	-1	11334364
:	O	-1	11334364
20	O	-1	11334364
mg/@@	O	-1	11334364
K@@	O	-1	11334364
g	O	-1	11334364
for	O	-1	11334364
4@@	O	-1	11334364
8	O	-1	11334364
h@@	O	-1	11334364
).	O	-1	11334364
P@@	O	-1	11334364
ar@@	O	-1	11334364
ame@@	O	-1	11334364
ters	O	-1	11334364
of	O	-1	11334364
study	O	-1	11334364
included	O	-1	11334364
analysis	O	-1	11334364
of	O	-1	11334364
serum	O	-1	11334364
chem@@	O	-1	11334364
ist@@	O	-1	11334364
r@@	O	-1	11334364
y	O	-1	11334364
(A@@	O	-1	11334364
LT@@	O	-1	11334364
,	O	-1	11334364
B@@	O	-1	11334364
U@@	O	-1	11334364
N	O	-1	11334364
and	O	-1	11334364
C@@	O	-1	11334364
P@@	O	-1	11334364
K@@	O	-1	11334364
),	O	-1	11334364
and	O	-1	11334364
or@@	O	-1	11334364
der@@	O	-1	11334364
ly	O	-1	11334364
f@@	O	-1	11334364
ra@@	O	-1	11334364
g@@	O	-1	11334364
ment@@	O	-1	11334364
ation	O	-1	11334364
of	O	-1	11334364
gen@@	O	-1	11334364
om@@	O	-1	11334364
ic	O	-1	11334364
D@@	O	-1	11334364
NA	O	-1	11334364
(@@	O	-1	11334364
both	O	-1	11334364
en@@	O	-1	11334364
d@@	O	-1	11334364
on@@	O	-1	11334364
ucle@@	O	-1	11334364
as@@	O	-1	11334364
e-@@	O	-1	11334364
dependent	O	-1	11334364
and	O	-1	11334364
in@@	O	-1	11334364
depend@@	O	-1	11334364
ent@@	O	-1	11334364
)	O	-1	11334364
in	O	-1	11334364
addition	O	-1	11334364
to	O	-1	11334364
micro@@	O	-1	11334364
sco@@	O	-1	11334364
p@@	O	-1	11334364
ic	O	-1	11334364
evalu@@	O	-1	11334364
ation	O	-1	11334364
of	O	-1	11334364
damage	O	-1	11334364
and/or	O	-1	11334364
prot@@	O	-1	11334364
ection	O	-1	11334364
in	O	-1	11334364
cor@@	O	-1	11334364
respon@@	O	-1	11334364
ding	O	-1	11334364
PA@@	O	-1	11334364
S	O	-1	11334364
st@@	O	-1	11334364
ained	O	-1	11334364
tissu@@	O	-1	11334364
es.	O	-1	11334364
R@@	O	-1	11334364
es@@	O	-1	11334364
ult@@	O	-1	11334364
s	O	-1	11334364
indicate	O	-1	11334364
that	O	-1	11334364
G@@	B-Chemical	C511402	11334364
S@@	I-Chemical	-1	11334364
P@@	I-Chemical	-1	11334364
E	I-Chemical	-1	11334364
pre@@	O	-1	11334364
exposure	O	-1	11334364
prior	O	-1	11334364
to	O	-1	11334364
A@@	B-Chemical	D000082	11334364
A@@	I-Chemical	-1	11334364
P	I-Chemical	-1	11334364
,	O	-1	11334364
AM@@	B-Chemical	D000638	11334364
I	I-Chemical	-1	11334364
and	O	-1	11334364
DO@@	B-Chemical	D004317	11334364
X	I-Chemical	-1	11334364
,	O	-1	11334364
pro@@	O	-1	11334364
vid@@	O	-1	11334364
ed	O	-1	11334364
ne@@	O	-1	11334364
ar	O	-1	11334364
complete	O	-1	11334364
prot@@	O	-1	11334364
ection	O	-1	11334364
in	O	-1	11334364
ter@@	O	-1	11334364
ms	O	-1	11334364
of	O	-1	11334364
serum	O	-1	11334364
chem@@	O	-1	11334364
ist@@	O	-1	11334364
r@@	O	-1	11334364
y	O	-1	11334364
changes	O	-1	11334364
(A@@	O	-1	11334364
LT@@	O	-1	11334364
,	O	-1	11334364
B@@	O	-1	11334364
U@@	O	-1	11334364
N	O	-1	11334364
and	O	-1	11334364
C@@	O	-1	11334364
P@@	O	-1	11334364
K@@	O	-1	11334364
),	O	-1	11334364
and	O	-1	11334364
significantly	O	-1	11334364
reduced	O	-1	11334364
D@@	O	-1	11334364
NA	O	-1	11334364
f@@	O	-1	11334364
ra@@	O	-1	11334364
g@@	O	-1	11334364
ment@@	O	-1	11334364
ation.	O	-1	11334364
H@@	O	-1	11334364
ist@@	O	-1	11334364
o@@	O	-1	11334364
path@@	O	-1	11334364
ological	O	-1	11334364
examin@@	O	-1	11334364
ation	O	-1	11334364
of	O	-1	11334364
kidne@@	O	-1	11334364
y,	O	-1	11334364
heart	O	-1	11334364
and	O	-1	11334364
l@@	O	-1	11334364
un@@	O	-1	11334364
g	O	-1	11334364
sec@@	O	-1	11334364
tions	O	-1	11334364
revealed	O	-1	11334364
moder@@	O	-1	11334364
ate	O	-1	11334364
to	O	-1	11334364
mas@@	O	-1	11334364
sive	O	-1	11334364
tissue	B-Disease	D017695	11334364
damage	I-Disease	-1	11334364
with	O	-1	11334364
a	O	-1	11334364
vari@@	O	-1	11334364
ety	O	-1	11334364
of	O	-1	11334364
morph@@	O	-1	11334364
ological	O	-1	11334364
ab@@	O	-1	11334364
er@@	O	-1	11334364
r@@	O	-1	11334364
ations	O	-1	11334364
by	O	-1	11334364
all	O	-1	11334364
the	O	-1	11334364
three	O	-1	11334364
drugs	O	-1	11334364
in	O	-1	11334364
the	O	-1	11334364
absence	O	-1	11334364
of	O	-1	11334364
G@@	B-Chemical	C511402	11334364
S@@	I-Chemical	-1	11334364
P@@	I-Chemical	-1	11334364
E	I-Chemical	-1	11334364
pre@@	O	-1	11334364
exposure	O	-1	11334364
than	O	-1	11334364
in	O	-1	11334364
its	O	-1	11334364
pres@@	O	-1	11334364
ence@@	O	-1	11334364
.	O	-1	11334364
G@@	B-Chemical	C511402	11334364
S@@	I-Chemical	-1	11334364
P@@	I-Chemical	-1	11334364
E	I-Chemical	-1	11334364
+@@	O	-1	11334364
drug	O	-1	11334364
exposed	O	-1	11334364
tissu@@	O	-1	11334364
es	O	-1	11334364
ex@@	O	-1	11334364
hib@@	O	-1	11334364
ited	O	-1	11334364
min@@	O	-1	11334364
or	O	-1	11334364
re@@	O	-1	11334364
si@@	O	-1	11334364
du@@	O	-1	11334364
al	O	-1	11334364
damage	O	-1	11334364
or	O	-1	11334364
ne@@	O	-1	11334364
ar	O	-1	11334364
total	O	-1	11334364
reco@@	O	-1	11334364
ver@@	O	-1	11334364
y.	O	-1	11334364
Ad@@	O	-1	11334364
di@@	O	-1	11334364
tion@@	O	-1	11334364
ally,	O	-1	11334364
histo@@	O	-1	11334364
path@@	O	-1	11334364
ological	O	-1	11334364
al@@	O	-1	11334364
ter@@	O	-1	11334364
ations	O	-1	11334364
m@@	O	-1	11334364
ir@@	O	-1	11334364
ro@@	O	-1	11334364
red	O	-1	11334364
both	O	-1	11334364
serum	O	-1	11334364
chem@@	O	-1	11334364
ist@@	O	-1	11334364
r@@	O	-1	11334364
y	O	-1	11334364
changes	O	-1	11334364
and	O	-1	11334364
the	O	-1	11334364
pat@@	O	-1	11334364
ter@@	O	-1	11334364
n	O	-1	11334364
of	O	-1	11334364
D@@	O	-1	11334364
NA	O	-1	11334364
f@@	O	-1	11334364
ra@@	O	-1	11334364
g@@	O	-1	11334364
ment@@	O	-1	11334364
ation.	O	-1	11334364
In@@	O	-1	11334364
te@@	O	-1	11334364
rest@@	O	-1	11334364
ing@@	O	-1	11334364
ly,	O	-1	11334364
all	O	-1	11334364
the	O	-1	11334364
drug@@	O	-1	11334364
s,	O	-1	11334364
such	O	-1	11334364
as@@	O	-1	11334364
,	O	-1	11334364
A@@	B-Chemical	D000082	11334364
A@@	I-Chemical	-1	11334364
P	I-Chemical	-1	11334364
,	O	-1	11334364
AM@@	B-Chemical	D000638	11334364
I	I-Chemical	-1	11334364
and	O	-1	11334364
DO@@	B-Chemical	D004317	11334364
X	I-Chemical	-1	11334364
induced	O	-1	11334364
apo@@	O	-1	11334364
pto@@	O	-1	11334364
tic	O	-1	11334364
death	O	-1	11334364
in	O	-1	11334364
addition	O	-1	11334364
to	O	-1	11334364
necro@@	B-Disease	D009336	11334364
sis	I-Disease	-1	11334364
in	O	-1	11334364
the	O	-1	11334364
resp@@	O	-1	11334364
ective	O	-1	11334364
org@@	O	-1	11334364
ans	O	-1	11334364
which	O	-1	11334364
was	O	-1	11334364
very	O	-1	11334364
eff@@	O	-1	11334364
ectively	O	-1	11334364
block@@	O	-1	11334364
ed	O	-1	11334364
by	O	-1	11334364
G@@	B-Chemical	C511402	11334364
S@@	I-Chemical	-1	11334364
P@@	I-Chemical	-1	11334364
E	I-Chemical	-1	11334364
.	O	-1	11334364
S@@	O	-1	11334364
inc@@	O	-1	11334364
e	O	-1	11334364
A@@	B-Chemical	D000082	11334364
A@@	I-Chemical	-1	11334364
P	I-Chemical	-1	11334364
,	O	-1	11334364
AM@@	B-Chemical	D000638	11334364
I	I-Chemical	-1	11334364
and	O	-1	11334364
DO@@	B-Chemical	D004317	11334364
X	I-Chemical	-1	11334364
under@@	O	-1	11334364
g@@	O	-1	11334364
o	O	-1	11334364
b@@	O	-1	11334364
i@@	O	-1	11334364
ot@@	O	-1	11334364
ran@@	O	-1	11334364
s@@	O	-1	11334364
formation	O	-1	11334364
and	O	-1	11334364
are	O	-1	11334364
known	O	-1	11334364
to	O	-1	11334364
produce	O	-1	11334364
dam@@	O	-1	11334364
ag@@	O	-1	11334364
ing	O	-1	11334364
ra@@	O	-1	11334364
dic@@	O	-1	11334364
als	O	-1	11334364
in	O	-1	11334364
viv@@	O	-1	11334364
o@@	O	-1	11334364
,	O	-1	11334364
the	O	-1	11334364
prot@@	O	-1	11334364
ection	O	-1	11334364
by	O	-1	11334364
G@@	B-Chemical	C511402	11334364
S@@	I-Chemical	-1	11334364
P@@	I-Chemical	-1	11334364
E	I-Chemical	-1	11334364
may	O	-1	11334364
be	O	-1	11334364
lin@@	O	-1	11334364
ked	O	-1	11334364
to	O	-1	11334364
both	O	-1	11334364
inhibition	O	-1	11334364
of	O	-1	11334364
metabol@@	O	-1	11334364
ism	O	-1	11334364
and/or	O	-1	11334364
de@@	O	-1	11334364
tox@@	O	-1	11334364
ification	O	-1	11334364
of	O	-1	11334364
cy@@	O	-1	11334364
tot@@	O	-1	11334364
ox@@	O	-1	11334364
ic	O	-1	11334364
ra@@	O	-1	11334364
dic@@	O	-1	11334364
al@@	O	-1	11334364
s.	O	-1	11334364
In	O	-1	11334364
addi@@	O	-1	11334364
tion,	O	-1	11334364
it@@	O	-1	11334364
s@@	O	-1	11334364
'	O	-1	11334364
pres@@	O	-1	11334364
um@@	O	-1	11334364
ed	O	-1	11334364
cont@@	O	-1	11334364
ri@@	O	-1	11334364
bu@@	O	-1	11334364
tion	O	-1	11334364
to	O	-1	11334364
D@@	O	-1	11334364
NA	O	-1	11334364
re@@	O	-1	11334364
pa@@	O	-1	11334364
ir	O	-1	11334364
may	O	-1	11334364
be	O	-1	11334364
an@@	O	-1	11334364
other	O	-1	11334364
important	O	-1	11334364
at@@	O	-1	11334364
tri@@	O	-1	11334364
bu@@	O	-1	11334364
te@@	O	-1	11334364
,	O	-1	11334364
which	O	-1	11334364
pl@@	O	-1	11334364
ayed	O	-1	11334364
a	O	-1	11334364
role	O	-1	11334364
in	O	-1	11334364
the	O	-1	11334364
chemo@@	O	-1	11334364
pre@@	O	-1	11334364
ven@@	O	-1	11334364
tion	O	-1	11334364
pro@@	O	-1	11334364
ces@@	O	-1	11334364
s.	O	-1	11334364
Ad@@	O	-1	11334364
di@@	O	-1	11334364
tion@@	O	-1	11334364
ally,	O	-1	11334364
this	O	-1	11334364
may	O	-1	11334364
have	O	-1	11334364
been	O	-1	11334364
the	O	-1	11334364
first	O	-1	11334364
report	O	-1	11334364
on	O	-1	11334364
AM@@	B-Chemical	D000638	11334364
I	I-Chemical	-1	11334364
-induced	O	-1	11334364
apo@@	O	-1	11334364
pto@@	O	-1	11334364
tic	O	-1	11334364
death	O	-1	11334364
in	O	-1	11334364
the	O	-1	11334364
l@@	O	-1	11334364
un@@	O	-1	11334364
g	O	-1	11334364
tissu@@	O	-1	11334364
e.	O	-1	11334364
T@@	O	-1	11334364
ak@@	O	-1	11334364
en	O	-1	11334364
to@@	O	-1	11334364
ge@@	O	-1	11334364
ther@@	O	-1	11334364
,	O	-1	11334364
these	O	-1	11334364
events	O	-1	11334364
un@@	O	-1	11334364
dou@@	O	-1	11334364
b@@	O	-1	11334364
te@@	O	-1	11334364
d@@	O	-1	11334364
ly	O	-1	11334364
est@@	O	-1	11334364
abl@@	O	-1	11334364
is@@	O	-1	11334364
h	O	-1	11334364
G@@	B-Chemical	C511402	11334364
S@@	I-Chemical	-1	11334364
P@@	I-Chemical	-1	11334364
E	I-Chemical	-1	11334364
's	O	-1	11334364
ab@@	O	-1	11334364
und@@	O	-1	11334364
ant	O	-1	11334364
bio@@	O	-1	11334364
av@@	O	-1	11334364
ail@@	O	-1	11334364
abil@@	O	-1	11334364
ity,	O	-1	11334364
and	O	-1	11334364
the	O	-1	11334364
po@@	O	-1	11334364
w@@	O	-1	11334364
er	O	-1	11334364
to	O	-1	11334364
def@@	O	-1	11334364
end	O	-1	11334364
multiple	O	-1	11334364
t@@	O	-1	11334364
arg@@	O	-1	11334364
et	O	-1	11334364
org@@	O	-1	11334364
ans	O	-1	11334364
from	O	-1	11334364
toxic	O	-1	11334364
ass@@	O	-1	11334364
a@@	O	-1	11334364
ult@@	O	-1	11334364
s	O	-1	11334364
induced	O	-1	11334364
by	O	-1	11334364
struct@@	O	-1	11334364
ur@@	O	-1	11334364
ally	O	-1	11334364
di@@	O	-1	11334364
verse	O	-1	11334364
and	O	-1	11334364
func@@	O	-1	11334364
tion@@	O	-1	11334364
ally	O	-1	11334364
different	O	-1	11334364
enti@@	O	-1	11334364
ties	O	-1	11334364
in	O	-1	11334364
viv@@	O	-1	11334364
o@@	O	-1	11334364
.	O	-1	11334364

P@@	B-Disease	D004409	11642480
al@@	I-Disease	-1	11642480
pe@@	I-Disease	-1	11642480
b@@	I-Disease	-1	11642480
ral	I-Disease	-1	11642480
t@@	I-Disease	-1	11642480
witch@@	I-Disease	-1	11642480
ing	I-Disease	-1	11642480
in	O	-1	11642480
a	O	-1	11642480
depress@@	B-Disease	D003866	11642480
ed	I-Disease	-1	11642480
ad@@	O	-1	11642480
ol@@	O	-1	11642480
es@@	O	-1	11642480
c@@	O	-1	11642480
ent	O	-1	11642480
on	O	-1	11642480
cit@@	B-Chemical	D015283	11642480
alo@@	I-Chemical	-1	11642480
pra@@	I-Chemical	-1	11642480
m	I-Chemical	-1	11642480
.	O	-1	11642480
C@@	O	-1	11642480
ur@@	O	-1	11642480
rent	O	-1	11642480
estim@@	O	-1	11642480
ates	O	-1	11642480
suggest	O	-1	11642480
that	O	-1	11642480
between	O	-1	11642480
0.@@	O	-1	11642480
4@@	O	-1	11642480
%	O	-1	11642480
and	O	-1	11642480
8.@@	O	-1	11642480
3@@	O	-1	11642480
%	O	-1	11642480
of	O	-1	11642480
children	O	-1	11642480
and	O	-1	11642480
ad@@	O	-1	11642480
ol@@	O	-1	11642480
es@@	O	-1	11642480
c@@	O	-1	11642480
ents	O	-1	11642480
are	O	-1	11642480
affected	O	-1	11642480
by	O	-1	11642480
major	B-Disease	D003865	11642480
de@@	I-Disease	-1	11642480
pression	I-Disease	-1	11642480
.	O	-1	11642480
We	O	-1	11642480
report	O	-1	11642480
a	O	-1	11642480
f@@	O	-1	11642480
av@@	O	-1	11642480
or@@	O	-1	11642480
able	O	-1	11642480
response	O	-1	11642480
to	O	-1	11642480
treatment	O	-1	11642480
with	O	-1	11642480
cit@@	B-Chemical	D015283	11642480
alo@@	I-Chemical	-1	11642480
pra@@	I-Chemical	-1	11642480
m	I-Chemical	-1	11642480
by	O	-1	11642480
a	O	-1	11642480
1@@	O	-1	11642480
5-@@	O	-1	11642480
year-old	O	-1	11642480
bo@@	O	-1	11642480
y	O	-1	11642480
with	O	-1	11642480
major	B-Disease	D003865	11642480
de@@	I-Disease	-1	11642480
pression	I-Disease	-1	11642480
who	O	-1	11642480
ex@@	O	-1	11642480
hib@@	O	-1	11642480
ited	O	-1	11642480
p@@	B-Disease	D004409	11642480
al@@	I-Disease	-1	11642480
pe@@	I-Disease	-1	11642480
b@@	I-Disease	-1	11642480
ral	I-Disease	-1	11642480
t@@	I-Disease	-1	11642480
witch@@	I-Disease	-1	11642480
ing	I-Disease	-1	11642480
during	O	-1	11642480
h@@	O	-1	11642480
is	O	-1	11642480
first	O	-1	11642480
2	O	-1	11642480
weeks	O	-1	11642480
of	O	-1	11642480
treatment.	O	-1	11642480
This	O	-1	11642480
may	O	-1	11642480
have	O	-1	11642480
been	O	-1	11642480
a	O	-1	11642480
side	O	-1	11642480
effect	O	-1	11642480
of	O	-1	11642480
cit@@	B-Chemical	D015283	11642480
alo@@	I-Chemical	-1	11642480
pra@@	I-Chemical	-1	11642480
m	I-Chemical	-1	11642480
as	O	-1	11642480
it	O	-1	11642480
re@@	O	-1	11642480
mit@@	O	-1	11642480
ted	O	-1	11642480
with	O	-1	11642480
re@@	O	-1	11642480
di@@	O	-1	11642480
stri@@	O	-1	11642480
bu@@	O	-1	11642480
tion	O	-1	11642480
of	O	-1	11642480
dos@@	O	-1	11642480
es.	O	-1	11642480

M@@	B-Chemical	D004177	12063090
et@@	I-Chemical	-1	12063090
am@@	I-Chemical	-1	12063090
iz@@	I-Chemical	-1	12063090
ol	I-Chemical	-1	12063090
potenti@@	O	-1	12063090
ates	O	-1	12063090
morphine	B-Chemical	D009020	12063090
ant@@	O	-1	12063090
in@@	O	-1	12063090
ocicep@@	O	-1	12063090
tion	O	-1	12063090
but	O	-1	12063090
not	O	-1	12063090
con@@	B-Disease	D003248	12063090
sti@@	I-Disease	-1	12063090
p@@	I-Disease	-1	12063090
ation	I-Disease	-1	12063090
after	O	-1	12063090
chronic	O	-1	12063090
treatment.	O	-1	12063090
This	O	-1	12063090
wor@@	O	-1	12063090
k	O	-1	12063090
evalu@@	O	-1	12063090
ates	O	-1	12063090
the	O	-1	12063090
ant@@	O	-1	12063090
in@@	O	-1	12063090
ocicep@@	O	-1	12063090
tive	O	-1	12063090
and	O	-1	12063090
con@@	B-Disease	D003248	12063090
sti@@	I-Disease	-1	12063090
p@@	I-Disease	-1	12063090
ating	I-Disease	-1	12063090
effects	O	-1	12063090
of	O	-1	12063090
the	O	-1	12063090
combination	O	-1	12063090
of	O	-1	12063090
3.@@	O	-1	12063090
2	O	-1	12063090
mg/kg	O	-1	12063090
s@@	O	-1	12063090
.@@	O	-1	12063090
c@@	O	-1	12063090
.	O	-1	12063090
morphine	B-Chemical	D009020	12063090
with	O	-1	12063090
17@@	O	-1	12063090
7.@@	O	-1	12063090
8	O	-1	12063090
mg/kg	O	-1	12063090
s@@	O	-1	12063090
.@@	O	-1	12063090
c@@	O	-1	12063090
.	O	-1	12063090
met@@	B-Chemical	D004177	12063090
am@@	I-Chemical	-1	12063090
iz@@	I-Chemical	-1	12063090
ol	I-Chemical	-1	12063090
in	O	-1	12063090
ac@@	O	-1	12063090
u@@	O	-1	12063090
te@@	O	-1	12063090
ly	O	-1	12063090
and	O	-1	12063090
chron@@	O	-1	12063090
ically	O	-1	12063090
treated	O	-1	12063090
(@@	O	-1	12063090
on@@	O	-1	12063090
ce	O	-1	12063090
a	O	-1	12063090
day	O	-1	12063090
for	O	-1	12063090
12	O	-1	12063090
da@@	O	-1	12063090
ys@@	O	-1	12063090
)	O	-1	12063090
rats.	O	-1	12063090
O@@	O	-1	12063090
n	O	-1	12063090
the	O	-1	12063090
13@@	O	-1	12063090
th	O	-1	12063090
da@@	O	-1	12063090
y,	O	-1	12063090
ant@@	O	-1	12063090
in@@	O	-1	12063090
ocicep@@	O	-1	12063090
tive	O	-1	12063090
effects	O	-1	12063090
were	O	-1	12063090
assessed	O	-1	12063090
using	O	-1	12063090
a	O	-1	12063090
model	O	-1	12063090
of	O	-1	12063090
inflam@@	O	-1	12063090
mat@@	O	-1	12063090
ory	O	-1	12063090
n@@	O	-1	12063090
ocicep@@	O	-1	12063090
tion,	O	-1	12063090
pain	B-Disease	D010146	12063090
-induced	O	-1	12063090
functional	O	-1	12063090
impair@@	O	-1	12063090
ment	O	-1	12063090
model@@	O	-1	12063090
,	O	-1	12063090
and	O	-1	12063090
the	O	-1	12063090
ch@@	B-Chemical	D002606	12063090
ar@@	I-Chemical	-1	12063090
co@@	I-Chemical	-1	12063090
al	I-Chemical	-1	12063090
me@@	O	-1	12063090
al	O	-1	12063090
test	O	-1	12063090
was	O	-1	12063090
used	O	-1	12063090
to	O	-1	12063090
evalu@@	O	-1	12063090
ate	O	-1	12063090
the	O	-1	12063090
in@@	O	-1	12063090
test@@	O	-1	12063090
inal	O	-1	12063090
trans@@	O	-1	12063090
it@@	O	-1	12063090
.	O	-1	12063090
S@@	O	-1	12063090
im@@	O	-1	12063090
ult@@	O	-1	12063090
aneous	O	-1	12063090
administration	O	-1	12063090
of	O	-1	12063090
morphine	B-Chemical	D009020	12063090
with	O	-1	12063090
met@@	B-Chemical	D004177	12063090
am@@	I-Chemical	-1	12063090
iz@@	I-Chemical	-1	12063090
ol	I-Chemical	-1	12063090
resulted	O	-1	12063090
in	O	-1	12063090
a	O	-1	12063090
mark@@	O	-1	12063090
ed@@	O	-1	12063090
ly	O	-1	12063090
ant@@	O	-1	12063090
in@@	O	-1	12063090
ocicep@@	O	-1	12063090
tive	O	-1	12063090
potenti@@	O	-1	12063090
ation	O	-1	12063090
and	O	-1	12063090
an	O	-1	12063090
increas@@	O	-1	12063090
ing	O	-1	12063090
of	O	-1	12063090
the	O	-1	12063090
duration	O	-1	12063090
of	O	-1	12063090
action	O	-1	12063090
after	O	-1	12063090
a	O	-1	12063090
single	O	-1	12063090
(2@@	O	-1	12063090
9@@	O	-1	12063090
8@@	O	-1	12063090
+/-@@	O	-1	12063090
7	O	-1	12063090
vs.	O	-1	12063090
13@@	O	-1	12063090
9@@	O	-1	12063090
+/-@@	O	-1	12063090
3@@	O	-1	12063090
6	O	-1	12063090
un@@	O	-1	12063090
its	O	-1	12063090
a@@	O	-1	12063090
re@@	O	-1	12063090
a	O	-1	12063090
(@@	O	-1	12063090
u@@	O	-1	12063090
a@@	O	-1	12063090
);	O	-1	12063090
P@@	O	-1	12063090
<@@	O	-1	12063090
0.00@@	O	-1	12063090
1)	O	-1	12063090
and	O	-1	12063090
repe@@	O	-1	12063090
ated	O	-1	12063090
administration	O	-1	12063090
(2@@	O	-1	12063090
80@@	O	-1	12063090
+/@@	O	-1	12063090
-1@@	O	-1	12063090
7	O	-1	12063090
vs.	O	-1	12063090
13@@	O	-1	12063090
1@@	O	-1	12063090
+/-@@	O	-1	12063090
2@@	O	-1	12063090
2	O	-1	12063090
u@@	O	-1	12063090
a@@	O	-1	12063090
;	O	-1	12063090
P@@	O	-1	12063090
<@@	O	-1	12063090
0.00@@	O	-1	12063090
1).	O	-1	12063090
An@@	O	-1	12063090
t@@	O	-1	12063090
in@@	O	-1	12063090
ocicep@@	O	-1	12063090
tive	O	-1	12063090
effect	O	-1	12063090
of	O	-1	12063090
morphine	B-Chemical	D009020	12063090
was	O	-1	12063090
reduced	O	-1	12063090
in	O	-1	12063090
chron@@	O	-1	12063090
ically	O	-1	12063090
treated	O	-1	12063090
rats	O	-1	12063090
(3@@	O	-1	12063090
9@@	O	-1	12063090
+/-@@	O	-1	12063090
10	O	-1	12063090
vs.	O	-1	12063090
18@@	O	-1	12063090
+/-@@	O	-1	12063090
5	O	-1	12063090
au@@	O	-1	12063090
)	O	-1	12063090
while	O	-1	12063090
the	O	-1	12063090
combin@@	O	-1	12063090
ation@@	O	-1	12063090
-induced	O	-1	12063090
ant@@	O	-1	12063090
in@@	O	-1	12063090
ocicep@@	O	-1	12063090
tion	O	-1	12063090
was	O	-1	12063090
remained	O	-1	12063090
similar	O	-1	12063090
as	O	-1	12063090
an	O	-1	12063090
acute	O	-1	12063090
treatment	O	-1	12063090
(2@@	O	-1	12063090
9@@	O	-1	12063090
8@@	O	-1	12063090
+/-@@	O	-1	12063090
7	O	-1	12063090
vs.	O	-1	12063090
2@@	O	-1	12063090
80@@	O	-1	12063090
+/@@	O	-1	12063090
-1@@	O	-1	12063090
7	O	-1	12063090
au@@	O	-1	12063090
).	O	-1	12063090
Ac@@	O	-1	12063090
ute	O	-1	12063090
ant@@	O	-1	12063090
in@@	O	-1	12063090
ocicep@@	O	-1	12063090
tive	O	-1	12063090
effects	O	-1	12063090
of	O	-1	12063090
the	O	-1	12063090
combination	O	-1	12063090
were	O	-1	12063090
par@@	O	-1	12063090
ti@@	O	-1	12063090
ally	O	-1	12063090
prevent@@	O	-1	12063090
ed	O	-1	12063090
by	O	-1	12063090
3.@@	O	-1	12063090
2	O	-1	12063090
mg/kg	O	-1	12063090
n@@	B-Chemical	D009270	12063090
al@@	I-Chemical	-1	12063090
ox@@	I-Chemical	-1	12063090
one	I-Chemical	-1	12063090
s@@	O	-1	12063090
.@@	O	-1	12063090
c@@	O	-1	12063090
.	O	-1	12063090
(P@@	O	-1	12063090
<@@	O	-1	12063090
0.05@@	O	-1	12063090
),	O	-1	12063090
suggesting	O	-1	12063090
the	O	-1	12063090
partial	O	-1	12063090
invol@@	O	-1	12063090
vement	O	-1	12063090
of	O	-1	12063090
the	O	-1	12063090
o@@	O	-1	12063090
pi@@	O	-1	12063090
oid@@	O	-1	12063090
ergic	O	-1	12063090
system	O	-1	12063090
in	O	-1	12063090
the	O	-1	12063090
syn@@	O	-1	12063090
erg@@	O	-1	12063090
ism	O	-1	12063090
obser@@	O	-1	12063090
ved.	O	-1	12063090
In	O	-1	12063090
in@@	O	-1	12063090
dependent	O	-1	12063090
group@@	O	-1	12063090
s,	O	-1	12063090
morphine	B-Chemical	D009020	12063090
inhibited	O	-1	12063090
the	O	-1	12063090
in@@	O	-1	12063090
test@@	O	-1	12063090
inal	O	-1	12063090
transi@@	O	-1	12063090
t	O	-1	12063090
in	O	-1	12063090
4@@	O	-1	12063090
8@@	O	-1	12063090
+/-@@	O	-1	12063090
4@@	O	-1	12063090
%	O	-1	12063090
and	O	-1	12063090
3@@	O	-1	12063090
8@@	O	-1	12063090
+/-@@	O	-1	12063090
4@@	O	-1	12063090
%	O	-1	12063090
after	O	-1	12063090
acute	O	-1	12063090
and	O	-1	12063090
chronic	O	-1	12063090
treatment,	O	-1	12063090
respectivel@@	O	-1	12063090
y,	O	-1	12063090
suggesting	O	-1	12063090
that	O	-1	12063090
toler@@	O	-1	12063090
ance	O	-1	12063090
did	O	-1	12063090
not	O	-1	12063090
deve@@	O	-1	12063090
lo@@	O	-1	12063090
p	O	-1	12063090
to	O	-1	12063090
the	O	-1	12063090
con@@	B-Disease	D003248	12063090
sti@@	I-Disease	-1	12063090
p@@	I-Disease	-1	12063090
ating	I-Disease	-1	12063090
effects.	O	-1	12063090
The	O	-1	12063090
combination	O	-1	12063090
inhibited	O	-1	12063090
in@@	O	-1	12063090
test@@	O	-1	12063090
inal	O	-1	12063090
transi@@	O	-1	12063090
t	O	-1	12063090
similar	O	-1	12063090
to	O	-1	12063090
that	O	-1	12063090
produced	O	-1	12063090
by	O	-1	12063090
morphine	B-Chemical	D009020	12063090
reg@@	O	-1	12063090
ar@@	O	-1	12063090
d@@	O	-1	12063090
less	O	-1	12063090
of	O	-1	12063090
the	O	-1	12063090
time	O	-1	12063090
of	O	-1	12063090
treatment,	O	-1	12063090
suggesting	O	-1	12063090
that	O	-1	12063090
met@@	B-Chemical	D004177	12063090
am@@	I-Chemical	-1	12063090
iz@@	I-Chemical	-1	12063090
ol	I-Chemical	-1	12063090
did	O	-1	12063090
not	O	-1	12063090
potenti@@	O	-1	12063090
ate	O	-1	12063090
morphine	B-Chemical	D009020	12063090
-induced	O	-1	12063090
con@@	B-Disease	D003248	12063090
sti@@	I-Disease	-1	12063090
p@@	I-Disease	-1	12063090
ation	I-Disease	-1	12063090
.	O	-1	12063090
These	O	-1	12063090
findings	O	-1	12063090
show	O	-1	12063090
a	O	-1	12063090
significant	O	-1	12063090
inter@@	O	-1	12063090
action	O	-1	12063090
between	O	-1	12063090
morphine	B-Chemical	D009020	12063090
and	O	-1	12063090
met@@	B-Chemical	D004177	12063090
am@@	I-Chemical	-1	12063090
iz@@	I-Chemical	-1	12063090
ol	I-Chemical	-1	12063090
in	O	-1	12063090
chron@@	O	-1	12063090
ically	O	-1	12063090
treated	O	-1	12063090
rats,	O	-1	12063090
suggesting	O	-1	12063090
that	O	-1	12063090
this	O	-1	12063090
combination	O	-1	12063090
could	O	-1	12063090
be	O	-1	12063090
use@@	O	-1	12063090
ful	O	-1	12063090
for	O	-1	12063090
the	O	-1	12063090
treatment	O	-1	12063090
of	O	-1	12063090
chronic	B-Disease	D059350	12063090
pain	I-Disease	-1	12063090
.	O	-1	12063090

I@@	B-Chemical	D007069	12084448
f@@	I-Chemical	-1	12084448
os@@	I-Chemical	-1	12084448
f@@	I-Chemical	-1	12084448
amide	I-Chemical	-1	12084448
encephalo@@	B-Disease	D001927	12084448
pathy	I-Disease	-1	12084448
present@@	O	-1	12084448
ing	O	-1	12084448
with	O	-1	12084448
ast@@	B-Disease	D020820	12084448
er@@	I-Disease	-1	12084448
i@@	I-Disease	-1	12084448
x@@	I-Disease	-1	12084448
is	I-Disease	-1	12084448
.	O	-1	12084448
C@@	O	-1	12084448
N@@	O	-1	12084448
S	O	-1	12084448
toxic	O	-1	12084448
effects	O	-1	12084448
of	O	-1	12084448
the	O	-1	12084448
ant@@	O	-1	12084448
ine@@	O	-1	12084448
o@@	O	-1	12084448
plas@@	O	-1	12084448
tic	O	-1	12084448
agent	O	-1	12084448
if@@	B-Chemical	D007069	12084448
os@@	I-Chemical	-1	12084448
f@@	I-Chemical	-1	12084448
amide	I-Chemical	-1	12084448
(	O	-1	12084448
I@@	B-Chemical	D007069	12084448
F@@	I-Chemical	-1	12084448
X	I-Chemical	-1	12084448
)	O	-1	12084448
are	O	-1	12084448
frequent	O	-1	12084448
and	O	-1	12084448
includ@@	O	-1	12084448
e	O	-1	12084448
a	O	-1	12084448
vari@@	O	-1	12084448
ety	O	-1	12084448
of	O	-1	12084448
neurolog@@	O	-1	12084448
ical	O	-1	12084448
symptoms	O	-1	12084448
that	O	-1	12084448
can	O	-1	12084448
lim@@	O	-1	12084448
it	O	-1	12084448
drug	O	-1	12084448
use.	O	-1	12084448
We	O	-1	12084448
report	O	-1	12084448
a	O	-1	12084448
case	O	-1	12084448
of	O	-1	12084448
a	O	-1	12084448
5@@	O	-1	12084448
1-@@	O	-1	12084448
year-old	O	-1	12084448
man	O	-1	12084448
who	O	-1	12084448
developed	O	-1	12084448
se@@	O	-1	12084448
ve@@	O	-1	12084448
re,	O	-1	12084448
dis@@	O	-1	12084448
abl@@	O	-1	12084448
ing	O	-1	12084448
negative	O	-1	12084448
my@@	B-Disease	D009207	12084448
oc@@	I-Disease	-1	12084448
lon@@	I-Disease	-1	12084448
us	I-Disease	-1	12084448
of	O	-1	12084448
the	O	-1	12084448
up@@	O	-1	12084448
per	O	-1	12084448
and	O	-1	12084448
lower	O	-1	12084448
ex@@	O	-1	12084448
trem@@	O	-1	12084448
ities	O	-1	12084448
after	O	-1	12084448
the	O	-1	12084448
infusion	O	-1	12084448
of	O	-1	12084448
if@@	B-Chemical	D007069	12084448
os@@	I-Chemical	-1	12084448
f@@	I-Chemical	-1	12084448
amide	I-Chemical	-1	12084448
for	O	-1	12084448
plas@@	B-Disease	D010954	12084448
mac@@	I-Disease	-1	12084448
y@@	I-Disease	-1	12084448
to@@	I-Disease	-1	12084448
ma	I-Disease	-1	12084448
.	O	-1	12084448
H@@	O	-1	12084448
e	O	-1	12084448
was	O	-1	12084448
aw@@	O	-1	12084448
ak@@	O	-1	12084448
e,	O	-1	12084448
revealed	O	-1	12084448
no	O	-1	12084448
changes	O	-1	12084448
of	O	-1	12084448
mental	O	-1	12084448
status	O	-1	12084448
and	O	-1	12084448
at	O	-1	12084448
res@@	O	-1	12084448
t	O	-1	12084448
there	O	-1	12084448
were	O	-1	12084448
no	O	-1	12084448
further	O	-1	12084448
motor	O	-1	12084448
symptom@@	O	-1	12084448
s.	O	-1	12084448
C@@	O	-1	12084448
ranial	O	-1	12084448
mag@@	O	-1	12084448
ne@@	O	-1	12084448
tic	O	-1	12084448
res@@	O	-1	12084448
on@@	O	-1	12084448
ance	O	-1	12084448
imaging	O	-1	12084448
and	O	-1	12084448
exten@@	O	-1	12084448
sive	O	-1	12084448
labor@@	O	-1	12084448
atory	O	-1	12084448
studies	O	-1	12084448
fail@@	O	-1	12084448
ed	O	-1	12084448
to	O	-1	12084448
reve@@	O	-1	12084448
al	O	-1	12084448
struct@@	B-Disease	D001927	12084448
ural	I-Disease	-1	12084448
lesions	I-Disease	-1	12084448
of	I-Disease	-1	12084448
the	I-Disease	-1	12084448
brain	I-Disease	-1	12084448
and	O	-1	12084448
met@@	B-Disease	D008659	12084448
ab@@	I-Disease	-1	12084448
olic	I-Disease	-1	12084448
abnormal@@	I-Disease	-1	12084448
ities	I-Disease	-1	12084448
.	O	-1	12084448
An	O	-1	12084448
electro@@	O	-1	12084448
encephalo@@	O	-1	12084448
gra@@	O	-1	12084448
m	O	-1	12084448
showed	O	-1	12084448
continu@@	O	-1	12084448
ou@@	O	-1	12084448
s,	O	-1	12084448
gener@@	O	-1	12084448
al@@	O	-1	12084448
ized	O	-1	12084448
ir@@	O	-1	12084448
reg@@	O	-1	12084448
ular	O	-1	12084448
s@@	O	-1	12084448
low@@	O	-1	12084448
ing	O	-1	12084448
with	O	-1	12084448
ad@@	O	-1	12084448
mi@@	O	-1	12084448
x@@	O	-1	12084448
ed	O	-1	12084448
perio@@	O	-1	12084448
di@@	O	-1	12084448
c	O	-1	12084448
tri@@	O	-1	12084448
pha@@	O	-1	12084448
sic	O	-1	12084448
w@@	O	-1	12084448
av@@	O	-1	12084448
es	O	-1	12084448
indicating	O	-1	12084448
symptom@@	O	-1	12084448
atic	O	-1	12084448
encephalo@@	B-Disease	D001927	12084448
pathy	I-Disease	-1	12084448
.	O	-1	12084448
The	O	-1	12084448
administration	O	-1	12084448
of	O	-1	12084448
if@@	B-Chemical	D007069	12084448
os@@	I-Chemical	-1	12084448
f@@	I-Chemical	-1	12084448
amide	I-Chemical	-1	12084448
was	O	-1	12084448
discontinu@@	O	-1	12084448
ed	O	-1	12084448
and	O	-1	12084448
within	O	-1	12084448
12	O	-1	12084448
h	O	-1	12084448
the	O	-1	12084448
ast@@	B-Disease	D020820	12084448
er@@	I-Disease	-1	12084448
i@@	I-Disease	-1	12084448
x@@	I-Disease	-1	12084448
is	I-Disease	-1	12084448
resol@@	O	-1	12084448
ved	O	-1	12084448
complete@@	O	-1	12084448
ly.	O	-1	12084448
In	O	-1	12084448
the	O	-1	12084448
patient	O	-1	12084448
descri@@	O	-1	12084448
be@@	O	-1	12084448
d,	O	-1	12084448
the	O	-1	12084448
presence	O	-1	12084448
of	O	-1	12084448
ast@@	B-Disease	D020820	12084448
er@@	I-Disease	-1	12084448
i@@	I-Disease	-1	12084448
x@@	I-Disease	-1	12084448
is	I-Disease	-1	12084448
during	O	-1	12084448
infusion	O	-1	12084448
of	O	-1	12084448
if@@	B-Chemical	D007069	12084448
os@@	I-Chemical	-1	12084448
f@@	I-Chemical	-1	12084448
amide	I-Chemical	-1	12084448
,	O	-1	12084448
normal	O	-1	12084448
labor@@	O	-1	12084448
atory	O	-1	12084448
findings	O	-1	12084448
and	O	-1	12084448
imaging	O	-1	12084448
studies	O	-1	12084448
and	O	-1	12084448
the	O	-1	12084448
resol@@	O	-1	12084448
u@@	O	-1	12084448
tion	O	-1	12084448
of	O	-1	12084448
symptoms	O	-1	12084448
following	O	-1	12084448
the	O	-1	12084448
discontinu@@	O	-1	12084448
ation	O	-1	12084448
of	O	-1	12084448
the	O	-1	12084448
drug	O	-1	12084448
suggest	O	-1	12084448
that	O	-1	12084448
negative	O	-1	12084448
my@@	B-Disease	D009207	12084448
oc@@	I-Disease	-1	12084448
lon@@	I-Disease	-1	12084448
us	I-Disease	-1	12084448
is	O	-1	12084448
associated	O	-1	12084448
with	O	-1	12084448
the	O	-1	12084448
use	O	-1	12084448
of	O	-1	12084448
I@@	B-Chemical	D007069	12084448
F@@	I-Chemical	-1	12084448
X	I-Chemical	-1	12084448
.	O	-1	12084448

S@@	O	-1	12684739
ub@@	O	-1	12684739
-@@	O	-1	12684739
chronic	O	-1	12684739
low	O	-1	12684739
dose	O	-1	12684739
gamma@@	B-Chemical	D020888	12684739
-@@	I-Chemical	-1	12684739
v@@	I-Chemical	-1	12684739
in@@	I-Chemical	-1	12684739
yl	I-Chemical	-1	12684739
G@@	I-Chemical	-1	12684739
A@@	I-Chemical	-1	12684739
B@@	I-Chemical	-1	12684739
A	I-Chemical	-1	12684739
(	O	-1	12684739
vi@@	B-Chemical	D020888	12684739
g@@	I-Chemical	-1	12684739
ab@@	I-Chemical	-1	12684739
at@@	I-Chemical	-1	12684739
rin	I-Chemical	-1	12684739
)	O	-1	12684739
inhibit@@	O	-1	12684739
s	O	-1	12684739
cocaine	B-Chemical	D003042	12684739
-induced	O	-1	12684739
increases	O	-1	12684739
in	O	-1	12684739
nucle@@	O	-1	12684739
us	O	-1	12684739
accum@@	O	-1	12684739
ben@@	O	-1	12684739
s	O	-1	12684739
dopamine	B-Chemical	D004298	12684739
.	O	-1	12684739
R@@	O	-1	12684739
AT@@	O	-1	12684739
ION@@	O	-1	12684739
AL@@	O	-1	12684739
E:	O	-1	12684739
gamma@@	B-Chemical	D020888	12684739
-@@	I-Chemical	-1	12684739
V@@	I-Chemical	-1	12684739
in@@	I-Chemical	-1	12684739
yl	I-Chemical	-1	12684739
G@@	I-Chemical	-1	12684739
A@@	I-Chemical	-1	12684739
B@@	I-Chemical	-1	12684739
A	I-Chemical	-1	12684739
(	O	-1	12684739
G@@	B-Chemical	D020888	12684739
V@@	I-Chemical	-1	12684739
G	I-Chemical	-1	12684739
)	O	-1	12684739
ir@@	O	-1	12684739
rever@@	O	-1	12684739
sib@@	O	-1	12684739
ly	O	-1	12684739
inhibit@@	O	-1	12684739
s	O	-1	12684739
G@@	B-Chemical	D005680	12684739
A@@	I-Chemical	-1	12684739
B@@	I-Chemical	-1	12684739
A	I-Chemical	-1	12684739
-@@	O	-1	12684739
trans@@	O	-1	12684739
amin@@	O	-1	12684739
as@@	O	-1	12684739
e.	O	-1	12684739
This	O	-1	12684739
non-@@	O	-1	12684739
receptor	O	-1	12684739
mediated	O	-1	12684739
inhibition	O	-1	12684739
requ@@	O	-1	12684739
i@@	O	-1	12684739
res	O	-1	12684739
de	O	-1	12684739
no@@	O	-1	12684739
v@@	O	-1	12684739
o	O	-1	12684739
syn@@	O	-1	12684739
thesis	O	-1	12684739
for	O	-1	12684739
rest@@	O	-1	12684739
or@@	O	-1	12684739
ation	O	-1	12684739
of	O	-1	12684739
functional	O	-1	12684739
G@@	B-Chemical	D005680	12684739
A@@	I-Chemical	-1	12684739
B@@	I-Chemical	-1	12684739
A	I-Chemical	-1	12684739
cat@@	O	-1	12684739
abol@@	O	-1	12684739
is@@	O	-1	12684739
m.	O	-1	12684739
OBJECTIV@@	O	-1	12684739
E@@	O	-1	12684739
S:	O	-1	12684739
G@@	O	-1	12684739
i@@	O	-1	12684739
ven	O	-1	12684739
its	O	-1	12684739
pre@@	O	-1	12684739
clinical	O	-1	12684739
suc@@	O	-1	12684739
cess	O	-1	12684739
for	O	-1	12684739
treat@@	O	-1	12684739
ing	O	-1	12684739
subst@@	B-Disease	D019966	12684739
ance	I-Disease	-1	12684739
ab@@	I-Disease	-1	12684739
use	I-Disease	-1	12684739
and	O	-1	12684739
the	O	-1	12684739
increased	O	-1	12684739
risk	O	-1	12684739
of	O	-1	12684739
visual	B-Disease	D005128	12684739
fi@@	I-Disease	-1	12684739
el@@	I-Disease	-1	12684739
d	I-Disease	-1	12684739
def@@	I-Disease	-1	12684739
ects	I-Disease	-1	12684739
(	O	-1	12684739
V@@	B-Disease	D005128	12684739
F@@	I-Disease	-1	12684739
D	I-Disease	-1	12684739
)	O	-1	12684739
associated	O	-1	12684739
with	O	-1	12684739
cum@@	O	-1	12684739
ul@@	O	-1	12684739
ative	O	-1	12684739
li@@	O	-1	12684739
fe@@	O	-1	12684739
time	O	-1	12684739
expos@@	O	-1	12684739
ure,	O	-1	12684739
we	O	-1	12684739
ex@@	O	-1	12684739
p@@	O	-1	12684739
lo@@	O	-1	12684739
red	O	-1	12684739
the	O	-1	12684739
effects	O	-1	12684739
of	O	-1	12684739
sub@@	O	-1	12684739
-@@	O	-1	12684739
chronic	O	-1	12684739
low	O	-1	12684739
dose	O	-1	12684739
G@@	B-Chemical	D020888	12684739
V@@	I-Chemical	-1	12684739
G	I-Chemical	-1	12684739
on	O	-1	12684739
cocaine	B-Chemical	D003042	12684739
-induced	O	-1	12684739
increases	O	-1	12684739
in	O	-1	12684739
nucle@@	O	-1	12684739
us	O	-1	12684739
accum@@	O	-1	12684739
ben@@	O	-1	12684739
s	O	-1	12684739
(N@@	O	-1	12684739
Ac@@	O	-1	12684739
c@@	O	-1	12684739
)	O	-1	12684739
dopamine	B-Chemical	D004298	12684739
(	O	-1	12684739
D@@	B-Chemical	D004298	12684739
A	I-Chemical	-1	12684739
).	O	-1	12684739
METHODS:	O	-1	12684739
U@@	O	-1	12684739
s@@	O	-1	12684739
ing	O	-1	12684739
in	O	-1	12684739
viv@@	O	-1	12684739
o	O	-1	12684739
micro@@	O	-1	12684739
dialy@@	O	-1	12684739
sis,	O	-1	12684739
we	O	-1	12684739
compared	O	-1	12684739
acute	O	-1	12684739
exposure	O	-1	12684739
(4@@	O	-1	12684739
50	O	-1	12684739
mg/kg)	O	-1	12684739
to	O	-1	12684739
an	O	-1	12684739
id@@	O	-1	12684739
en@@	O	-1	12684739
tical	O	-1	12684739
sub@@	O	-1	12684739
-@@	O	-1	12684739
chronic	O	-1	12684739
exposure	O	-1	12684739
(1@@	O	-1	12684739
50	O	-1	12684739
mg/kg	O	-1	12684739
per	O	-1	12684739
day	O	-1	12684739
for	O	-1	12684739
3	O	-1	12684739
da@@	O	-1	12684739
ys@@	O	-1	12684739
),	O	-1	12684739
followed	O	-1	12684739
by	O	-1	12684739
1@@	O	-1	12684739
-	O	-1	12684739
or	O	-1	12684739
3-@@	O	-1	12684739
day	O	-1	12684739
w@@	O	-1	12684739
as@@	O	-1	12684739
h@@	O	-1	12684739
out@@	O	-1	12684739
.	O	-1	12684739
F@@	O	-1	12684739
in@@	O	-1	12684739
ally,	O	-1	12684739
we	O	-1	12684739
examined	O	-1	12684739
the	O	-1	12684739
low	O	-1	12684739
dose	O	-1	12684739
of	O	-1	12684739
1@@	O	-1	12684739
50	O	-1	12684739
mg/kg	O	-1	12684739
(@@	O	-1	12684739
50	O	-1	12684739
mg/kg	O	-1	12684739
per	O	-1	12684739
day@@	O	-1	12684739
)	O	-1	12684739
using	O	-1	12684739
a	O	-1	12684739
similar	O	-1	12684739
w@@	O	-1	12684739
as@@	O	-1	12684739
h@@	O	-1	12684739
out	O	-1	12684739
perio@@	O	-1	12684739
d.	O	-1	12684739
RESULTS:	O	-1	12684739
S@@	O	-1	12684739
ub@@	O	-1	12684739
-@@	O	-1	12684739
chronic	O	-1	12684739
G@@	B-Chemical	D020888	12684739
V@@	I-Chemical	-1	12684739
G	I-Chemical	-1	12684739
exposure	O	-1	12684739
inhibited	O	-1	12684739
the	O	-1	12684739
effect	O	-1	12684739
of	O	-1	12684739
cocaine	B-Chemical	D003042	12684739
for	O	-1	12684739
3	O	-1	12684739
day@@	O	-1	12684739
s,	O	-1	12684739
which	O	-1	12684739
ex@@	O	-1	12684739
ce@@	O	-1	12684739
ed@@	O	-1	12684739
ed	O	-1	12684739
in	O	-1	12684739
mag@@	O	-1	12684739
nit@@	O	-1	12684739
ude	O	-1	12684739
and	O	-1	12684739
duration	O	-1	12684739
the	O	-1	12684739
id@@	O	-1	12684739
en@@	O	-1	12684739
tical	O	-1	12684739
acute	O	-1	12684739
dose.	O	-1	12684739
CONCLUSIONS:	O	-1	12684739
S@@	O	-1	12684739
ub@@	O	-1	12684739
-@@	O	-1	12684739
chronic	O	-1	12684739
low	O	-1	12684739
dose	O	-1	12684739
G@@	B-Chemical	D020888	12684739
V@@	I-Chemical	-1	12684739
G	I-Chemical	-1	12684739
potenti@@	O	-1	12684739
ates	O	-1	12684739
and	O	-1	12684739
exten@@	O	-1	12684739
ds	O	-1	12684739
the	O	-1	12684739
inhibition	O	-1	12684739
of	O	-1	12684739
cocaine	B-Chemical	D003042	12684739
-induced	O	-1	12684739
increases	O	-1	12684739
in	O	-1	12684739
dopamine	B-Chemical	D004298	12684739
,	O	-1	12684739
eff@@	O	-1	12684739
ectively	O	-1	12684739
reduc@@	O	-1	12684739
ing	O	-1	12684739
cum@@	O	-1	12684739
ul@@	O	-1	12684739
ative	O	-1	12684739
expos@@	O	-1	12684739
ures	O	-1	12684739
and	O	-1	12684739
the	O	-1	12684739
risk	O	-1	12684739
for	O	-1	12684739
V@@	O	-1	12684739
F@@	O	-1	12684739
D@@	O	-1	12684739
S@@	O	-1	12684739
.	O	-1	12684739

A@@	O	-1	12716030
m@@	O	-1	12716030
oun@@	O	-1	12716030
t	O	-1	12716030
of	O	-1	12716030
ble@@	B-Disease	D006470	12716030
ed@@	I-Disease	-1	12716030
ing	I-Disease	-1	12716030
and	O	-1	12716030
hemat@@	B-Disease	D006406	12716030
oma	I-Disease	-1	12716030
size	O	-1	12716030
in	O	-1	12716030
the	O	-1	12716030
coll@@	O	-1	12716030
ag@@	O	-1	12716030
en@@	O	-1	12716030
as@@	O	-1	12716030
e@@	O	-1	12716030
-induced	O	-1	12716030
intrac@@	B-Disease	D002543	12716030
e@@	I-Disease	-1	12716030
rebral	I-Disease	-1	12716030
hemorrh@@	I-Disease	-1	12716030
age	I-Disease	-1	12716030
rat	O	-1	12716030
model@@	O	-1	12716030
.	O	-1	12716030
The	O	-1	12716030
ag@@	O	-1	12716030
gra@@	O	-1	12716030
v@@	O	-1	12716030
ated	O	-1	12716030
risk	O	-1	12716030
on	O	-1	12716030
intrac@@	B-Disease	D002543	12716030
e@@	I-Disease	-1	12716030
rebral	I-Disease	-1	12716030
hemorrh@@	I-Disease	-1	12716030
age	I-Disease	-1	12716030
(	O	-1	12716030
IC@@	B-Disease	D002543	12716030
H	I-Disease	-1	12716030
)	O	-1	12716030
with	O	-1	12716030
drugs	O	-1	12716030
used	O	-1	12716030
for	O	-1	12716030
strok@@	B-Disease	D020521	12716030
e	I-Disease	-1	12716030
patients	O	-1	12716030
should	O	-1	12716030
be	O	-1	12716030
estim@@	O	-1	12716030
ated	O	-1	12716030
ca@@	O	-1	12716030
ref@@	O	-1	12716030
ul@@	O	-1	12716030
ly.	O	-1	12716030
We	O	-1	12716030
the@@	O	-1	12716030
re@@	O	-1	12716030
fore	O	-1	12716030
est@@	O	-1	12716030
abl@@	O	-1	12716030
ished	O	-1	12716030
sensitive	O	-1	12716030
qu@@	O	-1	12716030
anti@@	O	-1	12716030
fic@@	O	-1	12716030
ation	O	-1	12716030
meth@@	O	-1	12716030
o@@	O	-1	12716030
ds	O	-1	12716030
and	O	-1	12716030
pro@@	O	-1	12716030
vid@@	O	-1	12716030
ed	O	-1	12716030
a	O	-1	12716030
rat	O	-1	12716030
IC@@	B-Disease	D002543	12716030
H	I-Disease	-1	12716030
model	O	-1	12716030
for	O	-1	12716030
det@@	O	-1	12716030
ection	O	-1	12716030
of	O	-1	12716030
IC@@	B-Disease	D002543	12716030
H	I-Disease	-1	12716030
deter@@	O	-1	12716030
i@@	O	-1	12716030
or@@	O	-1	12716030
ation.	O	-1	12716030
In	O	-1	12716030
IC@@	B-Disease	D002543	12716030
H	I-Disease	-1	12716030
intra@@	O	-1	12716030
striat@@	O	-1	12716030
ally	O	-1	12716030
induced	O	-1	12716030
by	O	-1	12716030
0.0@@	O	-1	12716030
1@@	O	-1	12716030
4-@@	O	-1	12716030
un@@	O	-1	12716030
it@@	O	-1	12716030
,	O	-1	12716030
0.0@@	O	-1	12716030
7@@	O	-1	12716030
0-@@	O	-1	12716030
un@@	O	-1	12716030
it@@	O	-1	12716030
,	O	-1	12716030
and	O	-1	12716030
0.@@	O	-1	12716030
3@@	O	-1	12716030
50@@	O	-1	12716030
-@@	O	-1	12716030
un@@	O	-1	12716030
it	O	-1	12716030
coll@@	O	-1	12716030
ag@@	O	-1	12716030
en@@	O	-1	12716030
ase,	O	-1	12716030
the	O	-1	12716030
amoun@@	O	-1	12716030
t	O	-1	12716030
of	O	-1	12716030
ble@@	B-Disease	D006470	12716030
ed@@	I-Disease	-1	12716030
ing	I-Disease	-1	12716030
was	O	-1	12716030
measured	O	-1	12716030
using	O	-1	12716030
a	O	-1	12716030
hemo@@	O	-1	12716030
globin	O	-1	12716030
ass@@	O	-1	12716030
ay	O	-1	12716030
developed	O	-1	12716030
in	O	-1	12716030
the	O	-1	12716030
present	O	-1	12716030
study	O	-1	12716030
and	O	-1	12716030
was	O	-1	12716030
compared	O	-1	12716030
with	O	-1	12716030
the	O	-1	12716030
morph@@	O	-1	12716030
olog@@	O	-1	12716030
ically	O	-1	12716030
determined	O	-1	12716030
hemat@@	B-Disease	D006406	12716030
oma	I-Disease	-1	12716030
vol@@	O	-1	12716030
u@@	O	-1	12716030
me.	O	-1	12716030
The	O	-1	12716030
blood	O	-1	12716030
amoun@@	O	-1	12716030
ts	O	-1	12716030
and	O	-1	12716030
hemat@@	B-Disease	D006406	12716030
oma	I-Disease	-1	12716030
volum@@	O	-1	12716030
es	O	-1	12716030
were	O	-1	12716030
significantly	O	-1	12716030
correl@@	O	-1	12716030
at@@	O	-1	12716030
ed,	O	-1	12716030
and	O	-1	12716030
the	O	-1	12716030
hemat@@	B-Disease	D006406	12716030
oma	I-Disease	-1	12716030
induced	O	-1	12716030
by	O	-1	12716030
0.0@@	O	-1	12716030
1@@	O	-1	12716030
4-@@	O	-1	12716030
un@@	O	-1	12716030
it	O	-1	12716030
coll@@	O	-1	12716030
ag@@	O	-1	12716030
en@@	O	-1	12716030
ase	O	-1	12716030
was	O	-1	12716030
ade@@	O	-1	12716030
qu@@	O	-1	12716030
ate	O	-1	12716030
to	O	-1	12716030
det@@	O	-1	12716030
ect	O	-1	12716030
IC@@	B-Disease	D002543	12716030
H	I-Disease	-1	12716030
deter@@	O	-1	12716030
i@@	O	-1	12716030
or@@	O	-1	12716030
ation.	O	-1	12716030
In	O	-1	12716030
IC@@	B-Disease	D002543	12716030
H	I-Disease	-1	12716030
induction	O	-1	12716030
using	O	-1	12716030
0.0@@	O	-1	12716030
1@@	O	-1	12716030
4-@@	O	-1	12716030
un@@	O	-1	12716030
it	O	-1	12716030
coll@@	O	-1	12716030
ag@@	O	-1	12716030
en@@	O	-1	12716030
ase,	O	-1	12716030
hepar@@	B-Chemical	D006493	12716030
in	I-Chemical	-1	12716030
enhanced	O	-1	12716030
the	O	-1	12716030
hemat@@	B-Disease	D006406	12716030
oma	I-Disease	-1	12716030
volume	O	-1	12716030
3.@@	O	-1	12716030
4-@@	O	-1	12716030
fol@@	O	-1	12716030
d	O	-1	12716030
over	O	-1	12716030
that	O	-1	12716030
seen	O	-1	12716030
in	O	-1	12716030
control	O	-1	12716030
IC@@	B-Disease	D002543	12716030
H	I-Disease	-1	12716030
animals	O	-1	12716030
and	O	-1	12716030
the	O	-1	12716030
ble@@	B-Disease	D006470	12716030
ed@@	I-Disease	-1	12716030
ing	I-Disease	-1	12716030
7.@@	O	-1	12716030
6-@@	O	-1	12716030
fol@@	O	-1	12716030
d.	O	-1	12716030
D@@	O	-1	12716030
at@@	O	-1	12716030
a	O	-1	12716030
suggest	O	-1	12716030
that	O	-1	12716030
this	O	-1	12716030
sensitive	O	-1	12716030
hemo@@	O	-1	12716030
globin	O	-1	12716030
ass@@	O	-1	12716030
ay	O	-1	12716030
is	O	-1	12716030
use@@	O	-1	12716030
ful	O	-1	12716030
for	O	-1	12716030
IC@@	B-Disease	D002543	12716030
H	I-Disease	-1	12716030
det@@	O	-1	12716030
ec@@	O	-1	12716030
tion,	O	-1	12716030
and	O	-1	12716030
that	O	-1	12716030
a	O	-1	12716030
model	O	-1	12716030
with	O	-1	12716030
a	O	-1	12716030
sm@@	O	-1	12716030
all	O	-1	12716030
IC@@	B-Disease	D002543	12716030
H	I-Disease	-1	12716030
induced	O	-1	12716030
with	O	-1	12716030
a	O	-1	12716030
low@@	O	-1	12716030
-@@	O	-1	12716030
dose	O	-1	12716030
coll@@	O	-1	12716030
ag@@	O	-1	12716030
en@@	O	-1	12716030
ase	O	-1	12716030
should	O	-1	12716030
be	O	-1	12716030
used	O	-1	12716030
for	O	-1	12716030
evalu@@	O	-1	12716030
ation	O	-1	12716030
of	O	-1	12716030
drugs	O	-1	12716030
that	O	-1	12716030
may	O	-1	12716030
aff@@	O	-1	12716030
ect	O	-1	12716030
IC@@	B-Disease	D002543	12716030
H	I-Disease	-1	12716030
.	O	-1	12716030

E@@	B-Chemical	D004958	12757899
st@@	I-Chemical	-1	12757899
radi@@	I-Chemical	-1	12757899
ol	I-Chemical	-1	12757899
reduc@@	O	-1	12757899
es	O	-1	12757899
seizure	B-Disease	D012640	12757899
-induced	O	-1	12757899
hippocamp@@	B-Disease	D001930	12757899
al	I-Disease	-1	12757899
injury	I-Disease	-1	12757899
in	O	-1	12757899
o@@	O	-1	12757899
vari@@	O	-1	12757899
ect@@	O	-1	12757899
om@@	O	-1	12757899
ized	O	-1	12757899
female	O	-1	12757899
but	O	-1	12757899
not	O	-1	12757899
in	O	-1	12757899
male	O	-1	12757899
rats.	O	-1	12757899
E@@	O	-1	12757899
stro@@	O	-1	12757899
gen@@	O	-1	12757899
s	O	-1	12757899
prot@@	O	-1	12757899
ect	O	-1	12757899
o@@	O	-1	12757899
vari@@	O	-1	12757899
ect@@	O	-1	12757899
om@@	O	-1	12757899
ized	O	-1	12757899
rats	O	-1	12757899
from	O	-1	12757899
hippocamp@@	B-Disease	D001930	12757899
al	I-Disease	-1	12757899
injury	I-Disease	-1	12757899
induced	O	-1	12757899
by	O	-1	12757899
k@@	B-Chemical	D007608	12757899
ain@@	I-Chemical	-1	12757899
ic	I-Chemical	-1	12757899
acid	I-Chemical	-1	12757899
-induced	O	-1	12757899
status	B-Disease	D013226	12757899
epilep@@	I-Disease	-1	12757899
tic@@	I-Disease	-1	12757899
us	I-Disease	-1	12757899
(	O	-1	12757899
S@@	B-Disease	D013226	12757899
E	I-Disease	-1	12757899
).	O	-1	12757899
We	O	-1	12757899
compared	O	-1	12757899
the	O	-1	12757899
effects	O	-1	12757899
of	O	-1	12757899
17@@	B-Chemical	D004958	12757899
beta-@@	I-Chemical	-1	12757899
est@@	I-Chemical	-1	12757899
radi@@	I-Chemical	-1	12757899
ol	I-Chemical	-1	12757899
in	O	-1	12757899
ad@@	O	-1	12757899
ult	O	-1	12757899
male	O	-1	12757899
and	O	-1	12757899
o@@	O	-1	12757899
vari@@	O	-1	12757899
ect@@	O	-1	12757899
om@@	O	-1	12757899
ized	O	-1	12757899
female	O	-1	12757899
rats	O	-1	12757899
subj@@	O	-1	12757899
ected	O	-1	12757899
to	O	-1	12757899
lithium	B-Chemical	D008094	12757899
-	O	-1	12757899
pilocar@@	B-Chemical	D010862	12757899
pine	I-Chemical	-1	12757899
-induced	O	-1	12757899
S@@	B-Disease	D013226	12757899
E	I-Disease	-1	12757899
.	O	-1	12757899
R@@	O	-1	12757899
at@@	O	-1	12757899
s	O	-1	12757899
received	O	-1	12757899
sub@@	O	-1	12757899
c@@	O	-1	12757899
utaneous	O	-1	12757899
injec@@	O	-1	12757899
tions	O	-1	12757899
of	O	-1	12757899
17@@	B-Chemical	D004958	12757899
beta-@@	I-Chemical	-1	12757899
est@@	I-Chemical	-1	12757899
radi@@	I-Chemical	-1	12757899
ol	I-Chemical	-1	12757899
(@@	O	-1	12757899
2	O	-1	12757899
micro@@	O	-1	12757899
g/@@	O	-1	12757899
rat@@	O	-1	12757899
)	O	-1	12757899
or	O	-1	12757899
o@@	O	-1	12757899
il	O	-1	12757899
on@@	O	-1	12757899
ce	O	-1	12757899
daily	O	-1	12757899
for	O	-1	12757899
four	O	-1	12757899
con@@	O	-1	12757899
sec@@	O	-1	12757899
utive	O	-1	12757899
days.	O	-1	12757899
S@@	B-Disease	D013226	12757899
E	I-Disease	-1	12757899
was	O	-1	12757899
induced	O	-1	12757899
20	O	-1	12757899
h	O	-1	12757899
following	O	-1	12757899
the	O	-1	12757899
second	O	-1	12757899
injection	O	-1	12757899
and	O	-1	12757899
ter@@	O	-1	12757899
min@@	O	-1	12757899
ated	O	-1	12757899
3	O	-1	12757899
h	O	-1	12757899
lat@@	O	-1	12757899
er.	O	-1	12757899
The	O	-1	12757899
ext@@	O	-1	12757899
ent	O	-1	12757899
of	O	-1	12757899
si@@	B-Chemical	D012834	12757899
l@@	I-Chemical	-1	12757899
ver	I-Chemical	-1	12757899
-@@	O	-1	12757899
st@@	O	-1	12757899
ained	O	-1	12757899
CA@@	O	-1	12757899
3	O	-1	12757899
and	O	-1	12757899
CA@@	O	-1	12757899
1	O	-1	12757899
hippocamp@@	O	-1	12757899
al	O	-1	12757899
neuron@@	O	-1	12757899
s	O	-1	12757899
was	O	-1	12757899
evaluated	O	-1	12757899
2	O	-1	12757899
days	O	-1	12757899
after	O	-1	12757899
S@@	B-Disease	D013226	12757899
E	I-Disease	-1	12757899
.	O	-1	12757899
17@@	B-Chemical	D004958	12757899
beta-@@	I-Chemical	-1	12757899
E@@	I-Chemical	-1	12757899
st@@	I-Chemical	-1	12757899
radi@@	I-Chemical	-1	12757899
ol	I-Chemical	-1	12757899
did	O	-1	12757899
not	O	-1	12757899
al@@	O	-1	12757899
ter	O	-1	12757899
the	O	-1	12757899
onset	O	-1	12757899
of	O	-1	12757899
first	O	-1	12757899
clon@@	O	-1	12757899
us	O	-1	12757899
in	O	-1	12757899
o@@	O	-1	12757899
vari@@	O	-1	12757899
ect@@	O	-1	12757899
om@@	O	-1	12757899
ized	O	-1	12757899
rats	O	-1	12757899
but	O	-1	12757899
ac@@	O	-1	12757899
ce@@	O	-1	12757899
l@@	O	-1	12757899
er@@	O	-1	12757899
ated	O	-1	12757899
it	O	-1	12757899
in	O	-1	12757899
mal@@	O	-1	12757899
es.	O	-1	12757899
17@@	B-Chemical	D004958	12757899
beta-@@	I-Chemical	-1	12757899
E@@	I-Chemical	-1	12757899
st@@	I-Chemical	-1	12757899
radi@@	I-Chemical	-1	12757899
ol	I-Chemical	-1	12757899
reduced	O	-1	12757899
the	O	-1	12757899
arg@@	O	-1	12757899
yro@@	O	-1	12757899
ph@@	O	-1	12757899
il@@	O	-1	12757899
ic	O	-1	12757899
neuron@@	O	-1	12757899
s	O	-1	12757899
in	O	-1	12757899
the	O	-1	12757899
CA@@	O	-1	12757899
1	O	-1	12757899
and	O	-1	12757899
CA@@	O	-1	12757899
3-@@	O	-1	12757899
C	O	-1	12757899
s@@	O	-1	12757899
ect@@	O	-1	12757899
ors	O	-1	12757899
of	O	-1	12757899
o@@	O	-1	12757899
vari@@	O	-1	12757899
ect@@	O	-1	12757899
om@@	O	-1	12757899
ized	O	-1	12757899
rats.	O	-1	12757899
In	O	-1	12757899
mal@@	O	-1	12757899
es,	O	-1	12757899
est@@	B-Chemical	D004958	12757899
radi@@	I-Chemical	-1	12757899
ol	I-Chemical	-1	12757899
increased	O	-1	12757899
the	O	-1	12757899
total	O	-1	12757899
damage	O	-1	12757899
sco@@	O	-1	12757899
re.	O	-1	12757899
These	O	-1	12757899
findings	O	-1	12757899
suggest	O	-1	12757899
that	O	-1	12757899
the	O	-1	12757899
effects	O	-1	12757899
of	O	-1	12757899
est@@	B-Chemical	D004958	12757899
radi@@	I-Chemical	-1	12757899
ol	I-Chemical	-1	12757899
on	O	-1	12757899
seizure	B-Disease	D012640	12757899
th@@	O	-1	12757899
res@@	O	-1	12757899
h@@	O	-1	12757899
old	O	-1	12757899
and	O	-1	12757899
damage	O	-1	12757899
may	O	-1	12757899
be	O	-1	12757899
al@@	O	-1	12757899
te@@	O	-1	12757899
red	O	-1	12757899
by	O	-1	12757899
sex@@	O	-1	12757899
-@@	O	-1	12757899
related	O	-1	12757899
differences	O	-1	12757899
in	O	-1	12757899
the	O	-1	12757899
h@@	O	-1	12757899
orm@@	O	-1	12757899
on@@	O	-1	12757899
al	O	-1	12757899
en@@	O	-1	12757899
vi@@	O	-1	12757899
ron@@	O	-1	12757899
ment.	O	-1	12757899

De@@	B-Disease	D003693	12905102
li@@	I-Disease	-1	12905102
ri@@	I-Disease	-1	12905102
um	I-Disease	-1	12905102
during	O	-1	12905102
cloz@@	B-Chemical	D003024	12905102
apine	I-Chemical	-1	12905102
treatment@@	O	-1	12905102
:	O	-1	12905102
incidence	O	-1	12905102
and	O	-1	12905102
associated	O	-1	12905102
risk	O	-1	12905102
fact@@	O	-1	12905102
or@@	O	-1	12905102
s.	O	-1	12905102
BACKGROUND:	O	-1	12905102
In@@	O	-1	12905102
c@@	O	-1	12905102
idence	O	-1	12905102
and	O	-1	12905102
risk	O	-1	12905102
factors	O	-1	12905102
for	O	-1	12905102
de@@	B-Disease	D003693	12905102
li@@	I-Disease	-1	12905102
ri@@	I-Disease	-1	12905102
um	I-Disease	-1	12905102
during	O	-1	12905102
cloz@@	B-Chemical	D003024	12905102
apine	I-Chemical	-1	12905102
treatment	O	-1	12905102
requ@@	O	-1	12905102
ir@@	O	-1	12905102
e	O	-1	12905102
further	O	-1	12905102
cl@@	O	-1	12905102
ar@@	O	-1	12905102
ific@@	O	-1	12905102
ation.	O	-1	12905102
METHODS:	O	-1	12905102
We	O	-1	12905102
used	O	-1	12905102
comp@@	O	-1	12905102
u@@	O	-1	12905102
ter@@	O	-1	12905102
ized	O	-1	12905102
pharmac@@	O	-1	12905102
y	O	-1	12905102
recor@@	O	-1	12905102
ds	O	-1	12905102
to	O	-1	12905102
identi@@	O	-1	12905102
f@@	O	-1	12905102
y	O	-1	12905102
all	O	-1	12905102
ad@@	O	-1	12905102
ult	O	-1	12905102
psych@@	B-Disease	D001523	12905102
i@@	I-Disease	-1	12905102
atric	I-Disease	-1	12905102
in@@	O	-1	12905102
patients	O	-1	12905102
treated	O	-1	12905102
with	O	-1	12905102
cloz@@	B-Chemical	D003024	12905102
apine	I-Chemical	-1	12905102
(1@@	O	-1	12905102
9@@	O	-1	12905102
9@@	O	-1	12905102
5-@@	O	-1	12905102
9@@	O	-1	12905102
6@@	O	-1	12905102
),	O	-1	12905102
revie@@	O	-1	12905102
w@@	O	-1	12905102
ed	O	-1	12905102
their	O	-1	12905102
med@@	O	-1	12905102
ical	O	-1	12905102
recor@@	O	-1	12905102
ds	O	-1	12905102
to	O	-1	12905102
scor@@	O	-1	12905102
e	O	-1	12905102
incidence	O	-1	12905102
and	O	-1	12905102
severity	O	-1	12905102
of	O	-1	12905102
de@@	B-Disease	D003693	12905102
li@@	I-Disease	-1	12905102
ri@@	I-Disease	-1	12905102
um	I-Disease	-1	12905102
,	O	-1	12905102
and	O	-1	12905102
tested	O	-1	12905102
associ@@	O	-1	12905102
ations	O	-1	12905102
with	O	-1	12905102
potential	O	-1	12905102
risk	O	-1	12905102
fact@@	O	-1	12905102
or@@	O	-1	12905102
s.	O	-1	12905102
RESULTS:	O	-1	12905102
S@@	O	-1	12905102
ub@@	O	-1	12905102
j@@	O	-1	12905102
ects	O	-1	12905102
(n	O	-1	12905102
=	O	-1	12905102
13@@	O	-1	12905102
9@@	O	-1	12905102
)	O	-1	12905102
were	O	-1	12905102
7@@	O	-1	12905102
2	O	-1	12905102
women	O	-1	12905102
and	O	-1	12905102
6@@	O	-1	12905102
7	O	-1	12905102
men@@	O	-1	12905102
,	O	-1	12905102
aged	O	-1	12905102
4@@	O	-1	12905102
0.@@	O	-1	12905102
8	O	-1	12905102
+/-	O	-1	12905102
1@@	O	-1	12905102
2.@@	O	-1	12905102
1	O	-1	12905102
year@@	O	-1	12905102
s,	O	-1	12905102
hospit@@	O	-1	12905102
al@@	O	-1	12905102
ized	O	-1	12905102
for	O	-1	12905102
2@@	O	-1	12905102
4.@@	O	-1	12905102
9	O	-1	12905102
+/-	O	-1	12905102
2@@	O	-1	12905102
3.@@	O	-1	12905102
3	O	-1	12905102
day@@	O	-1	12905102
s,	O	-1	12905102
and	O	-1	12905102
given	O	-1	12905102
cloz@@	B-Chemical	D003024	12905102
apine	I-Chemical	-1	12905102
,	O	-1	12905102
gra@@	O	-1	12905102
du@@	O	-1	12905102
ally	O	-1	12905102
increased	O	-1	12905102
to	O	-1	12905102
an	O	-1	12905102
average	O	-1	12905102
daily	O	-1	12905102
dose	O	-1	12905102
of	O	-1	12905102
2@@	O	-1	12905102
8@@	O	-1	12905102
2	O	-1	12905102
+/-	O	-1	12905102
20@@	O	-1	12905102
3	O	-1	12905102
mg	O	-1	12905102
(@@	O	-1	12905102
3.@@	O	-1	12905102
4@@	O	-1	12905102
5	O	-1	12905102
+/-	O	-1	12905102
2.@@	O	-1	12905102
4@@	O	-1	12905102
5	O	-1	12905102
mg/kg)	O	-1	12905102
for	O	-1	12905102
1@@	O	-1	12905102
8.@@	O	-1	12905102
9	O	-1	12905102
+/-	O	-1	12905102
1@@	O	-1	12905102
6.@@	O	-1	12905102
4	O	-1	12905102
days.	O	-1	12905102
De@@	B-Disease	D003693	12905102
li@@	I-Disease	-1	12905102
ri@@	I-Disease	-1	12905102
um	I-Disease	-1	12905102
was	O	-1	12905102
diagnos@@	O	-1	12905102
ed	O	-1	12905102
in	O	-1	12905102
14	O	-1	12905102
(1@@	O	-1	12905102
0.@@	O	-1	12905102
1	O	-1	12905102
%	O	-1	12905102
inc@@	O	-1	12905102
id@@	O	-1	12905102
ence@@	O	-1	12905102
,	O	-1	12905102
or	O	-1	12905102
1.@@	O	-1	12905102
4@@	O	-1	12905102
8	O	-1	12905102
cas@@	O	-1	12905102
es@@	O	-1	12905102
/@@	O	-1	12905102
per@@	O	-1	12905102
son@@	O	-1	12905102
-@@	O	-1	12905102
years	O	-1	12905102
of	O	-1	12905102
expos@@	O	-1	12905102
ure@@	O	-1	12905102
);	O	-1	12905102
7@@	O	-1	12905102
1.@@	O	-1	12905102
4	O	-1	12905102
%	O	-1	12905102
of	O	-1	12905102
cases	O	-1	12905102
were	O	-1	12905102
moder@@	O	-1	12905102
ate	O	-1	12905102
or	O	-1	12905102
se@@	O	-1	12905102
ve@@	O	-1	12905102
re.	O	-1	12905102
A@@	O	-1	12905102
s@@	O	-1	12905102
s@@	O	-1	12905102
oci@@	O	-1	12905102
ated	O	-1	12905102
factors	O	-1	12905102
were	O	-1	12905102
co-@@	O	-1	12905102
treatment	O	-1	12905102
with	O	-1	12905102
other	O	-1	12905102
centr@@	O	-1	12905102
ally	O	-1	12905102
anti@@	O	-1	12905102
mus@@	O	-1	12905102
car@@	O	-1	12905102
inic	O	-1	12905102
agent@@	O	-1	12905102
s,	O	-1	12905102
po@@	O	-1	12905102
or	O	-1	12905102
clinical	O	-1	12905102
out@@	O	-1	12905102
co@@	O	-1	12905102
me,	O	-1	12905102
ol@@	O	-1	12905102
der	O	-1	12905102
age,	O	-1	12905102
and	O	-1	12905102
long@@	O	-1	12905102
er	O	-1	12905102
hospit@@	O	-1	12905102
al@@	O	-1	12905102
ization	O	-1	12905102
(@@	O	-1	12905102
by	O	-1	12905102
1@@	O	-1	12905102
7.@@	O	-1	12905102
5	O	-1	12905102
day@@	O	-1	12905102
s,	O	-1	12905102
increas@@	O	-1	12905102
ing	O	-1	12905102
co@@	O	-1	12905102
st@@	O	-1	12905102
);	O	-1	12905102
sex@@	O	-1	12905102
,	O	-1	12905102
diagnosis	O	-1	12905102
or	O	-1	12905102
med@@	O	-1	12905102
ical	O	-1	12905102
co-@@	O	-1	12905102
mor@@	O	-1	12905102
b@@	O	-1	12905102
id@@	O	-1	12905102
ity,	O	-1	12905102
and	O	-1	12905102
daily	O	-1	12905102
cloz@@	B-Chemical	D003024	12905102
apine	I-Chemical	-1	12905102
dose@@	O	-1	12905102
,	O	-1	12905102
which	O	-1	12905102
f@@	O	-1	12905102
el@@	O	-1	12905102
l	O	-1	12905102
with	O	-1	12905102
age,	O	-1	12905102
were	O	-1	12905102
un@@	O	-1	12905102
rel@@	O	-1	12905102
ated.	O	-1	12905102
CONCLUSIONS:	O	-1	12905102
De@@	B-Disease	D003693	12905102
li@@	I-Disease	-1	12905102
ri@@	I-Disease	-1	12905102
um	I-Disease	-1	12905102
was	O	-1	12905102
found	O	-1	12905102
in	O	-1	12905102
10	O	-1	12905102
%	O	-1	12905102
of	O	-1	12905102
cloz@@	B-Chemical	D003024	12905102
apine	I-Chemical	-1	12905102
-treated	O	-1	12905102
in@@	O	-1	12905102
patients,	O	-1	12905102
partic@@	O	-1	12905102
ul@@	O	-1	12905102
arly	O	-1	12905102
in	O	-1	12905102
ol@@	O	-1	12905102
der	O	-1	12905102
patients	O	-1	12905102
exposed	O	-1	12905102
to	O	-1	12905102
other	O	-1	12905102
central	O	-1	12905102
anti@@	O	-1	12905102
chol@@	O	-1	12905102
in@@	O	-1	12905102
erg@@	O	-1	12905102
ic@@	O	-1	12905102
s.	O	-1	12905102
De@@	B-Disease	D003693	12905102
li@@	I-Disease	-1	12905102
ri@@	I-Disease	-1	12905102
um	I-Disease	-1	12905102
was	O	-1	12905102
in@@	O	-1	12905102
consist@@	O	-1	12905102
ently	O	-1	12905102
reco@@	O	-1	12905102
gn@@	O	-1	12905102
ized	O	-1	12905102
clin@@	O	-1	12905102
ically	O	-1	12905102
in	O	-1	12905102
mil@@	O	-1	12905102
der	O	-1	12905102
cases	O	-1	12905102
and	O	-1	12905102
was	O	-1	12905102
associated	O	-1	12905102
with	O	-1	12905102
increased	O	-1	12905102
l@@	O	-1	12905102
en@@	O	-1	12905102
g@@	O	-1	12905102
th@@	O	-1	12905102
-@@	O	-1	12905102
of@@	O	-1	12905102
-@@	O	-1	12905102
st@@	O	-1	12905102
ay	O	-1	12905102
and	O	-1	12905102
higher	O	-1	12905102
co@@	O	-1	12905102
st@@	O	-1	12905102
s,	O	-1	12905102
and	O	-1	12905102
inf@@	O	-1	12905102
er@@	O	-1	12905102
ior	O	-1	12905102
clinical	O	-1	12905102
out@@	O	-1	12905102
co@@	O	-1	12905102
me.	O	-1	12905102

K@@	B-Chemical	D007654	14513889
e@@	I-Chemical	-1	14513889
to@@	I-Chemical	-1	14513889
con@@	I-Chemical	-1	14513889
azole	I-Chemical	-1	14513889
-induced	O	-1	14513889
neurolog@@	B-Disease	D009422	14513889
ic	I-Disease	-1	14513889
sequ@@	I-Disease	-1	14513889
el@@	I-Disease	-1	14513889
a@@	I-Disease	-1	14513889
e	I-Disease	-1	14513889
.	O	-1	14513889
A	O	-1	14513889
7@@	O	-1	14513889
7-@@	O	-1	14513889
y@@	O	-1	14513889
-old	O	-1	14513889
patient	O	-1	14513889
developed	O	-1	14513889
we@@	B-Disease	D018908	14513889
ak@@	I-Disease	-1	14513889
ness	I-Disease	-1	14513889
of	I-Disease	-1	14513889
ex@@	I-Disease	-1	14513889
trem@@	I-Disease	-1	14513889
ities	I-Disease	-1	14513889
,	O	-1	14513889
le@@	B-Disease	D010243	14513889
g@@	I-Disease	-1	14513889
s	I-Disease	-1	14513889
par@@	I-Disease	-1	14513889
aly@@	I-Disease	-1	14513889
sis	I-Disease	-1	14513889
,	O	-1	14513889
dys@@	B-Disease	D004401	14513889
arth@@	I-Disease	-1	14513889
ri@@	I-Disease	-1	14513889
a	I-Disease	-1	14513889
and	O	-1	14513889
trem@@	B-Disease	D014202	14513889
or	I-Disease	-1	14513889
1	O	-1	14513889
h	O	-1	14513889
after	O	-1	14513889
ing@@	O	-1	14513889
es@@	O	-1	14513889
tion	O	-1	14513889
of	O	-1	14513889
2@@	O	-1	14513889
00	O	-1	14513889
mg	O	-1	14513889
ke@@	B-Chemical	D007654	14513889
to@@	I-Chemical	-1	14513889
con@@	I-Chemical	-1	14513889
azole	I-Chemical	-1	14513889
for	O	-1	14513889
the	O	-1	14513889
first	O	-1	14513889
time	O	-1	14513889
in	O	-1	14513889
h@@	O	-1	14513889
is	O	-1	14513889
lif@@	O	-1	14513889
e.	O	-1	14513889
All	O	-1	14513889
com@@	O	-1	14513889
pl@@	O	-1	14513889
a@@	O	-1	14513889
int@@	O	-1	14513889
s	O	-1	14513889
f@@	O	-1	14513889
ad@@	O	-1	14513889
ed	O	-1	14513889
aw@@	O	-1	14513889
ay	O	-1	14513889
within	O	-1	14513889
24	O	-1	14513889
h@@	O	-1	14513889
.	O	-1	14513889
F@@	O	-1	14513889
e@@	O	-1	14513889
w	O	-1	14513889
days	O	-1	14513889
lat@@	O	-1	14513889
er,	O	-1	14513889
the	O	-1	14513889
patient	O	-1	14513889
used	O	-1	14513889
an@@	O	-1	14513889
other	O	-1	14513889
2@@	O	-1	14513889
00	O	-1	14513889
mg	O	-1	14513889
ke@@	B-Chemical	D007654	14513889
to@@	I-Chemical	-1	14513889
con@@	I-Chemical	-1	14513889
azole	I-Chemical	-1	14513889
t@@	O	-1	14513889
able@@	O	-1	14513889
t,	O	-1	14513889
and	O	-1	14513889
within	O	-1	14513889
an	O	-1	14513889
h@@	O	-1	14513889
our	O	-1	14513889
experienced	O	-1	14513889
a	O	-1	14513889
similar	O	-1	14513889
clinical	O	-1	14513889
p@@	O	-1	14513889
ic@@	O	-1	14513889
t@@	O	-1	14513889
ure,	O	-1	14513889
which	O	-1	14513889
resol@@	O	-1	14513889
ved	O	-1	14513889
ag@@	O	-1	14513889
ain	O	-1	14513889
spont@@	O	-1	14513889
ane@@	O	-1	14513889
ously	O	-1	14513889
within	O	-1	14513889
hour@@	O	-1	14513889
s.	O	-1	14513889
L@@	O	-1	14513889
abor@@	O	-1	14513889
atory	O	-1	14513889
evalu@@	O	-1	14513889
ation@@	O	-1	14513889
s,	O	-1	14513889
including	O	-1	14513889
he@@	O	-1	14513889
ad	O	-1	14513889
C@@	O	-1	14513889
T	O	-1	14513889
s@@	O	-1	14513889
can@@	O	-1	14513889
,	O	-1	14513889
were	O	-1	14513889
normal@@	O	-1	14513889
.	O	-1	14513889
This	O	-1	14513889
case	O	-1	14513889
il@@	O	-1	14513889
lu@@	O	-1	14513889
strat@@	O	-1	14513889
es	O	-1	14513889
the	O	-1	14513889
need	O	-1	14513889
for	O	-1	14513889
clo@@	O	-1	14513889
se	O	-1	14513889
vi@@	O	-1	14513889
g@@	O	-1	14513889
il@@	O	-1	14513889
ance	O	-1	14513889
in	O	-1	14513889
adverse	B-Disease	D064420	14513889
drug	I-Disease	-1	14513889
reactions	I-Disease	-1	14513889
,	O	-1	14513889
partic@@	O	-1	14513889
ul@@	O	-1	14513889
arly	O	-1	14513889
in	O	-1	14513889
the	O	-1	14513889
el@@	O	-1	14513889
der@@	O	-1	14513889
ly.	O	-1	14513889

N@@	O	-1	15009014
ox@@	O	-1	15009014
i@@	O	-1	15009014
ous	O	-1	15009014
chemical	O	-1	15009014
stimulation	O	-1	15009014
of	O	-1	15009014
rat	O	-1	15009014
fac@@	O	-1	15009014
ial	O	-1	15009014
m@@	O	-1	15009014
u@@	O	-1	15009014
co@@	O	-1	15009014
s@@	O	-1	15009014
a	O	-1	15009014
increases	O	-1	15009014
intrac@@	O	-1	15009014
ranial	O	-1	15009014
blood	O	-1	15009014
flow	O	-1	15009014
through	O	-1	15009014
a	O	-1	15009014
tri@@	O	-1	15009014
g@@	O	-1	15009014
em@@	O	-1	15009014
ino@@	O	-1	15009014
-@@	O	-1	15009014
par@@	O	-1	15009014
as@@	O	-1	15009014
ym@@	O	-1	15009014
pa@@	O	-1	15009014
thetic	O	-1	15009014
ref@@	O	-1	15009014
le@@	O	-1	15009014
x@@	O	-1	15009014
-@@	O	-1	15009014
-@@	O	-1	15009014
an	O	-1	15009014
experimental	O	-1	15009014
model	O	-1	15009014
for	O	-1	15009014
vascular	B-Disease	D002561	15009014
dysfunc@@	I-Disease	-1	15009014
tions	I-Disease	-1	15009014
in	O	-1	15009014
cl@@	B-Disease	D003027	15009014
ust@@	I-Disease	-1	15009014
er	I-Disease	-1	15009014
headac@@	I-Disease	-1	15009014
he	I-Disease	-1	15009014
.	O	-1	15009014
C@@	B-Disease	D003027	15009014
lu@@	I-Disease	-1	15009014
st@@	I-Disease	-1	15009014
er	I-Disease	-1	15009014
headac@@	I-Disease	-1	15009014
he	I-Disease	-1	15009014
is	O	-1	15009014
character@@	O	-1	15009014
ized	O	-1	15009014
by	O	-1	15009014
typ@@	O	-1	15009014
ical	O	-1	15009014
a@@	O	-1	15009014
ut@@	O	-1	15009014
on@@	O	-1	15009014
om@@	O	-1	15009014
ic	O	-1	15009014
dysfunc@@	O	-1	15009014
tions	O	-1	15009014
including	O	-1	15009014
fac@@	O	-1	15009014
ial	O	-1	15009014
and	O	-1	15009014
intrac@@	B-Disease	D002561	15009014
ranial	I-Disease	-1	15009014
vascular	I-Disease	-1	15009014
dist@@	I-Disease	-1	15009014
urb@@	I-Disease	-1	15009014
anc@@	I-Disease	-1	15009014
es	I-Disease	-1	15009014
.	O	-1	15009014
B@@	O	-1	15009014
oth	O	-1	15009014
the	O	-1	15009014
tri@@	O	-1	15009014
g@@	O	-1	15009014
em@@	O	-1	15009014
inal	O	-1	15009014
and	O	-1	15009014
the	O	-1	15009014
c@@	O	-1	15009014
ranial	O	-1	15009014
par@@	O	-1	15009014
as@@	O	-1	15009014
ym@@	O	-1	15009014
pa@@	O	-1	15009014
thetic	O	-1	15009014
system@@	O	-1	15009014
s	O	-1	15009014
may	O	-1	15009014
be	O	-1	15009014
involved	O	-1	15009014
in	O	-1	15009014
medi@@	O	-1	15009014
ating	O	-1	15009014
these	O	-1	15009014
dysfunc@@	O	-1	15009014
tions.	O	-1	15009014
An	O	-1	15009014
experimental	O	-1	15009014
model	O	-1	15009014
was	O	-1	15009014
developed	O	-1	15009014
in	O	-1	15009014
the	O	-1	15009014
rat	O	-1	15009014
to	O	-1	15009014
meas@@	O	-1	15009014
ure	O	-1	15009014
changes	O	-1	15009014
in	O	-1	15009014
l@@	O	-1	15009014
ac@@	O	-1	15009014
ri@@	O	-1	15009014
m@@	O	-1	15009014
ation	O	-1	15009014
and	O	-1	15009014
intrac@@	O	-1	15009014
ranial	O	-1	15009014
blood	O	-1	15009014
flow	O	-1	15009014
following	O	-1	15009014
no@@	O	-1	15009014
xi@@	O	-1	15009014
ous	O	-1	15009014
chemical	O	-1	15009014
stimulation	O	-1	15009014
of	O	-1	15009014
fac@@	O	-1	15009014
ial	O	-1	15009014
m@@	O	-1	15009014
u@@	O	-1	15009014
co@@	O	-1	15009014
s@@	O	-1	15009014
a.	O	-1	15009014
B@@	O	-1	15009014
lo@@	O	-1	15009014
od	O	-1	15009014
flow	O	-1	15009014
was	O	-1	15009014
monit@@	O	-1	15009014
o@@	O	-1	15009014
red	O	-1	15009014
in	O	-1	15009014
arter@@	O	-1	15009014
i@@	O	-1	15009014
es	O	-1	15009014
of	O	-1	15009014
the	O	-1	15009014
exposed	O	-1	15009014
c@@	O	-1	15009014
ranial	O	-1	15009014
dur@@	O	-1	15009014
a	O	-1	15009014
mat@@	O	-1	15009014
er	O	-1	15009014
and	O	-1	15009014
the	O	-1	15009014
par@@	O	-1	15009014
i@@	O	-1	15009014
et@@	O	-1	15009014
al	O	-1	15009014
cor@@	O	-1	15009014
te@@	O	-1	15009014
x	O	-1	15009014
using	O	-1	15009014
las@@	O	-1	15009014
er	O	-1	15009014
D@@	O	-1	15009014
op@@	O	-1	15009014
pl@@	O	-1	15009014
er	O	-1	15009014
f@@	O	-1	15009014
low@@	O	-1	15009014
met@@	O	-1	15009014
r@@	O	-1	15009014
y.	O	-1	15009014
C@@	B-Chemical	D002211	15009014
ap@@	I-Chemical	-1	15009014
sa@@	I-Chemical	-1	15009014
icin	I-Chemical	-1	15009014
(@@	O	-1	15009014
0.0@@	O	-1	15009014
1-@@	O	-1	15009014
1	O	-1	15009014
mm@@	O	-1	15009014
)	O	-1	15009014
ap@@	O	-1	15009014
pl@@	O	-1	15009014
ied	O	-1	15009014
to	O	-1	15009014
oral	O	-1	15009014
or	O	-1	15009014
n@@	O	-1	15009014
as@@	O	-1	15009014
al	O	-1	15009014
m@@	O	-1	15009014
u@@	O	-1	15009014
co@@	O	-1	15009014
s@@	O	-1	15009014
a	O	-1	15009014
induced	O	-1	15009014
increases	B-Disease	D006940	15009014
in	I-Disease	-1	15009014
dur@@	I-Disease	-1	15009014
al	I-Disease	-1	15009014
and	I-Disease	-1	15009014
cor@@	I-Disease	-1	15009014
tical	I-Disease	-1	15009014
blood	I-Disease	-1	15009014
flow	I-Disease	-1	15009014
and	O	-1	15009014
prov@@	O	-1	15009014
o@@	O	-1	15009014
ked	O	-1	15009014
l@@	O	-1	15009014
ac@@	O	-1	15009014
ri@@	O	-1	15009014
m@@	O	-1	15009014
ation.	O	-1	15009014
These	O	-1	15009014
responses	O	-1	15009014
were	O	-1	15009014
block@@	O	-1	15009014
ed	O	-1	15009014
by	O	-1	15009014
systemic	O	-1	15009014
pre-@@	O	-1	15009014
administration	O	-1	15009014
of	O	-1	15009014
he@@	B-Chemical	D018738	15009014
xameth@@	I-Chemical	-1	15009014
oni@@	I-Chemical	-1	15009014
um	I-Chemical	-1	15009014
chlor@@	I-Chemical	-1	15009014
ide	I-Chemical	-1	15009014
(2@@	O	-1	15009014
0	O	-1	15009014
mg/kg@@	O	-1	15009014
).	O	-1	15009014
The	O	-1	15009014
evoked	O	-1	15009014
increases	B-Disease	D006940	15009014
in	I-Disease	-1	15009014
dur@@	I-Disease	-1	15009014
al	I-Disease	-1	15009014
blood	I-Disease	-1	15009014
flow	I-Disease	-1	15009014
were	O	-1	15009014
also	O	-1	15009014
abol@@	O	-1	15009014
ished	O	-1	15009014
by	O	-1	15009014
to@@	O	-1	15009014
p@@	O	-1	15009014
ical	O	-1	15009014
pre-@@	O	-1	15009014
administration	O	-1	15009014
of	O	-1	15009014
atro@@	B-Chemical	D001285	15009014
pine	I-Chemical	-1	15009014
(@@	O	-1	15009014
1	O	-1	15009014
mm@@	O	-1	15009014
)	O	-1	15009014
and	O	-1	15009014
[@@	O	-1	15009014
L@@	O	-1	15009014
ys@@	O	-1	15009014
1,	O	-1	15009014
Pro@@	O	-1	15009014
2@@	O	-1	15009014
,@@	O	-1	15009014
5,	O	-1	15009014
A@@	O	-1	15009014
r@@	O	-1	15009014
g@@	O	-1	15009014
3@@	O	-1	15009014
,@@	O	-1	15009014
4@@	O	-1	15009014
,	O	-1	15009014
T@@	O	-1	15009014
y@@	O	-1	15009014
r@@	O	-1	15009014
6@@	O	-1	15009014
]@@	O	-1	15009014
-@@	O	-1	15009014
V@@	O	-1	15009014
I@@	O	-1	15009014
P	O	-1	15009014
(0.@@	O	-1	15009014
1	O	-1	15009014
mm@@	O	-1	15009014
),	O	-1	15009014
a	O	-1	15009014
vas@@	O	-1	15009014
o@@	O	-1	15009014
active	O	-1	15009014
in@@	O	-1	15009014
test@@	O	-1	15009014
inal	O	-1	15009014
poly@@	O	-1	15009014
p@@	O	-1	15009014
ep@@	O	-1	15009014
ti@@	O	-1	15009014
de	O	-1	15009014
(V@@	O	-1	15009014
I@@	O	-1	15009014
P)	O	-1	15009014
antagonist@@	O	-1	15009014
,	O	-1	15009014
on@@	O	-1	15009014
to	O	-1	15009014
the	O	-1	15009014
exposed	O	-1	15009014
dur@@	O	-1	15009014
a	O	-1	15009014
mat@@	O	-1	15009014
er.	O	-1	15009014
We	O	-1	15009014
concl@@	O	-1	15009014
ude	O	-1	15009014
that	O	-1	15009014
no@@	O	-1	15009014
xi@@	O	-1	15009014
ous	O	-1	15009014
stimulation	O	-1	15009014
of	O	-1	15009014
fac@@	O	-1	15009014
ial	O	-1	15009014
m@@	O	-1	15009014
u@@	O	-1	15009014
co@@	O	-1	15009014
s@@	O	-1	15009014
a	O	-1	15009014
increases	O	-1	15009014
intrac@@	O	-1	15009014
ranial	O	-1	15009014
blood	O	-1	15009014
flow	O	-1	15009014
and	O	-1	15009014
l@@	O	-1	15009014
ac@@	O	-1	15009014
ri@@	O	-1	15009014
m@@	O	-1	15009014
ation	O	-1	15009014
vi@@	O	-1	15009014
a	O	-1	15009014
a	O	-1	15009014
tri@@	O	-1	15009014
g@@	O	-1	15009014
em@@	O	-1	15009014
ino@@	O	-1	15009014
-@@	O	-1	15009014
par@@	O	-1	15009014
as@@	O	-1	15009014
ym@@	O	-1	15009014
pa@@	O	-1	15009014
thetic	O	-1	15009014
ref@@	O	-1	15009014
le@@	O	-1	15009014
x@@	O	-1	15009014
.	O	-1	15009014
The	O	-1	15009014
blood	O	-1	15009014
flow	O	-1	15009014
responses	O	-1	15009014
se@@	O	-1	15009014
em	O	-1	15009014
to	O	-1	15009014
be	O	-1	15009014
mediated	O	-1	15009014
by	O	-1	15009014
the	O	-1	15009014
release	O	-1	15009014
of	O	-1	15009014
acet@@	B-Chemical	D000109	15009014
ylcholine	I-Chemical	-1	15009014
and	O	-1	15009014
V@@	O	-1	15009014
I@@	O	-1	15009014
P	O	-1	15009014
within	O	-1	15009014
the	O	-1	15009014
men@@	O	-1	15009014
ing@@	O	-1	15009014
es.	O	-1	15009014
S@@	O	-1	15009014
im@@	O	-1	15009014
il@@	O	-1	15009014
ar	O	-1	15009014
mechanisms	O	-1	15009014
may	O	-1	15009014
be	O	-1	15009014
involved	O	-1	15009014
in	O	-1	15009014
the	O	-1	15009014
path@@	O	-1	15009014
o@@	O	-1	15009014
genesis	O	-1	15009014
of	O	-1	15009014
cl@@	B-Disease	D003027	15009014
ust@@	I-Disease	-1	15009014
er	I-Disease	-1	15009014
headac@@	I-Disease	-1	15009014
he	I-Disease	-1	15009014
.	O	-1	15009014

Rec@@	O	-1	15120741
ur@@	O	-1	15120741
rent	O	-1	15120741
ex@@	O	-1	15120741
cit@@	O	-1	15120741
ation	O	-1	15120741
in	O	-1	15120741
the	O	-1	15120741
d@@	O	-1	15120741
ent@@	O	-1	15120741
ate	O	-1	15120741
g@@	O	-1	15120741
y@@	O	-1	15120741
ru@@	O	-1	15120741
s	O	-1	15120741
of	O	-1	15120741
a	O	-1	15120741
m@@	O	-1	15120741
urine	O	-1	15120741
model	O	-1	15120741
of	O	-1	15120741
tempor@@	B-Disease	D004833	15120741
al	I-Disease	-1	15120741
lo@@	I-Disease	-1	15120741
be	I-Disease	-1	15120741
epilep@@	I-Disease	-1	15120741
sy	I-Disease	-1	15120741
.	O	-1	15120741
S@@	O	-1	15120741
im@@	O	-1	15120741
il@@	O	-1	15120741
ar	O	-1	15120741
to	O	-1	15120741
rats,	O	-1	15120741
systemic	O	-1	15120741
pilocar@@	B-Chemical	D010862	15120741
pine	I-Chemical	-1	15120741
injection	O	-1	15120741
causes	O	-1	15120741
status	B-Disease	D013226	15120741
epilep@@	I-Disease	-1	15120741
tic@@	I-Disease	-1	15120741
us	I-Disease	-1	15120741
(	O	-1	15120741
S@@	B-Disease	D013226	15120741
E	I-Disease	-1	15120741
)	O	-1	15120741
and	O	-1	15120741
the	O	-1	15120741
event@@	O	-1	15120741
ual	O	-1	15120741
development	O	-1	15120741
of	O	-1	15120741
spont@@	O	-1	15120741
aneous	O	-1	15120741
seizures	B-Disease	D012640	15120741
and	O	-1	15120741
m@@	O	-1	15120741
os@@	O	-1	15120741
sy	O	-1	15120741
fib@@	O	-1	15120741
er	O	-1	15120741
s@@	O	-1	15120741
pro@@	O	-1	15120741
ut@@	O	-1	15120741
ing	O	-1	15120741
in	O	-1	15120741
C@@	O	-1	15120741
5@@	O	-1	15120741
7@@	O	-1	15120741
B@@	O	-1	15120741
L@@	O	-1	15120741
/@@	O	-1	15120741
6	O	-1	15120741
and	O	-1	15120741
C@@	O	-1	15120741
D@@	O	-1	15120741
1	O	-1	15120741
mic@@	O	-1	15120741
e,	O	-1	15120741
but	O	-1	15120741
the	O	-1	15120741
physi@@	O	-1	15120741
ological	O	-1	15120741
correl@@	O	-1	15120741
ates	O	-1	15120741
of	O	-1	15120741
these	O	-1	15120741
events	O	-1	15120741
have	O	-1	15120741
not	O	-1	15120741
been	O	-1	15120741
identi@@	O	-1	15120741
fied	O	-1	15120741
in	O	-1	15120741
mice.	O	-1	15120741
P@@	O	-1	15120741
op@@	O	-1	15120741
ulation	O	-1	15120741
responses	O	-1	15120741
in	O	-1	15120741
gran@@	O	-1	15120741
ul@@	O	-1	15120741
e	O	-1	15120741
cells	O	-1	15120741
of	O	-1	15120741
the	O	-1	15120741
d@@	O	-1	15120741
ent@@	O	-1	15120741
ate	O	-1	15120741
g@@	O	-1	15120741
y@@	O	-1	15120741
ru@@	O	-1	15120741
s	O	-1	15120741
were	O	-1	15120741
examined	O	-1	15120741
in	O	-1	15120741
trans@@	O	-1	15120741
verse	O	-1	15120741
s@@	O	-1	15120741
l@@	O	-1	15120741
ic@@	O	-1	15120741
es	O	-1	15120741
of	O	-1	15120741
the	O	-1	15120741
ventr@@	O	-1	15120741
al	O	-1	15120741
hippocamp@@	O	-1	15120741
us	O	-1	15120741
from	O	-1	15120741
pilocar@@	B-Chemical	D010862	15120741
pine	I-Chemical	-1	15120741
-treated	O	-1	15120741
and	O	-1	15120741
un@@	O	-1	15120741
treated	O	-1	15120741
mice.	O	-1	15120741
In	O	-1	15120741
M@@	B-Chemical	D008274	15120741
g	I-Chemical	-1	15120741
(2@@	O	-1	15120741
+@@	O	-1	15120741
)-@@	O	-1	15120741
free	O	-1	15120741
b@@	O	-1	15120741
ath@@	O	-1	15120741
ing	O	-1	15120741
medi@@	O	-1	15120741
um	O	-1	15120741
containing	O	-1	15120741
b@@	B-Chemical	D001640	15120741
ic@@	I-Chemical	-1	15120741
uc@@	I-Chemical	-1	15120741
ul@@	I-Chemical	-1	15120741
line	I-Chemical	-1	15120741
,	O	-1	15120741
condi@@	O	-1	15120741
tions	O	-1	15120741
de@@	O	-1	15120741
signed	O	-1	15120741
to	O	-1	15120741
increase	O	-1	15120741
ex@@	O	-1	15120741
cit@@	O	-1	15120741
ability	O	-1	15120741
in	O	-1	15120741
the	O	-1	15120741
s@@	O	-1	15120741
l@@	O	-1	15120741
ic@@	O	-1	15120741
es,	O	-1	15120741
elect@@	O	-1	15120741
r@@	O	-1	15120741
ical	O	-1	15120741
stimulation	O	-1	15120741
of	O	-1	15120741
the	O	-1	15120741
h@@	O	-1	15120741
il@@	O	-1	15120741
us	O	-1	15120741
resulted	O	-1	15120741
in	O	-1	15120741
a	O	-1	15120741
single	O	-1	15120741
po@@	O	-1	15120741
p@@	O	-1	15120741
ulation	O	-1	15120741
s@@	O	-1	15120741
pi@@	O	-1	15120741
k@@	O	-1	15120741
e	O	-1	15120741
in	O	-1	15120741
gran@@	O	-1	15120741
ul@@	O	-1	15120741
e	O	-1	15120741
cells	O	-1	15120741
from	O	-1	15120741
control	O	-1	15120741
mice	O	-1	15120741
and	O	-1	15120741
pilocar@@	B-Chemical	D010862	15120741
pine	I-Chemical	-1	15120741
-treated	O	-1	15120741
mice	O	-1	15120741
that	O	-1	15120741
did	O	-1	15120741
not	O	-1	15120741
experi@@	O	-1	15120741
ence	O	-1	15120741
S@@	B-Disease	D013226	15120741
E	I-Disease	-1	15120741
.	O	-1	15120741
In	O	-1	15120741
S@@	B-Disease	D013226	15120741
E	I-Disease	-1	15120741
sur@@	O	-1	15120741
viv@@	O	-1	15120741
or@@	O	-1	15120741
s,	O	-1	15120741
similar	O	-1	15120741
stimulation	O	-1	15120741
resulted	O	-1	15120741
in	O	-1	15120741
a	O	-1	15120741
po@@	O	-1	15120741
p@@	O	-1	15120741
ulation	O	-1	15120741
s@@	O	-1	15120741
pi@@	O	-1	15120741
k@@	O	-1	15120741
e	O	-1	15120741
fol@@	O	-1	15120741
lo@@	O	-1	15120741
we@@	O	-1	15120741
d,	O	-1	15120741
at	O	-1	15120741
a	O	-1	15120741
vari@@	O	-1	15120741
able	O	-1	15120741
lat@@	O	-1	15120741
enc@@	O	-1	15120741
y,	O	-1	15120741
by	O	-1	15120741
negative	O	-1	15120741
D@@	O	-1	15120741
C	O	-1	15120741
shi@@	O	-1	15120741
f@@	O	-1	15120741
ts	O	-1	15120741
and	O	-1	15120741
repe@@	O	-1	15120741
ti@@	O	-1	15120741
tive	O	-1	15120741
af@@	O	-1	15120741
ter@@	O	-1	15120741
dis@@	O	-1	15120741
ch@@	O	-1	15120741
arg@@	O	-1	15120741
es	O	-1	15120741
of	O	-1	15120741
3-@@	O	-1	15120741
60	O	-1	15120741
s	O	-1	15120741
dur@@	O	-1	15120741
ation,	O	-1	15120741
which	O	-1	15120741
were	O	-1	15120741
block@@	O	-1	15120741
ed	O	-1	15120741
by	O	-1	15120741
i@@	O	-1	15120741
on@@	O	-1	15120741
ot@@	O	-1	15120741
ro@@	O	-1	15120741
p@@	O	-1	15120741
ic	O	-1	15120741
glutamate	B-Chemical	D018698	15120741
receptor	O	-1	15120741
antagonist@@	O	-1	15120741
s.	O	-1	15120741
F@@	O	-1	15120741
oc@@	O	-1	15120741
al	O	-1	15120741
glutamate	B-Chemical	D018698	15120741
ph@@	O	-1	15120741
ot@@	O	-1	15120741
os@@	O	-1	15120741
tim@@	O	-1	15120741
ulation	O	-1	15120741
of	O	-1	15120741
the	O	-1	15120741
gran@@	O	-1	15120741
ul@@	O	-1	15120741
e	O	-1	15120741
cell	O	-1	15120741
l@@	O	-1	15120741
ay@@	O	-1	15120741
er	O	-1	15120741
at	O	-1	15120741
sit@@	O	-1	15120741
es	O	-1	15120741
dist@@	O	-1	15120741
ant	O	-1	15120741
from	O	-1	15120741
the	O	-1	15120741
recor@@	O	-1	15120741
ding	O	-1	15120741
pi@@	O	-1	15120741
p@@	O	-1	15120741
et@@	O	-1	15120741
te	O	-1	15120741
resulted	O	-1	15120741
in	O	-1	15120741
po@@	O	-1	15120741
p@@	O	-1	15120741
ulation	O	-1	15120741
responses	O	-1	15120741
of	O	-1	15120741
1-@@	O	-1	15120741
30	O	-1	15120741
s	O	-1	15120741
duration	O	-1	15120741
in	O	-1	15120741
s@@	O	-1	15120741
l@@	O	-1	15120741
ic@@	O	-1	15120741
es	O	-1	15120741
from	O	-1	15120741
S@@	B-Disease	D013226	15120741
E	I-Disease	-1	15120741
sur@@	O	-1	15120741
viv@@	O	-1	15120741
ors	O	-1	15120741
but	O	-1	15120741
not	O	-1	15120741
other	O	-1	15120741
groups.	O	-1	15120741
These	O	-1	15120741
data	O	-1	15120741
suppor@@	O	-1	15120741
t	O	-1	15120741
the	O	-1	15120741
hypo@@	O	-1	15120741
thesis	O	-1	15120741
that	O	-1	15120741
S@@	B-Disease	D013226	15120741
E	I-Disease	-1	15120741
-induced	O	-1	15120741
m@@	O	-1	15120741
os@@	O	-1	15120741
sy	O	-1	15120741
fib@@	O	-1	15120741
er	O	-1	15120741
s@@	O	-1	15120741
pro@@	O	-1	15120741
ut@@	O	-1	15120741
ing	O	-1	15120741
and	O	-1	15120741
syn@@	O	-1	15120741
ap@@	O	-1	15120741
tic	O	-1	15120741
re@@	O	-1	15120741
org@@	O	-1	15120741
an@@	O	-1	15120741
ization	O	-1	15120741
are	O	-1	15120741
re@@	O	-1	15120741
lev@@	O	-1	15120741
ant	O	-1	15120741
character@@	O	-1	15120741
is@@	O	-1	15120741
tics	O	-1	15120741
of	O	-1	15120741
seizure	B-Disease	D012640	15120741
development	O	-1	15120741
in	O	-1	15120741
these	O	-1	15120741
m@@	O	-1	15120741
urine	O	-1	15120741
stra@@	O	-1	15120741
in@@	O	-1	15120741
s,	O	-1	15120741
re@@	O	-1	15120741
se@@	O	-1	15120741
m@@	O	-1	15120741
bl@@	O	-1	15120741
ing	O	-1	15120741
rat	O	-1	15120741
models	O	-1	15120741
of	O	-1	15120741
human	O	-1	15120741
tempor@@	B-Disease	D004833	15120741
al	I-Disease	-1	15120741
lo@@	I-Disease	-1	15120741
be	I-Disease	-1	15120741
epilep@@	I-Disease	-1	15120741
sy	I-Disease	-1	15120741
.	O	-1	15120741

The	O	-1	15275829
alpha@@	O	-1	15275829
3	O	-1	15275829
and	O	-1	15275829
beta@@	O	-1	15275829
4	O	-1	15275829
nicot@@	O	-1	15275829
inic	O	-1	15275829
acet@@	B-Chemical	D000109	15275829
ylcholine	I-Chemical	-1	15275829
receptor	O	-1	15275829
sub@@	O	-1	15275829
un@@	O	-1	15275829
its	O	-1	15275829
are	O	-1	15275829
nec@@	O	-1	15275829
ess@@	O	-1	15275829
ary	O	-1	15275829
for	O	-1	15275829
nicotine	B-Chemical	D009538	15275829
-induced	O	-1	15275829
seizures	B-Disease	D012640	15275829
and	O	-1	15275829
hypo@@	B-Disease	D006948	15275829
locom@@	I-Disease	-1	15275829
o@@	I-Disease	-1	15275829
tion	I-Disease	-1	15275829
in	O	-1	15275829
mice.	O	-1	15275829
B@@	O	-1	15275829
ind@@	O	-1	15275829
ing	O	-1	15275829
of	O	-1	15275829
nicotine	B-Chemical	D009538	15275829
to	O	-1	15275829
nicot@@	O	-1	15275829
inic	O	-1	15275829
acet@@	B-Chemical	D000109	15275829
ylcholine	I-Chemical	-1	15275829
receptors	O	-1	15275829
(n@@	O	-1	15275829
AC@@	O	-1	15275829
h@@	O	-1	15275829
R@@	O	-1	15275829
s)	O	-1	15275829
el@@	O	-1	15275829
ic@@	O	-1	15275829
its	O	-1	15275829
a	O	-1	15275829
seri@@	O	-1	15275829
es	O	-1	15275829
of	O	-1	15275829
dose-@@	O	-1	15275829
dependent	O	-1	15275829
behavi@@	O	-1	15275829
ors	O	-1	15275829
that	O	-1	15275829
g@@	O	-1	15275829
o	O	-1	15275829
from	O	-1	15275829
al@@	O	-1	15275829
te@@	O	-1	15275829
red	O	-1	15275829
expl@@	O	-1	15275829
or@@	O	-1	15275829
ation,	O	-1	15275829
sed@@	O	-1	15275829
ation,	O	-1	15275829
and	O	-1	15275829
tre@@	B-Disease	D014202	15275829
mor@@	I-Disease	-1	15275829
s	I-Disease	-1	15275829
,	O	-1	15275829
to	O	-1	15275829
seizures	B-Disease	D012640	15275829
and	O	-1	15275829
death	B-Disease	D003643	15275829
.	O	-1	15275829
n@@	O	-1	15275829
AC@@	O	-1	15275829
h@@	O	-1	15275829
R@@	O	-1	15275829
s	O	-1	15275829
are	O	-1	15275829
pent@@	O	-1	15275829
am@@	O	-1	15275829
er@@	O	-1	15275829
ic	O	-1	15275829
i@@	O	-1	15275829
on	O	-1	15275829
channe@@	O	-1	15275829
l@@	O	-1	15275829
s	O	-1	15275829
us@@	O	-1	15275829
ually	O	-1	15275829
com@@	O	-1	15275829
pos@@	O	-1	15275829
ed	O	-1	15275829
of	O	-1	15275829
al@@	O	-1	15275829
ph@@	O	-1	15275829
a	O	-1	15275829
and	O	-1	15275829
bet@@	O	-1	15275829
a	O	-1	15275829
sub@@	O	-1	15275829
un@@	O	-1	15275829
it@@	O	-1	15275829
s.	O	-1	15275829
A	O	-1	15275829
gen@@	O	-1	15275829
e	O	-1	15275829
cl@@	O	-1	15275829
ust@@	O	-1	15275829
er	O	-1	15275829
comp@@	O	-1	15275829
ri@@	O	-1	15275829
ses	O	-1	15275829
the	O	-1	15275829
alpha@@	O	-1	15275829
3,	O	-1	15275829
alpha@@	O	-1	15275829
5	O	-1	15275829
and	O	-1	15275829
beta@@	O	-1	15275829
4	O	-1	15275829
sub@@	O	-1	15275829
un@@	O	-1	15275829
it@@	O	-1	15275829
s,	O	-1	15275829
which	O	-1	15275829
co@@	O	-1	15275829
as@@	O	-1	15275829
se@@	O	-1	15275829
mb@@	O	-1	15275829
le	O	-1	15275829
to	O	-1	15275829
form	O	-1	15275829
functional	O	-1	15275829
receptor@@	O	-1	15275829
s.	O	-1	15275829
We	O	-1	15275829
examined	O	-1	15275829
the	O	-1	15275829
role	O	-1	15275829
of	O	-1	15275829
the	O	-1	15275829
beta@@	O	-1	15275829
4	O	-1	15275829
sub@@	O	-1	15275829
un@@	O	-1	15275829
its	O	-1	15275829
in	O	-1	15275829
nicotine	B-Chemical	D009538	15275829
-induced	O	-1	15275829
seizures	B-Disease	D012640	15275829
and	O	-1	15275829
hypo@@	B-Disease	D006948	15275829
locom@@	I-Disease	-1	15275829
o@@	I-Disease	-1	15275829
tion	I-Disease	-1	15275829
in	O	-1	15275829
beta@@	O	-1	15275829
4	O	-1	15275829
ho@@	O	-1	15275829
mo@@	O	-1	15275829
z@@	O	-1	15275829
y@@	O	-1	15275829
g@@	O	-1	15275829
ous	O	-1	15275829
n@@	O	-1	15275829
ul@@	O	-1	15275829
l	O	-1	15275829
(@@	O	-1	15275829
beta@@	O	-1	15275829
4	O	-1	15275829
-@@	O	-1	15275829
/@@	O	-1	15275829
-@@	O	-1	15275829
)	O	-1	15275829
and	O	-1	15275829
alpha@@	O	-1	15275829
3	O	-1	15275829
he@@	O	-1	15275829
ter@@	O	-1	15275829
o@@	O	-1	15275829
z@@	O	-1	15275829
y@@	O	-1	15275829
g@@	O	-1	15275829
ous	O	-1	15275829
(@@	O	-1	15275829
+/-@@	O	-1	15275829
)	O	-1	15275829
mice.	O	-1	15275829
beta@@	O	-1	15275829
4	O	-1	15275829
-@@	O	-1	15275829
/@@	O	-1	15275829
-	O	-1	15275829
mice	O	-1	15275829
were	O	-1	15275829
less	O	-1	15275829
sensitive	O	-1	15275829
to	O	-1	15275829
the	O	-1	15275829
effects	O	-1	15275829
of	O	-1	15275829
nicotine	B-Chemical	D009538	15275829
both	O	-1	15275829
at	O	-1	15275829
low	O	-1	15275829
dos@@	O	-1	15275829
es,	O	-1	15275829
measured	O	-1	15275829
as	O	-1	15275829
decreased	O	-1	15275829
expl@@	O	-1	15275829
or@@	O	-1	15275829
ation	O	-1	15275829
in	O	-1	15275829
an	O	-1	15275829
op@@	O	-1	15275829
en	O	-1	15275829
fi@@	O	-1	15275829
el@@	O	-1	15275829
d,	O	-1	15275829
and	O	-1	15275829
at	O	-1	15275829
high	O	-1	15275829
dos@@	O	-1	15275829
es,	O	-1	15275829
measured	O	-1	15275829
as	O	-1	15275829
sensitivity	O	-1	15275829
to	O	-1	15275829
nicotine	B-Chemical	D009538	15275829
-induced	O	-1	15275829
seizures	B-Disease	D012640	15275829
.	O	-1	15275829
U@@	O	-1	15275829
s@@	O	-1	15275829
ing	O	-1	15275829
in	O	-1	15275829
sit@@	O	-1	15275829
u	O	-1	15275829
hy@@	O	-1	15275829
b@@	O	-1	15275829
ri@@	O	-1	15275829
di@@	O	-1	15275829
z@@	O	-1	15275829
ation	O	-1	15275829
prob@@	O	-1	15275829
es	O	-1	15275829
for	O	-1	15275829
the	O	-1	15275829
alpha@@	O	-1	15275829
3	O	-1	15275829
and	O	-1	15275829
alpha@@	O	-1	15275829
5	O	-1	15275829
sub@@	O	-1	15275829
un@@	O	-1	15275829
it@@	O	-1	15275829
s,	O	-1	15275829
we	O	-1	15275829
showed	O	-1	15275829
that	O	-1	15275829
alpha@@	O	-1	15275829
5	O	-1	15275829
mRNA	O	-1	15275829
levels	O	-1	15275829
are	O	-1	15275829
un@@	O	-1	15275829
chang@@	O	-1	15275829
ed,	O	-1	15275829
whereas	O	-1	15275829
alpha@@	O	-1	15275829
3	O	-1	15275829
mRNA	O	-1	15275829
levels	O	-1	15275829
are	O	-1	15275829
sel@@	O	-1	15275829
ectively	O	-1	15275829
decreased	O	-1	15275829
in	O	-1	15275829
the	O	-1	15275829
mit@@	O	-1	15275829
ral	O	-1	15275829
cell	O	-1	15275829
l@@	O	-1	15275829
ay@@	O	-1	15275829
er	O	-1	15275829
of	O	-1	15275829
the	O	-1	15275829
ol@@	O	-1	15275829
fact@@	O	-1	15275829
ory	O	-1	15275829
b@@	O	-1	15275829
ul@@	O	-1	15275829
b@@	O	-1	15275829
,	O	-1	15275829
and	O	-1	15275829
the	O	-1	15275829
inf@@	O	-1	15275829
er@@	O	-1	15275829
ior	O	-1	15275829
and	O	-1	15275829
the	O	-1	15275829
su@@	O	-1	15275829
peri@@	O	-1	15275829
or	O	-1	15275829
coll@@	O	-1	15275829
ic@@	O	-1	15275829
ul@@	O	-1	15275829
us	O	-1	15275829
of	O	-1	15275829
beta@@	O	-1	15275829
4	O	-1	15275829
-@@	O	-1	15275829
/@@	O	-1	15275829
-	O	-1	15275829
bra@@	O	-1	15275829
in@@	O	-1	15275829
s.	O	-1	15275829
alpha@@	O	-1	15275829
3	O	-1	15275829
+/-	O	-1	15275829
mice	O	-1	15275829
were	O	-1	15275829
par@@	O	-1	15275829
ti@@	O	-1	15275829
ally	O	-1	15275829
resist@@	O	-1	15275829
ant	O	-1	15275829
to	O	-1	15275829
nicotine	B-Chemical	D009538	15275829
-induced	O	-1	15275829
seizures	B-Disease	D012640	15275829
when	O	-1	15275829
compared	O	-1	15275829
to	O	-1	15275829
wil@@	O	-1	15275829
d-@@	O	-1	15275829
type	O	-1	15275829
lit@@	O	-1	15275829
ter@@	O	-1	15275829
mat@@	O	-1	15275829
es.	O	-1	15275829
mRNA	O	-1	15275829
levels	O	-1	15275829
for	O	-1	15275829
the	O	-1	15275829
alpha@@	O	-1	15275829
5	O	-1	15275829
and	O	-1	15275829
the	O	-1	15275829
beta@@	O	-1	15275829
4	O	-1	15275829
sub@@	O	-1	15275829
un@@	O	-1	15275829
its	O	-1	15275829
were	O	-1	15275829
un@@	O	-1	15275829
chang@@	O	-1	15275829
ed	O	-1	15275829
in	O	-1	15275829
alpha@@	O	-1	15275829
3	O	-1	15275829
+/-	O	-1	15275829
bra@@	O	-1	15275829
in@@	O	-1	15275829
s.	O	-1	15275829
T@@	O	-1	15275829
o@@	O	-1	15275829
ge@@	O	-1	15275829
ther@@	O	-1	15275829
,	O	-1	15275829
these	O	-1	15275829
results	O	-1	15275829
suggest	O	-1	15275829
that	O	-1	15275829
the	O	-1	15275829
beta@@	O	-1	15275829
4	O	-1	15275829
and	O	-1	15275829
the	O	-1	15275829
alpha@@	O	-1	15275829
3	O	-1	15275829
sub@@	O	-1	15275829
un@@	O	-1	15275829
its	O	-1	15275829
are	O	-1	15275829
medi@@	O	-1	15275829
at@@	O	-1	15275829
ors	O	-1	15275829
of	O	-1	15275829
nicotine	B-Chemical	D009538	15275829
-induced	O	-1	15275829
seizures	B-Disease	D012640	15275829
and	O	-1	15275829
hypo@@	B-Disease	D006948	15275829
locom@@	I-Disease	-1	15275829
o@@	I-Disease	-1	15275829
tion	I-Disease	-1	15275829
.	O	-1	15275829

Rec@@	O	-1	15602202
ur@@	O	-1	15602202
rent	O	-1	15602202
acute	O	-1	15602202
interstitial	B-Disease	D009395	15602202
neph@@	I-Disease	-1	15602202
ritis	I-Disease	-1	15602202
induced	O	-1	15602202
by	O	-1	15602202
az@@	B-Chemical	D017963	15602202
i@@	I-Chemical	-1	15602202
throm@@	I-Chemical	-1	15602202
ycin	I-Chemical	-1	15602202
.	O	-1	15602202
A	O	-1	15602202
1@@	O	-1	15602202
4-@@	O	-1	15602202
year-old	O	-1	15602202
gi@@	O	-1	15602202
r@@	O	-1	15602202
l	O	-1	15602202
is	O	-1	15602202
reported	O	-1	15602202
with	O	-1	15602202
recur@@	O	-1	15602202
ren@@	O	-1	15602202
t,	O	-1	15602202
az@@	B-Chemical	D017963	15602202
i@@	I-Chemical	-1	15602202
throm@@	I-Chemical	-1	15602202
ycin	I-Chemical	-1	15602202
-@@	O	-1	15602202
induc@@	O	-1	15602202
ed,	O	-1	15602202
acute	O	-1	15602202
interstitial	B-Disease	D009395	15602202
neph@@	I-Disease	-1	15602202
ritis	I-Disease	-1	15602202
.	O	-1	15602202
The	O	-1	15602202
second	O	-1	15602202
episo@@	O	-1	15602202
de	O	-1	15602202
was	O	-1	15602202
more	O	-1	15602202
severe	O	-1	15602202
than	O	-1	15602202
the	O	-1	15602202
fir@@	O	-1	15602202
st@@	O	-1	15602202
;	O	-1	15602202
and	O	-1	15602202
although	O	-1	15602202
both	O	-1	15602202
were	O	-1	15602202
treated	O	-1	15602202
with	O	-1	15602202
int@@	O	-1	15602202
en@@	O	-1	15602202
sive	O	-1	15602202
cortico@@	O	-1	15602202
ster@@	O	-1	15602202
oid	O	-1	15602202
therapy,	O	-1	15602202
renal	O	-1	15602202
function	O	-1	15602202
remained	O	-1	15602202
impa@@	O	-1	15602202
i@@	O	-1	15602202
red.	O	-1	15602202
Although	O	-1	15602202
most	O	-1	15602202
cases	O	-1	15602202
of	O	-1	15602202
anti@@	O	-1	15602202
bio@@	O	-1	15602202
tic	O	-1	15602202
induced	O	-1	15602202
acute	O	-1	15602202
interstitial	B-Disease	D009395	15602202
neph@@	I-Disease	-1	15602202
ritis	I-Disease	-1	15602202
are	O	-1	15602202
ben@@	O	-1	15602202
ig@@	O	-1	15602202
n	O	-1	15602202
and	O	-1	15602202
sel@@	O	-1	15602202
f@@	O	-1	15602202
-@@	O	-1	15602202
lim@@	O	-1	15602202
it@@	O	-1	15602202
ed,	O	-1	15602202
some	O	-1	15602202
patients	O	-1	15602202
are	O	-1	15602202
at	O	-1	15602202
risk	O	-1	15602202
for	O	-1	15602202
per@@	O	-1	15602202
man@@	O	-1	15602202
ent	O	-1	15602202
renal	B-Disease	D007674	15602202
injury	I-Disease	-1	15602202
.	O	-1	15602202

V@@	B-Chemical	D014635	16181582
al@@	I-Chemical	-1	16181582
pro@@	I-Chemical	-1	16181582
ate	I-Chemical	-1	16181582
-induced	O	-1	16181582
encephalo@@	B-Disease	D001927	16181582
pathy	I-Disease	-1	16181582
.	O	-1	16181582
V@@	B-Chemical	D014635	16181582
al@@	I-Chemical	-1	16181582
pro@@	I-Chemical	-1	16181582
ate	I-Chemical	-1	16181582
-induced	O	-1	16181582
encephalo@@	B-Disease	D001927	16181582
pathy	I-Disease	-1	16181582
is	O	-1	16181582
a	O	-1	16181582
r@@	O	-1	16181582
are	O	-1	16181582
syndrome	O	-1	16181582
that	O	-1	16181582
may	O	-1	16181582
man@@	O	-1	16181582
if@@	O	-1	16181582
est	O	-1	16181582
in	O	-1	16181582
o@@	O	-1	16181582
ther@@	O	-1	16181582
w@@	O	-1	16181582
is@@	O	-1	16181582
e	O	-1	16181582
normal	O	-1	16181582
epileptic	B-Disease	D004827	16181582
individ@@	O	-1	16181582
u@@	O	-1	16181582
al@@	O	-1	16181582
s.	O	-1	16181582
It	O	-1	16181582
may	O	-1	16181582
even	O	-1	16181582
present	O	-1	16181582
in	O	-1	16181582
patients	O	-1	16181582
who	O	-1	16181582
have	O	-1	16181582
toler@@	O	-1	16181582
ated	O	-1	16181582
this	O	-1	16181582
medic@@	O	-1	16181582
ine	O	-1	16181582
well	O	-1	16181582
in	O	-1	16181582
the	O	-1	16181582
pa@@	O	-1	16181582
st@@	O	-1	16181582
.	O	-1	16181582
It	O	-1	16181582
is	O	-1	16181582
us@@	O	-1	16181582
ually	O	-1	16181582
but	O	-1	16181582
not	O	-1	16181582
nec@@	O	-1	16181582
ess@@	O	-1	16181582
ari@@	O	-1	16181582
ly	O	-1	16181582
associated	O	-1	16181582
with	O	-1	16181582
hyper@@	B-Disease	D022124	16181582
am@@	I-Disease	-1	16181582
mon@@	I-Disease	-1	16181582
emia	I-Disease	-1	16181582
.	O	-1	16181582
The	O	-1	16181582
E@@	O	-1	16181582
E@@	O	-1	16181582
G	O	-1	16181582
show@@	O	-1	16181582
s	O	-1	16181582
character@@	O	-1	16181582
istic	O	-1	16181582
tri@@	O	-1	16181582
pha@@	O	-1	16181582
sic	O	-1	16181582
w@@	O	-1	16181582
av@@	O	-1	16181582
es	O	-1	16181582
in	O	-1	16181582
most	O	-1	16181582
patients	O	-1	16181582
with	O	-1	16181582
this	O	-1	16181582
complic@@	O	-1	16181582
ation.	O	-1	16181582
A	O	-1	16181582
case	O	-1	16181582
of	O	-1	16181582
valpro@@	B-Chemical	D014635	16181582
ate	I-Chemical	-1	16181582
-induced	O	-1	16181582
encephalo@@	B-Disease	D001927	16181582
pathy	I-Disease	-1	16181582
is	O	-1	16181582
present@@	O	-1	16181582
ed.	O	-1	16181582
The	O	-1	16181582
pro@@	O	-1	16181582
ble@@	O	-1	16181582
ms	O	-1	16181582
in	O	-1	16181582
diagnos@@	O	-1	16181582
ing	O	-1	16181582
this	O	-1	16181582
condi@@	O	-1	16181582
tion	O	-1	16181582
are	O	-1	16181582
subsequ@@	O	-1	16181582
ently	O	-1	16181582
discus@@	O	-1	16181582
sed.	O	-1	16181582

N@@	B-Chemical	D019331	16298782
it@@	I-Chemical	-1	16298782
ro@@	I-Chemical	-1	16298782
-@@	I-Chemical	-1	16298782
L-@@	I-Chemical	-1	16298782
arg@@	I-Chemical	-1	16298782
inine	I-Chemical	-1	16298782
meth@@	I-Chemical	-1	16298782
yl	I-Chemical	-1	16298782
est@@	I-Chemical	-1	16298782
er	I-Chemical	-1	16298782
:	O	-1	16298782
a	O	-1	16298782
potential	O	-1	16298782
prot@@	O	-1	16298782
ect@@	O	-1	16298782
or	O	-1	16298782
against	O	-1	16298782
g@@	B-Chemical	D005839	16298782
ent@@	I-Chemical	-1	16298782
am@@	I-Chemical	-1	16298782
icin	I-Chemical	-1	16298782
ot@@	B-Disease	D006311	16298782
otoxicity	I-Disease	-1	16298782
.	O	-1	16298782
The	O	-1	16298782
nit@@	B-Chemical	D009569	16298782
ric	I-Chemical	-1	16298782
ox@@	I-Chemical	-1	16298782
ide	I-Chemical	-1	16298782
(	O	-1	16298782
N@@	B-Chemical	D009569	16298782
O	I-Chemical	-1	16298782
)	O	-1	16298782
inhibitor	O	-1	16298782
nitro@@	B-Chemical	D019331	16298782
-@@	I-Chemical	-1	16298782
L-@@	I-Chemical	-1	16298782
arg@@	I-Chemical	-1	16298782
inine	I-Chemical	-1	16298782
meth@@	I-Chemical	-1	16298782
yl	I-Chemical	-1	16298782
est@@	I-Chemical	-1	16298782
er	I-Chemical	-1	16298782
(	O	-1	16298782
L-@@	B-Chemical	D019331	16298782
N@@	I-Chemical	-1	16298782
AM@@	I-Chemical	-1	16298782
E	I-Chemical	-1	16298782
)	O	-1	16298782
may	O	-1	16298782
ac@@	O	-1	16298782
t	O	-1	16298782
as	O	-1	16298782
an	O	-1	16298782
ot@@	O	-1	16298782
o@@	O	-1	16298782
prot@@	O	-1	16298782
ect@@	O	-1	16298782
ant	O	-1	16298782
against	O	-1	16298782
high-@@	B-Disease	D006316	16298782
frequency	I-Disease	-1	16298782
hearing	I-Disease	-1	16298782
loss	I-Disease	-1	16298782
caused	O	-1	16298782
by	O	-1	16298782
g@@	B-Chemical	D005839	16298782
ent@@	I-Chemical	-1	16298782
am@@	I-Chemical	-1	16298782
icin	I-Chemical	-1	16298782
,	O	-1	16298782
but	O	-1	16298782
further	O	-1	16298782
studies	O	-1	16298782
are	O	-1	16298782
ne@@	O	-1	16298782
ed@@	O	-1	16298782
ed	O	-1	16298782
to	O	-1	16298782
con@@	O	-1	16298782
fir@@	O	-1	16298782
m	O	-1	16298782
thi@@	O	-1	16298782
s.	O	-1	16298782
A@@	B-Chemical	D000617	16298782
min@@	I-Chemical	-1	16298782
o@@	I-Chemical	-1	16298782
gly@@	I-Chemical	-1	16298782
co@@	I-Chemical	-1	16298782
side	I-Chemical	-1	16298782
anti@@	O	-1	16298782
bio@@	O	-1	16298782
tics	O	-1	16298782
are	O	-1	16298782
sti@@	O	-1	16298782
ll	O	-1	16298782
wi@@	O	-1	16298782
de@@	O	-1	16298782
ly	O	-1	16298782
used	O	-1	16298782
by	O	-1	16298782
vi@@	O	-1	16298782
r@@	O	-1	16298782
tu@@	O	-1	16298782
e	O	-1	16298782
of	O	-1	16298782
their	O	-1	16298782
efficacy	O	-1	16298782
and	O	-1	16298782
low	O	-1	16298782
co@@	O	-1	16298782
st@@	O	-1	16298782
.	O	-1	16298782
The@@	O	-1	16298782
ir	O	-1	16298782
ot@@	B-Disease	D006311	16298782
otoxicity	I-Disease	-1	16298782
is	O	-1	16298782
a	O	-1	16298782
seri@@	O	-1	16298782
ous	O	-1	16298782
heal@@	O	-1	16298782
th	O	-1	16298782
pro@@	O	-1	16298782
ble@@	O	-1	16298782
m	O	-1	16298782
and@@	O	-1	16298782
,	O	-1	16298782
as	O	-1	16298782
their	O	-1	16298782
ot@@	B-Disease	D006311	16298782
ot@@	I-Disease	-1	16298782
ox@@	I-Disease	-1	16298782
ic	I-Disease	-1	16298782
mechanism	O	-1	16298782
invol@@	O	-1	16298782
v@@	O	-1	16298782
es	O	-1	16298782
the	O	-1	16298782
pro@@	O	-1	16298782
duction	O	-1	16298782
of	O	-1	16298782
N@@	B-Chemical	D009569	16298782
O	I-Chemical	-1	16298782
,	O	-1	16298782
we	O	-1	16298782
need	O	-1	16298782
to	O	-1	16298782
ass@@	O	-1	16298782
ess	O	-1	16298782
the	O	-1	16298782
use	O	-1	16298782
of	O	-1	16298782
N@@	B-Chemical	D009569	16298782
O	I-Chemical	-1	16298782
inhibitors	O	-1	16298782
for	O	-1	16298782
the	O	-1	16298782
pre@@	O	-1	16298782
ven@@	O	-1	16298782
tion	O	-1	16298782
of	O	-1	16298782
amino@@	B-Chemical	D000617	16298782
gly@@	I-Chemical	-1	16298782
co@@	I-Chemical	-1	16298782
side	I-Chemical	-1	16298782
-induced	O	-1	16298782
sens@@	B-Disease	D006319	16298782
or@@	I-Disease	-1	16298782
ine@@	I-Disease	-1	16298782
ural	I-Disease	-1	16298782
hearing	I-Disease	-1	16298782
loss	I-Disease	-1	16298782
.	O	-1	16298782
In	O	-1	16298782
this	O	-1	16298782
experimental	O	-1	16298782
study	O	-1	16298782
we	O	-1	16298782
used	O	-1	16298782
30	O	-1	16298782
S@@	O	-1	16298782
pra@@	O	-1	16298782
gu@@	O	-1	16298782
e-@@	O	-1	16298782
D@@	O	-1	16298782
aw@@	O	-1	16298782
le@@	O	-1	16298782
y	O	-1	16298782
rats,	O	-1	16298782
2@@	O	-1	16298782
7	O	-1	16298782
of	O	-1	16298782
which	O	-1	16298782
had	O	-1	16298782
g@@	B-Chemical	D005839	16298782
ent@@	I-Chemical	-1	16298782
am@@	I-Chemical	-1	16298782
icin	I-Chemical	-1	16298782
insti@@	O	-1	16298782
lled	O	-1	16298782
into	O	-1	16298782
the	O	-1	16298782
mid@@	O	-1	16298782
d@@	O	-1	16298782
le	O	-1	16298782
ear@@	O	-1	16298782
.	O	-1	16298782
The	O	-1	16298782
ot@@	O	-1	16298782
o@@	O	-1	16298782
prot@@	O	-1	16298782
ect@@	O	-1	16298782
ant	O	-1	16298782
L-@@	B-Chemical	D019331	16298782
N@@	I-Chemical	-1	16298782
AM@@	I-Chemical	-1	16298782
E	I-Chemical	-1	16298782
was	O	-1	16298782
administered	O	-1	16298782
to@@	O	-1	16298782
p@@	O	-1	16298782
ically	O	-1	16298782
to	O	-1	16298782
12@@	O	-1	16298782
/@@	O	-1	16298782
2@@	O	-1	16298782
7	O	-1	16298782
anim@@	O	-1	16298782
al@@	O	-1	16298782
s.	O	-1	16298782
I@@	O	-1	16298782
ts	O	-1	16298782
effect	O	-1	16298782
was	O	-1	16298782
determined	O	-1	16298782
in	O	-1	16298782
ter@@	O	-1	16298782
ms	O	-1	16298782
of	O	-1	16298782
attenu@@	O	-1	16298782
ation	O	-1	16298782
of	O	-1	16298782
hearing	B-Disease	D034381	16298782
loss	I-Disease	-1	16298782
,	O	-1	16298782
measured	O	-1	16298782
by	O	-1	16298782
shi@@	O	-1	16298782
f@@	O	-1	16298782
ts	O	-1	16298782
in	O	-1	16298782
the	O	-1	16298782
a@@	O	-1	16298782
ud@@	O	-1	16298782
it@@	O	-1	16298782
ory	O	-1	16298782
bra@@	O	-1	16298782
in@@	O	-1	16298782
st@@	O	-1	16298782
em	O	-1	16298782
response	O	-1	16298782
th@@	O	-1	16298782
res@@	O	-1	16298782
h@@	O	-1	16298782
ol@@	O	-1	16298782
d.	O	-1	16298782
L-@@	B-Chemical	D019331	16298782
N@@	I-Chemical	-1	16298782
AM@@	I-Chemical	-1	16298782
E	I-Chemical	-1	16298782
reduced	O	-1	16298782
g@@	B-Chemical	D005839	16298782
ent@@	I-Chemical	-1	16298782
am@@	I-Chemical	-1	16298782
icin	I-Chemical	-1	16298782
-induced	O	-1	16298782
hearing	B-Disease	D034381	16298782
loss	I-Disease	-1	16298782
in	O	-1	16298782
the	O	-1	16298782
high-@@	O	-1	16298782
frequency	O	-1	16298782
rang@@	O	-1	16298782
e,	O	-1	16298782
but	O	-1	16298782
g@@	O	-1	16298782
a@@	O	-1	16298782
ve	O	-1	16298782
no	O	-1	16298782
prot@@	O	-1	16298782
ection	O	-1	16298782
in	O	-1	16298782
the	O	-1	16298782
mid@@	O	-1	16298782
d@@	O	-1	16298782
le	O	-1	16298782
or	O	-1	16298782
low	O	-1	16298782
frequ@@	O	-1	16298782
en@@	O	-1	16298782
ci@@	O	-1	16298782
es.	O	-1	16298782

C@@	B-Disease	D020293	16428221
e@@	I-Disease	-1	16428221
rebral	I-Disease	-1	16428221
vas@@	I-Disease	-1	16428221
cul@@	I-Disease	-1	16428221
iti@@	I-Disease	-1	16428221
s	I-Disease	-1	16428221
following	O	-1	16428221
oral	O	-1	16428221
methyl@@	B-Chemical	D008774	16428221
phen@@	I-Chemical	-1	16428221
id@@	I-Chemical	-1	16428221
ate	I-Chemical	-1	16428221
int@@	O	-1	16428221
ake	O	-1	16428221
in	O	-1	16428221
an	O	-1	16428221
ad@@	O	-1	16428221
ult@@	O	-1	16428221
:	O	-1	16428221
a	O	-1	16428221
case	O	-1	16428221
repor@@	O	-1	16428221
t.	O	-1	16428221
M@@	B-Chemical	D008774	16428221
eth@@	I-Chemical	-1	16428221
yl@@	I-Chemical	-1	16428221
phen@@	I-Chemical	-1	16428221
id@@	I-Chemical	-1	16428221
ate	I-Chemical	-1	16428221
is	O	-1	16428221
struct@@	O	-1	16428221
ur@@	O	-1	16428221
ally	O	-1	16428221
and	O	-1	16428221
func@@	O	-1	16428221
tion@@	O	-1	16428221
ally	O	-1	16428221
similar	O	-1	16428221
to	O	-1	16428221
amphetamine	B-Chemical	D000661	16428221
.	O	-1	16428221
C@@	B-Disease	D020293	16428221
e@@	I-Disease	-1	16428221
rebral	I-Disease	-1	16428221
vas@@	I-Disease	-1	16428221
cul@@	I-Disease	-1	16428221
iti@@	I-Disease	-1	16428221
s	I-Disease	-1	16428221
associated	O	-1	16428221
with	O	-1	16428221
amphetamine	B-Disease	D019969	16428221
ab@@	I-Disease	-1	16428221
use	I-Disease	-1	16428221
is	O	-1	16428221
well	O	-1	16428221
doc@@	O	-1	16428221
um@@	O	-1	16428221
ent@@	O	-1	16428221
ed,	O	-1	16428221
and	O	-1	16428221
in	O	-1	16428221
r@@	O	-1	16428221
are	O	-1	16428221
cases	O	-1	16428221
is@@	B-Disease	D002544	16428221
ch@@	I-Disease	-1	16428221
a@@	I-Disease	-1	16428221
em@@	I-Disease	-1	16428221
ic	I-Disease	-1	16428221
strok@@	I-Disease	-1	16428221
e	I-Disease	-1	16428221
has	O	-1	16428221
been	O	-1	16428221
reported	O	-1	16428221
after	O	-1	16428221
methyl@@	B-Chemical	D008774	16428221
phen@@	I-Chemical	-1	16428221
id@@	I-Chemical	-1	16428221
ate	I-Chemical	-1	16428221
int@@	O	-1	16428221
ake	O	-1	16428221
in	O	-1	16428221
child@@	O	-1	16428221
ren@@	O	-1	16428221
.	O	-1	16428221
We	O	-1	16428221
report	O	-1	16428221
the	O	-1	16428221
case	O	-1	16428221
of	O	-1	16428221
a	O	-1	16428221
6@@	O	-1	16428221
3-@@	O	-1	16428221
year-old	O	-1	16428221
female	O	-1	16428221
who	O	-1	16428221
was	O	-1	16428221
treated	O	-1	16428221
with	O	-1	16428221
methyl@@	B-Chemical	D008774	16428221
phen@@	I-Chemical	-1	16428221
id@@	I-Chemical	-1	16428221
ate	I-Chemical	-1	16428221
due	O	-1	16428221
to	O	-1	16428221
hyperactivity	B-Disease	D006948	16428221
and	O	-1	16428221
su@@	O	-1	16428221
ffe@@	O	-1	16428221
red	O	-1	16428221
from	O	-1	16428221
multiple	O	-1	16428221
is@@	B-Disease	D002544	16428221
ch@@	I-Disease	-1	16428221
a@@	I-Disease	-1	16428221
em@@	I-Disease	-1	16428221
ic	I-Disease	-1	16428221
strok@@	I-Disease	-1	16428221
es	I-Disease	-1	16428221
.	O	-1	16428221
We	O	-1	16428221
con@@	O	-1	16428221
si@@	O	-1	16428221
der	O	-1	16428221
drug@@	O	-1	16428221
-induced	O	-1	16428221
cerebral	B-Disease	D020293	16428221
vas@@	I-Disease	-1	16428221
cul@@	I-Disease	-1	16428221
iti@@	I-Disease	-1	16428221
s	I-Disease	-1	16428221
as	O	-1	16428221
the	O	-1	16428221
most	O	-1	16428221
likely	O	-1	16428221
cause	O	-1	16428221
of	O	-1	16428221
recur@@	O	-1	16428221
rent	O	-1	16428221
is@@	B-Disease	D002544	16428221
ch@@	I-Disease	-1	16428221
a@@	I-Disease	-1	16428221
em@@	I-Disease	-1	16428221
ic	I-Disease	-1	16428221
strok@@	I-Disease	-1	16428221
es	I-Disease	-1	16428221
in	O	-1	16428221
the	O	-1	16428221
absence	O	-1	16428221
of	O	-1	16428221
any	O	-1	16428221
path@@	O	-1	16428221
ological	O	-1	16428221
findings	O	-1	16428221
during	O	-1	16428221
the	O	-1	16428221
diagnos@@	O	-1	16428221
tic	O	-1	16428221
wor@@	O	-1	16428221
k@@	O	-1	16428221
-@@	O	-1	16428221
up@@	O	-1	16428221
.	O	-1	16428221
We	O	-1	16428221
concl@@	O	-1	16428221
ude	O	-1	16428221
that	O	-1	16428221
methyl@@	B-Chemical	D008774	16428221
phen@@	I-Chemical	-1	16428221
id@@	I-Chemical	-1	16428221
ate	I-Chemical	-1	16428221
mediated	O	-1	16428221
vas@@	B-Disease	D014657	16428221
cul@@	I-Disease	-1	16428221
iti@@	I-Disease	-1	16428221
s	I-Disease	-1	16428221
should	O	-1	16428221
be	O	-1	16428221
considered	O	-1	16428221
in	O	-1	16428221
patients	O	-1	16428221
with	O	-1	16428221
neurolog@@	O	-1	16428221
ical	O	-1	16428221
symptoms	O	-1	16428221
and	O	-1	16428221
a	O	-1	16428221
hist@@	O	-1	16428221
ory	O	-1	16428221
of	O	-1	16428221
methyl@@	B-Chemical	D008774	16428221
phen@@	I-Chemical	-1	16428221
id@@	I-Chemical	-1	16428221
ate	I-Chemical	-1	16428221
therapy.	O	-1	16428221
This	O	-1	16428221
potential	O	-1	16428221
side@@	O	-1	16428221
-@@	O	-1	16428221
effect@@	O	-1	16428221
,	O	-1	16428221
though	O	-1	16428221
very	O	-1	16428221
ra@@	O	-1	16428221
re,	O	-1	16428221
re@@	O	-1	16428221
pres@@	O	-1	16428221
ents	O	-1	16428221
one	O	-1	16428221
more	O	-1	16428221
reas@@	O	-1	16428221
on	O	-1	16428221
to	O	-1	16428221
be	O	-1	16428221
very	O	-1	16428221
re@@	O	-1	16428221
stric@@	O	-1	16428221
tive	O	-1	16428221
in	O	-1	16428221
the	O	-1	16428221
use	O	-1	16428221
of	O	-1	16428221
methyl@@	B-Chemical	D008774	16428221
phen@@	I-Chemical	-1	16428221
id@@	I-Chemical	-1	16428221
ate	I-Chemical	-1	16428221
.	O	-1	16428221

C@@	B-Disease	D002543	16858720
e@@	I-Disease	-1	16858720
rebral	I-Disease	-1	16858720
haem@@	I-Disease	-1	16858720
or@@	I-Disease	-1	16858720
rh@@	I-Disease	-1	16858720
age	I-Disease	-1	16858720
induced	O	-1	16858720
by	O	-1	16858720
war@@	B-Chemical	D014859	16858720
farin	I-Chemical	-1	16858720
-	O	-1	16858720
the	O	-1	16858720
influence	O	-1	16858720
of	O	-1	16858720
drug@@	O	-1	16858720
-@@	O	-1	16858720
drug	O	-1	16858720
inter@@	O	-1	16858720
ac@@	O	-1	16858720
tions.	O	-1	16858720
P@@	O	-1	16858720
U@@	O	-1	16858720
R@@	O	-1	16858720
P@@	O	-1	16858720
O@@	O	-1	16858720
S@@	O	-1	16858720
E:	O	-1	16858720
To	O	-1	16858720
evalu@@	O	-1	16858720
ate	O	-1	16858720
the	O	-1	16858720
frequ@@	O	-1	16858720
enc@@	O	-1	16858720
y,	O	-1	16858720
severity	O	-1	16858720
and	O	-1	16858720
prevent@@	O	-1	16858720
ability	O	-1	16858720
of	O	-1	16858720
war@@	B-Chemical	D014859	16858720
farin	I-Chemical	-1	16858720
-induced	O	-1	16858720
cerebral	B-Disease	D002543	16858720
haem@@	I-Disease	-1	16858720
or@@	I-Disease	-1	16858720
rh@@	I-Disease	-1	16858720
ages	I-Disease	-1	16858720
due	O	-1	16858720
to	O	-1	16858720
war@@	B-Chemical	D014859	16858720
farin	I-Chemical	-1	16858720
and	O	-1	16858720
war@@	B-Chemical	D014859	16858720
farin	I-Chemical	-1	16858720
-@@	O	-1	16858720
drug	O	-1	16858720
inter@@	O	-1	16858720
ac@@	O	-1	16858720
tions	O	-1	16858720
in	O	-1	16858720
patients	O	-1	16858720
li@@	O	-1	16858720
ving	O	-1	16858720
in	O	-1	16858720
the	O	-1	16858720
coun@@	O	-1	16858720
t@@	O	-1	16858720
y	O	-1	16858720
of	O	-1	16858720
O@@	O	-1	16858720
ster@@	O	-1	16858720
g	O	-1	16858720
t@@	O	-1	16858720
l@@	O	-1	16858720
and@@	O	-1	16858720
,	O	-1	16858720
S@@	O	-1	16858720
we@@	O	-1	16858720
d@@	O	-1	16858720
en@@	O	-1	16858720
.	O	-1	16858720
METHODS:	O	-1	16858720
All	O	-1	16858720
patients	O	-1	16858720
with	O	-1	16858720
a	O	-1	16858720
diagnos@@	O	-1	16858720
ed	O	-1	16858720
cerebral	B-Disease	D002543	16858720
haem@@	I-Disease	-1	16858720
or@@	I-Disease	-1	16858720
rh@@	I-Disease	-1	16858720
age	I-Disease	-1	16858720
at	O	-1	16858720
three	O	-1	16858720
hospit@@	O	-1	16858720
als	O	-1	16858720
during	O	-1	16858720
the	O	-1	16858720
period	O	-1	16858720
20@@	O	-1	16858720
0@@	O	-1	16858720
0-@@	O	-1	16858720
20@@	O	-1	16858720
0@@	O	-1	16858720
2	O	-1	16858720
were	O	-1	16858720
identi@@	O	-1	16858720
fi@@	O	-1	16858720
ed.	O	-1	16858720
M@@	O	-1	16858720
ed@@	O	-1	16858720
ical	O	-1	16858720
recor@@	O	-1	16858720
ds	O	-1	16858720
were	O	-1	16858720
studied	O	-1	16858720
ret@@	O	-1	16858720
ro@@	O	-1	16858720
sp@@	O	-1	16858720
ectively	O	-1	16858720
to	O	-1	16858720
evalu@@	O	-1	16858720
ate	O	-1	16858720
whether	O	-1	16858720
war@@	B-Chemical	D014859	16858720
farin	I-Chemical	-1	16858720
and	O	-1	16858720
war@@	B-Chemical	D014859	16858720
farin	I-Chemical	-1	16858720
-@@	O	-1	16858720
drug	O	-1	16858720
inter@@	O	-1	16858720
ac@@	O	-1	16858720
tions	O	-1	16858720
could	O	-1	16858720
have	O	-1	16858720
caused	O	-1	16858720
the	O	-1	16858720
cerebral	B-Disease	D002543	16858720
haem@@	I-Disease	-1	16858720
or@@	I-Disease	-1	16858720
rh@@	I-Disease	-1	16858720
age	I-Disease	-1	16858720
.	O	-1	16858720
The	O	-1	16858720
pro@@	O	-1	16858720
por@@	O	-1	16858720
tion	O	-1	16858720
of	O	-1	16858720
possib@@	O	-1	16858720
ly	O	-1	16858720
avoid@@	O	-1	16858720
able	O	-1	16858720
cases	O	-1	16858720
due	O	-1	16858720
to	O	-1	16858720
drug	O	-1	16858720
inter@@	O	-1	16858720
ac@@	O	-1	16858720
tions	O	-1	16858720
was	O	-1	16858720
estim@@	O	-1	16858720
ated.	O	-1	16858720
RESULTS:	O	-1	16858720
A@@	O	-1	16858720
mon@@	O	-1	16858720
g	O	-1	16858720
5@@	O	-1	16858720
9@@	O	-1	16858720
3	O	-1	16858720
patients	O	-1	16858720
with	O	-1	16858720
cerebral	B-Disease	D002543	16858720
haem@@	I-Disease	-1	16858720
or@@	I-Disease	-1	16858720
rh@@	I-Disease	-1	16858720
age	I-Disease	-1	16858720
,	O	-1	16858720
5@@	O	-1	16858720
9	O	-1	16858720
(@@	O	-1	16858720
10@@	O	-1	16858720
%)	O	-1	16858720
were	O	-1	16858720
assessed	O	-1	16858720
as	O	-1	16858720
related	O	-1	16858720
to	O	-1	16858720
war@@	B-Chemical	D014859	16858720
farin	I-Chemical	-1	16858720
treatment.	O	-1	16858720
This	O	-1	16858720
im@@	O	-1	16858720
p@@	O	-1	16858720
ly	O	-1	16858720
an	O	-1	16858720
incidence	O	-1	16858720
of	O	-1	16858720
1.@@	O	-1	16858720
7@@	O	-1	16858720
/@@	O	-1	16858720
10@@	O	-1	16858720
0@@	O	-1	16858720
,@@	O	-1	16858720
0@@	O	-1	16858720
00	O	-1	16858720
treatment	O	-1	16858720
year@@	O	-1	16858720
s.	O	-1	16858720
Of	O	-1	16858720
the	O	-1	16858720
5@@	O	-1	16858720
9	O	-1	16858720
cas@@	O	-1	16858720
es,	O	-1	16858720
2@@	O	-1	16858720
6	O	-1	16858720
(4@@	O	-1	16858720
4@@	O	-1	16858720
%)	O	-1	16858720
had	O	-1	16858720
a	O	-1	16858720
f@@	O	-1	16858720
atal	O	-1	16858720
out@@	O	-1	16858720
co@@	O	-1	16858720
me,	O	-1	16858720
compared	O	-1	16858720
to	O	-1	16858720
13@@	O	-1	16858720
6	O	-1	16858720
(2@@	O	-1	16858720
5@@	O	-1	16858720
%)	O	-1	16858720
among	O	-1	16858720
the	O	-1	16858720
non@@	O	-1	16858720
-	O	-1	16858720
war@@	B-Chemical	D014859	16858720
farin	I-Chemical	-1	16858720
patients	O	-1	16858720
(p	O	-1	16858720
<	O	-1	16858720
0.0@@	O	-1	16858720
1).	O	-1	16858720
A	O	-1	16858720
war@@	B-Chemical	D014859	16858720
farin	I-Chemical	-1	16858720
-@@	O	-1	16858720
drug	O	-1	16858720
inter@@	O	-1	16858720
action	O	-1	16858720
could	O	-1	16858720
have	O	-1	16858720
cont@@	O	-1	16858720
ri@@	O	-1	16858720
but@@	O	-1	16858720
ed	O	-1	16858720
to	O	-1	16858720
the	O	-1	16858720
haem@@	B-Disease	D006470	16858720
or@@	I-Disease	-1	16858720
rh@@	I-Disease	-1	16858720
age	I-Disease	-1	16858720
in	O	-1	16858720
24	O	-1	16858720
(4@@	O	-1	16858720
1@@	O	-1	16858720
%)	O	-1	16858720
of	O	-1	16858720
the	O	-1	16858720
war@@	B-Chemical	D014859	16858720
farin	I-Chemical	-1	16858720
patients	O	-1	16858720
and	O	-1	16858720
in	O	-1	16858720
7	O	-1	16858720
of	O	-1	16858720
these	O	-1	16858720
(1@@	O	-1	16858720
2@@	O	-1	16858720
%)	O	-1	16858720
the	O	-1	16858720
ble@@	B-Disease	D006470	16858720
ed@@	I-Disease	-1	16858720
ing	I-Disease	-1	16858720
complication	O	-1	16858720
was	O	-1	16858720
considered	O	-1	16858720
being	O	-1	16858720
possible	O	-1	16858720
to	O	-1	16858720
avoid@@	O	-1	16858720
.	O	-1	16858720
CONCLUSIONS:	O	-1	16858720
W@@	B-Chemical	D014859	16858720
ar@@	I-Chemical	-1	16858720
farin	I-Chemical	-1	16858720
-induced	O	-1	16858720
cerebral	B-Disease	D002543	16858720
haem@@	I-Disease	-1	16858720
or@@	I-Disease	-1	16858720
rh@@	I-Disease	-1	16858720
ages	I-Disease	-1	16858720
are	O	-1	16858720
a	O	-1	16858720
major	O	-1	16858720
clinical	O	-1	16858720
pro@@	O	-1	16858720
ble@@	O	-1	16858720
m	O	-1	16858720
with	O	-1	16858720
a	O	-1	16858720
high	O	-1	16858720
f@@	O	-1	16858720
at@@	O	-1	16858720
ality	O	-1	16858720
rat@@	O	-1	16858720
e.	O	-1	16858720
Al@@	O	-1	16858720
most	O	-1	16858720
h@@	O	-1	16858720
al@@	O	-1	16858720
f	O	-1	16858720
of	O	-1	16858720
the	O	-1	16858720
cases	O	-1	16858720
was	O	-1	16858720
related	O	-1	16858720
to	O	-1	16858720
a	O	-1	16858720
war@@	B-Chemical	D014859	16858720
farin	I-Chemical	-1	16858720
-@@	O	-1	16858720
drug	O	-1	16858720
inter@@	O	-1	16858720
ac@@	O	-1	16858720
tion.	O	-1	16858720
A	O	-1	16858720
significant	O	-1	16858720
pro@@	O	-1	16858720
por@@	O	-1	16858720
tion	O	-1	16858720
of	O	-1	16858720
war@@	B-Chemical	D014859	16858720
farin	I-Chemical	-1	16858720
-@@	O	-1	16858720
related	O	-1	16858720
cerebral	B-Disease	D002543	16858720
haem@@	I-Disease	-1	16858720
or@@	I-Disease	-1	16858720
rh@@	I-Disease	-1	16858720
ages	I-Disease	-1	16858720
might	O	-1	16858720
have	O	-1	16858720
been	O	-1	16858720
prevent@@	O	-1	16858720
ed	O	-1	16858720
if	O	-1	16858720
greater	O	-1	16858720
cau@@	O	-1	16858720
tion	O	-1	16858720
had	O	-1	16858720
been	O	-1	16858720
tak@@	O	-1	16858720
en	O	-1	16858720
when	O	-1	16858720
prescri@@	O	-1	16858720
b@@	O	-1	16858720
ing	O	-1	16858720
drugs	O	-1	16858720
known	O	-1	16858720
to	O	-1	16858720
inter@@	O	-1	16858720
ac@@	O	-1	16858720
t	O	-1	16858720
with	O	-1	16858720
war@@	B-Chemical	D014859	16858720
farin	I-Chemical	-1	16858720
.	O	-1	16858720

S@@	O	-1	17466854
ide	O	-1	17466854
effects	O	-1	17466854
of	O	-1	17466854
postoperative	O	-1	17466854
administration	O	-1	17466854
of	O	-1	17466854
methyl@@	B-Chemical	D008775	17466854
pre@@	I-Chemical	-1	17466854
d@@	I-Chemical	-1	17466854
n@@	I-Chemical	-1	17466854
isol@@	I-Chemical	-1	17466854
one	I-Chemical	-1	17466854
and	O	-1	17466854
g@@	B-Chemical	D005839	17466854
ent@@	I-Chemical	-1	17466854
am@@	I-Chemical	-1	17466854
icin	I-Chemical	-1	17466854
into	O	-1	17466854
the	O	-1	17466854
po@@	O	-1	17466854
ster@@	O	-1	17466854
ior	O	-1	17466854
sub@@	O	-1	17466854
-@@	O	-1	17466854
T@@	O	-1	17466854
en@@	O	-1	17466854
on@@	O	-1	17466854
's	O	-1	17466854
sp@@	O	-1	17466854
ac@@	O	-1	17466854
e.	O	-1	17466854
P@@	O	-1	17466854
U@@	O	-1	17466854
R@@	O	-1	17466854
P@@	O	-1	17466854
O@@	O	-1	17466854
S@@	O	-1	17466854
E:	O	-1	17466854
To	O	-1	17466854
ass@@	O	-1	17466854
ess	O	-1	17466854
the	O	-1	17466854
incidence	O	-1	17466854
of	O	-1	17466854
postoperative	O	-1	17466854
e@@	O	-1	17466854
me@@	O	-1	17466854
tic	O	-1	17466854
side	O	-1	17466854
effects	O	-1	17466854
after	O	-1	17466854
the	O	-1	17466854
administration	O	-1	17466854
of	O	-1	17466854
methyl@@	B-Chemical	D008775	17466854
pre@@	I-Chemical	-1	17466854
d@@	I-Chemical	-1	17466854
n@@	I-Chemical	-1	17466854
isol@@	I-Chemical	-1	17466854
one	I-Chemical	-1	17466854
and	O	-1	17466854
g@@	B-Chemical	D005839	17466854
ent@@	I-Chemical	-1	17466854
am@@	I-Chemical	-1	17466854
icin	I-Chemical	-1	17466854
into	O	-1	17466854
the	O	-1	17466854
po@@	O	-1	17466854
ster@@	O	-1	17466854
ior	O	-1	17466854
sub@@	O	-1	17466854
-@@	O	-1	17466854
T@@	O	-1	17466854
en@@	O	-1	17466854
on@@	O	-1	17466854
's	O	-1	17466854
sp@@	O	-1	17466854
ac@@	O	-1	17466854
e	O	-1	17466854
at	O	-1	17466854
the	O	-1	17466854
end	O	-1	17466854
of	O	-1	17466854
ro@@	O	-1	17466854
ut@@	O	-1	17466854
ine	O	-1	17466854
cat@@	B-Disease	D002386	17466854
arac@@	I-Disease	-1	17466854
t	I-Disease	-1	17466854
surger@@	O	-1	17466854
y.	O	-1	17466854
S@@	O	-1	17466854
ET@@	O	-1	17466854
TI@@	O	-1	17466854
N@@	O	-1	17466854
G@@	O	-1	17466854
:	O	-1	17466854
S@@	O	-1	17466854
t.	O	-1	17466854
L@@	O	-1	17466854
u@@	O	-1	17466854
ke@@	O	-1	17466854
's	O	-1	17466854
H@@	O	-1	17466854
ospit@@	O	-1	17466854
al,	O	-1	17466854
G@@	O	-1	17466854
war@@	O	-1	17466854
dam@@	O	-1	17466854
ang@@	O	-1	17466854
ia,	O	-1	17466854
M@@	O	-1	17466854
al@@	O	-1	17466854
t@@	O	-1	17466854
a.	O	-1	17466854
METHODS:	O	-1	17466854
A	O	-1	17466854
double-bl@@	O	-1	17466854
ind	O	-1	17466854
double-@@	O	-1	17466854
ar@@	O	-1	17466854
m@@	O	-1	17466854
ed	O	-1	17466854
pro@@	O	-1	17466854
sp@@	O	-1	17466854
ective	O	-1	17466854
study	O	-1	17466854
comp@@	O	-1	17466854
ris@@	O	-1	17466854
ed	O	-1	17466854
40	O	-1	17466854
patients	O	-1	17466854
who	O	-1	17466854
had	O	-1	17466854
un@@	O	-1	17466854
event@@	O	-1	17466854
ful	O	-1	17466854
su@@	O	-1	17466854
t@@	O	-1	17466854
ure@@	O	-1	17466854
less	O	-1	17466854
ph@@	O	-1	17466854
ac@@	O	-1	17466854
o@@	O	-1	17466854
em@@	O	-1	17466854
ul@@	O	-1	17466854
si@@	O	-1	17466854
fic@@	O	-1	17466854
ation	O	-1	17466854
under	O	-1	17466854
sub@@	O	-1	17466854
-@@	O	-1	17466854
T@@	O	-1	17466854
en@@	O	-1	17466854
on@@	O	-1	17466854
's	O	-1	17466854
loc@@	O	-1	17466854
al	O	-1	17466854
inf@@	O	-1	17466854
iltration	O	-1	17466854
of	O	-1	17466854
3	O	-1	17466854
m@@	O	-1	17466854
L	O	-1	17466854
of	O	-1	17466854
pl@@	O	-1	17466854
ain	O	-1	17466854
li@@	B-Chemical	D008012	17466854
gn@@	I-Chemical	-1	17466854
oc@@	I-Chemical	-1	17466854
aine	I-Chemical	-1	17466854
.	O	-1	17466854
A@@	O	-1	17466854
t	O	-1	17466854
the	O	-1	17466854
end	O	-1	17466854
of	O	-1	17466854
the	O	-1	17466854
proce@@	O	-1	17466854
d@@	O	-1	17466854
ure,	O	-1	17466854
Group	O	-1	17466854
A	O	-1	17466854
(n	O	-1	17466854
=	O	-1	17466854
20@@	O	-1	17466854
)	O	-1	17466854
had	O	-1	17466854
20	O	-1	17466854
mg/@@	O	-1	17466854
0.@@	O	-1	17466854
5	O	-1	17466854
m@@	O	-1	17466854
L	O	-1	17466854
of	O	-1	17466854
methyl@@	B-Chemical	D008775	17466854
pre@@	I-Chemical	-1	17466854
d@@	I-Chemical	-1	17466854
n@@	I-Chemical	-1	17466854
isol@@	I-Chemical	-1	17466854
one	I-Chemical	-1	17466854
and	O	-1	17466854
10	O	-1	17466854
mg/@@	O	-1	17466854
0.@@	O	-1	17466854
5	O	-1	17466854
m@@	O	-1	17466854
L	O	-1	17466854
of	O	-1	17466854
g@@	B-Chemical	D005839	17466854
ent@@	I-Chemical	-1	17466854
am@@	I-Chemical	-1	17466854
icin	I-Chemical	-1	17466854
injected	O	-1	17466854
into	O	-1	17466854
the	O	-1	17466854
po@@	O	-1	17466854
ster@@	O	-1	17466854
ior	O	-1	17466854
sub@@	O	-1	17466854
-@@	O	-1	17466854
T@@	O	-1	17466854
en@@	O	-1	17466854
on@@	O	-1	17466854
's	O	-1	17466854
sp@@	O	-1	17466854
ac@@	O	-1	17466854
e	O	-1	17466854
and	O	-1	17466854
Group	O	-1	17466854
B	O	-1	17466854
(n	O	-1	17466854
=	O	-1	17466854
20@@	O	-1	17466854
)	O	-1	17466854
had	O	-1	17466854
the	O	-1	17466854
same	O	-1	17466854
combination	O	-1	17466854
injected	O	-1	17466854
into	O	-1	17466854
the	O	-1	17466854
an@@	O	-1	17466854
ter@@	O	-1	17466854
ior	O	-1	17466854
sub@@	O	-1	17466854
-@@	O	-1	17466854
T@@	O	-1	17466854
en@@	O	-1	17466854
on@@	O	-1	17466854
's	O	-1	17466854
sp@@	O	-1	17466854
ac@@	O	-1	17466854
e.	O	-1	17466854
P@@	O	-1	17466854
o@@	O	-1	17466854
sto@@	O	-1	17466854
per@@	O	-1	17466854
ati@@	O	-1	17466854
vel@@	O	-1	17466854
y,	O	-1	17466854
all	O	-1	17466854
patients	O	-1	17466854
were	O	-1	17466854
assessed	O	-1	17466854
for	O	-1	17466854
symptoms	O	-1	17466854
of	O	-1	17466854
nause@@	B-Disease	D020250	17466854
a,	I-Disease	-1	17466854
v@@	I-Disease	-1	17466854
om@@	I-Disease	-1	17466854
it@@	I-Disease	-1	17466854
ing	I-Disease	-1	17466854
,	O	-1	17466854
and	O	-1	17466854
headac@@	B-Disease	D006261	17466854
he	I-Disease	-1	17466854
.	O	-1	17466854
A	O	-1	17466854
ch@@	O	-1	17466854
i@@	O	-1	17466854
-@@	O	-1	17466854
s@@	O	-1	17466854
qu@@	O	-1	17466854
are	O	-1	17466854
test	O	-1	17466854
was	O	-1	17466854
used	O	-1	17466854
to	O	-1	17466854
ass@@	O	-1	17466854
ess	O	-1	17466854
the	O	-1	17466854
statis@@	O	-1	17466854
tical	O	-1	17466854
signific@@	O	-1	17466854
ance	O	-1	17466854
of	O	-1	17466854
result@@	O	-1	17466854
s.	O	-1	17466854
RESULTS:	O	-1	17466854
Si@@	O	-1	17466854
x@@	O	-1	17466854
t@@	O	-1	17466854
y	O	-1	17466854
perc@@	O	-1	17466854
ent	O	-1	17466854
in	O	-1	17466854
Group	O	-1	17466854
A	O	-1	17466854
developed	O	-1	17466854
postoperative	B-Disease	D020250	17466854
e@@	I-Disease	-1	17466854
me@@	I-Disease	-1	17466854
tic	I-Disease	-1	17466854
symptoms	I-Disease	-1	17466854
,	O	-1	17466854
headac@@	B-Disease	D006261	17466854
he	I-Disease	-1	17466854
,	O	-1	17466854
or	O	-1	17466854
bo@@	O	-1	17466854
th@@	O	-1	17466854
;	O	-1	17466854
1	O	-1	17466854
patient	O	-1	17466854
in	O	-1	17466854
Group	O	-1	17466854
B	O	-1	17466854
developed	O	-1	17466854
symptom@@	O	-1	17466854
s.	O	-1	17466854
CONCLUSIONS:	O	-1	17466854
The	O	-1	17466854
administration	O	-1	17466854
of	O	-1	17466854
methyl@@	B-Chemical	D008775	17466854
pre@@	I-Chemical	-1	17466854
d@@	I-Chemical	-1	17466854
n@@	I-Chemical	-1	17466854
isol@@	I-Chemical	-1	17466854
one	I-Chemical	-1	17466854
and	O	-1	17466854
g@@	B-Chemical	D005839	17466854
ent@@	I-Chemical	-1	17466854
am@@	I-Chemical	-1	17466854
icin	I-Chemical	-1	17466854
in	O	-1	17466854
the	O	-1	17466854
po@@	O	-1	17466854
ster@@	O	-1	17466854
ior	O	-1	17466854
sub@@	O	-1	17466854
-@@	O	-1	17466854
T@@	O	-1	17466854
en@@	O	-1	17466854
on@@	O	-1	17466854
's	O	-1	17466854
sp@@	O	-1	17466854
ac@@	O	-1	17466854
e	O	-1	17466854
was	O	-1	17466854
related	O	-1	17466854
to	O	-1	17466854
a	O	-1	17466854
high	O	-1	17466854
incidence	O	-1	17466854
of	O	-1	17466854
side	O	-1	17466854
effects	O	-1	17466854
including	O	-1	17466854
nause@@	B-Disease	D020250	17466854
a,	I-Disease	-1	17466854
v@@	I-Disease	-1	17466854
om@@	I-Disease	-1	17466854
it@@	I-Disease	-1	17466854
ing	I-Disease	-1	17466854
,	O	-1	17466854
and	O	-1	17466854
headac@@	B-Disease	D006261	17466854
he	I-Disease	-1	17466854
.	O	-1	17466854
All	O	-1	17466854
adverse	O	-1	17466854
effects	O	-1	17466854
were	O	-1	17466854
sel@@	O	-1	17466854
f@@	O	-1	17466854
-@@	O	-1	17466854
lim@@	O	-1	17466854
it@@	O	-1	17466854
ing.	O	-1	17466854

C@@	O	-1	17562951
ardi@@	O	-1	17562951
a@@	O	-1	17562951
c	O	-1	17562951
An@@	O	-1	17562951
g@@	O	-1	17562951
io@@	O	-1	17562951
graph@@	O	-1	17562951
y	O	-1	17562951
in	O	-1	17562951
R@@	O	-1	17562951
en@@	O	-1	17562951
ally	O	-1	17562951
Im@@	O	-1	17562951
pa@@	O	-1	17562951
ired	O	-1	17562951
Patients	O	-1	17562951
(C@@	O	-1	17562951
A@@	O	-1	17562951
R@@	O	-1	17562951
E@@	O	-1	17562951
)	O	-1	17562951
stud@@	O	-1	17562951
y@@	O	-1	17562951
:	O	-1	17562951
a	O	-1	17562951
randomized	O	-1	17562951
double-bl@@	O	-1	17562951
ind	O	-1	17562951
trial	O	-1	17562951
of	O	-1	17562951
contrast@@	O	-1	17562951
-induced	O	-1	17562951
nephro@@	B-Disease	D007674	17562951
pathy	I-Disease	-1	17562951
in	O	-1	17562951
patients	O	-1	17562951
with	O	-1	17562951
chronic	B-Disease	D051436	17562951
kidney	I-Disease	-1	17562951
disease	I-Disease	-1	17562951
.	O	-1	17562951
BACKGROUND:	O	-1	17562951
No	O	-1	17562951
direct	O	-1	17562951
compar@@	O	-1	17562951
is@@	O	-1	17562951
ons	O	-1	17562951
ex@@	O	-1	17562951
ist	O	-1	17562951
of	O	-1	17562951
the	O	-1	17562951
renal	O	-1	17562951
toler@@	O	-1	17562951
ability	O	-1	17562951
of	O	-1	17562951
the	O	-1	17562951
low@@	O	-1	17562951
-@@	O	-1	17562951
os@@	O	-1	17562951
mol@@	O	-1	17562951
ality	O	-1	17562951
contr@@	B-Chemical	D003287	17562951
ast	I-Chemical	-1	17562951
medi@@	I-Chemical	-1	17562951
um	I-Chemical	-1	17562951
io@@	B-Chemical	D007479	17562951
p@@	I-Chemical	-1	17562951
am@@	I-Chemical	-1	17562951
id@@	I-Chemical	-1	17562951
ol	I-Chemical	-1	17562951
with	O	-1	17562951
that	O	-1	17562951
of	O	-1	17562951
the	O	-1	17562951
iso@@	O	-1	17562951
-@@	O	-1	17562951
os@@	O	-1	17562951
mol@@	O	-1	17562951
ality	O	-1	17562951
contr@@	B-Chemical	D003287	17562951
ast	I-Chemical	-1	17562951
medi@@	I-Chemical	-1	17562951
um	I-Chemical	-1	17562951
io@@	B-Chemical	C044834	17562951
di@@	I-Chemical	-1	17562951
x@@	I-Chemical	-1	17562951
an@@	I-Chemical	-1	17562951
ol	I-Chemical	-1	17562951
in	O	-1	17562951
high-@@	O	-1	17562951
risk	O	-1	17562951
patients.	O	-1	17562951
METHOD@@	O	-1	17562951
S	O	-1	17562951
AN@@	O	-1	17562951
D	O	-1	17562951
RESULTS:	O	-1	17562951
The	O	-1	17562951
present	O	-1	17562951
study	O	-1	17562951
is	O	-1	17562951
a	O	-1	17562951
mul@@	O	-1	17562951
tic@@	O	-1	17562951
ent@@	O	-1	17562951
er,	O	-1	17562951
random@@	O	-1	17562951
iz@@	O	-1	17562951
ed,	O	-1	17562951
double-bl@@	O	-1	17562951
ind	O	-1	17562951
compar@@	O	-1	17562951
ison	O	-1	17562951
of	O	-1	17562951
io@@	B-Chemical	D007479	17562951
p@@	I-Chemical	-1	17562951
am@@	I-Chemical	-1	17562951
id@@	I-Chemical	-1	17562951
ol	I-Chemical	-1	17562951
and	O	-1	17562951
io@@	B-Chemical	C044834	17562951
di@@	I-Chemical	-1	17562951
x@@	I-Chemical	-1	17562951
an@@	I-Chemical	-1	17562951
ol	I-Chemical	-1	17562951
in	O	-1	17562951
patients	O	-1	17562951
with	O	-1	17562951
chronic	B-Disease	D051436	17562951
kidney	I-Disease	-1	17562951
disease	I-Disease	-1	17562951
(@@	O	-1	17562951
estim@@	O	-1	17562951
ated	O	-1	17562951
glomerular	O	-1	17562951
f@@	O	-1	17562951
iltration	O	-1	17562951
rat@@	O	-1	17562951
e,	O	-1	17562951
20	O	-1	17562951
to	O	-1	17562951
5@@	O	-1	17562951
9	O	-1	17562951
m@@	O	-1	17562951
L@@	O	-1	17562951
/@@	O	-1	17562951
min@@	O	-1	17562951
)	O	-1	17562951
who	O	-1	17562951
under@@	O	-1	17562951
w@@	O	-1	17562951
ent	O	-1	17562951
cardiac	O	-1	17562951
angio@@	O	-1	17562951
graph@@	O	-1	17562951
y	O	-1	17562951
or	O	-1	17562951
perc@@	O	-1	17562951
utaneous	O	-1	17562951
coronary	O	-1	17562951
inter@@	O	-1	17562951
ven@@	O	-1	17562951
tions.	O	-1	17562951
S@@	O	-1	17562951
er@@	O	-1	17562951
um	O	-1	17562951
creatinine	B-Chemical	D003404	17562951
(S@@	O	-1	17562951
C@@	O	-1	17562951
r@@	O	-1	17562951
)	O	-1	17562951
levels	O	-1	17562951
and	O	-1	17562951
estim@@	O	-1	17562951
ated	O	-1	17562951
glomerular	O	-1	17562951
f@@	O	-1	17562951
iltration	O	-1	17562951
rate	O	-1	17562951
were	O	-1	17562951
assessed	O	-1	17562951
at	O	-1	17562951
baseline	O	-1	17562951
and	O	-1	17562951
2	O	-1	17562951
to	O	-1	17562951
5	O	-1	17562951
days	O	-1	17562951
after	O	-1	17562951
receiving	O	-1	17562951
medic@@	O	-1	17562951
ations.	O	-1	17562951
The	O	-1	17562951
prim@@	O	-1	17562951
ary	O	-1	17562951
outcom@@	O	-1	17562951
e	O	-1	17562951
was	O	-1	17562951
a	O	-1	17562951
post@@	O	-1	17562951
dose	O	-1	17562951
S@@	O	-1	17562951
C@@	O	-1	17562951
r	O	-1	17562951
increase	O	-1	17562951
>	O	-1	17562951
or	O	-1	17562951
=	O	-1	17562951
0.@@	O	-1	17562951
5	O	-1	17562951
mg/d@@	O	-1	17562951
L	O	-1	17562951
(4@@	O	-1	17562951
4.@@	O	-1	17562951
2	O	-1	17562951
mic@@	O	-1	17562951
rom@@	O	-1	17562951
ol@@	O	-1	17562951
/@@	O	-1	17562951
L@@	O	-1	17562951
)	O	-1	17562951
over	O	-1	17562951
basel@@	O	-1	17562951
ine.	O	-1	17562951
S@@	O	-1	17562951
ec@@	O	-1	17562951
ond@@	O	-1	17562951
ary	O	-1	17562951
outcom@@	O	-1	17562951
es	O	-1	17562951
were	O	-1	17562951
a	O	-1	17562951
post@@	O	-1	17562951
dose	O	-1	17562951
S@@	O	-1	17562951
C@@	O	-1	17562951
r	O	-1	17562951
increase	O	-1	17562951
>	O	-1	17562951
or	O	-1	17562951
=	O	-1	17562951
25@@	O	-1	17562951
%,	O	-1	17562951
a	O	-1	17562951
post@@	O	-1	17562951
dose	O	-1	17562951
estim@@	O	-1	17562951
ated	O	-1	17562951
glomerular	O	-1	17562951
f@@	O	-1	17562951
iltration	O	-1	17562951
rate	O	-1	17562951
decrease	O	-1	17562951
of	O	-1	17562951
>	O	-1	17562951
or	O	-1	17562951
=	O	-1	17562951
25@@	O	-1	17562951
%,	O	-1	17562951
and	O	-1	17562951
the	O	-1	17562951
mean	O	-1	17562951
pe@@	O	-1	17562951
a@@	O	-1	17562951
k	O	-1	17562951
change	O	-1	17562951
in	O	-1	17562951
S@@	O	-1	17562951
C@@	O	-1	17562951
r@@	O	-1	17562951
.	O	-1	17562951
In	O	-1	17562951
4@@	O	-1	17562951
14	O	-1	17562951
patients,	O	-1	17562951
contr@@	O	-1	17562951
ast	O	-1	17562951
vol@@	O	-1	17562951
u@@	O	-1	17562951
me,	O	-1	17562951
presence	O	-1	17562951
of	O	-1	17562951
dia@@	B-Disease	D003920	17562951
bet@@	I-Disease	-1	17562951
es	I-Disease	-1	17562951
me@@	I-Disease	-1	17562951
ll@@	I-Disease	-1	17562951
it@@	I-Disease	-1	17562951
us	I-Disease	-1	17562951
,	O	-1	17562951
use	O	-1	17562951
of	O	-1	17562951
N@@	B-Chemical	D000111	17562951
-@@	I-Chemical	-1	17562951
acet@@	I-Chemical	-1	17562951
yl@@	I-Chemical	-1	17562951
cy@@	I-Chemical	-1	17562951
ste@@	I-Chemical	-1	17562951
ine	I-Chemical	-1	17562951
,	O	-1	17562951
mean	O	-1	17562951
baseline	O	-1	17562951
S@@	O	-1	17562951
C@@	O	-1	17562951
r@@	O	-1	17562951
,	O	-1	17562951
and	O	-1	17562951
estim@@	O	-1	17562951
ated	O	-1	17562951
glomerular	O	-1	17562951
f@@	O	-1	17562951
iltration	O	-1	17562951
rate	O	-1	17562951
were	O	-1	17562951
compar@@	O	-1	17562951
able	O	-1	17562951
in	O	-1	17562951
the	O	-1	17562951
2	O	-1	17562951
groups.	O	-1	17562951
S@@	O	-1	17562951
C@@	O	-1	17562951
r	O	-1	17562951
increases	O	-1	17562951
>	O	-1	17562951
or	O	-1	17562951
=	O	-1	17562951
0.@@	O	-1	17562951
5	O	-1	17562951
mg/d@@	O	-1	17562951
L	O	-1	17562951
occurred	O	-1	17562951
in	O	-1	17562951
4.@@	O	-1	17562951
4@@	O	-1	17562951
%	O	-1	17562951
(@@	O	-1	17562951
9	O	-1	17562951
of	O	-1	17562951
20@@	O	-1	17562951
4	O	-1	17562951
patient@@	O	-1	17562951
s)	O	-1	17562951
after	O	-1	17562951
io@@	B-Chemical	D007479	17562951
p@@	I-Chemical	-1	17562951
am@@	I-Chemical	-1	17562951
id@@	I-Chemical	-1	17562951
ol	I-Chemical	-1	17562951
and	O	-1	17562951
6.@@	O	-1	17562951
7@@	O	-1	17562951
%	O	-1	17562951
(1@@	O	-1	17562951
4	O	-1	17562951
of	O	-1	17562951
2@@	O	-1	17562951
10	O	-1	17562951
patient@@	O	-1	17562951
s)	O	-1	17562951
after	O	-1	17562951
io@@	B-Chemical	C044834	17562951
di@@	I-Chemical	-1	17562951
x@@	I-Chemical	-1	17562951
an@@	I-Chemical	-1	17562951
ol	I-Chemical	-1	17562951
(P@@	O	-1	17562951
=@@	O	-1	17562951
0.@@	O	-1	17562951
3@@	O	-1	17562951
9@@	O	-1	17562951
),	O	-1	17562951
whereas	O	-1	17562951
rat@@	O	-1	17562951
es	O	-1	17562951
of	O	-1	17562951
S@@	O	-1	17562951
C@@	O	-1	17562951
r	O	-1	17562951
increases	O	-1	17562951
>	O	-1	17562951
or	O	-1	17562951
=	O	-1	17562951
2@@	O	-1	17562951
5%	O	-1	17562951
were	O	-1	17562951
9.@@	O	-1	17562951
8@@	O	-1	17562951
%	O	-1	17562951
and	O	-1	17562951
1@@	O	-1	17562951
2.@@	O	-1	17562951
4@@	O	-1	17562951
%,	O	-1	17562951
respecti@@	O	-1	17562951
vely	O	-1	17562951
(P@@	O	-1	17562951
=@@	O	-1	17562951
0.@@	O	-1	17562951
4@@	O	-1	17562951
4@@	O	-1	17562951
).	O	-1	17562951
In	O	-1	17562951
patients	O	-1	17562951
with	O	-1	17562951
dia@@	B-Disease	D003920	17562951
bet@@	I-Disease	-1	17562951
es	I-Disease	-1	17562951
,	O	-1	17562951
S@@	O	-1	17562951
C@@	O	-1	17562951
r	O	-1	17562951
increases	O	-1	17562951
>	O	-1	17562951
or	O	-1	17562951
=	O	-1	17562951
0.@@	O	-1	17562951
5	O	-1	17562951
mg/d@@	O	-1	17562951
L	O	-1	17562951
were	O	-1	17562951
5.@@	O	-1	17562951
1@@	O	-1	17562951
%	O	-1	17562951
(@@	O	-1	17562951
4	O	-1	17562951
of	O	-1	17562951
7@@	O	-1	17562951
8	O	-1	17562951
patient@@	O	-1	17562951
s)	O	-1	17562951
with	O	-1	17562951
io@@	B-Chemical	D007479	17562951
p@@	I-Chemical	-1	17562951
am@@	I-Chemical	-1	17562951
id@@	I-Chemical	-1	17562951
ol	I-Chemical	-1	17562951
and	O	-1	17562951
1@@	O	-1	17562951
3.@@	O	-1	17562951
0%	O	-1	17562951
(1@@	O	-1	17562951
2	O	-1	17562951
of	O	-1	17562951
9@@	O	-1	17562951
2	O	-1	17562951
patient@@	O	-1	17562951
s)	O	-1	17562951
with	O	-1	17562951
io@@	B-Chemical	C044834	17562951
di@@	I-Chemical	-1	17562951
x@@	I-Chemical	-1	17562951
an@@	I-Chemical	-1	17562951
ol	I-Chemical	-1	17562951
(P@@	O	-1	17562951
=@@	O	-1	17562951
0.@@	O	-1	17562951
1@@	O	-1	17562951
1),	O	-1	17562951
whereas	O	-1	17562951
S@@	O	-1	17562951
C@@	O	-1	17562951
r	O	-1	17562951
increases	O	-1	17562951
>	O	-1	17562951
or	O	-1	17562951
=	O	-1	17562951
2@@	O	-1	17562951
5%	O	-1	17562951
were	O	-1	17562951
1@@	O	-1	17562951
0.@@	O	-1	17562951
3@@	O	-1	17562951
%	O	-1	17562951
and	O	-1	17562951
1@@	O	-1	17562951
5.@@	O	-1	17562951
2@@	O	-1	17562951
%,	O	-1	17562951
respecti@@	O	-1	17562951
vely	O	-1	17562951
(P@@	O	-1	17562951
=@@	O	-1	17562951
0.@@	O	-1	17562951
3@@	O	-1	17562951
7@@	O	-1	17562951
).	O	-1	17562951
M@@	O	-1	17562951
e@@	O	-1	17562951
an	O	-1	17562951
post@@	O	-1	17562951
-@@	O	-1	17562951
S@@	O	-1	17562951
C@@	O	-1	17562951
r	O	-1	17562951
increases	O	-1	17562951
were	O	-1	17562951
significantly	O	-1	17562951
less	O	-1	17562951
with	O	-1	17562951
io@@	B-Chemical	D007479	17562951
p@@	I-Chemical	-1	17562951
am@@	I-Chemical	-1	17562951
id@@	I-Chemical	-1	17562951
ol	I-Chemical	-1	17562951
(@@	O	-1	17562951
all	O	-1	17562951
patient@@	O	-1	17562951
s:	O	-1	17562951
0.0@@	O	-1	17562951
7	O	-1	17562951
versus	O	-1	17562951
0.@@	O	-1	17562951
12	O	-1	17562951
mg/d@@	O	-1	17562951
L@@	O	-1	17562951
,	O	-1	17562951
6.@@	O	-1	17562951
2	O	-1	17562951
versus	O	-1	17562951
1@@	O	-1	17562951
0.@@	O	-1	17562951
6	O	-1	17562951
mic@@	O	-1	17562951
rom@@	O	-1	17562951
ol@@	O	-1	17562951
/@@	O	-1	17562951
L@@	O	-1	17562951
,	O	-1	17562951
P@@	O	-1	17562951
=@@	O	-1	17562951
0.0@@	O	-1	17562951
3@@	O	-1	17562951
;	O	-1	17562951
patients	O	-1	17562951
with	O	-1	17562951
dia@@	B-Disease	D003920	17562951
bet@@	I-Disease	-1	17562951
es	I-Disease	-1	17562951
:	O	-1	17562951
0.0@@	O	-1	17562951
7	O	-1	17562951
versus	O	-1	17562951
0.@@	O	-1	17562951
16	O	-1	17562951
mg/d@@	O	-1	17562951
L@@	O	-1	17562951
,	O	-1	17562951
6.@@	O	-1	17562951
2	O	-1	17562951
versus	O	-1	17562951
1@@	O	-1	17562951
4.@@	O	-1	17562951
1	O	-1	17562951
mic@@	O	-1	17562951
rom@@	O	-1	17562951
ol@@	O	-1	17562951
/@@	O	-1	17562951
L@@	O	-1	17562951
,	O	-1	17562951
P@@	O	-1	17562951
=@@	O	-1	17562951
0.0@@	O	-1	17562951
1).	O	-1	17562951
CONCLUSIONS:	O	-1	17562951
The	O	-1	17562951
rate	O	-1	17562951
of	O	-1	17562951
contrast@@	O	-1	17562951
-induced	O	-1	17562951
nephro@@	B-Disease	D007674	17562951
pathy	I-Disease	-1	17562951
,	O	-1	17562951
def@@	O	-1	17562951
in@@	O	-1	17562951
ed	O	-1	17562951
by	O	-1	17562951
multiple	O	-1	17562951
end	O	-1	17562951
po@@	O	-1	17562951
int@@	O	-1	17562951
s,	O	-1	17562951
is	O	-1	17562951
not	O	-1	17562951
statis@@	O	-1	17562951
tically	O	-1	17562951
different	O	-1	17562951
after	O	-1	17562951
the	O	-1	17562951
intra@@	O	-1	17562951
arterial	O	-1	17562951
administration	O	-1	17562951
of	O	-1	17562951
io@@	B-Chemical	D007479	17562951
p@@	I-Chemical	-1	17562951
am@@	I-Chemical	-1	17562951
id@@	I-Chemical	-1	17562951
ol	I-Chemical	-1	17562951
or	O	-1	17562951
io@@	B-Chemical	C044834	17562951
di@@	I-Chemical	-1	17562951
x@@	I-Chemical	-1	17562951
an@@	I-Chemical	-1	17562951
ol	I-Chemical	-1	17562951
to	O	-1	17562951
high-@@	O	-1	17562951
risk	O	-1	17562951
patients,	O	-1	17562951
with	O	-1	17562951
or	O	-1	17562951
without	O	-1	17562951
dia@@	B-Disease	D003920	17562951
bet@@	I-Disease	-1	17562951
es	I-Disease	-1	17562951
me@@	I-Disease	-1	17562951
ll@@	I-Disease	-1	17562951
it@@	I-Disease	-1	17562951
us	I-Disease	-1	17562951
.	O	-1	17562951
An@@	O	-1	17562951
y	O	-1	17562951
t@@	O	-1	17562951
ru@@	O	-1	17562951
e	O	-1	17562951
difference	O	-1	17562951
between	O	-1	17562951
the	O	-1	17562951
agents	O	-1	17562951
is	O	-1	17562951
sm@@	O	-1	17562951
all	O	-1	17562951
and	O	-1	17562951
not	O	-1	17562951
likely	O	-1	17562951
to	O	-1	17562951
be	O	-1	17562951
clin@@	O	-1	17562951
ically	O	-1	17562951
significant@@	O	-1	17562951
.	O	-1	17562951

A	O	-1	17600377
novel	O	-1	17600377
comp@@	O	-1	17600377
oun@@	O	-1	17600377
d,	O	-1	17600377
mal@@	B-Chemical	C524754	17600377
t@@	I-Chemical	-1	17600377
oly@@	I-Chemical	-1	17600377
l	I-Chemical	-1	17600377
p@@	I-Chemical	-1	17600377
-@@	I-Chemical	-1	17600377
co@@	I-Chemical	-1	17600377
um@@	I-Chemical	-1	17600377
ar@@	I-Chemical	-1	17600377
ate	I-Chemical	-1	17600377
,	O	-1	17600377
attenu@@	O	-1	17600377
ates	O	-1	17600377
cognitive	B-Disease	D003072	17600377
defic@@	I-Disease	-1	17600377
its	I-Disease	-1	17600377
and	O	-1	17600377
show@@	O	-1	17600377
s	O	-1	17600377
neuro@@	O	-1	17600377
protective	O	-1	17600377
effects	O	-1	17600377
in	O	-1	17600377
vit@@	O	-1	17600377
r@@	O	-1	17600377
o	O	-1	17600377
and	O	-1	17600377
in	O	-1	17600377
viv@@	O	-1	17600377
o	O	-1	17600377
de@@	B-Disease	D003704	17600377
m@@	I-Disease	-1	17600377
enti@@	I-Disease	-1	17600377
a	I-Disease	-1	17600377
model@@	O	-1	17600377
s.	O	-1	17600377
To	O	-1	17600377
deve@@	O	-1	17600377
lo@@	O	-1	17600377
p	O	-1	17600377
a	O	-1	17600377
novel	O	-1	17600377
and	O	-1	17600377
effective	O	-1	17600377
drug	O	-1	17600377
that	O	-1	17600377
could	O	-1	17600377
enh@@	O	-1	17600377
ance	O	-1	17600377
cognitive	O	-1	17600377
function	O	-1	17600377
and	O	-1	17600377
neuro@@	O	-1	17600377
prot@@	O	-1	17600377
ec@@	O	-1	17600377
tion,	O	-1	17600377
we	O	-1	17600377
ne@@	O	-1	17600377
w@@	O	-1	17600377
ly	O	-1	17600377
syn@@	O	-1	17600377
the@@	O	-1	17600377
si@@	O	-1	17600377
zed	O	-1	17600377
mal@@	B-Chemical	C524754	17600377
t@@	I-Chemical	-1	17600377
oly@@	I-Chemical	-1	17600377
l	I-Chemical	-1	17600377
p@@	I-Chemical	-1	17600377
-@@	I-Chemical	-1	17600377
co@@	I-Chemical	-1	17600377
um@@	I-Chemical	-1	17600377
ar@@	I-Chemical	-1	17600377
ate	I-Chemical	-1	17600377
by	O	-1	17600377
the	O	-1	17600377
est@@	O	-1	17600377
er@@	O	-1	17600377
ification	O	-1	17600377
of	O	-1	17600377
mal@@	B-Chemical	C008316	17600377
to@@	I-Chemical	-1	17600377
l	I-Chemical	-1	17600377
and	O	-1	17600377
p@@	B-Chemical	C032171	17600377
-@@	I-Chemical	-1	17600377
co@@	I-Chemical	-1	17600377
um@@	I-Chemical	-1	17600377
ar@@	I-Chemical	-1	17600377
ic	I-Chemical	-1	17600377
acid	I-Chemical	-1	17600377
.	O	-1	17600377
In	O	-1	17600377
the	O	-1	17600377
present	O	-1	17600377
study,	O	-1	17600377
we	O	-1	17600377
investigated	O	-1	17600377
whether	O	-1	17600377
mal@@	B-Chemical	C524754	17600377
t@@	I-Chemical	-1	17600377
oly@@	I-Chemical	-1	17600377
l	I-Chemical	-1	17600377
p@@	I-Chemical	-1	17600377
-@@	I-Chemical	-1	17600377
co@@	I-Chemical	-1	17600377
um@@	I-Chemical	-1	17600377
ar@@	I-Chemical	-1	17600377
ate	I-Chemical	-1	17600377
could	O	-1	17600377
impro@@	O	-1	17600377
ve	O	-1	17600377
cognitive	B-Disease	D003072	17600377
dec@@	I-Disease	-1	17600377
line	I-Disease	-1	17600377
in	O	-1	17600377
scopol@@	B-Chemical	D012601	17600377
amine	I-Chemical	-1	17600377
-@@	O	-1	17600377
injected	O	-1	17600377
rats	O	-1	17600377
and	O	-1	17600377
in	O	-1	17600377
am@@	B-Chemical	C544092	17600377
y@@	I-Chemical	-1	17600377
lo@@	I-Chemical	-1	17600377
id	I-Chemical	-1	17600377
bet@@	I-Chemical	-1	17600377
a	I-Chemical	-1	17600377
p@@	I-Chemical	-1	17600377
ep@@	I-Chemical	-1	17600377
ti@@	I-Chemical	-1	17600377
de@@	I-Chemical	-1	17600377
(1@@	I-Chemical	-1	17600377
-@@	I-Chemical	-1	17600377
4@@	I-Chemical	-1	17600377
2)	I-Chemical	-1	17600377
-@@	O	-1	17600377
inf@@	O	-1	17600377
used	O	-1	17600377
rats.	O	-1	17600377
M@@	B-Chemical	C524754	17600377
al@@	I-Chemical	-1	17600377
t@@	I-Chemical	-1	17600377
oly@@	I-Chemical	-1	17600377
l	I-Chemical	-1	17600377
p@@	I-Chemical	-1	17600377
-@@	I-Chemical	-1	17600377
co@@	I-Chemical	-1	17600377
um@@	I-Chemical	-1	17600377
ar@@	I-Chemical	-1	17600377
ate	I-Chemical	-1	17600377
was	O	-1	17600377
found	O	-1	17600377
to	O	-1	17600377
attenu@@	O	-1	17600377
ate	O	-1	17600377
cognitive	B-Disease	D003072	17600377
defic@@	I-Disease	-1	17600377
its	I-Disease	-1	17600377
in	O	-1	17600377
both	O	-1	17600377
rat	O	-1	17600377
models	O	-1	17600377
using	O	-1	17600377
p@@	O	-1	17600377
as@@	O	-1	17600377
sive	O	-1	17600377
avoid@@	O	-1	17600377
ance	O	-1	17600377
test	O	-1	17600377
and	O	-1	17600377
to	O	-1	17600377
re@@	O	-1	17600377
duce	O	-1	17600377
apo@@	O	-1	17600377
pto@@	O	-1	17600377
tic	O	-1	17600377
cell	O	-1	17600377
death	O	-1	17600377
observed	O	-1	17600377
in	O	-1	17600377
the	O	-1	17600377
hippocamp@@	O	-1	17600377
us	O	-1	17600377
of	O	-1	17600377
the	O	-1	17600377
am@@	B-Chemical	C544092	17600377
y@@	I-Chemical	-1	17600377
lo@@	I-Chemical	-1	17600377
id	I-Chemical	-1	17600377
bet@@	I-Chemical	-1	17600377
a	I-Chemical	-1	17600377
p@@	I-Chemical	-1	17600377
ep@@	I-Chemical	-1	17600377
ti@@	I-Chemical	-1	17600377
de@@	I-Chemical	-1	17600377
(1@@	I-Chemical	-1	17600377
-@@	I-Chemical	-1	17600377
4@@	I-Chemical	-1	17600377
2)	I-Chemical	-1	17600377
-@@	O	-1	17600377
inf@@	O	-1	17600377
used	O	-1	17600377
rats.	O	-1	17600377
We	O	-1	17600377
also	O	-1	17600377
examined	O	-1	17600377
the	O	-1	17600377
neuro@@	O	-1	17600377
protective	O	-1	17600377
effects	O	-1	17600377
of	O	-1	17600377
mal@@	B-Chemical	C524754	17600377
t@@	I-Chemical	-1	17600377
oly@@	I-Chemical	-1	17600377
l	I-Chemical	-1	17600377
p@@	I-Chemical	-1	17600377
-@@	I-Chemical	-1	17600377
co@@	I-Chemical	-1	17600377
um@@	I-Chemical	-1	17600377
ar@@	I-Chemical	-1	17600377
ate	I-Chemical	-1	17600377
in	O	-1	17600377
vit@@	O	-1	17600377
r@@	O	-1	17600377
o	O	-1	17600377
using	O	-1	17600377
S@@	O	-1	17600377
H@@	O	-1	17600377
-@@	O	-1	17600377
S@@	O	-1	17600377
Y@@	O	-1	17600377
5@@	O	-1	17600377
Y	O	-1	17600377
cell@@	O	-1	17600377
s.	O	-1	17600377
C@@	O	-1	17600377
ell@@	O	-1	17600377
s	O	-1	17600377
were	O	-1	17600377
pre@@	O	-1	17600377
treated	O	-1	17600377
with	O	-1	17600377
mal@@	B-Chemical	C524754	17600377
t@@	I-Chemical	-1	17600377
oly@@	I-Chemical	-1	17600377
l	I-Chemical	-1	17600377
p@@	I-Chemical	-1	17600377
-@@	I-Chemical	-1	17600377
co@@	I-Chemical	-1	17600377
um@@	I-Chemical	-1	17600377
ar@@	I-Chemical	-1	17600377
ate	I-Chemical	-1	17600377
,	O	-1	17600377
before	O	-1	17600377
exposed	O	-1	17600377
to	O	-1	17600377
am@@	B-Chemical	C544092	17600377
y@@	I-Chemical	-1	17600377
lo@@	I-Chemical	-1	17600377
id	I-Chemical	-1	17600377
bet@@	I-Chemical	-1	17600377
a	I-Chemical	-1	17600377
p@@	I-Chemical	-1	17600377
ep@@	I-Chemical	-1	17600377
ti@@	I-Chemical	-1	17600377
de@@	I-Chemical	-1	17600377
(1@@	I-Chemical	-1	17600377
-@@	I-Chemical	-1	17600377
4@@	I-Chemical	-1	17600377
2)	I-Chemical	-1	17600377
,	O	-1	17600377
glutamate	B-Chemical	D018698	17600377
or	O	-1	17600377
H@@	B-Chemical	D006861	17600377
2@@	I-Chemical	-1	17600377
O@@	I-Chemical	-1	17600377
2	I-Chemical	-1	17600377
.	O	-1	17600377
We	O	-1	17600377
found	O	-1	17600377
that	O	-1	17600377
mal@@	B-Chemical	C524754	17600377
t@@	I-Chemical	-1	17600377
oly@@	I-Chemical	-1	17600377
l	I-Chemical	-1	17600377
p@@	I-Chemical	-1	17600377
-@@	I-Chemical	-1	17600377
co@@	I-Chemical	-1	17600377
um@@	I-Chemical	-1	17600377
ar@@	I-Chemical	-1	17600377
ate	I-Chemical	-1	17600377
significantly	O	-1	17600377
decreased	O	-1	17600377
apo@@	O	-1	17600377
pto@@	O	-1	17600377
tic	O	-1	17600377
cell	O	-1	17600377
death	O	-1	17600377
and	O	-1	17600377
reduced	O	-1	17600377
reac@@	O	-1	17600377
tive	O	-1	17600377
oxy@@	O	-1	17600377
gen	O	-1	17600377
spec@@	O	-1	17600377
i@@	O	-1	17600377
es,	O	-1	17600377
cyto@@	O	-1	17600377
ch@@	O	-1	17600377
rom@@	O	-1	17600377
e	O	-1	17600377
c	O	-1	17600377
rele@@	O	-1	17600377
ase,	O	-1	17600377
and	O	-1	17600377
cas@@	O	-1	17600377
p@@	O	-1	17600377
ase	O	-1	17600377
3	O	-1	17600377
activ@@	O	-1	17600377
ation.	O	-1	17600377
T@@	O	-1	17600377
ak@@	O	-1	17600377
ing	O	-1	17600377
these	O	-1	17600377
in	O	-1	17600377
vit@@	O	-1	17600377
r@@	O	-1	17600377
o	O	-1	17600377
and	O	-1	17600377
in	O	-1	17600377
viv@@	O	-1	17600377
o	O	-1	17600377
results	O	-1	17600377
to@@	O	-1	17600377
ge@@	O	-1	17600377
ther@@	O	-1	17600377
,	O	-1	17600377
our	O	-1	17600377
study	O	-1	17600377
suggests	O	-1	17600377
that	O	-1	17600377
mal@@	B-Chemical	C524754	17600377
t@@	I-Chemical	-1	17600377
oly@@	I-Chemical	-1	17600377
l	I-Chemical	-1	17600377
p@@	I-Chemical	-1	17600377
-@@	I-Chemical	-1	17600377
co@@	I-Chemical	-1	17600377
um@@	I-Chemical	-1	17600377
ar@@	I-Chemical	-1	17600377
ate	I-Chemical	-1	17600377
is	O	-1	17600377
a	O	-1	17600377
potenti@@	O	-1	17600377
ally	O	-1	17600377
effective	O	-1	17600377
can@@	O	-1	17600377
di@@	O	-1	17600377
d@@	O	-1	17600377
ate	O	-1	17600377
against	O	-1	17600377
Al@@	B-Disease	D000544	17600377
z@@	I-Disease	-1	17600377
he@@	I-Disease	-1	17600377
im@@	I-Disease	-1	17600377
er@@	I-Disease	-1	17600377
's	I-Disease	-1	17600377
disease	I-Disease	-1	17600377
that	O	-1	17600377
is	O	-1	17600377
character@@	O	-1	17600377
ized	O	-1	17600377
by	O	-1	17600377
w@@	O	-1	17600377
ide	O	-1	17600377
s@@	O	-1	17600377
pre@@	O	-1	17600377
ad	O	-1	17600377
neuron@@	B-Disease	D009410	17600377
al	I-Disease	-1	17600377
death	I-Disease	-1	17600377
and	O	-1	17600377
progressive	O	-1	17600377
dec@@	B-Disease	D003072	17600377
line	I-Disease	-1	17600377
of	I-Disease	-1	17600377
cognitive	I-Disease	-1	17600377
function	I-Disease	-1	17600377
.	O	-1	17600377

In@@	O	-1	17639754
ter@@	O	-1	17639754
action	O	-1	17639754
between	O	-1	17639754
war@@	B-Chemical	D014859	17639754
farin	I-Chemical	-1	17639754
and	O	-1	17639754
lev@@	B-Chemical	D064704	17639754
of@@	I-Chemical	-1	17639754
lo@@	I-Chemical	-1	17639754
x@@	I-Chemical	-1	17639754
ac@@	I-Chemical	-1	17639754
in	I-Chemical	-1	17639754
:	O	-1	17639754
case	O	-1	17639754
seri@@	O	-1	17639754
es.	O	-1	17639754
W@@	B-Chemical	D014859	17639754
ar@@	I-Chemical	-1	17639754
farin	I-Chemical	-1	17639754
is	O	-1	17639754
the	O	-1	17639754
most	O	-1	17639754
wi@@	O	-1	17639754
de@@	O	-1	17639754
ly	O	-1	17639754
used	O	-1	17639754
oral	O	-1	17639754
anti@@	O	-1	17639754
co@@	O	-1	17639754
ag@@	O	-1	17639754
ul@@	O	-1	17639754
ant	O	-1	17639754
and	O	-1	17639754
is	O	-1	17639754
indic@@	O	-1	17639754
ated	O	-1	17639754
for	O	-1	17639754
man@@	O	-1	17639754
y	O	-1	17639754
clinical	O	-1	17639754
condi@@	O	-1	17639754
tions.	O	-1	17639754
L@@	B-Chemical	D064704	17639754
ev@@	I-Chemical	-1	17639754
of@@	I-Chemical	-1	17639754
lo@@	I-Chemical	-1	17639754
x@@	I-Chemical	-1	17639754
ac@@	I-Chemical	-1	17639754
in	I-Chemical	-1	17639754
,	O	-1	17639754
a	O	-1	17639754
fluoro@@	B-Chemical	D024841	17639754
qu@@	I-Chemical	-1	17639754
in@@	I-Chemical	-1	17639754
ol@@	I-Chemical	-1	17639754
one	I-Chemical	-1	17639754
,	O	-1	17639754
is	O	-1	17639754
one	O	-1	17639754
of	O	-1	17639754
the	O	-1	17639754
most	O	-1	17639754
common@@	O	-1	17639754
ly	O	-1	17639754
prescri@@	O	-1	17639754
bed	O	-1	17639754
anti@@	O	-1	17639754
bio@@	O	-1	17639754
tics	O	-1	17639754
in	O	-1	17639754
clinical	O	-1	17639754
p@@	O	-1	17639754
rac@@	O	-1	17639754
ti@@	O	-1	17639754
ce	O	-1	17639754
and	O	-1	17639754
is	O	-1	17639754
effective	O	-1	17639754
against	O	-1	17639754
G@@	O	-1	17639754
ram@@	O	-1	17639754
-@@	O	-1	17639754
posi@@	O	-1	17639754
ti@@	O	-1	17639754
ve,	O	-1	17639754
G@@	O	-1	17639754
ram@@	O	-1	17639754
-@@	O	-1	17639754
neg@@	O	-1	17639754
ati@@	O	-1	17639754
ve,	O	-1	17639754
and	O	-1	17639754
at@@	O	-1	17639754
yp@@	O	-1	17639754
ical	O	-1	17639754
bac@@	O	-1	17639754
ter@@	O	-1	17639754
ia.	O	-1	17639754
W@@	O	-1	17639754
h@@	O	-1	17639754
ile	O	-1	17639754
sm@@	O	-1	17639754
all	O	-1	17639754
pro@@	O	-1	17639754
sp@@	O	-1	17639754
ective	O	-1	17639754
studies	O	-1	17639754
have	O	-1	17639754
not	O	-1	17639754
revealed	O	-1	17639754
any	O	-1	17639754
significant	O	-1	17639754
drug@@	O	-1	17639754
-@@	O	-1	17639754
drug	O	-1	17639754
inter@@	O	-1	17639754
action	O	-1	17639754
between	O	-1	17639754
war@@	B-Chemical	D014859	17639754
farin	I-Chemical	-1	17639754
and	O	-1	17639754
lev@@	B-Chemical	D064704	17639754
of@@	I-Chemical	-1	17639754
lo@@	I-Chemical	-1	17639754
x@@	I-Chemical	-1	17639754
ac@@	I-Chemical	-1	17639754
in	I-Chemical	-1	17639754
,	O	-1	17639754
several	O	-1	17639754
case	O	-1	17639754
reports	O	-1	17639754
have	O	-1	17639754
indic@@	O	-1	17639754
ated	O	-1	17639754
that	O	-1	17639754
lev@@	B-Chemical	D064704	17639754
of@@	I-Chemical	-1	17639754
lo@@	I-Chemical	-1	17639754
x@@	I-Chemical	-1	17639754
ac@@	I-Chemical	-1	17639754
in	I-Chemical	-1	17639754
may	O	-1	17639754
significantly	O	-1	17639754
potenti@@	O	-1	17639754
ate	O	-1	17639754
the	O	-1	17639754
anti@@	O	-1	17639754
co@@	O	-1	17639754
ag@@	O	-1	17639754
ulation	O	-1	17639754
effect	O	-1	17639754
of	O	-1	17639754
war@@	B-Chemical	D014859	17639754
farin	I-Chemical	-1	17639754
.	O	-1	17639754
We	O	-1	17639754
report	O	-1	17639754
3	O	-1	17639754
cases	O	-1	17639754
of	O	-1	17639754
seri@@	O	-1	17639754
ous	O	-1	17639754
ble@@	B-Disease	D006470	17639754
ed@@	I-Disease	-1	17639754
ing	I-Disease	-1	17639754
complications	O	-1	17639754
that	O	-1	17639754
appe@@	O	-1	17639754
ar	O	-1	17639754
to	O	-1	17639754
be	O	-1	17639754
the	O	-1	17639754
result	O	-1	17639754
of	O	-1	17639754
the	O	-1	17639754
inter@@	O	-1	17639754
action	O	-1	17639754
between	O	-1	17639754
war@@	B-Chemical	D014859	17639754
farin	I-Chemical	-1	17639754
and	O	-1	17639754
lev@@	B-Chemical	D064704	17639754
of@@	I-Chemical	-1	17639754
lo@@	I-Chemical	-1	17639754
x@@	I-Chemical	-1	17639754
ac@@	I-Chemical	-1	17639754
in	I-Chemical	-1	17639754
.	O	-1	17639754
P@@	O	-1	17639754
hy@@	O	-1	17639754
si@@	O	-1	17639754
ci@@	O	-1	17639754
ans	O	-1	17639754
should	O	-1	17639754
be	O	-1	17639754
aw@@	O	-1	17639754
are	O	-1	17639754
of	O	-1	17639754
this	O	-1	17639754
potential	O	-1	17639754
inter@@	O	-1	17639754
action	O	-1	17639754
and	O	-1	17639754
use	O	-1	17639754
cau@@	O	-1	17639754
tion	O	-1	17639754
when	O	-1	17639754
prescri@@	O	-1	17639754
b@@	O	-1	17639754
ing	O	-1	17639754
lev@@	B-Chemical	D064704	17639754
of@@	I-Chemical	-1	17639754
lo@@	I-Chemical	-1	17639754
x@@	I-Chemical	-1	17639754
ac@@	I-Chemical	-1	17639754
in	I-Chemical	-1	17639754
to	O	-1	17639754
patients	O	-1	17639754
taking	O	-1	17639754
war@@	B-Chemical	D014859	17639754
farin	I-Chemical	-1	17639754
.	O	-1	17639754

M@@	O	-1	17854040
ut@@	O	-1	17854040
ations	O	-1	17854040
associated	O	-1	17854040
with	O	-1	17854040
lamivud@@	B-Chemical	D019259	17854040
ine	I-Chemical	-1	17854040
-@@	O	-1	17854040
resist@@	O	-1	17854040
ance	O	-1	17854040
in	O	-1	17854040
therap@@	O	-1	17854040
y@@	O	-1	17854040
-	O	-1	17854040
n@@	B-Chemical	D012964	17854040
a	I-Chemical	-1	17854040
ve	O	-1	17854040
hepatitis	B-Disease	D006509	17854040
B	I-Disease	-1	17854040
vi@@	I-Disease	-1	17854040
ru@@	I-Disease	-1	17854040
s	I-Disease	-1	17854040
(@@	I-Disease	-1	17854040
HB@@	I-Disease	-1	17854040
V@@	I-Disease	-1	17854040
)	I-Disease	-1	17854040
inf@@	I-Disease	-1	17854040
ected	I-Disease	-1	17854040
patients	O	-1	17854040
with	O	-1	17854040
and	O	-1	17854040
without	O	-1	17854040
H@@	B-Disease	D015658	17854040
IV	I-Disease	-1	17854040
co-@@	I-Disease	-1	17854040
inf@@	I-Disease	-1	17854040
ection	I-Disease	-1	17854040
:	O	-1	17854040
implic@@	O	-1	17854040
ations	O	-1	17854040
for	O	-1	17854040
anti@@	O	-1	17854040
ret@@	O	-1	17854040
ro@@	O	-1	17854040
viral	O	-1	17854040
therapy	O	-1	17854040
in	O	-1	17854040
HBV	B-Disease	D006509	17854040
and	I-Disease	-1	17854040
H@@	I-Disease	-1	17854040
IV	I-Disease	-1	17854040
co-@@	I-Disease	-1	17854040
inf@@	I-Disease	-1	17854040
ected	I-Disease	-1	17854040
HBV	B-Disease	D015658	17854040
and	I-Disease	-1	17854040
H@@	I-Disease	-1	17854040
IV	I-Disease	-1	17854040
co-@@	I-Disease	-1	17854040
inf@@	I-Disease	-1	17854040
ected	I-Disease	-1	17854040
S@@	O	-1	17854040
ou@@	O	-1	17854040
th	O	-1	17854040
Af@@	O	-1	17854040
r@@	O	-1	17854040
ic@@	O	-1	17854040
an	O	-1	17854040
patients.	O	-1	17854040
This	O	-1	17854040
was	O	-1	17854040
an	O	-1	17854040
expl@@	O	-1	17854040
or@@	O	-1	17854040
atory	O	-1	17854040
study	O	-1	17854040
to	O	-1	17854040
investigate	O	-1	17854040
lamivud@@	B-Chemical	D019259	17854040
ine	I-Chemical	-1	17854040
-@@	O	-1	17854040
resist@@	O	-1	17854040
ant	O	-1	17854040
hepatitis	B-Disease	D006509	17854040
B	I-Disease	-1	17854040
vi@@	O	-1	17854040
ru@@	O	-1	17854040
s	O	-1	17854040
(@@	O	-1	17854040
HB@@	O	-1	17854040
V@@	O	-1	17854040
)	O	-1	17854040
stra@@	O	-1	17854040
ins	O	-1	17854040
in	O	-1	17854040
sel@@	O	-1	17854040
ected	O	-1	17854040
lamivud@@	B-Chemical	D019259	17854040
ine	I-Chemical	-1	17854040
-	O	-1	17854040
n@@	B-Chemical	D012964	17854040
a	I-Chemical	-1	17854040
ve	O	-1	17854040
HBV	O	-1	17854040
car@@	O	-1	17854040
ri@@	O	-1	17854040
ers	O	-1	17854040
with	O	-1	17854040
and	O	-1	17854040
without	O	-1	17854040
human	B-Disease	D015658	17854040
immuno@@	I-Disease	-1	17854040
defici@@	I-Disease	-1	17854040
ency	I-Disease	-1	17854040
vi@@	I-Disease	-1	17854040
ru@@	I-Disease	-1	17854040
s	I-Disease	-1	17854040
(@@	I-Disease	-1	17854040
H@@	I-Disease	-1	17854040
I@@	I-Disease	-1	17854040
V@@	I-Disease	-1	17854040
)	I-Disease	-1	17854040
co-@@	I-Disease	-1	17854040
inf@@	I-Disease	-1	17854040
ection	I-Disease	-1	17854040
in	O	-1	17854040
S@@	O	-1	17854040
ou@@	O	-1	17854040
th	O	-1	17854040
Af@@	O	-1	17854040
r@@	O	-1	17854040
ic@@	O	-1	17854040
an	O	-1	17854040
patients.	O	-1	17854040
Th@@	O	-1	17854040
ir@@	O	-1	17854040
ty-@@	O	-1	17854040
five	O	-1	17854040
lamivud@@	B-Chemical	D019259	17854040
ine	I-Chemical	-1	17854040
-	O	-1	17854040
n@@	B-Chemical	D012964	17854040
a	I-Chemical	-1	17854040
ve	O	-1	17854040
HBV	B-Disease	D006509	17854040
inf@@	I-Disease	-1	17854040
ected	I-Disease	-1	17854040
patients	O	-1	17854040
with	O	-1	17854040
or	O	-1	17854040
without	O	-1	17854040
H@@	B-Disease	D015658	17854040
IV	I-Disease	-1	17854040
co-@@	I-Disease	-1	17854040
inf@@	I-Disease	-1	17854040
ection	I-Disease	-1	17854040
were	O	-1	17854040
studi@@	O	-1	17854040
ed@@	O	-1	17854040
:	O	-1	17854040
15	O	-1	17854040
chronic	O	-1	17854040
HBV	B-Disease	D006509	17854040
mon@@	I-Disease	-1	17854040
o@@	I-Disease	-1	17854040
-@@	I-Disease	-1	17854040
inf@@	I-Disease	-1	17854040
ected	I-Disease	-1	17854040
patients	O	-1	17854040
and	O	-1	17854040
20	O	-1	17854040
HB@@	B-Disease	D006509	17854040
V@@	I-Disease	-1	17854040
-H@@	I-Disease	-1	17854040
IV	I-Disease	-1	17854040
co-@@	I-Disease	-1	17854040
inf@@	I-Disease	-1	17854040
ected	I-Disease	-1	17854040
HB@@	B-Disease	D015658	17854040
V@@	I-Disease	-1	17854040
-H@@	I-Disease	-1	17854040
IV	I-Disease	-1	17854040
co-@@	I-Disease	-1	17854040
inf@@	I-Disease	-1	17854040
ected	I-Disease	-1	17854040
patients.	O	-1	17854040
The	O	-1	17854040
lat@@	O	-1	17854040
ter	O	-1	17854040
group	O	-1	17854040
was	O	-1	17854040
further	O	-1	17854040
sub@@	O	-1	17854040
-@@	O	-1	17854040
divid@@	O	-1	17854040
ed	O	-1	17854040
into	O	-1	17854040
13	O	-1	17854040
occ@@	O	-1	17854040
ult	O	-1	17854040
HBV	O	-1	17854040
(	O	-1	17854040
HB@@	B-Chemical	D006514	17854040
s@@	I-Chemical	-1	17854040
A@@	I-Chemical	-1	17854040
g	I-Chemical	-1	17854040
-@@	O	-1	17854040
neg@@	O	-1	17854040
ati@@	O	-1	17854040
ve@@	O	-1	17854040
)	O	-1	17854040
and	O	-1	17854040
7	O	-1	17854040
over@@	O	-1	17854040
t	O	-1	17854040
HBV	O	-1	17854040
(	O	-1	17854040
HB@@	B-Chemical	D006514	17854040
s@@	I-Chemical	-1	17854040
A@@	I-Chemical	-1	17854040
g	I-Chemical	-1	17854040
-	O	-1	17854040
posi@@	O	-1	17854040
ti@@	O	-1	17854040
ve@@	O	-1	17854040
)	O	-1	17854040
patients.	O	-1	17854040
HB@@	B-Chemical	D006514	17854040
s@@	I-Chemical	-1	17854040
A@@	I-Chemical	-1	17854040
g	I-Chemical	-1	17854040
,	O	-1	17854040
anti@@	O	-1	17854040
-@@	O	-1	17854040
HB@@	O	-1	17854040
s,	O	-1	17854040
anti@@	O	-1	17854040
-@@	O	-1	17854040
HB@@	O	-1	17854040
c@@	O	-1	17854040
,	O	-1	17854040
and	O	-1	17854040
anti@@	O	-1	17854040
-H@@	O	-1	17854040
IV	O	-1	17854040
1@@	O	-1	17854040
/@@	O	-1	17854040
2	O	-1	17854040
were	O	-1	17854040
determined	O	-1	17854040
as	O	-1	17854040
par@@	O	-1	17854040
t	O	-1	17854040
of	O	-1	17854040
ro@@	O	-1	17854040
ut@@	O	-1	17854040
ine	O	-1	17854040
diagnosis	O	-1	17854040
using	O	-1	17854040
A@@	O	-1	17854040
x@@	O	-1	17854040
sy@@	O	-1	17854040
m	O	-1	17854040
ass@@	O	-1	17854040
ays	O	-1	17854040
(A@@	O	-1	17854040
b@@	O	-1	17854040
b@@	O	-1	17854040
ot@@	O	-1	17854040
t	O	-1	17854040
L@@	O	-1	17854040
abor@@	O	-1	17854040
at@@	O	-1	17854040
or@@	O	-1	17854040
i@@	O	-1	17854040
es,	O	-1	17854040
N@@	O	-1	17854040
or@@	O	-1	17854040
th	O	-1	17854040
Ch@@	O	-1	17854040
ic@@	O	-1	17854040
ag@@	O	-1	17854040
o@@	O	-1	17854040
,	O	-1	17854040
I@@	O	-1	17854040
L@@	O	-1	17854040
).	O	-1	17854040
S@@	O	-1	17854040
er@@	O	-1	17854040
um	O	-1	17854040
sam@@	O	-1	17854040
ple@@	O	-1	17854040
s	O	-1	17854040
were	O	-1	17854040
P@@	O	-1	17854040
C@@	O	-1	17854040
R	O	-1	17854040
am@@	O	-1	17854040
pl@@	O	-1	17854040
if@@	O	-1	17854040
ied	O	-1	17854040
with	O	-1	17854040
HBV	O	-1	17854040
re@@	O	-1	17854040
verse	O	-1	17854040
trans@@	O	-1	17854040
cri@@	O	-1	17854040
pt@@	O	-1	17854040
ase	O	-1	17854040
(@@	O	-1	17854040
R@@	O	-1	17854040
T)	O	-1	17854040
pri@@	O	-1	17854040
mer@@	O	-1	17854040
s,	O	-1	17854040
followed	O	-1	17854040
by	O	-1	17854040
direct	O	-1	17854040
sequ@@	O	-1	17854040
enc@@	O	-1	17854040
ing	O	-1	17854040
ac@@	O	-1	17854040
ros@@	O	-1	17854040
s	O	-1	17854040
the	O	-1	17854040
ty@@	B-Chemical	D014443	17854040
ros@@	I-Chemical	-1	17854040
ine	I-Chemical	-1	17854040
-	O	-1	17854040
meth@@	B-Chemical	D008715	17854040
i@@	I-Chemical	-1	17854040
on@@	I-Chemical	-1	17854040
ine	I-Chemical	-1	17854040
-	O	-1	17854040
as@@	B-Chemical	D001224	17854040
part@@	I-Chemical	-1	17854040
ate	I-Chemical	-1	17854040
-	O	-1	17854040
as@@	B-Chemical	D001224	17854040
part@@	I-Chemical	-1	17854040
ate	I-Chemical	-1	17854040
(@@	O	-1	17854040
Y@@	O	-1	17854040
MD@@	O	-1	17854040
D)	O	-1	17854040
mo@@	O	-1	17854040
ti@@	O	-1	17854040
f	O	-1	17854040
of	O	-1	17854040
the	O	-1	17854040
major	O	-1	17854040
cat@@	O	-1	17854040
aly@@	O	-1	17854040
tic	O	-1	17854040
regi@@	O	-1	17854040
on	O	-1	17854040
in	O	-1	17854040
the	O	-1	17854040
C	O	-1	17854040
do@@	O	-1	17854040
ma@@	O	-1	17854040
in	O	-1	17854040
of	O	-1	17854040
the	O	-1	17854040
HBV	O	-1	17854040
R@@	O	-1	17854040
T	O	-1	17854040
enz@@	O	-1	17854040
y@@	O	-1	17854040
me.	O	-1	17854040
HBV	O	-1	17854040
viral	O	-1	17854040
lo@@	O	-1	17854040
ad	O	-1	17854040
was	O	-1	17854040
performed	O	-1	17854040
with	O	-1	17854040
A@@	O	-1	17854040
m@@	O	-1	17854040
plic@@	O	-1	17854040
or	O	-1	17854040
HBV	O	-1	17854040
M@@	O	-1	17854040
on@@	O	-1	17854040
it@@	O	-1	17854040
or	O	-1	17854040
test	O	-1	17854040
v@@	O	-1	17854040
2.@@	O	-1	17854040
0	O	-1	17854040
(@@	O	-1	17854040
R@@	O	-1	17854040
och@@	O	-1	17854040
e	O	-1	17854040
Di@@	O	-1	17854040
ag@@	O	-1	17854040
nos@@	O	-1	17854040
tic@@	O	-1	17854040
s,	O	-1	17854040
P@@	O	-1	17854040
enz@@	O	-1	17854040
b@@	O	-1	17854040
erg@@	O	-1	17854040
,	O	-1	17854040
G@@	O	-1	17854040
er@@	O	-1	17854040
man@@	O	-1	17854040
y@@	O	-1	17854040
).	O	-1	17854040
HBV	O	-1	17854040
lamivud@@	B-Chemical	D019259	17854040
ine	I-Chemical	-1	17854040
-@@	O	-1	17854040
resist@@	O	-1	17854040
ant	O	-1	17854040
stra@@	O	-1	17854040
ins	O	-1	17854040
were	O	-1	17854040
det@@	O	-1	17854040
ected	O	-1	17854040
in	O	-1	17854040
3	O	-1	17854040
of	O	-1	17854040
15	O	-1	17854040
mon@@	O	-1	17854040
o@@	O	-1	17854040
-@@	O	-1	17854040
inf@@	O	-1	17854040
ected	O	-1	17854040
chronic	O	-1	17854040
hepatitis	B-Disease	D006509	17854040
B	I-Disease	-1	17854040
patients	O	-1	17854040
and	O	-1	17854040
10	O	-1	17854040
of	O	-1	17854040
20	O	-1	17854040
HB@@	B-Disease	D006509	17854040
V@@	I-Disease	-1	17854040
-H@@	I-Disease	-1	17854040
IV	I-Disease	-1	17854040
co-@@	I-Disease	-1	17854040
inf@@	I-Disease	-1	17854040
ected	I-Disease	-1	17854040
HB@@	B-Disease	D015658	17854040
V@@	I-Disease	-1	17854040
-H@@	I-Disease	-1	17854040
IV	I-Disease	-1	17854040
co-@@	I-Disease	-1	17854040
inf@@	I-Disease	-1	17854040
ected	I-Disease	-1	17854040
patients.	O	-1	17854040
To	O	-1	17854040
the	O	-1	17854040
b@@	O	-1	17854040
est	O	-1	17854040
of	O	-1	17854040
our	O	-1	17854040
know@@	O	-1	17854040
le@@	O	-1	17854040
d@@	O	-1	17854040
g@@	O	-1	17854040
e,	O	-1	17854040
this	O	-1	17854040
con@@	O	-1	17854040
sti@@	O	-1	17854040
t@@	O	-1	17854040
ut@@	O	-1	17854040
es	O	-1	17854040
the	O	-1	17854040
first	O	-1	17854040
report	O	-1	17854040
of	O	-1	17854040
HBV	O	-1	17854040
lamivud@@	B-Chemical	D019259	17854040
ine	I-Chemical	-1	17854040
-@@	O	-1	17854040
resist@@	O	-1	17854040
ant	O	-1	17854040
stra@@	O	-1	17854040
ins	O	-1	17854040
in	O	-1	17854040
therap@@	O	-1	17854040
y@@	O	-1	17854040
-	O	-1	17854040
n@@	B-Chemical	D012964	17854040
a	I-Chemical	-1	17854040
ve	O	-1	17854040
HB@@	B-Disease	D006509	17854040
V@@	I-Disease	-1	17854040
-H@@	I-Disease	-1	17854040
IV	I-Disease	-1	17854040
co-@@	I-Disease	-1	17854040
inf@@	I-Disease	-1	17854040
ected	I-Disease	-1	17854040
HB@@	B-Disease	D015658	17854040
V@@	I-Disease	-1	17854040
-H@@	I-Disease	-1	17854040
IV	I-Disease	-1	17854040
co-@@	I-Disease	-1	17854040
inf@@	I-Disease	-1	17854040
ected	I-Disease	-1	17854040
patients.	O	-1	17854040
The	O	-1	17854040
HBV	O	-1	17854040
viral	O	-1	17854040
lo@@	O	-1	17854040
ad@@	O	-1	17854040
s	O	-1	17854040
for	O	-1	17854040
mon@@	O	-1	17854040
o@@	O	-1	17854040
-@@	O	-1	17854040
inf@@	O	-1	17854040
ected	O	-1	17854040
and	O	-1	17854040
co-@@	O	-1	17854040
inf@@	O	-1	17854040
ected	O	-1	17854040
patients	O	-1	17854040
rang@@	O	-1	17854040
ed	O	-1	17854040
from	O	-1	17854040
3.@@	O	-1	17854040
3@@	O	-1	17854040
2	O	-1	17854040
x	O	-1	17854040
10@@	O	-1	17854040
(2@@	O	-1	17854040
)	O	-1	17854040
to	O	-1	17854040
3.@@	O	-1	17854040
8@@	O	-1	17854040
2	O	-1	17854040
x	O	-1	17854040
10@@	O	-1	17854040
(@@	O	-1	17854040
7@@	O	-1	17854040
)	O	-1	17854040
and	O	-1	17854040
<@@	O	-1	17854040
2@@	O	-1	17854040
00	O	-1	17854040
to	O	-1	17854040
4.@@	O	-1	17854040
40	O	-1	17854040
x	O	-1	17854040
10@@	O	-1	17854040
(3@@	O	-1	17854040
)	O	-1	17854040
co@@	O	-1	17854040
pi@@	O	-1	17854040
es@@	O	-1	17854040
/@@	O	-1	17854040
ml@@	O	-1	17854040
,	O	-1	17854040
respectively.	O	-1	17854040
It	O	-1	17854040
remain@@	O	-1	17854040
s	O	-1	17854040
to	O	-1	17854040
be	O	-1	17854040
seen	O	-1	17854040
whether	O	-1	17854040
such	O	-1	17854040
pre-@@	O	-1	17854040
ex@@	O	-1	17854040
ist@@	O	-1	17854040
ing	O	-1	17854040
anti@@	O	-1	17854040
viral	O	-1	17854040
mut@@	O	-1	17854040
ations	O	-1	17854040
could	O	-1	17854040
result	O	-1	17854040
in	O	-1	17854040
w@@	O	-1	17854040
id@@	O	-1	17854040
es@@	O	-1	17854040
pre@@	O	-1	17854040
ad	O	-1	17854040
em@@	O	-1	17854040
er@@	O	-1	17854040
gen@@	O	-1	17854040
ce	O	-1	17854040
of	O	-1	17854040
HBV	O	-1	17854040
resist@@	O	-1	17854040
ant	O	-1	17854040
stra@@	O	-1	17854040
ins	O	-1	17854040
when	O	-1	17854040
lamivud@@	B-Chemical	D019259	17854040
ine	I-Chemical	-1	17854040
-@@	O	-1	17854040
containing	O	-1	17854040
high@@	O	-1	17854040
ly	O	-1	17854040
active	O	-1	17854040
anti@@	O	-1	17854040
ret@@	O	-1	17854040
ro@@	O	-1	17854040
viral	O	-1	17854040
(A@@	O	-1	17854040
R@@	O	-1	17854040
V@@	O	-1	17854040
)	O	-1	17854040
treatment	O	-1	17854040
(@@	O	-1	17854040
H@@	O	-1	17854040
A@@	O	-1	17854040
A@@	O	-1	17854040
R@@	O	-1	17854040
T)	O	-1	17854040
regimen@@	O	-1	17854040
s	O	-1	17854040
b@@	O	-1	17854040
ec@@	O	-1	17854040
ome	O	-1	17854040
wi@@	O	-1	17854040
de@@	O	-1	17854040
ly	O	-1	17854040
ap@@	O	-1	17854040
pl@@	O	-1	17854040
ied	O	-1	17854040
in	O	-1	17854040
S@@	O	-1	17854040
ou@@	O	-1	17854040
th	O	-1	17854040
Af@@	O	-1	17854040
r@@	O	-1	17854040
ic@@	O	-1	17854040
a,	O	-1	17854040
as	O	-1	17854040
this	O	-1	17854040
is	O	-1	17854040
likely	O	-1	17854040
to	O	-1	17854040
have	O	-1	17854040
potential	O	-1	17854040
implic@@	O	-1	17854040
ations	O	-1	17854040
in	O	-1	17854040
the	O	-1	17854040
man@@	O	-1	17854040
ag@@	O	-1	17854040
ement	O	-1	17854040
of	O	-1	17854040
HB@@	B-Disease	D006509	17854040
V@@	I-Disease	-1	17854040
-H@@	I-Disease	-1	17854040
IV	I-Disease	-1	17854040
co-@@	I-Disease	-1	17854040
inf@@	I-Disease	-1	17854040
ected	I-Disease	-1	17854040
HB@@	B-Disease	D015658	17854040
V@@	I-Disease	-1	17854040
-H@@	I-Disease	-1	17854040
IV	I-Disease	-1	17854040
co-@@	I-Disease	-1	17854040
inf@@	I-Disease	-1	17854040
ected	I-Disease	-1	17854040
patients.	O	-1	17854040

S@@	O	-1	18221780
e@@	O	-1	18221780
x	O	-1	18221780
differences	O	-1	18221780
in	O	-1	18221780
N@@	B-Chemical	D016202	18221780
MD@@	I-Chemical	-1	18221780
A	I-Chemical	-1	18221780
antagonist	O	-1	18221780
enh@@	O	-1	18221780
ance@@	O	-1	18221780
ment	O	-1	18221780
of	O	-1	18221780
morphine	B-Chemical	D009020	18221780
anti@@	O	-1	18221780
hyperalge@@	O	-1	18221780
sia	O	-1	18221780
in	O	-1	18221780
a	O	-1	18221780
cap@@	B-Chemical	D002211	18221780
sa@@	I-Chemical	-1	18221780
icin	I-Chemical	-1	18221780
model	O	-1	18221780
of	O	-1	18221780
per@@	O	-1	18221780
sist@@	O	-1	18221780
ent	O	-1	18221780
pain	B-Disease	D010146	18221780
:	O	-1	18221780
compar@@	O	-1	18221780
is@@	O	-1	18221780
ons	O	-1	18221780
to	O	-1	18221780
two	O	-1	18221780
models	O	-1	18221780
of	O	-1	18221780
acute	B-Disease	D059787	18221780
pain	I-Disease	-1	18221780
.	O	-1	18221780
In	O	-1	18221780
acute	B-Disease	D059787	18221780
pain	I-Disease	-1	18221780
model@@	O	-1	18221780
s,	O	-1	18221780
N@@	B-Chemical	D016202	18221780
-@@	I-Chemical	-1	18221780
methyl@@	I-Chemical	-1	18221780
-@@	I-Chemical	-1	18221780
D-@@	I-Chemical	-1	18221780
as@@	I-Chemical	-1	18221780
part@@	I-Chemical	-1	18221780
ate	I-Chemical	-1	18221780
(	O	-1	18221780
N@@	B-Chemical	D016202	18221780
MD@@	I-Chemical	-1	18221780
A	I-Chemical	-1	18221780
)	O	-1	18221780
antagonist@@	O	-1	18221780
s	O	-1	18221780
enh@@	O	-1	18221780
ance	O	-1	18221780
the	O	-1	18221780
ant@@	O	-1	18221780
in@@	O	-1	18221780
ocicep@@	O	-1	18221780
tive	O	-1	18221780
effects	O	-1	18221780
of	O	-1	18221780
morphine	B-Chemical	D009020	18221780
to	O	-1	18221780
a	O	-1	18221780
greater	O	-1	18221780
ext@@	O	-1	18221780
ent	O	-1	18221780
in	O	-1	18221780
mal@@	O	-1	18221780
es	O	-1	18221780
than	O	-1	18221780
femal@@	O	-1	18221780
es.	O	-1	18221780
The	O	-1	18221780
pur@@	O	-1	18221780
p@@	O	-1	18221780
ose	O	-1	18221780
of	O	-1	18221780
this	O	-1	18221780
investig@@	O	-1	18221780
ation	O	-1	18221780
was	O	-1	18221780
to	O	-1	18221780
exten@@	O	-1	18221780
d	O	-1	18221780
these	O	-1	18221780
findings	O	-1	18221780
to	O	-1	18221780
a	O	-1	18221780
per@@	O	-1	18221780
sist@@	O	-1	18221780
ent	O	-1	18221780
pain	B-Disease	D010146	18221780
model	O	-1	18221780
which	O	-1	18221780
could	O	-1	18221780
be	O	-1	18221780
dist@@	O	-1	18221780
ing@@	O	-1	18221780
u@@	O	-1	18221780
ished	O	-1	18221780
from	O	-1	18221780
acute	B-Disease	D059787	18221780
pain	I-Disease	-1	18221780
models	O	-1	18221780
on	O	-1	18221780
the	O	-1	18221780
b@@	O	-1	18221780
asis	O	-1	18221780
of	O	-1	18221780
the	O	-1	18221780
n@@	O	-1	18221780
ocicep@@	O	-1	18221780
tive	O	-1	18221780
fib@@	O	-1	18221780
ers	O	-1	18221780
activ@@	O	-1	18221780
at@@	O	-1	18221780
ed,	O	-1	18221780
neuro@@	O	-1	18221780
chemical	O	-1	18221780
sub@@	O	-1	18221780
strat@@	O	-1	18221780
es,	O	-1	18221780
and	O	-1	18221780
duration	O	-1	18221780
of	O	-1	18221780
the	O	-1	18221780
n@@	O	-1	18221780
ocicep@@	O	-1	18221780
tive	O	-1	18221780
stimul@@	O	-1	18221780
us.	O	-1	18221780
To	O	-1	18221780
this	O	-1	18221780
en@@	O	-1	18221780
d,	O	-1	18221780
per@@	O	-1	18221780
sist@@	O	-1	18221780
ent	O	-1	18221780
hyperalge@@	B-Disease	D006930	18221780
sia	I-Disease	-1	18221780
was	O	-1	18221780
induced	O	-1	18221780
by	O	-1	18221780
administration	O	-1	18221780
of	O	-1	18221780
cap@@	B-Chemical	D002211	18221780
sa@@	I-Chemical	-1	18221780
icin	I-Chemical	-1	18221780
in	O	-1	18221780
the	O	-1	18221780
t@@	O	-1	18221780
a@@	O	-1	18221780
il	O	-1	18221780
of	O	-1	18221780
g@@	O	-1	18221780
on@@	O	-1	18221780
ad@@	O	-1	18221780
ally	O	-1	18221780
int@@	O	-1	18221780
ac@@	O	-1	18221780
t	O	-1	18221780
F@@	O	-1	18221780
34@@	O	-1	18221780
4	O	-1	18221780
rats,	O	-1	18221780
following	O	-1	18221780
which	O	-1	18221780
the	O	-1	18221780
t@@	O	-1	18221780
a@@	O	-1	18221780
il	O	-1	18221780
was	O	-1	18221780
im@@	O	-1	18221780
mer@@	O	-1	18221780
sed	O	-1	18221780
in	O	-1	18221780
a	O	-1	18221780
mil@@	O	-1	18221780
d@@	O	-1	18221780
ly	O	-1	18221780
no@@	O	-1	18221780
xi@@	O	-1	18221780
ous	O	-1	18221780
ther@@	O	-1	18221780
m@@	O	-1	18221780
al	O	-1	18221780
stimul@@	O	-1	18221780
us,	O	-1	18221780
and	O	-1	18221780
t@@	O	-1	18221780
ail@@	O	-1	18221780
-@@	O	-1	18221780
withdrawal	O	-1	18221780
lat@@	O	-1	18221780
en@@	O	-1	18221780
ci@@	O	-1	18221780
es	O	-1	18221780
meas@@	O	-1	18221780
ure@@	O	-1	18221780
d.	O	-1	18221780
F@@	O	-1	18221780
or	O	-1	18221780
compar@@	O	-1	18221780
is@@	O	-1	18221780
on@@	O	-1	18221780
,	O	-1	18221780
tests	O	-1	18221780
were	O	-1	18221780
con@@	O	-1	18221780
duc@@	O	-1	18221780
ted	O	-1	18221780
in	O	-1	18221780
two	O	-1	18221780
acute	B-Disease	D059787	18221780
pain	I-Disease	-1	18221780
model@@	O	-1	18221780
s,	O	-1	18221780
the	O	-1	18221780
h@@	O	-1	18221780
ot@@	O	-1	18221780
pl@@	O	-1	18221780
ate	O	-1	18221780
and	O	-1	18221780
war@@	O	-1	18221780
m	O	-1	18221780
w@@	O	-1	18221780
at@@	O	-1	18221780
er	O	-1	18221780
t@@	O	-1	18221780
ail@@	O	-1	18221780
-@@	O	-1	18221780
withdrawal	O	-1	18221780
proce@@	O	-1	18221780
du@@	O	-1	18221780
res@@	O	-1	18221780
.	O	-1	18221780
In	O	-1	18221780
mal@@	O	-1	18221780
es,	O	-1	18221780
the	O	-1	18221780
non-@@	O	-1	18221780
comp@@	O	-1	18221780
e@@	O	-1	18221780
ti@@	O	-1	18221780
tive	O	-1	18221780
N@@	B-Chemical	D016202	18221780
MD@@	I-Chemical	-1	18221780
A	I-Chemical	-1	18221780
antagonist	O	-1	18221780
de@@	B-Chemical	D003915	18221780
x@@	I-Chemical	-1	18221780
tro@@	I-Chemical	-1	18221780
meth@@	I-Chemical	-1	18221780
or@@	I-Chemical	-1	18221780
ph@@	I-Chemical	-1	18221780
an	I-Chemical	-1	18221780
enhanced	O	-1	18221780
the	O	-1	18221780
anti@@	O	-1	18221780
hyperalge@@	O	-1	18221780
sic	O	-1	18221780
effect	O	-1	18221780
of	O	-1	18221780
low	O	-1	18221780
to	O	-1	18221780
moder@@	O	-1	18221780
ate	O	-1	18221780
doses	O	-1	18221780
of	O	-1	18221780
morphine	B-Chemical	D009020	18221780
in	O	-1	18221780
a	O	-1	18221780
dose-@@	O	-1	18221780
and	O	-1	18221780
ti@@	O	-1	18221780
me@@	O	-1	18221780
-@@	O	-1	18221780
dependent	O	-1	18221780
man@@	O	-1	18221780
ner@@	O	-1	18221780
.	O	-1	18221780
Ac@@	O	-1	18221780
ros@@	O	-1	18221780
s	O	-1	18221780
the	O	-1	18221780
doses	O	-1	18221780
and	O	-1	18221780
pretreatment	O	-1	18221780
times	O	-1	18221780
ex@@	O	-1	18221780
am@@	O	-1	18221780
ine@@	O	-1	18221780
d,	O	-1	18221780
enh@@	O	-1	18221780
ance@@	O	-1	18221780
ment	O	-1	18221780
was	O	-1	18221780
not	O	-1	18221780
observed	O	-1	18221780
in	O	-1	18221780
femal@@	O	-1	18221780
es.	O	-1	18221780
E@@	O	-1	18221780
n@@	O	-1	18221780
h@@	O	-1	18221780
ance@@	O	-1	18221780
ment	O	-1	18221780
of	O	-1	18221780
morphine	B-Chemical	D009020	18221780
ant@@	O	-1	18221780
in@@	O	-1	18221780
ocicep@@	O	-1	18221780
tion	O	-1	18221780
by	O	-1	18221780
de@@	B-Chemical	D003915	18221780
x@@	I-Chemical	-1	18221780
tro@@	I-Chemical	-1	18221780
meth@@	I-Chemical	-1	18221780
or@@	I-Chemical	-1	18221780
ph@@	I-Chemical	-1	18221780
an	I-Chemical	-1	18221780
was	O	-1	18221780
seen	O	-1	18221780
in	O	-1	18221780
both	O	-1	18221780
mal@@	O	-1	18221780
es	O	-1	18221780
and	O	-1	18221780
femal@@	O	-1	18221780
es	O	-1	18221780
in	O	-1	18221780
the	O	-1	18221780
acute	B-Disease	D059787	18221780
pain	I-Disease	-1	18221780
model@@	O	-1	18221780
s,	O	-1	18221780
with	O	-1	18221780
the	O	-1	18221780
mag@@	O	-1	18221780
nit@@	O	-1	18221780
ude	O	-1	18221780
of	O	-1	18221780
this	O	-1	18221780
effect	O	-1	18221780
being	O	-1	18221780
greater	O	-1	18221780
in	O	-1	18221780
mal@@	O	-1	18221780
es.	O	-1	18221780
These	O	-1	18221780
findings	O	-1	18221780
demon@@	O	-1	18221780
st@@	O	-1	18221780
rate	O	-1	18221780
a	O	-1	18221780
sex@@	O	-1	18221780
u@@	O	-1	18221780
all@@	O	-1	18221780
y-@@	O	-1	18221780
di@@	O	-1	18221780
morph@@	O	-1	18221780
ic	O	-1	18221780
inter@@	O	-1	18221780
action	O	-1	18221780
between	O	-1	18221780
N@@	B-Chemical	D016202	18221780
MD@@	I-Chemical	-1	18221780
A	I-Chemical	-1	18221780
antagonist@@	O	-1	18221780
s	O	-1	18221780
and	O	-1	18221780
morphine	B-Chemical	D009020	18221780
in	O	-1	18221780
a	O	-1	18221780
per@@	O	-1	18221780
sist@@	O	-1	18221780
ent	O	-1	18221780
pain	B-Disease	D010146	18221780
model	O	-1	18221780
that	O	-1	18221780
can	O	-1	18221780
be	O	-1	18221780
dist@@	O	-1	18221780
ing@@	O	-1	18221780
u@@	O	-1	18221780
ished	O	-1	18221780
from	O	-1	18221780
those	O	-1	18221780
observed	O	-1	18221780
in	O	-1	18221780
acute	B-Disease	D059787	18221780
pain	I-Disease	-1	18221780
model@@	O	-1	18221780
s.	O	-1	18221780

De@@	O	-1	18261172
ve@@	O	-1	18261172
lop@@	O	-1	18261172
ment	O	-1	18261172
of	O	-1	18261172
proteinuria	B-Disease	D011507	18261172
after	O	-1	18261172
s@@	O	-1	18261172
wit@@	O	-1	18261172
ch	O	-1	18261172
to	O	-1	18261172
sirolimus	B-Chemical	D020123	18261172
-@@	O	-1	18261172
bas@@	O	-1	18261172
ed	O	-1	18261172
immunosup@@	O	-1	18261172
pression	O	-1	18261172
in	O	-1	18261172
long-term	O	-1	18261172
cardiac	O	-1	18261172
transplant	O	-1	18261172
patients.	O	-1	18261172
C@@	O	-1	18261172
al@@	O	-1	18261172
c@@	O	-1	18261172
ine@@	O	-1	18261172
ur@@	O	-1	18261172
in-@@	O	-1	18261172
inhibitor	O	-1	18261172
therapy	O	-1	18261172
can	O	-1	18261172
le@@	O	-1	18261172
ad	O	-1	18261172
to	O	-1	18261172
renal	B-Disease	D007674	18261172
dysfunction	I-Disease	-1	18261172
in	O	-1	18261172
heart	O	-1	18261172
transplant@@	O	-1	18261172
ation	O	-1	18261172
patients.	O	-1	18261172
The	O	-1	18261172
novel	O	-1	18261172
immunosup@@	O	-1	18261172
pressive	O	-1	18261172
(@@	O	-1	18261172
I@@	O	-1	18261172
S)	O	-1	18261172
drug	O	-1	18261172
si@@	B-Chemical	D020123	18261172
ro@@	I-Chemical	-1	18261172
l@@	I-Chemical	-1	18261172
m@@	I-Chemical	-1	18261172
us	I-Chemical	-1	18261172
(	O	-1	18261172
S@@	B-Chemical	D020123	18261172
r@@	I-Chemical	-1	18261172
l	I-Chemical	-1	18261172
)	O	-1	18261172
l@@	O	-1	18261172
ac@@	O	-1	18261172
k@@	O	-1	18261172
s	O	-1	18261172
nephro@@	B-Disease	D007674	18261172
toxic	I-Disease	-1	18261172
effect@@	O	-1	18261172
s;	O	-1	18261172
however,	O	-1	18261172
proteinuria	B-Disease	D011507	18261172
associated	O	-1	18261172
with	O	-1	18261172
S@@	B-Chemical	D020123	18261172
r@@	I-Chemical	-1	18261172
l	I-Chemical	-1	18261172
has	O	-1	18261172
been	O	-1	18261172
reported	O	-1	18261172
following	O	-1	18261172
renal	O	-1	18261172
transplant@@	O	-1	18261172
ation.	O	-1	18261172
In	O	-1	18261172
cardiac	O	-1	18261172
transplant@@	O	-1	18261172
ation,	O	-1	18261172
the	O	-1	18261172
incidence	O	-1	18261172
of	O	-1	18261172
proteinuria	B-Disease	D011507	18261172
associated	O	-1	18261172
with	O	-1	18261172
S@@	B-Chemical	D020123	18261172
r@@	I-Chemical	-1	18261172
l	I-Chemical	-1	18261172
is	O	-1	18261172
un@@	O	-1	18261172
know@@	O	-1	18261172
n@@	O	-1	18261172
.	O	-1	18261172
In	O	-1	18261172
this	O	-1	18261172
study,	O	-1	18261172
long-term	O	-1	18261172
cardiac	O	-1	18261172
transplant	O	-1	18261172
patients	O	-1	18261172
were	O	-1	18261172
switch@@	O	-1	18261172
ed	O	-1	18261172
from	O	-1	18261172
cyclospor@@	B-Chemical	D016572	18261172
ine	I-Chemical	-1	18261172
to	O	-1	18261172
S@@	B-Chemical	D020123	18261172
r@@	I-Chemical	-1	18261172
l	I-Chemical	-1	18261172
-@@	O	-1	18261172
bas@@	O	-1	18261172
ed	O	-1	18261172
I@@	O	-1	18261172
S@@	O	-1	18261172
.	O	-1	18261172
Con@@	O	-1	18261172
comit@@	O	-1	18261172
ant	O	-1	18261172
I@@	O	-1	18261172
S	O	-1	18261172
consist@@	O	-1	18261172
ed	O	-1	18261172
of	O	-1	18261172
my@@	B-Chemical	C063008	18261172
co@@	I-Chemical	-1	18261172
phen@@	I-Chemical	-1	18261172
ol@@	I-Chemical	-1	18261172
ate	I-Chemical	-1	18261172
mo@@	I-Chemical	-1	18261172
fe@@	I-Chemical	-1	18261172
ti@@	I-Chemical	-1	18261172
l	I-Chemical	-1	18261172
+/-	O	-1	18261172
steroid@@	B-Chemical	D013256	18261172
s	I-Chemical	-1	18261172
.	O	-1	18261172
Pro@@	O	-1	18261172
te@@	O	-1	18261172
in@@	O	-1	18261172
uria	O	-1	18261172
increased	O	-1	18261172
significantly	O	-1	18261172
from	O	-1	18261172
a	O	-1	18261172
median	O	-1	18261172
of	O	-1	18261172
0.@@	O	-1	18261172
13	O	-1	18261172
g/@@	O	-1	18261172
day	O	-1	18261172
(@@	O	-1	18261172
range	O	-1	18261172
0-@@	O	-1	18261172
5.@@	O	-1	18261172
7@@	O	-1	18261172
)	O	-1	18261172
pres@@	O	-1	18261172
wit@@	O	-1	18261172
ch	O	-1	18261172
to	O	-1	18261172
0.@@	O	-1	18261172
2@@	O	-1	18261172
3	O	-1	18261172
g/@@	O	-1	18261172
day	O	-1	18261172
(@@	O	-1	18261172
0-@@	O	-1	18261172
9.@@	O	-1	18261172
8@@	O	-1	18261172
8@@	O	-1	18261172
)	O	-1	18261172
at	O	-1	18261172
24	O	-1	18261172
months	O	-1	18261172
post@@	O	-1	18261172
s@@	O	-1	18261172
wit@@	O	-1	18261172
ch	O	-1	18261172
(p	O	-1	18261172
=	O	-1	18261172
0.00@@	O	-1	18261172
2@@	O	-1	18261172
4@@	O	-1	18261172
).	O	-1	18261172
B@@	O	-1	18261172
e@@	O	-1	18261172
fore	O	-1	18261172
the	O	-1	18261172
switch@@	O	-1	18261172
,	O	-1	18261172
1@@	O	-1	18261172
1.@@	O	-1	18261172
5%	O	-1	18261172
of	O	-1	18261172
patients	O	-1	18261172
had	O	-1	18261172
high-@@	O	-1	18261172
gra@@	O	-1	18261172
de	O	-1	18261172
proteinuria	B-Disease	D011507	18261172
(@@	O	-1	18261172
>@@	O	-1	18261172
1.@@	O	-1	18261172
0	O	-1	18261172
g/@@	O	-1	18261172
day@@	O	-1	18261172
);	O	-1	18261172
this	O	-1	18261172
increased	O	-1	18261172
to	O	-1	18261172
2@@	O	-1	18261172
2.@@	O	-1	18261172
9@@	O	-1	18261172
%	O	-1	18261172
post@@	O	-1	18261172
s@@	O	-1	18261172
wit@@	O	-1	18261172
ch	O	-1	18261172
(p	O	-1	18261172
=	O	-1	18261172
0.00@@	O	-1	18261172
6@@	O	-1	18261172
).	O	-1	18261172
AC@@	B-Chemical	D000806	18261172
E	I-Chemical	-1	18261172
inhibitor	I-Chemical	-1	18261172
and	O	-1	18261172
angiotens@@	B-Chemical	D057911	18261172
in-@@	I-Chemical	-1	18261172
rele@@	I-Chemical	-1	18261172
as@@	I-Chemical	-1	18261172
ing	I-Chemical	-1	18261172
block@@	I-Chemical	-1	18261172
er	I-Chemical	-1	18261172
(	O	-1	18261172
A@@	B-Chemical	D057911	18261172
R@@	I-Chemical	-1	18261172
B	I-Chemical	-1	18261172
)	O	-1	18261172
therapy	O	-1	18261172
reduced	O	-1	18261172
proteinuria	B-Disease	D011507	18261172
develop@@	O	-1	18261172
ment.	O	-1	18261172
Patients	O	-1	18261172
without	O	-1	18261172
proteinuria	B-Disease	D011507	18261172
had	O	-1	18261172
increased	O	-1	18261172
renal	O	-1	18261172
function	O	-1	18261172
(@@	O	-1	18261172
median	O	-1	18261172
4@@	O	-1	18261172
2.@@	O	-1	18261172
5	O	-1	18261172
vs.	O	-1	18261172
6@@	O	-1	18261172
4.@@	O	-1	18261172
1,	O	-1	18261172
p	O	-1	18261172
=	O	-1	18261172
0.@@	O	-1	18261172
25@@	O	-1	18261172
),	O	-1	18261172
whereas	O	-1	18261172
patients	O	-1	18261172
who	O	-1	18261172
developed	O	-1	18261172
high-@@	O	-1	18261172
gra@@	O	-1	18261172
de	O	-1	18261172
proteinuria	B-Disease	D011507	18261172
showed	O	-1	18261172
decreased	O	-1	18261172
renal	O	-1	18261172
function	O	-1	18261172
at	O	-1	18261172
the	O	-1	18261172
end	O	-1	18261172
of	O	-1	18261172
follow-up	O	-1	18261172
(@@	O	-1	18261172
median	O	-1	18261172
3@@	O	-1	18261172
9.@@	O	-1	18261172
6	O	-1	18261172
vs.	O	-1	18261172
2@@	O	-1	18261172
9.@@	O	-1	18261172
2,	O	-1	18261172
p	O	-1	18261172
=	O	-1	18261172
0.@@	O	-1	18261172
12@@	O	-1	18261172
5@@	O	-1	18261172
).	O	-1	18261172
Th@@	O	-1	18261172
us,	O	-1	18261172
proteinuria	B-Disease	D011507	18261172
may	O	-1	18261172
deve@@	O	-1	18261172
lo@@	O	-1	18261172
p	O	-1	18261172
in	O	-1	18261172
cardiac	O	-1	18261172
transplant	O	-1	18261172
patients	O	-1	18261172
after	O	-1	18261172
s@@	O	-1	18261172
wit@@	O	-1	18261172
ch	O	-1	18261172
to	O	-1	18261172
S@@	B-Chemical	D020123	18261172
r@@	I-Chemical	-1	18261172
l	I-Chemical	-1	18261172
,	O	-1	18261172
which	O	-1	18261172
may	O	-1	18261172
have	O	-1	18261172
an	O	-1	18261172
adverse	O	-1	18261172
effect	O	-1	18261172
on	O	-1	18261172
renal	O	-1	18261172
function	O	-1	18261172
in	O	-1	18261172
these	O	-1	18261172
patients.	O	-1	18261172
S@@	B-Chemical	D020123	18261172
r@@	I-Chemical	-1	18261172
l	I-Chemical	-1	18261172
should	O	-1	18261172
be	O	-1	18261172
used	O	-1	18261172
with	O	-1	18261172
AC@@	B-Chemical	D000806	18261172
E@@	I-Chemical	-1	18261172
i	I-Chemical	-1	18261172
/	O	-1	18261172
A@@	B-Chemical	D057911	18261172
R@@	I-Chemical	-1	18261172
B	I-Chemical	-1	18261172
therapy	O	-1	18261172
and	O	-1	18261172
patients	O	-1	18261172
monit@@	O	-1	18261172
o@@	O	-1	18261172
red	O	-1	18261172
for	O	-1	18261172
proteinuria	B-Disease	D011507	18261172
and	O	-1	18261172
increased	O	-1	18261172
renal	B-Disease	D007674	18261172
dysfunction	I-Disease	-1	18261172
.	O	-1	18261172

S@@	O	-1	18329269
yn@@	O	-1	18329269
thesis	O	-1	18329269
of	O	-1	18329269
N@@	B-Chemical	D010642	18329269
-@@	I-Chemical	-1	18329269
pyri@@	I-Chemical	-1	18329269
mid@@	I-Chemical	-1	18329269
in@@	I-Chemical	-1	18329269
yl@@	I-Chemical	-1	18329269
-@@	I-Chemical	-1	18329269
2-@@	I-Chemical	-1	18329269
phen@@	I-Chemical	-1	18329269
oxy@@	I-Chemical	-1	18329269
acet@@	I-Chemical	-1	18329269
ami@@	I-Chemical	-1	18329269
des	I-Chemical	-1	18329269
as	O	-1	18329269
aden@@	B-Chemical	D000241	18329269
os@@	I-Chemical	-1	18329269
ine	I-Chemical	-1	18329269
A@@	O	-1	18329269
2@@	O	-1	18329269
A	O	-1	18329269
receptor	O	-1	18329269
antagonist@@	O	-1	18329269
s.	O	-1	18329269
A	O	-1	18329269
seri@@	O	-1	18329269
es	O	-1	18329269
of	O	-1	18329269
N@@	B-Chemical	D010642	18329269
-@@	I-Chemical	-1	18329269
pyri@@	I-Chemical	-1	18329269
mid@@	I-Chemical	-1	18329269
in@@	I-Chemical	-1	18329269
yl@@	I-Chemical	-1	18329269
-@@	I-Chemical	-1	18329269
2-@@	I-Chemical	-1	18329269
phen@@	I-Chemical	-1	18329269
oxy@@	I-Chemical	-1	18329269
acet@@	I-Chemical	-1	18329269
amide	I-Chemical	-1	18329269
aden@@	B-Chemical	D000241	18329269
os@@	I-Chemical	-1	18329269
ine	I-Chemical	-1	18329269
A@@	O	-1	18329269
(2@@	O	-1	18329269
A@@	O	-1	18329269
)	O	-1	18329269
antagonist@@	O	-1	18329269
s	O	-1	18329269
is	O	-1	18329269
descri@@	O	-1	18329269
be@@	O	-1	18329269
d.	O	-1	18329269
S@@	O	-1	18329269
A@@	O	-1	18329269
R	O	-1	18329269
studies	O	-1	18329269
l@@	O	-1	18329269
ed	O	-1	18329269
to	O	-1	18329269
comp@@	O	-1	18329269
ound	O	-1	18329269
14	O	-1	18329269
with	O	-1	18329269
ex@@	O	-1	18329269
cell@@	O	-1	18329269
ent	O	-1	18329269
poten@@	O	-1	18329269
c@@	O	-1	18329269
y	O	-1	18329269
(@@	O	-1	18329269
K@@	O	-1	18329269
(@@	O	-1	18329269
i@@	O	-1	18329269
)	O	-1	18329269
=	O	-1	18329269
0.@@	O	-1	18329269
4	O	-1	18329269
n@@	O	-1	18329269
M@@	O	-1	18329269
),	O	-1	18329269
sel@@	O	-1	18329269
ec@@	O	-1	18329269
tivity	O	-1	18329269
(A@@	O	-1	18329269
(1@@	O	-1	18329269
)@@	O	-1	18329269
/@@	O	-1	18329269
A@@	O	-1	18329269
(2@@	O	-1	18329269
A@@	O	-1	18329269
)	O	-1	18329269
>	O	-1	18329269
10@@	O	-1	18329269
0@@	O	-1	18329269
),	O	-1	18329269
and	O	-1	18329269
efficacy	O	-1	18329269
(@@	O	-1	18329269
M@@	O	-1	18329269
E@@	O	-1	18329269
D	O	-1	18329269
10	O	-1	18329269
mg/kg	O	-1	18329269
p.@@	O	-1	18329269
o@@	O	-1	18329269
.)	O	-1	18329269
in	O	-1	18329269
the	O	-1	18329269
rat	O	-1	18329269
haloperidol	B-Chemical	D006220	18329269
-induced	O	-1	18329269
cat@@	B-Disease	D002375	18329269
al@@	I-Disease	-1	18329269
ep@@	I-Disease	-1	18329269
sy	I-Disease	-1	18329269
model	O	-1	18329269
for	O	-1	18329269
Parkinson's	B-Disease	D010300	18329269
disease	I-Disease	-1	18329269
.	O	-1	18329269

M@@	B-Chemical	D008694	18410508
eth@@	I-Chemical	-1	18410508
amphetamine	I-Chemical	-1	18410508
-induced	O	-1	18410508
neuro@@	B-Disease	D020258	18410508
toxicity	I-Disease	-1	18410508
and	O	-1	18410508
micro@@	O	-1	18410508
g@@	O	-1	18410508
lial	O	-1	18410508
activation	O	-1	18410508
are	O	-1	18410508
not	O	-1	18410508
mediated	O	-1	18410508
by	O	-1	18410508
frac@@	O	-1	18410508
t@@	O	-1	18410508
al@@	O	-1	18410508
k@@	O	-1	18410508
ine	O	-1	18410508
receptor	O	-1	18410508
sign@@	O	-1	18410508
al@@	O	-1	18410508
ing.	O	-1	18410508
M@@	B-Chemical	D008694	18410508
eth@@	I-Chemical	-1	18410508
amphetamine	I-Chemical	-1	18410508
(	O	-1	18410508
MET@@	B-Chemical	D008694	18410508
H	I-Chemical	-1	18410508
)	O	-1	18410508
dam@@	O	-1	18410508
ages	O	-1	18410508
dopamine	B-Chemical	D004298	18410508
(	O	-1	18410508
D@@	B-Chemical	D004298	18410508
A	I-Chemical	-1	18410508
)	O	-1	18410508
nerve	O	-1	18410508
en@@	O	-1	18410508
d@@	O	-1	18410508
ings	O	-1	18410508
by	O	-1	18410508
a	O	-1	18410508
pro@@	O	-1	18410508
cess	O	-1	18410508
that	O	-1	18410508
has	O	-1	18410508
been	O	-1	18410508
lin@@	O	-1	18410508
ked	O	-1	18410508
to	O	-1	18410508
micro@@	O	-1	18410508
g@@	O	-1	18410508
lial	O	-1	18410508
activation	O	-1	18410508
but	O	-1	18410508
the	O	-1	18410508
sign@@	O	-1	18410508
al@@	O	-1	18410508
ing	O	-1	18410508
path@@	O	-1	18410508
w@@	O	-1	18410508
ays	O	-1	18410508
that	O	-1	18410508
medi@@	O	-1	18410508
ate	O	-1	18410508
this	O	-1	18410508
response	O	-1	18410508
have	O	-1	18410508
not	O	-1	18410508
y@@	O	-1	18410508
et	O	-1	18410508
been	O	-1	18410508
del@@	O	-1	18410508
ine@@	O	-1	18410508
ated.	O	-1	18410508
C@@	O	-1	18410508
ar@@	O	-1	18410508
d@@	O	-1	18410508
on@@	O	-1	18410508
a	O	-1	18410508
et	O	-1	18410508
al.	O	-1	18410508
[@@	O	-1	18410508
N@@	O	-1	18410508
at@@	O	-1	18410508
.	O	-1	18410508
Ne@@	O	-1	18410508
uro@@	O	-1	18410508
s@@	O	-1	18410508
ci@@	O	-1	18410508
.	O	-1	18410508
9	O	-1	18410508
(2@@	O	-1	18410508
0@@	O	-1	18410508
0@@	O	-1	18410508
6@@	O	-1	18410508
),	O	-1	18410508
9@@	O	-1	18410508
17@@	O	-1	18410508
]	O	-1	18410508
rec@@	O	-1	18410508
ently	O	-1	18410508
identi@@	O	-1	18410508
fied	O	-1	18410508
the	O	-1	18410508
micro@@	O	-1	18410508
g@@	O	-1	18410508
li@@	O	-1	18410508
al@@	O	-1	18410508
-@@	O	-1	18410508
specific	O	-1	18410508
frac@@	O	-1	18410508
t@@	O	-1	18410508
al@@	O	-1	18410508
k@@	O	-1	18410508
ine	O	-1	18410508
receptor	O	-1	18410508
(C@@	O	-1	18410508
X@@	O	-1	18410508
3@@	O	-1	18410508
CR@@	O	-1	18410508
1)	O	-1	18410508
as	O	-1	18410508
an	O	-1	18410508
important	O	-1	18410508
medi@@	O	-1	18410508
at@@	O	-1	18410508
or	O	-1	18410508
of	O	-1	18410508
MP@@	B-Chemical	D015632	18410508
T@@	I-Chemical	-1	18410508
P	I-Chemical	-1	18410508
-induced	O	-1	18410508
neuro@@	B-Disease	D009422	18410508
de@@	I-Disease	-1	18410508
generation	I-Disease	-1	18410508
of	O	-1	18410508
D@@	B-Chemical	D004298	18410508
A	I-Chemical	-1	18410508
neuron@@	O	-1	18410508
s.	O	-1	18410508
B@@	O	-1	18410508
ecause	O	-1	18410508
the	O	-1	18410508
C@@	B-Disease	D009422	18410508
N@@	I-Disease	-1	18410508
S	I-Disease	-1	18410508
damage	I-Disease	-1	18410508
caused	O	-1	18410508
by	O	-1	18410508
MET@@	B-Chemical	D008694	18410508
H	I-Chemical	-1	18410508
and	O	-1	18410508
MP@@	B-Chemical	D015632	18410508
T@@	I-Chemical	-1	18410508
P	I-Chemical	-1	18410508
is	O	-1	18410508
high@@	O	-1	18410508
ly	O	-1	18410508
selective	O	-1	18410508
for	O	-1	18410508
the	O	-1	18410508
D@@	B-Chemical	D004298	18410508
A	I-Chemical	-1	18410508
neuron@@	O	-1	18410508
al	O	-1	18410508
system	O	-1	18410508
in	O	-1	18410508
mouse	O	-1	18410508
models	O	-1	18410508
of	O	-1	18410508
neuro@@	B-Disease	D020258	18410508
toxicity	I-Disease	-1	18410508
,	O	-1	18410508
we	O	-1	18410508
hypo@@	O	-1	18410508
the@@	O	-1	18410508
si@@	O	-1	18410508
zed	O	-1	18410508
that	O	-1	18410508
the	O	-1	18410508
C@@	O	-1	18410508
X@@	O	-1	18410508
3@@	O	-1	18410508
CR@@	O	-1	18410508
1	O	-1	18410508
pl@@	O	-1	18410508
ays	O	-1	18410508
a	O	-1	18410508
role	O	-1	18410508
in	O	-1	18410508
MET@@	B-Chemical	D008694	18410508
H	I-Chemical	-1	18410508
-induced	O	-1	18410508
neuro@@	B-Disease	D020258	18410508
toxicity	I-Disease	-1	18410508
and	O	-1	18410508
micro@@	O	-1	18410508
g@@	O	-1	18410508
lial	O	-1	18410508
activ@@	O	-1	18410508
ation.	O	-1	18410508
M@@	O	-1	18410508
ic@@	O	-1	18410508
e	O	-1	18410508
in	O	-1	18410508
which	O	-1	18410508
the	O	-1	18410508
C@@	O	-1	18410508
X@@	O	-1	18410508
3@@	O	-1	18410508
CR@@	O	-1	18410508
1	O	-1	18410508
gen@@	O	-1	18410508
e	O	-1	18410508
has	O	-1	18410508
been	O	-1	18410508
de@@	O	-1	18410508
le@@	O	-1	18410508
ted	O	-1	18410508
and	O	-1	18410508
re@@	O	-1	18410508
pl@@	O	-1	18410508
ac@@	O	-1	18410508
ed	O	-1	18410508
with	O	-1	18410508
a	O	-1	18410508
c@@	O	-1	18410508
D@@	O	-1	18410508
NA	O	-1	18410508
en@@	O	-1	18410508
co@@	O	-1	18410508
ding	O	-1	18410508
enhanced	O	-1	18410508
gre@@	O	-1	18410508
en	O	-1	18410508
fluo@@	O	-1	18410508
res@@	O	-1	18410508
c@@	O	-1	18410508
ent	O	-1	18410508
protein	O	-1	18410508
(@@	O	-1	18410508
e@@	O	-1	18410508
GF@@	O	-1	18410508
P)	O	-1	18410508
were	O	-1	18410508
treated	O	-1	18410508
with	O	-1	18410508
MET@@	B-Chemical	D008694	18410508
H	I-Chemical	-1	18410508
and	O	-1	18410508
examined	O	-1	18410508
for	O	-1	18410508
stri@@	O	-1	18410508
atal	O	-1	18410508
neuro@@	B-Disease	D020258	18410508
toxicity	I-Disease	-1	18410508
.	O	-1	18410508
MET@@	B-Chemical	D008694	18410508
H	I-Chemical	-1	18410508
deple@@	O	-1	18410508
ted	O	-1	18410508
D@@	B-Chemical	D004298	18410508
A	I-Chemical	-1	18410508
,	O	-1	18410508
caused	O	-1	18410508
micro@@	O	-1	18410508
g@@	O	-1	18410508
lial	O	-1	18410508
activ@@	O	-1	18410508
ation,	O	-1	18410508
and	O	-1	18410508
increased	O	-1	18410508
body	O	-1	18410508
tem@@	O	-1	18410508
per@@	O	-1	18410508
at@@	O	-1	18410508
ure	O	-1	18410508
in	O	-1	18410508
C@@	O	-1	18410508
X@@	O	-1	18410508
3@@	O	-1	18410508
CR@@	O	-1	18410508
1	O	-1	18410508
k@@	O	-1	18410508
n@@	O	-1	18410508
oc@@	O	-1	18410508
k@@	O	-1	18410508
out	O	-1	18410508
mice	O	-1	18410508
to	O	-1	18410508
the	O	-1	18410508
same	O	-1	18410508
ext@@	O	-1	18410508
ent	O	-1	18410508
and	O	-1	18410508
over	O	-1	18410508
the	O	-1	18410508
same	O	-1	18410508
time	O	-1	18410508
course	O	-1	18410508
seen	O	-1	18410508
in	O	-1	18410508
wil@@	O	-1	18410508
d-@@	O	-1	18410508
type	O	-1	18410508
controls.	O	-1	18410508
The	O	-1	18410508
effects	O	-1	18410508
of	O	-1	18410508
MET@@	B-Chemical	D008694	18410508
H	I-Chemical	-1	18410508
in	O	-1	18410508
C@@	O	-1	18410508
X@@	O	-1	18410508
3@@	O	-1	18410508
CR@@	O	-1	18410508
1	O	-1	18410508
k@@	O	-1	18410508
n@@	O	-1	18410508
oc@@	O	-1	18410508
k@@	O	-1	18410508
out	O	-1	18410508
mice	O	-1	18410508
were	O	-1	18410508
not	O	-1	18410508
gen@@	O	-1	18410508
der@@	O	-1	18410508
-@@	O	-1	18410508
dependent	O	-1	18410508
and	O	-1	18410508
did	O	-1	18410508
not	O	-1	18410508
exten@@	O	-1	18410508
d	O	-1	18410508
be@@	O	-1	18410508
y@@	O	-1	18410508
on@@	O	-1	18410508
d	O	-1	18410508
the	O	-1	18410508
striat@@	O	-1	18410508
um@@	O	-1	18410508
.	O	-1	18410508
S@@	O	-1	18410508
tri@@	O	-1	18410508
atal	O	-1	18410508
micro@@	O	-1	18410508
g@@	O	-1	18410508
li@@	O	-1	18410508
a	O	-1	18410508
ex@@	O	-1	18410508
press@@	O	-1	18410508
ing	O	-1	18410508
e@@	O	-1	18410508
GF@@	O	-1	18410508
P	O	-1	18410508
con@@	O	-1	18410508
sti@@	O	-1	18410508
tu@@	O	-1	18410508
ti@@	O	-1	18410508
vely	O	-1	18410508
show	O	-1	18410508
morph@@	O	-1	18410508
ological	O	-1	18410508
changes	O	-1	18410508
after	O	-1	18410508
MET@@	B-Chemical	D008694	18410508
H	I-Chemical	-1	18410508
that	O	-1	18410508
are	O	-1	18410508
character@@	O	-1	18410508
istic	O	-1	18410508
of	O	-1	18410508
activ@@	O	-1	18410508
ation.	O	-1	18410508
This	O	-1	18410508
response	O	-1	18410508
was	O	-1	18410508
re@@	O	-1	18410508
stric@@	O	-1	18410508
ted	O	-1	18410508
to	O	-1	18410508
the	O	-1	18410508
striat@@	O	-1	18410508
um	O	-1	18410508
and	O	-1	18410508
contrast@@	O	-1	18410508
ed	O	-1	18410508
sh@@	O	-1	18410508
ar@@	O	-1	18410508
p@@	O	-1	18410508
ly	O	-1	18410508
with	O	-1	18410508
un@@	O	-1	18410508
respon@@	O	-1	18410508
sive	O	-1	18410508
e@@	O	-1	18410508
GF@@	O	-1	18410508
P@@	O	-1	18410508
-@@	O	-1	18410508
micro@@	O	-1	18410508
g@@	O	-1	18410508
li@@	O	-1	18410508
a	O	-1	18410508
in	O	-1	18410508
sur@@	O	-1	18410508
ro@@	O	-1	18410508
un@@	O	-1	18410508
ding	O	-1	18410508
brain	O	-1	18410508
a@@	O	-1	18410508
reas	O	-1	18410508
that	O	-1	18410508
are	O	-1	18410508
not	O	-1	18410508
dam@@	O	-1	18410508
aged	O	-1	18410508
by	O	-1	18410508
MET@@	B-Chemical	D008694	18410508
H	I-Chemical	-1	18410508
.	O	-1	18410508
We	O	-1	18410508
concl@@	O	-1	18410508
ude	O	-1	18410508
from	O	-1	18410508
these	O	-1	18410508
studies	O	-1	18410508
that	O	-1	18410508
C@@	O	-1	18410508
X@@	O	-1	18410508
3@@	O	-1	18410508
CR@@	O	-1	18410508
1	O	-1	18410508
sign@@	O	-1	18410508
al@@	O	-1	18410508
ing	O	-1	18410508
does	O	-1	18410508
not	O	-1	18410508
mod@@	O	-1	18410508
ul@@	O	-1	18410508
ate	O	-1	18410508
MET@@	B-Chemical	D008694	18410508
H	I-Chemical	-1	18410508
neuro@@	B-Disease	D020258	18410508
toxicity	I-Disease	-1	18410508
or	O	-1	18410508
micro@@	O	-1	18410508
g@@	O	-1	18410508
lial	O	-1	18410508
activ@@	O	-1	18410508
ation.	O	-1	18410508
F@@	O	-1	18410508
ur@@	O	-1	18410508
ther@@	O	-1	18410508
mo@@	O	-1	18410508
re,	O	-1	18410508
it	O	-1	18410508
appear@@	O	-1	18410508
s	O	-1	18410508
that	O	-1	18410508
striat@@	O	-1	18410508
al@@	O	-1	18410508
-@@	O	-1	18410508
re@@	O	-1	18410508
si@@	O	-1	18410508
d@@	O	-1	18410508
ent	O	-1	18410508
micro@@	O	-1	18410508
g@@	O	-1	18410508
li@@	O	-1	18410508
a	O	-1	18410508
respon@@	O	-1	18410508
d	O	-1	18410508
to	O	-1	18410508
MET@@	B-Chemical	D008694	18410508
H	I-Chemical	-1	18410508
with	O	-1	18410508
an	O	-1	18410508
activation	O	-1	18410508
cas@@	O	-1	18410508
c@@	O	-1	18410508
ade	O	-1	18410508
and	O	-1	18410508
then	O	-1	18410508
retur@@	O	-1	18410508
n	O	-1	18410508
to	O	-1	18410508
a	O	-1	18410508
sur@@	O	-1	18410508
ve@@	O	-1	18410508
y@@	O	-1	18410508
ing	O	-1	18410508
state	O	-1	18410508
without	O	-1	18410508
under@@	O	-1	18410508
go@@	O	-1	18410508
ing	O	-1	18410508
apo@@	O	-1	18410508
pto@@	O	-1	18410508
sis	O	-1	18410508
or	O	-1	18410508
mi@@	O	-1	18410508
g@@	O	-1	18410508
r@@	O	-1	18410508
ation.	O	-1	18410508

Rec@@	O	-1	18503483
o@@	O	-1	18503483
very	O	-1	18503483
of	O	-1	18503483
tacrolimus	B-Chemical	D016559	18503483
-@@	O	-1	18503483
associated	O	-1	18503483
b@@	B-Disease	D020968	18503483
rac@@	I-Disease	-1	18503483
hi@@	I-Disease	-1	18503483
al	I-Disease	-1	18503483
ne@@	I-Disease	-1	18503483
ur@@	I-Disease	-1	18503483
iti@@	I-Disease	-1	18503483
s	I-Disease	-1	18503483
after	O	-1	18503483
conver@@	O	-1	18503483
sion	O	-1	18503483
to	O	-1	18503483
e@@	B-Chemical	C107135	18503483
ver@@	I-Chemical	-1	18503483
ol@@	I-Chemical	-1	18503483
im@@	I-Chemical	-1	18503483
us	I-Chemical	-1	18503483
in	O	-1	18503483
a	O	-1	18503483
pe@@	O	-1	18503483
di@@	O	-1	18503483
atric	O	-1	18503483
renal	O	-1	18503483
transplant	O	-1	18503483
re@@	O	-1	18503483
ci@@	O	-1	18503483
pi@@	O	-1	18503483
ent@@	O	-1	18503483
-@@	O	-1	18503483
-@@	O	-1	18503483
case	O	-1	18503483
report	O	-1	18503483
and	O	-1	18503483
revie@@	O	-1	18503483
w	O	-1	18503483
of	O	-1	18503483
the	O	-1	18503483
literat@@	O	-1	18503483
ure.	O	-1	18503483
TA@@	B-Chemical	D016559	18503483
C	I-Chemical	-1	18503483
has	O	-1	18503483
been	O	-1	18503483
shown	O	-1	18503483
to	O	-1	18503483
be	O	-1	18503483
a	O	-1	18503483
pot@@	O	-1	18503483
ent	O	-1	18503483
immunosup@@	O	-1	18503483
pressive	O	-1	18503483
agent	O	-1	18503483
for	O	-1	18503483
sol@@	O	-1	18503483
id	O	-1	18503483
org@@	O	-1	18503483
an	O	-1	18503483
transplant@@	O	-1	18503483
ation	O	-1	18503483
in	O	-1	18503483
pe@@	O	-1	18503483
di@@	O	-1	18503483
at@@	O	-1	18503483
r@@	O	-1	18503483
ic@@	O	-1	18503483
s.	O	-1	18503483
Ne@@	B-Disease	D020258	18503483
uro@@	I-Disease	-1	18503483
toxicity	I-Disease	-1	18503483
is	O	-1	18503483
a	O	-1	18503483
potenti@@	O	-1	18503483
ally	O	-1	18503483
seri@@	O	-1	18503483
ous	O	-1	18503483
toxic	O	-1	18503483
effect@@	O	-1	18503483
.	O	-1	18503483
It	O	-1	18503483
is	O	-1	18503483
character@@	O	-1	18503483
ized	O	-1	18503483
by	O	-1	18503483
encephalo@@	B-Disease	D001927	18503483
pathy	I-Disease	-1	18503483
,	O	-1	18503483
headac@@	B-Disease	D006261	18503483
h@@	I-Disease	-1	18503483
es	I-Disease	-1	18503483
,	O	-1	18503483
seizures	B-Disease	D012640	18503483
,	O	-1	18503483
or	O	-1	18503483
neurolog@@	B-Disease	D009461	18503483
ical	I-Disease	-1	18503483
defic@@	I-Disease	-1	18503483
its	I-Disease	-1	18503483
.	O	-1	18503483
He@@	O	-1	18503483
re,	O	-1	18503483
we	O	-1	18503483
describe	O	-1	18503483
an	O	-1	18503483
e@@	O	-1	18503483
igh@@	O	-1	18503483
t-@@	O	-1	18503483
and@@	O	-1	18503483
-@@	O	-1	18503483
a@@	O	-1	18503483
-@@	O	-1	18503483
h@@	O	-1	18503483
al@@	O	-1	18503483
f@@	O	-1	18503483
-@@	O	-1	18503483
y@@	O	-1	18503483
r@@	O	-1	18503483
-old	O	-1	18503483
male	O	-1	18503483
renal	O	-1	18503483
transplant	O	-1	18503483
re@@	O	-1	18503483
ci@@	O	-1	18503483
pi@@	O	-1	18503483
ent	O	-1	18503483
with	O	-1	18503483
right	O	-1	18503483
B@@	O	-1	18503483
N@@	O	-1	18503483
.	O	-1	18503483
MR@@	O	-1	18503483
I	O	-1	18503483
demonstrated	O	-1	18503483
hyper@@	O	-1	18503483
int@@	O	-1	18503483
en@@	O	-1	18503483
se	O	-1	18503483
T@@	O	-1	18503483
2	O	-1	18503483
sign@@	O	-1	18503483
als	O	-1	18503483
in	O	-1	18503483
the	O	-1	18503483
cer@@	O	-1	18503483
v@@	O	-1	18503483
ical	O	-1	18503483
cor@@	O	-1	18503483
d	O	-1	18503483
and	O	-1	18503483
right	O	-1	18503483
b@@	O	-1	18503483
rac@@	O	-1	18503483
hi@@	O	-1	18503483
al	O	-1	18503483
ple@@	O	-1	18503483
x@@	O	-1	18503483
us	O	-1	18503483
ro@@	O	-1	18503483
ot@@	O	-1	18503483
s	O	-1	18503483
indic@@	O	-1	18503483
ative	O	-1	18503483
of	O	-1	18503483
both	O	-1	18503483
my@@	B-Disease	D009187	18503483
e@@	I-Disease	-1	18503483
li@@	I-Disease	-1	18503483
tis	I-Disease	-1	18503483
and	O	-1	18503483
right	O	-1	18503483
b@@	B-Disease	D020968	18503483
rac@@	I-Disease	-1	18503483
hi@@	I-Disease	-1	18503483
al	I-Disease	-1	18503483
ple@@	I-Disease	-1	18503483
x@@	I-Disease	-1	18503483
iti@@	I-Disease	-1	18503483
s	I-Disease	-1	18503483
.	O	-1	18503483
S@@	O	-1	18503483
ym@@	O	-1	18503483
pto@@	O	-1	18503483
ms	O	-1	18503483
per@@	O	-1	18503483
sist@@	O	-1	18503483
ed	O	-1	18503483
for	O	-1	18503483
three	O	-1	18503483
months	O	-1	18503483
des@@	O	-1	18503483
pit@@	O	-1	18503483
e	O	-1	18503483
TA@@	B-Chemical	D016559	18503483
C	I-Chemical	-1	18503483
dose	O	-1	18503483
reduc@@	O	-1	18503483
tion,	O	-1	18503483
administration	O	-1	18503483
of	O	-1	18503483
I@@	O	-1	18503483
V@@	O	-1	18503483
I@@	O	-1	18503483
G	O	-1	18503483
and	O	-1	18503483
four	O	-1	18503483
doses	O	-1	18503483
of	O	-1	18503483
methyl@@	B-Chemical	D008775	18503483
pre@@	I-Chemical	-1	18503483
d@@	I-Chemical	-1	18503483
n@@	I-Chemical	-1	18503483
isol@@	I-Chemical	-1	18503483
one	I-Chemical	-1	18503483
pul@@	O	-1	18503483
se	O	-1	18503483
therapy.	O	-1	18503483
Im@@	O	-1	18503483
pro@@	O	-1	18503483
vement	O	-1	18503483
and	O	-1	18503483
event@@	O	-1	18503483
ually	O	-1	18503483
ful@@	O	-1	18503483
l	O	-1	18503483
recovery	O	-1	18503483
only	O	-1	18503483
occurred	O	-1	18503483
after	O	-1	18503483
TA@@	B-Chemical	D016559	18503483
C	I-Chemical	-1	18503483
was	O	-1	18503483
complete@@	O	-1	18503483
ly	O	-1	18503483
discontinu@@	O	-1	18503483
ed	O	-1	18503483
and	O	-1	18503483
suc@@	O	-1	18503483
cess@@	O	-1	18503483
ful@@	O	-1	18503483
ly	O	-1	18503483
re@@	O	-1	18503483
pl@@	O	-1	18503483
ac@@	O	-1	18503483
ed	O	-1	18503483
by	O	-1	18503483
e@@	B-Chemical	C107135	18503483
ver@@	I-Chemical	-1	18503483
ol@@	I-Chemical	-1	18503483
im@@	I-Chemical	-1	18503483
us	I-Chemical	-1	18503483
.	O	-1	18503483

V@@	B-Disease	D006349	18560792
al@@	I-Disease	-1	18560792
v@@	I-Disease	-1	18560792
ular	I-Disease	-1	18560792
heart	I-Disease	-1	18560792
disease	I-Disease	-1	18560792
in	O	-1	18560792
patients	O	-1	18560792
with	O	-1	18560792
Parkinson's	B-Disease	D010300	18560792
disease	I-Disease	-1	18560792
treated	O	-1	18560792
with	O	-1	18560792
per@@	B-Chemical	D010479	18560792
g@@	I-Chemical	-1	18560792
ol@@	I-Chemical	-1	18560792
ide	I-Chemical	-1	18560792
.	O	-1	18560792
C@@	O	-1	18560792
o@@	O	-1	18560792
ur@@	O	-1	18560792
se	O	-1	18560792
following	O	-1	18560792
treatment	O	-1	18560792
mo@@	O	-1	18560792
di@@	O	-1	18560792
fic@@	O	-1	18560792
ations.	O	-1	18560792
V@@	B-Disease	D006349	18560792
al@@	I-Disease	-1	18560792
v@@	I-Disease	-1	18560792
ular	I-Disease	-1	18560792
heart	I-Disease	-1	18560792
abnormal@@	I-Disease	-1	18560792
ities	I-Disease	-1	18560792
have	O	-1	18560792
been	O	-1	18560792
reported	O	-1	18560792
in	O	-1	18560792
patients	O	-1	18560792
with	O	-1	18560792
Parkinson's	B-Disease	D010300	18560792
disease	I-Disease	-1	18560792
(	O	-1	18560792
P@@	B-Disease	D010300	18560792
D	I-Disease	-1	18560792
)	O	-1	18560792
treated	O	-1	18560792
with	O	-1	18560792
per@@	B-Chemical	D010479	18560792
g@@	I-Chemical	-1	18560792
ol@@	I-Chemical	-1	18560792
ide	I-Chemical	-1	18560792
.	O	-1	18560792
However,	O	-1	18560792
the	O	-1	18560792
incidence	O	-1	18560792
and	O	-1	18560792
severity	O	-1	18560792
of	O	-1	18560792
these	O	-1	18560792
abnormal@@	O	-1	18560792
ities	O	-1	18560792
v@@	O	-1	18560792
ary	O	-1	18560792
from	O	-1	18560792
study	O	-1	18560792
to	O	-1	18560792
study	O	-1	18560792
and	O	-1	18560792
their	O	-1	18560792
course	O	-1	18560792
after	O	-1	18560792
drug	O	-1	18560792
withdrawal	O	-1	18560792
has	O	-1	18560792
not	O	-1	18560792
been	O	-1	18560792
system@@	O	-1	18560792
ati@@	O	-1	18560792
c@@	O	-1	18560792
ally	O	-1	18560792
ass@@	O	-1	18560792
es@@	O	-1	18560792
sed.	O	-1	18560792
OBJECTIV@@	O	-1	18560792
E@@	O	-1	18560792
S:	O	-1	18560792
To	O	-1	18560792
estim@@	O	-1	18560792
ate	O	-1	18560792
the	O	-1	18560792
frequency	O	-1	18560792
and	O	-1	18560792
severity	O	-1	18560792
of	O	-1	18560792
val@@	B-Disease	D006349	18560792
v@@	I-Disease	-1	18560792
ular	I-Disease	-1	18560792
heart	I-Disease	-1	18560792
abnormal@@	I-Disease	-1	18560792
ity	I-Disease	-1	18560792
and	O	-1	18560792
its	O	-1	18560792
possible	O	-1	18560792
rever@@	O	-1	18560792
sib@@	O	-1	18560792
ility	O	-1	18560792
after	O	-1	18560792
drug	O	-1	18560792
withdrawal	O	-1	18560792
in	O	-1	18560792
a	O	-1	18560792
cas@@	O	-1	18560792
e-@@	O	-1	18560792
control	O	-1	18560792
study.	O	-1	18560792
METHODS:	O	-1	18560792
All	O	-1	18560792
P@@	B-Disease	D010300	18560792
D	I-Disease	-1	18560792
patients	O	-1	18560792
in	O	-1	18560792
the	O	-1	18560792
A@@	O	-1	18560792
mi@@	O	-1	18560792
en@@	O	-1	18560792
s	O	-1	18560792
a@@	O	-1	18560792
re@@	O	-1	18560792
a	O	-1	18560792
treated	O	-1	18560792
with	O	-1	18560792
per@@	B-Chemical	D010479	18560792
g@@	I-Chemical	-1	18560792
ol@@	I-Chemical	-1	18560792
ide	I-Chemical	-1	18560792
were	O	-1	18560792
inv@@	O	-1	18560792
ited	O	-1	18560792
to	O	-1	18560792
atten@@	O	-1	18560792
d	O	-1	18560792
a	O	-1	18560792
cardi@@	O	-1	18560792
ologic	O	-1	18560792
assess@@	O	-1	18560792
ment	O	-1	18560792
including	O	-1	18560792
trans@@	O	-1	18560792
th@@	O	-1	18560792
or@@	O	-1	18560792
ac@@	O	-1	18560792
ic	O	-1	18560792
echocardiograph@@	O	-1	18560792
y.	O	-1	18560792
Th@@	O	-1	18560792
ir@@	O	-1	18560792
t@@	O	-1	18560792
y	O	-1	18560792
P@@	B-Disease	D010300	18560792
D	I-Disease	-1	18560792
patients	O	-1	18560792
partic@@	O	-1	18560792
ip@@	O	-1	18560792
ated	O	-1	18560792
in	O	-1	18560792
the	O	-1	18560792
study.	O	-1	18560792
A	O	-1	18560792
second	O	-1	18560792
echocardiograph@@	O	-1	18560792
y	O	-1	18560792
was	O	-1	18560792
performed	O	-1	18560792
(@@	O	-1	18560792
median	O	-1	18560792
inter@@	O	-1	18560792
val@@	O	-1	18560792
:	O	-1	18560792
13	O	-1	18560792
month@@	O	-1	18560792
s)	O	-1	18560792
after	O	-1	18560792
per@@	B-Chemical	D010479	18560792
g@@	I-Chemical	-1	18560792
ol@@	I-Chemical	-1	18560792
ide	I-Chemical	-1	18560792
withdrawal	O	-1	18560792
(n@@	O	-1	18560792
=@@	O	-1	18560792
10	O	-1	18560792
patient@@	O	-1	18560792
s@@	O	-1	18560792
).	O	-1	18560792
C@@	O	-1	18560792
ont@@	O	-1	18560792
ro@@	O	-1	18560792
l@@	O	-1	18560792
s	O	-1	18560792
were	O	-1	18560792
ag@@	O	-1	18560792
e@@	O	-1	18560792
-	O	-1	18560792
and	O	-1	18560792
sex@@	O	-1	18560792
-@@	O	-1	18560792
mat@@	O	-1	18560792
ch@@	O	-1	18560792
ed	O	-1	18560792
non@@	O	-1	18560792
-	O	-1	18560792
P@@	B-Disease	D010300	18560792
D	I-Disease	-1	18560792
patients	O	-1	18560792
ref@@	O	-1	18560792
er@@	O	-1	18560792
red	O	-1	18560792
to	O	-1	18560792
the	O	-1	18560792
cardi@@	O	-1	18560792
ology	O	-1	18560792
de@@	O	-1	18560792
part@@	O	-1	18560792
ment.	O	-1	18560792
RESULTS:	O	-1	18560792
Com@@	O	-1	18560792
pared	O	-1	18560792
to	O	-1	18560792
control@@	O	-1	18560792
s,	O	-1	18560792
a@@	B-Disease	D001022	18560792
or@@	I-Disease	-1	18560792
tic	I-Disease	-1	18560792
reg@@	I-Disease	-1	18560792
ur@@	I-Disease	-1	18560792
g@@	I-Disease	-1	18560792
it@@	I-Disease	-1	18560792
ation	I-Disease	-1	18560792
(@@	O	-1	18560792
O@@	O	-1	18560792
R@@	O	-1	18560792
:	O	-1	18560792
3.@@	O	-1	18560792
1@@	O	-1	18560792
;	O	-1	18560792
95%	O	-1	18560792
IC@@	O	-1	18560792
:	O	-1	18560792
1.@@	O	-1	18560792
1-@@	O	-1	18560792
8.@@	O	-1	18560792
8@@	O	-1	18560792
)	O	-1	18560792
and	O	-1	18560792
mit@@	B-Disease	D008944	18560792
ral	I-Disease	-1	18560792
reg@@	I-Disease	-1	18560792
ur@@	I-Disease	-1	18560792
g@@	I-Disease	-1	18560792
it@@	I-Disease	-1	18560792
ation	I-Disease	-1	18560792
(@@	O	-1	18560792
O@@	O	-1	18560792
R@@	O	-1	18560792
:	O	-1	18560792
1@@	O	-1	18560792
0.@@	O	-1	18560792
7@@	O	-1	18560792
;	O	-1	18560792
95%	O	-1	18560792
IC@@	O	-1	18560792
:	O	-1	18560792
2.@@	O	-1	18560792
1-@@	O	-1	18560792
5@@	O	-1	18560792
3@@	O	-1	18560792
)	O	-1	18560792
were	O	-1	18560792
more	O	-1	18560792
frequent	O	-1	18560792
in	O	-1	18560792
P@@	B-Disease	D010300	18560792
D	I-Disease	-1	18560792
patients	O	-1	18560792
(@@	O	-1	18560792
tr@@	O	-1	18560792
ic@@	O	-1	18560792
us@@	O	-1	18560792
pid@@	O	-1	18560792
:	O	-1	18560792
N@@	O	-1	18560792
S@@	O	-1	18560792
).	O	-1	18560792
The	O	-1	18560792
number	O	-1	18560792
of	O	-1	18560792
affected	O	-1	18560792
val@@	O	-1	18560792
v@@	O	-1	18560792
es	O	-1	18560792
(n@@	O	-1	18560792
=@@	O	-1	18560792
2.@@	O	-1	18560792
4@@	O	-1	18560792
+/-@@	O	-1	18560792
0.@@	O	-1	18560792
7@@	O	-1	18560792
)	O	-1	18560792
and	O	-1	18560792
the	O	-1	18560792
su@@	O	-1	18560792
m	O	-1	18560792
of	O	-1	18560792
reg@@	O	-1	18560792
ur@@	O	-1	18560792
g@@	O	-1	18560792
it@@	O	-1	18560792
ation	O	-1	18560792
gra@@	O	-1	18560792
des	O	-1	18560792
(n@@	O	-1	18560792
=@@	O	-1	18560792
2.@@	O	-1	18560792
8@@	O	-1	18560792
+/-@@	O	-1	18560792
1.@@	O	-1	18560792
0@@	O	-1	18560792
9@@	O	-1	18560792
)	O	-1	18560792
were	O	-1	18560792
higher	O	-1	18560792
(p@@	O	-1	18560792
=@@	O	-1	18560792
0.00@@	O	-1	18560792
8	O	-1	18560792
and	O	-1	18560792
p@@	O	-1	18560792
=@@	O	-1	18560792
0.00@@	O	-1	18560792
6,	O	-1	18560792
respectivel@@	O	-1	18560792
y@@	O	-1	18560792
)	O	-1	18560792
in	O	-1	18560792
the	O	-1	18560792
per@@	B-Chemical	D010479	18560792
g@@	I-Chemical	-1	18560792
ol@@	I-Chemical	-1	18560792
ide	I-Chemical	-1	18560792
group.	O	-1	18560792
S@@	O	-1	18560792
e@@	O	-1	18560792
ver@@	O	-1	18560792
ity	O	-1	18560792
of	O	-1	18560792
reg@@	O	-1	18560792
ur@@	O	-1	18560792
g@@	O	-1	18560792
it@@	O	-1	18560792
ation	O	-1	18560792
was	O	-1	18560792
not	O	-1	18560792
cor@@	O	-1	18560792
related	O	-1	18560792
with	O	-1	18560792
per@@	B-Chemical	D010479	18560792
g@@	I-Chemical	-1	18560792
ol@@	I-Chemical	-1	18560792
ide	I-Chemical	-1	18560792
cum@@	O	-1	18560792
ul@@	O	-1	18560792
ative	O	-1	18560792
dose.	O	-1	18560792
A	O	-1	18560792
re@@	O	-1	18560792
stric@@	O	-1	18560792
tive	O	-1	18560792
pat@@	O	-1	18560792
ter@@	O	-1	18560792
n	O	-1	18560792
of	O	-1	18560792
val@@	B-Disease	D006349	18560792
v@@	I-Disease	-1	18560792
ular	I-Disease	-1	18560792
reg@@	I-Disease	-1	18560792
ur@@	I-Disease	-1	18560792
g@@	I-Disease	-1	18560792
it@@	I-Disease	-1	18560792
ation	I-Disease	-1	18560792
,	O	-1	18560792
sugg@@	O	-1	18560792
es@@	O	-1	18560792
tive	O	-1	18560792
of	O	-1	18560792
the	O	-1	18560792
role	O	-1	18560792
of	O	-1	18560792
per@@	B-Chemical	D010479	18560792
g@@	I-Chemical	-1	18560792
ol@@	I-Chemical	-1	18560792
ide	I-Chemical	-1	18560792
,	O	-1	18560792
was	O	-1	18560792
observed	O	-1	18560792
in	O	-1	18560792
12@@	O	-1	18560792
/@@	O	-1	18560792
30	O	-1	18560792
(4@@	O	-1	18560792
0@@	O	-1	18560792
%)	O	-1	18560792
patients	O	-1	18560792
including	O	-1	18560792
two	O	-1	18560792
with	O	-1	18560792
heart	B-Disease	D006333	18560792
failure	I-Disease	-1	18560792
.	O	-1	18560792
P@@	B-Chemical	D010479	18560792
erg@@	I-Chemical	-1	18560792
ol@@	I-Chemical	-1	18560792
ide	I-Chemical	-1	18560792
was	O	-1	18560792
discontinu@@	O	-1	18560792
ed	O	-1	18560792
in	O	-1	18560792
10	O	-1	18560792
patients	O	-1	18560792
with	O	-1	18560792
val@@	B-Disease	D006349	18560792
v@@	I-Disease	-1	18560792
ular	I-Disease	-1	18560792
heart	I-Disease	-1	18560792
disease	I-Disease	-1	18560792
,	O	-1	18560792
result@@	O	-1	18560792
ing	O	-1	18560792
in	O	-1	18560792
a	O	-1	18560792
lower	O	-1	18560792
reg@@	O	-1	18560792
ur@@	O	-1	18560792
g@@	O	-1	18560792
it@@	O	-1	18560792
ation	O	-1	18560792
gra@@	O	-1	18560792
de	O	-1	18560792
(p@@	O	-1	18560792
=@@	O	-1	18560792
0.0@@	O	-1	18560792
1)	O	-1	18560792
at	O	-1	18560792
the	O	-1	18560792
second	O	-1	18560792
trans@@	O	-1	18560792
th@@	O	-1	18560792
or@@	O	-1	18560792
ac@@	O	-1	18560792
ic	O	-1	18560792
echocardiograph@@	O	-1	18560792
y	O	-1	18560792
and	O	-1	18560792
the	O	-1	18560792
two	O	-1	18560792
patients	O	-1	18560792
with	O	-1	18560792
heart	B-Disease	D006333	18560792
failure	I-Disease	-1	18560792
retur@@	O	-1	18560792
n@@	O	-1	18560792
ed	O	-1	18560792
to	O	-1	18560792
ne@@	O	-1	18560792
arly	O	-1	18560792
normal	O	-1	18560792
clinical	O	-1	18560792
examin@@	O	-1	18560792
ation.	O	-1	18560792
This	O	-1	18560792
study	O	-1	18560792
suppor@@	O	-1	18560792
ts	O	-1	18560792
the	O	-1	18560792
high	O	-1	18560792
frequency	O	-1	18560792
of	O	-1	18560792
re@@	O	-1	18560792
stric@@	O	-1	18560792
tive	O	-1	18560792
val@@	B-Disease	D006349	18560792
ve	I-Disease	-1	18560792
reg@@	I-Disease	-1	18560792
ur@@	I-Disease	-1	18560792
g@@	I-Disease	-1	18560792
it@@	I-Disease	-1	18560792
ation	I-Disease	-1	18560792
in	O	-1	18560792
P@@	B-Disease	D010300	18560792
D	I-Disease	-1	18560792
patients	O	-1	18560792
treated	O	-1	18560792
with	O	-1	18560792
per@@	B-Chemical	D010479	18560792
g@@	I-Chemical	-1	18560792
ol@@	I-Chemical	-1	18560792
ide	I-Chemical	-1	18560792
and	O	-1	18560792
reve@@	O	-1	18560792
als	O	-1	18560792
that	O	-1	18560792
a	O	-1	18560792
significant	O	-1	18560792
impro@@	O	-1	18560792
vement	O	-1	18560792
is	O	-1	18560792
us@@	O	-1	18560792
ual	O	-1	18560792
when	O	-1	18560792
the	O	-1	18560792
treatment	O	-1	18560792
is	O	-1	18560792
conver@@	O	-1	18560792
ted	O	-1	18560792
to	O	-1	18560792
non-@@	O	-1	18560792
erg@@	O	-1	18560792
o@@	O	-1	18560792
t	O	-1	18560792
dopamine	B-Chemical	D004298	18560792
agon@@	O	-1	18560792
ist@@	O	-1	18560792
s.	O	-1	18560792

Ad@@	O	-1	18726058
verse	O	-1	18726058
effects	O	-1	18726058
of	O	-1	18726058
to@@	O	-1	18726058
p@@	O	-1	18726058
ical	O	-1	18726058
pap@@	B-Chemical	D010208	18726058
aver@@	I-Chemical	-1	18726058
ine	I-Chemical	-1	18726058
on	O	-1	18726058
a@@	O	-1	18726058
ud@@	O	-1	18726058
it@@	O	-1	18726058
ory	O	-1	18726058
nerve	O	-1	18726058
func@@	O	-1	18726058
tion.	O	-1	18726058
BACKGROUND:	O	-1	18726058
P@@	B-Chemical	D010208	18726058
ap@@	I-Chemical	-1	18726058
aver@@	I-Chemical	-1	18726058
ine	I-Chemical	-1	18726058
hydro@@	I-Chemical	-1	18726058
chlor@@	I-Chemical	-1	18726058
ide	I-Chemical	-1	18726058
is	O	-1	18726058
a	O	-1	18726058
direc@@	O	-1	18726058
t-@@	O	-1	18726058
act@@	O	-1	18726058
ing	O	-1	18726058
vas@@	O	-1	18726058
odi@@	O	-1	18726058
lat@@	O	-1	18726058
or	O	-1	18726058
used	O	-1	18726058
to	O	-1	18726058
man@@	O	-1	18726058
age	O	-1	18726058
vas@@	B-Disease	D020301	18726058
os@@	I-Disease	-1	18726058
p@@	I-Disease	-1	18726058
as@@	I-Disease	-1	18726058
m	I-Disease	-1	18726058
during	O	-1	18726058
various	O	-1	18726058
neuro@@	O	-1	18726058
surg@@	O	-1	18726058
ical	O	-1	18726058
o@@	O	-1	18726058
per@@	O	-1	18726058
ations.	O	-1	18726058
T@@	O	-1	18726058
ran@@	O	-1	18726058
si@@	O	-1	18726058
ent	O	-1	18726058
c@@	B-Disease	D003389	18726058
ranial	I-Disease	-1	18726058
nerve	I-Disease	-1	18726058
dysfunction	I-Disease	-1	18726058
has	O	-1	18726058
been	O	-1	18726058
descri@@	O	-1	18726058
bed	O	-1	18726058
in	O	-1	18726058
a	O	-1	18726058
fe@@	O	-1	18726058
w	O	-1	18726058
cases	O	-1	18726058
with	O	-1	18726058
to@@	O	-1	18726058
p@@	O	-1	18726058
ical	O	-1	18726058
pap@@	B-Chemical	D010208	18726058
aver@@	I-Chemical	-1	18726058
ine	I-Chemical	-1	18726058
.	O	-1	18726058
This	O	-1	18726058
study	O	-1	18726058
suppor@@	O	-1	18726058
ts	O	-1	18726058
previ@@	O	-1	18726058
ous	O	-1	18726058
reports	O	-1	18726058
and	O	-1	18726058
pro@@	O	-1	18726058
vi@@	O	-1	18726058
des	O	-1	18726058
neuro@@	O	-1	18726058
physi@@	O	-1	18726058
ological	O	-1	18726058
evidence	O	-1	18726058
of	O	-1	18726058
an	O	-1	18726058
adverse	O	-1	18726058
effect	O	-1	18726058
on	O	-1	18726058
the	O	-1	18726058
a@@	O	-1	18726058
ud@@	O	-1	18726058
it@@	O	-1	18726058
ory	O	-1	18726058
ner@@	O	-1	18726058
ve.	O	-1	18726058
METHODS:	O	-1	18726058
We	O	-1	18726058
con@@	O	-1	18726058
duc@@	O	-1	18726058
ted	O	-1	18726058
a	O	-1	18726058
ret@@	O	-1	18726058
ro@@	O	-1	18726058
sp@@	O	-1	18726058
ective	O	-1	18726058
revie@@	O	-1	18726058
w	O	-1	18726058
of	O	-1	18726058
7@@	O	-1	18726058
0	O	-1	18726058
con@@	O	-1	18726058
sec@@	O	-1	18726058
utive	O	-1	18726058
micro@@	O	-1	18726058
vascular	O	-1	18726058
dec@@	O	-1	18726058
om@@	O	-1	18726058
pression	O	-1	18726058
o@@	O	-1	18726058
per@@	O	-1	18726058
ations	O	-1	18726058
and	O	-1	18726058
studied	O	-1	18726058
those	O	-1	18726058
patients	O	-1	18726058
who	O	-1	18726058
received	O	-1	18726058
to@@	O	-1	18726058
p@@	O	-1	18726058
ical	O	-1	18726058
pap@@	B-Chemical	D010208	18726058
aver@@	I-Chemical	-1	18726058
ine	I-Chemical	-1	18726058
for	O	-1	18726058
vas@@	B-Disease	D020301	18726058
os@@	I-Disease	-1	18726058
p@@	I-Disease	-1	18726058
as@@	I-Disease	-1	18726058
m	I-Disease	-1	18726058
.	O	-1	18726058
T@@	O	-1	18726058
op@@	O	-1	18726058
ical	O	-1	18726058
pap@@	B-Chemical	D010208	18726058
aver@@	I-Chemical	-1	18726058
ine	I-Chemical	-1	18726058
was	O	-1	18726058
used	O	-1	18726058
as	O	-1	18726058
a	O	-1	18726058
direct	O	-1	18726058
therapeutic	O	-1	18726058
action	O	-1	18726058
to	O	-1	18726058
man@@	O	-1	18726058
age	O	-1	18726058
vas@@	B-Disease	D020301	18726058
os@@	I-Disease	-1	18726058
p@@	I-Disease	-1	18726058
as@@	I-Disease	-1	18726058
m	I-Disease	-1	18726058
in	O	-1	18726058
a	O	-1	18726058
total	O	-1	18726058
of	O	-1	18726058
11	O	-1	18726058
patients.	O	-1	18726058
The	O	-1	18726058
tim@@	O	-1	18726058
ing	O	-1	18726058
of	O	-1	18726058
pap@@	B-Chemical	D010208	18726058
aver@@	I-Chemical	-1	18726058
ine	I-Chemical	-1	18726058
ap@@	O	-1	18726058
plic@@	O	-1	18726058
ation	O	-1	18726058
and	O	-1	18726058
on@@	O	-1	18726058
go@@	O	-1	18726058
ing	O	-1	18726058
o@@	O	-1	18726058
perative	O	-1	18726058
events	O	-1	18726058
was	O	-1	18726058
revie@@	O	-1	18726058
w@@	O	-1	18726058
ed	O	-1	18726058
rel@@	O	-1	18726058
ative	O	-1	18726058
to	O	-1	18726058
changes	O	-1	18726058
in	O	-1	18726058
neuro@@	O	-1	18726058
physi@@	O	-1	18726058
ological	O	-1	18726058
recor@@	O	-1	18726058
d@@	O	-1	18726058
ing@@	O	-1	18726058
s.	O	-1	18726058
B@@	O	-1	18726058
ra@@	O	-1	18726058
in@@	O	-1	18726058
st@@	O	-1	18726058
em	O	-1	18726058
a@@	O	-1	18726058
ud@@	O	-1	18726058
it@@	O	-1	18726058
ory	O	-1	18726058
evoked	O	-1	18726058
potenti@@	O	-1	18726058
als	O	-1	18726058
(@@	O	-1	18726058
BA@@	O	-1	18726058
EP@@	O	-1	18726058
s)	O	-1	18726058
were	O	-1	18726058
ro@@	O	-1	18726058
ut@@	O	-1	18726058
ine@@	O	-1	18726058
ly	O	-1	18726058
used	O	-1	18726058
to	O	-1	18726058
monit@@	O	-1	18726058
or	O	-1	18726058
co@@	O	-1	18726058
ch@@	O	-1	18726058
le@@	O	-1	18726058
ar	O	-1	18726058
nerve	O	-1	18726058
function	O	-1	18726058
during	O	-1	18726058
these	O	-1	18726058
o@@	O	-1	18726058
per@@	O	-1	18726058
ations.	O	-1	18726058
F@@	O	-1	18726058
IN@@	O	-1	18726058
D@@	O	-1	18726058
IN@@	O	-1	18726058
G@@	O	-1	18726058
S:	O	-1	18726058
A	O	-1	18726058
tempor@@	O	-1	18726058
al	O	-1	18726058
rel@@	O	-1	18726058
ationship	O	-1	18726058
was	O	-1	18726058
found	O	-1	18726058
between	O	-1	18726058
to@@	O	-1	18726058
p@@	O	-1	18726058
ical	O	-1	18726058
pap@@	B-Chemical	D010208	18726058
aver@@	I-Chemical	-1	18726058
ine	I-Chemical	-1	18726058
and	O	-1	18726058
BA@@	O	-1	18726058
E@@	O	-1	18726058
P	O	-1	18726058
changes	O	-1	18726058
lead@@	O	-1	18726058
ing	O	-1	18726058
to	O	-1	18726058
complete	O	-1	18726058
w@@	O	-1	18726058
a@@	O	-1	18726058
ve@@	O	-1	18726058
form	O	-1	18726058
los@@	O	-1	18726058
s.	O	-1	18726058
The	O	-1	18726058
average	O	-1	18726058
tempor@@	O	-1	18726058
al	O	-1	18726058
del@@	O	-1	18726058
ay	O	-1	18726058
between	O	-1	18726058
pap@@	B-Chemical	D010208	18726058
aver@@	I-Chemical	-1	18726058
ine	I-Chemical	-1	18726058
and	O	-1	18726058
the	O	-1	18726058
onset	O	-1	18726058
of	O	-1	18726058
an	O	-1	18726058
adverse	O	-1	18726058
BA@@	O	-1	18726058
E@@	O	-1	18726058
P	O	-1	18726058
change	O	-1	18726058
was	O	-1	18726058
5	O	-1	18726058
min@@	O	-1	18726058
.	O	-1	18726058
In	O	-1	18726058
10	O	-1	18726058
of	O	-1	18726058
11	O	-1	18726058
patients,	O	-1	18726058
BA@@	O	-1	18726058
E@@	O	-1	18726058
P	O	-1	18726058
w@@	O	-1	18726058
av@@	O	-1	18726058
es	O	-1	18726058
II@@	O	-1	18726058
/@@	O	-1	18726058
II@@	O	-1	18726058
I@@	O	-1	18726058
-@@	O	-1	18726058
V	O	-1	18726058
complete@@	O	-1	18726058
ly	O	-1	18726058
dis@@	O	-1	18726058
appe@@	O	-1	18726058
a@@	O	-1	18726058
red	O	-1	18726058
within	O	-1	18726058
2	O	-1	18726058
to	O	-1	18726058
25	O	-1	18726058
min	O	-1	18726058
after	O	-1	18726058
pap@@	B-Chemical	D010208	18726058
aver@@	I-Chemical	-1	18726058
ine	I-Chemical	-1	18726058
.	O	-1	18726058
E@@	O	-1	18726058
ight	O	-1	18726058
of	O	-1	18726058
these	O	-1	18726058
10	O	-1	18726058
patients	O	-1	18726058
had	O	-1	18726058
complete	O	-1	18726058
loss	O	-1	18726058
of	O	-1	18726058
BA@@	O	-1	18726058
E@@	O	-1	18726058
P	O	-1	18726058
w@@	O	-1	18726058
a@@	O	-1	18726058
ve@@	O	-1	18726058
form@@	O	-1	18726058
s	O	-1	18726058
within	O	-1	18726058
10	O	-1	18726058
min@@	O	-1	18726058
.	O	-1	18726058
One	O	-1	18726058
patient	O	-1	18726058
showed	O	-1	18726058
no	O	-1	18726058
recovery	O	-1	18726058
of	O	-1	18726058
lat@@	O	-1	18726058
er	O	-1	18726058
w@@	O	-1	18726058
av@@	O	-1	18726058
es	O	-1	18726058
and	O	-1	18726058
a	O	-1	18726058
del@@	O	-1	18726058
ayed	O	-1	18726058
pro@@	O	-1	18726058
found	O	-1	18726058
sens@@	B-Disease	D006319	18726058
or@@	I-Disease	-1	18726058
ine@@	I-Disease	-1	18726058
ural	I-Disease	-1	18726058
hearing	I-Disease	-1	18726058
loss	I-Disease	-1	18726058
.	O	-1	18726058
The	O	-1	18726058
average	O	-1	18726058
recovery	O	-1	18726058
time	O	-1	18726058
of	O	-1	18726058
BA@@	O	-1	18726058
E@@	O	-1	18726058
P	O	-1	18726058
w@@	O	-1	18726058
a@@	O	-1	18726058
ve@@	O	-1	18726058
form@@	O	-1	18726058
s	O	-1	18726058
to	O	-1	18726058
pre@@	O	-1	18726058
-	O	-1	18726058
pap@@	B-Chemical	D010208	18726058
aver@@	I-Chemical	-1	18726058
ine	I-Chemical	-1	18726058
baseline	O	-1	18726058
values	O	-1	18726058
was	O	-1	18726058
3@@	O	-1	18726058
9	O	-1	18726058
min@@	O	-1	18726058
.	O	-1	18726058
CONCLUSIONS:	O	-1	18726058
T@@	O	-1	18726058
op@@	O	-1	18726058
ical	O	-1	18726058
pap@@	B-Chemical	D010208	18726058
aver@@	I-Chemical	-1	18726058
ine	I-Chemical	-1	18726058
for	O	-1	18726058
the	O	-1	18726058
treatment	O	-1	18726058
of	O	-1	18726058
vas@@	B-Disease	D020301	18726058
os@@	I-Disease	-1	18726058
p@@	I-Disease	-1	18726058
as@@	I-Disease	-1	18726058
m	I-Disease	-1	18726058
was	O	-1	18726058
associated	O	-1	18726058
with	O	-1	18726058
the	O	-1	18726058
onset	O	-1	18726058
of	O	-1	18726058
a	O	-1	18726058
transi@@	O	-1	18726058
ent	O	-1	18726058
dist@@	O	-1	18726058
urb@@	O	-1	18726058
ance	O	-1	18726058
in	O	-1	18726058
neuro@@	O	-1	18726058
physi@@	O	-1	18726058
ological	O	-1	18726058
function	O	-1	18726058
of	O	-1	18726058
the	O	-1	18726058
as@@	O	-1	18726058
c@@	O	-1	18726058
en@@	O	-1	18726058
ding	O	-1	18726058
a@@	O	-1	18726058
ud@@	O	-1	18726058
it@@	O	-1	18726058
ory	O	-1	18726058
bra@@	O	-1	18726058
in@@	O	-1	18726058
st@@	O	-1	18726058
em	O	-1	18726058
path@@	O	-1	18726058
w@@	O	-1	18726058
a@@	O	-1	18726058
y.	O	-1	18726058
The	O	-1	18726058
complete	O	-1	18726058
dis@@	O	-1	18726058
appear@@	O	-1	18726058
ance	O	-1	18726058
of	O	-1	18726058
BA@@	O	-1	18726058
E@@	O	-1	18726058
P	O	-1	18726058
w@@	O	-1	18726058
a@@	O	-1	18726058
ve@@	O	-1	18726058
form@@	O	-1	18726058
s	O	-1	18726058
with	O	-1	18726058
a	O	-1	18726058
consist@@	O	-1	18726058
ent	O	-1	18726058
tempor@@	O	-1	18726058
al	O	-1	18726058
del@@	O	-1	18726058
ay	O	-1	18726058
suggests	O	-1	18726058
a	O	-1	18726058
possible	O	-1	18726058
adverse	B-Disease	D000160	18726058
effect	I-Disease	-1	18726058
on	I-Disease	-1	18726058
the	I-Disease	-1	18726058
pro@@	I-Disease	-1	18726058
xim@@	I-Disease	-1	18726058
al	I-Disease	-1	18726058
e@@	I-Disease	-1	18726058
igh@@	I-Disease	-1	18726058
th	I-Disease	-1	18726058
nerve	I-Disease	-1	18726058
.	O	-1	18726058
Rec@@	O	-1	18726058
om@@	O	-1	18726058
men@@	O	-1	18726058
d@@	O	-1	18726058
ations	O	-1	18726058
to	O	-1	18726058
av@@	O	-1	18726058
oid	O	-1	18726058
potential	O	-1	18726058
c@@	B-Disease	D003389	18726058
ranial	I-Disease	-1	18726058
nerve	I-Disease	-1	18726058
defic@@	I-Disease	-1	18726058
its	I-Disease	-1	18726058
from	O	-1	18726058
pap@@	B-Chemical	D010208	18726058
aver@@	I-Chemical	-1	18726058
ine	I-Chemical	-1	18726058
are	O	-1	18726058
pro@@	O	-1	18726058
vi@@	O	-1	18726058
de@@	O	-1	18726058
d.	O	-1	18726058

M@@	O	-1	18754075
as@@	O	-1	18754075
sive	O	-1	18754075
proteinuria	B-Disease	D011507	18754075
and	O	-1	18754075
acute	B-Disease	D058186	18754075
renal	I-Disease	-1	18754075
failure	I-Disease	-1	18754075
after	O	-1	18754075
oral	O	-1	18754075
b@@	B-Chemical	D004164	18754075
is@@	I-Chemical	-1	18754075
phosph@@	I-Chemical	-1	18754075
on@@	I-Chemical	-1	18754075
ate	I-Chemical	-1	18754075
(	O	-1	18754075
al@@	B-Chemical	D019386	18754075
en@@	I-Chemical	-1	18754075
d@@	I-Chemical	-1	18754075
ron@@	I-Chemical	-1	18754075
ate	I-Chemical	-1	18754075
)	O	-1	18754075
administration	O	-1	18754075
in	O	-1	18754075
a	O	-1	18754075
patient	O	-1	18754075
with	O	-1	18754075
foc@@	B-Disease	D005923	18754075
al	I-Disease	-1	18754075
seg@@	I-Disease	-1	18754075
mental	I-Disease	-1	18754075
glomer@@	I-Disease	-1	18754075
u@@	I-Disease	-1	18754075
los@@	I-Disease	-1	18754075
clero@@	I-Disease	-1	18754075
sis	I-Disease	-1	18754075
.	O	-1	18754075
A	O	-1	18754075
6@@	O	-1	18754075
1-@@	O	-1	18754075
year-old	O	-1	18754075
J@@	O	-1	18754075
ap@@	O	-1	18754075
an@@	O	-1	18754075
ese	O	-1	18754075
man	O	-1	18754075
with	O	-1	18754075
nephro@@	B-Disease	D009404	18754075
tic	I-Disease	-1	18754075
syndrome	I-Disease	-1	18754075
due	O	-1	18754075
to	O	-1	18754075
foc@@	B-Disease	D005923	18754075
al	I-Disease	-1	18754075
seg@@	I-Disease	-1	18754075
mental	I-Disease	-1	18754075
glomer@@	I-Disease	-1	18754075
u@@	I-Disease	-1	18754075
los@@	I-Disease	-1	18754075
clero@@	I-Disease	-1	18754075
sis	I-Disease	-1	18754075
was	O	-1	18754075
initi@@	O	-1	18754075
ally	O	-1	18754075
respon@@	O	-1	18754075
ding	O	-1	18754075
well	O	-1	18754075
to	O	-1	18754075
ster@@	B-Chemical	D013256	18754075
oid	I-Chemical	-1	18754075
therapy.	O	-1	18754075
The	O	-1	18754075
amoun@@	O	-1	18754075
t	O	-1	18754075
of	O	-1	18754075
daily	O	-1	18754075
urinary	O	-1	18754075
protein	O	-1	18754075
decreased	O	-1	18754075
from	O	-1	18754075
1@@	O	-1	18754075
5.@@	O	-1	18754075
6	O	-1	18754075
to	O	-1	18754075
2.@@	O	-1	18754075
8	O	-1	18754075
g@@	O	-1	18754075
.	O	-1	18754075
W@@	O	-1	18754075
i@@	O	-1	18754075
th@@	O	-1	18754075
in	O	-1	18754075
14	O	-1	18754075
days	O	-1	18754075
of	O	-1	18754075
the	O	-1	18754075
oral	O	-1	18754075
b@@	B-Chemical	D004164	18754075
is@@	I-Chemical	-1	18754075
phosph@@	I-Chemical	-1	18754075
on@@	I-Chemical	-1	18754075
ate	I-Chemical	-1	18754075
(	O	-1	18754075
al@@	B-Chemical	D019386	18754075
en@@	I-Chemical	-1	18754075
d@@	I-Chemical	-1	18754075
ron@@	I-Chemical	-1	18754075
ate	I-Chemical	-1	18754075
sodium	I-Chemical	-1	18754075
)	O	-1	18754075
administr@@	O	-1	18754075
ation,	O	-1	18754075
the	O	-1	18754075
amoun@@	O	-1	18754075
t	O	-1	18754075
of	O	-1	18754075
daily	O	-1	18754075
urinary	O	-1	18754075
protein	O	-1	18754075
increased	O	-1	18754075
ra@@	O	-1	18754075
pid@@	O	-1	18754075
ly	O	-1	18754075
up	O	-1	18754075
to	O	-1	18754075
1@@	O	-1	18754075
2.@@	O	-1	18754075
8	O	-1	18754075
g	O	-1	18754075
with	O	-1	18754075
acute	B-Disease	D058186	18754075
renal	I-Disease	-1	18754075
failure	I-Disease	-1	18754075
.	O	-1	18754075
After	O	-1	18754075
discontinu@@	O	-1	18754075
ing	O	-1	18754075
the	O	-1	18754075
oral	O	-1	18754075
al@@	B-Chemical	D019386	18754075
en@@	I-Chemical	-1	18754075
d@@	I-Chemical	-1	18754075
ron@@	I-Chemical	-1	18754075
ate	I-Chemical	-1	18754075
,	O	-1	18754075
the	O	-1	18754075
patient	O	-1	18754075
under@@	O	-1	18754075
w@@	O	-1	18754075
ent	O	-1	18754075
six	O	-1	18754075
cyc@@	O	-1	18754075
le@@	O	-1	18754075
s	O	-1	18754075
of	O	-1	18754075
hemo@@	O	-1	18754075
dialy@@	O	-1	18754075
sis	O	-1	18754075
and	O	-1	18754075
four	O	-1	18754075
cyc@@	O	-1	18754075
le@@	O	-1	18754075
s	O	-1	18754075
of	O	-1	18754075
L@@	O	-1	18754075
D@@	O	-1	18754075
L	O	-1	18754075
a@@	O	-1	18754075
ph@@	O	-1	18754075
e@@	O	-1	18754075
re@@	O	-1	18754075
sis.	O	-1	18754075
U@@	O	-1	18754075
r@@	O	-1	18754075
inary	O	-1	18754075
volume	O	-1	18754075
and	O	-1	18754075
serum	O	-1	18754075
creatinine	B-Chemical	D003404	18754075
levels	O	-1	18754075
reco@@	O	-1	18754075
vered	O	-1	18754075
to	O	-1	18754075
the	O	-1	18754075
normal	O	-1	18754075
rang@@	O	-1	18754075
e,	O	-1	18754075
with	O	-1	18754075
urinary	O	-1	18754075
protein	O	-1	18754075
dis@@	O	-1	18754075
appear@@	O	-1	18754075
ing	O	-1	18754075
complete@@	O	-1	18754075
ly	O	-1	18754075
within	O	-1	18754075
40	O	-1	18754075
days.	O	-1	18754075
This	O	-1	18754075
report	O	-1	18754075
demon@@	O	-1	18754075
strat@@	O	-1	18754075
es	O	-1	18754075
that	O	-1	18754075
not	O	-1	18754075
only	O	-1	18754075
intra@@	O	-1	18754075
ven@@	O	-1	18754075
ou@@	O	-1	18754075
s,	O	-1	18754075
but	O	-1	18754075
also	O	-1	18754075
oral	O	-1	18754075
b@@	B-Chemical	D004164	18754075
is@@	I-Chemical	-1	18754075
phosph@@	I-Chemical	-1	18754075
on@@	I-Chemical	-1	18754075
ates	I-Chemical	-1	18754075
can	O	-1	18754075
ag@@	O	-1	18754075
gra@@	O	-1	18754075
v@@	O	-1	18754075
ate	O	-1	18754075
proteinuria	B-Disease	D011507	18754075
and	O	-1	18754075
acute	B-Disease	D058186	18754075
renal	I-Disease	-1	18754075
failure	I-Disease	-1	18754075
.	O	-1	18754075

S@@	O	-1	18768591
er@@	O	-1	18768591
um@@	O	-1	18768591
-	O	-1	18768591
and	O	-1	18768591
g@@	O	-1	18768591
lu@@	O	-1	18768591
co@@	O	-1	18768591
cortico@@	O	-1	18768591
id@@	O	-1	18768591
-@@	O	-1	18768591
induc@@	O	-1	18768591
i@@	O	-1	18768591
ble	O	-1	18768591
kin@@	O	-1	18768591
ase	O	-1	18768591
1	O	-1	18768591
in	O	-1	18768591
dox@@	B-Chemical	D004317	18768591
orub@@	I-Chemical	-1	18768591
icin	I-Chemical	-1	18768591
-induced	O	-1	18768591
nephro@@	B-Disease	D009404	18768591
tic	I-Disease	-1	18768591
syndrome	I-Disease	-1	18768591
.	O	-1	18768591
D@@	B-Chemical	D004317	18768591
ox@@	I-Chemical	-1	18768591
orub@@	I-Chemical	-1	18768591
icin	I-Chemical	-1	18768591
-induced	O	-1	18768591
nephro@@	B-Disease	D007674	18768591
pathy	I-Disease	-1	18768591
lead@@	O	-1	18768591
s	O	-1	18768591
to	O	-1	18768591
epi@@	O	-1	18768591
thelial	O	-1	18768591
sodium	B-Chemical	D012964	18768591
channel	O	-1	18768591
(@@	O	-1	18768591
E@@	O	-1	18768591
Na@@	O	-1	18768591
C@@	O	-1	18768591
)-@@	O	-1	18768591
dependent	O	-1	18768591
volume	B-Disease	D016055	18768591
re@@	I-Disease	-1	18768591
ten@@	I-Disease	-1	18768591
tion	I-Disease	-1	18768591
and	O	-1	18768591
renal	O	-1	18768591
fib@@	B-Disease	D005355	18768591
ro@@	I-Disease	-1	18768591
sis	I-Disease	-1	18768591
.	O	-1	18768591
The	O	-1	18768591
al@@	B-Chemical	D000450	18768591
do@@	I-Chemical	-1	18768591
sterone	I-Chemical	-1	18768591
-@@	O	-1	18768591
sensitive	O	-1	18768591
ser@@	O	-1	18768591
um@@	O	-1	18768591
-	O	-1	18768591
and	O	-1	18768591
g@@	O	-1	18768591
lu@@	O	-1	18768591
co@@	O	-1	18768591
cortico@@	O	-1	18768591
id@@	O	-1	18768591
-@@	O	-1	18768591
induc@@	O	-1	18768591
i@@	O	-1	18768591
ble	O	-1	18768591
kin@@	O	-1	18768591
ase	O	-1	18768591
S@@	O	-1	18768591
G@@	O	-1	18768591
K@@	O	-1	18768591
1	O	-1	18768591
has	O	-1	18768591
been	O	-1	18768591
shown	O	-1	18768591
to	O	-1	18768591
partic@@	O	-1	18768591
ip@@	O	-1	18768591
ate	O	-1	18768591
in	O	-1	18768591
the	O	-1	18768591
stimulation	O	-1	18768591
of	O	-1	18768591
E@@	O	-1	18768591
Na@@	O	-1	18768591
C	O	-1	18768591
and	O	-1	18768591
to	O	-1	18768591
medi@@	O	-1	18768591
ate	O	-1	18768591
renal	O	-1	18768591
fib@@	B-Disease	D005355	18768591
ro@@	I-Disease	-1	18768591
sis	I-Disease	-1	18768591
following	O	-1	18768591
min@@	O	-1	18768591
er@@	O	-1	18768591
al@@	O	-1	18768591
oc@@	O	-1	18768591
or@@	O	-1	18768591
tico@@	O	-1	18768591
id	O	-1	18768591
and	O	-1	18768591
sal@@	O	-1	18768591
t	O	-1	18768591
ex@@	O	-1	18768591
ces@@	O	-1	18768591
s.	O	-1	18768591
The	O	-1	18768591
present	O	-1	18768591
study	O	-1	18768591
was	O	-1	18768591
performed	O	-1	18768591
to	O	-1	18768591
el@@	O	-1	18768591
uc@@	O	-1	18768591
id@@	O	-1	18768591
ate	O	-1	18768591
the	O	-1	18768591
role	O	-1	18768591
of	O	-1	18768591
S@@	O	-1	18768591
G@@	O	-1	18768591
K@@	O	-1	18768591
1	O	-1	18768591
in	O	-1	18768591
the	O	-1	18768591
volume	B-Disease	D016055	18768591
re@@	I-Disease	-1	18768591
ten@@	I-Disease	-1	18768591
tion	I-Disease	-1	18768591
and	O	-1	18768591
fib@@	B-Disease	D005355	18768591
ro@@	I-Disease	-1	18768591
sis	I-Disease	-1	18768591
during	O	-1	18768591
nephro@@	B-Disease	D009404	18768591
tic	I-Disease	-1	18768591
syndrome	I-Disease	-1	18768591
.	O	-1	18768591
To	O	-1	18768591
this	O	-1	18768591
en@@	O	-1	18768591
d,	O	-1	18768591
dox@@	B-Chemical	D004317	18768591
orub@@	I-Chemical	-1	18768591
icin	I-Chemical	-1	18768591
(1@@	O	-1	18768591
5	O	-1	18768591
m@@	O	-1	18768591
u@@	O	-1	18768591
g/@@	O	-1	18768591
g	O	-1	18768591
body	O	-1	18768591
w@@	O	-1	18768591
t@@	O	-1	18768591
)	O	-1	18768591
was	O	-1	18768591
injected	O	-1	18768591
intra@@	O	-1	18768591
ven@@	O	-1	18768591
ously	O	-1	18768591
into	O	-1	18768591
gen@@	O	-1	18768591
e-@@	O	-1	18768591
t@@	O	-1	18768591
arg@@	O	-1	18768591
et@@	O	-1	18768591
ed	O	-1	18768591
mice	O	-1	18768591
l@@	O	-1	18768591
ac@@	O	-1	18768591
king	O	-1	18768591
S@@	O	-1	18768591
G@@	O	-1	18768591
K@@	O	-1	18768591
1	O	-1	18768591
(@@	O	-1	18768591
s@@	O	-1	18768591
g@@	O	-1	18768591
k@@	O	-1	18768591
1@@	O	-1	18768591
(-@@	O	-1	18768591
/@@	O	-1	18768591
-@@	O	-1	18768591
)@@	O	-1	18768591
)	O	-1	18768591
and	O	-1	18768591
their	O	-1	18768591
wil@@	O	-1	18768591
d-@@	O	-1	18768591
type	O	-1	18768591
lit@@	O	-1	18768591
ter@@	O	-1	18768591
mat@@	O	-1	18768591
es	O	-1	18768591
(@@	O	-1	18768591
s@@	O	-1	18768591
g@@	O	-1	18768591
k@@	O	-1	18768591
1@@	O	-1	18768591
(@@	O	-1	18768591
+/@@	O	-1	18768591
+@@	O	-1	18768591
)@@	O	-1	18768591
).	O	-1	18768591
D@@	B-Chemical	D004317	18768591
ox@@	I-Chemical	-1	18768591
orub@@	I-Chemical	-1	18768591
icin	I-Chemical	-1	18768591
treatment	O	-1	18768591
resulted	O	-1	18768591
in	O	-1	18768591
he@@	O	-1	18768591
av@@	O	-1	18768591
y	O	-1	18768591
proteinuria	B-Disease	D011507	18768591
(@@	O	-1	18768591
>@@	O	-1	18768591
100	O	-1	18768591
mg	O	-1	18768591
protein@@	O	-1	18768591
/@@	O	-1	18768591
mg	O	-1	18768591
cre@@	O	-1	18768591
a@@	O	-1	18768591
)	O	-1	18768591
in	O	-1	18768591
1@@	O	-1	18768591
5@@	O	-1	18768591
/@@	O	-1	18768591
4@@	O	-1	18768591
4	O	-1	18768591
of	O	-1	18768591
s@@	O	-1	18768591
g@@	O	-1	18768591
k@@	O	-1	18768591
1@@	O	-1	18768591
(@@	O	-1	18768591
+/@@	O	-1	18768591
+@@	O	-1	18768591
)	O	-1	18768591
and	O	-1	18768591
1@@	O	-1	18768591
5@@	O	-1	18768591
/@@	O	-1	18768591
4@@	O	-1	18768591
4	O	-1	18768591
of	O	-1	18768591
s@@	O	-1	18768591
g@@	O	-1	18768591
k@@	O	-1	18768591
1@@	O	-1	18768591
(-@@	O	-1	18768591
/@@	O	-1	18768591
-@@	O	-1	18768591
)	O	-1	18768591
mice	O	-1	18768591
lead@@	O	-1	18768591
ing	O	-1	18768591
to	O	-1	18768591
severe	O	-1	18768591
nephro@@	B-Disease	D009404	18768591
tic	I-Disease	-1	18768591
syndrome	I-Disease	-1	18768591
with	O	-1	18768591
as@@	B-Disease	D001201	18768591
cit@@	I-Disease	-1	18768591
es	I-Disease	-1	18768591
,	O	-1	18768591
li@@	B-Disease	D006949	18768591
pi@@	I-Disease	-1	18768591
de@@	I-Disease	-1	18768591
mia	I-Disease	-1	18768591
,	O	-1	18768591
and	O	-1	18768591
hypo@@	B-Disease	D034141	18768591
al@@	I-Disease	-1	18768591
b@@	I-Disease	-1	18768591
um@@	I-Disease	-1	18768591
ine@@	I-Disease	-1	18768591
mia	I-Disease	-1	18768591
in	O	-1	18768591
both	O	-1	18768591
gen@@	O	-1	18768591
ot@@	O	-1	18768591
yp@@	O	-1	18768591
es.	O	-1	18768591
P@@	O	-1	18768591
las@@	O	-1	18768591
ma	O	-1	18768591
al@@	B-Chemical	D000450	18768591
do@@	I-Chemical	-1	18768591
sterone	I-Chemical	-1	18768591
levels	O	-1	18768591
increased	O	-1	18768591
in	O	-1	18768591
nephro@@	B-Disease	D009404	18768591
tic	I-Disease	-1	18768591
mice	O	-1	18768591
of	O	-1	18768591
both	O	-1	18768591
gen@@	O	-1	18768591
ot@@	O	-1	18768591
yp@@	O	-1	18768591
es	O	-1	18768591
and	O	-1	18768591
was	O	-1	18768591
followed	O	-1	18768591
by	O	-1	18768591
increased	O	-1	18768591
S@@	O	-1	18768591
G@@	O	-1	18768591
K@@	O	-1	18768591
1	O	-1	18768591
protein	O	-1	18768591
expression	O	-1	18768591
in	O	-1	18768591
s@@	O	-1	18768591
g@@	O	-1	18768591
k@@	O	-1	18768591
1@@	O	-1	18768591
(@@	O	-1	18768591
+/@@	O	-1	18768591
+@@	O	-1	18768591
)	O	-1	18768591
mice.	O	-1	18768591
U@@	O	-1	18768591
r@@	O	-1	18768591
inary	O	-1	18768591
sodium	B-Chemical	D012964	18768591
ex@@	O	-1	18768591
cre@@	O	-1	18768591
tion	O	-1	18768591
reac@@	O	-1	18768591
h@@	O	-1	18768591
ed	O	-1	18768591
sign@@	O	-1	18768591
fic@@	O	-1	18768591
ant@@	O	-1	18768591
ly	O	-1	18768591
lower	O	-1	18768591
values	O	-1	18768591
in	O	-1	18768591
s@@	O	-1	18768591
g@@	O	-1	18768591
k@@	O	-1	18768591
1@@	O	-1	18768591
(@@	O	-1	18768591
+/@@	O	-1	18768591
+@@	O	-1	18768591
)	O	-1	18768591
mice	O	-1	18768591
(1@@	O	-1	18768591
5	O	-1	18768591
+/-	O	-1	18768591
5	O	-1	18768591
m@@	O	-1	18768591
um@@	O	-1	18768591
ol@@	O	-1	18768591
/@@	O	-1	18768591
mg	O	-1	18768591
cre@@	O	-1	18768591
a@@	O	-1	18768591
)	O	-1	18768591
than	O	-1	18768591
in	O	-1	18768591
s@@	O	-1	18768591
g@@	O	-1	18768591
k@@	O	-1	18768591
1@@	O	-1	18768591
(-@@	O	-1	18768591
/@@	O	-1	18768591
-@@	O	-1	18768591
)	O	-1	18768591
mice	O	-1	18768591
(3@@	O	-1	18768591
5	O	-1	18768591
+/-	O	-1	18768591
5	O	-1	18768591
m@@	O	-1	18768591
um@@	O	-1	18768591
ol@@	O	-1	18768591
/@@	O	-1	18768591
mg	O	-1	18768591
cre@@	O	-1	18768591
a@@	O	-1	18768591
)	O	-1	18768591
and	O	-1	18768591
was	O	-1	18768591
associated	O	-1	18768591
with	O	-1	18768591
a	O	-1	18768591
significantly	O	-1	18768591
higher	O	-1	18768591
body	O	-1	18768591
weight	B-Disease	D015430	18768591
g@@	I-Disease	-1	18768591
ain	I-Disease	-1	18768591
in	O	-1	18768591
s@@	O	-1	18768591
g@@	O	-1	18768591
k@@	O	-1	18768591
1@@	O	-1	18768591
(@@	O	-1	18768591
+/@@	O	-1	18768591
+@@	O	-1	18768591
)	O	-1	18768591
compared	O	-1	18768591
with	O	-1	18768591
s@@	O	-1	18768591
g@@	O	-1	18768591
k@@	O	-1	18768591
1@@	O	-1	18768591
(-@@	O	-1	18768591
/@@	O	-1	18768591
-@@	O	-1	18768591
)	O	-1	18768591
mice	O	-1	18768591
(@@	O	-1	18768591
+@@	O	-1	18768591
6.@@	O	-1	18768591
6	O	-1	18768591
+/-	O	-1	18768591
0.@@	O	-1	18768591
7	O	-1	18768591
vs.	O	-1	18768591
+@@	O	-1	18768591
4.@@	O	-1	18768591
1	O	-1	18768591
+/-	O	-1	18768591
0.@@	O	-1	18768591
8	O	-1	18768591
g@@	O	-1	18768591
).	O	-1	18768591
D@@	O	-1	18768591
uring	O	-1	18768591
the	O	-1	18768591
course	O	-1	18768591
of	O	-1	18768591
nephro@@	B-Disease	D009404	18768591
tic	I-Disease	-1	18768591
syndrome	I-Disease	-1	18768591
,	O	-1	18768591
serum	O	-1	18768591
ure@@	B-Chemical	D014508	18768591
a	I-Chemical	-1	18768591
concentrations	O	-1	18768591
increased	O	-1	18768591
significantly	O	-1	18768591
f@@	O	-1	18768591
ast@@	O	-1	18768591
er	O	-1	18768591
in	O	-1	18768591
s@@	O	-1	18768591
g@@	O	-1	18768591
k@@	O	-1	18768591
1@@	O	-1	18768591
(-@@	O	-1	18768591
/@@	O	-1	18768591
-@@	O	-1	18768591
)	O	-1	18768591
mice	O	-1	18768591
than	O	-1	18768591
in	O	-1	18768591
s@@	O	-1	18768591
g@@	O	-1	18768591
k@@	O	-1	18768591
1@@	O	-1	18768591
(@@	O	-1	18768591
+/@@	O	-1	18768591
+@@	O	-1	18768591
)	O	-1	18768591
mice	O	-1	18768591
lead@@	O	-1	18768591
ing	O	-1	18768591
to	O	-1	18768591
ure@@	B-Disease	D014511	18768591
mia	I-Disease	-1	18768591
and	O	-1	18768591
a	O	-1	18768591
reduced	O	-1	18768591
median	O	-1	18768591
sur@@	O	-1	18768591
viv@@	O	-1	18768591
al	O	-1	18768591
in	O	-1	18768591
s@@	O	-1	18768591
g@@	O	-1	18768591
k@@	O	-1	18768591
1@@	O	-1	18768591
(-@@	O	-1	18768591
/@@	O	-1	18768591
-@@	O	-1	18768591
)	O	-1	18768591
mice	O	-1	18768591
(2@@	O	-1	18768591
9	O	-1	18768591
vs.	O	-1	18768591
40	O	-1	18768591
days	O	-1	18768591
in	O	-1	18768591
s@@	O	-1	18768591
g@@	O	-1	18768591
k@@	O	-1	18768591
1@@	O	-1	18768591
(@@	O	-1	18768591
+/@@	O	-1	18768591
+@@	O	-1	18768591
)	O	-1	18768591
mic@@	O	-1	18768591
e@@	O	-1	18768591
).	O	-1	18768591
In	O	-1	18768591
concl@@	O	-1	18768591
u@@	O	-1	18768591
sion,	O	-1	18768591
gen@@	O	-1	18768591
e-@@	O	-1	18768591
t@@	O	-1	18768591
arg@@	O	-1	18768591
et@@	O	-1	18768591
ed	O	-1	18768591
mice	O	-1	18768591
l@@	O	-1	18768591
ac@@	O	-1	18768591
king	O	-1	18768591
S@@	O	-1	18768591
G@@	O	-1	18768591
K@@	O	-1	18768591
1	O	-1	18768591
showed	O	-1	18768591
bl@@	O	-1	18768591
un@@	O	-1	18768591
ted	O	-1	18768591
volume	B-Disease	D016055	18768591
re@@	I-Disease	-1	18768591
ten@@	I-Disease	-1	18768591
tion	I-Disease	-1	18768591
,	O	-1	18768591
y@@	O	-1	18768591
et	O	-1	18768591
were	O	-1	18768591
not	O	-1	18768591
prot@@	O	-1	18768591
ected	O	-1	18768591
against	O	-1	18768591
renal	O	-1	18768591
fib@@	B-Disease	D005355	18768591
ro@@	I-Disease	-1	18768591
sis	I-Disease	-1	18768591
during	O	-1	18768591
experimental	O	-1	18768591
nephro@@	B-Disease	D009404	18768591
tic	I-Disease	-1	18768591
syndrome	I-Disease	-1	18768591
.	O	-1	18768591

S@@	O	-1	19299179
ev@@	O	-1	19299179
ere	O	-1	19299179
and	O	-1	19299179
lon@@	O	-1	19299179
g	O	-1	19299179
l@@	O	-1	19299179
ast@@	O	-1	19299179
ing	O	-1	19299179
cholest@@	B-Disease	D002779	19299179
asis	I-Disease	-1	19299179
after	O	-1	19299179
high-dose	O	-1	19299179
co-@@	B-Chemical	D015662	19299179
tri@@	I-Chemical	-1	19299179
mo@@	I-Chemical	-1	19299179
x@@	I-Chemical	-1	19299179
azole	I-Chemical	-1	19299179
treatment	O	-1	19299179
for	O	-1	19299179
P@@	B-Disease	D011020	19299179
ne@@	I-Disease	-1	19299179
um@@	I-Disease	-1	19299179
oc@@	I-Disease	-1	19299179
ys@@	I-Disease	-1	19299179
tis	I-Disease	-1	19299179
p@@	I-Disease	-1	19299179
ne@@	I-Disease	-1	19299179
um@@	I-Disease	-1	19299179
on@@	I-Disease	-1	19299179
ia	I-Disease	-1	19299179
in	O	-1	19299179
H@@	B-Disease	D015658	19299179
I@@	I-Disease	-1	19299179
V@@	I-Disease	-1	19299179
-@@	I-Disease	-1	19299179
inf@@	I-Disease	-1	19299179
ected	I-Disease	-1	19299179
patient@@	O	-1	19299179
s-@@	O	-1	19299179
-@@	O	-1	19299179
a	O	-1	19299179
report	O	-1	19299179
of	O	-1	19299179
two	O	-1	19299179
cas@@	O	-1	19299179
es.	O	-1	19299179
P@@	B-Disease	D011020	19299179
ne@@	I-Disease	-1	19299179
um@@	I-Disease	-1	19299179
oc@@	I-Disease	-1	19299179
ys@@	I-Disease	-1	19299179
tis	I-Disease	-1	19299179
p@@	I-Disease	-1	19299179
ne@@	I-Disease	-1	19299179
um@@	I-Disease	-1	19299179
on@@	I-Disease	-1	19299179
ia	I-Disease	-1	19299179
(	O	-1	19299179
P@@	B-Disease	D011020	19299179
C@@	I-Disease	-1	19299179
P	I-Disease	-1	19299179
),	O	-1	19299179
a	O	-1	19299179
common	O	-1	19299179
op@@	B-Disease	D009894	19299179
port@@	I-Disease	-1	19299179
un@@	I-Disease	-1	19299179
istic	I-Disease	-1	19299179
inf@@	I-Disease	-1	19299179
ection	I-Disease	-1	19299179
in	O	-1	19299179
H@@	B-Disease	D015658	19299179
I@@	I-Disease	-1	19299179
V@@	I-Disease	-1	19299179
-@@	I-Disease	-1	19299179
inf@@	I-Disease	-1	19299179
ected	I-Disease	-1	19299179
individ@@	O	-1	19299179
u@@	O	-1	19299179
al@@	O	-1	19299179
s,	O	-1	19299179
is	O	-1	19299179
gener@@	O	-1	19299179
ally	O	-1	19299179
treated	O	-1	19299179
with	O	-1	19299179
high	O	-1	19299179
doses	O	-1	19299179
of	O	-1	19299179
co-@@	B-Chemical	D015662	19299179
tri@@	I-Chemical	-1	19299179
mo@@	I-Chemical	-1	19299179
x@@	I-Chemical	-1	19299179
azole	I-Chemical	-1	19299179
.	O	-1	19299179
However,	O	-1	19299179
treatment	O	-1	19299179
is	O	-1	19299179
often	O	-1	19299179
lim@@	O	-1	19299179
ited	O	-1	19299179
by	O	-1	19299179
adverse	O	-1	19299179
effects.	O	-1	19299179
He@@	O	-1	19299179
re,	O	-1	19299179
we	O	-1	19299179
report	O	-1	19299179
two	O	-1	19299179
cases	O	-1	19299179
of	O	-1	19299179
se@@	O	-1	19299179
ve@@	O	-1	19299179
re@@	O	-1	19299179
ly	O	-1	19299179
immuno@@	O	-1	19299179
com@@	O	-1	19299179
pro@@	O	-1	19299179
mis@@	O	-1	19299179
ed	O	-1	19299179
H@@	B-Disease	D015658	19299179
I@@	I-Disease	-1	19299179
V@@	I-Disease	-1	19299179
-@@	I-Disease	-1	19299179
inf@@	I-Disease	-1	19299179
ected	I-Disease	-1	19299179
patients	O	-1	19299179
who	O	-1	19299179
developed	O	-1	19299179
severe	O	-1	19299179
intra@@	B-Disease	D002780	19299179
hepatic	I-Disease	-1	19299179
cholest@@	I-Disease	-1	19299179
asis	I-Disease	-1	19299179
,	O	-1	19299179
and	O	-1	19299179
in	O	-1	19299179
one	O	-1	19299179
patient	O	-1	19299179
lesions	O	-1	19299179
m@@	O	-1	19299179
im@@	O	-1	19299179
ic@@	O	-1	19299179
king	O	-1	19299179
liver	B-Disease	D008100	19299179
abs@@	I-Disease	-1	19299179
cess	I-Disease	-1	19299179
formation	O	-1	19299179
on	O	-1	19299179
radi@@	O	-1	19299179
ologic	O	-1	19299179
ex@@	O	-1	19299179
am@@	O	-1	19299179
s,	O	-1	19299179
during	O	-1	19299179
co-@@	B-Chemical	D015662	19299179
tri@@	I-Chemical	-1	19299179
mo@@	I-Chemical	-1	19299179
x@@	I-Chemical	-1	19299179
azole	I-Chemical	-1	19299179
treatment	O	-1	19299179
for	O	-1	19299179
P@@	B-Disease	D011020	19299179
C@@	I-Disease	-1	19299179
P	I-Disease	-1	19299179
.	O	-1	19299179
Whe@@	O	-1	19299179
reas	O	-1	19299179
patient	O	-1	19299179
1	O	-1	19299179
showed	O	-1	19299179
lesions	O	-1	19299179
of	O	-1	19299179
up	O	-1	19299179
to	O	-1	19299179
1	O	-1	19299179
c@@	O	-1	19299179
m	O	-1	19299179
re@@	O	-1	19299179
a@@	O	-1	19299179
di@@	O	-1	19299179
ly	O	-1	19299179
det@@	O	-1	19299179
ect@@	O	-1	19299179
able	O	-1	19299179
on	O	-1	19299179
mag@@	O	-1	19299179
ne@@	O	-1	19299179
tic	O	-1	19299179
res@@	O	-1	19299179
on@@	O	-1	19299179
ance	O	-1	19299179
imaging	O	-1	19299179
under	O	-1	19299179
prolonged	O	-1	19299179
co-@@	B-Chemical	D015662	19299179
tri@@	I-Chemical	-1	19299179
mo@@	I-Chemical	-1	19299179
x@@	I-Chemical	-1	19299179
azole	I-Chemical	-1	19299179
treatment,	O	-1	19299179
therapy	O	-1	19299179
of	O	-1	19299179
patient	O	-1	19299179
2	O	-1	19299179
was	O	-1	19299179
switch@@	O	-1	19299179
ed	O	-1	19299179
ear@@	O	-1	19299179
ly.	O	-1	19299179

Clin@@	O	-1	19356053
ically	O	-1	19356053
significant	O	-1	19356053
proteinuria	B-Disease	D011507	19356053
following	O	-1	19356053
the	O	-1	19356053
administration	O	-1	19356053
of	O	-1	19356053
sirolimus	B-Chemical	D020123	19356053
to	O	-1	19356053
renal	O	-1	19356053
transplant	O	-1	19356053
re@@	O	-1	19356053
ci@@	O	-1	19356053
pi@@	O	-1	19356053
ent@@	O	-1	19356053
s.	O	-1	19356053
BACKGROUND:	O	-1	19356053
Si@@	B-Chemical	D020123	19356053
rolimus	I-Chemical	-1	19356053
is	O	-1	19356053
the	O	-1	19356053
lat@@	O	-1	19356053
est	O	-1	19356053
immunosup@@	O	-1	19356053
pressive	O	-1	19356053
agent	O	-1	19356053
used	O	-1	19356053
to	O	-1	19356053
prev@@	O	-1	19356053
ent	O	-1	19356053
re@@	O	-1	19356053
j@@	O	-1	19356053
ec@@	O	-1	19356053
tion,	O	-1	19356053
and	O	-1	19356053
may	O	-1	19356053
have	O	-1	19356053
less	O	-1	19356053
nephro@@	B-Disease	D007674	19356053
toxicity	I-Disease	-1	19356053
than	O	-1	19356053
calc@@	O	-1	19356053
ine@@	O	-1	19356053
ur@@	O	-1	19356053
in	O	-1	19356053
inhibitor	O	-1	19356053
(C@@	O	-1	19356053
N@@	O	-1	19356053
I@@	O	-1	19356053
)-@@	O	-1	19356053
bas@@	O	-1	19356053
ed	O	-1	19356053
regimen@@	O	-1	19356053
s.	O	-1	19356053
To	O	-1	19356053
d@@	O	-1	19356053
ate	O	-1	19356053
there	O	-1	19356053
has	O	-1	19356053
been	O	-1	19356053
lit@@	O	-1	19356053
t@@	O	-1	19356053
le	O	-1	19356053
doc@@	O	-1	19356053
um@@	O	-1	19356053
ent@@	O	-1	19356053
ation	O	-1	19356053
of	O	-1	19356053
clin@@	O	-1	19356053
ically	O	-1	19356053
significant	O	-1	19356053
proteinuria	B-Disease	D011507	19356053
lin@@	O	-1	19356053
ked	O	-1	19356053
with	O	-1	19356053
the	O	-1	19356053
use	O	-1	19356053
of	O	-1	19356053
sirolimus	B-Chemical	D020123	19356053
.	O	-1	19356053
We	O	-1	19356053
have	O	-1	19356053
en@@	O	-1	19356053
coun@@	O	-1	19356053
te@@	O	-1	19356053
red	O	-1	19356053
several	O	-1	19356053
patients	O	-1	19356053
who	O	-1	19356053
developed	O	-1	19356053
subst@@	O	-1	19356053
anti@@	O	-1	19356053
al	O	-1	19356053
proteinuria	B-Disease	D011507	19356053
associated	O	-1	19356053
with	O	-1	19356053
sirolimus	B-Chemical	D020123	19356053
use.	O	-1	19356053
In	O	-1	19356053
each	O	-1	19356053
patient@@	O	-1	19356053
,	O	-1	19356053
the	O	-1	19356053
clo@@	O	-1	19356053
se	O	-1	19356053
tempor@@	O	-1	19356053
al	O	-1	19356053
association	O	-1	19356053
between	O	-1	19356053
the	O	-1	19356053
comm@@	O	-1	19356053
ence@@	O	-1	19356053
ment	O	-1	19356053
of	O	-1	19356053
sirolimus	B-Chemical	D020123	19356053
therapy	O	-1	19356053
and	O	-1	19356053
proteinuria	B-Disease	D011507	19356053
implic@@	O	-1	19356053
ated	O	-1	19356053
sirolimus	B-Chemical	D020123	19356053
as	O	-1	19356053
the	O	-1	19356053
most	O	-1	19356053
likely	O	-1	19356053
e@@	O	-1	19356053
ti@@	O	-1	19356053
ology	O	-1	19356053
of	O	-1	19356053
the	O	-1	19356053
proteinuria	B-Disease	D011507	19356053
.	O	-1	19356053
METHODS:	O	-1	19356053
We	O	-1	19356053
analy@@	O	-1	19356053
zed	O	-1	19356053
the	O	-1	19356053
clinical	O	-1	19356053
and	O	-1	19356053
labor@@	O	-1	19356053
atory	O	-1	19356053
inf@@	O	-1	19356053
orm@@	O	-1	19356053
ation	O	-1	19356053
av@@	O	-1	19356053
ail@@	O	-1	19356053
able	O	-1	19356053
for	O	-1	19356053
all	O	-1	19356053
1@@	O	-1	19356053
1@@	O	-1	19356053
9	O	-1	19356053
patients	O	-1	19356053
transplant@@	O	-1	19356053
ed	O	-1	19356053
at	O	-1	19356053
the	O	-1	19356053
W@@	O	-1	19356053
as@@	O	-1	19356053
h@@	O	-1	19356053
ing@@	O	-1	19356053
t@@	O	-1	19356053
on	O	-1	19356053
H@@	O	-1	19356053
ospit@@	O	-1	19356053
al	O	-1	19356053
C@@	O	-1	19356053
ent@@	O	-1	19356053
er	O	-1	19356053
between	O	-1	19356053
19@@	O	-1	19356053
9@@	O	-1	19356053
9@@	O	-1	19356053
-@@	O	-1	19356053
20@@	O	-1	19356053
0@@	O	-1	19356053
3	O	-1	19356053
for	O	-1	19356053
whom	O	-1	19356053
sirolimus	B-Chemical	D020123	19356053
was	O	-1	19356053
a	O	-1	19356053
comp@@	O	-1	19356053
on@@	O	-1	19356053
ent	O	-1	19356053
of	O	-1	19356053
their	O	-1	19356053
immunosup@@	O	-1	19356053
press@@	O	-1	19356053
ant	O	-1	19356053
regimen@@	O	-1	19356053
.	O	-1	19356053
In	O	-1	19356053
these	O	-1	19356053
patients,	O	-1	19356053
the	O	-1	19356053
mag@@	O	-1	19356053
nit@@	O	-1	19356053
ude	O	-1	19356053
of	O	-1	19356053
proteinuria	B-Disease	D011507	19356053
was	O	-1	19356053
assessed	O	-1	19356053
on	O	-1	19356053
mor@@	O	-1	19356053
ning	O	-1	19356053
urine	O	-1	19356053
sam@@	O	-1	19356053
ple@@	O	-1	19356053
s	O	-1	19356053
by	O	-1	19356053
t@@	O	-1	19356053
urb@@	O	-1	19356053
id@@	O	-1	19356053
o@@	O	-1	19356053
me@@	O	-1	19356053
tri@@	O	-1	19356053
c	O	-1	19356053
meas@@	O	-1	19356053
ure@@	O	-1	19356053
ment	O	-1	19356053
or	O	-1	19356053
ran@@	O	-1	19356053
do@@	O	-1	19356053
m	O	-1	19356053
urine	O	-1	19356053
protein@@	O	-1	19356053
:	O	-1	19356053
creatinine	B-Chemical	D003404	19356053
rati@@	O	-1	19356053
os@@	O	-1	19356053
,	O	-1	19356053
an	O	-1	19356053
estim@@	O	-1	19356053
ate	O	-1	19356053
of	O	-1	19356053
gram@@	O	-1	19356053
s	O	-1	19356053
of	O	-1	19356053
proteinuria	B-Disease	D011507	19356053
/@@	O	-1	19356053
da@@	O	-1	19356053
y.	O	-1	19356053
L@@	O	-1	19356053
abor@@	O	-1	19356053
atory	O	-1	19356053
results	O	-1	19356053
were	O	-1	19356053
compared	O	-1	19356053
between	O	-1	19356053
pri@@	O	-1	19356053
or@@	O	-1	19356053
,	O	-1	19356053
during	O	-1	19356053
and	O	-1	19356053
following	O	-1	19356053
sirolimus	B-Chemical	D020123	19356053
use.	O	-1	19356053
RESULTS:	O	-1	19356053
Tw@@	O	-1	19356053
ent@@	O	-1	19356053
y-@@	O	-1	19356053
e@@	O	-1	19356053
ight	O	-1	19356053
patients	O	-1	19356053
(2@@	O	-1	19356053
4@@	O	-1	19356053
%)	O	-1	19356053
developed	O	-1	19356053
increased	O	-1	19356053
proteinuria	B-Disease	D011507	19356053
from	O	-1	19356053
baseline	O	-1	19356053
during	O	-1	19356053
their	O	-1	19356053
post@@	O	-1	19356053
-@@	O	-1	19356053
transplant@@	O	-1	19356053
ation	O	-1	19356053
cour@@	O	-1	19356053
se.	O	-1	19356053
In	O	-1	19356053
21	O	-1	19356053
patients	O	-1	19356053
an	O	-1	19356053
al@@	O	-1	19356053
tern@@	O	-1	19356053
ative	O	-1	19356053
cause	O	-1	19356053
of	O	-1	19356053
proteinuria	B-Disease	D011507	19356053
was	O	-1	19356053
either	O	-1	19356053
ob@@	O	-1	19356053
vi@@	O	-1	19356053
ous	O	-1	19356053
or	O	-1	19356053
in@@	O	-1	19356053
suffici@@	O	-1	19356053
ent	O	-1	19356053
data	O	-1	19356053
was	O	-1	19356053
av@@	O	-1	19356053
ail@@	O	-1	19356053
able	O	-1	19356053
to	O	-1	19356053
be	O	-1	19356053
concl@@	O	-1	19356053
u@@	O	-1	19356053
si@@	O	-1	19356053
ve.	O	-1	19356053
In	O	-1	19356053
7	O	-1	19356053
of	O	-1	19356053
the	O	-1	19356053
2@@	O	-1	19356053
8	O	-1	19356053
patients	O	-1	19356053
there	O	-1	19356053
was	O	-1	19356053
a	O	-1	19356053
stri@@	O	-1	19356053
king	O	-1	19356053
tempor@@	O	-1	19356053
al	O	-1	19356053
association	O	-1	19356053
between	O	-1	19356053
the	O	-1	19356053
initi@@	O	-1	19356053
ation	O	-1	19356053
of	O	-1	19356053
sirolimus	B-Chemical	D020123	19356053
and	O	-1	19356053
the	O	-1	19356053
development	O	-1	19356053
of	O	-1	19356053
nephro@@	B-Disease	D009404	19356053
tic	I-Disease	-1	19356053
-@@	O	-1	19356053
range	O	-1	19356053
proteinuria	B-Disease	D011507	19356053
.	O	-1	19356053
Pro@@	B-Disease	D011507	19356053
te@@	I-Disease	-1	19356053
in@@	I-Disease	-1	19356053
uria	I-Disease	-1	19356053
cor@@	O	-1	19356053
related	O	-1	19356053
most	O	-1	19356053
st@@	O	-1	19356053
ron@@	O	-1	19356053
g@@	O	-1	19356053
ly	O	-1	19356053
with	O	-1	19356053
sirolimus	B-Chemical	D020123	19356053
therapy	O	-1	19356053
when	O	-1	19356053
compared	O	-1	19356053
to	O	-1	19356053
other	O	-1	19356053
de@@	O	-1	19356053
mo@@	O	-1	19356053
graph@@	O	-1	19356053
ic	O	-1	19356053
and	O	-1	19356053
clinical	O	-1	19356053
vari@@	O	-1	19356053
abl@@	O	-1	19356053
es.	O	-1	19356053
In	O	-1	19356053
most	O	-1	19356053
patients,	O	-1	19356053
discontinu@@	O	-1	19356053
ation	O	-1	19356053
of	O	-1	19356053
sirolimus	B-Chemical	D020123	19356053
resulted	O	-1	19356053
in	O	-1	19356053
a	O	-1	19356053
decreas@@	O	-1	19356053
e,	O	-1	19356053
but	O	-1	19356053
not	O	-1	19356053
resol@@	O	-1	19356053
u@@	O	-1	19356053
tion,	O	-1	19356053
of	O	-1	19356053
proteinuria	B-Disease	D011507	19356053
.	O	-1	19356053
CONCLUSIONS:	O	-1	19356053
Si@@	B-Chemical	D020123	19356053
rolimus	I-Chemical	-1	19356053
induc@@	O	-1	19356053
es	O	-1	19356053
or	O	-1	19356053
ag@@	O	-1	19356053
gra@@	O	-1	19356053
v@@	O	-1	19356053
ates	O	-1	19356053
pre-@@	O	-1	19356053
ex@@	O	-1	19356053
ist@@	O	-1	19356053
ing	O	-1	19356053
proteinuria	B-Disease	D011507	19356053
in	O	-1	19356053
an	O	-1	19356053
un@@	O	-1	19356053
predic@@	O	-1	19356053
t@@	O	-1	19356053
able	O	-1	19356053
sub@@	O	-1	19356053
set	O	-1	19356053
of	O	-1	19356053
renal	O	-1	19356053
allogra@@	O	-1	19356053
ft	O	-1	19356053
re@@	O	-1	19356053
ci@@	O	-1	19356053
pi@@	O	-1	19356053
ent@@	O	-1	19356053
s.	O	-1	19356053
Pro@@	B-Disease	D011507	19356053
te@@	I-Disease	-1	19356053
in@@	I-Disease	-1	19356053
uria	I-Disease	-1	19356053
may	O	-1	19356053
impro@@	O	-1	19356053
ve,	O	-1	19356053
but	O	-1	19356053
does	O	-1	19356053
not	O	-1	19356053
resol@@	O	-1	19356053
ve,	O	-1	19356053
when	O	-1	19356053
sirolimus	B-Chemical	D020123	19356053
is	O	-1	19356053
withdraw@@	O	-1	19356053
n@@	O	-1	19356053
.	O	-1	19356053

Com@@	O	-1	19729346
par@@	O	-1	19729346
ative	O	-1	19729346
cognitive	O	-1	19729346
and	O	-1	19729346
subj@@	O	-1	19729346
ective	O	-1	19729346
side	O	-1	19729346
effects	O	-1	19729346
of	O	-1	19729346
immedi@@	O	-1	19729346
at@@	O	-1	19729346
e-@@	O	-1	19729346
release	O	-1	19729346
oxy@@	B-Chemical	D010098	19729346
co@@	I-Chemical	-1	19729346
d@@	I-Chemical	-1	19729346
one	I-Chemical	-1	19729346
in	O	-1	19729346
healthy	O	-1	19729346
mid@@	O	-1	19729346
d@@	O	-1	19729346
le@@	O	-1	19729346
-@@	O	-1	19729346
aged	O	-1	19729346
and	O	-1	19729346
ol@@	O	-1	19729346
der	O	-1	19729346
ad@@	O	-1	19729346
ult@@	O	-1	19729346
s.	O	-1	19729346
This	O	-1	19729346
study	O	-1	19729346
measured	O	-1	19729346
the	O	-1	19729346
ob@@	O	-1	19729346
j@@	O	-1	19729346
ective	O	-1	19729346
and	O	-1	19729346
subj@@	O	-1	19729346
ective	O	-1	19729346
neuro@@	O	-1	19729346
cognitive	O	-1	19729346
effects	O	-1	19729346
of	O	-1	19729346
a	O	-1	19729346
single	O	-1	19729346
10-@@	O	-1	19729346
mg	O	-1	19729346
dose	O	-1	19729346
of	O	-1	19729346
immedi@@	O	-1	19729346
at@@	O	-1	19729346
e-@@	O	-1	19729346
release	O	-1	19729346
oxy@@	B-Chemical	D010098	19729346
co@@	I-Chemical	-1	19729346
d@@	I-Chemical	-1	19729346
one	I-Chemical	-1	19729346
in	O	-1	19729346
health@@	O	-1	19729346
y,	O	-1	19729346
ol@@	O	-1	19729346
der	O	-1	19729346
(@@	O	-1	19729346
>	O	-1	19729346
6@@	O	-1	19729346
5	O	-1	19729346
year@@	O	-1	19729346
s),	O	-1	19729346
and	O	-1	19729346
mid@@	O	-1	19729346
d@@	O	-1	19729346
le@@	O	-1	19729346
-@@	O	-1	19729346
aged	O	-1	19729346
(3@@	O	-1	19729346
5	O	-1	19729346
to	O	-1	19729346
5@@	O	-1	19729346
5	O	-1	19729346
year@@	O	-1	19729346
s)	O	-1	19729346
ad@@	O	-1	19729346
ult@@	O	-1	19729346
s	O	-1	19729346
who	O	-1	19729346
were	O	-1	19729346
not	O	-1	19729346
suff@@	O	-1	19729346
ering	O	-1	19729346
from	O	-1	19729346
chronic	O	-1	19729346
or	O	-1	19729346
significant	O	-1	19729346
daily	O	-1	19729346
pain	B-Disease	D010146	19729346
.	O	-1	19729346
S@@	O	-1	19729346
event@@	O	-1	19729346
y-@@	O	-1	19729346
one	O	-1	19729346
partic@@	O	-1	19729346
ip@@	O	-1	19729346
ants	O	-1	19729346
comple@@	O	-1	19729346
ted	O	-1	19729346
2	O	-1	19729346
se@@	O	-1	19729346
par@@	O	-1	19729346
ate	O	-1	19729346
study	O	-1	19729346
days	O	-1	19729346
and	O	-1	19729346
were	O	-1	19729346
bl@@	O	-1	19729346
ind	O	-1	19729346
to	O	-1	19729346
medic@@	O	-1	19729346
ation	O	-1	19729346
condi@@	O	-1	19729346
tion	O	-1	19729346
(@@	O	-1	19729346
placebo@@	O	-1	19729346
,	O	-1	19729346
10-@@	O	-1	19729346
mg	O	-1	19729346
oxy@@	B-Chemical	D010098	19729346
co@@	I-Chemical	-1	19729346
d@@	I-Chemical	-1	19729346
one	I-Chemical	-1	19729346
).	O	-1	19729346
P@@	O	-1	19729346
las@@	O	-1	19729346
ma	O	-1	19729346
oxy@@	B-Chemical	D010098	19729346
co@@	I-Chemical	-1	19729346
d@@	I-Chemical	-1	19729346
one	I-Chemical	-1	19729346
concentration	O	-1	19729346
pe@@	O	-1	19729346
ak@@	O	-1	19729346
ed	O	-1	19729346
between	O	-1	19729346
60	O	-1	19729346
and	O	-1	19729346
9@@	O	-1	19729346
0	O	-1	19729346
minutes	O	-1	19729346
post@@	O	-1	19729346
dose	O	-1	19729346
(P	O	-1	19729346
<	O	-1	19729346
.@@	O	-1	19729346
0@@	O	-1	19729346
1)	O	-1	19729346
and	O	-1	19729346
pu@@	O	-1	19729346
pi@@	O	-1	19729346
l	O	-1	19729346
si@@	O	-1	19729346
z@@	O	-1	19729346
e,	O	-1	19729346
an	O	-1	19729346
indic@@	O	-1	19729346
ation	O	-1	19729346
of	O	-1	19729346
physi@@	O	-1	19729346
ological	O	-1	19729346
effects	O	-1	19729346
of	O	-1	19729346
the	O	-1	19729346
medic@@	O	-1	19729346
ation,	O	-1	19729346
pe@@	O	-1	19729346
ak@@	O	-1	19729346
ed	O	-1	19729346
at	O	-1	19729346
appro@@	O	-1	19729346
xim@@	O	-1	19729346
ately	O	-1	19729346
9@@	O	-1	19729346
0	O	-1	19729346
to	O	-1	19729346
1@@	O	-1	19729346
20	O	-1	19729346
minutes	O	-1	19729346
post@@	O	-1	19729346
dose	O	-1	19729346
(P	O	-1	19729346
<	O	-1	19729346
.@@	O	-1	19729346
0@@	O	-1	19729346
1).	O	-1	19729346
Si@@	O	-1	19729346
gn@@	O	-1	19729346
ific@@	O	-1	19729346
ant	O	-1	19729346
dec@@	B-Disease	D003072	19729346
lin@@	I-Disease	-1	19729346
es	I-Disease	-1	19729346
in	I-Disease	-1	19729346
sim@@	I-Disease	-1	19729346
ple	I-Disease	-1	19729346
and	I-Disease	-1	19729346
su@@	I-Disease	-1	19729346
st@@	I-Disease	-1	19729346
ained	I-Disease	-1	19729346
atten@@	I-Disease	-1	19729346
tion,	I-Disease	-1	19729346
wor@@	I-Disease	-1	19729346
king	I-Disease	-1	19729346
memor@@	I-Disease	-1	19729346
y,	I-Disease	-1	19729346
and	I-Disease	-1	19729346
ver@@	I-Disease	-1	19729346
b@@	I-Disease	-1	19729346
al	I-Disease	-1	19729346
memory	I-Disease	-1	19729346
dec@@	B-Disease	D008569	19729346
lin@@	I-Disease	-1	19729346
es	I-Disease	-1	19729346
in	I-Disease	-1	19729346
sim@@	I-Disease	-1	19729346
ple	I-Disease	-1	19729346
and	I-Disease	-1	19729346
su@@	I-Disease	-1	19729346
st@@	I-Disease	-1	19729346
ained	I-Disease	-1	19729346
atten@@	I-Disease	-1	19729346
tion,	I-Disease	-1	19729346
wor@@	I-Disease	-1	19729346
king	I-Disease	-1	19729346
memor@@	I-Disease	-1	19729346
y,	I-Disease	-1	19729346
and	I-Disease	-1	19729346
ver@@	I-Disease	-1	19729346
b@@	I-Disease	-1	19729346
al	I-Disease	-1	19729346
memory	I-Disease	-1	19729346
were	O	-1	19729346
observed	O	-1	19729346
at	O	-1	19729346
1	O	-1	19729346
h@@	O	-1	19729346
our	O	-1	19729346
post@@	O	-1	19729346
dose	O	-1	19729346
compared	O	-1	19729346
to	O	-1	19729346
baseline	O	-1	19729346
for	O	-1	19729346
both	O	-1	19729346
age	O	-1	19729346
groups	O	-1	19729346
with	O	-1	19729346
a	O	-1	19729346
tre@@	O	-1	19729346
n@@	O	-1	19729346
d	O	-1	19729346
to@@	O	-1	19729346
war@@	O	-1	19729346
d	O	-1	19729346
retur@@	O	-1	19729346
n	O	-1	19729346
to	O	-1	19729346
baseline	O	-1	19729346
by	O	-1	19729346
5	O	-1	19729346
hours	O	-1	19729346
post@@	O	-1	19729346
dose.	O	-1	19729346
F@@	O	-1	19729346
or	O	-1	19729346
al@@	O	-1	19729346
most	O	-1	19729346
all	O	-1	19729346
cognitive	O	-1	19729346
meas@@	O	-1	19729346
ures@@	O	-1	19729346
,	O	-1	19729346
there	O	-1	19729346
were	O	-1	19729346
no	O	-1	19729346
medic@@	O	-1	19729346
ation	O	-1	19729346
by	O	-1	19729346
ag@@	O	-1	19729346
e-@@	O	-1	19729346
inter@@	O	-1	19729346
action	O	-1	19729346
effect@@	O	-1	19729346
s,	O	-1	19729346
which	O	-1	19729346
indic@@	O	-1	19729346
ates	O	-1	19729346
that	O	-1	19729346
the	O	-1	19729346
2	O	-1	19729346
age	O	-1	19729346
groups	O	-1	19729346
ex@@	O	-1	19729346
hib@@	O	-1	19729346
ited	O	-1	19729346
similar	O	-1	19729346
responses	O	-1	19729346
to	O	-1	19729346
the	O	-1	19729346
medic@@	O	-1	19729346
ation	O	-1	19729346
ch@@	O	-1	19729346
all@@	O	-1	19729346
en@@	O	-1	19729346
g@@	O	-1	19729346
e.	O	-1	19729346
This	O	-1	19729346
study	O	-1	19729346
suggests	O	-1	19729346
that	O	-1	19729346
for	O	-1	19729346
healthy	O	-1	19729346
ol@@	O	-1	19729346
der	O	-1	19729346
ad@@	O	-1	19729346
ult@@	O	-1	19729346
s	O	-1	19729346
who	O	-1	19729346
are	O	-1	19729346
not	O	-1	19729346
suff@@	O	-1	19729346
ering	O	-1	19729346
from	O	-1	19729346
chronic	B-Disease	D059350	19729346
pain	I-Disease	-1	19729346
,	O	-1	19729346
neuro@@	O	-1	19729346
cognitive	O	-1	19729346
and	O	-1	19729346
pharmac@@	O	-1	19729346
o@@	O	-1	19729346
dynam@@	O	-1	19729346
ic	O	-1	19729346
changes	O	-1	19729346
in	O	-1	19729346
response	O	-1	19729346
to	O	-1	19729346
a	O	-1	19729346
10-@@	O	-1	19729346
mg	O	-1	19729346
dose	O	-1	19729346
of	O	-1	19729346
immedi@@	O	-1	19729346
at@@	O	-1	19729346
e-@@	O	-1	19729346
release	O	-1	19729346
oxy@@	B-Chemical	D010098	19729346
co@@	I-Chemical	-1	19729346
d@@	I-Chemical	-1	19729346
one	I-Chemical	-1	19729346
are	O	-1	19729346
similar	O	-1	19729346
to	O	-1	19729346
those	O	-1	19729346
observed	O	-1	19729346
for	O	-1	19729346
mid@@	O	-1	19729346
d@@	O	-1	19729346
le@@	O	-1	19729346
-@@	O	-1	19729346
aged	O	-1	19729346
ad@@	O	-1	19729346
ult@@	O	-1	19729346
s.	O	-1	19729346
P@@	O	-1	19729346
E@@	O	-1	19729346
R@@	O	-1	19729346
S@@	O	-1	19729346
P@@	O	-1	19729346
ECTIV@@	O	-1	19729346
E:	O	-1	19729346
S@@	O	-1	19729346
t@@	O	-1	19729346
ud@@	O	-1	19729346
y	O	-1	19729346
findings	O	-1	19729346
indicate	O	-1	19729346
that	O	-1	19729346
the	O	-1	19729346
metabol@@	O	-1	19729346
is@@	O	-1	19729346
m@@	O	-1	19729346
,	O	-1	19729346
neuro@@	O	-1	19729346
cognitive	O	-1	19729346
effect@@	O	-1	19729346
s,	O	-1	19729346
and	O	-1	19729346
physi@@	O	-1	19729346
c@@	O	-1	19729346
al	O	-1	19729346
side	O	-1	19729346
effects	O	-1	19729346
of	O	-1	19729346
oral	O	-1	19729346
oxy@@	B-Chemical	D010098	19729346
co@@	I-Chemical	-1	19729346
d@@	I-Chemical	-1	19729346
one	I-Chemical	-1	19729346
are	O	-1	19729346
similar	O	-1	19729346
for	O	-1	19729346
healthy	O	-1	19729346
mid@@	O	-1	19729346
d@@	O	-1	19729346
le@@	O	-1	19729346
-@@	O	-1	19729346
aged	O	-1	19729346
and	O	-1	19729346
ol@@	O	-1	19729346
der	O	-1	19729346
ad@@	O	-1	19729346
ult@@	O	-1	19729346
s.	O	-1	19729346
The@@	O	-1	19729346
refore,	O	-1	19729346
clin@@	O	-1	19729346
ici@@	O	-1	19729346
ans	O	-1	19729346
should	O	-1	19729346
not	O	-1	19729346
av@@	O	-1	19729346
oid	O	-1	19729346
prescri@@	O	-1	19729346
b@@	O	-1	19729346
ing	O	-1	19729346
oral	O	-1	19729346
o@@	O	-1	19729346
pi@@	O	-1	19729346
oid@@	O	-1	19729346
s	O	-1	19729346
to	O	-1	19729346
ol@@	O	-1	19729346
der	O	-1	19729346
ad@@	O	-1	19729346
ult@@	O	-1	19729346
s	O	-1	19729346
bas@@	O	-1	19729346
ed	O	-1	19729346
on	O	-1	19729346
the	O	-1	19729346
be@@	O	-1	19729346
li@@	O	-1	19729346
e@@	O	-1	19729346
f	O	-1	19729346
that	O	-1	19729346
ol@@	O	-1	19729346
der	O	-1	19729346
ad@@	O	-1	19729346
ult@@	O	-1	19729346
s	O	-1	19729346
are	O	-1	19729346
at	O	-1	19729346
higher	O	-1	19729346
risk	O	-1	19729346
for	O	-1	19729346
side	O	-1	19729346
effects	O	-1	19729346
than	O	-1	19729346
youn@@	O	-1	19729346
g@@	O	-1	19729346
er	O	-1	19729346
ad@@	O	-1	19729346
ult@@	O	-1	19729346
s.	O	-1	19729346

N@@	O	-1	20080983
orm@@	O	-1	20080983
al@@	O	-1	20080983
iz@@	O	-1	20080983
ing	O	-1	20080983
effects	O	-1	20080983
of	O	-1	20080983
mod@@	B-Chemical	C048833	20080983
af@@	I-Chemical	-1	20080983
in@@	I-Chemical	-1	20080983
il	I-Chemical	-1	20080983
on	O	-1	20080983
sleep	O	-1	20080983
in	O	-1	20080983
chronic	O	-1	20080983
cocaine	B-Chemical	D003042	20080983
us@@	O	-1	20080983
ers.	O	-1	20080983
OBJECTIVE:	O	-1	20080983
The	O	-1	20080983
pur@@	O	-1	20080983
p@@	O	-1	20080983
ose	O	-1	20080983
of	O	-1	20080983
the	O	-1	20080983
present	O	-1	20080983
study	O	-1	20080983
was	O	-1	20080983
to	O	-1	20080983
determine	O	-1	20080983
the	O	-1	20080983
effect	O	-1	20080983
of	O	-1	20080983
mor@@	O	-1	20080983
n@@	O	-1	20080983
ing@@	O	-1	20080983
-@@	O	-1	20080983
dos@@	O	-1	20080983
ed	O	-1	20080983
mod@@	B-Chemical	C048833	20080983
af@@	I-Chemical	-1	20080983
in@@	I-Chemical	-1	20080983
il	I-Chemical	-1	20080983
on	O	-1	20080983
sleep	O	-1	20080983
and	O	-1	20080983
day@@	B-Disease	D012893	20080983
time	I-Disease	-1	20080983
sle@@	I-Disease	-1	20080983
ep@@	I-Disease	-1	20080983
in@@	I-Disease	-1	20080983
ess	I-Disease	-1	20080983
in	O	-1	20080983
chronic	O	-1	20080983
cocaine	B-Chemical	D003042	20080983
us@@	O	-1	20080983
ers.	O	-1	20080983
METHOD@@	O	-1	20080983
:	O	-1	20080983
Tw@@	O	-1	20080983
ent@@	O	-1	20080983
y	O	-1	20080983
cocaine	B-Chemical	D003042	20080983
-@@	O	-1	20080983
dependent	O	-1	20080983
partic@@	O	-1	20080983
ip@@	O	-1	20080983
ants	O	-1	20080983
were	O	-1	20080983
random@@	O	-1	20080983
ly	O	-1	20080983
as@@	O	-1	20080983
signed	O	-1	20080983
to	O	-1	20080983
recei@@	O	-1	20080983
ve	O	-1	20080983
mod@@	B-Chemical	C048833	20080983
af@@	I-Chemical	-1	20080983
in@@	I-Chemical	-1	20080983
il	I-Chemical	-1	20080983
,	O	-1	20080983
4@@	O	-1	20080983
00	O	-1	20080983
mg	O	-1	20080983
(N@@	O	-1	20080983
=@@	O	-1	20080983
10@@	O	-1	20080983
),	O	-1	20080983
or	O	-1	20080983
placebo	O	-1	20080983
(N@@	O	-1	20080983
=@@	O	-1	20080983
10@@	O	-1	20080983
)	O	-1	20080983
every	O	-1	20080983
mor@@	O	-1	20080983
ning	O	-1	20080983
at	O	-1	20080983
7@@	O	-1	20080983
:@@	O	-1	20080983
30	O	-1	20080983
a@@	O	-1	20080983
.@@	O	-1	20080983
m.	O	-1	20080983
for	O	-1	20080983
16	O	-1	20080983
days	O	-1	20080983
in	O	-1	20080983
an	O	-1	20080983
in@@	O	-1	20080983
patient@@	O	-1	20080983
,	O	-1	20080983
double-bl@@	O	-1	20080983
ind	O	-1	20080983
randomized	O	-1	20080983
tri@@	O	-1	20080983
al.	O	-1	20080983
P@@	O	-1	20080983
ar@@	O	-1	20080983
tic@@	O	-1	20080983
ip@@	O	-1	20080983
ants	O	-1	20080983
under@@	O	-1	20080983
w@@	O	-1	20080983
ent	O	-1	20080983
pol@@	O	-1	20080983
ys@@	O	-1	20080983
om@@	O	-1	20080983
no@@	O	-1	20080983
graph@@	O	-1	20080983
ic	O	-1	20080983
sleep	O	-1	20080983
recor@@	O	-1	20080983
d@@	O	-1	20080983
ings	O	-1	20080983
on	O	-1	20080983
days	O	-1	20080983
1	O	-1	20080983
to	O	-1	20080983
3,	O	-1	20080983
7	O	-1	20080983
to	O	-1	20080983
9@@	O	-1	20080983
,	O	-1	20080983
and	O	-1	20080983
14	O	-1	20080983
to	O	-1	20080983
16	O	-1	20080983
(@@	O	-1	20080983
fir@@	O	-1	20080983
st@@	O	-1	20080983
,	O	-1	20080983
secon@@	O	-1	20080983
d,	O	-1	20080983
and	O	-1	20080983
thir@@	O	-1	20080983
d	O	-1	20080983
weeks	O	-1	20080983
of	O	-1	20080983
ab@@	O	-1	20080983
st@@	O	-1	20080983
in@@	O	-1	20080983
ence@@	O	-1	20080983
).	O	-1	20080983
The	O	-1	20080983
M@@	O	-1	20080983
ul@@	O	-1	20080983
ti@@	O	-1	20080983
ple	O	-1	20080983
S@@	O	-1	20080983
le@@	O	-1	20080983
ep	O	-1	20080983
L@@	O	-1	20080983
at@@	O	-1	20080983
ency	O	-1	20080983
T@@	O	-1	20080983
est	O	-1	20080983
was	O	-1	20080983
performed	O	-1	20080983
at	O	-1	20080983
1@@	O	-1	20080983
1@@	O	-1	20080983
:@@	O	-1	20080983
30	O	-1	20080983
a@@	O	-1	20080983
.@@	O	-1	20080983
m@@	O	-1	20080983
.,	O	-1	20080983
2@@	O	-1	20080983
:@@	O	-1	20080983
00	O	-1	20080983
p.@@	O	-1	20080983
m@@	O	-1	20080983
.,	O	-1	20080983
and	O	-1	20080983
4@@	O	-1	20080983
:@@	O	-1	20080983
30	O	-1	20080983
p.@@	O	-1	20080983
m.	O	-1	20080983
on	O	-1	20080983
days	O	-1	20080983
2,	O	-1	20080983
8@@	O	-1	20080983
,	O	-1	20080983
and	O	-1	20080983
1@@	O	-1	20080983
5@@	O	-1	20080983
.	O	-1	20080983
F@@	O	-1	20080983
or	O	-1	20080983
compar@@	O	-1	20080983
ison	O	-1	20080983
of	O	-1	20080983
sleep	O	-1	20080983
ar@@	O	-1	20080983
ch@@	O	-1	20080983
it@@	O	-1	20080983
ect@@	O	-1	20080983
ure	O	-1	20080983
vari@@	O	-1	20080983
abl@@	O	-1	20080983
es,	O	-1	20080983
12	O	-1	20080983
healthy	O	-1	20080983
compar@@	O	-1	20080983
ison	O	-1	20080983
partic@@	O	-1	20080983
ip@@	O	-1	20080983
ants	O	-1	20080983
under@@	O	-1	20080983
w@@	O	-1	20080983
ent	O	-1	20080983
a	O	-1	20080983
single	O	-1	20080983
n@@	O	-1	20080983
ight	O	-1	20080983
of	O	-1	20080983
experimental	O	-1	20080983
pol@@	O	-1	20080983
ys@@	O	-1	20080983
om@@	O	-1	20080983
no@@	O	-1	20080983
graph@@	O	-1	20080983
y	O	-1	20080983
that	O	-1	20080983
followed	O	-1	20080983
1	O	-1	20080983
n@@	O	-1	20080983
ight	O	-1	20080983
of	O	-1	20080983
ac@@	O	-1	20080983
com@@	O	-1	20080983
mod@@	O	-1	20080983
ation	O	-1	20080983
pol@@	O	-1	20080983
ys@@	O	-1	20080983
om@@	O	-1	20080983
no@@	O	-1	20080983
graph@@	O	-1	20080983
y.	O	-1	20080983
RESULTS:	O	-1	20080983
Pro@@	O	-1	20080983
gres@@	O	-1	20080983
sive	O	-1	20080983
ab@@	O	-1	20080983
st@@	O	-1	20080983
in@@	O	-1	20080983
ence	O	-1	20080983
from	O	-1	20080983
cocaine	B-Chemical	D003042	20080983
was	O	-1	20080983
associated	O	-1	20080983
with	O	-1	20080983
wor@@	O	-1	20080983
sen@@	O	-1	20080983
ing	O	-1	20080983
of	O	-1	20080983
all	O	-1	20080983
measured	O	-1	20080983
pol@@	O	-1	20080983
ys@@	O	-1	20080983
om@@	O	-1	20080983
no@@	O	-1	20080983
graph@@	O	-1	20080983
ic	O	-1	20080983
sleep	O	-1	20080983
outcom@@	O	-1	20080983
es.	O	-1	20080983
Com@@	O	-1	20080983
pared	O	-1	20080983
with	O	-1	20080983
placebo@@	O	-1	20080983
,	O	-1	20080983
mod@@	B-Chemical	C048833	20080983
af@@	I-Chemical	-1	20080983
in@@	I-Chemical	-1	20080983
il	I-Chemical	-1	20080983
decreased	O	-1	20080983
n@@	O	-1	20080983
igh@@	O	-1	20080983
t@@	O	-1	20080983
time	O	-1	20080983
sleep	O	-1	20080983
lat@@	O	-1	20080983
ency	O	-1	20080983
and	O	-1	20080983
increased	O	-1	20080983
s@@	O	-1	20080983
low@@	O	-1	20080983
-@@	O	-1	20080983
w@@	O	-1	20080983
a@@	O	-1	20080983
ve	O	-1	20080983
sleep	O	-1	20080983
time	O	-1	20080983
in	O	-1	20080983
cocaine	B-Chemical	D003042	20080983
-@@	O	-1	20080983
dependent	O	-1	20080983
partic@@	O	-1	20080983
ip@@	O	-1	20080983
ant@@	O	-1	20080983
s.	O	-1	20080983
The	O	-1	20080983
effect	O	-1	20080983
of	O	-1	20080983
mod@@	B-Chemical	C048833	20080983
af@@	I-Chemical	-1	20080983
in@@	I-Chemical	-1	20080983
il	I-Chemical	-1	20080983
inter@@	O	-1	20080983
ac@@	O	-1	20080983
ted	O	-1	20080983
with	O	-1	20080983
the	O	-1	20080983
ab@@	O	-1	20080983
st@@	O	-1	20080983
in@@	O	-1	20080983
ence	O	-1	20080983
week	O	-1	20080983
and	O	-1	20080983
was	O	-1	20080983
associated	O	-1	20080983
with	O	-1	20080983
long@@	O	-1	20080983
er	O	-1	20080983
total	O	-1	20080983
sleep	O	-1	20080983
time	O	-1	20080983
and	O	-1	20080983
sh@@	O	-1	20080983
or@@	O	-1	20080983
ter	O	-1	20080983
R@@	O	-1	20080983
E@@	O	-1	20080983
M	O	-1	20080983
sleep	O	-1	20080983
lat@@	O	-1	20080983
ency	O	-1	20080983
in	O	-1	20080983
the	O	-1	20080983
thir@@	O	-1	20080983
d	O	-1	20080983
week	O	-1	20080983
of	O	-1	20080983
ab@@	O	-1	20080983
st@@	O	-1	20080983
in@@	O	-1	20080983
ence@@	O	-1	20080983
.	O	-1	20080983
Com@@	O	-1	20080983
par@@	O	-1	20080983
ison	O	-1	20080983
of	O	-1	20080983
s@@	O	-1	20080983
low@@	O	-1	20080983
-@@	O	-1	20080983
w@@	O	-1	20080983
a@@	O	-1	20080983
ve	O	-1	20080983
sleep	O	-1	20080983
ti@@	O	-1	20080983
me,	O	-1	20080983
total	O	-1	20080983
sleep	O	-1	20080983
ti@@	O	-1	20080983
me,	O	-1	20080983
and	O	-1	20080983
sleep	O	-1	20080983
lat@@	O	-1	20080983
ency	O	-1	20080983
in	O	-1	20080983
cocaine	B-Chemical	D003042	20080983
-@@	O	-1	20080983
dependent	O	-1	20080983
and	O	-1	20080983
healthy	O	-1	20080983
partic@@	O	-1	20080983
ip@@	O	-1	20080983
ants	O	-1	20080983
revealed	O	-1	20080983
a	O	-1	20080983
normal@@	O	-1	20080983
iz@@	O	-1	20080983
ing	O	-1	20080983
effect	O	-1	20080983
of	O	-1	20080983
mod@@	B-Chemical	C048833	20080983
af@@	I-Chemical	-1	20080983
in@@	I-Chemical	-1	20080983
il	I-Chemical	-1	20080983
in	O	-1	20080983
cocaine	B-Chemical	D003042	20080983
-@@	O	-1	20080983
dependent	O	-1	20080983
partic@@	O	-1	20080983
ip@@	O	-1	20080983
ant@@	O	-1	20080983
s.	O	-1	20080983
M@@	B-Chemical	C048833	20080983
o@@	I-Chemical	-1	20080983
d@@	I-Chemical	-1	20080983
af@@	I-Chemical	-1	20080983
in@@	I-Chemical	-1	20080983
il	I-Chemical	-1	20080983
was	O	-1	20080983
associated	O	-1	20080983
with	O	-1	20080983
increased	O	-1	20080983
day@@	O	-1	20080983
time	O	-1	20080983
sleep	O	-1	20080983
lat@@	O	-1	20080983
enc@@	O	-1	20080983
y,	O	-1	20080983
as	O	-1	20080983
measured	O	-1	20080983
by	O	-1	20080983
the	O	-1	20080983
M@@	O	-1	20080983
ul@@	O	-1	20080983
ti@@	O	-1	20080983
ple	O	-1	20080983
S@@	O	-1	20080983
le@@	O	-1	20080983
ep	O	-1	20080983
L@@	O	-1	20080983
at@@	O	-1	20080983
ency	O	-1	20080983
T@@	O	-1	20080983
est@@	O	-1	20080983
,	O	-1	20080983
and	O	-1	20080983
a	O	-1	20080983
ne@@	O	-1	20080983
arly	O	-1	20080983
significant	O	-1	20080983
decrease	O	-1	20080983
in	O	-1	20080983
subj@@	O	-1	20080983
ective	O	-1	20080983
day@@	B-Disease	D012893	20080983
time	I-Disease	-1	20080983
sle@@	I-Disease	-1	20080983
ep@@	I-Disease	-1	20080983
in@@	I-Disease	-1	20080983
ess	I-Disease	-1	20080983
.	O	-1	20080983
CONCLUSIONS:	O	-1	20080983
M@@	O	-1	20080983
or@@	O	-1	20080983
n@@	O	-1	20080983
ing@@	O	-1	20080983
-@@	O	-1	20080983
dos@@	O	-1	20080983
ed	O	-1	20080983
mod@@	B-Chemical	C048833	20080983
af@@	I-Chemical	-1	20080983
in@@	I-Chemical	-1	20080983
il	I-Chemical	-1	20080983
pro@@	O	-1	20080983
m@@	O	-1	20080983
ot@@	O	-1	20080983
es	O	-1	20080983
n@@	O	-1	20080983
oc@@	O	-1	20080983
t@@	O	-1	20080983
ur@@	O	-1	20080983
n@@	O	-1	20080983
al	O	-1	20080983
sle@@	O	-1	20080983
ep@@	O	-1	20080983
,	O	-1	20080983
normal@@	O	-1	20080983
iz@@	O	-1	20080983
es	O	-1	20080983
sleep	O	-1	20080983
ar@@	O	-1	20080983
ch@@	O	-1	20080983
it@@	O	-1	20080983
ect@@	O	-1	20080983
ure,	O	-1	20080983
and	O	-1	20080983
decreas@@	O	-1	20080983
es	O	-1	20080983
day@@	B-Disease	D012893	20080983
time	I-Disease	-1	20080983
sle@@	I-Disease	-1	20080983
ep@@	I-Disease	-1	20080983
in@@	I-Disease	-1	20080983
ess	I-Disease	-1	20080983
in	O	-1	20080983
ab@@	O	-1	20080983
st@@	O	-1	20080983
in@@	O	-1	20080983
ent	O	-1	20080983
cocaine	B-Chemical	D003042	20080983
us@@	O	-1	20080983
ers.	O	-1	20080983
These	O	-1	20080983
effects	O	-1	20080983
may	O	-1	20080983
be	O	-1	20080983
re@@	O	-1	20080983
lev@@	O	-1	20080983
ant	O	-1	20080983
in	O	-1	20080983
the	O	-1	20080983
treatment	O	-1	20080983
of	O	-1	20080983
cocaine	B-Chemical	D003042	20080983
depend@@	O	-1	20080983
ence@@	O	-1	20080983
.	O	-1	20080983

Eff@@	O	-1	20520283
icac@@	O	-1	20520283
y	O	-1	20520283
and	O	-1	20520283
safety	O	-1	20520283
of	O	-1	20520283
as@@	B-Chemical	C522667	20520283
en@@	I-Chemical	-1	20520283
apine	I-Chemical	-1	20520283
in	O	-1	20520283
a	O	-1	20520283
placebo@@	O	-1	20520283
-	O	-1	20520283
and	O	-1	20520283
haloperidol	B-Chemical	D006220	20520283
-@@	O	-1	20520283
controlled	O	-1	20520283
trial	O	-1	20520283
in	O	-1	20520283
patients	O	-1	20520283
with	O	-1	20520283
acute	O	-1	20520283
ex@@	O	-1	20520283
ac@@	O	-1	20520283
er@@	O	-1	20520283
b@@	O	-1	20520283
ation	O	-1	20520283
of	O	-1	20520283
sch@@	B-Disease	D012559	20520283
iz@@	I-Disease	-1	20520283
oph@@	I-Disease	-1	20520283
ren@@	I-Disease	-1	20520283
ia	I-Disease	-1	20520283
.	O	-1	20520283
A@@	B-Chemical	C522667	20520283
sen@@	I-Chemical	-1	20520283
apine	I-Chemical	-1	20520283
is	O	-1	20520283
appro@@	O	-1	20520283
ved	O	-1	20520283
by	O	-1	20520283
the	O	-1	20520283
F@@	O	-1	20520283
o@@	O	-1	20520283
od	O	-1	20520283
and	O	-1	20520283
D@@	O	-1	20520283
ru@@	O	-1	20520283
g@@	O	-1	20520283
s	O	-1	20520283
Ad@@	O	-1	20520283
minist@@	O	-1	20520283
ration	O	-1	20520283
in	O	-1	20520283
ad@@	O	-1	20520283
ult@@	O	-1	20520283
s	O	-1	20520283
for	O	-1	20520283
acute	O	-1	20520283
treatment	O	-1	20520283
of	O	-1	20520283
sch@@	B-Disease	D012559	20520283
iz@@	I-Disease	-1	20520283
oph@@	I-Disease	-1	20520283
ren@@	I-Disease	-1	20520283
ia	I-Disease	-1	20520283
or	O	-1	20520283
of	O	-1	20520283
man@@	B-Disease	D001714	20520283
ic	I-Disease	-1	20520283
or	O	-1	20520283
mi@@	O	-1	20520283
x@@	O	-1	20520283
ed	O	-1	20520283
episo@@	O	-1	20520283
des	O	-1	20520283
associated	O	-1	20520283
with	O	-1	20520283
b@@	B-Disease	D001714	20520283
ip@@	I-Disease	-1	20520283
ol@@	I-Disease	-1	20520283
ar	I-Disease	-1	20520283
I	I-Disease	-1	20520283
disor@@	I-Disease	-1	20520283
der	I-Disease	-1	20520283
with	O	-1	20520283
or	O	-1	20520283
without	O	-1	20520283
psycho@@	B-Disease	D011618	20520283
tic	I-Disease	-1	20520283
feat@@	O	-1	20520283
ures@@	O	-1	20520283
.	O	-1	20520283
In	O	-1	20520283
a	O	-1	20520283
double-bl@@	O	-1	20520283
ind	O	-1	20520283
6-@@	O	-1	20520283
week	O	-1	20520283
tri@@	O	-1	20520283
al,	O	-1	20520283
4@@	O	-1	20520283
5@@	O	-1	20520283
8	O	-1	20520283
patients	O	-1	20520283
with	O	-1	20520283
acute	O	-1	20520283
sch@@	B-Disease	D012559	20520283
iz@@	I-Disease	-1	20520283
oph@@	I-Disease	-1	20520283
ren@@	I-Disease	-1	20520283
ia	I-Disease	-1	20520283
were	O	-1	20520283
random@@	O	-1	20520283
ly	O	-1	20520283
as@@	O	-1	20520283
signed	O	-1	20520283
to	O	-1	20520283
fi@@	O	-1	20520283
x@@	O	-1	20520283
ed@@	O	-1	20520283
-@@	O	-1	20520283
dose	O	-1	20520283
treatment	O	-1	20520283
with	O	-1	20520283
as@@	B-Chemical	C522667	20520283
en@@	I-Chemical	-1	20520283
apine	I-Chemical	-1	20520283
at	O	-1	20520283
5	O	-1	20520283
mg	O	-1	20520283
tw@@	O	-1	20520283
ic@@	O	-1	20520283
e	O	-1	20520283
daily	O	-1	20520283
(B@@	O	-1	20520283
I@@	O	-1	20520283
D@@	O	-1	20520283
),	O	-1	20520283
as@@	B-Chemical	C522667	20520283
en@@	I-Chemical	-1	20520283
apine	I-Chemical	-1	20520283
at	O	-1	20520283
10	O	-1	20520283
mg	O	-1	20520283
B@@	O	-1	20520283
I@@	O	-1	20520283
D@@	O	-1	20520283
,	O	-1	20520283
placebo@@	O	-1	20520283
,	O	-1	20520283
or	O	-1	20520283
haloperidol	B-Chemical	D006220	20520283
at	O	-1	20520283
4	O	-1	20520283
mg	O	-1	20520283
B@@	O	-1	20520283
I@@	O	-1	20520283
D	O	-1	20520283
(@@	O	-1	20520283
to	O	-1	20520283
ver@@	O	-1	20520283
if@@	O	-1	20520283
y	O	-1	20520283
ass@@	O	-1	20520283
ay	O	-1	20520283
sensi@@	O	-1	20520283
tiv@@	O	-1	20520283
it@@	O	-1	20520283
y@@	O	-1	20520283
).	O	-1	20520283
W@@	O	-1	20520283
it@@	O	-1	20520283
h	O	-1	20520283
las@@	O	-1	20520283
t	O	-1	20520283
observ@@	O	-1	20520283
ations	O	-1	20520283
car@@	O	-1	20520283
ri@@	O	-1	20520283
ed	O	-1	20520283
for@@	O	-1	20520283
war@@	O	-1	20520283
d	O	-1	20520283
(@@	O	-1	20520283
L@@	O	-1	20520283
O@@	O	-1	20520283
C@@	O	-1	20520283
F@@	O	-1	20520283
),	O	-1	20520283
mean	O	-1	20520283
P@@	O	-1	20520283
o@@	O	-1	20520283
si@@	O	-1	20520283
tive	O	-1	20520283
and	O	-1	20520283
Ne@@	O	-1	20520283
g@@	O	-1	20520283
ative	O	-1	20520283
S@@	O	-1	20520283
yn@@	O	-1	20520283
drom@@	O	-1	20520283
e	O	-1	20520283
S@@	O	-1	20520283
cal@@	O	-1	20520283
e	O	-1	20520283
total	O	-1	20520283
scor@@	O	-1	20520283
e	O	-1	20520283
reduc@@	O	-1	20520283
tions	O	-1	20520283
from	O	-1	20520283
baseline	O	-1	20520283
to	O	-1	20520283
en@@	O	-1	20520283
d@@	O	-1	20520283
po@@	O	-1	20520283
in@@	O	-1	20520283
t	O	-1	20520283
were	O	-1	20520283
significantly	O	-1	20520283
greater	O	-1	20520283
with	O	-1	20520283
as@@	B-Chemical	C522667	20520283
en@@	I-Chemical	-1	20520283
apine	I-Chemical	-1	20520283
at	O	-1	20520283
5	O	-1	20520283
mg	O	-1	20520283
B@@	O	-1	20520283
I@@	O	-1	20520283
D	O	-1	20520283
(@@	O	-1	20520283
-1@@	O	-1	20520283
6.@@	O	-1	20520283
2)	O	-1	20520283
and	O	-1	20520283
haloperidol	B-Chemical	D006220	20520283
(@@	O	-1	20520283
-1@@	O	-1	20520283
5.@@	O	-1	20520283
4@@	O	-1	20520283
)	O	-1	20520283
than	O	-1	20520283
placebo	O	-1	20520283
(@@	O	-1	20520283
-1@@	O	-1	20520283
0.@@	O	-1	20520283
7@@	O	-1	20520283
;	O	-1	20520283
both	O	-1	20520283
P	O	-1	20520283
<	O	-1	20520283
0.05@@	O	-1	20520283
);	O	-1	20520283
using	O	-1	20520283
mi@@	O	-1	20520283
x@@	O	-1	20520283
ed	O	-1	20520283
model	O	-1	20520283
for	O	-1	20520283
repe@@	O	-1	20520283
ated	O	-1	20520283
meas@@	O	-1	20520283
ures	O	-1	20520283
(@@	O	-1	20520283
M@@	O	-1	20520283
MR@@	O	-1	20520283
M@@	O	-1	20520283
),	O	-1	20520283
changes	O	-1	20520283
at	O	-1	20520283
day	O	-1	20520283
4@@	O	-1	20520283
2	O	-1	20520283
were	O	-1	20520283
significantly	O	-1	20520283
greater	O	-1	20520283
with	O	-1	20520283
as@@	B-Chemical	C522667	20520283
en@@	I-Chemical	-1	20520283
apine	I-Chemical	-1	20520283
at	O	-1	20520283
5	O	-1	20520283
and	O	-1	20520283
10	O	-1	20520283
mg	O	-1	20520283
B@@	O	-1	20520283
I@@	O	-1	20520283
D	O	-1	20520283
(-@@	O	-1	20520283
2@@	O	-1	20520283
1.@@	O	-1	20520283
3	O	-1	20520283
and	O	-1	20520283
-1@@	O	-1	20520283
9.@@	O	-1	20520283
4@@	O	-1	20520283
,	O	-1	20520283
respectivel@@	O	-1	20520283
y@@	O	-1	20520283
)	O	-1	20520283
and	O	-1	20520283
haloperidol	B-Chemical	D006220	20520283
(-@@	O	-1	20520283
2@@	O	-1	20520283
0.0@@	O	-1	20520283
)	O	-1	20520283
than	O	-1	20520283
placebo	O	-1	20520283
(@@	O	-1	20520283
-1@@	O	-1	20520283
4.@@	O	-1	20520283
6@@	O	-1	20520283
;	O	-1	20520283
all	O	-1	20520283
P	O	-1	20520283
<	O	-1	20520283
0.05@@	O	-1	20520283
).	O	-1	20520283
O@@	O	-1	20520283
n	O	-1	20520283
the	O	-1	20520283
P@@	O	-1	20520283
o@@	O	-1	20520283
si@@	O	-1	20520283
tive	O	-1	20520283
and	O	-1	20520283
Ne@@	O	-1	20520283
g@@	O	-1	20520283
ative	O	-1	20520283
S@@	O	-1	20520283
yn@@	O	-1	20520283
drom@@	O	-1	20520283
e	O	-1	20520283
S@@	O	-1	20520283
cal@@	O	-1	20520283
e	O	-1	20520283
positive	O	-1	20520283
sub@@	O	-1	20520283
s@@	O	-1	20520283
cal@@	O	-1	20520283
e,	O	-1	20520283
all	O	-1	20520283
treat@@	O	-1	20520283
ments	O	-1	20520283
were	O	-1	20520283
su@@	O	-1	20520283
peri@@	O	-1	20520283
or	O	-1	20520283
to	O	-1	20520283
placebo	O	-1	20520283
with	O	-1	20520283
L@@	O	-1	20520283
O@@	O	-1	20520283
C@@	O	-1	20520283
F	O	-1	20520283
and	O	-1	20520283
M@@	O	-1	20520283
MR@@	O	-1	20520283
M@@	O	-1	20520283
;	O	-1	20520283
as@@	B-Chemical	C522667	20520283
en@@	I-Chemical	-1	20520283
apine	I-Chemical	-1	20520283
at	O	-1	20520283
5	O	-1	20520283
mg	O	-1	20520283
B@@	O	-1	20520283
I@@	O	-1	20520283
D	O	-1	20520283
was	O	-1	20520283
su@@	O	-1	20520283
peri@@	O	-1	20520283
or	O	-1	20520283
to	O	-1	20520283
placebo	O	-1	20520283
on	O	-1	20520283
the	O	-1	20520283
negative	O	-1	20520283
sub@@	O	-1	20520283
s@@	O	-1	20520283
cal@@	O	-1	20520283
e	O	-1	20520283
with	O	-1	20520283
M@@	O	-1	20520283
MR@@	O	-1	20520283
M	O	-1	20520283
and	O	-1	20520283
on	O	-1	20520283
the	O	-1	20520283
gener@@	O	-1	20520283
al	O	-1	20520283
psycho@@	O	-1	20520283
path@@	O	-1	20520283
ology	O	-1	20520283
sub@@	O	-1	20520283
s@@	O	-1	20520283
cal@@	O	-1	20520283
e	O	-1	20520283
with	O	-1	20520283
L@@	O	-1	20520283
O@@	O	-1	20520283
C@@	O	-1	20520283
F	O	-1	20520283
and	O	-1	20520283
M@@	O	-1	20520283
MR@@	O	-1	20520283
M@@	O	-1	20520283
.	O	-1	20520283
Treat@@	O	-1	20520283
ment@@	O	-1	20520283
-@@	O	-1	20520283
related	O	-1	20520283
adverse	O	-1	20520283
events	O	-1	20520283
(A@@	O	-1	20520283
E@@	O	-1	20520283
s)	O	-1	20520283
occurred	O	-1	20520283
in	O	-1	20520283
4@@	O	-1	20520283
4@@	O	-1	20520283
%	O	-1	20520283
and	O	-1	20520283
5@@	O	-1	20520283
2@@	O	-1	20520283
%,	O	-1	20520283
5@@	O	-1	20520283
7@@	O	-1	20520283
%,	O	-1	20520283
and	O	-1	20520283
4@@	O	-1	20520283
1@@	O	-1	20520283
%	O	-1	20520283
of	O	-1	20520283
the	O	-1	20520283
as@@	B-Chemical	C522667	20520283
en@@	I-Chemical	-1	20520283
apine	I-Chemical	-1	20520283
at	O	-1	20520283
5	O	-1	20520283
and	O	-1	20520283
10	O	-1	20520283
mg	O	-1	20520283
B@@	O	-1	20520283
I@@	O	-1	20520283
D@@	O	-1	20520283
,	O	-1	20520283
haloperidol	B-Chemical	D006220	20520283
,	O	-1	20520283
and	O	-1	20520283
placebo	O	-1	20520283
group@@	O	-1	20520283
s,	O	-1	20520283
respectively.	O	-1	20520283
E@@	B-Disease	D001480	20520283
x@@	I-Disease	-1	20520283
tra@@	I-Disease	-1	20520283
py@@	I-Disease	-1	20520283
ram@@	I-Disease	-1	20520283
idal	I-Disease	-1	20520283
symptoms	I-Disease	-1	20520283
reported	O	-1	20520283
as	O	-1	20520283
A@@	O	-1	20520283
E@@	O	-1	20520283
s	O	-1	20520283
occurred	O	-1	20520283
in	O	-1	20520283
1@@	O	-1	20520283
5%	O	-1	20520283
and	O	-1	20520283
18@@	O	-1	20520283
%,	O	-1	20520283
34@@	O	-1	20520283
%,	O	-1	20520283
and	O	-1	20520283
10@@	O	-1	20520283
%	O	-1	20520283
of	O	-1	20520283
the	O	-1	20520283
as@@	B-Chemical	C522667	20520283
en@@	I-Chemical	-1	20520283
apine	I-Chemical	-1	20520283
at	O	-1	20520283
5	O	-1	20520283
and	O	-1	20520283
10	O	-1	20520283
mg	O	-1	20520283
B@@	O	-1	20520283
I@@	O	-1	20520283
D@@	O	-1	20520283
,	O	-1	20520283
haloperidol	B-Chemical	D006220	20520283
,	O	-1	20520283
and	O	-1	20520283
placebo	O	-1	20520283
group@@	O	-1	20520283
s,	O	-1	20520283
respectively.	O	-1	20520283
Ac@@	O	-1	20520283
ros@@	O	-1	20520283
s	O	-1	20520283
all	O	-1	20520283
group@@	O	-1	20520283
s,	O	-1	20520283
no	O	-1	20520283
more	O	-1	20520283
than	O	-1	20520283
5%	O	-1	20520283
of	O	-1	20520283
patients	O	-1	20520283
had	O	-1	20520283
clin@@	O	-1	20520283
ically	O	-1	20520283
significant	O	-1	20520283
weight	O	-1	20520283
chang@@	O	-1	20520283
e.	O	-1	20520283
P@@	O	-1	20520283
ost	O	-1	20520283
ho@@	O	-1	20520283
c	O	-1	20520283
analy@@	O	-1	20520283
ses	O	-1	20520283
indic@@	O	-1	20520283
ated	O	-1	20520283
that	O	-1	20520283
efficacy	O	-1	20520283
was	O	-1	20520283
similar	O	-1	20520283
with	O	-1	20520283
as@@	B-Chemical	C522667	20520283
en@@	I-Chemical	-1	20520283
apine	I-Chemical	-1	20520283
and	O	-1	20520283
haloperidol	B-Chemical	D006220	20520283
;	O	-1	20520283
greater	O	-1	20520283
contrast@@	O	-1	20520283
s	O	-1	20520283
were	O	-1	20520283
seen	O	-1	20520283
in	O	-1	20520283
A@@	O	-1	20520283
E@@	O	-1	20520283
s,	O	-1	20520283
es@@	O	-1	20520283
p@@	O	-1	20520283
ec@@	O	-1	20520283
i@@	O	-1	20520283
ally	O	-1	20520283
ext@@	B-Disease	D001480	20520283
ra@@	I-Disease	-1	20520283
py@@	I-Disease	-1	20520283
ram@@	I-Disease	-1	20520283
idal	I-Disease	-1	20520283
symptoms	I-Disease	-1	20520283
.	O	-1	20520283

P@@	O	-1	20588063
er@@	O	-1	20588063
me@@	O	-1	20588063
abil@@	O	-1	20588063
ity,	O	-1	20588063
ult@@	O	-1	20588063
ra@@	O	-1	20588063
struct@@	O	-1	20588063
ural	O	-1	20588063
chang@@	O	-1	20588063
es,	O	-1	20588063
and	O	-1	20588063
di@@	O	-1	20588063
stri@@	O	-1	20588063
bu@@	O	-1	20588063
tion	O	-1	20588063
of	O	-1	20588063
novel	O	-1	20588063
protein@@	O	-1	20588063
s	O	-1	20588063
in	O	-1	20588063
the	O	-1	20588063
glomerular	O	-1	20588063
bar@@	O	-1	20588063
ri@@	O	-1	20588063
er	O	-1	20588063
in	O	-1	20588063
early	O	-1	20588063
p@@	B-Chemical	D011692	20588063
uro@@	I-Chemical	-1	20588063
m@@	I-Chemical	-1	20588063
ycin	I-Chemical	-1	20588063
amin@@	I-Chemical	-1	20588063
on@@	I-Chemical	-1	20588063
ucle@@	I-Chemical	-1	20588063
o@@	I-Chemical	-1	20588063
side	I-Chemical	-1	20588063
nephro@@	B-Disease	D009401	20588063
sis	I-Disease	-1	20588063
.	O	-1	20588063
BACKGROUND@@	O	-1	20588063
/@@	O	-1	20588063
A@@	O	-1	20588063
I@@	O	-1	20588063
M@@	O	-1	20588063
S:	O	-1	20588063
It	O	-1	20588063
is	O	-1	20588063
sti@@	O	-1	20588063
ll	O	-1	20588063
unc@@	O	-1	20588063
le@@	O	-1	20588063
ar	O	-1	20588063
wh@@	O	-1	20588063
at	O	-1	20588063
h@@	O	-1	20588063
ap@@	O	-1	20588063
pen@@	O	-1	20588063
s	O	-1	20588063
in	O	-1	20588063
the	O	-1	20588063
glomerul@@	O	-1	20588063
us	O	-1	20588063
when	O	-1	20588063
proteinuria	B-Disease	D011507	20588063
star@@	O	-1	20588063
t@@	O	-1	20588063
s.	O	-1	20588063
U@@	O	-1	20588063
s@@	O	-1	20588063
ing	O	-1	20588063
p@@	B-Chemical	D011692	20588063
uro@@	I-Chemical	-1	20588063
m@@	I-Chemical	-1	20588063
ycin	I-Chemical	-1	20588063
amin@@	I-Chemical	-1	20588063
on@@	I-Chemical	-1	20588063
ucle@@	I-Chemical	-1	20588063
o@@	I-Chemical	-1	20588063
side	I-Chemical	-1	20588063
nephro@@	B-Disease	D009401	20588063
sis	I-Disease	-1	20588063
(@@	O	-1	20588063
PA@@	O	-1	20588063
N@@	O	-1	20588063
)	O	-1	20588063
rats,	O	-1	20588063
we	O	-1	20588063
studied	O	-1	20588063
early	O	-1	20588063
ult@@	O	-1	20588063
ra@@	O	-1	20588063
struct@@	O	-1	20588063
ural	O	-1	20588063
and	O	-1	20588063
per@@	O	-1	20588063
me@@	O	-1	20588063
ability	O	-1	20588063
changes	O	-1	20588063
in	O	-1	20588063
rel@@	O	-1	20588063
ation	O	-1	20588063
to	O	-1	20588063
the	O	-1	20588063
expression	O	-1	20588063
of	O	-1	20588063
the	O	-1	20588063
po@@	O	-1	20588063
d@@	O	-1	20588063
ocy@@	O	-1	20588063
te@@	O	-1	20588063
-@@	O	-1	20588063
associated	O	-1	20588063
mol@@	O	-1	20588063
ec@@	O	-1	20588063
ul@@	O	-1	20588063
es	O	-1	20588063
neph@@	O	-1	20588063
r@@	O	-1	20588063
in,	O	-1	20588063
a@@	O	-1	20588063
-@@	O	-1	20588063
act@@	O	-1	20588063
in@@	O	-1	20588063
in,	O	-1	20588063
d@@	O	-1	20588063
en@@	O	-1	20588063
d@@	O	-1	20588063
r@@	O	-1	20588063
in,	O	-1	20588063
and	O	-1	20588063
ple@@	O	-1	20588063
k@@	O	-1	20588063
h@@	O	-1	20588063
h@@	O	-1	20588063
2,	O	-1	20588063
the	O	-1	20588063
las@@	O	-1	20588063
t	O	-1	20588063
two	O	-1	20588063
of	O	-1	20588063
which	O	-1	20588063
were	O	-1	20588063
only	O	-1	20588063
rec@@	O	-1	20588063
ently	O	-1	20588063
dis@@	O	-1	20588063
co@@	O	-1	20588063
vered	O	-1	20588063
in	O	-1	20588063
po@@	O	-1	20588063
d@@	O	-1	20588063
ocy@@	O	-1	20588063
t@@	O	-1	20588063
es.	O	-1	20588063
METHODS:	O	-1	20588063
U@@	O	-1	20588063
s@@	O	-1	20588063
ing	O	-1	20588063
immun@@	O	-1	20588063
e	O	-1	20588063
st@@	O	-1	20588063
ain@@	O	-1	20588063
ing@@	O	-1	20588063
s,	O	-1	20588063
se@@	O	-1	20588063
mi@@	O	-1	20588063
qu@@	O	-1	20588063
anti@@	O	-1	20588063
t@@	O	-1	20588063
ative	O	-1	20588063
meas@@	O	-1	20588063
ure@@	O	-1	20588063
ment	O	-1	20588063
was	O	-1	20588063
performed	O	-1	20588063
under	O	-1	20588063
the	O	-1	20588063
electro@@	O	-1	20588063
n	O	-1	20588063
micro@@	O	-1	20588063
sco@@	O	-1	20588063
p@@	O	-1	20588063
e.	O	-1	20588063
P@@	O	-1	20588063
er@@	O	-1	20588063
me@@	O	-1	20588063
ability	O	-1	20588063
was	O	-1	20588063
assessed	O	-1	20588063
using	O	-1	20588063
isol@@	O	-1	20588063
ated	O	-1	20588063
kidney	O	-1	20588063
per@@	O	-1	20588063
f@@	O	-1	20588063
usion	O	-1	20588063
with	O	-1	20588063
trac@@	O	-1	20588063
ers.	O	-1	20588063
P@@	O	-1	20588063
os@@	O	-1	20588063
sible	O	-1	20588063
effects	O	-1	20588063
of	O	-1	20588063
AC@@	O	-1	20588063
E	O	-1	20588063
inhibition	O	-1	20588063
were	O	-1	20588063
test@@	O	-1	20588063
ed.	O	-1	20588063
RESULTS:	O	-1	20588063
B@@	O	-1	20588063
y	O	-1	20588063
day	O	-1	20588063
2,	O	-1	20588063
some	O	-1	20588063
pat@@	O	-1	20588063
ch@@	O	-1	20588063
y	O	-1	20588063
fo@@	O	-1	20588063
o@@	O	-1	20588063
t	O	-1	20588063
pro@@	O	-1	20588063
cess	O	-1	20588063
eff@@	O	-1	20588063
ac@@	O	-1	20588063
em@@	O	-1	20588063
ent@@	O	-1	20588063
,	O	-1	20588063
but	O	-1	20588063
no	O	-1	20588063
proteinuria	B-Disease	D011507	20588063
,	O	-1	20588063
appe@@	O	-1	20588063
a@@	O	-1	20588063
red.	O	-1	20588063
The	O	-1	20588063
amoun@@	O	-1	20588063
t	O	-1	20588063
of	O	-1	20588063
neph@@	O	-1	20588063
rin	O	-1	20588063
was	O	-1	20588063
reduced	O	-1	20588063
in	O	-1	20588063
both	O	-1	20588063
diseas@@	O	-1	20588063
ed	O	-1	20588063
and	O	-1	20588063
normal	O	-1	20588063
a@@	O	-1	20588063
reas@@	O	-1	20588063
.	O	-1	20588063
The	O	-1	20588063
other	O	-1	20588063
protein@@	O	-1	20588063
s	O	-1	20588063
showed	O	-1	20588063
fe@@	O	-1	20588063
w	O	-1	20588063
chang@@	O	-1	20588063
es,	O	-1	20588063
which	O	-1	20588063
were	O	-1	20588063
lim@@	O	-1	20588063
ited	O	-1	20588063
to	O	-1	20588063
diseas@@	O	-1	20588063
ed	O	-1	20588063
a@@	O	-1	20588063
reas@@	O	-1	20588063
.	O	-1	20588063
B@@	O	-1	20588063
y	O	-1	20588063
day	O	-1	20588063
4@@	O	-1	20588063
,	O	-1	20588063
fo@@	O	-1	20588063
o@@	O	-1	20588063
t	O	-1	20588063
pro@@	O	-1	20588063
cess	O	-1	20588063
eff@@	O	-1	20588063
ac@@	O	-1	20588063
ement	O	-1	20588063
was	O	-1	20588063
complete	O	-1	20588063
and	O	-1	20588063
proteinuria	B-Disease	D011507	20588063
appe@@	O	-1	20588063
a@@	O	-1	20588063
red	O	-1	20588063
in	O	-1	20588063
par@@	O	-1	20588063
al@@	O	-1	20588063
le@@	O	-1	20588063
l	O	-1	20588063
with	O	-1	20588063
signs	O	-1	20588063
of	O	-1	20588063
size	O	-1	20588063
bar@@	O	-1	20588063
ri@@	O	-1	20588063
er	O	-1	20588063
dam@@	O	-1	20588063
age.	O	-1	20588063
Ne@@	O	-1	20588063
ph@@	O	-1	20588063
rin	O	-1	20588063
decreased	O	-1	20588063
f@@	O	-1	20588063
ur@@	O	-1	20588063
ther@@	O	-1	20588063
,	O	-1	20588063
while	O	-1	20588063
d@@	O	-1	20588063
en@@	O	-1	20588063
d@@	O	-1	20588063
rin	O	-1	20588063
and	O	-1	20588063
ple@@	O	-1	20588063
k@@	O	-1	20588063
h@@	O	-1	20588063
h@@	O	-1	20588063
2	O	-1	20588063
also	O	-1	20588063
decreased	O	-1	20588063
but	O	-1	20588063
a@@	O	-1	20588063
-@@	O	-1	20588063
act@@	O	-1	20588063
in@@	O	-1	20588063
in	O	-1	20588063
remained	O	-1	20588063
un@@	O	-1	20588063
chang@@	O	-1	20588063
ed.	O	-1	20588063
AC@@	O	-1	20588063
E	O	-1	20588063
inhibition	O	-1	20588063
had	O	-1	20588063
no	O	-1	20588063
significant	O	-1	20588063
protective	O	-1	20588063
effect@@	O	-1	20588063
.	O	-1	20588063
CONCLUSIONS:	O	-1	20588063
PA@@	O	-1	20588063
N	O	-1	20588063
glomerul@@	O	-1	20588063
i	O	-1	20588063
al@@	O	-1	20588063
re@@	O	-1	20588063
ad@@	O	-1	20588063
y	O	-1	20588063
showed	O	-1	20588063
significant	O	-1	20588063
path@@	O	-1	20588063
ology	O	-1	20588063
by	O	-1	20588063
day	O	-1	20588063
4@@	O	-1	20588063
,	O	-1	20588063
des@@	O	-1	20588063
pit@@	O	-1	20588063
e	O	-1	20588063
rel@@	O	-1	20588063
atively	O	-1	20588063
mil@@	O	-1	20588063
d	O	-1	20588063
proteinuria	B-Disease	D011507	20588063
.	O	-1	20588063
This	O	-1	20588063
was	O	-1	20588063
pre@@	O	-1	20588063
ce@@	O	-1	20588063
ded	O	-1	20588063
by	O	-1	20588063
al@@	O	-1	20588063
te@@	O	-1	20588063
red	O	-1	20588063
neph@@	O	-1	20588063
rin	O	-1	20588063
ex@@	O	-1	20588063
pres@@	O	-1	20588063
sion,	O	-1	20588063
sup@@	O	-1	20588063
port@@	O	-1	20588063
ing	O	-1	20588063
its	O	-1	20588063
pi@@	O	-1	20588063
v@@	O	-1	20588063
ot@@	O	-1	20588063
al	O	-1	20588063
role	O	-1	20588063
in	O	-1	20588063
po@@	O	-1	20588063
d@@	O	-1	20588063
ocyte	O	-1	20588063
morph@@	O	-1	20588063
olog@@	O	-1	20588063
y.	O	-1	20588063
The	O	-1	20588063
novel	O	-1	20588063
protein@@	O	-1	20588063
s	O	-1	20588063
d@@	O	-1	20588063
en@@	O	-1	20588063
d@@	O	-1	20588063
rin	O	-1	20588063
and	O	-1	20588063
ple@@	O	-1	20588063
k@@	O	-1	20588063
h@@	O	-1	20588063
h@@	O	-1	20588063
2	O	-1	20588063
were	O	-1	20588063
both	O	-1	20588063
reduc@@	O	-1	20588063
ed,	O	-1	20588063
suggesting	O	-1	20588063
ro@@	O	-1	20588063
le@@	O	-1	20588063
s	O	-1	20588063
in	O	-1	20588063
PA@@	O	-1	20588063
N@@	O	-1	20588063
,	O	-1	20588063
whereas	O	-1	20588063
a@@	O	-1	20588063
-@@	O	-1	20588063
act@@	O	-1	20588063
in@@	O	-1	20588063
in	O	-1	20588063
was	O	-1	20588063
un@@	O	-1	20588063
chang@@	O	-1	20588063
ed.	O	-1	20588063

Tw@@	O	-1	19820426
in	O	-1	19820426
pre@@	O	-1	19820426
term	O	-1	19820426
ne@@	O	-1	19820426
on@@	O	-1	19820426
ates	O	-1	19820426
with	O	-1	19820426
cardiac	B-Disease	D066126	19820426
toxicity	I-Disease	-1	19820426
related	O	-1	19820426
to	O	-1	19820426
lop@@	B-Chemical	C558899	19820426
in@@	I-Chemical	-1	19820426
avi@@	I-Chemical	-1	19820426
r@@	I-Chemical	-1	19820426
/@@	I-Chemical	-1	19820426
rit@@	I-Chemical	-1	19820426
on@@	I-Chemical	-1	19820426
avi@@	I-Chemical	-1	19820426
r	I-Chemical	-1	19820426
therapy.	O	-1	19820426
We	O	-1	19820426
report	O	-1	19820426
tw@@	O	-1	19820426
in	O	-1	19820426
ne@@	O	-1	19820426
on@@	O	-1	19820426
ates	O	-1	19820426
who	O	-1	19820426
were	O	-1	19820426
b@@	O	-1	19820426
or@@	O	-1	19820426
n	O	-1	19820426
pre@@	O	-1	19820426
mat@@	O	-1	19820426
ure@@	O	-1	19820426
ly	O	-1	19820426
at	O	-1	19820426
3@@	O	-1	19820426
2	O	-1	19820426
weeks	O	-1	19820426
of	O	-1	19820426
g@@	O	-1	19820426
est@@	O	-1	19820426
ation	O	-1	19820426
to	O	-1	19820426
a	O	-1	19820426
mo@@	O	-1	19820426
ther	O	-1	19820426
with	O	-1	19820426
human	B-Disease	D015658	19820426
immuno@@	I-Disease	-1	19820426
defici@@	I-Disease	-1	19820426
ency	I-Disease	-1	19820426
vi@@	I-Disease	-1	19820426
ru@@	I-Disease	-1	19820426
s	I-Disease	-1	19820426
inf@@	I-Disease	-1	19820426
ection	I-Disease	-1	19820426
.	O	-1	19820426
One	O	-1	19820426
of	O	-1	19820426
the	O	-1	19820426
tw@@	O	-1	19820426
ins	O	-1	19820426
developed	O	-1	19820426
complete	O	-1	19820426
heart	B-Disease	D006327	19820426
bloc@@	I-Disease	-1	19820426
k	I-Disease	-1	19820426
and	O	-1	19820426
di@@	B-Disease	D002311	19820426
l@@	I-Disease	-1	19820426
ated	I-Disease	-1	19820426
cardi@@	I-Disease	-1	19820426
om@@	I-Disease	-1	19820426
yo@@	I-Disease	-1	19820426
pathy	I-Disease	-1	19820426
related	O	-1	19820426
to	O	-1	19820426
lop@@	B-Chemical	C558899	19820426
in@@	I-Chemical	-1	19820426
avi@@	I-Chemical	-1	19820426
r@@	I-Chemical	-1	19820426
/@@	I-Chemical	-1	19820426
rit@@	I-Chemical	-1	19820426
on@@	I-Chemical	-1	19820426
avi@@	I-Chemical	-1	19820426
r	I-Chemical	-1	19820426
therapy,	O	-1	19820426
a	O	-1	19820426
bo@@	O	-1	19820426
ost@@	O	-1	19820426
ed	O	-1	19820426
prote@@	O	-1	19820426
as@@	O	-1	19820426
e-@@	O	-1	19820426
inhibitor	O	-1	19820426
agent@@	O	-1	19820426
,	O	-1	19820426
while	O	-1	19820426
the	O	-1	19820426
other	O	-1	19820426
tw@@	O	-1	19820426
in	O	-1	19820426
developed	O	-1	19820426
mil@@	O	-1	19820426
d	O	-1	19820426
brady@@	B-Disease	D001919	19820426
cardia	I-Disease	-1	19820426
.	O	-1	19820426
We	O	-1	19820426
recomm@@	O	-1	19820426
end	O	-1	19820426
cau@@	O	-1	19820426
tion	O	-1	19820426
in	O	-1	19820426
the	O	-1	19820426
use	O	-1	19820426
of	O	-1	19820426
lop@@	B-Chemical	C558899	19820426
in@@	I-Chemical	-1	19820426
avi@@	I-Chemical	-1	19820426
r@@	I-Chemical	-1	19820426
/@@	I-Chemical	-1	19820426
rit@@	I-Chemical	-1	19820426
on@@	I-Chemical	-1	19820426
avi@@	I-Chemical	-1	19820426
r	I-Chemical	-1	19820426
in	O	-1	19820426
the	O	-1	19820426
immedi@@	O	-1	19820426
ate	O	-1	19820426
ne@@	O	-1	19820426
on@@	O	-1	19820426
atal	O	-1	19820426
perio@@	O	-1	19820426
d.	O	-1	19820426

L@@	O	-1	1616457
ear@@	O	-1	1616457
ning	O	-1	1616457
of	O	-1	1616457
rats	O	-1	1616457
under	O	-1	1616457
am@@	B-Disease	D000647	1616457
ne@@	I-Disease	-1	1616457
sia	I-Disease	-1	1616457
caused	O	-1	1616457
by	O	-1	1616457
pent@@	B-Chemical	D010424	1616457
obarbit@@	I-Chemical	-1	1616457
al	I-Chemical	-1	1616457
.	O	-1	1616457
D@@	O	-1	1616457
is@@	O	-1	1616457
s@@	O	-1	1616457
oci@@	O	-1	1616457
ated	O	-1	1616457
lear@@	O	-1	1616457
ning	O	-1	1616457
of	O	-1	1616457
rats	O	-1	1616457
in	O	-1	1616457
the	O	-1	1616457
normal	O	-1	1616457
state	O	-1	1616457
and	O	-1	1616457
the	O	-1	1616457
state	O	-1	1616457
of	O	-1	1616457
am@@	B-Disease	D000647	1616457
ne@@	I-Disease	-1	1616457
sia	I-Disease	-1	1616457
produced	O	-1	1616457
by	O	-1	1616457
pent@@	B-Chemical	D010424	1616457
obarbit@@	I-Chemical	-1	1616457
al	I-Chemical	-1	1616457
(1@@	O	-1	1616457
5	O	-1	1616457
mg/kg@@	O	-1	1616457
,	O	-1	1616457
ip@@	O	-1	1616457
)	O	-1	1616457
was	O	-1	1616457
car@@	O	-1	1616457
ri@@	O	-1	1616457
ed	O	-1	1616457
out@@	O	-1	1616457
.	O	-1	1616457
R@@	O	-1	1616457
at@@	O	-1	1616457
s	O	-1	1616457
were	O	-1	1616457
tra@@	O	-1	1616457
in@@	O	-1	1616457
ed	O	-1	1616457
to	O	-1	1616457
appro@@	O	-1	1616457
ach	O	-1	1616457
a	O	-1	1616457
s@@	O	-1	1616457
he@@	O	-1	1616457
l@@	O	-1	1616457
f	O	-1	1616457
wh@@	O	-1	1616457
ere	O	-1	1616457
they	O	-1	1616457
received	O	-1	1616457
fo@@	O	-1	1616457
od	O	-1	1616457
re@@	O	-1	1616457
inf@@	O	-1	1616457
or@@	O	-1	1616457
ce@@	O	-1	1616457
ment.	O	-1	1616457
In	O	-1	1616457
Group	O	-1	1616457
1	O	-1	1616457
the	O	-1	1616457
rats	O	-1	1616457
were	O	-1	1616457
tra@@	O	-1	1616457
in@@	O	-1	1616457
ed	O	-1	1616457
under	O	-1	1616457
the	O	-1	1616457
influence	O	-1	1616457
of	O	-1	1616457
pent@@	B-Chemical	D010424	1616457
obarbit@@	I-Chemical	-1	1616457
al	I-Chemical	-1	1616457
to	O	-1	1616457
ru@@	O	-1	1616457
n	O	-1	1616457
to	O	-1	1616457
the	O	-1	1616457
same	O	-1	1616457
s@@	O	-1	1616457
he@@	O	-1	1616457
l@@	O	-1	1616457
f	O	-1	1616457
as	O	-1	1616457
in	O	-1	1616457
the	O	-1	1616457
normal	O	-1	1616457
stat@@	O	-1	1616457
e.	O	-1	1616457
In	O	-1	1616457
Group	O	-1	1616457
2	O	-1	1616457
the	O	-1	1616457
rats	O	-1	1616457
were	O	-1	1616457
tra@@	O	-1	1616457
in@@	O	-1	1616457
ed	O	-1	1616457
to	O	-1	1616457
appro@@	O	-1	1616457
ach	O	-1	1616457
different	O	-1	1616457
s@@	O	-1	1616457
he@@	O	-1	1616457
l@@	O	-1	1616457
v@@	O	-1	1616457
es	O	-1	1616457
in	O	-1	1616457
different	O	-1	1616457
drug	O	-1	1616457
stat@@	O	-1	1616457
es.	O	-1	1616457
It	O	-1	1616457
was	O	-1	1616457
shown	O	-1	1616457
that	O	-1	1616457
memory	B-Disease	D008569	1616457
dis@@	I-Disease	-1	1616457
s@@	I-Disease	-1	1616457
oci@@	I-Disease	-1	1616457
ation	I-Disease	-1	1616457
occurred	O	-1	1616457
in	O	-1	1616457
both	O	-1	1616457
groups.	O	-1	1616457
Di@@	O	-1	1616457
fferen@@	O	-1	1616457
ces	O	-1	1616457
in	O	-1	1616457
the	O	-1	1616457
par@@	O	-1	1616457
ame@@	O	-1	1616457
ters	O	-1	1616457
of	O	-1	1616457
tra@@	O	-1	1616457
in@@	O	-1	1616457
ing	O	-1	1616457
under	O	-1	1616457
the	O	-1	1616457
influence	O	-1	1616457
of	O	-1	1616457
pent@@	B-Chemical	D010424	1616457
obarbit@@	I-Chemical	-1	1616457
al	I-Chemical	-1	1616457
between	O	-1	1616457
Grou@@	O	-1	1616457
p@@	O	-1	1616457
s	O	-1	1616457
1	O	-1	1616457
and	O	-1	1616457
2	O	-1	1616457
were	O	-1	1616457
reveal@@	O	-1	1616457
ed.	O	-1	1616457
These	O	-1	1616457
findings	O	-1	1616457
show	O	-1	1616457
that	O	-1	1616457
the	O	-1	1616457
bra@@	O	-1	1616457
in-@@	O	-1	1616457
dis@@	O	-1	1616457
s@@	O	-1	1616457
oci@@	O	-1	1616457
ated	O	-1	1616457
state	O	-1	1616457
induced	O	-1	1616457
by	O	-1	1616457
pent@@	B-Chemical	D010424	1616457
obarbit@@	I-Chemical	-1	1616457
al	I-Chemical	-1	1616457
is	O	-1	1616457
form@@	O	-1	1616457
ed	O	-1	1616457
with	O	-1	1616457
the	O	-1	1616457
partic@@	O	-1	1616457
ip@@	O	-1	1616457
ation	O	-1	1616457
of	O	-1	1616457
the	O	-1	1616457
mechanisms	O	-1	1616457
of	O	-1	1616457
inf@@	O	-1	1616457
orm@@	O	-1	1616457
ation	O	-1	1616457
per@@	O	-1	1616457
cep@@	O	-1	1616457
tion.	O	-1	1616457

An@@	B-Disease	D006394	567256
gi@@	I-Disease	-1	567256
os@@	I-Disease	-1	567256
ar@@	I-Disease	-1	567256
com@@	I-Disease	-1	567256
a	I-Disease	-1	567256
of	I-Disease	-1	567256
the	I-Disease	-1	567256
liver	I-Disease	-1	567256
An@@	B-Disease	D008113	567256
gi@@	I-Disease	-1	567256
os@@	I-Disease	-1	567256
ar@@	I-Disease	-1	567256
com@@	I-Disease	-1	567256
a	I-Disease	-1	567256
of	I-Disease	-1	567256
the	I-Disease	-1	567256
liver	I-Disease	-1	567256
associated	O	-1	567256
with	O	-1	567256
di@@	B-Chemical	D004054	567256
eth@@	I-Chemical	-1	567256
yl@@	I-Chemical	-1	567256
sti@@	I-Chemical	-1	567256
l@@	I-Chemical	-1	567256
be@@	I-Chemical	-1	567256
stro@@	I-Chemical	-1	567256
l	I-Chemical	-1	567256
.	O	-1	567256
An@@	B-Disease	D006394	567256
gi@@	I-Disease	-1	567256
os@@	I-Disease	-1	567256
ar@@	I-Disease	-1	567256
com@@	I-Disease	-1	567256
a	I-Disease	-1	567256
of	I-Disease	-1	567256
the	I-Disease	-1	567256
liver	I-Disease	-1	567256
An@@	B-Disease	D008113	567256
gi@@	I-Disease	-1	567256
os@@	I-Disease	-1	567256
ar@@	I-Disease	-1	567256
com@@	I-Disease	-1	567256
a	I-Disease	-1	567256
of	I-Disease	-1	567256
the	I-Disease	-1	567256
liver	I-Disease	-1	567256
occurred	O	-1	567256
in	O	-1	567256
a	O	-1	567256
7@@	O	-1	567256
6-@@	O	-1	567256
year-old	O	-1	567256
man	O	-1	567256
who	O	-1	567256
had	O	-1	567256
been	O	-1	567256
treated	O	-1	567256
for	O	-1	567256
a	O	-1	567256
we@@	O	-1	567256
ll@@	O	-1	567256
-@@	O	-1	567256
differen@@	O	-1	567256
ti@@	O	-1	567256
ated	O	-1	567256
aden@@	B-Disease	D000230	567256
oc@@	I-Disease	-1	567256
arc@@	I-Disease	-1	567256
in@@	I-Disease	-1	567256
oma	I-Disease	-1	567256
of	I-Disease	-1	567256
the	I-Disease	-1	567256
liver	I-Disease	-1	567256
aden@@	B-Disease	D008113	567256
oc@@	I-Disease	-1	567256
arc@@	I-Disease	-1	567256
in@@	I-Disease	-1	567256
oma	I-Disease	-1	567256
of	I-Disease	-1	567256
the	I-Disease	-1	567256
liver	I-Disease	-1	567256
with	O	-1	567256
di@@	B-Chemical	D004054	567256
eth@@	I-Chemical	-1	567256
yl@@	I-Chemical	-1	567256
sti@@	I-Chemical	-1	567256
l@@	I-Chemical	-1	567256
be@@	I-Chemical	-1	567256
stro@@	I-Chemical	-1	567256
l	I-Chemical	-1	567256
for	O	-1	567256
13	O	-1	567256
year@@	O	-1	567256
s.	O	-1	567256
An@@	B-Disease	D006394	567256
gi@@	I-Disease	-1	567256
os@@	I-Disease	-1	567256
ar@@	I-Disease	-1	567256
com@@	I-Disease	-1	567256
a	I-Disease	-1	567256
was	O	-1	567256
also	O	-1	567256
present	O	-1	567256
within	O	-1	567256
pulmonary	O	-1	567256
and	O	-1	567256
renal	O	-1	567256
arter@@	O	-1	567256
i@@	O	-1	567256
es.	O	-1	567256
The	O	-1	567256
possib@@	O	-1	567256
ility	O	-1	567256
that	O	-1	567256
the	O	-1	567256
intra@@	B-Disease	D014652	567256
arterial	I-Disease	-1	567256
lesions	I-Disease	-1	567256
might	O	-1	567256
re@@	O	-1	567256
present	O	-1	567256
in@@	O	-1	567256
dependent	O	-1	567256
prim@@	O	-1	567256
ary	O	-1	567256
tu@@	B-Disease	D009369	567256
mor@@	I-Disease	-1	567256
s	I-Disease	-1	567256
is	O	-1	567256
conside@@	O	-1	567256
red.	O	-1	567256

R@@	O	-1	17439425
ole	O	-1	17439425
of	O	-1	17439425
x@@	B-Chemical	D019820	17439425
an@@	I-Chemical	-1	17439425
th@@	I-Chemical	-1	17439425
ine	I-Chemical	-1	17439425
oxid@@	O	-1	17439425
ase	O	-1	17439425
in	O	-1	17439425
de@@	B-Chemical	D003907	17439425
xameth@@	I-Chemical	-1	17439425
as@@	I-Chemical	-1	17439425
one	I-Chemical	-1	17439425
-induced	O	-1	17439425
hypertension	B-Disease	D006973	17439425
in	O	-1	17439425
rats.	O	-1	17439425
1@@	O	-1	17439425
.	O	-1	17439425
G@@	O	-1	17439425
lu@@	O	-1	17439425
co@@	O	-1	17439425
cortico@@	O	-1	17439425
id@@	O	-1	17439425
-induced	O	-1	17439425
hypertension	B-Disease	D006973	17439425
(@@	O	-1	17439425
G@@	O	-1	17439425
C@@	O	-1	17439425
-	O	-1	17439425
H@@	B-Disease	D006973	17439425
T	I-Disease	-1	17439425
)	O	-1	17439425
in	O	-1	17439425
the	O	-1	17439425
rat	O	-1	17439425
is	O	-1	17439425
associated	O	-1	17439425
with	O	-1	17439425
nit@@	B-Chemical	D009569	17439425
ric	I-Chemical	-1	17439425
ox@@	I-Chemical	-1	17439425
ide	I-Chemical	-1	17439425
-@@	O	-1	17439425
re@@	O	-1	17439425
do@@	O	-1	17439425
x	O	-1	17439425
im@@	O	-1	17439425
b@@	O	-1	17439425
al@@	O	-1	17439425
ance@@	O	-1	17439425
.	O	-1	17439425
2@@	O	-1	17439425
.	O	-1	17439425
We	O	-1	17439425
studied	O	-1	17439425
the	O	-1	17439425
role	O	-1	17439425
of	O	-1	17439425
x@@	B-Chemical	D019820	17439425
an@@	I-Chemical	-1	17439425
th@@	I-Chemical	-1	17439425
ine	I-Chemical	-1	17439425
oxid@@	O	-1	17439425
ase	O	-1	17439425
(@@	O	-1	17439425
X@@	O	-1	17439425
O@@	O	-1	17439425
),	O	-1	17439425
which	O	-1	17439425
is	O	-1	17439425
implic@@	O	-1	17439425
ated	O	-1	17439425
in	O	-1	17439425
the	O	-1	17439425
pro@@	O	-1	17439425
duction	O	-1	17439425
of	O	-1	17439425
reac@@	O	-1	17439425
tive	O	-1	17439425
oxy@@	O	-1	17439425
gen	O	-1	17439425
spec@@	O	-1	17439425
i@@	O	-1	17439425
es,	O	-1	17439425
in	O	-1	17439425
de@@	B-Chemical	D003907	17439425
xameth@@	I-Chemical	-1	17439425
as@@	I-Chemical	-1	17439425
one	I-Chemical	-1	17439425
-induced	O	-1	17439425
hypertension	B-Disease	D006973	17439425
(	O	-1	17439425
de@@	B-Chemical	D003907	17439425
x	I-Chemical	-1	17439425
-	O	-1	17439425
H@@	B-Disease	D006973	17439425
T	I-Disease	-1	17439425
).	O	-1	17439425
3@@	O	-1	17439425
.	O	-1	17439425
Th@@	O	-1	17439425
ir@@	O	-1	17439425
t@@	O	-1	17439425
y	O	-1	17439425
male	O	-1	17439425
S@@	O	-1	17439425
pra@@	O	-1	17439425
gu@@	O	-1	17439425
e-@@	O	-1	17439425
D@@	O	-1	17439425
aw@@	O	-1	17439425
le@@	O	-1	17439425
y	O	-1	17439425
rats	O	-1	17439425
were	O	-1	17439425
divid@@	O	-1	17439425
ed	O	-1	17439425
random@@	O	-1	17439425
ly	O	-1	17439425
into	O	-1	17439425
four	O	-1	17439425
treatment	O	-1	17439425
group@@	O	-1	17439425
s:	O	-1	17439425
sal@@	O	-1	17439425
ine,	O	-1	17439425
de@@	B-Chemical	D003907	17439425
xameth@@	I-Chemical	-1	17439425
as@@	I-Chemical	-1	17439425
one	I-Chemical	-1	17439425
(	O	-1	17439425
de@@	B-Chemical	D003907	17439425
x	I-Chemical	-1	17439425
),	O	-1	17439425
al@@	B-Chemical	D000493	17439425
lop@@	I-Chemical	-1	17439425
ur@@	I-Chemical	-1	17439425
in@@	I-Chemical	-1	17439425
ol	I-Chemical	-1	17439425
plus	O	-1	17439425
sal@@	O	-1	17439425
ine,	O	-1	17439425
and	O	-1	17439425
al@@	B-Chemical	D000493	17439425
lop@@	I-Chemical	-1	17439425
ur@@	I-Chemical	-1	17439425
in@@	I-Chemical	-1	17439425
ol	I-Chemical	-1	17439425
plus	O	-1	17439425
de@@	B-Chemical	D003907	17439425
x	I-Chemical	-1	17439425
.	O	-1	17439425
4@@	O	-1	17439425
.	O	-1	17439425
S@@	O	-1	17439425
y@@	O	-1	17439425
st@@	O	-1	17439425
olic	O	-1	17439425
blood	O	-1	17439425
pressu@@	O	-1	17439425
res	O	-1	17439425
(S@@	O	-1	17439425
B@@	O	-1	17439425
P)	O	-1	17439425
and	O	-1	17439425
bo@@	O	-1	17439425
dy@@	O	-1	17439425
weigh@@	O	-1	17439425
ts	O	-1	17439425
were	O	-1	17439425
recor@@	O	-1	17439425
ded	O	-1	17439425
each	O	-1	17439425
al@@	O	-1	17439425
tern@@	O	-1	17439425
ate	O	-1	17439425
da@@	O	-1	17439425
y.	O	-1	17439425
Th@@	O	-1	17439425
ym@@	O	-1	17439425
us	O	-1	17439425
weight	O	-1	17439425
was	O	-1	17439425
used	O	-1	17439425
as	O	-1	17439425
a	O	-1	17439425
mark@@	O	-1	17439425
er	O	-1	17439425
of	O	-1	17439425
g@@	O	-1	17439425
lu@@	O	-1	17439425
co@@	O	-1	17439425
cortico@@	O	-1	17439425
id	O	-1	17439425
activ@@	O	-1	17439425
ity,	O	-1	17439425
and	O	-1	17439425
serum	O	-1	17439425
ur@@	B-Chemical	D014527	17439425
ate	I-Chemical	-1	17439425
to	O	-1	17439425
ass@@	O	-1	17439425
ess	O	-1	17439425
X@@	O	-1	17439425
O	O	-1	17439425
inhib@@	O	-1	17439425
i@@	O	-1	17439425
tion.	O	-1	17439425
5@@	O	-1	17439425
.	O	-1	17439425
De@@	B-Chemical	D003907	17439425
x	I-Chemical	-1	17439425
increased	B-Disease	D006973	17439425
S@@	I-Disease	-1	17439425
B@@	I-Disease	-1	17439425
P	I-Disease	-1	17439425
(1@@	O	-1	17439425
10	O	-1	17439425
+/-	O	-1	17439425
2-@@	O	-1	17439425
12@@	O	-1	17439425
6	O	-1	17439425
+/-	O	-1	17439425
3	O	-1	17439425
mm@@	O	-1	17439425
H@@	O	-1	17439425
g@@	O	-1	17439425
;	O	-1	17439425
P	O	-1	17439425
<	O	-1	17439425
0.00@@	O	-1	17439425
1)	O	-1	17439425
and	O	-1	17439425
decreased	B-Disease	D015431	17439425
th@@	I-Disease	-1	17439425
ym@@	I-Disease	-1	17439425
us	I-Disease	-1	17439425
(P	I-Disease	-1	17439425
<	I-Disease	-1	17439425
0.00@@	I-Disease	-1	17439425
1)	I-Disease	-1	17439425
and	I-Disease	-1	17439425
bo@@	I-Disease	-1	17439425
dy@@	I-Disease	-1	17439425
weigh@@	I-Disease	-1	17439425
ts	I-Disease	-1	17439425
(P@@	O	-1	17439425
"	O	-1	17439425
<	O	-1	17439425
0.0@@	O	-1	17439425
1).	O	-1	17439425
Al@@	B-Chemical	D000493	17439425
lop@@	I-Chemical	-1	17439425
ur@@	I-Chemical	-1	17439425
in@@	I-Chemical	-1	17439425
ol	I-Chemical	-1	17439425
decreased	O	-1	17439425
serum	O	-1	17439425
ur@@	B-Chemical	D014527	17439425
ate	I-Chemical	-1	17439425
from	O	-1	17439425
7@@	O	-1	17439425
6	O	-1	17439425
+/-	O	-1	17439425
5	O	-1	17439425
to	O	-1	17439425
30	O	-1	17439425
+/-	O	-1	17439425
3	O	-1	17439425
mic@@	O	-1	17439425
rom@@	O	-1	17439425
ol@@	O	-1	17439425
/@@	O	-1	17439425
L	O	-1	17439425
(P	O	-1	17439425
<	O	-1	17439425
0.00@@	O	-1	17439425
1)	O	-1	17439425
in	O	-1	17439425
saline	O	-1	17439425
and	O	-1	17439425
from	O	-1	17439425
8@@	O	-1	17439425
4	O	-1	17439425
+/-	O	-1	17439425
13	O	-1	17439425
to	O	-1	17439425
2@@	O	-1	17439425
8	O	-1	17439425
+/-	O	-1	17439425
2	O	-1	17439425
mic@@	O	-1	17439425
rom@@	O	-1	17439425
ol@@	O	-1	17439425
/@@	O	-1	17439425
L	O	-1	17439425
in	O	-1	17439425
de@@	B-Chemical	D003907	17439425
x	I-Chemical	-1	17439425
-treated	O	-1	17439425
(P	O	-1	17439425
<	O	-1	17439425
0.0@@	O	-1	17439425
1)	O	-1	17439425
groups.	O	-1	17439425
6@@	O	-1	17439425
.	O	-1	17439425
Al@@	B-Chemical	D000493	17439425
lop@@	I-Chemical	-1	17439425
ur@@	I-Chemical	-1	17439425
in@@	I-Chemical	-1	17439425
ol	I-Chemical	-1	17439425
did	O	-1	17439425
not	O	-1	17439425
prev@@	O	-1	17439425
ent	O	-1	17439425
de@@	B-Chemical	D003907	17439425
x	I-Chemical	-1	17439425
-	O	-1	17439425
H@@	B-Disease	D006973	17439425
T	I-Disease	-1	17439425
.	O	-1	17439425
Th@@	O	-1	17439425
is@@	O	-1	17439425
,	O	-1	17439425
to@@	O	-1	17439425
ge@@	O	-1	17439425
ther	O	-1	17439425
with	O	-1	17439425
our	O	-1	17439425
previ@@	O	-1	17439425
ous	O	-1	17439425
findings	O	-1	17439425
that	O	-1	17439425
al@@	B-Chemical	D000493	17439425
lop@@	I-Chemical	-1	17439425
ur@@	I-Chemical	-1	17439425
in@@	I-Chemical	-1	17439425
ol	I-Chemical	-1	17439425
fail@@	O	-1	17439425
ed	O	-1	17439425
to	O	-1	17439425
prev@@	O	-1	17439425
ent	O	-1	17439425
adren@@	O	-1	17439425
oc@@	O	-1	17439425
or@@	O	-1	17439425
tico@@	O	-1	17439425
tro@@	O	-1	17439425
ph@@	O	-1	17439425
ic	O	-1	17439425
h@@	O	-1	17439425
orm@@	O	-1	17439425
one	O	-1	17439425
induced	O	-1	17439425
hypertension	B-Disease	D006973	17439425
,	O	-1	17439425
suggests	O	-1	17439425
that	O	-1	17439425
X@@	O	-1	17439425
O	O	-1	17439425
activity	O	-1	17439425
is	O	-1	17439425
not	O	-1	17439425
a	O	-1	17439425
major	O	-1	17439425
determin@@	O	-1	17439425
ant	O	-1	17439425
of	O	-1	17439425
G@@	O	-1	17439425
C@@	O	-1	17439425
-	O	-1	17439425
H@@	B-Disease	D006973	17439425
T	I-Disease	-1	17439425
in	O	-1	17439425
the	O	-1	17439425
rat@@	O	-1	17439425
.	O	-1	17439425

E@@	O	-1	9351491
x@@	O	-1	9351491
tra@@	O	-1	9351491
py@@	O	-1	9351491
ram@@	O	-1	9351491
idal	O	-1	9351491
side	O	-1	9351491
effects	O	-1	9351491
with	O	-1	9351491
ris@@	B-Chemical	D018967	9351491
perid@@	I-Chemical	-1	9351491
one	I-Chemical	-1	9351491
and	O	-1	9351491
haloperidol	B-Chemical	D006220	9351491
at	O	-1	9351491
compar@@	O	-1	9351491
able	O	-1	9351491
D2	O	-1	9351491
receptor	O	-1	9351491
occ@@	O	-1	9351491
up@@	O	-1	9351491
anc@@	O	-1	9351491
y	O	-1	9351491
level@@	O	-1	9351491
s.	O	-1	9351491
R@@	B-Chemical	D018967	9351491
is@@	I-Chemical	-1	9351491
perid@@	I-Chemical	-1	9351491
one	I-Chemical	-1	9351491
is	O	-1	9351491
an	O	-1	9351491
anti@@	O	-1	9351491
psycho@@	O	-1	9351491
tic	O	-1	9351491
drug	O	-1	9351491
with	O	-1	9351491
high	O	-1	9351491
aff@@	O	-1	9351491
in@@	O	-1	9351491
ity	O	-1	9351491
at	O	-1	9351491
dopamine	B-Chemical	D004298	9351491
D2	O	-1	9351491
and	O	-1	9351491
seroton@@	B-Chemical	D044348	9351491
in	I-Chemical	-1	9351491
5-@@	I-Chemical	-1	9351491
H@@	I-Chemical	-1	9351491
T@@	I-Chemical	-1	9351491
2	I-Chemical	-1	9351491
receptor@@	O	-1	9351491
s.	O	-1	9351491
Pre@@	O	-1	9351491
vi@@	O	-1	9351491
ous	O	-1	9351491
clinical	O	-1	9351491
studies	O	-1	9351491
have	O	-1	9351491
pro@@	O	-1	9351491
pos@@	O	-1	9351491
ed	O	-1	9351491
that	O	-1	9351491
ris@@	B-Chemical	D018967	9351491
perid@@	I-Chemical	-1	9351491
one	I-Chemical	-1	9351491
's	O	-1	9351491
pharmac@@	O	-1	9351491
ologic	O	-1	9351491
prof@@	O	-1	9351491
ile	O	-1	9351491
may	O	-1	9351491
produce	O	-1	9351491
improved	O	-1	9351491
efficacy	O	-1	9351491
for	O	-1	9351491
negative	O	-1	9351491
psycho@@	B-Disease	D011618	9351491
tic	I-Disease	-1	9351491
symptoms	I-Disease	-1	9351491
and	O	-1	9351491
decreased	O	-1	9351491
pro@@	O	-1	9351491
pen@@	O	-1	9351491
s@@	O	-1	9351491
ity	O	-1	9351491
for	O	-1	9351491
ext@@	O	-1	9351491
ra@@	O	-1	9351491
py@@	O	-1	9351491
ram@@	O	-1	9351491
idal	O	-1	9351491
side	O	-1	9351491
effect@@	O	-1	9351491
s;	O	-1	9351491
feat@@	O	-1	9351491
ures	O	-1	9351491
s@@	O	-1	9351491
ha@@	O	-1	9351491
red	O	-1	9351491
by	O	-1	9351491
so@@	O	-1	9351491
-@@	O	-1	9351491
c@@	O	-1	9351491
all@@	O	-1	9351491
ed	O	-1	9351491
'@@	O	-1	9351491
at@@	O	-1	9351491
yp@@	O	-1	9351491
ic@@	O	-1	9351491
al@@	O	-1	9351491
'	O	-1	9351491
neuro@@	O	-1	9351491
le@@	O	-1	9351491
p@@	O	-1	9351491
tic@@	O	-1	9351491
s.	O	-1	9351491
To	O	-1	9351491
determine	O	-1	9351491
if	O	-1	9351491
ro@@	O	-1	9351491
ut@@	O	-1	9351491
ine	O	-1	9351491
ris@@	B-Chemical	D018967	9351491
perid@@	I-Chemical	-1	9351491
one	I-Chemical	-1	9351491
treatment	O	-1	9351491
is	O	-1	9351491
associated	O	-1	9351491
with	O	-1	9351491
a	O	-1	9351491
un@@	O	-1	9351491
i@@	O	-1	9351491
qu@@	O	-1	9351491
e	O	-1	9351491
de@@	O	-1	9351491
g@@	O	-1	9351491
ree	O	-1	9351491
of	O	-1	9351491
D2	O	-1	9351491
receptor	O	-1	9351491
occ@@	O	-1	9351491
up@@	O	-1	9351491
anc@@	O	-1	9351491
y	O	-1	9351491
and	O	-1	9351491
pat@@	O	-1	9351491
ter@@	O	-1	9351491
n	O	-1	9351491
of	O	-1	9351491
clinical	O	-1	9351491
effect@@	O	-1	9351491
s,	O	-1	9351491
we	O	-1	9351491
used	O	-1	9351491
[@@	O	-1	9351491
12@@	O	-1	9351491
3@@	O	-1	9351491
I@@	O	-1	9351491
]@@	O	-1	9351491
I@@	O	-1	9351491
B@@	O	-1	9351491
Z@@	O	-1	9351491
M	O	-1	9351491
S@@	O	-1	9351491
P@@	O	-1	9351491
EC@@	O	-1	9351491
T	O	-1	9351491
to	O	-1	9351491
determine	O	-1	9351491
D2	O	-1	9351491
occ@@	O	-1	9351491
up@@	O	-1	9351491
anc@@	O	-1	9351491
y	O	-1	9351491
in	O	-1	9351491
subjects	O	-1	9351491
treated	O	-1	9351491
with	O	-1	9351491
ro@@	O	-1	9351491
ut@@	O	-1	9351491
ine	O	-1	9351491
clinical	O	-1	9351491
doses	O	-1	9351491
of	O	-1	9351491
ris@@	B-Chemical	D018967	9351491
perid@@	I-Chemical	-1	9351491
one	I-Chemical	-1	9351491
(n	O	-1	9351491
=	O	-1	9351491
12@@	O	-1	9351491
)	O	-1	9351491
or	O	-1	9351491
haloperidol	B-Chemical	D006220	9351491
(n	O	-1	9351491
=	O	-1	9351491
7@@	O	-1	9351491
).	O	-1	9351491
B@@	O	-1	9351491
oth	O	-1	9351491
ris@@	B-Chemical	D018967	9351491
perid@@	I-Chemical	-1	9351491
one	I-Chemical	-1	9351491
and	O	-1	9351491
haloperidol	B-Chemical	D006220	9351491
produced	O	-1	9351491
D2	O	-1	9351491
occ@@	O	-1	9351491
up@@	O	-1	9351491
anc@@	O	-1	9351491
y	O	-1	9351491
levels	O	-1	9351491
between	O	-1	9351491
appro@@	O	-1	9351491
xim@@	O	-1	9351491
ately	O	-1	9351491
60	O	-1	9351491
and	O	-1	9351491
9@@	O	-1	9351491
0%	O	-1	9351491
at	O	-1	9351491
standard	O	-1	9351491
clinical	O	-1	9351491
dos@@	O	-1	9351491
es.	O	-1	9351491
There	O	-1	9351491
was	O	-1	9351491
no	O	-1	9351491
significant	O	-1	9351491
difference	O	-1	9351491
between	O	-1	9351491
occ@@	O	-1	9351491
up@@	O	-1	9351491
anc@@	O	-1	9351491
y	O	-1	9351491
levels	O	-1	9351491
obtained	O	-1	9351491
with	O	-1	9351491
haloperidol	B-Chemical	D006220	9351491
or	O	-1	9351491
ris@@	B-Chemical	D018967	9351491
perid@@	I-Chemical	-1	9351491
one	I-Chemical	-1	9351491
.	O	-1	9351491
D@@	B-Disease	D010302	9351491
ru@@	I-Disease	-1	9351491
g@@	I-Disease	-1	9351491
-induced	I-Disease	-1	9351491
par@@	I-Disease	-1	9351491
k@@	I-Disease	-1	9351491
inson@@	I-Disease	-1	9351491
ism	I-Disease	-1	9351491
was	O	-1	9351491
observed	O	-1	9351491
in	O	-1	9351491
subjects	O	-1	9351491
treated	O	-1	9351491
with	O	-1	9351491
ris@@	B-Chemical	D018967	9351491
perid@@	I-Chemical	-1	9351491
one	I-Chemical	-1	9351491
(4@@	O	-1	9351491
2@@	O	-1	9351491
%)	O	-1	9351491
and	O	-1	9351491
haloperidol	B-Chemical	D006220	9351491
(2@@	O	-1	9351491
9@@	O	-1	9351491
%)	O	-1	9351491
and	O	-1	9351491
was	O	-1	9351491
observed	O	-1	9351491
at	O	-1	9351491
occ@@	O	-1	9351491
up@@	O	-1	9351491
anc@@	O	-1	9351491
y	O	-1	9351491
levels	O	-1	9351491
ab@@	O	-1	9351491
o@@	O	-1	9351491
ve	O	-1	9351491
6@@	O	-1	9351491
0@@	O	-1	9351491
%.	O	-1	9351491
B@@	O	-1	9351491
as@@	O	-1	9351491
ed	O	-1	9351491
on	O	-1	9351491
these	O	-1	9351491
observ@@	O	-1	9351491
ation@@	O	-1	9351491
s,	O	-1	9351491
it	O	-1	9351491
is	O	-1	9351491
concl@@	O	-1	9351491
uded	O	-1	9351491
that	O	-1	9351491
5-@@	O	-1	9351491
H@@	O	-1	9351491
T@@	O	-1	9351491
2	O	-1	9351491
block@@	O	-1	9351491
ade	O	-1	9351491
obtained	O	-1	9351491
with	O	-1	9351491
ris@@	B-Chemical	D018967	9351491
perid@@	I-Chemical	-1	9351491
one	I-Chemical	-1	9351491
at	O	-1	9351491
D2	O	-1	9351491
occ@@	O	-1	9351491
up@@	O	-1	9351491
anc@@	O	-1	9351491
y	O	-1	9351491
rat@@	O	-1	9351491
es	O	-1	9351491
of	O	-1	9351491
6@@	O	-1	9351491
0%	O	-1	9351491
and	O	-1	9351491
ab@@	O	-1	9351491
o@@	O	-1	9351491
ve	O	-1	9351491
does	O	-1	9351491
not	O	-1	9351491
appe@@	O	-1	9351491
ar	O	-1	9351491
to	O	-1	9351491
prot@@	O	-1	9351491
ect	O	-1	9351491
against	O	-1	9351491
the	O	-1	9351491
risk	O	-1	9351491
for	O	-1	9351491
ext@@	O	-1	9351491
ra@@	O	-1	9351491
py@@	O	-1	9351491
ram@@	O	-1	9351491
idal	O	-1	9351491
side	O	-1	9351491
effects.	O	-1	9351491

S@@	B-Chemical	C492458	18752389
im@@	I-Chemical	-1	18752389
vast@@	I-Chemical	-1	18752389
at@@	I-Chemical	-1	18752389
in-@@	I-Chemical	-1	18752389
e@@	I-Chemical	-1	18752389
z@@	I-Chemical	-1	18752389
e@@	I-Chemical	-1	18752389
tim@@	I-Chemical	-1	18752389
i@@	I-Chemical	-1	18752389
be	I-Chemical	-1	18752389
-induced	O	-1	18752389
hepatic	B-Disease	D017093	18752389
failure	I-Disease	-1	18752389
nec@@	O	-1	18752389
ess@@	O	-1	18752389
it@@	O	-1	18752389
ating	O	-1	18752389
liver	O	-1	18752389
transplant@@	O	-1	18752389
ation.	O	-1	18752389
A@@	O	-1	18752389
b@@	O	-1	18752389
st@@	O	-1	18752389
rac@@	O	-1	18752389
t	O	-1	18752389
S@@	O	-1	18752389
er@@	O	-1	18752389
um	O	-1	18752389
amin@@	O	-1	18752389
ot@@	O	-1	18752389
ran@@	O	-1	18752389
s@@	O	-1	18752389
fer@@	O	-1	18752389
ase	O	-1	18752389
elev@@	O	-1	18752389
ations	O	-1	18752389
are	O	-1	18752389
a	O	-1	18752389
common@@	O	-1	18752389
ly	O	-1	18752389
known	O	-1	18752389
adverse	O	-1	18752389
effect	O	-1	18752389
of	O	-1	18752389
3-@@	O	-1	18752389
hydrox@@	O	-1	18752389
y-@@	O	-1	18752389
3-@@	O	-1	18752389
methyl@@	O	-1	18752389
glut@@	O	-1	18752389
ar@@	O	-1	18752389
yl	O	-1	18752389
co@@	O	-1	18752389
enzyme	O	-1	18752389
A	O	-1	18752389
reduc@@	O	-1	18752389
t@@	O	-1	18752389
ase	O	-1	18752389
inhibitor	O	-1	18752389
(	O	-1	18752389
st@@	B-Chemical	D019821	18752389
atin	I-Chemical	-1	18752389
)	O	-1	18752389
therapy.	O	-1	18752389
However,	O	-1	18752389
hepat@@	B-Disease	D056486	18752389
ot@@	I-Disease	-1	18752389
ox@@	I-Disease	-1	18752389
ic	I-Disease	-1	18752389
events	O	-1	18752389
have	O	-1	18752389
not	O	-1	18752389
been	O	-1	18752389
wi@@	O	-1	18752389
de@@	O	-1	18752389
ly	O	-1	18752389
pu@@	O	-1	18752389
bl@@	O	-1	18752389
ished	O	-1	18752389
with	O	-1	18752389
e@@	B-Chemical	C108606	18752389
z@@	I-Chemical	-1	18752389
e@@	I-Chemical	-1	18752389
tim@@	I-Chemical	-1	18752389
i@@	I-Chemical	-1	18752389
be	I-Chemical	-1	18752389
or	O	-1	18752389
the	O	-1	18752389
combination	O	-1	18752389
agent	O	-1	18752389
sim@@	B-Chemical	C492458	18752389
vast@@	I-Chemical	-1	18752389
at@@	I-Chemical	-1	18752389
in-@@	I-Chemical	-1	18752389
e@@	I-Chemical	-1	18752389
z@@	I-Chemical	-1	18752389
e@@	I-Chemical	-1	18752389
tim@@	I-Chemical	-1	18752389
i@@	I-Chemical	-1	18752389
be	I-Chemical	-1	18752389
.	O	-1	18752389
We	O	-1	18752389
describe	O	-1	18752389
a	O	-1	18752389
7@@	O	-1	18752389
0-@@	O	-1	18752389
year-old	O	-1	18752389
H@@	O	-1	18752389
is@@	O	-1	18752389
p@@	O	-1	18752389
anic	O	-1	18752389
woman	O	-1	18752389
who	O	-1	18752389
developed	O	-1	18752389
ful@@	B-Disease	D017114	18752389
min@@	I-Disease	-1	18752389
ant	I-Disease	-1	18752389
hepatic	I-Disease	-1	18752389
failure	I-Disease	-1	18752389
nec@@	O	-1	18752389
ess@@	O	-1	18752389
it@@	O	-1	18752389
ating	O	-1	18752389
liver	O	-1	18752389
transplant@@	O	-1	18752389
ation	O	-1	18752389
10	O	-1	18752389
weeks	O	-1	18752389
after	O	-1	18752389
conver@@	O	-1	18752389
sion	O	-1	18752389
from	O	-1	18752389
sim@@	B-Chemical	D019821	18752389
vastatin	I-Chemical	-1	18752389
40	O	-1	18752389
mg/@@	O	-1	18752389
day	O	-1	18752389
to	O	-1	18752389
sim@@	B-Chemical	C492458	18752389
vastatin	I-Chemical	-1	18752389
10	I-Chemical	-1	18752389
mg@@	I-Chemical	-1	18752389
-@@	I-Chemical	-1	18752389
e@@	I-Chemical	-1	18752389
z@@	I-Chemical	-1	18752389
e@@	I-Chemical	-1	18752389
tim@@	I-Chemical	-1	18752389
i@@	I-Chemical	-1	18752389
be	I-Chemical	-1	18752389
40	I-Chemical	-1	18752389
mg	I-Chemical	-1	18752389
/@@	O	-1	18752389
da@@	O	-1	18752389
y.	O	-1	18752389
The	O	-1	18752389
patient@@	O	-1	18752389
's	O	-1	18752389
li@@	O	-1	18752389
pid	O	-1	18752389
p@@	O	-1	18752389
ane@@	O	-1	18752389
l	O	-1	18752389
had	O	-1	18752389
been	O	-1	18752389
maint@@	O	-1	18752389
ained	O	-1	18752389
with	O	-1	18752389
sim@@	B-Chemical	D019821	18752389
vastatin	I-Chemical	-1	18752389
for	O	-1	18752389
1@@	O	-1	18752389
8	O	-1	18752389
months	O	-1	18752389
before	O	-1	18752389
the	O	-1	18752389
conver@@	O	-1	18752389
sion	O	-1	18752389
without	O	-1	18752389
evidence	O	-1	18752389
of	O	-1	18752389
hepat@@	B-Disease	D056486	18752389
otoxicity	I-Disease	-1	18752389
.	O	-1	18752389
A	O	-1	18752389
ro@@	O	-1	18752389
ut@@	O	-1	18752389
ine	O	-1	18752389
labor@@	O	-1	18752389
atory	O	-1	18752389
wor@@	O	-1	18752389
k@@	O	-1	18752389
-@@	O	-1	18752389
up	O	-1	18752389
10	O	-1	18752389
weeks	O	-1	18752389
after	O	-1	18752389
conver@@	O	-1	18752389
sion	O	-1	18752389
revealed	O	-1	18752389
elevated	O	-1	18752389
serum	O	-1	18752389
amin@@	O	-1	18752389
ot@@	O	-1	18752389
ran@@	O	-1	18752389
s@@	O	-1	18752389
fer@@	O	-1	18752389
ase	O	-1	18752389
level@@	O	-1	18752389
s.	O	-1	18752389
S@@	B-Chemical	C492458	18752389
im@@	I-Chemical	-1	18752389
vast@@	I-Chemical	-1	18752389
at@@	I-Chemical	-1	18752389
ine@@	I-Chemical	-1	18752389
z@@	I-Chemical	-1	18752389
e@@	I-Chemical	-1	18752389
tim@@	I-Chemical	-1	18752389
i@@	I-Chemical	-1	18752389
be	I-Chemical	-1	18752389
and	O	-1	18752389
es@@	B-Chemical	D015283	18752389
cit@@	I-Chemical	-1	18752389
alo@@	I-Chemical	-1	18752389
pra@@	I-Chemical	-1	18752389
m	I-Chemical	-1	18752389
(@@	O	-1	18752389
which	O	-1	18752389
sh@@	O	-1	18752389
e	O	-1	18752389
was	O	-1	18752389
taking	O	-1	18752389
for	O	-1	18752389
de@@	B-Disease	D003866	18752389
pression	I-Disease	-1	18752389
)	O	-1	18752389
were	O	-1	18752389
discontinu@@	O	-1	18752389
ed,	O	-1	18752389
and	O	-1	18752389
other	O	-1	18752389
potential	O	-1	18752389
causes	O	-1	18752389
of	O	-1	18752389
hepat@@	B-Disease	D056486	18752389
otoxicity	I-Disease	-1	18752389
were	O	-1	18752389
ex@@	O	-1	18752389
cl@@	O	-1	18752389
u@@	O	-1	18752389
de@@	O	-1	18752389
d.	O	-1	18752389
A	O	-1	18752389
repe@@	O	-1	18752389
at	O	-1	18752389
wor@@	O	-1	18752389
k@@	O	-1	18752389
-@@	O	-1	18752389
up	O	-1	18752389
revealed	O	-1	18752389
further	O	-1	18752389
elev@@	O	-1	18752389
ations	O	-1	18752389
in	O	-1	18752389
amin@@	O	-1	18752389
ot@@	O	-1	18752389
ran@@	O	-1	18752389
s@@	O	-1	18752389
fer@@	O	-1	18752389
ase	O	-1	18752389
level@@	O	-1	18752389
s,	O	-1	18752389
and	O	-1	18752389
liver	O	-1	18752389
biop@@	O	-1	18752389
sy	O	-1	18752389
revealed	O	-1	18752389
evidence	O	-1	18752389
of	O	-1	18752389
moder@@	O	-1	18752389
at@@	O	-1	18752389
e-@@	O	-1	18752389
to@@	O	-1	18752389
-@@	O	-1	18752389
severe	O	-1	18752389
drug	B-Disease	D064420	18752389
toxicity	I-Disease	-1	18752389
.	O	-1	18752389
S@@	O	-1	18752389
he	O	-1	18752389
under@@	O	-1	18752389
w@@	O	-1	18752389
ent	O	-1	18752389
liver	O	-1	18752389
transplant@@	O	-1	18752389
ation	O	-1	18752389
with	O	-1	18752389
an	O	-1	18752389
un@@	O	-1	18752389
event@@	O	-1	18752389
ful	O	-1	18752389
postoperative	O	-1	18752389
cour@@	O	-1	18752389
se.	O	-1	18752389
H@@	O	-1	18752389
er	O	-1	18752389
amin@@	O	-1	18752389
ot@@	O	-1	18752389
ran@@	O	-1	18752389
s@@	O	-1	18752389
fer@@	O	-1	18752389
ase	O	-1	18752389
levels	O	-1	18752389
retur@@	O	-1	18752389
n@@	O	-1	18752389
ed	O	-1	18752389
to	O	-1	18752389
normal	O	-1	18752389
by	O	-1	18752389
postoperative	O	-1	18752389
day	O	-1	18752389
2@@	O	-1	18752389
3,	O	-1	18752389
and	O	-1	18752389
h@@	O	-1	18752389
er	O	-1	18752389
2-@@	O	-1	18752389
year	O	-1	18752389
follow-up	O	-1	18752389
showed	O	-1	18752389
no	O	-1	18752389
adverse	O	-1	18752389
event@@	O	-1	18752389
s.	O	-1	18752389
E@@	B-Chemical	C108606	18752389
z@@	I-Chemical	-1	18752389
e@@	I-Chemical	-1	18752389
tim@@	I-Chemical	-1	18752389
i@@	I-Chemical	-1	18752389
be	I-Chemical	-1	18752389
under@@	O	-1	18752389
go@@	O	-1	18752389
es	O	-1	18752389
exten@@	O	-1	18752389
sive	O	-1	18752389
gl@@	O	-1	18752389
uc@@	O	-1	18752389
uron@@	O	-1	18752389
id@@	O	-1	18752389
ation	O	-1	18752389
by	O	-1	18752389
ur@@	B-Chemical	D014530	18752389
idine	I-Chemical	-1	18752389
di@@	I-Chemical	-1	18752389
phosph@@	I-Chemical	-1	18752389
ate	I-Chemical	-1	18752389
gl@@	O	-1	18752389
uc@@	O	-1	18752389
or@@	O	-1	18752389
on@@	O	-1	18752389
os@@	O	-1	18752389
yl@@	O	-1	18752389
trans@@	O	-1	18752389
fer@@	O	-1	18752389
as@@	O	-1	18752389
es	O	-1	18752389
(@@	O	-1	18752389
U@@	O	-1	18752389
G@@	O	-1	18752389
T)	O	-1	18752389
in	O	-1	18752389
the	O	-1	18752389
in@@	O	-1	18752389
test@@	O	-1	18752389
ine	O	-1	18752389
and	O	-1	18752389
liver	O	-1	18752389
and	O	-1	18752389
may	O	-1	18752389
have	O	-1	18752389
inhibited	O	-1	18752389
the	O	-1	18752389
gl@@	O	-1	18752389
uc@@	O	-1	18752389
uron@@	O	-1	18752389
id@@	O	-1	18752389
ation	O	-1	18752389
of	O	-1	18752389
sim@@	B-Chemical	C532833	18752389
vastatin	I-Chemical	-1	18752389
hydrox@@	I-Chemical	-1	18752389
y	I-Chemical	-1	18752389
acid	I-Chemical	-1	18752389
,	O	-1	18752389
result@@	O	-1	18752389
ing	O	-1	18752389
in	O	-1	18752389
increased	O	-1	18752389
sim@@	B-Chemical	D019821	18752389
vastatin	I-Chemical	-1	18752389
exposure	O	-1	18752389
and	O	-1	18752389
subsequ@@	O	-1	18752389
ent	O	-1	18752389
hepat@@	B-Disease	D056486	18752389
otoxicity	I-Disease	-1	18752389
.	O	-1	18752389
To	O	-1	18752389
our	O	-1	18752389
know@@	O	-1	18752389
le@@	O	-1	18752389
d@@	O	-1	18752389
g@@	O	-1	18752389
e,	O	-1	18752389
this	O	-1	18752389
is	O	-1	18752389
the	O	-1	18752389
first	O	-1	18752389
case	O	-1	18752389
report	O	-1	18752389
of	O	-1	18752389
sim@@	B-Chemical	C492458	18752389
vast@@	I-Chemical	-1	18752389
at@@	I-Chemical	-1	18752389
in-@@	I-Chemical	-1	18752389
e@@	I-Chemical	-1	18752389
z@@	I-Chemical	-1	18752389
e@@	I-Chemical	-1	18752389
tim@@	I-Chemical	-1	18752389
i@@	I-Chemical	-1	18752389
be	I-Chemical	-1	18752389
-induced	O	-1	18752389
liver	B-Disease	D017093	18752389
failure	I-Disease	-1	18752389
that	O	-1	18752389
resulted	O	-1	18752389
in	O	-1	18752389
liver	O	-1	18752389
transplant@@	O	-1	18752389
ation.	O	-1	18752389
We	O	-1	18752389
post@@	O	-1	18752389
ul@@	O	-1	18752389
ate	O	-1	18752389
that	O	-1	18752389
the	O	-1	18752389
mechanism	O	-1	18752389
of	O	-1	18752389
the	O	-1	18752389
sim@@	B-Chemical	C492458	18752389
vast@@	I-Chemical	-1	18752389
at@@	I-Chemical	-1	18752389
ine@@	I-Chemical	-1	18752389
z@@	I-Chemical	-1	18752389
e@@	I-Chemical	-1	18752389
tim@@	I-Chemical	-1	18752389
i@@	I-Chemical	-1	18752389
be	I-Chemical	-1	18752389
-induced	O	-1	18752389
hepat@@	B-Disease	D056486	18752389
otoxicity	I-Disease	-1	18752389
is	O	-1	18752389
the	O	-1	18752389
increased	O	-1	18752389
sim@@	B-Chemical	D019821	18752389
vastatin	I-Chemical	-1	18752389
exposure	O	-1	18752389
by	O	-1	18752389
e@@	B-Chemical	C108606	18752389
z@@	I-Chemical	-1	18752389
e@@	I-Chemical	-1	18752389
tim@@	I-Chemical	-1	18752389
i@@	I-Chemical	-1	18752389
be	I-Chemical	-1	18752389
inhibition	O	-1	18752389
of	O	-1	18752389
U@@	O	-1	18752389
G@@	O	-1	18752389
T	O	-1	18752389
enzym@@	O	-1	18752389
es.	O	-1	18752389
Clin@@	O	-1	18752389
ici@@	O	-1	18752389
ans	O	-1	18752389
should	O	-1	18752389
be	O	-1	18752389
aw@@	O	-1	18752389
are	O	-1	18752389
of	O	-1	18752389
potential	O	-1	18752389
hepat@@	B-Disease	D056486	18752389
otoxicity	I-Disease	-1	18752389
with	O	-1	18752389
sim@@	B-Chemical	C492458	18752389
vast@@	I-Chemical	-1	18752389
at@@	I-Chemical	-1	18752389
in-@@	I-Chemical	-1	18752389
e@@	I-Chemical	-1	18752389
z@@	I-Chemical	-1	18752389
e@@	I-Chemical	-1	18752389
tim@@	I-Chemical	-1	18752389
i@@	I-Chemical	-1	18752389
be	I-Chemical	-1	18752389
es@@	O	-1	18752389
p@@	O	-1	18752389
ec@@	O	-1	18752389
i@@	O	-1	18752389
ally	O	-1	18752389
in	O	-1	18752389
el@@	O	-1	18752389
der@@	O	-1	18752389
ly	O	-1	18752389
patients	O	-1	18752389
and	O	-1	18752389
should	O	-1	18752389
ca@@	O	-1	18752389
ref@@	O	-1	18752389
ul@@	O	-1	18752389
ly	O	-1	18752389
monit@@	O	-1	18752389
or	O	-1	18752389
serum	O	-1	18752389
amin@@	O	-1	18752389
ot@@	O	-1	18752389
ran@@	O	-1	18752389
s@@	O	-1	18752389
fer@@	O	-1	18752389
ase	O	-1	18752389
levels	O	-1	18752389
when	O	-1	18752389
star@@	O	-1	18752389
ting	O	-1	18752389
therapy	O	-1	18752389
and	O	-1	18752389
ti@@	O	-1	18752389
t@@	O	-1	18752389
rat@@	O	-1	18752389
ing	O	-1	18752389
the	O	-1	18752389
dos@@	O	-1	18752389
age.	O	-1	18752389

O@@	O	-1	20098969
ral	O	-1	20098969
man@@	O	-1	20098969
if@@	O	-1	20098969
est@@	O	-1	20098969
ations	O	-1	20098969
of	O	-1	20098969
"	O	-1	20098969
met@@	B-Disease	-1	20098969
h	I-Disease	-1	20098969
mou@@	I-Disease	-1	20098969
th	I-Disease	-1	20098969
"@@	O	-1	20098969
:	O	-1	20098969
a	O	-1	20098969
case	O	-1	20098969
repor@@	O	-1	20098969
t.	O	-1	20098969
A@@	O	-1	20098969
I@@	O	-1	20098969
M@@	O	-1	20098969
:	O	-1	20098969
The	O	-1	20098969
a@@	O	-1	20098969
im	O	-1	20098969
of	O	-1	20098969
the	O	-1	20098969
doc@@	O	-1	20098969
um@@	O	-1	20098969
ent@@	O	-1	20098969
ation	O	-1	20098969
of	O	-1	20098969
this	O	-1	20098969
clinical	O	-1	20098969
case	O	-1	20098969
is	O	-1	20098969
to	O	-1	20098969
ma@@	O	-1	20098969
k@@	O	-1	20098969
e	O	-1	20098969
clin@@	O	-1	20098969
ici@@	O	-1	20098969
ans	O	-1	20098969
aw@@	O	-1	20098969
are	O	-1	20098969
of	O	-1	20098969
"	O	-1	20098969
met@@	B-Disease	-1	20098969
h	I-Disease	-1	20098969
mou@@	I-Disease	-1	20098969
th	I-Disease	-1	20098969
"	O	-1	20098969
and	O	-1	20098969
the	O	-1	20098969
med@@	O	-1	20098969
ical	O	-1	20098969
ris@@	O	-1	20098969
k@@	O	-1	20098969
s	O	-1	20098969
associated	O	-1	20098969
with	O	-1	20098969
this	O	-1	20098969
seri@@	O	-1	20098969
ous	O	-1	20098969
condi@@	O	-1	20098969
tion.	O	-1	20098969
BACKGROUND:	O	-1	20098969
M@@	B-Chemical	D008694	20098969
eth@@	I-Chemical	-1	20098969
amphetamine	I-Chemical	-1	20098969
is	O	-1	20098969
a	O	-1	20098969
very	O	-1	20098969
ad@@	O	-1	20098969
dic@@	O	-1	20098969
ti@@	O	-1	20098969
ve,	O	-1	20098969
po@@	O	-1	20098969
w@@	O	-1	20098969
er@@	O	-1	20098969
ful	O	-1	20098969
stimul@@	O	-1	20098969
ant	O	-1	20098969
that	O	-1	20098969
increases	O	-1	20098969
w@@	O	-1	20098969
ak@@	O	-1	20098969
e@@	O	-1	20098969
ful@@	O	-1	20098969
ness	O	-1	20098969
and	O	-1	20098969
physi@@	O	-1	20098969
c@@	O	-1	20098969
al	O	-1	20098969
activity	O	-1	20098969
and	O	-1	20098969
can	O	-1	20098969
produce	O	-1	20098969
other	O	-1	20098969
effects	O	-1	20098969
such	O	-1	20098969
as	O	-1	20098969
cardiac	B-Disease	D001145	20098969
dys@@	I-Disease	-1	20098969
rhyth@@	I-Disease	-1	20098969
mi@@	I-Disease	-1	20098969
as	I-Disease	-1	20098969
,	O	-1	20098969
hypertension	B-Disease	D006973	20098969
,	O	-1	20098969
h@@	B-Disease	D006212	20098969
all@@	I-Disease	-1	20098969
uc@@	I-Disease	-1	20098969
in@@	I-Disease	-1	20098969
ations	I-Disease	-1	20098969
,	O	-1	20098969
and	O	-1	20098969
vi@@	B-Disease	D001523	20098969
ol@@	I-Disease	-1	20098969
ent	I-Disease	-1	20098969
behavi@@	I-Disease	-1	20098969
or	I-Disease	-1	20098969
.	O	-1	20098969
D@@	O	-1	20098969
ental	O	-1	20098969
patients	O	-1	20098969
ab@@	O	-1	20098969
using	O	-1	20098969
meth@@	B-Chemical	D008694	20098969
amphetamine	I-Chemical	-1	20098969
can	O	-1	20098969
present	O	-1	20098969
with	O	-1	20098969
po@@	O	-1	20098969
or	O	-1	20098969
oral	O	-1	20098969
hy@@	O	-1	20098969
gi@@	O	-1	20098969
en@@	O	-1	20098969
e,	O	-1	20098969
x@@	B-Disease	D014987	20098969
ero@@	I-Disease	-1	20098969
st@@	I-Disease	-1	20098969
om@@	I-Disease	-1	20098969
ia	I-Disease	-1	20098969
,	O	-1	20098969
ram@@	O	-1	20098969
p@@	O	-1	20098969
ant	O	-1	20098969
car@@	B-Disease	D003731	20098969
i@@	I-Disease	-1	20098969
es	I-Disease	-1	20098969
(@@	O	-1	20098969
"	O	-1	20098969
met@@	B-Disease	-1	20098969
h	I-Disease	-1	20098969
mou@@	I-Disease	-1	20098969
th	I-Disease	-1	20098969
"@@	O	-1	20098969
),	O	-1	20098969
and	O	-1	20098969
ex@@	O	-1	20098969
ces@@	O	-1	20098969
sive	O	-1	20098969
to@@	B-Disease	D057085	20098969
oth	I-Disease	-1	20098969
we@@	I-Disease	-1	20098969
ar	I-Disease	-1	20098969
.	O	-1	20098969
O@@	O	-1	20098969
ral	O	-1	20098969
re@@	O	-1	20098969
h@@	O	-1	20098969
abil@@	O	-1	20098969
it@@	O	-1	20098969
ation	O	-1	20098969
of	O	-1	20098969
patients	O	-1	20098969
using	O	-1	20098969
meth@@	B-Chemical	D008694	20098969
amphetamine	I-Chemical	-1	20098969
can	O	-1	20098969
be	O	-1	20098969
ch@@	O	-1	20098969
all@@	O	-1	20098969
en@@	O	-1	20098969
g@@	O	-1	20098969
ing.	O	-1	20098969
CA@@	O	-1	20098969
S@@	O	-1	20098969
E	O	-1	20098969
D@@	O	-1	20098969
ES@@	O	-1	20098969
CR@@	O	-1	20098969
I@@	O	-1	20098969
P@@	O	-1	20098969
T@@	O	-1	20098969
ION@@	O	-1	20098969
:	O	-1	20098969
A	O	-1	20098969
3@@	O	-1	20098969
0-@@	O	-1	20098969
year-old	O	-1	20098969
Ca@@	O	-1	20098969
uc@@	O	-1	20098969
a@@	O	-1	20098969
si@@	O	-1	20098969
an	O	-1	20098969
woman	O	-1	20098969
presented	O	-1	20098969
with	O	-1	20098969
d@@	O	-1	20098969
ental	O	-1	20098969
pain	B-Disease	D010146	20098969
,	O	-1	20098969
b@@	B-Disease	D012120	20098969
ad	I-Disease	-1	20098969
b@@	I-Disease	-1	20098969
reat@@	I-Disease	-1	20098969
h	I-Disease	-1	20098969
,	O	-1	20098969
and	O	-1	20098969
sel@@	O	-1	20098969
f@@	O	-1	20098969
-@@	O	-1	20098969
reported	O	-1	20098969
po@@	O	-1	20098969
or	O	-1	20098969
esthe@@	O	-1	20098969
tic@@	O	-1	20098969
s.	O	-1	20098969
A	O	-1	20098969
com@@	O	-1	20098969
pre@@	O	-1	20098969
h@@	O	-1	20098969
en@@	O	-1	20098969
sive	O	-1	20098969
examin@@	O	-1	20098969
ation	O	-1	20098969
including	O	-1	20098969
h@@	O	-1	20098969
er	O	-1	20098969
med@@	O	-1	20098969
ical	O	-1	20098969
hist@@	O	-1	20098969
or@@	O	-1	20098969
y,	O	-1	20098969
p@@	O	-1	20098969
an@@	O	-1	20098969
or@@	O	-1	20098969
am@@	O	-1	20098969
ic	O	-1	20098969
radi@@	O	-1	20098969
ograph@@	O	-1	20098969
,	O	-1	20098969
and	O	-1	20098969
intra@@	O	-1	20098969
oral	O	-1	20098969
examin@@	O	-1	20098969
ation	O	-1	20098969
revealed	O	-1	20098969
1@@	O	-1	20098969
9	O	-1	20098969
car@@	B-Disease	D003731	20098969
i@@	I-Disease	-1	20098969
ous	I-Disease	-1	20098969
lesions	I-Disease	-1	20098969
,	O	-1	20098969
which	O	-1	20098969
is	O	-1	20098969
not	O	-1	20098969
very	O	-1	20098969
common	O	-1	20098969
for	O	-1	20098969
a	O	-1	20098969
healthy	O	-1	20098969
ad@@	O	-1	20098969
ult@@	O	-1	20098969
.	O	-1	20098969
S@@	O	-1	20098969
he	O	-1	20098969
reported	O	-1	20098969
h@@	O	-1	20098969
er	O	-1	20098969
use	O	-1	20098969
of	O	-1	20098969
meth@@	B-Chemical	D008694	20098969
amphetamine	I-Chemical	-1	20098969
for	O	-1	20098969
five	O	-1	20098969
years	O	-1	20098969
and	O	-1	20098969
had	O	-1	20098969
not	O	-1	20098969
experienced	O	-1	20098969
any	O	-1	20098969
major	O	-1	20098969
car@@	B-Disease	D003731	20098969
i@@	I-Disease	-1	20098969
ous	I-Disease	-1	20098969
episo@@	I-Disease	-1	20098969
des	I-Disease	-1	20098969
before	O	-1	20098969
sh@@	O	-1	20098969
e	O	-1	20098969
star@@	O	-1	20098969
ted	O	-1	20098969
using	O	-1	20098969
the	O	-1	20098969
drug.	O	-1	20098969
S@@	O	-1	20098969
U@@	O	-1	20098969
M@@	O	-1	20098969
MA@@	O	-1	20098969
R@@	O	-1	20098969
Y@@	O	-1	20098969
:	O	-1	20098969
The	O	-1	20098969
patient@@	O	-1	20098969
's	O	-1	20098969
med@@	O	-1	20098969
ical	O	-1	20098969
and	O	-1	20098969
d@@	O	-1	20098969
ental	O	-1	20098969
hist@@	O	-1	20098969
or@@	O	-1	20098969
i@@	O	-1	20098969
es	O	-1	20098969
al@@	O	-1	20098969
ong	O	-1	20098969
with	O	-1	20098969
radi@@	O	-1	20098969
ograph@@	O	-1	20098969
ic	O	-1	20098969
and	O	-1	20098969
clinical	O	-1	20098969
findings	O	-1	20098969
le@@	O	-1	20098969
ad	O	-1	20098969
to	O	-1	20098969
a	O	-1	20098969
diagnosis	O	-1	20098969
of	O	-1	20098969
"	O	-1	20098969
met@@	B-Disease	-1	20098969
h	I-Disease	-1	20098969
mou@@	I-Disease	-1	20098969
th	I-Disease	-1	20098969
.@@	O	-1	20098969
"	O	-1	20098969
Although	O	-1	20098969
three	O	-1	20098969
different	O	-1	20098969
d@@	O	-1	20098969
ental	O	-1	20098969
treatment	O	-1	20098969
mod@@	O	-1	20098969
al@@	O	-1	20098969
ities	O	-1	20098969
(@@	O	-1	20098969
either	O	-1	20098969
con@@	O	-1	20098969
ven@@	O	-1	20098969
tional	O	-1	20098969
or	O	-1	20098969
im@@	O	-1	20098969
pl@@	O	-1	20098969
ant@@	O	-1	20098969
-@@	O	-1	20098969
suppor@@	O	-1	20098969
te@@	O	-1	20098969
d@@	O	-1	20098969
)	O	-1	20098969
have	O	-1	20098969
been	O	-1	20098969
o@@	O	-1	20098969
ffe@@	O	-1	20098969
red	O	-1	20098969
to	O	-1	20098969
the	O	-1	20098969
patient	O	-1	20098969
s@@	O	-1	20098969
inc@@	O	-1	20098969
e	O	-1	20098969
A@@	O	-1	20098969
u@@	O	-1	20098969
g@@	O	-1	20098969
us@@	O	-1	20098969
t	O	-1	20098969
20@@	O	-1	20098969
0@@	O	-1	20098969
7@@	O	-1	20098969
,	O	-1	20098969
the	O	-1	20098969
patient	O	-1	20098969
has	O	-1	20098969
y@@	O	-1	20098969
et	O	-1	20098969
to	O	-1	20098969
initi@@	O	-1	20098969
ate	O	-1	20098969
any	O	-1	20098969
treatment.	O	-1	20098969
CL@@	O	-1	20098969
IN@@	O	-1	20098969
I@@	O	-1	20098969
CA@@	O	-1	20098969
L	O	-1	20098969
S@@	O	-1	20098969
I@@	O	-1	20098969
G@@	O	-1	20098969
N@@	O	-1	20098969
I@@	O	-1	20098969
F@@	O	-1	20098969
I@@	O	-1	20098969
CA@@	O	-1	20098969
N@@	O	-1	20098969
C@@	O	-1	20098969
E:	O	-1	20098969
This	O	-1	20098969
clinical	O	-1	20098969
case	O	-1	20098969
show@@	O	-1	20098969
ing	O	-1	20098969
oral	O	-1	20098969
man@@	O	-1	20098969
if@@	O	-1	20098969
est@@	O	-1	20098969
ations	O	-1	20098969
of	O	-1	20098969
met@@	B-Disease	-1	20098969
h	I-Disease	-1	20098969
mou@@	I-Disease	-1	20098969
th	I-Disease	-1	20098969
was	O	-1	20098969
presented	O	-1	20098969
to	O	-1	20098969
he@@	O	-1	20098969
l@@	O	-1	20098969
p	O	-1	20098969
d@@	O	-1	20098969
ental	O	-1	20098969
p@@	O	-1	20098969
rac@@	O	-1	20098969
ti@@	O	-1	20098969
tion@@	O	-1	20098969
ers	O	-1	20098969
reco@@	O	-1	20098969
gn@@	O	-1	20098969
iz@@	O	-1	20098969
e	O	-1	20098969
and	O	-1	20098969
man@@	O	-1	20098969
age	O	-1	20098969
patients	O	-1	20098969
who	O	-1	20098969
may	O	-1	20098969
be	O	-1	20098969
ab@@	O	-1	20098969
using	O	-1	20098969
meth@@	B-Chemical	D008694	20098969
amphet@@	I-Chemical	-1	20098969
amin@@	I-Chemical	-1	20098969
es	I-Chemical	-1	20098969
.	O	-1	20098969
D@@	O	-1	20098969
ental	O	-1	20098969
p@@	O	-1	20098969
rac@@	O	-1	20098969
ti@@	O	-1	20098969
tion@@	O	-1	20098969
ers	O	-1	20098969
also	O	-1	20098969
may	O	-1	20098969
be	O	-1	20098969
s@@	O	-1	20098969
k@@	O	-1	20098969
ep@@	O	-1	20098969
tical	O	-1	20098969
about	O	-1	20098969
the	O	-1	20098969
re@@	O	-1	20098969
li@@	O	-1	20098969
ability	O	-1	20098969
of	O	-1	20098969
ap@@	O	-1	20098969
po@@	O	-1	20098969
int@@	O	-1	20098969
ment	O	-1	20098969
ke@@	O	-1	20098969
ep@@	O	-1	20098969
ing	O	-1	20098969
by	O	-1	20098969
these	O	-1	20098969
patients,	O	-1	20098969
as	O	-1	20098969
they	O	-1	20098969
frequ@@	O	-1	20098969
ently	O	-1	20098969
mis@@	O	-1	20098969
s	O	-1	20098969
their	O	-1	20098969
ap@@	O	-1	20098969
po@@	O	-1	20098969
int@@	O	-1	20098969
ments	O	-1	20098969
without	O	-1	20098969
reas@@	O	-1	20098969
on@@	O	-1	20098969
able	O	-1	20098969
j@@	O	-1	20098969
us@@	O	-1	20098969
ti@@	O	-1	20098969
fic@@	O	-1	20098969
ation.	O	-1	20098969

Th@@	B-Chemical	D013974	9653867
yro@@	I-Chemical	-1	9653867
x@@	I-Chemical	-1	9653867
ine	I-Chemical	-1	9653867
ab@@	O	-1	9653867
use@@	O	-1	9653867
:	O	-1	9653867
an	O	-1	9653867
un@@	O	-1	9653867
us@@	O	-1	9653867
ual	O	-1	9653867
case	O	-1	9653867
of	O	-1	9653867
th@@	B-Disease	D013971	9653867
yro@@	I-Disease	-1	9653867
toxic@@	I-Disease	-1	9653867
o@@	I-Disease	-1	9653867
sis	I-Disease	-1	9653867
in	O	-1	9653867
pregn@@	O	-1	9653867
anc@@	O	-1	9653867
y.	O	-1	9653867
E@@	B-Disease	D001068	9653867
ating	I-Disease	-1	9653867
disorder@@	I-Disease	-1	9653867
s	I-Disease	-1	9653867
and	O	-1	9653867
the	O	-1	9653867
associated	O	-1	9653867
behavi@@	O	-1	9653867
o@@	O	-1	9653867
ural	O	-1	9653867
pro@@	O	-1	9653867
ble@@	O	-1	9653867
ms	O	-1	9653867
and	O	-1	9653867
drug	B-Disease	D019966	9653867
ab@@	I-Disease	-1	9653867
use	I-Disease	-1	9653867
are	O	-1	9653867
un@@	O	-1	9653867
common	O	-1	9653867
in	O	-1	9653867
pregn@@	O	-1	9653867
anc@@	O	-1	9653867
y.	O	-1	9653867
Whe@@	O	-1	9653867
n	O	-1	9653867
they	O	-1	9653867
d@@	O	-1	9653867
o	O	-1	9653867
occ@@	O	-1	9653867
ur	O	-1	9653867
they	O	-1	9653867
are	O	-1	9653867
often	O	-1	9653867
un@@	O	-1	9653867
reco@@	O	-1	9653867
gn@@	O	-1	9653867
ized	O	-1	9653867
because	O	-1	9653867
of	O	-1	9653867
d@@	O	-1	9653867
en@@	O	-1	9653867
ial	O	-1	9653867
but	O	-1	9653867
when	O	-1	9653867
significant	O	-1	9653867
may	O	-1	9653867
p@@	O	-1	9653867
ose	O	-1	9653867
a	O	-1	9653867
risk	O	-1	9653867
to	O	-1	9653867
both	O	-1	9653867
the	O	-1	9653867
mo@@	O	-1	9653867
ther	O	-1	9653867
and	O	-1	9653867
h@@	O	-1	9653867
er	O	-1	9653867
f@@	O	-1	9653867
et@@	O	-1	9653867
us.	O	-1	9653867
This	O	-1	9653867
case	O	-1	9653867
il@@	O	-1	9653867
lu@@	O	-1	9653867
strat@@	O	-1	9653867
es	O	-1	9653867
a	O	-1	9653867
number	O	-1	9653867
of	O	-1	9653867
pro@@	O	-1	9653867
ble@@	O	-1	9653867
ms	O	-1	9653867
that	O	-1	9653867
may	O	-1	9653867
be	O	-1	9653867
en@@	O	-1	9653867
coun@@	O	-1	9653867
te@@	O	-1	9653867
red	O	-1	9653867
in	O	-1	9653867
women	O	-1	9653867
with	O	-1	9653867
e@@	B-Disease	D001068	9653867
ating	I-Disease	-1	9653867
disorder@@	I-Disease	-1	9653867
s	I-Disease	-1	9653867
in	O	-1	9653867
pregn@@	O	-1	9653867
anc@@	O	-1	9653867
y,	O	-1	9653867
including	O	-1	9653867
prolonged	O	-1	9653867
and	O	-1	9653867
recur@@	O	-1	9653867
rent	O	-1	9653867
met@@	O	-1	9653867
ab@@	O	-1	9653867
olic	O	-1	9653867
dist@@	O	-1	9653867
urb@@	O	-1	9653867
anc@@	O	-1	9653867
es	O	-1	9653867
and	O	-1	9653867
di@@	O	-1	9653867
ure@@	O	-1	9653867
tic	O	-1	9653867
ab@@	O	-1	9653867
use.	O	-1	9653867
In	O	-1	9653867
partic@@	O	-1	9653867
ular	O	-1	9653867
it	O	-1	9653867
il@@	O	-1	9653867
lu@@	O	-1	9653867
strat@@	O	-1	9653867
es	O	-1	9653867
the	O	-1	9653867
der@@	O	-1	9653867
ang@@	O	-1	9653867
em@@	O	-1	9653867
ents	O	-1	9653867
of	O	-1	9653867
th@@	O	-1	9653867
yro@@	O	-1	9653867
id	O	-1	9653867
function	O	-1	9653867
seen	O	-1	9653867
in	O	-1	9653867
pregn@@	O	-1	9653867
ant	O	-1	9653867
women	O	-1	9653867
with	O	-1	9653867
e@@	B-Disease	D001068	9653867
ating	I-Disease	-1	9653867
disorder@@	I-Disease	-1	9653867
s	I-Disease	-1	9653867
and	O	-1	9653867
re@@	O	-1	9653867
min@@	O	-1	9653867
ds	O	-1	9653867
us	O	-1	9653867
that	O	-1	9653867
when	O	-1	9653867
a	O	-1	9653867
cause	O	-1	9653867
for	O	-1	9653867
th@@	B-Disease	D013971	9653867
yro@@	I-Disease	-1	9653867
toxic@@	I-Disease	-1	9653867
o@@	I-Disease	-1	9653867
sis	I-Disease	-1	9653867
remain@@	O	-1	9653867
s	O	-1	9653867
ob@@	O	-1	9653867
s@@	O	-1	9653867
c@@	O	-1	9653867
ure,	O	-1	9653867
th@@	B-Chemical	D013974	9653867
yro@@	I-Chemical	-1	9653867
x@@	I-Chemical	-1	9653867
ine	I-Chemical	-1	9653867
ab@@	O	-1	9653867
use	O	-1	9653867
should	O	-1	9653867
be	O	-1	9653867
considered	O	-1	9653867
and	O	-1	9653867
ex@@	O	-1	9653867
p@@	O	-1	9653867
lo@@	O	-1	9653867
red.	O	-1	9653867

A@@	O	-1	17608141
t@@	O	-1	17608141
ten@@	O	-1	17608141
u@@	O	-1	17608141
ation	O	-1	17608141
of	O	-1	17608141
meth@@	B-Chemical	D008694	17608141
amphetamine	I-Chemical	-1	17608141
-induced	O	-1	17608141
n@@	O	-1	17608141
ig@@	O	-1	17608141
ro@@	O	-1	17608141
stri@@	O	-1	17608141
atal	O	-1	17608141
dop@@	O	-1	17608141
aminergic	O	-1	17608141
neuro@@	B-Disease	D020258	17608141
toxicity	I-Disease	-1	17608141
in	O	-1	17608141
mice	O	-1	17608141
by	O	-1	17608141
li@@	B-Chemical	D008070	17608141
po@@	I-Chemical	-1	17608141
pol@@	I-Chemical	-1	17608141
ys@@	I-Chemical	-1	17608141
ac@@	I-Chemical	-1	17608141
ch@@	I-Chemical	-1	17608141
ar@@	I-Chemical	-1	17608141
ide	I-Chemical	-1	17608141
pre@@	O	-1	17608141
treatment.	O	-1	17608141
Im@@	O	-1	17608141
mun@@	O	-1	17608141
ological	O	-1	17608141
activation	O	-1	17608141
has	O	-1	17608141
been	O	-1	17608141
pro@@	O	-1	17608141
pos@@	O	-1	17608141
ed	O	-1	17608141
to	O	-1	17608141
pl@@	O	-1	17608141
ay	O	-1	17608141
a	O	-1	17608141
role	O	-1	17608141
in	O	-1	17608141
meth@@	B-Chemical	D008694	17608141
amphetamine	I-Chemical	-1	17608141
-induced	O	-1	17608141
dop@@	B-Disease	D009422	17608141
aminergic	I-Disease	-1	17608141
ter@@	I-Disease	-1	17608141
min@@	I-Disease	-1	17608141
al	I-Disease	-1	17608141
damage	I-Disease	-1	17608141
.	O	-1	17608141
In	O	-1	17608141
this	O	-1	17608141
study,	O	-1	17608141
we	O	-1	17608141
examined	O	-1	17608141
the	O	-1	17608141
ro@@	O	-1	17608141
le@@	O	-1	17608141
s	O	-1	17608141
of	O	-1	17608141
li@@	B-Chemical	D008070	17608141
po@@	I-Chemical	-1	17608141
pol@@	I-Chemical	-1	17608141
ys@@	I-Chemical	-1	17608141
ac@@	I-Chemical	-1	17608141
ch@@	I-Chemical	-1	17608141
ar@@	I-Chemical	-1	17608141
ide	I-Chemical	-1	17608141
,	O	-1	17608141
a	O	-1	17608141
pro@@	O	-1	17608141
-@@	O	-1	17608141
inflam@@	O	-1	17608141
mat@@	O	-1	17608141
ory	O	-1	17608141
and	O	-1	17608141
inflam@@	O	-1	17608141
mat@@	O	-1	17608141
ory	O	-1	17608141
fact@@	O	-1	17608141
or@@	O	-1	17608141
,	O	-1	17608141
treatment	O	-1	17608141
in	O	-1	17608141
mod@@	O	-1	17608141
ul@@	O	-1	17608141
ating	O	-1	17608141
the	O	-1	17608141
meth@@	B-Chemical	D008694	17608141
amphetamine	I-Chemical	-1	17608141
-induced	O	-1	17608141
n@@	O	-1	17608141
ig@@	O	-1	17608141
ro@@	O	-1	17608141
stri@@	O	-1	17608141
atal	O	-1	17608141
dopamine	B-Chemical	D004298	17608141
neuro@@	B-Disease	D020258	17608141
toxicity	I-Disease	-1	17608141
.	O	-1	17608141
L@@	B-Chemical	D008070	17608141
i@@	I-Chemical	-1	17608141
po@@	I-Chemical	-1	17608141
pol@@	I-Chemical	-1	17608141
ys@@	I-Chemical	-1	17608141
ac@@	I-Chemical	-1	17608141
ch@@	I-Chemical	-1	17608141
ar@@	I-Chemical	-1	17608141
ide	I-Chemical	-1	17608141
pretreatment	O	-1	17608141
did	O	-1	17608141
not	O	-1	17608141
aff@@	O	-1	17608141
ect	O	-1	17608141
the	O	-1	17608141
bas@@	O	-1	17608141
al	O	-1	17608141
body	O	-1	17608141
tem@@	O	-1	17608141
per@@	O	-1	17608141
at@@	O	-1	17608141
ure	O	-1	17608141
or	O	-1	17608141
meth@@	B-Chemical	D008694	17608141
amphetamine	I-Chemical	-1	17608141
-@@	O	-1	17608141
el@@	O	-1	17608141
ic@@	O	-1	17608141
ited	O	-1	17608141
hyper@@	B-Disease	D005334	17608141
ther@@	I-Disease	-1	17608141
mia	I-Disease	-1	17608141
three	O	-1	17608141
days	O	-1	17608141
lat@@	O	-1	17608141
er.	O	-1	17608141
S@@	O	-1	17608141
uc@@	O	-1	17608141
h	O	-1	17608141
systemic	O	-1	17608141
li@@	B-Chemical	D008070	17608141
po@@	I-Chemical	-1	17608141
pol@@	I-Chemical	-1	17608141
ys@@	I-Chemical	-1	17608141
ac@@	I-Chemical	-1	17608141
ch@@	I-Chemical	-1	17608141
ar@@	I-Chemical	-1	17608141
ide	I-Chemical	-1	17608141
treatment	O	-1	17608141
m@@	O	-1	17608141
iti@@	O	-1	17608141
g@@	O	-1	17608141
ated	O	-1	17608141
meth@@	B-Chemical	D008694	17608141
amphetamine	I-Chemical	-1	17608141
-induced	O	-1	17608141
stri@@	O	-1	17608141
atal	O	-1	17608141
dopamine	B-Chemical	D004298	17608141
and	O	-1	17608141
3@@	B-Chemical	D015102	17608141
,@@	I-Chemical	-1	17608141
4-@@	I-Chemical	-1	17608141
di@@	I-Chemical	-1	17608141
hydrox@@	I-Chemical	-1	17608141
y@@	I-Chemical	-1	17608141
phenyl@@	I-Chemical	-1	17608141
ace@@	I-Chemical	-1	17608141
tic	I-Chemical	-1	17608141
acid	I-Chemical	-1	17608141
deple@@	O	-1	17608141
tions	O	-1	17608141
in	O	-1	17608141
a	O	-1	17608141
dose-@@	O	-1	17608141
dependent	O	-1	17608141
man@@	O	-1	17608141
ner@@	O	-1	17608141
.	O	-1	17608141
A@@	O	-1	17608141
s	O	-1	17608141
the	O	-1	17608141
most	O	-1	17608141
pot@@	O	-1	17608141
ent	O	-1	17608141
dose	O	-1	17608141
(@@	O	-1	17608141
1	O	-1	17608141
mg/kg)	O	-1	17608141
of	O	-1	17608141
li@@	B-Chemical	D008070	17608141
po@@	I-Chemical	-1	17608141
pol@@	I-Chemical	-1	17608141
ys@@	I-Chemical	-1	17608141
ac@@	I-Chemical	-1	17608141
ch@@	I-Chemical	-1	17608141
ar@@	I-Chemical	-1	17608141
ide	I-Chemical	-1	17608141
was	O	-1	17608141
administered	O	-1	17608141
two	O	-1	17608141
week@@	O	-1	17608141
s,	O	-1	17608141
one	O	-1	17608141
day	O	-1	17608141
before	O	-1	17608141
or	O	-1	17608141
after	O	-1	17608141
the	O	-1	17608141
meth@@	B-Chemical	D008694	17608141
amphetamine	I-Chemical	-1	17608141
dos@@	O	-1	17608141
ing	O	-1	17608141
regimen@@	O	-1	17608141
,	O	-1	17608141
meth@@	B-Chemical	D008694	17608141
amphetamine	I-Chemical	-1	17608141
-induced	O	-1	17608141
stri@@	O	-1	17608141
atal	O	-1	17608141
dopamine	B-Chemical	D004298	17608141
and	O	-1	17608141
3@@	B-Chemical	D015102	17608141
,@@	I-Chemical	-1	17608141
4-@@	I-Chemical	-1	17608141
di@@	I-Chemical	-1	17608141
hydrox@@	I-Chemical	-1	17608141
y@@	I-Chemical	-1	17608141
phenyl@@	I-Chemical	-1	17608141
ace@@	I-Chemical	-1	17608141
tic	I-Chemical	-1	17608141
acid	I-Chemical	-1	17608141
deple@@	O	-1	17608141
tions	O	-1	17608141
remained	O	-1	17608141
un@@	O	-1	17608141
al@@	O	-1	17608141
te@@	O	-1	17608141
red.	O	-1	17608141
M@@	O	-1	17608141
ore@@	O	-1	17608141
o@@	O	-1	17608141
ver,	O	-1	17608141
systemic	O	-1	17608141
li@@	B-Chemical	D008070	17608141
po@@	I-Chemical	-1	17608141
pol@@	I-Chemical	-1	17608141
ys@@	I-Chemical	-1	17608141
ac@@	I-Chemical	-1	17608141
ch@@	I-Chemical	-1	17608141
ar@@	I-Chemical	-1	17608141
ide	I-Chemical	-1	17608141
pretreatment	O	-1	17608141
(@@	O	-1	17608141
1	O	-1	17608141
mg/kg)	O	-1	17608141
attenu@@	O	-1	17608141
ated	O	-1	17608141
loc@@	O	-1	17608141
al	O	-1	17608141
meth@@	B-Chemical	D008694	17608141
amphetamine	I-Chemical	-1	17608141
infu@@	O	-1	17608141
sion@@	O	-1	17608141
-@@	O	-1	17608141
produced	O	-1	17608141
dopamine	B-Chemical	D004298	17608141
and	O	-1	17608141
3@@	B-Chemical	D015102	17608141
,@@	I-Chemical	-1	17608141
4-@@	I-Chemical	-1	17608141
di@@	I-Chemical	-1	17608141
hydrox@@	I-Chemical	-1	17608141
y@@	I-Chemical	-1	17608141
phenyl@@	I-Chemical	-1	17608141
ace@@	I-Chemical	-1	17608141
tic	I-Chemical	-1	17608141
acid	I-Chemical	-1	17608141
deple@@	O	-1	17608141
tions	O	-1	17608141
in	O	-1	17608141
the	O	-1	17608141
striat@@	O	-1	17608141
um,	O	-1	17608141
indicating	O	-1	17608141
that	O	-1	17608141
the	O	-1	17608141
protective	O	-1	17608141
effect	O	-1	17608141
of	O	-1	17608141
li@@	B-Chemical	D008070	17608141
po@@	I-Chemical	-1	17608141
pol@@	I-Chemical	-1	17608141
ys@@	I-Chemical	-1	17608141
ac@@	I-Chemical	-1	17608141
ch@@	I-Chemical	-1	17608141
ar@@	I-Chemical	-1	17608141
ide	I-Chemical	-1	17608141
is	O	-1	17608141
less	O	-1	17608141
likely	O	-1	17608141
due	O	-1	17608141
to	O	-1	17608141
inter@@	O	-1	17608141
ru@@	O	-1	17608141
pt@@	O	-1	17608141
ed	O	-1	17608141
peripheral	O	-1	17608141
di@@	O	-1	17608141
stri@@	O	-1	17608141
bu@@	O	-1	17608141
tion	O	-1	17608141
or	O	-1	17608141
metabol@@	O	-1	17608141
ism	O	-1	17608141
of	O	-1	17608141
meth@@	B-Chemical	D008694	17608141
amphetamine	I-Chemical	-1	17608141
.	O	-1	17608141
We	O	-1	17608141
concl@@	O	-1	17608141
uded	O	-1	17608141
a	O	-1	17608141
cri@@	O	-1	17608141
tical	O	-1	17608141
time	O	-1	17608141
w@@	O	-1	17608141
in@@	O	-1	17608141
do@@	O	-1	17608141
w	O	-1	17608141
for	O	-1	17608141
systemic	O	-1	17608141
li@@	B-Chemical	D008070	17608141
po@@	I-Chemical	-1	17608141
pol@@	I-Chemical	-1	17608141
ys@@	I-Chemical	-1	17608141
ac@@	I-Chemical	-1	17608141
ch@@	I-Chemical	-1	17608141
ar@@	I-Chemical	-1	17608141
ide	I-Chemical	-1	17608141
pretreatment	O	-1	17608141
in	O	-1	17608141
ex@@	O	-1	17608141
er@@	O	-1	17608141
ting	O	-1	17608141
effective	O	-1	17608141
prot@@	O	-1	17608141
ection	O	-1	17608141
against	O	-1	17608141
meth@@	B-Chemical	D008694	17608141
amphetamine	I-Chemical	-1	17608141
-induced	O	-1	17608141
n@@	O	-1	17608141
ig@@	O	-1	17608141
ro@@	O	-1	17608141
stri@@	O	-1	17608141
atal	O	-1	17608141
dopamine	B-Chemical	D004298	17608141
neuro@@	B-Disease	D020258	17608141
toxicity	I-Disease	-1	17608141
.	O	-1	17608141

Eff@@	O	-1	2559236
ect	O	-1	2559236
of	O	-1	2559236
conver@@	O	-1	2559236
ting	O	-1	2559236
enzyme	O	-1	2559236
inhibition	O	-1	2559236
on	O	-1	2559236
the	O	-1	2559236
course	O	-1	2559236
of	O	-1	2559236
adriam@@	B-Chemical	D004317	2559236
ycin	I-Chemical	-1	2559236
-induced	O	-1	2559236
nephro@@	B-Disease	D007674	2559236
pathy	I-Disease	-1	2559236
.	O	-1	2559236
The	O	-1	2559236
effect	O	-1	2559236
of	O	-1	2559236
the	O	-1	2559236
conver@@	O	-1	2559236
ting	O	-1	2559236
enzyme	O	-1	2559236
inhibitor	O	-1	2559236
(C@@	O	-1	2559236
E@@	O	-1	2559236
I@@	O	-1	2559236
)	O	-1	2559236
en@@	B-Chemical	D004656	2559236
al@@	I-Chemical	-1	2559236
apri@@	I-Chemical	-1	2559236
l	I-Chemical	-1	2559236
was	O	-1	2559236
assessed	O	-1	2559236
in	O	-1	2559236
M@@	O	-1	2559236
un@@	O	-1	2559236
ic@@	O	-1	2559236
h@@	O	-1	2559236
-@@	O	-1	2559236
Wistar	O	-1	2559236
rats	O	-1	2559236
with	O	-1	2559236
est@@	O	-1	2559236
abl@@	O	-1	2559236
ished	O	-1	2559236
adriam@@	B-Chemical	D004317	2559236
ycin	I-Chemical	-1	2559236
nephro@@	B-Disease	D009401	2559236
sis	I-Disease	-1	2559236
.	O	-1	2559236
R@@	O	-1	2559236
at@@	O	-1	2559236
s	O	-1	2559236
were	O	-1	2559236
given	O	-1	2559236
a	O	-1	2559236
single	O	-1	2559236
dose	O	-1	2559236
of	O	-1	2559236
adriam@@	B-Chemical	D004317	2559236
ycin	I-Chemical	-1	2559236
and	O	-1	2559236
one	O	-1	2559236
mon@@	O	-1	2559236
th	O	-1	2559236
lat@@	O	-1	2559236
er	O	-1	2559236
divid@@	O	-1	2559236
ed	O	-1	2559236
into	O	-1	2559236
four	O	-1	2559236
groups	O	-1	2559236
mat@@	O	-1	2559236
ch@@	O	-1	2559236
ed	O	-1	2559236
for	O	-1	2559236
al@@	B-Disease	D000419	2559236
bu@@	I-Disease	-1	2559236
min@@	I-Disease	-1	2559236
uria	I-Disease	-1	2559236
,	O	-1	2559236
blood	O	-1	2559236
pressu@@	O	-1	2559236
re,	O	-1	2559236
and	O	-1	2559236
plasma	O	-1	2559236
al@@	O	-1	2559236
b@@	O	-1	2559236
um@@	O	-1	2559236
in	O	-1	2559236
concentr@@	O	-1	2559236
ation.	O	-1	2559236
Grou@@	O	-1	2559236
p@@	O	-1	2559236
s	O	-1	2559236
1	O	-1	2559236
and	O	-1	2559236
3	O	-1	2559236
remained	O	-1	2559236
un@@	O	-1	2559236
treated	O	-1	2559236
while	O	-1	2559236
groups	O	-1	2559236
2	O	-1	2559236
and	O	-1	2559236
4	O	-1	2559236
received	O	-1	2559236
en@@	B-Chemical	D004656	2559236
al@@	I-Chemical	-1	2559236
apri@@	I-Chemical	-1	2559236
l	I-Chemical	-1	2559236
.	O	-1	2559236
Grou@@	O	-1	2559236
p@@	O	-1	2559236
s	O	-1	2559236
1	O	-1	2559236
and	O	-1	2559236
2	O	-1	2559236
under@@	O	-1	2559236
w@@	O	-1	2559236
ent	O	-1	2559236
micro@@	O	-1	2559236
p@@	O	-1	2559236
unc@@	O	-1	2559236
t@@	O	-1	2559236
ure	O	-1	2559236
studies	O	-1	2559236
after	O	-1	2559236
10	O	-1	2559236
days.	O	-1	2559236
These	O	-1	2559236
sh@@	O	-1	2559236
ort@@	O	-1	2559236
-term	O	-1	2559236
studies	O	-1	2559236
showed	O	-1	2559236
that	O	-1	2559236
en@@	B-Chemical	D004656	2559236
al@@	I-Chemical	-1	2559236
apri@@	I-Chemical	-1	2559236
l	I-Chemical	-1	2559236
reduced	O	-1	2559236
arterial	O	-1	2559236
blood	O	-1	2559236
pressure	O	-1	2559236
(@@	O	-1	2559236
10@@	O	-1	2559236
1	O	-1	2559236
+/-	O	-1	2559236
2	O	-1	2559236
vs.	O	-1	2559236
1@@	O	-1	2559236
24	O	-1	2559236
+/-	O	-1	2559236
3	O	-1	2559236
mm	O	-1	2559236
H@@	O	-1	2559236
g@@	O	-1	2559236
,	O	-1	2559236
group	O	-1	2559236
2	O	-1	2559236
vs.	O	-1	2559236
1,	O	-1	2559236
P	O	-1	2559236
less	O	-1	2559236
than	O	-1	2559236
0.05@@	O	-1	2559236
)	O	-1	2559236
and	O	-1	2559236
glomerular	O	-1	2559236
cap@@	O	-1	2559236
ill@@	O	-1	2559236
ary	O	-1	2559236
pressure	O	-1	2559236
(5@@	O	-1	2559236
4	O	-1	2559236
+/-	O	-1	2559236
1	O	-1	2559236
vs.	O	-1	2559236
6@@	O	-1	2559236
1	O	-1	2559236
+/-	O	-1	2559236
2	O	-1	2559236
mm	O	-1	2559236
H@@	O	-1	2559236
g@@	O	-1	2559236
,	O	-1	2559236
P	O	-1	2559236
less	O	-1	2559236
than	O	-1	2559236
0.05@@	O	-1	2559236
)	O	-1	2559236
without	O	-1	2559236
reduc@@	O	-1	2559236
ing	O	-1	2559236
al@@	B-Disease	D000419	2559236
bu@@	I-Disease	-1	2559236
min@@	I-Disease	-1	2559236
uria	I-Disease	-1	2559236
(6@@	O	-1	2559236
17	O	-1	2559236
+/-	O	-1	2559236
50	O	-1	2559236
vs.	O	-1	2559236
5@@	O	-1	2559236
7@@	O	-1	2559236
0	O	-1	2559236
+/-	O	-1	2559236
4@@	O	-1	2559236
7	O	-1	2559236
mg/@@	O	-1	2559236
day@@	O	-1	2559236
)	O	-1	2559236
or	O	-1	2559236
GF@@	O	-1	2559236
R	O	-1	2559236
(1@@	O	-1	2559236
.@@	O	-1	2559236
0@@	O	-1	2559236
3	O	-1	2559236
+/-	O	-1	2559236
0.0@@	O	-1	2559236
4	O	-1	2559236
vs.	O	-1	2559236
1.@@	O	-1	2559236
0@@	O	-1	2559236
4	O	-1	2559236
+/-	O	-1	2559236
0.@@	O	-1	2559236
11	O	-1	2559236
ml@@	O	-1	2559236
/@@	O	-1	2559236
min@@	O	-1	2559236
).	O	-1	2559236
Grou@@	O	-1	2559236
p@@	O	-1	2559236
s	O	-1	2559236
3	O	-1	2559236
and	O	-1	2559236
4	O	-1	2559236
were	O	-1	2559236
studied	O	-1	2559236
at	O	-1	2559236
four	O	-1	2559236
and	O	-1	2559236
at	O	-1	2559236
six	O	-1	2559236
months	O	-1	2559236
to	O	-1	2559236
ass@@	O	-1	2559236
ess	O	-1	2559236
the	O	-1	2559236
effect	O	-1	2559236
of	O	-1	2559236
en@@	B-Chemical	D004656	2559236
al@@	I-Chemical	-1	2559236
apri@@	I-Chemical	-1	2559236
l	I-Chemical	-1	2559236
on	O	-1	2559236
progres@@	O	-1	2559236
sion	O	-1	2559236
of	O	-1	2559236
renal	B-Disease	D007674	2559236
injury	I-Disease	-1	2559236
in	O	-1	2559236
adriam@@	B-Chemical	D004317	2559236
ycin	I-Chemical	-1	2559236
nephro@@	B-Disease	D009401	2559236
sis	I-Disease	-1	2559236
.	O	-1	2559236
Ch@@	O	-1	2559236
ron@@	O	-1	2559236
ic	O	-1	2559236
en@@	B-Chemical	D004656	2559236
al@@	I-Chemical	-1	2559236
apri@@	I-Chemical	-1	2559236
l	I-Chemical	-1	2559236
treatment	O	-1	2559236
reduced	O	-1	2559236
blood	O	-1	2559236
pressure	O	-1	2559236
without	O	-1	2559236
reduc@@	O	-1	2559236
ing	O	-1	2559236
al@@	B-Disease	D000419	2559236
bu@@	I-Disease	-1	2559236
min@@	I-Disease	-1	2559236
uria	I-Disease	-1	2559236
in	O	-1	2559236
group	O	-1	2559236
4@@	O	-1	2559236
.	O	-1	2559236
U@@	O	-1	2559236
n@@	O	-1	2559236
treated	O	-1	2559236
group	O	-1	2559236
3	O	-1	2559236
rats	O	-1	2559236
ex@@	O	-1	2559236
hib@@	O	-1	2559236
ited	O	-1	2559236
a	O	-1	2559236
progressive	O	-1	2559236
reduction	O	-1	2559236
in	O	-1	2559236
GF@@	O	-1	2559236
R	O	-1	2559236
(0.@@	O	-1	2559236
3@@	O	-1	2559236
5	O	-1	2559236
+/-	O	-1	2559236
0.0@@	O	-1	2559236
8	O	-1	2559236
ml@@	O	-1	2559236
/@@	O	-1	2559236
min	O	-1	2559236
at	O	-1	2559236
4	O	-1	2559236
month@@	O	-1	2559236
s,	O	-1	2559236
0.@@	O	-1	2559236
2@@	O	-1	2559236
7	O	-1	2559236
+/-	O	-1	2559236
0.0@@	O	-1	2559236
7	O	-1	2559236
ml@@	O	-1	2559236
/@@	O	-1	2559236
min	O	-1	2559236
at	O	-1	2559236
6	O	-1	2559236
month@@	O	-1	2559236
s@@	O	-1	2559236
).	O	-1	2559236
E@@	B-Chemical	D004656	2559236
n@@	I-Chemical	-1	2559236
al@@	I-Chemical	-1	2559236
apri@@	I-Chemical	-1	2559236
l	I-Chemical	-1	2559236
treatment	O	-1	2559236
bl@@	O	-1	2559236
un@@	O	-1	2559236
ted	O	-1	2559236
but	O	-1	2559236
did	O	-1	2559236
not	O	-1	2559236
prev@@	O	-1	2559236
ent	O	-1	2559236
reduction	O	-1	2559236
in	O	-1	2559236
GF@@	O	-1	2559236
R	O	-1	2559236
in	O	-1	2559236
group	O	-1	2559236
4	O	-1	2559236
(0.@@	O	-1	2559236
8@@	O	-1	2559236
6	O	-1	2559236
+/-	O	-1	2559236
0.@@	O	-1	2559236
15	O	-1	2559236
ml@@	O	-1	2559236
/@@	O	-1	2559236
min	O	-1	2559236
at	O	-1	2559236
4	O	-1	2559236
month@@	O	-1	2559236
s,	O	-1	2559236
0.@@	O	-1	2559236
6@@	O	-1	2559236
9	O	-1	2559236
+/-	O	-1	2559236
0.@@	O	-1	2559236
13	O	-1	2559236
ml@@	O	-1	2559236
/@@	O	-1	2559236
min	O	-1	2559236
at	O	-1	2559236
6	O	-1	2559236
month@@	O	-1	2559236
s,	O	-1	2559236
both	O	-1	2559236
P	O	-1	2559236
less	O	-1	2559236
than	O	-1	2559236
0.0@@	O	-1	2559236
5	O	-1	2559236
vs.	O	-1	2559236
group	O	-1	2559236
3@@	O	-1	2559236
).	O	-1	2559236
Re@@	O	-1	2559236
duction	O	-1	2559236
in	O	-1	2559236
GF@@	O	-1	2559236
R	O	-1	2559236
was	O	-1	2559236
associated	O	-1	2559236
with	O	-1	2559236
the	O	-1	2559236
development	O	-1	2559236
of	O	-1	2559236
glomerular	B-Disease	D007674	2559236
s@@	I-Disease	-1	2559236
clero@@	I-Disease	-1	2559236
sis	I-Disease	-1	2559236
in	O	-1	2559236
both	O	-1	2559236
treated	O	-1	2559236
and	O	-1	2559236
un@@	O	-1	2559236
treated	O	-1	2559236
rat@@	O	-1	2559236
s@@	O	-1	2559236
.@@	O	-1	2559236
(A@@	O	-1	2559236
B@@	O	-1	2559236
S@@	O	-1	2559236
TR@@	O	-1	2559236
AC@@	O	-1	2559236
T	O	-1	2559236
TR@@	O	-1	2559236
UN@@	O	-1	2559236
C@@	O	-1	2559236
AT@@	O	-1	2559236
E@@	O	-1	2559236
D	O	-1	2559236
A@@	O	-1	2559236
T	O	-1	2559236
2@@	O	-1	2559236
50	O	-1	2559236
W@@	O	-1	2559236
O@@	O	-1	2559236
RD@@	O	-1	2559236
S)	O	-1	2559236

B@@	O	-1	21029050
ut@@	O	-1	21029050
y@@	O	-1	21029050
r@@	O	-1	21029050
ylchol@@	O	-1	21029050
ine@@	O	-1	21029050
ster@@	O	-1	21029050
ase	O	-1	21029050
gen@@	O	-1	21029050
e	O	-1	21029050
mut@@	O	-1	21029050
ations	O	-1	21029050
in	O	-1	21029050
patients	O	-1	21029050
with	O	-1	21029050
prolonged	O	-1	21029050
ap@@	B-Disease	D001049	21029050
ne@@	I-Disease	-1	21029050
a	I-Disease	-1	21029050
after	O	-1	21029050
suc@@	B-Chemical	D013390	21029050
cin@@	I-Chemical	-1	21029050
ylcholine	I-Chemical	-1	21029050
for	O	-1	21029050
electro@@	O	-1	21029050
convul@@	O	-1	21029050
sive	O	-1	21029050
therapy.	O	-1	21029050
BACKGROUND:	O	-1	21029050
patients	O	-1	21029050
under@@	O	-1	21029050
go@@	O	-1	21029050
ing	O	-1	21029050
electro@@	O	-1	21029050
convul@@	O	-1	21029050
sive	O	-1	21029050
therapy	O	-1	21029050
(@@	O	-1	21029050
EC@@	O	-1	21029050
T)	O	-1	21029050
often	O	-1	21029050
recei@@	O	-1	21029050
ve	O	-1	21029050
suc@@	B-Chemical	D013390	21029050
cin@@	I-Chemical	-1	21029050
ylcholine	I-Chemical	-1	21029050
as	O	-1	21029050
par@@	O	-1	21029050
t	O	-1	21029050
of	O	-1	21029050
the	O	-1	21029050
anesthe@@	O	-1	21029050
tic	O	-1	21029050
proce@@	O	-1	21029050
d@@	O	-1	21029050
ure.	O	-1	21029050
The	O	-1	21029050
duration	O	-1	21029050
of	O	-1	21029050
action	O	-1	21029050
may	O	-1	21029050
be	O	-1	21029050
prolonged	O	-1	21029050
in	O	-1	21029050
patients	O	-1	21029050
with	O	-1	21029050
gene@@	O	-1	21029050
tic	O	-1	21029050
vari@@	O	-1	21029050
ants	O	-1	21029050
of	O	-1	21029050
the	O	-1	21029050
but@@	O	-1	21029050
y@@	O	-1	21029050
r@@	O	-1	21029050
ylchol@@	O	-1	21029050
ine@@	O	-1	21029050
ster@@	O	-1	21029050
ase	O	-1	21029050
enzyme	O	-1	21029050
(B@@	O	-1	21029050
Ch@@	O	-1	21029050
E@@	O	-1	21029050
),	O	-1	21029050
the	O	-1	21029050
most	O	-1	21029050
common	O	-1	21029050
being	O	-1	21029050
the	O	-1	21029050
K@@	O	-1	21029050
-	O	-1	21029050
and	O	-1	21029050
the	O	-1	21029050
A@@	O	-1	21029050
-@@	O	-1	21029050
vari@@	O	-1	21029050
ant@@	O	-1	21029050
s.	O	-1	21029050
The	O	-1	21029050
a@@	O	-1	21029050
im	O	-1	21029050
of	O	-1	21029050
the	O	-1	21029050
study	O	-1	21029050
was	O	-1	21029050
to	O	-1	21029050
ass@@	O	-1	21029050
ess	O	-1	21029050
the	O	-1	21029050
clinical	O	-1	21029050
signific@@	O	-1	21029050
ance	O	-1	21029050
of	O	-1	21029050
gene@@	O	-1	21029050
tic	O	-1	21029050
vari@@	O	-1	21029050
ants	O	-1	21029050
in	O	-1	21029050
but@@	O	-1	21029050
y@@	O	-1	21029050
r@@	O	-1	21029050
ylchol@@	O	-1	21029050
ine@@	O	-1	21029050
ster@@	O	-1	21029050
ase	O	-1	21029050
gen@@	O	-1	21029050
e	O	-1	21029050
(@@	O	-1	21029050
BC@@	O	-1	21029050
H@@	O	-1	21029050
E@@	O	-1	21029050
)	O	-1	21029050
in	O	-1	21029050
patients	O	-1	21029050
with	O	-1	21029050
a	O	-1	21029050
sus@@	O	-1	21029050
p@@	O	-1	21029050
ected	O	-1	21029050
prolonged	O	-1	21029050
duration	O	-1	21029050
of	O	-1	21029050
action	O	-1	21029050
of	O	-1	21029050
suc@@	B-Chemical	D013390	21029050
cin@@	I-Chemical	-1	21029050
ylcholine	I-Chemical	-1	21029050
after	O	-1	21029050
EC@@	O	-1	21029050
T@@	O	-1	21029050
.	O	-1	21029050
METHODS:	O	-1	21029050
a	O	-1	21029050
total	O	-1	21029050
of	O	-1	21029050
13	O	-1	21029050
patients	O	-1	21029050
were	O	-1	21029050
ref@@	O	-1	21029050
er@@	O	-1	21029050
red	O	-1	21029050
to	O	-1	21029050
the	O	-1	21029050
D@@	O	-1	21029050
an@@	O	-1	21029050
is@@	O	-1	21029050
h	O	-1	21029050
Ch@@	O	-1	21029050
ol@@	O	-1	21029050
ine@@	O	-1	21029050
ster@@	O	-1	21029050
ase	O	-1	21029050
R@@	O	-1	21029050
es@@	O	-1	21029050
ear@@	O	-1	21029050
ch	O	-1	21029050
U@@	O	-1	21029050
n@@	O	-1	21029050
it	O	-1	21029050
after	O	-1	21029050
EC@@	O	-1	21029050
T	O	-1	21029050
during	O	-1	21029050
3@@	O	-1	21029050
8	O	-1	21029050
months.	O	-1	21029050
We	O	-1	21029050
determined	O	-1	21029050
the	O	-1	21029050
B@@	O	-1	21029050
Ch@@	O	-1	21029050
E	O	-1	21029050
activity	O	-1	21029050
and	O	-1	21029050
the	O	-1	21029050
BC@@	O	-1	21029050
H@@	O	-1	21029050
E	O	-1	21029050
gen@@	O	-1	21029050
ot@@	O	-1	21029050
yp@@	O	-1	21029050
e	O	-1	21029050
using	O	-1	21029050
mol@@	O	-1	21029050
ec@@	O	-1	21029050
ular	O	-1	21029050
gene@@	O	-1	21029050
tic	O	-1	21029050
meth@@	O	-1	21029050
o@@	O	-1	21029050
d@@	O	-1	21029050
s,	O	-1	21029050
the	O	-1	21029050
duration	O	-1	21029050
of	O	-1	21029050
ap@@	B-Disease	D001049	21029050
ne@@	I-Disease	-1	21029050
a	I-Disease	-1	21029050
,	O	-1	21029050
time	O	-1	21029050
to	O	-1	21029050
suffici@@	O	-1	21029050
ent	O	-1	21029050
spont@@	O	-1	21029050
aneous	O	-1	21029050
ven@@	O	-1	21029050
til@@	O	-1	21029050
ation	O	-1	21029050
and	O	-1	21029050
whether	O	-1	21029050
neuro@@	O	-1	21029050
mus@@	O	-1	21029050
cular	O	-1	21029050
monit@@	O	-1	21029050
or@@	O	-1	21029050
ing	O	-1	21029050
was	O	-1	21029050
use@@	O	-1	21029050
d.	O	-1	21029050
The	O	-1	21029050
duration	O	-1	21029050
of	O	-1	21029050
ap@@	B-Disease	D001049	21029050
ne@@	I-Disease	-1	21029050
a	I-Disease	-1	21029050
was	O	-1	21029050
compared	O	-1	21029050
with	O	-1	21029050
pu@@	O	-1	21029050
bl@@	O	-1	21029050
ished	O	-1	21029050
data	O	-1	21029050
on	O	-1	21029050
normal	O	-1	21029050
subj@@	O	-1	21029050
ect@@	O	-1	21029050
s.	O	-1	21029050
RESULTS:	O	-1	21029050
in	O	-1	21029050
11	O	-1	21029050
patients,	O	-1	21029050
mut@@	O	-1	21029050
ations	O	-1	21029050
were	O	-1	21029050
found	O	-1	21029050
in	O	-1	21029050
the	O	-1	21029050
BC@@	O	-1	21029050
H@@	O	-1	21029050
E	O	-1	21029050
gen@@	O	-1	21029050
e,	O	-1	21029050
the	O	-1	21029050
K@@	O	-1	21029050
-@@	O	-1	21029050
vari@@	O	-1	21029050
ant	O	-1	21029050
being	O	-1	21029050
the	O	-1	21029050
most	O	-1	21029050
frequ@@	O	-1	21029050
ent@@	O	-1	21029050
.	O	-1	21029050
The	O	-1	21029050
duration	O	-1	21029050
of	O	-1	21029050
ap@@	B-Disease	D001049	21029050
ne@@	I-Disease	-1	21029050
a	I-Disease	-1	21029050
was	O	-1	21029050
5-@@	O	-1	21029050
15	O	-1	21029050
min	O	-1	21029050
compared	O	-1	21029050
with	O	-1	21029050
3-@@	O	-1	21029050
5.@@	O	-1	21029050
3	O	-1	21029050
min	O	-1	21029050
from	O	-1	21029050
the	O	-1	21029050
literat@@	O	-1	21029050
ure.	O	-1	21029050
S@@	O	-1	21029050
ev@@	O	-1	21029050
ere	O	-1	21029050
dist@@	O	-1	21029050
res@@	O	-1	21029050
s	O	-1	21029050
was	O	-1	21029050
not@@	O	-1	21029050
ed	O	-1	21029050
in	O	-1	21029050
the	O	-1	21029050
recovery	O	-1	21029050
phase	O	-1	21029050
in	O	-1	21029050
two	O	-1	21029050
patients.	O	-1	21029050
Ne@@	O	-1	21029050
uro@@	O	-1	21029050
mus@@	O	-1	21029050
cular	O	-1	21029050
monit@@	O	-1	21029050
or@@	O	-1	21029050
ing	O	-1	21029050
was	O	-1	21029050
used	O	-1	21029050
in	O	-1	21029050
two	O	-1	21029050
patients.	O	-1	21029050
CONCLUSION:	O	-1	21029050
e@@	O	-1	21029050
le@@	O	-1	21029050
ven	O	-1	21029050
of	O	-1	21029050
13	O	-1	21029050
patients	O	-1	21029050
with	O	-1	21029050
a	O	-1	21029050
prolonged	O	-1	21029050
duration	O	-1	21029050
of	O	-1	21029050
action	O	-1	21029050
of	O	-1	21029050
suc@@	B-Chemical	D013390	21029050
cin@@	I-Chemical	-1	21029050
ylcholine	I-Chemical	-1	21029050
had	O	-1	21029050
mut@@	O	-1	21029050
ations	O	-1	21029050
in	O	-1	21029050
BC@@	O	-1	21029050
H@@	O	-1	21029050
E@@	O	-1	21029050
,	O	-1	21029050
indicating	O	-1	21029050
that	O	-1	21029050
this	O	-1	21029050
is	O	-1	21029050
the	O	-1	21029050
possible	O	-1	21029050
reas@@	O	-1	21029050
on	O	-1	21029050
for	O	-1	21029050
a	O	-1	21029050
prolonged	O	-1	21029050
period	O	-1	21029050
of	O	-1	21029050
ap@@	B-Disease	D001049	21029050
ne@@	I-Disease	-1	21029050
a	I-Disease	-1	21029050
.	O	-1	21029050
We	O	-1	21029050
recomm@@	O	-1	21029050
end	O	-1	21029050
ob@@	O	-1	21029050
j@@	O	-1	21029050
ective	O	-1	21029050
neuro@@	O	-1	21029050
mus@@	O	-1	21029050
cular	O	-1	21029050
monit@@	O	-1	21029050
or@@	O	-1	21029050
ing	O	-1	21029050
during	O	-1	21029050
the	O	-1	21029050
first	O	-1	21029050
EC@@	O	-1	21029050
T@@	O	-1	21029050
.	O	-1	21029050

K@@	B-Chemical	D007649	10901305
et@@	I-Chemical	-1	10901305
amine	I-Chemical	-1	10901305
sed@@	O	-1	10901305
ation	O	-1	10901305
for	O	-1	10901305
the	O	-1	10901305
reduction	O	-1	10901305
of	O	-1	10901305
child@@	O	-1	10901305
ren@@	O	-1	10901305
's	O	-1	10901305
frac@@	B-Disease	D050723	10901305
t@@	I-Disease	-1	10901305
ures	I-Disease	-1	10901305
in	O	-1	10901305
the	O	-1	10901305
em@@	O	-1	10901305
er@@	O	-1	10901305
gen@@	O	-1	10901305
c@@	O	-1	10901305
y	O	-1	10901305
de@@	O	-1	10901305
part@@	O	-1	10901305
ment.	O	-1	10901305
BACKGROUND:	O	-1	10901305
There	O	-1	10901305
rec@@	O	-1	10901305
ently	O	-1	10901305
has	O	-1	10901305
been	O	-1	10901305
a	O	-1	10901305
res@@	O	-1	10901305
ur@@	O	-1	10901305
gen@@	O	-1	10901305
ce	O	-1	10901305
in	O	-1	10901305
the	O	-1	10901305
u@@	O	-1	10901305
ti@@	O	-1	10901305
li@@	O	-1	10901305
z@@	O	-1	10901305
ation	O	-1	10901305
of	O	-1	10901305
k@@	B-Chemical	D007649	10901305
et@@	I-Chemical	-1	10901305
amine	I-Chemical	-1	10901305
,	O	-1	10901305
a	O	-1	10901305
un@@	O	-1	10901305
i@@	O	-1	10901305
qu@@	O	-1	10901305
e	O	-1	10901305
anesthe@@	O	-1	10901305
tic@@	O	-1	10901305
,	O	-1	10901305
for	O	-1	10901305
em@@	O	-1	10901305
er@@	O	-1	10901305
gen@@	O	-1	10901305
cy@@	O	-1	10901305
-@@	O	-1	10901305
de@@	O	-1	10901305
part@@	O	-1	10901305
ment	O	-1	10901305
proce@@	O	-1	10901305
d@@	O	-1	10901305
ures	O	-1	10901305
requ@@	O	-1	10901305
ir@@	O	-1	10901305
ing	O	-1	10901305
sed@@	O	-1	10901305
ation.	O	-1	10901305
The	O	-1	10901305
pur@@	O	-1	10901305
p@@	O	-1	10901305
ose	O	-1	10901305
of	O	-1	10901305
the	O	-1	10901305
present	O	-1	10901305
study	O	-1	10901305
was	O	-1	10901305
to	O	-1	10901305
ex@@	O	-1	10901305
amine	O	-1	10901305
the	O	-1	10901305
safety	O	-1	10901305
and	O	-1	10901305
efficacy	O	-1	10901305
of	O	-1	10901305
k@@	B-Chemical	D007649	10901305
et@@	I-Chemical	-1	10901305
amine	I-Chemical	-1	10901305
for	O	-1	10901305
sed@@	O	-1	10901305
ation	O	-1	10901305
in	O	-1	10901305
the	O	-1	10901305
treatment	O	-1	10901305
of	O	-1	10901305
child@@	O	-1	10901305
ren@@	O	-1	10901305
's	O	-1	10901305
frac@@	B-Disease	D050723	10901305
t@@	I-Disease	-1	10901305
ures	I-Disease	-1	10901305
in	O	-1	10901305
the	O	-1	10901305
em@@	O	-1	10901305
er@@	O	-1	10901305
gen@@	O	-1	10901305
c@@	O	-1	10901305
y	O	-1	10901305
de@@	O	-1	10901305
part@@	O	-1	10901305
ment.	O	-1	10901305
METHODS:	O	-1	10901305
One	O	-1	10901305
h@@	O	-1	10901305
und@@	O	-1	10901305
red	O	-1	10901305
and	O	-1	10901305
fo@@	O	-1	10901305
ur@@	O	-1	10901305
te@@	O	-1	10901305
en	O	-1	10901305
children	O	-1	10901305
(@@	O	-1	10901305
average	O	-1	10901305
age,	O	-1	10901305
5.@@	O	-1	10901305
3	O	-1	10901305
year@@	O	-1	10901305
s;	O	-1	10901305
rang@@	O	-1	10901305
e,	O	-1	10901305
t@@	O	-1	10901305
we@@	O	-1	10901305
l@@	O	-1	10901305
ve	O	-1	10901305
months	O	-1	10901305
to	O	-1	10901305
ten	O	-1	10901305
years	O	-1	10901305
and	O	-1	10901305
ten	O	-1	10901305
month@@	O	-1	10901305
s)	O	-1	10901305
who	O	-1	10901305
under@@	O	-1	10901305
w@@	O	-1	10901305
ent	O	-1	10901305
c@@	O	-1	10901305
los@@	O	-1	10901305
ed	O	-1	10901305
reduction	O	-1	10901305
of	O	-1	10901305
an	O	-1	10901305
isol@@	O	-1	10901305
ated	O	-1	10901305
frac@@	B-Disease	D050723	10901305
t@@	I-Disease	-1	10901305
ure	I-Disease	-1	10901305
or	O	-1	10901305
dis@@	B-Disease	D004204	10901305
loc@@	I-Disease	-1	10901305
ation	I-Disease	-1	10901305
in	O	-1	10901305
the	O	-1	10901305
em@@	O	-1	10901305
er@@	O	-1	10901305
gen@@	O	-1	10901305
c@@	O	-1	10901305
y	O	-1	10901305
de@@	O	-1	10901305
part@@	O	-1	10901305
ment	O	-1	10901305
at	O	-1	10901305
a	O	-1	10901305
level@@	O	-1	10901305
-@@	O	-1	10901305
I	O	-1	10901305
tra@@	B-Disease	D014947	10901305
um@@	I-Disease	-1	10901305
a	I-Disease	-1	10901305
c@@	O	-1	10901305
ent@@	O	-1	10901305
er	O	-1	10901305
were	O	-1	10901305
pro@@	O	-1	10901305
sp@@	O	-1	10901305
ectively	O	-1	10901305
evalu@@	O	-1	10901305
ated.	O	-1	10901305
K@@	B-Chemical	D007649	10901305
et@@	I-Chemical	-1	10901305
amine	I-Chemical	-1	10901305
hydro@@	I-Chemical	-1	10901305
chlor@@	I-Chemical	-1	10901305
ide	I-Chemical	-1	10901305
was	O	-1	10901305
administered	O	-1	10901305
intra@@	O	-1	10901305
ven@@	O	-1	10901305
ously	O	-1	10901305
(@@	O	-1	10901305
at	O	-1	10901305
a	O	-1	10901305
dose	O	-1	10901305
of	O	-1	10901305
two	O	-1	10901305
mil@@	O	-1	10901305
li@@	O	-1	10901305
gram@@	O	-1	10901305
s	O	-1	10901305
per	O	-1	10901305
k@@	O	-1	10901305
i@@	O	-1	10901305
logra@@	O	-1	10901305
m	O	-1	10901305
of	O	-1	10901305
body	O	-1	10901305
weigh@@	O	-1	10901305
t@@	O	-1	10901305
)	O	-1	10901305
in	O	-1	10901305
n@@	O	-1	10901305
ine@@	O	-1	10901305
ty-@@	O	-1	10901305
n@@	O	-1	10901305
ine	O	-1	10901305
of	O	-1	10901305
the	O	-1	10901305
patients	O	-1	10901305
and	O	-1	10901305
int@@	O	-1	10901305
ram@@	O	-1	10901305
us@@	O	-1	10901305
cul@@	O	-1	10901305
arly	O	-1	10901305
(@@	O	-1	10901305
at	O	-1	10901305
a	O	-1	10901305
dose	O	-1	10901305
of	O	-1	10901305
four	O	-1	10901305
mil@@	O	-1	10901305
li@@	O	-1	10901305
gram@@	O	-1	10901305
s	O	-1	10901305
per	O	-1	10901305
k@@	O	-1	10901305
i@@	O	-1	10901305
logra@@	O	-1	10901305
m	O	-1	10901305
of	O	-1	10901305
body	O	-1	10901305
weigh@@	O	-1	10901305
t@@	O	-1	10901305
)	O	-1	10901305
in	O	-1	10901305
the	O	-1	10901305
other	O	-1	10901305
f@@	O	-1	10901305
if@@	O	-1	10901305
te@@	O	-1	10901305
en@@	O	-1	10901305
.	O	-1	10901305
A	O	-1	10901305
bo@@	O	-1	10901305
ar@@	O	-1	10901305
d-@@	O	-1	10901305
cer@@	O	-1	10901305
ti@@	O	-1	10901305
fied	O	-1	10901305
em@@	O	-1	10901305
er@@	O	-1	10901305
gen@@	O	-1	10901305
c@@	O	-1	10901305
y	O	-1	10901305
physi@@	O	-1	10901305
ci@@	O	-1	10901305
an	O	-1	10901305
s@@	O	-1	10901305
k@@	O	-1	10901305
ill@@	O	-1	10901305
ed	O	-1	10901305
in	O	-1	10901305
a@@	O	-1	10901305
ir@@	O	-1	10901305
w@@	O	-1	10901305
ay	O	-1	10901305
man@@	O	-1	10901305
ag@@	O	-1	10901305
ement	O	-1	10901305
su@@	O	-1	10901305
per@@	O	-1	10901305
v@@	O	-1	10901305
is@@	O	-1	10901305
ed	O	-1	10901305
administration	O	-1	10901305
of	O	-1	10901305
the	O	-1	10901305
anesthe@@	O	-1	10901305
tic@@	O	-1	10901305
,	O	-1	10901305
and	O	-1	10901305
the	O	-1	10901305
patients	O	-1	10901305
were	O	-1	10901305
monit@@	O	-1	10901305
o@@	O	-1	10901305
red	O	-1	10901305
by	O	-1	10901305
a	O	-1	10901305
reg@@	O	-1	10901305
ist@@	O	-1	10901305
ered	O	-1	10901305
n@@	O	-1	10901305
ur@@	O	-1	10901305
se.	O	-1	10901305
An@@	O	-1	10901305
y	O	-1	10901305
pain	B-Disease	D010146	10901305
during	O	-1	10901305
the	O	-1	10901305
reduction	O	-1	10901305
was	O	-1	10901305
r@@	O	-1	10901305
ated	O	-1	10901305
by	O	-1	10901305
the	O	-1	10901305
or@@	O	-1	10901305
th@@	O	-1	10901305
o@@	O	-1	10901305
pa@@	O	-1	10901305
edi@@	O	-1	10901305
c	O	-1	10901305
sur@@	O	-1	10901305
ge@@	O	-1	10901305
on	O	-1	10901305
treat@@	O	-1	10901305
ing	O	-1	10901305
the	O	-1	10901305
patient	O	-1	10901305
ac@@	O	-1	10901305
cor@@	O	-1	10901305
ding	O	-1	10901305
to	O	-1	10901305
the	O	-1	10901305
Ch@@	O	-1	10901305
ild@@	O	-1	10901305
ren@@	O	-1	10901305
's	O	-1	10901305
H@@	O	-1	10901305
ospit@@	O	-1	10901305
al	O	-1	10901305
of	O	-1	10901305
E@@	O	-1	10901305
ast@@	O	-1	10901305
er@@	O	-1	10901305
n	O	-1	10901305
On@@	O	-1	10901305
t@@	O	-1	10901305
ari@@	O	-1	10901305
o	O	-1	10901305
P@@	B-Disease	D010146	10901305
ain	I-Disease	-1	10901305
S@@	O	-1	10901305
cal@@	O	-1	10901305
e	O	-1	10901305
(C@@	O	-1	10901305
H@@	O	-1	10901305
E@@	O	-1	10901305
O@@	O	-1	10901305
P@@	O	-1	10901305
S@@	O	-1	10901305
).	O	-1	10901305
RESULTS:	O	-1	10901305
The	O	-1	10901305
average	O	-1	10901305
time	O	-1	10901305
from	O	-1	10901305
intravenous	O	-1	10901305
administration	O	-1	10901305
of	O	-1	10901305
k@@	B-Chemical	D007649	10901305
et@@	I-Chemical	-1	10901305
amine	I-Chemical	-1	10901305
to	O	-1	10901305
man@@	O	-1	10901305
ip@@	O	-1	10901305
ulation	O	-1	10901305
of	O	-1	10901305
the	O	-1	10901305
frac@@	B-Disease	D050723	10901305
t@@	I-Disease	-1	10901305
ure	I-Disease	-1	10901305
or	O	-1	10901305
dis@@	B-Disease	D004204	10901305
loc@@	I-Disease	-1	10901305
ation	I-Disease	-1	10901305
was	O	-1	10901305
one	O	-1	10901305
min@@	O	-1	10901305
ute	O	-1	10901305
and	O	-1	10901305
thir@@	O	-1	10901305
ty-@@	O	-1	10901305
six	O	-1	10901305
secon@@	O	-1	10901305
ds	O	-1	10901305
(@@	O	-1	10901305
rang@@	O	-1	10901305
e,	O	-1	10901305
tw@@	O	-1	10901305
ent@@	O	-1	10901305
y	O	-1	10901305
secon@@	O	-1	10901305
ds	O	-1	10901305
to	O	-1	10901305
five	O	-1	10901305
minut@@	O	-1	10901305
es@@	O	-1	10901305
),	O	-1	10901305
and	O	-1	10901305
the	O	-1	10901305
average	O	-1	10901305
time	O	-1	10901305
from	O	-1	10901305
int@@	O	-1	10901305
ram@@	O	-1	10901305
us@@	O	-1	10901305
cular	O	-1	10901305
administration	O	-1	10901305
to	O	-1	10901305
man@@	O	-1	10901305
ip@@	O	-1	10901305
ulation	O	-1	10901305
was	O	-1	10901305
four	O	-1	10901305
minutes	O	-1	10901305
and	O	-1	10901305
for@@	O	-1	10901305
ty-@@	O	-1	10901305
two	O	-1	10901305
secon@@	O	-1	10901305
ds	O	-1	10901305
(@@	O	-1	10901305
rang@@	O	-1	10901305
e,	O	-1	10901305
si@@	O	-1	10901305
x@@	O	-1	10901305
t@@	O	-1	10901305
y	O	-1	10901305
secon@@	O	-1	10901305
ds	O	-1	10901305
to	O	-1	10901305
f@@	O	-1	10901305
if@@	O	-1	10901305
te@@	O	-1	10901305
en	O	-1	10901305
minut@@	O	-1	10901305
es@@	O	-1	10901305
).	O	-1	10901305
The	O	-1	10901305
average	O	-1	10901305
scor@@	O	-1	10901305
e	O	-1	10901305
ac@@	O	-1	10901305
cor@@	O	-1	10901305
ding	O	-1	10901305
to	O	-1	10901305
the	O	-1	10901305
Ch@@	O	-1	10901305
ild@@	O	-1	10901305
ren@@	O	-1	10901305
's	O	-1	10901305
H@@	O	-1	10901305
ospit@@	O	-1	10901305
al	O	-1	10901305
of	O	-1	10901305
E@@	O	-1	10901305
ast@@	O	-1	10901305
er@@	O	-1	10901305
n	O	-1	10901305
On@@	O	-1	10901305
t@@	O	-1	10901305
ari@@	O	-1	10901305
o	O	-1	10901305
P@@	B-Disease	D010146	10901305
ain	I-Disease	-1	10901305
S@@	O	-1	10901305
cal@@	O	-1	10901305
e	O	-1	10901305
was	O	-1	10901305
6.@@	O	-1	10901305
4	O	-1	10901305
po@@	O	-1	10901305
int@@	O	-1	10901305
s	O	-1	10901305
(@@	O	-1	10901305
rang@@	O	-1	10901305
e,	O	-1	10901305
5	O	-1	10901305
to	O	-1	10901305
10	O	-1	10901305
po@@	O	-1	10901305
int@@	O	-1	10901305
s),	O	-1	10901305
ref@@	O	-1	10901305
l@@	O	-1	10901305
ect@@	O	-1	10901305
ing	O	-1	10901305
minim@@	O	-1	10901305
al	O	-1	10901305
or	O	-1	10901305
no	O	-1	10901305
pain	B-Disease	D010146	10901305
during	O	-1	10901305
frac@@	B-Disease	D050723	10901305
t@@	I-Disease	-1	10901305
ure	I-Disease	-1	10901305
reduc@@	O	-1	10901305
tion.	O	-1	10901305
A@@	O	-1	10901305
de@@	O	-1	10901305
qu@@	O	-1	10901305
ate	O	-1	10901305
frac@@	B-Disease	D050723	10901305
t@@	I-Disease	-1	10901305
ure	I-Disease	-1	10901305
reduction	O	-1	10901305
was	O	-1	10901305
obtained	O	-1	10901305
in	O	-1	10901305
1@@	O	-1	10901305
11	O	-1	10901305
of	O	-1	10901305
the	O	-1	10901305
child@@	O	-1	10901305
ren@@	O	-1	10901305
.	O	-1	10901305
N@@	O	-1	10901305
ine@@	O	-1	10901305
ty-@@	O	-1	10901305
n@@	O	-1	10901305
ine	O	-1	10901305
perc@@	O	-1	10901305
ent	O	-1	10901305
(@@	O	-1	10901305
si@@	O	-1	10901305
x@@	O	-1	10901305
ty-@@	O	-1	10901305
e@@	O	-1	10901305
igh@@	O	-1	10901305
t@@	O	-1	10901305
)	O	-1	10901305
of	O	-1	10901305
the	O	-1	10901305
si@@	O	-1	10901305
x@@	O	-1	10901305
ty-@@	O	-1	10901305
n@@	O	-1	10901305
ine	O	-1	10901305
pa@@	O	-1	10901305
ren@@	O	-1	10901305
ts	O	-1	10901305
present	O	-1	10901305
during	O	-1	10901305
the	O	-1	10901305
reduction	O	-1	10901305
were	O	-1	10901305
ple@@	O	-1	10901305
as@@	O	-1	10901305
ed	O	-1	10901305
with	O	-1	10901305
the	O	-1	10901305
sed@@	O	-1	10901305
ation	O	-1	10901305
and	O	-1	10901305
wo@@	O	-1	10901305
uld	O	-1	10901305
al@@	O	-1	10901305
low	O	-1	10901305
it	O	-1	10901305
to	O	-1	10901305
be	O	-1	10901305
used	O	-1	10901305
ag@@	O	-1	10901305
ain	O	-1	10901305
in	O	-1	10901305
a	O	-1	10901305
similar	O	-1	10901305
sit@@	O	-1	10901305
u@@	O	-1	10901305
ation.	O	-1	10901305
P@@	O	-1	10901305
at@@	O	-1	10901305
ency	O	-1	10901305
of	O	-1	10901305
the	O	-1	10901305
a@@	O	-1	10901305
ir@@	O	-1	10901305
w@@	O	-1	10901305
ay	O	-1	10901305
and	O	-1	10901305
in@@	O	-1	10901305
dependent	O	-1	10901305
res@@	O	-1	10901305
pi@@	O	-1	10901305
ration	O	-1	10901305
were	O	-1	10901305
maint@@	O	-1	10901305
ained	O	-1	10901305
in	O	-1	10901305
all	O	-1	10901305
of	O	-1	10901305
the	O	-1	10901305
patients.	O	-1	10901305
B@@	O	-1	10901305
lo@@	O	-1	10901305
od	O	-1	10901305
pressure	O	-1	10901305
and	O	-1	10901305
heart	O	-1	10901305
rate	O	-1	10901305
remained	O	-1	10901305
st@@	O	-1	10901305
able@@	O	-1	10901305
.	O	-1	10901305
M@@	O	-1	10901305
in@@	O	-1	10901305
or	O	-1	10901305
side	O	-1	10901305
effects	O	-1	10901305
included	O	-1	10901305
nausea	B-Disease	D009325	10901305
(@@	O	-1	10901305
thir@@	O	-1	10901305
te@@	O	-1	10901305
en	O	-1	10901305
patient@@	O	-1	10901305
s),	O	-1	10901305
e@@	B-Disease	D014839	10901305
me@@	I-Disease	-1	10901305
sis	I-Disease	-1	10901305
(@@	O	-1	10901305
e@@	O	-1	10901305
ight	O	-1	10901305
of	O	-1	10901305
the	O	-1	10901305
thir@@	O	-1	10901305
te@@	O	-1	10901305
en	O	-1	10901305
patients	O	-1	10901305
with	O	-1	10901305
nausea	B-Disease	D009325	10901305
),	O	-1	10901305
cl@@	B-Disease	D001259	10901305
um@@	I-Disease	-1	10901305
s@@	I-Disease	-1	10901305
in@@	I-Disease	-1	10901305
ess	I-Disease	-1	10901305
(@@	O	-1	10901305
ev@@	O	-1	10901305
id@@	O	-1	10901305
ent	O	-1	10901305
as	O	-1	10901305
at@@	B-Disease	D001259	10901305
ax@@	I-Disease	-1	10901305
ic	I-Disease	-1	10901305
mo@@	I-Disease	-1	10901305
ve@@	I-Disease	-1	10901305
ments	I-Disease	-1	10901305
in	O	-1	10901305
ten	O	-1	10901305
patient@@	O	-1	10901305
s),	O	-1	10901305
and	O	-1	10901305
dys@@	B-Disease	-1	10901305
ph@@	I-Disease	-1	10901305
or@@	I-Disease	-1	10901305
ic	I-Disease	-1	10901305
reaction	I-Disease	-1	10901305
(@@	O	-1	10901305
one	O	-1	10901305
patient@@	O	-1	10901305
).	O	-1	10901305
No	O	-1	10901305
long-term	O	-1	10901305
sequ@@	O	-1	10901305
el@@	O	-1	10901305
a@@	O	-1	10901305
e	O	-1	10901305
were	O	-1	10901305
not@@	O	-1	10901305
ed,	O	-1	10901305
and	O	-1	10901305
no	O	-1	10901305
patients	O	-1	10901305
had	O	-1	10901305
h@@	B-Disease	D006212	10901305
all@@	I-Disease	-1	10901305
uc@@	I-Disease	-1	10901305
in@@	I-Disease	-1	10901305
ations	I-Disease	-1	10901305
or	O	-1	10901305
n@@	O	-1	10901305
igh@@	O	-1	10901305
t@@	O	-1	10901305
ma@@	O	-1	10901305
res@@	O	-1	10901305
.	O	-1	10901305
CONCLUSIONS:	O	-1	10901305
K@@	B-Chemical	D007649	10901305
et@@	I-Chemical	-1	10901305
amine	I-Chemical	-1	10901305
re@@	O	-1	10901305
li@@	O	-1	10901305
ab@@	O	-1	10901305
ly,	O	-1	10901305
saf@@	O	-1	10901305
el@@	O	-1	10901305
y,	O	-1	10901305
and	O	-1	10901305
qu@@	O	-1	10901305
ic@@	O	-1	10901305
k@@	O	-1	10901305
ly	O	-1	10901305
pro@@	O	-1	10901305
vid@@	O	-1	10901305
ed	O	-1	10901305
ade@@	O	-1	10901305
qu@@	O	-1	10901305
ate	O	-1	10901305
sed@@	O	-1	10901305
ation	O	-1	10901305
to	O	-1	10901305
eff@@	O	-1	10901305
ectively	O	-1	10901305
fac@@	O	-1	10901305
il@@	O	-1	10901305
it@@	O	-1	10901305
ate	O	-1	10901305
the	O	-1	10901305
reduction	O	-1	10901305
of	O	-1	10901305
child@@	O	-1	10901305
ren@@	O	-1	10901305
's	O	-1	10901305
frac@@	B-Disease	D050723	10901305
t@@	I-Disease	-1	10901305
ures	I-Disease	-1	10901305
in	O	-1	10901305
the	O	-1	10901305
em@@	O	-1	10901305
er@@	O	-1	10901305
gen@@	O	-1	10901305
c@@	O	-1	10901305
y	O	-1	10901305
de@@	O	-1	10901305
part@@	O	-1	10901305
ment	O	-1	10901305
at	O	-1	10901305
our	O	-1	10901305
insti@@	O	-1	10901305
tu@@	O	-1	10901305
tion.	O	-1	10901305
K@@	B-Chemical	D007649	10901305
et@@	I-Chemical	-1	10901305
amine	I-Chemical	-1	10901305
should	O	-1	10901305
only	O	-1	10901305
be	O	-1	10901305
used	O	-1	10901305
in	O	-1	10901305
an	O	-1	10901305
en@@	O	-1	10901305
vi@@	O	-1	10901305
ron@@	O	-1	10901305
ment	O	-1	10901305
such	O	-1	10901305
as	O	-1	10901305
the	O	-1	10901305
em@@	O	-1	10901305
er@@	O	-1	10901305
gen@@	O	-1	10901305
c@@	O	-1	10901305
y	O	-1	10901305
de@@	O	-1	10901305
part@@	O	-1	10901305
ment@@	O	-1	10901305
,	O	-1	10901305
wh@@	O	-1	10901305
ere	O	-1	10901305
pro@@	O	-1	10901305
per	O	-1	10901305
on@@	O	-1	10901305
e-@@	O	-1	10901305
on@@	O	-1	10901305
-@@	O	-1	10901305
one	O	-1	10901305
monit@@	O	-1	10901305
or@@	O	-1	10901305
ing	O	-1	10901305
is	O	-1	10901305
used	O	-1	10901305
and	O	-1	10901305
bo@@	O	-1	10901305
ar@@	O	-1	10901305
d-@@	O	-1	10901305
cer@@	O	-1	10901305
ti@@	O	-1	10901305
fied	O	-1	10901305
physi@@	O	-1	10901305
ci@@	O	-1	10901305
ans	O	-1	10901305
s@@	O	-1	10901305
k@@	O	-1	10901305
ill@@	O	-1	10901305
ed	O	-1	10901305
in	O	-1	10901305
a@@	O	-1	10901305
ir@@	O	-1	10901305
w@@	O	-1	10901305
ay	O	-1	10901305
man@@	O	-1	10901305
ag@@	O	-1	10901305
ement	O	-1	10901305
are	O	-1	10901305
direc@@	O	-1	10901305
tly	O	-1	10901305
involved	O	-1	10901305
in	O	-1	10901305
the	O	-1	10901305
car@@	O	-1	10901305
e	O	-1	10901305
of	O	-1	10901305
the	O	-1	10901305
patient@@	O	-1	10901305
.	O	-1	10901305

Pro@@	O	-1	19037603
phyl@@	O	-1	19037603
ac@@	O	-1	19037603
tic	O	-1	19037603
use	O	-1	19037603
of	O	-1	19037603
lamivud@@	B-Chemical	D019259	19037603
ine	I-Chemical	-1	19037603
with	O	-1	19037603
chronic	O	-1	19037603
immunosup@@	O	-1	19037603
pressive	O	-1	19037603
therapy	O	-1	19037603
for	O	-1	19037603
r@@	B-Disease	D012216	19037603
he@@	I-Disease	-1	19037603
um@@	I-Disease	-1	19037603
at@@	I-Disease	-1	19037603
ologic	I-Disease	-1	19037603
disorder@@	I-Disease	-1	19037603
s	I-Disease	-1	19037603
.	O	-1	19037603
The	O	-1	19037603
ob@@	O	-1	19037603
j@@	O	-1	19037603
ective	O	-1	19037603
of	O	-1	19037603
this	O	-1	19037603
study	O	-1	19037603
was	O	-1	19037603
to	O	-1	19037603
report	O	-1	19037603
our	O	-1	19037603
experi@@	O	-1	19037603
ence	O	-1	19037603
con@@	O	-1	19037603
cer@@	O	-1	19037603
ning	O	-1	19037603
the	O	-1	19037603
eff@@	O	-1	19037603
ec@@	O	-1	19037603
tiv@@	O	-1	19037603
en@@	O	-1	19037603
ess	O	-1	19037603
of	O	-1	19037603
the	O	-1	19037603
pro@@	O	-1	19037603
phyl@@	O	-1	19037603
ac@@	O	-1	19037603
tic	O	-1	19037603
administration	O	-1	19037603
of	O	-1	19037603
lamivud@@	B-Chemical	D019259	19037603
ine	I-Chemical	-1	19037603
in	O	-1	19037603
hepatitis	B-Chemical	D006514	19037603
B	I-Chemical	-1	19037603
vi@@	I-Chemical	-1	19037603
ru@@	I-Chemical	-1	19037603
s	I-Chemical	-1	19037603
sur@@	I-Chemical	-1	19037603
fac@@	I-Chemical	-1	19037603
e	I-Chemical	-1	19037603
anti@@	I-Chemical	-1	19037603
gen	I-Chemical	-1	19037603
(	O	-1	19037603
HB@@	B-Chemical	D006514	19037603
s	I-Chemical	-1	19037603
A@@	I-Chemical	-1	19037603
g	I-Chemical	-1	19037603
)	O	-1	19037603
positive	O	-1	19037603
patients	O	-1	19037603
with	O	-1	19037603
r@@	B-Disease	D012216	19037603
he@@	I-Disease	-1	19037603
um@@	I-Disease	-1	19037603
at@@	I-Disease	-1	19037603
ologic	I-Disease	-1	19037603
disease	I-Disease	-1	19037603
.	O	-1	19037603
F@@	O	-1	19037603
rom	O	-1	19037603
J@@	O	-1	19037603
un@@	O	-1	19037603
e	O	-1	19037603
20@@	O	-1	19037603
0@@	O	-1	19037603
4	O	-1	19037603
to	O	-1	19037603
O@@	O	-1	19037603
c@@	O	-1	19037603
to@@	O	-1	19037603
b@@	O	-1	19037603
er	O	-1	19037603
20@@	O	-1	19037603
0@@	O	-1	19037603
6,	O	-1	19037603
11	O	-1	19037603
HB@@	B-Chemical	D006514	19037603
s	I-Chemical	-1	19037603
A@@	I-Chemical	-1	19037603
g	I-Chemical	-1	19037603
positive	O	-1	19037603
patients	O	-1	19037603
with	O	-1	19037603
r@@	B-Disease	D012216	19037603
he@@	I-Disease	-1	19037603
um@@	I-Disease	-1	19037603
at@@	I-Disease	-1	19037603
ologic	I-Disease	-1	19037603
diseas@@	I-Disease	-1	19037603
es	I-Disease	-1	19037603
,	O	-1	19037603
who	O	-1	19037603
were	O	-1	19037603
on	O	-1	19037603
both	O	-1	19037603
immunosup@@	O	-1	19037603
pressive	O	-1	19037603
and	O	-1	19037603
pro@@	O	-1	19037603
phyl@@	O	-1	19037603
ac@@	O	-1	19037603
tic	O	-1	19037603
lamivud@@	B-Chemical	D019259	19037603
ine	I-Chemical	-1	19037603
therap@@	O	-1	19037603
i@@	O	-1	19037603
es,	O	-1	19037603
were	O	-1	19037603
ret@@	O	-1	19037603
ro@@	O	-1	19037603
sp@@	O	-1	19037603
ectively	O	-1	19037603
ass@@	O	-1	19037603
es@@	O	-1	19037603
sed.	O	-1	19037603
L@@	O	-1	19037603
i@@	O	-1	19037603
ver	O	-1	19037603
function	O	-1	19037603
test@@	O	-1	19037603
s,	O	-1	19037603
hepatitis	B-Disease	D006509	19037603
B	I-Disease	-1	19037603
vi@@	O	-1	19037603
ru@@	O	-1	19037603
s	O	-1	19037603
(@@	O	-1	19037603
HB@@	O	-1	19037603
V@@	O	-1	19037603
)	O	-1	19037603
ser@@	O	-1	19037603
ologic	O	-1	19037603
mark@@	O	-1	19037603
er@@	O	-1	19037603
s,	O	-1	19037603
and	O	-1	19037603
HBV	O	-1	19037603
D@@	O	-1	19037603
NA	O	-1	19037603
levels	O	-1	19037603
of	O	-1	19037603
the	O	-1	19037603
patients	O	-1	19037603
during	O	-1	19037603
follow-up	O	-1	19037603
were	O	-1	19037603
obtained	O	-1	19037603
from	O	-1	19037603
hospit@@	O	-1	19037603
al	O	-1	19037603
f@@	O	-1	19037603
ile	O	-1	19037603
recor@@	O	-1	19037603
d@@	O	-1	19037603
s.	O	-1	19037603
E@@	O	-1	19037603
le@@	O	-1	19037603
ven	O	-1	19037603
patients	O	-1	19037603
(@@	O	-1	19037603
six	O	-1	19037603
mal@@	O	-1	19037603
e@@	O	-1	19037603
)	O	-1	19037603
with	O	-1	19037603
median	O	-1	19037603
age	O	-1	19037603
4@@	O	-1	19037603
7	O	-1	19037603
years	O	-1	19037603
(@@	O	-1	19037603
range	O	-1	19037603
27@@	O	-1	19037603
-@@	O	-1	19037603
7@@	O	-1	19037603
3@@	O	-1	19037603
),	O	-1	19037603
median	O	-1	19037603
disease	O	-1	19037603
duration	O	-1	19037603
50	O	-1	19037603
months	O	-1	19037603
(@@	O	-1	19037603
range	O	-1	19037603
9@@	O	-1	19037603
-1@@	O	-1	19037603
7@@	O	-1	19037603
8@@	O	-1	19037603
)	O	-1	19037603
and	O	-1	19037603
median	O	-1	19037603
follow-up	O	-1	19037603
period	O	-1	19037603
of	O	-1	19037603
patients	O	-1	19037603
1@@	O	-1	19037603
3.@@	O	-1	19037603
8	O	-1	19037603
months	O	-1	19037603
(@@	O	-1	19037603
range	O	-1	19037603
5-@@	O	-1	19037603
27@@	O	-1	19037603
)	O	-1	19037603
were	O	-1	19037603
en@@	O	-1	19037603
ro@@	O	-1	19037603
lled	O	-1	19037603
in	O	-1	19037603
this	O	-1	19037603
study.	O	-1	19037603
L@@	B-Chemical	D019259	19037603
amivud@@	I-Chemical	-1	19037603
ine	I-Chemical	-1	19037603
therapy	O	-1	19037603
was	O	-1	19037603
star@@	O	-1	19037603
ted	O	-1	19037603
3-@@	O	-1	19037603
7	O	-1	19037603
days	O	-1	19037603
prior	O	-1	19037603
to	O	-1	19037603
immunosup@@	O	-1	19037603
pressive	O	-1	19037603
therapy	O	-1	19037603
in	O	-1	19037603
all	O	-1	19037603
patients.	O	-1	19037603
B@@	O	-1	19037603
as@@	O	-1	19037603
el@@	O	-1	19037603
ine,	O	-1	19037603
liver	O	-1	19037603
function	O	-1	19037603
tests	O	-1	19037603
were	O	-1	19037603
elevated	O	-1	19037603
in	O	-1	19037603
two	O	-1	19037603
patients	O	-1	19037603
(@@	O	-1	19037603
fo@@	O	-1	19037603
ur@@	O	-1	19037603
th	O	-1	19037603
patient@@	O	-1	19037603
:	O	-1	19037603
A@@	O	-1	19037603
LT@@	O	-1	19037603
:@@	O	-1	19037603
12@@	O	-1	19037603
2	O	-1	19037603
I@@	O	-1	19037603
U@@	O	-1	19037603
/@@	O	-1	19037603
l@@	O	-1	19037603
,	O	-1	19037603
A@@	O	-1	19037603
S@@	O	-1	19037603
T@@	O	-1	19037603
:@@	O	-1	19037603
1@@	O	-1	19037603
11	O	-1	19037603
I@@	O	-1	19037603
U@@	O	-1	19037603
/@@	O	-1	19037603
l@@	O	-1	19037603
,	O	-1	19037603
t@@	O	-1	19037603
ent@@	O	-1	19037603
h	O	-1	19037603
patient@@	O	-1	19037603
:@@	O	-1	19037603
A@@	O	-1	19037603
LT@@	O	-1	19037603
:@@	O	-1	19037603
2@@	O	-1	19037603
9@@	O	-1	19037603
4	O	-1	19037603
I@@	O	-1	19037603
U@@	O	-1	19037603
/@@	O	-1	19037603
l@@	O	-1	19037603
,	O	-1	19037603
A@@	O	-1	19037603
S@@	O	-1	19037603
T@@	O	-1	19037603
:@@	O	-1	19037603
27@@	O	-1	19037603
4	O	-1	19037603
I@@	O	-1	19037603
U@@	O	-1	19037603
/@@	O	-1	19037603
l@@	O	-1	19037603
,	O	-1	19037603
with	O	-1	19037603
minim@@	O	-1	19037603
al	O	-1	19037603
changes	O	-1	19037603
in	O	-1	19037603
the	O	-1	19037603
liver	O	-1	19037603
biop@@	O	-1	19037603
sy	O	-1	19037603
in	O	-1	19037603
bo@@	O	-1	19037603
th@@	O	-1	19037603
).	O	-1	19037603
S@@	O	-1	19037603
h@@	O	-1	19037603
ort@@	O	-1	19037603
ly	O	-1	19037603
after	O	-1	19037603
treatment	O	-1	19037603
their	O	-1	19037603
tests	O	-1	19037603
normal@@	O	-1	19037603
ized	O	-1	19037603
and	O	-1	19037603
during	O	-1	19037603
follow-up	O	-1	19037603
period	O	-1	19037603
n@@	O	-1	19037603
one	O	-1	19037603
of	O	-1	19037603
the	O	-1	19037603
patients	O	-1	19037603
had	O	-1	19037603
ab@@	B-Disease	D056486	19037603
normal	I-Disease	-1	19037603
liver	I-Disease	-1	19037603
function	I-Disease	-1	19037603
test@@	O	-1	19037603
s.	O	-1	19037603
In	O	-1	19037603
four	O	-1	19037603
patients	O	-1	19037603
HBV	O	-1	19037603
D@@	O	-1	19037603
NA	O	-1	19037603
levels	O	-1	19037603
were	O	-1	19037603
higher	O	-1	19037603
than	O	-1	19037603
normal	O	-1	19037603
at	O	-1	19037603
basel@@	O	-1	19037603
ine.	O	-1	19037603
Two	O	-1	19037603
of	O	-1	19037603
these	O	-1	19037603
normal@@	O	-1	19037603
ized	O	-1	19037603
and	O	-1	19037603
the	O	-1	19037603
o@@	O	-1	19037603
ther@@	O	-1	19037603
s	O	-1	19037603
increased	O	-1	19037603
lat@@	O	-1	19037603
er.	O	-1	19037603
In	O	-1	19037603
three	O	-1	19037603
addi@@	O	-1	19037603
tional	O	-1	19037603
patients,	O	-1	19037603
HBV	O	-1	19037603
D@@	O	-1	19037603
NA	O	-1	19037603
levels	O	-1	19037603
were	O	-1	19037603
increased	O	-1	19037603
during	O	-1	19037603
follow-@@	O	-1	19037603
up@@	O	-1	19037603
.	O	-1	19037603
N@@	O	-1	19037603
one	O	-1	19037603
of	O	-1	19037603
the	O	-1	19037603
patients	O	-1	19037603
had	O	-1	19037603
significant	O	-1	19037603
clinical	O	-1	19037603
s@@	O	-1	19037603
ings	O	-1	19037603
of	O	-1	19037603
HBV	O	-1	19037603
activ@@	O	-1	19037603
ation.	O	-1	19037603
L@@	B-Chemical	D019259	19037603
amivud@@	I-Chemical	-1	19037603
ine	I-Chemical	-1	19037603
was	O	-1	19037603
well	O	-1	19037603
toler@@	O	-1	19037603
ated	O	-1	19037603
and	O	-1	19037603
was	O	-1	19037603
continu@@	O	-1	19037603
ed	O	-1	19037603
in	O	-1	19037603
all	O	-1	19037603
patients.	O	-1	19037603
Pro@@	O	-1	19037603
phyl@@	O	-1	19037603
ac@@	O	-1	19037603
tic	O	-1	19037603
administration	O	-1	19037603
of	O	-1	19037603
lamivud@@	B-Chemical	D019259	19037603
ine	I-Chemical	-1	19037603
in	O	-1	19037603
patients	O	-1	19037603
who	O	-1	19037603
requ@@	O	-1	19037603
ired	O	-1	19037603
immunosup@@	O	-1	19037603
pressive	O	-1	19037603
therapy	O	-1	19037603
se@@	O	-1	19037603
em@@	O	-1	19037603
s	O	-1	19037603
to	O	-1	19037603
be	O	-1	19037603
saf@@	O	-1	19037603
e,	O	-1	19037603
well	O	-1	19037603
toler@@	O	-1	19037603
ated	O	-1	19037603
and	O	-1	19037603
effective	O	-1	19037603
in	O	-1	19037603
prevent@@	O	-1	19037603
ing	O	-1	19037603
HBV	O	-1	19037603
re@@	O	-1	19037603
activ@@	O	-1	19037603
ation.	O	-1	19037603

S@@	O	-1	20084309
af@@	O	-1	20084309
ety	O	-1	20084309
of	O	-1	20084309
trans@@	O	-1	20084309
es@@	O	-1	20084309
oph@@	O	-1	20084309
ag@@	O	-1	20084309
e@@	O	-1	20084309
al	O	-1	20084309
echocardiograph@@	O	-1	20084309
y	O	-1	20084309
in	O	-1	20084309
ad@@	O	-1	20084309
ult@@	O	-1	20084309
s:	O	-1	20084309
study	O	-1	20084309
in	O	-1	20084309
a	O	-1	20084309
multi@@	O	-1	20084309
dis@@	O	-1	20084309
ci@@	O	-1	20084309
pl@@	O	-1	20084309
inary	O	-1	20084309
hospit@@	O	-1	20084309
al.	O	-1	20084309
BACKGROUND:	O	-1	20084309
TE@@	O	-1	20084309
E	O	-1	20084309
is	O	-1	20084309
a	O	-1	20084309
se@@	O	-1	20084309
mi@@	O	-1	20084309
-@@	O	-1	20084309
inv@@	O	-1	20084309
a@@	O	-1	20084309
sive	O	-1	20084309
to@@	O	-1	20084309
ol	O	-1	20084309
b@@	O	-1	20084309
ro@@	O	-1	20084309
ad@@	O	-1	20084309
ly	O	-1	20084309
used	O	-1	20084309
and	O	-1	20084309
its	O	-1	20084309
u@@	O	-1	20084309
ti@@	O	-1	20084309
li@@	O	-1	20084309
z@@	O	-1	20084309
ation	O	-1	20084309
associated	O	-1	20084309
to	O	-1	20084309
sed@@	O	-1	20084309
ati@@	O	-1	20084309
v@@	O	-1	20084309
es	O	-1	20084309
drugs	O	-1	20084309
might	O	-1	20084309
to	O	-1	20084309
aff@@	O	-1	20084309
ect	O	-1	20084309
the	O	-1	20084309
proce@@	O	-1	20084309
d@@	O	-1	20084309
ure	O	-1	20084309
saf@@	O	-1	20084309
et@@	O	-1	20084309
y.	O	-1	20084309
OBJECTIVE:	O	-1	20084309
to	O	-1	20084309
analy@@	O	-1	20084309
ze	O	-1	20084309
as@@	O	-1	20084309
p@@	O	-1	20084309
ects	O	-1	20084309
of	O	-1	20084309
TE@@	O	-1	20084309
E	O	-1	20084309
safety	O	-1	20084309
associated	O	-1	20084309
to	O	-1	20084309
the	O	-1	20084309
use	O	-1	20084309
of	O	-1	20084309
M@@	B-Chemical	D008874	20084309
id@@	I-Chemical	-1	20084309
azol@@	I-Chemical	-1	20084309
an	I-Chemical	-1	20084309
(	O	-1	20084309
M@@	B-Chemical	D008874	20084309
Z	I-Chemical	-1	20084309
)	O	-1	20084309
and	O	-1	20084309
F@@	B-Chemical	D005442	20084309
lu@@	I-Chemical	-1	20084309
ma@@	I-Chemical	-1	20084309
z@@	I-Chemical	-1	20084309
en@@	I-Chemical	-1	20084309
il	I-Chemical	-1	20084309
(	O	-1	20084309
F@@	B-Chemical	D005442	20084309
L	I-Chemical	-1	20084309
)	O	-1	20084309
and	O	-1	20084309
the	O	-1	20084309
influence	O	-1	20084309
of	O	-1	20084309
the	O	-1	20084309
clinical	O	-1	20084309
vari@@	O	-1	20084309
able@@	O	-1	20084309
s	O	-1	20084309
on	O	-1	20084309
the	O	-1	20084309
ev@@	O	-1	20084309
ent	O	-1	20084309
rat@@	O	-1	20084309
e.	O	-1	20084309
METHOD@@	O	-1	20084309
:	O	-1	20084309
pro@@	O	-1	20084309
sp@@	O	-1	20084309
ective	O	-1	20084309
study	O	-1	20084309
with	O	-1	20084309
13@@	O	-1	20084309
7	O	-1	20084309
patients	O	-1	20084309
that	O	-1	20084309
under@@	O	-1	20084309
w@@	O	-1	20084309
ent	O	-1	20084309
TE@@	O	-1	20084309
E	O	-1	20084309
with	O	-1	20084309
M@@	B-Chemical	D008874	20084309
Z	I-Chemical	-1	20084309
associated	O	-1	20084309
to	O	-1	20084309
moder@@	O	-1	20084309
ate	O	-1	20084309
sed@@	O	-1	20084309
ation.	O	-1	20084309
We	O	-1	20084309
analy@@	O	-1	20084309
zed	O	-1	20084309
the	O	-1	20084309
following	O	-1	20084309
event@@	O	-1	20084309
s:	O	-1	20084309
complications	O	-1	20084309
related	O	-1	20084309
with	O	-1	20084309
the	O	-1	20084309
to@@	O	-1	20084309
p@@	O	-1	20084309
ical	O	-1	20084309
anesthe@@	O	-1	20084309
si@@	O	-1	20084309
a,	O	-1	20084309
with	O	-1	20084309
M@@	B-Chemical	D008874	20084309
Z	I-Chemical	-1	20084309
use	O	-1	20084309
and	O	-1	20084309
with	O	-1	20084309
the	O	-1	20084309
proce@@	O	-1	20084309
d@@	O	-1	20084309
ure.	O	-1	20084309
U@@	O	-1	20084309
n@@	O	-1	20084309
i@@	O	-1	20084309
-	O	-1	20084309
and	O	-1	20084309
mul@@	O	-1	20084309
tiv@@	O	-1	20084309
ari@@	O	-1	20084309
ate	O	-1	20084309
analy@@	O	-1	20084309
ses	O	-1	20084309
were	O	-1	20084309
used	O	-1	20084309
to	O	-1	20084309
test	O	-1	20084309
the	O	-1	20084309
influence	O	-1	20084309
of	O	-1	20084309
the	O	-1	20084309
clinical	O	-1	20084309
vari@@	O	-1	20084309
abl@@	O	-1	20084309
es@@	O	-1	20084309
:	O	-1	20084309
age,	O	-1	20084309
sex@@	O	-1	20084309
,	O	-1	20084309
strok@@	B-Disease	D020521	20084309
e	I-Disease	-1	20084309
,	O	-1	20084309
myocardi@@	B-Disease	D009202	20084309
o@@	I-Disease	-1	20084309
pathy	I-Disease	-1	20084309
(	O	-1	20084309
M@@	B-Disease	D009202	20084309
P	I-Disease	-1	20084309
),	O	-1	20084309
duration	O	-1	20084309
of	O	-1	20084309
the	O	-1	20084309
test@@	O	-1	20084309
,	O	-1	20084309
mit@@	B-Disease	D008944	20084309
ral	I-Disease	-1	20084309
reg@@	I-Disease	-1	20084309
ur@@	I-Disease	-1	20084309
g@@	I-Disease	-1	20084309
it@@	I-Disease	-1	20084309
ation	I-Disease	-1	20084309
(	O	-1	20084309
M@@	B-Disease	D008944	20084309
R	I-Disease	-1	20084309
)	O	-1	20084309
and	O	-1	20084309
the	O	-1	20084309
M@@	B-Chemical	D008874	20084309
Z	I-Chemical	-1	20084309
dose.	O	-1	20084309
RESULTS:	O	-1	20084309
All	O	-1	20084309
patients	O	-1	20084309
(6@@	O	-1	20084309
5@@	O	-1	20084309
+/@@	O	-1	20084309
-1@@	O	-1	20084309
6	O	-1	20084309
y@@	O	-1	20084309
r@@	O	-1	20084309
s;	O	-1	20084309
5@@	O	-1	20084309
8@@	O	-1	20084309
%	O	-1	20084309
mal@@	O	-1	20084309
es@@	O	-1	20084309
)	O	-1	20084309
f@@	O	-1	20084309
in@@	O	-1	20084309
ished	O	-1	20084309
the	O	-1	20084309
examin@@	O	-1	20084309
ation.	O	-1	20084309
The	O	-1	20084309
mean	O	-1	20084309
doses	O	-1	20084309
of	O	-1	20084309
M@@	B-Chemical	D008874	20084309
Z	I-Chemical	-1	20084309
and	O	-1	20084309
F@@	B-Chemical	D005442	20084309
L	I-Chemical	-1	20084309
were	O	-1	20084309
4.@@	O	-1	20084309
3@@	O	-1	20084309
+/-@@	O	-1	20084309
1.@@	O	-1	20084309
9	O	-1	20084309
mg	O	-1	20084309
and	O	-1	20084309
0.@@	O	-1	20084309
2@@	O	-1	20084309
8@@	O	-1	20084309
+/-@@	O	-1	20084309
0.@@	O	-1	20084309
2	O	-1	20084309
mg@@	O	-1	20084309
,	O	-1	20084309
respectively.	O	-1	20084309
The	O	-1	20084309
duration	O	-1	20084309
of	O	-1	20084309
the	O	-1	20084309
examin@@	O	-1	20084309
ation	O	-1	20084309
and	O	-1	20084309
the	O	-1	20084309
mean	O	-1	20084309
e@@	O	-1	20084309
j@@	O	-1	20084309
ection	O	-1	20084309
frac@@	O	-1	20084309
tion	O	-1	20084309
(@@	O	-1	20084309
E@@	O	-1	20084309
F@@	O	-1	20084309
)	O	-1	20084309
were	O	-1	20084309
1@@	O	-1	20084309
6.@@	O	-1	20084309
4@@	O	-1	20084309
+/-@@	O	-1	20084309
6.@@	O	-1	20084309
1	O	-1	20084309
minutes	O	-1	20084309
and	O	-1	20084309
6@@	O	-1	20084309
0@@	O	-1	20084309
+/-@@	O	-1	20084309
9@@	O	-1	20084309
%,	O	-1	20084309
respectively.	O	-1	20084309
M@@	O	-1	20084309
il@@	O	-1	20084309
d	O	-1	20084309
hypo@@	B-Disease	D000860	20084309
x@@	I-Disease	-1	20084309
ia	I-Disease	-1	20084309
(S@@	O	-1	20084309
O@@	O	-1	20084309
2@@	O	-1	20084309
<@@	O	-1	20084309
9@@	O	-1	20084309
0@@	O	-1	20084309
%)	O	-1	20084309
was	O	-1	20084309
the	O	-1	20084309
most	O	-1	20084309
common	O	-1	20084309
ev@@	O	-1	20084309
ent	O	-1	20084309
(1@@	O	-1	20084309
1	O	-1	20084309
patient@@	O	-1	20084309
s@@	O	-1	20084309
);	O	-1	20084309
3	O	-1	20084309
patients	O	-1	20084309
(2@@	O	-1	20084309
%)	O	-1	20084309
presented	O	-1	20084309
transi@@	O	-1	20084309
ent	O	-1	20084309
hypo@@	B-Disease	D000860	20084309
x@@	I-Disease	-1	20084309
ia	I-Disease	-1	20084309
due	O	-1	20084309
to	O	-1	20084309
up@@	O	-1	20084309
per	O	-1	20084309
a@@	B-Disease	D000402	20084309
ir@@	I-Disease	-1	20084309
w@@	I-Disease	-1	20084309
ay	I-Disease	-1	20084309
ob@@	I-Disease	-1	20084309
struc@@	I-Disease	-1	20084309
tion	I-Disease	-1	20084309
by	O	-1	20084309
pro@@	O	-1	20084309
be	O	-1	20084309
int@@	O	-1	20084309
ro@@	O	-1	20084309
duction	O	-1	20084309
and	O	-1	20084309
8	O	-1	20084309
(@@	O	-1	20084309
5.@@	O	-1	20084309
8@@	O	-1	20084309
%)	O	-1	20084309
due	O	-1	20084309
to	O	-1	20084309
hypo@@	B-Disease	D000860	20084309
x@@	I-Disease	-1	20084309
ia	I-Disease	-1	20084309
caused	O	-1	20084309
by	O	-1	20084309
M@@	B-Chemical	D008874	20084309
Z	I-Chemical	-1	20084309
use.	O	-1	20084309
T@@	O	-1	20084309
ran@@	O	-1	20084309
si@@	O	-1	20084309
ent	O	-1	20084309
hypotension	B-Disease	D007022	20084309
(S@@	O	-1	20084309
A@@	O	-1	20084309
P@@	O	-1	20084309
<@@	O	-1	20084309
9@@	O	-1	20084309
0@@	O	-1	20084309
mm@@	O	-1	20084309
H@@	O	-1	20084309
g@@	O	-1	20084309
)	O	-1	20084309
occurred	O	-1	20084309
in	O	-1	20084309
1	O	-1	20084309
patient	O	-1	20084309
(0.@@	O	-1	20084309
7@@	O	-1	20084309
%).	O	-1	20084309
The	O	-1	20084309
mul@@	O	-1	20084309
tiv@@	O	-1	20084309
ari@@	O	-1	20084309
ate	O	-1	20084309
analysis	O	-1	20084309
showed	O	-1	20084309
that	O	-1	20084309
severe	O	-1	20084309
M@@	B-Disease	D008944	20084309
R	I-Disease	-1	20084309
,	O	-1	20084309
M@@	B-Disease	D009202	20084309
P	I-Disease	-1	20084309
(@@	O	-1	20084309
E@@	O	-1	20084309
F@@	O	-1	20084309
<@@	O	-1	20084309
4@@	O	-1	20084309
5@@	O	-1	20084309
%)	O	-1	20084309
and	O	-1	20084309
high	O	-1	20084309
doses	O	-1	20084309
of	O	-1	20084309
M@@	B-Chemical	D008874	20084309
Z	I-Chemical	-1	20084309
(@@	O	-1	20084309
>@@	O	-1	20084309
5@@	O	-1	20084309
mg@@	O	-1	20084309
)	O	-1	20084309
were	O	-1	20084309
associated	O	-1	20084309
with	O	-1	20084309
events	O	-1	20084309
(p@@	O	-1	20084309
<@@	O	-1	20084309
0.00@@	O	-1	20084309
1).	O	-1	20084309
The	O	-1	20084309
E@@	O	-1	20084309
F	O	-1	20084309
was	O	-1	20084309
4@@	O	-1	20084309
0@@	O	-1	20084309
%,	O	-1	20084309
in	O	-1	20084309
the	O	-1	20084309
group	O	-1	20084309
with	O	-1	20084309
M@@	B-Disease	D009202	20084309
P	I-Disease	-1	20084309
and	O	-1	20084309
4@@	O	-1	20084309
4@@	O	-1	20084309
%	O	-1	20084309
in	O	-1	20084309
the	O	-1	20084309
group	O	-1	20084309
with	O	-1	20084309
severe	O	-1	20084309
M@@	B-Disease	D008944	20084309
R	I-Disease	-1	20084309
and	O	-1	20084309
it	O	-1	20084309
can	O	-1	20084309
be	O	-1	20084309
a	O	-1	20084309
factor	O	-1	20084309
associated	O	-1	20084309
with	O	-1	20084309
clinical	O	-1	20084309
events	O	-1	20084309
in	O	-1	20084309
the	O	-1	20084309
las@@	O	-1	20084309
t	O	-1	20084309
group.	O	-1	20084309
CONCLUSION:	O	-1	20084309
TE@@	O	-1	20084309
E	O	-1	20084309
with	O	-1	20084309
sed@@	O	-1	20084309
ation	O	-1	20084309
pres@@	O	-1	20084309
ents	O	-1	20084309
a	O	-1	20084309
low	O	-1	20084309
rate	O	-1	20084309
of	O	-1	20084309
event@@	O	-1	20084309
s.	O	-1	20084309
There	O	-1	20084309
were	O	-1	20084309
no	O	-1	20084309
severe	O	-1	20084309
events	O	-1	20084309
and	O	-1	20084309
there	O	-1	20084309
was	O	-1	20084309
no	O	-1	20084309
need	O	-1	20084309
to	O	-1	20084309
inter@@	O	-1	20084309
ru@@	O	-1	20084309
p@@	O	-1	20084309
t	O	-1	20084309
the	O	-1	20084309
examin@@	O	-1	20084309
ations.	O	-1	20084309

Eff@@	O	-1	8231633
ects	O	-1	8231633
of	O	-1	8231633
calcium	B-Chemical	D002118	8231633
channel	O	-1	8231633
block@@	O	-1	8231633
ers	O	-1	8231633
on	O	-1	8231633
bupivac@@	B-Chemical	D002045	8231633
aine	I-Chemical	-1	8231633
-induced	O	-1	8231633
toxicity	B-Disease	D064420	8231633
.	O	-1	8231633
The	O	-1	8231633
pur@@	O	-1	8231633
p@@	O	-1	8231633
ose	O	-1	8231633
of	O	-1	8231633
this	O	-1	8231633
study	O	-1	8231633
was	O	-1	8231633
to	O	-1	8231633
investigate	O	-1	8231633
the	O	-1	8231633
influence	O	-1	8231633
of	O	-1	8231633
calcium	B-Chemical	D002118	8231633
channel	O	-1	8231633
block@@	O	-1	8231633
ers	O	-1	8231633
on	O	-1	8231633
bupivac@@	B-Chemical	D002045	8231633
aine	I-Chemical	-1	8231633
-induced	O	-1	8231633
acute	O	-1	8231633
toxicity	B-Disease	D064420	8231633
.	O	-1	8231633
F@@	O	-1	8231633
or	O	-1	8231633
each	O	-1	8231633
of	O	-1	8231633
the	O	-1	8231633
three	O	-1	8231633
tested	O	-1	8231633
calcium	B-Chemical	D002118	8231633
channel	O	-1	8231633
block@@	O	-1	8231633
ers	O	-1	8231633
(	O	-1	8231633
di@@	B-Chemical	D004110	8231633
l@@	I-Chemical	-1	8231633
ti@@	I-Chemical	-1	8231633
az@@	I-Chemical	-1	8231633
em	I-Chemical	-1	8231633
,	O	-1	8231633
verap@@	B-Chemical	D014700	8231633
ami@@	I-Chemical	-1	8231633
l	I-Chemical	-1	8231633
and	O	-1	8231633
be@@	B-Chemical	D015764	8231633
pri@@	I-Chemical	-1	8231633
di@@	I-Chemical	-1	8231633
l	I-Chemical	-1	8231633
)	O	-1	8231633
6	O	-1	8231633
groups	O	-1	8231633
of	O	-1	8231633
mice	O	-1	8231633
were	O	-1	8231633
treated	O	-1	8231633
by	O	-1	8231633
two	O	-1	8231633
different	O	-1	8231633
dos@@	O	-1	8231633
es,	O	-1	8231633
i.@@	O	-1	8231633
e.	O	-1	8231633
2	O	-1	8231633
and	O	-1	8231633
10	O	-1	8231633
mg/k@@	O	-1	8231633
g/@@	O	-1	8231633
i.p.@@	O	-1	8231633
,	O	-1	8231633
or	O	-1	8231633
an	O	-1	8231633
equ@@	O	-1	8231633
al	O	-1	8231633
volume	O	-1	8231633
of	O	-1	8231633
saline	O	-1	8231633
for	O	-1	8231633
the	O	-1	8231633
control	O	-1	8231633
group	O	-1	8231633
(n	O	-1	8231633
=	O	-1	8231633
20@@	O	-1	8231633
);	O	-1	8231633
15	O	-1	8231633
minutes	O	-1	8231633
lat@@	O	-1	8231633
er,	O	-1	8231633
all	O	-1	8231633
the	O	-1	8231633
animals	O	-1	8231633
were	O	-1	8231633
injected	O	-1	8231633
with	O	-1	8231633
a	O	-1	8231633
single	O	-1	8231633
50	O	-1	8231633
mg/k@@	O	-1	8231633
g/@@	O	-1	8231633
i.@@	O	-1	8231633
p@@	O	-1	8231633
.	O	-1	8231633
dose	O	-1	8231633
of	O	-1	8231633
bupivac@@	B-Chemical	D002045	8231633
aine	I-Chemical	-1	8231633
.	O	-1	8231633
The	O	-1	8231633
convul@@	O	-1	8231633
s@@	O	-1	8231633
ant	O	-1	8231633
activ@@	O	-1	8231633
ity,	O	-1	8231633
the	O	-1	8231633
time	O	-1	8231633
of	O	-1	8231633
lat@@	O	-1	8231633
ency	O	-1	8231633
to	O	-1	8231633
convul@@	O	-1	8231633
se	O	-1	8231633
and	O	-1	8231633
the	O	-1	8231633
mor@@	O	-1	8231633
t@@	O	-1	8231633
ality	O	-1	8231633
rate	O	-1	8231633
were	O	-1	8231633
assessed	O	-1	8231633
in	O	-1	8231633
each	O	-1	8231633
group.	O	-1	8231633
The	O	-1	8231633
loc@@	O	-1	8231633
al	O	-1	8231633
anesthe@@	O	-1	8231633
tic@@	O	-1	8231633
-induced	O	-1	8231633
mor@@	O	-1	8231633
t@@	O	-1	8231633
ality	O	-1	8231633
was	O	-1	8231633
significantly	O	-1	8231633
increased	O	-1	8231633
by	O	-1	8231633
the	O	-1	8231633
three	O	-1	8231633
different	O	-1	8231633
calcium	B-Chemical	D002118	8231633
channel	O	-1	8231633
block@@	O	-1	8231633
ers.	O	-1	8231633
The	O	-1	8231633
convul@@	O	-1	8231633
s@@	O	-1	8231633
ant	O	-1	8231633
activity	O	-1	8231633
of	O	-1	8231633
bupivac@@	B-Chemical	D002045	8231633
aine	I-Chemical	-1	8231633
was	O	-1	8231633
not	O	-1	8231633
significantly	O	-1	8231633
mo@@	O	-1	8231633
di@@	O	-1	8231633
fied	O	-1	8231633
but	O	-1	8231633
calcium	B-Chemical	D002118	8231633
channel	O	-1	8231633
block@@	O	-1	8231633
ers	O	-1	8231633
decreased	O	-1	8231633
the	O	-1	8231633
time	O	-1	8231633
of	O	-1	8231633
lat@@	O	-1	8231633
ency	O	-1	8231633
to	O	-1	8231633
obt@@	O	-1	8231633
ain	O	-1	8231633
bupivac@@	B-Chemical	D002045	8231633
aine	I-Chemical	-1	8231633
-induced	O	-1	8231633
convul@@	B-Disease	D012640	8231633
sions	I-Disease	-1	8231633
;	O	-1	8231633
this	O	-1	8231633
effect	O	-1	8231633
was	O	-1	8231633
less	O	-1	8231633
p@@	O	-1	8231633
ron@@	O	-1	8231633
oun@@	O	-1	8231633
c@@	O	-1	8231633
ed	O	-1	8231633
with	O	-1	8231633
be@@	B-Chemical	D015764	8231633
pri@@	I-Chemical	-1	8231633
di@@	I-Chemical	-1	8231633
l	I-Chemical	-1	8231633
.	O	-1	8231633

S@@	B-Chemical	D012642	10091617
e@@	I-Chemical	-1	10091617
le@@	I-Chemical	-1	10091617
g@@	I-Chemical	-1	10091617
il@@	I-Chemical	-1	10091617
ine	I-Chemical	-1	10091617
-induced	O	-1	10091617
post@@	B-Disease	D007024	10091617
ural	I-Disease	-1	10091617
hypotension	I-Disease	-1	10091617
in	O	-1	10091617
Parkinson's	B-Disease	D010300	10091617
disease	I-Disease	-1	10091617
:	O	-1	10091617
a	O	-1	10091617
long@@	O	-1	10091617
it@@	O	-1	10091617
ud@@	O	-1	10091617
inal	O	-1	10091617
study	O	-1	10091617
on	O	-1	10091617
the	O	-1	10091617
effects	O	-1	10091617
of	O	-1	10091617
drug	O	-1	10091617
withdraw@@	O	-1	10091617
al.	O	-1	10091617
OBJECTIV@@	O	-1	10091617
E@@	O	-1	10091617
S:	O	-1	10091617
The	O	-1	10091617
U@@	O	-1	10091617
nit@@	O	-1	10091617
ed	O	-1	10091617
K@@	O	-1	10091617
ing@@	O	-1	10091617
do@@	O	-1	10091617
m	O	-1	10091617
Parkinson's	B-Disease	D010300	10091617
Di@@	I-Disease	-1	10091617
se@@	I-Disease	-1	10091617
ase	I-Disease	-1	10091617
R@@	O	-1	10091617
es@@	O	-1	10091617
ear@@	O	-1	10091617
ch	O	-1	10091617
Group	O	-1	10091617
(@@	O	-1	10091617
U@@	O	-1	10091617
K@@	O	-1	10091617
P@@	O	-1	10091617
D@@	O	-1	10091617
R@@	O	-1	10091617
G@@	O	-1	10091617
)	O	-1	10091617
trial	O	-1	10091617
found	O	-1	10091617
an	O	-1	10091617
increased	O	-1	10091617
mor@@	O	-1	10091617
t@@	O	-1	10091617
ality	O	-1	10091617
in	O	-1	10091617
patients	O	-1	10091617
with	O	-1	10091617
Parkinson's	B-Disease	D010300	10091617
disease	I-Disease	-1	10091617
(	O	-1	10091617
P@@	B-Disease	D010300	10091617
D	I-Disease	-1	10091617
)	O	-1	10091617
randomized	O	-1	10091617
to	O	-1	10091617
recei@@	O	-1	10091617
ve	O	-1	10091617
10	O	-1	10091617
mg	O	-1	10091617
se@@	B-Chemical	D012642	10091617
le@@	I-Chemical	-1	10091617
g@@	I-Chemical	-1	10091617
il@@	I-Chemical	-1	10091617
ine	I-Chemical	-1	10091617
per	O	-1	10091617
day	O	-1	10091617
and	O	-1	10091617
L-@@	B-Chemical	D007980	10091617
dopa	I-Chemical	-1	10091617
compared	O	-1	10091617
with	O	-1	10091617
those	O	-1	10091617
taking	O	-1	10091617
L-@@	B-Chemical	D007980	10091617
dopa	I-Chemical	-1	10091617
al@@	O	-1	10091617
one.	O	-1	10091617
Rec@@	O	-1	10091617
ent@@	O	-1	10091617
ly,	O	-1	10091617
we	O	-1	10091617
found	O	-1	10091617
that	O	-1	10091617
therapy	O	-1	10091617
with	O	-1	10091617
se@@	B-Chemical	D012642	10091617
le@@	I-Chemical	-1	10091617
g@@	I-Chemical	-1	10091617
il@@	I-Chemical	-1	10091617
ine	I-Chemical	-1	10091617
and	O	-1	10091617
L-@@	B-Chemical	D007980	10091617
dopa	I-Chemical	-1	10091617
was	O	-1	10091617
associated	O	-1	10091617
with	O	-1	10091617
selective	O	-1	10091617
systolic	B-Disease	D007024	10091617
or@@	I-Disease	-1	10091617
th@@	I-Disease	-1	10091617
ost@@	I-Disease	-1	10091617
atic	I-Disease	-1	10091617
hypotension	I-Disease	-1	10091617
which	O	-1	10091617
was	O	-1	10091617
abol@@	O	-1	10091617
ished	O	-1	10091617
by	O	-1	10091617
withdrawal	O	-1	10091617
of	O	-1	10091617
se@@	B-Chemical	D012642	10091617
le@@	I-Chemical	-1	10091617
g@@	I-Chemical	-1	10091617
il@@	I-Chemical	-1	10091617
ine	I-Chemical	-1	10091617
.	O	-1	10091617
This	O	-1	10091617
un@@	O	-1	10091617
w@@	O	-1	10091617
ant@@	O	-1	10091617
ed	O	-1	10091617
effect	O	-1	10091617
on	O	-1	10091617
post@@	O	-1	10091617
ural	O	-1	10091617
blood	O	-1	10091617
pressure	O	-1	10091617
was	O	-1	10091617
not	O	-1	10091617
the	O	-1	10091617
result	O	-1	10091617
of	O	-1	10091617
underlying	O	-1	10091617
a@@	O	-1	10091617
ut@@	O	-1	10091617
on@@	O	-1	10091617
om@@	O	-1	10091617
ic	O	-1	10091617
failure.	O	-1	10091617
The	O	-1	10091617
a@@	O	-1	10091617
im@@	O	-1	10091617
s	O	-1	10091617
of	O	-1	10091617
this	O	-1	10091617
study	O	-1	10091617
were	O	-1	10091617
to	O	-1	10091617
con@@	O	-1	10091617
fir@@	O	-1	10091617
m	O	-1	10091617
our	O	-1	10091617
previ@@	O	-1	10091617
ous	O	-1	10091617
findings	O	-1	10091617
in	O	-1	10091617
a	O	-1	10091617
se@@	O	-1	10091617
par@@	O	-1	10091617
ate	O	-1	10091617
co@@	O	-1	10091617
h@@	O	-1	10091617
ort	O	-1	10091617
of	O	-1	10091617
patients	O	-1	10091617
and	O	-1	10091617
to	O	-1	10091617
determine	O	-1	10091617
the	O	-1	10091617
time	O	-1	10091617
course	O	-1	10091617
of	O	-1	10091617
the	O	-1	10091617
cardiovascular	O	-1	10091617
con@@	O	-1	10091617
sequ@@	O	-1	10091617
enc@@	O	-1	10091617
es	O	-1	10091617
of	O	-1	10091617
sto@@	O	-1	10091617
pp@@	O	-1	10091617
ing	O	-1	10091617
se@@	B-Chemical	D012642	10091617
le@@	I-Chemical	-1	10091617
g@@	I-Chemical	-1	10091617
il@@	I-Chemical	-1	10091617
ine	I-Chemical	-1	10091617
in	O	-1	10091617
the	O	-1	10091617
ex@@	O	-1	10091617
p@@	O	-1	10091617
ect@@	O	-1	10091617
ation	O	-1	10091617
that	O	-1	10091617
this	O	-1	10091617
might	O	-1	10091617
sh@@	O	-1	10091617
ed	O	-1	10091617
li@@	O	-1	10091617
ght	O	-1	10091617
on	O	-1	10091617
the	O	-1	10091617
mechanisms	O	-1	10091617
by	O	-1	10091617
which	O	-1	10091617
the	O	-1	10091617
drug	O	-1	10091617
causes	O	-1	10091617
or@@	B-Disease	D007024	10091617
th@@	I-Disease	-1	10091617
ost@@	I-Disease	-1	10091617
atic	I-Disease	-1	10091617
hypotension	I-Disease	-1	10091617
.	O	-1	10091617
METHODS:	O	-1	10091617
The	O	-1	10091617
cardiovascular	O	-1	10091617
responses	O	-1	10091617
to	O	-1	10091617
stand@@	O	-1	10091617
ing	O	-1	10091617
and	O	-1	10091617
head@@	O	-1	10091617
-@@	O	-1	10091617
up	O	-1	10091617
til@@	O	-1	10091617
t	O	-1	10091617
were	O	-1	10091617
studied	O	-1	10091617
repe@@	O	-1	10091617
ated@@	O	-1	10091617
ly	O	-1	10091617
in	O	-1	10091617
P@@	B-Disease	D010300	10091617
D	I-Disease	-1	10091617
patients	O	-1	10091617
receiving	O	-1	10091617
se@@	B-Chemical	D012642	10091617
le@@	I-Chemical	-1	10091617
g@@	I-Chemical	-1	10091617
il@@	I-Chemical	-1	10091617
ine	I-Chemical	-1	10091617
and	O	-1	10091617
as	O	-1	10091617
the	O	-1	10091617
drug	O	-1	10091617
was	O	-1	10091617
withdraw@@	O	-1	10091617
n@@	O	-1	10091617
.	O	-1	10091617
RESULTS:	O	-1	10091617
He@@	O	-1	10091617
ad@@	O	-1	10091617
-@@	O	-1	10091617
up	O	-1	10091617
til@@	O	-1	10091617
t	O	-1	10091617
caused	O	-1	10091617
systolic	B-Disease	D007024	10091617
or@@	I-Disease	-1	10091617
th@@	I-Disease	-1	10091617
ost@@	I-Disease	-1	10091617
atic	I-Disease	-1	10091617
hypotension	I-Disease	-1	10091617
which	O	-1	10091617
was	O	-1	10091617
mark@@	O	-1	10091617
ed	O	-1	10091617
in	O	-1	10091617
six	O	-1	10091617
of	O	-1	10091617
20	O	-1	10091617
P@@	B-Disease	D010300	10091617
D	I-Disease	-1	10091617
patients	O	-1	10091617
on	O	-1	10091617
se@@	B-Chemical	D012642	10091617
le@@	I-Chemical	-1	10091617
g@@	I-Chemical	-1	10091617
il@@	I-Chemical	-1	10091617
ine	I-Chemical	-1	10091617
,	O	-1	10091617
one	O	-1	10091617
of	O	-1	10091617
whom	O	-1	10091617
lo@@	O	-1	10091617
st	O	-1	10091617
con@@	O	-1	10091617
s@@	O	-1	10091617
ci@@	O	-1	10091617
ous@@	O	-1	10091617
ness	O	-1	10091617
with	O	-1	10091617
un@@	O	-1	10091617
recor@@	O	-1	10091617
d@@	O	-1	10091617
able	O	-1	10091617
blood	O	-1	10091617
pressu@@	O	-1	10091617
res@@	O	-1	10091617
.	O	-1	10091617
A	O	-1	10091617
l@@	O	-1	10091617
ess@@	O	-1	10091617
er	O	-1	10091617
de@@	O	-1	10091617
g@@	O	-1	10091617
ree	O	-1	10091617
of	O	-1	10091617
or@@	B-Disease	D007024	10091617
th@@	I-Disease	-1	10091617
ost@@	I-Disease	-1	10091617
atic	I-Disease	-1	10091617
hypotension	I-Disease	-1	10091617
occurred	O	-1	10091617
with	O	-1	10091617
stand@@	O	-1	10091617
ing.	O	-1	10091617
O@@	B-Disease	D007024	10091617
r@@	I-Disease	-1	10091617
th@@	I-Disease	-1	10091617
ost@@	I-Disease	-1	10091617
atic	I-Disease	-1	10091617
hypotension	I-Disease	-1	10091617
was	O	-1	10091617
ame@@	O	-1	10091617
li@@	O	-1	10091617
or@@	O	-1	10091617
ated	O	-1	10091617
4	O	-1	10091617
days	O	-1	10091617
after	O	-1	10091617
withdrawal	O	-1	10091617
of	O	-1	10091617
se@@	B-Chemical	D012642	10091617
le@@	I-Chemical	-1	10091617
g@@	I-Chemical	-1	10091617
il@@	I-Chemical	-1	10091617
ine	I-Chemical	-1	10091617
and	O	-1	10091617
tot@@	O	-1	10091617
ally	O	-1	10091617
abol@@	O	-1	10091617
ished	O	-1	10091617
7	O	-1	10091617
days	O	-1	10091617
after	O	-1	10091617
discontinu@@	O	-1	10091617
ation	O	-1	10091617
of	O	-1	10091617
the	O	-1	10091617
drug.	O	-1	10091617
S@@	O	-1	10091617
to@@	O	-1	10091617
pp@@	O	-1	10091617
ing	O	-1	10091617
se@@	B-Chemical	D012642	10091617
le@@	I-Chemical	-1	10091617
g@@	I-Chemical	-1	10091617
il@@	I-Chemical	-1	10091617
ine	I-Chemical	-1	10091617
also	O	-1	10091617
significantly	O	-1	10091617
reduced	B-Disease	D007024	10091617
the	I-Disease	-1	10091617
sup@@	I-Disease	-1	10091617
ine	I-Disease	-1	10091617
systolic	I-Disease	-1	10091617
and	I-Disease	-1	10091617
di@@	I-Disease	-1	10091617
ast@@	I-Disease	-1	10091617
olic	I-Disease	-1	10091617
blood	I-Disease	-1	10091617
pressu@@	I-Disease	-1	10091617
res	I-Disease	-1	10091617
consist@@	O	-1	10091617
ent	O	-1	10091617
with	O	-1	10091617
a	O	-1	10091617
previously	O	-1	10091617
un@@	O	-1	10091617
descri@@	O	-1	10091617
bed	O	-1	10091617
sup@@	O	-1	10091617
ine	O	-1	10091617
press@@	O	-1	10091617
or	O	-1	10091617
ac@@	O	-1	10091617
tion.	O	-1	10091617
CONCLUSION:	O	-1	10091617
This	O	-1	10091617
study	O	-1	10091617
con@@	O	-1	10091617
fir@@	O	-1	10091617
ms	O	-1	10091617
our	O	-1	10091617
previ@@	O	-1	10091617
ous	O	-1	10091617
find@@	O	-1	10091617
ing	O	-1	10091617
that	O	-1	10091617
se@@	B-Chemical	D012642	10091617
le@@	I-Chemical	-1	10091617
g@@	I-Chemical	-1	10091617
il@@	I-Chemical	-1	10091617
ine	I-Chemical	-1	10091617
in	O	-1	10091617
combination	O	-1	10091617
with	O	-1	10091617
L-@@	B-Chemical	D007980	10091617
dopa	I-Chemical	-1	10091617
is	O	-1	10091617
associated	O	-1	10091617
with	O	-1	10091617
selective	O	-1	10091617
or@@	B-Disease	D007024	10091617
th@@	I-Disease	-1	10091617
ost@@	I-Disease	-1	10091617
atic	I-Disease	-1	10091617
hypotension	I-Disease	-1	10091617
.	O	-1	10091617
The	O	-1	10091617
possib@@	O	-1	10091617
il@@	O	-1	10091617
ities	O	-1	10091617
that	O	-1	10091617
these	O	-1	10091617
cardiovascular	O	-1	10091617
findings	O	-1	10091617
might	O	-1	10091617
be	O	-1	10091617
the	O	-1	10091617
result	O	-1	10091617
of	O	-1	10091617
non-@@	O	-1	10091617
selective	O	-1	10091617
inhibition	O	-1	10091617
of	O	-1	10091617
mon@@	O	-1	10091617
o@@	O	-1	10091617
amine	O	-1	10091617
oxid@@	O	-1	10091617
ase	O	-1	10091617
or	O	-1	10091617
of	O	-1	10091617
amphetamine	B-Chemical	D000661	10091617
and	O	-1	10091617
met@@	B-Chemical	D008694	10091617
amphetamine	I-Chemical	-1	10091617
are	O	-1	10091617
discus@@	O	-1	10091617
sed.	O	-1	10091617

E@@	O	-1	19269743
x@@	O	-1	19269743
plic@@	O	-1	19269743
it	O	-1	19269743
ep@@	O	-1	19269743
is@@	O	-1	19269743
odi@@	O	-1	19269743
c	O	-1	19269743
memory	O	-1	19269743
for	O	-1	19269743
sens@@	O	-1	19269743
or@@	O	-1	19269743
y-@@	O	-1	19269743
dis@@	O	-1	19269743
cri@@	O	-1	19269743
min@@	O	-1	19269743
ative	O	-1	19269743
comp@@	O	-1	19269743
on@@	O	-1	19269743
ents	O	-1	19269743
of	O	-1	19269743
cap@@	B-Chemical	D002211	19269743
sa@@	I-Chemical	-1	19269743
icin	I-Chemical	-1	19269743
-induced	O	-1	19269743
pain	B-Disease	D010146	19269743
:	O	-1	19269743
immedi@@	O	-1	19269743
ate	O	-1	19269743
and	O	-1	19269743
del@@	O	-1	19269743
ayed	O	-1	19269743
rat@@	O	-1	19269743
ing@@	O	-1	19269743
s.	O	-1	19269743
P@@	B-Disease	D010146	19269743
ain	I-Disease	-1	19269743
memory	O	-1	19269743
is	O	-1	19269743
thou@@	O	-1	19269743
ght	O	-1	19269743
to	O	-1	19269743
aff@@	O	-1	19269743
ect	O	-1	19269743
f@@	O	-1	19269743
ut@@	O	-1	19269743
ure	O	-1	19269743
pain	B-Disease	D010146	19269743
sensitivity	O	-1	19269743
and	O	-1	19269743
th@@	O	-1	19269743
us	O	-1	19269743
cont@@	O	-1	19269743
rib@@	O	-1	19269743
ute	O	-1	19269743
to	O	-1	19269743
clinical	O	-1	19269743
pain	B-Disease	D010146	19269743
condi@@	O	-1	19269743
tions.	O	-1	19269743
S@@	O	-1	19269743
y@@	O	-1	19269743
st@@	O	-1	19269743
em@@	O	-1	19269743
atic	O	-1	19269743
investig@@	O	-1	19269743
ations	O	-1	19269743
of	O	-1	19269743
the	O	-1	19269743
human	O	-1	19269743
cap@@	O	-1	19269743
ac@@	O	-1	19269743
ity	O	-1	19269743
to	O	-1	19269743
re@@	O	-1	19269743
memb@@	O	-1	19269743
er	O	-1	19269743
sens@@	O	-1	19269743
ory	O	-1	19269743
feat@@	O	-1	19269743
ures	O	-1	19269743
of	O	-1	19269743
experimental	O	-1	19269743
pain	B-Disease	D010146	19269743
are	O	-1	19269743
s@@	O	-1	19269743
par@@	O	-1	19269743
se.	O	-1	19269743
In	O	-1	19269743
or@@	O	-1	19269743
der	O	-1	19269743
to	O	-1	19269743
ad@@	O	-1	19269743
d@@	O	-1	19269743
res@@	O	-1	19269743
s	O	-1	19269743
long-term	O	-1	19269743
pain	B-Disease	D010146	19269743
memor@@	O	-1	19269743
y,	O	-1	19269743
n@@	O	-1	19269743
ine	O	-1	19269743
healthy	O	-1	19269743
male	O	-1	19269743
vol@@	O	-1	19269743
un@@	O	-1	19269743
te@@	O	-1	19269743
ers	O	-1	19269743
received	O	-1	19269743
intra@@	O	-1	19269743
der@@	O	-1	19269743
m@@	O	-1	19269743
al	O	-1	19269743
injec@@	O	-1	19269743
tions	O	-1	19269743
of	O	-1	19269743
three	O	-1	19269743
doses	O	-1	19269743
of	O	-1	19269743
cap@@	B-Chemical	D002211	19269743
sa@@	I-Chemical	-1	19269743
icin	I-Chemical	-1	19269743
(@@	O	-1	19269743
0.05@@	O	-1	19269743
,	O	-1	19269743
1	O	-1	19269743
and	O	-1	19269743
20	O	-1	19269743
micro@@	O	-1	19269743
g@@	O	-1	19269743
,	O	-1	19269743
se@@	O	-1	19269743
par@@	O	-1	19269743
ated	O	-1	19269743
by	O	-1	19269743
15	O	-1	19269743
min	O	-1	19269743
b@@	O	-1	19269743
re@@	O	-1	19269743
ak@@	O	-1	19269743
s),	O	-1	19269743
each	O	-1	19269743
given	O	-1	19269743
three	O	-1	19269743
times	O	-1	19269743
in	O	-1	19269743
a	O	-1	19269743
b@@	O	-1	19269743
al@@	O	-1	19269743
anced	O	-1	19269743
desi@@	O	-1	19269743
g@@	O	-1	19269743
n	O	-1	19269743
ac@@	O	-1	19269743
ros@@	O	-1	19269743
s	O	-1	19269743
three	O	-1	19269743
s@@	O	-1	19269743
es@@	O	-1	19269743
sions	O	-1	19269743
at	O	-1	19269743
one	O	-1	19269743
week	O	-1	19269743
inter@@	O	-1	19269743
val@@	O	-1	19269743
s.	O	-1	19269743
P@@	B-Disease	D010146	19269743
ain	I-Disease	-1	19269743
rat@@	O	-1	19269743
ing	O	-1	19269743
was	O	-1	19269743
performed	O	-1	19269743
using	O	-1	19269743
a	O	-1	19269743
comp@@	O	-1	19269743
u@@	O	-1	19269743
ter@@	O	-1	19269743
ized	O	-1	19269743
visual	O	-1	19269743
an@@	O	-1	19269743
alo@@	O	-1	19269743
gu@@	O	-1	19269743
e	O	-1	19269743
s@@	O	-1	19269743
cal@@	O	-1	19269743
e	O	-1	19269743
(@@	O	-1	19269743
0-@@	O	-1	19269743
10@@	O	-1	19269743
0@@	O	-1	19269743
)	O	-1	19269743
di@@	O	-1	19269743
gi@@	O	-1	19269743
tiz@@	O	-1	19269743
ed	O	-1	19269743
at	O	-1	19269743
1@@	O	-1	19269743
/@@	O	-1	19269743
s,	O	-1	19269743
either	O	-1	19269743
immedi@@	O	-1	19269743
ately	O	-1	19269743
on@@	O	-1	19269743
line	O	-1	19269743
or	O	-1	19269743
one	O	-1	19269743
h@@	O	-1	19269743
our	O	-1	19269743
or	O	-1	19269743
one	O	-1	19269743
day	O	-1	19269743
after	O	-1	19269743
injec@@	O	-1	19269743
tion.	O	-1	19269743
S@@	O	-1	19269743
ub@@	O	-1	19269743
j@@	O	-1	19269743
ects	O	-1	19269743
also	O	-1	19269743
rec@@	O	-1	19269743
all@@	O	-1	19269743
ed	O	-1	19269743
their	O	-1	19269743
pa@@	B-Disease	D010146	19269743
ins	I-Disease	-1	19269743
one	O	-1	19269743
week	O	-1	19269743
lat@@	O	-1	19269743
er.	O	-1	19269743
C@@	B-Chemical	D002211	19269743
ap@@	I-Chemical	-1	19269743
sa@@	I-Chemical	-1	19269743
icin	I-Chemical	-1	19269743
injection	O	-1	19269743
re@@	O	-1	19269743
li@@	O	-1	19269743
ably	O	-1	19269743
induced	O	-1	19269743
a	O	-1	19269743
dose-@@	O	-1	19269743
dependent	O	-1	19269743
f@@	O	-1	19269743
l@@	O	-1	19269743
are	O	-1	19269743
(p@@	O	-1	19269743
<@@	O	-1	19269743
0.00@@	O	-1	19269743
1)	O	-1	19269743
without	O	-1	19269743
any	O	-1	19269743
difference	O	-1	19269743
within	O	-1	19269743
or	O	-1	19269743
ac@@	O	-1	19269743
ros@@	O	-1	19269743
s	O	-1	19269743
s@@	O	-1	19269743
es@@	O	-1	19269743
sion@@	O	-1	19269743
s.	O	-1	19269743
The	O	-1	19269743
st@@	O	-1	19269743
ron@@	O	-1	19269743
g	O	-1	19269743
b@@	O	-1	19269743
ur@@	O	-1	19269743
ning	O	-1	19269743
pain	B-Disease	D010146	19269743
dec@@	O	-1	19269743
ayed	O	-1	19269743
ex@@	O	-1	19269743
p@@	O	-1	19269743
on@@	O	-1	19269743
enti@@	O	-1	19269743
ally	O	-1	19269743
within	O	-1	19269743
a	O	-1	19269743
fe@@	O	-1	19269743
w	O	-1	19269743
minut@@	O	-1	19269743
es.	O	-1	19269743
S@@	O	-1	19269743
ub@@	O	-1	19269743
j@@	O	-1	19269743
ects	O	-1	19269743
were	O	-1	19269743
able	O	-1	19269743
to	O	-1	19269743
re@@	O	-1	19269743
li@@	O	-1	19269743
ably	O	-1	19269743
dis@@	O	-1	19269743
cri@@	O	-1	19269743
min@@	O	-1	19269743
ate	O	-1	19269743
pain	B-Disease	D010146	19269743
mag@@	O	-1	19269743
nit@@	O	-1	19269743
ude	O	-1	19269743
and	O	-1	19269743
duration	O	-1	19269743
ac@@	O	-1	19269743
ros@@	O	-1	19269743
s	O	-1	19269743
cap@@	B-Chemical	D002211	19269743
sa@@	I-Chemical	-1	19269743
icin	I-Chemical	-1	19269743
doses	O	-1	19269743
(@@	O	-1	19269743
both	O	-1	19269743
p@@	O	-1	19269743
<@@	O	-1	19269743
0.00@@	O	-1	19269743
1),	O	-1	19269743
reg@@	O	-1	19269743
ar@@	O	-1	19269743
d@@	O	-1	19269743
less	O	-1	19269743
of	O	-1	19269743
whether	O	-1	19269743
fir@@	O	-1	19269743
st@@	O	-1	19269743
-@@	O	-1	19269743
time	O	-1	19269743
rat@@	O	-1	19269743
ings	O	-1	19269743
were	O	-1	19269743
requ@@	O	-1	19269743
est@@	O	-1	19269743
ed	O	-1	19269743
immedi@@	O	-1	19269743
at@@	O	-1	19269743
el@@	O	-1	19269743
y,	O	-1	19269743
after	O	-1	19269743
one	O	-1	19269743
h@@	O	-1	19269743
our	O	-1	19269743
or	O	-1	19269743
after	O	-1	19269743
one	O	-1	19269743
da@@	O	-1	19269743
y.	O	-1	19269743
P@@	B-Disease	D010146	19269743
ain	I-Disease	-1	19269743
rec@@	O	-1	19269743
all	O	-1	19269743
after	O	-1	19269743
one	O	-1	19269743
week	O	-1	19269743
was	O	-1	19269743
simil@@	O	-1	19269743
arly	O	-1	19269743
pre@@	O	-1	19269743
cis@@	O	-1	19269743
e	O	-1	19269743
(@@	O	-1	19269743
mag@@	O	-1	19269743
nit@@	O	-1	19269743
u@@	O	-1	19269743
de@@	O	-1	19269743
:	O	-1	19269743
p@@	O	-1	19269743
<@@	O	-1	19269743
0.0@@	O	-1	19269743
1,	O	-1	19269743
dur@@	O	-1	19269743
ation@@	O	-1	19269743
:	O	-1	19269743
p@@	O	-1	19269743
<@@	O	-1	19269743
0.05@@	O	-1	19269743
).	O	-1	19269743
C@@	O	-1	19269743
or@@	O	-1	19269743
rel@@	O	-1	19269743
ation	O	-1	19269743
with	O	-1	19269743
rat@@	O	-1	19269743
ing	O	-1	19269743
rec@@	O	-1	19269743
all	O	-1	19269743
after	O	-1	19269743
one	O	-1	19269743
week	O	-1	19269743
was	O	-1	19269743
b@@	O	-1	19269743
est	O	-1	19269743
when	O	-1	19269743
fir@@	O	-1	19269743
st@@	O	-1	19269743
-@@	O	-1	19269743
time	O	-1	19269743
rat@@	O	-1	19269743
ings	O	-1	19269743
were	O	-1	19269743
requ@@	O	-1	19269743
est@@	O	-1	19269743
ed	O	-1	19269743
as	O	-1	19269743
l@@	O	-1	19269743
ate	O	-1	19269743
as	O	-1	19269743
one	O	-1	19269743
day	O	-1	19269743
after	O	-1	19269743
injection	O	-1	19269743
(@@	O	-1	19269743
R@@	O	-1	19269743
(2@@	O	-1	19269743
)@@	O	-1	19269743
=@@	O	-1	19269743
0.@@	O	-1	19269743
7@@	O	-1	19269743
9@@	O	-1	19269743
)	O	-1	19269743
indicating	O	-1	19269743
that	O	-1	19269743
both	O	-1	19269743
rat@@	O	-1	19269743
ing	O	-1	19269743
re@@	O	-1	19269743
tri@@	O	-1	19269743
ev@@	O	-1	19269743
als	O	-1	19269743
u@@	O	-1	19269743
ti@@	O	-1	19269743
li@@	O	-1	19269743
zed	O	-1	19269743
similar	O	-1	19269743
memory	O	-1	19269743
trac@@	O	-1	19269743
es.	O	-1	19269743
These	O	-1	19269743
results	O	-1	19269743
indicate	O	-1	19269743
a	O	-1	19269743
re@@	O	-1	19269743
li@@	O	-1	19269743
able	O	-1	19269743
memory	O	-1	19269743
for	O	-1	19269743
mag@@	O	-1	19269743
nit@@	O	-1	19269743
ude	O	-1	19269743
and	O	-1	19269743
duration	O	-1	19269743
of	O	-1	19269743
experim@@	O	-1	19269743
ent@@	O	-1	19269743
ally	O	-1	19269743
induced	O	-1	19269743
pain	B-Disease	D010146	19269743
.	O	-1	19269743
The	O	-1	19269743
data	O	-1	19269743
further	O	-1	19269743
suggest	O	-1	19269743
that	O	-1	19269743
the	O	-1	19269743
con@@	O	-1	19269743
sol@@	O	-1	19269743
id@@	O	-1	19269743
ation	O	-1	19269743
of	O	-1	19269743
this	O	-1	19269743
memory	O	-1	19269743
is	O	-1	19269743
an	O	-1	19269743
important	O	-1	19269743
inter@@	O	-1	19269743
im	O	-1	19269743
st@@	O	-1	19269743
age,	O	-1	19269743
and	O	-1	19269743
may	O	-1	19269743
tak@@	O	-1	19269743
e	O	-1	19269743
up	O	-1	19269743
to	O	-1	19269743
one	O	-1	19269743
da@@	O	-1	19269743
y.	O	-1	19269743

Re@@	O	-1	3070035
ver@@	O	-1	3070035
sib@@	O	-1	3070035
ility	O	-1	3070035
of	O	-1	3070035
cap@@	B-Chemical	D002216	3070035
to@@	I-Chemical	-1	3070035
pri@@	I-Chemical	-1	3070035
l	I-Chemical	-1	3070035
-induced	O	-1	3070035
renal	B-Disease	D051437	3070035
in@@	I-Disease	-1	3070035
suffici@@	I-Disease	-1	3070035
ency	I-Disease	-1	3070035
after	O	-1	3070035
prolonged	O	-1	3070035
use	O	-1	3070035
in	O	-1	3070035
an	O	-1	3070035
un@@	O	-1	3070035
us@@	O	-1	3070035
ual	O	-1	3070035
case	O	-1	3070035
of	O	-1	3070035
ren@@	B-Disease	D006978	3070035
o@@	I-Disease	-1	3070035
vascular	I-Disease	-1	3070035
hypertension	I-Disease	-1	3070035
.	O	-1	3070035
We	O	-1	3070035
report	O	-1	3070035
a	O	-1	3070035
case	O	-1	3070035
of	O	-1	3070035
severe	O	-1	3070035
hypertension	B-Disease	D006973	3070035
with	O	-1	3070035
an	O	-1	3070035
oc@@	O	-1	3070035
cl@@	O	-1	3070035
uded	O	-1	3070035
renal	O	-1	3070035
artery	O	-1	3070035
to	O	-1	3070035
a	O	-1	3070035
sol@@	O	-1	3070035
it@@	O	-1	3070035
ary	O	-1	3070035
kidne@@	O	-1	3070035
y,	O	-1	3070035
who	O	-1	3070035
developed	O	-1	3070035
su@@	B-Disease	D058186	3070035
d@@	I-Disease	-1	3070035
de@@	I-Disease	-1	3070035
n	I-Disease	-1	3070035
deter@@	I-Disease	-1	3070035
i@@	I-Disease	-1	3070035
or@@	I-Disease	-1	3070035
ation	I-Disease	-1	3070035
of	I-Disease	-1	3070035
renal	I-Disease	-1	3070035
function	I-Disease	-1	3070035
following	O	-1	3070035
treatment	O	-1	3070035
with	O	-1	3070035
cap@@	B-Chemical	D002216	3070035
to@@	I-Chemical	-1	3070035
pri@@	I-Chemical	-1	3070035
l	I-Chemical	-1	3070035
.	O	-1	3070035
H@@	O	-1	3070035
is	O	-1	3070035
renal	O	-1	3070035
function	O	-1	3070035
remained	O	-1	3070035
impaired	O	-1	3070035
but	O	-1	3070035
st@@	O	-1	3070035
able	O	-1	3070035
during	O	-1	3070035
2	O	-1	3070035
year@@	O	-1	3070035
s@@	O	-1	3070035
'	O	-1	3070035
treatment	O	-1	3070035
with	O	-1	3070035
cap@@	B-Chemical	D002216	3070035
to@@	I-Chemical	-1	3070035
pri@@	I-Chemical	-1	3070035
l	I-Chemical	-1	3070035
but	O	-1	3070035
retur@@	O	-1	3070035
n@@	O	-1	3070035
ed	O	-1	3070035
to	O	-1	3070035
pre-@@	O	-1	3070035
treatment	O	-1	3070035
levels	O	-1	3070035
so@@	O	-1	3070035
on	O	-1	3070035
after	O	-1	3070035
cess@@	O	-1	3070035
ation	O	-1	3070035
of	O	-1	3070035
the	O	-1	3070035
drug.	O	-1	3070035
This	O	-1	3070035
indic@@	O	-1	3070035
ates	O	-1	3070035
rever@@	O	-1	3070035
sib@@	O	-1	3070035
ility	O	-1	3070035
in	O	-1	3070035
cap@@	B-Chemical	D002216	3070035
to@@	I-Chemical	-1	3070035
pri@@	I-Chemical	-1	3070035
l	I-Chemical	-1	3070035
-induced	O	-1	3070035
renal	B-Disease	D051437	3070035
failure	I-Disease	-1	3070035
even	O	-1	3070035
after	O	-1	3070035
its	O	-1	3070035
prolonged	O	-1	3070035
use	O	-1	3070035
and	O	-1	3070035
suggests	O	-1	3070035
that	O	-1	3070035
no	O	-1	3070035
org@@	O	-1	3070035
anic	O	-1	3070035
damage	O	-1	3070035
occur@@	O	-1	3070035
s	O	-1	3070035
to	O	-1	3070035
glomerular	O	-1	3070035
arter@@	O	-1	3070035
i@@	O	-1	3070035
ol@@	O	-1	3070035
es	O	-1	3070035
following	O	-1	3070035
chronic	O	-1	3070035
AC@@	O	-1	3070035
E	O	-1	3070035
inhib@@	O	-1	3070035
i@@	O	-1	3070035
tion.	O	-1	3070035

L@@	B-Disease	D008107	1147734
i@@	I-Disease	-1	1147734
ver	I-Disease	-1	1147734
disease	I-Disease	-1	1147734
caused	O	-1	1147734
by	O	-1	1147734
prop@@	B-Chemical	D011441	1147734
yl@@	I-Chemical	-1	1147734
th@@	I-Chemical	-1	1147734
io@@	I-Chemical	-1	1147734
urac@@	I-Chemical	-1	1147734
il	I-Chemical	-1	1147734
.	O	-1	1147734
This	O	-1	1147734
report	O	-1	1147734
pres@@	O	-1	1147734
ents	O	-1	1147734
the	O	-1	1147734
clin@@	O	-1	1147734
ic@@	O	-1	1147734
al,	O	-1	1147734
labor@@	O	-1	1147734
at@@	O	-1	1147734
or@@	O	-1	1147734
y,	O	-1	1147734
and	O	-1	1147734
li@@	O	-1	1147734
ght	O	-1	1147734
and	O	-1	1147734
electro@@	O	-1	1147734
n	O	-1	1147734
micro@@	O	-1	1147734
sco@@	O	-1	1147734
p@@	O	-1	1147734
ic	O	-1	1147734
observ@@	O	-1	1147734
ations	O	-1	1147734
on	O	-1	1147734
a	O	-1	1147734
patient	O	-1	1147734
with	O	-1	1147734
chronic	B-Disease	D006521	1147734
active	I-Disease	-1	1147734
(@@	I-Disease	-1	1147734
ag@@	I-Disease	-1	1147734
gres@@	I-Disease	-1	1147734
si@@	I-Disease	-1	1147734
ve@@	I-Disease	-1	1147734
)	I-Disease	-1	1147734
hepatitis	I-Disease	-1	1147734
caused	O	-1	1147734
by	O	-1	1147734
the	O	-1	1147734
administration	O	-1	1147734
of	O	-1	1147734
prop@@	B-Chemical	D011441	1147734
yl@@	I-Chemical	-1	1147734
th@@	I-Chemical	-1	1147734
io@@	I-Chemical	-1	1147734
urac@@	I-Chemical	-1	1147734
il	I-Chemical	-1	1147734
.	O	-1	1147734
This	O	-1	1147734
is	O	-1	1147734
an	O	-1	1147734
addition	O	-1	1147734
to	O	-1	1147734
the	O	-1	1147734
l@@	O	-1	1147734
ist	O	-1	1147734
of	O	-1	1147734
drugs	O	-1	1147734
that	O	-1	1147734
mus@@	O	-1	1147734
t	O	-1	1147734
be	O	-1	1147734
considered	O	-1	1147734
in	O	-1	1147734
the	O	-1	1147734
evalu@@	O	-1	1147734
ation	O	-1	1147734
of	O	-1	1147734
chronic	O	-1	1147734
liver	B-Disease	D008107	1147734
disease	I-Disease	-1	1147734
.	O	-1	1147734

C@@	B-Chemical	D002211	12202650
ap@@	I-Chemical	-1	12202650
sa@@	I-Chemical	-1	12202650
icin	I-Chemical	-1	12202650
-induced	O	-1	12202650
musc@@	B-Disease	D063806	12202650
le	I-Disease	-1	12202650
pain	I-Disease	-1	12202650
al@@	O	-1	12202650
ters	O	-1	12202650
the	O	-1	12202650
ex@@	O	-1	12202650
cit@@	O	-1	12202650
ability	O	-1	12202650
of	O	-1	12202650
the	O	-1	12202650
human	O	-1	12202650
j@@	O	-1	12202650
aw@@	O	-1	12202650
-@@	O	-1	12202650
st@@	O	-1	12202650
ret@@	O	-1	12202650
ch	O	-1	12202650
ref@@	O	-1	12202650
le@@	O	-1	12202650
x@@	O	-1	12202650
.	O	-1	12202650
The	O	-1	12202650
path@@	O	-1	12202650
oph@@	O	-1	12202650
ysi@@	O	-1	12202650
ology	O	-1	12202650
of	O	-1	12202650
pa@@	O	-1	12202650
infu@@	O	-1	12202650
l	O	-1	12202650
tem@@	B-Disease	D013705	12202650
po@@	I-Disease	-1	12202650
rom@@	I-Disease	-1	12202650
an@@	I-Disease	-1	12202650
di@@	I-Disease	-1	12202650
b@@	I-Disease	-1	12202650
ular	I-Disease	-1	12202650
disorder@@	I-Disease	-1	12202650
s	I-Disease	-1	12202650
is	O	-1	12202650
not	O	-1	12202650
ful@@	O	-1	12202650
ly	O	-1	12202650
under@@	O	-1	12202650
sto@@	O	-1	12202650
o@@	O	-1	12202650
d,	O	-1	12202650
but	O	-1	12202650
evidence	O	-1	12202650
suggests	O	-1	12202650
that	O	-1	12202650
musc@@	B-Disease	D063806	12202650
le	I-Disease	-1	12202650
pain	I-Disease	-1	12202650
mod@@	O	-1	12202650
ul@@	O	-1	12202650
ates	O	-1	12202650
motor	O	-1	12202650
function	O	-1	12202650
in	O	-1	12202650
character@@	O	-1	12202650
istic	O	-1	12202650
w@@	O	-1	12202650
ay@@	O	-1	12202650
s.	O	-1	12202650
This	O	-1	12202650
study	O	-1	12202650
tested	O	-1	12202650
the	O	-1	12202650
hypo@@	O	-1	12202650
thesis	O	-1	12202650
that	O	-1	12202650
activation	O	-1	12202650
of	O	-1	12202650
n@@	B-Disease	D063806	12202650
ocicep@@	I-Disease	-1	12202650
tive	I-Disease	-1	12202650
musc@@	I-Disease	-1	12202650
le	I-Disease	-1	12202650
a@@	O	-1	12202650
fferen@@	O	-1	12202650
t	O	-1	12202650
fib@@	O	-1	12202650
ers	O	-1	12202650
wo@@	O	-1	12202650
uld	O	-1	12202650
be	O	-1	12202650
lin@@	O	-1	12202650
ked	O	-1	12202650
to	O	-1	12202650
an	O	-1	12202650
increased	O	-1	12202650
ex@@	O	-1	12202650
cit@@	O	-1	12202650
ability	O	-1	12202650
of	O	-1	12202650
the	O	-1	12202650
human	O	-1	12202650
j@@	O	-1	12202650
aw@@	O	-1	12202650
-@@	O	-1	12202650
st@@	O	-1	12202650
ret@@	O	-1	12202650
ch	O	-1	12202650
ref@@	O	-1	12202650
le@@	O	-1	12202650
x	O	-1	12202650
and	O	-1	12202650
whether	O	-1	12202650
this	O	-1	12202650
pro@@	O	-1	12202650
cess	O	-1	12202650
wo@@	O	-1	12202650
uld	O	-1	12202650
be	O	-1	12202650
sensitive	O	-1	12202650
to	O	-1	12202650
l@@	O	-1	12202650
en@@	O	-1	12202650
g@@	O	-1	12202650
th	O	-1	12202650
and	O	-1	12202650
ve@@	O	-1	12202650
loc@@	O	-1	12202650
ity	O	-1	12202650
of	O	-1	12202650
the	O	-1	12202650
st@@	O	-1	12202650
ret@@	O	-1	12202650
ch@@	O	-1	12202650
.	O	-1	12202650
C@@	B-Chemical	D002211	12202650
ap@@	I-Chemical	-1	12202650
sa@@	I-Chemical	-1	12202650
icin	I-Chemical	-1	12202650
(10	O	-1	12202650
mic@@	O	-1	12202650
r@@	O	-1	12202650
o	O	-1	12202650
g@@	O	-1	12202650
)	O	-1	12202650
was	O	-1	12202650
injected	O	-1	12202650
into	O	-1	12202650
the	O	-1	12202650
mas@@	O	-1	12202650
se@@	O	-1	12202650
ter	O	-1	12202650
musc@@	O	-1	12202650
le	O	-1	12202650
to	O	-1	12202650
induce	O	-1	12202650
pain	B-Disease	D010146	12202650
in	O	-1	12202650
11	O	-1	12202650
healthy	O	-1	12202650
vol@@	O	-1	12202650
un@@	O	-1	12202650
te@@	O	-1	12202650
ers.	O	-1	12202650
S@@	O	-1	12202650
h@@	O	-1	12202650
ort@@	O	-1	12202650
-@@	O	-1	12202650
lat@@	O	-1	12202650
ency	O	-1	12202650
ref@@	O	-1	12202650
le@@	O	-1	12202650
x	O	-1	12202650
responses	O	-1	12202650
were	O	-1	12202650
evoked	O	-1	12202650
in	O	-1	12202650
the	O	-1	12202650
mas@@	O	-1	12202650
se@@	O	-1	12202650
ter	O	-1	12202650
and	O	-1	12202650
tempor@@	O	-1	12202650
al@@	O	-1	12202650
is	O	-1	12202650
musc@@	O	-1	12202650
le@@	O	-1	12202650
s	O	-1	12202650
by	O	-1	12202650
a	O	-1	12202650
st@@	O	-1	12202650
ret@@	O	-1	12202650
ch	O	-1	12202650
de@@	O	-1	12202650
v@@	O	-1	12202650
ic@@	O	-1	12202650
e	O	-1	12202650
with	O	-1	12202650
different	O	-1	12202650
ve@@	O	-1	12202650
lo@@	O	-1	12202650
ci@@	O	-1	12202650
ties	O	-1	12202650
and	O	-1	12202650
dis@@	O	-1	12202650
pl@@	O	-1	12202650
ac@@	O	-1	12202650
em@@	O	-1	12202650
ents	O	-1	12202650
be@@	O	-1	12202650
fo@@	O	-1	12202650
re,	O	-1	12202650
dur@@	O	-1	12202650
ing,	O	-1	12202650
and	O	-1	12202650
after	O	-1	12202650
the	O	-1	12202650
pain	B-Disease	D010146	12202650
.	O	-1	12202650
The	O	-1	12202650
normal@@	O	-1	12202650
ized	O	-1	12202650
ref@@	O	-1	12202650
le@@	O	-1	12202650
x	O	-1	12202650
am@@	O	-1	12202650
pl@@	O	-1	12202650
it@@	O	-1	12202650
ude	O	-1	12202650
increased	O	-1	12202650
with	O	-1	12202650
an	O	-1	12202650
increase	O	-1	12202650
in	O	-1	12202650
ve@@	O	-1	12202650
loc@@	O	-1	12202650
ity	O	-1	12202650
at	O	-1	12202650
a	O	-1	12202650
given	O	-1	12202650
dis@@	O	-1	12202650
pl@@	O	-1	12202650
ac@@	O	-1	12202650
em@@	O	-1	12202650
ent@@	O	-1	12202650
,	O	-1	12202650
but	O	-1	12202650
remained	O	-1	12202650
con@@	O	-1	12202650
st@@	O	-1	12202650
ant	O	-1	12202650
with	O	-1	12202650
different	O	-1	12202650
dis@@	O	-1	12202650
pl@@	O	-1	12202650
ac@@	O	-1	12202650
em@@	O	-1	12202650
ents	O	-1	12202650
at	O	-1	12202650
a	O	-1	12202650
given	O	-1	12202650
ve@@	O	-1	12202650
loc@@	O	-1	12202650
ity.	O	-1	12202650
The	O	-1	12202650
normal@@	O	-1	12202650
ized	O	-1	12202650
ref@@	O	-1	12202650
le@@	O	-1	12202650
x	O	-1	12202650
am@@	O	-1	12202650
pl@@	O	-1	12202650
it@@	O	-1	12202650
ude	O	-1	12202650
was	O	-1	12202650
significantly	O	-1	12202650
higher	O	-1	12202650
during	O	-1	12202650
pain	B-Disease	D010146	12202650
,	O	-1	12202650
but	O	-1	12202650
only	O	-1	12202650
at	O	-1	12202650
f@@	O	-1	12202650
ast@@	O	-1	12202650
er	O	-1	12202650
st@@	O	-1	12202650
ret@@	O	-1	12202650
ch@@	O	-1	12202650
es	O	-1	12202650
in	O	-1	12202650
the	O	-1	12202650
pa@@	B-Disease	D063806	12202650
infu@@	I-Disease	-1	12202650
l	I-Disease	-1	12202650
musc@@	I-Disease	-1	12202650
le	I-Disease	-1	12202650
.	O	-1	12202650
In@@	O	-1	12202650
c@@	O	-1	12202650
reas@@	O	-1	12202650
ed	O	-1	12202650
sensitivity	O	-1	12202650
of	O	-1	12202650
the	O	-1	12202650
fu@@	O	-1	12202650
sim@@	O	-1	12202650
otor	O	-1	12202650
system	O	-1	12202650
during	O	-1	12202650
acute	O	-1	12202650
musc@@	B-Disease	D063806	12202650
le	I-Disease	-1	12202650
pain	I-Disease	-1	12202650
could	O	-1	12202650
be	O	-1	12202650
one	O	-1	12202650
likely	O	-1	12202650
mechanism	O	-1	12202650
to	O	-1	12202650
expl@@	O	-1	12202650
ain	O	-1	12202650
the	O	-1	12202650
find@@	O	-1	12202650
ing@@	O	-1	12202650
s.	O	-1	12202650

R@@	O	-1	18951540
ep@@	O	-1	18951540
e@@	O	-1	18951540
ti@@	O	-1	18951540
tive	O	-1	18951540
trans@@	O	-1	18951540
c@@	O	-1	18951540
ranial	O	-1	18951540
mag@@	O	-1	18951540
ne@@	O	-1	18951540
tic	O	-1	18951540
stimulation	O	-1	18951540
for	O	-1	18951540
levo@@	B-Chemical	D007980	18951540
dopa	I-Chemical	-1	18951540
-induced	O	-1	18951540
dyskine@@	B-Disease	D004409	18951540
si@@	I-Disease	-1	18951540
as	I-Disease	-1	18951540
in	O	-1	18951540
Parkinson's	B-Disease	D010300	18951540
disease	I-Disease	-1	18951540
.	O	-1	18951540
In	O	-1	18951540
a	O	-1	18951540
placebo@@	O	-1	18951540
-@@	O	-1	18951540
control@@	O	-1	18951540
le@@	O	-1	18951540
d,	O	-1	18951540
sing@@	O	-1	18951540
le@@	O	-1	18951540
-@@	O	-1	18951540
bl@@	O	-1	18951540
in@@	O	-1	18951540
de@@	O	-1	18951540
d,	O	-1	18951540
cros@@	O	-1	18951540
s@@	O	-1	18951540
over	O	-1	18951540
study,	O	-1	18951540
we	O	-1	18951540
assessed	O	-1	18951540
the	O	-1	18951540
effect	O	-1	18951540
of	O	-1	18951540
"@@	O	-1	18951540
re@@	O	-1	18951540
al@@	O	-1	18951540
"	O	-1	18951540
repe@@	O	-1	18951540
ti@@	O	-1	18951540
tive	O	-1	18951540
trans@@	O	-1	18951540
c@@	O	-1	18951540
ranial	O	-1	18951540
mag@@	O	-1	18951540
ne@@	O	-1	18951540
tic	O	-1	18951540
stimulation	O	-1	18951540
(@@	O	-1	18951540
r@@	O	-1	18951540
T@@	O	-1	18951540
M@@	O	-1	18951540
S)	O	-1	18951540
versus	O	-1	18951540
"@@	O	-1	18951540
sh@@	O	-1	18951540
am@@	O	-1	18951540
"	O	-1	18951540
r@@	O	-1	18951540
T@@	O	-1	18951540
M@@	O	-1	18951540
S	O	-1	18951540
(@@	O	-1	18951540
placebo@@	O	-1	18951540
)	O	-1	18951540
on	O	-1	18951540
pe@@	O	-1	18951540
a@@	O	-1	18951540
k	O	-1	18951540
dose	O	-1	18951540
dyskine@@	B-Disease	D004409	18951540
si@@	I-Disease	-1	18951540
as	I-Disease	-1	18951540
in	O	-1	18951540
patients	O	-1	18951540
with	O	-1	18951540
Parkinson's	B-Disease	D010300	18951540
disease	I-Disease	-1	18951540
(	O	-1	18951540
P@@	B-Disease	D010300	18951540
D	I-Disease	-1	18951540
).	O	-1	18951540
T@@	O	-1	18951540
en	O	-1	18951540
patients	O	-1	18951540
with	O	-1	18951540
P@@	B-Disease	D010300	18951540
D	I-Disease	-1	18951540
and	O	-1	18951540
pro@@	O	-1	18951540
min@@	O	-1	18951540
ent	O	-1	18951540
dyskine@@	B-Disease	D004409	18951540
si@@	I-Disease	-1	18951540
as	I-Disease	-1	18951540
had	O	-1	18951540
r@@	O	-1	18951540
T@@	O	-1	18951540
M@@	O	-1	18951540
S	O	-1	18951540
(1@@	O	-1	18951540
,@@	O	-1	18951540
8@@	O	-1	18951540
00	O	-1	18951540
pul@@	O	-1	18951540
s@@	O	-1	18951540
es@@	O	-1	18951540
;	O	-1	18951540
1	O	-1	18951540
H@@	O	-1	18951540
z	O	-1	18951540
rat@@	O	-1	18951540
e@@	O	-1	18951540
)	O	-1	18951540
de@@	O	-1	18951540
li@@	O	-1	18951540
vered	O	-1	18951540
over	O	-1	18951540
the	O	-1	18951540
motor	O	-1	18951540
cor@@	O	-1	18951540
te@@	O	-1	18951540
x	O	-1	18951540
for	O	-1	18951540
4	O	-1	18951540
con@@	O	-1	18951540
sec@@	O	-1	18951540
utive	O	-1	18951540
days	O	-1	18951540
tw@@	O	-1	18951540
ic@@	O	-1	18951540
e,	O	-1	18951540
on@@	O	-1	18951540
ce	O	-1	18951540
re@@	O	-1	18951540
al	O	-1	18951540
stimul@@	O	-1	18951540
i	O	-1	18951540
and	O	-1	18951540
on@@	O	-1	18951540
ce	O	-1	18951540
s@@	O	-1	18951540
ha@@	O	-1	18951540
m	O	-1	18951540
stimulation	O	-1	18951540
were	O	-1	18951540
use@@	O	-1	18951540
d@@	O	-1	18951540
;	O	-1	18951540
evalu@@	O	-1	18951540
ations	O	-1	18951540
were	O	-1	18951540
d@@	O	-1	18951540
one	O	-1	18951540
at	O	-1	18951540
the	O	-1	18951540
baseline	O	-1	18951540
and	O	-1	18951540
1	O	-1	18951540
day	O	-1	18951540
after	O	-1	18951540
the	O	-1	18951540
end	O	-1	18951540
of	O	-1	18951540
each	O	-1	18951540
of	O	-1	18951540
the	O	-1	18951540
treatment	O	-1	18951540
seri@@	O	-1	18951540
es.	O	-1	18951540
Di@@	O	-1	18951540
rec@@	O	-1	18951540
t	O	-1	18951540
compar@@	O	-1	18951540
ison	O	-1	18951540
between	O	-1	18951540
s@@	O	-1	18951540
ha@@	O	-1	18951540
m	O	-1	18951540
and	O	-1	18951540
re@@	O	-1	18951540
al	O	-1	18951540
r@@	O	-1	18951540
T@@	O	-1	18951540
M@@	O	-1	18951540
S	O	-1	18951540
effects	O	-1	18951540
showed	O	-1	18951540
no	O	-1	18951540
significant	O	-1	18951540
difference	O	-1	18951540
in	O	-1	18951540
clin@@	O	-1	18951540
ici@@	O	-1	18951540
an@@	O	-1	18951540
-@@	O	-1	18951540
assessed	O	-1	18951540
dyskine@@	B-Disease	D004409	18951540
sia	I-Disease	-1	18951540
sever@@	O	-1	18951540
ity.	O	-1	18951540
However,	O	-1	18951540
compar@@	O	-1	18951540
ison	O	-1	18951540
with	O	-1	18951540
the	O	-1	18951540
baseline	O	-1	18951540
showed	O	-1	18951540
sm@@	O	-1	18951540
all	O	-1	18951540
but	O	-1	18951540
significant	O	-1	18951540
reduction	O	-1	18951540
in	O	-1	18951540
dyskine@@	B-Disease	D004409	18951540
sia	I-Disease	-1	18951540
severity	O	-1	18951540
following	O	-1	18951540
re@@	O	-1	18951540
al	O	-1	18951540
r@@	O	-1	18951540
T@@	O	-1	18951540
M@@	O	-1	18951540
S	O	-1	18951540
but	O	-1	18951540
not	O	-1	18951540
placebo@@	O	-1	18951540
.	O	-1	18951540
The	O	-1	18951540
major	O	-1	18951540
effect	O	-1	18951540
was	O	-1	18951540
on	O	-1	18951540
dy@@	B-Disease	D004421	18951540
ston@@	I-Disease	-1	18951540
ia	I-Disease	-1	18951540
sub@@	O	-1	18951540
sco@@	O	-1	18951540
re.	O	-1	18951540
S@@	O	-1	18951540
im@@	O	-1	18951540
il@@	O	-1	18951540
ar@@	O	-1	18951540
ly,	O	-1	18951540
in	O	-1	18951540
patient	O	-1	18951540
di@@	O	-1	18951540
ari@@	O	-1	18951540
es,	O	-1	18951540
although	O	-1	18951540
both	O	-1	18951540
treat@@	O	-1	18951540
ments	O	-1	18951540
caused	O	-1	18951540
reduction	O	-1	18951540
in	O	-1	18951540
subj@@	O	-1	18951540
ective	O	-1	18951540
dyskine@@	B-Disease	D004409	18951540
sia	I-Disease	-1	18951540
sco@@	O	-1	18951540
res	O	-1	18951540
during	O	-1	18951540
the	O	-1	18951540
days	O	-1	18951540
of	O	-1	18951540
inter@@	O	-1	18951540
ven@@	O	-1	18951540
tion,	O	-1	18951540
the	O	-1	18951540
effect	O	-1	18951540
was	O	-1	18951540
su@@	O	-1	18951540
st@@	O	-1	18951540
ained	O	-1	18951540
for	O	-1	18951540
3	O	-1	18951540
days	O	-1	18951540
after	O	-1	18951540
the	O	-1	18951540
inter@@	O	-1	18951540
ven@@	O	-1	18951540
tion	O	-1	18951540
for	O	-1	18951540
the	O	-1	18951540
re@@	O	-1	18951540
al	O	-1	18951540
r@@	O	-1	18951540
T@@	O	-1	18951540
M@@	O	-1	18951540
S	O	-1	18951540
on@@	O	-1	18951540
ly.	O	-1	18951540
F@@	O	-1	18951540
ol@@	O	-1	18951540
low@@	O	-1	18951540
ing	O	-1	18951540
r@@	O	-1	18951540
T@@	O	-1	18951540
M@@	O	-1	18951540
S@@	O	-1	18951540
,	O	-1	18951540
no	O	-1	18951540
side	O	-1	18951540
effects	O	-1	18951540
and	O	-1	18951540
no	O	-1	18951540
adverse	O	-1	18951540
effects	O	-1	18951540
on	O	-1	18951540
motor	O	-1	18951540
function	O	-1	18951540
and	O	-1	18951540
P@@	B-Disease	D010300	18951540
D	I-Disease	-1	18951540
symptoms	O	-1	18951540
were	O	-1	18951540
not@@	O	-1	18951540
ed.	O	-1	18951540
The	O	-1	18951540
results	O	-1	18951540
suggest	O	-1	18951540
the	O	-1	18951540
ex@@	O	-1	18951540
ist@@	O	-1	18951540
ence	O	-1	18951540
of	O	-1	18951540
re@@	O	-1	18951540
si@@	O	-1	18951540
du@@	O	-1	18951540
al	O	-1	18951540
ben@@	O	-1	18951540
e@@	O	-1	18951540
fic@@	O	-1	18951540
ial	O	-1	18951540
clinical	O	-1	18951540
af@@	O	-1	18951540
te@@	O	-1	18951540
re@@	O	-1	18951540
ff@@	O	-1	18951540
ects	O	-1	18951540
of	O	-1	18951540
con@@	O	-1	18951540
sec@@	O	-1	18951540
utive	O	-1	18951540
daily	O	-1	18951540
ap@@	O	-1	18951540
plic@@	O	-1	18951540
ations	O	-1	18951540
of	O	-1	18951540
low@@	O	-1	18951540
-@@	O	-1	18951540
frequency	O	-1	18951540
r@@	O	-1	18951540
T@@	O	-1	18951540
M@@	O	-1	18951540
S	O	-1	18951540
on	O	-1	18951540
dyskine@@	B-Disease	D004409	18951540
si@@	I-Disease	-1	18951540
as	I-Disease	-1	18951540
in	O	-1	18951540
P@@	B-Disease	D010300	18951540
D	I-Disease	-1	18951540
.	O	-1	18951540
The	O	-1	18951540
effects	O	-1	18951540
may	O	-1	18951540
be	O	-1	18951540
further	O	-1	18951540
ex@@	O	-1	18951540
p@@	O	-1	18951540
lo@@	O	-1	18951540
ited	O	-1	18951540
for	O	-1	18951540
potential	O	-1	18951540
therapeutic	O	-1	18951540
us@@	O	-1	18951540
es.	O	-1	18951540

D@@	B-Chemical	D004221	19657887
is@@	I-Chemical	-1	19657887
ul@@	I-Chemical	-1	19657887
fi@@	I-Chemical	-1	19657887
ra@@	I-Chemical	-1	19657887
m	I-Chemical	-1	19657887
-@@	O	-1	19657887
like	O	-1	19657887
syndrome	O	-1	19657887
after	O	-1	19657887
hydro@@	B-Chemical	D003484	19657887
gen	I-Chemical	-1	19657887
cy@@	I-Chemical	-1	19657887
an@@	I-Chemical	-1	19657887
amide	I-Chemical	-1	19657887
prof@@	O	-1	19657887
es@@	O	-1	19657887
sion@@	O	-1	19657887
al	O	-1	19657887
s@@	O	-1	19657887
k@@	O	-1	19657887
in	O	-1	19657887
expos@@	O	-1	19657887
ure@@	O	-1	19657887
:	O	-1	19657887
two	O	-1	19657887
case	O	-1	19657887
reports	O	-1	19657887
in	O	-1	19657887
F@@	O	-1	19657887
ran@@	O	-1	19657887
ce@@	O	-1	19657887
.	O	-1	19657887
H@@	B-Chemical	D003484	19657887
y@@	I-Chemical	-1	19657887
dro@@	I-Chemical	-1	19657887
gen	I-Chemical	-1	19657887
cy@@	I-Chemical	-1	19657887
an@@	I-Chemical	-1	19657887
amide	I-Chemical	-1	19657887
is	O	-1	19657887
a	O	-1	19657887
pl@@	O	-1	19657887
ant	O	-1	19657887
growth	O	-1	19657887
reg@@	O	-1	19657887
ul@@	O	-1	19657887
at@@	O	-1	19657887
or	O	-1	19657887
used	O	-1	19657887
in	O	-1	19657887
ag@@	O	-1	19657887
r@@	O	-1	19657887
ic@@	O	-1	19657887
ult@@	O	-1	19657887
ure	O	-1	19657887
to	O	-1	19657887
induce	O	-1	19657887
bu@@	O	-1	19657887
d	O	-1	19657887
b@@	O	-1	19657887
re@@	O	-1	19657887
a@@	O	-1	19657887
k	O	-1	19657887
in	O	-1	19657887
f@@	O	-1	19657887
ru@@	O	-1	19657887
it	O	-1	19657887
tre@@	O	-1	19657887
es.	O	-1	19657887
Con@@	O	-1	19657887
tac@@	O	-1	19657887
t	O	-1	19657887
with	O	-1	19657887
the	O	-1	19657887
s@@	O	-1	19657887
k@@	O	-1	19657887
in	O	-1	19657887
can	O	-1	19657887
result	O	-1	19657887
in	O	-1	19657887
perc@@	O	-1	19657887
utaneous	O	-1	19657887
abs@@	O	-1	19657887
or@@	O	-1	19657887
ption	O	-1	19657887
of	O	-1	19657887
the	O	-1	19657887
subst@@	O	-1	19657887
ance	O	-1	19657887
that	O	-1	19657887
inhibit@@	O	-1	19657887
s	O	-1	19657887
al@@	B-Chemical	D000079	19657887
de@@	I-Chemical	-1	19657887
hy@@	I-Chemical	-1	19657887
de	I-Chemical	-1	19657887
de@@	O	-1	19657887
hydro@@	O	-1	19657887
gen@@	O	-1	19657887
ase	O	-1	19657887
and	O	-1	19657887
can	O	-1	19657887
induce	O	-1	19657887
acet@@	B-Chemical	D000079	19657887
al@@	I-Chemical	-1	19657887
de@@	I-Chemical	-1	19657887
hy@@	I-Chemical	-1	19657887
de	I-Chemical	-1	19657887
syndrome	O	-1	19657887
in	O	-1	19657887
case	O	-1	19657887
of	O	-1	19657887
alco@@	B-Chemical	D000431	19657887
hol	I-Chemical	-1	19657887
use.	O	-1	19657887
The	O	-1	19657887
pur@@	O	-1	19657887
p@@	O	-1	19657887
ose	O	-1	19657887
of	O	-1	19657887
this	O	-1	19657887
report	O	-1	19657887
is	O	-1	19657887
to	O	-1	19657887
describe	O	-1	19657887
two	O	-1	19657887
cases	O	-1	19657887
of	O	-1	19657887
a	O	-1	19657887
dis@@	B-Chemical	D004221	19657887
ul@@	I-Chemical	-1	19657887
fi@@	I-Chemical	-1	19657887
ra@@	I-Chemical	-1	19657887
m	I-Chemical	-1	19657887
-@@	O	-1	19657887
like	O	-1	19657887
syndrome	O	-1	19657887
following	O	-1	19657887
occ@@	O	-1	19657887
u@@	O	-1	19657887
pati@@	O	-1	19657887
on@@	O	-1	19657887
al	O	-1	19657887
exposure	O	-1	19657887
to	O	-1	19657887
hydro@@	B-Chemical	D003484	19657887
gen	I-Chemical	-1	19657887
cy@@	I-Chemical	-1	19657887
an@@	I-Chemical	-1	19657887
amide	I-Chemical	-1	19657887
.	O	-1	19657887
The	O	-1	19657887
first	O	-1	19657887
case	O	-1	19657887
involved	O	-1	19657887
a	O	-1	19657887
5@@	O	-1	19657887
9@@	O	-1	19657887
-@@	O	-1	19657887
year-old	O	-1	19657887
man	O	-1	19657887
who	O	-1	19657887
used	O	-1	19657887
D@@	B-Chemical	D003484	19657887
or@@	I-Chemical	-1	19657887
me@@	I-Chemical	-1	19657887
x	I-Chemical	-1	19657887
,	O	-1	19657887
which	O	-1	19657887
cont@@	O	-1	19657887
ain@@	O	-1	19657887
s	O	-1	19657887
hydro@@	B-Chemical	D003484	19657887
gen	I-Chemical	-1	19657887
cy@@	I-Chemical	-1	19657887
an@@	I-Chemical	-1	19657887
amide	I-Chemical	-1	19657887
,	O	-1	19657887
without	O	-1	19657887
prot@@	O	-1	19657887
ection	O	-1	19657887
after	O	-1	19657887
consum@@	O	-1	19657887
ing	O	-1	19657887
a	O	-1	19657887
larg@@	O	-1	19657887
e	O	-1	19657887
amoun@@	O	-1	19657887
t	O	-1	19657887
of	O	-1	19657887
alco@@	B-Chemical	D000431	19657887
hol	I-Chemical	-1	19657887
during	O	-1	19657887
a	O	-1	19657887
me@@	O	-1	19657887
al.	O	-1	19657887
In	O	-1	19657887
less	O	-1	19657887
than	O	-1	19657887
1	O	-1	19657887
h@@	O	-1	19657887
our	O	-1	19657887
after	O	-1	19657887
the	O	-1	19657887
ing@@	O	-1	19657887
es@@	O	-1	19657887
tion	O	-1	19657887
of	O	-1	19657887
alco@@	B-Chemical	D000431	19657887
hol	I-Chemical	-1	19657887
,	O	-1	19657887
he	O	-1	19657887
developed	O	-1	19657887
mal@@	O	-1	19657887
a@@	O	-1	19657887
is@@	O	-1	19657887
e	O	-1	19657887
with	O	-1	19657887
f@@	B-Disease	D005483	19657887
l@@	I-Disease	-1	19657887
us@@	I-Disease	-1	19657887
h@@	I-Disease	-1	19657887
ing	I-Disease	-1	19657887
of	I-Disease	-1	19657887
the	I-Disease	-1	19657887
fac@@	I-Disease	-1	19657887
e	I-Disease	-1	19657887
,	O	-1	19657887
tachycardia	B-Disease	D013610	19657887
,	O	-1	19657887
and	O	-1	19657887
dys@@	B-Disease	D004417	19657887
p@@	I-Disease	-1	19657887
ne@@	I-Disease	-1	19657887
a	I-Disease	-1	19657887
.	O	-1	19657887
M@@	O	-1	19657887
an@@	O	-1	19657887
if@@	O	-1	19657887
est@@	O	-1	19657887
ations	O	-1	19657887
reg@@	O	-1	19657887
res@@	O	-1	19657887
sed	O	-1	19657887
spont@@	O	-1	19657887
ane@@	O	-1	19657887
ously	O	-1	19657887
under	O	-1	19657887
sur@@	O	-1	19657887
ve@@	O	-1	19657887
ill@@	O	-1	19657887
ance	O	-1	19657887
in	O	-1	19657887
the	O	-1	19657887
hospit@@	O	-1	19657887
al.	O	-1	19657887
The	O	-1	19657887
second	O	-1	19657887
case	O	-1	19657887
occurred	O	-1	19657887
in	O	-1	19657887
a	O	-1	19657887
5@@	O	-1	19657887
5-@@	O	-1	19657887
year-old	O	-1	19657887
far@@	O	-1	19657887
m@@	O	-1	19657887
er	O	-1	19657887
following	O	-1	19657887
c@@	O	-1	19657887
utaneous	O	-1	19657887
cont@@	O	-1	19657887
ac@@	O	-1	19657887
t	O	-1	19657887
with	O	-1	19657887
D@@	B-Chemical	D003484	19657887
or@@	I-Chemical	-1	19657887
me@@	I-Chemical	-1	19657887
x	I-Chemical	-1	19657887
.	O	-1	19657887
F@@	O	-1	19657887
i@@	O	-1	19657887
ve	O	-1	19657887
hours	O	-1	19657887
after	O	-1	19657887
expos@@	O	-1	19657887
ure,	O	-1	19657887
he	O	-1	19657887
developed	O	-1	19657887
dis@@	B-Chemical	D004221	19657887
ul@@	I-Chemical	-1	19657887
fi@@	I-Chemical	-1	19657887
ra@@	I-Chemical	-1	19657887
m	I-Chemical	-1	19657887
-@@	O	-1	19657887
like	O	-1	19657887
syndrome	O	-1	19657887
with	O	-1	19657887
f@@	B-Disease	D005483	19657887
l@@	I-Disease	-1	19657887
us@@	I-Disease	-1	19657887
h@@	I-Disease	-1	19657887
ing	I-Disease	-1	19657887
,	O	-1	19657887
tachycardia	B-Disease	D013610	19657887
,	O	-1	19657887
and	O	-1	19657887
arterial	B-Disease	D007022	19657887
hypotension	I-Disease	-1	19657887
after	O	-1	19657887
consum@@	O	-1	19657887
ing	O	-1	19657887
three	O	-1	19657887
gl@@	O	-1	19657887
as@@	O	-1	19657887
ses	O	-1	19657887
of	O	-1	19657887
w@@	O	-1	19657887
ine.	O	-1	19657887
The	O	-1	19657887
patient	O	-1	19657887
reco@@	O	-1	19657887
vered	O	-1	19657887
spont@@	O	-1	19657887
ane@@	O	-1	19657887
ously	O	-1	19657887
in	O	-1	19657887
3	O	-1	19657887
hours	O	-1	19657887
under	O	-1	19657887
sur@@	O	-1	19657887
ve@@	O	-1	19657887
ill@@	O	-1	19657887
ance	O	-1	19657887
in	O	-1	19657887
the	O	-1	19657887
hospit@@	O	-1	19657887
al.	O	-1	19657887
These	O	-1	19657887
cases	O	-1	19657887
con@@	O	-1	19657887
fir@@	O	-1	19657887
m	O	-1	19657887
the	O	-1	19657887
nec@@	O	-1	19657887
ess@@	O	-1	19657887
ity	O	-1	19657887
of	O	-1	19657887
avoid@@	O	-1	19657887
ing	O	-1	19657887
alco@@	B-Chemical	D000431	19657887
hol	I-Chemical	-1	19657887
consum@@	O	-1	19657887
ption	O	-1	19657887
as	O	-1	19657887
recomm@@	O	-1	19657887
en@@	O	-1	19657887
ded	O	-1	19657887
in	O	-1	19657887
the	O	-1	19657887
in@@	O	-1	19657887
struc@@	O	-1	19657887
tions	O	-1	19657887
for	O	-1	19657887
use	O	-1	19657887
of	O	-1	19657887
D@@	B-Chemical	D003484	19657887
or@@	I-Chemical	-1	19657887
me@@	I-Chemical	-1	19657887
x	I-Chemical	-1	19657887
and	O	-1	19657887
of	O	-1	19657887
prevent@@	O	-1	19657887
ing	O	-1	19657887
c@@	O	-1	19657887
utaneous	O	-1	19657887
cont@@	O	-1	19657887
ac@@	O	-1	19657887
t	O	-1	19657887
during	O	-1	19657887
use.	O	-1	19657887

R@@	O	-1	9660111
ep@@	O	-1	9660111
e@@	O	-1	9660111
ated	O	-1	9660111
tri@@	B-Chemical	D014299	9660111
mi@@	I-Chemical	-1	9660111
pramine	I-Chemical	-1	9660111
induc@@	O	-1	9660111
es	O	-1	9660111
dopamine	B-Chemical	D004298	9660111
D@@	O	-1	9660111
2@@	O	-1	9660111
/@@	O	-1	9660111
D@@	O	-1	9660111
3	O	-1	9660111
and	O	-1	9660111
alpha@@	O	-1	9660111
1-@@	O	-1	9660111
adrenergic	O	-1	9660111
up@@	O	-1	9660111
-@@	O	-1	9660111
reg@@	O	-1	9660111
ul@@	O	-1	9660111
ation.	O	-1	9660111
T@@	B-Chemical	D014299	9660111
ri@@	I-Chemical	-1	9660111
mi@@	I-Chemical	-1	9660111
pramine	I-Chemical	-1	9660111
(	O	-1	9660111
TR@@	B-Chemical	D014299	9660111
I	I-Chemical	-1	9660111
),	O	-1	9660111
which	O	-1	9660111
show@@	O	-1	9660111
s	O	-1	9660111
a	O	-1	9660111
clinical	O	-1	9660111
antidepress@@	B-Chemical	D000928	9660111
ant	I-Chemical	-1	9660111
activ@@	O	-1	9660111
ity,	O	-1	9660111
is	O	-1	9660111
chem@@	O	-1	9660111
ically	O	-1	9660111
related	O	-1	9660111
to	O	-1	9660111
im@@	B-Chemical	D007099	9660111
ip@@	I-Chemical	-1	9660111
r@@	I-Chemical	-1	9660111
amine	I-Chemical	-1	9660111
but	O	-1	9660111
does	O	-1	9660111
not	O	-1	9660111
inhib@@	O	-1	9660111
it	O	-1	9660111
the	O	-1	9660111
re@@	O	-1	9660111
u@@	O	-1	9660111
pt@@	O	-1	9660111
ake	O	-1	9660111
of	O	-1	9660111
nor@@	B-Chemical	D009638	9660111
adren@@	I-Chemical	-1	9660111
aline	I-Chemical	-1	9660111
and	O	-1	9660111
5-@@	B-Chemical	D012701	9660111
hydrox@@	I-Chemical	-1	9660111
y@@	I-Chemical	-1	9660111
tr@@	I-Chemical	-1	9660111
y@@	I-Chemical	-1	9660111
pt@@	I-Chemical	-1	9660111
amine	I-Chemical	-1	9660111
,	O	-1	9660111
n@@	O	-1	9660111
or	O	-1	9660111
does	O	-1	9660111
it	O	-1	9660111
induce	O	-1	9660111
beta-@@	O	-1	9660111
adrenergic	O	-1	9660111
do@@	O	-1	9660111
w@@	O	-1	9660111
n@@	O	-1	9660111
-@@	O	-1	9660111
reg@@	O	-1	9660111
ul@@	O	-1	9660111
ation.	O	-1	9660111
The	O	-1	9660111
mechanism	O	-1	9660111
of	O	-1	9660111
its	O	-1	9660111
antidepress@@	B-Chemical	D000928	9660111
ant	I-Chemical	-1	9660111
activity	O	-1	9660111
is	O	-1	9660111
sti@@	O	-1	9660111
ll	O	-1	9660111
un@@	O	-1	9660111
know@@	O	-1	9660111
n@@	O	-1	9660111
.	O	-1	9660111
The	O	-1	9660111
a@@	O	-1	9660111
im	O	-1	9660111
of	O	-1	9660111
the	O	-1	9660111
present	O	-1	9660111
study	O	-1	9660111
was	O	-1	9660111
to	O	-1	9660111
f@@	O	-1	9660111
ind	O	-1	9660111
out	O	-1	9660111
whether	O	-1	9660111
TR@@	B-Chemical	D014299	9660111
I	I-Chemical	-1	9660111
given	O	-1	9660111
repe@@	O	-1	9660111
ated@@	O	-1	9660111
ly	O	-1	9660111
was	O	-1	9660111
able	O	-1	9660111
to	O	-1	9660111
induce	O	-1	9660111
ad@@	O	-1	9660111
ap@@	O	-1	9660111
tive	O	-1	9660111
changes	O	-1	9660111
in	O	-1	9660111
the	O	-1	9660111
dop@@	O	-1	9660111
aminergic	O	-1	9660111
and	O	-1	9660111
alpha@@	O	-1	9660111
1-@@	O	-1	9660111
adrenergic	O	-1	9660111
system@@	O	-1	9660111
s,	O	-1	9660111
demonstrated	O	-1	9660111
by	O	-1	9660111
us	O	-1	9660111
previously	O	-1	9660111
for	O	-1	9660111
various	O	-1	9660111
antidepress@@	B-Chemical	D000928	9660111
ants	I-Chemical	-1	9660111
.	O	-1	9660111
TR@@	B-Chemical	D014299	9660111
I	I-Chemical	-1	9660111
was	O	-1	9660111
given	O	-1	9660111
to	O	-1	9660111
male	O	-1	9660111
Wistar	O	-1	9660111
rats	O	-1	9660111
and	O	-1	9660111
male	O	-1	9660111
Al@@	O	-1	9660111
bin@@	O	-1	9660111
o	O	-1	9660111
S@@	O	-1	9660111
w@@	O	-1	9660111
is@@	O	-1	9660111
s	O	-1	9660111
mice	O	-1	9660111
per@@	O	-1	9660111
or@@	O	-1	9660111
ally	O	-1	9660111
tw@@	O	-1	9660111
ic@@	O	-1	9660111
e	O	-1	9660111
daily	O	-1	9660111
for	O	-1	9660111
14	O	-1	9660111
days.	O	-1	9660111
In	O	-1	9660111
the	O	-1	9660111
acute	O	-1	9660111
experim@@	O	-1	9660111
ent	O	-1	9660111
TR@@	B-Chemical	D014299	9660111
I	I-Chemical	-1	9660111
(@@	O	-1	9660111
given	O	-1	9660111
i.p.@@	O	-1	9660111
)	O	-1	9660111
does	O	-1	9660111
not	O	-1	9660111
antagon@@	O	-1	9660111
iz@@	O	-1	9660111
e	O	-1	9660111
the	O	-1	9660111
res@@	B-Chemical	D012110	9660111
er@@	I-Chemical	-1	9660111
pine	I-Chemical	-1	9660111
hypo@@	B-Disease	D007035	9660111
ther@@	I-Disease	-1	9660111
mia	I-Disease	-1	9660111
in	O	-1	9660111
mice	O	-1	9660111
and	O	-1	9660111
does	O	-1	9660111
not	O	-1	9660111
potenti@@	O	-1	9660111
ate	O	-1	9660111
the	O	-1	9660111
5-@@	B-Chemical	D006916	9660111
hydrox@@	I-Chemical	-1	9660111
y@@	I-Chemical	-1	9660111
tr@@	I-Chemical	-1	9660111
y@@	I-Chemical	-1	9660111
pto@@	I-Chemical	-1	9660111
ph@@	I-Chemical	-1	9660111
an	I-Chemical	-1	9660111
he@@	O	-1	9660111
ad	O	-1	9660111
t@@	O	-1	9660111
witch@@	O	-1	9660111
es	O	-1	9660111
in	O	-1	9660111
rats.	O	-1	9660111
TR@@	B-Chemical	D014299	9660111
I	I-Chemical	-1	9660111
given	O	-1	9660111
repe@@	O	-1	9660111
ated@@	O	-1	9660111
ly	O	-1	9660111
to	O	-1	9660111
rats	O	-1	9660111
increases	O	-1	9660111
the	O	-1	9660111
locomotor	O	-1	9660111
hyperactivity	B-Disease	D006948	9660111
induced	O	-1	9660111
by	O	-1	9660111
d-@@	B-Chemical	D003913	9660111
amphetamine	I-Chemical	-1	9660111
,	O	-1	9660111
qu@@	B-Chemical	D019257	9660111
in@@	I-Chemical	-1	9660111
pi@@	I-Chemical	-1	9660111
role	I-Chemical	-1	9660111
and	O	-1	9660111
(@@	O	-1	9660111
+@@	O	-1	9660111
)-@@	O	-1	9660111
7-@@	O	-1	9660111
hydrox@@	O	-1	9660111
y-@@	O	-1	9660111
di@@	O	-1	9660111
pro@@	O	-1	9660111
py@@	O	-1	9660111
lo@@	O	-1	9660111
amin@@	O	-1	9660111
ot@@	O	-1	9660111
et@@	O	-1	9660111
r@@	O	-1	9660111
al@@	O	-1	9660111
in	O	-1	9660111
(	O	-1	9660111
dopamine	B-Chemical	D004298	9660111
D2	O	-1	9660111
and	O	-1	9660111
D@@	O	-1	9660111
3	O	-1	9660111
effect@@	O	-1	9660111
s@@	O	-1	9660111
).	O	-1	9660111
The	O	-1	9660111
ste@@	O	-1	9660111
re@@	O	-1	9660111
ot@@	O	-1	9660111
y@@	O	-1	9660111
pi@@	O	-1	9660111
es	O	-1	9660111
induced	O	-1	9660111
by	O	-1	9660111
d-@@	B-Chemical	D003913	9660111
amphetamine	I-Chemical	-1	9660111
or	O	-1	9660111
apo@@	B-Chemical	D001058	9660111
morphine	I-Chemical	-1	9660111
are	O	-1	9660111
not	O	-1	9660111
potenti@@	O	-1	9660111
ated	O	-1	9660111
by	O	-1	9660111
TR@@	B-Chemical	D014299	9660111
I	I-Chemical	-1	9660111
.	O	-1	9660111
It	O	-1	9660111
increases	O	-1	9660111
the	O	-1	9660111
behavi@@	O	-1	9660111
our	O	-1	9660111
stimulation	O	-1	9660111
evoked	O	-1	9660111
by	O	-1	9660111
pheny@@	B-Chemical	D010656	9660111
le@@	I-Chemical	-1	9660111
phrine	I-Chemical	-1	9660111
(@@	O	-1	9660111
given	O	-1	9660111
intra@@	O	-1	9660111
ventric@@	O	-1	9660111
ul@@	O	-1	9660111
ar@@	O	-1	9660111
ly@@	O	-1	9660111
)	O	-1	9660111
in	O	-1	9660111
rats,	O	-1	9660111
evaluated	O	-1	9660111
in	O	-1	9660111
the	O	-1	9660111
op@@	O	-1	9660111
en	O	-1	9660111
fi@@	O	-1	9660111
el@@	O	-1	9660111
d	O	-1	9660111
test	O	-1	9660111
as	O	-1	9660111
well	O	-1	9660111
as	O	-1	9660111
the	O	-1	9660111
ag@@	B-Disease	D010554	9660111
gres@@	I-Disease	-1	9660111
si@@	I-Disease	-1	9660111
ven@@	I-Disease	-1	9660111
ess	I-Disease	-1	9660111
evoked	O	-1	9660111
by	O	-1	9660111
clonidine	B-Chemical	D003000	9660111
in	O	-1	9660111
mic@@	O	-1	9660111
e,	O	-1	9660111
both	O	-1	9660111
these	O	-1	9660111
effects	O	-1	9660111
being	O	-1	9660111
mediated	O	-1	9660111
by	O	-1	9660111
an	O	-1	9660111
alpha@@	O	-1	9660111
1-@@	O	-1	9660111
adrenergic	O	-1	9660111
receptor@@	O	-1	9660111
.	O	-1	9660111
It	O	-1	9660111
may	O	-1	9660111
be	O	-1	9660111
concl@@	O	-1	9660111
uded	O	-1	9660111
th@@	O	-1	9660111
at@@	O	-1	9660111
,	O	-1	9660111
like	O	-1	9660111
other	O	-1	9660111
tr@@	O	-1	9660111
ic@@	O	-1	9660111
y@@	O	-1	9660111
cl@@	O	-1	9660111
ic	O	-1	9660111
antidepress@@	B-Chemical	D000928	9660111
ants	I-Chemical	-1	9660111
studied	O	-1	9660111
previ@@	O	-1	9660111
ous@@	O	-1	9660111
ly,	O	-1	9660111
TR@@	B-Chemical	D014299	9660111
I	I-Chemical	-1	9660111
given	O	-1	9660111
repe@@	O	-1	9660111
ated@@	O	-1	9660111
ly	O	-1	9660111
increases	O	-1	9660111
the	O	-1	9660111
respon@@	O	-1	9660111
si@@	O	-1	9660111
ven@@	O	-1	9660111
ess	O	-1	9660111
of	O	-1	9660111
brain	O	-1	9660111
dopamine	B-Chemical	D004298	9660111
D2	O	-1	9660111
and	O	-1	9660111
D@@	O	-1	9660111
3	O	-1	9660111
(@@	O	-1	9660111
locomotor	O	-1	9660111
activity	O	-1	9660111
but	O	-1	9660111
not	O	-1	9660111
ste@@	O	-1	9660111
re@@	O	-1	9660111
ot@@	O	-1	9660111
y@@	O	-1	9660111
py@@	O	-1	9660111
)	O	-1	9660111
as	O	-1	9660111
well	O	-1	9660111
as	O	-1	9660111
alpha@@	O	-1	9660111
1-@@	O	-1	9660111
adrenergic	O	-1	9660111
receptors	O	-1	9660111
to	O	-1	9660111
their	O	-1	9660111
agon@@	O	-1	9660111
ist@@	O	-1	9660111
s.	O	-1	9660111
A	O	-1	9660111
qu@@	O	-1	9660111
es@@	O	-1	9660111
tion	O	-1	9660111
ari@@	O	-1	9660111
ses	O	-1	9660111
whether	O	-1	9660111
the	O	-1	9660111
re@@	O	-1	9660111
u@@	O	-1	9660111
pt@@	O	-1	9660111
ake	O	-1	9660111
inhibition	O	-1	9660111
is	O	-1	9660111
of	O	-1	9660111
any	O	-1	9660111
import@@	O	-1	9660111
ance	O	-1	9660111
to	O	-1	9660111
the	O	-1	9660111
ad@@	O	-1	9660111
ap@@	O	-1	9660111
tive	O	-1	9660111
changes	O	-1	9660111
induced	O	-1	9660111
by	O	-1	9660111
repe@@	O	-1	9660111
ated	O	-1	9660111
antidepress@@	B-Chemical	D000928	9660111
ants	I-Chemical	-1	9660111
,	O	-1	9660111
suggested	O	-1	9660111
to	O	-1	9660111
be	O	-1	9660111
respon@@	O	-1	9660111
sible	O	-1	9660111
for	O	-1	9660111
the	O	-1	9660111
antidepress@@	B-Chemical	D000928	9660111
ant	I-Chemical	-1	9660111
activ@@	O	-1	9660111
ity.	O	-1	9660111

R@@	B-Chemical	D011899	11431197
an@@	I-Chemical	-1	11431197
iti@@	I-Chemical	-1	11431197
d@@	I-Chemical	-1	11431197
ine	I-Chemical	-1	11431197
-induced	O	-1	11431197
acute	O	-1	11431197
interstitial	B-Disease	D009395	11431197
neph@@	I-Disease	-1	11431197
ritis	I-Disease	-1	11431197
in	O	-1	11431197
a	O	-1	11431197
c@@	O	-1	11431197
ad@@	O	-1	11431197
aver@@	O	-1	11431197
ic	O	-1	11431197
renal	O	-1	11431197
allogra@@	O	-1	11431197
f@@	O	-1	11431197
t.	O	-1	11431197
R@@	B-Chemical	D011899	11431197
an@@	I-Chemical	-1	11431197
iti@@	I-Chemical	-1	11431197
d@@	I-Chemical	-1	11431197
ine	I-Chemical	-1	11431197
frequ@@	O	-1	11431197
ently	O	-1	11431197
is	O	-1	11431197
used	O	-1	11431197
for	O	-1	11431197
prevent@@	O	-1	11431197
ing	O	-1	11431197
p@@	O	-1	11431197
ep@@	O	-1	11431197
tic	O	-1	11431197
ul@@	O	-1	11431197
cer@@	O	-1	11431197
ation	O	-1	11431197
after	O	-1	11431197
renal	O	-1	11431197
transplant@@	O	-1	11431197
ation.	O	-1	11431197
This	O	-1	11431197
drug	O	-1	11431197
oc@@	O	-1	11431197
ca@@	O	-1	11431197
sion@@	O	-1	11431197
ally	O	-1	11431197
has	O	-1	11431197
been	O	-1	11431197
associated	O	-1	11431197
with	O	-1	11431197
acute	O	-1	11431197
interstitial	B-Disease	D009395	11431197
neph@@	I-Disease	-1	11431197
ritis	I-Disease	-1	11431197
in	O	-1	11431197
n@@	O	-1	11431197
ative	O	-1	11431197
kidne@@	O	-1	11431197
y@@	O	-1	11431197
s.	O	-1	11431197
There	O	-1	11431197
are	O	-1	11431197
no	O	-1	11431197
similar	O	-1	11431197
reports	O	-1	11431197
with	O	-1	11431197
renal	O	-1	11431197
transplant@@	O	-1	11431197
ation.	O	-1	11431197
We	O	-1	11431197
report	O	-1	11431197
a	O	-1	11431197
case	O	-1	11431197
of	O	-1	11431197
ran@@	B-Chemical	D011899	11431197
iti@@	I-Chemical	-1	11431197
d@@	I-Chemical	-1	11431197
ine	I-Chemical	-1	11431197
-induced	O	-1	11431197
acute	O	-1	11431197
interstitial	B-Disease	D009395	11431197
neph@@	I-Disease	-1	11431197
ritis	I-Disease	-1	11431197
in	O	-1	11431197
a	O	-1	11431197
re@@	O	-1	11431197
ci@@	O	-1	11431197
pi@@	O	-1	11431197
ent	O	-1	11431197
of	O	-1	11431197
a	O	-1	11431197
c@@	O	-1	11431197
ad@@	O	-1	11431197
aver@@	O	-1	11431197
ic	O	-1	11431197
renal	O	-1	11431197
allogra@@	O	-1	11431197
ft	O	-1	11431197
present@@	O	-1	11431197
ing	O	-1	11431197
with	O	-1	11431197
acute	O	-1	11431197
allogra@@	O	-1	11431197
ft	O	-1	11431197
dysfunction	O	-1	11431197
within	O	-1	11431197
4@@	O	-1	11431197
8	O	-1	11431197
hours	O	-1	11431197
of	O	-1	11431197
exposure	O	-1	11431197
to	O	-1	11431197
the	O	-1	11431197
drug.	O	-1	11431197
The	O	-1	11431197
biop@@	O	-1	11431197
sy	O	-1	11431197
spec@@	O	-1	11431197
i@@	O	-1	11431197
men	O	-1	11431197
showed	O	-1	11431197
path@@	O	-1	11431197
o@@	O	-1	11431197
g@@	O	-1	11431197
no@@	O	-1	11431197
mon@@	O	-1	11431197
ic	O	-1	11431197
feat@@	O	-1	11431197
ures@@	O	-1	11431197
,	O	-1	11431197
including	O	-1	11431197
e@@	O	-1	11431197
os@@	O	-1	11431197
in@@	O	-1	11431197
oph@@	O	-1	11431197
il@@	O	-1	11431197
ic	O	-1	11431197
inf@@	O	-1	11431197
iltration	O	-1	11431197
of	O	-1	11431197
the	O	-1	11431197
interstitial	O	-1	11431197
compar@@	O	-1	11431197
t@@	O	-1	11431197
ment.	O	-1	11431197
Al@@	O	-1	11431197
logra@@	O	-1	11431197
ft	O	-1	11431197
function	O	-1	11431197
improved	O	-1	11431197
ra@@	O	-1	11431197
pid@@	O	-1	11431197
ly	O	-1	11431197
and	O	-1	11431197
retur@@	O	-1	11431197
n@@	O	-1	11431197
ed	O	-1	11431197
to	O	-1	11431197
baseline	O	-1	11431197
after	O	-1	11431197
sto@@	O	-1	11431197
pp@@	O	-1	11431197
ing	O	-1	11431197
the	O	-1	11431197
drug.	O	-1	11431197

L@@	O	-1	7449470
ate,	O	-1	7449470
l@@	O	-1	7449470
ate	O	-1	7449470
dox@@	B-Chemical	D004317	7449470
orub@@	I-Chemical	-1	7449470
icin	I-Chemical	-1	7449470
cardi@@	B-Disease	D066126	7449470
otoxicity	I-Disease	-1	7449470
.	O	-1	7449470
C@@	B-Disease	D066126	7449470
ardi@@	I-Disease	-1	7449470
a@@	I-Disease	-1	7449470
c	I-Disease	-1	7449470
toxicity	I-Disease	-1	7449470
is	O	-1	7449470
a	O	-1	7449470
major	O	-1	7449470
complication	O	-1	7449470
which	O	-1	7449470
lim@@	O	-1	7449470
its	O	-1	7449470
the	O	-1	7449470
use	O	-1	7449470
of	O	-1	7449470
adriam@@	B-Chemical	D004317	7449470
ycin	I-Chemical	-1	7449470
as	O	-1	7449470
a	O	-1	7449470
chemo@@	O	-1	7449470
therapeutic	O	-1	7449470
agent@@	O	-1	7449470
.	O	-1	7449470
C@@	B-Disease	D009202	7449470
ardi@@	I-Disease	-1	7449470
om@@	I-Disease	-1	7449470
yo@@	I-Disease	-1	7449470
pathy	I-Disease	-1	7449470
is	O	-1	7449470
frequent	O	-1	7449470
when	O	-1	7449470
the	O	-1	7449470
total	O	-1	7449470
dose	O	-1	7449470
ex@@	O	-1	7449470
ce@@	O	-1	7449470
ed@@	O	-1	7449470
s	O	-1	7449470
6@@	O	-1	7449470
00	O	-1	7449470
mg/m@@	O	-1	7449470
2	O	-1	7449470
and	O	-1	7449470
occur@@	O	-1	7449470
s	O	-1	7449470
within	O	-1	7449470
one	O	-1	7449470
to	O	-1	7449470
six	O	-1	7449470
months	O	-1	7449470
after	O	-1	7449470
cess@@	O	-1	7449470
ation	O	-1	7449470
of	O	-1	7449470
therapy.	O	-1	7449470
A	O	-1	7449470
patient	O	-1	7449470
is	O	-1	7449470
reported	O	-1	7449470
who	O	-1	7449470
developed	O	-1	7449470
progressive	O	-1	7449470
cardi@@	B-Disease	D009202	7449470
om@@	I-Disease	-1	7449470
yo@@	I-Disease	-1	7449470
pathy	I-Disease	-1	7449470
two	O	-1	7449470
and	O	-1	7449470
on@@	O	-1	7449470
e-@@	O	-1	7449470
h@@	O	-1	7449470
al@@	O	-1	7449470
f	O	-1	7449470
years	O	-1	7449470
after	O	-1	7449470
receiving	O	-1	7449470
5@@	O	-1	7449470
8@@	O	-1	7449470
0	O	-1	7449470
mg/m@@	O	-1	7449470
2	O	-1	7449470
which	O	-1	7449470
appa@@	O	-1	7449470
ren@@	O	-1	7449470
tly	O	-1	7449470
re@@	O	-1	7449470
pres@@	O	-1	7449470
ents	O	-1	7449470
lat@@	O	-1	7449470
e,	O	-1	7449470
l@@	O	-1	7449470
ate	O	-1	7449470
cardi@@	B-Disease	D066126	7449470
otoxicity	I-Disease	-1	7449470
.	O	-1	7449470

A@@	B-Chemical	D000086	8170551
ce@@	I-Chemical	-1	8170551
t@@	I-Chemical	-1	8170551
azol@@	I-Chemical	-1	8170551
amide	I-Chemical	-1	8170551
-induced	O	-1	8170551
nephro@@	B-Disease	D053040	8170551
li@@	I-Disease	-1	8170551
th@@	I-Disease	-1	8170551
ia@@	I-Disease	-1	8170551
sis	I-Disease	-1	8170551
:	O	-1	8170551
implic@@	O	-1	8170551
ations	O	-1	8170551
for	O	-1	8170551
treatment	O	-1	8170551
of	O	-1	8170551
neuro@@	B-Disease	D009468	8170551
mus@@	I-Disease	-1	8170551
cular	I-Disease	-1	8170551
disorder@@	I-Disease	-1	8170551
s	I-Disease	-1	8170551
.	O	-1	8170551
C@@	O	-1	8170551
arb@@	O	-1	8170551
onic	O	-1	8170551
an@@	O	-1	8170551
hy@@	O	-1	8170551
d@@	O	-1	8170551
r@@	O	-1	8170551
ase	O	-1	8170551
inhibitors	O	-1	8170551
can	O	-1	8170551
cause	O	-1	8170551
nephro@@	B-Disease	D053040	8170551
li@@	I-Disease	-1	8170551
th@@	I-Disease	-1	8170551
ia@@	I-Disease	-1	8170551
sis	I-Disease	-1	8170551
.	O	-1	8170551
We	O	-1	8170551
studied	O	-1	8170551
20	O	-1	8170551
patients	O	-1	8170551
receiving	O	-1	8170551
long-term	O	-1	8170551
carb@@	O	-1	8170551
onic	O	-1	8170551
an@@	O	-1	8170551
hy@@	O	-1	8170551
d@@	O	-1	8170551
r@@	O	-1	8170551
ase	O	-1	8170551
inhibitor	O	-1	8170551
treatment	O	-1	8170551
for	O	-1	8170551
perio@@	O	-1	8170551
di@@	O	-1	8170551
c	O	-1	8170551
par@@	B-Disease	D010243	8170551
aly@@	I-Disease	-1	8170551
sis	I-Disease	-1	8170551
and	O	-1	8170551
my@@	B-Disease	D009222	8170551
oton@@	I-Disease	-1	8170551
ia	I-Disease	-1	8170551
.	O	-1	8170551
Th@@	O	-1	8170551
ree	O	-1	8170551
patients	O	-1	8170551
on	O	-1	8170551
acet@@	B-Chemical	D000086	8170551
azol@@	I-Chemical	-1	8170551
amide	I-Chemical	-1	8170551
(1@@	O	-1	8170551
5@@	O	-1	8170551
%)	O	-1	8170551
developed	O	-1	8170551
renal	B-Disease	D007669	8170551
calc@@	I-Disease	-1	8170551
ul@@	I-Disease	-1	8170551
i	I-Disease	-1	8170551
.	O	-1	8170551
E@@	O	-1	8170551
x@@	O	-1	8170551
trac@@	O	-1	8170551
or@@	O	-1	8170551
po@@	O	-1	8170551
re@@	O	-1	8170551
al	O	-1	8170551
li@@	O	-1	8170551
th@@	O	-1	8170551
ot@@	O	-1	8170551
ri@@	O	-1	8170551
p@@	O	-1	8170551
sy	O	-1	8170551
suc@@	O	-1	8170551
cess@@	O	-1	8170551
ful@@	O	-1	8170551
ly	O	-1	8170551
re@@	O	-1	8170551
mo@@	O	-1	8170551
ved	O	-1	8170551
a	O	-1	8170551
renal	B-Disease	D007669	8170551
calc@@	I-Disease	-1	8170551
ul@@	I-Disease	-1	8170551
us	I-Disease	-1	8170551
in	O	-1	8170551
one	O	-1	8170551
patient	O	-1	8170551
and	O	-1	8170551
surger@@	O	-1	8170551
y	O	-1	8170551
re@@	O	-1	8170551
mo@@	O	-1	8170551
ved	O	-1	8170551
a	O	-1	8170551
st@@	O	-1	8170551
ag@@	O	-1	8170551
h@@	O	-1	8170551
or@@	O	-1	8170551
n	O	-1	8170551
calc@@	B-Disease	D002137	8170551
ul@@	I-Disease	-1	8170551
us	I-Disease	-1	8170551
in	O	-1	8170551
an@@	O	-1	8170551
o@@	O	-1	8170551
ther@@	O	-1	8170551
,	O	-1	8170551
per@@	O	-1	8170551
mit@@	O	-1	8170551
ting	O	-1	8170551
continu@@	O	-1	8170551
ed	O	-1	8170551
treatment.	O	-1	8170551
R@@	O	-1	8170551
en@@	O	-1	8170551
al	O	-1	8170551
function	O	-1	8170551
remained	O	-1	8170551
normal	O	-1	8170551
in	O	-1	8170551
all	O	-1	8170551
patients.	O	-1	8170551
Ne@@	B-Disease	D053040	8170551
ph@@	I-Disease	-1	8170551
ro@@	I-Disease	-1	8170551
li@@	I-Disease	-1	8170551
th@@	I-Disease	-1	8170551
ia@@	I-Disease	-1	8170551
sis	I-Disease	-1	8170551
is	O	-1	8170551
a	O	-1	8170551
complication	O	-1	8170551
of	O	-1	8170551
acet@@	B-Chemical	D000086	8170551
azol@@	I-Chemical	-1	8170551
amide	I-Chemical	-1	8170551
but	O	-1	8170551
does	O	-1	8170551
not	O	-1	8170551
pre@@	O	-1	8170551
cl@@	O	-1	8170551
ude	O	-1	8170551
its	O	-1	8170551
use.	O	-1	8170551

I@@	O	-1	2476560
s	O	-1	2476560
the	O	-1	2476560
treatment	O	-1	2476560
of	O	-1	2476560
s@@	B-Disease	D012532	2476560
c@@	I-Disease	-1	2476560
ab@@	I-Disease	-1	2476560
i@@	I-Disease	-1	2476560
es	I-Disease	-1	2476560
ha@@	O	-1	2476560
z@@	O	-1	2476560
ar@@	O	-1	2476560
d@@	O	-1	2476560
ous@@	O	-1	2476560
?	O	-1	2476560
Treat@@	O	-1	2476560
ment	O	-1	2476560
for	O	-1	2476560
s@@	B-Disease	D012532	2476560
c@@	I-Disease	-1	2476560
ab@@	I-Disease	-1	2476560
i@@	I-Disease	-1	2476560
es	I-Disease	-1	2476560
is	O	-1	2476560
us@@	O	-1	2476560
ually	O	-1	2476560
initi@@	O	-1	2476560
ated	O	-1	2476560
by	O	-1	2476560
gener@@	O	-1	2476560
al	O	-1	2476560
p@@	O	-1	2476560
rac@@	O	-1	2476560
ti@@	O	-1	2476560
tion@@	O	-1	2476560
er@@	O	-1	2476560
s;	O	-1	2476560
most	O	-1	2476560
con@@	O	-1	2476560
si@@	O	-1	2476560
der	O	-1	2476560
l@@	B-Chemical	D001556	2476560
ind@@	I-Chemical	-1	2476560
ane	I-Chemical	-1	2476560
(	O	-1	2476560
gam@@	B-Chemical	D001556	2476560
ma	I-Chemical	-1	2476560
b@@	I-Chemical	-1	2476560
enz@@	I-Chemical	-1	2476560
ene	I-Chemical	-1	2476560
he@@	I-Chemical	-1	2476560
x@@	I-Chemical	-1	2476560
ac@@	I-Chemical	-1	2476560
h@@	I-Chemical	-1	2476560
lor@@	I-Chemical	-1	2476560
ide	I-Chemical	-1	2476560
)	O	-1	2476560
the	O	-1	2476560
treatment	O	-1	2476560
of	O	-1	2476560
ch@@	O	-1	2476560
o@@	O	-1	2476560
ic@@	O	-1	2476560
e.	O	-1	2476560
L@@	B-Chemical	D001556	2476560
ind@@	I-Chemical	-1	2476560
ane	I-Chemical	-1	2476560
is	O	-1	2476560
also	O	-1	2476560
wi@@	O	-1	2476560
de@@	O	-1	2476560
ly	O	-1	2476560
used	O	-1	2476560
as	O	-1	2476560
an	O	-1	2476560
ag@@	O	-1	2476560
r@@	O	-1	2476560
ic@@	O	-1	2476560
ult@@	O	-1	2476560
ural	O	-1	2476560
and	O	-1	2476560
ind@@	O	-1	2476560
u@@	O	-1	2476560
stri@@	O	-1	2476560
al	O	-1	2476560
p@@	O	-1	2476560
es@@	O	-1	2476560
tic@@	O	-1	2476560
ide@@	O	-1	2476560
,	O	-1	2476560
and	O	-1	2476560
as	O	-1	2476560
a	O	-1	2476560
result	O	-1	2476560
the	O	-1	2476560
toxic	O	-1	2476560
prof@@	O	-1	2476560
ile	O	-1	2476560
of	O	-1	2476560
this	O	-1	2476560
in@@	O	-1	2476560
sec@@	O	-1	2476560
tic@@	O	-1	2476560
ide	O	-1	2476560
is	O	-1	2476560
well	O	-1	2476560
under@@	O	-1	2476560
sto@@	O	-1	2476560
o@@	O	-1	2476560
d.	O	-1	2476560
E@@	O	-1	2476560
v@@	O	-1	2476560
idence	O	-1	2476560
is	O	-1	2476560
accum@@	O	-1	2476560
ul@@	O	-1	2476560
ating	O	-1	2476560
that	O	-1	2476560
l@@	B-Chemical	D001556	2476560
ind@@	I-Chemical	-1	2476560
ane	I-Chemical	-1	2476560
can	O	-1	2476560
be	O	-1	2476560
toxic	B-Disease	D002493	2476560
to	I-Disease	-1	2476560
the	I-Disease	-1	2476560
central	I-Disease	-1	2476560
ner@@	I-Disease	-1	2476560
v@@	I-Disease	-1	2476560
ous	I-Disease	-1	2476560
system	I-Disease	-1	2476560
and	O	-1	2476560
may	O	-1	2476560
be	O	-1	2476560
associated	O	-1	2476560
with	O	-1	2476560
ap@@	B-Disease	D000741	2476560
las@@	I-Disease	-1	2476560
tic	I-Disease	-1	2476560
ana@@	I-Disease	-1	2476560
emia	I-Disease	-1	2476560
.	O	-1	2476560
Pre@@	O	-1	2476560
par@@	O	-1	2476560
ations	O	-1	2476560
containing	O	-1	2476560
l@@	B-Chemical	D001556	2476560
ind@@	I-Chemical	-1	2476560
ane	I-Chemical	-1	2476560
continu@@	O	-1	2476560
e	O	-1	2476560
to	O	-1	2476560
be	O	-1	2476560
s@@	O	-1	2476560
old	O	-1	2476560
over	O	-1	2476560
the	O	-1	2476560
coun@@	O	-1	2476560
ter	O	-1	2476560
and	O	-1	2476560
may	O	-1	2476560
re@@	O	-1	2476560
present	O	-1	2476560
a	O	-1	2476560
ha@@	O	-1	2476560
z@@	O	-1	2476560
ard	O	-1	2476560
to	O	-1	2476560
po@@	O	-1	2476560
or@@	O	-1	2476560
ly	O	-1	2476560
inf@@	O	-1	2476560
orm@@	O	-1	2476560
ed	O	-1	2476560
patients.	O	-1	2476560
This	O	-1	2476560
literat@@	O	-1	2476560
ure	O	-1	2476560
revie@@	O	-1	2476560
w	O	-1	2476560
suggests	O	-1	2476560
that	O	-1	2476560
gener@@	O	-1	2476560
al	O	-1	2476560
p@@	O	-1	2476560
rac@@	O	-1	2476560
ti@@	O	-1	2476560
tion@@	O	-1	2476560
ers	O	-1	2476560
should	O	-1	2476560
prescri@@	O	-1	2476560
be	O	-1	2476560
s@@	O	-1	2476560
c@@	O	-1	2476560
ab@@	O	-1	2476560
ici@@	O	-1	2476560
des	O	-1	2476560
with	O	-1	2476560
increased	O	-1	2476560
cau@@	O	-1	2476560
tion	O	-1	2476560
for	O	-1	2476560
cer@@	O	-1	2476560
t@@	O	-1	2476560
ain	O	-1	2476560
at@@	O	-1	2476560
-@@	O	-1	2476560
risk	O	-1	2476560
group@@	O	-1	2476560
s,	O	-1	2476560
and	O	-1	2476560
gi@@	O	-1	2476560
ve	O	-1	2476560
ade@@	O	-1	2476560
qu@@	O	-1	2476560
ate	O	-1	2476560
war@@	O	-1	2476560
n@@	O	-1	2476560
ings	O	-1	2476560
reg@@	O	-1	2476560
ar@@	O	-1	2476560
ding	O	-1	2476560
potential	O	-1	2476560
toxicity	B-Disease	D064420	2476560
.	O	-1	2476560

An@@	O	-1	19803309
a@@	O	-1	19803309
esthe@@	O	-1	19803309
ti@@	O	-1	19803309
st@@	O	-1	19803309
s@@	O	-1	19803309
'	O	-1	19803309
n@@	O	-1	19803309
igh@@	O	-1	19803309
t@@	O	-1	19803309
ma@@	O	-1	19803309
re@@	O	-1	19803309
:	O	-1	19803309
mas@@	B-Disease	D014313	19803309
se@@	I-Disease	-1	19803309
ter	I-Disease	-1	19803309
sp@@	I-Disease	-1	19803309
as@@	I-Disease	-1	19803309
m	I-Disease	-1	19803309
after	O	-1	19803309
induction	O	-1	19803309
in	O	-1	19803309
an	O	-1	19803309
un@@	O	-1	19803309
diagnos@@	O	-1	19803309
ed	O	-1	19803309
case	O	-1	19803309
of	O	-1	19803309
my@@	B-Disease	D009224	19803309
oton@@	I-Disease	-1	19803309
ia	I-Disease	-1	19803309
con@@	I-Disease	-1	19803309
gen@@	I-Disease	-1	19803309
it@@	I-Disease	-1	19803309
a	I-Disease	-1	19803309
.	O	-1	19803309
We	O	-1	19803309
report	O	-1	19803309
an	O	-1	19803309
un@@	O	-1	19803309
diagnos@@	O	-1	19803309
ed	O	-1	19803309
case	O	-1	19803309
of	O	-1	19803309
my@@	B-Disease	D009224	19803309
oton@@	I-Disease	-1	19803309
ia	I-Disease	-1	19803309
con@@	I-Disease	-1	19803309
gen@@	I-Disease	-1	19803309
it@@	I-Disease	-1	19803309
a	I-Disease	-1	19803309
in	O	-1	19803309
a	O	-1	19803309
2@@	O	-1	19803309
4-@@	O	-1	19803309
year-old	O	-1	19803309
previously	O	-1	19803309
healthy	O	-1	19803309
pri@@	O	-1	19803309
migra@@	O	-1	19803309
vid@@	O	-1	19803309
a,	O	-1	19803309
who	O	-1	19803309
developed	O	-1	19803309
lif@@	O	-1	19803309
e	O	-1	19803309
th@@	O	-1	19803309
reat@@	O	-1	19803309
en@@	O	-1	19803309
ing	O	-1	19803309
mas@@	B-Disease	D014313	19803309
se@@	I-Disease	-1	19803309
ter	I-Disease	-1	19803309
sp@@	I-Disease	-1	19803309
as@@	I-Disease	-1	19803309
m	I-Disease	-1	19803309
following	O	-1	19803309
a	O	-1	19803309
standard	O	-1	19803309
dose	O	-1	19803309
of	O	-1	19803309
intravenous	O	-1	19803309
su@@	B-Chemical	D013390	19803309
xameth@@	I-Chemical	-1	19803309
oni@@	I-Chemical	-1	19803309
um	I-Chemical	-1	19803309
for	O	-1	19803309
induction	O	-1	19803309
of	O	-1	19803309
anaesthe@@	O	-1	19803309
sia.	O	-1	19803309
N@@	O	-1	19803309
either	O	-1	19803309
the	O	-1	19803309
patient	O	-1	19803309
n@@	O	-1	19803309
or	O	-1	19803309
the	O	-1	19803309
anaesthe@@	O	-1	19803309
ti@@	O	-1	19803309
st	O	-1	19803309
was	O	-1	19803309
aw@@	O	-1	19803309
are	O	-1	19803309
of	O	-1	19803309
the	O	-1	19803309
diagnosis	O	-1	19803309
before	O	-1	19803309
this	O	-1	19803309
potenti@@	O	-1	19803309
ally	O	-1	19803309
le@@	O	-1	19803309
th@@	O	-1	19803309
al	O	-1	19803309
complication	O	-1	19803309
occur@@	O	-1	19803309
red.	O	-1	19803309

T@@	B-Disease	D064420	18821488
oxic@@	I-Disease	-1	18821488
ity	I-Disease	-1	18821488
in	O	-1	18821488
rh@@	O	-1	18821488
es@@	O	-1	18821488
us	O	-1	18821488
mon@@	O	-1	18821488
ke@@	O	-1	18821488
ys	O	-1	18821488
following	O	-1	18821488
administration	O	-1	18821488
of	O	-1	18821488
the	O	-1	18821488
8@@	B-Chemical	C080436	18821488
-@@	I-Chemical	-1	18821488
amino@@	I-Chemical	-1	18821488
qu@@	I-Chemical	-1	18821488
in@@	I-Chemical	-1	18821488
ol@@	I-Chemical	-1	18821488
ine	I-Chemical	-1	18821488
8@@	B-Chemical	C068820	18821488
-@@	I-Chemical	-1	18821488
[@@	I-Chemical	-1	18821488
(@@	I-Chemical	-1	18821488
4-@@	I-Chemical	-1	18821488
amino@@	I-Chemical	-1	18821488
-@@	I-Chemical	-1	18821488
l@@	I-Chemical	-1	18821488
-@@	I-Chemical	-1	18821488
methyl@@	I-Chemical	-1	18821488
but@@	I-Chemical	-1	18821488
yl@@	I-Chemical	-1	18821488
)@@	I-Chemical	-1	18821488
amino@@	I-Chemical	-1	18821488
]@@	I-Chemical	-1	18821488
-	I-Chemical	-1	18821488
5-@@	I-Chemical	-1	18821488
(@@	I-Chemical	-1	18821488
l@@	I-Chemical	-1	18821488
-@@	I-Chemical	-1	18821488
he@@	I-Chemical	-1	18821488
x@@	I-Chemical	-1	18821488
y@@	I-Chemical	-1	18821488
lo@@	I-Chemical	-1	18821488
x@@	I-Chemical	-1	18821488
y@@	I-Chemical	-1	18821488
)-@@	I-Chemical	-1	18821488
6-@@	I-Chemical	-1	18821488
meth@@	I-Chemical	-1	18821488
ox@@	I-Chemical	-1	18821488
y-@@	I-Chemical	-1	18821488
4-@@	I-Chemical	-1	18821488
methyl@@	I-Chemical	-1	18821488
qu@@	I-Chemical	-1	18821488
in@@	I-Chemical	-1	18821488
ol@@	I-Chemical	-1	18821488
ine	I-Chemical	-1	18821488
(	O	-1	18821488
W@@	B-Chemical	C068820	18821488
R@@	I-Chemical	-1	18821488
2@@	I-Chemical	-1	18821488
4@@	I-Chemical	-1	18821488
25@@	I-Chemical	-1	18821488
11	I-Chemical	-1	18821488
).	O	-1	18821488
IN@@	O	-1	18821488
T@@	O	-1	18821488
RO@@	O	-1	18821488
D@@	O	-1	18821488
U@@	O	-1	18821488
C@@	O	-1	18821488
T@@	O	-1	18821488
ION@@	O	-1	18821488
:	O	-1	18821488
M@@	O	-1	18821488
any	O	-1	18821488
subst@@	O	-1	18821488
anc@@	O	-1	18821488
es	O	-1	18821488
that	O	-1	18821488
form	O	-1	18821488
meth@@	O	-1	18821488
em@@	O	-1	18821488
o@@	O	-1	18821488
globin	O	-1	18821488
(@@	O	-1	18821488
M@@	O	-1	18821488
H@@	O	-1	18821488
b@@	O	-1	18821488
)	O	-1	18821488
eff@@	O	-1	18821488
ectively	O	-1	18821488
coun@@	O	-1	18821488
ter	O	-1	18821488
cy@@	O	-1	18821488
an@@	O	-1	18821488
ide	O	-1	18821488
(C@@	O	-1	18821488
N@@	O	-1	18821488
)	O	-1	18821488
toxicity	B-Disease	D064420	18821488
.	O	-1	18821488
Although	O	-1	18821488
M@@	O	-1	18821488
H@@	O	-1	18821488
b	O	-1	18821488
form@@	O	-1	18821488
ers	O	-1	18821488
are	O	-1	18821488
gener@@	O	-1	18821488
ally	O	-1	18821488
ap@@	O	-1	18821488
pl@@	O	-1	18821488
ied	O	-1	18821488
as	O	-1	18821488
treat@@	O	-1	18821488
ments	O	-1	18821488
for	O	-1	18821488
C@@	O	-1	18821488
N	O	-1	18821488
po@@	B-Disease	D011041	18821488
is@@	I-Disease	-1	18821488
on@@	I-Disease	-1	18821488
ing	I-Disease	-1	18821488
,	O	-1	18821488
it	O	-1	18821488
has	O	-1	18821488
been	O	-1	18821488
pro@@	O	-1	18821488
pos@@	O	-1	18821488
ed	O	-1	18821488
that	O	-1	18821488
a	O	-1	18821488
st@@	O	-1	18821488
able@@	O	-1	18821488
,	O	-1	18821488
long@@	O	-1	18821488
-@@	O	-1	18821488
act@@	O	-1	18821488
ing	O	-1	18821488
M@@	O	-1	18821488
H@@	O	-1	18821488
b	O	-1	18821488
form@@	O	-1	18821488
er	O	-1	18821488
could	O	-1	18821488
ser@@	O	-1	18821488
ve	O	-1	18821488
as	O	-1	18821488
a	O	-1	18821488
C@@	O	-1	18821488
N	O	-1	18821488
pre@@	O	-1	18821488
treatment.	O	-1	18821488
U@@	O	-1	18821488
s@@	O	-1	18821488
ing	O	-1	18821488
this	O	-1	18821488
r@@	O	-1	18821488
ation@@	O	-1	18821488
al@@	O	-1	18821488
e,	O	-1	18821488
the	O	-1	18821488
8@@	B-Chemical	C080436	18821488
-@@	I-Chemical	-1	18821488
amino@@	I-Chemical	-1	18821488
qu@@	I-Chemical	-1	18821488
in@@	I-Chemical	-1	18821488
ol@@	I-Chemical	-1	18821488
ine	I-Chemical	-1	18821488
W@@	B-Chemical	C068820	18821488
R@@	I-Chemical	-1	18821488
2@@	I-Chemical	-1	18821488
4@@	I-Chemical	-1	18821488
25@@	I-Chemical	-1	18821488
11	I-Chemical	-1	18821488
,	O	-1	18821488
a	O	-1	18821488
pot@@	O	-1	18821488
ent	O	-1	18821488
long@@	O	-1	18821488
-@@	O	-1	18821488
l@@	O	-1	18821488
ast@@	O	-1	18821488
ing	O	-1	18821488
M@@	O	-1	18821488
H@@	O	-1	18821488
b	O	-1	18821488
form@@	O	-1	18821488
er	O	-1	18821488
in	O	-1	18821488
ro@@	O	-1	18821488
d@@	O	-1	18821488
ents	O	-1	18821488
and	O	-1	18821488
be@@	O	-1	18821488
ag@@	O	-1	18821488
le	O	-1	18821488
dog@@	O	-1	18821488
s,	O	-1	18821488
was	O	-1	18821488
studied	O	-1	18821488
in	O	-1	18821488
the	O	-1	18821488
rh@@	O	-1	18821488
es@@	O	-1	18821488
us	O	-1	18821488
mon@@	O	-1	18821488
ke@@	O	-1	18821488
y	O	-1	18821488
for	O	-1	18821488
adv@@	O	-1	18821488
anced	O	-1	18821488
development	O	-1	18821488
as	O	-1	18821488
a	O	-1	18821488
potential	O	-1	18821488
C@@	O	-1	18821488
N	O	-1	18821488
pre@@	O	-1	18821488
treatment.	O	-1	18821488
METHODS:	O	-1	18821488
In	O	-1	18821488
this	O	-1	18821488
study,	O	-1	18821488
W@@	B-Chemical	C068820	18821488
R@@	I-Chemical	-1	18821488
2@@	I-Chemical	-1	18821488
4@@	I-Chemical	-1	18821488
25@@	I-Chemical	-1	18821488
11	I-Chemical	-1	18821488
was	O	-1	18821488
administered	O	-1	18821488
intra@@	O	-1	18821488
ven@@	O	-1	18821488
ously	O	-1	18821488
(@@	O	-1	18821488
I@@	O	-1	18821488
V@@	O	-1	18821488
)	O	-1	18821488
in	O	-1	18821488
2	O	-1	18821488
female	O	-1	18821488
and	O	-1	18821488
4	O	-1	18821488
male	O	-1	18821488
rh@@	O	-1	18821488
es@@	O	-1	18821488
us	O	-1	18821488
mon@@	O	-1	18821488
ke@@	O	-1	18821488
ys	O	-1	18821488
in	O	-1	18821488
doses	O	-1	18821488
of	O	-1	18821488
3.@@	O	-1	18821488
5	O	-1	18821488
and/or	O	-1	18821488
7.@@	O	-1	18821488
0	O	-1	18821488
mg/kg@@	O	-1	18821488
;	O	-1	18821488
a	O	-1	18821488
single	O	-1	18821488
male	O	-1	18821488
also	O	-1	18821488
received	O	-1	18821488
W@@	B-Chemical	C068820	18821488
R@@	I-Chemical	-1	18821488
2@@	I-Chemical	-1	18821488
4@@	I-Chemical	-1	18821488
25@@	I-Chemical	-1	18821488
11	I-Chemical	-1	18821488
or@@	O	-1	18821488
ally	O	-1	18821488
(P@@	O	-1	18821488
O@@	O	-1	18821488
)	O	-1	18821488
at	O	-1	18821488
7.@@	O	-1	18821488
0	O	-1	18821488
mg/kg@@	O	-1	18821488
.	O	-1	18821488
He@@	O	-1	18821488
al@@	O	-1	18821488
th	O	-1	18821488
status	O	-1	18821488
and	O	-1	18821488
M@@	O	-1	18821488
H@@	O	-1	18821488
b	O	-1	18821488
levels	O	-1	18821488
were	O	-1	18821488
monit@@	O	-1	18821488
o@@	O	-1	18821488
red	O	-1	18821488
following	O	-1	18821488
expos@@	O	-1	18821488
ure.	O	-1	18821488
RESULTS:	O	-1	18821488
The	O	-1	18821488
sel@@	O	-1	18821488
ected	O	-1	18821488
doses	O	-1	18821488
of	O	-1	18821488
W@@	B-Chemical	C068820	18821488
R@@	I-Chemical	-1	18821488
2@@	I-Chemical	-1	18821488
4@@	I-Chemical	-1	18821488
25@@	I-Chemical	-1	18821488
11	I-Chemical	-1	18821488
,	O	-1	18821488
which	O	-1	18821488
produced	O	-1	18821488
significant	O	-1	18821488
meth@@	B-Disease	D008708	18821488
em@@	I-Disease	-1	18821488
o@@	I-Disease	-1	18821488
glo@@	I-Disease	-1	18821488
b@@	I-Disease	-1	18821488
ine@@	I-Disease	-1	18821488
mia	I-Disease	-1	18821488
in	O	-1	18821488
be@@	O	-1	18821488
ag@@	O	-1	18821488
le	O	-1	18821488
dog@@	O	-1	18821488
s	O	-1	18821488
in	O	-1	18821488
ear@@	O	-1	18821488
li@@	O	-1	18821488
er	O	-1	18821488
studies	O	-1	18821488
con@@	O	-1	18821488
duc@@	O	-1	18821488
ted	O	-1	18821488
el@@	O	-1	18821488
se@@	O	-1	18821488
whe@@	O	-1	18821488
re,	O	-1	18821488
produced	O	-1	18821488
very	O	-1	18821488
lit@@	O	-1	18821488
t@@	O	-1	18821488
le	O	-1	18821488
M@@	O	-1	18821488
H@@	O	-1	18821488
b	O	-1	18821488
(@@	O	-1	18821488
mean	O	-1	18821488
<	O	-1	18821488
2.@@	O	-1	18821488
0@@	O	-1	18821488
%)	O	-1	18821488
in	O	-1	18821488
the	O	-1	18821488
rh@@	O	-1	18821488
es@@	O	-1	18821488
us	O	-1	18821488
mon@@	O	-1	18821488
ke@@	O	-1	18821488
y.	O	-1	18821488
F@@	O	-1	18821488
ur@@	O	-1	18821488
ther@@	O	-1	18821488
mo@@	O	-1	18821488
re,	O	-1	18821488
transi@@	O	-1	18821488
ent	O	-1	18821488
hemo@@	B-Disease	D006456	18821488
glo@@	I-Disease	-1	18821488
bin@@	I-Disease	-1	18821488
uria	I-Disease	-1	18821488
was	O	-1	18821488
not@@	O	-1	18821488
ed	O	-1	18821488
appro@@	O	-1	18821488
xim@@	O	-1	18821488
ately	O	-1	18821488
60	O	-1	18821488
minutes	O	-1	18821488
post@@	O	-1	18821488
injection	O	-1	18821488
of	O	-1	18821488
W@@	B-Chemical	C068820	18821488
R@@	I-Chemical	-1	18821488
2@@	I-Chemical	-1	18821488
4@@	I-Chemical	-1	18821488
25@@	I-Chemical	-1	18821488
11	I-Chemical	-1	18821488
(@@	O	-1	18821488
3.@@	O	-1	18821488
5	O	-1	18821488
or	O	-1	18821488
7.@@	O	-1	18821488
0	O	-1	18821488
mg/kg@@	O	-1	18821488
),	O	-1	18821488
and	O	-1	18821488
2	O	-1	18821488
le@@	O	-1	18821488
thal@@	O	-1	18821488
ities	O	-1	18821488
occurred	O	-1	18821488
(@@	O	-1	18821488
one	O	-1	18821488
IV	O	-1	18821488
and	O	-1	18821488
one	O	-1	18821488
P@@	O	-1	18821488
O@@	O	-1	18821488
)	O	-1	18821488
following	O	-1	18821488
the	O	-1	18821488
7.@@	O	-1	18821488
0	O	-1	18821488
mg/kg	O	-1	18821488
dose.	O	-1	18821488
M@@	B-Disease	D009212	18821488
yo@@	I-Disease	-1	18821488
glo@@	I-Disease	-1	18821488
bin@@	I-Disease	-1	18821488
uria	I-Disease	-1	18821488
was	O	-1	18821488
also	O	-1	18821488
observed	O	-1	18821488
following	O	-1	18821488
the	O	-1	18821488
7.@@	O	-1	18821488
0	O	-1	18821488
mg/kg	O	-1	18821488
dose.	O	-1	18821488
H@@	O	-1	18821488
ist@@	O	-1	18821488
o@@	O	-1	18821488
path@@	O	-1	18821488
ology	O	-1	18821488
analy@@	O	-1	18821488
ses	O	-1	18821488
in	O	-1	18821488
the	O	-1	18821488
2	O	-1	18821488
animals	O	-1	18821488
that	O	-1	18821488
di@@	O	-1	18821488
ed	O	-1	18821488
revealed	O	-1	18821488
liver	B-Disease	D056486	18821488
and	I-Disease	-1	18821488
kidney	I-Disease	-1	18821488
toxicity	I-Disease	-1	18821488
liver	B-Disease	D007674	18821488
and	I-Disease	-1	18821488
kidney	I-Disease	-1	18821488
toxicity	I-Disease	-1	18821488
,	O	-1	18821488
with	O	-1	18821488
greater	O	-1	18821488
severity	O	-1	18821488
in	O	-1	18821488
the	O	-1	18821488
or@@	O	-1	18821488
all@@	O	-1	18821488
y-@@	O	-1	18821488
treated	O	-1	18821488
anim@@	O	-1	18821488
al.	O	-1	18821488
CONCLUSIONS:	O	-1	18821488
These	O	-1	18821488
data	O	-1	18821488
demon@@	O	-1	18821488
st@@	O	-1	18821488
rate	O	-1	18821488
direct	O	-1	18821488
and/or	O	-1	18821488
in@@	O	-1	18821488
direct	O	-1	18821488
drug@@	O	-1	18821488
-induced	O	-1	18821488
toxicity	B-Disease	D064420	18821488
.	O	-1	18821488
It	O	-1	18821488
is	O	-1	18821488
concl@@	O	-1	18821488
uded	O	-1	18821488
that	O	-1	18821488
W@@	B-Chemical	C068820	18821488
R@@	I-Chemical	-1	18821488
2@@	I-Chemical	-1	18821488
4@@	I-Chemical	-1	18821488
25@@	I-Chemical	-1	18821488
11	I-Chemical	-1	18821488
should	O	-1	18821488
not	O	-1	18821488
be	O	-1	18821488
pur@@	O	-1	18821488
su@@	O	-1	18821488
ed	O	-1	18821488
as	O	-1	18821488
a	O	-1	18821488
pretreatment	O	-1	18821488
for	O	-1	18821488
C@@	O	-1	18821488
N	O	-1	18821488
po@@	B-Disease	D011041	18821488
is@@	I-Disease	-1	18821488
on@@	I-Disease	-1	18821488
ing	I-Disease	-1	18821488
un@@	O	-1	18821488
less	O	-1	18821488
the	O	-1	18821488
anti@@	O	-1	18821488
-@@	O	-1	18821488
C@@	O	-1	18821488
N	O	-1	18821488
character@@	O	-1	18821488
is@@	O	-1	18821488
tics	O	-1	18821488
of	O	-1	18821488
this	O	-1	18821488
comp@@	O	-1	18821488
ound	O	-1	18821488
can	O	-1	18821488
be	O	-1	18821488
suc@@	O	-1	18821488
cess@@	O	-1	18821488
ful@@	O	-1	18821488
ly	O	-1	18821488
dis@@	O	-1	18821488
s@@	O	-1	18821488
oci@@	O	-1	18821488
ated	O	-1	18821488
from	O	-1	18821488
those	O	-1	18821488
produc@@	O	-1	18821488
ing	O	-1	18821488
un@@	O	-1	18821488
desi@@	O	-1	18821488
ra@@	O	-1	18821488
ble	O	-1	18821488
toxicity	B-Disease	D064420	18821488
.	O	-1	18821488

Ne@@	O	-1	8372922
uro@@	O	-1	8372922
plas@@	O	-1	8372922
tic@@	O	-1	8372922
ity	O	-1	8372922
of	O	-1	8372922
the	O	-1	8372922
ad@@	O	-1	8372922
ult	O	-1	8372922
prim@@	O	-1	8372922
ate	O	-1	8372922
a@@	O	-1	8372922
ud@@	O	-1	8372922
it@@	O	-1	8372922
ory	O	-1	8372922
cor@@	O	-1	8372922
te@@	O	-1	8372922
x	O	-1	8372922
following	O	-1	8372922
co@@	O	-1	8372922
ch@@	O	-1	8372922
le@@	O	-1	8372922
ar	O	-1	8372922
hearing	B-Disease	D034381	8372922
loss	I-Disease	-1	8372922
.	O	-1	8372922
T@@	O	-1	8372922
on@@	O	-1	8372922
ot@@	O	-1	8372922
op@@	O	-1	8372922
ic	O	-1	8372922
org@@	O	-1	8372922
an@@	O	-1	8372922
ization	O	-1	8372922
is	O	-1	8372922
an	O	-1	8372922
es@@	O	-1	8372922
sen@@	O	-1	8372922
tial	O	-1	8372922
feat@@	O	-1	8372922
ure	O	-1	8372922
of	O	-1	8372922
the	O	-1	8372922
prim@@	O	-1	8372922
ary	O	-1	8372922
a@@	O	-1	8372922
ud@@	O	-1	8372922
it@@	O	-1	8372922
ory	O	-1	8372922
a@@	O	-1	8372922
re@@	O	-1	8372922
a	O	-1	8372922
(A@@	O	-1	8372922
1)	O	-1	8372922
of	O	-1	8372922
prim@@	O	-1	8372922
ate	O	-1	8372922
cor@@	O	-1	8372922
t@@	O	-1	8372922
ex@@	O	-1	8372922
.	O	-1	8372922
In	O	-1	8372922
A@@	O	-1	8372922
1	O	-1	8372922
of	O	-1	8372922
mac@@	O	-1	8372922
a@@	O	-1	8372922
qu@@	O	-1	8372922
e	O	-1	8372922
mon@@	O	-1	8372922
ke@@	O	-1	8372922
y@@	O	-1	8372922
s,	O	-1	8372922
low	O	-1	8372922
frequ@@	O	-1	8372922
en@@	O	-1	8372922
ci@@	O	-1	8372922
es	O	-1	8372922
are	O	-1	8372922
re@@	O	-1	8372922
presented	O	-1	8372922
ro@@	O	-1	8372922
stro@@	O	-1	8372922
lat@@	O	-1	8372922
er@@	O	-1	8372922
ally	O	-1	8372922
and	O	-1	8372922
high	O	-1	8372922
frequ@@	O	-1	8372922
en@@	O	-1	8372922
ci@@	O	-1	8372922
es	O	-1	8372922
are	O	-1	8372922
re@@	O	-1	8372922
presented	O	-1	8372922
cau@@	O	-1	8372922
do@@	O	-1	8372922
medi@@	O	-1	8372922
all@@	O	-1	8372922
y.	O	-1	8372922
The	O	-1	8372922
pur@@	O	-1	8372922
p@@	O	-1	8372922
ose	O	-1	8372922
of	O	-1	8372922
this	O	-1	8372922
study	O	-1	8372922
was	O	-1	8372922
to	O	-1	8372922
determine	O	-1	8372922
if	O	-1	8372922
changes	O	-1	8372922
occ@@	O	-1	8372922
ur	O	-1	8372922
in	O	-1	8372922
this	O	-1	8372922
t@@	O	-1	8372922
on@@	O	-1	8372922
ot@@	O	-1	8372922
op@@	O	-1	8372922
ic	O	-1	8372922
org@@	O	-1	8372922
an@@	O	-1	8372922
ization	O	-1	8372922
following	O	-1	8372922
co@@	O	-1	8372922
ch@@	O	-1	8372922
le@@	O	-1	8372922
ar	O	-1	8372922
hearing	B-Disease	D034381	8372922
loss	I-Disease	-1	8372922
.	O	-1	8372922
U@@	O	-1	8372922
n@@	O	-1	8372922
der	O	-1	8372922
anesthe@@	O	-1	8372922
si@@	O	-1	8372922
a,	O	-1	8372922
the	O	-1	8372922
su@@	O	-1	8372922
peri@@	O	-1	8372922
or	O	-1	8372922
tempor@@	O	-1	8372922
al	O	-1	8372922
g@@	O	-1	8372922
y@@	O	-1	8372922
ru@@	O	-1	8372922
s	O	-1	8372922
of	O	-1	8372922
ad@@	O	-1	8372922
ult	O	-1	8372922
mac@@	O	-1	8372922
a@@	O	-1	8372922
qu@@	O	-1	8372922
e	O	-1	8372922
mon@@	O	-1	8372922
ke@@	O	-1	8372922
ys	O	-1	8372922
was	O	-1	8372922
ex@@	O	-1	8372922
po@@	O	-1	8372922
se@@	O	-1	8372922
d,	O	-1	8372922
and	O	-1	8372922
the	O	-1	8372922
t@@	O	-1	8372922
on@@	O	-1	8372922
ot@@	O	-1	8372922
op@@	O	-1	8372922
ic	O	-1	8372922
org@@	O	-1	8372922
an@@	O	-1	8372922
ization	O	-1	8372922
of	O	-1	8372922
A@@	O	-1	8372922
1	O	-1	8372922
was	O	-1	8372922
m@@	O	-1	8372922
app@@	O	-1	8372922
ed	O	-1	8372922
using	O	-1	8372922
con@@	O	-1	8372922
ven@@	O	-1	8372922
tional	O	-1	8372922
micro@@	O	-1	8372922
electro@@	O	-1	8372922
de	O	-1	8372922
recor@@	O	-1	8372922
ding	O	-1	8372922
t@@	O	-1	8372922
ech@@	O	-1	8372922
n@@	O	-1	8372922
i@@	O	-1	8372922
qu@@	O	-1	8372922
es.	O	-1	8372922
F@@	O	-1	8372922
ol@@	O	-1	8372922
low@@	O	-1	8372922
ing	O	-1	8372922
reco@@	O	-1	8372922
ver@@	O	-1	8372922
y,	O	-1	8372922
the	O	-1	8372922
mon@@	O	-1	8372922
ke@@	O	-1	8372922
ys	O	-1	8372922
were	O	-1	8372922
sel@@	O	-1	8372922
ectively	O	-1	8372922
de@@	O	-1	8372922
af@@	O	-1	8372922
en@@	O	-1	8372922
ed	O	-1	8372922
for	O	-1	8372922
high	O	-1	8372922
frequ@@	O	-1	8372922
en@@	O	-1	8372922
ci@@	O	-1	8372922
es	O	-1	8372922
using	O	-1	8372922
k@@	B-Chemical	D007612	8372922
an@@	I-Chemical	-1	8372922
am@@	I-Chemical	-1	8372922
ycin	I-Chemical	-1	8372922
and	O	-1	8372922
f@@	B-Chemical	D005665	8372922
uro@@	I-Chemical	-1	8372922
se@@	I-Chemical	-1	8372922
m@@	I-Chemical	-1	8372922
ide	I-Chemical	-1	8372922
.	O	-1	8372922
The	O	-1	8372922
act@@	O	-1	8372922
ual	O	-1	8372922
frequ@@	O	-1	8372922
en@@	O	-1	8372922
ci@@	O	-1	8372922
es	O	-1	8372922
de@@	O	-1	8372922
af@@	O	-1	8372922
en@@	O	-1	8372922
ed	O	-1	8372922
were	O	-1	8372922
determined	O	-1	8372922
by	O	-1	8372922
the	O	-1	8372922
loss	O	-1	8372922
of	O	-1	8372922
t@@	O	-1	8372922
on@@	O	-1	8372922
e-@@	O	-1	8372922
b@@	O	-1	8372922
ur@@	O	-1	8372922
st	O	-1	8372922
el@@	O	-1	8372922
ic@@	O	-1	8372922
ited	O	-1	8372922
a@@	O	-1	8372922
ud@@	O	-1	8372922
it@@	O	-1	8372922
ory	O	-1	8372922
bra@@	O	-1	8372922
in@@	O	-1	8372922
st@@	O	-1	8372922
em	O	-1	8372922
respon@@	O	-1	8372922
s@@	O	-1	8372922
es.	O	-1	8372922
Th@@	O	-1	8372922
ree	O	-1	8372922
months	O	-1	8372922
after	O	-1	8372922
de@@	O	-1	8372922
af@@	O	-1	8372922
en@@	O	-1	8372922
ing,	O	-1	8372922
A@@	O	-1	8372922
1	O	-1	8372922
was	O	-1	8372922
re@@	O	-1	8372922
m@@	O	-1	8372922
app@@	O	-1	8372922
ed.	O	-1	8372922
P@@	O	-1	8372922
ost@@	O	-1	8372922
mor@@	O	-1	8372922
te@@	O	-1	8372922
m	O	-1	8372922
cyto@@	O	-1	8372922
ar@@	O	-1	8372922
ch@@	O	-1	8372922
it@@	O	-1	8372922
ect@@	O	-1	8372922
ural	O	-1	8372922
feat@@	O	-1	8372922
ures	O	-1	8372922
identi@@	O	-1	8372922
f@@	O	-1	8372922
y@@	O	-1	8372922
ing	O	-1	8372922
A@@	O	-1	8372922
1	O	-1	8372922
were	O	-1	8372922
cor@@	O	-1	8372922
related	O	-1	8372922
with	O	-1	8372922
the	O	-1	8372922
electro@@	O	-1	8372922
physi@@	O	-1	8372922
ologic	O	-1	8372922
dat@@	O	-1	8372922
a.	O	-1	8372922
The	O	-1	8372922
results	O	-1	8372922
indicate	O	-1	8372922
that	O	-1	8372922
the	O	-1	8372922
de@@	O	-1	8372922
pri@@	O	-1	8372922
ved	O	-1	8372922
a@@	O	-1	8372922
re@@	O	-1	8372922
a	O	-1	8372922
of	O	-1	8372922
A@@	O	-1	8372922
1	O	-1	8372922
under@@	O	-1	8372922
go@@	O	-1	8372922
es	O	-1	8372922
exten@@	O	-1	8372922
sive	O	-1	8372922
re@@	O	-1	8372922
org@@	O	-1	8372922
an@@	O	-1	8372922
ization	O	-1	8372922
and	O	-1	8372922
b@@	O	-1	8372922
ec@@	O	-1	8372922
om@@	O	-1	8372922
es	O	-1	8372922
respon@@	O	-1	8372922
sive	O	-1	8372922
to	O	-1	8372922
int@@	O	-1	8372922
ac@@	O	-1	8372922
t	O	-1	8372922
co@@	O	-1	8372922
ch@@	O	-1	8372922
le@@	O	-1	8372922
ar	O	-1	8372922
frequ@@	O	-1	8372922
en@@	O	-1	8372922
ci@@	O	-1	8372922
es.	O	-1	8372922
The	O	-1	8372922
regi@@	O	-1	8372922
on	O	-1	8372922
of	O	-1	8372922
cor@@	O	-1	8372922
te@@	O	-1	8372922
x	O	-1	8372922
that	O	-1	8372922
re@@	O	-1	8372922
pres@@	O	-1	8372922
ents	O	-1	8372922
the	O	-1	8372922
low	O	-1	8372922
frequ@@	O	-1	8372922
en@@	O	-1	8372922
ci@@	O	-1	8372922
es	O	-1	8372922
was	O	-1	8372922
not	O	-1	8372922
ob@@	O	-1	8372922
vi@@	O	-1	8372922
ously	O	-1	8372922
affected	O	-1	8372922
by	O	-1	8372922
the	O	-1	8372922
co@@	O	-1	8372922
ch@@	O	-1	8372922
le@@	O	-1	8372922
ar	O	-1	8372922
hearing	B-Disease	D034381	8372922
loss	I-Disease	-1	8372922
.	O	-1	8372922

The	O	-1	9195768
sit@@	O	-1	9195768
e	O	-1	9195768
of	O	-1	9195768
common	O	-1	9195768
side	O	-1	9195768
effects	O	-1	9195768
of	O	-1	9195768
su@@	B-Chemical	D018170	9195768
mat@@	I-Chemical	-1	9195768
ript@@	I-Chemical	-1	9195768
an	I-Chemical	-1	9195768
.	O	-1	9195768
A@@	B-Disease	D010292	9195768
typ@@	I-Disease	-1	9195768
ical	I-Disease	-1	9195768
sens@@	I-Disease	-1	9195768
ations	I-Disease	-1	9195768
following	O	-1	9195768
the	O	-1	9195768
use	O	-1	9195768
of	O	-1	9195768
sub@@	O	-1	9195768
c@@	O	-1	9195768
utaneous	O	-1	9195768
su@@	B-Chemical	D018170	9195768
mat@@	I-Chemical	-1	9195768
ript@@	I-Chemical	-1	9195768
an	I-Chemical	-1	9195768
are	O	-1	9195768
common@@	O	-1	9195768
,	O	-1	9195768
but	O	-1	9195768
of	O	-1	9195768
unc@@	O	-1	9195768
er@@	O	-1	9195768
t@@	O	-1	9195768
ain	O	-1	9195768
or@@	O	-1	9195768
ig@@	O	-1	9195768
in.	O	-1	9195768
The@@	O	-1	9195768
y	O	-1	9195768
are	O	-1	9195768
al@@	O	-1	9195768
most	O	-1	9195768
al@@	O	-1	9195768
w@@	O	-1	9195768
ays	O	-1	9195768
ben@@	O	-1	9195768
i@@	O	-1	9195768
gn@@	O	-1	9195768
,	O	-1	9195768
but	O	-1	9195768
can	O	-1	9195768
be	O	-1	9195768
m@@	O	-1	9195768
ist@@	O	-1	9195768
ak@@	O	-1	9195768
en	O	-1	9195768
for	O	-1	9195768
a	O	-1	9195768
seri@@	O	-1	9195768
ous	O	-1	9195768
adverse	O	-1	9195768
ev@@	O	-1	9195768
ent	O	-1	9195768
by	O	-1	9195768
the	O	-1	9195768
patient@@	O	-1	9195768
.	O	-1	9195768
Two	O	-1	9195768
patients	O	-1	9195768
are	O	-1	9195768
presented	O	-1	9195768
with	O	-1	9195768
t@@	B-Disease	D010292	9195768
ing@@	I-Disease	-1	9195768
l@@	I-Disease	-1	9195768
ing	I-Disease	-1	9195768
or	I-Disease	-1	9195768
b@@	I-Disease	-1	9195768
ur@@	I-Disease	-1	9195768
ning	I-Disease	-1	9195768
sens@@	I-Disease	-1	9195768
ations	I-Disease	-1	9195768
lim@@	O	-1	9195768
ited	O	-1	9195768
to	O	-1	9195768
a@@	O	-1	9195768
reas	O	-1	9195768
of	O	-1	9195768
he@@	O	-1	9195768
at	O	-1	9195768
exposure	O	-1	9195768
or	O	-1	9195768
su@@	B-Disease	D013471	9195768
n@@	I-Disease	-1	9195768
b@@	I-Disease	-1	9195768
ur@@	I-Disease	-1	9195768
n	I-Disease	-1	9195768
.	O	-1	9195768
In	O	-1	9195768
these	O	-1	9195768
individ@@	O	-1	9195768
u@@	O	-1	9195768
al@@	O	-1	9195768
s,	O	-1	9195768
side	O	-1	9195768
effects	O	-1	9195768
are	O	-1	9195768
most	O	-1	9195768
likely	O	-1	9195768
gener@@	O	-1	9195768
ated	O	-1	9195768
su@@	O	-1	9195768
per@@	O	-1	9195768
f@@	O	-1	9195768
ici@@	O	-1	9195768
ally	O	-1	9195768
in	O	-1	9195768
the	O	-1	9195768
s@@	O	-1	9195768
k@@	O	-1	9195768
in.	O	-1	9195768

T@@	B-Disease	D014202	15338796
re@@	I-Disease	-1	15338796
m@@	I-Disease	-1	15338796
or	I-Disease	-1	15338796
side	O	-1	15338796
effects	O	-1	15338796
of	O	-1	15338796
sal@@	B-Chemical	D000420	15338796
but@@	I-Chemical	-1	15338796
am@@	I-Chemical	-1	15338796
ol	I-Chemical	-1	15338796
,	O	-1	15338796
qu@@	O	-1	15338796
anti@@	O	-1	15338796
fied	O	-1	15338796
by	O	-1	15338796
a	O	-1	15338796
las@@	O	-1	15338796
er	O	-1	15338796
po@@	O	-1	15338796
in@@	O	-1	15338796
ter	O	-1	15338796
t@@	O	-1	15338796
ech@@	O	-1	15338796
n@@	O	-1	15338796
i@@	O	-1	15338796
qu@@	O	-1	15338796
e.	O	-1	15338796
OBJECTIVE:	O	-1	15338796
To	O	-1	15338796
study	O	-1	15338796
trem@@	B-Disease	D014202	15338796
or	I-Disease	-1	15338796
side	O	-1	15338796
effects	O	-1	15338796
of	O	-1	15338796
sal@@	B-Chemical	D000420	15338796
but@@	I-Chemical	-1	15338796
am@@	I-Chemical	-1	15338796
ol	I-Chemical	-1	15338796
an	O	-1	15338796
e@@	O	-1	15338796
a@@	O	-1	15338796
si@@	O	-1	15338796
ly	O	-1	15338796
ap@@	O	-1	15338796
plic@@	O	-1	15338796
able@@	O	-1	15338796
,	O	-1	15338796
qu@@	O	-1	15338796
ic@@	O	-1	15338796
k	O	-1	15338796
and	O	-1	15338796
low@@	O	-1	15338796
-@@	O	-1	15338796
pr@@	O	-1	15338796
ic@@	O	-1	15338796
ed	O	-1	15338796
meth@@	O	-1	15338796
od	O	-1	15338796
is	O	-1	15338796
ne@@	O	-1	15338796
e@@	O	-1	15338796
de@@	O	-1	15338796
d.	O	-1	15338796
A	O	-1	15338796
new	O	-1	15338796
meth@@	O	-1	15338796
od	O	-1	15338796
using	O	-1	15338796
a	O	-1	15338796
com@@	O	-1	15338796
mer@@	O	-1	15338796
ci@@	O	-1	15338796
ally	O	-1	15338796
av@@	O	-1	15338796
ail@@	O	-1	15338796
able@@	O	-1	15338796
,	O	-1	15338796
pen@@	O	-1	15338796
-@@	O	-1	15338796
sh@@	O	-1	15338796
ap@@	O	-1	15338796
ed	O	-1	15338796
las@@	O	-1	15338796
er	O	-1	15338796
po@@	O	-1	15338796
in@@	O	-1	15338796
ter	O	-1	15338796
was	O	-1	15338796
develop@@	O	-1	15338796
ed.	O	-1	15338796
A@@	O	-1	15338796
im	O	-1	15338796
of	O	-1	15338796
the	O	-1	15338796
study	O	-1	15338796
was	O	-1	15338796
to	O	-1	15338796
determine	O	-1	15338796
sensi@@	O	-1	15338796
tiv@@	O	-1	15338796
ity,	O	-1	15338796
re@@	O	-1	15338796
produc@@	O	-1	15338796
i@@	O	-1	15338796
bil@@	O	-1	15338796
ity,	O	-1	15338796
ref@@	O	-1	15338796
e@@	O	-1	15338796
rence	O	-1	15338796
values	O	-1	15338796
and	O	-1	15338796
the	O	-1	15338796
ag@@	O	-1	15338796
re@@	O	-1	15338796
ement	O	-1	15338796
with	O	-1	15338796
a	O	-1	15338796
qu@@	O	-1	15338796
es@@	O	-1	15338796
tion@@	O	-1	15338796
na@@	O	-1	15338796
i@@	O	-1	15338796
re.	O	-1	15338796
METHODS:	O	-1	15338796
T@@	B-Disease	D014202	15338796
re@@	I-Disease	-1	15338796
m@@	I-Disease	-1	15338796
or	I-Disease	-1	15338796
was	O	-1	15338796
measured	O	-1	15338796
using	O	-1	15338796
a	O	-1	15338796
las@@	O	-1	15338796
er	O	-1	15338796
po@@	O	-1	15338796
in@@	O	-1	15338796
ter	O	-1	15338796
t@@	O	-1	15338796
ech@@	O	-1	15338796
n@@	O	-1	15338796
i@@	O	-1	15338796
qu@@	O	-1	15338796
e.	O	-1	15338796
To	O	-1	15338796
determine	O	-1	15338796
sensitivity	O	-1	15338796
we	O	-1	15338796
assessed	O	-1	15338796
trem@@	B-Disease	D014202	15338796
or	I-Disease	-1	15338796
in	O	-1	15338796
4@@	O	-1	15338796
4	O	-1	15338796
patients	O	-1	15338796
with	O	-1	15338796
ob@@	B-Disease	D008173	15338796
struc@@	I-Disease	-1	15338796
tive	I-Disease	-1	15338796
l@@	I-Disease	-1	15338796
un@@	I-Disease	-1	15338796
g	I-Disease	-1	15338796
disease	I-Disease	-1	15338796
after	O	-1	15338796
administration	O	-1	15338796
of	O	-1	15338796
cum@@	O	-1	15338796
ul@@	O	-1	15338796
ative	O	-1	15338796
doses	O	-1	15338796
of	O	-1	15338796
sal@@	B-Chemical	D000420	15338796
but@@	I-Chemical	-1	15338796
am@@	I-Chemical	-1	15338796
ol	I-Chemical	-1	15338796
.	O	-1	15338796
S@@	O	-1	15338796
ub@@	O	-1	15338796
j@@	O	-1	15338796
ects	O	-1	15338796
were	O	-1	15338796
as@@	O	-1	15338796
ked	O	-1	15338796
to	O	-1	15338796
a@@	O	-1	15338796
im	O	-1	15338796
at	O	-1	15338796
the	O	-1	15338796
centr@@	O	-1	15338796
e	O	-1	15338796
of	O	-1	15338796
a	O	-1	15338796
t@@	O	-1	15338796
arg@@	O	-1	15338796
et@@	O	-1	15338796
,	O	-1	15338796
sub@@	O	-1	15338796
divid@@	O	-1	15338796
ed	O	-1	15338796
in	O	-1	15338796
con@@	O	-1	15338796
c@@	O	-1	15338796
ent@@	O	-1	15338796
ric	O	-1	15338796
cir@@	O	-1	15338796
cl@@	O	-1	15338796
es,	O	-1	15338796
from	O	-1	15338796
5	O	-1	15338796
m	O	-1	15338796
dist@@	O	-1	15338796
ance@@	O	-1	15338796
.	O	-1	15338796
The	O	-1	15338796
cir@@	O	-1	15338796
c@@	O	-1	15338796
le	O	-1	15338796
in	O	-1	15338796
which	O	-1	15338796
the	O	-1	15338796
partic@@	O	-1	15338796
ip@@	O	-1	15338796
ant	O	-1	15338796
suc@@	O	-1	15338796
ce@@	O	-1	15338796
ed@@	O	-1	15338796
ed	O	-1	15338796
to	O	-1	15338796
a@@	O	-1	15338796
im	O	-1	15338796
was	O	-1	15338796
recor@@	O	-1	15338796
ded	O	-1	15338796
in	O	-1	15338796
mil@@	O	-1	15338796
li@@	O	-1	15338796
me@@	O	-1	15338796
tre@@	O	-1	15338796
s	O	-1	15338796
radi@@	O	-1	15338796
us.	O	-1	15338796
In	O	-1	15338796
an@@	O	-1	15338796
other	O	-1	15338796
seri@@	O	-1	15338796
es	O	-1	15338796
of	O	-1	15338796
meas@@	O	-1	15338796
ure@@	O	-1	15338796
ment@@	O	-1	15338796
s,	O	-1	15338796
re@@	O	-1	15338796
produc@@	O	-1	15338796
i@@	O	-1	15338796
b@@	O	-1	15338796
ility	O	-1	15338796
and	O	-1	15338796
ref@@	O	-1	15338796
e@@	O	-1	15338796
rence	O	-1	15338796
values	O	-1	15338796
of	O	-1	15338796
the	O	-1	15338796
trem@@	B-Disease	D014202	15338796
or	I-Disease	-1	15338796
was	O	-1	15338796
assessed	O	-1	15338796
in	O	-1	15338796
6@@	O	-1	15338796
5	O	-1	15338796
healthy	O	-1	15338796
subjects	O	-1	15338796
in	O	-1	15338796
three	O	-1	15338796
s@@	O	-1	15338796
es@@	O	-1	15338796
sion@@	O	-1	15338796
s,	O	-1	15338796
at	O	-1	15338796
9	O	-1	15338796
a@@	O	-1	15338796
.@@	O	-1	15338796
m@@	O	-1	15338796
.,	O	-1	15338796
4	O	-1	15338796
p.@@	O	-1	15338796
m.	O	-1	15338796
and	O	-1	15338796
9	O	-1	15338796
a@@	O	-1	15338796
.@@	O	-1	15338796
m@@	O	-1	15338796
.,	O	-1	15338796
respectivel@@	O	-1	15338796
y,	O	-1	15338796
1	O	-1	15338796
week	O	-1	15338796
lat@@	O	-1	15338796
er.	O	-1	15338796
P@@	O	-1	15338796
ost@@	O	-1	15338796
ural	O	-1	15338796
trem@@	B-Disease	D014202	15338796
or	I-Disease	-1	15338796
was	O	-1	15338796
measured	O	-1	15338796
with	O	-1	15338796
the	O	-1	15338796
ar@@	O	-1	15338796
m	O	-1	15338796
h@@	O	-1	15338796
or@@	O	-1	15338796
iz@@	O	-1	15338796
ont@@	O	-1	15338796
ally	O	-1	15338796
out@@	O	-1	15338796
st@@	O	-1	15338796
ret@@	O	-1	15338796
ch@@	O	-1	15338796
ed	O	-1	15338796
res@@	O	-1	15338796
t	O	-1	15338796
trem@@	B-Disease	D014202	15338796
or	I-Disease	-1	15338796
with	O	-1	15338796
the	O	-1	15338796
ar@@	O	-1	15338796
m	O	-1	15338796
suppor@@	O	-1	15338796
ted	O	-1	15338796
by	O	-1	15338796
an	O	-1	15338796
ar@@	O	-1	15338796
m@@	O	-1	15338796
res@@	O	-1	15338796
t	O	-1	15338796
and	O	-1	15338796
f@@	O	-1	15338796
in@@	O	-1	15338796
ally	O	-1	15338796
trem@@	B-Disease	D014202	15338796
or	I-Disease	-1	15338796
was	O	-1	15338796
measured	O	-1	15338796
after	O	-1	15338796
h@@	O	-1	15338796
ol@@	O	-1	15338796
ding	O	-1	15338796
a	O	-1	15338796
2-@@	O	-1	15338796
k@@	O	-1	15338796
g	O	-1	15338796
weight	O	-1	15338796
un@@	O	-1	15338796
ti@@	O	-1	15338796
l	O	-1	15338796
ex@@	O	-1	15338796
ha@@	O	-1	15338796
us@@	O	-1	15338796
tion.	O	-1	15338796
In@@	O	-1	15338796
ter@@	O	-1	15338796
-@@	O	-1	15338796
obser@@	O	-1	15338796
ver	O	-1	15338796
vari@@	O	-1	15338796
ability	O	-1	15338796
was	O	-1	15338796
measured	O	-1	15338796
in	O	-1	15338796
a	O	-1	15338796
seri@@	O	-1	15338796
es	O	-1	15338796
of	O	-1	15338796
10	O	-1	15338796
healthy	O	-1	15338796
subj@@	O	-1	15338796
ect@@	O	-1	15338796
s.	O	-1	15338796
T@@	B-Disease	D014202	15338796
re@@	I-Disease	-1	15338796
m@@	I-Disease	-1	15338796
or	I-Disease	-1	15338796
was	O	-1	15338796
measured	O	-1	15338796
sim@@	O	-1	15338796
ult@@	O	-1	15338796
ane@@	O	-1	15338796
ously	O	-1	15338796
by	O	-1	15338796
two	O	-1	15338796
in@@	O	-1	15338796
dependent	O	-1	15338796
obser@@	O	-1	15338796
ver@@	O	-1	15338796
s.	O	-1	15338796
RESULTS:	O	-1	15338796
S@@	B-Chemical	D000420	15338796
al@@	I-Chemical	-1	15338796
but@@	I-Chemical	-1	15338796
am@@	I-Chemical	-1	15338796
ol	I-Chemical	-1	15338796
significantly	O	-1	15338796
increased	O	-1	15338796
trem@@	B-Disease	D014202	15338796
or	I-Disease	-1	15338796
severity	O	-1	15338796
in	O	-1	15338796
patients	O	-1	15338796
in	O	-1	15338796
a	O	-1	15338796
dose-@@	O	-1	15338796
dependent	O	-1	15338796
w@@	O	-1	15338796
a@@	O	-1	15338796
y.	O	-1	15338796
W@@	O	-1	15338796
i@@	O	-1	15338796
th@@	O	-1	15338796
in	O	-1	15338796
healthy	O	-1	15338796
ad@@	O	-1	15338796
ult@@	O	-1	15338796
s	O	-1	15338796
no	O	-1	15338796
ag@@	O	-1	15338796
e-@@	O	-1	15338796
depend@@	O	-1	15338796
ency	O	-1	15338796
could	O	-1	15338796
be	O	-1	15338796
found	O	-1	15338796
(@@	O	-1	15338796
b	O	-1	15338796
=	O	-1	15338796
0.@@	O	-1	15338796
2@@	O	-1	15338796
6@@	O	-1	15338796
2	O	-1	15338796
mm@@	O	-1	15338796
/@@	O	-1	15338796
year@@	O	-1	15338796
;	O	-1	15338796
P	O	-1	15338796
=	O	-1	15338796
0.@@	O	-1	15338796
7@@	O	-1	15338796
2@@	O	-1	15338796
).	O	-1	15338796
There	O	-1	15338796
was	O	-1	15338796
no	O	-1	15338796
ag@@	O	-1	15338796
re@@	O	-1	15338796
ement	O	-1	15338796
between	O	-1	15338796
the	O	-1	15338796
qu@@	O	-1	15338796
es@@	O	-1	15338796
tion@@	O	-1	15338796
na@@	O	-1	15338796
ir@@	O	-1	15338796
e	O	-1	15338796
and	O	-1	15338796
trem@@	B-Disease	D014202	15338796
or	I-Disease	-1	15338796
severity	O	-1	15338796
(@@	O	-1	15338796
r	O	-1	15338796
=	O	-1	15338796
0.0@@	O	-1	15338796
9@@	O	-1	15338796
3@@	O	-1	15338796
;	O	-1	15338796
P	O	-1	15338796
=	O	-1	15338796
0.@@	O	-1	15338796
5@@	O	-1	15338796
3@@	O	-1	15338796
).	O	-1	15338796
P@@	O	-1	15338796
ost@@	O	-1	15338796
ural	O	-1	15338796
trem@@	B-Disease	D014202	15338796
or	I-Disease	-1	15338796
showed	O	-1	15338796
no	O	-1	15338796
significant	O	-1	15338796
difference	O	-1	15338796
between	O	-1	15338796
the	O	-1	15338796
first	O	-1	15338796
and	O	-1	15338796
thir@@	O	-1	15338796
d	O	-1	15338796
s@@	O	-1	15338796
es@@	O	-1	15338796
sion	O	-1	15338796
(P	O	-1	15338796
=	O	-1	15338796
0.0@@	O	-1	15338796
7@@	O	-1	15338796
).	O	-1	15338796
S@@	O	-1	15338796
up@@	O	-1	15338796
por@@	O	-1	15338796
t	O	-1	15338796
of	O	-1	15338796
the	O	-1	15338796
ar@@	O	-1	15338796
m	O	-1	15338796
decreased	O	-1	15338796
trem@@	B-Disease	D014202	15338796
or	I-Disease	-1	15338796
sever@@	O	-1	15338796
ity,	O	-1	15338796
ex@@	O	-1	15338796
ha@@	O	-1	15338796
us@@	O	-1	15338796
tion	O	-1	15338796
increased	O	-1	15338796
trem@@	B-Disease	D014202	15338796
or	I-Disease	-1	15338796
severity	O	-1	15338796
significant@@	O	-1	15338796
ly.	O	-1	15338796
A	O	-1	15338796
go@@	O	-1	15338796
od	O	-1	15338796
ag@@	O	-1	15338796
re@@	O	-1	15338796
ement	O	-1	15338796
was	O	-1	15338796
found	O	-1	15338796
between	O	-1	15338796
two	O	-1	15338796
in@@	O	-1	15338796
dependent	O	-1	15338796
obser@@	O	-1	15338796
ver@@	O	-1	15338796
s	O	-1	15338796
(@@	O	-1	15338796
inter@@	O	-1	15338796
cl@@	O	-1	15338796
as@@	O	-1	15338796
s	O	-1	15338796
correl@@	O	-1	15338796
ation	O	-1	15338796
co@@	O	-1	15338796
eff@@	O	-1	15338796
ici@@	O	-1	15338796
ent	O	-1	15338796
0.@@	O	-1	15338796
7@@	O	-1	15338796
2@@	O	-1	15338796
).	O	-1	15338796
D@@	O	-1	15338796
I@@	O	-1	15338796
S@@	O	-1	15338796
C@@	O	-1	15338796
US@@	O	-1	15338796
S@@	O	-1	15338796
ION@@	O	-1	15338796
:	O	-1	15338796
Q@@	O	-1	15338796
u@@	O	-1	15338796
anti@@	O	-1	15338796
f@@	O	-1	15338796
y@@	O	-1	15338796
ing	O	-1	15338796
trem@@	B-Disease	D014202	15338796
or	I-Disease	-1	15338796
by	O	-1	15338796
using	O	-1	15338796
an	O	-1	15338796
in@@	O	-1	15338796
ex@@	O	-1	15338796
pen@@	O	-1	15338796
sive	O	-1	15338796
las@@	O	-1	15338796
er	O	-1	15338796
po@@	O	-1	15338796
in@@	O	-1	15338796
ter	O	-1	15338796
is@@	O	-1	15338796
,	O	-1	15338796
with	O	-1	15338796
the	O	-1	15338796
ex@@	O	-1	15338796
ce@@	O	-1	15338796
ption	O	-1	15338796
of	O	-1	15338796
children	O	-1	15338796
(@@	O	-1	15338796
<@@	O	-1	15338796
12	O	-1	15338796
year@@	O	-1	15338796
s)	O	-1	15338796
a	O	-1	15338796
sensitive	O	-1	15338796
and	O	-1	15338796
re@@	O	-1	15338796
produc@@	O	-1	15338796
i@@	O	-1	15338796
ble	O	-1	15338796
meth@@	O	-1	15338796
o@@	O	-1	15338796
d.	O	-1	15338796

In@@	O	-1	12627929
c@@	O	-1	12627929
reas@@	O	-1	12627929
ed	O	-1	12627929
frequency	O	-1	12627929
of	O	-1	12627929
venous	B-Disease	D054556	12627929
thrombo@@	I-Disease	-1	12627929
emb@@	I-Disease	-1	12627929
ol@@	I-Disease	-1	12627929
ism	I-Disease	-1	12627929
with	O	-1	12627929
the	O	-1	12627929
combination	O	-1	12627929
of	O	-1	12627929
doc@@	B-Chemical	C067311	12627929
et@@	I-Chemical	-1	12627929
ax@@	I-Chemical	-1	12627929
el	I-Chemical	-1	12627929
and	O	-1	12627929
thal@@	B-Chemical	D013792	12627929
id@@	I-Chemical	-1	12627929
om@@	I-Chemical	-1	12627929
ide	I-Chemical	-1	12627929
in	O	-1	12627929
patients	O	-1	12627929
with	O	-1	12627929
met@@	O	-1	12627929
ast@@	O	-1	12627929
atic	O	-1	12627929
and@@	O	-1	12627929
ro@@	O	-1	12627929
gen@@	O	-1	12627929
-@@	O	-1	12627929
in@@	O	-1	12627929
dependent	O	-1	12627929
pro@@	B-Disease	D011471	12627929
state	I-Disease	-1	12627929
cancer	I-Disease	-1	12627929
.	O	-1	12627929
S@@	O	-1	12627929
T@@	O	-1	12627929
U@@	O	-1	12627929
D@@	O	-1	12627929
Y	O	-1	12627929
OBJECTIVE:	O	-1	12627929
To	O	-1	12627929
evalu@@	O	-1	12627929
ate	O	-1	12627929
the	O	-1	12627929
frequency	O	-1	12627929
of	O	-1	12627929
venous	B-Disease	D054556	12627929
thrombo@@	I-Disease	-1	12627929
emb@@	I-Disease	-1	12627929
ol@@	I-Disease	-1	12627929
ism	I-Disease	-1	12627929
(	O	-1	12627929
V@@	B-Disease	D054556	12627929
T@@	I-Disease	-1	12627929
E	I-Disease	-1	12627929
)	O	-1	12627929
in	O	-1	12627929
patients	O	-1	12627929
with	O	-1	12627929
adv@@	O	-1	12627929
anced	O	-1	12627929
and@@	O	-1	12627929
ro@@	O	-1	12627929
gen@@	O	-1	12627929
-@@	O	-1	12627929
in@@	O	-1	12627929
dependent	O	-1	12627929
pro@@	B-Disease	D011471	12627929
state	I-Disease	-1	12627929
cancer	I-Disease	-1	12627929
who	O	-1	12627929
were	O	-1	12627929
treated	O	-1	12627929
with	O	-1	12627929
doc@@	B-Chemical	C067311	12627929
et@@	I-Chemical	-1	12627929
ax@@	I-Chemical	-1	12627929
el	I-Chemical	-1	12627929
alone	O	-1	12627929
or	O	-1	12627929
in	O	-1	12627929
combination	O	-1	12627929
with	O	-1	12627929
thal@@	B-Chemical	D013792	12627929
id@@	I-Chemical	-1	12627929
om@@	I-Chemical	-1	12627929
ide	I-Chemical	-1	12627929
.	O	-1	12627929
D@@	O	-1	12627929
ES@@	O	-1	12627929
I@@	O	-1	12627929
G@@	O	-1	12627929
N@@	O	-1	12627929
:	O	-1	12627929
R@@	O	-1	12627929
et@@	O	-1	12627929
ro@@	O	-1	12627929
sp@@	O	-1	12627929
ective	O	-1	12627929
analysis	O	-1	12627929
of	O	-1	12627929
a	O	-1	12627929
randomized	O	-1	12627929
phase	O	-1	12627929
II	O	-1	12627929
tri@@	O	-1	12627929
al.	O	-1	12627929
S@@	O	-1	12627929
ET@@	O	-1	12627929
TI@@	O	-1	12627929
N@@	O	-1	12627929
G@@	O	-1	12627929
:	O	-1	12627929
N@@	O	-1	12627929
ation@@	O	-1	12627929
al	O	-1	12627929
In@@	O	-1	12627929
sti@@	O	-1	12627929
t@@	O	-1	12627929
ut@@	O	-1	12627929
es	O	-1	12627929
of	O	-1	12627929
He@@	O	-1	12627929
al@@	O	-1	12627929
th	O	-1	12627929
clinical	O	-1	12627929
re@@	O	-1	12627929
se@@	O	-1	12627929
arc@@	O	-1	12627929
h	O	-1	12627929
c@@	O	-1	12627929
ent@@	O	-1	12627929
er.	O	-1	12627929
PA@@	O	-1	12627929
TI@@	O	-1	12627929
E@@	O	-1	12627929
N@@	O	-1	12627929
T@@	O	-1	12627929
S:	O	-1	12627929
S@@	O	-1	12627929
event@@	O	-1	12627929
y	O	-1	12627929
men@@	O	-1	12627929
,	O	-1	12627929
aged	O	-1	12627929
50@@	O	-1	12627929
-@@	O	-1	12627929
8@@	O	-1	12627929
0	O	-1	12627929
year@@	O	-1	12627929
s,	O	-1	12627929
with	O	-1	12627929
adv@@	O	-1	12627929
anced	O	-1	12627929
and@@	O	-1	12627929
ro@@	O	-1	12627929
gen@@	O	-1	12627929
-@@	O	-1	12627929
in@@	O	-1	12627929
dependent	O	-1	12627929
pro@@	B-Disease	D011471	12627929
state	I-Disease	-1	12627929
cancer	I-Disease	-1	12627929
.	O	-1	12627929
IN@@	O	-1	12627929
TE@@	O	-1	12627929
R@@	O	-1	12627929
V@@	O	-1	12627929
E@@	O	-1	12627929
N@@	O	-1	12627929
T@@	O	-1	12627929
ION@@	O	-1	12627929
:	O	-1	12627929
E@@	O	-1	12627929
ach	O	-1	12627929
patient	O	-1	12627929
received	O	-1	12627929
either	O	-1	12627929
intravenous	O	-1	12627929
doc@@	B-Chemical	C067311	12627929
et@@	I-Chemical	-1	12627929
ax@@	I-Chemical	-1	12627929
el	I-Chemical	-1	12627929
30	O	-1	12627929
mg/m@@	O	-1	12627929
2@@	O	-1	12627929
/@@	O	-1	12627929
week	O	-1	12627929
for	O	-1	12627929
3	O	-1	12627929
con@@	O	-1	12627929
sec@@	O	-1	12627929
utive	O	-1	12627929
week@@	O	-1	12627929
s,	O	-1	12627929
followed	O	-1	12627929
by	O	-1	12627929
1	O	-1	12627929
week	O	-1	12627929
o@@	O	-1	12627929
ff@@	O	-1	12627929
,	O	-1	12627929
or	O	-1	12627929
the	O	-1	12627929
combination	O	-1	12627929
of	O	-1	12627929
continu@@	O	-1	12627929
ous	O	-1	12627929
oral	O	-1	12627929
thal@@	B-Chemical	D013792	12627929
id@@	I-Chemical	-1	12627929
om@@	I-Chemical	-1	12627929
ide	I-Chemical	-1	12627929
2@@	O	-1	12627929
00	O	-1	12627929
mg	O	-1	12627929
every	O	-1	12627929
ev@@	O	-1	12627929
en@@	O	-1	12627929
ing	O	-1	12627929
plus	O	-1	12627929
the	O	-1	12627929
same	O	-1	12627929
doc@@	B-Chemical	C067311	12627929
et@@	I-Chemical	-1	12627929
ax@@	I-Chemical	-1	12627929
el	I-Chemical	-1	12627929
regimen@@	O	-1	12627929
.	O	-1	12627929
This	O	-1	12627929
4-@@	O	-1	12627929
week	O	-1	12627929
cyc@@	O	-1	12627929
le	O	-1	12627929
was	O	-1	12627929
repe@@	O	-1	12627929
ated	O	-1	12627929
un@@	O	-1	12627929
ti@@	O	-1	12627929
l	O	-1	12627929
there	O	-1	12627929
was	O	-1	12627929
evidence	O	-1	12627929
of	O	-1	12627929
ex@@	O	-1	12627929
ces@@	O	-1	12627929
sive	O	-1	12627929
toxicity	B-Disease	D064420	12627929
or	O	-1	12627929
disease	O	-1	12627929
progres@@	O	-1	12627929
sion.	O	-1	12627929
M@@	O	-1	12627929
E@@	O	-1	12627929
A@@	O	-1	12627929
S@@	O	-1	12627929
U@@	O	-1	12627929
R@@	O	-1	12627929
E@@	O	-1	12627929
M@@	O	-1	12627929
E@@	O	-1	12627929
N@@	O	-1	12627929
T@@	O	-1	12627929
S	O	-1	12627929
AN@@	O	-1	12627929
D	O	-1	12627929
MA@@	O	-1	12627929
I@@	O	-1	12627929
N	O	-1	12627929
RESULTS:	O	-1	12627929
N@@	O	-1	12627929
one	O	-1	12627929
of	O	-1	12627929
2@@	O	-1	12627929
3	O	-1	12627929
patients	O	-1	12627929
who	O	-1	12627929
received	O	-1	12627929
doc@@	B-Chemical	C067311	12627929
et@@	I-Chemical	-1	12627929
ax@@	I-Chemical	-1	12627929
el	I-Chemical	-1	12627929
alone	O	-1	12627929
developed	O	-1	12627929
V@@	B-Disease	D054556	12627929
T@@	I-Disease	-1	12627929
E	I-Disease	-1	12627929
,	O	-1	12627929
whereas	O	-1	12627929
9	O	-1	12627929
of	O	-1	12627929
4@@	O	-1	12627929
7	O	-1	12627929
patients	O	-1	12627929
(1@@	O	-1	12627929
9@@	O	-1	12627929
%)	O	-1	12627929
who	O	-1	12627929
received	O	-1	12627929
doc@@	B-Chemical	C067311	12627929
et@@	I-Chemical	-1	12627929
ax@@	I-Chemical	-1	12627929
el	I-Chemical	-1	12627929
plus	O	-1	12627929
thal@@	B-Chemical	D013792	12627929
id@@	I-Chemical	-1	12627929
om@@	I-Chemical	-1	12627929
ide	I-Chemical	-1	12627929
developed	O	-1	12627929
V@@	B-Disease	D054556	12627929
T@@	I-Disease	-1	12627929
E	I-Disease	-1	12627929
(p@@	O	-1	12627929
=@@	O	-1	12627929
0.0@@	O	-1	12627929
25@@	O	-1	12627929
).	O	-1	12627929
CONCLUSION:	O	-1	12627929
The	O	-1	12627929
addition	O	-1	12627929
of	O	-1	12627929
thal@@	B-Chemical	D013792	12627929
id@@	I-Chemical	-1	12627929
om@@	I-Chemical	-1	12627929
ide	I-Chemical	-1	12627929
to	O	-1	12627929
doc@@	B-Chemical	C067311	12627929
et@@	I-Chemical	-1	12627929
ax@@	I-Chemical	-1	12627929
el	I-Chemical	-1	12627929
in	O	-1	12627929
the	O	-1	12627929
treatment	O	-1	12627929
of	O	-1	12627929
pro@@	B-Disease	D011471	12627929
state	I-Disease	-1	12627929
cancer	I-Disease	-1	12627929
significantly	O	-1	12627929
increases	O	-1	12627929
the	O	-1	12627929
frequency	O	-1	12627929
of	O	-1	12627929
V@@	B-Disease	D054556	12627929
T@@	I-Disease	-1	12627929
E	I-Disease	-1	12627929
.	O	-1	12627929
Clin@@	O	-1	12627929
ici@@	O	-1	12627929
ans	O	-1	12627929
should	O	-1	12627929
be	O	-1	12627929
aw@@	O	-1	12627929
are	O	-1	12627929
of	O	-1	12627929
this	O	-1	12627929
potential	O	-1	12627929
complication	O	-1	12627929
when	O	-1	12627929
ad@@	O	-1	12627929
ding	O	-1	12627929
thal@@	B-Chemical	D013792	12627929
id@@	I-Chemical	-1	12627929
om@@	I-Chemical	-1	12627929
ide	I-Chemical	-1	12627929
to	O	-1	12627929
chemo@@	O	-1	12627929
therapeutic	O	-1	12627929
regimen@@	O	-1	12627929
s.	O	-1	12627929

S@@	O	-1	6634932
u@@	O	-1	6634932
bl@@	O	-1	6634932
ing@@	O	-1	6634932
ual	O	-1	6634932
abs@@	O	-1	6634932
or@@	O	-1	6634932
ption	O	-1	6634932
of	O	-1	6634932
the	O	-1	6634932
qu@@	B-Chemical	D000644	6634932
at@@	I-Chemical	-1	6634932
er@@	I-Chemical	-1	6634932
n@@	I-Chemical	-1	6634932
ary	I-Chemical	-1	6634932
am@@	I-Chemical	-1	6634932
mon@@	I-Chemical	-1	6634932
i@@	I-Chemical	-1	6634932
um	I-Chemical	-1	6634932
anti@@	O	-1	6634932
arrhyth@@	O	-1	6634932
mic	O	-1	6634932
agent@@	O	-1	6634932
,	O	-1	6634932
U@@	B-Chemical	C002616	6634932
M@@	I-Chemical	-1	6634932
-@@	I-Chemical	-1	6634932
27@@	I-Chemical	-1	6634932
2	I-Chemical	-1	6634932
.	O	-1	6634932
U@@	B-Chemical	C002616	6634932
M@@	I-Chemical	-1	6634932
-@@	I-Chemical	-1	6634932
27@@	I-Chemical	-1	6634932
2	I-Chemical	-1	6634932
(	O	-1	6634932
N@@	B-Chemical	C002616	6634932
,@@	I-Chemical	-1	6634932
N@@	I-Chemical	-1	6634932
-@@	I-Chemical	-1	6634932
di@@	I-Chemical	-1	6634932
methyl@@	I-Chemical	-1	6634932
prop@@	I-Chemical	-1	6634932
ran@@	I-Chemical	-1	6634932
o@@	I-Chemical	-1	6634932
lol	I-Chemical	-1	6634932
),	O	-1	6634932
a	O	-1	6634932
qu@@	O	-1	6634932
at@@	O	-1	6634932
er@@	O	-1	6634932
n@@	O	-1	6634932
ary	O	-1	6634932
anti@@	O	-1	6634932
arrhyth@@	O	-1	6634932
mic	O	-1	6634932
agent@@	O	-1	6634932
,	O	-1	6634932
was	O	-1	6634932
administered	O	-1	6634932
sub@@	O	-1	6634932
l@@	O	-1	6634932
ing@@	O	-1	6634932
ually	O	-1	6634932
to	O	-1	6634932
dog@@	O	-1	6634932
s	O	-1	6634932
with	O	-1	6634932
ou@@	B-Chemical	D010042	6634932
ab@@	I-Chemical	-1	6634932
ain	I-Chemical	-1	6634932
-induced	O	-1	6634932
ventricular	B-Disease	D017180	6634932
tachy@@	I-Disease	-1	6634932
cardi@@	I-Disease	-1	6634932
as	I-Disease	-1	6634932
.	O	-1	6634932
B@@	O	-1	6634932
oth	O	-1	6634932
anti@@	O	-1	6634932
-@@	O	-1	6634932
arrhyth@@	O	-1	6634932
mic	O	-1	6634932
efficacy	O	-1	6634932
and	O	-1	6634932
bio@@	O	-1	6634932
av@@	O	-1	6634932
ail@@	O	-1	6634932
ability	O	-1	6634932
were	O	-1	6634932
compared	O	-1	6634932
to	O	-1	6634932
oral	O	-1	6634932
drug.	O	-1	6634932
S@@	O	-1	6634932
u@@	O	-1	6634932
bl@@	O	-1	6634932
ing@@	O	-1	6634932
ual	O	-1	6634932
U@@	B-Chemical	C002616	6634932
M@@	I-Chemical	-1	6634932
-@@	I-Chemical	-1	6634932
27@@	I-Chemical	-1	6634932
2	I-Chemical	-1	6634932
conver@@	O	-1	6634932
ted	O	-1	6634932
ventricular	B-Disease	D017180	6634932
tachycardia	I-Disease	-1	6634932
to	O	-1	6634932
s@@	O	-1	6634932
in@@	O	-1	6634932
us	O	-1	6634932
rhyth@@	O	-1	6634932
m	O	-1	6634932
in	O	-1	6634932
all	O	-1	6634932
5	O	-1	6634932
dog@@	O	-1	6634932
s.	O	-1	6634932
The	O	-1	6634932
a@@	O	-1	6634932
re@@	O	-1	6634932
a	O	-1	6634932
under	O	-1	6634932
the	O	-1	6634932
plasma	O	-1	6634932
concentration	O	-1	6634932
time	O	-1	6634932
cur@@	O	-1	6634932
ve	O	-1	6634932
at	O	-1	6634932
9@@	O	-1	6634932
0	O	-1	6634932
min	O	-1	6634932
was	O	-1	6634932
4@@	O	-1	6634932
-1@@	O	-1	6634932
2	O	-1	6634932
times	O	-1	6634932
greater	O	-1	6634932
than	O	-1	6634932
for	O	-1	6634932
oral	O	-1	6634932
drug@@	O	-1	6634932
,	O	-1	6634932
suggesting	O	-1	6634932
the	O	-1	6634932
ex@@	O	-1	6634932
ist@@	O	-1	6634932
ence	O	-1	6634932
of	O	-1	6634932
an	O	-1	6634932
abs@@	O	-1	6634932
or@@	O	-1	6634932
p@@	O	-1	6634932
tion@@	O	-1	6634932
-@@	O	-1	6634932
lim@@	O	-1	6634932
it@@	O	-1	6634932
ing	O	-1	6634932
pro@@	O	-1	6634932
cess	O	-1	6634932
in	O	-1	6634932
the	O	-1	6634932
in@@	O	-1	6634932
test@@	O	-1	6634932
ine,	O	-1	6634932
and	O	-1	6634932
pro@@	O	-1	6634932
vid@@	O	-1	6634932
ing	O	-1	6634932
an	O	-1	6634932
al@@	O	-1	6634932
tern@@	O	-1	6634932
ate	O	-1	6634932
form	O	-1	6634932
of	O	-1	6634932
administration	O	-1	6634932
for	O	-1	6634932
qu@@	O	-1	6634932
at@@	O	-1	6634932
er@@	O	-1	6634932
n@@	O	-1	6634932
ary	O	-1	6634932
drug@@	O	-1	6634932
s.	O	-1	6634932

S@@	O	-1	18791946
ev@@	O	-1	18791946
ere	O	-1	18791946
throm@@	B-Disease	D013921	18791946
b@@	I-Disease	-1	18791946
ocyto@@	I-Disease	-1	18791946
pen@@	I-Disease	-1	18791946
ia	I-Disease	-1	18791946
and	O	-1	18791946
haem@@	B-Disease	D000743	18791946
oly@@	I-Disease	-1	18791946
tic	I-Disease	-1	18791946
ana@@	I-Disease	-1	18791946
emia	I-Disease	-1	18791946
associated	O	-1	18791946
with	O	-1	18791946
ci@@	B-Chemical	D002939	18791946
prof@@	I-Chemical	-1	18791946
lo@@	I-Chemical	-1	18791946
x@@	I-Chemical	-1	18791946
ac@@	I-Chemical	-1	18791946
in	I-Chemical	-1	18791946
:	O	-1	18791946
a	O	-1	18791946
case	O	-1	18791946
report	O	-1	18791946
with	O	-1	18791946
f@@	O	-1	18791946
atal	O	-1	18791946
out@@	O	-1	18791946
co@@	O	-1	18791946
me.	O	-1	18791946
H@@	O	-1	18791946
a@@	O	-1	18791946
em@@	O	-1	18791946
at@@	O	-1	18791946
ological	O	-1	18791946
adverse	O	-1	18791946
reactions	O	-1	18791946
associated	O	-1	18791946
with	O	-1	18791946
f@@	O	-1	18791946
atal	O	-1	18791946
outcom@@	O	-1	18791946
e	O	-1	18791946
are	O	-1	18791946
r@@	O	-1	18791946
are	O	-1	18791946
during	O	-1	18791946
treatment	O	-1	18791946
with	O	-1	18791946
ci@@	B-Chemical	D002939	18791946
prof@@	I-Chemical	-1	18791946
lo@@	I-Chemical	-1	18791946
x@@	I-Chemical	-1	18791946
ac@@	I-Chemical	-1	18791946
in	I-Chemical	-1	18791946
.	O	-1	18791946
A	O	-1	18791946
3@@	O	-1	18791946
0-@@	O	-1	18791946
year	O	-1	18791946
old	O	-1	18791946
Ca@@	O	-1	18791946
uc@@	O	-1	18791946
a@@	O	-1	18791946
si@@	O	-1	18791946
an	O	-1	18791946
man	O	-1	18791946
reported	O	-1	18791946
with	O	-1	18791946
ab@@	B-Disease	D015746	18791946
domin@@	I-Disease	-1	18791946
al	I-Disease	-1	18791946
pain	I-Disease	-1	18791946
and	O	-1	18791946
j@@	B-Disease	D007565	18791946
a@@	I-Disease	-1	18791946
un@@	I-Disease	-1	18791946
dic@@	I-Disease	-1	18791946
e	I-Disease	-1	18791946
after	O	-1	18791946
3-@@	O	-1	18791946
day	O	-1	18791946
administration	O	-1	18791946
of	O	-1	18791946
oral	O	-1	18791946
ci@@	B-Chemical	D002939	18791946
prof@@	I-Chemical	-1	18791946
lo@@	I-Chemical	-1	18791946
x@@	I-Chemical	-1	18791946
ac@@	I-Chemical	-1	18791946
in	I-Chemical	-1	18791946
for	O	-1	18791946
a	O	-1	18791946
sus@@	O	-1	18791946
p@@	O	-1	18791946
ect	O	-1	18791946
of	O	-1	18791946
urinary	B-Disease	D014552	18791946
trac@@	I-Disease	-1	18791946
t	I-Disease	-1	18791946
inf@@	I-Disease	-1	18791946
ection	I-Disease	-1	18791946
.	O	-1	18791946
Clin@@	O	-1	18791946
ical	O	-1	18791946
evalu@@	O	-1	18791946
ations	O	-1	18791946
suggested	O	-1	18791946
an	O	-1	18791946
initial	O	-1	18791946
diagnosis	O	-1	18791946
of	O	-1	18791946
severe	O	-1	18791946
throm@@	B-Disease	D013921	18791946
b@@	I-Disease	-1	18791946
ocyto@@	I-Disease	-1	18791946
pen@@	I-Disease	-1	18791946
ia	I-Disease	-1	18791946
and	O	-1	18791946
haem@@	B-Disease	D006461	18791946
oly@@	I-Disease	-1	18791946
sis	I-Disease	-1	18791946
.	O	-1	18791946
The	O	-1	18791946
patient	O	-1	18791946
progres@@	O	-1	18791946
si@@	O	-1	18791946
vely	O	-1	18791946
developed	O	-1	18791946
p@@	B-Disease	D011693	18791946
et@@	I-Disease	-1	18791946
ec@@	I-Disease	-1	18791946
hi@@	I-Disease	-1	18791946
a@@	I-Disease	-1	18791946
e	I-Disease	-1	18791946
and	O	-1	18791946
pur@@	B-Disease	D011693	18791946
pur@@	I-Disease	-1	18791946
a	I-Disease	-1	18791946
on	O	-1	18791946
th@@	O	-1	18791946
or@@	O	-1	18791946
a@@	O	-1	18791946
x	O	-1	18791946
and	O	-1	18791946
lower	O	-1	18791946
lim@@	O	-1	18791946
b@@	O	-1	18791946
s.	O	-1	18791946
D@@	O	-1	18791946
es@@	O	-1	18791946
pit@@	O	-1	18791946
e	O	-1	18791946
pharmac@@	O	-1	18791946
ological	O	-1	18791946
and	O	-1	18791946
suppor@@	O	-1	18791946
tive	O	-1	18791946
inter@@	O	-1	18791946
ven@@	O	-1	18791946
tion@@	O	-1	18791946
s,	O	-1	18791946
labor@@	O	-1	18791946
atory	O	-1	18791946
par@@	O	-1	18791946
ame@@	O	-1	18791946
ters	O	-1	18791946
wor@@	O	-1	18791946
sen@@	O	-1	18791946
ed	O	-1	18791946
and	O	-1	18791946
the	O	-1	18791946
patient	O	-1	18791946
di@@	O	-1	18791946
ed	O	-1	18791946
17	O	-1	18791946
hours	O	-1	18791946
after	O	-1	18791946
ad@@	O	-1	18791946
mis@@	O	-1	18791946
sion.	O	-1	18791946
An	O	-1	18791946
ac@@	O	-1	18791946
cur@@	O	-1	18791946
ate	O	-1	18791946
auto@@	O	-1	18791946
p@@	O	-1	18791946
sy	O	-1	18791946
revealed	O	-1	18791946
most	O	-1	18791946
org@@	O	-1	18791946
ans	O	-1	18791946
with	O	-1	18791946
diff@@	O	-1	18791946
use	O	-1	18791946
p@@	O	-1	18791946
et@@	O	-1	18791946
ec@@	O	-1	18791946
hi@@	O	-1	18791946
al	O	-1	18791946
haem@@	B-Disease	D006470	18791946
or@@	I-Disease	-1	18791946
rh@@	I-Disease	-1	18791946
ages	I-Disease	-1	18791946
.	O	-1	18791946
No	O	-1	18791946
signs	O	-1	18791946
of	O	-1	18791946
b@@	B-Disease	D001855	18791946
one	I-Disease	-1	18791946
m@@	I-Disease	-1	18791946
ar@@	I-Disease	-1	18791946
ro@@	I-Disease	-1	18791946
w	I-Disease	-1	18791946
de@@	I-Disease	-1	18791946
pression	I-Disease	-1	18791946
were	O	-1	18791946
f@@	O	-1	18791946
oun@@	O	-1	18791946
d.	O	-1	18791946
No	O	-1	18791946
throm@@	B-Disease	D013927	18791946
b@@	I-Disease	-1	18791946
i	I-Disease	-1	18791946
or	O	-1	18791946
signs	O	-1	18791946
of	O	-1	18791946
microangio@@	B-Disease	D014652	18791946
path@@	I-Disease	-1	18791946
i@@	I-Disease	-1	18791946
es	I-Disease	-1	18791946
were	O	-1	18791946
observed	O	-1	18791946
in	O	-1	18791946
arterial	O	-1	18791946
v@@	O	-1	18791946
es@@	O	-1	18791946
sel@@	O	-1	18791946
s.	O	-1	18791946
B@@	O	-1	18791946
lo@@	O	-1	18791946
od	O	-1	18791946
and	O	-1	18791946
urine	O	-1	18791946
c@@	O	-1	18791946
ult@@	O	-1	18791946
ures	O	-1	18791946
did	O	-1	18791946
not	O	-1	18791946
show	O	-1	18791946
any	O	-1	18791946
bac@@	O	-1	18791946
ter@@	O	-1	18791946
ial	O	-1	18791946
grow@@	O	-1	18791946
th@@	O	-1	18791946
.	O	-1	18791946
This	O	-1	18791946
case	O	-1	18791946
report	O	-1	18791946
show@@	O	-1	18791946
s	O	-1	18791946
that	O	-1	18791946
ci@@	B-Chemical	D002939	18791946
prof@@	I-Chemical	-1	18791946
lo@@	I-Chemical	-1	18791946
x@@	I-Chemical	-1	18791946
ac@@	I-Chemical	-1	18791946
in	I-Chemical	-1	18791946
may	O	-1	18791946
pre@@	O	-1	18791946
ci@@	O	-1	18791946
pit@@	O	-1	18791946
ate	O	-1	18791946
lif@@	O	-1	18791946
e-@@	O	-1	18791946
th@@	O	-1	18791946
reat@@	O	-1	18791946
en@@	O	-1	18791946
ing	O	-1	18791946
throm@@	B-Disease	D013921	18791946
b@@	I-Disease	-1	18791946
ocyto@@	I-Disease	-1	18791946
pen@@	I-Disease	-1	18791946
ia	I-Disease	-1	18791946
and	O	-1	18791946
haem@@	B-Disease	D000743	18791946
oly@@	I-Disease	-1	18791946
tic	I-Disease	-1	18791946
ana@@	I-Disease	-1	18791946
emia	I-Disease	-1	18791946
,	O	-1	18791946
even	O	-1	18791946
in	O	-1	18791946
the	O	-1	18791946
early	O	-1	18791946
ph@@	O	-1	18791946
as@@	O	-1	18791946
es	O	-1	18791946
of	O	-1	18791946
treatment	O	-1	18791946
and	O	-1	18791946
without	O	-1	18791946
appa@@	O	-1	18791946
rent	O	-1	18791946
previ@@	O	-1	18791946
ous	O	-1	18791946
expos@@	O	-1	18791946
ures@@	O	-1	18791946
.	O	-1	18791946

S@@	B-Chemical	D019821	17344566
im@@	I-Chemical	-1	17344566
vastatin	I-Chemical	-1	17344566
-induced	O	-1	17344566
bil@@	O	-1	17344566
ateral	O	-1	17344566
le@@	O	-1	17344566
g	O	-1	17344566
compar@@	B-Disease	D003161	17344566
t@@	I-Disease	-1	17344566
ment	I-Disease	-1	17344566
syndrome	I-Disease	-1	17344566
and	O	-1	17344566
my@@	B-Disease	D009135	17344566
on@@	I-Disease	-1	17344566
ec@@	I-Disease	-1	17344566
ro@@	I-Disease	-1	17344566
sis	I-Disease	-1	17344566
associated	O	-1	17344566
with	O	-1	17344566
hypo@@	B-Disease	D007037	17344566
th@@	I-Disease	-1	17344566
yro@@	I-Disease	-1	17344566
i@@	I-Disease	-1	17344566
dis@@	I-Disease	-1	17344566
m	I-Disease	-1	17344566
.	O	-1	17344566
A	O	-1	17344566
5@@	O	-1	17344566
4-@@	O	-1	17344566
year-old	O	-1	17344566
hypo@@	B-Disease	D007037	17344566
th@@	I-Disease	-1	17344566
yro@@	I-Disease	-1	17344566
id	I-Disease	-1	17344566
male	O	-1	17344566
taking	O	-1	17344566
th@@	B-Chemical	D013974	17344566
yro@@	I-Chemical	-1	17344566
x@@	I-Chemical	-1	17344566
ine	I-Chemical	-1	17344566
and	O	-1	17344566
sim@@	B-Chemical	D019821	17344566
vastatin	I-Chemical	-1	17344566
presented	O	-1	17344566
with	O	-1	17344566
bil@@	O	-1	17344566
ateral	O	-1	17344566
le@@	O	-1	17344566
g	O	-1	17344566
compar@@	B-Disease	D003161	17344566
t@@	I-Disease	-1	17344566
ment	I-Disease	-1	17344566
syndrome	I-Disease	-1	17344566
and	O	-1	17344566
my@@	B-Disease	D009135	17344566
on@@	I-Disease	-1	17344566
ec@@	I-Disease	-1	17344566
ro@@	I-Disease	-1	17344566
sis	I-Disease	-1	17344566
.	O	-1	17344566
U@@	O	-1	17344566
r@@	O	-1	17344566
g@@	O	-1	17344566
ent	O	-1	17344566
f@@	O	-1	17344566
as@@	O	-1	17344566
ci@@	O	-1	17344566
ot@@	O	-1	17344566
om@@	O	-1	17344566
i@@	O	-1	17344566
es	O	-1	17344566
were	O	-1	17344566
performed	O	-1	17344566
and	O	-1	17344566
the	O	-1	17344566
patient	O	-1	17344566
m@@	O	-1	17344566
ade	O	-1	17344566
an	O	-1	17344566
un@@	O	-1	17344566
event@@	O	-1	17344566
ful	O	-1	17344566
recovery	O	-1	17344566
with	O	-1	17344566
the	O	-1	17344566
withdrawal	O	-1	17344566
of	O	-1	17344566
sim@@	B-Chemical	D019821	17344566
vastatin	I-Chemical	-1	17344566
.	O	-1	17344566
It	O	-1	17344566
is	O	-1	17344566
likely	O	-1	17344566
that	O	-1	17344566
this	O	-1	17344566
complication	O	-1	17344566
wil@@	O	-1	17344566
l	O	-1	17344566
be	O	-1	17344566
seen	O	-1	17344566
more	O	-1	17344566
often	O	-1	17344566
with	O	-1	17344566
the	O	-1	17344566
increased	O	-1	17344566
wor@@	O	-1	17344566
l@@	O	-1	17344566
d@@	O	-1	17344566
w@@	O	-1	17344566
ide	O	-1	17344566
use	O	-1	17344566
of	O	-1	17344566
this	O	-1	17344566
drug	O	-1	17344566
and	O	-1	17344566
its	O	-1	17344566
appro@@	O	-1	17344566
v@@	O	-1	17344566
al	O	-1	17344566
for	O	-1	17344566
all	O	-1	17344566
arter@@	B-Disease	D014652	17344566
io@@	I-Disease	-1	17344566
path@@	I-Disease	-1	17344566
ic	I-Disease	-1	17344566
patients.	O	-1	17344566

B@@	B-Disease	D001650	9293063
ile	I-Disease	-1	9293063
duc@@	I-Disease	-1	9293063
t	I-Disease	-1	9293063
h@@	I-Disease	-1	9293063
am@@	I-Disease	-1	9293063
ar@@	I-Disease	-1	9293063
to@@	I-Disease	-1	9293063
ma	I-Disease	-1	9293063
B@@	B-Disease	D006222	9293063
ile	I-Disease	-1	9293063
duc@@	I-Disease	-1	9293063
t	I-Disease	-1	9293063
h@@	I-Disease	-1	9293063
am@@	I-Disease	-1	9293063
ar@@	I-Disease	-1	9293063
to@@	I-Disease	-1	9293063
ma	I-Disease	-1	9293063
occur@@	O	-1	9293063
r@@	O	-1	9293063
ing	O	-1	9293063
in	O	-1	9293063
association	O	-1	9293063
with	O	-1	9293063
long-term	O	-1	9293063
treatment	O	-1	9293063
with	O	-1	9293063
d@@	B-Chemical	D003613	9293063
an@@	I-Chemical	-1	9293063
az@@	I-Chemical	-1	9293063
ol	I-Chemical	-1	9293063
.	O	-1	9293063
We	O	-1	9293063
report	O	-1	9293063
a	O	-1	9293063
case	O	-1	9293063
of	O	-1	9293063
b@@	B-Disease	D001650	9293063
ile	I-Disease	-1	9293063
duc@@	I-Disease	-1	9293063
t	I-Disease	-1	9293063
h@@	I-Disease	-1	9293063
am@@	I-Disease	-1	9293063
ar@@	I-Disease	-1	9293063
to@@	I-Disease	-1	9293063
ma	I-Disease	-1	9293063
b@@	B-Disease	D006222	9293063
ile	I-Disease	-1	9293063
duc@@	I-Disease	-1	9293063
t	I-Disease	-1	9293063
h@@	I-Disease	-1	9293063
am@@	I-Disease	-1	9293063
ar@@	I-Disease	-1	9293063
to@@	I-Disease	-1	9293063
ma	I-Disease	-1	9293063
which	O	-1	9293063
developed	O	-1	9293063
in	O	-1	9293063
a	O	-1	9293063
patient	O	-1	9293063
who	O	-1	9293063
had	O	-1	9293063
been	O	-1	9293063
on	O	-1	9293063
long-term	O	-1	9293063
d@@	B-Chemical	D003613	9293063
an@@	I-Chemical	-1	9293063
az@@	I-Chemical	-1	9293063
ol	I-Chemical	-1	9293063
treatment.	O	-1	9293063
S@@	O	-1	9293063
uc@@	O	-1	9293063
h	O	-1	9293063
patients	O	-1	9293063
should	O	-1	9293063
be	O	-1	9293063
under	O	-1	9293063
clo@@	O	-1	9293063
se	O	-1	9293063
follow-@@	O	-1	9293063
up@@	O	-1	9293063
,	O	-1	9293063
pre@@	O	-1	9293063
fer@@	O	-1	9293063
ably	O	-1	9293063
with	O	-1	9293063
perio@@	O	-1	9293063
di@@	O	-1	9293063
c	O	-1	9293063
ult@@	O	-1	9293063
r@@	O	-1	9293063
as@@	O	-1	9293063
ound	O	-1	9293063
examin@@	O	-1	9293063
ation	O	-1	9293063
of	O	-1	9293063
the	O	-1	9293063
li@@	O	-1	9293063
ver@@	O	-1	9293063
.	O	-1	9293063
I@@	O	-1	9293063
f	O	-1	9293063
the	O	-1	9293063
patient	O	-1	9293063
develop@@	O	-1	9293063
s	O	-1	9293063
a	O	-1	9293063
liver	B-Disease	D008107	9293063
mas@@	I-Disease	-1	9293063
s	I-Disease	-1	9293063
,	O	-1	9293063
because	O	-1	9293063
of	O	-1	9293063
non-@@	O	-1	9293063
specific	O	-1	9293063
clinical	O	-1	9293063
feat@@	O	-1	9293063
ures	O	-1	9293063
and	O	-1	9293063
imaging	O	-1	9293063
appear@@	O	-1	9293063
anc@@	O	-1	9293063
es,	O	-1	9293063
biop@@	O	-1	9293063
sy	O	-1	9293063
may	O	-1	9293063
be	O	-1	9293063
the	O	-1	9293063
only	O	-1	9293063
w@@	O	-1	9293063
ay	O	-1	9293063
to	O	-1	9293063
achi@@	O	-1	9293063
e@@	O	-1	9293063
ve	O	-1	9293063
a	O	-1	9293063
def@@	O	-1	9293063
in@@	O	-1	9293063
itive	O	-1	9293063
diagno@@	O	-1	9293063
sis.	O	-1	9293063

G@@	B-Disease	D006099	1728522
ran@@	I-Disease	-1	1728522
ulo@@	I-Disease	-1	1728522
mat@@	I-Disease	-1	1728522
ous	I-Disease	-1	1728522
hepatitis	I-Disease	-1	1728522
G@@	B-Disease	D056486	1728522
ran@@	I-Disease	-1	1728522
ulo@@	I-Disease	-1	1728522
mat@@	I-Disease	-1	1728522
ous	I-Disease	-1	1728522
hepatitis	I-Disease	-1	1728522
due	O	-1	1728522
to	O	-1	1728522
combination	B-Chemical	D019980	1728522
of	I-Chemical	-1	1728522
am@@	I-Chemical	-1	1728522
oxic@@	I-Chemical	-1	1728522
ill@@	I-Chemical	-1	1728522
in	I-Chemical	-1	1728522
and	I-Chemical	-1	1728522
cl@@	I-Chemical	-1	1728522
av@@	I-Chemical	-1	1728522
ul@@	I-Chemical	-1	1728522
anic	I-Chemical	-1	1728522
acid	I-Chemical	-1	1728522
.	O	-1	1728522
We	O	-1	1728522
report	O	-1	1728522
the	O	-1	1728522
case	O	-1	1728522
of	O	-1	1728522
a	O	-1	1728522
patient	O	-1	1728522
with	O	-1	1728522
am@@	B-Chemical	D019980	1728522
oxic@@	I-Chemical	-1	1728522
ill@@	I-Chemical	-1	1728522
in-@@	I-Chemical	-1	1728522
cl@@	I-Chemical	-1	1728522
av@@	I-Chemical	-1	1728522
ul@@	I-Chemical	-1	1728522
anic	I-Chemical	-1	1728522
acid	I-Chemical	-1	1728522
-induced	O	-1	1728522
hepatitis	B-Disease	D056486	1728522
with	O	-1	1728522
hist@@	O	-1	1728522
ologic	O	-1	1728522
multiple	O	-1	1728522
gran@@	B-Disease	D006099	1728522
ulo@@	I-Disease	-1	1728522
m@@	I-Disease	-1	1728522
as	I-Disease	-1	1728522
.	O	-1	1728522
This	O	-1	1728522
type	O	-1	1728522
of	O	-1	1728522
le@@	O	-1	1728522
sion	O	-1	1728522
b@@	O	-1	1728522
ro@@	O	-1	1728522
aden@@	O	-1	1728522
s	O	-1	1728522
the	O	-1	1728522
sp@@	O	-1	1728522
ect@@	O	-1	1728522
ru@@	O	-1	1728522
m	O	-1	1728522
of	O	-1	1728522
liver	B-Disease	D056486	1728522
injury	I-Disease	-1	1728522
due	O	-1	1728522
to	O	-1	1728522
this	O	-1	1728522
drug	O	-1	1728522
combin@@	O	-1	1728522
ation,	O	-1	1728522
main@@	O	-1	1728522
ly	O	-1	1728522
re@@	O	-1	1728522
presented	O	-1	1728522
by	O	-1	1728522
a	O	-1	1728522
ben@@	O	-1	1728522
ig@@	O	-1	1728522
n	O	-1	1728522
cholest@@	B-Disease	D002779	1728522
atic	I-Disease	-1	1728522
syndrome	I-Disease	-1	1728522
.	O	-1	1728522
The	O	-1	1728522
association	O	-1	1728522
of	O	-1	1728522
gran@@	B-Disease	D006099	1728522
ulo@@	I-Disease	-1	1728522
m@@	I-Disease	-1	1728522
as	I-Disease	-1	1728522
and	O	-1	1728522
e@@	B-Disease	D004802	1728522
os@@	I-Disease	-1	1728522
in@@	I-Disease	-1	1728522
oph@@	I-Disease	-1	1728522
il@@	I-Disease	-1	1728522
ia	I-Disease	-1	1728522
f@@	O	-1	1728522
av@@	O	-1	1728522
or	O	-1	1728522
an	O	-1	1728522
immuno@@	O	-1	1728522
all@@	O	-1	1728522
ergic	O	-1	1728522
mechanis@@	O	-1	1728522
m.	O	-1	1728522
A@@	O	-1	1728522
s	O	-1	1728522
pen@@	B-Chemical	D010406	1728522
icill@@	I-Chemical	-1	1728522
in	I-Chemical	-1	1728522
der@@	O	-1	1728522
i@@	O	-1	1728522
v@@	O	-1	1728522
ati@@	O	-1	1728522
v@@	O	-1	1728522
es	O	-1	1728522
and	O	-1	1728522
am@@	B-Chemical	D000658	1728522
oxic@@	I-Chemical	-1	1728522
ill@@	I-Chemical	-1	1728522
in	I-Chemical	-1	1728522
alone	O	-1	1728522
are	O	-1	1728522
known	O	-1	1728522
to	O	-1	1728522
induce	O	-1	1728522
such	O	-1	1728522
typ@@	O	-1	1728522
es	O	-1	1728522
of	O	-1	1728522
le@@	O	-1	1728522
sion@@	O	-1	1728522
s,	O	-1	1728522
the	O	-1	1728522
am@@	B-Chemical	D000658	1728522
oxic@@	I-Chemical	-1	1728522
ill@@	I-Chemical	-1	1728522
in	I-Chemical	-1	1728522
comp@@	O	-1	1728522
on@@	O	-1	1728522
ent@@	O	-1	1728522
,	O	-1	1728522
with	O	-1	1728522
or	O	-1	1728522
without	O	-1	1728522
a	O	-1	1728522
potenti@@	O	-1	1728522
ating	O	-1	1728522
effect	O	-1	1728522
of	O	-1	1728522
cl@@	B-Chemical	D019818	1728522
av@@	I-Chemical	-1	1728522
ul@@	I-Chemical	-1	1728522
anic	I-Chemical	-1	1728522
acid	I-Chemical	-1	1728522
,	O	-1	1728522
might	O	-1	1728522
have	O	-1	1728522
a	O	-1	1728522
major	O	-1	1728522
ro@@	O	-1	1728522
le@@	O	-1	1728522
.	O	-1	1728522

In@@	B-Disease	D002532	10807237
trac@@	I-Disease	-1	10807237
ranial	I-Disease	-1	10807237
aneurys@@	I-Disease	-1	10807237
ms	I-Disease	-1	10807237
and	O	-1	10807237
cocaine	B-Disease	D019970	10807237
ab@@	I-Disease	-1	10807237
use	I-Disease	-1	10807237
:	O	-1	10807237
analysis	O	-1	10807237
of	O	-1	10807237
pro@@	O	-1	10807237
gn@@	O	-1	10807237
os@@	O	-1	10807237
tic	O	-1	10807237
indic@@	O	-1	10807237
at@@	O	-1	10807237
or@@	O	-1	10807237
s.	O	-1	10807237
OBJECTIVE:	O	-1	10807237
The	O	-1	10807237
outcom@@	O	-1	10807237
e	O	-1	10807237
of	O	-1	10807237
sub@@	B-Disease	D013345	10807237
arac@@	I-Disease	-1	10807237
h@@	I-Disease	-1	10807237
no@@	I-Disease	-1	10807237
id	I-Disease	-1	10807237
hemorrh@@	I-Disease	-1	10807237
age	I-Disease	-1	10807237
associated	O	-1	10807237
with	O	-1	10807237
cocaine	B-Disease	D019970	10807237
ab@@	I-Disease	-1	10807237
use	I-Disease	-1	10807237
is	O	-1	10807237
repor@@	O	-1	10807237
te@@	O	-1	10807237
d@@	O	-1	10807237
ly	O	-1	10807237
po@@	O	-1	10807237
or@@	O	-1	10807237
.	O	-1	10807237
However,	O	-1	10807237
no	O	-1	10807237
study	O	-1	10807237
in	O	-1	10807237
the	O	-1	10807237
literat@@	O	-1	10807237
ure	O	-1	10807237
has	O	-1	10807237
reported	O	-1	10807237
the	O	-1	10807237
use	O	-1	10807237
of	O	-1	10807237
a	O	-1	10807237
statis@@	O	-1	10807237
tical	O	-1	10807237
model	O	-1	10807237
to	O	-1	10807237
analy@@	O	-1	10807237
ze	O	-1	10807237
the	O	-1	10807237
vari@@	O	-1	10807237
able@@	O	-1	10807237
s	O	-1	10807237
that	O	-1	10807237
influence	O	-1	10807237
out@@	O	-1	10807237
co@@	O	-1	10807237
me.	O	-1	10807237
METHODS:	O	-1	10807237
A	O	-1	10807237
revie@@	O	-1	10807237
w	O	-1	10807237
of	O	-1	10807237
ad@@	O	-1	10807237
mis@@	O	-1	10807237
sions	O	-1	10807237
during	O	-1	10807237
a	O	-1	10807237
6-@@	O	-1	10807237
year	O	-1	10807237
period	O	-1	10807237
revealed	O	-1	10807237
14	O	-1	10807237
patients	O	-1	10807237
with	O	-1	10807237
cocaine	B-Chemical	D003042	10807237
-@@	O	-1	10807237
related	O	-1	10807237
aneurys@@	B-Disease	D000783	10807237
ms	I-Disease	-1	10807237
.	O	-1	10807237
This	O	-1	10807237
group	O	-1	10807237
was	O	-1	10807237
compared	O	-1	10807237
with	O	-1	10807237
a	O	-1	10807237
control	O	-1	10807237
group	O	-1	10807237
of	O	-1	10807237
13@@	O	-1	10807237
5	O	-1	10807237
patients	O	-1	10807237
with	O	-1	10807237
ru@@	B-Disease	D017542	10807237
pt@@	I-Disease	-1	10807237
ured	I-Disease	-1	10807237
aneurys@@	I-Disease	-1	10807237
ms	I-Disease	-1	10807237
and	O	-1	10807237
no	O	-1	10807237
hist@@	O	-1	10807237
ory	O	-1	10807237
of	O	-1	10807237
cocaine	B-Disease	D019970	10807237
ab@@	I-Disease	-1	10807237
use	I-Disease	-1	10807237
.	O	-1	10807237
A@@	O	-1	10807237
ge	O	-1	10807237
at	O	-1	10807237
present@@	O	-1	10807237
ation,	O	-1	10807237
time	O	-1	10807237
of	O	-1	10807237
ic@@	O	-1	10807237
t@@	O	-1	10807237
us	O	-1	10807237
after	O	-1	10807237
in@@	O	-1	10807237
toxic@@	O	-1	10807237
ation,	O	-1	10807237
H@@	O	-1	10807237
un@@	O	-1	10807237
t	O	-1	10807237
and	O	-1	10807237
H@@	O	-1	10807237
ess	O	-1	10807237
gra@@	O	-1	10807237
de	O	-1	10807237
of	O	-1	10807237
sub@@	B-Disease	D013345	10807237
arac@@	I-Disease	-1	10807237
h@@	I-Disease	-1	10807237
no@@	I-Disease	-1	10807237
id	I-Disease	-1	10807237
hemorrh@@	I-Disease	-1	10807237
age	I-Disease	-1	10807237
,	O	-1	10807237
size	O	-1	10807237
of	O	-1	10807237
the	O	-1	10807237
aneurys@@	B-Disease	D000783	10807237
m	I-Disease	-1	10807237
,	O	-1	10807237
loc@@	O	-1	10807237
ation	O	-1	10807237
of	O	-1	10807237
the	O	-1	10807237
aneurys@@	B-Disease	D000783	10807237
m	I-Disease	-1	10807237
,	O	-1	10807237
and	O	-1	10807237
the	O	-1	10807237
G@@	O	-1	10807237
las@@	O	-1	10807237
go@@	O	-1	10807237
w	O	-1	10807237
O@@	O	-1	10807237
ut@@	O	-1	10807237
com@@	O	-1	10807237
e	O	-1	10807237
S@@	O	-1	10807237
cal@@	O	-1	10807237
e	O	-1	10807237
scor@@	O	-1	10807237
e	O	-1	10807237
were	O	-1	10807237
assessed	O	-1	10807237
and	O	-1	10807237
com@@	O	-1	10807237
pa@@	O	-1	10807237
red.	O	-1	10807237
RESULTS:	O	-1	10807237
The	O	-1	10807237
patients	O	-1	10807237
in	O	-1	10807237
the	O	-1	10807237
study	O	-1	10807237
group	O	-1	10807237
were	O	-1	10807237
significantly	O	-1	10807237
youn@@	O	-1	10807237
g@@	O	-1	10807237
er	O	-1	10807237
than	O	-1	10807237
the	O	-1	10807237
patients	O	-1	10807237
in	O	-1	10807237
the	O	-1	10807237
control	O	-1	10807237
group	O	-1	10807237
(P	O	-1	10807237
<	O	-1	10807237
0.00@@	O	-1	10807237
2@@	O	-1	10807237
).	O	-1	10807237
In	O	-1	10807237
patients	O	-1	10807237
in	O	-1	10807237
the	O	-1	10807237
study	O	-1	10807237
group@@	O	-1	10807237
,	O	-1	10807237
all	O	-1	10807237
aneurys@@	B-Disease	D000783	10807237
ms	I-Disease	-1	10807237
were	O	-1	10807237
loc@@	O	-1	10807237
ated	O	-1	10807237
in	O	-1	10807237
the	O	-1	10807237
an@@	O	-1	10807237
ter@@	O	-1	10807237
ior	O	-1	10807237
cir@@	O	-1	10807237
cul@@	O	-1	10807237
ation.	O	-1	10807237
The	O	-1	10807237
maj@@	O	-1	10807237
or@@	O	-1	10807237
ity	O	-1	10807237
of	O	-1	10807237
these	O	-1	10807237
aneurys@@	B-Disease	D000783	10807237
ms	I-Disease	-1	10807237
were	O	-1	10807237
sm@@	O	-1	10807237
all@@	O	-1	10807237
er	O	-1	10807237
than	O	-1	10807237
those	O	-1	10807237
of	O	-1	10807237
the	O	-1	10807237
control	O	-1	10807237
group	O	-1	10807237
(@@	O	-1	10807237
8	O	-1	10807237
+/-	O	-1	10807237
6.@@	O	-1	10807237
0@@	O	-1	10807237
8	O	-1	10807237
mm	O	-1	10807237
versus	O	-1	10807237
11	O	-1	10807237
+/-	O	-1	10807237
5.@@	O	-1	10807237
4	O	-1	10807237
mm@@	O	-1	10807237
;	O	-1	10807237
P	O	-1	10807237
=	O	-1	10807237
0.05@@	O	-1	10807237
).	O	-1	10807237
The	O	-1	10807237
differences	O	-1	10807237
in	O	-1	10807237
mor@@	O	-1	10807237
t@@	O	-1	10807237
ality	O	-1	10807237
and	O	-1	10807237
mor@@	O	-1	10807237
b@@	O	-1	10807237
idity	O	-1	10807237
between	O	-1	10807237
the	O	-1	10807237
two	O	-1	10807237
groups	O	-1	10807237
were	O	-1	10807237
not	O	-1	10807237
significant@@	O	-1	10807237
.	O	-1	10807237
H@@	O	-1	10807237
un@@	O	-1	10807237
t	O	-1	10807237
and	O	-1	10807237
H@@	O	-1	10807237
ess	O	-1	10807237
gra@@	O	-1	10807237
de	O	-1	10807237
(P	O	-1	10807237
<	O	-1	10807237
0.00@@	O	-1	10807237
5@@	O	-1	10807237
)	O	-1	10807237
and	O	-1	10807237
age	O	-1	10807237
(P	O	-1	10807237
<	O	-1	10807237
0.00@@	O	-1	10807237
7@@	O	-1	10807237
)	O	-1	10807237
were	O	-1	10807237
significant	O	-1	10807237
predic@@	O	-1	10807237
t@@	O	-1	10807237
ors	O	-1	10807237
of	O	-1	10807237
outcom@@	O	-1	10807237
e	O	-1	10807237
for	O	-1	10807237
the	O	-1	10807237
patients	O	-1	10807237
with	O	-1	10807237
cocaine	B-Chemical	D003042	10807237
-@@	O	-1	10807237
related	O	-1	10807237
aneurys@@	B-Disease	D000783	10807237
ms	I-Disease	-1	10807237
.	O	-1	10807237
CONCLUSION:	O	-1	10807237
C@@	B-Chemical	D003042	10807237
oc@@	I-Chemical	-1	10807237
aine	I-Chemical	-1	10807237
use	O	-1	10807237
pre@@	O	-1	10807237
dis@@	O	-1	10807237
pos@@	O	-1	10807237
ed	O	-1	10807237
aneurys@@	B-Disease	D017542	10807237
m@@	I-Disease	-1	10807237
al	I-Disease	-1	10807237
ru@@	I-Disease	-1	10807237
pt@@	I-Disease	-1	10807237
ure	I-Disease	-1	10807237
at	O	-1	10807237
a	O	-1	10807237
significantly	O	-1	10807237
ear@@	O	-1	10807237
li@@	O	-1	10807237
er	O	-1	10807237
age	O	-1	10807237
and	O	-1	10807237
in	O	-1	10807237
m@@	O	-1	10807237
uc@@	O	-1	10807237
h	O	-1	10807237
sm@@	O	-1	10807237
all@@	O	-1	10807237
er	O	-1	10807237
aneurys@@	B-Disease	D000783	10807237
ms	I-Disease	-1	10807237
.	O	-1	10807237
C@@	O	-1	10807237
ont@@	O	-1	10807237
r@@	O	-1	10807237
ary	O	-1	10807237
to	O	-1	10807237
the	O	-1	10807237
pu@@	O	-1	10807237
bl@@	O	-1	10807237
ished	O	-1	10807237
literat@@	O	-1	10807237
ure,	O	-1	10807237
this	O	-1	10807237
group	O	-1	10807237
did	O	-1	10807237
reas@@	O	-1	10807237
on@@	O	-1	10807237
ably	O	-1	10807237
well	O	-1	10807237
with	O	-1	10807237
ag@@	O	-1	10807237
gres@@	O	-1	10807237
sive	O	-1	10807237
man@@	O	-1	10807237
ag@@	O	-1	10807237
em@@	O	-1	10807237
ent@@	O	-1	10807237
.	O	-1	10807237

An@@	O	-1	12536034
ti@@	O	-1	12536034
-	O	-1	12536034
epileptic	B-Disease	D004827	12536034
drug@@	O	-1	12536034
s@@	O	-1	12536034
-induced	O	-1	12536034
de	O	-1	12536034
no@@	O	-1	12536034
v@@	O	-1	12536034
o	O	-1	12536034
absence	B-Disease	D004832	12536034
seizures	I-Disease	-1	12536034
.	O	-1	12536034
The	O	-1	12536034
au@@	O	-1	12536034
th@@	O	-1	12536034
ors	O	-1	12536034
present	O	-1	12536034
three	O	-1	12536034
patients	O	-1	12536034
with	O	-1	12536034
de	O	-1	12536034
no@@	O	-1	12536034
v@@	O	-1	12536034
o	O	-1	12536034
absence	B-Disease	D004832	12536034
epilep@@	I-Disease	-1	12536034
sy	I-Disease	-1	12536034
after	O	-1	12536034
administration	O	-1	12536034
of	O	-1	12536034
carbamazepine	B-Chemical	D002220	12536034
and	O	-1	12536034
vi@@	B-Chemical	D020888	12536034
g@@	I-Chemical	-1	12536034
ab@@	I-Chemical	-1	12536034
at@@	I-Chemical	-1	12536034
rin	I-Chemical	-1	12536034
.	O	-1	12536034
D@@	O	-1	12536034
es@@	O	-1	12536034
pit@@	O	-1	12536034
e	O	-1	12536034
the	O	-1	12536034
underlying	O	-1	12536034
diseas@@	O	-1	12536034
es,	O	-1	12536034
the	O	-1	12536034
pro@@	O	-1	12536034
g@@	O	-1	12536034
no@@	O	-1	12536034
sis	O	-1	12536034
for	O	-1	12536034
drug@@	O	-1	12536034
-induced	O	-1	12536034
de	O	-1	12536034
no@@	O	-1	12536034
v@@	O	-1	12536034
o	O	-1	12536034
absence	B-Disease	D004832	12536034
seizure	I-Disease	-1	12536034
is	O	-1	12536034
go@@	O	-1	12536034
od	O	-1	12536034
because	O	-1	12536034
it	O	-1	12536034
sub@@	O	-1	12536034
side@@	O	-1	12536034
s	O	-1	12536034
ra@@	O	-1	12536034
pid@@	O	-1	12536034
ly	O	-1	12536034
after	O	-1	12536034
discontinu@@	O	-1	12536034
ing	O	-1	12536034
the	O	-1	12536034
use	O	-1	12536034
of	O	-1	12536034
the	O	-1	12536034
o@@	O	-1	12536034
ff@@	O	-1	12536034
en@@	O	-1	12536034
ding	O	-1	12536034
drug@@	O	-1	12536034
s.	O	-1	12536034
The	O	-1	12536034
gamma@@	B-Chemical	D005680	12536034
-@@	I-Chemical	-1	12536034
amin@@	I-Chemical	-1	12536034
ob@@	I-Chemical	-1	12536034
ut@@	I-Chemical	-1	12536034
y@@	I-Chemical	-1	12536034
ric	I-Chemical	-1	12536034
acid	I-Chemical	-1	12536034
-@@	O	-1	12536034
trans@@	O	-1	12536034
mit@@	O	-1	12536034
ted	O	-1	12536034
thal@@	O	-1	12536034
am@@	O	-1	12536034
oc@@	O	-1	12536034
or@@	O	-1	12536034
tical	O	-1	12536034
cir@@	O	-1	12536034
c@@	O	-1	12536034
u@@	O	-1	12536034
it@@	O	-1	12536034
r@@	O	-1	12536034
y	O	-1	12536034
ac@@	O	-1	12536034
coun@@	O	-1	12536034
ts	O	-1	12536034
for	O	-1	12536034
a	O	-1	12536034
major	O	-1	12536034
par@@	O	-1	12536034
t	O	-1	12536034
of	O	-1	12536034
the	O	-1	12536034
underlying	O	-1	12536034
neuro@@	O	-1	12536034
physi@@	O	-1	12536034
ology	O	-1	12536034
of	O	-1	12536034
the	O	-1	12536034
absence	B-Disease	D004832	12536034
epilep@@	I-Disease	-1	12536034
sy	I-Disease	-1	12536034
.	O	-1	12536034
B@@	O	-1	12536034
ecause	O	-1	12536034
drug@@	O	-1	12536034
-induced	O	-1	12536034
de	O	-1	12536034
no@@	O	-1	12536034
v@@	O	-1	12536034
o	O	-1	12536034
absence	B-Disease	D004832	12536034
seizure	I-Disease	-1	12536034
is	O	-1	12536034
ra@@	O	-1	12536034
re,	O	-1	12536034
pro@@	O	-1	12536034
-@@	O	-1	12536034
absence	O	-1	12536034
drugs	O	-1	12536034
can	O	-1	12536034
only	O	-1	12536034
be	O	-1	12536034
considered	O	-1	12536034
a	O	-1	12536034
pro@@	O	-1	12536034
m@@	O	-1	12536034
ot@@	O	-1	12536034
ing	O	-1	12536034
fact@@	O	-1	12536034
or@@	O	-1	12536034
.	O	-1	12536034
The	O	-1	12536034
underlying	O	-1	12536034
epile@@	O	-1	12536034
pto@@	O	-1	12536034
gen@@	O	-1	12536034
ec@@	O	-1	12536034
ity	O	-1	12536034
of	O	-1	12536034
the	O	-1	12536034
patients	O	-1	12536034
or	O	-1	12536034
the	O	-1	12536034
syn@@	O	-1	12536034
erg@@	O	-1	12536034
istic	O	-1	12536034
effects	O	-1	12536034
of	O	-1	12536034
the	O	-1	12536034
ac@@	O	-1	12536034
comp@@	O	-1	12536034
an@@	O	-1	12536034
y@@	O	-1	12536034
ing	O	-1	12536034
drugs	O	-1	12536034
is	O	-1	12536034
requ@@	O	-1	12536034
ired	O	-1	12536034
to	O	-1	12536034
tri@@	O	-1	12536034
g@@	O	-1	12536034
g@@	O	-1	12536034
er	O	-1	12536034
the	O	-1	12536034
de	O	-1	12536034
no@@	O	-1	12536034
v@@	O	-1	12536034
o	O	-1	12536034
absence	B-Disease	D004832	12536034
seizure	I-Disease	-1	12536034
.	O	-1	12536034
The	O	-1	12536034
possib@@	O	-1	12536034
ility	O	-1	12536034
of	O	-1	12536034
drug@@	O	-1	12536034
-induced	O	-1	12536034
ag@@	O	-1	12536034
gra@@	O	-1	12536034
v@@	O	-1	12536034
ation	O	-1	12536034
should	O	-1	12536034
be	O	-1	12536034
considered	O	-1	12536034
wh@@	O	-1	12536034
en@@	O	-1	12536034
ev@@	O	-1	12536034
er	O	-1	12536034
an	O	-1	12536034
un@@	O	-1	12536034
ex@@	O	-1	12536034
p@@	O	-1	12536034
ected	O	-1	12536034
increase	O	-1	12536034
in	O	-1	12536034
seizure	B-Disease	D012640	12536034
frequency	O	-1	12536034
and/or	O	-1	12536034
new	O	-1	12536034
seizure	B-Disease	D012640	12536034
typ@@	O	-1	12536034
es	O	-1	12536034
appe@@	O	-1	12536034
ar	O	-1	12536034
following	O	-1	12536034
a	O	-1	12536034
change	O	-1	12536034
in	O	-1	12536034
drug	O	-1	12536034
treatment.	O	-1	12536034
B@@	O	-1	12536034
y	O	-1	12536034
under@@	O	-1	12536034
stand@@	O	-1	12536034
ing	O	-1	12536034
the	O	-1	12536034
underlying	O	-1	12536034
mechanism	O	-1	12536034
of	O	-1	12536034
absence	B-Disease	D004832	12536034
epilep@@	I-Disease	-1	12536034
sy	I-Disease	-1	12536034
,	O	-1	12536034
we	O	-1	12536034
can	O	-1	12536034
av@@	O	-1	12536034
oid	O	-1	12536034
the	O	-1	12536034
in@@	O	-1	12536034
appro@@	O	-1	12536034
pri@@	O	-1	12536034
ate	O	-1	12536034
use	O	-1	12536034
of	O	-1	12536034
anti@@	O	-1	12536034
convul@@	O	-1	12536034
s@@	O	-1	12536034
ants	O	-1	12536034
in	O	-1	12536034
children	O	-1	12536034
with	O	-1	12536034
epilep@@	B-Disease	D004827	12536034
sy	I-Disease	-1	12536034
and	O	-1	12536034
prev@@	O	-1	12536034
ent	O	-1	12536034
drug@@	O	-1	12536034
-induced	O	-1	12536034
absence	B-Disease	D004832	12536034
seizures	I-Disease	-1	12536034
.	O	-1	12536034

Pro@@	B-Chemical	D011342	7234705
ca@@	I-Chemical	-1	7234705
in@@	I-Chemical	-1	7234705
amide	I-Chemical	-1	7234705
-induced	O	-1	7234705
poly@@	O	-1	7234705
morph@@	O	-1	7234705
ous	O	-1	7234705
ventricular	B-Disease	D017180	7234705
tachycardia	I-Disease	-1	7234705
.	O	-1	7234705
S@@	O	-1	7234705
even	O	-1	7234705
cases	O	-1	7234705
of	O	-1	7234705
pro@@	B-Chemical	D011342	7234705
ca@@	I-Chemical	-1	7234705
in@@	I-Chemical	-1	7234705
amide	I-Chemical	-1	7234705
-induced	O	-1	7234705
poly@@	O	-1	7234705
morph@@	O	-1	7234705
ous	O	-1	7234705
ventricular	B-Disease	D017180	7234705
tachycardia	I-Disease	-1	7234705
are	O	-1	7234705
present@@	O	-1	7234705
ed.	O	-1	7234705
In	O	-1	7234705
four	O	-1	7234705
patients,	O	-1	7234705
poly@@	O	-1	7234705
morph@@	O	-1	7234705
ous	O	-1	7234705
ventricular	B-Disease	D017180	7234705
tachycardia	I-Disease	-1	7234705
appe@@	O	-1	7234705
a@@	O	-1	7234705
red	O	-1	7234705
after	O	-1	7234705
intravenous	O	-1	7234705
administration	O	-1	7234705
of	O	-1	7234705
2@@	O	-1	7234705
00	O	-1	7234705
to	O	-1	7234705
4@@	O	-1	7234705
00	O	-1	7234705
mg	O	-1	7234705
of	O	-1	7234705
pro@@	B-Chemical	D011342	7234705
ca@@	I-Chemical	-1	7234705
in@@	I-Chemical	-1	7234705
amide	I-Chemical	-1	7234705
for	O	-1	7234705
the	O	-1	7234705
treatment	O	-1	7234705
of	O	-1	7234705
su@@	O	-1	7234705
st@@	O	-1	7234705
ained	O	-1	7234705
ventricular	B-Disease	D017180	7234705
tachycardia	I-Disease	-1	7234705
.	O	-1	7234705
In	O	-1	7234705
the	O	-1	7234705
remain@@	O	-1	7234705
ing	O	-1	7234705
three	O	-1	7234705
patients,	O	-1	7234705
pro@@	B-Chemical	D011342	7234705
ca@@	I-Chemical	-1	7234705
in@@	I-Chemical	-1	7234705
amide	I-Chemical	-1	7234705
was	O	-1	7234705
administered	O	-1	7234705
or@@	O	-1	7234705
ally	O	-1	7234705
for	O	-1	7234705
treatment	O	-1	7234705
of	O	-1	7234705
chronic	O	-1	7234705
pre@@	B-Disease	D018879	7234705
mat@@	I-Disease	-1	7234705
ure	I-Disease	-1	7234705
ventricular	I-Disease	-1	7234705
contrac@@	I-Disease	-1	7234705
tions	I-Disease	-1	7234705
or	O	-1	7234705
atrial	B-Disease	D001282	7234705
f@@	I-Disease	-1	7234705
l@@	I-Disease	-1	7234705
ut@@	I-Disease	-1	7234705
ter	I-Disease	-1	7234705
.	O	-1	7234705
These	O	-1	7234705
patients	O	-1	7234705
had	O	-1	7234705
Q@@	B-Disease	D008133	7234705
-@@	I-Disease	-1	7234705
T	I-Disease	-1	7234705
prolong@@	I-Disease	-1	7234705
ation	I-Disease	-1	7234705
and	O	-1	7234705
recur@@	O	-1	7234705
rent	O	-1	7234705
syn@@	B-Disease	D013575	7234705
co@@	I-Disease	-1	7234705
p@@	I-Disease	-1	7234705
e	I-Disease	-1	7234705
due	O	-1	7234705
to	O	-1	7234705
poly@@	O	-1	7234705
morph@@	O	-1	7234705
ous	O	-1	7234705
ventricular	B-Disease	D017180	7234705
tachycardia	I-Disease	-1	7234705
.	O	-1	7234705
In	O	-1	7234705
four	O	-1	7234705
patients,	O	-1	7234705
the	O	-1	7234705
arrhyth@@	B-Disease	D001145	7234705
mia	I-Disease	-1	7234705
was	O	-1	7234705
ra@@	O	-1	7234705
pid@@	O	-1	7234705
ly	O	-1	7234705
diagnos@@	O	-1	7234705
ed	O	-1	7234705
and	O	-1	7234705
treated	O	-1	7234705
with	O	-1	7234705
dis@@	O	-1	7234705
appear@@	O	-1	7234705
ance	O	-1	7234705
of	O	-1	7234705
further	O	-1	7234705
episo@@	O	-1	7234705
des	O	-1	7234705
of	O	-1	7234705
the	O	-1	7234705
arrhyth@@	B-Disease	D001145	7234705
mia	I-Disease	-1	7234705
.	O	-1	7234705
In	O	-1	7234705
two	O	-1	7234705
patients,	O	-1	7234705
the	O	-1	7234705
arrhyth@@	B-Disease	D001145	7234705
mia	I-Disease	-1	7234705
de@@	O	-1	7234705
gener@@	O	-1	7234705
ated	O	-1	7234705
into	O	-1	7234705
ir@@	O	-1	7234705
reversible	O	-1	7234705
ventricular	B-Disease	D014693	7234705
fibrill@@	I-Disease	-1	7234705
ation	I-Disease	-1	7234705
and	O	-1	7234705
both	O	-1	7234705
patients	O	-1	7234705
di@@	O	-1	7234705
ed.	O	-1	7234705
In	O	-1	7234705
the	O	-1	7234705
sev@@	O	-1	7234705
ent@@	O	-1	7234705
h	O	-1	7234705
patient@@	O	-1	7234705
,	O	-1	7234705
a	O	-1	7234705
per@@	O	-1	7234705
man@@	O	-1	7234705
ent	O	-1	7234705
ventricular	O	-1	7234705
pac@@	O	-1	7234705
em@@	O	-1	7234705
ak@@	O	-1	7234705
er	O	-1	7234705
was	O	-1	7234705
in@@	O	-1	7234705
ser@@	O	-1	7234705
ted	O	-1	7234705
and@@	O	-1	7234705
,	O	-1	7234705
des@@	O	-1	7234705
pit@@	O	-1	7234705
e	O	-1	7234705
continu@@	O	-1	7234705
ation	O	-1	7234705
of	O	-1	7234705
pro@@	B-Chemical	D011342	7234705
ca@@	I-Chemical	-1	7234705
in@@	I-Chemical	-1	7234705
amide	I-Chemical	-1	7234705
therapy,	O	-1	7234705
poly@@	O	-1	7234705
morph@@	O	-1	7234705
ous	O	-1	7234705
ventricular	B-Disease	D017180	7234705
tachycardia	I-Disease	-1	7234705
did	O	-1	7234705
not	O	-1	7234705
re@@	O	-1	7234705
occur@@	O	-1	7234705
.	O	-1	7234705
These	O	-1	7234705
seven	O	-1	7234705
cases	O	-1	7234705
demon@@	O	-1	7234705
st@@	O	-1	7234705
rate	O	-1	7234705
that	O	-1	7234705
pro@@	B-Chemical	D011342	7234705
ca@@	I-Chemical	-1	7234705
in@@	I-Chemical	-1	7234705
amide	I-Chemical	-1	7234705
can	O	-1	7234705
produce	O	-1	7234705
an	O	-1	7234705
ac@@	O	-1	7234705
qu@@	O	-1	7234705
ired	O	-1	7234705
prolonged	B-Disease	D008133	7234705
Q@@	I-Disease	-1	7234705
-@@	I-Disease	-1	7234705
T	I-Disease	-1	7234705
syndrome	I-Disease	-1	7234705
with	O	-1	7234705
poly@@	O	-1	7234705
morph@@	O	-1	7234705
ous	O	-1	7234705
ventricular	B-Disease	D017180	7234705
tachycardia	I-Disease	-1	7234705
.	O	-1	7234705

R@@	O	-1	8955532
ole	O	-1	8955532
of	O	-1	8955532
activation	O	-1	8955532
of	O	-1	8955532
brady@@	B-Chemical	D001920	8955532
kin@@	I-Chemical	-1	8955532
in	I-Chemical	-1	8955532
B@@	O	-1	8955532
2	O	-1	8955532
receptors	O	-1	8955532
in	O	-1	8955532
dis@@	O	-1	8955532
ru@@	O	-1	8955532
ption	O	-1	8955532
of	O	-1	8955532
the	O	-1	8955532
blo@@	O	-1	8955532
o@@	O	-1	8955532
d-@@	O	-1	8955532
brain	O	-1	8955532
bar@@	O	-1	8955532
ri@@	O	-1	8955532
er	O	-1	8955532
during	O	-1	8955532
acute	O	-1	8955532
hypertension	B-Disease	D006973	8955532
.	O	-1	8955532
C@@	O	-1	8955532
ell@@	O	-1	8955532
ular	O	-1	8955532
mechanisms	O	-1	8955532
which	O	-1	8955532
ac@@	O	-1	8955532
coun@@	O	-1	8955532
t	O	-1	8955532
for	O	-1	8955532
dis@@	O	-1	8955532
ru@@	O	-1	8955532
ption	O	-1	8955532
the	O	-1	8955532
blo@@	O	-1	8955532
o@@	O	-1	8955532
d-@@	O	-1	8955532
brain	O	-1	8955532
bar@@	O	-1	8955532
ri@@	O	-1	8955532
er	O	-1	8955532
during	O	-1	8955532
acute	O	-1	8955532
hypertension	B-Disease	D006973	8955532
are	O	-1	8955532
not	O	-1	8955532
clear@@	O	-1	8955532
.	O	-1	8955532
The	O	-1	8955532
go@@	O	-1	8955532
al	O	-1	8955532
of	O	-1	8955532
this	O	-1	8955532
study	O	-1	8955532
was	O	-1	8955532
to	O	-1	8955532
determine	O	-1	8955532
the	O	-1	8955532
role	O	-1	8955532
of	O	-1	8955532
syn@@	O	-1	8955532
the@@	O	-1	8955532
si@@	O	-1	8955532
s/@@	O	-1	8955532
release	O	-1	8955532
of	O	-1	8955532
brady@@	B-Chemical	D001920	8955532
kin@@	I-Chemical	-1	8955532
in	I-Chemical	-1	8955532
to	O	-1	8955532
activ@@	O	-1	8955532
ate	O	-1	8955532
B@@	O	-1	8955532
2	O	-1	8955532
receptors	O	-1	8955532
in	O	-1	8955532
dis@@	O	-1	8955532
ru@@	O	-1	8955532
ption	O	-1	8955532
of	O	-1	8955532
the	O	-1	8955532
blo@@	O	-1	8955532
o@@	O	-1	8955532
d-@@	O	-1	8955532
brain	O	-1	8955532
bar@@	O	-1	8955532
ri@@	O	-1	8955532
er	O	-1	8955532
during	O	-1	8955532
acute	O	-1	8955532
hypertension	B-Disease	D006973	8955532
.	O	-1	8955532
P@@	O	-1	8955532
er@@	O	-1	8955532
me@@	O	-1	8955532
ability	O	-1	8955532
of	O	-1	8955532
the	O	-1	8955532
blo@@	O	-1	8955532
o@@	O	-1	8955532
d-@@	O	-1	8955532
brain	O	-1	8955532
bar@@	O	-1	8955532
ri@@	O	-1	8955532
er	O	-1	8955532
was	O	-1	8955532
qu@@	O	-1	8955532
anti@@	O	-1	8955532
t@@	O	-1	8955532
ated	O	-1	8955532
by	O	-1	8955532
clear@@	O	-1	8955532
ance	O	-1	8955532
of	O	-1	8955532
fluo@@	O	-1	8955532
res@@	O	-1	8955532
c@@	O	-1	8955532
ent@@	O	-1	8955532
-@@	O	-1	8955532
l@@	O	-1	8955532
a@@	O	-1	8955532
be@@	O	-1	8955532
l@@	O	-1	8955532
ed	O	-1	8955532
de@@	B-Chemical	D003911	8955532
x@@	I-Chemical	-1	8955532
tra@@	I-Chemical	-1	8955532
n	I-Chemical	-1	8955532
before	O	-1	8955532
and	O	-1	8955532
during	O	-1	8955532
pheny@@	B-Chemical	D010656	8955532
le@@	I-Chemical	-1	8955532
phrine	I-Chemical	-1	8955532
-induced	O	-1	8955532
acute	O	-1	8955532
hypertension	B-Disease	D006973	8955532
in	O	-1	8955532
rats	O	-1	8955532
treated	O	-1	8955532
with	O	-1	8955532
ve@@	O	-1	8955532
h@@	O	-1	8955532
ic@@	O	-1	8955532
le	O	-1	8955532
and	O	-1	8955532
Ho@@	B-Chemical	C065679	8955532
e-@@	I-Chemical	-1	8955532
1@@	I-Chemical	-1	8955532
40	I-Chemical	-1	8955532
(0.@@	O	-1	8955532
1	O	-1	8955532
micro@@	O	-1	8955532
M@@	O	-1	8955532
).	O	-1	8955532
Ph@@	B-Chemical	D010656	8955532
en@@	I-Chemical	-1	8955532
y@@	I-Chemical	-1	8955532
le@@	I-Chemical	-1	8955532
phrine	I-Chemical	-1	8955532
infusion	O	-1	8955532
increased	O	-1	8955532
arterial	O	-1	8955532
pressu@@	O	-1	8955532
re,	O	-1	8955532
arter@@	O	-1	8955532
i@@	O	-1	8955532
ol@@	O	-1	8955532
ar	O	-1	8955532
di@@	O	-1	8955532
ame@@	O	-1	8955532
ter	O	-1	8955532
and	O	-1	8955532
clear@@	O	-1	8955532
ance	O	-1	8955532
of	O	-1	8955532
fluo@@	O	-1	8955532
res@@	O	-1	8955532
c@@	O	-1	8955532
ent	O	-1	8955532
de@@	B-Chemical	D003911	8955532
x@@	I-Chemical	-1	8955532
tra@@	I-Chemical	-1	8955532
n	I-Chemical	-1	8955532
by	O	-1	8955532
a	O	-1	8955532
similar	O	-1	8955532
mag@@	O	-1	8955532
nit@@	O	-1	8955532
ude	O	-1	8955532
in	O	-1	8955532
both	O	-1	8955532
groups.	O	-1	8955532
These	O	-1	8955532
findings	O	-1	8955532
suggest	O	-1	8955532
that	O	-1	8955532
dis@@	O	-1	8955532
ru@@	O	-1	8955532
ption	O	-1	8955532
of	O	-1	8955532
the	O	-1	8955532
blo@@	O	-1	8955532
o@@	O	-1	8955532
d-@@	O	-1	8955532
brain	O	-1	8955532
bar@@	O	-1	8955532
ri@@	O	-1	8955532
er	O	-1	8955532
during	O	-1	8955532
acute	O	-1	8955532
hypertension	B-Disease	D006973	8955532
is	O	-1	8955532
not	O	-1	8955532
related	O	-1	8955532
to	O	-1	8955532
the	O	-1	8955532
syn@@	O	-1	8955532
the@@	O	-1	8955532
si@@	O	-1	8955532
s/@@	O	-1	8955532
release	O	-1	8955532
of	O	-1	8955532
brady@@	B-Chemical	D001920	8955532
kin@@	I-Chemical	-1	8955532
in	I-Chemical	-1	8955532
to	O	-1	8955532
activ@@	O	-1	8955532
ate	O	-1	8955532
B@@	O	-1	8955532
2	O	-1	8955532
receptor@@	O	-1	8955532
s.	O	-1	8955532

5-@@	B-Chemical	D001374	2578334
az@@	I-Chemical	-1	2578334
ac@@	I-Chemical	-1	2578334
y@@	I-Chemical	-1	2578334
tid@@	I-Chemical	-1	2578334
ine	I-Chemical	-1	2578334
potenti@@	O	-1	2578334
ates	O	-1	2578334
initi@@	B-Disease	D011230	2578334
ation	I-Disease	-1	2578334
induced	I-Disease	-1	2578334
by	I-Disease	-1	2578334
carcino@@	I-Disease	-1	2578334
gen@@	I-Disease	-1	2578334
s	I-Disease	-1	2578334
in	O	-1	2578334
rat	O	-1	2578334
li@@	O	-1	2578334
ver@@	O	-1	2578334
.	O	-1	2578334
To	O	-1	2578334
test	O	-1	2578334
the	O	-1	2578334
val@@	O	-1	2578334
idity	O	-1	2578334
of	O	-1	2578334
the	O	-1	2578334
hypo@@	O	-1	2578334
thesis	O	-1	2578334
that	O	-1	2578334
hypo@@	O	-1	2578334
methyl@@	O	-1	2578334
ation	O	-1	2578334
of	O	-1	2578334
D@@	O	-1	2578334
NA	O	-1	2578334
pl@@	O	-1	2578334
ays	O	-1	2578334
an	O	-1	2578334
important	O	-1	2578334
role	O	-1	2578334
in	O	-1	2578334
the	O	-1	2578334
initi@@	B-Disease	D011230	2578334
ation	I-Disease	-1	2578334
of	I-Disease	-1	2578334
carcino@@	I-Disease	-1	2578334
genic	I-Disease	-1	2578334
pro@@	I-Disease	-1	2578334
cess	I-Disease	-1	2578334
,	O	-1	2578334
5-@@	B-Chemical	D001374	2578334
az@@	I-Chemical	-1	2578334
ac@@	I-Chemical	-1	2578334
y@@	I-Chemical	-1	2578334
tid@@	I-Chemical	-1	2578334
ine	I-Chemical	-1	2578334
(	O	-1	2578334
5-@@	B-Chemical	D001374	2578334
A@@	I-Chemical	-1	2578334
z@@	I-Chemical	-1	2578334
C	I-Chemical	-1	2578334
)	O	-1	2578334
(10	O	-1	2578334
mg/kg@@	O	-1	2578334
),	O	-1	2578334
an	O	-1	2578334
inhibitor	O	-1	2578334
of	O	-1	2578334
D@@	O	-1	2578334
NA	O	-1	2578334
methyl@@	O	-1	2578334
ation,	O	-1	2578334
was	O	-1	2578334
given	O	-1	2578334
to	O	-1	2578334
rats	O	-1	2578334
during	O	-1	2578334
the	O	-1	2578334
phase	O	-1	2578334
of	O	-1	2578334
re@@	O	-1	2578334
pa@@	O	-1	2578334
ir	O	-1	2578334
syn@@	O	-1	2578334
thesis	O	-1	2578334
induced	O	-1	2578334
by	O	-1	2578334
the	O	-1	2578334
three	O	-1	2578334
carcino@@	O	-1	2578334
gen@@	O	-1	2578334
s,	O	-1	2578334
b@@	B-Chemical	D001564	2578334
enz@@	I-Chemical	-1	2578334
o@@	I-Chemical	-1	2578334
[@@	I-Chemical	-1	2578334
a@@	I-Chemical	-1	2578334
]@@	I-Chemical	-1	2578334
-@@	I-Chemical	-1	2578334
py@@	I-Chemical	-1	2578334
ren@@	I-Chemical	-1	2578334
e	I-Chemical	-1	2578334
(2@@	O	-1	2578334
00	O	-1	2578334
mg/kg@@	O	-1	2578334
),	O	-1	2578334
N@@	B-Chemical	D008770	2578334
-@@	I-Chemical	-1	2578334
methyl@@	I-Chemical	-1	2578334
-@@	I-Chemical	-1	2578334
N@@	I-Chemical	-1	2578334
-@@	I-Chemical	-1	2578334
nit@@	I-Chemical	-1	2578334
ros@@	I-Chemical	-1	2578334
ou@@	I-Chemical	-1	2578334
re@@	I-Chemical	-1	2578334
a	I-Chemical	-1	2578334
(@@	O	-1	2578334
60	O	-1	2578334
mg/kg)	O	-1	2578334
and	O	-1	2578334
1@@	B-Chemical	D019813	2578334
,@@	I-Chemical	-1	2578334
2-@@	I-Chemical	-1	2578334
di@@	I-Chemical	-1	2578334
methyl@@	I-Chemical	-1	2578334
hy@@	I-Chemical	-1	2578334
dra@@	I-Chemical	-1	2578334
z@@	I-Chemical	-1	2578334
ine	I-Chemical	-1	2578334
(	O	-1	2578334
1@@	B-Chemical	D019813	2578334
,@@	I-Chemical	-1	2578334
2-@@	I-Chemical	-1	2578334
D@@	I-Chemical	-1	2578334
M@@	I-Chemical	-1	2578334
H	I-Chemical	-1	2578334
)	O	-1	2578334
(@@	O	-1	2578334
100	O	-1	2578334
mg/kg@@	O	-1	2578334
).	O	-1	2578334
The	O	-1	2578334
initi@@	O	-1	2578334
ated	O	-1	2578334
hepat@@	O	-1	2578334
ocy@@	O	-1	2578334
tes	O	-1	2578334
in	O	-1	2578334
the	O	-1	2578334
liver	O	-1	2578334
were	O	-1	2578334
ass@@	O	-1	2578334
ayed	O	-1	2578334
as	O	-1	2578334
the	O	-1	2578334
gamma@@	O	-1	2578334
-@@	O	-1	2578334
glutam@@	O	-1	2578334
yl@@	O	-1	2578334
trans@@	O	-1	2578334
fer@@	O	-1	2578334
ase	O	-1	2578334
(@@	O	-1	2578334
gamma@@	O	-1	2578334
-@@	O	-1	2578334
G@@	O	-1	2578334
T)	O	-1	2578334
positive	O	-1	2578334
foc@@	O	-1	2578334
i	O	-1	2578334
form@@	O	-1	2578334
ed	O	-1	2578334
following	O	-1	2578334
a	O	-1	2578334
2-@@	O	-1	2578334
week	O	-1	2578334
sel@@	O	-1	2578334
ection	O	-1	2578334
regi@@	O	-1	2578334
men	O	-1	2578334
consist@@	O	-1	2578334
ing	O	-1	2578334
of	O	-1	2578334
di@@	O	-1	2578334
et@@	O	-1	2578334
ary	O	-1	2578334
0.0@@	O	-1	2578334
2@@	O	-1	2578334
%	O	-1	2578334
2-@@	B-Chemical	D015073	2578334
acet@@	I-Chemical	-1	2578334
yl@@	I-Chemical	-1	2578334
amino@@	I-Chemical	-1	2578334
fluo@@	I-Chemical	-1	2578334
ren@@	I-Chemical	-1	2578334
e	I-Chemical	-1	2578334
co@@	O	-1	2578334
u@@	O	-1	2578334
pl@@	O	-1	2578334
ed	O	-1	2578334
with	O	-1	2578334
a	O	-1	2578334
necro@@	O	-1	2578334
genic	O	-1	2578334
dose	O	-1	2578334
of	O	-1	2578334
C@@	B-Chemical	D002251	2578334
Cl@@	I-Chemical	-1	2578334
4	I-Chemical	-1	2578334
.	O	-1	2578334
The	O	-1	2578334
results	O	-1	2578334
obtained	O	-1	2578334
indicate	O	-1	2578334
that	O	-1	2578334
with	O	-1	2578334
all	O	-1	2578334
three	O	-1	2578334
carcino@@	O	-1	2578334
gen@@	O	-1	2578334
s,	O	-1	2578334
administration	O	-1	2578334
of	O	-1	2578334
5-@@	B-Chemical	D001374	2578334
A@@	I-Chemical	-1	2578334
z@@	I-Chemical	-1	2578334
C	I-Chemical	-1	2578334
during	O	-1	2578334
re@@	O	-1	2578334
pa@@	O	-1	2578334
ir	O	-1	2578334
syn@@	O	-1	2578334
thesis	O	-1	2578334
increased	O	-1	2578334
the	O	-1	2578334
incidence	O	-1	2578334
of	O	-1	2578334
initi@@	O	-1	2578334
ated	O	-1	2578334
hepat@@	O	-1	2578334
ocy@@	O	-1	2578334
t@@	O	-1	2578334
es,	O	-1	2578334
for	O	-1	2578334
ex@@	O	-1	2578334
am@@	O	-1	2578334
ple	O	-1	2578334
10-@@	O	-1	2578334
20	O	-1	2578334
f@@	O	-1	2578334
oci@@	O	-1	2578334
/@@	O	-1	2578334
c@@	O	-1	2578334
m@@	O	-1	2578334
2	O	-1	2578334
in	O	-1	2578334
5-@@	B-Chemical	D001374	2578334
A@@	I-Chemical	-1	2578334
z@@	I-Chemical	-1	2578334
C	I-Chemical	-1	2578334
and	O	-1	2578334
carcino@@	O	-1	2578334
gen@@	O	-1	2578334
-treated	O	-1	2578334
rats	O	-1	2578334
compared	O	-1	2578334
with	O	-1	2578334
3-@@	O	-1	2578334
5	O	-1	2578334
f@@	O	-1	2578334
oci@@	O	-1	2578334
/@@	O	-1	2578334
c@@	O	-1	2578334
m@@	O	-1	2578334
2	O	-1	2578334
in	O	-1	2578334
rats	O	-1	2578334
treated	O	-1	2578334
with	O	-1	2578334
carcino@@	O	-1	2578334
gen	O	-1	2578334
on@@	O	-1	2578334
ly.	O	-1	2578334
Ad@@	O	-1	2578334
minist@@	O	-1	2578334
ration	O	-1	2578334
of	O	-1	2578334
[@@	B-Chemical	C014347	2578334
3@@	I-Chemical	-1	2578334
H@@	I-Chemical	-1	2578334
]@@	I-Chemical	-1	2578334
-@@	I-Chemical	-1	2578334
5-@@	I-Chemical	-1	2578334
az@@	I-Chemical	-1	2578334
ade@@	I-Chemical	-1	2578334
ox@@	I-Chemical	-1	2578334
yc@@	I-Chemical	-1	2578334
y@@	I-Chemical	-1	2578334
tid@@	I-Chemical	-1	2578334
ine	I-Chemical	-1	2578334
during	O	-1	2578334
the	O	-1	2578334
re@@	O	-1	2578334
pa@@	O	-1	2578334
ir	O	-1	2578334
syn@@	O	-1	2578334
thesis	O	-1	2578334
induced	O	-1	2578334
by	O	-1	2578334
1@@	B-Chemical	D019813	2578334
,@@	I-Chemical	-1	2578334
2-@@	I-Chemical	-1	2578334
D@@	I-Chemical	-1	2578334
M@@	I-Chemical	-1	2578334
H	I-Chemical	-1	2578334
further	O	-1	2578334
showed	O	-1	2578334
that	O	-1	2578334
0.0@@	O	-1	2578334
1@@	O	-1	2578334
9	O	-1	2578334
mo@@	O	-1	2578334
l	O	-1	2578334
%	O	-1	2578334
of	O	-1	2578334
cy@@	B-Chemical	D003596	2578334
t@@	I-Chemical	-1	2578334
os@@	I-Chemical	-1	2578334
ine	I-Chemical	-1	2578334
re@@	O	-1	2578334
si@@	O	-1	2578334
du@@	O	-1	2578334
es	O	-1	2578334
in	O	-1	2578334
D@@	O	-1	2578334
NA	O	-1	2578334
were	O	-1	2578334
sub@@	O	-1	2578334
sti@@	O	-1	2578334
t@@	O	-1	2578334
ut@@	O	-1	2578334
ed	O	-1	2578334
by	O	-1	2578334
the	O	-1	2578334
an@@	O	-1	2578334
alo@@	O	-1	2578334
gu@@	O	-1	2578334
e,	O	-1	2578334
indicating	O	-1	2578334
that	O	-1	2578334
inc@@	O	-1	2578334
or@@	O	-1	2578334
por@@	O	-1	2578334
ation	O	-1	2578334
of	O	-1	2578334
5-@@	B-Chemical	D001374	2578334
A@@	I-Chemical	-1	2578334
z@@	I-Chemical	-1	2578334
C	I-Chemical	-1	2578334
occur@@	O	-1	2578334
s	O	-1	2578334
during	O	-1	2578334
re@@	O	-1	2578334
pa@@	O	-1	2578334
ir	O	-1	2578334
syn@@	O	-1	2578334
the@@	O	-1	2578334
sis.	O	-1	2578334
In	O	-1	2578334
the	O	-1	2578334
absence	O	-1	2578334
of	O	-1	2578334
the	O	-1	2578334
carcino@@	O	-1	2578334
gen@@	O	-1	2578334
,	O	-1	2578334
5-@@	B-Chemical	D001374	2578334
A@@	I-Chemical	-1	2578334
z@@	I-Chemical	-1	2578334
C	I-Chemical	-1	2578334
given	O	-1	2578334
after	O	-1	2578334
a	O	-1	2578334
two	O	-1	2578334
thir@@	O	-1	2578334
ds	O	-1	2578334
partial	O	-1	2578334
hepat@@	O	-1	2578334
ect@@	O	-1	2578334
om@@	O	-1	2578334
y,	O	-1	2578334
when	O	-1	2578334
its	O	-1	2578334
inc@@	O	-1	2578334
or@@	O	-1	2578334
por@@	O	-1	2578334
ation	O	-1	2578334
should	O	-1	2578334
be	O	-1	2578334
maxim@@	O	-1	2578334
um,	O	-1	2578334
fail@@	O	-1	2578334
ed	O	-1	2578334
to	O	-1	2578334
induce	O	-1	2578334
any	O	-1	2578334
gamma@@	O	-1	2578334
-@@	O	-1	2578334
G@@	O	-1	2578334
T	O	-1	2578334
positive	O	-1	2578334
f@@	O	-1	2578334
oci@@	O	-1	2578334
.	O	-1	2578334
The	O	-1	2578334
results	O	-1	2578334
suggest	O	-1	2578334
that	O	-1	2578334
hypo@@	O	-1	2578334
methyl@@	O	-1	2578334
ation	O	-1	2578334
of	O	-1	2578334
D@@	O	-1	2578334
NA	O	-1	2578334
per	O	-1	2578334
se	O	-1	2578334
may	O	-1	2578334
not	O	-1	2578334
be	O	-1	2578334
suffici@@	O	-1	2578334
ent	O	-1	2578334
for	O	-1	2578334
initi@@	O	-1	2578334
ation.	O	-1	2578334
P@@	O	-1	2578334
er@@	O	-1	2578334
h@@	O	-1	2578334
ap@@	O	-1	2578334
s	O	-1	2578334
two	O	-1	2578334
events	O	-1	2578334
might	O	-1	2578334
be	O	-1	2578334
nec@@	O	-1	2578334
ess@@	O	-1	2578334
ary	O	-1	2578334
for	O	-1	2578334
initi@@	O	-1	2578334
ation,	O	-1	2578334
the	O	-1	2578334
first	O	-1	2578334
caused	O	-1	2578334
by	O	-1	2578334
the	O	-1	2578334
carcino@@	O	-1	2578334
gen	O	-1	2578334
and	O	-1	2578334
a	O	-1	2578334
second	O	-1	2578334
invol@@	O	-1	2578334
ving	O	-1	2578334
hypo@@	O	-1	2578334
methyl@@	O	-1	2578334
ation	O	-1	2578334
of	O	-1	2578334
D@@	O	-1	2578334
N@@	O	-1	2578334
A@@	O	-1	2578334
.	O	-1	2578334

W@@	B-Disease	D013375	11532387
i@@	I-Disease	-1	11532387
th@@	I-Disease	-1	11532387
draw@@	I-Disease	-1	11532387
al@@	I-Disease	-1	11532387
-@@	I-Disease	-1	11532387
em@@	I-Disease	-1	11532387
erg@@	I-Disease	-1	11532387
ent	I-Disease	-1	11532387
ra@@	I-Disease	-1	11532387
b@@	I-Disease	-1	11532387
b@@	I-Disease	-1	11532387
it	I-Disease	-1	11532387
syndrome	I-Disease	-1	11532387
W@@	B-Disease	D001480	11532387
i@@	I-Disease	-1	11532387
th@@	I-Disease	-1	11532387
draw@@	I-Disease	-1	11532387
al@@	I-Disease	-1	11532387
-@@	I-Disease	-1	11532387
em@@	I-Disease	-1	11532387
erg@@	I-Disease	-1	11532387
ent	I-Disease	-1	11532387
ra@@	I-Disease	-1	11532387
b@@	I-Disease	-1	11532387
b@@	I-Disease	-1	11532387
it	I-Disease	-1	11532387
syndrome	I-Disease	-1	11532387
during	O	-1	11532387
dose	O	-1	11532387
reduction	O	-1	11532387
of	O	-1	11532387
ris@@	B-Chemical	D018967	11532387
perid@@	I-Chemical	-1	11532387
one	I-Chemical	-1	11532387
.	O	-1	11532387
R@@	B-Disease	D001480	11532387
ab@@	I-Disease	-1	11532387
b@@	I-Disease	-1	11532387
it	I-Disease	-1	11532387
syndrome	I-Disease	-1	11532387
(	O	-1	11532387
R@@	B-Disease	D001480	11532387
S	I-Disease	-1	11532387
)	O	-1	11532387
is	O	-1	11532387
a	O	-1	11532387
r@@	O	-1	11532387
are	O	-1	11532387
ext@@	O	-1	11532387
ra@@	O	-1	11532387
py@@	O	-1	11532387
ram@@	O	-1	11532387
idal	O	-1	11532387
side	O	-1	11532387
effect	O	-1	11532387
caused	O	-1	11532387
by	O	-1	11532387
prolonged	O	-1	11532387
neuro@@	O	-1	11532387
le@@	O	-1	11532387
p@@	O	-1	11532387
tic	O	-1	11532387
medic@@	O	-1	11532387
ation.	O	-1	11532387
H@@	O	-1	11532387
ere	O	-1	11532387
we	O	-1	11532387
present	O	-1	11532387
a	O	-1	11532387
case	O	-1	11532387
of	O	-1	11532387
withdraw@@	B-Disease	D013375	11532387
al@@	I-Disease	-1	11532387
-@@	I-Disease	-1	11532387
em@@	I-Disease	-1	11532387
erg@@	I-Disease	-1	11532387
ent	I-Disease	-1	11532387
R@@	I-Disease	-1	11532387
S	I-Disease	-1	11532387
withdraw@@	B-Disease	D001480	11532387
al@@	I-Disease	-1	11532387
-@@	I-Disease	-1	11532387
em@@	I-Disease	-1	11532387
erg@@	I-Disease	-1	11532387
ent	I-Disease	-1	11532387
R@@	I-Disease	-1	11532387
S	I-Disease	-1	11532387
,	O	-1	11532387
which	O	-1	11532387
is	O	-1	11532387
the	O	-1	11532387
first	O	-1	11532387
of	O	-1	11532387
its	O	-1	11532387
k@@	O	-1	11532387
ind	O	-1	11532387
to	O	-1	11532387
be	O	-1	11532387
repor@@	O	-1	11532387
ted.	O	-1	11532387
The	O	-1	11532387
patient	O	-1	11532387
developed	O	-1	11532387
R@@	B-Disease	D001480	11532387
S	I-Disease	-1	11532387
during	O	-1	11532387
dose	O	-1	11532387
reduction	O	-1	11532387
of	O	-1	11532387
ris@@	B-Chemical	D018967	11532387
perid@@	I-Chemical	-1	11532387
one	I-Chemical	-1	11532387
.	O	-1	11532387
The	O	-1	11532387
sympto@@	O	-1	11532387
m	O	-1	11532387
was	O	-1	11532387
treated	O	-1	11532387
suc@@	O	-1	11532387
cess@@	O	-1	11532387
ful@@	O	-1	11532387
ly	O	-1	11532387
with	O	-1	11532387
tri@@	B-Chemical	D014282	11532387
he@@	I-Chemical	-1	11532387
x@@	I-Chemical	-1	11532387
y@@	I-Chemical	-1	11532387
phen@@	I-Chemical	-1	11532387
id@@	I-Chemical	-1	11532387
yl	I-Chemical	-1	11532387
anti@@	O	-1	11532387
cholinergic	O	-1	11532387
therapy.	O	-1	11532387
The	O	-1	11532387
underlying	O	-1	11532387
mechanism	O	-1	11532387
of	O	-1	11532387
withdraw@@	B-Disease	D013375	11532387
al@@	I-Disease	-1	11532387
-@@	I-Disease	-1	11532387
em@@	I-Disease	-1	11532387
erg@@	I-Disease	-1	11532387
ent	I-Disease	-1	11532387
R@@	I-Disease	-1	11532387
S	I-Disease	-1	11532387
withdraw@@	B-Disease	D001480	11532387
al@@	I-Disease	-1	11532387
-@@	I-Disease	-1	11532387
em@@	I-Disease	-1	11532387
erg@@	I-Disease	-1	11532387
ent	I-Disease	-1	11532387
R@@	I-Disease	-1	11532387
S	I-Disease	-1	11532387
in	O	-1	11532387
the	O	-1	11532387
present	O	-1	11532387
case	O	-1	11532387
may	O	-1	11532387
have	O	-1	11532387
been	O	-1	11532387
related	O	-1	11532387
to	O	-1	11532387
the	O	-1	11532387
pharmac@@	O	-1	11532387
ological	O	-1	11532387
prof@@	O	-1	11532387
ile	O	-1	11532387
of	O	-1	11532387
ris@@	B-Chemical	D018967	11532387
perid@@	I-Chemical	-1	11532387
one	I-Chemical	-1	11532387
,	O	-1	11532387
a	O	-1	11532387
seroton@@	B-Chemical	D012701	11532387
in	I-Chemical	-1	11532387
-	O	-1	11532387
dopamine	B-Chemical	D004298	11532387
antagonist@@	O	-1	11532387
,	O	-1	11532387
suggesting	O	-1	11532387
the	O	-1	11532387
path@@	O	-1	11532387
oph@@	O	-1	11532387
ysi@@	O	-1	11532387
ologic	O	-1	11532387
influence	O	-1	11532387
of	O	-1	11532387
the	O	-1	11532387
seroton@@	B-Chemical	D012701	11532387
in	I-Chemical	-1	11532387
system	O	-1	11532387
in	O	-1	11532387
the	O	-1	11532387
development	O	-1	11532387
of	O	-1	11532387
R@@	B-Disease	D001480	11532387
S	I-Disease	-1	11532387
.	O	-1	11532387

V@@	B-Chemical	D014700	3173179
er@@	I-Chemical	-1	3173179
ap@@	I-Chemical	-1	3173179
ami@@	I-Chemical	-1	3173179
l	I-Chemical	-1	3173179
withdrawal	O	-1	3173179
as	O	-1	3173179
a	O	-1	3173179
possible	O	-1	3173179
cause	O	-1	3173179
of	O	-1	3173179
myocardial	B-Disease	D009203	3173179
infarction	I-Disease	-1	3173179
in	O	-1	3173179
a	O	-1	3173179
hypertensive	B-Disease	D006973	3173179
woman	O	-1	3173179
with	O	-1	3173179
a	O	-1	3173179
normal	O	-1	3173179
coronary	O	-1	3173179
angio@@	O	-1	3173179
gram@@	O	-1	3173179
.	O	-1	3173179
V@@	B-Chemical	D014700	3173179
er@@	I-Chemical	-1	3173179
ap@@	I-Chemical	-1	3173179
ami@@	I-Chemical	-1	3173179
l	I-Chemical	-1	3173179
is	O	-1	3173179
an	O	-1	3173179
effective	O	-1	3173179
and	O	-1	3173179
rel@@	O	-1	3173179
ati@@	O	-1	3173179
vel@@	O	-1	3173179
y-@@	O	-1	3173179
saf@@	O	-1	3173179
e	O	-1	3173179
anti@@	O	-1	3173179
hypertensive	O	-1	3173179
drug.	O	-1	3173179
S@@	O	-1	3173179
er@@	O	-1	3173179
i@@	O	-1	3173179
ous	O	-1	3173179
adverse	O	-1	3173179
effects	O	-1	3173179
are	O	-1	3173179
un@@	O	-1	3173179
common	O	-1	3173179
and	O	-1	3173179
main@@	O	-1	3173179
ly	O	-1	3173179
have	O	-1	3173179
been	O	-1	3173179
related	O	-1	3173179
to	O	-1	3173179
the	O	-1	3173179
de@@	B-Disease	D003866	3173179
pression	I-Disease	-1	3173179
of	O	-1	3173179
cardiac	O	-1	3173179
contrac@@	O	-1	3173179
til@@	O	-1	3173179
ity	O	-1	3173179
and	O	-1	3173179
con@@	O	-1	3173179
duc@@	O	-1	3173179
tion,	O	-1	3173179
es@@	O	-1	3173179
p@@	O	-1	3173179
ec@@	O	-1	3173179
i@@	O	-1	3173179
ally	O	-1	3173179
when	O	-1	3173179
the	O	-1	3173179
drug	O	-1	3173179
is	O	-1	3173179
combined	O	-1	3173179
with	O	-1	3173179
beta-@@	O	-1	3173179
block@@	O	-1	3173179
ing	O	-1	3173179
agent@@	O	-1	3173179
s.	O	-1	3173179
We	O	-1	3173179
report	O	-1	3173179
a	O	-1	3173179
case	O	-1	3173179
in	O	-1	3173179
which	O	-1	3173179
myocardial	B-Disease	D009203	3173179
infarction	I-Disease	-1	3173179
co@@	O	-1	3173179
inc@@	O	-1	3173179
id@@	O	-1	3173179
ed	O	-1	3173179
with	O	-1	3173179
the	O	-1	3173179
int@@	O	-1	3173179
ro@@	O	-1	3173179
duction	O	-1	3173179
of	O	-1	3173179
cap@@	B-Chemical	D002216	3173179
to@@	I-Chemical	-1	3173179
pri@@	I-Chemical	-1	3173179
l	I-Chemical	-1	3173179
and	O	-1	3173179
the	O	-1	3173179
withdrawal	O	-1	3173179
of	O	-1	3173179
verap@@	B-Chemical	D014700	3173179
ami@@	I-Chemical	-1	3173179
l	I-Chemical	-1	3173179
in	O	-1	3173179
a	O	-1	3173179
previously	O	-1	3173179
as@@	O	-1	3173179
ym@@	O	-1	3173179
pto@@	O	-1	3173179
m@@	O	-1	3173179
atic	O	-1	3173179
woman	O	-1	3173179
with	O	-1	3173179
severe	O	-1	3173179
hypertension	B-Disease	D006973	3173179
.	O	-1	3173179
P@@	O	-1	3173179
os@@	O	-1	3173179
sible	O	-1	3173179
mechanisms	O	-1	3173179
that	O	-1	3173179
invol@@	O	-1	3173179
ve	O	-1	3173179
a	O	-1	3173179
verap@@	B-Chemical	D014700	3173179
ami@@	I-Chemical	-1	3173179
l	I-Chemical	-1	3173179
-@@	O	-1	3173179
related	O	-1	3173179
increase	O	-1	3173179
in	O	-1	3173179
platele@@	O	-1	3173179
t	O	-1	3173179
and/or	O	-1	3173179
vascular	O	-1	3173179
al@@	O	-1	3173179
ph@@	O	-1	3173179
a	O	-1	3173179
2-@@	O	-1	3173179
adren@@	O	-1	3173179
o@@	O	-1	3173179
receptor	O	-1	3173179
aff@@	O	-1	3173179
in@@	O	-1	3173179
ity	O	-1	3173179
for	O	-1	3173179
cat@@	B-Chemical	D002395	3173179
ech@@	I-Chemical	-1	3173179
ol@@	I-Chemical	-1	3173179
amin@@	I-Chemical	-1	3173179
es	I-Chemical	-1	3173179
are	O	-1	3173179
discus@@	O	-1	3173179
sed.	O	-1	3173179

R@@	O	-1	3856631
em@@	O	-1	3856631
is@@	O	-1	3856631
sion	O	-1	3856631
induction	O	-1	3856631
of	O	-1	3856631
men@@	B-Disease	D008577	3856631
ing@@	I-Disease	-1	3856631
e@@	I-Disease	-1	3856631
al	I-Disease	-1	3856631
leuk@@	I-Disease	-1	3856631
emia	I-Disease	-1	3856631
with	O	-1	3856631
high-dose	O	-1	3856631
intravenous	O	-1	3856631
meth@@	B-Chemical	D008727	3856631
ot@@	I-Chemical	-1	3856631
re@@	I-Chemical	-1	3856631
x@@	I-Chemical	-1	3856631
ate	I-Chemical	-1	3856631
.	O	-1	3856631
Tw@@	O	-1	3856631
ent@@	O	-1	3856631
y	O	-1	3856631
children	O	-1	3856631
with	O	-1	3856631
acute	B-Disease	D054198	3856631
lymph@@	I-Disease	-1	3856631
ob@@	I-Disease	-1	3856631
las@@	I-Disease	-1	3856631
tic	I-Disease	-1	3856631
leuk@@	I-Disease	-1	3856631
emia	I-Disease	-1	3856631
who	O	-1	3856631
developed	O	-1	3856631
men@@	B-Disease	D002493	3856631
ing@@	I-Disease	-1	3856631
e@@	I-Disease	-1	3856631
al	I-Disease	-1	3856631
disease	I-Disease	-1	3856631
were	O	-1	3856631
treated	O	-1	3856631
with	O	-1	3856631
a	O	-1	3856631
high-dose	O	-1	3856631
intravenous	O	-1	3856631
meth@@	B-Chemical	D008727	3856631
ot@@	I-Chemical	-1	3856631
re@@	I-Chemical	-1	3856631
x@@	I-Chemical	-1	3856631
ate	I-Chemical	-1	3856631
regi@@	O	-1	3856631
men	O	-1	3856631
that	O	-1	3856631
was	O	-1	3856631
de@@	O	-1	3856631
signed	O	-1	3856631
to	O	-1	3856631
achi@@	O	-1	3856631
e@@	O	-1	3856631
ve	O	-1	3856631
and	O	-1	3856631
maint@@	O	-1	3856631
ain	O	-1	3856631
C@@	O	-1	3856631
S@@	O	-1	3856631
F	O	-1	3856631
meth@@	B-Chemical	D008727	3856631
ot@@	I-Chemical	-1	3856631
re@@	I-Chemical	-1	3856631
x@@	I-Chemical	-1	3856631
ate	I-Chemical	-1	3856631
concentrations	O	-1	3856631
of	O	-1	3856631
10@@	O	-1	3856631
(-@@	O	-1	3856631
5@@	O	-1	3856631
)	O	-1	3856631
mol@@	O	-1	3856631
/@@	O	-1	3856631
L	O	-1	3856631
without	O	-1	3856631
the	O	-1	3856631
need	O	-1	3856631
for	O	-1	3856631
concomit@@	O	-1	3856631
ant	O	-1	3856631
intra@@	O	-1	3856631
th@@	O	-1	3856631
ec@@	O	-1	3856631
al	O	-1	3856631
dos@@	O	-1	3856631
ing.	O	-1	3856631
The	O	-1	3856631
meth@@	B-Chemical	D008727	3856631
ot@@	I-Chemical	-1	3856631
re@@	I-Chemical	-1	3856631
x@@	I-Chemical	-1	3856631
ate	I-Chemical	-1	3856631
was	O	-1	3856631
administered	O	-1	3856631
as	O	-1	3856631
a	O	-1	3856631
lo@@	O	-1	3856631
ad@@	O	-1	3856631
ing	O	-1	3856631
dose	O	-1	3856631
of	O	-1	3856631
6@@	O	-1	3856631
,@@	O	-1	3856631
0@@	O	-1	3856631
00	O	-1	3856631
mg/m@@	O	-1	3856631
2	O	-1	3856631
for	O	-1	3856631
a	O	-1	3856631
period	O	-1	3856631
of	O	-1	3856631
one	O	-1	3856631
h@@	O	-1	3856631
our	O	-1	3856631
followed	O	-1	3856631
by	O	-1	3856631
an	O	-1	3856631
infusion	O	-1	3856631
of	O	-1	3856631
1@@	O	-1	3856631
,@@	O	-1	3856631
2@@	O	-1	3856631
00	O	-1	3856631
mg/m@@	O	-1	3856631
2@@	O	-1	3856631
/@@	O	-1	3856631
h	O	-1	3856631
for	O	-1	3856631
2@@	O	-1	3856631
3	O	-1	3856631
hour@@	O	-1	3856631
s.	O	-1	3856631
L@@	B-Chemical	D002955	3856631
eu@@	I-Chemical	-1	3856631
co@@	I-Chemical	-1	3856631
v@@	I-Chemical	-1	3856631
or@@	I-Chemical	-1	3856631
in	I-Chemical	-1	3856631
res@@	O	-1	3856631
c@@	O	-1	3856631
u@@	O	-1	3856631
e	O	-1	3856631
was	O	-1	3856631
initi@@	O	-1	3856631
ated	O	-1	3856631
12	O	-1	3856631
hours	O	-1	3856631
after	O	-1	3856631
the	O	-1	3856631
end	O	-1	3856631
of	O	-1	3856631
the	O	-1	3856631
infusion	O	-1	3856631
with	O	-1	3856631
a	O	-1	3856631
lo@@	O	-1	3856631
ad@@	O	-1	3856631
ing	O	-1	3856631
dose	O	-1	3856631
of	O	-1	3856631
2@@	O	-1	3856631
00	O	-1	3856631
mg/m@@	O	-1	3856631
2	O	-1	3856631
followed	O	-1	3856631
by	O	-1	3856631
12	O	-1	3856631
mg/m@@	O	-1	3856631
2	O	-1	3856631
every	O	-1	3856631
three	O	-1	3856631
hours	O	-1	3856631
for	O	-1	3856631
six	O	-1	3856631
doses	O	-1	3856631
and	O	-1	3856631
then	O	-1	3856631
every	O	-1	3856631
six	O	-1	3856631
hours	O	-1	3856631
un@@	O	-1	3856631
ti@@	O	-1	3856631
l	O	-1	3856631
the	O	-1	3856631
plasma	O	-1	3856631
meth@@	B-Chemical	D008727	3856631
ot@@	I-Chemical	-1	3856631
re@@	I-Chemical	-1	3856631
x@@	I-Chemical	-1	3856631
ate	I-Chemical	-1	3856631
level	O	-1	3856631
decreased	O	-1	3856631
to	O	-1	3856631
less	O	-1	3856631
than	O	-1	3856631
1	O	-1	3856631
X	O	-1	3856631
10@@	O	-1	3856631
(-@@	O	-1	3856631
7@@	O	-1	3856631
)	O	-1	3856631
mol@@	O	-1	3856631
/@@	O	-1	3856631
L@@	O	-1	3856631
.	O	-1	3856631
The	O	-1	3856631
mean	O	-1	3856631
ste@@	O	-1	3856631
ad@@	O	-1	3856631
y-@@	O	-1	3856631
state	O	-1	3856631
plasma	O	-1	3856631
and	O	-1	3856631
C@@	O	-1	3856631
S@@	O	-1	3856631
F	O	-1	3856631
meth@@	B-Chemical	D008727	3856631
ot@@	I-Chemical	-1	3856631
re@@	I-Chemical	-1	3856631
x@@	I-Chemical	-1	3856631
ate	I-Chemical	-1	3856631
concentrations	O	-1	3856631
achi@@	O	-1	3856631
ev@@	O	-1	3856631
ed	O	-1	3856631
were	O	-1	3856631
1.@@	O	-1	3856631
1	O	-1	3856631
X	O	-1	3856631
10@@	O	-1	3856631
(-@@	O	-1	3856631
3@@	O	-1	3856631
)	O	-1	3856631
mol@@	O	-1	3856631
/@@	O	-1	3856631
L	O	-1	3856631
and	O	-1	3856631
3.@@	O	-1	3856631
6	O	-1	3856631
X	O	-1	3856631
10@@	O	-1	3856631
(-@@	O	-1	3856631
5@@	O	-1	3856631
)	O	-1	3856631
mol@@	O	-1	3856631
/@@	O	-1	3856631
L@@	O	-1	3856631
,	O	-1	3856631
respectively.	O	-1	3856631
All	O	-1	3856631
20	O	-1	3856631
patients	O	-1	3856631
respon@@	O	-1	3856631
ded	O	-1	3856631
to	O	-1	3856631
this	O	-1	3856631
regimen@@	O	-1	3856631
,	O	-1	3856631
1@@	O	-1	3856631
6@@	O	-1	3856631
/@@	O	-1	3856631
20	O	-1	3856631
(@@	O	-1	3856631
80@@	O	-1	3856631
%)	O	-1	3856631
achi@@	O	-1	3856631
ev@@	O	-1	3856631
ed	O	-1	3856631
a	O	-1	3856631
complete	O	-1	3856631
re@@	O	-1	3856631
mis@@	O	-1	3856631
sion,	O	-1	3856631
and	O	-1	3856631
20@@	O	-1	3856631
%	O	-1	3856631
obtained	O	-1	3856631
a	O	-1	3856631
partial	O	-1	3856631
re@@	O	-1	3856631
mis@@	O	-1	3856631
sion.	O	-1	3856631
The	O	-1	3856631
most	O	-1	3856631
common	O	-1	3856631
toxic@@	B-Disease	D064420	3856631
ities	I-Disease	-1	3856631
en@@	O	-1	3856631
coun@@	O	-1	3856631
te@@	O	-1	3856631
red	O	-1	3856631
were	O	-1	3856631
transi@@	O	-1	3856631
ent	O	-1	3856631
serum	O	-1	3856631
trans@@	O	-1	3856631
amin@@	O	-1	3856631
ase	O	-1	3856631
and	O	-1	3856631
bil@@	B-Chemical	D001663	3856631
i@@	I-Chemical	-1	3856631
ru@@	I-Chemical	-1	3856631
bin	I-Chemical	-1	3856631
elev@@	O	-1	3856631
ation@@	O	-1	3856631
s,	O	-1	3856631
ne@@	B-Disease	D009503	3856631
ut@@	I-Disease	-1	3856631
ro@@	I-Disease	-1	3856631
pen@@	I-Disease	-1	3856631
ia	I-Disease	-1	3856631
,	O	-1	3856631
and	O	-1	3856631
m@@	B-Disease	D052016	3856631
u@@	I-Disease	-1	3856631
co@@	I-Disease	-1	3856631
si@@	I-Disease	-1	3856631
tis	I-Disease	-1	3856631
.	O	-1	3856631
One	O	-1	3856631
patient	O	-1	3856631
had	O	-1	3856631
foc@@	O	-1	3856631
al	O	-1	3856631
seizures	B-Disease	D012640	3856631
and	O	-1	3856631
transi@@	B-Disease	D010291	3856631
ent	I-Disease	-1	3856631
he@@	I-Disease	-1	3856631
mi@@	I-Disease	-1	3856631
pa@@	I-Disease	-1	3856631
re@@	I-Disease	-1	3856631
sis	I-Disease	-1	3856631
but	O	-1	3856631
reco@@	O	-1	3856631
vered	O	-1	3856631
complete@@	O	-1	3856631
ly.	O	-1	3856631
H@@	O	-1	3856631
igh@@	O	-1	3856631
-@@	O	-1	3856631
dose	O	-1	3856631
intravenous	O	-1	3856631
meth@@	B-Chemical	D008727	3856631
ot@@	I-Chemical	-1	3856631
re@@	I-Chemical	-1	3856631
x@@	I-Chemical	-1	3856631
ate	I-Chemical	-1	3856631
is	O	-1	3856631
an	O	-1	3856631
effective	O	-1	3856631
treatment	O	-1	3856631
for	O	-1	3856631
the	O	-1	3856631
induction	O	-1	3856631
of	O	-1	3856631
re@@	O	-1	3856631
mission	O	-1	3856631
after	O	-1	3856631
men@@	O	-1	3856631
ing@@	O	-1	3856631
e@@	O	-1	3856631
al	O	-1	3856631
rel@@	O	-1	3856631
ap@@	O	-1	3856631
se	O	-1	3856631
in	O	-1	3856631
acute	B-Disease	D054198	3856631
lymph@@	I-Disease	-1	3856631
ob@@	I-Disease	-1	3856631
las@@	I-Disease	-1	3856631
tic	I-Disease	-1	3856631
leuk@@	I-Disease	-1	3856631
emia	I-Disease	-1	3856631
.	O	-1	3856631

H@@	B-Disease	D004342	2522601
y@@	I-Disease	-1	2522601
per@@	I-Disease	-1	2522601
sensitivity	I-Disease	-1	2522601
to	O	-1	2522601
carbamazepine	B-Chemical	D002220	2522601
present@@	O	-1	2522601
ing	O	-1	2522601
with	O	-1	2522601
a	O	-1	2522601
leuk@@	B-Disease	D007955	2522601
em@@	I-Disease	-1	2522601
oid	I-Disease	-1	2522601
reaction	I-Disease	-1	2522601
,	O	-1	2522601
e@@	B-Disease	D004802	2522601
os@@	I-Disease	-1	2522601
in@@	I-Disease	-1	2522601
oph@@	I-Disease	-1	2522601
il@@	I-Disease	-1	2522601
ia	I-Disease	-1	2522601
,	O	-1	2522601
erythro@@	B-Disease	D003873	2522601
der@@	I-Disease	-1	2522601
ma	I-Disease	-1	2522601
,	O	-1	2522601
and	O	-1	2522601
renal	B-Disease	D051437	2522601
failure	I-Disease	-1	2522601
.	O	-1	2522601
We	O	-1	2522601
report	O	-1	2522601
a	O	-1	2522601
patient	O	-1	2522601
in	O	-1	2522601
whom	O	-1	2522601
hyper@@	B-Disease	D004342	2522601
sensitivity	I-Disease	-1	2522601
to	O	-1	2522601
carbamazepine	B-Chemical	D002220	2522601
presented	O	-1	2522601
with	O	-1	2522601
gener@@	O	-1	2522601
al@@	O	-1	2522601
ized	O	-1	2522601
erythro@@	B-Disease	D003873	2522601
der@@	I-Disease	-1	2522601
ma	I-Disease	-1	2522601
,	O	-1	2522601
a	O	-1	2522601
severe	O	-1	2522601
leuk@@	B-Disease	D007955	2522601
em@@	I-Disease	-1	2522601
oid	I-Disease	-1	2522601
reaction	I-Disease	-1	2522601
,	O	-1	2522601
e@@	B-Disease	D004802	2522601
os@@	I-Disease	-1	2522601
in@@	I-Disease	-1	2522601
oph@@	I-Disease	-1	2522601
il@@	I-Disease	-1	2522601
ia	I-Disease	-1	2522601
,	O	-1	2522601
hy@@	B-Disease	D007010	2522601
p@@	I-Disease	-1	2522601
on@@	I-Disease	-1	2522601
at@@	I-Disease	-1	2522601
re@@	I-Disease	-1	2522601
mia	I-Disease	-1	2522601
,	O	-1	2522601
and	O	-1	2522601
renal	B-Disease	D051437	2522601
failure	I-Disease	-1	2522601
.	O	-1	2522601
This	O	-1	2522601
is	O	-1	2522601
the	O	-1	2522601
first	O	-1	2522601
report	O	-1	2522601
of	O	-1	2522601
such	O	-1	2522601
an	O	-1	2522601
un@@	O	-1	2522601
us@@	O	-1	2522601
ual	O	-1	2522601
reaction	O	-1	2522601
to	O	-1	2522601
carbamazepine	B-Chemical	D002220	2522601
.	O	-1	2522601

The	O	-1	8741744
inter@@	O	-1	8741744
p@@	O	-1	8741744
ed@@	O	-1	8741744
unc@@	O	-1	8741744
ular	O	-1	8741744
nucle@@	O	-1	8741744
us	O	-1	8741744
reg@@	O	-1	8741744
ul@@	O	-1	8741744
ates	O	-1	8741744
nicotine	B-Chemical	D009538	8741744
's	O	-1	8741744
effects	O	-1	8741744
on	O	-1	8741744
f@@	O	-1	8741744
re@@	O	-1	8741744
e-@@	O	-1	8741744
fi@@	O	-1	8741744
el@@	O	-1	8741744
d	O	-1	8741744
activ@@	O	-1	8741744
ity.	O	-1	8741744
P@@	O	-1	8741744
ar@@	O	-1	8741744
tial	O	-1	8741744
lesions	O	-1	8741744
were	O	-1	8741744
m@@	O	-1	8741744
ade	O	-1	8741744
with	O	-1	8741744
k@@	B-Chemical	D007608	8741744
ain@@	I-Chemical	-1	8741744
ic	I-Chemical	-1	8741744
acid	I-Chemical	-1	8741744
in	O	-1	8741744
the	O	-1	8741744
inter@@	O	-1	8741744
p@@	O	-1	8741744
ed@@	O	-1	8741744
unc@@	O	-1	8741744
ular	O	-1	8741744
nucle@@	O	-1	8741744
us	O	-1	8741744
of	O	-1	8741744
the	O	-1	8741744
ventr@@	O	-1	8741744
al	O	-1	8741744
mid@@	O	-1	8741744
brain	O	-1	8741744
of	O	-1	8741744
the	O	-1	8741744
rat@@	O	-1	8741744
.	O	-1	8741744
Com@@	O	-1	8741744
pared	O	-1	8741744
with	O	-1	8741744
sh@@	O	-1	8741744
am@@	O	-1	8741744
-@@	O	-1	8741744
o@@	O	-1	8741744
per@@	O	-1	8741744
ated	O	-1	8741744
control@@	O	-1	8741744
s,	O	-1	8741744
lesions	O	-1	8741744
significantly	O	-1	8741744
(p	O	-1	8741744
<	O	-1	8741744
0.@@	O	-1	8741744
25@@	O	-1	8741744
)	O	-1	8741744
bl@@	O	-1	8741744
un@@	O	-1	8741744
ted	O	-1	8741744
the	O	-1	8741744
early	O	-1	8741744
(@@	O	-1	8741744
<@@	O	-1	8741744
60	O	-1	8741744
min@@	O	-1	8741744
)	O	-1	8741744
f@@	O	-1	8741744
re@@	O	-1	8741744
e-@@	O	-1	8741744
fi@@	O	-1	8741744
el@@	O	-1	8741744
d	O	-1	8741744
locomotor	B-Disease	D009069	8741744
hypo@@	I-Disease	-1	8741744
activity	I-Disease	-1	8741744
caused	O	-1	8741744
by	O	-1	8741744
nicotine	B-Chemical	D009538	8741744
(0.@@	O	-1	8741744
5	O	-1	8741744
mg	O	-1	8741744
kg@@	O	-1	8741744
(@@	O	-1	8741744
-1@@	O	-1	8741744
),	O	-1	8741744
i.@@	O	-1	8741744
m@@	O	-1	8741744
.@@	O	-1	8741744
),	O	-1	8741744
enhanced	O	-1	8741744
the	O	-1	8741744
lat@@	O	-1	8741744
er	O	-1	8741744
(6@@	O	-1	8741744
0@@	O	-1	8741744
-1@@	O	-1	8741744
20	O	-1	8741744
min@@	O	-1	8741744
)	O	-1	8741744
nicotine	B-Chemical	D009538	8741744
-induced	O	-1	8741744
hyperactivity	B-Disease	D006948	8741744
,	O	-1	8741744
and	O	-1	8741744
ra@@	O	-1	8741744
is@@	O	-1	8741744
ed	O	-1	8741744
spont@@	O	-1	8741744
aneous	O	-1	8741744
n@@	O	-1	8741744
oc@@	O	-1	8741744
t@@	O	-1	8741744
ur@@	O	-1	8741744
n@@	O	-1	8741744
al	O	-1	8741744
activ@@	O	-1	8741744
ity.	O	-1	8741744
L@@	O	-1	8741744
e@@	O	-1	8741744
sions	O	-1	8741744
reduced	O	-1	8741744
the	O	-1	8741744
ext@@	O	-1	8741744
ent	O	-1	8741744
of	O	-1	8741744
immuno@@	O	-1	8741744
hist@@	O	-1	8741744
ological	O	-1	8741744
st@@	O	-1	8741744
aining	O	-1	8741744
for	O	-1	8741744
chol@@	B-Chemical	D002794	8741744
ine	I-Chemical	-1	8741744
acet@@	O	-1	8741744
yl@@	O	-1	8741744
trans@@	O	-1	8741744
fer@@	O	-1	8741744
ase	O	-1	8741744
in	O	-1	8741744
the	O	-1	8741744
inter@@	O	-1	8741744
p@@	O	-1	8741744
ed@@	O	-1	8741744
unc@@	O	-1	8741744
ular	O	-1	8741744
nucle@@	O	-1	8741744
us	O	-1	8741744
(p	O	-1	8741744
<@@	O	-1	8741744
0.0@@	O	-1	8741744
25@@	O	-1	8741744
),	O	-1	8741744
but	O	-1	8741744
not	O	-1	8741744
for	O	-1	8741744
ty@@	B-Chemical	D014443	8741744
ros@@	I-Chemical	-1	8741744
ine	I-Chemical	-1	8741744
hydrox@@	O	-1	8741744
yl@@	O	-1	8741744
ase	O	-1	8741744
in	O	-1	8741744
the	O	-1	8741744
sur@@	O	-1	8741744
ro@@	O	-1	8741744
un@@	O	-1	8741744
ding	O	-1	8741744
cat@@	O	-1	8741744
ech@@	O	-1	8741744
ol@@	O	-1	8741744
aminergic	O	-1	8741744
A@@	O	-1	8741744
10	O	-1	8741744
regi@@	O	-1	8741744
on@@	O	-1	8741744
.	O	-1	8741744
We	O	-1	8741744
concl@@	O	-1	8741744
ude	O	-1	8741744
that	O	-1	8741744
the	O	-1	8741744
inter@@	O	-1	8741744
p@@	O	-1	8741744
ed@@	O	-1	8741744
unc@@	O	-1	8741744
ular	O	-1	8741744
nucle@@	O	-1	8741744
us	O	-1	8741744
medi@@	O	-1	8741744
ates	O	-1	8741744
nicot@@	O	-1	8741744
inic	O	-1	8741744
de@@	B-Disease	D003866	8741744
pression	I-Disease	-1	8741744
of	O	-1	8741744
locomotor	O	-1	8741744
activity	O	-1	8741744
and	O	-1	8741744
dam@@	O	-1	8741744
pen@@	O	-1	8741744
s	O	-1	8741744
nicot@@	O	-1	8741744
inic	O	-1	8741744
a@@	O	-1	8741744
ro@@	O	-1	8741744
us@@	O	-1	8741744
al	O	-1	8741744
mechanisms	O	-1	8741744
loc@@	O	-1	8741744
ated	O	-1	8741744
el@@	O	-1	8741744
se@@	O	-1	8741744
wh@@	O	-1	8741744
ere	O	-1	8741744
in	O	-1	8741744
the	O	-1	8741744
bra@@	O	-1	8741744
in.	O	-1	8741744

A@@	O	-1	17491223
s@@	O	-1	17491223
s@@	O	-1	17491223
ess@@	O	-1	17491223
ment	O	-1	17491223
of	O	-1	17491223
a	O	-1	17491223
new	O	-1	17491223
non-@@	O	-1	17491223
inv@@	O	-1	17491223
a@@	O	-1	17491223
sive	O	-1	17491223
in@@	O	-1	17491223
de@@	O	-1	17491223
x	O	-1	17491223
of	O	-1	17491223
cardiac	O	-1	17491223
perform@@	O	-1	17491223
ance	O	-1	17491223
for	O	-1	17491223
det@@	O	-1	17491223
ection	O	-1	17491223
of	O	-1	17491223
do@@	B-Chemical	D004280	17491223
but@@	I-Chemical	-1	17491223
amine	I-Chemical	-1	17491223
-induced	O	-1	17491223
myocardial	B-Disease	D017202	17491223
ischem@@	I-Disease	-1	17491223
ia	I-Disease	-1	17491223
.	O	-1	17491223
BACKGROUND:	O	-1	17491223
E@@	O	-1	17491223
l@@	O	-1	17491223
ect@@	O	-1	17491223
ro@@	O	-1	17491223
cardio@@	O	-1	17491223
graph@@	O	-1	17491223
y	O	-1	17491223
has	O	-1	17491223
a	O	-1	17491223
very	O	-1	17491223
low	O	-1	17491223
sensitivity	O	-1	17491223
in	O	-1	17491223
det@@	O	-1	17491223
ect@@	O	-1	17491223
ing	O	-1	17491223
do@@	B-Chemical	D004280	17491223
but@@	I-Chemical	-1	17491223
amine	I-Chemical	-1	17491223
-induced	O	-1	17491223
myocardial	B-Disease	D017202	17491223
ischem@@	I-Disease	-1	17491223
ia	I-Disease	-1	17491223
.	O	-1	17491223
OBJECTIV@@	O	-1	17491223
E@@	O	-1	17491223
S:	O	-1	17491223
To	O	-1	17491223
ass@@	O	-1	17491223
ess	O	-1	17491223
the	O	-1	17491223
ad@@	O	-1	17491223
ded	O	-1	17491223
diagnos@@	O	-1	17491223
tic	O	-1	17491223
valu@@	O	-1	17491223
e	O	-1	17491223
of	O	-1	17491223
a	O	-1	17491223
new	O	-1	17491223
cardiac	O	-1	17491223
perform@@	O	-1	17491223
ance	O	-1	17491223
in@@	O	-1	17491223
de@@	O	-1	17491223
x	O	-1	17491223
(@@	O	-1	17491223
d@@	O	-1	17491223
P@@	O	-1	17491223
/@@	O	-1	17491223
d@@	O	-1	17491223
te@@	O	-1	17491223
j@@	O	-1	17491223
c@@	O	-1	17491223
)	O	-1	17491223
meas@@	O	-1	17491223
ure@@	O	-1	17491223
ment@@	O	-1	17491223
,	O	-1	17491223
bas@@	O	-1	17491223
ed	O	-1	17491223
on	O	-1	17491223
b@@	O	-1	17491223
rac@@	O	-1	17491223
hi@@	O	-1	17491223
al	O	-1	17491223
artery	O	-1	17491223
flow	O	-1	17491223
chang@@	O	-1	17491223
es,	O	-1	17491223
as	O	-1	17491223
compared	O	-1	17491223
to	O	-1	17491223
standard	O	-1	17491223
1@@	O	-1	17491223
2-@@	O	-1	17491223
le@@	O	-1	17491223
ad	O	-1	17491223
EC@@	O	-1	17491223
G@@	O	-1	17491223
,	O	-1	17491223
for	O	-1	17491223
det@@	O	-1	17491223
ect@@	O	-1	17491223
ing	O	-1	17491223
do@@	B-Chemical	D004280	17491223
but@@	I-Chemical	-1	17491223
amine	I-Chemical	-1	17491223
-induced	O	-1	17491223
myocardial	B-Disease	D017202	17491223
ischem@@	I-Disease	-1	17491223
ia	I-Disease	-1	17491223
,	O	-1	17491223
using	O	-1	17491223
T@@	B-Chemical	D017256	17491223
c@@	I-Chemical	-1	17491223
9@@	I-Chemical	-1	17491223
9@@	I-Chemical	-1	17491223
m@@	I-Chemical	-1	17491223
-@@	I-Chemical	-1	17491223
S@@	I-Chemical	-1	17491223
est@@	I-Chemical	-1	17491223
ami@@	I-Chemical	-1	17491223
b@@	I-Chemical	-1	17491223
i	I-Chemical	-1	17491223
sing@@	O	-1	17491223
le@@	O	-1	17491223
-@@	O	-1	17491223
ph@@	O	-1	17491223
ot@@	O	-1	17491223
on	O	-1	17491223
em@@	O	-1	17491223
is@@	O	-1	17491223
sion	O	-1	17491223
comp@@	O	-1	17491223
ut@@	O	-1	17491223
ed	O	-1	17491223
to@@	O	-1	17491223
mo@@	O	-1	17491223
graph@@	O	-1	17491223
y	O	-1	17491223
as	O	-1	17491223
the	O	-1	17491223
g@@	O	-1	17491223
old	O	-1	17491223
standard	O	-1	17491223
of	O	-1	17491223
compar@@	O	-1	17491223
ison	O	-1	17491223
to	O	-1	17491223
ass@@	O	-1	17491223
ess	O	-1	17491223
the	O	-1	17491223
presence	O	-1	17491223
or	O	-1	17491223
absence	O	-1	17491223
of	O	-1	17491223
ischem@@	B-Disease	D007511	17491223
ia	I-Disease	-1	17491223
.	O	-1	17491223
METHODS:	O	-1	17491223
The	O	-1	17491223
study	O	-1	17491223
group	O	-1	17491223
comp@@	O	-1	17491223
ris@@	O	-1	17491223
ed	O	-1	17491223
40	O	-1	17491223
patients	O	-1	17491223
under@@	O	-1	17491223
go@@	O	-1	17491223
ing	O	-1	17491223
S@@	B-Chemical	D017256	17491223
est@@	I-Chemical	-1	17491223
ami@@	I-Chemical	-1	17491223
b@@	I-Chemical	-1	17491223
i	I-Chemical	-1	17491223
-@@	O	-1	17491223
S@@	O	-1	17491223
P@@	O	-1	17491223
EC@@	O	-1	17491223
T@@	O	-1	17491223
/	O	-1	17491223
do@@	B-Chemical	D004280	17491223
but@@	I-Chemical	-1	17491223
amine	I-Chemical	-1	17491223
stres@@	O	-1	17491223
s	O	-1	17491223
test@@	O	-1	17491223
.	O	-1	17491223
S@@	O	-1	17491223
im@@	O	-1	17491223
ult@@	O	-1	17491223
aneous	O	-1	17491223
meas@@	O	-1	17491223
ure@@	O	-1	17491223
ments	O	-1	17491223
of	O	-1	17491223
EC@@	O	-1	17491223
G	O	-1	17491223
and	O	-1	17491223
b@@	O	-1	17491223
rac@@	O	-1	17491223
hi@@	O	-1	17491223
al	O	-1	17491223
artery	O	-1	17491223
d@@	O	-1	17491223
P@@	O	-1	17491223
/@@	O	-1	17491223
d@@	O	-1	17491223
te@@	O	-1	17491223
j@@	O	-1	17491223
c	O	-1	17491223
were	O	-1	17491223
performed	O	-1	17491223
at	O	-1	17491223
each	O	-1	17491223
do@@	B-Chemical	D004280	17491223
but@@	I-Chemical	-1	17491223
amine	I-Chemical	-1	17491223
level@@	O	-1	17491223
.	O	-1	17491223
In	O	-1	17491223
1@@	O	-1	17491223
9	O	-1	17491223
of	O	-1	17491223
the	O	-1	17491223
40	O	-1	17491223
patients	O	-1	17491223
per@@	O	-1	17491223
f@@	O	-1	17491223
usion	O	-1	17491223
def@@	O	-1	17491223
ects	O	-1	17491223
com@@	O	-1	17491223
pati@@	O	-1	17491223
ble	O	-1	17491223
with	O	-1	17491223
ischem@@	B-Disease	D007511	17491223
ia	I-Disease	-1	17491223
were	O	-1	17491223
det@@	O	-1	17491223
ected	O	-1	17491223
on	O	-1	17491223
S@@	O	-1	17491223
P@@	O	-1	17491223
EC@@	O	-1	17491223
T@@	O	-1	17491223
.	O	-1	17491223
The	O	-1	17491223
increase	O	-1	17491223
in	O	-1	17491223
d@@	O	-1	17491223
P@@	O	-1	17491223
/@@	O	-1	17491223
d@@	O	-1	17491223
te@@	O	-1	17491223
j@@	O	-1	17491223
c	O	-1	17491223
during	O	-1	17491223
infusion	O	-1	17491223
of	O	-1	17491223
do@@	B-Chemical	D004280	17491223
but@@	I-Chemical	-1	17491223
amine	I-Chemical	-1	17491223
in	O	-1	17491223
this	O	-1	17491223
group	O	-1	17491223
was	O	-1	17491223
se@@	O	-1	17491223
ve@@	O	-1	17491223
re@@	O	-1	17491223
ly	O	-1	17491223
impaired	O	-1	17491223
as	O	-1	17491223
compared	O	-1	17491223
to	O	-1	17491223
the	O	-1	17491223
non-@@	O	-1	17491223
ischem@@	O	-1	17491223
ic	O	-1	17491223
group.	O	-1	17491223
d@@	O	-1	17491223
P@@	O	-1	17491223
/@@	O	-1	17491223
d@@	O	-1	17491223
te@@	O	-1	17491223
j@@	O	-1	17491223
c	O	-1	17491223
outcom@@	O	-1	17491223
e	O	-1	17491223
was	O	-1	17491223
combined	O	-1	17491223
with	O	-1	17491223
the	O	-1	17491223
EC@@	O	-1	17491223
G	O	-1	17491223
result@@	O	-1	17491223
s,	O	-1	17491223
gi@@	O	-1	17491223
ving	O	-1	17491223
an	O	-1	17491223
EC@@	O	-1	17491223
G@@	O	-1	17491223
-@@	O	-1	17491223
enhanced	O	-1	17491223
valu@@	O	-1	17491223
e,	O	-1	17491223
and	O	-1	17491223
compared	O	-1	17491223
to	O	-1	17491223
EC@@	O	-1	17491223
G	O	-1	17491223
al@@	O	-1	17491223
one.	O	-1	17491223
RESULTS:	O	-1	17491223
The	O	-1	17491223
sensitivity	O	-1	17491223
improved	O	-1	17491223
d@@	O	-1	17491223
ram@@	O	-1	17491223
ati@@	O	-1	17491223
c@@	O	-1	17491223
ally	O	-1	17491223
from	O	-1	17491223
1@@	O	-1	17491223
6%	O	-1	17491223
to	O	-1	17491223
7@@	O	-1	17491223
9@@	O	-1	17491223
%,	O	-1	17491223
positive	O	-1	17491223
predic@@	O	-1	17491223
tive	O	-1	17491223
valu@@	O	-1	17491223
e	O	-1	17491223
increased	O	-1	17491223
from	O	-1	17491223
6@@	O	-1	17491223
0%	O	-1	17491223
to	O	-1	17491223
6@@	O	-1	17491223
8@@	O	-1	17491223
%	O	-1	17491223
and	O	-1	17491223
negative	O	-1	17491223
predic@@	O	-1	17491223
tive	O	-1	17491223
valu@@	O	-1	17491223
e	O	-1	17491223
from	O	-1	17491223
5@@	O	-1	17491223
4@@	O	-1	17491223
%	O	-1	17491223
to	O	-1	17491223
7@@	O	-1	17491223
8@@	O	-1	17491223
%,	O	-1	17491223
and	O	-1	17491223
spec@@	O	-1	17491223
ific@@	O	-1	17491223
ity	O	-1	17491223
decreased	O	-1	17491223
from	O	-1	17491223
9@@	O	-1	17491223
0%	O	-1	17491223
to	O	-1	17491223
6@@	O	-1	17491223
7@@	O	-1	17491223
%.	O	-1	17491223
CONCLUSIONS:	O	-1	17491223
I@@	O	-1	17491223
f	O	-1	17491223
EC@@	O	-1	17491223
G	O	-1	17491223
alone	O	-1	17491223
is	O	-1	17491223
used	O	-1	17491223
for	O	-1	17491223
spec@@	O	-1	17491223
ific@@	O	-1	17491223
ity,	O	-1	17491223
the	O	-1	17491223
combination	O	-1	17491223
with	O	-1	17491223
d@@	O	-1	17491223
P@@	O	-1	17491223
/@@	O	-1	17491223
d@@	O	-1	17491223
te@@	O	-1	17491223
j@@	O	-1	17491223
c	O	-1	17491223
improved	O	-1	17491223
the	O	-1	17491223
sensitivity	O	-1	17491223
of	O	-1	17491223
the	O	-1	17491223
test	O	-1	17491223
and	O	-1	17491223
could	O	-1	17491223
be	O	-1	17491223
a	O	-1	17491223
co@@	O	-1	17491223
st@@	O	-1	17491223
-@@	O	-1	17491223
s@@	O	-1	17491223
av@@	O	-1	17491223
ings	O	-1	17491223
al@@	O	-1	17491223
tern@@	O	-1	17491223
ative	O	-1	17491223
to	O	-1	17491223
cardiac	O	-1	17491223
imaging	O	-1	17491223
or	O	-1	17491223
per@@	O	-1	17491223
f@@	O	-1	17491223
usion	O	-1	17491223
studies	O	-1	17491223
to	O	-1	17491223
det@@	O	-1	17491223
ect	O	-1	17491223
myocardial	B-Disease	D017202	17491223
ischem@@	I-Disease	-1	17491223
ia	I-Disease	-1	17491223
,	O	-1	17491223
es@@	O	-1	17491223
p@@	O	-1	17491223
ec@@	O	-1	17491223
i@@	O	-1	17491223
ally	O	-1	17491223
in	O	-1	17491223
patients	O	-1	17491223
un@@	O	-1	17491223
able	O	-1	17491223
to	O	-1	17491223
ex@@	O	-1	17491223
er@@	O	-1	17491223
ci@@	O	-1	17491223
se.	O	-1	17491223

Ac@@	B-Disease	D017114	18004067
ute	I-Disease	-1	18004067
liver	I-Disease	-1	18004067
failure	I-Disease	-1	18004067
in	O	-1	18004067
two	O	-1	18004067
patients	O	-1	18004067
with	O	-1	18004067
reg@@	O	-1	18004067
ular	O	-1	18004067
alco@@	B-Chemical	D000431	18004067
hol	I-Chemical	-1	18004067
consum@@	O	-1	18004067
ption	O	-1	18004067
ing@@	O	-1	18004067
est@@	O	-1	18004067
ing	O	-1	18004067
par@@	B-Chemical	D000082	18004067
acet@@	I-Chemical	-1	18004067
am@@	I-Chemical	-1	18004067
ol	I-Chemical	-1	18004067
at	O	-1	18004067
therapeutic	O	-1	18004067
dos@@	O	-1	18004067
age.	O	-1	18004067
BACKGROUND:	O	-1	18004067
The	O	-1	18004067
possible	O	-1	18004067
role	O	-1	18004067
of	O	-1	18004067
alco@@	B-Chemical	D000431	18004067
hol	I-Chemical	-1	18004067
in	O	-1	18004067
the	O	-1	18004067
development	O	-1	18004067
of	O	-1	18004067
hepat@@	B-Disease	D056486	18004067
otoxicity	I-Disease	-1	18004067
associated	O	-1	18004067
with	O	-1	18004067
therapeutic	O	-1	18004067
doses	O	-1	18004067
of	O	-1	18004067
par@@	B-Chemical	D000082	18004067
acet@@	I-Chemical	-1	18004067
am@@	I-Chemical	-1	18004067
ol	I-Chemical	-1	18004067
(	O	-1	18004067
acet@@	B-Chemical	D000082	18004067
aminoph@@	I-Chemical	-1	18004067
en	I-Chemical	-1	18004067
)	O	-1	18004067
is	O	-1	18004067
cur@@	O	-1	18004067
ren@@	O	-1	18004067
tly	O	-1	18004067
de@@	O	-1	18004067
b@@	O	-1	18004067
ated.	O	-1	18004067
CA@@	O	-1	18004067
S@@	O	-1	18004067
E	O	-1	18004067
R@@	O	-1	18004067
EP@@	O	-1	18004067
O@@	O	-1	18004067
R@@	O	-1	18004067
T@@	O	-1	18004067
:	O	-1	18004067
We	O	-1	18004067
describe	O	-1	18004067
2	O	-1	18004067
patients	O	-1	18004067
who	O	-1	18004067
were	O	-1	18004067
reg@@	O	-1	18004067
ular	O	-1	18004067
consum@@	O	-1	18004067
ers	O	-1	18004067
of	O	-1	18004067
alco@@	B-Chemical	D000431	18004067
hol	I-Chemical	-1	18004067
and	O	-1	18004067
who	O	-1	18004067
developed	O	-1	18004067
liver	B-Disease	D017093	18004067
failure	I-Disease	-1	18004067
within	O	-1	18004067
3-@@	O	-1	18004067
5	O	-1	18004067
days	O	-1	18004067
after	O	-1	18004067
hospit@@	O	-1	18004067
al@@	O	-1	18004067
ization	O	-1	18004067
and	O	-1	18004067
sto@@	O	-1	18004067
pp@@	O	-1	18004067
ing	O	-1	18004067
alco@@	B-Chemical	D000431	18004067
hol	I-Chemical	-1	18004067
consum@@	O	-1	18004067
ption	O	-1	18004067
while	O	-1	18004067
being	O	-1	18004067
treated	O	-1	18004067
with	O	-1	18004067
4	O	-1	18004067
g	O	-1	18004067
par@@	B-Chemical	D000082	18004067
acet@@	I-Chemical	-1	18004067
am@@	I-Chemical	-1	18004067
ol	I-Chemical	-1	18004067
/@@	O	-1	18004067
da@@	O	-1	18004067
y.	O	-1	18004067
A	O	-1	18004067
par@@	B-Chemical	D000082	18004067
acet@@	I-Chemical	-1	18004067
am@@	I-Chemical	-1	18004067
ol	I-Chemical	-1	18004067
serum	O	-1	18004067
level	O	-1	18004067
obtained	O	-1	18004067
in	O	-1	18004067
one	O	-1	18004067
of	O	-1	18004067
these	O	-1	18004067
patients	O	-1	18004067
was	O	-1	18004067
not	O	-1	18004067
in	O	-1	18004067
the	O	-1	18004067
toxic	O	-1	18004067
rang@@	O	-1	18004067
e.	O	-1	18004067
P@@	O	-1	18004067
os@@	O	-1	18004067
sible	O	-1	18004067
risk	O	-1	18004067
factors	O	-1	18004067
for	O	-1	18004067
the	O	-1	18004067
development	O	-1	18004067
of	O	-1	18004067
hepat@@	B-Disease	D056486	18004067
otoxicity	I-Disease	-1	18004067
in	O	-1	18004067
patients	O	-1	18004067
treated	O	-1	18004067
with	O	-1	18004067
therapeutic	O	-1	18004067
doses	O	-1	18004067
of	O	-1	18004067
par@@	B-Chemical	D000082	18004067
acet@@	I-Chemical	-1	18004067
am@@	I-Chemical	-1	18004067
ol	I-Chemical	-1	18004067
are	O	-1	18004067
discus@@	O	-1	18004067
sed.	O	-1	18004067
CONCLUSION:	O	-1	18004067
In	O	-1	18004067
patients	O	-1	18004067
with	O	-1	18004067
risk	O	-1	18004067
fact@@	O	-1	18004067
or@@	O	-1	18004067
s,	O	-1	18004067
e@@	O	-1	18004067
.@@	O	-1	18004067
g@@	O	-1	18004067
.	O	-1	18004067
reg@@	O	-1	18004067
ular	O	-1	18004067
consum@@	O	-1	18004067
ption	O	-1	18004067
of	O	-1	18004067
alco@@	B-Chemical	D000431	18004067
hol	I-Chemical	-1	18004067
,	O	-1	18004067
liver	B-Disease	D017093	18004067
failure	I-Disease	-1	18004067
is	O	-1	18004067
possible	O	-1	18004067
when	O	-1	18004067
therapeutic	O	-1	18004067
doses	O	-1	18004067
are	O	-1	18004067
ing@@	O	-1	18004067
est@@	O	-1	18004067
ed.	O	-1	18004067
We	O	-1	18004067
prop@@	O	-1	18004067
ose	O	-1	18004067
that	O	-1	18004067
the	O	-1	18004067
par@@	B-Chemical	D000082	18004067
acet@@	I-Chemical	-1	18004067
am@@	I-Chemical	-1	18004067
ol	I-Chemical	-1	18004067
dose	O	-1	18004067
should	O	-1	18004067
not	O	-1	18004067
ex@@	O	-1	18004067
ce@@	O	-1	18004067
ed	O	-1	18004067
2	O	-1	18004067
g/@@	O	-1	18004067
day	O	-1	18004067
in	O	-1	18004067
such	O	-1	18004067
patients	O	-1	18004067
and	O	-1	18004067
that	O	-1	18004067
their	O	-1	18004067
liver	O	-1	18004067
function	O	-1	18004067
should	O	-1	18004067
be	O	-1	18004067
monit@@	O	-1	18004067
o@@	O	-1	18004067
red	O	-1	18004067
clo@@	O	-1	18004067
se@@	O	-1	18004067
ly	O	-1	18004067
while	O	-1	18004067
being	O	-1	18004067
treated	O	-1	18004067
with	O	-1	18004067
par@@	B-Chemical	D000082	18004067
acet@@	I-Chemical	-1	18004067
am@@	I-Chemical	-1	18004067
ol	I-Chemical	-1	18004067
.	O	-1	18004067

C@@	B-Chemical	D003042	12443032
oc@@	I-Chemical	-1	12443032
aine	I-Chemical	-1	12443032
related	O	-1	12443032
ch@@	B-Disease	D002637	12443032
est	I-Disease	-1	12443032
pain	I-Disease	-1	12443032
:	O	-1	12443032
are	O	-1	12443032
we	O	-1	12443032
se@@	O	-1	12443032
e@@	O	-1	12443032
ing	O	-1	12443032
the	O	-1	12443032
ti@@	O	-1	12443032
p	O	-1	12443032
of	O	-1	12443032
an	O	-1	12443032
ic@@	O	-1	12443032
e@@	O	-1	12443032
b@@	O	-1	12443032
erg@@	O	-1	12443032
?	O	-1	12443032
The	O	-1	12443032
rec@@	O	-1	12443032
re@@	O	-1	12443032
ation@@	O	-1	12443032
al	O	-1	12443032
use	O	-1	12443032
of	O	-1	12443032
cocaine	B-Chemical	D003042	12443032
is	O	-1	12443032
on	O	-1	12443032
the	O	-1	12443032
increas@@	O	-1	12443032
e.	O	-1	12443032
The	O	-1	12443032
em@@	O	-1	12443032
er@@	O	-1	12443032
gen@@	O	-1	12443032
c@@	O	-1	12443032
y	O	-1	12443032
n@@	O	-1	12443032
ur@@	O	-1	12443032
se	O	-1	12443032
ou@@	O	-1	12443032
ght	O	-1	12443032
to	O	-1	12443032
be	O	-1	12443032
f@@	O	-1	12443032
am@@	O	-1	12443032
il@@	O	-1	12443032
i@@	O	-1	12443032
ar	O	-1	12443032
with	O	-1	12443032
some	O	-1	12443032
of	O	-1	12443032
the	O	-1	12443032
cardiovascular	O	-1	12443032
con@@	O	-1	12443032
sequ@@	O	-1	12443032
enc@@	O	-1	12443032
es	O	-1	12443032
of	O	-1	12443032
cocaine	B-Chemical	D003042	12443032
use.	O	-1	12443032
In	O	-1	12443032
partic@@	O	-1	12443032
ul@@	O	-1	12443032
ar@@	O	-1	12443032
,	O	-1	12443032
the	O	-1	12443032
ten@@	O	-1	12443032
d@@	O	-1	12443032
ency	O	-1	12443032
of	O	-1	12443032
cocaine	B-Chemical	D003042	12443032
to	O	-1	12443032
produce	O	-1	12443032
ch@@	B-Disease	D002637	12443032
est	I-Disease	-1	12443032
pain	I-Disease	-1	12443032
ou@@	O	-1	12443032
ght	O	-1	12443032
to	O	-1	12443032
be	O	-1	12443032
in	O	-1	12443032
the	O	-1	12443032
min@@	O	-1	12443032
d	O	-1	12443032
of	O	-1	12443032
the	O	-1	12443032
em@@	O	-1	12443032
er@@	O	-1	12443032
gen@@	O	-1	12443032
c@@	O	-1	12443032
y	O	-1	12443032
n@@	O	-1	12443032
ur@@	O	-1	12443032
se	O	-1	12443032
when	O	-1	12443032
fac@@	O	-1	12443032
ed	O	-1	12443032
with	O	-1	12443032
a	O	-1	12443032
youn@@	O	-1	12443032
g	O	-1	12443032
v@@	O	-1	12443032
ic@@	O	-1	12443032
ti@@	O	-1	12443032
m	O	-1	12443032
of	O	-1	12443032
ch@@	B-Disease	D002637	12443032
est	I-Disease	-1	12443032
pain	I-Disease	-1	12443032
who	O	-1	12443032
is	O	-1	12443032
o@@	O	-1	12443032
ther@@	O	-1	12443032
w@@	O	-1	12443032
is@@	O	-1	12443032
e	O	-1	12443032
at	O	-1	12443032
low	O	-1	12443032
ris@@	O	-1	12443032
k@@	O	-1	12443032
.	O	-1	12443032
The	O	-1	12443032
mechanism	O	-1	12443032
of	O	-1	12443032
ch@@	B-Disease	D002637	12443032
est	I-Disease	-1	12443032
pain	I-Disease	-1	12443032
related	O	-1	12443032
to	O	-1	12443032
cocaine	B-Chemical	D003042	12443032
use	O	-1	12443032
is	O	-1	12443032
discus@@	O	-1	12443032
sed	O	-1	12443032
and	O	-1	12443032
treatment	O	-1	12443032
di@@	O	-1	12443032
le@@	O	-1	12443032
mm@@	O	-1	12443032
as	O	-1	12443032
are	O	-1	12443032
discus@@	O	-1	12443032
sed.	O	-1	12443032
F@@	O	-1	12443032
in@@	O	-1	12443032
ally,	O	-1	12443032
mor@@	O	-1	12443032
al	O	-1	12443032
is@@	O	-1	12443032
su@@	O	-1	12443032
es	O	-1	12443032
rel@@	O	-1	12443032
ating	O	-1	12443032
to	O	-1	12443032
the	O	-1	12443032
test@@	O	-1	12443032
ing	O	-1	12443032
of	O	-1	12443032
potential	O	-1	12443032
cocaine	B-Chemical	D003042	12443032
users	O	-1	12443032
wil@@	O	-1	12443032
l	O	-1	12443032
be	O	-1	12443032
ad@@	O	-1	12443032
d@@	O	-1	12443032
res@@	O	-1	12443032
sed.	O	-1	12443032

S@@	O	-1	17615423
ev@@	O	-1	17615423
ere	O	-1	17615423
rh@@	B-Disease	D012206	17615423
ab@@	I-Disease	-1	17615423
do@@	I-Disease	-1	17615423
my@@	I-Disease	-1	17615423
oly@@	I-Disease	-1	17615423
sis	I-Disease	-1	17615423
and	O	-1	17615423
acute	B-Disease	D058186	17615423
renal	I-Disease	-1	17615423
failure	I-Disease	-1	17615423
secondary	O	-1	17615423
to	O	-1	17615423
concomit@@	O	-1	17615423
ant	O	-1	17615423
use	O	-1	17615423
of	O	-1	17615423
sim@@	B-Chemical	D019821	17615423
vastatin	I-Chemical	-1	17615423
,	O	-1	17615423
am@@	B-Chemical	D000638	17615423
iodar@@	I-Chemical	-1	17615423
one	I-Chemical	-1	17615423
,	O	-1	17615423
and	O	-1	17615423
at@@	B-Chemical	C413408	17615423
az@@	I-Chemical	-1	17615423
an@@	I-Chemical	-1	17615423
avi@@	I-Chemical	-1	17615423
r	I-Chemical	-1	17615423
.	O	-1	17615423
OBJECTIVE:	O	-1	17615423
To	O	-1	17615423
report	O	-1	17615423
a	O	-1	17615423
case	O	-1	17615423
of	O	-1	17615423
a	O	-1	17615423
severe	O	-1	17615423
inter@@	O	-1	17615423
action	O	-1	17615423
between	O	-1	17615423
sim@@	B-Chemical	D019821	17615423
vastatin	I-Chemical	-1	17615423
,	O	-1	17615423
am@@	B-Chemical	D000638	17615423
iodar@@	I-Chemical	-1	17615423
one	I-Chemical	-1	17615423
,	O	-1	17615423
and	O	-1	17615423
at@@	B-Chemical	C413408	17615423
az@@	I-Chemical	-1	17615423
an@@	I-Chemical	-1	17615423
avi@@	I-Chemical	-1	17615423
r	I-Chemical	-1	17615423
result@@	O	-1	17615423
ing	O	-1	17615423
in	O	-1	17615423
rh@@	B-Disease	D012206	17615423
ab@@	I-Disease	-1	17615423
do@@	I-Disease	-1	17615423
my@@	I-Disease	-1	17615423
oly@@	I-Disease	-1	17615423
sis	I-Disease	-1	17615423
and	O	-1	17615423
acute	B-Disease	D058186	17615423
renal	I-Disease	-1	17615423
failure	I-Disease	-1	17615423
.	O	-1	17615423
BACKGROUND:	O	-1	17615423
A	O	-1	17615423
7@@	O	-1	17615423
2-@@	O	-1	17615423
year-old	O	-1	17615423
wh@@	O	-1	17615423
ite	O	-1	17615423
man	O	-1	17615423
with	O	-1	17615423
underlying	O	-1	17615423
human	B-Disease	D015658	17615423
immuno@@	I-Disease	-1	17615423
defici@@	I-Disease	-1	17615423
ency	I-Disease	-1	17615423
vi@@	I-Disease	-1	17615423
ru@@	I-Disease	-1	17615423
s	I-Disease	-1	17615423
,	O	-1	17615423
atrial	B-Disease	D001281	17615423
fibrill@@	I-Disease	-1	17615423
ation	I-Disease	-1	17615423
,	O	-1	17615423
coronary	B-Disease	D003324	17615423
artery	I-Disease	-1	17615423
disease	I-Disease	-1	17615423
,	O	-1	17615423
and	O	-1	17615423
hyper@@	B-Disease	D006949	17615423
li@@	I-Disease	-1	17615423
pi@@	I-Disease	-1	17615423
de@@	I-Disease	-1	17615423
mia	I-Disease	-1	17615423
presented	O	-1	17615423
with	O	-1	17615423
gener@@	O	-1	17615423
al@@	O	-1	17615423
ized	O	-1	17615423
pain	B-Disease	D010146	17615423
,	O	-1	17615423
f@@	B-Disease	D005221	17615423
ati@@	I-Disease	-1	17615423
gu@@	I-Disease	-1	17615423
e	I-Disease	-1	17615423
,	O	-1	17615423
and	O	-1	17615423
d@@	O	-1	17615423
ar@@	O	-1	17615423
k	O	-1	17615423
or@@	O	-1	17615423
ang@@	O	-1	17615423
e	O	-1	17615423
urine	O	-1	17615423
for	O	-1	17615423
3	O	-1	17615423
days.	O	-1	17615423
The	O	-1	17615423
patient	O	-1	17615423
was	O	-1	17615423
taking	O	-1	17615423
8@@	O	-1	17615423
0	O	-1	17615423
mg	O	-1	17615423
sim@@	B-Chemical	D019821	17615423
vastatin	I-Chemical	-1	17615423
at	O	-1	17615423
be@@	O	-1	17615423
d@@	O	-1	17615423
time	O	-1	17615423
(@@	O	-1	17615423
initi@@	O	-1	17615423
ated	O	-1	17615423
2@@	O	-1	17615423
7	O	-1	17615423
days	O	-1	17615423
ear@@	O	-1	17615423
li@@	O	-1	17615423
er@@	O	-1	17615423
);	O	-1	17615423
am@@	B-Chemical	D000638	17615423
iodar@@	I-Chemical	-1	17615423
one	I-Chemical	-1	17615423
at	O	-1	17615423
a	O	-1	17615423
dose	O	-1	17615423
of	O	-1	17615423
4@@	O	-1	17615423
00	O	-1	17615423
mg	O	-1	17615423
daily	O	-1	17615423
for	O	-1	17615423
7	O	-1	17615423
day@@	O	-1	17615423
s,	O	-1	17615423
then	O	-1	17615423
2@@	O	-1	17615423
00	O	-1	17615423
mg	O	-1	17615423
daily	O	-1	17615423
(@@	O	-1	17615423
initi@@	O	-1	17615423
ated	O	-1	17615423
1@@	O	-1	17615423
9	O	-1	17615423
days	O	-1	17615423
ear@@	O	-1	17615423
li@@	O	-1	17615423
er@@	O	-1	17615423
);	O	-1	17615423
and	O	-1	17615423
4@@	O	-1	17615423
00	O	-1	17615423
mg	O	-1	17615423
at@@	B-Chemical	C413408	17615423
az@@	I-Chemical	-1	17615423
an@@	I-Chemical	-1	17615423
avi@@	I-Chemical	-1	17615423
r	I-Chemical	-1	17615423
daily	O	-1	17615423
(@@	O	-1	17615423
initi@@	O	-1	17615423
ated	O	-1	17615423
at	O	-1	17615423
le@@	O	-1	17615423
ast	O	-1	17615423
2	O	-1	17615423
years	O	-1	17615423
previ@@	O	-1	17615423
ous@@	O	-1	17615423
ly@@	O	-1	17615423
).	O	-1	17615423
L@@	O	-1	17615423
abor@@	O	-1	17615423
atory	O	-1	17615423
evalu@@	O	-1	17615423
ation	O	-1	17615423
revealed	O	-1	17615423
6@@	O	-1	17615423
6@@	O	-1	17615423
,@@	O	-1	17615423
6@@	O	-1	17615423
8@@	O	-1	17615423
0	O	-1	17615423
U@@	O	-1	17615423
/@@	O	-1	17615423
L	O	-1	17615423
creat@@	B-Chemical	D003401	17615423
ine	I-Chemical	-1	17615423
kin@@	O	-1	17615423
ase,	O	-1	17615423
9@@	O	-1	17615423
3	O	-1	17615423
mg/d@@	O	-1	17615423
L	O	-1	17615423
blood	B-Chemical	D001806	17615423
ure@@	I-Chemical	-1	17615423
a	I-Chemical	-1	17615423
nitro@@	I-Chemical	-1	17615423
gen	I-Chemical	-1	17615423
,	O	-1	17615423
4.@@	O	-1	17615423
6	O	-1	17615423
mg/d@@	O	-1	17615423
L	O	-1	17615423
creatinine	B-Chemical	D003404	17615423
,	O	-1	17615423
1@@	O	-1	17615423
5@@	O	-1	17615423
7@@	O	-1	17615423
9	O	-1	17615423
U@@	O	-1	17615423
/@@	O	-1	17615423
L	O	-1	17615423
as@@	B-Chemical	D001224	17615423
part@@	I-Chemical	-1	17615423
ate	I-Chemical	-1	17615423
amin@@	O	-1	17615423
ot@@	O	-1	17615423
ran@@	O	-1	17615423
s@@	O	-1	17615423
fer@@	O	-1	17615423
ase,	O	-1	17615423
and	O	-1	17615423
7@@	O	-1	17615423
3@@	O	-1	17615423
8	O	-1	17615423
U@@	O	-1	17615423
/@@	O	-1	17615423
L	O	-1	17615423
al@@	B-Chemical	D000409	17615423
an@@	I-Chemical	-1	17615423
ine	I-Chemical	-1	17615423
amin@@	O	-1	17615423
ot@@	O	-1	17615423
ran@@	O	-1	17615423
s@@	O	-1	17615423
fer@@	O	-1	17615423
as@@	O	-1	17615423
e.	O	-1	17615423
S@@	B-Chemical	D019821	17615423
im@@	I-Chemical	-1	17615423
vastatin	I-Chemical	-1	17615423
,	O	-1	17615423
am@@	B-Chemical	D000638	17615423
iodar@@	I-Chemical	-1	17615423
one	I-Chemical	-1	17615423
,	O	-1	17615423
and	O	-1	17615423
the	O	-1	17615423
patient@@	O	-1	17615423
's	O	-1	17615423
human	B-Disease	D015658	17615423
immuno@@	I-Disease	-1	17615423
defici@@	I-Disease	-1	17615423
ency	I-Disease	-1	17615423
vi@@	I-Disease	-1	17615423
ru@@	I-Disease	-1	17615423
s	I-Disease	-1	17615423
medic@@	O	-1	17615423
ations	O	-1	17615423
were	O	-1	17615423
all	O	-1	17615423
tempor@@	O	-1	17615423
ari@@	O	-1	17615423
ly	O	-1	17615423
discontinu@@	O	-1	17615423
ed	O	-1	17615423
and	O	-1	17615423
the	O	-1	17615423
patient	O	-1	17615423
was	O	-1	17615423
given	O	-1	17615423
for@@	O	-1	17615423
c@@	O	-1	17615423
ed	O	-1	17615423
al@@	O	-1	17615423
k@@	O	-1	17615423
aline	O	-1	17615423
di@@	O	-1	17615423
ure@@	O	-1	17615423
sis	O	-1	17615423
and	O	-1	17615423
star@@	O	-1	17615423
ted	O	-1	17615423
on	O	-1	17615423
dialy@@	O	-1	17615423
sis.	O	-1	17615423
N@@	O	-1	17615423
ine	O	-1	17615423
days	O	-1	17615423
lat@@	O	-1	17615423
er	O	-1	17615423
the	O	-1	17615423
patient@@	O	-1	17615423
's	O	-1	17615423
creat@@	B-Chemical	D003401	17615423
ine	I-Chemical	-1	17615423
kin@@	O	-1	17615423
ase	O	-1	17615423
had	O	-1	17615423
dro@@	O	-1	17615423
pp@@	O	-1	17615423
ed	O	-1	17615423
to	O	-1	17615423
1@@	O	-1	17615423
6@@	O	-1	17615423
9@@	O	-1	17615423
5	O	-1	17615423
U@@	O	-1	17615423
/@@	O	-1	17615423
L	O	-1	17615423
and	O	-1	17615423
creatinine	B-Chemical	D003404	17615423
was	O	-1	17615423
3.@@	O	-1	17615423
3	O	-1	17615423
mg/d@@	O	-1	17615423
L@@	O	-1	17615423
.	O	-1	17615423
The	O	-1	17615423
patient	O	-1	17615423
was	O	-1	17615423
dis@@	O	-1	17615423
ch@@	O	-1	17615423
arg@@	O	-1	17615423
ed	O	-1	17615423
and	O	-1	17615423
continu@@	O	-1	17615423
ed	O	-1	17615423
out@@	O	-1	17615423
patient	O	-1	17615423
dialy@@	O	-1	17615423
sis	O	-1	17615423
for	O	-1	17615423
1	O	-1	17615423
mon@@	O	-1	17615423
th	O	-1	17615423
un@@	O	-1	17615423
ti@@	O	-1	17615423
l	O	-1	17615423
h@@	O	-1	17615423
is	O	-1	17615423
renal	O	-1	17615423
function	O	-1	17615423
reco@@	O	-1	17615423
ve@@	O	-1	17615423
red.	O	-1	17615423
D@@	O	-1	17615423
I@@	O	-1	17615423
S@@	O	-1	17615423
C@@	O	-1	17615423
US@@	O	-1	17615423
S@@	O	-1	17615423
ION@@	O	-1	17615423
:	O	-1	17615423
The	O	-1	17615423
risk	O	-1	17615423
of	O	-1	17615423
rh@@	B-Disease	D012206	17615423
ab@@	I-Disease	-1	17615423
do@@	I-Disease	-1	17615423
my@@	I-Disease	-1	17615423
oly@@	I-Disease	-1	17615423
sis	I-Disease	-1	17615423
is	O	-1	17615423
increased	O	-1	17615423
in	O	-1	17615423
the	O	-1	17615423
presence	O	-1	17615423
of	O	-1	17615423
concomit@@	O	-1	17615423
ant	O	-1	17615423
drugs	O	-1	17615423
that	O	-1	17615423
inhib@@	O	-1	17615423
it	O	-1	17615423
sim@@	B-Chemical	D019821	17615423
vastatin	I-Chemical	-1	17615423
metabol@@	O	-1	17615423
is@@	O	-1	17615423
m.	O	-1	17615423
S@@	B-Chemical	D019821	17615423
im@@	I-Chemical	-1	17615423
vastatin	I-Chemical	-1	17615423
is	O	-1	17615423
metabol@@	O	-1	17615423
ized	O	-1	17615423
by	O	-1	17615423
C@@	O	-1	17615423
Y@@	O	-1	17615423
P@@	O	-1	17615423
3@@	O	-1	17615423
A@@	O	-1	17615423
4@@	O	-1	17615423
.	O	-1	17615423
A@@	B-Chemical	D000638	17615423
m@@	I-Chemical	-1	17615423
iodar@@	I-Chemical	-1	17615423
one	I-Chemical	-1	17615423
and	O	-1	17615423
at@@	B-Chemical	C413408	17615423
az@@	I-Chemical	-1	17615423
an@@	I-Chemical	-1	17615423
avi@@	I-Chemical	-1	17615423
r	I-Chemical	-1	17615423
are	O	-1	17615423
reco@@	O	-1	17615423
gn@@	O	-1	17615423
ized	O	-1	17615423
C@@	O	-1	17615423
Y@@	O	-1	17615423
P@@	O	-1	17615423
3@@	O	-1	17615423
A@@	O	-1	17615423
4	O	-1	17615423
inhibitor@@	O	-1	17615423
s.	O	-1	17615423
CONCLUSIONS:	O	-1	17615423
Ph@@	O	-1	17615423
armac@@	O	-1	17615423
o@@	O	-1	17615423
kine@@	O	-1	17615423
tic	O	-1	17615423
differences	O	-1	17615423
in	O	-1	17615423
stat@@	B-Chemical	D019821	17615423
ins	I-Chemical	-1	17615423
are	O	-1	17615423
an	O	-1	17615423
important	O	-1	17615423
con@@	O	-1	17615423
si@@	O	-1	17615423
der@@	O	-1	17615423
ation	O	-1	17615423
for	O	-1	17615423
assess@@	O	-1	17615423
ing	O	-1	17615423
the	O	-1	17615423
risk	O	-1	17615423
of	O	-1	17615423
potential	O	-1	17615423
drug	O	-1	17615423
inter@@	O	-1	17615423
ac@@	O	-1	17615423
tions.	O	-1	17615423
In	O	-1	17615423
patients	O	-1	17615423
requ@@	O	-1	17615423
ir@@	O	-1	17615423
ing	O	-1	17615423
the	O	-1	17615423
con@@	O	-1	17615423
current	O	-1	17615423
use	O	-1	17615423
of	O	-1	17615423
stat@@	B-Chemical	D019821	17615423
ins	I-Chemical	-1	17615423
and	O	-1	17615423
C@@	O	-1	17615423
Y@@	O	-1	17615423
P@@	O	-1	17615423
3@@	O	-1	17615423
A@@	O	-1	17615423
4	O	-1	17615423
inhibitor@@	O	-1	17615423
s,	O	-1	17615423
pra@@	B-Chemical	D017035	17615423
vastatin	I-Chemical	-1	17615423
,	O	-1	17615423
flu@@	B-Chemical	C065180	17615423
vastatin	I-Chemical	-1	17615423
,	O	-1	17615423
and	O	-1	17615423
ro@@	B-Chemical	C422923	17615423
su@@	I-Chemical	-1	17615423
vastatin	I-Chemical	-1	17615423
car@@	O	-1	17615423
r@@	O	-1	17615423
y	O	-1	17615423
the	O	-1	17615423
low@@	O	-1	17615423
est	O	-1	17615423
risk	O	-1	17615423
of	O	-1	17615423
drug	O	-1	17615423
inter@@	O	-1	17615423
ac@@	O	-1	17615423
tion@@	O	-1	17615423
s;	O	-1	17615423
at@@	B-Chemical	C065179	17615423
or@@	I-Chemical	-1	17615423
vastatin	I-Chemical	-1	17615423
car@@	O	-1	17615423
ri@@	O	-1	17615423
es	O	-1	17615423
moder@@	O	-1	17615423
ate	O	-1	17615423
ris@@	O	-1	17615423
k@@	O	-1	17615423
,	O	-1	17615423
whereas	O	-1	17615423
sim@@	B-Chemical	D019821	17615423
vastatin	I-Chemical	-1	17615423
and	O	-1	17615423
lo@@	B-Chemical	D008148	17615423
vastatin	I-Chemical	-1	17615423
have	O	-1	17615423
the	O	-1	17615423
high@@	O	-1	17615423
est	O	-1	17615423
risk	O	-1	17615423
and	O	-1	17615423
should	O	-1	17615423
be	O	-1	17615423
avoid@@	O	-1	17615423
ed	O	-1	17615423
in	O	-1	17615423
patients	O	-1	17615423
taking	O	-1	17615423
concomit@@	O	-1	17615423
ant	O	-1	17615423
C@@	O	-1	17615423
Y@@	O	-1	17615423
P@@	O	-1	17615423
3@@	O	-1	17615423
A@@	O	-1	17615423
4	O	-1	17615423
inhibitor@@	O	-1	17615423
s.	O	-1	17615423

Ph@@	O	-1	8558192
ase	O	-1	8558192
II	O	-1	8558192
trial	O	-1	8558192
of	O	-1	8558192
v@@	B-Chemical	C030852	8558192
ino@@	I-Chemical	-1	8558192
rel@@	I-Chemical	-1	8558192
b@@	I-Chemical	-1	8558192
ine	I-Chemical	-1	8558192
in	O	-1	8558192
met@@	O	-1	8558192
ast@@	O	-1	8558192
atic	O	-1	8558192
s@@	B-Disease	C562729	8558192
qu@@	I-Disease	-1	8558192
am@@	I-Disease	-1	8558192
ous	I-Disease	-1	8558192
cell	I-Disease	-1	8558192
es@@	I-Disease	-1	8558192
oph@@	I-Disease	-1	8558192
ag@@	I-Disease	-1	8558192
e@@	I-Disease	-1	8558192
al	I-Disease	-1	8558192
carcin@@	I-Disease	-1	8558192
oma	I-Disease	-1	8558192
.	O	-1	8558192
E@@	O	-1	8558192
uro@@	O	-1	8558192
pe@@	O	-1	8558192
an	O	-1	8558192
O@@	O	-1	8558192
r@@	O	-1	8558192
g@@	O	-1	8558192
an@@	O	-1	8558192
ization	O	-1	8558192
for	O	-1	8558192
R@@	O	-1	8558192
es@@	O	-1	8558192
ear@@	O	-1	8558192
ch	O	-1	8558192
and	O	-1	8558192
Treat@@	O	-1	8558192
ment	O	-1	8558192
of	O	-1	8558192
C@@	B-Disease	D009369	8558192
anc@@	I-Disease	-1	8558192
er	I-Disease	-1	8558192
G@@	O	-1	8558192
ast@@	O	-1	8558192
ro@@	O	-1	8558192
in@@	O	-1	8558192
test@@	O	-1	8558192
inal	O	-1	8558192
T@@	O	-1	8558192
re@@	O	-1	8558192
at	O	-1	8558192
C@@	B-Disease	D009369	8558192
anc@@	I-Disease	-1	8558192
er	I-Disease	-1	8558192
C@@	O	-1	8558192
o@@	O	-1	8558192
o@@	O	-1	8558192
perative	O	-1	8558192
Grou@@	O	-1	8558192
p@@	O	-1	8558192
.	O	-1	8558192
P@@	O	-1	8558192
U@@	O	-1	8558192
R@@	O	-1	8558192
P@@	O	-1	8558192
O@@	O	-1	8558192
S@@	O	-1	8558192
E:	O	-1	8558192
To	O	-1	8558192
evalu@@	O	-1	8558192
ate	O	-1	8558192
the	O	-1	8558192
response	O	-1	8558192
rate	O	-1	8558192
and	O	-1	8558192
toxic	O	-1	8558192
effects	O	-1	8558192
of	O	-1	8558192
v@@	B-Chemical	C030852	8558192
ino@@	I-Chemical	-1	8558192
rel@@	I-Chemical	-1	8558192
b@@	I-Chemical	-1	8558192
ine	I-Chemical	-1	8558192
(	O	-1	8558192
V@@	B-Chemical	C030852	8558192
N@@	I-Chemical	-1	8558192
B	I-Chemical	-1	8558192
)	O	-1	8558192
administered	O	-1	8558192
as	O	-1	8558192
a	O	-1	8558192
single	O	-1	8558192
agent	O	-1	8558192
in	O	-1	8558192
met@@	O	-1	8558192
ast@@	O	-1	8558192
atic	O	-1	8558192
s@@	B-Disease	C562729	8558192
qu@@	I-Disease	-1	8558192
am@@	I-Disease	-1	8558192
ous	I-Disease	-1	8558192
cell	I-Disease	-1	8558192
es@@	I-Disease	-1	8558192
oph@@	I-Disease	-1	8558192
ag@@	I-Disease	-1	8558192
e@@	I-Disease	-1	8558192
al	I-Disease	-1	8558192
carcin@@	I-Disease	-1	8558192
oma	I-Disease	-1	8558192
.	O	-1	8558192
PA@@	O	-1	8558192
TI@@	O	-1	8558192
E@@	O	-1	8558192
N@@	O	-1	8558192
T@@	O	-1	8558192
S	O	-1	8558192
AN@@	O	-1	8558192
D	O	-1	8558192
METHODS:	O	-1	8558192
F@@	O	-1	8558192
or@@	O	-1	8558192
ty-@@	O	-1	8558192
six	O	-1	8558192
e@@	O	-1	8558192
li@@	O	-1	8558192
gi@@	O	-1	8558192
ble	O	-1	8558192
patients	O	-1	8558192
with	O	-1	8558192
meas@@	O	-1	8558192
ur@@	O	-1	8558192
able	O	-1	8558192
lesions	O	-1	8558192
were	O	-1	8558192
included	O	-1	8558192
and	O	-1	8558192
were	O	-1	8558192
str@@	O	-1	8558192
ati@@	O	-1	8558192
fied	O	-1	8558192
ac@@	O	-1	8558192
cor@@	O	-1	8558192
ding	O	-1	8558192
to	O	-1	8558192
previ@@	O	-1	8558192
ous	O	-1	8558192
chemo@@	O	-1	8558192
therapy.	O	-1	8558192
Th@@	O	-1	8558192
ir@@	O	-1	8558192
t@@	O	-1	8558192
y	O	-1	8558192
patients	O	-1	8558192
without	O	-1	8558192
prior	O	-1	8558192
chemotherapy	O	-1	8558192
and	O	-1	8558192
16	O	-1	8558192
pre@@	O	-1	8558192
treated	O	-1	8558192
with	O	-1	8558192
cisplatin	B-Chemical	D002945	8558192
-@@	O	-1	8558192
bas@@	O	-1	8558192
ed	O	-1	8558192
chemotherapy	O	-1	8558192
were	O	-1	8558192
assess@@	O	-1	8558192
able	O	-1	8558192
for	O	-1	8558192
toxicity	B-Disease	D064420	8558192
and	O	-1	8558192
respon@@	O	-1	8558192
se.	O	-1	8558192
V@@	B-Chemical	C030852	8558192
N@@	I-Chemical	-1	8558192
B	I-Chemical	-1	8558192
was	O	-1	8558192
administered	O	-1	8558192
week@@	O	-1	8558192
ly	O	-1	8558192
as	O	-1	8558192
a	O	-1	8558192
2@@	O	-1	8558192
5-@@	O	-1	8558192
mg/m@@	O	-1	8558192
2	O	-1	8558192
sh@@	O	-1	8558192
ort	O	-1	8558192
intravenous	O	-1	8558192
(@@	O	-1	8558192
i.v@@	O	-1	8558192
.)	O	-1	8558192
infu@@	O	-1	8558192
sion.	O	-1	8558192
RESULTS:	O	-1	8558192
Si@@	O	-1	8558192
x	O	-1	8558192
of	O	-1	8558192
30	O	-1	8558192
patients	O	-1	8558192
(2@@	O	-1	8558192
0@@	O	-1	8558192
%)	O	-1	8558192
without	O	-1	8558192
prior	O	-1	8558192
chemotherapy	O	-1	8558192
achi@@	O	-1	8558192
ev@@	O	-1	8558192
ed	O	-1	8558192
a	O	-1	8558192
partial	O	-1	8558192
response	O	-1	8558192
(P@@	O	-1	8558192
R@@	O	-1	8558192
)	O	-1	8558192
(@@	O	-1	8558192
95%	O	-1	8558192
conf@@	O	-1	8558192
idence	O	-1	8558192
interv@@	O	-1	8558192
al	O	-1	8558192
[@@	O	-1	8558192
CI@@	O	-1	8558192
]@@	O	-1	8558192
,	O	-1	8558192
8@@	O	-1	8558192
%	O	-1	8558192
to	O	-1	8558192
3@@	O	-1	8558192
9@@	O	-1	8558192
%).	O	-1	8558192
The	O	-1	8558192
median	O	-1	8558192
duration	O	-1	8558192
of	O	-1	8558192
response	O	-1	8558192
was	O	-1	8558192
21	O	-1	8558192
weeks	O	-1	8558192
(@@	O	-1	8558192
rang@@	O	-1	8558192
e,	O	-1	8558192
17	O	-1	8558192
to	O	-1	8558192
2@@	O	-1	8558192
8@@	O	-1	8558192
).	O	-1	8558192
One	O	-1	8558192
of	O	-1	8558192
16	O	-1	8558192
patients	O	-1	8558192
(6@@	O	-1	8558192
%)	O	-1	8558192
with	O	-1	8558192
prior	O	-1	8558192
chemotherapy	O	-1	8558192
had	O	-1	8558192
a	O	-1	8558192
complete	O	-1	8558192
response	O	-1	8558192
(C@@	O	-1	8558192
R@@	O	-1	8558192
)	O	-1	8558192
of	O	-1	8558192
3@@	O	-1	8558192
1	O	-1	8558192
week@@	O	-1	8558192
s@@	O	-1	8558192
'	O	-1	8558192
duration	O	-1	8558192
(@@	O	-1	8558192
95%	O	-1	8558192
CI@@	O	-1	8558192
,	O	-1	8558192
0%	O	-1	8558192
to	O	-1	8558192
3@@	O	-1	8558192
0@@	O	-1	8558192
%).	O	-1	8558192
The	O	-1	8558192
over@@	O	-1	8558192
all	O	-1	8558192
response	O	-1	8558192
rate	O	-1	8558192
(@@	O	-1	8558192
W@@	O	-1	8558192
or@@	O	-1	8558192
l@@	O	-1	8558192
d	O	-1	8558192
He@@	O	-1	8558192
al@@	O	-1	8558192
th	O	-1	8558192
O@@	O	-1	8558192
r@@	O	-1	8558192
g@@	O	-1	8558192
an@@	O	-1	8558192
ization	O	-1	8558192
[@@	O	-1	8558192
W@@	O	-1	8558192
HO@@	O	-1	8558192
]	O	-1	8558192
c@@	O	-1	8558192
rit@@	O	-1	8558192
er@@	O	-1	8558192
ia@@	O	-1	8558192
)	O	-1	8558192
was	O	-1	8558192
1@@	O	-1	8558192
5%	O	-1	8558192
(C@@	O	-1	8558192
R@@	O	-1	8558192
,	O	-1	8558192
2@@	O	-1	8558192
%@@	O	-1	8558192
;	O	-1	8558192
P@@	O	-1	8558192
R	O	-1	8558192
13@@	O	-1	8558192
%@@	O	-1	8558192
;	O	-1	8558192
95%	O	-1	8558192
CI@@	O	-1	8558192
,	O	-1	8558192
6%	O	-1	8558192
to	O	-1	8558192
2@@	O	-1	8558192
9@@	O	-1	8558192
%).	O	-1	8558192
The	O	-1	8558192
median	O	-1	8558192
dose-@@	O	-1	8558192
int@@	O	-1	8558192
ensity	O	-1	8558192
(D@@	O	-1	8558192
I@@	O	-1	8558192
)	O	-1	8558192
was	O	-1	8558192
20	O	-1	8558192
mg/m@@	O	-1	8558192
2@@	O	-1	8558192
/@@	O	-1	8558192
w@@	O	-1	8558192
k@@	O	-1	8558192
.	O	-1	8558192
V@@	B-Chemical	C030852	8558192
N@@	I-Chemical	-1	8558192
B	I-Chemical	-1	8558192
was	O	-1	8558192
well	O	-1	8558192
toler@@	O	-1	8558192
ated	O	-1	8558192
and	O	-1	8558192
z@@	O	-1	8558192
er@@	O	-1	8558192
o	O	-1	8558192
in@@	O	-1	8558192
st@@	O	-1	8558192
anc@@	O	-1	8558192
es	O	-1	8558192
of	O	-1	8558192
W@@	O	-1	8558192
H@@	O	-1	8558192
O	O	-1	8558192
gra@@	O	-1	8558192
de	O	-1	8558192
4	O	-1	8558192
non@@	O	-1	8558192
hemat@@	O	-1	8558192
ologic	O	-1	8558192
toxicity	B-Disease	D064420	8558192
occur@@	O	-1	8558192
red.	O	-1	8558192
A@@	O	-1	8558192
t	O	-1	8558192
le@@	O	-1	8558192
ast	O	-1	8558192
one	O	-1	8558192
episo@@	O	-1	8558192
de	O	-1	8558192
of	O	-1	8558192
gra@@	O	-1	8558192
de	O	-1	8558192
3	O	-1	8558192
or	O	-1	8558192
4	O	-1	8558192
gran@@	B-Disease	D000380	8558192
ulo@@	I-Disease	-1	8558192
cyto@@	I-Disease	-1	8558192
pen@@	I-Disease	-1	8558192
ia	I-Disease	-1	8558192
was	O	-1	8558192
seen	O	-1	8558192
in	O	-1	8558192
5@@	O	-1	8558192
9@@	O	-1	8558192
%	O	-1	8558192
of	O	-1	8558192
patients.	O	-1	8558192
A	O	-1	8558192
gra@@	O	-1	8558192
de	O	-1	8558192
2	O	-1	8558192
or	O	-1	8558192
3	O	-1	8558192
inf@@	B-Disease	D007239	8558192
ection	I-Disease	-1	8558192
occurred	O	-1	8558192
in	O	-1	8558192
1@@	O	-1	8558192
6%	O	-1	8558192
of	O	-1	8558192
patients,	O	-1	8558192
but	O	-1	8558192
no	O	-1	8558192
toxic	O	-1	8558192
de@@	B-Disease	D003643	8558192
ath@@	I-Disease	-1	8558192
s	I-Disease	-1	8558192
occur@@	O	-1	8558192
red.	O	-1	8558192
O@@	O	-1	8558192
ther	O	-1	8558192
side	O	-1	8558192
effects	O	-1	8558192
were	O	-1	8558192
ra@@	O	-1	8558192
re,	O	-1	8558192
and	O	-1	8558192
peripheral	B-Disease	D010523	8558192
neuro@@	I-Disease	-1	8558192
toxicity	I-Disease	-1	8558192
has	O	-1	8558192
been	O	-1	8558192
min@@	O	-1	8558192
or	O	-1	8558192
(2@@	O	-1	8558192
6%	O	-1	8558192
gra@@	O	-1	8558192
de	O	-1	8558192
1).	O	-1	8558192
CONCLUSION:	O	-1	8558192
These	O	-1	8558192
data	O	-1	8558192
indicate	O	-1	8558192
that	O	-1	8558192
V@@	B-Chemical	C030852	8558192
N@@	I-Chemical	-1	8558192
B	I-Chemical	-1	8558192
is	O	-1	8558192
an	O	-1	8558192
active	O	-1	8558192
agent	O	-1	8558192
in	O	-1	8558192
met@@	O	-1	8558192
ast@@	O	-1	8558192
atic	O	-1	8558192
es@@	B-Disease	C562729	8558192
oph@@	I-Disease	-1	8558192
ag@@	I-Disease	-1	8558192
e@@	I-Disease	-1	8558192
al	I-Disease	-1	8558192
s@@	I-Disease	-1	8558192
qu@@	I-Disease	-1	8558192
am@@	I-Disease	-1	8558192
ous	I-Disease	-1	8558192
cell	I-Disease	-1	8558192
carcin@@	I-Disease	-1	8558192
oma	I-Disease	-1	8558192
.	O	-1	8558192
G@@	O	-1	8558192
i@@	O	-1	8558192
ven	O	-1	8558192
its	O	-1	8558192
ex@@	O	-1	8558192
cell@@	O	-1	8558192
ent	O	-1	8558192
toler@@	O	-1	8558192
ance	O	-1	8558192
prof@@	O	-1	8558192
ile	O	-1	8558192
and	O	-1	8558192
low	O	-1	8558192
toxicity	B-Disease	D064420	8558192
,	O	-1	8558192
further	O	-1	8558192
evalu@@	O	-1	8558192
ation	O	-1	8558192
of	O	-1	8558192
V@@	B-Chemical	C030852	8558192
N@@	I-Chemical	-1	8558192
B	I-Chemical	-1	8558192
in	O	-1	8558192
combination	O	-1	8558192
therapy	O	-1	8558192
is	O	-1	8558192
war@@	O	-1	8558192
ran@@	O	-1	8558192
ted.	O	-1	8558192

P@@	B-Chemical	D017239	11135224
ac@@	I-Chemical	-1	11135224
litax@@	I-Chemical	-1	11135224
el	I-Chemical	-1	11135224
,	O	-1	11135224
cisplatin	B-Chemical	D002945	11135224
,	O	-1	11135224
and	O	-1	11135224
g@@	B-Chemical	C056507	11135224
em@@	I-Chemical	-1	11135224
cit@@	I-Chemical	-1	11135224
ab@@	I-Chemical	-1	11135224
ine	I-Chemical	-1	11135224
combination	O	-1	11135224
chemotherapy	O	-1	11135224
within	O	-1	11135224
a	O	-1	11135224
multi@@	O	-1	11135224
dis@@	O	-1	11135224
ci@@	O	-1	11135224
pl@@	O	-1	11135224
inary	O	-1	11135224
therapeutic	O	-1	11135224
appro@@	O	-1	11135224
ach	O	-1	11135224
in	O	-1	11135224
met@@	O	-1	11135224
ast@@	O	-1	11135224
atic	O	-1	11135224
non@@	B-Disease	D002289	11135224
sm@@	I-Disease	-1	11135224
all	I-Disease	-1	11135224
cell	I-Disease	-1	11135224
l@@	I-Disease	-1	11135224
un@@	I-Disease	-1	11135224
g	I-Disease	-1	11135224
carcin@@	I-Disease	-1	11135224
oma	I-Disease	-1	11135224
.	O	-1	11135224
BACKGROUND:	O	-1	11135224
C@@	B-Chemical	D002945	11135224
is@@	I-Chemical	-1	11135224
pl@@	I-Chemical	-1	11135224
atin	I-Chemical	-1	11135224
-@@	O	-1	11135224
bas@@	O	-1	11135224
ed	O	-1	11135224
chemotherapy	O	-1	11135224
combin@@	O	-1	11135224
ations	O	-1	11135224
impro@@	O	-1	11135224
ve	O	-1	11135224
qu@@	O	-1	11135224
ality	O	-1	11135224
of	O	-1	11135224
lif@@	O	-1	11135224
e	O	-1	11135224
and	O	-1	11135224
sur@@	O	-1	11135224
viv@@	O	-1	11135224
al	O	-1	11135224
in	O	-1	11135224
adv@@	O	-1	11135224
anced	O	-1	11135224
non@@	B-Disease	D002289	11135224
sm@@	I-Disease	-1	11135224
all	I-Disease	-1	11135224
cell	I-Disease	-1	11135224
l@@	I-Disease	-1	11135224
un@@	I-Disease	-1	11135224
g	I-Disease	-1	11135224
carcin@@	I-Disease	-1	11135224
oma	I-Disease	-1	11135224
(	O	-1	11135224
N@@	B-Disease	D002289	11135224
S@@	I-Disease	-1	11135224
CL@@	I-Disease	-1	11135224
C	I-Disease	-1	11135224
).	O	-1	11135224
The	O	-1	11135224
em@@	O	-1	11135224
er@@	O	-1	11135224
gen@@	O	-1	11135224
ce	O	-1	11135224
of	O	-1	11135224
new	O	-1	11135224
active	O	-1	11135224
drugs	O	-1	11135224
might	O	-1	11135224
trans@@	O	-1	11135224
l@@	O	-1	11135224
ate	O	-1	11135224
into	O	-1	11135224
more	O	-1	11135224
effective	O	-1	11135224
regimen@@	O	-1	11135224
s	O	-1	11135224
for	O	-1	11135224
the	O	-1	11135224
treatment	O	-1	11135224
of	O	-1	11135224
this	O	-1	11135224
disease.	O	-1	11135224
METHODS:	O	-1	11135224
The	O	-1	11135224
ob@@	O	-1	11135224
j@@	O	-1	11135224
ective	O	-1	11135224
of	O	-1	11135224
this	O	-1	11135224
study	O	-1	11135224
was	O	-1	11135224
to	O	-1	11135224
determine	O	-1	11135224
the	O	-1	11135224
fe@@	O	-1	11135224
a@@	O	-1	11135224
sib@@	O	-1	11135224
il@@	O	-1	11135224
ity,	O	-1	11135224
response	O	-1	11135224
rat@@	O	-1	11135224
e,	O	-1	11135224
and	O	-1	11135224
toxicity	B-Disease	D064420	11135224
of	O	-1	11135224
a	O	-1	11135224
paclitax@@	B-Chemical	D017239	11135224
el	I-Chemical	-1	11135224
,	O	-1	11135224
cisplatin	B-Chemical	D002945	11135224
,	O	-1	11135224
and	O	-1	11135224
g@@	B-Chemical	C056507	11135224
em@@	I-Chemical	-1	11135224
cit@@	I-Chemical	-1	11135224
ab@@	I-Chemical	-1	11135224
ine	I-Chemical	-1	11135224
combination	O	-1	11135224
to	O	-1	11135224
tre@@	O	-1	11135224
at	O	-1	11135224
met@@	O	-1	11135224
ast@@	O	-1	11135224
atic	O	-1	11135224
N@@	B-Disease	D002289	11135224
S@@	I-Disease	-1	11135224
CL@@	I-Disease	-1	11135224
C	I-Disease	-1	11135224
.	O	-1	11135224
Th@@	O	-1	11135224
ir@@	O	-1	11135224
ty-@@	O	-1	11135224
five	O	-1	11135224
con@@	O	-1	11135224
sec@@	O	-1	11135224
utive	O	-1	11135224
chemo@@	O	-1	11135224
therap@@	O	-1	11135224
y-@@	O	-1	11135224
na@@	O	-1	11135224
i@@	O	-1	11135224
ve	O	-1	11135224
patients	O	-1	11135224
with	O	-1	11135224
S@@	O	-1	11135224
t@@	O	-1	11135224
age	O	-1	11135224
IV	O	-1	11135224
N@@	B-Disease	D002289	11135224
S@@	I-Disease	-1	11135224
CL@@	I-Disease	-1	11135224
C	I-Disease	-1	11135224
and	O	-1	11135224
an	O	-1	11135224
E@@	O	-1	11135224
ast@@	O	-1	11135224
er@@	O	-1	11135224
n	O	-1	11135224
C@@	O	-1	11135224
o@@	O	-1	11135224
o@@	O	-1	11135224
perative	O	-1	11135224
On@@	O	-1	11135224
co@@	O	-1	11135224
log@@	O	-1	11135224
y	O	-1	11135224
Group	O	-1	11135224
perform@@	O	-1	11135224
ance	O	-1	11135224
status	O	-1	11135224
of	O	-1	11135224
0-@@	O	-1	11135224
2	O	-1	11135224
were	O	-1	11135224
treated	O	-1	11135224
with	O	-1	11135224
a	O	-1	11135224
combination	O	-1	11135224
of	O	-1	11135224
paclitax@@	B-Chemical	D017239	11135224
el	I-Chemical	-1	11135224
(1@@	O	-1	11135224
3@@	O	-1	11135224
5	O	-1	11135224
mg/m@@	O	-1	11135224
(2@@	O	-1	11135224
)	O	-1	11135224
given	O	-1	11135224
intra@@	O	-1	11135224
ven@@	O	-1	11135224
ously	O	-1	11135224
in	O	-1	11135224
3	O	-1	11135224
hour@@	O	-1	11135224
s)	O	-1	11135224
on	O	-1	11135224
D@@	O	-1	11135224
ay	O	-1	11135224
1,	O	-1	11135224
cisplatin	B-Chemical	D002945	11135224
(1@@	O	-1	11135224
20	O	-1	11135224
mg/m@@	O	-1	11135224
(2@@	O	-1	11135224
)	O	-1	11135224
given	O	-1	11135224
intra@@	O	-1	11135224
ven@@	O	-1	11135224
ously	O	-1	11135224
in	O	-1	11135224
6	O	-1	11135224
hour@@	O	-1	11135224
s)	O	-1	11135224
on	O	-1	11135224
D@@	O	-1	11135224
ay	O	-1	11135224
1,	O	-1	11135224
and	O	-1	11135224
g@@	B-Chemical	C056507	11135224
em@@	I-Chemical	-1	11135224
cit@@	I-Chemical	-1	11135224
ab@@	I-Chemical	-1	11135224
ine	I-Chemical	-1	11135224
(@@	O	-1	11135224
8@@	O	-1	11135224
00	O	-1	11135224
mg/m@@	O	-1	11135224
(2@@	O	-1	11135224
)	O	-1	11135224
given	O	-1	11135224
intra@@	O	-1	11135224
ven@@	O	-1	11135224
ously	O	-1	11135224
in	O	-1	11135224
30	O	-1	11135224
minut@@	O	-1	11135224
es@@	O	-1	11135224
)	O	-1	11135224
on	O	-1	11135224
D@@	O	-1	11135224
ays	O	-1	11135224
1	O	-1	11135224
and	O	-1	11135224
8@@	O	-1	11135224
,	O	-1	11135224
every	O	-1	11135224
4	O	-1	11135224
week@@	O	-1	11135224
s.	O	-1	11135224
Although	O	-1	11135224
respon@@	O	-1	11135224
ding	O	-1	11135224
patients	O	-1	11135224
were	O	-1	11135224
sch@@	O	-1	11135224
ed@@	O	-1	11135224
ul@@	O	-1	11135224
ed	O	-1	11135224
to	O	-1	11135224
recei@@	O	-1	11135224
ve	O	-1	11135224
con@@	O	-1	11135224
sol@@	O	-1	11135224
id@@	O	-1	11135224
ation	O	-1	11135224
radi@@	O	-1	11135224
o@@	O	-1	11135224
therapy	O	-1	11135224
and	O	-1	11135224
24	O	-1	11135224
patients	O	-1	11135224
received	O	-1	11135224
pre@@	O	-1	11135224
pl@@	O	-1	11135224
an@@	O	-1	11135224
n@@	O	-1	11135224
ed	O	-1	11135224
secon@@	O	-1	11135224
d-@@	O	-1	11135224
line	O	-1	11135224
chemotherapy	O	-1	11135224
after	O	-1	11135224
disease	O	-1	11135224
progres@@	O	-1	11135224
sion,	O	-1	11135224
the	O	-1	11135224
response	O	-1	11135224
and	O	-1	11135224
toxicity	B-Disease	D064420	11135224
rat@@	O	-1	11135224
es	O	-1	11135224
reported	O	-1	11135224
ref@@	O	-1	11135224
er	O	-1	11135224
only	O	-1	11135224
to	O	-1	11135224
the	O	-1	11135224
chemotherapy	O	-1	11135224
regi@@	O	-1	11135224
men	O	-1	11135224
gi@@	O	-1	11135224
ven@@	O	-1	11135224
.	O	-1	11135224
RESULTS:	O	-1	11135224
All	O	-1	11135224
the	O	-1	11135224
patients	O	-1	11135224
were	O	-1	11135224
examined	O	-1	11135224
for	O	-1	11135224
toxicity	B-Disease	D064420	11135224
;	O	-1	11135224
3@@	O	-1	11135224
4	O	-1	11135224
were	O	-1	11135224
examin@@	O	-1	11135224
able	O	-1	11135224
for	O	-1	11135224
respon@@	O	-1	11135224
se.	O	-1	11135224
An	O	-1	11135224
ob@@	O	-1	11135224
j@@	O	-1	11135224
ective	O	-1	11135224
response	O	-1	11135224
was	O	-1	11135224
observed	O	-1	11135224
in	O	-1	11135224
7@@	O	-1	11135224
3.@@	O	-1	11135224
5%	O	-1	11135224
of	O	-1	11135224
the	O	-1	11135224
patients	O	-1	11135224
(@@	O	-1	11135224
95%	O	-1	11135224
conf@@	O	-1	11135224
idence	O	-1	11135224
interv@@	O	-1	11135224
al	O	-1	11135224
[@@	O	-1	11135224
CI@@	O	-1	11135224
]@@	O	-1	11135224
,	O	-1	11135224
5@@	O	-1	11135224
5.@@	O	-1	11135224
6-@@	O	-1	11135224
8@@	O	-1	11135224
7.@@	O	-1	11135224
1@@	O	-1	11135224
%),	O	-1	11135224
including	O	-1	11135224
4	O	-1	11135224
complete	O	-1	11135224
responses	O	-1	11135224
(1@@	O	-1	11135224
1.@@	O	-1	11135224
7@@	O	-1	11135224
%).	O	-1	11135224
Ac@@	O	-1	11135224
cor@@	O	-1	11135224
ding	O	-1	11135224
to	O	-1	11135224
int@@	O	-1	11135224
en@@	O	-1	11135224
tion@@	O	-1	11135224
-@@	O	-1	11135224
to@@	O	-1	11135224
-@@	O	-1	11135224
treat@@	O	-1	11135224
,	O	-1	11135224
the	O	-1	11135224
over@@	O	-1	11135224
all	O	-1	11135224
response	O	-1	11135224
rate	O	-1	11135224
was	O	-1	11135224
7@@	O	-1	11135224
1.@@	O	-1	11135224
4@@	O	-1	11135224
%	O	-1	11135224
(@@	O	-1	11135224
95%	O	-1	11135224
CI@@	O	-1	11135224
,	O	-1	11135224
5@@	O	-1	11135224
3@@	O	-1	11135224
.	O	-1	11135224
7-@@	O	-1	11135224
8@@	O	-1	11135224
5.@@	O	-1	11135224
4@@	O	-1	11135224
%).	O	-1	11135224
After	O	-1	11135224
1@@	O	-1	11135224
5@@	O	-1	11135224
4	O	-1	11135224
cour@@	O	-1	11135224
ses	O	-1	11135224
of	O	-1	11135224
therapy,	O	-1	11135224
the	O	-1	11135224
median	O	-1	11135224
dose	O	-1	11135224
int@@	O	-1	11135224
ensity	O	-1	11135224
was	O	-1	11135224
13@@	O	-1	11135224
1	O	-1	11135224
mg/m@@	O	-1	11135224
(2@@	O	-1	11135224
)	O	-1	11135224
for	O	-1	11135224
paclitax@@	B-Chemical	D017239	11135224
el	I-Chemical	-1	11135224
(@@	O	-1	11135224
9@@	O	-1	11135224
7.@@	O	-1	11135224
3@@	O	-1	11135224
%),	O	-1	11135224
1@@	O	-1	11135224
17	O	-1	11135224
mg/m@@	O	-1	11135224
(2@@	O	-1	11135224
)	O	-1	11135224
for	O	-1	11135224
cisplatin	B-Chemical	D002945	11135224
(@@	O	-1	11135224
9@@	O	-1	11135224
7.@@	O	-1	11135224
3@@	O	-1	11135224
%),	O	-1	11135224
and	O	-1	11135224
13@@	O	-1	11135224
7@@	O	-1	11135224
8	O	-1	11135224
mg/m@@	O	-1	11135224
(2@@	O	-1	11135224
)	O	-1	11135224
for	O	-1	11135224
g@@	B-Chemical	C056507	11135224
em@@	I-Chemical	-1	11135224
cit@@	I-Chemical	-1	11135224
ab@@	I-Chemical	-1	11135224
ine	I-Chemical	-1	11135224
(@@	O	-1	11135224
8@@	O	-1	11135224
6.@@	O	-1	11135224
2@@	O	-1	11135224
%).	O	-1	11135224
W@@	O	-1	11135224
or@@	O	-1	11135224
l@@	O	-1	11135224
d	O	-1	11135224
He@@	O	-1	11135224
al@@	O	-1	11135224
th	O	-1	11135224
O@@	O	-1	11135224
r@@	O	-1	11135224
g@@	O	-1	11135224
an@@	O	-1	11135224
ization	O	-1	11135224
G@@	O	-1	11135224
ra@@	O	-1	11135224
de	O	-1	11135224
3-@@	O	-1	11135224
4	O	-1	11135224
ne@@	B-Disease	D009503	11135224
ut@@	I-Disease	-1	11135224
ro@@	I-Disease	-1	11135224
pen@@	I-Disease	-1	11135224
ia	I-Disease	-1	11135224
and	O	-1	11135224
throm@@	B-Disease	D013921	11135224
b@@	I-Disease	-1	11135224
ocyto@@	I-Disease	-1	11135224
pen@@	I-Disease	-1	11135224
ia	I-Disease	-1	11135224
occurred	O	-1	11135224
in	O	-1	11135224
3@@	O	-1	11135224
9.@@	O	-1	11135224
9@@	O	-1	11135224
%	O	-1	11135224
and	O	-1	11135224
1@@	O	-1	11135224
1.@@	O	-1	11135224
4@@	O	-1	11135224
%	O	-1	11135224
of	O	-1	11135224
patients,	O	-1	11135224
respectively.	O	-1	11135224
There	O	-1	11135224
was	O	-1	11135224
one	O	-1	11135224
treatment@@	O	-1	11135224
-@@	O	-1	11135224
related	O	-1	11135224
death	B-Disease	D003643	11135224
.	O	-1	11135224
N@@	O	-1	11135224
on@@	O	-1	11135224
hemat@@	O	-1	11135224
ologic	O	-1	11135224
toxic@@	B-Disease	D064420	11135224
ities	I-Disease	-1	11135224
were	O	-1	11135224
mil@@	O	-1	11135224
d.	O	-1	11135224
After	O	-1	11135224
a	O	-1	11135224
median	O	-1	11135224
follow-up	O	-1	11135224
of	O	-1	11135224
2@@	O	-1	11135224
2	O	-1	11135224
month@@	O	-1	11135224
s,	O	-1	11135224
the	O	-1	11135224
median	O	-1	11135224
progres@@	O	-1	11135224
sion	O	-1	11135224
free	O	-1	11135224
sur@@	O	-1	11135224
viv@@	O	-1	11135224
al	O	-1	11135224
rate	O	-1	11135224
was	O	-1	11135224
7	O	-1	11135224
month@@	O	-1	11135224
s,	O	-1	11135224
and	O	-1	11135224
the	O	-1	11135224
median	O	-1	11135224
sur@@	O	-1	11135224
viv@@	O	-1	11135224
al	O	-1	11135224
time	O	-1	11135224
was	O	-1	11135224
16	O	-1	11135224
months.	O	-1	11135224
CONCLUSIONS:	O	-1	11135224
The	O	-1	11135224
combination	O	-1	11135224
of	O	-1	11135224
paclitax@@	B-Chemical	D017239	11135224
el	I-Chemical	-1	11135224
,	O	-1	11135224
cisplatin	B-Chemical	D002945	11135224
,	O	-1	11135224
and	O	-1	11135224
g@@	B-Chemical	C056507	11135224
em@@	I-Chemical	-1	11135224
cit@@	I-Chemical	-1	11135224
ab@@	I-Chemical	-1	11135224
ine	I-Chemical	-1	11135224
is	O	-1	11135224
well	O	-1	11135224
toler@@	O	-1	11135224
ated	O	-1	11135224
and	O	-1	11135224
show@@	O	-1	11135224
s	O	-1	11135224
high	O	-1	11135224
activity	O	-1	11135224
in	O	-1	11135224
met@@	O	-1	11135224
ast@@	O	-1	11135224
atic	O	-1	11135224
N@@	B-Disease	D002289	11135224
S@@	I-Disease	-1	11135224
CL@@	I-Disease	-1	11135224
C	I-Disease	-1	11135224
.	O	-1	11135224
This	O	-1	11135224
treatment	O	-1	11135224
mer@@	O	-1	11135224
its	O	-1	11135224
further	O	-1	11135224
compar@@	O	-1	11135224
ison	O	-1	11135224
with	O	-1	11135224
other	O	-1	11135224
cisplatin	B-Chemical	D002945	11135224
-@@	O	-1	11135224
bas@@	O	-1	11135224
ed	O	-1	11135224
regimen@@	O	-1	11135224
s.	O	-1	11135224

E@@	O	-1	8590259
valu@@	O	-1	8590259
ation	O	-1	8590259
of	O	-1	8590259
adverse	O	-1	8590259
reactions	O	-1	8590259
of	O	-1	8590259
ap@@	B-Chemical	C016986	8590259
on@@	I-Chemical	-1	8590259
idine	I-Chemical	-1	8590259
hydro@@	I-Chemical	-1	8590259
chlor@@	I-Chemical	-1	8590259
ide	I-Chemical	-1	8590259
oph@@	O	-1	8590259
thal@@	O	-1	8590259
mic	O	-1	8590259
sol@@	O	-1	8590259
u@@	O	-1	8590259
tion.	O	-1	8590259
We	O	-1	8590259
pro@@	O	-1	8590259
sp@@	O	-1	8590259
ectively	O	-1	8590259
evaluated	O	-1	8590259
the	O	-1	8590259
adverse	O	-1	8590259
reactions	O	-1	8590259
of	O	-1	8590259
ap@@	B-Chemical	C016986	8590259
rac@@	I-Chemical	-1	8590259
lon@@	I-Chemical	-1	8590259
idine	I-Chemical	-1	8590259
in	O	-1	8590259
20	O	-1	8590259
normal	O	-1	8590259
vol@@	O	-1	8590259
un@@	O	-1	8590259
te@@	O	-1	8590259
ers	O	-1	8590259
by	O	-1	8590259
insti@@	O	-1	8590259
ll@@	O	-1	8590259
ing	O	-1	8590259
a	O	-1	8590259
single	O	-1	8590259
dro@@	O	-1	8590259
p	O	-1	8590259
of	O	-1	8590259
1@@	O	-1	8590259
%	O	-1	8590259
ap@@	B-Chemical	C016986	8590259
rac@@	I-Chemical	-1	8590259
lon@@	I-Chemical	-1	8590259
idine	I-Chemical	-1	8590259
in	O	-1	8590259
their	O	-1	8590259
right	O	-1	8590259
e@@	O	-1	8590259
y@@	O	-1	8590259
es.	O	-1	8590259
E@@	O	-1	8590259
x@@	O	-1	8590259
amin@@	O	-1	8590259
ation@@	O	-1	8590259
s,	O	-1	8590259
including	O	-1	8590259
blood	O	-1	8590259
pressu@@	O	-1	8590259
re,	O	-1	8590259
pul@@	O	-1	8590259
se	O	-1	8590259
rat@@	O	-1	8590259
e,	O	-1	8590259
con@@	O	-1	8590259
j@@	O	-1	8590259
unc@@	O	-1	8590259
tiv@@	O	-1	8590259
a	O	-1	8590259
and	O	-1	8590259
cor@@	O	-1	8590259
ne@@	O	-1	8590259
a,	O	-1	8590259
intra@@	O	-1	8590259
oc@@	O	-1	8590259
ular	O	-1	8590259
pressure	O	-1	8590259
(@@	O	-1	8590259
I@@	O	-1	8590259
O@@	O	-1	8590259
P@@	O	-1	8590259
),	O	-1	8590259
pu@@	O	-1	8590259
pi@@	O	-1	8590259
l	O	-1	8590259
di@@	O	-1	8590259
ame@@	O	-1	8590259
ter@@	O	-1	8590259
,	O	-1	8590259
bas@@	O	-1	8590259
al	O	-1	8590259
te@@	O	-1	8590259
ar	O	-1	8590259
secre@@	O	-1	8590259
tion	O	-1	8590259
and	O	-1	8590259
m@@	O	-1	8590259
arg@@	O	-1	8590259
in	O	-1	8590259
ref@@	O	-1	8590259
le@@	O	-1	8590259
x	O	-1	8590259
dist@@	O	-1	8590259
ance	O	-1	8590259
of	O	-1	8590259
both	O	-1	8590259
up@@	O	-1	8590259
per	O	-1	8590259
and	O	-1	8590259
lower	O	-1	8590259
e@@	O	-1	8590259
y@@	O	-1	8590259
el@@	O	-1	8590259
id@@	O	-1	8590259
s,	O	-1	8590259
were	O	-1	8590259
performed	O	-1	8590259
prior	O	-1	8590259
to	O	-1	8590259
entr@@	O	-1	8590259
y	O	-1	8590259
and	O	-1	8590259
at	O	-1	8590259
1,	O	-1	8590259
3,	O	-1	8590259
5	O	-1	8590259
and	O	-1	8590259
7	O	-1	8590259
hours	O	-1	8590259
after	O	-1	8590259
insti@@	O	-1	8590259
ll@@	O	-1	8590259
ation.	O	-1	8590259
The	O	-1	8590259
oc@@	B-Disease	D015814	8590259
ular	I-Disease	-1	8590259
hypoten@@	I-Disease	-1	8590259
sive	I-Disease	-1	8590259
effects	O	-1	8590259
were	O	-1	8590259
statis@@	O	-1	8590259
tically	O	-1	8590259
significant	O	-1	8590259
for	O	-1	8590259
ap@@	B-Chemical	C016986	8590259
rac@@	I-Chemical	-1	8590259
lon@@	I-Chemical	-1	8590259
idine	I-Chemical	-1	8590259
-treated	O	-1	8590259
e@@	O	-1	8590259
y@@	O	-1	8590259
es	O	-1	8590259
throu@@	O	-1	8590259
gh@@	O	-1	8590259
out	O	-1	8590259
the	O	-1	8590259
study	O	-1	8590259
and	O	-1	8590259
also	O	-1	8590259
statis@@	O	-1	8590259
tically	O	-1	8590259
significant	O	-1	8590259
for	O	-1	8590259
contr@@	O	-1	8590259
al@@	O	-1	8590259
ateral	O	-1	8590259
e@@	O	-1	8590259
y@@	O	-1	8590259
es	O	-1	8590259
from	O	-1	8590259
three	O	-1	8590259
hours	O	-1	8590259
after	O	-1	8590259
to@@	O	-1	8590259
p@@	O	-1	8590259
ical	O	-1	8590259
administration	O	-1	8590259
of	O	-1	8590259
1@@	O	-1	8590259
%	O	-1	8590259
ap@@	B-Chemical	C016986	8590259
rac@@	I-Chemical	-1	8590259
lon@@	I-Chemical	-1	8590259
idine	I-Chemical	-1	8590259
.	O	-1	8590259
D@@	B-Disease	D007022	8590259
ec@@	I-Disease	-1	8590259
reas@@	I-Disease	-1	8590259
es	I-Disease	-1	8590259
in	I-Disease	-1	8590259
systolic	I-Disease	-1	8590259
blood	I-Disease	-1	8590259
pressure	I-Disease	-1	8590259
were	O	-1	8590259
statis@@	O	-1	8590259
tic@@	O	-1	8590259
ally,	O	-1	8590259
but	O	-1	8590259
not	O	-1	8590259
clin@@	O	-1	8590259
ic@@	O	-1	8590259
ally,	O	-1	8590259
significant@@	O	-1	8590259
.	O	-1	8590259
No	O	-1	8590259
significant	O	-1	8590259
changes	O	-1	8590259
in	O	-1	8590259
di@@	O	-1	8590259
ast@@	O	-1	8590259
olic	O	-1	8590259
blood	O	-1	8590259
pressu@@	O	-1	8590259
re,	O	-1	8590259
pul@@	O	-1	8590259
se	O	-1	8590259
rate	O	-1	8590259
and	O	-1	8590259
bas@@	O	-1	8590259
al	O	-1	8590259
te@@	O	-1	8590259
ar	O	-1	8590259
secre@@	O	-1	8590259
tion	O	-1	8590259
were	O	-1	8590259
not@@	O	-1	8590259
ed.	O	-1	8590259
Con@@	B-Disease	D003229	8590259
j@@	I-Disease	-1	8590259
unc@@	I-Disease	-1	8590259
tiv@@	I-Disease	-1	8590259
al	I-Disease	-1	8590259
bl@@	I-Disease	-1	8590259
an@@	I-Disease	-1	8590259
ch@@	I-Disease	-1	8590259
ing	I-Disease	-1	8590259
and	O	-1	8590259
my@@	B-Disease	D015878	8590259
d@@	I-Disease	-1	8590259
ri@@	I-Disease	-1	8590259
asis	I-Disease	-1	8590259
were	O	-1	8590259
common@@	O	-1	8590259
ly	O	-1	8590259
f@@	O	-1	8590259
oun@@	O	-1	8590259
d.	O	-1	8590259
U@@	O	-1	8590259
p@@	O	-1	8590259
per	O	-1	8590259
li@@	O	-1	8590259
d	O	-1	8590259
ret@@	O	-1	8590259
rac@@	O	-1	8590259
tion	O	-1	8590259
was	O	-1	8590259
frequ@@	O	-1	8590259
ently	O	-1	8590259
not@@	O	-1	8590259
ed.	O	-1	8590259
W@@	O	-1	8590259
h@@	O	-1	8590259
ile	O	-1	8590259
the	O	-1	8590259
elev@@	O	-1	8590259
ations	O	-1	8590259
of	O	-1	8590259
the	O	-1	8590259
up@@	O	-1	8590259
per	O	-1	8590259
li@@	O	-1	8590259
d	O	-1	8590259
m@@	O	-1	8590259
arg@@	O	-1	8590259
in	O	-1	8590259
in	O	-1	8590259
most	O	-1	8590259
subjects	O	-1	8590259
were	O	-1	8590259
not	O	-1	8590259
more	O	-1	8590259
than	O	-1	8590259
2	O	-1	8590259
mm	O	-1	8590259
and	O	-1	8590259
did	O	-1	8590259
not	O	-1	8590259
cause	O	-1	8590259
no@@	O	-1	8590259
ti@@	O	-1	8590259
ce@@	O	-1	8590259
able	O	-1	8590259
change	O	-1	8590259
in	O	-1	8590259
appear@@	O	-1	8590259
ance@@	O	-1	8590259
,	O	-1	8590259
one	O	-1	8590259
subj@@	O	-1	8590259
ect	O	-1	8590259
su@@	O	-1	8590259
ffe@@	O	-1	8590259
red	O	-1	8590259
from	O	-1	8590259
mechan@@	O	-1	8590259
ical	O	-1	8590259
ent@@	B-Disease	D004774	8590259
ro@@	I-Disease	-1	8590259
pi@@	I-Disease	-1	8590259
on	I-Disease	-1	8590259
and	O	-1	8590259
mark@@	O	-1	8590259
ed	O	-1	8590259
cor@@	B-Disease	D003316	8590259
ne@@	I-Disease	-1	8590259
al	I-Disease	-1	8590259
ab@@	I-Disease	-1	8590259
ra@@	I-Disease	-1	8590259
sion	I-Disease	-1	8590259
3	O	-1	8590259
hours	O	-1	8590259
after	O	-1	8590259
insti@@	O	-1	8590259
ll@@	O	-1	8590259
ation	O	-1	8590259
of	O	-1	8590259
the	O	-1	8590259
medic@@	O	-1	8590259
ation.	O	-1	8590259
This	O	-1	8590259
may	O	-1	8590259
well	O	-1	8590259
be	O	-1	8590259
a	O	-1	8590259
partic@@	O	-1	8590259
ul@@	O	-1	8590259
arly	O	-1	8590259
not@@	O	-1	8590259
able	O	-1	8590259
find@@	O	-1	8590259
ing	O	-1	8590259
in	O	-1	8590259
A@@	O	-1	8590259
si@@	O	-1	8590259
an	O	-1	8590259
pe@@	O	-1	8590259
o@@	O	-1	8590259
ple@@	O	-1	8590259
.	O	-1	8590259

C@@	B-Chemical	C017367	2096243
ar@@	I-Chemical	-1	2096243
mo@@	I-Chemical	-1	2096243
fu@@	I-Chemical	-1	2096243
r	I-Chemical	-1	2096243
-induced	O	-1	2096243
org@@	B-Disease	D019965	2096243
anic	I-Disease	-1	2096243
mental	I-Disease	-1	2096243
disorder@@	I-Disease	-1	2096243
s	I-Disease	-1	2096243
.	O	-1	2096243
O@@	B-Disease	D019965	2096243
r@@	I-Disease	-1	2096243
g@@	I-Disease	-1	2096243
anic	I-Disease	-1	2096243
mental	I-Disease	-1	2096243
disor@@	I-Disease	-1	2096243
der	I-Disease	-1	2096243
was	O	-1	2096243
observed	O	-1	2096243
in	O	-1	2096243
a	O	-1	2096243
2@@	O	-1	2096243
9@@	O	-1	2096243
-@@	O	-1	2096243
year-old	O	-1	2096243
female	O	-1	2096243
in	O	-1	2096243
the	O	-1	2096243
pro@@	O	-1	2096243
gn@@	O	-1	2096243
os@@	O	-1	2096243
tic	O	-1	2096243
period	O	-1	2096243
after	O	-1	2096243
the	O	-1	2096243
onset	O	-1	2096243
of	O	-1	2096243
car@@	B-Chemical	C017367	2096243
mo@@	I-Chemical	-1	2096243
fu@@	I-Chemical	-1	2096243
r	I-Chemical	-1	2096243
-induced	O	-1	2096243
leuk@@	B-Disease	D056784	2096243
o@@	I-Disease	-1	2096243
encephalo@@	I-Disease	-1	2096243
pathy	I-Disease	-1	2096243
.	O	-1	2096243
S@@	O	-1	2096243
ym@@	O	-1	2096243
pto@@	O	-1	2096243
ms	O	-1	2096243
such	O	-1	2096243
as	O	-1	2096243
eu@@	O	-1	2096243
ph@@	O	-1	2096243
or@@	O	-1	2096243
ia,	O	-1	2096243
em@@	O	-1	2096243
o@@	O	-1	2096243
tional	O	-1	2096243
l@@	O	-1	2096243
ability	O	-1	2096243
and	O	-1	2096243
pu@@	O	-1	2096243
er@@	O	-1	2096243
ile	O	-1	2096243
at@@	O	-1	2096243
ti@@	O	-1	2096243
t@@	O	-1	2096243
ude	O	-1	2096243
not@@	O	-1	2096243
ed	O	-1	2096243
in	O	-1	2096243
the	O	-1	2096243
patient	O	-1	2096243
were	O	-1	2096243
diagnos@@	O	-1	2096243
ed	O	-1	2096243
as	O	-1	2096243
org@@	B-Disease	D010554	2096243
anic	I-Disease	-1	2096243
per@@	I-Disease	-1	2096243
son@@	I-Disease	-1	2096243
ality	I-Disease	-1	2096243
syndrome	I-Disease	-1	2096243
ac@@	O	-1	2096243
cor@@	O	-1	2096243
ding	O	-1	2096243
to	O	-1	2096243
the	O	-1	2096243
c@@	O	-1	2096243
rit@@	O	-1	2096243
er@@	O	-1	2096243
ia	O	-1	2096243
def@@	O	-1	2096243
in@@	O	-1	2096243
ed	O	-1	2096243
in	O	-1	2096243
the	O	-1	2096243
D@@	O	-1	2096243
S@@	O	-1	2096243
M@@	O	-1	2096243
-@@	O	-1	2096243
II@@	O	-1	2096243
I@@	O	-1	2096243
-@@	O	-1	2096243
R@@	O	-1	2096243
.	O	-1	2096243
It	O	-1	2096243
is	O	-1	2096243
ref@@	O	-1	2096243
er@@	O	-1	2096243
red	O	-1	2096243
to	O	-1	2096243
as	O	-1	2096243
a	O	-1	2096243
fron@@	B-Disease	D001927	2096243
t@@	I-Disease	-1	2096243
al	I-Disease	-1	2096243
lo@@	I-Disease	-1	2096243
be	I-Disease	-1	2096243
syndrome	I-Disease	-1	2096243
.	O	-1	2096243
B@@	O	-1	2096243
ra@@	O	-1	2096243
in	O	-1	2096243
C@@	O	-1	2096243
T	O	-1	2096243
revealed	O	-1	2096243
a	O	-1	2096243
peri@@	O	-1	2096243
ventricular	O	-1	2096243
low	O	-1	2096243
d@@	O	-1	2096243
ensity	O	-1	2096243
a@@	O	-1	2096243
re@@	O	-1	2096243
a	O	-1	2096243
in	O	-1	2096243
the	O	-1	2096243
fron@@	O	-1	2096243
t@@	O	-1	2096243
al	O	-1	2096243
wh@@	O	-1	2096243
ite	O	-1	2096243
mat@@	O	-1	2096243
ter	O	-1	2096243
and	O	-1	2096243
moder@@	O	-1	2096243
ate	O	-1	2096243
di@@	O	-1	2096243
lat@@	O	-1	2096243
ation	O	-1	2096243
of	O	-1	2096243
the	O	-1	2096243
lat@@	O	-1	2096243
eral	O	-1	2096243
ventric@@	O	-1	2096243
le@@	O	-1	2096243
s	O	-1	2096243
es@@	O	-1	2096243
p@@	O	-1	2096243
ec@@	O	-1	2096243
i@@	O	-1	2096243
ally	O	-1	2096243
at	O	-1	2096243
the	O	-1	2096243
bil@@	O	-1	2096243
ateral	O	-1	2096243
an@@	O	-1	2096243
ter@@	O	-1	2096243
ior	O	-1	2096243
h@@	O	-1	2096243
or@@	O	-1	2096243
n@@	O	-1	2096243
s.	O	-1	2096243
Con@@	O	-1	2096243
sequ@@	O	-1	2096243
ent@@	O	-1	2096243
ly,	O	-1	2096243
car@@	B-Chemical	C017367	2096243
mo@@	I-Chemical	-1	2096243
fu@@	I-Chemical	-1	2096243
r	I-Chemical	-1	2096243
-induced	O	-1	2096243
leuk@@	B-Disease	D056784	2096243
o@@	I-Disease	-1	2096243
encephalo@@	I-Disease	-1	2096243
pathy	I-Disease	-1	2096243
may	O	-1	2096243
un@@	O	-1	2096243
common@@	O	-1	2096243
ly	O	-1	2096243
result	O	-1	2096243
in	O	-1	2096243
org@@	B-Disease	D010554	2096243
anic	I-Disease	-1	2096243
per@@	I-Disease	-1	2096243
son@@	I-Disease	-1	2096243
ality	I-Disease	-1	2096243
syndrome	I-Disease	-1	2096243
in	O	-1	2096243
the	O	-1	2096243
re@@	O	-1	2096243
si@@	O	-1	2096243
du@@	O	-1	2096243
al	O	-1	2096243
stat@@	O	-1	2096243
e.	O	-1	2096243
It	O	-1	2096243
may	O	-1	2096243
be	O	-1	2096243
at@@	O	-1	2096243
tri@@	O	-1	2096243
but@@	O	-1	2096243
ed	O	-1	2096243
to	O	-1	2096243
the	O	-1	2096243
struct@@	B-Disease	D001927	2096243
ural	I-Disease	-1	2096243
damage	I-Disease	-1	2096243
to	I-Disease	-1	2096243
the	I-Disease	-1	2096243
fron@@	I-Disease	-1	2096243
t@@	I-Disease	-1	2096243
al	I-Disease	-1	2096243
lo@@	I-Disease	-1	2096243
be	I-Disease	-1	2096243
.	O	-1	2096243

In@@	O	-1	6209318
tern@@	O	-1	6209318
ation@@	O	-1	6209318
al	O	-1	6209318
me@@	B-Chemical	D008801	6209318
xi@@	I-Chemical	-1	6209318
le@@	I-Chemical	-1	6209318
t@@	I-Chemical	-1	6209318
ine	I-Chemical	-1	6209318
and	O	-1	6209318
placebo	O	-1	6209318
anti@@	O	-1	6209318
arrhyth@@	O	-1	6209318
mic	O	-1	6209318
coronary	O	-1	6209318
tri@@	O	-1	6209318
al@@	O	-1	6209318
:	O	-1	6209318
I@@	O	-1	6209318
.	O	-1	6209318
Re@@	O	-1	6209318
por@@	O	-1	6209318
t	O	-1	6209318
on	O	-1	6209318
arrhyth@@	B-Disease	D001145	6209318
mia	I-Disease	-1	6209318
and	O	-1	6209318
other	O	-1	6209318
find@@	O	-1	6209318
ing@@	O	-1	6209318
s.	O	-1	6209318
Im@@	O	-1	6209318
pac@@	O	-1	6209318
t	O	-1	6209318
R@@	O	-1	6209318
es@@	O	-1	6209318
ear@@	O	-1	6209318
ch	O	-1	6209318
Grou@@	O	-1	6209318
p@@	O	-1	6209318
.	O	-1	6209318
The	O	-1	6209318
anti@@	O	-1	6209318
arrhyth@@	O	-1	6209318
mic	O	-1	6209318
effects	O	-1	6209318
of	O	-1	6209318
the	O	-1	6209318
su@@	O	-1	6209318
st@@	O	-1	6209318
ained	O	-1	6209318
release	O	-1	6209318
form	O	-1	6209318
of	O	-1	6209318
me@@	B-Chemical	D008801	6209318
xi@@	I-Chemical	-1	6209318
le@@	I-Chemical	-1	6209318
t@@	I-Chemical	-1	6209318
ine	I-Chemical	-1	6209318
(	O	-1	6209318
M@@	B-Chemical	D008801	6209318
ex@@	I-Chemical	-1	6209318
iti@@	I-Chemical	-1	6209318
l@@	I-Chemical	-1	6209318
-@@	I-Chemical	-1	6209318
P@@	I-Chemical	-1	6209318
er@@	I-Chemical	-1	6209318
long@@	I-Chemical	-1	6209318
et@@	I-Chemical	-1	6209318
s	I-Chemical	-1	6209318
)	O	-1	6209318
were	O	-1	6209318
evaluated	O	-1	6209318
in	O	-1	6209318
a	O	-1	6209318
double-bl@@	O	-1	6209318
ind	O	-1	6209318
placebo	O	-1	6209318
trial	O	-1	6209318
in	O	-1	6209318
6@@	O	-1	6209318
30	O	-1	6209318
patients	O	-1	6209318
with	O	-1	6209318
rec@@	O	-1	6209318
ent	O	-1	6209318
doc@@	O	-1	6209318
um@@	O	-1	6209318
ent@@	O	-1	6209318
ed	O	-1	6209318
myocardial	B-Disease	D009203	6209318
infarction	I-Disease	-1	6209318
.	O	-1	6209318
The	O	-1	6209318
prim@@	O	-1	6209318
ary	O	-1	6209318
response	O	-1	6209318
vari@@	O	-1	6209318
able	O	-1	6209318
was	O	-1	6209318
bas@@	O	-1	6209318
ed	O	-1	6209318
on	O	-1	6209318
central	O	-1	6209318
re@@	O	-1	6209318
ad@@	O	-1	6209318
ing	O	-1	6209318
of	O	-1	6209318
24	O	-1	6209318
h@@	O	-1	6209318
our	O	-1	6209318
am@@	O	-1	6209318
b@@	O	-1	6209318
ul@@	O	-1	6209318
atory	O	-1	6209318
electro@@	O	-1	6209318
cardio@@	O	-1	6209318
graph@@	O	-1	6209318
ic	O	-1	6209318
recor@@	O	-1	6209318
d@@	O	-1	6209318
ings	O	-1	6209318
and	O	-1	6209318
was	O	-1	6209318
def@@	O	-1	6209318
in@@	O	-1	6209318
ed	O	-1	6209318
as	O	-1	6209318
the	O	-1	6209318
occur@@	O	-1	6209318
rence	O	-1	6209318
of	O	-1	6209318
30	O	-1	6209318
or	O	-1	6209318
more	O	-1	6209318
single	O	-1	6209318
pre@@	O	-1	6209318
mat@@	O	-1	6209318
ure	O	-1	6209318
ventricular	O	-1	6209318
comple@@	O	-1	6209318
x@@	O	-1	6209318
es	O	-1	6209318
in	O	-1	6209318
any	O	-1	6209318
two	O	-1	6209318
con@@	O	-1	6209318
sec@@	O	-1	6209318
utive	O	-1	6209318
30	O	-1	6209318
min@@	O	-1	6209318
ute	O	-1	6209318
block@@	O	-1	6209318
s	O	-1	6209318
or	O	-1	6209318
one	O	-1	6209318
or	O	-1	6209318
more	O	-1	6209318
r@@	O	-1	6209318
un@@	O	-1	6209318
s	O	-1	6209318
of	O	-1	6209318
two	O	-1	6209318
or	O	-1	6209318
more	O	-1	6209318
pre@@	O	-1	6209318
mat@@	O	-1	6209318
ure	O	-1	6209318
ventricular	O	-1	6209318
comple@@	O	-1	6209318
x@@	O	-1	6209318
es	O	-1	6209318
in	O	-1	6209318
the	O	-1	6209318
enti@@	O	-1	6209318
r@@	O	-1	6209318
e	O	-1	6209318
24	O	-1	6209318
h@@	O	-1	6209318
our	O	-1	6209318
electro@@	O	-1	6209318
cardio@@	O	-1	6209318
graph@@	O	-1	6209318
ic	O	-1	6209318
recor@@	O	-1	6209318
d@@	O	-1	6209318
ing.	O	-1	6209318
L@@	O	-1	6209318
arg@@	O	-1	6209318
e	O	-1	6209318
differen@@	O	-1	6209318
c@@	O	-1	6209318
es,	O	-1	6209318
reg@@	O	-1	6209318
ar@@	O	-1	6209318
ded	O	-1	6209318
as	O	-1	6209318
statis@@	O	-1	6209318
tically	O	-1	6209318
significant@@	O	-1	6209318
,	O	-1	6209318
between	O	-1	6209318
the	O	-1	6209318
me@@	B-Chemical	D008801	6209318
xi@@	I-Chemical	-1	6209318
le@@	I-Chemical	-1	6209318
t@@	I-Chemical	-1	6209318
ine	I-Chemical	-1	6209318
and	O	-1	6209318
placebo	O	-1	6209318
groups	O	-1	6209318
were	O	-1	6209318
not@@	O	-1	6209318
ed	O	-1	6209318
in	O	-1	6209318
that	O	-1	6209318
end	O	-1	6209318
po@@	O	-1	6209318
in@@	O	-1	6209318
t	O	-1	6209318
at	O	-1	6209318
months	O	-1	6209318
1	O	-1	6209318
and	O	-1	6209318
4@@	O	-1	6209318
,	O	-1	6209318
but	O	-1	6209318
only	O	-1	6209318
tre@@	O	-1	6209318
n@@	O	-1	6209318
ds	O	-1	6209318
were	O	-1	6209318
observed	O	-1	6209318
at	O	-1	6209318
mon@@	O	-1	6209318
th	O	-1	6209318
12@@	O	-1	6209318
.	O	-1	6209318
These	O	-1	6209318
differences	O	-1	6209318
were	O	-1	6209318
observed	O	-1	6209318
even	O	-1	6209318
though	O	-1	6209318
the	O	-1	6209318
serum	O	-1	6209318
me@@	B-Chemical	D008801	6209318
xi@@	I-Chemical	-1	6209318
le@@	I-Chemical	-1	6209318
t@@	I-Chemical	-1	6209318
ine	I-Chemical	-1	6209318
levels	O	-1	6209318
obtained	O	-1	6209318
in	O	-1	6209318
this	O	-1	6209318
study	O	-1	6209318
were	O	-1	6209318
gener@@	O	-1	6209318
ally	O	-1	6209318
lower	O	-1	6209318
than	O	-1	6209318
those	O	-1	6209318
observed	O	-1	6209318
in	O	-1	6209318
studies	O	-1	6209318
that	O	-1	6209318
have	O	-1	6209318
used	O	-1	6209318
the	O	-1	6209318
reg@@	O	-1	6209318
ular	O	-1	6209318
form	O	-1	6209318
of	O	-1	6209318
the	O	-1	6209318
drug.	O	-1	6209318
There	O	-1	6209318
were	O	-1	6209318
more	O	-1	6209318
de@@	B-Disease	D003643	6209318
ath@@	I-Disease	-1	6209318
s	I-Disease	-1	6209318
in	O	-1	6209318
the	O	-1	6209318
me@@	B-Chemical	D008801	6209318
xi@@	I-Chemical	-1	6209318
le@@	I-Chemical	-1	6209318
t@@	I-Chemical	-1	6209318
ine	I-Chemical	-1	6209318
group	O	-1	6209318
(@@	O	-1	6209318
7.@@	O	-1	6209318
6@@	O	-1	6209318
%)	O	-1	6209318
than	O	-1	6209318
in	O	-1	6209318
the	O	-1	6209318
placebo	O	-1	6209318
group	O	-1	6209318
(@@	O	-1	6209318
4.@@	O	-1	6209318
8@@	O	-1	6209318
%@@	O	-1	6209318
);	O	-1	6209318
the	O	-1	6209318
difference	O	-1	6209318
was	O	-1	6209318
not	O	-1	6209318
statis@@	O	-1	6209318
tically	O	-1	6209318
significant@@	O	-1	6209318
.	O	-1	6209318
The	O	-1	6209318
incidence	O	-1	6209318
of	O	-1	6209318
coronary	O	-1	6209318
events	O	-1	6209318
was	O	-1	6209318
similar	O	-1	6209318
in	O	-1	6209318
both	O	-1	6209318
groups.	O	-1	6209318
Pre@@	O	-1	6209318
vi@@	O	-1	6209318
ously	O	-1	6209318
reco@@	O	-1	6209318
gn@@	O	-1	6209318
ized	O	-1	6209318
side	O	-1	6209318
effect@@	O	-1	6209318
s,	O	-1	6209318
partic@@	O	-1	6209318
ul@@	O	-1	6209318
arly	O	-1	6209318
trem@@	B-Disease	D014202	6209318
or	I-Disease	-1	6209318
and	O	-1	6209318
gast@@	B-Disease	D012817	6209318
ro@@	I-Disease	-1	6209318
in@@	I-Disease	-1	6209318
test@@	I-Disease	-1	6209318
inal	I-Disease	-1	6209318
pro@@	I-Disease	-1	6209318
ble@@	I-Disease	-1	6209318
ms	I-Disease	-1	6209318
,	O	-1	6209318
were	O	-1	6209318
more	O	-1	6209318
frequent	O	-1	6209318
in	O	-1	6209318
the	O	-1	6209318
me@@	B-Chemical	D008801	6209318
xi@@	I-Chemical	-1	6209318
le@@	I-Chemical	-1	6209318
t@@	I-Chemical	-1	6209318
ine	I-Chemical	-1	6209318
group	O	-1	6209318
than	O	-1	6209318
in	O	-1	6209318
the	O	-1	6209318
placebo	O	-1	6209318
group.	O	-1	6209318

Re@@	O	-1	3615541
gi@@	O	-1	3615541
on@@	O	-1	3615541
al	O	-1	3615541
lo@@	O	-1	3615541
cal@@	O	-1	3615541
ization	O	-1	3615541
of	O	-1	3615541
the	O	-1	3615541
antagon@@	O	-1	3615541
ism	O	-1	3615541
of	O	-1	3615541
amphetamine	B-Chemical	D000661	3615541
-induced	O	-1	3615541
hyperactivity	B-Disease	D006948	3615541
by	O	-1	3615541
intrac@@	O	-1	3615541
e@@	O	-1	3615541
rebral	O	-1	3615541
calc@@	B-Chemical	D002116	3615541
it@@	I-Chemical	-1	3615541
on@@	I-Chemical	-1	3615541
in	I-Chemical	-1	3615541
injec@@	O	-1	3615541
tions.	O	-1	3615541
C@@	B-Chemical	D002116	3615541
al@@	I-Chemical	-1	3615541
cit@@	I-Chemical	-1	3615541
on@@	I-Chemical	-1	3615541
in	I-Chemical	-1	3615541
receptors	O	-1	3615541
are	O	-1	3615541
found	O	-1	3615541
in	O	-1	3615541
the	O	-1	3615541
bra@@	O	-1	3615541
in,	O	-1	3615541
and	O	-1	3615541
intrac@@	O	-1	3615541
e@@	O	-1	3615541
rebral	O	-1	3615541
infu@@	O	-1	3615541
sions	O	-1	3615541
of	O	-1	3615541
calc@@	B-Chemical	D002116	3615541
it@@	I-Chemical	-1	3615541
on@@	I-Chemical	-1	3615541
in	I-Chemical	-1	3615541
can	O	-1	3615541
produce	O	-1	3615541
behavioral	O	-1	3615541
effects.	O	-1	3615541
A@@	O	-1	3615541
mon@@	O	-1	3615541
g	O	-1	3615541
these	O	-1	3615541
behavioral	O	-1	3615541
effects	O	-1	3615541
are	O	-1	3615541
decreas@@	O	-1	3615541
es	O	-1	3615541
in	O	-1	3615541
fo@@	O	-1	3615541
od	O	-1	3615541
int@@	O	-1	3615541
ake	O	-1	3615541
and	O	-1	3615541
decreas@@	O	-1	3615541
es	O	-1	3615541
in	O	-1	3615541
amphetamine	B-Chemical	D000661	3615541
-induced	O	-1	3615541
locomotor	O	-1	3615541
activ@@	O	-1	3615541
ity.	O	-1	3615541
In	O	-1	3615541
previ@@	O	-1	3615541
ous	O	-1	3615541
experim@@	O	-1	3615541
ents	O	-1	3615541
we	O	-1	3615541
found	O	-1	3615541
that	O	-1	3615541
decreas@@	O	-1	3615541
es	O	-1	3615541
in	O	-1	3615541
fo@@	O	-1	3615541
od	O	-1	3615541
int@@	O	-1	3615541
ake	O	-1	3615541
were	O	-1	3615541
induced	O	-1	3615541
by	O	-1	3615541
loc@@	O	-1	3615541
al	O	-1	3615541
administration	O	-1	3615541
of	O	-1	3615541
calc@@	B-Chemical	D002116	3615541
it@@	I-Chemical	-1	3615541
on@@	I-Chemical	-1	3615541
in	I-Chemical	-1	3615541
into	O	-1	3615541
several	O	-1	3615541
hypo@@	O	-1	3615541
thal@@	O	-1	3615541
am@@	O	-1	3615541
ic	O	-1	3615541
sit@@	O	-1	3615541
es	O	-1	3615541
and	O	-1	3615541
into	O	-1	3615541
the	O	-1	3615541
nucle@@	O	-1	3615541
us	O	-1	3615541
accum@@	O	-1	3615541
ben@@	O	-1	3615541
s.	O	-1	3615541
In	O	-1	3615541
the	O	-1	3615541
present	O	-1	3615541
experim@@	O	-1	3615541
ent	O	-1	3615541
calc@@	B-Chemical	D002116	3615541
it@@	I-Chemical	-1	3615541
on@@	I-Chemical	-1	3615541
in	I-Chemical	-1	3615541
decreased	O	-1	3615541
locomotor	O	-1	3615541
activity	O	-1	3615541
when	O	-1	3615541
loc@@	O	-1	3615541
ally	O	-1	3615541
injected	O	-1	3615541
into	O	-1	3615541
the	O	-1	3615541
same	O	-1	3615541
sit@@	O	-1	3615541
es	O	-1	3615541
wh@@	O	-1	3615541
ere	O	-1	3615541
it	O	-1	3615541
decreas@@	O	-1	3615541
es	O	-1	3615541
fo@@	O	-1	3615541
od	O	-1	3615541
int@@	O	-1	3615541
ak@@	O	-1	3615541
e.	O	-1	3615541
The	O	-1	3615541
a@@	O	-1	3615541
reas	O	-1	3615541
wh@@	O	-1	3615541
ere	O	-1	3615541
calc@@	B-Chemical	D002116	3615541
it@@	I-Chemical	-1	3615541
on@@	I-Chemical	-1	3615541
in	I-Chemical	-1	3615541
is	O	-1	3615541
most	O	-1	3615541
effective	O	-1	3615541
in	O	-1	3615541
decreas@@	O	-1	3615541
ing	O	-1	3615541
locomotor	O	-1	3615541
activity	O	-1	3615541
are	O	-1	3615541
loc@@	O	-1	3615541
ated	O	-1	3615541
in	O	-1	3615541
the	O	-1	3615541
hypo@@	O	-1	3615541
thal@@	O	-1	3615541
am@@	O	-1	3615541
us	O	-1	3615541
and	O	-1	3615541
nucle@@	O	-1	3615541
us	O	-1	3615541
accum@@	O	-1	3615541
ben@@	O	-1	3615541
s,	O	-1	3615541
suggesting	O	-1	3615541
that	O	-1	3615541
these	O	-1	3615541
a@@	O	-1	3615541
reas	O	-1	3615541
are	O	-1	3615541
the	O	-1	3615541
major	O	-1	3615541
sit@@	O	-1	3615541
es	O	-1	3615541
of	O	-1	3615541
action	O	-1	3615541
of	O	-1	3615541
calc@@	B-Chemical	D002116	3615541
it@@	I-Chemical	-1	3615541
on@@	I-Chemical	-1	3615541
in	I-Chemical	-1	3615541
in	O	-1	3615541
inhibit@@	O	-1	3615541
ing	O	-1	3615541
amphetamine	B-Chemical	D000661	3615541
-induced	O	-1	3615541
locomotor	O	-1	3615541
activ@@	O	-1	3615541
ity.	O	-1	3615541

F@@	O	-1	8953972
atal	O	-1	8953972
intrac@@	B-Disease	D013345	8953972
ranial	I-Disease	-1	8953972
ble@@	I-Disease	-1	8953972
ed@@	I-Disease	-1	8953972
ing	I-Disease	-1	8953972
associated	O	-1	8953972
with	O	-1	8953972
pre@@	O	-1	8953972
hospit@@	O	-1	8953972
al	O	-1	8953972
use	O	-1	8953972
of	O	-1	8953972
ep@@	B-Chemical	D004837	8953972
ine@@	I-Chemical	-1	8953972
phrine	I-Chemical	-1	8953972
.	O	-1	8953972
We	O	-1	8953972
present	O	-1	8953972
a	O	-1	8953972
case	O	-1	8953972
of	O	-1	8953972
par@@	O	-1	8953972
ame@@	O	-1	8953972
di@@	O	-1	8953972
c	O	-1	8953972
mis@@	O	-1	8953972
j@@	O	-1	8953972
ud@@	O	-1	8953972
g@@	O	-1	8953972
ment	O	-1	8953972
in	O	-1	8953972
the	O	-1	8953972
ex@@	O	-1	8953972
ec@@	O	-1	8953972
u@@	O	-1	8953972
tion	O	-1	8953972
of	O	-1	8953972
a	O	-1	8953972
pro@@	O	-1	8953972
to@@	O	-1	8953972
co@@	O	-1	8953972
l	O	-1	8953972
for	O	-1	8953972
the	O	-1	8953972
treatment	O	-1	8953972
of	O	-1	8953972
all@@	B-Disease	D004342	8953972
ergic	I-Disease	-1	8953972
reaction	I-Disease	-1	8953972
in	O	-1	8953972
a	O	-1	8953972
case	O	-1	8953972
of	O	-1	8953972
pulmonary	B-Disease	D011654	8953972
e@@	I-Disease	-1	8953972
de@@	I-Disease	-1	8953972
ma	I-Disease	-1	8953972
with	O	-1	8953972
whe@@	B-Disease	D012135	8953972
e@@	I-Disease	-1	8953972
z@@	I-Disease	-1	8953972
ing	I-Disease	-1	8953972
.	O	-1	8953972
The	O	-1	8953972
su@@	O	-1	8953972
d@@	O	-1	8953972
de@@	O	-1	8953972
n	O	-1	8953972
onset	O	-1	8953972
of	O	-1	8953972
respiratory	B-Disease	D012128	8953972
dist@@	I-Disease	-1	8953972
res@@	I-Disease	-1	8953972
s	I-Disease	-1	8953972
,	O	-1	8953972
r@@	B-Disease	D005076	8953972
as@@	I-Disease	-1	8953972
h	I-Disease	-1	8953972
,	O	-1	8953972
and	O	-1	8953972
a	O	-1	8953972
hist@@	O	-1	8953972
ory	O	-1	8953972
of	O	-1	8953972
a	O	-1	8953972
new	O	-1	8953972
medic@@	O	-1	8953972
ine	O	-1	8953972
l@@	O	-1	8953972
ed	O	-1	8953972
the	O	-1	8953972
two	O	-1	8953972
par@@	O	-1	8953972
am@@	O	-1	8953972
ed@@	O	-1	8953972
ic@@	O	-1	8953972
s	O	-1	8953972
on	O	-1	8953972
the	O	-1	8953972
s@@	O	-1	8953972
c@@	O	-1	8953972
ene	O	-1	8953972
to	O	-1	8953972
administ@@	O	-1	8953972
er	O	-1	8953972
sub@@	O	-1	8953972
c@@	O	-1	8953972
utaneous	O	-1	8953972
ep@@	B-Chemical	D004837	8953972
ine@@	I-Chemical	-1	8953972
phrine	I-Chemical	-1	8953972
.	O	-1	8953972
S@@	O	-1	8953972
ub@@	O	-1	8953972
sequ@@	O	-1	8953972
ent@@	O	-1	8953972
ly,	O	-1	8953972
acute	O	-1	8953972
cardiac	B-Disease	D006323	8953972
ar@@	I-Disease	-1	8953972
res@@	I-Disease	-1	8953972
t	I-Disease	-1	8953972
and	O	-1	8953972
f@@	O	-1	8953972
atal	O	-1	8953972
sub@@	B-Disease	D013345	8953972
arac@@	I-Disease	-1	8953972
h@@	I-Disease	-1	8953972
no@@	I-Disease	-1	8953972
id	I-Disease	-1	8953972
hemorrh@@	I-Disease	-1	8953972
age	I-Disease	-1	8953972
occur@@	O	-1	8953972
red.	O	-1	8953972
E@@	B-Chemical	D004837	8953972
p@@	I-Chemical	-1	8953972
ine@@	I-Chemical	-1	8953972
phrine	I-Chemical	-1	8953972
has	O	-1	8953972
a	O	-1	8953972
pro@@	O	-1	8953972
ven	O	-1	8953972
role	O	-1	8953972
in	O	-1	8953972
cardiac	B-Disease	D006323	8953972
ar@@	I-Disease	-1	8953972
res@@	I-Disease	-1	8953972
t	I-Disease	-1	8953972
in	O	-1	8953972
pre@@	O	-1	8953972
hospit@@	O	-1	8953972
al	O	-1	8953972
ca@@	O	-1	8953972
re@@	O	-1	8953972
;	O	-1	8953972
however,	O	-1	8953972
use	O	-1	8953972
by	O	-1	8953972
par@@	O	-1	8953972
am@@	O	-1	8953972
ed@@	O	-1	8953972
ic@@	O	-1	8953972
s	O	-1	8953972
in	O	-1	8953972
patients	O	-1	8953972
with	O	-1	8953972
sus@@	O	-1	8953972
p@@	O	-1	8953972
ected	O	-1	8953972
all@@	B-Disease	D004342	8953972
ergic	I-Disease	-1	8953972
reaction	I-Disease	-1	8953972
and	O	-1	8953972
severe	O	-1	8953972
hypertension	B-Disease	D006973	8953972
should	O	-1	8953972
be	O	-1	8953972
vie@@	O	-1	8953972
w@@	O	-1	8953972
ed	O	-1	8953972
with	O	-1	8953972
cau@@	O	-1	8953972
tion.	O	-1	8953972

A	O	-1	3782049
case	O	-1	3782049
of	O	-1	3782049
mas@@	O	-1	3782049
sive	O	-1	3782049
rh@@	B-Disease	D012206	3782049
ab@@	I-Disease	-1	3782049
do@@	I-Disease	-1	3782049
my@@	I-Disease	-1	3782049
oly@@	I-Disease	-1	3782049
sis	I-Disease	-1	3782049
following	O	-1	3782049
mol@@	B-Chemical	D008972	3782049
ind@@	I-Chemical	-1	3782049
one	I-Chemical	-1	3782049
administr@@	O	-1	3782049
ation.	O	-1	3782049
R@@	B-Disease	D012206	3782049
h@@	I-Disease	-1	3782049
ab@@	I-Disease	-1	3782049
do@@	I-Disease	-1	3782049
my@@	I-Disease	-1	3782049
oly@@	I-Disease	-1	3782049
sis	I-Disease	-1	3782049
is	O	-1	3782049
a	O	-1	3782049
potenti@@	O	-1	3782049
ally	O	-1	3782049
le@@	O	-1	3782049
th@@	O	-1	3782049
al	O	-1	3782049
syndrome	O	-1	3782049
that	O	-1	3782049
psych@@	B-Disease	D001523	3782049
i@@	I-Disease	-1	3782049
atric	I-Disease	-1	3782049
patients	O	-1	3782049
se@@	O	-1	3782049
em	O	-1	3782049
pre@@	O	-1	3782049
dis@@	O	-1	3782049
pos@@	O	-1	3782049
ed	O	-1	3782049
to	O	-1	3782049
develop@@	O	-1	3782049
.	O	-1	3782049
The	O	-1	3782049
clinical	O	-1	3782049
signs	O	-1	3782049
and	O	-1	3782049
symptom@@	O	-1	3782049
s,	O	-1	3782049
typ@@	O	-1	3782049
ical	O	-1	3782049
labor@@	O	-1	3782049
atory	O	-1	3782049
feat@@	O	-1	3782049
ures@@	O	-1	3782049
,	O	-1	3782049
and	O	-1	3782049
complications	O	-1	3782049
of	O	-1	3782049
rh@@	B-Disease	D012206	3782049
ab@@	I-Disease	-1	3782049
do@@	I-Disease	-1	3782049
my@@	I-Disease	-1	3782049
oly@@	I-Disease	-1	3782049
sis	I-Disease	-1	3782049
are	O	-1	3782049
present@@	O	-1	3782049
ed.	O	-1	3782049
The	O	-1	3782049
case	O	-1	3782049
of	O	-1	3782049
a	O	-1	3782049
sch@@	B-Disease	D012559	3782049
iz@@	I-Disease	-1	3782049
oph@@	I-Disease	-1	3782049
ren@@	I-Disease	-1	3782049
ic	I-Disease	-1	3782049
patient	O	-1	3782049
is	O	-1	3782049
reported	O	-1	3782049
to	O	-1	3782049
il@@	O	-1	3782049
lu@@	O	-1	3782049
st@@	O	-1	3782049
rate	O	-1	3782049
mas@@	O	-1	3782049
sive	O	-1	3782049
rh@@	B-Disease	D012206	3782049
ab@@	I-Disease	-1	3782049
do@@	I-Disease	-1	3782049
my@@	I-Disease	-1	3782049
oly@@	I-Disease	-1	3782049
sis	I-Disease	-1	3782049
and	O	-1	3782049
subsequ@@	O	-1	3782049
ent	O	-1	3782049
acute	B-Disease	D058186	3782049
renal	I-Disease	-1	3782049
failure	I-Disease	-1	3782049
following	O	-1	3782049
mol@@	B-Chemical	D008972	3782049
ind@@	I-Chemical	-1	3782049
one	I-Chemical	-1	3782049
administr@@	O	-1	3782049
ation.	O	-1	3782049
P@@	O	-1	3782049
hy@@	O	-1	3782049
si@@	O	-1	3782049
ci@@	O	-1	3782049
ans	O	-1	3782049
who	O	-1	3782049
prescri@@	O	-1	3782049
be	O	-1	3782049
mol@@	B-Chemical	D008972	3782049
ind@@	I-Chemical	-1	3782049
one	I-Chemical	-1	3782049
should	O	-1	3782049
be	O	-1	3782049
aw@@	O	-1	3782049
are	O	-1	3782049
of	O	-1	3782049
this	O	-1	3782049
reac@@	O	-1	3782049
tion.	O	-1	3782049

C@@	B-Disease	D018376	9100294
ardi@@	I-Disease	-1	9100294
o@@	I-Disease	-1	9100294
vascular	I-Disease	-1	9100294
al@@	I-Disease	-1	9100294
ter@@	I-Disease	-1	9100294
ations	I-Disease	-1	9100294
in	O	-1	9100294
rat	O	-1	9100294
f@@	O	-1	9100294
et@@	O	-1	9100294
u@@	O	-1	9100294
ses	O	-1	9100294
exposed	O	-1	9100294
to	O	-1	9100294
calcium	B-Chemical	D002118	9100294
channel	O	-1	9100294
block@@	O	-1	9100294
ers.	O	-1	9100294
Pre@@	O	-1	9100294
clinical	O	-1	9100294
toxic@@	O	-1	9100294
ologic	O	-1	9100294
investig@@	O	-1	9100294
ation	O	-1	9100294
suggested	O	-1	9100294
that	O	-1	9100294
a	O	-1	9100294
new	O	-1	9100294
calcium	B-Chemical	D002118	9100294
channel	O	-1	9100294
block@@	O	-1	9100294
er,	O	-1	9100294
R@@	B-Chemical	D020748	9100294
o	I-Chemical	-1	9100294
4@@	I-Chemical	-1	9100294
0-@@	I-Chemical	-1	9100294
5@@	I-Chemical	-1	9100294
9@@	I-Chemical	-1	9100294
6@@	I-Chemical	-1	9100294
7	I-Chemical	-1	9100294
,	O	-1	9100294
induced	O	-1	9100294
cardiovascular	B-Disease	D018376	9100294
al@@	I-Disease	-1	9100294
ter@@	I-Disease	-1	9100294
ations	I-Disease	-1	9100294
in	O	-1	9100294
rat	O	-1	9100294
f@@	O	-1	9100294
et@@	O	-1	9100294
u@@	O	-1	9100294
ses	O	-1	9100294
exposed	O	-1	9100294
to	O	-1	9100294
this	O	-1	9100294
agent	O	-1	9100294
during	O	-1	9100294
org@@	O	-1	9100294
an@@	O	-1	9100294
o@@	O	-1	9100294
gene@@	O	-1	9100294
sis.	O	-1	9100294
The	O	-1	9100294
present	O	-1	9100294
study	O	-1	9100294
was	O	-1	9100294
de@@	O	-1	9100294
signed	O	-1	9100294
to	O	-1	9100294
investigate	O	-1	9100294
the	O	-1	9100294
hypo@@	O	-1	9100294
thesis	O	-1	9100294
that	O	-1	9100294
calcium	B-Chemical	D002118	9100294
channel	O	-1	9100294
block@@	O	-1	9100294
ers	O	-1	9100294
in	O	-1	9100294
gener@@	O	-1	9100294
al	O	-1	9100294
induce	O	-1	9100294
cardiovascular	B-Disease	D018376	9100294
mal@@	I-Disease	-1	9100294
form@@	I-Disease	-1	9100294
ations	I-Disease	-1	9100294
indicating	O	-1	9100294
a	O	-1	9100294
pharmac@@	O	-1	9100294
ologic	O	-1	9100294
cl@@	O	-1	9100294
as@@	O	-1	9100294
s	O	-1	9100294
effect@@	O	-1	9100294
.	O	-1	9100294
We	O	-1	9100294
studied	O	-1	9100294
three	O	-1	9100294
calcium	B-Chemical	D002118	9100294
channel	O	-1	9100294
block@@	O	-1	9100294
ers	O	-1	9100294
of	O	-1	9100294
different	O	-1	9100294
struct@@	O	-1	9100294
ure,	O	-1	9100294
n@@	B-Chemical	D009543	9100294
if@@	I-Chemical	-1	9100294
edi@@	I-Chemical	-1	9100294
pine	I-Chemical	-1	9100294
,	O	-1	9100294
di@@	B-Chemical	D004110	9100294
l@@	I-Chemical	-1	9100294
ti@@	I-Chemical	-1	9100294
az@@	I-Chemical	-1	9100294
em	I-Chemical	-1	9100294
,	O	-1	9100294
and	O	-1	9100294
verap@@	B-Chemical	D014700	9100294
ami@@	I-Chemical	-1	9100294
l	I-Chemical	-1	9100294
,	O	-1	9100294
al@@	O	-1	9100294
ong	O	-1	9100294
with	O	-1	9100294
the	O	-1	9100294
new	O	-1	9100294
agent@@	O	-1	9100294
.	O	-1	9100294
Pre@@	O	-1	9100294
gn@@	O	-1	9100294
ant	O	-1	9100294
rats	O	-1	9100294
were	O	-1	9100294
administered	O	-1	9100294
one	O	-1	9100294
of	O	-1	9100294
these	O	-1	9100294
calcium	B-Chemical	D002118	9100294
channel	O	-1	9100294
block@@	O	-1	9100294
ers	O	-1	9100294
during	O	-1	9100294
the	O	-1	9100294
period	O	-1	9100294
of	O	-1	9100294
cardiac	O	-1	9100294
morph@@	O	-1	9100294
o@@	O	-1	9100294
genesis	O	-1	9100294
and	O	-1	9100294
the	O	-1	9100294
o@@	O	-1	9100294
ff@@	O	-1	9100294
sp@@	O	-1	9100294
r@@	O	-1	9100294
ing	O	-1	9100294
examined	O	-1	9100294
on	O	-1	9100294
day	O	-1	9100294
20	O	-1	9100294
of	O	-1	9100294
g@@	O	-1	9100294
est@@	O	-1	9100294
ation	O	-1	9100294
for	O	-1	9100294
cardiovascular	B-Disease	D018376	9100294
mal@@	I-Disease	-1	9100294
form@@	I-Disease	-1	9100294
ations	I-Disease	-1	9100294
.	O	-1	9100294
A	O	-1	9100294
low	O	-1	9100294
incidence	O	-1	9100294
of	O	-1	9100294
cardiovascular	B-Disease	D018376	9100294
mal@@	I-Disease	-1	9100294
form@@	I-Disease	-1	9100294
ations	I-Disease	-1	9100294
was	O	-1	9100294
observed	O	-1	9100294
after	O	-1	9100294
exposure	O	-1	9100294
to	O	-1	9100294
each	O	-1	9100294
of	O	-1	9100294
the	O	-1	9100294
four	O	-1	9100294
calcium	B-Chemical	D002118	9100294
channel	O	-1	9100294
block@@	O	-1	9100294
er@@	O	-1	9100294
s,	O	-1	9100294
but	O	-1	9100294
this	O	-1	9100294
incidence	O	-1	9100294
was	O	-1	9100294
statis@@	O	-1	9100294
tically	O	-1	9100294
significant	O	-1	9100294
only	O	-1	9100294
for	O	-1	9100294
verap@@	B-Chemical	D014700	9100294
ami@@	I-Chemical	-1	9100294
l	I-Chemical	-1	9100294
and	O	-1	9100294
n@@	B-Chemical	D009543	9100294
if@@	I-Chemical	-1	9100294
edi@@	I-Chemical	-1	9100294
pine	I-Chemical	-1	9100294
.	O	-1	9100294
All	O	-1	9100294
four	O	-1	9100294
agents	O	-1	9100294
were	O	-1	9100294
associated	O	-1	9100294
with	O	-1	9100294
a@@	O	-1	9100294
or@@	O	-1	9100294
tic	O	-1	9100294
arc@@	O	-1	9100294
h	O	-1	9100294
b@@	O	-1	9100294
ran@@	O	-1	9100294
ch@@	O	-1	9100294
ing	O	-1	9100294
vari@@	O	-1	9100294
ant@@	O	-1	9100294
s,	O	-1	9100294
although	O	-1	9100294
significantly	O	-1	9100294
increased	O	-1	9100294
only	O	-1	9100294
for	O	-1	9100294
R@@	B-Chemical	D020748	9100294
o	I-Chemical	-1	9100294
4@@	I-Chemical	-1	9100294
0-@@	I-Chemical	-1	9100294
5@@	I-Chemical	-1	9100294
9@@	I-Chemical	-1	9100294
6@@	I-Chemical	-1	9100294
7	I-Chemical	-1	9100294
and	O	-1	9100294
verap@@	B-Chemical	D014700	9100294
ami@@	I-Chemical	-1	9100294
l	I-Chemical	-1	9100294
.	O	-1	9100294

Di@@	O	-1	19889778
fferen@@	O	-1	19889778
tial	O	-1	19889778
im@@	O	-1	19889778
pac@@	O	-1	19889778
t	O	-1	19889778
of	O	-1	19889778
immun@@	O	-1	19889778
e	O	-1	19889778
es@@	O	-1	19889778
cap@@	O	-1	19889778
e	O	-1	19889778
mut@@	O	-1	19889778
ations	O	-1	19889778
G@@	O	-1	19889778
14@@	O	-1	19889778
5@@	O	-1	19889778
R	O	-1	19889778
and	O	-1	19889778
P@@	O	-1	19889778
1@@	O	-1	19889778
20@@	O	-1	19889778
T	O	-1	19889778
on	O	-1	19889778
the	O	-1	19889778
re@@	O	-1	19889778
plic@@	O	-1	19889778
ation	O	-1	19889778
of	O	-1	19889778
lamivud@@	B-Chemical	D019259	19889778
ine	I-Chemical	-1	19889778
-@@	O	-1	19889778
resist@@	O	-1	19889778
ant	O	-1	19889778
hepatitis	B-Chemical	D006513	19889778
B	I-Chemical	-1	19889778
vi@@	I-Chemical	-1	19889778
ru@@	I-Chemical	-1	19889778
s	I-Chemical	-1	19889778
e	I-Chemical	-1	19889778
anti@@	I-Chemical	-1	19889778
gen	I-Chemical	-1	19889778
-@@	O	-1	19889778
positive	O	-1	19889778
and	O	-1	19889778
-@@	O	-1	19889778
negative	O	-1	19889778
stra@@	O	-1	19889778
in@@	O	-1	19889778
s.	O	-1	19889778
Im@@	O	-1	19889778
mun@@	O	-1	19889778
e	O	-1	19889778
es@@	O	-1	19889778
cap@@	O	-1	19889778
e	O	-1	19889778
vari@@	O	-1	19889778
ants	O	-1	19889778
of	O	-1	19889778
the	O	-1	19889778
hepatitis	B-Disease	D006509	19889778
B	I-Disease	-1	19889778
vi@@	O	-1	19889778
ru@@	O	-1	19889778
s	O	-1	19889778
(@@	O	-1	19889778
HB@@	O	-1	19889778
V@@	O	-1	19889778
)	O	-1	19889778
re@@	O	-1	19889778
present	O	-1	19889778
an	O	-1	19889778
em@@	O	-1	19889778
erg@@	O	-1	19889778
ing	O	-1	19889778
clinical	O	-1	19889778
ch@@	O	-1	19889778
all@@	O	-1	19889778
en@@	O	-1	19889778
g@@	O	-1	19889778
e,	O	-1	19889778
because	O	-1	19889778
they	O	-1	19889778
can	O	-1	19889778
be	O	-1	19889778
associated	O	-1	19889778
with	O	-1	19889778
vac@@	O	-1	19889778
c@@	O	-1	19889778
ine	O	-1	19889778
es@@	O	-1	19889778
cap@@	O	-1	19889778
e,	O	-1	19889778
HBV	O	-1	19889778
re@@	O	-1	19889778
activ@@	O	-1	19889778
ation,	O	-1	19889778
and	O	-1	19889778
failure	O	-1	19889778
of	O	-1	19889778
diagnos@@	O	-1	19889778
tic	O	-1	19889778
test@@	O	-1	19889778
s.	O	-1	19889778
Rec@@	O	-1	19889778
ent	O	-1	19889778
data	O	-1	19889778
suggest	O	-1	19889778
a	O	-1	19889778
pre@@	O	-1	19889778
fe@@	O	-1	19889778
ren@@	O	-1	19889778
tial	O	-1	19889778
sel@@	O	-1	19889778
ection	O	-1	19889778
of	O	-1	19889778
immun@@	O	-1	19889778
e	O	-1	19889778
es@@	O	-1	19889778
cap@@	O	-1	19889778
e	O	-1	19889778
mut@@	O	-1	19889778
ants	O	-1	19889778
in	O	-1	19889778
dist@@	O	-1	19889778
inc@@	O	-1	19889778
t	O	-1	19889778
peripheral	O	-1	19889778
blood	O	-1	19889778
leuk@@	O	-1	19889778
ocyte	O	-1	19889778
compar@@	O	-1	19889778
t@@	O	-1	19889778
ments	O	-1	19889778
of	O	-1	19889778
inf@@	O	-1	19889778
ected	O	-1	19889778
individ@@	O	-1	19889778
u@@	O	-1	19889778
al@@	O	-1	19889778
s.	O	-1	19889778
We	O	-1	19889778
the@@	O	-1	19889778
re@@	O	-1	19889778
fore	O	-1	19889778
system@@	O	-1	19889778
ati@@	O	-1	19889778
c@@	O	-1	19889778
ally	O	-1	19889778
analy@@	O	-1	19889778
zed	O	-1	19889778
the	O	-1	19889778
functional	O	-1	19889778
im@@	O	-1	19889778
pac@@	O	-1	19889778
t	O	-1	19889778
of	O	-1	19889778
the	O	-1	19889778
most	O	-1	19889778
prev@@	O	-1	19889778
al@@	O	-1	19889778
ent	O	-1	19889778
immun@@	O	-1	19889778
e	O	-1	19889778
es@@	O	-1	19889778
cap@@	O	-1	19889778
e	O	-1	19889778
vari@@	O	-1	19889778
ant@@	O	-1	19889778
s,	O	-1	19889778
the	O	-1	19889778
s@@	O	-1	19889778
G@@	O	-1	19889778
14@@	O	-1	19889778
5@@	O	-1	19889778
R	O	-1	19889778
and	O	-1	19889778
s@@	O	-1	19889778
P@@	O	-1	19889778
1@@	O	-1	19889778
20@@	O	-1	19889778
T	O	-1	19889778
mut@@	O	-1	19889778
ant@@	O	-1	19889778
s,	O	-1	19889778
on	O	-1	19889778
the	O	-1	19889778
viral	O	-1	19889778
re@@	O	-1	19889778
plic@@	O	-1	19889778
ation	O	-1	19889778
efficacy	O	-1	19889778
and	O	-1	19889778
anti@@	O	-1	19889778
viral	O	-1	19889778
drug	O	-1	19889778
sus@@	O	-1	19889778
cep@@	O	-1	19889778
ti@@	O	-1	19889778
b@@	O	-1	19889778
ility	O	-1	19889778
of	O	-1	19889778
common	O	-1	19889778
treatment@@	O	-1	19889778
-@@	O	-1	19889778
associated	O	-1	19889778
mut@@	O	-1	19889778
ants	O	-1	19889778
with	O	-1	19889778
resist@@	O	-1	19889778
ance	O	-1	19889778
to	O	-1	19889778
lamivud@@	B-Chemical	D019259	19889778
ine	I-Chemical	-1	19889778
(	O	-1	19889778
L@@	B-Chemical	D019259	19889778
A@@	I-Chemical	-1	19889778
M	I-Chemical	-1	19889778
)	O	-1	19889778
and/or	O	-1	19889778
HB@@	B-Chemical	D006513	19889778
e@@	I-Chemical	-1	19889778
A@@	I-Chemical	-1	19889778
g	I-Chemical	-1	19889778
neg@@	O	-1	19889778
ati@@	O	-1	19889778
v@@	O	-1	19889778
ity.	O	-1	19889778
Re@@	O	-1	19889778
plic@@	O	-1	19889778
ation@@	O	-1	19889778
-@@	O	-1	19889778
comp@@	O	-1	19889778
et@@	O	-1	19889778
ent	O	-1	19889778
HBV	O	-1	19889778
stra@@	O	-1	19889778
ins	O	-1	19889778
with	O	-1	19889778
s@@	O	-1	19889778
G@@	O	-1	19889778
14@@	O	-1	19889778
5@@	O	-1	19889778
R	O	-1	19889778
or	O	-1	19889778
s@@	O	-1	19889778
P@@	O	-1	19889778
1@@	O	-1	19889778
20@@	O	-1	19889778
T	O	-1	19889778
and	O	-1	19889778
L@@	B-Chemical	D019259	19889778
A@@	I-Chemical	-1	19889778
M	I-Chemical	-1	19889778
resist@@	O	-1	19889778
ance	O	-1	19889778
(@@	O	-1	19889778
r@@	O	-1	19889778
t@@	O	-1	19889778
M@@	O	-1	19889778
20@@	O	-1	19889778
4@@	O	-1	19889778
I	O	-1	19889778
or	O	-1	19889778
r@@	O	-1	19889778
t@@	O	-1	19889778
L@@	O	-1	19889778
18@@	O	-1	19889778
0@@	O	-1	19889778
M@@	O	-1	19889778
/@@	O	-1	19889778
r@@	O	-1	19889778
t@@	O	-1	19889778
M@@	O	-1	19889778
20@@	O	-1	19889778
4@@	O	-1	19889778
V@@	O	-1	19889778
)	O	-1	19889778
were	O	-1	19889778
gener@@	O	-1	19889778
ated	O	-1	19889778
on	O	-1	19889778
an	O	-1	19889778
HB@@	B-Chemical	D006513	19889778
e@@	I-Chemical	-1	19889778
A@@	I-Chemical	-1	19889778
g	I-Chemical	-1	19889778
-@@	O	-1	19889778
positive	O	-1	19889778
and	O	-1	19889778
an	O	-1	19889778
HB@@	B-Chemical	D006513	19889778
e@@	I-Chemical	-1	19889778
A@@	I-Chemical	-1	19889778
g	I-Chemical	-1	19889778
-@@	O	-1	19889778
negative	O	-1	19889778
bac@@	O	-1	19889778
kg@@	O	-1	19889778
ro@@	O	-1	19889778
un@@	O	-1	19889778
d	O	-1	19889778
with	O	-1	19889778
pre@@	O	-1	19889778
cor@@	O	-1	19889778
e	O	-1	19889778
(P@@	O	-1	19889778
C@@	O	-1	19889778
)	O	-1	19889778
and	O	-1	19889778
bas@@	O	-1	19889778
al	O	-1	19889778
cor@@	O	-1	19889778
e	O	-1	19889778
pro@@	O	-1	19889778
m@@	O	-1	19889778
ot@@	O	-1	19889778
er	O	-1	19889778
(@@	O	-1	19889778
BC@@	O	-1	19889778
P)	O	-1	19889778
mut@@	O	-1	19889778
ant@@	O	-1	19889778
s.	O	-1	19889778
The	O	-1	19889778
s@@	O	-1	19889778
G@@	O	-1	19889778
14@@	O	-1	19889778
5@@	O	-1	19889778
R	O	-1	19889778
mut@@	O	-1	19889778
ation	O	-1	19889778
st@@	O	-1	19889778
ron@@	O	-1	19889778
g@@	O	-1	19889778
ly	O	-1	19889778
reduced	O	-1	19889778
HB@@	B-Chemical	D006514	19889778
s@@	I-Chemical	-1	19889778
A@@	I-Chemical	-1	19889778
g	I-Chemical	-1	19889778
levels	O	-1	19889778
and	O	-1	19889778
was	O	-1	19889778
able	O	-1	19889778
to	O	-1	19889778
ful@@	O	-1	19889778
ly	O	-1	19889778
rest@@	O	-1	19889778
or@@	O	-1	19889778
e	O	-1	19889778
the	O	-1	19889778
impaired	O	-1	19889778
re@@	O	-1	19889778
plic@@	O	-1	19889778
ation	O	-1	19889778
of	O	-1	19889778
L@@	B-Chemical	D019259	19889778
A@@	I-Chemical	-1	19889778
M	I-Chemical	-1	19889778
-@@	O	-1	19889778
resist@@	O	-1	19889778
ant	O	-1	19889778
HBV	O	-1	19889778
mut@@	O	-1	19889778
ants	O	-1	19889778
to	O	-1	19889778
the	O	-1	19889778
levels	O	-1	19889778
of	O	-1	19889778
wil@@	O	-1	19889778
d-@@	O	-1	19889778
type	O	-1	19889778
HB@@	O	-1	19889778
V@@	O	-1	19889778
,	O	-1	19889778
and	O	-1	19889778
P@@	O	-1	19889778
C	O	-1	19889778
or	O	-1	19889778
BC@@	O	-1	19889778
P	O	-1	19889778
mut@@	O	-1	19889778
ations	O	-1	19889778
further	O	-1	19889778
enhanced	O	-1	19889778
viral	O	-1	19889778
re@@	O	-1	19889778
plic@@	O	-1	19889778
ation.	O	-1	19889778
Although	O	-1	19889778
the	O	-1	19889778
s@@	O	-1	19889778
P@@	O	-1	19889778
1@@	O	-1	19889778
20@@	O	-1	19889778
T	O	-1	19889778
sub@@	O	-1	19889778
sti@@	O	-1	19889778
tu@@	O	-1	19889778
tion	O	-1	19889778
also	O	-1	19889778
impaired	O	-1	19889778
HB@@	B-Chemical	D006514	19889778
s@@	I-Chemical	-1	19889778
A@@	I-Chemical	-1	19889778
g	I-Chemical	-1	19889778
secre@@	O	-1	19889778
tion,	O	-1	19889778
it	O	-1	19889778
did	O	-1	19889778
not	O	-1	19889778
enh@@	O	-1	19889778
ance	O	-1	19889778
the	O	-1	19889778
re@@	O	-1	19889778
plic@@	O	-1	19889778
ation	O	-1	19889778
of	O	-1	19889778
L@@	B-Chemical	D019259	19889778
A@@	I-Chemical	-1	19889778
M	I-Chemical	-1	19889778
-@@	O	-1	19889778
resist@@	O	-1	19889778
ant	O	-1	19889778
clon@@	O	-1	19889778
es.	O	-1	19889778
However,	O	-1	19889778
the	O	-1	19889778
concomit@@	O	-1	19889778
ant	O	-1	19889778
occur@@	O	-1	19889778
rence	O	-1	19889778
of	O	-1	19889778
HB@@	B-Chemical	D006513	19889778
e@@	I-Chemical	-1	19889778
A@@	I-Chemical	-1	19889778
g	I-Chemical	-1	19889778
neg@@	O	-1	19889778
ati@@	O	-1	19889778
v@@	O	-1	19889778
ity	O	-1	19889778
(P@@	O	-1	19889778
C@@	O	-1	19889778
/@@	O	-1	19889778
BC@@	O	-1	19889778
P@@	O	-1	19889778
),	O	-1	19889778
s@@	O	-1	19889778
P@@	O	-1	19889778
1@@	O	-1	19889778
20@@	O	-1	19889778
T@@	O	-1	19889778
,	O	-1	19889778
and	O	-1	19889778
L@@	B-Chemical	D019259	19889778
A@@	I-Chemical	-1	19889778
M	I-Chemical	-1	19889778
resist@@	O	-1	19889778
ance	O	-1	19889778
resulted	O	-1	19889778
in	O	-1	19889778
the	O	-1	19889778
rest@@	O	-1	19889778
or@@	O	-1	19889778
ation	O	-1	19889778
of	O	-1	19889778
re@@	O	-1	19889778
plic@@	O	-1	19889778
ation	O	-1	19889778
to	O	-1	19889778
levels	O	-1	19889778
of	O	-1	19889778
wil@@	O	-1	19889778
d-@@	O	-1	19889778
type	O	-1	19889778
HB@@	O	-1	19889778
V@@	O	-1	19889778
.	O	-1	19889778
In	O	-1	19889778
all	O	-1	19889778
clon@@	O	-1	19889778
es	O	-1	19889778
with	O	-1	19889778
combined	O	-1	19889778
immun@@	O	-1	19889778
e	O	-1	19889778
es@@	O	-1	19889778
cap@@	O	-1	19889778
e	O	-1	19889778
and	O	-1	19889778
L@@	B-Chemical	D019259	19889778
A@@	I-Chemical	-1	19889778
M	I-Chemical	-1	19889778
resist@@	O	-1	19889778
ance	O	-1	19889778
mut@@	O	-1	19889778
ation@@	O	-1	19889778
s,	O	-1	19889778
the	O	-1	19889778
nucle@@	B-Chemical	D009711	19889778
o@@	I-Chemical	-1	19889778
ti@@	I-Chemical	-1	19889778
de	I-Chemical	-1	19889778
an@@	O	-1	19889778
alo@@	O	-1	19889778
gu@@	O	-1	19889778
es	O	-1	19889778
a@@	B-Chemical	C053001	19889778
def@@	I-Chemical	-1	19889778
o@@	I-Chemical	-1	19889778
vi@@	I-Chemical	-1	19889778
r	I-Chemical	-1	19889778
and	O	-1	19889778
ten@@	B-Chemical	C096918	19889778
of@@	I-Chemical	-1	19889778
o@@	I-Chemical	-1	19889778
vi@@	I-Chemical	-1	19889778
r	I-Chemical	-1	19889778
remained	O	-1	19889778
effective	O	-1	19889778
in	O	-1	19889778
sup@@	O	-1	19889778
press@@	O	-1	19889778
ing	O	-1	19889778
viral	O	-1	19889778
re@@	O	-1	19889778
plic@@	O	-1	19889778
ation	O	-1	19889778
in	O	-1	19889778
vit@@	O	-1	19889778
ro@@	O	-1	19889778
.	O	-1	19889778
These	O	-1	19889778
findings	O	-1	19889778
reve@@	O	-1	19889778
al	O	-1	19889778
the	O	-1	19889778
differen@@	O	-1	19889778
tial	O	-1	19889778
im@@	O	-1	19889778
pac@@	O	-1	19889778
t	O	-1	19889778
of	O	-1	19889778
immun@@	O	-1	19889778
e	O	-1	19889778
es@@	O	-1	19889778
cap@@	O	-1	19889778
e	O	-1	19889778
vari@@	O	-1	19889778
ants	O	-1	19889778
on	O	-1	19889778
the	O	-1	19889778
re@@	O	-1	19889778
plic@@	O	-1	19889778
ation	O	-1	19889778
and	O	-1	19889778
drug	O	-1	19889778
sus@@	O	-1	19889778
cep@@	O	-1	19889778
ti@@	O	-1	19889778
b@@	O	-1	19889778
ility	O	-1	19889778
of	O	-1	19889778
comple@@	O	-1	19889778
x	O	-1	19889778
HBV	O	-1	19889778
mut@@	O	-1	19889778
ant@@	O	-1	19889778
s,	O	-1	19889778
sup@@	O	-1	19889778
port@@	O	-1	19889778
ing	O	-1	19889778
the	O	-1	19889778
need	O	-1	19889778
of	O	-1	19889778
clo@@	O	-1	19889778
se	O	-1	19889778
sur@@	O	-1	19889778
ve@@	O	-1	19889778
ill@@	O	-1	19889778
ance	O	-1	19889778
and	O	-1	19889778
treatment	O	-1	19889778
adjust@@	O	-1	19889778
ment	O	-1	19889778
in	O	-1	19889778
response	O	-1	19889778
to	O	-1	19889778
the	O	-1	19889778
sel@@	O	-1	19889778
ection	O	-1	19889778
of	O	-1	19889778
dist@@	O	-1	19889778
inc@@	O	-1	19889778
t	O	-1	19889778
mut@@	O	-1	19889778
ation@@	O	-1	19889778
al	O	-1	19889778
pat@@	O	-1	19889778
tern@@	O	-1	19889778
s.	O	-1	19889778

The	O	-1	15278670
effects	O	-1	15278670
of	O	-1	15278670
sev@@	B-Chemical	C009250	15278670
of@@	I-Chemical	-1	15278670
lur@@	I-Chemical	-1	15278670
ane	I-Chemical	-1	15278670
on	O	-1	15278670
lidocaine	B-Chemical	D008012	15278670
-induced	O	-1	15278670
convul@@	B-Disease	D012640	15278670
sions	I-Disease	-1	15278670
.	O	-1	15278670
The	O	-1	15278670
influence	O	-1	15278670
of	O	-1	15278670
sev@@	B-Chemical	C009250	15278670
of@@	I-Chemical	-1	15278670
lur@@	I-Chemical	-1	15278670
ane	I-Chemical	-1	15278670
on	O	-1	15278670
lidocaine	B-Chemical	D008012	15278670
-induced	O	-1	15278670
convul@@	B-Disease	D012640	15278670
sions	I-Disease	-1	15278670
was	O	-1	15278670
studied	O	-1	15278670
in	O	-1	15278670
cat@@	O	-1	15278670
s.	O	-1	15278670
The	O	-1	15278670
convul@@	B-Disease	D012640	15278670
sive	I-Disease	-1	15278670
th@@	O	-1	15278670
res@@	O	-1	15278670
h@@	O	-1	15278670
old	O	-1	15278670
(@@	O	-1	15278670
mean	O	-1	15278670
+/-	O	-1	15278670
S@@	O	-1	15278670
D)	O	-1	15278670
was	O	-1	15278670
4@@	O	-1	15278670
1.@@	O	-1	15278670
4	O	-1	15278670
+/-	O	-1	15278670
6.@@	O	-1	15278670
5	O	-1	15278670
mg@@	O	-1	15278670
.	O	-1	15278670
l@@	O	-1	15278670
(@@	O	-1	15278670
-1@@	O	-1	15278670
)	O	-1	15278670
with	O	-1	15278670
lidocaine	B-Chemical	D008012	15278670
infusion	O	-1	15278670
(@@	O	-1	15278670
6	O	-1	15278670
mg@@	O	-1	15278670
.@@	O	-1	15278670
kg@@	O	-1	15278670
(@@	O	-1	15278670
-1@@	O	-1	15278670
)@@	O	-1	15278670
.@@	O	-1	15278670
min@@	O	-1	15278670
(@@	O	-1	15278670
-1@@	O	-1	15278670
)@@	O	-1	15278670
),	O	-1	15278670
increas@@	O	-1	15278670
ing	O	-1	15278670
significantly	O	-1	15278670
to	O	-1	15278670
6@@	O	-1	15278670
6.@@	O	-1	15278670
6	O	-1	15278670
+/-	O	-1	15278670
1@@	O	-1	15278670
0.@@	O	-1	15278670
9	O	-1	15278670
mg@@	O	-1	15278670
.	O	-1	15278670
l@@	O	-1	15278670
(@@	O	-1	15278670
-1@@	O	-1	15278670
)	O	-1	15278670
when	O	-1	15278670
the	O	-1	15278670
en@@	O	-1	15278670
d-@@	O	-1	15278670
tid@@	O	-1	15278670
al	O	-1	15278670
concentration	O	-1	15278670
of	O	-1	15278670
sev@@	B-Chemical	C009250	15278670
of@@	I-Chemical	-1	15278670
lur@@	I-Chemical	-1	15278670
ane	I-Chemical	-1	15278670
was	O	-1	15278670
0.@@	O	-1	15278670
8@@	O	-1	15278670
%.	O	-1	15278670
However,	O	-1	15278670
the	O	-1	15278670
th@@	O	-1	15278670
res@@	O	-1	15278670
h@@	O	-1	15278670
old	O	-1	15278670
(6@@	O	-1	15278670
1.@@	O	-1	15278670
6	O	-1	15278670
+/-	O	-1	15278670
8.@@	O	-1	15278670
7	O	-1	15278670
mg@@	O	-1	15278670
.	O	-1	15278670
l@@	O	-1	15278670
(@@	O	-1	15278670
-1@@	O	-1	15278670
)@@	O	-1	15278670
)	O	-1	15278670
during	O	-1	15278670
1.@@	O	-1	15278670
6%	O	-1	15278670
sev@@	B-Chemical	C009250	15278670
of@@	I-Chemical	-1	15278670
lur@@	I-Chemical	-1	15278670
ane	I-Chemical	-1	15278670
was	O	-1	15278670
not	O	-1	15278670
significant	O	-1	15278670
from	O	-1	15278670
that	O	-1	15278670
during	O	-1	15278670
0.@@	O	-1	15278670
8@@	O	-1	15278670
%	O	-1	15278670
sev@@	B-Chemical	C009250	15278670
of@@	I-Chemical	-1	15278670
lur@@	I-Chemical	-1	15278670
ane	I-Chemical	-1	15278670
,	O	-1	15278670
indicating	O	-1	15278670
a	O	-1	15278670
cell@@	O	-1	15278670
ing	O	-1	15278670
effect@@	O	-1	15278670
.	O	-1	15278670
There	O	-1	15278670
was	O	-1	15278670
no	O	-1	15278670
significant	O	-1	15278670
difference	O	-1	15278670
in	O	-1	15278670
the	O	-1	15278670
convul@@	B-Disease	D012640	15278670
sive	I-Disease	-1	15278670
th@@	O	-1	15278670
res@@	O	-1	15278670
h@@	O	-1	15278670
old	O	-1	15278670
between	O	-1	15278670
sev@@	B-Chemical	C009250	15278670
of@@	I-Chemical	-1	15278670
lur@@	I-Chemical	-1	15278670
ane	I-Chemical	-1	15278670
and	O	-1	15278670
en@@	B-Chemical	D004737	15278670
f@@	I-Chemical	-1	15278670
lur@@	I-Chemical	-1	15278670
ane	I-Chemical	-1	15278670
.	O	-1	15278670
The	O	-1	15278670
ri@@	O	-1	15278670
se	O	-1	15278670
in	O	-1	15278670
blood	O	-1	15278670
pressure	O	-1	15278670
b@@	O	-1	15278670
ec@@	O	-1	15278670
am@@	O	-1	15278670
e	O	-1	15278670
less	O	-1	15278670
mark@@	O	-1	15278670
ed	O	-1	15278670
when	O	-1	15278670
higher	O	-1	15278670
concentrations	O	-1	15278670
of	O	-1	15278670
sev@@	B-Chemical	C009250	15278670
of@@	I-Chemical	-1	15278670
lur@@	I-Chemical	-1	15278670
ane	I-Chemical	-1	15278670
or	O	-1	15278670
en@@	B-Chemical	D004737	15278670
f@@	I-Chemical	-1	15278670
lur@@	I-Chemical	-1	15278670
ane	I-Chemical	-1	15278670
were	O	-1	15278670
administered	O	-1	15278670
and	O	-1	15278670
the	O	-1	15278670
blood	O	-1	15278670
pressure	O	-1	15278670
at	O	-1	15278670
convul@@	B-Disease	D012640	15278670
sions	I-Disease	-1	15278670
decreased	O	-1	15278670
significantly	O	-1	15278670
in	O	-1	15278670
1.@@	O	-1	15278670
6%	O	-1	15278670
sev@@	B-Chemical	C009250	15278670
of@@	I-Chemical	-1	15278670
lur@@	I-Chemical	-1	15278670
ane	I-Chemical	-1	15278670
,	O	-1	15278670
and	O	-1	15278670
in	O	-1	15278670
0.@@	O	-1	15278670
8@@	O	-1	15278670
%	O	-1	15278670
and	O	-1	15278670
1.@@	O	-1	15278670
6%	O	-1	15278670
en@@	B-Chemical	D004737	15278670
f@@	I-Chemical	-1	15278670
lur@@	I-Chemical	-1	15278670
ane	I-Chemical	-1	15278670
.	O	-1	15278670
However,	O	-1	15278670
there	O	-1	15278670
was	O	-1	15278670
no	O	-1	15278670
significant	O	-1	15278670
difference	O	-1	15278670
in	O	-1	15278670
the	O	-1	15278670
lidocaine	B-Chemical	D008012	15278670
concentrations	O	-1	15278670
measured	O	-1	15278670
when	O	-1	15278670
the	O	-1	15278670
systolic	O	-1	15278670
blood	O	-1	15278670
pressure	O	-1	15278670
b@@	O	-1	15278670
ec@@	O	-1	15278670
am@@	O	-1	15278670
e	O	-1	15278670
7@@	O	-1	15278670
0	O	-1	15278670
mm@@	O	-1	15278670
H@@	O	-1	15278670
g@@	O	-1	15278670
.	O	-1	15278670
A@@	B-Chemical	D001030	15278670
p@@	I-Chemical	-1	15278670
amin	I-Chemical	-1	15278670
,	O	-1	15278670
a	O	-1	15278670
selective	O	-1	15278670
block@@	O	-1	15278670
er	O	-1	15278670
of	O	-1	15278670
calcium	B-Chemical	D002118	15278670
-@@	O	-1	15278670
dependent	O	-1	15278670
pot@@	B-Chemical	D011188	15278670
assi@@	I-Chemical	-1	15278670
um	I-Chemical	-1	15278670
channe@@	O	-1	15278670
l@@	O	-1	15278670
s,	O	-1	15278670
was	O	-1	15278670
administered	O	-1	15278670
intrac@@	O	-1	15278670
e@@	O	-1	15278670
reb@@	O	-1	15278670
ro@@	O	-1	15278670
ventric@@	O	-1	15278670
ul@@	O	-1	15278670
arly	O	-1	15278670
in	O	-1	15278670
rats	O	-1	15278670
anesthe@@	O	-1	15278670
tiz@@	O	-1	15278670
ed	O	-1	15278670
with	O	-1	15278670
0.@@	O	-1	15278670
8@@	O	-1	15278670
%	O	-1	15278670
sev@@	B-Chemical	C009250	15278670
of@@	I-Chemical	-1	15278670
lur@@	I-Chemical	-1	15278670
ane	I-Chemical	-1	15278670
to	O	-1	15278670
investigate	O	-1	15278670
the	O	-1	15278670
mechanism	O	-1	15278670
of	O	-1	15278670
the	O	-1	15278670
anti@@	O	-1	15278670
convul@@	O	-1	15278670
sive	O	-1	15278670
effects.	O	-1	15278670
A@@	B-Chemical	D001030	15278670
p@@	I-Chemical	-1	15278670
amin	I-Chemical	-1	15278670
(10	O	-1	15278670
n@@	O	-1	15278670
g@@	O	-1	15278670
)	O	-1	15278670
had	O	-1	15278670
a	O	-1	15278670
ten@@	O	-1	15278670
d@@	O	-1	15278670
ency	O	-1	15278670
to	O	-1	15278670
decrease	O	-1	15278670
the	O	-1	15278670
convul@@	B-Disease	D012640	15278670
sive	I-Disease	-1	15278670
th@@	O	-1	15278670
res@@	O	-1	15278670
h@@	O	-1	15278670
old	O	-1	15278670
(2@@	O	-1	15278670
1.@@	O	-1	15278670
6	O	-1	15278670
+/-	O	-1	15278670
2.@@	O	-1	15278670
2	O	-1	15278670
to	O	-1	15278670
19@@	O	-1	15278670
.@@	O	-1	15278670
9	O	-1	15278670
+/-	O	-1	15278670
2.@@	O	-1	15278670
5	O	-1	15278670
mg@@	O	-1	15278670
.	O	-1	15278670
l@@	O	-1	15278670
(@@	O	-1	15278670
-1@@	O	-1	15278670
)@@	O	-1	15278670
)	O	-1	15278670
but	O	-1	15278670
this	O	-1	15278670
was	O	-1	15278670
not	O	-1	15278670
statis@@	O	-1	15278670
tically	O	-1	15278670
significant@@	O	-1	15278670
.	O	-1	15278670
It	O	-1	15278670
is	O	-1	15278670
suggested	O	-1	15278670
that	O	-1	15278670
sev@@	B-Chemical	C009250	15278670
of@@	I-Chemical	-1	15278670
lur@@	I-Chemical	-1	15278670
ane	I-Chemical	-1	15278670
reduc@@	O	-1	15278670
es	O	-1	15278670
the	O	-1	15278670
convul@@	B-Disease	D012640	15278670
sive	I-Disease	-1	15278670
effect	O	-1	15278670
of	O	-1	15278670
lidocaine	B-Chemical	D008012	15278670
toxicity	B-Disease	D064420	15278670
but	O	-1	15278670
car@@	O	-1	15278670
ri@@	O	-1	15278670
es	O	-1	15278670
some	O	-1	15278670
risk	O	-1	15278670
due	O	-1	15278670
to	O	-1	15278670
cir@@	O	-1	15278670
cul@@	O	-1	15278670
atory	O	-1	15278670
de@@	B-Disease	D003866	15278670
pression	I-Disease	-1	15278670
.	O	-1	15278670

An@@	O	-1	17042910
ti@@	O	-1	17042910
-@@	O	-1	17042910
oxid@@	O	-1	17042910
ant	O	-1	17042910
effects	O	-1	17042910
of	O	-1	17042910
at@@	B-Chemical	C065179	17042910
or@@	I-Chemical	-1	17042910
vastatin	I-Chemical	-1	17042910
in	O	-1	17042910
de@@	B-Chemical	D003907	17042910
xameth@@	I-Chemical	-1	17042910
as@@	I-Chemical	-1	17042910
one	I-Chemical	-1	17042910
-induced	O	-1	17042910
hypertension	B-Disease	D006973	17042910
in	O	-1	17042910
the	O	-1	17042910
rat@@	O	-1	17042910
.	O	-1	17042910
1@@	O	-1	17042910
.	O	-1	17042910
D@@	B-Chemical	D003907	17042910
ex@@	I-Chemical	-1	17042910
ameth@@	I-Chemical	-1	17042910
as@@	I-Chemical	-1	17042910
one	I-Chemical	-1	17042910
(	O	-1	17042910
De@@	B-Chemical	D003907	17042910
x	I-Chemical	-1	17042910
)@@	O	-1	17042910
-induced	O	-1	17042910
hypertension	B-Disease	D006973	17042910
is	O	-1	17042910
character@@	O	-1	17042910
ized	O	-1	17042910
by	O	-1	17042910
endothelial	O	-1	17042910
dysfunction	O	-1	17042910
associated	O	-1	17042910
with	O	-1	17042910
nit@@	B-Chemical	D009569	17042910
ric	I-Chemical	-1	17042910
ox@@	I-Chemical	-1	17042910
ide	I-Chemical	-1	17042910
(	O	-1	17042910
N@@	B-Chemical	D009569	17042910
O	I-Chemical	-1	17042910
)	O	-1	17042910
defici@@	O	-1	17042910
ency	O	-1	17042910
and	O	-1	17042910
increased	O	-1	17042910
su@@	B-Chemical	D013481	17042910
per@@	I-Chemical	-1	17042910
ox@@	I-Chemical	-1	17042910
ide	I-Chemical	-1	17042910
(	O	-1	17042910
O@@	B-Chemical	D013481	17042910
2@@	I-Chemical	-1	17042910
-	I-Chemical	-1	17042910
)	O	-1	17042910
produc@@	O	-1	17042910
tion.	O	-1	17042910
A@@	B-Chemical	C065179	17042910
t@@	I-Chemical	-1	17042910
or@@	I-Chemical	-1	17042910
vastatin	I-Chemical	-1	17042910
(	O	-1	17042910
A@@	B-Chemical	C065179	17042910
to	I-Chemical	-1	17042910
)	O	-1	17042910
pos@@	O	-1	17042910
s@@	O	-1	17042910
es@@	O	-1	17042910
ses	O	-1	17042910
ple@@	O	-1	17042910
i@@	O	-1	17042910
ot@@	O	-1	17042910
ro@@	O	-1	17042910
p@@	O	-1	17042910
ic	O	-1	17042910
pro@@	O	-1	17042910
per@@	O	-1	17042910
ties	O	-1	17042910
that	O	-1	17042910
have	O	-1	17042910
been	O	-1	17042910
reported	O	-1	17042910
to	O	-1	17042910
impro@@	O	-1	17042910
ve	O	-1	17042910
endothelial	O	-1	17042910
function	O	-1	17042910
through	O	-1	17042910
increased	O	-1	17042910
av@@	O	-1	17042910
ail@@	O	-1	17042910
ability	O	-1	17042910
of	O	-1	17042910
N@@	B-Chemical	D009569	17042910
O	I-Chemical	-1	17042910
and	O	-1	17042910
reduced	O	-1	17042910
O@@	B-Chemical	D013481	17042910
2@@	I-Chemical	-1	17042910
-	I-Chemical	-1	17042910
pro@@	O	-1	17042910
duction	O	-1	17042910
in	O	-1	17042910
various	O	-1	17042910
form@@	O	-1	17042910
s	O	-1	17042910
of	O	-1	17042910
hypertension	B-Disease	D006973	17042910
.	O	-1	17042910
In	O	-1	17042910
the	O	-1	17042910
present	O	-1	17042910
study,	O	-1	17042910
we	O	-1	17042910
investigated	O	-1	17042910
whether	O	-1	17042910
50	O	-1	17042910
mg/kg	O	-1	17042910
per	O	-1	17042910
da@@	O	-1	17042910
y,	O	-1	17042910
p.@@	O	-1	17042910
o@@	O	-1	17042910
.,	O	-1	17042910
A@@	B-Chemical	C065179	17042910
to	I-Chemical	-1	17042910
could	O	-1	17042910
prev@@	O	-1	17042910
ent	O	-1	17042910
endothelial	O	-1	17042910
N@@	B-Chemical	D009569	17042910
O	I-Chemical	-1	17042910
syn@@	O	-1	17042910
th@@	O	-1	17042910
ase	O	-1	17042910
(@@	O	-1	17042910
e@@	O	-1	17042910
NO@@	O	-1	17042910
S)	O	-1	17042910
do@@	O	-1	17042910
w@@	O	-1	17042910
n@@	O	-1	17042910
reg@@	O	-1	17042910
ulation	O	-1	17042910
and	O	-1	17042910
the	O	-1	17042910
increase	O	-1	17042910
in	O	-1	17042910
O@@	B-Chemical	D013481	17042910
2@@	I-Chemical	-1	17042910
-	I-Chemical	-1	17042910
in	O	-1	17042910
S@@	O	-1	17042910
pra@@	O	-1	17042910
gu@@	O	-1	17042910
e-@@	O	-1	17042910
D@@	O	-1	17042910
aw@@	O	-1	17042910
le@@	O	-1	17042910
y	O	-1	17042910
(S@@	O	-1	17042910
D)	O	-1	17042910
rats,	O	-1	17042910
the@@	O	-1	17042910
re@@	O	-1	17042910
by	O	-1	17042910
reduc@@	O	-1	17042910
ing	O	-1	17042910
blood	O	-1	17042910
pressu@@	O	-1	17042910
re.	O	-1	17042910
2@@	O	-1	17042910
.	O	-1	17042910
M@@	O	-1	17042910
al@@	O	-1	17042910
e	O	-1	17042910
S@@	O	-1	17042910
D	O	-1	17042910
rats	O	-1	17042910
(n	O	-1	17042910
=	O	-1	17042910
3@@	O	-1	17042910
0@@	O	-1	17042910
)	O	-1	17042910
were	O	-1	17042910
treated	O	-1	17042910
with	O	-1	17042910
A@@	B-Chemical	C065179	17042910
to	I-Chemical	-1	17042910
(@@	O	-1	17042910
50	O	-1	17042910
mg/kg	O	-1	17042910
per	O	-1	17042910
day	O	-1	17042910
in	O	-1	17042910
d@@	O	-1	17042910
r@@	O	-1	17042910
in@@	O	-1	17042910
king	O	-1	17042910
w@@	O	-1	17042910
at@@	O	-1	17042910
er@@	O	-1	17042910
)	O	-1	17042910
or	O	-1	17042910
t@@	O	-1	17042910
a@@	O	-1	17042910
p	O	-1	17042910
w@@	O	-1	17042910
at@@	O	-1	17042910
er	O	-1	17042910
for	O	-1	17042910
15	O	-1	17042910
days.	O	-1	17042910
D@@	B-Chemical	D003907	17042910
ex@@	I-Chemical	-1	17042910
ameth@@	I-Chemical	-1	17042910
as@@	I-Chemical	-1	17042910
one	I-Chemical	-1	17042910
(10	O	-1	17042910
micro@@	O	-1	17042910
g/@@	O	-1	17042910
k@@	O	-1	17042910
g	O	-1	17042910
per	O	-1	17042910
da@@	O	-1	17042910
y,	O	-1	17042910
s@@	O	-1	17042910
.@@	O	-1	17042910
c@@	O	-1	17042910
.)	O	-1	17042910
or	O	-1	17042910
saline	O	-1	17042910
was	O	-1	17042910
star@@	O	-1	17042910
ted	O	-1	17042910
after	O	-1	17042910
4	O	-1	17042910
days	O	-1	17042910
in	O	-1	17042910
A@@	B-Chemical	C065179	17042910
to	I-Chemical	-1	17042910
-treated	O	-1	17042910
and	O	-1	17042910
non-@@	O	-1	17042910
treated	O	-1	17042910
rats	O	-1	17042910
and	O	-1	17042910
continu@@	O	-1	17042910
ed	O	-1	17042910
for	O	-1	17042910
1@@	O	-1	17042910
1@@	O	-1	17042910
-1@@	O	-1	17042910
3	O	-1	17042910
days.	O	-1	17042910
S@@	O	-1	17042910
y@@	O	-1	17042910
st@@	O	-1	17042910
olic	O	-1	17042910
blood	O	-1	17042910
pressure	O	-1	17042910
(S@@	O	-1	17042910
B@@	O	-1	17042910
P)	O	-1	17042910
was	O	-1	17042910
measured	O	-1	17042910
on	O	-1	17042910
al@@	O	-1	17042910
tern@@	O	-1	17042910
ate	O	-1	17042910
days	O	-1	17042910
using	O	-1	17042910
the	O	-1	17042910
t@@	O	-1	17042910
ail@@	O	-1	17042910
-@@	O	-1	17042910
c@@	O	-1	17042910
u@@	O	-1	17042910
f@@	O	-1	17042910
f	O	-1	17042910
meth@@	O	-1	17042910
o@@	O	-1	17042910
d.	O	-1	17042910
E@@	O	-1	17042910
n@@	O	-1	17042910
do@@	O	-1	17042910
thelial	O	-1	17042910
function	O	-1	17042910
was	O	-1	17042910
assessed	O	-1	17042910
by	O	-1	17042910
acet@@	B-Chemical	D000109	17042910
ylcholine	I-Chemical	-1	17042910
-induced	O	-1	17042910
vas@@	O	-1	17042910
o@@	O	-1	17042910
rel@@	O	-1	17042910
ax@@	O	-1	17042910
ation	O	-1	17042910
and	O	-1	17042910
pheny@@	B-Chemical	D010656	17042910
le@@	I-Chemical	-1	17042910
phrine	I-Chemical	-1	17042910
-induced	O	-1	17042910
vas@@	O	-1	17042910
o@@	O	-1	17042910
con@@	O	-1	17042910
stric@@	O	-1	17042910
tion	O	-1	17042910
in	O	-1	17042910
a@@	O	-1	17042910
or@@	O	-1	17042910
tic	O	-1	17042910
seg@@	O	-1	17042910
ment@@	O	-1	17042910
s.	O	-1	17042910
V@@	O	-1	17042910
as@@	O	-1	17042910
cular	O	-1	17042910
e@@	O	-1	17042910
NO@@	O	-1	17042910
S	O	-1	17042910
mRNA	O	-1	17042910
was	O	-1	17042910
assessed	O	-1	17042910
by	O	-1	17042910
se@@	O	-1	17042910
mi@@	O	-1	17042910
-@@	O	-1	17042910
qu@@	O	-1	17042910
anti@@	O	-1	17042910
t@@	O	-1	17042910
ative	O	-1	17042910
re@@	O	-1	17042910
verse	O	-1	17042910
trans@@	O	-1	17042910
cri@@	O	-1	17042910
p@@	O	-1	17042910
tion@@	O	-1	17042910
-@@	O	-1	17042910
poly@@	O	-1	17042910
mer@@	O	-1	17042910
ase	O	-1	17042910
ch@@	O	-1	17042910
ain	O	-1	17042910
reac@@	O	-1	17042910
tion.	O	-1	17042910
3@@	O	-1	17042910
.	O	-1	17042910
In	O	-1	17042910
rats	O	-1	17042910
treated	O	-1	17042910
with	O	-1	17042910
De@@	B-Chemical	D003907	17042910
x	I-Chemical	-1	17042910
al@@	O	-1	17042910
one,	O	-1	17042910
S@@	O	-1	17042910
B@@	O	-1	17042910
P	O	-1	17042910
was	O	-1	17042910
increased	O	-1	17042910
from	O	-1	17042910
10@@	O	-1	17042910
9	O	-1	17042910
+/-	O	-1	17042910
2	O	-1	17042910
to	O	-1	17042910
13@@	O	-1	17042910
3	O	-1	17042910
+/-	O	-1	17042910
2	O	-1	17042910
mm@@	O	-1	17042910
H@@	O	-1	17042910
g	O	-1	17042910
on	O	-1	17042910
D@@	O	-1	17042910
ays	O	-1	17042910
4	O	-1	17042910
and	O	-1	17042910
D@@	O	-1	17042910
ay	O	-1	17042910
14@@	O	-1	17042910
,	O	-1	17042910
respecti@@	O	-1	17042910
vely	O	-1	17042910
(P	O	-1	17042910
<	O	-1	17042910
0.00@@	O	-1	17042910
1).	O	-1	17042910
In	O	-1	17042910
the	O	-1	17042910
A@@	B-Chemical	C065179	17042910
to	I-Chemical	-1	17042910
+	O	-1	17042910
De@@	B-Chemical	D003907	17042910
x	I-Chemical	-1	17042910
group@@	O	-1	17042910
,	O	-1	17042910
S@@	O	-1	17042910
B@@	O	-1	17042910
P	O	-1	17042910
was	O	-1	17042910
increased	O	-1	17042910
from	O	-1	17042910
1@@	O	-1	17042910
13	O	-1	17042910
+/-	O	-1	17042910
2	O	-1	17042910
to	O	-1	17042910
1@@	O	-1	17042910
1@@	O	-1	17042910
9	O	-1	17042910
+/-	O	-1	17042910
2	O	-1	17042910
mm@@	O	-1	17042910
H@@	O	-1	17042910
g	O	-1	17042910
on	O	-1	17042910
D@@	O	-1	17042910
ays	O	-1	17042910
4	O	-1	17042910
to	O	-1	17042910
14@@	O	-1	17042910
,	O	-1	17042910
respecti@@	O	-1	17042910
vely	O	-1	17042910
(P	O	-1	17042910
<	O	-1	17042910
0.00@@	O	-1	17042910
1),	O	-1	17042910
but	O	-1	17042910
was	O	-1	17042910
significantly	O	-1	17042910
lower	O	-1	17042910
than	O	-1	17042910
S@@	O	-1	17042910
B@@	O	-1	17042910
P	O	-1	17042910
in	O	-1	17042910
the	O	-1	17042910
group	O	-1	17042910
treated	O	-1	17042910
with	O	-1	17042910
De@@	B-Chemical	D003907	17042910
x	I-Chemical	-1	17042910
alone	O	-1	17042910
(P	O	-1	17042910
<	O	-1	17042910
0.05@@	O	-1	17042910
).	O	-1	17042910
E@@	O	-1	17042910
n@@	O	-1	17042910
do@@	O	-1	17042910
the@@	O	-1	17042910
li@@	O	-1	17042910
al@@	O	-1	17042910
-@@	O	-1	17042910
dependent	O	-1	17042910
rel@@	O	-1	17042910
ax@@	O	-1	17042910
ation	O	-1	17042910
and	O	-1	17042910
e@@	O	-1	17042910
NO@@	O	-1	17042910
S	O	-1	17042910
mRNA	O	-1	17042910
expression	O	-1	17042910
were	O	-1	17042910
greater	O	-1	17042910
in	O	-1	17042910
the	O	-1	17042910
De@@	B-Chemical	D003907	17042910
x	I-Chemical	-1	17042910
+	O	-1	17042910
A@@	B-Chemical	C065179	17042910
to	I-Chemical	-1	17042910
group	O	-1	17042910
than	O	-1	17042910
in	O	-1	17042910
the	O	-1	17042910
De@@	B-Chemical	D003907	17042910
x	I-Chemical	-1	17042910
only	O	-1	17042910
group	O	-1	17042910
(P	O	-1	17042910
<	O	-1	17042910
0.0@@	O	-1	17042910
5	O	-1	17042910
and	O	-1	17042910
P	O	-1	17042910
<	O	-1	17042910
0.00@@	O	-1	17042910
0@@	O	-1	17042910
1,	O	-1	17042910
respectivel@@	O	-1	17042910
y@@	O	-1	17042910
).	O	-1	17042910
A@@	O	-1	17042910
or@@	O	-1	17042910
tic	O	-1	17042910
su@@	B-Chemical	D013481	17042910
per@@	I-Chemical	-1	17042910
ox@@	I-Chemical	-1	17042910
ide	I-Chemical	-1	17042910
pro@@	O	-1	17042910
duction	O	-1	17042910
was	O	-1	17042910
lower	O	-1	17042910
in	O	-1	17042910
the	O	-1	17042910
De@@	B-Chemical	D003907	17042910
x	I-Chemical	-1	17042910
+	O	-1	17042910
A@@	B-Chemical	C065179	17042910
to	I-Chemical	-1	17042910
group	O	-1	17042910
compared	O	-1	17042910
with	O	-1	17042910
the	O	-1	17042910
group	O	-1	17042910
treated	O	-1	17042910
with	O	-1	17042910
De@@	B-Chemical	D003907	17042910
x	I-Chemical	-1	17042910
alone	O	-1	17042910
(P	O	-1	17042910
<	O	-1	17042910
0.00@@	O	-1	17042910
0@@	O	-1	17042910
1).	O	-1	17042910
4@@	O	-1	17042910
.	O	-1	17042910
Treat@@	O	-1	17042910
ment	O	-1	17042910
with	O	-1	17042910
A@@	B-Chemical	C065179	17042910
to	I-Chemical	-1	17042910
improved	O	-1	17042910
endothelial	O	-1	17042910
func@@	O	-1	17042910
tion,	O	-1	17042910
reduced	O	-1	17042910
su@@	B-Chemical	D013481	17042910
per@@	I-Chemical	-1	17042910
ox@@	I-Chemical	-1	17042910
ide	I-Chemical	-1	17042910
pro@@	O	-1	17042910
duction	O	-1	17042910
and	O	-1	17042910
reduced	O	-1	17042910
S@@	O	-1	17042910
B@@	O	-1	17042910
P	O	-1	17042910
in	O	-1	17042910
De@@	B-Chemical	D003907	17042910
x	I-Chemical	-1	17042910
-treated	O	-1	17042910
S@@	O	-1	17042910
D	O	-1	17042910
rats.	O	-1	17042910

9@@	B-Chemical	C067171	11897407
9@@	I-Chemical	-1	11897407
m@@	I-Chemical	-1	11897407
T@@	I-Chemical	-1	11897407
c@@	I-Chemical	-1	11897407
-@@	I-Chemical	-1	11897407
gl@@	I-Chemical	-1	11897407
uc@@	I-Chemical	-1	11897407
ar@@	I-Chemical	-1	11897407
ate	I-Chemical	-1	11897407
for	O	-1	11897407
det@@	O	-1	11897407
ection	O	-1	11897407
of	O	-1	11897407
isoproteren@@	B-Chemical	D007545	11897407
ol	I-Chemical	-1	11897407
-induced	O	-1	11897407
myocardial	B-Disease	D009203	11897407
infarction	I-Disease	-1	11897407
in	O	-1	11897407
rats.	O	-1	11897407
In@@	B-Disease	D007238	11897407
f@@	I-Disease	-1	11897407
arc@@	I-Disease	-1	11897407
t	I-Disease	-1	11897407
-@@	O	-1	11897407
avi@@	O	-1	11897407
d	O	-1	11897407
radi@@	O	-1	11897407
oph@@	O	-1	11897407
ar@@	O	-1	11897407
m@@	O	-1	11897407
ace@@	O	-1	11897407
u@@	O	-1	11897407
tic@@	O	-1	11897407
als	O	-1	11897407
are	O	-1	11897407
nec@@	O	-1	11897407
ess@@	O	-1	11897407
ary	O	-1	11897407
for	O	-1	11897407
ra@@	O	-1	11897407
pid	O	-1	11897407
and	O	-1	11897407
ti@@	O	-1	11897407
me@@	O	-1	11897407
ly	O	-1	11897407
diagnosis	O	-1	11897407
of	O	-1	11897407
acute	O	-1	11897407
myocardial	B-Disease	D009203	11897407
infarction	I-Disease	-1	11897407
.	O	-1	11897407
The	O	-1	11897407
anim@@	O	-1	11897407
al	O	-1	11897407
model	O	-1	11897407
used	O	-1	11897407
to	O	-1	11897407
produce	O	-1	11897407
infarction	B-Disease	D007238	11897407
im@@	O	-1	11897407
pl@@	O	-1	11897407
i@@	O	-1	11897407
es	O	-1	11897407
artery	O	-1	11897407
li@@	O	-1	11897407
g@@	O	-1	11897407
ation	O	-1	11897407
but	O	-1	11897407
chemical	O	-1	11897407
induction	O	-1	11897407
can	O	-1	11897407
be	O	-1	11897407
e@@	O	-1	11897407
a@@	O	-1	11897407
si@@	O	-1	11897407
ly	O	-1	11897407
obtained	O	-1	11897407
with	O	-1	11897407
isoproteren@@	B-Chemical	D007545	11897407
ol	I-Chemical	-1	11897407
.	O	-1	11897407
A	O	-1	11897407
new	O	-1	11897407
infarc@@	B-Disease	D007238	11897407
t	I-Disease	-1	11897407
-@@	O	-1	11897407
avi@@	O	-1	11897407
d	O	-1	11897407
radi@@	O	-1	11897407
oph@@	O	-1	11897407
ar@@	O	-1	11897407
m@@	O	-1	11897407
ace@@	O	-1	11897407
u@@	O	-1	11897407
tical	O	-1	11897407
bas@@	O	-1	11897407
ed	O	-1	11897407
on	O	-1	11897407
gl@@	B-Chemical	D005937	11897407
uc@@	I-Chemical	-1	11897407
ar@@	I-Chemical	-1	11897407
ic	I-Chemical	-1	11897407
acid	I-Chemical	-1	11897407
was	O	-1	11897407
pre@@	O	-1	11897407
pared	O	-1	11897407
in	O	-1	11897407
the	O	-1	11897407
hospit@@	O	-1	11897407
al	O	-1	11897407
radi@@	O	-1	11897407
oph@@	O	-1	11897407
armac@@	O	-1	11897407
y	O	-1	11897407
of	O	-1	11897407
the	O	-1	11897407
IN@@	O	-1	11897407
C@@	O	-1	11897407
M@@	O	-1	11897407
N@@	O	-1	11897407
S@@	O	-1	11897407
Z@@	O	-1	11897407
.	O	-1	11897407
9@@	B-Chemical	C067171	11897407
9@@	I-Chemical	-1	11897407
m@@	I-Chemical	-1	11897407
T@@	I-Chemical	-1	11897407
c@@	I-Chemical	-1	11897407
-@@	I-Chemical	-1	11897407
gl@@	I-Chemical	-1	11897407
uc@@	I-Chemical	-1	11897407
ar@@	I-Chemical	-1	11897407
ate	I-Chemical	-1	11897407
was	O	-1	11897407
e@@	O	-1	11897407
as@@	O	-1	11897407
y	O	-1	11897407
to	O	-1	11897407
pre@@	O	-1	11897407
pa@@	O	-1	11897407
re,	O	-1	11897407
st@@	O	-1	11897407
able	O	-1	11897407
for	O	-1	11897407
9@@	O	-1	11897407
6	O	-1	11897407
h	O	-1	11897407
and	O	-1	11897407
was	O	-1	11897407
used	O	-1	11897407
to	O	-1	11897407
study	O	-1	11897407
its	O	-1	11897407
bio@@	O	-1	11897407
di@@	O	-1	11897407
stri@@	O	-1	11897407
bu@@	O	-1	11897407
tion	O	-1	11897407
in	O	-1	11897407
rats	O	-1	11897407
with	O	-1	11897407
isoproteren@@	B-Chemical	D007545	11897407
ol	I-Chemical	-1	11897407
-induced	O	-1	11897407
acute	O	-1	11897407
myocardial	B-Disease	D009203	11897407
infarction	I-Disease	-1	11897407
.	O	-1	11897407
H@@	O	-1	11897407
ist@@	O	-1	11897407
ological	O	-1	11897407
studies	O	-1	11897407
demonstrated	O	-1	11897407
that	O	-1	11897407
the	O	-1	11897407
rats	O	-1	11897407
developed	O	-1	11897407
an	O	-1	11897407
infarc@@	B-Disease	D007238	11897407
t	I-Disease	-1	11897407
1@@	O	-1	11897407
8	O	-1	11897407
h	O	-1	11897407
after	O	-1	11897407
isoproteren@@	B-Chemical	D007545	11897407
ol	I-Chemical	-1	11897407
administr@@	O	-1	11897407
ation.	O	-1	11897407
The	O	-1	11897407
rat	O	-1	11897407
bio@@	O	-1	11897407
di@@	O	-1	11897407
stri@@	O	-1	11897407
bu@@	O	-1	11897407
tion	O	-1	11897407
studies	O	-1	11897407
showed	O	-1	11897407
a	O	-1	11897407
ra@@	O	-1	11897407
pid	O	-1	11897407
blood	O	-1	11897407
clear@@	O	-1	11897407
ance	O	-1	11897407
vi@@	O	-1	11897407
a	O	-1	11897407
the	O	-1	11897407
kidne@@	O	-1	11897407
y@@	O	-1	11897407
s.	O	-1	11897407
Th@@	O	-1	11897407
ir@@	O	-1	11897407
t@@	O	-1	11897407
y	O	-1	11897407
minutes	O	-1	11897407
after	O	-1	11897407
9@@	B-Chemical	C067171	11897407
9@@	I-Chemical	-1	11897407
m@@	I-Chemical	-1	11897407
T@@	I-Chemical	-1	11897407
c@@	I-Chemical	-1	11897407
-@@	I-Chemical	-1	11897407
gl@@	I-Chemical	-1	11897407
uc@@	I-Chemical	-1	11897407
ar@@	I-Chemical	-1	11897407
ate	I-Chemical	-1	11897407
administration	O	-1	11897407
the	O	-1	11897407
stand@@	O	-1	11897407
ar@@	O	-1	11897407
dis@@	O	-1	11897407
ed	O	-1	11897407
heart	O	-1	11897407
u@@	O	-1	11897407
pt@@	O	-1	11897407
ake	O	-1	11897407
valu@@	O	-1	11897407
e	O	-1	11897407
S@@	O	-1	11897407
(@@	O	-1	11897407
h@@	O	-1	11897407
)@@	O	-1	11897407
U@@	O	-1	11897407
V	O	-1	11897407
was	O	-1	11897407
4.@@	O	-1	11897407
7	O	-1	11897407
in	O	-1	11897407
infarc@@	O	-1	11897407
ted	O	-1	11897407
rat	O	-1	11897407
heart	O	-1	11897407
which	O	-1	11897407
is	O	-1	11897407
six	O	-1	11897407
times	O	-1	11897407
more	O	-1	11897407
than	O	-1	11897407
in	O	-1	11897407
normal	O	-1	11897407
rats.	O	-1	11897407
RO@@	O	-1	11897407
I@@	O	-1	11897407
s	O	-1	11897407
draw@@	O	-1	11897407
n	O	-1	11897407
over	O	-1	11897407
the	O	-1	11897407
gam@@	O	-1	11897407
ma	O	-1	11897407
c@@	O	-1	11897407
am@@	O	-1	11897407
er@@	O	-1	11897407
a	O	-1	11897407
imag@@	O	-1	11897407
es	O	-1	11897407
showed	O	-1	11897407
a	O	-1	11897407
rati@@	O	-1	11897407
o	O	-1	11897407
of	O	-1	11897407
4.@@	O	-1	11897407
4@@	O	-1	11897407
.	O	-1	11897407
The	O	-1	11897407
high	O	-1	11897407
im@@	O	-1	11897407
age	O	-1	11897407
qu@@	O	-1	11897407
ality	O	-1	11897407
suggests	O	-1	11897407
that	O	-1	11897407
high	O	-1	11897407
contr@@	O	-1	11897407
ast	O	-1	11897407
imag@@	O	-1	11897407
es	O	-1	11897407
can	O	-1	11897407
be	O	-1	11897407
obtained	O	-1	11897407
in	O	-1	11897407
hum@@	O	-1	11897407
ans	O	-1	11897407
and	O	-1	11897407
the	O	-1	11897407
9@@	O	-1	11897407
6	O	-1	11897407
h	O	-1	11897407
st@@	O	-1	11897407
ability	O	-1	11897407
ma@@	O	-1	11897407
k@@	O	-1	11897407
es	O	-1	11897407
it	O	-1	11897407
an	O	-1	11897407
ide@@	O	-1	11897407
al	O	-1	11897407
agent	O	-1	11897407
to	O	-1	11897407
det@@	O	-1	11897407
ect@@	O	-1	11897407
,	O	-1	11897407
in	O	-1	11897407
patients,	O	-1	11897407
early	O	-1	11897407
cardiac	B-Disease	D009203	11897407
infarction	I-Disease	-1	11897407
.	O	-1	11897407

A	O	-1	9812111
random@@	O	-1	9812111
iz@@	O	-1	9812111
ed,	O	-1	9812111
placebo@@	O	-1	9812111
-@@	O	-1	9812111
controlled	O	-1	9812111
dose-@@	O	-1	9812111
compar@@	O	-1	9812111
ison	O	-1	9812111
trial	O	-1	9812111
of	O	-1	9812111
haloperidol	B-Chemical	D006220	9812111
for	O	-1	9812111
psycho@@	B-Disease	D011618	9812111
sis	I-Disease	-1	9812111
and	O	-1	9812111
dis@@	B-Disease	D019958	9812111
ru@@	I-Disease	-1	9812111
p@@	I-Disease	-1	9812111
tive	I-Disease	-1	9812111
behavi@@	I-Disease	-1	9812111
ors	I-Disease	-1	9812111
in	O	-1	9812111
Al@@	B-Disease	D000544	9812111
z@@	I-Disease	-1	9812111
he@@	I-Disease	-1	9812111
im@@	I-Disease	-1	9812111
er@@	I-Disease	-1	9812111
's	I-Disease	-1	9812111
disease	I-Disease	-1	9812111
.	O	-1	9812111
OBJECTIVE:	O	-1	9812111
The	O	-1	9812111
go@@	O	-1	9812111
al	O	-1	9812111
of	O	-1	9812111
this	O	-1	9812111
study	O	-1	9812111
was	O	-1	9812111
to	O	-1	9812111
compar@@	O	-1	9812111
e	O	-1	9812111
the	O	-1	9812111
efficacy	O	-1	9812111
and	O	-1	9812111
side	O	-1	9812111
effects	O	-1	9812111
of	O	-1	9812111
two	O	-1	9812111
doses	O	-1	9812111
of	O	-1	9812111
haloperidol	B-Chemical	D006220	9812111
and	O	-1	9812111
placebo	O	-1	9812111
in	O	-1	9812111
the	O	-1	9812111
treatment	O	-1	9812111
of	O	-1	9812111
psycho@@	B-Disease	D011618	9812111
sis	I-Disease	-1	9812111
and	O	-1	9812111
dis@@	B-Disease	D019958	9812111
ru@@	I-Disease	-1	9812111
p@@	I-Disease	-1	9812111
tive	I-Disease	-1	9812111
behavi@@	I-Disease	-1	9812111
ors	I-Disease	-1	9812111
in	O	-1	9812111
patients	O	-1	9812111
with	O	-1	9812111
Al@@	B-Disease	D000544	9812111
z@@	I-Disease	-1	9812111
he@@	I-Disease	-1	9812111
im@@	I-Disease	-1	9812111
er@@	I-Disease	-1	9812111
's	I-Disease	-1	9812111
disease	I-Disease	-1	9812111
.	O	-1	9812111
METHOD@@	O	-1	9812111
:	O	-1	9812111
In	O	-1	9812111
a	O	-1	9812111
6-@@	O	-1	9812111
week	O	-1	9812111
random@@	O	-1	9812111
-@@	O	-1	9812111
as@@	O	-1	9812111
sign@@	O	-1	9812111
ment@@	O	-1	9812111
,	O	-1	9812111
double-bl@@	O	-1	9812111
ind@@	O	-1	9812111
,	O	-1	9812111
placebo@@	O	-1	9812111
-@@	O	-1	9812111
controlled	O	-1	9812111
trial	O	-1	9812111
(@@	O	-1	9812111
phase	O	-1	9812111
A@@	O	-1	9812111
),	O	-1	9812111
haloperidol	B-Chemical	D006220	9812111
,	O	-1	9812111
2-@@	O	-1	9812111
3	O	-1	9812111
mg/@@	O	-1	9812111
day	O	-1	9812111
(@@	O	-1	9812111
standard	O	-1	9812111
dose@@	O	-1	9812111
),	O	-1	9812111
and	O	-1	9812111
haloperidol	B-Chemical	D006220	9812111
,	O	-1	9812111
0.@@	O	-1	9812111
50@@	O	-1	9812111
-@@	O	-1	9812111
0.@@	O	-1	9812111
7@@	O	-1	9812111
5	O	-1	9812111
mg/@@	O	-1	9812111
day	O	-1	9812111
(@@	O	-1	9812111
low	O	-1	9812111
dose@@	O	-1	9812111
),	O	-1	9812111
were	O	-1	9812111
compared	O	-1	9812111
in	O	-1	9812111
7@@	O	-1	9812111
1	O	-1	9812111
out@@	O	-1	9812111
patients	O	-1	9812111
with	O	-1	9812111
Al@@	B-Disease	D000544	9812111
z@@	I-Disease	-1	9812111
he@@	I-Disease	-1	9812111
im@@	I-Disease	-1	9812111
er@@	I-Disease	-1	9812111
's	I-Disease	-1	9812111
disease	I-Disease	-1	9812111
.	O	-1	9812111
F@@	O	-1	9812111
or	O	-1	9812111
the	O	-1	9812111
subsequ@@	O	-1	9812111
ent	O	-1	9812111
6-@@	O	-1	9812111
week	O	-1	9812111
double-bl@@	O	-1	9812111
ind	O	-1	9812111
cros@@	O	-1	9812111
s@@	O	-1	9812111
over	O	-1	9812111
phase	O	-1	9812111
(@@	O	-1	9812111
phase	O	-1	9812111
B@@	O	-1	9812111
),	O	-1	9812111
patients	O	-1	9812111
taking	O	-1	9812111
stand@@	O	-1	9812111
ar@@	O	-1	9812111
d@@	O	-1	9812111
-	O	-1	9812111
or	O	-1	9812111
low@@	O	-1	9812111
-@@	O	-1	9812111
dose	O	-1	9812111
haloperidol	B-Chemical	D006220	9812111
were	O	-1	9812111
switch@@	O	-1	9812111
ed	O	-1	9812111
to	O	-1	9812111
placebo@@	O	-1	9812111
,	O	-1	9812111
and	O	-1	9812111
patients	O	-1	9812111
taking	O	-1	9812111
placebo	O	-1	9812111
were	O	-1	9812111
random@@	O	-1	9812111
ly	O	-1	9812111
as@@	O	-1	9812111
signed	O	-1	9812111
to	O	-1	9812111
stand@@	O	-1	9812111
ar@@	O	-1	9812111
d@@	O	-1	9812111
-	O	-1	9812111
or	O	-1	9812111
low@@	O	-1	9812111
-@@	O	-1	9812111
dose	O	-1	9812111
haloperidol	B-Chemical	D006220	9812111
.	O	-1	9812111
RESULTS:	O	-1	9812111
F@@	O	-1	9812111
or	O	-1	9812111
the	O	-1	9812111
60	O	-1	9812111
patients	O	-1	9812111
who	O	-1	9812111
comple@@	O	-1	9812111
ted	O	-1	9812111
phase	O	-1	9812111
A@@	O	-1	9812111
,	O	-1	9812111
stand@@	O	-1	9812111
ar@@	O	-1	9812111
d-@@	O	-1	9812111
dose	O	-1	9812111
haloperidol	B-Chemical	D006220	9812111
was	O	-1	9812111
efficac@@	O	-1	9812111
i@@	O	-1	9812111
ous	O	-1	9812111
and	O	-1	9812111
su@@	O	-1	9812111
peri@@	O	-1	9812111
or	O	-1	9812111
to	O	-1	9812111
both	O	-1	9812111
low@@	O	-1	9812111
-@@	O	-1	9812111
dose	O	-1	9812111
haloperidol	B-Chemical	D006220	9812111
and	O	-1	9812111
placebo	O	-1	9812111
for	O	-1	9812111
sco@@	O	-1	9812111
res	O	-1	9812111
on	O	-1	9812111
the	O	-1	9812111
B@@	O	-1	9812111
ri@@	O	-1	9812111
e@@	O	-1	9812111
f	O	-1	9812111
P@@	O	-1	9812111
sy@@	O	-1	9812111
ch@@	O	-1	9812111
i@@	O	-1	9812111
atric	O	-1	9812111
R@@	O	-1	9812111
ating	O	-1	9812111
S@@	O	-1	9812111
cal@@	O	-1	9812111
e	O	-1	9812111
psycho@@	B-Disease	D011618	9812111
sis	I-Disease	-1	9812111
factor	O	-1	9812111
and	O	-1	9812111
on	O	-1	9812111
psych@@	B-Disease	D011595	9812111
om@@	I-Disease	-1	9812111
otor	I-Disease	-1	9812111
ag@@	I-Disease	-1	9812111
it@@	I-Disease	-1	9812111
ation	I-Disease	-1	9812111
.	O	-1	9812111
R@@	O	-1	9812111
es@@	O	-1	9812111
p@@	O	-1	9812111
on@@	O	-1	9812111
se	O	-1	9812111
rat@@	O	-1	9812111
es	O	-1	9812111
ac@@	O	-1	9812111
cor@@	O	-1	9812111
ding	O	-1	9812111
to	O	-1	9812111
three	O	-1	9812111
se@@	O	-1	9812111
ts	O	-1	9812111
of	O	-1	9812111
c@@	O	-1	9812111
rit@@	O	-1	9812111
er@@	O	-1	9812111
ia	O	-1	9812111
were	O	-1	9812111
greater	O	-1	9812111
with	O	-1	9812111
the	O	-1	9812111
standard	O	-1	9812111
dose	O	-1	9812111
(5@@	O	-1	9812111
5@@	O	-1	9812111
%@@	O	-1	9812111
-@@	O	-1	9812111
6@@	O	-1	9812111
0@@	O	-1	9812111
%)	O	-1	9812111
than	O	-1	9812111
the	O	-1	9812111
low	O	-1	9812111
dose	O	-1	9812111
(2@@	O	-1	9812111
5@@	O	-1	9812111
%@@	O	-1	9812111
-@@	O	-1	9812111
3@@	O	-1	9812111
5@@	O	-1	9812111
%)	O	-1	9812111
and	O	-1	9812111
placebo	O	-1	9812111
(2@@	O	-1	9812111
5@@	O	-1	9812111
%@@	O	-1	9812111
-@@	O	-1	9812111
3@@	O	-1	9812111
0@@	O	-1	9812111
%).	O	-1	9812111
The	O	-1	9812111
adv@@	O	-1	9812111
ant@@	O	-1	9812111
age	O	-1	9812111
of	O	-1	9812111
standard	O	-1	9812111
dose	O	-1	9812111
over	O	-1	9812111
low	O	-1	9812111
dose	O	-1	9812111
was	O	-1	9812111
re@@	O	-1	9812111
plic@@	O	-1	9812111
ated	O	-1	9812111
in	O	-1	9812111
phase	O	-1	9812111
B@@	O	-1	9812111
.	O	-1	9812111
In	O	-1	9812111
phase	O	-1	9812111
A@@	O	-1	9812111
,	O	-1	9812111
ext@@	B-Disease	D001480	9812111
ra@@	I-Disease	-1	9812111
py@@	I-Disease	-1	9812111
ram@@	I-Disease	-1	9812111
idal	I-Disease	-1	9812111
signs	I-Disease	-1	9812111
ten@@	O	-1	9812111
ded	O	-1	9812111
to	O	-1	9812111
be	O	-1	9812111
greater	O	-1	9812111
with	O	-1	9812111
the	O	-1	9812111
standard	O	-1	9812111
dose	O	-1	9812111
than	O	-1	9812111
in	O	-1	9812111
the	O	-1	9812111
other	O	-1	9812111
two	O	-1	9812111
condi@@	O	-1	9812111
tion@@	O	-1	9812111
s,	O	-1	9812111
prim@@	O	-1	9812111
ari@@	O	-1	9812111
ly	O	-1	9812111
because	O	-1	9812111
of	O	-1	9812111
a	O	-1	9812111
sub@@	O	-1	9812111
group	O	-1	9812111
(2@@	O	-1	9812111
0@@	O	-1	9812111
%)	O	-1	9812111
who	O	-1	9812111
developed	O	-1	9812111
moder@@	O	-1	9812111
ate	O	-1	9812111
to	O	-1	9812111
severe	O	-1	9812111
sign@@	O	-1	9812111
s.	O	-1	9812111
L@@	O	-1	9812111
o@@	O	-1	9812111
w@@	O	-1	9812111
-@@	O	-1	9812111
dose	O	-1	9812111
haloperidol	B-Chemical	D006220	9812111
did	O	-1	9812111
not	O	-1	9812111
diff@@	O	-1	9812111
er	O	-1	9812111
from	O	-1	9812111
placebo	O	-1	9812111
on	O	-1	9812111
any	O	-1	9812111
meas@@	O	-1	9812111
ure	O	-1	9812111
of	O	-1	9812111
efficacy	O	-1	9812111
or	O	-1	9812111
side	O	-1	9812111
effects.	O	-1	9812111
CONCLUSIONS:	O	-1	9812111
The	O	-1	9812111
results	O	-1	9812111
indic@@	O	-1	9812111
ated	O	-1	9812111
a	O	-1	9812111
f@@	O	-1	9812111
av@@	O	-1	9812111
or@@	O	-1	9812111
able	O	-1	9812111
therapeutic	O	-1	9812111
prof@@	O	-1	9812111
ile	O	-1	9812111
for	O	-1	9812111
haloperidol	B-Chemical	D006220	9812111
in	O	-1	9812111
doses	O	-1	9812111
of	O	-1	9812111
2-@@	O	-1	9812111
3	O	-1	9812111
mg/@@	O	-1	9812111
da@@	O	-1	9812111
y,	O	-1	9812111
although	O	-1	9812111
a	O	-1	9812111
sub@@	O	-1	9812111
group	O	-1	9812111
developed	O	-1	9812111
moder@@	O	-1	9812111
ate	O	-1	9812111
to	O	-1	9812111
severe	O	-1	9812111
ext@@	B-Disease	D001480	9812111
ra@@	I-Disease	-1	9812111
py@@	I-Disease	-1	9812111
ram@@	I-Disease	-1	9812111
idal	I-Disease	-1	9812111
signs	I-Disease	-1	9812111
.	O	-1	9812111
A	O	-1	9812111
star@@	O	-1	9812111
ting	O	-1	9812111
dose	O	-1	9812111
of	O	-1	9812111
1	O	-1	9812111
mg/@@	O	-1	9812111
day	O	-1	9812111
with	O	-1	9812111
gra@@	O	-1	9812111
du@@	O	-1	9812111
al,	O	-1	9812111
up@@	O	-1	9812111
war@@	O	-1	9812111
d	O	-1	9812111
dose	O	-1	9812111
ti@@	O	-1	9812111
t@@	O	-1	9812111
ration	O	-1	9812111
is	O	-1	9812111
recomm@@	O	-1	9812111
en@@	O	-1	9812111
de@@	O	-1	9812111
d.	O	-1	9812111
The	O	-1	9812111
n@@	O	-1	9812111
ar@@	O	-1	9812111
ro@@	O	-1	9812111
w	O	-1	9812111
therapeutic	O	-1	9812111
w@@	O	-1	9812111
in@@	O	-1	9812111
do@@	O	-1	9812111
w	O	-1	9812111
observed	O	-1	9812111
with	O	-1	9812111
haloperidol	B-Chemical	D006220	9812111
may	O	-1	9812111
also	O	-1	9812111
app@@	O	-1	9812111
ly	O	-1	9812111
to	O	-1	9812111
other	O	-1	9812111
neuro@@	O	-1	9812111
le@@	O	-1	9812111
p@@	O	-1	9812111
tics	O	-1	9812111
used	O	-1	9812111
in	O	-1	9812111
Al@@	B-Disease	D000544	9812111
z@@	I-Disease	-1	9812111
he@@	I-Disease	-1	9812111
im@@	I-Disease	-1	9812111
er@@	I-Disease	-1	9812111
's	I-Disease	-1	9812111
disease	I-Disease	-1	9812111
patients	O	-1	9812111
with	O	-1	9812111
psycho@@	B-Disease	D011618	9812111
sis	I-Disease	-1	9812111
and	O	-1	9812111
dis@@	B-Disease	D019958	9812111
ru@@	I-Disease	-1	9812111
p@@	I-Disease	-1	9812111
tive	I-Disease	-1	9812111
behavi@@	I-Disease	-1	9812111
ors	I-Disease	-1	9812111
.	O	-1	9812111

In@@	O	-1	15572383
divid@@	O	-1	15572383
ual	O	-1	15572383
differences	O	-1	15572383
in	O	-1	15572383
renal	O	-1	15572383
AC@@	O	-1	15572383
E	O	-1	15572383
activity	O	-1	15572383
in	O	-1	15572383
healthy	O	-1	15572383
rats	O	-1	15572383
predic@@	O	-1	15572383
t	O	-1	15572383
sus@@	O	-1	15572383
cep@@	O	-1	15572383
ti@@	O	-1	15572383
b@@	O	-1	15572383
ility	O	-1	15572383
to	O	-1	15572383
adriam@@	B-Chemical	D004317	15572383
ycin	I-Chemical	-1	15572383
-induced	O	-1	15572383
renal	B-Disease	D007674	15572383
damage	I-Disease	-1	15572383
.	O	-1	15572383
BACKGROUND:	O	-1	15572383
In	O	-1	15572383
man@@	O	-1	15572383
,	O	-1	15572383
differences	O	-1	15572383
in	O	-1	15572383
angiotens@@	B-Chemical	D000809	15572383
in	I-Chemical	-1	15572383
-@@	O	-1	15572383
conver@@	O	-1	15572383
ting	O	-1	15572383
enzyme	O	-1	15572383
(@@	O	-1	15572383
AC@@	O	-1	15572383
E@@	O	-1	15572383
)	O	-1	15572383
level@@	O	-1	15572383
s,	O	-1	15572383
related	O	-1	15572383
to	O	-1	15572383
AC@@	O	-1	15572383
E	O	-1	15572383
(@@	O	-1	15572383
I@@	O	-1	15572383
/@@	O	-1	15572383
D)	O	-1	15572383
gen@@	O	-1	15572383
ot@@	O	-1	15572383
yp@@	O	-1	15572383
e,	O	-1	15572383
are	O	-1	15572383
associated	O	-1	15572383
with	O	-1	15572383
renal	O	-1	15572383
pro@@	O	-1	15572383
g@@	O	-1	15572383
no@@	O	-1	15572383
sis.	O	-1	15572383
This	O	-1	15572383
ra@@	O	-1	15572383
i@@	O	-1	15572383
ses	O	-1	15572383
the	O	-1	15572383
hypo@@	O	-1	15572383
thesis	O	-1	15572383
that	O	-1	15572383
individ@@	O	-1	15572383
ual	O	-1	15572383
differences	O	-1	15572383
in	O	-1	15572383
renal	O	-1	15572383
AC@@	O	-1	15572383
E	O	-1	15572383
activity	O	-1	15572383
are	O	-1	15572383
involved	O	-1	15572383
in	O	-1	15572383
renal	O	-1	15572383
sus@@	O	-1	15572383
cep@@	O	-1	15572383
ti@@	O	-1	15572383
b@@	O	-1	15572383
ility	O	-1	15572383
to	O	-1	15572383
inf@@	O	-1	15572383
l@@	O	-1	15572383
ic@@	O	-1	15572383
ted	O	-1	15572383
dam@@	O	-1	15572383
age.	O	-1	15572383
The@@	O	-1	15572383
refore,	O	-1	15572383
we	O	-1	15572383
studied	O	-1	15572383
the	O	-1	15572383
predic@@	O	-1	15572383
tive	O	-1	15572383
effect	O	-1	15572383
of	O	-1	15572383
renal	O	-1	15572383
AC@@	O	-1	15572383
E	O	-1	15572383
activity	O	-1	15572383
for	O	-1	15572383
the	O	-1	15572383
severity	O	-1	15572383
of	O	-1	15572383
renal	B-Disease	D007674	15572383
damage	I-Disease	-1	15572383
induced	O	-1	15572383
by	O	-1	15572383
a	O	-1	15572383
single	O	-1	15572383
injection	O	-1	15572383
of	O	-1	15572383
adriam@@	B-Chemical	D004317	15572383
ycin	I-Chemical	-1	15572383
in	O	-1	15572383
rats.	O	-1	15572383
METHODS:	O	-1	15572383
R@@	O	-1	15572383
en@@	O	-1	15572383
al	O	-1	15572383
AC@@	O	-1	15572383
E	O	-1	15572383
activity	O	-1	15572383
(	O	-1	15572383
H@@	B-Chemical	C010980	15572383
ip@@	I-Chemical	-1	15572383
-H@@	I-Chemical	-1	15572383
is@@	I-Chemical	-1	15572383
-@@	I-Chemical	-1	15572383
L@@	I-Chemical	-1	15572383
e@@	I-Chemical	-1	15572383
u	I-Chemical	-1	15572383
c@@	O	-1	15572383
le@@	O	-1	15572383
av@@	O	-1	15572383
age	O	-1	15572383
by	O	-1	15572383
cor@@	O	-1	15572383
tical	O	-1	15572383
ho@@	O	-1	15572383
mo@@	O	-1	15572383
gen@@	O	-1	15572383
at@@	O	-1	15572383
es@@	O	-1	15572383
)	O	-1	15572383
was	O	-1	15572383
determined	O	-1	15572383
by	O	-1	15572383
renal	O	-1	15572383
biop@@	O	-1	15572383
sy	O	-1	15572383
in	O	-1	15572383
2@@	O	-1	15572383
7	O	-1	15572383
ad@@	O	-1	15572383
ult	O	-1	15572383
male	O	-1	15572383
Wistar	O	-1	15572383
rats.	O	-1	15572383
After	O	-1	15572383
1	O	-1	15572383
week	O	-1	15572383
of	O	-1	15572383
reco@@	O	-1	15572383
ver@@	O	-1	15572383
y,	O	-1	15572383
proteinuria	B-Disease	D011507	15572383
was	O	-1	15572383
induced	O	-1	15572383
by	O	-1	15572383
adriam@@	B-Chemical	D004317	15572383
ycin	I-Chemical	-1	15572383
[@@	O	-1	15572383
1.@@	O	-1	15572383
5	O	-1	15572383
mg/kg	O	-1	15572383
intra@@	O	-1	15572383
ven@@	O	-1	15572383
ously	O	-1	15572383
(@@	O	-1	15572383
i.v@@	O	-1	15572383
.)	O	-1	15572383
n	O	-1	15572383
=	O	-1	15572383
18@@	O	-1	15572383
;	O	-1	15572383
control@@	O	-1	15572383
s,	O	-1	15572383
saline	O	-1	15572383
i.v@@	O	-1	15572383
.	O	-1	15572383
n	O	-1	15572383
=	O	-1	15572383
9@@	O	-1	15572383
]@@	O	-1	15572383
.	O	-1	15572383
Pro@@	B-Disease	D011507	15572383
te@@	I-Disease	-1	15572383
in@@	I-Disease	-1	15572383
uria	I-Disease	-1	15572383
was	O	-1	15572383
measured	O	-1	15572383
every	O	-1	15572383
2	O	-1	15572383
week@@	O	-1	15572383
s.	O	-1	15572383
After	O	-1	15572383
12	O	-1	15572383
week@@	O	-1	15572383
s,	O	-1	15572383
rats	O	-1	15572383
were	O	-1	15572383
s@@	O	-1	15572383
ac@@	O	-1	15572383
ri@@	O	-1	15572383
fic@@	O	-1	15572383
ed	O	-1	15572383
and	O	-1	15572383
their	O	-1	15572383
kidne@@	O	-1	15572383
ys	O	-1	15572383
h@@	O	-1	15572383
ar@@	O	-1	15572383
ve@@	O	-1	15572383
st@@	O	-1	15572383
ed.	O	-1	15572383
RESULTS:	O	-1	15572383
A@@	O	-1	15572383
s	O	-1	15572383
anti@@	O	-1	15572383
ci@@	O	-1	15572383
pat@@	O	-1	15572383
ed,	O	-1	15572383
adriam@@	B-Chemical	D004317	15572383
ycin	I-Chemical	-1	15572383
el@@	O	-1	15572383
ic@@	O	-1	15572383
ited	O	-1	15572383
nephro@@	B-Disease	D009404	15572383
tic	I-Disease	-1	15572383
range	O	-1	15572383
proteinuria	B-Disease	D011507	15572383
,	O	-1	15572383
renal	B-Disease	D007674	15572383
interstitial	I-Disease	-1	15572383
damage	I-Disease	-1	15572383
and	O	-1	15572383
mil@@	O	-1	15572383
d	O	-1	15572383
foc@@	B-Disease	D005923	15572383
al	I-Disease	-1	15572383
glomer@@	I-Disease	-1	15572383
u@@	I-Disease	-1	15572383
los@@	I-Disease	-1	15572383
clero@@	I-Disease	-1	15572383
sis	I-Disease	-1	15572383
.	O	-1	15572383
B@@	O	-1	15572383
as@@	O	-1	15572383
el@@	O	-1	15572383
ine	O	-1	15572383
renal	O	-1	15572383
AC@@	O	-1	15572383
E	O	-1	15572383
posi@@	O	-1	15572383
ti@@	O	-1	15572383
vely	O	-1	15572383
cor@@	O	-1	15572383
related	O	-1	15572383
with	O	-1	15572383
the	O	-1	15572383
rel@@	O	-1	15572383
ative	O	-1	15572383
ri@@	O	-1	15572383
se	O	-1	15572383
in	O	-1	15572383
proteinuria	B-Disease	D011507	15572383
after	O	-1	15572383
adriam@@	B-Chemical	D004317	15572383
ycin	I-Chemical	-1	15572383
(@@	O	-1	15572383
r	O	-1	15572383
=	O	-1	15572383
0.@@	O	-1	15572383
6@@	O	-1	15572383
2,	O	-1	15572383
P@@	O	-1	15572383
<@@	O	-1	15572383
0.0@@	O	-1	15572383
1),	O	-1	15572383
renal	O	-1	15572383
interstitial	O	-1	15572383
alpha-@@	O	-1	15572383
smo@@	O	-1	15572383
oth	O	-1	15572383
musc@@	O	-1	15572383
le	O	-1	15572383
actin	O	-1	15572383
(@@	O	-1	15572383
r	O	-1	15572383
=	O	-1	15572383
0.@@	O	-1	15572383
4@@	O	-1	15572383
9@@	O	-1	15572383
,	O	-1	15572383
P@@	O	-1	15572383
<@@	O	-1	15572383
0.05@@	O	-1	15572383
),	O	-1	15572383
interstitial	O	-1	15572383
mac@@	O	-1	15572383
ro@@	O	-1	15572383
ph@@	O	-1	15572383
age	O	-1	15572383
influ@@	O	-1	15572383
x	O	-1	15572383
(@@	O	-1	15572383
r	O	-1	15572383
=	O	-1	15572383
0.@@	O	-1	15572383
5@@	O	-1	15572383
6,	O	-1	15572383
P@@	O	-1	15572383
<@@	O	-1	15572383
0.05@@	O	-1	15572383
),	O	-1	15572383
interstitial	O	-1	15572383
coll@@	O	-1	15572383
ag@@	O	-1	15572383
en	O	-1	15572383
I@@	O	-1	15572383
II	O	-1	15572383
(@@	O	-1	15572383
r	O	-1	15572383
=	O	-1	15572383
0.@@	O	-1	15572383
5@@	O	-1	15572383
3,	O	-1	15572383
P@@	O	-1	15572383
<@@	O	-1	15572383
0.05@@	O	-1	15572383
),	O	-1	15572383
glomerular	O	-1	15572383
alpha-@@	O	-1	15572383
smo@@	O	-1	15572383
oth	O	-1	15572383
musc@@	O	-1	15572383
le	O	-1	15572383
actin	O	-1	15572383
(@@	O	-1	15572383
r	O	-1	15572383
=	O	-1	15572383
0.@@	O	-1	15572383
7@@	O	-1	15572383
4@@	O	-1	15572383
,	O	-1	15572383
P@@	O	-1	15572383
<@@	O	-1	15572383
0.0@@	O	-1	15572383
1)	O	-1	15572383
and	O	-1	15572383
glomerular	O	-1	15572383
des@@	O	-1	15572383
min	O	-1	15572383
(@@	O	-1	15572383
r	O	-1	15572383
=	O	-1	15572383
0.@@	O	-1	15572383
4@@	O	-1	15572383
8@@	O	-1	15572383
,	O	-1	15572383
P@@	O	-1	15572383
<@@	O	-1	15572383
0.05@@	O	-1	15572383
).	O	-1	15572383
B@@	O	-1	15572383
as@@	O	-1	15572383
el@@	O	-1	15572383
ine	O	-1	15572383
renal	O	-1	15572383
AC@@	O	-1	15572383
E	O	-1	15572383
did	O	-1	15572383
not	O	-1	15572383
correl@@	O	-1	15572383
ate	O	-1	15572383
with	O	-1	15572383
foc@@	B-Disease	D005923	15572383
al	I-Disease	-1	15572383
glomer@@	I-Disease	-1	15572383
u@@	I-Disease	-1	15572383
los@@	I-Disease	-1	15572383
clero@@	I-Disease	-1	15572383
sis	I-Disease	-1	15572383
(@@	O	-1	15572383
r	O	-1	15572383
=	O	-1	15572383
0.@@	O	-1	15572383
2@@	O	-1	15572383
2,	O	-1	15572383
N@@	O	-1	15572383
S@@	O	-1	15572383
).	O	-1	15572383
In	O	-1	15572383
control@@	O	-1	15572383
s,	O	-1	15572383
no	O	-1	15572383
predic@@	O	-1	15572383
tive	O	-1	15572383
values	O	-1	15572383
for	O	-1	15572383
renal	O	-1	15572383
par@@	O	-1	15572383
ame@@	O	-1	15572383
ters	O	-1	15572383
were	O	-1	15572383
obser@@	O	-1	15572383
ved.	O	-1	15572383
CONCLUSION:	O	-1	15572383
In@@	O	-1	15572383
divid@@	O	-1	15572383
ual	O	-1	15572383
differences	O	-1	15572383
in	O	-1	15572383
renal	O	-1	15572383
AC@@	O	-1	15572383
E	O	-1	15572383
activity	O	-1	15572383
predic@@	O	-1	15572383
t	O	-1	15572383
the	O	-1	15572383
severity	O	-1	15572383
of	O	-1	15572383
adriam@@	B-Chemical	D004317	15572383
ycin	I-Chemical	-1	15572383
-induced	O	-1	15572383
renal	B-Disease	D007674	15572383
damage	I-Disease	-1	15572383
in	O	-1	15572383
this	O	-1	15572383
out@@	O	-1	15572383
b@@	O	-1	15572383
red	O	-1	15572383
rat	O	-1	15572383
stra@@	O	-1	15572383
in.	O	-1	15572383
This	O	-1	15572383
suppor@@	O	-1	15572383
ts	O	-1	15572383
the	O	-1	15572383
as@@	O	-1	15572383
sum@@	O	-1	15572383
ption	O	-1	15572383
that	O	-1	15572383
differences	O	-1	15572383
in	O	-1	15572383
renal	O	-1	15572383
AC@@	O	-1	15572383
E	O	-1	15572383
activity	O	-1	15572383
pre@@	O	-1	15572383
dis@@	O	-1	15572383
p@@	O	-1	15572383
ose	O	-1	15572383
to	O	-1	15572383
a	O	-1	15572383
less	O	-1	15572383
f@@	O	-1	15572383
av@@	O	-1	15572383
o@@	O	-1	15572383
ur@@	O	-1	15572383
able	O	-1	15572383
course	O	-1	15572383
of	O	-1	15572383
renal	B-Disease	D007674	15572383
damage	I-Disease	-1	15572383
.	O	-1	15572383

Clin@@	O	-1	7420681
ical	O	-1	7420681
nephro@@	B-Disease	D007674	7420681
toxicity	I-Disease	-1	7420681
of	O	-1	7420681
to@@	B-Chemical	D014031	7420681
b@@	I-Chemical	-1	7420681
ram@@	I-Chemical	-1	7420681
ycin	I-Chemical	-1	7420681
and	O	-1	7420681
g@@	B-Chemical	D005839	7420681
ent@@	I-Chemical	-1	7420681
am@@	I-Chemical	-1	7420681
icin	I-Chemical	-1	7420681
.	O	-1	7420681
A	O	-1	7420681
pro@@	O	-1	7420681
sp@@	O	-1	7420681
ective	O	-1	7420681
study.	O	-1	7420681
N@@	O	-1	7420681
early	O	-1	7420681
3.@@	O	-1	7420681
2	O	-1	7420681
mil@@	O	-1	7420681
li@@	O	-1	7420681
on	O	-1	7420681
pe@@	O	-1	7420681
o@@	O	-1	7420681
ple	O	-1	7420681
in	O	-1	7420681
this	O	-1	7420681
coun@@	O	-1	7420681
tr@@	O	-1	7420681
y	O	-1	7420681
recei@@	O	-1	7420681
ve	O	-1	7420681
amino@@	B-Chemical	D000617	7420681
gly@@	I-Chemical	-1	7420681
co@@	I-Chemical	-1	7420681
side	I-Chemical	-1	7420681
anti@@	O	-1	7420681
bio@@	O	-1	7420681
tics	O	-1	7420681
an@@	O	-1	7420681
n@@	O	-1	7420681
u@@	O	-1	7420681
all@@	O	-1	7420681
y.	O	-1	7420681
G@@	B-Chemical	D005839	7420681
ent@@	I-Chemical	-1	7420681
am@@	I-Chemical	-1	7420681
icin	I-Chemical	-1	7420681
sulf@@	I-Chemical	-1	7420681
ate	I-Chemical	-1	7420681
and	O	-1	7420681
to@@	B-Chemical	D014031	7420681
b@@	I-Chemical	-1	7420681
ram@@	I-Chemical	-1	7420681
ycin	I-Chemical	-1	7420681
sulf@@	I-Chemical	-1	7420681
ate	I-Chemical	-1	7420681
continu@@	O	-1	7420681
e	O	-1	7420681
to	O	-1	7420681
demon@@	O	-1	7420681
st@@	O	-1	7420681
rate	O	-1	7420681
ot@@	B-Disease	D006311	7420681
otoxicity	I-Disease	-1	7420681
and	O	-1	7420681
nephro@@	B-Disease	D007674	7420681
toxicity	I-Disease	-1	7420681
in	O	-1	7420681
both	O	-1	7420681
anim@@	O	-1	7420681
al	O	-1	7420681
and	O	-1	7420681
clinical	O	-1	7420681
studi@@	O	-1	7420681
es.	O	-1	7420681
In	O	-1	7420681
this	O	-1	7420681
study,	O	-1	7420681
6@@	O	-1	7420681
2	O	-1	7420681
patients	O	-1	7420681
with	O	-1	7420681
con@@	O	-1	7420681
fir@@	O	-1	7420681
m@@	O	-1	7420681
ed	O	-1	7420681
initial	O	-1	7420681
normal	O	-1	7420681
renal	O	-1	7420681
function	O	-1	7420681
and	O	-1	7420681
treated	O	-1	7420681
with	O	-1	7420681
2	O	-1	7420681
to	O	-1	7420681
5	O	-1	7420681
mg/k@@	O	-1	7420681
g/@@	O	-1	7420681
day	O	-1	7420681
of	O	-1	7420681
g@@	B-Chemical	D005839	7420681
ent@@	I-Chemical	-1	7420681
am@@	I-Chemical	-1	7420681
icin	I-Chemical	-1	7420681
sulf@@	I-Chemical	-1	7420681
ate	I-Chemical	-1	7420681
or	O	-1	7420681
to@@	B-Chemical	D014031	7420681
b@@	I-Chemical	-1	7420681
ram@@	I-Chemical	-1	7420681
ycin	I-Chemical	-1	7420681
sulf@@	I-Chemical	-1	7420681
ate	I-Chemical	-1	7420681
for	O	-1	7420681
a	O	-1	7420681
minim@@	O	-1	7420681
um	O	-1	7420681
of	O	-1	7420681
seven	O	-1	7420681
days	O	-1	7420681
were	O	-1	7420681
followed	O	-1	7420681
up	O	-1	7420681
pro@@	O	-1	7420681
sp@@	O	-1	7420681
ectively	O	-1	7420681
for	O	-1	7420681
the	O	-1	7420681
development	O	-1	7420681
of	O	-1	7420681
amino@@	B-Chemical	D000617	7420681
gly@@	I-Chemical	-1	7420681
co@@	I-Chemical	-1	7420681
side	I-Chemical	-1	7420681
-@@	O	-1	7420681
related	O	-1	7420681
renal	B-Disease	D051437	7420681
failure	I-Disease	-1	7420681
,	O	-1	7420681
def@@	O	-1	7420681
in@@	O	-1	7420681
ed	O	-1	7420681
as	O	-1	7420681
at	O	-1	7420681
le@@	O	-1	7420681
ast	O	-1	7420681
a	O	-1	7420681
on@@	O	-1	7420681
e-@@	O	-1	7420681
thir@@	O	-1	7420681
d	O	-1	7420681
reduction	O	-1	7420681
in	O	-1	7420681
renal	O	-1	7420681
func@@	O	-1	7420681
tion.	O	-1	7420681
In	O	-1	7420681
these	O	-1	7420681
6@@	O	-1	7420681
2	O	-1	7420681
patients,	O	-1	7420681
no	O	-1	7420681
other	O	-1	7420681
causes	O	-1	7420681
for	O	-1	7420681
renal	B-Disease	D051437	7420681
failure	I-Disease	-1	7420681
could	O	-1	7420681
be	O	-1	7420681
identi@@	O	-1	7420681
fi@@	O	-1	7420681
ed.	O	-1	7420681
F@@	O	-1	7420681
i@@	O	-1	7420681
ve	O	-1	7420681
of	O	-1	7420681
3@@	O	-1	7420681
3	O	-1	7420681
(1@@	O	-1	7420681
5@@	O	-1	7420681
%)	O	-1	7420681
of	O	-1	7420681
the	O	-1	7420681
to@@	B-Chemical	D014031	7420681
b@@	I-Chemical	-1	7420681
ram@@	I-Chemical	-1	7420681
ycin	I-Chemical	-1	7420681
-treated	O	-1	7420681
patients	O	-1	7420681
and	O	-1	7420681
16	O	-1	7420681
of	O	-1	7420681
2@@	O	-1	7420681
9	O	-1	7420681
(5@@	O	-1	7420681
5.@@	O	-1	7420681
2@@	O	-1	7420681
%)	O	-1	7420681
of	O	-1	7420681
the	O	-1	7420681
g@@	B-Chemical	D005839	7420681
ent@@	I-Chemical	-1	7420681
am@@	I-Chemical	-1	7420681
icin	I-Chemical	-1	7420681
-treated	O	-1	7420681
patients	O	-1	7420681
had	O	-1	7420681
renal	B-Disease	D051437	7420681
failure	I-Disease	-1	7420681
.	O	-1	7420681
Th@@	O	-1	7420681
us,	O	-1	7420681
g@@	B-Chemical	D005839	7420681
ent@@	I-Chemical	-1	7420681
am@@	I-Chemical	-1	7420681
icin	I-Chemical	-1	7420681
was	O	-1	7420681
associated	O	-1	7420681
with	O	-1	7420681
renal	B-Disease	D051437	7420681
failure	I-Disease	-1	7420681
more	O	-1	7420681
than	O	-1	7420681
three	O	-1	7420681
times	O	-1	7420681
as	O	-1	7420681
often	O	-1	7420681
as	O	-1	7420681
was	O	-1	7420681
to@@	B-Chemical	D014031	7420681
b@@	I-Chemical	-1	7420681
ram@@	I-Chemical	-1	7420681
ycin	I-Chemical	-1	7420681
.	O	-1	7420681

Ne@@	O	-1	12907309
uro@@	O	-1	12907309
protective	O	-1	12907309
action	O	-1	12907309
of	O	-1	12907309
MP@@	B-Chemical	C121465	12907309
E@@	I-Chemical	-1	12907309
P	I-Chemical	-1	12907309
,	O	-1	12907309
a	O	-1	12907309
selective	O	-1	12907309
m@@	O	-1	12907309
G@@	O	-1	12907309
lu@@	O	-1	12907309
R@@	O	-1	12907309
5	O	-1	12907309
antagonist@@	O	-1	12907309
,	O	-1	12907309
in	O	-1	12907309
meth@@	B-Chemical	D008694	12907309
amphetamine	I-Chemical	-1	12907309
-induced	O	-1	12907309
dop@@	O	-1	12907309
aminergic	O	-1	12907309
neuro@@	B-Disease	D020258	12907309
toxicity	I-Disease	-1	12907309
is	O	-1	12907309
associated	O	-1	12907309
with	O	-1	12907309
a	O	-1	12907309
decrease	O	-1	12907309
in	O	-1	12907309
dopamine	B-Chemical	D004298	12907309
out@@	O	-1	12907309
flow	O	-1	12907309
and	O	-1	12907309
inhibition	O	-1	12907309
of	O	-1	12907309
hyper@@	B-Disease	D005334	12907309
ther@@	I-Disease	-1	12907309
mia	I-Disease	-1	12907309
in	O	-1	12907309
rats.	O	-1	12907309
The	O	-1	12907309
a@@	O	-1	12907309
im	O	-1	12907309
of	O	-1	12907309
this	O	-1	12907309
study	O	-1	12907309
was	O	-1	12907309
to	O	-1	12907309
ex@@	O	-1	12907309
amine	O	-1	12907309
the	O	-1	12907309
role	O	-1	12907309
of	O	-1	12907309
met@@	O	-1	12907309
ab@@	O	-1	12907309
ot@@	O	-1	12907309
ro@@	O	-1	12907309
p@@	O	-1	12907309
ic	O	-1	12907309
glutamate	B-Chemical	D018698	12907309
receptor	O	-1	12907309
5	O	-1	12907309
(@@	O	-1	12907309
m@@	O	-1	12907309
G@@	O	-1	12907309
lu@@	O	-1	12907309
R@@	O	-1	12907309
5@@	O	-1	12907309
)	O	-1	12907309
in	O	-1	12907309
the	O	-1	12907309
toxic	O	-1	12907309
action	O	-1	12907309
of	O	-1	12907309
meth@@	B-Chemical	D008694	12907309
amphetamine	I-Chemical	-1	12907309
on	O	-1	12907309
dop@@	O	-1	12907309
aminergic	O	-1	12907309
neuron@@	O	-1	12907309
es	O	-1	12907309
in	O	-1	12907309
rats.	O	-1	12907309
M@@	B-Chemical	D008694	12907309
eth@@	I-Chemical	-1	12907309
amphetamine	I-Chemical	-1	12907309
(10	O	-1	12907309
mg/kg	O	-1	12907309
s@@	O	-1	12907309
c@@	O	-1	12907309
),	O	-1	12907309
administered	O	-1	12907309
five	O	-1	12907309
tim@@	O	-1	12907309
es,	O	-1	12907309
reduced	O	-1	12907309
the	O	-1	12907309
levels	O	-1	12907309
of	O	-1	12907309
dopamine	B-Chemical	D004298	12907309
and	O	-1	12907309
its	O	-1	12907309
metabol@@	O	-1	12907309
it@@	O	-1	12907309
es	O	-1	12907309
in	O	-1	12907309
stri@@	O	-1	12907309
atal	O	-1	12907309
tissue	O	-1	12907309
when	O	-1	12907309
measured	O	-1	12907309
7@@	O	-1	12907309
2	O	-1	12907309
h	O	-1	12907309
after	O	-1	12907309
the	O	-1	12907309
las@@	O	-1	12907309
t	O	-1	12907309
injec@@	O	-1	12907309
tion.	O	-1	12907309
A	O	-1	12907309
selective	O	-1	12907309
antagonist	O	-1	12907309
of	O	-1	12907309
m@@	O	-1	12907309
G@@	O	-1	12907309
lu@@	O	-1	12907309
R@@	O	-1	12907309
5,	O	-1	12907309
2-@@	B-Chemical	C121465	12907309
methyl@@	I-Chemical	-1	12907309
-@@	I-Chemical	-1	12907309
6-@@	I-Chemical	-1	12907309
(@@	I-Chemical	-1	12907309
pheny@@	I-Chemical	-1	12907309
le@@	I-Chemical	-1	12907309
th@@	I-Chemical	-1	12907309
yn@@	I-Chemical	-1	12907309
yl@@	I-Chemical	-1	12907309
)@@	I-Chemical	-1	12907309
pyri@@	I-Chemical	-1	12907309
d@@	I-Chemical	-1	12907309
ine	I-Chemical	-1	12907309
(	O	-1	12907309
MP@@	B-Chemical	C121465	12907309
E@@	I-Chemical	-1	12907309
P	I-Chemical	-1	12907309
;	O	-1	12907309
5	O	-1	12907309
mg/kg	O	-1	12907309
ip@@	O	-1	12907309
),	O	-1	12907309
when	O	-1	12907309
administered	O	-1	12907309
five	O	-1	12907309
times	O	-1	12907309
immedi@@	O	-1	12907309
ately	O	-1	12907309
before	O	-1	12907309
each	O	-1	12907309
meth@@	B-Chemical	D008694	12907309
amphetamine	I-Chemical	-1	12907309
injection	O	-1	12907309
reversed	O	-1	12907309
the	O	-1	12907309
ab@@	O	-1	12907309
o@@	O	-1	12907309
ve@@	O	-1	12907309
-@@	O	-1	12907309
men@@	O	-1	12907309
tion@@	O	-1	12907309
ed	O	-1	12907309
meth@@	B-Chemical	D008694	12907309
amphetamine	I-Chemical	-1	12907309
effects.	O	-1	12907309
A	O	-1	12907309
single	O	-1	12907309
MP@@	B-Chemical	C121465	12907309
E@@	I-Chemical	-1	12907309
P	I-Chemical	-1	12907309
(@@	O	-1	12907309
5	O	-1	12907309
mg/kg	O	-1	12907309
ip@@	O	-1	12907309
)	O	-1	12907309
injection	O	-1	12907309
reduced	O	-1	12907309
the	O	-1	12907309
bas@@	O	-1	12907309
al	O	-1	12907309
extrac@@	O	-1	12907309
ell@@	O	-1	12907309
ular	O	-1	12907309
dopamine	B-Chemical	D004298	12907309
level	O	-1	12907309
in	O	-1	12907309
the	O	-1	12907309
striat@@	O	-1	12907309
um,	O	-1	12907309
as	O	-1	12907309
well	O	-1	12907309
as	O	-1	12907309
dopamine	B-Chemical	D004298	12907309
release	O	-1	12907309
stimul@@	O	-1	12907309
ated	O	-1	12907309
either	O	-1	12907309
by	O	-1	12907309
meth@@	B-Chemical	D008694	12907309
amphetamine	I-Chemical	-1	12907309
(10	O	-1	12907309
mg/kg	O	-1	12907309
s@@	O	-1	12907309
c@@	O	-1	12907309
)	O	-1	12907309
or	O	-1	12907309
by	O	-1	12907309
intra@@	O	-1	12907309
striat@@	O	-1	12907309
ally	O	-1	12907309
administered	O	-1	12907309
ver@@	B-Chemical	D014701	12907309
atri@@	I-Chemical	-1	12907309
d@@	I-Chemical	-1	12907309
ine	I-Chemical	-1	12907309
(@@	O	-1	12907309
100	O	-1	12907309
micro@@	O	-1	12907309
M@@	O	-1	12907309
).	O	-1	12907309
M@@	O	-1	12907309
ore@@	O	-1	12907309
o@@	O	-1	12907309
ver,	O	-1	12907309
it	O	-1	12907309
transi@@	O	-1	12907309
ently	O	-1	12907309
di@@	O	-1	12907309
min@@	O	-1	12907309
ished	O	-1	12907309
the	O	-1	12907309
meth@@	B-Chemical	D008694	12907309
amphetamine	I-Chemical	-1	12907309
(10	O	-1	12907309
mg/kg	O	-1	12907309
s@@	O	-1	12907309
c@@	O	-1	12907309
)@@	O	-1	12907309
-induced	O	-1	12907309
hyper@@	B-Disease	D005334	12907309
ther@@	I-Disease	-1	12907309
mia	I-Disease	-1	12907309
and	O	-1	12907309
reduced	O	-1	12907309
bas@@	O	-1	12907309
al	O	-1	12907309
body	O	-1	12907309
tem@@	O	-1	12907309
per@@	O	-1	12907309
at@@	O	-1	12907309
ure.	O	-1	12907309
MP@@	B-Chemical	C121465	12907309
E@@	I-Chemical	-1	12907309
P	I-Chemical	-1	12907309
administered	O	-1	12907309
into	O	-1	12907309
the	O	-1	12907309
striat@@	O	-1	12907309
um	O	-1	12907309
at	O	-1	12907309
high	O	-1	12907309
concentrations	O	-1	12907309
(5@@	O	-1	12907309
00	O	-1	12907309
micro@@	O	-1	12907309
M@@	O	-1	12907309
)	O	-1	12907309
increased	O	-1	12907309
extrac@@	O	-1	12907309
ell@@	O	-1	12907309
ular	O	-1	12907309
dopamine	B-Chemical	D004298	12907309
level@@	O	-1	12907309
s,	O	-1	12907309
while	O	-1	12907309
lower	O	-1	12907309
concentrations	O	-1	12907309
(@@	O	-1	12907309
50@@	O	-1	12907309
-@@	O	-1	12907309
100	O	-1	12907309
micro@@	O	-1	12907309
M@@	O	-1	12907309
)	O	-1	12907309
were	O	-1	12907309
de@@	O	-1	12907309
v@@	O	-1	12907309
oid	O	-1	12907309
of	O	-1	12907309
any	O	-1	12907309
effect@@	O	-1	12907309
.	O	-1	12907309
The	O	-1	12907309
results	O	-1	12907309
of	O	-1	12907309
this	O	-1	12907309
study	O	-1	12907309
suggest	O	-1	12907309
that	O	-1	12907309
the	O	-1	12907309
block@@	O	-1	12907309
ade	O	-1	12907309
of	O	-1	12907309
m@@	O	-1	12907309
G@@	O	-1	12907309
lu@@	O	-1	12907309
R@@	O	-1	12907309
5	O	-1	12907309
by	O	-1	12907309
MP@@	B-Chemical	C121465	12907309
E@@	I-Chemical	-1	12907309
P	I-Chemical	-1	12907309
may	O	-1	12907309
prot@@	O	-1	12907309
ect	O	-1	12907309
dop@@	O	-1	12907309
aminergic	O	-1	12907309
neuron@@	O	-1	12907309
es	O	-1	12907309
against	O	-1	12907309
meth@@	B-Chemical	D008694	12907309
amphetamine	I-Chemical	-1	12907309
-induced	O	-1	12907309
toxicity	B-Disease	D064420	12907309
.	O	-1	12907309
Ne@@	O	-1	12907309
uro@@	O	-1	12907309
prot@@	O	-1	12907309
ection	O	-1	12907309
ren@@	O	-1	12907309
de@@	O	-1	12907309
red	O	-1	12907309
by	O	-1	12907309
MP@@	B-Chemical	C121465	12907309
E@@	I-Chemical	-1	12907309
P	I-Chemical	-1	12907309
may	O	-1	12907309
be	O	-1	12907309
associated	O	-1	12907309
with	O	-1	12907309
the	O	-1	12907309
reduction	O	-1	12907309
of	O	-1	12907309
the	O	-1	12907309
meth@@	B-Chemical	D008694	12907309
amphetamine	I-Chemical	-1	12907309
-induced	O	-1	12907309
dopamine	B-Chemical	D004298	12907309
eff@@	O	-1	12907309
lu@@	O	-1	12907309
x	O	-1	12907309
in	O	-1	12907309
the	O	-1	12907309
striat@@	O	-1	12907309
um	O	-1	12907309
due	O	-1	12907309
to	O	-1	12907309
the	O	-1	12907309
block@@	O	-1	12907309
ade	O	-1	12907309
of	O	-1	12907309
ext@@	O	-1	12907309
ra@@	O	-1	12907309
stri@@	O	-1	12907309
atal	O	-1	12907309
m@@	O	-1	12907309
G@@	O	-1	12907309
lu@@	O	-1	12907309
R@@	O	-1	12907309
5,	O	-1	12907309
and	O	-1	12907309
with	O	-1	12907309
a	O	-1	12907309
decrease	O	-1	12907309
in	O	-1	12907309
hyper@@	B-Disease	D005334	12907309
ther@@	I-Disease	-1	12907309
mia	I-Disease	-1	12907309
.	O	-1	12907309

Ph@@	O	-1	16680561
armac@@	O	-1	16680561
o@@	O	-1	16680561
kine@@	O	-1	16680561
tics	O	-1	16680561
of	O	-1	16680561
desi@@	B-Chemical	D003891	16680561
pramine	I-Chemical	-1	16680561
HC@@	I-Chemical	-1	16680561
l	I-Chemical	-1	16680561
when	O	-1	16680561
administered	O	-1	16680561
with	O	-1	16680561
cin@@	B-Chemical	C476217	16680561
ac@@	I-Chemical	-1	16680561
al@@	I-Chemical	-1	16680561
ce@@	I-Chemical	-1	16680561
t	I-Chemical	-1	16680561
HC@@	I-Chemical	-1	16680561
l	I-Chemical	-1	16680561
.	O	-1	16680561
OBJECTIVE:	O	-1	16680561
In	O	-1	16680561
vit@@	O	-1	16680561
r@@	O	-1	16680561
o	O	-1	16680561
wor@@	O	-1	16680561
k	O	-1	16680561
has	O	-1	16680561
demonstrated	O	-1	16680561
that	O	-1	16680561
cin@@	B-Chemical	C476217	16680561
ac@@	I-Chemical	-1	16680561
al@@	I-Chemical	-1	16680561
ce@@	I-Chemical	-1	16680561
t	I-Chemical	-1	16680561
is	O	-1	16680561
a	O	-1	16680561
st@@	O	-1	16680561
ron@@	O	-1	16680561
g	O	-1	16680561
inhibitor	O	-1	16680561
of	O	-1	16680561
cyto@@	O	-1	16680561
ch@@	O	-1	16680561
rom@@	O	-1	16680561
e	O	-1	16680561
P@@	O	-1	16680561
4@@	O	-1	16680561
50	O	-1	16680561
iso@@	O	-1	16680561
enzyme	O	-1	16680561
(C@@	O	-1	16680561
Y@@	O	-1	16680561
P)	O	-1	16680561
2@@	O	-1	16680561
D@@	O	-1	16680561
6@@	O	-1	16680561
.	O	-1	16680561
The	O	-1	16680561
pur@@	O	-1	16680561
p@@	O	-1	16680561
ose	O	-1	16680561
of	O	-1	16680561
this	O	-1	16680561
study	O	-1	16680561
was	O	-1	16680561
to	O	-1	16680561
evalu@@	O	-1	16680561
ate	O	-1	16680561
the	O	-1	16680561
effect	O	-1	16680561
of	O	-1	16680561
cin@@	B-Chemical	C476217	16680561
ac@@	I-Chemical	-1	16680561
al@@	I-Chemical	-1	16680561
ce@@	I-Chemical	-1	16680561
t	I-Chemical	-1	16680561
on	O	-1	16680561
C@@	O	-1	16680561
Y@@	O	-1	16680561
P@@	O	-1	16680561
2@@	O	-1	16680561
D@@	O	-1	16680561
6	O	-1	16680561
activ@@	O	-1	16680561
ity,	O	-1	16680561
using	O	-1	16680561
desi@@	B-Chemical	D003891	16680561
pramine	I-Chemical	-1	16680561
as	O	-1	16680561
a	O	-1	16680561
pro@@	O	-1	16680561
be	O	-1	16680561
sub@@	O	-1	16680561
strat@@	O	-1	16680561
e,	O	-1	16680561
in	O	-1	16680561
healthy	O	-1	16680561
subj@@	O	-1	16680561
ect@@	O	-1	16680561
s.	O	-1	16680561
METHODS:	O	-1	16680561
S@@	O	-1	16680561
event@@	O	-1	16680561
e@@	O	-1	16680561
en	O	-1	16680561
subjects	O	-1	16680561
who	O	-1	16680561
were	O	-1	16680561
gen@@	O	-1	16680561
ot@@	O	-1	16680561
yp@@	O	-1	16680561
ed	O	-1	16680561
as	O	-1	16680561
C@@	O	-1	16680561
Y@@	O	-1	16680561
P@@	O	-1	16680561
2@@	O	-1	16680561
D@@	O	-1	16680561
6	O	-1	16680561
exten@@	O	-1	16680561
sive	O	-1	16680561
metabol@@	O	-1	16680561
iz@@	O	-1	16680561
ers	O	-1	16680561
were	O	-1	16680561
en@@	O	-1	16680561
ro@@	O	-1	16680561
lled	O	-1	16680561
in	O	-1	16680561
this	O	-1	16680561
random@@	O	-1	16680561
iz@@	O	-1	16680561
ed,	O	-1	16680561
o@@	O	-1	16680561
pen@@	O	-1	16680561
-@@	O	-1	16680561
l@@	O	-1	16680561
a@@	O	-1	16680561
be@@	O	-1	16680561
l@@	O	-1	16680561
,	O	-1	16680561
cros@@	O	-1	16680561
s@@	O	-1	16680561
over	O	-1	16680561
study	O	-1	16680561
to	O	-1	16680561
recei@@	O	-1	16680561
ve	O	-1	16680561
a	O	-1	16680561
single	O	-1	16680561
oral	O	-1	16680561
dose	O	-1	16680561
of	O	-1	16680561
desi@@	B-Chemical	D003891	16680561
pramine	I-Chemical	-1	16680561
(@@	O	-1	16680561
50	O	-1	16680561
mg@@	O	-1	16680561
)	O	-1	16680561
on	O	-1	16680561
two	O	-1	16680561
se@@	O	-1	16680561
par@@	O	-1	16680561
ate	O	-1	16680561
oc@@	O	-1	16680561
ca@@	O	-1	16680561
sion@@	O	-1	16680561
s,	O	-1	16680561
on@@	O	-1	16680561
ce	O	-1	16680561
alone	O	-1	16680561
and	O	-1	16680561
on@@	O	-1	16680561
ce	O	-1	16680561
after	O	-1	16680561
multiple	O	-1	16680561
doses	O	-1	16680561
of	O	-1	16680561
cin@@	B-Chemical	C476217	16680561
ac@@	I-Chemical	-1	16680561
al@@	I-Chemical	-1	16680561
ce@@	I-Chemical	-1	16680561
t	I-Chemical	-1	16680561
(@@	O	-1	16680561
9@@	O	-1	16680561
0	O	-1	16680561
mg	O	-1	16680561
for	O	-1	16680561
7	O	-1	16680561
da@@	O	-1	16680561
ys@@	O	-1	16680561
).	O	-1	16680561
B@@	O	-1	16680561
lo@@	O	-1	16680561
od	O	-1	16680561
sam@@	O	-1	16680561
ple@@	O	-1	16680561
s	O	-1	16680561
were	O	-1	16680561
obtained	O	-1	16680561
pre@@	O	-1	16680561
dose	O	-1	16680561
and	O	-1	16680561
up	O	-1	16680561
to	O	-1	16680561
7@@	O	-1	16680561
2	O	-1	16680561
h	O	-1	16680561
post@@	O	-1	16680561
dose.	O	-1	16680561
RESULTS:	O	-1	16680561
F@@	O	-1	16680561
o@@	O	-1	16680561
ur@@	O	-1	16680561
te@@	O	-1	16680561
en	O	-1	16680561
subjects	O	-1	16680561
comple@@	O	-1	16680561
ted	O	-1	16680561
both	O	-1	16680561
treatment	O	-1	16680561
ar@@	O	-1	16680561
m@@	O	-1	16680561
s.	O	-1	16680561
R@@	O	-1	16680561
el@@	O	-1	16680561
ative	O	-1	16680561
to	O	-1	16680561
desi@@	B-Chemical	D003891	16680561
pramine	I-Chemical	-1	16680561
al@@	O	-1	16680561
one,	O	-1	16680561
mean	O	-1	16680561
A@@	O	-1	16680561
U@@	O	-1	16680561
C	O	-1	16680561
and	O	-1	16680561
C@@	O	-1	16680561
(@@	O	-1	16680561
ma@@	O	-1	16680561
x@@	O	-1	16680561
)	O	-1	16680561
of	O	-1	16680561
desi@@	B-Chemical	D003891	16680561
pramine	I-Chemical	-1	16680561
increased	O	-1	16680561
3.@@	O	-1	16680561
6@@	O	-1	16680561
-	O	-1	16680561
and	O	-1	16680561
1.@@	O	-1	16680561
8@@	O	-1	16680561
-@@	O	-1	16680561
fol@@	O	-1	16680561
d	O	-1	16680561
when	O	-1	16680561
co@@	O	-1	16680561
administered	O	-1	16680561
with	O	-1	16680561
cin@@	B-Chemical	C476217	16680561
ac@@	I-Chemical	-1	16680561
al@@	I-Chemical	-1	16680561
ce@@	I-Chemical	-1	16680561
t	I-Chemical	-1	16680561
.	O	-1	16680561
The	O	-1	16680561
t	O	-1	16680561
(1@@	O	-1	16680561
/@@	O	-1	16680561
2@@	O	-1	16680561
,@@	O	-1	16680561
z@@	O	-1	16680561
)	O	-1	16680561
of	O	-1	16680561
desi@@	B-Chemical	D003891	16680561
pramine	I-Chemical	-1	16680561
was	O	-1	16680561
long@@	O	-1	16680561
er	O	-1	16680561
when	O	-1	16680561
desi@@	B-Chemical	D003891	16680561
pramine	I-Chemical	-1	16680561
was	O	-1	16680561
co@@	O	-1	16680561
administered	O	-1	16680561
with	O	-1	16680561
cin@@	B-Chemical	C476217	16680561
ac@@	I-Chemical	-1	16680561
al@@	I-Chemical	-1	16680561
ce@@	I-Chemical	-1	16680561
t	I-Chemical	-1	16680561
(2@@	O	-1	16680561
1.@@	O	-1	16680561
0	O	-1	16680561
versus	O	-1	16680561
4@@	O	-1	16680561
3.@@	O	-1	16680561
3	O	-1	16680561
h@@	O	-1	16680561
s@@	O	-1	16680561
).	O	-1	16680561
The	O	-1	16680561
t	O	-1	16680561
(@@	O	-1	16680561
ma@@	O	-1	16680561
x@@	O	-1	16680561
)	O	-1	16680561
was	O	-1	16680561
similar	O	-1	16680561
between	O	-1	16680561
the	O	-1	16680561
regimen@@	O	-1	16680561
s.	O	-1	16680561
F@@	O	-1	16680561
e@@	O	-1	16680561
w@@	O	-1	16680561
er	O	-1	16680561
subjects	O	-1	16680561
reported	O	-1	16680561
adverse	O	-1	16680561
events	O	-1	16680561
following	O	-1	16680561
treatment	O	-1	16680561
with	O	-1	16680561
desi@@	B-Chemical	D003891	16680561
pramine	I-Chemical	-1	16680561
alone	O	-1	16680561
than	O	-1	16680561
when	O	-1	16680561
receiving	O	-1	16680561
desi@@	B-Chemical	D003891	16680561
pramine	I-Chemical	-1	16680561
with	O	-1	16680561
cin@@	B-Chemical	C476217	16680561
ac@@	I-Chemical	-1	16680561
al@@	I-Chemical	-1	16680561
ce@@	I-Chemical	-1	16680561
t	I-Chemical	-1	16680561
(3@@	O	-1	16680561
3	O	-1	16680561
versus	O	-1	16680561
8@@	O	-1	16680561
6@@	O	-1	16680561
%),	O	-1	16680561
the	O	-1	16680561
most	O	-1	16680561
frequent	O	-1	16680561
of	O	-1	16680561
which	O	-1	16680561
(	O	-1	16680561
nausea	B-Disease	D009325	16680561
and	O	-1	16680561
headac@@	B-Disease	D006261	16680561
he	I-Disease	-1	16680561
)	O	-1	16680561
have	O	-1	16680561
been	O	-1	16680561
reported	O	-1	16680561
for	O	-1	16680561
patients	O	-1	16680561
treated	O	-1	16680561
with	O	-1	16680561
either	O	-1	16680561
desi@@	B-Chemical	D003891	16680561
pramine	I-Chemical	-1	16680561
or	O	-1	16680561
cin@@	B-Chemical	C476217	16680561
ac@@	I-Chemical	-1	16680561
al@@	I-Chemical	-1	16680561
ce@@	I-Chemical	-1	16680561
t	I-Chemical	-1	16680561
.	O	-1	16680561
CONCLUSION:	O	-1	16680561
This	O	-1	16680561
study	O	-1	16680561
demon@@	O	-1	16680561
strat@@	O	-1	16680561
es	O	-1	16680561
that	O	-1	16680561
cin@@	B-Chemical	C476217	16680561
ac@@	I-Chemical	-1	16680561
al@@	I-Chemical	-1	16680561
ce@@	I-Chemical	-1	16680561
t	I-Chemical	-1	16680561
is	O	-1	16680561
a	O	-1	16680561
st@@	O	-1	16680561
ron@@	O	-1	16680561
g	O	-1	16680561
inhibitor	O	-1	16680561
of	O	-1	16680561
C@@	O	-1	16680561
Y@@	O	-1	16680561
P@@	O	-1	16680561
2@@	O	-1	16680561
D@@	O	-1	16680561
6@@	O	-1	16680561
.	O	-1	16680561
These	O	-1	16680561
data	O	-1	16680561
suggest	O	-1	16680561
that	O	-1	16680561
during	O	-1	16680561
concomit@@	O	-1	16680561
ant	O	-1	16680561
treatment	O	-1	16680561
with	O	-1	16680561
cin@@	B-Chemical	C476217	16680561
ac@@	I-Chemical	-1	16680561
al@@	I-Chemical	-1	16680561
ce@@	I-Chemical	-1	16680561
t	I-Chemical	-1	16680561
,	O	-1	16680561
dose	O	-1	16680561
adjust@@	O	-1	16680561
ment	O	-1	16680561
may	O	-1	16680561
be	O	-1	16680561
nec@@	O	-1	16680561
ess@@	O	-1	16680561
ary	O	-1	16680561
for	O	-1	16680561
drugs	O	-1	16680561
that	O	-1	16680561
demon@@	O	-1	16680561
st@@	O	-1	16680561
rate	O	-1	16680561
a	O	-1	16680561
n@@	O	-1	16680561
ar@@	O	-1	16680561
ro@@	O	-1	16680561
w	O	-1	16680561
therapeutic	O	-1	16680561
in@@	O	-1	16680561
de@@	O	-1	16680561
x	O	-1	16680561
and	O	-1	16680561
are	O	-1	16680561
metabol@@	O	-1	16680561
ized	O	-1	16680561
by	O	-1	16680561
C@@	O	-1	16680561
Y@@	O	-1	16680561
P@@	O	-1	16680561
2@@	O	-1	16680561
D@@	O	-1	16680561
6@@	O	-1	16680561
.	O	-1	16680561

Pro@@	O	-1	17532790
te@@	O	-1	17532790
om@@	O	-1	17532790
ic	O	-1	17532790
analysis	O	-1	17532790
of	O	-1	17532790
stri@@	O	-1	17532790
atal	O	-1	17532790
protein@@	O	-1	17532790
s	O	-1	17532790
in	O	-1	17532790
the	O	-1	17532790
rat	O	-1	17532790
model	O	-1	17532790
of	O	-1	17532790
L-@@	B-Chemical	D007980	17532790
DO@@	I-Chemical	-1	17532790
P@@	I-Chemical	-1	17532790
A	I-Chemical	-1	17532790
-induced	O	-1	17532790
dyskine@@	B-Disease	D004409	17532790
sia	I-Disease	-1	17532790
.	O	-1	17532790
L-@@	B-Chemical	D007980	17532790
DO@@	I-Chemical	-1	17532790
P@@	I-Chemical	-1	17532790
A	I-Chemical	-1	17532790
-induced	O	-1	17532790
dyskine@@	B-Disease	D004409	17532790
sia	I-Disease	-1	17532790
(	O	-1	17532790
L@@	B-Disease	D004409	17532790
I@@	I-Disease	-1	17532790
D	I-Disease	-1	17532790
)	O	-1	17532790
is	O	-1	17532790
among	O	-1	17532790
the	O	-1	17532790
motor	O	-1	17532790
complications	O	-1	17532790
that	O	-1	17532790
ar@@	O	-1	17532790
is@@	O	-1	17532790
e	O	-1	17532790
in	O	-1	17532790
Parkinson's	B-Disease	D010300	17532790
disease	I-Disease	-1	17532790
(	O	-1	17532790
P@@	B-Disease	D010300	17532790
D	I-Disease	-1	17532790
)	O	-1	17532790
patients	O	-1	17532790
after	O	-1	17532790
a	O	-1	17532790
prolonged	O	-1	17532790
treatment	O	-1	17532790
with	O	-1	17532790
L-@@	B-Chemical	D007980	17532790
DO@@	I-Chemical	-1	17532790
P@@	I-Chemical	-1	17532790
A	I-Chemical	-1	17532790
.	O	-1	17532790
To	O	-1	17532790
this	O	-1	17532790
da@@	O	-1	17532790
y,	O	-1	17532790
trans@@	O	-1	17532790
cri@@	O	-1	17532790
pto@@	O	-1	17532790
m@@	O	-1	17532790
e	O	-1	17532790
analysis	O	-1	17532790
has	O	-1	17532790
been	O	-1	17532790
performed	O	-1	17532790
in	O	-1	17532790
a	O	-1	17532790
rat	O	-1	17532790
model	O	-1	17532790
of	O	-1	17532790
L@@	B-Disease	D004409	17532790
I@@	I-Disease	-1	17532790
D	I-Disease	-1	17532790
[@@	O	-1	17532790
Ne@@	O	-1	17532790
uro@@	O	-1	17532790
b@@	O	-1	17532790
i@@	O	-1	17532790
ol@@	O	-1	17532790
.	O	-1	17532790
D@@	O	-1	17532790
is@@	O	-1	17532790
.,	O	-1	17532790
17	O	-1	17532790
(2@@	O	-1	17532790
0@@	O	-1	17532790
0@@	O	-1	17532790
4@@	O	-1	17532790
),	O	-1	17532790
2@@	O	-1	17532790
19@@	O	-1	17532790
]	O	-1	17532790
but	O	-1	17532790
inf@@	O	-1	17532790
orm@@	O	-1	17532790
ation	O	-1	17532790
reg@@	O	-1	17532790
ar@@	O	-1	17532790
ding	O	-1	17532790
the	O	-1	17532790
prote@@	O	-1	17532790
ome	O	-1	17532790
is	O	-1	17532790
sti@@	O	-1	17532790
ll	O	-1	17532790
l@@	O	-1	17532790
ac@@	O	-1	17532790
k@@	O	-1	17532790
ing.	O	-1	17532790
In	O	-1	17532790
the	O	-1	17532790
present	O	-1	17532790
study,	O	-1	17532790
we	O	-1	17532790
investigated	O	-1	17532790
the	O	-1	17532790
changes	O	-1	17532790
occur@@	O	-1	17532790
r@@	O	-1	17532790
ing	O	-1	17532790
at	O	-1	17532790
the	O	-1	17532790
protein	O	-1	17532790
level	O	-1	17532790
in	O	-1	17532790
stri@@	O	-1	17532790
atal	O	-1	17532790
sam@@	O	-1	17532790
ple@@	O	-1	17532790
s	O	-1	17532790
obtained	O	-1	17532790
from	O	-1	17532790
the	O	-1	17532790
un@@	O	-1	17532790
il@@	O	-1	17532790
at@@	O	-1	17532790
er@@	O	-1	17532790
ally	O	-1	17532790
6-@@	B-Chemical	D016627	17532790
hydrox@@	I-Chemical	-1	17532790
y@@	I-Chemical	-1	17532790
dopamine	I-Chemical	-1	17532790
-@@	O	-1	17532790
le@@	O	-1	17532790
sion	O	-1	17532790
rat	O	-1	17532790
model	O	-1	17532790
of	O	-1	17532790
P@@	B-Disease	D010300	17532790
D	I-Disease	-1	17532790
treated	O	-1	17532790
with	O	-1	17532790
sal@@	O	-1	17532790
ine,	O	-1	17532790
L-@@	B-Chemical	D007980	17532790
DO@@	I-Chemical	-1	17532790
P@@	I-Chemical	-1	17532790
A	I-Chemical	-1	17532790
or	O	-1	17532790
brom@@	B-Chemical	D001971	17532790
oc@@	I-Chemical	-1	17532790
ript@@	I-Chemical	-1	17532790
ine	I-Chemical	-1	17532790
using	O	-1	17532790
tw@@	O	-1	17532790
o@@	O	-1	17532790
-@@	O	-1	17532790
di@@	O	-1	17532790
men@@	O	-1	17532790
sion@@	O	-1	17532790
al	O	-1	17532790
difference	O	-1	17532790
ge@@	O	-1	17532790
l	O	-1	17532790
electro@@	O	-1	17532790
ph@@	O	-1	17532790
ore@@	O	-1	17532790
sis	O	-1	17532790
and	O	-1	17532790
mas@@	O	-1	17532790
s	O	-1	17532790
sp@@	O	-1	17532790
ect@@	O	-1	17532790
ro@@	O	-1	17532790
met@@	O	-1	17532790
r@@	O	-1	17532790
y	O	-1	17532790
(@@	O	-1	17532790
M@@	O	-1	17532790
S@@	O	-1	17532790
).	O	-1	17532790
R@@	O	-1	17532790
at@@	O	-1	17532790
s	O	-1	17532790
treated	O	-1	17532790
with	O	-1	17532790
L-@@	B-Chemical	D007980	17532790
DO@@	I-Chemical	-1	17532790
P@@	I-Chemical	-1	17532790
A	I-Chemical	-1	17532790
were	O	-1	17532790
al@@	O	-1	17532790
loc@@	O	-1	17532790
ated	O	-1	17532790
to	O	-1	17532790
two	O	-1	17532790
groups	O	-1	17532790
bas@@	O	-1	17532790
ed	O	-1	17532790
on	O	-1	17532790
the	O	-1	17532790
presence	O	-1	17532790
or	O	-1	17532790
absence	O	-1	17532790
of	O	-1	17532790
L@@	B-Disease	D004409	17532790
I@@	I-Disease	-1	17532790
D	I-Disease	-1	17532790
.	O	-1	17532790
A@@	O	-1	17532790
mon@@	O	-1	17532790
g	O	-1	17532790
the	O	-1	17532790
20@@	O	-1	17532790
00	O	-1	17532790
sp@@	O	-1	17532790
ot@@	O	-1	17532790
s	O	-1	17532790
compared	O	-1	17532790
for	O	-1	17532790
statis@@	O	-1	17532790
tical	O	-1	17532790
differen@@	O	-1	17532790
ce@@	O	-1	17532790
,	O	-1	17532790
6@@	O	-1	17532790
7	O	-1	17532790
sp@@	O	-1	17532790
ot@@	O	-1	17532790
s	O	-1	17532790
were	O	-1	17532790
significantly	O	-1	17532790
chang@@	O	-1	17532790
ed	O	-1	17532790
in	O	-1	17532790
ab@@	O	-1	17532790
und@@	O	-1	17532790
ance	O	-1	17532790
and	O	-1	17532790
identi@@	O	-1	17532790
fied	O	-1	17532790
using	O	-1	17532790
mat@@	O	-1	17532790
ri@@	O	-1	17532790
x@@	O	-1	17532790
-@@	O	-1	17532790
as@@	O	-1	17532790
sist@@	O	-1	17532790
ed	O	-1	17532790
las@@	O	-1	17532790
er	O	-1	17532790
des@@	O	-1	17532790
or@@	O	-1	17532790
p@@	O	-1	17532790
tion@@	O	-1	17532790
/@@	O	-1	17532790
i@@	O	-1	17532790
on@@	O	-1	17532790
ization	O	-1	17532790
ti@@	O	-1	17532790
me@@	O	-1	17532790
-@@	O	-1	17532790
of@@	O	-1	17532790
-@@	O	-1	17532790
f@@	O	-1	17532790
li@@	O	-1	17532790
ght	O	-1	17532790
M@@	O	-1	17532790
S@@	O	-1	17532790
,	O	-1	17532790
at@@	O	-1	17532790
m@@	O	-1	17532790
osph@@	O	-1	17532790
er@@	O	-1	17532790
ic	O	-1	17532790
pressure	O	-1	17532790
mat@@	O	-1	17532790
ri@@	O	-1	17532790
x@@	O	-1	17532790
-@@	O	-1	17532790
as@@	O	-1	17532790
sist@@	O	-1	17532790
ed	O	-1	17532790
las@@	O	-1	17532790
er	O	-1	17532790
des@@	O	-1	17532790
or@@	O	-1	17532790
p@@	O	-1	17532790
tion@@	O	-1	17532790
/@@	O	-1	17532790
i@@	O	-1	17532790
on@@	O	-1	17532790
ization	O	-1	17532790
and	O	-1	17532790
H@@	O	-1	17532790
P@@	O	-1	17532790
L@@	O	-1	17532790
C	O	-1	17532790
co@@	O	-1	17532790
u@@	O	-1	17532790
pl@@	O	-1	17532790
ed	O	-1	17532790
t@@	O	-1	17532790
an@@	O	-1	17532790
de@@	O	-1	17532790
m	O	-1	17532790
M@@	O	-1	17532790
S	O	-1	17532790
(@@	O	-1	17532790
L@@	O	-1	17532790
C@@	O	-1	17532790
/@@	O	-1	17532790
M@@	O	-1	17532790
S@@	O	-1	17532790
/@@	O	-1	17532790
M@@	O	-1	17532790
S@@	O	-1	17532790
).	O	-1	17532790
O@@	O	-1	17532790
u@@	O	-1	17532790
t	O	-1	17532790
of	O	-1	17532790
these	O	-1	17532790
6@@	O	-1	17532790
7	O	-1	17532790
protein@@	O	-1	17532790
s,	O	-1	17532790
L@@	B-Disease	D004409	17532790
I@@	I-Disease	-1	17532790
D	I-Disease	-1	17532790
significantly	O	-1	17532790
chang@@	O	-1	17532790
ed	O	-1	17532790
the	O	-1	17532790
expression	O	-1	17532790
level	O	-1	17532790
of	O	-1	17532790
five	O	-1	17532790
protein@@	O	-1	17532790
s:	O	-1	17532790
alpha@@	O	-1	17532790
beta-@@	O	-1	17532790
c@@	O	-1	17532790
r@@	O	-1	17532790
y@@	O	-1	17532790
st@@	O	-1	17532790
al@@	O	-1	17532790
in,	O	-1	17532790
gamma@@	O	-1	17532790
-@@	O	-1	17532790
en@@	O	-1	17532790
ol@@	O	-1	17532790
ase,	O	-1	17532790
gu@@	O	-1	17532790
an@@	O	-1	17532790
id@@	O	-1	17532790
o@@	O	-1	17532790
acet@@	O	-1	17532790
ate	O	-1	17532790
methyl@@	O	-1	17532790
trans@@	O	-1	17532790
fer@@	O	-1	17532790
ase,	O	-1	17532790
v@@	O	-1	17532790
inc@@	O	-1	17532790
ul@@	O	-1	17532790
in,	O	-1	17532790
and	O	-1	17532790
prote@@	O	-1	17532790
as@@	O	-1	17532790
ome	O	-1	17532790
alpha-@@	O	-1	17532790
2	O	-1	17532790
sub@@	O	-1	17532790
un@@	O	-1	17532790
it@@	O	-1	17532790
.	O	-1	17532790
Com@@	O	-1	17532790
ple@@	O	-1	17532790
ment@@	O	-1	17532790
ary	O	-1	17532790
t@@	O	-1	17532790
ech@@	O	-1	17532790
n@@	O	-1	17532790
i@@	O	-1	17532790
qu@@	O	-1	17532790
es	O	-1	17532790
such	O	-1	17532790
as	O	-1	17532790
we@@	O	-1	17532790
ster@@	O	-1	17532790
n	O	-1	17532790
immun@@	O	-1	17532790
ob@@	O	-1	17532790
lo@@	O	-1	17532790
t@@	O	-1	17532790
ting	O	-1	17532790
and	O	-1	17532790
immuno@@	O	-1	17532790
histo@@	O	-1	17532790
chem@@	O	-1	17532790
ist@@	O	-1	17532790
r@@	O	-1	17532790
y	O	-1	17532790
were	O	-1	17532790
performed	O	-1	17532790
to	O	-1	17532790
investigate	O	-1	17532790
the	O	-1	17532790
val@@	O	-1	17532790
idity	O	-1	17532790
of	O	-1	17532790
the	O	-1	17532790
data	O	-1	17532790
obtained	O	-1	17532790
using	O	-1	17532790
the	O	-1	17532790
prote@@	O	-1	17532790
om@@	O	-1	17532790
ic	O	-1	17532790
appro@@	O	-1	17532790
ac@@	O	-1	17532790
h@@	O	-1	17532790
.	O	-1	17532790
In	O	-1	17532790
concl@@	O	-1	17532790
u@@	O	-1	17532790
sion,	O	-1	17532790
this	O	-1	17532790
study	O	-1	17532790
pro@@	O	-1	17532790
vi@@	O	-1	17532790
des	O	-1	17532790
new	O	-1	17532790
in@@	O	-1	17532790
si@@	O	-1	17532790
gh@@	O	-1	17532790
ts	O	-1	17532790
into	O	-1	17532790
the	O	-1	17532790
protein	O	-1	17532790
changes	O	-1	17532790
occur@@	O	-1	17532790
r@@	O	-1	17532790
ing	O	-1	17532790
in	O	-1	17532790
L@@	B-Disease	D004409	17532790
I@@	I-Disease	-1	17532790
D	I-Disease	-1	17532790
.	O	-1	17532790

P@@	O	-1	7582165
se@@	O	-1	7582165
u@@	O	-1	7582165
do@@	O	-1	7582165
-	O	-1	7582165
all@@	B-Disease	D004342	7582165
ergic	I-Disease	-1	7582165
reactions	I-Disease	-1	7582165
to	O	-1	7582165
cortico@@	B-Chemical	D000305	7582165
steroid@@	I-Chemical	-1	7582165
s	I-Chemical	-1	7582165
:	O	-1	7582165
diagnosis	O	-1	7582165
and	O	-1	7582165
al@@	O	-1	7582165
tern@@	O	-1	7582165
ati@@	O	-1	7582165
v@@	O	-1	7582165
es.	O	-1	7582165
Two	O	-1	7582165
patients	O	-1	7582165
treated	O	-1	7582165
with	O	-1	7582165
pa@@	O	-1	7582165
ren@@	O	-1	7582165
ter@@	O	-1	7582165
al	O	-1	7582165
par@@	B-Chemical	D010248	7582165
ameth@@	I-Chemical	-1	7582165
as@@	I-Chemical	-1	7582165
one	I-Chemical	-1	7582165
(T@@	O	-1	7582165
r@@	O	-1	7582165
in@@	O	-1	7582165
i@@	O	-1	7582165
ol@@	O	-1	7582165
)	O	-1	7582165
and	O	-1	7582165
de@@	B-Chemical	D003907	7582165
xameth@@	I-Chemical	-1	7582165
as@@	I-Chemical	-1	7582165
one	I-Chemical	-1	7582165
(S@@	O	-1	7582165
edi@@	O	-1	7582165
on@@	O	-1	7582165
be@@	O	-1	7582165
l@@	O	-1	7582165
)	O	-1	7582165
are	O	-1	7582165
descri@@	O	-1	7582165
be@@	O	-1	7582165
d.	O	-1	7582165
A	O	-1	7582165
fe@@	O	-1	7582165
w	O	-1	7582165
minutes	O	-1	7582165
after	O	-1	7582165
administration	O	-1	7582165
of	O	-1	7582165
the	O	-1	7582165
drug@@	O	-1	7582165
s,	O	-1	7582165
they	O	-1	7582165
presented	O	-1	7582165
ur@@	B-Disease	D014581	7582165
ti@@	I-Disease	-1	7582165
car@@	I-Disease	-1	7582165
ia	I-Disease	-1	7582165
(@@	O	-1	7582165
patients	O	-1	7582165
1	O	-1	7582165
and	O	-1	7582165
2)	O	-1	7582165
and	O	-1	7582165
con@@	B-Disease	D003231	7582165
j@@	I-Disease	-1	7582165
unc@@	I-Disease	-1	7582165
ti@@	I-Disease	-1	7582165
vi@@	I-Disease	-1	7582165
tis	I-Disease	-1	7582165
(@@	O	-1	7582165
patient	O	-1	7582165
1).	O	-1	7582165
The	O	-1	7582165
pur@@	O	-1	7582165
p@@	O	-1	7582165
ose	O	-1	7582165
of	O	-1	7582165
our	O	-1	7582165
study	O	-1	7582165
was	O	-1	7582165
to	O	-1	7582165
determine	O	-1	7582165
the	O	-1	7582165
cause	O	-1	7582165
of	O	-1	7582165
the	O	-1	7582165
patient@@	O	-1	7582165
s@@	O	-1	7582165
'	O	-1	7582165
reac@@	O	-1	7582165
tion@@	O	-1	7582165
s,	O	-1	7582165
the	O	-1	7582165
immun@@	O	-1	7582165
ological	O	-1	7582165
mechanisms	O	-1	7582165
involved	O	-1	7582165
and	O	-1	7582165
whether	O	-1	7582165
these	O	-1	7582165
patients	O	-1	7582165
wo@@	O	-1	7582165
uld	O	-1	7582165
be	O	-1	7582165
able	O	-1	7582165
to	O	-1	7582165
toler@@	O	-1	7582165
ate	O	-1	7582165
any	O	-1	7582165
k@@	O	-1	7582165
ind	O	-1	7582165
of	O	-1	7582165
cortico@@	O	-1	7582165
id@@	O	-1	7582165
.	O	-1	7582165
Clin@@	O	-1	7582165
ical	O	-1	7582165
examin@@	O	-1	7582165
ations	O	-1	7582165
and	O	-1	7582165
s@@	O	-1	7582165
k@@	O	-1	7582165
in,	O	-1	7582165
oral	O	-1	7582165
and	O	-1	7582165
pa@@	O	-1	7582165
ren@@	O	-1	7582165
ter@@	O	-1	7582165
al	O	-1	7582165
ch@@	O	-1	7582165
all@@	O	-1	7582165
en@@	O	-1	7582165
g@@	O	-1	7582165
es	O	-1	7582165
with	O	-1	7582165
different	O	-1	7582165
cortico@@	B-Chemical	D000305	7582165
steroid@@	I-Chemical	-1	7582165
s	I-Chemical	-1	7582165
and	O	-1	7582165
E@@	O	-1	7582165
L@@	O	-1	7582165
I@@	O	-1	7582165
S@@	O	-1	7582165
A	O	-1	7582165
tests	O	-1	7582165
were	O	-1	7582165
per@@	O	-1	7582165
for@@	O	-1	7582165
me@@	O	-1	7582165
d.	O	-1	7582165
In	O	-1	7582165
the	O	-1	7582165
two	O	-1	7582165
patients,	O	-1	7582165
s@@	O	-1	7582165
k@@	O	-1	7582165
in	O	-1	7582165
and	O	-1	7582165
E@@	O	-1	7582165
L@@	O	-1	7582165
I@@	O	-1	7582165
S@@	O	-1	7582165
A	O	-1	7582165
tests	O	-1	7582165
with	O	-1	7582165
par@@	B-Chemical	D010248	7582165
ameth@@	I-Chemical	-1	7582165
as@@	I-Chemical	-1	7582165
one	I-Chemical	-1	7582165
were	O	-1	7582165
neg@@	O	-1	7582165
ati@@	O	-1	7582165
ve,	O	-1	7582165
as	O	-1	7582165
was	O	-1	7582165
the	O	-1	7582165
pr@@	O	-1	7582165
ic@@	O	-1	7582165
k	O	-1	7582165
test	O	-1	7582165
with	O	-1	7582165
each	O	-1	7582165
of	O	-1	7582165
its	O	-1	7582165
ex@@	O	-1	7582165
ci@@	O	-1	7582165
pi@@	O	-1	7582165
ent@@	O	-1	7582165
s.	O	-1	7582165
A	O	-1	7582165
sing@@	O	-1	7582165
le@@	O	-1	7582165
-@@	O	-1	7582165
bl@@	O	-1	7582165
ind	O	-1	7582165
pa@@	O	-1	7582165
ren@@	O	-1	7582165
ter@@	O	-1	7582165
al	O	-1	7582165
ch@@	O	-1	7582165
all@@	O	-1	7582165
enge	O	-1	7582165
with	O	-1	7582165
T@@	O	-1	7582165
r@@	O	-1	7582165
in@@	O	-1	7582165
io@@	O	-1	7582165
l	O	-1	7582165
was	O	-1	7582165
positive	O	-1	7582165
in	O	-1	7582165
both	O	-1	7582165
patients	O	-1	7582165
after	O	-1	7582165
the	O	-1	7582165
administration	O	-1	7582165
of	O	-1	7582165
1	O	-1	7582165
m@@	O	-1	7582165
l	O	-1	7582165
of	O	-1	7582165
the	O	-1	7582165
drug@@	O	-1	7582165
,	O	-1	7582165
and	O	-1	7582165
negative	O	-1	7582165
with	O	-1	7582165
its	O	-1	7582165
ex@@	O	-1	7582165
ci@@	O	-1	7582165
pi@@	O	-1	7582165
ent@@	O	-1	7582165
s.	O	-1	7582165
We	O	-1	7582165
also	O	-1	7582165
car@@	O	-1	7582165
ri@@	O	-1	7582165
ed	O	-1	7582165
out	O	-1	7582165
oral	O	-1	7582165
and	O	-1	7582165
pa@@	O	-1	7582165
ren@@	O	-1	7582165
ter@@	O	-1	7582165
al	O	-1	7582165
ch@@	O	-1	7582165
all@@	O	-1	7582165
en@@	O	-1	7582165
g@@	O	-1	7582165
es	O	-1	7582165
with	O	-1	7582165
other	O	-1	7582165
cortico@@	B-Chemical	D000305	7582165
steroid@@	I-Chemical	-1	7582165
s	I-Chemical	-1	7582165
and	O	-1	7582165
found	O	-1	7582165
int@@	O	-1	7582165
oler@@	O	-1	7582165
ance	O	-1	7582165
to	O	-1	7582165
some	O	-1	7582165
of	O	-1	7582165
th@@	O	-1	7582165
em@@	O	-1	7582165
.	O	-1	7582165
These	O	-1	7582165
results	O	-1	7582165
suggest	O	-1	7582165
that	O	-1	7582165
par@@	B-Chemical	D010248	7582165
ameth@@	I-Chemical	-1	7582165
as@@	I-Chemical	-1	7582165
one	I-Chemical	-1	7582165
caused	O	-1	7582165
p@@	O	-1	7582165
se@@	O	-1	7582165
u@@	O	-1	7582165
do@@	O	-1	7582165
all@@	O	-1	7582165
ergic	O	-1	7582165
reactions	O	-1	7582165
in	O	-1	7582165
our	O	-1	7582165
patients.	O	-1	7582165
C@@	O	-1	7582165
or@@	O	-1	7582165
tico@@	O	-1	7582165
steroid@@	O	-1	7582165
s	O	-1	7582165
different	O	-1	7582165
from	O	-1	7582165
par@@	B-Chemical	D010248	7582165
ameth@@	I-Chemical	-1	7582165
as@@	I-Chemical	-1	7582165
one	I-Chemical	-1	7582165
also	O	-1	7582165
produced	O	-1	7582165
hyper@@	B-Disease	D004342	7582165
sensitivity	I-Disease	-1	7582165
reactions	O	-1	7582165
in	O	-1	7582165
these	O	-1	7582165
patient@@	O	-1	7582165
s;	O	-1	7582165
however,	O	-1	7582165
a	O	-1	7582165
fe@@	O	-1	7582165
w	O	-1	7582165
of	O	-1	7582165
the@@	O	-1	7582165
m	O	-1	7582165
were	O	-1	7582165
toler@@	O	-1	7582165
ated.	O	-1	7582165
The	O	-1	7582165
b@@	O	-1	7582165
a@@	O	-1	7582165
sic	O	-1	7582165
mechanisms	O	-1	7582165
of	O	-1	7582165
those	O	-1	7582165
reactions	O	-1	7582165
are	O	-1	7582165
not	O	-1	7582165
y@@	O	-1	7582165
et	O	-1	7582165
ful@@	O	-1	7582165
ly	O	-1	7582165
under@@	O	-1	7582165
sto@@	O	-1	7582165
o@@	O	-1	7582165
d.	O	-1	7582165
To	O	-1	7582165
our	O	-1	7582165
know@@	O	-1	7582165
le@@	O	-1	7582165
d@@	O	-1	7582165
g@@	O	-1	7582165
e,	O	-1	7582165
this	O	-1	7582165
is	O	-1	7582165
the	O	-1	7582165
first	O	-1	7582165
report	O	-1	7582165
of	O	-1	7582165
a	O	-1	7582165
p@@	O	-1	7582165
se@@	O	-1	7582165
u@@	O	-1	7582165
do@@	O	-1	7582165
-	O	-1	7582165
all@@	B-Disease	D004342	7582165
erg@@	I-Disease	-1	7582165
y	I-Disease	-1	7582165
caused	O	-1	7582165
by	O	-1	7582165
par@@	B-Chemical	D010248	7582165
ameth@@	I-Chemical	-1	7582165
as@@	I-Chemical	-1	7582165
one	I-Chemical	-1	7582165
.	O	-1	7582165

V@@	B-Chemical	D014635	16787750
al@@	I-Chemical	-1	16787750
pro@@	I-Chemical	-1	16787750
ic	I-Chemical	-1	16787750
acid	I-Chemical	-1	16787750
induced	O	-1	16787750
encephalo@@	B-Disease	D001927	16787750
pathy	I-Disease	-1	16787750
-@@	O	-1	16787750
-1@@	O	-1	16787750
9	O	-1	16787750
new	O	-1	16787750
cases	O	-1	16787750
in	O	-1	16787750
G@@	O	-1	16787750
er@@	O	-1	16787750
man@@	O	-1	16787750
y	O	-1	16787750
from	O	-1	16787750
19@@	O	-1	16787750
9@@	O	-1	16787750
4	O	-1	16787750
to	O	-1	16787750
20@@	O	-1	16787750
0@@	O	-1	16787750
3-@@	O	-1	16787750
-@@	O	-1	16787750
a	O	-1	16787750
side	O	-1	16787750
effect	O	-1	16787750
associated	O	-1	16787750
to	O	-1	16787750
V@@	B-Chemical	D014635	16787750
P@@	I-Chemical	-1	16787750
A	I-Chemical	-1	16787750
-@@	O	-1	16787750
therapy	O	-1	16787750
not	O	-1	16787750
only	O	-1	16787750
in	O	-1	16787750
youn@@	O	-1	16787750
g	O	-1	16787750
child@@	O	-1	16787750
ren@@	O	-1	16787750
.	O	-1	16787750
V@@	B-Chemical	D014635	16787750
al@@	I-Chemical	-1	16787750
pro@@	I-Chemical	-1	16787750
ic	I-Chemical	-1	16787750
acid	I-Chemical	-1	16787750
(	O	-1	16787750
V@@	B-Chemical	D014635	16787750
P@@	I-Chemical	-1	16787750
A	I-Chemical	-1	16787750
)	O	-1	16787750
is	O	-1	16787750
a	O	-1	16787750
b@@	O	-1	16787750
ro@@	O	-1	16787750
ad@@	O	-1	16787750
-@@	O	-1	16787750
sp@@	O	-1	16787750
ect@@	O	-1	16787750
ru@@	O	-1	16787750
m	O	-1	16787750
anti@@	O	-1	16787750
epileptic	O	-1	16787750
drug	O	-1	16787750
and	O	-1	16787750
is	O	-1	16787750
us@@	O	-1	16787750
ually	O	-1	16787750
we@@	O	-1	16787750
ll@@	O	-1	16787750
-@@	O	-1	16787750
toler@@	O	-1	16787750
ated.	O	-1	16787750
R@@	O	-1	16787750
are	O	-1	16787750
seri@@	O	-1	16787750
ous	O	-1	16787750
complications	O	-1	16787750
may	O	-1	16787750
occ@@	O	-1	16787750
ur	O	-1	16787750
in	O	-1	16787750
some	O	-1	16787750
patients,	O	-1	16787750
including	O	-1	16787750
haem@@	O	-1	16787750
or@@	O	-1	16787750
rh@@	O	-1	16787750
ag@@	O	-1	16787750
ic	O	-1	16787750
p@@	B-Disease	D010195	16787750
anc@@	I-Disease	-1	16787750
re@@	I-Disease	-1	16787750
ati@@	I-Disease	-1	16787750
tis	I-Disease	-1	16787750
,	O	-1	16787750
b@@	B-Disease	D001855	16787750
one	I-Disease	-1	16787750
m@@	I-Disease	-1	16787750
ar@@	I-Disease	-1	16787750
ro@@	I-Disease	-1	16787750
w	I-Disease	-1	16787750
sup@@	I-Disease	-1	16787750
pression	I-Disease	-1	16787750
,	O	-1	16787750
V@@	B-Chemical	D014635	16787750
P@@	I-Chemical	-1	16787750
A	I-Chemical	-1	16787750
-induced	O	-1	16787750
hepat@@	B-Disease	D056486	16787750
otoxicity	I-Disease	-1	16787750
and	O	-1	16787750
V@@	B-Chemical	D014635	16787750
P@@	I-Chemical	-1	16787750
A	I-Chemical	-1	16787750
-induced	O	-1	16787750
encephalo@@	B-Disease	D001927	16787750
pathy	I-Disease	-1	16787750
.	O	-1	16787750
The	O	-1	16787750
typ@@	O	-1	16787750
ical	O	-1	16787750
signs	O	-1	16787750
of	O	-1	16787750
V@@	B-Chemical	D014635	16787750
P@@	I-Chemical	-1	16787750
A	I-Chemical	-1	16787750
-induced	O	-1	16787750
encephalo@@	B-Disease	D001927	16787750
pathy	I-Disease	-1	16787750
are	O	-1	16787750
impaired	B-Disease	D003244	16787750
con@@	I-Disease	-1	16787750
s@@	I-Disease	-1	16787750
ci@@	I-Disease	-1	16787750
ous@@	I-Disease	-1	16787750
ness	I-Disease	-1	16787750
,	O	-1	16787750
so@@	O	-1	16787750
me@@	O	-1	16787750
times	O	-1	16787750
mark@@	O	-1	16787750
ed	O	-1	16787750
E@@	O	-1	16787750
E@@	O	-1	16787750
G	O	-1	16787750
bac@@	O	-1	16787750
kg@@	O	-1	16787750
ro@@	O	-1	16787750
un@@	O	-1	16787750
d	O	-1	16787750
s@@	O	-1	16787750
low@@	O	-1	16787750
ing,	O	-1	16787750
increased	O	-1	16787750
seizure	B-Disease	D012640	16787750
frequ@@	O	-1	16787750
enc@@	O	-1	16787750
y,	O	-1	16787750
with	O	-1	16787750
or	O	-1	16787750
without	O	-1	16787750
hyper@@	B-Disease	D022124	16787750
am@@	I-Disease	-1	16787750
mon@@	I-Disease	-1	16787750
emia	I-Disease	-1	16787750
.	O	-1	16787750
There	O	-1	16787750
is	O	-1	16787750
sti@@	O	-1	16787750
ll	O	-1	16787750
no	O	-1	16787750
pro@@	O	-1	16787750
of	O	-1	16787750
of	O	-1	16787750
ca@@	O	-1	16787750
us@@	O	-1	16787750
ative	O	-1	16787750
effect	O	-1	16787750
of	O	-1	16787750
V@@	B-Chemical	D014635	16787750
P@@	I-Chemical	-1	16787750
A	I-Chemical	-1	16787750
in	O	-1	16787750
patients	O	-1	16787750
with	O	-1	16787750
encephalo@@	B-Disease	D001927	16787750
pathy	I-Disease	-1	16787750
,	O	-1	16787750
but	O	-1	16787750
only	O	-1	16787750
of	O	-1	16787750
an	O	-1	16787750
association	O	-1	16787750
with	O	-1	16787750
an	O	-1	16787750
as@@	O	-1	16787750
sum@@	O	-1	16787750
ed	O	-1	16787750
ca@@	O	-1	16787750
us@@	O	-1	16787750
al	O	-1	16787750
rel@@	O	-1	16787750
ation.	O	-1	16787750
We	O	-1	16787750
report	O	-1	16787750
1@@	O	-1	16787750
9	O	-1	16787750
patients	O	-1	16787750
with	O	-1	16787750
V@@	B-Chemical	D014635	16787750
P@@	I-Chemical	-1	16787750
A	I-Chemical	-1	16787750
-@@	O	-1	16787750
associated	O	-1	16787750
encephalo@@	B-Disease	D001927	16787750
pathy	I-Disease	-1	16787750
in	O	-1	16787750
G@@	O	-1	16787750
er@@	O	-1	16787750
man@@	O	-1	16787750
y	O	-1	16787750
from	O	-1	16787750
the	O	-1	16787750
years	O	-1	16787750
19@@	O	-1	16787750
9@@	O	-1	16787750
4	O	-1	16787750
to	O	-1	16787750
20@@	O	-1	16787750
0@@	O	-1	16787750
3,	O	-1	16787750
n@@	O	-1	16787750
one	O	-1	16787750
of	O	-1	16787750
whom	O	-1	16787750
had	O	-1	16787750
been	O	-1	16787750
pu@@	O	-1	16787750
bl@@	O	-1	16787750
ished	O	-1	16787750
previ@@	O	-1	16787750
ous@@	O	-1	16787750
ly.	O	-1	16787750

H@@	B-Disease	D006463	3173180
a@@	I-Disease	-1	3173180
em@@	I-Disease	-1	3173180
oly@@	I-Disease	-1	3173180
tic@@	I-Disease	-1	3173180
-@@	I-Disease	-1	3173180
ur@@	I-Disease	-1	3173180
a@@	I-Disease	-1	3173180
em@@	I-Disease	-1	3173180
ic	I-Disease	-1	3173180
syndrome	I-Disease	-1	3173180
after	O	-1	3173180
treatment	O	-1	3173180
with	O	-1	3173180
met@@	B-Chemical	D008795	3173180
ron@@	I-Chemical	-1	3173180
id@@	I-Chemical	-1	3173180
azole	I-Chemical	-1	3173180
.	O	-1	3173180
This	O	-1	3173180
pap@@	O	-1	3173180
er	O	-1	3173180
descri@@	O	-1	3173180
b@@	O	-1	3173180
es	O	-1	3173180
the	O	-1	3173180
clinical	O	-1	3173180
feat@@	O	-1	3173180
ures	O	-1	3173180
of	O	-1	3173180
six	O	-1	3173180
children	O	-1	3173180
who	O	-1	3173180
developed	O	-1	3173180
the	O	-1	3173180
haem@@	B-Disease	D006463	3173180
oly@@	I-Disease	-1	3173180
tic@@	I-Disease	-1	3173180
-@@	I-Disease	-1	3173180
ur@@	I-Disease	-1	3173180
a@@	I-Disease	-1	3173180
em@@	I-Disease	-1	3173180
ic	I-Disease	-1	3173180
syndrome	I-Disease	-1	3173180
after	O	-1	3173180
treatment	O	-1	3173180
with	O	-1	3173180
met@@	B-Chemical	D008795	3173180
ron@@	I-Chemical	-1	3173180
id@@	I-Chemical	-1	3173180
azole	I-Chemical	-1	3173180
.	O	-1	3173180
These	O	-1	3173180
children	O	-1	3173180
were	O	-1	3173180
ol@@	O	-1	3173180
der	O	-1	3173180
and	O	-1	3173180
were	O	-1	3173180
more	O	-1	3173180
likely	O	-1	3173180
to	O	-1	3173180
have	O	-1	3173180
under@@	O	-1	3173180
g@@	O	-1	3173180
one	O	-1	3173180
rec@@	O	-1	3173180
ent	O	-1	3173180
bo@@	O	-1	3173180
we@@	O	-1	3173180
l	O	-1	3173180
surger@@	O	-1	3173180
y	O	-1	3173180
than	O	-1	3173180
are	O	-1	3173180
other	O	-1	3173180
children	O	-1	3173180
with	O	-1	3173180
this	O	-1	3173180
condi@@	O	-1	3173180
tion.	O	-1	3173180
W@@	O	-1	3173180
h@@	O	-1	3173180
ile	O	-1	3173180
the	O	-1	3173180
invol@@	O	-1	3173180
vement	O	-1	3173180
of	O	-1	3173180
met@@	B-Chemical	D008795	3173180
ron@@	I-Chemical	-1	3173180
id@@	I-Chemical	-1	3173180
azole	I-Chemical	-1	3173180
in	O	-1	3173180
the	O	-1	3173180
a@@	O	-1	3173180
e@@	O	-1	3173180
ti@@	O	-1	3173180
ology	O	-1	3173180
of	O	-1	3173180
the	O	-1	3173180
haem@@	B-Disease	D006463	3173180
oly@@	I-Disease	-1	3173180
tic@@	I-Disease	-1	3173180
-@@	I-Disease	-1	3173180
ur@@	I-Disease	-1	3173180
a@@	I-Disease	-1	3173180
em@@	I-Disease	-1	3173180
ic	I-Disease	-1	3173180
syndrome	I-Disease	-1	3173180
is	O	-1	3173180
not	O	-1	3173180
est@@	O	-1	3173180
abl@@	O	-1	3173180
ished	O	-1	3173180
fir@@	O	-1	3173180
m@@	O	-1	3173180
ly,	O	-1	3173180
the	O	-1	3173180
action	O	-1	3173180
of	O	-1	3173180
this	O	-1	3173180
drug	O	-1	3173180
in	O	-1	3173180
sensi@@	O	-1	3173180
tiz@@	O	-1	3173180
ing	O	-1	3173180
tissu@@	O	-1	3173180
es	O	-1	3173180
to	O	-1	3173180
oxid@@	O	-1	3173180
ation	O	-1	3173180
injury	O	-1	3173180
and	O	-1	3173180
the	O	-1	3173180
reported	O	-1	3173180
evidence	O	-1	3173180
of	O	-1	3173180
oxid@@	O	-1	3173180
ation	O	-1	3173180
changes	O	-1	3173180
in	O	-1	3173180
the	O	-1	3173180
haem@@	B-Disease	D006463	3173180
oly@@	I-Disease	-1	3173180
tic@@	I-Disease	-1	3173180
-@@	I-Disease	-1	3173180
ur@@	I-Disease	-1	3173180
a@@	I-Disease	-1	3173180
em@@	I-Disease	-1	3173180
ic	I-Disease	-1	3173180
syndrome	I-Disease	-1	3173180
suggest	O	-1	3173180
a	O	-1	3173180
possible	O	-1	3173180
lin@@	O	-1	3173180
k	O	-1	3173180
between	O	-1	3173180
met@@	B-Chemical	D008795	3173180
ron@@	I-Chemical	-1	3173180
id@@	I-Chemical	-1	3173180
azole	I-Chemical	-1	3173180
treatment	O	-1	3173180
and	O	-1	3173180
some	O	-1	3173180
cases	O	-1	3173180
of	O	-1	3173180
the	O	-1	3173180
haem@@	B-Disease	D006463	3173180
oly@@	I-Disease	-1	3173180
tic@@	I-Disease	-1	3173180
-@@	I-Disease	-1	3173180
ur@@	I-Disease	-1	3173180
a@@	I-Disease	-1	3173180
em@@	I-Disease	-1	3173180
ic	I-Disease	-1	3173180
syndrome	I-Disease	-1	3173180
.	O	-1	3173180

R@@	O	-1	8996652
is@@	O	-1	8996652
k	O	-1	8996652
factors	O	-1	8996652
of	O	-1	8996652
sens@@	B-Disease	D006319	8996652
or@@	I-Disease	-1	8996652
ine@@	I-Disease	-1	8996652
ural	I-Disease	-1	8996652
hearing	I-Disease	-1	8996652
loss	I-Disease	-1	8996652
in	O	-1	8996652
pre@@	O	-1	8996652
term	O	-1	8996652
inf@@	O	-1	8996652
ant@@	O	-1	8996652
s.	O	-1	8996652
A@@	O	-1	8996652
mon@@	O	-1	8996652
g	O	-1	8996652
5@@	O	-1	8996652
4@@	O	-1	8996652
7	O	-1	8996652
pre@@	O	-1	8996652
term	O	-1	8996652
inf@@	O	-1	8996652
ants	O	-1	8996652
of	O	-1	8996652
<	O	-1	8996652
or	O	-1	8996652
=	O	-1	8996652
3@@	O	-1	8996652
4	O	-1	8996652
weeks	O	-1	8996652
g@@	O	-1	8996652
est@@	O	-1	8996652
ation	O	-1	8996652
b@@	O	-1	8996652
or@@	O	-1	8996652
n	O	-1	8996652
between	O	-1	8996652
19@@	O	-1	8996652
8@@	O	-1	8996652
7	O	-1	8996652
and	O	-1	8996652
19@@	O	-1	8996652
9@@	O	-1	8996652
1,	O	-1	8996652
8	O	-1	8996652
children	O	-1	8996652
(1@@	O	-1	8996652
.@@	O	-1	8996652
4@@	O	-1	8996652
6@@	O	-1	8996652
%)	O	-1	8996652
developed	O	-1	8996652
severe	O	-1	8996652
progressive	O	-1	8996652
and	O	-1	8996652
bil@@	O	-1	8996652
ateral	O	-1	8996652
sens@@	B-Disease	D006319	8996652
or@@	I-Disease	-1	8996652
ine@@	I-Disease	-1	8996652
ural	I-Disease	-1	8996652
hearing	I-Disease	-1	8996652
loss	I-Disease	-1	8996652
.	O	-1	8996652
P@@	O	-1	8996652
er@@	O	-1	8996652
in@@	O	-1	8996652
atal	O	-1	8996652
risk	O	-1	8996652
factors	O	-1	8996652
of	O	-1	8996652
inf@@	O	-1	8996652
ants	O	-1	8996652
with	O	-1	8996652
hearing	B-Disease	D034381	8996652
loss	I-Disease	-1	8996652
were	O	-1	8996652
compared	O	-1	8996652
with	O	-1	8996652
those	O	-1	8996652
of	O	-1	8996652
two	O	-1	8996652
control	O	-1	8996652
groups	O	-1	8996652
mat@@	O	-1	8996652
ch@@	O	-1	8996652
ed	O	-1	8996652
for	O	-1	8996652
g@@	O	-1	8996652
est@@	O	-1	8996652
ation	O	-1	8996652
and	O	-1	8996652
b@@	O	-1	8996652
ir@@	O	-1	8996652
th	O	-1	8996652
weight	O	-1	8996652
and	O	-1	8996652
for	O	-1	8996652
per@@	O	-1	8996652
in@@	O	-1	8996652
atal	O	-1	8996652
complic@@	O	-1	8996652
ations.	O	-1	8996652
Our	O	-1	8996652
observ@@	O	-1	8996652
ations	O	-1	8996652
demonstrated	O	-1	8996652
an	O	-1	8996652
association	O	-1	8996652
of	O	-1	8996652
hearing	B-Disease	D034381	8996652
loss	I-Disease	-1	8996652
with	O	-1	8996652
a	O	-1	8996652
higher	O	-1	8996652
incidence	O	-1	8996652
of	O	-1	8996652
per@@	O	-1	8996652
in@@	O	-1	8996652
atal	O	-1	8996652
complic@@	O	-1	8996652
ations.	O	-1	8996652
O@@	B-Disease	D006311	8996652
tot@@	I-Disease	-1	8996652
oxic@@	I-Disease	-1	8996652
ity	I-Disease	-1	8996652
appe@@	O	-1	8996652
a@@	O	-1	8996652
red	O	-1	8996652
clo@@	O	-1	8996652
se@@	O	-1	8996652
ly	O	-1	8996652
related	O	-1	8996652
to	O	-1	8996652
a	O	-1	8996652
prolonged	O	-1	8996652
administration	O	-1	8996652
and	O	-1	8996652
higher	O	-1	8996652
total	O	-1	8996652
dose	O	-1	8996652
of	O	-1	8996652
ot@@	B-Disease	D006311	8996652
ot@@	I-Disease	-1	8996652
ox@@	I-Disease	-1	8996652
ic	I-Disease	-1	8996652
drug@@	O	-1	8996652
s,	O	-1	8996652
partic@@	O	-1	8996652
ul@@	O	-1	8996652
arly	O	-1	8996652
amino@@	B-Chemical	D000617	8996652
gly@@	I-Chemical	-1	8996652
co@@	I-Chemical	-1	8996652
side@@	I-Chemical	-1	8996652
s	I-Chemical	-1	8996652
and	O	-1	8996652
f@@	B-Chemical	D005665	8996652
uro@@	I-Chemical	-1	8996652
se@@	I-Chemical	-1	8996652
m@@	I-Chemical	-1	8996652
ide	I-Chemical	-1	8996652
.	O	-1	8996652
F@@	O	-1	8996652
in@@	O	-1	8996652
ally,	O	-1	8996652
we	O	-1	8996652
st@@	O	-1	8996652
ron@@	O	-1	8996652
g@@	O	-1	8996652
ly	O	-1	8996652
recomm@@	O	-1	8996652
end	O	-1	8996652
to	O	-1	8996652
pro@@	O	-1	8996652
sp@@	O	-1	8996652
ectively	O	-1	8996652
and	O	-1	8996652
reg@@	O	-1	8996652
ul@@	O	-1	8996652
arly	O	-1	8996652
per@@	O	-1	8996652
form	O	-1	8996652
a@@	O	-1	8996652
udi@@	O	-1	8996652
ologic	O	-1	8996652
assess@@	O	-1	8996652
ment	O	-1	8996652
in	O	-1	8996652
si@@	O	-1	8996652
c@@	O	-1	8996652
k	O	-1	8996652
pre@@	O	-1	8996652
term	O	-1	8996652
children	O	-1	8996652
as	O	-1	8996652
hearing	B-Disease	D034381	8996652
loss	I-Disease	-1	8996652
is	O	-1	8996652
of	O	-1	8996652
del@@	O	-1	8996652
ayed	O	-1	8996652
onset	O	-1	8996652
and	O	-1	8996652
in	O	-1	8996652
most	O	-1	8996652
cases	O	-1	8996652
bil@@	O	-1	8996652
ateral	O	-1	8996652
and	O	-1	8996652
se@@	O	-1	8996652
ve@@	O	-1	8996652
re.	O	-1	8996652

Ph@@	O	-1	84204
armac@@	O	-1	84204
o@@	O	-1	84204
kine@@	O	-1	84204
tic	O	-1	84204
and	O	-1	84204
clinical	O	-1	84204
studies	O	-1	84204
in	O	-1	84204
patients	O	-1	84204
with	O	-1	84204
cimetid@@	B-Chemical	D002927	84204
ine	I-Chemical	-1	84204
-@@	O	-1	84204
associated	O	-1	84204
mental	O	-1	84204
conf@@	B-Disease	D003221	84204
usion	I-Disease	-1	84204
.	O	-1	84204
15	O	-1	84204
cases	O	-1	84204
of	O	-1	84204
cimetid@@	B-Chemical	D002927	84204
ine	I-Chemical	-1	84204
-@@	O	-1	84204
associated	O	-1	84204
mental	O	-1	84204
conf@@	B-Disease	D003221	84204
usion	I-Disease	-1	84204
have	O	-1	84204
been	O	-1	84204
repor@@	O	-1	84204
ted.	O	-1	84204
In	O	-1	84204
or@@	O	-1	84204
der	O	-1	84204
that	O	-1	84204
this	O	-1	84204
syndrome	O	-1	84204
might	O	-1	84204
be	O	-1	84204
investigated	O	-1	84204
changes	O	-1	84204
in	O	-1	84204
mental	O	-1	84204
status	O	-1	84204
(@@	O	-1	84204
M@@	O	-1	84204
.@@	O	-1	84204
S@@	O	-1	84204
.)	O	-1	84204
were	O	-1	84204
cor@@	O	-1	84204
related	O	-1	84204
with	O	-1	84204
serum	O	-1	84204
concentrations	O	-1	84204
and	O	-1	84204
renal	O	-1	84204
and	O	-1	84204
hepatic	O	-1	84204
function	O	-1	84204
in	O	-1	84204
3@@	O	-1	84204
6	O	-1	84204
patients,	O	-1	84204
30	O	-1	84204
patients	O	-1	84204
had	O	-1	84204
no	O	-1	84204
M@@	O	-1	84204
.@@	O	-1	84204
S@@	O	-1	84204
.	O	-1	84204
change	O	-1	84204
on	O	-1	84204
cimetid@@	B-Chemical	D002927	84204
ine	I-Chemical	-1	84204
and	O	-1	84204
6	O	-1	84204
had	O	-1	84204
moder@@	O	-1	84204
ate	O	-1	84204
to	O	-1	84204
severe	O	-1	84204
chang@@	O	-1	84204
es.	O	-1	84204
These	O	-1	84204
6	O	-1	84204
patients	O	-1	84204
had	O	-1	84204
both	O	-1	84204
renal	B-Disease	D051437	84204
and	I-Disease	-1	84204
liver	I-Disease	-1	84204
dysfunction	I-Disease	-1	84204
renal	B-Disease	D008107	84204
and	I-Disease	-1	84204
liver	I-Disease	-1	84204
dysfunction	I-Disease	-1	84204
(P	O	-1	84204
less	O	-1	84204
than	O	-1	84204
0.05@@	O	-1	84204
),	O	-1	84204
as	O	-1	84204
well	O	-1	84204
as	O	-1	84204
cimetid@@	B-Chemical	D002927	84204
ine	I-Chemical	-1	84204
t@@	O	-1	84204
rou@@	O	-1	84204
gh@@	O	-1	84204
-@@	O	-1	84204
concentrations	O	-1	84204
of	O	-1	84204
more	O	-1	84204
than	O	-1	84204
1.@@	O	-1	84204
25	O	-1	84204
microgram@@	O	-1	84204
/@@	O	-1	84204
m@@	O	-1	84204
l	O	-1	84204
(P	O	-1	84204
less	O	-1	84204
than	O	-1	84204
0.05@@	O	-1	84204
).	O	-1	84204
The	O	-1	84204
severity	O	-1	84204
of	O	-1	84204
M@@	O	-1	84204
.@@	O	-1	84204
S@@	O	-1	84204
.	O	-1	84204
changes	O	-1	84204
increased	O	-1	84204
as	O	-1	84204
t@@	O	-1	84204
rou@@	O	-1	84204
gh@@	O	-1	84204
-@@	O	-1	84204
concentrations	O	-1	84204
ro@@	O	-1	84204
se@@	O	-1	84204
,	O	-1	84204
5	O	-1	84204
patients	O	-1	84204
had	O	-1	84204
l@@	O	-1	84204
umb@@	O	-1	84204
ar	O	-1	84204
p@@	O	-1	84204
unc@@	O	-1	84204
t@@	O	-1	84204
ure.	O	-1	84204
The	O	-1	84204
ce@@	O	-1	84204
reb@@	O	-1	84204
ro@@	O	-1	84204
spinal	O	-1	84204
flu@@	O	-1	84204
id@@	O	-1	84204
:	O	-1	84204
serum	O	-1	84204
rati@@	O	-1	84204
o	O	-1	84204
of	O	-1	84204
cimetid@@	B-Chemical	D002927	84204
ine	I-Chemical	-1	84204
concentrations	O	-1	84204
was	O	-1	84204
0.@@	O	-1	84204
2@@	O	-1	84204
4@@	O	-1	84204
:@@	O	-1	84204
1	O	-1	84204
and	O	-1	84204
indic@@	O	-1	84204
ates	O	-1	84204
that	O	-1	84204
cimetid@@	B-Chemical	D002927	84204
ine	I-Chemical	-1	84204
p@@	O	-1	84204
as@@	O	-1	84204
ses	O	-1	84204
the	O	-1	84204
blo@@	O	-1	84204
o@@	O	-1	84204
d-@@	O	-1	84204
brain	O	-1	84204
bar@@	O	-1	84204
ri@@	O	-1	84204
er@@	O	-1	84204
;	O	-1	84204
it	O	-1	84204
also	O	-1	84204
ra@@	O	-1	84204
i@@	O	-1	84204
ses	O	-1	84204
the	O	-1	84204
possib@@	O	-1	84204
ility	O	-1	84204
that	O	-1	84204
M@@	O	-1	84204
.@@	O	-1	84204
S@@	O	-1	84204
.	O	-1	84204
changes	O	-1	84204
are	O	-1	84204
due	O	-1	84204
to	O	-1	84204
block@@	O	-1	84204
ade	O	-1	84204
of	O	-1	84204
hist@@	B-Chemical	D006632	84204
amine	I-Chemical	-1	84204
H@@	O	-1	84204
2-@@	O	-1	84204
receptors	O	-1	84204
in	O	-1	84204
the	O	-1	84204
central	O	-1	84204
ner@@	O	-1	84204
v@@	O	-1	84204
ous	O	-1	84204
system@@	O	-1	84204
.	O	-1	84204
Patients	O	-1	84204
likely	O	-1	84204
to	O	-1	84204
have	O	-1	84204
both	O	-1	84204
ra@@	O	-1	84204
is@@	O	-1	84204
ed	O	-1	84204
t@@	O	-1	84204
rou@@	O	-1	84204
gh@@	O	-1	84204
-@@	O	-1	84204
concentrations	O	-1	84204
and	O	-1	84204
mental	O	-1	84204
conf@@	B-Disease	D003221	84204
usion	I-Disease	-1	84204
are	O	-1	84204
those	O	-1	84204
with	O	-1	84204
both	O	-1	84204
severe	O	-1	84204
renal	B-Disease	D051437	84204
and	I-Disease	-1	84204
hepatic	I-Disease	-1	84204
dysfunction	I-Disease	-1	84204
renal	B-Disease	D008107	84204
and	I-Disease	-1	84204
hepatic	I-Disease	-1	84204
dysfunction	I-Disease	-1	84204
.	O	-1	84204
The@@	O	-1	84204
y	O	-1	84204
should	O	-1	84204
be	O	-1	84204
clo@@	O	-1	84204
se@@	O	-1	84204
ly	O	-1	84204
observed	O	-1	84204
and	O	-1	84204
should	O	-1	84204
be	O	-1	84204
given	O	-1	84204
reduced	O	-1	84204
doses	O	-1	84204
of	O	-1	84204
cimetid@@	B-Chemical	D002927	84204
ine	I-Chemical	-1	84204
.	O	-1	84204

Di@@	O	-1	9862868
fferen@@	O	-1	9862868
t	O	-1	9862868
lo@@	O	-1	9862868
b@@	O	-1	9862868
ular	O	-1	9862868
di@@	O	-1	9862868
stri@@	O	-1	9862868
bu@@	O	-1	9862868
tions	O	-1	9862868
of	O	-1	9862868
al@@	O	-1	9862868
te@@	O	-1	9862868
red	O	-1	9862868
hepat@@	O	-1	9862868
ocyte	O	-1	9862868
ti@@	O	-1	9862868
ght	O	-1	9862868
j@@	O	-1	9862868
unc@@	O	-1	9862868
tions	O	-1	9862868
in	O	-1	9862868
rat	O	-1	9862868
models	O	-1	9862868
of	O	-1	9862868
intra@@	B-Disease	D002780	9862868
hepatic	I-Disease	-1	9862868
and	I-Disease	-1	9862868
ext@@	I-Disease	-1	9862868
ra@@	I-Disease	-1	9862868
hepatic	I-Disease	-1	9862868
cholest@@	I-Disease	-1	9862868
asis	I-Disease	-1	9862868
intra@@	B-Disease	D001651	9862868
hepatic	I-Disease	-1	9862868
and	I-Disease	-1	9862868
ext@@	I-Disease	-1	9862868
ra@@	I-Disease	-1	9862868
hepatic	I-Disease	-1	9862868
cholest@@	I-Disease	-1	9862868
asis	I-Disease	-1	9862868
.	O	-1	9862868
H@@	O	-1	9862868
ep@@	O	-1	9862868
at@@	O	-1	9862868
ocyte	O	-1	9862868
ti@@	O	-1	9862868
ght	O	-1	9862868
j@@	O	-1	9862868
unc@@	O	-1	9862868
tions	O	-1	9862868
(T@@	O	-1	9862868
J@@	O	-1	9862868
s),	O	-1	9862868
the	O	-1	9862868
only	O	-1	9862868
inter@@	O	-1	9862868
cell@@	O	-1	9862868
ular	O	-1	9862868
bar@@	O	-1	9862868
ri@@	O	-1	9862868
er	O	-1	9862868
between	O	-1	9862868
the	O	-1	9862868
s@@	O	-1	9862868
in@@	O	-1	9862868
us@@	O	-1	9862868
oid@@	O	-1	9862868
al	O	-1	9862868
and	O	-1	9862868
the	O	-1	9862868
can@@	O	-1	9862868
al@@	O	-1	9862868
ic@@	O	-1	9862868
ular	O	-1	9862868
sp@@	O	-1	9862868
ac@@	O	-1	9862868
es,	O	-1	9862868
pl@@	O	-1	9862868
ay	O	-1	9862868
a	O	-1	9862868
ke@@	O	-1	9862868
y	O	-1	9862868
role	O	-1	9862868
in	O	-1	9862868
b@@	O	-1	9862868
ile	O	-1	9862868
form@@	O	-1	9862868
ation.	O	-1	9862868
Although	O	-1	9862868
hepat@@	O	-1	9862868
ocyte	O	-1	9862868
T@@	O	-1	9862868
J@@	O	-1	9862868
s	O	-1	9862868
are	O	-1	9862868
impaired	O	-1	9862868
in	O	-1	9862868
cholest@@	B-Disease	D002779	9862868
asis	I-Disease	-1	9862868
,	O	-1	9862868
at@@	O	-1	9862868
tem@@	O	-1	9862868
pt@@	O	-1	9862868
s	O	-1	9862868
to	O	-1	9862868
lo@@	O	-1	9862868
cal@@	O	-1	9862868
iz@@	O	-1	9862868
e	O	-1	9862868
the	O	-1	9862868
pre@@	O	-1	9862868
cis@@	O	-1	9862868
e	O	-1	9862868
sit@@	O	-1	9862868
e	O	-1	9862868
of	O	-1	9862868
hepat@@	O	-1	9862868
ocyte	O	-1	9862868
T@@	O	-1	9862868
J	O	-1	9862868
damage	O	-1	9862868
by	O	-1	9862868
f@@	O	-1	9862868
re@@	O	-1	9862868
e@@	O	-1	9862868
z@@	O	-1	9862868
e-@@	O	-1	9862868
frac@@	O	-1	9862868
t@@	O	-1	9862868
ure	O	-1	9862868
electro@@	O	-1	9862868
n	O	-1	9862868
micro@@	O	-1	9862868
sco@@	O	-1	9862868
p@@	O	-1	9862868
y	O	-1	9862868
have	O	-1	9862868
produced	O	-1	9862868
lim@@	O	-1	9862868
ited	O	-1	9862868
inf@@	O	-1	9862868
orm@@	O	-1	9862868
ation.	O	-1	9862868
Rec@@	O	-1	9862868
ent@@	O	-1	9862868
ly,	O	-1	9862868
several	O	-1	9862868
T@@	O	-1	9862868
J@@	O	-1	9862868
-@@	O	-1	9862868
associated	O	-1	9862868
protein@@	O	-1	9862868
s	O	-1	9862868
like	O	-1	9862868
Z@@	O	-1	9862868
O@@	O	-1	9862868
-1	O	-1	9862868
and	O	-1	9862868
7@@	O	-1	9862868
H@@	O	-1	9862868
6	O	-1	9862868
have	O	-1	9862868
been	O	-1	9862868
identi@@	O	-1	9862868
fied	O	-1	9862868
and	O	-1	9862868
character@@	O	-1	9862868
iz@@	O	-1	9862868
ed.	O	-1	9862868
Im@@	O	-1	9862868
mun@@	O	-1	9862868
o@@	O	-1	9862868
lo@@	O	-1	9862868
cal@@	O	-1	9862868
ization	O	-1	9862868
of	O	-1	9862868
7@@	O	-1	9862868
H@@	O	-1	9862868
6	O	-1	9862868
appear@@	O	-1	9862868
s	O	-1	9862868
to	O	-1	9862868
clo@@	O	-1	9862868
se@@	O	-1	9862868
ly	O	-1	9862868
correl@@	O	-1	9862868
ate	O	-1	9862868
with	O	-1	9862868
par@@	O	-1	9862868
ace@@	O	-1	9862868
ll@@	O	-1	9862868
ular	O	-1	9862868
per@@	O	-1	9862868
me@@	O	-1	9862868
abil@@	O	-1	9862868
ity.	O	-1	9862868
We	O	-1	9862868
used	O	-1	9862868
rat	O	-1	9862868
models	O	-1	9862868
of	O	-1	9862868
intra@@	B-Disease	D002780	9862868
hepatic	I-Disease	-1	9862868
cholest@@	I-Disease	-1	9862868
asis	I-Disease	-1	9862868
by	O	-1	9862868
eth@@	B-Chemical	D004997	9862868
in@@	I-Chemical	-1	9862868
yl	I-Chemical	-1	9862868
est@@	I-Chemical	-1	9862868
radi@@	I-Chemical	-1	9862868
ol	I-Chemical	-1	9862868
(	O	-1	9862868
E@@	B-Chemical	D004997	9862868
E	I-Chemical	-1	9862868
)	O	-1	9862868
treatment	O	-1	9862868
and	O	-1	9862868
ext@@	B-Disease	D001651	9862868
ra@@	I-Disease	-1	9862868
hepatic	I-Disease	-1	9862868
cholest@@	I-Disease	-1	9862868
asis	I-Disease	-1	9862868
by	O	-1	9862868
b@@	O	-1	9862868
ile	O	-1	9862868
duc@@	O	-1	9862868
t	O	-1	9862868
li@@	O	-1	9862868
g@@	O	-1	9862868
ation	O	-1	9862868
(B@@	O	-1	9862868
D@@	O	-1	9862868
L@@	O	-1	9862868
)	O	-1	9862868
to	O	-1	9862868
pre@@	O	-1	9862868
ci@@	O	-1	9862868
se@@	O	-1	9862868
ly	O	-1	9862868
determine	O	-1	9862868
the	O	-1	9862868
sit@@	O	-1	9862868
e	O	-1	9862868
of	O	-1	9862868
T@@	O	-1	9862868
J	O	-1	9862868
dam@@	O	-1	9862868
age.	O	-1	9862868
Al@@	O	-1	9862868
ter@@	O	-1	9862868
ations	O	-1	9862868
in	O	-1	9862868
hepat@@	O	-1	9862868
ocyte	O	-1	9862868
T@@	O	-1	9862868
J@@	O	-1	9862868
s	O	-1	9862868
were	O	-1	9862868
assessed	O	-1	9862868
by	O	-1	9862868
double-@@	O	-1	9862868
immun@@	O	-1	9862868
ol@@	O	-1	9862868
a@@	O	-1	9862868
be@@	O	-1	9862868
l@@	O	-1	9862868
ing	O	-1	9862868
for	O	-1	9862868
7@@	O	-1	9862868
H@@	O	-1	9862868
6	O	-1	9862868
and	O	-1	9862868
Z@@	O	-1	9862868
O@@	O	-1	9862868
-1	O	-1	9862868
using	O	-1	9862868
a	O	-1	9862868
conf@@	O	-1	9862868
oc@@	O	-1	9862868
al	O	-1	9862868
las@@	O	-1	9862868
er	O	-1	9862868
s@@	O	-1	9862868
can@@	O	-1	9862868
ning	O	-1	9862868
micro@@	O	-1	9862868
sco@@	O	-1	9862868
p@@	O	-1	9862868
e.	O	-1	9862868
In	O	-1	9862868
control	O	-1	9862868
rats,	O	-1	9862868
immun@@	O	-1	9862868
ost@@	O	-1	9862868
aining	O	-1	9862868
for	O	-1	9862868
7@@	O	-1	9862868
H@@	O	-1	9862868
6	O	-1	9862868
and	O	-1	9862868
Z@@	O	-1	9862868
O@@	O	-1	9862868
-1	O	-1	9862868
co@@	O	-1	9862868
lo@@	O	-1	9862868
cal@@	O	-1	9862868
ized	O	-1	9862868
to	O	-1	9862868
out@@	O	-1	9862868
line	O	-1	9862868
b@@	O	-1	9862868
ile	O	-1	9862868
can@@	O	-1	9862868
al@@	O	-1	9862868
ic@@	O	-1	9862868
ul@@	O	-1	9862868
i	O	-1	9862868
in	O	-1	9862868
a	O	-1	9862868
continu@@	O	-1	9862868
ous	O	-1	9862868
f@@	O	-1	9862868
as@@	O	-1	9862868
hi@@	O	-1	9862868
on@@	O	-1	9862868
.	O	-1	9862868
In	O	-1	9862868
contrast@@	O	-1	9862868
,	O	-1	9862868
7@@	O	-1	9862868
H@@	O	-1	9862868
6	O	-1	9862868
and	O	-1	9862868
Z@@	O	-1	9862868
O@@	O	-1	9862868
-1	O	-1	9862868
immun@@	O	-1	9862868
ost@@	O	-1	9862868
aining	O	-1	9862868
was	O	-1	9862868
more	O	-1	9862868
discontinu@@	O	-1	9862868
ou@@	O	-1	9862868
s,	O	-1	9862868
out@@	O	-1	9862868
lin@@	O	-1	9862868
ing	O	-1	9862868
the	O	-1	9862868
b@@	O	-1	9862868
ile	O	-1	9862868
can@@	O	-1	9862868
al@@	O	-1	9862868
ic@@	O	-1	9862868
ul@@	O	-1	9862868
i	O	-1	9862868
after	O	-1	9862868
B@@	O	-1	9862868
D@@	O	-1	9862868
L@@	O	-1	9862868
.	O	-1	9862868
Im@@	O	-1	9862868
mun@@	O	-1	9862868
ost@@	O	-1	9862868
aining	O	-1	9862868
for	O	-1	9862868
7@@	O	-1	9862868
H@@	O	-1	9862868
6,	O	-1	9862868
not	O	-1	9862868
Z@@	O	-1	9862868
O@@	O	-1	9862868
-1@@	O	-1	9862868
,	O	-1	9862868
decreased	O	-1	9862868
and	O	-1	9862868
pre@@	O	-1	9862868
domin@@	O	-1	9862868
ant@@	O	-1	9862868
ly	O	-1	9862868
appe@@	O	-1	9862868
a@@	O	-1	9862868
red	O	-1	9862868
as	O	-1	9862868
disc@@	O	-1	9862868
ret@@	O	-1	9862868
e	O	-1	9862868
sign@@	O	-1	9862868
als	O	-1	9862868
in	O	-1	9862868
the	O	-1	9862868
sub@@	O	-1	9862868
membran@@	O	-1	9862868
ous	O	-1	9862868
cyto@@	O	-1	9862868
plas@@	O	-1	9862868
m	O	-1	9862868
of	O	-1	9862868
peri@@	O	-1	9862868
port@@	O	-1	9862868
al	O	-1	9862868
hepat@@	O	-1	9862868
ocy@@	O	-1	9862868
tes	O	-1	9862868
after	O	-1	9862868
B@@	O	-1	9862868
D@@	O	-1	9862868
L@@	O	-1	9862868
.	O	-1	9862868
After	O	-1	9862868
E@@	B-Chemical	D004997	9862868
E	I-Chemical	-1	9862868
treatment,	O	-1	9862868
changes	O	-1	9862868
in	O	-1	9862868
immun@@	O	-1	9862868
ost@@	O	-1	9862868
aining	O	-1	9862868
for	O	-1	9862868
7@@	O	-1	9862868
H@@	O	-1	9862868
6	O	-1	9862868
and	O	-1	9862868
Z@@	O	-1	9862868
O@@	O	-1	9862868
-1	O	-1	9862868
were	O	-1	9862868
similar	O	-1	9862868
to	O	-1	9862868
those	O	-1	9862868
seen	O	-1	9862868
in	O	-1	9862868
peri@@	O	-1	9862868
port@@	O	-1	9862868
al	O	-1	9862868
hepat@@	O	-1	9862868
ocy@@	O	-1	9862868
tes	O	-1	9862868
after	O	-1	9862868
B@@	O	-1	9862868
D@@	O	-1	9862868
L@@	O	-1	9862868
,	O	-1	9862868
but	O	-1	9862868
di@@	O	-1	9862868
stri@@	O	-1	9862868
but@@	O	-1	9862868
ed	O	-1	9862868
more	O	-1	9862868
diff@@	O	-1	9862868
use@@	O	-1	9862868
ly	O	-1	9862868
throu@@	O	-1	9862868
gh@@	O	-1	9862868
out	O	-1	9862868
the	O	-1	9862868
lo@@	O	-1	9862868
b@@	O	-1	9862868
ul@@	O	-1	9862868
e.	O	-1	9862868
This	O	-1	9862868
study	O	-1	9862868
is	O	-1	9862868
the	O	-1	9862868
first	O	-1	9862868
to	O	-1	9862868
demon@@	O	-1	9862868
st@@	O	-1	9862868
rate	O	-1	9862868
that	O	-1	9862868
impair@@	O	-1	9862868
ment	O	-1	9862868
of	O	-1	9862868
hepat@@	O	-1	9862868
ocyte	O	-1	9862868
T@@	O	-1	9862868
J@@	O	-1	9862868
s	O	-1	9862868
occur@@	O	-1	9862868
s	O	-1	9862868
he@@	O	-1	9862868
ter@@	O	-1	9862868
o@@	O	-1	9862868
gen@@	O	-1	9862868
ously	O	-1	9862868
in	O	-1	9862868
the	O	-1	9862868
liver	O	-1	9862868
lo@@	O	-1	9862868
b@@	O	-1	9862868
ul@@	O	-1	9862868
e	O	-1	9862868
after	O	-1	9862868
B@@	O	-1	9862868
D@@	O	-1	9862868
L	O	-1	9862868
and	O	-1	9862868
suggests	O	-1	9862868
that	O	-1	9862868
B@@	O	-1	9862868
D@@	O	-1	9862868
L	O	-1	9862868
and	O	-1	9862868
E@@	B-Chemical	D004997	9862868
E	I-Chemical	-1	9862868
treat@@	O	-1	9862868
ments	O	-1	9862868
produce	O	-1	9862868
different	O	-1	9862868
lo@@	O	-1	9862868
b@@	O	-1	9862868
ular	O	-1	9862868
di@@	O	-1	9862868
stri@@	O	-1	9862868
bu@@	O	-1	9862868
tions	O	-1	9862868
of	O	-1	9862868
increased	O	-1	9862868
par@@	O	-1	9862868
ace@@	O	-1	9862868
ll@@	O	-1	9862868
ular	O	-1	9862868
per@@	O	-1	9862868
me@@	O	-1	9862868
abil@@	O	-1	9862868
ity.	O	-1	9862868

L@@	O	-1	15515654
ong	O	-1	15515654
term	O	-1	15515654
a@@	O	-1	15515654
udi@@	O	-1	15515654
ological	O	-1	15515654
evalu@@	O	-1	15515654
ation	O	-1	15515654
of	O	-1	15515654
beta-@@	B-Disease	D017086	15515654
thal@@	I-Disease	-1	15515654
as@@	I-Disease	-1	15515654
se@@	I-Disease	-1	15515654
mic	I-Disease	-1	15515654
patients.	O	-1	15515654
OBJECTIVE:	O	-1	15515654
The	O	-1	15515654
ob@@	O	-1	15515654
j@@	O	-1	15515654
ective	O	-1	15515654
of	O	-1	15515654
this	O	-1	15515654
study	O	-1	15515654
was	O	-1	15515654
to	O	-1	15515654
identi@@	O	-1	15515654
f@@	O	-1	15515654
y	O	-1	15515654
the	O	-1	15515654
incidence	O	-1	15515654
and	O	-1	15515654
to	O	-1	15515654
monit@@	O	-1	15515654
or	O	-1	15515654
the	O	-1	15515654
progres@@	O	-1	15515654
sion	O	-1	15515654
of	O	-1	15515654
hearing	B-Disease	D034381	15515654
loss	I-Disease	-1	15515654
in	O	-1	15515654
children	O	-1	15515654
and	O	-1	15515654
youn@@	O	-1	15515654
g	O	-1	15515654
ad@@	O	-1	15515654
ult@@	O	-1	15515654
s	O	-1	15515654
with	O	-1	15515654
beta-@@	B-Disease	D017086	15515654
thal@@	I-Disease	-1	15515654
as@@	I-Disease	-1	15515654
se@@	I-Disease	-1	15515654
mia	I-Disease	-1	15515654
maj@@	O	-1	15515654
or@@	O	-1	15515654
.	O	-1	15515654
METHODS:	O	-1	15515654
One	O	-1	15515654
h@@	O	-1	15515654
und@@	O	-1	15515654
red	O	-1	15515654
and	O	-1	15515654
four	O	-1	15515654
(@@	O	-1	15515654
10@@	O	-1	15515654
4@@	O	-1	15515654
)	O	-1	15515654
patients	O	-1	15515654
aged	O	-1	15515654
6-@@	O	-1	15515654
3@@	O	-1	15515654
5	O	-1	15515654
years	O	-1	15515654
(@@	O	-1	15515654
mean	O	-1	15515654
17@@	O	-1	15515654
,@@	O	-1	15515654
2	O	-1	15515654
year@@	O	-1	15515654
s)	O	-1	15515654
partic@@	O	-1	15515654
ip@@	O	-1	15515654
ated	O	-1	15515654
in	O	-1	15515654
the	O	-1	15515654
study.	O	-1	15515654
All	O	-1	15515654
patients	O	-1	15515654
were	O	-1	15515654
on	O	-1	15515654
a	O	-1	15515654
reg@@	O	-1	15515654
ular	O	-1	15515654
trans@@	O	-1	15515654
fu@@	O	-1	15515654
sion@@	O	-1	15515654
-@@	O	-1	15515654
ch@@	O	-1	15515654
el@@	O	-1	15515654
ation	O	-1	15515654
pro@@	O	-1	15515654
gra@@	O	-1	15515654
m	O	-1	15515654
maint@@	O	-1	15515654
aining	O	-1	15515654
a	O	-1	15515654
mean	O	-1	15515654
hemo@@	O	-1	15515654
globin	O	-1	15515654
level	O	-1	15515654
of	O	-1	15515654
9.@@	O	-1	15515654
5	O	-1	15515654
g@@	O	-1	15515654
r@@	O	-1	15515654
/@@	O	-1	15515654
d@@	O	-1	15515654
l@@	O	-1	15515654
.	O	-1	15515654
S@@	O	-1	15515654
ub@@	O	-1	15515654
j@@	O	-1	15515654
ects	O	-1	15515654
were	O	-1	15515654
receiving	O	-1	15515654
des@@	B-Chemical	D003676	15515654
fer@@	I-Chemical	-1	15515654
ri@@	I-Chemical	-1	15515654
ox@@	I-Chemical	-1	15515654
amine	I-Chemical	-1	15515654
(	O	-1	15515654
DF@@	B-Chemical	D003676	15515654
O	I-Chemical	-1	15515654
)	O	-1	15515654
ch@@	O	-1	15515654
el@@	O	-1	15515654
ation	O	-1	15515654
treatment	O	-1	15515654
with	O	-1	15515654
a	O	-1	15515654
mean	O	-1	15515654
daily	O	-1	15515654
dose	O	-1	15515654
of	O	-1	15515654
50@@	O	-1	15515654
-@@	O	-1	15515654
60	O	-1	15515654
mg/kg@@	O	-1	15515654
,	O	-1	15515654
5-@@	O	-1	15515654
6	O	-1	15515654
days	O	-1	15515654
a	O	-1	15515654
week	O	-1	15515654
during	O	-1	15515654
the	O	-1	15515654
first	O	-1	15515654
six	O	-1	15515654
years	O	-1	15515654
of	O	-1	15515654
the	O	-1	15515654
study,	O	-1	15515654
which	O	-1	15515654
was	O	-1	15515654
then	O	-1	15515654
reduced	O	-1	15515654
to	O	-1	15515654
4@@	O	-1	15515654
0-@@	O	-1	15515654
50	O	-1	15515654
mg/kg	O	-1	15515654
for	O	-1	15515654
the	O	-1	15515654
following	O	-1	15515654
e@@	O	-1	15515654
ight	O	-1	15515654
year@@	O	-1	15515654
s.	O	-1	15515654
Patients	O	-1	15515654
were	O	-1	15515654
followed	O	-1	15515654
for	O	-1	15515654
8@@	O	-1	15515654
-1@@	O	-1	15515654
4	O	-1	15515654
year@@	O	-1	15515654
s.	O	-1	15515654
RESULTS:	O	-1	15515654
O@@	O	-1	15515654
ver@@	O	-1	15515654
all@@	O	-1	15515654
,	O	-1	15515654
21	O	-1	15515654
out	O	-1	15515654
of	O	-1	15515654
10@@	O	-1	15515654
4	O	-1	15515654
patients	O	-1	15515654
(2@@	O	-1	15515654
0.@@	O	-1	15515654
2@@	O	-1	15515654
%)	O	-1	15515654
presented	O	-1	15515654
with	O	-1	15515654
high	O	-1	15515654
frequency	O	-1	15515654
sens@@	B-Disease	D006319	15515654
or@@	I-Disease	-1	15515654
ine@@	I-Disease	-1	15515654
ural	I-Disease	-1	15515654
hearing	I-Disease	-1	15515654
loss	I-Disease	-1	15515654
(	O	-1	15515654
S@@	B-Disease	D006319	15515654
N@@	I-Disease	-1	15515654
H@@	I-Disease	-1	15515654
L	I-Disease	-1	15515654
),	O	-1	15515654
either	O	-1	15515654
un@@	O	-1	15515654
il@@	O	-1	15515654
ateral	O	-1	15515654
or	O	-1	15515654
bil@@	O	-1	15515654
at@@	O	-1	15515654
er@@	O	-1	15515654
al.	O	-1	15515654
No	O	-1	15515654
ot@@	B-Disease	D006311	15515654
ot@@	I-Disease	-1	15515654
ox@@	I-Disease	-1	15515654
ic	I-Disease	-1	15515654
fact@@	O	-1	15515654
or@@	O	-1	15515654
,	O	-1	15515654
other	O	-1	15515654
than	O	-1	15515654
DF@@	B-Chemical	D003676	15515654
O	I-Chemical	-1	15515654
,	O	-1	15515654
was	O	-1	15515654
present	O	-1	15515654
in	O	-1	15515654
any	O	-1	15515654
of	O	-1	15515654
the	O	-1	15515654
patients.	O	-1	15515654
Patients	O	-1	15515654
with	O	-1	15515654
S@@	B-Disease	D006319	15515654
N@@	I-Disease	-1	15515654
H@@	I-Disease	-1	15515654
L	I-Disease	-1	15515654
presented	O	-1	15515654
with	O	-1	15515654
rel@@	O	-1	15515654
atively	O	-1	15515654
lower	O	-1	15515654
serum	O	-1	15515654
fer@@	O	-1	15515654
ri@@	O	-1	15515654
tin	O	-1	15515654
levels	O	-1	15515654
than	O	-1	15515654
those	O	-1	15515654
with	O	-1	15515654
normal	O	-1	15515654
hear@@	O	-1	15515654
ing,	O	-1	15515654
however,	O	-1	15515654
no	O	-1	15515654
statis@@	O	-1	15515654
tically	O	-1	15515654
significant	O	-1	15515654
difference	O	-1	15515654
was	O	-1	15515654
obser@@	O	-1	15515654
ved.	O	-1	15515654
S@@	O	-1	15515654
ub@@	O	-1	15515654
j@@	O	-1	15515654
ects	O	-1	15515654
with	O	-1	15515654
S@@	B-Disease	D006319	15515654
N@@	I-Disease	-1	15515654
H@@	I-Disease	-1	15515654
L	I-Disease	-1	15515654
were	O	-1	15515654
sub@@	O	-1	15515654
mit@@	O	-1	15515654
ted	O	-1	15515654
to	O	-1	15515654
DF@@	B-Chemical	D003676	15515654
O	I-Chemical	-1	15515654
reduction	O	-1	15515654
or	O	-1	15515654
tempor@@	O	-1	15515654
ary	O	-1	15515654
withdraw@@	O	-1	15515654
al.	O	-1	15515654
F@@	O	-1	15515654
ol@@	O	-1	15515654
low@@	O	-1	15515654
ing	O	-1	15515654
inter@@	O	-1	15515654
ven@@	O	-1	15515654
tion,	O	-1	15515654
7	O	-1	15515654
out	O	-1	15515654
of	O	-1	15515654
21	O	-1	15515654
affected	O	-1	15515654
patients	O	-1	15515654
reco@@	O	-1	15515654
ve@@	O	-1	15515654
re@@	O	-1	15515654
d,	O	-1	15515654
10	O	-1	15515654
remained	O	-1	15515654
st@@	O	-1	15515654
able	O	-1	15515654
and	O	-1	15515654
4	O	-1	15515654
demonstrated	O	-1	15515654
ag@@	O	-1	15515654
gra@@	O	-1	15515654
v@@	O	-1	15515654
ation.	O	-1	15515654
CONCLUSION:	O	-1	15515654
The	O	-1	15515654
findings	O	-1	15515654
are	O	-1	15515654
indic@@	O	-1	15515654
ative	O	-1	15515654
of	O	-1	15515654
DF@@	B-Chemical	D003676	15515654
O	I-Chemical	-1	15515654
's	O	-1	15515654
cont@@	O	-1	15515654
ri@@	O	-1	15515654
but@@	O	-1	15515654
ing	O	-1	15515654
role	O	-1	15515654
in	O	-1	15515654
the	O	-1	15515654
development	O	-1	15515654
of	O	-1	15515654
hearing	B-Disease	D034381	15515654
impair@@	I-Disease	-1	15515654
ment	I-Disease	-1	15515654
.	O	-1	15515654
Re@@	O	-1	15515654
g@@	O	-1	15515654
ular	O	-1	15515654
a@@	O	-1	15515654
udi@@	O	-1	15515654
ologic	O	-1	15515654
evalu@@	O	-1	15515654
ation	O	-1	15515654
is	O	-1	15515654
im@@	O	-1	15515654
perative	O	-1	15515654
in	O	-1	15515654
all	O	-1	15515654
thal@@	B-Disease	D013789	15515654
as@@	I-Disease	-1	15515654
se@@	I-Disease	-1	15515654
mic	I-Disease	-1	15515654
patients	O	-1	15515654
so	O	-1	15515654
that	O	-1	15515654
early	O	-1	15515654
changes	O	-1	15515654
may	O	-1	15515654
be	O	-1	15515654
reco@@	O	-1	15515654
gn@@	O	-1	15515654
ized	O	-1	15515654
and	O	-1	15515654
treatment	O	-1	15515654
may	O	-1	15515654
be	O	-1	15515654
j@@	O	-1	15515654
ud@@	O	-1	15515654
ici@@	O	-1	15515654
ously	O	-1	15515654
adjust@@	O	-1	15515654
ed	O	-1	15515654
in	O	-1	15515654
or@@	O	-1	15515654
der	O	-1	15515654
to	O	-1	15515654
prev@@	O	-1	15515654
ent	O	-1	15515654
or	O	-1	15515654
re@@	O	-1	15515654
verse	O	-1	15515654
hearing	B-Disease	D034381	15515654
impair@@	I-Disease	-1	15515654
ment	I-Disease	-1	15515654
.	O	-1	15515654

De@@	O	-1	2024540
si@@	O	-1	2024540
g@@	O	-1	2024540
n	O	-1	2024540
and	O	-1	2024540
analysis	O	-1	2024540
of	O	-1	2024540
the	O	-1	2024540
H@@	O	-1	2024540
Y@@	O	-1	2024540
P@@	O	-1	2024540
R@@	O	-1	2024540
E@@	O	-1	2024540
N@@	O	-1	2024540
-@@	O	-1	2024540
tri@@	O	-1	2024540
al@@	O	-1	2024540
:	O	-1	2024540
safety	O	-1	2024540
of	O	-1	2024540
en@@	B-Chemical	D004656	2024540
al@@	I-Chemical	-1	2024540
apri@@	I-Chemical	-1	2024540
l	I-Chemical	-1	2024540
and	O	-1	2024540
praz@@	B-Chemical	D011224	2024540
os@@	I-Chemical	-1	2024540
in	I-Chemical	-1	2024540
in	O	-1	2024540
the	O	-1	2024540
initial	O	-1	2024540
treatment	O	-1	2024540
phase	O	-1	2024540
of	O	-1	2024540
patients	O	-1	2024540
with	O	-1	2024540
con@@	B-Disease	D006333	2024540
g@@	I-Disease	-1	2024540
es@@	I-Disease	-1	2024540
tive	I-Disease	-1	2024540
heart	I-Disease	-1	2024540
failure	I-Disease	-1	2024540
.	O	-1	2024540
S@@	O	-1	2024540
inc@@	O	-1	2024540
e	O	-1	2024540
the	O	-1	2024540
int@@	O	-1	2024540
ro@@	O	-1	2024540
duction	O	-1	2024540
of	O	-1	2024540
angiotens@@	B-Chemical	D000806	2024540
in	I-Chemical	-1	2024540
conver@@	I-Chemical	-1	2024540
ting	I-Chemical	-1	2024540
enzyme	I-Chemical	-1	2024540
(@@	I-Chemical	-1	2024540
AC@@	I-Chemical	-1	2024540
E@@	I-Chemical	-1	2024540
)	I-Chemical	-1	2024540
inhibitors	I-Chemical	-1	2024540
into	O	-1	2024540
the	O	-1	2024540
adj@@	O	-1	2024540
unc@@	O	-1	2024540
tive	O	-1	2024540
treatment	O	-1	2024540
of	O	-1	2024540
patients	O	-1	2024540
with	O	-1	2024540
con@@	B-Disease	D006333	2024540
g@@	I-Disease	-1	2024540
es@@	I-Disease	-1	2024540
tive	I-Disease	-1	2024540
heart	I-Disease	-1	2024540
failure	I-Disease	-1	2024540
,	O	-1	2024540
cases	O	-1	2024540
of	O	-1	2024540
severe	O	-1	2024540
hypotension	B-Disease	D007022	2024540
,	O	-1	2024540
es@@	O	-1	2024540
p@@	O	-1	2024540
ec@@	O	-1	2024540
i@@	O	-1	2024540
ally	O	-1	2024540
on	O	-1	2024540
the	O	-1	2024540
first	O	-1	2024540
day	O	-1	2024540
of	O	-1	2024540
treatment,	O	-1	2024540
have	O	-1	2024540
oc@@	O	-1	2024540
ca@@	O	-1	2024540
sion@@	O	-1	2024540
ally	O	-1	2024540
been	O	-1	2024540
repor@@	O	-1	2024540
ted.	O	-1	2024540
To	O	-1	2024540
ass@@	O	-1	2024540
ess	O	-1	2024540
the	O	-1	2024540
safety	O	-1	2024540
of	O	-1	2024540
the	O	-1	2024540
AC@@	B-Chemical	D000806	2024540
E	I-Chemical	-1	2024540
inhibitor	I-Chemical	-1	2024540
en@@	B-Chemical	D004656	2024540
al@@	I-Chemical	-1	2024540
apri@@	I-Chemical	-1	2024540
l	I-Chemical	-1	2024540
a	O	-1	2024540
mul@@	O	-1	2024540
tic@@	O	-1	2024540
ent@@	O	-1	2024540
er,	O	-1	2024540
random@@	O	-1	2024540
iz@@	O	-1	2024540
ed,	O	-1	2024540
praz@@	B-Chemical	D011224	2024540
os@@	I-Chemical	-1	2024540
in	I-Chemical	-1	2024540
-@@	O	-1	2024540
controlled	O	-1	2024540
trial	O	-1	2024540
was	O	-1	2024540
de@@	O	-1	2024540
signed	O	-1	2024540
that	O	-1	2024540
compared	O	-1	2024540
the	O	-1	2024540
incidence	O	-1	2024540
and	O	-1	2024540
severity	O	-1	2024540
of	O	-1	2024540
symptom@@	O	-1	2024540
atic	O	-1	2024540
hypotension	B-Disease	D007022	2024540
on	O	-1	2024540
the	O	-1	2024540
first	O	-1	2024540
day	O	-1	2024540
of	O	-1	2024540
treatment.	O	-1	2024540
T@@	O	-1	2024540
rial	O	-1	2024540
medic@@	O	-1	2024540
ation	O	-1	2024540
was	O	-1	2024540
2.@@	O	-1	2024540
5	O	-1	2024540
mg	O	-1	2024540
en@@	B-Chemical	D004656	2024540
al@@	I-Chemical	-1	2024540
apri@@	I-Chemical	-1	2024540
l	I-Chemical	-1	2024540
or	O	-1	2024540
0.@@	O	-1	2024540
5	O	-1	2024540
praz@@	B-Chemical	D011224	2024540
os@@	I-Chemical	-1	2024540
in	I-Chemical	-1	2024540
.	O	-1	2024540
S@@	O	-1	2024540
ub@@	O	-1	2024540
j@@	O	-1	2024540
ects	O	-1	2024540
were	O	-1	2024540
12@@	O	-1	2024540
10	O	-1	2024540
in@@	O	-1	2024540
patients	O	-1	2024540
with	O	-1	2024540
Ne@@	O	-1	2024540
w	O	-1	2024540
Y@@	O	-1	2024540
or@@	O	-1	2024540
k	O	-1	2024540
H@@	O	-1	2024540
ear@@	O	-1	2024540
t	O	-1	2024540
A@@	O	-1	2024540
s@@	O	-1	2024540
s@@	O	-1	2024540
oci@@	O	-1	2024540
ation	O	-1	2024540
(N@@	O	-1	2024540
Y@@	O	-1	2024540
H@@	O	-1	2024540
A@@	O	-1	2024540
)	O	-1	2024540
functional	O	-1	2024540
cl@@	O	-1	2024540
as@@	O	-1	2024540
s	O	-1	2024540
II	O	-1	2024540
and	O	-1	2024540
II@@	O	-1	2024540
I@@	O	-1	2024540
.	O	-1	2024540
Patients	O	-1	2024540
who	O	-1	2024540
received	O	-1	2024540
en@@	B-Chemical	D004656	2024540
al@@	I-Chemical	-1	2024540
apri@@	I-Chemical	-1	2024540
l	I-Chemical	-1	2024540
experienced	O	-1	2024540
clin@@	O	-1	2024540
ically	O	-1	2024540
and	O	-1	2024540
statis@@	O	-1	2024540
tically	O	-1	2024540
significantly	O	-1	2024540
less	O	-1	2024540
symptom@@	O	-1	2024540
atic	O	-1	2024540
hypotension	B-Disease	D007022	2024540
(@@	O	-1	2024540
5.@@	O	-1	2024540
2@@	O	-1	2024540
%)	O	-1	2024540
than	O	-1	2024540
the	O	-1	2024540
patients	O	-1	2024540
who	O	-1	2024540
received	O	-1	2024540
praz@@	B-Chemical	D011224	2024540
os@@	I-Chemical	-1	2024540
in	I-Chemical	-1	2024540
(1@@	O	-1	2024540
2.@@	O	-1	2024540
9@@	O	-1	2024540
%).	O	-1	2024540
All	O	-1	2024540
patients	O	-1	2024540
reco@@	O	-1	2024540
ve@@	O	-1	2024540
red.	O	-1	2024540
It	O	-1	2024540
was	O	-1	2024540
concl@@	O	-1	2024540
uded	O	-1	2024540
that	O	-1	2024540
treatment	O	-1	2024540
with	O	-1	2024540
en@@	B-Chemical	D004656	2024540
al@@	I-Chemical	-1	2024540
apri@@	I-Chemical	-1	2024540
l	I-Chemical	-1	2024540
was	O	-1	2024540
well	O	-1	2024540
toler@@	O	-1	2024540
ated	O	-1	2024540
and	O	-1	2024540
it	O	-1	2024540
is@@	O	-1	2024540
,	O	-1	2024540
the@@	O	-1	2024540
refore,	O	-1	2024540
un@@	O	-1	2024540
reas@@	O	-1	2024540
on@@	O	-1	2024540
able	O	-1	2024540
to	O	-1	2024540
re@@	O	-1	2024540
stric@@	O	-1	2024540
t	O	-1	2024540
the	O	-1	2024540
initi@@	O	-1	2024540
ation	O	-1	2024540
of	O	-1	2024540
treatment	O	-1	2024540
with	O	-1	2024540
en@@	B-Chemical	D004656	2024540
al@@	I-Chemical	-1	2024540
apri@@	I-Chemical	-1	2024540
l	I-Chemical	-1	2024540
to	O	-1	2024540
in@@	O	-1	2024540
patients.	O	-1	2024540

An@@	O	-1	12090760
t@@	O	-1	12090760
agon@@	O	-1	12090760
ism	O	-1	12090760
between	O	-1	12090760
inter@@	O	-1	12090760
leuk@@	O	-1	12090760
in	O	-1	12090760
3	O	-1	12090760
and	O	-1	12090760
erythro@@	O	-1	12090760
po@@	O	-1	12090760
i@@	O	-1	12090760
e@@	O	-1	12090760
tin	O	-1	12090760
in	O	-1	12090760
mice	O	-1	12090760
with	O	-1	12090760
az@@	B-Chemical	D015215	12090760
id@@	I-Chemical	-1	12090760
o@@	I-Chemical	-1	12090760
th@@	I-Chemical	-1	12090760
ym@@	I-Chemical	-1	12090760
idine	I-Chemical	-1	12090760
-induced	O	-1	12090760
anemia	B-Disease	D000740	12090760
and	O	-1	12090760
in	O	-1	12090760
b@@	O	-1	12090760
one	O	-1	12090760
m@@	O	-1	12090760
ar@@	O	-1	12090760
ro@@	O	-1	12090760
w	O	-1	12090760
endothelial	O	-1	12090760
cell@@	O	-1	12090760
s.	O	-1	12090760
A@@	B-Chemical	D015215	12090760
z@@	I-Chemical	-1	12090760
id@@	I-Chemical	-1	12090760
o@@	I-Chemical	-1	12090760
th@@	I-Chemical	-1	12090760
ym@@	I-Chemical	-1	12090760
idine	I-Chemical	-1	12090760
(	O	-1	12090760
A@@	B-Chemical	D015215	12090760
Z@@	I-Chemical	-1	12090760
T	I-Chemical	-1	12090760
)@@	O	-1	12090760
-induced	O	-1	12090760
anemia	B-Disease	D000740	12090760
in	O	-1	12090760
mice	O	-1	12090760
can	O	-1	12090760
be	O	-1	12090760
reversed	O	-1	12090760
by	O	-1	12090760
the	O	-1	12090760
administration	O	-1	12090760
of	O	-1	12090760
I@@	O	-1	12090760
GF@@	O	-1	12090760
-@@	O	-1	12090760
I@@	O	-1	12090760
L-@@	O	-1	12090760
3	O	-1	12090760
(@@	O	-1	12090760
f@@	O	-1	12090760
usion	O	-1	12090760
protein	O	-1	12090760
of	O	-1	12090760
in@@	O	-1	12090760
sul@@	O	-1	12090760
in-@@	O	-1	12090760
like	O	-1	12090760
growth	O	-1	12090760
factor	O	-1	12090760
II	O	-1	12090760
(@@	O	-1	12090760
I@@	O	-1	12090760
G@@	O	-1	12090760
F	O	-1	12090760
II@@	O	-1	12090760
)	O	-1	12090760
and	O	-1	12090760
inter@@	O	-1	12090760
leuk@@	O	-1	12090760
in	O	-1	12090760
3@@	O	-1	12090760
).	O	-1	12090760
Although	O	-1	12090760
inter@@	O	-1	12090760
leuk@@	O	-1	12090760
in	O	-1	12090760
3	O	-1	12090760
(@@	O	-1	12090760
I@@	O	-1	12090760
L-@@	O	-1	12090760
3@@	O	-1	12090760
)	O	-1	12090760
and	O	-1	12090760
erythro@@	O	-1	12090760
po@@	O	-1	12090760
i@@	O	-1	12090760
e@@	O	-1	12090760
tin	O	-1	12090760
(@@	O	-1	12090760
EP@@	O	-1	12090760
O@@	O	-1	12090760
)	O	-1	12090760
are	O	-1	12090760
known	O	-1	12090760
to	O	-1	12090760
ac@@	O	-1	12090760
t	O	-1	12090760
syn@@	O	-1	12090760
erg@@	O	-1	12090760
is@@	O	-1	12090760
tically	O	-1	12090760
on	O	-1	12090760
hemat@@	O	-1	12090760
o@@	O	-1	12090760
po@@	O	-1	12090760
i@@	O	-1	12090760
e@@	O	-1	12090760
tic	O	-1	12090760
cell	O	-1	12090760
pro@@	O	-1	12090760
li@@	O	-1	12090760
fer@@	O	-1	12090760
ation	O	-1	12090760
in	O	-1	12090760
vit@@	O	-1	12090760
ro@@	O	-1	12090760
,	O	-1	12090760
injection	O	-1	12090760
of	O	-1	12090760
I@@	O	-1	12090760
GF@@	O	-1	12090760
-@@	O	-1	12090760
I@@	O	-1	12090760
L-@@	O	-1	12090760
3	O	-1	12090760
and	O	-1	12090760
EP@@	O	-1	12090760
O	O	-1	12090760
in	O	-1	12090760
A@@	B-Chemical	D015215	12090760
Z@@	I-Chemical	-1	12090760
T	I-Chemical	-1	12090760
-treated	O	-1	12090760
mice	O	-1	12090760
resulted	O	-1	12090760
in	O	-1	12090760
a	O	-1	12090760
reduction	O	-1	12090760
of	O	-1	12090760
red	O	-1	12090760
cells	O	-1	12090760
and	O	-1	12090760
an	O	-1	12090760
increase	O	-1	12090760
of	O	-1	12090760
plasma	O	-1	12090760
EP@@	O	-1	12090760
O	O	-1	12090760
levels	O	-1	12090760
as	O	-1	12090760
compared	O	-1	12090760
to	O	-1	12090760
animals	O	-1	12090760
treated	O	-1	12090760
with	O	-1	12090760
I@@	O	-1	12090760
GF@@	O	-1	12090760
-@@	O	-1	12090760
I@@	O	-1	12090760
L-@@	O	-1	12090760
3	O	-1	12090760
or	O	-1	12090760
EP@@	O	-1	12090760
O	O	-1	12090760
al@@	O	-1	12090760
one.	O	-1	12090760
We	O	-1	12090760
tested	O	-1	12090760
the	O	-1	12090760
hypo@@	O	-1	12090760
thesis	O	-1	12090760
that	O	-1	12090760
the	O	-1	12090760
antagon@@	O	-1	12090760
istic	O	-1	12090760
effect	O	-1	12090760
of	O	-1	12090760
I@@	O	-1	12090760
L-@@	O	-1	12090760
3	O	-1	12090760
and	O	-1	12090760
EP@@	O	-1	12090760
O	O	-1	12090760
on	O	-1	12090760
erythro@@	O	-1	12090760
id	O	-1	12090760
cells	O	-1	12090760
may	O	-1	12090760
be	O	-1	12090760
mediated	O	-1	12090760
by	O	-1	12090760
endothelial	O	-1	12090760
cell@@	O	-1	12090760
s.	O	-1	12090760
B@@	O	-1	12090760
o@@	O	-1	12090760
v@@	O	-1	12090760
ine	O	-1	12090760
liver	O	-1	12090760
erythro@@	O	-1	12090760
id	O	-1	12090760
cells	O	-1	12090760
were	O	-1	12090760
c@@	O	-1	12090760
ult@@	O	-1	12090760
ured	O	-1	12090760
on	O	-1	12090760
mon@@	O	-1	12090760
ol@@	O	-1	12090760
ay@@	O	-1	12090760
ers	O	-1	12090760
of	O	-1	12090760
human	O	-1	12090760
b@@	O	-1	12090760
one	O	-1	12090760
m@@	O	-1	12090760
ar@@	O	-1	12090760
ro@@	O	-1	12090760
w	O	-1	12090760
endothelial	O	-1	12090760
cells	O	-1	12090760
previously	O	-1	12090760
treated	O	-1	12090760
with	O	-1	12090760
EP@@	O	-1	12090760
O	O	-1	12090760
and	O	-1	12090760
I@@	O	-1	12090760
GF@@	O	-1	12090760
-@@	O	-1	12090760
I@@	O	-1	12090760
L-@@	O	-1	12090760
3@@	O	-1	12090760
.	O	-1	12090760
There	O	-1	12090760
was	O	-1	12090760
a	O	-1	12090760
significant	O	-1	12090760
reduction	O	-1	12090760
of	O	-1	12090760
th@@	B-Chemical	D013936	12090760
ym@@	I-Chemical	-1	12090760
idine	I-Chemical	-1	12090760
inc@@	O	-1	12090760
or@@	O	-1	12090760
por@@	O	-1	12090760
ation	O	-1	12090760
into	O	-1	12090760
both	O	-1	12090760
erythro@@	O	-1	12090760
id	O	-1	12090760
and	O	-1	12090760
endothelial	O	-1	12090760
cells	O	-1	12090760
in	O	-1	12090760
c@@	O	-1	12090760
ult@@	O	-1	12090760
ures	O	-1	12090760
pre@@	O	-1	12090760
-treated	O	-1	12090760
with	O	-1	12090760
I@@	O	-1	12090760
GF@@	O	-1	12090760
-@@	O	-1	12090760
I@@	O	-1	12090760
L-@@	O	-1	12090760
3	O	-1	12090760
and	O	-1	12090760
EP@@	O	-1	12090760
O@@	O	-1	12090760
.	O	-1	12090760
E@@	O	-1	12090760
n@@	O	-1	12090760
do@@	O	-1	12090760
thelial	O	-1	12090760
cell	O	-1	12090760
c@@	O	-1	12090760
ult@@	O	-1	12090760
ure	O	-1	12090760
su@@	O	-1	12090760
per@@	O	-1	12090760
n@@	O	-1	12090760
at@@	O	-1	12090760
ants	O	-1	12090760
se@@	O	-1	12090760
par@@	O	-1	12090760
ated	O	-1	12090760
by	O	-1	12090760
ult@@	O	-1	12090760
ra@@	O	-1	12090760
f@@	O	-1	12090760
iltration	O	-1	12090760
and	O	-1	12090760
ult@@	O	-1	12090760
rac@@	O	-1	12090760
ent@@	O	-1	12090760
ri@@	O	-1	12090760
fu@@	O	-1	12090760
g@@	O	-1	12090760
ation	O	-1	12090760
from	O	-1	12090760
cells	O	-1	12090760
treated	O	-1	12090760
with	O	-1	12090760
EP@@	O	-1	12090760
O	O	-1	12090760
and	O	-1	12090760
I@@	O	-1	12090760
L-@@	O	-1	12090760
3	O	-1	12090760
significantly	O	-1	12090760
reduced	O	-1	12090760
th@@	B-Chemical	D013936	12090760
ym@@	I-Chemical	-1	12090760
idine	I-Chemical	-1	12090760
inc@@	O	-1	12090760
or@@	O	-1	12090760
por@@	O	-1	12090760
ation	O	-1	12090760
into	O	-1	12090760
erythro@@	O	-1	12090760
id	O	-1	12090760
cells	O	-1	12090760
as	O	-1	12090760
compared	O	-1	12090760
to	O	-1	12090760
id@@	O	-1	12090760
en@@	O	-1	12090760
tical	O	-1	12090760
frac@@	O	-1	12090760
tions	O	-1	12090760
obtained	O	-1	12090760
from	O	-1	12090760
the	O	-1	12090760
medi@@	O	-1	12090760
a	O	-1	12090760
of	O	-1	12090760
cells	O	-1	12090760
c@@	O	-1	12090760
ult@@	O	-1	12090760
ured	O	-1	12090760
with	O	-1	12090760
EP@@	O	-1	12090760
O	O	-1	12090760
al@@	O	-1	12090760
one.	O	-1	12090760
These	O	-1	12090760
results	O	-1	12090760
suggest	O	-1	12090760
that	O	-1	12090760
endothelial	O	-1	12090760
cells	O	-1	12090760
treated	O	-1	12090760
sim@@	O	-1	12090760
ult@@	O	-1	12090760
ane@@	O	-1	12090760
ously	O	-1	12090760
with	O	-1	12090760
EP@@	O	-1	12090760
O	O	-1	12090760
and	O	-1	12090760
I@@	O	-1	12090760
L-@@	O	-1	12090760
3	O	-1	12090760
have	O	-1	12090760
a	O	-1	12090760
negative	O	-1	12090760
effect	O	-1	12090760
on	O	-1	12090760
erythro@@	O	-1	12090760
id	O	-1	12090760
cell	O	-1	12090760
produc@@	O	-1	12090760
tion.	O	-1	12090760

In@@	O	-1	7516729
ter@@	O	-1	7516729
active	O	-1	7516729
effects	O	-1	7516729
of	O	-1	7516729
vari@@	O	-1	7516729
ations	O	-1	7516729
in	O	-1	7516729
[	O	-1	7516729
N@@	B-Chemical	D012964	7516729
a	I-Chemical	-1	7516729
]@@	O	-1	7516729
o	O	-1	7516729
and	O	-1	7516729
[	O	-1	7516729
C@@	B-Chemical	D002118	7516729
a	I-Chemical	-1	7516729
]@@	O	-1	7516729
o	O	-1	7516729
on	O	-1	7516729
rat	O	-1	7516729
atrial	O	-1	7516729
spont@@	O	-1	7516729
aneous	O	-1	7516729
frequ@@	O	-1	7516729
enc@@	O	-1	7516729
y.	O	-1	7516729
The	O	-1	7516729
effects	O	-1	7516729
of	O	-1	7516729
v@@	O	-1	7516729
ar@@	O	-1	7516729
y@@	O	-1	7516729
ing	O	-1	7516729
the	O	-1	7516729
extrac@@	O	-1	7516729
ell@@	O	-1	7516729
ular	O	-1	7516729
concentrations	O	-1	7516729
of	O	-1	7516729
N@@	B-Chemical	D012964	7516729
a	I-Chemical	-1	7516729
and	O	-1	7516729
C@@	B-Chemical	D002118	7516729
a	I-Chemical	-1	7516729
(@@	O	-1	7516729
[	O	-1	7516729
N@@	B-Chemical	D012964	7516729
a	I-Chemical	-1	7516729
]@@	O	-1	7516729
o	O	-1	7516729
and	O	-1	7516729
[	O	-1	7516729
C@@	B-Chemical	D002118	7516729
a	I-Chemical	-1	7516729
]@@	O	-1	7516729
o@@	O	-1	7516729
)	O	-1	7516729
on	O	-1	7516729
bo@@	O	-1	7516729
th@@	O	-1	7516729
,	O	-1	7516729
the	O	-1	7516729
spont@@	O	-1	7516729
aneous	O	-1	7516729
be@@	O	-1	7516729
ating	O	-1	7516729
and	O	-1	7516729
the	O	-1	7516729
negative	O	-1	7516729
chron@@	O	-1	7516729
ot@@	O	-1	7516729
ro@@	O	-1	7516729
p@@	O	-1	7516729
ic	O	-1	7516729
action	O	-1	7516729
of	O	-1	7516729
verap@@	B-Chemical	D014700	7516729
ami@@	I-Chemical	-1	7516729
l	I-Chemical	-1	7516729
,	O	-1	7516729
were	O	-1	7516729
studied	O	-1	7516729
in	O	-1	7516729
the	O	-1	7516729
isol@@	O	-1	7516729
ated	O	-1	7516729
rat	O	-1	7516729
atri@@	O	-1	7516729
a.	O	-1	7516729
B@@	O	-1	7516729
as@@	O	-1	7516729
al	O	-1	7516729
frequency	O	-1	7516729
(B@@	O	-1	7516729
F@@	O	-1	7516729
)	O	-1	7516729
evaluated	O	-1	7516729
by	O	-1	7516729
sur@@	O	-1	7516729
fac@@	O	-1	7516729
e	O	-1	7516729
electro@@	O	-1	7516729
gra@@	O	-1	7516729
m	O	-1	7516729
was	O	-1	7516729
2@@	O	-1	7516729
2@@	O	-1	7516729
3	O	-1	7516729
+/-	O	-1	7516729
4	O	-1	7516729
be@@	O	-1	7516729
at@@	O	-1	7516729
s/@@	O	-1	7516729
min@@	O	-1	7516729
.	O	-1	7516729
in	O	-1	7516729
control	O	-1	7516729
K@@	O	-1	7516729
reb@@	O	-1	7516729
s-@@	O	-1	7516729
R@@	O	-1	7516729
ing@@	O	-1	7516729
er	O	-1	7516729
containing	O	-1	7516729
13@@	O	-1	7516729
7	O	-1	7516729
m@@	O	-1	7516729
M	O	-1	7516729
N@@	B-Chemical	D012964	7516729
a	I-Chemical	-1	7516729
and	O	-1	7516729
1.@@	O	-1	7516729
3@@	O	-1	7516729
5	O	-1	7516729
m@@	O	-1	7516729
M	O	-1	7516729
C@@	B-Chemical	D002118	7516729
a	I-Chemical	-1	7516729
(N@@	O	-1	7516729
).	O	-1	7516729
It	O	-1	7516729
decreased	O	-1	7516729
by	O	-1	7516729
16	O	-1	7516729
+/-	O	-1	7516729
3@@	O	-1	7516729
%	O	-1	7516729
by	O	-1	7516729
low@@	O	-1	7516729
ering	O	-1	7516729
[	O	-1	7516729
N@@	B-Chemical	D012964	7516729
a	I-Chemical	-1	7516729
]@@	O	-1	7516729
o	O	-1	7516729
to	O	-1	7516729
7@@	O	-1	7516729
8	O	-1	7516729
m@@	O	-1	7516729
M	O	-1	7516729
(@@	O	-1	7516729
L@@	O	-1	7516729
Na@@	O	-1	7516729
),	O	-1	7516729
2@@	O	-1	7516729
3	O	-1	7516729
+/-	O	-1	7516729
2@@	O	-1	7516729
%	O	-1	7516729
by	O	-1	7516729
low@@	O	-1	7516729
ering	O	-1	7516729
sim@@	O	-1	7516729
ult@@	O	-1	7516729
ane@@	O	-1	7516729
ously	O	-1	7516729
[	O	-1	7516729
N@@	B-Chemical	D012964	7516729
a	I-Chemical	-1	7516729
]@@	O	-1	7516729
o	O	-1	7516729
to	O	-1	7516729
7@@	O	-1	7516729
8	O	-1	7516729
m@@	O	-1	7516729
M	O	-1	7516729
and	O	-1	7516729
[	O	-1	7516729
C@@	B-Chemical	D002118	7516729
a	I-Chemical	-1	7516729
]@@	O	-1	7516729
o	O	-1	7516729
to	O	-1	7516729
0.@@	O	-1	7516729
6@@	O	-1	7516729
7@@	O	-1	7516729
5	O	-1	7516729
m@@	O	-1	7516729
M	O	-1	7516729
(@@	O	-1	7516729
L@@	O	-1	7516729
Na@@	O	-1	7516729
+@@	O	-1	7516729
L@@	O	-1	7516729
Ca@@	O	-1	7516729
)	O	-1	7516729
and	O	-1	7516729
3@@	O	-1	7516729
1	O	-1	7516729
+/-	O	-1	7516729
5%	O	-1	7516729
by	O	-1	7516729
low@@	O	-1	7516729
ering	O	-1	7516729
[	O	-1	7516729
N@@	B-Chemical	D012964	7516729
a	I-Chemical	-1	7516729
]@@	O	-1	7516729
o	O	-1	7516729
to	O	-1	7516729
7@@	O	-1	7516729
8	O	-1	7516729
m@@	O	-1	7516729
M	O	-1	7516729
plus	O	-1	7516729
increas@@	O	-1	7516729
ing	O	-1	7516729
[	O	-1	7516729
C@@	B-Chemical	D002118	7516729
a	I-Chemical	-1	7516729
]@@	O	-1	7516729
o	O	-1	7516729
to	O	-1	7516729
3.@@	O	-1	7516729
6	O	-1	7516729
m@@	O	-1	7516729
M	O	-1	7516729
(@@	O	-1	7516729
L@@	O	-1	7516729
Na@@	O	-1	7516729
+@@	O	-1	7516729
H@@	O	-1	7516729
Ca@@	O	-1	7516729
).	O	-1	7516729
A@@	O	-1	7516729
t	O	-1	7516729
normal	O	-1	7516729
[	O	-1	7516729
N@@	B-Chemical	D012964	7516729
a	I-Chemical	-1	7516729
]@@	O	-1	7516729
o@@	O	-1	7516729
,	O	-1	7516729
decrease	O	-1	7516729
(0.@@	O	-1	7516729
6@@	O	-1	7516729
7@@	O	-1	7516729
5	O	-1	7516729
m@@	O	-1	7516729
M@@	O	-1	7516729
)	O	-1	7516729
or	O	-1	7516729
increase	O	-1	7516729
(@@	O	-1	7516729
3.@@	O	-1	7516729
6	O	-1	7516729
m@@	O	-1	7516729
M@@	O	-1	7516729
)	O	-1	7516729
of	O	-1	7516729
[	O	-1	7516729
C@@	B-Chemical	D002118	7516729
a	I-Chemical	-1	7516729
]@@	O	-1	7516729
o	O	-1	7516729
did	O	-1	7516729
not	O	-1	7516729
mo@@	O	-1	7516729
di@@	O	-1	7516729
f@@	O	-1	7516729
y	O	-1	7516729
B@@	O	-1	7516729
F@@	O	-1	7516729
;	O	-1	7516729
a	O	-1	7516729
reduction	O	-1	7516729
of	O	-1	7516729
ten	O	-1	7516729
times	O	-1	7516729
(0.@@	O	-1	7516729
13@@	O	-1	7516729
5	O	-1	7516729
m@@	O	-1	7516729
M	O	-1	7516729
of	O	-1	7516729
normal	O	-1	7516729
[	O	-1	7516729
C@@	B-Chemical	D002118	7516729
a	I-Chemical	-1	7516729
]@@	O	-1	7516729
o	O	-1	7516729
was	O	-1	7516729
effective	O	-1	7516729
to	O	-1	7516729
re@@	O	-1	7516729
duce	O	-1	7516729
B@@	O	-1	7516729
F	O	-1	7516729
by	O	-1	7516729
40	O	-1	7516729
+/-	O	-1	7516729
13@@	O	-1	7516729
%.	O	-1	7516729
All	O	-1	7516729
negative	O	-1	7516729
chron@@	O	-1	7516729
ot@@	O	-1	7516729
ro@@	O	-1	7516729
p@@	O	-1	7516729
ic	O	-1	7516729
effects	O	-1	7516729
were	O	-1	7516729
B@@	O	-1	7516729
F@@	O	-1	7516729
-@@	O	-1	7516729
depend@@	O	-1	7516729
ent@@	O	-1	7516729
.	O	-1	7516729
D@@	O	-1	7516729
o@@	O	-1	7516729
se@@	O	-1	7516729
-@@	O	-1	7516729
dependent	O	-1	7516729
brady@@	B-Disease	D001919	7516729
cardia	I-Disease	-1	7516729
induced	O	-1	7516729
by	O	-1	7516729
verap@@	B-Chemical	D014700	7516729
ami@@	I-Chemical	-1	7516729
l	I-Chemical	-1	7516729
was	O	-1	7516729
potenti@@	O	-1	7516729
ated	O	-1	7516729
by	O	-1	7516729
L@@	O	-1	7516729
Na@@	O	-1	7516729
,	O	-1	7516729
L@@	O	-1	7516729
C@@	O	-1	7516729
a,	O	-1	7516729
and	O	-1	7516729
HC@@	O	-1	7516729
a.	O	-1	7516729
In@@	O	-1	7516729
dependent	O	-1	7516729
but	O	-1	7516729
not	O	-1	7516729
addi@@	O	-1	7516729
tive	O	-1	7516729
effects	O	-1	7516729
of	O	-1	7516729
N@@	B-Chemical	D012964	7516729
a	I-Chemical	-1	7516729
and	O	-1	7516729
C@@	B-Chemical	D002118	7516729
a	I-Chemical	-1	7516729
are	O	-1	7516729
shown	O	-1	7516729
by	O	-1	7516729
decreas@@	O	-1	7516729
es	O	-1	7516729
in	O	-1	7516729
the	O	-1	7516729
values	O	-1	7516729
of	O	-1	7516729
[	O	-1	7516729
verap@@	B-Chemical	D014700	7516729
ami@@	I-Chemical	-1	7516729
l	I-Chemical	-1	7516729
]@@	O	-1	7516729
o	O	-1	7516729
ne@@	O	-1	7516729
ed@@	O	-1	7516729
ed	O	-1	7516729
to	O	-1	7516729
re@@	O	-1	7516729
duce	O	-1	7516729
B@@	O	-1	7516729
F	O	-1	7516729
by	O	-1	7516729
3@@	O	-1	7516729
0%	O	-1	7516729
(@@	O	-1	7516729
IC@@	O	-1	7516729
3@@	O	-1	7516729
0@@	O	-1	7516729
)	O	-1	7516729
with	O	-1	7516729
the	O	-1	7516729
following	O	-1	7516729
or@@	O	-1	7516729
der	O	-1	7516729
of	O	-1	7516729
inhibit@@	O	-1	7516729
ory	O	-1	7516729
poten@@	O	-1	7516729
cy@@	O	-1	7516729
:	O	-1	7516729
L@@	O	-1	7516729
N@@	O	-1	7516729
a	O	-1	7516729
>	O	-1	7516729
L@@	O	-1	7516729
C@@	O	-1	7516729
a	O	-1	7516729
>	O	-1	7516729
HC@@	O	-1	7516729
a	O	-1	7516729
>	O	-1	7516729
N@@	O	-1	7516729
,	O	-1	7516729
result@@	O	-1	7516729
ing	O	-1	7516729
L@@	O	-1	7516729
Na@@	O	-1	7516729
+@@	O	-1	7516729
HC@@	O	-1	7516729
a	O	-1	7516729
similar	O	-1	7516729
to	O	-1	7516729
L@@	O	-1	7516729
Na@@	O	-1	7516729
.	O	-1	7516729
The	O	-1	7516729
[	O	-1	7516729
verap@@	B-Chemical	D014700	7516729
ami@@	I-Chemical	-1	7516729
l	I-Chemical	-1	7516729
]@@	O	-1	7516729
o	O	-1	7516729
that	O	-1	7516729
ar@@	O	-1	7516729
rest@@	O	-1	7516729
ed	O	-1	7516729
atrial	O	-1	7516729
be@@	O	-1	7516729
ating	O	-1	7516729
(@@	O	-1	7516729
AC@@	O	-1	7516729
)	O	-1	7516729
was	O	-1	7516729
also	O	-1	7516729
potenti@@	O	-1	7516729
ated	O	-1	7516729
with	O	-1	7516729
the	O	-1	7516729
or@@	O	-1	7516729
der	O	-1	7516729
L@@	O	-1	7516729
N@@	O	-1	7516729
a	O	-1	7516729
=	O	-1	7516729
L@@	O	-1	7516729
Na@@	O	-1	7516729
+@@	O	-1	7516729
L@@	O	-1	7516729
C@@	O	-1	7516729
a	O	-1	7516729
=	O	-1	7516729
L@@	O	-1	7516729
Na@@	O	-1	7516729
+@@	O	-1	7516729
HC@@	O	-1	7516729
a	O	-1	7516729
=	O	-1	7516729
L@@	O	-1	7516729
C@@	O	-1	7516729
a	O	-1	7516729
>	O	-1	7516729
HC@@	O	-1	7516729
a	O	-1	7516729
=	O	-1	7516729
N@@	O	-1	7516729
.	O	-1	7516729
The	O	-1	7516729
results	O	-1	7516729
indicate	O	-1	7516729
that	O	-1	7516729
rat	O	-1	7516729
atrial	O	-1	7516729
spont@@	O	-1	7516729
aneous	O	-1	7516729
be@@	O	-1	7516729
ating	O	-1	7516729
is	O	-1	7516729
more	O	-1	7516729
dependent	O	-1	7516729
on	O	-1	7516729
[	O	-1	7516729
N@@	B-Chemical	D012964	7516729
a	I-Chemical	-1	7516729
]@@	O	-1	7516729
o	O	-1	7516729
than	O	-1	7516729
on	O	-1	7516729
[	O	-1	7516729
C@@	B-Chemical	D002118	7516729
a	I-Chemical	-1	7516729
]@@	O	-1	7516729
o	O	-1	7516729
in	O	-1	7516729
a	O	-1	7516729
range	O	-1	7516729
of	O	-1	7516729
+/-	O	-1	7516729
50@@	O	-1	7516729
%	O	-1	7516729
of	O	-1	7516729
their	O	-1	7516729
normal	O	-1	7516729
concentr@@	O	-1	7516729
ation.	O	-1	7516729
Al@@	O	-1	7516729
so	O	-1	7516729
the	O	-1	7516729
enh@@	O	-1	7516729
ance@@	O	-1	7516729
ment	O	-1	7516729
of	O	-1	7516729
verap@@	B-Chemical	D014700	7516729
ami@@	I-Chemical	-1	7516729
l	I-Chemical	-1	7516729
effects	O	-1	7516729
on	O	-1	7516729
atrial	O	-1	7516729
be@@	O	-1	7516729
ating	O	-1	7516729
was	O	-1	7516729
more	O	-1	7516729
p@@	O	-1	7516729
ron@@	O	-1	7516729
oun@@	O	-1	7516729
c@@	O	-1	7516729
ed	O	-1	7516729
at	O	-1	7516729
L@@	O	-1	7516729
N@@	O	-1	7516729
a	O	-1	7516729
than	O	-1	7516729
at	O	-1	7516729
L@@	O	-1	7516729
Ca@@	O	-1	7516729
.@@	O	-1	7516729
(A@@	O	-1	7516729
B@@	O	-1	7516729
S@@	O	-1	7516729
TR@@	O	-1	7516729
AC@@	O	-1	7516729
T	O	-1	7516729
TR@@	O	-1	7516729
UN@@	O	-1	7516729
C@@	O	-1	7516729
AT@@	O	-1	7516729
E@@	O	-1	7516729
D	O	-1	7516729
A@@	O	-1	7516729
T	O	-1	7516729
2@@	O	-1	7516729
50	O	-1	7516729
W@@	O	-1	7516729
O@@	O	-1	7516729
RD@@	O	-1	7516729
S)	O	-1	7516729

S@@	B-Chemical	D012964	2802551
odium	I-Chemical	-1	2802551
status	O	-1	2802551
influ@@	O	-1	2802551
enc@@	O	-1	2802551
es	O	-1	2802551
chronic	O	-1	2802551
amph@@	B-Chemical	D000666	2802551
ot@@	I-Chemical	-1	2802551
er@@	I-Chemical	-1	2802551
icin	I-Chemical	-1	2802551
B	I-Chemical	-1	2802551
nephro@@	B-Disease	D007674	2802551
toxicity	I-Disease	-1	2802551
in	O	-1	2802551
rats.	O	-1	2802551
The	O	-1	2802551
nephro@@	B-Disease	D007674	2802551
toxic	I-Disease	-1	2802551
potential	O	-1	2802551
of	O	-1	2802551
amph@@	B-Chemical	D000666	2802551
ot@@	I-Chemical	-1	2802551
er@@	I-Chemical	-1	2802551
icin	I-Chemical	-1	2802551
B	I-Chemical	-1	2802551
(@@	O	-1	2802551
5	O	-1	2802551
mg/kg	O	-1	2802551
per	O	-1	2802551
day	O	-1	2802551
intra@@	O	-1	2802551
per@@	O	-1	2802551
it@@	O	-1	2802551
one@@	O	-1	2802551
ally	O	-1	2802551
for	O	-1	2802551
3	O	-1	2802551
week@@	O	-1	2802551
s)	O	-1	2802551
has	O	-1	2802551
been	O	-1	2802551
investigated	O	-1	2802551
in	O	-1	2802551
sal@@	O	-1	2802551
t-@@	O	-1	2802551
deple@@	O	-1	2802551
te@@	O	-1	2802551
d,	O	-1	2802551
normal@@	O	-1	2802551
-@@	O	-1	2802551
sal@@	O	-1	2802551
t,	O	-1	2802551
and	O	-1	2802551
sal@@	O	-1	2802551
t-@@	O	-1	2802551
lo@@	O	-1	2802551
ad@@	O	-1	2802551
ed	O	-1	2802551
rats.	O	-1	2802551
In	O	-1	2802551
sal@@	O	-1	2802551
t-@@	O	-1	2802551
deple@@	O	-1	2802551
ted	O	-1	2802551
rats,	O	-1	2802551
amph@@	B-Chemical	D000666	2802551
ot@@	I-Chemical	-1	2802551
er@@	I-Chemical	-1	2802551
icin	I-Chemical	-1	2802551
B	I-Chemical	-1	2802551
decreased	O	-1	2802551
creatinine	B-Chemical	D003404	2802551
clear@@	O	-1	2802551
ance	O	-1	2802551
l@@	O	-1	2802551
ine@@	O	-1	2802551
arly	O	-1	2802551
with	O	-1	2802551
ti@@	O	-1	2802551
me,	O	-1	2802551
with	O	-1	2802551
an	O	-1	2802551
8@@	O	-1	2802551
5%	O	-1	2802551
reduction	O	-1	2802551
by	O	-1	2802551
week	O	-1	2802551
3@@	O	-1	2802551
.	O	-1	2802551
In	O	-1	2802551
contrast@@	O	-1	2802551
,	O	-1	2802551
in	O	-1	2802551
normal@@	O	-1	2802551
-@@	O	-1	2802551
sal@@	O	-1	2802551
t	O	-1	2802551
rats	O	-1	2802551
creatinine	B-Chemical	D003404	2802551
clear@@	O	-1	2802551
ance	O	-1	2802551
was	O	-1	2802551
decreased	O	-1	2802551
but	O	-1	2802551
to	O	-1	2802551
a	O	-1	2802551
l@@	O	-1	2802551
ess@@	O	-1	2802551
er	O	-1	2802551
ext@@	O	-1	2802551
ent	O	-1	2802551
at	O	-1	2802551
week	O	-1	2802551
2	O	-1	2802551
and	O	-1	2802551
3,	O	-1	2802551
and	O	-1	2802551
in	O	-1	2802551
sal@@	O	-1	2802551
t-@@	O	-1	2802551
lo@@	O	-1	2802551
ad@@	O	-1	2802551
ed	O	-1	2802551
rats	O	-1	2802551
creatinine	B-Chemical	D003404	2802551
clear@@	O	-1	2802551
ance	O	-1	2802551
did	O	-1	2802551
not	O	-1	2802551
change	O	-1	2802551
for	O	-1	2802551
2	O	-1	2802551
weeks	O	-1	2802551
and	O	-1	2802551
was	O	-1	2802551
decreased	O	-1	2802551
by	O	-1	2802551
4@@	O	-1	2802551
3@@	O	-1	2802551
%	O	-1	2802551
at	O	-1	2802551
week	O	-1	2802551
3@@	O	-1	2802551
.	O	-1	2802551
All	O	-1	2802551
rats	O	-1	2802551
in	O	-1	2802551
the	O	-1	2802551
sodium	B-Chemical	D012964	2802551
-@@	O	-1	2802551
deple@@	O	-1	2802551
ted	O	-1	2802551
group	O	-1	2802551
had	O	-1	2802551
histo@@	O	-1	2802551
path@@	O	-1	2802551
ological	O	-1	2802551
evidence	O	-1	2802551
of	O	-1	2802551
pat@@	O	-1	2802551
ch@@	O	-1	2802551
y	O	-1	2802551
tub@@	O	-1	2802551
ular	O	-1	2802551
cyto@@	O	-1	2802551
plas@@	O	-1	2802551
mic	O	-1	2802551
de@@	O	-1	2802551
generation	O	-1	2802551
in	O	-1	2802551
tub@@	O	-1	2802551
ul@@	O	-1	2802551
es	O	-1	2802551
that	O	-1	2802551
was	O	-1	2802551
not	O	-1	2802551
observed	O	-1	2802551
in	O	-1	2802551
any	O	-1	2802551
normal@@	O	-1	2802551
-@@	O	-1	2802551
sal@@	O	-1	2802551
t	O	-1	2802551
or	O	-1	2802551
sal@@	O	-1	2802551
t-@@	O	-1	2802551
lo@@	O	-1	2802551
ad@@	O	-1	2802551
ed	O	-1	2802551
rat@@	O	-1	2802551
.	O	-1	2802551
Con@@	O	-1	2802551
centr@@	O	-1	2802551
ations	O	-1	2802551
of	O	-1	2802551
amph@@	B-Chemical	D000666	2802551
ot@@	I-Chemical	-1	2802551
er@@	I-Chemical	-1	2802551
icin	I-Chemical	-1	2802551
B	I-Chemical	-1	2802551
in	O	-1	2802551
plasma	O	-1	2802551
were	O	-1	2802551
not	O	-1	2802551
significantly	O	-1	2802551
different	O	-1	2802551
among	O	-1	2802551
the	O	-1	2802551
three	O	-1	2802551
groups	O	-1	2802551
at	O	-1	2802551
any	O	-1	2802551
time	O	-1	2802551
during	O	-1	2802551
the	O	-1	2802551
study.	O	-1	2802551
However,	O	-1	2802551
at	O	-1	2802551
the	O	-1	2802551
end	O	-1	2802551
of	O	-1	2802551
3	O	-1	2802551
week@@	O	-1	2802551
s,	O	-1	2802551
amph@@	B-Chemical	D000666	2802551
ot@@	I-Chemical	-1	2802551
er@@	I-Chemical	-1	2802551
icin	I-Chemical	-1	2802551
B	I-Chemical	-1	2802551
levels	O	-1	2802551
in	O	-1	2802551
the	O	-1	2802551
kidne@@	O	-1	2802551
ys	O	-1	2802551
and	O	-1	2802551
liver	O	-1	2802551
were	O	-1	2802551
significantly	O	-1	2802551
higher	O	-1	2802551
in	O	-1	2802551
sal@@	O	-1	2802551
t-@@	O	-1	2802551
deple@@	O	-1	2802551
ted	O	-1	2802551
and	O	-1	2802551
normal@@	O	-1	2802551
-@@	O	-1	2802551
sal@@	O	-1	2802551
t	O	-1	2802551
rats	O	-1	2802551
than	O	-1	2802551
those	O	-1	2802551
in	O	-1	2802551
sal@@	O	-1	2802551
t-@@	O	-1	2802551
lo@@	O	-1	2802551
ad@@	O	-1	2802551
ed	O	-1	2802551
rats,	O	-1	2802551
with	O	-1	2802551
plas@@	O	-1	2802551
ma@@	O	-1	2802551
/@@	O	-1	2802551
kidney	O	-1	2802551
rati@@	O	-1	2802551
o@@	O	-1	2802551
s	O	-1	2802551
of	O	-1	2802551
2@@	O	-1	2802551
1,	O	-1	2802551
14@@	O	-1	2802551
,	O	-1	2802551
and	O	-1	2802551
8	O	-1	2802551
in	O	-1	2802551
sal@@	O	-1	2802551
t-@@	O	-1	2802551
deple@@	O	-1	2802551
te@@	O	-1	2802551
d,	O	-1	2802551
normal@@	O	-1	2802551
-@@	O	-1	2802551
sal@@	O	-1	2802551
t,	O	-1	2802551
and	O	-1	2802551
sal@@	O	-1	2802551
t-@@	O	-1	2802551
lo@@	O	-1	2802551
ad@@	O	-1	2802551
ed	O	-1	2802551
rats,	O	-1	2802551
respectively.	O	-1	2802551
In	O	-1	2802551
concl@@	O	-1	2802551
u@@	O	-1	2802551
sion,	O	-1	2802551
reduc@@	O	-1	2802551
tions	O	-1	2802551
in	O	-1	2802551
creatinine	B-Chemical	D003404	2802551
clear@@	O	-1	2802551
ance	O	-1	2802551
and	O	-1	2802551
renal	O	-1	2802551
amph@@	B-Chemical	D000666	2802551
ot@@	I-Chemical	-1	2802551
er@@	I-Chemical	-1	2802551
icin	I-Chemical	-1	2802551
B	I-Chemical	-1	2802551
accum@@	O	-1	2802551
ulation	O	-1	2802551
after	O	-1	2802551
chronic	O	-1	2802551
amph@@	B-Chemical	D000666	2802551
ot@@	I-Chemical	-1	2802551
er@@	I-Chemical	-1	2802551
icin	I-Chemical	-1	2802551
B	I-Chemical	-1	2802551
administration	O	-1	2802551
were	O	-1	2802551
enhanced	O	-1	2802551
by	O	-1	2802551
sal@@	O	-1	2802551
t	O	-1	2802551
deple@@	O	-1	2802551
tion	O	-1	2802551
and	O	-1	2802551
attenu@@	O	-1	2802551
ated	O	-1	2802551
by	O	-1	2802551
sodium	B-Chemical	D012964	2802551
lo@@	O	-1	2802551
ad@@	O	-1	2802551
ing	O	-1	2802551
in	O	-1	2802551
rats.	O	-1	2802551

Re@@	O	-1	19346865
ver@@	O	-1	19346865
sible	O	-1	19346865
inf@@	B-Disease	D001927	19346865
er@@	I-Disease	-1	19346865
ior	I-Disease	-1	19346865
coll@@	I-Disease	-1	19346865
ic@@	I-Disease	-1	19346865
ul@@	I-Disease	-1	19346865
us	I-Disease	-1	19346865
le@@	I-Disease	-1	19346865
sion	I-Disease	-1	19346865
in	O	-1	19346865
met@@	B-Chemical	D008795	19346865
ron@@	I-Chemical	-1	19346865
id@@	I-Chemical	-1	19346865
azole	I-Chemical	-1	19346865
-induced	O	-1	19346865
encephalo@@	B-Disease	D001927	19346865
pathy	I-Disease	-1	19346865
:	O	-1	19346865
mag@@	O	-1	19346865
ne@@	O	-1	19346865
tic	O	-1	19346865
res@@	O	-1	19346865
on@@	O	-1	19346865
ance	O	-1	19346865
findings	O	-1	19346865
on	O	-1	19346865
diff@@	O	-1	19346865
u@@	O	-1	19346865
sion@@	O	-1	19346865
-@@	O	-1	19346865
weigh@@	O	-1	19346865
ted	O	-1	19346865
and	O	-1	19346865
flu@@	O	-1	19346865
id	O	-1	19346865
attenu@@	O	-1	19346865
ated	O	-1	19346865
in@@	O	-1	19346865
ver@@	O	-1	19346865
sion	O	-1	19346865
recovery	O	-1	19346865
imag@@	O	-1	19346865
ing.	O	-1	19346865
OBJECTIVE:	O	-1	19346865
This	O	-1	19346865
is	O	-1	19346865
to	O	-1	19346865
present	O	-1	19346865
reversible	O	-1	19346865
inf@@	B-Disease	D001927	19346865
er@@	I-Disease	-1	19346865
ior	I-Disease	-1	19346865
coll@@	I-Disease	-1	19346865
ic@@	I-Disease	-1	19346865
ul@@	I-Disease	-1	19346865
us	I-Disease	-1	19346865
lesions	I-Disease	-1	19346865
in	O	-1	19346865
met@@	B-Chemical	D008795	19346865
ron@@	I-Chemical	-1	19346865
id@@	I-Chemical	-1	19346865
azole	I-Chemical	-1	19346865
-induced	O	-1	19346865
encephalo@@	B-Disease	D001927	19346865
pathy	I-Disease	-1	19346865
,	O	-1	19346865
to	O	-1	19346865
foc@@	O	-1	19346865
us	O	-1	19346865
on	O	-1	19346865
the	O	-1	19346865
diff@@	O	-1	19346865
u@@	O	-1	19346865
sion@@	O	-1	19346865
-@@	O	-1	19346865
weigh@@	O	-1	19346865
ted	O	-1	19346865
imaging	O	-1	19346865
(D@@	O	-1	19346865
W@@	O	-1	19346865
I@@	O	-1	19346865
)	O	-1	19346865
and	O	-1	19346865
flu@@	O	-1	19346865
id	O	-1	19346865
attenu@@	O	-1	19346865
ated	O	-1	19346865
in@@	O	-1	19346865
ver@@	O	-1	19346865
sion	O	-1	19346865
recovery	O	-1	19346865
(@@	O	-1	19346865
F@@	O	-1	19346865
L@@	O	-1	19346865
A@@	O	-1	19346865
I@@	O	-1	19346865
R@@	O	-1	19346865
)	O	-1	19346865
imag@@	O	-1	19346865
ing.	O	-1	19346865
M@@	O	-1	19346865
AT@@	O	-1	19346865
E@@	O	-1	19346865
R@@	O	-1	19346865
I@@	O	-1	19346865
AL@@	O	-1	19346865
S	O	-1	19346865
AN@@	O	-1	19346865
D	O	-1	19346865
METHODS:	O	-1	19346865
F@@	O	-1	19346865
rom	O	-1	19346865
N@@	O	-1	19346865
o@@	O	-1	19346865
ve@@	O	-1	19346865
mb@@	O	-1	19346865
er	O	-1	19346865
20@@	O	-1	19346865
0@@	O	-1	19346865
5	O	-1	19346865
to	O	-1	19346865
S@@	O	-1	19346865
e@@	O	-1	19346865
pt@@	O	-1	19346865
emb@@	O	-1	19346865
er	O	-1	19346865
20@@	O	-1	19346865
0@@	O	-1	19346865
7@@	O	-1	19346865
,	O	-1	19346865
8	O	-1	19346865
patients	O	-1	19346865
(@@	O	-1	19346865
5	O	-1	19346865
men	O	-1	19346865
and	O	-1	19346865
3	O	-1	19346865
wom@@	O	-1	19346865
en@@	O	-1	19346865
)	O	-1	19346865
were	O	-1	19346865
diagnos@@	O	-1	19346865
ed	O	-1	19346865
as	O	-1	19346865
ha@@	O	-1	19346865
ving	O	-1	19346865
met@@	B-Chemical	D008795	19346865
ron@@	I-Chemical	-1	19346865
id@@	I-Chemical	-1	19346865
azole	I-Chemical	-1	19346865
-induced	O	-1	19346865
encephalo@@	B-Disease	D001927	19346865
pathy	I-Disease	-1	19346865
(@@	O	-1	19346865
age	O	-1	19346865
ran@@	O	-1	19346865
ge@@	O	-1	19346865
;	O	-1	19346865
4@@	O	-1	19346865
3-@@	O	-1	19346865
7@@	O	-1	19346865
8	O	-1	19346865
year@@	O	-1	19346865
s@@	O	-1	19346865
).	O	-1	19346865
The@@	O	-1	19346865
y	O	-1	19346865
had	O	-1	19346865
been	O	-1	19346865
taking	O	-1	19346865
met@@	B-Chemical	D008795	19346865
ron@@	I-Chemical	-1	19346865
id@@	I-Chemical	-1	19346865
azole	I-Chemical	-1	19346865
(@@	O	-1	19346865
total	O	-1	19346865
dos@@	O	-1	19346865
age,	O	-1	19346865
4@@	O	-1	19346865
5-@@	O	-1	19346865
1@@	O	-1	19346865
20	O	-1	19346865
g@@	O	-1	19346865
;	O	-1	19346865
dur@@	O	-1	19346865
ation,	O	-1	19346865
30	O	-1	19346865
days	O	-1	19346865
to	O	-1	19346865
2	O	-1	19346865
month@@	O	-1	19346865
s)	O	-1	19346865
to	O	-1	19346865
tre@@	O	-1	19346865
at	O	-1	19346865
the	O	-1	19346865
inf@@	B-Disease	D007239	19346865
ection	I-Disease	-1	19346865
in	O	-1	19346865
various	O	-1	19346865
org@@	O	-1	19346865
an@@	O	-1	19346865
s.	O	-1	19346865
In@@	O	-1	19346865
iti@@	O	-1	19346865
al	O	-1	19346865
brain	O	-1	19346865
mag@@	O	-1	19346865
ne@@	O	-1	19346865
tic	O	-1	19346865
res@@	O	-1	19346865
on@@	O	-1	19346865
ance	O	-1	19346865
imaging	O	-1	19346865
(@@	O	-1	19346865
MR@@	O	-1	19346865
I@@	O	-1	19346865
)	O	-1	19346865
were	O	-1	19346865
obtained	O	-1	19346865
after	O	-1	19346865
the	O	-1	19346865
hospit@@	O	-1	19346865
al@@	O	-1	19346865
iz@@	O	-1	19346865
ation,	O	-1	19346865
including	O	-1	19346865
D@@	O	-1	19346865
W@@	O	-1	19346865
I	O	-1	19346865
(@@	O	-1	19346865
8@@	O	-1	19346865
/@@	O	-1	19346865
8@@	O	-1	19346865
),	O	-1	19346865
appa@@	O	-1	19346865
rent	O	-1	19346865
diff@@	O	-1	19346865
usion	O	-1	19346865
co@@	O	-1	19346865
eff@@	O	-1	19346865
ici@@	O	-1	19346865
ent	O	-1	19346865
(A@@	O	-1	19346865
D@@	O	-1	19346865
C@@	O	-1	19346865
)	O	-1	19346865
ma@@	O	-1	19346865
p	O	-1	19346865
(4@@	O	-1	19346865
/@@	O	-1	19346865
8@@	O	-1	19346865
),	O	-1	19346865
F@@	O	-1	19346865
L@@	O	-1	19346865
A@@	O	-1	19346865
I@@	O	-1	19346865
R	O	-1	19346865
(@@	O	-1	19346865
7@@	O	-1	19346865
/@@	O	-1	19346865
8@@	O	-1	19346865
),	O	-1	19346865
and	O	-1	19346865
T@@	O	-1	19346865
2-@@	O	-1	19346865
weigh@@	O	-1	19346865
ted	O	-1	19346865
im@@	O	-1	19346865
age	O	-1	19346865
(@@	O	-1	19346865
8@@	O	-1	19346865
/@@	O	-1	19346865
8@@	O	-1	19346865
).	O	-1	19346865
F@@	O	-1	19346865
ol@@	O	-1	19346865
low@@	O	-1	19346865
-@@	O	-1	19346865
up	O	-1	19346865
MR@@	O	-1	19346865
I@@	O	-1	19346865
s	O	-1	19346865
were	O	-1	19346865
performed	O	-1	19346865
on	O	-1	19346865
5	O	-1	19346865
patients	O	-1	19346865
from	O	-1	19346865
thir@@	O	-1	19346865
d	O	-1	19346865
to	O	-1	19346865
14@@	O	-1	19346865
th	O	-1	19346865
days	O	-1	19346865
after	O	-1	19346865
discontinu@@	O	-1	19346865
ation	O	-1	19346865
of	O	-1	19346865
met@@	B-Chemical	D008795	19346865
ron@@	I-Chemical	-1	19346865
id@@	I-Chemical	-1	19346865
azole	I-Chemical	-1	19346865
administr@@	O	-1	19346865
ation.	O	-1	19346865
F@@	O	-1	19346865
ind@@	O	-1	19346865
ings	O	-1	19346865
of	O	-1	19346865
initial	O	-1	19346865
and	O	-1	19346865
follow-up	O	-1	19346865
MR@@	O	-1	19346865
I@@	O	-1	19346865
s	O	-1	19346865
were	O	-1	19346865
ret@@	O	-1	19346865
ro@@	O	-1	19346865
sp@@	O	-1	19346865
ectively	O	-1	19346865
evaluated	O	-1	19346865
by	O	-1	19346865
2	O	-1	19346865
neuro@@	O	-1	19346865
radi@@	O	-1	19346865
olog@@	O	-1	19346865
ist@@	O	-1	19346865
s	O	-1	19346865
by	O	-1	19346865
con@@	O	-1	19346865
sens@@	O	-1	19346865
us,	O	-1	19346865
to	O	-1	19346865
analy@@	O	-1	19346865
ze	O	-1	19346865
the	O	-1	19346865
presence	O	-1	19346865
of	O	-1	19346865
ab@@	O	-1	19346865
normal	O	-1	19346865
sign@@	O	-1	19346865
al	O	-1	19346865
int@@	O	-1	19346865
en@@	O	-1	19346865
si@@	O	-1	19346865
ti@@	O	-1	19346865
es,	O	-1	19346865
their	O	-1	19346865
loc@@	O	-1	19346865
ation@@	O	-1	19346865
s,	O	-1	19346865
and	O	-1	19346865
sign@@	O	-1	19346865
al	O	-1	19346865
changes	O	-1	19346865
on	O	-1	19346865
follow-up	O	-1	19346865
imag@@	O	-1	19346865
es.	O	-1	19346865
RESULTS:	O	-1	19346865
In@@	O	-1	19346865
iti@@	O	-1	19346865
al	O	-1	19346865
MR@@	O	-1	19346865
I@@	O	-1	19346865
s	O	-1	19346865
showed	O	-1	19346865
ab@@	O	-1	19346865
normal	O	-1	19346865
high	O	-1	19346865
sign@@	O	-1	19346865
al	O	-1	19346865
int@@	O	-1	19346865
en@@	O	-1	19346865
si@@	O	-1	19346865
ties	O	-1	19346865
on	O	-1	19346865
D@@	O	-1	19346865
W@@	O	-1	19346865
I	O	-1	19346865
and	O	-1	19346865
F@@	O	-1	19346865
L@@	O	-1	19346865
A@@	O	-1	19346865
I@@	O	-1	19346865
R	O	-1	19346865
(@@	O	-1	19346865
or	O	-1	19346865
T@@	O	-1	19346865
2-@@	O	-1	19346865
weigh@@	O	-1	19346865
ted	O	-1	19346865
imag@@	O	-1	19346865
e@@	O	-1	19346865
)	O	-1	19346865
at	O	-1	19346865
the	O	-1	19346865
d@@	O	-1	19346865
ent@@	O	-1	19346865
ate	O	-1	19346865
nucle@@	O	-1	19346865
us	O	-1	19346865
(@@	O	-1	19346865
8@@	O	-1	19346865
/@@	O	-1	19346865
8@@	O	-1	19346865
),	O	-1	19346865
inf@@	O	-1	19346865
er@@	O	-1	19346865
ior	O	-1	19346865
coll@@	O	-1	19346865
ic@@	O	-1	19346865
ul@@	O	-1	19346865
us	O	-1	19346865
(6@@	O	-1	19346865
/@@	O	-1	19346865
8@@	O	-1	19346865
),	O	-1	19346865
cor@@	O	-1	19346865
p@@	O	-1	19346865
us	O	-1	19346865
cal@@	O	-1	19346865
lo@@	O	-1	19346865
su@@	O	-1	19346865
m	O	-1	19346865
(2@@	O	-1	19346865
/@@	O	-1	19346865
8@@	O	-1	19346865
),	O	-1	19346865
p@@	O	-1	19346865
ons	O	-1	19346865
(2@@	O	-1	19346865
/@@	O	-1	19346865
8@@	O	-1	19346865
),	O	-1	19346865
med@@	O	-1	19346865
ul@@	O	-1	19346865
l@@	O	-1	19346865
a	O	-1	19346865
(1@@	O	-1	19346865
/@@	O	-1	19346865
8@@	O	-1	19346865
),	O	-1	19346865
and	O	-1	19346865
bil@@	O	-1	19346865
ateral	O	-1	19346865
cerebral	O	-1	19346865
wh@@	O	-1	19346865
ite	O	-1	19346865
mat@@	O	-1	19346865
ter	O	-1	19346865
(1@@	O	-1	19346865
/@@	O	-1	19346865
8@@	O	-1	19346865
).	O	-1	19346865
H@@	O	-1	19346865
igh@@	O	-1	19346865
-@@	O	-1	19346865
sign@@	O	-1	19346865
al	O	-1	19346865
int@@	O	-1	19346865
ensity	O	-1	19346865
lesions	O	-1	19346865
on	O	-1	19346865
D@@	O	-1	19346865
W@@	O	-1	19346865
I	O	-1	19346865
ten@@	O	-1	19346865
ded	O	-1	19346865
to	O	-1	19346865
show	O	-1	19346865
low	O	-1	19346865
sign@@	O	-1	19346865
al	O	-1	19346865
int@@	O	-1	19346865
ensity	O	-1	19346865
on	O	-1	19346865
AD@@	O	-1	19346865
C	O	-1	19346865
ma@@	O	-1	19346865
p	O	-1	19346865
(3@@	O	-1	19346865
/@@	O	-1	19346865
4@@	O	-1	19346865
),	O	-1	19346865
but	O	-1	19346865
in	O	-1	19346865
one	O	-1	19346865
patient@@	O	-1	19346865
,	O	-1	19346865
high	O	-1	19346865
sign@@	O	-1	19346865
al	O	-1	19346865
int@@	O	-1	19346865
ensity	O	-1	19346865
was	O	-1	19346865
shown	O	-1	19346865
at	O	-1	19346865
bil@@	O	-1	19346865
ateral	O	-1	19346865
d@@	O	-1	19346865
ent@@	O	-1	19346865
ate	O	-1	19346865
nucle@@	O	-1	19346865
i	O	-1	19346865
on	O	-1	19346865
not	O	-1	19346865
only	O	-1	19346865
D@@	O	-1	19346865
W@@	O	-1	19346865
I	O	-1	19346865
but	O	-1	19346865
also	O	-1	19346865
AD@@	O	-1	19346865
C	O	-1	19346865
m@@	O	-1	19346865
ap@@	O	-1	19346865
.	O	-1	19346865
All	O	-1	19346865
the	O	-1	19346865
lesions	O	-1	19346865
in	O	-1	19346865
d@@	O	-1	19346865
ent@@	O	-1	19346865
ate,	O	-1	19346865
inf@@	O	-1	19346865
er@@	O	-1	19346865
ior	O	-1	19346865
coll@@	O	-1	19346865
ic@@	O	-1	19346865
ul@@	O	-1	19346865
us,	O	-1	19346865
p@@	O	-1	19346865
on@@	O	-1	19346865
s,	O	-1	19346865
and	O	-1	19346865
med@@	O	-1	19346865
ul@@	O	-1	19346865
l@@	O	-1	19346865
as	O	-1	19346865
had	O	-1	19346865
been	O	-1	19346865
resol@@	O	-1	19346865
ved	O	-1	19346865
complete@@	O	-1	19346865
ly	O	-1	19346865
on	O	-1	19346865
follow-up	O	-1	19346865
MR@@	O	-1	19346865
I@@	O	-1	19346865
s	O	-1	19346865
in	O	-1	19346865
5	O	-1	19346865
patients,	O	-1	19346865
but	O	-1	19346865
in	O	-1	19346865
1	O	-1	19346865
patient	O	-1	19346865
of	O	-1	19346865
th@@	O	-1	19346865
em@@	O	-1	19346865
,	O	-1	19346865
cor@@	O	-1	19346865
p@@	O	-1	19346865
us	O	-1	19346865
cal@@	B-Disease	D001927	19346865
los@@	I-Disease	-1	19346865
al	I-Disease	-1	19346865
le@@	I-Disease	-1	19346865
sion	I-Disease	-1	19346865
per@@	O	-1	19346865
sist@@	O	-1	19346865
ed.	O	-1	19346865
CONCLUSIONS:	O	-1	19346865
Re@@	O	-1	19346865
ver@@	O	-1	19346865
sible	O	-1	19346865
inf@@	B-Disease	D001927	19346865
er@@	I-Disease	-1	19346865
ior	I-Disease	-1	19346865
coll@@	I-Disease	-1	19346865
ic@@	I-Disease	-1	19346865
ul@@	I-Disease	-1	19346865
us	I-Disease	-1	19346865
lesions	I-Disease	-1	19346865
could	O	-1	19346865
be	O	-1	19346865
considered	O	-1	19346865
as	O	-1	19346865
the	O	-1	19346865
character@@	O	-1	19346865
istic	O	-1	19346865
for	O	-1	19346865
met@@	B-Chemical	D008795	19346865
ron@@	I-Chemical	-1	19346865
id@@	I-Chemical	-1	19346865
azole	I-Chemical	-1	19346865
-induced	O	-1	19346865
encephalo@@	B-Disease	D001927	19346865
pathy	I-Disease	-1	19346865
,	O	-1	19346865
ne@@	O	-1	19346865
x@@	O	-1	19346865
t	O	-1	19346865
to	O	-1	19346865
the	O	-1	19346865
d@@	O	-1	19346865
ent@@	O	-1	19346865
ate	O	-1	19346865
nucle@@	O	-1	19346865
us	O	-1	19346865
invol@@	O	-1	19346865
ve@@	O	-1	19346865
ment.	O	-1	19346865

Com@@	O	-1	2334618
par@@	O	-1	2334618
ison	O	-1	2334618
of	O	-1	2334618
the	O	-1	2334618
respiratory	O	-1	2334618
effects	O	-1	2334618
of	O	-1	2334618
i.v@@	O	-1	2334618
.	O	-1	2334618
infu@@	O	-1	2334618
sions	O	-1	2334618
of	O	-1	2334618
morphine	B-Chemical	D009020	2334618
and	O	-1	2334618
regi@@	O	-1	2334618
on@@	O	-1	2334618
al	O	-1	2334618
analge@@	O	-1	2334618
sia	O	-1	2334618
by	O	-1	2334618
ext@@	O	-1	2334618
ra@@	O	-1	2334618
dur@@	O	-1	2334618
al	O	-1	2334618
block@@	O	-1	2334618
.	O	-1	2334618
The	O	-1	2334618
incidence	O	-1	2334618
of	O	-1	2334618
postoperative	O	-1	2334618
respiratory	O	-1	2334618
ap@@	B-Disease	D001049	2334618
no@@	I-Disease	-1	2334618
e@@	I-Disease	-1	2334618
a	I-Disease	-1	2334618
was	O	-1	2334618
compared	O	-1	2334618
between	O	-1	2334618
five	O	-1	2334618
patients	O	-1	2334618
receiving	O	-1	2334618
a	O	-1	2334618
continu@@	O	-1	2334618
ous	O	-1	2334618
i.v@@	O	-1	2334618
.	O	-1	2334618
infusion	O	-1	2334618
of	O	-1	2334618
morphine	B-Chemical	D009020	2334618
(@@	O	-1	2334618
mean	O	-1	2334618
7@@	O	-1	2334618
3.@@	O	-1	2334618
6	O	-1	2334618
mg@@	O	-1	2334618
)	O	-1	2334618
and	O	-1	2334618
five	O	-1	2334618
patients	O	-1	2334618
receiving	O	-1	2334618
a	O	-1	2334618
continu@@	O	-1	2334618
ous	O	-1	2334618
ext@@	O	-1	2334618
ra@@	O	-1	2334618
dur@@	O	-1	2334618
al	O	-1	2334618
infusion	O	-1	2334618
of	O	-1	2334618
0.@@	O	-1	2334618
2@@	O	-1	2334618
5%	O	-1	2334618
bupivac@@	B-Chemical	D002045	2334618
aine	I-Chemical	-1	2334618
(@@	O	-1	2334618
mean	O	-1	2334618
19@@	O	-1	2334618
2	O	-1	2334618
mg@@	O	-1	2334618
)	O	-1	2334618
in	O	-1	2334618
the	O	-1	2334618
2@@	O	-1	2334618
4-@@	O	-1	2334618
h	O	-1	2334618
period	O	-1	2334618
following	O	-1	2334618
up@@	O	-1	2334618
per	O	-1	2334618
ab@@	O	-1	2334618
domin@@	O	-1	2334618
al	O	-1	2334618
surger@@	O	-1	2334618
y.	O	-1	2334618
M@@	O	-1	2334618
on@@	O	-1	2334618
it@@	O	-1	2334618
or@@	O	-1	2334618
ing	O	-1	2334618
consist@@	O	-1	2334618
ed	O	-1	2334618
of	O	-1	2334618
a@@	O	-1	2334618
ir@@	O	-1	2334618
flow	O	-1	2334618
det@@	O	-1	2334618
ection	O	-1	2334618
by	O	-1	2334618
a	O	-1	2334618
carb@@	B-Chemical	D002245	2334618
on	I-Chemical	-1	2334618
di@@	I-Chemical	-1	2334618
ox@@	I-Chemical	-1	2334618
ide	I-Chemical	-1	2334618
analy@@	O	-1	2334618
ser@@	O	-1	2334618
,	O	-1	2334618
ch@@	O	-1	2334618
est	O	-1	2334618
w@@	O	-1	2334618
all	O	-1	2334618
mo@@	O	-1	2334618
vement	O	-1	2334618
det@@	O	-1	2334618
ected	O	-1	2334618
by	O	-1	2334618
p@@	O	-1	2334618
ne@@	O	-1	2334618
um@@	O	-1	2334618
atic	O	-1	2334618
cap@@	O	-1	2334618
sul@@	O	-1	2334618
es,	O	-1	2334618
and	O	-1	2334618
continu@@	O	-1	2334618
ous	O	-1	2334618
electro@@	O	-1	2334618
cardio@@	O	-1	2334618
gra@@	O	-1	2334618
p@@	O	-1	2334618
h	O	-1	2334618
recor@@	O	-1	2334618
ded	O	-1	2334618
with	O	-1	2334618
a	O	-1	2334618
H@@	O	-1	2334618
ol@@	O	-1	2334618
ter	O	-1	2334618
am@@	O	-1	2334618
b@@	O	-1	2334618
ul@@	O	-1	2334618
atory	O	-1	2334618
monit@@	O	-1	2334618
or@@	O	-1	2334618
.	O	-1	2334618
B@@	O	-1	2334618
oth	O	-1	2334618
ob@@	B-Disease	D020181	2334618
struc@@	I-Disease	-1	2334618
tive	I-Disease	-1	2334618
(P	I-Disease	-1	2334618
less	I-Disease	-1	2334618
than	I-Disease	-1	2334618
0.05@@	I-Disease	-1	2334618
)	I-Disease	-1	2334618
and	I-Disease	-1	2334618
central	I-Disease	-1	2334618
ap@@	I-Disease	-1	2334618
no@@	I-Disease	-1	2334618
e@@	I-Disease	-1	2334618
a	I-Disease	-1	2334618
ob@@	B-Disease	D020182	2334618
struc@@	I-Disease	-1	2334618
tive	I-Disease	-1	2334618
(P	I-Disease	-1	2334618
less	I-Disease	-1	2334618
than	I-Disease	-1	2334618
0.05@@	I-Disease	-1	2334618
)	I-Disease	-1	2334618
and	I-Disease	-1	2334618
central	I-Disease	-1	2334618
ap@@	I-Disease	-1	2334618
no@@	I-Disease	-1	2334618
e@@	I-Disease	-1	2334618
a	I-Disease	-1	2334618
(P	O	-1	2334618
less	O	-1	2334618
than	O	-1	2334618
0.05@@	O	-1	2334618
)	O	-1	2334618
occurred	O	-1	2334618
more	O	-1	2334618
frequ@@	O	-1	2334618
ently	O	-1	2334618
in	O	-1	2334618
patients	O	-1	2334618
who	O	-1	2334618
had	O	-1	2334618
a	O	-1	2334618
morphine	B-Chemical	D009020	2334618
infu@@	O	-1	2334618
sion.	O	-1	2334618
There	O	-1	2334618
was	O	-1	2334618
also	O	-1	2334618
a	O	-1	2334618
higher	O	-1	2334618
incidence	O	-1	2334618
of	O	-1	2334618
tachy@@	B-Disease	D013610	2334618
arrhyth@@	I-Disease	-1	2334618
mi@@	I-Disease	-1	2334618
as	I-Disease	-1	2334618
(P	O	-1	2334618
less	O	-1	2334618
than	O	-1	2334618
0.05@@	O	-1	2334618
)	O	-1	2334618
and	O	-1	2334618
ventricular	B-Disease	D018879	2334618
ect@@	I-Disease	-1	2334618
op@@	I-Disease	-1	2334618
ic	I-Disease	-1	2334618
be@@	I-Disease	-1	2334618
at@@	I-Disease	-1	2334618
s	I-Disease	-1	2334618
(P	O	-1	2334618
less	O	-1	2334618
than	O	-1	2334618
0.05@@	O	-1	2334618
)	O	-1	2334618
in	O	-1	2334618
the	O	-1	2334618
morphine	B-Chemical	D009020	2334618
infusion	O	-1	2334618
group.	O	-1	2334618

M@@	O	-1	8864707
ag@@	O	-1	8864707
ne@@	O	-1	8864707
tic	O	-1	8864707
res@@	O	-1	8864707
on@@	O	-1	8864707
ance	O	-1	8864707
vol@@	O	-1	8864707
u@@	O	-1	8864707
met@@	O	-1	8864707
r@@	O	-1	8864707
y	O	-1	8864707
of	O	-1	8864707
the	O	-1	8864707
ce@@	O	-1	8864707
re@@	O	-1	8864707
bell@@	O	-1	8864707
um	O	-1	8864707
in	O	-1	8864707
epileptic	B-Disease	D004827	8864707
patients	O	-1	8864707
after	O	-1	8864707
pheny@@	B-Chemical	D010672	8864707
to@@	I-Chemical	-1	8864707
in	I-Chemical	-1	8864707
over@@	B-Disease	D062787	8864707
dos@@	I-Disease	-1	8864707
ages	I-Disease	-1	8864707
.	O	-1	8864707
The	O	-1	8864707
a@@	O	-1	8864707
im	O	-1	8864707
of	O	-1	8864707
this	O	-1	8864707
study	O	-1	8864707
was	O	-1	8864707
to	O	-1	8864707
evalu@@	O	-1	8864707
ate	O	-1	8864707
the	O	-1	8864707
rel@@	O	-1	8864707
ationship	O	-1	8864707
between	O	-1	8864707
pheny@@	B-Chemical	D010672	8864707
to@@	I-Chemical	-1	8864707
in	I-Chemical	-1	8864707
medic@@	O	-1	8864707
ation	O	-1	8864707
and	O	-1	8864707
ce@@	B-Disease	D002526	8864707
re@@	I-Disease	-1	8864707
bell@@	I-Disease	-1	8864707
ar	I-Disease	-1	8864707
atro@@	I-Disease	-1	8864707
ph@@	I-Disease	-1	8864707
y	I-Disease	-1	8864707
in	O	-1	8864707
patients	O	-1	8864707
who	O	-1	8864707
had	O	-1	8864707
experienced	O	-1	8864707
clinical	O	-1	8864707
in@@	O	-1	8864707
toxic@@	O	-1	8864707
ation.	O	-1	8864707
F@@	O	-1	8864707
i@@	O	-1	8864707
ve	O	-1	8864707
femal@@	O	-1	8864707
es	O	-1	8864707
and	O	-1	8864707
6	O	-1	8864707
mal@@	O	-1	8864707
es,	O	-1	8864707
2@@	O	-1	8864707
1-@@	O	-1	8864707
5@@	O	-1	8864707
9	O	-1	8864707
years	O	-1	8864707
of	O	-1	8864707
age,	O	-1	8864707
were	O	-1	8864707
examined	O	-1	8864707
with	O	-1	8864707
a	O	-1	8864707
1.@@	O	-1	8864707
5-@@	O	-1	8864707
T	O	-1	8864707
wh@@	O	-1	8864707
ol@@	O	-1	8864707
e-@@	O	-1	8864707
body	O	-1	8864707
system	O	-1	8864707
using	O	-1	8864707
a	O	-1	8864707
cir@@	O	-1	8864707
cular	O	-1	8864707
pol@@	O	-1	8864707
ar@@	O	-1	8864707
ized	O	-1	8864707
he@@	O	-1	8864707
ad	O	-1	8864707
co@@	O	-1	8864707
il@@	O	-1	8864707
.	O	-1	8864707
Con@@	O	-1	8864707
ven@@	O	-1	8864707
tional	O	-1	8864707
sp@@	O	-1	8864707
in	O	-1	8864707
ech@@	O	-1	8864707
o	O	-1	8864707
imag@@	O	-1	8864707
es	O	-1	8864707
were	O	-1	8864707
ac@@	O	-1	8864707
qu@@	O	-1	8864707
ired	O	-1	8864707
in	O	-1	8864707
the	O	-1	8864707
s@@	O	-1	8864707
ag@@	O	-1	8864707
it@@	O	-1	8864707
t@@	O	-1	8864707
al	O	-1	8864707
and	O	-1	8864707
trans@@	O	-1	8864707
verse	O	-1	8864707
or@@	O	-1	8864707
i@@	O	-1	8864707
ent@@	O	-1	8864707
ation.	O	-1	8864707
In	O	-1	8864707
addi@@	O	-1	8864707
tion,	O	-1	8864707
we	O	-1	8864707
performed	O	-1	8864707
a	O	-1	8864707
high-@@	O	-1	8864707
resol@@	O	-1	8864707
u@@	O	-1	8864707
tion	O	-1	8864707
3@@	O	-1	8864707
D	O	-1	8864707
gra@@	O	-1	8864707
di@@	O	-1	8864707
ent	O	-1	8864707
ec@@	O	-1	8864707
ho@@	O	-1	8864707
,	O	-1	8864707
T@@	O	-1	8864707
1-@@	O	-1	8864707
weigh@@	O	-1	8864707
ted	O	-1	8864707
sequ@@	O	-1	8864707
enc@@	O	-1	8864707
es	O	-1	8864707
at	O	-1	8864707
a	O	-1	8864707
1-@@	O	-1	8864707
mm	O	-1	8864707
s@@	O	-1	8864707
l@@	O	-1	8864707
ic@@	O	-1	8864707
e	O	-1	8864707
th@@	O	-1	8864707
ic@@	O	-1	8864707
k@@	O	-1	8864707
n@@	O	-1	8864707
es@@	O	-1	8864707
s.	O	-1	8864707
The	O	-1	8864707
imag@@	O	-1	8864707
es	O	-1	8864707
were	O	-1	8864707
subsequ@@	O	-1	8864707
ently	O	-1	8864707
pro@@	O	-1	8864707
cess@@	O	-1	8864707
ed	O	-1	8864707
to	O	-1	8864707
obt@@	O	-1	8864707
ain	O	-1	8864707
vol@@	O	-1	8864707
u@@	O	-1	8864707
me@@	O	-1	8864707
tri@@	O	-1	8864707
c	O	-1	8864707
data	O	-1	8864707
for	O	-1	8864707
the	O	-1	8864707
ce@@	O	-1	8864707
re@@	O	-1	8864707
bell@@	O	-1	8864707
um@@	O	-1	8864707
.	O	-1	8864707
C@@	O	-1	8864707
e@@	O	-1	8864707
re@@	O	-1	8864707
bell@@	O	-1	8864707
ar	O	-1	8864707
volume	O	-1	8864707
for	O	-1	8864707
the	O	-1	8864707
patient	O	-1	8864707
group	O	-1	8864707
rang@@	O	-1	8864707
ed	O	-1	8864707
between	O	-1	8864707
6@@	O	-1	8864707
7.@@	O	-1	8864707
6@@	O	-1	8864707
6	O	-1	8864707
and	O	-1	8864707
13@@	O	-1	8864707
1.@@	O	-1	8864707
0@@	O	-1	8864707
8	O	-1	8864707
m@@	O	-1	8864707
l	O	-1	8864707
(@@	O	-1	8864707
mean	O	-1	8864707
10@@	O	-1	8864707
8.@@	O	-1	8864707
9	O	-1	8864707
ml@@	O	-1	8864707
).	O	-1	8864707
In	O	-1	8864707
addition	O	-1	8864707
3@@	O	-1	8864707
D	O	-1	8864707
gra@@	O	-1	8864707
di@@	O	-1	8864707
ent	O	-1	8864707
ech@@	O	-1	8864707
o	O	-1	8864707
data	O	-1	8864707
se@@	O	-1	8864707
ts	O	-1	8864707
from	O	-1	8864707
10	O	-1	8864707
healthy	O	-1	8864707
male	O	-1	8864707
and	O	-1	8864707
10	O	-1	8864707
healthy	O	-1	8864707
female	O	-1	8864707
ag@@	O	-1	8864707
e-@@	O	-1	8864707
mat@@	O	-1	8864707
ch@@	O	-1	8864707
ed	O	-1	8864707
vol@@	O	-1	8864707
un@@	O	-1	8864707
te@@	O	-1	8864707
ers	O	-1	8864707
were	O	-1	8864707
used	O	-1	8864707
to	O	-1	8864707
compar@@	O	-1	8864707
e	O	-1	8864707
ce@@	O	-1	8864707
re@@	O	-1	8864707
bell@@	O	-1	8864707
ar	O	-1	8864707
volum@@	O	-1	8864707
es.	O	-1	8864707
U@@	O	-1	8864707
s@@	O	-1	8864707
ing	O	-1	8864707
l@@	O	-1	8864707
ine@@	O	-1	8864707
ar	O	-1	8864707
reg@@	O	-1	8864707
res@@	O	-1	8864707
sion	O	-1	8864707
we	O	-1	8864707
found	O	-1	8864707
that	O	-1	8864707
no	O	-1	8864707
correl@@	O	-1	8864707
ation	O	-1	8864707
ex@@	O	-1	8864707
ist@@	O	-1	8864707
s	O	-1	8864707
between	O	-1	8864707
seizure	B-Disease	D012640	8864707
dur@@	O	-1	8864707
ation,	O	-1	8864707
elev@@	O	-1	8864707
ation	O	-1	8864707
of	O	-1	8864707
pheny@@	B-Chemical	D010672	8864707
to@@	I-Chemical	-1	8864707
in	I-Chemical	-1	8864707
serum	O	-1	8864707
levels	O	-1	8864707
and	O	-1	8864707
ce@@	O	-1	8864707
re@@	O	-1	8864707
bell@@	O	-1	8864707
ar	O	-1	8864707
vol@@	O	-1	8864707
u@@	O	-1	8864707
me.	O	-1	8864707
However,	O	-1	8864707
multiple	O	-1	8864707
reg@@	O	-1	8864707
res@@	O	-1	8864707
sion	O	-1	8864707
for	O	-1	8864707
the	O	-1	8864707
daily	O	-1	8864707
dos@@	O	-1	8864707
age,	O	-1	8864707
duration	O	-1	8864707
of	O	-1	8864707
pheny@@	B-Chemical	D010672	8864707
to@@	I-Chemical	-1	8864707
in	I-Chemical	-1	8864707
treatment	O	-1	8864707
and	O	-1	8864707
ce@@	O	-1	8864707
re@@	O	-1	8864707
bell@@	O	-1	8864707
ar	O	-1	8864707
volume	O	-1	8864707
revealed	O	-1	8864707
a	O	-1	8864707
correl@@	O	-1	8864707
ation	O	-1	8864707
of	O	-1	8864707
these	O	-1	8864707
par@@	O	-1	8864707
ame@@	O	-1	8864707
ter@@	O	-1	8864707
s.	O	-1	8864707
We	O	-1	8864707
concl@@	O	-1	8864707
ude	O	-1	8864707
that	O	-1	8864707
pheny@@	B-Chemical	D010672	8864707
to@@	I-Chemical	-1	8864707
in	I-Chemical	-1	8864707
over@@	B-Disease	D062787	8864707
dos@@	I-Disease	-1	8864707
age	I-Disease	-1	8864707
does	O	-1	8864707
not	O	-1	8864707
nec@@	O	-1	8864707
ess@@	O	-1	8864707
ari@@	O	-1	8864707
ly	O	-1	8864707
result	O	-1	8864707
in	O	-1	8864707
ce@@	B-Disease	D002526	8864707
re@@	I-Disease	-1	8864707
bell@@	I-Disease	-1	8864707
ar	I-Disease	-1	8864707
atro@@	I-Disease	-1	8864707
ph@@	I-Disease	-1	8864707
y	I-Disease	-1	8864707
and	O	-1	8864707
it	O	-1	8864707
is	O	-1	8864707
un@@	O	-1	8864707
likely	O	-1	8864707
that	O	-1	8864707
pheny@@	B-Chemical	D010672	8864707
to@@	I-Chemical	-1	8864707
in	I-Chemical	-1	8864707
medic@@	O	-1	8864707
ation	O	-1	8864707
was	O	-1	8864707
the	O	-1	8864707
only	O	-1	8864707
cause	O	-1	8864707
of	O	-1	8864707
ce@@	B-Disease	D002526	8864707
re@@	I-Disease	-1	8864707
bell@@	I-Disease	-1	8864707
ar	I-Disease	-1	8864707
atro@@	I-Disease	-1	8864707
ph@@	I-Disease	-1	8864707
y	I-Disease	-1	8864707
in	O	-1	8864707
the	O	-1	8864707
remain@@	O	-1	8864707
ing	O	-1	8864707
patients.	O	-1	8864707
Q@@	O	-1	8864707
u@@	O	-1	8864707
anti@@	O	-1	8864707
t@@	O	-1	8864707
ative	O	-1	8864707
morph@@	O	-1	8864707
o@@	O	-1	8864707
me@@	O	-1	8864707
tri@@	O	-1	8864707
c	O	-1	8864707
studies	O	-1	8864707
of	O	-1	8864707
the	O	-1	8864707
ce@@	O	-1	8864707
re@@	O	-1	8864707
bell@@	O	-1	8864707
um	O	-1	8864707
prov@@	O	-1	8864707
ide	O	-1	8864707
valu@@	O	-1	8864707
able	O	-1	8864707
in@@	O	-1	8864707
si@@	O	-1	8864707
gh@@	O	-1	8864707
ts	O	-1	8864707
into	O	-1	8864707
the	O	-1	8864707
path@@	O	-1	8864707
o@@	O	-1	8864707
genesis	O	-1	8864707
of	O	-1	8864707
ce@@	B-Disease	D002526	8864707
re@@	I-Disease	-1	8864707
bell@@	I-Disease	-1	8864707
ar	I-Disease	-1	8864707
disorder@@	I-Disease	-1	8864707
s	I-Disease	-1	8864707
.	O	-1	8864707

E@@	O	-1	12589964
valu@@	O	-1	12589964
ation	O	-1	12589964
of	O	-1	12589964
cardiac	O	-1	12589964
tro@@	O	-1	12589964
p@@	O	-1	12589964
on@@	O	-1	12589964
in	O	-1	12589964
I	O	-1	12589964
and	O	-1	12589964
T	O	-1	12589964
levels	O	-1	12589964
as	O	-1	12589964
mark@@	O	-1	12589964
ers	O	-1	12589964
of	O	-1	12589964
myocardial	B-Disease	D009202	12589964
damage	I-Disease	-1	12589964
in	O	-1	12589964
dox@@	B-Chemical	D004317	12589964
orub@@	I-Chemical	-1	12589964
icin	I-Chemical	-1	12589964
-induced	O	-1	12589964
cardi@@	B-Disease	D009202	12589964
om@@	I-Disease	-1	12589964
yo@@	I-Disease	-1	12589964
pathy	I-Disease	-1	12589964
rats,	O	-1	12589964
and	O	-1	12589964
their	O	-1	12589964
rel@@	O	-1	12589964
ationship	O	-1	12589964
with	O	-1	12589964
echocardiograph@@	O	-1	12589964
ic	O	-1	12589964
and	O	-1	12589964
hist@@	O	-1	12589964
ological	O	-1	12589964
find@@	O	-1	12589964
ing@@	O	-1	12589964
s.	O	-1	12589964
BACKGROUND:	O	-1	12589964
C@@	O	-1	12589964
ardi@@	O	-1	12589964
a@@	O	-1	12589964
c	O	-1	12589964
tro@@	O	-1	12589964
p@@	O	-1	12589964
on@@	O	-1	12589964
ins	O	-1	12589964
I	O	-1	12589964
(@@	O	-1	12589964
cTn@@	O	-1	12589964
I@@	O	-1	12589964
)	O	-1	12589964
and	O	-1	12589964
T	O	-1	12589964
(@@	O	-1	12589964
cTn@@	O	-1	12589964
T)	O	-1	12589964
have	O	-1	12589964
been	O	-1	12589964
shown	O	-1	12589964
to	O	-1	12589964
be	O	-1	12589964
high@@	O	-1	12589964
ly	O	-1	12589964
sensitive	O	-1	12589964
and	O	-1	12589964
specific	O	-1	12589964
mark@@	O	-1	12589964
ers	O	-1	12589964
of	O	-1	12589964
myocardial	B-Disease	D009202	12589964
cell	I-Disease	-1	12589964
injury	I-Disease	-1	12589964
.	O	-1	12589964
We	O	-1	12589964
investigated	O	-1	12589964
the	O	-1	12589964
diagnos@@	O	-1	12589964
tic	O	-1	12589964
valu@@	O	-1	12589964
e	O	-1	12589964
of	O	-1	12589964
cTn@@	O	-1	12589964
I	O	-1	12589964
and	O	-1	12589964
cTn@@	O	-1	12589964
T	O	-1	12589964
for	O	-1	12589964
the	O	-1	12589964
diagnosis	O	-1	12589964
of	O	-1	12589964
myocardial	B-Disease	D009202	12589964
damage	I-Disease	-1	12589964
in	O	-1	12589964
a	O	-1	12589964
rat	O	-1	12589964
model	O	-1	12589964
of	O	-1	12589964
dox@@	B-Chemical	D004317	12589964
orub@@	I-Chemical	-1	12589964
icin	I-Chemical	-1	12589964
(	O	-1	12589964
DO@@	B-Chemical	D004317	12589964
X	I-Chemical	-1	12589964
)@@	O	-1	12589964
-induced	O	-1	12589964
cardi@@	B-Disease	D009202	12589964
om@@	I-Disease	-1	12589964
yo@@	I-Disease	-1	12589964
pathy	I-Disease	-1	12589964
,	O	-1	12589964
and	O	-1	12589964
we	O	-1	12589964
examined	O	-1	12589964
the	O	-1	12589964
rel@@	O	-1	12589964
ationship	O	-1	12589964
between	O	-1	12589964
ser@@	O	-1	12589964
ial	O	-1	12589964
cTn@@	O	-1	12589964
I	O	-1	12589964
and	O	-1	12589964
cTn@@	O	-1	12589964
T	O	-1	12589964
with	O	-1	12589964
the	O	-1	12589964
development	O	-1	12589964
of	O	-1	12589964
cardiac	B-Disease	D006331	12589964
disorder@@	I-Disease	-1	12589964
s	I-Disease	-1	12589964
monit@@	O	-1	12589964
o@@	O	-1	12589964
red	O	-1	12589964
by	O	-1	12589964
echocardiograph@@	O	-1	12589964
y	O	-1	12589964
and	O	-1	12589964
hist@@	O	-1	12589964
ological	O	-1	12589964
examin@@	O	-1	12589964
ations	O	-1	12589964
in	O	-1	12589964
this	O	-1	12589964
model@@	O	-1	12589964
.	O	-1	12589964
METHODS:	O	-1	12589964
Th@@	O	-1	12589964
ir@@	O	-1	12589964
ty-@@	O	-1	12589964
five	O	-1	12589964
Wistar	O	-1	12589964
rats	O	-1	12589964
were	O	-1	12589964
given	O	-1	12589964
1.@@	O	-1	12589964
5	O	-1	12589964
mg/kg	O	-1	12589964
DO@@	B-Chemical	D004317	12589964
X	I-Chemical	-1	12589964
,	O	-1	12589964
i.v@@	O	-1	12589964
.,	O	-1	12589964
week@@	O	-1	12589964
ly	O	-1	12589964
for	O	-1	12589964
up	O	-1	12589964
to	O	-1	12589964
8	O	-1	12589964
weeks	O	-1	12589964
for	O	-1	12589964
a	O	-1	12589964
total	O	-1	12589964
cum@@	O	-1	12589964
ul@@	O	-1	12589964
ative	O	-1	12589964
dose	O	-1	12589964
of	O	-1	12589964
12	O	-1	12589964
mg/kg	O	-1	12589964
B@@	O	-1	12589964
W@@	O	-1	12589964
.	O	-1	12589964
T@@	O	-1	12589964
en	O	-1	12589964
rats	O	-1	12589964
received	O	-1	12589964
saline	O	-1	12589964
as	O	-1	12589964
a	O	-1	12589964
control	O	-1	12589964
group.	O	-1	12589964
cTn@@	O	-1	12589964
I	O	-1	12589964
was	O	-1	12589964
measured	O	-1	12589964
with	O	-1	12589964
Ac@@	O	-1	12589964
cess@@	O	-1	12589964
(@@	O	-1	12589964
R@@	O	-1	12589964
)	O	-1	12589964
(n@@	O	-1	12589964
g/@@	O	-1	12589964
ml@@	O	-1	12589964
)	O	-1	12589964
and	O	-1	12589964
a	O	-1	12589964
re@@	O	-1	12589964
se@@	O	-1	12589964
arc@@	O	-1	12589964
h	O	-1	12589964
immuno@@	O	-1	12589964
ass@@	O	-1	12589964
ay	O	-1	12589964
(p@@	O	-1	12589964
g/@@	O	-1	12589964
ml@@	O	-1	12589964
),	O	-1	12589964
and	O	-1	12589964
compared	O	-1	12589964
with	O	-1	12589964
cTn@@	O	-1	12589964
T@@	O	-1	12589964
,	O	-1	12589964
C@@	O	-1	12589964
K@@	O	-1	12589964
-@@	O	-1	12589964
M@@	O	-1	12589964
B	O	-1	12589964
mas@@	O	-1	12589964
s	O	-1	12589964
and	O	-1	12589964
C@@	O	-1	12589964
K@@	O	-1	12589964
.	O	-1	12589964
B@@	O	-1	12589964
y	O	-1	12589964
using	O	-1	12589964
trans@@	O	-1	12589964
th@@	O	-1	12589964
or@@	O	-1	12589964
ac@@	O	-1	12589964
ic	O	-1	12589964
echocardiograph@@	O	-1	12589964
y,	O	-1	12589964
an@@	O	-1	12589964
ter@@	O	-1	12589964
ior	O	-1	12589964
and	O	-1	12589964
po@@	O	-1	12589964
ster@@	O	-1	12589964
ior	O	-1	12589964
w@@	O	-1	12589964
all	O	-1	12589964
th@@	O	-1	12589964
ic@@	O	-1	12589964
k@@	O	-1	12589964
n@@	O	-1	12589964
es@@	O	-1	12589964
s,	O	-1	12589964
L@@	O	-1	12589964
V	O	-1	12589964
di@@	O	-1	12589964
ame@@	O	-1	12589964
ters	O	-1	12589964
and	O	-1	12589964
L@@	O	-1	12589964
V	O	-1	12589964
frac@@	O	-1	12589964
tional	O	-1	12589964
sh@@	O	-1	12589964
or@@	O	-1	12589964
ten@@	O	-1	12589964
ing	O	-1	12589964
(@@	O	-1	12589964
F@@	O	-1	12589964
S)	O	-1	12589964
were	O	-1	12589964
measured	O	-1	12589964
in	O	-1	12589964
all	O	-1	12589964
rats	O	-1	12589964
before	O	-1	12589964
DO@@	B-Chemical	D004317	12589964
X	I-Chemical	-1	12589964
or	O	-1	12589964
sal@@	O	-1	12589964
ine,	O	-1	12589964
and	O	-1	12589964
at	O	-1	12589964
weeks	O	-1	12589964
6	O	-1	12589964
and	O	-1	12589964
9	O	-1	12589964
after	O	-1	12589964
treatment	O	-1	12589964
in	O	-1	12589964
all	O	-1	12589964
sur@@	O	-1	12589964
vi@@	O	-1	12589964
ving	O	-1	12589964
rats.	O	-1	12589964
H@@	O	-1	12589964
ist@@	O	-1	12589964
ology	O	-1	12589964
was	O	-1	12589964
performed	O	-1	12589964
in	O	-1	12589964
DO@@	B-Chemical	D004317	12589964
X	I-Chemical	-1	12589964
-@@	O	-1	12589964
rats	O	-1	12589964
at	O	-1	12589964
6	O	-1	12589964
and	O	-1	12589964
9	O	-1	12589964
weeks	O	-1	12589964
after	O	-1	12589964
the	O	-1	12589964
las@@	O	-1	12589964
t	O	-1	12589964
DO@@	B-Chemical	D004317	12589964
X	I-Chemical	-1	12589964
dose	O	-1	12589964
and	O	-1	12589964
in	O	-1	12589964
all	O	-1	12589964
controls.	O	-1	12589964
RESULTS:	O	-1	12589964
E@@	O	-1	12589964
igh@@	O	-1	12589964
te@@	O	-1	12589964
en	O	-1	12589964
of	O	-1	12589964
the	O	-1	12589964
DO@@	B-Chemical	D004317	12589964
X	I-Chemical	-1	12589964
rats	O	-1	12589964
di@@	O	-1	12589964
ed	O	-1	12589964
pre@@	O	-1	12589964
mat@@	O	-1	12589964
ure@@	O	-1	12589964
ly	O	-1	12589964
of	O	-1	12589964
gener@@	O	-1	12589964
al	O	-1	12589964
toxicity	B-Disease	D064420	12589964
during	O	-1	12589964
the	O	-1	12589964
9@@	O	-1	12589964
-@@	O	-1	12589964
week	O	-1	12589964
perio@@	O	-1	12589964
d.	O	-1	12589964
E@@	O	-1	12589964
n@@	O	-1	12589964
d-@@	O	-1	12589964
di@@	O	-1	12589964
ast@@	O	-1	12589964
olic	O	-1	12589964
(@@	O	-1	12589964
E@@	O	-1	12589964
D)	O	-1	12589964
and	O	-1	12589964
en@@	O	-1	12589964
d-@@	O	-1	12589964
systolic	O	-1	12589964
(@@	O	-1	12589964
ES@@	O	-1	12589964
)	O	-1	12589964
L@@	O	-1	12589964
V	O	-1	12589964
di@@	O	-1	12589964
ame@@	O	-1	12589964
ter@@	O	-1	12589964
s/@@	O	-1	12589964
B@@	O	-1	12589964
W	O	-1	12589964
significantly	O	-1	12589964
increas@@	O	-1	12589964
ed,	O	-1	12589964
whereas	O	-1	12589964
L@@	O	-1	12589964
V	O	-1	12589964
F@@	O	-1	12589964
S	O	-1	12589964
was	O	-1	12589964
decreased	O	-1	12589964
after	O	-1	12589964
9	O	-1	12589964
weeks	O	-1	12589964
in	O	-1	12589964
the	O	-1	12589964
DO@@	B-Chemical	D004317	12589964
X	I-Chemical	-1	12589964
group	O	-1	12589964
(p@@	O	-1	12589964
<@@	O	-1	12589964
0.00@@	O	-1	12589964
1).	O	-1	12589964
These	O	-1	12589964
par@@	O	-1	12589964
ame@@	O	-1	12589964
ters	O	-1	12589964
remained	O	-1	12589964
un@@	O	-1	12589964
chang@@	O	-1	12589964
ed	O	-1	12589964
in	O	-1	12589964
controls.	O	-1	12589964
H@@	O	-1	12589964
ist@@	O	-1	12589964
ological	O	-1	12589964
evalu@@	O	-1	12589964
ation	O	-1	12589964
of	O	-1	12589964
hear@@	O	-1	12589964
ts	O	-1	12589964
from	O	-1	12589964
all	O	-1	12589964
rats	O	-1	12589964
given	O	-1	12589964
DO@@	B-Chemical	D004317	12589964
X	I-Chemical	-1	12589964
revealed	O	-1	12589964
significant	O	-1	12589964
s@@	O	-1	12589964
li@@	O	-1	12589964
ght	O	-1	12589964
de@@	O	-1	12589964
gre@@	O	-1	12589964
es	O	-1	12589964
of	O	-1	12589964
peri@@	O	-1	12589964
vascular	O	-1	12589964
and	O	-1	12589964
interstitial	O	-1	12589964
fib@@	B-Disease	D005355	12589964
ro@@	I-Disease	-1	12589964
sis	I-Disease	-1	12589964
.	O	-1	12589964
In	O	-1	12589964
7	O	-1	12589964
of	O	-1	12589964
the	O	-1	12589964
1@@	O	-1	12589964
8	O	-1	12589964
rats,	O	-1	12589964
de@@	O	-1	12589964
generation	O	-1	12589964
and	O	-1	12589964
my@@	O	-1	12589964
ocyte	O	-1	12589964
vac@@	O	-1	12589964
u@@	O	-1	12589964
ol@@	O	-1	12589964
is@@	O	-1	12589964
ation	O	-1	12589964
were	O	-1	12589964
f@@	O	-1	12589964
oun@@	O	-1	12589964
d.	O	-1	12589964
On@@	O	-1	12589964
ly	O	-1	12589964
five	O	-1	12589964
of	O	-1	12589964
the	O	-1	12589964
controls	O	-1	12589964
ex@@	O	-1	12589964
hib@@	O	-1	12589964
ited	O	-1	12589964
evidence	O	-1	12589964
of	O	-1	12589964
very	O	-1	12589964
s@@	O	-1	12589964
li@@	O	-1	12589964
ght	O	-1	12589964
peri@@	O	-1	12589964
vascular	O	-1	12589964
fib@@	B-Disease	D005355	12589964
ro@@	I-Disease	-1	12589964
sis	I-Disease	-1	12589964
.	O	-1	12589964
A	O	-1	12589964
significant	O	-1	12589964
ri@@	O	-1	12589964
se	O	-1	12589964
in	O	-1	12589964
cTn@@	O	-1	12589964
T	O	-1	12589964
was	O	-1	12589964
found	O	-1	12589964
in	O	-1	12589964
DO@@	B-Chemical	D004317	12589964
X	I-Chemical	-1	12589964
rats	O	-1	12589964
after	O	-1	12589964
cum@@	O	-1	12589964
ul@@	O	-1	12589964
ative	O	-1	12589964
doses	O	-1	12589964
of	O	-1	12589964
7.@@	O	-1	12589964
5	O	-1	12589964
and	O	-1	12589964
12	O	-1	12589964
mg/kg	O	-1	12589964
in	O	-1	12589964
compar@@	O	-1	12589964
ison	O	-1	12589964
with	O	-1	12589964
baseline	O	-1	12589964
(p@@	O	-1	12589964
<@@	O	-1	12589964
0.05@@	O	-1	12589964
).	O	-1	12589964
cTn@@	O	-1	12589964
T	O	-1	12589964
found	O	-1	12589964
in	O	-1	12589964
rats	O	-1	12589964
after	O	-1	12589964
12	O	-1	12589964
mg/kg	O	-1	12589964
were	O	-1	12589964
significantly	O	-1	12589964
greater	O	-1	12589964
than	O	-1	12589964
that	O	-1	12589964
found	O	-1	12589964
after	O	-1	12589964
7.@@	O	-1	12589964
5	O	-1	12589964
mg/kg	O	-1	12589964
DO@@	B-Chemical	D004317	12589964
X	I-Chemical	-1	12589964
.	O	-1	12589964
M@@	O	-1	12589964
ax@@	O	-1	12589964
im@@	O	-1	12589964
al	O	-1	12589964
cTn@@	O	-1	12589964
I	O	-1	12589964
(p@@	O	-1	12589964
g/@@	O	-1	12589964
ml@@	O	-1	12589964
)	O	-1	12589964
and	O	-1	12589964
cTn@@	O	-1	12589964
T	O	-1	12589964
levels	O	-1	12589964
were	O	-1	12589964
significantly	O	-1	12589964
increased	O	-1	12589964
in	O	-1	12589964
DO@@	B-Chemical	D004317	12589964
X	I-Chemical	-1	12589964
rats	O	-1	12589964
compared	O	-1	12589964
with	O	-1	12589964
controls	O	-1	12589964
(p@@	O	-1	12589964
=@@	O	-1	12589964
0.00@@	O	-1	12589964
6,	O	-1	12589964
0.00@@	O	-1	12589964
7@@	O	-1	12589964
).	O	-1	12589964
cTn@@	O	-1	12589964
I	O	-1	12589964
(n@@	O	-1	12589964
g/@@	O	-1	12589964
ml@@	O	-1	12589964
),	O	-1	12589964
C@@	O	-1	12589964
K@@	O	-1	12589964
-@@	O	-1	12589964
M@@	O	-1	12589964
B	O	-1	12589964
mas@@	O	-1	12589964
s	O	-1	12589964
and	O	-1	12589964
C@@	O	-1	12589964
K	O	-1	12589964
remained	O	-1	12589964
un@@	O	-1	12589964
chang@@	O	-1	12589964
ed	O	-1	12589964
in	O	-1	12589964
DO@@	B-Chemical	D004317	12589964
X	I-Chemical	-1	12589964
rats	O	-1	12589964
compared	O	-1	12589964
with	O	-1	12589964
controls.	O	-1	12589964
All	O	-1	12589964
mark@@	O	-1	12589964
ers	O	-1	12589964
remained	O	-1	12589964
st@@	O	-1	12589964
able	O	-1	12589964
in	O	-1	12589964
controls.	O	-1	12589964
An@@	O	-1	12589964
aly@@	O	-1	12589964
sis	O	-1	12589964
of	O	-1	12589964
data	O	-1	12589964
revealed	O	-1	12589964
a	O	-1	12589964
significant	O	-1	12589964
correl@@	O	-1	12589964
ation	O	-1	12589964
between	O	-1	12589964
maxim@@	O	-1	12589964
al	O	-1	12589964
cTn@@	O	-1	12589964
T	O	-1	12589964
and	O	-1	12589964
E@@	O	-1	12589964
D	O	-1	12589964
and	O	-1	12589964
E@@	O	-1	12589964
S	O	-1	12589964
L@@	O	-1	12589964
V	O	-1	12589964
di@@	O	-1	12589964
ame@@	O	-1	12589964
ter@@	O	-1	12589964
s/@@	O	-1	12589964
B@@	O	-1	12589964
W	O	-1	12589964
(@@	O	-1	12589964
r@@	O	-1	12589964
=@@	O	-1	12589964
0.@@	O	-1	12589964
8@@	O	-1	12589964
1	O	-1	12589964
and	O	-1	12589964
0.@@	O	-1	12589964
6@@	O	-1	12589964
5@@	O	-1	12589964
;	O	-1	12589964
p@@	O	-1	12589964
<@@	O	-1	12589964
0.00@@	O	-1	12589964
0@@	O	-1	12589964
1).	O	-1	12589964
A	O	-1	12589964
significant	O	-1	12589964
rel@@	O	-1	12589964
ationship	O	-1	12589964
was	O	-1	12589964
observed	O	-1	12589964
between	O	-1	12589964
maxim@@	O	-1	12589964
al	O	-1	12589964
cTn@@	O	-1	12589964
T	O	-1	12589964
and	O	-1	12589964
the	O	-1	12589964
ext@@	O	-1	12589964
ent	O	-1	12589964
of	O	-1	12589964
myocardial	O	-1	12589964
morph@@	O	-1	12589964
ological	O	-1	12589964
chang@@	O	-1	12589964
es,	O	-1	12589964
and	O	-1	12589964
between	O	-1	12589964
L@@	O	-1	12589964
V	O	-1	12589964
di@@	O	-1	12589964
ame@@	O	-1	12589964
ter@@	O	-1	12589964
s/@@	O	-1	12589964
B@@	O	-1	12589964
W	O	-1	12589964
and	O	-1	12589964
hist@@	O	-1	12589964
ological	O	-1	12589964
find@@	O	-1	12589964
ing@@	O	-1	12589964
s.	O	-1	12589964
CONCLUSIONS:	O	-1	12589964
A@@	O	-1	12589964
mon@@	O	-1	12589964
g	O	-1	12589964
mark@@	O	-1	12589964
ers	O	-1	12589964
of	O	-1	12589964
ischem@@	B-Disease	D017202	12589964
ic	I-Disease	-1	12589964
injury	I-Disease	-1	12589964
after	O	-1	12589964
DO@@	B-Chemical	D004317	12589964
X	I-Chemical	-1	12589964
in	O	-1	12589964
rats,	O	-1	12589964
cTn@@	O	-1	12589964
T	O	-1	12589964
showed	O	-1	12589964
the	O	-1	12589964
great@@	O	-1	12589964
est	O	-1	12589964
ability	O	-1	12589964
to	O	-1	12589964
det@@	O	-1	12589964
ect	O	-1	12589964
myocardial	B-Disease	D009202	12589964
damage	I-Disease	-1	12589964
assessed	O	-1	12589964
by	O	-1	12589964
echocardiograph@@	O	-1	12589964
ic	O	-1	12589964
det@@	O	-1	12589964
ection	O	-1	12589964
and	O	-1	12589964
hist@@	O	-1	12589964
ological	O	-1	12589964
chang@@	O	-1	12589964
es.	O	-1	12589964
Although	O	-1	12589964
there	O	-1	12589964
was	O	-1	12589964
a	O	-1	12589964
disc@@	O	-1	12589964
re@@	O	-1	12589964
p@@	O	-1	12589964
anc@@	O	-1	12589964
y	O	-1	12589964
between	O	-1	12589964
the	O	-1	12589964
amoun@@	O	-1	12589964
t	O	-1	12589964
of	O	-1	12589964
cTn@@	O	-1	12589964
I	O	-1	12589964
and	O	-1	12589964
cTn@@	O	-1	12589964
T	O	-1	12589964
after	O	-1	12589964
DO@@	B-Chemical	D004317	12589964
X	I-Chemical	-1	12589964
,	O	-1	12589964
prob@@	O	-1	12589964
ably	O	-1	12589964
due	O	-1	12589964
to	O	-1	12589964
he@@	O	-1	12589964
ter@@	O	-1	12589964
o@@	O	-1	12589964
gene@@	O	-1	12589964
ity	O	-1	12589964
in	O	-1	12589964
cros@@	O	-1	12589964
s-@@	O	-1	12589964
reac@@	O	-1	12589964
ti@@	O	-1	12589964
vi@@	O	-1	12589964
ties	O	-1	12589964
of	O	-1	12589964
m@@	O	-1	12589964
A@@	O	-1	12589964
b@@	O	-1	12589964
s	O	-1	12589964
to	O	-1	12589964
various	O	-1	12589964
cTn@@	O	-1	12589964
I	O	-1	12589964
and	O	-1	12589964
cTn@@	O	-1	12589964
T	O	-1	12589964
form@@	O	-1	12589964
s,	O	-1	12589964
it	O	-1	12589964
is	O	-1	12589964
likely	O	-1	12589964
that	O	-1	12589964
cTn@@	O	-1	12589964
T	O	-1	12589964
in	O	-1	12589964
rats	O	-1	12589964
after	O	-1	12589964
DO@@	B-Chemical	D004317	12589964
X	I-Chemical	-1	12589964
indic@@	O	-1	12589964
ates	O	-1	12589964
cell	O	-1	12589964
damage	O	-1	12589964
determined	O	-1	12589964
by	O	-1	12589964
the	O	-1	12589964
mag@@	O	-1	12589964
nit@@	O	-1	12589964
ude	O	-1	12589964
of	O	-1	12589964
injury	O	-1	12589964
induced	O	-1	12589964
and	O	-1	12589964
that	O	-1	12589964
cTn@@	O	-1	12589964
T	O	-1	12589964
should	O	-1	12589964
be	O	-1	12589964
a	O	-1	12589964
use@@	O	-1	12589964
ful	O	-1	12589964
mark@@	O	-1	12589964
er	O	-1	12589964
for	O	-1	12589964
the	O	-1	12589964
predic@@	O	-1	12589964
tion	O	-1	12589964
of	O	-1	12589964
experim@@	O	-1	12589964
ent@@	O	-1	12589964
ally	O	-1	12589964
induced	O	-1	12589964
cardi@@	B-Disease	D066126	12589964
otoxicity	I-Disease	-1	12589964
and	O	-1	12589964
possib@@	O	-1	12589964
ly	O	-1	12589964
for	O	-1	12589964
cardio@@	O	-1	12589964
protective	O	-1	12589964
experim@@	O	-1	12589964
ent@@	O	-1	12589964
s.	O	-1	12589964

C@@	O	-1	11263551
al@@	O	-1	11263551
c@@	O	-1	11263551
ine@@	O	-1	11263551
ur@@	O	-1	11263551
in-@@	O	-1	11263551
inhibitor	O	-1	11263551
induced	O	-1	11263551
pain	B-Disease	D010146	11263551
syndrome	O	-1	11263551
(	O	-1	11263551
CI@@	B-Disease	-1	11263551
P@@	I-Disease	-1	11263551
S	I-Disease	-1	11263551
)@@	O	-1	11263551
:	O	-1	11263551
a	O	-1	11263551
severe	O	-1	11263551
dis@@	O	-1	11263551
abl@@	O	-1	11263551
ing	O	-1	11263551
complication	O	-1	11263551
after	O	-1	11263551
org@@	O	-1	11263551
an	O	-1	11263551
transplant@@	O	-1	11263551
ation.	O	-1	11263551
B@@	O	-1	11263551
one	O	-1	11263551
pain	B-Disease	D010146	11263551
after	O	-1	11263551
transplant@@	O	-1	11263551
ation	O	-1	11263551
is	O	-1	11263551
a	O	-1	11263551
frequent	O	-1	11263551
complication	O	-1	11263551
that	O	-1	11263551
can	O	-1	11263551
be	O	-1	11263551
caused	O	-1	11263551
by	O	-1	11263551
several	O	-1	11263551
diseas@@	O	-1	11263551
es.	O	-1	11263551
Treat@@	O	-1	11263551
ment	O	-1	11263551
strat@@	O	-1	11263551
e@@	O	-1	11263551
gi@@	O	-1	11263551
es	O	-1	11263551
depen@@	O	-1	11263551
d	O	-1	11263551
on	O	-1	11263551
the	O	-1	11263551
cor@@	O	-1	11263551
rec@@	O	-1	11263551
t	O	-1	11263551
diagnosis	O	-1	11263551
of	O	-1	11263551
the	O	-1	11263551
pain	B-Disease	D010146	11263551
.	O	-1	11263551
N@@	O	-1	11263551
ine	O	-1	11263551
patients	O	-1	11263551
with	O	-1	11263551
severe	O	-1	11263551
pain	B-Disease	D010146	11263551
in	O	-1	11263551
their	O	-1	11263551
fe@@	O	-1	11263551
et@@	O	-1	11263551
,	O	-1	11263551
which	O	-1	11263551
was	O	-1	11263551
reg@@	O	-1	11263551
ist@@	O	-1	11263551
ered	O	-1	11263551
after	O	-1	11263551
transplant@@	O	-1	11263551
ation,	O	-1	11263551
were	O	-1	11263551
investig@@	O	-1	11263551
ated.	O	-1	11263551
B@@	O	-1	11263551
one	O	-1	11263551
s@@	O	-1	11263551
c@@	O	-1	11263551
ans	O	-1	11263551
showed	O	-1	11263551
an	O	-1	11263551
increased	O	-1	11263551
trac@@	O	-1	11263551
er	O	-1	11263551
u@@	O	-1	11263551
pt@@	O	-1	11263551
ake	O	-1	11263551
of	O	-1	11263551
the	O	-1	11263551
fo@@	O	-1	11263551
o@@	O	-1	11263551
t	O	-1	11263551
b@@	O	-1	11263551
on@@	O	-1	11263551
es.	O	-1	11263551
M@@	O	-1	11263551
ag@@	O	-1	11263551
ne@@	O	-1	11263551
tic	O	-1	11263551
res@@	O	-1	11263551
on@@	O	-1	11263551
ance	O	-1	11263551
imaging	O	-1	11263551
demonstrated	O	-1	11263551
b@@	B-Disease	D001855	11263551
one	I-Disease	-1	11263551
m@@	I-Disease	-1	11263551
ar@@	I-Disease	-1	11263551
ro@@	I-Disease	-1	11263551
w	I-Disease	-1	11263551
o@@	I-Disease	-1	11263551
e@@	I-Disease	-1	11263551
de@@	I-Disease	-1	11263551
ma	I-Disease	-1	11263551
b@@	B-Disease	D004487	11263551
one	I-Disease	-1	11263551
m@@	I-Disease	-1	11263551
ar@@	I-Disease	-1	11263551
ro@@	I-Disease	-1	11263551
w	I-Disease	-1	11263551
o@@	I-Disease	-1	11263551
e@@	I-Disease	-1	11263551
de@@	I-Disease	-1	11263551
ma	I-Disease	-1	11263551
in	O	-1	11263551
the	O	-1	11263551
pa@@	O	-1	11263551
infu@@	O	-1	11263551
l	O	-1	11263551
b@@	O	-1	11263551
on@@	O	-1	11263551
es.	O	-1	11263551
P@@	B-Disease	D010146	11263551
ain	I-Disease	-1	11263551
was	O	-1	11263551
not	O	-1	11263551
expl@@	O	-1	11263551
ained	O	-1	11263551
by	O	-1	11263551
other	O	-1	11263551
diseas@@	O	-1	11263551
es	O	-1	11263551
ca@@	O	-1	11263551
using	O	-1	11263551
fo@@	O	-1	11263551
o@@	O	-1	11263551
t	O	-1	11263551
pain	B-Disease	D010146	11263551
,	O	-1	11263551
like	O	-1	11263551
ref@@	B-Disease	D012019	11263551
le@@	I-Disease	-1	11263551
x	I-Disease	-1	11263551
sym@@	I-Disease	-1	11263551
pa@@	I-Disease	-1	11263551
thetic	I-Disease	-1	11263551
dy@@	I-Disease	-1	11263551
stro@@	I-Disease	-1	11263551
ph@@	I-Disease	-1	11263551
y	I-Disease	-1	11263551
,	O	-1	11263551
poly@@	B-Disease	D011115	11263551
neuropathy	I-Disease	-1	11263551
,	O	-1	11263551
M@@	B-Disease	D009437	11263551
ort@@	I-Disease	-1	11263551
on@@	I-Disease	-1	11263551
's	I-Disease	-1	11263551
ne@@	I-Disease	-1	11263551
ur@@	I-Disease	-1	11263551
al@@	I-Disease	-1	11263551
g@@	I-Disease	-1	11263551
ia	I-Disease	-1	11263551
,	O	-1	11263551
g@@	B-Disease	D006073	11263551
out	I-Disease	-1	11263551
,	O	-1	11263551
ost@@	B-Disease	D010024	11263551
e@@	I-Disease	-1	11263551
o@@	I-Disease	-1	11263551
po@@	I-Disease	-1	11263551
ro@@	I-Disease	-1	11263551
sis	I-Disease	-1	11263551
,	O	-1	11263551
a@@	B-Disease	D010020	11263551
vascular	I-Disease	-1	11263551
necro@@	I-Disease	-1	11263551
sis	I-Disease	-1	11263551
,	O	-1	11263551
inter@@	B-Disease	D007383	11263551
mit@@	I-Disease	-1	11263551
t@@	I-Disease	-1	11263551
ent	I-Disease	-1	11263551
cl@@	I-Disease	-1	11263551
a@@	I-Disease	-1	11263551
ud@@	I-Disease	-1	11263551
ic@@	I-Disease	-1	11263551
ation	I-Disease	-1	11263551
,	O	-1	11263551
or@@	O	-1	11263551
th@@	O	-1	11263551
o@@	O	-1	11263551
pa@@	O	-1	11263551
edi@@	O	-1	11263551
c	O	-1	11263551
fo@@	B-Disease	D005530	11263551
o@@	I-Disease	-1	11263551
t	I-Disease	-1	11263551
de@@	I-Disease	-1	11263551
form@@	I-Disease	-1	11263551
ities	I-Disease	-1	11263551
,	O	-1	11263551
stres@@	B-Disease	D015775	11263551
s	I-Disease	-1	11263551
frac@@	I-Disease	-1	11263551
t@@	I-Disease	-1	11263551
ures	I-Disease	-1	11263551
,	O	-1	11263551
and	O	-1	11263551
hyper@@	B-Disease	D006961	11263551
par@@	I-Disease	-1	11263551
ath@@	I-Disease	-1	11263551
yro@@	I-Disease	-1	11263551
i@@	I-Disease	-1	11263551
dis@@	I-Disease	-1	11263551
m	I-Disease	-1	11263551
.	O	-1	11263551
The	O	-1	11263551
reduction	O	-1	11263551
of	O	-1	11263551
cyclospor@@	B-Chemical	D016572	11263551
ine	I-Chemical	-1	11263551
-	O	-1	11263551
or	O	-1	11263551
tacrolimus	B-Chemical	D016559	11263551
t@@	O	-1	11263551
rou@@	O	-1	11263551
gh	O	-1	11263551
levels	O	-1	11263551
and	O	-1	11263551
the	O	-1	11263551
administration	O	-1	11263551
of	O	-1	11263551
calcium	B-Chemical	D002118	11263551
channel	O	-1	11263551
block@@	O	-1	11263551
ers	O	-1	11263551
l@@	O	-1	11263551
ed	O	-1	11263551
to	O	-1	11263551
re@@	O	-1	11263551
li@@	O	-1	11263551
e@@	O	-1	11263551
f	O	-1	11263551
of	O	-1	11263551
pain	B-Disease	D010146	11263551
.	O	-1	11263551
The	O	-1	11263551
C@@	O	-1	11263551
al@@	O	-1	11263551
c@@	O	-1	11263551
ine@@	O	-1	11263551
ur@@	O	-1	11263551
in-@@	O	-1	11263551
inhibitor	O	-1	11263551
In@@	O	-1	11263551
duced	O	-1	11263551
P@@	B-Disease	D010146	11263551
ain	I-Disease	-1	11263551
S@@	O	-1	11263551
yn@@	O	-1	11263551
drom@@	O	-1	11263551
e	O	-1	11263551
(	O	-1	11263551
CI@@	B-Disease	-1	11263551
P@@	I-Disease	-1	11263551
S	I-Disease	-1	11263551
)	O	-1	11263551
is	O	-1	11263551
a	O	-1	11263551
r@@	O	-1	11263551
are	O	-1	11263551
but	O	-1	11263551
severe	O	-1	11263551
side	O	-1	11263551
effect	O	-1	11263551
of	O	-1	11263551
cyclospor@@	B-Chemical	D016572	11263551
ine	I-Chemical	-1	11263551
or	O	-1	11263551
tacrolimus	B-Chemical	D016559	11263551
and	O	-1	11263551
is	O	-1	11263551
ac@@	O	-1	11263551
cur@@	O	-1	11263551
ately	O	-1	11263551
diagnos@@	O	-1	11263551
ed	O	-1	11263551
by	O	-1	11263551
its	O	-1	11263551
typ@@	O	-1	11263551
ical	O	-1	11263551
present@@	O	-1	11263551
ation,	O	-1	11263551
mag@@	O	-1	11263551
ne@@	O	-1	11263551
tic	O	-1	11263551
res@@	O	-1	11263551
on@@	O	-1	11263551
ance	O	-1	11263551
imaging	O	-1	11263551
and	O	-1	11263551
b@@	O	-1	11263551
one	O	-1	11263551
s@@	O	-1	11263551
can@@	O	-1	11263551
s.	O	-1	11263551
In@@	O	-1	11263551
cor@@	O	-1	11263551
rec@@	O	-1	11263551
t	O	-1	11263551
diagnosis	O	-1	11263551
of	O	-1	11263551
the	O	-1	11263551
syndrome	O	-1	11263551
wil@@	O	-1	11263551
l	O	-1	11263551
le@@	O	-1	11263551
ad	O	-1	11263551
to	O	-1	11263551
a	O	-1	11263551
significant	O	-1	11263551
reduction	O	-1	11263551
of	O	-1	11263551
lif@@	O	-1	11263551
e	O	-1	11263551
qu@@	O	-1	11263551
ality	O	-1	11263551
in	O	-1	11263551
patients	O	-1	11263551
suff@@	O	-1	11263551
ering	O	-1	11263551
from	O	-1	11263551
CI@@	B-Disease	-1	11263551
P@@	I-Disease	-1	11263551
S	I-Disease	-1	11263551
.	O	-1	11263551

The	O	-1	10520387
haem@@	O	-1	10520387
o@@	O	-1	10520387
dynam@@	O	-1	10520387
ic	O	-1	10520387
effects	O	-1	10520387
of	O	-1	10520387
pro@@	B-Chemical	D015742	10520387
po@@	I-Chemical	-1	10520387
f@@	I-Chemical	-1	10520387
ol	I-Chemical	-1	10520387
in	O	-1	10520387
combination	O	-1	10520387
with	O	-1	10520387
e@@	B-Chemical	D004809	10520387
ph@@	I-Chemical	-1	10520387
ed@@	I-Chemical	-1	10520387
rine	I-Chemical	-1	10520387
in	O	-1	10520387
el@@	O	-1	10520387
der@@	O	-1	10520387
ly	O	-1	10520387
patients	O	-1	10520387
(A@@	O	-1	10520387
S@@	O	-1	10520387
A	O	-1	10520387
groups	O	-1	10520387
3	O	-1	10520387
and	O	-1	10520387
4@@	O	-1	10520387
).	O	-1	10520387
The	O	-1	10520387
mark@@	O	-1	10520387
ed	O	-1	10520387
vas@@	O	-1	10520387
odi@@	O	-1	10520387
lat@@	O	-1	10520387
or	O	-1	10520387
and	O	-1	10520387
negative	O	-1	10520387
in@@	O	-1	10520387
ot@@	O	-1	10520387
ro@@	O	-1	10520387
p@@	O	-1	10520387
ic	O	-1	10520387
effects	O	-1	10520387
of	O	-1	10520387
pro@@	B-Chemical	D015742	10520387
po@@	I-Chemical	-1	10520387
f@@	I-Chemical	-1	10520387
ol	I-Chemical	-1	10520387
are	O	-1	10520387
dis@@	O	-1	10520387
adv@@	O	-1	10520387
ant@@	O	-1	10520387
ages	O	-1	10520387
in	O	-1	10520387
f@@	O	-1	10520387
ra@@	O	-1	10520387
il	O	-1	10520387
el@@	O	-1	10520387
der@@	O	-1	10520387
ly	O	-1	10520387
patients.	O	-1	10520387
We	O	-1	10520387
investigated	O	-1	10520387
the	O	-1	10520387
safety	O	-1	10520387
and	O	-1	10520387
efficacy	O	-1	10520387
of	O	-1	10520387
ad@@	O	-1	10520387
ding	O	-1	10520387
different	O	-1	10520387
doses	O	-1	10520387
of	O	-1	10520387
e@@	B-Chemical	D004809	10520387
ph@@	I-Chemical	-1	10520387
ed@@	I-Chemical	-1	10520387
rine	I-Chemical	-1	10520387
to	O	-1	10520387
pro@@	B-Chemical	D015742	10520387
po@@	I-Chemical	-1	10520387
f@@	I-Chemical	-1	10520387
ol	I-Chemical	-1	10520387
in	O	-1	10520387
or@@	O	-1	10520387
der	O	-1	10520387
to	O	-1	10520387
obt@@	O	-1	10520387
un@@	O	-1	10520387
d	O	-1	10520387
the	O	-1	10520387
hypoten@@	B-Disease	D007022	10520387
sive	I-Disease	-1	10520387
respon@@	O	-1	10520387
se.	O	-1	10520387
The	O	-1	10520387
haem@@	O	-1	10520387
o@@	O	-1	10520387
dynam@@	O	-1	10520387
ic	O	-1	10520387
effects	O	-1	10520387
of	O	-1	10520387
ad@@	O	-1	10520387
ding	O	-1	10520387
1@@	O	-1	10520387
5,	O	-1	10520387
20	O	-1	10520387
or	O	-1	10520387
25	O	-1	10520387
mg	O	-1	10520387
of	O	-1	10520387
e@@	B-Chemical	D004809	10520387
ph@@	I-Chemical	-1	10520387
ed@@	I-Chemical	-1	10520387
rine	I-Chemical	-1	10520387
to	O	-1	10520387
2@@	O	-1	10520387
00	O	-1	10520387
mg	O	-1	10520387
of	O	-1	10520387
pro@@	B-Chemical	D015742	10520387
po@@	I-Chemical	-1	10520387
f@@	I-Chemical	-1	10520387
ol	I-Chemical	-1	10520387
were	O	-1	10520387
compared	O	-1	10520387
to	O	-1	10520387
control	O	-1	10520387
in	O	-1	10520387
40	O	-1	10520387
A@@	O	-1	10520387
S@@	O	-1	10520387
A	O	-1	10520387
3@@	O	-1	10520387
/@@	O	-1	10520387
4	O	-1	10520387
patients	O	-1	10520387
over	O	-1	10520387
60	O	-1	10520387
years	O	-1	10520387
present@@	O	-1	10520387
ing	O	-1	10520387
for	O	-1	10520387
gen@@	O	-1	10520387
it@@	O	-1	10520387
o@@	O	-1	10520387
-@@	O	-1	10520387
urinary	O	-1	10520387
surger@@	O	-1	10520387
y.	O	-1	10520387
The	O	-1	10520387
addition	O	-1	10520387
of	O	-1	10520387
e@@	B-Chemical	D004809	10520387
ph@@	I-Chemical	-1	10520387
ed@@	I-Chemical	-1	10520387
rine	I-Chemical	-1	10520387
to	O	-1	10520387
pro@@	B-Chemical	D015742	10520387
po@@	I-Chemical	-1	10520387
f@@	I-Chemical	-1	10520387
ol	I-Chemical	-1	10520387
appear@@	O	-1	10520387
s	O	-1	10520387
to	O	-1	10520387
be	O	-1	10520387
an	O	-1	10520387
effective	O	-1	10520387
meth@@	O	-1	10520387
od	O	-1	10520387
of	O	-1	10520387
obt@@	O	-1	10520387
un@@	O	-1	10520387
ding	O	-1	10520387
the	O	-1	10520387
hypoten@@	B-Disease	D007022	10520387
sive	I-Disease	-1	10520387
response	O	-1	10520387
to	O	-1	10520387
pro@@	B-Chemical	D015742	10520387
po@@	I-Chemical	-1	10520387
f@@	I-Chemical	-1	10520387
ol	I-Chemical	-1	10520387
at	O	-1	10520387
all	O	-1	10520387
doses	O	-1	10520387
used	O	-1	10520387
in	O	-1	10520387
this	O	-1	10520387
study.	O	-1	10520387
However,	O	-1	10520387
mark@@	O	-1	10520387
ed	O	-1	10520387
tachycardia	B-Disease	D013610	10520387
associated	O	-1	10520387
with	O	-1	10520387
the	O	-1	10520387
use	O	-1	10520387
of	O	-1	10520387
e@@	B-Chemical	D004809	10520387
ph@@	I-Chemical	-1	10520387
ed@@	I-Chemical	-1	10520387
rine	I-Chemical	-1	10520387
in	O	-1	10520387
combination	O	-1	10520387
with	O	-1	10520387
pro@@	B-Chemical	D015742	10520387
po@@	I-Chemical	-1	10520387
f@@	I-Chemical	-1	10520387
ol	I-Chemical	-1	10520387
occurred	O	-1	10520387
in	O	-1	10520387
the	O	-1	10520387
maj@@	O	-1	10520387
or@@	O	-1	10520387
ity	O	-1	10520387
of	O	-1	10520387
patients,	O	-1	10520387
oc@@	O	-1	10520387
ca@@	O	-1	10520387
sion@@	O	-1	10520387
ally	O	-1	10520387
reac@@	O	-1	10520387
h@@	O	-1	10520387
ing	O	-1	10520387
high	O	-1	10520387
levels	O	-1	10520387
in	O	-1	10520387
individ@@	O	-1	10520387
ual	O	-1	10520387
patients.	O	-1	10520387
D@@	O	-1	10520387
u@@	O	-1	10520387
e	O	-1	10520387
to	O	-1	10520387
the	O	-1	10520387
risk	O	-1	10520387
of	O	-1	10520387
this	O	-1	10520387
tachycardia	B-Disease	D013610	10520387
induc@@	O	-1	10520387
ing	O	-1	10520387
myocardial	B-Disease	D017202	10520387
ischem@@	I-Disease	-1	10520387
ia	I-Disease	-1	10520387
,	O	-1	10520387
we	O	-1	10520387
wo@@	O	-1	10520387
uld	O	-1	10520387
not	O	-1	10520387
recomm@@	O	-1	10520387
end	O	-1	10520387
the	O	-1	10520387
use	O	-1	10520387
in	O	-1	10520387
el@@	O	-1	10520387
der@@	O	-1	10520387
ly	O	-1	10520387
patients	O	-1	10520387
of	O	-1	10520387
any	O	-1	10520387
of	O	-1	10520387
the	O	-1	10520387
e@@	B-Chemical	D004809	10520387
ph@@	I-Chemical	-1	10520387
ed@@	I-Chemical	-1	10520387
rine	I-Chemical	-1	10520387
/	O	-1	10520387
pro@@	B-Chemical	D015742	10520387
po@@	I-Chemical	-1	10520387
f@@	I-Chemical	-1	10520387
ol	I-Chemical	-1	10520387
/@@	O	-1	10520387
mi@@	O	-1	10520387
x@@	O	-1	10520387
t@@	O	-1	10520387
ures	O	-1	10520387
studi@@	O	-1	10520387
ed.	O	-1	10520387

Ne@@	B-Disease	D020258	230316
uro@@	I-Disease	-1	230316
toxicity	I-Disease	-1	230316
of	O	-1	230316
halo@@	B-Chemical	D006912	230316
gen@@	I-Chemical	-1	230316
ated	I-Chemical	-1	230316
hydrox@@	I-Chemical	-1	230316
y@@	I-Chemical	-1	230316
qu@@	I-Chemical	-1	230316
in@@	I-Chemical	-1	230316
ol@@	I-Chemical	-1	230316
in@@	I-Chemical	-1	230316
es	I-Chemical	-1	230316
:	O	-1	230316
clinical	O	-1	230316
analysis	O	-1	230316
of	O	-1	230316
cases	O	-1	230316
reported	O	-1	230316
out@@	O	-1	230316
side	O	-1	230316
J@@	O	-1	230316
ap@@	O	-1	230316
an@@	O	-1	230316
.	O	-1	230316
An	O	-1	230316
analysis	O	-1	230316
is	O	-1	230316
presented	O	-1	230316
of	O	-1	230316
2@@	O	-1	230316
20	O	-1	230316
cases	O	-1	230316
of	O	-1	230316
possible	O	-1	230316
neuro@@	B-Disease	D020258	230316
toxic	I-Disease	-1	230316
reactions	O	-1	230316
to	O	-1	230316
halo@@	B-Chemical	D006912	230316
gen@@	I-Chemical	-1	230316
ated	I-Chemical	-1	230316
hydrox@@	I-Chemical	-1	230316
y@@	I-Chemical	-1	230316
qu@@	I-Chemical	-1	230316
in@@	I-Chemical	-1	230316
ol@@	I-Chemical	-1	230316
in@@	I-Chemical	-1	230316
es	I-Chemical	-1	230316
reported	O	-1	230316
from	O	-1	230316
out@@	O	-1	230316
side	O	-1	230316
J@@	O	-1	230316
ap@@	O	-1	230316
an@@	O	-1	230316
.	O	-1	230316
In	O	-1	230316
8@@	O	-1	230316
0	O	-1	230316
cases	O	-1	230316
in@@	O	-1	230316
suffici@@	O	-1	230316
ent	O	-1	230316
inf@@	O	-1	230316
orm@@	O	-1	230316
ation	O	-1	230316
was	O	-1	230316
av@@	O	-1	230316
ail@@	O	-1	230316
able	O	-1	230316
for	O	-1	230316
ade@@	O	-1	230316
qu@@	O	-1	230316
ate	O	-1	230316
com@@	O	-1	230316
ment	O	-1	230316
and	O	-1	230316
in	O	-1	230316
2@@	O	-1	230316
9	O	-1	230316
a	O	-1	230316
rel@@	O	-1	230316
ationship	O	-1	230316
to	O	-1	230316
the	O	-1	230316
administration	O	-1	230316
of	O	-1	230316
c@@	B-Chemical	D007464	230316
li@@	I-Chemical	-1	230316
o@@	I-Chemical	-1	230316
qu@@	I-Chemical	-1	230316
in@@	I-Chemical	-1	230316
ol	I-Chemical	-1	230316
could	O	-1	230316
be	O	-1	230316
ex@@	O	-1	230316
cl@@	O	-1	230316
u@@	O	-1	230316
de@@	O	-1	230316
d.	O	-1	230316
Of	O	-1	230316
the	O	-1	230316
re@@	O	-1	230316
ma@@	O	-1	230316
ind@@	O	-1	230316
er,	O	-1	230316
a	O	-1	230316
rel@@	O	-1	230316
ationship	O	-1	230316
to	O	-1	230316
c@@	B-Chemical	D007464	230316
li@@	I-Chemical	-1	230316
o@@	I-Chemical	-1	230316
qu@@	I-Chemical	-1	230316
in@@	I-Chemical	-1	230316
ol	I-Chemical	-1	230316
was	O	-1	230316
considered	O	-1	230316
prob@@	O	-1	230316
able	O	-1	230316
in	O	-1	230316
4@@	O	-1	230316
2	O	-1	230316
and	O	-1	230316
possible	O	-1	230316
in	O	-1	230316
6@@	O	-1	230316
9	O	-1	230316
cas@@	O	-1	230316
es.	O	-1	230316
In	O	-1	230316
six	O	-1	230316
of	O	-1	230316
the	O	-1	230316
prob@@	O	-1	230316
able	O	-1	230316
cases	O	-1	230316
the	O	-1	230316
neurolog@@	B-Disease	D009422	230316
ical	I-Disease	-1	230316
dist@@	I-Disease	-1	230316
urb@@	I-Disease	-1	230316
ance	I-Disease	-1	230316
consist@@	O	-1	230316
ed	O	-1	230316
of	O	-1	230316
an	O	-1	230316
acute	O	-1	230316
reversible	O	-1	230316
encephalo@@	B-Disease	D001927	230316
pathy	I-Disease	-1	230316
us@@	O	-1	230316
ually	O	-1	230316
related	O	-1	230316
to	O	-1	230316
the	O	-1	230316
ing@@	O	-1	230316
es@@	O	-1	230316
tion	O	-1	230316
of	O	-1	230316
a	O	-1	230316
high	O	-1	230316
dose	O	-1	230316
of	O	-1	230316
c@@	B-Chemical	D007464	230316
li@@	I-Chemical	-1	230316
o@@	I-Chemical	-1	230316
qu@@	I-Chemical	-1	230316
in@@	I-Chemical	-1	230316
ol	I-Chemical	-1	230316
over	O	-1	230316
a	O	-1	230316
sh@@	O	-1	230316
ort	O	-1	230316
perio@@	O	-1	230316
d.	O	-1	230316
The	O	-1	230316
most	O	-1	230316
common	O	-1	230316
man@@	O	-1	230316
if@@	O	-1	230316
est@@	O	-1	230316
ation,	O	-1	230316
observed	O	-1	230316
in	O	-1	230316
15	O	-1	230316
further	O	-1	230316
cas@@	O	-1	230316
es,	O	-1	230316
was	O	-1	230316
isol@@	O	-1	230316
ated	O	-1	230316
op@@	B-Disease	D009896	230316
tic	I-Disease	-1	230316
atro@@	I-Disease	-1	230316
ph@@	I-Disease	-1	230316
y	I-Disease	-1	230316
.	O	-1	230316
This	O	-1	230316
was	O	-1	230316
most	O	-1	230316
frequ@@	O	-1	230316
ently	O	-1	230316
found	O	-1	230316
in	O	-1	230316
child@@	O	-1	230316
ren@@	O	-1	230316
,	O	-1	230316
man@@	O	-1	230316
y	O	-1	230316
of	O	-1	230316
whom	O	-1	230316
had	O	-1	230316
received	O	-1	230316
c@@	B-Chemical	D007464	230316
li@@	I-Chemical	-1	230316
o@@	I-Chemical	-1	230316
qu@@	I-Chemical	-1	230316
in@@	I-Chemical	-1	230316
ol	I-Chemical	-1	230316
as	O	-1	230316
treatment	O	-1	230316
for	O	-1	230316
ac@@	B-Disease	C538178	230316
ro@@	I-Disease	-1	230316
der@@	I-Disease	-1	230316
m@@	I-Disease	-1	230316
ati@@	I-Disease	-1	230316
tis	I-Disease	-1	230316
ent@@	I-Disease	-1	230316
ero@@	I-Disease	-1	230316
path@@	I-Disease	-1	230316
ic@@	I-Disease	-1	230316
a	I-Disease	-1	230316
.	O	-1	230316
In	O	-1	230316
the	O	-1	230316
remain@@	O	-1	230316
ing	O	-1	230316
cas@@	O	-1	230316
es,	O	-1	230316
a	O	-1	230316
combination	O	-1	230316
of	O	-1	230316
my@@	B-Disease	D013118	230316
e@@	I-Disease	-1	230316
lo@@	I-Disease	-1	230316
pathy	I-Disease	-1	230316
,	O	-1	230316
visual	B-Disease	D014786	230316
dist@@	I-Disease	-1	230316
urb@@	I-Disease	-1	230316
ance	I-Disease	-1	230316
,	O	-1	230316
and	O	-1	230316
peripheral	B-Disease	D010523	230316
neuropathy	I-Disease	-1	230316
was	O	-1	230316
the	O	-1	230316
most	O	-1	230316
common	O	-1	230316
man@@	O	-1	230316
if@@	O	-1	230316
est@@	O	-1	230316
ation.	O	-1	230316
I@@	O	-1	230316
sol@@	O	-1	230316
ated	O	-1	230316
my@@	B-Disease	D013118	230316
e@@	I-Disease	-1	230316
lo@@	I-Disease	-1	230316
pathy	I-Disease	-1	230316
or	O	-1	230316
peripheral	B-Disease	D010523	230316
neuropathy	I-Disease	-1	230316
,	O	-1	230316
or	O	-1	230316
these	O	-1	230316
man@@	O	-1	230316
if@@	O	-1	230316
est@@	O	-1	230316
ations	O	-1	230316
occur@@	O	-1	230316
r@@	O	-1	230316
ing	O	-1	230316
to@@	O	-1	230316
ge@@	O	-1	230316
ther@@	O	-1	230316
,	O	-1	230316
were	O	-1	230316
inf@@	O	-1	230316
requ@@	O	-1	230316
ent@@	O	-1	230316
.	O	-1	230316
The	O	-1	230316
onset	O	-1	230316
of	O	-1	230316
all	O	-1	230316
man@@	O	-1	230316
if@@	O	-1	230316
est@@	O	-1	230316
ations	O	-1	230316
(@@	O	-1	230316
ex@@	O	-1	230316
cep@@	O	-1	230316
t	O	-1	230316
toxic	O	-1	230316
encephalo@@	B-Disease	D001927	230316
pathy	I-Disease	-1	230316
)	O	-1	230316
was	O	-1	230316
us@@	O	-1	230316
ually	O	-1	230316
sub@@	O	-1	230316
ac@@	O	-1	230316
u@@	O	-1	230316
te@@	O	-1	230316
,	O	-1	230316
with	O	-1	230316
subsequ@@	O	-1	230316
ent	O	-1	230316
partial	O	-1	230316
reco@@	O	-1	230316
ver@@	O	-1	230316
y.	O	-1	230316
O@@	O	-1	230316
l@@	O	-1	230316
der	O	-1	230316
subjects	O	-1	230316
ten@@	O	-1	230316
ded	O	-1	230316
to	O	-1	230316
dis@@	O	-1	230316
pl@@	O	-1	230316
ay	O	-1	230316
more	O	-1	230316
side	O	-1	230316
effects.	O	-1	230316
The	O	-1	230316
ful@@	O	-1	230316
l	O	-1	230316
syndrome	O	-1	230316
of	O	-1	230316
sub@@	O	-1	230316
acute	O	-1	230316
my@@	B-Disease	D013118	230316
e@@	I-Disease	-1	230316
lo@@	I-Disease	-1	230316
-@@	I-Disease	-1	230316
op@@	I-Disease	-1	230316
tic	I-Disease	-1	230316
neuropathy	I-Disease	-1	230316
my@@	B-Disease	D009901	230316
e@@	I-Disease	-1	230316
lo@@	I-Disease	-1	230316
-@@	I-Disease	-1	230316
op@@	I-Disease	-1	230316
tic	I-Disease	-1	230316
neuropathy	I-Disease	-1	230316
was	O	-1	230316
more	O	-1	230316
frequent	O	-1	230316
in	O	-1	230316
wom@@	O	-1	230316
en@@	O	-1	230316
,	O	-1	230316
but	O	-1	230316
they	O	-1	230316
ten@@	O	-1	230316
ded	O	-1	230316
to	O	-1	230316
have	O	-1	230316
tak@@	O	-1	230316
en	O	-1	230316
greater	O	-1	230316
qu@@	O	-1	230316
anti@@	O	-1	230316
ties	O	-1	230316
of	O	-1	230316
the	O	-1	230316
drug.	O	-1	230316

E@@	B-Disease	D004827	11807648
pi@@	I-Disease	-1	11807648
le@@	I-Disease	-1	11807648
p@@	I-Disease	-1	11807648
tic	I-Disease	-1	11807648
seizures	I-Disease	-1	11807648
following	O	-1	11807648
cor@@	O	-1	11807648
tical	O	-1	11807648
ap@@	O	-1	11807648
plic@@	O	-1	11807648
ation	O	-1	11807648
of	O	-1	11807648
fib@@	O	-1	11807648
rin	O	-1	11807648
se@@	O	-1	11807648
al@@	O	-1	11807648
ants	O	-1	11807648
containing	O	-1	11807648
tran@@	B-Chemical	D014148	11807648
ex@@	I-Chemical	-1	11807648
am@@	I-Chemical	-1	11807648
ic	I-Chemical	-1	11807648
acid	I-Chemical	-1	11807648
in	O	-1	11807648
rats.	O	-1	11807648
BACKGROUND:	O	-1	11807648
F@@	O	-1	11807648
i@@	O	-1	11807648
b@@	O	-1	11807648
rin	O	-1	11807648
se@@	O	-1	11807648
al@@	O	-1	11807648
ants	O	-1	11807648
(@@	O	-1	11807648
F@@	O	-1	11807648
S)	O	-1	11807648
der@@	O	-1	11807648
i@@	O	-1	11807648
ved	O	-1	11807648
from	O	-1	11807648
human	O	-1	11807648
plasma	O	-1	11807648
are	O	-1	11807648
frequ@@	O	-1	11807648
ently	O	-1	11807648
used	O	-1	11807648
in	O	-1	11807648
neuro@@	O	-1	11807648
surger@@	O	-1	11807648
y.	O	-1	11807648
In	O	-1	11807648
or@@	O	-1	11807648
der	O	-1	11807648
to	O	-1	11807648
increase	O	-1	11807648
clo@@	O	-1	11807648
t	O	-1	11807648
st@@	O	-1	11807648
abil@@	O	-1	11807648
ity,	O	-1	11807648
F@@	O	-1	11807648
S	O	-1	11807648
typ@@	O	-1	11807648
ically	O	-1	11807648
cont@@	O	-1	11807648
ain	O	-1	11807648
a@@	O	-1	11807648
prot@@	O	-1	11807648
in@@	O	-1	11807648
in,	O	-1	11807648
a	O	-1	11807648
n@@	O	-1	11807648
at@@	O	-1	11807648
ural	O	-1	11807648
fib@@	O	-1	11807648
r@@	O	-1	11807648
in@@	O	-1	11807648
oly@@	O	-1	11807648
sis	O	-1	11807648
inhibitor@@	O	-1	11807648
.	O	-1	11807648
Rec@@	O	-1	11807648
ent@@	O	-1	11807648
ly,	O	-1	11807648
syn@@	O	-1	11807648
thetic	O	-1	11807648
fib@@	O	-1	11807648
r@@	O	-1	11807648
in@@	O	-1	11807648
oly@@	O	-1	11807648
sis	O	-1	11807648
inhibitors	O	-1	11807648
such	O	-1	11807648
as	O	-1	11807648
tran@@	B-Chemical	D014148	11807648
ex@@	I-Chemical	-1	11807648
am@@	I-Chemical	-1	11807648
ic	I-Chemical	-1	11807648
acid	I-Chemical	-1	11807648
(	O	-1	11807648
t@@	B-Chemical	D014148	11807648
AM@@	I-Chemical	-1	11807648
C@@	I-Chemical	-1	11807648
A	I-Chemical	-1	11807648
)	O	-1	11807648
have	O	-1	11807648
been	O	-1	11807648
considered	O	-1	11807648
as	O	-1	11807648
sub@@	O	-1	11807648
sti@@	O	-1	11807648
t@@	O	-1	11807648
ut@@	O	-1	11807648
es	O	-1	11807648
for	O	-1	11807648
a@@	O	-1	11807648
prot@@	O	-1	11807648
in@@	O	-1	11807648
in.	O	-1	11807648
However,	O	-1	11807648
t@@	B-Chemical	D014148	11807648
AM@@	I-Chemical	-1	11807648
C@@	I-Chemical	-1	11807648
A	I-Chemical	-1	11807648
has	O	-1	11807648
been	O	-1	11807648
shown	O	-1	11807648
to	O	-1	11807648
cause	O	-1	11807648
epileptic	B-Disease	D004827	11807648
seizures	I-Disease	-1	11807648
.	O	-1	11807648
We	O	-1	11807648
w@@	O	-1	11807648
ant@@	O	-1	11807648
ed	O	-1	11807648
to	O	-1	11807648
study	O	-1	11807648
whether	O	-1	11807648
t@@	B-Chemical	D014148	11807648
AM@@	I-Chemical	-1	11807648
C@@	I-Chemical	-1	11807648
A	I-Chemical	-1	11807648
ret@@	O	-1	11807648
ain@@	O	-1	11807648
s	O	-1	11807648
its	O	-1	11807648
convul@@	B-Disease	D012640	11807648
sive	I-Disease	-1	11807648
action	O	-1	11807648
if	O	-1	11807648
inc@@	O	-1	11807648
or@@	O	-1	11807648
por@@	O	-1	11807648
ated	O	-1	11807648
into	O	-1	11807648
a	O	-1	11807648
F@@	O	-1	11807648
S@@	O	-1	11807648
.	O	-1	11807648
METHOD@@	O	-1	11807648
:	O	-1	11807648
F@@	O	-1	11807648
S	O	-1	11807648
containing	O	-1	11807648
a@@	O	-1	11807648
prot@@	O	-1	11807648
in@@	O	-1	11807648
in	O	-1	11807648
or	O	-1	11807648
different	O	-1	11807648
concentrations	O	-1	11807648
of	O	-1	11807648
t@@	B-Chemical	D014148	11807648
AM@@	I-Chemical	-1	11807648
C@@	I-Chemical	-1	11807648
A	I-Chemical	-1	11807648
(0.@@	O	-1	11807648
5-@@	O	-1	11807648
4@@	O	-1	11807648
7.@@	O	-1	11807648
5	O	-1	11807648
mg/m@@	O	-1	11807648
l@@	O	-1	11807648
)	O	-1	11807648
were	O	-1	11807648
ap@@	O	-1	11807648
pl@@	O	-1	11807648
ied	O	-1	11807648
to	O	-1	11807648
the	O	-1	11807648
pi@@	O	-1	11807648
al	O	-1	11807648
sur@@	O	-1	11807648
fac@@	O	-1	11807648
e	O	-1	11807648
of	O	-1	11807648
the	O	-1	11807648
cor@@	O	-1	11807648
te@@	O	-1	11807648
x	O	-1	11807648
of	O	-1	11807648
anaesthe@@	O	-1	11807648
tiz@@	O	-1	11807648
ed	O	-1	11807648
rats.	O	-1	11807648
The	O	-1	11807648
response	O	-1	11807648
of	O	-1	11807648
the	O	-1	11807648
animals	O	-1	11807648
was	O	-1	11807648
evaluated	O	-1	11807648
using	O	-1	11807648
electro@@	O	-1	11807648
encephalo@@	O	-1	11807648
graph@@	O	-1	11807648
y	O	-1	11807648
and	O	-1	11807648
by	O	-1	11807648
monit@@	O	-1	11807648
or@@	O	-1	11807648
ing	O	-1	11807648
the	O	-1	11807648
clinical	O	-1	11807648
behavi@@	O	-1	11807648
our	O	-1	11807648
during	O	-1	11807648
and	O	-1	11807648
after	O	-1	11807648
recovery	O	-1	11807648
from	O	-1	11807648
anaesthe@@	O	-1	11807648
sia.	O	-1	11807648
F@@	O	-1	11807648
IN@@	O	-1	11807648
D@@	O	-1	11807648
IN@@	O	-1	11807648
G@@	O	-1	11807648
S:	O	-1	11807648
F@@	O	-1	11807648
S	O	-1	11807648
containing	O	-1	11807648
t@@	B-Chemical	D014148	11807648
AM@@	I-Chemical	-1	11807648
C@@	I-Chemical	-1	11807648
A	I-Chemical	-1	11807648
caused	O	-1	11807648
pa@@	O	-1	11807648
ro@@	O	-1	11807648
x@@	O	-1	11807648
ys@@	O	-1	11807648
m@@	O	-1	11807648
al	O	-1	11807648
brain	O	-1	11807648
activity	O	-1	11807648
which	O	-1	11807648
was	O	-1	11807648
associated	O	-1	11807648
with	O	-1	11807648
dist@@	O	-1	11807648
inc@@	O	-1	11807648
t	O	-1	11807648
convul@@	B-Disease	D012640	11807648
sive	I-Disease	-1	11807648
behavi@@	O	-1	11807648
o@@	O	-1	11807648
ur@@	O	-1	11807648
s.	O	-1	11807648
The	O	-1	11807648
de@@	O	-1	11807648
g@@	O	-1	11807648
ree	O	-1	11807648
of	O	-1	11807648
these	O	-1	11807648
seizures	B-Disease	D012640	11807648
increased	O	-1	11807648
with	O	-1	11807648
increas@@	O	-1	11807648
ing	O	-1	11807648
concentration	O	-1	11807648
of	O	-1	11807648
t@@	B-Chemical	D014148	11807648
AM@@	I-Chemical	-1	11807648
C@@	I-Chemical	-1	11807648
A	I-Chemical	-1	11807648
.	O	-1	11807648
Th@@	O	-1	11807648
us,	O	-1	11807648
F@@	O	-1	11807648
S	O	-1	11807648
containing	O	-1	11807648
4@@	O	-1	11807648
7.@@	O	-1	11807648
5	O	-1	11807648
mg/m@@	O	-1	11807648
l	O	-1	11807648
t@@	B-Chemical	D014148	11807648
AM@@	I-Chemical	-1	11807648
C@@	I-Chemical	-1	11807648
A	I-Chemical	-1	11807648
evoked	O	-1	11807648
gener@@	B-Disease	D012640	11807648
al@@	I-Disease	-1	11807648
ized	I-Disease	-1	11807648
seizures	I-Disease	-1	11807648
in	O	-1	11807648
all	O	-1	11807648
tested	O	-1	11807648
rats	O	-1	11807648
(n@@	O	-1	11807648
=@@	O	-1	11807648
6@@	O	-1	11807648
)	O	-1	11807648
while	O	-1	11807648
the	O	-1	11807648
low@@	O	-1	11807648
est	O	-1	11807648
concentration	O	-1	11807648
of	O	-1	11807648
t@@	B-Chemical	D014148	11807648
AM@@	I-Chemical	-1	11807648
C@@	I-Chemical	-1	11807648
A	I-Chemical	-1	11807648
(0.@@	O	-1	11807648
5	O	-1	11807648
mg/m@@	O	-1	11807648
l@@	O	-1	11807648
)	O	-1	11807648
only	O	-1	11807648
evoked	O	-1	11807648
b@@	O	-1	11807648
ri@@	O	-1	11807648
e@@	O	-1	11807648
f	O	-1	11807648
episo@@	O	-1	11807648
des	O	-1	11807648
of	O	-1	11807648
j@@	O	-1	11807648
er@@	O	-1	11807648
k@@	O	-1	11807648
-@@	O	-1	11807648
cor@@	O	-1	11807648
related	O	-1	11807648
convul@@	B-Disease	D012640	11807648
sive	I-Disease	-1	11807648
potenti@@	O	-1	11807648
als	O	-1	11807648
in	O	-1	11807648
1	O	-1	11807648
of	O	-1	11807648
6	O	-1	11807648
rats.	O	-1	11807648
In	O	-1	11807648
contrast@@	O	-1	11807648
,	O	-1	11807648
F@@	O	-1	11807648
S	O	-1	11807648
containing	O	-1	11807648
a@@	O	-1	11807648
prot@@	O	-1	11807648
in@@	O	-1	11807648
in	O	-1	11807648
did	O	-1	11807648
not	O	-1	11807648
evo@@	O	-1	11807648
k@@	O	-1	11807648
e	O	-1	11807648
any	O	-1	11807648
pa@@	O	-1	11807648
ro@@	O	-1	11807648
x@@	O	-1	11807648
ys@@	O	-1	11807648
m@@	O	-1	11807648
al	O	-1	11807648
activ@@	O	-1	11807648
ity.	O	-1	11807648
IN@@	O	-1	11807648
TE@@	O	-1	11807648
R@@	O	-1	11807648
P@@	O	-1	11807648
R@@	O	-1	11807648
ET@@	O	-1	11807648
AT@@	O	-1	11807648
ION@@	O	-1	11807648
:	O	-1	11807648
T@@	B-Chemical	D014148	11807648
ran@@	I-Chemical	-1	11807648
ex@@	I-Chemical	-1	11807648
am@@	I-Chemical	-1	11807648
ic	I-Chemical	-1	11807648
acid	I-Chemical	-1	11807648
ret@@	O	-1	11807648
ain@@	O	-1	11807648
s	O	-1	11807648
its	O	-1	11807648
convul@@	B-Disease	D012640	11807648
sive	I-Disease	-1	11807648
action	O	-1	11807648
within	O	-1	11807648
F@@	O	-1	11807648
S@@	O	-1	11807648
.	O	-1	11807648
Th@@	O	-1	11807648
us,	O	-1	11807648
use	O	-1	11807648
of	O	-1	11807648
F@@	O	-1	11807648
S	O	-1	11807648
containing	O	-1	11807648
t@@	B-Chemical	D014148	11807648
AM@@	I-Chemical	-1	11807648
C@@	I-Chemical	-1	11807648
A	I-Chemical	-1	11807648
for	O	-1	11807648
surger@@	O	-1	11807648
y	O	-1	11807648
within	O	-1	11807648
or	O	-1	11807648
clo@@	O	-1	11807648
se	O	-1	11807648
to	O	-1	11807648
the	O	-1	11807648
C@@	O	-1	11807648
N@@	O	-1	11807648
S	O	-1	11807648
may	O	-1	11807648
p@@	O	-1	11807648
ose	O	-1	11807648
a	O	-1	11807648
subst@@	O	-1	11807648
anti@@	O	-1	11807648
al	O	-1	11807648
risk	O	-1	11807648
to	O	-1	11807648
the	O	-1	11807648
patient@@	O	-1	11807648
.	O	-1	11807648

A	O	-1	14596845
diet	O	-1	14596845
pro@@	O	-1	14596845
m@@	O	-1	14596845
ot@@	O	-1	14596845
ing	O	-1	14596845
sug@@	B-Disease	D019966	14596845
ar	I-Disease	-1	14596845
depend@@	I-Disease	-1	14596845
ency	I-Disease	-1	14596845
causes	O	-1	14596845
behavioral	B-Disease	D006948	14596845
cros@@	I-Disease	-1	14596845
s-@@	I-Disease	-1	14596845
sensi@@	I-Disease	-1	14596845
tiz@@	I-Disease	-1	14596845
ation	I-Disease	-1	14596845
to	O	-1	14596845
a	O	-1	14596845
low	O	-1	14596845
dose	O	-1	14596845
of	O	-1	14596845
amphetamine	B-Chemical	D000661	14596845
.	O	-1	14596845
Pre@@	O	-1	14596845
vi@@	O	-1	14596845
ous	O	-1	14596845
re@@	O	-1	14596845
se@@	O	-1	14596845
arc@@	O	-1	14596845
h	O	-1	14596845
in	O	-1	14596845
this	O	-1	14596845
labor@@	O	-1	14596845
atory	O	-1	14596845
has	O	-1	14596845
shown	O	-1	14596845
that	O	-1	14596845
a	O	-1	14596845
diet	O	-1	14596845
of	O	-1	14596845
inter@@	O	-1	14596845
mit@@	O	-1	14596845
t@@	O	-1	14596845
ent	O	-1	14596845
ex@@	O	-1	14596845
ces@@	O	-1	14596845
sive	O	-1	14596845
sug@@	O	-1	14596845
ar	O	-1	14596845
consum@@	O	-1	14596845
ption	O	-1	14596845
produc@@	O	-1	14596845
es	O	-1	14596845
a	O	-1	14596845
state	O	-1	14596845
with	O	-1	14596845
neuro@@	O	-1	14596845
chemical	O	-1	14596845
and	O	-1	14596845
behavioral	O	-1	14596845
simil@@	O	-1	14596845
ar@@	O	-1	14596845
ities	O	-1	14596845
to	O	-1	14596845
drug	B-Disease	D019966	14596845
depend@@	I-Disease	-1	14596845
ency	I-Disease	-1	14596845
.	O	-1	14596845
The	O	-1	14596845
present	O	-1	14596845
study	O	-1	14596845
examined	O	-1	14596845
whether	O	-1	14596845
female	O	-1	14596845
rats	O	-1	14596845
on	O	-1	14596845
various	O	-1	14596845
regimen@@	O	-1	14596845
s	O	-1	14596845
of	O	-1	14596845
sug@@	O	-1	14596845
ar	O	-1	14596845
ac@@	O	-1	14596845
cess	O	-1	14596845
wo@@	O	-1	14596845
uld	O	-1	14596845
show	O	-1	14596845
behavioral	B-Disease	D006948	14596845
cros@@	I-Disease	-1	14596845
s-@@	I-Disease	-1	14596845
sensi@@	I-Disease	-1	14596845
tiz@@	I-Disease	-1	14596845
ation	I-Disease	-1	14596845
to	O	-1	14596845
a	O	-1	14596845
low	O	-1	14596845
dose	O	-1	14596845
of	O	-1	14596845
amphetamine	B-Chemical	D000661	14596845
.	O	-1	14596845
After	O	-1	14596845
a	O	-1	14596845
3@@	O	-1	14596845
0-@@	O	-1	14596845
min	O	-1	14596845
baseline	O	-1	14596845
meas@@	O	-1	14596845
ure	O	-1	14596845
of	O	-1	14596845
locomotor	O	-1	14596845
activity	O	-1	14596845
(@@	O	-1	14596845
day	O	-1	14596845
0@@	O	-1	14596845
),	O	-1	14596845
animals	O	-1	14596845
were	O	-1	14596845
maint@@	O	-1	14596845
ained	O	-1	14596845
on	O	-1	14596845
a	O	-1	14596845
cy@@	O	-1	14596845
cl@@	O	-1	14596845
ic	O	-1	14596845
diet	O	-1	14596845
of	O	-1	14596845
1@@	O	-1	14596845
2-@@	O	-1	14596845
h	O	-1	14596845
de@@	O	-1	14596845
pri@@	O	-1	14596845
v@@	O	-1	14596845
ation	O	-1	14596845
followed	O	-1	14596845
by	O	-1	14596845
1@@	O	-1	14596845
2-@@	O	-1	14596845
h	O	-1	14596845
ac@@	O	-1	14596845
cess	O	-1	14596845
to	O	-1	14596845
10@@	O	-1	14596845
%	O	-1	14596845
suc@@	B-Chemical	D013395	14596845
ro@@	I-Chemical	-1	14596845
se	I-Chemical	-1	14596845
sol@@	O	-1	14596845
u@@	O	-1	14596845
tion	O	-1	14596845
and	O	-1	14596845
ch@@	O	-1	14596845
o@@	O	-1	14596845
w	O	-1	14596845
p@@	O	-1	14596845
el@@	O	-1	14596845
le@@	O	-1	14596845
ts	O	-1	14596845
(1@@	O	-1	14596845
2	O	-1	14596845
h	O	-1	14596845
ac@@	O	-1	14596845
cess	O	-1	14596845
star@@	O	-1	14596845
ting	O	-1	14596845
4	O	-1	14596845
h	O	-1	14596845
after	O	-1	14596845
onset	O	-1	14596845
of	O	-1	14596845
the	O	-1	14596845
d@@	O	-1	14596845
ar@@	O	-1	14596845
k	O	-1	14596845
perio@@	O	-1	14596845
d@@	O	-1	14596845
)	O	-1	14596845
for	O	-1	14596845
21	O	-1	14596845
days.	O	-1	14596845
L@@	O	-1	14596845
o@@	O	-1	14596845
com@@	O	-1	14596845
otor	O	-1	14596845
activity	O	-1	14596845
was	O	-1	14596845
measured	O	-1	14596845
ag@@	O	-1	14596845
ain	O	-1	14596845
for	O	-1	14596845
30	O	-1	14596845
min	O	-1	14596845
at	O	-1	14596845
the	O	-1	14596845
be@@	O	-1	14596845
g@@	O	-1	14596845
in@@	O	-1	14596845
ning	O	-1	14596845
of	O	-1	14596845
days	O	-1	14596845
1	O	-1	14596845
and	O	-1	14596845
21	O	-1	14596845
of	O	-1	14596845
sug@@	O	-1	14596845
ar	O	-1	14596845
ac@@	O	-1	14596845
ces@@	O	-1	14596845
s.	O	-1	14596845
B@@	O	-1	14596845
e@@	O	-1	14596845
g@@	O	-1	14596845
in@@	O	-1	14596845
ning	O	-1	14596845
on	O	-1	14596845
day	O	-1	14596845
2@@	O	-1	14596845
2,	O	-1	14596845
all	O	-1	14596845
rats	O	-1	14596845
were	O	-1	14596845
maint@@	O	-1	14596845
ained	O	-1	14596845
on	O	-1	14596845
ad	O	-1	14596845
li@@	O	-1	14596845
b@@	O	-1	14596845
it@@	O	-1	14596845
um	O	-1	14596845
ch@@	O	-1	14596845
o@@	O	-1	14596845
w@@	O	-1	14596845
.	O	-1	14596845
N@@	O	-1	14596845
ine	O	-1	14596845
days	O	-1	14596845
lat@@	O	-1	14596845
er	O	-1	14596845
locomotor	O	-1	14596845
activity	O	-1	14596845
was	O	-1	14596845
measured	O	-1	14596845
in	O	-1	14596845
response	O	-1	14596845
to	O	-1	14596845
a	O	-1	14596845
single	O	-1	14596845
low	O	-1	14596845
dose	O	-1	14596845
of	O	-1	14596845
amphetamine	B-Chemical	D000661	14596845
(0.@@	O	-1	14596845
5	O	-1	14596845
mg/kg@@	O	-1	14596845
).	O	-1	14596845
The	O	-1	14596845
animals	O	-1	14596845
that	O	-1	14596845
had	O	-1	14596845
experienced	O	-1	14596845
cy@@	O	-1	14596845
cl@@	O	-1	14596845
ic	O	-1	14596845
suc@@	B-Chemical	D013395	14596845
ro@@	I-Chemical	-1	14596845
se	I-Chemical	-1	14596845
and	O	-1	14596845
ch@@	O	-1	14596845
o@@	O	-1	14596845
w	O	-1	14596845
were	O	-1	14596845
hyper@@	B-Disease	D006948	14596845
active	I-Disease	-1	14596845
in	O	-1	14596845
response	O	-1	14596845
to	O	-1	14596845
amphetamine	B-Chemical	D000661	14596845
compared	O	-1	14596845
with	O	-1	14596845
four	O	-1	14596845
control	O	-1	14596845
groups	O	-1	14596845
(@@	O	-1	14596845
ad	O	-1	14596845
li@@	O	-1	14596845
b@@	O	-1	14596845
it@@	O	-1	14596845
um	O	-1	14596845
10@@	O	-1	14596845
%	O	-1	14596845
suc@@	B-Chemical	D013395	14596845
ro@@	I-Chemical	-1	14596845
se	I-Chemical	-1	14596845
and	O	-1	14596845
ch@@	O	-1	14596845
o@@	O	-1	14596845
w	O	-1	14596845
followed	O	-1	14596845
by	O	-1	14596845
amphetamine	B-Chemical	D000661	14596845
injec@@	O	-1	14596845
tion,	O	-1	14596845
cy@@	O	-1	14596845
cl@@	O	-1	14596845
ic	O	-1	14596845
ch@@	O	-1	14596845
o@@	O	-1	14596845
w	O	-1	14596845
followed	O	-1	14596845
by	O	-1	14596845
amphetamine	B-Chemical	D000661	14596845
injec@@	O	-1	14596845
tion,	O	-1	14596845
ad	O	-1	14596845
li@@	O	-1	14596845
b@@	O	-1	14596845
it@@	O	-1	14596845
um	O	-1	14596845
ch@@	O	-1	14596845
o@@	O	-1	14596845
w	O	-1	14596845
with	O	-1	14596845
amphetamine	B-Chemical	D000661	14596845
,	O	-1	14596845
or	O	-1	14596845
cy@@	O	-1	14596845
cl@@	O	-1	14596845
ic	O	-1	14596845
10@@	O	-1	14596845
%	O	-1	14596845
suc@@	B-Chemical	D013395	14596845
ro@@	I-Chemical	-1	14596845
se	I-Chemical	-1	14596845
and	O	-1	14596845
ch@@	O	-1	14596845
o@@	O	-1	14596845
w	O	-1	14596845
with	O	-1	14596845
a	O	-1	14596845
saline	O	-1	14596845
injec@@	O	-1	14596845
tion@@	O	-1	14596845
).	O	-1	14596845
These	O	-1	14596845
results	O	-1	14596845
suggest	O	-1	14596845
that	O	-1	14596845
a	O	-1	14596845
diet	O	-1	14596845
comp@@	O	-1	14596845
ris@@	O	-1	14596845
ed	O	-1	14596845
of	O	-1	14596845
al@@	O	-1	14596845
tern@@	O	-1	14596845
ating	O	-1	14596845
de@@	O	-1	14596845
pri@@	O	-1	14596845
v@@	O	-1	14596845
ation	O	-1	14596845
and	O	-1	14596845
ac@@	O	-1	14596845
cess	O	-1	14596845
to	O	-1	14596845
a	O	-1	14596845
sug@@	O	-1	14596845
ar	O	-1	14596845
sol@@	O	-1	14596845
u@@	O	-1	14596845
tion	O	-1	14596845
and	O	-1	14596845
ch@@	O	-1	14596845
o@@	O	-1	14596845
w	O	-1	14596845
produc@@	O	-1	14596845
es	O	-1	14596845
b@@	O	-1	14596845
ing@@	O	-1	14596845
e@@	O	-1	14596845
ing	O	-1	14596845
on	O	-1	14596845
sug@@	O	-1	14596845
ar	O	-1	14596845
that	O	-1	14596845
lead@@	O	-1	14596845
s	O	-1	14596845
to	O	-1	14596845
a	O	-1	14596845
lon@@	O	-1	14596845
g	O	-1	14596845
l@@	O	-1	14596845
ast@@	O	-1	14596845
ing	O	-1	14596845
state	O	-1	14596845
of	O	-1	14596845
increased	O	-1	14596845
sensitivity	O	-1	14596845
to	O	-1	14596845
amphetamine	B-Chemical	D000661	14596845
,	O	-1	14596845
possib@@	O	-1	14596845
ly	O	-1	14596845
due	O	-1	14596845
to	O	-1	14596845
a	O	-1	14596845
l@@	O	-1	14596845
ast@@	O	-1	14596845
ing	O	-1	14596845
al@@	O	-1	14596845
ter@@	O	-1	14596845
ation	O	-1	14596845
in	O	-1	14596845
the	O	-1	14596845
dopamine	B-Chemical	D004298	14596845
system@@	O	-1	14596845
.	O	-1	14596845

D-@@	B-Chemical	D010396	6666578
pen@@	I-Chemical	-1	6666578
icill@@	I-Chemical	-1	6666578
amine	I-Chemical	-1	6666578
-induced	O	-1	6666578
angio@@	B-Disease	D001018	6666578
pathy	I-Disease	-1	6666578
in	O	-1	6666578
rats.	O	-1	6666578
The	O	-1	6666578
effect	O	-1	6666578
of	O	-1	6666578
high	O	-1	6666578
dose	O	-1	6666578
D-@@	B-Chemical	D010396	6666578
pen@@	I-Chemical	-1	6666578
icill@@	I-Chemical	-1	6666578
amine	I-Chemical	-1	6666578
treatment	O	-1	6666578
on	O	-1	6666578
a@@	O	-1	6666578
or@@	O	-1	6666578
tic	O	-1	6666578
per@@	O	-1	6666578
me@@	O	-1	6666578
ability	O	-1	6666578
to	O	-1	6666578
al@@	O	-1	6666578
b@@	O	-1	6666578
um@@	O	-1	6666578
in	O	-1	6666578
and	O	-1	6666578
on	O	-1	6666578
the	O	-1	6666578
ult@@	O	-1	6666578
ra@@	O	-1	6666578
struct@@	O	-1	6666578
ure	O	-1	6666578
of	O	-1	6666578
the	O	-1	6666578
v@@	O	-1	6666578
es@@	O	-1	6666578
sel@@	O	-1	6666578
.	O	-1	6666578
M@@	O	-1	6666578
al@@	O	-1	6666578
e	O	-1	6666578
S@@	O	-1	6666578
pra@@	O	-1	6666578
gu@@	O	-1	6666578
e-@@	O	-1	6666578
D@@	O	-1	6666578
aw@@	O	-1	6666578
le@@	O	-1	6666578
y	O	-1	6666578
rats	O	-1	6666578
were	O	-1	6666578
treated	O	-1	6666578
with	O	-1	6666578
D-@@	B-Chemical	D010396	6666578
pen@@	I-Chemical	-1	6666578
icill@@	I-Chemical	-1	6666578
amine	I-Chemical	-1	6666578
(	O	-1	6666578
D-@@	B-Chemical	D010396	6666578
p@@	I-Chemical	-1	6666578
en	I-Chemical	-1	6666578
)	O	-1	6666578
5@@	O	-1	6666578
00	O	-1	6666578
mg/k@@	O	-1	6666578
g/@@	O	-1	6666578
day	O	-1	6666578
for	O	-1	6666578
10	O	-1	6666578
or	O	-1	6666578
4@@	O	-1	6666578
2	O	-1	6666578
days.	O	-1	6666578
P@@	O	-1	6666578
a@@	O	-1	6666578
ir	O	-1	6666578
f@@	O	-1	6666578
ed	O	-1	6666578
rats	O	-1	6666578
ser@@	O	-1	6666578
ved	O	-1	6666578
as	O	-1	6666578
controls.	O	-1	6666578
Ch@@	O	-1	6666578
ang@@	O	-1	6666578
es	O	-1	6666578
in	O	-1	6666578
a@@	O	-1	6666578
or@@	O	-1	6666578
tic	O	-1	6666578
morph@@	O	-1	6666578
ology	O	-1	6666578
were	O	-1	6666578
examined	O	-1	6666578
by	O	-1	6666578
li@@	O	-1	6666578
gh@@	O	-1	6666578
t@@	O	-1	6666578
-	O	-1	6666578
and	O	-1	6666578
trans@@	O	-1	6666578
mis@@	O	-1	6666578
sion@@	O	-1	6666578
-@@	O	-1	6666578
electro@@	O	-1	6666578
n	O	-1	6666578
micro@@	O	-1	6666578
sco@@	O	-1	6666578
p@@	O	-1	6666578
y	O	-1	6666578
(T@@	O	-1	6666578
E@@	O	-1	6666578
M@@	O	-1	6666578
).	O	-1	6666578
In	O	-1	6666578
addi@@	O	-1	6666578
tion,	O	-1	6666578
the	O	-1	6666578
endothelial	O	-1	6666578
per@@	O	-1	6666578
me@@	O	-1	6666578
ability	O	-1	6666578
and	O	-1	6666578
the	O	-1	6666578
pen@@	O	-1	6666578
et@@	O	-1	6666578
ration	O	-1	6666578
through	O	-1	6666578
the	O	-1	6666578
a@@	O	-1	6666578
or@@	O	-1	6666578
tic	O	-1	6666578
w@@	O	-1	6666578
all	O	-1	6666578
of	O	-1	6666578
al@@	O	-1	6666578
b@@	O	-1	6666578
um@@	O	-1	6666578
in	O	-1	6666578
were	O	-1	6666578
studied	O	-1	6666578
10	O	-1	6666578
minut@@	O	-1	6666578
es,	O	-1	6666578
24	O	-1	6666578
and	O	-1	6666578
4@@	O	-1	6666578
8	O	-1	6666578
hours	O	-1	6666578
after	O	-1	6666578
i@@	O	-1	6666578
.	O	-1	6666578
v@@	O	-1	6666578
.	O	-1	6666578
injection	O	-1	6666578
of	O	-1	6666578
human	O	-1	6666578
serum	O	-1	6666578
13@@	O	-1	6666578
1@@	O	-1	6666578
I@@	O	-1	6666578
-@@	O	-1	6666578
al@@	O	-1	6666578
b@@	O	-1	6666578
um@@	O	-1	6666578
in	O	-1	6666578
(1@@	O	-1	6666578
3@@	O	-1	6666578
1@@	O	-1	6666578
I@@	O	-1	6666578
-H@@	O	-1	6666578
S@@	O	-1	6666578
A@@	O	-1	6666578
).	O	-1	6666578
TE@@	O	-1	6666578
M	O	-1	6666578
revealed	O	-1	6666578
exten@@	O	-1	6666578
sive	O	-1	6666578
el@@	O	-1	6666578
ast@@	O	-1	6666578
oly@@	O	-1	6666578
sis	O	-1	6666578
in	O	-1	6666578
the	O	-1	6666578
arterial	O	-1	6666578
w@@	O	-1	6666578
all	O	-1	6666578
of	O	-1	6666578
D-@@	B-Chemical	D010396	6666578
p@@	I-Chemical	-1	6666578
en	I-Chemical	-1	6666578
-treated	O	-1	6666578
rats,	O	-1	6666578
consist@@	O	-1	6666578
ent	O	-1	6666578
with	O	-1	6666578
an	O	-1	6666578
inhibit@@	O	-1	6666578
ory	O	-1	6666578
effect	O	-1	6666578
on	O	-1	6666578
cros@@	O	-1	6666578
s@@	O	-1	6666578
lin@@	O	-1	6666578
k	O	-1	6666578
form@@	O	-1	6666578
ation.	O	-1	6666578
In	O	-1	6666578
experimental	O	-1	6666578
animals	O	-1	6666578
ex@@	O	-1	6666578
cess	O	-1	6666578
de@@	O	-1	6666578
posi@@	O	-1	6666578
tion	O	-1	6666578
of	O	-1	6666578
coll@@	O	-1	6666578
ag@@	O	-1	6666578
en	O	-1	6666578
and	O	-1	6666578
gly@@	O	-1	6666578
co@@	O	-1	6666578
amino@@	O	-1	6666578
glyc@@	O	-1	6666578
ans	O	-1	6666578
was	O	-1	6666578
observed	O	-1	6666578
in	O	-1	6666578
the	O	-1	6666578
sub@@	O	-1	6666578
endothelial	O	-1	6666578
and	O	-1	6666578
medi@@	O	-1	6666578
al	O	-1	6666578
l@@	O	-1	6666578
ay@@	O	-1	6666578
er	O	-1	6666578
of	O	-1	6666578
the	O	-1	6666578
a@@	O	-1	6666578
or@@	O	-1	6666578
tic	O	-1	6666578
w@@	O	-1	6666578
all@@	O	-1	6666578
,	O	-1	6666578
to@@	O	-1	6666578
ge@@	O	-1	6666578
ther	O	-1	6666578
with	O	-1	6666578
pro@@	O	-1	6666578
min@@	O	-1	6666578
ent	O	-1	6666578
bas@@	O	-1	6666578
al	O	-1	6666578
membran@@	O	-1	6666578
e	O	-1	6666578
subst@@	O	-1	6666578
ance	O	-1	6666578
a@@	O	-1	6666578
ro@@	O	-1	6666578
un@@	O	-1	6666578
d	O	-1	6666578
a@@	O	-1	6666578
or@@	O	-1	6666578
tic	O	-1	6666578
smo@@	O	-1	6666578
oth	O	-1	6666578
musc@@	O	-1	6666578
le	O	-1	6666578
cell@@	O	-1	6666578
s.	O	-1	6666578
The	O	-1	6666578
a@@	O	-1	6666578
ort@@	O	-1	6666578
a@@	O	-1	6666578
/@@	O	-1	6666578
ser@@	O	-1	6666578
um@@	O	-1	6666578
-@@	O	-1	6666578
rati@@	O	-1	6666578
o	O	-1	6666578
and	O	-1	6666578
the	O	-1	6666578
radi@@	O	-1	6666578
o@@	O	-1	6666578
active	O	-1	6666578
bu@@	O	-1	6666578
il@@	O	-1	6666578
d-@@	O	-1	6666578
up	O	-1	6666578
24	O	-1	6666578
and	O	-1	6666578
4@@	O	-1	6666578
8	O	-1	6666578
hours	O	-1	6666578
after	O	-1	6666578
injection	O	-1	6666578
of	O	-1	6666578
13@@	O	-1	6666578
1@@	O	-1	6666578
I@@	O	-1	6666578
-H@@	O	-1	6666578
S@@	O	-1	6666578
A	O	-1	6666578
was	O	-1	6666578
reduced	O	-1	6666578
in	O	-1	6666578
animals	O	-1	6666578
treated	O	-1	6666578
with	O	-1	6666578
D-@@	B-Chemical	D010396	6666578
p@@	I-Chemical	-1	6666578
en	I-Chemical	-1	6666578
for	O	-1	6666578
4@@	O	-1	6666578
2	O	-1	6666578
day@@	O	-1	6666578
s,	O	-1	6666578
indicating	O	-1	6666578
an	O	-1	6666578
im@@	O	-1	6666578
p@@	O	-1	6666578
ed@@	O	-1	6666578
ed	O	-1	6666578
trans@@	O	-1	6666578
m@@	O	-1	6666578
ural	O	-1	6666578
trans@@	O	-1	6666578
por@@	O	-1	6666578
t	O	-1	6666578
of	O	-1	6666578
trac@@	O	-1	6666578
er	O	-1	6666578
which	O	-1	6666578
may	O	-1	6666578
be	O	-1	6666578
caused	O	-1	6666578
by	O	-1	6666578
a	O	-1	6666578
ster@@	O	-1	6666578
ic	O	-1	6666578
ex@@	O	-1	6666578
cl@@	O	-1	6666578
usion	O	-1	6666578
effect	O	-1	6666578
of	O	-1	6666578
ab@@	O	-1	6666578
und@@	O	-1	6666578
ant	O	-1	6666578
hy@@	B-Chemical	D006820	6666578
al@@	I-Chemical	-1	6666578
uron@@	I-Chemical	-1	6666578
ate	I-Chemical	-1	6666578
.	O	-1	6666578
The	O	-1	6666578
endothelial	O	-1	6666578
ult@@	O	-1	6666578
ra@@	O	-1	6666578
struct@@	O	-1	6666578
ure	O	-1	6666578
was	O	-1	6666578
un@@	O	-1	6666578
affected	O	-1	6666578
by	O	-1	6666578
D-@@	B-Chemical	D010396	6666578
p@@	I-Chemical	-1	6666578
en	I-Chemical	-1	6666578
,	O	-1	6666578
and	O	-1	6666578
no	O	-1	6666578
differences	O	-1	6666578
in	O	-1	6666578
a@@	O	-1	6666578
or@@	O	-1	6666578
tic	O	-1	6666578
13@@	O	-1	6666578
1@@	O	-1	6666578
I@@	O	-1	6666578
-H@@	O	-1	6666578
S@@	O	-1	6666578
A	O	-1	6666578
radi@@	O	-1	6666578
o@@	O	-1	6666578
activity	O	-1	6666578
or	O	-1	6666578
a@@	O	-1	6666578
ort@@	O	-1	6666578
a@@	O	-1	6666578
/@@	O	-1	6666578
ser@@	O	-1	6666578
um@@	O	-1	6666578
-@@	O	-1	6666578
rati@@	O	-1	6666578
o	O	-1	6666578
were	O	-1	6666578
recor@@	O	-1	6666578
ded	O	-1	6666578
between	O	-1	6666578
experimental	O	-1	6666578
and	O	-1	6666578
control	O	-1	6666578
groups	O	-1	6666578
10	O	-1	6666578
minutes	O	-1	6666578
after	O	-1	6666578
trac@@	O	-1	6666578
er	O	-1	6666578
injec@@	O	-1	6666578
tion,	O	-1	6666578
indicating	O	-1	6666578
that	O	-1	6666578
the	O	-1	6666578
per@@	O	-1	6666578
me@@	O	-1	6666578
ability	O	-1	6666578
of	O	-1	6666578
the	O	-1	6666578
endothelial	O	-1	6666578
bar@@	O	-1	6666578
ri@@	O	-1	6666578
er	O	-1	6666578
to	O	-1	6666578
al@@	O	-1	6666578
b@@	O	-1	6666578
um@@	O	-1	6666578
in	O	-1	6666578
remained	O	-1	6666578
un@@	O	-1	6666578
affected	O	-1	6666578
by	O	-1	6666578
D-@@	B-Chemical	D010396	6666578
p@@	I-Chemical	-1	6666578
en	I-Chemical	-1	6666578
treatment.	O	-1	6666578
These	O	-1	6666578
observ@@	O	-1	6666578
ations	O	-1	6666578
suppor@@	O	-1	6666578
t	O	-1	6666578
the	O	-1	6666578
hypo@@	O	-1	6666578
thesis	O	-1	6666578
that	O	-1	6666578
treatment	O	-1	6666578
with	O	-1	6666578
high	O	-1	6666578
doses	O	-1	6666578
of	O	-1	6666578
D-@@	B-Chemical	D010396	6666578
p@@	I-Chemical	-1	6666578
en	I-Chemical	-1	6666578
may	O	-1	6666578
induce	O	-1	6666578
a	O	-1	6666578
fib@@	O	-1	6666578
ro@@	O	-1	6666578
pro@@	O	-1	6666578
li@@	O	-1	6666578
fer@@	O	-1	6666578
ative	O	-1	6666578
response	O	-1	6666578
in	O	-1	6666578
rat	O	-1	6666578
a@@	O	-1	6666578
ort@@	O	-1	6666578
a,	O	-1	6666578
possib@@	O	-1	6666578
ly	O	-1	6666578
by	O	-1	6666578
an	O	-1	6666578
inhibit@@	O	-1	6666578
ory	O	-1	6666578
effect	O	-1	6666578
on	O	-1	6666578
the	O	-1	6666578
cros@@	O	-1	6666578
s-@@	O	-1	6666578
lin@@	O	-1	6666578
king	O	-1	6666578
of	O	-1	6666578
coll@@	O	-1	6666578
ag@@	O	-1	6666578
en	O	-1	6666578
and	O	-1	6666578
el@@	O	-1	6666578
ast@@	O	-1	6666578
in.	O	-1	6666578

B@@	O	-1	11279304
ra@@	O	-1	11279304
in	O	-1	11279304
n@@	O	-1	11279304
atri@@	O	-1	11279304
ure@@	O	-1	11279304
tic	O	-1	11279304
p@@	O	-1	11279304
ep@@	O	-1	11279304
ti@@	O	-1	11279304
de	O	-1	11279304
is	O	-1	11279304
a	O	-1	11279304
predic@@	O	-1	11279304
t@@	O	-1	11279304
or	O	-1	11279304
of	O	-1	11279304
an@@	B-Chemical	D018943	11279304
th@@	I-Chemical	-1	11279304
rac@@	I-Chemical	-1	11279304
y@@	I-Chemical	-1	11279304
cl@@	I-Chemical	-1	11279304
ine	I-Chemical	-1	11279304
-induced	O	-1	11279304
cardi@@	B-Disease	D066126	11279304
otoxicity	I-Disease	-1	11279304
.	O	-1	11279304
An@@	B-Chemical	D018943	11279304
th@@	I-Chemical	-1	11279304
rac@@	I-Chemical	-1	11279304
y@@	I-Chemical	-1	11279304
clin@@	I-Chemical	-1	11279304
es	I-Chemical	-1	11279304
are	O	-1	11279304
effective	O	-1	11279304
ant@@	O	-1	11279304
ine@@	O	-1	11279304
o@@	O	-1	11279304
plas@@	O	-1	11279304
tic	O	-1	11279304
drug@@	O	-1	11279304
s,	O	-1	11279304
but	O	-1	11279304
they	O	-1	11279304
frequ@@	O	-1	11279304
ently	O	-1	11279304
cause	O	-1	11279304
dose-@@	O	-1	11279304
related	O	-1	11279304
cardi@@	B-Disease	D066126	11279304
otoxicity	I-Disease	-1	11279304
.	O	-1	11279304
The	O	-1	11279304
cardi@@	B-Disease	D066126	11279304
otoxicity	I-Disease	-1	11279304
of	O	-1	11279304
con@@	O	-1	11279304
ven@@	O	-1	11279304
tional	O	-1	11279304
an@@	B-Chemical	D018943	11279304
th@@	I-Chemical	-1	11279304
rac@@	I-Chemical	-1	11279304
y@@	I-Chemical	-1	11279304
cl@@	I-Chemical	-1	11279304
ine	I-Chemical	-1	11279304
therapy	O	-1	11279304
high@@	O	-1	11279304
li@@	O	-1	11279304
gh@@	O	-1	11279304
ts	O	-1	11279304
a	O	-1	11279304
need	O	-1	11279304
to	O	-1	11279304
se@@	O	-1	11279304
arc@@	O	-1	11279304
h	O	-1	11279304
for	O	-1	11279304
meth@@	O	-1	11279304
o@@	O	-1	11279304
ds	O	-1	11279304
that	O	-1	11279304
are	O	-1	11279304
high@@	O	-1	11279304
ly	O	-1	11279304
sensitive	O	-1	11279304
and	O	-1	11279304
cap@@	O	-1	11279304
able	O	-1	11279304
of	O	-1	11279304
predic@@	O	-1	11279304
ting	O	-1	11279304
cardiac	B-Disease	D006331	11279304
dysfunction	I-Disease	-1	11279304
.	O	-1	11279304
We	O	-1	11279304
measured	O	-1	11279304
the	O	-1	11279304
plasma	O	-1	11279304
level	O	-1	11279304
of	O	-1	11279304
brain	O	-1	11279304
n@@	O	-1	11279304
atri@@	O	-1	11279304
ure@@	O	-1	11279304
tic	O	-1	11279304
p@@	O	-1	11279304
ep@@	O	-1	11279304
ti@@	O	-1	11279304
de	O	-1	11279304
(B@@	O	-1	11279304
N@@	O	-1	11279304
P)	O	-1	11279304
to	O	-1	11279304
determine	O	-1	11279304
whether	O	-1	11279304
B@@	O	-1	11279304
N@@	O	-1	11279304
P	O	-1	11279304
might	O	-1	11279304
ser@@	O	-1	11279304
ve	O	-1	11279304
as	O	-1	11279304
a	O	-1	11279304
sim@@	O	-1	11279304
ple	O	-1	11279304
diagnos@@	O	-1	11279304
tic	O	-1	11279304
indic@@	O	-1	11279304
at@@	O	-1	11279304
or	O	-1	11279304
of	O	-1	11279304
an@@	B-Chemical	D018943	11279304
th@@	I-Chemical	-1	11279304
rac@@	I-Chemical	-1	11279304
y@@	I-Chemical	-1	11279304
cl@@	I-Chemical	-1	11279304
ine	I-Chemical	-1	11279304
-induced	O	-1	11279304
cardi@@	B-Disease	D066126	11279304
otoxicity	I-Disease	-1	11279304
in	O	-1	11279304
patients	O	-1	11279304
with	O	-1	11279304
acute	B-Disease	D015470	11279304
leuk@@	I-Disease	-1	11279304
emia	I-Disease	-1	11279304
treated	O	-1	11279304
with	O	-1	11279304
a	O	-1	11279304
da@@	B-Chemical	D003630	11279304
un@@	I-Chemical	-1	11279304
orub@@	I-Chemical	-1	11279304
icin	I-Chemical	-1	11279304
(	O	-1	11279304
D@@	B-Chemical	D003630	11279304
N@@	I-Chemical	-1	11279304
R	I-Chemical	-1	11279304
)-@@	O	-1	11279304
containing	O	-1	11279304
regimen@@	O	-1	11279304
.	O	-1	11279304
Th@@	O	-1	11279304
ir@@	O	-1	11279304
te@@	O	-1	11279304
en	O	-1	11279304
patients	O	-1	11279304
with	O	-1	11279304
acute	B-Disease	D015470	11279304
leuk@@	I-Disease	-1	11279304
emia	I-Disease	-1	11279304
were	O	-1	11279304
treated	O	-1	11279304
with	O	-1	11279304
a	O	-1	11279304
D@@	B-Chemical	D003630	11279304
N@@	I-Chemical	-1	11279304
R	I-Chemical	-1	11279304
-@@	O	-1	11279304
containing	O	-1	11279304
regimen@@	O	-1	11279304
.	O	-1	11279304
C@@	O	-1	11279304
ardi@@	O	-1	11279304
a@@	O	-1	11279304
c	O	-1	11279304
func@@	O	-1	11279304
tions	O	-1	11279304
were	O	-1	11279304
evaluated	O	-1	11279304
with	O	-1	11279304
radi@@	O	-1	11279304
on@@	O	-1	11279304
uc@@	O	-1	11279304
l@@	O	-1	11279304
ide	O	-1	11279304
angio@@	O	-1	11279304
graph@@	O	-1	11279304
y	O	-1	11279304
before	O	-1	11279304
chemo@@	O	-1	11279304
therap@@	O	-1	11279304
i@@	O	-1	11279304
es.	O	-1	11279304
The	O	-1	11279304
plasma	O	-1	11279304
levels	O	-1	11279304
of	O	-1	11279304
atrial	O	-1	11279304
n@@	O	-1	11279304
atri@@	O	-1	11279304
ure@@	O	-1	11279304
tic	O	-1	11279304
p@@	O	-1	11279304
ep@@	O	-1	11279304
ti@@	O	-1	11279304
de	O	-1	11279304
(A@@	O	-1	11279304
N@@	O	-1	11279304
P)	O	-1	11279304
and	O	-1	11279304
B@@	O	-1	11279304
N@@	O	-1	11279304
P	O	-1	11279304
were	O	-1	11279304
measured	O	-1	11279304
at	O	-1	11279304
the	O	-1	11279304
time	O	-1	11279304
of	O	-1	11279304
radi@@	O	-1	11279304
on@@	O	-1	11279304
uc@@	O	-1	11279304
l@@	O	-1	11279304
ide	O	-1	11279304
angio@@	O	-1	11279304
graph@@	O	-1	11279304
y.	O	-1	11279304
Th@@	O	-1	11279304
ree	O	-1	11279304
patients	O	-1	11279304
developed	O	-1	11279304
con@@	B-Disease	D006333	11279304
g@@	I-Disease	-1	11279304
es@@	I-Disease	-1	11279304
tive	I-Disease	-1	11279304
heart	I-Disease	-1	11279304
failure	I-Disease	-1	11279304
after	O	-1	11279304
the	O	-1	11279304
comple@@	O	-1	11279304
tion	O	-1	11279304
of	O	-1	11279304
chemo@@	O	-1	11279304
therapy.	O	-1	11279304
F@@	O	-1	11279304
i@@	O	-1	11279304
ve	O	-1	11279304
patients	O	-1	11279304
were	O	-1	11279304
diagnos@@	O	-1	11279304
ed	O	-1	11279304
as	O	-1	11279304
ha@@	O	-1	11279304
ving	O	-1	11279304
sub@@	O	-1	11279304
clinical	O	-1	11279304
heart	B-Disease	D006333	11279304
failure	I-Disease	-1	11279304
after	O	-1	11279304
the	O	-1	11279304
comple@@	O	-1	11279304
tion	O	-1	11279304
of	O	-1	11279304
chemo@@	O	-1	11279304
therapy.	O	-1	11279304
The	O	-1	11279304
plasma	O	-1	11279304
levels	O	-1	11279304
of	O	-1	11279304
B@@	O	-1	11279304
N@@	O	-1	11279304
P	O	-1	11279304
in	O	-1	11279304
all	O	-1	11279304
the	O	-1	11279304
patients	O	-1	11279304
with	O	-1	11279304
clinical	O	-1	11279304
and	O	-1	11279304
sub@@	O	-1	11279304
clinical	O	-1	11279304
heart	B-Disease	D006333	11279304
failure	I-Disease	-1	11279304
increased	O	-1	11279304
ab@@	O	-1	11279304
o@@	O	-1	11279304
ve	O	-1	11279304
the	O	-1	11279304
normal	O	-1	11279304
lim@@	O	-1	11279304
it	O	-1	11279304
(@@	O	-1	11279304
40	O	-1	11279304
p@@	O	-1	11279304
g/@@	O	-1	11279304
ml@@	O	-1	11279304
)	O	-1	11279304
before	O	-1	11279304
the	O	-1	11279304
det@@	O	-1	11279304
ection	O	-1	11279304
of	O	-1	11279304
clinical	O	-1	11279304
or	O	-1	11279304
sub@@	O	-1	11279304
clinical	O	-1	11279304
heart	B-Disease	D006333	11279304
failure	I-Disease	-1	11279304
by	O	-1	11279304
radi@@	O	-1	11279304
on@@	O	-1	11279304
uc@@	O	-1	11279304
l@@	O	-1	11279304
ide	O	-1	11279304
angio@@	O	-1	11279304
graph@@	O	-1	11279304
y.	O	-1	11279304
O@@	O	-1	11279304
n	O	-1	11279304
the	O	-1	11279304
other	O	-1	11279304
h@@	O	-1	11279304
and@@	O	-1	11279304
,	O	-1	11279304
B@@	O	-1	11279304
N@@	O	-1	11279304
P	O	-1	11279304
did	O	-1	11279304
not	O	-1	11279304
increase	O	-1	11279304
in	O	-1	11279304
the	O	-1	11279304
patients	O	-1	11279304
without	O	-1	11279304
heart	B-Disease	D006333	11279304
failure	I-Disease	-1	11279304
given	O	-1	11279304
D@@	B-Chemical	D003630	11279304
N@@	I-Chemical	-1	11279304
R	I-Chemical	-1	11279304
,	O	-1	11279304
even	O	-1	11279304
at	O	-1	11279304
more	O	-1	11279304
than	O	-1	11279304
7@@	O	-1	11279304
00	O	-1	11279304
mg/m@@	O	-1	11279304
(2@@	O	-1	11279304
).	O	-1	11279304
The	O	-1	11279304
plasma	O	-1	11279304
level	O	-1	11279304
of	O	-1	11279304
AN@@	O	-1	11279304
P	O	-1	11279304
did	O	-1	11279304
not	O	-1	11279304
al@@	O	-1	11279304
w@@	O	-1	11279304
ays	O	-1	11279304
increase	O	-1	11279304
in	O	-1	11279304
all	O	-1	11279304
the	O	-1	11279304
patients	O	-1	11279304
with	O	-1	11279304
clinical	O	-1	11279304
and	O	-1	11279304
sub@@	O	-1	11279304
clinical	O	-1	11279304
heart	B-Disease	D006333	11279304
failure	I-Disease	-1	11279304
.	O	-1	11279304
These	O	-1	11279304
pre@@	O	-1	11279304
lim@@	O	-1	11279304
inary	O	-1	11279304
results	O	-1	11279304
suggest	O	-1	11279304
that	O	-1	11279304
B@@	O	-1	11279304
N@@	O	-1	11279304
P	O	-1	11279304
may	O	-1	11279304
be	O	-1	11279304
use@@	O	-1	11279304
ful	O	-1	11279304
as	O	-1	11279304
an	O	-1	11279304
early	O	-1	11279304
and	O	-1	11279304
sensitive	O	-1	11279304
indic@@	O	-1	11279304
at@@	O	-1	11279304
or	O	-1	11279304
of	O	-1	11279304
an@@	B-Chemical	D018943	11279304
th@@	I-Chemical	-1	11279304
rac@@	I-Chemical	-1	11279304
y@@	I-Chemical	-1	11279304
cl@@	I-Chemical	-1	11279304
ine	I-Chemical	-1	11279304
-induced	O	-1	11279304
cardi@@	B-Disease	D066126	11279304
otoxicity	I-Disease	-1	11279304
.	O	-1	11279304

An@@	O	-1	19884587
ti@@	O	-1	19884587
bac@@	O	-1	19884587
ter@@	O	-1	19884587
ial	O	-1	19884587
medic@@	O	-1	19884587
ation	O	-1	19884587
use	O	-1	19884587
during	O	-1	19884587
pregn@@	O	-1	19884587
anc@@	O	-1	19884587
y	O	-1	19884587
and	O	-1	19884587
risk	O	-1	19884587
of	O	-1	19884587
b@@	B-Disease	D000014	19884587
ir@@	I-Disease	-1	19884587
th	I-Disease	-1	19884587
def@@	I-Disease	-1	19884587
ects	I-Disease	-1	19884587
:	O	-1	19884587
N@@	O	-1	19884587
ation@@	O	-1	19884587
al	O	-1	19884587
B@@	B-Disease	D000014	19884587
ir@@	I-Disease	-1	19884587
th	I-Disease	-1	19884587
De@@	I-Disease	-1	19884587
f@@	I-Disease	-1	19884587
ects	I-Disease	-1	19884587
Pre@@	O	-1	19884587
ven@@	O	-1	19884587
tion	O	-1	19884587
S@@	O	-1	19884587
t@@	O	-1	19884587
ud@@	O	-1	19884587
y.	O	-1	19884587
OBJECTIVE:	O	-1	19884587
To	O	-1	19884587
estim@@	O	-1	19884587
ate	O	-1	19884587
the	O	-1	19884587
association	O	-1	19884587
between	O	-1	19884587
anti@@	O	-1	19884587
bac@@	O	-1	19884587
ter@@	O	-1	19884587
ial	O	-1	19884587
medic@@	O	-1	19884587
ations	O	-1	19884587
and	O	-1	19884587
sel@@	O	-1	19884587
ected	O	-1	19884587
b@@	B-Disease	D000014	19884587
ir@@	I-Disease	-1	19884587
th	I-Disease	-1	19884587
def@@	I-Disease	-1	19884587
ects	I-Disease	-1	19884587
.	O	-1	19884587
D@@	O	-1	19884587
ES@@	O	-1	19884587
I@@	O	-1	19884587
G@@	O	-1	19884587
N@@	O	-1	19884587
,	O	-1	19884587
S@@	O	-1	19884587
ET@@	O	-1	19884587
TI@@	O	-1	19884587
N@@	O	-1	19884587
G@@	O	-1	19884587
,	O	-1	19884587
AN@@	O	-1	19884587
D	O	-1	19884587
PA@@	O	-1	19884587
R@@	O	-1	19884587
TI@@	O	-1	19884587
CI@@	O	-1	19884587
PA@@	O	-1	19884587
N@@	O	-1	19884587
T@@	O	-1	19884587
S:	O	-1	19884587
P@@	O	-1	19884587
o@@	O	-1	19884587
pul@@	O	-1	19884587
ation@@	O	-1	19884587
-@@	O	-1	19884587
bas@@	O	-1	19884587
ed,	O	-1	19884587
mul@@	O	-1	19884587
tis@@	O	-1	19884587
it@@	O	-1	19884587
e,	O	-1	19884587
cas@@	O	-1	19884587
e-@@	O	-1	19884587
control	O	-1	19884587
study	O	-1	19884587
of	O	-1	19884587
women	O	-1	19884587
who	O	-1	19884587
had	O	-1	19884587
pregn@@	O	-1	19884587
an@@	O	-1	19884587
ci@@	O	-1	19884587
es	O	-1	19884587
affected	O	-1	19884587
by	O	-1	19884587
1	O	-1	19884587
of	O	-1	19884587
more	O	-1	19884587
than	O	-1	19884587
30	O	-1	19884587
e@@	O	-1	19884587
li@@	O	-1	19884587
gi@@	O	-1	19884587
ble	O	-1	19884587
major	O	-1	19884587
b@@	B-Disease	D000014	19884587
ir@@	I-Disease	-1	19884587
th	I-Disease	-1	19884587
def@@	I-Disease	-1	19884587
ects	I-Disease	-1	19884587
identi@@	O	-1	19884587
fied	O	-1	19884587
vi@@	O	-1	19884587
a	O	-1	19884587
b@@	B-Disease	D000014	19884587
ir@@	I-Disease	-1	19884587
th	I-Disease	-1	19884587
def@@	I-Disease	-1	19884587
ect	I-Disease	-1	19884587
sur@@	O	-1	19884587
ve@@	O	-1	19884587
ill@@	O	-1	19884587
ance	O	-1	19884587
pro@@	O	-1	19884587
gram@@	O	-1	19884587
s	O	-1	19884587
in	O	-1	19884587
10	O	-1	19884587
st@@	O	-1	19884587
ates	O	-1	19884587
(n	O	-1	19884587
=	O	-1	19884587
13	O	-1	19884587
1@@	O	-1	19884587
55@@	O	-1	19884587
)	O	-1	19884587
and	O	-1	19884587
control	O	-1	19884587
women	O	-1	19884587
random@@	O	-1	19884587
ly	O	-1	19884587
sel@@	O	-1	19884587
ected	O	-1	19884587
from	O	-1	19884587
the	O	-1	19884587
same	O	-1	19884587
ge@@	O	-1	19884587
ograph@@	O	-1	19884587
ical	O	-1	19884587
regi@@	O	-1	19884587
ons	O	-1	19884587
(n	O	-1	19884587
=	O	-1	19884587
4@@	O	-1	19884587
9@@	O	-1	19884587
4@@	O	-1	19884587
1).	O	-1	19884587
MA@@	O	-1	19884587
I@@	O	-1	19884587
N	O	-1	19884587
E@@	O	-1	19884587
X@@	O	-1	19884587
P@@	O	-1	19884587
O@@	O	-1	19884587
S@@	O	-1	19884587
U@@	O	-1	19884587
R@@	O	-1	19884587
E:	O	-1	19884587
Re@@	O	-1	19884587
por@@	O	-1	19884587
ted	O	-1	19884587
mat@@	O	-1	19884587
er@@	O	-1	19884587
n@@	O	-1	19884587
al	O	-1	19884587
use	O	-1	19884587
of	O	-1	19884587
anti@@	O	-1	19884587
bac@@	O	-1	19884587
ter@@	O	-1	19884587
i@@	O	-1	19884587
als	O	-1	19884587
(@@	O	-1	19884587
1	O	-1	19884587
mon@@	O	-1	19884587
th	O	-1	19884587
before	O	-1	19884587
pregn@@	O	-1	19884587
anc@@	O	-1	19884587
y	O	-1	19884587
through	O	-1	19884587
the	O	-1	19884587
end	O	-1	19884587
of	O	-1	19884587
the	O	-1	19884587
first	O	-1	19884587
tri@@	O	-1	19884587
me@@	O	-1	19884587
ster@@	O	-1	19884587
).	O	-1	19884587
MA@@	O	-1	19884587
I@@	O	-1	19884587
N	O	-1	19884587
O@@	O	-1	19884587
U@@	O	-1	19884587
T@@	O	-1	19884587
CO@@	O	-1	19884587
M@@	O	-1	19884587
E	O	-1	19884587
M@@	O	-1	19884587
E@@	O	-1	19884587
A@@	O	-1	19884587
S@@	O	-1	19884587
U@@	O	-1	19884587
R@@	O	-1	19884587
E:	O	-1	19884587
O@@	O	-1	19884587
d@@	O	-1	19884587
ds	O	-1	19884587
rati@@	O	-1	19884587
o@@	O	-1	19884587
s	O	-1	19884587
(@@	O	-1	19884587
O@@	O	-1	19884587
R@@	O	-1	19884587
s)	O	-1	19884587
meas@@	O	-1	19884587
uring	O	-1	19884587
the	O	-1	19884587
association	O	-1	19884587
between	O	-1	19884587
anti@@	O	-1	19884587
bac@@	O	-1	19884587
ter@@	O	-1	19884587
ial	O	-1	19884587
use	O	-1	19884587
and	O	-1	19884587
sel@@	O	-1	19884587
ected	O	-1	19884587
b@@	B-Disease	D000014	19884587
ir@@	I-Disease	-1	19884587
th	I-Disease	-1	19884587
def@@	I-Disease	-1	19884587
ects	I-Disease	-1	19884587
adjust@@	O	-1	19884587
ed	O	-1	19884587
for	O	-1	19884587
potential	O	-1	19884587
conf@@	O	-1	19884587
oun@@	O	-1	19884587
der@@	O	-1	19884587
s.	O	-1	19884587
RESULTS:	O	-1	19884587
The	O	-1	19884587
reported	O	-1	19884587
use	O	-1	19884587
of	O	-1	19884587
anti@@	O	-1	19884587
bac@@	O	-1	19884587
ter@@	O	-1	19884587
i@@	O	-1	19884587
als	O	-1	19884587
increased	O	-1	19884587
during	O	-1	19884587
pregn@@	O	-1	19884587
anc@@	O	-1	19884587
y,	O	-1	19884587
pe@@	O	-1	19884587
ak@@	O	-1	19884587
ing	O	-1	19884587
during	O	-1	19884587
the	O	-1	19884587
thir@@	O	-1	19884587
d	O	-1	19884587
month@@	O	-1	19884587
.	O	-1	19884587
S@@	B-Chemical	D013449	19884587
ul@@	I-Chemical	-1	19884587
f@@	I-Chemical	-1	19884587
on@@	I-Chemical	-1	19884587
ami@@	I-Chemical	-1	19884587
des	I-Chemical	-1	19884587
were	O	-1	19884587
associated	O	-1	19884587
with	O	-1	19884587
an@@	B-Disease	D000757	19884587
encephal@@	I-Disease	-1	19884587
y	I-Disease	-1	19884587
(@@	O	-1	19884587
adjust@@	O	-1	19884587
ed	O	-1	19884587
O@@	O	-1	19884587
R	O	-1	19884587
[@@	O	-1	19884587
A@@	O	-1	19884587
O@@	O	-1	19884587
R@@	O	-1	19884587
]	O	-1	19884587
=	O	-1	19884587
3.@@	O	-1	19884587
4@@	O	-1	19884587
;	O	-1	19884587
95%	O	-1	19884587
conf@@	O	-1	19884587
idence	O	-1	19884587
interv@@	O	-1	19884587
al	O	-1	19884587
[@@	O	-1	19884587
CI@@	O	-1	19884587
]@@	O	-1	19884587
,	O	-1	19884587
1.@@	O	-1	19884587
3-@@	O	-1	19884587
8.@@	O	-1	19884587
8@@	O	-1	19884587
),	O	-1	19884587
hypo@@	B-Disease	D018636	19884587
plas@@	I-Disease	-1	19884587
tic	I-Disease	-1	19884587
left	I-Disease	-1	19884587
heart	I-Disease	-1	19884587
syndrome	I-Disease	-1	19884587
(A@@	O	-1	19884587
O@@	O	-1	19884587
R	O	-1	19884587
=	O	-1	19884587
3.@@	O	-1	19884587
2@@	O	-1	19884587
;	O	-1	19884587
95%	O	-1	19884587
CI@@	O	-1	19884587
,	O	-1	19884587
1.@@	O	-1	19884587
3-@@	O	-1	19884587
7.@@	O	-1	19884587
6@@	O	-1	19884587
),	O	-1	19884587
co@@	B-Disease	D001017	19884587
arc@@	I-Disease	-1	19884587
t@@	I-Disease	-1	19884587
ation	I-Disease	-1	19884587
of	I-Disease	-1	19884587
the	I-Disease	-1	19884587
a@@	I-Disease	-1	19884587
ort@@	I-Disease	-1	19884587
a	I-Disease	-1	19884587
(A@@	O	-1	19884587
O@@	O	-1	19884587
R	O	-1	19884587
=	O	-1	19884587
2.@@	O	-1	19884587
7@@	O	-1	19884587
;	O	-1	19884587
95%	O	-1	19884587
CI@@	O	-1	19884587
,	O	-1	19884587
1.@@	O	-1	19884587
3-@@	O	-1	19884587
5.@@	O	-1	19884587
6@@	O	-1	19884587
),	O	-1	19884587
ch@@	B-Disease	D002754	19884587
o@@	I-Disease	-1	19884587
an@@	I-Disease	-1	19884587
al	I-Disease	-1	19884587
at@@	I-Disease	-1	19884587
re@@	I-Disease	-1	19884587
sia	I-Disease	-1	19884587
(A@@	O	-1	19884587
O@@	O	-1	19884587
R	O	-1	19884587
=	O	-1	19884587
8.@@	O	-1	19884587
0@@	O	-1	19884587
;	O	-1	19884587
95%	O	-1	19884587
CI@@	O	-1	19884587
,	O	-1	19884587
2.@@	O	-1	19884587
7-@@	O	-1	19884587
2@@	O	-1	19884587
3.@@	O	-1	19884587
5@@	O	-1	19884587
),	O	-1	19884587
trans@@	B-Disease	D017880	19884587
verse	I-Disease	-1	19884587
lim@@	I-Disease	-1	19884587
b	I-Disease	-1	19884587
defici@@	I-Disease	-1	19884587
ency	I-Disease	-1	19884587
(A@@	O	-1	19884587
O@@	O	-1	19884587
R	O	-1	19884587
=	O	-1	19884587
2.@@	O	-1	19884587
5@@	O	-1	19884587
;	O	-1	19884587
95%	O	-1	19884587
CI@@	O	-1	19884587
,	O	-1	19884587
1.@@	O	-1	19884587
0-@@	O	-1	19884587
5.@@	O	-1	19884587
9@@	O	-1	19884587
),	O	-1	19884587
and	O	-1	19884587
dia@@	B-Disease	D006548	19884587
ph@@	I-Disease	-1	19884587
ra@@	I-Disease	-1	19884587
g@@	I-Disease	-1	19884587
m@@	I-Disease	-1	19884587
atic	I-Disease	-1	19884587
h@@	I-Disease	-1	19884587
er@@	I-Disease	-1	19884587
n@@	I-Disease	-1	19884587
ia	I-Disease	-1	19884587
(A@@	O	-1	19884587
O@@	O	-1	19884587
R	O	-1	19884587
=	O	-1	19884587
2.@@	O	-1	19884587
4@@	O	-1	19884587
;	O	-1	19884587
95%	O	-1	19884587
CI@@	O	-1	19884587
,	O	-1	19884587
1.@@	O	-1	19884587
1-@@	O	-1	19884587
5.@@	O	-1	19884587
4@@	O	-1	19884587
).	O	-1	19884587
N@@	B-Chemical	D009582	19884587
it@@	I-Chemical	-1	19884587
ro@@	I-Chemical	-1	19884587
f@@	I-Chemical	-1	19884587
ur@@	I-Chemical	-1	19884587
an@@	I-Chemical	-1	19884587
to@@	I-Chemical	-1	19884587
ins	I-Chemical	-1	19884587
were	O	-1	19884587
associated	O	-1	19884587
with	O	-1	19884587
an@@	B-Disease	D000853	19884587
oph@@	I-Disease	-1	19884587
thal@@	I-Disease	-1	19884587
mia	I-Disease	-1	19884587
or	O	-1	19884587
micro@@	B-Disease	D008850	19884587
ph@@	I-Disease	-1	19884587
thal@@	I-Disease	-1	19884587
mo@@	I-Disease	-1	19884587
s	I-Disease	-1	19884587
(A@@	O	-1	19884587
O@@	O	-1	19884587
R	O	-1	19884587
=	O	-1	19884587
3.@@	O	-1	19884587
7@@	O	-1	19884587
;	O	-1	19884587
95%	O	-1	19884587
CI@@	O	-1	19884587
,	O	-1	19884587
1.@@	O	-1	19884587
1@@	O	-1	19884587
-1@@	O	-1	19884587
2.@@	O	-1	19884587
2@@	O	-1	19884587
),	O	-1	19884587
hypo@@	B-Disease	D018636	19884587
plas@@	I-Disease	-1	19884587
tic	I-Disease	-1	19884587
left	I-Disease	-1	19884587
heart	I-Disease	-1	19884587
syndrome	I-Disease	-1	19884587
(A@@	O	-1	19884587
O@@	O	-1	19884587
R	O	-1	19884587
=	O	-1	19884587
4.@@	O	-1	19884587
2@@	O	-1	19884587
;	O	-1	19884587
95%	O	-1	19884587
CI@@	O	-1	19884587
,	O	-1	19884587
1.@@	O	-1	19884587
9@@	O	-1	19884587
-@@	O	-1	19884587
9.@@	O	-1	19884587
1),	O	-1	19884587
atrial	B-Disease	D006344	19884587
se@@	I-Disease	-1	19884587
pt@@	I-Disease	-1	19884587
al	I-Disease	-1	19884587
def@@	I-Disease	-1	19884587
ects	I-Disease	-1	19884587
(A@@	O	-1	19884587
O@@	O	-1	19884587
R	O	-1	19884587
=	O	-1	19884587
1.@@	O	-1	19884587
9@@	O	-1	19884587
;	O	-1	19884587
95%	O	-1	19884587
CI@@	O	-1	19884587
,	O	-1	19884587
1.@@	O	-1	19884587
1-@@	O	-1	19884587
3.@@	O	-1	19884587
4@@	O	-1	19884587
),	O	-1	19884587
and	O	-1	19884587
c@@	B-Disease	D002971	19884587
left	I-Disease	-1	19884587
li@@	I-Disease	-1	19884587
p	I-Disease	-1	19884587
with	O	-1	19884587
c@@	B-Disease	D002972	19884587
left	I-Disease	-1	19884587
p@@	I-Disease	-1	19884587
al@@	I-Disease	-1	19884587
ate	I-Disease	-1	19884587
(A@@	O	-1	19884587
O@@	O	-1	19884587
R	O	-1	19884587
=	O	-1	19884587
2.@@	O	-1	19884587
1@@	O	-1	19884587
;	O	-1	19884587
95%	O	-1	19884587
CI@@	O	-1	19884587
,	O	-1	19884587
1.@@	O	-1	19884587
2-@@	O	-1	19884587
3.@@	O	-1	19884587
9@@	O	-1	19884587
).	O	-1	19884587
O@@	O	-1	19884587
ther	O	-1	19884587
anti@@	O	-1	19884587
bac@@	O	-1	19884587
ter@@	O	-1	19884587
ial	O	-1	19884587
agents	O	-1	19884587
that	O	-1	19884587
showed	O	-1	19884587
associ@@	O	-1	19884587
ations	O	-1	19884587
included	O	-1	19884587
ery@@	B-Chemical	D004917	19884587
throm@@	I-Chemical	-1	19884587
yc@@	I-Chemical	-1	19884587
ins	I-Chemical	-1	19884587
(@@	O	-1	19884587
2	O	-1	19884587
def@@	O	-1	19884587
ect@@	O	-1	19884587
s),	O	-1	19884587
pen@@	B-Chemical	D010406	19884587
icill@@	I-Chemical	-1	19884587
ins	I-Chemical	-1	19884587
(@@	O	-1	19884587
1	O	-1	19884587
def@@	O	-1	19884587
ect@@	O	-1	19884587
),	O	-1	19884587
ce@@	B-Chemical	D002511	19884587
ph@@	I-Chemical	-1	19884587
al@@	I-Chemical	-1	19884587
os@@	I-Chemical	-1	19884587
por@@	I-Chemical	-1	19884587
ins	I-Chemical	-1	19884587
(@@	O	-1	19884587
1	O	-1	19884587
def@@	O	-1	19884587
ect@@	O	-1	19884587
),	O	-1	19884587
and	O	-1	19884587
qu@@	B-Chemical	D015363	19884587
in@@	I-Chemical	-1	19884587
ol@@	I-Chemical	-1	19884587
on@@	I-Chemical	-1	19884587
es	I-Chemical	-1	19884587
(@@	O	-1	19884587
1	O	-1	19884587
def@@	O	-1	19884587
ect@@	O	-1	19884587
).	O	-1	19884587
CONCLUSIONS:	O	-1	19884587
Re@@	O	-1	19884587
ass@@	O	-1	19884587
ur@@	O	-1	19884587
ing@@	O	-1	19884587
ly,	O	-1	19884587
pen@@	B-Chemical	D010406	19884587
icill@@	I-Chemical	-1	19884587
ins	I-Chemical	-1	19884587
,	O	-1	19884587
ery@@	B-Chemical	D004917	19884587
throm@@	I-Chemical	-1	19884587
yc@@	I-Chemical	-1	19884587
ins	I-Chemical	-1	19884587
,	O	-1	19884587
and	O	-1	19884587
ce@@	B-Chemical	D002511	19884587
ph@@	I-Chemical	-1	19884587
al@@	I-Chemical	-1	19884587
os@@	I-Chemical	-1	19884587
por@@	I-Chemical	-1	19884587
ins	I-Chemical	-1	19884587
,	O	-1	19884587
although	O	-1	19884587
used	O	-1	19884587
common@@	O	-1	19884587
ly	O	-1	19884587
by	O	-1	19884587
pregn@@	O	-1	19884587
ant	O	-1	19884587
wom@@	O	-1	19884587
en@@	O	-1	19884587
,	O	-1	19884587
were	O	-1	19884587
not	O	-1	19884587
associated	O	-1	19884587
with	O	-1	19884587
man@@	O	-1	19884587
y	O	-1	19884587
b@@	B-Disease	D000014	19884587
ir@@	I-Disease	-1	19884587
th	I-Disease	-1	19884587
def@@	I-Disease	-1	19884587
ects	I-Disease	-1	19884587
.	O	-1	19884587
S@@	B-Chemical	D013449	19884587
ul@@	I-Chemical	-1	19884587
f@@	I-Chemical	-1	19884587
on@@	I-Chemical	-1	19884587
ami@@	I-Chemical	-1	19884587
des	I-Chemical	-1	19884587
and	O	-1	19884587
nitro@@	B-Chemical	D009582	19884587
f@@	I-Chemical	-1	19884587
ur@@	I-Chemical	-1	19884587
an@@	I-Chemical	-1	19884587
to@@	I-Chemical	-1	19884587
ins	I-Chemical	-1	19884587
were	O	-1	19884587
associated	O	-1	19884587
with	O	-1	19884587
several	O	-1	19884587
b@@	B-Disease	D000014	19884587
ir@@	I-Disease	-1	19884587
th	I-Disease	-1	19884587
def@@	I-Disease	-1	19884587
ects	I-Disease	-1	19884587
,	O	-1	19884587
indicating	O	-1	19884587
a	O	-1	19884587
need	O	-1	19884587
for	O	-1	19884587
addi@@	O	-1	19884587
tional	O	-1	19884587
s@@	O	-1	19884587
c@@	O	-1	19884587
r@@	O	-1	19884587
ut@@	O	-1	19884587
in@@	O	-1	19884587
y.	O	-1	19884587

In@@	O	-1	3970039
c@@	O	-1	3970039
idence	O	-1	3970039
of	O	-1	3970039
ne@@	B-Disease	D009369	3970039
o@@	I-Disease	-1	3970039
plas@@	I-Disease	-1	3970039
ms	I-Disease	-1	3970039
in	O	-1	3970039
patients	O	-1	3970039
with	O	-1	3970039
r@@	B-Disease	D001172	3970039
he@@	I-Disease	-1	3970039
um@@	I-Disease	-1	3970039
at@@	I-Disease	-1	3970039
oid	I-Disease	-1	3970039
arth@@	I-Disease	-1	3970039
ritis	I-Disease	-1	3970039
exposed	O	-1	3970039
to	O	-1	3970039
different	O	-1	3970039
treatment	O	-1	3970039
regimen@@	O	-1	3970039
s.	O	-1	3970039
Im@@	O	-1	3970039
mun@@	O	-1	3970039
osup@@	O	-1	3970039
pressive	O	-1	3970039
drugs	O	-1	3970039
have	O	-1	3970039
been	O	-1	3970039
used	O	-1	3970039
during	O	-1	3970039
the	O	-1	3970039
las@@	O	-1	3970039
t	O	-1	3970039
30	O	-1	3970039
years	O	-1	3970039
in	O	-1	3970039
treatment	O	-1	3970039
of	O	-1	3970039
patients	O	-1	3970039
with	O	-1	3970039
severe	O	-1	3970039
r@@	B-Disease	D001172	3970039
he@@	I-Disease	-1	3970039
um@@	I-Disease	-1	3970039
at@@	I-Disease	-1	3970039
oid	I-Disease	-1	3970039
arth@@	I-Disease	-1	3970039
ritis	I-Disease	-1	3970039
.	O	-1	3970039
The	O	-1	3970039
drugs	O	-1	3970039
common@@	O	-1	3970039
ly	O	-1	3970039
used	O	-1	3970039
are	O	-1	3970039
cyclophosph@@	B-Chemical	D003520	3970039
amide	I-Chemical	-1	3970039
and	O	-1	3970039
chlor@@	B-Chemical	D002699	3970039
am@@	I-Chemical	-1	3970039
b@@	I-Chemical	-1	3970039
uc@@	I-Chemical	-1	3970039
il	I-Chemical	-1	3970039
(	O	-1	3970039
al@@	B-Chemical	D000477	3970039
k@@	I-Chemical	-1	3970039
yl@@	I-Chemical	-1	3970039
ating	I-Chemical	-1	3970039
agents	I-Chemical	-1	3970039
),	O	-1	3970039
az@@	B-Chemical	D001379	3970039
ath@@	I-Chemical	-1	3970039
io@@	I-Chemical	-1	3970039
p@@	I-Chemical	-1	3970039
rine	I-Chemical	-1	3970039
(	O	-1	3970039
pur@@	B-Chemical	D011687	3970039
ine	I-Chemical	-1	3970039
an@@	O	-1	3970039
alo@@	O	-1	3970039
gu@@	O	-1	3970039
e@@	O	-1	3970039
),	O	-1	3970039
and	O	-1	3970039
meth@@	B-Chemical	D008727	3970039
ot@@	I-Chemical	-1	3970039
re@@	I-Chemical	-1	3970039
x@@	I-Chemical	-1	3970039
ate	I-Chemical	-1	3970039
(	O	-1	3970039
fol@@	B-Chemical	D005492	3970039
ic	I-Chemical	-1	3970039
acid	I-Chemical	-1	3970039
an@@	O	-1	3970039
alo@@	O	-1	3970039
gu@@	O	-1	3970039
e@@	O	-1	3970039
).	O	-1	3970039
There	O	-1	3970039
is	O	-1	3970039
evidence	O	-1	3970039
that	O	-1	3970039
all	O	-1	3970039
four	O	-1	3970039
immunosup@@	O	-1	3970039
pressive	O	-1	3970039
drugs	O	-1	3970039
can	O	-1	3970039
re@@	O	-1	3970039
duce	O	-1	3970039
sy@@	B-Disease	D013585	3970039
no@@	I-Disease	-1	3970039
vi@@	I-Disease	-1	3970039
tis	I-Disease	-1	3970039
,	O	-1	3970039
but	O	-1	3970039
disease	O	-1	3970039
activity	O	-1	3970039
al@@	O	-1	3970039
most	O	-1	3970039
al@@	O	-1	3970039
w@@	O	-1	3970039
ays	O	-1	3970039
recur@@	O	-1	3970039
s	O	-1	3970039
after	O	-1	3970039
therapy	O	-1	3970039
is	O	-1	3970039
sto@@	O	-1	3970039
pp@@	O	-1	3970039
ed.	O	-1	3970039
S@@	O	-1	3970039
inc@@	O	-1	3970039
e	O	-1	3970039
adverse	O	-1	3970039
reactions	O	-1	3970039
are	O	-1	3970039
frequ@@	O	-1	3970039
ent@@	O	-1	3970039
,	O	-1	3970039
less	O	-1	3970039
than	O	-1	3970039
50	O	-1	3970039
perc@@	O	-1	3970039
ent	O	-1	3970039
of	O	-1	3970039
patients	O	-1	3970039
are	O	-1	3970039
able	O	-1	3970039
to	O	-1	3970039
continu@@	O	-1	3970039
e	O	-1	3970039
a	O	-1	3970039
partic@@	O	-1	3970039
ular	O	-1	3970039
drug	O	-1	3970039
for	O	-1	3970039
more	O	-1	3970039
than	O	-1	3970039
one	O	-1	3970039
year@@	O	-1	3970039
.	O	-1	3970039
S@@	O	-1	3970039
inc@@	O	-1	3970039
e	O	-1	3970039
it	O	-1	3970039
tak@@	O	-1	3970039
es	O	-1	3970039
three	O	-1	3970039
to	O	-1	3970039
12	O	-1	3970039
months	O	-1	3970039
to	O	-1	3970039
achi@@	O	-1	3970039
e@@	O	-1	3970039
ve	O	-1	3970039
maxim@@	O	-1	3970039
al	O	-1	3970039
effect@@	O	-1	3970039
s,	O	-1	3970039
those	O	-1	3970039
patients	O	-1	3970039
who	O	-1	3970039
are	O	-1	3970039
un@@	O	-1	3970039
able	O	-1	3970039
to	O	-1	3970039
continu@@	O	-1	3970039
e	O	-1	3970039
the	O	-1	3970039
drug	O	-1	3970039
recei@@	O	-1	3970039
ve	O	-1	3970039
lit@@	O	-1	3970039
t@@	O	-1	3970039
le	O	-1	3970039
ben@@	O	-1	3970039
e@@	O	-1	3970039
fi@@	O	-1	3970039
t	O	-1	3970039
from	O	-1	3970039
it@@	O	-1	3970039
.	O	-1	3970039
Patients	O	-1	3970039
treated	O	-1	3970039
with	O	-1	3970039
al@@	B-Chemical	D000477	3970039
k@@	I-Chemical	-1	3970039
yl@@	I-Chemical	-1	3970039
ating	I-Chemical	-1	3970039
agents	I-Chemical	-1	3970039
have	O	-1	3970039
an	O	-1	3970039
increased	O	-1	3970039
risk	O	-1	3970039
of	O	-1	3970039
development	O	-1	3970039
of	O	-1	3970039
acute	B-Disease	D015470	3970039
non@@	I-Disease	-1	3970039
lymph@@	I-Disease	-1	3970039
ocy@@	I-Disease	-1	3970039
tic	I-Disease	-1	3970039
leuk@@	I-Disease	-1	3970039
emia	I-Disease	-1	3970039
,	O	-1	3970039
and	O	-1	3970039
both	O	-1	3970039
al@@	B-Chemical	D000477	3970039
k@@	I-Chemical	-1	3970039
yl@@	I-Chemical	-1	3970039
ating	I-Chemical	-1	3970039
agents	I-Chemical	-1	3970039
and	O	-1	3970039
az@@	B-Chemical	D001379	3970039
ath@@	I-Chemical	-1	3970039
io@@	I-Chemical	-1	3970039
p@@	I-Chemical	-1	3970039
rine	I-Chemical	-1	3970039
are	O	-1	3970039
associated	O	-1	3970039
with	O	-1	3970039
the	O	-1	3970039
development	O	-1	3970039
of	O	-1	3970039
non-@@	B-Disease	D008228	3970039
Ho@@	I-Disease	-1	3970039
d@@	I-Disease	-1	3970039
g@@	I-Disease	-1	3970039
kin@@	I-Disease	-1	3970039
's	I-Disease	-1	3970039
lymph@@	I-Disease	-1	3970039
oma	I-Disease	-1	3970039
.	O	-1	3970039
C@@	B-Chemical	D003520	3970039
yc@@	I-Chemical	-1	3970039
lo@@	I-Chemical	-1	3970039
phosph@@	I-Chemical	-1	3970039
amide	I-Chemical	-1	3970039
therapy	O	-1	3970039
increases	O	-1	3970039
the	O	-1	3970039
risk	O	-1	3970039
of	O	-1	3970039
carcin@@	B-Disease	D001749	3970039
oma	I-Disease	-1	3970039
of	I-Disease	-1	3970039
the	I-Disease	-1	3970039
bladder	I-Disease	-1	3970039
carcin@@	B-Disease	D002277	3970039
oma	I-Disease	-1	3970039
of	I-Disease	-1	3970039
the	I-Disease	-1	3970039
bladder	I-Disease	-1	3970039
.	O	-1	3970039
There	O	-1	3970039
have	O	-1	3970039
been	O	-1	3970039
several	O	-1	3970039
long-term	O	-1	3970039
studies	O	-1	3970039
of	O	-1	3970039
patients	O	-1	3970039
with	O	-1	3970039
r@@	B-Disease	D001172	3970039
he@@	I-Disease	-1	3970039
um@@	I-Disease	-1	3970039
at@@	I-Disease	-1	3970039
oid	I-Disease	-1	3970039
arth@@	I-Disease	-1	3970039
ritis	I-Disease	-1	3970039
treated	O	-1	3970039
with	O	-1	3970039
az@@	B-Chemical	D001379	3970039
ath@@	I-Chemical	-1	3970039
io@@	I-Chemical	-1	3970039
p@@	I-Chemical	-1	3970039
rine	I-Chemical	-1	3970039
and	O	-1	3970039
cyclophosph@@	B-Chemical	D003520	3970039
amide	I-Chemical	-1	3970039
and	O	-1	3970039
the	O	-1	3970039
incidence	O	-1	3970039
of	O	-1	3970039
most	O	-1	3970039
of	O	-1	3970039
the	O	-1	3970039
common	O	-1	3970039
canc@@	B-Disease	D009369	3970039
ers	I-Disease	-1	3970039
is	O	-1	3970039
not	O	-1	3970039
increas@@	O	-1	3970039
ed.	O	-1	3970039
D@@	O	-1	3970039
at@@	O	-1	3970039
a	O	-1	3970039
on	O	-1	3970039
the	O	-1	3970039
possible	O	-1	3970039
increased	O	-1	3970039
risk	O	-1	3970039
of	O	-1	3970039
mal@@	B-Disease	D009369	3970039
i@@	I-Disease	-1	3970039
gn@@	I-Disease	-1	3970039
anc@@	I-Disease	-1	3970039
y	I-Disease	-1	3970039
in	O	-1	3970039
r@@	B-Disease	D001172	3970039
he@@	I-Disease	-1	3970039
um@@	I-Disease	-1	3970039
at@@	I-Disease	-1	3970039
oid	I-Disease	-1	3970039
arth@@	I-Disease	-1	3970039
ritis	I-Disease	-1	3970039
are	O	-1	3970039
sti@@	O	-1	3970039
ll	O	-1	3970039
being	O	-1	3970039
coll@@	O	-1	3970039
ect@@	O	-1	3970039
ed,	O	-1	3970039
and	O	-1	3970039
un@@	O	-1	3970039
ti@@	O	-1	3970039
l	O	-1	3970039
further	O	-1	3970039
inf@@	O	-1	3970039
orm@@	O	-1	3970039
ation	O	-1	3970039
is	O	-1	3970039
av@@	O	-1	3970039
ail@@	O	-1	3970039
able@@	O	-1	3970039
,	O	-1	3970039
the	O	-1	3970039
use	O	-1	3970039
of	O	-1	3970039
immunosup@@	O	-1	3970039
pressive	O	-1	3970039
drug@@	O	-1	3970039
s,	O	-1	3970039
partic@@	O	-1	3970039
ul@@	O	-1	3970039
arly	O	-1	3970039
al@@	B-Chemical	D000477	3970039
k@@	I-Chemical	-1	3970039
yl@@	I-Chemical	-1	3970039
ating	I-Chemical	-1	3970039
agents	I-Chemical	-1	3970039
,	O	-1	3970039
in	O	-1	3970039
the	O	-1	3970039
treatment	O	-1	3970039
of	O	-1	3970039
r@@	B-Disease	D001172	3970039
he@@	I-Disease	-1	3970039
um@@	I-Disease	-1	3970039
at@@	I-Disease	-1	3970039
oid	I-Disease	-1	3970039
arth@@	I-Disease	-1	3970039
ritis	I-Disease	-1	3970039
should	O	-1	3970039
be	O	-1	3970039
res@@	O	-1	3970039
er@@	O	-1	3970039
ved	O	-1	3970039
for	O	-1	3970039
patients	O	-1	3970039
with	O	-1	3970039
severe	O	-1	3970039
progressive	O	-1	3970039
disease	O	-1	3970039
or	O	-1	3970039
lif@@	O	-1	3970039
e-@@	O	-1	3970039
th@@	O	-1	3970039
reat@@	O	-1	3970039
en@@	O	-1	3970039
ing	O	-1	3970039
complic@@	O	-1	3970039
ations.	O	-1	3970039

P@@	O	-1	424937
at@@	O	-1	424937
tern@@	O	-1	424937
s	O	-1	424937
of	O	-1	424937
hepatic	B-Disease	D056486	424937
injury	I-Disease	-1	424937
induced	O	-1	424937
by	O	-1	424937
methyl@@	B-Chemical	D008750	424937
dopa	I-Chemical	-1	424937
.	O	-1	424937
T@@	O	-1	424937
we@@	O	-1	424937
l@@	O	-1	424937
ve	O	-1	424937
patients	O	-1	424937
with	O	-1	424937
liver	B-Disease	D008107	424937
disease	I-Disease	-1	424937
related	O	-1	424937
to	O	-1	424937
methyl@@	B-Chemical	D008750	424937
dopa	I-Chemical	-1	424937
were	O	-1	424937
seen	O	-1	424937
between	O	-1	424937
19@@	O	-1	424937
6@@	O	-1	424937
7	O	-1	424937
and	O	-1	424937
19@@	O	-1	424937
7@@	O	-1	424937
7@@	O	-1	424937
.	O	-1	424937
I@@	O	-1	424937
ll@@	O	-1	424937
ness	O	-1	424937
occurred	O	-1	424937
within	O	-1	424937
1-@@	O	-1	424937
-@@	O	-1	424937
9	O	-1	424937
weeks	O	-1	424937
of	O	-1	424937
comm@@	O	-1	424937
ence@@	O	-1	424937
ment	O	-1	424937
of	O	-1	424937
therapy	O	-1	424937
in	O	-1	424937
9	O	-1	424937
patients,	O	-1	424937
the	O	-1	424937
remain@@	O	-1	424937
ing	O	-1	424937
3	O	-1	424937
patients	O	-1	424937
ha@@	O	-1	424937
ving	O	-1	424937
received	O	-1	424937
the	O	-1	424937
drug	O	-1	424937
for	O	-1	424937
13	O	-1	424937
month@@	O	-1	424937
s,	O	-1	424937
15	O	-1	424937
months	O	-1	424937
and	O	-1	424937
7	O	-1	424937
years	O	-1	424937
before	O	-1	424937
experienc@@	O	-1	424937
ing	O	-1	424937
symptom@@	O	-1	424937
s.	O	-1	424937
J@@	B-Disease	D007565	424937
a@@	I-Disease	-1	424937
un@@	I-Disease	-1	424937
dic@@	I-Disease	-1	424937
e	I-Disease	-1	424937
with	O	-1	424937
ten@@	O	-1	424937
der	O	-1	424937
hepat@@	B-Disease	D006529	424937
o@@	I-Disease	-1	424937
me@@	I-Disease	-1	424937
g@@	I-Disease	-1	424937
al@@	I-Disease	-1	424937
y	I-Disease	-1	424937
,	O	-1	424937
us@@	O	-1	424937
ually	O	-1	424937
pre@@	O	-1	424937
ce@@	O	-1	424937
ded	O	-1	424937
by	O	-1	424937
symptoms	O	-1	424937
of	O	-1	424937
mal@@	O	-1	424937
a@@	O	-1	424937
i@@	O	-1	424937
se@@	O	-1	424937
,	O	-1	424937
an@@	B-Disease	D000855	424937
ore@@	I-Disease	-1	424937
x@@	I-Disease	-1	424937
ia	I-Disease	-1	424937
,	O	-1	424937
nausea	B-Disease	D009325	424937
and	O	-1	424937
v@@	B-Disease	D014839	424937
om@@	I-Disease	-1	424937
it@@	I-Disease	-1	424937
ing	I-Disease	-1	424937
,	O	-1	424937
and	O	-1	424937
associated	O	-1	424937
with	O	-1	424937
up@@	O	-1	424937
per	O	-1	424937
ab@@	B-Disease	D015746	424937
domin@@	I-Disease	-1	424937
al	I-Disease	-1	424937
pain	I-Disease	-1	424937
,	O	-1	424937
was	O	-1	424937
an	O	-1	424937
inv@@	O	-1	424937
ari@@	O	-1	424937
able	O	-1	424937
find@@	O	-1	424937
ing	O	-1	424937
in	O	-1	424937
all	O	-1	424937
patients.	O	-1	424937
B@@	O	-1	424937
io@@	O	-1	424937
chemical	O	-1	424937
liver	O	-1	424937
function	O	-1	424937
tests	O	-1	424937
indic@@	O	-1	424937
ated	O	-1	424937
hepat@@	O	-1	424937
oc@@	O	-1	424937
ell@@	O	-1	424937
ular	O	-1	424937
necro@@	B-Disease	D009336	424937
sis	I-Disease	-1	424937
and	O	-1	424937
cor@@	O	-1	424937
related	O	-1	424937
with	O	-1	424937
histo@@	O	-1	424937
path@@	O	-1	424937
ological	O	-1	424937
evidence	O	-1	424937
of	O	-1	424937
hepatic	B-Disease	D056486	424937
injury	I-Disease	-1	424937
,	O	-1	424937
the	O	-1	424937
sp@@	O	-1	424937
ect@@	O	-1	424937
ru@@	O	-1	424937
m	O	-1	424937
of	O	-1	424937
which	O	-1	424937
rang@@	O	-1	424937
ed	O	-1	424937
from	O	-1	424937
f@@	B-Disease	D005234	424937
at@@	I-Disease	-1	424937
t@@	I-Disease	-1	424937
y	I-Disease	-1	424937
change	I-Disease	-1	424937
and	O	-1	424937
foc@@	O	-1	424937
al	O	-1	424937
hepat@@	O	-1	424937
oc@@	O	-1	424937
ell@@	O	-1	424937
ular	O	-1	424937
necro@@	B-Disease	D009336	424937
sis	I-Disease	-1	424937
to	O	-1	424937
mas@@	B-Disease	D047508	424937
sive	I-Disease	-1	424937
hepatic	I-Disease	-1	424937
necro@@	I-Disease	-1	424937
sis	I-Disease	-1	424937
.	O	-1	424937
M@@	O	-1	424937
ost	O	-1	424937
patients	O	-1	424937
showed	O	-1	424937
moder@@	O	-1	424937
ate	O	-1	424937
to	O	-1	424937
severe	O	-1	424937
acute	B-Disease	D017114	424937
hepatitis	I-Disease	-1	424937
or	O	-1	424937
chronic	B-Disease	D006521	424937
active	I-Disease	-1	424937
hepatitis	I-Disease	-1	424937
with	O	-1	424937
associated	O	-1	424937
cholest@@	B-Disease	D002779	424937
asis	I-Disease	-1	424937
.	O	-1	424937
The	O	-1	424937
drug	O	-1	424937
was	O	-1	424937
withdraw@@	O	-1	424937
n	O	-1	424937
on	O	-1	424937
present@@	O	-1	424937
ation	O	-1	424937
to	O	-1	424937
hospit@@	O	-1	424937
al	O	-1	424937
in	O	-1	424937
11	O	-1	424937
patients,	O	-1	424937
with	O	-1	424937
ra@@	O	-1	424937
pid	O	-1	424937
clinical	O	-1	424937
impro@@	O	-1	424937
vement	O	-1	424937
in	O	-1	424937
9@@	O	-1	424937
.	O	-1	424937
One	O	-1	424937
patient	O	-1	424937
di@@	O	-1	424937
ed,	O	-1	424937
ha@@	O	-1	424937
ving	O	-1	424937
presented	O	-1	424937
in	O	-1	424937
hepatic	B-Disease	D017093	424937
failure	I-Disease	-1	424937
,	O	-1	424937
and	O	-1	424937
an@@	O	-1	424937
o@@	O	-1	424937
ther@@	O	-1	424937
,	O	-1	424937
who	O	-1	424937
had	O	-1	424937
been	O	-1	424937
taking	O	-1	424937
methyl@@	B-Chemical	D008750	424937
dopa	I-Chemical	-1	424937
for	O	-1	424937
7	O	-1	424937
year@@	O	-1	424937
s,	O	-1	424937
showed	O	-1	424937
s@@	O	-1	424937
lower	O	-1	424937
clinical	O	-1	424937
and	O	-1	424937
bio@@	O	-1	424937
chemical	O	-1	424937
resol@@	O	-1	424937
u@@	O	-1	424937
tion	O	-1	424937
over	O	-1	424937
a	O	-1	424937
period	O	-1	424937
of	O	-1	424937
several	O	-1	424937
months.	O	-1	424937
The	O	-1	424937
remain@@	O	-1	424937
ing	O	-1	424937
patient	O	-1	424937
in	O	-1	424937
the	O	-1	424937
seri@@	O	-1	424937
es	O	-1	424937
developed	O	-1	424937
ful@@	B-Disease	D017114	424937
min@@	I-Disease	-1	424937
ant	I-Disease	-1	424937
hepatitis	I-Disease	-1	424937
when	O	-1	424937
the	O	-1	424937
drug	O	-1	424937
was	O	-1	424937
ac@@	O	-1	424937
c@@	O	-1	424937
id@@	O	-1	424937
ent@@	O	-1	424937
ally	O	-1	424937
recomm@@	O	-1	424937
enc@@	O	-1	424937
ed	O	-1	424937
1	O	-1	424937
year	O	-1	424937
after	O	-1	424937
a	O	-1	424937
prior	O	-1	424937
episo@@	O	-1	424937
de	O	-1	424937
of	O	-1	424937
methyl@@	B-Chemical	D008750	424937
dopa	I-Chemical	-1	424937
-induced	O	-1	424937
hepatitis	B-Disease	D056486	424937
.	O	-1	424937
In	O	-1	424937
this	O	-1	424937
lat@@	O	-1	424937
ter	O	-1	424937
patient@@	O	-1	424937
,	O	-1	424937
and	O	-1	424937
in	O	-1	424937
2	O	-1	424937
o@@	O	-1	424937
ther@@	O	-1	424937
s,	O	-1	424937
the	O	-1	424937
ca@@	O	-1	424937
us@@	O	-1	424937
al	O	-1	424937
rel@@	O	-1	424937
ationship	O	-1	424937
between	O	-1	424937
methyl@@	B-Chemical	D008750	424937
dopa	I-Chemical	-1	424937
and	O	-1	424937
hepatic	B-Disease	D008107	424937
dysfunction	I-Disease	-1	424937
was	O	-1	424937
pro@@	O	-1	424937
ved	O	-1	424937
with	O	-1	424937
the	O	-1	424937
recur@@	O	-1	424937
rence	O	-1	424937
of	O	-1	424937
hepatitis	B-Disease	D056486	424937
within	O	-1	424937
2	O	-1	424937
weeks	O	-1	424937
of	O	-1	424937
re@@	O	-1	424937
-@@	O	-1	424937
exposure	O	-1	424937
to	O	-1	424937
the	O	-1	424937
drug.	O	-1	424937

A	O	-1	8643971
phase	O	-1	8643971
I@@	O	-1	8643971
/@@	O	-1	8643971
II	O	-1	8643971
study	O	-1	8643971
of	O	-1	8643971
paclitax@@	B-Chemical	D017239	8643971
el	I-Chemical	-1	8643971
plus	O	-1	8643971
cisplatin	B-Chemical	D002945	8643971
as	O	-1	8643971
fir@@	O	-1	8643971
st@@	O	-1	8643971
-@@	O	-1	8643971
line	O	-1	8643971
therapy	O	-1	8643971
for	O	-1	8643971
he@@	B-Disease	D006258	8643971
ad	I-Disease	-1	8643971
and	I-Disease	-1	8643971
nec@@	I-Disease	-1	8643971
k	I-Disease	-1	8643971
canc@@	I-Disease	-1	8643971
ers	I-Disease	-1	8643971
:	O	-1	8643971
pre@@	O	-1	8643971
lim@@	O	-1	8643971
inary	O	-1	8643971
result@@	O	-1	8643971
s.	O	-1	8643971
Im@@	O	-1	8643971
pro@@	O	-1	8643971
ved	O	-1	8643971
outcom@@	O	-1	8643971
es	O	-1	8643971
among	O	-1	8643971
patients	O	-1	8643971
with	O	-1	8643971
he@@	B-Disease	D006258	8643971
ad	I-Disease	-1	8643971
and	I-Disease	-1	8643971
nec@@	I-Disease	-1	8643971
k	I-Disease	-1	8643971
carcin@@	I-Disease	-1	8643971
om@@	I-Disease	-1	8643971
as	I-Disease	-1	8643971
requ@@	O	-1	8643971
ir@@	O	-1	8643971
e	O	-1	8643971
investig@@	O	-1	8643971
ations	O	-1	8643971
of	O	-1	8643971
new	O	-1	8643971
drugs	O	-1	8643971
for	O	-1	8643971
induction	O	-1	8643971
therapy.	O	-1	8643971
P@@	O	-1	8643971
rel@@	O	-1	8643971
im@@	O	-1	8643971
inary	O	-1	8643971
results	O	-1	8643971
of	O	-1	8643971
an	O	-1	8643971
E@@	O	-1	8643971
ast@@	O	-1	8643971
er@@	O	-1	8643971
n	O	-1	8643971
C@@	O	-1	8643971
o@@	O	-1	8643971
o@@	O	-1	8643971
perative	O	-1	8643971
On@@	O	-1	8643971
co@@	O	-1	8643971
log@@	O	-1	8643971
y	O	-1	8643971
Group	O	-1	8643971
study	O	-1	8643971
of	O	-1	8643971
sing@@	O	-1	8643971
le@@	O	-1	8643971
-@@	O	-1	8643971
agent	O	-1	8643971
paclitax@@	B-Chemical	D017239	8643971
el	I-Chemical	-1	8643971
(	O	-1	8643971
T@@	B-Chemical	D017239	8643971
ax@@	I-Chemical	-1	8643971
ol	I-Chemical	-1	8643971
;	O	-1	8643971
B@@	O	-1	8643971
ri@@	O	-1	8643971
st@@	O	-1	8643971
ol@@	O	-1	8643971
-@@	O	-1	8643971
M@@	O	-1	8643971
y@@	O	-1	8643971
ers	O	-1	8643971
S@@	O	-1	8643971
qu@@	O	-1	8643971
i@@	O	-1	8643971
b@@	O	-1	8643971
b	O	-1	8643971
Com@@	O	-1	8643971
p@@	O	-1	8643971
an@@	O	-1	8643971
y,	O	-1	8643971
P@@	O	-1	8643971
r@@	O	-1	8643971
in@@	O	-1	8643971
ce@@	O	-1	8643971
t@@	O	-1	8643971
on@@	O	-1	8643971
,	O	-1	8643971
N@@	O	-1	8643971
J@@	O	-1	8643971
)	O	-1	8643971
reported	O	-1	8643971
a	O	-1	8643971
3@@	O	-1	8643971
7@@	O	-1	8643971
%	O	-1	8643971
response	O	-1	8643971
rate	O	-1	8643971
in	O	-1	8643971
patients	O	-1	8643971
with	O	-1	8643971
he@@	B-Disease	D006258	8643971
ad	I-Disease	-1	8643971
and	I-Disease	-1	8643971
nec@@	I-Disease	-1	8643971
k	I-Disease	-1	8643971
cancer	I-Disease	-1	8643971
,	O	-1	8643971
and	O	-1	8643971
the	O	-1	8643971
paclitax@@	B-Chemical	D017239	8643971
el	I-Chemical	-1	8643971
/	O	-1	8643971
cisplatin	B-Chemical	D002945	8643971
combination	O	-1	8643971
has	O	-1	8643971
been	O	-1	8643971
used	O	-1	8643971
suc@@	O	-1	8643971
cess@@	O	-1	8643971
ful@@	O	-1	8643971
ly	O	-1	8643971
and	O	-1	8643971
has	O	-1	8643971
significantly	O	-1	8643971
improved	O	-1	8643971
median	O	-1	8643971
response	O	-1	8643971
duration	O	-1	8643971
in	O	-1	8643971
o@@	B-Disease	D010051	8643971
vari@@	I-Disease	-1	8643971
an	I-Disease	-1	8643971
cancer	I-Disease	-1	8643971
patients.	O	-1	8643971
We	O	-1	8643971
initi@@	O	-1	8643971
ated	O	-1	8643971
a	O	-1	8643971
phase	O	-1	8643971
I@@	O	-1	8643971
/@@	O	-1	8643971
II	O	-1	8643971
trial	O	-1	8643971
to	O	-1	8643971
determine	O	-1	8643971
the	O	-1	8643971
response	O	-1	8643971
and	O	-1	8643971
toxicity	B-Disease	D064420	8643971
of	O	-1	8643971
es@@	O	-1	8643971
cal@@	O	-1	8643971
ating	O	-1	8643971
paclitax@@	B-Chemical	D017239	8643971
el	I-Chemical	-1	8643971
doses	O	-1	8643971
combined	O	-1	8643971
with	O	-1	8643971
fi@@	O	-1	8643971
x@@	O	-1	8643971
ed@@	O	-1	8643971
-@@	O	-1	8643971
dose	O	-1	8643971
cisplatin	B-Chemical	D002945	8643971
with	O	-1	8643971
gran@@	O	-1	8643971
ulo@@	O	-1	8643971
cy@@	O	-1	8643971
te	O	-1	8643971
co@@	O	-1	8643971
lon@@	O	-1	8643971
y-@@	O	-1	8643971
stimul@@	O	-1	8643971
ating	O	-1	8643971
factor	O	-1	8643971
suppor@@	O	-1	8643971
t	O	-1	8643971
in	O	-1	8643971
patients	O	-1	8643971
with	O	-1	8643971
un@@	O	-1	8643971
treated	O	-1	8643971
loc@@	O	-1	8643971
ally	O	-1	8643971
adv@@	O	-1	8643971
anced	O	-1	8643971
ino@@	O	-1	8643971
per@@	O	-1	8643971
able	O	-1	8643971
he@@	B-Disease	D006258	8643971
ad	I-Disease	-1	8643971
and	I-Disease	-1	8643971
nec@@	I-Disease	-1	8643971
k	I-Disease	-1	8643971
carcin@@	I-Disease	-1	8643971
oma	I-Disease	-1	8643971
.	O	-1	8643971
To	O	-1	8643971
dat@@	O	-1	8643971
e,	O	-1	8643971
2@@	O	-1	8643971
3	O	-1	8643971
men	O	-1	8643971
with	O	-1	8643971
a	O	-1	8643971
median	O	-1	8643971
age	O	-1	8643971
of	O	-1	8643971
50	O	-1	8643971
years	O	-1	8643971
and	O	-1	8643971
go@@	O	-1	8643971
od	O	-1	8643971
perform@@	O	-1	8643971
ance	O	-1	8643971
status	O	-1	8643971
have	O	-1	8643971
ent@@	O	-1	8643971
ered	O	-1	8643971
the	O	-1	8643971
tri@@	O	-1	8643971
al.	O	-1	8643971
P@@	O	-1	8643971
ri@@	O	-1	8643971
m@@	O	-1	8643971
ary	O	-1	8643971
tumor	B-Disease	D009369	8643971
sit@@	O	-1	8643971
es	O	-1	8643971
were	O	-1	8643971
o@@	O	-1	8643971
ro@@	O	-1	8643971
ph@@	O	-1	8643971
ar@@	O	-1	8643971
yn@@	O	-1	8643971
x@@	O	-1	8643971
,	O	-1	8643971
10	O	-1	8643971
patient@@	O	-1	8643971
s;	O	-1	8643971
hypo@@	O	-1	8643971
ph@@	O	-1	8643971
ar@@	O	-1	8643971
yn@@	O	-1	8643971
x@@	O	-1	8643971
,	O	-1	8643971
fo@@	O	-1	8643971
ur@@	O	-1	8643971
;	O	-1	8643971
l@@	O	-1	8643971
ar@@	O	-1	8643971
yn@@	O	-1	8643971
x@@	O	-1	8643971
,	O	-1	8643971
tw@@	O	-1	8643971
o@@	O	-1	8643971
;	O	-1	8643971
oral	O	-1	8643971
ca@@	O	-1	8643971
vit@@	O	-1	8643971
y,	O	-1	8643971
th@@	O	-1	8643971
re@@	O	-1	8643971
e@@	O	-1	8643971
;	O	-1	8643971
un@@	O	-1	8643971
known	O	-1	8643971
prim@@	O	-1	8643971
ar@@	O	-1	8643971
y,	O	-1	8643971
tw@@	O	-1	8643971
o@@	O	-1	8643971
;	O	-1	8643971
and	O	-1	8643971
n@@	O	-1	8643971
as@@	O	-1	8643971
al	O	-1	8643971
ca@@	O	-1	8643971
v@@	O	-1	8643971
ity	O	-1	8643971
and	O	-1	8643971
pa@@	O	-1	8643971
ro@@	O	-1	8643971
ti@@	O	-1	8643971
d	O	-1	8643971
gl@@	O	-1	8643971
and@@	O	-1	8643971
,	O	-1	8643971
one	O	-1	8643971
e@@	O	-1	8643971
ac@@	O	-1	8643971
h@@	O	-1	8643971
.	O	-1	8643971
Of	O	-1	8643971
20	O	-1	8643971
patients	O	-1	8643971
evalu@@	O	-1	8643971
able	O	-1	8643971
for	O	-1	8643971
toxicity	B-Disease	D064420	8643971
,	O	-1	8643971
four	O	-1	8643971
had	O	-1	8643971
st@@	O	-1	8643971
age	O	-1	8643971
I@@	O	-1	8643971
II	O	-1	8643971
and	O	-1	8643971
16	O	-1	8643971
had	O	-1	8643971
st@@	O	-1	8643971
age	O	-1	8643971
IV	O	-1	8643971
disease.	O	-1	8643971
Treat@@	O	-1	8643971
ment@@	O	-1	8643971
,	O	-1	8643971
given	O	-1	8643971
every	O	-1	8643971
21	O	-1	8643971
days	O	-1	8643971
for	O	-1	8643971
a	O	-1	8643971
maxim@@	O	-1	8643971
um	O	-1	8643971
of	O	-1	8643971
three	O	-1	8643971
cy@@	O	-1	8643971
cl@@	O	-1	8643971
es,	O	-1	8643971
consist@@	O	-1	8643971
ed	O	-1	8643971
of	O	-1	8643971
paclitax@@	B-Chemical	D017239	8643971
el	I-Chemical	-1	8643971
by	O	-1	8643971
3-@@	O	-1	8643971
h@@	O	-1	8643971
our	O	-1	8643971
infusion	O	-1	8643971
followed	O	-1	8643971
the	O	-1	8643971
ne@@	O	-1	8643971
x@@	O	-1	8643971
t	O	-1	8643971
day	O	-1	8643971
by	O	-1	8643971
a	O	-1	8643971
fi@@	O	-1	8643971
x@@	O	-1	8643971
ed	O	-1	8643971
dose	O	-1	8643971
of	O	-1	8643971
cisplatin	B-Chemical	D002945	8643971
(@@	O	-1	8643971
7@@	O	-1	8643971
5	O	-1	8643971
mg/m@@	O	-1	8643971
2@@	O	-1	8643971
).	O	-1	8643971
The	O	-1	8643971
dose	O	-1	8643971
levels	O	-1	8643971
inc@@	O	-1	8643971
or@@	O	-1	8643971
por@@	O	-1	8643971
ate	O	-1	8643971
es@@	O	-1	8643971
cal@@	O	-1	8643971
ating	O	-1	8643971
paclitax@@	B-Chemical	D017239	8643971
el	I-Chemical	-1	8643971
dos@@	O	-1	8643971
es,	O	-1	8643971
and	O	-1	8643971
intra@@	O	-1	8643971
patient	O	-1	8643971
es@@	O	-1	8643971
cal@@	O	-1	8643971
ations	O	-1	8643971
within	O	-1	8643971
a	O	-1	8643971
given	O	-1	8643971
dose	O	-1	8643971
level	O	-1	8643971
are	O	-1	8643971
per@@	O	-1	8643971
mit@@	O	-1	8643971
ted	O	-1	8643971
if	O	-1	8643971
toxicity	B-Disease	D064420	8643971
per@@	O	-1	8643971
mit@@	O	-1	8643971
s.	O	-1	8643971
A@@	O	-1	8643971
t	O	-1	8643971
the	O	-1	8643971
time	O	-1	8643971
of	O	-1	8643971
this	O	-1	8643971
w@@	O	-1	8643971
rit@@	O	-1	8643971
ing,	O	-1	8643971
dose	O	-1	8643971
level	O	-1	8643971
4	O	-1	8643971
(2@@	O	-1	8643971
6@@	O	-1	8643971
0@@	O	-1	8643971
,	O	-1	8643971
27@@	O	-1	8643971
0@@	O	-1	8643971
,	O	-1	8643971
and	O	-1	8643971
2@@	O	-1	8643971
8@@	O	-1	8643971
0	O	-1	8643971
mg/m@@	O	-1	8643971
2)	O	-1	8643971
is	O	-1	8643971
being	O	-1	8643971
evalu@@	O	-1	8643971
ated@@	O	-1	8643971
;	O	-1	8643971
three	O	-1	8643971
patients	O	-1	8643971
from	O	-1	8643971
this	O	-1	8643971
level	O	-1	8643971
are	O	-1	8643971
evalu@@	O	-1	8643971
able@@	O	-1	8643971
.	O	-1	8643971
W@@	O	-1	8643971
it@@	O	-1	8643971
h	O	-1	8643971
paclitax@@	B-Chemical	D017239	8643971
el	I-Chemical	-1	8643971
doses	O	-1	8643971
of	O	-1	8643971
2@@	O	-1	8643971
00	O	-1	8643971
mg/m@@	O	-1	8643971
2	O	-1	8643971
and	O	-1	8643971
high@@	O	-1	8643971
er,	O	-1	8643971
gran@@	O	-1	8643971
ulo@@	O	-1	8643971
cy@@	O	-1	8643971
te	O	-1	8643971
co@@	O	-1	8643971
lon@@	O	-1	8643971
y-@@	O	-1	8643971
stimul@@	O	-1	8643971
ating	O	-1	8643971
factor	O	-1	8643971
5	O	-1	8643971
microgram@@	O	-1	8643971
s/@@	O	-1	8643971
k@@	O	-1	8643971
g/@@	O	-1	8643971
d	O	-1	8643971
is	O	-1	8643971
given	O	-1	8643971
(@@	O	-1	8643971
days	O	-1	8643971
4	O	-1	8643971
through	O	-1	8643971
12@@	O	-1	8643971
).	O	-1	8643971
Of	O	-1	8643971
1@@	O	-1	8643971
8	O	-1	8643971
patients	O	-1	8643971
evalu@@	O	-1	8643971
able	O	-1	8643971
for	O	-1	8643971
respon@@	O	-1	8643971
se@@	O	-1	8643971
,	O	-1	8643971
seven	O	-1	8643971
(3@@	O	-1	8643971
9@@	O	-1	8643971
%)	O	-1	8643971
achi@@	O	-1	8643971
ev@@	O	-1	8643971
ed	O	-1	8643971
a	O	-1	8643971
complete	O	-1	8643971
response	O	-1	8643971
and	O	-1	8643971
six	O	-1	8643971
(3@@	O	-1	8643971
3@@	O	-1	8643971
%)	O	-1	8643971
achi@@	O	-1	8643971
ev@@	O	-1	8643971
ed	O	-1	8643971
a	O	-1	8643971
partial	O	-1	8643971
respon@@	O	-1	8643971
se.	O	-1	8643971
Th@@	O	-1	8643971
ree	O	-1	8643971
patients	O	-1	8643971
had	O	-1	8643971
no	O	-1	8643971
change	O	-1	8643971
and	O	-1	8643971
disease	O	-1	8643971
progres@@	O	-1	8643971
sed	O	-1	8643971
in	O	-1	8643971
tw@@	O	-1	8643971
o@@	O	-1	8643971
.	O	-1	8643971
The	O	-1	8643971
over@@	O	-1	8643971
all	O	-1	8643971
response	O	-1	8643971
rate	O	-1	8643971
is	O	-1	8643971
7@@	O	-1	8643971
2@@	O	-1	8643971
%.	O	-1	8643971
E@@	O	-1	8643971
le@@	O	-1	8643971
ven	O	-1	8643971
respon@@	O	-1	8643971
ding	O	-1	8643971
patients	O	-1	8643971
had	O	-1	8643971
subsequ@@	O	-1	8643971
ent	O	-1	8643971
surg@@	O	-1	8643971
ery@@	O	-1	8643971
/@@	O	-1	8643971
radi@@	O	-1	8643971
o@@	O	-1	8643971
therapy	O	-1	8643971
or	O	-1	8643971
ra@@	O	-1	8643971
d@@	O	-1	8643971
ical	O	-1	8643971
radi@@	O	-1	8643971
o@@	O	-1	8643971
therapy.	O	-1	8643971
Two	O	-1	8643971
path@@	O	-1	8643971
ologic	O	-1	8643971
complete	O	-1	8643971
responses	O	-1	8643971
were	O	-1	8643971
observed	O	-1	8643971
in	O	-1	8643971
patients	O	-1	8643971
who	O	-1	8643971
had	O	-1	8643971
achi@@	O	-1	8643971
ev@@	O	-1	8643971
ed	O	-1	8643971
clinical	O	-1	8643971
complete	O	-1	8643971
respon@@	O	-1	8643971
s@@	O	-1	8643971
es.	O	-1	8643971
A@@	B-Disease	D000505	8643971
lop@@	I-Disease	-1	8643971
ec@@	I-Disease	-1	8643971
ia	I-Disease	-1	8643971
,	O	-1	8643971
pa@@	B-Disease	D010292	8643971
res@@	I-Disease	-1	8643971
the@@	I-Disease	-1	8643971
si@@	I-Disease	-1	8643971
as	I-Disease	-1	8643971
,	O	-1	8643971
and	O	-1	8643971
arth@@	B-Disease	D018771	8643971
r@@	I-Disease	-1	8643971
al@@	I-Disease	-1	8643971
gi@@	I-Disease	-1	8643971
as	I-Disease	-1	8643971
/	O	-1	8643971
my@@	B-Disease	D063806	8643971
al@@	I-Disease	-1	8643971
gi@@	I-Disease	-1	8643971
as	I-Disease	-1	8643971
have	O	-1	8643971
occurred	O	-1	8643971
frequ@@	O	-1	8643971
ent@@	O	-1	8643971
ly,	O	-1	8643971
but	O	-1	8643971
with	O	-1	8643971
one	O	-1	8643971
ex@@	O	-1	8643971
ce@@	O	-1	8643971
ption	O	-1	8643971
(@@	O	-1	8643971
a	O	-1	8643971
gra@@	O	-1	8643971
de	O	-1	8643971
3	O	-1	8643971
my@@	B-Disease	D063806	8643971
al@@	I-Disease	-1	8643971
g@@	I-Disease	-1	8643971
ia	I-Disease	-1	8643971
)	O	-1	8643971
they	O	-1	8643971
have	O	-1	8643971
been	O	-1	8643971
gra@@	O	-1	8643971
de	O	-1	8643971
1	O	-1	8643971
or	O	-1	8643971
2@@	O	-1	8643971
.	O	-1	8643971
No	O	-1	8643971
dose-@@	O	-1	8643971
lim@@	O	-1	8643971
it@@	O	-1	8643971
ing	O	-1	8643971
hemat@@	O	-1	8643971
ologic	O	-1	8643971
toxicity	B-Disease	D064420	8643971
has	O	-1	8643971
been	O	-1	8643971
se@@	O	-1	8643971
en@@	O	-1	8643971
.	O	-1	8643971
P@@	B-Chemical	D017239	8643971
ac@@	I-Chemical	-1	8643971
litax@@	I-Chemical	-1	8643971
el	I-Chemical	-1	8643971
/	O	-1	8643971
cisplatin	B-Chemical	D002945	8643971
is	O	-1	8643971
an	O	-1	8643971
effective	O	-1	8643971
fir@@	O	-1	8643971
st@@	O	-1	8643971
-@@	O	-1	8643971
line	O	-1	8643971
regi@@	O	-1	8643971
men	O	-1	8643971
for	O	-1	8643971
lo@@	O	-1	8643971
co@@	O	-1	8643971
regi@@	O	-1	8643971
on@@	O	-1	8643971
ally	O	-1	8643971
adv@@	O	-1	8643971
anced	O	-1	8643971
he@@	B-Disease	D006258	8643971
ad	I-Disease	-1	8643971
and	I-Disease	-1	8643971
nec@@	I-Disease	-1	8643971
k	I-Disease	-1	8643971
cancer	I-Disease	-1	8643971
and	O	-1	8643971
continu@@	O	-1	8643971
ed	O	-1	8643971
study	O	-1	8643971
is	O	-1	8643971
war@@	O	-1	8643971
ran@@	O	-1	8643971
ted.	O	-1	8643971
R@@	O	-1	8643971
es@@	O	-1	8643971
ult@@	O	-1	8643971
s	O	-1	8643971
th@@	O	-1	8643971
us	O	-1	8643971
f@@	O	-1	8643971
ar	O	-1	8643971
suggest	O	-1	8643971
no	O	-1	8643971
dose-@@	O	-1	8643971
response	O	-1	8643971
effect	O	-1	8643971
for	O	-1	8643971
paclitax@@	B-Chemical	D017239	8643971
el	I-Chemical	-1	8643971
doses	O	-1	8643971
ab@@	O	-1	8643971
o@@	O	-1	8643971
ve	O	-1	8643971
2@@	O	-1	8643971
00	O	-1	8643971
mg/m@@	O	-1	8643971
2@@	O	-1	8643971
.	O	-1	8643971

A	O	-1	2224762
phase	O	-1	2224762
I	O	-1	2224762
study	O	-1	2224762
of	O	-1	2224762
4@@	B-Chemical	C027260	2224762
'@@	I-Chemical	-1	2224762
-@@	I-Chemical	-1	2224762
0-@@	I-Chemical	-1	2224762
te@@	I-Chemical	-1	2224762
tra@@	I-Chemical	-1	2224762
hydro@@	I-Chemical	-1	2224762
py@@	I-Chemical	-1	2224762
ran@@	I-Chemical	-1	2224762
yl@@	I-Chemical	-1	2224762
adriam@@	I-Chemical	-1	2224762
ycin	I-Chemical	-1	2224762
.	O	-1	2224762
Clin@@	O	-1	2224762
ical	O	-1	2224762
pharmac@@	O	-1	2224762
ology	O	-1	2224762
and	O	-1	2224762
pharmac@@	O	-1	2224762
o@@	O	-1	2224762
kine@@	O	-1	2224762
tic@@	O	-1	2224762
s.	O	-1	2224762
A	O	-1	2224762
Ph@@	O	-1	2224762
ase	O	-1	2224762
I	O	-1	2224762
study	O	-1	2224762
of	O	-1	2224762
intravenous	O	-1	2224762
(@@	O	-1	2224762
I@@	O	-1	2224762
V@@	O	-1	2224762
)	O	-1	2224762
b@@	O	-1	2224762
ol@@	O	-1	2224762
us	O	-1	2224762
4@@	B-Chemical	C027260	2224762
'@@	I-Chemical	-1	2224762
-@@	I-Chemical	-1	2224762
0-@@	I-Chemical	-1	2224762
te@@	I-Chemical	-1	2224762
tra@@	I-Chemical	-1	2224762
hydro@@	I-Chemical	-1	2224762
py@@	I-Chemical	-1	2224762
ran@@	I-Chemical	-1	2224762
yl@@	I-Chemical	-1	2224762
adriam@@	I-Chemical	-1	2224762
ycin	I-Chemical	-1	2224762
(	O	-1	2224762
P@@	B-Chemical	C027260	2224762
ir@@	I-Chemical	-1	2224762
ar@@	I-Chemical	-1	2224762
ub@@	I-Chemical	-1	2224762
icin	I-Chemical	-1	2224762
)	O	-1	2224762
was	O	-1	2224762
d@@	O	-1	2224762
one	O	-1	2224762
in	O	-1	2224762
5@@	O	-1	2224762
5	O	-1	2224762
patients	O	-1	2224762
in	O	-1	2224762
go@@	O	-1	2224762
od	O	-1	2224762
perform@@	O	-1	2224762
ance	O	-1	2224762
status	O	-1	2224762
with	O	-1	2224762
ref@@	O	-1	2224762
rac@@	O	-1	2224762
t@@	O	-1	2224762
ory	O	-1	2224762
tu@@	B-Disease	D009369	2224762
mor@@	I-Disease	-1	2224762
s	I-Disease	-1	2224762
.	O	-1	2224762
Tw@@	O	-1	2224762
ent@@	O	-1	2224762
y-@@	O	-1	2224762
six	O	-1	2224762
had	O	-1	2224762
minim@@	O	-1	2224762
al	O	-1	2224762
prior	O	-1	2224762
therapy	O	-1	2224762
(@@	O	-1	2224762
go@@	O	-1	2224762
od	O	-1	2224762
ris@@	O	-1	2224762
k@@	O	-1	2224762
),	O	-1	2224762
2@@	O	-1	2224762
3	O	-1	2224762
had	O	-1	2224762
exten@@	O	-1	2224762
sive	O	-1	2224762
prior	O	-1	2224762
therapy	O	-1	2224762
(@@	O	-1	2224762
po@@	O	-1	2224762
or	O	-1	2224762
ris@@	O	-1	2224762
k@@	O	-1	2224762
),	O	-1	2224762
and	O	-1	2224762
six	O	-1	2224762
had	O	-1	2224762
renal	B-Disease	D007674	2224762
and/or	I-Disease	-1	2224762
hepatic	I-Disease	-1	2224762
dysfunction	I-Disease	-1	2224762
renal	B-Disease	D008107	2224762
and/or	I-Disease	-1	2224762
hepatic	I-Disease	-1	2224762
dysfunction	I-Disease	-1	2224762
.	O	-1	2224762
A	O	-1	2224762
total	O	-1	2224762
of	O	-1	2224762
1@@	O	-1	2224762
6@@	O	-1	2224762
7	O	-1	2224762
cour@@	O	-1	2224762
ses	O	-1	2224762
at	O	-1	2224762
doses	O	-1	2224762
of	O	-1	2224762
15	O	-1	2224762
to	O	-1	2224762
7@@	O	-1	2224762
0	O	-1	2224762
mg/m@@	O	-1	2224762
2	O	-1	2224762
were	O	-1	2224762
evalu@@	O	-1	2224762
able@@	O	-1	2224762
.	O	-1	2224762
M@@	O	-1	2224762
ax@@	O	-1	2224762
im@@	O	-1	2224762
um	O	-1	2224762
toler@@	O	-1	2224762
ated	O	-1	2224762
dose	O	-1	2224762
in	O	-1	2224762
go@@	O	-1	2224762
o@@	O	-1	2224762
d-@@	O	-1	2224762
risk	O	-1	2224762
patients	O	-1	2224762
was	O	-1	2224762
7@@	O	-1	2224762
0	O	-1	2224762
mg/m@@	O	-1	2224762
2,	O	-1	2224762
and	O	-1	2224762
in	O	-1	2224762
po@@	O	-1	2224762
or@@	O	-1	2224762
-@@	O	-1	2224762
risk	O	-1	2224762
patients,	O	-1	2224762
60	O	-1	2224762
mg/m@@	O	-1	2224762
2@@	O	-1	2224762
.	O	-1	2224762
The	O	-1	2224762
dose-@@	O	-1	2224762
lim@@	O	-1	2224762
it@@	O	-1	2224762
ing	O	-1	2224762
toxic	O	-1	2224762
effect	O	-1	2224762
was	O	-1	2224762
transi@@	O	-1	2224762
ent	O	-1	2224762
non@@	O	-1	2224762
cum@@	O	-1	2224762
ul@@	O	-1	2224762
ative	O	-1	2224762
gran@@	B-Disease	D000380	2224762
ulo@@	I-Disease	-1	2224762
cyto@@	I-Disease	-1	2224762
pen@@	I-Disease	-1	2224762
ia	I-Disease	-1	2224762
.	O	-1	2224762
G@@	O	-1	2224762
ran@@	O	-1	2224762
ulo@@	O	-1	2224762
cy@@	O	-1	2224762
te	O	-1	2224762
na@@	O	-1	2224762
di@@	O	-1	2224762
r	O	-1	2224762
was	O	-1	2224762
on	O	-1	2224762
day	O	-1	2224762
14	O	-1	2224762
(@@	O	-1	2224762
rang@@	O	-1	2224762
e,	O	-1	2224762
4-@@	O	-1	2224762
2@@	O	-1	2224762
2@@	O	-1	2224762
).	O	-1	2224762
L@@	O	-1	2224762
ess	O	-1	2224762
frequent	O	-1	2224762
toxic	O	-1	2224762
effects	O	-1	2224762
included	O	-1	2224762
throm@@	B-Disease	D013921	2224762
b@@	I-Disease	-1	2224762
ocyto@@	I-Disease	-1	2224762
pen@@	I-Disease	-1	2224762
ia	I-Disease	-1	2224762
,	O	-1	2224762
anemia	B-Disease	D000740	2224762
,	O	-1	2224762
nausea	B-Disease	D009325	2224762
,	O	-1	2224762
mil@@	O	-1	2224762
d	O	-1	2224762
alo@@	B-Disease	D000505	2224762
p@@	I-Disease	-1	2224762
ec@@	I-Disease	-1	2224762
ia	I-Disease	-1	2224762
,	O	-1	2224762
ph@@	B-Disease	D010689	2224762
le@@	I-Disease	-1	2224762
b@@	I-Disease	-1	2224762
iti@@	I-Disease	-1	2224762
s	I-Disease	-1	2224762
,	O	-1	2224762
and	O	-1	2224762
m@@	B-Disease	D052016	2224762
u@@	I-Disease	-1	2224762
co@@	I-Disease	-1	2224762
si@@	I-Disease	-1	2224762
tis	I-Disease	-1	2224762
.	O	-1	2224762
M@@	B-Disease	D001855	2224762
ye@@	I-Disease	-1	2224762
lo@@	I-Disease	-1	2224762
sup@@	I-Disease	-1	2224762
pression	I-Disease	-1	2224762
was	O	-1	2224762
more	O	-1	2224762
in	O	-1	2224762
patients	O	-1	2224762
with	O	-1	2224762
hepatic	B-Disease	D008107	2224762
dysfunction	I-Disease	-1	2224762
.	O	-1	2224762
Ph@@	O	-1	2224762
armac@@	O	-1	2224762
o@@	O	-1	2224762
kine@@	O	-1	2224762
tic	O	-1	2224762
analy@@	O	-1	2224762
ses	O	-1	2224762
in	O	-1	2224762
21	O	-1	2224762
patients	O	-1	2224762
revealed	O	-1	2224762
P@@	B-Chemical	C027260	2224762
ir@@	I-Chemical	-1	2224762
ar@@	I-Chemical	-1	2224762
ub@@	I-Chemical	-1	2224762
icin	I-Chemical	-1	2224762
plasma	O	-1	2224762
T	O	-1	2224762
1@@	O	-1	2224762
/@@	O	-1	2224762
2	O	-1	2224762
al@@	O	-1	2224762
ph@@	O	-1	2224762
a	O	-1	2224762
(@@	O	-1	2224762
+/-	O	-1	2224762
S@@	O	-1	2224762
E@@	O	-1	2224762
)	O	-1	2224762
of	O	-1	2224762
2.@@	O	-1	2224762
5	O	-1	2224762
+/-	O	-1	2224762
0.@@	O	-1	2224762
8@@	O	-1	2224762
5	O	-1	2224762
minut@@	O	-1	2224762
es,	O	-1	2224762
T	O	-1	2224762
bet@@	O	-1	2224762
a	O	-1	2224762
1@@	O	-1	2224762
/@@	O	-1	2224762
2	O	-1	2224762
of	O	-1	2224762
2@@	O	-1	2224762
5.@@	O	-1	2224762
6	O	-1	2224762
+/-	O	-1	2224762
6.@@	O	-1	2224762
5	O	-1	2224762
minut@@	O	-1	2224762
es,	O	-1	2224762
and	O	-1	2224762
T	O	-1	2224762
1@@	O	-1	2224762
/@@	O	-1	2224762
2	O	-1	2224762
gam@@	O	-1	2224762
ma	O	-1	2224762
of	O	-1	2224762
2@@	O	-1	2224762
3.@@	O	-1	2224762
6	O	-1	2224762
+/-	O	-1	2224762
7.@@	O	-1	2224762
6	O	-1	2224762
hour@@	O	-1	2224762
s.	O	-1	2224762
The	O	-1	2224762
a@@	O	-1	2224762
re@@	O	-1	2224762
a	O	-1	2224762
under	O	-1	2224762
the	O	-1	2224762
cur@@	O	-1	2224762
ve	O	-1	2224762
was	O	-1	2224762
5@@	O	-1	2224762
3@@	O	-1	2224762
7	O	-1	2224762
+/-	O	-1	2224762
14@@	O	-1	2224762
9	O	-1	2224762
n@@	O	-1	2224762
g/@@	O	-1	2224762
m@@	O	-1	2224762
l	O	-1	2224762
x	O	-1	2224762
hour@@	O	-1	2224762
s,	O	-1	2224762
volume	O	-1	2224762
of	O	-1	2224762
di@@	O	-1	2224762
stri@@	O	-1	2224762
bu@@	O	-1	2224762
tion	O	-1	2224762
(V@@	O	-1	2224762
d@@	O	-1	2224762
)	O	-1	2224762
3@@	O	-1	2224762
50@@	O	-1	2224762
4	O	-1	2224762
+/-	O	-1	2224762
6@@	O	-1	2224762
4@@	O	-1	2224762
4	O	-1	2224762
l@@	O	-1	2224762
/@@	O	-1	2224762
m@@	O	-1	2224762
2,	O	-1	2224762
and	O	-1	2224762
total	O	-1	2224762
clear@@	O	-1	2224762
ance	O	-1	2224762
(C@@	O	-1	2224762
l@@	O	-1	2224762
T)	O	-1	2224762
was	O	-1	2224762
20@@	O	-1	2224762
4	O	-1	2224762
+	O	-1	2224762
3@@	O	-1	2224762
9.@@	O	-1	2224762
3	O	-1	2224762
l@@	O	-1	2224762
/@@	O	-1	2224762
hour@@	O	-1	2224762
/@@	O	-1	2224762
m@@	O	-1	2224762
2@@	O	-1	2224762
.	O	-1	2224762
Ad@@	B-Chemical	C010013	2224762
riam@@	I-Chemical	-1	2224762
yc@@	I-Chemical	-1	2224762
in@@	I-Chemical	-1	2224762
ol	I-Chemical	-1	2224762
,	O	-1	2224762
dox@@	B-Chemical	D004317	2224762
orub@@	I-Chemical	-1	2224762
icin	I-Chemical	-1	2224762
,	O	-1	2224762
adriam@@	B-Chemical	C010012	2224762
yc@@	I-Chemical	-1	2224762
in@@	I-Chemical	-1	2224762
one	I-Chemical	-1	2224762
,	O	-1	2224762
and	O	-1	2224762
te@@	B-Chemical	C027260	2224762
tra@@	I-Chemical	-1	2224762
hydro@@	I-Chemical	-1	2224762
py@@	I-Chemical	-1	2224762
ran@@	I-Chemical	-1	2224762
yl@@	I-Chemical	-1	2224762
adriam@@	I-Chemical	-1	2224762
yc@@	I-Chemical	-1	2224762
in@@	I-Chemical	-1	2224762
ol	I-Chemical	-1	2224762
were	O	-1	2224762
the	O	-1	2224762
metabol@@	O	-1	2224762
it@@	O	-1	2224762
es	O	-1	2224762
det@@	O	-1	2224762
ected	O	-1	2224762
in	O	-1	2224762
plasma	O	-1	2224762
and	O	-1	2224762
the	O	-1	2224762
amoun@@	O	-1	2224762
t	O	-1	2224762
of	O	-1	2224762
dox@@	B-Chemical	D004317	2224762
orub@@	I-Chemical	-1	2224762
icin	I-Chemical	-1	2224762
was	O	-1	2224762
less	O	-1	2224762
than	O	-1	2224762
or	O	-1	2224762
equ@@	O	-1	2224762
al	O	-1	2224762
to	O	-1	2224762
10@@	O	-1	2224762
%	O	-1	2224762
of	O	-1	2224762
the	O	-1	2224762
total	O	-1	2224762
metabol@@	O	-1	2224762
it@@	O	-1	2224762
es.	O	-1	2224762
U@@	O	-1	2224762
r@@	O	-1	2224762
inary	O	-1	2224762
ex@@	O	-1	2224762
cre@@	O	-1	2224762
tion	O	-1	2224762
of	O	-1	2224762
P@@	B-Chemical	C027260	2224762
ir@@	I-Chemical	-1	2224762
ar@@	I-Chemical	-1	2224762
ub@@	I-Chemical	-1	2224762
icin	I-Chemical	-1	2224762
in	O	-1	2224762
the	O	-1	2224762
first	O	-1	2224762
24	O	-1	2224762
hours	O	-1	2224762
was	O	-1	2224762
less	O	-1	2224762
than	O	-1	2224762
or	O	-1	2224762
equ@@	O	-1	2224762
al	O	-1	2224762
to	O	-1	2224762
10@@	O	-1	2224762
%.	O	-1	2224762
Ac@@	O	-1	2224762
tivity	O	-1	2224762
was	O	-1	2224762
not@@	O	-1	2224762
ed	O	-1	2224762
in	O	-1	2224762
m@@	B-Disease	D008654	2224762
es@@	I-Disease	-1	2224762
o@@	I-Disease	-1	2224762
the@@	I-Disease	-1	2224762
li@@	I-Disease	-1	2224762
oma	I-Disease	-1	2224762
,	O	-1	2224762
le@@	B-Disease	D007890	2224762
i@@	I-Disease	-1	2224762
om@@	I-Disease	-1	2224762
y@@	I-Disease	-1	2224762
os@@	I-Disease	-1	2224762
ar@@	I-Disease	-1	2224762
com@@	I-Disease	-1	2224762
a	I-Disease	-1	2224762
,	O	-1	2224762
and	O	-1	2224762
bas@@	B-Disease	D002280	2224762
al	I-Disease	-1	2224762
cell	I-Disease	-1	2224762
carcin@@	I-Disease	-1	2224762
oma	I-Disease	-1	2224762
.	O	-1	2224762
The	O	-1	2224762
recomm@@	O	-1	2224762
en@@	O	-1	2224762
ded	O	-1	2224762
star@@	O	-1	2224762
ting	O	-1	2224762
dose	O	-1	2224762
for	O	-1	2224762
Ph@@	O	-1	2224762
ase	O	-1	2224762
II	O	-1	2224762
tri@@	O	-1	2224762
als	O	-1	2224762
is	O	-1	2224762
60	O	-1	2224762
mg/m@@	O	-1	2224762
2	O	-1	2224762
IV	O	-1	2224762
b@@	O	-1	2224762
ol@@	O	-1	2224762
us	O	-1	2224762
every	O	-1	2224762
3	O	-1	2224762
week@@	O	-1	2224762
s.	O	-1	2224762

Di@@	O	-1	2440413
fferen@@	O	-1	2440413
tial	O	-1	2440413
effects	O	-1	2440413
of	O	-1	2440413
gamma@@	B-Chemical	D001556	2440413
-@@	I-Chemical	-1	2440413
he@@	I-Chemical	-1	2440413
x@@	I-Chemical	-1	2440413
ac@@	I-Chemical	-1	2440413
h@@	I-Chemical	-1	2440413
loro@@	I-Chemical	-1	2440413
cyclo@@	I-Chemical	-1	2440413
he@@	I-Chemical	-1	2440413
x@@	I-Chemical	-1	2440413
ane	I-Chemical	-1	2440413
(	O	-1	2440413
l@@	B-Chemical	D001556	2440413
ind@@	I-Chemical	-1	2440413
ane	I-Chemical	-1	2440413
)	O	-1	2440413
on	O	-1	2440413
pharmac@@	O	-1	2440413
olog@@	O	-1	2440413
ic@@	O	-1	2440413
all@@	O	-1	2440413
y@@	O	-1	2440413
-induced	O	-1	2440413
seizures	B-Disease	D012640	2440413
.	O	-1	2440413
G@@	B-Chemical	D001556	2440413
am@@	I-Chemical	-1	2440413
ma@@	I-Chemical	-1	2440413
-@@	I-Chemical	-1	2440413
he@@	I-Chemical	-1	2440413
x@@	I-Chemical	-1	2440413
ac@@	I-Chemical	-1	2440413
h@@	I-Chemical	-1	2440413
loro@@	I-Chemical	-1	2440413
cyclo@@	I-Chemical	-1	2440413
he@@	I-Chemical	-1	2440413
x@@	I-Chemical	-1	2440413
ane	I-Chemical	-1	2440413
(	O	-1	2440413
gamma@@	B-Chemical	D001556	2440413
-H@@	I-Chemical	-1	2440413
C@@	I-Chemical	-1	2440413
H	I-Chemical	-1	2440413
),	O	-1	2440413
the	O	-1	2440413
active	O	-1	2440413
ing@@	O	-1	2440413
re@@	O	-1	2440413
di@@	O	-1	2440413
ent	O	-1	2440413
of	O	-1	2440413
the	O	-1	2440413
in@@	O	-1	2440413
sec@@	O	-1	2440413
tic@@	O	-1	2440413
ide	O	-1	2440413
l@@	B-Chemical	D001556	2440413
ind@@	I-Chemical	-1	2440413
ane	I-Chemical	-1	2440413
,	O	-1	2440413
has	O	-1	2440413
been	O	-1	2440413
shown	O	-1	2440413
to	O	-1	2440413
decrease	O	-1	2440413
seizure	B-Disease	D012640	2440413
th@@	O	-1	2440413
res@@	O	-1	2440413
h@@	O	-1	2440413
old	O	-1	2440413
to	O	-1	2440413
pent@@	O	-1	2440413
yl@@	O	-1	2440413
en@@	O	-1	2440413
et@@	O	-1	2440413
ra@@	O	-1	2440413
z@@	O	-1	2440413
ol	O	-1	2440413
(	O	-1	2440413
P@@	B-Chemical	D010433	2440413
T@@	I-Chemical	-1	2440413
Z	I-Chemical	-1	2440413
)	O	-1	2440413
3	O	-1	2440413
h	O	-1	2440413
after	O	-1	2440413
exposure	O	-1	2440413
to	O	-1	2440413
gamma@@	B-Chemical	D001556	2440413
-H@@	I-Chemical	-1	2440413
C@@	I-Chemical	-1	2440413
H	I-Chemical	-1	2440413
and	O	-1	2440413
conver@@	O	-1	2440413
se@@	O	-1	2440413
ly	O	-1	2440413
increase	O	-1	2440413
th@@	O	-1	2440413
res@@	O	-1	2440413
h@@	O	-1	2440413
old	O	-1	2440413
to	O	-1	2440413
P@@	B-Chemical	D010433	2440413
T@@	I-Chemical	-1	2440413
Z	I-Chemical	-1	2440413
-induced	O	-1	2440413
seizures	B-Disease	D012640	2440413
24	O	-1	2440413
h	O	-1	2440413
after	O	-1	2440413
exposure	O	-1	2440413
to	O	-1	2440413
gamma@@	B-Chemical	D001556	2440413
-H@@	I-Chemical	-1	2440413
C@@	I-Chemical	-1	2440413
H	I-Chemical	-1	2440413
(V@@	O	-1	2440413
o@@	O	-1	2440413
h@@	O	-1	2440413
l@@	O	-1	2440413
and	O	-1	2440413
et	O	-1	2440413
al.	O	-1	2440413
19@@	O	-1	2440413
8@@	O	-1	2440413
1).	O	-1	2440413
In	O	-1	2440413
this	O	-1	2440413
study,	O	-1	2440413
the	O	-1	2440413
severity	O	-1	2440413
of	O	-1	2440413
response	O	-1	2440413
to	O	-1	2440413
other	O	-1	2440413
seizure	B-Disease	D012640	2440413
-@@	O	-1	2440413
induc@@	O	-1	2440413
ing	O	-1	2440413
agents	O	-1	2440413
was	O	-1	2440413
tested	O	-1	2440413
in	O	-1	2440413
mice	O	-1	2440413
1	O	-1	2440413
and	O	-1	2440413
24	O	-1	2440413
h	O	-1	2440413
after	O	-1	2440413
intra@@	O	-1	2440413
per@@	O	-1	2440413
it@@	O	-1	2440413
one@@	O	-1	2440413
al	O	-1	2440413
administration	O	-1	2440413
of	O	-1	2440413
8@@	O	-1	2440413
0	O	-1	2440413
mg/kg	O	-1	2440413
gamma@@	B-Chemical	D001556	2440413
-H@@	I-Chemical	-1	2440413
C@@	I-Chemical	-1	2440413
H	I-Chemical	-1	2440413
.	O	-1	2440413
One	O	-1	2440413
h@@	O	-1	2440413
our	O	-1	2440413
after	O	-1	2440413
the	O	-1	2440413
administration	O	-1	2440413
of	O	-1	2440413
gamma@@	B-Chemical	D001556	2440413
-H@@	I-Chemical	-1	2440413
C@@	I-Chemical	-1	2440413
H	I-Chemical	-1	2440413
,	O	-1	2440413
the	O	-1	2440413
activity	O	-1	2440413
of	O	-1	2440413
seizure	B-Disease	D012640	2440413
-@@	O	-1	2440413
induc@@	O	-1	2440413
ing	O	-1	2440413
agents	O	-1	2440413
was	O	-1	2440413
increas@@	O	-1	2440413
ed,	O	-1	2440413
reg@@	O	-1	2440413
ar@@	O	-1	2440413
d@@	O	-1	2440413
less	O	-1	2440413
of	O	-1	2440413
their	O	-1	2440413
mechanis@@	O	-1	2440413
m@@	O	-1	2440413
,	O	-1	2440413
while	O	-1	2440413
24	O	-1	2440413
h	O	-1	2440413
after	O	-1	2440413
gamma@@	B-Chemical	D001556	2440413
-H@@	I-Chemical	-1	2440413
C@@	I-Chemical	-1	2440413
H	I-Chemical	-1	2440413
a	O	-1	2440413
differen@@	O	-1	2440413
tial	O	-1	2440413
response	O	-1	2440413
was	O	-1	2440413
obser@@	O	-1	2440413
ved.	O	-1	2440413
S@@	B-Disease	D012640	2440413
e@@	I-Disease	-1	2440413
iz@@	I-Disease	-1	2440413
ure	I-Disease	-1	2440413
activity	O	-1	2440413
due	O	-1	2440413
to	O	-1	2440413
P@@	B-Chemical	D010433	2440413
T@@	I-Chemical	-1	2440413
Z	I-Chemical	-1	2440413
and	O	-1	2440413
p@@	B-Chemical	D010852	2440413
ic@@	I-Chemical	-1	2440413
ro@@	I-Chemical	-1	2440413
tox@@	I-Chemical	-1	2440413
in	I-Chemical	-1	2440413
(	O	-1	2440413
P@@	B-Chemical	D010852	2440413
T@@	I-Chemical	-1	2440413
X	I-Chemical	-1	2440413
)	O	-1	2440413
was	O	-1	2440413
significantly	O	-1	2440413
decreas@@	O	-1	2440413
ed@@	O	-1	2440413
;	O	-1	2440413
however,	O	-1	2440413
seizure	B-Disease	D012640	2440413
activity	O	-1	2440413
due	O	-1	2440413
to	O	-1	2440413
3-@@	B-Chemical	D015097	2440413
mer@@	I-Chemical	-1	2440413
cap@@	I-Chemical	-1	2440413
to@@	I-Chemical	-1	2440413
pro@@	I-Chemical	-1	2440413
pi@@	I-Chemical	-1	2440413
onic	I-Chemical	-1	2440413
acid	I-Chemical	-1	2440413
(	O	-1	2440413
MP@@	B-Chemical	D015097	2440413
A	I-Chemical	-1	2440413
),	O	-1	2440413
b@@	B-Chemical	D001640	2440413
ic@@	I-Chemical	-1	2440413
uc@@	I-Chemical	-1	2440413
ul@@	I-Chemical	-1	2440413
line	I-Chemical	-1	2440413
(	O	-1	2440413
BC@@	B-Chemical	D001640	2440413
C	I-Chemical	-1	2440413
),	O	-1	2440413
meth@@	B-Chemical	C034818	2440413
yl	I-Chemical	-1	2440413
6@@	I-Chemical	-1	2440413
,@@	I-Chemical	-1	2440413
7-@@	I-Chemical	-1	2440413
di@@	I-Chemical	-1	2440413
meth@@	I-Chemical	-1	2440413
ox@@	I-Chemical	-1	2440413
y-@@	I-Chemical	-1	2440413
4-@@	I-Chemical	-1	2440413
eth@@	I-Chemical	-1	2440413
yl@@	I-Chemical	-1	2440413
-@@	I-Chemical	-1	2440413
B@@	I-Chemical	-1	2440413
-@@	I-Chemical	-1	2440413
carb@@	I-Chemical	-1	2440413
ol@@	I-Chemical	-1	2440413
ine-@@	I-Chemical	-1	2440413
3-@@	I-Chemical	-1	2440413
carb@@	I-Chemical	-1	2440413
ox@@	I-Chemical	-1	2440413
yl@@	I-Chemical	-1	2440413
ate	I-Chemical	-1	2440413
(	O	-1	2440413
D@@	B-Chemical	C034818	2440413
M@@	I-Chemical	-1	2440413
C@@	I-Chemical	-1	2440413
M	I-Chemical	-1	2440413
),	O	-1	2440413
or	O	-1	2440413
str@@	B-Chemical	D013331	2440413
y@@	I-Chemical	-1	2440413
ch@@	I-Chemical	-1	2440413
n@@	I-Chemical	-1	2440413
ine	I-Chemical	-1	2440413
(	O	-1	2440413
S@@	B-Chemical	D013331	2440413
T@@	I-Chemical	-1	2440413
R	I-Chemical	-1	2440413
)	O	-1	2440413
was	O	-1	2440413
not	O	-1	2440413
different	O	-1	2440413
from	O	-1	2440413
control@@	O	-1	2440413
.	O	-1	2440413
In	O	-1	2440413
vit@@	O	-1	2440413
ro@@	O	-1	2440413
,	O	-1	2440413
gamma@@	B-Chemical	D001556	2440413
-H@@	I-Chemical	-1	2440413
C@@	I-Chemical	-1	2440413
H	I-Chemical	-1	2440413
,	O	-1	2440413
pent@@	B-Chemical	D010433	2440413
yl@@	I-Chemical	-1	2440413
en@@	I-Chemical	-1	2440413
e@@	I-Chemical	-1	2440413
te@@	I-Chemical	-1	2440413
tra@@	I-Chemical	-1	2440413
z@@	I-Chemical	-1	2440413
ol	I-Chemical	-1	2440413
and	O	-1	2440413
p@@	B-Chemical	D010852	2440413
ic@@	I-Chemical	-1	2440413
ro@@	I-Chemical	-1	2440413
tox@@	I-Chemical	-1	2440413
in	I-Chemical	-1	2440413
were	O	-1	2440413
shown	O	-1	2440413
to	O	-1	2440413
inhib@@	O	-1	2440413
it	O	-1	2440413
3@@	B-Chemical	C046308	2440413
H@@	I-Chemical	-1	2440413
-@@	I-Chemical	-1	2440413
T@@	I-Chemical	-1	2440413
B@@	I-Chemical	-1	2440413
O@@	I-Chemical	-1	2440413
B	I-Chemical	-1	2440413
b@@	O	-1	2440413
ind@@	O	-1	2440413
ing	O	-1	2440413
in	O	-1	2440413
mouse	O	-1	2440413
wh@@	O	-1	2440413
ole	O	-1	2440413
bra@@	O	-1	2440413
in,	O	-1	2440413
with	O	-1	2440413
IC@@	O	-1	2440413
50	O	-1	2440413
values	O	-1	2440413
of	O	-1	2440413
4.@@	O	-1	2440413
6,	O	-1	2440413
4@@	O	-1	2440413
0@@	O	-1	2440413
4	O	-1	2440413
and	O	-1	2440413
9.@@	O	-1	2440413
4	O	-1	2440413
micro@@	O	-1	2440413
M@@	O	-1	2440413
,	O	-1	2440413
respectively.	O	-1	2440413
MP@@	B-Chemical	D015097	2440413
A	I-Chemical	-1	2440413
,	O	-1	2440413
BC@@	B-Chemical	D001640	2440413
C	I-Chemical	-1	2440413
,	O	-1	2440413
D@@	B-Chemical	C034818	2440413
M@@	I-Chemical	-1	2440413
C@@	I-Chemical	-1	2440413
M	I-Chemical	-1	2440413
,	O	-1	2440413
and	O	-1	2440413
S@@	B-Chemical	D013331	2440413
T@@	I-Chemical	-1	2440413
R	I-Chemical	-1	2440413
showed	O	-1	2440413
no	O	-1	2440413
inhibition	O	-1	2440413
of	O	-1	2440413
3@@	B-Chemical	C046308	2440413
H@@	I-Chemical	-1	2440413
-@@	I-Chemical	-1	2440413
T@@	I-Chemical	-1	2440413
B@@	I-Chemical	-1	2440413
O@@	I-Chemical	-1	2440413
B	I-Chemical	-1	2440413
(	O	-1	2440413
t-@@	B-Chemical	C046308	2440413
but@@	I-Chemical	-1	2440413
yl	I-Chemical	-1	2440413
b@@	I-Chemical	-1	2440413
ic@@	I-Chemical	-1	2440413
yc@@	I-Chemical	-1	2440413
lo@@	I-Chemical	-1	2440413
-@@	I-Chemical	-1	2440413
or@@	I-Chemical	-1	2440413
th@@	I-Chemical	-1	2440413
ob@@	I-Chemical	-1	2440413
enz@@	I-Chemical	-1	2440413
o@@	I-Chemical	-1	2440413
ate	I-Chemical	-1	2440413
)	O	-1	2440413
b@@	O	-1	2440413
ind@@	O	-1	2440413
ing	O	-1	2440413
at	O	-1	2440413
concentrations	O	-1	2440413
of	O	-1	2440413
100	O	-1	2440413
mic@@	O	-1	2440413
ron@@	O	-1	2440413
.	O	-1	2440413
The	O	-1	2440413
pharmac@@	O	-1	2440413
ological	O	-1	2440413
ch@@	O	-1	2440413
all@@	O	-1	2440413
enge	O	-1	2440413
data	O	-1	2440413
suggest	O	-1	2440413
that	O	-1	2440413
toler@@	O	-1	2440413
ance	O	-1	2440413
may	O	-1	2440413
occ@@	O	-1	2440413
ur	O	-1	2440413
to	O	-1	2440413
seizure	B-Disease	D012640	2440413
activity	O	-1	2440413
induced	O	-1	2440413
by	O	-1	2440413
P@@	B-Chemical	D010433	2440413
T@@	I-Chemical	-1	2440413
Z	I-Chemical	-1	2440413
and	O	-1	2440413
P@@	B-Chemical	D010852	2440413
T@@	I-Chemical	-1	2440413
X	I-Chemical	-1	2440413
24	O	-1	2440413
h	O	-1	2440413
after	O	-1	2440413
gamma@@	B-Chemical	D001556	2440413
-H@@	I-Chemical	-1	2440413
C@@	I-Chemical	-1	2440413
H	I-Chemical	-1	2440413
,	O	-1	2440413
s@@	O	-1	2440413
inc@@	O	-1	2440413
e	O	-1	2440413
the	O	-1	2440413
response	O	-1	2440413
to	O	-1	2440413
only	O	-1	2440413
these	O	-1	2440413
two	O	-1	2440413
seizure	B-Disease	D012640	2440413
-@@	O	-1	2440413
induc@@	O	-1	2440413
ing	O	-1	2440413
agents	O	-1	2440413
is	O	-1	2440413
decreas@@	O	-1	2440413
ed.	O	-1	2440413
The	O	-1	2440413
in	O	-1	2440413
vit@@	O	-1	2440413
r@@	O	-1	2440413
o	O	-1	2440413
data	O	-1	2440413
suggest	O	-1	2440413
that	O	-1	2440413
the	O	-1	2440413
sit@@	O	-1	2440413
e	O	-1	2440413
respon@@	O	-1	2440413
sible	O	-1	2440413
for	O	-1	2440413
the	O	-1	2440413
decrease	O	-1	2440413
in	O	-1	2440413
seizure	B-Disease	D012640	2440413
activity	O	-1	2440413
24	O	-1	2440413
h	O	-1	2440413
after	O	-1	2440413
gamma@@	B-Chemical	D001556	2440413
-H@@	I-Chemical	-1	2440413
C@@	I-Chemical	-1	2440413
H	I-Chemical	-1	2440413
may	O	-1	2440413
be	O	-1	2440413
the	O	-1	2440413
G@@	B-Chemical	D005680	2440413
A@@	I-Chemical	-1	2440413
B@@	I-Chemical	-1	2440413
A	I-Chemical	-1	2440413
-@@	O	-1	2440413
A	O	-1	2440413
receptor@@	O	-1	2440413
-@@	O	-1	2440413
lin@@	O	-1	2440413
ked	O	-1	2440413
chlor@@	O	-1	2440413
ide	O	-1	2440413
channe@@	O	-1	2440413
l@@	O	-1	2440413
.	O	-1	2440413

S@@	O	-1	12483326
ev@@	O	-1	12483326
ere	O	-1	12483326
oc@@	B-Disease	D005128	12483326
ular	I-Disease	-1	12483326
and	I-Disease	-1	12483326
or@@	I-Disease	-1	12483326
b@@	I-Disease	-1	12483326
it@@	I-Disease	-1	12483326
al	I-Disease	-1	12483326
toxicity	I-Disease	-1	12483326
oc@@	B-Disease	D009916	12483326
ular	I-Disease	-1	12483326
and	I-Disease	-1	12483326
or@@	I-Disease	-1	12483326
b@@	I-Disease	-1	12483326
it@@	I-Disease	-1	12483326
al	I-Disease	-1	12483326
toxicity	I-Disease	-1	12483326
after	O	-1	12483326
intrac@@	O	-1	12483326
a@@	O	-1	12483326
ro@@	O	-1	12483326
ti@@	O	-1	12483326
d	O	-1	12483326
injection	O	-1	12483326
of	O	-1	12483326
car@@	B-Chemical	D016190	12483326
bo@@	I-Chemical	-1	12483326
pl@@	I-Chemical	-1	12483326
atin	I-Chemical	-1	12483326
for	O	-1	12483326
recur@@	O	-1	12483326
rent	O	-1	12483326
g@@	B-Disease	D005909	12483326
li@@	I-Disease	-1	12483326
ob@@	I-Disease	-1	12483326
l@@	I-Disease	-1	12483326
ast@@	I-Disease	-1	12483326
om@@	I-Disease	-1	12483326
as	I-Disease	-1	12483326
.	O	-1	12483326
BACKGROUND:	O	-1	12483326
G@@	B-Disease	D005909	12483326
li@@	I-Disease	-1	12483326
ob@@	I-Disease	-1	12483326
l@@	I-Disease	-1	12483326
ast@@	I-Disease	-1	12483326
oma	I-Disease	-1	12483326
is	O	-1	12483326
a	O	-1	12483326
mal@@	B-Disease	D009369	12483326
i@@	I-Disease	-1	12483326
gn@@	I-Disease	-1	12483326
ant	I-Disease	-1	12483326
tumor	I-Disease	-1	12483326
that	O	-1	12483326
occur@@	O	-1	12483326
s	O	-1	12483326
in	O	-1	12483326
the	O	-1	12483326
ce@@	O	-1	12483326
reb@@	O	-1	12483326
ru@@	O	-1	12483326
m	O	-1	12483326
during	O	-1	12483326
ad@@	O	-1	12483326
ul@@	O	-1	12483326
th@@	O	-1	12483326
o@@	O	-1	12483326
o@@	O	-1	12483326
d.	O	-1	12483326
W@@	O	-1	12483326
it@@	O	-1	12483326
h	O	-1	12483326
current	O	-1	12483326
treatment	O	-1	12483326
regimen@@	O	-1	12483326
s	O	-1	12483326
including	O	-1	12483326
combined	O	-1	12483326
surger@@	O	-1	12483326
y,	O	-1	12483326
radi@@	O	-1	12483326
ation	O	-1	12483326
and	O	-1	12483326
chemo@@	O	-1	12483326
therapy,	O	-1	12483326
the	O	-1	12483326
average	O	-1	12483326
lif@@	O	-1	12483326
e	O	-1	12483326
ex@@	O	-1	12483326
p@@	O	-1	12483326
ect@@	O	-1	12483326
anc@@	O	-1	12483326
y	O	-1	12483326
of	O	-1	12483326
the	O	-1	12483326
patients	O	-1	12483326
is	O	-1	12483326
lim@@	O	-1	12483326
ited	O	-1	12483326
to	O	-1	12483326
appro@@	O	-1	12483326
xim@@	O	-1	12483326
ately	O	-1	12483326
1	O	-1	12483326
year@@	O	-1	12483326
.	O	-1	12483326
The@@	O	-1	12483326
refore,	O	-1	12483326
patients	O	-1	12483326
with	O	-1	12483326
g@@	B-Disease	D005909	12483326
li@@	I-Disease	-1	12483326
ob@@	I-Disease	-1	12483326
l@@	I-Disease	-1	12483326
ast@@	I-Disease	-1	12483326
oma	I-Disease	-1	12483326
so@@	O	-1	12483326
me@@	O	-1	12483326
times	O	-1	12483326
have	O	-1	12483326
intrac@@	O	-1	12483326
a@@	O	-1	12483326
ro@@	O	-1	12483326
ti@@	O	-1	12483326
d	O	-1	12483326
injection	O	-1	12483326
of	O	-1	12483326
carcin@@	O	-1	12483326
ost@@	O	-1	12483326
ati@@	O	-1	12483326
c@@	O	-1	12483326
s	O	-1	12483326
ad@@	O	-1	12483326
ded	O	-1	12483326
to	O	-1	12483326
the	O	-1	12483326
treatment	O	-1	12483326
regimen@@	O	-1	12483326
.	O	-1	12483326
G@@	O	-1	12483326
en@@	O	-1	12483326
er@@	O	-1	12483326
ally,	O	-1	12483326
car@@	B-Chemical	D016190	12483326
bo@@	I-Chemical	-1	12483326
pl@@	I-Chemical	-1	12483326
atin	I-Chemical	-1	12483326
is	O	-1	12483326
sa@@	O	-1	12483326
id	O	-1	12483326
to	O	-1	12483326
have	O	-1	12483326
mil@@	O	-1	12483326
der	O	-1	12483326
side	O	-1	12483326
effects	O	-1	12483326
than	O	-1	12483326
cisplatin	B-Chemical	D002945	12483326
,	O	-1	12483326
wh@@	O	-1	12483326
ose	O	-1	12483326
oc@@	B-Disease	D005128	12483326
ular	I-Disease	-1	12483326
and	I-Disease	-1	12483326
or@@	I-Disease	-1	12483326
b@@	I-Disease	-1	12483326
it@@	I-Disease	-1	12483326
al	I-Disease	-1	12483326
toxicity	I-Disease	-1	12483326
oc@@	B-Disease	D009916	12483326
ular	I-Disease	-1	12483326
and	I-Disease	-1	12483326
or@@	I-Disease	-1	12483326
b@@	I-Disease	-1	12483326
it@@	I-Disease	-1	12483326
al	I-Disease	-1	12483326
toxicity	I-Disease	-1	12483326
are	O	-1	12483326
well	O	-1	12483326
know@@	O	-1	12483326
n@@	O	-1	12483326
.	O	-1	12483326
However,	O	-1	12483326
we	O	-1	12483326
experienced	O	-1	12483326
a	O	-1	12483326
case	O	-1	12483326
of	O	-1	12483326
severe	O	-1	12483326
oc@@	B-Disease	D005128	12483326
ular	I-Disease	-1	12483326
and	I-Disease	-1	12483326
or@@	I-Disease	-1	12483326
b@@	I-Disease	-1	12483326
it@@	I-Disease	-1	12483326
al	I-Disease	-1	12483326
toxicity	I-Disease	-1	12483326
oc@@	B-Disease	D009916	12483326
ular	I-Disease	-1	12483326
and	I-Disease	-1	12483326
or@@	I-Disease	-1	12483326
b@@	I-Disease	-1	12483326
it@@	I-Disease	-1	12483326
al	I-Disease	-1	12483326
toxicity	I-Disease	-1	12483326
after	O	-1	12483326
intrac@@	O	-1	12483326
a@@	O	-1	12483326
ro@@	O	-1	12483326
ti@@	O	-1	12483326
d	O	-1	12483326
injection	O	-1	12483326
of	O	-1	12483326
car@@	B-Chemical	D016190	12483326
bo@@	I-Chemical	-1	12483326
pl@@	I-Chemical	-1	12483326
atin	I-Chemical	-1	12483326
,	O	-1	12483326
which	O	-1	12483326
is	O	-1	12483326
inf@@	O	-1	12483326
requ@@	O	-1	12483326
ently	O	-1	12483326
repor@@	O	-1	12483326
ted.	O	-1	12483326
CA@@	O	-1	12483326
S@@	O	-1	12483326
E:	O	-1	12483326
A	O	-1	12483326
5@@	O	-1	12483326
8@@	O	-1	12483326
-@@	O	-1	12483326
year-old	O	-1	12483326
man	O	-1	12483326
received	O	-1	12483326
an	O	-1	12483326
intrac@@	O	-1	12483326
a@@	O	-1	12483326
ro@@	O	-1	12483326
ti@@	O	-1	12483326
d	O	-1	12483326
injection	O	-1	12483326
of	O	-1	12483326
car@@	B-Chemical	D016190	12483326
bo@@	I-Chemical	-1	12483326
pl@@	I-Chemical	-1	12483326
atin	I-Chemical	-1	12483326
for	O	-1	12483326
recur@@	O	-1	12483326
rent	O	-1	12483326
g@@	B-Disease	D005909	12483326
li@@	I-Disease	-1	12483326
ob@@	I-Disease	-1	12483326
l@@	I-Disease	-1	12483326
ast@@	I-Disease	-1	12483326
om@@	I-Disease	-1	12483326
as	I-Disease	-1	12483326
in	O	-1	12483326
h@@	O	-1	12483326
is	O	-1	12483326
left	O	-1	12483326
tempor@@	O	-1	12483326
al	O	-1	12483326
lo@@	O	-1	12483326
be@@	O	-1	12483326
.	O	-1	12483326
H@@	O	-1	12483326
e	O	-1	12483326
com@@	O	-1	12483326
pl@@	O	-1	12483326
ained	O	-1	12483326
of	O	-1	12483326
pain	B-Disease	D058447	12483326
and	I-Disease	-1	12483326
visual	I-Disease	-1	12483326
dist@@	I-Disease	-1	12483326
urb@@	I-Disease	-1	12483326
ance	I-Disease	-1	12483326
in	I-Disease	-1	12483326
the	I-Disease	-1	12483326
ip@@	I-Disease	-1	12483326
si@@	I-Disease	-1	12483326
lat@@	I-Disease	-1	12483326
eral	I-Disease	-1	12483326
e@@	I-Disease	-1	12483326
y@@	I-Disease	-1	12483326
e	I-Disease	-1	12483326
pain	B-Disease	D014786	12483326
and	I-Disease	-1	12483326
visual	I-Disease	-1	12483326
dist@@	I-Disease	-1	12483326
urb@@	I-Disease	-1	12483326
ance	I-Disease	-1	12483326
in	I-Disease	-1	12483326
the	I-Disease	-1	12483326
ip@@	I-Disease	-1	12483326
si@@	I-Disease	-1	12483326
lat@@	I-Disease	-1	12483326
eral	I-Disease	-1	12483326
e@@	I-Disease	-1	12483326
y@@	I-Disease	-1	12483326
e	I-Disease	-1	12483326
30	O	-1	12483326
h	O	-1	12483326
after	O	-1	12483326
the	O	-1	12483326
injec@@	O	-1	12483326
tion.	O	-1	12483326
V@@	O	-1	12483326
ari@@	O	-1	12483326
ous	O	-1	12483326
oc@@	O	-1	12483326
ular	O	-1	12483326
symptoms	O	-1	12483326
and	O	-1	12483326
findings	O	-1	12483326
caused	O	-1	12483326
by	O	-1	12483326
car@@	B-Chemical	D016190	12483326
bo@@	I-Chemical	-1	12483326
pl@@	I-Chemical	-1	12483326
atin	I-Chemical	-1	12483326
toxicity	B-Disease	D064420	12483326
were	O	-1	12483326
se@@	O	-1	12483326
en@@	O	-1	12483326
.	O	-1	12483326
RESULTS:	O	-1	12483326
H@@	O	-1	12483326
e	O	-1	12483326
was	O	-1	12483326
treated	O	-1	12483326
with	O	-1	12483326
intravenous	O	-1	12483326
administration	O	-1	12483326
of	O	-1	12483326
cortico@@	O	-1	12483326
steroid@@	O	-1	12483326
s	O	-1	12483326
and	O	-1	12483326
glycer@@	B-Chemical	D005990	12483326
in	I-Chemical	-1	12483326
for	O	-1	12483326
6	O	-1	12483326
days	O	-1	12483326
after	O	-1	12483326
the	O	-1	12483326
injec@@	O	-1	12483326
tion.	O	-1	12483326
Although	O	-1	12483326
the	O	-1	12483326
intra@@	O	-1	12483326
oc@@	O	-1	12483326
ular	O	-1	12483326
pressure	O	-1	12483326
elev@@	O	-1	12483326
ation	O	-1	12483326
caused	O	-1	12483326
by	O	-1	12483326
secondary	O	-1	12483326
acute	O	-1	12483326
ang@@	O	-1	12483326
le@@	O	-1	12483326
-@@	O	-1	12483326
c@@	O	-1	12483326
los@@	O	-1	12483326
ure	O	-1	12483326
gl@@	B-Disease	D005901	12483326
au@@	I-Disease	-1	12483326
com@@	I-Disease	-1	12483326
a	I-Disease	-1	12483326
decreased	O	-1	12483326
and	O	-1	12483326
oc@@	B-Disease	D058447	12483326
ular	I-Disease	-1	12483326
pain	I-Disease	-1	12483326
di@@	O	-1	12483326
min@@	O	-1	12483326
is@@	O	-1	12483326
he@@	O	-1	12483326
d,	O	-1	12483326
in@@	O	-1	12483326
ex@@	O	-1	12483326
or@@	O	-1	12483326
able	O	-1	12483326
pap@@	B-Disease	D010211	12483326
il@@	I-Disease	-1	12483326
le@@	I-Disease	-1	12483326
de@@	I-Disease	-1	12483326
ma	I-Disease	-1	12483326
and	O	-1	12483326
ex@@	O	-1	12483326
ud@@	O	-1	12483326
ative	O	-1	12483326
ret@@	B-Disease	D012163	12483326
inal	I-Disease	-1	12483326
de@@	I-Disease	-1	12483326
tac@@	I-Disease	-1	12483326
h@@	I-Disease	-1	12483326
ment	I-Disease	-1	12483326
continu@@	O	-1	12483326
ed	O	-1	12483326
for	O	-1	12483326
3	O	-1	12483326
week@@	O	-1	12483326
s.	O	-1	12483326
F@@	O	-1	12483326
in@@	O	-1	12483326
ally,	O	-1	12483326
6	O	-1	12483326
weeks	O	-1	12483326
lat@@	O	-1	12483326
er,	O	-1	12483326
diff@@	O	-1	12483326
use	O	-1	12483326
ch@@	B-Disease	C566236	12483326
or@@	I-Disease	-1	12483326
io@@	I-Disease	-1	12483326
ret@@	I-Disease	-1	12483326
inal	I-Disease	-1	12483326
atro@@	I-Disease	-1	12483326
ph@@	I-Disease	-1	12483326
y	I-Disease	-1	12483326
with	O	-1	12483326
op@@	B-Disease	D009896	12483326
tic	I-Disease	-1	12483326
atro@@	I-Disease	-1	12483326
ph@@	I-Disease	-1	12483326
y	I-Disease	-1	12483326
occurred	O	-1	12483326
and	O	-1	12483326
the	O	-1	12483326
vi@@	O	-1	12483326
sion	O	-1	12483326
in	O	-1	12483326
h@@	O	-1	12483326
is	O	-1	12483326
left	O	-1	12483326
e@@	O	-1	12483326
y@@	O	-1	12483326
e	O	-1	12483326
was	O	-1	12483326
lo@@	O	-1	12483326
st@@	O	-1	12483326
.	O	-1	12483326
CONCLUSION:	O	-1	12483326
Whe@@	O	-1	12483326
n	O	-1	12483326
perform@@	O	-1	12483326
ing	O	-1	12483326
intrac@@	O	-1	12483326
a@@	O	-1	12483326
ro@@	O	-1	12483326
ti@@	O	-1	12483326
d	O	-1	12483326
injection	O	-1	12483326
of	O	-1	12483326
car@@	B-Chemical	D016190	12483326
bo@@	I-Chemical	-1	12483326
pl@@	I-Chemical	-1	12483326
atin	I-Chemical	-1	12483326
,	O	-1	12483326
we	O	-1	12483326
mus@@	O	-1	12483326
t	O	-1	12483326
be	O	-1	12483326
aw@@	O	-1	12483326
are	O	-1	12483326
of	O	-1	12483326
its	O	-1	12483326
potenti@@	O	-1	12483326
ally	O	-1	12483326
bl@@	O	-1	12483326
ind@@	O	-1	12483326
ing	O	-1	12483326
oc@@	B-Disease	D005128	12483326
ular	I-Disease	-1	12483326
toxicity	I-Disease	-1	12483326
.	O	-1	12483326
It	O	-1	12483326
is	O	-1	12483326
recomm@@	O	-1	12483326
en@@	O	-1	12483326
ded	O	-1	12483326
that	O	-1	12483326
further	O	-1	12483326
studies	O	-1	12483326
and	O	-1	12483326
investig@@	O	-1	12483326
ations	O	-1	12483326
are	O	-1	12483326
under@@	O	-1	12483326
tak@@	O	-1	12483326
en	O	-1	12483326
in	O	-1	12483326
the	O	-1	12483326
eff@@	O	-1	12483326
ort	O	-1	12483326
to	O	-1	12483326
minim@@	O	-1	12483326
iz@@	O	-1	12483326
e	O	-1	12483326
such	O	-1	12483326
severe	O	-1	12483326
side	O	-1	12483326
effects.	O	-1	12483326

Ph@@	O	-1	1664218
ase	O	-1	1664218
II	O	-1	1664218
study	O	-1	1664218
of	O	-1	1664218
the	O	-1	1664218
am@@	B-Chemical	D000677	1664218
s@@	I-Chemical	-1	1664218
ac@@	I-Chemical	-1	1664218
rine	I-Chemical	-1	1664218
an@@	O	-1	1664218
alo@@	O	-1	1664218
gu@@	O	-1	1664218
e	O	-1	1664218
CI@@	B-Chemical	C042315	1664218
-@@	I-Chemical	-1	1664218
9@@	I-Chemical	-1	1664218
21	I-Chemical	-1	1664218
(	O	-1	1664218
N@@	B-Chemical	C042315	1664218
S@@	I-Chemical	-1	1664218
C	I-Chemical	-1	1664218
34@@	I-Chemical	-1	1664218
34@@	I-Chemical	-1	1664218
9@@	I-Chemical	-1	1664218
9	I-Chemical	-1	1664218
)	O	-1	1664218
in	O	-1	1664218
non-@@	B-Disease	D002289	1664218
sm@@	I-Disease	-1	1664218
all	I-Disease	-1	1664218
cell	I-Disease	-1	1664218
l@@	I-Disease	-1	1664218
un@@	I-Disease	-1	1664218
g	I-Disease	-1	1664218
cancer	I-Disease	-1	1664218
.	O	-1	1664218
CI@@	B-Chemical	C042315	1664218
-@@	I-Chemical	-1	1664218
9@@	I-Chemical	-1	1664218
21	I-Chemical	-1	1664218
(	O	-1	1664218
N@@	B-Chemical	C042315	1664218
S@@	I-Chemical	-1	1664218
C	I-Chemical	-1	1664218
34@@	I-Chemical	-1	1664218
34@@	I-Chemical	-1	1664218
9@@	I-Chemical	-1	1664218
9	I-Chemical	-1	1664218
;	O	-1	1664218
9@@	B-Chemical	C042315	1664218
-@@	I-Chemical	-1	1664218
[@@	I-Chemical	-1	1664218
[@@	I-Chemical	-1	1664218
2-@@	I-Chemical	-1	1664218
meth@@	I-Chemical	-1	1664218
ox@@	I-Chemical	-1	1664218
y-@@	I-Chemical	-1	1664218
4-@@	I-Chemical	-1	1664218
[@@	I-Chemical	-1	1664218
(@@	I-Chemical	-1	1664218
methyl@@	I-Chemical	-1	1664218
sul@@	I-Chemical	-1	1664218
ph@@	I-Chemical	-1	1664218
on@@	I-Chemical	-1	1664218
yl@@	I-Chemical	-1	1664218
)@@	I-Chemical	-1	1664218
amino@@	I-Chemical	-1	1664218
]@@	I-Chemical	-1	1664218
phenyl@@	I-Chemical	-1	1664218
]@@	I-Chemical	-1	1664218
amino@@	I-Chemical	-1	1664218
]	I-Chemical	-1	1664218
-@@	I-Chemical	-1	1664218
N@@	I-Chemical	-1	1664218
,@@	I-Chemical	-1	1664218
5-@@	I-Chemical	-1	1664218
di@@	I-Chemical	-1	1664218
methyl@@	I-Chemical	-1	1664218
-	I-Chemical	-1	1664218
4-@@	I-Chemical	-1	1664218
ac@@	I-Chemical	-1	1664218
ri@@	I-Chemical	-1	1664218
d@@	I-Chemical	-1	1664218
in@@	I-Chemical	-1	1664218
ec@@	I-Chemical	-1	1664218
arb@@	I-Chemical	-1	1664218
ox@@	I-Chemical	-1	1664218
amide	I-Chemical	-1	1664218
)	O	-1	1664218
is	O	-1	1664218
a	O	-1	1664218
to@@	O	-1	1664218
po@@	O	-1	1664218
is@@	O	-1	1664218
om@@	O	-1	1664218
er@@	O	-1	1664218
ase	O	-1	1664218
II	O	-1	1664218
po@@	O	-1	1664218
ison	O	-1	1664218
with	O	-1	1664218
high	O	-1	1664218
experimental	O	-1	1664218
anti@@	O	-1	1664218
tum@@	O	-1	1664218
our	O	-1	1664218
activ@@	O	-1	1664218
ity.	O	-1	1664218
It	O	-1	1664218
was	O	-1	1664218
administered	O	-1	1664218
by	O	-1	1664218
15	O	-1	1664218
min	O	-1	1664218
infusion	O	-1	1664218
to	O	-1	1664218
16	O	-1	1664218
evalu@@	O	-1	1664218
able	O	-1	1664218
patients	O	-1	1664218
with	O	-1	1664218
non-@@	B-Disease	D002289	1664218
sm@@	I-Disease	-1	1664218
all	I-Disease	-1	1664218
cell	I-Disease	-1	1664218
l@@	I-Disease	-1	1664218
un@@	I-Disease	-1	1664218
g	I-Disease	-1	1664218
cancer	I-Disease	-1	1664218
(	O	-1	1664218
N@@	B-Disease	D002289	1664218
S@@	I-Disease	-1	1664218
CL@@	I-Disease	-1	1664218
C	I-Disease	-1	1664218
)	O	-1	1664218
(@@	O	-1	1664218
7	O	-1	1664218
with	O	-1	1664218
no	O	-1	1664218
prior	O	-1	1664218
treatment,	O	-1	1664218
9	O	-1	1664218
patients	O	-1	1664218
in	O	-1	1664218
rel@@	O	-1	1664218
ap@@	O	-1	1664218
se	O	-1	1664218
following	O	-1	1664218
surg@@	O	-1	1664218
ery@@	O	-1	1664218
/@@	O	-1	1664218
radi@@	O	-1	1664218
o@@	O	-1	1664218
therap@@	O	-1	1664218
y@@	O	-1	1664218
)	O	-1	1664218
at	O	-1	1664218
a	O	-1	1664218
dose	O	-1	1664218
(6@@	O	-1	1664218
4@@	O	-1	1664218
8	O	-1	1664218
mg/m@@	O	-1	1664218
2	O	-1	1664218
divid@@	O	-1	1664218
ed	O	-1	1664218
over	O	-1	1664218
3	O	-1	1664218
day@@	O	-1	1664218
s,	O	-1	1664218
repe@@	O	-1	1664218
ated	O	-1	1664218
every	O	-1	1664218
3	O	-1	1664218
week@@	O	-1	1664218
s)	O	-1	1664218
determined	O	-1	1664218
by	O	-1	1664218
phase	O	-1	1664218
I	O	-1	1664218
tri@@	O	-1	1664218
al.	O	-1	1664218
Patients	O	-1	1664218
had	O	-1	1664218
a	O	-1	1664218
median	O	-1	1664218
perform@@	O	-1	1664218
ance	O	-1	1664218
status	O	-1	1664218
of	O	-1	1664218
1	O	-1	1664218
(@@	O	-1	1664218
W@@	O	-1	1664218
HO@@	O	-1	1664218
),	O	-1	1664218
and	O	-1	1664218
median	O	-1	1664218
age	O	-1	1664218
of	O	-1	1664218
6@@	O	-1	1664218
1	O	-1	1664218
year@@	O	-1	1664218
s.	O	-1	1664218
The	O	-1	1664218
hist@@	O	-1	1664218
ology	O	-1	1664218
comp@@	O	-1	1664218
ris@@	O	-1	1664218
ed	O	-1	1664218
s@@	B-Disease	D002294	1664218
qu@@	I-Disease	-1	1664218
am@@	I-Disease	-1	1664218
ous	I-Disease	-1	1664218
carcin@@	I-Disease	-1	1664218
oma	I-Disease	-1	1664218
(1@@	O	-1	1664218
1),	O	-1	1664218
aden@@	B-Disease	D000230	1664218
oc@@	I-Disease	-1	1664218
arc@@	I-Disease	-1	1664218
in@@	I-Disease	-1	1664218
oma	I-Disease	-1	1664218
(1@@	O	-1	1664218
),	O	-1	1664218
mi@@	O	-1	1664218
x@@	O	-1	1664218
ed	O	-1	1664218
hist@@	O	-1	1664218
ology	O	-1	1664218
(2@@	O	-1	1664218
),	O	-1	1664218
b@@	B-Disease	D002282	1664218
ron@@	I-Disease	-1	1664218
ch@@	I-Disease	-1	1664218
io@@	I-Disease	-1	1664218
-@@	I-Disease	-1	1664218
al@@	I-Disease	-1	1664218
ve@@	I-Disease	-1	1664218
ol@@	I-Disease	-1	1664218
ar	I-Disease	-1	1664218
carcin@@	I-Disease	-1	1664218
oma	I-Disease	-1	1664218
(1@@	O	-1	1664218
)	O	-1	1664218
and	O	-1	1664218
larg@@	O	-1	1664218
e	O	-1	1664218
cell	O	-1	1664218
un@@	B-Disease	D002277	1664218
differen@@	I-Disease	-1	1664218
ti@@	I-Disease	-1	1664218
ated	I-Disease	-1	1664218
carcin@@	I-Disease	-1	1664218
oma	I-Disease	-1	1664218
(1@@	O	-1	1664218
).	O	-1	1664218
Ne@@	B-Disease	D009503	1664218
ut@@	I-Disease	-1	1664218
ro@@	I-Disease	-1	1664218
pen@@	I-Disease	-1	1664218
ia	I-Disease	-1	1664218
gra@@	O	-1	1664218
de	O	-1	1664218
greater	O	-1	1664218
than	O	-1	1664218
or	O	-1	1664218
equ@@	O	-1	1664218
al	O	-1	1664218
to	O	-1	1664218
3	O	-1	1664218
was	O	-1	1664218
seen	O	-1	1664218
in	O	-1	1664218
15	O	-1	1664218
patients,	O	-1	1664218
inf@@	B-Disease	D007239	1664218
ec@@	I-Disease	-1	1664218
tions	I-Disease	-1	1664218
with	O	-1	1664218
recovery	O	-1	1664218
in	O	-1	1664218
3,	O	-1	1664218
and	O	-1	1664218
g@@	O	-1	1664218
r@@	O	-1	1664218
and	O	-1	1664218
m@@	O	-1	1664218
al	O	-1	1664218
seizures	B-Disease	D012640	1664218
in	O	-1	1664218
1	O	-1	1664218
patient@@	O	-1	1664218
.	O	-1	1664218
G@@	O	-1	1664218
ra@@	O	-1	1664218
de	O	-1	1664218
less	O	-1	1664218
than	O	-1	1664218
or	O	-1	1664218
equ@@	O	-1	1664218
al	O	-1	1664218
to	O	-1	1664218
2	O	-1	1664218
nausea	B-Disease	D009325	1664218
and	O	-1	1664218
v@@	B-Disease	D014839	1664218
om@@	I-Disease	-1	1664218
it@@	I-Disease	-1	1664218
ing	I-Disease	-1	1664218
occurred	O	-1	1664218
in	O	-1	1664218
6@@	O	-1	1664218
6%	O	-1	1664218
cour@@	O	-1	1664218
ses	O	-1	1664218
and	O	-1	1664218
ph@@	B-Disease	D010689	1664218
le@@	I-Disease	-1	1664218
b@@	I-Disease	-1	1664218
iti@@	I-Disease	-1	1664218
s	I-Disease	-1	1664218
in	O	-1	1664218
the	O	-1	1664218
infusion	O	-1	1664218
ar@@	O	-1	1664218
m	O	-1	1664218
in	O	-1	1664218
3@@	O	-1	1664218
7@@	O	-1	1664218
%.	O	-1	1664218
1	O	-1	1664218
patient	O	-1	1664218
with	O	-1	1664218
s@@	B-Disease	D002294	1664218
qu@@	I-Disease	-1	1664218
am@@	I-Disease	-1	1664218
ous	I-Disease	-1	1664218
cell	I-Disease	-1	1664218
carcin@@	I-Disease	-1	1664218
oma	I-Disease	-1	1664218
achi@@	O	-1	1664218
ev@@	O	-1	1664218
ed	O	-1	1664218
a	O	-1	1664218
partial	O	-1	1664218
response	O	-1	1664218
l@@	O	-1	1664218
ast@@	O	-1	1664218
ing	O	-1	1664218
5	O	-1	1664218
months.	O	-1	1664218
F@@	O	-1	1664218
urther	O	-1	1664218
test@@	O	-1	1664218
ing	O	-1	1664218
in	O	-1	1664218
this	O	-1	1664218
and	O	-1	1664218
other	O	-1	1664218
tum@@	B-Disease	D009369	1664218
our	I-Disease	-1	1664218
typ@@	O	-1	1664218
es	O	-1	1664218
using	O	-1	1664218
multiple	O	-1	1664218
daily	O	-1	1664218
sch@@	O	-1	1664218
ed@@	O	-1	1664218
ul@@	O	-1	1664218
es	O	-1	1664218
is	O	-1	1664218
war@@	O	-1	1664218
ran@@	O	-1	1664218
ted.	O	-1	1664218

Al@@	B-Chemical	D008063	18809400
pha@@	I-Chemical	-1	18809400
-@@	I-Chemical	-1	18809400
li@@	I-Chemical	-1	18809400
po@@	I-Chemical	-1	18809400
ic	I-Chemical	-1	18809400
acid	I-Chemical	-1	18809400
prev@@	O	-1	18809400
ents	O	-1	18809400
mitochondrial	B-Disease	D028361	18809400
damage	I-Disease	-1	18809400
and	O	-1	18809400
neuro@@	B-Disease	D020258	18809400
toxicity	I-Disease	-1	18809400
in	O	-1	18809400
experimental	O	-1	18809400
chemotherapy	O	-1	18809400
neuropathy	B-Disease	D009422	18809400
.	O	-1	18809400
The	O	-1	18809400
study	O	-1	18809400
investig@@	O	-1	18809400
ates	O	-1	18809400
if	O	-1	18809400
alpha-@@	B-Chemical	D008063	18809400
li@@	I-Chemical	-1	18809400
po@@	I-Chemical	-1	18809400
ic	I-Chemical	-1	18809400
acid	I-Chemical	-1	18809400
is	O	-1	18809400
neuro@@	O	-1	18809400
protective	O	-1	18809400
against	O	-1	18809400
chemotherapy	O	-1	18809400
induced	O	-1	18809400
neuro@@	B-Disease	D020258	18809400
toxicity	I-Disease	-1	18809400
,	O	-1	18809400
if	O	-1	18809400
mitochondrial	B-Disease	D028361	18809400
damage	I-Disease	-1	18809400
pl@@	O	-1	18809400
ays	O	-1	18809400
a	O	-1	18809400
cri@@	O	-1	18809400
tical	O	-1	18809400
role	O	-1	18809400
in	O	-1	18809400
toxic	B-Disease	D009410	18809400
neuro@@	I-Disease	-1	18809400
de@@	I-Disease	-1	18809400
gener@@	I-Disease	-1	18809400
ative	I-Disease	-1	18809400
cas@@	I-Disease	-1	18809400
c@@	I-Disease	-1	18809400
ade	I-Disease	-1	18809400
,	O	-1	18809400
and	O	-1	18809400
if	O	-1	18809400
neuro@@	O	-1	18809400
protective	O	-1	18809400
effects	O	-1	18809400
of	O	-1	18809400
alpha-@@	B-Chemical	D008063	18809400
li@@	I-Chemical	-1	18809400
po@@	I-Chemical	-1	18809400
ic	I-Chemical	-1	18809400
acid	I-Chemical	-1	18809400
depen@@	O	-1	18809400
d	O	-1	18809400
on	O	-1	18809400
mitochond@@	O	-1	18809400
ri@@	O	-1	18809400
a	O	-1	18809400
prot@@	O	-1	18809400
ec@@	O	-1	18809400
tion.	O	-1	18809400
We	O	-1	18809400
used	O	-1	18809400
an	O	-1	18809400
in	O	-1	18809400
vit@@	O	-1	18809400
r@@	O	-1	18809400
o	O	-1	18809400
model	O	-1	18809400
of	O	-1	18809400
chemotherapy	O	-1	18809400
induced	O	-1	18809400
peripheral	B-Disease	D010523	18809400
neuropathy	I-Disease	-1	18809400
that	O	-1	18809400
clo@@	O	-1	18809400
se@@	O	-1	18809400
ly	O	-1	18809400
m@@	O	-1	18809400
im@@	O	-1	18809400
ic	O	-1	18809400
the	O	-1	18809400
in	O	-1	18809400
viv@@	O	-1	18809400
o	O	-1	18809400
condi@@	O	-1	18809400
tion	O	-1	18809400
by	O	-1	18809400
expos@@	O	-1	18809400
ing	O	-1	18809400
prim@@	O	-1	18809400
ary	O	-1	18809400
c@@	O	-1	18809400
ult@@	O	-1	18809400
ures	O	-1	18809400
of	O	-1	18809400
d@@	O	-1	18809400
or@@	O	-1	18809400
s@@	O	-1	18809400
al	O	-1	18809400
ro@@	O	-1	18809400
o@@	O	-1	18809400
t	O	-1	18809400
g@@	O	-1	18809400
ang@@	O	-1	18809400
li@@	O	-1	18809400
on	O	-1	18809400
(D@@	O	-1	18809400
R@@	O	-1	18809400
G@@	O	-1	18809400
)	O	-1	18809400
sens@@	O	-1	18809400
ory	O	-1	18809400
neuron@@	O	-1	18809400
s	O	-1	18809400
to	O	-1	18809400
paclitax@@	B-Chemical	D017239	18809400
el	I-Chemical	-1	18809400
and	O	-1	18809400
cisplatin	B-Chemical	D002945	18809400
,	O	-1	18809400
two	O	-1	18809400
wi@@	O	-1	18809400
de@@	O	-1	18809400
ly	O	-1	18809400
used	O	-1	18809400
and	O	-1	18809400
high@@	O	-1	18809400
ly	O	-1	18809400
effective	O	-1	18809400
chemo@@	O	-1	18809400
therapeutic	O	-1	18809400
drug@@	O	-1	18809400
s.	O	-1	18809400
This	O	-1	18809400
appro@@	O	-1	18809400
ach	O	-1	18809400
al@@	O	-1	18809400
low@@	O	-1	18809400
ed	O	-1	18809400
investig@@	O	-1	18809400
ating	O	-1	18809400
the	O	-1	18809400
efficacy	O	-1	18809400
of	O	-1	18809400
alpha-@@	B-Chemical	D008063	18809400
li@@	I-Chemical	-1	18809400
po@@	I-Chemical	-1	18809400
ic	I-Chemical	-1	18809400
acid	I-Chemical	-1	18809400
in	O	-1	18809400
prevent@@	O	-1	18809400
ing	O	-1	18809400
ax@@	B-Disease	D001480	18809400
on@@	I-Disease	-1	18809400
al	I-Disease	-1	18809400
damage	I-Disease	-1	18809400
and	O	-1	18809400
apo@@	O	-1	18809400
pto@@	O	-1	18809400
sis	O	-1	18809400
and	O	-1	18809400
the	O	-1	18809400
function	O	-1	18809400
and	O	-1	18809400
ult@@	O	-1	18809400
ra@@	O	-1	18809400
struct@@	O	-1	18809400
ural	O	-1	18809400
morph@@	O	-1	18809400
ology	O	-1	18809400
of	O	-1	18809400
mitochond@@	O	-1	18809400
ri@@	O	-1	18809400
a	O	-1	18809400
after	O	-1	18809400
exposure	O	-1	18809400
to	O	-1	18809400
toxic	O	-1	18809400
agents	O	-1	18809400
and	O	-1	18809400
alpha-@@	B-Chemical	D008063	18809400
li@@	I-Chemical	-1	18809400
po@@	I-Chemical	-1	18809400
ic	I-Chemical	-1	18809400
acid	I-Chemical	-1	18809400
.	O	-1	18809400
Our	O	-1	18809400
results	O	-1	18809400
demon@@	O	-1	18809400
st@@	O	-1	18809400
rate	O	-1	18809400
that	O	-1	18809400
both	O	-1	18809400
cisplatin	B-Chemical	D002945	18809400
and	O	-1	18809400
paclitax@@	B-Chemical	D017239	18809400
el	I-Chemical	-1	18809400
cause	O	-1	18809400
early	O	-1	18809400
mitochondrial	B-Disease	D028361	18809400
impair@@	I-Disease	-1	18809400
ment	I-Disease	-1	18809400
with	O	-1	18809400
loss	O	-1	18809400
of	O	-1	18809400
membran@@	O	-1	18809400
e	O	-1	18809400
potential	O	-1	18809400
and	O	-1	18809400
induction	O	-1	18809400
of	O	-1	18809400
auto@@	O	-1	18809400
ph@@	O	-1	18809400
ag@@	O	-1	18809400
ic	O	-1	18809400
vac@@	O	-1	18809400
u@@	O	-1	18809400
ol@@	O	-1	18809400
es	O	-1	18809400
in	O	-1	18809400
neuron@@	O	-1	18809400
s.	O	-1	18809400
Al@@	B-Chemical	D008063	18809400
pha@@	I-Chemical	-1	18809400
-@@	I-Chemical	-1	18809400
li@@	I-Chemical	-1	18809400
po@@	I-Chemical	-1	18809400
ic	I-Chemical	-1	18809400
acid	I-Chemical	-1	18809400
ex@@	O	-1	18809400
er@@	O	-1	18809400
ts	O	-1	18809400
neuro@@	O	-1	18809400
protective	O	-1	18809400
effects	O	-1	18809400
against	O	-1	18809400
chemotherapy	O	-1	18809400
induced	O	-1	18809400
neuro@@	B-Disease	D020258	18809400
toxicity	I-Disease	-1	18809400
in	O	-1	18809400
sens@@	O	-1	18809400
ory	O	-1	18809400
neuron@@	O	-1	18809400
s:	O	-1	18809400
it	O	-1	18809400
res@@	O	-1	18809400
c@@	O	-1	18809400
u@@	O	-1	18809400
es	O	-1	18809400
the	O	-1	18809400
mitochondrial	B-Disease	D028361	18809400
toxicity	I-Disease	-1	18809400
and	O	-1	18809400
induc@@	O	-1	18809400
es	O	-1	18809400
the	O	-1	18809400
expression	O	-1	18809400
of	O	-1	18809400
f@@	O	-1	18809400
rat@@	O	-1	18809400
ax@@	O	-1	18809400
in,	O	-1	18809400
an	O	-1	18809400
es@@	O	-1	18809400
sen@@	O	-1	18809400
tial	O	-1	18809400
mitochondrial	O	-1	18809400
protein	O	-1	18809400
with	O	-1	18809400
anti@@	O	-1	18809400
-@@	O	-1	18809400
oxid@@	O	-1	18809400
ant	O	-1	18809400
and	O	-1	18809400
ch@@	O	-1	18809400
a@@	O	-1	18809400
per@@	O	-1	18809400
one	O	-1	18809400
pro@@	O	-1	18809400
per@@	O	-1	18809400
ti@@	O	-1	18809400
es.	O	-1	18809400
In	O	-1	18809400
concl@@	O	-1	18809400
usion	O	-1	18809400
mitochondrial	B-Disease	D028361	18809400
toxicity	I-Disease	-1	18809400
is	O	-1	18809400
an	O	-1	18809400
early	O	-1	18809400
common	O	-1	18809400
ev@@	O	-1	18809400
ent	O	-1	18809400
both	O	-1	18809400
in	O	-1	18809400
paclitax@@	B-Chemical	D017239	18809400
el	I-Chemical	-1	18809400
and	O	-1	18809400
cisplatin	B-Chemical	D002945	18809400
induced	O	-1	18809400
neuro@@	B-Disease	D020258	18809400
toxicity	I-Disease	-1	18809400
.	O	-1	18809400
Al@@	B-Chemical	D008063	18809400
pha@@	I-Chemical	-1	18809400
-@@	I-Chemical	-1	18809400
li@@	I-Chemical	-1	18809400
po@@	I-Chemical	-1	18809400
ic	I-Chemical	-1	18809400
acid	I-Chemical	-1	18809400
prot@@	O	-1	18809400
ects	O	-1	18809400
sens@@	O	-1	18809400
ory	O	-1	18809400
neuron@@	O	-1	18809400
s	O	-1	18809400
through	O	-1	18809400
its	O	-1	18809400
anti@@	O	-1	18809400
-@@	O	-1	18809400
oxid@@	O	-1	18809400
ant	O	-1	18809400
and	O	-1	18809400
mitochondrial	O	-1	18809400
reg@@	O	-1	18809400
ul@@	O	-1	18809400
atory	O	-1	18809400
func@@	O	-1	18809400
tion@@	O	-1	18809400
s,	O	-1	18809400
possib@@	O	-1	18809400
ly	O	-1	18809400
induc@@	O	-1	18809400
ing	O	-1	18809400
the	O	-1	18809400
expression	O	-1	18809400
of	O	-1	18809400
f@@	O	-1	18809400
rat@@	O	-1	18809400
ax@@	O	-1	18809400
in.	O	-1	18809400
These	O	-1	18809400
findings	O	-1	18809400
suggest	O	-1	18809400
that	O	-1	18809400
alpha-@@	B-Chemical	D008063	18809400
li@@	I-Chemical	-1	18809400
po@@	I-Chemical	-1	18809400
ic	I-Chemical	-1	18809400
acid	I-Chemical	-1	18809400
might	O	-1	18809400
re@@	O	-1	18809400
duce	O	-1	18809400
the	O	-1	18809400
risk	O	-1	18809400
of	O	-1	18809400
develop@@	O	-1	18809400
ing	O	-1	18809400
peripheral	B-Disease	D010523	18809400
nerve	I-Disease	-1	18809400
toxicity	I-Disease	-1	18809400
in	O	-1	18809400
patients	O	-1	18809400
under@@	O	-1	18809400
go@@	O	-1	18809400
ing	O	-1	18809400
chemotherapy	O	-1	18809400
and	O	-1	18809400
en@@	O	-1	18809400
cour@@	O	-1	18809400
age	O	-1	18809400
further	O	-1	18809400
con@@	O	-1	18809400
fir@@	O	-1	18809400
mat@@	O	-1	18809400
ory	O	-1	18809400
clinical	O	-1	18809400
tri@@	O	-1	18809400
al@@	O	-1	18809400
s.	O	-1	18809400

O@@	O	-1	17020434
p@@	O	-1	17020434
tim@@	O	-1	17020434
is@@	O	-1	17020434
ing	O	-1	17020434
strok@@	B-Disease	D020521	17020434
e	I-Disease	-1	17020434
pre@@	O	-1	17020434
ven@@	O	-1	17020434
tion	O	-1	17020434
in	O	-1	17020434
non-@@	O	-1	17020434
val@@	O	-1	17020434
v@@	O	-1	17020434
ular	O	-1	17020434
atrial	B-Disease	D001281	17020434
fibrill@@	I-Disease	-1	17020434
ation	I-Disease	-1	17020434
.	O	-1	17020434
A@@	B-Disease	D001281	17020434
trial	I-Disease	-1	17020434
fibrill@@	I-Disease	-1	17020434
ation	I-Disease	-1	17020434
is	O	-1	17020434
associated	O	-1	17020434
with	O	-1	17020434
subst@@	O	-1	17020434
anti@@	O	-1	17020434
al	O	-1	17020434
mor@@	O	-1	17020434
b@@	O	-1	17020434
idity	O	-1	17020434
and	O	-1	17020434
mor@@	O	-1	17020434
t@@	O	-1	17020434
al@@	O	-1	17020434
ity.	O	-1	17020434
P@@	O	-1	17020434
o@@	O	-1	17020434
ol@@	O	-1	17020434
ed	O	-1	17020434
data	O	-1	17020434
from	O	-1	17020434
tri@@	O	-1	17020434
als	O	-1	17020434
compar@@	O	-1	17020434
ing	O	-1	17020434
anti@@	O	-1	17020434
thrombotic	O	-1	17020434
treatment	O	-1	17020434
with	O	-1	17020434
placebo	O	-1	17020434
have	O	-1	17020434
shown	O	-1	17020434
that	O	-1	17020434
war@@	B-Chemical	D014859	17020434
farin	I-Chemical	-1	17020434
reduc@@	O	-1	17020434
es	O	-1	17020434
the	O	-1	17020434
risk	O	-1	17020434
of	O	-1	17020434
strok@@	B-Disease	D020521	17020434
e	I-Disease	-1	17020434
by	O	-1	17020434
6@@	O	-1	17020434
2@@	O	-1	17020434
%,	O	-1	17020434
and	O	-1	17020434
that	O	-1	17020434
as@@	B-Chemical	D001241	17020434
pi@@	I-Chemical	-1	17020434
rin	I-Chemical	-1	17020434
alone	O	-1	17020434
reduc@@	O	-1	17020434
es	O	-1	17020434
the	O	-1	17020434
risk	O	-1	17020434
by	O	-1	17020434
2@@	O	-1	17020434
2@@	O	-1	17020434
%.	O	-1	17020434
O@@	O	-1	17020434
ver@@	O	-1	17020434
all@@	O	-1	17020434
,	O	-1	17020434
in	O	-1	17020434
high-@@	O	-1	17020434
risk	O	-1	17020434
patients,	O	-1	17020434
war@@	B-Chemical	D014859	17020434
farin	I-Chemical	-1	17020434
is	O	-1	17020434
su@@	O	-1	17020434
peri@@	O	-1	17020434
or	O	-1	17020434
to	O	-1	17020434
as@@	B-Chemical	D001241	17020434
pi@@	I-Chemical	-1	17020434
rin	I-Chemical	-1	17020434
in	O	-1	17020434
prevent@@	O	-1	17020434
ing	O	-1	17020434
strok@@	B-Disease	D020521	17020434
es	I-Disease	-1	17020434
,	O	-1	17020434
with	O	-1	17020434
a	O	-1	17020434
rel@@	O	-1	17020434
ative	O	-1	17020434
risk	O	-1	17020434
reduction	O	-1	17020434
of	O	-1	17020434
3@@	O	-1	17020434
6@@	O	-1	17020434
%.	O	-1	17020434
X@@	B-Chemical	C426686	17020434
i@@	I-Chemical	-1	17020434
me@@	I-Chemical	-1	17020434
l@@	I-Chemical	-1	17020434
ag@@	I-Chemical	-1	17020434
at@@	I-Chemical	-1	17020434
ra@@	I-Chemical	-1	17020434
n	I-Chemical	-1	17020434
,	O	-1	17020434
an	O	-1	17020434
oral	O	-1	17020434
direct	O	-1	17020434
throm@@	O	-1	17020434
bin	O	-1	17020434
inhibitor@@	O	-1	17020434
,	O	-1	17020434
was	O	-1	17020434
found	O	-1	17020434
to	O	-1	17020434
be	O	-1	17020434
as	O	-1	17020434
eff@@	O	-1	17020434
ici@@	O	-1	17020434
ent	O	-1	17020434
as	O	-1	17020434
vitamin	B-Chemical	D014812	17020434
K	I-Chemical	-1	17020434
antagonist	O	-1	17020434
drugs	O	-1	17020434
in	O	-1	17020434
the	O	-1	17020434
pre@@	O	-1	17020434
ven@@	O	-1	17020434
tion	O	-1	17020434
of	O	-1	17020434
emb@@	B-Disease	D004617	17020434
olic	I-Disease	-1	17020434
events	I-Disease	-1	17020434
,	O	-1	17020434
but	O	-1	17020434
has	O	-1	17020434
been	O	-1	17020434
rec@@	O	-1	17020434
ently	O	-1	17020434
withdraw@@	O	-1	17020434
n	O	-1	17020434
because	O	-1	17020434
of	O	-1	17020434
ab@@	B-Disease	D056486	17020434
normal	I-Disease	-1	17020434
liver	I-Disease	-1	17020434
function	I-Disease	-1	17020434
test@@	O	-1	17020434
s.	O	-1	17020434
The	O	-1	17020434
AC@@	O	-1	17020434
TIV@@	O	-1	17020434
E@@	O	-1	17020434
-@@	O	-1	17020434
W	O	-1	17020434
(	O	-1	17020434
A@@	B-Disease	D001281	17020434
trial	I-Disease	-1	17020434
F@@	I-Disease	-1	17020434
i@@	I-Disease	-1	17020434
b@@	I-Disease	-1	17020434
rill@@	I-Disease	-1	17020434
ation	I-Disease	-1	17020434
C@@	B-Chemical	C055162	17020434
lop@@	I-Chemical	-1	17020434
id@@	I-Chemical	-1	17020434
o@@	I-Chemical	-1	17020434
gre@@	I-Chemical	-1	17020434
l	I-Chemical	-1	17020434
T@@	O	-1	17020434
rial	O	-1	17020434
with	O	-1	17020434
I@@	B-Chemical	C081309	17020434
r@@	I-Chemical	-1	17020434
b@@	I-Chemical	-1	17020434
es@@	I-Chemical	-1	17020434
ar@@	I-Chemical	-1	17020434
t@@	I-Chemical	-1	17020434
an	I-Chemical	-1	17020434
for	O	-1	17020434
Pre@@	O	-1	17020434
ven@@	O	-1	17020434
tion	O	-1	17020434
of	O	-1	17020434
V@@	O	-1	17020434
as@@	O	-1	17020434
cular	O	-1	17020434
E@@	O	-1	17020434
v@@	O	-1	17020434
ent@@	O	-1	17020434
s)	O	-1	17020434
study	O	-1	17020434
has	O	-1	17020434
demonstrated	O	-1	17020434
that	O	-1	17020434
war@@	B-Chemical	D014859	17020434
farin	I-Chemical	-1	17020434
is	O	-1	17020434
su@@	O	-1	17020434
peri@@	O	-1	17020434
or	O	-1	17020434
to	O	-1	17020434
platele@@	O	-1	17020434
t	O	-1	17020434
therapy	O	-1	17020434
(	O	-1	17020434
c@@	B-Chemical	C055162	17020434
lop@@	I-Chemical	-1	17020434
id@@	I-Chemical	-1	17020434
o@@	I-Chemical	-1	17020434
gre@@	I-Chemical	-1	17020434
l	I-Chemical	-1	17020434
plus	O	-1	17020434
as@@	B-Chemical	D001241	17020434
pi@@	I-Chemical	-1	17020434
rin	I-Chemical	-1	17020434
)	O	-1	17020434
in	O	-1	17020434
the	O	-1	17020434
pre@@	O	-1	17020434
ven@@	O	-1	17020434
tion	O	-1	17020434
a@@	O	-1	17020434
f	O	-1	17020434
emb@@	B-Disease	D004617	17020434
olic	I-Disease	-1	17020434
events	I-Disease	-1	17020434
.	O	-1	17020434
I@@	B-Chemical	C479958	17020434
dra@@	I-Chemical	-1	17020434
par@@	I-Chemical	-1	17020434
in@@	I-Chemical	-1	17020434
u@@	I-Chemical	-1	17020434
x	I-Chemical	-1	17020434
,	O	-1	17020434
a	O	-1	17020434
F@@	O	-1	17020434
act@@	O	-1	17020434
or	O	-1	17020434
X@@	O	-1	17020434
a	O	-1	17020434
inhibitor@@	O	-1	17020434
,	O	-1	17020434
is	O	-1	17020434
being	O	-1	17020434
evaluated	O	-1	17020434
in	O	-1	17020434
patients	O	-1	17020434
with	O	-1	17020434
atrial	B-Disease	D001281	17020434
fibrill@@	I-Disease	-1	17020434
ation	I-Disease	-1	17020434
.	O	-1	17020434
An@@	B-Chemical	D000809	17020434
gi@@	I-Chemical	-1	17020434
otens@@	I-Chemical	-1	17020434
in	I-Chemical	-1	17020434
-@@	O	-1	17020434
conver@@	O	-1	17020434
ting	O	-1	17020434
enzyme	O	-1	17020434
inhibitors	O	-1	17020434
and	O	-1	17020434
angiotens@@	B-Chemical	D000804	17020434
in	I-Chemical	-1	17020434
II	I-Chemical	-1	17020434
receptor@@	O	-1	17020434
-@@	O	-1	17020434
block@@	O	-1	17020434
ing	O	-1	17020434
drugs	O	-1	17020434
h@@	O	-1	17020434
old	O	-1	17020434
pro@@	O	-1	17020434
mis@@	O	-1	17020434
e	O	-1	17020434
in	O	-1	17020434
atrial	B-Disease	D001281	17020434
fibrill@@	I-Disease	-1	17020434
ation	I-Disease	-1	17020434
through	O	-1	17020434
cardiac	B-Disease	D020257	17020434
re@@	I-Disease	-1	17020434
mode@@	I-Disease	-1	17020434
ll@@	I-Disease	-1	17020434
ing	I-Disease	-1	17020434
.	O	-1	17020434
P@@	O	-1	17020434
rel@@	O	-1	17020434
im@@	O	-1	17020434
inary	O	-1	17020434
studies	O	-1	17020434
suggest	O	-1	17020434
that	O	-1	17020434
stat@@	B-Chemical	D019821	17020434
ins	I-Chemical	-1	17020434
could	O	-1	17020434
inter@@	O	-1	17020434
f@@	O	-1	17020434
ere	O	-1	17020434
with	O	-1	17020434
the	O	-1	17020434
risk	O	-1	17020434
of	O	-1	17020434
recur@@	O	-1	17020434
rence	O	-1	17020434
after	O	-1	17020434
elect@@	O	-1	17020434
r@@	O	-1	17020434
ical	O	-1	17020434
cardio@@	O	-1	17020434
ver@@	O	-1	17020434
sion.	O	-1	17020434
F@@	O	-1	17020434
in@@	O	-1	17020434
ally,	O	-1	17020434
perc@@	O	-1	17020434
utaneous	O	-1	17020434
meth@@	O	-1	17020434
o@@	O	-1	17020434
ds	O	-1	17020434
for	O	-1	17020434
the	O	-1	17020434
ex@@	O	-1	17020434
cl@@	O	-1	17020434
usion	O	-1	17020434
of	O	-1	17020434
left	O	-1	17020434
atrial	O	-1	17020434
ap@@	O	-1	17020434
pen@@	O	-1	17020434
d@@	O	-1	17020434
age	O	-1	17020434
are	O	-1	17020434
under	O	-1	17020434
investig@@	O	-1	17020434
ation	O	-1	17020434
in	O	-1	17020434
high-@@	O	-1	17020434
risk	O	-1	17020434
patients.	O	-1	17020434

In@@	O	-1	3865016
ter@@	O	-1	3865016
action	O	-1	3865016
of	O	-1	3865016
cyclospor@@	B-Chemical	D016572	3865016
in	I-Chemical	-1	3865016
A	I-Chemical	-1	3865016
with	O	-1	3865016
ant@@	O	-1	3865016
ine@@	O	-1	3865016
o@@	O	-1	3865016
plas@@	O	-1	3865016
tic	O	-1	3865016
agent@@	O	-1	3865016
s.	O	-1	3865016
A	O	-1	3865016
syn@@	O	-1	3865016
erg@@	O	-1	3865016
istic	O	-1	3865016
effect	O	-1	3865016
of	O	-1	3865016
e@@	B-Chemical	D005047	3865016
to@@	I-Chemical	-1	3865016
po@@	I-Chemical	-1	3865016
side	I-Chemical	-1	3865016
and	O	-1	3865016
cyclospor@@	B-Chemical	D016572	3865016
in	I-Chemical	-1	3865016
A	I-Chemical	-1	3865016
was	O	-1	3865016
observed	O	-1	3865016
in	O	-1	3865016
a	O	-1	3865016
patient	O	-1	3865016
with	O	-1	3865016
acute	B-Disease	D054218	3865016
T@@	I-Disease	-1	3865016
-@@	I-Disease	-1	3865016
lymph@@	I-Disease	-1	3865016
ocy@@	I-Disease	-1	3865016
tic	I-Disease	-1	3865016
leuk@@	I-Disease	-1	3865016
emia	I-Disease	-1	3865016
in	O	-1	3865016
rel@@	O	-1	3865016
ap@@	O	-1	3865016
se.	O	-1	3865016
The	O	-1	3865016
concomit@@	O	-1	3865016
ant	O	-1	3865016
administration	O	-1	3865016
of	O	-1	3865016
e@@	B-Chemical	D005047	3865016
to@@	I-Chemical	-1	3865016
po@@	I-Chemical	-1	3865016
side	I-Chemical	-1	3865016
and	O	-1	3865016
cyclospor@@	B-Chemical	D016572	3865016
in	I-Chemical	-1	3865016
A	I-Chemical	-1	3865016
resulted	O	-1	3865016
in	O	-1	3865016
er@@	O	-1	3865016
ad@@	O	-1	3865016
ic@@	O	-1	3865016
ation	O	-1	3865016
of	O	-1	3865016
hi@@	O	-1	3865016
ther@@	O	-1	3865016
to	O	-1	3865016
ref@@	O	-1	3865016
rac@@	O	-1	3865016
t@@	O	-1	3865016
ory	O	-1	3865016
leuk@@	B-Disease	D017254	3865016
em@@	I-Disease	-1	3865016
ic	I-Disease	-1	3865016
inf@@	I-Disease	-1	3865016
iltration	I-Disease	-1	3865016
of	O	-1	3865016
b@@	O	-1	3865016
one	O	-1	3865016
m@@	O	-1	3865016
ar@@	O	-1	3865016
row@@	O	-1	3865016
.	O	-1	3865016
S@@	O	-1	3865016
ev@@	O	-1	3865016
ere	O	-1	3865016
side	O	-1	3865016
effects	O	-1	3865016
in	O	-1	3865016
ter@@	O	-1	3865016
ms	O	-1	3865016
of	O	-1	3865016
mental	O	-1	3865016
conf@@	B-Disease	D003221	3865016
usion	I-Disease	-1	3865016
and	O	-1	3865016
progressive	O	-1	3865016
hyper@@	B-Disease	D006932	3865016
bil@@	I-Disease	-1	3865016
i@@	I-Disease	-1	3865016
ru@@	I-Disease	-1	3865016
b@@	I-Disease	-1	3865016
ine@@	I-Disease	-1	3865016
mia	I-Disease	-1	3865016
,	O	-1	3865016
however,	O	-1	3865016
po@@	O	-1	3865016
in@@	O	-1	3865016
t	O	-1	3865016
to	O	-1	3865016
an	O	-1	3865016
enh@@	O	-1	3865016
ance@@	O	-1	3865016
ment	O	-1	3865016
not	O	-1	3865016
only	O	-1	3865016
of	O	-1	3865016
ant@@	O	-1	3865016
ine@@	O	-1	3865016
o@@	O	-1	3865016
plas@@	O	-1	3865016
tic	O	-1	3865016
effects	O	-1	3865016
but	O	-1	3865016
also	O	-1	3865016
of	O	-1	3865016
toxicity	B-Disease	D064420	3865016
in	O	-1	3865016
normal	O	-1	3865016
tissu@@	O	-1	3865016
es.	O	-1	3865016
This	O	-1	3865016
report	O	-1	3865016
demon@@	O	-1	3865016
strat@@	O	-1	3865016
es	O	-1	3865016
for	O	-1	3865016
the	O	-1	3865016
first	O	-1	3865016
time	O	-1	3865016
that	O	-1	3865016
the	O	-1	3865016
pharmac@@	O	-1	3865016
o@@	O	-1	3865016
dynam@@	O	-1	3865016
ic	O	-1	3865016
pro@@	O	-1	3865016
per@@	O	-1	3865016
ties	O	-1	3865016
of	O	-1	3865016
cyclospor@@	B-Chemical	D016572	3865016
in	I-Chemical	-1	3865016
A	I-Chemical	-1	3865016
may	O	-1	3865016
not	O	-1	3865016
be	O	-1	3865016
conf@@	O	-1	3865016
in@@	O	-1	3865016
ed	O	-1	3865016
stric@@	O	-1	3865016
tly	O	-1	3865016
to	O	-1	3865016
sup@@	O	-1	3865016
pression	O	-1	3865016
of	O	-1	3865016
normal	O	-1	3865016
T@@	O	-1	3865016
-@@	O	-1	3865016
cell	O	-1	3865016
func@@	O	-1	3865016
tions.	O	-1	3865016

The	O	-1	3629586
hemat@@	O	-1	3629586
ologic	O	-1	3629586
effects	O	-1	3629586
of	O	-1	3629586
ce@@	B-Chemical	D015790	3629586
f@@	I-Chemical	-1	3629586
on@@	I-Chemical	-1	3629586
ic@@	I-Chemical	-1	3629586
id	I-Chemical	-1	3629586
and	O	-1	3629586
ce@@	B-Chemical	C021341	3629586
f@@	I-Chemical	-1	3629586
az@@	I-Chemical	-1	3629586
ed@@	I-Chemical	-1	3629586
one	I-Chemical	-1	3629586
in	O	-1	3629586
the	O	-1	3629586
dog@@	O	-1	3629586
:	O	-1	3629586
a	O	-1	3629586
potential	O	-1	3629586
model	O	-1	3629586
of	O	-1	3629586
ce@@	B-Chemical	D002511	3629586
ph@@	I-Chemical	-1	3629586
al@@	I-Chemical	-1	3629586
os@@	I-Chemical	-1	3629586
por@@	I-Chemical	-1	3629586
in	I-Chemical	-1	3629586
hemat@@	B-Disease	D006402	3629586
otoxicity	I-Disease	-1	3629586
in	O	-1	3629586
man@@	O	-1	3629586
.	O	-1	3629586
C@@	B-Chemical	D002511	3629586
e@@	I-Chemical	-1	3629586
ph@@	I-Chemical	-1	3629586
al@@	I-Chemical	-1	3629586
os@@	I-Chemical	-1	3629586
por@@	I-Chemical	-1	3629586
in	I-Chemical	-1	3629586
anti@@	O	-1	3629586
bio@@	O	-1	3629586
tics	O	-1	3629586
cause	O	-1	3629586
a	O	-1	3629586
vari@@	O	-1	3629586
ety	O	-1	3629586
of	O	-1	3629586
hemat@@	B-Disease	D006402	3629586
ologic	I-Disease	-1	3629586
dist@@	I-Disease	-1	3629586
urb@@	I-Disease	-1	3629586
anc@@	I-Disease	-1	3629586
es	I-Disease	-1	3629586
in	O	-1	3629586
man@@	O	-1	3629586
,	O	-1	3629586
the	O	-1	3629586
path@@	O	-1	3629586
o@@	O	-1	3629586
gen@@	O	-1	3629586
es@@	O	-1	3629586
es	O	-1	3629586
and	O	-1	3629586
hemat@@	O	-1	3629586
o@@	O	-1	3629586
path@@	O	-1	3629586
ology	O	-1	3629586
of	O	-1	3629586
which	O	-1	3629586
re@@	O	-1	3629586
ma@@	O	-1	3629586
in	O	-1	3629586
po@@	O	-1	3629586
or@@	O	-1	3629586
ly	O	-1	3629586
character@@	O	-1	3629586
iz@@	O	-1	3629586
ed.	O	-1	3629586
There	O	-1	3629586
is	O	-1	3629586
a	O	-1	3629586
need	O	-1	3629586
for	O	-1	3629586
a	O	-1	3629586
we@@	O	-1	3629586
ll@@	O	-1	3629586
-@@	O	-1	3629586
def@@	O	-1	3629586
in@@	O	-1	3629586
ed	O	-1	3629586
anim@@	O	-1	3629586
al	O	-1	3629586
model	O	-1	3629586
in	O	-1	3629586
which	O	-1	3629586
these	O	-1	3629586
blood	B-Disease	D006402	3629586
dys@@	I-Disease	-1	3629586
c@@	I-Disease	-1	3629586
ra@@	I-Disease	-1	3629586
si@@	I-Disease	-1	3629586
as	I-Disease	-1	3629586
can	O	-1	3629586
be	O	-1	3629586
studi@@	O	-1	3629586
ed.	O	-1	3629586
In	O	-1	3629586
four	O	-1	3629586
sub@@	O	-1	3629586
acute	O	-1	3629586
toxicity	B-Disease	D064420	3629586
studi@@	O	-1	3629586
es,	O	-1	3629586
the	O	-1	3629586
intravenous	O	-1	3629586
administration	O	-1	3629586
of	O	-1	3629586
ce@@	B-Chemical	D015790	3629586
f@@	I-Chemical	-1	3629586
on@@	I-Chemical	-1	3629586
ic@@	I-Chemical	-1	3629586
id	I-Chemical	-1	3629586
or	O	-1	3629586
ce@@	B-Chemical	C021341	3629586
f@@	I-Chemical	-1	3629586
az@@	I-Chemical	-1	3629586
ed@@	I-Chemical	-1	3629586
one	I-Chemical	-1	3629586
to	O	-1	3629586
be@@	O	-1	3629586
ag@@	O	-1	3629586
le	O	-1	3629586
dog@@	O	-1	3629586
s	O	-1	3629586
caused	O	-1	3629586
a	O	-1	3629586
dose-@@	O	-1	3629586
dependent	O	-1	3629586
incidence	O	-1	3629586
of	O	-1	3629586
anemia	B-Disease	D000740	3629586
,	O	-1	3629586
ne@@	B-Disease	D009503	3629586
ut@@	I-Disease	-1	3629586
ro@@	I-Disease	-1	3629586
pen@@	I-Disease	-1	3629586
ia	I-Disease	-1	3629586
,	O	-1	3629586
and	O	-1	3629586
throm@@	B-Disease	D013921	3629586
b@@	I-Disease	-1	3629586
ocyto@@	I-Disease	-1	3629586
pen@@	I-Disease	-1	3629586
ia	I-Disease	-1	3629586
after	O	-1	3629586
1-@@	O	-1	3629586
3	O	-1	3629586
months	O	-1	3629586
of	O	-1	3629586
treatment.	O	-1	3629586
A	O	-1	3629586
non@@	O	-1	3629586
re@@	O	-1	3629586
gener@@	O	-1	3629586
ative	O	-1	3629586
anemia	B-Disease	D000740	3629586
was	O	-1	3629586
the	O	-1	3629586
most	O	-1	3629586
com@@	O	-1	3629586
pro@@	O	-1	3629586
mis@@	O	-1	3629586
ing	O	-1	3629586
of	O	-1	3629586
the	O	-1	3629586
cyto@@	B-Disease	D006402	3629586
pen@@	I-Disease	-1	3629586
i@@	I-Disease	-1	3629586
as	I-Disease	-1	3629586
and	O	-1	3629586
occurred	O	-1	3629586
in	O	-1	3629586
appro@@	O	-1	3629586
xim@@	O	-1	3629586
ately	O	-1	3629586
50@@	O	-1	3629586
%	O	-1	3629586
of	O	-1	3629586
dog@@	O	-1	3629586
s	O	-1	3629586
receiving	O	-1	3629586
4@@	O	-1	3629586
0@@	O	-1	3629586
0-@@	O	-1	3629586
5@@	O	-1	3629586
00	O	-1	3629586
mg/kg	O	-1	3629586
ce@@	B-Chemical	D015790	3629586
f@@	I-Chemical	-1	3629586
on@@	I-Chemical	-1	3629586
ic@@	I-Chemical	-1	3629586
id	I-Chemical	-1	3629586
or	O	-1	3629586
5@@	O	-1	3629586
4@@	O	-1	3629586
0-@@	O	-1	3629586
8@@	O	-1	3629586
40	O	-1	3629586
mg/kg	O	-1	3629586
ce@@	B-Chemical	C021341	3629586
f@@	I-Chemical	-1	3629586
az@@	I-Chemical	-1	3629586
ed@@	I-Chemical	-1	3629586
one	I-Chemical	-1	3629586
.	O	-1	3629586
All	O	-1	3629586
three	O	-1	3629586
cyto@@	B-Disease	D006402	3629586
pen@@	I-Disease	-1	3629586
i@@	I-Disease	-1	3629586
as	I-Disease	-1	3629586
were	O	-1	3629586
complete@@	O	-1	3629586
ly	O	-1	3629586
reversible	O	-1	3629586
following	O	-1	3629586
cess@@	O	-1	3629586
ation	O	-1	3629586
of	O	-1	3629586
treatment@@	O	-1	3629586
;	O	-1	3629586
the	O	-1	3629586
time	O	-1	3629586
requ@@	O	-1	3629586
ired	O	-1	3629586
for	O	-1	3629586
recovery	O	-1	3629586
of	O	-1	3629586
the	O	-1	3629586
erythro@@	O	-1	3629586
n	O	-1	3629586
(@@	O	-1	3629586
appro@@	O	-1	3629586
xim@@	O	-1	3629586
ately	O	-1	3629586
1	O	-1	3629586
month@@	O	-1	3629586
)	O	-1	3629586
was	O	-1	3629586
con@@	O	-1	3629586
si@@	O	-1	3629586
der@@	O	-1	3629586
ably	O	-1	3629586
long@@	O	-1	3629586
er	O	-1	3629586
than	O	-1	3629586
that	O	-1	3629586
of	O	-1	3629586
the	O	-1	3629586
gran@@	O	-1	3629586
ulo@@	O	-1	3629586
cy@@	O	-1	3629586
tes	O	-1	3629586
and	O	-1	3629586
platele@@	O	-1	3629586
ts	O	-1	3629586
(@@	O	-1	3629586
hours	O	-1	3629586
to	O	-1	3629586
a	O	-1	3629586
fe@@	O	-1	3629586
w	O	-1	3629586
da@@	O	-1	3629586
ys@@	O	-1	3629586
).	O	-1	3629586
U@@	O	-1	3629586
p@@	O	-1	3629586
on	O	-1	3629586
re@@	O	-1	3629586
ch@@	O	-1	3629586
all@@	O	-1	3629586
enge	O	-1	3629586
with	O	-1	3629586
either	O	-1	3629586
ce@@	B-Chemical	D002511	3629586
ph@@	I-Chemical	-1	3629586
al@@	I-Chemical	-1	3629586
os@@	I-Chemical	-1	3629586
por@@	I-Chemical	-1	3629586
in	I-Chemical	-1	3629586
,	O	-1	3629586
the	O	-1	3629586
hemat@@	B-Disease	D006402	3629586
ologic	I-Disease	-1	3629586
syndrome	I-Disease	-1	3629586
was	O	-1	3629586
re@@	O	-1	3629586
produced	O	-1	3629586
in	O	-1	3629586
most	O	-1	3629586
dog@@	O	-1	3629586
s	O	-1	3629586
test@@	O	-1	3629586
ed@@	O	-1	3629586
;	O	-1	3629586
ce@@	B-Chemical	D015790	3629586
f@@	I-Chemical	-1	3629586
on@@	I-Chemical	-1	3629586
ic@@	I-Chemical	-1	3629586
id	I-Chemical	-1	3629586
(@@	O	-1	3629586
but	O	-1	3629586
not	O	-1	3629586
ce@@	B-Chemical	C021341	3629586
f@@	I-Chemical	-1	3629586
az@@	I-Chemical	-1	3629586
ed@@	I-Chemical	-1	3629586
one	I-Chemical	-1	3629586
)-@@	O	-1	3629586
treated	O	-1	3629586
dog@@	O	-1	3629586
s	O	-1	3629586
showed	O	-1	3629586
a	O	-1	3629586
subst@@	O	-1	3629586
anti@@	O	-1	3629586
ally	O	-1	3629586
reduced	O	-1	3629586
induction	O	-1	3629586
period	O	-1	3629586
(1@@	O	-1	3629586
5	O	-1	3629586
+/-	O	-1	3629586
5	O	-1	3629586
da@@	O	-1	3629586
ys@@	O	-1	3629586
)	O	-1	3629586
compared	O	-1	3629586
to	O	-1	3629586
that	O	-1	3629586
of	O	-1	3629586
the	O	-1	3629586
first	O	-1	3629586
exposure	O	-1	3629586
to	O	-1	3629586
the	O	-1	3629586
drug	O	-1	3629586
(6@@	O	-1	3629586
1	O	-1	3629586
+/-	O	-1	3629586
24	O	-1	3629586
da@@	O	-1	3629586
ys@@	O	-1	3629586
).	O	-1	3629586
This	O	-1	3629586
observ@@	O	-1	3629586
ation,	O	-1	3629586
al@@	O	-1	3629586
ong	O	-1	3629586
with	O	-1	3629586
the	O	-1	3629586
ra@@	O	-1	3629586
pid	O	-1	3629586
rate	O	-1	3629586
of	O	-1	3629586
dec@@	O	-1	3629586
line	O	-1	3629586
in	O	-1	3629586
red	O	-1	3629586
cell	O	-1	3629586
mas@@	O	-1	3629586
s	O	-1	3629586
par@@	O	-1	3629586
ame@@	O	-1	3629586
ters	O	-1	3629586
of	O	-1	3629586
affected	O	-1	3629586
dog@@	O	-1	3629586
s,	O	-1	3629586
suggests	O	-1	3629586
that	O	-1	3629586
a	O	-1	3629586
hemolytic	B-Disease	D006461	3629586
comp@@	O	-1	3629586
on@@	O	-1	3629586
ent	O	-1	3629586
complic@@	O	-1	3629586
ated	O	-1	3629586
the	O	-1	3629586
red	O	-1	3629586
cell	O	-1	3629586
pro@@	O	-1	3629586
duction	O	-1	3629586
pro@@	O	-1	3629586
ble@@	O	-1	3629586
m	O	-1	3629586
and	O	-1	3629586
that	O	-1	3629586
multiple	O	-1	3629586
toxic@@	O	-1	3629586
ologic	O	-1	3629586
mechanisms	O	-1	3629586
cont@@	O	-1	3629586
ri@@	O	-1	3629586
but@@	O	-1	3629586
ed	O	-1	3629586
to	O	-1	3629586
the	O	-1	3629586
cyto@@	B-Disease	D006402	3629586
pen@@	I-Disease	-1	3629586
ia	I-Disease	-1	3629586
.	O	-1	3629586
We	O	-1	3629586
concl@@	O	-1	3629586
ude	O	-1	3629586
that	O	-1	3629586
the	O	-1	3629586
administration	O	-1	3629586
of	O	-1	3629586
high	O	-1	3629586
doses	O	-1	3629586
of	O	-1	3629586
ce@@	B-Chemical	D015790	3629586
f@@	I-Chemical	-1	3629586
on@@	I-Chemical	-1	3629586
ic@@	I-Chemical	-1	3629586
id	I-Chemical	-1	3629586
or	O	-1	3629586
ce@@	B-Chemical	C021341	3629586
f@@	I-Chemical	-1	3629586
az@@	I-Chemical	-1	3629586
ed@@	I-Chemical	-1	3629586
one	I-Chemical	-1	3629586
to	O	-1	3629586
dog@@	O	-1	3629586
s	O	-1	3629586
can	O	-1	3629586
induce	O	-1	3629586
hemat@@	B-Disease	D006402	3629586
otoxicity	I-Disease	-1	3629586
similar	O	-1	3629586
to	O	-1	3629586
the	O	-1	3629586
ce@@	B-Chemical	D002511	3629586
ph@@	I-Chemical	-1	3629586
al@@	I-Chemical	-1	3629586
os@@	I-Chemical	-1	3629586
por@@	I-Chemical	-1	3629586
in	I-Chemical	-1	3629586
-induced	O	-1	3629586
blood	B-Disease	D006402	3629586
dys@@	I-Disease	-1	3629586
c@@	I-Disease	-1	3629586
ra@@	I-Disease	-1	3629586
si@@	I-Disease	-1	3629586
as	I-Disease	-1	3629586
descri@@	O	-1	3629586
bed	O	-1	3629586
in	O	-1	3629586
man	O	-1	3629586
and	O	-1	3629586
th@@	O	-1	3629586
us	O	-1	3629586
pro@@	O	-1	3629586
vi@@	O	-1	3629586
des	O	-1	3629586
a	O	-1	3629586
use@@	O	-1	3629586
ful	O	-1	3629586
model	O	-1	3629586
for	O	-1	3629586
stud@@	O	-1	3629586
y@@	O	-1	3629586
ing	O	-1	3629586
the	O	-1	3629586
mechanisms	O	-1	3629586
of	O	-1	3629586
these	O	-1	3629586
disorder@@	O	-1	3629586
s.	O	-1	3629586

A	O	-1	150790
pyri@@	B-Chemical	D011736	150790
dox@@	I-Chemical	-1	150790
ine	I-Chemical	-1	150790
-@@	O	-1	150790
dependent	O	-1	150790
behavioral	B-Disease	D002653	150790
disor@@	I-Disease	-1	150790
der	I-Disease	-1	150790
un@@	O	-1	150790
mas@@	O	-1	150790
ked	O	-1	150790
by	O	-1	150790
is@@	B-Chemical	D007538	150790
oni@@	I-Chemical	-1	150790
az@@	I-Chemical	-1	150790
id	I-Chemical	-1	150790
.	O	-1	150790
A	O	-1	150790
3-@@	O	-1	150790
year-old	O	-1	150790
gi@@	O	-1	150790
r@@	O	-1	150790
l	O	-1	150790
had	O	-1	150790
behavioral	B-Disease	D002653	150790
deter@@	I-Disease	-1	150790
i@@	I-Disease	-1	150790
or@@	I-Disease	-1	150790
ation	I-Disease	-1	150790
,	O	-1	150790
with	O	-1	150790
hyper@@	B-Disease	D006948	150790
kine@@	I-Disease	-1	150790
sis	I-Disease	-1	150790
,	O	-1	150790
ir@@	B-Disease	D001523	150790
rit@@	I-Disease	-1	150790
ability	I-Disease	-1	150790
,	O	-1	150790
and	O	-1	150790
sle@@	B-Disease	D012893	150790
ep@@	I-Disease	-1	150790
ing	I-Disease	-1	150790
diff@@	I-Disease	-1	150790
ic@@	I-Disease	-1	150790
ul@@	I-Disease	-1	150790
ties	I-Disease	-1	150790
after	O	-1	150790
the	O	-1	150790
therapeutic	O	-1	150790
administration	O	-1	150790
of	O	-1	150790
is@@	B-Chemical	D007538	150790
oni@@	I-Chemical	-1	150790
az@@	I-Chemical	-1	150790
id	I-Chemical	-1	150790
.	O	-1	150790
The	O	-1	150790
administration	O	-1	150790
of	O	-1	150790
pharmac@@	O	-1	150790
ologic	O	-1	150790
doses	O	-1	150790
of	O	-1	150790
pyri@@	B-Chemical	D011736	150790
dox@@	I-Chemical	-1	150790
ine	I-Chemical	-1	150790
hydro@@	I-Chemical	-1	150790
chlor@@	I-Chemical	-1	150790
ide	I-Chemical	-1	150790
l@@	O	-1	150790
ed	O	-1	150790
to	O	-1	150790
a	O	-1	150790
dis@@	O	-1	150790
appear@@	O	-1	150790
ance	O	-1	150790
of	O	-1	150790
symptom@@	O	-1	150790
s.	O	-1	150790
After	O	-1	150790
discontinu@@	O	-1	150790
ing	O	-1	150790
is@@	B-Chemical	D007538	150790
oni@@	I-Chemical	-1	150790
az@@	I-Chemical	-1	150790
id	I-Chemical	-1	150790
therapy	O	-1	150790
a	O	-1	150790
similar	O	-1	150790
pat@@	O	-1	150790
ter@@	O	-1	150790
n	O	-1	150790
of	O	-1	150790
behavi@@	O	-1	150790
or	O	-1	150790
was	O	-1	150790
not@@	O	-1	150790
ed	O	-1	150790
that	O	-1	150790
was	O	-1	150790
controlled	O	-1	150790
by	O	-1	150790
pyri@@	B-Chemical	D011736	150790
dox@@	I-Chemical	-1	150790
ine	I-Chemical	-1	150790
.	O	-1	150790
A	O	-1	150790
placebo	O	-1	150790
had	O	-1	150790
no	O	-1	150790
effect@@	O	-1	150790
,	O	-1	150790
but	O	-1	150790
n@@	B-Chemical	D009536	150790
i@@	I-Chemical	-1	150790
ac@@	I-Chemical	-1	150790
in@@	I-Chemical	-1	150790
amide	I-Chemical	-1	150790
was	O	-1	150790
as	O	-1	150790
effective	O	-1	150790
as	O	-1	150790
pyri@@	B-Chemical	D011736	150790
dox@@	I-Chemical	-1	150790
ine	I-Chemical	-1	150790
.	O	-1	150790
P@@	O	-1	150790
er@@	O	-1	150790
io@@	O	-1	150790
di@@	O	-1	150790
c	O	-1	150790
withdrawal	O	-1	150790
of	O	-1	150790
pyri@@	B-Chemical	D011736	150790
dox@@	I-Chemical	-1	150790
ine	I-Chemical	-1	150790
was	O	-1	150790
associated	O	-1	150790
with	O	-1	150790
retur@@	O	-1	150790
n	O	-1	150790
of	O	-1	150790
the	O	-1	150790
hyper@@	B-Disease	D006948	150790
kine@@	I-Disease	-1	150790
sis	I-Disease	-1	150790
.	O	-1	150790
The	O	-1	150790
level	O	-1	150790
of	O	-1	150790
pyri@@	B-Chemical	D011730	150790
dox@@	I-Chemical	-1	150790
al	I-Chemical	-1	150790
in	O	-1	150790
the	O	-1	150790
blood	O	-1	150790
was	O	-1	150790
normal	O	-1	150790
during	O	-1	150790
the	O	-1	150790
perio@@	O	-1	150790
ds	O	-1	150790
of	O	-1	150790
rel@@	O	-1	150790
ap@@	O	-1	150790
se.	O	-1	150790
M@@	O	-1	150790
et@@	O	-1	150790
ab@@	O	-1	150790
olic	O	-1	150790
studies	O	-1	150790
suggested	O	-1	150790
a	O	-1	150790
bloc@@	O	-1	150790
k	O	-1	150790
in	O	-1	150790
the	O	-1	150790
k@@	B-Chemical	D007737	150790
yn@@	I-Chemical	-1	150790
u@@	I-Chemical	-1	150790
ren@@	I-Chemical	-1	150790
ine	I-Chemical	-1	150790
path@@	O	-1	150790
w@@	O	-1	150790
ay	O	-1	150790
of	O	-1	150790
tr@@	B-Chemical	D014364	150790
y@@	I-Chemical	-1	150790
pto@@	I-Chemical	-1	150790
ph@@	I-Chemical	-1	150790
an	I-Chemical	-1	150790
metabol@@	O	-1	150790
is@@	O	-1	150790
m.	O	-1	150790
The	O	-1	150790
patient	O	-1	150790
has	O	-1	150790
been	O	-1	150790
followed	O	-1	150790
for	O	-1	150790
six	O	-1	150790
years	O	-1	150790
and	O	-1	150790
has	O	-1	150790
requ@@	O	-1	150790
ired	O	-1	150790
pharmac@@	O	-1	150790
ologic	O	-1	150790
doses	O	-1	150790
of	O	-1	150790
pyri@@	B-Chemical	D011736	150790
dox@@	I-Chemical	-1	150790
ine	I-Chemical	-1	150790
to	O	-1	150790
control	O	-1	150790
h@@	O	-1	150790
er	O	-1	150790
behavi@@	O	-1	150790
or@@	O	-1	150790
.	O	-1	150790

A	O	-1	10579464
selective	O	-1	10579464
dopamine	B-Chemical	D004298	10579464
D@@	O	-1	10579464
4	O	-1	10579464
receptor	O	-1	10579464
antagonist@@	O	-1	10579464
,	O	-1	10579464
N@@	B-Chemical	C121249	10579464
R@@	I-Chemical	-1	10579464
A@@	I-Chemical	-1	10579464
0@@	I-Chemical	-1	10579464
1@@	I-Chemical	-1	10579464
60	I-Chemical	-1	10579464
:	O	-1	10579464
a	O	-1	10579464
pre@@	O	-1	10579464
clinical	O	-1	10579464
neuro@@	O	-1	10579464
pharmac@@	O	-1	10579464
ological	O	-1	10579464
pro@@	O	-1	10579464
fi@@	O	-1	10579464
le@@	O	-1	10579464
.	O	-1	10579464
N@@	B-Chemical	C121249	10579464
R@@	I-Chemical	-1	10579464
A@@	I-Chemical	-1	10579464
0@@	I-Chemical	-1	10579464
1@@	I-Chemical	-1	10579464
60	I-Chemical	-1	10579464
,	O	-1	10579464
5	B-Chemical	C121249	10579464
-	I-Chemical	-1	10579464
[@@	I-Chemical	-1	10579464
2@@	I-Chemical	-1	10579464
-	I-Chemical	-1	10579464
(	I-Chemical	-1	10579464
4@@	I-Chemical	-1	10579464
-	I-Chemical	-1	10579464
(	I-Chemical	-1	10579464
3	I-Chemical	-1	10579464
-	I-Chemical	-1	10579464
fluoro@@	I-Chemical	-1	10579464
b@@	I-Chemical	-1	10579464
enz@@	I-Chemical	-1	10579464
yl@@	I-Chemical	-1	10579464
id@@	I-Chemical	-1	10579464
en@@	I-Chemical	-1	10579464
e@@	I-Chemical	-1	10579464
)	I-Chemical	-1	10579464
pi@@	I-Chemical	-1	10579464
perid@@	I-Chemical	-1	10579464
in-@@	I-Chemical	-1	10579464
1-@@	I-Chemical	-1	10579464
yl@@	I-Chemical	-1	10579464
)	I-Chemical	-1	10579464
eth@@	I-Chemical	-1	10579464
yl@@	I-Chemical	-1	10579464
]	I-Chemical	-1	10579464
-	I-Chemical	-1	10579464
4	I-Chemical	-1	10579464
-@@	I-Chemical	-1	10579464
(@@	I-Chemical	-1	10579464
4-@@	I-Chemical	-1	10579464
fluoro@@	I-Chemical	-1	10579464
phenyl@@	I-Chemical	-1	10579464
)	I-Chemical	-1	10579464
thi@@	I-Chemical	-1	10579464
azol@@	I-Chemical	-1	10579464
e-@@	I-Chemical	-1	10579464
2-@@	I-Chemical	-1	10579464
carb@@	I-Chemical	-1	10579464
ox@@	I-Chemical	-1	10579464
amide	I-Chemical	-1	10579464
,	O	-1	10579464
has	O	-1	10579464
a	O	-1	10579464
high	O	-1	10579464
aff@@	O	-1	10579464
in@@	O	-1	10579464
ity	O	-1	10579464
for	O	-1	10579464
human	O	-1	10579464
clon@@	O	-1	10579464
ed	O	-1	10579464
dopamine	B-Chemical	D004298	10579464
D@@	O	-1	10579464
4.@@	O	-1	10579464
2,	O	-1	10579464
D@@	O	-1	10579464
4.@@	O	-1	10579464
4	O	-1	10579464
and	O	-1	10579464
D@@	O	-1	10579464
4.@@	O	-1	10579464
7	O	-1	10579464
receptor@@	O	-1	10579464
s,	O	-1	10579464
with	O	-1	10579464
K@@	O	-1	10579464
i	O	-1	10579464
values	O	-1	10579464
of	O	-1	10579464
0.@@	O	-1	10579464
5,	O	-1	10579464
0.@@	O	-1	10579464
9	O	-1	10579464
and	O	-1	10579464
2.@@	O	-1	10579464
7	O	-1	10579464
n@@	O	-1	10579464
M@@	O	-1	10579464
,	O	-1	10579464
respectively.	O	-1	10579464
N@@	B-Chemical	C121249	10579464
R@@	I-Chemical	-1	10579464
A@@	I-Chemical	-1	10579464
0@@	I-Chemical	-1	10579464
1@@	I-Chemical	-1	10579464
60	I-Chemical	-1	10579464
is	O	-1	10579464
over	O	-1	10579464
20@@	O	-1	10579464
,@@	O	-1	10579464
0@@	O	-1	10579464
0@@	O	-1	10579464
0@@	O	-1	10579464
fol@@	O	-1	10579464
d	O	-1	10579464
more	O	-1	10579464
pot@@	O	-1	10579464
ent	O	-1	10579464
at	O	-1	10579464
the	O	-1	10579464
dopamine	B-Chemical	D004298	10579464
D@@	O	-1	10579464
4.@@	O	-1	10579464
2	O	-1	10579464
receptor	O	-1	10579464
compared	O	-1	10579464
with	O	-1	10579464
the	O	-1	10579464
human	O	-1	10579464
clon@@	O	-1	10579464
ed	O	-1	10579464
dopamine	B-Chemical	D004298	10579464
D@@	O	-1	10579464
2@@	O	-1	10579464
L	O	-1	10579464
receptor@@	O	-1	10579464
.	O	-1	10579464
N@@	B-Chemical	C121249	10579464
R@@	I-Chemical	-1	10579464
A@@	I-Chemical	-1	10579464
0@@	I-Chemical	-1	10579464
1@@	I-Chemical	-1	10579464
60	I-Chemical	-1	10579464
has	O	-1	10579464
neg@@	O	-1	10579464
li@@	O	-1	10579464
gi@@	O	-1	10579464
ble	O	-1	10579464
aff@@	O	-1	10579464
in@@	O	-1	10579464
ity	O	-1	10579464
for	O	-1	10579464
the	O	-1	10579464
human	O	-1	10579464
clon@@	O	-1	10579464
ed	O	-1	10579464
dopamine	B-Chemical	D004298	10579464
D@@	O	-1	10579464
3	O	-1	10579464
receptor	O	-1	10579464
(@@	O	-1	10579464
K@@	O	-1	10579464
i@@	O	-1	10579464
=@@	O	-1	10579464
3@@	O	-1	10579464
9	O	-1	10579464
n@@	O	-1	10579464
M@@	O	-1	10579464
),	O	-1	10579464
rat	O	-1	10579464
seroton@@	B-Chemical	D012701	10579464
in	I-Chemical	-1	10579464
(	O	-1	10579464
5-@@	B-Chemical	D012701	10579464
H@@	I-Chemical	-1	10579464
T	I-Chemical	-1	10579464
)@@	O	-1	10579464
2@@	O	-1	10579464
A	O	-1	10579464
receptors	O	-1	10579464
(@@	O	-1	10579464
K@@	O	-1	10579464
i@@	O	-1	10579464
=@@	O	-1	10579464
18@@	O	-1	10579464
0	O	-1	10579464
n@@	O	-1	10579464
M@@	O	-1	10579464
)	O	-1	10579464
and	O	-1	10579464
rat	O	-1	10579464
alpha@@	O	-1	10579464
1	O	-1	10579464
adren@@	O	-1	10579464
oc@@	O	-1	10579464
e@@	O	-1	10579464
pt@@	O	-1	10579464
or	O	-1	10579464
(@@	O	-1	10579464
K@@	O	-1	10579464
i@@	O	-1	10579464
=@@	O	-1	10579464
2@@	O	-1	10579464
3@@	O	-1	10579464
7	O	-1	10579464
n@@	O	-1	10579464
M@@	O	-1	10579464
).	O	-1	10579464
N@@	B-Chemical	C121249	10579464
R@@	I-Chemical	-1	10579464
A@@	I-Chemical	-1	10579464
0@@	I-Chemical	-1	10579464
1@@	I-Chemical	-1	10579464
60	I-Chemical	-1	10579464
and	O	-1	10579464
cloz@@	B-Chemical	D003024	10579464
apine	I-Chemical	-1	10579464
antagon@@	O	-1	10579464
ized	O	-1	10579464
locomotor	O	-1	10579464
hyperactivity	B-Disease	D006948	10579464
induced	O	-1	10579464
by	O	-1	10579464
meth@@	B-Chemical	D008694	10579464
amphetamine	I-Chemical	-1	10579464
(	O	-1	10579464
MA@@	B-Chemical	D008694	10579464
P	I-Chemical	-1	10579464
)	O	-1	10579464
in	O	-1	10579464
mice.	O	-1	10579464
N@@	B-Chemical	C121249	10579464
R@@	I-Chemical	-1	10579464
A@@	I-Chemical	-1	10579464
0@@	I-Chemical	-1	10579464
1@@	I-Chemical	-1	10579464
60	I-Chemical	-1	10579464
and	O	-1	10579464
cloz@@	B-Chemical	D003024	10579464
apine	I-Chemical	-1	10579464
antagon@@	O	-1	10579464
ized	O	-1	10579464
MA@@	B-Chemical	D008694	10579464
P	I-Chemical	-1	10579464
-induced	O	-1	10579464
ste@@	O	-1	10579464
re@@	O	-1	10579464
ot@@	O	-1	10579464
yp@@	O	-1	10579464
ed	O	-1	10579464
behavi@@	O	-1	10579464
or	O	-1	10579464
in	O	-1	10579464
mic@@	O	-1	10579464
e,	O	-1	10579464
although	O	-1	10579464
their	O	-1	10579464
effects	O	-1	10579464
did	O	-1	10579464
not	O	-1	10579464
ex@@	O	-1	10579464
ce@@	O	-1	10579464
ed	O	-1	10579464
50@@	O	-1	10579464
%	O	-1	10579464
inhib@@	O	-1	10579464
i@@	O	-1	10579464
tion,	O	-1	10579464
even	O	-1	10579464
at	O	-1	10579464
the	O	-1	10579464
high@@	O	-1	10579464
est	O	-1	10579464
dose	O	-1	10579464
gi@@	O	-1	10579464
ven@@	O	-1	10579464
.	O	-1	10579464
N@@	B-Chemical	C121249	10579464
R@@	I-Chemical	-1	10579464
A@@	I-Chemical	-1	10579464
0@@	I-Chemical	-1	10579464
1@@	I-Chemical	-1	10579464
60	I-Chemical	-1	10579464
and	O	-1	10579464
cloz@@	B-Chemical	D003024	10579464
apine	I-Chemical	-1	10579464
significantly	O	-1	10579464
induced	O	-1	10579464
cat@@	B-Disease	D002375	10579464
al@@	I-Disease	-1	10579464
ep@@	I-Disease	-1	10579464
sy	I-Disease	-1	10579464
in	O	-1	10579464
rats,	O	-1	10579464
although	O	-1	10579464
their	O	-1	10579464
effects	O	-1	10579464
did	O	-1	10579464
not	O	-1	10579464
ex@@	O	-1	10579464
ce@@	O	-1	10579464
ed	O	-1	10579464
50@@	O	-1	10579464
%	O	-1	10579464
induction	O	-1	10579464
even	O	-1	10579464
at	O	-1	10579464
the	O	-1	10579464
high@@	O	-1	10579464
est	O	-1	10579464
dose	O	-1	10579464
gi@@	O	-1	10579464
ven@@	O	-1	10579464
.	O	-1	10579464
N@@	B-Chemical	C121249	10579464
R@@	I-Chemical	-1	10579464
A@@	I-Chemical	-1	10579464
0@@	I-Chemical	-1	10579464
1@@	I-Chemical	-1	10579464
60	I-Chemical	-1	10579464
and	O	-1	10579464
cloz@@	B-Chemical	D003024	10579464
apine	I-Chemical	-1	10579464
significantly	O	-1	10579464
reversed	O	-1	10579464
the	O	-1	10579464
dis@@	O	-1	10579464
ru@@	O	-1	10579464
ption	O	-1	10579464
of	O	-1	10579464
pre@@	O	-1	10579464
pul@@	O	-1	10579464
se	O	-1	10579464
inhibition	O	-1	10579464
(P@@	O	-1	10579464
P@@	O	-1	10579464
I@@	O	-1	10579464
)	O	-1	10579464
in	O	-1	10579464
rats	O	-1	10579464
produced	O	-1	10579464
by	O	-1	10579464
apo@@	B-Chemical	D001058	10579464
morphine	I-Chemical	-1	10579464
.	O	-1	10579464
N@@	B-Chemical	C121249	10579464
R@@	I-Chemical	-1	10579464
A@@	I-Chemical	-1	10579464
0@@	I-Chemical	-1	10579464
1@@	I-Chemical	-1	10579464
60	I-Chemical	-1	10579464
and	O	-1	10579464
cloz@@	B-Chemical	D003024	10579464
apine	I-Chemical	-1	10579464
significantly	O	-1	10579464
sh@@	O	-1	10579464
or@@	O	-1	10579464
ten@@	O	-1	10579464
ed	O	-1	10579464
the	O	-1	10579464
ph@@	B-Chemical	D010622	10579464
enc@@	I-Chemical	-1	10579464
y@@	I-Chemical	-1	10579464
cl@@	I-Chemical	-1	10579464
idine	I-Chemical	-1	10579464
(	O	-1	10579464
P@@	B-Chemical	D010622	10579464
C@@	I-Chemical	-1	10579464
P	I-Chemical	-1	10579464
)@@	O	-1	10579464
-induced	O	-1	10579464
prolonged	O	-1	10579464
s@@	O	-1	10579464
w@@	O	-1	10579464
im@@	O	-1	10579464
m@@	O	-1	10579464
ing	O	-1	10579464
lat@@	O	-1	10579464
ency	O	-1	10579464
in	O	-1	10579464
rats	O	-1	10579464
in	O	-1	10579464
a	O	-1	10579464
w@@	O	-1	10579464
at@@	O	-1	10579464
er	O	-1	10579464
ma@@	O	-1	10579464
ze	O	-1	10579464
t@@	O	-1	10579464
as@@	O	-1	10579464
k@@	O	-1	10579464
.	O	-1	10579464
These	O	-1	10579464
findings	O	-1	10579464
suggest	O	-1	10579464
that	O	-1	10579464
N@@	B-Chemical	C121249	10579464
R@@	I-Chemical	-1	10579464
A@@	I-Chemical	-1	10579464
0@@	I-Chemical	-1	10579464
1@@	I-Chemical	-1	10579464
60	I-Chemical	-1	10579464
may	O	-1	10579464
have	O	-1	10579464
un@@	O	-1	10579464
i@@	O	-1	10579464
qu@@	O	-1	10579464
e	O	-1	10579464
anti@@	O	-1	10579464
psycho@@	O	-1	10579464
tic	O	-1	10579464
ac@@	O	-1	10579464
ti@@	O	-1	10579464
vi@@	O	-1	10579464
ties	O	-1	10579464
without	O	-1	10579464
the	O	-1	10579464
li@@	O	-1	10579464
ability	O	-1	10579464
of	O	-1	10579464
motor	O	-1	10579464
side	O	-1	10579464
effects	O	-1	10579464
typ@@	O	-1	10579464
ical	O	-1	10579464
of	O	-1	10579464
cl@@	O	-1	10579464
assi@@	O	-1	10579464
c@@	O	-1	10579464
al	O	-1	10579464
anti@@	O	-1	10579464
psycho@@	O	-1	10579464
tic@@	O	-1	10579464
s.	O	-1	10579464

Pro@@	O	-1	3496378
long@@	O	-1	3496378
ed	O	-1	3496378
cholest@@	B-Disease	D002779	3496378
asis	I-Disease	-1	3496378
after	O	-1	3496378
tro@@	B-Chemical	D014217	3496378
le@@	I-Chemical	-1	3496378
an@@	I-Chemical	-1	3496378
dom@@	I-Chemical	-1	3496378
ycin	I-Chemical	-1	3496378
-induced	O	-1	3496378
acute	O	-1	3496378
hepatitis	B-Disease	D056486	3496378
.	O	-1	3496378
We	O	-1	3496378
report	O	-1	3496378
the	O	-1	3496378
case	O	-1	3496378
of	O	-1	3496378
a	O	-1	3496378
patient	O	-1	3496378
in	O	-1	3496378
whom	O	-1	3496378
tro@@	B-Chemical	D014217	3496378
le@@	I-Chemical	-1	3496378
an@@	I-Chemical	-1	3496378
dom@@	I-Chemical	-1	3496378
ycin	I-Chemical	-1	3496378
-induced	O	-1	3496378
hepatitis	B-Disease	D056486	3496378
was	O	-1	3496378
followed	O	-1	3496378
by	O	-1	3496378
prolonged	O	-1	3496378
an@@	O	-1	3496378
ic@@	O	-1	3496378
ter@@	O	-1	3496378
ic	O	-1	3496378
cholest@@	B-Disease	D002779	3496378
asis	I-Disease	-1	3496378
.	O	-1	3496378
J@@	B-Disease	D007565	3496378
a@@	I-Disease	-1	3496378
un@@	I-Disease	-1	3496378
dic@@	I-Disease	-1	3496378
e	I-Disease	-1	3496378
occurred	O	-1	3496378
after	O	-1	3496378
administration	O	-1	3496378
of	O	-1	3496378
tro@@	B-Chemical	D014217	3496378
le@@	I-Chemical	-1	3496378
an@@	I-Chemical	-1	3496378
dom@@	I-Chemical	-1	3496378
ycin	I-Chemical	-1	3496378
for	O	-1	3496378
7	O	-1	3496378
days	O	-1	3496378
and	O	-1	3496378
was	O	-1	3496378
associated	O	-1	3496378
with	O	-1	3496378
hy@@	B-Disease	D004802	3496378
pe@@	I-Disease	-1	3496378
re@@	I-Disease	-1	3496378
os@@	I-Disease	-1	3496378
in@@	I-Disease	-1	3496378
oph@@	I-Disease	-1	3496378
il@@	I-Disease	-1	3496378
ia	I-Disease	-1	3496378
.	O	-1	3496378
J@@	B-Disease	D007565	3496378
a@@	I-Disease	-1	3496378
un@@	I-Disease	-1	3496378
dic@@	I-Disease	-1	3496378
e	I-Disease	-1	3496378
dis@@	O	-1	3496378
appe@@	O	-1	3496378
a@@	O	-1	3496378
red	O	-1	3496378
within	O	-1	3496378
3	O	-1	3496378
months	O	-1	3496378
but	O	-1	3496378
was	O	-1	3496378
followed	O	-1	3496378
by	O	-1	3496378
prolonged	O	-1	3496378
an@@	O	-1	3496378
ic@@	O	-1	3496378
ter@@	O	-1	3496378
ic	O	-1	3496378
cholest@@	B-Disease	D002779	3496378
asis	I-Disease	-1	3496378
mark@@	O	-1	3496378
ed	O	-1	3496378
by	O	-1	3496378
pr@@	B-Disease	D011537	3496378
ur@@	I-Disease	-1	3496378
it@@	I-Disease	-1	3496378
us	I-Disease	-1	3496378
and	O	-1	3496378
high	O	-1	3496378
levels	O	-1	3496378
of	O	-1	3496378
al@@	O	-1	3496378
k@@	O	-1	3496378
aline	O	-1	3496378
phosph@@	O	-1	3496378
at@@	O	-1	3496378
ase	O	-1	3496378
and	O	-1	3496378
gam@@	O	-1	3496378
mag@@	O	-1	3496378
l@@	O	-1	3496378
ut@@	O	-1	3496378
am@@	O	-1	3496378
yl@@	O	-1	3496378
trans@@	O	-1	3496378
fer@@	O	-1	3496378
ase	O	-1	3496378
ac@@	O	-1	3496378
ti@@	O	-1	3496378
vi@@	O	-1	3496378
ti@@	O	-1	3496378
es.	O	-1	3496378
F@@	O	-1	3496378
in@@	O	-1	3496378
ally,	O	-1	3496378
pr@@	B-Disease	D011537	3496378
ur@@	I-Disease	-1	3496378
it@@	I-Disease	-1	3496378
us	I-Disease	-1	3496378
dis@@	O	-1	3496378
appe@@	O	-1	3496378
a@@	O	-1	3496378
red	O	-1	3496378
within	O	-1	3496378
1@@	O	-1	3496378
9	O	-1	3496378
month@@	O	-1	3496378
s,	O	-1	3496378
and	O	-1	3496378
liver	O	-1	3496378
tests	O	-1	3496378
retur@@	O	-1	3496378
n@@	O	-1	3496378
ed	O	-1	3496378
to	O	-1	3496378
normal	O	-1	3496378
2@@	O	-1	3496378
7	O	-1	3496378
months	O	-1	3496378
after	O	-1	3496378
the	O	-1	3496378
onset	O	-1	3496378
of	O	-1	3496378
hepatitis	B-Disease	D056486	3496378
.	O	-1	3496378
This	O	-1	3496378
observ@@	O	-1	3496378
ation	O	-1	3496378
demon@@	O	-1	3496378
strat@@	O	-1	3496378
es	O	-1	3496378
that	O	-1	3496378
prolonged	O	-1	3496378
cholest@@	B-Disease	D002779	3496378
asis	I-Disease	-1	3496378
can	O	-1	3496378
fol@@	O	-1	3496378
low	O	-1	3496378
tro@@	B-Chemical	D014217	3496378
le@@	I-Chemical	-1	3496378
an@@	I-Chemical	-1	3496378
dom@@	I-Chemical	-1	3496378
ycin	I-Chemical	-1	3496378
-induced	O	-1	3496378
acute	O	-1	3496378
hepatitis	B-Disease	D056486	3496378
.	O	-1	3496378

H@@	O	-1	3076126
M@@	O	-1	3076126
G	O	-1	3076126
C@@	O	-1	3076126
o@@	O	-1	3076126
A	O	-1	3076126
reduc@@	O	-1	3076126
t@@	O	-1	3076126
ase	O	-1	3076126
inhibitor@@	O	-1	3076126
s.	O	-1	3076126
C@@	O	-1	3076126
ur@@	O	-1	3076126
rent	O	-1	3076126
clinical	O	-1	3076126
experi@@	O	-1	3076126
ence@@	O	-1	3076126
.	O	-1	3076126
L@@	B-Chemical	D008148	3076126
o@@	I-Chemical	-1	3076126
vastatin	I-Chemical	-1	3076126
and	O	-1	3076126
sim@@	B-Chemical	D019821	3076126
vastatin	I-Chemical	-1	3076126
are	O	-1	3076126
the	O	-1	3076126
2	O	-1	3076126
be@@	O	-1	3076126
st@@	O	-1	3076126
-@@	O	-1	3076126
known	O	-1	3076126
memb@@	O	-1	3076126
ers	O	-1	3076126
of	O	-1	3076126
the	O	-1	3076126
cl@@	O	-1	3076126
as@@	O	-1	3076126
s	O	-1	3076126
of	O	-1	3076126
hy@@	O	-1	3076126
pol@@	O	-1	3076126
ip@@	O	-1	3076126
id@@	O	-1	3076126
a@@	O	-1	3076126
em@@	O	-1	3076126
ic	O	-1	3076126
agents	O	-1	3076126
known	O	-1	3076126
as	O	-1	3076126
H@@	O	-1	3076126
M@@	O	-1	3076126
G	O	-1	3076126
C@@	O	-1	3076126
o@@	O	-1	3076126
A	O	-1	3076126
reduc@@	O	-1	3076126
t@@	O	-1	3076126
ase	O	-1	3076126
inhibitor@@	O	-1	3076126
s.	O	-1	3076126
Clin@@	O	-1	3076126
ical	O	-1	3076126
experi@@	O	-1	3076126
ence	O	-1	3076126
with	O	-1	3076126
lo@@	B-Chemical	D008148	3076126
vastatin	I-Chemical	-1	3076126
inc@@	O	-1	3076126
lu@@	O	-1	3076126
des	O	-1	3076126
over	O	-1	3076126
50@@	O	-1	3076126
00	O	-1	3076126
patients,	O	-1	3076126
7@@	O	-1	3076126
00	O	-1	3076126
of	O	-1	3076126
whom	O	-1	3076126
have	O	-1	3076126
been	O	-1	3076126
treated	O	-1	3076126
for	O	-1	3076126
2	O	-1	3076126
years	O	-1	3076126
or	O	-1	3076126
mo@@	O	-1	3076126
re,	O	-1	3076126
and	O	-1	3076126
experi@@	O	-1	3076126
ence	O	-1	3076126
with	O	-1	3076126
sim@@	B-Chemical	D019821	3076126
vastatin	I-Chemical	-1	3076126
inc@@	O	-1	3076126
lu@@	O	-1	3076126
des	O	-1	3076126
over	O	-1	3076126
3@@	O	-1	3076126
5@@	O	-1	3076126
00	O	-1	3076126
patients,	O	-1	3076126
of	O	-1	3076126
whom	O	-1	3076126
3@@	O	-1	3076126
50	O	-1	3076126
have	O	-1	3076126
been	O	-1	3076126
treated	O	-1	3076126
for	O	-1	3076126
1@@	O	-1	3076126
8	O	-1	3076126
months	O	-1	3076126
or	O	-1	3076126
mo@@	O	-1	3076126
re.	O	-1	3076126
L@@	B-Chemical	D008148	3076126
o@@	I-Chemical	-1	3076126
vastatin	I-Chemical	-1	3076126
has	O	-1	3076126
been	O	-1	3076126
mark@@	O	-1	3076126
et@@	O	-1	3076126
ed	O	-1	3076126
in	O	-1	3076126
the	O	-1	3076126
U@@	O	-1	3076126
nit@@	O	-1	3076126
ed	O	-1	3076126
S@@	O	-1	3076126
t@@	O	-1	3076126
ates	O	-1	3076126
for	O	-1	3076126
over	O	-1	3076126
6	O	-1	3076126
months.	O	-1	3076126
B@@	O	-1	3076126
oth	O	-1	3076126
agents	O	-1	3076126
show	O	-1	3076126
subst@@	O	-1	3076126
anti@@	O	-1	3076126
al	O	-1	3076126
clinical	O	-1	3076126
efficac@@	O	-1	3076126
y,	O	-1	3076126
with	O	-1	3076126
reduc@@	O	-1	3076126
tions	O	-1	3076126
in	O	-1	3076126
total	O	-1	3076126
cholester@@	B-Chemical	D002784	3076126
ol	I-Chemical	-1	3076126
of	O	-1	3076126
over	O	-1	3076126
3@@	O	-1	3076126
0%	O	-1	3076126
and	O	-1	3076126
in	O	-1	3076126
L@@	O	-1	3076126
D@@	O	-1	3076126
L@@	O	-1	3076126
-	O	-1	3076126
cholester@@	B-Chemical	D002784	3076126
ol	I-Chemical	-1	3076126
of	O	-1	3076126
4@@	O	-1	3076126
0%	O	-1	3076126
in	O	-1	3076126
clinical	O	-1	3076126
studi@@	O	-1	3076126
es.	O	-1	3076126
M@@	O	-1	3076126
o@@	O	-1	3076126
d@@	O	-1	3076126
est	O	-1	3076126
increases	O	-1	3076126
in	O	-1	3076126
H@@	O	-1	3076126
D@@	O	-1	3076126
L@@	O	-1	3076126
-	O	-1	3076126
cholester@@	B-Chemical	D002784	3076126
ol	I-Chemical	-1	3076126
levels	O	-1	3076126
of	O	-1	3076126
about	O	-1	3076126
10@@	O	-1	3076126
%	O	-1	3076126
are	O	-1	3076126
also	O	-1	3076126
repor@@	O	-1	3076126
ted.	O	-1	3076126
Clin@@	O	-1	3076126
ical	O	-1	3076126
toler@@	O	-1	3076126
ability	O	-1	3076126
of	O	-1	3076126
both	O	-1	3076126
agents	O	-1	3076126
has	O	-1	3076126
been	O	-1	3076126
go@@	O	-1	3076126
o@@	O	-1	3076126
d,	O	-1	3076126
with	O	-1	3076126
fe@@	O	-1	3076126
w@@	O	-1	3076126
er	O	-1	3076126
than	O	-1	3076126
3@@	O	-1	3076126
%	O	-1	3076126
of	O	-1	3076126
patients	O	-1	3076126
withdraw@@	O	-1	3076126
n	O	-1	3076126
from	O	-1	3076126
treatment	O	-1	3076126
because	O	-1	3076126
of	O	-1	3076126
clinical	O	-1	3076126
adverse	O	-1	3076126
experienc@@	O	-1	3076126
es.	O	-1	3076126
O@@	O	-1	3076126
ph@@	O	-1	3076126
thal@@	O	-1	3076126
mo@@	O	-1	3076126
log@@	O	-1	3076126
ical	O	-1	3076126
examin@@	O	-1	3076126
ations	O	-1	3076126
in	O	-1	3076126
over	O	-1	3076126
1@@	O	-1	3076126
100	O	-1	3076126
patients	O	-1	3076126
treated	O	-1	3076126
with	O	-1	3076126
one	O	-1	3076126
or	O	-1	3076126
the	O	-1	3076126
other	O	-1	3076126
agent	O	-1	3076126
have	O	-1	3076126
revealed	O	-1	3076126
no	O	-1	3076126
evidence	O	-1	3076126
of	O	-1	3076126
significant	O	-1	3076126
sh@@	O	-1	3076126
ort	O	-1	3076126
term	O	-1	3076126
(@@	O	-1	3076126
up	O	-1	3076126
to	O	-1	3076126
2	O	-1	3076126
year@@	O	-1	3076126
s)	O	-1	3076126
cat@@	O	-1	3076126
arac@@	O	-1	3076126
to@@	O	-1	3076126
genic	O	-1	3076126
potenti@@	O	-1	3076126
al.	O	-1	3076126
One	O	-1	3076126
to	O	-1	3076126
2@@	O	-1	3076126
%	O	-1	3076126
of	O	-1	3076126
patients	O	-1	3076126
have	O	-1	3076126
elev@@	O	-1	3076126
ations	O	-1	3076126
of	O	-1	3076126
serum	O	-1	3076126
trans@@	O	-1	3076126
amin@@	O	-1	3076126
as@@	O	-1	3076126
es	O	-1	3076126
to	O	-1	3076126
greater	O	-1	3076126
than	O	-1	3076126
3	O	-1	3076126
times	O	-1	3076126
the	O	-1	3076126
up@@	O	-1	3076126
per	O	-1	3076126
lim@@	O	-1	3076126
it	O	-1	3076126
of	O	-1	3076126
normal@@	O	-1	3076126
.	O	-1	3076126
These	O	-1	3076126
episo@@	O	-1	3076126
des	O	-1	3076126
are	O	-1	3076126
as@@	O	-1	3076126
ym@@	O	-1	3076126
pto@@	O	-1	3076126
m@@	O	-1	3076126
atic	O	-1	3076126
and	O	-1	3076126
reversible	O	-1	3076126
when	O	-1	3076126
therapy	O	-1	3076126
is	O	-1	3076126
discontinu@@	O	-1	3076126
ed.	O	-1	3076126
M@@	O	-1	3076126
in@@	O	-1	3076126
or	O	-1	3076126
elev@@	O	-1	3076126
ations	O	-1	3076126
of	O	-1	3076126
creat@@	B-Chemical	D003401	3076126
ine	I-Chemical	-1	3076126
kin@@	O	-1	3076126
ase	O	-1	3076126
levels	O	-1	3076126
are	O	-1	3076126
reported	O	-1	3076126
in	O	-1	3076126
about	O	-1	3076126
5%	O	-1	3076126
of	O	-1	3076126
patients.	O	-1	3076126
M@@	B-Disease	D009135	3076126
yo@@	I-Disease	-1	3076126
pathy	I-Disease	-1	3076126
,	O	-1	3076126
associated	O	-1	3076126
in	O	-1	3076126
some	O	-1	3076126
cases	O	-1	3076126
with	O	-1	3076126
my@@	B-Disease	D009212	3076126
o@@	I-Disease	-1	3076126
glo@@	I-Disease	-1	3076126
bin@@	I-Disease	-1	3076126
uria	I-Disease	-1	3076126
,	O	-1	3076126
and	O	-1	3076126
in	O	-1	3076126
2	O	-1	3076126
cases	O	-1	3076126
with	O	-1	3076126
transi@@	O	-1	3076126
ent	O	-1	3076126
renal	B-Disease	D051437	3076126
failure	I-Disease	-1	3076126
,	O	-1	3076126
has	O	-1	3076126
been	O	-1	3076126
ra@@	O	-1	3076126
re@@	O	-1	3076126
ly	O	-1	3076126
reported	O	-1	3076126
with	O	-1	3076126
lo@@	B-Chemical	D008148	3076126
vastatin	I-Chemical	-1	3076126
,	O	-1	3076126
es@@	O	-1	3076126
p@@	O	-1	3076126
ec@@	O	-1	3076126
i@@	O	-1	3076126
ally	O	-1	3076126
in	O	-1	3076126
patients	O	-1	3076126
concomit@@	O	-1	3076126
ant@@	O	-1	3076126
ly	O	-1	3076126
treated	O	-1	3076126
with	O	-1	3076126
cyclospor@@	B-Chemical	D016572	3076126
in	I-Chemical	-1	3076126
,	O	-1	3076126
g@@	B-Chemical	D015248	3076126
em@@	I-Chemical	-1	3076126
fib@@	I-Chemical	-1	3076126
ro@@	I-Chemical	-1	3076126
z@@	I-Chemical	-1	3076126
il	I-Chemical	-1	3076126
or	O	-1	3076126
n@@	B-Chemical	D009525	3076126
i@@	I-Chemical	-1	3076126
ac@@	I-Chemical	-1	3076126
in	I-Chemical	-1	3076126
.	O	-1	3076126
L@@	B-Chemical	D008148	3076126
o@@	I-Chemical	-1	3076126
vastatin	I-Chemical	-1	3076126
and	O	-1	3076126
sim@@	B-Chemical	D019821	3076126
vastatin	I-Chemical	-1	3076126
are	O	-1	3076126
both	O	-1	3076126
effective	O	-1	3076126
and	O	-1	3076126
we@@	O	-1	3076126
ll@@	O	-1	3076126
-@@	O	-1	3076126
toler@@	O	-1	3076126
ated	O	-1	3076126
agents	O	-1	3076126
for	O	-1	3076126
low@@	O	-1	3076126
ering	O	-1	3076126
elevated	O	-1	3076126
levels	O	-1	3076126
of	O	-1	3076126
serum	O	-1	3076126
cholester@@	B-Chemical	D002784	3076126
ol	I-Chemical	-1	3076126
.	O	-1	3076126
A@@	O	-1	3076126
s	O	-1	3076126
w@@	O	-1	3076126
id@@	O	-1	3076126
er	O	-1	3076126
use	O	-1	3076126
con@@	O	-1	3076126
fir@@	O	-1	3076126
ms	O	-1	3076126
their	O	-1	3076126
safety	O	-1	3076126
pro@@	O	-1	3076126
fi@@	O	-1	3076126
le@@	O	-1	3076126
,	O	-1	3076126
they	O	-1	3076126
wil@@	O	-1	3076126
l	O	-1	3076126
g@@	O	-1	3076126
ain	O	-1	3076126
increas@@	O	-1	3076126
ing	O	-1	3076126
import@@	O	-1	3076126
ance	O	-1	3076126
in	O	-1	3076126
the	O	-1	3076126
therapeutic	O	-1	3076126
appro@@	O	-1	3076126
ach	O	-1	3076126
to	O	-1	3076126
hyper@@	B-Disease	D006937	3076126
cholester@@	I-Disease	-1	3076126
ol@@	I-Disease	-1	3076126
a@@	I-Disease	-1	3076126
emia	I-Disease	-1	3076126
and	O	-1	3076126
its	O	-1	3076126
con@@	O	-1	3076126
sequ@@	O	-1	3076126
enc@@	O	-1	3076126
es.	O	-1	3076126

S@@	B-Chemical	D012460	2894766
ul@@	I-Chemical	-1	2894766
f@@	I-Chemical	-1	2894766
as@@	I-Chemical	-1	2894766
al@@	I-Chemical	-1	2894766
az@@	I-Chemical	-1	2894766
ine	I-Chemical	-1	2894766
-induced	O	-1	2894766
lu@@	B-Disease	D008180	2894766
p@@	I-Disease	-1	2894766
us	I-Disease	-1	2894766
eryth@@	I-Disease	-1	2894766
em@@	I-Disease	-1	2894766
at@@	I-Disease	-1	2894766
os@@	I-Disease	-1	2894766
us	I-Disease	-1	2894766
.	O	-1	2894766
P@@	B-Disease	D011014	2894766
ne@@	I-Disease	-1	2894766
um@@	I-Disease	-1	2894766
on@@	I-Disease	-1	2894766
iti@@	I-Disease	-1	2894766
s	I-Disease	-1	2894766
,	O	-1	2894766
bil@@	O	-1	2894766
ateral	O	-1	2894766
ple@@	B-Disease	D010996	2894766
ural	I-Disease	-1	2894766
eff@@	I-Disease	-1	2894766
u@@	I-Disease	-1	2894766
sions	I-Disease	-1	2894766
,	O	-1	2894766
echocardiograph@@	O	-1	2894766
ic	O	-1	2894766
evidence	O	-1	2894766
of	O	-1	2894766
cardiac	B-Disease	D002305	2894766
t@@	I-Disease	-1	2894766
amp@@	I-Disease	-1	2894766
on@@	I-Disease	-1	2894766
ade	I-Disease	-1	2894766
,	O	-1	2894766
and	O	-1	2894766
positive	O	-1	2894766
auto@@	O	-1	2894766
anti@@	O	-1	2894766
bo@@	O	-1	2894766
di@@	O	-1	2894766
es	O	-1	2894766
developed	O	-1	2894766
in	O	-1	2894766
a	O	-1	2894766
4@@	O	-1	2894766
3-@@	O	-1	2894766
year-old	O	-1	2894766
man@@	O	-1	2894766
,	O	-1	2894766
who	O	-1	2894766
was	O	-1	2894766
receiving	O	-1	2894766
long-term	O	-1	2894766
sulf@@	B-Chemical	D012460	2894766
as@@	I-Chemical	-1	2894766
al@@	I-Chemical	-1	2894766
az@@	I-Chemical	-1	2894766
ine	I-Chemical	-1	2894766
therapy	O	-1	2894766
for	O	-1	2894766
chronic	O	-1	2894766
ul@@	B-Disease	D003093	2894766
cer@@	I-Disease	-1	2894766
ative	I-Disease	-1	2894766
co@@	I-Disease	-1	2894766
li@@	I-Disease	-1	2894766
tis	I-Disease	-1	2894766
.	O	-1	2894766
After	O	-1	2894766
cess@@	O	-1	2894766
ation	O	-1	2894766
of	O	-1	2894766
the	O	-1	2894766
sulf@@	B-Chemical	D012460	2894766
as@@	I-Chemical	-1	2894766
al@@	I-Chemical	-1	2894766
az@@	I-Chemical	-1	2894766
ine	I-Chemical	-1	2894766
and	O	-1	2894766
comple@@	O	-1	2894766
tion	O	-1	2894766
of	O	-1	2894766
a	O	-1	2894766
si@@	O	-1	2894766
x@@	O	-1	2894766
-@@	O	-1	2894766
week	O	-1	2894766
course	O	-1	2894766
of	O	-1	2894766
cortico@@	O	-1	2894766
steroid@@	O	-1	2894766
s,	O	-1	2894766
these	O	-1	2894766
pro@@	O	-1	2894766
ble@@	O	-1	2894766
ms	O	-1	2894766
resol@@	O	-1	2894766
ved	O	-1	2894766
over	O	-1	2894766
a	O	-1	2894766
period	O	-1	2894766
of	O	-1	2894766
four	O	-1	2894766
to	O	-1	2894766
six	O	-1	2894766
months.	O	-1	2894766
It	O	-1	2894766
is	O	-1	2894766
suggested	O	-1	2894766
that	O	-1	2894766
the	O	-1	2894766
patient	O	-1	2894766
had	O	-1	2894766
sulf@@	B-Chemical	D012460	2894766
as@@	I-Chemical	-1	2894766
al@@	I-Chemical	-1	2894766
az@@	I-Chemical	-1	2894766
ine	I-Chemical	-1	2894766
-induced	O	-1	2894766
lu@@	B-Disease	D008180	2894766
p@@	I-Disease	-1	2894766
us	I-Disease	-1	2894766
,	O	-1	2894766
which	O	-1	2894766
man@@	O	-1	2894766
if@@	O	-1	2894766
est@@	O	-1	2894766
ed	O	-1	2894766
with	O	-1	2894766
ser@@	B-Disease	D012700	2894766
o@@	I-Disease	-1	2894766
si@@	I-Disease	-1	2894766
tis	I-Disease	-1	2894766
and	O	-1	2894766
pulmonary	O	-1	2894766
pa@@	O	-1	2894766
ren@@	O	-1	2894766
ch@@	O	-1	2894766
ym@@	O	-1	2894766
al	O	-1	2894766
invol@@	O	-1	2894766
vement	O	-1	2894766
in	O	-1	2894766
the	O	-1	2894766
absence	O	-1	2894766
of	O	-1	2894766
j@@	O	-1	2894766
o@@	O	-1	2894766
in@@	O	-1	2894766
t	O	-1	2894766
symptom@@	O	-1	2894766
s.	O	-1	2894766
P@@	O	-1	2894766
hy@@	O	-1	2894766
si@@	O	-1	2894766
ci@@	O	-1	2894766
ans	O	-1	2894766
who	O	-1	2894766
use	O	-1	2894766
sulf@@	B-Chemical	D012460	2894766
as@@	I-Chemical	-1	2894766
al@@	I-Chemical	-1	2894766
az@@	I-Chemical	-1	2894766
ine	I-Chemical	-1	2894766
to	O	-1	2894766
tre@@	O	-1	2894766
at	O	-1	2894766
patients	O	-1	2894766
with	O	-1	2894766
inflam@@	B-Disease	D015212	2894766
mat@@	I-Disease	-1	2894766
ory	I-Disease	-1	2894766
bo@@	I-Disease	-1	2894766
we@@	I-Disease	-1	2894766
l	I-Disease	-1	2894766
disease	I-Disease	-1	2894766
should	O	-1	2894766
be	O	-1	2894766
aw@@	O	-1	2894766
are	O	-1	2894766
of	O	-1	2894766
the	O	-1	2894766
signs	O	-1	2894766
of	O	-1	2894766
sulf@@	B-Chemical	D012460	2894766
as@@	I-Chemical	-1	2894766
al@@	I-Chemical	-1	2894766
az@@	I-Chemical	-1	2894766
ine	I-Chemical	-1	2894766
-induced	O	-1	2894766
lu@@	B-Disease	D008180	2894766
p@@	I-Disease	-1	2894766
us	I-Disease	-1	2894766
syndrome	I-Disease	-1	2894766
.	O	-1	2894766

O@@	O	-1	1549199
p@@	O	-1	1549199
tim@@	O	-1	1549199
ization	O	-1	1549199
of	O	-1	1549199
levo@@	B-Chemical	D007980	1549199
dopa	I-Chemical	-1	1549199
therapy.	O	-1	1549199
W@@	O	-1	1549199
h@@	O	-1	1549199
ile	O	-1	1549199
there	O	-1	1549199
is	O	-1	1549199
no	O	-1	1549199
single	O	-1	1549199
cor@@	O	-1	1549199
rec@@	O	-1	1549199
t	O	-1	1549199
star@@	O	-1	1549199
ting	O	-1	1549199
dose	O	-1	1549199
for	O	-1	1549199
levo@@	B-Chemical	D007980	1549199
dopa	I-Chemical	-1	1549199
therapy,	O	-1	1549199
man@@	O	-1	1549199
y	O	-1	1549199
individ@@	O	-1	1549199
u@@	O	-1	1549199
als	O	-1	1549199
can	O	-1	1549199
be	O	-1	1549199
star@@	O	-1	1549199
ted	O	-1	1549199
on	O	-1	1549199
either	O	-1	1549199
the	O	-1	1549199
25@@	O	-1	1549199
/@@	O	-1	1549199
100	O	-1	1549199
or	O	-1	1549199
control@@	O	-1	1549199
le@@	O	-1	1549199
d-@@	O	-1	1549199
release	O	-1	1549199
form@@	O	-1	1549199
ul@@	O	-1	1549199
a,	O	-1	1549199
following	O	-1	1549199
the	O	-1	1549199
gener@@	O	-1	1549199
al	O	-1	1549199
r@@	O	-1	1549199
ul@@	O	-1	1549199
e	O	-1	1549199
not	O	-1	1549199
to	O	-1	1549199
at@@	O	-1	1549199
tem@@	O	-1	1549199
p@@	O	-1	1549199
t	O	-1	1549199
to	O	-1	1549199
ti@@	O	-1	1549199
t@@	O	-1	1549199
rate	O	-1	1549199
carb@@	B-Chemical	D002230	1549199
id@@	I-Chemical	-1	1549199
op@@	I-Chemical	-1	1549199
a	I-Chemical	-1	1549199
-	O	-1	1549199
levo@@	B-Chemical	D007980	1549199
dopa	I-Chemical	-1	1549199
to	O	-1	1549199
the	O	-1	1549199
po@@	O	-1	1549199
in@@	O	-1	1549199
t	O	-1	1549199
of	O	-1	1549199
"@@	O	-1	1549199
normal@@	O	-1	1549199
it@@	O	-1	1549199
y@@	O	-1	1549199
,@@	O	-1	1549199
"	O	-1	1549199
which	O	-1	1549199
can	O	-1	1549199
le@@	O	-1	1549199
ad	O	-1	1549199
to	O	-1	1549199
toxicity	B-Disease	D064420	1549199
.	O	-1	1549199
The	O	-1	1549199
physi@@	O	-1	1549199
ci@@	O	-1	1549199
an	O	-1	1549199
should	O	-1	1549199
also	O	-1	1549199
determine	O	-1	1549199
the	O	-1	1549199
pro@@	O	-1	1549199
per	O	-1	1549199
use	O	-1	1549199
of	O	-1	1549199
any	O	-1	1549199
adj@@	O	-1	1549199
unc@@	O	-1	1549199
tive	O	-1	1549199
medic@@	O	-1	1549199
ation@@	O	-1	1549199
s;	O	-1	1549199
such	O	-1	1549199
combined	O	-1	1549199
therapy	O	-1	1549199
has	O	-1	1549199
b@@	O	-1	1549199
ec@@	O	-1	1549199
ome	O	-1	1549199
the	O	-1	1549199
standard	O	-1	1549199
appro@@	O	-1	1549199
ach	O	-1	1549199
to	O	-1	1549199
treatment.	O	-1	1549199
F@@	O	-1	1549199
ol@@	O	-1	1549199
low@@	O	-1	1549199
ing	O	-1	1549199
the	O	-1	1549199
initial	O	-1	1549199
period	O	-1	1549199
of	O	-1	1549199
therapy,	O	-1	1549199
em@@	O	-1	1549199
erg@@	O	-1	1549199
ing	O	-1	1549199
diff@@	O	-1	1549199
ic@@	O	-1	1549199
ul@@	O	-1	1549199
ties	O	-1	1549199
requ@@	O	-1	1549199
ir@@	O	-1	1549199
e	O	-1	1549199
a	O	-1	1549199
reas@@	O	-1	1549199
s@@	O	-1	1549199
ess@@	O	-1	1549199
ment	O	-1	1549199
of	O	-1	1549199
therapeutic	O	-1	1549199
appro@@	O	-1	1549199
ac@@	O	-1	1549199
h@@	O	-1	1549199
es,	O	-1	1549199
such	O	-1	1549199
as	O	-1	1549199
dos@@	O	-1	1549199
age	O	-1	1549199
adjust@@	O	-1	1549199
ment	O	-1	1549199
or	O	-1	1549199
int@@	O	-1	1549199
ro@@	O	-1	1549199
duction	O	-1	1549199
of	O	-1	1549199
a	O	-1	1549199
dopamine	B-Chemical	D004298	1549199
agon@@	O	-1	1549199
ist@@	O	-1	1549199
.	O	-1	1549199
O@@	O	-1	1549199
ther	O	-1	1549199
possible	O	-1	1549199
adverse	O	-1	1549199
effect@@	O	-1	1549199
s-@@	O	-1	1549199
-@@	O	-1	1549199
such	O	-1	1549199
as	O	-1	1549199
gast@@	B-Disease	D005767	1549199
ro@@	I-Disease	-1	1549199
in@@	I-Disease	-1	1549199
test@@	I-Disease	-1	1549199
inal	I-Disease	-1	1549199
disorder@@	I-Disease	-1	1549199
s	I-Disease	-1	1549199
,	O	-1	1549199
or@@	B-Disease	D007024	1549199
th@@	I-Disease	-1	1549199
ost@@	I-Disease	-1	1549199
atic	I-Disease	-1	1549199
hypotension	I-Disease	-1	1549199
,	O	-1	1549199
levo@@	B-Chemical	D007980	1549199
dopa	I-Chemical	-1	1549199
-induced	O	-1	1549199
psycho@@	B-Disease	D011618	1549199
sis	I-Disease	-1	1549199
,	O	-1	1549199
sleep	B-Disease	D012893	1549199
dist@@	I-Disease	-1	1549199
urb@@	I-Disease	-1	1549199
anc@@	I-Disease	-1	1549199
es	I-Disease	-1	1549199
or	O	-1	1549199
par@@	B-Disease	D020447	1549199
as@@	I-Disease	-1	1549199
om@@	I-Disease	-1	1549199
n@@	I-Disease	-1	1549199
i@@	I-Disease	-1	1549199
as	I-Disease	-1	1549199
,	O	-1	1549199
or	O	-1	1549199
drug	O	-1	1549199
inter@@	O	-1	1549199
ac@@	O	-1	1549199
tion@@	O	-1	1549199
s-@@	O	-1	1549199
-@@	O	-1	1549199
also	O	-1	1549199
requ@@	O	-1	1549199
ir@@	O	-1	1549199
e	O	-1	1549199
ca@@	O	-1	1549199
ref@@	O	-1	1549199
ul@@	O	-1	1549199
ly	O	-1	1549199
monit@@	O	-1	1549199
o@@	O	-1	1549199
red	O	-1	1549199
individ@@	O	-1	1549199
ual	O	-1	1549199
treatment.	O	-1	1549199
N@@	O	-1	1549199
on@@	O	-1	1549199
pharmac@@	O	-1	1549199
ologic	O	-1	1549199
con@@	O	-1	1549199
cer@@	O	-1	1549199
n@@	O	-1	1549199
s	O	-1	1549199
can	O	-1	1549199
he@@	O	-1	1549199
l@@	O	-1	1549199
p	O	-1	1549199
the	O	-1	1549199
Parkinson's	B-Disease	D010300	1549199
disease	I-Disease	-1	1549199
patient	O	-1	1549199
achi@@	O	-1	1549199
e@@	O	-1	1549199
ve	O	-1	1549199
and	O	-1	1549199
maint@@	O	-1	1549199
ain	O	-1	1549199
op@@	O	-1	1549199
tim@@	O	-1	1549199
al	O	-1	1549199
func@@	O	-1	1549199
tion@@	O	-1	1549199
ing,	O	-1	1549199
including	O	-1	1549199
daily	O	-1	1549199
ex@@	O	-1	1549199
er@@	O	-1	1549199
ci@@	O	-1	1549199
se@@	O	-1	1549199
,	O	-1	1549199
physi@@	O	-1	1549199
c@@	O	-1	1549199
al	O	-1	1549199
therapy,	O	-1	1549199
and	O	-1	1549199
invol@@	O	-1	1549199
vement	O	-1	1549199
with	O	-1	1549199
suppor@@	O	-1	1549199
t	O	-1	1549199
groups.	O	-1	1549199

Al@@	O	-1	88336
ph@@	O	-1	88336
a	O	-1	88336
and	O	-1	88336
bet@@	O	-1	88336
a	O	-1	88336
com@@	B-Disease	D003128	88336
a	I-Disease	-1	88336
in	O	-1	88336
drug	O	-1	88336
in@@	O	-1	88336
toxic@@	O	-1	88336
ation	O	-1	88336
un@@	O	-1	88336
complic@@	O	-1	88336
ated	O	-1	88336
by	O	-1	88336
cerebral	B-Disease	D002534	88336
hypo@@	I-Disease	-1	88336
x@@	I-Disease	-1	88336
ia	I-Disease	-1	88336
.	O	-1	88336
F@@	O	-1	88336
our	O	-1	88336
patients	O	-1	88336
who	O	-1	88336
were	O	-1	88336
ren@@	O	-1	88336
de@@	O	-1	88336
red	O	-1	88336
com@@	B-Disease	D003128	88336
at@@	I-Disease	-1	88336
ose	I-Disease	-1	88336
or	O	-1	88336
st@@	B-Disease	D053608	88336
u@@	I-Disease	-1	88336
po@@	I-Disease	-1	88336
rou@@	I-Disease	-1	88336
s	I-Disease	-1	88336
by	O	-1	88336
drug	O	-1	88336
in@@	O	-1	88336
toxic@@	O	-1	88336
ation,	O	-1	88336
but	O	-1	88336
who	O	-1	88336
were	O	-1	88336
not	O	-1	88336
hypo@@	O	-1	88336
x@@	O	-1	88336
ic@@	O	-1	88336
,	O	-1	88336
are	O	-1	88336
descri@@	O	-1	88336
be@@	O	-1	88336
d.	O	-1	88336
Th@@	O	-1	88336
ree	O	-1	88336
patients	O	-1	88336
received	O	-1	88336
high	O	-1	88336
doses	O	-1	88336
of	O	-1	88336
chlor@@	B-Chemical	D002719	88336
meth@@	I-Chemical	-1	88336
i@@	I-Chemical	-1	88336
azole	I-Chemical	-1	88336
for	O	-1	88336
alco@@	B-Chemical	D000431	88336
hol	I-Chemical	-1	88336
withdrawal	B-Disease	D013375	88336
symptoms	I-Disease	-1	88336
,	O	-1	88336
and	O	-1	88336
one	O	-1	88336
to@@	O	-1	88336
o@@	O	-1	88336
k	O	-1	88336
a	O	-1	88336
su@@	O	-1	88336
ic@@	O	-1	88336
idal	O	-1	88336
over@@	B-Disease	D062787	88336
dose	I-Disease	-1	88336
of	O	-1	88336
nit@@	B-Chemical	D009567	88336
ra@@	I-Chemical	-1	88336
z@@	I-Chemical	-1	88336
epam	I-Chemical	-1	88336
.	O	-1	88336
The	O	-1	88336
patient	O	-1	88336
with	O	-1	88336
nit@@	B-Chemical	D009567	88336
ra@@	I-Chemical	-1	88336
z@@	I-Chemical	-1	88336
epam	I-Chemical	-1	88336
over@@	B-Disease	D062787	88336
dose	I-Disease	-1	88336
and	O	-1	88336
two	O	-1	88336
of	O	-1	88336
those	O	-1	88336
with	O	-1	88336
chlor@@	B-Chemical	D002719	88336
meth@@	I-Chemical	-1	88336
i@@	I-Chemical	-1	88336
azole	I-Chemical	-1	88336
in@@	O	-1	88336
toxic@@	O	-1	88336
ation	O	-1	88336
con@@	O	-1	88336
form@@	O	-1	88336
ed	O	-1	88336
to	O	-1	88336
the	O	-1	88336
c@@	O	-1	88336
rit@@	O	-1	88336
er@@	O	-1	88336
ia	O	-1	88336
of	O	-1	88336
'@@	O	-1	88336
al@@	O	-1	88336
ph@@	O	-1	88336
a	O	-1	88336
com@@	B-Disease	D003128	88336
a	I-Disease	-1	88336
'@@	O	-1	88336
,	O	-1	88336
show@@	O	-1	88336
ing	O	-1	88336
non-@@	O	-1	88336
reac@@	O	-1	88336
tive	O	-1	88336
gener@@	O	-1	88336
al@@	O	-1	88336
ized	O	-1	88336
or	O	-1	88336
fron@@	O	-1	88336
t@@	O	-1	88336
ally	O	-1	88336
pre@@	O	-1	88336
domin@@	O	-1	88336
ant	O	-1	88336
al@@	O	-1	88336
ph@@	O	-1	88336
a	O	-1	88336
activity	O	-1	88336
in	O	-1	88336
the	O	-1	88336
E@@	O	-1	88336
E@@	O	-1	88336
G@@	O	-1	88336
.	O	-1	88336
The	O	-1	88336
fo@@	O	-1	88336
ur@@	O	-1	88336
th	O	-1	88336
patient	O	-1	88336
who	O	-1	88336
was	O	-1	88336
un@@	O	-1	88336
con@@	O	-1	88336
s@@	O	-1	88336
ci@@	O	-1	88336
ous	O	-1	88336
after	O	-1	88336
chlor@@	B-Chemical	D002719	88336
meth@@	I-Chemical	-1	88336
i@@	I-Chemical	-1	88336
azole	I-Chemical	-1	88336
administration	O	-1	88336
ex@@	O	-1	88336
hib@@	O	-1	88336
ite	O	-1	88336
gener@@	O	-1	88336
al@@	O	-1	88336
ized	O	-1	88336
non-@@	O	-1	88336
reac@@	O	-1	88336
tive	O	-1	88336
activity	O	-1	88336
in	O	-1	88336
the	O	-1	88336
s@@	O	-1	88336
low	O	-1	88336
bet@@	O	-1	88336
a	O	-1	88336
rang@@	O	-1	88336
e.	O	-1	88336
All	O	-1	88336
four	O	-1	88336
reco@@	O	-1	88336
vered	O	-1	88336
complete@@	O	-1	88336
ly	O	-1	88336
without	O	-1	88336
neurolog@@	B-Disease	D009422	88336
ical	I-Disease	-1	88336
sequ@@	I-Disease	-1	88336
el@@	I-Disease	-1	88336
a@@	I-Disease	-1	88336
e	I-Disease	-1	88336
following	O	-1	88336
the	O	-1	88336
withdrawal	O	-1	88336
of	O	-1	88336
the	O	-1	88336
o@@	O	-1	88336
ff@@	O	-1	88336
en@@	O	-1	88336
ding	O	-1	88336
agent@@	O	-1	88336
s.	O	-1	88336
The	O	-1	88336
simil@@	O	-1	88336
ar@@	O	-1	88336
ities	O	-1	88336
between	O	-1	88336
the	O	-1	88336
effects	O	-1	88336
of	O	-1	88336
struct@@	O	-1	88336
ural	O	-1	88336
lesions	O	-1	88336
and	O	-1	88336
pharmac@@	O	-1	88336
ological	O	-1	88336
de@@	B-Disease	D003866	88336
pression	I-Disease	-1	88336
of	O	-1	88336
the	O	-1	88336
brain	O	-1	88336
st@@	O	-1	88336
em	O	-1	88336
re@@	O	-1	88336
tic@@	O	-1	88336
ular	O	-1	88336
formation	O	-1	88336
are	O	-1	88336
discus@@	O	-1	88336
sed.	O	-1	88336
It	O	-1	88336
is	O	-1	88336
suggested	O	-1	88336
that	O	-1	88336
in	O	-1	88336
both	O	-1	88336
sit@@	O	-1	88336
u@@	O	-1	88336
ations	O	-1	88336
dist@@	O	-1	88336
ur@@	O	-1	88336
bed	O	-1	88336
re@@	O	-1	88336
tic@@	O	-1	88336
ulo@@	O	-1	88336
-@@	O	-1	88336
thal@@	O	-1	88336
am@@	O	-1	88336
ic	O	-1	88336
inter@@	O	-1	88336
ac@@	O	-1	88336
tions	O	-1	88336
are	O	-1	88336
important	O	-1	88336
in	O	-1	88336
the	O	-1	88336
path@@	O	-1	88336
o@@	O	-1	88336
genesis	O	-1	88336
of	O	-1	88336
al@@	O	-1	88336
ph@@	O	-1	88336
a	O	-1	88336
com@@	B-Disease	D003128	88336
a	I-Disease	-1	88336
.	O	-1	88336
It	O	-1	88336
is	O	-1	88336
concl@@	O	-1	88336
uded	O	-1	88336
that	O	-1	88336
when	O	-1	88336
this	O	-1	88336
electro@@	O	-1	88336
encephalo@@	O	-1	88336
graph@@	O	-1	88336
ic	O	-1	88336
and	O	-1	88336
behavi@@	O	-1	88336
o@@	O	-1	88336
ural	O	-1	88336
p@@	O	-1	88336
ic@@	O	-1	88336
t@@	O	-1	88336
ure	O	-1	88336
is	O	-1	88336
seen	O	-1	88336
in	O	-1	88336
drug	O	-1	88336
in@@	O	-1	88336
toxic@@	O	-1	88336
ation,	O	-1	88336
in	O	-1	88336
the	O	-1	88336
absence	O	-1	88336
of	O	-1	88336
significant	O	-1	88336
hypo@@	B-Disease	D000860	88336
x@@	I-Disease	-1	88336
a@@	I-Disease	-1	88336
emia	I-Disease	-1	88336
,	O	-1	88336
a	O	-1	88336
f@@	O	-1	88336
av@@	O	-1	88336
o@@	O	-1	88336
ur@@	O	-1	88336
able	O	-1	88336
outcom@@	O	-1	88336
e	O	-1	88336
may	O	-1	88336
be	O	-1	88336
anti@@	O	-1	88336
ci@@	O	-1	88336
pat@@	O	-1	88336
ed.	O	-1	88336

O@@	O	-1	18544179
mit@@	O	-1	18544179
ting	O	-1	18544179
f@@	B-Chemical	D005283	18544179
entan@@	I-Chemical	-1	18544179
yl	I-Chemical	-1	18544179
reduc@@	O	-1	18544179
es	O	-1	18544179
nausea	B-Disease	D009325	18544179
and	O	-1	18544179
v@@	B-Disease	D014839	18544179
om@@	I-Disease	-1	18544179
it@@	I-Disease	-1	18544179
ing	I-Disease	-1	18544179
,	O	-1	18544179
without	O	-1	18544179
increas@@	O	-1	18544179
ing	O	-1	18544179
pain	B-Disease	D010146	18544179
,	O	-1	18544179
after	O	-1	18544179
sev@@	B-Chemical	C009250	18544179
of@@	I-Chemical	-1	18544179
lur@@	I-Chemical	-1	18544179
ane	I-Chemical	-1	18544179
for	O	-1	18544179
day	O	-1	18544179
surger@@	O	-1	18544179
y.	O	-1	18544179
BACKGROUN@@	O	-1	18544179
D	O	-1	18544179
AN@@	O	-1	18544179
D	O	-1	18544179
OBJECTIVE:	O	-1	18544179
D@@	O	-1	18544179
es@@	O	-1	18544179
pit@@	O	-1	18544179
e	O	-1	18544179
adv@@	O	-1	18544179
ant@@	O	-1	18544179
ages	O	-1	18544179
of	O	-1	18544179
induction	O	-1	18544179
and	O	-1	18544179
maint@@	O	-1	18544179
en@@	O	-1	18544179
ance	O	-1	18544179
of	O	-1	18544179
anaesthe@@	O	-1	18544179
sia	O	-1	18544179
with	O	-1	18544179
sev@@	B-Chemical	C009250	18544179
of@@	I-Chemical	-1	18544179
lur@@	I-Chemical	-1	18544179
ane	I-Chemical	-1	18544179
,	O	-1	18544179
postoperative	B-Disease	D020250	18544179
nausea	I-Disease	-1	18544179
and	I-Disease	-1	18544179
v@@	I-Disease	-1	18544179
om@@	I-Disease	-1	18544179
it@@	I-Disease	-1	18544179
ing	I-Disease	-1	18544179
occur@@	O	-1	18544179
s	O	-1	18544179
frequ@@	O	-1	18544179
ent@@	O	-1	18544179
ly.	O	-1	18544179
F@@	B-Chemical	D005283	18544179
entan@@	I-Chemical	-1	18544179
yl	I-Chemical	-1	18544179
is	O	-1	18544179
a	O	-1	18544179
common@@	O	-1	18544179
ly	O	-1	18544179
used	O	-1	18544179
sup@@	O	-1	18544179
ple@@	O	-1	18544179
ment	O	-1	18544179
that	O	-1	18544179
may	O	-1	18544179
cont@@	O	-1	18544179
rib@@	O	-1	18544179
ute	O	-1	18544179
to	O	-1	18544179
th@@	O	-1	18544179
is@@	O	-1	18544179
,	O	-1	18544179
although	O	-1	18544179
it	O	-1	18544179
may	O	-1	18544179
also	O	-1	18544179
impro@@	O	-1	18544179
ve	O	-1	18544179
analge@@	O	-1	18544179
sia.	O	-1	18544179
METHODS:	O	-1	18544179
This	O	-1	18544179
double-bl@@	O	-1	18544179
ind	O	-1	18544179
study	O	-1	18544179
examined	O	-1	18544179
the	O	-1	18544179
incidence	O	-1	18544179
and	O	-1	18544179
severity	O	-1	18544179
of	O	-1	18544179
postoperative	B-Disease	D020250	18544179
nausea	I-Disease	-1	18544179
and	I-Disease	-1	18544179
v@@	I-Disease	-1	18544179
om@@	I-Disease	-1	18544179
it@@	I-Disease	-1	18544179
ing	I-Disease	-1	18544179
and	O	-1	18544179
pain	B-Disease	D010146	18544179
in	O	-1	18544179
the	O	-1	18544179
first	O	-1	18544179
24	O	-1	18544179
h	O	-1	18544179
after	O	-1	18544179
sev@@	B-Chemical	C009250	18544179
of@@	I-Chemical	-1	18544179
lur@@	I-Chemical	-1	18544179
ane	I-Chemical	-1	18544179
anaesthe@@	O	-1	18544179
sia	O	-1	18544179
in	O	-1	18544179
2@@	O	-1	18544179
16	O	-1	18544179
ad@@	O	-1	18544179
ult	O	-1	18544179
day	O	-1	18544179
surger@@	O	-1	18544179
y	O	-1	18544179
patients.	O	-1	18544179
Patients	O	-1	18544179
were	O	-1	18544179
random@@	O	-1	18544179
ly	O	-1	18544179
al@@	O	-1	18544179
loc@@	O	-1	18544179
ated	O	-1	18544179
to	O	-1	18544179
either	O	-1	18544179
recei@@	O	-1	18544179
ve	O	-1	18544179
or	O	-1	18544179
not	O	-1	18544179
recei@@	O	-1	18544179
ve	O	-1	18544179
1	O	-1	18544179
1	O	-1	18544179
f@@	B-Chemical	D005283	18544179
entan@@	I-Chemical	-1	18544179
yl	I-Chemical	-1	18544179
,	O	-1	18544179
while	O	-1	18544179
a	O	-1	18544179
thir@@	O	-1	18544179
d	O	-1	18544179
group	O	-1	18544179
received	O	-1	18544179
de@@	B-Chemical	D003907	18544179
xameth@@	I-Chemical	-1	18544179
as@@	I-Chemical	-1	18544179
one	I-Chemical	-1	18544179
in	O	-1	18544179
addition	O	-1	18544179
to	O	-1	18544179
f@@	B-Chemical	D005283	18544179
entan@@	I-Chemical	-1	18544179
yl	I-Chemical	-1	18544179
.	O	-1	18544179
RESULTS:	O	-1	18544179
O@@	O	-1	18544179
mission	O	-1	18544179
of	O	-1	18544179
f@@	B-Chemical	D005283	18544179
entan@@	I-Chemical	-1	18544179
yl	I-Chemical	-1	18544179
did	O	-1	18544179
not	O	-1	18544179
re@@	O	-1	18544179
duce	O	-1	18544179
the	O	-1	18544179
over@@	O	-1	18544179
all	O	-1	18544179
incidence	O	-1	18544179
of	O	-1	18544179
postoperative	B-Disease	D020250	18544179
nausea	I-Disease	-1	18544179
and	I-Disease	-1	18544179
v@@	I-Disease	-1	18544179
om@@	I-Disease	-1	18544179
it@@	I-Disease	-1	18544179
ing	I-Disease	-1	18544179
,	O	-1	18544179
but	O	-1	18544179
did	O	-1	18544179
re@@	O	-1	18544179
duce	O	-1	18544179
the	O	-1	18544179
incidence	O	-1	18544179
of	O	-1	18544179
v@@	B-Disease	D014839	18544179
om@@	I-Disease	-1	18544179
it@@	I-Disease	-1	18544179
ing	I-Disease	-1	18544179
and/or	O	-1	18544179
moder@@	O	-1	18544179
ate	O	-1	18544179
to	O	-1	18544179
severe	O	-1	18544179
nausea	B-Disease	D009325	18544179
prior	O	-1	18544179
to	O	-1	18544179
dis@@	O	-1	18544179
ch@@	O	-1	18544179
arg@@	O	-1	18544179
e	O	-1	18544179
from	O	-1	18544179
20@@	O	-1	18544179
%	O	-1	18544179
and	O	-1	18544179
17@@	O	-1	18544179
%	O	-1	18544179
with	O	-1	18544179
f@@	B-Chemical	D005283	18544179
entan@@	I-Chemical	-1	18544179
yl	I-Chemical	-1	18544179
and	O	-1	18544179
f@@	B-Chemical	D005283	18544179
entan@@	I-Chemical	-1	18544179
yl	I-Chemical	-1	18544179
-	O	-1	18544179
de@@	B-Chemical	D003907	18544179
xameth@@	I-Chemical	-1	18544179
as@@	I-Chemical	-1	18544179
one	I-Chemical	-1	18544179
,	O	-1	18544179
respectivel@@	O	-1	18544179
y,	O	-1	18544179
to	O	-1	18544179
5%	O	-1	18544179
(P	O	-1	18544179
=	O	-1	18544179
0.0@@	O	-1	18544179
13@@	O	-1	18544179
).	O	-1	18544179
An@@	O	-1	18544179
ti@@	O	-1	18544179
e@@	O	-1	18544179
me@@	O	-1	18544179
tic	O	-1	18544179
requ@@	O	-1	18544179
i@@	O	-1	18544179
re@@	O	-1	18544179
ments	O	-1	18544179
were	O	-1	18544179
reduced	O	-1	18544179
from	O	-1	18544179
2@@	O	-1	18544179
4@@	O	-1	18544179
%	O	-1	18544179
and	O	-1	18544179
3@@	O	-1	18544179
1@@	O	-1	18544179
%	O	-1	18544179
to	O	-1	18544179
7@@	O	-1	18544179
%	O	-1	18544179
(P	O	-1	18544179
=	O	-1	18544179
0.00@@	O	-1	18544179
12@@	O	-1	18544179
).	O	-1	18544179
D@@	B-Chemical	D003907	18544179
ex@@	I-Chemical	-1	18544179
ameth@@	I-Chemical	-1	18544179
as@@	I-Chemical	-1	18544179
one	I-Chemical	-1	18544179
had	O	-1	18544179
no	O	-1	18544179
significant	O	-1	18544179
effect	O	-1	18544179
on	O	-1	18544179
the	O	-1	18544179
incidence	O	-1	18544179
or	O	-1	18544179
severity	O	-1	18544179
of	O	-1	18544179
postoperative	B-Disease	D020250	18544179
nausea	I-Disease	-1	18544179
and	I-Disease	-1	18544179
v@@	I-Disease	-1	18544179
om@@	I-Disease	-1	18544179
it@@	I-Disease	-1	18544179
ing	I-Disease	-1	18544179
.	O	-1	18544179
Com@@	O	-1	18544179
bin@@	O	-1	18544179
ing	O	-1	18544179
the	O	-1	18544179
two	O	-1	18544179
f@@	B-Chemical	D005283	18544179
entan@@	I-Chemical	-1	18544179
yl	I-Chemical	-1	18544179
groups	O	-1	18544179
revealed	O	-1	18544179
further	O	-1	18544179
significant	O	-1	18544179
ben@@	O	-1	18544179
e@@	O	-1	18544179
f@@	O	-1	18544179
its	O	-1	18544179
from	O	-1	18544179
the	O	-1	18544179
avoid@@	O	-1	18544179
ance	O	-1	18544179
of	O	-1	18544179
o@@	O	-1	18544179
pi@@	O	-1	18544179
oid@@	O	-1	18544179
s,	O	-1	18544179
reduc@@	O	-1	18544179
ing	O	-1	18544179
postoperative	B-Disease	D020250	18544179
nausea	I-Disease	-1	18544179
and	I-Disease	-1	18544179
v@@	I-Disease	-1	18544179
om@@	I-Disease	-1	18544179
it@@	I-Disease	-1	18544179
ing	I-Disease	-1	18544179
and	O	-1	18544179
nausea	B-Disease	D009325	18544179
prior	O	-1	18544179
to	O	-1	18544179
dis@@	O	-1	18544179
ch@@	O	-1	18544179
arg@@	O	-1	18544179
e	O	-1	18544179
from	O	-1	18544179
3@@	O	-1	18544179
5%	O	-1	18544179
and	O	-1	18544179
3@@	O	-1	18544179
3@@	O	-1	18544179
%	O	-1	18544179
to	O	-1	18544179
2@@	O	-1	18544179
2@@	O	-1	18544179
%	O	-1	18544179
and	O	-1	18544179
19@@	O	-1	18544179
%	O	-1	18544179
(P	O	-1	18544179
=	O	-1	18544179
0.0@@	O	-1	18544179
4@@	O	-1	18544179
9	O	-1	18544179
and	O	-1	18544179
P	O	-1	18544179
=	O	-1	18544179
0.0@@	O	-1	18544179
3@@	O	-1	18544179
5@@	O	-1	18544179
),	O	-1	18544179
respectivel@@	O	-1	18544179
y,	O	-1	18544179
while	O	-1	18544179
nausea	B-Disease	D009325	18544179
in	O	-1	18544179
the	O	-1	18544179
first	O	-1	18544179
24	O	-1	18544179
h	O	-1	18544179
was	O	-1	18544179
decreased	O	-1	18544179
from	O	-1	18544179
4@@	O	-1	18544179
2@@	O	-1	18544179
%	O	-1	18544179
to	O	-1	18544179
27@@	O	-1	18544179
%	O	-1	18544179
(P	O	-1	18544179
=	O	-1	18544179
0.0@@	O	-1	18544179
34@@	O	-1	18544179
).	O	-1	18544179
P@@	B-Disease	D010146	18544179
ain	I-Disease	-1	18544179
severity	O	-1	18544179
and	O	-1	18544179
analge@@	O	-1	18544179
sic	O	-1	18544179
requ@@	O	-1	18544179
i@@	O	-1	18544179
re@@	O	-1	18544179
ments	O	-1	18544179
were	O	-1	18544179
un@@	O	-1	18544179
affected	O	-1	18544179
by	O	-1	18544179
the	O	-1	18544179
om@@	O	-1	18544179
is@@	O	-1	18544179
sion	O	-1	18544179
of	O	-1	18544179
f@@	B-Chemical	D005283	18544179
entan@@	I-Chemical	-1	18544179
yl	I-Chemical	-1	18544179
.	O	-1	18544179
F@@	B-Chemical	D005283	18544179
entan@@	I-Chemical	-1	18544179
yl	I-Chemical	-1	18544179
did	O	-1	18544179
re@@	O	-1	18544179
duce	O	-1	18544179
min@@	O	-1	18544179
or	O	-1	18544179
intra@@	O	-1	18544179
o@@	O	-1	18544179
perative	O	-1	18544179
mo@@	O	-1	18544179
vement	O	-1	18544179
but	O	-1	18544179
had	O	-1	18544179
no	O	-1	18544179
sev@@	B-Chemical	C009250	18544179
of@@	I-Chemical	-1	18544179
lur@@	I-Chemical	-1	18544179
ane	I-Chemical	-1	18544179
-@@	O	-1	18544179
s@@	O	-1	18544179
par@@	O	-1	18544179
ing	O	-1	18544179
effect	O	-1	18544179
and	O	-1	18544179
increased	O	-1	18544179
respiratory	B-Disease	D012131	18544179
de@@	I-Disease	-1	18544179
pression	I-Disease	-1	18544179
,	O	-1	18544179
hypotension	B-Disease	D007022	18544179
and	O	-1	18544179
brady@@	B-Disease	D001919	18544179
cardia	I-Disease	-1	18544179
.	O	-1	18544179
CONCLUSION:	O	-1	18544179
A@@	O	-1	18544179
s	O	-1	18544179
f@@	B-Chemical	D005283	18544179
entan@@	I-Chemical	-1	18544179
yl	I-Chemical	-1	18544179
ex@@	O	-1	18544179
ac@@	O	-1	18544179
er@@	O	-1	18544179
b@@	O	-1	18544179
ated	O	-1	18544179
postoperative	B-Disease	D020250	18544179
nausea	I-Disease	-1	18544179
and	I-Disease	-1	18544179
v@@	I-Disease	-1	18544179
om@@	I-Disease	-1	18544179
it@@	I-Disease	-1	18544179
ing	I-Disease	-1	18544179
without	O	-1	18544179
an	O	-1	18544179
impro@@	O	-1	18544179
vement	O	-1	18544179
in	O	-1	18544179
postoperative	B-Disease	D010149	18544179
pain	I-Disease	-1	18544179
and	O	-1	18544179
also	O	-1	18544179
had	O	-1	18544179
adverse	O	-1	18544179
cardio@@	O	-1	18544179
respiratory	O	-1	18544179
effect@@	O	-1	18544179
s,	O	-1	18544179
it	O	-1	18544179
appear@@	O	-1	18544179
s	O	-1	18544179
to	O	-1	18544179
be	O	-1	18544179
an	O	-1	18544179
un@@	O	-1	18544179
nec@@	O	-1	18544179
ess@@	O	-1	18544179
ary	O	-1	18544179
and	O	-1	18544179
possib@@	O	-1	18544179
ly	O	-1	18544179
de@@	O	-1	18544179
tri@@	O	-1	18544179
mental	O	-1	18544179
sup@@	O	-1	18544179
ple@@	O	-1	18544179
ment	O	-1	18544179
to	O	-1	18544179
sev@@	B-Chemical	C009250	18544179
of@@	I-Chemical	-1	18544179
lur@@	I-Chemical	-1	18544179
ane	I-Chemical	-1	18544179
in	O	-1	18544179
day	O	-1	18544179
surger@@	O	-1	18544179
y.	O	-1	18544179

R@@	B-Disease	D005198	18186898
en@@	I-Disease	-1	18186898
al	I-Disease	-1	18186898
F@@	I-Disease	-1	18186898
an@@	I-Disease	-1	18186898
con@@	I-Disease	-1	18186898
i	I-Disease	-1	18186898
syndrome	I-Disease	-1	18186898
and	O	-1	18186898
my@@	B-Disease	D009135	18186898
o@@	I-Disease	-1	18186898
pathy	I-Disease	-1	18186898
after	O	-1	18186898
liver	O	-1	18186898
transplant@@	O	-1	18186898
ation@@	O	-1	18186898
:	O	-1	18186898
drug@@	O	-1	18186898
-@@	O	-1	18186898
related	O	-1	18186898
mitochondrial	B-Disease	C540770	18186898
cyto@@	I-Disease	-1	18186898
pathy	I-Disease	-1	18186898
?	O	-1	18186898
Ad@@	O	-1	18186898
v@@	O	-1	18186898
anc@@	O	-1	18186898
es	O	-1	18186898
in	O	-1	18186898
the	O	-1	18186898
fi@@	O	-1	18186898
el@@	O	-1	18186898
d	O	-1	18186898
of	O	-1	18186898
transplant@@	O	-1	18186898
ation	O	-1	18186898
prov@@	O	-1	18186898
ide	O	-1	18186898
a	O	-1	18186898
bet@@	O	-1	18186898
ter	O	-1	18186898
qu@@	O	-1	18186898
ality	O	-1	18186898
of	O	-1	18186898
lif@@	O	-1	18186898
e	O	-1	18186898
and	O	-1	18186898
al@@	O	-1	18186898
low	O	-1	18186898
more	O	-1	18186898
f@@	O	-1	18186898
av@@	O	-1	18186898
or@@	O	-1	18186898
able	O	-1	18186898
condi@@	O	-1	18186898
tions	O	-1	18186898
for	O	-1	18186898
growth	O	-1	18186898
and	O	-1	18186898
development	O	-1	18186898
in	O	-1	18186898
child@@	O	-1	18186898
ren@@	O	-1	18186898
.	O	-1	18186898
However,	O	-1	18186898
combin@@	O	-1	18186898
ations	O	-1	18186898
of	O	-1	18186898
different	O	-1	18186898
therapeutic	O	-1	18186898
regimen@@	O	-1	18186898
s	O	-1	18186898
requ@@	O	-1	18186898
ir@@	O	-1	18186898
e	O	-1	18186898
con@@	O	-1	18186898
si@@	O	-1	18186898
der@@	O	-1	18186898
ation	O	-1	18186898
of	O	-1	18186898
potential	O	-1	18186898
adverse	O	-1	18186898
reac@@	O	-1	18186898
tions.	O	-1	18186898
We	O	-1	18186898
describe	O	-1	18186898
a	O	-1	18186898
1@@	O	-1	18186898
5-@@	O	-1	18186898
y@@	O	-1	18186898
r@@	O	-1	18186898
-old	O	-1	18186898
gi@@	O	-1	18186898
r@@	O	-1	18186898
l	O	-1	18186898
who	O	-1	18186898
had	O	-1	18186898
or@@	O	-1	18186898
th@@	O	-1	18186898
ot@@	O	-1	18186898
op@@	O	-1	18186898
ic	O	-1	18186898
liver	O	-1	18186898
transplant@@	O	-1	18186898
ation	O	-1	18186898
because	O	-1	18186898
of	O	-1	18186898
W@@	B-Disease	D006527	18186898
il@@	I-Disease	-1	18186898
son@@	I-Disease	-1	18186898
's	I-Disease	-1	18186898
disease	I-Disease	-1	18186898
.	O	-1	18186898
T@@	B-Chemical	D016559	18186898
ac@@	I-Chemical	-1	18186898
rolimus	I-Chemical	-1	18186898
,	O	-1	18186898
M@@	B-Chemical	-1	18186898
M@@	I-Chemical	-1	18186898
F	I-Chemical	-1	18186898
,	O	-1	18186898
and	O	-1	18186898
steroid@@	B-Chemical	D013256	18186898
s	I-Chemical	-1	18186898
were	O	-1	18186898
given	O	-1	18186898
as	O	-1	18186898
immunosup@@	O	-1	18186898
press@@	O	-1	18186898
ant@@	O	-1	18186898
.	O	-1	18186898
L@@	B-Chemical	D019259	18186898
amivud@@	I-Chemical	-1	18186898
ine	I-Chemical	-1	18186898
was	O	-1	18186898
ad@@	O	-1	18186898
ded	O	-1	18186898
because	O	-1	18186898
of	O	-1	18186898
de	O	-1	18186898
no@@	O	-1	18186898
v@@	O	-1	18186898
a	O	-1	18186898
hepatitis	B-Disease	D006509	18186898
B	I-Disease	-1	18186898
inf@@	I-Disease	-1	18186898
ection	I-Disease	-1	18186898
during	O	-1	18186898
h@@	O	-1	18186898
er	O	-1	18186898
follow-@@	O	-1	18186898
up@@	O	-1	18186898
.	O	-1	18186898
Th@@	O	-1	18186898
ree	O	-1	18186898
y@@	O	-1	18186898
r	O	-1	18186898
after	O	-1	18186898
transplant@@	O	-1	18186898
ation	O	-1	18186898
sh@@	O	-1	18186898
e	O	-1	18186898
developed	O	-1	18186898
renal	B-Disease	D005198	18186898
F@@	I-Disease	-1	18186898
an@@	I-Disease	-1	18186898
con@@	I-Disease	-1	18186898
i	I-Disease	-1	18186898
syndrome	I-Disease	-1	18186898
with	O	-1	18186898
severe	O	-1	18186898
met@@	B-Disease	D000138	18186898
ab@@	I-Disease	-1	18186898
olic	I-Disease	-1	18186898
acid@@	I-Disease	-1	18186898
o@@	I-Disease	-1	18186898
sis	I-Disease	-1	18186898
,	O	-1	18186898
hypo@@	B-Disease	D017674	18186898
phosph@@	I-Disease	-1	18186898
at@@	I-Disease	-1	18186898
emia	I-Disease	-1	18186898
,	O	-1	18186898
gly@@	B-Disease	D006029	18186898
co@@	I-Disease	-1	18186898
sur@@	I-Disease	-1	18186898
ia	I-Disease	-1	18186898
,	O	-1	18186898
and	O	-1	18186898
amino@@	B-Disease	D000608	18186898
acid@@	I-Disease	-1	18186898
uria	I-Disease	-1	18186898
.	O	-1	18186898
Although	O	-1	18186898
tacrolimus	B-Chemical	D016559	18186898
was	O	-1	18186898
sus@@	O	-1	18186898
p@@	O	-1	18186898
ected	O	-1	18186898
to	O	-1	18186898
be	O	-1	18186898
the	O	-1	18186898
cause	O	-1	18186898
of	O	-1	18186898
l@@	O	-1	18186898
ate	O	-1	18186898
post@@	O	-1	18186898
-@@	O	-1	18186898
transplant	O	-1	18186898
renal	O	-1	18186898
acid@@	B-Disease	D000138	18186898
o@@	I-Disease	-1	18186898
sis	I-Disease	-1	18186898
and	O	-1	18186898
was	O	-1	18186898
re@@	O	-1	18186898
pl@@	O	-1	18186898
ac@@	O	-1	18186898
ed	O	-1	18186898
by	O	-1	18186898
sirolimus	B-Chemical	D020123	18186898
,	O	-1	18186898
acid@@	B-Disease	D000138	18186898
o@@	I-Disease	-1	18186898
sis	I-Disease	-1	18186898
,	O	-1	18186898
and	O	-1	18186898
electro@@	O	-1	18186898
ly@@	O	-1	18186898
te	O	-1	18186898
im@@	O	-1	18186898
b@@	O	-1	18186898
al@@	O	-1	18186898
ance	O	-1	18186898
go@@	O	-1	18186898
t	O	-1	18186898
wor@@	O	-1	18186898
se.	O	-1	18186898
Pro@@	O	-1	18186898
xim@@	O	-1	18186898
al	O	-1	18186898
musc@@	B-Disease	D018908	18186898
le	I-Disease	-1	18186898
we@@	I-Disease	-1	18186898
ak@@	I-Disease	-1	18186898
ness	I-Disease	-1	18186898
has	O	-1	18186898
developed	O	-1	18186898
during	O	-1	18186898
h@@	O	-1	18186898
er	O	-1	18186898
follow-@@	O	-1	18186898
up@@	O	-1	18186898
.	O	-1	18186898
F@@	B-Disease	D005198	18186898
an@@	I-Disease	-1	18186898
con@@	I-Disease	-1	18186898
i	I-Disease	-1	18186898
syndrome	I-Disease	-1	18186898
,	O	-1	18186898
as	O	-1	18186898
well	O	-1	18186898
as	O	-1	18186898
my@@	B-Disease	D009135	18186898
o@@	I-Disease	-1	18186898
pathy	I-Disease	-1	18186898
,	O	-1	18186898
is	O	-1	18186898
well	O	-1	18186898
reco@@	O	-1	18186898
gn@@	O	-1	18186898
ized	O	-1	18186898
in	O	-1	18186898
patients	O	-1	18186898
with	O	-1	18186898
mitochondrial	B-Disease	D028361	18186898
disorder@@	I-Disease	-1	18186898
s	I-Disease	-1	18186898
and	O	-1	18186898
caused	O	-1	18186898
by	O	-1	18186898
deple@@	O	-1	18186898
tion	O	-1	18186898
of	O	-1	18186898
m@@	O	-1	18186898
t@@	O	-1	18186898
D@@	O	-1	18186898
N@@	O	-1	18186898
A@@	O	-1	18186898
.	O	-1	18186898
We	O	-1	18186898
suggest	O	-1	18186898
that	O	-1	18186898
our	O	-1	18186898
patient@@	O	-1	18186898
's	O	-1	18186898
tub@@	B-Disease	D005198	18186898
ular	I-Disease	-1	18186898
dysfunction	I-Disease	-1	18186898
and	O	-1	18186898
my@@	B-Disease	D009135	18186898
o@@	I-Disease	-1	18186898
pathy	I-Disease	-1	18186898
may	O	-1	18186898
have	O	-1	18186898
resulted	O	-1	18186898
from	O	-1	18186898
mitochondrial	B-Disease	D028361	18186898
dysfunction	I-Disease	-1	18186898
which	O	-1	18186898
is	O	-1	18186898
tri@@	O	-1	18186898
g@@	O	-1	18186898
ge@@	O	-1	18186898
red	O	-1	18186898
by	O	-1	18186898
tacrolimus	B-Chemical	D016559	18186898
and	O	-1	18186898
au@@	O	-1	18186898
g@@	O	-1	18186898
ment@@	O	-1	18186898
ed	O	-1	18186898
by	O	-1	18186898
lamivud@@	B-Chemical	D019259	18186898
ine	I-Chemical	-1	18186898
.	O	-1	18186898

An@@	O	-1	16867021
ti@@	O	-1	16867021
psycho@@	O	-1	16867021
tic@@	O	-1	16867021
-@@	O	-1	16867021
like	O	-1	16867021
prof@@	O	-1	16867021
ile	O	-1	16867021
of	O	-1	16867021
th@@	B-Chemical	C052075	16867021
io@@	I-Chemical	-1	16867021
per@@	I-Chemical	-1	16867021
amide	I-Chemical	-1	16867021
,	O	-1	16867021
a	O	-1	16867021
selective	O	-1	16867021
H@@	O	-1	16867021
3-@@	O	-1	16867021
receptor	O	-1	16867021
antagonist	O	-1	16867021
in	O	-1	16867021
mice.	O	-1	16867021
E@@	O	-1	16867021
x@@	O	-1	16867021
per@@	O	-1	16867021
im@@	O	-1	16867021
ental	O	-1	16867021
and	O	-1	16867021
clinical	O	-1	16867021
evidence	O	-1	16867021
po@@	O	-1	16867021
int@@	O	-1	16867021
s	O	-1	16867021
to	O	-1	16867021
a	O	-1	16867021
role	O	-1	16867021
of	O	-1	16867021
central	O	-1	16867021
hist@@	O	-1	16867021
aminergic	O	-1	16867021
system	O	-1	16867021
in	O	-1	16867021
the	O	-1	16867021
path@@	O	-1	16867021
o@@	O	-1	16867021
genesis	O	-1	16867021
of	O	-1	16867021
sch@@	B-Disease	D012559	16867021
iz@@	I-Disease	-1	16867021
oph@@	I-Disease	-1	16867021
ren@@	I-Disease	-1	16867021
ia	I-Disease	-1	16867021
.	O	-1	16867021
The	O	-1	16867021
present	O	-1	16867021
study	O	-1	16867021
was	O	-1	16867021
de@@	O	-1	16867021
signed	O	-1	16867021
to	O	-1	16867021
study	O	-1	16867021
the	O	-1	16867021
effect	O	-1	16867021
of	O	-1	16867021
hist@@	B-Chemical	D006632	16867021
amine	I-Chemical	-1	16867021
H@@	O	-1	16867021
(3@@	O	-1	16867021
)-@@	O	-1	16867021
receptor	O	-1	16867021
li@@	O	-1	16867021
g@@	O	-1	16867021
and@@	O	-1	16867021
s	O	-1	16867021
on	O	-1	16867021
neuro@@	O	-1	16867021
le@@	O	-1	16867021
p@@	O	-1	16867021
tic@@	O	-1	16867021
-induced	O	-1	16867021
cat@@	B-Disease	D002375	16867021
al@@	I-Disease	-1	16867021
ep@@	I-Disease	-1	16867021
sy	I-Disease	-1	16867021
,	O	-1	16867021
apo@@	B-Chemical	D001058	16867021
morphine	I-Chemical	-1	16867021
-induced	O	-1	16867021
cl@@	O	-1	16867021
im@@	O	-1	16867021
b@@	O	-1	16867021
ing	O	-1	16867021
behavi@@	O	-1	16867021
or	O	-1	16867021
and	O	-1	16867021
amphetamine	B-Chemical	D000661	16867021
-induced	O	-1	16867021
locomotor	O	-1	16867021
ac@@	O	-1	16867021
ti@@	O	-1	16867021
vi@@	O	-1	16867021
ties	O	-1	16867021
in	O	-1	16867021
mice.	O	-1	16867021
C@@	B-Disease	D002375	16867021
at@@	I-Disease	-1	16867021
al@@	I-Disease	-1	16867021
ep@@	I-Disease	-1	16867021
sy	I-Disease	-1	16867021
was	O	-1	16867021
induced	O	-1	16867021
by	O	-1	16867021
haloperidol	B-Chemical	D006220	16867021
(@@	O	-1	16867021
2	O	-1	16867021
mg/kg	O	-1	16867021
p.@@	O	-1	16867021
o@@	O	-1	16867021
.@@	O	-1	16867021
),	O	-1	16867021
while	O	-1	16867021
apo@@	B-Chemical	D001058	16867021
morphine	I-Chemical	-1	16867021
(1@@	O	-1	16867021
.@@	O	-1	16867021
5	O	-1	16867021
mg/kg	O	-1	16867021
s@@	O	-1	16867021
.@@	O	-1	16867021
c@@	O	-1	16867021
.)	O	-1	16867021
and	O	-1	16867021
amphetamine	B-Chemical	D000661	16867021
(@@	O	-1	16867021
2	O	-1	16867021
mg/kg	O	-1	16867021
s@@	O	-1	16867021
.@@	O	-1	16867021
c@@	O	-1	16867021
.)	O	-1	16867021
were	O	-1	16867021
used	O	-1	16867021
for	O	-1	16867021
stud@@	O	-1	16867021
y@@	O	-1	16867021
ing	O	-1	16867021
cl@@	O	-1	16867021
im@@	O	-1	16867021
b@@	O	-1	16867021
ing	O	-1	16867021
behavi@@	O	-1	16867021
or	O	-1	16867021
and	O	-1	16867021
locomotor	O	-1	16867021
ac@@	O	-1	16867021
ti@@	O	-1	16867021
vi@@	O	-1	16867021
ti@@	O	-1	16867021
es,	O	-1	16867021
respectively.	O	-1	16867021
(@@	B-Chemical	C069357	16867021
R@@	I-Chemical	-1	16867021
)-@@	I-Chemical	-1	16867021
alpha-@@	I-Chemical	-1	16867021
methyl@@	I-Chemical	-1	16867021
hist@@	I-Chemical	-1	16867021
amine	I-Chemical	-1	16867021
(	O	-1	16867021
R@@	B-Chemical	C069357	16867021
AM@@	I-Chemical	-1	16867021
H	I-Chemical	-1	16867021
)	O	-1	16867021
(@@	O	-1	16867021
5	O	-1	16867021
micro@@	O	-1	16867021
g	O	-1	16867021
i.@@	O	-1	16867021
c@@	O	-1	16867021
.@@	O	-1	16867021
v@@	O	-1	16867021
.)	O	-1	16867021
and	O	-1	16867021
th@@	B-Chemical	C052075	16867021
io@@	I-Chemical	-1	16867021
per@@	I-Chemical	-1	16867021
amide	I-Chemical	-1	16867021
(	O	-1	16867021
T@@	B-Chemical	C052075	16867021
H@@	I-Chemical	-1	16867021
P	I-Chemical	-1	16867021
)	O	-1	16867021
(1@@	O	-1	16867021
5	O	-1	16867021
mg/kg	O	-1	16867021
i.p.@@	O	-1	16867021
),	O	-1	16867021
per	O	-1	16867021
se	O	-1	16867021
did	O	-1	16867021
not	O	-1	16867021
cause	O	-1	16867021
cat@@	B-Disease	D002375	16867021
al@@	I-Disease	-1	16867021
ep@@	I-Disease	-1	16867021
sy	I-Disease	-1	16867021
.	O	-1	16867021
Ad@@	O	-1	16867021
minist@@	O	-1	16867021
ration	O	-1	16867021
of	O	-1	16867021
T@@	B-Chemical	C052075	16867021
H@@	I-Chemical	-1	16867021
P	I-Chemical	-1	16867021
(@@	O	-1	16867021
3.@@	O	-1	16867021
7@@	O	-1	16867021
5,	O	-1	16867021
7.@@	O	-1	16867021
5	O	-1	16867021
and	O	-1	16867021
15	O	-1	16867021
mg/kg	O	-1	16867021
i.p.@@	O	-1	16867021
)	O	-1	16867021
1	O	-1	16867021
h	O	-1	16867021
prior	O	-1	16867021
to	O	-1	16867021
haloperidol	B-Chemical	D006220	16867021
resulted	O	-1	16867021
in	O	-1	16867021
a	O	-1	16867021
dose-@@	O	-1	16867021
dependent	O	-1	16867021
increase	O	-1	16867021
in	O	-1	16867021
the	O	-1	16867021
cat@@	B-Disease	D002375	16867021
al@@	I-Disease	-1	16867021
ep@@	I-Disease	-1	16867021
sy	I-Disease	-1	16867021
times	O	-1	16867021
(P	O	-1	16867021
<	O	-1	16867021
0.05@@	O	-1	16867021
).	O	-1	16867021
However,	O	-1	16867021
pretreatment	O	-1	16867021
with	O	-1	16867021
R@@	B-Chemical	C069357	16867021
AM@@	I-Chemical	-1	16867021
H	I-Chemical	-1	16867021
significantly	O	-1	16867021
reversed	O	-1	16867021
such	O	-1	16867021
an	O	-1	16867021
effect	O	-1	16867021
of	O	-1	16867021
T@@	B-Chemical	C052075	16867021
H@@	I-Chemical	-1	16867021
P	I-Chemical	-1	16867021
(1@@	O	-1	16867021
5	O	-1	16867021
mg/kg	O	-1	16867021
i.p.@@	O	-1	16867021
).	O	-1	16867021
R@@	B-Chemical	C069357	16867021
AM@@	I-Chemical	-1	16867021
H	I-Chemical	-1	16867021
per	O	-1	16867021
se	O	-1	16867021
showed	O	-1	16867021
significant	O	-1	16867021
reduction	O	-1	16867021
in	O	-1	16867021
locomotor	O	-1	16867021
ti@@	O	-1	16867021
me,	O	-1	16867021
dist@@	O	-1	16867021
ance	O	-1	16867021
tra@@	O	-1	16867021
vel@@	O	-1	16867021
ed	O	-1	16867021
and	O	-1	16867021
average	O	-1	16867021
sp@@	O	-1	16867021
e@@	O	-1	16867021
ed	O	-1	16867021
but	O	-1	16867021
T@@	B-Chemical	C052075	16867021
H@@	I-Chemical	-1	16867021
P	I-Chemical	-1	16867021
(1@@	O	-1	16867021
5	O	-1	16867021
mg/kg	O	-1	16867021
i.p.@@	O	-1	16867021
)	O	-1	16867021
per	O	-1	16867021
se	O	-1	16867021
had	O	-1	16867021
no	O	-1	16867021
effect	O	-1	16867021
on	O	-1	16867021
these	O	-1	16867021
par@@	O	-1	16867021
ame@@	O	-1	16867021
ter@@	O	-1	16867021
s.	O	-1	16867021
O@@	O	-1	16867021
n	O	-1	16867021
amphetamine	B-Chemical	D000661	16867021
-induced	O	-1	16867021
hyperactivity	B-Disease	D006948	16867021
,	O	-1	16867021
T@@	B-Chemical	C052075	16867021
H@@	I-Chemical	-1	16867021
P	I-Chemical	-1	16867021
(@@	O	-1	16867021
3.@@	O	-1	16867021
7@@	O	-1	16867021
5	O	-1	16867021
and	O	-1	16867021
7.@@	O	-1	16867021
5	O	-1	16867021
mg/kg	O	-1	16867021
i.p.@@	O	-1	16867021
)	O	-1	16867021
reduced	O	-1	16867021
locomotor	O	-1	16867021
ti@@	O	-1	16867021
me,	O	-1	16867021
dist@@	O	-1	16867021
ance	O	-1	16867021
tra@@	O	-1	16867021
vel@@	O	-1	16867021
ed	O	-1	16867021
and	O	-1	16867021
average	O	-1	16867021
sp@@	O	-1	16867021
e@@	O	-1	16867021
ed	O	-1	16867021
(P	O	-1	16867021
<	O	-1	16867021
0.05@@	O	-1	16867021
).	O	-1	16867021
Pre@@	O	-1	16867021
treatment	O	-1	16867021
with	O	-1	16867021
R@@	B-Chemical	C069357	16867021
AM@@	I-Chemical	-1	16867021
H	I-Chemical	-1	16867021
(@@	O	-1	16867021
5	O	-1	16867021
micro@@	O	-1	16867021
g	O	-1	16867021
i.@@	O	-1	16867021
c@@	O	-1	16867021
.@@	O	-1	16867021
v@@	O	-1	16867021
.)	O	-1	16867021
could	O	-1	16867021
par@@	O	-1	16867021
ti@@	O	-1	16867021
ally	O	-1	16867021
re@@	O	-1	16867021
verse	O	-1	16867021
such	O	-1	16867021
effects	O	-1	16867021
of	O	-1	16867021
T@@	B-Chemical	C052075	16867021
H@@	I-Chemical	-1	16867021
P	I-Chemical	-1	16867021
(@@	O	-1	16867021
3.@@	O	-1	16867021
7@@	O	-1	16867021
5	O	-1	16867021
mg/kg	O	-1	16867021
i.p.@@	O	-1	16867021
).	O	-1	16867021
C@@	O	-1	16867021
lim@@	O	-1	16867021
b@@	O	-1	16867021
ing	O	-1	16867021
behavi@@	O	-1	16867021
or	O	-1	16867021
induced	O	-1	16867021
by	O	-1	16867021
apo@@	B-Chemical	D001058	16867021
morphine	I-Chemical	-1	16867021
was	O	-1	16867021
reduced	O	-1	16867021
in	O	-1	16867021
animals	O	-1	16867021
treated	O	-1	16867021
with	O	-1	16867021
T@@	B-Chemical	C052075	16867021
H@@	I-Chemical	-1	16867021
P	I-Chemical	-1	16867021
.	O	-1	16867021
S@@	O	-1	16867021
uc@@	O	-1	16867021
h	O	-1	16867021
an	O	-1	16867021
effect	O	-1	16867021
w@@	O	-1	16867021
as@@	O	-1	16867021
,	O	-1	16867021
however,	O	-1	16867021
reversed	O	-1	16867021
in	O	-1	16867021
presence	O	-1	16867021
of	O	-1	16867021
R@@	B-Chemical	C069357	16867021
AM@@	I-Chemical	-1	16867021
H	I-Chemical	-1	16867021
.	O	-1	16867021
T@@	B-Chemical	C052075	16867021
H@@	I-Chemical	-1	16867021
P	I-Chemical	-1	16867021
ex@@	O	-1	16867021
hib@@	O	-1	16867021
ited	O	-1	16867021
an	O	-1	16867021
anti@@	O	-1	16867021
psycho@@	O	-1	16867021
tic@@	O	-1	16867021
-@@	O	-1	16867021
like	O	-1	16867021
prof@@	O	-1	16867021
ile	O	-1	16867021
by	O	-1	16867021
potenti@@	O	-1	16867021
ating	O	-1	16867021
haloperidol	B-Chemical	D006220	16867021
-induced	O	-1	16867021
cat@@	B-Disease	D002375	16867021
al@@	I-Disease	-1	16867021
ep@@	I-Disease	-1	16867021
sy	I-Disease	-1	16867021
,	O	-1	16867021
reduc@@	O	-1	16867021
ing	O	-1	16867021
amphetamine	B-Chemical	D000661	16867021
-induced	O	-1	16867021
hyperactivity	B-Disease	D006948	16867021
and	O	-1	16867021
reduc@@	O	-1	16867021
ing	O	-1	16867021
apo@@	B-Chemical	D001058	16867021
morphine	I-Chemical	-1	16867021
-induced	O	-1	16867021
cl@@	O	-1	16867021
im@@	O	-1	16867021
b@@	O	-1	16867021
ing	O	-1	16867021
in	O	-1	16867021
mice.	O	-1	16867021
S@@	O	-1	16867021
uc@@	O	-1	16867021
h	O	-1	16867021
effects	O	-1	16867021
of	O	-1	16867021
T@@	B-Chemical	C052075	16867021
H@@	I-Chemical	-1	16867021
P	I-Chemical	-1	16867021
were	O	-1	16867021
reversed	O	-1	16867021
by	O	-1	16867021
R@@	B-Chemical	C069357	16867021
AM@@	I-Chemical	-1	16867021
H	I-Chemical	-1	16867021
indicating	O	-1	16867021
the	O	-1	16867021
invol@@	O	-1	16867021
vement	O	-1	16867021
of	O	-1	16867021
hist@@	B-Chemical	D006632	16867021
amine	I-Chemical	-1	16867021
H@@	O	-1	16867021
(3@@	O	-1	16867021
)-@@	O	-1	16867021
receptor@@	O	-1	16867021
s.	O	-1	16867021
F@@	O	-1	16867021
ind@@	O	-1	16867021
ings	O	-1	16867021
suggest	O	-1	16867021
a	O	-1	16867021
potential	O	-1	16867021
for	O	-1	16867021
H@@	O	-1	16867021
(3@@	O	-1	16867021
)-@@	O	-1	16867021
receptor	O	-1	16867021
antagonist@@	O	-1	16867021
s	O	-1	16867021
in	O	-1	16867021
impro@@	O	-1	16867021
ving	O	-1	16867021
the	O	-1	16867021
ref@@	O	-1	16867021
rac@@	O	-1	16867021
t@@	O	-1	16867021
ory	O	-1	16867021
cases	O	-1	16867021
of	O	-1	16867021
sch@@	B-Disease	D012559	16867021
iz@@	I-Disease	-1	16867021
oph@@	I-Disease	-1	16867021
ren@@	I-Disease	-1	16867021
ia	I-Disease	-1	16867021
.	O	-1	16867021

T@@	O	-1	14976857
ran@@	O	-1	14976857
si@@	O	-1	14976857
ent	O	-1	14976857
pl@@	B-Disease	-1	14976857
at@@	I-Disease	-1	14976857
yp@@	I-Disease	-1	14976857
ne@@	I-Disease	-1	14976857
a@@	I-Disease	-1	14976857
-@@	I-Disease	-1	14976857
or@@	I-Disease	-1	14976857
th@@	I-Disease	-1	14976857
o@@	I-Disease	-1	14976857
de@@	I-Disease	-1	14976857
ox@@	I-Disease	-1	14976857
ia@@	I-Disease	-1	14976857
-@@	I-Disease	-1	14976857
like	I-Disease	-1	14976857
syndrome	I-Disease	-1	14976857
induced	O	-1	14976857
by	O	-1	14976857
pro@@	B-Chemical	D011405	14976857
pa@@	I-Chemical	-1	14976857
f@@	I-Chemical	-1	14976857
en@@	I-Chemical	-1	14976857
one	I-Chemical	-1	14976857
over@@	B-Disease	D062787	14976857
dose	I-Disease	-1	14976857
in	O	-1	14976857
a	O	-1	14976857
youn@@	O	-1	14976857
g	O	-1	14976857
woman	O	-1	14976857
with	O	-1	14976857
E@@	B-Disease	D004437	14976857
b@@	I-Disease	-1	14976857
ste@@	I-Disease	-1	14976857
in@@	I-Disease	-1	14976857
's	I-Disease	-1	14976857
an@@	I-Disease	-1	14976857
om@@	I-Disease	-1	14976857
al@@	I-Disease	-1	14976857
y	I-Disease	-1	14976857
.	O	-1	14976857
In	O	-1	14976857
this	O	-1	14976857
report	O	-1	14976857
we	O	-1	14976857
describe	O	-1	14976857
the	O	-1	14976857
case	O	-1	14976857
of	O	-1	14976857
a	O	-1	14976857
3@@	O	-1	14976857
7-@@	O	-1	14976857
year-old	O	-1	14976857
wh@@	O	-1	14976857
ite	O	-1	14976857
woman	O	-1	14976857
with	O	-1	14976857
E@@	B-Disease	D004437	14976857
b@@	I-Disease	-1	14976857
ste@@	I-Disease	-1	14976857
in@@	I-Disease	-1	14976857
's	I-Disease	-1	14976857
an@@	I-Disease	-1	14976857
om@@	I-Disease	-1	14976857
al@@	I-Disease	-1	14976857
y	I-Disease	-1	14976857
,	O	-1	14976857
who	O	-1	14976857
developed	O	-1	14976857
a	O	-1	14976857
r@@	O	-1	14976857
are	O	-1	14976857
syndrome	O	-1	14976857
c@@	O	-1	14976857
all@@	O	-1	14976857
ed	O	-1	14976857
pl@@	B-Disease	-1	14976857
at@@	I-Disease	-1	14976857
yp@@	I-Disease	-1	14976857
ne@@	I-Disease	-1	14976857
a@@	I-Disease	-1	14976857
-@@	I-Disease	-1	14976857
or@@	I-Disease	-1	14976857
th@@	I-Disease	-1	14976857
o@@	I-Disease	-1	14976857
de@@	I-Disease	-1	14976857
ox@@	I-Disease	-1	14976857
ia	I-Disease	-1	14976857
,	O	-1	14976857
character@@	O	-1	14976857
ized	O	-1	14976857
by	O	-1	14976857
mas@@	O	-1	14976857
sive	O	-1	14976857
ri@@	O	-1	14976857
gh@@	O	-1	14976857
t-@@	O	-1	14976857
to@@	O	-1	14976857
-@@	O	-1	14976857
left	O	-1	14976857
inter@@	O	-1	14976857
atrial	O	-1	14976857
sh@@	O	-1	14976857
un@@	O	-1	14976857
ting	O	-1	14976857
with	O	-1	14976857
transi@@	O	-1	14976857
ent	O	-1	14976857
pro@@	O	-1	14976857
found	O	-1	14976857
hypo@@	B-Disease	D000860	14976857
x@@	I-Disease	-1	14976857
ia	I-Disease	-1	14976857
and	O	-1	14976857
cy@@	B-Disease	D003490	14976857
an@@	I-Disease	-1	14976857
o@@	I-Disease	-1	14976857
sis	I-Disease	-1	14976857
.	O	-1	14976857
This	O	-1	14976857
sh@@	O	-1	14976857
un@@	O	-1	14976857
t	O	-1	14976857
of	O	-1	14976857
blood	O	-1	14976857
vi@@	O	-1	14976857
a	O	-1	14976857
a	O	-1	14976857
pat@@	B-Disease	D054092	14976857
ent	I-Disease	-1	14976857
for@@	I-Disease	-1	14976857
am@@	I-Disease	-1	14976857
en	I-Disease	-1	14976857
o@@	I-Disease	-1	14976857
val@@	I-Disease	-1	14976857
e	I-Disease	-1	14976857
occurred	O	-1	14976857
in	O	-1	14976857
the	O	-1	14976857
presence	O	-1	14976857
of	O	-1	14976857
a	O	-1	14976857
normal	O	-1	14976857
pulmonary	O	-1	14976857
artery	O	-1	14976857
pressu@@	O	-1	14976857
re,	O	-1	14976857
and	O	-1	14976857
was	O	-1	14976857
prob@@	O	-1	14976857
ably	O	-1	14976857
pre@@	O	-1	14976857
ci@@	O	-1	14976857
pit@@	O	-1	14976857
ated	O	-1	14976857
by	O	-1	14976857
a	O	-1	14976857
pro@@	B-Chemical	D011405	14976857
pa@@	I-Chemical	-1	14976857
f@@	I-Chemical	-1	14976857
en@@	I-Chemical	-1	14976857
one	I-Chemical	-1	14976857
over@@	B-Disease	D062787	14976857
dose	I-Disease	-1	14976857
.	O	-1	14976857
This	O	-1	14976857
drug	O	-1	14976857
caused	O	-1	14976857
b@@	B-Disease	D018754	14976857
i@@	I-Disease	-1	14976857
ventricular	I-Disease	-1	14976857
dysfunction	I-Disease	-1	14976857
,	O	-1	14976857
due	O	-1	14976857
to	O	-1	14976857
its	O	-1	14976857
negative	O	-1	14976857
in@@	O	-1	14976857
ot@@	O	-1	14976857
ro@@	O	-1	14976857
p@@	O	-1	14976857
ic	O	-1	14976857
effect@@	O	-1	14976857
,	O	-1	14976857
and	O	-1	14976857
hypotension	B-Disease	D007022	14976857
,	O	-1	14976857
due	O	-1	14976857
to	O	-1	14976857
its	O	-1	14976857
peripheral	O	-1	14976857
vas@@	O	-1	14976857
odi@@	O	-1	14976857
lat@@	O	-1	14976857
ory	O	-1	14976857
effect@@	O	-1	14976857
.	O	-1	14976857
These	O	-1	14976857
effects	O	-1	14976857
g@@	O	-1	14976857
a@@	O	-1	14976857
ve	O	-1	14976857
ri@@	O	-1	14976857
se	O	-1	14976857
to	O	-1	14976857
an	O	-1	14976857
increase	O	-1	14976857
in	O	-1	14976857
the	O	-1	14976857
right	O	-1	14976857
atrial	O	-1	14976857
pressure	O	-1	14976857
and	O	-1	14976857
a	O	-1	14976857
decrease	O	-1	14976857
in	O	-1	14976857
the	O	-1	14976857
left	O	-1	14976857
one	O	-1	14976857
with	O	-1	14976857
a	O	-1	14976857
con@@	O	-1	14976857
sequ@@	O	-1	14976857
ent	O	-1	14976857
st@@	O	-1	14976857
ret@@	O	-1	14976857
ch@@	O	-1	14976857
ing	O	-1	14976857
of	O	-1	14976857
the	O	-1	14976857
for@@	O	-1	14976857
am@@	O	-1	14976857
en	O	-1	14976857
o@@	O	-1	14976857
val@@	O	-1	14976857
e	O	-1	14976857
and	O	-1	14976857
the	O	-1	14976857
cre@@	O	-1	14976857
ation	O	-1	14976857
of	O	-1	14976857
mas@@	O	-1	14976857
sive	O	-1	14976857
ri@@	O	-1	14976857
gh@@	O	-1	14976857
t-@@	O	-1	14976857
to@@	O	-1	14976857
-@@	O	-1	14976857
left	O	-1	14976857
sh@@	O	-1	14976857
un@@	O	-1	14976857
t@@	O	-1	14976857
ing.	O	-1	14976857
In	O	-1	14976857
our	O	-1	14976857
case	O	-1	14976857
this	O	-1	14976857
inter@@	O	-1	14976857
atrial	O	-1	14976857
sh@@	O	-1	14976857
un@@	O	-1	14976857
t	O	-1	14976857
was	O	-1	14976857
very	O	-1	14976857
ac@@	O	-1	14976857
cur@@	O	-1	14976857
ately	O	-1	14976857
det@@	O	-1	14976857
ected	O	-1	14976857
at	O	-1	14976857
bu@@	O	-1	14976857
b@@	O	-1	14976857
ble	O	-1	14976857
contr@@	O	-1	14976857
ast	O	-1	14976857
echocardiograph@@	O	-1	14976857
y.	O	-1	14976857

A	O	-1	11745184
Ph@@	O	-1	11745184
ase	O	-1	11745184
II	O	-1	11745184
trial	O	-1	11745184
of	O	-1	11745184
cisplatin	B-Chemical	D002945	11745184
plus	O	-1	11745184
W@@	B-Chemical	D004999	11745184
R@@	I-Chemical	-1	11745184
-@@	I-Chemical	-1	11745184
27@@	I-Chemical	-1	11745184
21	I-Chemical	-1	11745184
(	O	-1	11745184
am@@	B-Chemical	D004999	11745184
if@@	I-Chemical	-1	11745184
ost@@	I-Chemical	-1	11745184
ine	I-Chemical	-1	11745184
)	O	-1	11745184
for	O	-1	11745184
met@@	O	-1	11745184
ast@@	O	-1	11745184
atic	O	-1	11745184
b@@	B-Disease	D001943	11745184
reas@@	I-Disease	-1	11745184
t	I-Disease	-1	11745184
carcin@@	I-Disease	-1	11745184
oma	I-Disease	-1	11745184
:	O	-1	11745184
an	O	-1	11745184
E@@	O	-1	11745184
ast@@	O	-1	11745184
er@@	O	-1	11745184
n	O	-1	11745184
C@@	O	-1	11745184
o@@	O	-1	11745184
o@@	O	-1	11745184
perative	O	-1	11745184
On@@	O	-1	11745184
co@@	O	-1	11745184
log@@	O	-1	11745184
y	O	-1	11745184
Group	O	-1	11745184
S@@	O	-1	11745184
t@@	O	-1	11745184
ud@@	O	-1	11745184
y	O	-1	11745184
(@@	O	-1	11745184
E@@	O	-1	11745184
8@@	O	-1	11745184
18@@	O	-1	11745184
8@@	O	-1	11745184
).	O	-1	11745184
BACKGROUND:	O	-1	11745184
C@@	B-Chemical	D002945	11745184
is@@	I-Chemical	-1	11745184
pl@@	I-Chemical	-1	11745184
atin	I-Chemical	-1	11745184
has	O	-1	11745184
minim@@	O	-1	11745184
al	O	-1	11745184
anti@@	O	-1	11745184
tumor	O	-1	11745184
activity	O	-1	11745184
when	O	-1	11745184
used	O	-1	11745184
as	O	-1	11745184
second@@	O	-1	11745184
-	O	-1	11745184
or	O	-1	11745184
thir@@	O	-1	11745184
d-@@	O	-1	11745184
line	O	-1	11745184
treatment	O	-1	11745184
of	O	-1	11745184
met@@	O	-1	11745184
ast@@	O	-1	11745184
atic	O	-1	11745184
b@@	B-Disease	D001943	11745184
reas@@	I-Disease	-1	11745184
t	I-Disease	-1	11745184
carcin@@	I-Disease	-1	11745184
oma	I-Disease	-1	11745184
.	O	-1	11745184
O@@	O	-1	11745184
l@@	O	-1	11745184
der	O	-1	11745184
reports	O	-1	11745184
suggest	O	-1	11745184
an	O	-1	11745184
ob@@	O	-1	11745184
j@@	O	-1	11745184
ective	O	-1	11745184
response	O	-1	11745184
rate	O	-1	11745184
of	O	-1	11745184
8@@	O	-1	11745184
%	O	-1	11745184
when	O	-1	11745184
6@@	O	-1	11745184
0@@	O	-1	11745184
-1@@	O	-1	11745184
20	O	-1	11745184
mg/m@@	O	-1	11745184
2	O	-1	11745184
of	O	-1	11745184
cisplatin	B-Chemical	D002945	11745184
is	O	-1	11745184
administered	O	-1	11745184
every	O	-1	11745184
3-@@	O	-1	11745184
4	O	-1	11745184
week@@	O	-1	11745184
s.	O	-1	11745184
Although	O	-1	11745184
a	O	-1	11745184
dose-@@	O	-1	11745184
response	O	-1	11745184
effect	O	-1	11745184
has	O	-1	11745184
been	O	-1	11745184
observed	O	-1	11745184
with	O	-1	11745184
cisplatin	B-Chemical	D002945	11745184
,	O	-1	11745184
the	O	-1	11745184
dose-@@	O	-1	11745184
lim@@	O	-1	11745184
it@@	O	-1	11745184
ing	O	-1	11745184
toxic@@	B-Disease	D064420	11745184
ities	I-Disease	-1	11745184
associated	O	-1	11745184
with	O	-1	11745184
cisplatin	B-Chemical	D002945	11745184
(@@	O	-1	11745184
e@@	O	-1	11745184
.@@	O	-1	11745184
g@@	O	-1	11745184
.,	O	-1	11745184
nephro@@	B-Disease	D007674	11745184
toxicity	I-Disease	-1	11745184
,	O	-1	11745184
ot@@	B-Disease	D006311	11745184
otoxicity	I-Disease	-1	11745184
,	O	-1	11745184
and	O	-1	11745184
neuro@@	B-Disease	D020258	11745184
toxicity	I-Disease	-1	11745184
)	O	-1	11745184
have	O	-1	11745184
lim@@	O	-1	11745184
ited	O	-1	11745184
its	O	-1	11745184
use	O	-1	11745184
as	O	-1	11745184
a	O	-1	11745184
treatment	O	-1	11745184
for	O	-1	11745184
b@@	B-Disease	D001943	11745184
reas@@	I-Disease	-1	11745184
t	I-Disease	-1	11745184
carcin@@	I-Disease	-1	11745184
oma	I-Disease	-1	11745184
.	O	-1	11745184
W@@	B-Chemical	D004999	11745184
R@@	I-Chemical	-1	11745184
-@@	I-Chemical	-1	11745184
27@@	I-Chemical	-1	11745184
21	I-Chemical	-1	11745184
or	O	-1	11745184
am@@	B-Chemical	D004999	11745184
if@@	I-Chemical	-1	11745184
ost@@	I-Chemical	-1	11745184
ine	I-Chemical	-1	11745184
initi@@	O	-1	11745184
ally	O	-1	11745184
was	O	-1	11745184
developed	O	-1	11745184
to	O	-1	11745184
prot@@	O	-1	11745184
ect	O	-1	11745184
mil@@	O	-1	11745184
it@@	O	-1	11745184
ary	O	-1	11745184
per@@	O	-1	11745184
son@@	O	-1	11745184
ne@@	O	-1	11745184
l	O	-1	11745184
in	O	-1	11745184
the	O	-1	11745184
ev@@	O	-1	11745184
ent	O	-1	11745184
of	O	-1	11745184
nucle@@	O	-1	11745184
ar	O	-1	11745184
war@@	O	-1	11745184
.	O	-1	11745184
A@@	B-Chemical	D004999	11745184
m@@	I-Chemical	-1	11745184
if@@	I-Chemical	-1	11745184
ost@@	I-Chemical	-1	11745184
ine	I-Chemical	-1	11745184
subsequ@@	O	-1	11745184
ently	O	-1	11745184
was	O	-1	11745184
shown	O	-1	11745184
to	O	-1	11745184
prot@@	O	-1	11745184
ect	O	-1	11745184
normal	O	-1	11745184
tissu@@	O	-1	11745184
es	O	-1	11745184
from	O	-1	11745184
the	O	-1	11745184
toxic	O	-1	11745184
effects	O	-1	11745184
of	O	-1	11745184
al@@	B-Chemical	D000477	11745184
k@@	I-Chemical	-1	11745184
yl@@	I-Chemical	-1	11745184
ating	I-Chemical	-1	11745184
agents	I-Chemical	-1	11745184
and	O	-1	11745184
cisplatin	B-Chemical	D002945	11745184
without	O	-1	11745184
decreas@@	O	-1	11745184
ing	O	-1	11745184
the	O	-1	11745184
anti@@	O	-1	11745184
tumor	O	-1	11745184
effect	O	-1	11745184
of	O	-1	11745184
the	O	-1	11745184
chemo@@	O	-1	11745184
therapy.	O	-1	11745184
E@@	O	-1	11745184
arly	O	-1	11745184
tri@@	O	-1	11745184
als	O	-1	11745184
of	O	-1	11745184
cisplatin	B-Chemical	D002945	11745184
and	O	-1	11745184
am@@	B-Chemical	D004999	11745184
if@@	I-Chemical	-1	11745184
ost@@	I-Chemical	-1	11745184
ine	I-Chemical	-1	11745184
also	O	-1	11745184
suggested	O	-1	11745184
that	O	-1	11745184
the	O	-1	11745184
incidence	O	-1	11745184
and	O	-1	11745184
severity	O	-1	11745184
of	O	-1	11745184
cisplatin	B-Chemical	D002945	11745184
-induced	O	-1	11745184
nephro@@	B-Disease	D007674	11745184
toxicity	I-Disease	-1	11745184
,	O	-1	11745184
ot@@	B-Disease	D006311	11745184
otoxicity	I-Disease	-1	11745184
,	O	-1	11745184
and	O	-1	11745184
neuropathy	B-Disease	D009422	11745184
were	O	-1	11745184
reduc@@	O	-1	11745184
ed.	O	-1	11745184
METHODS:	O	-1	11745184
A	O	-1	11745184
Ph@@	O	-1	11745184
ase	O	-1	11745184
II	O	-1	11745184
study	O	-1	11745184
of	O	-1	11745184
the	O	-1	11745184
combination	O	-1	11745184
of	O	-1	11745184
cisplatin	B-Chemical	D002945	11745184
plus	O	-1	11745184
am@@	B-Chemical	D004999	11745184
if@@	I-Chemical	-1	11745184
ost@@	I-Chemical	-1	11745184
ine	I-Chemical	-1	11745184
was	O	-1	11745184
con@@	O	-1	11745184
duc@@	O	-1	11745184
ted	O	-1	11745184
in	O	-1	11745184
patients	O	-1	11745184
with	O	-1	11745184
progressive	O	-1	11745184
met@@	O	-1	11745184
ast@@	O	-1	11745184
atic	O	-1	11745184
b@@	B-Disease	D001943	11745184
reas@@	I-Disease	-1	11745184
t	I-Disease	-1	11745184
carcin@@	I-Disease	-1	11745184
oma	I-Disease	-1	11745184
who	O	-1	11745184
had	O	-1	11745184
received	O	-1	11745184
one,	O	-1	11745184
but	O	-1	11745184
not	O	-1	11745184
more	O	-1	11745184
than	O	-1	11745184
one,	O	-1	11745184
chemotherapy	O	-1	11745184
regi@@	O	-1	11745184
men	O	-1	11745184
for	O	-1	11745184
met@@	O	-1	11745184
ast@@	O	-1	11745184
atic	O	-1	11745184
disease.	O	-1	11745184
Patients	O	-1	11745184
received	O	-1	11745184
am@@	B-Chemical	D004999	11745184
if@@	I-Chemical	-1	11745184
ost@@	I-Chemical	-1	11745184
ine	I-Chemical	-1	11745184
,	O	-1	11745184
9@@	O	-1	11745184
10	O	-1	11745184
mg/m@@	O	-1	11745184
2	O	-1	11745184
intra@@	O	-1	11745184
ven@@	O	-1	11745184
ously	O	-1	11745184
over	O	-1	11745184
15	O	-1	11745184
minut@@	O	-1	11745184
es.	O	-1	11745184
After	O	-1	11745184
comple@@	O	-1	11745184
tion	O	-1	11745184
of	O	-1	11745184
the	O	-1	11745184
am@@	B-Chemical	D004999	11745184
if@@	I-Chemical	-1	11745184
ost@@	I-Chemical	-1	11745184
ine	I-Chemical	-1	11745184
infu@@	O	-1	11745184
sion,	O	-1	11745184
cisplatin	B-Chemical	D002945	11745184
1@@	O	-1	11745184
20	O	-1	11745184
mg/m@@	O	-1	11745184
2	O	-1	11745184
was	O	-1	11745184
administered	O	-1	11745184
over	O	-1	11745184
30	O	-1	11745184
minut@@	O	-1	11745184
es.	O	-1	11745184
In@@	O	-1	11745184
tra@@	O	-1	11745184
venous	O	-1	11745184
hy@@	O	-1	11745184
d@@	O	-1	11745184
ration	O	-1	11745184
and	O	-1	11745184
man@@	B-Chemical	D008353	11745184
nit@@	I-Chemical	-1	11745184
ol	I-Chemical	-1	11745184
was	O	-1	11745184
administered	O	-1	11745184
before	O	-1	11745184
and	O	-1	11745184
after	O	-1	11745184
cisplatin	B-Chemical	D002945	11745184
.	O	-1	11745184
Treat@@	O	-1	11745184
ment	O	-1	11745184
was	O	-1	11745184
administered	O	-1	11745184
every	O	-1	11745184
3	O	-1	11745184
weeks	O	-1	11745184
un@@	O	-1	11745184
ti@@	O	-1	11745184
l	O	-1	11745184
disease	O	-1	11745184
progres@@	O	-1	11745184
sion.	O	-1	11745184
RESULTS:	O	-1	11745184
F@@	O	-1	11745184
or@@	O	-1	11745184
ty-@@	O	-1	11745184
four	O	-1	11745184
patients	O	-1	11745184
were	O	-1	11745184
en@@	O	-1	11745184
ro@@	O	-1	11745184
lled	O	-1	11745184
in	O	-1	11745184
the	O	-1	11745184
study	O	-1	11745184
of	O	-1	11745184
which	O	-1	11745184
7	O	-1	11745184
(1@@	O	-1	11745184
6@@	O	-1	11745184
%)	O	-1	11745184
were	O	-1	11745184
ine@@	O	-1	11745184
li@@	O	-1	11745184
gi@@	O	-1	11745184
ble@@	O	-1	11745184
.	O	-1	11745184
A	O	-1	11745184
median	O	-1	11745184
of	O	-1	11745184
2	O	-1	11745184
cyc@@	O	-1	11745184
le@@	O	-1	11745184
s	O	-1	11745184
of	O	-1	11745184
therapy	O	-1	11745184
was	O	-1	11745184
administered	O	-1	11745184
to	O	-1	11745184
the	O	-1	11745184
3@@	O	-1	11745184
7	O	-1	11745184
e@@	O	-1	11745184
li@@	O	-1	11745184
gi@@	O	-1	11745184
ble	O	-1	11745184
patients.	O	-1	11745184
Si@@	O	-1	11745184
x	O	-1	11745184
partial	O	-1	11745184
responses	O	-1	11745184
were	O	-1	11745184
observed	O	-1	11745184
for	O	-1	11745184
an	O	-1	11745184
over@@	O	-1	11745184
all	O	-1	11745184
response	O	-1	11745184
rate	O	-1	11745184
of	O	-1	11745184
1@@	O	-1	11745184
6@@	O	-1	11745184
%.	O	-1	11745184
M@@	O	-1	11745184
ost	O	-1	11745184
patients	O	-1	11745184
(5@@	O	-1	11745184
7@@	O	-1	11745184
%)	O	-1	11745184
sto@@	O	-1	11745184
pp@@	O	-1	11745184
ed	O	-1	11745184
treatment	O	-1	11745184
because	O	-1	11745184
of	O	-1	11745184
disease	O	-1	11745184
progres@@	O	-1	11745184
sion.	O	-1	11745184
Ne@@	B-Disease	D020258	11745184
uro@@	I-Disease	-1	11745184
log@@	I-Disease	-1	11745184
ic	I-Disease	-1	11745184
toxicity	I-Disease	-1	11745184
was	O	-1	11745184
reported	O	-1	11745184
in	O	-1	11745184
5@@	O	-1	11745184
2@@	O	-1	11745184
%	O	-1	11745184
of	O	-1	11745184
patients.	O	-1	11745184
S@@	O	-1	11745184
even	O	-1	11745184
different	O	-1	11745184
lif@@	O	-1	11745184
e-@@	O	-1	11745184
th@@	O	-1	11745184
reat@@	O	-1	11745184
en@@	O	-1	11745184
ing	O	-1	11745184
toxic@@	B-Disease	D064420	11745184
ities	I-Disease	-1	11745184
were	O	-1	11745184
observed	O	-1	11745184
in	O	-1	11745184
patients	O	-1	11745184
while	O	-1	11745184
receiving	O	-1	11745184
treatment.	O	-1	11745184
CONCLUSIONS:	O	-1	11745184
The	O	-1	11745184
combination	O	-1	11745184
of	O	-1	11745184
cisplatin	B-Chemical	D002945	11745184
and	O	-1	11745184
am@@	B-Chemical	D004999	11745184
if@@	I-Chemical	-1	11745184
ost@@	I-Chemical	-1	11745184
ine	I-Chemical	-1	11745184
in	O	-1	11745184
this	O	-1	11745184
study	O	-1	11745184
resulted	O	-1	11745184
in	O	-1	11745184
an	O	-1	11745184
over@@	O	-1	11745184
all	O	-1	11745184
response	O	-1	11745184
rate	O	-1	11745184
of	O	-1	11745184
1@@	O	-1	11745184
6@@	O	-1	11745184
%.	O	-1	11745184
N@@	O	-1	11745184
either	O	-1	11745184
a	O	-1	11745184
tumor	B-Disease	D009369	11745184
-@@	O	-1	11745184
protective	O	-1	11745184
effect	O	-1	11745184
n@@	O	-1	11745184
or	O	-1	11745184
reduced	O	-1	11745184
toxicity	B-Disease	D064420	11745184
to	O	-1	11745184
normal	O	-1	11745184
tissu@@	O	-1	11745184
es	O	-1	11745184
was	O	-1	11745184
observed	O	-1	11745184
with	O	-1	11745184
the	O	-1	11745184
addition	O	-1	11745184
of	O	-1	11745184
am@@	B-Chemical	D004999	11745184
if@@	I-Chemical	-1	11745184
ost@@	I-Chemical	-1	11745184
ine	I-Chemical	-1	11745184
to	O	-1	11745184
cisplatin	B-Chemical	D002945	11745184
in	O	-1	11745184
this	O	-1	11745184
tri@@	O	-1	11745184
al.	O	-1	11745184

W@@	B-Chemical	D014859	3985451
ar@@	I-Chemical	-1	3985451
farin	I-Chemical	-1	3985451
-induced	O	-1	3985451
il@@	O	-1	3985451
io@@	O	-1	3985451
p@@	O	-1	3985451
so@@	O	-1	3985451
as	O	-1	3985451
hemorrh@@	B-Disease	D006470	3985451
age	I-Disease	-1	3985451
with	O	-1	3985451
subsequ@@	O	-1	3985451
ent	O	-1	3985451
fem@@	B-Disease	D020428	3985451
oral	I-Disease	-1	3985451
nerve	I-Disease	-1	3985451
p@@	I-Disease	-1	3985451
al@@	I-Disease	-1	3985451
sy	I-Disease	-1	3985451
.	O	-1	3985451
We	O	-1	3985451
present	O	-1	3985451
the	O	-1	3985451
case	O	-1	3985451
of	O	-1	3985451
a	O	-1	3985451
2@@	O	-1	3985451
8@@	O	-1	3985451
-@@	O	-1	3985451
year-old	O	-1	3985451
man	O	-1	3985451
on	O	-1	3985451
chronic	O	-1	3985451
war@@	B-Chemical	D014859	3985451
farin	I-Chemical	-1	3985451
therapy	O	-1	3985451
who	O	-1	3985451
su@@	O	-1	3985451
st@@	O	-1	3985451
ained	O	-1	3985451
a	O	-1	3985451
min@@	O	-1	3985451
or	O	-1	3985451
musc@@	B-Disease	D009135	3985451
le	I-Disease	-1	3985451
te@@	I-Disease	-1	3985451
ar	I-Disease	-1	3985451
and	O	-1	3985451
developed	O	-1	3985451
increas@@	O	-1	3985451
ing	O	-1	3985451
pain	B-Disease	D010146	3985451
and	O	-1	3985451
a	O	-1	3985451
f@@	O	-1	3985451
le@@	O	-1	3985451
x@@	O	-1	3985451
ure	O	-1	3985451
contrac@@	B-Disease	D003286	3985451
t@@	I-Disease	-1	3985451
ure	I-Disease	-1	3985451
of	O	-1	3985451
the	O	-1	3985451
right	O	-1	3985451
hi@@	O	-1	3985451
p@@	O	-1	3985451
.	O	-1	3985451
S@@	O	-1	3985451
ur@@	O	-1	3985451
g@@	O	-1	3985451
ical	O	-1	3985451
expl@@	O	-1	3985451
or@@	O	-1	3985451
ation	O	-1	3985451
revealed	O	-1	3985451
an	O	-1	3985451
il@@	O	-1	3985451
io@@	O	-1	3985451
p@@	O	-1	3985451
so@@	O	-1	3985451
as	O	-1	3985451
hemat@@	B-Disease	D006406	3985451
oma	I-Disease	-1	3985451
and	O	-1	3985451
fem@@	O	-1	3985451
oral	O	-1	3985451
nerve	B-Disease	D009408	3985451
ent@@	I-Disease	-1	3985451
ra@@	I-Disease	-1	3985451
p@@	I-Disease	-1	3985451
ment	I-Disease	-1	3985451
,	O	-1	3985451
result@@	O	-1	3985451
ing	O	-1	3985451
in	O	-1	3985451
a	O	-1	3985451
fem@@	B-Disease	D020428	3985451
oral	I-Disease	-1	3985451
nerve	I-Disease	-1	3985451
p@@	I-Disease	-1	3985451
al@@	I-Disease	-1	3985451
sy	I-Disease	-1	3985451
and	O	-1	3985451
partial	B-Disease	D009135	3985451
loss	I-Disease	-1	3985451
of	I-Disease	-1	3985451
qu@@	I-Disease	-1	3985451
ad@@	I-Disease	-1	3985451
r@@	I-Disease	-1	3985451
icep@@	I-Disease	-1	3985451
s	I-Disease	-1	3985451
func@@	I-Disease	-1	3985451
tions	I-Disease	-1	3985451
.	O	-1	3985451
An@@	O	-1	3985451
tico@@	O	-1	3985451
ag@@	O	-1	3985451
ul@@	O	-1	3985451
ant@@	O	-1	3985451
-induced	O	-1	3985451
fem@@	B-Disease	D020428	3985451
oral	I-Disease	-1	3985451
nerve	I-Disease	-1	3985451
p@@	I-Disease	-1	3985451
al@@	I-Disease	-1	3985451
sy	I-Disease	-1	3985451
re@@	O	-1	3985451
pres@@	O	-1	3985451
ents	O	-1	3985451
the	O	-1	3985451
most	O	-1	3985451
common	O	-1	3985451
form	O	-1	3985451
of	O	-1	3985451
war@@	B-Chemical	D014859	3985451
farin	I-Chemical	-1	3985451
-induced	O	-1	3985451
peripheral	B-Disease	D010523	3985451
neuropathy	I-Disease	-1	3985451
;	O	-1	3985451
it	O	-1	3985451
is	O	-1	3985451
character@@	O	-1	3985451
ized	O	-1	3985451
by	O	-1	3985451
severe	O	-1	3985451
pain	B-Disease	D010146	3985451
in	O	-1	3985451
the	O	-1	3985451
ing@@	O	-1	3985451
u@@	O	-1	3985451
inal	O	-1	3985451
regi@@	O	-1	3985451
on@@	O	-1	3985451
,	O	-1	3985451
v@@	O	-1	3985451
ar@@	O	-1	3985451
y@@	O	-1	3985451
ing	O	-1	3985451
de@@	O	-1	3985451
gre@@	O	-1	3985451
es	O	-1	3985451
of	O	-1	3985451
motor	B-Disease	D015417	3985451
and	I-Disease	-1	3985451
sens@@	I-Disease	-1	3985451
ory	I-Disease	-1	3985451
impair@@	I-Disease	-1	3985451
ment	I-Disease	-1	3985451
,	O	-1	3985451
and	O	-1	3985451
f@@	O	-1	3985451
le@@	O	-1	3985451
x@@	O	-1	3985451
ure	O	-1	3985451
contrac@@	B-Disease	D003286	3985451
t@@	I-Disease	-1	3985451
ure	I-Disease	-1	3985451
of	O	-1	3985451
the	O	-1	3985451
involved	O	-1	3985451
ex@@	O	-1	3985451
trem@@	O	-1	3985451
ity.	O	-1	3985451

M@@	B-Disease	D009157	3750012
y@@	I-Disease	-1	3750012
as@@	I-Disease	-1	3750012
th@@	I-Disease	-1	3750012
en@@	I-Disease	-1	3750012
ia	I-Disease	-1	3750012
gra@@	I-Disease	-1	3750012
v@@	I-Disease	-1	3750012
is	I-Disease	-1	3750012
caused	O	-1	3750012
by	O	-1	3750012
pen@@	B-Chemical	D010396	3750012
icill@@	I-Chemical	-1	3750012
amine	I-Chemical	-1	3750012
and	O	-1	3750012
ch@@	B-Chemical	D002738	3750012
loro@@	I-Chemical	-1	3750012
qu@@	I-Chemical	-1	3750012
ine	I-Chemical	-1	3750012
therapy	O	-1	3750012
for	O	-1	3750012
r@@	B-Disease	D001172	3750012
he@@	I-Disease	-1	3750012
um@@	I-Disease	-1	3750012
at@@	I-Disease	-1	3750012
oid	I-Disease	-1	3750012
arth@@	I-Disease	-1	3750012
ritis	I-Disease	-1	3750012
.	O	-1	3750012
We	O	-1	3750012
have	O	-1	3750012
descri@@	O	-1	3750012
bed	O	-1	3750012
a	O	-1	3750012
un@@	O	-1	3750012
i@@	O	-1	3750012
qu@@	O	-1	3750012
e	O	-1	3750012
patient	O	-1	3750012
who	O	-1	3750012
had	O	-1	3750012
reversible	O	-1	3750012
and	O	-1	3750012
dose-@@	O	-1	3750012
related	O	-1	3750012
my@@	B-Disease	D009157	3750012
as@@	I-Disease	-1	3750012
th@@	I-Disease	-1	3750012
en@@	I-Disease	-1	3750012
ia	I-Disease	-1	3750012
gra@@	I-Disease	-1	3750012
v@@	I-Disease	-1	3750012
is	I-Disease	-1	3750012
after	O	-1	3750012
pen@@	B-Chemical	D010396	3750012
icill@@	I-Chemical	-1	3750012
amine	I-Chemical	-1	3750012
and	O	-1	3750012
ch@@	B-Chemical	D002738	3750012
loro@@	I-Chemical	-1	3750012
qu@@	I-Chemical	-1	3750012
ine	I-Chemical	-1	3750012
therapy	O	-1	3750012
for	O	-1	3750012
r@@	B-Disease	D001172	3750012
he@@	I-Disease	-1	3750012
um@@	I-Disease	-1	3750012
at@@	I-Disease	-1	3750012
oid	I-Disease	-1	3750012
arth@@	I-Disease	-1	3750012
ritis	I-Disease	-1	3750012
.	O	-1	3750012
Although	O	-1	3750012
acet@@	B-Chemical	D000109	3750012
ylcholine	I-Chemical	-1	3750012
receptor	O	-1	3750012
anti@@	O	-1	3750012
bo@@	O	-1	3750012
di@@	O	-1	3750012
es	O	-1	3750012
were	O	-1	3750012
not	O	-1	3750012
det@@	O	-1	3750012
ect@@	O	-1	3750012
able@@	O	-1	3750012
,	O	-1	3750012
the	O	-1	3750012
time	O	-1	3750012
course	O	-1	3750012
was	O	-1	3750012
consist@@	O	-1	3750012
ent	O	-1	3750012
with	O	-1	3750012
an	O	-1	3750012
auto@@	O	-1	3750012
immun@@	O	-1	3750012
e	O	-1	3750012
pro@@	O	-1	3750012
ces@@	O	-1	3750012
s.	O	-1	3750012

Ne@@	B-Disease	D007674	1130930
ph@@	I-Disease	-1	1130930
ro@@	I-Disease	-1	1130930
toxicity	I-Disease	-1	1130930
of	O	-1	1130930
combined	O	-1	1130930
ce@@	B-Chemical	D002512	1130930
ph@@	I-Chemical	-1	1130930
alo@@	I-Chemical	-1	1130930
th@@	I-Chemical	-1	1130930
in	I-Chemical	-1	1130930
-	O	-1	1130930
g@@	B-Chemical	D005839	1130930
ent@@	I-Chemical	-1	1130930
am@@	I-Chemical	-1	1130930
icin	I-Chemical	-1	1130930
regimen@@	O	-1	1130930
.	O	-1	1130930
Two	O	-1	1130930
patients	O	-1	1130930
developed	O	-1	1130930
acute	B-Disease	D007683	1130930
tub@@	I-Disease	-1	1130930
ular	I-Disease	-1	1130930
necro@@	I-Disease	-1	1130930
sis	I-Disease	-1	1130930
,	O	-1	1130930
character@@	O	-1	1130930
ized	O	-1	1130930
clin@@	O	-1	1130930
ically	O	-1	1130930
by	O	-1	1130930
acute	O	-1	1130930
ol@@	B-Disease	D009846	1130930
ig@@	I-Disease	-1	1130930
ur@@	I-Disease	-1	1130930
ic	I-Disease	-1	1130930
renal	I-Disease	-1	1130930
failure	I-Disease	-1	1130930
ol@@	B-Disease	D051437	1130930
ig@@	I-Disease	-1	1130930
ur@@	I-Disease	-1	1130930
ic	I-Disease	-1	1130930
renal	I-Disease	-1	1130930
failure	I-Disease	-1	1130930
,	O	-1	1130930
while	O	-1	1130930
they	O	-1	1130930
were	O	-1	1130930
receiving	O	-1	1130930
a	O	-1	1130930
combination	O	-1	1130930
of	O	-1	1130930
ce@@	B-Chemical	D002512	1130930
ph@@	I-Chemical	-1	1130930
alo@@	I-Chemical	-1	1130930
th@@	I-Chemical	-1	1130930
in	I-Chemical	-1	1130930
sodium	I-Chemical	-1	1130930
and	O	-1	1130930
g@@	B-Chemical	D005839	1130930
ent@@	I-Chemical	-1	1130930
am@@	I-Chemical	-1	1130930
icin	I-Chemical	-1	1130930
sulf@@	I-Chemical	-1	1130930
ate	I-Chemical	-1	1130930
therapy.	O	-1	1130930
Patients	O	-1	1130930
who	O	-1	1130930
are	O	-1	1130930
given	O	-1	1130930
this	O	-1	1130930
drug	O	-1	1130930
regi@@	O	-1	1130930
men	O	-1	1130930
should	O	-1	1130930
be	O	-1	1130930
observed	O	-1	1130930
very	O	-1	1130930
ca@@	O	-1	1130930
ref@@	O	-1	1130930
ul@@	O	-1	1130930
ly	O	-1	1130930
for	O	-1	1130930
early	O	-1	1130930
signs	O	-1	1130930
of	O	-1	1130930
nephro@@	B-Disease	D007674	1130930
toxicity	I-Disease	-1	1130930
.	O	-1	1130930
H@@	O	-1	1130930
i@@	O	-1	1130930
gh	O	-1	1130930
doses	O	-1	1130930
of	O	-1	1130930
this	O	-1	1130930
anti@@	O	-1	1130930
bio@@	O	-1	1130930
tic	O	-1	1130930
combination	O	-1	1130930
should	O	-1	1130930
be	O	-1	1130930
avoid@@	O	-1	1130930
ed	O	-1	1130930
es@@	O	-1	1130930
p@@	O	-1	1130930
ec@@	O	-1	1130930
i@@	O	-1	1130930
ally	O	-1	1130930
in	O	-1	1130930
el@@	O	-1	1130930
der@@	O	-1	1130930
ly	O	-1	1130930
patients.	O	-1	1130930
Patients	O	-1	1130930
with	O	-1	1130930
renal	B-Disease	D051437	1130930
in@@	I-Disease	-1	1130930
suffici@@	I-Disease	-1	1130930
ency	I-Disease	-1	1130930
should	O	-1	1130930
not	O	-1	1130930
be	O	-1	1130930
given	O	-1	1130930
this	O	-1	1130930
regimen@@	O	-1	1130930
.	O	-1	1130930

Com@@	O	-1	19356307
p@@	O	-1	19356307
on@@	O	-1	19356307
ents	O	-1	19356307
of	O	-1	19356307
le@@	O	-1	19356307
m@@	O	-1	19356307
on	O	-1	19356307
es@@	O	-1	19356307
sen@@	O	-1	19356307
tial	O	-1	19356307
o@@	O	-1	19356307
il	O	-1	19356307
attenu@@	O	-1	19356307
ate	O	-1	19356307
de@@	B-Disease	D003704	19356307
m@@	I-Disease	-1	19356307
enti@@	I-Disease	-1	19356307
a	I-Disease	-1	19356307
induced	O	-1	19356307
by	O	-1	19356307
scopol@@	B-Chemical	D012601	19356307
amine	I-Chemical	-1	19356307
.	O	-1	19356307
The	O	-1	19356307
anti@@	O	-1	19356307
-	O	-1	19356307
de@@	B-Disease	D003704	19356307
m@@	I-Disease	-1	19356307
enti@@	I-Disease	-1	19356307
a	I-Disease	-1	19356307
effects	O	-1	19356307
of	O	-1	19356307
s-@@	B-Chemical	C008281	19356307
lim@@	I-Chemical	-1	19356307
on@@	I-Chemical	-1	19356307
ene	I-Chemical	-1	19356307
and	O	-1	19356307
s-@@	B-Chemical	C032208	19356307
per@@	I-Chemical	-1	19356307
ill@@	I-Chemical	-1	19356307
yl	I-Chemical	-1	19356307
alco@@	I-Chemical	-1	19356307
hol	I-Chemical	-1	19356307
were	O	-1	19356307
observed	O	-1	19356307
using	O	-1	19356307
the	O	-1	19356307
p@@	O	-1	19356307
as@@	O	-1	19356307
sive	O	-1	19356307
avoid@@	O	-1	19356307
ance	O	-1	19356307
test	O	-1	19356307
(@@	O	-1	19356307
PA@@	O	-1	19356307
)	O	-1	19356307
and	O	-1	19356307
the	O	-1	19356307
op@@	O	-1	19356307
en	O	-1	19356307
fi@@	O	-1	19356307
el@@	O	-1	19356307
d	O	-1	19356307
h@@	O	-1	19356307
ab@@	O	-1	19356307
it@@	O	-1	19356307
u@@	O	-1	19356307
ation	O	-1	19356307
test	O	-1	19356307
(@@	O	-1	19356307
O@@	O	-1	19356307
F@@	O	-1	19356307
H@@	O	-1	19356307
).	O	-1	19356307
These	O	-1	19356307
le@@	O	-1	19356307
m@@	O	-1	19356307
on	O	-1	19356307
es@@	O	-1	19356307
sen@@	O	-1	19356307
tial	O	-1	19356307
o@@	O	-1	19356307
il@@	O	-1	19356307
s	O	-1	19356307
showed	O	-1	19356307
st@@	O	-1	19356307
ron@@	O	-1	19356307
g	O	-1	19356307
ability	O	-1	19356307
to	O	-1	19356307
impro@@	O	-1	19356307
ve	O	-1	19356307
memory	B-Disease	D008569	19356307
impaired	I-Disease	-1	19356307
by	O	-1	19356307
scopol@@	B-Chemical	D012601	19356307
amine	I-Chemical	-1	19356307
;	O	-1	19356307
however,	O	-1	19356307
s-@@	B-Chemical	C032208	19356307
per@@	I-Chemical	-1	19356307
ill@@	I-Chemical	-1	19356307
yl	I-Chemical	-1	19356307
alco@@	I-Chemical	-1	19356307
hol	I-Chemical	-1	19356307
re@@	O	-1	19356307
li@@	O	-1	19356307
ev@@	O	-1	19356307
ed	O	-1	19356307
the	O	-1	19356307
defic@@	B-Disease	D008569	19356307
it	I-Disease	-1	19356307
of	I-Disease	-1	19356307
associ@@	I-Disease	-1	19356307
ative	I-Disease	-1	19356307
memory	I-Disease	-1	19356307
in	O	-1	19356307
P@@	O	-1	19356307
A	O	-1	19356307
on@@	O	-1	19356307
ly,	O	-1	19356307
and	O	-1	19356307
did	O	-1	19356307
not	O	-1	19356307
impro@@	O	-1	19356307
ve	O	-1	19356307
non-@@	O	-1	19356307
associ@@	O	-1	19356307
ative	O	-1	19356307
memory	O	-1	19356307
significantly	O	-1	19356307
in	O	-1	19356307
O@@	O	-1	19356307
F@@	O	-1	19356307
H@@	O	-1	19356307
.	O	-1	19356307
An@@	O	-1	19356307
aly@@	O	-1	19356307
sis	O	-1	19356307
of	O	-1	19356307
neuro@@	O	-1	19356307
trans@@	O	-1	19356307
mit@@	O	-1	19356307
ter	O	-1	19356307
concentration	O	-1	19356307
in	O	-1	19356307
some	O	-1	19356307
brain	O	-1	19356307
regi@@	O	-1	19356307
ons	O	-1	19356307
on	O	-1	19356307
the	O	-1	19356307
test	O	-1	19356307
day	O	-1	19356307
showed	O	-1	19356307
that	O	-1	19356307
dopamine	B-Chemical	D004298	19356307
concentration	O	-1	19356307
of	O	-1	19356307
the	O	-1	19356307
ve@@	O	-1	19356307
h@@	O	-1	19356307
ic@@	O	-1	19356307
le@@	O	-1	19356307
/	O	-1	19356307
scopol@@	B-Chemical	D012601	19356307
amine	I-Chemical	-1	19356307
group	O	-1	19356307
was	O	-1	19356307
significantly	O	-1	19356307
lower	O	-1	19356307
than	O	-1	19356307
that	O	-1	19356307
of	O	-1	19356307
the	O	-1	19356307
ve@@	O	-1	19356307
h@@	O	-1	19356307
ic@@	O	-1	19356307
le@@	O	-1	19356307
/@@	O	-1	19356307
ve@@	O	-1	19356307
h@@	O	-1	19356307
ic@@	O	-1	19356307
le	O	-1	19356307
group@@	O	-1	19356307
,	O	-1	19356307
but	O	-1	19356307
this	O	-1	19356307
phen@@	O	-1	19356307
om@@	O	-1	19356307
en@@	O	-1	19356307
on	O	-1	19356307
was	O	-1	19356307
reversed	O	-1	19356307
when	O	-1	19356307
s-@@	B-Chemical	C008281	19356307
lim@@	I-Chemical	-1	19356307
on@@	I-Chemical	-1	19356307
ene	I-Chemical	-1	19356307
or	O	-1	19356307
s-@@	B-Chemical	C032208	19356307
per@@	I-Chemical	-1	19356307
ill@@	I-Chemical	-1	19356307
yl	I-Chemical	-1	19356307
alco@@	I-Chemical	-1	19356307
hol	I-Chemical	-1	19356307
were	O	-1	19356307
administered	O	-1	19356307
before	O	-1	19356307
the	O	-1	19356307
injection	O	-1	19356307
of	O	-1	19356307
scopol@@	B-Chemical	D012601	19356307
amine	I-Chemical	-1	19356307
.	O	-1	19356307
S@@	O	-1	19356307
im@@	O	-1	19356307
ult@@	O	-1	19356307
ane@@	O	-1	19356307
ous@@	O	-1	19356307
ly,	O	-1	19356307
we	O	-1	19356307
found	O	-1	19356307
that	O	-1	19356307
these	O	-1	19356307
two	O	-1	19356307
le@@	O	-1	19356307
m@@	O	-1	19356307
on	O	-1	19356307
es@@	O	-1	19356307
sen@@	O	-1	19356307
tial	O	-1	19356307
o@@	O	-1	19356307
il	O	-1	19356307
comp@@	O	-1	19356307
on@@	O	-1	19356307
ents	O	-1	19356307
could	O	-1	19356307
inhib@@	O	-1	19356307
it	O	-1	19356307
acet@@	O	-1	19356307
ylchol@@	O	-1	19356307
ine@@	O	-1	19356307
ster@@	O	-1	19356307
ase	O	-1	19356307
activity	O	-1	19356307
in	O	-1	19356307
vit@@	O	-1	19356307
r@@	O	-1	19356307
o	O	-1	19356307
using	O	-1	19356307
the	O	-1	19356307
E@@	O	-1	19356307
ll@@	O	-1	19356307
man	O	-1	19356307
meth@@	O	-1	19356307
o@@	O	-1	19356307
d.	O	-1	19356307

The	O	-1	15957009
selective	O	-1	15957009
5-@@	O	-1	15957009
H@@	O	-1	15957009
T@@	O	-1	15957009
6	O	-1	15957009
receptor	O	-1	15957009
antagonist	O	-1	15957009
R@@	B-Chemical	C507242	15957009
o@@	I-Chemical	-1	15957009
4@@	I-Chemical	-1	15957009
3@@	I-Chemical	-1	15957009
6@@	I-Chemical	-1	15957009
8@@	I-Chemical	-1	15957009
55@@	I-Chemical	-1	15957009
4	I-Chemical	-1	15957009
re@@	O	-1	15957009
sto@@	O	-1	15957009
res	O	-1	15957009
memory	O	-1	15957009
perform@@	O	-1	15957009
ance	O	-1	15957009
in	O	-1	15957009
cholinergic	O	-1	15957009
and	O	-1	15957009
seroton@@	O	-1	15957009
ergic	O	-1	15957009
models	O	-1	15957009
of	O	-1	15957009
memory	B-Disease	D008569	15957009
defici@@	I-Disease	-1	15957009
ency	I-Disease	-1	15957009
in	O	-1	15957009
the	O	-1	15957009
rat@@	O	-1	15957009
.	O	-1	15957009
An@@	O	-1	15957009
t@@	O	-1	15957009
agon@@	O	-1	15957009
ist@@	O	-1	15957009
s	O	-1	15957009
at	O	-1	15957009
seroton@@	B-Chemical	D012701	15957009
in	I-Chemical	-1	15957009
type	O	-1	15957009
6	O	-1	15957009
(	O	-1	15957009
5-@@	B-Chemical	D012701	15957009
H@@	I-Chemical	-1	15957009
T	I-Chemical	-1	15957009
(6@@	O	-1	15957009
)@@	O	-1	15957009
)	O	-1	15957009
receptors	O	-1	15957009
show	O	-1	15957009
activity	O	-1	15957009
in	O	-1	15957009
models	O	-1	15957009
of	O	-1	15957009
lear@@	O	-1	15957009
ning	O	-1	15957009
and	O	-1	15957009
memor@@	O	-1	15957009
y.	O	-1	15957009
Although	O	-1	15957009
the	O	-1	15957009
underlying	O	-1	15957009
mechanis@@	O	-1	15957009
m@@	O	-1	15957009
(@@	O	-1	15957009
s)	O	-1	15957009
are	O	-1	15957009
not	O	-1	15957009
well	O	-1	15957009
under@@	O	-1	15957009
sto@@	O	-1	15957009
o@@	O	-1	15957009
d,	O	-1	15957009
these	O	-1	15957009
effects	O	-1	15957009
may	O	-1	15957009
invol@@	O	-1	15957009
ve	O	-1	15957009
an	O	-1	15957009
increase	O	-1	15957009
in	O	-1	15957009
acet@@	B-Chemical	D000109	15957009
ylcholine	I-Chemical	-1	15957009
(	O	-1	15957009
AC@@	B-Chemical	D000109	15957009
h	I-Chemical	-1	15957009
)	O	-1	15957009
level@@	O	-1	15957009
s.	O	-1	15957009
The	O	-1	15957009
present	O	-1	15957009
study	O	-1	15957009
s@@	O	-1	15957009
ou@@	O	-1	15957009
ght	O	-1	15957009
to	O	-1	15957009
character@@	O	-1	15957009
iz@@	O	-1	15957009
e	O	-1	15957009
the	O	-1	15957009
cogn@@	O	-1	15957009
iti@@	O	-1	15957009
ve@@	O	-1	15957009
-@@	O	-1	15957009
enh@@	O	-1	15957009
anc@@	O	-1	15957009
ing	O	-1	15957009
effects	O	-1	15957009
of	O	-1	15957009
the	O	-1	15957009
5-@@	B-Chemical	D012701	15957009
H@@	I-Chemical	-1	15957009
T	I-Chemical	-1	15957009
(6@@	O	-1	15957009
)	O	-1	15957009
antagonist	O	-1	15957009
R@@	B-Chemical	C507242	15957009
o@@	I-Chemical	-1	15957009
4@@	I-Chemical	-1	15957009
3@@	I-Chemical	-1	15957009
6@@	I-Chemical	-1	15957009
8@@	I-Chemical	-1	15957009
55@@	I-Chemical	-1	15957009
4	I-Chemical	-1	15957009
(	O	-1	15957009
3-@@	B-Chemical	C507242	15957009
b@@	I-Chemical	-1	15957009
enz@@	I-Chemical	-1	15957009
en@@	I-Chemical	-1	15957009
es@@	I-Chemical	-1	15957009
ul@@	I-Chemical	-1	15957009
f@@	I-Chemical	-1	15957009
on@@	I-Chemical	-1	15957009
yl@@	I-Chemical	-1	15957009
-@@	I-Chemical	-1	15957009
7-@@	I-Chemical	-1	15957009
(@@	I-Chemical	-1	15957009
4-@@	I-Chemical	-1	15957009
methyl@@	I-Chemical	-1	15957009
-@@	I-Chemical	-1	15957009
pi@@	I-Chemical	-1	15957009
per@@	I-Chemical	-1	15957009
az@@	I-Chemical	-1	15957009
in-@@	I-Chemical	-1	15957009
1-@@	I-Chemical	-1	15957009
yl@@	I-Chemical	-1	15957009
)@@	I-Chemical	-1	15957009
1@@	I-Chemical	-1	15957009
H@@	I-Chemical	-1	15957009
-@@	I-Chemical	-1	15957009
ind@@	I-Chemical	-1	15957009
ole	I-Chemical	-1	15957009
)	O	-1	15957009
in	O	-1	15957009
a	O	-1	15957009
rat	O	-1	15957009
ob@@	O	-1	15957009
j@@	O	-1	15957009
ect	O	-1	15957009
reco@@	O	-1	15957009
gn@@	O	-1	15957009
ition	O	-1	15957009
t@@	O	-1	15957009
as@@	O	-1	15957009
k	O	-1	15957009
em@@	O	-1	15957009
p@@	O	-1	15957009
lo@@	O	-1	15957009
y@@	O	-1	15957009
ing	O	-1	15957009
a	O	-1	15957009
cholinergic	O	-1	15957009
(	O	-1	15957009
scopol@@	B-Chemical	D012601	15957009
amine	I-Chemical	-1	15957009
pre@@	O	-1	15957009
treatment@@	O	-1	15957009
)	O	-1	15957009
and	O	-1	15957009
a	O	-1	15957009
seroton@@	O	-1	15957009
erg@@	O	-1	15957009
ic@@	O	-1	15957009
-	O	-1	15957009
(	O	-1	15957009
tr@@	B-Chemical	D014364	15957009
y@@	I-Chemical	-1	15957009
pto@@	I-Chemical	-1	15957009
ph@@	I-Chemical	-1	15957009
an	I-Chemical	-1	15957009
(	O	-1	15957009
TR@@	B-Chemical	D014364	15957009
P	I-Chemical	-1	15957009
)	O	-1	15957009
deple@@	O	-1	15957009
tion@@	O	-1	15957009
)	O	-1	15957009
defici@@	O	-1	15957009
ent	O	-1	15957009
model@@	O	-1	15957009
,	O	-1	15957009
and	O	-1	15957009
compared	O	-1	15957009
its	O	-1	15957009
pat@@	O	-1	15957009
ter@@	O	-1	15957009
n	O	-1	15957009
of	O	-1	15957009
action	O	-1	15957009
with	O	-1	15957009
that	O	-1	15957009
of	O	-1	15957009
the	O	-1	15957009
acet@@	O	-1	15957009
ylchol@@	O	-1	15957009
ine@@	O	-1	15957009
ster@@	O	-1	15957009
ase	O	-1	15957009
inhibitor	O	-1	15957009
me@@	B-Chemical	D014236	15957009
tri@@	I-Chemical	-1	15957009
f@@	I-Chemical	-1	15957009
on@@	I-Chemical	-1	15957009
ate	I-Chemical	-1	15957009
.	O	-1	15957009
In@@	O	-1	15957009
iti@@	O	-1	15957009
al	O	-1	15957009
test@@	O	-1	15957009
ing	O	-1	15957009
in	O	-1	15957009
a	O	-1	15957009
ti@@	O	-1	15957009
me@@	O	-1	15957009
-@@	O	-1	15957009
dependent	O	-1	15957009
for@@	O	-1	15957009
g@@	O	-1	15957009
et@@	O	-1	15957009
ting	O	-1	15957009
t@@	O	-1	15957009
as@@	O	-1	15957009
k	O	-1	15957009
em@@	O	-1	15957009
p@@	O	-1	15957009
lo@@	O	-1	15957009
y@@	O	-1	15957009
ing	O	-1	15957009
a	O	-1	15957009
2@@	O	-1	15957009
4-@@	O	-1	15957009
h	O	-1	15957009
del@@	O	-1	15957009
ay	O	-1	15957009
between	O	-1	15957009
tra@@	O	-1	15957009
in@@	O	-1	15957009
ing	O	-1	15957009
and	O	-1	15957009
test@@	O	-1	15957009
ing	O	-1	15957009
showed	O	-1	15957009
that	O	-1	15957009
me@@	B-Chemical	D014236	15957009
tri@@	I-Chemical	-1	15957009
f@@	I-Chemical	-1	15957009
on@@	I-Chemical	-1	15957009
ate	I-Chemical	-1	15957009
improved	O	-1	15957009
ob@@	O	-1	15957009
j@@	O	-1	15957009
ect	O	-1	15957009
reco@@	O	-1	15957009
gn@@	O	-1	15957009
ition	O	-1	15957009
(@@	O	-1	15957009
at	O	-1	15957009
10	O	-1	15957009
and	O	-1	15957009
30	O	-1	15957009
mg/kg@@	O	-1	15957009
,	O	-1	15957009
p.@@	O	-1	15957009
o@@	O	-1	15957009
.@@	O	-1	15957009
),	O	-1	15957009
whereas	O	-1	15957009
R@@	B-Chemical	C507242	15957009
o@@	I-Chemical	-1	15957009
4@@	I-Chemical	-1	15957009
3@@	I-Chemical	-1	15957009
6@@	I-Chemical	-1	15957009
8@@	I-Chemical	-1	15957009
55@@	I-Chemical	-1	15957009
4	I-Chemical	-1	15957009
was	O	-1	15957009
in@@	O	-1	15957009
ac@@	O	-1	15957009
ti@@	O	-1	15957009
ve.	O	-1	15957009
B@@	O	-1	15957009
o@@	O	-1	15957009
th@@	O	-1	15957009
,	O	-1	15957009
R@@	B-Chemical	C507242	15957009
o@@	I-Chemical	-1	15957009
4@@	I-Chemical	-1	15957009
3@@	I-Chemical	-1	15957009
6@@	I-Chemical	-1	15957009
8@@	I-Chemical	-1	15957009
55@@	I-Chemical	-1	15957009
4	I-Chemical	-1	15957009
(@@	O	-1	15957009
3	O	-1	15957009
and	O	-1	15957009
10	O	-1	15957009
mg/kg@@	O	-1	15957009
,	O	-1	15957009
intra@@	O	-1	15957009
per@@	O	-1	15957009
it@@	O	-1	15957009
one@@	O	-1	15957009
ally	O	-1	15957009
(@@	O	-1	15957009
i.p.@@	O	-1	15957009
)@@	O	-1	15957009
)	O	-1	15957009
and	O	-1	15957009
me@@	B-Chemical	D014236	15957009
tri@@	I-Chemical	-1	15957009
f@@	I-Chemical	-1	15957009
on@@	I-Chemical	-1	15957009
ate	I-Chemical	-1	15957009
(10	O	-1	15957009
mg/kg@@	O	-1	15957009
,	O	-1	15957009
p.@@	O	-1	15957009
o@@	O	-1	15957009
.,	O	-1	15957009
respectivel@@	O	-1	15957009
y@@	O	-1	15957009
)	O	-1	15957009
reversed	O	-1	15957009
memory	B-Disease	D008569	15957009
defic@@	I-Disease	-1	15957009
its	I-Disease	-1	15957009
induced	O	-1	15957009
by	O	-1	15957009
scopol@@	B-Chemical	D012601	15957009
amine	I-Chemical	-1	15957009
and	O	-1	15957009
TR@@	B-Chemical	D014364	15957009
P	I-Chemical	-1	15957009
deple@@	O	-1	15957009
tion	O	-1	15957009
(10	O	-1	15957009
mg/kg@@	O	-1	15957009
,	O	-1	15957009
i.p.@@	O	-1	15957009
,	O	-1	15957009
and	O	-1	15957009
3	O	-1	15957009
mg/kg@@	O	-1	15957009
,	O	-1	15957009
p.@@	O	-1	15957009
o@@	O	-1	15957009
.,	O	-1	15957009
respectivel@@	O	-1	15957009
y@@	O	-1	15957009
).	O	-1	15957009
In	O	-1	15957009
concl@@	O	-1	15957009
u@@	O	-1	15957009
sion,	O	-1	15957009
although	O	-1	15957009
R@@	B-Chemical	C507242	15957009
o@@	I-Chemical	-1	15957009
4@@	I-Chemical	-1	15957009
3@@	I-Chemical	-1	15957009
6@@	I-Chemical	-1	15957009
8@@	I-Chemical	-1	15957009
55@@	I-Chemical	-1	15957009
4	I-Chemical	-1	15957009
did	O	-1	15957009
not	O	-1	15957009
impro@@	O	-1	15957009
ve	O	-1	15957009
a	O	-1	15957009
ti@@	O	-1	15957009
me@@	O	-1	15957009
-@@	O	-1	15957009
related	O	-1	15957009
re@@	O	-1	15957009
ten@@	O	-1	15957009
tion	O	-1	15957009
defic@@	O	-1	15957009
it@@	O	-1	15957009
,	O	-1	15957009
it	O	-1	15957009
reversed	O	-1	15957009
a	O	-1	15957009
cholinergic	O	-1	15957009
and	O	-1	15957009
a	O	-1	15957009
seroton@@	O	-1	15957009
ergic	O	-1	15957009
memory	B-Disease	D008569	15957009
defic@@	I-Disease	-1	15957009
it	I-Disease	-1	15957009
,	O	-1	15957009
suggesting	O	-1	15957009
that	O	-1	15957009
both	O	-1	15957009
mechanisms	O	-1	15957009
may	O	-1	15957009
be	O	-1	15957009
involved	O	-1	15957009
in	O	-1	15957009
the	O	-1	15957009
fac@@	O	-1	15957009
il@@	O	-1	15957009
it@@	O	-1	15957009
ation	O	-1	15957009
of	O	-1	15957009
ob@@	O	-1	15957009
j@@	O	-1	15957009
ect	O	-1	15957009
memory	O	-1	15957009
by	O	-1	15957009
R@@	B-Chemical	C507242	15957009
o@@	I-Chemical	-1	15957009
4@@	I-Chemical	-1	15957009
3@@	I-Chemical	-1	15957009
6@@	I-Chemical	-1	15957009
8@@	I-Chemical	-1	15957009
55@@	I-Chemical	-1	15957009
4	I-Chemical	-1	15957009
and@@	O	-1	15957009
,	O	-1	15957009
possib@@	O	-1	15957009
ly,	O	-1	15957009
other	O	-1	15957009
5-@@	B-Chemical	D012701	15957009
H@@	I-Chemical	-1	15957009
T	I-Chemical	-1	15957009
(6@@	O	-1	15957009
)	O	-1	15957009
receptor	O	-1	15957009
antagonist@@	O	-1	15957009
s.	O	-1	15957009

L@@	O	-1	15899738
one	O	-1	15899738
atrial	B-Disease	D001281	15899738
fibrill@@	I-Disease	-1	15899738
ation	I-Disease	-1	15899738
associated	O	-1	15899738
with	O	-1	15899738
creat@@	B-Chemical	D003401	15899738
ine	I-Chemical	-1	15899738
mon@@	O	-1	15899738
o@@	O	-1	15899738
hy@@	O	-1	15899738
d@@	O	-1	15899738
rate	O	-1	15899738
sup@@	O	-1	15899738
ple@@	O	-1	15899738
ment@@	O	-1	15899738
ation.	O	-1	15899738
A@@	B-Disease	D001281	15899738
trial	I-Disease	-1	15899738
fibrill@@	I-Disease	-1	15899738
ation	I-Disease	-1	15899738
in	O	-1	15899738
youn@@	O	-1	15899738
g	O	-1	15899738
patients	O	-1	15899738
without	O	-1	15899738
struct@@	O	-1	15899738
ural	O	-1	15899738
heart	B-Disease	D006331	15899738
disease	I-Disease	-1	15899738
is	O	-1	15899738
ra@@	O	-1	15899738
re.	O	-1	15899738
The@@	O	-1	15899738
refore,	O	-1	15899738
when	O	-1	15899738
the	O	-1	15899738
arrhyth@@	B-Disease	D001145	15899738
mia	I-Disease	-1	15899738
is	O	-1	15899738
present	O	-1	15899738
in	O	-1	15899738
this	O	-1	15899738
po@@	O	-1	15899738
pul@@	O	-1	15899738
ation,	O	-1	15899738
reversible	O	-1	15899738
causes	O	-1	15899738
mus@@	O	-1	15899738
t	O	-1	15899738
be	O	-1	15899738
identi@@	O	-1	15899738
fied	O	-1	15899738
and	O	-1	15899738
resol@@	O	-1	15899738
ved.	O	-1	15899738
Th@@	B-Disease	D013959	15899738
yro@@	I-Disease	-1	15899738
id	I-Disease	-1	15899738
disorder@@	I-Disease	-1	15899738
s	I-Disease	-1	15899738
,	O	-1	15899738
ill@@	O	-1	15899738
ic@@	O	-1	15899738
it	O	-1	15899738
drug	O	-1	15899738
or	O	-1	15899738
stimul@@	O	-1	15899738
ant	O	-1	15899738
use@@	O	-1	15899738
,	O	-1	15899738
and	O	-1	15899738
acute	B-Disease	D000435	15899738
alco@@	I-Disease	-1	15899738
hol	I-Disease	-1	15899738
in@@	I-Disease	-1	15899738
toxic@@	I-Disease	-1	15899738
ation	I-Disease	-1	15899738
are	O	-1	15899738
among	O	-1	15899738
these	O	-1	15899738
ca@@	O	-1	15899738
us@@	O	-1	15899738
es.	O	-1	15899738
We	O	-1	15899738
report	O	-1	15899738
the	O	-1	15899738
case	O	-1	15899738
of	O	-1	15899738
a	O	-1	15899738
3@@	O	-1	15899738
0-@@	O	-1	15899738
year-old	O	-1	15899738
Ca@@	O	-1	15899738
uc@@	O	-1	15899738
a@@	O	-1	15899738
si@@	O	-1	15899738
an	O	-1	15899738
man	O	-1	15899738
who	O	-1	15899738
c@@	O	-1	15899738
am@@	O	-1	15899738
e	O	-1	15899738
to	O	-1	15899738
the	O	-1	15899738
em@@	O	-1	15899738
er@@	O	-1	15899738
gen@@	O	-1	15899738
c@@	O	-1	15899738
y	O	-1	15899738
de@@	O	-1	15899738
part@@	O	-1	15899738
ment	O	-1	15899738
in	O	-1	15899738
atrial	B-Disease	D001281	15899738
fibrill@@	I-Disease	-1	15899738
ation	I-Disease	-1	15899738
with	O	-1	15899738
ra@@	O	-1	15899738
pid	O	-1	15899738
ventricular	O	-1	15899738
respon@@	O	-1	15899738
se.	O	-1	15899738
H@@	O	-1	15899738
is	O	-1	15899738
med@@	O	-1	15899738
ical	O	-1	15899738
hist@@	O	-1	15899738
ory	O	-1	15899738
was	O	-1	15899738
un@@	O	-1	15899738
re@@	O	-1	15899738
mark@@	O	-1	15899738
able@@	O	-1	15899738
,	O	-1	15899738
ex@@	O	-1	15899738
cep@@	O	-1	15899738
t	O	-1	15899738
for	O	-1	15899738
min@@	O	-1	15899738
or	O	-1	15899738
frac@@	B-Disease	D050723	15899738
t@@	I-Disease	-1	15899738
ures	I-Disease	-1	15899738
of	O	-1	15899738
the	O	-1	15899738
f@@	O	-1	15899738
ing@@	O	-1	15899738
ers	O	-1	15899738
and	O	-1	15899738
fo@@	O	-1	15899738
ot@@	O	-1	15899738
.	O	-1	15899738
Th@@	O	-1	15899738
yro@@	O	-1	15899738
id@@	O	-1	15899738
-@@	O	-1	15899738
stimul@@	O	-1	15899738
ating	O	-1	15899738
h@@	O	-1	15899738
orm@@	O	-1	15899738
one,	O	-1	15899738
mag@@	B-Chemical	D008274	15899738
ne@@	I-Chemical	-1	15899738
si@@	I-Chemical	-1	15899738
um	I-Chemical	-1	15899738
,	O	-1	15899738
and	O	-1	15899738
pot@@	B-Chemical	D011188	15899738
assi@@	I-Chemical	-1	15899738
um	I-Chemical	-1	15899738
levels	O	-1	15899738
were	O	-1	15899738
within	O	-1	15899738
normal	O	-1	15899738
lim@@	O	-1	15899738
it@@	O	-1	15899738
s,	O	-1	15899738
urine	O	-1	15899738
drug	O	-1	15899738
s@@	O	-1	15899738
cre@@	O	-1	15899738
en	O	-1	15899738
was	O	-1	15899738
neg@@	O	-1	15899738
ati@@	O	-1	15899738
ve,	O	-1	15899738
and	O	-1	15899738
alco@@	B-Chemical	D000431	15899738
hol	I-Chemical	-1	15899738
use	O	-1	15899738
was	O	-1	15899738
d@@	O	-1	15899738
en@@	O	-1	15899738
i@@	O	-1	15899738
ed.	O	-1	15899738
However,	O	-1	15899738
when	O	-1	15899738
the	O	-1	15899738
patient	O	-1	15899738
was	O	-1	15899738
qu@@	O	-1	15899738
es@@	O	-1	15899738
tion@@	O	-1	15899738
ed	O	-1	15899738
about	O	-1	15899738
use	O	-1	15899738
of	O	-1	15899738
h@@	O	-1	15899738
er@@	O	-1	15899738
b@@	O	-1	15899738
al	O	-1	15899738
produc@@	O	-1	15899738
ts	O	-1	15899738
and	O	-1	15899738
sup@@	O	-1	15899738
ple@@	O	-1	15899738
ment@@	O	-1	15899738
s,	O	-1	15899738
the	O	-1	15899738
use	O	-1	15899738
of	O	-1	15899738
creat@@	B-Chemical	D003401	15899738
ine	I-Chemical	-1	15899738
mon@@	O	-1	15899738
o@@	O	-1	15899738
hy@@	O	-1	15899738
d@@	O	-1	15899738
rate	O	-1	15899738
was	O	-1	15899738
reveal@@	O	-1	15899738
ed.	O	-1	15899738
The	O	-1	15899738
patient	O	-1	15899738
was	O	-1	15899738
ad@@	O	-1	15899738
mit@@	O	-1	15899738
ted	O	-1	15899738
to	O	-1	15899738
the	O	-1	15899738
hospit@@	O	-1	15899738
al,	O	-1	15899738
anti@@	O	-1	15899738
co@@	O	-1	15899738
ag@@	O	-1	15899738
ul@@	O	-1	15899738
ated	O	-1	15899738
with	O	-1	15899738
un@@	O	-1	15899738
frac@@	O	-1	15899738
tion@@	O	-1	15899738
ated	O	-1	15899738
hepar@@	B-Chemical	D006493	15899738
in	I-Chemical	-1	15899738
,	O	-1	15899738
and	O	-1	15899738
given	O	-1	15899738
intravenous	O	-1	15899738
di@@	B-Chemical	D004110	15899738
l@@	I-Chemical	-1	15899738
ti@@	I-Chemical	-1	15899738
az@@	I-Chemical	-1	15899738
em	I-Chemical	-1	15899738
for	O	-1	15899738
rate	O	-1	15899738
control	O	-1	15899738
and	O	-1	15899738
intravenous	O	-1	15899738
am@@	B-Chemical	D000638	15899738
iodar@@	I-Chemical	-1	15899738
one	I-Chemical	-1	15899738
for	O	-1	15899738
rate	O	-1	15899738
and	O	-1	15899738
rhyth@@	O	-1	15899738
m	O	-1	15899738
control@@	O	-1	15899738
.	O	-1	15899738
Whe@@	O	-1	15899738
n	O	-1	15899738
dis@@	O	-1	15899738
ch@@	O	-1	15899738
arg@@	O	-1	15899738
ed	O	-1	15899738
less	O	-1	15899738
than	O	-1	15899738
24	O	-1	15899738
hours	O	-1	15899738
lat@@	O	-1	15899738
er,	O	-1	15899738
he	O	-1	15899738
was	O	-1	15899738
receiving	O	-1	15899738
me@@	B-Chemical	D008790	15899738
to@@	I-Chemical	-1	15899738
pro@@	I-Chemical	-1	15899738
lol	I-Chemical	-1	15899738
and	O	-1	15899738
as@@	B-Chemical	D001241	15899738
pi@@	I-Chemical	-1	15899738
rin	I-Chemical	-1	15899738
,	O	-1	15899738
with	O	-1	15899738
follow-up	O	-1	15899738
pl@@	O	-1	15899738
ans	O	-1	15899738
for	O	-1	15899738
echocardiograph@@	O	-1	15899738
y	O	-1	15899738
and	O	-1	15899738
nucle@@	O	-1	15899738
ar	O	-1	15899738
imaging	O	-1	15899738
to	O	-1	15899738
ass@@	O	-1	15899738
ess	O	-1	15899738
per@@	O	-1	15899738
fu@@	O	-1	15899738
sion.	O	-1	15899738
E@@	O	-1	15899738
x@@	O	-1	15899738
o@@	O	-1	15899738
gen@@	O	-1	15899738
ous	O	-1	15899738
creat@@	B-Chemical	D003401	15899738
ine	I-Chemical	-1	15899738
is	O	-1	15899738
used	O	-1	15899738
by	O	-1	15899738
ath@@	O	-1	15899738
le@@	O	-1	15899738
tes	O	-1	15899738
to	O	-1	15899738
the@@	O	-1	15899738
ore@@	O	-1	15899738
tically	O	-1	15899738
impro@@	O	-1	15899738
ve	O	-1	15899738
ex@@	O	-1	15899738
er@@	O	-1	15899738
cis@@	O	-1	15899738
e	O	-1	15899738
perform@@	O	-1	15899738
ance@@	O	-1	15899738
.	O	-1	15899738
V@@	O	-1	15899738
e@@	O	-1	15899738
g@@	O	-1	15899738
et@@	O	-1	15899738
ari@@	O	-1	15899738
ans	O	-1	15899738
may	O	-1	15899738
also	O	-1	15899738
tak@@	O	-1	15899738
e	O	-1	15899738
creat@@	B-Chemical	D003401	15899738
ine	I-Chemical	-1	15899738
to	O	-1	15899738
re@@	O	-1	15899738
pl@@	O	-1	15899738
ac@@	O	-1	15899738
e	O	-1	15899738
wh@@	O	-1	15899738
at	O	-1	15899738
they	O	-1	15899738
are	O	-1	15899738
not	O	-1	15899738
consum@@	O	-1	15899738
ing	O	-1	15899738
from	O	-1	15899738
me@@	O	-1	15899738
at@@	O	-1	15899738
,	O	-1	15899738
f@@	O	-1	15899738
ish@@	O	-1	15899738
,	O	-1	15899738
and	O	-1	15899738
other	O	-1	15899738
anim@@	O	-1	15899738
al	O	-1	15899738
produc@@	O	-1	15899738
t@@	O	-1	15899738
s.	O	-1	15899738
Pre@@	O	-1	15899738
vi@@	O	-1	15899738
ous	O	-1	15899738
an@@	O	-1	15899738
ec@@	O	-1	15899738
d@@	O	-1	15899738
ot@@	O	-1	15899738
al	O	-1	15899738
reports	O	-1	15899738
have	O	-1	15899738
lin@@	O	-1	15899738
ked	O	-1	15899738
creat@@	B-Chemical	D003401	15899738
ine	I-Chemical	-1	15899738
to	O	-1	15899738
the	O	-1	15899738
development	O	-1	15899738
of	O	-1	15899738
arrhyth@@	B-Disease	D001145	15899738
mia	I-Disease	-1	15899738
.	O	-1	15899738
Clin@@	O	-1	15899738
ici@@	O	-1	15899738
ans	O	-1	15899738
mus@@	O	-1	15899738
t	O	-1	15899738
be	O	-1	15899738
di@@	O	-1	15899738
li@@	O	-1	15899738
g@@	O	-1	15899738
ent	O	-1	15899738
when	O	-1	15899738
inter@@	O	-1	15899738
vie@@	O	-1	15899738
w@@	O	-1	15899738
ing	O	-1	15899738
patients	O	-1	15899738
about	O	-1	15899738
their	O	-1	15899738
drug	O	-1	15899738
therapy	O	-1	15899738
hist@@	O	-1	15899738
or@@	O	-1	15899738
i@@	O	-1	15899738
es	O	-1	15899738
and	O	-1	15899738
includ@@	O	-1	15899738
e	O	-1	15899738
qu@@	O	-1	15899738
es@@	O	-1	15899738
tions	O	-1	15899738
about	O	-1	15899738
their	O	-1	15899738
use	O	-1	15899738
of	O	-1	15899738
h@@	O	-1	15899738
er@@	O	-1	15899738
b@@	O	-1	15899738
al	O	-1	15899738
produc@@	O	-1	15899738
ts	O	-1	15899738
and	O	-1	15899738
di@@	O	-1	15899738
et@@	O	-1	15899738
ary	O	-1	15899738
sup@@	O	-1	15899738
ple@@	O	-1	15899738
ment@@	O	-1	15899738
s.	O	-1	15899738
In	O	-1	15899738
addi@@	O	-1	15899738
tion,	O	-1	15899738
it	O	-1	15899738
is	O	-1	15899738
important	O	-1	15899738
to	O	-1	15899738
report	O	-1	15899738
adverse	O	-1	15899738
effects	O	-1	15899738
associated	O	-1	15899738
with	O	-1	15899738
frequ@@	O	-1	15899738
ently	O	-1	15899738
consum@@	O	-1	15899738
ed	O	-1	15899738
sup@@	O	-1	15899738
ple@@	O	-1	15899738
ments	O	-1	15899738
and	O	-1	15899738
h@@	O	-1	15899738
er@@	O	-1	15899738
b@@	O	-1	15899738
al	O	-1	15899738
produc@@	O	-1	15899738
ts	O	-1	15899738
to	O	-1	15899738
the	O	-1	15899738
F@@	O	-1	15899738
o@@	O	-1	15899738
od	O	-1	15899738
and	O	-1	15899738
D@@	O	-1	15899738
ru@@	O	-1	15899738
g	O	-1	15899738
Ad@@	O	-1	15899738
minist@@	O	-1	15899738
ration	O	-1	15899738
and	O	-1	15899738
in	O	-1	15899738
the	O	-1	15899738
literat@@	O	-1	15899738
ure.	O	-1	15899738

Com@@	O	-1	15863244
par@@	O	-1	15863244
ison	O	-1	15863244
of	O	-1	15863244
develop@@	O	-1	15863244
mental	O	-1	15863244
toxicity	B-Disease	D064420	15863244
of	O	-1	15863244
selective	O	-1	15863244
and	O	-1	15863244
non-@@	O	-1	15863244
selective	O	-1	15863244
cyclo@@	O	-1	15863244
oxy@@	O	-1	15863244
gen@@	O	-1	15863244
as@@	O	-1	15863244
e-@@	O	-1	15863244
2	O	-1	15863244
inhibitors	O	-1	15863244
in	O	-1	15863244
CR@@	O	-1	15863244
L@@	O	-1	15863244
:@@	O	-1	15863244
(@@	O	-1	15863244
W@@	O	-1	15863244
I@@	O	-1	15863244
)@@	O	-1	15863244
W@@	O	-1	15863244
U@@	O	-1	15863244
B@@	O	-1	15863244
R	O	-1	15863244
Wistar	O	-1	15863244
rat@@	O	-1	15863244
s-@@	O	-1	15863244
-	O	-1	15863244
DF@@	B-Chemical	C106876	15863244
U	I-Chemical	-1	15863244
and	O	-1	15863244
pi@@	B-Chemical	D010894	15863244
ro@@	I-Chemical	-1	15863244
x@@	I-Chemical	-1	15863244
ic@@	I-Chemical	-1	15863244
am	I-Chemical	-1	15863244
study.	O	-1	15863244
BACKGROUND:	O	-1	15863244
C@@	O	-1	15863244
yc@@	O	-1	15863244
lo@@	O	-1	15863244
oxy@@	O	-1	15863244
gen@@	O	-1	15863244
ase	O	-1	15863244
(C@@	O	-1	15863244
O@@	O	-1	15863244
X@@	O	-1	15863244
)	O	-1	15863244
inhibitors	O	-1	15863244
are	O	-1	15863244
one	O	-1	15863244
of	O	-1	15863244
the	O	-1	15863244
most	O	-1	15863244
often	O	-1	15863244
ing@@	O	-1	15863244
est@@	O	-1	15863244
ed	O	-1	15863244
drugs	O	-1	15863244
during	O	-1	15863244
pregn@@	O	-1	15863244
anc@@	O	-1	15863244
y.	O	-1	15863244
U@@	O	-1	15863244
n@@	O	-1	15863244
like	O	-1	15863244
gener@@	O	-1	15863244
al	O	-1	15863244
toxicity	B-Disease	D064420	15863244
dat@@	O	-1	15863244
a,	O	-1	15863244
their	O	-1	15863244
p@@	O	-1	15863244
ren@@	O	-1	15863244
atal	O	-1	15863244
toxic	O	-1	15863244
effects	O	-1	15863244
were	O	-1	15863244
not	O	-1	15863244
exten@@	O	-1	15863244
si@@	O	-1	15863244
vely	O	-1	15863244
studied	O	-1	15863244
be@@	O	-1	15863244
fo@@	O	-1	15863244
re.	O	-1	15863244
The	O	-1	15863244
a@@	O	-1	15863244
im	O	-1	15863244
of	O	-1	15863244
the	O	-1	15863244
experim@@	O	-1	15863244
ent	O	-1	15863244
was	O	-1	15863244
to	O	-1	15863244
evalu@@	O	-1	15863244
ate	O	-1	15863244
the	O	-1	15863244
develop@@	O	-1	15863244
mental	O	-1	15863244
toxicity	B-Disease	D064420	15863244
of	O	-1	15863244
the	O	-1	15863244
non-@@	O	-1	15863244
selective	O	-1	15863244
(	O	-1	15863244
pi@@	B-Chemical	D010894	15863244
ro@@	I-Chemical	-1	15863244
x@@	I-Chemical	-1	15863244
ic@@	I-Chemical	-1	15863244
am	I-Chemical	-1	15863244
)	O	-1	15863244
and	O	-1	15863244
selective	O	-1	15863244
(	O	-1	15863244
DF@@	B-Chemical	C106876	15863244
U	I-Chemical	-1	15863244
;	O	-1	15863244
5@@	B-Chemical	C106876	15863244
,@@	I-Chemical	-1	15863244
5-@@	I-Chemical	-1	15863244
di@@	I-Chemical	-1	15863244
methyl@@	I-Chemical	-1	15863244
-@@	I-Chemical	-1	15863244
3-@@	I-Chemical	-1	15863244
(3@@	I-Chemical	-1	15863244
-@@	I-Chemical	-1	15863244
fluoro@@	I-Chemical	-1	15863244
phenyl@@	I-Chemical	-1	15863244
)-@@	I-Chemical	-1	15863244
4-@@	I-Chemical	-1	15863244
(@@	I-Chemical	-1	15863244
4-@@	I-Chemical	-1	15863244
methyl@@	I-Chemical	-1	15863244
sul@@	I-Chemical	-1	15863244
ph@@	I-Chemical	-1	15863244
on@@	I-Chemical	-1	15863244
yl@@	I-Chemical	-1	15863244
)	I-Chemical	-1	15863244
phenyl@@	I-Chemical	-1	15863244
-@@	I-Chemical	-1	15863244
2@@	I-Chemical	-1	15863244
(5@@	I-Chemical	-1	15863244
H@@	I-Chemical	-1	15863244
)-@@	I-Chemical	-1	15863244
f@@	I-Chemical	-1	15863244
ur@@	I-Chemical	-1	15863244
an@@	I-Chemical	-1	15863244
on	I-Chemical	-1	15863244
)	O	-1	15863244
CO@@	O	-1	15863244
X@@	O	-1	15863244
-@@	O	-1	15863244
2	O	-1	15863244
inhibitor@@	O	-1	15863244
s.	O	-1	15863244
METHODS:	O	-1	15863244
D@@	O	-1	15863244
ru@@	O	-1	15863244
g@@	O	-1	15863244
s	O	-1	15863244
were	O	-1	15863244
se@@	O	-1	15863244
par@@	O	-1	15863244
at@@	O	-1	15863244
el@@	O	-1	15863244
y,	O	-1	15863244
or@@	O	-1	15863244
ally	O	-1	15863244
on@@	O	-1	15863244
ce	O	-1	15863244
daily	O	-1	15863244
dos@@	O	-1	15863244
ed	O	-1	15863244
to	O	-1	15863244
pregn@@	O	-1	15863244
ant	O	-1	15863244
rats	O	-1	15863244
from	O	-1	15863244
day	O	-1	15863244
8	O	-1	15863244
to	O	-1	15863244
21	O	-1	15863244
(@@	O	-1	15863244
G@@	O	-1	15863244
D@@	O	-1	15863244
1@@	O	-1	15863244
=@@	O	-1	15863244
pl@@	O	-1	15863244
u@@	O	-1	15863244
g	O	-1	15863244
day@@	O	-1	15863244
).	O	-1	15863244
D@@	O	-1	15863244
o@@	O	-1	15863244
ses	O	-1	15863244
were	O	-1	15863244
set	O	-1	15863244
at	O	-1	15863244
0.@@	O	-1	15863244
3,	O	-1	15863244
3.@@	O	-1	15863244
0	O	-1	15863244
and	O	-1	15863244
3@@	O	-1	15863244
0.0@@	O	-1	15863244
mg/kg	O	-1	15863244
for	O	-1	15863244
pi@@	B-Chemical	D010894	15863244
ro@@	I-Chemical	-1	15863244
x@@	I-Chemical	-1	15863244
ic@@	I-Chemical	-1	15863244
am	I-Chemical	-1	15863244
and	O	-1	15863244
0.@@	O	-1	15863244
2,	O	-1	15863244
2.@@	O	-1	15863244
0	O	-1	15863244
and	O	-1	15863244
2@@	O	-1	15863244
0.0@@	O	-1	15863244
mg/kg	O	-1	15863244
for	O	-1	15863244
DF@@	B-Chemical	C106876	15863244
U	I-Chemical	-1	15863244
.	O	-1	15863244
F@@	O	-1	15863244
et@@	O	-1	15863244
u@@	O	-1	15863244
ses	O	-1	15863244
were	O	-1	15863244
de@@	O	-1	15863244
li@@	O	-1	15863244
vered	O	-1	15863244
on	O	-1	15863244
G@@	O	-1	15863244
D	O	-1	15863244
21	O	-1	15863244
and	O	-1	15863244
ro@@	O	-1	15863244
ut@@	O	-1	15863244
ine@@	O	-1	15863244
ly	O	-1	15863244
ex@@	O	-1	15863244
am@@	O	-1	15863244
ine@@	O	-1	15863244
d.	O	-1	15863244
Com@@	O	-1	15863244
pre@@	O	-1	15863244
h@@	O	-1	15863244
en@@	O	-1	15863244
sive	O	-1	15863244
clinical	O	-1	15863244
and	O	-1	15863244
develop@@	O	-1	15863244
mental	O	-1	15863244
meas@@	O	-1	15863244
ure@@	O	-1	15863244
ments	O	-1	15863244
were	O	-1	15863244
d@@	O	-1	15863244
one.	O	-1	15863244
The	O	-1	15863244
po@@	O	-1	15863244
ol@@	O	-1	15863244
ed	O	-1	15863244
statis@@	O	-1	15863244
tical	O	-1	15863244
analysis	O	-1	15863244
for	O	-1	15863244
ventricular	B-Disease	D006345	15863244
se@@	I-Disease	-1	15863244
pt@@	I-Disease	-1	15863244
al	I-Disease	-1	15863244
(V@@	I-Disease	-1	15863244
S@@	I-Disease	-1	15863244
D)	I-Disease	-1	15863244
and	I-Disease	-1	15863244
mid@@	I-Disease	-1	15863244
line	I-Disease	-1	15863244
(@@	I-Disease	-1	15863244
MD@@	I-Disease	-1	15863244
)	I-Disease	-1	15863244
def@@	I-Disease	-1	15863244
ects	I-Disease	-1	15863244
ventricular	B-Disease	D009436	15863244
se@@	I-Disease	-1	15863244
pt@@	I-Disease	-1	15863244
al	I-Disease	-1	15863244
(V@@	I-Disease	-1	15863244
S@@	I-Disease	-1	15863244
D)	I-Disease	-1	15863244
and	I-Disease	-1	15863244
mid@@	I-Disease	-1	15863244
line	I-Disease	-1	15863244
(@@	I-Disease	-1	15863244
MD@@	I-Disease	-1	15863244
)	I-Disease	-1	15863244
def@@	I-Disease	-1	15863244
ects	I-Disease	-1	15863244
was	O	-1	15863244
performed	O	-1	15863244
for	O	-1	15863244
rat	O	-1	15863244
f@@	O	-1	15863244
et@@	O	-1	15863244
u@@	O	-1	15863244
ses	O	-1	15863244
exposed	O	-1	15863244
to	O	-1	15863244
pi@@	B-Chemical	D010894	15863244
ro@@	I-Chemical	-1	15863244
x@@	I-Chemical	-1	15863244
ic@@	I-Chemical	-1	15863244
am	I-Chemical	-1	15863244
,	O	-1	15863244
selective	O	-1	15863244
and	O	-1	15863244
non-@@	O	-1	15863244
selective	O	-1	15863244
CO@@	O	-1	15863244
X@@	O	-1	15863244
-@@	O	-1	15863244
2	O	-1	15863244
inhibitor	O	-1	15863244
bas@@	O	-1	15863244
ed	O	-1	15863244
on	O	-1	15863244
present	O	-1	15863244
and	O	-1	15863244
hist@@	O	-1	15863244
or@@	O	-1	15863244
ic	O	-1	15863244
dat@@	O	-1	15863244
a.	O	-1	15863244
RESULTS:	O	-1	15863244
M@@	O	-1	15863244
at@@	O	-1	15863244
er@@	O	-1	15863244
n@@	O	-1	15863244
al	O	-1	15863244
toxicity	B-Disease	D064420	15863244
,	O	-1	15863244
intra@@	B-Disease	D005317	15863244
u@@	I-Disease	-1	15863244
ter@@	I-Disease	-1	15863244
ine	I-Disease	-1	15863244
growth	I-Disease	-1	15863244
ret@@	I-Disease	-1	15863244
ar@@	I-Disease	-1	15863244
d@@	I-Disease	-1	15863244
ation	I-Disease	-1	15863244
,	O	-1	15863244
and	O	-1	15863244
increase	B-Disease	D009139	15863244
of	I-Disease	-1	15863244
ex@@	I-Disease	-1	15863244
tern@@	I-Disease	-1	15863244
al	I-Disease	-1	15863244
and	I-Disease	-1	15863244
s@@	I-Disease	-1	15863244
ke@@	I-Disease	-1	15863244
le@@	I-Disease	-1	15863244
t@@	I-Disease	-1	15863244
al	I-Disease	-1	15863244
vari@@	I-Disease	-1	15863244
ations	I-Disease	-1	15863244
were	O	-1	15863244
found	O	-1	15863244
in	O	-1	15863244
rats	O	-1	15863244
treated	O	-1	15863244
with	O	-1	15863244
the	O	-1	15863244
high@@	O	-1	15863244
est	O	-1	15863244
dose	O	-1	15863244
of	O	-1	15863244
pi@@	B-Chemical	D010894	15863244
ro@@	I-Chemical	-1	15863244
x@@	I-Chemical	-1	15863244
ic@@	I-Chemical	-1	15863244
am	I-Chemical	-1	15863244
.	O	-1	15863244
D@@	O	-1	15863244
ec@@	O	-1	15863244
reas@@	O	-1	15863244
e	O	-1	15863244
of	O	-1	15863244
f@@	O	-1	15863244
et@@	O	-1	15863244
al	O	-1	15863244
l@@	O	-1	15863244
en@@	O	-1	15863244
g@@	O	-1	15863244
th	O	-1	15863244
was	O	-1	15863244
the	O	-1	15863244
only	O	-1	15863244
signs	O	-1	15863244
of	O	-1	15863244
the	O	-1	15863244
DF@@	B-Chemical	C106876	15863244
U	I-Chemical	-1	15863244
develop@@	O	-1	15863244
mental	O	-1	15863244
toxicity	B-Disease	D064420	15863244
observed	O	-1	15863244
in	O	-1	15863244
p@@	O	-1	15863244
up@@	O	-1	15863244
s	O	-1	15863244
exposed	O	-1	15863244
to	O	-1	15863244
the	O	-1	15863244
high@@	O	-1	15863244
est	O	-1	15863244
comp@@	O	-1	15863244
ound	O	-1	15863244
dose.	O	-1	15863244
L@@	O	-1	15863244
ac@@	O	-1	15863244
k	O	-1	15863244
of	O	-1	15863244
ter@@	O	-1	15863244
at@@	O	-1	15863244
o@@	O	-1	15863244
gen@@	O	-1	15863244
ic@@	O	-1	15863244
ity	O	-1	15863244
was	O	-1	15863244
found	O	-1	15863244
in	O	-1	15863244
pi@@	B-Chemical	D010894	15863244
ro@@	I-Chemical	-1	15863244
x@@	I-Chemical	-1	15863244
ic@@	I-Chemical	-1	15863244
am	I-Chemical	-1	15863244
and	O	-1	15863244
DF@@	B-Chemical	C106876	15863244
U	I-Chemical	-1	15863244
-@@	O	-1	15863244
exposed	O	-1	15863244
groups.	O	-1	15863244
P@@	O	-1	15863244
ren@@	O	-1	15863244
atal	O	-1	15863244
exposure	O	-1	15863244
to	O	-1	15863244
non-@@	O	-1	15863244
selective	O	-1	15863244
CO@@	O	-1	15863244
X	O	-1	15863244
inhibitors	O	-1	15863244
increases	O	-1	15863244
the	O	-1	15863244
risk	O	-1	15863244
of	O	-1	15863244
V@@	O	-1	15863244
S@@	O	-1	15863244
D	O	-1	15863244
and	O	-1	15863244
M@@	O	-1	15863244
D	O	-1	15863244
when	O	-1	15863244
compared	O	-1	15863244
to	O	-1	15863244
hist@@	O	-1	15863244
or@@	O	-1	15863244
ic	O	-1	15863244
control	O	-1	15863244
but	O	-1	15863244
not	O	-1	15863244
with	O	-1	15863244
selective	O	-1	15863244
CO@@	O	-1	15863244
X@@	O	-1	15863244
-@@	O	-1	15863244
2	O	-1	15863244
inhibitor@@	O	-1	15863244
s.	O	-1	15863244
CONCLUSION:	O	-1	15863244
B@@	O	-1	15863244
oth	O	-1	15863244
selective	O	-1	15863244
and	O	-1	15863244
non-@@	O	-1	15863244
selective	O	-1	15863244
CO@@	O	-1	15863244
X@@	O	-1	15863244
-@@	O	-1	15863244
2	O	-1	15863244
inhibitors	O	-1	15863244
were	O	-1	15863244
toxic	O	-1	15863244
for	O	-1	15863244
rats	O	-1	15863244
f@@	O	-1	15863244
et@@	O	-1	15863244
u@@	O	-1	15863244
ses	O	-1	15863244
when	O	-1	15863244
administered	O	-1	15863244
in	O	-1	15863244
the	O	-1	15863244
high@@	O	-1	15863244
est	O	-1	15863244
dose.	O	-1	15863244
U@@	O	-1	15863244
n@@	O	-1	15863244
like	O	-1	15863244
DF@@	B-Chemical	C106876	15863244
U	I-Chemical	-1	15863244
,	O	-1	15863244
pi@@	B-Chemical	D010894	15863244
ro@@	I-Chemical	-1	15863244
x@@	I-Chemical	-1	15863244
ic@@	I-Chemical	-1	15863244
am	I-Chemical	-1	15863244
was	O	-1	15863244
also	O	-1	15863244
high@@	O	-1	15863244
ly	O	-1	15863244
toxic	O	-1	15863244
to	O	-1	15863244
the	O	-1	15863244
dam@@	O	-1	15863244
s.	O	-1	15863244
P@@	O	-1	15863244
ren@@	O	-1	15863244
atal	O	-1	15863244
exposure	O	-1	15863244
to	O	-1	15863244
selective	O	-1	15863244
CO@@	O	-1	15863244
X@@	O	-1	15863244
-@@	O	-1	15863244
2	O	-1	15863244
inhibitors	O	-1	15863244
does	O	-1	15863244
not	O	-1	15863244
increase	O	-1	15863244
the	O	-1	15863244
risk	O	-1	15863244
of	O	-1	15863244
ventricular	B-Disease	D006345	15863244
se@@	I-Disease	-1	15863244
pt@@	I-Disease	-1	15863244
al	I-Disease	-1	15863244
and	I-Disease	-1	15863244
mid@@	I-Disease	-1	15863244
line	I-Disease	-1	15863244
def@@	I-Disease	-1	15863244
ects	I-Disease	-1	15863244
ventricular	B-Disease	D009436	15863244
se@@	I-Disease	-1	15863244
pt@@	I-Disease	-1	15863244
al	I-Disease	-1	15863244
and	I-Disease	-1	15863244
mid@@	I-Disease	-1	15863244
line	I-Disease	-1	15863244
def@@	I-Disease	-1	15863244
ects	I-Disease	-1	15863244
in	O	-1	15863244
rat	O	-1	15863244
when	O	-1	15863244
compared	O	-1	15863244
to	O	-1	15863244
non-@@	O	-1	15863244
selective	O	-1	15863244
drugs	O	-1	15863244
and	O	-1	15863244
hist@@	O	-1	15863244
or@@	O	-1	15863244
ic	O	-1	15863244
control@@	O	-1	15863244
.	O	-1	15863244

Pro@@	O	-1	12921865
t@@	O	-1	12921865
ective	O	-1	12921865
efficacy	O	-1	12921865
of	O	-1	12921865
neuro@@	O	-1	12921865
active	O	-1	12921865
steroid@@	B-Chemical	D013256	12921865
s	I-Chemical	-1	12921865
against	O	-1	12921865
cocaine	B-Chemical	D003042	12921865
k@@	O	-1	12921865
ind@@	O	-1	12921865
le@@	O	-1	12921865
d@@	O	-1	12921865
-	O	-1	12921865
seizures	B-Disease	D012640	12921865
in	O	-1	12921865
mice.	O	-1	12921865
Ne@@	O	-1	12921865
uro@@	O	-1	12921865
active	O	-1	12921865
steroid@@	B-Chemical	D013256	12921865
s	I-Chemical	-1	12921865
demon@@	O	-1	12921865
st@@	O	-1	12921865
rate	O	-1	12921865
pharmac@@	O	-1	12921865
ological	O	-1	12921865
ac@@	O	-1	12921865
tions	O	-1	12921865
that	O	-1	12921865
have	O	-1	12921865
re@@	O	-1	12921865
lev@@	O	-1	12921865
ance	O	-1	12921865
for	O	-1	12921865
a	O	-1	12921865
h@@	O	-1	12921865
ost	O	-1	12921865
of	O	-1	12921865
neurolog@@	B-Disease	D009422	12921865
ical	I-Disease	-1	12921865
and	I-Disease	-1	12921865
psych@@	I-Disease	-1	12921865
i@@	I-Disease	-1	12921865
atric	I-Disease	-1	12921865
disorder@@	I-Disease	-1	12921865
s	I-Disease	-1	12921865
neurolog@@	B-Disease	D001523	12921865
ical	I-Disease	-1	12921865
and	I-Disease	-1	12921865
psych@@	I-Disease	-1	12921865
i@@	I-Disease	-1	12921865
atric	I-Disease	-1	12921865
disorder@@	I-Disease	-1	12921865
s	I-Disease	-1	12921865
.	O	-1	12921865
The@@	O	-1	12921865
y	O	-1	12921865
o@@	O	-1	12921865
ff@@	O	-1	12921865
er	O	-1	12921865
prot@@	O	-1	12921865
ection	O	-1	12921865
against	O	-1	12921865
seizures	B-Disease	D012640	12921865
in	O	-1	12921865
a	O	-1	12921865
range	O	-1	12921865
of	O	-1	12921865
models	O	-1	12921865
and	O	-1	12921865
se@@	O	-1	12921865
em	O	-1	12921865
to	O	-1	12921865
inhib@@	O	-1	12921865
it	O	-1	12921865
cer@@	O	-1	12921865
t@@	O	-1	12921865
ain	O	-1	12921865
st@@	O	-1	12921865
ages	O	-1	12921865
of	O	-1	12921865
drug	B-Disease	D019966	12921865
depend@@	I-Disease	-1	12921865
ence	I-Disease	-1	12921865
in	O	-1	12921865
pre@@	O	-1	12921865
clinical	O	-1	12921865
assess@@	O	-1	12921865
ment@@	O	-1	12921865
s.	O	-1	12921865
The	O	-1	12921865
present	O	-1	12921865
study	O	-1	12921865
was	O	-1	12921865
de@@	O	-1	12921865
signed	O	-1	12921865
to	O	-1	12921865
evalu@@	O	-1	12921865
ate	O	-1	12921865
two	O	-1	12921865
endo@@	O	-1	12921865
gen@@	O	-1	12921865
ous	O	-1	12921865
and	O	-1	12921865
one	O	-1	12921865
syn@@	O	-1	12921865
thetic	O	-1	12921865
neuro@@	O	-1	12921865
active	O	-1	12921865
ster@@	B-Chemical	D013256	12921865
oid	I-Chemical	-1	12921865
that	O	-1	12921865
posi@@	O	-1	12921865
ti@@	O	-1	12921865
vely	O	-1	12921865
mod@@	O	-1	12921865
ul@@	O	-1	12921865
ate	O	-1	12921865
the	O	-1	12921865
gamma@@	B-Chemical	D005680	12921865
-@@	I-Chemical	-1	12921865
amin@@	I-Chemical	-1	12921865
ob@@	I-Chemical	-1	12921865
ut@@	I-Chemical	-1	12921865
y@@	I-Chemical	-1	12921865
ric	I-Chemical	-1	12921865
acid	I-Chemical	-1	12921865
(	O	-1	12921865
G@@	B-Chemical	D005680	12921865
A@@	I-Chemical	-1	12921865
B@@	I-Chemical	-1	12921865
A	I-Chemical	-1	12921865
(A@@	O	-1	12921865
)@@	O	-1	12921865
)	O	-1	12921865
receptor	O	-1	12921865
against	O	-1	12921865
the	O	-1	12921865
increase	O	-1	12921865
in	O	-1	12921865
sensitivity	O	-1	12921865
to	O	-1	12921865
the	O	-1	12921865
convul@@	O	-1	12921865
s@@	O	-1	12921865
ant	O	-1	12921865
effects	O	-1	12921865
of	O	-1	12921865
cocaine	B-Chemical	D003042	12921865
en@@	O	-1	12921865
gen@@	O	-1	12921865
de@@	O	-1	12921865
red	O	-1	12921865
by	O	-1	12921865
repe@@	O	-1	12921865
ated	O	-1	12921865
cocaine	B-Chemical	D003042	12921865
administration	O	-1	12921865
(	O	-1	12921865
seizure	B-Disease	D012640	12921865
k@@	O	-1	12921865
ind@@	O	-1	12921865
l@@	O	-1	12921865
ing@@	O	-1	12921865
).	O	-1	12921865
Al@@	B-Chemical	D011280	12921865
lo@@	I-Chemical	-1	12921865
pregn@@	I-Chemical	-1	12921865
an@@	I-Chemical	-1	12921865
ol@@	I-Chemical	-1	12921865
one	I-Chemical	-1	12921865
(	O	-1	12921865
3@@	B-Chemical	D011280	12921865
alpha-@@	I-Chemical	-1	12921865
hydrox@@	I-Chemical	-1	12921865
y-@@	I-Chemical	-1	12921865
5@@	I-Chemical	-1	12921865
alpha-@@	I-Chemical	-1	12921865
pregn@@	I-Chemical	-1	12921865
an@@	I-Chemical	-1	12921865
-@@	I-Chemical	-1	12921865
20@@	I-Chemical	-1	12921865
-@@	I-Chemical	-1	12921865
one	I-Chemical	-1	12921865
),	O	-1	12921865
pregn@@	B-Chemical	D011280	12921865
an@@	I-Chemical	-1	12921865
ol@@	I-Chemical	-1	12921865
one	I-Chemical	-1	12921865
(	O	-1	12921865
3@@	B-Chemical	D011280	12921865
alpha-@@	I-Chemical	-1	12921865
hydrox@@	I-Chemical	-1	12921865
y-@@	I-Chemical	-1	12921865
5@@	I-Chemical	-1	12921865
beta-@@	I-Chemical	-1	12921865
pregn@@	I-Chemical	-1	12921865
an@@	I-Chemical	-1	12921865
-@@	I-Chemical	-1	12921865
20@@	I-Chemical	-1	12921865
-@@	I-Chemical	-1	12921865
one	I-Chemical	-1	12921865
)	O	-1	12921865
and	O	-1	12921865
g@@	B-Chemical	C105051	12921865
an@@	I-Chemical	-1	12921865
ax@@	I-Chemical	-1	12921865
ol@@	I-Chemical	-1	12921865
one	I-Chemical	-1	12921865
(@@	O	-1	12921865
a	O	-1	12921865
syn@@	O	-1	12921865
thetic	O	-1	12921865
der@@	O	-1	12921865
i@@	O	-1	12921865
v@@	O	-1	12921865
ative	O	-1	12921865
of	O	-1	12921865
al@@	B-Chemical	D011280	12921865
lo@@	I-Chemical	-1	12921865
pregn@@	I-Chemical	-1	12921865
an@@	I-Chemical	-1	12921865
ol@@	I-Chemical	-1	12921865
one	I-Chemical	-1	12921865
3@@	B-Chemical	C105051	12921865
alpha-@@	I-Chemical	-1	12921865
hydrox@@	I-Chemical	-1	12921865
y-@@	I-Chemical	-1	12921865
3@@	I-Chemical	-1	12921865
beta-@@	I-Chemical	-1	12921865
methyl@@	I-Chemical	-1	12921865
-@@	I-Chemical	-1	12921865
5@@	I-Chemical	-1	12921865
alpha-@@	I-Chemical	-1	12921865
pregn@@	I-Chemical	-1	12921865
an@@	I-Chemical	-1	12921865
-@@	I-Chemical	-1	12921865
20@@	I-Chemical	-1	12921865
-@@	I-Chemical	-1	12921865
one	I-Chemical	-1	12921865
)	O	-1	12921865
were	O	-1	12921865
tested	O	-1	12921865
for	O	-1	12921865
their	O	-1	12921865
ability	O	-1	12921865
to	O	-1	12921865
sup@@	O	-1	12921865
pres@@	O	-1	12921865
s	O	-1	12921865
the	O	-1	12921865
expression	O	-1	12921865
(@@	O	-1	12921865
anti@@	O	-1	12921865
convul@@	O	-1	12921865
s@@	O	-1	12921865
ant	O	-1	12921865
effect@@	O	-1	12921865
)	O	-1	12921865
and	O	-1	12921865
development	O	-1	12921865
(@@	O	-1	12921865
anti@@	O	-1	12921865
epile@@	O	-1	12921865
pto@@	O	-1	12921865
genic	O	-1	12921865
effect@@	O	-1	12921865
)	O	-1	12921865
of	O	-1	12921865
cocaine	B-Chemical	D003042	12921865
-@@	O	-1	12921865
k@@	O	-1	12921865
ind@@	O	-1	12921865
l@@	O	-1	12921865
ed	O	-1	12921865
seizures	B-Disease	D012640	12921865
in	O	-1	12921865
mal@@	O	-1	12921865
e,	O	-1	12921865
S@@	O	-1	12921865
w@@	O	-1	12921865
is@@	O	-1	12921865
s-@@	O	-1	12921865
W@@	O	-1	12921865
e@@	O	-1	12921865
b@@	O	-1	12921865
st@@	O	-1	12921865
er	O	-1	12921865
mice.	O	-1	12921865
K@@	O	-1	12921865
ind@@	O	-1	12921865
l@@	O	-1	12921865
ed	O	-1	12921865
seizures	B-Disease	D012640	12921865
were	O	-1	12921865
induced	O	-1	12921865
by	O	-1	12921865
daily	O	-1	12921865
administration	O	-1	12921865
of	O	-1	12921865
60	O	-1	12921865
mg/kg	O	-1	12921865
cocaine	B-Chemical	D003042	12921865
for	O	-1	12921865
5	O	-1	12921865
days.	O	-1	12921865
All	O	-1	12921865
of	O	-1	12921865
these	O	-1	12921865
positive	O	-1	12921865
G@@	B-Chemical	D005680	12921865
A@@	I-Chemical	-1	12921865
B@@	I-Chemical	-1	12921865
A	I-Chemical	-1	12921865
(A@@	O	-1	12921865
)	O	-1	12921865
mod@@	O	-1	12921865
ul@@	O	-1	12921865
at@@	O	-1	12921865
ors	O	-1	12921865
sup@@	O	-1	12921865
press@@	O	-1	12921865
ed	O	-1	12921865
the	O	-1	12921865
expression	O	-1	12921865
of	O	-1	12921865
k@@	O	-1	12921865
ind@@	O	-1	12921865
l@@	O	-1	12921865
ed	O	-1	12921865
seizures	B-Disease	D012640	12921865
,	O	-1	12921865
whereas	O	-1	12921865
only	O	-1	12921865
al@@	B-Chemical	D011280	12921865
lo@@	I-Chemical	-1	12921865
pregn@@	I-Chemical	-1	12921865
an@@	I-Chemical	-1	12921865
ol@@	I-Chemical	-1	12921865
one	I-Chemical	-1	12921865
and	O	-1	12921865
g@@	B-Chemical	C105051	12921865
an@@	I-Chemical	-1	12921865
ax@@	I-Chemical	-1	12921865
ol@@	I-Chemical	-1	12921865
one	I-Chemical	-1	12921865
inhibited	O	-1	12921865
the	O	-1	12921865
development	O	-1	12921865
of	O	-1	12921865
k@@	O	-1	12921865
ind@@	O	-1	12921865
l@@	O	-1	12921865
ing.	O	-1	12921865
Al@@	B-Chemical	D011280	12921865
lo@@	I-Chemical	-1	12921865
pregn@@	I-Chemical	-1	12921865
an@@	I-Chemical	-1	12921865
ol@@	I-Chemical	-1	12921865
one	I-Chemical	-1	12921865
and	O	-1	12921865
pregn@@	B-Chemical	D011280	12921865
an@@	I-Chemical	-1	12921865
ol@@	I-Chemical	-1	12921865
one	I-Chemical	-1	12921865
,	O	-1	12921865
but	O	-1	12921865
not	O	-1	12921865
g@@	B-Chemical	C105051	12921865
an@@	I-Chemical	-1	12921865
ax@@	I-Chemical	-1	12921865
ol@@	I-Chemical	-1	12921865
one	I-Chemical	-1	12921865
,	O	-1	12921865
also	O	-1	12921865
reduced	O	-1	12921865
cum@@	O	-1	12921865
ul@@	O	-1	12921865
ative	O	-1	12921865
le@@	O	-1	12921865
thal@@	O	-1	12921865
ity	O	-1	12921865
associated	O	-1	12921865
with	O	-1	12921865
k@@	O	-1	12921865
ind@@	O	-1	12921865
l@@	O	-1	12921865
ing.	O	-1	12921865
These	O	-1	12921865
findings	O	-1	12921865
demon@@	O	-1	12921865
st@@	O	-1	12921865
rate	O	-1	12921865
that	O	-1	12921865
some	O	-1	12921865
neuro@@	O	-1	12921865
active	O	-1	12921865
steroid@@	B-Chemical	D013256	12921865
s	I-Chemical	-1	12921865
attenu@@	O	-1	12921865
ate	O	-1	12921865
convul@@	O	-1	12921865
s@@	O	-1	12921865
ant	O	-1	12921865
and	O	-1	12921865
sensi@@	O	-1	12921865
tiz@@	O	-1	12921865
ing	O	-1	12921865
pro@@	O	-1	12921865
per@@	O	-1	12921865
ties	O	-1	12921865
of	O	-1	12921865
cocaine	B-Chemical	D003042	12921865
and	O	-1	12921865
ad@@	O	-1	12921865
d	O	-1	12921865
to	O	-1	12921865
a	O	-1	12921865
grow@@	O	-1	12921865
ing	O	-1	12921865
literat@@	O	-1	12921865
ure	O	-1	12921865
on	O	-1	12921865
their	O	-1	12921865
potential	O	-1	12921865
use	O	-1	12921865
in	O	-1	12921865
the	O	-1	12921865
mod@@	O	-1	12921865
ulation	O	-1	12921865
of	O	-1	12921865
effects	O	-1	12921865
of	O	-1	12921865
drugs	O	-1	12921865
of	O	-1	12921865
ab@@	O	-1	12921865
use.	O	-1	12921865

K@@	O	-1	12584269
idne@@	O	-1	12584269
y	O	-1	12584269
function	O	-1	12584269
and	O	-1	12584269
morph@@	O	-1	12584269
ology	O	-1	12584269
after	O	-1	12584269
sh@@	O	-1	12584269
ort@@	O	-1	12584269
-term	O	-1	12584269
combination	O	-1	12584269
therapy	O	-1	12584269
with	O	-1	12584269
cyclospor@@	B-Chemical	D016572	12584269
ine	I-Chemical	-1	12584269
A	I-Chemical	-1	12584269
,	O	-1	12584269
tacrolimus	B-Chemical	D016559	12584269
and	O	-1	12584269
sirolimus	B-Chemical	D020123	12584269
in	O	-1	12584269
the	O	-1	12584269
rat@@	O	-1	12584269
.	O	-1	12584269
BACKGROUND:	O	-1	12584269
Si@@	B-Chemical	D020123	12584269
rolimus	I-Chemical	-1	12584269
(	O	-1	12584269
SR@@	B-Chemical	D020123	12584269
L	I-Chemical	-1	12584269
)	O	-1	12584269
may	O	-1	12584269
sup@@	O	-1	12584269
ple@@	O	-1	12584269
ment	O	-1	12584269
calc@@	O	-1	12584269
ine@@	O	-1	12584269
ur@@	O	-1	12584269
in	O	-1	12584269
inhibitors	O	-1	12584269
in	O	-1	12584269
clinical	O	-1	12584269
org@@	O	-1	12584269
an	O	-1	12584269
transplant@@	O	-1	12584269
ation.	O	-1	12584269
These	O	-1	12584269
are	O	-1	12584269
nephro@@	B-Disease	D007674	12584269
toxic	I-Disease	-1	12584269
,	O	-1	12584269
but	O	-1	12584269
SR@@	B-Chemical	D020123	12584269
L	I-Chemical	-1	12584269
se@@	O	-1	12584269
em@@	O	-1	12584269
s	O	-1	12584269
to	O	-1	12584269
ac@@	O	-1	12584269
t	O	-1	12584269
differen@@	O	-1	12584269
tly	O	-1	12584269
dis@@	O	-1	12584269
pl@@	O	-1	12584269
ay@@	O	-1	12584269
ing	O	-1	12584269
only	O	-1	12584269
min@@	O	-1	12584269
or	O	-1	12584269
nephro@@	B-Disease	D007674	12584269
toxic	I-Disease	-1	12584269
effect@@	O	-1	12584269
s,	O	-1	12584269
although	O	-1	12584269
this	O	-1	12584269
qu@@	O	-1	12584269
es@@	O	-1	12584269
tion	O	-1	12584269
is	O	-1	12584269
sti@@	O	-1	12584269
ll	O	-1	12584269
o@@	O	-1	12584269
pen@@	O	-1	12584269
.	O	-1	12584269
In	O	-1	12584269
a	O	-1	12584269
number	O	-1	12584269
of	O	-1	12584269
treatment	O	-1	12584269
pro@@	O	-1	12584269
to@@	O	-1	12584269
co@@	O	-1	12584269
l@@	O	-1	12584269
s	O	-1	12584269
wh@@	O	-1	12584269
ere	O	-1	12584269
SR@@	B-Chemical	D020123	12584269
L	I-Chemical	-1	12584269
was	O	-1	12584269
combined	O	-1	12584269
with	O	-1	12584269
a	O	-1	12584269
calc@@	O	-1	12584269
ine@@	O	-1	12584269
ur@@	O	-1	12584269
in	O	-1	12584269
inhibitor	O	-1	12584269
indic@@	O	-1	12584269
ations	O	-1	12584269
of	O	-1	12584269
a	O	-1	12584269
syn@@	O	-1	12584269
erg@@	O	-1	12584269
istic	O	-1	12584269
nephro@@	B-Disease	D007674	12584269
toxic	I-Disease	-1	12584269
effect	O	-1	12584269
were	O	-1	12584269
descri@@	O	-1	12584269
be@@	O	-1	12584269
d.	O	-1	12584269
The	O	-1	12584269
a@@	O	-1	12584269
im	O	-1	12584269
of	O	-1	12584269
this	O	-1	12584269
study	O	-1	12584269
was	O	-1	12584269
to	O	-1	12584269
ex@@	O	-1	12584269
amine	O	-1	12584269
further	O	-1	12584269
the	O	-1	12584269
renal	O	-1	12584269
func@@	O	-1	12584269
tion,	O	-1	12584269
including	O	-1	12584269
morph@@	O	-1	12584269
ological	O	-1	12584269
analysis	O	-1	12584269
of	O	-1	12584269
the	O	-1	12584269
kidne@@	O	-1	12584269
ys	O	-1	12584269
of	O	-1	12584269
male	O	-1	12584269
S@@	O	-1	12584269
pra@@	O	-1	12584269
gu@@	O	-1	12584269
e-@@	O	-1	12584269
D@@	O	-1	12584269
aw@@	O	-1	12584269
le@@	O	-1	12584269
y	O	-1	12584269
rats	O	-1	12584269
treated	O	-1	12584269
with	O	-1	12584269
either	O	-1	12584269
cyclospor@@	B-Chemical	D016572	12584269
ine	I-Chemical	-1	12584269
A	I-Chemical	-1	12584269
(	O	-1	12584269
C@@	B-Chemical	D016572	12584269
s@@	I-Chemical	-1	12584269
A	I-Chemical	-1	12584269
),	O	-1	12584269
tacrolimus	B-Chemical	D016559	12584269
(	O	-1	12584269
FK50@@	B-Chemical	D016559	12584269
6	I-Chemical	-1	12584269
)	O	-1	12584269
or	O	-1	12584269
SR@@	B-Chemical	D020123	12584269
L	I-Chemical	-1	12584269
as	O	-1	12584269
mon@@	O	-1	12584269
o@@	O	-1	12584269
therap@@	O	-1	12584269
i@@	O	-1	12584269
es	O	-1	12584269
or	O	-1	12584269
in	O	-1	12584269
different	O	-1	12584269
combin@@	O	-1	12584269
ations.	O	-1	12584269
METHODS:	O	-1	12584269
F@@	O	-1	12584269
or	O	-1	12584269
a	O	-1	12584269
period	O	-1	12584269
of	O	-1	12584269
2	O	-1	12584269
week@@	O	-1	12584269
s,	O	-1	12584269
C@@	B-Chemical	D016572	12584269
s@@	I-Chemical	-1	12584269
A	I-Chemical	-1	12584269
15	O	-1	12584269
mg/k@@	O	-1	12584269
g/@@	O	-1	12584269
day	O	-1	12584269
(@@	O	-1	12584269
given	O	-1	12584269
or@@	O	-1	12584269
all@@	O	-1	12584269
y@@	O	-1	12584269
),	O	-1	12584269
FK50@@	B-Chemical	D016559	12584269
6	I-Chemical	-1	12584269
3.@@	O	-1	12584269
0	O	-1	12584269
mg/k@@	O	-1	12584269
g/@@	O	-1	12584269
day	O	-1	12584269
(@@	O	-1	12584269
given	O	-1	12584269
or@@	O	-1	12584269
all@@	O	-1	12584269
y@@	O	-1	12584269
)	O	-1	12584269
or	O	-1	12584269
SR@@	B-Chemical	D020123	12584269
L	I-Chemical	-1	12584269
0.@@	O	-1	12584269
4	O	-1	12584269
mg/k@@	O	-1	12584269
g/@@	O	-1	12584269
day	O	-1	12584269
(@@	O	-1	12584269
given	O	-1	12584269
intra@@	O	-1	12584269
per@@	O	-1	12584269
it@@	O	-1	12584269
one@@	O	-1	12584269
all@@	O	-1	12584269
y@@	O	-1	12584269
)	O	-1	12584269
was	O	-1	12584269
administered	O	-1	12584269
on@@	O	-1	12584269
ce	O	-1	12584269
a	O	-1	12584269
day	O	-1	12584269
as	O	-1	12584269
these	O	-1	12584269
doses	O	-1	12584269
have	O	-1	12584269
ear@@	O	-1	12584269
li@@	O	-1	12584269
er	O	-1	12584269
been	O	-1	12584269
found	O	-1	12584269
to	O	-1	12584269
achi@@	O	-1	12584269
e@@	O	-1	12584269
ve	O	-1	12584269
a	O	-1	12584269
significant	O	-1	12584269
immunosup@@	O	-1	12584269
pressive	O	-1	12584269
effect	O	-1	12584269
in	O	-1	12584269
S@@	O	-1	12584269
pra@@	O	-1	12584269
gu@@	O	-1	12584269
e-@@	O	-1	12584269
D@@	O	-1	12584269
aw@@	O	-1	12584269
le@@	O	-1	12584269
y	O	-1	12584269
rats.	O	-1	12584269
In	O	-1	12584269
the	O	-1	12584269
'@@	O	-1	12584269
con@@	O	-1	12584269
s@@	O	-1	12584269
ci@@	O	-1	12584269
ous	O	-1	12584269
ca@@	O	-1	12584269
the@@	O	-1	12584269
ter@@	O	-1	12584269
ized	O	-1	12584269
rat@@	O	-1	12584269
'	O	-1	12584269
model@@	O	-1	12584269
,	O	-1	12584269
the	O	-1	12584269
glomerular	O	-1	12584269
f@@	O	-1	12584269
iltration	O	-1	12584269
rate	O	-1	12584269
(@@	O	-1	12584269
GF@@	O	-1	12584269
R@@	O	-1	12584269
)	O	-1	12584269
was	O	-1	12584269
measured	O	-1	12584269
as	O	-1	12584269
the	O	-1	12584269
clear@@	O	-1	12584269
ance	O	-1	12584269
of	O	-1	12584269
C@@	O	-1	12584269
r@@	O	-1	12584269
(@@	O	-1	12584269
E@@	O	-1	12584269
D@@	O	-1	12584269
TA@@	O	-1	12584269
).	O	-1	12584269
The	O	-1	12584269
morph@@	O	-1	12584269
ological	O	-1	12584269
analysis	O	-1	12584269
of	O	-1	12584269
the	O	-1	12584269
kidne@@	O	-1	12584269
ys	O	-1	12584269
included	O	-1	12584269
a	O	-1	12584269
se@@	O	-1	12584269
mi@@	O	-1	12584269
-@@	O	-1	12584269
qu@@	O	-1	12584269
anti@@	O	-1	12584269
t@@	O	-1	12584269
ative	O	-1	12584269
scor@@	O	-1	12584269
ing	O	-1	12584269
system	O	-1	12584269
an@@	O	-1	12584269
al@@	O	-1	12584269
ys@@	O	-1	12584269
ing	O	-1	12584269
the	O	-1	12584269
de@@	O	-1	12584269
g@@	O	-1	12584269
ree	O	-1	12584269
of	O	-1	12584269
stri@@	O	-1	12584269
p@@	O	-1	12584269
ed	O	-1	12584269
fib@@	B-Disease	D005355	12584269
ro@@	I-Disease	-1	12584269
sis	I-Disease	-1	12584269
,	O	-1	12584269
sub@@	O	-1	12584269
cap@@	O	-1	12584269
s@@	O	-1	12584269
ular	O	-1	12584269
fib@@	B-Disease	D005355	12584269
ro@@	I-Disease	-1	12584269
sis	I-Disease	-1	12584269
and	O	-1	12584269
the	O	-1	12584269
number	O	-1	12584269
of	O	-1	12584269
bas@@	O	-1	12584269
oph@@	O	-1	12584269
il@@	O	-1	12584269
ic	O	-1	12584269
tub@@	O	-1	12584269
ul@@	O	-1	12584269
es,	O	-1	12584269
plus	O	-1	12584269
an	O	-1	12584269
addi@@	O	-1	12584269
tional	O	-1	12584269
ste@@	O	-1	12584269
re@@	O	-1	12584269
ological	O	-1	12584269
analysis	O	-1	12584269
of	O	-1	12584269
the	O	-1	12584269
total	O	-1	12584269
gra@@	O	-1	12584269
de	O	-1	12584269
of	O	-1	12584269
fib@@	B-Disease	D005355	12584269
ro@@	I-Disease	-1	12584269
sis	I-Disease	-1	12584269
in	O	-1	12584269
the	O	-1	12584269
cor@@	O	-1	12584269
te@@	O	-1	12584269
x	O	-1	12584269
st@@	O	-1	12584269
ained	O	-1	12584269
with	O	-1	12584269
Si@@	O	-1	12584269
ri@@	O	-1	12584269
us	O	-1	12584269
R@@	O	-1	12584269
ed.	O	-1	12584269
RESULTS:	O	-1	12584269
C@@	B-Chemical	D016572	12584269
s@@	I-Chemical	-1	12584269
A	I-Chemical	-1	12584269
,	O	-1	12584269
FK50@@	B-Chemical	D016559	12584269
6	I-Chemical	-1	12584269
and	O	-1	12584269
SR@@	B-Chemical	D020123	12584269
L	I-Chemical	-1	12584269
all	O	-1	12584269
significantly	O	-1	12584269
decreased	O	-1	12584269
the	O	-1	12584269
GF@@	O	-1	12584269
R@@	O	-1	12584269
.	O	-1	12584269
A	O	-1	12584269
further	O	-1	12584269
deter@@	O	-1	12584269
i@@	O	-1	12584269
or@@	O	-1	12584269
ation	O	-1	12584269
was	O	-1	12584269
seen	O	-1	12584269
when	O	-1	12584269
C@@	B-Chemical	D016572	12584269
s@@	I-Chemical	-1	12584269
A	I-Chemical	-1	12584269
was	O	-1	12584269
combined	O	-1	12584269
with	O	-1	12584269
either	O	-1	12584269
FK50@@	B-Chemical	D016559	12584269
6	I-Chemical	-1	12584269
or	O	-1	12584269
SR@@	B-Chemical	D020123	12584269
L	I-Chemical	-1	12584269
,	O	-1	12584269
whereas	O	-1	12584269
the	O	-1	12584269
GF@@	O	-1	12584269
R	O	-1	12584269
remained	O	-1	12584269
un@@	O	-1	12584269
chang@@	O	-1	12584269
ed	O	-1	12584269
in	O	-1	12584269
the	O	-1	12584269
group	O	-1	12584269
treated	O	-1	12584269
with	O	-1	12584269
FK50@@	B-Chemical	D016559	12584269
6	I-Chemical	-1	12584269
plus	O	-1	12584269
SR@@	B-Chemical	D020123	12584269
L	I-Chemical	-1	12584269
when	O	-1	12584269
compared	O	-1	12584269
with	O	-1	12584269
treatment	O	-1	12584269
with	O	-1	12584269
any	O	-1	12584269
of	O	-1	12584269
the	O	-1	12584269
single	O	-1	12584269
subst@@	O	-1	12584269
anc@@	O	-1	12584269
es.	O	-1	12584269
The	O	-1	12584269
morph@@	O	-1	12584269
ological	O	-1	12584269
changes	O	-1	12584269
presented	O	-1	12584269
a	O	-1	12584269
similar	O	-1	12584269
pat@@	O	-1	12584269
tern@@	O	-1	12584269
.	O	-1	12584269
The	O	-1	12584269
se@@	O	-1	12584269
mi@@	O	-1	12584269
-@@	O	-1	12584269
qu@@	O	-1	12584269
anti@@	O	-1	12584269
t@@	O	-1	12584269
ative	O	-1	12584269
scor@@	O	-1	12584269
ing	O	-1	12584269
was	O	-1	12584269
significantly	O	-1	12584269
wor@@	O	-1	12584269
st	O	-1	12584269
in	O	-1	12584269
the	O	-1	12584269
group	O	-1	12584269
treated	O	-1	12584269
with	O	-1	12584269
C@@	B-Chemical	D016572	12584269
s@@	I-Chemical	-1	12584269
A	I-Chemical	-1	12584269
plus	O	-1	12584269
SR@@	B-Chemical	D020123	12584269
L	I-Chemical	-1	12584269
(P@@	O	-1	12584269
<@@	O	-1	12584269
0.00@@	O	-1	12584269
1	O	-1	12584269
compared	O	-1	12584269
with	O	-1	12584269
control@@	O	-1	12584269
s)	O	-1	12584269
and	O	-1	12584269
the	O	-1	12584269
analysis	O	-1	12584269
of	O	-1	12584269
the	O	-1	12584269
total	O	-1	12584269
gra@@	O	-1	12584269
de	O	-1	12584269
of	O	-1	12584269
fib@@	B-Disease	D005355	12584269
ro@@	I-Disease	-1	12584269
sis	I-Disease	-1	12584269
also	O	-1	12584269
showed	O	-1	12584269
the	O	-1	12584269
high@@	O	-1	12584269
est	O	-1	12584269
pro@@	O	-1	12584269
por@@	O	-1	12584269
tion	O	-1	12584269
in	O	-1	12584269
the	O	-1	12584269
same	O	-1	12584269
group	O	-1	12584269
and	O	-1	12584269
was	O	-1	12584269
significantly	O	-1	12584269
different	O	-1	12584269
from	O	-1	12584269
controls	O	-1	12584269
(P@@	O	-1	12584269
<@@	O	-1	12584269
0.0@@	O	-1	12584269
2@@	O	-1	12584269
).	O	-1	12584269
The	O	-1	12584269
FK50@@	B-Chemical	D016559	12584269
6	I-Chemical	-1	12584269
plus	O	-1	12584269
SR@@	B-Chemical	D020123	12584269
L	I-Chemical	-1	12584269
combination	O	-1	12584269
showed	O	-1	12584269
only	O	-1	12584269
a	O	-1	12584269
m@@	O	-1	12584269
arg@@	O	-1	12584269
in@@	O	-1	12584269
ally	O	-1	12584269
higher	O	-1	12584269
de@@	O	-1	12584269
g@@	O	-1	12584269
ree	O	-1	12584269
of	O	-1	12584269
fib@@	B-Disease	D005355	12584269
ro@@	I-Disease	-1	12584269
sis	I-Disease	-1	12584269
as	O	-1	12584269
compared	O	-1	12584269
with	O	-1	12584269
controls	O	-1	12584269
(P@@	O	-1	12584269
=@@	O	-1	12584269
0.05@@	O	-1	12584269
).	O	-1	12584269
CONCLUSION:	O	-1	12584269
This	O	-1	12584269
rat	O	-1	12584269
study	O	-1	12584269
demonstrated	O	-1	12584269
a	O	-1	12584269
syn@@	O	-1	12584269
erg@@	O	-1	12584269
istic	O	-1	12584269
nephro@@	B-Disease	D007674	12584269
toxic	I-Disease	-1	12584269
effect	O	-1	12584269
of	O	-1	12584269
C@@	B-Chemical	D016572	12584269
s@@	I-Chemical	-1	12584269
A	I-Chemical	-1	12584269
plus	O	-1	12584269
SR@@	B-Chemical	D020123	12584269
L	I-Chemical	-1	12584269
,	O	-1	12584269
whereas	O	-1	12584269
FK50@@	B-Chemical	D016559	12584269
6	I-Chemical	-1	12584269
plus	O	-1	12584269
SR@@	B-Chemical	D020123	12584269
L	I-Chemical	-1	12584269
was	O	-1	12584269
bet@@	O	-1	12584269
ter	O	-1	12584269
toler@@	O	-1	12584269
ated.	O	-1	12584269

Eff@@	O	-1	10406016
ect	O	-1	10406016
of	O	-1	10406016
fu@@	B-Chemical	C007789	10406016
co@@	I-Chemical	-1	10406016
id@@	I-Chemical	-1	10406016
an	I-Chemical	-1	10406016
treatment	O	-1	10406016
on	O	-1	10406016
coll@@	O	-1	10406016
ag@@	O	-1	10406016
en@@	O	-1	10406016
as@@	O	-1	10406016
e@@	O	-1	10406016
-induced	O	-1	10406016
intrac@@	B-Disease	D002543	10406016
e@@	I-Disease	-1	10406016
rebral	I-Disease	-1	10406016
hemorrh@@	I-Disease	-1	10406016
age	I-Disease	-1	10406016
in	O	-1	10406016
rats.	O	-1	10406016
In@@	O	-1	10406016
f@@	O	-1	10406016
lam@@	O	-1	10406016
mat@@	O	-1	10406016
ory	O	-1	10406016
cells	O	-1	10406016
are	O	-1	10406016
post@@	O	-1	10406016
ul@@	O	-1	10406016
ated	O	-1	10406016
to	O	-1	10406016
medi@@	O	-1	10406016
ate	O	-1	10406016
some	O	-1	10406016
of	O	-1	10406016
the	O	-1	10406016
brain	B-Disease	D001925	10406016
damage	I-Disease	-1	10406016
following	O	-1	10406016
ischem@@	B-Disease	D002544	10406016
ic	I-Disease	-1	10406016
strok@@	I-Disease	-1	10406016
e	I-Disease	-1	10406016
.	O	-1	10406016
In@@	B-Disease	D002543	10406016
trac@@	I-Disease	-1	10406016
e@@	I-Disease	-1	10406016
rebral	I-Disease	-1	10406016
hemorrh@@	I-Disease	-1	10406016
age	I-Disease	-1	10406016
is	O	-1	10406016
associated	O	-1	10406016
with	O	-1	10406016
more	O	-1	10406016
inflam@@	B-Disease	D007249	10406016
m@@	I-Disease	-1	10406016
ation	I-Disease	-1	10406016
than	O	-1	10406016
ischem@@	B-Disease	D002544	10406016
ic	I-Disease	-1	10406016
strok@@	I-Disease	-1	10406016
e	I-Disease	-1	10406016
.	O	-1	10406016
We	O	-1	10406016
tested	O	-1	10406016
the	O	-1	10406016
sulf@@	O	-1	10406016
ated	O	-1	10406016
pol@@	O	-1	10406016
ys@@	O	-1	10406016
ac@@	O	-1	10406016
ch@@	O	-1	10406016
ar@@	O	-1	10406016
ide	O	-1	10406016
fu@@	B-Chemical	C007789	10406016
co@@	I-Chemical	-1	10406016
id@@	I-Chemical	-1	10406016
an	I-Chemical	-1	10406016
,	O	-1	10406016
which	O	-1	10406016
has	O	-1	10406016
been	O	-1	10406016
reported	O	-1	10406016
to	O	-1	10406016
re@@	O	-1	10406016
duce	O	-1	10406016
inflam@@	O	-1	10406016
mat@@	O	-1	10406016
ory	O	-1	10406016
brain	B-Disease	D001925	10406016
damage	I-Disease	-1	10406016
,	O	-1	10406016
in	O	-1	10406016
a	O	-1	10406016
rat	O	-1	10406016
model	O	-1	10406016
of	O	-1	10406016
intrac@@	B-Disease	D002543	10406016
e@@	I-Disease	-1	10406016
rebral	I-Disease	-1	10406016
hemorrh@@	I-Disease	-1	10406016
age	I-Disease	-1	10406016
induced	O	-1	10406016
by	O	-1	10406016
injection	O	-1	10406016
of	O	-1	10406016
bac@@	O	-1	10406016
ter@@	O	-1	10406016
ial	O	-1	10406016
coll@@	O	-1	10406016
ag@@	O	-1	10406016
en@@	O	-1	10406016
ase	O	-1	10406016
into	O	-1	10406016
the	O	-1	10406016
ca@@	O	-1	10406016
ud@@	O	-1	10406016
ate	O	-1	10406016
nucle@@	O	-1	10406016
us.	O	-1	10406016
R@@	O	-1	10406016
at@@	O	-1	10406016
s	O	-1	10406016
were	O	-1	10406016
treated	O	-1	10406016
with	O	-1	10406016
seven	O	-1	10406016
day	O	-1	10406016
intravenous	O	-1	10406016
infusion	O	-1	10406016
of	O	-1	10406016
fu@@	B-Chemical	C007789	10406016
co@@	I-Chemical	-1	10406016
id@@	I-Chemical	-1	10406016
an	I-Chemical	-1	10406016
(@@	O	-1	10406016
30	O	-1	10406016
microgram@@	O	-1	10406016
s	O	-1	10406016
h@@	O	-1	10406016
-1@@	O	-1	10406016
)	O	-1	10406016
or	O	-1	10406016
ve@@	O	-1	10406016
h@@	O	-1	10406016
ic@@	O	-1	10406016
le@@	O	-1	10406016
.	O	-1	10406016
The	O	-1	10406016
hemat@@	B-Disease	D006406	10406016
oma	I-Disease	-1	10406016
was	O	-1	10406016
assessed	O	-1	10406016
in	O	-1	10406016
viv@@	O	-1	10406016
o	O	-1	10406016
by	O	-1	10406016
mag@@	O	-1	10406016
ne@@	O	-1	10406016
tic	O	-1	10406016
res@@	O	-1	10406016
on@@	O	-1	10406016
ance	O	-1	10406016
imag@@	O	-1	10406016
ing.	O	-1	10406016
M@@	O	-1	10406016
otor	O	-1	10406016
behavi@@	O	-1	10406016
or@@	O	-1	10406016
,	O	-1	10406016
p@@	O	-1	10406016
as@@	O	-1	10406016
sive	O	-1	10406016
avoid@@	O	-1	10406016
ance@@	O	-1	10406016
,	O	-1	10406016
and	O	-1	10406016
s@@	O	-1	10406016
k@@	O	-1	10406016
ill@@	O	-1	10406016
ed	O	-1	10406016
fo@@	O	-1	10406016
rel@@	O	-1	10406016
im@@	O	-1	10406016
b	O	-1	10406016
function	O	-1	10406016
were	O	-1	10406016
tested	O	-1	10406016
repe@@	O	-1	10406016
ated@@	O	-1	10406016
ly	O	-1	10406016
for	O	-1	10406016
six	O	-1	10406016
week@@	O	-1	10406016
s.	O	-1	10406016
F@@	B-Chemical	C007789	10406016
u@@	I-Chemical	-1	10406016
co@@	I-Chemical	-1	10406016
id@@	I-Chemical	-1	10406016
an	I-Chemical	-1	10406016
-treated	O	-1	10406016
rats	O	-1	10406016
ex@@	O	-1	10406016
hib@@	O	-1	10406016
ited	O	-1	10406016
evidence	O	-1	10406016
of	O	-1	10406016
impaired	B-Disease	D020141	10406016
blood	I-Disease	-1	10406016
clo@@	I-Disease	-1	10406016
t@@	I-Disease	-1	10406016
ting	I-Disease	-1	10406016
and	O	-1	10406016
hemo@@	B-Disease	D020141	10406016
di@@	I-Disease	-1	10406016
lu@@	I-Disease	-1	10406016
tion	I-Disease	-1	10406016
,	O	-1	10406016
had	O	-1	10406016
larg@@	O	-1	10406016
er	O	-1	10406016
hemat@@	B-Disease	D006406	10406016
om@@	I-Disease	-1	10406016
as	I-Disease	-1	10406016
,	O	-1	10406016
and	O	-1	10406016
ten@@	O	-1	10406016
ded	O	-1	10406016
to	O	-1	10406016
have	O	-1	10406016
less	O	-1	10406016
inflam@@	B-Disease	D007249	10406016
m@@	I-Disease	-1	10406016
ation	I-Disease	-1	10406016
in	O	-1	10406016
the	O	-1	10406016
v@@	O	-1	10406016
ic@@	O	-1	10406016
in@@	O	-1	10406016
ity	O	-1	10406016
of	O	-1	10406016
the	O	-1	10406016
hemat@@	B-Disease	D006406	10406016
oma	I-Disease	-1	10406016
after	O	-1	10406016
three	O	-1	10406016
days.	O	-1	10406016
The@@	O	-1	10406016
y	O	-1	10406016
showed	O	-1	10406016
significantly	O	-1	10406016
more	O	-1	10406016
ra@@	O	-1	10406016
pid	O	-1	10406016
impro@@	O	-1	10406016
vement	O	-1	10406016
of	O	-1	10406016
motor	O	-1	10406016
function	O	-1	10406016
in	O	-1	10406016
the	O	-1	10406016
first	O	-1	10406016
week	O	-1	10406016
following	O	-1	10406016
hemorrh@@	B-Disease	D006470	10406016
age	I-Disease	-1	10406016
and	O	-1	10406016
bet@@	O	-1	10406016
ter	O	-1	10406016
memory	O	-1	10406016
re@@	O	-1	10406016
ten@@	O	-1	10406016
tion	O	-1	10406016
in	O	-1	10406016
the	O	-1	10406016
p@@	O	-1	10406016
as@@	O	-1	10406016
sive	O	-1	10406016
avoid@@	O	-1	10406016
ance	O	-1	10406016
test@@	O	-1	10406016
.	O	-1	10406016
Ac@@	O	-1	10406016
ute	O	-1	10406016
wh@@	B-Disease	D001929	10406016
ite	I-Disease	-1	10406016
mat@@	I-Disease	-1	10406016
ter	I-Disease	-1	10406016
e@@	I-Disease	-1	10406016
de@@	I-Disease	-1	10406016
ma	I-Disease	-1	10406016
and	O	-1	10406016
event@@	O	-1	10406016
ual	O	-1	10406016
neuron@@	B-Disease	D009410	10406016
al	I-Disease	-1	10406016
loss	I-Disease	-1	10406016
in	O	-1	10406016
the	O	-1	10406016
striat@@	O	-1	10406016
um	O	-1	10406016
adj@@	O	-1	10406016
ac@@	O	-1	10406016
ent	O	-1	10406016
to	O	-1	10406016
the	O	-1	10406016
hemat@@	B-Disease	D006406	10406016
oma	I-Disease	-1	10406016
did	O	-1	10406016
not	O	-1	10406016
diff@@	O	-1	10406016
er	O	-1	10406016
between	O	-1	10406016
the	O	-1	10406016
two	O	-1	10406016
groups.	O	-1	10406016
In@@	O	-1	10406016
v@@	O	-1	10406016
estig@@	O	-1	10406016
ation	O	-1	10406016
of	O	-1	10406016
more	O	-1	10406016
specific	O	-1	10406016
anti@@	O	-1	10406016
-@@	O	-1	10406016
inflam@@	O	-1	10406016
mat@@	O	-1	10406016
ory	O	-1	10406016
agents	O	-1	10406016
and	O	-1	10406016
hemo@@	O	-1	10406016
di@@	O	-1	10406016
l@@	O	-1	10406016
ut@@	O	-1	10406016
ing	O	-1	10406016
agents	O	-1	10406016
are	O	-1	10406016
war@@	O	-1	10406016
ran@@	O	-1	10406016
ted	O	-1	10406016
in	O	-1	10406016
intrac@@	B-Disease	D002543	10406016
e@@	I-Disease	-1	10406016
rebral	I-Disease	-1	10406016
hemorrh@@	I-Disease	-1	10406016
age	I-Disease	-1	10406016
.	O	-1	10406016

P@@	B-Chemical	D000082	3403780
ar@@	I-Chemical	-1	3403780
acet@@	I-Chemical	-1	3403780
am@@	I-Chemical	-1	3403780
ol	I-Chemical	-1	3403780
-@@	O	-1	3403780
associated	O	-1	3403780
com@@	B-Disease	D003128	3403780
a	I-Disease	-1	3403780
,	O	-1	3403780
met@@	B-Disease	D000138	3403780
ab@@	I-Disease	-1	3403780
olic	I-Disease	-1	3403780
acid@@	I-Disease	-1	3403780
o@@	I-Disease	-1	3403780
sis	I-Disease	-1	3403780
,	O	-1	3403780
renal	B-Disease	D058186	3403780
and	I-Disease	-1	3403780
hepatic	I-Disease	-1	3403780
failure	I-Disease	-1	3403780
renal	B-Disease	D017093	3403780
and	I-Disease	-1	3403780
hepatic	I-Disease	-1	3403780
failure	I-Disease	-1	3403780
.	O	-1	3403780
A	O	-1	3403780
case	O	-1	3403780
of	O	-1	3403780
met@@	B-Disease	D000138	3403780
ab@@	I-Disease	-1	3403780
olic	I-Disease	-1	3403780
acid@@	I-Disease	-1	3403780
o@@	I-Disease	-1	3403780
sis	I-Disease	-1	3403780
,	O	-1	3403780
acute	B-Disease	D058186	3403780
renal	I-Disease	-1	3403780
failure	I-Disease	-1	3403780
and	I-Disease	-1	3403780
hepatic	I-Disease	-1	3403780
failure	I-Disease	-1	3403780
acute	B-Disease	D017114	3403780
renal	I-Disease	-1	3403780
failure	I-Disease	-1	3403780
and	I-Disease	-1	3403780
hepatic	I-Disease	-1	3403780
failure	I-Disease	-1	3403780
following	O	-1	3403780
par@@	B-Chemical	D000082	3403780
acet@@	I-Chemical	-1	3403780
am@@	I-Chemical	-1	3403780
ol	I-Chemical	-1	3403780
ing@@	O	-1	3403780
es@@	O	-1	3403780
tion	O	-1	3403780
is	O	-1	3403780
present@@	O	-1	3403780
ed.	O	-1	3403780
The	O	-1	3403780
diagnos@@	O	-1	3403780
tic	O	-1	3403780
diff@@	O	-1	3403780
ic@@	O	-1	3403780
ult@@	O	-1	3403780
y	O	-1	3403780
at	O	-1	3403780
present@@	O	-1	3403780
ation	O	-1	3403780
is	O	-1	3403780
high@@	O	-1	3403780
li@@	O	-1	3403780
gh@@	O	-1	3403780
ted.	O	-1	3403780
C@@	O	-1	3403780
ont@@	O	-1	3403780
in@@	O	-1	3403780
u@@	O	-1	3403780
ous	O	-1	3403780
arter@@	O	-1	3403780
io@@	O	-1	3403780
venous	O	-1	3403780
haem@@	O	-1	3403780
of@@	O	-1	3403780
iltration	O	-1	3403780
pro@@	O	-1	3403780
ved	O	-1	3403780
a	O	-1	3403780
valu@@	O	-1	3403780
able	O	-1	3403780
me@@	O	-1	3403780
ans	O	-1	3403780
of	O	-1	3403780
maint@@	O	-1	3403780
aining	O	-1	3403780
flu@@	O	-1	3403780
id	O	-1	3403780
and	O	-1	3403780
electro@@	O	-1	3403780
ly@@	O	-1	3403780
te	O	-1	3403780
b@@	O	-1	3403780
al@@	O	-1	3403780
ance@@	O	-1	3403780
.	O	-1	3403780
The	O	-1	3403780
patient	O	-1	3403780
reco@@	O	-1	3403780
ve@@	O	-1	3403780
red.	O	-1	3403780

He@@	O	-1	3101906
pati@@	O	-1	3101906
c	O	-1	3101906
reactions	O	-1	3101906
associated	O	-1	3101906
with	O	-1	3101906
ke@@	B-Chemical	D007654	3101906
to@@	I-Chemical	-1	3101906
con@@	I-Chemical	-1	3101906
azole	I-Chemical	-1	3101906
in	O	-1	3101906
the	O	-1	3101906
U@@	O	-1	3101906
nit@@	O	-1	3101906
ed	O	-1	3101906
K@@	O	-1	3101906
ing@@	O	-1	3101906
dom@@	O	-1	3101906
.	O	-1	3101906
K@@	B-Chemical	D007654	3101906
e@@	I-Chemical	-1	3101906
to@@	I-Chemical	-1	3101906
con@@	I-Chemical	-1	3101906
azole	I-Chemical	-1	3101906
was	O	-1	3101906
int@@	O	-1	3101906
ro@@	O	-1	3101906
duced	O	-1	3101906
in	O	-1	3101906
the	O	-1	3101906
U@@	O	-1	3101906
nit@@	O	-1	3101906
ed	O	-1	3101906
K@@	O	-1	3101906
ing@@	O	-1	3101906
do@@	O	-1	3101906
m	O	-1	3101906
in	O	-1	3101906
19@@	O	-1	3101906
8@@	O	-1	3101906
1@@	O	-1	3101906
.	O	-1	3101906
B@@	O	-1	3101906
y	O	-1	3101906
N@@	O	-1	3101906
o@@	O	-1	3101906
ve@@	O	-1	3101906
mb@@	O	-1	3101906
er	O	-1	3101906
19@@	O	-1	3101906
8@@	O	-1	3101906
4	O	-1	3101906
the	O	-1	3101906
Com@@	O	-1	3101906
mit@@	O	-1	3101906
te@@	O	-1	3101906
e	O	-1	3101906
on	O	-1	3101906
S@@	O	-1	3101906
af@@	O	-1	3101906
ety	O	-1	3101906
of	O	-1	3101906
M@@	O	-1	3101906
ed@@	O	-1	3101906
ic@@	O	-1	3101906
in@@	O	-1	3101906
es	O	-1	3101906
had	O	-1	3101906
received	O	-1	3101906
8@@	O	-1	3101906
2	O	-1	3101906
reports	O	-1	3101906
of	O	-1	3101906
possible	O	-1	3101906
hepat@@	B-Disease	D056486	3101906
otoxicity	I-Disease	-1	3101906
associated	O	-1	3101906
with	O	-1	3101906
the	O	-1	3101906
drug@@	O	-1	3101906
,	O	-1	3101906
including	O	-1	3101906
five	O	-1	3101906
de@@	B-Disease	D003643	3101906
ath@@	I-Disease	-1	3101906
s	I-Disease	-1	3101906
.	O	-1	3101906
An	O	-1	3101906
analysis	O	-1	3101906
of	O	-1	3101906
the	O	-1	3101906
7@@	O	-1	3101906
5	O	-1	3101906
cases	O	-1	3101906
that	O	-1	3101906
had	O	-1	3101906
been	O	-1	3101906
ade@@	O	-1	3101906
qu@@	O	-1	3101906
ately	O	-1	3101906
followed	O	-1	3101906
up	O	-1	3101906
suggested	O	-1	3101906
that	O	-1	3101906
1@@	O	-1	3101906
6,	O	-1	3101906
including	O	-1	3101906
three	O	-1	3101906
de@@	B-Disease	D003643	3101906
ath@@	I-Disease	-1	3101906
s	I-Disease	-1	3101906
,	O	-1	3101906
were	O	-1	3101906
prob@@	O	-1	3101906
ably	O	-1	3101906
related	O	-1	3101906
to	O	-1	3101906
treatment	O	-1	3101906
with	O	-1	3101906
the	O	-1	3101906
drug.	O	-1	3101906
Of	O	-1	3101906
the	O	-1	3101906
re@@	O	-1	3101906
ma@@	O	-1	3101906
ind@@	O	-1	3101906
er,	O	-1	3101906
4@@	O	-1	3101906
8	O	-1	3101906
were	O	-1	3101906
possib@@	O	-1	3101906
ly	O	-1	3101906
related	O	-1	3101906
to	O	-1	3101906
treatment,	O	-1	3101906
five	O	-1	3101906
were	O	-1	3101906
un@@	O	-1	3101906
likely	O	-1	3101906
to	O	-1	3101906
be	O	-1	3101906
so@@	O	-1	3101906
,	O	-1	3101906
and	O	-1	3101906
six	O	-1	3101906
were	O	-1	3101906
un@@	O	-1	3101906
cl@@	O	-1	3101906
assi@@	O	-1	3101906
fi@@	O	-1	3101906
able@@	O	-1	3101906
.	O	-1	3101906
The	O	-1	3101906
mean	O	-1	3101906
age	O	-1	3101906
of	O	-1	3101906
patients	O	-1	3101906
in	O	-1	3101906
the	O	-1	3101906
16	O	-1	3101906
prob@@	O	-1	3101906
able	O	-1	3101906
cases	O	-1	3101906
was	O	-1	3101906
5@@	O	-1	3101906
7.@@	O	-1	3101906
9@@	O	-1	3101906
,	O	-1	3101906
with	O	-1	3101906
hepat@@	B-Disease	D056486	3101906
otoxicity	I-Disease	-1	3101906
being	O	-1	3101906
more	O	-1	3101906
common	O	-1	3101906
in	O	-1	3101906
wom@@	O	-1	3101906
en@@	O	-1	3101906
.	O	-1	3101906
The	O	-1	3101906
average	O	-1	3101906
duration	O	-1	3101906
of	O	-1	3101906
treatment	O	-1	3101906
before	O	-1	3101906
the	O	-1	3101906
onset	O	-1	3101906
of	O	-1	3101906
j@@	B-Disease	D007565	3101906
a@@	I-Disease	-1	3101906
un@@	I-Disease	-1	3101906
dic@@	I-Disease	-1	3101906
e	I-Disease	-1	3101906
was	O	-1	3101906
6@@	O	-1	3101906
1	O	-1	3101906
days.	O	-1	3101906
N@@	O	-1	3101906
one	O	-1	3101906
of	O	-1	3101906
these	O	-1	3101906
well	O	-1	3101906
val@@	O	-1	3101906
id@@	O	-1	3101906
ated	O	-1	3101906
cases	O	-1	3101906
occurred	O	-1	3101906
within	O	-1	3101906
the	O	-1	3101906
first	O	-1	3101906
10	O	-1	3101906
days	O	-1	3101906
after	O	-1	3101906
treatment.	O	-1	3101906
The	O	-1	3101906
results	O	-1	3101906
of	O	-1	3101906
serum	O	-1	3101906
liver	O	-1	3101906
function	O	-1	3101906
tests	O	-1	3101906
suggested	O	-1	3101906
hepat@@	B-Disease	D056486	3101906
oc@@	I-Disease	-1	3101906
ell@@	I-Disease	-1	3101906
ular	I-Disease	-1	3101906
injury	I-Disease	-1	3101906
in	O	-1	3101906
10	O	-1	3101906
(6@@	O	-1	3101906
3@@	O	-1	3101906
%@@	O	-1	3101906
);	O	-1	3101906
the	O	-1	3101906
res@@	O	-1	3101906
t	O	-1	3101906
showed	O	-1	3101906
a	O	-1	3101906
mi@@	O	-1	3101906
x@@	O	-1	3101906
ed	O	-1	3101906
pat@@	O	-1	3101906
tern@@	O	-1	3101906
.	O	-1	3101906
In	O	-1	3101906
contrast@@	O	-1	3101906
,	O	-1	3101906
the	O	-1	3101906
results	O	-1	3101906
of	O	-1	3101906
hist@@	O	-1	3101906
ological	O	-1	3101906
examin@@	O	-1	3101906
ation	O	-1	3101906
of	O	-1	3101906
the	O	-1	3101906
liver	O	-1	3101906
often	O	-1	3101906
showed	O	-1	3101906
evidence	O	-1	3101906
of	O	-1	3101906
cholest@@	B-Disease	D002779	3101906
asis	I-Disease	-1	3101906
.	O	-1	3101906
The	O	-1	3101906
character@@	O	-1	3101906
is@@	O	-1	3101906
tics	O	-1	3101906
of	O	-1	3101906
the	O	-1	3101906
4@@	O	-1	3101906
8	O	-1	3101906
patients	O	-1	3101906
in	O	-1	3101906
the	O	-1	3101906
possible	O	-1	3101906
cases	O	-1	3101906
were	O	-1	3101906
simil@@	O	-1	3101906
ar@@	O	-1	3101906
.	O	-1	3101906
A@@	O	-1	3101906
ll@@	O	-1	3101906
ergic	O	-1	3101906
man@@	O	-1	3101906
if@@	O	-1	3101906
est@@	O	-1	3101906
ations	O	-1	3101906
such	O	-1	3101906
as	O	-1	3101906
r@@	B-Disease	D005076	3101906
as@@	I-Disease	-1	3101906
h	I-Disease	-1	3101906
and	O	-1	3101906
e@@	B-Disease	D004802	3101906
os@@	I-Disease	-1	3101906
in@@	I-Disease	-1	3101906
oph@@	I-Disease	-1	3101906
il@@	I-Disease	-1	3101906
ia	I-Disease	-1	3101906
were	O	-1	3101906
ra@@	O	-1	3101906
re.	O	-1	3101906
He@@	B-Disease	D056486	3101906
pati@@	I-Disease	-1	3101906
tis	I-Disease	-1	3101906
was	O	-1	3101906
us@@	O	-1	3101906
ually	O	-1	3101906
reversible	O	-1	3101906
when	O	-1	3101906
treatment	O	-1	3101906
was	O	-1	3101906
sto@@	O	-1	3101906
pp@@	O	-1	3101906
ed,	O	-1	3101906
with	O	-1	3101906
the	O	-1	3101906
results	O	-1	3101906
of	O	-1	3101906
liver	O	-1	3101906
function	O	-1	3101906
tests	O	-1	3101906
retur@@	O	-1	3101906
ning	O	-1	3101906
to	O	-1	3101906
normal	O	-1	3101906
after	O	-1	3101906
an	O	-1	3101906
average	O	-1	3101906
of	O	-1	3101906
3.@@	O	-1	3101906
1	O	-1	3101906
months.	O	-1	3101906
In	O	-1	3101906
two	O	-1	3101906
of	O	-1	3101906
the	O	-1	3101906
three	O	-1	3101906
de@@	B-Disease	D003643	3101906
ath@@	I-Disease	-1	3101906
s	I-Disease	-1	3101906
prob@@	O	-1	3101906
ably	O	-1	3101906
associated	O	-1	3101906
with	O	-1	3101906
ke@@	B-Chemical	D007654	3101906
to@@	I-Chemical	-1	3101906
con@@	I-Chemical	-1	3101906
azole	I-Chemical	-1	3101906
treatment	O	-1	3101906
the	O	-1	3101906
drug	O	-1	3101906
had	O	-1	3101906
been	O	-1	3101906
continu@@	O	-1	3101906
ed	O	-1	3101906
after	O	-1	3101906
the	O	-1	3101906
onset	O	-1	3101906
of	O	-1	3101906
j@@	B-Disease	D007565	3101906
a@@	I-Disease	-1	3101906
un@@	I-Disease	-1	3101906
dic@@	I-Disease	-1	3101906
e	I-Disease	-1	3101906
and	O	-1	3101906
other	O	-1	3101906
symptoms	O	-1	3101906
of	O	-1	3101906
hepatitis	B-Disease	D056486	3101906
.	O	-1	3101906
Clin@@	O	-1	3101906
ical	O	-1	3101906
and	O	-1	3101906
bio@@	O	-1	3101906
chemical	O	-1	3101906
monit@@	O	-1	3101906
or@@	O	-1	3101906
ing	O	-1	3101906
at	O	-1	3101906
reg@@	O	-1	3101906
ular	O	-1	3101906
interv@@	O	-1	3101906
als	O	-1	3101906
for	O	-1	3101906
evidence	O	-1	3101906
of	O	-1	3101906
hepatitis	B-Disease	D056486	3101906
is	O	-1	3101906
adv@@	O	-1	3101906
is@@	O	-1	3101906
ed	O	-1	3101906
during	O	-1	3101906
lon@@	O	-1	3101906
g	O	-1	3101906
term	O	-1	3101906
treatment	O	-1	3101906
with	O	-1	3101906
ke@@	B-Chemical	D007654	3101906
to@@	I-Chemical	-1	3101906
con@@	I-Chemical	-1	3101906
azole	I-Chemical	-1	3101906
to	O	-1	3101906
prev@@	O	-1	3101906
ent	O	-1	3101906
possible	O	-1	3101906
seri@@	O	-1	3101906
ous	O	-1	3101906
hepatic	B-Disease	D056486	3101906
injury	I-Disease	-1	3101906
.	O	-1	3101906

Com@@	O	-1	9088814
bin@@	O	-1	9088814
ed	O	-1	9088814
effects	O	-1	9088814
of	O	-1	9088814
prolonged	O	-1	9088814
pro@@	B-Chemical	D000527	9088814
st@@	I-Chemical	-1	9088814
ag@@	I-Chemical	-1	9088814
l@@	I-Chemical	-1	9088814
and@@	I-Chemical	-1	9088814
in	I-Chemical	-1	9088814
E@@	I-Chemical	-1	9088814
1	I-Chemical	-1	9088814
-induced	O	-1	9088814
hypotension	B-Disease	D007022	9088814
and	O	-1	9088814
haem@@	B-Disease	D020141	9088814
odi@@	I-Disease	-1	9088814
lu@@	I-Disease	-1	9088814
tion	I-Disease	-1	9088814
on	O	-1	9088814
human	O	-1	9088814
hepatic	O	-1	9088814
func@@	O	-1	9088814
tion.	O	-1	9088814
Com@@	O	-1	9088814
bin@@	O	-1	9088814
ed	O	-1	9088814
effects	O	-1	9088814
of	O	-1	9088814
prolonged	O	-1	9088814
pro@@	B-Chemical	D000527	9088814
st@@	I-Chemical	-1	9088814
ag@@	I-Chemical	-1	9088814
l@@	I-Chemical	-1	9088814
and@@	I-Chemical	-1	9088814
in	I-Chemical	-1	9088814
E@@	I-Chemical	-1	9088814
1	I-Chemical	-1	9088814
(	O	-1	9088814
PG@@	B-Chemical	D000527	9088814
E@@	I-Chemical	-1	9088814
1	I-Chemical	-1	9088814
)@@	O	-1	9088814
-induced	O	-1	9088814
hypotension	B-Disease	D007022	9088814
and	O	-1	9088814
haem@@	B-Disease	D020141	9088814
odi@@	I-Disease	-1	9088814
lu@@	I-Disease	-1	9088814
tion	I-Disease	-1	9088814
on	O	-1	9088814
hepatic	O	-1	9088814
function	O	-1	9088814
were	O	-1	9088814
studied	O	-1	9088814
in	O	-1	9088814
30	O	-1	9088814
patients	O	-1	9088814
under@@	O	-1	9088814
go@@	O	-1	9088814
ing	O	-1	9088814
hi@@	O	-1	9088814
p	O	-1	9088814
surger@@	O	-1	9088814
y.	O	-1	9088814
The	O	-1	9088814
patients	O	-1	9088814
were	O	-1	9088814
random@@	O	-1	9088814
ly	O	-1	9088814
al@@	O	-1	9088814
loc@@	O	-1	9088814
ated	O	-1	9088814
to	O	-1	9088814
one	O	-1	9088814
of	O	-1	9088814
three	O	-1	9088814
group@@	O	-1	9088814
s;	O	-1	9088814
those	O	-1	9088814
in	O	-1	9088814
group	O	-1	9088814
A	O	-1	9088814
(n	O	-1	9088814
=	O	-1	9088814
10@@	O	-1	9088814
)	O	-1	9088814
were	O	-1	9088814
subj@@	O	-1	9088814
ected	O	-1	9088814
to	O	-1	9088814
controlled	O	-1	9088814
hypotension	B-Disease	D007022	9088814
al@@	O	-1	9088814
one,	O	-1	9088814
those	O	-1	9088814
in	O	-1	9088814
group	O	-1	9088814
B	O	-1	9088814
(n	O	-1	9088814
=	O	-1	9088814
10@@	O	-1	9088814
)	O	-1	9088814
to	O	-1	9088814
haem@@	B-Disease	D020141	9088814
odi@@	I-Disease	-1	9088814
lu@@	I-Disease	-1	9088814
tion	I-Disease	-1	9088814
alone	O	-1	9088814
and	O	-1	9088814
those	O	-1	9088814
in	O	-1	9088814
group	O	-1	9088814
C	O	-1	9088814
(n	O	-1	9088814
=	O	-1	9088814
10@@	O	-1	9088814
)	O	-1	9088814
to	O	-1	9088814
both	O	-1	9088814
controlled	O	-1	9088814
hypotension	B-Disease	D007022	9088814
and	O	-1	9088814
haem@@	B-Disease	D020141	9088814
odi@@	I-Disease	-1	9088814
lu@@	I-Disease	-1	9088814
tion	I-Disease	-1	9088814
.	O	-1	9088814
H@@	B-Disease	D020141	9088814
a@@	I-Disease	-1	9088814
em@@	I-Disease	-1	9088814
odi@@	I-Disease	-1	9088814
lu@@	I-Disease	-1	9088814
tion	I-Disease	-1	9088814
in	O	-1	9088814
groups	O	-1	9088814
B	O	-1	9088814
and	O	-1	9088814
C	O	-1	9088814
was	O	-1	9088814
produced	O	-1	9088814
by	O	-1	9088814
withdraw@@	O	-1	9088814
ing	O	-1	9088814
appro@@	O	-1	9088814
xim@@	O	-1	9088814
ately	O	-1	9088814
10@@	O	-1	9088814
00	O	-1	9088814
m@@	O	-1	9088814
L	O	-1	9088814
of	O	-1	9088814
blood	O	-1	9088814
and	O	-1	9088814
re@@	O	-1	9088814
pl@@	O	-1	9088814
ac@@	O	-1	9088814
ing	O	-1	9088814
it	O	-1	9088814
with	O	-1	9088814
the	O	-1	9088814
same	O	-1	9088814
amoun@@	O	-1	9088814
t	O	-1	9088814
of	O	-1	9088814
de@@	B-Chemical	D003911	9088814
x@@	I-Chemical	-1	9088814
tra@@	I-Chemical	-1	9088814
n	I-Chemical	-1	9088814
sol@@	O	-1	9088814
u@@	O	-1	9088814
tion,	O	-1	9088814
and	O	-1	9088814
f@@	O	-1	9088814
inal	O	-1	9088814
haem@@	O	-1	9088814
at@@	O	-1	9088814
oc@@	O	-1	9088814
ri@@	O	-1	9088814
t	O	-1	9088814
values	O	-1	9088814
were	O	-1	9088814
21	O	-1	9088814
or	O	-1	9088814
2@@	O	-1	9088814
2@@	O	-1	9088814
%.	O	-1	9088814
C@@	O	-1	9088814
ont@@	O	-1	9088814
ro@@	O	-1	9088814
lled	O	-1	9088814
hypotension	B-Disease	D007022	9088814
in	O	-1	9088814
groups	O	-1	9088814
A	O	-1	9088814
and	O	-1	9088814
C	O	-1	9088814
was	O	-1	9088814
induced	O	-1	9088814
with	O	-1	9088814
PG@@	B-Chemical	D000527	9088814
E@@	I-Chemical	-1	9088814
1	I-Chemical	-1	9088814
to	O	-1	9088814
maint@@	O	-1	9088814
ain	O	-1	9088814
mean	O	-1	9088814
arterial	O	-1	9088814
blood	O	-1	9088814
pressure	O	-1	9088814
at	O	-1	9088814
5@@	O	-1	9088814
5	O	-1	9088814
mm@@	O	-1	9088814
H@@	O	-1	9088814
g	O	-1	9088814
for	O	-1	9088814
18@@	O	-1	9088814
0	O	-1	9088814
min@@	O	-1	9088814
.	O	-1	9088814
M@@	O	-1	9088814
e@@	O	-1	9088814
as@@	O	-1	9088814
ure@@	O	-1	9088814
ments	O	-1	9088814
included	O	-1	9088814
arterial	O	-1	9088814
k@@	O	-1	9088814
et@@	O	-1	9088814
one	O	-1	9088814
body	O	-1	9088814
rati@@	O	-1	9088814
o	O	-1	9088814
(A@@	O	-1	9088814
K@@	O	-1	9088814
B@@	O	-1	9088814
R@@	O	-1	9088814
,	O	-1	9088814
ace@@	B-Chemical	C016635	9088814
to@@	I-Chemical	-1	9088814
-@@	I-Chemical	-1	9088814
acet@@	I-Chemical	-1	9088814
ate	I-Chemical	-1	9088814
/	O	-1	9088814
3-@@	B-Chemical	D020155	9088814
hydrox@@	I-Chemical	-1	9088814
y@@	I-Chemical	-1	9088814
but@@	I-Chemical	-1	9088814
y@@	I-Chemical	-1	9088814
rate	I-Chemical	-1	9088814
)	O	-1	9088814
and	O	-1	9088814
clinical	O	-1	9088814
hepatic	O	-1	9088814
function	O	-1	9088814
par@@	O	-1	9088814
ame@@	O	-1	9088814
ter@@	O	-1	9088814
s.	O	-1	9088814
A@@	O	-1	9088814
K@@	O	-1	9088814
B@@	O	-1	9088814
R	O	-1	9088814
and	O	-1	9088814
bio@@	O	-1	9088814
log@@	O	-1	9088814
ical	O	-1	9088814
hepatic	O	-1	9088814
function	O	-1	9088814
tests	O	-1	9088814
showed	O	-1	9088814
no	O	-1	9088814
change	O	-1	9088814
throu@@	O	-1	9088814
gh@@	O	-1	9088814
out	O	-1	9088814
the	O	-1	9088814
time	O	-1	9088814
course	O	-1	9088814
in	O	-1	9088814
groups	O	-1	9088814
A	O	-1	9088814
and	O	-1	9088814
B@@	O	-1	9088814
.	O	-1	9088814
In	O	-1	9088814
group	O	-1	9088814
C@@	O	-1	9088814
,	O	-1	9088814
A@@	O	-1	9088814
K@@	O	-1	9088814
B@@	O	-1	9088814
R	O	-1	9088814
showed	O	-1	9088814
a	O	-1	9088814
significant	O	-1	9088814
decrease	O	-1	9088814
at	O	-1	9088814
1@@	O	-1	9088814
20	O	-1	9088814
min	O	-1	9088814
(-@@	O	-1	9088814
4@@	O	-1	9088814
0@@	O	-1	9088814
%)	O	-1	9088814
and	O	-1	9088814
at	O	-1	9088814
18@@	O	-1	9088814
0	O	-1	9088814
min	O	-1	9088814
(-@@	O	-1	9088814
4@@	O	-1	9088814
9@@	O	-1	9088814
%)	O	-1	9088814
after	O	-1	9088814
the	O	-1	9088814
star@@	O	-1	9088814
t	O	-1	9088814
of	O	-1	9088814
hypotension	B-Disease	D007022	9088814
and	O	-1	9088814
at	O	-1	9088814
60	O	-1	9088814
min	O	-1	9088814
(-@@	O	-1	9088814
3@@	O	-1	9088814
2@@	O	-1	9088814
%)	O	-1	9088814
after	O	-1	9088814
recovery	O	-1	9088814
of	O	-1	9088814
norm@@	O	-1	9088814
oten@@	O	-1	9088814
sion,	O	-1	9088814
and	O	-1	9088814
S@@	O	-1	9088814
G@@	O	-1	9088814
O@@	O	-1	9088814
T@@	O	-1	9088814
,	O	-1	9088814
S@@	O	-1	9088814
G@@	O	-1	9088814
P@@	O	-1	9088814
T@@	O	-1	9088814
,	O	-1	9088814
L@@	O	-1	9088814
D@@	O	-1	9088814
H	O	-1	9088814
and	O	-1	9088814
total	O	-1	9088814
bil@@	B-Chemical	D001663	9088814
i@@	I-Chemical	-1	9088814
ru@@	I-Chemical	-1	9088814
bin	I-Chemical	-1	9088814
showed	O	-1	9088814
significant	O	-1	9088814
increases	O	-1	9088814
after	O	-1	9088814
o@@	O	-1	9088814
per@@	O	-1	9088814
ation.	O	-1	9088814
The	O	-1	9088814
results	O	-1	9088814
suggest	O	-1	9088814
that	O	-1	9088814
a	O	-1	9088814
prolonged	O	-1	9088814
combination	O	-1	9088814
of	O	-1	9088814
more	O	-1	9088814
than	O	-1	9088814
1@@	O	-1	9088814
20	O	-1	9088814
min	O	-1	9088814
of	O	-1	9088814
PG@@	B-Chemical	D000527	9088814
E@@	I-Chemical	-1	9088814
1	I-Chemical	-1	9088814
-induced	O	-1	9088814
hypotension	B-Disease	D007022	9088814
and	O	-1	9088814
moder@@	O	-1	9088814
ate	O	-1	9088814
haem@@	B-Disease	D020141	9088814
odi@@	I-Disease	-1	9088814
lu@@	I-Disease	-1	9088814
tion	I-Disease	-1	9088814
wo@@	O	-1	9088814
uld	O	-1	9088814
cause	O	-1	9088814
impair@@	B-Disease	D008107	9088814
ment	I-Disease	-1	9088814
of	I-Disease	-1	9088814
hepatic	I-Disease	-1	9088814
function	I-Disease	-1	9088814
.	O	-1	9088814

L@@	B-Chemical	D007980	20880751
evo@@	I-Chemical	-1	20880751
dopa	I-Chemical	-1	20880751
-induced	O	-1	20880751
dyskine@@	B-Disease	D004409	20880751
si@@	I-Disease	-1	20880751
as	I-Disease	-1	20880751
in	O	-1	20880751
patients	O	-1	20880751
with	O	-1	20880751
Parkinson's	B-Disease	D010300	20880751
disease	I-Disease	-1	20880751
:	O	-1	20880751
f@@	O	-1	20880751
ill@@	O	-1	20880751
ing	O	-1	20880751
the	O	-1	20880751
ben@@	O	-1	20880751
ch@@	O	-1	20880751
-@@	O	-1	20880751
to@@	O	-1	20880751
-@@	O	-1	20880751
be@@	O	-1	20880751
d@@	O	-1	20880751
side	O	-1	20880751
g@@	O	-1	20880751
ap@@	O	-1	20880751
.	O	-1	20880751
L@@	B-Chemical	D007980	20880751
evo@@	I-Chemical	-1	20880751
dopa	I-Chemical	-1	20880751
is	O	-1	20880751
the	O	-1	20880751
most	O	-1	20880751
effective	O	-1	20880751
drug	O	-1	20880751
for	O	-1	20880751
the	O	-1	20880751
treatment	O	-1	20880751
of	O	-1	20880751
Parkinson's	B-Disease	D010300	20880751
disease	I-Disease	-1	20880751
.	O	-1	20880751
However,	O	-1	20880751
the	O	-1	20880751
long-term	O	-1	20880751
use	O	-1	20880751
of	O	-1	20880751
this	O	-1	20880751
dopamine	B-Chemical	D004298	20880751
pre@@	O	-1	20880751
cur@@	O	-1	20880751
s@@	O	-1	20880751
or	O	-1	20880751
is	O	-1	20880751
complic@@	O	-1	20880751
ated	O	-1	20880751
by	O	-1	20880751
high@@	O	-1	20880751
ly	O	-1	20880751
dis@@	O	-1	20880751
abl@@	O	-1	20880751
ing	O	-1	20880751
f@@	O	-1	20880751
l@@	O	-1	20880751
uc@@	O	-1	20880751
tu@@	O	-1	20880751
ations	O	-1	20880751
and	O	-1	20880751
dyskine@@	B-Disease	D004409	20880751
si@@	I-Disease	-1	20880751
as	I-Disease	-1	20880751
.	O	-1	20880751
Although	O	-1	20880751
pre@@	O	-1	20880751
clinical	O	-1	20880751
and	O	-1	20880751
clinical	O	-1	20880751
findings	O	-1	20880751
suggest	O	-1	20880751
pul@@	O	-1	20880751
s@@	O	-1	20880751
ati@@	O	-1	20880751
le	O	-1	20880751
stimulation	O	-1	20880751
of	O	-1	20880751
stri@@	O	-1	20880751
atal	O	-1	20880751
post@@	O	-1	20880751
syn@@	O	-1	20880751
ap@@	O	-1	20880751
tic	O	-1	20880751
receptors	O	-1	20880751
as	O	-1	20880751
a	O	-1	20880751
ke@@	O	-1	20880751
y	O	-1	20880751
mechanism	O	-1	20880751
underlying	O	-1	20880751
levo@@	B-Chemical	D007980	20880751
dopa	I-Chemical	-1	20880751
-induced	O	-1	20880751
dyskine@@	B-Disease	D004409	20880751
si@@	I-Disease	-1	20880751
as	I-Disease	-1	20880751
,	O	-1	20880751
their	O	-1	20880751
path@@	O	-1	20880751
o@@	O	-1	20880751
genesis	O	-1	20880751
is	O	-1	20880751
sti@@	O	-1	20880751
ll	O	-1	20880751
unc@@	O	-1	20880751
lear@@	O	-1	20880751
.	O	-1	20880751
In	O	-1	20880751
rec@@	O	-1	20880751
ent	O	-1	20880751
year@@	O	-1	20880751
s,	O	-1	20880751
evidence	O	-1	20880751
from	O	-1	20880751
anim@@	O	-1	20880751
al	O	-1	20880751
models	O	-1	20880751
of	O	-1	20880751
Parkinson's	B-Disease	D010300	20880751
disease	I-Disease	-1	20880751
has	O	-1	20880751
pro@@	O	-1	20880751
vid@@	O	-1	20880751
ed	O	-1	20880751
important	O	-1	20880751
inf@@	O	-1	20880751
orm@@	O	-1	20880751
ation	O	-1	20880751
to	O	-1	20880751
under@@	O	-1	20880751
st@@	O	-1	20880751
and	O	-1	20880751
the	O	-1	20880751
effect	O	-1	20880751
of	O	-1	20880751
specific	O	-1	20880751
receptor	O	-1	20880751
and	O	-1	20880751
post@@	O	-1	20880751
-@@	O	-1	20880751
receptor	O	-1	20880751
mol@@	O	-1	20880751
ec@@	O	-1	20880751
ular	O	-1	20880751
mechanisms	O	-1	20880751
underlying	O	-1	20880751
the	O	-1	20880751
development	O	-1	20880751
of	O	-1	20880751
dyskine@@	B-Disease	D004409	20880751
tic	I-Disease	-1	20880751
mo@@	I-Disease	-1	20880751
ve@@	I-Disease	-1	20880751
ments	I-Disease	-1	20880751
.	O	-1	20880751
Rec@@	O	-1	20880751
ent	O	-1	20880751
pre@@	O	-1	20880751
clinical	O	-1	20880751
and	O	-1	20880751
clinical	O	-1	20880751
data	O	-1	20880751
from	O	-1	20880751
pro@@	O	-1	20880751
mis@@	O	-1	20880751
ing	O	-1	20880751
lin@@	O	-1	20880751
es	O	-1	20880751
of	O	-1	20880751
re@@	O	-1	20880751
se@@	O	-1	20880751
arc@@	O	-1	20880751
h	O	-1	20880751
foc@@	O	-1	20880751
us	O	-1	20880751
on	O	-1	20880751
the	O	-1	20880751
differen@@	O	-1	20880751
tial	O	-1	20880751
role	O	-1	20880751
of	O	-1	20880751
pres@@	O	-1	20880751
yn@@	O	-1	20880751
ap@@	O	-1	20880751
tic	O	-1	20880751
versus	O	-1	20880751
post@@	O	-1	20880751
syn@@	O	-1	20880751
ap@@	O	-1	20880751
tic	O	-1	20880751
mechanis@@	O	-1	20880751
m@@	O	-1	20880751
s,	O	-1	20880751
dopamine	B-Chemical	D004298	20880751
receptor	O	-1	20880751
sub@@	O	-1	20880751
typ@@	O	-1	20880751
es,	O	-1	20880751
i@@	O	-1	20880751
on@@	O	-1	20880751
ot@@	O	-1	20880751
ro@@	O	-1	20880751
p@@	O	-1	20880751
ic	O	-1	20880751
and	O	-1	20880751
met@@	O	-1	20880751
ab@@	O	-1	20880751
ot@@	O	-1	20880751
ro@@	O	-1	20880751
p@@	O	-1	20880751
ic	O	-1	20880751
glutamate	B-Chemical	D018698	20880751
receptor@@	O	-1	20880751
s,	O	-1	20880751
and	O	-1	20880751
non-@@	O	-1	20880751
dop@@	O	-1	20880751
aminergic	O	-1	20880751
neuro@@	O	-1	20880751
trans@@	O	-1	20880751
mit@@	O	-1	20880751
ter	O	-1	20880751
system@@	O	-1	20880751
s	O	-1	20880751
in	O	-1	20880751
the	O	-1	20880751
path@@	O	-1	20880751
oph@@	O	-1	20880751
ysi@@	O	-1	20880751
ology	O	-1	20880751
of	O	-1	20880751
levo@@	B-Chemical	D007980	20880751
dopa	I-Chemical	-1	20880751
-induced	O	-1	20880751
dyskine@@	B-Disease	D004409	20880751
si@@	I-Disease	-1	20880751
as	I-Disease	-1	20880751
.	O	-1	20880751

Pre@@	O	-1	20080419
ven@@	O	-1	20080419
tion	O	-1	20080419
of	O	-1	20080419
seizures	B-Disease	D012640	20080419
and	O	-1	20080419
re@@	O	-1	20080419
org@@	O	-1	20080419
an@@	O	-1	20080419
ization	O	-1	20080419
of	O	-1	20080419
hippocamp@@	O	-1	20080419
al	O	-1	20080419
func@@	O	-1	20080419
tions	O	-1	20080419
by	O	-1	20080419
transplant@@	O	-1	20080419
ation	O	-1	20080419
of	O	-1	20080419
b@@	O	-1	20080419
one	O	-1	20080419
m@@	O	-1	20080419
ar@@	O	-1	20080419
ro@@	O	-1	20080419
w	O	-1	20080419
cells	O	-1	20080419
in	O	-1	20080419
the	O	-1	20080419
acute	O	-1	20080419
phase	O	-1	20080419
of	O	-1	20080419
experimental	O	-1	20080419
epilep@@	B-Disease	D004827	20080419
sy	I-Disease	-1	20080419
.	O	-1	20080419
In	O	-1	20080419
this	O	-1	20080419
study,	O	-1	20080419
we	O	-1	20080419
investigated	O	-1	20080419
the	O	-1	20080419
therapeutic	O	-1	20080419
potential	O	-1	20080419
of	O	-1	20080419
b@@	O	-1	20080419
one	O	-1	20080419
m@@	O	-1	20080419
ar@@	O	-1	20080419
ro@@	O	-1	20080419
w	O	-1	20080419
mon@@	O	-1	20080419
on@@	O	-1	20080419
ucle@@	O	-1	20080419
ar	O	-1	20080419
cells	O	-1	20080419
(B@@	O	-1	20080419
M@@	O	-1	20080419
C@@	O	-1	20080419
s)	O	-1	20080419
in	O	-1	20080419
a	O	-1	20080419
model	O	-1	20080419
of	O	-1	20080419
epilep@@	B-Disease	D004827	20080419
sy	I-Disease	-1	20080419
induced	O	-1	20080419
by	O	-1	20080419
pilocar@@	B-Chemical	D010862	20080419
pine	I-Chemical	-1	20080419
in	O	-1	20080419
rats.	O	-1	20080419
B@@	O	-1	20080419
M@@	O	-1	20080419
C@@	O	-1	20080419
s	O	-1	20080419
obtained	O	-1	20080419
from	O	-1	20080419
gre@@	O	-1	20080419
en	O	-1	20080419
fluo@@	O	-1	20080419
res@@	O	-1	20080419
c@@	O	-1	20080419
ent	O	-1	20080419
protein	O	-1	20080419
(@@	O	-1	20080419
GF@@	O	-1	20080419
P)	O	-1	20080419
trans@@	O	-1	20080419
genic	O	-1	20080419
mice	O	-1	20080419
or	O	-1	20080419
rats	O	-1	20080419
were	O	-1	20080419
transplant@@	O	-1	20080419
ed	O	-1	20080419
intra@@	O	-1	20080419
ven@@	O	-1	20080419
ously	O	-1	20080419
after	O	-1	20080419
induction	O	-1	20080419
of	O	-1	20080419
status	B-Disease	D013226	20080419
epilep@@	I-Disease	-1	20080419
tic@@	I-Disease	-1	20080419
us	I-Disease	-1	20080419
(	O	-1	20080419
S@@	B-Disease	D013226	20080419
E	I-Disease	-1	20080419
).	O	-1	20080419
S@@	B-Disease	-1	20080419
p@@	I-Disease	-1	20080419
ont@@	I-Disease	-1	20080419
aneous	I-Disease	-1	20080419
recur@@	I-Disease	-1	20080419
rent	I-Disease	-1	20080419
seizures	I-Disease	-1	20080419
(	O	-1	20080419
SR@@	B-Disease	-1	20080419
S	I-Disease	-1	20080419
)	O	-1	20080419
were	O	-1	20080419
monit@@	O	-1	20080419
o@@	O	-1	20080419
red	O	-1	20080419
using	O	-1	20080419
R@@	O	-1	20080419
ac@@	O	-1	20080419
ine@@	O	-1	20080419
's	O	-1	20080419
seizure	B-Disease	D012640	20080419
severity	O	-1	20080419
s@@	O	-1	20080419
cal@@	O	-1	20080419
e.	O	-1	20080419
All	O	-1	20080419
of	O	-1	20080419
the	O	-1	20080419
rats	O	-1	20080419
in	O	-1	20080419
the	O	-1	20080419
sal@@	O	-1	20080419
ine-@@	O	-1	20080419
treated	O	-1	20080419
epileptic	B-Disease	D004827	20080419
control	O	-1	20080419
group	O	-1	20080419
developed	O	-1	20080419
SR@@	B-Disease	-1	20080419
S	I-Disease	-1	20080419
,	O	-1	20080419
whereas	O	-1	20080419
n@@	O	-1	20080419
one	O	-1	20080419
of	O	-1	20080419
the	O	-1	20080419
B@@	O	-1	20080419
M@@	O	-1	20080419
C@@	O	-1	20080419
-treated	O	-1	20080419
epileptic	B-Disease	D004827	20080419
animals	O	-1	20080419
had	O	-1	20080419
seizures	B-Disease	D012640	20080419
in	O	-1	20080419
the	O	-1	20080419
sh@@	O	-1	20080419
ort	O	-1	20080419
term	O	-1	20080419
(1@@	O	-1	20080419
5	O	-1	20080419
days	O	-1	20080419
after	O	-1	20080419
transplant@@	O	-1	20080419
ation@@	O	-1	20080419
),	O	-1	20080419
reg@@	O	-1	20080419
ar@@	O	-1	20080419
d@@	O	-1	20080419
less	O	-1	20080419
of	O	-1	20080419
the	O	-1	20080419
B@@	O	-1	20080419
M@@	O	-1	20080419
C	O	-1	20080419
so@@	O	-1	20080419
ur@@	O	-1	20080419
ce@@	O	-1	20080419
.	O	-1	20080419
O@@	O	-1	20080419
ver	O	-1	20080419
the	O	-1	20080419
long-term	O	-1	20080419
chronic	O	-1	20080419
phase	O	-1	20080419
(1@@	O	-1	20080419
20	O	-1	20080419
days	O	-1	20080419
after	O	-1	20080419
transplant@@	O	-1	20080419
ation@@	O	-1	20080419
),	O	-1	20080419
only	O	-1	20080419
2@@	O	-1	20080419
5%	O	-1	20080419
of	O	-1	20080419
B@@	O	-1	20080419
M@@	O	-1	20080419
C@@	O	-1	20080419
-treated	O	-1	20080419
epileptic	B-Disease	D004827	20080419
animals	O	-1	20080419
had	O	-1	20080419
seizures	B-Disease	D012640	20080419
,	O	-1	20080419
but	O	-1	20080419
with	O	-1	20080419
a	O	-1	20080419
lower	O	-1	20080419
frequency	O	-1	20080419
and	O	-1	20080419
duration	O	-1	20080419
compared	O	-1	20080419
to	O	-1	20080419
the	O	-1	20080419
epileptic	B-Disease	D004827	20080419
control	O	-1	20080419
group.	O	-1	20080419
The	O	-1	20080419
d@@	O	-1	20080419
ensity	O	-1	20080419
of	O	-1	20080419
hippocamp@@	O	-1	20080419
al	O	-1	20080419
neuron@@	O	-1	20080419
s	O	-1	20080419
in	O	-1	20080419
the	O	-1	20080419
bra@@	O	-1	20080419
ins	O	-1	20080419
of	O	-1	20080419
animals	O	-1	20080419
treated	O	-1	20080419
with	O	-1	20080419
B@@	O	-1	20080419
M@@	O	-1	20080419
C@@	O	-1	20080419
s	O	-1	20080419
was	O	-1	20080419
mark@@	O	-1	20080419
ed@@	O	-1	20080419
ly	O	-1	20080419
pres@@	O	-1	20080419
er@@	O	-1	20080419
ved.	O	-1	20080419
A@@	O	-1	20080419
t	O	-1	20080419
hippocamp@@	O	-1	20080419
al	O	-1	20080419
S@@	O	-1	20080419
ch@@	O	-1	20080419
a@@	O	-1	20080419
eff@@	O	-1	20080419
er	O	-1	20080419
coll@@	O	-1	20080419
at@@	O	-1	20080419
er@@	O	-1	20080419
al@@	O	-1	20080419
-@@	O	-1	20080419
CA@@	O	-1	20080419
1	O	-1	20080419
syn@@	O	-1	20080419
ap@@	O	-1	20080419
s@@	O	-1	20080419
es,	O	-1	20080419
long-term	O	-1	20080419
potenti@@	O	-1	20080419
ation	O	-1	20080419
was	O	-1	20080419
pres@@	O	-1	20080419
er@@	O	-1	20080419
ved	O	-1	20080419
in	O	-1	20080419
B@@	O	-1	20080419
M@@	O	-1	20080419
C@@	O	-1	20080419
-@@	O	-1	20080419
transplant@@	O	-1	20080419
ed	O	-1	20080419
rats	O	-1	20080419
compared	O	-1	20080419
to	O	-1	20080419
epileptic	B-Disease	D004827	20080419
controls.	O	-1	20080419
The	O	-1	20080419
d@@	O	-1	20080419
on@@	O	-1	20080419
or@@	O	-1	20080419
-@@	O	-1	20080419
der@@	O	-1	20080419
i@@	O	-1	20080419
ved	O	-1	20080419
GF@@	O	-1	20080419
P@@	O	-1	20080419
(@@	O	-1	20080419
+@@	O	-1	20080419
)	O	-1	20080419
cells	O	-1	20080419
were	O	-1	20080419
ra@@	O	-1	20080419
re@@	O	-1	20080419
ly	O	-1	20080419
found	O	-1	20080419
in	O	-1	20080419
the	O	-1	20080419
bra@@	O	-1	20080419
ins	O	-1	20080419
of	O	-1	20080419
transplant@@	O	-1	20080419
ed	O	-1	20080419
epileptic	B-Disease	D004827	20080419
rats.	O	-1	20080419
In	O	-1	20080419
concl@@	O	-1	20080419
u@@	O	-1	20080419
sion,	O	-1	20080419
treatment	O	-1	20080419
with	O	-1	20080419
B@@	O	-1	20080419
M@@	O	-1	20080419
C@@	O	-1	20080419
s	O	-1	20080419
can	O	-1	20080419
prev@@	O	-1	20080419
ent	O	-1	20080419
the	O	-1	20080419
development	O	-1	20080419
of	O	-1	20080419
chronic	O	-1	20080419
seizures	B-Disease	D012640	20080419
,	O	-1	20080419
re@@	O	-1	20080419
duce	O	-1	20080419
neuron@@	B-Disease	D009410	20080419
al	I-Disease	-1	20080419
loss	I-Disease	-1	20080419
,	O	-1	20080419
and	O	-1	20080419
influence	O	-1	20080419
the	O	-1	20080419
re@@	O	-1	20080419
org@@	O	-1	20080419
an@@	O	-1	20080419
ization	O	-1	20080419
of	O	-1	20080419
the	O	-1	20080419
hippocamp@@	O	-1	20080419
al	O	-1	20080419
neuron@@	O	-1	20080419
al	O	-1	20080419
ne@@	O	-1	20080419
tw@@	O	-1	20080419
or@@	O	-1	20080419
k@@	O	-1	20080419
.	O	-1	20080419

C@@	O	-1	19445921
ardi@@	O	-1	19445921
o@@	O	-1	19445921
protective	O	-1	19445921
effect	O	-1	19445921
of	O	-1	19445921
sal@@	B-Chemical	C066201	19445921
vi@@	I-Chemical	-1	19445921
an@@	I-Chemical	-1	19445921
olic	I-Chemical	-1	19445921
acid	I-Chemical	-1	19445921
A	I-Chemical	-1	19445921
on	O	-1	19445921
isoproteren@@	B-Chemical	D007545	19445921
ol	I-Chemical	-1	19445921
-induced	O	-1	19445921
myocardial	B-Disease	D009203	19445921
infarction	I-Disease	-1	19445921
in	O	-1	19445921
rats.	O	-1	19445921
The	O	-1	19445921
present	O	-1	19445921
study	O	-1	19445921
was	O	-1	19445921
de@@	O	-1	19445921
signed	O	-1	19445921
to	O	-1	19445921
evalu@@	O	-1	19445921
ate	O	-1	19445921
the	O	-1	19445921
cardio@@	O	-1	19445921
protective	O	-1	19445921
potential	O	-1	19445921
of	O	-1	19445921
sal@@	B-Chemical	C066201	19445921
vi@@	I-Chemical	-1	19445921
an@@	I-Chemical	-1	19445921
olic	I-Chemical	-1	19445921
acid	I-Chemical	-1	19445921
A	I-Chemical	-1	19445921
on	O	-1	19445921
isoproteren@@	B-Chemical	D007545	19445921
ol	I-Chemical	-1	19445921
-induced	O	-1	19445921
myocardial	B-Disease	D009203	19445921
infarction	I-Disease	-1	19445921
in	O	-1	19445921
rats.	O	-1	19445921
H@@	O	-1	19445921
em@@	O	-1	19445921
o@@	O	-1	19445921
dynam@@	O	-1	19445921
ic	O	-1	19445921
par@@	O	-1	19445921
ame@@	O	-1	19445921
ters	O	-1	19445921
and	O	-1	19445921
le@@	O	-1	19445921
ad	O	-1	19445921
II	O	-1	19445921
electro@@	O	-1	19445921
cardio@@	O	-1	19445921
gra@@	O	-1	19445921
p@@	O	-1	19445921
h	O	-1	19445921
were	O	-1	19445921
monit@@	O	-1	19445921
o@@	O	-1	19445921
red	O	-1	19445921
and	O	-1	19445921
recor@@	O	-1	19445921
ded	O	-1	19445921
continu@@	O	-1	19445921
ous@@	O	-1	19445921
ly.	O	-1	19445921
C@@	O	-1	19445921
ardi@@	O	-1	19445921
a@@	O	-1	19445921
c	O	-1	19445921
mark@@	O	-1	19445921
er	O	-1	19445921
enzym@@	O	-1	19445921
es	O	-1	19445921
and	O	-1	19445921
anti@@	O	-1	19445921
oxid@@	O	-1	19445921
ative	O	-1	19445921
par@@	O	-1	19445921
ame@@	O	-1	19445921
ters	O	-1	19445921
in	O	-1	19445921
serum	O	-1	19445921
and	O	-1	19445921
heart	O	-1	19445921
tissu@@	O	-1	19445921
es	O	-1	19445921
were	O	-1	19445921
meas@@	O	-1	19445921
ure@@	O	-1	19445921
d.	O	-1	19445921
A@@	O	-1	19445921
s@@	O	-1	19445921
s@@	O	-1	19445921
ay	O	-1	19445921
for	O	-1	19445921
mitochondrial	O	-1	19445921
respiratory	O	-1	19445921
function	O	-1	19445921
and	O	-1	19445921
histo@@	O	-1	19445921
path@@	O	-1	19445921
ological	O	-1	19445921
examin@@	O	-1	19445921
ation	O	-1	19445921
of	O	-1	19445921
heart	O	-1	19445921
tissu@@	O	-1	19445921
es	O	-1	19445921
were	O	-1	19445921
per@@	O	-1	19445921
for@@	O	-1	19445921
me@@	O	-1	19445921
d.	O	-1	19445921
I@@	B-Chemical	D007545	19445921
so@@	I-Chemical	-1	19445921
proteren@@	I-Chemical	-1	19445921
ol	I-Chemical	-1	19445921
-treated	O	-1	19445921
rats	O	-1	19445921
showed	O	-1	19445921
significant	O	-1	19445921
increases	O	-1	19445921
in	O	-1	19445921
the	O	-1	19445921
levels	O	-1	19445921
of	O	-1	19445921
l@@	B-Chemical	D019344	19445921
act@@	I-Chemical	-1	19445921
ate	I-Chemical	-1	19445921
de@@	O	-1	19445921
hydro@@	O	-1	19445921
gen@@	O	-1	19445921
ase,	O	-1	19445921
as@@	B-Chemical	D001224	19445921
part@@	I-Chemical	-1	19445921
ate	I-Chemical	-1	19445921
trans@@	O	-1	19445921
amin@@	O	-1	19445921
ase,	O	-1	19445921
creat@@	B-Chemical	D003401	19445921
ine	I-Chemical	-1	19445921
kin@@	O	-1	19445921
ase	O	-1	19445921
and	O	-1	19445921
mal@@	B-Chemical	D008315	19445921
on@@	I-Chemical	-1	19445921
di@@	I-Chemical	-1	19445921
al@@	I-Chemical	-1	19445921
de@@	I-Chemical	-1	19445921
hy@@	I-Chemical	-1	19445921
de	I-Chemical	-1	19445921
and	O	-1	19445921
significant	O	-1	19445921
decreas@@	O	-1	19445921
es	O	-1	19445921
in	O	-1	19445921
the	O	-1	19445921
ac@@	O	-1	19445921
ti@@	O	-1	19445921
vi@@	O	-1	19445921
ties	O	-1	19445921
of	O	-1	19445921
su@@	B-Chemical	D013481	19445921
per@@	I-Chemical	-1	19445921
ox@@	I-Chemical	-1	19445921
ide	I-Chemical	-1	19445921
dis@@	O	-1	19445921
mut@@	O	-1	19445921
ase,	O	-1	19445921
cat@@	O	-1	19445921
al@@	O	-1	19445921
ase	O	-1	19445921
and	O	-1	19445921
glut@@	B-Chemical	D005978	19445921
athi@@	I-Chemical	-1	19445921
one	I-Chemical	-1	19445921
per@@	O	-1	19445921
oxid@@	O	-1	19445921
ase	O	-1	19445921
in	O	-1	19445921
serum	O	-1	19445921
and	O	-1	19445921
hear@@	O	-1	19445921
t.	O	-1	19445921
These	O	-1	19445921
rats	O	-1	19445921
also	O	-1	19445921
showed	O	-1	19445921
dec@@	O	-1	19445921
lin@@	O	-1	19445921
es	O	-1	19445921
in	O	-1	19445921
left	O	-1	19445921
ventricular	O	-1	19445921
systolic	O	-1	19445921
pressu@@	O	-1	19445921
re,	O	-1	19445921
maxim@@	O	-1	19445921
um	O	-1	19445921
and	O	-1	19445921
minim@@	O	-1	19445921
um	O	-1	19445921
rate	O	-1	19445921
of	O	-1	19445921
developed	O	-1	19445921
left	O	-1	19445921
ventricular	O	-1	19445921
pressu@@	O	-1	19445921
re,	O	-1	19445921
and	O	-1	19445921
elev@@	O	-1	19445921
ation	O	-1	19445921
of	O	-1	19445921
left	O	-1	19445921
ventricular	O	-1	19445921
en@@	O	-1	19445921
d-@@	O	-1	19445921
di@@	O	-1	19445921
ast@@	O	-1	19445921
olic	O	-1	19445921
pressure	O	-1	19445921
and	O	-1	19445921
S@@	O	-1	19445921
T@@	O	-1	19445921
-@@	O	-1	19445921
seg@@	O	-1	19445921
ment.	O	-1	19445921
In	O	-1	19445921
addi@@	O	-1	19445921
tion,	O	-1	19445921
mitochondrial	O	-1	19445921
respiratory	B-Disease	D012131	19445921
dysfunction	I-Disease	-1	19445921
character@@	O	-1	19445921
ized	O	-1	19445921
by	O	-1	19445921
decreased	O	-1	19445921
respiratory	O	-1	19445921
control	O	-1	19445921
rati@@	O	-1	19445921
o	O	-1	19445921
and	O	-1	19445921
AD@@	B-Chemical	D000244	19445921
P	I-Chemical	-1	19445921
/@@	O	-1	19445921
O	O	-1	19445921
was	O	-1	19445921
observed	O	-1	19445921
in	O	-1	19445921
isoproteren@@	B-Chemical	D007545	19445921
ol	I-Chemical	-1	19445921
-treated	O	-1	19445921
rats.	O	-1	19445921
Ad@@	O	-1	19445921
minist@@	O	-1	19445921
ration	O	-1	19445921
of	O	-1	19445921
sal@@	B-Chemical	C066201	19445921
vi@@	I-Chemical	-1	19445921
an@@	I-Chemical	-1	19445921
olic	I-Chemical	-1	19445921
acid	I-Chemical	-1	19445921
A	I-Chemical	-1	19445921
for	O	-1	19445921
a	O	-1	19445921
period	O	-1	19445921
of	O	-1	19445921
8	O	-1	19445921
days	O	-1	19445921
significantly	O	-1	19445921
attenu@@	O	-1	19445921
ated	O	-1	19445921
isoproteren@@	B-Chemical	D007545	19445921
ol	I-Chemical	-1	19445921
-induced	O	-1	19445921
cardiac	B-Disease	D006331	19445921
dysfunction	I-Disease	-1	19445921
and	O	-1	19445921
myocardial	B-Disease	D009202	19445921
injury	I-Disease	-1	19445921
and	O	-1	19445921
improved	O	-1	19445921
mitochondrial	O	-1	19445921
respiratory	O	-1	19445921
func@@	O	-1	19445921
tion.	O	-1	19445921
The	O	-1	19445921
protective	O	-1	19445921
role	O	-1	19445921
of	O	-1	19445921
sal@@	B-Chemical	C066201	19445921
vi@@	I-Chemical	-1	19445921
an@@	I-Chemical	-1	19445921
olic	I-Chemical	-1	19445921
acid	I-Chemical	-1	19445921
A	I-Chemical	-1	19445921
against	O	-1	19445921
isoproteren@@	B-Chemical	D007545	19445921
ol	I-Chemical	-1	19445921
-induced	O	-1	19445921
myocardial	B-Disease	D009202	19445921
damage	I-Disease	-1	19445921
was	O	-1	19445921
further	O	-1	19445921
con@@	O	-1	19445921
fir@@	O	-1	19445921
m@@	O	-1	19445921
ed	O	-1	19445921
by	O	-1	19445921
histo@@	O	-1	19445921
path@@	O	-1	19445921
ological	O	-1	19445921
examin@@	O	-1	19445921
ation.	O	-1	19445921
The	O	-1	19445921
results	O	-1	19445921
of	O	-1	19445921
our	O	-1	19445921
study	O	-1	19445921
suggest	O	-1	19445921
that	O	-1	19445921
sal@@	B-Chemical	C066201	19445921
vi@@	I-Chemical	-1	19445921
an@@	I-Chemical	-1	19445921
olic	I-Chemical	-1	19445921
acid	I-Chemical	-1	19445921
A	I-Chemical	-1	19445921
pos@@	O	-1	19445921
s@@	O	-1	19445921
ess@@	O	-1	19445921
ing	O	-1	19445921
anti@@	O	-1	19445921
oxid@@	O	-1	19445921
ant	O	-1	19445921
activity	O	-1	19445921
has	O	-1	19445921
a	O	-1	19445921
significant	O	-1	19445921
protective	O	-1	19445921
effect	O	-1	19445921
against	O	-1	19445921
isoproteren@@	B-Chemical	D007545	19445921
ol	I-Chemical	-1	19445921
-induced	O	-1	19445921
myocardial	B-Disease	D009203	19445921
infarction	I-Disease	-1	19445921
.	O	-1	19445921

Ac@@	O	-1	18439803
ute	O	-1	18439803
effects	O	-1	18439803
of	O	-1	18439803
N@@	B-Chemical	C108761	18439803
-@@	I-Chemical	-1	18439803
(2@@	I-Chemical	-1	18439803
-@@	I-Chemical	-1	18439803
prop@@	I-Chemical	-1	18439803
yl@@	I-Chemical	-1	18439803
pent@@	I-Chemical	-1	18439803
an@@	I-Chemical	-1	18439803
o@@	I-Chemical	-1	18439803
yl@@	I-Chemical	-1	18439803
)@@	I-Chemical	-1	18439803
ure@@	I-Chemical	-1	18439803
a	I-Chemical	-1	18439803
on	O	-1	18439803
hippocamp@@	O	-1	18439803
al	O	-1	18439803
amin@@	B-Chemical	D000596	18439803
o	I-Chemical	-1	18439803
acid	I-Chemical	-1	18439803
neuro@@	O	-1	18439803
trans@@	O	-1	18439803
mit@@	O	-1	18439803
ters	O	-1	18439803
in	O	-1	18439803
pilocar@@	B-Chemical	D010862	18439803
pine	I-Chemical	-1	18439803
-induced	O	-1	18439803
seizure	B-Disease	D012640	18439803
in	O	-1	18439803
rats.	O	-1	18439803
The	O	-1	18439803
present	O	-1	18439803
study	O	-1	18439803
a@@	O	-1	18439803
im@@	O	-1	18439803
ed	O	-1	18439803
to	O	-1	18439803
investigate	O	-1	18439803
the	O	-1	18439803
anti@@	O	-1	18439803
convul@@	O	-1	18439803
s@@	O	-1	18439803
ant	O	-1	18439803
activity	O	-1	18439803
as	O	-1	18439803
well	O	-1	18439803
as	O	-1	18439803
the	O	-1	18439803
effects	O	-1	18439803
on	O	-1	18439803
the	O	-1	18439803
level	O	-1	18439803
of	O	-1	18439803
hippocamp@@	O	-1	18439803
al	O	-1	18439803
amin@@	B-Chemical	D000596	18439803
o	I-Chemical	-1	18439803
acid	I-Chemical	-1	18439803
neuro@@	O	-1	18439803
trans@@	O	-1	18439803
mit@@	O	-1	18439803
ters	O	-1	18439803
(	O	-1	18439803
glutamate	B-Chemical	D018698	18439803
,	O	-1	18439803
as@@	B-Chemical	D001224	18439803
part@@	I-Chemical	-1	18439803
ate	I-Chemical	-1	18439803
,	O	-1	18439803
glyc@@	B-Chemical	D005998	18439803
ine	I-Chemical	-1	18439803
and	O	-1	18439803
G@@	B-Chemical	D005680	18439803
A@@	I-Chemical	-1	18439803
B@@	I-Chemical	-1	18439803
A	I-Chemical	-1	18439803
)	O	-1	18439803
of	O	-1	18439803
N@@	B-Chemical	C108761	18439803
-@@	I-Chemical	-1	18439803
(2@@	I-Chemical	-1	18439803
-@@	I-Chemical	-1	18439803
prop@@	I-Chemical	-1	18439803
yl@@	I-Chemical	-1	18439803
pent@@	I-Chemical	-1	18439803
an@@	I-Chemical	-1	18439803
o@@	I-Chemical	-1	18439803
yl@@	I-Chemical	-1	18439803
)@@	I-Chemical	-1	18439803
ure@@	I-Chemical	-1	18439803
a	I-Chemical	-1	18439803
(	O	-1	18439803
V@@	B-Chemical	C108761	18439803
P@@	I-Chemical	-1	18439803
U	I-Chemical	-1	18439803
)	O	-1	18439803
in	O	-1	18439803
compar@@	O	-1	18439803
ison	O	-1	18439803
to	O	-1	18439803
its	O	-1	18439803
pa@@	O	-1	18439803
rent	O	-1	18439803
comp@@	O	-1	18439803
oun@@	O	-1	18439803
d,	O	-1	18439803
valpro@@	B-Chemical	D014635	18439803
ic	I-Chemical	-1	18439803
acid	I-Chemical	-1	18439803
(	O	-1	18439803
V@@	B-Chemical	D014635	18439803
P@@	I-Chemical	-1	18439803
A	I-Chemical	-1	18439803
).	O	-1	18439803
V@@	B-Chemical	C108761	18439803
P@@	I-Chemical	-1	18439803
U	I-Chemical	-1	18439803
was	O	-1	18439803
more	O	-1	18439803
pot@@	O	-1	18439803
ent	O	-1	18439803
than	O	-1	18439803
V@@	B-Chemical	D014635	18439803
P@@	I-Chemical	-1	18439803
A	I-Chemical	-1	18439803
,	O	-1	18439803
ex@@	O	-1	18439803
hib@@	O	-1	18439803
it@@	O	-1	18439803
ing	O	-1	18439803
the	O	-1	18439803
median	O	-1	18439803
effective	O	-1	18439803
dose	O	-1	18439803
(@@	O	-1	18439803
E@@	O	-1	18439803
D@@	O	-1	18439803
(@@	O	-1	18439803
50@@	O	-1	18439803
)@@	O	-1	18439803
)	O	-1	18439803
of	O	-1	18439803
4@@	O	-1	18439803
9	O	-1	18439803
mg/kg	O	-1	18439803
in	O	-1	18439803
prot@@	O	-1	18439803
ect@@	O	-1	18439803
ing	O	-1	18439803
rats	O	-1	18439803
against	O	-1	18439803
pilocar@@	B-Chemical	D010862	18439803
pine	I-Chemical	-1	18439803
-induced	O	-1	18439803
seizure	B-Disease	D012640	18439803
whereas	O	-1	18439803
the	O	-1	18439803
cor@@	O	-1	18439803
respon@@	O	-1	18439803
ding	O	-1	18439803
valu@@	O	-1	18439803
e	O	-1	18439803
for	O	-1	18439803
V@@	B-Chemical	D014635	18439803
P@@	I-Chemical	-1	18439803
A	I-Chemical	-1	18439803
was	O	-1	18439803
3@@	O	-1	18439803
2@@	O	-1	18439803
2	O	-1	18439803
mg/kg@@	O	-1	18439803
.	O	-1	18439803
In	O	-1	18439803
viv@@	O	-1	18439803
o	O	-1	18439803
micro@@	O	-1	18439803
dialy@@	O	-1	18439803
sis	O	-1	18439803
demonstrated	O	-1	18439803
that	O	-1	18439803
an	O	-1	18439803
intra@@	O	-1	18439803
per@@	O	-1	18439803
it@@	O	-1	18439803
one@@	O	-1	18439803
al	O	-1	18439803
administration	O	-1	18439803
of	O	-1	18439803
pilocar@@	B-Chemical	D010862	18439803
pine	I-Chemical	-1	18439803
induced	O	-1	18439803
a	O	-1	18439803
p@@	O	-1	18439803
ron@@	O	-1	18439803
oun@@	O	-1	18439803
c@@	O	-1	18439803
ed	O	-1	18439803
inc@@	O	-1	18439803
re@@	O	-1	18439803
ment	O	-1	18439803
of	O	-1	18439803
hippocamp@@	O	-1	18439803
al	O	-1	18439803
glutamate	B-Chemical	D018698	18439803
and	O	-1	18439803
as@@	B-Chemical	D001224	18439803
part@@	I-Chemical	-1	18439803
ate	I-Chemical	-1	18439803
whereas	O	-1	18439803
no	O	-1	18439803
significant	O	-1	18439803
change	O	-1	18439803
was	O	-1	18439803
observed	O	-1	18439803
on	O	-1	18439803
the	O	-1	18439803
level	O	-1	18439803
of	O	-1	18439803
glyc@@	B-Chemical	D005998	18439803
ine	I-Chemical	-1	18439803
and	O	-1	18439803
G@@	B-Chemical	D005680	18439803
A@@	I-Chemical	-1	18439803
B@@	I-Chemical	-1	18439803
A	I-Chemical	-1	18439803
.	O	-1	18439803
Pre@@	O	-1	18439803
treatment	O	-1	18439803
with	O	-1	18439803
either	O	-1	18439803
V@@	B-Chemical	C108761	18439803
P@@	I-Chemical	-1	18439803
U	I-Chemical	-1	18439803
(@@	O	-1	18439803
50	O	-1	18439803
and	O	-1	18439803
100	O	-1	18439803
mg/kg)	O	-1	18439803
or	O	-1	18439803
V@@	B-Chemical	D014635	18439803
P@@	I-Chemical	-1	18439803
A	I-Chemical	-1	18439803
(3@@	O	-1	18439803
00	O	-1	18439803
and	O	-1	18439803
6@@	O	-1	18439803
00	O	-1	18439803
mg/kg)	O	-1	18439803
complete@@	O	-1	18439803
ly	O	-1	18439803
abol@@	O	-1	18439803
ished	O	-1	18439803
pilocar@@	B-Chemical	D010862	18439803
pine	I-Chemical	-1	18439803
-@@	O	-1	18439803
evoked	O	-1	18439803
increases	O	-1	18439803
in	O	-1	18439803
extrac@@	O	-1	18439803
ell@@	O	-1	18439803
ular	O	-1	18439803
glutamate	B-Chemical	D018698	18439803
and	O	-1	18439803
as@@	B-Chemical	D001224	18439803
part@@	I-Chemical	-1	18439803
ate	I-Chemical	-1	18439803
.	O	-1	18439803
In	O	-1	18439803
addi@@	O	-1	18439803
tion,	O	-1	18439803
a	O	-1	18439803
statis@@	O	-1	18439803
tically	O	-1	18439803
significant	O	-1	18439803
reduction	O	-1	18439803
was	O	-1	18439803
also	O	-1	18439803
observed	O	-1	18439803
on	O	-1	18439803
the	O	-1	18439803
level	O	-1	18439803
of	O	-1	18439803
G@@	B-Chemical	D005680	18439803
A@@	I-Chemical	-1	18439803
B@@	I-Chemical	-1	18439803
A	I-Chemical	-1	18439803
and	O	-1	18439803
glyc@@	B-Chemical	D005998	18439803
ine	I-Chemical	-1	18439803
but	O	-1	18439803
less	O	-1	18439803
than	O	-1	18439803
a	O	-1	18439803
d@@	O	-1	18439803
r@@	O	-1	18439803
as@@	O	-1	18439803
tic	O	-1	18439803
reduction	O	-1	18439803
of	O	-1	18439803
glutamate	B-Chemical	D018698	18439803
and	O	-1	18439803
as@@	B-Chemical	D001224	18439803
part@@	I-Chemical	-1	18439803
ate	I-Chemical	-1	18439803
level@@	O	-1	18439803
.	O	-1	18439803
B@@	O	-1	18439803
as@@	O	-1	18439803
ed	O	-1	18439803
on	O	-1	18439803
the	O	-1	18439803
find@@	O	-1	18439803
ing	O	-1	18439803
that	O	-1	18439803
V@@	B-Chemical	C108761	18439803
P@@	I-Chemical	-1	18439803
U	I-Chemical	-1	18439803
and	O	-1	18439803
V@@	B-Chemical	D014635	18439803
P@@	I-Chemical	-1	18439803
A	I-Chemical	-1	18439803
could	O	-1	18439803
prot@@	O	-1	18439803
ect	O	-1	18439803
the	O	-1	18439803
animals	O	-1	18439803
against	O	-1	18439803
pilocar@@	B-Chemical	D010862	18439803
pine	I-Chemical	-1	18439803
-induced	O	-1	18439803
seizure	B-Disease	D012640	18439803
it	O	-1	18439803
is	O	-1	18439803
suggested	O	-1	18439803
that	O	-1	18439803
the	O	-1	18439803
reduction	O	-1	18439803
of	O	-1	18439803
inhibit@@	O	-1	18439803
ory	O	-1	18439803
amin@@	B-Chemical	D000596	18439803
o	I-Chemical	-1	18439803
acid	I-Chemical	-1	18439803
neuro@@	O	-1	18439803
trans@@	O	-1	18439803
mit@@	O	-1	18439803
ters	O	-1	18439803
was	O	-1	18439803
compar@@	O	-1	18439803
atively	O	-1	18439803
min@@	O	-1	18439803
or	O	-1	18439803
and	O	-1	18439803
o@@	O	-1	18439803
ff@@	O	-1	18439803
set	O	-1	18439803
by	O	-1	18439803
a	O	-1	18439803
p@@	O	-1	18439803
ron@@	O	-1	18439803
oun@@	O	-1	18439803
c@@	O	-1	18439803
ed	O	-1	18439803
reduction	O	-1	18439803
of	O	-1	18439803
glutamate	B-Chemical	D018698	18439803
and	O	-1	18439803
as@@	B-Chemical	D001224	18439803
part@@	I-Chemical	-1	18439803
ate	I-Chemical	-1	18439803
.	O	-1	18439803
The@@	O	-1	18439803
refore,	O	-1	18439803
like	O	-1	18439803
V@@	B-Chemical	D014635	18439803
P@@	I-Chemical	-1	18439803
A	I-Chemical	-1	18439803
,	O	-1	18439803
the	O	-1	18439803
find@@	O	-1	18439803
ing	O	-1	18439803
that	O	-1	18439803
V@@	B-Chemical	C108761	18439803
P@@	I-Chemical	-1	18439803
U	I-Chemical	-1	18439803
could	O	-1	18439803
d@@	O	-1	18439803
r@@	O	-1	18439803
as@@	O	-1	18439803
tically	O	-1	18439803
re@@	O	-1	18439803
duce	O	-1	18439803
pilocar@@	B-Chemical	D010862	18439803
pine	I-Chemical	-1	18439803
-induced	O	-1	18439803
increases	O	-1	18439803
in	O	-1	18439803
glutamate	B-Chemical	D018698	18439803
and	O	-1	18439803
as@@	B-Chemical	D001224	18439803
part@@	I-Chemical	-1	18439803
ate	I-Chemical	-1	18439803
should	O	-1	18439803
ac@@	O	-1	18439803
coun@@	O	-1	18439803
t,	O	-1	18439803
at	O	-1	18439803
le@@	O	-1	18439803
ast	O	-1	18439803
part@@	O	-1	18439803
ly,	O	-1	18439803
for	O	-1	18439803
its	O	-1	18439803
anti@@	O	-1	18439803
convul@@	O	-1	18439803
s@@	O	-1	18439803
ant	O	-1	18439803
activity	O	-1	18439803
observed	O	-1	18439803
in	O	-1	18439803
pilocar@@	B-Chemical	D010862	18439803
pine	I-Chemical	-1	18439803
-induced	O	-1	18439803
seizure	B-Disease	D012640	18439803
in	O	-1	18439803
experimental	O	-1	18439803
anim@@	O	-1	18439803
al@@	O	-1	18439803
s.	O	-1	18439803
S@@	O	-1	18439803
ome	O	-1	18439803
other	O	-1	18439803
mechanism	O	-1	18439803
than	O	-1	18439803
those	O	-1	18439803
being	O	-1	18439803
reported	O	-1	18439803
he@@	O	-1	18439803
re@@	O	-1	18439803
in	O	-1	18439803
should	O	-1	18439803
be	O	-1	18439803
further	O	-1	18439803
investig@@	O	-1	18439803
ated.	O	-1	18439803

Ac@@	O	-1	17919553
ute	O	-1	17919553
hepatitis	B-Disease	D056486	17919553
at@@	O	-1	17919553
tac@@	O	-1	17919553
k	O	-1	17919553
after	O	-1	17919553
exposure	O	-1	17919553
to	O	-1	17919553
te@@	B-Chemical	C106791	17919553
li@@	I-Chemical	-1	17919553
throm@@	I-Chemical	-1	17919553
ycin	I-Chemical	-1	17919553
.	O	-1	17919553
IN@@	O	-1	17919553
T@@	O	-1	17919553
RO@@	O	-1	17919553
D@@	O	-1	17919553
U@@	O	-1	17919553
C@@	O	-1	17919553
T@@	O	-1	17919553
ION@@	O	-1	17919553
:	O	-1	17919553
An@@	O	-1	17919553
ti@@	O	-1	17919553
bio@@	O	-1	17919553
tic@@	O	-1	17919553
-@@	O	-1	17919553
associated	O	-1	17919553
hepat@@	B-Disease	D056486	17919553
otoxicity	I-Disease	-1	17919553
is	O	-1	17919553
ra@@	O	-1	17919553
re.	O	-1	17919553
W@@	O	-1	17919553
it@@	O	-1	17919553
h	O	-1	17919553
w@@	O	-1	17919553
id@@	O	-1	17919553
es@@	O	-1	17919553
pre@@	O	-1	17919553
ad	O	-1	17919553
use	O	-1	17919553
of	O	-1	17919553
anti@@	O	-1	17919553
micro@@	O	-1	17919553
b@@	O	-1	17919553
ial	O	-1	17919553
agent@@	O	-1	17919553
s,	O	-1	17919553
however,	O	-1	17919553
hepatic	B-Disease	D056486	17919553
injury	I-Disease	-1	17919553
occur@@	O	-1	17919553
s	O	-1	17919553
frequ@@	O	-1	17919553
ent@@	O	-1	17919553
ly,	O	-1	17919553
and	O	-1	17919553
among	O	-1	17919553
adverse	B-Disease	D064420	17919553
drug	I-Disease	-1	17919553
reactions	I-Disease	-1	17919553
,	O	-1	17919553
i@@	O	-1	17919553
di@@	O	-1	17919553
os@@	O	-1	17919553
yn@@	O	-1	17919553
c@@	O	-1	17919553
r@@	O	-1	17919553
atic	O	-1	17919553
reactions	O	-1	17919553
are	O	-1	17919553
the	O	-1	17919553
most	O	-1	17919553
seri@@	O	-1	17919553
ou@@	O	-1	17919553
s.	O	-1	17919553
CA@@	O	-1	17919553
S@@	O	-1	17919553
E	O	-1	17919553
S@@	O	-1	17919553
U@@	O	-1	17919553
M@@	O	-1	17919553
MA@@	O	-1	17919553
R@@	O	-1	17919553
Y@@	O	-1	17919553
:	O	-1	17919553
A	O	-1	17919553
2@@	O	-1	17919553
5-@@	O	-1	17919553
year-old	O	-1	17919553
male	O	-1	17919553
patient@@	O	-1	17919553
,	O	-1	17919553
with	O	-1	17919553
a	O	-1	17919553
he@@	O	-1	17919553
ight	O	-1	17919553
of	O	-1	17919553
17@@	O	-1	17919553
5	O	-1	17919553
c@@	O	-1	17919553
m	O	-1	17919553
and	O	-1	17919553
weight	O	-1	17919553
of	O	-1	17919553
7@@	O	-1	17919553
2	O	-1	17919553
k@@	O	-1	17919553
g	O	-1	17919553
presented	O	-1	17919553
to	O	-1	17919553
M@@	O	-1	17919553
ar@@	O	-1	17919553
m@@	O	-1	17919553
ar@@	O	-1	17919553
a	O	-1	17919553
U@@	O	-1	17919553
n@@	O	-1	17919553
i@@	O	-1	17919553
ver@@	O	-1	17919553
s@@	O	-1	17919553
ity	O	-1	17919553
H@@	O	-1	17919553
ospit@@	O	-1	17919553
al	O	-1	17919553
E@@	O	-1	17919553
mer@@	O	-1	17919553
gen@@	O	-1	17919553
c@@	O	-1	17919553
y	O	-1	17919553
De@@	O	-1	17919553
part@@	O	-1	17919553
ment@@	O	-1	17919553
,	O	-1	17919553
I@@	O	-1	17919553
st@@	O	-1	17919553
an@@	O	-1	17919553
b@@	O	-1	17919553
ul@@	O	-1	17919553
,	O	-1	17919553
T@@	O	-1	17919553
ur@@	O	-1	17919553
ke@@	O	-1	17919553
y,	O	-1	17919553
with	O	-1	17919553
5	O	-1	17919553
da@@	O	-1	17919553
ys@@	O	-1	17919553
'	O	-1	17919553
hist@@	O	-1	17919553
ory	O	-1	17919553
of	O	-1	17919553
j@@	B-Disease	D007565	17919553
a@@	I-Disease	-1	17919553
un@@	I-Disease	-1	17919553
dic@@	I-Disease	-1	17919553
e	I-Disease	-1	17919553
,	O	-1	17919553
mal@@	O	-1	17919553
a@@	O	-1	17919553
i@@	O	-1	17919553
se@@	O	-1	17919553
,	O	-1	17919553
nausea	B-Disease	D009325	17919553
,	O	-1	17919553
and	O	-1	17919553
v@@	B-Disease	D014839	17919553
om@@	I-Disease	-1	17919553
it@@	I-Disease	-1	17919553
ing	I-Disease	-1	17919553
.	O	-1	17919553
H@@	O	-1	17919553
e	O	-1	17919553
had	O	-1	17919553
been	O	-1	17919553
prescri@@	O	-1	17919553
bed	O	-1	17919553
te@@	B-Chemical	C106791	17919553
li@@	I-Chemical	-1	17919553
throm@@	I-Chemical	-1	17919553
ycin	I-Chemical	-1	17919553
4@@	O	-1	17919553
00	O	-1	17919553
mg/@@	O	-1	17919553
d	O	-1	17919553
P@@	O	-1	17919553
O	O	-1	17919553
to	O	-1	17919553
tre@@	O	-1	17919553
at	O	-1	17919553
an	O	-1	17919553
up@@	B-Disease	D012141	17919553
per	I-Disease	-1	17919553
respiratory	I-Disease	-1	17919553
trac@@	I-Disease	-1	17919553
t	I-Disease	-1	17919553
inf@@	I-Disease	-1	17919553
ection	I-Disease	-1	17919553
7	O	-1	17919553
days	O	-1	17919553
pri@@	O	-1	17919553
or@@	O	-1	17919553
.	O	-1	17919553
Ad@@	O	-1	17919553
mission	O	-1	17919553
labor@@	O	-1	17919553
atory	O	-1	17919553
tests	O	-1	17919553
were	O	-1	17919553
as	O	-1	17919553
follow@@	O	-1	17919553
s:	O	-1	17919553
al@@	B-Chemical	D000409	17919553
an@@	I-Chemical	-1	17919553
ine	I-Chemical	-1	17919553
amin@@	O	-1	17919553
ot@@	O	-1	17919553
ran@@	O	-1	17919553
s@@	O	-1	17919553
fer@@	O	-1	17919553
ase,	O	-1	17919553
6@@	O	-1	17919553
7	O	-1	17919553
U@@	O	-1	17919553
/@@	O	-1	17919553
L	O	-1	17919553
(@@	O	-1	17919553
ref@@	O	-1	17919553
e@@	O	-1	17919553
rence	O	-1	17919553
rang@@	O	-1	17919553
e,	O	-1	17919553
10-@@	O	-1	17919553
3@@	O	-1	17919553
7	O	-1	17919553
U@@	O	-1	17919553
/@@	O	-1	17919553
L@@	O	-1	17919553
);	O	-1	17919553
as@@	B-Chemical	D001224	17919553
part@@	I-Chemical	-1	17919553
ate	I-Chemical	-1	17919553
amin@@	O	-1	17919553
ot@@	O	-1	17919553
ran@@	O	-1	17919553
s@@	O	-1	17919553
fer@@	O	-1	17919553
ase,	O	-1	17919553
9@@	O	-1	17919553
8	O	-1	17919553
U@@	O	-1	17919553
/@@	O	-1	17919553
L	O	-1	17919553
(@@	O	-1	17919553
10-@@	O	-1	17919553
40	O	-1	17919553
U@@	O	-1	17919553
/@@	O	-1	17919553
L@@	O	-1	17919553
);	O	-1	17919553
al@@	O	-1	17919553
k@@	O	-1	17919553
aline	O	-1	17919553
phosph@@	O	-1	17919553
at@@	O	-1	17919553
ase,	O	-1	17919553
5@@	O	-1	17919553
13	O	-1	17919553
U@@	O	-1	17919553
/@@	O	-1	17919553
L	O	-1	17919553
(@@	O	-1	17919553
0-@@	O	-1	17919553
27@@	O	-1	17919553
0	O	-1	17919553
U@@	O	-1	17919553
/@@	O	-1	17919553
L@@	O	-1	17919553
);	O	-1	17919553
gamma@@	O	-1	17919553
-@@	O	-1	17919553
glutam@@	O	-1	17919553
yl@@	O	-1	17919553
trans@@	O	-1	17919553
fer@@	O	-1	17919553
ase,	O	-1	17919553
3@@	O	-1	17919553
2	O	-1	17919553
U@@	O	-1	17919553
/@@	O	-1	17919553
L	O	-1	17919553
(@@	O	-1	17919553
7-@@	O	-1	17919553
4@@	O	-1	17919553
9	O	-1	17919553
U@@	O	-1	17919553
/@@	O	-1	17919553
L@@	O	-1	17919553
);	O	-1	17919553
am@@	O	-1	17919553
yl@@	O	-1	17919553
ase,	O	-1	17919553
4@@	O	-1	17919553
6	O	-1	17919553
U@@	O	-1	17919553
/@@	O	-1	17919553
L	O	-1	17919553
(@@	O	-1	17919553
0-@@	O	-1	17919553
2@@	O	-1	17919553
20	O	-1	17919553
U@@	O	-1	17919553
/@@	O	-1	17919553
L@@	O	-1	17919553
);	O	-1	17919553
total	O	-1	17919553
bil@@	B-Chemical	D001663	17919553
i@@	I-Chemical	-1	17919553
ru@@	I-Chemical	-1	17919553
bin	I-Chemical	-1	17919553
,	O	-1	17919553
2@@	O	-1	17919553
0.@@	O	-1	17919553
1	O	-1	17919553
mg/d@@	O	-1	17919553
L	O	-1	17919553
(0.@@	O	-1	17919553
2-@@	O	-1	17919553
1.@@	O	-1	17919553
0	O	-1	17919553
mg/d@@	O	-1	17919553
L@@	O	-1	17919553
);	O	-1	17919553
direct	O	-1	17919553
bil@@	B-Chemical	D001663	17919553
i@@	I-Chemical	-1	17919553
ru@@	I-Chemical	-1	17919553
bin	I-Chemical	-1	17919553
,	O	-1	17919553
1@@	O	-1	17919553
4.@@	O	-1	17919553
8	O	-1	17919553
mg/d@@	O	-1	17919553
L	O	-1	17919553
(@@	O	-1	17919553
0-@@	O	-1	17919553
0.@@	O	-1	17919553
3	O	-1	17919553
mg/d@@	O	-1	17919553
L@@	O	-1	17919553
);	O	-1	17919553
and	O	-1	17919553
al@@	O	-1	17919553
bu@@	O	-1	17919553
min@@	O	-1	17919553
,	O	-1	17919553
4.@@	O	-1	17919553
7	O	-1	17919553
mg/d@@	O	-1	17919553
L	O	-1	17919553
(@@	O	-1	17919553
3.@@	O	-1	17919553
5-@@	O	-1	17919553
5.@@	O	-1	17919553
4	O	-1	17919553
mg/d@@	O	-1	17919553
L@@	O	-1	17919553
).	O	-1	17919553
No	O	-1	17919553
tox@@	O	-1	17919553
in,	O	-1	17919553
alco@@	B-Chemical	D000431	17919553
hol	I-Chemical	-1	17919553
,	O	-1	17919553
or	O	-1	17919553
other	O	-1	17919553
drugs	O	-1	17919553
were	O	-1	17919553
repor@@	O	-1	17919553
ted.	O	-1	17919553
The	O	-1	17919553
patient	O	-1	17919553
had	O	-1	17919553
su@@	O	-1	17919553
ffe@@	O	-1	17919553
red	O	-1	17919553
a	O	-1	17919553
previ@@	O	-1	17919553
ous	O	-1	17919553
episo@@	O	-1	17919553
de	O	-1	17919553
of	O	-1	17919553
"@@	O	-1	17919553
acute	O	-1	17919553
hepatitis	B-Disease	D056486	17919553
of	O	-1	17919553
un@@	O	-1	17919553
known	O	-1	17919553
or@@	O	-1	17919553
ig@@	O	-1	17919553
in@@	O	-1	17919553
,@@	O	-1	17919553
"	O	-1	17919553
that	O	-1	17919553
occurred	O	-1	17919553
after	O	-1	17919553
te@@	B-Chemical	C106791	17919553
li@@	I-Chemical	-1	17919553
throm@@	I-Chemical	-1	17919553
ycin	I-Chemical	-1	17919553
us@@	O	-1	17919553
age.	O	-1	17919553
B@@	O	-1	17919553
oth	O	-1	17919553
inc@@	O	-1	17919553
id@@	O	-1	17919553
ents	O	-1	17919553
occurred	O	-1	17919553
within	O	-1	17919553
a	O	-1	17919553
year@@	O	-1	17919553
.	O	-1	17919553
D@@	O	-1	17919553
I@@	O	-1	17919553
S@@	O	-1	17919553
C@@	O	-1	17919553
US@@	O	-1	17919553
S@@	O	-1	17919553
ION@@	O	-1	17919553
:	O	-1	17919553
T@@	B-Chemical	C106791	17919553
e@@	I-Chemical	-1	17919553
li@@	I-Chemical	-1	17919553
throm@@	I-Chemical	-1	17919553
ycin	I-Chemical	-1	17919553
is	O	-1	17919553
the	O	-1	17919553
first	O	-1	17919553
of	O	-1	17919553
the	O	-1	17919553
k@@	O	-1	17919553
et@@	O	-1	17919553
ol@@	O	-1	17919553
ide	O	-1	17919553
anti@@	O	-1	17919553
bac@@	O	-1	17919553
ter@@	O	-1	17919553
i@@	O	-1	17919553
als	O	-1	17919553
to	O	-1	17919553
recei@@	O	-1	17919553
ve	O	-1	17919553
U@@	O	-1	17919553
S	O	-1	17919553
F@@	O	-1	17919553
o@@	O	-1	17919553
od	O	-1	17919553
and	O	-1	17919553
D@@	O	-1	17919553
ru@@	O	-1	17919553
g	O	-1	17919553
Ad@@	O	-1	17919553
minist@@	O	-1	17919553
ration	O	-1	17919553
appro@@	O	-1	17919553
v@@	O	-1	17919553
al	O	-1	17919553
for	O	-1	17919553
clinical	O	-1	17919553
use.	O	-1	17919553
It	O	-1	17919553
has	O	-1	17919553
been	O	-1	17919553
associated	O	-1	17919553
with	O	-1	17919553
inf@@	O	-1	17919553
requ@@	O	-1	17919553
ent	O	-1	17919553
and	O	-1	17919553
us@@	O	-1	17919553
ually	O	-1	17919553
reversible	O	-1	17919553
severe	O	-1	17919553
hepatic	B-Disease	D008107	17919553
dysfunction	I-Disease	-1	17919553
.	O	-1	17919553
B@@	O	-1	17919553
as@@	O	-1	17919553
ed	O	-1	17919553
on	O	-1	17919553
a	O	-1	17919553
scor@@	O	-1	17919553
e	O	-1	17919553
of	O	-1	17919553
8	O	-1	17919553
on	O	-1	17919553
the	O	-1	17919553
N@@	O	-1	17919553
ar@@	O	-1	17919553
an@@	O	-1	17919553
j@@	O	-1	17919553
o	O	-1	17919553
adverse	B-Disease	D064420	17919553
drug	I-Disease	-1	17919553
reaction	I-Disease	-1	17919553
prob@@	O	-1	17919553
ability	O	-1	17919553
s@@	O	-1	17919553
cal@@	O	-1	17919553
e,	O	-1	17919553
te@@	B-Chemical	C106791	17919553
li@@	I-Chemical	-1	17919553
throm@@	I-Chemical	-1	17919553
ycin	I-Chemical	-1	17919553
was	O	-1	17919553
the	O	-1	17919553
prob@@	O	-1	17919553
able	O	-1	17919553
cause	O	-1	17919553
of	O	-1	17919553
acute	O	-1	17919553
hepatitis	B-Disease	D056486	17919553
in	O	-1	17919553
this	O	-1	17919553
patient@@	O	-1	17919553
,	O	-1	17919553
and	O	-1	17919553
path@@	O	-1	17919553
ological	O	-1	17919553
findings	O	-1	17919553
suggested	O	-1	17919553
drug@@	O	-1	17919553
-induced	O	-1	17919553
toxic	B-Disease	D056486	17919553
hepatitis	I-Disease	-1	17919553
.	O	-1	17919553
Rec@@	O	-1	17919553
ur@@	O	-1	17919553
rence	O	-1	17919553
of	O	-1	17919553
hepatitis	B-Disease	D056486	17919553
at@@	O	-1	17919553
tac@@	O	-1	17919553
k	O	-1	17919553
might	O	-1	17919553
have	O	-1	17919553
been	O	-1	17919553
avoid@@	O	-1	17919553
ed	O	-1	17919553
if	O	-1	17919553
the	O	-1	17919553
initial	O	-1	17919553
inc@@	O	-1	17919553
id@@	O	-1	17919553
ent	O	-1	17919553
had	O	-1	17919553
been	O	-1	17919553
com@@	O	-1	17919553
mun@@	O	-1	17919553
ic@@	O	-1	17919553
ated	O	-1	17919553
to	O	-1	17919553
the	O	-1	17919553
atten@@	O	-1	17919553
ding	O	-1	17919553
physi@@	O	-1	17919553
ci@@	O	-1	17919553
an	O	-1	17919553
who	O	-1	17919553
prescri@@	O	-1	17919553
bed	O	-1	17919553
te@@	B-Chemical	C106791	17919553
li@@	I-Chemical	-1	17919553
throm@@	I-Chemical	-1	17919553
ycin	I-Chemical	-1	17919553
the	O	-1	17919553
second	O	-1	17919553
ti@@	O	-1	17919553
me.	O	-1	17919553
CONCLUSION:	O	-1	17919553
H@@	O	-1	17919553
ere	O	-1	17919553
we	O	-1	17919553
report	O	-1	17919553
a	O	-1	17919553
case	O	-1	17919553
of	O	-1	17919553
acute	O	-1	17919553
hepatitis	B-Disease	D056486	17919553
prob@@	O	-1	17919553
ably	O	-1	17919553
associated	O	-1	17919553
with	O	-1	17919553
the	O	-1	17919553
administration	O	-1	17919553
of	O	-1	17919553
te@@	B-Chemical	C106791	17919553
li@@	I-Chemical	-1	17919553
throm@@	I-Chemical	-1	17919553
ycin	I-Chemical	-1	17919553
.	O	-1	17919553

S@@	B-Chemical	D013148	15632880
pi@@	I-Chemical	-1	15632880
ron@@	I-Chemical	-1	15632880
ol@@	I-Chemical	-1	15632880
act@@	I-Chemical	-1	15632880
one	I-Chemical	-1	15632880
-induced	O	-1	15632880
renal	B-Disease	D051437	15632880
in@@	I-Disease	-1	15632880
suffici@@	I-Disease	-1	15632880
ency	I-Disease	-1	15632880
and	O	-1	15632880
hyper@@	B-Disease	D006947	15632880
k@@	I-Disease	-1	15632880
al@@	I-Disease	-1	15632880
emia	I-Disease	-1	15632880
in	O	-1	15632880
patients	O	-1	15632880
with	O	-1	15632880
heart	B-Disease	D006333	15632880
failure	I-Disease	-1	15632880
.	O	-1	15632880
BACKGROUND:	O	-1	15632880
A	O	-1	15632880
previ@@	O	-1	15632880
ous	O	-1	15632880
randomized	O	-1	15632880
controlled	O	-1	15632880
trial	O	-1	15632880
evalu@@	O	-1	15632880
ating	O	-1	15632880
the	O	-1	15632880
use	O	-1	15632880
of	O	-1	15632880
s@@	B-Chemical	D013148	15632880
pi@@	I-Chemical	-1	15632880
ron@@	I-Chemical	-1	15632880
ol@@	I-Chemical	-1	15632880
act@@	I-Chemical	-1	15632880
one	I-Chemical	-1	15632880
in	O	-1	15632880
heart	B-Disease	D006333	15632880
failure	I-Disease	-1	15632880
patients	O	-1	15632880
reported	O	-1	15632880
a	O	-1	15632880
low	O	-1	15632880
risk	O	-1	15632880
of	O	-1	15632880
hyper@@	B-Disease	D006947	15632880
k@@	I-Disease	-1	15632880
al@@	I-Disease	-1	15632880
emia	I-Disease	-1	15632880
(2@@	O	-1	15632880
%)	O	-1	15632880
and	O	-1	15632880
renal	B-Disease	D051437	15632880
in@@	I-Disease	-1	15632880
suffici@@	I-Disease	-1	15632880
ency	I-Disease	-1	15632880
(@@	O	-1	15632880
0@@	O	-1	15632880
%).	O	-1	15632880
B@@	O	-1	15632880
ecause	O	-1	15632880
treat@@	O	-1	15632880
ments	O	-1	15632880
for	O	-1	15632880
heart	B-Disease	D006333	15632880
failure	I-Disease	-1	15632880
have	O	-1	15632880
chang@@	O	-1	15632880
ed	O	-1	15632880
s@@	O	-1	15632880
inc@@	O	-1	15632880
e	O	-1	15632880
the	O	-1	15632880
ben@@	O	-1	15632880
e@@	O	-1	15632880
f@@	O	-1	15632880
its	O	-1	15632880
of	O	-1	15632880
s@@	B-Chemical	D013148	15632880
pi@@	I-Chemical	-1	15632880
ron@@	I-Chemical	-1	15632880
ol@@	I-Chemical	-1	15632880
act@@	I-Chemical	-1	15632880
one	I-Chemical	-1	15632880
were	O	-1	15632880
repor@@	O	-1	15632880
te@@	O	-1	15632880
d,	O	-1	15632880
the	O	-1	15632880
prev@@	O	-1	15632880
al@@	O	-1	15632880
ence	O	-1	15632880
of	O	-1	15632880
these	O	-1	15632880
complications	O	-1	15632880
may	O	-1	15632880
diff@@	O	-1	15632880
er	O	-1	15632880
in	O	-1	15632880
current	O	-1	15632880
clinical	O	-1	15632880
p@@	O	-1	15632880
rac@@	O	-1	15632880
ti@@	O	-1	15632880
ce@@	O	-1	15632880
.	O	-1	15632880
We	O	-1	15632880
the@@	O	-1	15632880
re@@	O	-1	15632880
fore	O	-1	15632880
s@@	O	-1	15632880
ou@@	O	-1	15632880
ght	O	-1	15632880
to	O	-1	15632880
determine	O	-1	15632880
the	O	-1	15632880
prev@@	O	-1	15632880
al@@	O	-1	15632880
ence	O	-1	15632880
and	O	-1	15632880
clinical	O	-1	15632880
associ@@	O	-1	15632880
ations	O	-1	15632880
of	O	-1	15632880
hyper@@	B-Disease	D006947	15632880
k@@	I-Disease	-1	15632880
al@@	I-Disease	-1	15632880
emia	I-Disease	-1	15632880
and	O	-1	15632880
renal	B-Disease	D051437	15632880
in@@	I-Disease	-1	15632880
suffici@@	I-Disease	-1	15632880
ency	I-Disease	-1	15632880
in	O	-1	15632880
heart	B-Disease	D006333	15632880
failure	I-Disease	-1	15632880
patients	O	-1	15632880
treated	O	-1	15632880
with	O	-1	15632880
s@@	B-Chemical	D013148	15632880
pi@@	I-Chemical	-1	15632880
ron@@	I-Chemical	-1	15632880
ol@@	I-Chemical	-1	15632880
act@@	I-Chemical	-1	15632880
one	I-Chemical	-1	15632880
.	O	-1	15632880
METHODS:	O	-1	15632880
We	O	-1	15632880
performed	O	-1	15632880
a	O	-1	15632880
case	O	-1	15632880
control	O	-1	15632880
study	O	-1	15632880
of	O	-1	15632880
heart	B-Disease	D006333	15632880
failure	I-Disease	-1	15632880
patients	O	-1	15632880
treated	O	-1	15632880
with	O	-1	15632880
s@@	B-Chemical	D013148	15632880
pi@@	I-Chemical	-1	15632880
ron@@	I-Chemical	-1	15632880
ol@@	I-Chemical	-1	15632880
act@@	I-Chemical	-1	15632880
one	I-Chemical	-1	15632880
in	O	-1	15632880
our	O	-1	15632880
clinical	O	-1	15632880
p@@	O	-1	15632880
rac@@	O	-1	15632880
ti@@	O	-1	15632880
ce@@	O	-1	15632880
.	O	-1	15632880
C@@	O	-1	15632880
as@@	O	-1	15632880
es	O	-1	15632880
were	O	-1	15632880
patients	O	-1	15632880
who	O	-1	15632880
developed	O	-1	15632880
hyper@@	B-Disease	D006947	15632880
k@@	I-Disease	-1	15632880
al@@	I-Disease	-1	15632880
emia	I-Disease	-1	15632880
(	O	-1	15632880
K	B-Chemical	D011188	15632880
(@@	O	-1	15632880
+@@	O	-1	15632880
)	O	-1	15632880
>@@	O	-1	15632880
5.@@	O	-1	15632880
0	O	-1	15632880
m@@	O	-1	15632880
E@@	O	-1	15632880
q@@	O	-1	15632880
/@@	O	-1	15632880
L@@	O	-1	15632880
)	O	-1	15632880
or	O	-1	15632880
renal	B-Disease	D051437	15632880
in@@	I-Disease	-1	15632880
suffici@@	I-Disease	-1	15632880
ency	I-Disease	-1	15632880
(	O	-1	15632880
C@@	B-Chemical	D002857	15632880
r	I-Chemical	-1	15632880
>@@	O	-1	15632880
or@@	O	-1	15632880
=@@	O	-1	15632880
2.@@	O	-1	15632880
5	O	-1	15632880
mg/d@@	O	-1	15632880
L@@	O	-1	15632880
),	O	-1	15632880
and	O	-1	15632880
they	O	-1	15632880
were	O	-1	15632880
compared	O	-1	15632880
to	O	-1	15632880
2	O	-1	15632880
random@@	O	-1	15632880
ly	O	-1	15632880
sel@@	O	-1	15632880
ected	O	-1	15632880
controls	O	-1	15632880
per	O	-1	15632880
cas@@	O	-1	15632880
e.	O	-1	15632880
Clin@@	O	-1	15632880
ical	O	-1	15632880
character@@	O	-1	15632880
is@@	O	-1	15632880
tic@@	O	-1	15632880
s,	O	-1	15632880
medic@@	O	-1	15632880
ation@@	O	-1	15632880
s,	O	-1	15632880
and	O	-1	15632880
serum	O	-1	15632880
chem@@	O	-1	15632880
ist@@	O	-1	15632880
ri@@	O	-1	15632880
es	O	-1	15632880
at	O	-1	15632880
baseline	O	-1	15632880
and	O	-1	15632880
follow-up	O	-1	15632880
time	O	-1	15632880
perio@@	O	-1	15632880
ds	O	-1	15632880
were	O	-1	15632880
com@@	O	-1	15632880
pa@@	O	-1	15632880
red.	O	-1	15632880
RESULTS:	O	-1	15632880
Si@@	O	-1	15632880
x@@	O	-1	15632880
ty-@@	O	-1	15632880
seven	O	-1	15632880
of	O	-1	15632880
9@@	O	-1	15632880
2@@	O	-1	15632880
6	O	-1	15632880
patients	O	-1	15632880
(@@	O	-1	15632880
7.@@	O	-1	15632880
2@@	O	-1	15632880
%)	O	-1	15632880
requ@@	O	-1	15632880
ired	O	-1	15632880
discontinu@@	O	-1	15632880
ation	O	-1	15632880
of	O	-1	15632880
s@@	B-Chemical	D013148	15632880
pi@@	I-Chemical	-1	15632880
ron@@	I-Chemical	-1	15632880
ol@@	I-Chemical	-1	15632880
act@@	I-Chemical	-1	15632880
one	I-Chemical	-1	15632880
due	O	-1	15632880
to	O	-1	15632880
hyper@@	B-Disease	D006947	15632880
k@@	I-Disease	-1	15632880
al@@	I-Disease	-1	15632880
emia	I-Disease	-1	15632880
(n	O	-1	15632880
=	O	-1	15632880
3@@	O	-1	15632880
3@@	O	-1	15632880
)	O	-1	15632880
or	O	-1	15632880
renal	B-Disease	D051437	15632880
failure	I-Disease	-1	15632880
(n	O	-1	15632880
=	O	-1	15632880
34@@	O	-1	15632880
).	O	-1	15632880
Patients	O	-1	15632880
who	O	-1	15632880
developed	O	-1	15632880
hyper@@	B-Disease	D006947	15632880
k@@	I-Disease	-1	15632880
al@@	I-Disease	-1	15632880
emia	I-Disease	-1	15632880
were	O	-1	15632880
ol@@	O	-1	15632880
der	O	-1	15632880
and	O	-1	15632880
more	O	-1	15632880
likely	O	-1	15632880
to	O	-1	15632880
have	O	-1	15632880
dia@@	B-Disease	D003920	15632880
bet@@	I-Disease	-1	15632880
es	I-Disease	-1	15632880
,	O	-1	15632880
had	O	-1	15632880
higher	O	-1	15632880
baseline	O	-1	15632880
serum	O	-1	15632880
pot@@	B-Chemical	D011188	15632880
assi@@	I-Chemical	-1	15632880
um	I-Chemical	-1	15632880
levels	O	-1	15632880
and	O	-1	15632880
lower	O	-1	15632880
baseline	O	-1	15632880
pot@@	B-Chemical	D011188	15632880
assi@@	I-Chemical	-1	15632880
um	I-Chemical	-1	15632880
sup@@	O	-1	15632880
ple@@	O	-1	15632880
ment	O	-1	15632880
dos@@	O	-1	15632880
es,	O	-1	15632880
and	O	-1	15632880
were	O	-1	15632880
more	O	-1	15632880
likely	O	-1	15632880
to	O	-1	15632880
be	O	-1	15632880
treated	O	-1	15632880
with	O	-1	15632880
beta-@@	O	-1	15632880
block@@	O	-1	15632880
ers	O	-1	15632880
than	O	-1	15632880
controls	O	-1	15632880
(n	O	-1	15632880
=	O	-1	15632880
13@@	O	-1	15632880
4@@	O	-1	15632880
).	O	-1	15632880
Patients	O	-1	15632880
who	O	-1	15632880
developed	O	-1	15632880
renal	B-Disease	D051437	15632880
in@@	I-Disease	-1	15632880
suffici@@	I-Disease	-1	15632880
ency	I-Disease	-1	15632880
had	O	-1	15632880
lower	O	-1	15632880
baseline	O	-1	15632880
body	O	-1	15632880
weight	O	-1	15632880
and	O	-1	15632880
higher	O	-1	15632880
baseline	O	-1	15632880
serum	O	-1	15632880
creatinine	B-Chemical	D003404	15632880
,	O	-1	15632880
requ@@	O	-1	15632880
ired	O	-1	15632880
higher	O	-1	15632880
doses	O	-1	15632880
of	O	-1	15632880
lo@@	O	-1	15632880
o@@	O	-1	15632880
p	O	-1	15632880
di@@	O	-1	15632880
ure@@	O	-1	15632880
tic@@	O	-1	15632880
s,	O	-1	15632880
and	O	-1	15632880
were	O	-1	15632880
more	O	-1	15632880
likely	O	-1	15632880
to	O	-1	15632880
be	O	-1	15632880
treated	O	-1	15632880
with	O	-1	15632880
thi@@	B-Chemical	D049971	15632880
az@@	I-Chemical	-1	15632880
ide	I-Chemical	-1	15632880
di@@	O	-1	15632880
ure@@	O	-1	15632880
tics	O	-1	15632880
than	O	-1	15632880
controls.	O	-1	15632880
CONCLUSIONS:	O	-1	15632880
S@@	B-Chemical	D013148	15632880
pi@@	I-Chemical	-1	15632880
ron@@	I-Chemical	-1	15632880
ol@@	I-Chemical	-1	15632880
act@@	I-Chemical	-1	15632880
one	I-Chemical	-1	15632880
-induced	O	-1	15632880
hyper@@	B-Disease	D006947	15632880
k@@	I-Disease	-1	15632880
al@@	I-Disease	-1	15632880
emia	I-Disease	-1	15632880
and	O	-1	15632880
renal	B-Disease	D051437	15632880
in@@	I-Disease	-1	15632880
suffici@@	I-Disease	-1	15632880
ency	I-Disease	-1	15632880
are	O	-1	15632880
more	O	-1	15632880
common	O	-1	15632880
in	O	-1	15632880
our	O	-1	15632880
clinical	O	-1	15632880
experi@@	O	-1	15632880
ence	O	-1	15632880
than	O	-1	15632880
reported	O	-1	15632880
previ@@	O	-1	15632880
ous@@	O	-1	15632880
ly.	O	-1	15632880
This	O	-1	15632880
difference	O	-1	15632880
is	O	-1	15632880
expl@@	O	-1	15632880
ained	O	-1	15632880
by	O	-1	15632880
patient	O	-1	15632880
com@@	O	-1	15632880
or@@	O	-1	15632880
b@@	O	-1	15632880
i@@	O	-1	15632880
di@@	O	-1	15632880
ties	O	-1	15632880
and	O	-1	15632880
more	O	-1	15632880
frequent	O	-1	15632880
use	O	-1	15632880
of	O	-1	15632880
beta-@@	O	-1	15632880
block@@	O	-1	15632880
ers.	O	-1	15632880

E@@	B-Disease	D007676	11773892
n@@	I-Disease	-1	11773892
d-@@	I-Disease	-1	11773892
st@@	I-Disease	-1	11773892
age	I-Disease	-1	11773892
renal	I-Disease	-1	11773892
disease	I-Disease	-1	11773892
(	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
)	O	-1	11773892
after	O	-1	11773892
or@@	O	-1	11773892
th@@	O	-1	11773892
ot@@	O	-1	11773892
op@@	O	-1	11773892
ic	O	-1	11773892
liver	O	-1	11773892
transplant@@	O	-1	11773892
ation	O	-1	11773892
(@@	O	-1	11773892
O@@	O	-1	11773892
LT@@	O	-1	11773892
X@@	O	-1	11773892
)	O	-1	11773892
using	O	-1	11773892
calc@@	O	-1	11773892
ine@@	O	-1	11773892
ur@@	O	-1	11773892
in-@@	O	-1	11773892
bas@@	O	-1	11773892
ed	O	-1	11773892
immuno@@	O	-1	11773892
therap@@	O	-1	11773892
y@@	O	-1	11773892
:	O	-1	11773892
risk	O	-1	11773892
of	O	-1	11773892
development	O	-1	11773892
and	O	-1	11773892
treatment.	O	-1	11773892
BACKGROUND:	O	-1	11773892
The	O	-1	11773892
calc@@	O	-1	11773892
ine@@	O	-1	11773892
ur@@	O	-1	11773892
in	O	-1	11773892
inhibitors	O	-1	11773892
cyclospor@@	B-Chemical	D016572	11773892
ine	I-Chemical	-1	11773892
and	O	-1	11773892
tacrolimus	B-Chemical	D016559	11773892
are	O	-1	11773892
both	O	-1	11773892
known	O	-1	11773892
to	O	-1	11773892
be	O	-1	11773892
nephro@@	B-Disease	D007674	11773892
toxic	I-Disease	-1	11773892
.	O	-1	11773892
The@@	O	-1	11773892
ir	O	-1	11773892
use	O	-1	11773892
in	O	-1	11773892
or@@	O	-1	11773892
th@@	O	-1	11773892
ot@@	O	-1	11773892
op@@	O	-1	11773892
ic	O	-1	11773892
liver	O	-1	11773892
transplant@@	O	-1	11773892
ation	O	-1	11773892
(@@	O	-1	11773892
O@@	O	-1	11773892
LT@@	O	-1	11773892
X@@	O	-1	11773892
)	O	-1	11773892
has	O	-1	11773892
d@@	O	-1	11773892
ram@@	O	-1	11773892
ati@@	O	-1	11773892
c@@	O	-1	11773892
ally	O	-1	11773892
improved	O	-1	11773892
suc@@	O	-1	11773892
cess	O	-1	11773892
rat@@	O	-1	11773892
es.	O	-1	11773892
Rec@@	O	-1	11773892
ent@@	O	-1	11773892
ly,	O	-1	11773892
however,	O	-1	11773892
we	O	-1	11773892
have	O	-1	11773892
had	O	-1	11773892
an	O	-1	11773892
increase	O	-1	11773892
of	O	-1	11773892
patients	O	-1	11773892
who	O	-1	11773892
are	O	-1	11773892
present@@	O	-1	11773892
ing	O	-1	11773892
after	O	-1	11773892
O@@	O	-1	11773892
LT@@	O	-1	11773892
X	O	-1	11773892
with	O	-1	11773892
en@@	B-Disease	D007676	11773892
d-@@	I-Disease	-1	11773892
st@@	I-Disease	-1	11773892
age	I-Disease	-1	11773892
renal	I-Disease	-1	11773892
disease	I-Disease	-1	11773892
(	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
).	O	-1	11773892
This	O	-1	11773892
ret@@	O	-1	11773892
ro@@	O	-1	11773892
sp@@	O	-1	11773892
ective	O	-1	11773892
study	O	-1	11773892
examin@@	O	-1	11773892
es	O	-1	11773892
the	O	-1	11773892
incidence	O	-1	11773892
and	O	-1	11773892
treatment	O	-1	11773892
of	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
and	O	-1	11773892
chronic	B-Disease	D007676	11773892
renal	I-Disease	-1	11773892
failure	I-Disease	-1	11773892
(	O	-1	11773892
CR@@	B-Disease	D007676	11773892
F	I-Disease	-1	11773892
)	O	-1	11773892
in	O	-1	11773892
O@@	O	-1	11773892
LT@@	O	-1	11773892
X	O	-1	11773892
patients.	O	-1	11773892
METHODS:	O	-1	11773892
Patients	O	-1	11773892
receiving	O	-1	11773892
an	O	-1	11773892
O@@	O	-1	11773892
LT@@	O	-1	11773892
X	O	-1	11773892
only	O	-1	11773892
from	O	-1	11773892
J@@	O	-1	11773892
un@@	O	-1	11773892
e	O	-1	11773892
19@@	O	-1	11773892
8@@	O	-1	11773892
5	O	-1	11773892
through	O	-1	11773892
D@@	O	-1	11773892
ec@@	O	-1	11773892
emb@@	O	-1	11773892
er	O	-1	11773892
of	O	-1	11773892
19@@	O	-1	11773892
9@@	O	-1	11773892
4	O	-1	11773892
who	O	-1	11773892
sur@@	O	-1	11773892
vi@@	O	-1	11773892
ved	O	-1	11773892
6	O	-1	11773892
months	O	-1	11773892
posto@@	O	-1	11773892
per@@	O	-1	11773892
atively	O	-1	11773892
were	O	-1	11773892
studied	O	-1	11773892
(n@@	O	-1	11773892
=@@	O	-1	11773892
8@@	O	-1	11773892
34@@	O	-1	11773892
).	O	-1	11773892
Our	O	-1	11773892
pro@@	O	-1	11773892
sp@@	O	-1	11773892
ectively	O	-1	11773892
coll@@	O	-1	11773892
ected	O	-1	11773892
dat@@	O	-1	11773892
ab@@	O	-1	11773892
ase	O	-1	11773892
was	O	-1	11773892
the	O	-1	11773892
so@@	O	-1	11773892
ur@@	O	-1	11773892
ce	O	-1	11773892
of	O	-1	11773892
inf@@	O	-1	11773892
orm@@	O	-1	11773892
ation.	O	-1	11773892
Patients	O	-1	11773892
were	O	-1	11773892
divid@@	O	-1	11773892
ed	O	-1	11773892
into	O	-1	11773892
three	O	-1	11773892
group@@	O	-1	11773892
s:	O	-1	11773892
C@@	O	-1	11773892
ont@@	O	-1	11773892
ro@@	O	-1	11773892
l@@	O	-1	11773892
s,	O	-1	11773892
no	O	-1	11773892
CR@@	B-Disease	D007676	11773892
F	I-Disease	-1	11773892
or	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
,	O	-1	11773892
n@@	O	-1	11773892
=@@	O	-1	11773892
7@@	O	-1	11773892
4@@	O	-1	11773892
8@@	O	-1	11773892
;	O	-1	11773892
CR@@	B-Disease	D007676	11773892
F	I-Disease	-1	11773892
,	O	-1	11773892
su@@	O	-1	11773892
st@@	O	-1	11773892
ained	O	-1	11773892
serum	O	-1	11773892
creatinine	B-Chemical	D003404	11773892
>@@	O	-1	11773892
2.@@	O	-1	11773892
5	O	-1	11773892
mg/d@@	O	-1	11773892
l@@	O	-1	11773892
,	O	-1	11773892
n@@	O	-1	11773892
=@@	O	-1	11773892
4@@	O	-1	11773892
1@@	O	-1	11773892
;	O	-1	11773892
and	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
,	O	-1	11773892
n@@	O	-1	11773892
=@@	O	-1	11773892
4@@	O	-1	11773892
5@@	O	-1	11773892
.	O	-1	11773892
Grou@@	O	-1	11773892
p@@	O	-1	11773892
s	O	-1	11773892
were	O	-1	11773892
compared	O	-1	11773892
for	O	-1	11773892
pre@@	O	-1	11773892
o@@	O	-1	11773892
perative	O	-1	11773892
labor@@	O	-1	11773892
atory	O	-1	11773892
vari@@	O	-1	11773892
abl@@	O	-1	11773892
es,	O	-1	11773892
diagno@@	O	-1	11773892
sis,	O	-1	11773892
postoperative	O	-1	11773892
vari@@	O	-1	11773892
abl@@	O	-1	11773892
es,	O	-1	11773892
sur@@	O	-1	11773892
vi@@	O	-1	11773892
val@@	O	-1	11773892
,	O	-1	11773892
type	O	-1	11773892
of	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
therapy,	O	-1	11773892
and	O	-1	11773892
sur@@	O	-1	11773892
viv@@	O	-1	11773892
al	O	-1	11773892
from	O	-1	11773892
onset	O	-1	11773892
of	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
.	O	-1	11773892
RESULTS:	O	-1	11773892
A@@	O	-1	11773892
t	O	-1	11773892
13	O	-1	11773892
years	O	-1	11773892
after	O	-1	11773892
O@@	O	-1	11773892
LT@@	O	-1	11773892
X@@	O	-1	11773892
,	O	-1	11773892
the	O	-1	11773892
incidence	O	-1	11773892
of	O	-1	11773892
severe	O	-1	11773892
renal	B-Disease	D007674	11773892
dysfunction	I-Disease	-1	11773892
was	O	-1	11773892
1@@	O	-1	11773892
8.@@	O	-1	11773892
1@@	O	-1	11773892
%	O	-1	11773892
(	O	-1	11773892
CR@@	B-Disease	D007676	11773892
F	I-Disease	-1	11773892
8.@@	O	-1	11773892
6%	O	-1	11773892
and	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
9.@@	O	-1	11773892
5@@	O	-1	11773892
%).	O	-1	11773892
Com@@	O	-1	11773892
pared	O	-1	11773892
with	O	-1	11773892
control	O	-1	11773892
patients,	O	-1	11773892
CR@@	B-Disease	D007676	11773892
F	I-Disease	-1	11773892
and	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
patients	O	-1	11773892
had	O	-1	11773892
higher	O	-1	11773892
pre@@	O	-1	11773892
o@@	O	-1	11773892
perative	O	-1	11773892
serum	O	-1	11773892
creatinine	B-Chemical	D003404	11773892
level@@	O	-1	11773892
s,	O	-1	11773892
a	O	-1	11773892
greater	O	-1	11773892
perc@@	O	-1	11773892
ent@@	O	-1	11773892
age	O	-1	11773892
of	O	-1	11773892
patients	O	-1	11773892
with	O	-1	11773892
hepat@@	B-Disease	D006530	11773892
o@@	I-Disease	-1	11773892
renal	I-Disease	-1	11773892
syndrome	I-Disease	-1	11773892
,	O	-1	11773892
higher	O	-1	11773892
perc@@	O	-1	11773892
ent@@	O	-1	11773892
age	O	-1	11773892
requ@@	O	-1	11773892
i@@	O	-1	11773892
re@@	O	-1	11773892
ment	O	-1	11773892
for	O	-1	11773892
dialy@@	O	-1	11773892
sis	O	-1	11773892
in	O	-1	11773892
the	O	-1	11773892
first	O	-1	11773892
3	O	-1	11773892
months	O	-1	11773892
posto@@	O	-1	11773892
per@@	O	-1	11773892
ati@@	O	-1	11773892
vel@@	O	-1	11773892
y,	O	-1	11773892
and	O	-1	11773892
a	O	-1	11773892
higher	O	-1	11773892
1-@@	O	-1	11773892
year	O	-1	11773892
serum	O	-1	11773892
creatinine	B-Chemical	D003404	11773892
.	O	-1	11773892
M@@	O	-1	11773892
ul@@	O	-1	11773892
tiv@@	O	-1	11773892
ari@@	O	-1	11773892
ate	O	-1	11773892
st@@	O	-1	11773892
ep@@	O	-1	11773892
w@@	O	-1	11773892
is@@	O	-1	11773892
e	O	-1	11773892
log@@	O	-1	11773892
istic	O	-1	11773892
reg@@	O	-1	11773892
res@@	O	-1	11773892
sion	O	-1	11773892
analysis	O	-1	11773892
using	O	-1	11773892
pre@@	O	-1	11773892
o@@	O	-1	11773892
perative	O	-1	11773892
and	O	-1	11773892
postoperative	O	-1	11773892
vari@@	O	-1	11773892
able@@	O	-1	11773892
s	O	-1	11773892
identi@@	O	-1	11773892
fied	O	-1	11773892
that	O	-1	11773892
an	O	-1	11773892
increase	O	-1	11773892
of	O	-1	11773892
serum	O	-1	11773892
creatinine	B-Chemical	D003404	11773892
compared	O	-1	11773892
with	O	-1	11773892
average	O	-1	11773892
at	O	-1	11773892
1	O	-1	11773892
year@@	O	-1	11773892
,	O	-1	11773892
3	O	-1	11773892
month@@	O	-1	11773892
s,	O	-1	11773892
and	O	-1	11773892
4	O	-1	11773892
weeks	O	-1	11773892
posto@@	O	-1	11773892
per@@	O	-1	11773892
atively	O	-1	11773892
were	O	-1	11773892
in@@	O	-1	11773892
dependent	O	-1	11773892
risk	O	-1	11773892
factors	O	-1	11773892
for	O	-1	11773892
the	O	-1	11773892
development	O	-1	11773892
of	O	-1	11773892
CR@@	B-Disease	D007676	11773892
F	I-Disease	-1	11773892
or	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
with	O	-1	11773892
o@@	O	-1	11773892
d@@	O	-1	11773892
ds	O	-1	11773892
rati@@	O	-1	11773892
o@@	O	-1	11773892
s	O	-1	11773892
of	O	-1	11773892
2.@@	O	-1	11773892
6,	O	-1	11773892
2.@@	O	-1	11773892
2,	O	-1	11773892
and	O	-1	11773892
1.@@	O	-1	11773892
6,	O	-1	11773892
respectively.	O	-1	11773892
O@@	O	-1	11773892
ver@@	O	-1	11773892
all	O	-1	11773892
sur@@	O	-1	11773892
viv@@	O	-1	11773892
al	O	-1	11773892
from	O	-1	11773892
the	O	-1	11773892
time	O	-1	11773892
of	O	-1	11773892
O@@	O	-1	11773892
LT@@	O	-1	11773892
X	O	-1	11773892
was	O	-1	11773892
not	O	-1	11773892
significantly	O	-1	11773892
different	O	-1	11773892
among	O	-1	11773892
group@@	O	-1	11773892
s,	O	-1	11773892
but	O	-1	11773892
by	O	-1	11773892
year	O	-1	11773892
13@@	O	-1	11773892
,	O	-1	11773892
the	O	-1	11773892
sur@@	O	-1	11773892
viv@@	O	-1	11773892
al	O	-1	11773892
of	O	-1	11773892
the	O	-1	11773892
patients	O	-1	11773892
who	O	-1	11773892
had	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
was	O	-1	11773892
only	O	-1	11773892
2@@	O	-1	11773892
8.@@	O	-1	11773892
2@@	O	-1	11773892
%	O	-1	11773892
compared	O	-1	11773892
with	O	-1	11773892
5@@	O	-1	11773892
4.@@	O	-1	11773892
6%	O	-1	11773892
in	O	-1	11773892
the	O	-1	11773892
control	O	-1	11773892
group.	O	-1	11773892
Patients	O	-1	11773892
develop@@	O	-1	11773892
ing	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
had	O	-1	11773892
a	O	-1	11773892
6-@@	O	-1	11773892
year	O	-1	11773892
sur@@	O	-1	11773892
viv@@	O	-1	11773892
al	O	-1	11773892
after	O	-1	11773892
onset	O	-1	11773892
of	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
of	O	-1	11773892
27@@	O	-1	11773892
%	O	-1	11773892
for	O	-1	11773892
the	O	-1	11773892
patients	O	-1	11773892
receiving	O	-1	11773892
hemo@@	O	-1	11773892
dialy@@	O	-1	11773892
sis	O	-1	11773892
versus	O	-1	11773892
7@@	O	-1	11773892
1.@@	O	-1	11773892
4@@	O	-1	11773892
%	O	-1	11773892
for	O	-1	11773892
the	O	-1	11773892
patients	O	-1	11773892
develop@@	O	-1	11773892
ing	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
who	O	-1	11773892
subsequ@@	O	-1	11773892
ently	O	-1	11773892
received	O	-1	11773892
kidney	O	-1	11773892
transplant@@	O	-1	11773892
s.	O	-1	11773892
CONCLUSIONS:	O	-1	11773892
Patients	O	-1	11773892
who	O	-1	11773892
are	O	-1	11773892
more	O	-1	11773892
than	O	-1	11773892
10	O	-1	11773892
years	O	-1	11773892
post@@	O	-1	11773892
-@@	O	-1	11773892
O@@	O	-1	11773892
LT@@	O	-1	11773892
X	O	-1	11773892
have	O	-1	11773892
CR@@	B-Disease	D007676	11773892
F	I-Disease	-1	11773892
and	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
at	O	-1	11773892
a	O	-1	11773892
high	O	-1	11773892
rat@@	O	-1	11773892
e.	O	-1	11773892
The	O	-1	11773892
development	O	-1	11773892
of	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
decreas@@	O	-1	11773892
es	O	-1	11773892
sur@@	O	-1	11773892
vi@@	O	-1	11773892
val@@	O	-1	11773892
,	O	-1	11773892
partic@@	O	-1	11773892
ul@@	O	-1	11773892
arly	O	-1	11773892
in	O	-1	11773892
those	O	-1	11773892
patients	O	-1	11773892
treated	O	-1	11773892
with	O	-1	11773892
dialy@@	O	-1	11773892
sis	O	-1	11773892
on@@	O	-1	11773892
ly.	O	-1	11773892
Patients	O	-1	11773892
who	O	-1	11773892
deve@@	O	-1	11773892
lo@@	O	-1	11773892
p	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
have	O	-1	11773892
a	O	-1	11773892
higher	O	-1	11773892
pre@@	O	-1	11773892
o@@	O	-1	11773892
perative	O	-1	11773892
and	O	-1	11773892
1-@@	O	-1	11773892
year	O	-1	11773892
serum	O	-1	11773892
creatinine	B-Chemical	D003404	11773892
and	O	-1	11773892
are	O	-1	11773892
more	O	-1	11773892
likely	O	-1	11773892
to	O	-1	11773892
have	O	-1	11773892
hepat@@	B-Disease	D006530	11773892
o@@	I-Disease	-1	11773892
renal	I-Disease	-1	11773892
syndrome	I-Disease	-1	11773892
.	O	-1	11773892
However,	O	-1	11773892
an	O	-1	11773892
increase	O	-1	11773892
of	O	-1	11773892
serum	O	-1	11773892
creatinine	B-Chemical	D003404	11773892
at	O	-1	11773892
various	O	-1	11773892
times	O	-1	11773892
posto@@	O	-1	11773892
per@@	O	-1	11773892
atively	O	-1	11773892
is	O	-1	11773892
more	O	-1	11773892
predic@@	O	-1	11773892
tive	O	-1	11773892
of	O	-1	11773892
the	O	-1	11773892
development	O	-1	11773892
of	O	-1	11773892
CR@@	B-Disease	D007676	11773892
F	I-Disease	-1	11773892
or	O	-1	11773892
ES@@	B-Disease	D007676	11773892
R@@	I-Disease	-1	11773892
D	I-Disease	-1	11773892
.	O	-1	11773892
Ne@@	O	-1	11773892
w	O	-1	11773892
strat@@	O	-1	11773892
e@@	O	-1	11773892
gi@@	O	-1	11773892
es	O	-1	11773892
for	O	-1	11773892
long-term	O	-1	11773892
immunosup@@	O	-1	11773892
pression	O	-1	11773892
may	O	-1	11773892
be	O	-1	11773892
ne@@	O	-1	11773892
ed@@	O	-1	11773892
ed	O	-1	11773892
to	O	-1	11773892
decrease	O	-1	11773892
this	O	-1	11773892
complic@@	O	-1	11773892
ation.	O	-1	11773892

Eff@@	O	-1	10835440
ect	O	-1	10835440
of	O	-1	10835440
intravenous	O	-1	10835440
n@@	B-Chemical	D009553	10835440
im@@	I-Chemical	-1	10835440
odi@@	I-Chemical	-1	10835440
pine	I-Chemical	-1	10835440
on	O	-1	10835440
blood	O	-1	10835440
pressure	O	-1	10835440
and	O	-1	10835440
outcom@@	O	-1	10835440
e	O	-1	10835440
after	O	-1	10835440
acute	B-Disease	D020521	10835440
strok@@	I-Disease	-1	10835440
e	I-Disease	-1	10835440
.	O	-1	10835440
BACKGROUN@@	O	-1	10835440
D	O	-1	10835440
AN@@	O	-1	10835440
D	O	-1	10835440
P@@	O	-1	10835440
U@@	O	-1	10835440
R@@	O	-1	10835440
P@@	O	-1	10835440
O@@	O	-1	10835440
S@@	O	-1	10835440
E:	O	-1	10835440
The	O	-1	10835440
In@@	O	-1	10835440
tra@@	O	-1	10835440
venous	O	-1	10835440
N@@	B-Chemical	D009553	10835440
im@@	I-Chemical	-1	10835440
odi@@	I-Chemical	-1	10835440
pine	I-Chemical	-1	10835440
W@@	O	-1	10835440
est	O	-1	10835440
E@@	O	-1	10835440
uro@@	O	-1	10835440
pe@@	O	-1	10835440
an	O	-1	10835440
S@@	B-Disease	D020521	10835440
tro@@	I-Disease	-1	10835440
k@@	I-Disease	-1	10835440
e	I-Disease	-1	10835440
T@@	O	-1	10835440
rial	O	-1	10835440
(@@	O	-1	10835440
IN@@	O	-1	10835440
W@@	O	-1	10835440
ES@@	O	-1	10835440
T)	O	-1	10835440
found	O	-1	10835440
a	O	-1	10835440
correl@@	O	-1	10835440
ation	O	-1	10835440
between	O	-1	10835440
n@@	B-Chemical	D009553	10835440
im@@	I-Chemical	-1	10835440
odi@@	I-Chemical	-1	10835440
pine	I-Chemical	-1	10835440
-induced	O	-1	10835440
reduction	B-Disease	D007022	10835440
in	I-Disease	-1	10835440
blood	I-Disease	-1	10835440
pressure	I-Disease	-1	10835440
(B@@	O	-1	10835440
P)	O	-1	10835440
and	O	-1	10835440
an	O	-1	10835440
un@@	O	-1	10835440
f@@	O	-1	10835440
av@@	O	-1	10835440
or@@	O	-1	10835440
able	O	-1	10835440
outcom@@	O	-1	10835440
e	O	-1	10835440
in	O	-1	10835440
acute	B-Disease	D020521	10835440
strok@@	I-Disease	-1	10835440
e	I-Disease	-1	10835440
.	O	-1	10835440
We	O	-1	10835440
s@@	O	-1	10835440
ou@@	O	-1	10835440
ght	O	-1	10835440
to	O	-1	10835440
con@@	O	-1	10835440
fir@@	O	-1	10835440
m	O	-1	10835440
this	O	-1	10835440
correl@@	O	-1	10835440
ation	O	-1	10835440
with	O	-1	10835440
and	O	-1	10835440
without	O	-1	10835440
adjust@@	O	-1	10835440
ment	O	-1	10835440
for	O	-1	10835440
pro@@	O	-1	10835440
gn@@	O	-1	10835440
os@@	O	-1	10835440
tic	O	-1	10835440
vari@@	O	-1	10835440
able@@	O	-1	10835440
s	O	-1	10835440
and	O	-1	10835440
to	O	-1	10835440
investigate	O	-1	10835440
outcom@@	O	-1	10835440
e	O	-1	10835440
in	O	-1	10835440
sub@@	O	-1	10835440
groups	O	-1	10835440
with	O	-1	10835440
increas@@	O	-1	10835440
ing	O	-1	10835440
levels	O	-1	10835440
of	O	-1	10835440
B@@	B-Disease	D007022	10835440
P	I-Disease	-1	10835440
reduction	I-Disease	-1	10835440
.	O	-1	10835440
METHODS:	O	-1	10835440
Patients	O	-1	10835440
with	O	-1	10835440
a	O	-1	10835440
clinical	O	-1	10835440
diagnosis	O	-1	10835440
of	O	-1	10835440
ischem@@	B-Disease	D002544	10835440
ic	I-Disease	-1	10835440
strok@@	I-Disease	-1	10835440
e	I-Disease	-1	10835440
(@@	O	-1	10835440
within	O	-1	10835440
24	O	-1	10835440
hour@@	O	-1	10835440
s)	O	-1	10835440
were	O	-1	10835440
con@@	O	-1	10835440
sec@@	O	-1	10835440
u@@	O	-1	10835440
ti@@	O	-1	10835440
vely	O	-1	10835440
al@@	O	-1	10835440
loc@@	O	-1	10835440
ated	O	-1	10835440
to	O	-1	10835440
recei@@	O	-1	10835440
ve	O	-1	10835440
placebo	O	-1	10835440
(n@@	O	-1	10835440
=@@	O	-1	10835440
10@@	O	-1	10835440
0@@	O	-1	10835440
),	O	-1	10835440
1	O	-1	10835440
mg/@@	O	-1	10835440
h	O	-1	10835440
(@@	O	-1	10835440
low@@	O	-1	10835440
-@@	O	-1	10835440
dose@@	O	-1	10835440
)	O	-1	10835440
n@@	B-Chemical	D009553	10835440
im@@	I-Chemical	-1	10835440
odi@@	I-Chemical	-1	10835440
pine	I-Chemical	-1	10835440
(n@@	O	-1	10835440
=@@	O	-1	10835440
10@@	O	-1	10835440
1),	O	-1	10835440
or	O	-1	10835440
2	O	-1	10835440
mg/@@	O	-1	10835440
h	O	-1	10835440
(@@	O	-1	10835440
high-@@	O	-1	10835440
dose@@	O	-1	10835440
)	O	-1	10835440
n@@	B-Chemical	D009553	10835440
im@@	I-Chemical	-1	10835440
odi@@	I-Chemical	-1	10835440
pine	I-Chemical	-1	10835440
(n@@	O	-1	10835440
=@@	O	-1	10835440
9@@	O	-1	10835440
4@@	O	-1	10835440
).	O	-1	10835440
The	O	-1	10835440
correl@@	O	-1	10835440
ation	O	-1	10835440
between	O	-1	10835440
average	O	-1	10835440
B@@	O	-1	10835440
P	O	-1	10835440
change	O	-1	10835440
during	O	-1	10835440
the	O	-1	10835440
first	O	-1	10835440
2	O	-1	10835440
days	O	-1	10835440
and	O	-1	10835440
the	O	-1	10835440
outcom@@	O	-1	10835440
e	O	-1	10835440
at	O	-1	10835440
day	O	-1	10835440
21	O	-1	10835440
was	O	-1	10835440
analy@@	O	-1	10835440
z@@	O	-1	10835440
ed.	O	-1	10835440
RESULTS:	O	-1	10835440
Two	O	-1	10835440
h@@	O	-1	10835440
und@@	O	-1	10835440
red	O	-1	10835440
si@@	O	-1	10835440
x@@	O	-1	10835440
ty-@@	O	-1	10835440
five	O	-1	10835440
patients	O	-1	10835440
were	O	-1	10835440
included	O	-1	10835440
in	O	-1	10835440
this	O	-1	10835440
analysis	O	-1	10835440
(n@@	O	-1	10835440
=@@	O	-1	10835440
9@@	O	-1	10835440
2,	O	-1	10835440
9@@	O	-1	10835440
3,	O	-1	10835440
and	O	-1	10835440
8@@	O	-1	10835440
0	O	-1	10835440
for	O	-1	10835440
placebo@@	O	-1	10835440
,	O	-1	10835440
low	O	-1	10835440
dose@@	O	-1	10835440
,	O	-1	10835440
and	O	-1	10835440
high	O	-1	10835440
dose@@	O	-1	10835440
,	O	-1	10835440
respectivel@@	O	-1	10835440
y@@	O	-1	10835440
).	O	-1	10835440
N@@	B-Chemical	D009553	10835440
im@@	I-Chemical	-1	10835440
odi@@	I-Chemical	-1	10835440
pine	I-Chemical	-1	10835440
treatment	O	-1	10835440
resulted	O	-1	10835440
in	O	-1	10835440
a	O	-1	10835440
statis@@	O	-1	10835440
tically	O	-1	10835440
significant	O	-1	10835440
reduction	B-Disease	D007022	10835440
in	I-Disease	-1	10835440
systolic	I-Disease	-1	10835440
B@@	I-Disease	-1	10835440
P	I-Disease	-1	10835440
(S@@	O	-1	10835440
B@@	O	-1	10835440
P)	O	-1	10835440
and	O	-1	10835440
di@@	O	-1	10835440
ast@@	O	-1	10835440
olic	O	-1	10835440
B@@	O	-1	10835440
P	O	-1	10835440
(D@@	O	-1	10835440
B@@	O	-1	10835440
P)	O	-1	10835440
from	O	-1	10835440
baseline	O	-1	10835440
compared	O	-1	10835440
with	O	-1	10835440
placebo	O	-1	10835440
during	O	-1	10835440
the	O	-1	10835440
first	O	-1	10835440
fe@@	O	-1	10835440
w	O	-1	10835440
days.	O	-1	10835440
In	O	-1	10835440
mul@@	O	-1	10835440
tiv@@	O	-1	10835440
ari@@	O	-1	10835440
ate	O	-1	10835440
analy@@	O	-1	10835440
sis,	O	-1	10835440
a	O	-1	10835440
significant	O	-1	10835440
correl@@	O	-1	10835440
ation	O	-1	10835440
between	O	-1	10835440
D@@	B-Disease	D007022	10835440
B@@	I-Disease	-1	10835440
P	I-Disease	-1	10835440
reduction	I-Disease	-1	10835440
and	O	-1	10835440
wor@@	O	-1	10835440
sen@@	O	-1	10835440
ing	O	-1	10835440
of	O	-1	10835440
the	O	-1	10835440
neurolog@@	O	-1	10835440
ical	O	-1	10835440
scor@@	O	-1	10835440
e	O	-1	10835440
was	O	-1	10835440
found	O	-1	10835440
for	O	-1	10835440
the	O	-1	10835440
high-dose	O	-1	10835440
group	O	-1	10835440
(@@	O	-1	10835440
beta@@	O	-1	10835440
=@@	O	-1	10835440
0.@@	O	-1	10835440
4@@	O	-1	10835440
9@@	O	-1	10835440
,	O	-1	10835440
P@@	O	-1	10835440
=@@	O	-1	10835440
0@@	O	-1	10835440
.	O	-1	10835440
0@@	O	-1	10835440
4@@	O	-1	10835440
8@@	O	-1	10835440
).	O	-1	10835440
Patients	O	-1	10835440
with	O	-1	10835440
a	O	-1	10835440
D@@	B-Disease	D007022	10835440
B@@	I-Disease	-1	10835440
P	I-Disease	-1	10835440
reduction	I-Disease	-1	10835440
of	O	-1	10835440
>	O	-1	10835440
or	O	-1	10835440
=@@	O	-1	10835440
20@@	O	-1	10835440
%	O	-1	10835440
in	O	-1	10835440
the	O	-1	10835440
high-dose	O	-1	10835440
group	O	-1	10835440
had	O	-1	10835440
a	O	-1	10835440
significantly	O	-1	10835440
increased	O	-1	10835440
adjust@@	O	-1	10835440
ed	O	-1	10835440
O@@	O	-1	10835440
R	O	-1	10835440
for	O	-1	10835440
the	O	-1	10835440
comp@@	O	-1	10835440
ound	O	-1	10835440
outcom@@	O	-1	10835440
e	O	-1	10835440
vari@@	O	-1	10835440
able	O	-1	10835440
death	B-Disease	D003643	10835440
or	O	-1	10835440
depend@@	O	-1	10835440
ency	O	-1	10835440
(B@@	O	-1	10835440
ar@@	O	-1	10835440
the@@	O	-1	10835440
l	O	-1	10835440
In@@	O	-1	10835440
de@@	O	-1	10835440
x	O	-1	10835440
<@@	O	-1	10835440
6@@	O	-1	10835440
0@@	O	-1	10835440
)	O	-1	10835440
(n@@	O	-1	10835440
/@@	O	-1	10835440
N@@	O	-1	10835440
=@@	O	-1	10835440
25@@	O	-1	10835440
/@@	O	-1	10835440
2@@	O	-1	10835440
6,	O	-1	10835440
O@@	O	-1	10835440
R	O	-1	10835440
10@@	O	-1	10835440
.	O	-1	10835440
1@@	O	-1	10835440
6,	O	-1	10835440
95%	O	-1	10835440
C@@	O	-1	10835440
I	O	-1	10835440
1.@@	O	-1	10835440
0@@	O	-1	10835440
2	O	-1	10835440
to	O	-1	10835440
10@@	O	-1	10835440
1.@@	O	-1	10835440
7@@	O	-1	10835440
4@@	O	-1	10835440
)	O	-1	10835440
and	O	-1	10835440
death	B-Disease	D003643	10835440
alone	O	-1	10835440
(n@@	O	-1	10835440
/@@	O	-1	10835440
N@@	O	-1	10835440
=@@	O	-1	10835440
9@@	O	-1	10835440
/@@	O	-1	10835440
2@@	O	-1	10835440
6,	O	-1	10835440
O@@	O	-1	10835440
R	O	-1	10835440
4.@@	O	-1	10835440
3@@	O	-1	10835440
3@@	O	-1	10835440
6,	O	-1	10835440
95%	O	-1	10835440
C@@	O	-1	10835440
I	O	-1	10835440
1.@@	O	-1	10835440
13@@	O	-1	10835440
1	O	-1	10835440
1@@	O	-1	10835440
6.@@	O	-1	10835440
6@@	O	-1	10835440
19@@	O	-1	10835440
)	O	-1	10835440
compared	O	-1	10835440
with	O	-1	10835440
all	O	-1	10835440
placebo	O	-1	10835440
patients	O	-1	10835440
(n@@	O	-1	10835440
/@@	O	-1	10835440
N@@	O	-1	10835440
=@@	O	-1	10835440
6@@	O	-1	10835440
2@@	O	-1	10835440
/@@	O	-1	10835440
9@@	O	-1	10835440
2	O	-1	10835440
and	O	-1	10835440
14@@	O	-1	10835440
/@@	O	-1	10835440
9@@	O	-1	10835440
2,	O	-1	10835440
respectivel@@	O	-1	10835440
y@@	O	-1	10835440
).	O	-1	10835440
There	O	-1	10835440
was	O	-1	10835440
no	O	-1	10835440
correl@@	O	-1	10835440
ation	O	-1	10835440
between	O	-1	10835440
S@@	O	-1	10835440
B@@	O	-1	10835440
P	O	-1	10835440
change	O	-1	10835440
and	O	-1	10835440
out@@	O	-1	10835440
co@@	O	-1	10835440
me.	O	-1	10835440
CONCLUSIONS:	O	-1	10835440
D@@	O	-1	10835440
B@@	O	-1	10835440
P@@	O	-1	10835440
,	O	-1	10835440
but	O	-1	10835440
not	O	-1	10835440
S@@	O	-1	10835440
B@@	O	-1	10835440
P@@	O	-1	10835440
,	O	-1	10835440
reduction	O	-1	10835440
was	O	-1	10835440
associated	O	-1	10835440
with	O	-1	10835440
neurolog@@	O	-1	10835440
ical	O	-1	10835440
wor@@	O	-1	10835440
sen@@	O	-1	10835440
ing	O	-1	10835440
after	O	-1	10835440
the	O	-1	10835440
intravenous	O	-1	10835440
administration	O	-1	10835440
of	O	-1	10835440
high-dose	O	-1	10835440
n@@	B-Chemical	D009553	10835440
im@@	I-Chemical	-1	10835440
odi@@	I-Chemical	-1	10835440
pine	I-Chemical	-1	10835440
after	O	-1	10835440
acute	B-Disease	D020521	10835440
strok@@	I-Disease	-1	10835440
e	I-Disease	-1	10835440
.	O	-1	10835440
F@@	O	-1	10835440
or	O	-1	10835440
low@@	O	-1	10835440
-@@	O	-1	10835440
dose	O	-1	10835440
n@@	B-Chemical	D009553	10835440
im@@	I-Chemical	-1	10835440
odi@@	I-Chemical	-1	10835440
pine	I-Chemical	-1	10835440
,	O	-1	10835440
the	O	-1	10835440
results	O	-1	10835440
were	O	-1	10835440
not	O	-1	10835440
concl@@	O	-1	10835440
u@@	O	-1	10835440
si@@	O	-1	10835440
ve.	O	-1	10835440
These	O	-1	10835440
results	O	-1	10835440
d@@	O	-1	10835440
o	O	-1	10835440
not	O	-1	10835440
con@@	O	-1	10835440
fir@@	O	-1	10835440
m	O	-1	10835440
or	O	-1	10835440
ex@@	O	-1	10835440
cl@@	O	-1	10835440
ude	O	-1	10835440
a	O	-1	10835440
neuro@@	O	-1	10835440
protective	O	-1	10835440
pro@@	O	-1	10835440
per@@	O	-1	10835440
t@@	O	-1	10835440
y	O	-1	10835440
of	O	-1	10835440
n@@	B-Chemical	D009553	10835440
im@@	I-Chemical	-1	10835440
odi@@	I-Chemical	-1	10835440
pine	I-Chemical	-1	10835440
.	O	-1	10835440

T@@	B-Disease	D009422	9523805
ran@@	I-Disease	-1	9523805
si@@	I-Disease	-1	9523805
ent	I-Disease	-1	9523805
neurolog@@	I-Disease	-1	9523805
ic	I-Disease	-1	9523805
symptoms	I-Disease	-1	9523805
after	O	-1	9523805
spinal	O	-1	9523805
anesthe@@	O	-1	9523805
si@@	O	-1	9523805
a@@	O	-1	9523805
:	O	-1	9523805
a	O	-1	9523805
lower	O	-1	9523805
incidence	O	-1	9523805
with	O	-1	9523805
pri@@	B-Chemical	D011318	9523805
lo@@	I-Chemical	-1	9523805
ca@@	I-Chemical	-1	9523805
ine	I-Chemical	-1	9523805
and	O	-1	9523805
bupivac@@	B-Chemical	D002045	9523805
aine	I-Chemical	-1	9523805
than	O	-1	9523805
with	O	-1	9523805
lidocaine	B-Chemical	D008012	9523805
.	O	-1	9523805
BACKGROUND:	O	-1	9523805
Rec@@	O	-1	9523805
ent	O	-1	9523805
evidence	O	-1	9523805
suggests	O	-1	9523805
that	O	-1	9523805
transi@@	B-Disease	D009422	9523805
ent	I-Disease	-1	9523805
neurolog@@	I-Disease	-1	9523805
ic	I-Disease	-1	9523805
symptoms	I-Disease	-1	9523805
(	O	-1	9523805
T@@	B-Disease	D009422	9523805
N@@	I-Disease	-1	9523805
S@@	I-Disease	-1	9523805
s	I-Disease	-1	9523805
)	O	-1	9523805
frequ@@	O	-1	9523805
ently	O	-1	9523805
fol@@	O	-1	9523805
low	O	-1	9523805
lidocaine	B-Chemical	D008012	9523805
spinal	O	-1	9523805
anesthe@@	O	-1	9523805
sia	O	-1	9523805
but	O	-1	9523805
are	O	-1	9523805
inf@@	O	-1	9523805
requ@@	O	-1	9523805
ent	O	-1	9523805
with	O	-1	9523805
bupivac@@	B-Chemical	D002045	9523805
aine	I-Chemical	-1	9523805
.	O	-1	9523805
However,	O	-1	9523805
identi@@	O	-1	9523805
fic@@	O	-1	9523805
ation	O	-1	9523805
of	O	-1	9523805
a	O	-1	9523805
sh@@	O	-1	9523805
ort@@	O	-1	9523805
-@@	O	-1	9523805
act@@	O	-1	9523805
ing	O	-1	9523805
loc@@	O	-1	9523805
al	O	-1	9523805
anesthe@@	O	-1	9523805
tic	O	-1	9523805
to	O	-1	9523805
sub@@	O	-1	9523805
sti@@	O	-1	9523805
t@@	O	-1	9523805
ute	O	-1	9523805
for	O	-1	9523805
lidocaine	B-Chemical	D008012	9523805
for	O	-1	9523805
b@@	O	-1	9523805
ri@@	O	-1	9523805
e@@	O	-1	9523805
f	O	-1	9523805
surg@@	O	-1	9523805
ical	O	-1	9523805
proce@@	O	-1	9523805
d@@	O	-1	9523805
ures	O	-1	9523805
remain@@	O	-1	9523805
s	O	-1	9523805
an	O	-1	9523805
important	O	-1	9523805
go@@	O	-1	9523805
al.	O	-1	9523805
P@@	B-Chemical	D011318	9523805
ri@@	I-Chemical	-1	9523805
lo@@	I-Chemical	-1	9523805
ca@@	I-Chemical	-1	9523805
ine	I-Chemical	-1	9523805
is	O	-1	9523805
an	O	-1	9523805
amide	O	-1	9523805
loc@@	O	-1	9523805
al	O	-1	9523805
anesthe@@	O	-1	9523805
tic	O	-1	9523805
with	O	-1	9523805
a	O	-1	9523805
duration	O	-1	9523805
of	O	-1	9523805
action	O	-1	9523805
similar	O	-1	9523805
to	O	-1	9523805
that	O	-1	9523805
of	O	-1	9523805
lidocaine	B-Chemical	D008012	9523805
.	O	-1	9523805
Ac@@	O	-1	9523805
cor@@	O	-1	9523805
d@@	O	-1	9523805
ing@@	O	-1	9523805
ly,	O	-1	9523805
the	O	-1	9523805
present@@	O	-1	9523805
,	O	-1	9523805
pro@@	O	-1	9523805
sp@@	O	-1	9523805
ective	O	-1	9523805
double-bl@@	O	-1	9523805
ind	O	-1	9523805
study	O	-1	9523805
com@@	O	-1	9523805
pa@@	O	-1	9523805
res	O	-1	9523805
pri@@	B-Chemical	D011318	9523805
lo@@	I-Chemical	-1	9523805
ca@@	I-Chemical	-1	9523805
ine	I-Chemical	-1	9523805
with	O	-1	9523805
lidocaine	B-Chemical	D008012	9523805
and	O	-1	9523805
bupivac@@	B-Chemical	D002045	9523805
aine	I-Chemical	-1	9523805
with	O	-1	9523805
resp@@	O	-1	9523805
ect	O	-1	9523805
to	O	-1	9523805
duration	O	-1	9523805
of	O	-1	9523805
action	O	-1	9523805
and	O	-1	9523805
rel@@	O	-1	9523805
ative	O	-1	9523805
risk	O	-1	9523805
of	O	-1	9523805
T@@	B-Disease	D009422	9523805
N@@	I-Disease	-1	9523805
S@@	I-Disease	-1	9523805
s	I-Disease	-1	9523805
.	O	-1	9523805
METHODS:	O	-1	9523805
N@@	O	-1	9523805
ine@@	O	-1	9523805
t@@	O	-1	9523805
y	O	-1	9523805
patients	O	-1	9523805
cl@@	O	-1	9523805
assi@@	O	-1	9523805
fied	O	-1	9523805
as	O	-1	9523805
A@@	O	-1	9523805
mer@@	O	-1	9523805
ic@@	O	-1	9523805
an	O	-1	9523805
S@@	O	-1	9523805
oci@@	O	-1	9523805
ety	O	-1	9523805
of	O	-1	9523805
An@@	O	-1	9523805
esthe@@	O	-1	9523805
si@@	O	-1	9523805
olog@@	O	-1	9523805
ist@@	O	-1	9523805
s	O	-1	9523805
physi@@	O	-1	9523805
c@@	O	-1	9523805
al	O	-1	9523805
status	O	-1	9523805
I	O	-1	9523805
or	O	-1	9523805
II	O	-1	9523805
who	O	-1	9523805
were	O	-1	9523805
sch@@	O	-1	9523805
ed@@	O	-1	9523805
ul@@	O	-1	9523805
ed	O	-1	9523805
for	O	-1	9523805
sh@@	O	-1	9523805
ort	O	-1	9523805
g@@	O	-1	9523805
y@@	O	-1	9523805
nec@@	O	-1	9523805
ologic	O	-1	9523805
proce@@	O	-1	9523805
d@@	O	-1	9523805
ures	O	-1	9523805
under	O	-1	9523805
spinal	O	-1	9523805
anesthe@@	O	-1	9523805
sia	O	-1	9523805
were	O	-1	9523805
random@@	O	-1	9523805
ly	O	-1	9523805
al@@	O	-1	9523805
loc@@	O	-1	9523805
ated	O	-1	9523805
to	O	-1	9523805
recei@@	O	-1	9523805
ve	O	-1	9523805
2.@@	O	-1	9523805
5	O	-1	9523805
m@@	O	-1	9523805
l	O	-1	9523805
2@@	O	-1	9523805
%	O	-1	9523805
lidocaine	B-Chemical	D008012	9523805
in	O	-1	9523805
7.@@	O	-1	9523805
5%	O	-1	9523805
g@@	B-Chemical	D005947	9523805
lu@@	I-Chemical	-1	9523805
co@@	I-Chemical	-1	9523805
se	I-Chemical	-1	9523805
,	O	-1	9523805
2@@	O	-1	9523805
%	O	-1	9523805
pri@@	B-Chemical	D011318	9523805
lo@@	I-Chemical	-1	9523805
ca@@	I-Chemical	-1	9523805
ine	I-Chemical	-1	9523805
in	O	-1	9523805
7.@@	O	-1	9523805
5%	O	-1	9523805
g@@	B-Chemical	D005947	9523805
lu@@	I-Chemical	-1	9523805
co@@	I-Chemical	-1	9523805
se	I-Chemical	-1	9523805
,	O	-1	9523805
or	O	-1	9523805
0.@@	O	-1	9523805
5%	O	-1	9523805
bupivac@@	B-Chemical	D002045	9523805
aine	I-Chemical	-1	9523805
in	O	-1	9523805
7.@@	O	-1	9523805
5%	O	-1	9523805
g@@	B-Chemical	D005947	9523805
lu@@	I-Chemical	-1	9523805
co@@	I-Chemical	-1	9523805
se	I-Chemical	-1	9523805
.	O	-1	9523805
All	O	-1	9523805
sol@@	O	-1	9523805
u@@	O	-1	9523805
tions	O	-1	9523805
were	O	-1	9523805
pro@@	O	-1	9523805
vid@@	O	-1	9523805
ed	O	-1	9523805
in	O	-1	9523805
bl@@	O	-1	9523805
ind@@	O	-1	9523805
ed	O	-1	9523805
vi@@	O	-1	9523805
als	O	-1	9523805
by	O	-1	9523805
the	O	-1	9523805
hospit@@	O	-1	9523805
al	O	-1	9523805
pharmac@@	O	-1	9523805
y.	O	-1	9523805
D@@	O	-1	9523805
et@@	O	-1	9523805
ail@@	O	-1	9523805
s	O	-1	9523805
of	O	-1	9523805
spinal	O	-1	9523805
p@@	O	-1	9523805
unc@@	O	-1	9523805
t@@	O	-1	9523805
ure,	O	-1	9523805
exten@@	O	-1	9523805
sion	O	-1	9523805
and	O	-1	9523805
reg@@	O	-1	9523805
res@@	O	-1	9523805
sion	O	-1	9523805
of	O	-1	9523805
spinal	O	-1	9523805
block@@	O	-1	9523805
,	O	-1	9523805
and	O	-1	9523805
the	O	-1	9523805
times	O	-1	9523805
to	O	-1	9523805
reac@@	O	-1	9523805
h	O	-1	9523805
dis@@	O	-1	9523805
ch@@	O	-1	9523805
arg@@	O	-1	9523805
e	O	-1	9523805
c@@	O	-1	9523805
rit@@	O	-1	9523805
er@@	O	-1	9523805
ia	O	-1	9523805
were	O	-1	9523805
not@@	O	-1	9523805
ed.	O	-1	9523805
In	O	-1	9523805
the	O	-1	9523805
ev@@	O	-1	9523805
en@@	O	-1	9523805
ing	O	-1	9523805
of	O	-1	9523805
postoperative	O	-1	9523805
day	O	-1	9523805
1,	O	-1	9523805
patients	O	-1	9523805
were	O	-1	9523805
evaluated	O	-1	9523805
for	O	-1	9523805
T@@	B-Disease	D009422	9523805
N@@	I-Disease	-1	9523805
S@@	I-Disease	-1	9523805
s	I-Disease	-1	9523805
by	O	-1	9523805
a	O	-1	9523805
physi@@	O	-1	9523805
ci@@	O	-1	9523805
an	O	-1	9523805
un@@	O	-1	9523805
aw@@	O	-1	9523805
are	O	-1	9523805
of	O	-1	9523805
the	O	-1	9523805
drug	O	-1	9523805
administered	O	-1	9523805
and	O	-1	9523805
the	O	-1	9523805
det@@	O	-1	9523805
ail@@	O	-1	9523805
s	O	-1	9523805
of	O	-1	9523805
the	O	-1	9523805
anesthe@@	O	-1	9523805
tic	O	-1	9523805
proce@@	O	-1	9523805
d@@	O	-1	9523805
ure.	O	-1	9523805
RESULTS:	O	-1	9523805
N@@	O	-1	9523805
ine	O	-1	9523805
of	O	-1	9523805
30	O	-1	9523805
patients	O	-1	9523805
receiving	O	-1	9523805
lidocaine	B-Chemical	D008012	9523805
experienced	O	-1	9523805
T@@	B-Disease	D009422	9523805
N@@	I-Disease	-1	9523805
S@@	I-Disease	-1	9523805
s	I-Disease	-1	9523805
,	O	-1	9523805
1	O	-1	9523805
of	O	-1	9523805
30	O	-1	9523805
patients	O	-1	9523805
receiving	O	-1	9523805
pri@@	B-Chemical	D011318	9523805
lo@@	I-Chemical	-1	9523805
ca@@	I-Chemical	-1	9523805
ine	I-Chemical	-1	9523805
(P	O	-1	9523805
=	O	-1	9523805
0.0@@	O	-1	9523805
3@@	O	-1	9523805
)	O	-1	9523805
had	O	-1	9523805
th@@	O	-1	9523805
em@@	O	-1	9523805
,	O	-1	9523805
and	O	-1	9523805
n@@	O	-1	9523805
one	O	-1	9523805
of	O	-1	9523805
30	O	-1	9523805
patients	O	-1	9523805
receiving	O	-1	9523805
bupivac@@	B-Chemical	D002045	9523805
aine	I-Chemical	-1	9523805
had	O	-1	9523805
T@@	B-Disease	D009422	9523805
N@@	I-Disease	-1	9523805
S@@	I-Disease	-1	9523805
s	I-Disease	-1	9523805
.	O	-1	9523805
T@@	O	-1	9523805
im@@	O	-1	9523805
es	O	-1	9523805
to	O	-1	9523805
am@@	O	-1	9523805
b@@	O	-1	9523805
ul@@	O	-1	9523805
ate	O	-1	9523805
and	O	-1	9523805
to	O	-1	9523805
v@@	O	-1	9523805
oid	O	-1	9523805
were	O	-1	9523805
similar	O	-1	9523805
after	O	-1	9523805
lidocaine	B-Chemical	D008012	9523805
and	O	-1	9523805
pri@@	B-Chemical	D011318	9523805
lo@@	I-Chemical	-1	9523805
ca@@	I-Chemical	-1	9523805
ine	I-Chemical	-1	9523805
(1@@	O	-1	9523805
50	O	-1	9523805
vs.	O	-1	9523805
1@@	O	-1	9523805
6@@	O	-1	9523805
5	O	-1	9523805
min	O	-1	9523805
and	O	-1	9523805
2@@	O	-1	9523805
3@@	O	-1	9523805
8	O	-1	9523805
vs.	O	-1	9523805
25@@	O	-1	9523805
3	O	-1	9523805
min@@	O	-1	9523805
,	O	-1	9523805
respectivel@@	O	-1	9523805
y@@	O	-1	9523805
)	O	-1	9523805
but	O	-1	9523805
prolonged	O	-1	9523805
after	O	-1	9523805
bupivac@@	B-Chemical	D002045	9523805
aine	I-Chemical	-1	9523805
(2@@	O	-1	9523805
00	O	-1	9523805
and	O	-1	9523805
2@@	O	-1	9523805
9@@	O	-1	9523805
9	O	-1	9523805
min@@	O	-1	9523805
,	O	-1	9523805
respectivel@@	O	-1	9523805
y@@	O	-1	9523805
;	O	-1	9523805
P	O	-1	9523805
<	O	-1	9523805
0.05@@	O	-1	9523805
).	O	-1	9523805
CONCLUSIONS:	O	-1	9523805
P@@	B-Chemical	D011318	9523805
ri@@	I-Chemical	-1	9523805
lo@@	I-Chemical	-1	9523805
ca@@	I-Chemical	-1	9523805
ine	I-Chemical	-1	9523805
may	O	-1	9523805
be	O	-1	9523805
pre@@	O	-1	9523805
fer@@	O	-1	9523805
able	O	-1	9523805
to	O	-1	9523805
lidocaine	B-Chemical	D008012	9523805
for	O	-1	9523805
sh@@	O	-1	9523805
ort	O	-1	9523805
surg@@	O	-1	9523805
ical	O	-1	9523805
proce@@	O	-1	9523805
d@@	O	-1	9523805
ures	O	-1	9523805
because	O	-1	9523805
it	O	-1	9523805
has	O	-1	9523805
a	O	-1	9523805
similar	O	-1	9523805
duration	O	-1	9523805
of	O	-1	9523805
action	O	-1	9523805
but	O	-1	9523805
a	O	-1	9523805
lower	O	-1	9523805
incidence	O	-1	9523805
of	O	-1	9523805
T@@	B-Disease	D009422	9523805
N@@	I-Disease	-1	9523805
S@@	I-Disease	-1	9523805
s	I-Disease	-1	9523805
.	O	-1	9523805

The	O	-1	9245658
role	O	-1	9245658
of	O	-1	9245658
nicotine	B-Chemical	D009538	9245658
in	O	-1	9245658
smo@@	O	-1	9245658
k@@	O	-1	9245658
ing@@	O	-1	9245658
-@@	O	-1	9245658
related	O	-1	9245658
cardiovascular	B-Disease	D002318	9245658
disease	I-Disease	-1	9245658
.	O	-1	9245658
N@@	B-Chemical	D009538	9245658
icot@@	I-Chemical	-1	9245658
ine	I-Chemical	-1	9245658
activ@@	O	-1	9245658
ates	O	-1	9245658
the	O	-1	9245658
sym@@	O	-1	9245658
pa@@	O	-1	9245658
thetic	O	-1	9245658
ner@@	O	-1	9245658
v@@	O	-1	9245658
ous	O	-1	9245658
system	O	-1	9245658
and	O	-1	9245658
in	O	-1	9245658
this	O	-1	9245658
w@@	O	-1	9245658
ay	O	-1	9245658
could	O	-1	9245658
cont@@	O	-1	9245658
rib@@	O	-1	9245658
ute	O	-1	9245658
to	O	-1	9245658
cardiovascular	B-Disease	D002318	9245658
disease	I-Disease	-1	9245658
.	O	-1	9245658
An@@	O	-1	9245658
im@@	O	-1	9245658
al	O	-1	9245658
studies	O	-1	9245658
and	O	-1	9245658
mechanis@@	O	-1	9245658
tic	O	-1	9245658
studies	O	-1	9245658
indicate	O	-1	9245658
that	O	-1	9245658
nicotine	B-Chemical	D009538	9245658
could	O	-1	9245658
pl@@	O	-1	9245658
ay	O	-1	9245658
a	O	-1	9245658
role	O	-1	9245658
in	O	-1	9245658
ac@@	O	-1	9245658
ce@@	O	-1	9245658
l@@	O	-1	9245658
er@@	O	-1	9245658
ating	O	-1	9245658
a@@	B-Disease	D050197	9245658
therosclero@@	I-Disease	-1	9245658
sis	I-Disease	-1	9245658
,	O	-1	9245658
but	O	-1	9245658
evidence	O	-1	9245658
among	O	-1	9245658
hum@@	O	-1	9245658
ans	O	-1	9245658
is	O	-1	9245658
to@@	O	-1	9245658
o	O	-1	9245658
in@@	O	-1	9245658
ade@@	O	-1	9245658
qu@@	O	-1	9245658
ate	O	-1	9245658
to	O	-1	9245658
be	O	-1	9245658
def@@	O	-1	9245658
in@@	O	-1	9245658
itive	O	-1	9245658
about	O	-1	9245658
such	O	-1	9245658
an	O	-1	9245658
effect@@	O	-1	9245658
.	O	-1	9245658
Al@@	O	-1	9245658
most	O	-1	9245658
cer@@	O	-1	9245658
t@@	O	-1	9245658
ain@@	O	-1	9245658
ly,	O	-1	9245658
nicotine	B-Chemical	D009538	9245658
vi@@	O	-1	9245658
a	O	-1	9245658
its	O	-1	9245658
hemo@@	O	-1	9245658
dynam@@	O	-1	9245658
ic	O	-1	9245658
effects	O	-1	9245658
cont@@	O	-1	9245658
ri@@	O	-1	9245658
but@@	O	-1	9245658
es	O	-1	9245658
to	O	-1	9245658
acute	O	-1	9245658
cardiovascular	O	-1	9245658
event@@	O	-1	9245658
s,	O	-1	9245658
although	O	-1	9245658
current	O	-1	9245658
evidence	O	-1	9245658
suggests	O	-1	9245658
that	O	-1	9245658
the	O	-1	9245658
effects	O	-1	9245658
of	O	-1	9245658
nicotine	B-Chemical	D009538	9245658
are	O	-1	9245658
m@@	O	-1	9245658
uc@@	O	-1	9245658
h	O	-1	9245658
less	O	-1	9245658
important	O	-1	9245658
than	O	-1	9245658
are	O	-1	9245658
the	O	-1	9245658
pro@@	O	-1	9245658
thrombotic	O	-1	9245658
effects	O	-1	9245658
of	O	-1	9245658
ci@@	O	-1	9245658
g@@	O	-1	9245658
a@@	O	-1	9245658
ret@@	O	-1	9245658
te	O	-1	9245658
smo@@	O	-1	9245658
king	O	-1	9245658
or	O	-1	9245658
the	O	-1	9245658
effects	O	-1	9245658
of	O	-1	9245658
carb@@	B-Chemical	D002248	9245658
on	I-Chemical	-1	9245658
mon@@	I-Chemical	-1	9245658
ox@@	I-Chemical	-1	9245658
ide	I-Chemical	-1	9245658
.	O	-1	9245658
N@@	B-Chemical	D009538	9245658
icot@@	I-Chemical	-1	9245658
ine	I-Chemical	-1	9245658
does	O	-1	9245658
not	O	-1	9245658
appe@@	O	-1	9245658
ar	O	-1	9245658
to	O	-1	9245658
enh@@	O	-1	9245658
ance	O	-1	9245658
thrombo@@	B-Disease	D013927	9245658
sis	I-Disease	-1	9245658
among	O	-1	9245658
hum@@	O	-1	9245658
an@@	O	-1	9245658
s.	O	-1	9245658
Clin@@	O	-1	9245658
ical	O	-1	9245658
studies	O	-1	9245658
of	O	-1	9245658
pi@@	O	-1	9245658
p@@	O	-1	9245658
e	O	-1	9245658
smo@@	O	-1	9245658
k@@	O	-1	9245658
ers	O	-1	9245658
and	O	-1	9245658
pe@@	O	-1	9245658
o@@	O	-1	9245658
ple	O	-1	9245658
using	O	-1	9245658
trans@@	O	-1	9245658
der@@	O	-1	9245658
m@@	O	-1	9245658
al	O	-1	9245658
nicotine	B-Chemical	D009538	9245658
suppor@@	O	-1	9245658
t	O	-1	9245658
the	O	-1	9245658
ide@@	O	-1	9245658
a	O	-1	9245658
that	O	-1	9245658
tox@@	O	-1	9245658
ins	O	-1	9245658
other	O	-1	9245658
than	O	-1	9245658
nicotine	B-Chemical	D009538	9245658
are	O	-1	9245658
the	O	-1	9245658
most	O	-1	9245658
important	O	-1	9245658
causes	O	-1	9245658
of	O	-1	9245658
acute	O	-1	9245658
cardiovascular	O	-1	9245658
event@@	O	-1	9245658
s.	O	-1	9245658
F@@	O	-1	9245658
in@@	O	-1	9245658
ally,	O	-1	9245658
the	O	-1	9245658
dose	O	-1	9245658
response	O	-1	9245658
for	O	-1	9245658
cardiovascular	O	-1	9245658
events	O	-1	9245658
of	O	-1	9245658
nicotine	B-Chemical	D009538	9245658
appear@@	O	-1	9245658
s	O	-1	9245658
to	O	-1	9245658
be	O	-1	9245658
f@@	O	-1	9245658
lat@@	O	-1	9245658
,	O	-1	9245658
suggesting	O	-1	9245658
that	O	-1	9245658
if	O	-1	9245658
nicotine	B-Chemical	D009538	9245658
is	O	-1	9245658
invol@@	O	-1	9245658
ve@@	O	-1	9245658
d,	O	-1	9245658
adverse	O	-1	9245658
effects	O	-1	9245658
might	O	-1	9245658
be	O	-1	9245658
seen	O	-1	9245658
with	O	-1	9245658
rel@@	O	-1	9245658
atively	O	-1	9245658
low@@	O	-1	9245658
-@@	O	-1	9245658
level	O	-1	9245658
ci@@	O	-1	9245658
g@@	O	-1	9245658
a@@	O	-1	9245658
ret@@	O	-1	9245658
te	O	-1	9245658
expos@@	O	-1	9245658
ures@@	O	-1	9245658
.	O	-1	9245658

S@@	B-Disease	D012640	9034419
e@@	I-Disease	-1	9034419
iz@@	I-Disease	-1	9034419
ure	I-Disease	-1	9034419
result@@	O	-1	9034419
ing	O	-1	9034419
from	O	-1	9034419
a	O	-1	9034419
ven@@	B-Chemical	C047426	9034419
l@@	I-Chemical	-1	9034419
af@@	I-Chemical	-1	9034419
ax@@	I-Chemical	-1	9034419
ine	I-Chemical	-1	9034419
over@@	B-Disease	D062787	9034419
dose	I-Disease	-1	9034419
.	O	-1	9034419
OBJECTIVE:	O	-1	9034419
To	O	-1	9034419
report	O	-1	9034419
a	O	-1	9034419
case	O	-1	9034419
of	O	-1	9034419
ven@@	B-Chemical	C047426	9034419
l@@	I-Chemical	-1	9034419
af@@	I-Chemical	-1	9034419
ax@@	I-Chemical	-1	9034419
ine	I-Chemical	-1	9034419
over@@	B-Disease	D062787	9034419
dose	I-Disease	-1	9034419
.	O	-1	9034419
CA@@	O	-1	9034419
S@@	O	-1	9034419
E	O	-1	9034419
S@@	O	-1	9034419
U@@	O	-1	9034419
M@@	O	-1	9034419
MA@@	O	-1	9034419
R@@	O	-1	9034419
Y@@	O	-1	9034419
:	O	-1	9034419
A	O	-1	9034419
4@@	O	-1	9034419
0-@@	O	-1	9034419
year-old	O	-1	9034419
woman	O	-1	9034419
with	O	-1	9034419
major	B-Disease	D003865	9034419
de@@	I-Disease	-1	9034419
pression	I-Disease	-1	9034419
to@@	O	-1	9034419
o@@	O	-1	9034419
k	O	-1	9034419
an	O	-1	9034419
over@@	B-Disease	D062787	9034419
dose	I-Disease	-1	9034419
of	O	-1	9034419
ven@@	B-Chemical	C047426	9034419
l@@	I-Chemical	-1	9034419
af@@	I-Chemical	-1	9034419
ax@@	I-Chemical	-1	9034419
ine	I-Chemical	-1	9034419
in	O	-1	9034419
an	O	-1	9034419
appa@@	O	-1	9034419
rent	O	-1	9034419
su@@	O	-1	9034419
ic@@	O	-1	9034419
ide	O	-1	9034419
at@@	O	-1	9034419
tem@@	O	-1	9034419
pt@@	O	-1	9034419
.	O	-1	9034419
After	O	-1	9034419
the	O	-1	9034419
ing@@	O	-1	9034419
es@@	O	-1	9034419
tion	O	-1	9034419
of	O	-1	9034419
2@@	O	-1	9034419
6	O	-1	9034419
ven@@	B-Chemical	C047426	9034419
l@@	I-Chemical	-1	9034419
af@@	I-Chemical	-1	9034419
ax@@	I-Chemical	-1	9034419
ine	I-Chemical	-1	9034419
50@@	O	-1	9034419
-@@	O	-1	9034419
mg	O	-1	9034419
t@@	O	-1	9034419
able@@	O	-1	9034419
t@@	O	-1	9034419
s,	O	-1	9034419
the	O	-1	9034419
patient	O	-1	9034419
experienced	O	-1	9034419
a	O	-1	9034419
wit@@	O	-1	9034419
n@@	O	-1	9034419
ess@@	O	-1	9034419
ed	O	-1	9034419
gener@@	O	-1	9034419
al@@	O	-1	9034419
ized	O	-1	9034419
seizure	B-Disease	D012640	9034419
.	O	-1	9034419
S@@	O	-1	9034419
he	O	-1	9034419
was	O	-1	9034419
ad@@	O	-1	9034419
mit@@	O	-1	9034419
ted	O	-1	9034419
to	O	-1	9034419
the	O	-1	9034419
med@@	O	-1	9034419
ical	O	-1	9034419
int@@	O	-1	9034419
en@@	O	-1	9034419
sive	O	-1	9034419
car@@	O	-1	9034419
e	O	-1	9034419
un@@	O	-1	9034419
it@@	O	-1	9034419
,	O	-1	9034419
ven@@	B-Chemical	C047426	9034419
l@@	I-Chemical	-1	9034419
af@@	I-Chemical	-1	9034419
ax@@	I-Chemical	-1	9034419
ine	I-Chemical	-1	9034419
was	O	-1	9034419
discontinu@@	O	-1	9034419
ed,	O	-1	9034419
and	O	-1	9034419
no	O	-1	9034419
further	O	-1	9034419
sequ@@	O	-1	9034419
el@@	O	-1	9034419
a@@	O	-1	9034419
e	O	-1	9034419
were	O	-1	9034419
se@@	O	-1	9034419
en@@	O	-1	9034419
.	O	-1	9034419
D@@	O	-1	9034419
I@@	O	-1	9034419
S@@	O	-1	9034419
C@@	O	-1	9034419
US@@	O	-1	9034419
S@@	O	-1	9034419
ION@@	O	-1	9034419
:	O	-1	9034419
To	O	-1	9034419
our	O	-1	9034419
know@@	O	-1	9034419
le@@	O	-1	9034419
d@@	O	-1	9034419
g@@	O	-1	9034419
e,	O	-1	9034419
this	O	-1	9034419
is	O	-1	9034419
the	O	-1	9034419
first	O	-1	9034419
reported	O	-1	9034419
case	O	-1	9034419
of	O	-1	9034419
ven@@	B-Chemical	C047426	9034419
l@@	I-Chemical	-1	9034419
af@@	I-Chemical	-1	9034419
ax@@	I-Chemical	-1	9034419
ine	I-Chemical	-1	9034419
over@@	B-Disease	D062787	9034419
dose	I-Disease	-1	9034419
that	O	-1	9034419
resulted	O	-1	9034419
in	O	-1	9034419
a	O	-1	9034419
gener@@	O	-1	9034419
al@@	O	-1	9034419
ized	O	-1	9034419
seizure	B-Disease	D012640	9034419
.	O	-1	9034419
B@@	O	-1	9034419
as@@	O	-1	9034419
ed	O	-1	9034419
on	O	-1	9034419
non@@	O	-1	9034419
over@@	O	-1	9034419
dose	O	-1	9034419
pharmac@@	O	-1	9034419
o@@	O	-1	9034419
kine@@	O	-1	9034419
tics	O	-1	9034419
and	O	-1	9034419
pharmac@@	O	-1	9034419
o@@	O	-1	9034419
dynam@@	O	-1	9034419
ic@@	O	-1	9034419
s	O	-1	9034419
of	O	-1	9034419
ven@@	B-Chemical	C047426	9034419
l@@	I-Chemical	-1	9034419
af@@	I-Chemical	-1	9034419
ax@@	I-Chemical	-1	9034419
ine	I-Chemical	-1	9034419
and	O	-1	9034419
the	O	-1	9034419
potential	O	-1	9034419
ris@@	O	-1	9034419
k@@	O	-1	9034419
s	O	-1	9034419
of	O	-1	9034419
av@@	O	-1	9034419
ail@@	O	-1	9034419
able	O	-1	9034419
inter@@	O	-1	9034419
ven@@	O	-1	9034419
tion@@	O	-1	9034419
s,	O	-1	9034419
no	O	-1	9034419
em@@	O	-1	9034419
erg@@	O	-1	9034419
ent	O	-1	9034419
therapy	O	-1	9034419
was	O	-1	9034419
insti@@	O	-1	9034419
tu@@	O	-1	9034419
ted.	O	-1	9034419
CONCLUSIONS:	O	-1	9034419
The	O	-1	9034419
ven@@	B-Chemical	C047426	9034419
l@@	I-Chemical	-1	9034419
af@@	I-Chemical	-1	9034419
ax@@	I-Chemical	-1	9034419
ine	I-Chemical	-1	9034419
over@@	B-Disease	D062787	9034419
dose	I-Disease	-1	9034419
in	O	-1	9034419
our	O	-1	9034419
patient	O	-1	9034419
resulted	O	-1	9034419
in	O	-1	9034419
a	O	-1	9034419
single	O	-1	9034419
episo@@	O	-1	9034419
de	O	-1	9034419
of	O	-1	9034419
gener@@	O	-1	9034419
al@@	O	-1	9034419
ized	O	-1	9034419
seizure	B-Disease	D012640	9034419
but	O	-1	9034419
el@@	O	-1	9034419
ic@@	O	-1	9034419
ited	O	-1	9034419
no	O	-1	9034419
further	O	-1	9034419
sequ@@	O	-1	9034419
el@@	O	-1	9034419
a@@	O	-1	9034419
e.	O	-1	9034419

Eff@@	O	-1	8829025
ect	O	-1	8829025
of	O	-1	8829025
n@@	B-Chemical	D009543	8829025
if@@	I-Chemical	-1	8829025
edi@@	I-Chemical	-1	8829025
pine	I-Chemical	-1	8829025
on	O	-1	8829025
renal	O	-1	8829025
function	O	-1	8829025
in	O	-1	8829025
liver	O	-1	8829025
transplant	O	-1	8829025
re@@	O	-1	8829025
ci@@	O	-1	8829025
pi@@	O	-1	8829025
ents	O	-1	8829025
receiving	O	-1	8829025
tacrolimus	B-Chemical	D016559	8829025
.	O	-1	8829025
The	O	-1	8829025
effect	O	-1	8829025
of	O	-1	8829025
n@@	B-Chemical	D009543	8829025
if@@	I-Chemical	-1	8829025
edi@@	I-Chemical	-1	8829025
pine	I-Chemical	-1	8829025
on	O	-1	8829025
renal	O	-1	8829025
function	O	-1	8829025
in	O	-1	8829025
liver	O	-1	8829025
transplant	O	-1	8829025
re@@	O	-1	8829025
ci@@	O	-1	8829025
pi@@	O	-1	8829025
ents	O	-1	8829025
who	O	-1	8829025
were	O	-1	8829025
receiving	O	-1	8829025
tacrolimus	B-Chemical	D016559	8829025
was	O	-1	8829025
evaluated	O	-1	8829025
between	O	-1	8829025
J@@	O	-1	8829025
an@@	O	-1	8829025
u@@	O	-1	8829025
ary	O	-1	8829025
19@@	O	-1	8829025
9@@	O	-1	8829025
2	O	-1	8829025
and	O	-1	8829025
J@@	O	-1	8829025
an@@	O	-1	8829025
u@@	O	-1	8829025
ary	O	-1	8829025
19@@	O	-1	8829025
9@@	O	-1	8829025
6@@	O	-1	8829025
.	O	-1	8829025
Two	O	-1	8829025
groups	O	-1	8829025
of	O	-1	8829025
patients	O	-1	8829025
receiving	O	-1	8829025
tacrolimus	B-Chemical	D016559	8829025
were	O	-1	8829025
compared	O	-1	8829025
over	O	-1	8829025
a	O	-1	8829025
period	O	-1	8829025
of	O	-1	8829025
1	O	-1	8829025
year@@	O	-1	8829025
,	O	-1	8829025
one	O	-1	8829025
group	O	-1	8829025
comp@@	O	-1	8829025
ris@@	O	-1	8829025
ing	O	-1	8829025
hypertensive	B-Disease	D006973	8829025
patients	O	-1	8829025
who	O	-1	8829025
were	O	-1	8829025
receiving	O	-1	8829025
n@@	B-Chemical	D009543	8829025
if@@	I-Chemical	-1	8829025
edi@@	I-Chemical	-1	8829025
pine	I-Chemical	-1	8829025
,	O	-1	8829025
and	O	-1	8829025
the	O	-1	8829025
other	O	-1	8829025
comp@@	O	-1	8829025
ris@@	O	-1	8829025
ing	O	-1	8829025
non@@	O	-1	8829025
hypertensive	O	-1	8829025
patients	O	-1	8829025
not	O	-1	8829025
receiving	O	-1	8829025
n@@	B-Chemical	D009543	8829025
if@@	I-Chemical	-1	8829025
edi@@	I-Chemical	-1	8829025
pine	I-Chemical	-1	8829025
.	O	-1	8829025
The	O	-1	8829025
time	O	-1	8829025
from	O	-1	8829025
transplant	O	-1	8829025
to	O	-1	8829025
baseline	O	-1	8829025
was	O	-1	8829025
similar	O	-1	8829025
in	O	-1	8829025
all	O	-1	8829025
patients.	O	-1	8829025
N@@	B-Chemical	D009543	8829025
if@@	I-Chemical	-1	8829025
edi@@	I-Chemical	-1	8829025
pine	I-Chemical	-1	8829025
significantly	O	-1	8829025
improved	O	-1	8829025
kidney	O	-1	8829025
function	O	-1	8829025
as	O	-1	8829025
indic@@	O	-1	8829025
ated	O	-1	8829025
by	O	-1	8829025
a	O	-1	8829025
significant	O	-1	8829025
low@@	O	-1	8829025
ering	O	-1	8829025
of	O	-1	8829025
serum	O	-1	8829025
creatinine	B-Chemical	D003404	8829025
levels	O	-1	8829025
at	O	-1	8829025
6	O	-1	8829025
and	O	-1	8829025
12	O	-1	8829025
months.	O	-1	8829025
The	O	-1	8829025
observed	O	-1	8829025
positive	O	-1	8829025
im@@	O	-1	8829025
pac@@	O	-1	8829025
t	O	-1	8829025
of	O	-1	8829025
n@@	B-Chemical	D009543	8829025
if@@	I-Chemical	-1	8829025
edi@@	I-Chemical	-1	8829025
pine	I-Chemical	-1	8829025
on	O	-1	8829025
reduc@@	O	-1	8829025
ing	O	-1	8829025
the	O	-1	8829025
nephro@@	B-Disease	D007674	8829025
toxicity	I-Disease	-1	8829025
associated	O	-1	8829025
with	O	-1	8829025
tacrolimus	B-Chemical	D016559	8829025
in	O	-1	8829025
liver	O	-1	8829025
transplant	O	-1	8829025
re@@	O	-1	8829025
ci@@	O	-1	8829025
pi@@	O	-1	8829025
ents	O	-1	8829025
should	O	-1	8829025
be	O	-1	8829025
an	O	-1	8829025
important	O	-1	8829025
factor	O	-1	8829025
in	O	-1	8829025
sel@@	O	-1	8829025
ect@@	O	-1	8829025
ing	O	-1	8829025
an	O	-1	8829025
agent	O	-1	8829025
to	O	-1	8829025
tre@@	O	-1	8829025
at	O	-1	8829025
hypertension	B-Disease	D006973	8829025
in	O	-1	8829025
this	O	-1	8829025
po@@	O	-1	8829025
pul@@	O	-1	8829025
ation.	O	-1	8829025

S@@	B-Disease	D054138	8437969
in@@	I-Disease	-1	8437969
us	I-Disease	-1	8437969
ar@@	I-Disease	-1	8437969
res@@	I-Disease	-1	8437969
t	I-Disease	-1	8437969
associated	O	-1	8437969
with	O	-1	8437969
continu@@	O	-1	8437969
ous@@	O	-1	8437969
-@@	O	-1	8437969
infusion	O	-1	8437969
cimetid@@	B-Chemical	D002927	8437969
ine	I-Chemical	-1	8437969
.	O	-1	8437969
The	O	-1	8437969
administration	O	-1	8437969
of	O	-1	8437969
inter@@	O	-1	8437969
mit@@	O	-1	8437969
t@@	O	-1	8437969
ent	O	-1	8437969
intravenous	O	-1	8437969
infu@@	O	-1	8437969
sions	O	-1	8437969
of	O	-1	8437969
cimetid@@	B-Chemical	D002927	8437969
ine	I-Chemical	-1	8437969
is	O	-1	8437969
inf@@	O	-1	8437969
requ@@	O	-1	8437969
ently	O	-1	8437969
associated	O	-1	8437969
with	O	-1	8437969
the	O	-1	8437969
development	O	-1	8437969
of	O	-1	8437969
brady@@	B-Disease	D001919	8437969
arrhyth@@	I-Disease	-1	8437969
mi@@	I-Disease	-1	8437969
as	I-Disease	-1	8437969
.	O	-1	8437969
A	O	-1	8437969
4@@	O	-1	8437969
0-@@	O	-1	8437969
year-old	O	-1	8437969
man	O	-1	8437969
with	O	-1	8437969
leuk@@	B-Disease	D007938	8437969
emia	I-Disease	-1	8437969
and	O	-1	8437969
no	O	-1	8437969
hist@@	O	-1	8437969
ory	O	-1	8437969
of	O	-1	8437969
cardiac	B-Disease	D006331	8437969
disease	I-Disease	-1	8437969
developed	O	-1	8437969
recur@@	O	-1	8437969
ren@@	O	-1	8437969
t,	O	-1	8437969
b@@	O	-1	8437969
ri@@	O	-1	8437969
e@@	O	-1	8437969
f	O	-1	8437969
episo@@	O	-1	8437969
des	O	-1	8437969
of	O	-1	8437969
appa@@	O	-1	8437969
rent	O	-1	8437969
s@@	B-Disease	D054138	8437969
in@@	I-Disease	-1	8437969
us	I-Disease	-1	8437969
ar@@	I-Disease	-1	8437969
res@@	I-Disease	-1	8437969
t	I-Disease	-1	8437969
while	O	-1	8437969
receiving	O	-1	8437969
continu@@	O	-1	8437969
ous@@	O	-1	8437969
-@@	O	-1	8437969
infusion	O	-1	8437969
cimetid@@	B-Chemical	D002927	8437969
ine	I-Chemical	-1	8437969
50	O	-1	8437969
mg/@@	O	-1	8437969
hour@@	O	-1	8437969
.	O	-1	8437969
The	O	-1	8437969
arrhyth@@	B-Disease	D001145	8437969
mi@@	I-Disease	-1	8437969
as	I-Disease	-1	8437969
were	O	-1	8437969
tempor@@	O	-1	8437969
ally	O	-1	8437969
related	O	-1	8437969
to	O	-1	8437969
cimetid@@	B-Chemical	D002927	8437969
ine	I-Chemical	-1	8437969
administr@@	O	-1	8437969
ation,	O	-1	8437969
dis@@	O	-1	8437969
appe@@	O	-1	8437969
a@@	O	-1	8437969
red	O	-1	8437969
after	O	-1	8437969
dec@@	O	-1	8437969
h@@	O	-1	8437969
all@@	O	-1	8437969
en@@	O	-1	8437969
g@@	O	-1	8437969
e,	O	-1	8437969
and	O	-1	8437969
did	O	-1	8437969
not	O	-1	8437969
rec@@	O	-1	8437969
ur	O	-1	8437969
during	O	-1	8437969
ran@@	B-Chemical	D011899	8437969
iti@@	I-Chemical	-1	8437969
d@@	I-Chemical	-1	8437969
ine	I-Chemical	-1	8437969
treatment.	O	-1	8437969
This	O	-1	8437969
is	O	-1	8437969
the	O	-1	8437969
first	O	-1	8437969
reported	O	-1	8437969
case	O	-1	8437969
of	O	-1	8437969
s@@	B-Disease	D054138	8437969
in@@	I-Disease	-1	8437969
us	I-Disease	-1	8437969
ar@@	I-Disease	-1	8437969
res@@	I-Disease	-1	8437969
t	I-Disease	-1	8437969
associated	O	-1	8437969
with	O	-1	8437969
continu@@	O	-1	8437969
ous@@	O	-1	8437969
-@@	O	-1	8437969
infusion	O	-1	8437969
cimetid@@	B-Chemical	D002927	8437969
ine	I-Chemical	-1	8437969
.	O	-1	8437969

Com@@	O	-1	7890216
posi@@	O	-1	7890216
tion	O	-1	7890216
of	O	-1	7890216
g@@	B-Disease	D042882	7890216
all	I-Disease	-1	7890216
bladder	I-Disease	-1	7890216
ston@@	I-Disease	-1	7890216
es	I-Disease	-1	7890216
associated	O	-1	7890216
with	O	-1	7890216
oc@@	B-Chemical	D015282	7890216
tre@@	I-Chemical	-1	7890216
o@@	I-Chemical	-1	7890216
ti@@	I-Chemical	-1	7890216
de	I-Chemical	-1	7890216
:	O	-1	7890216
response	O	-1	7890216
to	O	-1	7890216
oral	O	-1	7890216
ur@@	B-Chemical	D014580	7890216
so@@	I-Chemical	-1	7890216
de@@	I-Chemical	-1	7890216
oxy@@	I-Chemical	-1	7890216
chol@@	I-Chemical	-1	7890216
ic	I-Chemical	-1	7890216
acid	I-Chemical	-1	7890216
.	O	-1	7890216
O@@	B-Chemical	D015282	7890216
c@@	I-Chemical	-1	7890216
tre@@	I-Chemical	-1	7890216
o@@	I-Chemical	-1	7890216
ti@@	I-Chemical	-1	7890216
de	I-Chemical	-1	7890216
,	O	-1	7890216
an	O	-1	7890216
effective	O	-1	7890216
treatment	O	-1	7890216
for	O	-1	7890216
ac@@	B-Disease	D000172	7890216
ro@@	I-Disease	-1	7890216
me@@	I-Disease	-1	7890216
g@@	I-Disease	-1	7890216
al@@	I-Disease	-1	7890216
y	I-Disease	-1	7890216
,	O	-1	7890216
induc@@	O	-1	7890216
es	O	-1	7890216
g@@	B-Disease	D042882	7890216
all	I-Disease	-1	7890216
bladder	I-Disease	-1	7890216
ston@@	I-Disease	-1	7890216
es	I-Disease	-1	7890216
in	O	-1	7890216
1@@	O	-1	7890216
3-@@	O	-1	7890216
6@@	O	-1	7890216
0%	O	-1	7890216
of	O	-1	7890216
patients.	O	-1	7890216
B@@	O	-1	7890216
ecause	O	-1	7890216
know@@	O	-1	7890216
le@@	O	-1	7890216
d@@	O	-1	7890216
ge	O	-1	7890216
of	O	-1	7890216
st@@	O	-1	7890216
one	O	-1	7890216
com@@	O	-1	7890216
posi@@	O	-1	7890216
tion	O	-1	7890216
is	O	-1	7890216
es@@	O	-1	7890216
sen@@	O	-1	7890216
tial	O	-1	7890216
for	O	-1	7890216
studies	O	-1	7890216
of	O	-1	7890216
their	O	-1	7890216
path@@	O	-1	7890216
o@@	O	-1	7890216
gene@@	O	-1	7890216
sis,	O	-1	7890216
treatment,	O	-1	7890216
and	O	-1	7890216
pre@@	O	-1	7890216
ven@@	O	-1	7890216
tion,	O	-1	7890216
this	O	-1	7890216
was	O	-1	7890216
investigated	O	-1	7890216
by	O	-1	7890216
direct	O	-1	7890216
and	O	-1	7890216
in@@	O	-1	7890216
direct	O	-1	7890216
meth@@	O	-1	7890216
o@@	O	-1	7890216
ds	O	-1	7890216
in	O	-1	7890216
14	O	-1	7890216
oc@@	B-Chemical	D015282	7890216
tre@@	I-Chemical	-1	7890216
o@@	I-Chemical	-1	7890216
ti@@	I-Chemical	-1	7890216
de	I-Chemical	-1	7890216
treated	O	-1	7890216
ac@@	B-Disease	D000172	7890216
ro@@	I-Disease	-1	7890216
me@@	I-Disease	-1	7890216
g@@	I-Disease	-1	7890216
al@@	I-Disease	-1	7890216
ic	I-Disease	-1	7890216
patients	O	-1	7890216
with	O	-1	7890216
g@@	B-Disease	D042882	7890216
all	I-Disease	-1	7890216
ston@@	I-Disease	-1	7890216
es	I-Disease	-1	7890216
.	O	-1	7890216
C@@	O	-1	7890216
hem@@	O	-1	7890216
ical	O	-1	7890216
analysis	O	-1	7890216
of	O	-1	7890216
g@@	B-Disease	D042882	7890216
all	I-Disease	-1	7890216
ston@@	I-Disease	-1	7890216
es	I-Disease	-1	7890216
re@@	O	-1	7890216
tri@@	O	-1	7890216
ev@@	O	-1	7890216
ed	O	-1	7890216
at	O	-1	7890216
chol@@	O	-1	7890216
ec@@	O	-1	7890216
y@@	O	-1	7890216
st@@	O	-1	7890216
ect@@	O	-1	7890216
om@@	O	-1	7890216
y	O	-1	7890216
from	O	-1	7890216
two	O	-1	7890216
patients,	O	-1	7890216
showed	O	-1	7890216
that	O	-1	7890216
they	O	-1	7890216
cont@@	O	-1	7890216
ained	O	-1	7890216
7@@	O	-1	7890216
1@@	O	-1	7890216
%	O	-1	7890216
and	O	-1	7890216
8@@	O	-1	7890216
7@@	O	-1	7890216
%	O	-1	7890216
cholester@@	B-Chemical	D002784	7890216
ol	I-Chemical	-1	7890216
by	O	-1	7890216
weigh@@	O	-1	7890216
t.	O	-1	7890216
In	O	-1	7890216
the	O	-1	7890216
remain@@	O	-1	7890216
ing	O	-1	7890216
12	O	-1	7890216
patients,	O	-1	7890216
lo@@	O	-1	7890216
cal@@	O	-1	7890216
is@@	O	-1	7890216
ed	O	-1	7890216
comp@@	O	-1	7890216
ut@@	O	-1	7890216
ed	O	-1	7890216
to@@	O	-1	7890216
mo@@	O	-1	7890216
graph@@	O	-1	7890216
y	O	-1	7890216
of	O	-1	7890216
the	O	-1	7890216
g@@	O	-1	7890216
all	O	-1	7890216
bladder	O	-1	7890216
showed	O	-1	7890216
that	O	-1	7890216
e@@	O	-1	7890216
ight	O	-1	7890216
had	O	-1	7890216
ston@@	O	-1	7890216
es	O	-1	7890216
with	O	-1	7890216
maxim@@	O	-1	7890216
um	O	-1	7890216
attenu@@	O	-1	7890216
ation	O	-1	7890216
sco@@	O	-1	7890216
res	O	-1	7890216
of	O	-1	7890216
<	O	-1	7890216
100	O	-1	7890216
H@@	O	-1	7890216
oun@@	O	-1	7890216
s@@	O	-1	7890216
fi@@	O	-1	7890216
el@@	O	-1	7890216
d	O	-1	7890216
un@@	O	-1	7890216
its	O	-1	7890216
(@@	O	-1	7890216
values	O	-1	7890216
of	O	-1	7890216
<	O	-1	7890216
100	O	-1	7890216
H@@	O	-1	7890216
U	O	-1	7890216
predic@@	O	-1	7890216
t	O	-1	7890216
cholester@@	B-Chemical	D002784	7890216
ol	I-Chemical	-1	7890216
r@@	O	-1	7890216
ic@@	O	-1	7890216
h@@	O	-1	7890216
,	O	-1	7890216
dis@@	O	-1	7890216
sol@@	O	-1	7890216
v@@	O	-1	7890216
able	O	-1	7890216
ston@@	O	-1	7890216
es@@	O	-1	7890216
).	O	-1	7890216
G@@	O	-1	7890216
all	O	-1	7890216
bladder	O	-1	7890216
b@@	O	-1	7890216
ile	O	-1	7890216
was	O	-1	7890216
obtained	O	-1	7890216
by	O	-1	7890216
ult@@	O	-1	7890216
r@@	O	-1	7890216
as@@	O	-1	7890216
ound	O	-1	7890216
gu@@	O	-1	7890216
ide@@	O	-1	7890216
d,	O	-1	7890216
f@@	O	-1	7890216
ine	O	-1	7890216
ne@@	O	-1	7890216
ed@@	O	-1	7890216
le	O	-1	7890216
p@@	O	-1	7890216
unc@@	O	-1	7890216
t@@	O	-1	7890216
ure	O	-1	7890216
from	O	-1	7890216
six	O	-1	7890216
patients.	O	-1	7890216
All	O	-1	7890216
six	O	-1	7890216
patients	O	-1	7890216
had	O	-1	7890216
su@@	O	-1	7890216
per@@	O	-1	7890216
s@@	O	-1	7890216
at@@	O	-1	7890216
ur@@	O	-1	7890216
ated	O	-1	7890216
b@@	O	-1	7890216
ile	O	-1	7890216
(@@	O	-1	7890216
mean	O	-1	7890216
(S@@	O	-1	7890216
E@@	O	-1	7890216
M@@	O	-1	7890216
)	O	-1	7890216
cholester@@	B-Chemical	D002784	7890216
ol	I-Chemical	-1	7890216
s@@	O	-1	7890216
at@@	O	-1	7890216
ur@@	O	-1	7890216
ation	O	-1	7890216
in@@	O	-1	7890216
de@@	O	-1	7890216
x	O	-1	7890216
of	O	-1	7890216
1.@@	O	-1	7890216
1@@	O	-1	7890216
9	O	-1	7890216
(@@	O	-1	7890216
0.0@@	O	-1	7890216
8@@	O	-1	7890216
)	O	-1	7890216
(@@	O	-1	7890216
range	O	-1	7890216
1.@@	O	-1	7890216
0@@	O	-1	7890216
1-@@	O	-1	7890216
1.@@	O	-1	7890216
5@@	O	-1	7890216
3@@	O	-1	7890216
)@@	O	-1	7890216
)	O	-1	7890216
and	O	-1	7890216
all	O	-1	7890216
had	O	-1	7890216
ab@@	O	-1	7890216
norm@@	O	-1	7890216
ally	O	-1	7890216
ra@@	O	-1	7890216
pid	O	-1	7890216
cholester@@	B-Chemical	D002784	7890216
ol	I-Chemical	-1	7890216
micro@@	O	-1	7890216
c@@	O	-1	7890216
r@@	O	-1	7890216
y@@	O	-1	7890216
st@@	O	-1	7890216
al	O	-1	7890216
nucle@@	O	-1	7890216
ation	O	-1	7890216
times	O	-1	7890216
(@@	O	-1	7890216
<	O	-1	7890216
4	O	-1	7890216
days	O	-1	7890216
(@@	O	-1	7890216
range	O	-1	7890216
1-@@	O	-1	7890216
4@@	O	-1	7890216
)@@	O	-1	7890216
),	O	-1	7890216
wh@@	O	-1	7890216
il@@	O	-1	7890216
st	O	-1	7890216
in	O	-1	7890216
fo@@	O	-1	7890216
ur@@	O	-1	7890216
,	O	-1	7890216
the	O	-1	7890216
b@@	O	-1	7890216
ile	O	-1	7890216
cont@@	O	-1	7890216
ained	O	-1	7890216
cholester@@	B-Chemical	D002784	7890216
ol	I-Chemical	-1	7890216
micro@@	O	-1	7890216
c@@	O	-1	7890216
r@@	O	-1	7890216
y@@	O	-1	7890216
st@@	O	-1	7890216
als	O	-1	7890216
immedi@@	O	-1	7890216
ately	O	-1	7890216
after	O	-1	7890216
sam@@	O	-1	7890216
pl@@	O	-1	7890216
ing.	O	-1	7890216
Of	O	-1	7890216
the	O	-1	7890216
12	O	-1	7890216
patients	O	-1	7890216
considered	O	-1	7890216
for	O	-1	7890216
oral	O	-1	7890216
ur@@	B-Chemical	D014580	7890216
so@@	I-Chemical	-1	7890216
de@@	I-Chemical	-1	7890216
oxy@@	I-Chemical	-1	7890216
chol@@	I-Chemical	-1	7890216
ic	I-Chemical	-1	7890216
acid	I-Chemical	-1	7890216
(	O	-1	7890216
U@@	B-Chemical	D014580	7890216
D@@	I-Chemical	-1	7890216
C@@	I-Chemical	-1	7890216
A	I-Chemical	-1	7890216
)	O	-1	7890216
treatment,	O	-1	7890216
two	O	-1	7890216
had	O	-1	7890216
a	O	-1	7890216
block@@	O	-1	7890216
ed	O	-1	7890216
cys@@	O	-1	7890216
tic	O	-1	7890216
duc@@	O	-1	7890216
t	O	-1	7890216
and	O	-1	7890216
were	O	-1	7890216
not	O	-1	7890216
star@@	O	-1	7890216
ted	O	-1	7890216
on	O	-1	7890216
U@@	B-Chemical	D014580	7890216
D@@	I-Chemical	-1	7890216
C@@	I-Chemical	-1	7890216
A	I-Chemical	-1	7890216
while	O	-1	7890216
one	O	-1	7890216
was	O	-1	7890216
lo@@	O	-1	7890216
st	O	-1	7890216
to	O	-1	7890216
fol@@	O	-1	7890216
low	O	-1	7890216
up@@	O	-1	7890216
.	O	-1	7890216
After	O	-1	7890216
one	O	-1	7890216
year	O	-1	7890216
of	O	-1	7890216
treatment,	O	-1	7890216
five	O	-1	7890216
of	O	-1	7890216
the	O	-1	7890216
remain@@	O	-1	7890216
ing	O	-1	7890216
n@@	O	-1	7890216
ine	O	-1	7890216
patients	O	-1	7890216
showed	O	-1	7890216
either	O	-1	7890216
partial	O	-1	7890216
(n	O	-1	7890216
=	O	-1	7890216
3@@	O	-1	7890216
)	O	-1	7890216
or	O	-1	7890216
complete	O	-1	7890216
(n	O	-1	7890216
=	O	-1	7890216
2)	O	-1	7890216
g@@	B-Disease	D042882	7890216
all	I-Disease	-1	7890216
st@@	I-Disease	-1	7890216
one	I-Disease	-1	7890216
dis@@	O	-1	7890216
sol@@	O	-1	7890216
u@@	O	-1	7890216
tion,	O	-1	7890216
suggesting	O	-1	7890216
that	O	-1	7890216
their	O	-1	7890216
ston@@	O	-1	7890216
es	O	-1	7890216
were	O	-1	7890216
cholester@@	B-Chemical	D002784	7890216
ol	I-Chemical	-1	7890216
r@@	O	-1	7890216
ic@@	O	-1	7890216
h@@	O	-1	7890216
.	O	-1	7890216
This	O	-1	7890216
cor@@	O	-1	7890216
respon@@	O	-1	7890216
d@@	O	-1	7890216
s,	O	-1	7890216
by	O	-1	7890216
act@@	O	-1	7890216
u@@	O	-1	7890216
ari@@	O	-1	7890216
al	O	-1	7890216
(@@	O	-1	7890216
lif@@	O	-1	7890216
e	O	-1	7890216
t@@	O	-1	7890216
able@@	O	-1	7890216
)	O	-1	7890216
analy@@	O	-1	7890216
sis,	O	-1	7890216
to	O	-1	7890216
a	O	-1	7890216
combined	O	-1	7890216
g@@	B-Disease	D042882	7890216
all	I-Disease	-1	7890216
st@@	I-Disease	-1	7890216
one	I-Disease	-1	7890216
dis@@	O	-1	7890216
sol@@	O	-1	7890216
u@@	O	-1	7890216
tion	O	-1	7890216
rate	O	-1	7890216
of	O	-1	7890216
5@@	O	-1	7890216
8.@@	O	-1	7890216
3	O	-1	7890216
(1@@	O	-1	7890216
5.@@	O	-1	7890216
9@@	O	-1	7890216
%).	O	-1	7890216
In	O	-1	7890216
concl@@	O	-1	7890216
u@@	O	-1	7890216
sion,	O	-1	7890216
oc@@	B-Chemical	D015282	7890216
tre@@	I-Chemical	-1	7890216
o@@	I-Chemical	-1	7890216
ti@@	I-Chemical	-1	7890216
de	I-Chemical	-1	7890216
induced	O	-1	7890216
g@@	B-Disease	D042882	7890216
all	I-Disease	-1	7890216
ston@@	I-Disease	-1	7890216
es	I-Disease	-1	7890216
are	O	-1	7890216
gener@@	O	-1	7890216
ally	O	-1	7890216
sm@@	O	-1	7890216
all@@	O	-1	7890216
,	O	-1	7890216
multi@@	O	-1	7890216
ple@@	O	-1	7890216
,	O	-1	7890216
and	O	-1	7890216
cholester@@	B-Chemical	D002784	7890216
ol	I-Chemical	-1	7890216
r@@	O	-1	7890216
ich	O	-1	7890216
al@@	O	-1	7890216
thou@@	O	-1	7890216
gh@@	O	-1	7890216
,	O	-1	7890216
in	O	-1	7890216
common	O	-1	7890216
with	O	-1	7890216
spont@@	O	-1	7890216
aneous	O	-1	7890216
g@@	B-Disease	D042882	7890216
all	I-Disease	-1	7890216
st@@	I-Disease	-1	7890216
one	I-Disease	-1	7890216
disease	I-Disease	-1	7890216
,	O	-1	7890216
at	O	-1	7890216
present@@	O	-1	7890216
ation	O	-1	7890216
some	O	-1	7890216
patients	O	-1	7890216
wil@@	O	-1	7890216
l	O	-1	7890216
have	O	-1	7890216
a	O	-1	7890216
block@@	O	-1	7890216
ed	O	-1	7890216
cys@@	O	-1	7890216
tic	O	-1	7890216
duc@@	O	-1	7890216
t	O	-1	7890216
and	O	-1	7890216
some	O	-1	7890216
g@@	B-Disease	D042882	7890216
all	I-Disease	-1	7890216
ston@@	I-Disease	-1	7890216
es	I-Disease	-1	7890216
containing	O	-1	7890216
calcium	B-Chemical	D002118	7890216
.	O	-1	7890216

C@@	B-Disease	D002318	7468724
ardi@@	I-Disease	-1	7468724
o@@	I-Disease	-1	7468724
vascular	I-Disease	-1	7468724
complications	I-Disease	-1	7468724
associated	O	-1	7468724
with	O	-1	7468724
ter@@	B-Chemical	D013726	7468724
but@@	I-Chemical	-1	7468724
aline	I-Chemical	-1	7468724
treatment	O	-1	7468724
for	O	-1	7468724
pre@@	B-Disease	D007752	7468724
term	I-Disease	-1	7468724
l@@	I-Disease	-1	7468724
ab@@	I-Disease	-1	7468724
or	I-Disease	-1	7468724
.	O	-1	7468724
S@@	O	-1	7468724
ev@@	O	-1	7468724
ere	O	-1	7468724
cardiovascular	B-Disease	D002318	7468724
complications	I-Disease	-1	7468724
occurred	O	-1	7468724
in	O	-1	7468724
e@@	O	-1	7468724
ight	O	-1	7468724
of	O	-1	7468724
1@@	O	-1	7468724
60	O	-1	7468724
patients	O	-1	7468724
treated	O	-1	7468724
with	O	-1	7468724
ter@@	B-Chemical	D013726	7468724
but@@	I-Chemical	-1	7468724
aline	I-Chemical	-1	7468724
for	O	-1	7468724
pre@@	B-Disease	D007752	7468724
term	I-Disease	-1	7468724
l@@	I-Disease	-1	7468724
ab@@	I-Disease	-1	7468724
or	I-Disease	-1	7468724
.	O	-1	7468724
A@@	O	-1	7468724
s@@	O	-1	7468724
s@@	O	-1	7468724
oci@@	O	-1	7468724
ated	O	-1	7468724
cortico@@	O	-1	7468724
ster@@	O	-1	7468724
oid	O	-1	7468724
therapy	O	-1	7468724
and	O	-1	7468724
tw@@	O	-1	7468724
in	O	-1	7468724
g@@	O	-1	7468724
est@@	O	-1	7468724
ations	O	-1	7468724
appe@@	O	-1	7468724
ar	O	-1	7468724
to	O	-1	7468724
be	O	-1	7468724
pre@@	O	-1	7468724
dis@@	O	-1	7468724
pos@@	O	-1	7468724
ing	O	-1	7468724
fact@@	O	-1	7468724
or@@	O	-1	7468724
s.	O	-1	7468724
P@@	O	-1	7468724
oten@@	O	-1	7468724
tial	O	-1	7468724
mechanisms	O	-1	7468724
of	O	-1	7468724
the	O	-1	7468724
path@@	O	-1	7468724
oph@@	O	-1	7468724
ysi@@	O	-1	7468724
ology	O	-1	7468724
are	O	-1	7468724
b@@	O	-1	7468724
ri@@	O	-1	7468724
e@@	O	-1	7468724
f@@	O	-1	7468724
ly	O	-1	7468724
discus@@	O	-1	7468724
sed.	O	-1	7468724

Ne@@	O	-1	7199841
uro@@	O	-1	7199841
log@@	O	-1	7199841
ic	O	-1	7199841
effects	O	-1	7199841
of	O	-1	7199841
sub@@	O	-1	7199841
arac@@	O	-1	7199841
h@@	O	-1	7199841
no@@	O	-1	7199841
id	O	-1	7199841
administration	O	-1	7199841
of	O	-1	7199841
2-@@	B-Chemical	C004616	7199841
ch@@	I-Chemical	-1	7199841
loro@@	I-Chemical	-1	7199841
pro@@	I-Chemical	-1	7199841
ca@@	I-Chemical	-1	7199841
ine-@@	I-Chemical	-1	7199841
C@@	I-Chemical	-1	7199841
E	I-Chemical	-1	7199841
,	O	-1	7199841
bupivac@@	B-Chemical	D002045	7199841
aine	I-Chemical	-1	7199841
,	O	-1	7199841
and	O	-1	7199841
low	O	-1	7199841
p@@	O	-1	7199841
H	O	-1	7199841
normal	O	-1	7199841
saline	O	-1	7199841
in	O	-1	7199841
dog@@	O	-1	7199841
s.	O	-1	7199841
The	O	-1	7199841
pur@@	O	-1	7199841
p@@	O	-1	7199841
ose	O	-1	7199841
of	O	-1	7199841
this	O	-1	7199841
study	O	-1	7199841
was	O	-1	7199841
to	O	-1	7199841
evalu@@	O	-1	7199841
ate	O	-1	7199841
the	O	-1	7199841
neurolog@@	O	-1	7199841
ic	O	-1	7199841
con@@	O	-1	7199841
sequ@@	O	-1	7199841
enc@@	O	-1	7199841
es	O	-1	7199841
of	O	-1	7199841
de@@	O	-1	7199841
li@@	O	-1	7199841
b@@	O	-1	7199841
er@@	O	-1	7199841
ate	O	-1	7199841
sub@@	O	-1	7199841
arac@@	O	-1	7199841
h@@	O	-1	7199841
no@@	O	-1	7199841
id	O	-1	7199841
injection	O	-1	7199841
of	O	-1	7199841
larg@@	O	-1	7199841
e	O	-1	7199841
volum@@	O	-1	7199841
es	O	-1	7199841
of	O	-1	7199841
2-@@	B-Chemical	C004616	7199841
ch@@	I-Chemical	-1	7199841
loro@@	I-Chemical	-1	7199841
pro@@	I-Chemical	-1	7199841
ca@@	I-Chemical	-1	7199841
ine-@@	I-Chemical	-1	7199841
C@@	I-Chemical	-1	7199841
E	I-Chemical	-1	7199841
in	O	-1	7199841
experimental	O	-1	7199841
anim@@	O	-1	7199841
al@@	O	-1	7199841
s.	O	-1	7199841
The	O	-1	7199841
possible	O	-1	7199841
role	O	-1	7199841
of	O	-1	7199841
low	O	-1	7199841
p@@	O	-1	7199841
H	O	-1	7199841
as	O	-1	7199841
well	O	-1	7199841
as	O	-1	7199841
total	O	-1	7199841
volume	O	-1	7199841
as	O	-1	7199841
potential	O	-1	7199841
factors	O	-1	7199841
in	O	-1	7199841
ca@@	O	-1	7199841
using	O	-1	7199841
neuro@@	B-Disease	D020258	7199841
toxicity	I-Disease	-1	7199841
was	O	-1	7199841
evalu@@	O	-1	7199841
ated.	O	-1	7199841
The	O	-1	7199841
6@@	O	-1	7199841
5	O	-1	7199841
dog@@	O	-1	7199841
s	O	-1	7199841
in	O	-1	7199841
the	O	-1	7199841
study	O	-1	7199841
received	O	-1	7199841
injec@@	O	-1	7199841
tions	O	-1	7199841
in	O	-1	7199841
the	O	-1	7199841
sub@@	O	-1	7199841
arac@@	O	-1	7199841
h@@	O	-1	7199841
no@@	O	-1	7199841
id	O	-1	7199841
sp@@	O	-1	7199841
ac@@	O	-1	7199841
e	O	-1	7199841
as	O	-1	7199841
follow@@	O	-1	7199841
s:	O	-1	7199841
6	O	-1	7199841
to	O	-1	7199841
8	O	-1	7199841
m@@	O	-1	7199841
l	O	-1	7199841
of	O	-1	7199841
bupivac@@	B-Chemical	D002045	7199841
aine	I-Chemical	-1	7199841
(@@	O	-1	7199841
N	O	-1	7199841
=	O	-1	7199841
1@@	O	-1	7199841
5@@	O	-1	7199841
),	O	-1	7199841
2-@@	B-Chemical	C004616	7199841
ch@@	I-Chemical	-1	7199841
loro@@	I-Chemical	-1	7199841
pro@@	I-Chemical	-1	7199841
ca@@	I-Chemical	-1	7199841
ine-@@	I-Chemical	-1	7199841
C@@	I-Chemical	-1	7199841
E	I-Chemical	-1	7199841
(@@	O	-1	7199841
N	O	-1	7199841
=	O	-1	7199841
20@@	O	-1	7199841
),	O	-1	7199841
low	O	-1	7199841
p@@	O	-1	7199841
H	O	-1	7199841
normal	O	-1	7199841
saline	O	-1	7199841
(p@@	O	-1	7199841
H	O	-1	7199841
3.@@	O	-1	7199841
0@@	O	-1	7199841
)	O	-1	7199841
(@@	O	-1	7199841
N	O	-1	7199841
=	O	-1	7199841
20@@	O	-1	7199841
),	O	-1	7199841
or	O	-1	7199841
normal	O	-1	7199841
saline	O	-1	7199841
(@@	O	-1	7199841
N	O	-1	7199841
=	O	-1	7199841
10@@	O	-1	7199841
).	O	-1	7199841
Of	O	-1	7199841
the	O	-1	7199841
20	O	-1	7199841
animals	O	-1	7199841
that	O	-1	7199841
received	O	-1	7199841
sub@@	O	-1	7199841
arac@@	O	-1	7199841
h@@	O	-1	7199841
no@@	O	-1	7199841
id	O	-1	7199841
injection	O	-1	7199841
of	O	-1	7199841
2-@@	B-Chemical	C004616	7199841
ch@@	I-Chemical	-1	7199841
loro@@	I-Chemical	-1	7199841
pro@@	I-Chemical	-1	7199841
ca@@	I-Chemical	-1	7199841
ine-@@	I-Chemical	-1	7199841
C@@	I-Chemical	-1	7199841
E	I-Chemical	-1	7199841
seven	O	-1	7199841
(3@@	O	-1	7199841
5@@	O	-1	7199841
%)	O	-1	7199841
developed	O	-1	7199841
h@@	O	-1	7199841
ind@@	O	-1	7199841
-@@	O	-1	7199841
lim@@	O	-1	7199841
b	O	-1	7199841
par@@	B-Disease	D010243	7199841
aly@@	I-Disease	-1	7199841
sis	I-Disease	-1	7199841
.	O	-1	7199841
N@@	O	-1	7199841
one	O	-1	7199841
of	O	-1	7199841
the	O	-1	7199841
animals	O	-1	7199841
that	O	-1	7199841
received	O	-1	7199841
bupivac@@	B-Chemical	D002045	7199841
aine	I-Chemical	-1	7199841
,	O	-1	7199841
normal	O	-1	7199841
sal@@	O	-1	7199841
ine,	O	-1	7199841
or	O	-1	7199841
normal	O	-1	7199841
saline	O	-1	7199841
ti@@	O	-1	7199841
tr@@	O	-1	7199841
ated	O	-1	7199841
to	O	-1	7199841
a	O	-1	7199841
p@@	O	-1	7199841
H	O	-1	7199841
3.@@	O	-1	7199841
0	O	-1	7199841
developed	O	-1	7199841
h@@	O	-1	7199841
ind@@	O	-1	7199841
-@@	O	-1	7199841
lim@@	O	-1	7199841
b	O	-1	7199841
par@@	B-Disease	D010243	7199841
aly@@	I-Disease	-1	7199841
sis	I-Disease	-1	7199841
.	O	-1	7199841
Of	O	-1	7199841
the	O	-1	7199841
15	O	-1	7199841
spinal	O	-1	7199841
cor@@	O	-1	7199841
ds	O	-1	7199841
of	O	-1	7199841
the	O	-1	7199841
animals	O	-1	7199841
that	O	-1	7199841
received	O	-1	7199841
2-@@	B-Chemical	C004616	7199841
ch@@	I-Chemical	-1	7199841
loro@@	I-Chemical	-1	7199841
pro@@	I-Chemical	-1	7199841
ca@@	I-Chemical	-1	7199841
ine-@@	I-Chemical	-1	7199841
C@@	I-Chemical	-1	7199841
E	I-Chemical	-1	7199841
,	O	-1	7199841
13	O	-1	7199841
showed	O	-1	7199841
sub@@	B-Disease	D013118	7199841
pi@@	I-Disease	-1	7199841
al	I-Disease	-1	7199841
necro@@	I-Disease	-1	7199841
sis	I-Disease	-1	7199841
;	O	-1	7199841
the	O	-1	7199841
nerve	O	-1	7199841
ro@@	O	-1	7199841
ot@@	O	-1	7199841
s	O	-1	7199841
and	O	-1	7199841
sub@@	O	-1	7199841
arac@@	O	-1	7199841
h@@	O	-1	7199841
no@@	O	-1	7199841
id	O	-1	7199841
v@@	O	-1	7199841
es@@	O	-1	7199841
sel@@	O	-1	7199841
s	O	-1	7199841
were	O	-1	7199841
normal@@	O	-1	7199841
.	O	-1	7199841
The	O	-1	7199841
spinal	O	-1	7199841
cor@@	O	-1	7199841
ds	O	-1	7199841
of	O	-1	7199841
the	O	-1	7199841
animals	O	-1	7199841
that	O	-1	7199841
received	O	-1	7199841
bupivac@@	B-Chemical	D002045	7199841
aine	I-Chemical	-1	7199841
,	O	-1	7199841
low	O	-1	7199841
p@@	O	-1	7199841
H	O	-1	7199841
normal	O	-1	7199841
saline	O	-1	7199841
(p@@	O	-1	7199841
H	O	-1	7199841
3.@@	O	-1	7199841
0@@	O	-1	7199841
),	O	-1	7199841
or	O	-1	7199841
normal	O	-1	7199841
saline	O	-1	7199841
did	O	-1	7199841
not	O	-1	7199841
show	O	-1	7199841
ab@@	O	-1	7199841
normal	O	-1	7199841
find@@	O	-1	7199841
ing@@	O	-1	7199841
s.	O	-1	7199841

E@@	O	-1	6640832
arly	O	-1	6640832
adj@@	O	-1	6640832
u@@	O	-1	6640832
v@@	O	-1	6640832
ant	O	-1	6640832
adriam@@	B-Chemical	D004317	6640832
ycin	I-Chemical	-1	6640832
in	O	-1	6640832
su@@	O	-1	6640832
per@@	O	-1	6640832
fic@@	O	-1	6640832
ial	O	-1	6640832
bladder	B-Disease	D001749	6640832
carcin@@	I-Disease	-1	6640832
oma	I-Disease	-1	6640832
bladder	B-Disease	D002277	6640832
carcin@@	I-Disease	-1	6640832
oma	I-Disease	-1	6640832
.	O	-1	6640832
A	O	-1	6640832
mul@@	O	-1	6640832
tic@@	O	-1	6640832
ent@@	O	-1	6640832
er	O	-1	6640832
study	O	-1	6640832
was	O	-1	6640832
performed	O	-1	6640832
in	O	-1	6640832
1@@	O	-1	6640832
10	O	-1	6640832
patients	O	-1	6640832
with	O	-1	6640832
su@@	O	-1	6640832
per@@	O	-1	6640832
fic@@	O	-1	6640832
ial	O	-1	6640832
transi@@	O	-1	6640832
tional	O	-1	6640832
cell	O	-1	6640832
carcin@@	B-Disease	D001749	6640832
oma	I-Disease	-1	6640832
of	I-Disease	-1	6640832
the	I-Disease	-1	6640832
bladder	I-Disease	-1	6640832
carcin@@	B-Disease	D002277	6640832
oma	I-Disease	-1	6640832
of	I-Disease	-1	6640832
the	I-Disease	-1	6640832
bladder	I-Disease	-1	6640832
.	O	-1	6640832
Ad@@	B-Chemical	D004317	6640832
riam@@	I-Chemical	-1	6640832
ycin	I-Chemical	-1	6640832
(@@	O	-1	6640832
50	O	-1	6640832
mg/@@	O	-1	6640832
50	O	-1	6640832
ml@@	O	-1	6640832
)	O	-1	6640832
was	O	-1	6640832
administered	O	-1	6640832
intra@@	O	-1	6640832
ve@@	O	-1	6640832
si@@	O	-1	6640832
c@@	O	-1	6640832
ally	O	-1	6640832
within	O	-1	6640832
24	O	-1	6640832
h	O	-1	6640832
after	O	-1	6640832
tran@@	O	-1	6640832
su@@	O	-1	6640832
re@@	O	-1	6640832
th@@	O	-1	6640832
ral	O	-1	6640832
res@@	O	-1	6640832
ection	O	-1	6640832
of	O	-1	6640832
TA@@	O	-1	6640832
-@@	O	-1	6640832
T@@	O	-1	6640832
1	O	-1	6640832
(@@	O	-1	6640832
O@@	O	-1	6640832
-@@	O	-1	6640832
A@@	O	-1	6640832
)	O	-1	6640832
bladder	B-Disease	D001749	6640832
tu@@	I-Disease	-1	6640832
mor@@	I-Disease	-1	6640832
s	I-Disease	-1	6640832
.	O	-1	6640832
In@@	O	-1	6640832
sti@@	O	-1	6640832
ll@@	O	-1	6640832
ation	O	-1	6640832
was	O	-1	6640832
repe@@	O	-1	6640832
ated	O	-1	6640832
tw@@	O	-1	6640832
ic@@	O	-1	6640832
e	O	-1	6640832
during	O	-1	6640832
the	O	-1	6640832
first	O	-1	6640832
week@@	O	-1	6640832
,	O	-1	6640832
then	O	-1	6640832
week@@	O	-1	6640832
ly	O	-1	6640832
during	O	-1	6640832
the	O	-1	6640832
first	O	-1	6640832
mon@@	O	-1	6640832
th	O	-1	6640832
and	O	-1	6640832
af@@	O	-1	6640832
ter@@	O	-1	6640832
war@@	O	-1	6640832
ds	O	-1	6640832
month@@	O	-1	6640832
ly	O	-1	6640832
for	O	-1	6640832
1	O	-1	6640832
year@@	O	-1	6640832
.	O	-1	6640832
The	O	-1	6640832
toler@@	O	-1	6640832
ance	O	-1	6640832
was	O	-1	6640832
evaluated	O	-1	6640832
in	O	-1	6640832
these	O	-1	6640832
1@@	O	-1	6640832
10	O	-1	6640832
patients,	O	-1	6640832
and	O	-1	6640832
2@@	O	-1	6640832
9	O	-1	6640832
patients	O	-1	6640832
presented	O	-1	6640832
with	O	-1	6640832
loc@@	O	-1	6640832
al	O	-1	6640832
side@@	O	-1	6640832
-@@	O	-1	6640832
effects.	O	-1	6640832
In	O	-1	6640832
24	O	-1	6640832
of	O	-1	6640832
these	O	-1	6640832
patients	O	-1	6640832
chemical	O	-1	6640832
cys@@	B-Disease	D003556	6640832
ti@@	I-Disease	-1	6640832
tis	I-Disease	-1	6640832
was	O	-1	6640832
severe	O	-1	6640832
en@@	O	-1	6640832
ou@@	O	-1	6640832
gh	O	-1	6640832
for	O	-1	6640832
the@@	O	-1	6640832
m	O	-1	6640832
to	O	-1	6640832
dro@@	O	-1	6640832
p	O	-1	6640832
out	O	-1	6640832
of	O	-1	6640832
the	O	-1	6640832
study.	O	-1	6640832
No	O	-1	6640832
systemic	O	-1	6640832
side@@	O	-1	6640832
-@@	O	-1	6640832
effects	O	-1	6640832
were	O	-1	6640832
obser@@	O	-1	6640832
ved.	O	-1	6640832
Rec@@	O	-1	6640832
ur@@	O	-1	6640832
rence	O	-1	6640832
was	O	-1	6640832
studied	O	-1	6640832
in	O	-1	6640832
8@@	O	-1	6640832
2	O	-1	6640832
evalu@@	O	-1	6640832
able	O	-1	6640832
patients	O	-1	6640832
after	O	-1	6640832
1	O	-1	6640832
year	O	-1	6640832
of	O	-1	6640832
follow-up	O	-1	6640832
and	O	-1	6640832
in	O	-1	6640832
7@@	O	-1	6640832
2	O	-1	6640832
patients	O	-1	6640832
followed	O	-1	6640832
for	O	-1	6640832
2-@@	O	-1	6640832
3	O	-1	6640832
years	O	-1	6640832
(@@	O	-1	6640832
mean	O	-1	6640832
3@@	O	-1	6640832
2	O	-1	6640832
month@@	O	-1	6640832
s@@	O	-1	6640832
).	O	-1	6640832
Of	O	-1	6640832
the	O	-1	6640832
8@@	O	-1	6640832
2	O	-1	6640832
patients	O	-1	6640832
studied	O	-1	6640832
after	O	-1	6640832
1	O	-1	6640832
year@@	O	-1	6640832
,	O	-1	6640832
2@@	O	-1	6640832
3	O	-1	6640832
had	O	-1	6640832
prim@@	O	-1	6640832
ary	O	-1	6640832
and	O	-1	6640832
5@@	O	-1	6640832
9	O	-1	6640832
recur@@	O	-1	6640832
rent	O	-1	6640832
disease.	O	-1	6640832
Of	O	-1	6640832
the	O	-1	6640832
8@@	O	-1	6640832
2	O	-1	6640832
evalu@@	O	-1	6640832
able	O	-1	6640832
patients,	O	-1	6640832
50	O	-1	6640832
did	O	-1	6640832
not	O	-1	6640832
show	O	-1	6640832
any	O	-1	6640832
recur@@	O	-1	6640832
rence	O	-1	6640832
after	O	-1	6640832
1	O	-1	6640832
year	O	-1	6640832
(6@@	O	-1	6640832
1@@	O	-1	6640832
%),	O	-1	6640832
while	O	-1	6640832
3@@	O	-1	6640832
2	O	-1	6640832
presented	O	-1	6640832
with	O	-1	6640832
one	O	-1	6640832
or	O	-1	6640832
more	O	-1	6640832
recur@@	O	-1	6640832
ren@@	O	-1	6640832
ces	O	-1	6640832
(3@@	O	-1	6640832
9@@	O	-1	6640832
%).	O	-1	6640832
Of	O	-1	6640832
these	O	-1	6640832
recur@@	O	-1	6640832
ren@@	O	-1	6640832
c@@	O	-1	6640832
es,	O	-1	6640832
2@@	O	-1	6640832
7	O	-1	6640832
were	O	-1	6640832
T@@	O	-1	6640832
1	O	-1	6640832
tu@@	B-Disease	D009369	6640832
mor@@	I-Disease	-1	6640832
s	I-Disease	-1	6640832
while	O	-1	6640832
five	O	-1	6640832
progres@@	O	-1	6640832
sed	O	-1	6640832
to	O	-1	6640832
more	O	-1	6640832
high@@	O	-1	6640832
ly	O	-1	6640832
inv@@	O	-1	6640832
a@@	O	-1	6640832
sive	O	-1	6640832
le@@	O	-1	6640832
sion@@	O	-1	6640832
s.	O	-1	6640832
In	O	-1	6640832
patients	O	-1	6640832
that	O	-1	6640832
were	O	-1	6640832
free	O	-1	6640832
of	O	-1	6640832
recur@@	O	-1	6640832
rence	O	-1	6640832
during	O	-1	6640832
the	O	-1	6640832
first	O	-1	6640832
year@@	O	-1	6640832
,	O	-1	6640832
8@@	O	-1	6640832
0%	O	-1	6640832
remained	O	-1	6640832
tumor	B-Disease	D009369	6640832
-@@	O	-1	6640832
free	O	-1	6640832
during	O	-1	6640832
the	O	-1	6640832
2@@	O	-1	6640832
-	O	-1	6640832
to	O	-1	6640832
3-@@	O	-1	6640832
year	O	-1	6640832
follow-up	O	-1	6640832
perio@@	O	-1	6640832
d.	O	-1	6640832
Of	O	-1	6640832
the	O	-1	6640832
patients	O	-1	6640832
develop@@	O	-1	6640832
ing	O	-1	6640832
one	O	-1	6640832
or	O	-1	6640832
more	O	-1	6640832
recur@@	O	-1	6640832
ren@@	O	-1	6640832
ces	O	-1	6640832
during	O	-1	6640832
the	O	-1	6640832
first	O	-1	6640832
year@@	O	-1	6640832
,	O	-1	6640832
only	O	-1	6640832
50@@	O	-1	6640832
%	O	-1	6640832
presented	O	-1	6640832
with	O	-1	6640832
further	O	-1	6640832
recur@@	O	-1	6640832
rence	O	-1	6640832
on@@	O	-1	6640832
ce	O	-1	6640832
the	O	-1	6640832
insti@@	O	-1	6640832
ll@@	O	-1	6640832
ations	O	-1	6640832
were	O	-1	6640832
sto@@	O	-1	6640832
pp@@	O	-1	6640832
ed.	O	-1	6640832
The	O	-1	6640832
ben@@	O	-1	6640832
e@@	O	-1	6640832
fic@@	O	-1	6640832
ial	O	-1	6640832
effect	O	-1	6640832
of	O	-1	6640832
Ad@@	B-Chemical	D004317	6640832
riam@@	I-Chemical	-1	6640832
ycin	I-Chemical	-1	6640832
appear@@	O	-1	6640832
s	O	-1	6640832
ob@@	O	-1	6640832
vi@@	O	-1	6640832
ous	O	-1	6640832
and	O	-1	6640832
might	O	-1	6640832
be	O	-1	6640832
related	O	-1	6640832
to	O	-1	6640832
the	O	-1	6640832
drug	O	-1	6640832
it@@	O	-1	6640832
sel@@	O	-1	6640832
f@@	O	-1	6640832
,	O	-1	6640832
the	O	-1	6640832
early	O	-1	6640832
and	O	-1	6640832
repe@@	O	-1	6640832
ated	O	-1	6640832
insti@@	O	-1	6640832
ll@@	O	-1	6640832
ations	O	-1	6640832
after	O	-1	6640832
T@@	O	-1	6640832
U@@	O	-1	6640832
R@@	O	-1	6640832
,	O	-1	6640832
or	O	-1	6640832
bo@@	O	-1	6640832
th@@	O	-1	6640832
.	O	-1	6640832

H@@	B-Disease	D006947	3560096
y@@	I-Disease	-1	3560096
per@@	I-Disease	-1	3560096
k@@	I-Disease	-1	3560096
al@@	I-Disease	-1	3560096
emia	I-Disease	-1	3560096
associated	O	-1	3560096
with	O	-1	3560096
sul@@	B-Chemical	D013467	3560096
in@@	I-Chemical	-1	3560096
da@@	I-Chemical	-1	3560096
c	I-Chemical	-1	3560096
therapy.	O	-1	3560096
H@@	B-Disease	D006947	3560096
y@@	I-Disease	-1	3560096
per@@	I-Disease	-1	3560096
k@@	I-Disease	-1	3560096
al@@	I-Disease	-1	3560096
emia	I-Disease	-1	3560096
has	O	-1	3560096
rec@@	O	-1	3560096
ently	O	-1	3560096
been	O	-1	3560096
reco@@	O	-1	3560096
gn@@	O	-1	3560096
ized	O	-1	3560096
as	O	-1	3560096
a	O	-1	3560096
complication	O	-1	3560096
of	O	-1	3560096
non@@	O	-1	3560096
steroid@@	O	-1	3560096
al	O	-1	3560096
anti@@	O	-1	3560096
inflam@@	O	-1	3560096
mat@@	O	-1	3560096
ory	O	-1	3560096
agents	O	-1	3560096
(N@@	O	-1	3560096
S@@	O	-1	3560096
A@@	O	-1	3560096
I@@	O	-1	3560096
D)	O	-1	3560096
such	O	-1	3560096
as	O	-1	3560096
in@@	B-Chemical	D007213	3560096
do@@	I-Chemical	-1	3560096
meth@@	I-Chemical	-1	3560096
ac@@	I-Chemical	-1	3560096
in	I-Chemical	-1	3560096
.	O	-1	3560096
S@@	O	-1	3560096
e@@	O	-1	3560096
ver@@	O	-1	3560096
al	O	-1	3560096
rec@@	O	-1	3560096
ent	O	-1	3560096
studies	O	-1	3560096
have	O	-1	3560096
stres@@	O	-1	3560096
sed	O	-1	3560096
the	O	-1	3560096
renal	O	-1	3560096
s@@	O	-1	3560096
par@@	O	-1	3560096
ing	O	-1	3560096
feat@@	O	-1	3560096
ures	O	-1	3560096
of	O	-1	3560096
sul@@	B-Chemical	D013467	3560096
in@@	I-Chemical	-1	3560096
da@@	I-Chemical	-1	3560096
c	I-Chemical	-1	3560096
,	O	-1	3560096
o@@	O	-1	3560096
w@@	O	-1	3560096
ing	O	-1	3560096
to	O	-1	3560096
its	O	-1	3560096
l@@	O	-1	3560096
ac@@	O	-1	3560096
k	O	-1	3560096
of	O	-1	3560096
inter@@	O	-1	3560096
fe@@	O	-1	3560096
rence	O	-1	3560096
with	O	-1	3560096
renal	O	-1	3560096
pro@@	B-Chemical	D011464	3560096
st@@	I-Chemical	-1	3560096
ac@@	I-Chemical	-1	3560096
y@@	I-Chemical	-1	3560096
cl@@	I-Chemical	-1	3560096
in	I-Chemical	-1	3560096
syn@@	O	-1	3560096
the@@	O	-1	3560096
sis.	O	-1	3560096
We	O	-1	3560096
describe	O	-1	3560096
4	O	-1	3560096
patients	O	-1	3560096
in	O	-1	3560096
whom	O	-1	3560096
hyper@@	B-Disease	D006947	3560096
k@@	I-Disease	-1	3560096
al@@	I-Disease	-1	3560096
emia	I-Disease	-1	3560096
rang@@	O	-1	3560096
ing	O	-1	3560096
from	O	-1	3560096
6.@@	O	-1	3560096
1	O	-1	3560096
to	O	-1	3560096
6.@@	O	-1	3560096
9	O	-1	3560096
m@@	O	-1	3560096
E@@	O	-1	3560096
q@@	O	-1	3560096
/@@	O	-1	3560096
l	O	-1	3560096
developed	O	-1	3560096
within	O	-1	3560096
3	O	-1	3560096
to	O	-1	3560096
8	O	-1	3560096
days	O	-1	3560096
of	O	-1	3560096
sul@@	B-Chemical	D013467	3560096
in@@	I-Chemical	-1	3560096
da@@	I-Chemical	-1	3560096
c	I-Chemical	-1	3560096
administr@@	O	-1	3560096
ation.	O	-1	3560096
In	O	-1	3560096
all	O	-1	3560096
of	O	-1	3560096
the@@	O	-1	3560096
m	O	-1	3560096
normal	O	-1	3560096
serum	O	-1	3560096
pot@@	B-Chemical	D011188	3560096
assi@@	I-Chemical	-1	3560096
um	I-Chemical	-1	3560096
levels	O	-1	3560096
reac@@	O	-1	3560096
h@@	O	-1	3560096
ed	O	-1	3560096
within	O	-1	3560096
2	O	-1	3560096
to	O	-1	3560096
4	O	-1	3560096
days	O	-1	3560096
of	O	-1	3560096
sto@@	O	-1	3560096
pp@@	O	-1	3560096
ing	O	-1	3560096
sul@@	B-Chemical	D013467	3560096
in@@	I-Chemical	-1	3560096
da@@	I-Chemical	-1	3560096
c	I-Chemical	-1	3560096
.	O	-1	3560096
A@@	O	-1	3560096
s	O	-1	3560096
no	O	-1	3560096
other	O	-1	3560096
medic@@	O	-1	3560096
ations	O	-1	3560096
known	O	-1	3560096
to	O	-1	3560096
effect	O	-1	3560096
serum	O	-1	3560096
pot@@	B-Chemical	D011188	3560096
assi@@	I-Chemical	-1	3560096
um	I-Chemical	-1	3560096
had	O	-1	3560096
been	O	-1	3560096
given	O	-1	3560096
concomit@@	O	-1	3560096
ant@@	O	-1	3560096
ly,	O	-1	3560096
this	O	-1	3560096
course	O	-1	3560096
of	O	-1	3560096
events	O	-1	3560096
is	O	-1	3560096
sugg@@	O	-1	3560096
es@@	O	-1	3560096
tive	O	-1	3560096
of	O	-1	3560096
a	O	-1	3560096
ca@@	O	-1	3560096
use@@	O	-1	3560096
-@@	O	-1	3560096
and@@	O	-1	3560096
-@@	O	-1	3560096
effect	O	-1	3560096
rel@@	O	-1	3560096
ationship	O	-1	3560096
between	O	-1	3560096
sul@@	B-Chemical	D013467	3560096
in@@	I-Chemical	-1	3560096
da@@	I-Chemical	-1	3560096
c	I-Chemical	-1	3560096
and	O	-1	3560096
hyper@@	B-Disease	D006947	3560096
k@@	I-Disease	-1	3560096
al@@	I-Disease	-1	3560096
emia	I-Disease	-1	3560096
.	O	-1	3560096
These	O	-1	3560096
observ@@	O	-1	3560096
ations	O	-1	3560096
indicate	O	-1	3560096
that	O	-1	3560096
initial	O	-1	3560096
ho@@	O	-1	3560096
p@@	O	-1	3560096
es	O	-1	3560096
that	O	-1	3560096
sul@@	B-Chemical	D013467	3560096
in@@	I-Chemical	-1	3560096
da@@	I-Chemical	-1	3560096
c	I-Chemical	-1	3560096
may	O	-1	3560096
not	O	-1	3560096
be	O	-1	3560096
associated	O	-1	3560096
with	O	-1	3560096
the	O	-1	3560096
adverse	O	-1	3560096
renal	O	-1	3560096
effects	O	-1	3560096
of	O	-1	3560096
other	O	-1	3560096
N@@	O	-1	3560096
S@@	O	-1	3560096
A@@	O	-1	3560096
I@@	O	-1	3560096
D	O	-1	3560096
are	O	-1	3560096
prob@@	O	-1	3560096
ably	O	-1	3560096
not	O	-1	3560096
j@@	O	-1	3560096
us@@	O	-1	3560096
ti@@	O	-1	3560096
fi@@	O	-1	3560096
ed.	O	-1	3560096

V@@	B-Disease	D014693	3358181
entr@@	I-Disease	-1	3358181
ic@@	I-Disease	-1	3358181
ular	I-Disease	-1	3358181
tachy@@	I-Disease	-1	3358181
arrhyth@@	I-Disease	-1	3358181
mi@@	I-Disease	-1	3358181
as	I-Disease	-1	3358181
during	O	-1	3358181
ces@@	O	-1	3358181
a@@	O	-1	3358181
re@@	O	-1	3358181
an	O	-1	3358181
sec@@	O	-1	3358181
tion	O	-1	3358181
after	O	-1	3358181
rit@@	B-Chemical	D012312	3358181
o@@	I-Chemical	-1	3358181
d@@	I-Chemical	-1	3358181
rine	I-Chemical	-1	3358181
therap@@	O	-1	3358181
y@@	O	-1	3358181
:	O	-1	3358181
inter@@	O	-1	3358181
action	O	-1	3358181
with	O	-1	3358181
anesthe@@	O	-1	3358181
tic@@	O	-1	3358181
s.	O	-1	3358181
This	O	-1	3358181
case	O	-1	3358181
il@@	O	-1	3358181
lu@@	O	-1	3358181
strat@@	O	-1	3358181
es	O	-1	3358181
that	O	-1	3358181
patients	O	-1	3358181
receiving	O	-1	3358181
rit@@	B-Chemical	D012312	3358181
o@@	I-Chemical	-1	3358181
d@@	I-Chemical	-1	3358181
rine	I-Chemical	-1	3358181
for	O	-1	3358181
pre@@	B-Disease	D007752	3358181
term	I-Disease	-1	3358181
l@@	I-Disease	-1	3358181
ab@@	I-Disease	-1	3358181
or	I-Disease	-1	3358181
may	O	-1	3358181
risk	O	-1	3358181
inter@@	O	-1	3358181
ac@@	O	-1	3358181
tions	O	-1	3358181
between	O	-1	3358181
the	O	-1	3358181
re@@	O	-1	3358181
si@@	O	-1	3358181
du@@	O	-1	3358181
al	O	-1	3358181
bet@@	O	-1	3358181
ami@@	O	-1	3358181
me@@	O	-1	3358181
tic	O	-1	3358181
effects	O	-1	3358181
of	O	-1	3358181
rit@@	B-Chemical	D012312	3358181
o@@	I-Chemical	-1	3358181
d@@	I-Chemical	-1	3358181
rine	I-Chemical	-1	3358181
and	O	-1	3358181
the	O	-1	3358181
effects	O	-1	3358181
of	O	-1	3358181
anesthe@@	O	-1	3358181
tics	O	-1	3358181
during	O	-1	3358181
ces@@	O	-1	3358181
a@@	O	-1	3358181
re@@	O	-1	3358181
an	O	-1	3358181
sec@@	O	-1	3358181
tion.	O	-1	3358181
S@@	O	-1	3358181
uc@@	O	-1	3358181
h	O	-1	3358181
inter@@	O	-1	3358181
ac@@	O	-1	3358181
tions	O	-1	3358181
may	O	-1	3358181
result	O	-1	3358181
in	O	-1	3358181
seri@@	O	-1	3358181
ous	O	-1	3358181
cardiovascular	B-Disease	D002318	3358181
complications	I-Disease	-1	3358181
even	O	-1	3358181
after	O	-1	3358181
cess@@	O	-1	3358181
ation	O	-1	3358181
of	O	-1	3358181
an	O	-1	3358181
infusion	O	-1	3358181
of	O	-1	3358181
rit@@	B-Chemical	D012312	3358181
o@@	I-Chemical	-1	3358181
d@@	I-Chemical	-1	3358181
rine	I-Chemical	-1	3358181
.	O	-1	3358181
Pre@@	O	-1	3358181
o@@	O	-1	3358181
perative	O	-1	3358181
assess@@	O	-1	3358181
ment	O	-1	3358181
should	O	-1	3358181
foc@@	O	-1	3358181
us	O	-1	3358181
on	O	-1	3358181
cardiovascular	O	-1	3358181
status	O	-1	3358181
and	O	-1	3358181
serum	O	-1	3358181
pot@@	B-Chemical	D011188	3358181
assi@@	I-Chemical	-1	3358181
um	I-Chemical	-1	3358181
level@@	O	-1	3358181
.	O	-1	3358181
D@@	O	-1	3358181
el@@	O	-1	3358181
ay@@	O	-1	3358181
ing	O	-1	3358181
induction	O	-1	3358181
of	O	-1	3358181
anesthe@@	O	-1	3358181
sia	O	-1	3358181
should	O	-1	3358181
be	O	-1	3358181
considered	O	-1	3358181
wh@@	O	-1	3358181
en@@	O	-1	3358181
ev@@	O	-1	3358181
er	O	-1	3358181
possib@@	O	-1	3358181
le@@	O	-1	3358181
.	O	-1	3358181
Ca@@	O	-1	3358181
ref@@	O	-1	3358181
u@@	O	-1	3358181
l	O	-1	3358181
flu@@	O	-1	3358181
id	O	-1	3358181
administration	O	-1	3358181
and	O	-1	3358181
cau@@	O	-1	3358181
ti@@	O	-1	3358181
ous	O	-1	3358181
use	O	-1	3358181
of	O	-1	3358181
ti@@	O	-1	3358181
tr@@	O	-1	3358181
ated	O	-1	3358181
doses	O	-1	3358181
of	O	-1	3358181
e@@	B-Chemical	D004809	3358181
ph@@	I-Chemical	-1	3358181
ed@@	I-Chemical	-1	3358181
rine	I-Chemical	-1	3358181
are	O	-1	3358181
ad@@	O	-1	3358181
vi@@	O	-1	3358181
sed.	O	-1	3358181
After	O	-1	3358181
de@@	O	-1	3358181
li@@	O	-1	3358181
very	O	-1	3358181
of	O	-1	3358181
the	O	-1	3358181
inf@@	O	-1	3358181
ant@@	O	-1	3358181
,	O	-1	3358181
there	O	-1	3358181
should	O	-1	3358181
be	O	-1	3358181
no	O	-1	3358181
contra@@	O	-1	3358181
indic@@	O	-1	3358181
ation	O	-1	3358181
to	O	-1	3358181
the	O	-1	3358181
use	O	-1	3358181
of	O	-1	3358181
an	O	-1	3358181
alpha-@@	O	-1	3358181
adrenergic	O	-1	3358181
vas@@	O	-1	3358181
o@@	O	-1	3358181
press@@	O	-1	3358181
or	O	-1	3358181
such	O	-1	3358181
as	O	-1	3358181
pheny@@	B-Chemical	D010656	3358181
le@@	I-Chemical	-1	3358181
phrine	I-Chemical	-1	3358181
to	O	-1	3358181
tre@@	O	-1	3358181
at	O	-1	3358181
hypoten@@	B-Disease	D007022	3358181
sive	I-Disease	-1	3358181
patients	O	-1	3358181
with	O	-1	3358181
tachycardia	B-Disease	D013610	3358181
.	O	-1	3358181

Im@@	O	-1	2887062
mun@@	O	-1	2887062
o@@	O	-1	2887062
histo@@	O	-1	2887062
chem@@	O	-1	2887062
ic@@	O	-1	2887062
al,	O	-1	2887062
electro@@	O	-1	2887062
n	O	-1	2887062
micro@@	O	-1	2887062
sco@@	O	-1	2887062
p@@	O	-1	2887062
ic	O	-1	2887062
and	O	-1	2887062
morph@@	O	-1	2887062
o@@	O	-1	2887062
me@@	O	-1	2887062
tri@@	O	-1	2887062
c	O	-1	2887062
studies	O	-1	2887062
of	O	-1	2887062
est@@	B-Chemical	D004967	2887062
ro@@	I-Chemical	-1	2887062
gen	I-Chemical	-1	2887062
-induced	O	-1	2887062
rat	O	-1	2887062
prol@@	B-Disease	D015175	2887062
act@@	I-Disease	-1	2887062
in@@	I-Disease	-1	2887062
om@@	I-Disease	-1	2887062
as	I-Disease	-1	2887062
after	O	-1	2887062
brom@@	B-Chemical	D001971	2887062
oc@@	I-Chemical	-1	2887062
ript@@	I-Chemical	-1	2887062
ine	I-Chemical	-1	2887062
treatment.	O	-1	2887062
To	O	-1	2887062
cl@@	O	-1	2887062
ar@@	O	-1	2887062
if@@	O	-1	2887062
y	O	-1	2887062
the	O	-1	2887062
effects	O	-1	2887062
of	O	-1	2887062
brom@@	B-Chemical	D001971	2887062
oc@@	I-Chemical	-1	2887062
ript@@	I-Chemical	-1	2887062
ine	I-Chemical	-1	2887062
on	O	-1	2887062
prol@@	B-Disease	D015175	2887062
act@@	I-Disease	-1	2887062
in@@	I-Disease	-1	2887062
oma	I-Disease	-1	2887062
cells	O	-1	2887062
in	O	-1	2887062
viv@@	O	-1	2887062
o@@	O	-1	2887062
,	O	-1	2887062
immuno@@	O	-1	2887062
histo@@	O	-1	2887062
chem@@	O	-1	2887062
ic@@	O	-1	2887062
al,	O	-1	2887062
ult@@	O	-1	2887062
ra@@	O	-1	2887062
struct@@	O	-1	2887062
ural	O	-1	2887062
and	O	-1	2887062
morph@@	O	-1	2887062
o@@	O	-1	2887062
met@@	O	-1	2887062
r@@	O	-1	2887062
ical	O	-1	2887062
analy@@	O	-1	2887062
ses	O	-1	2887062
were	O	-1	2887062
ap@@	O	-1	2887062
pl@@	O	-1	2887062
ied	O	-1	2887062
to	O	-1	2887062
est@@	B-Chemical	D004967	2887062
ro@@	I-Chemical	-1	2887062
gen	I-Chemical	-1	2887062
-induced	O	-1	2887062
rat	O	-1	2887062
prol@@	B-Disease	D015175	2887062
act@@	I-Disease	-1	2887062
in@@	I-Disease	-1	2887062
oma	I-Disease	-1	2887062
cells	O	-1	2887062
1	O	-1	2887062
h	O	-1	2887062
and	O	-1	2887062
6	O	-1	2887062
h	O	-1	2887062
after	O	-1	2887062
injection	O	-1	2887062
of	O	-1	2887062
brom@@	B-Chemical	D001971	2887062
oc@@	I-Chemical	-1	2887062
ript@@	I-Chemical	-1	2887062
ine	I-Chemical	-1	2887062
(@@	O	-1	2887062
3	O	-1	2887062
mg/kg	O	-1	2887062
of	O	-1	2887062
body	O	-1	2887062
weigh@@	O	-1	2887062
t@@	O	-1	2887062
).	O	-1	2887062
One	O	-1	2887062
h	O	-1	2887062
after	O	-1	2887062
treatment,	O	-1	2887062
serum	O	-1	2887062
prolactin	O	-1	2887062
levels	O	-1	2887062
decreased	O	-1	2887062
mark@@	O	-1	2887062
ed@@	O	-1	2887062
ly.	O	-1	2887062
E@@	O	-1	2887062
l@@	O	-1	2887062
ect@@	O	-1	2887062
ro@@	O	-1	2887062
n	O	-1	2887062
micro@@	O	-1	2887062
sco@@	O	-1	2887062
p@@	O	-1	2887062
y	O	-1	2887062
disc@@	O	-1	2887062
los@@	O	-1	2887062
ed	O	-1	2887062
man@@	O	-1	2887062
y	O	-1	2887062
sec@@	O	-1	2887062
ret@@	O	-1	2887062
ory	O	-1	2887062
gran@@	O	-1	2887062
ul@@	O	-1	2887062
es,	O	-1	2887062
s@@	O	-1	2887062
li@@	O	-1	2887062
gh@@	O	-1	2887062
tly	O	-1	2887062
dist@@	O	-1	2887062
or@@	O	-1	2887062
ted	O	-1	2887062
rou@@	O	-1	2887062
gh	O	-1	2887062
endo@@	O	-1	2887062
plas@@	O	-1	2887062
mic	O	-1	2887062
re@@	O	-1	2887062
tic@@	O	-1	2887062
ul@@	O	-1	2887062
um,	O	-1	2887062
and	O	-1	2887062
par@@	O	-1	2887062
ti@@	O	-1	2887062
ally	O	-1	2887062
di@@	O	-1	2887062
l@@	O	-1	2887062
ated	O	-1	2887062
G@@	O	-1	2887062
ol@@	O	-1	2887062
g@@	O	-1	2887062
i	O	-1	2887062
c@@	O	-1	2887062
ist@@	O	-1	2887062
er@@	O	-1	2887062
na@@	O	-1	2887062
e	O	-1	2887062
in	O	-1	2887062
the	O	-1	2887062
prol@@	B-Disease	D015175	2887062
act@@	I-Disease	-1	2887062
in@@	I-Disease	-1	2887062
oma	I-Disease	-1	2887062
cell@@	O	-1	2887062
s.	O	-1	2887062
M@@	O	-1	2887062
or@@	O	-1	2887062
ph@@	O	-1	2887062
o@@	O	-1	2887062
me@@	O	-1	2887062
tri@@	O	-1	2887062
c	O	-1	2887062
analysis	O	-1	2887062
revealed	O	-1	2887062
that	O	-1	2887062
the	O	-1	2887062
volume	O	-1	2887062
d@@	O	-1	2887062
ensity	O	-1	2887062
of	O	-1	2887062
sec@@	O	-1	2887062
ret@@	O	-1	2887062
ory	O	-1	2887062
gran@@	O	-1	2887062
ul@@	O	-1	2887062
es	O	-1	2887062
increas@@	O	-1	2887062
ed,	O	-1	2887062
while	O	-1	2887062
the	O	-1	2887062
volume	O	-1	2887062
d@@	O	-1	2887062
ensity	O	-1	2887062
of	O	-1	2887062
cyto@@	O	-1	2887062
plas@@	O	-1	2887062
mic	O	-1	2887062
micro@@	O	-1	2887062
tub@@	O	-1	2887062
ul@@	O	-1	2887062
es	O	-1	2887062
decreas@@	O	-1	2887062
ed.	O	-1	2887062
These	O	-1	2887062
findings	O	-1	2887062
suggest	O	-1	2887062
that	O	-1	2887062
lo@@	O	-1	2887062
we@@	O	-1	2887062
red	O	-1	2887062
serum	O	-1	2887062
prolactin	O	-1	2887062
levels	O	-1	2887062
in	O	-1	2887062
the	O	-1	2887062
early	O	-1	2887062
phase	O	-1	2887062
of	O	-1	2887062
brom@@	B-Chemical	D001971	2887062
oc@@	I-Chemical	-1	2887062
ript@@	I-Chemical	-1	2887062
ine	I-Chemical	-1	2887062
treatment	O	-1	2887062
may	O	-1	2887062
result	O	-1	2887062
from	O	-1	2887062
an	O	-1	2887062
impaired	O	-1	2887062
secre@@	O	-1	2887062
tion	O	-1	2887062
of	O	-1	2887062
prolactin	O	-1	2887062
due	O	-1	2887062
to	O	-1	2887062
decreas@@	O	-1	2887062
ing	O	-1	2887062
numb@@	O	-1	2887062
ers	O	-1	2887062
of	O	-1	2887062
cyto@@	O	-1	2887062
plas@@	O	-1	2887062
mic	O	-1	2887062
micro@@	O	-1	2887062
tub@@	O	-1	2887062
ul@@	O	-1	2887062
es.	O	-1	2887062
A@@	O	-1	2887062
t	O	-1	2887062
6	O	-1	2887062
h	O	-1	2887062
after	O	-1	2887062
injec@@	O	-1	2887062
tion,	O	-1	2887062
serum	O	-1	2887062
prolactin	O	-1	2887062
levels	O	-1	2887062
were	O	-1	2887062
sti@@	O	-1	2887062
ll	O	-1	2887062
con@@	O	-1	2887062
si@@	O	-1	2887062
der@@	O	-1	2887062
ably	O	-1	2887062
lower	O	-1	2887062
than	O	-1	2887062
in	O	-1	2887062
controls.	O	-1	2887062
The	O	-1	2887062
prol@@	B-Disease	D015175	2887062
act@@	I-Disease	-1	2887062
in@@	I-Disease	-1	2887062
oma	I-Disease	-1	2887062
cells	O	-1	2887062
at	O	-1	2887062
this	O	-1	2887062
time	O	-1	2887062
were	O	-1	2887062
well	O	-1	2887062
gran@@	O	-1	2887062
ul@@	O	-1	2887062
at@@	O	-1	2887062
ed,	O	-1	2887062
with	O	-1	2887062
ve@@	O	-1	2887062
si@@	O	-1	2887062
cul@@	O	-1	2887062
ated	O	-1	2887062
rou@@	O	-1	2887062
gh	O	-1	2887062
endo@@	O	-1	2887062
plas@@	O	-1	2887062
mic	O	-1	2887062
re@@	O	-1	2887062
tic@@	O	-1	2887062
ul@@	O	-1	2887062
um	O	-1	2887062
and	O	-1	2887062
mark@@	O	-1	2887062
ed@@	O	-1	2887062
ly	O	-1	2887062
di@@	O	-1	2887062
l@@	O	-1	2887062
ated	O	-1	2887062
G@@	O	-1	2887062
ol@@	O	-1	2887062
g@@	O	-1	2887062
i	O	-1	2887062
c@@	O	-1	2887062
ist@@	O	-1	2887062
er@@	O	-1	2887062
na@@	O	-1	2887062
e.	O	-1	2887062
E@@	O	-1	2887062
l@@	O	-1	2887062
ect@@	O	-1	2887062
ro@@	O	-1	2887062
n	O	-1	2887062
micro@@	O	-1	2887062
sco@@	O	-1	2887062
p@@	O	-1	2887062
ical	O	-1	2887062
immuno@@	O	-1	2887062
histo@@	O	-1	2887062
chem@@	O	-1	2887062
ist@@	O	-1	2887062
r@@	O	-1	2887062
y	O	-1	2887062
revealed	O	-1	2887062
positive	O	-1	2887062
reaction	O	-1	2887062
produc@@	O	-1	2887062
ts	O	-1	2887062
not@@	O	-1	2887062
ed	O	-1	2887062
on	O	-1	2887062
the	O	-1	2887062
sec@@	O	-1	2887062
ret@@	O	-1	2887062
ory	O	-1	2887062
gran@@	O	-1	2887062
ul@@	O	-1	2887062
es,	O	-1	2887062
G@@	O	-1	2887062
ol@@	O	-1	2887062
g@@	O	-1	2887062
i	O	-1	2887062
c@@	O	-1	2887062
ist@@	O	-1	2887062
er@@	O	-1	2887062
na@@	O	-1	2887062
e,	O	-1	2887062
and	O	-1	2887062
endo@@	O	-1	2887062
plas@@	O	-1	2887062
mic	O	-1	2887062
re@@	O	-1	2887062
tic@@	O	-1	2887062
ul@@	O	-1	2887062
um	O	-1	2887062
of	O	-1	2887062
the	O	-1	2887062
un@@	O	-1	2887062
treated	O	-1	2887062
rat	O	-1	2887062
prol@@	B-Disease	D015175	2887062
act@@	I-Disease	-1	2887062
in@@	I-Disease	-1	2887062
oma	I-Disease	-1	2887062
cell@@	O	-1	2887062
s.	O	-1	2887062
However,	O	-1	2887062
only	O	-1	2887062
sec@@	O	-1	2887062
ret@@	O	-1	2887062
ory	O	-1	2887062
gran@@	O	-1	2887062
ul@@	O	-1	2887062
es	O	-1	2887062
showed	O	-1	2887062
the	O	-1	2887062
positive	O	-1	2887062
reaction	O	-1	2887062
produc@@	O	-1	2887062
ts	O	-1	2887062
for	O	-1	2887062
prolactin	O	-1	2887062
6	O	-1	2887062
h	O	-1	2887062
after	O	-1	2887062
brom@@	B-Chemical	D001971	2887062
oc@@	I-Chemical	-1	2887062
ript@@	I-Chemical	-1	2887062
ine	I-Chemical	-1	2887062
treatment	O	-1	2887062
of	O	-1	2887062
the	O	-1	2887062
aden@@	B-Disease	D000236	2887062
oma	I-Disease	-1	2887062
cell@@	O	-1	2887062
s.	O	-1	2887062
An	O	-1	2887062
increase	O	-1	2887062
in	O	-1	2887062
the	O	-1	2887062
volume	O	-1	2887062
d@@	O	-1	2887062
ensity	O	-1	2887062
of	O	-1	2887062
sec@@	O	-1	2887062
ret@@	O	-1	2887062
ory	O	-1	2887062
gran@@	O	-1	2887062
ul@@	O	-1	2887062
es	O	-1	2887062
and	O	-1	2887062
a	O	-1	2887062
decrease	O	-1	2887062
in	O	-1	2887062
the	O	-1	2887062
volume	O	-1	2887062
d@@	O	-1	2887062
en@@	O	-1	2887062
si@@	O	-1	2887062
ties	O	-1	2887062
of	O	-1	2887062
rou@@	O	-1	2887062
gh	O	-1	2887062
endo@@	O	-1	2887062
plas@@	O	-1	2887062
mic	O	-1	2887062
re@@	O	-1	2887062
tic@@	O	-1	2887062
ul@@	O	-1	2887062
um	O	-1	2887062
and	O	-1	2887062
micro@@	O	-1	2887062
tub@@	O	-1	2887062
ul@@	O	-1	2887062
es	O	-1	2887062
was	O	-1	2887062
determined	O	-1	2887062
by	O	-1	2887062
morph@@	O	-1	2887062
o@@	O	-1	2887062
me@@	O	-1	2887062
tri@@	O	-1	2887062
c	O	-1	2887062
analy@@	O	-1	2887062
sis,	O	-1	2887062
suggesting	O	-1	2887062
that	O	-1	2887062
brom@@	B-Chemical	D001971	2887062
oc@@	I-Chemical	-1	2887062
ript@@	I-Chemical	-1	2887062
ine	I-Chemical	-1	2887062
inhibit@@	O	-1	2887062
s	O	-1	2887062
protein	O	-1	2887062
syn@@	O	-1	2887062
thesis	O	-1	2887062
as	O	-1	2887062
well	O	-1	2887062
as	O	-1	2887062
b@@	O	-1	2887062
r@@	O	-1	2887062
ing@@	O	-1	2887062
ing	O	-1	2887062
about	O	-1	2887062
a	O	-1	2887062
dist@@	O	-1	2887062
urb@@	O	-1	2887062
ance	O	-1	2887062
of	O	-1	2887062
the	O	-1	2887062
prolactin	O	-1	2887062
secre@@	O	-1	2887062
tion.	O	-1	2887062

O@@	O	-1	2425813
n	O	-1	2425813
two	O	-1	2425813
par@@	O	-1	2425813
ad@@	O	-1	2425813
ox@@	O	-1	2425813
ical	O	-1	2425813
side@@	O	-1	2425813
-@@	O	-1	2425813
effects	O	-1	2425813
of	O	-1	2425813
pre@@	B-Chemical	D011239	2425813
d@@	I-Chemical	-1	2425813
n@@	I-Chemical	-1	2425813
isol@@	I-Chemical	-1	2425813
one	I-Chemical	-1	2425813
in	O	-1	2425813
rats,	O	-1	2425813
rib@@	O	-1	2425813
os@@	O	-1	2425813
om@@	O	-1	2425813
al	O	-1	2425813
R@@	O	-1	2425813
NA	O	-1	2425813
b@@	O	-1	2425813
i@@	O	-1	2425813
os@@	O	-1	2425813
yn@@	O	-1	2425813
th@@	O	-1	2425813
es@@	O	-1	2425813
es,	O	-1	2425813
and	O	-1	2425813
a	O	-1	2425813
mechanism	O	-1	2425813
of	O	-1	2425813
ac@@	O	-1	2425813
tion.	O	-1	2425813
L@@	B-Disease	D006529	2425813
i@@	I-Disease	-1	2425813
ver	I-Disease	-1	2425813
en@@	I-Disease	-1	2425813
larg@@	I-Disease	-1	2425813
ement	I-Disease	-1	2425813
and	O	-1	2425813
musc@@	B-Disease	D009133	2425813
le	I-Disease	-1	2425813
w@@	I-Disease	-1	2425813
ast@@	I-Disease	-1	2425813
age	I-Disease	-1	2425813
occurred	O	-1	2425813
in	O	-1	2425813
Wistar	O	-1	2425813
rats	O	-1	2425813
following	O	-1	2425813
the	O	-1	2425813
sub@@	O	-1	2425813
c@@	O	-1	2425813
utaneous	O	-1	2425813
administration	O	-1	2425813
of	O	-1	2425813
pre@@	B-Chemical	D011239	2425813
d@@	I-Chemical	-1	2425813
n@@	I-Chemical	-1	2425813
isol@@	I-Chemical	-1	2425813
one	I-Chemical	-1	2425813
.	O	-1	2425813
In	O	-1	2425813
the	O	-1	2425813
liver	O	-1	2425813
both	O	-1	2425813
the	O	-1	2425813
cont@@	O	-1	2425813
ent	O	-1	2425813
of	O	-1	2425813
R@@	O	-1	2425813
NA	O	-1	2425813
and	O	-1	2425813
the	O	-1	2425813
b@@	O	-1	2425813
i@@	O	-1	2425813
os@@	O	-1	2425813
yn@@	O	-1	2425813
thesis	O	-1	2425813
of	O	-1	2425813
rib@@	O	-1	2425813
os@@	O	-1	2425813
om@@	O	-1	2425813
al	O	-1	2425813
R@@	O	-1	2425813
NA	O	-1	2425813
increased	O	-1	2425813
while	O	-1	2425813
both	O	-1	2425813
the	O	-1	2425813
R@@	O	-1	2425813
NA	O	-1	2425813
cont@@	O	-1	2425813
ent	O	-1	2425813
and	O	-1	2425813
rib@@	O	-1	2425813
os@@	O	-1	2425813
om@@	O	-1	2425813
al	O	-1	2425813
R@@	O	-1	2425813
NA	O	-1	2425813
b@@	O	-1	2425813
i@@	O	-1	2425813
os@@	O	-1	2425813
yn@@	O	-1	2425813
thesis	O	-1	2425813
were	O	-1	2425813
reduced	O	-1	2425813
in	O	-1	2425813
the	O	-1	2425813
gast@@	O	-1	2425813
ro@@	O	-1	2425813
c@@	O	-1	2425813
ne@@	O	-1	2425813
mi@@	O	-1	2425813
us	O	-1	2425813
musc@@	O	-1	2425813
le@@	O	-1	2425813
.	O	-1	2425813
It	O	-1	2425813
is	O	-1	2425813
suggested	O	-1	2425813
that	O	-1	2425813
the	O	-1	2425813
drug	O	-1	2425813
ac@@	O	-1	2425813
ted	O	-1	2425813
in	O	-1	2425813
a	O	-1	2425813
selective	O	-1	2425813
and	O	-1	2425813
tissu@@	O	-1	2425813
e-@@	O	-1	2425813
specific	O	-1	2425813
man@@	O	-1	2425813
n@@	O	-1	2425813
er	O	-1	2425813
to	O	-1	2425813
enh@@	O	-1	2425813
ance	O	-1	2425813
rib@@	O	-1	2425813
os@@	O	-1	2425813
om@@	O	-1	2425813
al	O	-1	2425813
R@@	O	-1	2425813
NA	O	-1	2425813
syn@@	O	-1	2425813
thesis	O	-1	2425813
in	O	-1	2425813
the	O	-1	2425813
liver	O	-1	2425813
and	O	-1	2425813
de@@	O	-1	2425813
pres@@	O	-1	2425813
s	O	-1	2425813
such	O	-1	2425813
syn@@	O	-1	2425813
thesis	O	-1	2425813
in	O	-1	2425813
the	O	-1	2425813
musc@@	O	-1	2425813
le@@	O	-1	2425813
.	O	-1	2425813
This	O	-1	2425813
vie@@	O	-1	2425813
w	O	-1	2425813
suppor@@	O	-1	2425813
ts	O	-1	2425813
the	O	-1	2425813
cont@@	O	-1	2425813
en@@	O	-1	2425813
tion	O	-1	2425813
that	O	-1	2425813
the	O	-1	2425813
liver	O	-1	2425813
and	O	-1	2425813
musc@@	O	-1	2425813
le	O	-1	2425813
are	O	-1	2425813
in@@	O	-1	2425813
dependent	O	-1	2425813
sit@@	O	-1	2425813
es	O	-1	2425813
of	O	-1	2425813
pre@@	B-Chemical	D011239	2425813
d@@	I-Chemical	-1	2425813
n@@	I-Chemical	-1	2425813
isol@@	I-Chemical	-1	2425813
one	I-Chemical	-1	2425813
ac@@	O	-1	2425813
tion.	O	-1	2425813

P@@	O	-1	2375138
os@@	O	-1	2375138
sible	O	-1	2375138
int@@	O	-1	2375138
ram@@	O	-1	2375138
us@@	O	-1	2375138
cular	O	-1	2375138
mid@@	B-Chemical	D008874	2375138
azol@@	I-Chemical	-1	2375138
am	I-Chemical	-1	2375138
-@@	O	-1	2375138
associated	O	-1	2375138
cardio@@	B-Disease	D006323	2375138
respiratory	I-Disease	-1	2375138
ar@@	I-Disease	-1	2375138
res@@	I-Disease	-1	2375138
t	I-Disease	-1	2375138
and	O	-1	2375138
death	B-Disease	D003643	2375138
.	O	-1	2375138
M@@	B-Chemical	D008874	2375138
id@@	I-Chemical	-1	2375138
azol@@	I-Chemical	-1	2375138
am	I-Chemical	-1	2375138
hydro@@	I-Chemical	-1	2375138
chlor@@	I-Chemical	-1	2375138
ide	I-Chemical	-1	2375138
is	O	-1	2375138
common@@	O	-1	2375138
ly	O	-1	2375138
used	O	-1	2375138
for	O	-1	2375138
d@@	O	-1	2375138
ental	O	-1	2375138
or	O	-1	2375138
en@@	O	-1	2375138
dos@@	O	-1	2375138
co@@	O	-1	2375138
p@@	O	-1	2375138
ic	O	-1	2375138
proce@@	O	-1	2375138
du@@	O	-1	2375138
res@@	O	-1	2375138
.	O	-1	2375138
Although	O	-1	2375138
gener@@	O	-1	2375138
ally	O	-1	2375138
consist@@	O	-1	2375138
ed	O	-1	2375138
saf@@	O	-1	2375138
e	O	-1	2375138
when	O	-1	2375138
given	O	-1	2375138
int@@	O	-1	2375138
ram@@	O	-1	2375138
us@@	O	-1	2375138
cul@@	O	-1	2375138
ar@@	O	-1	2375138
ly,	O	-1	2375138
intravenous	O	-1	2375138
administration	O	-1	2375138
is	O	-1	2375138
known	O	-1	2375138
to	O	-1	2375138
cause	O	-1	2375138
respiratory	B-Disease	D012140	2375138
and	I-Disease	-1	2375138
cardiovascular	I-Disease	-1	2375138
de@@	I-Disease	-1	2375138
pression	I-Disease	-1	2375138
respiratory	B-Disease	D002318	2375138
and	I-Disease	-1	2375138
cardiovascular	I-Disease	-1	2375138
de@@	I-Disease	-1	2375138
pression	I-Disease	-1	2375138
.	O	-1	2375138
This	O	-1	2375138
report	O	-1	2375138
descri@@	O	-1	2375138
b@@	O	-1	2375138
es	O	-1	2375138
the	O	-1	2375138
first	O	-1	2375138
pu@@	O	-1	2375138
bl@@	O	-1	2375138
ished	O	-1	2375138
case	O	-1	2375138
of	O	-1	2375138
cardio@@	B-Disease	D006323	2375138
respiratory	I-Disease	-1	2375138
ar@@	I-Disease	-1	2375138
res@@	I-Disease	-1	2375138
t	I-Disease	-1	2375138
and	O	-1	2375138
death	B-Disease	D003643	2375138
associated	O	-1	2375138
with	O	-1	2375138
int@@	O	-1	2375138
ram@@	O	-1	2375138
us@@	O	-1	2375138
cular	O	-1	2375138
administration	O	-1	2375138
of	O	-1	2375138
mid@@	B-Chemical	D008874	2375138
azol@@	I-Chemical	-1	2375138
am	I-Chemical	-1	2375138
.	O	-1	2375138
In@@	O	-1	2375138
formation	O	-1	2375138
reg@@	O	-1	2375138
ar@@	O	-1	2375138
ding	O	-1	2375138
mid@@	B-Chemical	D008874	2375138
azol@@	I-Chemical	-1	2375138
am	I-Chemical	-1	2375138
use	O	-1	2375138
is	O	-1	2375138
revie@@	O	-1	2375138
w@@	O	-1	2375138
ed	O	-1	2375138
to	O	-1	2375138
prov@@	O	-1	2375138
ide	O	-1	2375138
recomm@@	O	-1	2375138
en@@	O	-1	2375138
d@@	O	-1	2375138
ation	O	-1	2375138
for	O	-1	2375138
saf@@	O	-1	2375138
e	O	-1	2375138
administr@@	O	-1	2375138
ation.	O	-1	2375138

S@@	O	-1	2265898
er@@	O	-1	2265898
ial	O	-1	2265898
epilep@@	B-Disease	D004827	2265898
sy	I-Disease	-1	2265898
caused	O	-1	2265898
by	O	-1	2265898
levo@@	B-Chemical	C009265	2265898
do@@	I-Chemical	-1	2265898
pa@@	I-Chemical	-1	2265898
/@@	I-Chemical	-1	2265898
carb@@	I-Chemical	-1	2265898
id@@	I-Chemical	-1	2265898
op@@	I-Chemical	-1	2265898
a	I-Chemical	-1	2265898
administration	O	-1	2265898
in	O	-1	2265898
two	O	-1	2265898
patients	O	-1	2265898
on	O	-1	2265898
hemo@@	O	-1	2265898
dialy@@	O	-1	2265898
sis.	O	-1	2265898
Two	O	-1	2265898
patients	O	-1	2265898
with	O	-1	2265898
similar	O	-1	2265898
clinical	O	-1	2265898
feat@@	O	-1	2265898
ures	O	-1	2265898
are	O	-1	2265898
present@@	O	-1	2265898
ed@@	O	-1	2265898
:	O	-1	2265898
both	O	-1	2265898
patients	O	-1	2265898
had	O	-1	2265898
chronic	B-Disease	D007676	2265898
renal	I-Disease	-1	2265898
failure	I-Disease	-1	2265898
,	O	-1	2265898
on	O	-1	2265898
hemo@@	O	-1	2265898
dialy@@	O	-1	2265898
sis	O	-1	2265898
for	O	-1	2265898
man@@	O	-1	2265898
y	O	-1	2265898
years	O	-1	2265898
but	O	-1	2265898
rec@@	O	-1	2265898
ently	O	-1	2265898
be@@	O	-1	2265898
gu@@	O	-1	2265898
n	O	-1	2265898
on	O	-1	2265898
a	O	-1	2265898
high-@@	O	-1	2265898
flu@@	O	-1	2265898
x	O	-1	2265898
dialy@@	O	-1	2265898
z@@	O	-1	2265898
er@@	O	-1	2265898
;	O	-1	2265898
both	O	-1	2265898
had	O	-1	2265898
been	O	-1	2265898
receiving	O	-1	2265898
a	O	-1	2265898
carb@@	B-Chemical	C009265	2265898
id@@	I-Chemical	-1	2265898
o@@	I-Chemical	-1	2265898
pa@@	I-Chemical	-1	2265898
/@@	I-Chemical	-1	2265898
levo@@	I-Chemical	-1	2265898
dopa	I-Chemical	-1	2265898
pre@@	O	-1	2265898
par@@	O	-1	2265898
ation@@	O	-1	2265898
;	O	-1	2265898
and	O	-1	2265898
both	O	-1	2265898
had	O	-1	2265898
the	O	-1	2265898
onset	O	-1	2265898
of	O	-1	2265898
h@@	B-Disease	D001523	2265898
all@@	I-Disease	-1	2265898
uc@@	I-Disease	-1	2265898
ino@@	I-Disease	-1	2265898
sis	I-Disease	-1	2265898
and	O	-1	2265898
recur@@	O	-1	2265898
rent	O	-1	2265898
seizures	B-Disease	D012640	2265898
,	O	-1	2265898
which	O	-1	2265898
were	O	-1	2265898
ref@@	O	-1	2265898
rac@@	O	-1	2265898
t@@	O	-1	2265898
ory	O	-1	2265898
to	O	-1	2265898
anti@@	O	-1	2265898
convul@@	O	-1	2265898
s@@	O	-1	2265898
ant@@	O	-1	2265898
s.	O	-1	2265898
The	O	-1	2265898
first	O	-1	2265898
patient	O	-1	2265898
di@@	O	-1	2265898
ed	O	-1	2265898
without	O	-1	2265898
a	O	-1	2265898
diagno@@	O	-1	2265898
si@@	O	-1	2265898
s;	O	-1	2265898
the	O	-1	2265898
second	O	-1	2265898
patient	O	-1	2265898
had	O	-1	2265898
a	O	-1	2265898
d@@	O	-1	2265898
ram@@	O	-1	2265898
atic	O	-1	2265898
recovery	O	-1	2265898
following	O	-1	2265898
the	O	-1	2265898
administration	O	-1	2265898
of	O	-1	2265898
vitamin	B-Chemical	D025101	2265898
B@@	I-Chemical	-1	2265898
6	I-Chemical	-1	2265898
.	O	-1	2265898
N@@	O	-1	2265898
either	O	-1	2265898
patient	O	-1	2265898
was	O	-1	2265898
considered	O	-1	2265898
to	O	-1	2265898
have	O	-1	2265898
a	O	-1	2265898
renal	O	-1	2265898
state	O	-1	2265898
suffici@@	O	-1	2265898
ently	O	-1	2265898
severe	O	-1	2265898
en@@	O	-1	2265898
ou@@	O	-1	2265898
gh	O	-1	2265898
to	O	-1	2265898
expl@@	O	-1	2265898
ain	O	-1	2265898
their	O	-1	2265898
present@@	O	-1	2265898
ation.	O	-1	2265898

Eff@@	O	-1	2071257
ect	O	-1	2071257
of	O	-1	2071257
L-@@	B-Chemical	D005997	2071257
alpha-@@	I-Chemical	-1	2071257
glycer@@	I-Chemical	-1	2071257
yl@@	I-Chemical	-1	2071257
-@@	I-Chemical	-1	2071257
phosph@@	I-Chemical	-1	2071257
or@@	I-Chemical	-1	2071257
ylcholine	I-Chemical	-1	2071257
on	O	-1	2071257
am@@	B-Disease	D000647	2071257
ne@@	I-Disease	-1	2071257
sia	I-Disease	-1	2071257
caused	O	-1	2071257
by	O	-1	2071257
scopol@@	B-Chemical	D012601	2071257
amine	I-Chemical	-1	2071257
.	O	-1	2071257
The	O	-1	2071257
present	O	-1	2071257
study	O	-1	2071257
was	O	-1	2071257
car@@	O	-1	2071257
ri@@	O	-1	2071257
ed	O	-1	2071257
out	O	-1	2071257
to	O	-1	2071257
test	O	-1	2071257
the	O	-1	2071257
effects	O	-1	2071257
of	O	-1	2071257
L-@@	B-Chemical	D005997	2071257
alpha-@@	I-Chemical	-1	2071257
glycer@@	I-Chemical	-1	2071257
yl@@	I-Chemical	-1	2071257
phosph@@	I-Chemical	-1	2071257
or@@	I-Chemical	-1	2071257
ylcholine	I-Chemical	-1	2071257
(	O	-1	2071257
L-@@	B-Chemical	D005997	2071257
alpha-@@	I-Chemical	-1	2071257
GF@@	I-Chemical	-1	2071257
C	I-Chemical	-1	2071257
)	O	-1	2071257
on	O	-1	2071257
memory	B-Disease	D008569	2071257
impair@@	I-Disease	-1	2071257
ment	I-Disease	-1	2071257
induced	O	-1	2071257
by	O	-1	2071257
scopol@@	B-Chemical	D012601	2071257
amine	I-Chemical	-1	2071257
in	O	-1	2071257
man@@	O	-1	2071257
.	O	-1	2071257
Th@@	O	-1	2071257
ir@@	O	-1	2071257
ty-@@	O	-1	2071257
two	O	-1	2071257
healthy	O	-1	2071257
youn@@	O	-1	2071257
g	O	-1	2071257
vol@@	O	-1	2071257
un@@	O	-1	2071257
te@@	O	-1	2071257
ers	O	-1	2071257
were	O	-1	2071257
random@@	O	-1	2071257
ly	O	-1	2071257
al@@	O	-1	2071257
loc@@	O	-1	2071257
ated	O	-1	2071257
to	O	-1	2071257
four	O	-1	2071257
different	O	-1	2071257
groups.	O	-1	2071257
The@@	O	-1	2071257
y	O	-1	2071257
were	O	-1	2071257
given	O	-1	2071257
a	O	-1	2071257
ten	O	-1	2071257
day	O	-1	2071257
pretreatment	O	-1	2071257
with	O	-1	2071257
either	O	-1	2071257
L-@@	B-Chemical	D005997	2071257
alpha-@@	I-Chemical	-1	2071257
GF@@	I-Chemical	-1	2071257
C	I-Chemical	-1	2071257
or	O	-1	2071257
placebo@@	O	-1	2071257
,	O	-1	2071257
p.@@	O	-1	2071257
o@@	O	-1	2071257
.,	O	-1	2071257
and	O	-1	2071257
on	O	-1	2071257
the	O	-1	2071257
elev@@	O	-1	2071257
ent@@	O	-1	2071257
h	O	-1	2071257
day	O	-1	2071257
either	O	-1	2071257
scopol@@	B-Chemical	D012601	2071257
amine	I-Chemical	-1	2071257
or	O	-1	2071257
placebo@@	O	-1	2071257
,	O	-1	2071257
i.@@	O	-1	2071257
m.	O	-1	2071257
B@@	O	-1	2071257
e@@	O	-1	2071257
fore	O	-1	2071257
and	O	-1	2071257
0.@@	O	-1	2071257
5,	O	-1	2071257
1,	O	-1	2071257
2,	O	-1	2071257
3,	O	-1	2071257
and	O	-1	2071257
6	O	-1	2071257
h	O	-1	2071257
after	O	-1	2071257
injection	O	-1	2071257
the	O	-1	2071257
subjects	O	-1	2071257
were	O	-1	2071257
given	O	-1	2071257
atten@@	O	-1	2071257
tion	O	-1	2071257
and	O	-1	2071257
m@@	O	-1	2071257
ne@@	O	-1	2071257
mon@@	O	-1	2071257
ic	O	-1	2071257
test@@	O	-1	2071257
s.	O	-1	2071257
The	O	-1	2071257
findings	O	-1	2071257
of	O	-1	2071257
this	O	-1	2071257
study	O	-1	2071257
indicate	O	-1	2071257
that	O	-1	2071257
the	O	-1	2071257
drug	O	-1	2071257
is	O	-1	2071257
able	O	-1	2071257
to	O	-1	2071257
antagon@@	O	-1	2071257
iz@@	O	-1	2071257
e	O	-1	2071257
impair@@	B-Disease	D008569	2071257
ment	I-Disease	-1	2071257
of	I-Disease	-1	2071257
atten@@	I-Disease	-1	2071257
tion	I-Disease	-1	2071257
and	I-Disease	-1	2071257
memory	I-Disease	-1	2071257
induced	O	-1	2071257
by	O	-1	2071257
scopol@@	B-Chemical	D012601	2071257
amine	I-Chemical	-1	2071257
.	O	-1	2071257

S@@	B-Disease	D012640	1592014
e@@	I-Disease	-1	1592014
iz@@	I-Disease	-1	1592014
ures	I-Disease	-1	1592014
induced	O	-1	1592014
by	O	-1	1592014
the	O	-1	1592014
cocaine	B-Chemical	D003042	1592014
metabol@@	O	-1	1592014
ite	O	-1	1592014
b@@	B-Chemical	C005618	1592014
enz@@	I-Chemical	-1	1592014
o@@	I-Chemical	-1	1592014
yl@@	I-Chemical	-1	1592014
ec@@	I-Chemical	-1	1592014
g@@	I-Chemical	-1	1592014
on@@	I-Chemical	-1	1592014
ine	I-Chemical	-1	1592014
in	O	-1	1592014
rats.	O	-1	1592014
The	O	-1	1592014
h@@	O	-1	1592014
al@@	O	-1	1592014
f@@	O	-1	1592014
-@@	O	-1	1592014
lif@@	O	-1	1592014
e	O	-1	1592014
(@@	O	-1	1592014
t@@	O	-1	1592014
1@@	O	-1	1592014
/@@	O	-1	1592014
2)	O	-1	1592014
of	O	-1	1592014
cocaine	B-Chemical	D003042	1592014
is	O	-1	1592014
rel@@	O	-1	1592014
atively	O	-1	1592014
sh@@	O	-1	1592014
ort@@	O	-1	1592014
,	O	-1	1592014
but	O	-1	1592014
some	O	-1	1592014
of	O	-1	1592014
the	O	-1	1592014
con@@	O	-1	1592014
sequ@@	O	-1	1592014
enc@@	O	-1	1592014
es	O	-1	1592014
of	O	-1	1592014
its	O	-1	1592014
use@@	O	-1	1592014
,	O	-1	1592014
such	O	-1	1592014
as	O	-1	1592014
seizures	B-Disease	D012640	1592014
and	O	-1	1592014
strok@@	B-Disease	D020521	1592014
es	I-Disease	-1	1592014
,	O	-1	1592014
can	O	-1	1592014
occ@@	O	-1	1592014
ur	O	-1	1592014
hours	O	-1	1592014
after	O	-1	1592014
expos@@	O	-1	1592014
ure.	O	-1	1592014
This	O	-1	1592014
l@@	O	-1	1592014
ed	O	-1	1592014
us	O	-1	1592014
to	O	-1	1592014
hypo@@	O	-1	1592014
the@@	O	-1	1592014
size	O	-1	1592014
that	O	-1	1592014
a	O	-1	1592014
metabol@@	O	-1	1592014
ite	O	-1	1592014
of	O	-1	1592014
cocaine	B-Chemical	D003042	1592014
may	O	-1	1592014
be	O	-1	1592014
respon@@	O	-1	1592014
sible	O	-1	1592014
for	O	-1	1592014
some	O	-1	1592014
of	O	-1	1592014
those	O	-1	1592014
del@@	O	-1	1592014
ayed	O	-1	1592014
sequ@@	O	-1	1592014
el@@	O	-1	1592014
a@@	O	-1	1592014
e.	O	-1	1592014
We	O	-1	1592014
evaluated	O	-1	1592014
the	O	-1	1592014
potential	O	-1	1592014
of	O	-1	1592014
the	O	-1	1592014
major	O	-1	1592014
metabol@@	O	-1	1592014
ite	O	-1	1592014
of	O	-1	1592014
cocaine	B-Chemical	D003042	1592014
,	O	-1	1592014
b@@	B-Chemical	C005618	1592014
enz@@	I-Chemical	-1	1592014
o@@	I-Chemical	-1	1592014
yl@@	I-Chemical	-1	1592014
ec@@	I-Chemical	-1	1592014
g@@	I-Chemical	-1	1592014
on@@	I-Chemical	-1	1592014
ine	I-Chemical	-1	1592014
(	O	-1	1592014
B@@	B-Chemical	C005618	1592014
E	I-Chemical	-1	1592014
),	O	-1	1592014
to	O	-1	1592014
cause	O	-1	1592014
seizures	B-Disease	D012640	1592014
.	O	-1	1592014
Two	O	-1	1592014
se@@	O	-1	1592014
par@@	O	-1	1592014
ate	O	-1	1592014
equ@@	O	-1	1592014
im@@	O	-1	1592014
ol@@	O	-1	1592014
ar	O	-1	1592014
doses	O	-1	1592014
(0.@@	O	-1	1592014
2	O	-1	1592014
and	O	-1	1592014
0.@@	O	-1	1592014
4	O	-1	1592014
m@@	O	-1	1592014
um@@	O	-1	1592014
ol@@	O	-1	1592014
)	O	-1	1592014
of	O	-1	1592014
either	O	-1	1592014
cocaine	B-Chemical	D003042	1592014
or	O	-1	1592014
B@@	B-Chemical	C005618	1592014
E	I-Chemical	-1	1592014
were	O	-1	1592014
injected	O	-1	1592014
ventric@@	O	-1	1592014
ul@@	O	-1	1592014
arly	O	-1	1592014
in	O	-1	1592014
un@@	O	-1	1592014
anesthe@@	O	-1	1592014
tiz@@	O	-1	1592014
ed	O	-1	1592014
j@@	O	-1	1592014
u@@	O	-1	1592014
ven@@	O	-1	1592014
ile	O	-1	1592014
rats.	O	-1	1592014
T@@	O	-1	1592014
re@@	O	-1	1592014
ated	O	-1	1592014
rats	O	-1	1592014
were	O	-1	1592014
then	O	-1	1592014
evaluated	O	-1	1592014
for	O	-1	1592014
inc@@	O	-1	1592014
id@@	O	-1	1592014
ence@@	O	-1	1592014
,	O	-1	1592014
lat@@	O	-1	1592014
enc@@	O	-1	1592014
y,	O	-1	1592014
and	O	-1	1592014
seizure	B-Disease	D012640	1592014
pat@@	O	-1	1592014
ter@@	O	-1	1592014
n	O	-1	1592014
or	O	-1	1592014
for	O	-1	1592014
locomotor	O	-1	1592014
activity	O	-1	1592014
in	O	-1	1592014
animals	O	-1	1592014
without	O	-1	1592014
seizures	B-Disease	D012640	1592014
.	O	-1	1592014
B@@	B-Chemical	C005618	1592014
E	I-Chemical	-1	1592014
-@@	O	-1	1592014
In@@	O	-1	1592014
duced	O	-1	1592014
seizures	B-Disease	D012640	1592014
occurred	O	-1	1592014
more	O	-1	1592014
frequ@@	O	-1	1592014
ently	O	-1	1592014
and	O	-1	1592014
had	O	-1	1592014
significantly	O	-1	1592014
long@@	O	-1	1592014
er	O	-1	1592014
lat@@	O	-1	1592014
en@@	O	-1	1592014
ci@@	O	-1	1592014
es	O	-1	1592014
than	O	-1	1592014
those	O	-1	1592014
induced	O	-1	1592014
by	O	-1	1592014
equ@@	O	-1	1592014
im@@	O	-1	1592014
ol@@	O	-1	1592014
ar	O	-1	1592014
amoun@@	O	-1	1592014
ts	O	-1	1592014
of	O	-1	1592014
cocaine	B-Chemical	D003042	1592014
.	O	-1	1592014
Whe@@	O	-1	1592014
reas	O	-1	1592014
cocaine	B-Chemical	D003042	1592014
-induced	O	-1	1592014
seizures	B-Disease	D012640	1592014
were	O	-1	1592014
b@@	O	-1	1592014
est	O	-1	1592014
character@@	O	-1	1592014
ized	O	-1	1592014
as	O	-1	1592014
b@@	O	-1	1592014
ri@@	O	-1	1592014
e@@	O	-1	1592014
f@@	O	-1	1592014
,	O	-1	1592014
gener@@	O	-1	1592014
al@@	O	-1	1592014
iz@@	O	-1	1592014
ed,	O	-1	1592014
and	O	-1	1592014
t@@	O	-1	1592014
onic	O	-1	1592014
and	O	-1	1592014
resulted	O	-1	1592014
in	O	-1	1592014
death	B-Disease	D003643	1592014
,	O	-1	1592014
those	O	-1	1592014
induced	O	-1	1592014
by	O	-1	1592014
B@@	B-Chemical	C005618	1592014
E	I-Chemical	-1	1592014
were	O	-1	1592014
prolong@@	O	-1	1592014
ed,	O	-1	1592014
often	O	-1	1592014
multiple	O	-1	1592014
and	O	-1	1592014
mi@@	O	-1	1592014
x@@	O	-1	1592014
ed	O	-1	1592014
in	O	-1	1592014
typ@@	O	-1	1592014
e,	O	-1	1592014
and	O	-1	1592014
ra@@	O	-1	1592014
re@@	O	-1	1592014
ly	O	-1	1592014
resulted	O	-1	1592014
in	O	-1	1592014
death	B-Disease	D003643	1592014
.	O	-1	1592014
E@@	O	-1	1592014
l@@	O	-1	1592014
ect@@	O	-1	1592014
r@@	O	-1	1592014
ical	O	-1	1592014
recor@@	O	-1	1592014
d@@	O	-1	1592014
ings	O	-1	1592014
from	O	-1	1592014
the	O	-1	1592014
hippocamp@@	O	-1	1592014
us	O	-1	1592014
showed	O	-1	1592014
a	O	-1	1592014
rhyth@@	O	-1	1592014
mic	O	-1	1592014
progres@@	O	-1	1592014
sion	O	-1	1592014
in	O	-1	1592014
E@@	O	-1	1592014
E@@	O	-1	1592014
G	O	-1	1592014
frequency	O	-1	1592014
and	O	-1	1592014
vol@@	O	-1	1592014
t@@	O	-1	1592014
age	O	-1	1592014
with	O	-1	1592014
clinical	O	-1	1592014
seizure	B-Disease	D012640	1592014
ex@@	O	-1	1592014
pres@@	O	-1	1592014
sion.	O	-1	1592014
B@@	B-Chemical	C005618	1592014
E	I-Chemical	-1	1592014
-@@	O	-1	1592014
In@@	O	-1	1592014
j@@	O	-1	1592014
ected	O	-1	1592014
rats	O	-1	1592014
that	O	-1	1592014
did	O	-1	1592014
not	O	-1	1592014
have	O	-1	1592014
seizures	B-Disease	D012640	1592014
had	O	-1	1592014
significantly	O	-1	1592014
more	O	-1	1592014
locomotor	O	-1	1592014
activity	O	-1	1592014
than	O	-1	1592014
cocaine	B-Chemical	D003042	1592014
-@@	O	-1	1592014
injected	O	-1	1592014
animals	O	-1	1592014
without	O	-1	1592014
seizures	B-Disease	D012640	1592014
.	O	-1	1592014
The	O	-1	1592014
find@@	O	-1	1592014
ing	O	-1	1592014
that	O	-1	1592014
cocaine	B-Chemical	D003042	1592014
-	O	-1	1592014
and	O	-1	1592014
B@@	B-Chemical	C005618	1592014
E	I-Chemical	-1	1592014
-induced	O	-1	1592014
seizures	B-Disease	D012640	1592014
diff@@	O	-1	1592014
er	O	-1	1592014
in	O	-1	1592014
several	O	-1	1592014
resp@@	O	-1	1592014
ects	O	-1	1592014
suggests	O	-1	1592014
more	O	-1	1592014
than	O	-1	1592014
one	O	-1	1592014
mechanism	O	-1	1592014
for	O	-1	1592014
cocaine	B-Chemical	D003042	1592014
-induced	O	-1	1592014
seizures	B-Disease	D012640	1592014
and	O	-1	1592014
em@@	O	-1	1592014
pha@@	O	-1	1592014
si@@	O	-1	1592014
z@@	O	-1	1592014
es	O	-1	1592014
the	O	-1	1592014
import@@	O	-1	1592014
ance	O	-1	1592014
of	O	-1	1592014
a	O	-1	1592014
cocaine	B-Chemical	D003042	1592014
metabol@@	O	-1	1592014
it@@	O	-1	1592014
e,	O	-1	1592014
B@@	B-Chemical	C005618	1592014
E	I-Chemical	-1	1592014
.	O	-1	1592014

Pro@@	O	-1	1436384
t@@	O	-1	1436384
ection	O	-1	1436384
against	O	-1	1436384
amphetamine	B-Chemical	D000661	1436384
-induced	O	-1	1436384
neuro@@	B-Disease	D020258	1436384
toxicity	I-Disease	-1	1436384
to@@	O	-1	1436384
war@@	O	-1	1436384
d	O	-1	1436384
stri@@	O	-1	1436384
atal	O	-1	1436384
dopamine	B-Chemical	D004298	1436384
neuron@@	O	-1	1436384
s	O	-1	1436384
in	O	-1	1436384
ro@@	O	-1	1436384
d@@	O	-1	1436384
ents	O	-1	1436384
by	O	-1	1436384
L@@	B-Chemical	C070935	1436384
Y@@	I-Chemical	-1	1436384
27@@	I-Chemical	-1	1436384
4@@	I-Chemical	-1	1436384
6@@	I-Chemical	-1	1436384
14	I-Chemical	-1	1436384
,	O	-1	1436384
an	O	-1	1436384
ex@@	O	-1	1436384
cit@@	O	-1	1436384
atory	O	-1	1436384
amin@@	B-Chemical	D000596	1436384
o	I-Chemical	-1	1436384
acid	I-Chemical	-1	1436384
antagonist@@	O	-1	1436384
.	O	-1	1436384
L@@	B-Chemical	C070935	1436384
Y@@	I-Chemical	-1	1436384
27@@	I-Chemical	-1	1436384
4@@	I-Chemical	-1	1436384
6@@	I-Chemical	-1	1436384
14	I-Chemical	-1	1436384
,	O	-1	1436384
3@@	B-Chemical	C070935	1436384
SR@@	I-Chemical	-1	1436384
,@@	I-Chemical	-1	1436384
4@@	I-Chemical	-1	1436384
a@@	I-Chemical	-1	1436384
R@@	I-Chemical	-1	1436384
S@@	I-Chemical	-1	1436384
,@@	I-Chemical	-1	1436384
6@@	I-Chemical	-1	1436384
SR@@	I-Chemical	-1	1436384
,@@	I-Chemical	-1	1436384
8@@	I-Chemical	-1	1436384
a@@	I-Chemical	-1	1436384
R@@	I-Chemical	-1	1436384
S@@	I-Chemical	-1	1436384
-@@	I-Chemical	-1	1436384
6-@@	I-Chemical	-1	1436384
[@@	I-Chemical	-1	1436384
phosph@@	I-Chemical	-1	1436384
on@@	I-Chemical	-1	1436384
o@@	I-Chemical	-1	1436384
methyl@@	I-Chemical	-1	1436384
]@@	I-Chemical	-1	1436384
dec@@	I-Chemical	-1	1436384
a@@	I-Chemical	-1	1436384
hy@@	I-Chemical	-1	1436384
d@@	I-Chemical	-1	1436384
r	I-Chemical	-1	1436384
o@@	I-Chemical	-1	1436384
iso@@	I-Chemical	-1	1436384
qu@@	I-Chemical	-1	1436384
in@@	I-Chemical	-1	1436384
ol@@	I-Chemical	-1	1436384
ine-@@	I-Chemical	-1	1436384
3@@	I-Chemical	-1	1436384
-	I-Chemical	-1	1436384
carb@@	I-Chemical	-1	1436384
ox@@	I-Chemical	-1	1436384
yl@@	I-Chemical	-1	1436384
ic	I-Chemical	-1	1436384
acid	I-Chemical	-1	1436384
,	O	-1	1436384
has	O	-1	1436384
been	O	-1	1436384
descri@@	O	-1	1436384
bed	O	-1	1436384
as	O	-1	1436384
a	O	-1	1436384
pot@@	O	-1	1436384
ent	O	-1	1436384
antagonist	O	-1	1436384
of	O	-1	1436384
the	O	-1	1436384
N@@	B-Chemical	D016202	1436384
-@@	I-Chemical	-1	1436384
methyl@@	I-Chemical	-1	1436384
-@@	I-Chemical	-1	1436384
D-@@	I-Chemical	-1	1436384
as@@	I-Chemical	-1	1436384
part@@	I-Chemical	-1	1436384
ate	I-Chemical	-1	1436384
(	O	-1	1436384
N@@	B-Chemical	D016202	1436384
MD@@	I-Chemical	-1	1436384
A	I-Chemical	-1	1436384
)	O	-1	1436384
sub@@	O	-1	1436384
type	O	-1	1436384
of	O	-1	1436384
glutamate	B-Chemical	D018698	1436384
receptor@@	O	-1	1436384
.	O	-1	1436384
H@@	O	-1	1436384
ere	O	-1	1436384
its	O	-1	1436384
ability	O	-1	1436384
to	O	-1	1436384
antagon@@	O	-1	1436384
iz@@	O	-1	1436384
e	O	-1	1436384
the	O	-1	1436384
prolonged	O	-1	1436384
deple@@	O	-1	1436384
tion	O	-1	1436384
of	O	-1	1436384
dopamine	B-Chemical	D004298	1436384
in	O	-1	1436384
the	O	-1	1436384
striat@@	O	-1	1436384
um	O	-1	1436384
by	O	-1	1436384
amphetamine	B-Chemical	D000661	1436384
in	O	-1	1436384
ip@@	B-Chemical	D007488	1436384
r@@	I-Chemical	-1	1436384
ind@@	I-Chemical	-1	1436384
ole	I-Chemical	-1	1436384
-treated	O	-1	1436384
rats	O	-1	1436384
is	O	-1	1436384
repor@@	O	-1	1436384
ted.	O	-1	1436384
A	O	-1	1436384
single	O	-1	1436384
1@@	O	-1	1436384
8.@@	O	-1	1436384
4	O	-1	1436384
mg/kg	O	-1	1436384
(@@	O	-1	1436384
i.p.@@	O	-1	1436384
)	O	-1	1436384
dose	O	-1	1436384
of	O	-1	1436384
(@@	O	-1	1436384
+/-@@	O	-1	1436384
)@@	O	-1	1436384
-	O	-1	1436384
amphetamine	B-Chemical	D000661	1436384
he@@	O	-1	1436384
mis@@	O	-1	1436384
ul@@	O	-1	1436384
f@@	O	-1	1436384
ate,	O	-1	1436384
given	O	-1	1436384
to	O	-1	1436384
rats	O	-1	1436384
pre@@	O	-1	1436384
treated	O	-1	1436384
with	O	-1	1436384
ip@@	B-Chemical	D007488	1436384
r@@	I-Chemical	-1	1436384
ind@@	I-Chemical	-1	1436384
ole	I-Chemical	-1	1436384
,	O	-1	1436384
resulted	O	-1	1436384
in	O	-1	1436384
per@@	O	-1	1436384
sist@@	O	-1	1436384
ent	O	-1	1436384
deple@@	O	-1	1436384
tion	O	-1	1436384
of	O	-1	1436384
dopamine	B-Chemical	D004298	1436384
in	O	-1	1436384
the	O	-1	1436384
striat@@	O	-1	1436384
um	O	-1	1436384
1	O	-1	1436384
week	O	-1	1436384
lat@@	O	-1	1436384
er.	O	-1	1436384
This	O	-1	1436384
prolonged	O	-1	1436384
deple@@	O	-1	1436384
tion	O	-1	1436384
of	O	-1	1436384
dopamine	B-Chemical	D004298	1436384
in	O	-1	1436384
the	O	-1	1436384
striat@@	O	-1	1436384
um	O	-1	1436384
was	O	-1	1436384
antagon@@	O	-1	1436384
ized	O	-1	1436384
by	O	-1	1436384
di@@	B-Chemical	D016291	1436384
z@@	I-Chemical	-1	1436384
oc@@	I-Chemical	-1	1436384
il@@	I-Chemical	-1	1436384
pine	I-Chemical	-1	1436384
(	O	-1	1436384
M@@	B-Chemical	D016291	1436384
K@@	I-Chemical	-1	1436384
-@@	I-Chemical	-1	1436384
80@@	I-Chemical	-1	1436384
1	I-Chemical	-1	1436384
,	O	-1	1436384
a	O	-1	1436384
non-@@	O	-1	1436384
comp@@	O	-1	1436384
e@@	O	-1	1436384
ti@@	O	-1	1436384
tive	O	-1	1436384
antagonist	O	-1	1436384
of	O	-1	1436384
N@@	B-Chemical	D016202	1436384
MD@@	I-Chemical	-1	1436384
A	I-Chemical	-1	1436384
receptor@@	O	-1	1436384
s)	O	-1	1436384
or	O	-1	1436384
by	O	-1	1436384
L@@	B-Chemical	C070935	1436384
Y@@	I-Chemical	-1	1436384
27@@	I-Chemical	-1	1436384
4@@	I-Chemical	-1	1436384
6@@	I-Chemical	-1	1436384
14	I-Chemical	-1	1436384
(@@	O	-1	1436384
a	O	-1	1436384
comp@@	O	-1	1436384
e@@	O	-1	1436384
ti@@	O	-1	1436384
tive	O	-1	1436384
antagonist	O	-1	1436384
of	O	-1	1436384
N@@	B-Chemical	D016202	1436384
MD@@	I-Chemical	-1	1436384
A	I-Chemical	-1	1436384
receptor@@	O	-1	1436384
s@@	O	-1	1436384
).	O	-1	1436384
The	O	-1	1436384
protective	O	-1	1436384
effect	O	-1	1436384
of	O	-1	1436384
L@@	B-Chemical	C070935	1436384
Y@@	I-Chemical	-1	1436384
27@@	I-Chemical	-1	1436384
4@@	I-Chemical	-1	1436384
6@@	I-Chemical	-1	1436384
14	I-Chemical	-1	1436384
was	O	-1	1436384
dose-@@	O	-1	1436384
depend@@	O	-1	1436384
ent@@	O	-1	1436384
,	O	-1	1436384
being	O	-1	1436384
maxim@@	O	-1	1436384
um	O	-1	1436384
at	O	-1	1436384
10-@@	O	-1	1436384
40	O	-1	1436384
mg@@	O	-1	1436384
k@@	O	-1	1436384
g	O	-1	1436384
(@@	O	-1	1436384
i.p.@@	O	-1	1436384
).	O	-1	1436384
A	O	-1	1436384
10	O	-1	1436384
mg/kg	O	-1	1436384
dose	O	-1	1436384
of	O	-1	1436384
L@@	B-Chemical	C070935	1436384
Y@@	I-Chemical	-1	1436384
27@@	I-Chemical	-1	1436384
4@@	I-Chemical	-1	1436384
6@@	I-Chemical	-1	1436384
14	I-Chemical	-1	1436384
was	O	-1	1436384
effective	O	-1	1436384
in	O	-1	1436384
antagon@@	O	-1	1436384
iz@@	O	-1	1436384
ing	O	-1	1436384
the	O	-1	1436384
deple@@	O	-1	1436384
tion	O	-1	1436384
of	O	-1	1436384
dopamine	B-Chemical	D004298	1436384
in	O	-1	1436384
the	O	-1	1436384
striat@@	O	-1	1436384
um,	O	-1	1436384
when	O	-1	1436384
given	O	-1	1436384
as	O	-1	1436384
lon@@	O	-1	1436384
g	O	-1	1436384
as	O	-1	1436384
8	O	-1	1436384
h@@	O	-1	1436384
r	O	-1	1436384
prior	O	-1	1436384
to	O	-1	1436384
amphetamine	B-Chemical	D000661	1436384
but	O	-1	1436384
not	O	-1	1436384
when	O	-1	1436384
given	O	-1	1436384
24	O	-1	1436384
h@@	O	-1	1436384
r	O	-1	1436384
prior	O	-1	1436384
to	O	-1	1436384
amphetamine	B-Chemical	D000661	1436384
.	O	-1	1436384
D@@	O	-1	1436384
ep@@	O	-1	1436384
le@@	O	-1	1436384
tion	O	-1	1436384
of	O	-1	1436384
dopamine	B-Chemical	D004298	1436384
in	O	-1	1436384
the	O	-1	1436384
striat@@	O	-1	1436384
um	O	-1	1436384
was	O	-1	1436384
also	O	-1	1436384
antagon@@	O	-1	1436384
ized	O	-1	1436384
when	O	-1	1436384
L@@	B-Chemical	C070935	1436384
Y@@	I-Chemical	-1	1436384
27@@	I-Chemical	-1	1436384
4@@	I-Chemical	-1	1436384
6@@	I-Chemical	-1	1436384
14	I-Chemical	-1	1436384
was	O	-1	1436384
given	O	-1	1436384
after	O	-1	1436384
the	O	-1	1436384
injection	O	-1	1436384
of	O	-1	1436384
amphetamine	B-Chemical	D000661	1436384
;	O	-1	1436384
L@@	B-Chemical	C070935	1436384
Y@@	I-Chemical	-1	1436384
27@@	I-Chemical	-1	1436384
4@@	I-Chemical	-1	1436384
6@@	I-Chemical	-1	1436384
14	I-Chemical	-1	1436384
prot@@	O	-1	1436384
ected	O	-1	1436384
when	O	-1	1436384
given	O	-1	1436384
up	O	-1	1436384
to	O	-1	1436384
4	O	-1	1436384
h@@	O	-1	1436384
r	O	-1	1436384
after	O	-1	1436384
but	O	-1	1436384
not	O	-1	1436384
when	O	-1	1436384
given	O	-1	1436384
8	O	-1	1436384
or	O	-1	1436384
24	O	-1	1436384
h@@	O	-1	1436384
r	O	-1	1436384
after	O	-1	1436384
amphetamine	B-Chemical	D000661	1436384
.	O	-1	1436384
The	O	-1	1436384
prolonged	O	-1	1436384
deple@@	O	-1	1436384
tion	O	-1	1436384
of	O	-1	1436384
dopamine	B-Chemical	D004298	1436384
in	O	-1	1436384
the	O	-1	1436384
striat@@	O	-1	1436384
um	O	-1	1436384
in	O	-1	1436384
mic@@	O	-1	1436384
e,	O	-1	1436384
given	O	-1	1436384
multiple	O	-1	1436384
injec@@	O	-1	1436384
tions	O	-1	1436384
of	O	-1	1436384
meth@@	B-Chemical	D008694	1436384
amphetamine	I-Chemical	-1	1436384
,	O	-1	1436384
was	O	-1	1436384
also	O	-1	1436384
antagon@@	O	-1	1436384
ized	O	-1	1436384
dose-@@	O	-1	1436384
depend@@	O	-1	1436384
ently	O	-1	1436384
and	O	-1	1436384
complete@@	O	-1	1436384
ly	O	-1	1436384
by	O	-1	1436384
L@@	B-Chemical	C070935	1436384
Y@@	I-Chemical	-1	1436384
27@@	I-Chemical	-1	1436384
4@@	I-Chemical	-1	1436384
6@@	I-Chemical	-1	1436384
14	I-Chemical	-1	1436384
.	O	-1	1436384
The	O	-1	1436384
data	O	-1	1436384
st@@	O	-1	1436384
ren@@	O	-1	1436384
g@@	O	-1	1436384
then	O	-1	1436384
the	O	-1	1436384
evidence	O	-1	1436384
that	O	-1	1436384
the	O	-1	1436384
neuro@@	B-Disease	D020258	1436384
toxic	I-Disease	-1	1436384
effect	O	-1	1436384
of	O	-1	1436384
amphetamine	B-Chemical	D000661	1436384
and	O	-1	1436384
related	O	-1	1436384
comp@@	O	-1	1436384
oun@@	O	-1	1436384
ds	O	-1	1436384
to@@	O	-1	1436384
war@@	O	-1	1436384
d	O	-1	1436384
n@@	O	-1	1436384
ig@@	O	-1	1436384
ro@@	O	-1	1436384
stri@@	O	-1	1436384
atal	O	-1	1436384
dopamine	B-Chemical	D004298	1436384
neuron@@	O	-1	1436384
s	O	-1	1436384
invol@@	O	-1	1436384
v@@	O	-1	1436384
es	O	-1	1436384
N@@	B-Chemical	D016202	1436384
MD@@	I-Chemical	-1	1436384
A	I-Chemical	-1	1436384
receptors	O	-1	1436384
and	O	-1	1436384
that	O	-1	1436384
L@@	B-Chemical	C070935	1436384
Y@@	I-Chemical	-1	1436384
27@@	I-Chemical	-1	1436384
4@@	I-Chemical	-1	1436384
6@@	I-Chemical	-1	1436384
14	I-Chemical	-1	1436384
is	O	-1	1436384
an	O	-1	1436384
N@@	B-Chemical	D016202	1436384
MD@@	I-Chemical	-1	1436384
A	I-Chemical	-1	1436384
receptor	O	-1	1436384
antagonist	O	-1	1436384
with	O	-1	1436384
long@@	O	-1	1436384
-@@	O	-1	1436384
l@@	O	-1	1436384
ast@@	O	-1	1436384
ing	O	-1	1436384
in	O	-1	1436384
viv@@	O	-1	1436384
o	O	-1	1436384
effects	O	-1	1436384
in	O	-1	1436384
rats.	O	-1	1436384

Ne@@	O	-1	1085609
on@@	O	-1	1085609
atal	O	-1	1085609
pyri@@	B-Chemical	D011736	1085609
dox@@	I-Chemical	-1	1085609
ine	I-Chemical	-1	1085609
respon@@	O	-1	1085609
sive	O	-1	1085609
convul@@	B-Disease	D012640	1085609
sions	I-Disease	-1	1085609
due	O	-1	1085609
to	O	-1	1085609
is@@	B-Chemical	D007538	1085609
oni@@	I-Chemical	-1	1085609
az@@	I-Chemical	-1	1085609
id	I-Chemical	-1	1085609
therapy.	O	-1	1085609
A	O	-1	1085609
17@@	O	-1	1085609
-@@	O	-1	1085609
day@@	O	-1	1085609
-old	O	-1	1085609
inf@@	O	-1	1085609
ant	O	-1	1085609
on	O	-1	1085609
is@@	B-Chemical	D007538	1085609
oni@@	I-Chemical	-1	1085609
az@@	I-Chemical	-1	1085609
id	I-Chemical	-1	1085609
therapy	O	-1	1085609
13	O	-1	1085609
mg/kg	O	-1	1085609
daily	O	-1	1085609
from	O	-1	1085609
b@@	O	-1	1085609
ir@@	O	-1	1085609
th	O	-1	1085609
because	O	-1	1085609
of	O	-1	1085609
mat@@	O	-1	1085609
er@@	O	-1	1085609
n@@	O	-1	1085609
al	O	-1	1085609
tub@@	B-Disease	D014376	1085609
er@@	I-Disease	-1	1085609
c@@	I-Disease	-1	1085609
ulo@@	I-Disease	-1	1085609
sis	I-Disease	-1	1085609
was	O	-1	1085609
ad@@	O	-1	1085609
mit@@	O	-1	1085609
ted	O	-1	1085609
after	O	-1	1085609
4	O	-1	1085609
days	O	-1	1085609
of	O	-1	1085609
clon@@	B-Disease	D012640	1085609
ic	I-Disease	-1	1085609
f@@	I-Disease	-1	1085609
its	I-Disease	-1	1085609
.	O	-1	1085609
No	O	-1	1085609
underlying	O	-1	1085609
inf@@	O	-1	1085609
ective	O	-1	1085609
or	O	-1	1085609
bio@@	O	-1	1085609
chemical	O	-1	1085609
cause	O	-1	1085609
could	O	-1	1085609
be	O	-1	1085609
f@@	O	-1	1085609
oun@@	O	-1	1085609
d.	O	-1	1085609
The	O	-1	1085609
f@@	B-Disease	D012640	1085609
its	I-Disease	-1	1085609
ce@@	O	-1	1085609
as@@	O	-1	1085609
ed	O	-1	1085609
within	O	-1	1085609
4	O	-1	1085609
hours	O	-1	1085609
of	O	-1	1085609
administ@@	O	-1	1085609
ering	O	-1	1085609
int@@	O	-1	1085609
ram@@	O	-1	1085609
us@@	O	-1	1085609
cular	O	-1	1085609
pyri@@	B-Chemical	D011736	1085609
dox@@	I-Chemical	-1	1085609
ine	I-Chemical	-1	1085609
,	O	-1	1085609
suggesting	O	-1	1085609
an	O	-1	1085609
a@@	O	-1	1085609
e@@	O	-1	1085609
ti@@	O	-1	1085609
ology	O	-1	1085609
of	O	-1	1085609
pyri@@	B-Chemical	D011736	1085609
dox@@	I-Chemical	-1	1085609
ine	I-Chemical	-1	1085609
defici@@	O	-1	1085609
ency	O	-1	1085609
secondary	O	-1	1085609
to	O	-1	1085609
is@@	B-Chemical	D007538	1085609
oni@@	I-Chemical	-1	1085609
az@@	I-Chemical	-1	1085609
id	I-Chemical	-1	1085609
medic@@	O	-1	1085609
ation.	O	-1	1085609

Re@@	O	-1	809711
ver@@	O	-1	809711
s@@	O	-1	809711
al	O	-1	809711
by	O	-1	809711
pheny@@	B-Chemical	D010656	809711
le@@	I-Chemical	-1	809711
phrine	I-Chemical	-1	809711
of	O	-1	809711
the	O	-1	809711
ben@@	O	-1	809711
e@@	O	-1	809711
fic@@	O	-1	809711
ial	O	-1	809711
effects	O	-1	809711
of	O	-1	809711
intravenous	O	-1	809711
nitro@@	B-Chemical	D005996	809711
glycer@@	I-Chemical	-1	809711
in	I-Chemical	-1	809711
in	O	-1	809711
patients	O	-1	809711
with	O	-1	809711
acute	B-Disease	D009203	809711
myocardial	I-Disease	-1	809711
infarction	I-Disease	-1	809711
.	O	-1	809711
N@@	B-Chemical	D005996	809711
it@@	I-Chemical	-1	809711
ro@@	I-Chemical	-1	809711
glycer@@	I-Chemical	-1	809711
in	I-Chemical	-1	809711
has	O	-1	809711
been	O	-1	809711
shown	O	-1	809711
to	O	-1	809711
re@@	O	-1	809711
duce	O	-1	809711
S@@	O	-1	809711
T@@	O	-1	809711
-@@	O	-1	809711
seg@@	O	-1	809711
ment	O	-1	809711
elev@@	O	-1	809711
ation	O	-1	809711
during	O	-1	809711
acute	B-Disease	D009203	809711
myocardial	I-Disease	-1	809711
infarction	I-Disease	-1	809711
,	O	-1	809711
an	O	-1	809711
effect	O	-1	809711
potenti@@	O	-1	809711
ated	O	-1	809711
in	O	-1	809711
the	O	-1	809711
do@@	O	-1	809711
g	O	-1	809711
by	O	-1	809711
agents	O	-1	809711
that	O	-1	809711
re@@	O	-1	809711
verse	O	-1	809711
nitro@@	B-Chemical	D005996	809711
glycer@@	I-Chemical	-1	809711
in	I-Chemical	-1	809711
-induced	O	-1	809711
hypotension	B-Disease	D007022	809711
.	O	-1	809711
Our	O	-1	809711
study	O	-1	809711
was	O	-1	809711
de@@	O	-1	809711
signed	O	-1	809711
to	O	-1	809711
determine	O	-1	809711
the	O	-1	809711
effects	O	-1	809711
of	O	-1	809711
combined	O	-1	809711
nitro@@	B-Chemical	D005996	809711
glycer@@	I-Chemical	-1	809711
in	I-Chemical	-1	809711
and	O	-1	809711
pheny@@	B-Chemical	D010656	809711
le@@	I-Chemical	-1	809711
phrine	I-Chemical	-1	809711
therapy.	O	-1	809711
T@@	O	-1	809711
en	O	-1	809711
patients	O	-1	809711
with	O	-1	809711
acute	O	-1	809711
trans@@	O	-1	809711
m@@	O	-1	809711
ural	O	-1	809711
myocardial	B-Disease	D009203	809711
infarc@@	I-Disease	-1	809711
tions	I-Disease	-1	809711
received	O	-1	809711
intravenous	O	-1	809711
nitro@@	B-Chemical	D005996	809711
glycer@@	I-Chemical	-1	809711
in	I-Chemical	-1	809711
,	O	-1	809711
suffici@@	O	-1	809711
ent	O	-1	809711
to	O	-1	809711
re@@	O	-1	809711
duce	O	-1	809711
mean	O	-1	809711
arterial	O	-1	809711
pressure	O	-1	809711
from	O	-1	809711
10@@	O	-1	809711
7	O	-1	809711
+/-	O	-1	809711
6	O	-1	809711
to	O	-1	809711
8@@	O	-1	809711
5	O	-1	809711
+/-	O	-1	809711
6	O	-1	809711
mm	O	-1	809711
H@@	O	-1	809711
g	O	-1	809711
(P	O	-1	809711
less	O	-1	809711
than	O	-1	809711
0.00@@	O	-1	809711
1),	O	-1	809711
for	O	-1	809711
60	O	-1	809711
minut@@	O	-1	809711
es.	O	-1	809711
L@@	O	-1	809711
e@@	O	-1	809711
ft	O	-1	809711
ventricular	O	-1	809711
f@@	O	-1	809711
ill@@	O	-1	809711
ing	O	-1	809711
pressure	O	-1	809711
decreased	O	-1	809711
from	O	-1	809711
1@@	O	-1	809711
9	O	-1	809711
+/-	O	-1	809711
2	O	-1	809711
to	O	-1	809711
11	O	-1	809711
+/-	O	-1	809711
2	O	-1	809711
mm	O	-1	809711
H@@	O	-1	809711
g	O	-1	809711
(P	O	-1	809711
less	O	-1	809711
than	O	-1	809711
0.00@@	O	-1	809711
1).	O	-1	809711
Si@@	O	-1	809711
g@@	O	-1	809711
ma@@	O	-1	809711
S@@	O	-1	809711
T@@	O	-1	809711
,	O	-1	809711
the	O	-1	809711
su@@	O	-1	809711
m	O	-1	809711
of	O	-1	809711
S@@	O	-1	809711
T@@	O	-1	809711
-@@	O	-1	809711
seg@@	O	-1	809711
ment	O	-1	809711
elev@@	O	-1	809711
ations	O	-1	809711
in	O	-1	809711
16	O	-1	809711
pre@@	O	-1	809711
cor@@	O	-1	809711
di@@	O	-1	809711
al	O	-1	809711
lead@@	O	-1	809711
s,	O	-1	809711
decreased	O	-1	809711
(P	O	-1	809711
less	O	-1	809711
than	O	-1	809711
0.0@@	O	-1	809711
2)	O	-1	809711
with	O	-1	809711
intravenous	O	-1	809711
nitro@@	B-Chemical	D005996	809711
glycer@@	I-Chemical	-1	809711
in	I-Chemical	-1	809711
.	O	-1	809711
S@@	O	-1	809711
ub@@	O	-1	809711
sequ@@	O	-1	809711
ent	O	-1	809711
addition	O	-1	809711
of	O	-1	809711
pheny@@	B-Chemical	D010656	809711
le@@	I-Chemical	-1	809711
phrine	I-Chemical	-1	809711
infu@@	O	-1	809711
sion,	O	-1	809711
suffici@@	O	-1	809711
ent	O	-1	809711
to	O	-1	809711
re@@	O	-1	809711
-@@	O	-1	809711
elev@@	O	-1	809711
ate	O	-1	809711
mean	O	-1	809711
arterial	O	-1	809711
pressure	O	-1	809711
to	O	-1	809711
10@@	O	-1	809711
6	O	-1	809711
+/-	O	-1	809711
4	O	-1	809711
mm	O	-1	809711
H@@	O	-1	809711
g	O	-1	809711
(P	O	-1	809711
less	O	-1	809711
than	O	-1	809711
0.00@@	O	-1	809711
1)	O	-1	809711
for	O	-1	809711
30	O	-1	809711
minut@@	O	-1	809711
es,	O	-1	809711
increased	O	-1	809711
left	O	-1	809711
ventricular	O	-1	809711
f@@	O	-1	809711
ill@@	O	-1	809711
ing	O	-1	809711
pressure	O	-1	809711
to	O	-1	809711
17	O	-1	809711
+/-	O	-1	809711
2	O	-1	809711
mm	O	-1	809711
H@@	O	-1	809711
g	O	-1	809711
(P	O	-1	809711
less	O	-1	809711
than	O	-1	809711
0.05@@	O	-1	809711
)	O	-1	809711
and	O	-1	809711
also	O	-1	809711
significantly	O	-1	809711
increased	O	-1	809711
si@@	O	-1	809711
g@@	O	-1	809711
ma@@	O	-1	809711
S@@	O	-1	809711
T	O	-1	809711
(P	O	-1	809711
less	O	-1	809711
than	O	-1	809711
0.05@@	O	-1	809711
).	O	-1	809711
Our	O	-1	809711
results	O	-1	809711
suggest	O	-1	809711
that	O	-1	809711
addition	O	-1	809711
of	O	-1	809711
pheny@@	B-Chemical	D010656	809711
le@@	I-Chemical	-1	809711
phrine	I-Chemical	-1	809711
to	O	-1	809711
nitro@@	B-Chemical	D005996	809711
glycer@@	I-Chemical	-1	809711
in	I-Chemical	-1	809711
is	O	-1	809711
not	O	-1	809711
ben@@	O	-1	809711
e@@	O	-1	809711
fic@@	O	-1	809711
ial	O	-1	809711
in	O	-1	809711
the	O	-1	809711
treatment	O	-1	809711
of	O	-1	809711
patients	O	-1	809711
with	O	-1	809711
acute	B-Disease	D009203	809711
myocardial	I-Disease	-1	809711
infarction	I-Disease	-1	809711
.	O	-1	809711

E@@	O	-1	20621845
lev@@	O	-1	20621845
ation	O	-1	20621845
of	O	-1	20621845
AD@@	O	-1	20621845
AM@@	O	-1	20621845
10@@	O	-1	20621845
,	O	-1	20621845
AD@@	O	-1	20621845
AM@@	O	-1	20621845
17@@	O	-1	20621845
,	O	-1	20621845
M@@	O	-1	20621845
MP@@	O	-1	20621845
-@@	O	-1	20621845
2	O	-1	20621845
and	O	-1	20621845
M@@	O	-1	20621845
MP@@	O	-1	20621845
-@@	O	-1	20621845
9	O	-1	20621845
expression	O	-1	20621845
with	O	-1	20621845
medi@@	O	-1	20621845
a	O	-1	20621845
de@@	O	-1	20621845
generation	O	-1	20621845
feat@@	O	-1	20621845
ures	O	-1	20621845
Ca@@	B-Chemical	D002122	20621845
Cl@@	I-Chemical	-1	20621845
2	I-Chemical	-1	20621845
-induced	O	-1	20621845
th@@	B-Disease	D017545	20621845
or@@	I-Disease	-1	20621845
ac@@	I-Disease	-1	20621845
ic	I-Disease	-1	20621845
a@@	I-Disease	-1	20621845
or@@	I-Disease	-1	20621845
tic	I-Disease	-1	20621845
aneurys@@	I-Disease	-1	20621845
m	I-Disease	-1	20621845
in	O	-1	20621845
a	O	-1	20621845
rat	O	-1	20621845
model@@	O	-1	20621845
.	O	-1	20621845
P@@	O	-1	20621845
U@@	O	-1	20621845
R@@	O	-1	20621845
P@@	O	-1	20621845
O@@	O	-1	20621845
S@@	O	-1	20621845
E:	O	-1	20621845
This	O	-1	20621845
study	O	-1	20621845
was	O	-1	20621845
de@@	O	-1	20621845
signed	O	-1	20621845
to	O	-1	20621845
est@@	O	-1	20621845
abl@@	O	-1	20621845
is@@	O	-1	20621845
h	O	-1	20621845
a	O	-1	20621845
rat	O	-1	20621845
model	O	-1	20621845
of	O	-1	20621845
th@@	B-Disease	D017545	20621845
or@@	I-Disease	-1	20621845
ac@@	I-Disease	-1	20621845
ic	I-Disease	-1	20621845
a@@	I-Disease	-1	20621845
or@@	I-Disease	-1	20621845
tic	I-Disease	-1	20621845
aneurys@@	I-Disease	-1	20621845
m	I-Disease	-1	20621845
(	O	-1	20621845
TA@@	B-Disease	D017545	20621845
A	I-Disease	-1	20621845
)	O	-1	20621845
by	O	-1	20621845
calcium	B-Chemical	D002122	20621845
chlor@@	I-Chemical	-1	20621845
ide	I-Chemical	-1	20621845
(	O	-1	20621845
Ca@@	B-Chemical	D002122	20621845
Cl@@	I-Chemical	-1	20621845
(2@@	I-Chemical	-1	20621845
)	I-Chemical	-1	20621845
)@@	O	-1	20621845
-induced	O	-1	20621845
arterial	B-Disease	D014652	20621845
injury	I-Disease	-1	20621845
and	O	-1	20621845
to	O	-1	20621845
expl@@	O	-1	20621845
or@@	O	-1	20621845
e	O	-1	20621845
the	O	-1	20621845
potential	O	-1	20621845
role	O	-1	20621845
of	O	-1	20621845
a	O	-1	20621845
dis@@	O	-1	20621845
in@@	O	-1	20621845
te@@	O	-1	20621845
g@@	O	-1	20621845
rin	O	-1	20621845
and	O	-1	20621845
met@@	O	-1	20621845
al@@	O	-1	20621845
lo@@	O	-1	20621845
protein@@	O	-1	20621845
ase	O	-1	20621845
(A@@	O	-1	20621845
D@@	O	-1	20621845
AM@@	O	-1	20621845
),	O	-1	20621845
mat@@	O	-1	20621845
ri@@	O	-1	20621845
x	O	-1	20621845
met@@	O	-1	20621845
al@@	O	-1	20621845
lo@@	O	-1	20621845
protein@@	O	-1	20621845
as@@	O	-1	20621845
es	O	-1	20621845
(@@	O	-1	20621845
M@@	O	-1	20621845
MP@@	O	-1	20621845
s)	O	-1	20621845
and	O	-1	20621845
their	O	-1	20621845
endo@@	O	-1	20621845
gen@@	O	-1	20621845
ous	O	-1	20621845
inhibitors	O	-1	20621845
(@@	O	-1	20621845
TI@@	O	-1	20621845
MP@@	O	-1	20621845
s)	O	-1	20621845
in	O	-1	20621845
TA@@	B-Disease	D017545	20621845
A	I-Disease	-1	20621845
form@@	O	-1	20621845
ation.	O	-1	20621845
METHODS:	O	-1	20621845
Th@@	O	-1	20621845
or@@	O	-1	20621845
ac@@	O	-1	20621845
ic	O	-1	20621845
a@@	O	-1	20621845
ort@@	O	-1	20621845
a	O	-1	20621845
of	O	-1	20621845
male	O	-1	20621845
S@@	O	-1	20621845
pra@@	O	-1	20621845
gu@@	O	-1	20621845
e-@@	O	-1	20621845
D@@	O	-1	20621845
aw@@	O	-1	20621845
le@@	O	-1	20621845
y	O	-1	20621845
rats	O	-1	20621845
was	O	-1	20621845
exposed	O	-1	20621845
to	O	-1	20621845
0.@@	O	-1	20621845
5@@	O	-1	20621845
M	O	-1	20621845
Ca@@	B-Chemical	D002122	20621845
Cl@@	I-Chemical	-1	20621845
(2@@	I-Chemical	-1	20621845
)	I-Chemical	-1	20621845
or	O	-1	20621845
normal	O	-1	20621845
saline	O	-1	20621845
(	O	-1	20621845
Na@@	B-Chemical	D012965	20621845
C@@	I-Chemical	-1	20621845
l	I-Chemical	-1	20621845
).	O	-1	20621845
After	O	-1	20621845
12@@	O	-1	20621845
week@@	O	-1	20621845
s,	O	-1	20621845
animals	O	-1	20621845
were	O	-1	20621845
eu@@	O	-1	20621845
th@@	O	-1	20621845
an@@	O	-1	20621845
iz@@	O	-1	20621845
ed,	O	-1	20621845
and	O	-1	20621845
Ca@@	B-Chemical	D002122	20621845
Cl@@	I-Chemical	-1	20621845
(2@@	I-Chemical	-1	20621845
)	I-Chemical	-1	20621845
-@@	O	-1	20621845
treat@@	O	-1	20621845
ed,	O	-1	20621845
Ca@@	B-Chemical	D002122	20621845
Cl@@	I-Chemical	-1	20621845
(2@@	I-Chemical	-1	20621845
)	I-Chemical	-1	20621845
-@@	O	-1	20621845
un@@	O	-1	20621845
treated	O	-1	20621845
(n@@	O	-1	20621845
=@@	O	-1	20621845
12@@	O	-1	20621845
)	O	-1	20621845
and	O	-1	20621845
Na@@	B-Chemical	D012965	20621845
C@@	I-Chemical	-1	20621845
l	I-Chemical	-1	20621845
-treated	O	-1	20621845
a@@	O	-1	20621845
or@@	O	-1	20621845
tic	O	-1	20621845
seg@@	O	-1	20621845
ments	O	-1	20621845
(n@@	O	-1	20621845
=@@	O	-1	20621845
12@@	O	-1	20621845
)	O	-1	20621845
were	O	-1	20621845
coll@@	O	-1	20621845
ected	O	-1	20621845
for	O	-1	20621845
hist@@	O	-1	20621845
ological	O	-1	20621845
and	O	-1	20621845
mol@@	O	-1	20621845
ec@@	O	-1	20621845
ular	O	-1	20621845
assess@@	O	-1	20621845
ment@@	O	-1	20621845
s.	O	-1	20621845
M@@	O	-1	20621845
MP@@	O	-1	20621845
-@@	O	-1	20621845
TI@@	O	-1	20621845
M@@	O	-1	20621845
P	O	-1	20621845
and	O	-1	20621845
AD@@	O	-1	20621845
A@@	O	-1	20621845
M	O	-1	20621845
mR@@	O	-1	20621845
N@@	O	-1	20621845
A@@	O	-1	20621845
s	O	-1	20621845
were	O	-1	20621845
se@@	O	-1	20621845
mi@@	O	-1	20621845
-@@	O	-1	20621845
qu@@	O	-1	20621845
anti@@	O	-1	20621845
t@@	O	-1	20621845
atively	O	-1	20621845
analy@@	O	-1	20621845
zed	O	-1	20621845
and	O	-1	20621845
protein	O	-1	20621845
ex@@	O	-1	20621845
pres@@	O	-1	20621845
sions	O	-1	20621845
were	O	-1	20621845
determined	O	-1	20621845
by	O	-1	20621845
immuno@@	O	-1	20621845
histo@@	O	-1	20621845
chem@@	O	-1	20621845
ist@@	O	-1	20621845
r@@	O	-1	20621845
y.	O	-1	20621845
RESULTS:	O	-1	20621845
D@@	O	-1	20621845
es@@	O	-1	20621845
pit@@	O	-1	20621845
e	O	-1	20621845
similar	O	-1	20621845
ex@@	O	-1	20621845
tern@@	O	-1	20621845
al	O	-1	20621845
di@@	O	-1	20621845
ame@@	O	-1	20621845
ters	O	-1	20621845
among	O	-1	20621845
Ca@@	B-Chemical	D002122	20621845
Cl@@	I-Chemical	-1	20621845
(2@@	I-Chemical	-1	20621845
)	I-Chemical	-1	20621845
-@@	O	-1	20621845
treat@@	O	-1	20621845
ed,	O	-1	20621845
non@@	O	-1	20621845
-	O	-1	20621845
Ca@@	B-Chemical	D002122	20621845
Cl@@	I-Chemical	-1	20621845
(2@@	I-Chemical	-1	20621845
)	I-Chemical	-1	20621845
-treated	O	-1	20621845
and	O	-1	20621845
Na@@	B-Chemical	D012965	20621845
C@@	I-Chemical	-1	20621845
l	I-Chemical	-1	20621845
-treated	O	-1	20621845
seg@@	O	-1	20621845
ment@@	O	-1	20621845
s,	O	-1	20621845
aneur@@	O	-1	20621845
ym@@	O	-1	20621845
al	O	-1	20621845
al@@	O	-1	20621845
ter@@	O	-1	20621845
ation	O	-1	20621845
(n@@	O	-1	20621845
=@@	O	-1	20621845
6,	O	-1	20621845
50@@	O	-1	20621845
%),	O	-1	20621845
medi@@	O	-1	20621845
a	O	-1	20621845
de@@	O	-1	20621845
generation	O	-1	20621845
with	O	-1	20621845
regi@@	O	-1	20621845
on@@	O	-1	20621845
al	O	-1	20621845
dis@@	O	-1	20621845
ru@@	O	-1	20621845
p@@	O	-1	20621845
tion,	O	-1	20621845
f@@	O	-1	20621845
ra@@	O	-1	20621845
g@@	O	-1	20621845
ment@@	O	-1	20621845
ation	O	-1	20621845
of	O	-1	20621845
el@@	O	-1	20621845
as@@	O	-1	20621845
tic	O	-1	20621845
fib@@	O	-1	20621845
er,	O	-1	20621845
and	O	-1	20621845
increased	O	-1	20621845
coll@@	O	-1	20621845
ag@@	O	-1	20621845
en	O	-1	20621845
de@@	O	-1	20621845
posi@@	O	-1	20621845
tion	O	-1	20621845
(n@@	O	-1	20621845
=@@	O	-1	20621845
12@@	O	-1	20621845
,	O	-1	20621845
10@@	O	-1	20621845
0@@	O	-1	20621845
%)	O	-1	20621845
were	O	-1	20621845
demonstrated	O	-1	20621845
in	O	-1	20621845
Ca@@	B-Chemical	D002122	20621845
Cl@@	I-Chemical	-1	20621845
(2@@	I-Chemical	-1	20621845
)	I-Chemical	-1	20621845
-treated	O	-1	20621845
seg@@	O	-1	20621845
ment@@	O	-1	20621845
s.	O	-1	20621845
M@@	O	-1	20621845
MP@@	O	-1	20621845
-@@	O	-1	20621845
2,	O	-1	20621845
M@@	O	-1	20621845
MP@@	O	-1	20621845
-@@	O	-1	20621845
9@@	O	-1	20621845
,	O	-1	20621845
AD@@	O	-1	20621845
AM@@	O	-1	20621845
-@@	O	-1	20621845
10	O	-1	20621845
and	O	-1	20621845
AD@@	O	-1	20621845
AM@@	O	-1	20621845
-1@@	O	-1	20621845
7	O	-1	20621845
mRNA	O	-1	20621845
levels	O	-1	20621845
were	O	-1	20621845
increased	O	-1	20621845
in	O	-1	20621845
Ca@@	B-Chemical	D002122	20621845
Cl@@	I-Chemical	-1	20621845
(2@@	I-Chemical	-1	20621845
)	I-Chemical	-1	20621845
-treated	O	-1	20621845
seg@@	O	-1	20621845
ments	O	-1	20621845
(@@	O	-1	20621845
all	O	-1	20621845
p@@	O	-1	20621845
<@@	O	-1	20621845
0.0@@	O	-1	20621845
1),	O	-1	20621845
with	O	-1	20621845
tre@@	O	-1	20621845
n@@	O	-1	20621845
ds	O	-1	20621845
of	O	-1	20621845
elev@@	O	-1	20621845
ation	O	-1	20621845
in	O	-1	20621845
Ca@@	B-Chemical	D002122	20621845
Cl@@	I-Chemical	-1	20621845
(2@@	I-Chemical	-1	20621845
)	I-Chemical	-1	20621845
-@@	O	-1	20621845
un@@	O	-1	20621845
treated	O	-1	20621845
seg@@	O	-1	20621845
ment@@	O	-1	20621845
s,	O	-1	20621845
as	O	-1	20621845
compared	O	-1	20621845
with	O	-1	20621845
Na@@	B-Chemical	D012965	20621845
C@@	I-Chemical	-1	20621845
l	I-Chemical	-1	20621845
-treated	O	-1	20621845
seg@@	O	-1	20621845
ment@@	O	-1	20621845
s.	O	-1	20621845
Im@@	O	-1	20621845
mun@@	O	-1	20621845
o@@	O	-1	20621845
histo@@	O	-1	20621845
chem@@	O	-1	20621845
ist@@	O	-1	20621845
r@@	O	-1	20621845
y	O	-1	20621845
dis@@	O	-1	20621845
pl@@	O	-1	20621845
ayed	O	-1	20621845
significantly	O	-1	20621845
increased	O	-1	20621845
ex@@	O	-1	20621845
pres@@	O	-1	20621845
sions	O	-1	20621845
of	O	-1	20621845
M@@	O	-1	20621845
MP@@	O	-1	20621845
-@@	O	-1	20621845
2,	O	-1	20621845
M@@	O	-1	20621845
MP@@	O	-1	20621845
-@@	O	-1	20621845
9@@	O	-1	20621845
,	O	-1	20621845
AD@@	O	-1	20621845
AM@@	O	-1	20621845
-@@	O	-1	20621845
10	O	-1	20621845
and	O	-1	20621845
AD@@	O	-1	20621845
AM@@	O	-1	20621845
-1@@	O	-1	20621845
7	O	-1	20621845
(@@	O	-1	20621845
all	O	-1	20621845
p@@	O	-1	20621845
<@@	O	-1	20621845
0.0@@	O	-1	20621845
1)	O	-1	20621845
in	O	-1	20621845
in@@	O	-1	20621845
tim@@	O	-1	20621845
a	O	-1	20621845
and	O	-1	20621845
medi@@	O	-1	20621845
a	O	-1	20621845
for	O	-1	20621845
Ca@@	B-Chemical	D002122	20621845
Cl@@	I-Chemical	-1	20621845
(2@@	I-Chemical	-1	20621845
)	I-Chemical	-1	20621845
-treated	O	-1	20621845
seg@@	O	-1	20621845
ment@@	O	-1	20621845
s.	O	-1	20621845
TI@@	O	-1	20621845
M@@	O	-1	20621845
P	O	-1	20621845
mRNA	O	-1	20621845
and	O	-1	20621845
tissue	O	-1	20621845
levels	O	-1	20621845
did	O	-1	20621845
not	O	-1	20621845
diff@@	O	-1	20621845
er	O	-1	20621845
ob@@	O	-1	20621845
vi@@	O	-1	20621845
ously	O	-1	20621845
among	O	-1	20621845
the	O	-1	20621845
three	O	-1	20621845
a@@	O	-1	20621845
or@@	O	-1	20621845
tic	O	-1	20621845
seg@@	O	-1	20621845
ment@@	O	-1	20621845
s.	O	-1	20621845
CONCLUSION:	O	-1	20621845
This	O	-1	20621845
study	O	-1	20621845
est@@	O	-1	20621845
abl@@	O	-1	20621845
ish@@	O	-1	20621845
es	O	-1	20621845
a	O	-1	20621845
TA@@	B-Disease	D017545	20621845
A	I-Disease	-1	20621845
model	O	-1	20621845
by	O	-1	20621845
peri@@	O	-1	20621845
arterial	O	-1	20621845
Ca@@	B-Chemical	D002122	20621845
Cl@@	I-Chemical	-1	20621845
(2@@	I-Chemical	-1	20621845
)	I-Chemical	-1	20621845
exposure	O	-1	20621845
in	O	-1	20621845
rats,	O	-1	20621845
and	O	-1	20621845
demon@@	O	-1	20621845
strat@@	O	-1	20621845
es	O	-1	20621845
a	O	-1	20621845
significant	O	-1	20621845
elev@@	O	-1	20621845
ation	O	-1	20621845
of	O	-1	20621845
expression	O	-1	20621845
of	O	-1	20621845
M@@	O	-1	20621845
MP@@	O	-1	20621845
-@@	O	-1	20621845
2,	O	-1	20621845
M@@	O	-1	20621845
MP@@	O	-1	20621845
-@@	O	-1	20621845
9@@	O	-1	20621845
,	O	-1	20621845
AD@@	O	-1	20621845
AM@@	O	-1	20621845
10	O	-1	20621845
and	O	-1	20621845
AD@@	O	-1	20621845
AM@@	O	-1	20621845
17	O	-1	20621845
in	O	-1	20621845
the	O	-1	20621845
path@@	O	-1	20621845
o@@	O	-1	20621845
genesis	O	-1	20621845
of	O	-1	20621845
vascular	O	-1	20621845
re@@	O	-1	20621845
model@@	O	-1	20621845
ing.	O	-1	20621845

Whe@@	O	-1	19843802
n	O	-1	19843802
drugs	O	-1	19843802
dis@@	O	-1	19843802
appe@@	O	-1	19843802
ar	O	-1	19843802
from	O	-1	19843802
the	O	-1	19843802
patient@@	O	-1	19843802
:	O	-1	19843802
el@@	O	-1	19843802
im@@	O	-1	19843802
in@@	O	-1	19843802
ation	O	-1	19843802
of	O	-1	19843802
intravenous	O	-1	19843802
medic@@	O	-1	19843802
ation	O	-1	19843802
by	O	-1	19843802
hemo@@	O	-1	19843802
di@@	O	-1	19843802
af@@	O	-1	19843802
il@@	O	-1	19843802
tr@@	O	-1	19843802
ation.	O	-1	19843802
Tw@@	O	-1	19843802
ent@@	O	-1	19843802
y-@@	O	-1	19843802
three	O	-1	19843802
hours	O	-1	19843802
after	O	-1	19843802
heart	O	-1	19843802
transplant@@	O	-1	19843802
ation,	O	-1	19843802
lif@@	O	-1	19843802
e-@@	O	-1	19843802
th@@	O	-1	19843802
reat@@	O	-1	19843802
en@@	O	-1	19843802
ing	O	-1	19843802
acute	O	-1	19843802
right	B-Disease	D006333	19843802
heart	I-Disease	-1	19843802
failure	I-Disease	-1	19843802
was	O	-1	19843802
diagnos@@	O	-1	19843802
ed	O	-1	19843802
in	O	-1	19843802
a	O	-1	19843802
patient	O	-1	19843802
requ@@	O	-1	19843802
ir@@	O	-1	19843802
ing	O	-1	19843802
continu@@	O	-1	19843802
ous	O	-1	19843802
ven@@	O	-1	19843802
o@@	O	-1	19843802
venous	O	-1	19843802
hemo@@	O	-1	19843802
di@@	O	-1	19843802
af@@	O	-1	19843802
iltration	O	-1	19843802
(C@@	O	-1	19843802
V@@	O	-1	19843802
V@@	O	-1	19843802
H@@	O	-1	19843802
DF@@	O	-1	19843802
).	O	-1	19843802
In@@	O	-1	19843802
c@@	O	-1	19843802
reas@@	O	-1	19843802
ing	O	-1	19843802
doses	O	-1	19843802
of	O	-1	19843802
cat@@	B-Chemical	D002395	19843802
ech@@	I-Chemical	-1	19843802
ol@@	I-Chemical	-1	19843802
amin@@	I-Chemical	-1	19843802
es	I-Chemical	-1	19843802
,	O	-1	19843802
sed@@	O	-1	19843802
ati@@	O	-1	19843802
v@@	O	-1	19843802
es,	O	-1	19843802
and	O	-1	19843802
musc@@	O	-1	19843802
le	O	-1	19843802
rel@@	O	-1	19843802
ax@@	O	-1	19843802
ants	O	-1	19843802
administered	O	-1	19843802
through	O	-1	19843802
a	O	-1	19843802
central	O	-1	19843802
venous	O	-1	19843802
ca@@	O	-1	19843802
the@@	O	-1	19843802
ter	O	-1	19843802
were	O	-1	19843802
ine@@	O	-1	19843802
ff@@	O	-1	19843802
ecti@@	O	-1	19843802
ve.	O	-1	19843802
However,	O	-1	19843802
a	O	-1	19843802
b@@	O	-1	19843802
ol@@	O	-1	19843802
us	O	-1	19843802
of	O	-1	19843802
ep@@	B-Chemical	D004837	19843802
ine@@	I-Chemical	-1	19843802
phrine	I-Chemical	-1	19843802
injected	O	-1	19843802
through	O	-1	19843802
an	O	-1	19843802
al@@	O	-1	19843802
tern@@	O	-1	19843802
ative	O	-1	19843802
ca@@	O	-1	19843802
the@@	O	-1	19843802
ter	O	-1	19843802
prov@@	O	-1	19843802
o@@	O	-1	19843802
ked	O	-1	19843802
a	O	-1	19843802
hypertensive	B-Disease	D006973	19843802
cri@@	O	-1	19843802
sis.	O	-1	19843802
Th@@	O	-1	19843802
us,	O	-1	19843802
inter@@	O	-1	19843802
fe@@	O	-1	19843802
rence	O	-1	19843802
with	O	-1	19843802
the	O	-1	19843802
central	O	-1	19843802
venous	O	-1	19843802
infusion	O	-1	19843802
by	O	-1	19843802
the	O	-1	19843802
dialy@@	O	-1	19843802
sis	O	-1	19843802
ca@@	O	-1	19843802
the@@	O	-1	19843802
ter	O	-1	19843802
was	O	-1	19843802
sus@@	O	-1	19843802
p@@	O	-1	19843802
ect@@	O	-1	19843802
ed.	O	-1	19843802
The	O	-1	19843802
ca@@	O	-1	19843802
the@@	O	-1	19843802
ters	O	-1	19843802
were	O	-1	19843802
chang@@	O	-1	19843802
ed,	O	-1	19843802
and	O	-1	19843802
hemo@@	O	-1	19843802
dynam@@	O	-1	19843802
ic@@	O	-1	19843802
s	O	-1	19843802
st@@	O	-1	19843802
abil@@	O	-1	19843802
ized	O	-1	19843802
at	O	-1	19843802
lower	O	-1	19843802
cat@@	B-Chemical	D002395	19843802
ech@@	I-Chemical	-1	19843802
ol@@	I-Chemical	-1	19843802
amine	I-Chemical	-1	19843802
dos@@	O	-1	19843802
es.	O	-1	19843802
Whe@@	O	-1	19843802
n	O	-1	19843802
the	O	-1	19843802
effects	O	-1	19843802
of	O	-1	19843802
IV	O	-1	19843802
drugs	O	-1	19843802
are	O	-1	19843802
in@@	O	-1	19843802
ade@@	O	-1	19843802
qu@@	O	-1	19843802
ate	O	-1	19843802
in	O	-1	19843802
patients	O	-1	19843802
receiving	O	-1	19843802
C@@	O	-1	19843802
V@@	O	-1	19843802
V@@	O	-1	19843802
H@@	O	-1	19843802
DF@@	O	-1	19843802
,	O	-1	19843802
inter@@	O	-1	19843802
fe@@	O	-1	19843802
rence	O	-1	19843802
with	O	-1	19843802
adj@@	O	-1	19843802
ac@@	O	-1	19843802
ent	O	-1	19843802
ca@@	O	-1	19843802
the@@	O	-1	19843802
ters	O	-1	19843802
result@@	O	-1	19843802
ing	O	-1	19843802
in	O	-1	19843802
el@@	O	-1	19843802
im@@	O	-1	19843802
in@@	O	-1	19843802
ation	O	-1	19843802
of	O	-1	19843802
the	O	-1	19843802
drug	O	-1	19843802
by	O	-1	19843802
C@@	O	-1	19843802
V@@	O	-1	19843802
V@@	O	-1	19843802
H@@	O	-1	19843802
D@@	O	-1	19843802
F	O	-1	19843802
should	O	-1	19843802
be	O	-1	19843802
sus@@	O	-1	19843802
p@@	O	-1	19843802
ect@@	O	-1	19843802
ed.	O	-1	19843802

L@@	O	-1	19473225
on@@	O	-1	19473225
g@@	O	-1	19473225
-term	O	-1	19473225
glutamate	B-Chemical	D018698	19473225
sup@@	O	-1	19473225
ple@@	O	-1	19473225
ment@@	O	-1	19473225
ation	O	-1	19473225
fail@@	O	-1	19473225
ed	O	-1	19473225
to	O	-1	19473225
prot@@	O	-1	19473225
ect	O	-1	19473225
against	O	-1	19473225
peripheral	B-Disease	D010523	19473225
neuro@@	I-Disease	-1	19473225
toxicity	I-Disease	-1	19473225
of	O	-1	19473225
paclitax@@	B-Chemical	D017239	19473225
el	I-Chemical	-1	19473225
.	O	-1	19473225
T@@	O	-1	19473225
ox@@	O	-1	19473225
ic	O	-1	19473225
peripheral	B-Disease	D010523	19473225
neuropathy	I-Disease	-1	19473225
is	O	-1	19473225
sti@@	O	-1	19473225
ll	O	-1	19473225
a	O	-1	19473225
significant	O	-1	19473225
lim@@	O	-1	19473225
it@@	O	-1	19473225
ing	O	-1	19473225
factor	O	-1	19473225
for	O	-1	19473225
chemotherapy	O	-1	19473225
with	O	-1	19473225
paclitax@@	B-Chemical	D017239	19473225
el	I-Chemical	-1	19473225
(	O	-1	19473225
PA@@	B-Chemical	D017239	19473225
C	I-Chemical	-1	19473225
),	O	-1	19473225
although	O	-1	19473225
glutamate	B-Chemical	D018698	19473225
and	O	-1	19473225
its	O	-1	19473225
clo@@	O	-1	19473225
se@@	O	-1	19473225
ly	O	-1	19473225
related	O	-1	19473225
amin@@	B-Chemical	D000596	19473225
o	I-Chemical	-1	19473225
acid	I-Chemical	-1	19473225
glut@@	B-Chemical	D018698	19473225
amine	I-Chemical	-1	19473225
were	O	-1	19473225
cl@@	O	-1	19473225
a@@	O	-1	19473225
im@@	O	-1	19473225
ed	O	-1	19473225
to	O	-1	19473225
ame@@	O	-1	19473225
li@@	O	-1	19473225
or@@	O	-1	19473225
ate	O	-1	19473225
PA@@	B-Chemical	D017239	19473225
C	I-Chemical	-1	19473225
neuro@@	B-Disease	D020258	19473225
toxicity	I-Disease	-1	19473225
.	O	-1	19473225
This	O	-1	19473225
pilo@@	O	-1	19473225
t	O	-1	19473225
trial	O	-1	19473225
a@@	O	-1	19473225
im@@	O	-1	19473225
ed	O	-1	19473225
to	O	-1	19473225
evalu@@	O	-1	19473225
ate	O	-1	19473225
the	O	-1	19473225
role	O	-1	19473225
of	O	-1	19473225
glutamate	B-Chemical	D018698	19473225
sup@@	O	-1	19473225
ple@@	O	-1	19473225
ment@@	O	-1	19473225
ation	O	-1	19473225
for	O	-1	19473225
prevent@@	O	-1	19473225
ing	O	-1	19473225
PA@@	B-Chemical	D017239	19473225
C	I-Chemical	-1	19473225
-induced	O	-1	19473225
peripheral	B-Disease	D010523	19473225
neuropathy	I-Disease	-1	19473225
in	O	-1	19473225
a	O	-1	19473225
random@@	O	-1	19473225
iz@@	O	-1	19473225
ed,	O	-1	19473225
placebo@@	O	-1	19473225
-@@	O	-1	19473225
control@@	O	-1	19473225
le@@	O	-1	19473225
d,	O	-1	19473225
double-bl@@	O	-1	19473225
ind@@	O	-1	19473225
ed	O	-1	19473225
clinical	O	-1	19473225
and	O	-1	19473225
electro@@	O	-1	19473225
-@@	O	-1	19473225
diagnos@@	O	-1	19473225
tic	O	-1	19473225
study.	O	-1	19473225
F@@	O	-1	19473225
or@@	O	-1	19473225
ty-@@	O	-1	19473225
three	O	-1	19473225
o@@	B-Disease	D010051	19473225
vari@@	I-Disease	-1	19473225
an	I-Disease	-1	19473225
cancer	I-Disease	-1	19473225
patients	O	-1	19473225
were	O	-1	19473225
av@@	O	-1	19473225
ail@@	O	-1	19473225
able	O	-1	19473225
for	O	-1	19473225
analysis	O	-1	19473225
following	O	-1	19473225
six	O	-1	19473225
cyc@@	O	-1	19473225
le@@	O	-1	19473225
s	O	-1	19473225
of	O	-1	19473225
the	O	-1	19473225
same	O	-1	19473225
PA@@	B-Chemical	D017239	19473225
C	I-Chemical	-1	19473225
-@@	O	-1	19473225
containing	O	-1	19473225
regimen@@	O	-1	19473225
:	O	-1	19473225
2@@	O	-1	19473225
3	O	-1	19473225
had	O	-1	19473225
been	O	-1	19473225
sup@@	O	-1	19473225
ple@@	O	-1	19473225
ment@@	O	-1	19473225
ed	O	-1	19473225
by	O	-1	19473225
glutamate	B-Chemical	D018698	19473225
all	O	-1	19473225
al@@	O	-1	19473225
ong	O	-1	19473225
the	O	-1	19473225
treatment	O	-1	19473225
perio@@	O	-1	19473225
d,	O	-1	19473225
at	O	-1	19473225
a	O	-1	19473225
daily	O	-1	19473225
dose	O	-1	19473225
of	O	-1	19473225
three	O	-1	19473225
times	O	-1	19473225
5@@	O	-1	19473225
00	O	-1	19473225
mg	O	-1	19473225
(@@	O	-1	19473225
group	O	-1	19473225
G@@	O	-1	19473225
),	O	-1	19473225
and	O	-1	19473225
20	O	-1	19473225
had	O	-1	19473225
received	O	-1	19473225
a	O	-1	19473225
placebo	O	-1	19473225
(@@	O	-1	19473225
group	O	-1	19473225
P@@	O	-1	19473225
).	O	-1	19473225
Patients	O	-1	19473225
were	O	-1	19473225
evaluated	O	-1	19473225
by	O	-1	19473225
neurolog@@	O	-1	19473225
ical	O	-1	19473225
examin@@	O	-1	19473225
ation@@	O	-1	19473225
s,	O	-1	19473225
qu@@	O	-1	19473225
es@@	O	-1	19473225
tion@@	O	-1	19473225
na@@	O	-1	19473225
i@@	O	-1	19473225
res	O	-1	19473225
and	O	-1	19473225
sens@@	O	-1	19473225
or@@	O	-1	19473225
y-@@	O	-1	19473225
motor	O	-1	19473225
nerve	O	-1	19473225
con@@	O	-1	19473225
duction	O	-1	19473225
studi@@	O	-1	19473225
es.	O	-1	19473225
There	O	-1	19473225
was	O	-1	19473225
no	O	-1	19473225
significant	O	-1	19473225
difference	O	-1	19473225
in	O	-1	19473225
the	O	-1	19473225
frequency	O	-1	19473225
of	O	-1	19473225
signs	O	-1	19473225
or	O	-1	19473225
symptoms	O	-1	19473225
between	O	-1	19473225
the	O	-1	19473225
two	O	-1	19473225
groups	O	-1	19473225
although	O	-1	19473225
neuro@@	B-Disease	D020258	19473225
toxicity	I-Disease	-1	19473225
symptoms	O	-1	19473225
presented	O	-1	19473225
mo@@	O	-1	19473225
st@@	O	-1	19473225
ly	O	-1	19473225
with	O	-1	19473225
lower	O	-1	19473225
sco@@	O	-1	19473225
res	O	-1	19473225
of	O	-1	19473225
severity	O	-1	19473225
in	O	-1	19473225
group	O	-1	19473225
G@@	O	-1	19473225
.	O	-1	19473225
However,	O	-1	19473225
this	O	-1	19473225
difference	O	-1	19473225
reac@@	O	-1	19473225
h@@	O	-1	19473225
ed	O	-1	19473225
statis@@	O	-1	19473225
tical	O	-1	19473225
signific@@	O	-1	19473225
ance	O	-1	19473225
only	O	-1	19473225
with	O	-1	19473225
reg@@	O	-1	19473225
ard	O	-1	19473225
to	O	-1	19473225
reported	O	-1	19473225
pain	B-Disease	D010146	19473225
sens@@	O	-1	19473225
ation	O	-1	19473225
(P	O	-1	19473225
=	O	-1	19473225
0.0@@	O	-1	19473225
1@@	O	-1	19473225
1).	O	-1	19473225
Al@@	O	-1	19473225
so	O	-1	19473225
the	O	-1	19473225
frequency	O	-1	19473225
of	O	-1	19473225
ab@@	O	-1	19473225
normal	O	-1	19473225
electro@@	O	-1	19473225
-@@	O	-1	19473225
diagnos@@	O	-1	19473225
tic	O	-1	19473225
findings	O	-1	19473225
showed	O	-1	19473225
simil@@	O	-1	19473225
ar@@	O	-1	19473225
ity	O	-1	19473225
between	O	-1	19473225
the	O	-1	19473225
two	O	-1	19473225
groups	O	-1	19473225
(@@	O	-1	19473225
G@@	O	-1	19473225
:	O	-1	19473225
7@@	O	-1	19473225
/@@	O	-1	19473225
2@@	O	-1	19473225
3	O	-1	19473225
=	O	-1	19473225
3@@	O	-1	19473225
0.@@	O	-1	19473225
4@@	O	-1	19473225
%@@	O	-1	19473225
;	O	-1	19473225
P@@	O	-1	19473225
:	O	-1	19473225
6@@	O	-1	19473225
/@@	O	-1	19473225
20	O	-1	19473225
=	O	-1	19473225
3@@	O	-1	19473225
0@@	O	-1	19473225
%).	O	-1	19473225
This	O	-1	19473225
pilo@@	O	-1	19473225
t	O	-1	19473225
study	O	-1	19473225
lead@@	O	-1	19473225
s	O	-1	19473225
to	O	-1	19473225
the	O	-1	19473225
concl@@	O	-1	19473225
usion	O	-1	19473225
that	O	-1	19473225
glutamate	B-Chemical	D018698	19473225
sup@@	O	-1	19473225
ple@@	O	-1	19473225
ment@@	O	-1	19473225
ation	O	-1	19473225
at	O	-1	19473225
the	O	-1	19473225
ch@@	O	-1	19473225
o@@	O	-1	19473225
se@@	O	-1	19473225
n	O	-1	19473225
regi@@	O	-1	19473225
men	O	-1	19473225
fail@@	O	-1	19473225
s	O	-1	19473225
to	O	-1	19473225
prot@@	O	-1	19473225
ect	O	-1	19473225
against	O	-1	19473225
peripheral	B-Disease	D010523	19473225
neuro@@	I-Disease	-1	19473225
toxicity	I-Disease	-1	19473225
of	O	-1	19473225
PA@@	B-Chemical	D017239	19473225
C	I-Chemical	-1	19473225
.	O	-1	19473225

A@@	O	-1	19387625
t@@	O	-1	19387625
ten@@	O	-1	19387625
tional	O	-1	19387625
mod@@	O	-1	19387625
ulation	O	-1	19387625
of	O	-1	19387625
per@@	O	-1	19387625
ce@@	O	-1	19387625
i@@	O	-1	19387625
ved	O	-1	19387625
pain	B-Disease	D010146	19387625
int@@	O	-1	19387625
ensity	O	-1	19387625
in	O	-1	19387625
cap@@	B-Chemical	D002211	19387625
sa@@	I-Chemical	-1	19387625
icin	I-Chemical	-1	19387625
-induced	O	-1	19387625
secondary	O	-1	19387625
hyperalge@@	B-Disease	D006930	19387625
sia	I-Disease	-1	19387625
.	O	-1	19387625
P@@	O	-1	19387625
er@@	O	-1	19387625
ce@@	O	-1	19387625
i@@	O	-1	19387625
ved	O	-1	19387625
pain	B-Disease	D010146	19387625
int@@	O	-1	19387625
ensity	O	-1	19387625
is	O	-1	19387625
mod@@	O	-1	19387625
ul@@	O	-1	19387625
ated	O	-1	19387625
by	O	-1	19387625
atten@@	O	-1	19387625
tion.	O	-1	19387625
However,	O	-1	19387625
it	O	-1	19387625
is	O	-1	19387625
not	O	-1	19387625
known	O	-1	19387625
that	O	-1	19387625
ho@@	O	-1	19387625
w	O	-1	19387625
pain	B-Disease	D010146	19387625
int@@	O	-1	19387625
ensity	O	-1	19387625
rat@@	O	-1	19387625
ings	O	-1	19387625
are	O	-1	19387625
affected	O	-1	19387625
by	O	-1	19387625
atten@@	O	-1	19387625
tion	O	-1	19387625
in	O	-1	19387625
cap@@	B-Chemical	D002211	19387625
sa@@	I-Chemical	-1	19387625
icin	I-Chemical	-1	19387625
-induced	O	-1	19387625
secondary	O	-1	19387625
hyperalge@@	B-Disease	D006930	19387625
sia	I-Disease	-1	19387625
.	O	-1	19387625
H@@	O	-1	19387625
ere	O	-1	19387625
we	O	-1	19387625
show	O	-1	19387625
that	O	-1	19387625
per@@	O	-1	19387625
ce@@	O	-1	19387625
i@@	O	-1	19387625
ved	O	-1	19387625
pain	B-Disease	D010146	19387625
int@@	O	-1	19387625
ensity	O	-1	19387625
in	O	-1	19387625
secondary	O	-1	19387625
hyperalge@@	B-Disease	D006930	19387625
sia	I-Disease	-1	19387625
is	O	-1	19387625
decreased	O	-1	19387625
when	O	-1	19387625
atten@@	O	-1	19387625
tion	O	-1	19387625
is	O	-1	19387625
dist@@	O	-1	19387625
rac@@	O	-1	19387625
ted	O	-1	19387625
aw@@	O	-1	19387625
ay	O	-1	19387625
from	O	-1	19387625
the	O	-1	19387625
pa@@	O	-1	19387625
infu@@	O	-1	19387625
l	O	-1	19387625
p@@	O	-1	19387625
in@@	O	-1	19387625
pr@@	O	-1	19387625
ic@@	O	-1	19387625
k	O	-1	19387625
stimul@@	O	-1	19387625
us	O	-1	19387625
with	O	-1	19387625
a	O	-1	19387625
visual	O	-1	19387625
t@@	O	-1	19387625
as@@	O	-1	19387625
k@@	O	-1	19387625
.	O	-1	19387625
F@@	O	-1	19387625
ur@@	O	-1	19387625
ther@@	O	-1	19387625
mo@@	O	-1	19387625
re,	O	-1	19387625
it	O	-1	19387625
was	O	-1	19387625
found	O	-1	19387625
that	O	-1	19387625
the	O	-1	19387625
mag@@	O	-1	19387625
nit@@	O	-1	19387625
ude	O	-1	19387625
of	O	-1	19387625
atten@@	O	-1	19387625
tional	O	-1	19387625
mod@@	O	-1	19387625
ulation	O	-1	19387625
in	O	-1	19387625
secondary	O	-1	19387625
hyperalge@@	B-Disease	D006930	19387625
sia	I-Disease	-1	19387625
is	O	-1	19387625
very	O	-1	19387625
similar	O	-1	19387625
to	O	-1	19387625
that	O	-1	19387625
of	O	-1	19387625
cap@@	B-Chemical	D002211	19387625
sa@@	I-Chemical	-1	19387625
icin	I-Chemical	-1	19387625
-@@	O	-1	19387625
un@@	O	-1	19387625
treat@@	O	-1	19387625
ed,	O	-1	19387625
control	O	-1	19387625
condi@@	O	-1	19387625
tion.	O	-1	19387625
Our	O	-1	19387625
find@@	O	-1	19387625
ing@@	O	-1	19387625
s,	O	-1	19387625
show@@	O	-1	19387625
ing	O	-1	19387625
no	O	-1	19387625
inter@@	O	-1	19387625
action	O	-1	19387625
between	O	-1	19387625
cap@@	B-Chemical	D002211	19387625
sa@@	I-Chemical	-1	19387625
icin	I-Chemical	-1	19387625
treatment	O	-1	19387625
and	O	-1	19387625
atten@@	O	-1	19387625
tional	O	-1	19387625
mod@@	O	-1	19387625
ulation	O	-1	19387625
suggest	O	-1	19387625
that	O	-1	19387625
cap@@	B-Chemical	D002211	19387625
sa@@	I-Chemical	-1	19387625
icin	I-Chemical	-1	19387625
-induced	O	-1	19387625
secondary	O	-1	19387625
hyperalge@@	B-Disease	D006930	19387625
sia	I-Disease	-1	19387625
and	O	-1	19387625
atten@@	O	-1	19387625
tion	O	-1	19387625
might	O	-1	19387625
aff@@	O	-1	19387625
ect	O	-1	19387625
mechan@@	O	-1	19387625
ical	O	-1	19387625
pain	B-Disease	D010146	19387625
through	O	-1	19387625
in@@	O	-1	19387625
dependent	O	-1	19387625
mechanis@@	O	-1	19387625
m@@	O	-1	19387625
s.	O	-1	19387625

T@@	B-Chemical	D013739	19211690
est@@	I-Chemical	-1	19211690
osterone	I-Chemical	-1	19211690
-@@	O	-1	19211690
dependent	O	-1	19211690
hypertension	B-Disease	D006973	19211690
and	O	-1	19211690
u@@	O	-1	19211690
pre@@	O	-1	19211690
g@@	O	-1	19211690
ulation	O	-1	19211690
of	O	-1	19211690
intra@@	O	-1	19211690
renal	O	-1	19211690
angiotens@@	O	-1	19211690
ino@@	O	-1	19211690
gen	O	-1	19211690
in	O	-1	19211690
D@@	O	-1	19211690
a@@	O	-1	19211690
h@@	O	-1	19211690
l	O	-1	19211690
sal@@	B-Chemical	D017673	19211690
t	I-Chemical	-1	19211690
-@@	O	-1	19211690
sensitive	O	-1	19211690
rats.	O	-1	19211690
B@@	O	-1	19211690
lo@@	O	-1	19211690
od	O	-1	19211690
pressure	O	-1	19211690
(B@@	O	-1	19211690
P)	O	-1	19211690
is	O	-1	19211690
more	O	-1	19211690
sal@@	B-Chemical	D017673	19211690
t	I-Chemical	-1	19211690
sensitive	O	-1	19211690
in	O	-1	19211690
men	O	-1	19211690
than	O	-1	19211690
in	O	-1	19211690
pre@@	O	-1	19211690
men@@	O	-1	19211690
o@@	O	-1	19211690
pa@@	O	-1	19211690
us@@	O	-1	19211690
al	O	-1	19211690
wom@@	O	-1	19211690
en@@	O	-1	19211690
.	O	-1	19211690
In	O	-1	19211690
D@@	O	-1	19211690
a@@	O	-1	19211690
h@@	O	-1	19211690
l	O	-1	19211690
sal@@	B-Chemical	D017673	19211690
t	I-Chemical	-1	19211690
-@@	O	-1	19211690
sensitive	O	-1	19211690
rats	O	-1	19211690
(D@@	O	-1	19211690
S@@	O	-1	19211690
),	O	-1	19211690
high@@	O	-1	19211690
-	O	-1	19211690
sal@@	B-Chemical	D017673	19211690
t	I-Chemical	-1	19211690
(@@	O	-1	19211690
H@@	O	-1	19211690
S)	O	-1	19211690
diet	O	-1	19211690
increases	O	-1	19211690
B@@	O	-1	19211690
P	O	-1	19211690
more	O	-1	19211690
in	O	-1	19211690
mal@@	O	-1	19211690
es	O	-1	19211690
than	O	-1	19211690
femal@@	O	-1	19211690
es.	O	-1	19211690
In	O	-1	19211690
contr@@	O	-1	19211690
ast	O	-1	19211690
to	O	-1	19211690
the	O	-1	19211690
systemic	O	-1	19211690
ren@@	O	-1	19211690
in@@	O	-1	19211690
-	O	-1	19211690
angiotens@@	B-Chemical	D000809	19211690
in	I-Chemical	-1	19211690
system@@	O	-1	19211690
,	O	-1	19211690
which	O	-1	19211690
is	O	-1	19211690
sup@@	O	-1	19211690
press@@	O	-1	19211690
ed	O	-1	19211690
in	O	-1	19211690
response	O	-1	19211690
to	O	-1	19211690
H@@	O	-1	19211690
S	O	-1	19211690
in	O	-1	19211690
male	O	-1	19211690
D@@	O	-1	19211690
S@@	O	-1	19211690
,	O	-1	19211690
intra@@	O	-1	19211690
renal	O	-1	19211690
angiotens@@	O	-1	19211690
ino@@	O	-1	19211690
gen	O	-1	19211690
expression	O	-1	19211690
is	O	-1	19211690
increas@@	O	-1	19211690
ed,	O	-1	19211690
and	O	-1	19211690
intra@@	O	-1	19211690
renal	O	-1	19211690
levels	O	-1	19211690
of	O	-1	19211690
AN@@	O	-1	19211690
G	O	-1	19211690
II	O	-1	19211690
are	O	-1	19211690
not	O	-1	19211690
sup@@	O	-1	19211690
pres@@	O	-1	19211690
sed.	O	-1	19211690
In	O	-1	19211690
this	O	-1	19211690
study,	O	-1	19211690
the	O	-1	19211690
hypo@@	O	-1	19211690
thesis	O	-1	19211690
was	O	-1	19211690
tested	O	-1	19211690
that	O	-1	19211690
there	O	-1	19211690
is	O	-1	19211690
a	O	-1	19211690
sex@@	O	-1	19211690
ual	O	-1	19211690
di@@	O	-1	19211690
morph@@	O	-1	19211690
ism	O	-1	19211690
in	O	-1	19211690
H@@	O	-1	19211690
S@@	O	-1	19211690
-induced	O	-1	19211690
u@@	O	-1	19211690
pre@@	O	-1	19211690
g@@	O	-1	19211690
ulation	O	-1	19211690
of	O	-1	19211690
intra@@	O	-1	19211690
renal	O	-1	19211690
angiotens@@	O	-1	19211690
ino@@	O	-1	19211690
gen	O	-1	19211690
mediated	O	-1	19211690
by	O	-1	19211690
test@@	B-Chemical	D013739	19211690
osterone	I-Chemical	-1	19211690
that	O	-1	19211690
also	O	-1	19211690
causes	O	-1	19211690
increases	O	-1	19211690
in	O	-1	19211690
B@@	O	-1	19211690
P	O	-1	19211690
and	O	-1	19211690
renal	B-Disease	D007674	19211690
injury	I-Disease	-1	19211690
.	O	-1	19211690
O@@	O	-1	19211690
n	O	-1	19211690
a	O	-1	19211690
low@@	O	-1	19211690
-	O	-1	19211690
sal@@	B-Chemical	D017673	19211690
t	I-Chemical	-1	19211690
(@@	O	-1	19211690
L@@	O	-1	19211690
S)	O	-1	19211690
di@@	O	-1	19211690
et@@	O	-1	19211690
,	O	-1	19211690
male	O	-1	19211690
D@@	O	-1	19211690
S	O	-1	19211690
had	O	-1	19211690
higher	O	-1	19211690
levels	O	-1	19211690
of	O	-1	19211690
intra@@	O	-1	19211690
renal	O	-1	19211690
angiotens@@	O	-1	19211690
ino@@	O	-1	19211690
gen	O	-1	19211690
mRNA	O	-1	19211690
than	O	-1	19211690
femal@@	O	-1	19211690
es.	O	-1	19211690
H@@	O	-1	19211690
S	O	-1	19211690
diet	O	-1	19211690
for	O	-1	19211690
4	O	-1	19211690
w@@	O	-1	19211690
k	O	-1	19211690
increased	O	-1	19211690
renal	O	-1	19211690
cor@@	O	-1	19211690
tical	O	-1	19211690
angiotens@@	O	-1	19211690
ino@@	O	-1	19211690
gen	O	-1	19211690
mRNA	O	-1	19211690
and	O	-1	19211690
protein	O	-1	19211690
only	O	-1	19211690
in	O	-1	19211690
male	O	-1	19211690
D@@	O	-1	19211690
S@@	O	-1	19211690
,	O	-1	19211690
which	O	-1	19211690
was	O	-1	19211690
prevent@@	O	-1	19211690
ed	O	-1	19211690
by	O	-1	19211690
ca@@	O	-1	19211690
str@@	O	-1	19211690
ation.	O	-1	19211690
O@@	O	-1	19211690
vari@@	O	-1	19211690
ect@@	O	-1	19211690
om@@	O	-1	19211690
y	O	-1	19211690
of	O	-1	19211690
female	O	-1	19211690
D@@	O	-1	19211690
S	O	-1	19211690
had	O	-1	19211690
no	O	-1	19211690
effect	O	-1	19211690
on	O	-1	19211690
intra@@	O	-1	19211690
renal	O	-1	19211690
angiotens@@	O	-1	19211690
ino@@	O	-1	19211690
gen	O	-1	19211690
expression	O	-1	19211690
on	O	-1	19211690
either	O	-1	19211690
di@@	O	-1	19211690
et@@	O	-1	19211690
.	O	-1	19211690
R@@	O	-1	19211690
a@@	O	-1	19211690
di@@	O	-1	19211690
ot@@	O	-1	19211690
e@@	O	-1	19211690
le@@	O	-1	19211690
me@@	O	-1	19211690
tri@@	O	-1	19211690
c	O	-1	19211690
B@@	O	-1	19211690
P	O	-1	19211690
was	O	-1	19211690
similar	O	-1	19211690
between	O	-1	19211690
mal@@	O	-1	19211690
es	O	-1	19211690
and	O	-1	19211690
ca@@	O	-1	19211690
strated	O	-1	19211690
rats	O	-1	19211690
on	O	-1	19211690
L@@	O	-1	19211690
S	O	-1	19211690
di@@	O	-1	19211690
et@@	O	-1	19211690
.	O	-1	19211690
H@@	O	-1	19211690
S	O	-1	19211690
diet	O	-1	19211690
for	O	-1	19211690
4	O	-1	19211690
w@@	O	-1	19211690
k	O	-1	19211690
caused	O	-1	19211690
a	O	-1	19211690
progressive	O	-1	19211690
increase	O	-1	19211690
in	O	-1	19211690
B@@	O	-1	19211690
P@@	O	-1	19211690
,	O	-1	19211690
protein	O	-1	19211690
and	O	-1	19211690
al@@	O	-1	19211690
b@@	O	-1	19211690
um@@	O	-1	19211690
in	O	-1	19211690
ex@@	O	-1	19211690
cre@@	O	-1	19211690
tion,	O	-1	19211690
and	O	-1	19211690
glomerular	B-Disease	D007674	19211690
s@@	I-Disease	-1	19211690
clero@@	I-Disease	-1	19211690
sis	I-Disease	-1	19211690
in	O	-1	19211690
male	O	-1	19211690
D@@	O	-1	19211690
S	O	-1	19211690
rats,	O	-1	19211690
which	O	-1	19211690
were	O	-1	19211690
attenu@@	O	-1	19211690
ated	O	-1	19211690
by	O	-1	19211690
ca@@	O	-1	19211690
str@@	O	-1	19211690
ation.	O	-1	19211690
T@@	B-Chemical	D013739	19211690
est@@	I-Chemical	-1	19211690
osterone	I-Chemical	-1	19211690
re@@	O	-1	19211690
pl@@	O	-1	19211690
ac@@	O	-1	19211690
ement	O	-1	19211690
in	O	-1	19211690
ca@@	O	-1	19211690
strated	O	-1	19211690
D@@	O	-1	19211690
S	O	-1	19211690
rats	O	-1	19211690
increased	O	-1	19211690
B@@	O	-1	19211690
P@@	O	-1	19211690
,	O	-1	19211690
renal	B-Disease	D007674	19211690
injury	I-Disease	-1	19211690
,	O	-1	19211690
and	O	-1	19211690
u@@	O	-1	19211690
pre@@	O	-1	19211690
g@@	O	-1	19211690
ulation	O	-1	19211690
of	O	-1	19211690
renal	O	-1	19211690
angiotens@@	O	-1	19211690
ino@@	O	-1	19211690
gen	O	-1	19211690
associated	O	-1	19211690
with	O	-1	19211690
H@@	O	-1	19211690
S	O	-1	19211690
di@@	O	-1	19211690
et@@	O	-1	19211690
.	O	-1	19211690
T@@	B-Chemical	D013739	19211690
est@@	I-Chemical	-1	19211690
osterone	I-Chemical	-1	19211690
cont@@	O	-1	19211690
ri@@	O	-1	19211690
but@@	O	-1	19211690
es	O	-1	19211690
to	O	-1	19211690
the	O	-1	19211690
development	O	-1	19211690
of	O	-1	19211690
hypertension	B-Disease	D006973	19211690
and	O	-1	19211690
renal	B-Disease	D007674	19211690
injury	I-Disease	-1	19211690
in	O	-1	19211690
male	O	-1	19211690
D@@	O	-1	19211690
S	O	-1	19211690
rats	O	-1	19211690
on	O	-1	19211690
H@@	O	-1	19211690
S	O	-1	19211690
diet	O	-1	19211690
possib@@	O	-1	19211690
ly	O	-1	19211690
through	O	-1	19211690
u@@	O	-1	19211690
pre@@	O	-1	19211690
g@@	O	-1	19211690
ulation	O	-1	19211690
of	O	-1	19211690
the	O	-1	19211690
intra@@	O	-1	19211690
renal	O	-1	19211690
ren@@	O	-1	19211690
in@@	O	-1	19211690
-	O	-1	19211690
angiotens@@	B-Chemical	D000809	19211690
in	I-Chemical	-1	19211690
system@@	O	-1	19211690
.	O	-1	19211690

P@@	O	-1	18703024
ren@@	O	-1	18703024
atal	O	-1	18703024
protein	O	-1	18703024
de@@	O	-1	18703024
pri@@	O	-1	18703024
v@@	O	-1	18703024
ation	O	-1	18703024
al@@	O	-1	18703024
ters	O	-1	18703024
dopamine	B-Chemical	D004298	18703024
-@@	O	-1	18703024
mediated	O	-1	18703024
behavi@@	O	-1	18703024
ors	O	-1	18703024
and	O	-1	18703024
dop@@	O	-1	18703024
aminergic	O	-1	18703024
and	O	-1	18703024
glutam@@	O	-1	18703024
at@@	O	-1	18703024
ergic	O	-1	18703024
receptor	O	-1	18703024
b@@	O	-1	18703024
ind@@	O	-1	18703024
ing.	O	-1	18703024
E@@	O	-1	18703024
pi@@	O	-1	18703024
de@@	O	-1	18703024
m@@	O	-1	18703024
io@@	O	-1	18703024
log@@	O	-1	18703024
ical	O	-1	18703024
evidence	O	-1	18703024
indic@@	O	-1	18703024
ates	O	-1	18703024
that	O	-1	18703024
p@@	O	-1	18703024
ren@@	O	-1	18703024
atal	O	-1	18703024
n@@	O	-1	18703024
ut@@	O	-1	18703024
ri@@	O	-1	18703024
tional	O	-1	18703024
de@@	O	-1	18703024
pri@@	O	-1	18703024
v@@	O	-1	18703024
ation	O	-1	18703024
may	O	-1	18703024
increase	O	-1	18703024
the	O	-1	18703024
risk	O	-1	18703024
of	O	-1	18703024
sch@@	B-Disease	D012559	18703024
iz@@	I-Disease	-1	18703024
oph@@	I-Disease	-1	18703024
ren@@	I-Disease	-1	18703024
ia	I-Disease	-1	18703024
.	O	-1	18703024
The	O	-1	18703024
go@@	O	-1	18703024
al	O	-1	18703024
of	O	-1	18703024
these	O	-1	18703024
studies	O	-1	18703024
was	O	-1	18703024
to	O	-1	18703024
use	O	-1	18703024
an	O	-1	18703024
anim@@	O	-1	18703024
al	O	-1	18703024
model	O	-1	18703024
to	O	-1	18703024
ex@@	O	-1	18703024
amine	O	-1	18703024
the	O	-1	18703024
effects	O	-1	18703024
of	O	-1	18703024
p@@	O	-1	18703024
ren@@	O	-1	18703024
atal	O	-1	18703024
protein	O	-1	18703024
de@@	O	-1	18703024
pri@@	O	-1	18703024
v@@	O	-1	18703024
ation	O	-1	18703024
on	O	-1	18703024
behavi@@	O	-1	18703024
ors	O	-1	18703024
and	O	-1	18703024
receptor	O	-1	18703024
b@@	O	-1	18703024
ind@@	O	-1	18703024
ing	O	-1	18703024
with	O	-1	18703024
re@@	O	-1	18703024
lev@@	O	-1	18703024
ance	O	-1	18703024
to	O	-1	18703024
sch@@	B-Disease	D012559	18703024
iz@@	I-Disease	-1	18703024
oph@@	I-Disease	-1	18703024
ren@@	I-Disease	-1	18703024
ia	I-Disease	-1	18703024
.	O	-1	18703024
We	O	-1	18703024
report	O	-1	18703024
that	O	-1	18703024
p@@	O	-1	18703024
ren@@	O	-1	18703024
at@@	O	-1	18703024
ally	O	-1	18703024
protein	O	-1	18703024
de@@	O	-1	18703024
pri@@	O	-1	18703024
ved	O	-1	18703024
(P@@	O	-1	18703024
D)	O	-1	18703024
female	O	-1	18703024
rats	O	-1	18703024
showed	O	-1	18703024
an	O	-1	18703024
increased	O	-1	18703024
ste@@	O	-1	18703024
re@@	O	-1	18703024
ot@@	O	-1	18703024
yp@@	O	-1	18703024
ic	O	-1	18703024
response	O	-1	18703024
to	O	-1	18703024
apo@@	B-Chemical	D001058	18703024
morphine	I-Chemical	-1	18703024
and	O	-1	18703024
an	O	-1	18703024
increased	O	-1	18703024
locomotor	O	-1	18703024
response	O	-1	18703024
to	O	-1	18703024
amphetamine	B-Chemical	D000661	18703024
in	O	-1	18703024
ad@@	O	-1	18703024
ul@@	O	-1	18703024
th@@	O	-1	18703024
o@@	O	-1	18703024
o@@	O	-1	18703024
d.	O	-1	18703024
These	O	-1	18703024
differences	O	-1	18703024
were	O	-1	18703024
not	O	-1	18703024
observed	O	-1	18703024
during	O	-1	18703024
p@@	O	-1	18703024
ub@@	O	-1	18703024
er@@	O	-1	18703024
t@@	O	-1	18703024
y.	O	-1	18703024
No	O	-1	18703024
changes	O	-1	18703024
in	O	-1	18703024
haloperidol	B-Chemical	D006220	18703024
-induced	O	-1	18703024
cat@@	B-Disease	D002375	18703024
al@@	I-Disease	-1	18703024
ep@@	I-Disease	-1	18703024
sy	I-Disease	-1	18703024
or	O	-1	18703024
M@@	B-Chemical	D016291	18703024
K@@	I-Chemical	-1	18703024
-@@	I-Chemical	-1	18703024
80@@	I-Chemical	-1	18703024
1	I-Chemical	-1	18703024
-induced	O	-1	18703024
locom@@	O	-1	18703024
o@@	O	-1	18703024
tion	O	-1	18703024
were	O	-1	18703024
seen	O	-1	18703024
following	O	-1	18703024
P@@	O	-1	18703024
D@@	O	-1	18703024
.	O	-1	18703024
In	O	-1	18703024
addi@@	O	-1	18703024
tion,	O	-1	18703024
P@@	O	-1	18703024
D	O	-1	18703024
female	O	-1	18703024
rats	O	-1	18703024
showed	O	-1	18703024
increased	O	-1	18703024
(3@@	O	-1	18703024
)	O	-1	18703024
H	B-Chemical	D006859	18703024
-	O	-1	18703024
M@@	B-Chemical	D016291	18703024
K@@	I-Chemical	-1	18703024
-@@	I-Chemical	-1	18703024
80@@	I-Chemical	-1	18703024
1	I-Chemical	-1	18703024
b@@	O	-1	18703024
ind@@	O	-1	18703024
ing	O	-1	18703024
in	O	-1	18703024
the	O	-1	18703024
striat@@	O	-1	18703024
um	O	-1	18703024
and	O	-1	18703024
hippocamp@@	O	-1	18703024
us,	O	-1	18703024
but	O	-1	18703024
not	O	-1	18703024
in	O	-1	18703024
the	O	-1	18703024
cor@@	O	-1	18703024
t@@	O	-1	18703024
ex@@	O	-1	18703024
.	O	-1	18703024
P@@	O	-1	18703024
D	O	-1	18703024
female	O	-1	18703024
rats	O	-1	18703024
also	O	-1	18703024
showed	O	-1	18703024
increased	O	-1	18703024
(3@@	O	-1	18703024
)	O	-1	18703024
H	B-Chemical	D006859	18703024
-	O	-1	18703024
haloperidol	B-Chemical	D006220	18703024
b@@	O	-1	18703024
ind@@	O	-1	18703024
ing	O	-1	18703024
and	O	-1	18703024
decreased	O	-1	18703024
dopamine	B-Chemical	D004298	18703024
trans@@	O	-1	18703024
por@@	O	-1	18703024
ter	O	-1	18703024
b@@	O	-1	18703024
ind@@	O	-1	18703024
ing	O	-1	18703024
in	O	-1	18703024
striat@@	O	-1	18703024
um@@	O	-1	18703024
.	O	-1	18703024
No	O	-1	18703024
statis@@	O	-1	18703024
tically	O	-1	18703024
significant	O	-1	18703024
changes	O	-1	18703024
in	O	-1	18703024
behavi@@	O	-1	18703024
or	O	-1	18703024
or	O	-1	18703024
receptor	O	-1	18703024
b@@	O	-1	18703024
ind@@	O	-1	18703024
ing	O	-1	18703024
were	O	-1	18703024
found	O	-1	18703024
in	O	-1	18703024
P@@	O	-1	18703024
D	O	-1	18703024
mal@@	O	-1	18703024
es	O	-1	18703024
with	O	-1	18703024
the	O	-1	18703024
ex@@	O	-1	18703024
ce@@	O	-1	18703024
ption	O	-1	18703024
of	O	-1	18703024
increased	O	-1	18703024
(3@@	O	-1	18703024
)	O	-1	18703024
H	B-Chemical	D006859	18703024
-	O	-1	18703024
M@@	B-Chemical	D016291	18703024
K@@	I-Chemical	-1	18703024
-@@	I-Chemical	-1	18703024
80@@	I-Chemical	-1	18703024
1	I-Chemical	-1	18703024
b@@	O	-1	18703024
ind@@	O	-1	18703024
ing	O	-1	18703024
in	O	-1	18703024
cor@@	O	-1	18703024
t@@	O	-1	18703024
ex@@	O	-1	18703024
.	O	-1	18703024
This	O	-1	18703024
anim@@	O	-1	18703024
al	O	-1	18703024
model	O	-1	18703024
may	O	-1	18703024
be	O	-1	18703024
use@@	O	-1	18703024
ful	O	-1	18703024
to	O	-1	18703024
expl@@	O	-1	18703024
or@@	O	-1	18703024
e	O	-1	18703024
the	O	-1	18703024
mechanisms	O	-1	18703024
by	O	-1	18703024
which	O	-1	18703024
p@@	O	-1	18703024
ren@@	O	-1	18703024
atal	O	-1	18703024
n@@	B-Disease	D044342	18703024
ut@@	I-Disease	-1	18703024
ri@@	I-Disease	-1	18703024
tional	I-Disease	-1	18703024
defici@@	I-Disease	-1	18703024
ency	I-Disease	-1	18703024
enh@@	O	-1	18703024
anc@@	O	-1	18703024
es	O	-1	18703024
risk	O	-1	18703024
for	O	-1	18703024
sch@@	B-Disease	D012559	18703024
iz@@	I-Disease	-1	18703024
oph@@	I-Disease	-1	18703024
ren@@	I-Disease	-1	18703024
ia	I-Disease	-1	18703024
in	O	-1	18703024
hum@@	O	-1	18703024
ans	O	-1	18703024
and	O	-1	18703024
may	O	-1	18703024
also	O	-1	18703024
have	O	-1	18703024
implic@@	O	-1	18703024
ations	O	-1	18703024
for	O	-1	18703024
develop@@	O	-1	18703024
mental	O	-1	18703024
pro@@	O	-1	18703024
ces@@	O	-1	18703024
ses	O	-1	18703024
lead@@	O	-1	18703024
ing	O	-1	18703024
to	O	-1	18703024
differen@@	O	-1	18703024
tial	O	-1	18703024
sensitivity	O	-1	18703024
to	O	-1	18703024
drugs	O	-1	18703024
of	O	-1	18703024
ab@@	O	-1	18703024
use.	O	-1	18703024

m@@	O	-1	18631865
T@@	O	-1	18631865
o@@	O	-1	18631865
R	O	-1	18631865
inhibitor@@	O	-1	18631865
s@@	O	-1	18631865
-induced	O	-1	18631865
proteinuria	B-Disease	D011507	18631865
:	O	-1	18631865
mechanis@@	O	-1	18631865
m@@	O	-1	18631865
s,	O	-1	18631865
signific@@	O	-1	18631865
ance@@	O	-1	18631865
,	O	-1	18631865
and	O	-1	18631865
man@@	O	-1	18631865
ag@@	O	-1	18631865
em@@	O	-1	18631865
ent@@	O	-1	18631865
.	O	-1	18631865
M@@	O	-1	18631865
as@@	O	-1	18631865
sive	O	-1	18631865
urinary	O	-1	18631865
protein	O	-1	18631865
ex@@	O	-1	18631865
cre@@	O	-1	18631865
tion	O	-1	18631865
has	O	-1	18631865
been	O	-1	18631865
observed	O	-1	18631865
after	O	-1	18631865
conver@@	O	-1	18631865
sion	O	-1	18631865
from	O	-1	18631865
calc@@	O	-1	18631865
ine@@	O	-1	18631865
ur@@	O	-1	18631865
in	O	-1	18631865
inhibitors	O	-1	18631865
to	O	-1	18631865
m@@	O	-1	18631865
am@@	O	-1	18631865
mal@@	O	-1	18631865
i@@	O	-1	18631865
an	O	-1	18631865
t@@	O	-1	18631865
arg@@	O	-1	18631865
et	O	-1	18631865
of	O	-1	18631865
ra@@	B-Chemical	D020123	18631865
p@@	I-Chemical	-1	18631865
am@@	I-Chemical	-1	18631865
ycin	I-Chemical	-1	18631865
(@@	O	-1	18631865
m@@	O	-1	18631865
T@@	O	-1	18631865
o@@	O	-1	18631865
R@@	O	-1	18631865
)	O	-1	18631865
inhibitor@@	O	-1	18631865
s,	O	-1	18631865
es@@	O	-1	18631865
p@@	O	-1	18631865
ec@@	O	-1	18631865
i@@	O	-1	18631865
ally	O	-1	18631865
sirolimus	B-Chemical	D020123	18631865
,	O	-1	18631865
in	O	-1	18631865
renal	O	-1	18631865
transplant	O	-1	18631865
re@@	O	-1	18631865
ci@@	O	-1	18631865
pi@@	O	-1	18631865
ents	O	-1	18631865
with	O	-1	18631865
chronic	B-Disease	D051436	18631865
allogra@@	I-Disease	-1	18631865
ft	I-Disease	-1	18631865
nephro@@	I-Disease	-1	18631865
pathy	I-Disease	-1	18631865
.	O	-1	18631865
B@@	O	-1	18631865
ecause	O	-1	18631865
proteinuria	B-Disease	D011507	18631865
is	O	-1	18631865
a	O	-1	18631865
major	O	-1	18631865
predic@@	O	-1	18631865
tive	O	-1	18631865
factor	O	-1	18631865
of	O	-1	18631865
po@@	O	-1	18631865
or	O	-1	18631865
transplant@@	O	-1	18631865
ation	O	-1	18631865
out@@	O	-1	18631865
co@@	O	-1	18631865
me,	O	-1	18631865
man@@	O	-1	18631865
y	O	-1	18631865
studies	O	-1	18631865
foc@@	O	-1	18631865
used	O	-1	18631865
on	O	-1	18631865
this	O	-1	18631865
adverse	O	-1	18631865
ev@@	O	-1	18631865
ent	O	-1	18631865
during	O	-1	18631865
the	O	-1	18631865
p@@	O	-1	18631865
ast	O	-1	18631865
year@@	O	-1	18631865
s.	O	-1	18631865
Whe@@	O	-1	18631865
ther	O	-1	18631865
proteinuria	B-Disease	D011507	18631865
was	O	-1	18631865
due	O	-1	18631865
to	O	-1	18631865
sirolimus	B-Chemical	D020123	18631865
or	O	-1	18631865
only	O	-1	18631865
a	O	-1	18631865
con@@	O	-1	18631865
sequ@@	O	-1	18631865
ence	O	-1	18631865
of	O	-1	18631865
calc@@	O	-1	18631865
ine@@	O	-1	18631865
ur@@	O	-1	18631865
in	O	-1	18631865
inhibitors	O	-1	18631865
withdrawal	O	-1	18631865
remained	O	-1	18631865
un@@	O	-1	18631865
sol@@	O	-1	18631865
ved	O	-1	18631865
un@@	O	-1	18631865
ti@@	O	-1	18631865
l	O	-1	18631865
high	O	-1	18631865
range	O	-1	18631865
proteinuria	B-Disease	D011507	18631865
has	O	-1	18631865
been	O	-1	18631865
observed	O	-1	18631865
during	O	-1	18631865
sirolimus	B-Chemical	D020123	18631865
therapy	O	-1	18631865
in	O	-1	18631865
is@@	O	-1	18631865
le@@	O	-1	18631865
t	O	-1	18631865
transplant@@	O	-1	18631865
ation	O	-1	18631865
and	O	-1	18631865
in	O	-1	18631865
patients	O	-1	18631865
who	O	-1	18631865
received	O	-1	18631865
sirolimus	B-Chemical	D020123	18631865
de	O	-1	18631865
no@@	O	-1	18631865
v@@	O	-1	18631865
o@@	O	-1	18631865
.	O	-1	18631865
P@@	O	-1	18631865
o@@	O	-1	18631865
d@@	O	-1	18631865
ocyte	O	-1	18631865
injury	O	-1	18631865
and	O	-1	18631865
foc@@	O	-1	18631865
al	O	-1	18631865
seg@@	O	-1	18631865
mental	O	-1	18631865
glomer@@	B-Disease	D005921	18631865
u@@	I-Disease	-1	18631865
los@@	I-Disease	-1	18631865
clero@@	I-Disease	-1	18631865
sis	I-Disease	-1	18631865
have	O	-1	18631865
been	O	-1	18631865
related	O	-1	18631865
to	O	-1	18631865
m@@	O	-1	18631865
T@@	O	-1	18631865
o@@	O	-1	18631865
R	O	-1	18631865
inhibition	O	-1	18631865
in	O	-1	18631865
some	O	-1	18631865
patients,	O	-1	18631865
but	O	-1	18631865
the	O	-1	18631865
path@@	O	-1	18631865
w@@	O	-1	18631865
ays	O	-1	18631865
underlying	O	-1	18631865
these	O	-1	18631865
lesions	O	-1	18631865
re@@	O	-1	18631865
ma@@	O	-1	18631865
in	O	-1	18631865
hypo@@	O	-1	18631865
the@@	O	-1	18631865
tic@@	O	-1	18631865
.	O	-1	18631865
We	O	-1	18631865
discus@@	O	-1	18631865
s	O	-1	18631865
he@@	O	-1	18631865
re@@	O	-1	18631865
in	O	-1	18631865
the	O	-1	18631865
possible	O	-1	18631865
mechanisms	O	-1	18631865
and	O	-1	18631865
the	O	-1	18631865
signific@@	O	-1	18631865
ance	O	-1	18631865
of	O	-1	18631865
m@@	O	-1	18631865
T@@	O	-1	18631865
o@@	O	-1	18631865
R	O	-1	18631865
block@@	O	-1	18631865
ade@@	O	-1	18631865
-induced	O	-1	18631865
proteinuria	B-Disease	D011507	18631865
.	O	-1	18631865

H@@	O	-1	18162529
y@@	O	-1	18162529
po@@	O	-1	18162529
thal@@	O	-1	18162529
am@@	O	-1	18162529
ic	O	-1	18162529
prolactin	O	-1	18162529
receptor	O	-1	18162529
m@@	O	-1	18162529
es@@	O	-1	18162529
sen@@	O	-1	18162529
g@@	O	-1	18162529
er	O	-1	18162529
rib@@	B-Chemical	D012313	18162529
on@@	I-Chemical	-1	18162529
ucle@@	I-Chemical	-1	18162529
ic	I-Chemical	-1	18162529
acid	I-Chemical	-1	18162529
level@@	O	-1	18162529
s,	O	-1	18162529
prolactin	O	-1	18162529
sign@@	O	-1	18162529
al@@	O	-1	18162529
ing,	O	-1	18162529
and	O	-1	18162529
hyper@@	B-Disease	D006966	18162529
prol@@	I-Disease	-1	18162529
act@@	I-Disease	-1	18162529
ine@@	I-Disease	-1	18162529
mic	I-Disease	-1	18162529
inhibition	O	-1	18162529
of	O	-1	18162529
pul@@	O	-1	18162529
s@@	O	-1	18162529
ati@@	O	-1	18162529
le	O	-1	18162529
lu@@	O	-1	18162529
te@@	O	-1	18162529
in@@	O	-1	18162529
iz@@	O	-1	18162529
ing	O	-1	18162529
h@@	O	-1	18162529
orm@@	O	-1	18162529
one	O	-1	18162529
secre@@	O	-1	18162529
tion	O	-1	18162529
are	O	-1	18162529
dependent	O	-1	18162529
on	O	-1	18162529
est@@	B-Chemical	D004958	18162529
radi@@	I-Chemical	-1	18162529
ol	I-Chemical	-1	18162529
.	O	-1	18162529
H@@	B-Disease	D006966	18162529
y@@	I-Disease	-1	18162529
per@@	I-Disease	-1	18162529
prol@@	I-Disease	-1	18162529
act@@	I-Disease	-1	18162529
ine@@	I-Disease	-1	18162529
mia	I-Disease	-1	18162529
can	O	-1	18162529
re@@	O	-1	18162529
duce	O	-1	18162529
fer@@	O	-1	18162529
til@@	O	-1	18162529
ity	O	-1	18162529
and	O	-1	18162529
li@@	O	-1	18162529
b@@	O	-1	18162529
id@@	O	-1	18162529
o@@	O	-1	18162529
.	O	-1	18162529
Although	O	-1	18162529
central	O	-1	18162529
prolactin	O	-1	18162529
ac@@	O	-1	18162529
tions	O	-1	18162529
are	O	-1	18162529
thou@@	O	-1	18162529
ght	O	-1	18162529
to	O	-1	18162529
cont@@	O	-1	18162529
rib@@	O	-1	18162529
ute	O	-1	18162529
to	O	-1	18162529
th@@	O	-1	18162529
is@@	O	-1	18162529
,	O	-1	18162529
the	O	-1	18162529
mechanisms	O	-1	18162529
are	O	-1	18162529
po@@	O	-1	18162529
or@@	O	-1	18162529
ly	O	-1	18162529
under@@	O	-1	18162529
sto@@	O	-1	18162529
o@@	O	-1	18162529
d.	O	-1	18162529
We	O	-1	18162529
first	O	-1	18162529
tested	O	-1	18162529
whether	O	-1	18162529
chronic	O	-1	18162529
hyper@@	B-Disease	D006966	18162529
prol@@	I-Disease	-1	18162529
act@@	I-Disease	-1	18162529
ine@@	I-Disease	-1	18162529
mia	I-Disease	-1	18162529
inhibited	O	-1	18162529
two	O	-1	18162529
neuro@@	O	-1	18162529
en@@	O	-1	18162529
doc@@	O	-1	18162529
rine	O	-1	18162529
par@@	O	-1	18162529
ame@@	O	-1	18162529
ters	O	-1	18162529
nec@@	O	-1	18162529
ess@@	O	-1	18162529
ary	O	-1	18162529
for	O	-1	18162529
female	O	-1	18162529
fer@@	O	-1	18162529
ti@@	O	-1	18162529
lit@@	O	-1	18162529
y@@	O	-1	18162529
:	O	-1	18162529
pul@@	O	-1	18162529
s@@	O	-1	18162529
ati@@	O	-1	18162529
le	O	-1	18162529
L@@	O	-1	18162529
H	O	-1	18162529
secre@@	O	-1	18162529
tion	O	-1	18162529
and	O	-1	18162529
the	O	-1	18162529
est@@	B-Chemical	D004967	18162529
ro@@	I-Chemical	-1	18162529
gen	I-Chemical	-1	18162529
-induced	O	-1	18162529
L@@	O	-1	18162529
H	O	-1	18162529
surg@@	O	-1	18162529
e.	O	-1	18162529
Ch@@	O	-1	18162529
ron@@	O	-1	18162529
ic	O	-1	18162529
hyper@@	B-Disease	D006966	18162529
prol@@	I-Disease	-1	18162529
act@@	I-Disease	-1	18162529
ine@@	I-Disease	-1	18162529
mia	I-Disease	-1	18162529
induced	O	-1	18162529
by	O	-1	18162529
the	O	-1	18162529
dopamine	B-Chemical	D004298	18162529
antagonist	O	-1	18162529
sul@@	B-Chemical	D013469	18162529
pi@@	I-Chemical	-1	18162529
ri@@	I-Chemical	-1	18162529
de	I-Chemical	-1	18162529
caused	O	-1	18162529
a	O	-1	18162529
4@@	O	-1	18162529
0%	O	-1	18162529
reduction	O	-1	18162529
L@@	O	-1	18162529
H	O	-1	18162529
pul@@	O	-1	18162529
se	O	-1	18162529
frequency	O	-1	18162529
in	O	-1	18162529
o@@	O	-1	18162529
vari@@	O	-1	18162529
ect@@	O	-1	18162529
om@@	O	-1	18162529
ized	O	-1	18162529
rats,	O	-1	18162529
but	O	-1	18162529
only	O	-1	18162529
in	O	-1	18162529
the	O	-1	18162529
presence	O	-1	18162529
of	O	-1	18162529
chronic	O	-1	18162529
low	O	-1	18162529
levels	O	-1	18162529
of	O	-1	18162529
est@@	B-Chemical	D004958	18162529
radi@@	I-Chemical	-1	18162529
ol	I-Chemical	-1	18162529
.	O	-1	18162529
S@@	B-Chemical	D013469	18162529
ul@@	I-Chemical	-1	18162529
pi@@	I-Chemical	-1	18162529
ri@@	I-Chemical	-1	18162529
de	I-Chemical	-1	18162529
did	O	-1	18162529
not	O	-1	18162529
aff@@	O	-1	18162529
ect	O	-1	18162529
the	O	-1	18162529
mag@@	O	-1	18162529
nit@@	O	-1	18162529
ude	O	-1	18162529
of	O	-1	18162529
a	O	-1	18162529
ster@@	B-Chemical	D013256	18162529
oid	I-Chemical	-1	18162529
-induced	O	-1	18162529
L@@	O	-1	18162529
H	O	-1	18162529
sur@@	O	-1	18162529
ge	O	-1	18162529
or	O	-1	18162529
the	O	-1	18162529
perc@@	O	-1	18162529
ent@@	O	-1	18162529
age	O	-1	18162529
of	O	-1	18162529
G@@	O	-1	18162529
n@@	O	-1	18162529
R@@	O	-1	18162529
H	O	-1	18162529
neuron@@	O	-1	18162529
s	O	-1	18162529
activ@@	O	-1	18162529
ated	O	-1	18162529
during	O	-1	18162529
the	O	-1	18162529
surg@@	O	-1	18162529
e.	O	-1	18162529
E@@	B-Chemical	D004958	18162529
st@@	I-Chemical	-1	18162529
radi@@	I-Chemical	-1	18162529
ol	I-Chemical	-1	18162529
is	O	-1	18162529
known	O	-1	18162529
to	O	-1	18162529
influence	O	-1	18162529
expression	O	-1	18162529
of	O	-1	18162529
the	O	-1	18162529
lon@@	O	-1	18162529
g	O	-1	18162529
form	O	-1	18162529
of	O	-1	18162529
prolactin	O	-1	18162529
receptors	O	-1	18162529
(P@@	O	-1	18162529
R@@	O	-1	18162529
L-@@	O	-1	18162529
R@@	O	-1	18162529
)	O	-1	18162529
and	O	-1	18162529
comp@@	O	-1	18162529
on@@	O	-1	18162529
ents	O	-1	18162529
of	O	-1	18162529
prol@@	O	-1	18162529
act@@	O	-1	18162529
in@@	O	-1	18162529
's	O	-1	18162529
sign@@	O	-1	18162529
al@@	O	-1	18162529
ing	O	-1	18162529
path@@	O	-1	18162529
w@@	O	-1	18162529
a@@	O	-1	18162529
y.	O	-1	18162529
To	O	-1	18162529
test	O	-1	18162529
the	O	-1	18162529
hypo@@	O	-1	18162529
thesis	O	-1	18162529
that	O	-1	18162529
est@@	B-Chemical	D004967	18162529
ro@@	I-Chemical	-1	18162529
gen	I-Chemical	-1	18162529
increases	O	-1	18162529
P@@	O	-1	18162529
R@@	O	-1	18162529
L-@@	O	-1	18162529
R	O	-1	18162529
expression	O	-1	18162529
and	O	-1	18162529
sensitivity	O	-1	18162529
to	O	-1	18162529
prol@@	O	-1	18162529
act@@	O	-1	18162529
in,	O	-1	18162529
we	O	-1	18162529
ne@@	O	-1	18162529
x@@	O	-1	18162529
t	O	-1	18162529
demonstrated	O	-1	18162529
that	O	-1	18162529
est@@	B-Chemical	D004958	18162529
radi@@	I-Chemical	-1	18162529
ol	I-Chemical	-1	18162529
great@@	O	-1	18162529
ly	O	-1	18162529
au@@	O	-1	18162529
g@@	O	-1	18162529
ments	O	-1	18162529
prol@@	O	-1	18162529
act@@	O	-1	18162529
in-induced	O	-1	18162529
S@@	O	-1	18162529
T@@	O	-1	18162529
AT@@	O	-1	18162529
5	O	-1	18162529
activ@@	O	-1	18162529
ation.	O	-1	18162529
L@@	O	-1	18162529
ast@@	O	-1	18162529
ly,	O	-1	18162529
we	O	-1	18162529
measured	O	-1	18162529
P@@	O	-1	18162529
R@@	O	-1	18162529
L-@@	O	-1	18162529
R	O	-1	18162529
and	O	-1	18162529
sup@@	O	-1	18162529
press@@	O	-1	18162529
or	O	-1	18162529
of	O	-1	18162529
cyto@@	O	-1	18162529
k@@	O	-1	18162529
ine	O	-1	18162529
sign@@	O	-1	18162529
al@@	O	-1	18162529
ing	O	-1	18162529
(S@@	O	-1	18162529
O@@	O	-1	18162529
C@@	O	-1	18162529
S@@	O	-1	18162529
-1	O	-1	18162529
and	O	-1	18162529
-@@	O	-1	18162529
3	O	-1	18162529
and	O	-1	18162529
CI@@	O	-1	18162529
S@@	O	-1	18162529
,	O	-1	18162529
which	O	-1	18162529
ref@@	O	-1	18162529
l@@	O	-1	18162529
ect	O	-1	18162529
the	O	-1	18162529
level	O	-1	18162529
of	O	-1	18162529
prolactin	O	-1	18162529
sign@@	O	-1	18162529
al@@	O	-1	18162529
ing@@	O	-1	18162529
)	O	-1	18162529
mR@@	O	-1	18162529
N@@	O	-1	18162529
A@@	O	-1	18162529
s	O	-1	18162529
in	O	-1	18162529
response	O	-1	18162529
to	O	-1	18162529
sul@@	B-Chemical	D013469	18162529
pi@@	I-Chemical	-1	18162529
ri@@	I-Chemical	-1	18162529
de	I-Chemical	-1	18162529
and	O	-1	18162529
est@@	B-Chemical	D004958	18162529
radi@@	I-Chemical	-1	18162529
ol	I-Chemical	-1	18162529
.	O	-1	18162529
S@@	B-Chemical	D013469	18162529
ul@@	I-Chemical	-1	18162529
pi@@	I-Chemical	-1	18162529
ri@@	I-Chemical	-1	18162529
de	I-Chemical	-1	18162529
induced	O	-1	18162529
only	O	-1	18162529
S@@	O	-1	18162529
O@@	O	-1	18162529
C@@	O	-1	18162529
S@@	O	-1	18162529
-1	O	-1	18162529
in	O	-1	18162529
the	O	-1	18162529
medi@@	O	-1	18162529
al	O	-1	18162529
pre@@	O	-1	18162529
op@@	O	-1	18162529
tic	O	-1	18162529
a@@	O	-1	18162529
re@@	O	-1	18162529
a,	O	-1	18162529
wh@@	O	-1	18162529
ere	O	-1	18162529
G@@	O	-1	18162529
n@@	O	-1	18162529
R@@	O	-1	18162529
H	O	-1	18162529
neuron@@	O	-1	18162529
s	O	-1	18162529
are	O	-1	18162529
reg@@	O	-1	18162529
ul@@	O	-1	18162529
at@@	O	-1	18162529
ed,	O	-1	18162529
but	O	-1	18162529
in	O	-1	18162529
the	O	-1	18162529
arc@@	O	-1	18162529
u@@	O	-1	18162529
ate	O	-1	18162529
nucle@@	O	-1	18162529
us	O	-1	18162529
and	O	-1	18162529
ch@@	O	-1	18162529
o@@	O	-1	18162529
ro@@	O	-1	18162529
id	O	-1	18162529
ple@@	O	-1	18162529
x@@	O	-1	18162529
us,	O	-1	18162529
P@@	O	-1	18162529
R@@	O	-1	18162529
L-@@	O	-1	18162529
R@@	O	-1	18162529
,	O	-1	18162529
S@@	O	-1	18162529
O@@	O	-1	18162529
C@@	O	-1	18162529
S@@	O	-1	18162529
-@@	O	-1	18162529
3,	O	-1	18162529
and	O	-1	18162529
CI@@	O	-1	18162529
S	O	-1	18162529
mRNA	O	-1	18162529
levels	O	-1	18162529
were	O	-1	18162529
also	O	-1	18162529
induc@@	O	-1	18162529
ed.	O	-1	18162529
E@@	B-Chemical	D004958	18162529
st@@	I-Chemical	-1	18162529
radi@@	I-Chemical	-1	18162529
ol	I-Chemical	-1	18162529
enhanced	O	-1	18162529
these	O	-1	18162529
effects	O	-1	18162529
on	O	-1	18162529
S@@	O	-1	18162529
O@@	O	-1	18162529
C@@	O	-1	18162529
S@@	O	-1	18162529
-@@	O	-1	18162529
3	O	-1	18162529
and	O	-1	18162529
CI@@	O	-1	18162529
S@@	O	-1	18162529
.	O	-1	18162529
In@@	O	-1	18162529
te@@	O	-1	18162529
rest@@	O	-1	18162529
ing@@	O	-1	18162529
ly,	O	-1	18162529
est@@	B-Chemical	D004958	18162529
radi@@	I-Chemical	-1	18162529
ol	I-Chemical	-1	18162529
also	O	-1	18162529
induced	O	-1	18162529
P@@	O	-1	18162529
R@@	O	-1	18162529
L-@@	O	-1	18162529
R@@	O	-1	18162529
,	O	-1	18162529
S@@	O	-1	18162529
O@@	O	-1	18162529
C@@	O	-1	18162529
S@@	O	-1	18162529
-@@	O	-1	18162529
3,	O	-1	18162529
and	O	-1	18162529
CI@@	O	-1	18162529
S	O	-1	18162529
mRNA	O	-1	18162529
levels	O	-1	18162529
in@@	O	-1	18162529
depend@@	O	-1	18162529
ent@@	O	-1	18162529
ly.	O	-1	18162529
These	O	-1	18162529
data	O	-1	18162529
show	O	-1	18162529
that	O	-1	18162529
G@@	O	-1	18162529
n@@	O	-1	18162529
R@@	O	-1	18162529
H	O	-1	18162529
pul@@	O	-1	18162529
se	O	-1	18162529
frequency	O	-1	18162529
is	O	-1	18162529
inhibited	O	-1	18162529
by	O	-1	18162529
chronic	O	-1	18162529
hyper@@	B-Disease	D006966	18162529
prol@@	I-Disease	-1	18162529
act@@	I-Disease	-1	18162529
ine@@	I-Disease	-1	18162529
mia	I-Disease	-1	18162529
in	O	-1	18162529
a	O	-1	18162529
ster@@	B-Chemical	D013256	18162529
oid	I-Chemical	-1	18162529
-@@	O	-1	18162529
dependent	O	-1	18162529
man@@	O	-1	18162529
ner@@	O	-1	18162529
.	O	-1	18162529
The@@	O	-1	18162529
y	O	-1	18162529
also	O	-1	18162529
prov@@	O	-1	18162529
ide	O	-1	18162529
evidence	O	-1	18162529
for	O	-1	18162529
est@@	B-Chemical	D004958	18162529
radi@@	I-Chemical	-1	18162529
ol	I-Chemical	-1	18162529
-@@	O	-1	18162529
dependent	O	-1	18162529
and	O	-1	18162529
brain	O	-1	18162529
regi@@	O	-1	18162529
on@@	O	-1	18162529
-@@	O	-1	18162529
specific	O	-1	18162529
reg@@	O	-1	18162529
ulation	O	-1	18162529
of	O	-1	18162529
P@@	O	-1	18162529
R@@	O	-1	18162529
L-@@	O	-1	18162529
R	O	-1	18162529
expression	O	-1	18162529
and	O	-1	18162529
sign@@	O	-1	18162529
al@@	O	-1	18162529
ing	O	-1	18162529
responses	O	-1	18162529
by	O	-1	18162529
prol@@	O	-1	18162529
act@@	O	-1	18162529
in.	O	-1	18162529

E@@	O	-1	17879945
stro@@	O	-1	17879945
gen	O	-1	17879945
prev@@	O	-1	17879945
ents	O	-1	17879945
cholest@@	B-Chemical	D002788	17879945
ery@@	I-Chemical	-1	17879945
l	I-Chemical	-1	17879945
est@@	I-Chemical	-1	17879945
er	I-Chemical	-1	17879945
accum@@	O	-1	17879945
ulation	O	-1	17879945
in	O	-1	17879945
mac@@	O	-1	17879945
ro@@	O	-1	17879945
ph@@	O	-1	17879945
ages	O	-1	17879945
induced	O	-1	17879945
by	O	-1	17879945
the	O	-1	17879945
H@@	O	-1	17879945
IV	O	-1	17879945
prote@@	O	-1	17879945
ase	O	-1	17879945
inhibitor	O	-1	17879945
rit@@	B-Chemical	D019438	17879945
on@@	I-Chemical	-1	17879945
avi@@	I-Chemical	-1	17879945
r	I-Chemical	-1	17879945
.	O	-1	17879945
In@@	O	-1	17879945
divid@@	O	-1	17879945
u@@	O	-1	17879945
als	O	-1	17879945
with	O	-1	17879945
H@@	O	-1	17879945
IV	O	-1	17879945
can	O	-1	17879945
no@@	O	-1	17879945
w	O	-1	17879945
li@@	O	-1	17879945
ve	O	-1	17879945
lon@@	O	-1	17879945
g	O	-1	17879945
li@@	O	-1	17879945
v@@	O	-1	17879945
es	O	-1	17879945
with	O	-1	17879945
drug	O	-1	17879945
therapy	O	-1	17879945
that	O	-1	17879945
often	O	-1	17879945
inc@@	O	-1	17879945
lu@@	O	-1	17879945
des	O	-1	17879945
prote@@	O	-1	17879945
ase	O	-1	17879945
inhibitors	O	-1	17879945
such	O	-1	17879945
as	O	-1	17879945
rit@@	B-Chemical	D019438	17879945
on@@	I-Chemical	-1	17879945
avi@@	I-Chemical	-1	17879945
r	I-Chemical	-1	17879945
.	O	-1	17879945
M@@	O	-1	17879945
any	O	-1	17879945
patients,	O	-1	17879945
however,	O	-1	17879945
deve@@	O	-1	17879945
lo@@	O	-1	17879945
p	O	-1	17879945
negative	O	-1	17879945
long-term	O	-1	17879945
side	O	-1	17879945
effects	O	-1	17879945
such	O	-1	17879945
as	O	-1	17879945
pre@@	B-Disease	D050197	17879945
mat@@	I-Disease	-1	17879945
ure	I-Disease	-1	17879945
a@@	I-Disease	-1	17879945
therosclero@@	I-Disease	-1	17879945
sis	I-Disease	-1	17879945
.	O	-1	17879945
We	O	-1	17879945
have	O	-1	17879945
previously	O	-1	17879945
demonstrated	O	-1	17879945
that	O	-1	17879945
rit@@	B-Chemical	D019438	17879945
on@@	I-Chemical	-1	17879945
avi@@	I-Chemical	-1	17879945
r	I-Chemical	-1	17879945
treatment	O	-1	17879945
increases	O	-1	17879945
a@@	B-Disease	D050197	17879945
therosclero@@	I-Disease	-1	17879945
tic	I-Disease	-1	17879945
le@@	I-Disease	-1	17879945
sion	I-Disease	-1	17879945
formation	O	-1	17879945
in	O	-1	17879945
male	O	-1	17879945
mice	O	-1	17879945
to	O	-1	17879945
a	O	-1	17879945
greater	O	-1	17879945
ext@@	O	-1	17879945
ent	O	-1	17879945
than	O	-1	17879945
in	O	-1	17879945
female	O	-1	17879945
mice.	O	-1	17879945
F@@	O	-1	17879945
ur@@	O	-1	17879945
ther@@	O	-1	17879945
mo@@	O	-1	17879945
re,	O	-1	17879945
peripheral	O	-1	17879945
blood	O	-1	17879945
mon@@	O	-1	17879945
ocy@@	O	-1	17879945
tes	O	-1	17879945
isol@@	O	-1	17879945
ated	O	-1	17879945
from	O	-1	17879945
rit@@	B-Chemical	D019438	17879945
on@@	I-Chemical	-1	17879945
avi@@	I-Chemical	-1	17879945
r	I-Chemical	-1	17879945
-treated	O	-1	17879945
femal@@	O	-1	17879945
es	O	-1	17879945
had	O	-1	17879945
less	O	-1	17879945
cholest@@	B-Chemical	D002788	17879945
ery@@	I-Chemical	-1	17879945
l	I-Chemical	-1	17879945
est@@	I-Chemical	-1	17879945
er	I-Chemical	-1	17879945
accum@@	O	-1	17879945
ul@@	O	-1	17879945
ation.	O	-1	17879945
In	O	-1	17879945
the	O	-1	17879945
present	O	-1	17879945
study,	O	-1	17879945
we	O	-1	17879945
have	O	-1	17879945
investigated	O	-1	17879945
the	O	-1	17879945
mol@@	O	-1	17879945
ec@@	O	-1	17879945
ular	O	-1	17879945
mechanisms	O	-1	17879945
by	O	-1	17879945
which	O	-1	17879945
female	O	-1	17879945
h@@	O	-1	17879945
orm@@	O	-1	17879945
on@@	O	-1	17879945
es	O	-1	17879945
influence	O	-1	17879945
cholester@@	B-Chemical	D002784	17879945
ol	I-Chemical	-1	17879945
metabol@@	O	-1	17879945
ism	O	-1	17879945
in	O	-1	17879945
mac@@	O	-1	17879945
ro@@	O	-1	17879945
ph@@	O	-1	17879945
ages	O	-1	17879945
in	O	-1	17879945
response	O	-1	17879945
to	O	-1	17879945
the	O	-1	17879945
H@@	O	-1	17879945
IV	O	-1	17879945
prote@@	O	-1	17879945
ase	O	-1	17879945
inhibitor	O	-1	17879945
rit@@	B-Chemical	D019438	17879945
on@@	I-Chemical	-1	17879945
avi@@	I-Chemical	-1	17879945
r	I-Chemical	-1	17879945
.	O	-1	17879945
We	O	-1	17879945
have	O	-1	17879945
u@@	O	-1	17879945
ti@@	O	-1	17879945
li@@	O	-1	17879945
zed	O	-1	17879945
the	O	-1	17879945
human	O	-1	17879945
mon@@	O	-1	17879945
ocyte	O	-1	17879945
cell	O	-1	17879945
l@@	O	-1	17879945
ine,	O	-1	17879945
T@@	O	-1	17879945
H@@	O	-1	17879945
P@@	O	-1	17879945
-1	O	-1	17879945
as	O	-1	17879945
a	O	-1	17879945
model	O	-1	17879945
to	O	-1	17879945
ad@@	O	-1	17879945
d@@	O	-1	17879945
res@@	O	-1	17879945
s	O	-1	17879945
this	O	-1	17879945
qu@@	O	-1	17879945
es@@	O	-1	17879945
tion.	O	-1	17879945
B@@	O	-1	17879945
ri@@	O	-1	17879945
e@@	O	-1	17879945
f@@	O	-1	17879945
ly,	O	-1	17879945
cells	O	-1	17879945
were	O	-1	17879945
differen@@	O	-1	17879945
ti@@	O	-1	17879945
ated	O	-1	17879945
for	O	-1	17879945
7@@	O	-1	17879945
2	O	-1	17879945
h	O	-1	17879945
with	O	-1	17879945
100	O	-1	17879945
n@@	O	-1	17879945
M	O	-1	17879945
P@@	O	-1	17879945
M@@	O	-1	17879945
A	O	-1	17879945
to	O	-1	17879945
obt@@	O	-1	17879945
ain	O	-1	17879945
a	O	-1	17879945
mac@@	O	-1	17879945
ro@@	O	-1	17879945
ph@@	O	-1	17879945
ag@@	O	-1	17879945
e-@@	O	-1	17879945
like	O	-1	17879945
phen@@	O	-1	17879945
ot@@	O	-1	17879945
yp@@	O	-1	17879945
e	O	-1	17879945
in	O	-1	17879945
the	O	-1	17879945
presence	O	-1	17879945
or	O	-1	17879945
absence	O	-1	17879945
of	O	-1	17879945
1	O	-1	17879945
n@@	O	-1	17879945
M	O	-1	17879945
17@@	B-Chemical	D004958	17879945
beta-@@	I-Chemical	-1	17879945
est@@	I-Chemical	-1	17879945
radi@@	I-Chemical	-1	17879945
ol	I-Chemical	-1	17879945
(	O	-1	17879945
E@@	B-Chemical	D004958	17879945
2	I-Chemical	-1	17879945
),	O	-1	17879945
100	O	-1	17879945
n@@	O	-1	17879945
M	O	-1	17879945
pro@@	B-Chemical	D011374	17879945
g@@	I-Chemical	-1	17879945
est@@	I-Chemical	-1	17879945
er@@	I-Chemical	-1	17879945
one	I-Chemical	-1	17879945
or	O	-1	17879945
ve@@	O	-1	17879945
h@@	O	-1	17879945
ic@@	O	-1	17879945
le	O	-1	17879945
(@@	O	-1	17879945
0.0@@	O	-1	17879945
1@@	O	-1	17879945
%	O	-1	17879945
eth@@	B-Chemical	D000431	17879945
an@@	I-Chemical	-1	17879945
ol	I-Chemical	-1	17879945
).	O	-1	17879945
C@@	O	-1	17879945
ell@@	O	-1	17879945
s	O	-1	17879945
were	O	-1	17879945
then	O	-1	17879945
treated	O	-1	17879945
with	O	-1	17879945
30	O	-1	17879945
n@@	O	-1	17879945
g/@@	O	-1	17879945
m@@	O	-1	17879945
l	O	-1	17879945
rit@@	B-Chemical	D019438	17879945
on@@	I-Chemical	-1	17879945
avi@@	I-Chemical	-1	17879945
r	I-Chemical	-1	17879945
or	O	-1	17879945
ve@@	O	-1	17879945
h@@	O	-1	17879945
ic@@	O	-1	17879945
le	O	-1	17879945
in	O	-1	17879945
the	O	-1	17879945
presence	O	-1	17879945
of	O	-1	17879945
ag@@	O	-1	17879945
g@@	O	-1	17879945
reg@@	O	-1	17879945
ated	O	-1	17879945
L@@	O	-1	17879945
D@@	O	-1	17879945
L	O	-1	17879945
for	O	-1	17879945
24	O	-1	17879945
h@@	O	-1	17879945
.	O	-1	17879945
C@@	O	-1	17879945
el@@	O	-1	17879945
l	O	-1	17879945
extrac@@	O	-1	17879945
ts	O	-1	17879945
were	O	-1	17879945
h@@	O	-1	17879945
ar@@	O	-1	17879945
ve@@	O	-1	17879945
st@@	O	-1	17879945
ed,	O	-1	17879945
and	O	-1	17879945
li@@	O	-1	17879945
pid	O	-1	17879945
or	O	-1	17879945
total	O	-1	17879945
R@@	O	-1	17879945
NA	O	-1	17879945
was	O	-1	17879945
isol@@	O	-1	17879945
ated.	O	-1	17879945
E@@	B-Chemical	D004958	17879945
2	I-Chemical	-1	17879945
decreased	O	-1	17879945
the	O	-1	17879945
accum@@	O	-1	17879945
ulation	O	-1	17879945
of	O	-1	17879945
cholest@@	B-Chemical	D002788	17879945
ery@@	I-Chemical	-1	17879945
l	I-Chemical	-1	17879945
est@@	I-Chemical	-1	17879945
ers	I-Chemical	-1	17879945
in	O	-1	17879945
mac@@	O	-1	17879945
ro@@	O	-1	17879945
ph@@	O	-1	17879945
ages	O	-1	17879945
following	O	-1	17879945
rit@@	B-Chemical	D019438	17879945
on@@	I-Chemical	-1	17879945
avi@@	I-Chemical	-1	17879945
r	I-Chemical	-1	17879945
treatment.	O	-1	17879945
R@@	B-Chemical	D019438	17879945
it@@	I-Chemical	-1	17879945
on@@	I-Chemical	-1	17879945
avi@@	I-Chemical	-1	17879945
r	I-Chemical	-1	17879945
increased	O	-1	17879945
the	O	-1	17879945
expression	O	-1	17879945
of	O	-1	17879945
the	O	-1	17879945
s@@	O	-1	17879945
ca@@	O	-1	17879945
ven@@	O	-1	17879945
g@@	O	-1	17879945
er	O	-1	17879945
receptor@@	O	-1	17879945
,	O	-1	17879945
C@@	O	-1	17879945
D@@	O	-1	17879945
3@@	O	-1	17879945
6	O	-1	17879945
mR@@	O	-1	17879945
N@@	O	-1	17879945
A@@	O	-1	17879945
,	O	-1	17879945
respon@@	O	-1	17879945
sible	O	-1	17879945
for	O	-1	17879945
the	O	-1	17879945
u@@	O	-1	17879945
pt@@	O	-1	17879945
ake	O	-1	17879945
of	O	-1	17879945
L@@	O	-1	17879945
D@@	O	-1	17879945
L@@	O	-1	17879945
.	O	-1	17879945
Ad@@	O	-1	17879945
di@@	O	-1	17879945
tion@@	O	-1	17879945
ally,	O	-1	17879945
rit@@	B-Chemical	D019438	17879945
on@@	I-Chemical	-1	17879945
avi@@	I-Chemical	-1	17879945
r	I-Chemical	-1	17879945
treatment	O	-1	17879945
sel@@	O	-1	17879945
ectively	O	-1	17879945
increased	O	-1	17879945
the	O	-1	17879945
rel@@	O	-1	17879945
ative	O	-1	17879945
levels	O	-1	17879945
of	O	-1	17879945
P@@	O	-1	17879945
PA@@	O	-1	17879945
R@@	O	-1	17879945
gam@@	O	-1	17879945
ma	O	-1	17879945
mR@@	O	-1	17879945
N@@	O	-1	17879945
A@@	O	-1	17879945
,	O	-1	17879945
a	O	-1	17879945
trans@@	O	-1	17879945
cri@@	O	-1	17879945
ption	O	-1	17879945
factor	O	-1	17879945
respon@@	O	-1	17879945
sible	O	-1	17879945
for	O	-1	17879945
the	O	-1	17879945
reg@@	O	-1	17879945
ulation	O	-1	17879945
of	O	-1	17879945
C@@	O	-1	17879945
D@@	O	-1	17879945
3@@	O	-1	17879945
6	O	-1	17879945
mRNA	O	-1	17879945
ex@@	O	-1	17879945
pres@@	O	-1	17879945
sion.	O	-1	17879945
Treat@@	O	-1	17879945
ment	O	-1	17879945
with	O	-1	17879945
E@@	B-Chemical	D004958	17879945
2	I-Chemical	-1	17879945
,	O	-1	17879945
however,	O	-1	17879945
fail@@	O	-1	17879945
ed	O	-1	17879945
to	O	-1	17879945
prev@@	O	-1	17879945
ent	O	-1	17879945
these	O	-1	17879945
increases	O	-1	17879945
at	O	-1	17879945
the	O	-1	17879945
mRNA	O	-1	17879945
level@@	O	-1	17879945
.	O	-1	17879945
E@@	B-Chemical	D004958	17879945
2	I-Chemical	-1	17879945
di@@	O	-1	17879945
d,	O	-1	17879945
however,	O	-1	17879945
significantly	O	-1	17879945
sup@@	O	-1	17879945
pres@@	O	-1	17879945
s	O	-1	17879945
C@@	O	-1	17879945
D@@	O	-1	17879945
3@@	O	-1	17879945
6	O	-1	17879945
protein	O	-1	17879945
levels	O	-1	17879945
as	O	-1	17879945
measured	O	-1	17879945
by	O	-1	17879945
fluo@@	O	-1	17879945
res@@	O	-1	17879945
c@@	O	-1	17879945
ent	O	-1	17879945
immun@@	O	-1	17879945
ocyto@@	O	-1	17879945
chem@@	O	-1	17879945
ist@@	O	-1	17879945
r@@	O	-1	17879945
y.	O	-1	17879945
This	O	-1	17879945
data	O	-1	17879945
suggests	O	-1	17879945
that	O	-1	17879945
E@@	B-Chemical	D004958	17879945
2	I-Chemical	-1	17879945
mo@@	O	-1	17879945
di@@	O	-1	17879945
fi@@	O	-1	17879945
es	O	-1	17879945
the	O	-1	17879945
expression	O	-1	17879945
of	O	-1	17879945
C@@	O	-1	17879945
D@@	O	-1	17879945
3@@	O	-1	17879945
6	O	-1	17879945
at	O	-1	17879945
the	O	-1	17879945
level	O	-1	17879945
of	O	-1	17879945
protein	O	-1	17879945
expression	O	-1	17879945
in	O	-1	17879945
mon@@	O	-1	17879945
ocy@@	O	-1	17879945
te@@	O	-1	17879945
-@@	O	-1	17879945
der@@	O	-1	17879945
i@@	O	-1	17879945
ved	O	-1	17879945
mac@@	O	-1	17879945
ro@@	O	-1	17879945
ph@@	O	-1	17879945
ages	O	-1	17879945
result@@	O	-1	17879945
ing	O	-1	17879945
in	O	-1	17879945
reduced	O	-1	17879945
cholest@@	B-Chemical	D002788	17879945
ery@@	I-Chemical	-1	17879945
l	I-Chemical	-1	17879945
est@@	I-Chemical	-1	17879945
er	I-Chemical	-1	17879945
accum@@	O	-1	17879945
ulation	O	-1	17879945
following	O	-1	17879945
rit@@	B-Chemical	D019438	17879945
on@@	I-Chemical	-1	17879945
avi@@	I-Chemical	-1	17879945
r	I-Chemical	-1	17879945
treatment.	O	-1	17879945

U@@	O	-1	17437408
pre@@	O	-1	17437408
g@@	O	-1	17437408
ulation	O	-1	17437408
of	O	-1	17437408
brain	O	-1	17437408
expression	O	-1	17437408
of	O	-1	17437408
P@@	O	-1	17437408
-@@	O	-1	17437408
gly@@	O	-1	17437408
co@@	O	-1	17437408
protein	O	-1	17437408
in	O	-1	17437408
MR@@	O	-1	17437408
P@@	O	-1	17437408
2-@@	O	-1	17437408
defici@@	O	-1	17437408
ent	O	-1	17437408
TR@@	O	-1	17437408
(-@@	O	-1	17437408
)	O	-1	17437408
rats	O	-1	17437408
re@@	O	-1	17437408
se@@	O	-1	17437408
m@@	O	-1	17437408
ble@@	O	-1	17437408
s	O	-1	17437408
seizure	B-Disease	D012640	17437408
-induced	O	-1	17437408
up@@	O	-1	17437408
-@@	O	-1	17437408
reg@@	O	-1	17437408
ulation	O	-1	17437408
of	O	-1	17437408
this	O	-1	17437408
drug	O	-1	17437408
eff@@	O	-1	17437408
lu@@	O	-1	17437408
x	O	-1	17437408
trans@@	O	-1	17437408
por@@	O	-1	17437408
ter	O	-1	17437408
in	O	-1	17437408
normal	O	-1	17437408
rats.	O	-1	17437408
P@@	O	-1	17437408
U@@	O	-1	17437408
R@@	O	-1	17437408
P@@	O	-1	17437408
O@@	O	-1	17437408
S@@	O	-1	17437408
E:	O	-1	17437408
The	O	-1	17437408
multi@@	O	-1	17437408
drug	O	-1	17437408
resist@@	O	-1	17437408
ance	O	-1	17437408
protein	O	-1	17437408
2	O	-1	17437408
(@@	O	-1	17437408
MR@@	O	-1	17437408
P@@	O	-1	17437408
2)	O	-1	17437408
is	O	-1	17437408
a	O	-1	17437408
drug	O	-1	17437408
eff@@	O	-1	17437408
lu@@	O	-1	17437408
x	O	-1	17437408
trans@@	O	-1	17437408
por@@	O	-1	17437408
ter	O	-1	17437408
that	O	-1	17437408
is	O	-1	17437408
ex@@	O	-1	17437408
press@@	O	-1	17437408
ed	O	-1	17437408
pre@@	O	-1	17437408
domin@@	O	-1	17437408
ant@@	O	-1	17437408
ly	O	-1	17437408
at	O	-1	17437408
the	O	-1	17437408
ap@@	O	-1	17437408
ical	O	-1	17437408
do@@	O	-1	17437408
ma@@	O	-1	17437408
in	O	-1	17437408
of	O	-1	17437408
hepat@@	O	-1	17437408
ocy@@	O	-1	17437408
tes	O	-1	17437408
but	O	-1	17437408
se@@	O	-1	17437408
em@@	O	-1	17437408
s	O	-1	17437408
also	O	-1	17437408
to	O	-1	17437408
be	O	-1	17437408
ex@@	O	-1	17437408
press@@	O	-1	17437408
ed	O	-1	17437408
at	O	-1	17437408
the	O	-1	17437408
ap@@	O	-1	17437408
ical	O	-1	17437408
membran@@	O	-1	17437408
e	O	-1	17437408
of	O	-1	17437408
brain	O	-1	17437408
cap@@	O	-1	17437408
ill@@	O	-1	17437408
ary	O	-1	17437408
endothelial	O	-1	17437408
cells	O	-1	17437408
that	O	-1	17437408
form	O	-1	17437408
the	O	-1	17437408
blo@@	O	-1	17437408
o@@	O	-1	17437408
d-@@	O	-1	17437408
brain	O	-1	17437408
bar@@	O	-1	17437408
ri@@	O	-1	17437408
er	O	-1	17437408
(B@@	O	-1	17437408
B@@	O	-1	17437408
B@@	O	-1	17437408
).	O	-1	17437408
MR@@	O	-1	17437408
P@@	O	-1	17437408
2	O	-1	17437408
is	O	-1	17437408
abs@@	O	-1	17437408
ent	O	-1	17437408
in	O	-1	17437408
the	O	-1	17437408
trans@@	O	-1	17437408
port@@	O	-1	17437408
-@@	O	-1	17437408
defici@@	O	-1	17437408
ent	O	-1	17437408
(@@	O	-1	17437408
TR@@	O	-1	17437408
(-@@	O	-1	17437408
)@@	O	-1	17437408
)	O	-1	17437408
Wistar	O	-1	17437408
rat	O	-1	17437408
mut@@	O	-1	17437408
ant@@	O	-1	17437408
,	O	-1	17437408
so	O	-1	17437408
that	O	-1	17437408
this	O	-1	17437408
rat	O	-1	17437408
stra@@	O	-1	17437408
in	O	-1	17437408
was	O	-1	17437408
very	O	-1	17437408
he@@	O	-1	17437408
l@@	O	-1	17437408
p@@	O	-1	17437408
ful	O	-1	17437408
in	O	-1	17437408
def@@	O	-1	17437408
in@@	O	-1	17437408
ing	O	-1	17437408
sub@@	O	-1	17437408
strat@@	O	-1	17437408
es	O	-1	17437408
of	O	-1	17437408
MR@@	O	-1	17437408
P@@	O	-1	17437408
2	O	-1	17437408
by	O	-1	17437408
compar@@	O	-1	17437408
ing	O	-1	17437408
tissue	O	-1	17437408
concentrations	O	-1	17437408
or	O	-1	17437408
functional	O	-1	17437408
ac@@	O	-1	17437408
ti@@	O	-1	17437408
vi@@	O	-1	17437408
ties	O	-1	17437408
of	O	-1	17437408
comp@@	O	-1	17437408
oun@@	O	-1	17437408
ds	O	-1	17437408
in	O	-1	17437408
MR@@	O	-1	17437408
P@@	O	-1	17437408
2-@@	O	-1	17437408
defici@@	O	-1	17437408
ent	O	-1	17437408
rats	O	-1	17437408
with	O	-1	17437408
those	O	-1	17437408
in	O	-1	17437408
trans@@	O	-1	17437408
port@@	O	-1	17437408
-@@	O	-1	17437408
comp@@	O	-1	17437408
et@@	O	-1	17437408
ent	O	-1	17437408
Wistar	O	-1	17437408
rats.	O	-1	17437408
B@@	O	-1	17437408
y	O	-1	17437408
using	O	-1	17437408
this	O	-1	17437408
strat@@	O	-1	17437408
e@@	O	-1	17437408
g@@	O	-1	17437408
y	O	-1	17437408
to	O	-1	17437408
study	O	-1	17437408
the	O	-1	17437408
invol@@	O	-1	17437408
vement	O	-1	17437408
of	O	-1	17437408
MR@@	O	-1	17437408
P@@	O	-1	17437408
2	O	-1	17437408
in	O	-1	17437408
brain	O	-1	17437408
ac@@	O	-1	17437408
cess	O	-1	17437408
of	O	-1	17437408
anti@@	O	-1	17437408
epileptic	O	-1	17437408
drugs	O	-1	17437408
(A@@	O	-1	17437408
E@@	O	-1	17437408
D@@	O	-1	17437408
s),	O	-1	17437408
we	O	-1	17437408
rec@@	O	-1	17437408
ently	O	-1	17437408
reported	O	-1	17437408
that	O	-1	17437408
pheny@@	B-Chemical	D010672	17437408
to@@	I-Chemical	-1	17437408
in	I-Chemical	-1	17437408
is	O	-1	17437408
a	O	-1	17437408
subst@@	O	-1	17437408
rate	O	-1	17437408
for	O	-1	17437408
MR@@	O	-1	17437408
P@@	O	-1	17437408
2	O	-1	17437408
in	O	-1	17437408
the	O	-1	17437408
B@@	O	-1	17437408
B@@	O	-1	17437408
B@@	O	-1	17437408
.	O	-1	17437408
However,	O	-1	17437408
one	O	-1	17437408
draw@@	O	-1	17437408
bac@@	O	-1	17437408
k	O	-1	17437408
of	O	-1	17437408
such	O	-1	17437408
studies	O	-1	17437408
in	O	-1	17437408
gene@@	O	-1	17437408
tically	O	-1	17437408
defici@@	O	-1	17437408
ent	O	-1	17437408
rats	O	-1	17437408
is	O	-1	17437408
the	O	-1	17437408
fac@@	O	-1	17437408
t	O	-1	17437408
that	O	-1	17437408
com@@	O	-1	17437408
pen@@	O	-1	17437408
s@@	O	-1	17437408
atory	O	-1	17437408
changes	O	-1	17437408
with	O	-1	17437408
u@@	O	-1	17437408
pre@@	O	-1	17437408
g@@	O	-1	17437408
ulation	O	-1	17437408
of	O	-1	17437408
other	O	-1	17437408
trans@@	O	-1	17437408
por@@	O	-1	17437408
ters	O	-1	17437408
can	O	-1	17437408
occur@@	O	-1	17437408
.	O	-1	17437408
This	O	-1	17437408
pro@@	O	-1	17437408
m@@	O	-1	17437408
pt@@	O	-1	17437408
ed	O	-1	17437408
us	O	-1	17437408
to	O	-1	17437408
study	O	-1	17437408
the	O	-1	17437408
brain	O	-1	17437408
expression	O	-1	17437408
of	O	-1	17437408
P@@	O	-1	17437408
-@@	O	-1	17437408
gly@@	O	-1	17437408
co@@	O	-1	17437408
protein	O	-1	17437408
(P@@	O	-1	17437408
g@@	O	-1	17437408
p@@	O	-1	17437408
),	O	-1	17437408
a	O	-1	17437408
major	O	-1	17437408
drug	O	-1	17437408
eff@@	O	-1	17437408
lu@@	O	-1	17437408
x	O	-1	17437408
trans@@	O	-1	17437408
por@@	O	-1	17437408
ter	O	-1	17437408
in	O	-1	17437408
man@@	O	-1	17437408
y	O	-1	17437408
tissu@@	O	-1	17437408
es,	O	-1	17437408
including	O	-1	17437408
the	O	-1	17437408
B@@	O	-1	17437408
B@@	O	-1	17437408
B@@	O	-1	17437408
,	O	-1	17437408
in	O	-1	17437408
TR@@	O	-1	17437408
(-@@	O	-1	17437408
)	O	-1	17437408
rats	O	-1	17437408
compared	O	-1	17437408
with	O	-1	17437408
non@@	O	-1	17437408
mut@@	O	-1	17437408
ant	O	-1	17437408
(@@	O	-1	17437408
wil@@	O	-1	17437408
d-@@	O	-1	17437408
ty@@	O	-1	17437408
pe@@	O	-1	17437408
)	O	-1	17437408
Wistar	O	-1	17437408
rats.	O	-1	17437408
METHODS:	O	-1	17437408
The	O	-1	17437408
expression	O	-1	17437408
of	O	-1	17437408
MR@@	O	-1	17437408
P@@	O	-1	17437408
2	O	-1	17437408
and	O	-1	17437408
P@@	O	-1	17437408
g@@	O	-1	17437408
p	O	-1	17437408
in	O	-1	17437408
brain	O	-1	17437408
and	O	-1	17437408
liver	O	-1	17437408
sec@@	O	-1	17437408
tions	O	-1	17437408
of	O	-1	17437408
TR@@	O	-1	17437408
(-@@	O	-1	17437408
)	O	-1	17437408
rats	O	-1	17437408
and	O	-1	17437408
normal	O	-1	17437408
Wistar	O	-1	17437408
rats	O	-1	17437408
was	O	-1	17437408
determined	O	-1	17437408
with	O	-1	17437408
immuno@@	O	-1	17437408
histo@@	O	-1	17437408
chem@@	O	-1	17437408
ist@@	O	-1	17437408
r@@	O	-1	17437408
y,	O	-1	17437408
by	O	-1	17437408
using	O	-1	17437408
a	O	-1	17437408
no@@	O	-1	17437408
vel@@	O	-1	17437408
,	O	-1	17437408
high@@	O	-1	17437408
ly	O	-1	17437408
selective	O	-1	17437408
mon@@	O	-1	17437408
oc@@	O	-1	17437408
lon@@	O	-1	17437408
al	O	-1	17437408
MR@@	O	-1	17437408
P@@	O	-1	17437408
2	O	-1	17437408
anti@@	O	-1	17437408
body	O	-1	17437408
and	O	-1	17437408
the	O	-1	17437408
mon@@	O	-1	17437408
oc@@	O	-1	17437408
lon@@	O	-1	17437408
al	O	-1	17437408
P@@	O	-1	17437408
g@@	O	-1	17437408
p	O	-1	17437408
anti@@	O	-1	17437408
body	O	-1	17437408
C@@	O	-1	17437408
2@@	O	-1	17437408
19@@	O	-1	17437408
,	O	-1	17437408
respectively.	O	-1	17437408
RESULTS:	O	-1	17437408
Im@@	O	-1	17437408
mun@@	O	-1	17437408
o@@	O	-1	17437408
fluo@@	O	-1	17437408
res@@	O	-1	17437408
c@@	O	-1	17437408
ence	O	-1	17437408
st@@	O	-1	17437408
aining	O	-1	17437408
with	O	-1	17437408
the	O	-1	17437408
MR@@	O	-1	17437408
P@@	O	-1	17437408
2	O	-1	17437408
anti@@	O	-1	17437408
body	O	-1	17437408
was	O	-1	17437408
found	O	-1	17437408
to	O	-1	17437408
l@@	O	-1	17437408
a@@	O	-1	17437408
be@@	O	-1	17437408
l	O	-1	17437408
a	O	-1	17437408
high	O	-1	17437408
number	O	-1	17437408
of	O	-1	17437408
micro@@	O	-1	17437408
v@@	O	-1	17437408
es@@	O	-1	17437408
sel@@	O	-1	17437408
s	O	-1	17437408
throu@@	O	-1	17437408
gh@@	O	-1	17437408
out	O	-1	17437408
the	O	-1	17437408
brain	O	-1	17437408
in	O	-1	17437408
normal	O	-1	17437408
Wistar	O	-1	17437408
rats,	O	-1	17437408
whereas	O	-1	17437408
such	O	-1	17437408
l@@	O	-1	17437408
a@@	O	-1	17437408
be@@	O	-1	17437408
l@@	O	-1	17437408
ing	O	-1	17437408
was	O	-1	17437408
abs@@	O	-1	17437408
ent	O	-1	17437408
in	O	-1	17437408
TR@@	O	-1	17437408
(-@@	O	-1	17437408
)	O	-1	17437408
rats.	O	-1	17437408
TR@@	O	-1	17437408
(-@@	O	-1	17437408
)	O	-1	17437408
rats	O	-1	17437408
ex@@	O	-1	17437408
hib@@	O	-1	17437408
ited	O	-1	17437408
a	O	-1	17437408
significant	O	-1	17437408
up@@	O	-1	17437408
-@@	O	-1	17437408
reg@@	O	-1	17437408
ulation	O	-1	17437408
of	O	-1	17437408
P@@	O	-1	17437408
g@@	O	-1	17437408
p	O	-1	17437408
in	O	-1	17437408
brain	O	-1	17437408
cap@@	O	-1	17437408
ill@@	O	-1	17437408
ary	O	-1	17437408
endothelial	O	-1	17437408
cells	O	-1	17437408
compared	O	-1	17437408
with	O	-1	17437408
wil@@	O	-1	17437408
d-@@	O	-1	17437408
type	O	-1	17437408
controls.	O	-1	17437408
No	O	-1	17437408
such	O	-1	17437408
ob@@	O	-1	17437408
vi@@	O	-1	17437408
ous	O	-1	17437408
u@@	O	-1	17437408
pre@@	O	-1	17437408
g@@	O	-1	17437408
ulation	O	-1	17437408
of	O	-1	17437408
P@@	O	-1	17437408
g@@	O	-1	17437408
p	O	-1	17437408
was	O	-1	17437408
observed	O	-1	17437408
in	O	-1	17437408
liver	O	-1	17437408
sec@@	O	-1	17437408
tions.	O	-1	17437408
A	O	-1	17437408
compar@@	O	-1	17437408
able	O	-1	17437408
o@@	O	-1	17437408
ve@@	O	-1	17437408
re@@	O	-1	17437408
x@@	O	-1	17437408
pression	O	-1	17437408
of	O	-1	17437408
P@@	O	-1	17437408
g@@	O	-1	17437408
p	O	-1	17437408
in	O	-1	17437408
the	O	-1	17437408
B@@	O	-1	17437408
B@@	O	-1	17437408
B	O	-1	17437408
was	O	-1	17437408
obtained	O	-1	17437408
after	O	-1	17437408
pilocar@@	B-Chemical	D010862	17437408
pine	I-Chemical	-1	17437408
-induced	O	-1	17437408
seizures	B-Disease	D012640	17437408
in	O	-1	17437408
wil@@	O	-1	17437408
d-@@	O	-1	17437408
type	O	-1	17437408
Wistar	O	-1	17437408
rats.	O	-1	17437408
E@@	O	-1	17437408
x@@	O	-1	17437408
per@@	O	-1	17437408
im@@	O	-1	17437408
ents	O	-1	17437408
with	O	-1	17437408
systemic	O	-1	17437408
administration	O	-1	17437408
of	O	-1	17437408
the	O	-1	17437408
P@@	O	-1	17437408
g@@	O	-1	17437408
p	O	-1	17437408
subst@@	O	-1	17437408
rate	O	-1	17437408
phenobarbit@@	B-Chemical	D010634	17437408
al	I-Chemical	-1	17437408
and	O	-1	17437408
the	O	-1	17437408
selective	O	-1	17437408
P@@	O	-1	17437408
g@@	O	-1	17437408
p	O	-1	17437408
inhibitor	O	-1	17437408
t@@	B-Chemical	C402343	17437408
ari@@	I-Chemical	-1	17437408
qu@@	I-Chemical	-1	17437408
id@@	I-Chemical	-1	17437408
ar	I-Chemical	-1	17437408
in	O	-1	17437408
TR@@	O	-1	17437408
(-@@	O	-1	17437408
)	O	-1	17437408
rats	O	-1	17437408
subst@@	O	-1	17437408
anti@@	O	-1	17437408
ated	O	-1	17437408
that	O	-1	17437408
P@@	O	-1	17437408
g@@	O	-1	17437408
p	O	-1	17437408
is	O	-1	17437408
functional	O	-1	17437408
and	O	-1	17437408
com@@	O	-1	17437408
pen@@	O	-1	17437408
s@@	O	-1	17437408
ates	O	-1	17437408
for	O	-1	17437408
the	O	-1	17437408
l@@	O	-1	17437408
ac@@	O	-1	17437408
k	O	-1	17437408
of	O	-1	17437408
MR@@	O	-1	17437408
P@@	O	-1	17437408
2	O	-1	17437408
in	O	-1	17437408
the	O	-1	17437408
B@@	O	-1	17437408
B@@	O	-1	17437408
B@@	O	-1	17437408
.	O	-1	17437408
CONCLUSIONS:	O	-1	17437408
The	O	-1	17437408
data	O	-1	17437408
on	O	-1	17437408
TR@@	O	-1	17437408
(-@@	O	-1	17437408
)	O	-1	17437408
rats	O	-1	17437408
indicate	O	-1	17437408
that	O	-1	17437408
P@@	O	-1	17437408
g@@	O	-1	17437408
p	O	-1	17437408
pl@@	O	-1	17437408
ays	O	-1	17437408
an	O	-1	17437408
important	O	-1	17437408
role	O	-1	17437408
in	O	-1	17437408
the	O	-1	17437408
com@@	O	-1	17437408
pen@@	O	-1	17437408
s@@	O	-1	17437408
ation	O	-1	17437408
of	O	-1	17437408
MR@@	O	-1	17437408
P@@	O	-1	17437408
2	O	-1	17437408
defici@@	O	-1	17437408
ency	O	-1	17437408
in	O	-1	17437408
the	O	-1	17437408
B@@	O	-1	17437408
B@@	O	-1	17437408
B@@	O	-1	17437408
.	O	-1	17437408
B@@	O	-1	17437408
ecause	O	-1	17437408
such	O	-1	17437408
a	O	-1	17437408
com@@	O	-1	17437408
pen@@	O	-1	17437408
s@@	O	-1	17437408
atory	O	-1	17437408
mechanism	O	-1	17437408
most	O	-1	17437408
likely	O	-1	17437408
occur@@	O	-1	17437408
s	O	-1	17437408
to	O	-1	17437408
re@@	O	-1	17437408
duce	O	-1	17437408
injury	B-Disease	D001927	17437408
to	I-Disease	-1	17437408
the	I-Disease	-1	17437408
brain	I-Disease	-1	17437408
from	O	-1	17437408
cy@@	O	-1	17437408
tot@@	O	-1	17437408
ox@@	O	-1	17437408
ic	O	-1	17437408
comp@@	O	-1	17437408
oun@@	O	-1	17437408
d@@	O	-1	17437408
s,	O	-1	17437408
the	O	-1	17437408
present	O	-1	17437408
data	O	-1	17437408
subst@@	O	-1	17437408
anti@@	O	-1	17437408
ate	O	-1	17437408
the	O	-1	17437408
con@@	O	-1	17437408
cep@@	O	-1	17437408
t	O	-1	17437408
that	O	-1	17437408
MR@@	O	-1	17437408
P@@	O	-1	17437408
2	O	-1	17437408
perform@@	O	-1	17437408
s	O	-1	17437408
a	O	-1	17437408
protective	O	-1	17437408
role	O	-1	17437408
in	O	-1	17437408
the	O	-1	17437408
B@@	O	-1	17437408
B@@	O	-1	17437408
B@@	O	-1	17437408
.	O	-1	17437408
F@@	O	-1	17437408
ur@@	O	-1	17437408
ther@@	O	-1	17437408
mo@@	O	-1	17437408
re,	O	-1	17437408
our	O	-1	17437408
data	O	-1	17437408
suggest	O	-1	17437408
that	O	-1	17437408
TR@@	O	-1	17437408
(-@@	O	-1	17437408
)	O	-1	17437408
rats	O	-1	17437408
are	O	-1	17437408
an	O	-1	17437408
in@@	O	-1	17437408
te@@	O	-1	17437408
rest@@	O	-1	17437408
ing	O	-1	17437408
to@@	O	-1	17437408
ol	O	-1	17437408
to	O	-1	17437408
study	O	-1	17437408
con@@	O	-1	17437408
sequ@@	O	-1	17437408
enc@@	O	-1	17437408
es	O	-1	17437408
of	O	-1	17437408
o@@	O	-1	17437408
ve@@	O	-1	17437408
re@@	O	-1	17437408
x@@	O	-1	17437408
pression	O	-1	17437408
of	O	-1	17437408
P@@	O	-1	17437408
g@@	O	-1	17437408
p	O	-1	17437408
in	O	-1	17437408
the	O	-1	17437408
B@@	O	-1	17437408
B@@	O	-1	17437408
B	O	-1	17437408
on	O	-1	17437408
ac@@	O	-1	17437408
cess	O	-1	17437408
of	O	-1	17437408
drugs	O	-1	17437408
in	O	-1	17437408
the	O	-1	17437408
bra@@	O	-1	17437408
in,	O	-1	17437408
without	O	-1	17437408
the	O	-1	17437408
need	O	-1	17437408
of	O	-1	17437408
induc@@	O	-1	17437408
ing	O	-1	17437408
seizures	B-Disease	D012640	17437408
or	O	-1	17437408
other	O	-1	17437408
P@@	O	-1	17437408
g@@	O	-1	17437408
p@@	O	-1	17437408
-@@	O	-1	17437408
enh@@	O	-1	17437408
anc@@	O	-1	17437408
ing	O	-1	17437408
events	O	-1	17437408
for	O	-1	17437408
this	O	-1	17437408
pur@@	O	-1	17437408
po@@	O	-1	17437408
se.	O	-1	17437408

U@@	O	-1	17242861
se	O	-1	17242861
of	O	-1	17242861
ch@@	O	-1	17242861
rom@@	O	-1	17242861
os@@	O	-1	17242861
ome	O	-1	17242861
sub@@	O	-1	17242861
sti@@	O	-1	17242861
tu@@	O	-1	17242861
tion	O	-1	17242861
stra@@	O	-1	17242861
ins	O	-1	17242861
to	O	-1	17242861
identi@@	O	-1	17242861
f@@	O	-1	17242861
y	O	-1	17242861
seizure	B-Disease	D012640	17242861
sus@@	O	-1	17242861
cep@@	O	-1	17242861
ti@@	O	-1	17242861
b@@	O	-1	17242861
ility	O	-1	17242861
loc@@	O	-1	17242861
i	O	-1	17242861
in	O	-1	17242861
mice.	O	-1	17242861
S@@	B-Disease	D012640	17242861
e@@	I-Disease	-1	17242861
iz@@	I-Disease	-1	17242861
ure	I-Disease	-1	17242861
sus@@	O	-1	17242861
cep@@	O	-1	17242861
ti@@	O	-1	17242861
b@@	O	-1	17242861
ility	O	-1	17242861
vari@@	O	-1	17242861
es	O	-1	17242861
among	O	-1	17242861
in@@	O	-1	17242861
b@@	O	-1	17242861
red	O	-1	17242861
mouse	O	-1	17242861
stra@@	O	-1	17242861
in@@	O	-1	17242861
s.	O	-1	17242861
Ch@@	O	-1	17242861
rom@@	O	-1	17242861
os@@	O	-1	17242861
ome	O	-1	17242861
sub@@	O	-1	17242861
sti@@	O	-1	17242861
tu@@	O	-1	17242861
tion	O	-1	17242861
stra@@	O	-1	17242861
ins	O	-1	17242861
(C@@	O	-1	17242861
S@@	O	-1	17242861
S@@	O	-1	17242861
),	O	-1	17242861
in	O	-1	17242861
which	O	-1	17242861
a	O	-1	17242861
single	O	-1	17242861
ch@@	O	-1	17242861
rom@@	O	-1	17242861
os@@	O	-1	17242861
ome	O	-1	17242861
from	O	-1	17242861
one	O	-1	17242861
in@@	O	-1	17242861
b@@	O	-1	17242861
red	O	-1	17242861
stra@@	O	-1	17242861
in	O	-1	17242861
(@@	O	-1	17242861
d@@	O	-1	17242861
on@@	O	-1	17242861
or@@	O	-1	17242861
)	O	-1	17242861
has	O	-1	17242861
been	O	-1	17242861
trans@@	O	-1	17242861
fer@@	O	-1	17242861
red	O	-1	17242861
on@@	O	-1	17242861
to	O	-1	17242861
a	O	-1	17242861
second	O	-1	17242861
stra@@	O	-1	17242861
in	O	-1	17242861
(@@	O	-1	17242861
ho@@	O	-1	17242861
st@@	O	-1	17242861
)	O	-1	17242861
by	O	-1	17242861
repe@@	O	-1	17242861
ated	O	-1	17242861
bac@@	O	-1	17242861
k@@	O	-1	17242861
cros@@	O	-1	17242861
sing@@	O	-1	17242861
,	O	-1	17242861
may	O	-1	17242861
be	O	-1	17242861
used	O	-1	17242861
to	O	-1	17242861
identi@@	O	-1	17242861
f@@	O	-1	17242861
y	O	-1	17242861
qu@@	O	-1	17242861
anti@@	O	-1	17242861
t@@	O	-1	17242861
ative	O	-1	17242861
tra@@	O	-1	17242861
it	O	-1	17242861
loc@@	O	-1	17242861
i	O	-1	17242861
(@@	O	-1	17242861
Q@@	O	-1	17242861
T@@	O	-1	17242861
L@@	O	-1	17242861
s)	O	-1	17242861
that	O	-1	17242861
cont@@	O	-1	17242861
rib@@	O	-1	17242861
ute	O	-1	17242861
to	O	-1	17242861
seizure	B-Disease	D012640	17242861
sus@@	O	-1	17242861
cep@@	O	-1	17242861
ti@@	O	-1	17242861
bil@@	O	-1	17242861
ity.	O	-1	17242861
Q@@	O	-1	17242861
T@@	O	-1	17242861
L@@	O	-1	17242861
s	O	-1	17242861
for	O	-1	17242861
sus@@	O	-1	17242861
cep@@	O	-1	17242861
ti@@	O	-1	17242861
b@@	O	-1	17242861
ility	O	-1	17242861
to	O	-1	17242861
pilocar@@	B-Chemical	D010862	17242861
pine	I-Chemical	-1	17242861
-induced	O	-1	17242861
seizures	B-Disease	D012640	17242861
,	O	-1	17242861
a	O	-1	17242861
model	O	-1	17242861
of	O	-1	17242861
tempor@@	B-Disease	D004833	17242861
al	I-Disease	-1	17242861
lo@@	I-Disease	-1	17242861
be	I-Disease	-1	17242861
epilep@@	I-Disease	-1	17242861
sy	I-Disease	-1	17242861
,	O	-1	17242861
have	O	-1	17242861
not	O	-1	17242861
been	O	-1	17242861
repor@@	O	-1	17242861
te@@	O	-1	17242861
d,	O	-1	17242861
and	O	-1	17242861
C@@	O	-1	17242861
S@@	O	-1	17242861
S	O	-1	17242861
have	O	-1	17242861
not	O	-1	17242861
previously	O	-1	17242861
been	O	-1	17242861
used	O	-1	17242861
to	O	-1	17242861
lo@@	O	-1	17242861
cal@@	O	-1	17242861
iz@@	O	-1	17242861
e	O	-1	17242861
seizure	B-Disease	D012640	17242861
sus@@	O	-1	17242861
cep@@	O	-1	17242861
ti@@	O	-1	17242861
b@@	O	-1	17242861
ility	O	-1	17242861
gen@@	O	-1	17242861
es.	O	-1	17242861
We	O	-1	17242861
report	O	-1	17242861
Q@@	O	-1	17242861
T@@	O	-1	17242861
L@@	O	-1	17242861
s	O	-1	17242861
identi@@	O	-1	17242861
fied	O	-1	17242861
using	O	-1	17242861
a	O	-1	17242861
B@@	O	-1	17242861
6	O	-1	17242861
(@@	O	-1	17242861
ho@@	O	-1	17242861
st@@	O	-1	17242861
)	O	-1	17242861
x	O	-1	17242861
A@@	O	-1	17242861
/@@	O	-1	17242861
J	O	-1	17242861
(@@	O	-1	17242861
d@@	O	-1	17242861
on@@	O	-1	17242861
or@@	O	-1	17242861
)	O	-1	17242861
C@@	O	-1	17242861
S@@	O	-1	17242861
S	O	-1	17242861
p@@	O	-1	17242861
ane@@	O	-1	17242861
l	O	-1	17242861
to	O	-1	17242861
lo@@	O	-1	17242861
cal@@	O	-1	17242861
iz@@	O	-1	17242861
e	O	-1	17242861
gen@@	O	-1	17242861
es	O	-1	17242861
involved	O	-1	17242861
in	O	-1	17242861
sus@@	O	-1	17242861
cep@@	O	-1	17242861
ti@@	O	-1	17242861
b@@	O	-1	17242861
ility	O	-1	17242861
to	O	-1	17242861
pilocar@@	B-Chemical	D010862	17242861
pine	I-Chemical	-1	17242861
-induced	O	-1	17242861
seizures	B-Disease	D012640	17242861
.	O	-1	17242861
Th@@	O	-1	17242861
ree	O	-1	17242861
h@@	O	-1	17242861
und@@	O	-1	17242861
red	O	-1	17242861
f@@	O	-1	17242861
if@@	O	-1	17242861
ty-@@	O	-1	17242861
five	O	-1	17242861
ad@@	O	-1	17242861
ult	O	-1	17242861
male	O	-1	17242861
C@@	O	-1	17242861
S@@	O	-1	17242861
S	O	-1	17242861
mic@@	O	-1	17242861
e,	O	-1	17242861
5@@	O	-1	17242861
8	O	-1	17242861
B@@	O	-1	17242861
6,	O	-1	17242861
and	O	-1	17242861
3@@	O	-1	17242861
9	O	-1	17242861
A@@	O	-1	17242861
/@@	O	-1	17242861
J	O	-1	17242861
were	O	-1	17242861
tested	O	-1	17242861
for	O	-1	17242861
sus@@	O	-1	17242861
cep@@	O	-1	17242861
ti@@	O	-1	17242861
b@@	O	-1	17242861
ility	O	-1	17242861
to	O	-1	17242861
pilocar@@	B-Chemical	D010862	17242861
pine	I-Chemical	-1	17242861
-induced	O	-1	17242861
seizures	B-Disease	D012640	17242861
.	O	-1	17242861
H@@	O	-1	17242861
igh@@	O	-1	17242861
est	O	-1	17242861
st@@	O	-1	17242861
age	O	-1	17242861
reac@@	O	-1	17242861
h@@	O	-1	17242861
ed	O	-1	17242861
and	O	-1	17242861
lat@@	O	-1	17242861
ency	O	-1	17242861
to	O	-1	17242861
each	O	-1	17242861
st@@	O	-1	17242861
age	O	-1	17242861
were	O	-1	17242861
recor@@	O	-1	17242861
ded	O	-1	17242861
for	O	-1	17242861
all	O	-1	17242861
mice.	O	-1	17242861
B@@	O	-1	17242861
6	O	-1	17242861
mice	O	-1	17242861
were	O	-1	17242861
resist@@	O	-1	17242861
ant	O	-1	17242861
to	O	-1	17242861
seizures	B-Disease	D012640	17242861
and	O	-1	17242861
s@@	O	-1	17242861
lower	O	-1	17242861
to	O	-1	17242861
reac@@	O	-1	17242861
h	O	-1	17242861
st@@	O	-1	17242861
ages	O	-1	17242861
compared	O	-1	17242861
to	O	-1	17242861
A@@	O	-1	17242861
/@@	O	-1	17242861
J	O	-1	17242861
mice.	O	-1	17242861
The	O	-1	17242861
C@@	O	-1	17242861
S@@	O	-1	17242861
S	O	-1	17242861
for	O	-1	17242861
Ch@@	O	-1	17242861
rom@@	O	-1	17242861
os@@	O	-1	17242861
om@@	O	-1	17242861
es	O	-1	17242861
10	O	-1	17242861
and	O	-1	17242861
1@@	O	-1	17242861
8	O	-1	17242861
progres@@	O	-1	17242861
sed	O	-1	17242861
to	O	-1	17242861
the	O	-1	17242861
most	O	-1	17242861
severe	O	-1	17242861
st@@	O	-1	17242861
ag@@	O	-1	17242861
es,	O	-1	17242861
di@@	O	-1	17242861
ver@@	O	-1	17242861
g@@	O	-1	17242861
ing	O	-1	17242861
d@@	O	-1	17242861
ram@@	O	-1	17242861
ati@@	O	-1	17242861
c@@	O	-1	17242861
ally	O	-1	17242861
from	O	-1	17242861
the	O	-1	17242861
B@@	O	-1	17242861
6	O	-1	17242861
phen@@	O	-1	17242861
ot@@	O	-1	17242861
yp@@	O	-1	17242861
e.	O	-1	17242861
L@@	O	-1	17242861
at@@	O	-1	17242861
en@@	O	-1	17242861
ci@@	O	-1	17242861
es	O	-1	17242861
to	O	-1	17242861
st@@	O	-1	17242861
ages	O	-1	17242861
were	O	-1	17242861
also	O	-1	17242861
significantly	O	-1	17242861
sh@@	O	-1	17242861
or@@	O	-1	17242861
ter	O	-1	17242861
for	O	-1	17242861
C@@	O	-1	17242861
S@@	O	-1	17242861
S@@	O	-1	17242861
10	O	-1	17242861
and	O	-1	17242861
C@@	O	-1	17242861
S@@	O	-1	17242861
S@@	O	-1	17242861
1@@	O	-1	17242861
8	O	-1	17242861
mice.	O	-1	17242861
C@@	O	-1	17242861
S@@	O	-1	17242861
S	O	-1	17242861
m@@	O	-1	17242861
app@@	O	-1	17242861
ing	O	-1	17242861
suggests	O	-1	17242861
seizure	B-Disease	D012640	17242861
sus@@	O	-1	17242861
cep@@	O	-1	17242861
ti@@	O	-1	17242861
b@@	O	-1	17242861
ility	O	-1	17242861
loc@@	O	-1	17242861
i	O	-1	17242861
on	O	-1	17242861
mouse	O	-1	17242861
Ch@@	O	-1	17242861
rom@@	O	-1	17242861
os@@	O	-1	17242861
om@@	O	-1	17242861
es	O	-1	17242861
10	O	-1	17242861
and	O	-1	17242861
18@@	O	-1	17242861
.	O	-1	17242861
This	O	-1	17242861
appro@@	O	-1	17242861
ach	O	-1	17242861
pro@@	O	-1	17242861
vi@@	O	-1	17242861
des	O	-1	17242861
a	O	-1	17242861
f@@	O	-1	17242861
ram@@	O	-1	17242861
e@@	O	-1	17242861
wor@@	O	-1	17242861
k	O	-1	17242861
for	O	-1	17242861
identi@@	O	-1	17242861
f@@	O	-1	17242861
y@@	O	-1	17242861
ing	O	-1	17242861
potenti@@	O	-1	17242861
ally	O	-1	17242861
novel	O	-1	17242861
ho@@	O	-1	17242861
mo@@	O	-1	17242861
log@@	O	-1	17242861
ous	O	-1	17242861
can@@	O	-1	17242861
di@@	O	-1	17242861
d@@	O	-1	17242861
ate	O	-1	17242861
gen@@	O	-1	17242861
es	O	-1	17242861
for	O	-1	17242861
human	O	-1	17242861
tempor@@	B-Disease	D004833	17242861
al	I-Disease	-1	17242861
lo@@	I-Disease	-1	17242861
be	I-Disease	-1	17242861
epilep@@	I-Disease	-1	17242861
sy	I-Disease	-1	17242861
.	O	-1	17242861

In@@	O	-1	16337777
v@@	O	-1	16337777
estig@@	O	-1	16337777
ation	O	-1	16337777
of	O	-1	16337777
mitochondrial	O	-1	16337777
invol@@	O	-1	16337777
vement	O	-1	16337777
in	O	-1	16337777
the	O	-1	16337777
experimental	O	-1	16337777
model	O	-1	16337777
of	O	-1	16337777
epilep@@	B-Disease	D004827	16337777
sy	I-Disease	-1	16337777
induced	O	-1	16337777
by	O	-1	16337777
pilocar@@	B-Chemical	D010862	16337777
pine	I-Chemical	-1	16337777
.	O	-1	16337777
M@@	B-Disease	D028361	16337777
it@@	I-Disease	-1	16337777
ochond@@	I-Disease	-1	16337777
rial	I-Disease	-1	16337777
abnormal@@	I-Disease	-1	16337777
ities	I-Disease	-1	16337777
have	O	-1	16337777
been	O	-1	16337777
associated	O	-1	16337777
with	O	-1	16337777
several	O	-1	16337777
as@@	O	-1	16337777
p@@	O	-1	16337777
ects	O	-1	16337777
of	O	-1	16337777
epile@@	O	-1	16337777
pto@@	O	-1	16337777
gene@@	O	-1	16337777
sis,	O	-1	16337777
such	O	-1	16337777
as	O	-1	16337777
en@@	O	-1	16337777
erg@@	O	-1	16337777
y	O	-1	16337777
gener@@	O	-1	16337777
ation,	O	-1	16337777
control	O	-1	16337777
of	O	-1	16337777
cell	O	-1	16337777
death	B-Disease	D003643	16337777
,	O	-1	16337777
neuro@@	O	-1	16337777
trans@@	O	-1	16337777
mit@@	O	-1	16337777
ter	O	-1	16337777
syn@@	O	-1	16337777
the@@	O	-1	16337777
sis,	O	-1	16337777
and	O	-1	16337777
free	O	-1	16337777
ra@@	O	-1	16337777
d@@	O	-1	16337777
ical	O	-1	16337777
(@@	O	-1	16337777
F@@	O	-1	16337777
R@@	O	-1	16337777
)	O	-1	16337777
produc@@	O	-1	16337777
tion.	O	-1	16337777
In@@	O	-1	16337777
c@@	O	-1	16337777
reas@@	O	-1	16337777
ed	O	-1	16337777
pro@@	O	-1	16337777
duction	O	-1	16337777
of	O	-1	16337777
F@@	O	-1	16337777
R@@	O	-1	16337777
s	O	-1	16337777
may	O	-1	16337777
cause	O	-1	16337777
m@@	O	-1	16337777
t@@	O	-1	16337777
D@@	O	-1	16337777
NA	O	-1	16337777
damage	O	-1	16337777
lead@@	O	-1	16337777
ing	O	-1	16337777
to	O	-1	16337777
decreased	O	-1	16337777
ac@@	O	-1	16337777
ti@@	O	-1	16337777
vi@@	O	-1	16337777
ties	O	-1	16337777
of	O	-1	16337777
oxid@@	O	-1	16337777
ative	O	-1	16337777
phosph@@	O	-1	16337777
or@@	O	-1	16337777
yl@@	O	-1	16337777
ation	O	-1	16337777
comple@@	O	-1	16337777
x@@	O	-1	16337777
es	O	-1	16337777
containing	O	-1	16337777
m@@	O	-1	16337777
t@@	O	-1	16337777
D@@	O	-1	16337777
N@@	O	-1	16337777
A@@	O	-1	16337777
-@@	O	-1	16337777
en@@	O	-1	16337777
co@@	O	-1	16337777
ded	O	-1	16337777
sub@@	O	-1	16337777
un@@	O	-1	16337777
it@@	O	-1	16337777
s.	O	-1	16337777
In	O	-1	16337777
this	O	-1	16337777
study,	O	-1	16337777
we	O	-1	16337777
investigated	O	-1	16337777
whether	O	-1	16337777
increased	O	-1	16337777
generation	O	-1	16337777
of	O	-1	16337777
F@@	O	-1	16337777
R	O	-1	16337777
during	O	-1	16337777
status	B-Disease	D013226	16337777
epilep@@	I-Disease	-1	16337777
tic@@	I-Disease	-1	16337777
us	I-Disease	-1	16337777
wo@@	O	-1	16337777
uld	O	-1	16337777
be	O	-1	16337777
suffici@@	O	-1	16337777
ent	O	-1	16337777
to	O	-1	16337777
prov@@	O	-1	16337777
o@@	O	-1	16337777
k@@	O	-1	16337777
e	O	-1	16337777
abnormal@@	O	-1	16337777
ities	O	-1	16337777
in	O	-1	16337777
m@@	O	-1	16337777
t@@	O	-1	16337777
D@@	O	-1	16337777
NA	O	-1	16337777
and	O	-1	16337777
in	O	-1	16337777
the	O	-1	16337777
expression	O	-1	16337777
and	O	-1	16337777
activity	O	-1	16337777
of	O	-1	16337777
cyto@@	O	-1	16337777
ch@@	O	-1	16337777
rom@@	O	-1	16337777
e	O	-1	16337777
c	O	-1	16337777
oxid@@	O	-1	16337777
ase	O	-1	16337777
(C@@	O	-1	16337777
CO@@	O	-1	16337777
),	O	-1	16337777
comple@@	O	-1	16337777
x	O	-1	16337777
IV	O	-1	16337777
of	O	-1	16337777
the	O	-1	16337777
respiratory	O	-1	16337777
ch@@	O	-1	16337777
ain@@	O	-1	16337777
,	O	-1	16337777
in	O	-1	16337777
the	O	-1	16337777
chronic	O	-1	16337777
phase	O	-1	16337777
of	O	-1	16337777
the	O	-1	16337777
pilocar@@	B-Chemical	D010862	16337777
pine	I-Chemical	-1	16337777
model	O	-1	16337777
of	O	-1	16337777
tempor@@	B-Disease	D004833	16337777
al	I-Disease	-1	16337777
lo@@	I-Disease	-1	16337777
be	I-Disease	-1	16337777
epilep@@	I-Disease	-1	16337777
sy	I-Disease	-1	16337777
.	O	-1	16337777
D@@	O	-1	16337777
NA	O	-1	16337777
analysis	O	-1	16337777
revealed	O	-1	16337777
low	O	-1	16337777
amoun@@	O	-1	16337777
ts	O	-1	16337777
of	O	-1	16337777
a	O	-1	16337777
4.@@	O	-1	16337777
8	O	-1	16337777
k@@	O	-1	16337777
b	O	-1	16337777
m@@	O	-1	16337777
t@@	O	-1	16337777
D@@	O	-1	16337777
NA	O	-1	16337777
de@@	O	-1	16337777
le@@	O	-1	16337777
tion	O	-1	16337777
but	O	-1	16337777
with	O	-1	16337777
no	O	-1	16337777
differences	O	-1	16337777
in	O	-1	16337777
frequency	O	-1	16337777
or	O	-1	16337777
qu@@	O	-1	16337777
anti@@	O	-1	16337777
t@@	O	-1	16337777
y	O	-1	16337777
in	O	-1	16337777
the	O	-1	16337777
control	O	-1	16337777
and	O	-1	16337777
experimental	O	-1	16337777
groups.	O	-1	16337777
We	O	-1	16337777
did	O	-1	16337777
not	O	-1	16337777
f@@	O	-1	16337777
ind	O	-1	16337777
abnormal@@	O	-1	16337777
ities	O	-1	16337777
in	O	-1	16337777
the	O	-1	16337777
expression	O	-1	16337777
and	O	-1	16337777
di@@	O	-1	16337777
stri@@	O	-1	16337777
bu@@	O	-1	16337777
tion	O	-1	16337777
of	O	-1	16337777
an	O	-1	16337777
m@@	O	-1	16337777
t@@	O	-1	16337777
D@@	O	-1	16337777
N@@	O	-1	16337777
A@@	O	-1	16337777
-@@	O	-1	16337777
en@@	O	-1	16337777
co@@	O	-1	16337777
ded	O	-1	16337777
sub@@	O	-1	16337777
un@@	O	-1	16337777
it	O	-1	16337777
of	O	-1	16337777
C@@	O	-1	16337777
C@@	O	-1	16337777
O	O	-1	16337777
(C@@	O	-1	16337777
CO@@	O	-1	16337777
-@@	O	-1	16337777
I@@	O	-1	16337777
)	O	-1	16337777
or	O	-1	16337777
a	O	-1	16337777
rel@@	O	-1	16337777
ative	O	-1	16337777
decrease	O	-1	16337777
in	O	-1	16337777
C@@	O	-1	16337777
CO@@	O	-1	16337777
-@@	O	-1	16337777
I	O	-1	16337777
when	O	-1	16337777
compared	O	-1	16337777
with	O	-1	16337777
n@@	O	-1	16337777
uc@@	O	-1	16337777
lear@@	O	-1	16337777
-@@	O	-1	16337777
en@@	O	-1	16337777
co@@	O	-1	16337777
ded	O	-1	16337777
sub@@	O	-1	16337777
un@@	O	-1	16337777
its	O	-1	16337777
(C@@	O	-1	16337777
CO@@	O	-1	16337777
-@@	O	-1	16337777
IV	O	-1	16337777
and	O	-1	16337777
S@@	O	-1	16337777
D@@	O	-1	16337777
H@@	O	-1	16337777
-@@	O	-1	16337777
f@@	O	-1	16337777
p@@	O	-1	16337777
).	O	-1	16337777
No	O	-1	16337777
abnormal@@	O	-1	16337777
ity	O	-1	16337777
in	O	-1	16337777
C@@	O	-1	16337777
C@@	O	-1	16337777
O	O	-1	16337777
activity	O	-1	16337777
was	O	-1	16337777
observed	O	-1	16337777
through	O	-1	16337777
histo@@	O	-1	16337777
chem@@	O	-1	16337777
ist@@	O	-1	16337777
r@@	O	-1	16337777
y.	O	-1	16337777
Although	O	-1	16337777
ev@@	O	-1	16337777
id@@	O	-1	16337777
enc@@	O	-1	16337777
es	O	-1	16337777
of	O	-1	16337777
mitochondrial	B-Disease	D028361	16337777
abnormal@@	I-Disease	-1	16337777
ities	I-Disease	-1	16337777
were	O	-1	16337777
found	O	-1	16337777
in	O	-1	16337777
previously	O	-1	16337777
pu@@	O	-1	16337777
bl@@	O	-1	16337777
ished	O	-1	16337777
studi@@	O	-1	16337777
es,	O	-1	16337777
our	O	-1	16337777
results	O	-1	16337777
d@@	O	-1	16337777
o	O	-1	16337777
not	O	-1	16337777
suggest	O	-1	16337777
that	O	-1	16337777
the	O	-1	16337777
F@@	O	-1	16337777
R@@	O	-1	16337777
s,	O	-1	16337777
gener@@	O	-1	16337777
ated	O	-1	16337777
during	O	-1	16337777
the	O	-1	16337777
acute	O	-1	16337777
ph@@	O	-1	16337777
ase,	O	-1	16337777
determined	O	-1	16337777
important	O	-1	16337777
abnormal@@	O	-1	16337777
ities	O	-1	16337777
in	O	-1	16337777
m@@	O	-1	16337777
t@@	O	-1	16337777
D@@	O	-1	16337777
N@@	O	-1	16337777
A@@	O	-1	16337777
,	O	-1	16337777
in	O	-1	16337777
expression	O	-1	16337777
of	O	-1	16337777
C@@	O	-1	16337777
CO@@	O	-1	16337777
-@@	O	-1	16337777
I@@	O	-1	16337777
,	O	-1	16337777
and	O	-1	16337777
in	O	-1	16337777
C@@	O	-1	16337777
C@@	O	-1	16337777
O	O	-1	16337777
activ@@	O	-1	16337777
ity.	O	-1	16337777

C@@	O	-1	15859940
au@@	O	-1	15859940
ses	O	-1	15859940
of	O	-1	15859940
acute	O	-1	15859940
thrombotic	B-Disease	D057049	15859940
microangio@@	I-Disease	-1	15859940
pathy	I-Disease	-1	15859940
in	O	-1	15859940
patients	O	-1	15859940
receiving	O	-1	15859940
kidney	O	-1	15859940
transplant@@	O	-1	15859940
ation.	O	-1	15859940
OBJECTIV@@	O	-1	15859940
E@@	O	-1	15859940
S:	O	-1	15859940
Th@@	B-Disease	D057049	15859940
rom@@	I-Disease	-1	15859940
bo@@	I-Disease	-1	15859940
tic	I-Disease	-1	15859940
microangio@@	I-Disease	-1	15859940
pathy	I-Disease	-1	15859940
is	O	-1	15859940
a	O	-1	15859940
we@@	O	-1	15859940
ll@@	O	-1	15859940
-@@	O	-1	15859940
known	O	-1	15859940
pro@@	O	-1	15859940
ble@@	O	-1	15859940
m	O	-1	15859940
in	O	-1	15859940
patients	O	-1	15859940
following	O	-1	15859940
renal	O	-1	15859940
transplant@@	O	-1	15859940
ation.	O	-1	15859940
In	O	-1	15859940
post@@	O	-1	15859940
renal	O	-1	15859940
transplant@@	O	-1	15859940
ation,	O	-1	15859940
thrombotic	B-Disease	D057049	15859940
microangio@@	I-Disease	-1	15859940
pathy	I-Disease	-1	15859940
is	O	-1	15859940
often	O	-1	15859940
a	O	-1	15859940
ref@@	O	-1	15859940
l@@	O	-1	15859940
ection	O	-1	15859940
of	O	-1	15859940
hemolytic	B-Disease	D006463	15859940
ure@@	I-Disease	-1	15859940
mic	I-Disease	-1	15859940
syndrome	I-Disease	-1	15859940
.	O	-1	15859940
We	O	-1	15859940
a@@	O	-1	15859940
im@@	O	-1	15859940
ed	O	-1	15859940
to	O	-1	15859940
determine	O	-1	15859940
the	O	-1	15859940
causes	O	-1	15859940
of	O	-1	15859940
thrombotic	B-Disease	D057049	15859940
microangio@@	I-Disease	-1	15859940
pathy	I-Disease	-1	15859940
in	O	-1	15859940
a	O	-1	15859940
po@@	O	-1	15859940
p@@	O	-1	15859940
ulation	O	-1	15859940
of	O	-1	15859940
renal	O	-1	15859940
transplant@@	O	-1	15859940
ation	O	-1	15859940
re@@	O	-1	15859940
ci@@	O	-1	15859940
pi@@	O	-1	15859940
ents	O	-1	15859940
and	O	-1	15859940
discus@@	O	-1	15859940
s	O	-1	15859940
the	O	-1	15859940
literat@@	O	-1	15859940
ure.	O	-1	15859940
M@@	O	-1	15859940
AT@@	O	-1	15859940
E@@	O	-1	15859940
R@@	O	-1	15859940
I@@	O	-1	15859940
AL@@	O	-1	15859940
S	O	-1	15859940
AN@@	O	-1	15859940
D	O	-1	15859940
METHODS:	O	-1	15859940
We	O	-1	15859940
investigated	O	-1	15859940
the	O	-1	15859940
causes	O	-1	15859940
of	O	-1	15859940
thrombotic	B-Disease	D057049	15859940
microangio@@	I-Disease	-1	15859940
pathy	I-Disease	-1	15859940
during	O	-1	15859940
a	O	-1	15859940
1-@@	O	-1	15859940
year	O	-1	15859940
perio@@	O	-1	15859940
d,	O	-1	15859940
from	O	-1	15859940
J@@	O	-1	15859940
un@@	O	-1	15859940
e	O	-1	15859940
20@@	O	-1	15859940
0@@	O	-1	15859940
3	O	-1	15859940
to	O	-1	15859940
J@@	O	-1	15859940
un@@	O	-1	15859940
e	O	-1	15859940
20@@	O	-1	15859940
0@@	O	-1	15859940
4@@	O	-1	15859940
,	O	-1	15859940
at	O	-1	15859940
the	O	-1	15859940
K@@	O	-1	15859940
ing	O	-1	15859940
F@@	O	-1	15859940
a@@	O	-1	15859940
had	O	-1	15859940
N@@	O	-1	15859940
ation@@	O	-1	15859940
al	O	-1	15859940
G@@	O	-1	15859940
u@@	O	-1	15859940
ard	O	-1	15859940
H@@	O	-1	15859940
ospit@@	O	-1	15859940
al	O	-1	15859940
in	O	-1	15859940
R@@	O	-1	15859940
i@@	O	-1	15859940
y@@	O	-1	15859940
ad@@	O	-1	15859940
h@@	O	-1	15859940
,	O	-1	15859940
S@@	O	-1	15859940
a@@	O	-1	15859940
ud@@	O	-1	15859940
i	O	-1	15859940
A@@	O	-1	15859940
ra@@	O	-1	15859940
b@@	O	-1	15859940
ia,	O	-1	15859940
by	O	-1	15859940
revie@@	O	-1	15859940
w@@	O	-1	15859940
ing	O	-1	15859940
the	O	-1	15859940
s@@	O	-1	15859940
li@@	O	-1	15859940
des	O	-1	15859940
of	O	-1	15859940
all	O	-1	15859940
transplant	O	-1	15859940
biop@@	O	-1	15859940
si@@	O	-1	15859940
es	O	-1	15859940
(n@@	O	-1	15859940
=@@	O	-1	15859940
25@@	O	-1	15859940
)	O	-1	15859940
performed	O	-1	15859940
during	O	-1	15859940
this	O	-1	15859940
inter@@	O	-1	15859940
val@@	O	-1	15859940
.	O	-1	15859940
Pre@@	O	-1	15859940
-	O	-1	15859940
and	O	-1	15859940
post@@	O	-1	15859940
transplant	O	-1	15859940
cros@@	O	-1	15859940
s@@	O	-1	15859940
mat@@	O	-1	15859940
ch@@	O	-1	15859940
ing	O	-1	15859940
was	O	-1	15859940
d@@	O	-1	15859940
one	O	-1	15859940
when	O	-1	15859940
possib@@	O	-1	15859940
le@@	O	-1	15859940
.	O	-1	15859940
RESULTS:	O	-1	15859940
F@@	O	-1	15859940
i@@	O	-1	15859940
ve	O	-1	15859940
cases	O	-1	15859940
of	O	-1	15859940
thrombotic	B-Disease	D057049	15859940
microangio@@	I-Disease	-1	15859940
pathy	I-Disease	-1	15859940
were	O	-1	15859940
f@@	O	-1	15859940
oun@@	O	-1	15859940
d.	O	-1	15859940
Th@@	O	-1	15859940
ree	O	-1	15859940
of	O	-1	15859940
these	O	-1	15859940
cases	O	-1	15859940
were	O	-1	15859940
from	O	-1	15859940
the	O	-1	15859940
25	O	-1	15859940
transplant@@	O	-1	15859940
ations	O	-1	15859940
performed	O	-1	15859940
at	O	-1	15859940
K@@	O	-1	15859940
ing	O	-1	15859940
F@@	O	-1	15859940
a@@	O	-1	15859940
had	O	-1	15859940
N@@	O	-1	15859940
ation@@	O	-1	15859940
al	O	-1	15859940
G@@	O	-1	15859940
u@@	O	-1	15859940
ard	O	-1	15859940
H@@	O	-1	15859940
ospit@@	O	-1	15859940
al,	O	-1	15859940
while	O	-1	15859940
the	O	-1	15859940
other	O	-1	15859940
2	O	-1	15859940
transplant@@	O	-1	15859940
ations	O	-1	15859940
had	O	-1	15859940
been	O	-1	15859940
performed	O	-1	15859940
ab@@	O	-1	15859940
ro@@	O	-1	15859940
ad	O	-1	15859940
and	O	-1	15859940
were	O	-1	15859940
ref@@	O	-1	15859940
er@@	O	-1	15859940
red	O	-1	15859940
to	O	-1	15859940
us	O	-1	15859940
for	O	-1	15859940
follow-@@	O	-1	15859940
up@@	O	-1	15859940
.	O	-1	15859940
Th@@	O	-1	15859940
ree	O	-1	15859940
cases	O	-1	15859940
were	O	-1	15859940
related	O	-1	15859940
to	O	-1	15859940
cyclospor@@	B-Chemical	D016572	15859940
ine	I-Chemical	-1	15859940
,	O	-1	15859940
and	O	-1	15859940
1	O	-1	15859940
case	O	-1	15859940
was	O	-1	15859940
secondary	O	-1	15859940
to	O	-1	15859940
both	O	-1	15859940
cyclospor@@	B-Chemical	D016572	15859940
ine	I-Chemical	-1	15859940
and	O	-1	15859940
tacrolimus	B-Chemical	D016559	15859940
.	O	-1	15859940
The	O	-1	15859940
f@@	O	-1	15859940
if@@	O	-1	15859940
th	O	-1	15859940
case	O	-1	15859940
had	O	-1	15859940
feat@@	O	-1	15859940
ures	O	-1	15859940
of	O	-1	15859940
thrombotic	B-Disease	D057049	15859940
microangio@@	I-Disease	-1	15859940
pathy	I-Disease	-1	15859940
related	O	-1	15859940
to	O	-1	15859940
an	O	-1	15859940
anti@@	B-Disease	D016736	15859940
phosph@@	I-Disease	-1	15859940
ol@@	I-Disease	-1	15859940
i@@	I-Disease	-1	15859940
pid	I-Disease	-1	15859940
syndrome	I-Disease	-1	15859940
in	O	-1	15859940
a	O	-1	15859940
patient	O	-1	15859940
with	O	-1	15859940
systemic	B-Disease	D008180	15859940
lu@@	I-Disease	-1	15859940
p@@	I-Disease	-1	15859940
us	I-Disease	-1	15859940
eryth@@	I-Disease	-1	15859940
em@@	I-Disease	-1	15859940
at@@	I-Disease	-1	15859940
os@@	I-Disease	-1	15859940
us	I-Disease	-1	15859940
.	O	-1	15859940
CONCLUSIONS:	O	-1	15859940
In	O	-1	15859940
the	O	-1	15859940
literat@@	O	-1	15859940
ure,	O	-1	15859940
the	O	-1	15859940
mo@@	O	-1	15859940
st@@	O	-1	15859940
-@@	O	-1	15859940
frequent	O	-1	15859940
cause	O	-1	15859940
of	O	-1	15859940
hemolytic	B-Disease	D006463	15859940
ure@@	I-Disease	-1	15859940
mic	I-Disease	-1	15859940
syndrome	I-Disease	-1	15859940
in	O	-1	15859940
patients	O	-1	15859940
following	O	-1	15859940
renal	O	-1	15859940
transplant@@	O	-1	15859940
ation	O	-1	15859940
is	O	-1	15859940
recur@@	O	-1	15859940
rence	O	-1	15859940
of	O	-1	15859940
the	O	-1	15859940
hemolytic	B-Disease	D006463	15859940
ure@@	I-Disease	-1	15859940
mic	I-Disease	-1	15859940
syndrome	I-Disease	-1	15859940
.	O	-1	15859940
O@@	O	-1	15859940
ther	O	-1	15859940
causes	O	-1	15859940
includ@@	O	-1	15859940
e	O	-1	15859940
drug@@	O	-1	15859940
-@@	O	-1	15859940
related	O	-1	15859940
(	O	-1	15859940
cyclospor@@	B-Chemical	D016572	15859940
ine	I-Chemical	-1	15859940
,	O	-1	15859940
tacrolimus	B-Chemical	D016559	15859940
)	O	-1	15859940
toxicity	B-Disease	D064420	15859940
,	O	-1	15859940
pro@@	O	-1	15859940
co@@	O	-1	15859940
ag@@	O	-1	15859940
ul@@	O	-1	15859940
ant	O	-1	15859940
stat@@	O	-1	15859940
us,	O	-1	15859940
and	O	-1	15859940
anti@@	O	-1	15859940
bo@@	O	-1	15859940
dy@@	O	-1	15859940
-@@	O	-1	15859940
mediated	O	-1	15859940
re@@	O	-1	15859940
j@@	O	-1	15859940
ec@@	O	-1	15859940
tion.	O	-1	15859940
We	O	-1	15859940
found	O	-1	15859940
that	O	-1	15859940
the	O	-1	15859940
mo@@	O	-1	15859940
st@@	O	-1	15859940
-@@	O	-1	15859940
frequent	O	-1	15859940
cause	O	-1	15859940
of	O	-1	15859940
thrombotic	B-Disease	D057049	15859940
microangio@@	I-Disease	-1	15859940
pathy	I-Disease	-1	15859940
was	O	-1	15859940
drug	O	-1	15859940
rel@@	O	-1	15859940
at@@	O	-1	15859940
ed,	O	-1	15859940
secondary	O	-1	15859940
main@@	O	-1	15859940
ly	O	-1	15859940
to	O	-1	15859940
cyclospor@@	B-Chemical	D016572	15859940
ine	I-Chemical	-1	15859940
.	O	-1	15859940
In	O	-1	15859940
the	O	-1	15859940
current	O	-1	15859940
study,	O	-1	15859940
the	O	-1	15859940
frequency	O	-1	15859940
of	O	-1	15859940
thrombotic	B-Disease	D057049	15859940
microangio@@	I-Disease	-1	15859940
pathy	I-Disease	-1	15859940
was	O	-1	15859940
similar	O	-1	15859940
to	O	-1	15859940
the	O	-1	15859940
perc@@	O	-1	15859940
ent@@	O	-1	15859940
age	O	-1	15859940
reported	O	-1	15859940
in	O	-1	15859940
the	O	-1	15859940
literat@@	O	-1	15859940
ure	O	-1	15859940
(2@@	O	-1	15859940
0@@	O	-1	15859940
%).	O	-1	15859940

S@@	O	-1	15188772
ev@@	O	-1	15188772
ere	O	-1	15188772
reversible	O	-1	15188772
left	B-Disease	D018487	15188772
ventricular	I-Disease	-1	15188772
systolic	I-Disease	-1	15188772
and	I-Disease	-1	15188772
di@@	I-Disease	-1	15188772
ast@@	I-Disease	-1	15188772
olic	I-Disease	-1	15188772
dysfunction	I-Disease	-1	15188772
due	O	-1	15188772
to	O	-1	15188772
ac@@	O	-1	15188772
c@@	O	-1	15188772
id@@	O	-1	15188772
ental	O	-1	15188772
i@@	O	-1	15188772
atro@@	O	-1	15188772
genic	O	-1	15188772
ep@@	B-Chemical	D004837	15188772
ine@@	I-Chemical	-1	15188772
phrine	I-Chemical	-1	15188772
over@@	B-Disease	D062787	15188772
dose	I-Disease	-1	15188772
.	O	-1	15188772
C@@	B-Chemical	D002395	15188772
at@@	I-Chemical	-1	15188772
ech@@	I-Chemical	-1	15188772
ol@@	I-Chemical	-1	15188772
amine	I-Chemical	-1	15188772
-induced	O	-1	15188772
cardi@@	B-Disease	D009202	15188772
om@@	I-Disease	-1	15188772
yo@@	I-Disease	-1	15188772
pathy	I-Disease	-1	15188772
due	O	-1	15188772
to	O	-1	15188772
chronic	O	-1	15188772
ex@@	O	-1	15188772
cess	O	-1	15188772
of	O	-1	15188772
endo@@	O	-1	15188772
gen@@	O	-1	15188772
ous	O	-1	15188772
cat@@	B-Chemical	D002395	15188772
ech@@	I-Chemical	-1	15188772
ol@@	I-Chemical	-1	15188772
amin@@	I-Chemical	-1	15188772
es	I-Chemical	-1	15188772
has	O	-1	15188772
been	O	-1	15188772
reco@@	O	-1	15188772
gn@@	O	-1	15188772
ized	O	-1	15188772
for	O	-1	15188772
dec@@	O	-1	15188772
a@@	O	-1	15188772
des	O	-1	15188772
as	O	-1	15188772
a	O	-1	15188772
clinical	O	-1	15188772
phen@@	O	-1	15188772
om@@	O	-1	15188772
en@@	O	-1	15188772
on@@	O	-1	15188772
.	O	-1	15188772
In	O	-1	15188772
contrast@@	O	-1	15188772
,	O	-1	15188772
reports	O	-1	15188772
of	O	-1	15188772
myocardial	B-Disease	D009202	15188772
dysfunction	I-Disease	-1	15188772
due	O	-1	15188772
to	O	-1	15188772
acute	O	-1	15188772
i@@	O	-1	15188772
atro@@	O	-1	15188772
genic	O	-1	15188772
over@@	B-Disease	D062787	15188772
dose	I-Disease	-1	15188772
are	O	-1	15188772
ra@@	O	-1	15188772
re.	O	-1	15188772
A	O	-1	15188772
3@@	O	-1	15188772
5-@@	O	-1	15188772
year-old	O	-1	15188772
woman	O	-1	15188772
wh@@	O	-1	15188772
ose	O	-1	15188772
cer@@	O	-1	15188772
vi@@	O	-1	15188772
x	O	-1	15188772
u@@	O	-1	15188772
ter@@	O	-1	15188772
i	O	-1	15188772
was	O	-1	15188772
in@@	O	-1	15188772
ad@@	O	-1	15188772
ver@@	O	-1	15188772
t@@	O	-1	15188772
ently	O	-1	15188772
injected	O	-1	15188772
with	O	-1	15188772
8	O	-1	15188772
mg	O	-1	15188772
of	O	-1	15188772
ep@@	B-Chemical	D004837	15188772
ine@@	I-Chemical	-1	15188772
phrine	I-Chemical	-1	15188772
developed	O	-1	15188772
myocardial	B-Disease	D017682	15188772
st@@	I-Disease	-1	15188772
un@@	I-Disease	-1	15188772
ning	I-Disease	-1	15188772
that	O	-1	15188772
was	O	-1	15188772
character@@	O	-1	15188772
ized	O	-1	15188772
by	O	-1	15188772
severe	O	-1	15188772
hemo@@	O	-1	15188772
dynam@@	O	-1	15188772
ic	O	-1	15188772
com@@	O	-1	15188772
pro@@	O	-1	15188772
mi@@	O	-1	15188772
se@@	O	-1	15188772
,	O	-1	15188772
prof@@	O	-1	15188772
oun@@	O	-1	15188772
d,	O	-1	15188772
al@@	O	-1	15188772
be@@	O	-1	15188772
it	O	-1	15188772
transi@@	O	-1	15188772
ent@@	O	-1	15188772
,	O	-1	15188772
left	B-Disease	D018487	15188772
ventricular	I-Disease	-1	15188772
systolic	I-Disease	-1	15188772
and	I-Disease	-1	15188772
di@@	I-Disease	-1	15188772
ast@@	I-Disease	-1	15188772
olic	I-Disease	-1	15188772
dysfunction	I-Disease	-1	15188772
,	O	-1	15188772
and	O	-1	15188772
only	O	-1	15188772
mode@@	O	-1	15188772
st@@	O	-1	15188772
ly	O	-1	15188772
elevated	O	-1	15188772
bio@@	O	-1	15188772
chemical	O	-1	15188772
mark@@	O	-1	15188772
ers	O	-1	15188772
of	O	-1	15188772
myocardial	B-Disease	D009202	15188772
necro@@	I-Disease	-1	15188772
sis	I-Disease	-1	15188772
.	O	-1	15188772
Our	O	-1	15188772
case	O	-1	15188772
il@@	O	-1	15188772
lu@@	O	-1	15188772
strat@@	O	-1	15188772
es	O	-1	15188772
the	O	-1	15188772
seri@@	O	-1	15188772
ous	O	-1	15188772
con@@	O	-1	15188772
sequ@@	O	-1	15188772
enc@@	O	-1	15188772
es	O	-1	15188772
of	O	-1	15188772
med@@	O	-1	15188772
ical	O	-1	15188772
er@@	O	-1	15188772
ro@@	O	-1	15188772
r@@	O	-1	15188772
s	O	-1	15188772
that	O	-1	15188772
can	O	-1	15188772
be	O	-1	15188772
avoid@@	O	-1	15188772
ed	O	-1	15188772
through	O	-1	15188772
improved	O	-1	15188772
medic@@	O	-1	15188772
ation	O	-1	15188772
l@@	O	-1	15188772
a@@	O	-1	15188772
be@@	O	-1	15188772
l@@	O	-1	15188772
ing	O	-1	15188772
and	O	-1	15188772
st@@	O	-1	15188772
af@@	O	-1	15188772
f	O	-1	15188772
su@@	O	-1	15188772
per@@	O	-1	15188772
vi@@	O	-1	15188772
sion.	O	-1	15188772

U@@	B-Disease	D001749	15130900
r@@	I-Disease	-1	15130900
inary	I-Disease	-1	15130900
bladder	I-Disease	-1	15130900
cancer	I-Disease	-1	15130900
in	O	-1	15130900
W@@	B-Disease	D014890	15130900
e@@	I-Disease	-1	15130900
gener@@	I-Disease	-1	15130900
's	I-Disease	-1	15130900
gran@@	I-Disease	-1	15130900
ulo@@	I-Disease	-1	15130900
mat@@	I-Disease	-1	15130900
o@@	I-Disease	-1	15130900
sis	I-Disease	-1	15130900
:	O	-1	15130900
ris@@	O	-1	15130900
k@@	O	-1	15130900
s	O	-1	15130900
and	O	-1	15130900
rel@@	O	-1	15130900
ation	O	-1	15130900
to	O	-1	15130900
cyclophosph@@	B-Chemical	D003520	15130900
amide	I-Chemical	-1	15130900
.	O	-1	15130900
OBJECTIVE:	O	-1	15130900
To	O	-1	15130900
ass@@	O	-1	15130900
ess	O	-1	15130900
and	O	-1	15130900
character@@	O	-1	15130900
is@@	O	-1	15130900
e	O	-1	15130900
the	O	-1	15130900
risk	O	-1	15130900
of	O	-1	15130900
bladder	B-Disease	D001749	15130900
cancer	I-Disease	-1	15130900
,	O	-1	15130900
and	O	-1	15130900
its	O	-1	15130900
rel@@	O	-1	15130900
ation	O	-1	15130900
to	O	-1	15130900
cyclophosph@@	B-Chemical	D003520	15130900
amide	I-Chemical	-1	15130900
,	O	-1	15130900
in	O	-1	15130900
patients	O	-1	15130900
with	O	-1	15130900
W@@	B-Disease	D014890	15130900
e@@	I-Disease	-1	15130900
gener@@	I-Disease	-1	15130900
's	I-Disease	-1	15130900
gran@@	I-Disease	-1	15130900
ulo@@	I-Disease	-1	15130900
mat@@	I-Disease	-1	15130900
o@@	I-Disease	-1	15130900
sis	I-Disease	-1	15130900
.	O	-1	15130900
METHODS:	O	-1	15130900
In	O	-1	15130900
the	O	-1	15130900
po@@	O	-1	15130900
p@@	O	-1	15130900
ulation	O	-1	15130900
bas@@	O	-1	15130900
ed,	O	-1	15130900
n@@	O	-1	15130900
ation@@	O	-1	15130900
w@@	O	-1	15130900
ide	O	-1	15130900
S@@	O	-1	15130900
we@@	O	-1	15130900
dis@@	O	-1	15130900
h	O	-1	15130900
In@@	O	-1	15130900
patient	O	-1	15130900
Re@@	O	-1	15130900
g@@	O	-1	15130900
ist@@	O	-1	15130900
er	O	-1	15130900
a	O	-1	15130900
co@@	O	-1	15130900
h@@	O	-1	15130900
ort	O	-1	15130900
of	O	-1	15130900
10@@	O	-1	15130900
6@@	O	-1	15130900
5	O	-1	15130900
patients	O	-1	15130900
with	O	-1	15130900
W@@	B-Disease	D014890	15130900
e@@	I-Disease	-1	15130900
gener@@	I-Disease	-1	15130900
's	I-Disease	-1	15130900
gran@@	I-Disease	-1	15130900
ulo@@	I-Disease	-1	15130900
mat@@	I-Disease	-1	15130900
o@@	I-Disease	-1	15130900
sis	I-Disease	-1	15130900
,	O	-1	15130900
19@@	O	-1	15130900
6@@	O	-1	15130900
9@@	O	-1	15130900
-@@	O	-1	15130900
9@@	O	-1	15130900
5,	O	-1	15130900
was	O	-1	15130900
identi@@	O	-1	15130900
fi@@	O	-1	15130900
ed.	O	-1	15130900
Th@@	O	-1	15130900
rou@@	O	-1	15130900
gh	O	-1	15130900
lin@@	O	-1	15130900
k@@	O	-1	15130900
age	O	-1	15130900
with	O	-1	15130900
the	O	-1	15130900
S@@	O	-1	15130900
we@@	O	-1	15130900
dis@@	O	-1	15130900
h	O	-1	15130900
C@@	B-Disease	D009369	15130900
anc@@	I-Disease	-1	15130900
er	I-Disease	-1	15130900
Re@@	O	-1	15130900
g@@	O	-1	15130900
ist@@	O	-1	15130900
er,	O	-1	15130900
all	O	-1	15130900
subjects	O	-1	15130900
in	O	-1	15130900
this	O	-1	15130900
co@@	O	-1	15130900
h@@	O	-1	15130900
ort	O	-1	15130900
diagnos@@	O	-1	15130900
ed	O	-1	15130900
with	O	-1	15130900
bladder	B-Disease	D001749	15130900
cancer	I-Disease	-1	15130900
were	O	-1	15130900
identi@@	O	-1	15130900
fi@@	O	-1	15130900
ed.	O	-1	15130900
N@@	O	-1	15130900
est@@	O	-1	15130900
ed	O	-1	15130900
within	O	-1	15130900
the	O	-1	15130900
co@@	O	-1	15130900
h@@	O	-1	15130900
ort@@	O	-1	15130900
,	O	-1	15130900
a	O	-1	15130900
mat@@	O	-1	15130900
ch@@	O	-1	15130900
ed	O	-1	15130900
cas@@	O	-1	15130900
e-@@	O	-1	15130900
control	O	-1	15130900
study	O	-1	15130900
was	O	-1	15130900
performed	O	-1	15130900
to	O	-1	15130900
estim@@	O	-1	15130900
ate	O	-1	15130900
the	O	-1	15130900
association	O	-1	15130900
between	O	-1	15130900
cyclophosph@@	B-Chemical	D003520	15130900
amide	I-Chemical	-1	15130900
and	O	-1	15130900
bladder	B-Disease	D001749	15130900
cancer	I-Disease	-1	15130900
using	O	-1	15130900
o@@	O	-1	15130900
d@@	O	-1	15130900
ds	O	-1	15130900
rati@@	O	-1	15130900
o@@	O	-1	15130900
s	O	-1	15130900
(@@	O	-1	15130900
O@@	O	-1	15130900
R@@	O	-1	15130900
s)	O	-1	15130900
as	O	-1	15130900
rel@@	O	-1	15130900
ative	O	-1	15130900
ris@@	O	-1	15130900
k@@	O	-1	15130900
.	O	-1	15130900
In	O	-1	15130900
the	O	-1	15130900
co@@	O	-1	15130900
h@@	O	-1	15130900
ort	O	-1	15130900
the	O	-1	15130900
cum@@	O	-1	15130900
ul@@	O	-1	15130900
ative	O	-1	15130900
risk	O	-1	15130900
of	O	-1	15130900
bladder	B-Disease	D001749	15130900
cancer	I-Disease	-1	15130900
after	O	-1	15130900
W@@	B-Disease	D014890	15130900
e@@	I-Disease	-1	15130900
gener@@	I-Disease	-1	15130900
's	I-Disease	-1	15130900
gran@@	I-Disease	-1	15130900
ulo@@	I-Disease	-1	15130900
mat@@	I-Disease	-1	15130900
o@@	I-Disease	-1	15130900
sis	I-Disease	-1	15130900
,	O	-1	15130900
and	O	-1	15130900
the	O	-1	15130900
rel@@	O	-1	15130900
ative	O	-1	15130900
prev@@	O	-1	15130900
al@@	O	-1	15130900
ence	O	-1	15130900
of	O	-1	15130900
a	O	-1	15130900
hist@@	O	-1	15130900
ory	O	-1	15130900
of	O	-1	15130900
bladder	B-Disease	D001749	15130900
cancer	I-Disease	-1	15130900
at	O	-1	15130900
the	O	-1	15130900
time	O	-1	15130900
of	O	-1	15130900
diagnosis	O	-1	15130900
of	O	-1	15130900
W@@	B-Disease	D014890	15130900
e@@	I-Disease	-1	15130900
gener@@	I-Disease	-1	15130900
's	I-Disease	-1	15130900
gran@@	I-Disease	-1	15130900
ulo@@	I-Disease	-1	15130900
mat@@	I-Disease	-1	15130900
o@@	I-Disease	-1	15130900
sis	I-Disease	-1	15130900
,	O	-1	15130900
were	O	-1	15130900
also	O	-1	15130900
estim@@	O	-1	15130900
ated.	O	-1	15130900
RESULTS:	O	-1	15130900
The	O	-1	15130900
median	O	-1	15130900
cum@@	O	-1	15130900
ul@@	O	-1	15130900
ative	O	-1	15130900
doses	O	-1	15130900
of	O	-1	15130900
cyclophosph@@	B-Chemical	D003520	15130900
amide	I-Chemical	-1	15130900
among	O	-1	15130900
cases	O	-1	15130900
(n	O	-1	15130900
=	O	-1	15130900
1@@	O	-1	15130900
1)	O	-1	15130900
and	O	-1	15130900
controls	O	-1	15130900
(n	O	-1	15130900
=	O	-1	15130900
25@@	O	-1	15130900
)	O	-1	15130900
were	O	-1	15130900
1@@	O	-1	15130900
13	O	-1	15130900
g	O	-1	15130900
and	O	-1	15130900
25	O	-1	15130900
g@@	O	-1	15130900
,	O	-1	15130900
respectively.	O	-1	15130900
The	O	-1	15130900
risk	O	-1	15130900
of	O	-1	15130900
bladder	B-Disease	D001749	15130900
cancer	I-Disease	-1	15130900
dou@@	O	-1	15130900
bl@@	O	-1	15130900
ed	O	-1	15130900
for	O	-1	15130900
every	O	-1	15130900
10	O	-1	15130900
g	O	-1	15130900
inc@@	O	-1	15130900
re@@	O	-1	15130900
ment	O	-1	15130900
in	O	-1	15130900
cyclophosph@@	B-Chemical	D003520	15130900
amide	I-Chemical	-1	15130900
(@@	O	-1	15130900
O@@	O	-1	15130900
R	O	-1	15130900
=	O	-1	15130900
2.@@	O	-1	15130900
0@@	O	-1	15130900
,	O	-1	15130900
95%	O	-1	15130900
conf@@	O	-1	15130900
idence	O	-1	15130900
interv@@	O	-1	15130900
al	O	-1	15130900
(C@@	O	-1	15130900
I@@	O	-1	15130900
)	O	-1	15130900
0.@@	O	-1	15130900
8	O	-1	15130900
to	O	-1	15130900
4.@@	O	-1	15130900
9@@	O	-1	15130900
).	O	-1	15130900
Treat@@	O	-1	15130900
ment	O	-1	15130900
duration	O	-1	15130900
long@@	O	-1	15130900
er	O	-1	15130900
than	O	-1	15130900
1	O	-1	15130900
year	O	-1	15130900
was	O	-1	15130900
associated	O	-1	15130900
with	O	-1	15130900
an	O	-1	15130900
e@@	O	-1	15130900
igh@@	O	-1	15130900
t@@	O	-1	15130900
fol@@	O	-1	15130900
d	O	-1	15130900
increased	O	-1	15130900
risk	O	-1	15130900
(@@	O	-1	15130900
O@@	O	-1	15130900
R	O	-1	15130900
=	O	-1	15130900
7.@@	O	-1	15130900
7@@	O	-1	15130900
,	O	-1	15130900
95%	O	-1	15130900
C@@	O	-1	15130900
I	O	-1	15130900
0.@@	O	-1	15130900
9	O	-1	15130900
to	O	-1	15130900
6@@	O	-1	15130900
9@@	O	-1	15130900
).	O	-1	15130900
The	O	-1	15130900
abs@@	O	-1	15130900
ol@@	O	-1	15130900
ute	O	-1	15130900
risk	O	-1	15130900
for	O	-1	15130900
bladder	B-Disease	D001749	15130900
cancer	I-Disease	-1	15130900
in	O	-1	15130900
the	O	-1	15130900
co@@	O	-1	15130900
h@@	O	-1	15130900
ort	O	-1	15130900
reac@@	O	-1	15130900
h@@	O	-1	15130900
ed	O	-1	15130900
10@@	O	-1	15130900
%	O	-1	15130900
16	O	-1	15130900
years	O	-1	15130900
after	O	-1	15130900
diagnosis	O	-1	15130900
of	O	-1	15130900
W@@	B-Disease	D014890	15130900
e@@	I-Disease	-1	15130900
gener@@	I-Disease	-1	15130900
's	I-Disease	-1	15130900
gran@@	I-Disease	-1	15130900
ulo@@	I-Disease	-1	15130900
mat@@	I-Disease	-1	15130900
o@@	I-Disease	-1	15130900
sis	I-Disease	-1	15130900
,	O	-1	15130900
and	O	-1	15130900
a	O	-1	15130900
hist@@	O	-1	15130900
ory	O	-1	15130900
of	O	-1	15130900
bladder	B-Disease	D001749	15130900
cancer	I-Disease	-1	15130900
was	O	-1	15130900
(@@	O	-1	15130900
non-@@	O	-1	15130900
significant@@	O	-1	15130900
ly@@	O	-1	15130900
)	O	-1	15130900
tw@@	O	-1	15130900
ic@@	O	-1	15130900
e	O	-1	15130900
as	O	-1	15130900
common	O	-1	15130900
as	O	-1	15130900
ex@@	O	-1	15130900
p@@	O	-1	15130900
ected	O	-1	15130900
at	O	-1	15130900
the	O	-1	15130900
time	O	-1	15130900
of	O	-1	15130900
diagnosis	O	-1	15130900
of	O	-1	15130900
W@@	B-Disease	D014890	15130900
e@@	I-Disease	-1	15130900
gener@@	I-Disease	-1	15130900
's	I-Disease	-1	15130900
gran@@	I-Disease	-1	15130900
ulo@@	I-Disease	-1	15130900
mat@@	I-Disease	-1	15130900
o@@	I-Disease	-1	15130900
sis	I-Disease	-1	15130900
.	O	-1	15130900
CONCLUSION:	O	-1	15130900
The	O	-1	15130900
results	O	-1	15130900
indicate	O	-1	15130900
a	O	-1	15130900
dose-@@	O	-1	15130900
response	O	-1	15130900
rel@@	O	-1	15130900
ationship	O	-1	15130900
between	O	-1	15130900
cyclophosph@@	B-Chemical	D003520	15130900
amide	I-Chemical	-1	15130900
and	O	-1	15130900
the	O	-1	15130900
risk	O	-1	15130900
of	O	-1	15130900
bladder	B-Disease	D001749	15130900
cancer	I-Disease	-1	15130900
,	O	-1	15130900
high	O	-1	15130900
cum@@	O	-1	15130900
ul@@	O	-1	15130900
ative	O	-1	15130900
ris@@	O	-1	15130900
k@@	O	-1	15130900
s	O	-1	15130900
in	O	-1	15130900
the	O	-1	15130900
enti@@	O	-1	15130900
r@@	O	-1	15130900
e	O	-1	15130900
co@@	O	-1	15130900
h@@	O	-1	15130900
ort@@	O	-1	15130900
,	O	-1	15130900
and	O	-1	15130900
also	O	-1	15130900
the	O	-1	15130900
possib@@	O	-1	15130900
ility	O	-1	15130900
of	O	-1	15130900
risk	O	-1	15130900
factors	O	-1	15130900
o@@	O	-1	15130900
per@@	O	-1	15130900
ating	O	-1	15130900
even	O	-1	15130900
before	O	-1	15130900
W@@	B-Disease	D014890	15130900
e@@	I-Disease	-1	15130900
gener@@	I-Disease	-1	15130900
's	I-Disease	-1	15130900
gran@@	I-Disease	-1	15130900
ulo@@	I-Disease	-1	15130900
mat@@	I-Disease	-1	15130900
o@@	I-Disease	-1	15130900
sis	I-Disease	-1	15130900
.	O	-1	15130900

L-@@	B-Chemical	D001120	12707296
arg@@	I-Chemical	-1	12707296
inine	I-Chemical	-1	12707296
trans@@	O	-1	12707296
por@@	O	-1	12707296
t	O	-1	12707296
in	O	-1	12707296
hum@@	O	-1	12707296
ans	O	-1	12707296
with	O	-1	12707296
cor@@	B-Chemical	D006854	12707296
tis@@	I-Chemical	-1	12707296
ol	I-Chemical	-1	12707296
-induced	O	-1	12707296
hypertension	B-Disease	D006973	12707296
.	O	-1	12707296
A	O	-1	12707296
defici@@	O	-1	12707296
ent	O	-1	12707296
L-@@	B-Chemical	D001120	12707296
arg@@	I-Chemical	-1	12707296
inine	I-Chemical	-1	12707296
-	O	-1	12707296
nit@@	B-Chemical	D009569	12707296
ric	I-Chemical	-1	12707296
ox@@	I-Chemical	-1	12707296
ide	I-Chemical	-1	12707296
system	O	-1	12707296
is	O	-1	12707296
implic@@	O	-1	12707296
ated	O	-1	12707296
in	O	-1	12707296
cor@@	B-Chemical	D006854	12707296
tis@@	I-Chemical	-1	12707296
ol	I-Chemical	-1	12707296
-induced	O	-1	12707296
hypertension	B-Disease	D006973	12707296
.	O	-1	12707296
We	O	-1	12707296
investigate	O	-1	12707296
whether	O	-1	12707296
abnormal@@	O	-1	12707296
ities	O	-1	12707296
in	O	-1	12707296
L-@@	B-Chemical	D001120	12707296
arg@@	I-Chemical	-1	12707296
inine	I-Chemical	-1	12707296
u@@	O	-1	12707296
pt@@	O	-1	12707296
ake	O	-1	12707296
cont@@	O	-1	12707296
rib@@	O	-1	12707296
ute	O	-1	12707296
to	O	-1	12707296
this	O	-1	12707296
defici@@	O	-1	12707296
enc@@	O	-1	12707296
y.	O	-1	12707296
E@@	O	-1	12707296
ight	O	-1	12707296
healthy	O	-1	12707296
men	O	-1	12707296
were	O	-1	12707296
rec@@	O	-1	12707296
ru@@	O	-1	12707296
it@@	O	-1	12707296
ed.	O	-1	12707296
H@@	B-Chemical	C021650	12707296
y@@	I-Chemical	-1	12707296
dro@@	I-Chemical	-1	12707296
cor@@	I-Chemical	-1	12707296
tis@@	I-Chemical	-1	12707296
one	I-Chemical	-1	12707296
acet@@	I-Chemical	-1	12707296
ate	I-Chemical	-1	12707296
(@@	O	-1	12707296
50	O	-1	12707296
mg@@	O	-1	12707296
)	O	-1	12707296
was	O	-1	12707296
given	O	-1	12707296
or@@	O	-1	12707296
ally	O	-1	12707296
every	O	-1	12707296
6	O	-1	12707296
hours	O	-1	12707296
for	O	-1	12707296
24	O	-1	12707296
hours	O	-1	12707296
after	O	-1	12707296
a	O	-1	12707296
5-@@	O	-1	12707296
day	O	-1	12707296
fi@@	O	-1	12707296
x@@	O	-1	12707296
ed@@	O	-1	12707296
-@@	O	-1	12707296
sal@@	O	-1	12707296
t	O	-1	12707296
diet	O	-1	12707296
(1@@	O	-1	12707296
50	O	-1	12707296
m@@	O	-1	12707296
mol@@	O	-1	12707296
/@@	O	-1	12707296
d@@	O	-1	12707296
).	O	-1	12707296
C@@	O	-1	12707296
ros@@	O	-1	12707296
s@@	O	-1	12707296
over	O	-1	12707296
studies	O	-1	12707296
were	O	-1	12707296
performed	O	-1	12707296
2	O	-1	12707296
weeks	O	-1	12707296
ap@@	O	-1	12707296
ar@@	O	-1	12707296
t.	O	-1	12707296
Th@@	O	-1	12707296
ir@@	O	-1	12707296
t@@	O	-1	12707296
y	O	-1	12707296
mil@@	O	-1	12707296
l@@	O	-1	12707296
il@@	O	-1	12707296
it@@	O	-1	12707296
ers	O	-1	12707296
of	O	-1	12707296
blood	O	-1	12707296
was	O	-1	12707296
obtained	O	-1	12707296
for	O	-1	12707296
isol@@	O	-1	12707296
ation	O	-1	12707296
of	O	-1	12707296
peripheral	O	-1	12707296
blood	O	-1	12707296
mon@@	O	-1	12707296
on@@	O	-1	12707296
ucle@@	O	-1	12707296
ar	O	-1	12707296
cells	O	-1	12707296
after	O	-1	12707296
each	O	-1	12707296
treatment	O	-1	12707296
perio@@	O	-1	12707296
d.	O	-1	12707296
L-@@	B-Chemical	D001120	12707296
arg@@	I-Chemical	-1	12707296
inine	I-Chemical	-1	12707296
u@@	O	-1	12707296
pt@@	O	-1	12707296
ake	O	-1	12707296
was	O	-1	12707296
assessed	O	-1	12707296
in	O	-1	12707296
mon@@	O	-1	12707296
on@@	O	-1	12707296
ucle@@	O	-1	12707296
ar	O	-1	12707296
cells	O	-1	12707296
inc@@	O	-1	12707296
ub@@	O	-1	12707296
ated	O	-1	12707296
with	O	-1	12707296
L-@@	B-Chemical	D001120	12707296
arg@@	I-Chemical	-1	12707296
inine	I-Chemical	-1	12707296
(@@	O	-1	12707296
1	O	-1	12707296
to	O	-1	12707296
3@@	O	-1	12707296
00	O	-1	12707296
mic@@	O	-1	12707296
rom@@	O	-1	12707296
ol@@	O	-1	12707296
/@@	O	-1	12707296
L@@	O	-1	12707296
),	O	-1	12707296
inc@@	O	-1	12707296
or@@	O	-1	12707296
por@@	O	-1	12707296
ating	O	-1	12707296
100	O	-1	12707296
n@@	O	-1	12707296
mol@@	O	-1	12707296
/@@	O	-1	12707296
L	O	-1	12707296
[@@	B-Chemical	D001120	12707296
3@@	I-Chemical	-1	12707296
H@@	I-Chemical	-1	12707296
]@@	I-Chemical	-1	12707296
-@@	I-Chemical	-1	12707296
l@@	I-Chemical	-1	12707296
-@@	I-Chemical	-1	12707296
arg@@	I-Chemical	-1	12707296
inine	I-Chemical	-1	12707296
for	O	-1	12707296
a	O	-1	12707296
period	O	-1	12707296
of	O	-1	12707296
5	O	-1	12707296
minutes	O	-1	12707296
at	O	-1	12707296
3@@	O	-1	12707296
7	O	-1	12707296
de@@	O	-1	12707296
gre@@	O	-1	12707296
es	O	-1	12707296
C@@	O	-1	12707296
.	O	-1	12707296
F@@	O	-1	12707296
ore@@	O	-1	12707296
ar@@	O	-1	12707296
m	O	-1	12707296
[@@	B-Chemical	D001120	12707296
3@@	I-Chemical	-1	12707296
H@@	I-Chemical	-1	12707296
]@@	I-Chemical	-1	12707296
-@@	I-Chemical	-1	12707296
L-@@	I-Chemical	-1	12707296
arg@@	I-Chemical	-1	12707296
inine	I-Chemical	-1	12707296
extrac@@	O	-1	12707296
tion	O	-1	12707296
was	O	-1	12707296
calc@@	O	-1	12707296
ul@@	O	-1	12707296
ated	O	-1	12707296
after	O	-1	12707296
infusion	O	-1	12707296
of	O	-1	12707296
[@@	B-Chemical	D001120	12707296
3@@	I-Chemical	-1	12707296
H@@	I-Chemical	-1	12707296
]@@	I-Chemical	-1	12707296
-@@	I-Chemical	-1	12707296
L-@@	I-Chemical	-1	12707296
arg@@	I-Chemical	-1	12707296
inine	I-Chemical	-1	12707296
into	O	-1	12707296
the	O	-1	12707296
b@@	O	-1	12707296
rac@@	O	-1	12707296
hi@@	O	-1	12707296
al	O	-1	12707296
artery	O	-1	12707296
at	O	-1	12707296
a	O	-1	12707296
rate	O	-1	12707296
of	O	-1	12707296
100	O	-1	12707296
n@@	O	-1	12707296
C@@	O	-1	12707296
i@@	O	-1	12707296
/@@	O	-1	12707296
min	O	-1	12707296
for	O	-1	12707296
8@@	O	-1	12707296
0	O	-1	12707296
minut@@	O	-1	12707296
es.	O	-1	12707296
De@@	O	-1	12707296
ep	O	-1	12707296
fo@@	O	-1	12707296
re@@	O	-1	12707296
ar@@	O	-1	12707296
m	O	-1	12707296
venous	O	-1	12707296
sam@@	O	-1	12707296
ple@@	O	-1	12707296
s	O	-1	12707296
were	O	-1	12707296
coll@@	O	-1	12707296
ected	O	-1	12707296
for	O	-1	12707296
determin@@	O	-1	12707296
ation	O	-1	12707296
of	O	-1	12707296
L-@@	B-Chemical	D001120	12707296
arg@@	I-Chemical	-1	12707296
inine	I-Chemical	-1	12707296
extrac@@	O	-1	12707296
tion.	O	-1	12707296
P@@	O	-1	12707296
las@@	O	-1	12707296
ma	O	-1	12707296
cor@@	B-Chemical	D006854	12707296
tis@@	I-Chemical	-1	12707296
ol	I-Chemical	-1	12707296
concentrations	O	-1	12707296
were	O	-1	12707296
significantly	O	-1	12707296
ra@@	O	-1	12707296
is@@	O	-1	12707296
ed	O	-1	12707296
during	O	-1	12707296
the	O	-1	12707296
active	O	-1	12707296
phase	O	-1	12707296
(3@@	O	-1	12707296
2@@	O	-1	12707296
3@@	O	-1	12707296
+/-@@	O	-1	12707296
4@@	O	-1	12707296
3	O	-1	12707296
to	O	-1	12707296
10@@	O	-1	12707296
8@@	O	-1	12707296
2@@	O	-1	12707296
+/-@@	O	-1	12707296
2@@	O	-1	12707296
4@@	O	-1	12707296
5	O	-1	12707296
m@@	O	-1	12707296
mol@@	O	-1	12707296
/@@	O	-1	12707296
L@@	O	-1	12707296
,	O	-1	12707296
P@@	O	-1	12707296
<@@	O	-1	12707296
0.05@@	O	-1	12707296
).	O	-1	12707296
S@@	O	-1	12707296
y@@	O	-1	12707296
st@@	O	-1	12707296
olic	O	-1	12707296
blood	O	-1	12707296
pressure	O	-1	12707296
was	O	-1	12707296
elevated	O	-1	12707296
by	O	-1	12707296
an	O	-1	12707296
average	O	-1	12707296
of	O	-1	12707296
7	O	-1	12707296
mm	O	-1	12707296
H@@	O	-1	12707296
g@@	O	-1	12707296
.	O	-1	12707296
N@@	O	-1	12707296
either	O	-1	12707296
L-@@	B-Chemical	D001120	12707296
arg@@	I-Chemical	-1	12707296
inine	I-Chemical	-1	12707296
trans@@	O	-1	12707296
por@@	O	-1	12707296
t	O	-1	12707296
into	O	-1	12707296
mon@@	O	-1	12707296
on@@	O	-1	12707296
ucle@@	O	-1	12707296
ar	O	-1	12707296
cells	O	-1	12707296
(@@	O	-1	12707296
placebo	O	-1	12707296
v@@	O	-1	12707296
s	O	-1	12707296
ac@@	O	-1	12707296
ti@@	O	-1	12707296
ve,	O	-1	12707296
2@@	O	-1	12707296
6.@@	O	-1	12707296
3@@	O	-1	12707296
+/-@@	O	-1	12707296
3.@@	O	-1	12707296
6	O	-1	12707296
v@@	O	-1	12707296
s	O	-1	12707296
2@@	O	-1	12707296
9.@@	O	-1	12707296
0@@	O	-1	12707296
+/-@@	O	-1	12707296
2.@@	O	-1	12707296
1	O	-1	12707296
p@@	O	-1	12707296
mol@@	O	-1	12707296
/@@	O	-1	12707296
10	O	-1	12707296
0@@	O	-1	12707296
00	O	-1	12707296
cells	O	-1	12707296
per	O	-1	12707296
5	O	-1	12707296
minut@@	O	-1	12707296
es,	O	-1	12707296
respectivel@@	O	-1	12707296
y,	O	-1	12707296
at	O	-1	12707296
an	O	-1	12707296
l@@	B-Chemical	D001120	12707296
-@@	I-Chemical	-1	12707296
arg@@	I-Chemical	-1	12707296
inine	I-Chemical	-1	12707296
concentration	O	-1	12707296
of	O	-1	12707296
3@@	O	-1	12707296
00	O	-1	12707296
mic@@	O	-1	12707296
rom@@	O	-1	12707296
ol@@	O	-1	12707296
/@@	O	-1	12707296
L@@	O	-1	12707296
)	O	-1	12707296
n@@	O	-1	12707296
or	O	-1	12707296
L-@@	B-Chemical	D001120	12707296
arg@@	I-Chemical	-1	12707296
inine	I-Chemical	-1	12707296
extrac@@	O	-1	12707296
tion	O	-1	12707296
in	O	-1	12707296
the	O	-1	12707296
fo@@	O	-1	12707296
re@@	O	-1	12707296
ar@@	O	-1	12707296
m	O	-1	12707296
(@@	O	-1	12707296
at	O	-1	12707296
8@@	O	-1	12707296
0	O	-1	12707296
minut@@	O	-1	12707296
es,	O	-1	12707296
placebo	O	-1	12707296
v@@	O	-1	12707296
s	O	-1	12707296
ac@@	O	-1	12707296
ti@@	O	-1	12707296
ve,	O	-1	12707296
1	O	-1	12707296
8@@	O	-1	12707296
6@@	O	-1	12707296
8	O	-1	12707296
9@@	O	-1	12707296
0@@	O	-1	12707296
4@@	O	-1	12707296
+/-@@	O	-1	12707296
4@@	O	-1	12707296
3@@	O	-1	12707296
4	O	-1	12707296
9@@	O	-1	12707296
6@@	O	-1	12707296
2	O	-1	12707296
v@@	O	-1	12707296
s	O	-1	12707296
2	O	-1	12707296
0@@	O	-1	12707296
13	O	-1	12707296
9@@	O	-1	12707296
10@@	O	-1	12707296
+/-@@	O	-1	12707296
7@@	O	-1	12707296
7@@	O	-1	12707296
0	O	-1	12707296
6@@	O	-1	12707296
1@@	O	-1	12707296
9	O	-1	12707296
dis@@	O	-1	12707296
in@@	O	-1	12707296
te@@	O	-1	12707296
g@@	O	-1	12707296
r@@	O	-1	12707296
ations	O	-1	12707296
per	O	-1	12707296
min@@	O	-1	12707296
u@@	O	-1	12707296
te@@	O	-1	12707296
)	O	-1	12707296
was	O	-1	12707296
affected	O	-1	12707296
by	O	-1	12707296
cor@@	B-Chemical	D006854	12707296
tis@@	I-Chemical	-1	12707296
ol	I-Chemical	-1	12707296
treatment@@	O	-1	12707296
;	O	-1	12707296
i@@	O	-1	12707296
e,	O	-1	12707296
that	O	-1	12707296
L-@@	B-Chemical	D001120	12707296
arg@@	I-Chemical	-1	12707296
inine	I-Chemical	-1	12707296
u@@	O	-1	12707296
pt@@	O	-1	12707296
ake	O	-1	12707296
is	O	-1	12707296
not	O	-1	12707296
affected	O	-1	12707296
by	O	-1	12707296
sh@@	O	-1	12707296
ort@@	O	-1	12707296
-term	O	-1	12707296
cor@@	B-Chemical	D006854	12707296
tis@@	I-Chemical	-1	12707296
ol	I-Chemical	-1	12707296
treatment.	O	-1	12707296
We	O	-1	12707296
concl@@	O	-1	12707296
ude	O	-1	12707296
that	O	-1	12707296
cor@@	B-Chemical	D006854	12707296
tis@@	I-Chemical	-1	12707296
ol	I-Chemical	-1	12707296
-induced	O	-1	12707296
increases	B-Disease	D006973	12707296
in	I-Disease	-1	12707296
blood	I-Disease	-1	12707296
pressure	I-Disease	-1	12707296
are	O	-1	12707296
not	O	-1	12707296
associated	O	-1	12707296
with	O	-1	12707296
abnormal@@	O	-1	12707296
ities	O	-1	12707296
in	O	-1	12707296
the	O	-1	12707296
l@@	B-Chemical	D001120	12707296
-@@	I-Chemical	-1	12707296
arg@@	I-Chemical	-1	12707296
inine	I-Chemical	-1	12707296
trans@@	O	-1	12707296
por@@	O	-1	12707296
t	O	-1	12707296
system@@	O	-1	12707296
.	O	-1	12707296

M@@	O	-1	12695819
R	O	-1	12695819
imaging	O	-1	12695819
with	O	-1	12695819
qu@@	O	-1	12695819
anti@@	O	-1	12695819
t@@	O	-1	12695819
ative	O	-1	12695819
diff@@	O	-1	12695819
usion	O	-1	12695819
m@@	O	-1	12695819
app@@	O	-1	12695819
ing	O	-1	12695819
of	O	-1	12695819
tacrolimus	B-Chemical	D016559	12695819
-induced	O	-1	12695819
neuro@@	B-Disease	D020258	12695819
toxicity	I-Disease	-1	12695819
in	O	-1	12695819
org@@	O	-1	12695819
an	O	-1	12695819
transplant	O	-1	12695819
patients.	O	-1	12695819
Our	O	-1	12695819
ob@@	O	-1	12695819
j@@	O	-1	12695819
ective	O	-1	12695819
was	O	-1	12695819
to	O	-1	12695819
investigate	O	-1	12695819
brain	O	-1	12695819
M@@	O	-1	12695819
R	O	-1	12695819
imaging	O	-1	12695819
findings	O	-1	12695819
and	O	-1	12695819
the	O	-1	12695819
u@@	O	-1	12695819
til@@	O	-1	12695819
ity	O	-1	12695819
of	O	-1	12695819
diff@@	O	-1	12695819
u@@	O	-1	12695819
sion@@	O	-1	12695819
-@@	O	-1	12695819
weigh@@	O	-1	12695819
ted	O	-1	12695819
(D@@	O	-1	12695819
W@@	O	-1	12695819
)	O	-1	12695819
imaging	O	-1	12695819
in	O	-1	12695819
org@@	O	-1	12695819
an	O	-1	12695819
transplant	O	-1	12695819
patients	O	-1	12695819
who	O	-1	12695819
developed	O	-1	12695819
neurolog@@	O	-1	12695819
ic	O	-1	12695819
symptoms	O	-1	12695819
during	O	-1	12695819
tacrolimus	B-Chemical	D016559	12695819
therapy.	O	-1	12695819
B@@	O	-1	12695819
ra@@	O	-1	12695819
in	O	-1	12695819
M@@	O	-1	12695819
R	O	-1	12695819
studi@@	O	-1	12695819
es,	O	-1	12695819
including	O	-1	12695819
D@@	O	-1	12695819
W	O	-1	12695819
imag@@	O	-1	12695819
ing,	O	-1	12695819
were	O	-1	12695819
pro@@	O	-1	12695819
sp@@	O	-1	12695819
ectively	O	-1	12695819
performed	O	-1	12695819
in	O	-1	12695819
14	O	-1	12695819
org@@	O	-1	12695819
an	O	-1	12695819
transplant	O	-1	12695819
patients	O	-1	12695819
receiving	O	-1	12695819
tacrolimus	B-Chemical	D016559	12695819
who	O	-1	12695819
developed	O	-1	12695819
neurolog@@	B-Disease	D009422	12695819
ic	I-Disease	-1	12695819
complications	I-Disease	-1	12695819
.	O	-1	12695819
In	O	-1	12695819
each	O	-1	12695819
patient	O	-1	12695819
who	O	-1	12695819
had	O	-1	12695819
abnormal@@	O	-1	12695819
ities	O	-1	12695819
on	O	-1	12695819
the	O	-1	12695819
initial	O	-1	12695819
M@@	O	-1	12695819
R	O	-1	12695819
study,	O	-1	12695819
a	O	-1	12695819
follow-up	O	-1	12695819
M@@	O	-1	12695819
R	O	-1	12695819
study	O	-1	12695819
was	O	-1	12695819
performed	O	-1	12695819
1	O	-1	12695819
mon@@	O	-1	12695819
th	O	-1	12695819
lat@@	O	-1	12695819
er.	O	-1	12695819
A@@	O	-1	12695819
p@@	O	-1	12695819
pa@@	O	-1	12695819
rent	O	-1	12695819
diff@@	O	-1	12695819
usion	O	-1	12695819
co@@	O	-1	12695819
eff@@	O	-1	12695819
ici@@	O	-1	12695819
ent	O	-1	12695819
(A@@	O	-1	12695819
D@@	O	-1	12695819
C@@	O	-1	12695819
)	O	-1	12695819
values	O	-1	12695819
on	O	-1	12695819
the	O	-1	12695819
initial	O	-1	12695819
M@@	O	-1	12695819
R	O	-1	12695819
study	O	-1	12695819
were	O	-1	12695819
cor@@	O	-1	12695819
related	O	-1	12695819
with	O	-1	12695819
rever@@	O	-1	12695819
sib@@	O	-1	12695819
ility	O	-1	12695819
of	O	-1	12695819
the	O	-1	12695819
le@@	O	-1	12695819
sion@@	O	-1	12695819
s.	O	-1	12695819
Of	O	-1	12695819
the	O	-1	12695819
14	O	-1	12695819
patients,	O	-1	12695819
5	O	-1	12695819
(3@@	O	-1	12695819
5.@@	O	-1	12695819
7@@	O	-1	12695819
%)	O	-1	12695819
had	O	-1	12695819
wh@@	B-Disease	D056784	12695819
ite	I-Disease	-1	12695819
mat@@	I-Disease	-1	12695819
ter	I-Disease	-1	12695819
abnormal@@	I-Disease	-1	12695819
ities	I-Disease	-1	12695819
,	O	-1	12695819
1	O	-1	12695819
(@@	O	-1	12695819
7.@@	O	-1	12695819
1@@	O	-1	12695819
%)	O	-1	12695819
had	O	-1	12695819
p@@	B-Disease	D020146	12695819
ut@@	I-Disease	-1	12695819
amin@@	I-Disease	-1	12695819
al	I-Disease	-1	12695819
hemorrh@@	I-Disease	-1	12695819
age	I-Disease	-1	12695819
,	O	-1	12695819
and	O	-1	12695819
8	O	-1	12695819
(5@@	O	-1	12695819
7.@@	O	-1	12695819
1@@	O	-1	12695819
%)	O	-1	12695819
had	O	-1	12695819
normal	O	-1	12695819
findings	O	-1	12695819
on	O	-1	12695819
initial	O	-1	12695819
M@@	O	-1	12695819
R	O	-1	12695819
imag@@	O	-1	12695819
es.	O	-1	12695819
A@@	O	-1	12695819
mon@@	O	-1	12695819
g	O	-1	12695819
the	O	-1	12695819
5	O	-1	12695819
patients	O	-1	12695819
with	O	-1	12695819
wh@@	B-Disease	D056784	12695819
ite	I-Disease	-1	12695819
mat@@	I-Disease	-1	12695819
ter	I-Disease	-1	12695819
abnormal@@	I-Disease	-1	12695819
ities	I-Disease	-1	12695819
,	O	-1	12695819
4	O	-1	12695819
patients	O	-1	12695819
(@@	O	-1	12695819
8@@	O	-1	12695819
0.0@@	O	-1	12695819
%)	O	-1	12695819
showed	O	-1	12695819
higher	O	-1	12695819
than	O	-1	12695819
normal	O	-1	12695819
AD@@	O	-1	12695819
C	O	-1	12695819
values	O	-1	12695819
on	O	-1	12695819
initial	O	-1	12695819
M@@	O	-1	12695819
R	O	-1	12695819
imag@@	O	-1	12695819
es,	O	-1	12695819
and	O	-1	12695819
all	O	-1	12695819
showed	O	-1	12695819
complete	O	-1	12695819
resol@@	O	-1	12695819
u@@	O	-1	12695819
tion	O	-1	12695819
on	O	-1	12695819
follow-up	O	-1	12695819
imag@@	O	-1	12695819
es.	O	-1	12695819
The	O	-1	12695819
remain@@	O	-1	12695819
ing	O	-1	12695819
1	O	-1	12695819
patient	O	-1	12695819
(2@@	O	-1	12695819
0.0@@	O	-1	12695819
%)	O	-1	12695819
showed	O	-1	12695819
lower	O	-1	12695819
than	O	-1	12695819
normal	O	-1	12695819
AD@@	O	-1	12695819
C	O	-1	12695819
valu@@	O	-1	12695819
e	O	-1	12695819
and	O	-1	12695819
showed	O	-1	12695819
in@@	O	-1	12695819
complete	O	-1	12695819
resol@@	O	-1	12695819
u@@	O	-1	12695819
tion	O	-1	12695819
with	O	-1	12695819
cor@@	B-Disease	D001927	12695819
tical	I-Disease	-1	12695819
l@@	I-Disease	-1	12695819
amin@@	I-Disease	-1	12695819
ar	I-Disease	-1	12695819
necro@@	I-Disease	-1	12695819
sis	I-Disease	-1	12695819
.	O	-1	12695819
Di@@	O	-1	12695819
ff@@	O	-1	12695819
u@@	O	-1	12695819
sion@@	O	-1	12695819
-@@	O	-1	12695819
weigh@@	O	-1	12695819
ted	O	-1	12695819
imaging	O	-1	12695819
may	O	-1	12695819
be	O	-1	12695819
use@@	O	-1	12695819
ful	O	-1	12695819
in	O	-1	12695819
predic@@	O	-1	12695819
ting	O	-1	12695819
the	O	-1	12695819
outcom@@	O	-1	12695819
es	O	-1	12695819
of	O	-1	12695819
the	O	-1	12695819
lesions	O	-1	12695819
of	O	-1	12695819
tacrolimus	B-Chemical	D016559	12695819
-induced	O	-1	12695819
neuro@@	B-Disease	D020258	12695819
toxicity	I-Disease	-1	12695819
.	O	-1	12695819

O@@	B-Chemical	D015282	12596116
c@@	I-Chemical	-1	12596116
tre@@	I-Chemical	-1	12596116
o@@	I-Chemical	-1	12596116
ti@@	I-Chemical	-1	12596116
de	I-Chemical	-1	12596116
-induced	O	-1	12596116
hypo@@	B-Disease	D000860	12596116
x@@	I-Disease	-1	12596116
emia	I-Disease	-1	12596116
and	O	-1	12596116
pulmonary	B-Disease	D006976	12596116
hypertension	I-Disease	-1	12596116
in	O	-1	12596116
pre@@	O	-1	12596116
mat@@	O	-1	12596116
ure	O	-1	12596116
ne@@	O	-1	12596116
on@@	O	-1	12596116
at@@	O	-1	12596116
es.	O	-1	12596116
The	O	-1	12596116
au@@	O	-1	12596116
th@@	O	-1	12596116
ors	O	-1	12596116
report	O	-1	12596116
2	O	-1	12596116
cases	O	-1	12596116
of	O	-1	12596116
pre@@	O	-1	12596116
mat@@	O	-1	12596116
ure	O	-1	12596116
ne@@	O	-1	12596116
on@@	O	-1	12596116
ates	O	-1	12596116
who	O	-1	12596116
had	O	-1	12596116
ent@@	O	-1	12596116
er@@	O	-1	12596116
oc@@	O	-1	12596116
utaneous	O	-1	12596116
f@@	B-Disease	D005402	12596116
ist@@	I-Disease	-1	12596116
ul@@	I-Disease	-1	12596116
a	I-Disease	-1	12596116
complic@@	O	-1	12596116
ating	O	-1	12596116
necro@@	B-Disease	D020345	12596116
tiz@@	I-Disease	-1	12596116
ing	I-Disease	-1	12596116
ent@@	I-Disease	-1	12596116
ero@@	I-Disease	-1	12596116
co@@	I-Disease	-1	12596116
li@@	I-Disease	-1	12596116
tis	I-Disease	-1	12596116
.	O	-1	12596116
P@@	B-Disease	D006976	12596116
ul@@	I-Disease	-1	12596116
monary	I-Disease	-1	12596116
hypertension	I-Disease	-1	12596116
developed	O	-1	12596116
after	O	-1	12596116
administration	O	-1	12596116
of	O	-1	12596116
a	O	-1	12596116
s@@	O	-1	12596116
om@@	O	-1	12596116
at@@	O	-1	12596116
ost@@	O	-1	12596116
atin	O	-1	12596116
an@@	O	-1	12596116
alo@@	O	-1	12596116
gu@@	O	-1	12596116
e,	O	-1	12596116
oc@@	B-Chemical	D015282	12596116
tre@@	I-Chemical	-1	12596116
o@@	I-Chemical	-1	12596116
ti@@	I-Chemical	-1	12596116
de	I-Chemical	-1	12596116
,	O	-1	12596116
to	O	-1	12596116
enh@@	O	-1	12596116
ance	O	-1	12596116
resol@@	O	-1	12596116
u@@	O	-1	12596116
tion	O	-1	12596116
of	O	-1	12596116
the	O	-1	12596116
f@@	B-Disease	D005402	12596116
ist@@	I-Disease	-1	12596116
ul@@	I-Disease	-1	12596116
a	I-Disease	-1	12596116
.	O	-1	12596116
The	O	-1	12596116
au@@	O	-1	12596116
th@@	O	-1	12596116
ors	O	-1	12596116
discus@@	O	-1	12596116
s	O	-1	12596116
the	O	-1	12596116
mechanism	O	-1	12596116
of	O	-1	12596116
the	O	-1	12596116
occur@@	O	-1	12596116
rence	O	-1	12596116
of	O	-1	12596116
this	O	-1	12596116
complication	O	-1	12596116
and	O	-1	12596116
recomm@@	O	-1	12596116
end	O	-1	12596116
cau@@	O	-1	12596116
tion	O	-1	12596116
of	O	-1	12596116
its	O	-1	12596116
use	O	-1	12596116
in	O	-1	12596116
high-@@	O	-1	12596116
risk	O	-1	12596116
pre@@	O	-1	12596116
mat@@	O	-1	12596116
ure	O	-1	12596116
ne@@	O	-1	12596116
on@@	O	-1	12596116
at@@	O	-1	12596116
es.	O	-1	12596116

S@@	O	-1	11875660
equ@@	O	-1	11875660
en@@	O	-1	11875660
tial	O	-1	11875660
observ@@	O	-1	11875660
ations	O	-1	11875660
of	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
y	I-Disease	-1	11875660
and	O	-1	11875660
subsequ@@	O	-1	11875660
ent	O	-1	11875660
morph@@	O	-1	11875660
ological	O	-1	11875660
changes	O	-1	11875660
by	O	-1	11875660
mouse	O	-1	11875660
ex@@	O	-1	11875660
o	O	-1	11875660
u@@	O	-1	11875660
ter@@	O	-1	11875660
o	O	-1	11875660
development	O	-1	11875660
system@@	O	-1	11875660
:	O	-1	11875660
analysis	O	-1	11875660
of	O	-1	11875660
the	O	-1	11875660
mechanism	O	-1	11875660
of	O	-1	11875660
trans@@	O	-1	11875660
formation	O	-1	11875660
from	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
y	I-Disease	-1	11875660
to	O	-1	11875660
an@@	B-Disease	D000757	11875660
encephal@@	I-Disease	-1	11875660
y	I-Disease	-1	11875660
.	O	-1	11875660
An@@	B-Disease	D000757	11875660
encephal@@	I-Disease	-1	11875660
y	I-Disease	-1	11875660
has	O	-1	11875660
been	O	-1	11875660
suggested	O	-1	11875660
to	O	-1	11875660
deve@@	O	-1	11875660
lo@@	O	-1	11875660
p	O	-1	11875660
from	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
y	I-Disease	-1	11875660
;	O	-1	11875660
however,	O	-1	11875660
there	O	-1	11875660
is	O	-1	11875660
lit@@	O	-1	11875660
t@@	O	-1	11875660
le	O	-1	11875660
direct	O	-1	11875660
experimental	O	-1	11875660
evidence	O	-1	11875660
to	O	-1	11875660
suppor@@	O	-1	11875660
t	O	-1	11875660
th@@	O	-1	11875660
is@@	O	-1	11875660
,	O	-1	11875660
and	O	-1	11875660
the	O	-1	11875660
mechanism	O	-1	11875660
of	O	-1	11875660
trans@@	O	-1	11875660
formation	O	-1	11875660
remain@@	O	-1	11875660
s	O	-1	11875660
unc@@	O	-1	11875660
lear@@	O	-1	11875660
.	O	-1	11875660
We	O	-1	11875660
examined	O	-1	11875660
this	O	-1	11875660
the@@	O	-1	11875660
ory	O	-1	11875660
using	O	-1	11875660
the	O	-1	11875660
ex@@	O	-1	11875660
o	O	-1	11875660
u@@	O	-1	11875660
ter@@	O	-1	11875660
o	O	-1	11875660
development	O	-1	11875660
system	O	-1	11875660
that	O	-1	11875660
al@@	O	-1	11875660
low@@	O	-1	11875660
s	O	-1	11875660
direct	O	-1	11875660
and	O	-1	11875660
sequ@@	O	-1	11875660
en@@	O	-1	11875660
tial	O	-1	11875660
observ@@	O	-1	11875660
ations	O	-1	11875660
of	O	-1	11875660
mid@@	O	-1	11875660
-	O	-1	11875660
to	O	-1	11875660
lat@@	O	-1	11875660
e-@@	O	-1	11875660
g@@	O	-1	11875660
est@@	O	-1	11875660
ation	O	-1	11875660
mouse	O	-1	11875660
emb@@	O	-1	11875660
r@@	O	-1	11875660
yo@@	O	-1	11875660
s.	O	-1	11875660
We	O	-1	11875660
observed	O	-1	11875660
the	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
y	I-Disease	-1	11875660
induced	O	-1	11875660
by	O	-1	11875660
5-@@	B-Chemical	D001374	11875660
az@@	I-Chemical	-1	11875660
ac@@	I-Chemical	-1	11875660
y@@	I-Chemical	-1	11875660
tid@@	I-Chemical	-1	11875660
ine	I-Chemical	-1	11875660
at	O	-1	11875660
emb@@	O	-1	11875660
r@@	O	-1	11875660
y@@	O	-1	11875660
onic	O	-1	11875660
day	O	-1	11875660
1@@	O	-1	11875660
3.@@	O	-1	11875660
5	O	-1	11875660
(@@	O	-1	11875660
E@@	O	-1	11875660
1@@	O	-1	11875660
3.@@	O	-1	11875660
5@@	O	-1	11875660
),	O	-1	11875660
le@@	O	-1	11875660
t	O	-1	11875660
the	O	-1	11875660
emb@@	O	-1	11875660
r@@	O	-1	11875660
yo@@	O	-1	11875660
s	O	-1	11875660
deve@@	O	-1	11875660
lo@@	O	-1	11875660
p	O	-1	11875660
ex@@	O	-1	11875660
o	O	-1	11875660
u@@	O	-1	11875660
ter@@	O	-1	11875660
o	O	-1	11875660
un@@	O	-1	11875660
ti@@	O	-1	11875660
l	O	-1	11875660
E@@	O	-1	11875660
1@@	O	-1	11875660
8.@@	O	-1	11875660
5,	O	-1	11875660
and	O	-1	11875660
re@@	O	-1	11875660
-@@	O	-1	11875660
observed	O	-1	11875660
the	O	-1	11875660
same	O	-1	11875660
emb@@	O	-1	11875660
r@@	O	-1	11875660
yo@@	O	-1	11875660
s	O	-1	11875660
at	O	-1	11875660
E@@	O	-1	11875660
1@@	O	-1	11875660
8.@@	O	-1	11875660
5@@	O	-1	11875660
.	O	-1	11875660
We	O	-1	11875660
con@@	O	-1	11875660
fir@@	O	-1	11875660
m@@	O	-1	11875660
ed	O	-1	11875660
several	O	-1	11875660
cases	O	-1	11875660
of	O	-1	11875660
trans@@	O	-1	11875660
formation	O	-1	11875660
from	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
y	I-Disease	-1	11875660
to	O	-1	11875660
an@@	B-Disease	D000757	11875660
encephal@@	I-Disease	-1	11875660
y	I-Disease	-1	11875660
.	O	-1	11875660
However,	O	-1	11875660
in	O	-1	11875660
man@@	O	-1	11875660
y	O	-1	11875660
cas@@	O	-1	11875660
es,	O	-1	11875660
the	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
ic	I-Disease	-1	11875660
brain	O	-1	11875660
tissue	O	-1	11875660
was	O	-1	11875660
pres@@	O	-1	11875660
er@@	O	-1	11875660
ved	O	-1	11875660
with	O	-1	11875660
more	O	-1	11875660
or	O	-1	11875660
less	O	-1	11875660
reduction	O	-1	11875660
during	O	-1	11875660
this	O	-1	11875660
perio@@	O	-1	11875660
d.	O	-1	11875660
To	O	-1	11875660
analy@@	O	-1	11875660
ze	O	-1	11875660
the	O	-1	11875660
trans@@	O	-1	11875660
formation	O	-1	11875660
pat@@	O	-1	11875660
tern@@	O	-1	11875660
s,	O	-1	11875660
we	O	-1	11875660
cl@@	O	-1	11875660
assi@@	O	-1	11875660
fied	O	-1	11875660
the	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
y	I-Disease	-1	11875660
by	O	-1	11875660
size	O	-1	11875660
and	O	-1	11875660
sh@@	O	-1	11875660
ap@@	O	-1	11875660
e	O	-1	11875660
of	O	-1	11875660
the	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
ic	I-Disease	-1	11875660
tissue	O	-1	11875660
into	O	-1	11875660
several	O	-1	11875660
typ@@	O	-1	11875660
es	O	-1	11875660
at	O	-1	11875660
E@@	O	-1	11875660
1@@	O	-1	11875660
3.@@	O	-1	11875660
5	O	-1	11875660
and	O	-1	11875660
E@@	O	-1	11875660
1@@	O	-1	11875660
8.@@	O	-1	11875660
5@@	O	-1	11875660
.	O	-1	11875660
It	O	-1	11875660
was	O	-1	11875660
found	O	-1	11875660
that	O	-1	11875660
the	O	-1	11875660
trans@@	O	-1	11875660
formation	O	-1	11875660
of	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
ic	I-Disease	-1	11875660
tissue	O	-1	11875660
was	O	-1	11875660
not	O	-1	11875660
sim@@	O	-1	11875660
p@@	O	-1	11875660
ly	O	-1	11875660
si@@	O	-1	11875660
z@@	O	-1	11875660
e-@@	O	-1	11875660
depend@@	O	-1	11875660
ent@@	O	-1	11875660
,	O	-1	11875660
and	O	-1	11875660
all	O	-1	11875660
cases	O	-1	11875660
of	O	-1	11875660
an@@	B-Disease	D000757	11875660
encephal@@	I-Disease	-1	11875660
y	I-Disease	-1	11875660
at	O	-1	11875660
E@@	O	-1	11875660
1@@	O	-1	11875660
8.@@	O	-1	11875660
5	O	-1	11875660
resulted	O	-1	11875660
from	O	-1	11875660
emb@@	O	-1	11875660
r@@	O	-1	11875660
yo@@	O	-1	11875660
s	O	-1	11875660
with	O	-1	11875660
a	O	-1	11875660
larg@@	O	-1	11875660
e	O	-1	11875660
amoun@@	O	-1	11875660
t	O	-1	11875660
of	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
ic	I-Disease	-1	11875660
tissue	O	-1	11875660
at	O	-1	11875660
E@@	O	-1	11875660
1@@	O	-1	11875660
3.@@	O	-1	11875660
5@@	O	-1	11875660
.	O	-1	11875660
M@@	O	-1	11875660
ic@@	O	-1	11875660
ro@@	O	-1	11875660
sco@@	O	-1	11875660
p@@	O	-1	11875660
ic	O	-1	11875660
observ@@	O	-1	11875660
ation	O	-1	11875660
showed	O	-1	11875660
the	O	-1	11875660
con@@	O	-1	11875660
fi@@	O	-1	11875660
g@@	O	-1	11875660
ur@@	O	-1	11875660
ation	O	-1	11875660
of	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
y	I-Disease	-1	11875660
at	O	-1	11875660
E@@	O	-1	11875660
1@@	O	-1	11875660
3.@@	O	-1	11875660
5,	O	-1	11875660
frequent	O	-1	11875660
hemorrh@@	B-Disease	D006470	11875660
ag@@	I-Disease	-1	11875660
ing	I-Disease	-1	11875660
and	O	-1	11875660
de@@	O	-1	11875660
tac@@	O	-1	11875660
h@@	O	-1	11875660
ment	O	-1	11875660
of	O	-1	11875660
the	O	-1	11875660
ne@@	O	-1	11875660
ural	O	-1	11875660
pl@@	O	-1	11875660
ate	O	-1	11875660
from	O	-1	11875660
sur@@	O	-1	11875660
fac@@	O	-1	11875660
e	O	-1	11875660
ect@@	O	-1	11875660
o@@	O	-1	11875660
der@@	O	-1	11875660
m	O	-1	11875660
in	O	-1	11875660
the	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
ic	I-Disease	-1	11875660
he@@	O	-1	11875660
ad	O	-1	11875660
at	O	-1	11875660
E@@	O	-1	11875660
1@@	O	-1	11875660
5.@@	O	-1	11875660
5,	O	-1	11875660
and	O	-1	11875660
multiple	O	-1	11875660
mode@@	O	-1	11875660
s	O	-1	11875660
of	O	-1	11875660
reduction	O	-1	11875660
in	O	-1	11875660
the	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
ic	I-Disease	-1	11875660
tissue	O	-1	11875660
at	O	-1	11875660
E@@	O	-1	11875660
1@@	O	-1	11875660
8.@@	O	-1	11875660
5@@	O	-1	11875660
.	O	-1	11875660
F@@	O	-1	11875660
rom	O	-1	11875660
observ@@	O	-1	11875660
ations	O	-1	11875660
of	O	-1	11875660
the	O	-1	11875660
vas@@	O	-1	11875660
cul@@	O	-1	11875660
at@@	O	-1	11875660
ure,	O	-1	11875660
al@@	O	-1	11875660
te@@	O	-1	11875660
red	O	-1	11875660
di@@	O	-1	11875660
stri@@	O	-1	11875660
bu@@	O	-1	11875660
tion	O	-1	11875660
pat@@	O	-1	11875660
tern@@	O	-1	11875660
s	O	-1	11875660
of	O	-1	11875660
v@@	O	-1	11875660
es@@	O	-1	11875660
sel@@	O	-1	11875660
s	O	-1	11875660
were	O	-1	11875660
identi@@	O	-1	11875660
fied	O	-1	11875660
in	O	-1	11875660
the	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
ic	I-Disease	-1	11875660
head@@	O	-1	11875660
.	O	-1	11875660
These	O	-1	11875660
findings	O	-1	11875660
suggest	O	-1	11875660
that	O	-1	11875660
over@@	O	-1	11875660
growth	O	-1	11875660
of	O	-1	11875660
the	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
ic	I-Disease	-1	11875660
ne@@	O	-1	11875660
ural	O	-1	11875660
tissue	O	-1	11875660
causes	O	-1	11875660
the	O	-1	11875660
al@@	O	-1	11875660
te@@	O	-1	11875660
red	O	-1	11875660
di@@	O	-1	11875660
stri@@	O	-1	11875660
bu@@	O	-1	11875660
tion	O	-1	11875660
pat@@	O	-1	11875660
tern@@	O	-1	11875660
s	O	-1	11875660
of	O	-1	11875660
v@@	O	-1	11875660
es@@	O	-1	11875660
sel@@	O	-1	11875660
s,	O	-1	11875660
subsequ@@	O	-1	11875660
ent	O	-1	11875660
peripheral	O	-1	11875660
cir@@	B-Disease	D012769	11875660
cul@@	I-Disease	-1	11875660
atory	I-Disease	-1	11875660
failure	I-Disease	-1	11875660
and/or	O	-1	11875660
hemorrh@@	B-Disease	D006470	11875660
ag@@	I-Disease	-1	11875660
ing	I-Disease	-1	11875660
in	O	-1	11875660
various	O	-1	11875660
par@@	O	-1	11875660
ts	O	-1	11875660
of	O	-1	11875660
the	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
ic	I-Disease	-1	11875660
head@@	O	-1	11875660
,	O	-1	11875660
lead@@	O	-1	11875660
ing	O	-1	11875660
to	O	-1	11875660
the	O	-1	11875660
multiple	O	-1	11875660
mode@@	O	-1	11875660
s	O	-1	11875660
of	O	-1	11875660
tissue	O	-1	11875660
reduction	O	-1	11875660
during	O	-1	11875660
trans@@	O	-1	11875660
formation	O	-1	11875660
from	O	-1	11875660
ex@@	B-Disease	D009436	11875660
encephal@@	I-Disease	-1	11875660
y	I-Disease	-1	11875660
to	O	-1	11875660
an@@	B-Disease	D000757	11875660
encephal@@	I-Disease	-1	11875660
y	I-Disease	-1	11875660
.	O	-1	11875660

Ac@@	O	-1	11166519
ute	O	-1	11166519
cocaine	B-Chemical	D003042	11166519
-induced	O	-1	11166519
seizures	B-Disease	D012640	11166519
:	O	-1	11166519
differen@@	O	-1	11166519
tial	O	-1	11166519
sensitivity	O	-1	11166519
of	O	-1	11166519
six	O	-1	11166519
in@@	O	-1	11166519
b@@	O	-1	11166519
red	O	-1	11166519
mouse	O	-1	11166519
stra@@	O	-1	11166519
in@@	O	-1	11166519
s.	O	-1	11166519
M@@	O	-1	11166519
at@@	O	-1	11166519
ure	O	-1	11166519
male	O	-1	11166519
and	O	-1	11166519
female	O	-1	11166519
mice	O	-1	11166519
from	O	-1	11166519
six	O	-1	11166519
in@@	O	-1	11166519
b@@	O	-1	11166519
red	O	-1	11166519
st@@	O	-1	11166519
ain@@	O	-1	11166519
s	O	-1	11166519
were	O	-1	11166519
tested	O	-1	11166519
for	O	-1	11166519
sus@@	O	-1	11166519
cep@@	O	-1	11166519
ti@@	O	-1	11166519
b@@	O	-1	11166519
ility	O	-1	11166519
to	O	-1	11166519
behavioral	O	-1	11166519
seizures	B-Disease	D012640	11166519
induced	O	-1	11166519
by	O	-1	11166519
a	O	-1	11166519
single	O	-1	11166519
injection	O	-1	11166519
of	O	-1	11166519
cocaine	B-Chemical	D003042	11166519
.	O	-1	11166519
C@@	B-Chemical	D003042	11166519
oc@@	I-Chemical	-1	11166519
aine	I-Chemical	-1	11166519
was	O	-1	11166519
injected	O	-1	11166519
i@@	O	-1	11166519
p	O	-1	11166519
over	O	-1	11166519
a	O	-1	11166519
range	O	-1	11166519
of	O	-1	11166519
doses	O	-1	11166519
(@@	O	-1	11166519
50@@	O	-1	11166519
-@@	O	-1	11166519
100	O	-1	11166519
mg/kg)	O	-1	11166519
and	O	-1	11166519
behavi@@	O	-1	11166519
or	O	-1	11166519
was	O	-1	11166519
monit@@	O	-1	11166519
o@@	O	-1	11166519
red	O	-1	11166519
for	O	-1	11166519
20	O	-1	11166519
minut@@	O	-1	11166519
es.	O	-1	11166519
S@@	B-Disease	D012640	11166519
e@@	I-Disease	-1	11166519
iz@@	I-Disease	-1	11166519
ure	I-Disease	-1	11166519
end	O	-1	11166519
po@@	O	-1	11166519
int@@	O	-1	11166519
s	O	-1	11166519
included	O	-1	11166519
lat@@	O	-1	11166519
ency	O	-1	11166519
to	O	-1	11166519
fo@@	O	-1	11166519
rel@@	O	-1	11166519
im@@	O	-1	11166519
b	O	-1	11166519
or	O	-1	11166519
h@@	O	-1	11166519
ind@@	O	-1	11166519
lim@@	O	-1	11166519
b	O	-1	11166519
clon@@	O	-1	11166519
us,	O	-1	11166519
lat@@	O	-1	11166519
ency	O	-1	11166519
to	O	-1	11166519
clon@@	O	-1	11166519
ic	O	-1	11166519
r@@	O	-1	11166519
un@@	O	-1	11166519
ning	O	-1	11166519
seizure	B-Disease	D012640	11166519
and	O	-1	11166519
lat@@	O	-1	11166519
ency	O	-1	11166519
to	O	-1	11166519
j@@	O	-1	11166519
um@@	O	-1	11166519
p@@	O	-1	11166519
ing	O	-1	11166519
b@@	O	-1	11166519
oun@@	O	-1	11166519
c@@	O	-1	11166519
ing	O	-1	11166519
seizure	B-Disease	D012640	11166519
.	O	-1	11166519
A	O	-1	11166519
range	O	-1	11166519
of	O	-1	11166519
stra@@	O	-1	11166519
in	O	-1	11166519
specific	O	-1	11166519
sensi@@	O	-1	11166519
ti@@	O	-1	11166519
vi@@	O	-1	11166519
ties	O	-1	11166519
was	O	-1	11166519
doc@@	O	-1	11166519
um@@	O	-1	11166519
ent@@	O	-1	11166519
ed	O	-1	11166519
with	O	-1	11166519
A@@	O	-1	11166519
/@@	O	-1	11166519
J	O	-1	11166519
and	O	-1	11166519
S@@	O	-1	11166519
J@@	O	-1	11166519
L	O	-1	11166519
mice	O	-1	11166519
being	O	-1	11166519
most	O	-1	11166519
sensitive	O	-1	11166519
and	O	-1	11166519
C@@	O	-1	11166519
5@@	O	-1	11166519
7@@	O	-1	11166519
B@@	O	-1	11166519
L@@	O	-1	11166519
/@@	O	-1	11166519
6@@	O	-1	11166519
J	O	-1	11166519
most	O	-1	11166519
resist@@	O	-1	11166519
ant@@	O	-1	11166519
.	O	-1	11166519
D@@	O	-1	11166519
BA@@	O	-1	11166519
/@@	O	-1	11166519
2@@	O	-1	11166519
J@@	O	-1	11166519
,	O	-1	11166519
BA@@	O	-1	11166519
L@@	O	-1	11166519
B@@	O	-1	11166519
/@@	O	-1	11166519
c@@	O	-1	11166519
B@@	O	-1	11166519
y@@	O	-1	11166519
J	O	-1	11166519
and	O	-1	11166519
N@@	O	-1	11166519
Z@@	O	-1	11166519
W@@	O	-1	11166519
/@@	O	-1	11166519
L@@	O	-1	11166519
ac@@	O	-1	11166519
J	O	-1	11166519
stra@@	O	-1	11166519
ins	O	-1	11166519
ex@@	O	-1	11166519
hib@@	O	-1	11166519
ited	O	-1	11166519
inter@@	O	-1	11166519
medi@@	O	-1	11166519
ate	O	-1	11166519
sensi@@	O	-1	11166519
tiv@@	O	-1	11166519
ity.	O	-1	11166519
E@@	O	-1	11166519
E@@	O	-1	11166519
G	O	-1	11166519
recor@@	O	-1	11166519
d@@	O	-1	11166519
ings	O	-1	11166519
were	O	-1	11166519
m@@	O	-1	11166519
ade	O	-1	11166519
in	O	-1	11166519
S@@	O	-1	11166519
J@@	O	-1	11166519
L@@	O	-1	11166519
,	O	-1	11166519
A@@	O	-1	11166519
/@@	O	-1	11166519
J	O	-1	11166519
and	O	-1	11166519
C@@	O	-1	11166519
5@@	O	-1	11166519
7@@	O	-1	11166519
B@@	O	-1	11166519
L@@	O	-1	11166519
/@@	O	-1	11166519
6@@	O	-1	11166519
J	O	-1	11166519
mice	O	-1	11166519
reveal@@	O	-1	11166519
ing	O	-1	11166519
a	O	-1	11166519
clo@@	O	-1	11166519
se	O	-1	11166519
cor@@	O	-1	11166519
respon@@	O	-1	11166519
d@@	O	-1	11166519
ence	O	-1	11166519
between	O	-1	11166519
elect@@	O	-1	11166519
r@@	O	-1	11166519
ical	O	-1	11166519
activity	O	-1	11166519
and	O	-1	11166519
behavi@@	O	-1	11166519
or@@	O	-1	11166519
.	O	-1	11166519
Ad@@	O	-1	11166519
di@@	O	-1	11166519
tion@@	O	-1	11166519
ally,	O	-1	11166519
levels	O	-1	11166519
of	O	-1	11166519
cocaine	B-Chemical	D003042	11166519
determined	O	-1	11166519
in	O	-1	11166519
hippocamp@@	O	-1	11166519
us	O	-1	11166519
and	O	-1	11166519
cor@@	O	-1	11166519
te@@	O	-1	11166519
x	O	-1	11166519
were	O	-1	11166519
not	O	-1	11166519
different	O	-1	11166519
between	O	-1	11166519
sensitive	O	-1	11166519
and	O	-1	11166519
resist@@	O	-1	11166519
ant	O	-1	11166519
stra@@	O	-1	11166519
in@@	O	-1	11166519
s.	O	-1	11166519
Ad@@	O	-1	11166519
di@@	O	-1	11166519
tional	O	-1	11166519
studies	O	-1	11166519
of	O	-1	11166519
these	O	-1	11166519
m@@	O	-1	11166519
urine	O	-1	11166519
stra@@	O	-1	11166519
ins	O	-1	11166519
may	O	-1	11166519
be	O	-1	11166519
use@@	O	-1	11166519
ful	O	-1	11166519
for	O	-1	11166519
investig@@	O	-1	11166519
ating	O	-1	11166519
gene@@	O	-1	11166519
tic	O	-1	11166519
influ@@	O	-1	11166519
enc@@	O	-1	11166519
es	O	-1	11166519
on	O	-1	11166519
cocaine	B-Chemical	D003042	11166519
-induced	O	-1	11166519
seizures	B-Disease	D012640	11166519
.	O	-1	11166519

M@@	B-Disease	D000743	8701950
ic@@	I-Disease	-1	8701950
ro@@	I-Disease	-1	8701950
angio@@	I-Disease	-1	8701950
path@@	I-Disease	-1	8701950
ic	I-Disease	-1	8701950
hemolytic	I-Disease	-1	8701950
anemia	I-Disease	-1	8701950
complic@@	O	-1	8701950
ating	O	-1	8701950
FK50@@	B-Chemical	D016559	8701950
6	I-Chemical	-1	8701950
(	O	-1	8701950
tacrolimus	B-Chemical	D016559	8701950
)	O	-1	8701950
therapy.	O	-1	8701950
We	O	-1	8701950
describe	O	-1	8701950
3	O	-1	8701950
episo@@	O	-1	8701950
des	O	-1	8701950
of	O	-1	8701950
microangio@@	B-Disease	D000743	8701950
path@@	I-Disease	-1	8701950
ic	I-Disease	-1	8701950
hemolytic	I-Disease	-1	8701950
anemia	I-Disease	-1	8701950
(	O	-1	8701950
MA@@	B-Disease	D000743	8701950
H@@	I-Disease	-1	8701950
A	I-Disease	-1	8701950
)	O	-1	8701950
in	O	-1	8701950
2	O	-1	8701950
sol@@	O	-1	8701950
id	O	-1	8701950
org@@	O	-1	8701950
an	O	-1	8701950
re@@	O	-1	8701950
ci@@	O	-1	8701950
pi@@	O	-1	8701950
ents	O	-1	8701950
under	O	-1	8701950
FK50@@	B-Chemical	D016559	8701950
6	I-Chemical	-1	8701950
(	O	-1	8701950
tacrolimus	B-Chemical	D016559	8701950
)	O	-1	8701950
therapy.	O	-1	8701950
In	O	-1	8701950
both	O	-1	8701950
cas@@	O	-1	8701950
es,	O	-1	8701950
discontinu@@	O	-1	8701950
ation	O	-1	8701950
of	O	-1	8701950
FK50@@	B-Chemical	D016559	8701950
6	I-Chemical	-1	8701950
and	O	-1	8701950
treatment	O	-1	8701950
with	O	-1	8701950
plasma	O	-1	8701950
ex@@	O	-1	8701950
chang@@	O	-1	8701950
e,	O	-1	8701950
f@@	O	-1	8701950
res@@	O	-1	8701950
h	O	-1	8701950
f@@	O	-1	8701950
ro@@	O	-1	8701950
z@@	O	-1	8701950
en	O	-1	8701950
plasma	O	-1	8701950
re@@	O	-1	8701950
pl@@	O	-1	8701950
ac@@	O	-1	8701950
em@@	O	-1	8701950
ent@@	O	-1	8701950
,	O	-1	8701950
cortico@@	B-Chemical	D000305	8701950
steroid@@	I-Chemical	-1	8701950
s	I-Chemical	-1	8701950
,	O	-1	8701950
as@@	B-Chemical	D001241	8701950
pi@@	I-Chemical	-1	8701950
rin	I-Chemical	-1	8701950
,	O	-1	8701950
and	O	-1	8701950
di@@	B-Chemical	D004176	8701950
pyri@@	I-Chemical	-1	8701950
dam@@	I-Chemical	-1	8701950
ole	I-Chemical	-1	8701950
l@@	O	-1	8701950
ed	O	-1	8701950
to	O	-1	8701950
resol@@	O	-1	8701950
u@@	O	-1	8701950
tion	O	-1	8701950
of	O	-1	8701950
MA@@	B-Disease	D000743	8701950
H@@	I-Disease	-1	8701950
A	I-Disease	-1	8701950
.	O	-1	8701950
In	O	-1	8701950
one	O	-1	8701950
patient@@	O	-1	8701950
,	O	-1	8701950
re@@	O	-1	8701950
int@@	O	-1	8701950
ro@@	O	-1	8701950
duction	O	-1	8701950
of	O	-1	8701950
FK50@@	B-Chemical	D016559	8701950
6	I-Chemical	-1	8701950
l@@	O	-1	8701950
ed	O	-1	8701950
to	O	-1	8701950
ra@@	O	-1	8701950
pid	O	-1	8701950
recur@@	O	-1	8701950
rence	O	-1	8701950
of	O	-1	8701950
MA@@	B-Disease	D000743	8701950
H@@	I-Disease	-1	8701950
A	I-Disease	-1	8701950
.	O	-1	8701950
FK50@@	B-Chemical	D016559	8701950
6	I-Chemical	-1	8701950
-@@	O	-1	8701950
associated	O	-1	8701950
MA@@	B-Disease	D000743	8701950
H@@	I-Disease	-1	8701950
A	I-Disease	-1	8701950
is	O	-1	8701950
prob@@	O	-1	8701950
ably	O	-1	8701950
r@@	O	-1	8701950
are	O	-1	8701950
but	O	-1	8701950
physi@@	O	-1	8701950
ci@@	O	-1	8701950
ans	O	-1	8701950
mus@@	O	-1	8701950
t	O	-1	8701950
be	O	-1	8701950
aw@@	O	-1	8701950
are	O	-1	8701950
of	O	-1	8701950
this	O	-1	8701950
severe	O	-1	8701950
complic@@	O	-1	8701950
ation.	O	-1	8701950
In	O	-1	8701950
our	O	-1	8701950
experi@@	O	-1	8701950
ence	O	-1	8701950
and	O	-1	8701950
ac@@	O	-1	8701950
cor@@	O	-1	8701950
ding	O	-1	8701950
to	O	-1	8701950
the	O	-1	8701950
literat@@	O	-1	8701950
ure,	O	-1	8701950
FK50@@	B-Chemical	D016559	8701950
6	I-Chemical	-1	8701950
does	O	-1	8701950
not	O	-1	8701950
se@@	O	-1	8701950
em	O	-1	8701950
to	O	-1	8701950
cros@@	O	-1	8701950
s-@@	O	-1	8701950
reac@@	O	-1	8701950
t	O	-1	8701950
with	O	-1	8701950
cyclospor@@	B-Chemical	D016572	8701950
in	I-Chemical	-1	8701950
A	I-Chemical	-1	8701950
(	O	-1	8701950
C@@	B-Chemical	D016572	8701950
y@@	I-Chemical	-1	8701950
A	I-Chemical	-1	8701950
),	O	-1	8701950
an	O	-1	8701950
immuno@@	O	-1	8701950
-@@	O	-1	8701950
sup@@	O	-1	8701950
pressive	O	-1	8701950
drug	O	-1	8701950
al@@	O	-1	8701950
re@@	O	-1	8701950
ad@@	O	-1	8701950
y	O	-1	8701950
known	O	-1	8701950
to	O	-1	8701950
induce	O	-1	8701950
MA@@	B-Disease	D000743	8701950
H@@	I-Disease	-1	8701950
A	I-Disease	-1	8701950
.	O	-1	8701950

V@@	O	-1	7292072
ari@@	O	-1	7292072
ant	O	-1	7292072
ventricular	B-Disease	D017180	7292072
tachycardia	I-Disease	-1	7292072
in	O	-1	7292072
desi@@	B-Chemical	D003891	7292072
pramine	I-Chemical	-1	7292072
toxicity	B-Disease	D064420	7292072
.	O	-1	7292072
We	O	-1	7292072
report	O	-1	7292072
a	O	-1	7292072
case	O	-1	7292072
of	O	-1	7292072
vari@@	O	-1	7292072
ant	O	-1	7292072
ventricular	B-Disease	D017180	7292072
tachycardia	I-Disease	-1	7292072
induced	O	-1	7292072
by	O	-1	7292072
desi@@	B-Chemical	D003891	7292072
pramine	I-Chemical	-1	7292072
toxicity	B-Disease	D064420	7292072
.	O	-1	7292072
U@@	O	-1	7292072
n@@	O	-1	7292072
us@@	O	-1	7292072
ual	O	-1	7292072
feat@@	O	-1	7292072
ures	O	-1	7292072
of	O	-1	7292072
the	O	-1	7292072
arrhyth@@	B-Disease	D001145	7292072
mia	I-Disease	-1	7292072
are	O	-1	7292072
repe@@	O	-1	7292072
ti@@	O	-1	7292072
tive	O	-1	7292072
group	O	-1	7292072
be@@	O	-1	7292072
at@@	O	-1	7292072
ing,	O	-1	7292072
progressive	O	-1	7292072
sh@@	O	-1	7292072
or@@	O	-1	7292072
ten@@	O	-1	7292072
ing	O	-1	7292072
of	O	-1	7292072
the	O	-1	7292072
R@@	O	-1	7292072
-@@	O	-1	7292072
R	O	-1	7292072
inter@@	O	-1	7292072
val@@	O	-1	7292072
,	O	-1	7292072
progressive	O	-1	7292072
w@@	O	-1	7292072
id@@	O	-1	7292072
en@@	O	-1	7292072
ing	O	-1	7292072
of	O	-1	7292072
the	O	-1	7292072
Q@@	O	-1	7292072
R@@	O	-1	7292072
S	O	-1	7292072
comple@@	O	-1	7292072
x	O	-1	7292072
with	O	-1	7292072
event@@	O	-1	7292072
ual	O	-1	7292072
failure	O	-1	7292072
of	O	-1	7292072
intra@@	O	-1	7292072
ventricular	O	-1	7292072
con@@	O	-1	7292072
duc@@	O	-1	7292072
tion,	O	-1	7292072
and	O	-1	7292072
changes	O	-1	7292072
in	O	-1	7292072
direc@@	O	-1	7292072
tion	O	-1	7292072
of	O	-1	7292072
the	O	-1	7292072
Q@@	O	-1	7292072
R@@	O	-1	7292072
S	O	-1	7292072
ax@@	O	-1	7292072
i@@	O	-1	7292072
s.	O	-1	7292072
Rec@@	O	-1	7292072
o@@	O	-1	7292072
gn@@	O	-1	7292072
ition	O	-1	7292072
of	O	-1	7292072
vari@@	O	-1	7292072
ant	O	-1	7292072
ventricular	B-Disease	D017180	7292072
tachycardia	I-Disease	-1	7292072
is	O	-1	7292072
important	O	-1	7292072
because	O	-1	7292072
therapy	O	-1	7292072
diff@@	O	-1	7292072
ers	O	-1	7292072
from	O	-1	7292072
that	O	-1	7292072
of	O	-1	7292072
cl@@	O	-1	7292072
as@@	O	-1	7292072
sic	O	-1	7292072
ventricular	B-Disease	D017180	7292072
tachycardia	I-Disease	-1	7292072
.	O	-1	7292072

De@@	B-Chemical	D003891	4027862
si@@	I-Chemical	-1	4027862
pramine	I-Chemical	-1	4027862
-induced	O	-1	4027862
de@@	B-Disease	D003693	4027862
li@@	I-Disease	-1	4027862
ri@@	I-Disease	-1	4027862
um	I-Disease	-1	4027862
at	O	-1	4027862
"@@	O	-1	4027862
sub@@	O	-1	4027862
therapeu@@	O	-1	4027862
tic@@	O	-1	4027862
"	O	-1	4027862
concentr@@	O	-1	4027862
ation@@	O	-1	4027862
s:	O	-1	4027862
a	O	-1	4027862
case	O	-1	4027862
repor@@	O	-1	4027862
t.	O	-1	4027862
An	O	-1	4027862
el@@	O	-1	4027862
der@@	O	-1	4027862
ly	O	-1	4027862
patient	O	-1	4027862
treated	O	-1	4027862
with	O	-1	4027862
low	O	-1	4027862
dose	O	-1	4027862
De@@	B-Chemical	D003891	4027862
si@@	I-Chemical	-1	4027862
pramine	I-Chemical	-1	4027862
developed	O	-1	4027862
a	O	-1	4027862
de@@	B-Disease	D003693	4027862
li@@	I-Disease	-1	4027862
ri@@	I-Disease	-1	4027862
um	I-Disease	-1	4027862
while	O	-1	4027862
h@@	O	-1	4027862
er	O	-1	4027862
plasma	O	-1	4027862
level	O	-1	4027862
was	O	-1	4027862
in	O	-1	4027862
the	O	-1	4027862
"@@	O	-1	4027862
sub@@	O	-1	4027862
therapeu@@	O	-1	4027862
tic@@	O	-1	4027862
"	O	-1	4027862
rang@@	O	-1	4027862
e.	O	-1	4027862
De@@	B-Disease	D003693	4027862
li@@	I-Disease	-1	4027862
ri@@	I-Disease	-1	4027862
um	I-Disease	-1	4027862
,	O	-1	4027862
which	O	-1	4027862
may	O	-1	4027862
be	O	-1	4027862
induced	O	-1	4027862
by	O	-1	4027862
tr@@	O	-1	4027862
ic@@	O	-1	4027862
y@@	O	-1	4027862
cl@@	O	-1	4027862
ic	O	-1	4027862
drug	O	-1	4027862
therapy	O	-1	4027862
in	O	-1	4027862
the	O	-1	4027862
el@@	O	-1	4027862
der@@	O	-1	4027862
ly,	O	-1	4027862
can	O	-1	4027862
be	O	-1	4027862
caused	O	-1	4027862
by	O	-1	4027862
tr@@	O	-1	4027862
ic@@	O	-1	4027862
y@@	O	-1	4027862
cl@@	O	-1	4027862
ic@@	O	-1	4027862
s	O	-1	4027862
with	O	-1	4027862
low	O	-1	4027862
anti@@	O	-1	4027862
cholinergic	O	-1	4027862
poten@@	O	-1	4027862
c@@	O	-1	4027862
y.	O	-1	4027862
Th@@	O	-1	4027862
er@@	O	-1	4027862
ap@@	O	-1	4027862
eu@@	O	-1	4027862
tic	O	-1	4027862
rang@@	O	-1	4027862
es	O	-1	4027862
for	O	-1	4027862
antidepress@@	B-Chemical	D000928	4027862
ants	I-Chemical	-1	4027862
that	O	-1	4027862
have	O	-1	4027862
been	O	-1	4027862
der@@	O	-1	4027862
i@@	O	-1	4027862
ved	O	-1	4027862
from	O	-1	4027862
gener@@	O	-1	4027862
al	O	-1	4027862
ad@@	O	-1	4027862
ult	O	-1	4027862
po@@	O	-1	4027862
p@@	O	-1	4027862
ulation	O	-1	4027862
studies	O	-1	4027862
may	O	-1	4027862
not	O	-1	4027862
be	O	-1	4027862
appro@@	O	-1	4027862
pri@@	O	-1	4027862
ate	O	-1	4027862
for	O	-1	4027862
the	O	-1	4027862
el@@	O	-1	4027862
der@@	O	-1	4027862
ly.	O	-1	4027862
F@@	O	-1	4027862
urther	O	-1	4027862
studies	O	-1	4027862
of	O	-1	4027862
spec@@	O	-1	4027862
ific@@	O	-1	4027862
ally	O	-1	4027862
el@@	O	-1	4027862
der@@	O	-1	4027862
ly	O	-1	4027862
patients	O	-1	4027862
are	O	-1	4027862
no@@	O	-1	4027862
w	O	-1	4027862
requ@@	O	-1	4027862
ired	O	-1	4027862
to	O	-1	4027862
est@@	O	-1	4027862
abl@@	O	-1	4027862
is@@	O	-1	4027862
h	O	-1	4027862
saf@@	O	-1	4027862
er	O	-1	4027862
and	O	-1	4027862
more	O	-1	4027862
appro@@	O	-1	4027862
pri@@	O	-1	4027862
ate	O	-1	4027862
gu@@	O	-1	4027862
ide@@	O	-1	4027862
lin@@	O	-1	4027862
es	O	-1	4027862
for	O	-1	4027862
drug	O	-1	4027862
therapy.	O	-1	4027862

M@@	O	-1	2484011
ou@@	O	-1	2484011
se	O	-1	2484011
stra@@	O	-1	2484011
in-@@	O	-1	2484011
dependent	O	-1	2484011
effect	O	-1	2484011
of	O	-1	2484011
am@@	B-Chemical	D000547	2484011
ant@@	I-Chemical	-1	2484011
ad@@	I-Chemical	-1	2484011
ine	I-Chemical	-1	2484011
on	O	-1	2484011
mo@@	O	-1	2484011
til@@	O	-1	2484011
ity	O	-1	2484011
and	O	-1	2484011
brain	O	-1	2484011
bio@@	O	-1	2484011
genic	O	-1	2484011
amin@@	B-Chemical	D000588	2484011
es	I-Chemical	-1	2484011
.	O	-1	2484011
The	O	-1	2484011
effect	O	-1	2484011
of	O	-1	2484011
am@@	B-Chemical	D000547	2484011
ant@@	I-Chemical	-1	2484011
ad@@	I-Chemical	-1	2484011
ine	I-Chemical	-1	2484011
hydro@@	I-Chemical	-1	2484011
chlor@@	I-Chemical	-1	2484011
ide	I-Chemical	-1	2484011
,	O	-1	2484011
injected	O	-1	2484011
i.@@	O	-1	2484011
p@@	O	-1	2484011
.	O	-1	2484011
in	O	-1	2484011
6	O	-1	2484011
inc@@	O	-1	2484011
re@@	O	-1	2484011
ments	O	-1	2484011
of	O	-1	2484011
100	O	-1	2484011
mg/kg	O	-1	2484011
each	O	-1	2484011
over	O	-1	2484011
30	O	-1	2484011
h@@	O	-1	2484011
r@@	O	-1	2484011
,	O	-1	2484011
on	O	-1	2484011
mouse	O	-1	2484011
mo@@	O	-1	2484011
til@@	O	-1	2484011
ity	O	-1	2484011
and	O	-1	2484011
wh@@	O	-1	2484011
ole	O	-1	2484011
brain	O	-1	2484011
cont@@	O	-1	2484011
ent	O	-1	2484011
of	O	-1	2484011
sel@@	O	-1	2484011
ected	O	-1	2484011
bio@@	O	-1	2484011
genic	O	-1	2484011
amin@@	B-Chemical	D000588	2484011
es	I-Chemical	-1	2484011
and	O	-1	2484011
major	O	-1	2484011
metabol@@	O	-1	2484011
it@@	O	-1	2484011
es	O	-1	2484011
was	O	-1	2484011
studied	O	-1	2484011
in	O	-1	2484011
4	O	-1	2484011
stra@@	O	-1	2484011
ins	O	-1	2484011
of	O	-1	2484011
mice.	O	-1	2484011
These	O	-1	2484011
were	O	-1	2484011
the	O	-1	2484011
al@@	O	-1	2484011
bin@@	O	-1	2484011
o	O	-1	2484011
S@@	O	-1	2484011
pra@@	O	-1	2484011
gu@@	O	-1	2484011
e-@@	O	-1	2484011
D@@	O	-1	2484011
aw@@	O	-1	2484011
le@@	O	-1	2484011
y	O	-1	2484011
IC@@	O	-1	2484011
R	O	-1	2484011
and	O	-1	2484011
BA@@	O	-1	2484011
L@@	O	-1	2484011
B@@	O	-1	2484011
/@@	O	-1	2484011
C@@	O	-1	2484011
,	O	-1	2484011
the	O	-1	2484011
bl@@	O	-1	2484011
ac@@	O	-1	2484011
k	O	-1	2484011
C@@	O	-1	2484011
5@@	O	-1	2484011
7@@	O	-1	2484011
B@@	O	-1	2484011
L@@	O	-1	2484011
/@@	O	-1	2484011
6	O	-1	2484011
and	O	-1	2484011
the	O	-1	2484011
b@@	O	-1	2484011
row@@	O	-1	2484011
n	O	-1	2484011
C@@	O	-1	2484011
DF@@	O	-1	2484011
-@@	O	-1	2484011
I	O	-1	2484011
mouse	O	-1	2484011
stra@@	O	-1	2484011
in@@	O	-1	2484011
s.	O	-1	2484011
A@@	B-Chemical	D000547	2484011
m@@	I-Chemical	-1	2484011
ant@@	I-Chemical	-1	2484011
ad@@	I-Chemical	-1	2484011
ine	I-Chemical	-1	2484011
treatment	O	-1	2484011
produced	O	-1	2484011
a	O	-1	2484011
b@@	O	-1	2484011
i@@	O	-1	2484011
pha@@	O	-1	2484011
sic	O	-1	2484011
effect	O	-1	2484011
on	O	-1	2484011
mouse	O	-1	2484011
mo@@	O	-1	2484011
til@@	O	-1	2484011
ity.	O	-1	2484011
The	O	-1	2484011
initial	O	-1	2484011
dose	O	-1	2484011
of	O	-1	2484011
am@@	B-Chemical	D000547	2484011
ant@@	I-Chemical	-1	2484011
ad@@	I-Chemical	-1	2484011
ine	I-Chemical	-1	2484011
depress@@	B-Disease	D003866	2484011
ed	I-Disease	-1	2484011
locomotor	O	-1	2484011
activity	O	-1	2484011
in	O	-1	2484011
all	O	-1	2484011
mouse	O	-1	2484011
stra@@	O	-1	2484011
ins	O	-1	2484011
studied	O	-1	2484011
with	O	-1	2484011
the	O	-1	2484011
BA@@	O	-1	2484011
L@@	O	-1	2484011
B@@	O	-1	2484011
/@@	O	-1	2484011
C	O	-1	2484011
mice	O	-1	2484011
being	O	-1	2484011
the	O	-1	2484011
most	O	-1	2484011
sensi@@	O	-1	2484011
ti@@	O	-1	2484011
ve.	O	-1	2484011
S@@	O	-1	2484011
ub@@	O	-1	2484011
sequ@@	O	-1	2484011
ent	O	-1	2484011
am@@	B-Chemical	D000547	2484011
ant@@	I-Chemical	-1	2484011
ad@@	I-Chemical	-1	2484011
ine	I-Chemical	-1	2484011
treat@@	O	-1	2484011
ments	O	-1	2484011
produced	O	-1	2484011
enh@@	O	-1	2484011
ance@@	O	-1	2484011
ment	O	-1	2484011
of	O	-1	2484011
mo@@	O	-1	2484011
til@@	O	-1	2484011
ity	O	-1	2484011
from	O	-1	2484011
cor@@	O	-1	2484011
respon@@	O	-1	2484011
ding	O	-1	2484011
control	O	-1	2484011
in	O	-1	2484011
all	O	-1	2484011
mouse	O	-1	2484011
stra@@	O	-1	2484011
ins	O	-1	2484011
with	O	-1	2484011
the	O	-1	2484011
BA@@	O	-1	2484011
L@@	O	-1	2484011
B@@	O	-1	2484011
/@@	O	-1	2484011
C	O	-1	2484011
mice	O	-1	2484011
being	O	-1	2484011
the	O	-1	2484011
le@@	O	-1	2484011
ast	O	-1	2484011
sensi@@	O	-1	2484011
ti@@	O	-1	2484011
ve.	O	-1	2484011
The	O	-1	2484011
locomotor	O	-1	2484011
activity	O	-1	2484011
was	O	-1	2484011
decreased	O	-1	2484011
from	O	-1	2484011
cor@@	O	-1	2484011
respon@@	O	-1	2484011
ding	O	-1	2484011
controls	O	-1	2484011
in	O	-1	2484011
all	O	-1	2484011
stra@@	O	-1	2484011
ins	O	-1	2484011
studi@@	O	-1	2484011
ed,	O	-1	2484011
ex@@	O	-1	2484011
cep@@	O	-1	2484011
t	O	-1	2484011
for	O	-1	2484011
the	O	-1	2484011
IC@@	O	-1	2484011
R	O	-1	2484011
mic@@	O	-1	2484011
e,	O	-1	2484011
during	O	-1	2484011
an	O	-1	2484011
over@@	O	-1	2484011
n@@	O	-1	2484011
ight	O	-1	2484011
drug@@	O	-1	2484011
-@@	O	-1	2484011
free	O	-1	2484011
period	O	-1	2484011
following	O	-1	2484011
the	O	-1	2484011
fo@@	O	-1	2484011
ur@@	O	-1	2484011
th	O	-1	2484011
am@@	B-Chemical	D000547	2484011
ant@@	I-Chemical	-1	2484011
ad@@	I-Chemical	-1	2484011
ine	I-Chemical	-1	2484011
treatment.	O	-1	2484011
Re@@	O	-1	2484011
administration	O	-1	2484011
of	O	-1	2484011
am@@	B-Chemical	D000547	2484011
ant@@	I-Chemical	-1	2484011
ad@@	I-Chemical	-1	2484011
ine	I-Chemical	-1	2484011
,	O	-1	2484011
after	O	-1	2484011
a	O	-1	2484011
drug@@	O	-1	2484011
-@@	O	-1	2484011
free	O	-1	2484011
over@@	O	-1	2484011
n@@	O	-1	2484011
ight	O	-1	2484011
perio@@	O	-1	2484011
d,	O	-1	2484011
increased	O	-1	2484011
mo@@	O	-1	2484011
til@@	O	-1	2484011
ity	O	-1	2484011
from	O	-1	2484011
resp@@	O	-1	2484011
ective	O	-1	2484011
saline	O	-1	2484011
control	O	-1	2484011
in	O	-1	2484011
all	O	-1	2484011
stra@@	O	-1	2484011
ins	O	-1	2484011
with	O	-1	2484011
ex@@	O	-1	2484011
ce@@	O	-1	2484011
ption	O	-1	2484011
of	O	-1	2484011
the	O	-1	2484011
BA@@	O	-1	2484011
L@@	O	-1	2484011
B@@	O	-1	2484011
/@@	O	-1	2484011
C	O	-1	2484011
mice	O	-1	2484011
wh@@	O	-1	2484011
ere	O	-1	2484011
sup@@	B-Disease	D011596	2484011
pression	I-Disease	-1	2484011
of	I-Disease	-1	2484011
mo@@	I-Disease	-1	2484011
til@@	I-Disease	-1	2484011
ity	I-Disease	-1	2484011
occur@@	O	-1	2484011
red.	O	-1	2484011
Treat@@	O	-1	2484011
ment	O	-1	2484011
with	O	-1	2484011
am@@	B-Chemical	D000547	2484011
ant@@	I-Chemical	-1	2484011
ad@@	I-Chemical	-1	2484011
ine	I-Chemical	-1	2484011
did	O	-1	2484011
not	O	-1	2484011
al@@	O	-1	2484011
ter	O	-1	2484011
wh@@	O	-1	2484011
ole	O	-1	2484011
brain	O	-1	2484011
dopamine	B-Chemical	D004298	2484011
levels	O	-1	2484011
but	O	-1	2484011
decreased	O	-1	2484011
the	O	-1	2484011
amoun@@	O	-1	2484011
ts	O	-1	2484011
of	O	-1	2484011
3@@	B-Chemical	D015102	2484011
,@@	I-Chemical	-1	2484011
4-@@	I-Chemical	-1	2484011
di@@	I-Chemical	-1	2484011
hydrox@@	I-Chemical	-1	2484011
y@@	I-Chemical	-1	2484011
phenyl@@	I-Chemical	-1	2484011
ace@@	I-Chemical	-1	2484011
tic	I-Chemical	-1	2484011
acid	I-Chemical	-1	2484011
in	O	-1	2484011
the	O	-1	2484011
BA@@	O	-1	2484011
L@@	O	-1	2484011
B@@	O	-1	2484011
/@@	O	-1	2484011
C	O	-1	2484011
mice	O	-1	2484011
compared	O	-1	2484011
to	O	-1	2484011
saline	O	-1	2484011
control@@	O	-1	2484011
.	O	-1	2484011
Con@@	O	-1	2484011
ver@@	O	-1	2484011
sel@@	O	-1	2484011
y,	O	-1	2484011
brain	O	-1	2484011
nor@@	B-Chemical	D009647	2484011
met@@	I-Chemical	-1	2484011
ane@@	I-Chemical	-1	2484011
phrine	I-Chemical	-1	2484011
concentration	O	-1	2484011
was	O	-1	2484011
increased	O	-1	2484011
from	O	-1	2484011
saline	O	-1	2484011
control	O	-1	2484011
by	O	-1	2484011
am@@	B-Chemical	D000547	2484011
ant@@	I-Chemical	-1	2484011
ad@@	I-Chemical	-1	2484011
ine	I-Chemical	-1	2484011
in	O	-1	2484011
the	O	-1	2484011
BA@@	O	-1	2484011
L@@	O	-1	2484011
B@@	O	-1	2484011
/@@	O	-1	2484011
C	O	-1	2484011
mice.	O	-1	2484011
The	O	-1	2484011
results	O	-1	2484011
suggest	O	-1	2484011
a	O	-1	2484011
stra@@	O	-1	2484011
in-@@	O	-1	2484011
dependent	O	-1	2484011
effect	O	-1	2484011
of	O	-1	2484011
am@@	B-Chemical	D000547	2484011
ant@@	I-Chemical	-1	2484011
ad@@	I-Chemical	-1	2484011
ine	I-Chemical	-1	2484011
on	O	-1	2484011
mo@@	O	-1	2484011
til@@	O	-1	2484011
ity	O	-1	2484011
and	O	-1	2484011
indicate	O	-1	2484011
a	O	-1	2484011
differen@@	O	-1	2484011
tial	O	-1	2484011
response	O	-1	2484011
to	O	-1	2484011
the	O	-1	2484011
acute	O	-1	2484011
and	O	-1	2484011
multiple	O	-1	2484011
dose	O	-1	2484011
regimen@@	O	-1	2484011
s	O	-1	2484011
use@@	O	-1	2484011
d.	O	-1	2484011
The	O	-1	2484011
BA@@	O	-1	2484011
L@@	O	-1	2484011
B@@	O	-1	2484011
/@@	O	-1	2484011
C	O	-1	2484011
mouse	O	-1	2484011
was	O	-1	2484011
the	O	-1	2484011
most	O	-1	2484011
sensitive	O	-1	2484011
stra@@	O	-1	2484011
in	O	-1	2484011
and	O	-1	2484011
could	O	-1	2484011
ser@@	O	-1	2484011
ve	O	-1	2484011
as	O	-1	2484011
the	O	-1	2484011
stra@@	O	-1	2484011
in	O	-1	2484011
of	O	-1	2484011
ch@@	O	-1	2484011
o@@	O	-1	2484011
ic@@	O	-1	2484011
e	O	-1	2484011
for	O	-1	2484011
evalu@@	O	-1	2484011
ating	O	-1	2484011
the	O	-1	2484011
side	O	-1	2484011
effects	O	-1	2484011
of	O	-1	2484011
am@@	B-Chemical	D000547	2484011
ant@@	I-Chemical	-1	2484011
ad@@	I-Chemical	-1	2484011
ine	I-Chemical	-1	2484011
.	O	-1	2484011
The	O	-1	2484011
bio@@	O	-1	2484011
chemical	O	-1	2484011
results	O	-1	2484011
of	O	-1	2484011
brain	O	-1	2484011
bio@@	O	-1	2484011
genic	O	-1	2484011
amin@@	B-Chemical	D000588	2484011
es	I-Chemical	-1	2484011
of	O	-1	2484011
BA@@	O	-1	2484011
L@@	O	-1	2484011
B@@	O	-1	2484011
/@@	O	-1	2484011
C	O	-1	2484011
mouse	O	-1	2484011
stra@@	O	-1	2484011
in	O	-1	2484011
suggest	O	-1	2484011
a	O	-1	2484011
prob@@	O	-1	2484011
able	O	-1	2484011
decrease	O	-1	2484011
of	O	-1	2484011
cat@@	B-Chemical	D002395	2484011
ech@@	I-Chemical	-1	2484011
ol@@	I-Chemical	-1	2484011
amine	I-Chemical	-1	2484011
t@@	O	-1	2484011
ur@@	O	-1	2484011
no@@	O	-1	2484011
ver	O	-1	2484011
rate	O	-1	2484011
and/or	O	-1	2484011
metabol@@	O	-1	2484011
ism	O	-1	2484011
by	O	-1	2484011
mon@@	O	-1	2484011
o@@	O	-1	2484011
amine	O	-1	2484011
oxid@@	O	-1	2484011
ase	O	-1	2484011
and	O	-1	2484011
a	O	-1	2484011
result@@	O	-1	2484011
ing	O	-1	2484011
increase	O	-1	2484011
in	O	-1	2484011
O@@	O	-1	2484011
-@@	O	-1	2484011
methyl@@	O	-1	2484011
ation	O	-1	2484011
of	O	-1	2484011
no@@	B-Chemical	D009638	2484011
re@@	I-Chemical	-1	2484011
p@@	I-Chemical	-1	2484011
ine@@	I-Chemical	-1	2484011
phrine	I-Chemical	-1	2484011
which	O	-1	2484011
may	O	-1	2484011
ac@@	O	-1	2484011
coun@@	O	-1	2484011
t	O	-1	2484011
for	O	-1	2484011
a	O	-1	2484011
behavioral	B-Disease	D011596	2484011
de@@	I-Disease	-1	2484011
pression	I-Disease	-1	2484011
caused	O	-1	2484011
by	O	-1	2484011
am@@	B-Chemical	D000547	2484011
ant@@	I-Chemical	-1	2484011
ad@@	I-Chemical	-1	2484011
ine	I-Chemical	-1	2484011
in	O	-1	2484011
the	O	-1	2484011
BA@@	O	-1	2484011
L@@	O	-1	2484011
B@@	O	-1	2484011
/@@	O	-1	2484011
C	O	-1	2484011
mice.	O	-1	2484011

No	O	-1	2396046
enh@@	O	-1	2396046
ance@@	O	-1	2396046
ment	O	-1	2396046
by	O	-1	2396046
phenobarbit@@	B-Chemical	D010634	2396046
al	I-Chemical	-1	2396046
of	O	-1	2396046
the	O	-1	2396046
hepat@@	O	-1	2396046
oc@@	O	-1	2396046
arc@@	O	-1	2396046
ino@@	O	-1	2396046
gen@@	O	-1	2396046
ic@@	O	-1	2396046
ity	O	-1	2396046
of	O	-1	2396046
a	O	-1	2396046
chol@@	B-Chemical	D002794	2396046
ine	I-Chemical	-1	2396046
-@@	O	-1	2396046
de@@	O	-1	2396046
v@@	O	-1	2396046
oid	O	-1	2396046
diet	O	-1	2396046
in	O	-1	2396046
the	O	-1	2396046
rat@@	O	-1	2396046
.	O	-1	2396046
An	O	-1	2396046
experim@@	O	-1	2396046
ent	O	-1	2396046
was	O	-1	2396046
performed	O	-1	2396046
to	O	-1	2396046
test	O	-1	2396046
whether	O	-1	2396046
inc@@	O	-1	2396046
lu@@	O	-1	2396046
sion	O	-1	2396046
of	O	-1	2396046
phenobarbit@@	B-Chemical	D010634	2396046
al	I-Chemical	-1	2396046
in	O	-1	2396046
a	O	-1	2396046
chol@@	B-Chemical	D002794	2396046
ine	I-Chemical	-1	2396046
-@@	O	-1	2396046
de@@	O	-1	2396046
v@@	O	-1	2396046
oid	O	-1	2396046
diet	O	-1	2396046
wo@@	O	-1	2396046
uld	O	-1	2396046
increase	O	-1	2396046
the	O	-1	2396046
hepat@@	O	-1	2396046
oc@@	O	-1	2396046
arc@@	O	-1	2396046
ino@@	O	-1	2396046
gen@@	O	-1	2396046
ic@@	O	-1	2396046
ity	O	-1	2396046
of	O	-1	2396046
the	O	-1	2396046
di@@	O	-1	2396046
et@@	O	-1	2396046
.	O	-1	2396046
Grou@@	O	-1	2396046
p@@	O	-1	2396046
s	O	-1	2396046
of	O	-1	2396046
5-@@	O	-1	2396046
week	O	-1	2396046
old	O	-1	2396046
male	O	-1	2396046
F@@	O	-1	2396046
is@@	O	-1	2396046
ch@@	O	-1	2396046
er@@	O	-1	2396046
-@@	O	-1	2396046
34@@	O	-1	2396046
4	O	-1	2396046
rats	O	-1	2396046
were	O	-1	2396046
f@@	O	-1	2396046
ed	O	-1	2396046
for	O	-1	2396046
7-@@	O	-1	2396046
25	O	-1	2396046
months	O	-1	2396046
se@@	O	-1	2396046
mi@@	O	-1	2396046
pur@@	O	-1	2396046
if@@	O	-1	2396046
ied	O	-1	2396046
chol@@	B-Chemical	D002794	2396046
ine	I-Chemical	-1	2396046
-@@	O	-1	2396046
de@@	O	-1	2396046
v@@	O	-1	2396046
oid	O	-1	2396046
or	O	-1	2396046
chol@@	B-Chemical	D002794	2396046
ine	I-Chemical	-1	2396046
-@@	O	-1	2396046
sup@@	O	-1	2396046
ple@@	O	-1	2396046
ment@@	O	-1	2396046
ed	O	-1	2396046
di@@	O	-1	2396046
et@@	O	-1	2396046
s,	O	-1	2396046
containing	O	-1	2396046
or	O	-1	2396046
not	O	-1	2396046
0.0@@	O	-1	2396046
6%	O	-1	2396046
phenobarbit@@	B-Chemical	D010634	2396046
al	I-Chemical	-1	2396046
.	O	-1	2396046
No	O	-1	2396046
hepatic	O	-1	2396046
pre@@	O	-1	2396046
ne@@	O	-1	2396046
o@@	O	-1	2396046
plas@@	O	-1	2396046
tic	O	-1	2396046
no@@	O	-1	2396046
d@@	O	-1	2396046
ul@@	O	-1	2396046
es	O	-1	2396046
or	O	-1	2396046
hepat@@	B-Disease	D006528	2396046
oc@@	I-Disease	-1	2396046
ell@@	I-Disease	-1	2396046
ular	I-Disease	-1	2396046
carcin@@	I-Disease	-1	2396046
om@@	I-Disease	-1	2396046
as	I-Disease	-1	2396046
developed	O	-1	2396046
in	O	-1	2396046
rats	O	-1	2396046
f@@	O	-1	2396046
ed	O	-1	2396046
the	O	-1	2396046
pl@@	O	-1	2396046
ain	O	-1	2396046
chol@@	B-Chemical	D002794	2396046
ine	I-Chemical	-1	2396046
-@@	O	-1	2396046
sup@@	O	-1	2396046
ple@@	O	-1	2396046
ment@@	O	-1	2396046
ed	O	-1	2396046
di@@	O	-1	2396046
et@@	O	-1	2396046
,	O	-1	2396046
while	O	-1	2396046
one	O	-1	2396046
pre@@	O	-1	2396046
ne@@	O	-1	2396046
o@@	O	-1	2396046
plas@@	O	-1	2396046
tic	O	-1	2396046
no@@	O	-1	2396046
d@@	O	-1	2396046
ul@@	O	-1	2396046
e	O	-1	2396046
and	O	-1	2396046
one	O	-1	2396046
hepat@@	B-Disease	D006528	2396046
oc@@	I-Disease	-1	2396046
ell@@	I-Disease	-1	2396046
ular	I-Disease	-1	2396046
carcin@@	I-Disease	-1	2396046
oma	I-Disease	-1	2396046
developed	O	-1	2396046
in	O	-1	2396046
two	O	-1	2396046
rats	O	-1	2396046
f@@	O	-1	2396046
ed	O	-1	2396046
the	O	-1	2396046
same	O	-1	2396046
diet	O	-1	2396046
containing	O	-1	2396046
phenobarbit@@	B-Chemical	D010634	2396046
al	I-Chemical	-1	2396046
.	O	-1	2396046
The	O	-1	2396046
incidence	O	-1	2396046
of	O	-1	2396046
pre@@	O	-1	2396046
ne@@	O	-1	2396046
o@@	O	-1	2396046
plas@@	O	-1	2396046
tic	O	-1	2396046
no@@	O	-1	2396046
d@@	O	-1	2396046
ul@@	O	-1	2396046
es	O	-1	2396046
and	O	-1	2396046
of	O	-1	2396046
hepat@@	B-Disease	D006528	2396046
oc@@	I-Disease	-1	2396046
ell@@	I-Disease	-1	2396046
ular	I-Disease	-1	2396046
carcin@@	I-Disease	-1	2396046
om@@	I-Disease	-1	2396046
as	I-Disease	-1	2396046
was	O	-1	2396046
10@@	O	-1	2396046
%	O	-1	2396046
and	O	-1	2396046
3@@	O	-1	2396046
7@@	O	-1	2396046
%,	O	-1	2396046
respectivel@@	O	-1	2396046
y,	O	-1	2396046
in	O	-1	2396046
rats	O	-1	2396046
f@@	O	-1	2396046
ed	O	-1	2396046
the	O	-1	2396046
pl@@	O	-1	2396046
ain	O	-1	2396046
chol@@	B-Chemical	D002794	2396046
ine	I-Chemical	-1	2396046
-@@	O	-1	2396046
de@@	O	-1	2396046
v@@	O	-1	2396046
oid	O	-1	2396046
di@@	O	-1	2396046
et@@	O	-1	2396046
,	O	-1	2396046
and	O	-1	2396046
17@@	O	-1	2396046
%	O	-1	2396046
and	O	-1	2396046
3@@	O	-1	2396046
0@@	O	-1	2396046
%,	O	-1	2396046
in	O	-1	2396046
rats	O	-1	2396046
f@@	O	-1	2396046
ed	O	-1	2396046
the	O	-1	2396046
phenobarbit@@	B-Chemical	D010634	2396046
al	I-Chemical	-1	2396046
-@@	O	-1	2396046
containing	O	-1	2396046
chol@@	B-Chemical	D002794	2396046
ine	I-Chemical	-1	2396046
-@@	O	-1	2396046
de@@	O	-1	2396046
v@@	O	-1	2396046
oid	O	-1	2396046
di@@	O	-1	2396046
et@@	O	-1	2396046
.	O	-1	2396046
The	O	-1	2396046
results	O	-1	2396046
ev@@	O	-1	2396046
inc@@	O	-1	2396046
ed	O	-1	2396046
no	O	-1	2396046
enh@@	O	-1	2396046
ance@@	O	-1	2396046
ment	O	-1	2396046
of	O	-1	2396046
the	O	-1	2396046
hepat@@	O	-1	2396046
oc@@	O	-1	2396046
arc@@	O	-1	2396046
ino@@	O	-1	2396046
gen@@	O	-1	2396046
ic@@	O	-1	2396046
ity	O	-1	2396046
of	O	-1	2396046
the	O	-1	2396046
chol@@	B-Chemical	D002794	2396046
ine	I-Chemical	-1	2396046
-@@	O	-1	2396046
de@@	O	-1	2396046
v@@	O	-1	2396046
oid	O	-1	2396046
diet	O	-1	2396046
by	O	-1	2396046
phenobarbit@@	B-Chemical	D010634	2396046
al	I-Chemical	-1	2396046
.	O	-1	2396046
S@@	O	-1	2396046
por@@	O	-1	2396046
a@@	O	-1	2396046
di@@	O	-1	2396046
c	O	-1	2396046
ne@@	O	-1	2396046
o@@	O	-1	2396046
plas@@	O	-1	2396046
tic	O	-1	2396046
lesions	O	-1	2396046
were	O	-1	2396046
observed	O	-1	2396046
in	O	-1	2396046
org@@	O	-1	2396046
ans	O	-1	2396046
other	O	-1	2396046
than	O	-1	2396046
the	O	-1	2396046
liver	O	-1	2396046
of	O	-1	2396046
some	O	-1	2396046
of	O	-1	2396046
the	O	-1	2396046
anim@@	O	-1	2396046
al@@	O	-1	2396046
s,	O	-1	2396046
ir@@	O	-1	2396046
resp@@	O	-1	2396046
ective	O	-1	2396046
of	O	-1	2396046
the	O	-1	2396046
diet	O	-1	2396046
f@@	O	-1	2396046
ed.	O	-1	2396046

Eff@@	O	-1	2008831
ect	O	-1	2008831
of	O	-1	2008831
direct	O	-1	2008831
intrac@@	O	-1	2008831
or@@	O	-1	2008831
onary	O	-1	2008831
administration	O	-1	2008831
of	O	-1	2008831
methyl@@	B-Chemical	D008755	2008831
erg@@	I-Chemical	-1	2008831
on@@	I-Chemical	-1	2008831
o@@	I-Chemical	-1	2008831
v@@	I-Chemical	-1	2008831
ine	I-Chemical	-1	2008831
in	O	-1	2008831
patients	O	-1	2008831
with	O	-1	2008831
and	O	-1	2008831
without	O	-1	2008831
vari@@	B-Disease	D000788	2008831
ant	I-Disease	-1	2008831
ang@@	I-Disease	-1	2008831
in@@	I-Disease	-1	2008831
a	I-Disease	-1	2008831
.	O	-1	2008831
The	O	-1	2008831
effects	O	-1	2008831
of	O	-1	2008831
intrac@@	O	-1	2008831
or@@	O	-1	2008831
onary	O	-1	2008831
administration	O	-1	2008831
of	O	-1	2008831
methyl@@	B-Chemical	D008755	2008831
erg@@	I-Chemical	-1	2008831
on@@	I-Chemical	-1	2008831
o@@	I-Chemical	-1	2008831
v@@	I-Chemical	-1	2008831
ine	I-Chemical	-1	2008831
were	O	-1	2008831
studied	O	-1	2008831
in	O	-1	2008831
21	O	-1	2008831
patients	O	-1	2008831
with	O	-1	2008831
vari@@	B-Disease	D000788	2008831
ant	I-Disease	-1	2008831
ang@@	I-Disease	-1	2008831
in@@	I-Disease	-1	2008831
a	I-Disease	-1	2008831
and	O	-1	2008831
2@@	O	-1	2008831
2	O	-1	2008831
patients	O	-1	2008831
with	O	-1	2008831
at@@	O	-1	2008831
yp@@	O	-1	2008831
ical	O	-1	2008831
ch@@	B-Disease	D002637	2008831
est	I-Disease	-1	2008831
pain	I-Disease	-1	2008831
and	O	-1	2008831
in	O	-1	2008831
o@@	O	-1	2008831
ther@@	O	-1	2008831
s	O	-1	2008831
without	O	-1	2008831
ang@@	B-Disease	D000787	2008831
in@@	I-Disease	-1	2008831
a	I-Disease	-1	2008831
p@@	I-Disease	-1	2008831
ect@@	I-Disease	-1	2008831
or@@	I-Disease	-1	2008831
is	I-Disease	-1	2008831
(@@	O	-1	2008831
control	O	-1	2008831
group@@	O	-1	2008831
).	O	-1	2008831
M@@	B-Chemical	D008755	2008831
eth@@	I-Chemical	-1	2008831
yl@@	I-Chemical	-1	2008831
erg@@	I-Chemical	-1	2008831
on@@	I-Chemical	-1	2008831
o@@	I-Chemical	-1	2008831
v@@	I-Chemical	-1	2008831
ine	I-Chemical	-1	2008831
was	O	-1	2008831
administered	O	-1	2008831
continu@@	O	-1	2008831
ously	O	-1	2008831
at	O	-1	2008831
a	O	-1	2008831
rate	O	-1	2008831
of	O	-1	2008831
10	O	-1	2008831
microgram@@	O	-1	2008831
s/@@	O	-1	2008831
min	O	-1	2008831
up	O	-1	2008831
to	O	-1	2008831
50	O	-1	2008831
microgram@@	O	-1	2008831
s.	O	-1	2008831
In	O	-1	2008831
all	O	-1	2008831
patients	O	-1	2008831
with	O	-1	2008831
vari@@	B-Disease	D000788	2008831
ant	I-Disease	-1	2008831
ang@@	I-Disease	-1	2008831
in@@	I-Disease	-1	2008831
a	I-Disease	-1	2008831
,	O	-1	2008831
coronary	B-Disease	D003329	2008831
sp@@	I-Disease	-1	2008831
as@@	I-Disease	-1	2008831
m	I-Disease	-1	2008831
was	O	-1	2008831
prov@@	O	-1	2008831
o@@	O	-1	2008831
ked	O	-1	2008831
at	O	-1	2008831
a	O	-1	2008831
mean	O	-1	2008831
dose	O	-1	2008831
of	O	-1	2008831
2@@	O	-1	2008831
8	O	-1	2008831
+/-	O	-1	2008831
13	O	-1	2008831
microgram@@	O	-1	2008831
s	O	-1	2008831
(@@	O	-1	2008831
mean	O	-1	2008831
+/-	O	-1	2008831
S@@	O	-1	2008831
D@@	O	-1	2008831
).	O	-1	2008831
In	O	-1	2008831
the	O	-1	2008831
control	O	-1	2008831
group	O	-1	2008831
ne@@	O	-1	2008831
ither	O	-1	2008831
ischem@@	O	-1	2008831
ic	O	-1	2008831
S@@	O	-1	2008831
T	O	-1	2008831
change	O	-1	2008831
n@@	O	-1	2008831
or	O	-1	2008831
lo@@	O	-1	2008831
cal@@	O	-1	2008831
ized	O	-1	2008831
sp@@	B-Disease	D013035	2008831
as@@	I-Disease	-1	2008831
m	I-Disease	-1	2008831
occur@@	O	-1	2008831
red.	O	-1	2008831
The	O	-1	2008831
bas@@	O	-1	2008831
al	O	-1	2008831
t@@	O	-1	2008831
one	O	-1	2008831
of	O	-1	2008831
the	O	-1	2008831
right	O	-1	2008831
coronary	O	-1	2008831
artery	O	-1	2008831
was	O	-1	2008831
significantly	O	-1	2008831
lower	O	-1	2008831
than	O	-1	2008831
that	O	-1	2008831
of	O	-1	2008831
the	O	-1	2008831
left	O	-1	2008831
coronary	O	-1	2008831
arter@@	O	-1	2008831
y.	O	-1	2008831
The	O	-1	2008831
perc@@	O	-1	2008831
ent@@	O	-1	2008831
age	O	-1	2008831
of	O	-1	2008831
vas@@	O	-1	2008831
o@@	O	-1	2008831
con@@	O	-1	2008831
stric@@	O	-1	2008831
tion	O	-1	2008831
of	O	-1	2008831
the	O	-1	2008831
right	O	-1	2008831
coronary	O	-1	2008831
artery	O	-1	2008831
was	O	-1	2008831
significantly	O	-1	2008831
higher	O	-1	2008831
than	O	-1	2008831
that	O	-1	2008831
of	O	-1	2008831
the	O	-1	2008831
left	O	-1	2008831
coronary	O	-1	2008831
arter@@	O	-1	2008831
y.	O	-1	2008831
These	O	-1	2008831
results	O	-1	2008831
suggest	O	-1	2008831
that	O	-1	2008831
sp@@	B-Disease	D013035	2008831
as@@	I-Disease	-1	2008831
m	I-Disease	-1	2008831
prov@@	O	-1	2008831
oc@@	O	-1	2008831
ation	O	-1	2008831
test@@	O	-1	2008831
s,	O	-1	2008831
which	O	-1	2008831
use	O	-1	2008831
an	O	-1	2008831
intrac@@	O	-1	2008831
or@@	O	-1	2008831
onary	O	-1	2008831
injection	O	-1	2008831
of	O	-1	2008831
a	O	-1	2008831
rel@@	O	-1	2008831
atively	O	-1	2008831
low	O	-1	2008831
dose	O	-1	2008831
of	O	-1	2008831
methyl@@	B-Chemical	D008755	2008831
erg@@	I-Chemical	-1	2008831
on@@	I-Chemical	-1	2008831
o@@	I-Chemical	-1	2008831
v@@	I-Chemical	-1	2008831
ine	I-Chemical	-1	2008831
,	O	-1	2008831
have	O	-1	2008831
a	O	-1	2008831
high	O	-1	2008831
sensitivity	O	-1	2008831
in	O	-1	2008831
vari@@	B-Disease	D000788	2008831
ant	I-Disease	-1	2008831
ang@@	I-Disease	-1	2008831
in@@	I-Disease	-1	2008831
a	I-Disease	-1	2008831
and	O	-1	2008831
the	O	-1	2008831
vas@@	O	-1	2008831
ore@@	O	-1	2008831
activity	O	-1	2008831
of	O	-1	2008831
the	O	-1	2008831
right	O	-1	2008831
coronary	O	-1	2008831
artery	O	-1	2008831
may	O	-1	2008831
be	O	-1	2008831
greater	O	-1	2008831
than	O	-1	2008831
that	O	-1	2008831
of	O	-1	2008831
the	O	-1	2008831
other	O	-1	2008831
coronary	O	-1	2008831
arter@@	O	-1	2008831
i@@	O	-1	2008831
es.	O	-1	2008831

D@@	B-Chemical	D004280	1732369
ob@@	I-Chemical	-1	1732369
ut@@	I-Chemical	-1	1732369
amine	I-Chemical	-1	1732369
stres@@	O	-1	1732369
s	O	-1	1732369
echocardiograph@@	O	-1	1732369
y@@	O	-1	1732369
:	O	-1	1732369
a	O	-1	1732369
sensitive	O	-1	1732369
indic@@	O	-1	1732369
at@@	O	-1	1732369
or	O	-1	1732369
of	O	-1	1732369
di@@	O	-1	1732369
min@@	O	-1	1732369
ished	O	-1	1732369
myocardial	O	-1	1732369
function	O	-1	1732369
in	O	-1	1732369
as@@	O	-1	1732369
ym@@	O	-1	1732369
pto@@	O	-1	1732369
m@@	O	-1	1732369
atic	O	-1	1732369
dox@@	B-Chemical	D004317	1732369
orub@@	I-Chemical	-1	1732369
icin	I-Chemical	-1	1732369
-treated	O	-1	1732369
long-term	O	-1	1732369
sur@@	O	-1	1732369
viv@@	O	-1	1732369
ors	O	-1	1732369
of	O	-1	1732369
child@@	O	-1	1732369
ho@@	O	-1	1732369
od	O	-1	1732369
cancer	B-Disease	D009369	1732369
.	O	-1	1732369
D@@	B-Chemical	D004317	1732369
ox@@	I-Chemical	-1	1732369
orub@@	I-Chemical	-1	1732369
icin	I-Chemical	-1	1732369
is	O	-1	1732369
an	O	-1	1732369
effective	O	-1	1732369
anti@@	O	-1	1732369
cancer	O	-1	1732369
chemo@@	O	-1	1732369
therapeutic	O	-1	1732369
agent	O	-1	1732369
known	O	-1	1732369
to	O	-1	1732369
cause	O	-1	1732369
acute	O	-1	1732369
and	O	-1	1732369
chronic	O	-1	1732369
cardi@@	B-Disease	D009202	1732369
om@@	I-Disease	-1	1732369
yo@@	I-Disease	-1	1732369
pathy	I-Disease	-1	1732369
.	O	-1	1732369
To	O	-1	1732369
deve@@	O	-1	1732369
lo@@	O	-1	1732369
p	O	-1	1732369
a	O	-1	1732369
more	O	-1	1732369
sensitive	O	-1	1732369
echocardiograph@@	O	-1	1732369
ic	O	-1	1732369
s@@	O	-1	1732369
cre@@	O	-1	1732369
en@@	O	-1	1732369
ing	O	-1	1732369
test	O	-1	1732369
for	O	-1	1732369
cardiac	B-Disease	D006331	1732369
damage	I-Disease	-1	1732369
due	O	-1	1732369
to	O	-1	1732369
dox@@	B-Chemical	D004317	1732369
orub@@	I-Chemical	-1	1732369
icin	I-Chemical	-1	1732369
,	O	-1	1732369
a	O	-1	1732369
co@@	O	-1	1732369
h@@	O	-1	1732369
ort	O	-1	1732369
study	O	-1	1732369
was	O	-1	1732369
performed	O	-1	1732369
using	O	-1	1732369
do@@	B-Chemical	D004280	1732369
but@@	I-Chemical	-1	1732369
amine	I-Chemical	-1	1732369
infusion	O	-1	1732369
to	O	-1	1732369
differen@@	O	-1	1732369
ti@@	O	-1	1732369
ate	O	-1	1732369
as@@	O	-1	1732369
ym@@	O	-1	1732369
pto@@	O	-1	1732369
m@@	O	-1	1732369
atic	O	-1	1732369
long-term	O	-1	1732369
sur@@	O	-1	1732369
viv@@	O	-1	1732369
ors	O	-1	1732369
of	O	-1	1732369
child@@	O	-1	1732369
ho@@	O	-1	1732369
od	O	-1	1732369
cancer	B-Disease	D009369	1732369
treated	O	-1	1732369
with	O	-1	1732369
dox@@	B-Chemical	D004317	1732369
orub@@	I-Chemical	-1	1732369
icin	I-Chemical	-1	1732369
from	O	-1	1732369
healthy	O	-1	1732369
control	O	-1	1732369
subj@@	O	-1	1732369
ect@@	O	-1	1732369
s.	O	-1	1732369
E@@	O	-1	1732369
ch@@	O	-1	1732369
ocardiograph@@	O	-1	1732369
ic	O	-1	1732369
data	O	-1	1732369
from	O	-1	1732369
the	O	-1	1732369
experimental	O	-1	1732369
group	O	-1	1732369
of	O	-1	1732369
21	O	-1	1732369
patients	O	-1	1732369
(@@	O	-1	1732369
mean	O	-1	1732369
age	O	-1	1732369
16	O	-1	1732369
+/-	O	-1	1732369
5	O	-1	1732369
year@@	O	-1	1732369
s)	O	-1	1732369
treated	O	-1	1732369
from	O	-1	1732369
1.@@	O	-1	1732369
6	O	-1	1732369
to	O	-1	1732369
1@@	O	-1	1732369
4.@@	O	-1	1732369
3	O	-1	1732369
years	O	-1	1732369
(@@	O	-1	1732369
median	O	-1	1732369
5.@@	O	-1	1732369
3@@	O	-1	1732369
)	O	-1	1732369
before	O	-1	1732369
this	O	-1	1732369
study	O	-1	1732369
with	O	-1	1732369
2@@	O	-1	1732369
7	O	-1	1732369
to	O	-1	1732369
5@@	O	-1	1732369
3@@	O	-1	1732369
2	O	-1	1732369
mg/m@@	O	-1	1732369
2	O	-1	1732369
of	O	-1	1732369
dox@@	B-Chemical	D004317	1732369
orub@@	I-Chemical	-1	1732369
icin	I-Chemical	-1	1732369
(@@	O	-1	1732369
mean	O	-1	1732369
19@@	O	-1	1732369
6@@	O	-1	1732369
)	O	-1	1732369
were	O	-1	1732369
compared	O	-1	1732369
with	O	-1	1732369
echocardiograph@@	O	-1	1732369
ic	O	-1	1732369
data	O	-1	1732369
from	O	-1	1732369
12	O	-1	1732369
normal	O	-1	1732369
ag@@	O	-1	1732369
e-@@	O	-1	1732369
mat@@	O	-1	1732369
ch@@	O	-1	1732369
ed	O	-1	1732369
control	O	-1	1732369
subj@@	O	-1	1732369
ect@@	O	-1	1732369
s.	O	-1	1732369
G@@	O	-1	1732369
ra@@	O	-1	1732369
ded	O	-1	1732369
do@@	B-Chemical	D004280	1732369
but@@	I-Chemical	-1	1732369
amine	I-Chemical	-1	1732369
infu@@	O	-1	1732369
sions	O	-1	1732369
of	O	-1	1732369
0.@@	O	-1	1732369
5,	O	-1	1732369
2.@@	O	-1	1732369
5,	O	-1	1732369
5	O	-1	1732369
and	O	-1	1732369
10	O	-1	1732369
microgram@@	O	-1	1732369
s/@@	O	-1	1732369
k@@	O	-1	1732369
g	O	-1	1732369
per	O	-1	1732369
min	O	-1	1732369
were	O	-1	1732369
administ@@	O	-1	1732369
e@@	O	-1	1732369
red.	O	-1	1732369
E@@	O	-1	1732369
ch@@	O	-1	1732369
ocardiograph@@	O	-1	1732369
ic	O	-1	1732369
D@@	O	-1	1732369
op@@	O	-1	1732369
pl@@	O	-1	1732369
er	O	-1	1732369
studies	O	-1	1732369
were	O	-1	1732369
performed	O	-1	1732369
before	O	-1	1732369
infusion	O	-1	1732369
and	O	-1	1732369
after	O	-1	1732369
15	O	-1	1732369
min	O	-1	1732369
of	O	-1	1732369
infusion	O	-1	1732369
at	O	-1	1732369
each	O	-1	1732369
rat@@	O	-1	1732369
e.	O	-1	1732369
D@@	B-Chemical	D004280	1732369
ob@@	I-Chemical	-1	1732369
ut@@	I-Chemical	-1	1732369
amine	I-Chemical	-1	1732369
infusion	O	-1	1732369
at	O	-1	1732369
10	O	-1	1732369
microgram@@	O	-1	1732369
s/@@	O	-1	1732369
k@@	O	-1	1732369
g	O	-1	1732369
per	O	-1	1732369
min	O	-1	1732369
was	O	-1	1732369
discontinu@@	O	-1	1732369
ed	O	-1	1732369
after	O	-1	1732369
six	O	-1	1732369
studies	O	-1	1732369
secondary	O	-1	1732369
to	O	-1	1732369
a	O	-1	1732369
50@@	O	-1	1732369
%	O	-1	1732369
incidence	O	-1	1732369
rate	O	-1	1732369
of	O	-1	1732369
adverse	O	-1	1732369
symptom@@	O	-1	1732369
s.	O	-1	1732369
The	O	-1	1732369
most	O	-1	1732369
important	O	-1	1732369
findings	O	-1	1732369
were	O	-1	1732369
that	O	-1	1732369
compared	O	-1	1732369
with	O	-1	1732369
values	O	-1	1732369
in	O	-1	1732369
control	O	-1	1732369
subj@@	O	-1	1732369
ect@@	O	-1	1732369
s,	O	-1	1732369
en@@	O	-1	1732369
d-@@	O	-1	1732369
systolic	O	-1	1732369
left	O	-1	1732369
ventricular	O	-1	1732369
po@@	O	-1	1732369
ster@@	O	-1	1732369
ior	O	-1	1732369
w@@	O	-1	1732369
all	O	-1	1732369
di@@	O	-1	1732369
men@@	O	-1	1732369
sion	O	-1	1732369
and	O	-1	1732369
perc@@	O	-1	1732369
ent	O	-1	1732369
of	O	-1	1732369
left	O	-1	1732369
ventricular	O	-1	1732369
po@@	O	-1	1732369
ster@@	O	-1	1732369
ior	O	-1	1732369
w@@	O	-1	1732369
all	O	-1	1732369
th@@	O	-1	1732369
ic@@	O	-1	1732369
k@@	O	-1	1732369
en@@	O	-1	1732369
ing	O	-1	1732369
in	O	-1	1732369
dox@@	B-Chemical	D004317	1732369
orub@@	I-Chemical	-1	1732369
icin	I-Chemical	-1	1732369
-treated	O	-1	1732369
patients	O	-1	1732369
were	O	-1	1732369
decreased	O	-1	1732369
at	O	-1	1732369
baseline	O	-1	1732369
study	O	-1	1732369
and	O	-1	1732369
these	O	-1	1732369
findings	O	-1	1732369
were	O	-1	1732369
more	O	-1	1732369
clear@@	O	-1	1732369
ly	O	-1	1732369
del@@	O	-1	1732369
ine@@	O	-1	1732369
ated	O	-1	1732369
with	O	-1	1732369
do@@	B-Chemical	D004280	1732369
but@@	I-Chemical	-1	1732369
amine	I-Chemical	-1	1732369
stimul@@	O	-1	1732369
ation.	O	-1	1732369
E@@	O	-1	1732369
n@@	O	-1	1732369
d-@@	O	-1	1732369
systolic	O	-1	1732369
left	O	-1	1732369
ventricular	O	-1	1732369
po@@	O	-1	1732369
ster@@	O	-1	1732369
ior	O	-1	1732369
w@@	O	-1	1732369
all	O	-1	1732369
di@@	O	-1	1732369
men@@	O	-1	1732369
sion	O	-1	1732369
at	O	-1	1732369
baseline	O	-1	1732369
for	O	-1	1732369
the	O	-1	1732369
dox@@	B-Chemical	D004317	1732369
orub@@	I-Chemical	-1	1732369
icin	I-Chemical	-1	1732369
-treated	O	-1	1732369
group	O	-1	1732369
was	O	-1	1732369
11	O	-1	1732369
+/-	O	-1	1732369
1.@@	O	-1	1732369
9	O	-1	1732369
mm	O	-1	1732369
versus	O	-1	1732369
1@@	O	-1	1732369
3.@@	O	-1	1732369
1	O	-1	1732369
+/-	O	-1	1732369
1.@@	O	-1	1732369
5	O	-1	1732369
mm	O	-1	1732369
for	O	-1	1732369
control	O	-1	1732369
subjects	O	-1	1732369
(p	O	-1	1732369
less	O	-1	1732369
than	O	-1	1732369
0.0@@	O	-1	1732369
1).	O	-1	1732369
E@@	O	-1	1732369
n@@	O	-1	1732369
d-@@	O	-1	1732369
systolic	O	-1	1732369
left	O	-1	1732369
ventricular	O	-1	1732369
po@@	O	-1	1732369
ster@@	O	-1	1732369
ior	O	-1	1732369
w@@	O	-1	1732369
all	O	-1	1732369
di@@	O	-1	1732369
men@@	O	-1	1732369
sion	O	-1	1732369
at	O	-1	1732369
the	O	-1	1732369
5-@@	O	-1	1732369
microgram@@	O	-1	1732369
s/@@	O	-1	1732369
k@@	O	-1	1732369
g	O	-1	1732369
per	O	-1	1732369
min	O	-1	1732369
do@@	B-Chemical	D004280	1732369
but@@	I-Chemical	-1	1732369
amine	I-Chemical	-1	1732369
infusion	O	-1	1732369
for	O	-1	1732369
the	O	-1	1732369
dox@@	B-Chemical	D004317	1732369
orub@@	I-Chemical	-1	1732369
icin	I-Chemical	-1	1732369
-treated	O	-1	1732369
group	O	-1	1732369
was	O	-1	1732369
1@@	O	-1	1732369
4.@@	O	-1	1732369
1	O	-1	1732369
+/-	O	-1	1732369
2.@@	O	-1	1732369
4	O	-1	1732369
mm	O	-1	1732369
versus	O	-1	1732369
19@@	O	-1	1732369
.@@	O	-1	1732369
3	O	-1	1732369
+/-	O	-1	1732369
2.@@	O	-1	1732369
6	O	-1	1732369
mm	O	-1	1732369
for	O	-1	1732369
control	O	-1	1732369
subjects	O	-1	1732369
(p	O	-1	1732369
less	O	-1	1732369
than	O	-1	1732369
0.0@@	O	-1	1732369
1@@	O	-1	1732369
)@@	O	-1	1732369
.@@	O	-1	1732369
(A@@	O	-1	1732369
B@@	O	-1	1732369
S@@	O	-1	1732369
TR@@	O	-1	1732369
AC@@	O	-1	1732369
T	O	-1	1732369
TR@@	O	-1	1732369
UN@@	O	-1	1732369
C@@	O	-1	1732369
AT@@	O	-1	1732369
E@@	O	-1	1732369
D	O	-1	1732369
A@@	O	-1	1732369
T	O	-1	1732369
2@@	O	-1	1732369
50	O	-1	1732369
W@@	O	-1	1732369
O@@	O	-1	1732369
RD@@	O	-1	1732369
S)	O	-1	1732369

Eff@@	O	-1	234669
ects	O	-1	234669
of	O	-1	234669
aminoph@@	B-Chemical	D000628	234669
yl@@	I-Chemical	-1	234669
line	I-Chemical	-1	234669
on	O	-1	234669
the	O	-1	234669
th@@	O	-1	234669
res@@	O	-1	234669
h@@	O	-1	234669
old	O	-1	234669
for	O	-1	234669
initi@@	O	-1	234669
ating	O	-1	234669
ventricular	B-Disease	D014693	234669
fibrill@@	I-Disease	-1	234669
ation	I-Disease	-1	234669
during	O	-1	234669
respiratory	B-Disease	D012131	234669
failure	I-Disease	-1	234669
.	O	-1	234669
C@@	B-Disease	D001145	234669
ardi@@	I-Disease	-1	234669
a@@	I-Disease	-1	234669
c	I-Disease	-1	234669
arrhyth@@	I-Disease	-1	234669
mi@@	I-Disease	-1	234669
as	I-Disease	-1	234669
have	O	-1	234669
frequ@@	O	-1	234669
ently	O	-1	234669
been	O	-1	234669
reported	O	-1	234669
in	O	-1	234669
association	O	-1	234669
with	O	-1	234669
respiratory	B-Disease	D012131	234669
failure	I-Disease	-1	234669
.	O	-1	234669
The	O	-1	234669
possible	O	-1	234669
addi@@	O	-1	234669
tive	O	-1	234669
role	O	-1	234669
of	O	-1	234669
pharmac@@	O	-1	234669
ologic	O	-1	234669
agents	O	-1	234669
in	O	-1	234669
pre@@	O	-1	234669
ci@@	O	-1	234669
pit@@	O	-1	234669
ating	O	-1	234669
cardiac	B-Disease	D006331	234669
dist@@	I-Disease	-1	234669
urb@@	I-Disease	-1	234669
anc@@	I-Disease	-1	234669
es	I-Disease	-1	234669
in	O	-1	234669
patients	O	-1	234669
with	O	-1	234669
respiratory	B-Disease	D012131	234669
failure	I-Disease	-1	234669
has	O	-1	234669
only	O	-1	234669
rec@@	O	-1	234669
ently	O	-1	234669
been	O	-1	234669
em@@	O	-1	234669
pha@@	O	-1	234669
si@@	O	-1	234669
z@@	O	-1	234669
ed.	O	-1	234669
The	O	-1	234669
effects	O	-1	234669
of	O	-1	234669
aminoph@@	B-Chemical	D000628	234669
yl@@	I-Chemical	-1	234669
line	I-Chemical	-1	234669
on	O	-1	234669
the	O	-1	234669
ventricular	B-Disease	D014693	234669
fibrill@@	I-Disease	-1	234669
ation	I-Disease	-1	234669
th@@	O	-1	234669
res@@	O	-1	234669
h@@	O	-1	234669
old	O	-1	234669
during	O	-1	234669
normal	O	-1	234669
acid@@	O	-1	234669
-@@	O	-1	234669
b@@	O	-1	234669
ase	O	-1	234669
condi@@	O	-1	234669
tions	O	-1	234669
and	O	-1	234669
during	O	-1	234669
respiratory	B-Disease	D012131	234669
failure	I-Disease	-1	234669
were	O	-1	234669
studied	O	-1	234669
in	O	-1	234669
anesthe@@	O	-1	234669
tiz@@	O	-1	234669
ed	O	-1	234669
op@@	O	-1	234669
en	O	-1	234669
ch@@	O	-1	234669
est	O	-1	234669
dog@@	O	-1	234669
s.	O	-1	234669
The	O	-1	234669
ventricular	B-Disease	D014693	234669
fibrill@@	I-Disease	-1	234669
ation	I-Disease	-1	234669
th@@	O	-1	234669
res@@	O	-1	234669
h@@	O	-1	234669
old	O	-1	234669
was	O	-1	234669
measured	O	-1	234669
by	O	-1	234669
p@@	O	-1	234669
ass@@	O	-1	234669
ing	O	-1	234669
a	O	-1	234669
g@@	O	-1	234669
ated	O	-1	234669
tra@@	O	-1	234669
in	O	-1	234669
of	O	-1	234669
12	O	-1	234669
con@@	O	-1	234669
st@@	O	-1	234669
ant	O	-1	234669
current	O	-1	234669
pul@@	O	-1	234669
ses	O	-1	234669
through	O	-1	234669
the	O	-1	234669
ventricular	O	-1	234669
myocardi@@	O	-1	234669
um	O	-1	234669
during	O	-1	234669
the	O	-1	234669
vul@@	O	-1	234669
ner@@	O	-1	234669
able	O	-1	234669
period	O	-1	234669
of	O	-1	234669
the	O	-1	234669
cardiac	O	-1	234669
cyc@@	O	-1	234669
le@@	O	-1	234669
.	O	-1	234669
D@@	O	-1	234669
uring	O	-1	234669
the	O	-1	234669
infusion	O	-1	234669
of	O	-1	234669
aminoph@@	B-Chemical	D000628	234669
yl@@	I-Chemical	-1	234669
line	I-Chemical	-1	234669
,	O	-1	234669
the	O	-1	234669
ventricular	B-Disease	D014693	234669
fibrill@@	I-Disease	-1	234669
ation	I-Disease	-1	234669
th@@	O	-1	234669
res@@	O	-1	234669
h@@	O	-1	234669
old	O	-1	234669
was	O	-1	234669
reduced	O	-1	234669
by	O	-1	234669
30	O	-1	234669
to	O	-1	234669
40	O	-1	234669
perc@@	O	-1	234669
ent	O	-1	234669
of	O	-1	234669
the	O	-1	234669
control	O	-1	234669
when	O	-1	234669
p@@	O	-1	234669
H	O	-1	234669
and	O	-1	234669
partial	O	-1	234669
pressu@@	O	-1	234669
res	O	-1	234669
of	O	-1	234669
oxy@@	B-Chemical	D010100	234669
gen	I-Chemical	-1	234669
(	O	-1	234669
P@@	B-Chemical	C093415	234669
O@@	I-Chemical	-1	234669
2	I-Chemical	-1	234669
)	O	-1	234669
and	O	-1	234669
carb@@	B-Chemical	D002245	234669
on	I-Chemical	-1	234669
di@@	I-Chemical	-1	234669
ox@@	I-Chemical	-1	234669
ide	I-Chemical	-1	234669
(	O	-1	234669
CO@@	B-Chemical	D002245	234669
2	I-Chemical	-1	234669
)	O	-1	234669
were	O	-1	234669
k@@	O	-1	234669
ep@@	O	-1	234669
t	O	-1	234669
within	O	-1	234669
normal	O	-1	234669
lim@@	O	-1	234669
it@@	O	-1	234669
s.	O	-1	234669
Whe@@	O	-1	234669
n	O	-1	234669
respiratory	B-Disease	D012131	234669
failure	I-Disease	-1	234669
was	O	-1	234669
produced	O	-1	234669
by	O	-1	234669
hypo@@	B-Disease	D007040	234669
ven@@	I-Disease	-1	234669
til@@	I-Disease	-1	234669
ation	I-Disease	-1	234669
(p@@	O	-1	234669
H	O	-1	234669
7.@@	O	-1	234669
0@@	O	-1	234669
5	O	-1	234669
to	O	-1	234669
7.@@	O	-1	234669
25@@	O	-1	234669
;	O	-1	234669
P@@	O	-1	234669
C@@	O	-1	234669
0@@	O	-1	234669
2	O	-1	234669
7@@	O	-1	234669
0	O	-1	234669
to	O	-1	234669
100	O	-1	234669
mm	O	-1	234669
H@@	O	-1	234669
g@@	O	-1	234669
:	O	-1	234669
P@@	O	-1	234669
0@@	O	-1	234669
2	O	-1	234669
20	O	-1	234669
to	O	-1	234669
40	O	-1	234669
mm	O	-1	234669
H@@	O	-1	234669
g@@	O	-1	234669
),	O	-1	234669
infusion	O	-1	234669
of	O	-1	234669
aminoph@@	B-Chemical	D000628	234669
yl@@	I-Chemical	-1	234669
line	I-Chemical	-1	234669
resulted	O	-1	234669
in	O	-1	234669
an	O	-1	234669
even	O	-1	234669
greater	O	-1	234669
decrease	O	-1	234669
in	O	-1	234669
ventricular	B-Disease	D014693	234669
fibrill@@	I-Disease	-1	234669
ation	I-Disease	-1	234669
th@@	O	-1	234669
res@@	O	-1	234669
h@@	O	-1	234669
old	O	-1	234669
to	O	-1	234669
60	O	-1	234669
perc@@	O	-1	234669
ent	O	-1	234669
of	O	-1	234669
the	O	-1	234669
control	O	-1	234669
level@@	O	-1	234669
.	O	-1	234669
These	O	-1	234669
experim@@	O	-1	234669
ents	O	-1	234669
suggest	O	-1	234669
that	O	-1	234669
although	O	-1	234669
man@@	O	-1	234669
y	O	-1	234669
factors	O	-1	234669
may	O	-1	234669
cont@@	O	-1	234669
rib@@	O	-1	234669
ute	O	-1	234669
to	O	-1	234669
the	O	-1	234669
increased	O	-1	234669
incidence	O	-1	234669
of	O	-1	234669
ventricular	B-Disease	D001145	234669
arrhyth@@	I-Disease	-1	234669
mi@@	I-Disease	-1	234669
as	I-Disease	-1	234669
in	O	-1	234669
respiratory	B-Disease	D012131	234669
failure	I-Disease	-1	234669
,	O	-1	234669
pharmac@@	O	-1	234669
ologic	O	-1	234669
agent@@	O	-1	234669
s,	O	-1	234669
partic@@	O	-1	234669
ul@@	O	-1	234669
arly	O	-1	234669
aminoph@@	B-Chemical	D000628	234669
yl@@	I-Chemical	-1	234669
line	I-Chemical	-1	234669
,	O	-1	234669
may	O	-1	234669
pl@@	O	-1	234669
ay	O	-1	234669
a	O	-1	234669
significant	O	-1	234669
ro@@	O	-1	234669
le@@	O	-1	234669
.	O	-1	234669

C@@	O	-1	16740173
ase	O	-1	16740173
repor@@	O	-1	16740173
t@@	O	-1	16740173
:	O	-1	16740173
acute	O	-1	16740173
un@@	O	-1	16740173
int@@	O	-1	16740173
en@@	O	-1	16740173
tional	O	-1	16740173
carb@@	B-Chemical	D002217	16740173
ac@@	I-Chemical	-1	16740173
hol	I-Chemical	-1	16740173
in@@	O	-1	16740173
toxic@@	O	-1	16740173
ation.	O	-1	16740173
IN@@	O	-1	16740173
T@@	O	-1	16740173
RO@@	O	-1	16740173
D@@	O	-1	16740173
U@@	O	-1	16740173
C@@	O	-1	16740173
T@@	O	-1	16740173
ION@@	O	-1	16740173
:	O	-1	16740173
In@@	O	-1	16740173
toxic@@	O	-1	16740173
ations	O	-1	16740173
with	O	-1	16740173
carb@@	B-Chemical	D002217	16740173
ac@@	I-Chemical	-1	16740173
hol	I-Chemical	-1	16740173
,	O	-1	16740173
a	O	-1	16740173
mus@@	O	-1	16740173
car@@	O	-1	16740173
inic	O	-1	16740173
cholinergic	O	-1	16740173
receptor	O	-1	16740173
agon@@	O	-1	16740173
ist	O	-1	16740173
are	O	-1	16740173
ra@@	O	-1	16740173
re.	O	-1	16740173
We	O	-1	16740173
report	O	-1	16740173
an	O	-1	16740173
in@@	O	-1	16740173
te@@	O	-1	16740173
rest@@	O	-1	16740173
ing	O	-1	16740173
case	O	-1	16740173
investig@@	O	-1	16740173
ating	O	-1	16740173
a	O	-1	16740173
(@@	O	-1	16740173
ne@@	O	-1	16740173
ar@@	O	-1	16740173
)	O	-1	16740173
f@@	O	-1	16740173
atal	O	-1	16740173
po@@	B-Disease	D011041	16740173
is@@	I-Disease	-1	16740173
on@@	I-Disease	-1	16740173
ing	I-Disease	-1	16740173
.	O	-1	16740173
METHODS:	O	-1	16740173
The	O	-1	16740173
s@@	O	-1	16740173
on	O	-1	16740173
of	O	-1	16740173
an	O	-1	16740173
8@@	O	-1	16740173
4-@@	O	-1	16740173
year-old	O	-1	16740173
male	O	-1	16740173
dis@@	O	-1	16740173
co@@	O	-1	16740173
vered	O	-1	16740173
a	O	-1	16740173
ne@@	O	-1	16740173
w@@	O	-1	16740173
sp@@	O	-1	16740173
ap@@	O	-1	16740173
er	O	-1	16740173
report	O	-1	16740173
st@@	O	-1	16740173
ating	O	-1	16740173
clinical	O	-1	16740173
suc@@	O	-1	16740173
cess	O	-1	16740173
with	O	-1	16740173
pl@@	O	-1	16740173
ant	O	-1	16740173
extrac@@	O	-1	16740173
ts	O	-1	16740173
in	O	-1	16740173
Al@@	B-Disease	D000544	16740173
z@@	I-Disease	-1	16740173
he@@	I-Disease	-1	16740173
im@@	I-Disease	-1	16740173
er@@	I-Disease	-1	16740173
's	I-Disease	-1	16740173
disease	I-Disease	-1	16740173
.	O	-1	16740173
The	O	-1	16740173
mo@@	O	-1	16740173
de	O	-1	16740173
of	O	-1	16740173
action	O	-1	16740173
was	O	-1	16740173
sa@@	O	-1	16740173
id	O	-1	16740173
to	O	-1	16740173
be	O	-1	16740173
compar@@	O	-1	16740173
able	O	-1	16740173
to	O	-1	16740173
that	O	-1	16740173
of	O	-1	16740173
the	O	-1	16740173
syn@@	O	-1	16740173
thetic	O	-1	16740173
comp@@	O	-1	16740173
ound	O	-1	16740173
'	O	-1	16740173
carbam@@	B-Chemical	D002217	16740173
ylchol@@	I-Chemical	-1	16740173
in	I-Chemical	-1	16740173
'@@	O	-1	16740173
;	O	-1	16740173
that	O	-1	16740173
is@@	O	-1	16740173
,	O	-1	16740173
carb@@	B-Chemical	D002217	16740173
ac@@	I-Chemical	-1	16740173
hol	I-Chemical	-1	16740173
.	O	-1	16740173
H@@	O	-1	16740173
e	O	-1	16740173
b@@	O	-1	16740173
ou@@	O	-1	16740173
ght	O	-1	16740173
25	O	-1	16740173
g	O	-1	16740173
of	O	-1	16740173
carb@@	B-Chemical	D002217	16740173
ac@@	I-Chemical	-1	16740173
hol	I-Chemical	-1	16740173
as	O	-1	16740173
p@@	O	-1	16740173
ure	O	-1	16740173
subst@@	O	-1	16740173
ance	O	-1	16740173
in	O	-1	16740173
a	O	-1	16740173
pharmac@@	O	-1	16740173
y,	O	-1	16740173
and	O	-1	16740173
the	O	-1	16740173
f@@	O	-1	16740173
a@@	O	-1	16740173
ther	O	-1	16740173
was	O	-1	16740173
administered	O	-1	16740173
4@@	O	-1	16740173
00	O	-1	16740173
to	O	-1	16740173
5@@	O	-1	16740173
00	O	-1	16740173
mg@@	O	-1	16740173
.	O	-1	16740173
C@@	B-Chemical	D002217	16740173
arb@@	I-Chemical	-1	16740173
ac@@	I-Chemical	-1	16740173
hol	I-Chemical	-1	16740173
concentrations	O	-1	16740173
in	O	-1	16740173
serum	O	-1	16740173
and	O	-1	16740173
urine	O	-1	16740173
on	O	-1	16740173
day	O	-1	16740173
1	O	-1	16740173
and	O	-1	16740173
2	O	-1	16740173
of	O	-1	16740173
hospit@@	O	-1	16740173
al	O	-1	16740173
ad@@	O	-1	16740173
mission	O	-1	16740173
were	O	-1	16740173
an@@	O	-1	16740173
al@@	O	-1	16740173
ys@@	O	-1	16740173
ed	O	-1	16740173
by	O	-1	16740173
H@@	O	-1	16740173
P@@	O	-1	16740173
L@@	O	-1	16740173
C@@	O	-1	16740173
-@@	O	-1	16740173
mas@@	O	-1	16740173
s	O	-1	16740173
sp@@	O	-1	16740173
ect@@	O	-1	16740173
ro@@	O	-1	16740173
met@@	O	-1	16740173
r@@	O	-1	16740173
y.	O	-1	16740173
RESULTS:	O	-1	16740173
M@@	O	-1	16740173
in@@	O	-1	16740173
ut@@	O	-1	16740173
es	O	-1	16740173
after	O	-1	16740173
oral	O	-1	16740173
administr@@	O	-1	16740173
ation,	O	-1	16740173
the	O	-1	16740173
patient	O	-1	16740173
developed	O	-1	16740173
nausea	B-Disease	D009325	16740173
,	O	-1	16740173
s@@	O	-1	16740173
we@@	O	-1	16740173
ating	O	-1	16740173
and	O	-1	16740173
hypotension	B-Disease	D007022	16740173
,	O	-1	16740173
and	O	-1	16740173
f@@	O	-1	16740173
in@@	O	-1	16740173
ally	O	-1	16740173
coll@@	O	-1	16740173
ap@@	O	-1	16740173
sed.	O	-1	16740173
B@@	B-Disease	D001919	16740173
ra@@	I-Disease	-1	16740173
dy@@	I-Disease	-1	16740173
cardia	I-Disease	-1	16740173
,	O	-1	16740173
cholinergic	O	-1	16740173
symptoms	O	-1	16740173
and	O	-1	16740173
as@@	B-Disease	D006323	16740173
y@@	I-Disease	-1	16740173
st@@	I-Disease	-1	16740173
ole	I-Disease	-1	16740173
occur@@	O	-1	16740173
red.	O	-1	16740173
In@@	O	-1	16740173
iti@@	O	-1	16740173
al	O	-1	16740173
cardio@@	O	-1	16740173
pulmonary	O	-1	16740173
res@@	O	-1	16740173
us@@	O	-1	16740173
cit@@	O	-1	16740173
ation	O	-1	16740173
and	O	-1	16740173
immedi@@	O	-1	16740173
ate	O	-1	16740173
treatment	O	-1	16740173
with	O	-1	16740173
adren@@	B-Chemical	D004837	16740173
aline	I-Chemical	-1	16740173
(	O	-1	16740173
ep@@	B-Chemical	D004837	16740173
ine@@	I-Chemical	-1	16740173
phrine	I-Chemical	-1	16740173
),	O	-1	16740173
atro@@	B-Chemical	D001285	16740173
pine	I-Chemical	-1	16740173
and	O	-1	16740173
f@@	B-Chemical	D005665	16740173
uro@@	I-Chemical	-1	16740173
se@@	I-Chemical	-1	16740173
m@@	I-Chemical	-1	16740173
ide	I-Chemical	-1	16740173
was	O	-1	16740173
suc@@	O	-1	16740173
cess@@	O	-1	16740173
ful@@	O	-1	16740173
.	O	-1	16740173
O@@	O	-1	16740173
n	O	-1	16740173
hospit@@	O	-1	16740173
al	O	-1	16740173
ad@@	O	-1	16740173
mis@@	O	-1	16740173
sion,	O	-1	16740173
blood	O	-1	16740173
pressure	O	-1	16740173
of	O	-1	16740173
the	O	-1	16740173
int@@	O	-1	16740173
ub@@	O	-1	16740173
at@@	O	-1	16740173
ed,	O	-1	16740173
brady@@	O	-1	16740173
arrhyth@@	O	-1	16740173
mic	O	-1	16740173
patient	O	-1	16740173
was	O	-1	16740173
10@@	O	-1	16740173
0@@	O	-1	16740173
/@@	O	-1	16740173
6@@	O	-1	16740173
5	O	-1	16740173
mm@@	O	-1	16740173
H@@	O	-1	16740173
g@@	O	-1	16740173
.	O	-1	16740173
F@@	O	-1	16740173
urther	O	-1	16740173
signs	O	-1	16740173
were	O	-1	16740173
hyper@@	B-Disease	D006945	16740173
h@@	I-Disease	-1	16740173
id@@	I-Disease	-1	16740173
ro@@	I-Disease	-1	16740173
sis	I-Disease	-1	16740173
,	O	-1	16740173
hyper@@	B-Disease	D012798	16740173
sal@@	I-Disease	-1	16740173
i@@	I-Disease	-1	16740173
v@@	I-Disease	-1	16740173
ation	I-Disease	-1	16740173
,	O	-1	16740173
b@@	B-Disease	-1	16740173
ron@@	I-Disease	-1	16740173
ch@@	I-Disease	-1	16740173
or@@	I-Disease	-1	16740173
r@@	I-Disease	-1	16740173
ho@@	I-Disease	-1	16740173
e@@	I-Disease	-1	16740173
a	I-Disease	-1	16740173
,	O	-1	16740173
and	O	-1	16740173
severe	O	-1	16740173
m@@	B-Disease	D015877	16740173
io@@	I-Disease	-1	16740173
sis	I-Disease	-1	16740173
;	O	-1	16740173
the	O	-1	16740173
electro@@	O	-1	16740173
cardio@@	O	-1	16740173
graph@@	O	-1	16740173
ic	O	-1	16740173
find@@	O	-1	16740173
ing	O	-1	16740173
was	O	-1	16740173
atri@@	B-Disease	D006327	16740173
o@@	I-Disease	-1	16740173
-@@	I-Disease	-1	16740173
ventricular	I-Disease	-1	16740173
dis@@	I-Disease	-1	16740173
s@@	I-Disease	-1	16740173
oci@@	I-Disease	-1	16740173
ation	I-Disease	-1	16740173
.	O	-1	16740173
H@@	O	-1	16740173
i@@	O	-1	16740173
gh	O	-1	16740173
doses	O	-1	16740173
of	O	-1	16740173
atro@@	B-Chemical	D001285	16740173
pine	I-Chemical	-1	16740173
(@@	O	-1	16740173
up	O	-1	16740173
to	O	-1	16740173
50	O	-1	16740173
mg	O	-1	16740173
per	O	-1	16740173
24	O	-1	16740173
hour@@	O	-1	16740173
s),	O	-1	16740173
adren@@	B-Chemical	D004837	16740173
aline	I-Chemical	-1	16740173
and	O	-1	16740173
dopamine	B-Chemical	D004298	16740173
were	O	-1	16740173
nec@@	O	-1	16740173
ess@@	O	-1	16740173
ar@@	O	-1	16740173
y.	O	-1	16740173
The	O	-1	16740173
patient	O	-1	16740173
was	O	-1	16740173
ext@@	O	-1	16740173
ub@@	O	-1	16740173
ated	O	-1	16740173
1	O	-1	16740173
week	O	-1	16740173
lat@@	O	-1	16740173
er.	O	-1	16740173
However,	O	-1	16740173
increased	O	-1	16740173
dys@@	B-Disease	D004417	16740173
p@@	I-Disease	-1	16740173
no@@	I-Disease	-1	16740173
e@@	I-Disease	-1	16740173
a	I-Disease	-1	16740173
and	O	-1	16740173
b@@	B-Disease	D001986	16740173
ron@@	I-Disease	-1	16740173
ch@@	I-Disease	-1	16740173
os@@	I-Disease	-1	16740173
p@@	I-Disease	-1	16740173
as@@	I-Disease	-1	16740173
m	I-Disease	-1	16740173
nec@@	O	-1	16740173
ess@@	O	-1	16740173
it@@	O	-1	16740173
ated	O	-1	16740173
re@@	O	-1	16740173
int@@	O	-1	16740173
ub@@	O	-1	16740173
ation.	O	-1	16740173
R@@	B-Disease	D012131	16740173
es@@	I-Disease	-1	16740173
piratory	I-Disease	-1	16740173
in@@	I-Disease	-1	16740173
suffici@@	I-Disease	-1	16740173
ency	I-Disease	-1	16740173
was	O	-1	16740173
further	O	-1	16740173
wor@@	O	-1	16740173
sen@@	O	-1	16740173
ed	O	-1	16740173
by	O	-1	16740173
Pro@@	B-Disease	D011512	16740173
te@@	I-Disease	-1	16740173
us	I-Disease	-1	16740173
mi@@	I-Disease	-1	16740173
ra@@	I-Disease	-1	16740173
bil@@	I-Disease	-1	16740173
is	I-Disease	-1	16740173
inf@@	I-Disease	-1	16740173
ection	I-Disease	-1	16740173
and	O	-1	16740173
severe	O	-1	16740173
b@@	O	-1	16740173
ron@@	O	-1	16740173
ch@@	O	-1	16740173
o@@	O	-1	16740173
con@@	O	-1	16740173
stric@@	O	-1	16740173
tion.	O	-1	16740173
One	O	-1	16740173
week	O	-1	16740173
lat@@	O	-1	16740173
er,	O	-1	16740173
the	O	-1	16740173
patient	O	-1	16740173
was	O	-1	16740173
ag@@	O	-1	16740173
ain	O	-1	16740173
ext@@	O	-1	16740173
ub@@	O	-1	16740173
ated	O	-1	16740173
and	O	-1	16740173
3	O	-1	16740173
days	O	-1	16740173
lat@@	O	-1	16740173
er	O	-1	16740173
was	O	-1	16740173
trans@@	O	-1	16740173
fer@@	O	-1	16740173
red	O	-1	16740173
to	O	-1	16740173
a	O	-1	16740173
peripheral	O	-1	16740173
war@@	O	-1	16740173
d.	O	-1	16740173
O@@	O	-1	16740173
n	O	-1	16740173
the	O	-1	16740173
ne@@	O	-1	16740173
x@@	O	-1	16740173
t	O	-1	16740173
day	O	-1	16740173
he	O	-1	16740173
di@@	O	-1	16740173
ed,	O	-1	16740173
prob@@	O	-1	16740173
ably	O	-1	16740173
as	O	-1	16740173
a	O	-1	16740173
result	O	-1	16740173
of	O	-1	16740173
heart	B-Disease	D006333	16740173
failure	I-Disease	-1	16740173
.	O	-1	16740173
S@@	O	-1	16740173
er@@	O	-1	16740173
um	O	-1	16740173
sam@@	O	-1	16740173
ple@@	O	-1	16740173
s	O	-1	16740173
from	O	-1	16740173
the	O	-1	16740173
first	O	-1	16740173
and	O	-1	16740173
second	O	-1	16740173
days	O	-1	16740173
cont@@	O	-1	16740173
ained	O	-1	16740173
3.@@	O	-1	16740173
6	O	-1	16740173
and	O	-1	16740173
1.@@	O	-1	16740173
9	O	-1	16740173
mg/@@	O	-1	16740173
l	O	-1	16740173
carb@@	B-Chemical	D002217	16740173
ac@@	I-Chemical	-1	16740173
hol	I-Chemical	-1	16740173
,	O	-1	16740173
respectively.	O	-1	16740173
The	O	-1	16740173
cor@@	O	-1	16740173
respon@@	O	-1	16740173
ding	O	-1	16740173
urine	O	-1	16740173
concentrations	O	-1	16740173
amoun@@	O	-1	16740173
ted	O	-1	16740173
to	O	-1	16740173
3@@	O	-1	16740173
7@@	O	-1	16740173
4	O	-1	16740173
and	O	-1	16740173
55@@	O	-1	16740173
4	O	-1	16740173
mg/@@	O	-1	16740173
l@@	O	-1	16740173
.	O	-1	16740173
CONCLUSION:	O	-1	16740173
This	O	-1	16740173
case	O	-1	16740173
star@@	O	-1	16740173
ted	O	-1	16740173
with	O	-1	16740173
a	O	-1	16740173
medi@@	O	-1	16740173
a	O	-1	16740173
report	O	-1	16740173
in	O	-1	16740173
a	O	-1	16740173
po@@	O	-1	16740173
p@@	O	-1	16740173
ular	O	-1	16740173
ne@@	O	-1	16740173
w@@	O	-1	16740173
s@@	O	-1	16740173
pa@@	O	-1	16740173
per@@	O	-1	16740173
,	O	-1	16740173
initi@@	O	-1	16740173
ated	O	-1	16740173
by	O	-1	16740173
pu@@	O	-1	16740173
bl@@	O	-1	16740173
is@@	O	-1	16740173
he@@	O	-1	16740173
d,	O	-1	16740173
pe@@	O	-1	16740173
er@@	O	-1	16740173
-@@	O	-1	16740173
revie@@	O	-1	16740173
w@@	O	-1	16740173
ed	O	-1	16740173
re@@	O	-1	16740173
se@@	O	-1	16740173
arc@@	O	-1	16740173
h	O	-1	16740173
on	O	-1	16740173
h@@	O	-1	16740173
er@@	O	-1	16740173
b@@	O	-1	16740173
al@@	O	-1	16740173
s,	O	-1	16740173
and	O	-1	16740173
involved	O	-1	16740173
human	O	-1	16740173
failure	O	-1	16740173
in	O	-1	16740173
a	O	-1	16740173
case	O	-1	16740173
hist@@	O	-1	16740173
or@@	O	-1	16740173
y,	O	-1	16740173
med@@	O	-1	16740173
ical	O	-1	16740173
examin@@	O	-1	16740173
ation	O	-1	16740173
and	O	-1	16740173
clinical	O	-1	16740173
treatment.	O	-1	16740173
F@@	O	-1	16740173
or	O	-1	16740173
the	O	-1	16740173
first	O	-1	16740173
ti@@	O	-1	16740173
me,	O	-1	16740173
an	O	-1	16740173
analy@@	O	-1	16740173
tical	O	-1	16740173
meth@@	O	-1	16740173
od	O	-1	16740173
for	O	-1	16740173
the	O	-1	16740173
determin@@	O	-1	16740173
ation	O	-1	16740173
of	O	-1	16740173
carb@@	B-Chemical	D002217	16740173
ac@@	I-Chemical	-1	16740173
hol	I-Chemical	-1	16740173
in	O	-1	16740173
plasma	O	-1	16740173
and	O	-1	16740173
urine	O	-1	16740173
has	O	-1	16740173
been	O	-1	16740173
develop@@	O	-1	16740173
ed.	O	-1	16740173
The	O	-1	16740173
an@@	O	-1	16740173
al@@	O	-1	16740173
ys@@	O	-1	16740173
ed	O	-1	16740173
carb@@	B-Chemical	D002217	16740173
ac@@	I-Chemical	-1	16740173
hol	I-Chemical	-1	16740173
concentration	O	-1	16740173
ex@@	O	-1	16740173
ce@@	O	-1	16740173
ed@@	O	-1	16740173
ed	O	-1	16740173
the	O	-1	16740173
sup@@	O	-1	16740173
pos@@	O	-1	16740173
ed	O	-1	16740173
serum	O	-1	16740173
level	O	-1	16740173
result@@	O	-1	16740173
ing	O	-1	16740173
from	O	-1	16740173
a	O	-1	16740173
therapeutic	O	-1	16740173
dose	O	-1	16740173
by	O	-1	16740173
a	O	-1	16740173
factor	O	-1	16740173
of	O	-1	16740173
1@@	O	-1	16740173
30	O	-1	16740173
to	O	-1	16740173
2@@	O	-1	16740173
6@@	O	-1	16740173
0@@	O	-1	16740173
.	O	-1	16740173
E@@	O	-1	16740173
spec@@	O	-1	16740173
i@@	O	-1	16740173
ally	O	-1	16740173
in	O	-1	16740173
old	O	-1	16740173
patients,	O	-1	16740173
int@@	O	-1	16740173
en@@	O	-1	16740173
si@@	O	-1	16740173
vi@@	O	-1	16740173
st@@	O	-1	16740173
s	O	-1	16740173
should	O	-1	16740173
con@@	O	-1	16740173
si@@	O	-1	16740173
der	O	-1	16740173
in@@	O	-1	16740173
toxic@@	O	-1	16740173
ations	O	-1	16740173
(@@	O	-1	16740173
with	O	-1	16740173
chol@@	O	-1	16740173
in@@	O	-1	16740173
erg@@	O	-1	16740173
ic@@	O	-1	16740173
s)	O	-1	16740173
as	O	-1	16740173
a	O	-1	16740173
cause	O	-1	16740173
of	O	-1	16740173
acute	B-Disease	D002318	16740173
cardiovascular	I-Disease	-1	16740173
failure	I-Disease	-1	16740173
.	O	-1	16740173

C@@	O	-1	12464714
ros@@	O	-1	12464714
s@@	O	-1	12464714
over	O	-1	12464714
compar@@	O	-1	12464714
ison	O	-1	12464714
of	O	-1	12464714
efficacy	O	-1	12464714
and	O	-1	12464714
pre@@	O	-1	12464714
fe@@	O	-1	12464714
rence	O	-1	12464714
for	O	-1	12464714
ri@@	B-Chemical	C093622	12464714
z@@	I-Chemical	-1	12464714
atri@@	I-Chemical	-1	12464714
pt@@	I-Chemical	-1	12464714
an	I-Chemical	-1	12464714
10	O	-1	12464714
mg	O	-1	12464714
versus	O	-1	12464714
erg@@	B-Chemical	D004878	12464714
ot@@	I-Chemical	-1	12464714
amine	I-Chemical	-1	12464714
/	O	-1	12464714
caffe@@	B-Chemical	D002110	12464714
ine	I-Chemical	-1	12464714
in	O	-1	12464714
migra@@	B-Disease	D008881	12464714
ine	I-Disease	-1	12464714
.	O	-1	12464714
R@@	B-Chemical	C093622	12464714
iz@@	I-Chemical	-1	12464714
atri@@	I-Chemical	-1	12464714
pt@@	I-Chemical	-1	12464714
an	I-Chemical	-1	12464714
is	O	-1	12464714
a	O	-1	12464714
selective	O	-1	12464714
5-@@	B-Chemical	D012701	12464714
H@@	I-Chemical	-1	12464714
T	I-Chemical	-1	12464714
(1@@	O	-1	12464714
B@@	O	-1	12464714
/@@	O	-1	12464714
1@@	O	-1	12464714
D)	O	-1	12464714
receptor	O	-1	12464714
agon@@	O	-1	12464714
ist	O	-1	12464714
with	O	-1	12464714
ra@@	O	-1	12464714
pid	O	-1	12464714
oral	O	-1	12464714
abs@@	O	-1	12464714
or@@	O	-1	12464714
ption	O	-1	12464714
and	O	-1	12464714
early	O	-1	12464714
onset	O	-1	12464714
of	O	-1	12464714
action	O	-1	12464714
in	O	-1	12464714
the	O	-1	12464714
acute	O	-1	12464714
treatment	O	-1	12464714
of	O	-1	12464714
migra@@	B-Disease	D008881	12464714
ine	I-Disease	-1	12464714
.	O	-1	12464714
This	O	-1	12464714
randomized	O	-1	12464714
double@@	O	-1	12464714
-	O	-1	12464714
bl@@	O	-1	12464714
ind	O	-1	12464714
cros@@	O	-1	12464714
s@@	O	-1	12464714
over	O	-1	12464714
out@@	O	-1	12464714
patient	O	-1	12464714
study	O	-1	12464714
assessed	O	-1	12464714
the	O	-1	12464714
pre@@	O	-1	12464714
fe@@	O	-1	12464714
rence	O	-1	12464714
for	O	-1	12464714
1	O	-1	12464714
ri@@	B-Chemical	C093622	12464714
z@@	I-Chemical	-1	12464714
atri@@	I-Chemical	-1	12464714
pt@@	I-Chemical	-1	12464714
an	I-Chemical	-1	12464714
10	O	-1	12464714
mg	O	-1	12464714
t@@	O	-1	12464714
able@@	O	-1	12464714
t	O	-1	12464714
to	O	-1	12464714
2	O	-1	12464714
erg@@	B-Chemical	D004878	12464714
ot@@	I-Chemical	-1	12464714
amine	I-Chemical	-1	12464714
1	O	-1	12464714
mg@@	O	-1	12464714
/	O	-1	12464714
caffe@@	B-Chemical	D002110	12464714
ine	I-Chemical	-1	12464714
100	O	-1	12464714
mg	O	-1	12464714
t@@	O	-1	12464714
able@@	O	-1	12464714
ts	O	-1	12464714
in	O	-1	12464714
4@@	O	-1	12464714
3@@	O	-1	12464714
9	O	-1	12464714
patients	O	-1	12464714
treat@@	O	-1	12464714
ing	O	-1	12464714
a	O	-1	12464714
single	O	-1	12464714
migra@@	B-Disease	D008881	12464714
ine	I-Disease	-1	12464714
at@@	O	-1	12464714
tac@@	O	-1	12464714
k	O	-1	12464714
with	O	-1	12464714
each	O	-1	12464714
therapy.	O	-1	12464714
Of	O	-1	12464714
patients	O	-1	12464714
ex@@	O	-1	12464714
press@@	O	-1	12464714
ing	O	-1	12464714
a	O	-1	12464714
pre@@	O	-1	12464714
fe@@	O	-1	12464714
rence	O	-1	12464714
(@@	O	-1	12464714
8@@	O	-1	12464714
9.@@	O	-1	12464714
1@@	O	-1	12464714
%),	O	-1	12464714
more	O	-1	12464714
than	O	-1	12464714
tw@@	O	-1	12464714
ic@@	O	-1	12464714
e	O	-1	12464714
as	O	-1	12464714
man@@	O	-1	12464714
y	O	-1	12464714
pre@@	O	-1	12464714
fer@@	O	-1	12464714
red	O	-1	12464714
ri@@	B-Chemical	C093622	12464714
z@@	I-Chemical	-1	12464714
atri@@	I-Chemical	-1	12464714
pt@@	I-Chemical	-1	12464714
an	I-Chemical	-1	12464714
to	O	-1	12464714
erg@@	B-Chemical	D004878	12464714
ot@@	I-Chemical	-1	12464714
amine	I-Chemical	-1	12464714
/	O	-1	12464714
caffe@@	B-Chemical	D002110	12464714
ine	I-Chemical	-1	12464714
(6@@	O	-1	12464714
9.@@	O	-1	12464714
9	O	-1	12464714
vs.	O	-1	12464714
3@@	O	-1	12464714
0.@@	O	-1	12464714
1@@	O	-1	12464714
%,	O	-1	12464714
p	O	-1	12464714
<	O	-1	12464714
or	O	-1	12464714
=	O	-1	12464714
0.00@@	O	-1	12464714
1).	O	-1	12464714
F@@	O	-1	12464714
ast@@	O	-1	12464714
er	O	-1	12464714
re@@	O	-1	12464714
li@@	O	-1	12464714
e@@	O	-1	12464714
f	O	-1	12464714
of	O	-1	12464714
headac@@	B-Disease	D006261	12464714
he	I-Disease	-1	12464714
was	O	-1	12464714
the	O	-1	12464714
most	O	-1	12464714
important	O	-1	12464714
reas@@	O	-1	12464714
on	O	-1	12464714
for	O	-1	12464714
pre@@	O	-1	12464714
fe@@	O	-1	12464714
ren@@	O	-1	12464714
ce@@	O	-1	12464714
,	O	-1	12464714
c@@	O	-1	12464714
ited	O	-1	12464714
by	O	-1	12464714
6@@	O	-1	12464714
7.@@	O	-1	12464714
3@@	O	-1	12464714
%	O	-1	12464714
of	O	-1	12464714
patients	O	-1	12464714
pre@@	O	-1	12464714
fer@@	O	-1	12464714
r@@	O	-1	12464714
ing	O	-1	12464714
ri@@	B-Chemical	C093622	12464714
z@@	I-Chemical	-1	12464714
atri@@	I-Chemical	-1	12464714
pt@@	I-Chemical	-1	12464714
an	I-Chemical	-1	12464714
and	O	-1	12464714
5@@	O	-1	12464714
4.@@	O	-1	12464714
2@@	O	-1	12464714
%	O	-1	12464714
of	O	-1	12464714
patients	O	-1	12464714
who	O	-1	12464714
pre@@	O	-1	12464714
fer@@	O	-1	12464714
red	O	-1	12464714
erg@@	B-Chemical	D004878	12464714
ot@@	I-Chemical	-1	12464714
amine	I-Chemical	-1	12464714
/	O	-1	12464714
caffe@@	B-Chemical	D002110	12464714
ine	I-Chemical	-1	12464714
.	O	-1	12464714
The	O	-1	12464714
co-@@	O	-1	12464714
prim@@	O	-1	12464714
ary	O	-1	12464714
en@@	O	-1	12464714
d@@	O	-1	12464714
po@@	O	-1	12464714
in@@	O	-1	12464714
t	O	-1	12464714
of	O	-1	12464714
being	O	-1	12464714
pain	B-Disease	D010146	12464714
free	O	-1	12464714
at	O	-1	12464714
2	O	-1	12464714
h	O	-1	12464714
was	O	-1	12464714
also	O	-1	12464714
in	O	-1	12464714
f@@	O	-1	12464714
av@@	O	-1	12464714
or	O	-1	12464714
of	O	-1	12464714
ri@@	B-Chemical	C093622	12464714
z@@	I-Chemical	-1	12464714
atri@@	I-Chemical	-1	12464714
pt@@	I-Chemical	-1	12464714
an	I-Chemical	-1	12464714
.	O	-1	12464714
F@@	O	-1	12464714
or@@	O	-1	12464714
ty-@@	O	-1	12464714
n@@	O	-1	12464714
ine	O	-1	12464714
perc@@	O	-1	12464714
ent	O	-1	12464714
of	O	-1	12464714
patients	O	-1	12464714
were	O	-1	12464714
pain	B-Disease	D010146	12464714
free	O	-1	12464714
2	O	-1	12464714
h	O	-1	12464714
after	O	-1	12464714
ri@@	B-Chemical	C093622	12464714
z@@	I-Chemical	-1	12464714
atri@@	I-Chemical	-1	12464714
pt@@	I-Chemical	-1	12464714
an	I-Chemical	-1	12464714
,	O	-1	12464714
compared	O	-1	12464714
with	O	-1	12464714
2@@	O	-1	12464714
4.@@	O	-1	12464714
3@@	O	-1	12464714
%	O	-1	12464714
treated	O	-1	12464714
with	O	-1	12464714
erg@@	B-Chemical	D004878	12464714
ot@@	I-Chemical	-1	12464714
amine	I-Chemical	-1	12464714
/	O	-1	12464714
caffe@@	B-Chemical	D002110	12464714
ine	I-Chemical	-1	12464714
(p	O	-1	12464714
<	O	-1	12464714
or	O	-1	12464714
=	O	-1	12464714
0.00@@	O	-1	12464714
1),	O	-1	12464714
ri@@	B-Chemical	C093622	12464714
z@@	I-Chemical	-1	12464714
atri@@	I-Chemical	-1	12464714
pt@@	I-Chemical	-1	12464714
an	I-Chemical	-1	12464714
being	O	-1	12464714
su@@	O	-1	12464714
peri@@	O	-1	12464714
or	O	-1	12464714
within	O	-1	12464714
1	O	-1	12464714
h	O	-1	12464714
of	O	-1	12464714
treatment.	O	-1	12464714
He@@	B-Disease	D006261	12464714
ad@@	I-Disease	-1	12464714
ac@@	I-Disease	-1	12464714
he	I-Disease	-1	12464714
re@@	O	-1	12464714
li@@	O	-1	12464714
e@@	O	-1	12464714
f	O	-1	12464714
at	O	-1	12464714
2	O	-1	12464714
h	O	-1	12464714
was	O	-1	12464714
7@@	O	-1	12464714
5.@@	O	-1	12464714
9@@	O	-1	12464714
%	O	-1	12464714
for	O	-1	12464714
ri@@	B-Chemical	C093622	12464714
z@@	I-Chemical	-1	12464714
atri@@	I-Chemical	-1	12464714
pt@@	I-Chemical	-1	12464714
an	I-Chemical	-1	12464714
and	O	-1	12464714
4@@	O	-1	12464714
7.@@	O	-1	12464714
3@@	O	-1	12464714
%	O	-1	12464714
for	O	-1	12464714
erg@@	B-Chemical	D004878	12464714
ot@@	I-Chemical	-1	12464714
amine	I-Chemical	-1	12464714
/	O	-1	12464714
caffe@@	B-Chemical	D002110	12464714
ine	I-Chemical	-1	12464714
(p	O	-1	12464714
<	O	-1	12464714
or	O	-1	12464714
=	O	-1	12464714
0.00@@	O	-1	12464714
1),	O	-1	12464714
with	O	-1	12464714
ri@@	B-Chemical	C093622	12464714
z@@	I-Chemical	-1	12464714
atri@@	I-Chemical	-1	12464714
pt@@	I-Chemical	-1	12464714
an	I-Chemical	-1	12464714
being	O	-1	12464714
su@@	O	-1	12464714
peri@@	O	-1	12464714
or	O	-1	12464714
to	O	-1	12464714
erg@@	B-Chemical	D004878	12464714
ot@@	I-Chemical	-1	12464714
amine	I-Chemical	-1	12464714
/	O	-1	12464714
caffe@@	B-Chemical	D002110	12464714
ine	I-Chemical	-1	12464714
within	O	-1	12464714
30	O	-1	12464714
min	O	-1	12464714
of	O	-1	12464714
dos@@	O	-1	12464714
ing.	O	-1	12464714
Al@@	O	-1	12464714
most	O	-1	12464714
3@@	O	-1	12464714
6%	O	-1	12464714
of	O	-1	12464714
patients	O	-1	12464714
taking	O	-1	12464714
ri@@	B-Chemical	C093622	12464714
z@@	I-Chemical	-1	12464714
atri@@	I-Chemical	-1	12464714
pt@@	I-Chemical	-1	12464714
an	I-Chemical	-1	12464714
were	O	-1	12464714
pain	B-Disease	D010146	12464714
free	O	-1	12464714
at	O	-1	12464714
2	O	-1	12464714
h	O	-1	12464714
and	O	-1	12464714
had	O	-1	12464714
no	O	-1	12464714
recur@@	O	-1	12464714
rence	O	-1	12464714
or	O	-1	12464714
need	O	-1	12464714
for	O	-1	12464714
addi@@	O	-1	12464714
tional	O	-1	12464714
medic@@	O	-1	12464714
ation	O	-1	12464714
within	O	-1	12464714
24	O	-1	12464714
h@@	O	-1	12464714
,	O	-1	12464714
compared	O	-1	12464714
to	O	-1	12464714
20@@	O	-1	12464714
%	O	-1	12464714
of	O	-1	12464714
patients	O	-1	12464714
on	O	-1	12464714
erg@@	B-Chemical	D004878	12464714
ot@@	I-Chemical	-1	12464714
amine	I-Chemical	-1	12464714
/	O	-1	12464714
caffe@@	B-Chemical	D002110	12464714
ine	I-Chemical	-1	12464714
(p	O	-1	12464714
<	O	-1	12464714
or	O	-1	12464714
=	O	-1	12464714
0.00@@	O	-1	12464714
1).	O	-1	12464714
R@@	B-Chemical	C093622	12464714
iz@@	I-Chemical	-1	12464714
atri@@	I-Chemical	-1	12464714
pt@@	I-Chemical	-1	12464714
an	I-Chemical	-1	12464714
was	O	-1	12464714
also	O	-1	12464714
su@@	O	-1	12464714
peri@@	O	-1	12464714
or	O	-1	12464714
to	O	-1	12464714
erg@@	B-Chemical	D004878	12464714
ot@@	I-Chemical	-1	12464714
amine	I-Chemical	-1	12464714
/	O	-1	12464714
caffe@@	B-Chemical	D002110	12464714
ine	I-Chemical	-1	12464714
in	O	-1	12464714
the	O	-1	12464714
pro@@	O	-1	12464714
por@@	O	-1	12464714
tions	O	-1	12464714
of	O	-1	12464714
patients	O	-1	12464714
with	O	-1	12464714
no	O	-1	12464714
nausea	B-Disease	D009325	12464714
,	O	-1	12464714
v@@	B-Disease	D014839	12464714
om@@	I-Disease	-1	12464714
it@@	I-Disease	-1	12464714
ing	I-Disease	-1	12464714
,	O	-1	12464714
ph@@	B-Disease	D012001	12464714
on@@	I-Disease	-1	12464714
oph@@	I-Disease	-1	12464714
ob@@	I-Disease	-1	12464714
ia	I-Disease	-1	12464714
or	O	-1	12464714
ph@@	B-Disease	D020795	12464714
ot@@	I-Disease	-1	12464714
oph@@	I-Disease	-1	12464714
ob@@	I-Disease	-1	12464714
ia	I-Disease	-1	12464714
and	O	-1	12464714
for	O	-1	12464714
patients	O	-1	12464714
with	O	-1	12464714
normal	O	-1	12464714
function	O	-1	12464714
2	O	-1	12464714
h	O	-1	12464714
after	O	-1	12464714
drug	O	-1	12464714
int@@	O	-1	12464714
ake	O	-1	12464714
(p	O	-1	12464714
<	O	-1	12464714
or	O	-1	12464714
=	O	-1	12464714
0.00@@	O	-1	12464714
1).	O	-1	12464714
M@@	O	-1	12464714
or@@	O	-1	12464714
e	O	-1	12464714
patients	O	-1	12464714
were	O	-1	12464714
(@@	O	-1	12464714
complete@@	O	-1	12464714
ly,	O	-1	12464714
very	O	-1	12464714
or	O	-1	12464714
so@@	O	-1	12464714
me@@	O	-1	12464714
wh@@	O	-1	12464714
at@@	O	-1	12464714
)	O	-1	12464714
s@@	O	-1	12464714
atis@@	O	-1	12464714
fied	O	-1	12464714
2	O	-1	12464714
h	O	-1	12464714
after	O	-1	12464714
treatment	O	-1	12464714
with	O	-1	12464714
ri@@	B-Chemical	C093622	12464714
z@@	I-Chemical	-1	12464714
atri@@	I-Chemical	-1	12464714
pt@@	I-Chemical	-1	12464714
an	I-Chemical	-1	12464714
(6@@	O	-1	12464714
9.@@	O	-1	12464714
8@@	O	-1	12464714
%)	O	-1	12464714
than	O	-1	12464714
at	O	-1	12464714
2	O	-1	12464714
h	O	-1	12464714
after	O	-1	12464714
treatment	O	-1	12464714
with	O	-1	12464714
erg@@	B-Chemical	D004878	12464714
ot@@	I-Chemical	-1	12464714
amine	I-Chemical	-1	12464714
/	O	-1	12464714
caffe@@	B-Chemical	D002110	12464714
ine	I-Chemical	-1	12464714
(3@@	O	-1	12464714
8.@@	O	-1	12464714
6@@	O	-1	12464714
%,	O	-1	12464714
p	O	-1	12464714
<	O	-1	12464714
or	O	-1	12464714
=	O	-1	12464714
0.00@@	O	-1	12464714
1).	O	-1	12464714
Rec@@	O	-1	12464714
ur@@	O	-1	12464714
rence	O	-1	12464714
rat@@	O	-1	12464714
es	O	-1	12464714
were	O	-1	12464714
3@@	O	-1	12464714
1.@@	O	-1	12464714
4@@	O	-1	12464714
%	O	-1	12464714
with	O	-1	12464714
ri@@	B-Chemical	C093622	12464714
z@@	I-Chemical	-1	12464714
atri@@	I-Chemical	-1	12464714
pt@@	I-Chemical	-1	12464714
an	I-Chemical	-1	12464714
and	O	-1	12464714
1@@	O	-1	12464714
5.@@	O	-1	12464714
3@@	O	-1	12464714
%	O	-1	12464714
with	O	-1	12464714
erg@@	B-Chemical	D004878	12464714
ot@@	I-Chemical	-1	12464714
amine	I-Chemical	-1	12464714
/	O	-1	12464714
caffe@@	B-Chemical	D002110	12464714
ine	I-Chemical	-1	12464714
.	O	-1	12464714
B@@	O	-1	12464714
oth	O	-1	12464714
active	O	-1	12464714
treat@@	O	-1	12464714
ments	O	-1	12464714
were	O	-1	12464714
well	O	-1	12464714
toler@@	O	-1	12464714
ated.	O	-1	12464714
The	O	-1	12464714
most	O	-1	12464714
common	O	-1	12464714
adverse	O	-1	12464714
events	O	-1	12464714
(@@	O	-1	12464714
incidence	O	-1	12464714
>	O	-1	12464714
or	O	-1	12464714
=	O	-1	12464714
5%	O	-1	12464714
in	O	-1	12464714
one	O	-1	12464714
group@@	O	-1	12464714
)	O	-1	12464714
after	O	-1	12464714
ri@@	B-Chemical	C093622	12464714
z@@	I-Chemical	-1	12464714
atri@@	I-Chemical	-1	12464714
pt@@	I-Chemical	-1	12464714
an	I-Chemical	-1	12464714
and	O	-1	12464714
erg@@	B-Chemical	D004878	12464714
ot@@	I-Chemical	-1	12464714
amine	I-Chemical	-1	12464714
/	O	-1	12464714
caffe@@	B-Chemical	D002110	12464714
ine	I-Chemical	-1	12464714
,	O	-1	12464714
respectivel@@	O	-1	12464714
y,	O	-1	12464714
were	O	-1	12464714
di@@	B-Disease	D004244	12464714
z@@	I-Disease	-1	12464714
z@@	I-Disease	-1	12464714
in@@	I-Disease	-1	12464714
ess	I-Disease	-1	12464714
(@@	O	-1	12464714
6.@@	O	-1	12464714
7	O	-1	12464714
and	O	-1	12464714
5.@@	O	-1	12464714
3@@	O	-1	12464714
%),	O	-1	12464714
nausea	B-Disease	D009325	12464714
(@@	O	-1	12464714
4.@@	O	-1	12464714
2	O	-1	12464714
and	O	-1	12464714
8.@@	O	-1	12464714
5@@	O	-1	12464714
%)	O	-1	12464714
and	O	-1	12464714
s@@	B-Disease	D006970	12464714
om@@	I-Disease	-1	12464714
n@@	I-Disease	-1	12464714
ol@@	I-Disease	-1	12464714
ence	I-Disease	-1	12464714
(@@	O	-1	12464714
5.@@	O	-1	12464714
5	O	-1	12464714
and	O	-1	12464714
2.@@	O	-1	12464714
3@@	O	-1	12464714
%).	O	-1	12464714

Th@@	B-Disease	D057049	6203452
rom@@	I-Disease	-1	6203452
bo@@	I-Disease	-1	6203452
tic	I-Disease	-1	6203452
microangio@@	I-Disease	-1	6203452
pathy	I-Disease	-1	6203452
and	O	-1	6203452
renal	B-Disease	D051437	6203452
failure	I-Disease	-1	6203452
associated	O	-1	6203452
with	O	-1	6203452
ant@@	O	-1	6203452
ine@@	O	-1	6203452
o@@	O	-1	6203452
plas@@	O	-1	6203452
tic	O	-1	6203452
chemo@@	O	-1	6203452
therapy.	O	-1	6203452
F@@	O	-1	6203452
i@@	O	-1	6203452
ve	O	-1	6203452
patients	O	-1	6203452
with	O	-1	6203452
carcin@@	B-Disease	D002277	6203452
oma	I-Disease	-1	6203452
developed	O	-1	6203452
thrombotic	B-Disease	D057049	6203452
microangio@@	I-Disease	-1	6203452
pathy	I-Disease	-1	6203452
(@@	O	-1	6203452
character@@	O	-1	6203452
ized	O	-1	6203452
by	O	-1	6203452
renal	B-Disease	D051437	6203452
in@@	I-Disease	-1	6203452
suffici@@	I-Disease	-1	6203452
ency	I-Disease	-1	6203452
,	O	-1	6203452
microangio@@	B-Disease	D000743	6203452
path@@	I-Disease	-1	6203452
ic	I-Disease	-1	6203452
hemolytic	I-Disease	-1	6203452
anemia	I-Disease	-1	6203452
,	O	-1	6203452
and	O	-1	6203452
us@@	O	-1	6203452
ually	O	-1	6203452
throm@@	B-Disease	D013921	6203452
b@@	I-Disease	-1	6203452
ocyto@@	I-Disease	-1	6203452
pen@@	I-Disease	-1	6203452
ia	I-Disease	-1	6203452
)	O	-1	6203452
after	O	-1	6203452
treatment	O	-1	6203452
with	O	-1	6203452
cisplatin	B-Chemical	D002945	6203452
,	O	-1	6203452
ble@@	B-Chemical	D001761	6203452
om@@	I-Chemical	-1	6203452
ycin	I-Chemical	-1	6203452
,	O	-1	6203452
and	O	-1	6203452
a	O	-1	6203452
v@@	B-Chemical	D014748	6203452
inc@@	I-Chemical	-1	6203452
a	I-Chemical	-1	6203452
al@@	I-Chemical	-1	6203452
k@@	I-Chemical	-1	6203452
alo@@	I-Chemical	-1	6203452
id	I-Chemical	-1	6203452
.	O	-1	6203452
One	O	-1	6203452
patient	O	-1	6203452
had	O	-1	6203452
thrombotic	B-Disease	D011697	6203452
throm@@	I-Disease	-1	6203452
b@@	I-Disease	-1	6203452
ocyto@@	I-Disease	-1	6203452
pen@@	I-Disease	-1	6203452
ic	I-Disease	-1	6203452
pur@@	I-Disease	-1	6203452
pur@@	I-Disease	-1	6203452
a	I-Disease	-1	6203452
,	O	-1	6203452
three	O	-1	6203452
the	O	-1	6203452
hemoly@@	B-Disease	D006463	6203452
tic@@	I-Disease	-1	6203452
-@@	I-Disease	-1	6203452
ure@@	I-Disease	-1	6203452
mic	I-Disease	-1	6203452
syndrome	I-Disease	-1	6203452
,	O	-1	6203452
and	O	-1	6203452
one	O	-1	6203452
an	O	-1	6203452
appa@@	O	-1	6203452
rent	O	-1	6203452
form@@	O	-1	6203452
e	O	-1	6203452
f@@	O	-1	6203452
ru@@	O	-1	6203452
st@@	O	-1	6203452
e	O	-1	6203452
of	O	-1	6203452
one	O	-1	6203452
of	O	-1	6203452
these	O	-1	6203452
disorder@@	O	-1	6203452
s.	O	-1	6203452
H@@	O	-1	6203452
ist@@	O	-1	6203452
ologic	O	-1	6203452
examin@@	O	-1	6203452
ation	O	-1	6203452
of	O	-1	6203452
the	O	-1	6203452
renal	O	-1	6203452
tissue	O	-1	6203452
showed	O	-1	6203452
evidence	O	-1	6203452
of	O	-1	6203452
intra@@	B-Disease	D004211	6203452
vascular	I-Disease	-1	6203452
co@@	I-Disease	-1	6203452
ag@@	I-Disease	-1	6203452
ulation	I-Disease	-1	6203452
,	O	-1	6203452
prim@@	O	-1	6203452
ari@@	O	-1	6203452
ly	O	-1	6203452
aff@@	O	-1	6203452
ect@@	O	-1	6203452
ing	O	-1	6203452
the	O	-1	6203452
sm@@	O	-1	6203452
all	O	-1	6203452
arter@@	O	-1	6203452
i@@	O	-1	6203452
es,	O	-1	6203452
arter@@	O	-1	6203452
i@@	O	-1	6203452
ol@@	O	-1	6203452
es,	O	-1	6203452
and	O	-1	6203452
glomerul@@	O	-1	6203452
i@@	O	-1	6203452
.	O	-1	6203452
B@@	O	-1	6203452
ecause	O	-1	6203452
each	O	-1	6203452
patient	O	-1	6203452
was	O	-1	6203452
tumor	B-Disease	D009369	6203452
-@@	O	-1	6203452
free	O	-1	6203452
or	O	-1	6203452
had	O	-1	6203452
only	O	-1	6203452
a	O	-1	6203452
sm@@	O	-1	6203452
all	O	-1	6203452
tumor	B-Disease	D009369	6203452
at	O	-1	6203452
the	O	-1	6203452
onset	O	-1	6203452
of	O	-1	6203452
this	O	-1	6203452
syndro@@	O	-1	6203452
me,	O	-1	6203452
the	O	-1	6203452
thrombotic	B-Disease	D057049	6203452
microangio@@	I-Disease	-1	6203452
pathy	I-Disease	-1	6203452
may	O	-1	6203452
have	O	-1	6203452
been	O	-1	6203452
induced	O	-1	6203452
by	O	-1	6203452
chemo@@	O	-1	6203452
therapy.	O	-1	6203452
Di@@	O	-1	6203452
ag@@	O	-1	6203452
no@@	O	-1	6203452
sis	O	-1	6203452
of	O	-1	6203452
this	O	-1	6203452
potenti@@	O	-1	6203452
ally	O	-1	6203452
f@@	O	-1	6203452
atal	O	-1	6203452
complication	O	-1	6203452
may	O	-1	6203452
be	O	-1	6203452
del@@	O	-1	6203452
ayed	O	-1	6203452
or	O	-1	6203452
mis@@	O	-1	6203452
sed	O	-1	6203452
if	O	-1	6203452
renal	O	-1	6203452
tissue	O	-1	6203452
or	O	-1	6203452
the	O	-1	6203452
peripheral	O	-1	6203452
blood	O	-1	6203452
s@@	O	-1	6203452
me@@	O	-1	6203452
ar	O	-1	6203452
is	O	-1	6203452
not	O	-1	6203452
ex@@	O	-1	6203452
am@@	O	-1	6203452
ine@@	O	-1	6203452
d,	O	-1	6203452
because	O	-1	6203452
renal	B-Disease	D051437	6203452
failure	I-Disease	-1	6203452
may	O	-1	6203452
be	O	-1	6203452
as@@	O	-1	6203452
cri@@	O	-1	6203452
bed	O	-1	6203452
to	O	-1	6203452
cisplatin	B-Chemical	D002945	6203452
nephro@@	B-Disease	D007674	6203452
toxicity	I-Disease	-1	6203452
and	O	-1	6203452
the	O	-1	6203452
anemia	B-Disease	D000740	6203452
and	O	-1	6203452
throm@@	B-Disease	D013921	6203452
b@@	I-Disease	-1	6203452
ocyto@@	I-Disease	-1	6203452
pen@@	I-Disease	-1	6203452
ia	I-Disease	-1	6203452
to	O	-1	6203452
drug@@	O	-1	6203452
-induced	O	-1	6203452
b@@	B-Disease	D001855	6203452
one	I-Disease	-1	6203452
m@@	I-Disease	-1	6203452
ar@@	I-Disease	-1	6203452
ro@@	I-Disease	-1	6203452
w	I-Disease	-1	6203452
sup@@	I-Disease	-1	6203452
pression	I-Disease	-1	6203452
.	O	-1	6203452

S@@	O	-1	20528871
al@@	O	-1	20528871
v@@	O	-1	20528871
age	O	-1	20528871
therapy	O	-1	20528871
with	O	-1	20528871
ne@@	B-Chemical	C104457	20528871
l@@	I-Chemical	-1	20528871
ar@@	I-Chemical	-1	20528871
ab@@	I-Chemical	-1	20528871
ine	I-Chemical	-1	20528871
,	O	-1	20528871
e@@	B-Chemical	D005047	20528871
to@@	I-Chemical	-1	20528871
po@@	I-Chemical	-1	20528871
side	I-Chemical	-1	20528871
,	O	-1	20528871
and	O	-1	20528871
cyclophosph@@	B-Chemical	D003520	20528871
amide	I-Chemical	-1	20528871
in	O	-1	20528871
rel@@	O	-1	20528871
ap@@	O	-1	20528871
sed@@	O	-1	20528871
/@@	O	-1	20528871
ref@@	O	-1	20528871
rac@@	O	-1	20528871
t@@	O	-1	20528871
ory	O	-1	20528871
pa@@	O	-1	20528871
edi@@	O	-1	20528871
atric	O	-1	20528871
T@@	B-Disease	D015458	20528871
-@@	I-Disease	-1	20528871
cell	I-Disease	-1	20528871
lymph@@	I-Disease	-1	20528871
ob@@	I-Disease	-1	20528871
las@@	I-Disease	-1	20528871
tic	I-Disease	-1	20528871
leuk@@	I-Disease	-1	20528871
a@@	I-Disease	-1	20528871
emia	I-Disease	-1	20528871
and	I-Disease	-1	20528871
lymph@@	I-Disease	-1	20528871
oma	I-Disease	-1	20528871
T@@	B-Disease	D016399	20528871
-@@	I-Disease	-1	20528871
cell	I-Disease	-1	20528871
lymph@@	I-Disease	-1	20528871
ob@@	I-Disease	-1	20528871
las@@	I-Disease	-1	20528871
tic	I-Disease	-1	20528871
leuk@@	I-Disease	-1	20528871
a@@	I-Disease	-1	20528871
emia	I-Disease	-1	20528871
and	I-Disease	-1	20528871
lymph@@	I-Disease	-1	20528871
oma	I-Disease	-1	20528871
.	O	-1	20528871
A	O	-1	20528871
combination	O	-1	20528871
of	O	-1	20528871
5	O	-1	20528871
d	O	-1	20528871
of	O	-1	20528871
ne@@	B-Chemical	C104457	20528871
l@@	I-Chemical	-1	20528871
ar@@	I-Chemical	-1	20528871
ab@@	I-Chemical	-1	20528871
ine	I-Chemical	-1	20528871
(	O	-1	20528871
A@@	B-Chemical	C104457	20528871
ra@@	I-Chemical	-1	20528871
G	I-Chemical	-1	20528871
)	O	-1	20528871
with	O	-1	20528871
5	O	-1	20528871
d	O	-1	20528871
of	O	-1	20528871
e@@	B-Chemical	D005047	20528871
to@@	I-Chemical	-1	20528871
po@@	I-Chemical	-1	20528871
side	I-Chemical	-1	20528871
(	O	-1	20528871
V@@	B-Chemical	D005047	20528871
P	I-Chemical	-1	20528871
)	O	-1	20528871
and	O	-1	20528871
cyclophosph@@	B-Chemical	D003520	20528871
amide	I-Chemical	-1	20528871
(	O	-1	20528871
C@@	B-Chemical	D003520	20528871
P@@	I-Chemical	-1	20528871
M	I-Chemical	-1	20528871
)	O	-1	20528871
and	O	-1	20528871
pro@@	O	-1	20528871
phyl@@	O	-1	20528871
ac@@	O	-1	20528871
tic	O	-1	20528871
intra@@	O	-1	20528871
th@@	O	-1	20528871
ec@@	O	-1	20528871
al	O	-1	20528871
chemotherapy	O	-1	20528871
was	O	-1	20528871
used	O	-1	20528871
as	O	-1	20528871
sal@@	O	-1	20528871
v@@	O	-1	20528871
age	O	-1	20528871
therapy	O	-1	20528871
in	O	-1	20528871
seven	O	-1	20528871
children	O	-1	20528871
with	O	-1	20528871
ref@@	O	-1	20528871
rac@@	O	-1	20528871
t@@	O	-1	20528871
ory	O	-1	20528871
or	O	-1	20528871
rel@@	O	-1	20528871
ap@@	O	-1	20528871
sed	O	-1	20528871
T@@	B-Disease	D015458	20528871
-@@	I-Disease	-1	20528871
cell	I-Disease	-1	20528871
leuk@@	I-Disease	-1	20528871
a@@	I-Disease	-1	20528871
emia	I-Disease	-1	20528871
or	I-Disease	-1	20528871
lymph@@	I-Disease	-1	20528871
oma	I-Disease	-1	20528871
T@@	B-Disease	D016399	20528871
-@@	I-Disease	-1	20528871
cell	I-Disease	-1	20528871
leuk@@	I-Disease	-1	20528871
a@@	I-Disease	-1	20528871
emia	I-Disease	-1	20528871
or	I-Disease	-1	20528871
lymph@@	I-Disease	-1	20528871
oma	I-Disease	-1	20528871
.	O	-1	20528871
The	O	-1	20528871
most	O	-1	20528871
common	O	-1	20528871
side	O	-1	20528871
effects	O	-1	20528871
at@@	O	-1	20528871
tri@@	O	-1	20528871
but@@	O	-1	20528871
able	O	-1	20528871
to	O	-1	20528871
the	O	-1	20528871
A@@	B-Chemical	C104457	20528871
ra@@	I-Chemical	-1	20528871
G	I-Chemical	-1	20528871
included	O	-1	20528871
G@@	O	-1	20528871
ra@@	O	-1	20528871
de	O	-1	20528871
2	O	-1	20528871
and	O	-1	20528871
3	O	-1	20528871
sens@@	O	-1	20528871
ory	O	-1	20528871
and	O	-1	20528871
motor	O	-1	20528871
neuropathy	B-Disease	D009422	20528871
and	O	-1	20528871
musc@@	B-Disease	D059352	20528871
u@@	I-Disease	-1	20528871
los@@	I-Disease	-1	20528871
ke@@	I-Disease	-1	20528871
le@@	I-Disease	-1	20528871
t@@	I-Disease	-1	20528871
al	I-Disease	-1	20528871
pain	I-Disease	-1	20528871
.	O	-1	20528871
H@@	B-Disease	D006402	20528871
a@@	I-Disease	-1	20528871
em@@	I-Disease	-1	20528871
at@@	I-Disease	-1	20528871
ological	I-Disease	-1	20528871
toxicity	I-Disease	-1	20528871
was	O	-1	20528871
greater	O	-1	20528871
for	O	-1	20528871
the	O	-1	20528871
combination	O	-1	20528871
than	O	-1	20528871
A@@	B-Chemical	C104457	20528871
ra@@	I-Chemical	-1	20528871
G	I-Chemical	-1	20528871
al@@	O	-1	20528871
one,	O	-1	20528871
although	O	-1	20528871
median	O	-1	20528871
time	O	-1	20528871
to	O	-1	20528871
ne@@	O	-1	20528871
ut@@	O	-1	20528871
ro@@	O	-1	20528871
ph@@	O	-1	20528871
il	O	-1	20528871
and	O	-1	20528871
platele@@	O	-1	20528871
t	O	-1	20528871
recovery	O	-1	20528871
was	O	-1	20528871
consist@@	O	-1	20528871
ent	O	-1	20528871
with	O	-1	20528871
other	O	-1	20528871
sal@@	O	-1	20528871
v@@	O	-1	20528871
age	O	-1	20528871
therap@@	O	-1	20528871
i@@	O	-1	20528871
es.	O	-1	20528871
All	O	-1	20528871
patients	O	-1	20528871
had	O	-1	20528871
some	O	-1	20528871
response	O	-1	20528871
to	O	-1	20528871
the	O	-1	20528871
combined	O	-1	20528871
therapy	O	-1	20528871
and	O	-1	20528871
five	O	-1	20528871
of	O	-1	20528871
the	O	-1	20528871
seven	O	-1	20528871
w@@	O	-1	20528871
ent	O	-1	20528871
into	O	-1	20528871
complete	O	-1	20528871
re@@	O	-1	20528871
mission	O	-1	20528871
after	O	-1	20528871
one	O	-1	20528871
or	O	-1	20528871
two	O	-1	20528871
cour@@	O	-1	20528871
ses	O	-1	20528871
of	O	-1	20528871
A@@	B-Chemical	C104457	20528871
ra@@	I-Chemical	-1	20528871
G	I-Chemical	-1	20528871
/	O	-1	20528871
V@@	B-Chemical	D005047	20528871
P	I-Chemical	-1	20528871
/	O	-1	20528871
C@@	B-Chemical	D003520	20528871
P@@	I-Chemical	-1	20528871
M	I-Chemical	-1	20528871
.	O	-1	20528871
Our	O	-1	20528871
experi@@	O	-1	20528871
ence	O	-1	20528871
suppor@@	O	-1	20528871
ts	O	-1	20528871
the	O	-1	20528871
safety	O	-1	20528871
of	O	-1	20528871
gi@@	O	-1	20528871
ving	O	-1	20528871
A@@	B-Chemical	C104457	20528871
ra@@	I-Chemical	-1	20528871
G	I-Chemical	-1	20528871
as	O	-1	20528871
sal@@	O	-1	20528871
v@@	O	-1	20528871
age	O	-1	20528871
therapy	O	-1	20528871
in	O	-1	20528871
syn@@	O	-1	20528871
chron@@	O	-1	20528871
y	O	-1	20528871
with	O	-1	20528871
e@@	B-Chemical	D005047	20528871
to@@	I-Chemical	-1	20528871
po@@	I-Chemical	-1	20528871
side	I-Chemical	-1	20528871
and	O	-1	20528871
cyclophosph@@	B-Chemical	D003520	20528871
amide	I-Chemical	-1	20528871
,	O	-1	20528871
although	O	-1	20528871
neurolog@@	B-Disease	D009422	20528871
ical	I-Disease	-1	20528871
toxicity	I-Disease	-1	20528871
mus@@	O	-1	20528871
t	O	-1	20528871
be	O	-1	20528871
clo@@	O	-1	20528871
se@@	O	-1	20528871
ly	O	-1	20528871
monit@@	O	-1	20528871
o@@	O	-1	20528871
red.	O	-1	20528871

The	O	-1	11672959
3-@@	O	-1	11672959
week	O	-1	11672959
sul@@	B-Chemical	D012460	11672959
ph@@	I-Chemical	-1	11672959
as@@	I-Chemical	-1	11672959
al@@	I-Chemical	-1	11672959
az@@	I-Chemical	-1	11672959
ine	I-Chemical	-1	11672959
syndrome	O	-1	11672959
stri@@	O	-1	11672959
k@@	O	-1	11672959
es	O	-1	11672959
again@@	O	-1	11672959
.	O	-1	11672959
A	O	-1	11672959
3@@	O	-1	11672959
4-@@	O	-1	11672959
year-old	O	-1	11672959
l@@	O	-1	11672959
ad@@	O	-1	11672959
y	O	-1	11672959
developed	O	-1	11672959
a	O	-1	11672959
con@@	O	-1	11672959
st@@	O	-1	11672959
ell@@	O	-1	11672959
ation	O	-1	11672959
of	O	-1	11672959
der@@	B-Disease	D003872	11672959
m@@	I-Disease	-1	11672959
ati@@	I-Disease	-1	11672959
tis	I-Disease	-1	11672959
,	O	-1	11672959
f@@	B-Disease	D005334	11672959
ev@@	I-Disease	-1	11672959
er	I-Disease	-1	11672959
,	O	-1	11672959
lymph@@	B-Disease	D008206	11672959
aden@@	I-Disease	-1	11672959
o@@	I-Disease	-1	11672959
pathy	I-Disease	-1	11672959
and	O	-1	11672959
hepatitis	B-Disease	D056486	11672959
,	O	-1	11672959
be@@	O	-1	11672959
g@@	O	-1	11672959
in@@	O	-1	11672959
ning	O	-1	11672959
on	O	-1	11672959
the	O	-1	11672959
17@@	O	-1	11672959
th	O	-1	11672959
day	O	-1	11672959
of	O	-1	11672959
a	O	-1	11672959
course	O	-1	11672959
of	O	-1	11672959
oral	O	-1	11672959
sul@@	B-Chemical	D012460	11672959
ph@@	I-Chemical	-1	11672959
as@@	I-Chemical	-1	11672959
al@@	I-Chemical	-1	11672959
az@@	I-Chemical	-1	11672959
ine	I-Chemical	-1	11672959
for	O	-1	11672959
ser@@	O	-1	11672959
o@@	O	-1	11672959
-@@	O	-1	11672959
negative	O	-1	11672959
r@@	B-Disease	D001172	11672959
he@@	I-Disease	-1	11672959
um@@	I-Disease	-1	11672959
at@@	I-Disease	-1	11672959
oid	I-Disease	-1	11672959
arth@@	I-Disease	-1	11672959
ritis	I-Disease	-1	11672959
.	O	-1	11672959
C@@	O	-1	11672959
er@@	O	-1	11672959
v@@	O	-1	11672959
ical	O	-1	11672959
and	O	-1	11672959
ing@@	O	-1	11672959
u@@	O	-1	11672959
inal	O	-1	11672959
lym@@	O	-1	11672959
p@@	O	-1	11672959
h	O	-1	11672959
no@@	O	-1	11672959
de	O	-1	11672959
biop@@	O	-1	11672959
si@@	O	-1	11672959
es	O	-1	11672959
showed	O	-1	11672959
the	O	-1	11672959
feat@@	O	-1	11672959
ures	O	-1	11672959
of	O	-1	11672959
severe	O	-1	11672959
necro@@	O	-1	11672959
tis@@	O	-1	11672959
ing	O	-1	11672959
lymph@@	B-Disease	D008199	11672959
aden@@	I-Disease	-1	11672959
iti@@	I-Disease	-1	11672959
s	I-Disease	-1	11672959
,	O	-1	11672959
associated	O	-1	11672959
with	O	-1	11672959
erythro@@	O	-1	11672959
ph@@	O	-1	11672959
ag@@	O	-1	11672959
ocyto@@	O	-1	11672959
sis	O	-1	11672959
and	O	-1	11672959
pro@@	O	-1	11672959
min@@	O	-1	11672959
ent	O	-1	11672959
e@@	O	-1	11672959
os@@	O	-1	11672959
in@@	O	-1	11672959
oph@@	O	-1	11672959
il@@	O	-1	11672959
ic	O	-1	11672959
inf@@	O	-1	11672959
ilt@@	O	-1	11672959
rat@@	O	-1	11672959
es,	O	-1	11672959
without	O	-1	11672959
viral	O	-1	11672959
inc@@	O	-1	11672959
lu@@	O	-1	11672959
sion	O	-1	11672959
bo@@	O	-1	11672959
di@@	O	-1	11672959
es,	O	-1	11672959
sugg@@	O	-1	11672959
es@@	O	-1	11672959
tive	O	-1	11672959
of	O	-1	11672959
an	O	-1	11672959
adverse	B-Disease	D064420	11672959
drug	I-Disease	-1	11672959
reaction	I-Disease	-1	11672959
.@@	O	-1	11672959
A	O	-1	11672959
week	O	-1	11672959
lat@@	O	-1	11672959
er,	O	-1	11672959
ful@@	O	-1	11672959
min@@	O	-1	11672959
ant	O	-1	11672959
drug@@	B-Disease	D056486	11672959
-induced	I-Disease	-1	11672959
hepatitis	I-Disease	-1	11672959
,	O	-1	11672959
associated	O	-1	11672959
with	O	-1	11672959
the	O	-1	11672959
presence	O	-1	11672959
of	O	-1	11672959
anti@@	O	-1	11672959
-@@	O	-1	11672959
nucle@@	O	-1	11672959
ar	O	-1	11672959
auto@@	O	-1	11672959
anti@@	O	-1	11672959
bo@@	O	-1	11672959
di@@	O	-1	11672959
es	O	-1	11672959
(@@	O	-1	11672959
but	O	-1	11672959
not	O	-1	11672959
with	O	-1	11672959
other	O	-1	11672959
mark@@	O	-1	11672959
ers	O	-1	11672959
of	O	-1	11672959
auto@@	B-Disease	D001327	11672959
immun@@	I-Disease	-1	11672959
ity	I-Disease	-1	11672959
),	O	-1	11672959
and	O	-1	11672959
ac@@	O	-1	11672959
comp@@	O	-1	11672959
an@@	O	-1	11672959
ied	O	-1	11672959
by	O	-1	11672959
multi@@	B-Disease	D009102	11672959
-@@	I-Disease	-1	11672959
org@@	I-Disease	-1	11672959
an	I-Disease	-1	11672959
failure	I-Disease	-1	11672959
and	O	-1	11672959
se@@	B-Disease	D018805	11672959
p@@	I-Disease	-1	11672959
sis	I-Disease	-1	11672959
,	O	-1	11672959
su@@	O	-1	11672959
per@@	O	-1	11672959
ven@@	O	-1	11672959
ed.	O	-1	11672959
S@@	O	-1	11672959
he	O	-1	11672959
subsequ@@	O	-1	11672959
ently	O	-1	11672959
di@@	O	-1	11672959
ed	O	-1	11672959
some	O	-1	11672959
5	O	-1	11672959
weeks	O	-1	11672959
after	O	-1	11672959
the	O	-1	11672959
comm@@	O	-1	11672959
ence@@	O	-1	11672959
ment	O	-1	11672959
of	O	-1	11672959
h@@	O	-1	11672959
er	O	-1	11672959
drug	O	-1	11672959
therap@@	O	-1	11672959
y@@	O	-1	11672959
.@@	O	-1	11672959
P@@	O	-1	11672959
ost@@	O	-1	11672959
-@@	O	-1	11672959
mor@@	O	-1	11672959
te@@	O	-1	11672959
m	O	-1	11672959
examin@@	O	-1	11672959
ation	O	-1	11672959
showed	O	-1	11672959
evidence	O	-1	11672959
of	O	-1	11672959
mas@@	B-Disease	D047508	11672959
sive	I-Disease	-1	11672959
hepat@@	I-Disease	-1	11672959
oc@@	I-Disease	-1	11672959
ell@@	I-Disease	-1	11672959
ular	I-Disease	-1	11672959
necro@@	I-Disease	-1	11672959
sis	I-Disease	-1	11672959
,	O	-1	11672959
acute	O	-1	11672959
hyper@@	O	-1	11672959
sensitivity	O	-1	11672959
myocardi@@	B-Disease	D009205	11672959
tis	I-Disease	-1	11672959
,	O	-1	11672959
foc@@	O	-1	11672959
al	O	-1	11672959
acute	O	-1	11672959
tu@@	O	-1	11672959
bu@@	O	-1	11672959
lo@@	O	-1	11672959
-@@	O	-1	11672959
interstitial	O	-1	11672959
neph@@	B-Disease	D009393	11672959
ritis	I-Disease	-1	11672959
and	O	-1	11672959
exten@@	O	-1	11672959
sive	O	-1	11672959
b@@	B-Disease	D001855	11672959
one	I-Disease	-1	11672959
m@@	I-Disease	-1	11672959
ar@@	I-Disease	-1	11672959
ro@@	I-Disease	-1	11672959
w	I-Disease	-1	11672959
necro@@	I-Disease	-1	11672959
sis	I-Disease	-1	11672959
,	O	-1	11672959
with	O	-1	11672959
no	O	-1	11672959
evidence	O	-1	11672959
of	O	-1	11672959
mal@@	B-Disease	D009369	11672959
i@@	I-Disease	-1	11672959
gn@@	I-Disease	-1	11672959
anc@@	I-Disease	-1	11672959
y	I-Disease	-1	11672959
.	O	-1	11672959
It	O	-1	11672959
is	O	-1	11672959
thou@@	O	-1	11672959
ght	O	-1	11672959
that	O	-1	11672959
the	O	-1	11672959
clin@@	O	-1	11672959
ic@@	O	-1	11672959
o@@	O	-1	11672959
-@@	O	-1	11672959
path@@	O	-1	11672959
ological	O	-1	11672959
feat@@	O	-1	11672959
ures	O	-1	11672959
and	O	-1	11672959
chron@@	O	-1	11672959
ology	O	-1	11672959
of	O	-1	11672959
this	O	-1	11672959
case	O	-1	11672959
b@@	O	-1	11672959
or@@	O	-1	11672959
e	O	-1	11672959
the	O	-1	11672959
h@@	O	-1	11672959
all@@	O	-1	11672959
mark@@	O	-1	11672959
s	O	-1	11672959
of	O	-1	11672959
the	O	-1	11672959
so@@	O	-1	11672959
-@@	O	-1	11672959
c@@	O	-1	11672959
all@@	O	-1	11672959
ed	O	-1	11672959
"@@	O	-1	11672959
3-@@	O	-1	11672959
week	O	-1	11672959
sul@@	B-Chemical	D012460	11672959
ph@@	I-Chemical	-1	11672959
as@@	I-Chemical	-1	11672959
al@@	I-Chemical	-1	11672959
az@@	I-Chemical	-1	11672959
ine	I-Chemical	-1	11672959
syndro@@	O	-1	11672959
me@@	O	-1	11672959
"@@	O	-1	11672959
,	O	-1	11672959
a	O	-1	11672959
ra@@	O	-1	11672959
re,	O	-1	11672959
but	O	-1	11672959
often	O	-1	11672959
f@@	O	-1	11672959
at@@	O	-1	11672959
al,	O	-1	11672959
immuno@@	O	-1	11672959
all@@	O	-1	11672959
ergic	O	-1	11672959
reaction	O	-1	11672959
to	O	-1	11672959
sul@@	B-Chemical	D012460	11672959
ph@@	I-Chemical	-1	11672959
as@@	I-Chemical	-1	11672959
al@@	I-Chemical	-1	11672959
az@@	I-Chemical	-1	11672959
ine	I-Chemical	-1	11672959
.	O	-1	11672959

B@@	B-Chemical	D016642	11928786
u@@	I-Chemical	-1	11928786
pro@@	I-Chemical	-1	11928786
pi@@	I-Chemical	-1	11928786
on	I-Chemical	-1	11928786
(	O	-1	11928786
Z@@	B-Chemical	D016642	11928786
y@@	I-Chemical	-1	11928786
b@@	I-Chemical	-1	11928786
an	I-Chemical	-1	11928786
)	O	-1	11928786
toxicity	B-Disease	D064420	11928786
.	O	-1	11928786
B@@	B-Chemical	D016642	11928786
u@@	I-Chemical	-1	11928786
pro@@	I-Chemical	-1	11928786
pi@@	I-Chemical	-1	11928786
on	I-Chemical	-1	11928786
is	O	-1	11928786
a	O	-1	11928786
mon@@	O	-1	11928786
ocy@@	O	-1	11928786
cl@@	O	-1	11928786
ic	O	-1	11928786
antidepress@@	B-Chemical	D000928	11928786
ant	I-Chemical	-1	11928786
struct@@	O	-1	11928786
ur@@	O	-1	11928786
ally	O	-1	11928786
related	O	-1	11928786
to	O	-1	11928786
amphetamine	B-Chemical	D000661	11928786
.	O	-1	11928786
Z@@	B-Chemical	D016642	11928786
y@@	I-Chemical	-1	11928786
b@@	I-Chemical	-1	11928786
an	I-Chemical	-1	11928786
,	O	-1	11928786
a	O	-1	11928786
su@@	O	-1	11928786
st@@	O	-1	11928786
a@@	O	-1	11928786
ine@@	O	-1	11928786
d-@@	O	-1	11928786
release	O	-1	11928786
form@@	O	-1	11928786
ulation	O	-1	11928786
of	O	-1	11928786
bu@@	B-Chemical	D016642	11928786
pro@@	I-Chemical	-1	11928786
pi@@	I-Chemical	-1	11928786
on	I-Chemical	-1	11928786
hydro@@	I-Chemical	-1	11928786
chlor@@	I-Chemical	-1	11928786
ide	I-Chemical	-1	11928786
,	O	-1	11928786
was	O	-1	11928786
rec@@	O	-1	11928786
ently	O	-1	11928786
rele@@	O	-1	11928786
as@@	O	-1	11928786
ed	O	-1	11928786
in	O	-1	11928786
I@@	O	-1	11928786
rel@@	O	-1	11928786
and@@	O	-1	11928786
,	O	-1	11928786
as	O	-1	11928786
a	O	-1	11928786
smo@@	O	-1	11928786
king	O	-1	11928786
cess@@	O	-1	11928786
ation	O	-1	11928786
a@@	O	-1	11928786
id@@	O	-1	11928786
.	O	-1	11928786
In	O	-1	11928786
the	O	-1	11928786
initial	O	-1	11928786
6	O	-1	11928786
months	O	-1	11928786
s@@	O	-1	11928786
inc@@	O	-1	11928786
e	O	-1	11928786
it@@	O	-1	11928786
's	O	-1	11928786
int@@	O	-1	11928786
ro@@	O	-1	11928786
duc@@	O	-1	11928786
tion,	O	-1	11928786
12	O	-1	11928786
over@@	B-Disease	D062787	11928786
dose	I-Disease	-1	11928786
cases	O	-1	11928786
have	O	-1	11928786
been	O	-1	11928786
reported	O	-1	11928786
to	O	-1	11928786
The	O	-1	11928786
N@@	O	-1	11928786
ation@@	O	-1	11928786
al	O	-1	11928786
P@@	O	-1	11928786
o@@	O	-1	11928786
is@@	O	-1	11928786
ons	O	-1	11928786
In@@	O	-1	11928786
formation	O	-1	11928786
C@@	O	-1	11928786
ent@@	O	-1	11928786
re.	O	-1	11928786
8	O	-1	11928786
patients	O	-1	11928786
developed	O	-1	11928786
symptoms	O	-1	11928786
of	O	-1	11928786
toxicity	B-Disease	D064420	11928786
.	O	-1	11928786
Com@@	O	-1	11928786
m@@	O	-1	11928786
on	O	-1	11928786
feat@@	O	-1	11928786
ures	O	-1	11928786
included	O	-1	11928786
tachycardia	B-Disease	D013610	11928786
,	O	-1	11928786
dro@@	O	-1	11928786
w@@	O	-1	11928786
s@@	O	-1	11928786
in@@	O	-1	11928786
es@@	O	-1	11928786
s,	O	-1	11928786
h@@	B-Disease	D006212	11928786
all@@	I-Disease	-1	11928786
uc@@	I-Disease	-1	11928786
in@@	I-Disease	-1	11928786
ations	I-Disease	-1	11928786
and	O	-1	11928786
convul@@	B-Disease	D012640	11928786
sions	I-Disease	-1	11928786
.	O	-1	11928786
Two	O	-1	11928786
patients	O	-1	11928786
developed	O	-1	11928786
severe	O	-1	11928786
cardiac	B-Disease	D001145	11928786
arrhyth@@	I-Disease	-1	11928786
mi@@	I-Disease	-1	11928786
as	I-Disease	-1	11928786
,	O	-1	11928786
including	O	-1	11928786
one	O	-1	11928786
patient	O	-1	11928786
who	O	-1	11928786
was	O	-1	11928786
res@@	O	-1	11928786
us@@	O	-1	11928786
cit@@	O	-1	11928786
ated	O	-1	11928786
following	O	-1	11928786
a	O	-1	11928786
cardiac	B-Disease	D006323	11928786
ar@@	I-Disease	-1	11928786
res@@	I-Disease	-1	11928786
t	I-Disease	-1	11928786
.	O	-1	11928786
All	O	-1	11928786
patients	O	-1	11928786
reco@@	O	-1	11928786
vered	O	-1	11928786
without	O	-1	11928786
sequ@@	O	-1	11928786
el@@	O	-1	11928786
a@@	O	-1	11928786
e.	O	-1	11928786
We	O	-1	11928786
report	O	-1	11928786
a	O	-1	11928786
case	O	-1	11928786
of	O	-1	11928786
a	O	-1	11928786
3@@	O	-1	11928786
1	O	-1	11928786
year	O	-1	11928786
old	O	-1	11928786
female	O	-1	11928786
who	O	-1	11928786
requ@@	O	-1	11928786
ired	O	-1	11928786
ad@@	O	-1	11928786
mission	O	-1	11928786
to	O	-1	11928786
the	O	-1	11928786
In@@	O	-1	11928786
ten@@	O	-1	11928786
sive	O	-1	11928786
C@@	O	-1	11928786
are	O	-1	11928786
U@@	O	-1	11928786
n@@	O	-1	11928786
it	O	-1	11928786
for	O	-1	11928786
ven@@	O	-1	11928786
til@@	O	-1	11928786
ation	O	-1	11928786
and	O	-1	11928786
ful@@	O	-1	11928786
l	O	-1	11928786
suppor@@	O	-1	11928786
tive	O	-1	11928786
therapy,	O	-1	11928786
following	O	-1	11928786
ing@@	O	-1	11928786
es@@	O	-1	11928786
tion	O	-1	11928786
of	O	-1	11928786
1@@	O	-1	11928786
3.@@	O	-1	11928786
5@@	O	-1	11928786
g	O	-1	11928786
bu@@	B-Chemical	D016642	11928786
pro@@	I-Chemical	-1	11928786
pi@@	I-Chemical	-1	11928786
on	I-Chemical	-1	11928786
.	O	-1	11928786
Rec@@	O	-1	11928786
ur@@	O	-1	11928786
rent	O	-1	11928786
seizures	B-Disease	D012640	11928786
were	O	-1	11928786
treated	O	-1	11928786
with	O	-1	11928786
di@@	B-Chemical	D003975	11928786
az@@	I-Chemical	-1	11928786
epam	I-Chemical	-1	11928786
and	O	-1	11928786
b@@	O	-1	11928786
ro@@	O	-1	11928786
ad	O	-1	11928786
comple@@	O	-1	11928786
x	O	-1	11928786
tachycardia	B-Disease	D013610	11928786
was	O	-1	11928786
suc@@	O	-1	11928786
cess@@	O	-1	11928786
ful@@	O	-1	11928786
ly	O	-1	11928786
treated	O	-1	11928786
with	O	-1	11928786
aden@@	B-Chemical	D000241	11928786
os@@	I-Chemical	-1	11928786
ine	I-Chemical	-1	11928786
.	O	-1	11928786
Z@@	B-Chemical	D016642	11928786
y@@	I-Chemical	-1	11928786
b@@	I-Chemical	-1	11928786
an	I-Chemical	-1	11928786
caused	O	-1	11928786
significant	O	-1	11928786
neurolog@@	B-Disease	D020258	11928786
ical	I-Disease	-1	11928786
and	I-Disease	-1	11928786
cardiovascular	I-Disease	-1	11928786
toxicity	I-Disease	-1	11928786
neurolog@@	B-Disease	D002318	11928786
ical	I-Disease	-1	11928786
and	I-Disease	-1	11928786
cardiovascular	I-Disease	-1	11928786
toxicity	I-Disease	-1	11928786
in	O	-1	11928786
over@@	B-Disease	D062787	11928786
dose	I-Disease	-1	11928786
.	O	-1	11928786
The	O	-1	11928786
potential	O	-1	11928786
toxic	O	-1	11928786
effects	O	-1	11928786
should	O	-1	11928786
be	O	-1	11928786
considered	O	-1	11928786
when	O	-1	11928786
prescri@@	O	-1	11928786
b@@	O	-1	11928786
ing	O	-1	11928786
it	O	-1	11928786
as	O	-1	11928786
a	O	-1	11928786
smo@@	O	-1	11928786
king	O	-1	11928786
cess@@	O	-1	11928786
ation	O	-1	11928786
a@@	O	-1	11928786
id@@	O	-1	11928786
.	O	-1	11928786

S@@	O	-1	7977601
ur@@	O	-1	7977601
ve@@	O	-1	7977601
y	O	-1	7977601
of	O	-1	7977601
complications	O	-1	7977601
of	O	-1	7977601
ind@@	B-Chemical	D007208	7977601
ocy@@	I-Chemical	-1	7977601
an@@	I-Chemical	-1	7977601
ine	I-Chemical	-1	7977601
gre@@	I-Chemical	-1	7977601
en	I-Chemical	-1	7977601
angio@@	O	-1	7977601
graph@@	O	-1	7977601
y	O	-1	7977601
in	O	-1	7977601
J@@	O	-1	7977601
ap@@	O	-1	7977601
an@@	O	-1	7977601
.	O	-1	7977601
P@@	O	-1	7977601
U@@	O	-1	7977601
R@@	O	-1	7977601
P@@	O	-1	7977601
O@@	O	-1	7977601
S@@	O	-1	7977601
E:	O	-1	7977601
We	O	-1	7977601
evaluated	O	-1	7977601
the	O	-1	7977601
safety	O	-1	7977601
of	O	-1	7977601
ind@@	B-Chemical	D007208	7977601
ocy@@	I-Chemical	-1	7977601
an@@	I-Chemical	-1	7977601
ine	I-Chemical	-1	7977601
gre@@	I-Chemical	-1	7977601
en	I-Chemical	-1	7977601
for	O	-1	7977601
use	O	-1	7977601
in	O	-1	7977601
f@@	O	-1	7977601
und@@	O	-1	7977601
us	O	-1	7977601
angio@@	O	-1	7977601
graph@@	O	-1	7977601
y.	O	-1	7977601
METHODS:	O	-1	7977601
We	O	-1	7977601
s@@	O	-1	7977601
ent	O	-1	7977601
a	O	-1	7977601
qu@@	O	-1	7977601
es@@	O	-1	7977601
tion@@	O	-1	7977601
na@@	O	-1	7977601
ir@@	O	-1	7977601
e	O	-1	7977601
con@@	O	-1	7977601
cer@@	O	-1	7977601
ning	O	-1	7977601
complications	O	-1	7977601
of	O	-1	7977601
ind@@	B-Chemical	D007208	7977601
ocy@@	I-Chemical	-1	7977601
an@@	I-Chemical	-1	7977601
ine	I-Chemical	-1	7977601
gre@@	I-Chemical	-1	7977601
en	I-Chemical	-1	7977601
to	O	-1	7977601
3@@	O	-1	7977601
2	O	-1	7977601
insti@@	O	-1	7977601
tu@@	O	-1	7977601
tions	O	-1	7977601
in	O	-1	7977601
J@@	O	-1	7977601
ap@@	O	-1	7977601
an@@	O	-1	7977601
,	O	-1	7977601
which	O	-1	7977601
were	O	-1	7977601
sel@@	O	-1	7977601
ected	O	-1	7977601
on	O	-1	7977601
the	O	-1	7977601
b@@	O	-1	7977601
asis	O	-1	7977601
of	O	-1	7977601
the	O	-1	7977601
c@@	O	-1	7977601
li@@	O	-1	7977601
ent	O	-1	7977601
l@@	O	-1	7977601
ist	O	-1	7977601
from	O	-1	7977601
the	O	-1	7977601
T@@	O	-1	7977601
op@@	O	-1	7977601
c@@	O	-1	7977601
on	O	-1	7977601
Com@@	O	-1	7977601
p@@	O	-1	7977601
an@@	O	-1	7977601
y,	O	-1	7977601
which	O	-1	7977601
man@@	O	-1	7977601
u@@	O	-1	7977601
fact@@	O	-1	7977601
ures	O	-1	7977601
the	O	-1	7977601
ind@@	B-Chemical	D007208	7977601
ocy@@	I-Chemical	-1	7977601
an@@	I-Chemical	-1	7977601
ine	I-Chemical	-1	7977601
gre@@	I-Chemical	-1	7977601
en	I-Chemical	-1	7977601
f@@	O	-1	7977601
und@@	O	-1	7977601
us	O	-1	7977601
c@@	O	-1	7977601
am@@	O	-1	7977601
er@@	O	-1	7977601
a.	O	-1	7977601
RESULTS:	O	-1	7977601
O@@	O	-1	7977601
ph@@	O	-1	7977601
thal@@	O	-1	7977601
mo@@	O	-1	7977601
log@@	O	-1	7977601
ist@@	O	-1	7977601
s	O	-1	7977601
at	O	-1	7977601
15	O	-1	7977601
insti@@	O	-1	7977601
tu@@	O	-1	7977601
tions	O	-1	7977601
respon@@	O	-1	7977601
de@@	O	-1	7977601
d,	O	-1	7977601
repor@@	O	-1	7977601
ting	O	-1	7977601
a	O	-1	7977601
total	O	-1	7977601
of	O	-1	7977601
3@@	O	-1	7977601
,@@	O	-1	7977601
7@@	O	-1	7977601
7@@	O	-1	7977601
4	O	-1	7977601
ind@@	B-Chemical	D007208	7977601
ocy@@	I-Chemical	-1	7977601
an@@	I-Chemical	-1	7977601
ine	I-Chemical	-1	7977601
gre@@	I-Chemical	-1	7977601
en	I-Chemical	-1	7977601
angio@@	O	-1	7977601
gram@@	O	-1	7977601
s	O	-1	7977601
performed	O	-1	7977601
on	O	-1	7977601
2@@	O	-1	7977601
,@@	O	-1	7977601
8@@	O	-1	7977601
20	O	-1	7977601
patients	O	-1	7977601
between	O	-1	7977601
J@@	O	-1	7977601
un@@	O	-1	7977601
e	O	-1	7977601
19@@	O	-1	7977601
8@@	O	-1	7977601
4	O	-1	7977601
and	O	-1	7977601
S@@	O	-1	7977601
e@@	O	-1	7977601
pt@@	O	-1	7977601
emb@@	O	-1	7977601
er	O	-1	7977601
19@@	O	-1	7977601
9@@	O	-1	7977601
2@@	O	-1	7977601
.	O	-1	7977601
B@@	O	-1	7977601
e@@	O	-1	7977601
fore	O	-1	7977601
angio@@	O	-1	7977601
graph@@	O	-1	7977601
y,	O	-1	7977601
intra@@	O	-1	7977601
der@@	O	-1	7977601
m@@	O	-1	7977601
al	O	-1	7977601
or	O	-1	7977601
intravenous	O	-1	7977601
ind@@	B-Chemical	D007208	7977601
ocy@@	I-Chemical	-1	7977601
an@@	I-Chemical	-1	7977601
ine	I-Chemical	-1	7977601
gre@@	I-Chemical	-1	7977601
en	I-Chemical	-1	7977601
test@@	O	-1	7977601
ing,	O	-1	7977601
or	O	-1	7977601
both	O	-1	7977601
was	O	-1	7977601
performed	O	-1	7977601
at	O	-1	7977601
13	O	-1	7977601
of	O	-1	7977601
15	O	-1	7977601
insti@@	O	-1	7977601
tu@@	O	-1	7977601
tions.	O	-1	7977601
F@@	O	-1	7977601
or	O	-1	7977601
three	O	-1	7977601
patients,	O	-1	7977601
the	O	-1	7977601
dec@@	O	-1	7977601
i@@	O	-1	7977601
sion	O	-1	7977601
was	O	-1	7977601
m@@	O	-1	7977601
ade	O	-1	7977601
not	O	-1	7977601
to	O	-1	7977601
proce@@	O	-1	7977601
ed	O	-1	7977601
with	O	-1	7977601
angio@@	O	-1	7977601
graph@@	O	-1	7977601
y	O	-1	7977601
after	O	-1	7977601
positive	O	-1	7977601
pre@@	O	-1	7977601
angio@@	O	-1	7977601
graph@@	O	-1	7977601
ic	O	-1	7977601
test@@	O	-1	7977601
ing.	O	-1	7977601
The	O	-1	7977601
dos@@	O	-1	7977601
age	O	-1	7977601
of	O	-1	7977601
ind@@	B-Chemical	D007208	7977601
ocy@@	I-Chemical	-1	7977601
an@@	I-Chemical	-1	7977601
ine	I-Chemical	-1	7977601
gre@@	I-Chemical	-1	7977601
en	I-Chemical	-1	7977601
used	O	-1	7977601
for	O	-1	7977601
angio@@	O	-1	7977601
graph@@	O	-1	7977601
y	O	-1	7977601
vari@@	O	-1	7977601
ed	O	-1	7977601
from	O	-1	7977601
25	O	-1	7977601
to	O	-1	7977601
7@@	O	-1	7977601
5	O	-1	7977601
mg@@	O	-1	7977601
,	O	-1	7977601
depend@@	O	-1	7977601
ing	O	-1	7977601
up@@	O	-1	7977601
on	O	-1	7977601
the	O	-1	7977601
insti@@	O	-1	7977601
tu@@	O	-1	7977601
tion.	O	-1	7977601
There	O	-1	7977601
were	O	-1	7977601
13	O	-1	7977601
cases	O	-1	7977601
of	O	-1	7977601
adverse	O	-1	7977601
reactions	O	-1	7977601
(0.@@	O	-1	7977601
34@@	O	-1	7977601
%),	O	-1	7977601
ten	O	-1	7977601
of	O	-1	7977601
which	O	-1	7977601
were	O	-1	7977601
mil@@	O	-1	7977601
d	O	-1	7977601
reactions	O	-1	7977601
such	O	-1	7977601
as	O	-1	7977601
nausea	B-Disease	D009325	7977601
,	O	-1	7977601
ex@@	B-Disease	D005076	7977601
an@@	I-Disease	-1	7977601
th@@	I-Disease	-1	7977601
em@@	I-Disease	-1	7977601
a	I-Disease	-1	7977601
,	O	-1	7977601
ur@@	B-Disease	D014581	7977601
tic@@	I-Disease	-1	7977601
ation	I-Disease	-1	7977601
,	O	-1	7977601
it@@	B-Disease	D011537	7977601
ch@@	I-Disease	-1	7977601
in@@	I-Disease	-1	7977601
ess	I-Disease	-1	7977601
,	O	-1	7977601
and	O	-1	7977601
ur@@	O	-1	7977601
gen@@	O	-1	7977601
c@@	O	-1	7977601
y	O	-1	7977601
to	O	-1	7977601
def@@	O	-1	7977601
ec@@	O	-1	7977601
ate,	O	-1	7977601
and	O	-1	7977601
did	O	-1	7977601
not	O	-1	7977601
requ@@	O	-1	7977601
ir@@	O	-1	7977601
e	O	-1	7977601
treatment.	O	-1	7977601
Al@@	O	-1	7977601
so	O	-1	7977601
recor@@	O	-1	7977601
ded	O	-1	7977601
were	O	-1	7977601
one	O	-1	7977601
case	O	-1	7977601
of	O	-1	7977601
pain	B-Disease	D010146	7977601
of	O	-1	7977601
the	O	-1	7977601
ve@@	O	-1	7977601
in,	O	-1	7977601
which	O	-1	7977601
requ@@	O	-1	7977601
ired	O	-1	7977601
treatment,	O	-1	7977601
and	O	-1	7977601
two	O	-1	7977601
cases	O	-1	7977601
of	O	-1	7977601
hypotension	B-Disease	D007022	7977601
.	O	-1	7977601
The	O	-1	7977601
two	O	-1	7977601
hypoten@@	B-Disease	D007022	7977601
sive	I-Disease	-1	7977601
patients	O	-1	7977601
requ@@	O	-1	7977601
ired	O	-1	7977601
treatment	O	-1	7977601
for	O	-1	7977601
sh@@	B-Disease	D012769	7977601
oc@@	I-Disease	-1	7977601
k	I-Disease	-1	7977601
.	O	-1	7977601
CONCLUSIONS:	O	-1	7977601
A	O	-1	7977601
compar@@	O	-1	7977601
ison	O	-1	7977601
of	O	-1	7977601
frequency	O	-1	7977601
of	O	-1	7977601
adverse	O	-1	7977601
reactions	O	-1	7977601
to	O	-1	7977601
ind@@	B-Chemical	D007208	7977601
ocy@@	I-Chemical	-1	7977601
an@@	I-Chemical	-1	7977601
ine	I-Chemical	-1	7977601
gre@@	I-Chemical	-1	7977601
en	I-Chemical	-1	7977601
with	O	-1	7977601
the	O	-1	7977601
previously	O	-1	7977601
reported	O	-1	7977601
frequency	O	-1	7977601
of	O	-1	7977601
such	O	-1	7977601
reactions	O	-1	7977601
to	O	-1	7977601
fluo@@	B-Chemical	D019793	7977601
res@@	I-Chemical	-1	7977601
ce@@	I-Chemical	-1	7977601
in	I-Chemical	-1	7977601
sodium	I-Chemical	-1	7977601
indic@@	O	-1	7977601
ated	O	-1	7977601
that	O	-1	7977601
ind@@	B-Chemical	D007208	7977601
ocy@@	I-Chemical	-1	7977601
an@@	I-Chemical	-1	7977601
ine	I-Chemical	-1	7977601
gre@@	I-Chemical	-1	7977601
en	I-Chemical	-1	7977601
is	O	-1	7977601
a	O	-1	7977601
saf@@	O	-1	7977601
e	O	-1	7977601
as	O	-1	7977601
fluo@@	B-Chemical	D019793	7977601
res@@	I-Chemical	-1	7977601
ce@@	I-Chemical	-1	7977601
in	I-Chemical	-1	7977601
for	O	-1	7977601
use	O	-1	7977601
in	O	-1	7977601
angio@@	O	-1	7977601
graph@@	O	-1	7977601
y.	O	-1	7977601

B@@	B-Chemical	D001920	19300402
ra@@	I-Chemical	-1	19300402
dy@@	I-Chemical	-1	19300402
kin@@	I-Chemical	-1	19300402
in	I-Chemical	-1	19300402
receptors	O	-1	19300402
antagonist@@	O	-1	19300402
s	O	-1	19300402
and	O	-1	19300402
nit@@	B-Chemical	D009569	19300402
ric	I-Chemical	-1	19300402
ox@@	I-Chemical	-1	19300402
ide	I-Chemical	-1	19300402
syn@@	O	-1	19300402
th@@	O	-1	19300402
ase	O	-1	19300402
inhibitors	O	-1	19300402
in	O	-1	19300402
v@@	B-Chemical	D014750	19300402
inc@@	I-Chemical	-1	19300402
ri@@	I-Chemical	-1	19300402
st@@	I-Chemical	-1	19300402
ine	I-Chemical	-1	19300402
and	O	-1	19300402
st@@	B-Chemical	D013311	19300402
re@@	I-Chemical	-1	19300402
pto@@	I-Chemical	-1	19300402
z@@	I-Chemical	-1	19300402
ot@@	I-Chemical	-1	19300402
oc@@	I-Chemical	-1	19300402
in	I-Chemical	-1	19300402
induced	O	-1	19300402
hyperalge@@	B-Disease	D006930	19300402
sia	I-Disease	-1	19300402
in	O	-1	19300402
chemotherapy	O	-1	19300402
and	O	-1	19300402
dia@@	B-Disease	D003929	19300402
be@@	I-Disease	-1	19300402
tic	I-Disease	-1	19300402
neuropathy	I-Disease	-1	19300402
rat	O	-1	19300402
model@@	O	-1	19300402
.	O	-1	19300402
P@@	O	-1	19300402
U@@	O	-1	19300402
R@@	O	-1	19300402
P@@	O	-1	19300402
O@@	O	-1	19300402
S@@	O	-1	19300402
E:	O	-1	19300402
The	O	-1	19300402
influence	O	-1	19300402
of	O	-1	19300402
an	O	-1	19300402
ir@@	O	-1	19300402
reversible	O	-1	19300402
inhibitor	O	-1	19300402
of	O	-1	19300402
con@@	O	-1	19300402
sti@@	O	-1	19300402
tu@@	O	-1	19300402
tive	O	-1	19300402
N@@	B-Chemical	D009569	19300402
O	I-Chemical	-1	19300402
syn@@	O	-1	19300402
th@@	O	-1	19300402
ase	O	-1	19300402
(@@	O	-1	19300402
L-@@	O	-1	19300402
NO@@	O	-1	19300402
A@@	O	-1	19300402
r@@	O	-1	19300402
g@@	O	-1	19300402
;	O	-1	19300402
1.@@	O	-1	19300402
0	O	-1	19300402
mg/kg	O	-1	19300402
ip@@	O	-1	19300402
),	O	-1	19300402
a	O	-1	19300402
rel@@	O	-1	19300402
atively	O	-1	19300402
selective	O	-1	19300402
inhibitor	O	-1	19300402
of	O	-1	19300402
induc@@	O	-1	19300402
i@@	O	-1	19300402
ble	O	-1	19300402
N@@	B-Chemical	D009569	19300402
O	I-Chemical	-1	19300402
syn@@	O	-1	19300402
th@@	O	-1	19300402
ase	O	-1	19300402
(@@	O	-1	19300402
L-@@	O	-1	19300402
N@@	O	-1	19300402
I@@	O	-1	19300402
L@@	O	-1	19300402
;	O	-1	19300402
1.@@	O	-1	19300402
0	O	-1	19300402
mg/kg	O	-1	19300402
ip@@	O	-1	19300402
)	O	-1	19300402
and	O	-1	19300402
a	O	-1	19300402
rel@@	O	-1	19300402
atively	O	-1	19300402
specific	O	-1	19300402
inhibitor	O	-1	19300402
of	O	-1	19300402
neuron@@	O	-1	19300402
al	O	-1	19300402
N@@	B-Chemical	D009569	19300402
O	I-Chemical	-1	19300402
syn@@	O	-1	19300402
th@@	O	-1	19300402
ase	O	-1	19300402
(@@	O	-1	19300402
7-@@	O	-1	19300402
N@@	O	-1	19300402
I@@	O	-1	19300402
;	O	-1	19300402
0.@@	O	-1	19300402
1	O	-1	19300402
mg/kg	O	-1	19300402
ip@@	O	-1	19300402
),	O	-1	19300402
on	O	-1	19300402
anti@@	O	-1	19300402
hyperalge@@	O	-1	19300402
sic	O	-1	19300402
action	O	-1	19300402
of	O	-1	19300402
selective	O	-1	19300402
antagonist@@	O	-1	19300402
s	O	-1	19300402
of	O	-1	19300402
B@@	O	-1	19300402
2	O	-1	19300402
and	O	-1	19300402
B@@	O	-1	19300402
1	O	-1	19300402
receptor@@	O	-1	19300402
s:	O	-1	19300402
D-@@	O	-1	19300402
A@@	O	-1	19300402
r@@	O	-1	19300402
g@@	O	-1	19300402
-@@	O	-1	19300402
[@@	O	-1	19300402
H@@	O	-1	19300402
yp@@	O	-1	19300402
3@@	O	-1	19300402
,@@	O	-1	19300402
Th@@	O	-1	19300402
i@@	O	-1	19300402
5@@	O	-1	19300402
,@@	O	-1	19300402
D-@@	O	-1	19300402
T@@	O	-1	19300402
ic@@	O	-1	19300402
7@@	O	-1	19300402
,@@	O	-1	19300402
O@@	O	-1	19300402
ic@@	O	-1	19300402
8@@	O	-1	19300402
]	O	-1	19300402
brady@@	B-Chemical	D001920	19300402
kin@@	I-Chemical	-1	19300402
in	I-Chemical	-1	19300402
(	O	-1	19300402
HO@@	B-Chemical	C065679	19300402
E	I-Chemical	-1	19300402
1@@	I-Chemical	-1	19300402
40	I-Chemical	-1	19300402
;	O	-1	19300402
7@@	O	-1	19300402
0	O	-1	19300402
n@@	O	-1	19300402
mol@@	O	-1	19300402
/@@	O	-1	19300402
k@@	O	-1	19300402
g	O	-1	19300402
ip@@	O	-1	19300402
)	O	-1	19300402
or	O	-1	19300402
des	B-Chemical	C078665	19300402
A@@	I-Chemical	-1	19300402
r@@	I-Chemical	-1	19300402
g@@	I-Chemical	-1	19300402
10	I-Chemical	-1	19300402
HO@@	I-Chemical	-1	19300402
E	I-Chemical	-1	19300402
1@@	I-Chemical	-1	19300402
40	I-Chemical	-1	19300402
(@@	O	-1	19300402
7@@	O	-1	19300402
0	O	-1	19300402
n@@	O	-1	19300402
mol@@	O	-1	19300402
/@@	O	-1	19300402
k@@	O	-1	19300402
g	O	-1	19300402
ip@@	O	-1	19300402
)	O	-1	19300402
respectivel@@	O	-1	19300402
y,	O	-1	19300402
in	O	-1	19300402
model	O	-1	19300402
of	O	-1	19300402
dia@@	B-Disease	D003929	19300402
be@@	I-Disease	-1	19300402
tic	I-Disease	-1	19300402
(@@	I-Disease	-1	19300402
st@@	I-Disease	-1	19300402
re@@	I-Disease	-1	19300402
pto@@	I-Disease	-1	19300402
z@@	I-Disease	-1	19300402
ot@@	I-Disease	-1	19300402
oc@@	I-Disease	-1	19300402
in-@@	I-Disease	-1	19300402
induc@@	I-Disease	-1	19300402
ed@@	I-Disease	-1	19300402
)	I-Disease	-1	19300402
and	I-Disease	-1	19300402
toxic	I-Disease	-1	19300402
(@@	I-Disease	-1	19300402
v@@	I-Disease	-1	19300402
inc@@	I-Disease	-1	19300402
ri@@	I-Disease	-1	19300402
st@@	I-Disease	-1	19300402
ine-@@	I-Disease	-1	19300402
induc@@	I-Disease	-1	19300402
ed@@	I-Disease	-1	19300402
)	I-Disease	-1	19300402
neuropathy	I-Disease	-1	19300402
dia@@	B-Disease	D010523	19300402
be@@	I-Disease	-1	19300402
tic	I-Disease	-1	19300402
(@@	I-Disease	-1	19300402
st@@	I-Disease	-1	19300402
re@@	I-Disease	-1	19300402
pto@@	I-Disease	-1	19300402
z@@	I-Disease	-1	19300402
ot@@	I-Disease	-1	19300402
oc@@	I-Disease	-1	19300402
in-@@	I-Disease	-1	19300402
induc@@	I-Disease	-1	19300402
ed@@	I-Disease	-1	19300402
)	I-Disease	-1	19300402
and	I-Disease	-1	19300402
toxic	I-Disease	-1	19300402
(@@	I-Disease	-1	19300402
v@@	I-Disease	-1	19300402
inc@@	I-Disease	-1	19300402
ri@@	I-Disease	-1	19300402
st@@	I-Disease	-1	19300402
ine-@@	I-Disease	-1	19300402
induc@@	I-Disease	-1	19300402
ed@@	I-Disease	-1	19300402
)	I-Disease	-1	19300402
neuropathy	I-Disease	-1	19300402
was	O	-1	19300402
investig@@	O	-1	19300402
ated.	O	-1	19300402
METHODS:	O	-1	19300402
The	O	-1	19300402
changes	O	-1	19300402
in	O	-1	19300402
pain	B-Disease	D010146	19300402
th@@	O	-1	19300402
res@@	O	-1	19300402
h@@	O	-1	19300402
ol@@	O	-1	19300402
ds	O	-1	19300402
were	O	-1	19300402
determined	O	-1	19300402
using	O	-1	19300402
mechan@@	O	-1	19300402
ical	O	-1	19300402
stimul@@	O	-1	19300402
i@@	O	-1	19300402
-@@	O	-1	19300402
-@@	O	-1	19300402
the	O	-1	19300402
mo@@	O	-1	19300402
di@@	O	-1	19300402
fic@@	O	-1	19300402
ation	O	-1	19300402
of	O	-1	19300402
the	O	-1	19300402
cl@@	O	-1	19300402
as@@	O	-1	19300402
sic	O	-1	19300402
pa@@	O	-1	19300402
w	O	-1	19300402
withdrawal	O	-1	19300402
test	O	-1	19300402
descri@@	O	-1	19300402
bed	O	-1	19300402
by	O	-1	19300402
R@@	O	-1	19300402
and@@	O	-1	19300402
all@@	O	-1	19300402
-@@	O	-1	19300402
S@@	O	-1	19300402
el@@	O	-1	19300402
it@@	O	-1	19300402
to@@	O	-1	19300402
.	O	-1	19300402
RESULTS:	O	-1	19300402
The	O	-1	19300402
results	O	-1	19300402
of	O	-1	19300402
this	O	-1	19300402
pap@@	O	-1	19300402
er	O	-1	19300402
con@@	O	-1	19300402
fir@@	O	-1	19300402
m	O	-1	19300402
that	O	-1	19300402
inhibition	O	-1	19300402
of	O	-1	19300402
brady@@	B-Chemical	D001920	19300402
kin@@	I-Chemical	-1	19300402
in	I-Chemical	-1	19300402
receptors	O	-1	19300402
and	O	-1	19300402
induc@@	O	-1	19300402
i@@	O	-1	19300402
ble	O	-1	19300402
N@@	B-Chemical	D009569	19300402
O	I-Chemical	-1	19300402
syn@@	O	-1	19300402
th@@	O	-1	19300402
ase	O	-1	19300402
but	O	-1	19300402
not	O	-1	19300402
neuron@@	O	-1	19300402
al	O	-1	19300402
N@@	B-Chemical	D009569	19300402
O	I-Chemical	-1	19300402
syn@@	O	-1	19300402
th@@	O	-1	19300402
ase	O	-1	19300402
activity	O	-1	19300402
reduc@@	O	-1	19300402
es	O	-1	19300402
dia@@	B-Disease	D006930	19300402
be@@	I-Disease	-1	19300402
tic	I-Disease	-1	19300402
hyperalge@@	I-Disease	-1	19300402
sia	I-Disease	-1	19300402
.	O	-1	19300402
Pre@@	O	-1	19300402
treatment	O	-1	19300402
with	O	-1	19300402
L-@@	O	-1	19300402
NO@@	O	-1	19300402
A@@	O	-1	19300402
r@@	O	-1	19300402
g	O	-1	19300402
and	O	-1	19300402
L-@@	O	-1	19300402
N@@	O	-1	19300402
I@@	O	-1	19300402
L	O	-1	19300402
but	O	-1	19300402
not	O	-1	19300402
7-@@	O	-1	19300402
N@@	O	-1	19300402
I@@	O	-1	19300402
,	O	-1	19300402
significantly	O	-1	19300402
increases	O	-1	19300402
anti@@	O	-1	19300402
hyperalge@@	O	-1	19300402
sic	O	-1	19300402
activity	O	-1	19300402
both	O	-1	19300402
HO@@	B-Chemical	C065679	19300402
E	I-Chemical	-1	19300402
1@@	I-Chemical	-1	19300402
40	I-Chemical	-1	19300402
and	O	-1	19300402
des	B-Chemical	C078665	19300402
A@@	I-Chemical	-1	19300402
r@@	I-Chemical	-1	19300402
g@@	I-Chemical	-1	19300402
10	I-Chemical	-1	19300402
HO@@	I-Chemical	-1	19300402
E	I-Chemical	-1	19300402
1@@	I-Chemical	-1	19300402
40	I-Chemical	-1	19300402
.	O	-1	19300402
It	O	-1	19300402
was	O	-1	19300402
also	O	-1	19300402
shown	O	-1	19300402
that	O	-1	19300402
both	O	-1	19300402
produc@@	O	-1	19300402
ts	O	-1	19300402
of	O	-1	19300402
induc@@	O	-1	19300402
i@@	O	-1	19300402
ble	O	-1	19300402
N@@	B-Chemical	D009569	19300402
O	I-Chemical	-1	19300402
syn@@	O	-1	19300402
th@@	O	-1	19300402
ase	O	-1	19300402
and	O	-1	19300402
neuron@@	O	-1	19300402
al	O	-1	19300402
N@@	B-Chemical	D009569	19300402
O	I-Chemical	-1	19300402
syn@@	O	-1	19300402
th@@	O	-1	19300402
ase	O	-1	19300402
activation	O	-1	19300402
as	O	-1	19300402
well	O	-1	19300402
as	O	-1	19300402
brady@@	B-Chemical	D001920	19300402
kin@@	I-Chemical	-1	19300402
in	I-Chemical	-1	19300402
are	O	-1	19300402
involved	O	-1	19300402
in	O	-1	19300402
hyperalge@@	B-Disease	D006930	19300402
sia	I-Disease	-1	19300402
produced	O	-1	19300402
by	O	-1	19300402
v@@	B-Chemical	D014750	19300402
inc@@	I-Chemical	-1	19300402
ri@@	I-Chemical	-1	19300402
st@@	I-Chemical	-1	19300402
ine	I-Chemical	-1	19300402
.	O	-1	19300402
M@@	O	-1	19300402
ore@@	O	-1	19300402
o@@	O	-1	19300402
ver,	O	-1	19300402
L-@@	O	-1	19300402
NO@@	O	-1	19300402
A@@	O	-1	19300402
r@@	O	-1	19300402
g	O	-1	19300402
and	O	-1	19300402
7-@@	O	-1	19300402
N@@	O	-1	19300402
I	O	-1	19300402
but	O	-1	19300402
not	O	-1	19300402
L-@@	O	-1	19300402
N@@	O	-1	19300402
I@@	O	-1	19300402
L	O	-1	19300402
int@@	O	-1	19300402
en@@	O	-1	19300402
si@@	O	-1	19300402
f@@	O	-1	19300402
y	O	-1	19300402
anti@@	O	-1	19300402
hyperalge@@	O	-1	19300402
sic	O	-1	19300402
activity	O	-1	19300402
of	O	-1	19300402
HO@@	B-Chemical	C065679	19300402
E	I-Chemical	-1	19300402
1@@	I-Chemical	-1	19300402
40	I-Chemical	-1	19300402
or	O	-1	19300402
des@@	B-Chemical	C078665	19300402
-@@	I-Chemical	-1	19300402
A@@	I-Chemical	-1	19300402
r@@	I-Chemical	-1	19300402
g@@	I-Chemical	-1	19300402
10@@	I-Chemical	-1	19300402
HO@@	I-Chemical	-1	19300402
E	I-Chemical	-1	19300402
1@@	I-Chemical	-1	19300402
40	I-Chemical	-1	19300402
in	O	-1	19300402
toxic	B-Disease	D010523	19300402
neuropathy	I-Disease	-1	19300402
.	O	-1	19300402
CONCLUSIONS:	O	-1	19300402
R@@	O	-1	19300402
es@@	O	-1	19300402
ult@@	O	-1	19300402
s	O	-1	19300402
of	O	-1	19300402
these	O	-1	19300402
studies	O	-1	19300402
suggest	O	-1	19300402
that	O	-1	19300402
B@@	O	-1	19300402
1	O	-1	19300402
and	O	-1	19300402
B@@	O	-1	19300402
2	O	-1	19300402
receptors	O	-1	19300402
are	O	-1	19300402
en@@	O	-1	19300402
g@@	O	-1	19300402
aged	O	-1	19300402
in	O	-1	19300402
trans@@	O	-1	19300402
mission	O	-1	19300402
of	O	-1	19300402
n@@	O	-1	19300402
ocicep@@	O	-1	19300402
tive	O	-1	19300402
stimul@@	O	-1	19300402
i	O	-1	19300402
in	O	-1	19300402
both	O	-1	19300402
dia@@	B-Disease	D003929	19300402
be@@	I-Disease	-1	19300402
tic	I-Disease	-1	19300402
and	I-Disease	-1	19300402
toxic	I-Disease	-1	19300402
neuropathy	I-Disease	-1	19300402
dia@@	B-Disease	D010523	19300402
be@@	I-Disease	-1	19300402
tic	I-Disease	-1	19300402
and	I-Disease	-1	19300402
toxic	I-Disease	-1	19300402
neuropathy	I-Disease	-1	19300402
.	O	-1	19300402
In	O	-1	19300402
st@@	B-Chemical	D013311	19300402
re@@	I-Chemical	-1	19300402
pto@@	I-Chemical	-1	19300402
z@@	I-Chemical	-1	19300402
ot@@	I-Chemical	-1	19300402
oc@@	I-Chemical	-1	19300402
in	I-Chemical	-1	19300402
-induced	O	-1	19300402
hyperalge@@	B-Disease	D006930	19300402
sia	I-Disease	-1	19300402
,	O	-1	19300402
induc@@	O	-1	19300402
i@@	O	-1	19300402
ble	O	-1	19300402
N@@	B-Chemical	D009569	19300402
O	I-Chemical	-1	19300402
syn@@	O	-1	19300402
th@@	O	-1	19300402
ase	O	-1	19300402
partic@@	O	-1	19300402
i@@	O	-1	19300402
pat@@	O	-1	19300402
es	O	-1	19300402
in	O	-1	19300402
p@@	O	-1	19300402
ron@@	O	-1	19300402
ocicep@@	O	-1	19300402
tive	O	-1	19300402
activity	O	-1	19300402
of	O	-1	19300402
brady@@	B-Chemical	D001920	19300402
kin@@	I-Chemical	-1	19300402
in	I-Chemical	-1	19300402
,	O	-1	19300402
whereas	O	-1	19300402
in	O	-1	19300402
v@@	B-Chemical	D014750	19300402
inc@@	I-Chemical	-1	19300402
ri@@	I-Chemical	-1	19300402
st@@	I-Chemical	-1	19300402
ine	I-Chemical	-1	19300402
-induced	O	-1	19300402
hyperalge@@	B-Disease	D006930	19300402
sia	I-Disease	-1	19300402
brady@@	B-Chemical	D001920	19300402
kin@@	I-Chemical	-1	19300402
in	I-Chemical	-1	19300402
se@@	O	-1	19300402
em@@	O	-1	19300402
ed	O	-1	19300402
to	O	-1	19300402
activ@@	O	-1	19300402
ate	O	-1	19300402
neuron@@	O	-1	19300402
al	O	-1	19300402
N@@	B-Chemical	D009569	19300402
O	I-Chemical	-1	19300402
syn@@	O	-1	19300402
th@@	O	-1	19300402
ase	O	-1	19300402
path@@	O	-1	19300402
w@@	O	-1	19300402
a@@	O	-1	19300402
y.	O	-1	19300402
The@@	O	-1	19300402
refore,	O	-1	19300402
concomit@@	O	-1	19300402
ant	O	-1	19300402
administration	O	-1	19300402
of	O	-1	19300402
sm@@	O	-1	19300402
all	O	-1	19300402
doses	O	-1	19300402
of	O	-1	19300402
brady@@	B-Chemical	D001920	19300402
kin@@	I-Chemical	-1	19300402
in	I-Chemical	-1	19300402
receptor	O	-1	19300402
antagonist@@	O	-1	19300402
s	O	-1	19300402
and	O	-1	19300402
N@@	B-Chemical	D009569	19300402
O	I-Chemical	-1	19300402
syn@@	O	-1	19300402
th@@	O	-1	19300402
ase	O	-1	19300402
inhibitors	O	-1	19300402
can	O	-1	19300402
be	O	-1	19300402
effective	O	-1	19300402
in	O	-1	19300402
al@@	O	-1	19300402
le@@	O	-1	19300402
vi@@	O	-1	19300402
ation	O	-1	19300402
of	O	-1	19300402
neuro@@	B-Disease	D009437	19300402
path@@	I-Disease	-1	19300402
ic	I-Disease	-1	19300402
pain	I-Disease	-1	19300402
,	O	-1	19300402
even	O	-1	19300402
in	O	-1	19300402
hospit@@	O	-1	19300402
al	O	-1	19300402
ca@@	O	-1	19300402
re.	O	-1	19300402

C@@	B-Disease	D066126	15325671
ardi@@	I-Disease	-1	15325671
a@@	I-Disease	-1	15325671
c	I-Disease	-1	15325671
toxicity	I-Disease	-1	15325671
observed	O	-1	15325671
in	O	-1	15325671
association	O	-1	15325671
with	O	-1	15325671
high-dose	O	-1	15325671
cyclophosph@@	B-Chemical	D003520	15325671
amide	I-Chemical	-1	15325671
-@@	O	-1	15325671
bas@@	O	-1	15325671
ed	O	-1	15325671
chemotherapy	O	-1	15325671
for	O	-1	15325671
met@@	O	-1	15325671
ast@@	O	-1	15325671
atic	O	-1	15325671
b@@	B-Disease	D001943	15325671
reas@@	I-Disease	-1	15325671
t	I-Disease	-1	15325671
cancer	I-Disease	-1	15325671
.	O	-1	15325671
IN@@	O	-1	15325671
T@@	O	-1	15325671
RO@@	O	-1	15325671
D@@	O	-1	15325671
U@@	O	-1	15325671
C@@	O	-1	15325671
T@@	O	-1	15325671
ION@@	O	-1	15325671
:	O	-1	15325671
C@@	B-Chemical	D003520	15325671
yc@@	I-Chemical	-1	15325671
lo@@	I-Chemical	-1	15325671
phosph@@	I-Chemical	-1	15325671
amide	I-Chemical	-1	15325671
is	O	-1	15325671
an	O	-1	15325671
al@@	O	-1	15325671
k@@	O	-1	15325671
yl@@	O	-1	15325671
ating	O	-1	15325671
agent	O	-1	15325671
given	O	-1	15325671
frequ@@	O	-1	15325671
ently	O	-1	15325671
as	O	-1	15325671
a	O	-1	15325671
comp@@	O	-1	15325671
on@@	O	-1	15325671
ent	O	-1	15325671
of	O	-1	15325671
man@@	O	-1	15325671
y	O	-1	15325671
condi@@	O	-1	15325671
tion@@	O	-1	15325671
ing	O	-1	15325671
regimen@@	O	-1	15325671
s.	O	-1	15325671
In	O	-1	15325671
high	O	-1	15325671
dos@@	O	-1	15325671
es,	O	-1	15325671
its	O	-1	15325671
non@@	O	-1	15325671
hemat@@	O	-1	15325671
ological	O	-1	15325671
dose-@@	O	-1	15325671
lim@@	O	-1	15325671
it@@	O	-1	15325671
ing	O	-1	15325671
toxicity	B-Disease	D064420	15325671
is	O	-1	15325671
cardi@@	B-Disease	D009202	15325671
om@@	I-Disease	-1	15325671
yo@@	I-Disease	-1	15325671
pathy	I-Disease	-1	15325671
.	O	-1	15325671
S@@	O	-1	15325671
T@@	O	-1	15325671
U@@	O	-1	15325671
D@@	O	-1	15325671
Y	O	-1	15325671
D@@	O	-1	15325671
ES@@	O	-1	15325671
I@@	O	-1	15325671
G@@	O	-1	15325671
N@@	O	-1	15325671
:	O	-1	15325671
We	O	-1	15325671
combined	O	-1	15325671
paclitax@@	B-Chemical	D017239	15325671
el	I-Chemical	-1	15325671
,	O	-1	15325671
me@@	B-Chemical	D008558	15325671
l@@	I-Chemical	-1	15325671
ph@@	I-Chemical	-1	15325671
al@@	I-Chemical	-1	15325671
an	I-Chemical	-1	15325671
and	O	-1	15325671
high-dose	O	-1	15325671
cyclophosph@@	B-Chemical	D003520	15325671
amide	I-Chemical	-1	15325671
,	O	-1	15325671
thi@@	B-Chemical	D013852	15325671
ot@@	I-Chemical	-1	15325671
ep@@	I-Chemical	-1	15325671
a	I-Chemical	-1	15325671
,	O	-1	15325671
and	O	-1	15325671
car@@	B-Chemical	D016190	15325671
bo@@	I-Chemical	-1	15325671
pl@@	I-Chemical	-1	15325671
atin	I-Chemical	-1	15325671
in	O	-1	15325671
a	O	-1	15325671
tri@@	O	-1	15325671
ple	O	-1	15325671
sequ@@	O	-1	15325671
en@@	O	-1	15325671
tial	O	-1	15325671
high-dose	O	-1	15325671
regi@@	O	-1	15325671
men	O	-1	15325671
for	O	-1	15325671
patients	O	-1	15325671
with	O	-1	15325671
met@@	O	-1	15325671
ast@@	O	-1	15325671
atic	O	-1	15325671
b@@	B-Disease	D001943	15325671
reas@@	I-Disease	-1	15325671
t	I-Disease	-1	15325671
cancer	I-Disease	-1	15325671
.	O	-1	15325671
An@@	O	-1	15325671
aly@@	O	-1	15325671
sis	O	-1	15325671
was	O	-1	15325671
performed	O	-1	15325671
on	O	-1	15325671
6@@	O	-1	15325671
1	O	-1	15325671
women	O	-1	15325671
with	O	-1	15325671
chemo@@	O	-1	15325671
therap@@	O	-1	15325671
y-@@	O	-1	15325671
respon@@	O	-1	15325671
sive	O	-1	15325671
met@@	O	-1	15325671
ast@@	O	-1	15325671
atic	O	-1	15325671
b@@	B-Disease	D001943	15325671
reas@@	I-Disease	-1	15325671
t	I-Disease	-1	15325671
cancer	I-Disease	-1	15325671
receiving	O	-1	15325671
9@@	O	-1	15325671
6-@@	O	-1	15325671
h	O	-1	15325671
infu@@	O	-1	15325671
sion@@	O	-1	15325671
al	O	-1	15325671
cyclophosph@@	B-Chemical	D003520	15325671
amide	I-Chemical	-1	15325671
as	O	-1	15325671
par@@	O	-1	15325671
t	O	-1	15325671
of	O	-1	15325671
a	O	-1	15325671
tri@@	O	-1	15325671
ple	O	-1	15325671
sequ@@	O	-1	15325671
en@@	O	-1	15325671
tial	O	-1	15325671
high-dose	O	-1	15325671
regi@@	O	-1	15325671
men	O	-1	15325671
to	O	-1	15325671
ass@@	O	-1	15325671
ess	O	-1	15325671
association	O	-1	15325671
between	O	-1	15325671
presence	O	-1	15325671
of	O	-1	15325671
per@@	O	-1	15325671
it@@	O	-1	15325671
ran@@	O	-1	15325671
s@@	O	-1	15325671
pl@@	O	-1	15325671
ant	O	-1	15325671
con@@	B-Disease	D006333	15325671
g@@	I-Disease	-1	15325671
es@@	I-Disease	-1	15325671
tive	I-Disease	-1	15325671
heart	I-Disease	-1	15325671
failure	I-Disease	-1	15325671
(	O	-1	15325671
C@@	B-Disease	D006333	15325671
H@@	I-Disease	-1	15325671
F	I-Disease	-1	15325671
)	O	-1	15325671
and	O	-1	15325671
the	O	-1	15325671
following	O	-1	15325671
pretreatment	O	-1	15325671
character@@	O	-1	15325671
is@@	O	-1	15325671
tic@@	O	-1	15325671
s:	O	-1	15325671
presence	O	-1	15325671
of	O	-1	15325671
electro@@	O	-1	15325671
cardio@@	O	-1	15325671
gra@@	O	-1	15325671
m	O	-1	15325671
(@@	O	-1	15325671
E@@	O	-1	15325671
KG@@	O	-1	15325671
)	O	-1	15325671
abnormal@@	O	-1	15325671
iti@@	O	-1	15325671
es,	O	-1	15325671
age,	O	-1	15325671
hypertension	B-Disease	D006973	15325671
,	O	-1	15325671
prior	O	-1	15325671
cardiac	O	-1	15325671
hist@@	O	-1	15325671
or@@	O	-1	15325671
y,	O	-1	15325671
smo@@	O	-1	15325671
k@@	O	-1	15325671
ing,	O	-1	15325671
dia@@	B-Disease	D003920	15325671
bet@@	I-Disease	-1	15325671
es	I-Disease	-1	15325671
me@@	I-Disease	-1	15325671
ll@@	I-Disease	-1	15325671
it@@	I-Disease	-1	15325671
us	I-Disease	-1	15325671
,	O	-1	15325671
prior	O	-1	15325671
use	O	-1	15325671
of	O	-1	15325671
an@@	B-Chemical	D018943	15325671
th@@	I-Chemical	-1	15325671
rac@@	I-Chemical	-1	15325671
y@@	I-Chemical	-1	15325671
clin@@	I-Chemical	-1	15325671
es	I-Chemical	-1	15325671
,	O	-1	15325671
and	O	-1	15325671
le@@	O	-1	15325671
f@@	O	-1	15325671
t-@@	O	-1	15325671
si@@	O	-1	15325671
ded	O	-1	15325671
ch@@	O	-1	15325671
est	O	-1	15325671
ir@@	O	-1	15325671
radi@@	O	-1	15325671
ation.	O	-1	15325671
RESULTS:	O	-1	15325671
Si@@	O	-1	15325671
x	O	-1	15325671
of	O	-1	15325671
6@@	O	-1	15325671
1	O	-1	15325671
women	O	-1	15325671
(@@	O	-1	15325671
10@@	O	-1	15325671
%)	O	-1	15325671
developed	O	-1	15325671
clin@@	O	-1	15325671
ically	O	-1	15325671
reversible	O	-1	15325671
gra@@	O	-1	15325671
de	O	-1	15325671
3	O	-1	15325671
C@@	B-Disease	D006333	15325671
H@@	I-Disease	-1	15325671
F	I-Disease	-1	15325671
following	O	-1	15325671
infu@@	O	-1	15325671
sion@@	O	-1	15325671
al	O	-1	15325671
cyclophosph@@	B-Chemical	D003520	15325671
amide	I-Chemical	-1	15325671
with	O	-1	15325671
a	O	-1	15325671
median	O	-1	15325671
perc@@	O	-1	15325671
ent	O	-1	15325671
dec@@	O	-1	15325671
line	O	-1	15325671
in	O	-1	15325671
e@@	O	-1	15325671
j@@	O	-1	15325671
ection	O	-1	15325671
frac@@	O	-1	15325671
tion	O	-1	15325671
of	O	-1	15325671
3@@	O	-1	15325671
1@@	O	-1	15325671
%.	O	-1	15325671
In@@	O	-1	15325671
c@@	O	-1	15325671
idence	O	-1	15325671
of	O	-1	15325671
transi@@	O	-1	15325671
ent	O	-1	15325671
cyclophosph@@	B-Chemical	D003520	15325671
amide	I-Chemical	-1	15325671
-@@	O	-1	15325671
related	O	-1	15325671
cardiac	B-Disease	D066126	15325671
toxicity	I-Disease	-1	15325671
(@@	O	-1	15325671
10@@	O	-1	15325671
%)	O	-1	15325671
is	O	-1	15325671
compar@@	O	-1	15325671
able	O	-1	15325671
to	O	-1	15325671
previ@@	O	-1	15325671
ous	O	-1	15325671
recor@@	O	-1	15325671
ded	O	-1	15325671
literat@@	O	-1	15325671
ure.	O	-1	15325671
O@@	O	-1	15325671
l@@	O	-1	15325671
der	O	-1	15325671
age	O	-1	15325671
was	O	-1	15325671
significantly	O	-1	15325671
cor@@	O	-1	15325671
related	O	-1	15325671
with	O	-1	15325671
the	O	-1	15325671
C@@	B-Disease	D006333	15325671
H@@	I-Disease	-1	15325671
F	I-Disease	-1	15325671
develop@@	O	-1	15325671
ment@@	O	-1	15325671
;	O	-1	15325671
with	O	-1	15325671
median	O	-1	15325671
ages	O	-1	15325671
for	O	-1	15325671
the	O	-1	15325671
enti@@	O	-1	15325671
r@@	O	-1	15325671
e	O	-1	15325671
group	O	-1	15325671
and	O	-1	15325671
for	O	-1	15325671
patients	O	-1	15325671
develop@@	O	-1	15325671
ing	O	-1	15325671
C@@	B-Disease	D006333	15325671
H@@	I-Disease	-1	15325671
F	I-Disease	-1	15325671
of	O	-1	15325671
4@@	O	-1	15325671
5	O	-1	15325671
and	O	-1	15325671
5@@	O	-1	15325671
9@@	O	-1	15325671
,	O	-1	15325671
respectively.	O	-1	15325671
No	O	-1	15325671
association	O	-1	15325671
was	O	-1	15325671
found	O	-1	15325671
with	O	-1	15325671
other	O	-1	15325671
pretreatment	O	-1	15325671
character@@	O	-1	15325671
is@@	O	-1	15325671
tic@@	O	-1	15325671
s.	O	-1	15325671
CONCLUSIONS:	O	-1	15325671
A@@	O	-1	15325671
s	O	-1	15325671
a	O	-1	15325671
result	O	-1	15325671
of	O	-1	15325671
these	O	-1	15325671
find@@	O	-1	15325671
ing@@	O	-1	15325671
s,	O	-1	15325671
on@@	O	-1	15325671
co@@	O	-1	15325671
log@@	O	-1	15325671
ist@@	O	-1	15325671
s	O	-1	15325671
should	O	-1	15325671
ca@@	O	-1	15325671
ref@@	O	-1	15325671
ul@@	O	-1	15325671
ly	O	-1	15325671
monit@@	O	-1	15325671
or	O	-1	15325671
flu@@	O	-1	15325671
id	O	-1	15325671
b@@	O	-1	15325671
al@@	O	-1	15325671
ance	O	-1	15325671
in	O	-1	15325671
ol@@	O	-1	15325671
der	O	-1	15325671
patients.	O	-1	15325671
R@@	O	-1	15325671
out@@	O	-1	15325671
ine	O	-1	15325671
E@@	O	-1	15325671
K@@	O	-1	15325671
G	O	-1	15325671
monit@@	O	-1	15325671
or@@	O	-1	15325671
ing	O	-1	15325671
during	O	-1	15325671
infu@@	O	-1	15325671
sion@@	O	-1	15325671
al	O	-1	15325671
cyclophosph@@	B-Chemical	D003520	15325671
amide	I-Chemical	-1	15325671
did	O	-1	15325671
not	O	-1	15325671
predic@@	O	-1	15325671
t	O	-1	15325671
C@@	B-Disease	D006333	15325671
H@@	I-Disease	-1	15325671
F	I-Disease	-1	15325671
develop@@	O	-1	15325671
ment.	O	-1	15325671

In@@	O	-1	9746003
appro@@	O	-1	9746003
pri@@	O	-1	9746003
ate	O	-1	9746003
use	O	-1	9746003
of	O	-1	9746003
carbamazepine	B-Chemical	D002220	9746003
and	O	-1	9746003
vi@@	B-Chemical	D020888	9746003
g@@	I-Chemical	-1	9746003
ab@@	I-Chemical	-1	9746003
at@@	I-Chemical	-1	9746003
rin	I-Chemical	-1	9746003
in	O	-1	9746003
typ@@	O	-1	9746003
ical	O	-1	9746003
absence	B-Disease	D004832	9746003
seizures	I-Disease	-1	9746003
.	O	-1	9746003
C@@	B-Chemical	D002220	9746003
arb@@	I-Chemical	-1	9746003
am@@	I-Chemical	-1	9746003
azepine	I-Chemical	-1	9746003
and	O	-1	9746003
vi@@	B-Chemical	D020888	9746003
g@@	I-Chemical	-1	9746003
ab@@	I-Chemical	-1	9746003
at@@	I-Chemical	-1	9746003
rin	I-Chemical	-1	9746003
are	O	-1	9746003
contra@@	O	-1	9746003
indic@@	O	-1	9746003
ated	O	-1	9746003
in	O	-1	9746003
typ@@	O	-1	9746003
ical	O	-1	9746003
absence	B-Disease	D004832	9746003
seizures	I-Disease	-1	9746003
.	O	-1	9746003
Of	O	-1	9746003
1@@	O	-1	9746003
8	O	-1	9746003
con@@	O	-1	9746003
sec@@	O	-1	9746003
utive	O	-1	9746003
ref@@	O	-1	9746003
er@@	O	-1	9746003
r@@	O	-1	9746003
als	O	-1	9746003
of	O	-1	9746003
children	O	-1	9746003
with	O	-1	9746003
resist@@	O	-1	9746003
ant	O	-1	9746003
typ@@	O	-1	9746003
ical	O	-1	9746003
abs@@	O	-1	9746003
enc@@	O	-1	9746003
es	O	-1	9746003
on@@	O	-1	9746003
ly,	O	-1	9746003
e@@	O	-1	9746003
ight	O	-1	9746003
were	O	-1	9746003
er@@	O	-1	9746003
ron@@	O	-1	9746003
e@@	O	-1	9746003
ously	O	-1	9746003
treated	O	-1	9746003
with	O	-1	9746003
carbamazepine	B-Chemical	D002220	9746003
either	O	-1	9746003
as	O	-1	9746003
mon@@	O	-1	9746003
o@@	O	-1	9746003
therapy	O	-1	9746003
or	O	-1	9746003
as	O	-1	9746003
an	O	-1	9746003
ad@@	O	-1	9746003
d-@@	O	-1	9746003
on@@	O	-1	9746003
.	O	-1	9746003
V@@	B-Chemical	D020888	9746003
ig@@	I-Chemical	-1	9746003
ab@@	I-Chemical	-1	9746003
at@@	I-Chemical	-1	9746003
rin	I-Chemical	-1	9746003
was	O	-1	9746003
also	O	-1	9746003
used	O	-1	9746003
in	O	-1	9746003
the	O	-1	9746003
treatment	O	-1	9746003
of	O	-1	9746003
two	O	-1	9746003
child@@	O	-1	9746003
ren@@	O	-1	9746003
.	O	-1	9746003
F@@	O	-1	9746003
requ@@	O	-1	9746003
ency	O	-1	9746003
of	O	-1	9746003
abs@@	O	-1	9746003
enc@@	O	-1	9746003
es	O	-1	9746003
increased	O	-1	9746003
in	O	-1	9746003
four	O	-1	9746003
children	O	-1	9746003
treated	O	-1	9746003
with	O	-1	9746003
carbamazepine	B-Chemical	D002220	9746003
and	O	-1	9746003
two	O	-1	9746003
of	O	-1	9746003
these	O	-1	9746003
developed	O	-1	9746003
my@@	B-Disease	D009207	9746003
oc@@	I-Disease	-1	9746003
lon@@	I-Disease	-1	9746003
ic	I-Disease	-1	9746003
j@@	I-Disease	-1	9746003
er@@	I-Disease	-1	9746003
k@@	I-Disease	-1	9746003
s	I-Disease	-1	9746003
,	O	-1	9746003
which	O	-1	9746003
resol@@	O	-1	9746003
ved	O	-1	9746003
on	O	-1	9746003
withdrawal	O	-1	9746003
of	O	-1	9746003
carbamazepine	B-Chemical	D002220	9746003
.	O	-1	9746003
A@@	O	-1	9746003
b@@	O	-1	9746003
s@@	O	-1	9746003
enc@@	O	-1	9746003
es	O	-1	9746003
were	O	-1	9746003
ag@@	O	-1	9746003
gra@@	O	-1	9746003
v@@	O	-1	9746003
ated	O	-1	9746003
in	O	-1	9746003
both	O	-1	9746003
cases	O	-1	9746003
wh@@	O	-1	9746003
ere	O	-1	9746003
vi@@	B-Chemical	D020888	9746003
g@@	I-Chemical	-1	9746003
ab@@	I-Chemical	-1	9746003
at@@	I-Chemical	-1	9746003
rin	I-Chemical	-1	9746003
was	O	-1	9746003
ad@@	O	-1	9746003
ded	O	-1	9746003
on	O	-1	9746003
to	O	-1	9746003
con@@	O	-1	9746003
current	O	-1	9746003
treatment.	O	-1	9746003
O@@	O	-1	9746003
p@@	O	-1	9746003
tim@@	O	-1	9746003
al	O	-1	9746003
control	O	-1	9746003
of	O	-1	9746003
the	O	-1	9746003
abs@@	O	-1	9746003
enc@@	O	-1	9746003
es	O	-1	9746003
was	O	-1	9746003
achi@@	O	-1	9746003
ev@@	O	-1	9746003
ed	O	-1	9746003
with	O	-1	9746003
sodium	B-Chemical	D014635	9746003
valpro@@	I-Chemical	-1	9746003
ate	I-Chemical	-1	9746003
,	O	-1	9746003
lam@@	B-Chemical	C047781	9746003
ot@@	I-Chemical	-1	9746003
rig@@	I-Chemical	-1	9746003
ine	I-Chemical	-1	9746003
,	O	-1	9746003
or	O	-1	9746003
eth@@	B-Chemical	D005013	9746003
os@@	I-Chemical	-1	9746003
u@@	I-Chemical	-1	9746003
xim@@	I-Chemical	-1	9746003
ide	I-Chemical	-1	9746003
alone	O	-1	9746003
or	O	-1	9746003
in	O	-1	9746003
combin@@	O	-1	9746003
ation.	O	-1	9746003

H@@	B-Disease	D000743	1992636
em@@	I-Disease	-1	1992636
oly@@	I-Disease	-1	1992636
tic	I-Disease	-1	1992636
anemia	I-Disease	-1	1992636
associated	O	-1	1992636
with	O	-1	1992636
the	O	-1	1992636
use	O	-1	1992636
of	O	-1	1992636
o@@	B-Chemical	D009853	1992636
me@@	I-Chemical	-1	1992636
praz@@	I-Chemical	-1	1992636
ole	I-Chemical	-1	1992636
.	O	-1	1992636
O@@	B-Chemical	D009853	1992636
me@@	I-Chemical	-1	1992636
praz@@	I-Chemical	-1	1992636
ole	I-Chemical	-1	1992636
is	O	-1	1992636
the	O	-1	1992636
first	O	-1	1992636
drug	O	-1	1992636
de@@	O	-1	1992636
signed	O	-1	1992636
to	O	-1	1992636
bloc@@	O	-1	1992636
k	O	-1	1992636
the	O	-1	1992636
f@@	O	-1	1992636
inal	O	-1	1992636
st@@	O	-1	1992636
ep	O	-1	1992636
in	O	-1	1992636
the	O	-1	1992636
acid	O	-1	1992636
sec@@	O	-1	1992636
ret@@	O	-1	1992636
ory	O	-1	1992636
pro@@	O	-1	1992636
cess	O	-1	1992636
within	O	-1	1992636
the	O	-1	1992636
par@@	O	-1	1992636
i@@	O	-1	1992636
et@@	O	-1	1992636
al	O	-1	1992636
cell@@	O	-1	1992636
.	O	-1	1992636
It	O	-1	1992636
has	O	-1	1992636
been	O	-1	1992636
shown	O	-1	1992636
to	O	-1	1992636
be	O	-1	1992636
ex@@	O	-1	1992636
tre@@	O	-1	1992636
me@@	O	-1	1992636
ly	O	-1	1992636
effective	O	-1	1992636
in	O	-1	1992636
the	O	-1	1992636
treatment	O	-1	1992636
of	O	-1	1992636
p@@	B-Disease	D010437	1992636
ep@@	I-Disease	-1	1992636
tic	I-Disease	-1	1992636
ul@@	I-Disease	-1	1992636
c@@	I-Disease	-1	1992636
er	I-Disease	-1	1992636
disease	I-Disease	-1	1992636
,	O	-1	1992636
ref@@	B-Disease	D005764	1992636
lu@@	I-Disease	-1	1992636
x	I-Disease	-1	1992636
es@@	I-Disease	-1	1992636
oph@@	I-Disease	-1	1992636
ag@@	I-Disease	-1	1992636
iti@@	I-Disease	-1	1992636
s	I-Disease	-1	1992636
,	O	-1	1992636
and	O	-1	1992636
the	O	-1	1992636
Z@@	B-Disease	D015043	1992636
ol@@	I-Disease	-1	1992636
l@@	I-Disease	-1	1992636
ing@@	I-Disease	-1	1992636
er@@	I-Disease	-1	1992636
-@@	I-Disease	-1	1992636
E@@	I-Disease	-1	1992636
ll@@	I-Disease	-1	1992636
ison	I-Disease	-1	1992636
syndrome	I-Disease	-1	1992636
.	O	-1	1992636
Although	O	-1	1992636
clinical	O	-1	1992636
experi@@	O	-1	1992636
ence	O	-1	1992636
with	O	-1	1992636
o@@	B-Chemical	D009853	1992636
me@@	I-Chemical	-1	1992636
praz@@	I-Chemical	-1	1992636
ole	I-Chemical	-1	1992636
is	O	-1	1992636
sti@@	O	-1	1992636
ll	O	-1	1992636
lim@@	O	-1	1992636
it@@	O	-1	1992636
ed,	O	-1	1992636
man@@	O	-1	1992636
y	O	-1	1992636
controlled	O	-1	1992636
studies	O	-1	1992636
have	O	-1	1992636
est@@	O	-1	1992636
abl@@	O	-1	1992636
ished	O	-1	1992636
the	O	-1	1992636
sh@@	O	-1	1992636
ort@@	O	-1	1992636
-term	O	-1	1992636
safety	O	-1	1992636
of	O	-1	1992636
this	O	-1	1992636
drug.	O	-1	1992636
We	O	-1	1992636
report	O	-1	1992636
the	O	-1	1992636
first	O	-1	1992636
case	O	-1	1992636
of	O	-1	1992636
a	O	-1	1992636
seri@@	O	-1	1992636
ous	O	-1	1992636
sh@@	O	-1	1992636
ort@@	O	-1	1992636
-term	O	-1	1992636
adverse	O	-1	1992636
reaction	O	-1	1992636
with	O	-1	1992636
the	O	-1	1992636
use	O	-1	1992636
of	O	-1	1992636
o@@	B-Chemical	D009853	1992636
me@@	I-Chemical	-1	1992636
praz@@	I-Chemical	-1	1992636
ole	I-Chemical	-1	1992636
:	O	-1	1992636
hemolytic	B-Disease	D000743	1992636
anemia	I-Disease	-1	1992636
.	O	-1	1992636
The	O	-1	1992636
patient	O	-1	1992636
developed	O	-1	1992636
we@@	O	-1	1992636
ak@@	O	-1	1992636
n@@	O	-1	1992636
es@@	O	-1	1992636
s,	O	-1	1992636
le@@	B-Disease	D053609	1992636
th@@	I-Disease	-1	1992636
arg@@	I-Disease	-1	1992636
y	I-Disease	-1	1992636
,	O	-1	1992636
and	O	-1	1992636
sh@@	B-Disease	D004417	1992636
ort@@	I-Disease	-1	1992636
ness	I-Disease	-1	1992636
of	I-Disease	-1	1992636
b@@	I-Disease	-1	1992636
reat@@	I-Disease	-1	1992636
h	I-Disease	-1	1992636
2	O	-1	1992636
days	O	-1	1992636
after	O	-1	1992636
star@@	O	-1	1992636
ting	O	-1	1992636
therapy	O	-1	1992636
with	O	-1	1992636
o@@	B-Chemical	D009853	1992636
me@@	I-Chemical	-1	1992636
praz@@	I-Chemical	-1	1992636
ole	I-Chemical	-1	1992636
.	O	-1	1992636
Two	O	-1	1992636
weeks	O	-1	1992636
after	O	-1	1992636
the	O	-1	1992636
initi@@	O	-1	1992636
ation	O	-1	1992636
of	O	-1	1992636
therapy,	O	-1	1992636
h@@	O	-1	1992636
er	O	-1	1992636
hemat@@	O	-1	1992636
oc@@	O	-1	1992636
ri@@	O	-1	1992636
t	O	-1	1992636
had	O	-1	1992636
decreased	O	-1	1992636
from	O	-1	1992636
4@@	O	-1	1992636
4.@@	O	-1	1992636
1@@	O	-1	1992636
%	O	-1	1992636
to	O	-1	1992636
2@@	O	-1	1992636
0.@@	O	-1	1992636
4@@	O	-1	1992636
%,	O	-1	1992636
and	O	-1	1992636
sh@@	O	-1	1992636
e	O	-1	1992636
had	O	-1	1992636
a	O	-1	1992636
positive	O	-1	1992636
direct	O	-1	1992636
C@@	O	-1	1992636
o@@	O	-1	1992636
om@@	O	-1	1992636
b@@	O	-1	1992636
s	O	-1	1992636
anti@@	O	-1	1992636
glo@@	O	-1	1992636
b@@	O	-1	1992636
ul@@	O	-1	1992636
in	O	-1	1992636
test	O	-1	1992636
and	O	-1	1992636
an	O	-1	1992636
elevated	O	-1	1992636
in@@	O	-1	1992636
direct	O	-1	1992636
bil@@	B-Chemical	D001663	1992636
i@@	I-Chemical	-1	1992636
ru@@	I-Chemical	-1	1992636
bin	I-Chemical	-1	1992636
.	O	-1	1992636
After	O	-1	1992636
sh@@	O	-1	1992636
e	O	-1	1992636
discontinu@@	O	-1	1992636
ed	O	-1	1992636
the	O	-1	1992636
o@@	B-Chemical	D009853	1992636
me@@	I-Chemical	-1	1992636
praz@@	I-Chemical	-1	1992636
ole	I-Chemical	-1	1992636
,	O	-1	1992636
h@@	O	-1	1992636
er	O	-1	1992636
hemo@@	O	-1	1992636
globin	O	-1	1992636
and	O	-1	1992636
hemat@@	O	-1	1992636
oc@@	O	-1	1992636
ri@@	O	-1	1992636
t	O	-1	1992636
gra@@	O	-1	1992636
du@@	O	-1	1992636
ally	O	-1	1992636
retur@@	O	-1	1992636
n@@	O	-1	1992636
ed	O	-1	1992636
to	O	-1	1992636
normal@@	O	-1	1992636
.	O	-1	1992636
The	O	-1	1992636
mechanism	O	-1	1992636
by	O	-1	1992636
which	O	-1	1992636
o@@	B-Chemical	D009853	1992636
me@@	I-Chemical	-1	1992636
praz@@	I-Chemical	-1	1992636
ole	I-Chemical	-1	1992636
caused	O	-1	1992636
the	O	-1	1992636
patient@@	O	-1	1992636
's	O	-1	1992636
hemolytic	B-Disease	D000743	1992636
anemia	I-Disease	-1	1992636
is	O	-1	1992636
unc@@	O	-1	1992636
er@@	O	-1	1992636
t@@	O	-1	1992636
ain@@	O	-1	1992636
,	O	-1	1992636
but	O	-1	1992636
physi@@	O	-1	1992636
ci@@	O	-1	1992636
ans	O	-1	1992636
should	O	-1	1992636
be	O	-1	1992636
al@@	O	-1	1992636
er@@	O	-1	1992636
ted	O	-1	1992636
to	O	-1	1992636
this	O	-1	1992636
possible	O	-1	1992636
adverse	O	-1	1992636
effect@@	O	-1	1992636
.	O	-1	1992636

The	O	-1	8387218
use	O	-1	8387218
and	O	-1	8387218
toxicity	B-Disease	D064420	8387218
of	O	-1	8387218
di@@	B-Chemical	D016049	8387218
d@@	I-Chemical	-1	8387218
an@@	I-Chemical	-1	8387218
os@@	I-Chemical	-1	8387218
ine	I-Chemical	-1	8387218
(	O	-1	8387218
d@@	B-Chemical	D016049	8387218
d@@	I-Chemical	-1	8387218
I	I-Chemical	-1	8387218
)	O	-1	8387218
in	O	-1	8387218
H@@	B-Disease	D015658	8387218
IV	I-Disease	-1	8387218
anti@@	I-Disease	-1	8387218
bo@@	I-Disease	-1	8387218
dy@@	I-Disease	-1	8387218
-@@	I-Disease	-1	8387218
positive	I-Disease	-1	8387218
individ@@	O	-1	8387218
u@@	O	-1	8387218
als	O	-1	8387218
int@@	O	-1	8387218
oler@@	O	-1	8387218
ant	O	-1	8387218
to	O	-1	8387218
z@@	B-Chemical	D015215	8387218
id@@	I-Chemical	-1	8387218
o@@	I-Chemical	-1	8387218
vud@@	I-Chemical	-1	8387218
ine	I-Chemical	-1	8387218
(	O	-1	8387218
A@@	B-Chemical	D015215	8387218
Z@@	I-Chemical	-1	8387218
T	I-Chemical	-1	8387218
)	O	-1	8387218
One	O	-1	8387218
h@@	O	-1	8387218
und@@	O	-1	8387218
red	O	-1	8387218
and	O	-1	8387218
f@@	O	-1	8387218
if@@	O	-1	8387218
ty-@@	O	-1	8387218
one	O	-1	8387218
patients	O	-1	8387218
int@@	O	-1	8387218
oler@@	O	-1	8387218
ant	O	-1	8387218
to	O	-1	8387218
z@@	B-Chemical	D015215	8387218
id@@	I-Chemical	-1	8387218
o@@	I-Chemical	-1	8387218
vud@@	I-Chemical	-1	8387218
ine	I-Chemical	-1	8387218
(	O	-1	8387218
A@@	B-Chemical	D015215	8387218
Z@@	I-Chemical	-1	8387218
T	I-Chemical	-1	8387218
)	O	-1	8387218
received	O	-1	8387218
di@@	B-Chemical	D016049	8387218
d@@	I-Chemical	-1	8387218
an@@	I-Chemical	-1	8387218
os@@	I-Chemical	-1	8387218
ine	I-Chemical	-1	8387218
(	O	-1	8387218
d@@	B-Chemical	D016049	8387218
d@@	I-Chemical	-1	8387218
I	I-Chemical	-1	8387218
)	O	-1	8387218
to	O	-1	8387218
a	O	-1	8387218
maxim@@	O	-1	8387218
um	O	-1	8387218
dose	O	-1	8387218
of	O	-1	8387218
1@@	O	-1	8387218
2.@@	O	-1	8387218
5	O	-1	8387218
mg/k@@	O	-1	8387218
g/@@	O	-1	8387218
da@@	O	-1	8387218
y.	O	-1	8387218
Pati@@	O	-1	8387218
ent	O	-1	8387218
response	O	-1	8387218
was	O	-1	8387218
assessed	O	-1	8387218
using	O	-1	8387218
changes	O	-1	8387218
in	O	-1	8387218
C@@	O	-1	8387218
D@@	O	-1	8387218
4@@	O	-1	8387218
+	O	-1	8387218
lymph@@	O	-1	8387218
ocyte	O	-1	8387218
sub@@	O	-1	8387218
set	O	-1	8387218
coun@@	O	-1	8387218
t,	O	-1	8387218
H@@	O	-1	8387218
IV	O	-1	8387218
p@@	O	-1	8387218
24	O	-1	8387218
anti@@	O	-1	8387218
gen@@	O	-1	8387218
,	O	-1	8387218
weigh@@	O	-1	8387218
t,	O	-1	8387218
and	O	-1	8387218
qu@@	O	-1	8387218
ality	O	-1	8387218
of	O	-1	8387218
lif@@	O	-1	8387218
e.	O	-1	8387218
S@@	O	-1	8387218
event@@	O	-1	8387218
y	O	-1	8387218
patients	O	-1	8387218
developed	O	-1	8387218
major	O	-1	8387218
op@@	B-Disease	D009894	8387218
port@@	I-Disease	-1	8387218
un@@	I-Disease	-1	8387218
istic	I-Disease	-1	8387218
inf@@	I-Disease	-1	8387218
ec@@	I-Disease	-1	8387218
tions	I-Disease	-1	8387218
wh@@	O	-1	8387218
il@@	O	-1	8387218
st	O	-1	8387218
on	O	-1	8387218
therap@@	O	-1	8387218
y@@	O	-1	8387218
;	O	-1	8387218
this	O	-1	8387218
was	O	-1	8387218
the	O	-1	8387218
first	O	-1	8387218
A@@	B-Disease	D000163	8387218
I@@	I-Disease	-1	8387218
D@@	I-Disease	-1	8387218
S	I-Disease	-1	8387218
diagnosis	O	-1	8387218
in	O	-1	8387218
17@@	O	-1	8387218
.	O	-1	8387218
On@@	O	-1	8387218
ly	O	-1	8387218
min@@	O	-1	8387218
or	O	-1	8387218
changes	O	-1	8387218
in	O	-1	8387218
C@@	O	-1	8387218
D@@	O	-1	8387218
4@@	O	-1	8387218
+	O	-1	8387218
lymph@@	O	-1	8387218
ocyte	O	-1	8387218
sub@@	O	-1	8387218
set	O	-1	8387218
coun@@	O	-1	8387218
t	O	-1	8387218
were	O	-1	8387218
observed	O	-1	8387218
in	O	-1	8387218
A@@	B-Disease	D000163	8387218
I@@	I-Disease	-1	8387218
D@@	I-Disease	-1	8387218
S	I-Disease	-1	8387218
patients,	O	-1	8387218
although	O	-1	8387218
a	O	-1	8387218
more	O	-1	8387218
significant	O	-1	8387218
ri@@	O	-1	8387218
se	O	-1	8387218
occurred	O	-1	8387218
in	O	-1	8387218
those	O	-1	8387218
with	O	-1	8387218
ear@@	O	-1	8387218
li@@	O	-1	8387218
er	O	-1	8387218
st@@	O	-1	8387218
ages	O	-1	8387218
of	O	-1	8387218
disease.	O	-1	8387218
Of	O	-1	8387218
those	O	-1	8387218
positive	O	-1	8387218
for	O	-1	8387218
p@@	O	-1	8387218
24	O	-1	8387218
anti@@	O	-1	8387218
gen	O	-1	8387218
at	O	-1	8387218
the	O	-1	8387218
comm@@	O	-1	8387218
ence@@	O	-1	8387218
ment	O	-1	8387218
of	O	-1	8387218
the	O	-1	8387218
study	O	-1	8387218
6@@	O	-1	8387218
7@@	O	-1	8387218
%	O	-1	8387218
showed	O	-1	8387218
a	O	-1	8387218
positive	O	-1	8387218
respon@@	O	-1	8387218
se@@	O	-1	8387218
,	O	-1	8387218
and	O	-1	8387218
this	O	-1	8387218
was	O	-1	8387218
most	O	-1	8387218
likely	O	-1	8387218
in	O	-1	8387218
those	O	-1	8387218
with	O	-1	8387218
C@@	O	-1	8387218
D@@	O	-1	8387218
4@@	O	-1	8387218
+	O	-1	8387218
lymph@@	O	-1	8387218
ocyte	O	-1	8387218
sub@@	O	-1	8387218
set	O	-1	8387218
coun@@	O	-1	8387218
ts	O	-1	8387218
ab@@	O	-1	8387218
o@@	O	-1	8387218
ve	O	-1	8387218
100	O	-1	8387218
mm@@	O	-1	8387218
3@@	O	-1	8387218
.	O	-1	8387218
A	O	-1	8387218
positive	O	-1	8387218
weight	O	-1	8387218
response	O	-1	8387218
was	O	-1	8387218
seen	O	-1	8387218
in	O	-1	8387218
1@@	O	-1	8387218
6%	O	-1	8387218
of	O	-1	8387218
patients.	O	-1	8387218
M@@	O	-1	8387218
ost	O	-1	8387218
patients	O	-1	8387218
showed	O	-1	8387218
impro@@	O	-1	8387218
vement	O	-1	8387218
in	O	-1	8387218
individ@@	O	-1	8387218
ual	O	-1	8387218
par@@	O	-1	8387218
ame@@	O	-1	8387218
ters	O	-1	8387218
and	O	-1	8387218
glo@@	O	-1	8387218
b@@	O	-1	8387218
al	O	-1	8387218
scor@@	O	-1	8387218
e	O	-1	8387218
of	O	-1	8387218
qu@@	O	-1	8387218
ality	O	-1	8387218
of	O	-1	8387218
lif@@	O	-1	8387218
e.	O	-1	8387218
Ad@@	O	-1	8387218
verse	O	-1	8387218
reactions	O	-1	8387218
possib@@	O	-1	8387218
ly	O	-1	8387218
at@@	O	-1	8387218
tri@@	O	-1	8387218
but@@	O	-1	8387218
able	O	-1	8387218
to	O	-1	8387218
di@@	B-Chemical	D016049	8387218
d@@	I-Chemical	-1	8387218
an@@	I-Chemical	-1	8387218
os@@	I-Chemical	-1	8387218
ine	I-Chemical	-1	8387218
were	O	-1	8387218
common@@	O	-1	8387218
.	O	-1	8387218
The	O	-1	8387218
most	O	-1	8387218
common	O	-1	8387218
side@@	O	-1	8387218
-@@	O	-1	8387218
effect	O	-1	8387218
was	O	-1	8387218
di@@	B-Disease	D003967	8387218
ar@@	I-Disease	-1	8387218
r@@	I-Disease	-1	8387218
ho@@	I-Disease	-1	8387218
e@@	I-Disease	-1	8387218
a	I-Disease	-1	8387218
,	O	-1	8387218
which	O	-1	8387218
resulted	O	-1	8387218
in	O	-1	8387218
cess@@	O	-1	8387218
ation	O	-1	8387218
of	O	-1	8387218
therapy	O	-1	8387218
in	O	-1	8387218
1@@	O	-1	8387218
9	O	-1	8387218
individ@@	O	-1	8387218
u@@	O	-1	8387218
al@@	O	-1	8387218
s.	O	-1	8387218
P@@	B-Disease	D010523	8387218
er@@	I-Disease	-1	8387218
i@@	I-Disease	-1	8387218
pheral	I-Disease	-1	8387218
neuropathy	I-Disease	-1	8387218
occurred	O	-1	8387218
in	O	-1	8387218
12	O	-1	8387218
patients	O	-1	8387218
and	O	-1	8387218
p@@	B-Disease	D010195	8387218
anc@@	I-Disease	-1	8387218
re@@	I-Disease	-1	8387218
ati@@	I-Disease	-1	8387218
tis	I-Disease	-1	8387218
in	O	-1	8387218
si@@	O	-1	8387218
x@@	O	-1	8387218
.	O	-1	8387218
Th@@	O	-1	8387218
ir@@	O	-1	8387218
te@@	O	-1	8387218
en	O	-1	8387218
patients	O	-1	8387218
developed	O	-1	8387218
a	O	-1	8387218
ra@@	O	-1	8387218
is@@	O	-1	8387218
ed	O	-1	8387218
serum	O	-1	8387218
am@@	O	-1	8387218
yl@@	O	-1	8387218
ase	O	-1	8387218
without	O	-1	8387218
ab@@	B-Disease	D015746	8387218
domin@@	I-Disease	-1	8387218
al	I-Disease	-1	8387218
pain	I-Disease	-1	8387218
.	O	-1	8387218
S@@	O	-1	8387218
even	O	-1	8387218
patients	O	-1	8387218
developed	O	-1	8387218
g@@	B-Disease	D018149	8387218
lu@@	I-Disease	-1	8387218
co@@	I-Disease	-1	8387218
se	I-Disease	-1	8387218
toler@@	I-Disease	-1	8387218
ance	I-Disease	-1	8387218
cur@@	I-Disease	-1	8387218
v@@	I-Disease	-1	8387218
es	I-Disease	-1	8387218
character@@	O	-1	8387218
istic	O	-1	8387218
of	O	-1	8387218
dia@@	B-Disease	D003920	8387218
bet@@	I-Disease	-1	8387218
es	I-Disease	-1	8387218
but	O	-1	8387218
these	O	-1	8387218
were	O	-1	8387218
mil@@	O	-1	8387218
d,	O	-1	8387218
did	O	-1	8387218
not	O	-1	8387218
requ@@	O	-1	8387218
ir@@	O	-1	8387218
e	O	-1	8387218
treatment	O	-1	8387218
and	O	-1	8387218
retur@@	O	-1	8387218
n@@	O	-1	8387218
ed	O	-1	8387218
to	O	-1	8387218
normal	O	-1	8387218
on	O	-1	8387218
ce@@	O	-1	8387218
as@@	O	-1	8387218
ing	O	-1	8387218
di@@	B-Chemical	D016049	8387218
d@@	I-Chemical	-1	8387218
an@@	I-Chemical	-1	8387218
os@@	I-Chemical	-1	8387218
ine	I-Chemical	-1	8387218
.	O	-1	8387218

C@@	O	-1	20698227
an	O	-1	20698227
angio@@	O	-1	20698227
genesis	O	-1	20698227
be	O	-1	20698227
a	O	-1	20698227
t@@	O	-1	20698227
arg@@	O	-1	20698227
et	O	-1	20698227
of	O	-1	20698227
treatment	O	-1	20698227
for	O	-1	20698227
rib@@	B-Chemical	D012254	20698227
avi@@	I-Chemical	-1	20698227
rin	I-Chemical	-1	20698227
associated	O	-1	20698227
hemolytic	B-Disease	D000743	20698227
anemia	I-Disease	-1	20698227
?	O	-1	20698227
BACKGROUND@@	O	-1	20698227
/@@	O	-1	20698227
A@@	O	-1	20698227
I@@	O	-1	20698227
M@@	O	-1	20698227
S:	O	-1	20698227
Rec@@	O	-1	20698227
ently	O	-1	20698227
rib@@	B-Chemical	D012254	20698227
avi@@	I-Chemical	-1	20698227
rin	I-Chemical	-1	20698227
has	O	-1	20698227
been	O	-1	20698227
found	O	-1	20698227
to	O	-1	20698227
inhib@@	O	-1	20698227
it	O	-1	20698227
angio@@	O	-1	20698227
genesis	O	-1	20698227
and	O	-1	20698227
a	O	-1	20698227
number	O	-1	20698227
of	O	-1	20698227
angio@@	O	-1	20698227
genesis	O	-1	20698227
inhibitors	O	-1	20698227
such	O	-1	20698227
as	O	-1	20698227
su@@	B-Chemical	C473478	20698227
nit@@	I-Chemical	-1	20698227
in@@	I-Chemical	-1	20698227
i@@	I-Chemical	-1	20698227
b	I-Chemical	-1	20698227
and	O	-1	20698227
s@@	B-Chemical	C471405	20698227
or@@	I-Chemical	-1	20698227
af@@	I-Chemical	-1	20698227
en@@	I-Chemical	-1	20698227
i@@	I-Chemical	-1	20698227
b	I-Chemical	-1	20698227
have	O	-1	20698227
been	O	-1	20698227
found	O	-1	20698227
to	O	-1	20698227
cause	O	-1	20698227
acute	O	-1	20698227
hemoly@@	B-Disease	D006461	20698227
sis	I-Disease	-1	20698227
.	O	-1	20698227
We	O	-1	20698227
a@@	O	-1	20698227
im@@	O	-1	20698227
ed	O	-1	20698227
to	O	-1	20698227
investigate	O	-1	20698227
whether	O	-1	20698227
there	O	-1	20698227
is	O	-1	20698227
a	O	-1	20698227
rel@@	O	-1	20698227
ation	O	-1	20698227
between	O	-1	20698227
hemo@@	O	-1	20698227
glo@@	O	-1	20698227
bin@@	O	-1	20698227
,	O	-1	20698227
h@@	O	-1	20698227
ap@@	O	-1	20698227
to@@	O	-1	20698227
globin	O	-1	20698227
and	O	-1	20698227
angio@@	O	-1	20698227
genesis	O	-1	20698227
sol@@	O	-1	20698227
ub@@	O	-1	20698227
le	O	-1	20698227
mark@@	O	-1	20698227
ers	O	-1	20698227
which	O	-1	20698227
are	O	-1	20698227
mo@@	O	-1	20698227
di@@	O	-1	20698227
fi@@	O	-1	20698227
able	O	-1	20698227
and	O	-1	20698227
can	O	-1	20698227
he@@	O	-1	20698227
l@@	O	-1	20698227
p	O	-1	20698227
in	O	-1	20698227
develop@@	O	-1	20698227
ing	O	-1	20698227
strat@@	O	-1	20698227
e@@	O	-1	20698227
gi@@	O	-1	20698227
es	O	-1	20698227
against	O	-1	20698227
anemia	B-Disease	D000740	20698227
.	O	-1	20698227
METHODS:	O	-1	20698227
F@@	O	-1	20698227
o@@	O	-1	20698227
ur@@	O	-1	20698227
te@@	O	-1	20698227
en	O	-1	20698227
patients	O	-1	20698227
chron@@	B-Disease	D019698	20698227
ically	I-Disease	-1	20698227
inf@@	I-Disease	-1	20698227
ected	I-Disease	-1	20698227
with	I-Disease	-1	20698227
hepatitis	I-Disease	-1	20698227
C	I-Disease	-1	20698227
vi@@	I-Disease	-1	20698227
ru@@	I-Disease	-1	20698227
s	I-Disease	-1	20698227
were	O	-1	20698227
treated	O	-1	20698227
by	O	-1	20698227
pe@@	B-Chemical	C100416	20698227
g@@	I-Chemical	-1	20698227
yl@@	I-Chemical	-1	20698227
ated	I-Chemical	-1	20698227
inter@@	I-Chemical	-1	20698227
fer@@	I-Chemical	-1	20698227
on	I-Chemical	-1	20698227
al@@	I-Chemical	-1	20698227
ph@@	I-Chemical	-1	20698227
a	I-Chemical	-1	20698227
2@@	I-Chemical	-1	20698227
a	I-Chemical	-1	20698227
and	O	-1	20698227
rib@@	B-Chemical	D012254	20698227
avi@@	I-Chemical	-1	20698227
rin	I-Chemical	-1	20698227
.	O	-1	20698227
S@@	O	-1	20698227
er@@	O	-1	20698227
um	O	-1	20698227
hemo@@	O	-1	20698227
glo@@	O	-1	20698227
bin@@	O	-1	20698227
,	O	-1	20698227
h@@	O	-1	20698227
ap@@	O	-1	20698227
to@@	O	-1	20698227
globin	O	-1	20698227
and	O	-1	20698227
angio@@	O	-1	20698227
genesis	O	-1	20698227
mark@@	O	-1	20698227
ers	O	-1	20698227
of	O	-1	20698227
vascular	O	-1	20698227
endothelial	O	-1	20698227
growth	O	-1	20698227
factor	O	-1	20698227
and	O	-1	20698227
angio@@	O	-1	20698227
po@@	O	-1	20698227
et@@	O	-1	20698227
in-@@	O	-1	20698227
2	O	-1	20698227
were	O	-1	20698227
investigated	O	-1	20698227
before	O	-1	20698227
and	O	-1	20698227
after	O	-1	20698227
therapy.	O	-1	20698227
RESULTS:	O	-1	20698227
We	O	-1	20698227
observed	O	-1	20698227
a	O	-1	20698227
significant	O	-1	20698227
decrease	O	-1	20698227
in	O	-1	20698227
h@@	O	-1	20698227
ap@@	O	-1	20698227
to@@	O	-1	20698227
globin	O	-1	20698227
levels	O	-1	20698227
at	O	-1	20698227
the	O	-1	20698227
end	O	-1	20698227
of	O	-1	20698227
the	O	-1	20698227
treatment	O	-1	20698227
perio@@	O	-1	20698227
d.	O	-1	20698227
H@@	O	-1	20698227
em@@	O	-1	20698227
o@@	O	-1	20698227
globin	O	-1	20698227
levels	O	-1	20698227
also	O	-1	20698227
decreased	O	-1	20698227
but	O	-1	20698227
in@@	O	-1	20698227
significantly	O	-1	20698227
by	O	-1	20698227
treatment.	O	-1	20698227
In	O	-1	20698227
contr@@	O	-1	20698227
ast	O	-1	20698227
with	O	-1	20698227
the	O	-1	20698227
literat@@	O	-1	20698227
ure,	O	-1	20698227
serum	O	-1	20698227
levels	O	-1	20698227
of	O	-1	20698227
angio@@	O	-1	20698227
genesis	O	-1	20698227
factors	O	-1	20698227
did	O	-1	20698227
not	O	-1	20698227
change	O	-1	20698227
significantly	O	-1	20698227
by	O	-1	20698227
pe@@	B-Chemical	C417083	20698227
g@@	I-Chemical	-1	20698227
yl@@	I-Chemical	-1	20698227
ated	I-Chemical	-1	20698227
inter@@	I-Chemical	-1	20698227
fer@@	I-Chemical	-1	20698227
on	I-Chemical	-1	20698227
and	O	-1	20698227
rib@@	B-Chemical	D012254	20698227
avi@@	I-Chemical	-1	20698227
rin	I-Chemical	-1	20698227
therapy.	O	-1	20698227
We	O	-1	20698227
found	O	-1	20698227
no	O	-1	20698227
correl@@	O	-1	20698227
ation	O	-1	20698227
of	O	-1	20698227
angio@@	O	-1	20698227
genesis	O	-1	20698227
sol@@	O	-1	20698227
ub@@	O	-1	20698227
le	O	-1	20698227
mark@@	O	-1	20698227
ers	O	-1	20698227
with	O	-1	20698227
either	O	-1	20698227
hemo@@	O	-1	20698227
globin	O	-1	20698227
or	O	-1	20698227
h@@	O	-1	20698227
ap@@	O	-1	20698227
to@@	O	-1	20698227
glo@@	O	-1	20698227
bin@@	O	-1	20698227
.	O	-1	20698227
CONCLUSION:	O	-1	20698227
This	O	-1	20698227
is	O	-1	20698227
the	O	-1	20698227
first	O	-1	20698227
study	O	-1	20698227
in	O	-1	20698227
the	O	-1	20698227
literat@@	O	-1	20698227
ure	O	-1	20698227
investig@@	O	-1	20698227
ating	O	-1	20698227
a	O	-1	20698227
lin@@	O	-1	20698227
k	O	-1	20698227
between	O	-1	20698227
angio@@	O	-1	20698227
genesis	O	-1	20698227
sol@@	O	-1	20698227
ub@@	O	-1	20698227
le	O	-1	20698227
mark@@	O	-1	20698227
ers	O	-1	20698227
and	O	-1	20698227
rib@@	B-Chemical	D012254	20698227
avi@@	I-Chemical	-1	20698227
rin	I-Chemical	-1	20698227
induced	O	-1	20698227
anemia	B-Disease	D000740	20698227
in	O	-1	20698227
patients	O	-1	20698227
with	O	-1	20698227
hepatitis	B-Disease	D019698	20698227
C	I-Disease	-1	20698227
and	O	-1	20698227
we	O	-1	20698227
could	O	-1	20698227
not	O	-1	20698227
f@@	O	-1	20698227
ind	O	-1	20698227
any	O	-1	20698227
rel@@	O	-1	20698227
ation.	O	-1	20698227
F@@	O	-1	20698227
ut@@	O	-1	20698227
ure	O	-1	20698227
re@@	O	-1	20698227
se@@	O	-1	20698227
arc@@	O	-1	20698227
h	O	-1	20698227
with	O	-1	20698227
larg@@	O	-1	20698227
er	O	-1	20698227
number	O	-1	20698227
of	O	-1	20698227
patients	O	-1	20698227
is	O	-1	20698227
ne@@	O	-1	20698227
ed@@	O	-1	20698227
ed	O	-1	20698227
to	O	-1	20698227
f@@	O	-1	20698227
ind	O	-1	20698227
out	O	-1	20698227
mo@@	O	-1	20698227
di@@	O	-1	20698227
fi@@	O	-1	20698227
able	O	-1	20698227
factors	O	-1	20698227
that	O	-1	20698227
wil@@	O	-1	20698227
l	O	-1	20698227
impro@@	O	-1	20698227
ve	O	-1	20698227
the	O	-1	20698227
safety	O	-1	20698227
of	O	-1	20698227
rib@@	B-Chemical	D012254	20698227
avi@@	I-Chemical	-1	20698227
rin	I-Chemical	-1	20698227
therapy.	O	-1	20698227

C@@	B-Chemical	D003042	20477932
oc@@	I-Chemical	-1	20477932
aine	I-Chemical	-1	20477932
causes	O	-1	20477932
memory	B-Disease	D008569	20477932
and	I-Disease	-1	20477932
lear@@	I-Disease	-1	20477932
ning	I-Disease	-1	20477932
impair@@	I-Disease	-1	20477932
ments	I-Disease	-1	20477932
memory	B-Disease	D007859	20477932
and	I-Disease	-1	20477932
lear@@	I-Disease	-1	20477932
ning	I-Disease	-1	20477932
impair@@	I-Disease	-1	20477932
ments	I-Disease	-1	20477932
in	O	-1	20477932
rat@@	O	-1	20477932
s:	O	-1	20477932
invol@@	O	-1	20477932
vement	O	-1	20477932
of	O	-1	20477932
nucle@@	O	-1	20477932
ar	O	-1	20477932
factor	O	-1	20477932
k@@	O	-1	20477932
app@@	O	-1	20477932
a	O	-1	20477932
B	O	-1	20477932
and	O	-1	20477932
oxid@@	O	-1	20477932
ative	O	-1	20477932
stres@@	O	-1	20477932
s,	O	-1	20477932
and	O	-1	20477932
pre@@	O	-1	20477932
ven@@	O	-1	20477932
tion	O	-1	20477932
by	O	-1	20477932
to@@	B-Chemical	C052342	20477932
pi@@	I-Chemical	-1	20477932
ram@@	I-Chemical	-1	20477932
ate	I-Chemical	-1	20477932
.	O	-1	20477932
Di@@	O	-1	20477932
fferen@@	O	-1	20477932
t	O	-1	20477932
mechanisms	O	-1	20477932
have	O	-1	20477932
been	O	-1	20477932
suggested	O	-1	20477932
for	O	-1	20477932
cocaine	B-Chemical	D003042	20477932
toxicity	B-Disease	D064420	20477932
including	O	-1	20477932
an	O	-1	20477932
increase	O	-1	20477932
in	O	-1	20477932
oxid@@	O	-1	20477932
ative	O	-1	20477932
stres@@	O	-1	20477932
s	O	-1	20477932
but	O	-1	20477932
the	O	-1	20477932
association	O	-1	20477932
between	O	-1	20477932
oxid@@	O	-1	20477932
ative	O	-1	20477932
status	O	-1	20477932
in	O	-1	20477932
the	O	-1	20477932
brain	O	-1	20477932
and	O	-1	20477932
cocaine	B-Chemical	D003042	20477932
induc@@	O	-1	20477932
ed@@	O	-1	20477932
-@@	O	-1	20477932
behavi@@	O	-1	20477932
our	O	-1	20477932
is	O	-1	20477932
po@@	O	-1	20477932
or@@	O	-1	20477932
ly	O	-1	20477932
under@@	O	-1	20477932
sto@@	O	-1	20477932
o@@	O	-1	20477932
d.	O	-1	20477932
N@@	O	-1	20477932
ucle@@	O	-1	20477932
ar	O	-1	20477932
factor	O	-1	20477932
k@@	O	-1	20477932
app@@	O	-1	20477932
a	O	-1	20477932
B	O	-1	20477932
(N@@	O	-1	20477932
F@@	O	-1	20477932
k@@	O	-1	20477932
appa@@	O	-1	20477932
B@@	O	-1	20477932
)	O	-1	20477932
is	O	-1	20477932
a	O	-1	20477932
sens@@	O	-1	20477932
or	O	-1	20477932
of	O	-1	20477932
oxid@@	O	-1	20477932
ative	O	-1	20477932
stres@@	O	-1	20477932
s	O	-1	20477932
and	O	-1	20477932
partic@@	O	-1	20477932
i@@	O	-1	20477932
pat@@	O	-1	20477932
es	O	-1	20477932
in	O	-1	20477932
memory	O	-1	20477932
formation	O	-1	20477932
that	O	-1	20477932
could	O	-1	20477932
be	O	-1	20477932
involved	O	-1	20477932
in	O	-1	20477932
drug	O	-1	20477932
toxicity	B-Disease	D064420	20477932
and	O	-1	20477932
ad@@	O	-1	20477932
dic@@	O	-1	20477932
tion	O	-1	20477932
mechanis@@	O	-1	20477932
m@@	O	-1	20477932
s.	O	-1	20477932
The@@	O	-1	20477932
re@@	O	-1	20477932
fore	O	-1	20477932
N@@	O	-1	20477932
F@@	O	-1	20477932
k@@	O	-1	20477932
appa@@	O	-1	20477932
B	O	-1	20477932
activ@@	O	-1	20477932
ity,	O	-1	20477932
oxid@@	O	-1	20477932
ative	O	-1	20477932
stres@@	O	-1	20477932
s,	O	-1	20477932
neuron@@	O	-1	20477932
al	O	-1	20477932
nit@@	B-Chemical	D009569	20477932
ric	I-Chemical	-1	20477932
ox@@	I-Chemical	-1	20477932
ide	I-Chemical	-1	20477932
syn@@	O	-1	20477932
th@@	O	-1	20477932
ase	O	-1	20477932
(n@@	O	-1	20477932
NO@@	O	-1	20477932
S)	O	-1	20477932
activ@@	O	-1	20477932
ity,	O	-1	20477932
s@@	O	-1	20477932
pati@@	O	-1	20477932
al	O	-1	20477932
lear@@	O	-1	20477932
ning	O	-1	20477932
and	O	-1	20477932
memory	O	-1	20477932
as	O	-1	20477932
well	O	-1	20477932
as	O	-1	20477932
the	O	-1	20477932
effect	O	-1	20477932
of	O	-1	20477932
to@@	B-Chemical	C052342	20477932
pi@@	I-Chemical	-1	20477932
ram@@	I-Chemical	-1	20477932
ate	I-Chemical	-1	20477932
,	O	-1	20477932
a	O	-1	20477932
previously	O	-1	20477932
pro@@	O	-1	20477932
pos@@	O	-1	20477932
ed	O	-1	20477932
therapy	O	-1	20477932
for	O	-1	20477932
cocaine	B-Disease	D019970	20477932
ad@@	I-Disease	-1	20477932
dic@@	I-Disease	-1	20477932
tion	I-Disease	-1	20477932
,	O	-1	20477932
were	O	-1	20477932
evaluated	O	-1	20477932
in	O	-1	20477932
an	O	-1	20477932
experimental	O	-1	20477932
model	O	-1	20477932
of	O	-1	20477932
cocaine	B-Chemical	D003042	20477932
administration	O	-1	20477932
in	O	-1	20477932
rats.	O	-1	20477932
N@@	O	-1	20477932
F@@	O	-1	20477932
k@@	O	-1	20477932
appa@@	O	-1	20477932
B	O	-1	20477932
activity	O	-1	20477932
was	O	-1	20477932
decreased	O	-1	20477932
in	O	-1	20477932
the	O	-1	20477932
fron@@	O	-1	20477932
t@@	O	-1	20477932
al	O	-1	20477932
cor@@	O	-1	20477932
te@@	O	-1	20477932
x	O	-1	20477932
of	O	-1	20477932
cocaine	B-Chemical	D003042	20477932
treated	O	-1	20477932
rats,	O	-1	20477932
as	O	-1	20477932
well	O	-1	20477932
as	O	-1	20477932
G@@	B-Chemical	D005978	20477932
S@@	I-Chemical	-1	20477932
H	I-Chemical	-1	20477932
concentration	O	-1	20477932
and	O	-1	20477932
glut@@	B-Chemical	D005978	20477932
athi@@	I-Chemical	-1	20477932
one	I-Chemical	-1	20477932
per@@	O	-1	20477932
oxid@@	O	-1	20477932
ase	O	-1	20477932
activity	O	-1	20477932
in	O	-1	20477932
the	O	-1	20477932
hippocamp@@	O	-1	20477932
us,	O	-1	20477932
whereas	O	-1	20477932
n@@	O	-1	20477932
NO@@	O	-1	20477932
S	O	-1	20477932
activity	O	-1	20477932
in	O	-1	20477932
the	O	-1	20477932
hippocamp@@	O	-1	20477932
us	O	-1	20477932
was	O	-1	20477932
increas@@	O	-1	20477932
ed.	O	-1	20477932
M@@	O	-1	20477932
em@@	O	-1	20477932
ory	O	-1	20477932
re@@	O	-1	20477932
tri@@	O	-1	20477932
ev@@	O	-1	20477932
al	O	-1	20477932
of	O	-1	20477932
experienc@@	O	-1	20477932
es	O	-1	20477932
ac@@	O	-1	20477932
qu@@	O	-1	20477932
ired	O	-1	20477932
prior	O	-1	20477932
to	O	-1	20477932
cocaine	B-Chemical	D003042	20477932
administration	O	-1	20477932
was	O	-1	20477932
impaired	O	-1	20477932
and	O	-1	20477932
neg@@	O	-1	20477932
atively	O	-1	20477932
cor@@	O	-1	20477932
related	O	-1	20477932
with	O	-1	20477932
N@@	O	-1	20477932
F@@	O	-1	20477932
k@@	O	-1	20477932
appa@@	O	-1	20477932
B	O	-1	20477932
activity	O	-1	20477932
in	O	-1	20477932
the	O	-1	20477932
fron@@	O	-1	20477932
t@@	O	-1	20477932
al	O	-1	20477932
cor@@	O	-1	20477932
t@@	O	-1	20477932
ex@@	O	-1	20477932
.	O	-1	20477932
In	O	-1	20477932
contrast@@	O	-1	20477932
,	O	-1	20477932
lear@@	O	-1	20477932
ning	O	-1	20477932
of	O	-1	20477932
new	O	-1	20477932
t@@	O	-1	20477932
as@@	O	-1	20477932
k@@	O	-1	20477932
s	O	-1	20477932
was	O	-1	20477932
enhanced	O	-1	20477932
and	O	-1	20477932
cor@@	O	-1	20477932
related	O	-1	20477932
with	O	-1	20477932
the	O	-1	20477932
increase	O	-1	20477932
of	O	-1	20477932
n@@	O	-1	20477932
NO@@	O	-1	20477932
S	O	-1	20477932
activity	O	-1	20477932
and	O	-1	20477932
the	O	-1	20477932
decrease	O	-1	20477932
of	O	-1	20477932
glut@@	B-Chemical	D005978	20477932
athi@@	I-Chemical	-1	20477932
one	I-Chemical	-1	20477932
per@@	O	-1	20477932
oxid@@	O	-1	20477932
as@@	O	-1	20477932
e.	O	-1	20477932
These	O	-1	20477932
results	O	-1	20477932
prov@@	O	-1	20477932
ide	O	-1	20477932
evidence	O	-1	20477932
for	O	-1	20477932
a	O	-1	20477932
possible	O	-1	20477932
mechanis@@	O	-1	20477932
tic	O	-1	20477932
role	O	-1	20477932
of	O	-1	20477932
oxid@@	O	-1	20477932
ative	O	-1	20477932
and	O	-1	20477932
nit@@	O	-1	20477932
ros@@	O	-1	20477932
ative	O	-1	20477932
stres@@	O	-1	20477932
s	O	-1	20477932
and	O	-1	20477932
N@@	O	-1	20477932
F@@	O	-1	20477932
k@@	O	-1	20477932
appa@@	O	-1	20477932
B	O	-1	20477932
in	O	-1	20477932
the	O	-1	20477932
al@@	O	-1	20477932
ter@@	O	-1	20477932
ations	O	-1	20477932
induced	O	-1	20477932
by	O	-1	20477932
cocaine	B-Chemical	D003042	20477932
.	O	-1	20477932
T@@	B-Chemical	C052342	20477932
o@@	I-Chemical	-1	20477932
pi@@	I-Chemical	-1	20477932
ram@@	I-Chemical	-1	20477932
ate	I-Chemical	-1	20477932
prevent@@	O	-1	20477932
ed	O	-1	20477932
all	O	-1	20477932
the	O	-1	20477932
al@@	O	-1	20477932
ter@@	O	-1	20477932
ations	O	-1	20477932
obser@@	O	-1	20477932
ve@@	O	-1	20477932
d,	O	-1	20477932
show@@	O	-1	20477932
ing	O	-1	20477932
novel	O	-1	20477932
neuro@@	O	-1	20477932
protective	O	-1	20477932
pro@@	O	-1	20477932
per@@	O	-1	20477932
ti@@	O	-1	20477932
es.	O	-1	20477932

An@@	O	-1	9495837
t@@	O	-1	9495837
in@@	O	-1	9495837
ocicep@@	O	-1	9495837
tive	O	-1	9495837
and	O	-1	9495837
anti@@	O	-1	9495837
am@@	O	-1	9495837
ne@@	O	-1	9495837
sic	O	-1	9495837
pro@@	O	-1	9495837
per@@	O	-1	9495837
ties	O	-1	9495837
of	O	-1	9495837
the	O	-1	9495837
pres@@	O	-1	9495837
yn@@	O	-1	9495837
ap@@	O	-1	9495837
tic	O	-1	9495837
cholinergic	O	-1	9495837
am@@	O	-1	9495837
pl@@	O	-1	9495837
if@@	O	-1	9495837
i@@	O	-1	9495837
er	O	-1	9495837
PG@@	B-Chemical	C087567	9495837
-@@	I-Chemical	-1	9495837
9	I-Chemical	-1	9495837
.	O	-1	9495837
The	O	-1	9495837
ant@@	O	-1	9495837
in@@	O	-1	9495837
ocicep@@	O	-1	9495837
tive	O	-1	9495837
effect	O	-1	9495837
of	O	-1	9495837
3	B-Chemical	C087567	9495837
alpha-@@	I-Chemical	-1	9495837
tro@@	I-Chemical	-1	9495837
py@@	I-Chemical	-1	9495837
l	I-Chemical	-1	9495837
2-@@	I-Chemical	-1	9495837
(p@@	I-Chemical	-1	9495837
-@@	I-Chemical	-1	9495837
b@@	I-Chemical	-1	9495837
ro@@	I-Chemical	-1	9495837
mo@@	I-Chemical	-1	9495837
phenyl@@	I-Chemical	-1	9495837
)@@	I-Chemical	-1	9495837
pro@@	I-Chemical	-1	9495837
pi@@	I-Chemical	-1	9495837
on@@	I-Chemical	-1	9495837
ate	I-Chemical	-1	9495837
[@@	O	-1	9495837
(@@	O	-1	9495837
+/-@@	O	-1	9495837
)@@	O	-1	9495837
-	O	-1	9495837
PG@@	B-Chemical	C087567	9495837
-@@	I-Chemical	-1	9495837
9	I-Chemical	-1	9495837
]	O	-1	9495837
(@@	O	-1	9495837
10-@@	O	-1	9495837
40	O	-1	9495837
mg	O	-1	9495837
kg@@	O	-1	9495837
-1	O	-1	9495837
s@@	O	-1	9495837
.@@	O	-1	9495837
c@@	O	-1	9495837
.@@	O	-1	9495837
;	O	-1	9495837
3@@	O	-1	9495837
0-@@	O	-1	9495837
60	O	-1	9495837
mg	O	-1	9495837
kg@@	O	-1	9495837
-1	O	-1	9495837
p.@@	O	-1	9495837
o@@	O	-1	9495837
.@@	O	-1	9495837
;	O	-1	9495837
10-@@	O	-1	9495837
30	O	-1	9495837
mg	O	-1	9495837
kg@@	O	-1	9495837
-1	O	-1	9495837
i.v@@	O	-1	9495837
.@@	O	-1	9495837
;	O	-1	9495837
10-@@	O	-1	9495837
30	O	-1	9495837
microgram@@	O	-1	9495837
s/@@	O	-1	9495837
mouse	O	-1	9495837
i.@@	O	-1	9495837
c@@	O	-1	9495837
.@@	O	-1	9495837
v@@	O	-1	9495837
.)	O	-1	9495837
was	O	-1	9495837
examined	O	-1	9495837
in	O	-1	9495837
mic@@	O	-1	9495837
e,	O	-1	9495837
rats	O	-1	9495837
and	O	-1	9495837
gu@@	O	-1	9495837
ine@@	O	-1	9495837
a	O	-1	9495837
pi@@	O	-1	9495837
g@@	O	-1	9495837
s	O	-1	9495837
by	O	-1	9495837
use	O	-1	9495837
of	O	-1	9495837
the	O	-1	9495837
h@@	O	-1	9495837
ot@@	O	-1	9495837
-@@	O	-1	9495837
pl@@	O	-1	9495837
ate,	O	-1	9495837
ab@@	O	-1	9495837
domin@@	O	-1	9495837
al@@	O	-1	9495837
-@@	O	-1	9495837
con@@	O	-1	9495837
stric@@	O	-1	9495837
tion,	O	-1	9495837
t@@	O	-1	9495837
ail@@	O	-1	9495837
-@@	O	-1	9495837
f@@	O	-1	9495837
l@@	O	-1	9495837
ic@@	O	-1	9495837
k	O	-1	9495837
and	O	-1	9495837
pa@@	O	-1	9495837
w@@	O	-1	9495837
-@@	O	-1	9495837
pressure	O	-1	9495837
test@@	O	-1	9495837
s.	O	-1	9495837
(@@	O	-1	9495837
+/-@@	O	-1	9495837
)@@	O	-1	9495837
-	O	-1	9495837
PG@@	B-Chemical	C087567	9495837
-@@	I-Chemical	-1	9495837
9	I-Chemical	-1	9495837
ant@@	O	-1	9495837
in@@	O	-1	9495837
ocicep@@	O	-1	9495837
tion	O	-1	9495837
pe@@	O	-1	9495837
ak@@	O	-1	9495837
ed	O	-1	9495837
15	O	-1	9495837
min	O	-1	9495837
after	O	-1	9495837
injection	O	-1	9495837
and	O	-1	9495837
then	O	-1	9495837
s@@	O	-1	9495837
low@@	O	-1	9495837
ly	O	-1	9495837
di@@	O	-1	9495837
min@@	O	-1	9495837
is@@	O	-1	9495837
he@@	O	-1	9495837
d.	O	-1	9495837
The	O	-1	9495837
ant@@	O	-1	9495837
in@@	O	-1	9495837
ocicep@@	O	-1	9495837
tion	O	-1	9495837
produced	O	-1	9495837
by	O	-1	9495837
(@@	O	-1	9495837
+/-@@	O	-1	9495837
)@@	O	-1	9495837
-	O	-1	9495837
PG@@	B-Chemical	C087567	9495837
-@@	I-Chemical	-1	9495837
9	I-Chemical	-1	9495837
was	O	-1	9495837
prevent@@	O	-1	9495837
ed	O	-1	9495837
by	O	-1	9495837
the	O	-1	9495837
un@@	O	-1	9495837
selective	O	-1	9495837
mus@@	O	-1	9495837
car@@	O	-1	9495837
inic	O	-1	9495837
antagonist	O	-1	9495837
atro@@	B-Chemical	D001285	9495837
pine	I-Chemical	-1	9495837
,	O	-1	9495837
the	O	-1	9495837
M@@	O	-1	9495837
1-@@	O	-1	9495837
selective	O	-1	9495837
antagonist@@	O	-1	9495837
s	O	-1	9495837
pi@@	B-Chemical	D010890	9495837
ren@@	I-Chemical	-1	9495837
z@@	I-Chemical	-1	9495837
ep@@	I-Chemical	-1	9495837
ine	I-Chemical	-1	9495837
and	O	-1	9495837
dic@@	B-Chemical	D004025	9495837
yc@@	I-Chemical	-1	9495837
lo@@	I-Chemical	-1	9495837
mine	I-Chemical	-1	9495837
and	O	-1	9495837
the	O	-1	9495837
acet@@	B-Chemical	D000109	9495837
ylcholine	I-Chemical	-1	9495837
deple@@	O	-1	9495837
t@@	O	-1	9495837
or	O	-1	9495837
he@@	B-Chemical	D006426	9495837
mic@@	I-Chemical	-1	9495837
h@@	I-Chemical	-1	9495837
ol@@	I-Chemical	-1	9495837
in@@	I-Chemical	-1	9495837
i@@	I-Chemical	-1	9495837
um@@	I-Chemical	-1	9495837
-@@	I-Chemical	-1	9495837
3	I-Chemical	-1	9495837
,	O	-1	9495837
but	O	-1	9495837
not	O	-1	9495837
by	O	-1	9495837
the	O	-1	9495837
o@@	O	-1	9495837
pi@@	O	-1	9495837
oid	O	-1	9495837
antagonist	O	-1	9495837
n@@	B-Chemical	D009270	9495837
al@@	I-Chemical	-1	9495837
ox@@	I-Chemical	-1	9495837
one	I-Chemical	-1	9495837
,	O	-1	9495837
the	O	-1	9495837
gamma@@	B-Chemical	D005680	9495837
-@@	I-Chemical	-1	9495837
amin@@	I-Chemical	-1	9495837
ob@@	I-Chemical	-1	9495837
ut@@	I-Chemical	-1	9495837
y@@	I-Chemical	-1	9495837
ric	I-Chemical	-1	9495837
acid@@	I-Chemical	-1	9495837
B	I-Chemical	-1	9495837
antagonist	O	-1	9495837
3-@@	B-Chemical	C066430	9495837
amino@@	I-Chemical	-1	9495837
prop@@	I-Chemical	-1	9495837
yl@@	I-Chemical	-1	9495837
-@@	I-Chemical	-1	9495837
di@@	I-Chemical	-1	9495837
eth@@	I-Chemical	-1	9495837
ox@@	I-Chemical	-1	9495837
y-@@	I-Chemical	-1	9495837
methyl@@	I-Chemical	-1	9495837
-@@	I-Chemical	-1	9495837
phosph@@	I-Chemical	-1	9495837
inic	I-Chemical	-1	9495837
acid	I-Chemical	-1	9495837
,	O	-1	9495837
the	O	-1	9495837
H@@	O	-1	9495837
3	O	-1	9495837
agon@@	O	-1	9495837
ist	O	-1	9495837
R@@	B-Chemical	C069357	9495837
-@@	I-Chemical	-1	9495837
(@@	I-Chemical	-1	9495837
alpha@@	I-Chemical	-1	9495837
)-@@	I-Chemical	-1	9495837
methyl@@	I-Chemical	-1	9495837
hist@@	I-Chemical	-1	9495837
amine	I-Chemical	-1	9495837
,	O	-1	9495837
the	O	-1	9495837
D2	O	-1	9495837
antagonist	O	-1	9495837
qu@@	B-Chemical	D019257	9495837
in@@	I-Chemical	-1	9495837
pi@@	I-Chemical	-1	9495837
role	I-Chemical	-1	9495837
,	O	-1	9495837
the	O	-1	9495837
5-@@	B-Chemical	D012701	9495837
hydrox@@	I-Chemical	-1	9495837
y@@	I-Chemical	-1	9495837
tr@@	I-Chemical	-1	9495837
y@@	I-Chemical	-1	9495837
pt@@	I-Chemical	-1	9495837
am@@	I-Chemical	-1	9495837
ine@@	I-Chemical	-1	9495837
4	I-Chemical	-1	9495837
antagonist	O	-1	9495837
2-@@	B-Chemical	C072790	9495837
meth@@	I-Chemical	-1	9495837
ox@@	I-Chemical	-1	9495837
y-@@	I-Chemical	-1	9495837
4-@@	I-Chemical	-1	9495837
amino@@	I-Chemical	-1	9495837
-@@	I-Chemical	-1	9495837
5-@@	I-Chemical	-1	9495837
ch@@	I-Chemical	-1	9495837
loro@@	I-Chemical	-1	9495837
b@@	I-Chemical	-1	9495837
enz@@	I-Chemical	-1	9495837
o@@	I-Chemical	-1	9495837
ic	I-Chemical	-1	9495837
acid	I-Chemical	-1	9495837
2-@@	I-Chemical	-1	9495837
(@@	I-Chemical	-1	9495837
di@@	I-Chemical	-1	9495837
eth@@	I-Chemical	-1	9495837
yl@@	I-Chemical	-1	9495837
amino@@	I-Chemical	-1	9495837
)@@	I-Chemical	-1	9495837
eth@@	I-Chemical	-1	9495837
yl	I-Chemical	-1	9495837
est@@	I-Chemical	-1	9495837
er	I-Chemical	-1	9495837
hydro@@	O	-1	9495837
chlor@@	O	-1	9495837
ide@@	O	-1	9495837
,	O	-1	9495837
the	O	-1	9495837
5-@@	B-Chemical	D012701	9495837
hydrox@@	I-Chemical	-1	9495837
y@@	I-Chemical	-1	9495837
tr@@	I-Chemical	-1	9495837
y@@	I-Chemical	-1	9495837
pt@@	I-Chemical	-1	9495837
amin@@	I-Chemical	-1	9495837
1@@	I-Chemical	-1	9495837
A	I-Chemical	-1	9495837
antagonist	O	-1	9495837
1-@@	B-Chemical	C058895	9495837
(2@@	I-Chemical	-1	9495837
-@@	I-Chemical	-1	9495837
meth@@	I-Chemical	-1	9495837
oxy@@	I-Chemical	-1	9495837
phenyl@@	I-Chemical	-1	9495837
)-@@	I-Chemical	-1	9495837
4-@@	I-Chemical	-1	9495837
[@@	I-Chemical	-1	9495837
4-@@	I-Chemical	-1	9495837
(2@@	I-Chemical	-1	9495837
-@@	I-Chemical	-1	9495837
ph@@	I-Chemical	-1	9495837
thal@@	I-Chemical	-1	9495837
im@@	I-Chemical	-1	9495837
id@@	I-Chemical	-1	9495837
o@@	I-Chemical	-1	9495837
)@@	I-Chemical	-1	9495837
but@@	I-Chemical	-1	9495837
yl@@	I-Chemical	-1	9495837
]@@	I-Chemical	-1	9495837
pi@@	I-Chemical	-1	9495837
per@@	I-Chemical	-1	9495837
az@@	I-Chemical	-1	9495837
ine	I-Chemical	-1	9495837
hydro@@	O	-1	9495837
brom@@	O	-1	9495837
ide	O	-1	9495837
and	O	-1	9495837
the	O	-1	9495837
poly@@	O	-1	9495837
amin@@	O	-1	9495837
es	O	-1	9495837
deple@@	O	-1	9495837
t@@	O	-1	9495837
or	O	-1	9495837
res@@	B-Chemical	D012110	9495837
er@@	I-Chemical	-1	9495837
pine	I-Chemical	-1	9495837
.	O	-1	9495837
B@@	O	-1	9495837
as@@	O	-1	9495837
ed	O	-1	9495837
on	O	-1	9495837
these	O	-1	9495837
dat@@	O	-1	9495837
a,	O	-1	9495837
it	O	-1	9495837
can	O	-1	9495837
be	O	-1	9495837
post@@	O	-1	9495837
ul@@	O	-1	9495837
ated	O	-1	9495837
that	O	-1	9495837
(@@	O	-1	9495837
+/-@@	O	-1	9495837
)@@	O	-1	9495837
-	O	-1	9495837
PG@@	B-Chemical	C087567	9495837
-@@	I-Chemical	-1	9495837
9	I-Chemical	-1	9495837
ex@@	O	-1	9495837
er@@	O	-1	9495837
ted	O	-1	9495837
an	O	-1	9495837
ant@@	O	-1	9495837
in@@	O	-1	9495837
ocicep@@	O	-1	9495837
tive	O	-1	9495837
effect	O	-1	9495837
mediated	O	-1	9495837
by	O	-1	9495837
a	O	-1	9495837
central	O	-1	9495837
potenti@@	O	-1	9495837
ation	O	-1	9495837
of	O	-1	9495837
cholinergic	O	-1	9495837
trans@@	O	-1	9495837
mis@@	O	-1	9495837
sion.	O	-1	9495837
(@@	O	-1	9495837
+/-@@	O	-1	9495837
)@@	O	-1	9495837
-	O	-1	9495837
PG@@	B-Chemical	C087567	9495837
-@@	I-Chemical	-1	9495837
9	I-Chemical	-1	9495837
(@@	O	-1	9495837
10-@@	O	-1	9495837
40	O	-1	9495837
mg	O	-1	9495837
kg@@	O	-1	9495837
-1	O	-1	9495837
i.p.@@	O	-1	9495837
)	O	-1	9495837
was	O	-1	9495837
able	O	-1	9495837
to	O	-1	9495837
prev@@	O	-1	9495837
ent	O	-1	9495837
am@@	B-Disease	D000647	9495837
ne@@	I-Disease	-1	9495837
sia	I-Disease	-1	9495837
induced	O	-1	9495837
by	O	-1	9495837
scopol@@	B-Chemical	D012601	9495837
amine	I-Chemical	-1	9495837
(@@	O	-1	9495837
1	O	-1	9495837
mg	O	-1	9495837
kg@@	O	-1	9495837
-1	O	-1	9495837
i.p.@@	O	-1	9495837
)	O	-1	9495837
and	O	-1	9495837
dic@@	B-Chemical	D004025	9495837
yc@@	I-Chemical	-1	9495837
lo@@	I-Chemical	-1	9495837
mine	I-Chemical	-1	9495837
(@@	O	-1	9495837
2	O	-1	9495837
mg	O	-1	9495837
kg@@	O	-1	9495837
-1	O	-1	9495837
i.p.@@	O	-1	9495837
)	O	-1	9495837
in	O	-1	9495837
the	O	-1	9495837
mouse	O	-1	9495837
p@@	O	-1	9495837
assi@@	O	-1	9495837
ve@@	O	-1	9495837
-@@	O	-1	9495837
avoid@@	O	-1	9495837
ance	O	-1	9495837
test@@	O	-1	9495837
.	O	-1	9495837
A@@	O	-1	9495837
ff@@	O	-1	9495837
in@@	O	-1	9495837
ity	O	-1	9495837
pro@@	O	-1	9495837
fi@@	O	-1	9495837
le@@	O	-1	9495837
s	O	-1	9495837
of	O	-1	9495837
(@@	O	-1	9495837
+/-@@	O	-1	9495837
)@@	O	-1	9495837
-	O	-1	9495837
PG@@	B-Chemical	C087567	9495837
-@@	I-Chemical	-1	9495837
9	I-Chemical	-1	9495837
for	O	-1	9495837
mus@@	O	-1	9495837
car@@	O	-1	9495837
inic	O	-1	9495837
receptor	O	-1	9495837
sub@@	O	-1	9495837
typ@@	O	-1	9495837
es,	O	-1	9495837
determined	O	-1	9495837
by	O	-1	9495837
functional	O	-1	9495837
studies	O	-1	9495837
(@@	O	-1	9495837
ra@@	O	-1	9495837
b@@	O	-1	9495837
b@@	O	-1	9495837
it	O	-1	9495837
v@@	O	-1	9495837
as	O	-1	9495837
def@@	O	-1	9495837
e@@	O	-1	9495837
ren@@	O	-1	9495837
s	O	-1	9495837
for	O	-1	9495837
M@@	O	-1	9495837
1,	O	-1	9495837
gu@@	O	-1	9495837
ine@@	O	-1	9495837
a	O	-1	9495837
pi@@	O	-1	9495837
g	O	-1	9495837
atri@@	O	-1	9495837
um	O	-1	9495837
for	O	-1	9495837
M@@	O	-1	9495837
2,	O	-1	9495837
gu@@	O	-1	9495837
ine@@	O	-1	9495837
a	O	-1	9495837
pi@@	O	-1	9495837
g	O	-1	9495837
i@@	O	-1	9495837
le@@	O	-1	9495837
um	O	-1	9495837
for	O	-1	9495837
M@@	O	-1	9495837
3	O	-1	9495837
and	O	-1	9495837
im@@	O	-1	9495837
mat@@	O	-1	9495837
ure	O	-1	9495837
gu@@	O	-1	9495837
ine@@	O	-1	9495837
a	O	-1	9495837
pi@@	O	-1	9495837
g	O	-1	9495837
u@@	O	-1	9495837
ter@@	O	-1	9495837
us	O	-1	9495837
for	O	-1	9495837
p@@	O	-1	9495837
ut@@	O	-1	9495837
ative	O	-1	9495837
M@@	O	-1	9495837
4@@	O	-1	9495837
),	O	-1	9495837
have	O	-1	9495837
shown	O	-1	9495837
an	O	-1	9495837
M@@	O	-1	9495837
4@@	O	-1	9495837
/@@	O	-1	9495837
M@@	O	-1	9495837
1	O	-1	9495837
sel@@	O	-1	9495837
ec@@	O	-1	9495837
tivity	O	-1	9495837
rati@@	O	-1	9495837
o	O	-1	9495837
of	O	-1	9495837
1@@	O	-1	9495837
0.@@	O	-1	9495837
2	O	-1	9495837
that	O	-1	9495837
might	O	-1	9495837
be	O	-1	9495837
respon@@	O	-1	9495837
sible	O	-1	9495837
for	O	-1	9495837
the	O	-1	9495837
ant@@	O	-1	9495837
in@@	O	-1	9495837
ocicep@@	O	-1	9495837
tion	O	-1	9495837
and	O	-1	9495837
the	O	-1	9495837
anti@@	O	-1	9495837
-	O	-1	9495837
am@@	B-Disease	D000647	9495837
ne@@	I-Disease	-1	9495837
sic	I-Disease	-1	9495837
effect	O	-1	9495837
induced	O	-1	9495837
by	O	-1	9495837
(@@	O	-1	9495837
+/-@@	O	-1	9495837
)@@	O	-1	9495837
-	O	-1	9495837
PG@@	B-Chemical	C087567	9495837
-@@	I-Chemical	-1	9495837
9	I-Chemical	-1	9495837
through	O	-1	9495837
an	O	-1	9495837
increase	O	-1	9495837
in	O	-1	9495837
acet@@	B-Chemical	D000109	9495837
ylcholine	I-Chemical	-1	9495837
extrac@@	O	-1	9495837
ell@@	O	-1	9495837
ular	O	-1	9495837
level@@	O	-1	9495837
s.	O	-1	9495837
In	O	-1	9495837
the	O	-1	9495837
ant@@	O	-1	9495837
in@@	O	-1	9495837
ocicep@@	O	-1	9495837
tive	O	-1	9495837
and	O	-1	9495837
anti@@	O	-1	9495837
am@@	O	-1	9495837
ne@@	O	-1	9495837
sic	O	-1	9495837
dose	O	-1	9495837
rang@@	O	-1	9495837
e,	O	-1	9495837
(@@	O	-1	9495837
+/-@@	O	-1	9495837
)@@	O	-1	9495837
-	O	-1	9495837
PG@@	B-Chemical	C087567	9495837
-@@	I-Chemical	-1	9495837
9	I-Chemical	-1	9495837
did	O	-1	9495837
not	O	-1	9495837
impa@@	O	-1	9495837
ir	O	-1	9495837
mouse	O	-1	9495837
perform@@	O	-1	9495837
ance	O	-1	9495837
evaluated	O	-1	9495837
by	O	-1	9495837
the	O	-1	9495837
ro@@	O	-1	9495837
t@@	O	-1	9495837
a@@	O	-1	9495837
-@@	O	-1	9495837
ro@@	O	-1	9495837
d	O	-1	9495837
test	O	-1	9495837
and	O	-1	9495837
An@@	O	-1	9495837
i@@	O	-1	9495837
me@@	O	-1	9495837
x	O	-1	9495837
ap@@	O	-1	9495837
par@@	O	-1	9495837
at@@	O	-1	9495837
us.	O	-1	9495837

H@@	O	-1	1468485
y@@	O	-1	1468485
per@@	O	-1	1468485
bar@@	O	-1	1468485
ic	O	-1	1468485
oxy@@	B-Chemical	D010100	1468485
gen	I-Chemical	-1	1468485
therapy	O	-1	1468485
for	O	-1	1468485
control	O	-1	1468485
of	O	-1	1468485
intrac@@	O	-1	1468485
t@@	O	-1	1468485
able	O	-1	1468485
cyclophosph@@	B-Chemical	D003520	1468485
amide	I-Chemical	-1	1468485
-induced	O	-1	1468485
hemorrh@@	B-Disease	D006470	1468485
ag@@	I-Disease	-1	1468485
ic	I-Disease	-1	1468485
cys@@	I-Disease	-1	1468485
ti@@	I-Disease	-1	1468485
tis	I-Disease	-1	1468485
hemorrh@@	B-Disease	D003556	1468485
ag@@	I-Disease	-1	1468485
ic	I-Disease	-1	1468485
cys@@	I-Disease	-1	1468485
ti@@	I-Disease	-1	1468485
tis	I-Disease	-1	1468485
.	O	-1	1468485
We	O	-1	1468485
report	O	-1	1468485
a	O	-1	1468485
case	O	-1	1468485
of	O	-1	1468485
intrac@@	O	-1	1468485
t@@	O	-1	1468485
able	O	-1	1468485
hemorrh@@	B-Disease	D006470	1468485
ag@@	I-Disease	-1	1468485
ic	I-Disease	-1	1468485
cys@@	I-Disease	-1	1468485
ti@@	I-Disease	-1	1468485
tis	I-Disease	-1	1468485
hemorrh@@	B-Disease	D003556	1468485
ag@@	I-Disease	-1	1468485
ic	I-Disease	-1	1468485
cys@@	I-Disease	-1	1468485
ti@@	I-Disease	-1	1468485
tis	I-Disease	-1	1468485
due	O	-1	1468485
to	O	-1	1468485
cyclophosph@@	B-Chemical	D003520	1468485
amide	I-Chemical	-1	1468485
therapy	O	-1	1468485
for	O	-1	1468485
W@@	B-Disease	D014890	1468485
e@@	I-Disease	-1	1468485
gener@@	I-Disease	-1	1468485
's	I-Disease	-1	1468485
gran@@	I-Disease	-1	1468485
ulo@@	I-Disease	-1	1468485
mat@@	I-Disease	-1	1468485
o@@	I-Disease	-1	1468485
sis	I-Disease	-1	1468485
.	O	-1	1468485
Con@@	O	-1	1468485
ser@@	O	-1	1468485
v@@	O	-1	1468485
ative	O	-1	1468485
treatment,	O	-1	1468485
including	O	-1	1468485
bladder	O	-1	1468485
ir@@	O	-1	1468485
rig@@	O	-1	1468485
ation	O	-1	1468485
with	O	-1	1468485
physi@@	O	-1	1468485
ological	O	-1	1468485
saline	O	-1	1468485
and	O	-1	1468485
insti@@	O	-1	1468485
ll@@	O	-1	1468485
ation	O	-1	1468485
of	O	-1	1468485
pro@@	B-Chemical	D015237	1468485
st@@	I-Chemical	-1	1468485
ag@@	I-Chemical	-1	1468485
l@@	I-Chemical	-1	1468485
and@@	I-Chemical	-1	1468485
in	I-Chemical	-1	1468485
F@@	I-Chemical	-1	1468485
2	I-Chemical	-1	1468485
al@@	I-Chemical	-1	1468485
ph@@	I-Chemical	-1	1468485
a	I-Chemical	-1	1468485
,	O	-1	1468485
fail@@	O	-1	1468485
ed	O	-1	1468485
to	O	-1	1468485
tot@@	O	-1	1468485
ally	O	-1	1468485
control	O	-1	1468485
hemorrh@@	B-Disease	D006470	1468485
age	I-Disease	-1	1468485
.	O	-1	1468485
We	O	-1	1468485
then	O	-1	1468485
used	O	-1	1468485
hyper@@	O	-1	1468485
bar@@	O	-1	1468485
ic	O	-1	1468485
oxy@@	B-Chemical	D010100	1468485
gen	I-Chemical	-1	1468485
at	O	-1	1468485
an	O	-1	1468485
abs@@	O	-1	1468485
ol@@	O	-1	1468485
ute	O	-1	1468485
pressure	O	-1	1468485
of	O	-1	1468485
2	O	-1	1468485
at@@	O	-1	1468485
m@@	O	-1	1468485
,	O	-1	1468485
5	O	-1	1468485
days	O	-1	1468485
a	O	-1	1468485
week	O	-1	1468485
for	O	-1	1468485
8	O	-1	1468485
con@@	O	-1	1468485
sec@@	O	-1	1468485
utive	O	-1	1468485
week@@	O	-1	1468485
s.	O	-1	1468485
The	O	-1	1468485
ble@@	B-Disease	D006470	1468485
ed@@	I-Disease	-1	1468485
ing	I-Disease	-1	1468485
ce@@	O	-1	1468485
as@@	O	-1	1468485
ed	O	-1	1468485
complete@@	O	-1	1468485
ly	O	-1	1468485
by	O	-1	1468485
the	O	-1	1468485
end	O	-1	1468485
of	O	-1	1468485
treatment	O	-1	1468485
and	O	-1	1468485
the	O	-1	1468485
patient	O	-1	1468485
remained	O	-1	1468485
free	O	-1	1468485
of	O	-1	1468485
hemat@@	B-Disease	D006417	1468485
uria	I-Disease	-1	1468485
the@@	O	-1	1468485
re@@	O	-1	1468485
af@@	O	-1	1468485
ter@@	O	-1	1468485
.	O	-1	1468485
No	O	-1	1468485
side	O	-1	1468485
effect	O	-1	1468485
was	O	-1	1468485
not@@	O	-1	1468485
ed	O	-1	1468485
during	O	-1	1468485
the	O	-1	1468485
course	O	-1	1468485
of	O	-1	1468485
therapy.	O	-1	1468485
In	O	-1	1468485
f@@	O	-1	1468485
ut@@	O	-1	1468485
ure,	O	-1	1468485
this	O	-1	1468485
form	O	-1	1468485
of	O	-1	1468485
therapy	O	-1	1468485
can	O	-1	1468485
o@@	O	-1	1468485
ff@@	O	-1	1468485
er	O	-1	1468485
a	O	-1	1468485
saf@@	O	-1	1468485
e	O	-1	1468485
al@@	O	-1	1468485
tern@@	O	-1	1468485
ative	O	-1	1468485
in	O	-1	1468485
the	O	-1	1468485
treatment	O	-1	1468485
of	O	-1	1468485
cyclophosph@@	B-Chemical	D003520	1468485
amide	I-Chemical	-1	1468485
-induced	O	-1	1468485
hemorrh@@	B-Disease	D006470	1468485
ag@@	I-Disease	-1	1468485
ic	I-Disease	-1	1468485
cys@@	I-Disease	-1	1468485
ti@@	I-Disease	-1	1468485
tis	I-Disease	-1	1468485
hemorrh@@	B-Disease	D003556	1468485
ag@@	I-Disease	-1	1468485
ic	I-Disease	-1	1468485
cys@@	I-Disease	-1	1468485
ti@@	I-Disease	-1	1468485
tis	I-Disease	-1	1468485
.	O	-1	1468485

F@@	O	-1	1009330
urther	O	-1	1009330
studies	O	-1	1009330
on	O	-1	1009330
effects	O	-1	1009330
of	O	-1	1009330
ir@@	O	-1	1009330
rig@@	O	-1	1009330
ation	O	-1	1009330
sol@@	O	-1	1009330
u@@	O	-1	1009330
tions	O	-1	1009330
on	O	-1	1009330
rat	O	-1	1009330
blad@@	O	-1	1009330
der@@	O	-1	1009330
s.	O	-1	1009330
F@@	O	-1	1009330
urther	O	-1	1009330
studies	O	-1	1009330
on	O	-1	1009330
the	O	-1	1009330
effects	O	-1	1009330
of	O	-1	1009330
cer@@	O	-1	1009330
t@@	O	-1	1009330
ain	O	-1	1009330
ir@@	O	-1	1009330
rig@@	O	-1	1009330
ating	O	-1	1009330
flu@@	O	-1	1009330
id@@	O	-1	1009330
s	O	-1	1009330
on	O	-1	1009330
the	O	-1	1009330
rat	O	-1	1009330
bladder	O	-1	1009330
for	O	-1	1009330
1@@	O	-1	1009330
8	O	-1	1009330
hours	O	-1	1009330
are	O	-1	1009330
repor@@	O	-1	1009330
ted.	O	-1	1009330
The	O	-1	1009330
results	O	-1	1009330
have	O	-1	1009330
shown	O	-1	1009330
that	O	-1	1009330
the	O	-1	1009330
de@@	O	-1	1009330
gra@@	O	-1	1009330
d@@	O	-1	1009330
ation	O	-1	1009330
produc@@	O	-1	1009330
t	O	-1	1009330
p@@	B-Chemical	C004658	1009330
-@@	I-Chemical	-1	1009330
ch@@	I-Chemical	-1	1009330
o@@	I-Chemical	-1	1009330
loro@@	I-Chemical	-1	1009330
an@@	I-Chemical	-1	1009330
il@@	I-Chemical	-1	1009330
ine	I-Chemical	-1	1009330
is	O	-1	1009330
not	O	-1	1009330
a	O	-1	1009330
significant	O	-1	1009330
factor	O	-1	1009330
in	O	-1	1009330
chlor@@	B-Chemical	C010882	1009330
he@@	I-Chemical	-1	1009330
x@@	I-Chemical	-1	1009330
id@@	I-Chemical	-1	1009330
ine-@@	I-Chemical	-1	1009330
di@@	I-Chemical	-1	1009330
gl@@	I-Chemical	-1	1009330
uc@@	I-Chemical	-1	1009330
on@@	I-Chemical	-1	1009330
ate	I-Chemical	-1	1009330
associated	O	-1	1009330
ero@@	O	-1	1009330
sive	O	-1	1009330
cys@@	B-Disease	D003556	1009330
ti@@	I-Disease	-1	1009330
tis	I-Disease	-1	1009330
.	O	-1	1009330
A	O	-1	1009330
high	O	-1	1009330
perc@@	O	-1	1009330
ent@@	O	-1	1009330
age	O	-1	1009330
of	O	-1	1009330
k@@	B-Chemical	D007612	1009330
an@@	I-Chemical	-1	1009330
am@@	I-Chemical	-1	1009330
ycin	I-Chemical	-1	1009330
-	O	-1	1009330
co@@	B-Chemical	D003091	1009330
l@@	I-Chemical	-1	1009330
is@@	I-Chemical	-1	1009330
tin	I-Chemical	-1	1009330
and	O	-1	1009330
po@@	B-Chemical	D011206	1009330
vid@@	I-Chemical	-1	1009330
on@@	I-Chemical	-1	1009330
e-@@	I-Chemical	-1	1009330
iod@@	I-Chemical	-1	1009330
ine	I-Chemical	-1	1009330
ir@@	O	-1	1009330
rig@@	O	-1	1009330
ations	O	-1	1009330
were	O	-1	1009330
associated	O	-1	1009330
with	O	-1	1009330
ero@@	O	-1	1009330
sive	O	-1	1009330
cys@@	B-Disease	D003556	1009330
ti@@	I-Disease	-1	1009330
tis	I-Disease	-1	1009330
and	O	-1	1009330
suggested	O	-1	1009330
a	O	-1	1009330
possible	O	-1	1009330
complication	O	-1	1009330
with	O	-1	1009330
human	O	-1	1009330
us@@	O	-1	1009330
age.	O	-1	1009330
P@@	B-Chemical	C005253	1009330
ic@@	I-Chemical	-1	1009330
lo@@	I-Chemical	-1	1009330
x@@	I-Chemical	-1	1009330
y@@	I-Chemical	-1	1009330
d@@	I-Chemical	-1	1009330
ine	I-Chemical	-1	1009330
ir@@	O	-1	1009330
rig@@	O	-1	1009330
ations	O	-1	1009330
appe@@	O	-1	1009330
a@@	O	-1	1009330
red	O	-1	1009330
to	O	-1	1009330
have	O	-1	1009330
a	O	-1	1009330
lower	O	-1	1009330
incidence	O	-1	1009330
of	O	-1	1009330
ero@@	O	-1	1009330
sive	O	-1	1009330
cys@@	B-Disease	D003556	1009330
ti@@	I-Disease	-1	1009330
tis	I-Disease	-1	1009330
but	O	-1	1009330
further	O	-1	1009330
studies	O	-1	1009330
wo@@	O	-1	1009330
uld	O	-1	1009330
have	O	-1	1009330
to	O	-1	1009330
be	O	-1	1009330
performed	O	-1	1009330
before	O	-1	1009330
it	O	-1	1009330
could	O	-1	1009330
be	O	-1	1009330
recomm@@	O	-1	1009330
en@@	O	-1	1009330
ded	O	-1	1009330
for	O	-1	1009330
use	O	-1	1009330
in	O	-1	1009330
uro@@	O	-1	1009330
log@@	O	-1	1009330
ical	O	-1	1009330
proce@@	O	-1	1009330
du@@	O	-1	1009330
res@@	O	-1	1009330
.	O	-1	1009330

Clin@@	O	-1	347884
ical	O	-1	347884
experienc@@	O	-1	347884
es	O	-1	347884
in	O	-1	347884
an	O	-1	347884
op@@	O	-1	347884
en	O	-1	347884
and	O	-1	347884
a	O	-1	347884
double-bl@@	O	-1	347884
ind	O	-1	347884
tri@@	O	-1	347884
al.	O	-1	347884
A	O	-1	347884
total	O	-1	347884
of	O	-1	347884
si@@	O	-1	347884
x@@	O	-1	347884
t@@	O	-1	347884
y	O	-1	347884
patients	O	-1	347884
were	O	-1	347884
tr@@	O	-1	347884
ated	O	-1	347884
with	O	-1	347884
brom@@	B-Chemical	C006820	347884
perid@@	I-Chemical	-1	347884
ol	I-Chemical	-1	347884
first	O	-1	347884
in	O	-1	347884
op@@	O	-1	347884
en	O	-1	347884
condi@@	O	-1	347884
tions	O	-1	347884
(2@@	O	-1	347884
0	O	-1	347884
patient@@	O	-1	347884
s),	O	-1	347884
then	O	-1	347884
on	O	-1	347884
a	O	-1	347884
dou@@	O	-1	347884
ble	O	-1	347884
bl@@	O	-1	347884
ind	O	-1	347884
b@@	O	-1	347884
asis	O	-1	347884
(@@	O	-1	347884
40	O	-1	347884
patient@@	O	-1	347884
s)	O	-1	347884
with	O	-1	347884
haloperidol	B-Chemical	D006220	347884
as	O	-1	347884
the	O	-1	347884
ref@@	O	-1	347884
e@@	O	-1	347884
rence	O	-1	347884
subst@@	O	-1	347884
ance@@	O	-1	347884
.	O	-1	347884
The	O	-1	347884
op@@	O	-1	347884
en	O	-1	347884
study	O	-1	347884
l@@	O	-1	347884
ast@@	O	-1	347884
ed	O	-1	347884
for	O	-1	347884
four	O	-1	347884
week@@	O	-1	347884
s;	O	-1	347884
the	O	-1	347884
drug	O	-1	347884
was	O	-1	347884
administr@@	O	-1	347884
ated	O	-1	347884
in	O	-1	347884
the	O	-1	347884
form	O	-1	347884
of	O	-1	347884
1	O	-1	347884
mg	O	-1	347884
t@@	O	-1	347884
able@@	O	-1	347884
t@@	O	-1	347884
s.	O	-1	347884
The	O	-1	347884
daily	O	-1	347884
dose	O	-1	347884
(@@	O	-1	347884
initial	O	-1	347884
dose@@	O	-1	347884
:	O	-1	347884
1	O	-1	347884
mg@@	O	-1	347884
;	O	-1	347884
mean	O	-1	347884
dose	O	-1	347884
at	O	-1	347884
the	O	-1	347884
end	O	-1	347884
of	O	-1	347884
the	O	-1	347884
tri@@	O	-1	347884
al@@	O	-1	347884
:	O	-1	347884
4.@@	O	-1	347884
4@@	O	-1	347884
7	O	-1	347884
mg@@	O	-1	347884
)	O	-1	347884
was	O	-1	347884
al@@	O	-1	347884
w@@	O	-1	347884
ays	O	-1	347884
administered	O	-1	347884
in	O	-1	347884
one	O	-1	347884
single	O	-1	347884
dose.	O	-1	347884
N@@	O	-1	347884
ine@@	O	-1	347884
te@@	O	-1	347884
en	O	-1	347884
patients	O	-1	347884
f@@	O	-1	347884
in@@	O	-1	347884
ished	O	-1	347884
the	O	-1	347884
tri@@	O	-1	347884
al,	O	-1	347884
and	O	-1	347884
in	O	-1	347884
1@@	O	-1	347884
8	O	-1	347884
cases	O	-1	347884
the	O	-1	347884
therapeutic	O	-1	347884
result	O	-1	347884
was	O	-1	347884
considered	O	-1	347884
very	O	-1	347884
go@@	O	-1	347884
od	O	-1	347884
to	O	-1	347884
go@@	O	-1	347884
o@@	O	-1	347884
d.	O	-1	347884
These	O	-1	347884
results	O	-1	347884
were	O	-1	347884
con@@	O	-1	347884
fir@@	O	-1	347884
m@@	O	-1	347884
ed	O	-1	347884
by	O	-1	347884
statis@@	O	-1	347884
tical	O	-1	347884
analy@@	O	-1	347884
sis.	O	-1	347884
N@@	O	-1	347884
ine	O	-1	347884
patients	O	-1	347884
ex@@	O	-1	347884
hib@@	O	-1	347884
ited	O	-1	347884
mil@@	O	-1	347884
d	O	-1	347884
to	O	-1	347884
moder@@	O	-1	347884
ate	O	-1	347884
ext@@	B-Disease	D001480	347884
ra@@	I-Disease	-1	347884
py@@	I-Disease	-1	347884
ram@@	I-Disease	-1	347884
idal	I-Disease	-1	347884
concomit@@	I-Disease	-1	347884
ant	I-Disease	-1	347884
symptoms	I-Disease	-1	347884
;	O	-1	347884
no	O	-1	347884
other	O	-1	347884
side	O	-1	347884
effects	O	-1	347884
were	O	-1	347884
obser@@	O	-1	347884
ved.	O	-1	347884
The	O	-1	347884
results	O	-1	347884
of	O	-1	347884
det@@	O	-1	347884
ail@@	O	-1	347884
ed	O	-1	347884
labor@@	O	-1	347884
atory	O	-1	347884
tests	O	-1	347884
and	O	-1	347884
evalu@@	O	-1	347884
ations	O	-1	347884
of	O	-1	347884
various	O	-1	347884
qu@@	O	-1	347884
anti@@	O	-1	347884
t@@	O	-1	347884
ative	O	-1	347884
and	O	-1	347884
qu@@	O	-1	347884
al@@	O	-1	347884
it@@	O	-1	347884
ative	O	-1	347884
toler@@	O	-1	347884
ability	O	-1	347884
par@@	O	-1	347884
ame@@	O	-1	347884
ters	O	-1	347884
were	O	-1	347884
not	O	-1	347884
indic@@	O	-1	347884
ative	O	-1	347884
of	O	-1	347884
toxic	O	-1	347884
effects.	O	-1	347884
In	O	-1	347884
the	O	-1	347884
dou@@	O	-1	347884
ble	O	-1	347884
bl@@	O	-1	347884
ind	O	-1	347884
study	O	-1	347884
with	O	-1	347884
haloperidol	B-Chemical	D006220	347884
,	O	-1	347884
both	O	-1	347884
subst@@	O	-1	347884
anc@@	O	-1	347884
es	O	-1	347884
were	O	-1	347884
found	O	-1	347884
to	O	-1	347884
be	O	-1	347884
high@@	O	-1	347884
ly	O	-1	347884
effective	O	-1	347884
in	O	-1	347884
the	O	-1	347884
treatment	O	-1	347884
of	O	-1	347884
psycho@@	B-Disease	D019967	347884
tic	I-Disease	-1	347884
syndrom@@	I-Disease	-1	347884
es	I-Disease	-1	347884
be@@	I-Disease	-1	347884
long@@	I-Disease	-1	347884
ing	I-Disease	-1	347884
pre@@	I-Disease	-1	347884
domin@@	I-Disease	-1	347884
ant@@	I-Disease	-1	347884
ly	I-Disease	-1	347884
to	I-Disease	-1	347884
the	I-Disease	-1	347884
sch@@	I-Disease	-1	347884
iz@@	I-Disease	-1	347884
oph@@	I-Disease	-1	347884
ren@@	I-Disease	-1	347884
ia	I-Disease	-1	347884
group	I-Disease	-1	347884
.	O	-1	347884
C@@	O	-1	347884
er@@	O	-1	347884
t@@	O	-1	347884
ain	O	-1	347884
cl@@	O	-1	347884
u@@	O	-1	347884
es,	O	-1	347884
including	O	-1	347884
the	O	-1	347884
onset	O	-1	347884
of	O	-1	347884
ac@@	O	-1	347884
tion,	O	-1	347884
se@@	O	-1	347884
em	O	-1	347884
to	O	-1	347884
be	O	-1	347884
indic@@	O	-1	347884
ative	O	-1	347884
of	O	-1	347884
the	O	-1	347884
su@@	O	-1	347884
peri@@	O	-1	347884
or@@	O	-1	347884
ity	O	-1	347884
of	O	-1	347884
brom@@	B-Chemical	C006820	347884
perid@@	I-Chemical	-1	347884
ol	I-Chemical	-1	347884
.	O	-1	347884
No	O	-1	347884
differences	O	-1	347884
were	O	-1	347884
observed	O	-1	347884
with	O	-1	347884
resp@@	O	-1	347884
ect	O	-1	347884
to	O	-1	347884
side	O	-1	347884
effects	O	-1	347884
and	O	-1	347884
gener@@	O	-1	347884
al	O	-1	347884
toler@@	O	-1	347884
abil@@	O	-1	347884
ity.	O	-1	347884

C@@	B-Chemical	D003474	20667451
ur@@	I-Chemical	-1	20667451
cum@@	I-Chemical	-1	20667451
in	I-Chemical	-1	20667451
ame@@	O	-1	20667451
li@@	O	-1	20667451
or@@	O	-1	20667451
ates	O	-1	20667451
cognitive	B-Disease	D003072	20667451
dysfunction	I-Disease	-1	20667451
and	O	-1	20667451
oxid@@	O	-1	20667451
ative	O	-1	20667451
damage	O	-1	20667451
in	O	-1	20667451
phenobarbit@@	B-Chemical	D010634	20667451
one	I-Chemical	-1	20667451
and	O	-1	20667451
carbamazepine	B-Chemical	D002220	20667451
administered	O	-1	20667451
rats.	O	-1	20667451
The	O	-1	20667451
anti@@	O	-1	20667451
epileptic	O	-1	20667451
drug@@	O	-1	20667451
s,	O	-1	20667451
phenobarbit@@	B-Chemical	D010634	20667451
one	I-Chemical	-1	20667451
and	O	-1	20667451
carbamazepine	B-Chemical	D002220	20667451
are	O	-1	20667451
well	O	-1	20667451
known	O	-1	20667451
to	O	-1	20667451
cause	O	-1	20667451
cognitive	B-Disease	D003072	20667451
impair@@	I-Disease	-1	20667451
ment	I-Disease	-1	20667451
on	O	-1	20667451
chronic	O	-1	20667451
use.	O	-1	20667451
The	O	-1	20667451
increase	O	-1	20667451
in	O	-1	20667451
free	O	-1	20667451
ra@@	O	-1	20667451
d@@	O	-1	20667451
ical	O	-1	20667451
generation	O	-1	20667451
has	O	-1	20667451
been	O	-1	20667451
implic@@	O	-1	20667451
ated	O	-1	20667451
as	O	-1	20667451
one	O	-1	20667451
of	O	-1	20667451
the	O	-1	20667451
important	O	-1	20667451
mechanisms	O	-1	20667451
of	O	-1	20667451
cognitive	B-Disease	D003072	20667451
impair@@	I-Disease	-1	20667451
ment	I-Disease	-1	20667451
by	O	-1	20667451
anti@@	O	-1	20667451
epileptic	O	-1	20667451
drug@@	O	-1	20667451
s.	O	-1	20667451
C@@	B-Chemical	D003474	20667451
ur@@	I-Chemical	-1	20667451
cum@@	I-Chemical	-1	20667451
in	I-Chemical	-1	20667451
has	O	-1	20667451
shown	O	-1	20667451
anti@@	O	-1	20667451
oxid@@	O	-1	20667451
ant@@	O	-1	20667451
,	O	-1	20667451
anti@@	O	-1	20667451
-@@	O	-1	20667451
inflam@@	O	-1	20667451
mat@@	O	-1	20667451
ory	O	-1	20667451
and	O	-1	20667451
neuro@@	O	-1	20667451
-@@	O	-1	20667451
protective	O	-1	20667451
pro@@	O	-1	20667451
per@@	O	-1	20667451
ti@@	O	-1	20667451
es.	O	-1	20667451
The@@	O	-1	20667451
refore,	O	-1	20667451
the	O	-1	20667451
present	O	-1	20667451
study	O	-1	20667451
was	O	-1	20667451
car@@	O	-1	20667451
ri@@	O	-1	20667451
ed	O	-1	20667451
out	O	-1	20667451
to	O	-1	20667451
investigate	O	-1	20667451
the	O	-1	20667451
effect	O	-1	20667451
of	O	-1	20667451
chronic	O	-1	20667451
cur@@	B-Chemical	D003474	20667451
cum@@	I-Chemical	-1	20667451
in	I-Chemical	-1	20667451
administration	O	-1	20667451
on	O	-1	20667451
phenobarbit@@	B-Chemical	D010634	20667451
one	I-Chemical	-1	20667451
-	O	-1	20667451
and	O	-1	20667451
carbamazepine	B-Chemical	D002220	20667451
-induced	O	-1	20667451
cognitive	B-Disease	D003072	20667451
impair@@	I-Disease	-1	20667451
ment	I-Disease	-1	20667451
and	O	-1	20667451
oxid@@	O	-1	20667451
ative	O	-1	20667451
stres@@	O	-1	20667451
s	O	-1	20667451
in	O	-1	20667451
rats.	O	-1	20667451
Ph@@	O	-1	20667451
armac@@	O	-1	20667451
o@@	O	-1	20667451
kine@@	O	-1	20667451
tic	O	-1	20667451
inter@@	O	-1	20667451
ac@@	O	-1	20667451
tions	O	-1	20667451
of	O	-1	20667451
cur@@	B-Chemical	D003474	20667451
cum@@	I-Chemical	-1	20667451
in	I-Chemical	-1	20667451
with	O	-1	20667451
phenobarbit@@	B-Chemical	D010634	20667451
one	I-Chemical	-1	20667451
and	O	-1	20667451
carbamazepine	B-Chemical	D002220	20667451
were	O	-1	20667451
also	O	-1	20667451
studi@@	O	-1	20667451
ed.	O	-1	20667451
V@@	O	-1	20667451
e@@	O	-1	20667451
h@@	O	-1	20667451
ic@@	O	-1	20667451
le@@	O	-1	20667451
/@@	O	-1	20667451
drugs	O	-1	20667451
were	O	-1	20667451
administered	O	-1	20667451
daily	O	-1	20667451
for	O	-1	20667451
2@@	O	-1	20667451
1@@	O	-1	20667451
days	O	-1	20667451
to	O	-1	20667451
male	O	-1	20667451
Wistar	O	-1	20667451
rats.	O	-1	20667451
P@@	O	-1	20667451
as@@	O	-1	20667451
sive	O	-1	20667451
avoid@@	O	-1	20667451
ance	O	-1	20667451
par@@	O	-1	20667451
a@@	O	-1	20667451
di@@	O	-1	20667451
g@@	O	-1	20667451
m	O	-1	20667451
and	O	-1	20667451
elevated	O	-1	20667451
plus	O	-1	20667451
ma@@	O	-1	20667451
ze	O	-1	20667451
test	O	-1	20667451
were	O	-1	20667451
used	O	-1	20667451
to	O	-1	20667451
ass@@	O	-1	20667451
ess	O	-1	20667451
cognitive	O	-1	20667451
func@@	O	-1	20667451
tion.	O	-1	20667451
A@@	O	-1	20667451
t	O	-1	20667451
the	O	-1	20667451
end	O	-1	20667451
of	O	-1	20667451
study	O	-1	20667451
perio@@	O	-1	20667451
d,	O	-1	20667451
serum	O	-1	20667451
phenobarbit@@	B-Chemical	D010634	20667451
one	I-Chemical	-1	20667451
and	O	-1	20667451
carbamazepine	B-Chemical	D002220	20667451
,	O	-1	20667451
wh@@	O	-1	20667451
ole	O	-1	20667451
brain	O	-1	20667451
mal@@	B-Chemical	D008315	20667451
on@@	I-Chemical	-1	20667451
di@@	I-Chemical	-1	20667451
al@@	I-Chemical	-1	20667451
de@@	I-Chemical	-1	20667451
hy@@	I-Chemical	-1	20667451
de	I-Chemical	-1	20667451
and	O	-1	20667451
reduced	O	-1	20667451
glut@@	B-Chemical	D005978	20667451
athi@@	I-Chemical	-1	20667451
one	I-Chemical	-1	20667451
levels	O	-1	20667451
were	O	-1	20667451
estim@@	O	-1	20667451
ated.	O	-1	20667451
The	O	-1	20667451
administration	O	-1	20667451
of	O	-1	20667451
phenobarbit@@	B-Chemical	D010634	20667451
one	I-Chemical	-1	20667451
and	O	-1	20667451
carbamazepine	B-Chemical	D002220	20667451
for	O	-1	20667451
2@@	O	-1	20667451
1@@	O	-1	20667451
days	O	-1	20667451
caused	O	-1	20667451
a	O	-1	20667451
significant	O	-1	20667451
impair@@	B-Disease	D003072	20667451
ment	I-Disease	-1	20667451
of	I-Disease	-1	20667451
lear@@	I-Disease	-1	20667451
ning	I-Disease	-1	20667451
and	I-Disease	-1	20667451
memory	I-Disease	-1	20667451
as	O	-1	20667451
well	O	-1	20667451
as	O	-1	20667451
an	O	-1	20667451
increased	O	-1	20667451
oxid@@	O	-1	20667451
ative	O	-1	20667451
stres@@	O	-1	20667451
s.	O	-1	20667451
Con@@	O	-1	20667451
comit@@	O	-1	20667451
ant	O	-1	20667451
cur@@	B-Chemical	D003474	20667451
cum@@	I-Chemical	-1	20667451
in	I-Chemical	-1	20667451
administration	O	-1	20667451
prevent@@	O	-1	20667451
ed	O	-1	20667451
the	O	-1	20667451
cognitive	B-Disease	D003072	20667451
impair@@	I-Disease	-1	20667451
ment	I-Disease	-1	20667451
and	O	-1	20667451
decreased	O	-1	20667451
the	O	-1	20667451
increased	O	-1	20667451
oxid@@	O	-1	20667451
ative	O	-1	20667451
stres@@	O	-1	20667451
s	O	-1	20667451
induced	O	-1	20667451
by	O	-1	20667451
these	O	-1	20667451
anti@@	O	-1	20667451
epileptic	O	-1	20667451
drug@@	O	-1	20667451
s.	O	-1	20667451
C@@	B-Chemical	D003474	20667451
ur@@	I-Chemical	-1	20667451
cum@@	I-Chemical	-1	20667451
in	I-Chemical	-1	20667451
co-@@	O	-1	20667451
administration	O	-1	20667451
did	O	-1	20667451
not	O	-1	20667451
cause	O	-1	20667451
any	O	-1	20667451
significant	O	-1	20667451
al@@	O	-1	20667451
ter@@	O	-1	20667451
ation	O	-1	20667451
in	O	-1	20667451
the	O	-1	20667451
serum	O	-1	20667451
concentrations	O	-1	20667451
of	O	-1	20667451
both	O	-1	20667451
phenobarbit@@	B-Chemical	D010634	20667451
one	I-Chemical	-1	20667451
as	O	-1	20667451
well	O	-1	20667451
as	O	-1	20667451
carbamazepine	B-Chemical	D002220	20667451
.	O	-1	20667451
These	O	-1	20667451
results	O	-1	20667451
show	O	-1	20667451
that	O	-1	20667451
cur@@	B-Chemical	D003474	20667451
cum@@	I-Chemical	-1	20667451
in	I-Chemical	-1	20667451
has	O	-1	20667451
ben@@	O	-1	20667451
e@@	O	-1	20667451
fic@@	O	-1	20667451
ial	O	-1	20667451
effect	O	-1	20667451
in	O	-1	20667451
m@@	O	-1	20667451
iti@@	O	-1	20667451
g@@	O	-1	20667451
ating	O	-1	20667451
the	O	-1	20667451
deter@@	B-Disease	D003072	20667451
i@@	I-Disease	-1	20667451
or@@	I-Disease	-1	20667451
ation	I-Disease	-1	20667451
of	I-Disease	-1	20667451
cognitive	I-Disease	-1	20667451
func@@	I-Disease	-1	20667451
tions	I-Disease	-1	20667451
and	O	-1	20667451
oxid@@	O	-1	20667451
ative	O	-1	20667451
damage	O	-1	20667451
in	O	-1	20667451
rats	O	-1	20667451
treated	O	-1	20667451
with	O	-1	20667451
phenobarbit@@	B-Chemical	D010634	20667451
one	I-Chemical	-1	20667451
and	O	-1	20667451
carbamazepine	B-Chemical	D002220	20667451
without	O	-1	20667451
significantly	O	-1	20667451
al@@	O	-1	20667451
ter@@	O	-1	20667451
ing	O	-1	20667451
their	O	-1	20667451
serum	O	-1	20667451
concentr@@	O	-1	20667451
ations.	O	-1	20667451
The	O	-1	20667451
findings	O	-1	20667451
suggest	O	-1	20667451
that	O	-1	20667451
cur@@	B-Chemical	D003474	20667451
cum@@	I-Chemical	-1	20667451
in	I-Chemical	-1	20667451
can	O	-1	20667451
be	O	-1	20667451
considered	O	-1	20667451
as	O	-1	20667451
a	O	-1	20667451
potential	O	-1	20667451
saf@@	O	-1	20667451
e	O	-1	20667451
and	O	-1	20667451
effective	O	-1	20667451
adj@@	O	-1	20667451
u@@	O	-1	20667451
v@@	O	-1	20667451
ant	O	-1	20667451
to	O	-1	20667451
phenobarbit@@	B-Chemical	D010634	20667451
one	I-Chemical	-1	20667451
and	O	-1	20667451
carbamazepine	B-Chemical	D002220	20667451
therapy	O	-1	20667451
in	O	-1	20667451
prevent@@	O	-1	20667451
ing	O	-1	20667451
cognitive	B-Disease	D003072	20667451
impair@@	I-Disease	-1	20667451
ment	I-Disease	-1	20667451
associated	O	-1	20667451
with	O	-1	20667451
these	O	-1	20667451
drug@@	O	-1	20667451
s.	O	-1	20667451

P@@	B-Chemical	C020972	19767176
y@@	I-Chemical	-1	19767176
r@@	I-Chemical	-1	19767176
ro@@	I-Chemical	-1	19767176
l@@	I-Chemical	-1	19767176
idine	I-Chemical	-1	19767176
di@@	I-Chemical	-1	19767176
thi@@	I-Chemical	-1	19767176
oc@@	I-Chemical	-1	19767176
arb@@	I-Chemical	-1	19767176
am@@	I-Chemical	-1	19767176
ate	I-Chemical	-1	19767176
prot@@	O	-1	19767176
ects	O	-1	19767176
the	O	-1	19767176
pi@@	O	-1	19767176
ri@@	O	-1	19767176
form	O	-1	19767176
cor@@	O	-1	19767176
te@@	O	-1	19767176
x	O	-1	19767176
in	O	-1	19767176
the	O	-1	19767176
pilocar@@	B-Chemical	D010862	19767176
pine	I-Chemical	-1	19767176
status	B-Disease	D013226	19767176
epilep@@	I-Disease	-1	19767176
tic@@	I-Disease	-1	19767176
us	I-Disease	-1	19767176
model@@	O	-1	19767176
.	O	-1	19767176
P@@	B-Chemical	C020972	19767176
y@@	I-Chemical	-1	19767176
r@@	I-Chemical	-1	19767176
ro@@	I-Chemical	-1	19767176
l@@	I-Chemical	-1	19767176
idine	I-Chemical	-1	19767176
di@@	I-Chemical	-1	19767176
thi@@	I-Chemical	-1	19767176
oc@@	I-Chemical	-1	19767176
arb@@	I-Chemical	-1	19767176
am@@	I-Chemical	-1	19767176
ate	I-Chemical	-1	19767176
(	O	-1	19767176
P@@	B-Chemical	C020972	19767176
D@@	I-Chemical	-1	19767176
T@@	I-Chemical	-1	19767176
C	I-Chemical	-1	19767176
)	O	-1	19767176
has	O	-1	19767176
a	O	-1	19767176
du@@	O	-1	19767176
al	O	-1	19767176
mechanism	O	-1	19767176
of	O	-1	19767176
action	O	-1	19767176
as	O	-1	19767176
an	O	-1	19767176
anti@@	O	-1	19767176
oxid@@	O	-1	19767176
ant	O	-1	19767176
and	O	-1	19767176
an	O	-1	19767176
inhibitor	O	-1	19767176
of	O	-1	19767176
the	O	-1	19767176
trans@@	O	-1	19767176
cri@@	O	-1	19767176
ption	O	-1	19767176
factor	O	-1	19767176
k@@	O	-1	19767176
appa@@	O	-1	19767176
-@@	O	-1	19767176
beta@@	O	-1	19767176
.	O	-1	19767176
B@@	O	-1	19767176
o@@	O	-1	19767176
th@@	O	-1	19767176
,	O	-1	19767176
pro@@	O	-1	19767176
duction	O	-1	19767176
of	O	-1	19767176
reac@@	O	-1	19767176
tive	O	-1	19767176
oxy@@	B-Chemical	D010100	19767176
gen	I-Chemical	-1	19767176
spec@@	O	-1	19767176
i@@	O	-1	19767176
es	O	-1	19767176
as	O	-1	19767176
well	O	-1	19767176
as	O	-1	19767176
activation	O	-1	19767176
of	O	-1	19767176
N@@	O	-1	19767176
F@@	O	-1	19767176
-@@	O	-1	19767176
k@@	O	-1	19767176
appa@@	O	-1	19767176
B	O	-1	19767176
have	O	-1	19767176
been	O	-1	19767176
implic@@	O	-1	19767176
ated	O	-1	19767176
in	O	-1	19767176
severe	O	-1	19767176
neuron@@	B-Disease	D009410	19767176
al	I-Disease	-1	19767176
damage	I-Disease	-1	19767176
in	O	-1	19767176
different	O	-1	19767176
sub@@	O	-1	19767176
-@@	O	-1	19767176
regi@@	O	-1	19767176
ons	O	-1	19767176
of	O	-1	19767176
the	O	-1	19767176
hippocamp@@	O	-1	19767176
us	O	-1	19767176
as	O	-1	19767176
well	O	-1	19767176
as	O	-1	19767176
in	O	-1	19767176
the	O	-1	19767176
sur@@	O	-1	19767176
ro@@	O	-1	19767176
un@@	O	-1	19767176
ding	O	-1	19767176
cor@@	O	-1	19767176
tic@@	O	-1	19767176
es.	O	-1	19767176
The	O	-1	19767176
effect	O	-1	19767176
of	O	-1	19767176
P@@	B-Chemical	C020972	19767176
D@@	I-Chemical	-1	19767176
T@@	I-Chemical	-1	19767176
C	I-Chemical	-1	19767176
on	O	-1	19767176
status	B-Disease	D013226	19767176
epilep@@	I-Disease	-1	19767176
tic@@	I-Disease	-1	19767176
us	I-Disease	-1	19767176
-@@	O	-1	19767176
associated	O	-1	19767176
cell	O	-1	19767176
loss	O	-1	19767176
in	O	-1	19767176
the	O	-1	19767176
hippocamp@@	O	-1	19767176
us	O	-1	19767176
and	O	-1	19767176
pi@@	O	-1	19767176
ri@@	O	-1	19767176
form	O	-1	19767176
cor@@	O	-1	19767176
te@@	O	-1	19767176
x	O	-1	19767176
was	O	-1	19767176
evaluated	O	-1	19767176
in	O	-1	19767176
the	O	-1	19767176
rat	O	-1	19767176
frac@@	O	-1	19767176
tion@@	O	-1	19767176
ated	O	-1	19767176
pilocar@@	B-Chemical	D010862	19767176
pine	I-Chemical	-1	19767176
model@@	O	-1	19767176
.	O	-1	19767176
Treat@@	O	-1	19767176
ment	O	-1	19767176
with	O	-1	19767176
1@@	O	-1	19767176
50	O	-1	19767176
mg/kg	O	-1	19767176
P@@	B-Chemical	C020972	19767176
D@@	I-Chemical	-1	19767176
T@@	I-Chemical	-1	19767176
C	I-Chemical	-1	19767176
before	O	-1	19767176
and	O	-1	19767176
following	O	-1	19767176
status	B-Disease	D013226	19767176
epilep@@	I-Disease	-1	19767176
tic@@	I-Disease	-1	19767176
us	I-Disease	-1	19767176
significantly	O	-1	19767176
increased	O	-1	19767176
the	O	-1	19767176
mor@@	O	-1	19767176
t@@	O	-1	19767176
ality	O	-1	19767176
rate	O	-1	19767176
to	O	-1	19767176
10@@	O	-1	19767176
0@@	O	-1	19767176
%.	O	-1	19767176
Ad@@	O	-1	19767176
minist@@	O	-1	19767176
ration	O	-1	19767176
of	O	-1	19767176
50	O	-1	19767176
mg/kg	O	-1	19767176
P@@	B-Chemical	C020972	19767176
D@@	I-Chemical	-1	19767176
T@@	I-Chemical	-1	19767176
C	I-Chemical	-1	19767176
(@@	O	-1	19767176
low@@	O	-1	19767176
-@@	O	-1	19767176
dose@@	O	-1	19767176
)	O	-1	19767176
did	O	-1	19767176
not	O	-1	19767176
ex@@	O	-1	19767176
er@@	O	-1	19767176
t	O	-1	19767176
major	O	-1	19767176
effects	O	-1	19767176
on	O	-1	19767176
the	O	-1	19767176
development	O	-1	19767176
of	O	-1	19767176
a	O	-1	19767176
status	B-Disease	D013226	19767176
epilep@@	I-Disease	-1	19767176
tic@@	I-Disease	-1	19767176
us	I-Disease	-1	19767176
or	O	-1	19767176
the	O	-1	19767176
mor@@	O	-1	19767176
t@@	O	-1	19767176
ality	O	-1	19767176
rat@@	O	-1	19767176
e.	O	-1	19767176
In	O	-1	19767176
ve@@	O	-1	19767176
h@@	O	-1	19767176
ic@@	O	-1	19767176
le@@	O	-1	19767176
-treated	O	-1	19767176
rats,	O	-1	19767176
status	B-Disease	D013226	19767176
epilep@@	I-Disease	-1	19767176
tic@@	I-Disease	-1	19767176
us	I-Disease	-1	19767176
caused	O	-1	19767176
p@@	O	-1	19767176
ron@@	O	-1	19767176
oun@@	O	-1	19767176
c@@	O	-1	19767176
ed	O	-1	19767176
neuron@@	B-Disease	D009410	19767176
al	I-Disease	-1	19767176
damage	I-Disease	-1	19767176
in	O	-1	19767176
the	O	-1	19767176
pi@@	O	-1	19767176
ri@@	O	-1	19767176
form	O	-1	19767176
cor@@	O	-1	19767176
te@@	O	-1	19767176
x	O	-1	19767176
comp@@	O	-1	19767176
ris@@	O	-1	19767176
ing	O	-1	19767176
both	O	-1	19767176
py@@	O	-1	19767176
ram@@	O	-1	19767176
idal	O	-1	19767176
cells	O	-1	19767176
and	O	-1	19767176
inter@@	O	-1	19767176
neuron@@	O	-1	19767176
s.	O	-1	19767176
L@@	O	-1	19767176
o@@	O	-1	19767176
w@@	O	-1	19767176
-@@	O	-1	19767176
dose	O	-1	19767176
P@@	B-Chemical	C020972	19767176
D@@	I-Chemical	-1	19767176
T@@	I-Chemical	-1	19767176
C	I-Chemical	-1	19767176
treatment	O	-1	19767176
al@@	O	-1	19767176
most	O	-1	19767176
complete@@	O	-1	19767176
ly	O	-1	19767176
prot@@	O	-1	19767176
ected	O	-1	19767176
from	O	-1	19767176
lesions	O	-1	19767176
in	O	-1	19767176
the	O	-1	19767176
pi@@	O	-1	19767176
ri@@	O	-1	19767176
form	O	-1	19767176
cor@@	O	-1	19767176
t@@	O	-1	19767176
ex@@	O	-1	19767176
.	O	-1	19767176
A	O	-1	19767176
significant	O	-1	19767176
decrease	O	-1	19767176
in	O	-1	19767176
neuron@@	O	-1	19767176
al	O	-1	19767176
d@@	O	-1	19767176
ensity	O	-1	19767176
of	O	-1	19767176
the	O	-1	19767176
hippocamp@@	O	-1	19767176
al	O	-1	19767176
h@@	O	-1	19767176
il@@	O	-1	19767176
ar	O	-1	19767176
formation	O	-1	19767176
was	O	-1	19767176
identi@@	O	-1	19767176
fied	O	-1	19767176
in	O	-1	19767176
ve@@	O	-1	19767176
h@@	O	-1	19767176
ic@@	O	-1	19767176
le@@	O	-1	19767176
-	O	-1	19767176
and	O	-1	19767176
P@@	B-Chemical	C020972	19767176
D@@	I-Chemical	-1	19767176
T@@	I-Chemical	-1	19767176
C	I-Chemical	-1	19767176
-treated	O	-1	19767176
rats	O	-1	19767176
following	O	-1	19767176
status	B-Disease	D013226	19767176
epilep@@	I-Disease	-1	19767176
tic@@	I-Disease	-1	19767176
us	I-Disease	-1	19767176
.	O	-1	19767176
In	O	-1	19767176
concl@@	O	-1	19767176
u@@	O	-1	19767176
sion,	O	-1	19767176
the	O	-1	19767176
N@@	O	-1	19767176
F@@	O	-1	19767176
-@@	O	-1	19767176
k@@	O	-1	19767176
appa@@	O	-1	19767176
B	O	-1	19767176
inhibitor	O	-1	19767176
and	O	-1	19767176
anti@@	O	-1	19767176
oxid@@	O	-1	19767176
ant	O	-1	19767176
P@@	B-Chemical	C020972	19767176
D@@	I-Chemical	-1	19767176
T@@	I-Chemical	-1	19767176
C	I-Chemical	-1	19767176
prot@@	O	-1	19767176
ected	O	-1	19767176
the	O	-1	19767176
pi@@	O	-1	19767176
ri@@	O	-1	19767176
form	O	-1	19767176
cor@@	O	-1	19767176
t@@	O	-1	19767176
ex@@	O	-1	19767176
,	O	-1	19767176
whereas	O	-1	19767176
it	O	-1	19767176
did	O	-1	19767176
not	O	-1	19767176
aff@@	O	-1	19767176
ect	O	-1	19767176
h@@	O	-1	19767176
il@@	O	-1	19767176
ar	O	-1	19767176
neuron@@	B-Disease	D009410	19767176
al	I-Disease	-1	19767176
loss	I-Disease	-1	19767176
.	O	-1	19767176
These	O	-1	19767176
data	O	-1	19767176
might	O	-1	19767176
indicate	O	-1	19767176
that	O	-1	19767176
the	O	-1	19767176
generation	O	-1	19767176
of	O	-1	19767176
reac@@	O	-1	19767176
tive	O	-1	19767176
oxy@@	B-Chemical	D010100	19767176
gen	I-Chemical	-1	19767176
spec@@	O	-1	19767176
i@@	O	-1	19767176
es	O	-1	19767176
and	O	-1	19767176
activation	O	-1	19767176
of	O	-1	19767176
N@@	O	-1	19767176
F@@	O	-1	19767176
-@@	O	-1	19767176
k@@	O	-1	19767176
appa@@	O	-1	19767176
B	O	-1	19767176
pl@@	O	-1	19767176
ays	O	-1	19767176
a	O	-1	19767176
more	O	-1	19767176
central	O	-1	19767176
role	O	-1	19767176
in	O	-1	19767176
seizure	B-Disease	D012640	19767176
-@@	O	-1	19767176
associated	O	-1	19767176
neuron@@	B-Disease	D009410	19767176
al	I-Disease	-1	19767176
damage	I-Disease	-1	19767176
in	O	-1	19767176
the	O	-1	19767176
tempor@@	O	-1	19767176
al	O	-1	19767176
cor@@	O	-1	19767176
te@@	O	-1	19767176
x	O	-1	19767176
as	O	-1	19767176
compared	O	-1	19767176
to	O	-1	19767176
the	O	-1	19767176
hippocamp@@	O	-1	19767176
al	O	-1	19767176
h@@	O	-1	19767176
il@@	O	-1	19767176
us.	O	-1	19767176
However,	O	-1	19767176
f@@	O	-1	19767176
ut@@	O	-1	19767176
ure	O	-1	19767176
investig@@	O	-1	19767176
ations	O	-1	19767176
are	O	-1	19767176
nec@@	O	-1	19767176
ess@@	O	-1	19767176
ary	O	-1	19767176
to	O	-1	19767176
ex@@	O	-1	19767176
act@@	O	-1	19767176
ly	O	-1	19767176
analy@@	O	-1	19767176
ze	O	-1	19767176
the	O	-1	19767176
bio@@	O	-1	19767176
chemical	O	-1	19767176
mechanisms	O	-1	19767176
by	O	-1	19767176
which	O	-1	19767176
P@@	B-Chemical	C020972	19767176
D@@	I-Chemical	-1	19767176
T@@	I-Chemical	-1	19767176
C	I-Chemical	-1	19767176
ex@@	O	-1	19767176
er@@	O	-1	19767176
ted	O	-1	19767176
its	O	-1	19767176
ben@@	O	-1	19767176
e@@	O	-1	19767176
fic@@	O	-1	19767176
ial	O	-1	19767176
effects	O	-1	19767176
in	O	-1	19767176
the	O	-1	19767176
pi@@	O	-1	19767176
ri@@	O	-1	19767176
form	O	-1	19767176
cor@@	O	-1	19767176
t@@	O	-1	19767176
ex@@	O	-1	19767176
.	O	-1	19767176

S@@	O	-1	16330293
af@@	O	-1	16330293
ety	O	-1	16330293
prof@@	O	-1	16330293
ile	O	-1	16330293
of	O	-1	16330293
a	O	-1	16330293
nicotine	B-Chemical	D009538	16330293
lo@@	O	-1	16330293
z@@	O	-1	16330293
enge	O	-1	16330293
compared	O	-1	16330293
with	O	-1	16330293
that	O	-1	16330293
of	O	-1	16330293
nicotine	B-Chemical	D009538	16330293
g@@	O	-1	16330293
um	O	-1	16330293
in	O	-1	16330293
ad@@	O	-1	16330293
ult	O	-1	16330293
smo@@	O	-1	16330293
k@@	O	-1	16330293
ers	O	-1	16330293
with	O	-1	16330293
underlying	O	-1	16330293
med@@	O	-1	16330293
ical	O	-1	16330293
condi@@	O	-1	16330293
tion@@	O	-1	16330293
s:	O	-1	16330293
a	O	-1	16330293
1@@	O	-1	16330293
2-@@	O	-1	16330293
week@@	O	-1	16330293
,	O	-1	16330293
random@@	O	-1	16330293
iz@@	O	-1	16330293
ed,	O	-1	16330293
o@@	O	-1	16330293
pen@@	O	-1	16330293
-@@	O	-1	16330293
l@@	O	-1	16330293
a@@	O	-1	16330293
be@@	O	-1	16330293
l	O	-1	16330293
study.	O	-1	16330293
BACKGROUND:	O	-1	16330293
N@@	B-Chemical	D009538	16330293
icot@@	I-Chemical	-1	16330293
ine	I-Chemical	-1	16330293
pol@@	O	-1	16330293
ac@@	O	-1	16330293
ri@@	O	-1	16330293
le@@	O	-1	16330293
x	O	-1	16330293
lo@@	O	-1	16330293
z@@	O	-1	16330293
en@@	O	-1	16330293
g@@	O	-1	16330293
es	O	-1	16330293
de@@	O	-1	16330293
liver	O	-1	16330293
2@@	O	-1	16330293
5%	O	-1	16330293
to	O	-1	16330293
27@@	O	-1	16330293
%	O	-1	16330293
more	O	-1	16330293
nicotine	B-Chemical	D009538	16330293
compared	O	-1	16330293
with	O	-1	16330293
equ@@	O	-1	16330293
i@@	O	-1	16330293
val@@	O	-1	16330293
ent	O	-1	16330293
doses	O	-1	16330293
of	O	-1	16330293
nicotine	B-Chemical	D009538	16330293
pol@@	O	-1	16330293
ac@@	O	-1	16330293
ri@@	O	-1	16330293
le@@	O	-1	16330293
x	O	-1	16330293
g@@	O	-1	16330293
um@@	O	-1	16330293
.	O	-1	16330293
The	O	-1	16330293
increased	O	-1	16330293
nicotine	B-Chemical	D009538	16330293
exposure	O	-1	16330293
from	O	-1	16330293
the	O	-1	16330293
lo@@	O	-1	16330293
z@@	O	-1	16330293
enge	O	-1	16330293
has	O	-1	16330293
ra@@	O	-1	16330293
is@@	O	-1	16330293
ed	O	-1	16330293
qu@@	O	-1	16330293
es@@	O	-1	16330293
tions	O	-1	16330293
about	O	-1	16330293
the	O	-1	16330293
rel@@	O	-1	16330293
ative	O	-1	16330293
safety	O	-1	16330293
of	O	-1	16330293
the	O	-1	16330293
lo@@	O	-1	16330293
z@@	O	-1	16330293
enge	O	-1	16330293
and	O	-1	16330293
g@@	O	-1	16330293
um@@	O	-1	16330293
.	O	-1	16330293
OBJECTIVE:	O	-1	16330293
The	O	-1	16330293
ob@@	O	-1	16330293
j@@	O	-1	16330293
ective	O	-1	16330293
of	O	-1	16330293
this	O	-1	16330293
study	O	-1	16330293
was	O	-1	16330293
to	O	-1	16330293
compar@@	O	-1	16330293
e	O	-1	16330293
the	O	-1	16330293
safety	O	-1	16330293
pro@@	O	-1	16330293
fi@@	O	-1	16330293
le@@	O	-1	16330293
s	O	-1	16330293
of	O	-1	16330293
the	O	-1	16330293
4-@@	O	-1	16330293
mg	O	-1	16330293
nicotine	B-Chemical	D009538	16330293
lo@@	O	-1	16330293
z@@	O	-1	16330293
enge	O	-1	16330293
and	O	-1	16330293
4-@@	O	-1	16330293
mg	O	-1	16330293
nicotine	B-Chemical	D009538	16330293
g@@	O	-1	16330293
um	O	-1	16330293
in	O	-1	16330293
smo@@	O	-1	16330293
k@@	O	-1	16330293
ers	O	-1	16330293
with	O	-1	16330293
sel@@	O	-1	16330293
ected	O	-1	16330293
l@@	O	-1	16330293
a@@	O	-1	16330293
be@@	O	-1	16330293
l@@	O	-1	16330293
-@@	O	-1	16330293
re@@	O	-1	16330293
stric@@	O	-1	16330293
ted	O	-1	16330293
diseas@@	O	-1	16330293
es.	O	-1	16330293
METHODS:	O	-1	16330293
This	O	-1	16330293
was	O	-1	16330293
a	O	-1	16330293
mul@@	O	-1	16330293
tic@@	O	-1	16330293
ent@@	O	-1	16330293
er,	O	-1	16330293
random@@	O	-1	16330293
iz@@	O	-1	16330293
ed,	O	-1	16330293
o@@	O	-1	16330293
pen@@	O	-1	16330293
-@@	O	-1	16330293
l@@	O	-1	16330293
a@@	O	-1	16330293
be@@	O	-1	16330293
l	O	-1	16330293
study	O	-1	16330293
in	O	-1	16330293
ad@@	O	-1	16330293
ult	O	-1	16330293
smo@@	O	-1	16330293
k@@	O	-1	16330293
ers	O	-1	16330293
with	O	-1	16330293
heart	B-Disease	D006331	16330293
disease	I-Disease	-1	16330293
,	O	-1	16330293
hypertension	B-Disease	D006973	16330293
not	O	-1	16330293
controlled	O	-1	16330293
by	O	-1	16330293
medic@@	O	-1	16330293
ation,	O	-1	16330293
and/or	O	-1	16330293
dia@@	B-Disease	D003920	16330293
bet@@	I-Disease	-1	16330293
es	I-Disease	-1	16330293
me@@	I-Disease	-1	16330293
ll@@	I-Disease	-1	16330293
it@@	I-Disease	-1	16330293
us	I-Disease	-1	16330293
.	O	-1	16330293
Patients	O	-1	16330293
were	O	-1	16330293
randomized	O	-1	16330293
in	O	-1	16330293
a	O	-1	16330293
1@@	O	-1	16330293
:@@	O	-1	16330293
1	O	-1	16330293
rati@@	O	-1	16330293
o	O	-1	16330293
to	O	-1	16330293
recei@@	O	-1	16330293
ve	O	-1	16330293
the	O	-1	16330293
4-@@	O	-1	16330293
mg	O	-1	16330293
nicotine	B-Chemical	D009538	16330293
lo@@	O	-1	16330293
z@@	O	-1	16330293
enge	O	-1	16330293
or	O	-1	16330293
4-@@	O	-1	16330293
mg	O	-1	16330293
nicotine	B-Chemical	D009538	16330293
g@@	O	-1	16330293
um@@	O	-1	16330293
.	O	-1	16330293
S@@	O	-1	16330293
af@@	O	-1	16330293
ety	O	-1	16330293
assess@@	O	-1	16330293
ments	O	-1	16330293
were	O	-1	16330293
m@@	O	-1	16330293
ade	O	-1	16330293
at	O	-1	16330293
baseline	O	-1	16330293
and	O	-1	16330293
at	O	-1	16330293
2,	O	-1	16330293
4@@	O	-1	16330293
,	O	-1	16330293
6,	O	-1	16330293
and	O	-1	16330293
12	O	-1	16330293
weeks	O	-1	16330293
after	O	-1	16330293
the	O	-1	16330293
star@@	O	-1	16330293
t	O	-1	16330293
of	O	-1	16330293
produc@@	O	-1	16330293
t	O	-1	16330293
use.	O	-1	16330293
RESULTS:	O	-1	16330293
N@@	O	-1	16330293
ine	O	-1	16330293
h@@	O	-1	16330293
und@@	O	-1	16330293
red	O	-1	16330293
one	O	-1	16330293
patients	O	-1	16330293
were	O	-1	16330293
randomized	O	-1	16330293
to	O	-1	16330293
treatment,	O	-1	16330293
4@@	O	-1	16330293
4@@	O	-1	16330293
7	O	-1	16330293
who	O	-1	16330293
received	O	-1	16330293
the	O	-1	16330293
lo@@	O	-1	16330293
z@@	O	-1	16330293
enge	O	-1	16330293
and	O	-1	16330293
4@@	O	-1	16330293
5@@	O	-1	16330293
4	O	-1	16330293
who	O	-1	16330293
received	O	-1	16330293
the	O	-1	16330293
g@@	O	-1	16330293
um	O	-1	16330293
(@@	O	-1	16330293
safety	O	-1	16330293
po@@	O	-1	16330293
pul@@	O	-1	16330293
ation@@	O	-1	16330293
).	O	-1	16330293
The	O	-1	16330293
maj@@	O	-1	16330293
or@@	O	-1	16330293
ity	O	-1	16330293
were	O	-1	16330293
women	O	-1	16330293
(5@@	O	-1	16330293
2.@@	O	-1	16330293
7@@	O	-1	16330293
%).	O	-1	16330293
Pati@@	O	-1	16330293
ent@@	O	-1	16330293
s@@	O	-1	16330293
'	O	-1	16330293
mean	O	-1	16330293
age	O	-1	16330293
was	O	-1	16330293
5@@	O	-1	16330293
3.@@	O	-1	16330293
9	O	-1	16330293
year@@	O	-1	16330293
s,	O	-1	16330293
their	O	-1	16330293
mean	O	-1	16330293
weight	O	-1	16330293
was	O	-1	16330293
19@@	O	-1	16330293
3.@@	O	-1	16330293
9	O	-1	16330293
p@@	O	-1	16330293
oun@@	O	-1	16330293
d@@	O	-1	16330293
s,	O	-1	16330293
and	O	-1	16330293
they	O	-1	16330293
smo@@	O	-1	16330293
ked	O	-1	16330293
a	O	-1	16330293
mean	O	-1	16330293
of	O	-1	16330293
2@@	O	-1	16330293
5.@@	O	-1	16330293
2	O	-1	16330293
ci@@	O	-1	16330293
g@@	O	-1	16330293
a@@	O	-1	16330293
ret@@	O	-1	16330293
tes	O	-1	16330293
per	O	-1	16330293
day	O	-1	16330293
at	O	-1	16330293
basel@@	O	-1	16330293
ine.	O	-1	16330293
F@@	O	-1	16330293
i@@	O	-1	16330293
ve	O	-1	16330293
h@@	O	-1	16330293
und@@	O	-1	16330293
red	O	-1	16330293
f@@	O	-1	16330293
if@@	O	-1	16330293
ty-@@	O	-1	16330293
three	O	-1	16330293
patients,	O	-1	16330293
2@@	O	-1	16330293
6@@	O	-1	16330293
4	O	-1	16330293
taking	O	-1	16330293
the	O	-1	16330293
lo@@	O	-1	16330293
z@@	O	-1	16330293
enge	O	-1	16330293
and	O	-1	16330293
2@@	O	-1	16330293
8@@	O	-1	16330293
9	O	-1	16330293
taking	O	-1	16330293
the	O	-1	16330293
g@@	O	-1	16330293
um,	O	-1	16330293
used	O	-1	16330293
the	O	-1	16330293
study	O	-1	16330293
produc@@	O	-1	16330293
t	O	-1	16330293
for	O	-1	16330293
>	O	-1	16330293
or	O	-1	16330293
=@@	O	-1	16330293
4	O	-1	16330293
days	O	-1	16330293
per	O	-1	16330293
week	O	-1	16330293
during	O	-1	16330293
the	O	-1	16330293
first	O	-1	16330293
2	O	-1	16330293
weeks	O	-1	16330293
(@@	O	-1	16330293
evalu@@	O	-1	16330293
able	O	-1	16330293
po@@	O	-1	16330293
pul@@	O	-1	16330293
ation@@	O	-1	16330293
).	O	-1	16330293
The	O	-1	16330293
nicotine	B-Chemical	D009538	16330293
lo@@	O	-1	16330293
z@@	O	-1	16330293
enge	O	-1	16330293
and	O	-1	16330293
nicotine	B-Chemical	D009538	16330293
g@@	O	-1	16330293
um	O	-1	16330293
were	O	-1	16330293
equ@@	O	-1	16330293
ally	O	-1	16330293
well	O	-1	16330293
toler@@	O	-1	16330293
at@@	O	-1	16330293
ed,	O	-1	16330293
des@@	O	-1	16330293
pit@@	O	-1	16330293
e	O	-1	16330293
increased	O	-1	16330293
nicotine	B-Chemical	D009538	16330293
exposure	O	-1	16330293
from	O	-1	16330293
the	O	-1	16330293
lo@@	O	-1	16330293
z@@	O	-1	16330293
en@@	O	-1	16330293
g@@	O	-1	16330293
e.	O	-1	16330293
The	O	-1	16330293
incidence	O	-1	16330293
of	O	-1	16330293
adverse	O	-1	16330293
events	O	-1	16330293
in	O	-1	16330293
the	O	-1	16330293
2	O	-1	16330293
groups	O	-1	16330293
was	O	-1	16330293
similar	O	-1	16330293
during	O	-1	16330293
the	O	-1	16330293
first	O	-1	16330293
2	O	-1	16330293
weeks	O	-1	16330293
of	O	-1	16330293
produc@@	O	-1	16330293
t	O	-1	16330293
use	O	-1	16330293
(@@	O	-1	16330293
evalu@@	O	-1	16330293
ation	O	-1	16330293
po@@	O	-1	16330293
pul@@	O	-1	16330293
ation@@	O	-1	16330293
:	O	-1	16330293
5@@	O	-1	16330293
5.@@	O	-1	16330293
3@@	O	-1	16330293
%	O	-1	16330293
lo@@	O	-1	16330293
z@@	O	-1	16330293
en@@	O	-1	16330293
g@@	O	-1	16330293
e,	O	-1	16330293
5@@	O	-1	16330293
4.@@	O	-1	16330293
7@@	O	-1	16330293
%	O	-1	16330293
g@@	O	-1	16330293
um@@	O	-1	16330293
),	O	-1	16330293
as	O	-1	16330293
well	O	-1	16330293
as	O	-1	16330293
during	O	-1	16330293
the	O	-1	16330293
enti@@	O	-1	16330293
r@@	O	-1	16330293
e	O	-1	16330293
study	O	-1	16330293
(@@	O	-1	16330293
safety	O	-1	16330293
po@@	O	-1	16330293
pul@@	O	-1	16330293
ation@@	O	-1	16330293
:	O	-1	16330293
6@@	O	-1	16330293
3.@@	O	-1	16330293
8@@	O	-1	16330293
%	O	-1	16330293
and	O	-1	16330293
5@@	O	-1	16330293
8.@@	O	-1	16330293
6@@	O	-1	16330293
%,	O	-1	16330293
respectivel@@	O	-1	16330293
y@@	O	-1	16330293
).	O	-1	16330293
S@@	O	-1	16330293
tr@@	O	-1	16330293
ati@@	O	-1	16330293
fic@@	O	-1	16330293
ation	O	-1	16330293
of	O	-1	16330293
patients	O	-1	16330293
by	O	-1	16330293
sex@@	O	-1	16330293
,	O	-1	16330293
age,	O	-1	16330293
ext@@	O	-1	16330293
ent	O	-1	16330293
of	O	-1	16330293
con@@	O	-1	16330293
current	O	-1	16330293
smo@@	O	-1	16330293
k@@	O	-1	16330293
ing,	O	-1	16330293
ext@@	O	-1	16330293
ent	O	-1	16330293
of	O	-1	16330293
produc@@	O	-1	16330293
t	O	-1	16330293
use@@	O	-1	16330293
,	O	-1	16330293
and	O	-1	16330293
severity	O	-1	16330293
of	O	-1	16330293
adverse	O	-1	16330293
events	O	-1	16330293
revealed	O	-1	16330293
no	O	-1	16330293
clin@@	O	-1	16330293
ically	O	-1	16330293
significant	O	-1	16330293
differences	O	-1	16330293
between	O	-1	16330293
the	O	-1	16330293
lo@@	O	-1	16330293
z@@	O	-1	16330293
enge	O	-1	16330293
and	O	-1	16330293
g@@	O	-1	16330293
um@@	O	-1	16330293
.	O	-1	16330293
The	O	-1	16330293
most	O	-1	16330293
common	O	-1	16330293
adverse	O	-1	16330293
events	O	-1	16330293
were	O	-1	16330293
nausea	B-Disease	D009325	16330293
(1@@	O	-1	16330293
7.@@	O	-1	16330293
2@@	O	-1	16330293
%	O	-1	16330293
and	O	-1	16330293
1@@	O	-1	16330293
6.@@	O	-1	16330293
1@@	O	-1	16330293
%@@	O	-1	16330293
;	O	-1	16330293
95%	O	-1	16330293
CI@@	O	-1	16330293
,	O	-1	16330293
-@@	O	-1	16330293
3.@@	O	-1	16330293
7	O	-1	16330293
to	O	-1	16330293
6.@@	O	-1	16330293
0@@	O	-1	16330293
),	O	-1	16330293
h@@	B-Disease	D006606	16330293
ic@@	I-Disease	-1	16330293
c@@	I-Disease	-1	16330293
up@@	I-Disease	-1	16330293
s	I-Disease	-1	16330293
(1@@	O	-1	16330293
0.@@	O	-1	16330293
7@@	O	-1	16330293
%	O	-1	16330293
and	O	-1	16330293
6.@@	O	-1	16330293
6@@	O	-1	16330293
%@@	O	-1	16330293
;	O	-1	16330293
95%	O	-1	16330293
CI@@	O	-1	16330293
,	O	-1	16330293
0.@@	O	-1	16330293
5	O	-1	16330293
to	O	-1	16330293
7.@@	O	-1	16330293
8@@	O	-1	16330293
),	O	-1	16330293
and	O	-1	16330293
headac@@	B-Disease	D006261	16330293
he	I-Disease	-1	16330293
(@@	O	-1	16330293
8.@@	O	-1	16330293
7@@	O	-1	16330293
%	O	-1	16330293
and	O	-1	16330293
9.@@	O	-1	16330293
9@@	O	-1	16330293
%@@	O	-1	16330293
;	O	-1	16330293
95%	O	-1	16330293
Cl@@	O	-1	16330293
,	O	-1	16330293
-@@	O	-1	16330293
5.@@	O	-1	16330293
0	O	-1	16330293
to	O	-1	16330293
2.@@	O	-1	16330293
6@@	O	-1	16330293
).	O	-1	16330293
S@@	O	-1	16330293
er@@	O	-1	16330293
i@@	O	-1	16330293
ous	O	-1	16330293
adverse	O	-1	16330293
events	O	-1	16330293
were	O	-1	16330293
reported	O	-1	16330293
in	O	-1	16330293
11	O	-1	16330293
and	O	-1	16330293
13	O	-1	16330293
patients	O	-1	16330293
in	O	-1	16330293
the	O	-1	16330293
resp@@	O	-1	16330293
ective	O	-1	16330293
groups.	O	-1	16330293
F@@	O	-1	16330293
e@@	O	-1	16330293
w@@	O	-1	16330293
er	O	-1	16330293
than	O	-1	16330293
6%	O	-1	16330293
of	O	-1	16330293
patients	O	-1	16330293
in	O	-1	16330293
either	O	-1	16330293
group	O	-1	16330293
were	O	-1	16330293
considered	O	-1	16330293
by	O	-1	16330293
the	O	-1	16330293
investig@@	O	-1	16330293
at@@	O	-1	16330293
or	O	-1	16330293
to	O	-1	16330293
have	O	-1	16330293
a	O	-1	16330293
wor@@	O	-1	16330293
sen@@	O	-1	16330293
ing	O	-1	16330293
of	O	-1	16330293
their	O	-1	16330293
over@@	O	-1	16330293
all	O	-1	16330293
disease	O	-1	16330293
condi@@	O	-1	16330293
tion	O	-1	16330293
during	O	-1	16330293
the	O	-1	16330293
study.	O	-1	16330293
The	O	-1	16330293
maj@@	O	-1	16330293
or@@	O	-1	16330293
ity	O	-1	16330293
of	O	-1	16330293
patients	O	-1	16330293
(@@	O	-1	16330293
>@@	O	-1	16330293
6@@	O	-1	16330293
0@@	O	-1	16330293
%)	O	-1	16330293
experienced	O	-1	16330293
no	O	-1	16330293
change	O	-1	16330293
in	O	-1	16330293
their	O	-1	16330293
disease	O	-1	16330293
status	O	-1	16330293
from	O	-1	16330293
basel@@	O	-1	16330293
ine.	O	-1	16330293
CONCLUSION:	O	-1	16330293
The	O	-1	16330293
4-@@	O	-1	16330293
mg	O	-1	16330293
nicotine	B-Chemical	D009538	16330293
lo@@	O	-1	16330293
z@@	O	-1	16330293
enge	O	-1	16330293
and	O	-1	16330293
4-@@	O	-1	16330293
mg	O	-1	16330293
nicotine	B-Chemical	D009538	16330293
g@@	O	-1	16330293
um	O	-1	16330293
had	O	-1	16330293
compar@@	O	-1	16330293
able	O	-1	16330293
safety	O	-1	16330293
pro@@	O	-1	16330293
fi@@	O	-1	16330293
le@@	O	-1	16330293
s	O	-1	16330293
in	O	-1	16330293
these	O	-1	16330293
patients	O	-1	16330293
with	O	-1	16330293
l@@	O	-1	16330293
a@@	O	-1	16330293
be@@	O	-1	16330293
l@@	O	-1	16330293
-@@	O	-1	16330293
re@@	O	-1	16330293
stric@@	O	-1	16330293
ted	O	-1	16330293
med@@	O	-1	16330293
ical	O	-1	16330293
condi@@	O	-1	16330293
tions.	O	-1	16330293

De@@	O	-1	14568327
ve@@	O	-1	14568327
lop@@	O	-1	14568327
ment	O	-1	14568327
of	O	-1	14568327
levo@@	B-Chemical	D007980	14568327
dopa	I-Chemical	-1	14568327
-induced	O	-1	14568327
dyskine@@	B-Disease	D004409	14568327
si@@	I-Disease	-1	14568327
as	I-Disease	-1	14568327
in	O	-1	14568327
par@@	B-Disease	D010300	14568327
k@@	I-Disease	-1	14568327
inson@@	I-Disease	-1	14568327
i@@	I-Disease	-1	14568327
an	I-Disease	-1	14568327
mon@@	O	-1	14568327
ke@@	O	-1	14568327
ys	O	-1	14568327
may	O	-1	14568327
depen@@	O	-1	14568327
d	O	-1	14568327
up@@	O	-1	14568327
on	O	-1	14568327
rate	O	-1	14568327
of	O	-1	14568327
sympto@@	O	-1	14568327
m	O	-1	14568327
onset	O	-1	14568327
and/or	O	-1	14568327
duration	O	-1	14568327
of	O	-1	14568327
symptom@@	O	-1	14568327
s.	O	-1	14568327
L@@	B-Chemical	D007980	14568327
evo@@	I-Chemical	-1	14568327
dopa	I-Chemical	-1	14568327
-induced	O	-1	14568327
dyskine@@	B-Disease	D004409	14568327
si@@	I-Disease	-1	14568327
as	I-Disease	-1	14568327
(	O	-1	14568327
L@@	B-Disease	D004409	14568327
I@@	I-Disease	-1	14568327
D@@	I-Disease	-1	14568327
s	I-Disease	-1	14568327
)	O	-1	14568327
present	O	-1	14568327
a	O	-1	14568327
major	O	-1	14568327
pro@@	O	-1	14568327
ble@@	O	-1	14568327
m	O	-1	14568327
for	O	-1	14568327
the	O	-1	14568327
long-term	O	-1	14568327
man@@	O	-1	14568327
ag@@	O	-1	14568327
ement	O	-1	14568327
of	O	-1	14568327
Parkinson's	B-Disease	D010300	14568327
disease	I-Disease	-1	14568327
(	O	-1	14568327
P@@	B-Disease	D010300	14568327
D	I-Disease	-1	14568327
)	O	-1	14568327
patients.	O	-1	14568327
D@@	O	-1	14568327
u@@	O	-1	14568327
e	O	-1	14568327
to	O	-1	14568327
the	O	-1	14568327
inter@@	O	-1	14568327
depend@@	O	-1	14568327
ence	O	-1	14568327
of	O	-1	14568327
risk	O	-1	14568327
factors	O	-1	14568327
in	O	-1	14568327
clinical	O	-1	14568327
po@@	O	-1	14568327
pul@@	O	-1	14568327
ation@@	O	-1	14568327
s,	O	-1	14568327
it	O	-1	14568327
is	O	-1	14568327
diff@@	O	-1	14568327
ic@@	O	-1	14568327
ult	O	-1	14568327
to	O	-1	14568327
in@@	O	-1	14568327
depend@@	O	-1	14568327
ently	O	-1	14568327
ex@@	O	-1	14568327
amine	O	-1	14568327
factors	O	-1	14568327
that	O	-1	14568327
may	O	-1	14568327
influence	O	-1	14568327
the	O	-1	14568327
development	O	-1	14568327
of	O	-1	14568327
L@@	B-Disease	D004409	14568327
I@@	I-Disease	-1	14568327
D@@	I-Disease	-1	14568327
s	I-Disease	-1	14568327
.	O	-1	14568327
U@@	O	-1	14568327
s@@	O	-1	14568327
ing	O	-1	14568327
mac@@	O	-1	14568327
a@@	O	-1	14568327
qu@@	O	-1	14568327
e	O	-1	14568327
mon@@	O	-1	14568327
ke@@	O	-1	14568327
ys	O	-1	14568327
with	O	-1	14568327
different	O	-1	14568327
typ@@	O	-1	14568327
es	O	-1	14568327
of	O	-1	14568327
MP@@	B-Chemical	D015632	14568327
T@@	I-Chemical	-1	14568327
P	I-Chemical	-1	14568327
-induced	O	-1	14568327
par@@	B-Disease	D010302	14568327
k@@	I-Disease	-1	14568327
inson@@	I-Disease	-1	14568327
ism	I-Disease	-1	14568327
,	O	-1	14568327
the	O	-1	14568327
current	O	-1	14568327
study	O	-1	14568327
evaluated	O	-1	14568327
the	O	-1	14568327
de@@	O	-1	14568327
g@@	O	-1	14568327
ree	O	-1	14568327
to	O	-1	14568327
which	O	-1	14568327
rate	O	-1	14568327
of	O	-1	14568327
sympto@@	O	-1	14568327
m	O	-1	14568327
progres@@	O	-1	14568327
sion,	O	-1	14568327
sympto@@	O	-1	14568327
m	O	-1	14568327
sever@@	O	-1	14568327
ity,	O	-1	14568327
and	O	-1	14568327
response	O	-1	14568327
to	O	-1	14568327
and	O	-1	14568327
duration	O	-1	14568327
of	O	-1	14568327
levo@@	B-Chemical	D007980	14568327
dopa	I-Chemical	-1	14568327
therapy	O	-1	14568327
may	O	-1	14568327
be	O	-1	14568327
involved	O	-1	14568327
in	O	-1	14568327
the	O	-1	14568327
development	O	-1	14568327
of	O	-1	14568327
L@@	B-Disease	D004409	14568327
I@@	I-Disease	-1	14568327
D@@	I-Disease	-1	14568327
s	I-Disease	-1	14568327
.	O	-1	14568327
M@@	O	-1	14568327
on@@	O	-1	14568327
ke@@	O	-1	14568327
ys	O	-1	14568327
with	O	-1	14568327
acute	O	-1	14568327
(@@	O	-1	14568327
sh@@	O	-1	14568327
ort@@	O	-1	14568327
-@@	O	-1	14568327
ter@@	O	-1	14568327
m@@	O	-1	14568327
)	O	-1	14568327
MP@@	B-Chemical	D015632	14568327
T@@	I-Chemical	-1	14568327
P	I-Chemical	-1	14568327
expos@@	O	-1	14568327
ure,	O	-1	14568327
ra@@	O	-1	14568327
pid	O	-1	14568327
sympto@@	O	-1	14568327
m	O	-1	14568327
onset	O	-1	14568327
and	O	-1	14568327
sh@@	O	-1	14568327
ort	O	-1	14568327
sympto@@	O	-1	14568327
m	O	-1	14568327
duration	O	-1	14568327
prior	O	-1	14568327
to	O	-1	14568327
initi@@	O	-1	14568327
ation	O	-1	14568327
of	O	-1	14568327
levo@@	B-Chemical	D007980	14568327
dopa	I-Chemical	-1	14568327
therapy	O	-1	14568327
developed	O	-1	14568327
dyskine@@	B-Disease	D004409	14568327
sia	I-Disease	-1	14568327
between	O	-1	14568327
11	O	-1	14568327
and	O	-1	14568327
24	O	-1	14568327
days	O	-1	14568327
of	O	-1	14568327
daily	O	-1	14568327
levo@@	B-Chemical	D007980	14568327
dopa	I-Chemical	-1	14568327
administr@@	O	-1	14568327
ation.	O	-1	14568327
In	O	-1	14568327
contrast@@	O	-1	14568327
,	O	-1	14568327
mon@@	O	-1	14568327
ke@@	O	-1	14568327
ys	O	-1	14568327
with	O	-1	14568327
long-term	O	-1	14568327
MP@@	B-Chemical	D015632	14568327
T@@	I-Chemical	-1	14568327
P	I-Chemical	-1	14568327
expos@@	O	-1	14568327
ure,	O	-1	14568327
s@@	O	-1	14568327
low	O	-1	14568327
sympto@@	O	-1	14568327
m	O	-1	14568327
progres@@	O	-1	14568327
sion	O	-1	14568327
and/or	O	-1	14568327
lon@@	O	-1	14568327
g	O	-1	14568327
sympto@@	O	-1	14568327
m	O	-1	14568327
duration	O	-1	14568327
prior	O	-1	14568327
to	O	-1	14568327
initi@@	O	-1	14568327
ation	O	-1	14568327
of	O	-1	14568327
levo@@	B-Chemical	D007980	14568327
dopa	I-Chemical	-1	14568327
therapy	O	-1	14568327
were	O	-1	14568327
more	O	-1	14568327
resist@@	O	-1	14568327
ant	O	-1	14568327
to	O	-1	14568327
develop@@	O	-1	14568327
ing	O	-1	14568327
L@@	B-Disease	D004409	14568327
I@@	I-Disease	-1	14568327
D@@	I-Disease	-1	14568327
s	I-Disease	-1	14568327
(@@	O	-1	14568327
e@@	O	-1	14568327
.@@	O	-1	14568327
g@@	O	-1	14568327
.,	O	-1	14568327
dyskine@@	B-Disease	D004409	14568327
sia	I-Disease	-1	14568327
developed	O	-1	14568327
no	O	-1	14568327
so@@	O	-1	14568327
on@@	O	-1	14568327
er	O	-1	14568327
than	O	-1	14568327
14@@	O	-1	14568327
6	O	-1	14568327
days	O	-1	14568327
of	O	-1	14568327
chronic	O	-1	14568327
levo@@	B-Chemical	D007980	14568327
dopa	I-Chemical	-1	14568327
administr@@	O	-1	14568327
ation@@	O	-1	14568327
).	O	-1	14568327
All	O	-1	14568327
animals	O	-1	14568327
were	O	-1	14568327
simil@@	O	-1	14568327
arly	O	-1	14568327
symptom@@	O	-1	14568327
atic	O	-1	14568327
at	O	-1	14568327
the	O	-1	14568327
star@@	O	-1	14568327
t	O	-1	14568327
of	O	-1	14568327
levo@@	B-Chemical	D007980	14568327
dopa	I-Chemical	-1	14568327
treatment	O	-1	14568327
and	O	-1	14568327
had	O	-1	14568327
similar	O	-1	14568327
therapeutic	O	-1	14568327
responses	O	-1	14568327
to	O	-1	14568327
the	O	-1	14568327
drug.	O	-1	14568327
These	O	-1	14568327
data	O	-1	14568327
suggest	O	-1	14568327
dist@@	O	-1	14568327
inc@@	O	-1	14568327
t	O	-1	14568327
differences	O	-1	14568327
in	O	-1	14568327
the	O	-1	14568327
pro@@	O	-1	14568327
pen@@	O	-1	14568327
s@@	O	-1	14568327
ity	O	-1	14568327
to	O	-1	14568327
deve@@	O	-1	14568327
lo@@	O	-1	14568327
p	O	-1	14568327
L@@	B-Disease	D004409	14568327
I@@	I-Disease	-1	14568327
D@@	I-Disease	-1	14568327
s	I-Disease	-1	14568327
in	O	-1	14568327
mon@@	O	-1	14568327
ke@@	O	-1	14568327
ys	O	-1	14568327
with	O	-1	14568327
different	O	-1	14568327
rat@@	O	-1	14568327
es	O	-1	14568327
of	O	-1	14568327
sympto@@	O	-1	14568327
m	O	-1	14568327
progres@@	O	-1	14568327
sion	O	-1	14568327
or	O	-1	14568327
sympto@@	O	-1	14568327
m	O	-1	14568327
dur@@	O	-1	14568327
ations	O	-1	14568327
prior	O	-1	14568327
to	O	-1	14568327
levo@@	B-Chemical	D007980	14568327
dopa	I-Chemical	-1	14568327
and	O	-1	14568327
demon@@	O	-1	14568327
st@@	O	-1	14568327
rate	O	-1	14568327
the	O	-1	14568327
valu@@	O	-1	14568327
e	O	-1	14568327
of	O	-1	14568327
these	O	-1	14568327
models	O	-1	14568327
for	O	-1	14568327
further	O	-1	14568327
stud@@	O	-1	14568327
y@@	O	-1	14568327
ing	O	-1	14568327
the	O	-1	14568327
path@@	O	-1	14568327
oph@@	O	-1	14568327
ysi@@	O	-1	14568327
ology	O	-1	14568327
of	O	-1	14568327
L@@	B-Disease	D004409	14568327
I@@	I-Disease	-1	14568327
D@@	I-Disease	-1	14568327
s	I-Disease	-1	14568327
.	O	-1	14568327

Pro@@	B-Chemical	D011441	11250767
p@@	I-Chemical	-1	11250767
yl@@	I-Chemical	-1	11250767
th@@	I-Chemical	-1	11250767
io@@	I-Chemical	-1	11250767
urac@@	I-Chemical	-1	11250767
il	I-Chemical	-1	11250767
-induced	O	-1	11250767
per@@	O	-1	11250767
in@@	O	-1	11250767
uc@@	O	-1	11250767
lear@@	O	-1	11250767
-@@	O	-1	11250767
st@@	O	-1	11250767
aining	O	-1	11250767
ant@@	O	-1	11250767
ine@@	O	-1	11250767
ut@@	O	-1	11250767
ro@@	O	-1	11250767
ph@@	O	-1	11250767
il	O	-1	11250767
cyto@@	O	-1	11250767
plas@@	O	-1	11250767
mic	O	-1	11250767
auto@@	O	-1	11250767
anti@@	O	-1	11250767
bo@@	O	-1	11250767
dy@@	O	-1	11250767
-@@	O	-1	11250767
positive	O	-1	11250767
vas@@	B-Disease	D014657	11250767
cul@@	I-Disease	-1	11250767
iti@@	I-Disease	-1	11250767
s	I-Disease	-1	11250767
in	O	-1	11250767
con@@	O	-1	11250767
j@@	O	-1	11250767
unc@@	O	-1	11250767
tion	O	-1	11250767
with	O	-1	11250767
per@@	B-Disease	D010493	11250767
ic@@	I-Disease	-1	11250767
ardi@@	I-Disease	-1	11250767
tis	I-Disease	-1	11250767
.	O	-1	11250767
OBJECTIVE:	O	-1	11250767
To	O	-1	11250767
describe	O	-1	11250767
a	O	-1	11250767
case	O	-1	11250767
of	O	-1	11250767
prop@@	B-Chemical	D011441	11250767
yl@@	I-Chemical	-1	11250767
th@@	I-Chemical	-1	11250767
io@@	I-Chemical	-1	11250767
urac@@	I-Chemical	-1	11250767
il	I-Chemical	-1	11250767
-induced	O	-1	11250767
vas@@	B-Disease	D014657	11250767
cul@@	I-Disease	-1	11250767
iti@@	I-Disease	-1	11250767
s	I-Disease	-1	11250767
man@@	O	-1	11250767
if@@	O	-1	11250767
est@@	O	-1	11250767
ing	O	-1	11250767
with	O	-1	11250767
per@@	B-Disease	D010493	11250767
ic@@	I-Disease	-1	11250767
ardi@@	I-Disease	-1	11250767
tis	I-Disease	-1	11250767
.	O	-1	11250767
METHODS:	O	-1	11250767
We	O	-1	11250767
present	O	-1	11250767
the	O	-1	11250767
first	O	-1	11250767
case	O	-1	11250767
report	O	-1	11250767
of	O	-1	11250767
a	O	-1	11250767
woman	O	-1	11250767
with	O	-1	11250767
hyper@@	B-Disease	D006980	11250767
th@@	I-Disease	-1	11250767
yro@@	I-Disease	-1	11250767
i@@	I-Disease	-1	11250767
dis@@	I-Disease	-1	11250767
m	I-Disease	-1	11250767
treated	O	-1	11250767
with	O	-1	11250767
prop@@	B-Chemical	D011441	11250767
yl@@	I-Chemical	-1	11250767
th@@	I-Chemical	-1	11250767
io@@	I-Chemical	-1	11250767
urac@@	I-Chemical	-1	11250767
il	I-Chemical	-1	11250767
in	O	-1	11250767
whom	O	-1	11250767
a	O	-1	11250767
syndrome	O	-1	11250767
of	O	-1	11250767
per@@	B-Disease	D010493	11250767
ic@@	I-Disease	-1	11250767
ardi@@	I-Disease	-1	11250767
tis	I-Disease	-1	11250767
,	O	-1	11250767
f@@	B-Disease	D005334	11250767
ev@@	I-Disease	-1	11250767
er	I-Disease	-1	11250767
,	O	-1	11250767
and	O	-1	11250767
glomerul@@	B-Disease	D005921	11250767
one@@	I-Disease	-1	11250767
ph@@	I-Disease	-1	11250767
ritis	I-Disease	-1	11250767
develop@@	O	-1	11250767
ed.	O	-1	11250767
S@@	O	-1	11250767
er@@	O	-1	11250767
ologic	O	-1	11250767
test@@	O	-1	11250767
ing	O	-1	11250767
and	O	-1	11250767
immun@@	O	-1	11250767
ologic	O	-1	11250767
studies	O	-1	11250767
were	O	-1	11250767
d@@	O	-1	11250767
one,	O	-1	11250767
and	O	-1	11250767
a	O	-1	11250767
per@@	O	-1	11250767
ic@@	O	-1	11250767
ardi@@	O	-1	11250767
al	O	-1	11250767
biop@@	O	-1	11250767
sy	O	-1	11250767
was	O	-1	11250767
per@@	O	-1	11250767
for@@	O	-1	11250767
me@@	O	-1	11250767
d.	O	-1	11250767
RESULTS:	O	-1	11250767
A	O	-1	11250767
2@@	O	-1	11250767
5-@@	O	-1	11250767
year-old	O	-1	11250767
woman	O	-1	11250767
with	O	-1	11250767
G@@	B-Disease	D006111	11250767
ra@@	I-Disease	-1	11250767
v@@	I-Disease	-1	11250767
es@@	I-Disease	-1	11250767
'	I-Disease	-1	11250767
disease	I-Disease	-1	11250767
had	O	-1	11250767
a	O	-1	11250767
fe@@	B-Disease	D005334	11250767
b@@	I-Disease	-1	11250767
ri@@	I-Disease	-1	11250767
le	I-Disease	-1	11250767
ill@@	I-Disease	-1	11250767
ness	I-Disease	-1	11250767
and	O	-1	11250767
evidence	O	-1	11250767
of	O	-1	11250767
per@@	B-Disease	D010493	11250767
ic@@	I-Disease	-1	11250767
ardi@@	I-Disease	-1	11250767
tis	I-Disease	-1	11250767
,	O	-1	11250767
which	O	-1	11250767
was	O	-1	11250767
con@@	O	-1	11250767
fir@@	O	-1	11250767
m@@	O	-1	11250767
ed	O	-1	11250767
by	O	-1	11250767
bio@@	O	-1	11250767
psy@@	O	-1	11250767
.	O	-1	11250767
S@@	O	-1	11250767
er@@	O	-1	11250767
ologic	O	-1	11250767
evalu@@	O	-1	11250767
ation	O	-1	11250767
revealed	O	-1	11250767
the	O	-1	11250767
presence	O	-1	11250767
of	O	-1	11250767
per@@	O	-1	11250767
in@@	O	-1	11250767
uc@@	O	-1	11250767
lear@@	O	-1	11250767
-@@	O	-1	11250767
st@@	O	-1	11250767
aining	O	-1	11250767
ant@@	O	-1	11250767
ine@@	O	-1	11250767
ut@@	O	-1	11250767
ro@@	O	-1	11250767
ph@@	O	-1	11250767
il	O	-1	11250767
cyto@@	O	-1	11250767
plas@@	O	-1	11250767
mic	O	-1	11250767
auto@@	O	-1	11250767
anti@@	O	-1	11250767
bo@@	O	-1	11250767
di@@	O	-1	11250767
es	O	-1	11250767
(p@@	O	-1	11250767
AN@@	O	-1	11250767
CA@@	O	-1	11250767
)	O	-1	11250767
against	O	-1	11250767
my@@	O	-1	11250767
e@@	O	-1	11250767
lo@@	O	-1	11250767
per@@	O	-1	11250767
oxid@@	O	-1	11250767
ase	O	-1	11250767
(@@	O	-1	11250767
MP@@	O	-1	11250767
O@@	O	-1	11250767
).	O	-1	11250767
Pro@@	B-Chemical	D011441	11250767
p@@	I-Chemical	-1	11250767
yl@@	I-Chemical	-1	11250767
th@@	I-Chemical	-1	11250767
io@@	I-Chemical	-1	11250767
urac@@	I-Chemical	-1	11250767
il	I-Chemical	-1	11250767
therapy	O	-1	11250767
was	O	-1	11250767
withdraw@@	O	-1	11250767
n@@	O	-1	11250767
,	O	-1	11250767
and	O	-1	11250767
sh@@	O	-1	11250767
e	O	-1	11250767
was	O	-1	11250767
treated	O	-1	11250767
with	O	-1	11250767
a	O	-1	11250767
1-@@	O	-1	11250767
mon@@	O	-1	11250767
th	O	-1	11250767
course	O	-1	11250767
of	O	-1	11250767
pre@@	B-Chemical	D011241	11250767
d@@	I-Chemical	-1	11250767
n@@	I-Chemical	-1	11250767
is@@	I-Chemical	-1	11250767
one	I-Chemical	-1	11250767
,	O	-1	11250767
which	O	-1	11250767
al@@	O	-1	11250767
le@@	O	-1	11250767
vi@@	O	-1	11250767
ated	O	-1	11250767
h@@	O	-1	11250767
er	O	-1	11250767
symptom@@	O	-1	11250767
s.	O	-1	11250767
A	O	-1	11250767
literat@@	O	-1	11250767
ure	O	-1	11250767
revie@@	O	-1	11250767
w	O	-1	11250767
revealed	O	-1	11250767
no	O	-1	11250767
prior	O	-1	11250767
reports	O	-1	11250767
of	O	-1	11250767
per@@	B-Disease	D010493	11250767
ic@@	I-Disease	-1	11250767
ardi@@	I-Disease	-1	11250767
tis	I-Disease	-1	11250767
in	O	-1	11250767
anti@@	O	-1	11250767
-@@	O	-1	11250767
MP@@	O	-1	11250767
O	O	-1	11250767
p@@	O	-1	11250767
AN@@	O	-1	11250767
CA@@	O	-1	11250767
-@@	O	-1	11250767
positive	O	-1	11250767
vas@@	B-Disease	D014657	11250767
cul@@	I-Disease	-1	11250767
iti@@	I-Disease	-1	11250767
s	I-Disease	-1	11250767
associated	O	-1	11250767
with	O	-1	11250767
prop@@	B-Chemical	D011441	11250767
yl@@	I-Chemical	-1	11250767
th@@	I-Chemical	-1	11250767
io@@	I-Chemical	-1	11250767
-	I-Chemical	-1	11250767
urac@@	I-Chemical	-1	11250767
il	I-Chemical	-1	11250767
therapy.	O	-1	11250767
CONCLUSION:	O	-1	11250767
P@@	B-Disease	D010493	11250767
er@@	I-Disease	-1	11250767
ic@@	I-Disease	-1	11250767
ardi@@	I-Disease	-1	11250767
tis	I-Disease	-1	11250767
may	O	-1	11250767
be	O	-1	11250767
the	O	-1	11250767
initial	O	-1	11250767
man@@	O	-1	11250767
if@@	O	-1	11250767
est@@	O	-1	11250767
ation	O	-1	11250767
of	O	-1	11250767
drug@@	O	-1	11250767
-induced	O	-1	11250767
vas@@	B-Disease	D014657	11250767
cul@@	I-Disease	-1	11250767
iti@@	I-Disease	-1	11250767
s	I-Disease	-1	11250767
at@@	O	-1	11250767
tri@@	O	-1	11250767
but@@	O	-1	11250767
able	O	-1	11250767
to	O	-1	11250767
prop@@	B-Chemical	D011441	11250767
yl@@	I-Chemical	-1	11250767
th@@	I-Chemical	-1	11250767
io@@	I-Chemical	-1	11250767
-	I-Chemical	-1	11250767
urac@@	I-Chemical	-1	11250767
il	I-Chemical	-1	11250767
therapy.	O	-1	11250767

Two	O	-1	11206082
mouse	O	-1	11206082
lin@@	O	-1	11206082
es	O	-1	11206082
sel@@	O	-1	11206082
ected	O	-1	11206082
for	O	-1	11206082
differen@@	O	-1	11206082
tial	O	-1	11206082
sensi@@	O	-1	11206082
ti@@	O	-1	11206082
vi@@	O	-1	11206082
ties	O	-1	11206082
to	O	-1	11206082
beta-@@	B-Chemical	C036150	11206082
carb@@	I-Chemical	-1	11206082
ol@@	I-Chemical	-1	11206082
ine	I-Chemical	-1	11206082
-induced	O	-1	11206082
seizures	B-Disease	D012640	11206082
are	O	-1	11206082
also	O	-1	11206082
differen@@	O	-1	11206082
ti@@	O	-1	11206082
ally	O	-1	11206082
sensitive	O	-1	11206082
to	O	-1	11206082
various	O	-1	11206082
pharmac@@	O	-1	11206082
ological	O	-1	11206082
effects	O	-1	11206082
of	O	-1	11206082
other	O	-1	11206082
G@@	B-Chemical	D005680	11206082
A@@	I-Chemical	-1	11206082
B@@	I-Chemical	-1	11206082
A	I-Chemical	-1	11206082
(A@@	O	-1	11206082
)	O	-1	11206082
receptor	O	-1	11206082
li@@	O	-1	11206082
g@@	O	-1	11206082
and@@	O	-1	11206082
s.	O	-1	11206082
Two	O	-1	11206082
mouse	O	-1	11206082
lin@@	O	-1	11206082
es	O	-1	11206082
were	O	-1	11206082
sel@@	O	-1	11206082
ectively	O	-1	11206082
b@@	O	-1	11206082
red	O	-1	11206082
ac@@	O	-1	11206082
cor@@	O	-1	11206082
ding	O	-1	11206082
to	O	-1	11206082
their	O	-1	11206082
sensitivity	O	-1	11206082
(B@@	O	-1	11206082
S	O	-1	11206082
l@@	O	-1	11206082
ine@@	O	-1	11206082
)	O	-1	11206082
or	O	-1	11206082
resist@@	O	-1	11206082
ance	O	-1	11206082
(B@@	O	-1	11206082
R	O	-1	11206082
l@@	O	-1	11206082
ine@@	O	-1	11206082
)	O	-1	11206082
to	O	-1	11206082
seizures	B-Disease	D012640	11206082
induced	O	-1	11206082
by	O	-1	11206082
a	O	-1	11206082
single	O	-1	11206082
i.@@	O	-1	11206082
p@@	O	-1	11206082
.	O	-1	11206082
injection	O	-1	11206082
of	O	-1	11206082
meth@@	B-Chemical	C036150	11206082
yl	I-Chemical	-1	11206082
beta-@@	I-Chemical	-1	11206082
carb@@	I-Chemical	-1	11206082
ol@@	I-Chemical	-1	11206082
ine-@@	I-Chemical	-1	11206082
3-@@	I-Chemical	-1	11206082
carb@@	I-Chemical	-1	11206082
ox@@	I-Chemical	-1	11206082
yl@@	I-Chemical	-1	11206082
ate	I-Chemical	-1	11206082
(	O	-1	11206082
beta-@@	B-Chemical	C036150	11206082
C@@	I-Chemical	-1	11206082
C@@	I-Chemical	-1	11206082
M	I-Chemical	-1	11206082
),	O	-1	11206082
an	O	-1	11206082
in@@	O	-1	11206082
verse	O	-1	11206082
agon@@	O	-1	11206082
ist	O	-1	11206082
of	O	-1	11206082
the	O	-1	11206082
G@@	B-Chemical	D005680	11206082
A@@	I-Chemical	-1	11206082
B@@	I-Chemical	-1	11206082
A	I-Chemical	-1	11206082
(A@@	O	-1	11206082
)	O	-1	11206082
receptor	O	-1	11206082
b@@	B-Chemical	D001569	11206082
enz@@	I-Chemical	-1	11206082
odi@@	I-Chemical	-1	11206082
azepine	I-Chemical	-1	11206082
sit@@	O	-1	11206082
e.	O	-1	11206082
Our	O	-1	11206082
a@@	O	-1	11206082
im	O	-1	11206082
was	O	-1	11206082
to	O	-1	11206082
character@@	O	-1	11206082
iz@@	O	-1	11206082
e	O	-1	11206082
both	O	-1	11206082
lin@@	O	-1	11206082
es@@	O	-1	11206082
'	O	-1	11206082
sensi@@	O	-1	11206082
ti@@	O	-1	11206082
vi@@	O	-1	11206082
ties	O	-1	11206082
to	O	-1	11206082
various	O	-1	11206082
physi@@	O	-1	11206082
ological	O	-1	11206082
effects	O	-1	11206082
of	O	-1	11206082
other	O	-1	11206082
li@@	O	-1	11206082
g@@	O	-1	11206082
and@@	O	-1	11206082
s	O	-1	11206082
of	O	-1	11206082
the	O	-1	11206082
G@@	B-Chemical	D005680	11206082
A@@	I-Chemical	-1	11206082
B@@	I-Chemical	-1	11206082
A	I-Chemical	-1	11206082
(A@@	O	-1	11206082
)	O	-1	11206082
receptor@@	O	-1	11206082
.	O	-1	11206082
We	O	-1	11206082
measured	O	-1	11206082
di@@	B-Chemical	D003975	11206082
az@@	I-Chemical	-1	11206082
epam	I-Chemical	-1	11206082
-induced	O	-1	11206082
an@@	O	-1	11206082
xi@@	O	-1	11206082
oly@@	O	-1	11206082
sis	O	-1	11206082
with	O	-1	11206082
the	O	-1	11206082
elevated	O	-1	11206082
pl@@	O	-1	11206082
us@@	O	-1	11206082
-@@	O	-1	11206082
ma@@	O	-1	11206082
ze	O	-1	11206082
test@@	O	-1	11206082
,	O	-1	11206082
di@@	B-Chemical	D003975	11206082
az@@	I-Chemical	-1	11206082
epam	I-Chemical	-1	11206082
-induced	O	-1	11206082
sed@@	O	-1	11206082
ation	O	-1	11206082
by	O	-1	11206082
recor@@	O	-1	11206082
ding	O	-1	11206082
the	O	-1	11206082
vi@@	O	-1	11206082
g@@	O	-1	11206082
il@@	O	-1	11206082
ance	O	-1	11206082
stat@@	O	-1	11206082
es,	O	-1	11206082
and	O	-1	11206082
p@@	B-Chemical	D010852	11206082
ic@@	I-Chemical	-1	11206082
ro@@	I-Chemical	-1	11206082
tox@@	I-Chemical	-1	11206082
in	I-Chemical	-1	11206082
-	O	-1	11206082
and	O	-1	11206082
pent@@	B-Chemical	D010433	11206082
yl@@	I-Chemical	-1	11206082
en@@	I-Chemical	-1	11206082
e@@	I-Chemical	-1	11206082
te@@	I-Chemical	-1	11206082
tra@@	I-Chemical	-1	11206082
z@@	I-Chemical	-1	11206082
ol	I-Chemical	-1	11206082
-induced	O	-1	11206082
seizures	B-Disease	D012640	11206082
after	O	-1	11206082
i.@@	O	-1	11206082
p@@	O	-1	11206082
.	O	-1	11206082
injec@@	O	-1	11206082
tions.	O	-1	11206082
R@@	O	-1	11206082
es@@	O	-1	11206082
ult@@	O	-1	11206082
s	O	-1	11206082
presented	O	-1	11206082
h@@	O	-1	11206082
ere	O	-1	11206082
show	O	-1	11206082
that	O	-1	11206082
the	O	-1	11206082
differen@@	O	-1	11206082
tial	O	-1	11206082
sensi@@	O	-1	11206082
ti@@	O	-1	11206082
vi@@	O	-1	11206082
ties	O	-1	11206082
of	O	-1	11206082
B@@	O	-1	11206082
S	O	-1	11206082
and	O	-1	11206082
B@@	O	-1	11206082
R	O	-1	11206082
lin@@	O	-1	11206082
es	O	-1	11206082
to	O	-1	11206082
beta-@@	B-Chemical	C036150	11206082
C@@	I-Chemical	-1	11206082
C@@	I-Chemical	-1	11206082
M	I-Chemical	-1	11206082
can	O	-1	11206082
be	O	-1	11206082
exten@@	O	-1	11206082
ded	O	-1	11206082
to	O	-1	11206082
di@@	B-Chemical	D003975	11206082
az@@	I-Chemical	-1	11206082
epam	I-Chemical	-1	11206082
,	O	-1	11206082
p@@	B-Chemical	D010852	11206082
ic@@	I-Chemical	-1	11206082
ro@@	I-Chemical	-1	11206082
tox@@	I-Chemical	-1	11206082
in	I-Chemical	-1	11206082
,	O	-1	11206082
and	O	-1	11206082
pent@@	B-Chemical	D010433	11206082
yl@@	I-Chemical	-1	11206082
en@@	I-Chemical	-1	11206082
e@@	I-Chemical	-1	11206082
te@@	I-Chemical	-1	11206082
tra@@	I-Chemical	-1	11206082
z@@	I-Chemical	-1	11206082
ol	I-Chemical	-1	11206082
,	O	-1	11206082
suggesting	O	-1	11206082
a	O	-1	11206082
gene@@	O	-1	11206082
tic	O	-1	11206082
sel@@	O	-1	11206082
ection	O	-1	11206082
of	O	-1	11206082
a	O	-1	11206082
gener@@	O	-1	11206082
al	O	-1	11206082
sensitivity	O	-1	11206082
and	O	-1	11206082
resist@@	O	-1	11206082
ance	O	-1	11206082
to	O	-1	11206082
several	O	-1	11206082
li@@	O	-1	11206082
g@@	O	-1	11206082
and@@	O	-1	11206082
s	O	-1	11206082
of	O	-1	11206082
the	O	-1	11206082
G@@	B-Chemical	D005680	11206082
A@@	I-Chemical	-1	11206082
B@@	I-Chemical	-1	11206082
A	I-Chemical	-1	11206082
(A@@	O	-1	11206082
)	O	-1	11206082
receptor@@	O	-1	11206082
.	O	-1	11206082

An@@	O	-1	11027905
alge@@	O	-1	11027905
sic	O	-1	11027905
effect	O	-1	11027905
of	O	-1	11027905
intravenous	O	-1	11027905
k@@	B-Chemical	D007649	11027905
et@@	I-Chemical	-1	11027905
amine	I-Chemical	-1	11027905
in	O	-1	11027905
cancer	B-Disease	D009369	11027905
patients	O	-1	11027905
on	O	-1	11027905
morphine	B-Chemical	D009020	11027905
therap@@	O	-1	11027905
y@@	O	-1	11027905
:	O	-1	11027905
a	O	-1	11027905
random@@	O	-1	11027905
iz@@	O	-1	11027905
ed,	O	-1	11027905
control@@	O	-1	11027905
le@@	O	-1	11027905
d,	O	-1	11027905
double-bl@@	O	-1	11027905
ind@@	O	-1	11027905
,	O	-1	11027905
cros@@	O	-1	11027905
so@@	O	-1	11027905
ver,	O	-1	11027905
double-@@	O	-1	11027905
dose	O	-1	11027905
study.	O	-1	11027905
P@@	B-Disease	D010146	11027905
ain	I-Disease	-1	11027905
not	O	-1	11027905
respon@@	O	-1	11027905
sive	O	-1	11027905
to	O	-1	11027905
morphine	B-Chemical	D009020	11027905
is	O	-1	11027905
often	O	-1	11027905
pro@@	O	-1	11027905
ble@@	O	-1	11027905
m@@	O	-1	11027905
ati@@	O	-1	11027905
c@@	O	-1	11027905
.	O	-1	11027905
An@@	O	-1	11027905
im@@	O	-1	11027905
al	O	-1	11027905
and	O	-1	11027905
clinical	O	-1	11027905
studies	O	-1	11027905
have	O	-1	11027905
suggested	O	-1	11027905
that	O	-1	11027905
N@@	B-Chemical	D016202	11027905
-@@	I-Chemical	-1	11027905
methyl@@	I-Chemical	-1	11027905
-@@	I-Chemical	-1	11027905
D-@@	I-Chemical	-1	11027905
as@@	I-Chemical	-1	11027905
part@@	I-Chemical	-1	11027905
ate	I-Chemical	-1	11027905
(	O	-1	11027905
N@@	B-Chemical	D016202	11027905
MD@@	I-Chemical	-1	11027905
A	I-Chemical	-1	11027905
)	O	-1	11027905
antagonist@@	O	-1	11027905
s,	O	-1	11027905
such	O	-1	11027905
as	O	-1	11027905
k@@	B-Chemical	D007649	11027905
et@@	I-Chemical	-1	11027905
amine	I-Chemical	-1	11027905
,	O	-1	11027905
may	O	-1	11027905
be	O	-1	11027905
effective	O	-1	11027905
in	O	-1	11027905
impro@@	O	-1	11027905
ving	O	-1	11027905
o@@	O	-1	11027905
pi@@	O	-1	11027905
oid	O	-1	11027905
analge@@	O	-1	11027905
sia	O	-1	11027905
in	O	-1	11027905
diff@@	O	-1	11027905
ic@@	O	-1	11027905
ult	O	-1	11027905
pain	B-Disease	D010146	11027905
syndrom@@	O	-1	11027905
es,	O	-1	11027905
such	O	-1	11027905
as	O	-1	11027905
neuro@@	B-Disease	D009437	11027905
path@@	I-Disease	-1	11027905
ic	I-Disease	-1	11027905
pain	I-Disease	-1	11027905
.	O	-1	11027905
A	O	-1	11027905
s@@	O	-1	11027905
low	O	-1	11027905
b@@	O	-1	11027905
ol@@	O	-1	11027905
us	O	-1	11027905
of	O	-1	11027905
sub@@	O	-1	11027905
hy@@	O	-1	11027905
p@@	O	-1	11027905
no@@	O	-1	11027905
tic	O	-1	11027905
doses	O	-1	11027905
of	O	-1	11027905
k@@	B-Chemical	D007649	11027905
et@@	I-Chemical	-1	11027905
amine	I-Chemical	-1	11027905
(0.@@	O	-1	11027905
25	O	-1	11027905
mg/kg	O	-1	11027905
or	O	-1	11027905
0.@@	O	-1	11027905
50	O	-1	11027905
mg/kg)	O	-1	11027905
was	O	-1	11027905
given	O	-1	11027905
to	O	-1	11027905
10	O	-1	11027905
cancer	B-Disease	D009369	11027905
patients	O	-1	11027905
wh@@	O	-1	11027905
ose	O	-1	11027905
pain	B-Disease	D010146	11027905
was	O	-1	11027905
un@@	O	-1	11027905
re@@	O	-1	11027905
li@@	O	-1	11027905
ev@@	O	-1	11027905
ed	O	-1	11027905
by	O	-1	11027905
morphine	B-Chemical	D009020	11027905
in	O	-1	11027905
a	O	-1	11027905
random@@	O	-1	11027905
iz@@	O	-1	11027905
ed,	O	-1	11027905
double-bl@@	O	-1	11027905
ind@@	O	-1	11027905
,	O	-1	11027905
cros@@	O	-1	11027905
so@@	O	-1	11027905
ver,	O	-1	11027905
double-@@	O	-1	11027905
dose	O	-1	11027905
study.	O	-1	11027905
P@@	B-Disease	D010146	11027905
ain	I-Disease	-1	11027905
int@@	O	-1	11027905
ensity	O	-1	11027905
on	O	-1	11027905
a	O	-1	11027905
0	O	-1	11027905
to	O	-1	11027905
10	O	-1	11027905
n@@	O	-1	11027905
um@@	O	-1	11027905
er@@	O	-1	11027905
ical	O	-1	11027905
s@@	O	-1	11027905
cal@@	O	-1	11027905
e@@	O	-1	11027905
;	O	-1	11027905
nausea	B-Disease	D009325	11027905
and	O	-1	11027905
v@@	B-Disease	D014839	11027905
om@@	I-Disease	-1	11027905
it@@	I-Disease	-1	11027905
ing	I-Disease	-1	11027905
,	O	-1	11027905
dro@@	O	-1	11027905
w@@	O	-1	11027905
s@@	O	-1	11027905
in@@	O	-1	11027905
es@@	O	-1	11027905
s,	O	-1	11027905
conf@@	B-Disease	D003221	11027905
usion	I-Disease	-1	11027905
,	O	-1	11027905
and	O	-1	11027905
d@@	B-Disease	D014987	11027905
r@@	I-Disease	-1	11027905
y	I-Disease	-1	11027905
mou@@	I-Disease	-1	11027905
th	I-Disease	-1	11027905
,	O	-1	11027905
using	O	-1	11027905
a	O	-1	11027905
s@@	O	-1	11027905
cal@@	O	-1	11027905
e	O	-1	11027905
from	O	-1	11027905
0	O	-1	11027905
to	O	-1	11027905
3	O	-1	11027905
(@@	O	-1	11027905
not	O	-1	11027905
at	O	-1	11027905
all@@	O	-1	11027905
,	O	-1	11027905
s@@	O	-1	11027905
li@@	O	-1	11027905
gh@@	O	-1	11027905
t,	O	-1	11027905
a	O	-1	11027905
lo@@	O	-1	11027905
t,	O	-1	11027905
aw@@	O	-1	11027905
ful@@	O	-1	11027905
);	O	-1	11027905
M@@	O	-1	11027905
in@@	O	-1	11027905
i@@	O	-1	11027905
-@@	O	-1	11027905
M@@	O	-1	11027905
ental	O	-1	11027905
S@@	O	-1	11027905
t@@	O	-1	11027905
ate	O	-1	11027905
E@@	O	-1	11027905
x@@	O	-1	11027905
amin@@	O	-1	11027905
ation	O	-1	11027905
(@@	O	-1	11027905
M@@	O	-1	11027905
M@@	O	-1	11027905
S@@	O	-1	11027905
E@@	O	-1	11027905
)	O	-1	11027905
(@@	O	-1	11027905
0-@@	O	-1	11027905
3@@	O	-1	11027905
0@@	O	-1	11027905
);	O	-1	11027905
and	O	-1	11027905
arterial	O	-1	11027905
pressure	O	-1	11027905
were	O	-1	11027905
recor@@	O	-1	11027905
ded	O	-1	11027905
before	O	-1	11027905
administration	O	-1	11027905
of	O	-1	11027905
drugs	O	-1	11027905
(T@@	O	-1	11027905
0@@	O	-1	11027905
)	O	-1	11027905
and	O	-1	11027905
after	O	-1	11027905
30	O	-1	11027905
minutes	O	-1	11027905
(T@@	O	-1	11027905
3@@	O	-1	11027905
0@@	O	-1	11027905
),	O	-1	11027905
60	O	-1	11027905
minutes	O	-1	11027905
(T@@	O	-1	11027905
6@@	O	-1	11027905
0@@	O	-1	11027905
),	O	-1	11027905
1@@	O	-1	11027905
20	O	-1	11027905
minutes	O	-1	11027905
(T@@	O	-1	11027905
1@@	O	-1	11027905
20@@	O	-1	11027905
),	O	-1	11027905
and	O	-1	11027905
18@@	O	-1	11027905
0	O	-1	11027905
minutes	O	-1	11027905
(T@@	O	-1	11027905
18@@	O	-1	11027905
0@@	O	-1	11027905
).	O	-1	11027905
K@@	B-Chemical	D007649	11027905
et@@	I-Chemical	-1	11027905
amine	I-Chemical	-1	11027905
,	O	-1	11027905
but	O	-1	11027905
not	O	-1	11027905
saline	O	-1	11027905
sol@@	O	-1	11027905
u@@	O	-1	11027905
tion,	O	-1	11027905
significantly	O	-1	11027905
reduced	O	-1	11027905
the	O	-1	11027905
pain	B-Disease	D010146	11027905
int@@	O	-1	11027905
ensity	O	-1	11027905
in	O	-1	11027905
al@@	O	-1	11027905
most	O	-1	11027905
all	O	-1	11027905
the	O	-1	11027905
patients	O	-1	11027905
at	O	-1	11027905
both	O	-1	11027905
dos@@	O	-1	11027905
es.	O	-1	11027905
This	O	-1	11027905
effect	O	-1	11027905
was	O	-1	11027905
more	O	-1	11027905
re@@	O	-1	11027905
lev@@	O	-1	11027905
ant	O	-1	11027905
in	O	-1	11027905
patients	O	-1	11027905
treated	O	-1	11027905
with	O	-1	11027905
higher	O	-1	11027905
dos@@	O	-1	11027905
es.	O	-1	11027905
H@@	B-Disease	D006212	11027905
all@@	I-Disease	-1	11027905
uc@@	I-Disease	-1	11027905
in@@	I-Disease	-1	11027905
ations	I-Disease	-1	11027905
occurred	O	-1	11027905
in	O	-1	11027905
4	O	-1	11027905
patients,	O	-1	11027905
and	O	-1	11027905
an	O	-1	11027905
un@@	O	-1	11027905
ple@@	O	-1	11027905
as@@	O	-1	11027905
ant	O	-1	11027905
sens@@	O	-1	11027905
ation	O	-1	11027905
(@@	O	-1	11027905
"@@	O	-1	11027905
em@@	O	-1	11027905
pt@@	O	-1	11027905
y	O	-1	11027905
head@@	O	-1	11027905
"@@	O	-1	11027905
)	O	-1	11027905
was	O	-1	11027905
also	O	-1	11027905
reported	O	-1	11027905
by	O	-1	11027905
2	O	-1	11027905
patients.	O	-1	11027905
These	O	-1	11027905
episo@@	O	-1	11027905
des	O	-1	11027905
reversed	O	-1	11027905
after	O	-1	11027905
the	O	-1	11027905
administration	O	-1	11027905
of	O	-1	11027905
di@@	B-Chemical	D003975	11027905
az@@	I-Chemical	-1	11027905
epam	I-Chemical	-1	11027905
1	O	-1	11027905
mg	O	-1	11027905
intra@@	O	-1	11027905
ven@@	O	-1	11027905
ous@@	O	-1	11027905
ly.	O	-1	11027905
Si@@	O	-1	11027905
gn@@	O	-1	11027905
ific@@	O	-1	11027905
ant	O	-1	11027905
increases	O	-1	11027905
in	O	-1	11027905
dro@@	O	-1	11027905
w@@	O	-1	11027905
s@@	O	-1	11027905
in@@	O	-1	11027905
ess	O	-1	11027905
were	O	-1	11027905
reported	O	-1	11027905
in	O	-1	11027905
patients	O	-1	11027905
treated	O	-1	11027905
with	O	-1	11027905
k@@	B-Chemical	D007649	11027905
et@@	I-Chemical	-1	11027905
amine	I-Chemical	-1	11027905
in	O	-1	11027905
both	O	-1	11027905
groups	O	-1	11027905
and	O	-1	11027905
were	O	-1	11027905
more	O	-1	11027905
mark@@	O	-1	11027905
ed	O	-1	11027905
with	O	-1	11027905
k@@	B-Chemical	D007649	11027905
et@@	I-Chemical	-1	11027905
amine	I-Chemical	-1	11027905
0.@@	O	-1	11027905
50	O	-1	11027905
mg/kg@@	O	-1	11027905
.	O	-1	11027905
A	O	-1	11027905
significant	O	-1	11027905
difference	O	-1	11027905
in	O	-1	11027905
M@@	O	-1	11027905
M@@	O	-1	11027905
S@@	O	-1	11027905
E	O	-1	11027905
was	O	-1	11027905
observed	O	-1	11027905
at	O	-1	11027905
T@@	O	-1	11027905
30	O	-1	11027905
in	O	-1	11027905
patients	O	-1	11027905
who	O	-1	11027905
received	O	-1	11027905
0.@@	O	-1	11027905
50	O	-1	11027905
mg/kg	O	-1	11027905
of	O	-1	11027905
k@@	B-Chemical	D007649	11027905
et@@	I-Chemical	-1	11027905
amine	I-Chemical	-1	11027905
.	O	-1	11027905
K@@	B-Chemical	D007649	11027905
et@@	I-Chemical	-1	11027905
amine	I-Chemical	-1	11027905
can	O	-1	11027905
impro@@	O	-1	11027905
ve	O	-1	11027905
morphine	B-Chemical	D009020	11027905
analge@@	O	-1	11027905
sia	O	-1	11027905
in	O	-1	11027905
diff@@	O	-1	11027905
ic@@	O	-1	11027905
ult	O	-1	11027905
pain	B-Disease	D010146	11027905
syndrom@@	O	-1	11027905
es,	O	-1	11027905
such	O	-1	11027905
as	O	-1	11027905
neuro@@	B-Disease	D009437	11027905
path@@	I-Disease	-1	11027905
ic	I-Disease	-1	11027905
pain	I-Disease	-1	11027905
.	O	-1	11027905
However,	O	-1	11027905
the	O	-1	11027905
occur@@	O	-1	11027905
rence	O	-1	11027905
of	O	-1	11027905
central	O	-1	11027905
adverse	O	-1	11027905
effects	O	-1	11027905
should	O	-1	11027905
be	O	-1	11027905
tak@@	O	-1	11027905
en	O	-1	11027905
into	O	-1	11027905
ac@@	O	-1	11027905
coun@@	O	-1	11027905
t,	O	-1	11027905
es@@	O	-1	11027905
p@@	O	-1	11027905
ec@@	O	-1	11027905
i@@	O	-1	11027905
ally	O	-1	11027905
when	O	-1	11027905
using	O	-1	11027905
higher	O	-1	11027905
dos@@	O	-1	11027905
es.	O	-1	11027905
This	O	-1	11027905
observ@@	O	-1	11027905
ation	O	-1	11027905
should	O	-1	11027905
be	O	-1	11027905
tested	O	-1	11027905
in	O	-1	11027905
studies	O	-1	11027905
of	O	-1	11027905
prolonged	O	-1	11027905
k@@	B-Chemical	D007649	11027905
et@@	I-Chemical	-1	11027905
amine	I-Chemical	-1	11027905
administr@@	O	-1	11027905
ation.	O	-1	11027905

E@@	O	-1	9334596
n@@	O	-1	9334596
doc@@	O	-1	9334596
rine	O	-1	9334596
s@@	O	-1	9334596
cre@@	O	-1	9334596
en@@	O	-1	9334596
ing	O	-1	9334596
in	O	-1	9334596
1@@	O	-1	9334596
,@@	O	-1	9334596
0@@	O	-1	9334596
2@@	O	-1	9334596
2	O	-1	9334596
men	O	-1	9334596
with	O	-1	9334596
e@@	B-Disease	D007172	9334596
rec@@	I-Disease	-1	9334596
ti@@	I-Disease	-1	9334596
le	I-Disease	-1	9334596
dysfunction	I-Disease	-1	9334596
:	O	-1	9334596
clinical	O	-1	9334596
signific@@	O	-1	9334596
ance	O	-1	9334596
and	O	-1	9334596
co@@	O	-1	9334596
st@@	O	-1	9334596
-@@	O	-1	9334596
effective	O	-1	9334596
strat@@	O	-1	9334596
e@@	O	-1	9334596
g@@	O	-1	9334596
y.	O	-1	9334596
P@@	O	-1	9334596
U@@	O	-1	9334596
R@@	O	-1	9334596
P@@	O	-1	9334596
O@@	O	-1	9334596
S@@	O	-1	9334596
E:	O	-1	9334596
We	O	-1	9334596
revie@@	O	-1	9334596
w@@	O	-1	9334596
ed	O	-1	9334596
the	O	-1	9334596
results	O	-1	9334596
of	O	-1	9334596
serum	O	-1	9334596
test@@	B-Chemical	D013739	9334596
osterone	I-Chemical	-1	9334596
and	O	-1	9334596
prolactin	O	-1	9334596
determin@@	O	-1	9334596
ation	O	-1	9334596
in	O	-1	9334596
1@@	O	-1	9334596
,@@	O	-1	9334596
0@@	O	-1	9334596
2@@	O	-1	9334596
2	O	-1	9334596
patients	O	-1	9334596
ref@@	O	-1	9334596
er@@	O	-1	9334596
red	O	-1	9334596
because	O	-1	9334596
of	O	-1	9334596
e@@	B-Disease	D007172	9334596
rec@@	I-Disease	-1	9334596
ti@@	I-Disease	-1	9334596
le	I-Disease	-1	9334596
dysfunction	I-Disease	-1	9334596
and	O	-1	9334596
compared	O	-1	9334596
the	O	-1	9334596
data	O	-1	9334596
with	O	-1	9334596
hist@@	O	-1	9334596
or@@	O	-1	9334596
y,	O	-1	9334596
results	O	-1	9334596
of	O	-1	9334596
physi@@	O	-1	9334596
c@@	O	-1	9334596
al	O	-1	9334596
examin@@	O	-1	9334596
ation,	O	-1	9334596
other	O	-1	9334596
e@@	O	-1	9334596
ti@@	O	-1	9334596
ological	O	-1	9334596
investig@@	O	-1	9334596
ations	O	-1	9334596
and	O	-1	9334596
effects	O	-1	9334596
of	O	-1	9334596
en@@	O	-1	9334596
doc@@	O	-1	9334596
rine	O	-1	9334596
therapy	O	-1	9334596
to	O	-1	9334596
ref@@	O	-1	9334596
ine	O	-1	9334596
the	O	-1	9334596
r@@	O	-1	9334596
ul@@	O	-1	9334596
es	O	-1	9334596
of	O	-1	9334596
co@@	O	-1	9334596
st@@	O	-1	9334596
-@@	O	-1	9334596
effective	O	-1	9334596
en@@	O	-1	9334596
doc@@	O	-1	9334596
rine	O	-1	9334596
s@@	O	-1	9334596
cre@@	O	-1	9334596
en@@	O	-1	9334596
ing	O	-1	9334596
and	O	-1	9334596
to	O	-1	9334596
p@@	O	-1	9334596
in@@	O	-1	9334596
po@@	O	-1	9334596
in@@	O	-1	9334596
t	O	-1	9334596
act@@	O	-1	9334596
ual	O	-1	9334596
respon@@	O	-1	9334596
sib@@	O	-1	9334596
ility	O	-1	9334596
for	O	-1	9334596
h@@	O	-1	9334596
orm@@	O	-1	9334596
on@@	O	-1	9334596
al	O	-1	9334596
abnormal@@	O	-1	9334596
iti@@	O	-1	9334596
es.	O	-1	9334596
M@@	O	-1	9334596
AT@@	O	-1	9334596
E@@	O	-1	9334596
R@@	O	-1	9334596
I@@	O	-1	9334596
AL@@	O	-1	9334596
S	O	-1	9334596
AN@@	O	-1	9334596
D	O	-1	9334596
METHODS:	O	-1	9334596
T@@	B-Chemical	D013739	9334596
est@@	I-Chemical	-1	9334596
osterone	I-Chemical	-1	9334596
and	O	-1	9334596
prolactin	O	-1	9334596
were	O	-1	9334596
determined	O	-1	9334596
by	O	-1	9334596
radi@@	O	-1	9334596
o@@	O	-1	9334596
immuno@@	O	-1	9334596
ass@@	O	-1	9334596
a@@	O	-1	9334596
y.	O	-1	9334596
E@@	O	-1	9334596
very	O	-1	9334596
patient	O	-1	9334596
was	O	-1	9334596
s@@	O	-1	9334596
cre@@	O	-1	9334596
en@@	O	-1	9334596
ed	O	-1	9334596
for	O	-1	9334596
test@@	B-Chemical	D013739	9334596
osterone	I-Chemical	-1	9334596
and	O	-1	9334596
4@@	O	-1	9334596
5@@	O	-1	9334596
1	O	-1	9334596
were	O	-1	9334596
s@@	O	-1	9334596
cre@@	O	-1	9334596
en@@	O	-1	9334596
ed	O	-1	9334596
for	O	-1	9334596
prolactin	O	-1	9334596
on	O	-1	9334596
the	O	-1	9334596
b@@	O	-1	9334596
asis	O	-1	9334596
of	O	-1	9334596
low	B-Disease	D020018	9334596
sex@@	I-Disease	-1	9334596
ual	I-Disease	-1	9334596
desi@@	I-Disease	-1	9334596
r@@	I-Disease	-1	9334596
e	I-Disease	-1	9334596
,	O	-1	9334596
g@@	B-Disease	D006177	9334596
y@@	I-Disease	-1	9334596
nec@@	I-Disease	-1	9334596
om@@	I-Disease	-1	9334596
as@@	I-Disease	-1	9334596
ti@@	I-Disease	-1	9334596
a	I-Disease	-1	9334596
or	O	-1	9334596
test@@	B-Chemical	D013739	9334596
osterone	I-Chemical	-1	9334596
less	O	-1	9334596
than	O	-1	9334596
4	O	-1	9334596
n@@	O	-1	9334596
g@@	O	-1	9334596
.@@	O	-1	9334596
/@@	O	-1	9334596
ml@@	O	-1	9334596
.	O	-1	9334596
De@@	O	-1	9334596
ter@@	O	-1	9334596
min@@	O	-1	9334596
ation	O	-1	9334596
was	O	-1	9334596
repe@@	O	-1	9334596
ated	O	-1	9334596
in	O	-1	9334596
case	O	-1	9334596
of	O	-1	9334596
ab@@	O	-1	9334596
normal	O	-1	9334596
first	O	-1	9334596
result@@	O	-1	9334596
s.	O	-1	9334596
Pro@@	O	-1	9334596
l@@	O	-1	9334596
actin	O	-1	9334596
results	O	-1	9334596
were	O	-1	9334596
compared	O	-1	9334596
with	O	-1	9334596
those	O	-1	9334596
of	O	-1	9334596
a	O	-1	9334596
previ@@	O	-1	9334596
ous	O	-1	9334596
per@@	O	-1	9334596
son@@	O	-1	9334596
al	O	-1	9334596
co@@	O	-1	9334596
h@@	O	-1	9334596
ort	O	-1	9334596
of	O	-1	9334596
1@@	O	-1	9334596
,@@	O	-1	9334596
3@@	O	-1	9334596
40	O	-1	9334596
patients	O	-1	9334596
with	O	-1	9334596
e@@	B-Disease	D007172	9334596
rec@@	I-Disease	-1	9334596
ti@@	I-Disease	-1	9334596
le	I-Disease	-1	9334596
dysfunction	I-Disease	-1	9334596
and	O	-1	9334596
system@@	O	-1	9334596
atic	O	-1	9334596
prolactin	O	-1	9334596
determin@@	O	-1	9334596
ation.	O	-1	9334596
M@@	O	-1	9334596
ain	O	-1	9334596
clinical	O	-1	9334596
c@@	O	-1	9334596
rit@@	O	-1	9334596
er@@	O	-1	9334596
ia	O	-1	9334596
tested	O	-1	9334596
reg@@	O	-1	9334596
ar@@	O	-1	9334596
ding	O	-1	9334596
eff@@	O	-1	9334596
ici@@	O	-1	9334596
ency	O	-1	9334596
in	O	-1	9334596
h@@	O	-1	9334596
orm@@	O	-1	9334596
one	O	-1	9334596
determin@@	O	-1	9334596
ation	O	-1	9334596
were	O	-1	9334596
low	B-Disease	D020018	9334596
sex@@	I-Disease	-1	9334596
ual	I-Disease	-1	9334596
desi@@	I-Disease	-1	9334596
r@@	I-Disease	-1	9334596
e	I-Disease	-1	9334596
,	O	-1	9334596
sm@@	O	-1	9334596
all	O	-1	9334596
test@@	O	-1	9334596
es	O	-1	9334596
and	O	-1	9334596
g@@	B-Disease	D006177	9334596
y@@	I-Disease	-1	9334596
nec@@	I-Disease	-1	9334596
om@@	I-Disease	-1	9334596
as@@	I-Disease	-1	9334596
ti@@	I-Disease	-1	9334596
a	I-Disease	-1	9334596
.	O	-1	9334596
E@@	O	-1	9334596
n@@	O	-1	9334596
doc@@	O	-1	9334596
rine	O	-1	9334596
therapy	O	-1	9334596
consist@@	O	-1	9334596
ed	O	-1	9334596
of	O	-1	9334596
test@@	B-Chemical	C004648	9334596
osterone	I-Chemical	-1	9334596
he@@	I-Chemical	-1	9334596
pt@@	I-Chemical	-1	9334596
yl@@	I-Chemical	-1	9334596
ate	I-Chemical	-1	9334596
or	O	-1	9334596
human	O	-1	9334596
ch@@	O	-1	9334596
or@@	O	-1	9334596
i@@	O	-1	9334596
onic	O	-1	9334596
g@@	O	-1	9334596
on@@	O	-1	9334596
ad@@	O	-1	9334596
ot@@	O	-1	9334596
ro@@	O	-1	9334596
p@@	O	-1	9334596
in	O	-1	9334596
for	O	-1	9334596
hypo@@	B-Disease	D007006	9334596
g@@	I-Disease	-1	9334596
on@@	I-Disease	-1	9334596
a@@	I-Disease	-1	9334596
dis@@	I-Disease	-1	9334596
m	I-Disease	-1	9334596
and	O	-1	9334596
brom@@	B-Chemical	D001971	9334596
oc@@	I-Chemical	-1	9334596
ript@@	I-Chemical	-1	9334596
ine	I-Chemical	-1	9334596
for	O	-1	9334596
hyper@@	B-Disease	D006966	9334596
prol@@	I-Disease	-1	9334596
act@@	I-Disease	-1	9334596
ine@@	I-Disease	-1	9334596
mia	I-Disease	-1	9334596
.	O	-1	9334596
RESULTS:	O	-1	9334596
T@@	B-Chemical	D013739	9334596
est@@	I-Chemical	-1	9334596
osterone	I-Chemical	-1	9334596
was	O	-1	9334596
less	O	-1	9334596
than	O	-1	9334596
3	O	-1	9334596
n@@	O	-1	9334596
g@@	O	-1	9334596
.@@	O	-1	9334596
/@@	O	-1	9334596
ml@@	O	-1	9334596
.	O	-1	9334596
in	O	-1	9334596
10@@	O	-1	9334596
7	O	-1	9334596
patients	O	-1	9334596
but	O	-1	9334596
normal	O	-1	9334596
in	O	-1	9334596
4@@	O	-1	9334596
0%	O	-1	9334596
at	O	-1	9334596
repe@@	O	-1	9334596
at	O	-1	9334596
determin@@	O	-1	9334596
ation.	O	-1	9334596
The	O	-1	9334596
prev@@	O	-1	9334596
al@@	O	-1	9334596
ence	O	-1	9334596
of	O	-1	9334596
repe@@	O	-1	9334596
ated@@	O	-1	9334596
ly	O	-1	9334596
low	O	-1	9334596
test@@	B-Chemical	D013739	9334596
osterone	I-Chemical	-1	9334596
increased	O	-1	9334596
with	O	-1	9334596
age	O	-1	9334596
(4@@	O	-1	9334596
%	O	-1	9334596
before	O	-1	9334596
age	O	-1	9334596
50	O	-1	9334596
years	O	-1	9334596
and	O	-1	9334596
9@@	O	-1	9334596
%	O	-1	9334596
50	O	-1	9334596
years	O	-1	9334596
or	O	-1	9334596
ol@@	O	-1	9334596
der@@	O	-1	9334596
).	O	-1	9334596
Two	O	-1	9334596
pit@@	B-Disease	D010911	9334596
u@@	I-Disease	-1	9334596
it@@	I-Disease	-1	9334596
ary	I-Disease	-1	9334596
tu@@	I-Disease	-1	9334596
mor@@	I-Disease	-1	9334596
s	I-Disease	-1	9334596
were	O	-1	9334596
dis@@	O	-1	9334596
co@@	O	-1	9334596
vered	O	-1	9334596
after	O	-1	9334596
test@@	B-Chemical	D013739	9334596
osterone	I-Chemical	-1	9334596
determin@@	O	-1	9334596
ation.	O	-1	9334596
M@@	O	-1	9334596
ost	O	-1	9334596
of	O	-1	9334596
the	O	-1	9334596
other	O	-1	9334596
low	O	-1	9334596
test@@	B-Chemical	D013739	9334596
osterone	I-Chemical	-1	9334596
levels	O	-1	9334596
se@@	O	-1	9334596
em@@	O	-1	9334596
ed	O	-1	9334596
to	O	-1	9334596
result	O	-1	9334596
from	O	-1	9334596
non@@	O	-1	9334596
org@@	O	-1	9334596
anic	O	-1	9334596
hypo@@	B-Disease	D007027	9334596
thal@@	I-Disease	-1	9334596
am@@	I-Disease	-1	9334596
ic	I-Disease	-1	9334596
dysfunction	I-Disease	-1	9334596
because	O	-1	9334596
of	O	-1	9334596
normal	O	-1	9334596
serum	O	-1	9334596
lu@@	O	-1	9334596
te@@	O	-1	9334596
in@@	O	-1	9334596
iz@@	O	-1	9334596
ing	O	-1	9334596
h@@	O	-1	9334596
orm@@	O	-1	9334596
one	O	-1	9334596
and	O	-1	9334596
prolactin	O	-1	9334596
and	O	-1	9334596
to	O	-1	9334596
have	O	-1	9334596
only	O	-1	9334596
a	O	-1	9334596
sm@@	O	-1	9334596
all	O	-1	9334596
role	O	-1	9334596
in	O	-1	9334596
e@@	B-Disease	D007172	9334596
rec@@	I-Disease	-1	9334596
ti@@	I-Disease	-1	9334596
le	I-Disease	-1	9334596
dysfunction	I-Disease	-1	9334596
(@@	O	-1	9334596
def@@	O	-1	9334596
in@@	O	-1	9334596
ite	O	-1	9334596
impro@@	O	-1	9334596
vement	O	-1	9334596
in	O	-1	9334596
only	O	-1	9334596
16	O	-1	9334596
of	O	-1	9334596
4@@	O	-1	9334596
4	O	-1	9334596
[@@	O	-1	9334596
3@@	O	-1	9334596
6@@	O	-1	9334596
%@@	O	-1	9334596
]	O	-1	9334596
after	O	-1	9334596
and@@	O	-1	9334596
ro@@	O	-1	9334596
gen	O	-1	9334596
therapy,	O	-1	9334596
normal	O	-1	9334596
mor@@	O	-1	9334596
ning	O	-1	9334596
or	O	-1	9334596
n@@	O	-1	9334596
oc@@	O	-1	9334596
t@@	O	-1	9334596
ur@@	O	-1	9334596
n@@	O	-1	9334596
al	O	-1	9334596
e@@	O	-1	9334596
rec@@	O	-1	9334596
tions	O	-1	9334596
in	O	-1	9334596
3@@	O	-1	9334596
0%	O	-1	9334596
and	O	-1	9334596
def@@	O	-1	9334596
in@@	O	-1	9334596
ite	O	-1	9334596
vas@@	O	-1	9334596
c@@	O	-1	9334596
u@@	O	-1	9334596
log@@	O	-1	9334596
en@@	O	-1	9334596
ic	O	-1	9334596
cont@@	O	-1	9334596
ri@@	O	-1	9334596
bu@@	O	-1	9334596
tions	O	-1	9334596
in	O	-1	9334596
4@@	O	-1	9334596
2@@	O	-1	9334596
%).	O	-1	9334596
De@@	O	-1	9334596
ter@@	O	-1	9334596
min@@	O	-1	9334596
ing	O	-1	9334596
test@@	B-Chemical	D013739	9334596
osterone	I-Chemical	-1	9334596
only	O	-1	9334596
in	O	-1	9334596
cases	O	-1	9334596
of	O	-1	9334596
low	B-Disease	D020018	9334596
sex@@	I-Disease	-1	9334596
ual	I-Disease	-1	9334596
desi@@	I-Disease	-1	9334596
r@@	I-Disease	-1	9334596
e	I-Disease	-1	9334596
or	O	-1	9334596
ab@@	O	-1	9334596
normal	O	-1	9334596
physi@@	O	-1	9334596
c@@	O	-1	9334596
al	O	-1	9334596
examin@@	O	-1	9334596
ation	O	-1	9334596
wo@@	O	-1	9334596
uld	O	-1	9334596
have	O	-1	9334596
mis@@	O	-1	9334596
sed	O	-1	9334596
4@@	O	-1	9334596
0%	O	-1	9334596
of	O	-1	9334596
the	O	-1	9334596
cases	O	-1	9334596
with	O	-1	9334596
low	O	-1	9334596
test@@	B-Chemical	D013739	9334596
osterone	I-Chemical	-1	9334596
,	O	-1	9334596
including	O	-1	9334596
3@@	O	-1	9334596
7@@	O	-1	9334596
%	O	-1	9334596
of	O	-1	9334596
those	O	-1	9334596
subsequ@@	O	-1	9334596
ently	O	-1	9334596
improved	O	-1	9334596
by	O	-1	9334596
and@@	O	-1	9334596
ro@@	O	-1	9334596
gen	O	-1	9334596
therapy.	O	-1	9334596
Pro@@	O	-1	9334596
l@@	O	-1	9334596
actin	O	-1	9334596
ex@@	O	-1	9334596
ce@@	O	-1	9334596
ed@@	O	-1	9334596
ed	O	-1	9334596
20	O	-1	9334596
n@@	O	-1	9334596
g@@	O	-1	9334596
.@@	O	-1	9334596
/@@	O	-1	9334596
ml@@	O	-1	9334596
.	O	-1	9334596
in	O	-1	9334596
5	O	-1	9334596
men	O	-1	9334596
and	O	-1	9334596
was	O	-1	9334596
normal	O	-1	9334596
in	O	-1	9334596
2	O	-1	9334596
at	O	-1	9334596
repe@@	O	-1	9334596
at	O	-1	9334596
determin@@	O	-1	9334596
ation.	O	-1	9334596
On@@	O	-1	9334596
ly	O	-1	9334596
1	O	-1	9334596
prol@@	B-Disease	D015175	9334596
act@@	I-Disease	-1	9334596
in@@	I-Disease	-1	9334596
oma	I-Disease	-1	9334596
was	O	-1	9334596
dis@@	O	-1	9334596
co@@	O	-1	9334596
ve@@	O	-1	9334596
red.	O	-1	9334596
These	O	-1	9334596
data	O	-1	9334596
are	O	-1	9334596
lower	O	-1	9334596
than	O	-1	9334596
those	O	-1	9334596
we	O	-1	9334596
found	O	-1	9334596
during	O	-1	9334596
the	O	-1	9334596
las@@	O	-1	9334596
t	O	-1	9334596
2	O	-1	9334596
dec@@	O	-1	9334596
a@@	O	-1	9334596
des	O	-1	9334596
(@@	O	-1	9334596
over@@	O	-1	9334596
all	O	-1	9334596
prolactin	O	-1	9334596
greater	O	-1	9334596
than	O	-1	9334596
20	O	-1	9334596
n@@	O	-1	9334596
g@@	O	-1	9334596
.@@	O	-1	9334596
/@@	O	-1	9334596
ml@@	O	-1	9334596
.	O	-1	9334596
in	O	-1	9334596
1.@@	O	-1	9334596
8@@	O	-1	9334596
6%	O	-1	9334596
of	O	-1	9334596
1@@	O	-1	9334596
,@@	O	-1	9334596
8@@	O	-1	9334596
21	O	-1	9334596
patients,	O	-1	9334596
prol@@	B-Disease	D015175	9334596
act@@	I-Disease	-1	9334596
in@@	I-Disease	-1	9334596
om@@	I-Disease	-1	9334596
as	I-Disease	-1	9334596
in	O	-1	9334596
7@@	O	-1	9334596
,	O	-1	9334596
0.@@	O	-1	9334596
3@@	O	-1	9334596
8@@	O	-1	9334596
%).	O	-1	9334596
B@@	B-Chemical	D001971	9334596
rom@@	I-Chemical	-1	9334596
oc@@	I-Chemical	-1	9334596
ript@@	I-Chemical	-1	9334596
ine	I-Chemical	-1	9334596
was	O	-1	9334596
def@@	O	-1	9334596
in@@	O	-1	9334596
it@@	O	-1	9334596
ely	O	-1	9334596
effective	O	-1	9334596
in	O	-1	9334596
cases	O	-1	9334596
with	O	-1	9334596
prolactin	O	-1	9334596
greater	O	-1	9334596
than	O	-1	9334596
3@@	O	-1	9334596
5	O	-1	9334596
n@@	O	-1	9334596
g@@	O	-1	9334596
.@@	O	-1	9334596
/@@	O	-1	9334596
ml@@	O	-1	9334596
.	O	-1	9334596
(@@	O	-1	9334596
8	O	-1	9334596
of	O	-1	9334596
12	O	-1	9334596
compared	O	-1	9334596
to	O	-1	9334596
only	O	-1	9334596
9	O	-1	9334596
of	O	-1	9334596
2@@	O	-1	9334596
2	O	-1	9334596
cases	O	-1	9334596
with	O	-1	9334596
prolactin	O	-1	9334596
between	O	-1	9334596
20	O	-1	9334596
and	O	-1	9334596
3@@	O	-1	9334596
5	O	-1	9334596
n@@	O	-1	9334596
g@@	O	-1	9334596
.@@	O	-1	9334596
/@@	O	-1	9334596
ml@@	O	-1	9334596
.@@	O	-1	9334596
).	O	-1	9334596
T@@	B-Chemical	D013739	9334596
est@@	I-Chemical	-1	9334596
osterone	I-Chemical	-1	9334596
was	O	-1	9334596
low	O	-1	9334596
in	O	-1	9334596
less	O	-1	9334596
than	O	-1	9334596
50@@	O	-1	9334596
%	O	-1	9334596
of	O	-1	9334596
cases	O	-1	9334596
with	O	-1	9334596
prolactin	O	-1	9334596
greater	O	-1	9334596
than	O	-1	9334596
3@@	O	-1	9334596
5	O	-1	9334596
n@@	O	-1	9334596
g@@	O	-1	9334596
.@@	O	-1	9334596
/@@	O	-1	9334596
ml@@	O	-1	9334596
.	O	-1	9334596
CONCLUSIONS:	O	-1	9334596
L@@	O	-1	9334596
o@@	O	-1	9334596
w	O	-1	9334596
prev@@	O	-1	9334596
al@@	O	-1	9334596
enc@@	O	-1	9334596
es	O	-1	9334596
and	O	-1	9334596
effects	O	-1	9334596
of	O	-1	9334596
low	O	-1	9334596
test@@	B-Chemical	D013739	9334596
osterone	I-Chemical	-1	9334596
and	O	-1	9334596
high	O	-1	9334596
prolactin	O	-1	9334596
in	O	-1	9334596
e@@	B-Disease	D007172	9334596
rec@@	I-Disease	-1	9334596
ti@@	I-Disease	-1	9334596
le	I-Disease	-1	9334596
dysfunction	I-Disease	-1	9334596
can@@	O	-1	9334596
not	O	-1	9334596
j@@	O	-1	9334596
us@@	O	-1	9334596
ti@@	O	-1	9334596
f@@	O	-1	9334596
y	O	-1	9334596
their	O	-1	9334596
ro@@	O	-1	9334596
ut@@	O	-1	9334596
ine	O	-1	9334596
determin@@	O	-1	9334596
ation.	O	-1	9334596
However,	O	-1	9334596
co@@	O	-1	9334596
st@@	O	-1	9334596
-@@	O	-1	9334596
effective	O	-1	9334596
s@@	O	-1	9334596
cre@@	O	-1	9334596
en@@	O	-1	9334596
ing	O	-1	9334596
strat@@	O	-1	9334596
e@@	O	-1	9334596
gi@@	O	-1	9334596
es	O	-1	9334596
recomm@@	O	-1	9334596
en@@	O	-1	9334596
ded	O	-1	9334596
so	O	-1	9334596
f@@	O	-1	9334596
ar	O	-1	9334596
mis@@	O	-1	9334596
sed	O	-1	9334596
40	O	-1	9334596
to	O	-1	9334596
50@@	O	-1	9334596
%	O	-1	9334596
of	O	-1	9334596
cases	O	-1	9334596
improved	O	-1	9334596
with	O	-1	9334596
en@@	O	-1	9334596
doc@@	O	-1	9334596
rine	O	-1	9334596
therapy	O	-1	9334596
and	O	-1	9334596
the	O	-1	9334596
pit@@	B-Disease	D010911	9334596
u@@	I-Disease	-1	9334596
it@@	I-Disease	-1	9334596
ary	I-Disease	-1	9334596
tu@@	I-Disease	-1	9334596
mor@@	I-Disease	-1	9334596
s	I-Disease	-1	9334596
.	O	-1	9334596
We	O	-1	9334596
no@@	O	-1	9334596
w	O	-1	9334596
adv@@	O	-1	9334596
oc@@	O	-1	9334596
ate	O	-1	9334596
that	O	-1	9334596
before	O	-1	9334596
age	O	-1	9334596
50	O	-1	9334596
years	O	-1	9334596
test@@	B-Chemical	D013739	9334596
osterone	I-Chemical	-1	9334596
be	O	-1	9334596
determined	O	-1	9334596
only	O	-1	9334596
in	O	-1	9334596
cases	O	-1	9334596
of	O	-1	9334596
low	B-Disease	D020018	9334596
sex@@	I-Disease	-1	9334596
ual	I-Disease	-1	9334596
desi@@	I-Disease	-1	9334596
r@@	I-Disease	-1	9334596
e	I-Disease	-1	9334596
and	O	-1	9334596
ab@@	O	-1	9334596
normal	O	-1	9334596
physi@@	O	-1	9334596
c@@	O	-1	9334596
al	O	-1	9334596
examin@@	O	-1	9334596
ation	O	-1	9334596
but	O	-1	9334596
that	O	-1	9334596
it	O	-1	9334596
be	O	-1	9334596
measured	O	-1	9334596
in	O	-1	9334596
all	O	-1	9334596
men	O	-1	9334596
ol@@	O	-1	9334596
der	O	-1	9334596
than	O	-1	9334596
50	O	-1	9334596
year@@	O	-1	9334596
s.	O	-1	9334596
Pro@@	O	-1	9334596
l@@	O	-1	9334596
actin	O	-1	9334596
should	O	-1	9334596
be	O	-1	9334596
determined	O	-1	9334596
only	O	-1	9334596
in	O	-1	9334596
cases	O	-1	9334596
of	O	-1	9334596
low	B-Disease	D020018	9334596
sex@@	I-Disease	-1	9334596
ual	I-Disease	-1	9334596
desi@@	I-Disease	-1	9334596
r@@	I-Disease	-1	9334596
e	I-Disease	-1	9334596
,	O	-1	9334596
g@@	B-Disease	D006177	9334596
y@@	I-Disease	-1	9334596
nec@@	I-Disease	-1	9334596
om@@	I-Disease	-1	9334596
as@@	I-Disease	-1	9334596
ti@@	I-Disease	-1	9334596
a	I-Disease	-1	9334596
and/or	O	-1	9334596
test@@	B-Chemical	D013739	9334596
osterone	I-Chemical	-1	9334596
less	O	-1	9334596
than	O	-1	9334596
4	O	-1	9334596
n@@	O	-1	9334596
g@@	O	-1	9334596
.@@	O	-1	9334596
/@@	O	-1	9334596
ml@@	O	-1	9334596
.	O	-1	9334596

Th@@	B-Chemical	D013874	8595686
io@@	I-Chemical	-1	8595686
pent@@	I-Chemical	-1	8595686
one	I-Chemical	-1	8595686
pretreatment	O	-1	8595686
for	O	-1	8595686
pro@@	B-Chemical	D015742	8595686
po@@	I-Chemical	-1	8595686
f@@	I-Chemical	-1	8595686
ol	I-Chemical	-1	8595686
injection	O	-1	8595686
pain	B-Disease	D010146	8595686
in	O	-1	8595686
am@@	O	-1	8595686
b@@	O	-1	8595686
ul@@	O	-1	8595686
atory	O	-1	8595686
patients.	O	-1	8595686
This	O	-1	8595686
study	O	-1	8595686
investigated	O	-1	8595686
pro@@	B-Chemical	D015742	8595686
po@@	I-Chemical	-1	8595686
f@@	I-Chemical	-1	8595686
ol	I-Chemical	-1	8595686
injection	O	-1	8595686
pain	B-Disease	D010146	8595686
in	O	-1	8595686
patients	O	-1	8595686
under@@	O	-1	8595686
go@@	O	-1	8595686
ing	O	-1	8595686
am@@	O	-1	8595686
b@@	O	-1	8595686
ul@@	O	-1	8595686
atory	O	-1	8595686
anaesthe@@	O	-1	8595686
sia.	O	-1	8595686
In	O	-1	8595686
a	O	-1	8595686
random@@	O	-1	8595686
iz@@	O	-1	8595686
ed,	O	-1	8595686
double-bl@@	O	-1	8595686
ind	O	-1	8595686
tri@@	O	-1	8595686
al,	O	-1	8595686
9@@	O	-1	8595686
0	O	-1	8595686
women	O	-1	8595686
were	O	-1	8595686
al@@	O	-1	8595686
loc@@	O	-1	8595686
ated	O	-1	8595686
to	O	-1	8595686
recei@@	O	-1	8595686
ve	O	-1	8595686
one	O	-1	8595686
of	O	-1	8595686
three	O	-1	8595686
treat@@	O	-1	8595686
ments	O	-1	8595686
prior	O	-1	8595686
to	O	-1	8595686
induction	O	-1	8595686
of	O	-1	8595686
anaesthe@@	O	-1	8595686
sia	O	-1	8595686
with	O	-1	8595686
pro@@	B-Chemical	D015742	8595686
po@@	I-Chemical	-1	8595686
f@@	I-Chemical	-1	8595686
ol	I-Chemical	-1	8595686
.	O	-1	8595686
Patients	O	-1	8595686
in	O	-1	8595686
Group	O	-1	8595686
C	O	-1	8595686
received	O	-1	8595686
2	O	-1	8595686
m@@	O	-1	8595686
l	O	-1	8595686
normal	O	-1	8595686
sal@@	O	-1	8595686
ine,	O	-1	8595686
Group	O	-1	8595686
L@@	O	-1	8595686
,	O	-1	8595686
2	O	-1	8595686
ml@@	O	-1	8595686
,	O	-1	8595686
lidocaine	B-Chemical	D008012	8595686
2@@	O	-1	8595686
%	O	-1	8595686
(@@	O	-1	8595686
40	O	-1	8595686
mg@@	O	-1	8595686
)	O	-1	8595686
and	O	-1	8595686
Group	O	-1	8595686
T@@	O	-1	8595686
,	O	-1	8595686
2	O	-1	8595686
m@@	O	-1	8595686
l	O	-1	8595686
th@@	B-Chemical	D013874	8595686
io@@	I-Chemical	-1	8595686
pent@@	I-Chemical	-1	8595686
one	I-Chemical	-1	8595686
2.@@	O	-1	8595686
5%	O	-1	8595686
(@@	O	-1	8595686
50	O	-1	8595686
mg@@	O	-1	8595686
).	O	-1	8595686
V@@	O	-1	8595686
en@@	O	-1	8595686
ous	O	-1	8595686
dis@@	O	-1	8595686
com@@	O	-1	8595686
for@@	O	-1	8595686
t	O	-1	8595686
was	O	-1	8595686
assessed	O	-1	8595686
with	O	-1	8595686
a	O	-1	8595686
visual	O	-1	8595686
an@@	O	-1	8595686
alo@@	O	-1	8595686
gu@@	O	-1	8595686
e	O	-1	8595686
s@@	O	-1	8595686
cal@@	O	-1	8595686
e	O	-1	8595686
(V@@	O	-1	8595686
A@@	O	-1	8595686
S)	O	-1	8595686
5-@@	O	-1	8595686
15	O	-1	8595686
se@@	O	-1	8595686
c	O	-1	8595686
after	O	-1	8595686
comm@@	O	-1	8595686
enc@@	O	-1	8595686
ing	O	-1	8595686
pro@@	B-Chemical	D015742	8595686
po@@	I-Chemical	-1	8595686
f@@	I-Chemical	-1	8595686
ol	I-Chemical	-1	8595686
administration	O	-1	8595686
using	O	-1	8595686
an	O	-1	8595686
infusion	O	-1	8595686
p@@	O	-1	8595686
um@@	O	-1	8595686
p	O	-1	8595686
(@@	O	-1	8595686
rate	O	-1	8595686
10@@	O	-1	8595686
00	O	-1	8595686
microgram@@	O	-1	8595686
s@@	O	-1	8595686
.@@	O	-1	8595686
kg@@	O	-1	8595686
-@@	O	-1	8595686
1.@@	O	-1	8595686
min@@	O	-1	8595686
-1@@	O	-1	8595686
).	O	-1	8595686
L@@	B-Disease	D014474	8595686
os@@	I-Disease	-1	8595686
s	I-Disease	-1	8595686
of	I-Disease	-1	8595686
con@@	I-Disease	-1	8595686
s@@	I-Disease	-1	8595686
ci@@	I-Disease	-1	8595686
ous@@	I-Disease	-1	8595686
ness	I-Disease	-1	8595686
occurred	O	-1	8595686
in	O	-1	8595686
6@@	O	-1	8595686
0-@@	O	-1	8595686
9@@	O	-1	8595686
0	O	-1	8595686
sec@@	O	-1	8595686
.	O	-1	8595686
V@@	O	-1	8595686
i@@	O	-1	8595686
sual	O	-1	8595686
an@@	O	-1	8595686
alo@@	O	-1	8595686
gu@@	O	-1	8595686
e	O	-1	8595686
sco@@	O	-1	8595686
res	O	-1	8595686
(@@	O	-1	8595686
mean	O	-1	8595686
+/-	O	-1	8595686
S@@	O	-1	8595686
D)	O	-1	8595686
during	O	-1	8595686
induction	O	-1	8595686
were	O	-1	8595686
lower	O	-1	8595686
in	O	-1	8595686
Grou@@	O	-1	8595686
p@@	O	-1	8595686
s	O	-1	8595686
L	O	-1	8595686
(@@	O	-1	8595686
3.@@	O	-1	8595686
3	O	-1	8595686
+/-	O	-1	8595686
2.@@	O	-1	8595686
5@@	O	-1	8595686
)	O	-1	8595686
and	O	-1	8595686
T	O	-1	8595686
(@@	O	-1	8595686
4.@@	O	-1	8595686
1	O	-1	8595686
+/-	O	-1	8595686
2.@@	O	-1	8595686
7@@	O	-1	8595686
)	O	-1	8595686
than	O	-1	8595686
in	O	-1	8595686
Group	O	-1	8595686
C	O	-1	8595686
(@@	O	-1	8595686
5.@@	O	-1	8595686
6	O	-1	8595686
+/-	O	-1	8595686
2.@@	O	-1	8595686
3@@	O	-1	8595686
);	O	-1	8595686
P	O	-1	8595686
=	O	-1	8595686
0.00@@	O	-1	8595686
3@@	O	-1	8595686
1@@	O	-1	8595686
.	O	-1	8595686
The	O	-1	8595686
incidence	O	-1	8595686
of	O	-1	8595686
venous	O	-1	8595686
dis@@	O	-1	8595686
com@@	O	-1	8595686
for@@	O	-1	8595686
t	O	-1	8595686
was	O	-1	8595686
lower	O	-1	8595686
in	O	-1	8595686
Group	O	-1	8595686
L	O	-1	8595686
(@@	O	-1	8595686
7@@	O	-1	8595686
6.@@	O	-1	8595686
6@@	O	-1	8595686
%@@	O	-1	8595686
;	O	-1	8595686
P	O	-1	8595686
<	O	-1	8595686
0.05@@	O	-1	8595686
)	O	-1	8595686
than	O	-1	8595686
in	O	-1	8595686
Group	O	-1	8595686
C	O	-1	8595686
(@@	O	-1	8595686
10@@	O	-1	8595686
0@@	O	-1	8595686
%)	O	-1	8595686
but	O	-1	8595686
not	O	-1	8595686
different	O	-1	8595686
from	O	-1	8595686
Group	O	-1	8595686
T	O	-1	8595686
(@@	O	-1	8595686
9@@	O	-1	8595686
0@@	O	-1	8595686
%).	O	-1	8595686
The	O	-1	8595686
V@@	O	-1	8595686
A@@	O	-1	8595686
S	O	-1	8595686
sco@@	O	-1	8595686
res	O	-1	8595686
for	O	-1	8595686
rec@@	O	-1	8595686
all	O	-1	8595686
of	O	-1	8595686
pain	B-Disease	D010146	8595686
in	O	-1	8595686
the	O	-1	8595686
recovery	O	-1	8595686
ro@@	O	-1	8595686
o@@	O	-1	8595686
m	O	-1	8595686
were	O	-1	8595686
cor@@	O	-1	8595686
related	O	-1	8595686
with	O	-1	8595686
the	O	-1	8595686
V@@	O	-1	8595686
A@@	O	-1	8595686
S	O	-1	8595686
sco@@	O	-1	8595686
res	O	-1	8595686
during	O	-1	8595686
induction	O	-1	8595686
(@@	O	-1	8595686
r	O	-1	8595686
=	O	-1	8595686
0.@@	O	-1	8595686
7@@	O	-1	8595686
0@@	O	-1	8595686
4@@	O	-1	8595686
5@@	O	-1	8595686
;	O	-1	8595686
P	O	-1	8595686
<	O	-1	8595686
0.00@@	O	-1	8595686
0@@	O	-1	8595686
1).	O	-1	8595686
Rec@@	O	-1	8595686
o@@	O	-1	8595686
very	O	-1	8595686
ro@@	O	-1	8595686
o@@	O	-1	8595686
m	O	-1	8595686
dis@@	O	-1	8595686
ch@@	O	-1	8595686
arg@@	O	-1	8595686
e	O	-1	8595686
times	O	-1	8595686
were	O	-1	8595686
simil@@	O	-1	8595686
ar@@	O	-1	8595686
:	O	-1	8595686
C	O	-1	8595686
(@@	O	-1	8595686
7@@	O	-1	8595686
5.@@	O	-1	8595686
9	O	-1	8595686
+/-	O	-1	8595686
19@@	O	-1	8595686
.@@	O	-1	8595686
4	O	-1	8595686
min@@	O	-1	8595686
);	O	-1	8595686
L	O	-1	8595686
7@@	O	-1	8595686
3.@@	O	-1	8595686
6	O	-1	8595686
+/-	O	-1	8595686
2@@	O	-1	8595686
1.@@	O	-1	8595686
6	O	-1	8595686
min@@	O	-1	8595686
);	O	-1	8595686
T	O	-1	8595686
(@@	O	-1	8595686
7@@	O	-1	8595686
7.@@	O	-1	8595686
1	O	-1	8595686
+/-	O	-1	8595686
1@@	O	-1	8595686
8.@@	O	-1	8595686
9	O	-1	8595686
min@@	O	-1	8595686
).	O	-1	8595686
A@@	O	-1	8595686
s@@	O	-1	8595686
s@@	O	-1	8595686
ess@@	O	-1	8595686
ing	O	-1	8595686
their	O	-1	8595686
over@@	O	-1	8595686
all	O	-1	8595686
s@@	O	-1	8595686
atis@@	O	-1	8595686
fac@@	O	-1	8595686
tion,	O	-1	8595686
8@@	O	-1	8595686
9.@@	O	-1	8595686
7@@	O	-1	8595686
%	O	-1	8595686
wo@@	O	-1	8595686
uld	O	-1	8595686
ch@@	O	-1	8595686
o@@	O	-1	8595686
ose	O	-1	8595686
pro@@	B-Chemical	D015742	8595686
po@@	I-Chemical	-1	8595686
f@@	I-Chemical	-1	8595686
ol	I-Chemical	-1	8595686
anaesthe@@	O	-1	8595686
sia	O	-1	8595686
again@@	O	-1	8595686
.	O	-1	8595686
We	O	-1	8595686
concl@@	O	-1	8595686
ude	O	-1	8595686
that	O	-1	8595686
lidocaine	B-Chemical	D008012	8595686
reduc@@	O	-1	8595686
es	O	-1	8595686
the	O	-1	8595686
incidence	O	-1	8595686
and	O	-1	8595686
severity	O	-1	8595686
of	O	-1	8595686
pro@@	B-Chemical	D015742	8595686
po@@	I-Chemical	-1	8595686
f@@	I-Chemical	-1	8595686
ol	I-Chemical	-1	8595686
injection	O	-1	8595686
pain	B-Disease	D010146	8595686
in	O	-1	8595686
am@@	O	-1	8595686
b@@	O	-1	8595686
ul@@	O	-1	8595686
atory	O	-1	8595686
patients	O	-1	8595686
whereas	O	-1	8595686
th@@	B-Chemical	D013874	8595686
io@@	I-Chemical	-1	8595686
pent@@	I-Chemical	-1	8595686
one	I-Chemical	-1	8595686
only	O	-1	8595686
reduc@@	O	-1	8595686
es	O	-1	8595686
its	O	-1	8595686
sever@@	O	-1	8595686
ity.	O	-1	8595686

Com@@	O	-1	6466532
par@@	O	-1	6466532
ison	O	-1	6466532
of	O	-1	6466532
i.v@@	O	-1	6466532
.	O	-1	6466532
gly@@	B-Chemical	D006024	6466532
co@@	I-Chemical	-1	6466532
py@@	I-Chemical	-1	6466532
r@@	I-Chemical	-1	6466532
ro@@	I-Chemical	-1	6466532
l@@	I-Chemical	-1	6466532
ate	I-Chemical	-1	6466532
and	O	-1	6466532
atro@@	B-Chemical	D001285	6466532
pine	I-Chemical	-1	6466532
in	O	-1	6466532
the	O	-1	6466532
pre@@	O	-1	6466532
ven@@	O	-1	6466532
tion	O	-1	6466532
of	O	-1	6466532
brady@@	B-Disease	D001919	6466532
cardia	I-Disease	-1	6466532
and	O	-1	6466532
arrhyth@@	B-Disease	D001145	6466532
mi@@	I-Disease	-1	6466532
as	I-Disease	-1	6466532
following	O	-1	6466532
repe@@	O	-1	6466532
ated	O	-1	6466532
doses	O	-1	6466532
of	O	-1	6466532
su@@	B-Chemical	D013390	6466532
xameth@@	I-Chemical	-1	6466532
oni@@	I-Chemical	-1	6466532
um	I-Chemical	-1	6466532
in	O	-1	6466532
child@@	O	-1	6466532
ren@@	O	-1	6466532
.	O	-1	6466532
The	O	-1	6466532
eff@@	O	-1	6466532
ec@@	O	-1	6466532
tiv@@	O	-1	6466532
en@@	O	-1	6466532
ess	O	-1	6466532
of	O	-1	6466532
administration	O	-1	6466532
of	O	-1	6466532
gly@@	B-Chemical	D006024	6466532
co@@	I-Chemical	-1	6466532
py@@	I-Chemical	-1	6466532
r@@	I-Chemical	-1	6466532
ro@@	I-Chemical	-1	6466532
l@@	I-Chemical	-1	6466532
ate	I-Chemical	-1	6466532
5	O	-1	6466532
and	O	-1	6466532
10	O	-1	6466532
microgram@@	O	-1	6466532
s	O	-1	6466532
kg@@	O	-1	6466532
-1	O	-1	6466532
and	O	-1	6466532
atro@@	B-Chemical	D001285	6466532
pine	I-Chemical	-1	6466532
10	O	-1	6466532
and	O	-1	6466532
20	O	-1	6466532
microgram@@	O	-1	6466532
s	O	-1	6466532
kg@@	O	-1	6466532
-1	O	-1	6466532
i.v@@	O	-1	6466532
.	O	-1	6466532
immedi@@	O	-1	6466532
ately	O	-1	6466532
before	O	-1	6466532
the	O	-1	6466532
induction	O	-1	6466532
of	O	-1	6466532
anaesthe@@	O	-1	6466532
si@@	O	-1	6466532
a,	O	-1	6466532
to	O	-1	6466532
prev@@	O	-1	6466532
ent	O	-1	6466532
arrhyth@@	B-Disease	D001145	6466532
mia	I-Disease	-1	6466532
and	O	-1	6466532
brady@@	B-Disease	D001919	6466532
cardia	I-Disease	-1	6466532
following	O	-1	6466532
repe@@	O	-1	6466532
ated	O	-1	6466532
doses	O	-1	6466532
of	O	-1	6466532
su@@	B-Chemical	D013390	6466532
xameth@@	I-Chemical	-1	6466532
oni@@	I-Chemical	-1	6466532
um	I-Chemical	-1	6466532
in	O	-1	6466532
child@@	O	-1	6466532
ren@@	O	-1	6466532
,	O	-1	6466532
was	O	-1	6466532
studi@@	O	-1	6466532
ed.	O	-1	6466532
A	O	-1	6466532
control	O	-1	6466532
group	O	-1	6466532
was	O	-1	6466532
included	O	-1	6466532
for	O	-1	6466532
compar@@	O	-1	6466532
ison	O	-1	6466532
with	O	-1	6466532
the	O	-1	6466532
lower	O	-1	6466532
dose	O	-1	6466532
range	O	-1	6466532
of	O	-1	6466532
gly@@	B-Chemical	D006024	6466532
co@@	I-Chemical	-1	6466532
py@@	I-Chemical	-1	6466532
r@@	I-Chemical	-1	6466532
ro@@	I-Chemical	-1	6466532
l@@	I-Chemical	-1	6466532
ate	I-Chemical	-1	6466532
and	O	-1	6466532
atro@@	B-Chemical	D001285	6466532
pine	I-Chemical	-1	6466532
.	O	-1	6466532
A	O	-1	6466532
frequency	O	-1	6466532
of	O	-1	6466532
brady@@	B-Disease	D001919	6466532
cardia	I-Disease	-1	6466532
of	O	-1	6466532
50@@	O	-1	6466532
%	O	-1	6466532
was	O	-1	6466532
not@@	O	-1	6466532
ed	O	-1	6466532
in	O	-1	6466532
the	O	-1	6466532
control	O	-1	6466532
group@@	O	-1	6466532
,	O	-1	6466532
but	O	-1	6466532
this	O	-1	6466532
was	O	-1	6466532
not	O	-1	6466532
significantly	O	-1	6466532
different	O	-1	6466532
from	O	-1	6466532
the	O	-1	6466532
frequency	O	-1	6466532
with	O	-1	6466532
the	O	-1	6466532
active	O	-1	6466532
drug@@	O	-1	6466532
s.	O	-1	6466532
B@@	B-Disease	D001919	6466532
ra@@	I-Disease	-1	6466532
dy@@	I-Disease	-1	6466532
cardia	I-Disease	-1	6466532
(@@	O	-1	6466532
def@@	O	-1	6466532
in@@	O	-1	6466532
ed	O	-1	6466532
as	O	-1	6466532
a	O	-1	6466532
decrease	O	-1	6466532
in	O	-1	6466532
heart	O	-1	6466532
rate	O	-1	6466532
to	O	-1	6466532
less	O	-1	6466532
than	O	-1	6466532
50	O	-1	6466532
be@@	O	-1	6466532
at	O	-1	6466532
min@@	O	-1	6466532
-1@@	O	-1	6466532
)	O	-1	6466532
was	O	-1	6466532
prevent@@	O	-1	6466532
ed	O	-1	6466532
when	O	-1	6466532
the	O	-1	6466532
larg@@	O	-1	6466532
er	O	-1	6466532
dose	O	-1	6466532
of	O	-1	6466532
either	O	-1	6466532
active	O	-1	6466532
drug	O	-1	6466532
was	O	-1	6466532
use@@	O	-1	6466532
d.	O	-1	6466532
It	O	-1	6466532
is	O	-1	6466532
recomm@@	O	-1	6466532
en@@	O	-1	6466532
ded	O	-1	6466532
that	O	-1	6466532
either	O	-1	6466532
gly@@	B-Chemical	D006024	6466532
co@@	I-Chemical	-1	6466532
py@@	I-Chemical	-1	6466532
r@@	I-Chemical	-1	6466532
ro@@	I-Chemical	-1	6466532
l@@	I-Chemical	-1	6466532
ate	I-Chemical	-1	6466532
10	O	-1	6466532
microgram@@	O	-1	6466532
s	O	-1	6466532
kg@@	O	-1	6466532
-1	O	-1	6466532
or	O	-1	6466532
atro@@	B-Chemical	D001285	6466532
pine	I-Chemical	-1	6466532
20	O	-1	6466532
microgram@@	O	-1	6466532
s	O	-1	6466532
kg@@	O	-1	6466532
-1	O	-1	6466532
i.v@@	O	-1	6466532
.	O	-1	6466532
should	O	-1	6466532
immedi@@	O	-1	6466532
ately	O	-1	6466532
pre@@	O	-1	6466532
ce@@	O	-1	6466532
de	O	-1	6466532
induction	O	-1	6466532
of	O	-1	6466532
anaesthe@@	O	-1	6466532
si@@	O	-1	6466532
a,	O	-1	6466532
in	O	-1	6466532
child@@	O	-1	6466532
ren@@	O	-1	6466532
,	O	-1	6466532
if	O	-1	6466532
the	O	-1	6466532
repe@@	O	-1	6466532
ated	O	-1	6466532
administration	O	-1	6466532
of	O	-1	6466532
su@@	B-Chemical	D013390	6466532
xameth@@	I-Chemical	-1	6466532
oni@@	I-Chemical	-1	6466532
um	I-Chemical	-1	6466532
is	O	-1	6466532
anti@@	O	-1	6466532
ci@@	O	-1	6466532
pat@@	O	-1	6466532
ed.	O	-1	6466532

Re@@	O	-1	6308277
duction	O	-1	6308277
in	O	-1	6308277
caffe@@	B-Chemical	D002110	6308277
ine	I-Chemical	-1	6308277
toxicity	B-Disease	D064420	6308277
by	O	-1	6308277
acet@@	B-Chemical	D000082	6308277
aminoph@@	I-Chemical	-1	6308277
en	I-Chemical	-1	6308277
.	O	-1	6308277
A	O	-1	6308277
patient	O	-1	6308277
who	O	-1	6308277
al@@	O	-1	6308277
le@@	O	-1	6308277
g@@	O	-1	6308277
ed@@	O	-1	6308277
ly	O	-1	6308277
consum@@	O	-1	6308277
ed	O	-1	6308277
100	O	-1	6308277
t@@	O	-1	6308277
able@@	O	-1	6308277
ts	O	-1	6308277
of	O	-1	6308277
an	O	-1	6308277
over@@	O	-1	6308277
-@@	O	-1	6308277
the@@	O	-1	6308277
-@@	O	-1	6308277
coun@@	O	-1	6308277
ter	O	-1	6308277
analge@@	O	-1	6308277
sic	O	-1	6308277
containing	O	-1	6308277
sodium	B-Chemical	-1	6308277
acet@@	I-Chemical	-1	6308277
yl@@	I-Chemical	-1	6308277
sal@@	I-Chemical	-1	6308277
ic@@	I-Chemical	-1	6308277
yl@@	I-Chemical	-1	6308277
ate	I-Chemical	-1	6308277
,	O	-1	6308277
caffe@@	B-Chemical	D002110	6308277
ine	I-Chemical	-1	6308277
,	O	-1	6308277
and	O	-1	6308277
acet@@	B-Chemical	D000082	6308277
aminoph@@	I-Chemical	-1	6308277
en	I-Chemical	-1	6308277
dis@@	O	-1	6308277
pl@@	O	-1	6308277
ayed	O	-1	6308277
no	O	-1	6308277
significant	O	-1	6308277
C@@	O	-1	6308277
N@@	O	-1	6308277
S	O	-1	6308277
stimulation	O	-1	6308277
des@@	O	-1	6308277
pit@@	O	-1	6308277
e	O	-1	6308277
the	O	-1	6308277
presence	O	-1	6308277
of	O	-1	6308277
17@@	O	-1	6308277
5	O	-1	6308277
microgram@@	O	-1	6308277
s	O	-1	6308277
of	O	-1	6308277
caffe@@	B-Chemical	D002110	6308277
ine	I-Chemical	-1	6308277
per	O	-1	6308277
m@@	O	-1	6308277
L	O	-1	6308277
of	O	-1	6308277
ser@@	O	-1	6308277
um@@	O	-1	6308277
.	O	-1	6308277
B@@	O	-1	6308277
ecause	O	-1	6308277
sal@@	O	-1	6308277
ic@@	O	-1	6308277
yl@@	O	-1	6308277
ates	O	-1	6308277
have	O	-1	6308277
been	O	-1	6308277
reported	O	-1	6308277
to	O	-1	6308277
au@@	O	-1	6308277
g@@	O	-1	6308277
ment	O	-1	6308277
the	O	-1	6308277
stimul@@	O	-1	6308277
atory	O	-1	6308277
effects	O	-1	6308277
of	O	-1	6308277
caffe@@	B-Chemical	D002110	6308277
ine	I-Chemical	-1	6308277
on	O	-1	6308277
the	O	-1	6308277
C@@	O	-1	6308277
N@@	O	-1	6308277
S@@	O	-1	6308277
,	O	-1	6308277
atten@@	O	-1	6308277
tion	O	-1	6308277
was	O	-1	6308277
foc@@	O	-1	6308277
used	O	-1	6308277
on	O	-1	6308277
the	O	-1	6308277
possib@@	O	-1	6308277
ility	O	-1	6308277
that	O	-1	6308277
the	O	-1	6308277
presence	O	-1	6308277
of	O	-1	6308277
acet@@	B-Chemical	D000082	6308277
aminoph@@	I-Chemical	-1	6308277
en	I-Chemical	-1	6308277
(5@@	O	-1	6308277
2	O	-1	6308277
microgram@@	O	-1	6308277
s/@@	O	-1	6308277
m@@	O	-1	6308277
L@@	O	-1	6308277
)	O	-1	6308277
reduced	O	-1	6308277
the	O	-1	6308277
C@@	O	-1	6308277
N@@	O	-1	6308277
S	O	-1	6308277
toxicity	B-Disease	D064420	6308277
of	O	-1	6308277
caffe@@	B-Chemical	D002110	6308277
ine	I-Chemical	-1	6308277
.	O	-1	6308277
S@@	O	-1	6308277
t@@	O	-1	6308277
udi@@	O	-1	6308277
es	O	-1	6308277
in	O	-1	6308277
D@@	O	-1	6308277
BA@@	O	-1	6308277
/@@	O	-1	6308277
2@@	O	-1	6308277
J	O	-1	6308277
mice	O	-1	6308277
showed	O	-1	6308277
th@@	O	-1	6308277
at@@	O	-1	6308277
:	O	-1	6308277
1)	O	-1	6308277
pretreatment	O	-1	6308277
with	O	-1	6308277
acet@@	B-Chemical	D000082	6308277
aminoph@@	I-Chemical	-1	6308277
en	I-Chemical	-1	6308277
(@@	O	-1	6308277
100	O	-1	6308277
mg/kg)	O	-1	6308277
increased	O	-1	6308277
the	O	-1	6308277
interv@@	O	-1	6308277
al	O	-1	6308277
between	O	-1	6308277
the	O	-1	6308277
administration	O	-1	6308277
of	O	-1	6308277
caffe@@	B-Chemical	D002110	6308277
ine	I-Chemical	-1	6308277
(3@@	O	-1	6308277
00	O	-1	6308277
to	O	-1	6308277
4@@	O	-1	6308277
50	O	-1	6308277
mg/kg	O	-1	6308277
I@@	O	-1	6308277
P)	O	-1	6308277
and	O	-1	6308277
the	O	-1	6308277
onset	O	-1	6308277
of	O	-1	6308277
f@@	O	-1	6308277
atal	O	-1	6308277
convul@@	B-Disease	D012640	6308277
sions	I-Disease	-1	6308277
by	O	-1	6308277
a	O	-1	6308277
factor	O	-1	6308277
of	O	-1	6308277
about	O	-1	6308277
tw@@	O	-1	6308277
o@@	O	-1	6308277
;	O	-1	6308277
and	O	-1	6308277
2)	O	-1	6308277
pretreatment	O	-1	6308277
with	O	-1	6308277
acet@@	B-Chemical	D000082	6308277
aminoph@@	I-Chemical	-1	6308277
en	I-Chemical	-1	6308277
(@@	O	-1	6308277
7@@	O	-1	6308277
5	O	-1	6308277
mg/kg)	O	-1	6308277
reduced	O	-1	6308277
the	O	-1	6308277
incidence	O	-1	6308277
of	O	-1	6308277
a@@	O	-1	6308277
udi@@	O	-1	6308277
o@@	O	-1	6308277
genic	O	-1	6308277
seizures	B-Disease	D012640	6308277
produced	O	-1	6308277
in	O	-1	6308277
the	O	-1	6308277
presence	O	-1	6308277
of	O	-1	6308277
caffe@@	B-Chemical	D002110	6308277
ine	I-Chemical	-1	6308277
(1@@	O	-1	6308277
2.@@	O	-1	6308277
5	O	-1	6308277
to	O	-1	6308277
7@@	O	-1	6308277
5	O	-1	6308277
mg/kg	O	-1	6308277
I@@	O	-1	6308277
P@@	O	-1	6308277
).	O	-1	6308277
The	O	-1	6308277
frequency	O	-1	6308277
of	O	-1	6308277
s@@	O	-1	6308277
oun@@	O	-1	6308277
d@@	O	-1	6308277
-induced	O	-1	6308277
seizures	B-Disease	D012640	6308277
after	O	-1	6308277
1@@	O	-1	6308277
2.@@	O	-1	6308277
5	O	-1	6308277
or	O	-1	6308277
25	O	-1	6308277
mg/kg	O	-1	6308277
caffe@@	B-Chemical	D002110	6308277
ine	I-Chemical	-1	6308277
was	O	-1	6308277
reduced	O	-1	6308277
from	O	-1	6308277
50	O	-1	6308277
to	O	-1	6308277
5%	O	-1	6308277
by	O	-1	6308277
acet@@	B-Chemical	D000082	6308277
aminoph@@	I-Chemical	-1	6308277
en	I-Chemical	-1	6308277
.	O	-1	6308277
In	O	-1	6308277
the	O	-1	6308277
absence	O	-1	6308277
of	O	-1	6308277
caffe@@	B-Chemical	D002110	6308277
ine	I-Chemical	-1	6308277
,	O	-1	6308277
acet@@	B-Chemical	D000082	6308277
aminoph@@	I-Chemical	-1	6308277
en	I-Chemical	-1	6308277
(@@	O	-1	6308277
up	O	-1	6308277
to	O	-1	6308277
3@@	O	-1	6308277
00	O	-1	6308277
mg/kg)	O	-1	6308277
did	O	-1	6308277
not	O	-1	6308277
mo@@	O	-1	6308277
di@@	O	-1	6308277
f@@	O	-1	6308277
y	O	-1	6308277
the	O	-1	6308277
seizures	B-Disease	D012640	6308277
induced	O	-1	6308277
by	O	-1	6308277
maxim@@	O	-1	6308277
al	O	-1	6308277
electro@@	O	-1	6308277
sh@@	O	-1	6308277
oc@@	O	-1	6308277
k	O	-1	6308277
and	O	-1	6308277
did	O	-1	6308277
not	O	-1	6308277
al@@	O	-1	6308277
ter	O	-1	6308277
the	O	-1	6308277
convul@@	O	-1	6308277
s@@	O	-1	6308277
ant	O	-1	6308277
dose	O	-1	6308277
of	O	-1	6308277
pent@@	B-Chemical	D010433	6308277
yl@@	I-Chemical	-1	6308277
en@@	I-Chemical	-1	6308277
e@@	I-Chemical	-1	6308277
te@@	I-Chemical	-1	6308277
tre@@	I-Chemical	-1	6308277
z@@	I-Chemical	-1	6308277
ol	I-Chemical	-1	6308277
in	O	-1	6308277
mice	O	-1	6308277
(@@	O	-1	6308277
tests	O	-1	6308277
performed	O	-1	6308277
by	O	-1	6308277
the	O	-1	6308277
An@@	O	-1	6308277
ti@@	O	-1	6308277
convul@@	O	-1	6308277
s@@	O	-1	6308277
ant	O	-1	6308277
S@@	O	-1	6308277
cre@@	O	-1	6308277
en@@	O	-1	6308277
ing	O	-1	6308277
Pro@@	O	-1	6308277
j@@	O	-1	6308277
ect	O	-1	6308277
of	O	-1	6308277
N@@	O	-1	6308277
IN@@	O	-1	6308277
C@@	O	-1	6308277
D@@	O	-1	6308277
S@@	O	-1	6308277
).	O	-1	6308277
A@@	B-Chemical	D000082	6308277
ce@@	I-Chemical	-1	6308277
t@@	I-Chemical	-1	6308277
aminoph@@	I-Chemical	-1	6308277
en	I-Chemical	-1	6308277
(@@	O	-1	6308277
up	O	-1	6308277
to	O	-1	6308277
1@@	O	-1	6308277
50	O	-1	6308277
microgram@@	O	-1	6308277
s/@@	O	-1	6308277
m@@	O	-1	6308277
L@@	O	-1	6308277
)	O	-1	6308277
did	O	-1	6308277
not	O	-1	6308277
ret@@	O	-1	6308277
ard	O	-1	6308277
the	O	-1	6308277
inc@@	O	-1	6308277
or@@	O	-1	6308277
por@@	O	-1	6308277
ation	O	-1	6308277
of	O	-1	6308277
radi@@	O	-1	6308277
o@@	O	-1	6308277
active	O	-1	6308277
aden@@	B-Chemical	D000241	6308277
os@@	I-Chemical	-1	6308277
ine	I-Chemical	-1	6308277
into	O	-1	6308277
AT@@	B-Chemical	D000255	6308277
P	I-Chemical	-1	6308277
in	O	-1	6308277
s@@	O	-1	6308277
l@@	O	-1	6308277
ic@@	O	-1	6308277
es	O	-1	6308277
of	O	-1	6308277
rat	O	-1	6308277
cerebral	O	-1	6308277
cor@@	O	-1	6308277
t@@	O	-1	6308277
ex@@	O	-1	6308277
.	O	-1	6308277
Th@@	O	-1	6308277
us	O	-1	6308277
the	O	-1	6308277
mechanism	O	-1	6308277
by	O	-1	6308277
which	O	-1	6308277
acet@@	B-Chemical	D000082	6308277
aminoph@@	I-Chemical	-1	6308277
en	I-Chemical	-1	6308277
antagon@@	O	-1	6308277
iz@@	O	-1	6308277
es	O	-1	6308277
the	O	-1	6308277
ac@@	O	-1	6308277
tions	O	-1	6308277
of	O	-1	6308277
caffe@@	B-Chemical	D002110	6308277
ine	I-Chemical	-1	6308277
in	O	-1	6308277
the	O	-1	6308277
C@@	O	-1	6308277
N@@	O	-1	6308277
S	O	-1	6308277
remain@@	O	-1	6308277
s	O	-1	6308277
un@@	O	-1	6308277
know@@	O	-1	6308277
n@@	O	-1	6308277
.	O	-1	6308277

F@@	B-Chemical	C047847	2870085
le@@	I-Chemical	-1	2870085
sto@@	I-Chemical	-1	2870085
lol	I-Chemical	-1	2870085
:	O	-1	2870085
an	O	-1	2870085
ult@@	O	-1	2870085
ra@@	O	-1	2870085
-@@	O	-1	2870085
sh@@	O	-1	2870085
ort@@	O	-1	2870085
-@@	O	-1	2870085
act@@	O	-1	2870085
ing	O	-1	2870085
beta-@@	O	-1	2870085
adrenergic	O	-1	2870085
block@@	O	-1	2870085
ing	O	-1	2870085
agent@@	O	-1	2870085
.	O	-1	2870085
F@@	B-Chemical	C047847	2870085
le@@	I-Chemical	-1	2870085
sto@@	I-Chemical	-1	2870085
lol	I-Chemical	-1	2870085
(	O	-1	2870085
AC@@	B-Chemical	C047847	2870085
C@@	I-Chemical	-1	2870085
-@@	I-Chemical	-1	2870085
9@@	I-Chemical	-1	2870085
0@@	I-Chemical	-1	2870085
8@@	I-Chemical	-1	2870085
9	I-Chemical	-1	2870085
)	O	-1	2870085
is	O	-1	2870085
a	O	-1	2870085
non@@	O	-1	2870085
sel@@	O	-1	2870085
ecti@@	O	-1	2870085
ve,	O	-1	2870085
comp@@	O	-1	2870085
e@@	O	-1	2870085
ti@@	O	-1	2870085
ti@@	O	-1	2870085
ve,	O	-1	2870085
ult@@	O	-1	2870085
ra@@	O	-1	2870085
-@@	O	-1	2870085
sh@@	O	-1	2870085
ort@@	O	-1	2870085
-@@	O	-1	2870085
act@@	O	-1	2870085
ing	O	-1	2870085
beta-@@	O	-1	2870085
adrenergic	O	-1	2870085
block@@	O	-1	2870085
ing	O	-1	2870085
agent@@	O	-1	2870085
,	O	-1	2870085
without	O	-1	2870085
any	O	-1	2870085
int@@	O	-1	2870085
r@@	O	-1	2870085
in@@	O	-1	2870085
sic	O	-1	2870085
sym@@	O	-1	2870085
path@@	O	-1	2870085
om@@	O	-1	2870085
i@@	O	-1	2870085
me@@	O	-1	2870085
tic	O	-1	2870085
activ@@	O	-1	2870085
ity.	O	-1	2870085
F@@	B-Chemical	C047847	2870085
le@@	I-Chemical	-1	2870085
sto@@	I-Chemical	-1	2870085
lol	I-Chemical	-1	2870085
is	O	-1	2870085
metabol@@	O	-1	2870085
ized	O	-1	2870085
by	O	-1	2870085
plasma	O	-1	2870085
est@@	O	-1	2870085
er@@	O	-1	2870085
as@@	O	-1	2870085
es	O	-1	2870085
and	O	-1	2870085
has	O	-1	2870085
an	O	-1	2870085
el@@	O	-1	2870085
im@@	O	-1	2870085
in@@	O	-1	2870085
ation	O	-1	2870085
h@@	O	-1	2870085
al@@	O	-1	2870085
f@@	O	-1	2870085
-@@	O	-1	2870085
lif@@	O	-1	2870085
e	O	-1	2870085
of	O	-1	2870085
appro@@	O	-1	2870085
xim@@	O	-1	2870085
ately	O	-1	2870085
6.@@	O	-1	2870085
5	O	-1	2870085
minut@@	O	-1	2870085
es.	O	-1	2870085
This	O	-1	2870085
agent	O	-1	2870085
was	O	-1	2870085
well	O	-1	2870085
toler@@	O	-1	2870085
ated	O	-1	2870085
in	O	-1	2870085
healthy	O	-1	2870085
vol@@	O	-1	2870085
un@@	O	-1	2870085
te@@	O	-1	2870085
ers	O	-1	2870085
at	O	-1	2870085
doses	O	-1	2870085
up	O	-1	2870085
to	O	-1	2870085
100	O	-1	2870085
microgram@@	O	-1	2870085
s/@@	O	-1	2870085
k@@	O	-1	2870085
g/@@	O	-1	2870085
min@@	O	-1	2870085
.	O	-1	2870085
In	O	-1	2870085
long-term	O	-1	2870085
infusion	O	-1	2870085
studi@@	O	-1	2870085
es,	O	-1	2870085
f@@	B-Chemical	C047847	2870085
le@@	I-Chemical	-1	2870085
sto@@	I-Chemical	-1	2870085
lol	I-Chemical	-1	2870085
was	O	-1	2870085
well	O	-1	2870085
toler@@	O	-1	2870085
ated	O	-1	2870085
at	O	-1	2870085
the	O	-1	2870085
effective	O	-1	2870085
beta-@@	O	-1	2870085
block@@	O	-1	2870085
ing	O	-1	2870085
dose	O	-1	2870085
(@@	O	-1	2870085
5	O	-1	2870085
microgram@@	O	-1	2870085
s/@@	O	-1	2870085
k@@	O	-1	2870085
g/@@	O	-1	2870085
min@@	O	-1	2870085
)	O	-1	2870085
for	O	-1	2870085
up	O	-1	2870085
to	O	-1	2870085
seven	O	-1	2870085
days.	O	-1	2870085
F@@	B-Chemical	C047847	2870085
le@@	I-Chemical	-1	2870085
sto@@	I-Chemical	-1	2870085
lol	I-Chemical	-1	2870085
blood	O	-1	2870085
concentrations	O	-1	2870085
increased	O	-1	2870085
l@@	O	-1	2870085
ine@@	O	-1	2870085
arly	O	-1	2870085
with	O	-1	2870085
increas@@	O	-1	2870085
ing	O	-1	2870085
dose	O	-1	2870085
and	O	-1	2870085
go@@	O	-1	2870085
od	O	-1	2870085
correl@@	O	-1	2870085
ation	O	-1	2870085
ex@@	O	-1	2870085
ist@@	O	-1	2870085
s	O	-1	2870085
between	O	-1	2870085
blood	O	-1	2870085
concentrations	O	-1	2870085
of	O	-1	2870085
f@@	B-Chemical	C047847	2870085
le@@	I-Chemical	-1	2870085
sto@@	I-Chemical	-1	2870085
lol	I-Chemical	-1	2870085
and	O	-1	2870085
beta-@@	O	-1	2870085
adrenergic	O	-1	2870085
block@@	O	-1	2870085
ade@@	O	-1	2870085
.	O	-1	2870085
F@@	B-Chemical	C047847	2870085
le@@	I-Chemical	-1	2870085
sto@@	I-Chemical	-1	2870085
lol	I-Chemical	-1	2870085
produced	O	-1	2870085
a	O	-1	2870085
dose-@@	O	-1	2870085
dependent	O	-1	2870085
attenu@@	O	-1	2870085
ation	O	-1	2870085
of	O	-1	2870085
isoproteren@@	B-Chemical	D007545	2870085
ol	I-Chemical	-1	2870085
-induced	O	-1	2870085
tachycardia	B-Disease	D013610	2870085
.	O	-1	2870085
E@@	O	-1	2870085
l@@	O	-1	2870085
ect@@	O	-1	2870085
ro@@	O	-1	2870085
physi@@	O	-1	2870085
ologic	O	-1	2870085
and	O	-1	2870085
hemo@@	O	-1	2870085
dynam@@	O	-1	2870085
ic	O	-1	2870085
effects	O	-1	2870085
of	O	-1	2870085
f@@	B-Chemical	C047847	2870085
le@@	I-Chemical	-1	2870085
sto@@	I-Chemical	-1	2870085
lol	I-Chemical	-1	2870085
are	O	-1	2870085
similar	O	-1	2870085
to	O	-1	2870085
those	O	-1	2870085
of	O	-1	2870085
other	O	-1	2870085
bet@@	O	-1	2870085
a	O	-1	2870085
block@@	O	-1	2870085
ers.	O	-1	2870085
In	O	-1	2870085
contr@@	O	-1	2870085
ast	O	-1	2870085
with	O	-1	2870085
other	O	-1	2870085
bet@@	O	-1	2870085
a	O	-1	2870085
block@@	O	-1	2870085
er@@	O	-1	2870085
s,	O	-1	2870085
f@@	B-Chemical	C047847	2870085
le@@	I-Chemical	-1	2870085
sto@@	I-Chemical	-1	2870085
lol	I-Chemical	-1	2870085
-induced	O	-1	2870085
effects	O	-1	2870085
re@@	O	-1	2870085
verse	O	-1	2870085
ra@@	O	-1	2870085
pid@@	O	-1	2870085
ly	O	-1	2870085
(@@	O	-1	2870085
within	O	-1	2870085
30	O	-1	2870085
minut@@	O	-1	2870085
es@@	O	-1	2870085
)	O	-1	2870085
following	O	-1	2870085
discontinu@@	O	-1	2870085
ation	O	-1	2870085
because	O	-1	2870085
of	O	-1	2870085
its	O	-1	2870085
sh@@	O	-1	2870085
ort	O	-1	2870085
h@@	O	-1	2870085
al@@	O	-1	2870085
f@@	O	-1	2870085
-@@	O	-1	2870085
lif@@	O	-1	2870085
e.	O	-1	2870085
F@@	B-Chemical	C047847	2870085
le@@	I-Chemical	-1	2870085
sto@@	I-Chemical	-1	2870085
lol	I-Chemical	-1	2870085
eff@@	O	-1	2870085
ectively	O	-1	2870085
reduced	O	-1	2870085
heart	O	-1	2870085
rate	O	-1	2870085
in	O	-1	2870085
patients	O	-1	2870085
with	O	-1	2870085
sup@@	B-Disease	D013617	2870085
ra@@	I-Disease	-1	2870085
ventricular	I-Disease	-1	2870085
tachy@@	I-Disease	-1	2870085
arrhyth@@	I-Disease	-1	2870085
mia	I-Disease	-1	2870085
.	O	-1	2870085
In	O	-1	2870085
patients	O	-1	2870085
with	O	-1	2870085
un@@	B-Disease	D000789	2870085
st@@	I-Disease	-1	2870085
able	I-Disease	-1	2870085
ang@@	I-Disease	-1	2870085
in@@	I-Disease	-1	2870085
a	I-Disease	-1	2870085
,	O	-1	2870085
f@@	B-Chemical	C047847	2870085
le@@	I-Chemical	-1	2870085
sto@@	I-Chemical	-1	2870085
lol	I-Chemical	-1	2870085
infusion	O	-1	2870085
was	O	-1	2870085
found	O	-1	2870085
to	O	-1	2870085
be	O	-1	2870085
saf@@	O	-1	2870085
e	O	-1	2870085
and	O	-1	2870085
effective	O	-1	2870085
in	O	-1	2870085
contro@@	O	-1	2870085
ll@@	O	-1	2870085
ing	O	-1	2870085
ch@@	B-Disease	D002637	2870085
est	I-Disease	-1	2870085
pain	I-Disease	-1	2870085
.	O	-1	2870085
It	O	-1	2870085
is	O	-1	2870085
concl@@	O	-1	2870085
uded	O	-1	2870085
that	O	-1	2870085
f@@	B-Chemical	C047847	2870085
le@@	I-Chemical	-1	2870085
sto@@	I-Chemical	-1	2870085
lol	I-Chemical	-1	2870085
is	O	-1	2870085
a	O	-1	2870085
pot@@	O	-1	2870085
ent@@	O	-1	2870085
,	O	-1	2870085
we@@	O	-1	2870085
ll@@	O	-1	2870085
-@@	O	-1	2870085
toler@@	O	-1	2870085
at@@	O	-1	2870085
ed,	O	-1	2870085
ult@@	O	-1	2870085
ra@@	O	-1	2870085
-@@	O	-1	2870085
sh@@	O	-1	2870085
ort@@	O	-1	2870085
-@@	O	-1	2870085
act@@	O	-1	2870085
ing	O	-1	2870085
beta-@@	O	-1	2870085
adrenergic	O	-1	2870085
block@@	O	-1	2870085
ing	O	-1	2870085
agent@@	O	-1	2870085
.	O	-1	2870085
U@@	O	-1	2870085
se	O	-1	2870085
of	O	-1	2870085
f@@	B-Chemical	C047847	2870085
le@@	I-Chemical	-1	2870085
sto@@	I-Chemical	-1	2870085
lol	I-Chemical	-1	2870085
in	O	-1	2870085
the	O	-1	2870085
cri@@	O	-1	2870085
tical	O	-1	2870085
car@@	O	-1	2870085
e	O	-1	2870085
se@@	O	-1	2870085
t@@	O	-1	2870085
ting	O	-1	2870085
is	O	-1	2870085
cur@@	O	-1	2870085
ren@@	O	-1	2870085
tly	O	-1	2870085
under@@	O	-1	2870085
go@@	O	-1	2870085
ing	O	-1	2870085
investig@@	O	-1	2870085
ation.	O	-1	2870085

Ad@@	O	-1	1639466
verse	O	-1	1639466
effect	O	-1	1639466
of	O	-1	1639466
the	O	-1	1639466
calcium	B-Chemical	D002118	1639466
channel	O	-1	1639466
block@@	O	-1	1639466
er	O	-1	1639466
nit@@	B-Chemical	D009568	1639466
ren@@	I-Chemical	-1	1639466
di@@	I-Chemical	-1	1639466
pine	I-Chemical	-1	1639466
on	O	-1	1639466
nephro@@	B-Disease	D009400	1639466
s@@	I-Disease	-1	1639466
clero@@	I-Disease	-1	1639466
sis	I-Disease	-1	1639466
in	O	-1	1639466
rats	O	-1	1639466
with	O	-1	1639466
ren@@	B-Disease	D006978	1639466
o@@	I-Disease	-1	1639466
vascular	I-Disease	-1	1639466
hypertension	I-Disease	-1	1639466
.	O	-1	1639466
The	O	-1	1639466
effect	O	-1	1639466
of	O	-1	1639466
a	O	-1	1639466
6-@@	O	-1	1639466
week	O	-1	1639466
treatment	O	-1	1639466
with	O	-1	1639466
the	O	-1	1639466
calcium	B-Chemical	D002118	1639466
channel	O	-1	1639466
block@@	O	-1	1639466
er	O	-1	1639466
nit@@	B-Chemical	D009568	1639466
ren@@	I-Chemical	-1	1639466
di@@	I-Chemical	-1	1639466
pine	I-Chemical	-1	1639466
or	O	-1	1639466
the	O	-1	1639466
angiotens@@	B-Chemical	D000809	1639466
in	I-Chemical	-1	1639466
conver@@	O	-1	1639466
ting	O	-1	1639466
enzyme	O	-1	1639466
inhibitor	O	-1	1639466
en@@	B-Chemical	D004656	1639466
al@@	I-Chemical	-1	1639466
apri@@	I-Chemical	-1	1639466
l	I-Chemical	-1	1639466
on	O	-1	1639466
blood	O	-1	1639466
pressu@@	O	-1	1639466
re,	O	-1	1639466
al@@	B-Disease	D000419	1639466
bu@@	I-Disease	-1	1639466
min@@	I-Disease	-1	1639466
uria	I-Disease	-1	1639466
,	O	-1	1639466
renal	O	-1	1639466
hemo@@	O	-1	1639466
dynam@@	O	-1	1639466
ic@@	O	-1	1639466
s,	O	-1	1639466
and	O	-1	1639466
morph@@	O	-1	1639466
ology	O	-1	1639466
of	O	-1	1639466
the	O	-1	1639466
non@@	O	-1	1639466
c@@	O	-1	1639466
li@@	O	-1	1639466
pp@@	O	-1	1639466
ed	O	-1	1639466
kidney	O	-1	1639466
was	O	-1	1639466
studied	O	-1	1639466
in	O	-1	1639466
rats	O	-1	1639466
with	O	-1	1639466
tw@@	O	-1	1639466
o@@	O	-1	1639466
-@@	O	-1	1639466
kidne@@	O	-1	1639466
y,	O	-1	1639466
one	O	-1	1639466
c@@	O	-1	1639466
li@@	O	-1	1639466
p	O	-1	1639466
ren@@	B-Disease	D006978	1639466
o@@	I-Disease	-1	1639466
vascular	I-Disease	-1	1639466
hypertension	I-Disease	-1	1639466
.	O	-1	1639466
Si@@	O	-1	1639466
x	O	-1	1639466
weeks	O	-1	1639466
after	O	-1	1639466
c@@	O	-1	1639466
li@@	O	-1	1639466
pp@@	O	-1	1639466
ing	O	-1	1639466
of	O	-1	1639466
one	O	-1	1639466
renal	O	-1	1639466
arter@@	O	-1	1639466
y,	O	-1	1639466
hypertensive	B-Disease	D006973	1639466
rats	O	-1	1639466
(1@@	O	-1	1639466
7@@	O	-1	1639466
8	O	-1	1639466
+/-	O	-1	1639466
4	O	-1	1639466
mm	O	-1	1639466
H@@	O	-1	1639466
g@@	O	-1	1639466
)	O	-1	1639466
were	O	-1	1639466
random@@	O	-1	1639466
ly	O	-1	1639466
as@@	O	-1	1639466
signed	O	-1	1639466
to	O	-1	1639466
three	O	-1	1639466
group@@	O	-1	1639466
s:	O	-1	1639466
un@@	O	-1	1639466
treated	O	-1	1639466
hypertensive	B-Disease	D006973	1639466
controls	O	-1	1639466
(n	O	-1	1639466
=	O	-1	1639466
8@@	O	-1	1639466
),	O	-1	1639466
en@@	B-Chemical	D004656	1639466
al@@	I-Chemical	-1	1639466
apri@@	I-Chemical	-1	1639466
l	I-Chemical	-1	1639466
-treated	O	-1	1639466
(n	O	-1	1639466
=	O	-1	1639466
8@@	O	-1	1639466
),	O	-1	1639466
or	O	-1	1639466
nit@@	B-Chemical	D009568	1639466
ren@@	I-Chemical	-1	1639466
di@@	I-Chemical	-1	1639466
pine	I-Chemical	-1	1639466
-treated	O	-1	1639466
(n	O	-1	1639466
=	O	-1	1639466
10@@	O	-1	1639466
).	O	-1	1639466
S@@	O	-1	1639466
h@@	O	-1	1639466
am@@	O	-1	1639466
-@@	O	-1	1639466
o@@	O	-1	1639466
per@@	O	-1	1639466
ated	O	-1	1639466
rats	O	-1	1639466
ser@@	O	-1	1639466
ved	O	-1	1639466
as	O	-1	1639466
norm@@	O	-1	1639466
oten@@	O	-1	1639466
sive	O	-1	1639466
controls	O	-1	1639466
(1@@	O	-1	1639466
2@@	O	-1	1639466
8	O	-1	1639466
+/-	O	-1	1639466
3	O	-1	1639466
mm	O	-1	1639466
H@@	O	-1	1639466
g@@	O	-1	1639466
,	O	-1	1639466
n	O	-1	1639466
=	O	-1	1639466
8@@	O	-1	1639466
).	O	-1	1639466
After	O	-1	1639466
6	O	-1	1639466
weeks	O	-1	1639466
of	O	-1	1639466
treatment,	O	-1	1639466
renal	O	-1	1639466
hemo@@	O	-1	1639466
dynam@@	O	-1	1639466
ic@@	O	-1	1639466
s	O	-1	1639466
(@@	O	-1	1639466
glomerular	O	-1	1639466
f@@	O	-1	1639466
iltration	O	-1	1639466
rate	O	-1	1639466
and	O	-1	1639466
renal	O	-1	1639466
plasma	O	-1	1639466
f@@	O	-1	1639466
low@@	O	-1	1639466
)	O	-1	1639466
were	O	-1	1639466
measured	O	-1	1639466
in	O	-1	1639466
the	O	-1	1639466
anesthe@@	O	-1	1639466
tiz@@	O	-1	1639466
ed	O	-1	1639466
rats.	O	-1	1639466
R@@	O	-1	1639466
en@@	O	-1	1639466
al	O	-1	1639466
tissue	O	-1	1639466
was	O	-1	1639466
obtained	O	-1	1639466
for	O	-1	1639466
determin@@	O	-1	1639466
ation	O	-1	1639466
of	O	-1	1639466
glomerular	O	-1	1639466
size	O	-1	1639466
and	O	-1	1639466
s@@	O	-1	1639466
clero@@	O	-1	1639466
sis.	O	-1	1639466
E@@	B-Chemical	D004656	1639466
n@@	I-Chemical	-1	1639466
al@@	I-Chemical	-1	1639466
apri@@	I-Chemical	-1	1639466
l	I-Chemical	-1	1639466
but	O	-1	1639466
not	O	-1	1639466
nit@@	B-Chemical	D009568	1639466
ren@@	I-Chemical	-1	1639466
di@@	I-Chemical	-1	1639466
pine	I-Chemical	-1	1639466
reduced	O	-1	1639466
blood	O	-1	1639466
pressure	O	-1	1639466
significant@@	O	-1	1639466
ly.	O	-1	1639466
After	O	-1	1639466
6	O	-1	1639466
weeks	O	-1	1639466
of	O	-1	1639466
therapy,	O	-1	1639466
glomerular	O	-1	1639466
f@@	O	-1	1639466
iltration	O	-1	1639466
rate	O	-1	1639466
was	O	-1	1639466
not	O	-1	1639466
different	O	-1	1639466
among	O	-1	1639466
the	O	-1	1639466
studied	O	-1	1639466
groups.	O	-1	1639466
R@@	O	-1	1639466
en@@	O	-1	1639466
al	O	-1	1639466
plasma	O	-1	1639466
flow	O	-1	1639466
increas@@	O	-1	1639466
ed,	O	-1	1639466
but	O	-1	1639466
al@@	O	-1	1639466
b@@	O	-1	1639466
um@@	O	-1	1639466
in	O	-1	1639466
ex@@	O	-1	1639466
cre@@	O	-1	1639466
tion	O	-1	1639466
and	O	-1	1639466
glomer@@	B-Disease	D005921	1639466
u@@	I-Disease	-1	1639466
los@@	I-Disease	-1	1639466
clero@@	I-Disease	-1	1639466
sis	I-Disease	-1	1639466
did	O	-1	1639466
not	O	-1	1639466
change	O	-1	1639466
after	O	-1	1639466
en@@	B-Chemical	D004656	1639466
al@@	I-Chemical	-1	1639466
apri@@	I-Chemical	-1	1639466
l	I-Chemical	-1	1639466
treatment.	O	-1	1639466
In	O	-1	1639466
contrast@@	O	-1	1639466
,	O	-1	1639466
in	O	-1	1639466
the	O	-1	1639466
nit@@	B-Chemical	D009568	1639466
ren@@	I-Chemical	-1	1639466
di@@	I-Chemical	-1	1639466
pine	I-Chemical	-1	1639466
-treated	O	-1	1639466
group	O	-1	1639466
al@@	B-Disease	D000419	1639466
bu@@	I-Disease	-1	1639466
min@@	I-Disease	-1	1639466
uria	I-Disease	-1	1639466
increased	O	-1	1639466
from	O	-1	1639466
1@@	O	-1	1639466
2.@@	O	-1	1639466
8	O	-1	1639466
+/-	O	-1	1639466
2	O	-1	1639466
progres@@	O	-1	1639466
si@@	O	-1	1639466
vely	O	-1	1639466
to	O	-1	1639466
1@@	O	-1	1639466
6@@	O	-1	1639466
3	O	-1	1639466
+/-	O	-1	1639466
5@@	O	-1	1639466
5	O	-1	1639466
compared	O	-1	1639466
with	O	-1	1639466
19@@	O	-1	1639466
.@@	O	-1	1639466
2	O	-1	1639466
+/-	O	-1	1639466
9	O	-1	1639466
mg/@@	O	-1	1639466
24	O	-1	1639466
h@@	O	-1	1639466
r	O	-1	1639466
in	O	-1	1639466
the	O	-1	1639466
hypertensive	B-Disease	D006973	1639466
controls.	O	-1	1639466
F@@	O	-1	1639466
ur@@	O	-1	1639466
ther@@	O	-1	1639466
mo@@	O	-1	1639466
re,	O	-1	1639466
glomer@@	B-Disease	D005921	1639466
u@@	I-Disease	-1	1639466
los@@	I-Disease	-1	1639466
clero@@	I-Disease	-1	1639466
sis	I-Disease	-1	1639466
in@@	O	-1	1639466
de@@	O	-1	1639466
x	O	-1	1639466
was	O	-1	1639466
significantly	O	-1	1639466
increased	O	-1	1639466
in	O	-1	1639466
the	O	-1	1639466
nit@@	B-Chemical	D009568	1639466
ren@@	I-Chemical	-1	1639466
di@@	I-Chemical	-1	1639466
pine	I-Chemical	-1	1639466
-treated	O	-1	1639466
group	O	-1	1639466
compared	O	-1	1639466
with	O	-1	1639466
the	O	-1	1639466
hypertensive	B-Disease	D006973	1639466
controls	O	-1	1639466
(0.@@	O	-1	1639466
3@@	O	-1	1639466
8	O	-1	1639466
+/-	O	-1	1639466
0.@@	O	-1	1639466
1	O	-1	1639466
versus	O	-1	1639466
0.@@	O	-1	1639466
13	O	-1	1639466
+/-	O	-1	1639466
0.0@@	O	-1	1639466
4@@	O	-1	1639466
).	O	-1	1639466
In	O	-1	1639466
addi@@	O	-1	1639466
tion,	O	-1	1639466
glomerular	O	-1	1639466
size	O	-1	1639466
was	O	-1	1639466
higher	O	-1	1639466
in	O	-1	1639466
the	O	-1	1639466
nit@@	B-Chemical	D009568	1639466
ren@@	I-Chemical	-1	1639466
di@@	I-Chemical	-1	1639466
pine	I-Chemical	-1	1639466
-treated	O	-1	1639466
group	O	-1	1639466
(1@@	O	-1	1639466
4.@@	O	-1	1639466
9	O	-1	1639466
+/-	O	-1	1639466
0.@@	O	-1	1639466
17	O	-1	1639466
10@@	O	-1	1639466
(-@@	O	-1	1639466
3@@	O	-1	1639466
)	O	-1	1639466
mm@@	O	-1	1639466
2)	O	-1	1639466
but	O	-1	1639466
lower	O	-1	1639466
in	O	-1	1639466
the	O	-1	1639466
en@@	B-Chemical	D004656	1639466
al@@	I-Chemical	-1	1639466
apri@@	I-Chemical	-1	1639466
l	I-Chemical	-1	1639466
-treated	O	-1	1639466
group	O	-1	1639466
(1@@	O	-1	1639466
1.@@	O	-1	1639466
5	O	-1	1639466
+/-	O	-1	1639466
0.@@	O	-1	1639466
15	O	-1	1639466
10@@	O	-1	1639466
(-@@	O	-1	1639466
3@@	O	-1	1639466
)	O	-1	1639466
mm@@	O	-1	1639466
2)	O	-1	1639466
compared	O	-1	1639466
with	O	-1	1639466
the	O	-1	1639466
hypertensive	B-Disease	D006973	1639466
controls	O	-1	1639466
(1@@	O	-1	1639466
2.@@	O	-1	1639466
1	O	-1	1639466
+/-	O	-1	1639466
0.@@	O	-1	1639466
17	O	-1	1639466
10@@	O	-1	1639466
(-@@	O	-1	1639466
3@@	O	-1	1639466
)	O	-1	1639466
mm@@	O	-1	1639466
2@@	O	-1	1639466
)@@	O	-1	1639466
.@@	O	-1	1639466
(A@@	O	-1	1639466
B@@	O	-1	1639466
S@@	O	-1	1639466
TR@@	O	-1	1639466
AC@@	O	-1	1639466
T	O	-1	1639466
TR@@	O	-1	1639466
UN@@	O	-1	1639466
C@@	O	-1	1639466
AT@@	O	-1	1639466
E@@	O	-1	1639466
D	O	-1	1639466
A@@	O	-1	1639466
T	O	-1	1639466
2@@	O	-1	1639466
50	O	-1	1639466
W@@	O	-1	1639466
O@@	O	-1	1639466
RD@@	O	-1	1639466
S)	O	-1	1639466

Treat@@	O	-1	1527456
ment	O	-1	1527456
of	O	-1	1527456
t@@	B-Disease	D014012	1527456
in@@	I-Disease	-1	1527456
nit@@	I-Disease	-1	1527456
us	I-Disease	-1	1527456
by	O	-1	1527456
int@@	O	-1	1527456
rat@@	O	-1	1527456
ym@@	O	-1	1527456
p@@	O	-1	1527456
anic	O	-1	1527456
insti@@	O	-1	1527456
ll@@	O	-1	1527456
ation	O	-1	1527456
of	O	-1	1527456
li@@	B-Chemical	D008012	1527456
gn@@	I-Chemical	-1	1527456
oc@@	I-Chemical	-1	1527456
aine	I-Chemical	-1	1527456
(	O	-1	1527456
lidocaine	B-Chemical	D008012	1527456
)	O	-1	1527456
2	O	-1	1527456
per	O	-1	1527456
c@@	O	-1	1527456
ent	O	-1	1527456
through	O	-1	1527456
ven@@	O	-1	1527456
til@@	O	-1	1527456
ation	O	-1	1527456
tub@@	O	-1	1527456
es.	O	-1	1527456
I@@	B-Disease	D014012	1527456
di@@	I-Disease	-1	1527456
o@@	I-Disease	-1	1527456
path@@	I-Disease	-1	1527456
ic	I-Disease	-1	1527456
subj@@	I-Disease	-1	1527456
ective	I-Disease	-1	1527456
t@@	I-Disease	-1	1527456
in@@	I-Disease	-1	1527456
nit@@	I-Disease	-1	1527456
us	I-Disease	-1	1527456
(	O	-1	1527456
I@@	B-Disease	D014012	1527456
S@@	I-Disease	-1	1527456
T	I-Disease	-1	1527456
)	O	-1	1527456
is	O	-1	1527456
one	O	-1	1527456
of	O	-1	1527456
the	O	-1	1527456
most	O	-1	1527456
ob@@	O	-1	1527456
s@@	O	-1	1527456
c@@	O	-1	1527456
ure	O	-1	1527456
ot@@	O	-1	1527456
ological	O	-1	1527456
path@@	O	-1	1527456
olog@@	O	-1	1527456
i@@	O	-1	1527456
es.	O	-1	1527456
This	O	-1	1527456
pap@@	O	-1	1527456
er	O	-1	1527456
pres@@	O	-1	1527456
ents	O	-1	1527456
the	O	-1	1527456
results	O	-1	1527456
of	O	-1	1527456
treat@@	O	-1	1527456
ing	O	-1	1527456
I@@	B-Disease	D014012	1527456
S@@	I-Disease	-1	1527456
T	I-Disease	-1	1527456
by	O	-1	1527456
int@@	O	-1	1527456
rat@@	O	-1	1527456
ym@@	O	-1	1527456
p@@	O	-1	1527456
anic	O	-1	1527456
insti@@	O	-1	1527456
ll@@	O	-1	1527456
ation	O	-1	1527456
of	O	-1	1527456
li@@	B-Chemical	D008012	1527456
gn@@	I-Chemical	-1	1527456
oc@@	I-Chemical	-1	1527456
aine	I-Chemical	-1	1527456
(	O	-1	1527456
lidocaine	B-Chemical	D008012	1527456
)	O	-1	1527456
2	O	-1	1527456
per	O	-1	1527456
c@@	O	-1	1527456
ent	O	-1	1527456
through	O	-1	1527456
a	O	-1	1527456
g@@	O	-1	1527456
rom@@	O	-1	1527456
met@@	O	-1	1527456
,	O	-1	1527456
for	O	-1	1527456
five	O	-1	1527456
week@@	O	-1	1527456
ly	O	-1	1527456
cour@@	O	-1	1527456
s@@	O	-1	1527456
es.	O	-1	1527456
F@@	O	-1	1527456
if@@	O	-1	1527456
ty-@@	O	-1	1527456
two	O	-1	1527456
patients	O	-1	1527456
suff@@	O	-1	1527456
ering	O	-1	1527456
from	O	-1	1527456
intrac@@	O	-1	1527456
t@@	O	-1	1527456
able	O	-1	1527456
t@@	B-Disease	D014012	1527456
in@@	I-Disease	-1	1527456
nit@@	I-Disease	-1	1527456
us	I-Disease	-1	1527456
ent@@	O	-1	1527456
ered	O	-1	1527456
this	O	-1	1527456
therapeutic	O	-1	1527456
tri@@	O	-1	1527456
al,	O	-1	1527456
but	O	-1	1527456
only	O	-1	1527456
n@@	O	-1	1527456
ine	O	-1	1527456
f@@	O	-1	1527456
in@@	O	-1	1527456
ished	O	-1	1527456
all	O	-1	1527456
five	O	-1	1527456
cour@@	O	-1	1527456
s@@	O	-1	1527456
es.	O	-1	1527456
In	O	-1	1527456
one	O	-1	1527456
patient@@	O	-1	1527456
,	O	-1	1527456
the	O	-1	1527456
t@@	B-Disease	D014012	1527456
in@@	I-Disease	-1	1527456
nit@@	I-Disease	-1	1527456
us	I-Disease	-1	1527456
was	O	-1	1527456
al@@	O	-1	1527456
most	O	-1	1527456
complete@@	O	-1	1527456
ly	O	-1	1527456
abol@@	O	-1	1527456
is@@	O	-1	1527456
he@@	O	-1	1527456
d,	O	-1	1527456
but	O	-1	1527456
in	O	-1	1527456
all	O	-1	1527456
the	O	-1	1527456
n@@	O	-1	1527456
ine	O	-1	1527456
patients	O	-1	1527456
the	O	-1	1527456
dec@@	O	-1	1527456
om@@	O	-1	1527456
pen@@	O	-1	1527456
s@@	O	-1	1527456
ated	O	-1	1527456
t@@	B-Disease	D014012	1527456
in@@	I-Disease	-1	1527456
nit@@	I-Disease	-1	1527456
us	I-Disease	-1	1527456
chang@@	O	-1	1527456
ed	O	-1	1527456
to	O	-1	1527456
a	O	-1	1527456
com@@	O	-1	1527456
pen@@	O	-1	1527456
s@@	O	-1	1527456
ated	O	-1	1527456
one.	O	-1	1527456
We	O	-1	1527456
suggest	O	-1	1527456
this	O	-1	1527456
mo@@	O	-1	1527456
de	O	-1	1527456
of	O	-1	1527456
treatment	O	-1	1527456
for	O	-1	1527456
patients	O	-1	1527456
that	O	-1	1527456
were	O	-1	1527456
previously	O	-1	1527456
treated	O	-1	1527456
by	O	-1	1527456
drug@@	O	-1	1527456
s,	O	-1	1527456
ac@@	O	-1	1527456
up@@	O	-1	1527456
unc@@	O	-1	1527456
t@@	O	-1	1527456
ure	O	-1	1527456
and	O	-1	1527456
bio@@	O	-1	1527456
fe@@	O	-1	1527456
ed@@	O	-1	1527456
bac@@	O	-1	1527456
k@@	O	-1	1527456
,	O	-1	1527456
with	O	-1	1527456
dis@@	O	-1	1527456
ap@@	O	-1	1527456
po@@	O	-1	1527456
int@@	O	-1	1527456
ing	O	-1	1527456
result@@	O	-1	1527456
s.	O	-1	1527456
Patients	O	-1	1527456
should	O	-1	1527456
be	O	-1	1527456
war@@	O	-1	1527456
n@@	O	-1	1527456
ed	O	-1	1527456
about	O	-1	1527456
the	O	-1	1527456
side	O	-1	1527456
effects	O	-1	1527456
of	O	-1	1527456
ver@@	B-Disease	D014717	1527456
tig@@	I-Disease	-1	1527456
o	I-Disease	-1	1527456
and	O	-1	1527456
v@@	B-Disease	D014839	1527456
om@@	I-Disease	-1	1527456
it@@	I-Disease	-1	1527456
ing	I-Disease	-1	1527456
,	O	-1	1527456
which	O	-1	1527456
sub@@	O	-1	1527456
side@@	O	-1	1527456
s	O	-1	1527456
gra@@	O	-1	1527456
du@@	O	-1	1527456
ally	O	-1	1527456
with	O	-1	1527456
every	O	-1	1527456
new	O	-1	1527456
insti@@	O	-1	1527456
ll@@	O	-1	1527456
ation,	O	-1	1527456
and	O	-1	1527456
that	O	-1	1527456
the	O	-1	1527456
t@@	B-Disease	D014012	1527456
in@@	I-Disease	-1	1527456
nit@@	I-Disease	-1	1527456
us	I-Disease	-1	1527456
may	O	-1	1527456
not	O	-1	1527456
dis@@	O	-1	1527456
appe@@	O	-1	1527456
ar	O	-1	1527456
but	O	-1	1527456
wil@@	O	-1	1527456
l	O	-1	1527456
be	O	-1	1527456
al@@	O	-1	1527456
le@@	O	-1	1527456
vi@@	O	-1	1527456
at@@	O	-1	1527456
ed,	O	-1	1527456
en@@	O	-1	1527456
abl@@	O	-1	1527456
ing	O	-1	1527456
the@@	O	-1	1527456
m	O	-1	1527456
to	O	-1	1527456
co@@	O	-1	1527456
p@@	O	-1	1527456
e	O	-1	1527456
more	O	-1	1527456
e@@	O	-1	1527456
a@@	O	-1	1527456
si@@	O	-1	1527456
ly	O	-1	1527456
with	O	-1	1527456
the	O	-1	1527456
disease	O	-1	1527456
and	O	-1	1527456
le@@	O	-1	1527456
ad	O	-1	1527456
a	O	-1	1527456
more	O	-1	1527456
normal	O	-1	1527456
lif@@	O	-1	1527456
e.	O	-1	1527456

P@@	B-Chemical	C023470	220563
er@@	I-Chemical	-1	220563
he@@	I-Chemical	-1	220563
x@@	I-Chemical	-1	220563
il@@	I-Chemical	-1	220563
ine	I-Chemical	-1	220563
mal@@	I-Chemical	-1	220563
e@@	I-Chemical	-1	220563
ate	I-Chemical	-1	220563
and	O	-1	220563
peripheral	B-Disease	D010523	220563
neuropathy	I-Disease	-1	220563
.	O	-1	220563
P@@	B-Disease	D010523	220563
er@@	I-Disease	-1	220563
i@@	I-Disease	-1	220563
pheral	I-Disease	-1	220563
neuropathy	I-Disease	-1	220563
has	O	-1	220563
been	O	-1	220563
not@@	O	-1	220563
ed	O	-1	220563
as	O	-1	220563
a	O	-1	220563
complication	O	-1	220563
of	O	-1	220563
therapy	O	-1	220563
with	O	-1	220563
per@@	B-Chemical	C023470	220563
he@@	I-Chemical	-1	220563
x@@	I-Chemical	-1	220563
il@@	I-Chemical	-1	220563
ine	I-Chemical	-1	220563
mal@@	I-Chemical	-1	220563
e@@	I-Chemical	-1	220563
ate	I-Chemical	-1	220563
,	O	-1	220563
a	O	-1	220563
drug	O	-1	220563
wi@@	O	-1	220563
de@@	O	-1	220563
ly	O	-1	220563
used	O	-1	220563
in	O	-1	220563
F@@	O	-1	220563
ran@@	O	-1	220563
ce	O	-1	220563
(@@	O	-1	220563
and	O	-1	220563
in	O	-1	220563
clinical	O	-1	220563
tri@@	O	-1	220563
als	O	-1	220563
in	O	-1	220563
the	O	-1	220563
U@@	O	-1	220563
nit@@	O	-1	220563
ed	O	-1	220563
S@@	O	-1	220563
t@@	O	-1	220563
at@@	O	-1	220563
es@@	O	-1	220563
)	O	-1	220563
for	O	-1	220563
the	O	-1	220563
pro@@	O	-1	220563
phyl@@	O	-1	220563
ac@@	O	-1	220563
tic	O	-1	220563
treatment	O	-1	220563
of	O	-1	220563
ang@@	B-Disease	D000787	220563
in@@	I-Disease	-1	220563
a	I-Disease	-1	220563
p@@	I-Disease	-1	220563
ect@@	I-Disease	-1	220563
or@@	I-Disease	-1	220563
is	I-Disease	-1	220563
.	O	-1	220563
In	O	-1	220563
24	O	-1	220563
patients	O	-1	220563
with	O	-1	220563
this	O	-1	220563
complic@@	O	-1	220563
ation,	O	-1	220563
the	O	-1	220563
mark@@	O	-1	220563
ed	O	-1	220563
s@@	O	-1	220563
low@@	O	-1	220563
ing	O	-1	220563
of	O	-1	220563
motor	O	-1	220563
nerve	O	-1	220563
con@@	O	-1	220563
duction	O	-1	220563
ve@@	O	-1	220563
loc@@	O	-1	220563
ity	O	-1	220563
and	O	-1	220563
the	O	-1	220563
elect@@	O	-1	220563
rom@@	O	-1	220563
y@@	O	-1	220563
ograph@@	O	-1	220563
ic	O	-1	220563
changes	O	-1	220563
im@@	O	-1	220563
p@@	O	-1	220563
ly	O	-1	220563
main@@	O	-1	220563
ly	O	-1	220563
a	O	-1	220563
de@@	B-Disease	D003711	220563
my@@	I-Disease	-1	220563
el@@	I-Disease	-1	220563
in@@	I-Disease	-1	220563
ating	I-Disease	-1	220563
disor@@	I-Disease	-1	220563
der	I-Disease	-1	220563
.	O	-1	220563
Im@@	O	-1	220563
pro@@	O	-1	220563
vement	O	-1	220563
was	O	-1	220563
not@@	O	-1	220563
ed	O	-1	220563
with	O	-1	220563
cess@@	O	-1	220563
ation	O	-1	220563
of	O	-1	220563
therapy.	O	-1	220563
In	O	-1	220563
a	O	-1	220563
fe@@	O	-1	220563
w	O	-1	220563
cases	O	-1	220563
the	O	-1	220563
presence	O	-1	220563
of	O	-1	220563
active	O	-1	220563
d@@	O	-1	220563
en@@	O	-1	220563
er@@	O	-1	220563
v@@	O	-1	220563
ation	O	-1	220563
sign@@	O	-1	220563
if@@	O	-1	220563
ied	O	-1	220563
a	O	-1	220563
po@@	O	-1	220563
or	O	-1	220563
pro@@	O	-1	220563
g@@	O	-1	220563
no@@	O	-1	220563
sis,	O	-1	220563
with	O	-1	220563
only	O	-1	220563
s@@	O	-1	220563
li@@	O	-1	220563
ght	O	-1	220563
impro@@	O	-1	220563
ve@@	O	-1	220563
ment.	O	-1	220563
The	O	-1	220563
underlying	O	-1	220563
mechanism	O	-1	220563
ca@@	O	-1	220563
using	O	-1	220563
the	O	-1	220563
neuropathy	B-Disease	D009422	220563
is	O	-1	220563
not	O	-1	220563
y@@	O	-1	220563
et	O	-1	220563
ful@@	O	-1	220563
ly	O	-1	220563
know@@	O	-1	220563
n@@	O	-1	220563
,	O	-1	220563
although	O	-1	220563
some	O	-1	220563
evidence	O	-1	220563
indic@@	O	-1	220563
ates	O	-1	220563
that	O	-1	220563
it	O	-1	220563
may	O	-1	220563
be	O	-1	220563
a	O	-1	220563
li@@	O	-1	220563
pid	O	-1	220563
st@@	O	-1	220563
or@@	O	-1	220563
age	O	-1	220563
pro@@	O	-1	220563
ces@@	O	-1	220563
s.	O	-1	220563

Eff@@	O	-1	137340
ect	O	-1	137340
of	O	-1	137340
h@@	O	-1	137340
u@@	O	-1	137340
mor@@	O	-1	137340
al	O	-1	137340
mod@@	O	-1	137340
ul@@	O	-1	137340
at@@	O	-1	137340
ors	O	-1	137340
of	O	-1	137340
morphine	B-Chemical	D009020	137340
-induced	O	-1	137340
increase	B-Disease	D006948	137340
in	I-Disease	-1	137340
locomotor	I-Disease	-1	137340
activity	I-Disease	-1	137340
of	O	-1	137340
mice.	O	-1	137340
The	O	-1	137340
effect	O	-1	137340
of	O	-1	137340
h@@	O	-1	137340
u@@	O	-1	137340
mor@@	O	-1	137340
al	O	-1	137340
mod@@	O	-1	137340
ul@@	O	-1	137340
at@@	O	-1	137340
ors	O	-1	137340
on	O	-1	137340
the	O	-1	137340
morphine	B-Chemical	D009020	137340
-induced	O	-1	137340
increase	B-Disease	D006948	137340
in	I-Disease	-1	137340
locomotor	I-Disease	-1	137340
activity	I-Disease	-1	137340
of	O	-1	137340
mice	O	-1	137340
was	O	-1	137340
studi@@	O	-1	137340
ed.	O	-1	137340
The	O	-1	137340
sub@@	O	-1	137340
c@@	O	-1	137340
utaneous	O	-1	137340
administration	O	-1	137340
of	O	-1	137340
10	O	-1	137340
mg/kg	O	-1	137340
of	O	-1	137340
morphine	B-Chemical	D009020	137340
-H@@	O	-1	137340
C@@	O	-1	137340
1	O	-1	137340
produced	O	-1	137340
a	O	-1	137340
mark@@	O	-1	137340
ed	O	-1	137340
increase	B-Disease	D006948	137340
in	I-Disease	-1	137340
locomotor	I-Disease	-1	137340
activity	I-Disease	-1	137340
in	O	-1	137340
mice.	O	-1	137340
The	O	-1	137340
morphine	B-Chemical	D009020	137340
-induced	O	-1	137340
hyperactivity	B-Disease	D006948	137340
was	O	-1	137340
potenti@@	O	-1	137340
ated	O	-1	137340
by	O	-1	137340
scopol@@	B-Chemical	D012601	137340
amine	I-Chemical	-1	137340
and	O	-1	137340
attenu@@	O	-1	137340
ated	O	-1	137340
by	O	-1	137340
ph@@	B-Chemical	D010830	137340
ys@@	I-Chemical	-1	137340
os@@	I-Chemical	-1	137340
tig@@	I-Chemical	-1	137340
mine	I-Chemical	-1	137340
.	O	-1	137340
In	O	-1	137340
contrast@@	O	-1	137340
,	O	-1	137340
both	O	-1	137340
meth@@	B-Chemical	D019832	137340
scopol@@	I-Chemical	-1	137340
amine	I-Chemical	-1	137340
and	O	-1	137340
ne@@	B-Chemical	D009388	137340
os@@	I-Chemical	-1	137340
tig@@	I-Chemical	-1	137340
mine	I-Chemical	-1	137340
,	O	-1	137340
which	O	-1	137340
d@@	O	-1	137340
o	O	-1	137340
not	O	-1	137340
pen@@	O	-1	137340
et@@	O	-1	137340
rate	O	-1	137340
the	O	-1	137340
blo@@	O	-1	137340
o@@	O	-1	137340
d-@@	O	-1	137340
brain	O	-1	137340
bar@@	O	-1	137340
ri@@	O	-1	137340
er,	O	-1	137340
had	O	-1	137340
no	O	-1	137340
effect	O	-1	137340
on	O	-1	137340
the	O	-1	137340
hyperactivity	B-Disease	D006948	137340
produced	O	-1	137340
by	O	-1	137340
morphine	B-Chemical	D009020	137340
.	O	-1	137340
Pre@@	O	-1	137340
treatment	O	-1	137340
of	O	-1	137340
mice	O	-1	137340
with	O	-1	137340
alpha-@@	B-Chemical	D019805	137340
methyl@@	I-Chemical	-1	137340
ty@@	I-Chemical	-1	137340
ros@@	I-Chemical	-1	137340
ine	I-Chemical	-1	137340
(2@@	O	-1	137340
0	O	-1	137340
mg/kg	O	-1	137340
i.p.@@	O	-1	137340
,	O	-1	137340
one	O	-1	137340
hour@@	O	-1	137340
),	O	-1	137340
an	O	-1	137340
inhibitor	O	-1	137340
of	O	-1	137340
ty@@	B-Chemical	D014443	137340
ros@@	I-Chemical	-1	137340
ine	I-Chemical	-1	137340
hydrox@@	O	-1	137340
yl@@	O	-1	137340
ase,	O	-1	137340
significantly	O	-1	137340
decreased	O	-1	137340
the	O	-1	137340
activ@@	O	-1	137340
it@@	O	-1	137340
y-@@	O	-1	137340
increas@@	O	-1	137340
ing	O	-1	137340
effects	O	-1	137340
of	O	-1	137340
morphine	B-Chemical	D009020	137340
.	O	-1	137340
O@@	O	-1	137340
n	O	-1	137340
the	O	-1	137340
other	O	-1	137340
h@@	O	-1	137340
and@@	O	-1	137340
,	O	-1	137340
pretreatment	O	-1	137340
with	O	-1	137340
p@@	B-Chemical	D010134	137340
-@@	I-Chemical	-1	137340
ch@@	I-Chemical	-1	137340
loro@@	I-Chemical	-1	137340
phenyl@@	I-Chemical	-1	137340
al@@	I-Chemical	-1	137340
amine	I-Chemical	-1	137340
(@@	O	-1	137340
3	O	-1	137340
X	O	-1	137340
3@@	O	-1	137340
20	O	-1	137340
mg/kg	O	-1	137340
i.p.@@	O	-1	137340
,	O	-1	137340
24	O	-1	137340
h@@	O	-1	137340
r@@	O	-1	137340
),	O	-1	137340
a	O	-1	137340
seroton@@	B-Chemical	D012701	137340
in	I-Chemical	-1	137340
deple@@	O	-1	137340
t@@	O	-1	137340
or@@	O	-1	137340
,	O	-1	137340
caused	O	-1	137340
no	O	-1	137340
significant	O	-1	137340
change	O	-1	137340
in	O	-1	137340
the	O	-1	137340
hyperactivity	B-Disease	D006948	137340
.	O	-1	137340
The	O	-1	137340
study	O	-1	137340
suggests	O	-1	137340
that	O	-1	137340
the	O	-1	137340
activ@@	O	-1	137340
it@@	O	-1	137340
y-@@	O	-1	137340
increas@@	O	-1	137340
ing	O	-1	137340
effects	O	-1	137340
of	O	-1	137340
morphine	B-Chemical	D009020	137340
are	O	-1	137340
mediated	O	-1	137340
by	O	-1	137340
the	O	-1	137340
release	O	-1	137340
of	O	-1	137340
cat@@	B-Chemical	D002395	137340
ech@@	I-Chemical	-1	137340
ol@@	I-Chemical	-1	137340
amin@@	I-Chemical	-1	137340
es	I-Chemical	-1	137340
from	O	-1	137340
adrenergic	O	-1	137340
neuron@@	O	-1	137340
s	O	-1	137340
in	O	-1	137340
the	O	-1	137340
bra@@	O	-1	137340
in.	O	-1	137340
An@@	O	-1	137340
d	O	-1	137340
the	O	-1	137340
results	O	-1	137340
are	O	-1	137340
consist@@	O	-1	137340
ent	O	-1	137340
with	O	-1	137340
the	O	-1	137340
hypo@@	O	-1	137340
thesis	O	-1	137340
that	O	-1	137340
morphine	B-Chemical	D009020	137340
act@@	O	-1	137340
s	O	-1	137340
by	O	-1	137340
ret@@	O	-1	137340
ar@@	O	-1	137340
ding	O	-1	137340
the	O	-1	137340
release	O	-1	137340
of	O	-1	137340
acet@@	B-Chemical	D000109	137340
ylcholine	I-Chemical	-1	137340
at	O	-1	137340
some	O	-1	137340
central	O	-1	137340
cholinergic	O	-1	137340
syn@@	O	-1	137340
ap@@	O	-1	137340
s@@	O	-1	137340
es.	O	-1	137340
It	O	-1	137340
is	O	-1	137340
also	O	-1	137340
suggested	O	-1	137340
from	O	-1	137340
coll@@	O	-1	137340
ected	O	-1	137340
evidence	O	-1	137340
that	O	-1	137340
the	O	-1	137340
activ@@	O	-1	137340
it@@	O	-1	137340
y-@@	O	-1	137340
increas@@	O	-1	137340
ing	O	-1	137340
effects	O	-1	137340
of	O	-1	137340
morphine	B-Chemical	D009020	137340
in	O	-1	137340
mice	O	-1	137340
are	O	-1	137340
mediated	O	-1	137340
by	O	-1	137340
mechanisms	O	-1	137340
different	O	-1	137340
from	O	-1	137340
those	O	-1	137340
which	O	-1	137340
medi@@	O	-1	137340
ate	O	-1	137340
the	O	-1	137340
activ@@	O	-1	137340
it@@	O	-1	137340
y-@@	O	-1	137340
increas@@	O	-1	137340
ing	O	-1	137340
effects	O	-1	137340
of	O	-1	137340
morphine	B-Chemical	D009020	137340
in	O	-1	137340
rats.	O	-1	137340

M@@	O	-1	9931093
echan@@	O	-1	9931093
is@@	O	-1	9931093
ms	O	-1	9931093
of	O	-1	9931093
F@@	B-Chemical	D016559	9931093
K	I-Chemical	-1	9931093
50@@	I-Chemical	-1	9931093
6	I-Chemical	-1	9931093
-induced	O	-1	9931093
hypertension	B-Disease	D006973	9931093
in	O	-1	9931093
the	O	-1	9931093
rat@@	O	-1	9931093
.	O	-1	9931093
-	O	-1	9931093
T@@	B-Chemical	D016559	9931093
ac@@	I-Chemical	-1	9931093
rolimus	I-Chemical	-1	9931093
(	O	-1	9931093
F@@	B-Chemical	D016559	9931093
K	I-Chemical	-1	9931093
50@@	I-Chemical	-1	9931093
6	I-Chemical	-1	9931093
)	O	-1	9931093
is	O	-1	9931093
a	O	-1	9931093
po@@	O	-1	9931093
w@@	O	-1	9931093
er@@	O	-1	9931093
ful@@	O	-1	9931093
,	O	-1	9931093
wi@@	O	-1	9931093
de@@	O	-1	9931093
ly	O	-1	9931093
used	O	-1	9931093
immunosup@@	O	-1	9931093
press@@	O	-1	9931093
ant@@	O	-1	9931093
.	O	-1	9931093
The	O	-1	9931093
clinical	O	-1	9931093
u@@	O	-1	9931093
til@@	O	-1	9931093
ity	O	-1	9931093
of	O	-1	9931093
F@@	B-Chemical	D016559	9931093
K	I-Chemical	-1	9931093
50@@	I-Chemical	-1	9931093
6	I-Chemical	-1	9931093
is	O	-1	9931093
complic@@	O	-1	9931093
ated	O	-1	9931093
by	O	-1	9931093
subst@@	O	-1	9931093
anti@@	O	-1	9931093
al	O	-1	9931093
hypertension	B-Disease	D006973	9931093
and	O	-1	9931093
nephro@@	B-Disease	D007674	9931093
toxicity	I-Disease	-1	9931093
.	O	-1	9931093
To	O	-1	9931093
cl@@	O	-1	9931093
ar@@	O	-1	9931093
if@@	O	-1	9931093
y	O	-1	9931093
the	O	-1	9931093
mechanisms	O	-1	9931093
of	O	-1	9931093
F@@	B-Chemical	D016559	9931093
K	I-Chemical	-1	9931093
50@@	I-Chemical	-1	9931093
6	I-Chemical	-1	9931093
-induced	O	-1	9931093
hypertension	B-Disease	D006973	9931093
,	O	-1	9931093
we	O	-1	9931093
studied	O	-1	9931093
the	O	-1	9931093
chronic	O	-1	9931093
effects	O	-1	9931093
of	O	-1	9931093
F@@	B-Chemical	D016559	9931093
K	I-Chemical	-1	9931093
50@@	I-Chemical	-1	9931093
6	I-Chemical	-1	9931093
on	O	-1	9931093
the	O	-1	9931093
syn@@	O	-1	9931093
thesis	O	-1	9931093
of	O	-1	9931093
endo@@	O	-1	9931093
the@@	O	-1	9931093
l@@	O	-1	9931093
in-@@	O	-1	9931093
1	O	-1	9931093
(@@	O	-1	9931093
ET@@	O	-1	9931093
-1@@	O	-1	9931093
),	O	-1	9931093
the	O	-1	9931093
expression	O	-1	9931093
of	O	-1	9931093
mRNA	O	-1	9931093
of	O	-1	9931093
ET@@	O	-1	9931093
-1	O	-1	9931093
and	O	-1	9931093
endo@@	O	-1	9931093
the@@	O	-1	9931093
l@@	O	-1	9931093
in-@@	O	-1	9931093
conver@@	O	-1	9931093
ting	O	-1	9931093
enz@@	O	-1	9931093
y@@	O	-1	9931093
me@@	O	-1	9931093
-1	O	-1	9931093
(@@	O	-1	9931093
EC@@	O	-1	9931093
E@@	O	-1	9931093
-1@@	O	-1	9931093
),	O	-1	9931093
the	O	-1	9931093
endothelial	O	-1	9931093
nit@@	B-Chemical	D009569	9931093
ric	I-Chemical	-1	9931093
ox@@	I-Chemical	-1	9931093
ide	I-Chemical	-1	9931093
syn@@	O	-1	9931093
th@@	O	-1	9931093
ase	O	-1	9931093
(@@	O	-1	9931093
e@@	O	-1	9931093
NO@@	O	-1	9931093
S)	O	-1	9931093
activ@@	O	-1	9931093
ity,	O	-1	9931093
and	O	-1	9931093
the	O	-1	9931093
expression	O	-1	9931093
of	O	-1	9931093
mRNA	O	-1	9931093
of	O	-1	9931093
e@@	O	-1	9931093
NO@@	O	-1	9931093
S	O	-1	9931093
and	O	-1	9931093
C@@	O	-1	9931093
-@@	O	-1	9931093
type	O	-1	9931093
n@@	O	-1	9931093
atri@@	O	-1	9931093
ure@@	O	-1	9931093
tic	O	-1	9931093
p@@	O	-1	9931093
ep@@	O	-1	9931093
ti@@	O	-1	9931093
de	O	-1	9931093
(C@@	O	-1	9931093
N@@	O	-1	9931093
P)	O	-1	9931093
in	O	-1	9931093
rat	O	-1	9931093
blood	O	-1	9931093
v@@	O	-1	9931093
es@@	O	-1	9931093
sel@@	O	-1	9931093
s.	O	-1	9931093
In	O	-1	9931093
addi@@	O	-1	9931093
tion,	O	-1	9931093
the	O	-1	9931093
effect	O	-1	9931093
of	O	-1	9931093
the	O	-1	9931093
specific	O	-1	9931093
endo@@	O	-1	9931093
the@@	O	-1	9931093
l@@	O	-1	9931093
in	O	-1	9931093
type	O	-1	9931093
A	O	-1	9931093
receptor	O	-1	9931093
antagonist	O	-1	9931093
F@@	B-Chemical	C079574	9931093
R	I-Chemical	-1	9931093
13@@	I-Chemical	-1	9931093
9@@	I-Chemical	-1	9931093
3@@	I-Chemical	-1	9931093
17	I-Chemical	-1	9931093
on	O	-1	9931093
F@@	B-Chemical	D016559	9931093
K	I-Chemical	-1	9931093
50@@	I-Chemical	-1	9931093
6	I-Chemical	-1	9931093
-induced	O	-1	9931093
hypertension	B-Disease	D006973	9931093
in	O	-1	9931093
rats	O	-1	9931093
was	O	-1	9931093
studi@@	O	-1	9931093
ed.	O	-1	9931093
F@@	B-Chemical	D016559	9931093
K	I-Chemical	-1	9931093
50@@	I-Chemical	-1	9931093
6	I-Chemical	-1	9931093
,	O	-1	9931093
5	O	-1	9931093
mg@@	O	-1	9931093
.	O	-1	9931093
kg@@	O	-1	9931093
-1@@	O	-1	9931093
.	O	-1	9931093
d-@@	O	-1	9931093
1	O	-1	9931093
given	O	-1	9931093
for	O	-1	9931093
4	O	-1	9931093
week@@	O	-1	9931093
s,	O	-1	9931093
elevated	O	-1	9931093
blood	O	-1	9931093
pressure	O	-1	9931093
from	O	-1	9931093
10@@	O	-1	9931093
2@@	O	-1	9931093
+/@@	O	-1	9931093
-1@@	O	-1	9931093
3	O	-1	9931093
to	O	-1	9931093
1@@	O	-1	9931093
5@@	O	-1	9931093
2@@	O	-1	9931093
+/@@	O	-1	9931093
-1@@	O	-1	9931093
5	O	-1	9931093
mm	O	-1	9931093
H@@	O	-1	9931093
g	O	-1	9931093
and	O	-1	9931093
increased	O	-1	9931093
the	O	-1	9931093
syn@@	O	-1	9931093
thesis	O	-1	9931093
of	O	-1	9931093
ET@@	O	-1	9931093
-1	O	-1	9931093
and	O	-1	9931093
the	O	-1	9931093
levels	O	-1	9931093
of	O	-1	9931093
ET@@	O	-1	9931093
-1	O	-1	9931093
mRNA	O	-1	9931093
in	O	-1	9931093
the	O	-1	9931093
m@@	O	-1	9931093
es@@	O	-1	9931093
ent@@	O	-1	9931093
er@@	O	-1	9931093
ic	O	-1	9931093
artery	O	-1	9931093
(2@@	O	-1	9931093
4@@	O	-1	9931093
0%	O	-1	9931093
and	O	-1	9931093
2@@	O	-1	9931093
3@@	O	-1	9931093
0@@	O	-1	9931093
%,	O	-1	9931093
respectivel@@	O	-1	9931093
y@@	O	-1	9931093
).	O	-1	9931093
L@@	O	-1	9931093
it@@	O	-1	9931093
t@@	O	-1	9931093
le	O	-1	9931093
change	O	-1	9931093
was	O	-1	9931093
observed	O	-1	9931093
in	O	-1	9931093
the	O	-1	9931093
expression	O	-1	9931093
of	O	-1	9931093
EC@@	O	-1	9931093
E@@	O	-1	9931093
-1	O	-1	9931093
mRNA	O	-1	9931093
and	O	-1	9931093
C@@	O	-1	9931093
N@@	O	-1	9931093
P	O	-1	9931093
mR@@	O	-1	9931093
N@@	O	-1	9931093
A@@	O	-1	9931093
.	O	-1	9931093
F@@	B-Chemical	D016559	9931093
K	I-Chemical	-1	9931093
50@@	I-Chemical	-1	9931093
6	I-Chemical	-1	9931093
decreased	O	-1	9931093
e@@	O	-1	9931093
NO@@	O	-1	9931093
S	O	-1	9931093
activity	O	-1	9931093
and	O	-1	9931093
the	O	-1	9931093
levels	O	-1	9931093
of	O	-1	9931093
e@@	O	-1	9931093
NO@@	O	-1	9931093
S	O	-1	9931093
mRNA	O	-1	9931093
in	O	-1	9931093
the	O	-1	9931093
a@@	O	-1	9931093
ort@@	O	-1	9931093
a	O	-1	9931093
(4@@	O	-1	9931093
8@@	O	-1	9931093
%	O	-1	9931093
and	O	-1	9931093
55@@	O	-1	9931093
%,	O	-1	9931093
respectivel@@	O	-1	9931093
y@@	O	-1	9931093
).	O	-1	9931093
The	O	-1	9931093
administration	O	-1	9931093
of	O	-1	9931093
F@@	B-Chemical	C079574	9931093
R	I-Chemical	-1	9931093
13@@	I-Chemical	-1	9931093
9@@	I-Chemical	-1	9931093
3@@	I-Chemical	-1	9931093
17	I-Chemical	-1	9931093
(10	O	-1	9931093
mg@@	O	-1	9931093
.	O	-1	9931093
kg@@	O	-1	9931093
-1@@	O	-1	9931093
.	O	-1	9931093
d-@@	O	-1	9931093
1)	O	-1	9931093
prevent@@	O	-1	9931093
ed	O	-1	9931093
F@@	B-Chemical	D016559	9931093
K	I-Chemical	-1	9931093
50@@	I-Chemical	-1	9931093
6	I-Chemical	-1	9931093
-induced	O	-1	9931093
hypertension	B-Disease	D006973	9931093
in	O	-1	9931093
rats.	O	-1	9931093
These	O	-1	9931093
results	O	-1	9931093
indicate	O	-1	9931093
that	O	-1	9931093
F@@	B-Chemical	D016559	9931093
K	I-Chemical	-1	9931093
50@@	I-Chemical	-1	9931093
6	I-Chemical	-1	9931093
may	O	-1	9931093
increase	O	-1	9931093
blood	O	-1	9931093
pressure	O	-1	9931093
not	O	-1	9931093
only	O	-1	9931093
by	O	-1	9931093
increas@@	O	-1	9931093
ing	O	-1	9931093
ET@@	O	-1	9931093
-1	O	-1	9931093
pro@@	O	-1	9931093
duction	O	-1	9931093
but	O	-1	9931093
also	O	-1	9931093
by	O	-1	9931093
decreas@@	O	-1	9931093
ing	O	-1	9931093
N@@	B-Chemical	D009569	9931093
O	I-Chemical	-1	9931093
syn@@	O	-1	9931093
thesis	O	-1	9931093
in	O	-1	9931093
the	O	-1	9931093
vas@@	O	-1	9931093
cul@@	O	-1	9931093
at@@	O	-1	9931093
ure.	O	-1	9931093

S@@	B-Chemical	D013390	20633755
u@@	I-Chemical	-1	20633755
xameth@@	I-Chemical	-1	20633755
oni@@	I-Chemical	-1	20633755
um	I-Chemical	-1	20633755
induced	O	-1	20633755
prolonged	O	-1	20633755
ap@@	B-Disease	D001049	20633755
ne@@	I-Disease	-1	20633755
a	I-Disease	-1	20633755
in	O	-1	20633755
a	O	-1	20633755
patient	O	-1	20633755
receiving	O	-1	20633755
electro@@	O	-1	20633755
convul@@	O	-1	20633755
sive	O	-1	20633755
therapy.	O	-1	20633755
S@@	B-Chemical	D013390	20633755
u@@	I-Chemical	-1	20633755
xameth@@	I-Chemical	-1	20633755
oni@@	I-Chemical	-1	20633755
um	I-Chemical	-1	20633755
causes	O	-1	20633755
prolonged	O	-1	20633755
ap@@	B-Disease	D001049	20633755
ne@@	I-Disease	-1	20633755
a	I-Disease	-1	20633755
in	O	-1	20633755
patients	O	-1	20633755
in	O	-1	20633755
whom	O	-1	20633755
p@@	O	-1	20633755
se@@	O	-1	20633755
u@@	O	-1	20633755
do@@	O	-1	20633755
chol@@	O	-1	20633755
ine@@	O	-1	20633755
ster@@	O	-1	20633755
ase	O	-1	20633755
enzyme	O	-1	20633755
g@@	O	-1	20633755
et@@	O	-1	20633755
s	O	-1	20633755
de@@	O	-1	20633755
activ@@	O	-1	20633755
ated	O	-1	20633755
by	O	-1	20633755
org@@	B-Chemical	D009943	20633755
an@@	I-Chemical	-1	20633755
oph@@	I-Chemical	-1	20633755
osph@@	I-Chemical	-1	20633755
or@@	I-Chemical	-1	20633755
us	I-Chemical	-1	20633755
(@@	I-Chemical	-1	20633755
O@@	I-Chemical	-1	20633755
P)	I-Chemical	-1	20633755
po@@	I-Chemical	-1	20633755
is@@	I-Chemical	-1	20633755
ons	I-Chemical	-1	20633755
.	O	-1	20633755
He@@	O	-1	20633755
re,	O	-1	20633755
we	O	-1	20633755
present	O	-1	20633755
a	O	-1	20633755
similar	O	-1	20633755
inc@@	O	-1	20633755
id@@	O	-1	20633755
ent	O	-1	20633755
in	O	-1	20633755
a	O	-1	20633755
se@@	O	-1	20633755
ve@@	O	-1	20633755
re@@	O	-1	20633755
ly	O	-1	20633755
depress@@	B-Disease	D003866	20633755
ed	I-Disease	-1	20633755
patient	O	-1	20633755
who	O	-1	20633755
received	O	-1	20633755
electro@@	O	-1	20633755
convul@@	O	-1	20633755
sive	O	-1	20633755
therapy	O	-1	20633755
(@@	O	-1	20633755
EC@@	O	-1	20633755
T@@	O	-1	20633755
).	O	-1	20633755
Pro@@	O	-1	20633755
long@@	O	-1	20633755
ed	O	-1	20633755
ap@@	B-Disease	D001049	20633755
ne@@	I-Disease	-1	20633755
a	I-Disease	-1	20633755
in	O	-1	20633755
our	O	-1	20633755
case	O	-1	20633755
en@@	O	-1	20633755
su@@	O	-1	20633755
ed	O	-1	20633755
because	O	-1	20633755
the	O	-1	20633755
inf@@	O	-1	20633755
orm@@	O	-1	20633755
ation	O	-1	20633755
about	O	-1	20633755
su@@	O	-1	20633755
ic@@	O	-1	20633755
idal	O	-1	20633755
at@@	O	-1	20633755
tem@@	O	-1	20633755
p@@	O	-1	20633755
t	O	-1	20633755
by	O	-1	20633755
O@@	B-Chemical	D009943	20633755
P	I-Chemical	-1	20633755
comp@@	I-Chemical	-1	20633755
ound	I-Chemical	-1	20633755
was	O	-1	20633755
con@@	O	-1	20633755
ce@@	O	-1	20633755
al@@	O	-1	20633755
ed	O	-1	20633755
from	O	-1	20633755
the	O	-1	20633755
treat@@	O	-1	20633755
ing	O	-1	20633755
te@@	O	-1	20633755
am@@	O	-1	20633755
.	O	-1	20633755

The	O	-1	20067456
effects	O	-1	20067456
of	O	-1	20067456
the	O	-1	20067456
adj@@	O	-1	20067456
unc@@	O	-1	20067456
tive	O	-1	20067456
bu@@	B-Chemical	D016642	20067456
pro@@	I-Chemical	-1	20067456
pi@@	I-Chemical	-1	20067456
on	I-Chemical	-1	20067456
on	O	-1	20067456
male	O	-1	20067456
sex@@	B-Disease	D012735	20067456
ual	I-Disease	-1	20067456
dysfunction	I-Disease	-1	20067456
induced	O	-1	20067456
by	O	-1	20067456
a	O	-1	20067456
selective	B-Chemical	D017367	20067456
seroton@@	I-Chemical	-1	20067456
in	I-Chemical	-1	20067456
re@@	I-Chemical	-1	20067456
u@@	I-Chemical	-1	20067456
pt@@	I-Chemical	-1	20067456
ake	I-Chemical	-1	20067456
inhibitor	I-Chemical	-1	20067456
:	O	-1	20067456
a	O	-1	20067456
double-bl@@	O	-1	20067456
ind	O	-1	20067456
placebo@@	O	-1	20067456
-@@	O	-1	20067456
controlled	O	-1	20067456
and	O	-1	20067456
randomized	O	-1	20067456
study.	O	-1	20067456
OBJECTIVE:	O	-1	20067456
To	O	-1	20067456
determine	O	-1	20067456
the	O	-1	20067456
safety	O	-1	20067456
and	O	-1	20067456
efficacy	O	-1	20067456
of	O	-1	20067456
adj@@	O	-1	20067456
unc@@	O	-1	20067456
tive	O	-1	20067456
bu@@	B-Chemical	D016642	20067456
pro@@	I-Chemical	-1	20067456
pi@@	I-Chemical	-1	20067456
on	I-Chemical	-1	20067456
su@@	O	-1	20067456
st@@	O	-1	20067456
a@@	O	-1	20067456
ine@@	O	-1	20067456
d-@@	O	-1	20067456
release	O	-1	20067456
(@@	O	-1	20067456
SR@@	O	-1	20067456
)	O	-1	20067456
on	O	-1	20067456
male	O	-1	20067456
sex@@	B-Disease	D012735	20067456
ual	I-Disease	-1	20067456
dysfunction	I-Disease	-1	20067456
(	O	-1	20067456
S@@	B-Disease	D012735	20067456
D	I-Disease	-1	20067456
)	O	-1	20067456
induced	O	-1	20067456
by	O	-1	20067456
a	O	-1	20067456
selective	B-Chemical	D017367	20067456
seroton@@	I-Chemical	-1	20067456
in	I-Chemical	-1	20067456
re@@	I-Chemical	-1	20067456
u@@	I-Chemical	-1	20067456
pt@@	I-Chemical	-1	20067456
ake	I-Chemical	-1	20067456
inhibitor	I-Chemical	-1	20067456
(	O	-1	20067456
S@@	B-Chemical	D017367	20067456
SR@@	I-Chemical	-1	20067456
I	I-Chemical	-1	20067456
),	O	-1	20067456
as	O	-1	20067456
S@@	B-Disease	D012735	20067456
D	I-Disease	-1	20067456
is	O	-1	20067456
a	O	-1	20067456
common	O	-1	20067456
side@@	O	-1	20067456
-@@	O	-1	20067456
effect	O	-1	20067456
of	O	-1	20067456
S@@	B-Chemical	D017367	20067456
SR@@	I-Chemical	-1	20067456
I@@	I-Chemical	-1	20067456
s	I-Chemical	-1	20067456
and	O	-1	20067456
the	O	-1	20067456
most	O	-1	20067456
effective	O	-1	20067456
treat@@	O	-1	20067456
ments	O	-1	20067456
have	O	-1	20067456
y@@	O	-1	20067456
et	O	-1	20067456
to	O	-1	20067456
be	O	-1	20067456
deter@@	O	-1	20067456
m@@	O	-1	20067456
ine@@	O	-1	20067456
d.	O	-1	20067456
PA@@	O	-1	20067456
TI@@	O	-1	20067456
E@@	O	-1	20067456
N@@	O	-1	20067456
T@@	O	-1	20067456
S	O	-1	20067456
AN@@	O	-1	20067456
D	O	-1	20067456
METHODS:	O	-1	20067456
The	O	-1	20067456
randomized	O	-1	20067456
sam@@	O	-1	20067456
ple	O	-1	20067456
consist@@	O	-1	20067456
ed	O	-1	20067456
of	O	-1	20067456
2@@	O	-1	20067456
3@@	O	-1	20067456
4	O	-1	20067456
eu@@	O	-1	20067456
th@@	O	-1	20067456
ym@@	O	-1	20067456
ic	O	-1	20067456
men	O	-1	20067456
who	O	-1	20067456
were	O	-1	20067456
receiving	O	-1	20067456
some	O	-1	20067456
type	O	-1	20067456
of	O	-1	20067456
S@@	B-Chemical	D017367	20067456
SR@@	I-Chemical	-1	20067456
I	I-Chemical	-1	20067456
.	O	-1	20067456
The	O	-1	20067456
men	O	-1	20067456
were	O	-1	20067456
random@@	O	-1	20067456
ly	O	-1	20067456
as@@	O	-1	20067456
signed	O	-1	20067456
to	O	-1	20067456
bu@@	B-Chemical	D016642	20067456
pro@@	I-Chemical	-1	20067456
pi@@	I-Chemical	-1	20067456
on	I-Chemical	-1	20067456
S@@	O	-1	20067456
R	O	-1	20067456
(1@@	O	-1	20067456
50	O	-1	20067456
mg	O	-1	20067456
tw@@	O	-1	20067456
ic@@	O	-1	20067456
e	O	-1	20067456
da@@	O	-1	20067456
il@@	O	-1	20067456
y,	O	-1	20067456
1@@	O	-1	20067456
17@@	O	-1	20067456
)	O	-1	20067456
or	O	-1	20067456
placebo	O	-1	20067456
(@@	O	-1	20067456
tw@@	O	-1	20067456
ic@@	O	-1	20067456
e	O	-1	20067456
da@@	O	-1	20067456
il@@	O	-1	20067456
y,	O	-1	20067456
1@@	O	-1	20067456
17@@	O	-1	20067456
)	O	-1	20067456
for	O	-1	20067456
12	O	-1	20067456
week@@	O	-1	20067456
s.	O	-1	20067456
Eff@@	O	-1	20067456
icac@@	O	-1	20067456
y	O	-1	20067456
was	O	-1	20067456
evaluated	O	-1	20067456
using	O	-1	20067456
the	O	-1	20067456
Clin@@	O	-1	20067456
ical	O	-1	20067456
G@@	O	-1	20067456
lo@@	O	-1	20067456
b@@	O	-1	20067456
al	O	-1	20067456
Im@@	O	-1	20067456
pres@@	O	-1	20067456
sion@@	O	-1	20067456
-@@	O	-1	20067456
S@@	O	-1	20067456
ex@@	O	-1	20067456
ual	O	-1	20067456
F@@	O	-1	20067456
unc@@	O	-1	20067456
tion	O	-1	20067456
(C@@	O	-1	20067456
G@@	O	-1	20067456
I@@	O	-1	20067456
-@@	O	-1	20067456
S@@	O	-1	20067456
F@@	O	-1	20067456
;	O	-1	20067456
the	O	-1	20067456
prim@@	O	-1	20067456
ary	O	-1	20067456
outcom@@	O	-1	20067456
e	O	-1	20067456
meas@@	O	-1	20067456
ure@@	O	-1	20067456
),	O	-1	20067456
the	O	-1	20067456
In@@	O	-1	20067456
tern@@	O	-1	20067456
ation@@	O	-1	20067456
al	O	-1	20067456
In@@	O	-1	20067456
de@@	O	-1	20067456
x	O	-1	20067456
of	O	-1	20067456
E@@	O	-1	20067456
rec@@	O	-1	20067456
ti@@	O	-1	20067456
le	O	-1	20067456
F@@	O	-1	20067456
unc@@	O	-1	20067456
tion	O	-1	20067456
(@@	O	-1	20067456
II@@	O	-1	20067456
E@@	O	-1	20067456
F@@	O	-1	20067456
),	O	-1	20067456
A@@	O	-1	20067456
ri@@	O	-1	20067456
z@@	O	-1	20067456
on@@	O	-1	20067456
a	O	-1	20067456
S@@	O	-1	20067456
ex@@	O	-1	20067456
ual	O	-1	20067456
E@@	O	-1	20067456
x@@	O	-1	20067456
peri@@	O	-1	20067456
ence	O	-1	20067456
S@@	O	-1	20067456
cal@@	O	-1	20067456
e	O	-1	20067456
(A@@	O	-1	20067456
S@@	O	-1	20067456
E@@	O	-1	20067456
X@@	O	-1	20067456
),	O	-1	20067456
and	O	-1	20067456
E@@	B-Disease	D007172	20067456
rec@@	I-Disease	-1	20067456
ti@@	I-Disease	-1	20067456
le	I-Disease	-1	20067456
D@@	I-Disease	-1	20067456
ys@@	I-Disease	-1	20067456
function	I-Disease	-1	20067456
In@@	O	-1	20067456
v@@	O	-1	20067456
ent@@	O	-1	20067456
ory	O	-1	20067456
of	O	-1	20067456
Treat@@	O	-1	20067456
ment	O	-1	20067456
S@@	O	-1	20067456
atis@@	O	-1	20067456
f@@	O	-1	20067456
action	O	-1	20067456
(@@	O	-1	20067456
E@@	O	-1	20067456
D@@	O	-1	20067456
I@@	O	-1	20067456
T@@	O	-1	20067456
S)	O	-1	20067456
(@@	O	-1	20067456
secondary	O	-1	20067456
outcom@@	O	-1	20067456
e	O	-1	20067456
meas@@	O	-1	20067456
ures@@	O	-1	20067456
).	O	-1	20067456
P@@	O	-1	20067456
ar@@	O	-1	20067456
tic@@	O	-1	20067456
ip@@	O	-1	20067456
ants	O	-1	20067456
were	O	-1	20067456
followed	O	-1	20067456
b@@	O	-1	20067456
i@@	O	-1	20067456
week@@	O	-1	20067456
ly	O	-1	20067456
during	O	-1	20067456
study	O	-1	20067456
perio@@	O	-1	20067456
d.	O	-1	20067456
RESULTS:	O	-1	20067456
After	O	-1	20067456
12	O	-1	20067456
weeks	O	-1	20067456
of	O	-1	20067456
treatment,	O	-1	20067456
the	O	-1	20067456
mean	O	-1	20067456
(@@	O	-1	20067456
s@@	O	-1	20067456
d@@	O	-1	20067456
)	O	-1	20067456
sco@@	O	-1	20067456
res	O	-1	20067456
for	O	-1	20067456
C@@	O	-1	20067456
G@@	O	-1	20067456
I@@	O	-1	20067456
-@@	O	-1	20067456
S@@	O	-1	20067456
F	O	-1	20067456
were	O	-1	20067456
significantly	O	-1	20067456
low@@	O	-1	20067456
er,	O	-1	20067456
i.@@	O	-1	20067456
e.	O	-1	20067456
bet@@	O	-1	20067456
ter@@	O	-1	20067456
,	O	-1	20067456
in	O	-1	20067456
patients	O	-1	20067456
on	O	-1	20067456
bu@@	B-Chemical	D016642	20067456
pro@@	I-Chemical	-1	20067456
pi@@	I-Chemical	-1	20067456
on	I-Chemical	-1	20067456
SR@@	O	-1	20067456
,	O	-1	20067456
at	O	-1	20067456
2.@@	O	-1	20067456
4	O	-1	20067456
(1@@	O	-1	20067456
.@@	O	-1	20067456
2@@	O	-1	20067456
),	O	-1	20067456
than	O	-1	20067456
in	O	-1	20067456
the	O	-1	20067456
placebo	O	-1	20067456
group@@	O	-1	20067456
,	O	-1	20067456
at	O	-1	20067456
3.@@	O	-1	20067456
9	O	-1	20067456
(1@@	O	-1	20067456
.@@	O	-1	20067456
1)	O	-1	20067456
(P@@	O	-1	20067456
=	O	-1	20067456
0.0@@	O	-1	20067456
1).	O	-1	20067456
M@@	O	-1	20067456
en	O	-1	20067456
who	O	-1	20067456
received	O	-1	20067456
bu@@	B-Chemical	D016642	20067456
pro@@	I-Chemical	-1	20067456
pi@@	I-Chemical	-1	20067456
on	I-Chemical	-1	20067456
had	O	-1	20067456
a	O	-1	20067456
significant	O	-1	20067456
increase	O	-1	20067456
in	O	-1	20067456
the	O	-1	20067456
total	O	-1	20067456
II@@	O	-1	20067456
E@@	O	-1	20067456
F	O	-1	20067456
scor@@	O	-1	20067456
e	O	-1	20067456
(5@@	O	-1	20067456
4.@@	O	-1	20067456
4@@	O	-1	20067456
%	O	-1	20067456
v@@	O	-1	20067456
s	O	-1	20067456
1.@@	O	-1	20067456
2@@	O	-1	20067456
%@@	O	-1	20067456
;	O	-1	20067456
P@@	O	-1	20067456
=	O	-1	20067456
0.00@@	O	-1	20067456
3@@	O	-1	20067456
),	O	-1	20067456
and	O	-1	20067456
in	O	-1	20067456
the	O	-1	20067456
five	O	-1	20067456
different	O	-1	20067456
do@@	O	-1	20067456
main@@	O	-1	20067456
s	O	-1	20067456
of	O	-1	20067456
the	O	-1	20067456
II@@	O	-1	20067456
E@@	O	-1	20067456
F@@	O	-1	20067456
.	O	-1	20067456
T@@	O	-1	20067456
ot@@	O	-1	20067456
al	O	-1	20067456
A@@	O	-1	20067456
S@@	O	-1	20067456
E@@	O	-1	20067456
X	O	-1	20067456
sco@@	O	-1	20067456
res	O	-1	20067456
were	O	-1	20067456
significantly	O	-1	20067456
low@@	O	-1	20067456
er,	O	-1	20067456
i.@@	O	-1	20067456
e.	O	-1	20067456
bet@@	O	-1	20067456
ter@@	O	-1	20067456
,	O	-1	20067456
among	O	-1	20067456
men	O	-1	20067456
who	O	-1	20067456
received	O	-1	20067456
bu@@	B-Chemical	D016642	20067456
pro@@	I-Chemical	-1	20067456
pi@@	I-Chemical	-1	20067456
on	I-Chemical	-1	20067456
than	O	-1	20067456
placebo@@	O	-1	20067456
,	O	-1	20067456
at	O	-1	20067456
1@@	O	-1	20067456
5.@@	O	-1	20067456
5	O	-1	20067456
(@@	O	-1	20067456
4.@@	O	-1	20067456
3@@	O	-1	20067456
)	O	-1	20067456
v@@	O	-1	20067456
s	O	-1	20067456
2@@	O	-1	20067456
1.@@	O	-1	20067456
5	O	-1	20067456
(@@	O	-1	20067456
4.@@	O	-1	20067456
7@@	O	-1	20067456
)	O	-1	20067456
(P@@	O	-1	20067456
=	O	-1	20067456
0.00@@	O	-1	20067456
2@@	O	-1	20067456
).	O	-1	20067456
The	O	-1	20067456
E@@	O	-1	20067456
D@@	O	-1	20067456
I@@	O	-1	20067456
T@@	O	-1	20067456
S	O	-1	20067456
sco@@	O	-1	20067456
res	O	-1	20067456
were	O	-1	20067456
6@@	O	-1	20067456
7.@@	O	-1	20067456
4	O	-1	20067456
(1@@	O	-1	20067456
0.@@	O	-1	20067456
2)	O	-1	20067456
for	O	-1	20067456
the	O	-1	20067456
bu@@	B-Chemical	D016642	20067456
pro@@	I-Chemical	-1	20067456
pi@@	I-Chemical	-1	20067456
on	I-Chemical	-1	20067456
and	O	-1	20067456
3@@	O	-1	20067456
6.@@	O	-1	20067456
3	O	-1	20067456
(1@@	O	-1	20067456
1.@@	O	-1	20067456
7@@	O	-1	20067456
)	O	-1	20067456
for	O	-1	20067456
the	O	-1	20067456
placebo	O	-1	20067456
group	O	-1	20067456
(P@@	O	-1	20067456
=	O	-1	20067456
0.00@@	O	-1	20067456
1).	O	-1	20067456
The	O	-1	20067456
A@@	O	-1	20067456
S@@	O	-1	20067456
E@@	O	-1	20067456
X	O	-1	20067456
scor@@	O	-1	20067456
e	O	-1	20067456
and	O	-1	20067456
C@@	O	-1	20067456
G@@	O	-1	20067456
I@@	O	-1	20067456
-@@	O	-1	20067456
S@@	O	-1	20067456
F	O	-1	20067456
scor@@	O	-1	20067456
e	O	-1	20067456
were	O	-1	20067456
cor@@	O	-1	20067456
related	O	-1	20067456
(P@@	O	-1	20067456
=	O	-1	20067456
0.00@@	O	-1	20067456
3@@	O	-1	20067456
).	O	-1	20067456
In	O	-1	20067456
l@@	O	-1	20067456
ine@@	O	-1	20067456
ar	O	-1	20067456
reg@@	O	-1	20067456
res@@	O	-1	20067456
sion	O	-1	20067456
analy@@	O	-1	20067456
ses	O	-1	20067456
the	O	-1	20067456
C@@	O	-1	20067456
G@@	O	-1	20067456
I@@	O	-1	20067456
-@@	O	-1	20067456
S@@	O	-1	20067456
F	O	-1	20067456
scor@@	O	-1	20067456
e	O	-1	20067456
was	O	-1	20067456
not	O	-1	20067456
affected	O	-1	20067456
significantly	O	-1	20067456
by	O	-1	20067456
the	O	-1	20067456
duration	O	-1	20067456
of	O	-1	20067456
S@@	B-Disease	D012735	20067456
D	I-Disease	-1	20067456
,	O	-1	20067456
type	O	-1	20067456
of	O	-1	20067456
S@@	B-Chemical	D017367	20067456
SR@@	I-Chemical	-1	20067456
I	I-Chemical	-1	20067456
used	O	-1	20067456
and	O	-1	20067456
age.	O	-1	20067456
CONCLUSIONS:	O	-1	20067456
B@@	B-Chemical	D016642	20067456
u@@	I-Chemical	-1	20067456
pro@@	I-Chemical	-1	20067456
pi@@	I-Chemical	-1	20067456
on	I-Chemical	-1	20067456
is	O	-1	20067456
an	O	-1	20067456
effective	O	-1	20067456
treatment	O	-1	20067456
for	O	-1	20067456
male	O	-1	20067456
S@@	B-Disease	D012735	20067456
D	I-Disease	-1	20067456
induced	O	-1	20067456
by	O	-1	20067456
S@@	B-Chemical	D017367	20067456
SR@@	I-Chemical	-1	20067456
I@@	I-Chemical	-1	20067456
s	I-Chemical	-1	20067456
.	O	-1	20067456
These	O	-1	20067456
results	O	-1	20067456
prov@@	O	-1	20067456
ide	O	-1	20067456
em@@	O	-1	20067456
pi@@	O	-1	20067456
r@@	O	-1	20067456
ical	O	-1	20067456
suppor@@	O	-1	20067456
t	O	-1	20067456
for	O	-1	20067456
con@@	O	-1	20067456
duc@@	O	-1	20067456
ting	O	-1	20067456
a	O	-1	20067456
further	O	-1	20067456
study	O	-1	20067456
of	O	-1	20067456
bu@@	B-Chemical	D016642	20067456
pro@@	I-Chemical	-1	20067456
pi@@	I-Chemical	-1	20067456
on	I-Chemical	-1	20067456
.	O	-1	20067456

L@@	B-Chemical	D019259	18464113
amivud@@	I-Chemical	-1	18464113
ine	I-Chemical	-1	18464113
for	O	-1	18464113
the	O	-1	18464113
pre@@	O	-1	18464113
ven@@	O	-1	18464113
tion	O	-1	18464113
of	O	-1	18464113
hepatitis	B-Disease	D006509	18464113
B	I-Disease	-1	18464113
vi@@	O	-1	18464113
ru@@	O	-1	18464113
s	O	-1	18464113
re@@	O	-1	18464113
activation	O	-1	18464113
in	O	-1	18464113
hepati@@	B-Chemical	D006514	18464113
tis@@	I-Chemical	-1	18464113
-@@	I-Chemical	-1	18464113
B	I-Chemical	-1	18464113
sur@@	I-Chemical	-1	18464113
fac@@	I-Chemical	-1	18464113
e	I-Chemical	-1	18464113
anti@@	I-Chemical	-1	18464113
gen	I-Chemical	-1	18464113
(	O	-1	18464113
HB@@	B-Chemical	D006514	18464113
S@@	I-Chemical	-1	18464113
A@@	I-Chemical	-1	18464113
G	I-Chemical	-1	18464113
)	O	-1	18464113
ser@@	O	-1	18464113
o@@	O	-1	18464113
positive	O	-1	18464113
cancer	B-Disease	D009369	18464113
patients	O	-1	18464113
under@@	O	-1	18464113
go@@	O	-1	18464113
ing	O	-1	18464113
cy@@	O	-1	18464113
tot@@	O	-1	18464113
ox@@	O	-1	18464113
ic	O	-1	18464113
chemo@@	O	-1	18464113
therapy.	O	-1	18464113
He@@	B-Disease	D006509	18464113
pati@@	I-Disease	-1	18464113
tis	I-Disease	-1	18464113
B	I-Disease	-1	18464113
vi@@	O	-1	18464113
ru@@	O	-1	18464113
s	O	-1	18464113
(@@	O	-1	18464113
HB@@	O	-1	18464113
V@@	O	-1	18464113
)	O	-1	18464113
is	O	-1	18464113
one	O	-1	18464113
of	O	-1	18464113
the	O	-1	18464113
major	O	-1	18464113
causes	O	-1	18464113
of	O	-1	18464113
chronic	O	-1	18464113
liver	B-Disease	D008107	18464113
disease	I-Disease	-1	18464113
wor@@	O	-1	18464113
l@@	O	-1	18464113
d@@	O	-1	18464113
wi@@	O	-1	18464113
de@@	O	-1	18464113
.	O	-1	18464113
C@@	B-Disease	D009369	18464113
anc@@	I-Disease	-1	18464113
er	I-Disease	-1	18464113
patients	O	-1	18464113
who	O	-1	18464113
are	O	-1	18464113
chronic	O	-1	18464113
car@@	O	-1	18464113
ri@@	O	-1	18464113
ers	O	-1	18464113
of	O	-1	18464113
HBV	O	-1	18464113
have	O	-1	18464113
a	O	-1	18464113
higher	O	-1	18464113
hepatic	B-Disease	D008107	18464113
complication	I-Disease	-1	18464113
rate	O	-1	18464113
while	O	-1	18464113
receiving	O	-1	18464113
cy@@	O	-1	18464113
tot@@	O	-1	18464113
ox@@	O	-1	18464113
ic	O	-1	18464113
chemotherapy	O	-1	18464113
(C@@	O	-1	18464113
T)	O	-1	18464113
and	O	-1	18464113
this	O	-1	18464113
has	O	-1	18464113
main@@	O	-1	18464113
ly	O	-1	18464113
been	O	-1	18464113
at@@	O	-1	18464113
tri@@	O	-1	18464113
but@@	O	-1	18464113
ed	O	-1	18464113
to	O	-1	18464113
HBV	O	-1	18464113
re@@	O	-1	18464113
activ@@	O	-1	18464113
ation.	O	-1	18464113
In	O	-1	18464113
this	O	-1	18464113
study,	O	-1	18464113
cancer	B-Disease	D009369	18464113
patients	O	-1	18464113
who	O	-1	18464113
have	O	-1	18464113
sol@@	O	-1	18464113
id	O	-1	18464113
and	O	-1	18464113
hemat@@	B-Disease	D019337	18464113
ological	I-Disease	-1	18464113
mal@@	I-Disease	-1	18464113
i@@	I-Disease	-1	18464113
gn@@	I-Disease	-1	18464113
an@@	I-Disease	-1	18464113
ci@@	I-Disease	-1	18464113
es	I-Disease	-1	18464113
with	O	-1	18464113
chronic	O	-1	18464113
HBV	B-Disease	D006509	18464113
inf@@	I-Disease	-1	18464113
ection	I-Disease	-1	18464113
received	O	-1	18464113
the	O	-1	18464113
anti@@	O	-1	18464113
viral	O	-1	18464113
agent	O	-1	18464113
lamivud@@	B-Chemical	D019259	18464113
ine	I-Chemical	-1	18464113
prior	O	-1	18464113
and	O	-1	18464113
during	O	-1	18464113
C@@	O	-1	18464113
T	O	-1	18464113
compared	O	-1	18464113
with	O	-1	18464113
hist@@	O	-1	18464113
or@@	O	-1	18464113
ical	O	-1	18464113
control	O	-1	18464113
group	O	-1	18464113
who	O	-1	18464113
did	O	-1	18464113
not	O	-1	18464113
recei@@	O	-1	18464113
ve	O	-1	18464113
lamivud@@	B-Chemical	D019259	18464113
ine	I-Chemical	-1	18464113
.	O	-1	18464113
The	O	-1	18464113
ob@@	O	-1	18464113
j@@	O	-1	18464113
ec@@	O	-1	18464113
tiv@@	O	-1	18464113
es	O	-1	18464113
were	O	-1	18464113
to	O	-1	18464113
ass@@	O	-1	18464113
ess	O	-1	18464113
the	O	-1	18464113
efficacy	O	-1	18464113
of	O	-1	18464113
lamivud@@	B-Chemical	D019259	18464113
ine	I-Chemical	-1	18464113
in	O	-1	18464113
reduc@@	O	-1	18464113
ing	O	-1	18464113
the	O	-1	18464113
incidence	O	-1	18464113
of	O	-1	18464113
HBV	O	-1	18464113
re@@	O	-1	18464113
activ@@	O	-1	18464113
ation,	O	-1	18464113
and	O	-1	18464113
di@@	O	-1	18464113
min@@	O	-1	18464113
ish@@	O	-1	18464113
ing	O	-1	18464113
mor@@	O	-1	18464113
b@@	O	-1	18464113
idity	O	-1	18464113
and	O	-1	18464113
mor@@	O	-1	18464113
t@@	O	-1	18464113
ality	O	-1	18464113
during	O	-1	18464113
C@@	O	-1	18464113
T@@	O	-1	18464113
.	O	-1	18464113
Two	O	-1	18464113
groups	O	-1	18464113
were	O	-1	18464113
compared	O	-1	18464113
in	O	-1	18464113
this	O	-1	18464113
study.	O	-1	18464113
The	O	-1	18464113
pro@@	O	-1	18464113
phyl@@	O	-1	18464113
ac@@	O	-1	18464113
tic	O	-1	18464113
lamivud@@	B-Chemical	D019259	18464113
in	I-Chemical	-1	18464113
group	O	-1	18464113
consist@@	O	-1	18464113
ed	O	-1	18464113
of	O	-1	18464113
3@@	O	-1	18464113
7	O	-1	18464113
patients	O	-1	18464113
who	O	-1	18464113
received	O	-1	18464113
pro@@	O	-1	18464113
phyl@@	O	-1	18464113
ac@@	O	-1	18464113
tic	O	-1	18464113
lamivud@@	B-Chemical	D019259	18464113
ine	I-Chemical	-1	18464113
treatment.	O	-1	18464113
The	O	-1	18464113
hist@@	O	-1	18464113
or@@	O	-1	18464113
ical	O	-1	18464113
controls	O	-1	18464113
consist@@	O	-1	18464113
ed	O	-1	18464113
of	O	-1	18464113
50	O	-1	18464113
con@@	O	-1	18464113
sec@@	O	-1	18464113
utive	O	-1	18464113
patients	O	-1	18464113
who	O	-1	18464113
under@@	O	-1	18464113
w@@	O	-1	18464113
ent	O	-1	18464113
C@@	O	-1	18464113
T	O	-1	18464113
without	O	-1	18464113
pro@@	O	-1	18464113
phyl@@	O	-1	18464113
ac@@	O	-1	18464113
tic	O	-1	18464113
lamivud@@	B-Chemical	D019259	18464113
ine	I-Chemical	-1	18464113
.	O	-1	18464113
The@@	O	-1	18464113
y	O	-1	18464113
were	O	-1	18464113
followed	O	-1	18464113
up	O	-1	18464113
during	O	-1	18464113
and	O	-1	18464113
for	O	-1	18464113
8	O	-1	18464113
weeks	O	-1	18464113
after	O	-1	18464113
C@@	O	-1	18464113
T@@	O	-1	18464113
.	O	-1	18464113
The	O	-1	18464113
outcom@@	O	-1	18464113
es	O	-1	18464113
were	O	-1	18464113
compared	O	-1	18464113
for	O	-1	18464113
both	O	-1	18464113
groups.	O	-1	18464113
Of	O	-1	18464113
our	O	-1	18464113
control	O	-1	18464113
group	O	-1	18464113
(n@@	O	-1	18464113
=	O	-1	18464113
50@@	O	-1	18464113
),	O	-1	18464113
21	O	-1	18464113
patients	O	-1	18464113
(4@@	O	-1	18464113
2@@	O	-1	18464113
%)	O	-1	18464113
were	O	-1	18464113
est@@	O	-1	18464113
abl@@	O	-1	18464113
ished	O	-1	18464113
hepatitis	B-Disease	D056486	18464113
.	O	-1	18464113
T@@	O	-1	18464113
we@@	O	-1	18464113
l@@	O	-1	18464113
ve	O	-1	18464113
(2@@	O	-1	18464113
4@@	O	-1	18464113
%)	O	-1	18464113
of	O	-1	18464113
the@@	O	-1	18464113
m	O	-1	18464113
were	O	-1	18464113
evaluated	O	-1	18464113
as	O	-1	18464113
severe	O	-1	18464113
hepatitis	B-Disease	D056486	18464113
.	O	-1	18464113
In	O	-1	18464113
the	O	-1	18464113
pro@@	O	-1	18464113
phyl@@	O	-1	18464113
ac@@	O	-1	18464113
tic	O	-1	18464113
lamivud@@	B-Chemical	D019259	18464113
ine	I-Chemical	-1	18464113
group	O	-1	18464113
severe	O	-1	18464113
hepatitis	B-Disease	D056486	18464113
were	O	-1	18464113
observed	O	-1	18464113
only	O	-1	18464113
in	O	-1	18464113
1	O	-1	18464113
patient	O	-1	18464113
(2@@	O	-1	18464113
.@@	O	-1	18464113
7@@	O	-1	18464113
%)	O	-1	18464113
of	O	-1	18464113
3@@	O	-1	18464113
7	O	-1	18464113
patients	O	-1	18464113
(p	O	-1	18464113
<	O	-1	18464113
0.00@@	O	-1	18464113
6@@	O	-1	18464113
).	O	-1	18464113
Com@@	O	-1	18464113
par@@	O	-1	18464113
ison	O	-1	18464113
of	O	-1	18464113
the	O	-1	18464113
mean	O	-1	18464113
AL@@	O	-1	18464113
T	O	-1	18464113
values	O	-1	18464113
revealed	O	-1	18464113
significantly	O	-1	18464113
higher	O	-1	18464113
mean	O	-1	18464113
al@@	B-Chemical	D000409	18464113
an@@	I-Chemical	-1	18464113
ine	I-Chemical	-1	18464113
amin@@	O	-1	18464113
ot@@	O	-1	18464113
ran@@	O	-1	18464113
s@@	O	-1	18464113
fer@@	O	-1	18464113
ase	O	-1	18464113
(A@@	O	-1	18464113
LT@@	O	-1	18464113
)	O	-1	18464113
values	O	-1	18464113
in	O	-1	18464113
the	O	-1	18464113
control	O	-1	18464113
group	O	-1	18464113
than	O	-1	18464113
the	O	-1	18464113
pro@@	O	-1	18464113
phyl@@	O	-1	18464113
ac@@	O	-1	18464113
tic	O	-1	18464113
lamivud@@	B-Chemical	D019259	18464113
ine	I-Chemical	-1	18464113
group@@	O	-1	18464113
;	O	-1	18464113
1@@	O	-1	18464113
5@@	O	-1	18464113
4@@	O	-1	18464113
:@@	O	-1	18464113
6@@	O	-1	18464113
4	O	-1	18464113
(p	O	-1	18464113
<	O	-1	18464113
0.@@	O	-1	18464113
3@@	O	-1	18464113
2@@	O	-1	18464113
).	O	-1	18464113
Our	O	-1	18464113
study	O	-1	18464113
suggests	O	-1	18464113
that	O	-1	18464113
pro@@	O	-1	18464113
phyl@@	O	-1	18464113
ac@@	O	-1	18464113
tic	O	-1	18464113
lamivud@@	B-Chemical	D019259	18464113
ine	I-Chemical	-1	18464113
significantly	O	-1	18464113
decreas@@	O	-1	18464113
es	O	-1	18464113
the	O	-1	18464113
incidence	O	-1	18464113
of	O	-1	18464113
HBV	O	-1	18464113
re@@	O	-1	18464113
activation	O	-1	18464113
and	O	-1	18464113
over@@	O	-1	18464113
all	O	-1	18464113
mor@@	O	-1	18464113
b@@	O	-1	18464113
idity	O	-1	18464113
in	O	-1	18464113
cancer	B-Disease	D009369	18464113
patients	O	-1	18464113
during	O	-1	18464113
and	O	-1	18464113
after	O	-1	18464113
immunosup@@	O	-1	18464113
pressive	O	-1	18464113
therapy.	O	-1	18464113
F@@	O	-1	18464113
urther	O	-1	18464113
studies	O	-1	18464113
are	O	-1	18464113
ne@@	O	-1	18464113
ed@@	O	-1	18464113
ed	O	-1	18464113
to	O	-1	18464113
determine	O	-1	18464113
the	O	-1	18464113
most	O	-1	18464113
appro@@	O	-1	18464113
pri@@	O	-1	18464113
ate	O	-1	18464113
nucle@@	B-Chemical	D009705	18464113
o@@	I-Chemical	-1	18464113
side	I-Chemical	-1	18464113
or	O	-1	18464113
nucle@@	B-Chemical	D009711	18464113
o@@	I-Chemical	-1	18464113
ti@@	I-Chemical	-1	18464113
de	I-Chemical	-1	18464113
an@@	O	-1	18464113
alo@@	O	-1	18464113
gu@@	O	-1	18464113
e	O	-1	18464113
for	O	-1	18464113
anti@@	O	-1	18464113
viral	O	-1	18464113
pro@@	O	-1	18464113
phyl@@	O	-1	18464113
ax@@	O	-1	18464113
is	O	-1	18464113
during	O	-1	18464113
C@@	O	-1	18464113
T	O	-1	18464113
and	O	-1	18464113
the	O	-1	18464113
op@@	O	-1	18464113
tim@@	O	-1	18464113
al	O	-1	18464113
duration	O	-1	18464113
of	O	-1	18464113
administration	O	-1	18464113
after	O	-1	18464113
comple@@	O	-1	18464113
tion	O	-1	18464113
of	O	-1	18464113
C@@	O	-1	18464113
T@@	O	-1	18464113
.	O	-1	18464113

G@@	B-Chemical	C035054	18308784
in@@	I-Chemical	-1	18308784
sen@@	I-Chemical	-1	18308784
o@@	I-Chemical	-1	18308784
side	I-Chemical	-1	18308784
R@@	I-Chemical	-1	18308784
g@@	I-Chemical	-1	18308784
1	I-Chemical	-1	18308784
re@@	O	-1	18308784
sto@@	O	-1	18308784
res	O	-1	18308784
the	O	-1	18308784
impair@@	B-Disease	D007859	18308784
ment	I-Disease	-1	18308784
of	I-Disease	-1	18308784
lear@@	I-Disease	-1	18308784
ning	I-Disease	-1	18308784
induced	O	-1	18308784
by	O	-1	18308784
chronic	O	-1	18308784
morphine	B-Chemical	D009020	18308784
administration	O	-1	18308784
in	O	-1	18308784
rats.	O	-1	18308784
R@@	B-Chemical	C035054	18308784
g@@	I-Chemical	-1	18308784
1	I-Chemical	-1	18308784
,	O	-1	18308784
as	O	-1	18308784
a	O	-1	18308784
g@@	B-Chemical	D036145	18308784
in@@	I-Chemical	-1	18308784
sen@@	I-Chemical	-1	18308784
o@@	I-Chemical	-1	18308784
side	I-Chemical	-1	18308784
extrac@@	O	-1	18308784
ted	O	-1	18308784
from	O	-1	18308784
P@@	O	-1	18308784
ana@@	O	-1	18308784
x	O	-1	18308784
g@@	O	-1	18308784
in@@	O	-1	18308784
sen@@	O	-1	18308784
g@@	O	-1	18308784
,	O	-1	18308784
could	O	-1	18308784
ame@@	O	-1	18308784
li@@	O	-1	18308784
or@@	O	-1	18308784
ate	O	-1	18308784
s@@	O	-1	18308784
pati@@	O	-1	18308784
al	O	-1	18308784
lear@@	B-Disease	D007859	18308784
ning	I-Disease	-1	18308784
impair@@	I-Disease	-1	18308784
ment	I-Disease	-1	18308784
.	O	-1	18308784
Pre@@	O	-1	18308784
vi@@	O	-1	18308784
ous	O	-1	18308784
studies	O	-1	18308784
have	O	-1	18308784
demonstrated	O	-1	18308784
that	O	-1	18308784
R@@	B-Chemical	C035054	18308784
g@@	I-Chemical	-1	18308784
1	I-Chemical	-1	18308784
might	O	-1	18308784
be	O	-1	18308784
a	O	-1	18308784
use@@	O	-1	18308784
ful	O	-1	18308784
agent	O	-1	18308784
for	O	-1	18308784
the	O	-1	18308784
pre@@	O	-1	18308784
ven@@	O	-1	18308784
tion	O	-1	18308784
and	O	-1	18308784
treatment	O	-1	18308784
of	O	-1	18308784
the	O	-1	18308784
adverse	O	-1	18308784
effects	O	-1	18308784
of	O	-1	18308784
morphine	B-Chemical	D009020	18308784
.	O	-1	18308784
The	O	-1	18308784
a@@	O	-1	18308784
im	O	-1	18308784
of	O	-1	18308784
this	O	-1	18308784
study	O	-1	18308784
was	O	-1	18308784
to	O	-1	18308784
investigate	O	-1	18308784
the	O	-1	18308784
effect	O	-1	18308784
of	O	-1	18308784
R@@	B-Chemical	C035054	18308784
g@@	I-Chemical	-1	18308784
1	I-Chemical	-1	18308784
on	O	-1	18308784
lear@@	B-Disease	D007859	18308784
ning	I-Disease	-1	18308784
impair@@	I-Disease	-1	18308784
ment	I-Disease	-1	18308784
by	O	-1	18308784
chronic	O	-1	18308784
morphine	B-Chemical	D009020	18308784
administration	O	-1	18308784
and	O	-1	18308784
the	O	-1	18308784
mechanism	O	-1	18308784
respon@@	O	-1	18308784
sible	O	-1	18308784
for	O	-1	18308784
this	O	-1	18308784
effect@@	O	-1	18308784
.	O	-1	18308784
M@@	O	-1	18308784
al@@	O	-1	18308784
e	O	-1	18308784
rats	O	-1	18308784
were	O	-1	18308784
sub@@	O	-1	18308784
c@@	O	-1	18308784
ut@@	O	-1	18308784
ane@@	O	-1	18308784
ously	O	-1	18308784
injected	O	-1	18308784
with	O	-1	18308784
morphine	B-Chemical	D009020	18308784
(10	O	-1	18308784
mg/kg)	O	-1	18308784
tw@@	O	-1	18308784
ic@@	O	-1	18308784
e	O	-1	18308784
a	O	-1	18308784
day	O	-1	18308784
at	O	-1	18308784
12	O	-1	18308784
h@@	O	-1	18308784
our	O	-1	18308784
interv@@	O	-1	18308784
als	O	-1	18308784
for	O	-1	18308784
10	O	-1	18308784
day@@	O	-1	18308784
s,	O	-1	18308784
and	O	-1	18308784
R@@	B-Chemical	C035054	18308784
g@@	I-Chemical	-1	18308784
1	I-Chemical	-1	18308784
(@@	O	-1	18308784
30	O	-1	18308784
mg/kg)	O	-1	18308784
was	O	-1	18308784
intra@@	O	-1	18308784
per@@	O	-1	18308784
it@@	O	-1	18308784
one@@	O	-1	18308784
ally	O	-1	18308784
injected	O	-1	18308784
2	O	-1	18308784
hours	O	-1	18308784
after	O	-1	18308784
the	O	-1	18308784
second	O	-1	18308784
injection	O	-1	18308784
of	O	-1	18308784
morphine	B-Chemical	D009020	18308784
on@@	O	-1	18308784
ce	O	-1	18308784
a	O	-1	18308784
day	O	-1	18308784
for	O	-1	18308784
10	O	-1	18308784
days.	O	-1	18308784
S@@	O	-1	18308784
pati@@	O	-1	18308784
al	O	-1	18308784
lear@@	O	-1	18308784
ning	O	-1	18308784
cap@@	O	-1	18308784
ac@@	O	-1	18308784
ity	O	-1	18308784
was	O	-1	18308784
assessed	O	-1	18308784
in	O	-1	18308784
the	O	-1	18308784
M@@	O	-1	18308784
or@@	O	-1	18308784
ri@@	O	-1	18308784
s	O	-1	18308784
w@@	O	-1	18308784
at@@	O	-1	18308784
er	O	-1	18308784
ma@@	O	-1	18308784
z@@	O	-1	18308784
e.	O	-1	18308784
The	O	-1	18308784
results	O	-1	18308784
showed	O	-1	18308784
that	O	-1	18308784
rats	O	-1	18308784
treated	O	-1	18308784
with	O	-1	18308784
M@@	B-Chemical	D009020	18308784
or@@	I-Chemical	-1	18308784
ph@@	I-Chemical	-1	18308784
ine	I-Chemical	-1	18308784
/	O	-1	18308784
R@@	B-Chemical	C035054	18308784
g@@	I-Chemical	-1	18308784
1	I-Chemical	-1	18308784
decreased	O	-1	18308784
es@@	O	-1	18308784
cap@@	O	-1	18308784
e	O	-1	18308784
lat@@	O	-1	18308784
ency	O	-1	18308784
and	O	-1	18308784
increased	O	-1	18308784
the	O	-1	18308784
time	O	-1	18308784
sp@@	O	-1	18308784
ent	O	-1	18308784
in	O	-1	18308784
pl@@	O	-1	18308784
at@@	O	-1	18308784
form	O	-1	18308784
qu@@	O	-1	18308784
ad@@	O	-1	18308784
ran@@	O	-1	18308784
t	O	-1	18308784
and	O	-1	18308784
ent@@	O	-1	18308784
ering	O	-1	18308784
frequ@@	O	-1	18308784
enc@@	O	-1	18308784
y.	O	-1	18308784
B@@	O	-1	18308784
y	O	-1	18308784
im@@	O	-1	18308784
pl@@	O	-1	18308784
ant@@	O	-1	18308784
ation	O	-1	18308784
of	O	-1	18308784
electro@@	O	-1	18308784
des	O	-1	18308784
and	O	-1	18308784
electro@@	O	-1	18308784
physi@@	O	-1	18308784
ological	O	-1	18308784
recor@@	O	-1	18308784
ding	O	-1	18308784
in	O	-1	18308784
viv@@	O	-1	18308784
o@@	O	-1	18308784
,	O	-1	18308784
the	O	-1	18308784
results	O	-1	18308784
showed	O	-1	18308784
that	O	-1	18308784
R@@	B-Chemical	C035054	18308784
g@@	I-Chemical	-1	18308784
1	I-Chemical	-1	18308784
re@@	O	-1	18308784
sto@@	O	-1	18308784
red	O	-1	18308784
the	O	-1	18308784
long-term	O	-1	18308784
potenti@@	O	-1	18308784
ation	O	-1	18308784
(@@	O	-1	18308784
LT@@	O	-1	18308784
P)	O	-1	18308784
impaired	O	-1	18308784
by	O	-1	18308784
morphine	B-Chemical	D009020	18308784
in	O	-1	18308784
both	O	-1	18308784
f@@	O	-1	18308784
re@@	O	-1	18308784
ely	O	-1	18308784
mo@@	O	-1	18308784
ving	O	-1	18308784
and	O	-1	18308784
anaesthe@@	O	-1	18308784
tis@@	O	-1	18308784
ed	O	-1	18308784
rats.	O	-1	18308784
The	O	-1	18308784
electro@@	O	-1	18308784
physi@@	O	-1	18308784
ological	O	-1	18308784
recor@@	O	-1	18308784
ding	O	-1	18308784
in	O	-1	18308784
vit@@	O	-1	18308784
r@@	O	-1	18308784
o	O	-1	18308784
showed	O	-1	18308784
that	O	-1	18308784
R@@	B-Chemical	C035054	18308784
g@@	I-Chemical	-1	18308784
1	I-Chemical	-1	18308784
re@@	O	-1	18308784
sto@@	O	-1	18308784
red	O	-1	18308784
the	O	-1	18308784
LT@@	O	-1	18308784
P	O	-1	18308784
in	O	-1	18308784
s@@	O	-1	18308784
l@@	O	-1	18308784
ic@@	O	-1	18308784
es	O	-1	18308784
from	O	-1	18308784
the	O	-1	18308784
rats	O	-1	18308784
treated	O	-1	18308784
with	O	-1	18308784
morphine	B-Chemical	D009020	18308784
,	O	-1	18308784
but	O	-1	18308784
not	O	-1	18308784
chang@@	O	-1	18308784
ed	O	-1	18308784
LT@@	O	-1	18308784
P	O	-1	18308784
in	O	-1	18308784
the	O	-1	18308784
s@@	O	-1	18308784
l@@	O	-1	18308784
ic@@	O	-1	18308784
es	O	-1	18308784
from	O	-1	18308784
normal	O	-1	18308784
sal@@	O	-1	18308784
ine@@	O	-1	18308784
-	O	-1	18308784
or	O	-1	18308784
morphine	B-Chemical	D009020	18308784
/	O	-1	18308784
R@@	B-Chemical	C035054	18308784
g@@	I-Chemical	-1	18308784
1	I-Chemical	-1	18308784
-treated	O	-1	18308784
rat@@	O	-1	18308784
s;	O	-1	18308784
this	O	-1	18308784
rest@@	O	-1	18308784
or@@	O	-1	18308784
ation	O	-1	18308784
could	O	-1	18308784
be	O	-1	18308784
inhibited	O	-1	18308784
by	O	-1	18308784
N@@	B-Chemical	D016202	18308784
-@@	I-Chemical	-1	18308784
methyl@@	I-Chemical	-1	18308784
-@@	I-Chemical	-1	18308784
D-@@	I-Chemical	-1	18308784
as@@	I-Chemical	-1	18308784
part@@	I-Chemical	-1	18308784
ate	I-Chemical	-1	18308784
(	O	-1	18308784
N@@	B-Chemical	D016202	18308784
MD@@	I-Chemical	-1	18308784
A	I-Chemical	-1	18308784
)	O	-1	18308784
receptor	O	-1	18308784
antagonist	O	-1	18308784
M@@	B-Chemical	D016291	18308784
K@@	I-Chemical	-1	18308784
80@@	I-Chemical	-1	18308784
1	I-Chemical	-1	18308784
.	O	-1	18308784
We	O	-1	18308784
concl@@	O	-1	18308784
ude	O	-1	18308784
that	O	-1	18308784
R@@	B-Chemical	C035054	18308784
g@@	I-Chemical	-1	18308784
1	I-Chemical	-1	18308784
may	O	-1	18308784
significantly	O	-1	18308784
impro@@	O	-1	18308784
ve	O	-1	18308784
the	O	-1	18308784
s@@	O	-1	18308784
pati@@	O	-1	18308784
al	O	-1	18308784
lear@@	O	-1	18308784
ning	O	-1	18308784
cap@@	O	-1	18308784
ac@@	O	-1	18308784
ity	O	-1	18308784
impaired	O	-1	18308784
by	O	-1	18308784
ch@@	O	-1	18308784
onic	O	-1	18308784
morphine	B-Chemical	D009020	18308784
administration	O	-1	18308784
and	O	-1	18308784
rest@@	O	-1	18308784
or@@	O	-1	18308784
e	O	-1	18308784
the	O	-1	18308784
morphine	B-Chemical	D009020	18308784
-@@	O	-1	18308784
inhibited	O	-1	18308784
LT@@	O	-1	18308784
P@@	O	-1	18308784
.	O	-1	18308784
This	O	-1	18308784
effect	O	-1	18308784
is	O	-1	18308784
N@@	B-Chemical	D016202	18308784
MD@@	I-Chemical	-1	18308784
A	I-Chemical	-1	18308784
receptor	O	-1	18308784
depend@@	O	-1	18308784
ent@@	O	-1	18308784
.	O	-1	18308784

A	O	-1	17931375
study	O	-1	17931375
on	O	-1	17931375
the	O	-1	17931375
effect	O	-1	17931375
of	O	-1	17931375
the	O	-1	17931375
duration	O	-1	17931375
of	O	-1	17931375
sub@@	O	-1	17931375
c@@	O	-1	17931375
utaneous	O	-1	17931375
hepar@@	B-Chemical	D006493	17931375
in	I-Chemical	-1	17931375
injection	O	-1	17931375
on	O	-1	17931375
b@@	B-Disease	D003288	17931375
ru@@	I-Disease	-1	17931375
is@@	I-Disease	-1	17931375
ing	I-Disease	-1	17931375
and	O	-1	17931375
pain	B-Disease	D010146	17931375
.	O	-1	17931375
A@@	O	-1	17931375
I@@	O	-1	17931375
M@@	O	-1	17931375
:	O	-1	17931375
This	O	-1	17931375
study	O	-1	17931375
was	O	-1	17931375
car@@	O	-1	17931375
ri@@	O	-1	17931375
ed	O	-1	17931375
out	O	-1	17931375
to	O	-1	17931375
determine	O	-1	17931375
the	O	-1	17931375
effect	O	-1	17931375
of	O	-1	17931375
injection	O	-1	17931375
duration	O	-1	17931375
on	O	-1	17931375
b@@	B-Disease	D003288	17931375
ru@@	I-Disease	-1	17931375
is@@	I-Disease	-1	17931375
ing	I-Disease	-1	17931375
and	O	-1	17931375
pain	B-Disease	D010146	17931375
following	O	-1	17931375
the	O	-1	17931375
administration	O	-1	17931375
of	O	-1	17931375
the	O	-1	17931375
sub@@	O	-1	17931375
c@@	O	-1	17931375
utaneous	O	-1	17931375
injection	O	-1	17931375
of	O	-1	17931375
hepar@@	B-Chemical	D006493	17931375
in	I-Chemical	-1	17931375
.	O	-1	17931375
BACKGROUND:	O	-1	17931375
Although	O	-1	17931375
different	O	-1	17931375
meth@@	O	-1	17931375
o@@	O	-1	17931375
ds	O	-1	17931375
to	O	-1	17931375
prev@@	O	-1	17931375
ent	O	-1	17931375
b@@	B-Disease	D003288	17931375
ru@@	I-Disease	-1	17931375
is@@	I-Disease	-1	17931375
ing	I-Disease	-1	17931375
and	O	-1	17931375
pain	B-Disease	D010146	17931375
following	O	-1	17931375
the	O	-1	17931375
sub@@	O	-1	17931375
c@@	O	-1	17931375
utaneous	O	-1	17931375
injection	O	-1	17931375
of	O	-1	17931375
hepar@@	B-Chemical	D006493	17931375
in	I-Chemical	-1	17931375
have	O	-1	17931375
been	O	-1	17931375
wi@@	O	-1	17931375
de@@	O	-1	17931375
ly	O	-1	17931375
studied	O	-1	17931375
and	O	-1	17931375
descri@@	O	-1	17931375
be@@	O	-1	17931375
d,	O	-1	17931375
the	O	-1	17931375
effect	O	-1	17931375
of	O	-1	17931375
injection	O	-1	17931375
duration	O	-1	17931375
on	O	-1	17931375
the	O	-1	17931375
occur@@	O	-1	17931375
rence	O	-1	17931375
of	O	-1	17931375
b@@	B-Disease	D003288	17931375
ru@@	I-Disease	-1	17931375
is@@	I-Disease	-1	17931375
ing	I-Disease	-1	17931375
and	O	-1	17931375
pain	B-Disease	D010146	17931375
is	O	-1	17931375
lit@@	O	-1	17931375
t@@	O	-1	17931375
le	O	-1	17931375
doc@@	O	-1	17931375
um@@	O	-1	17931375
ent@@	O	-1	17931375
ed.	O	-1	17931375
D@@	O	-1	17931375
ES@@	O	-1	17931375
I@@	O	-1	17931375
G@@	O	-1	17931375
N@@	O	-1	17931375
:	O	-1	17931375
This	O	-1	17931375
study	O	-1	17931375
was	O	-1	17931375
de@@	O	-1	17931375
signed	O	-1	17931375
as	O	-1	17931375
with@@	O	-1	17931375
in-@@	O	-1	17931375
subj@@	O	-1	17931375
ect@@	O	-1	17931375
,	O	-1	17931375
qu@@	O	-1	17931375
a@@	O	-1	17931375
si@@	O	-1	17931375
-@@	O	-1	17931375
experimental	O	-1	17931375
re@@	O	-1	17931375
se@@	O	-1	17931375
ar@@	O	-1	17931375
ch@@	O	-1	17931375
.	O	-1	17931375
METHOD@@	O	-1	17931375
:	O	-1	17931375
The	O	-1	17931375
sam@@	O	-1	17931375
ple	O	-1	17931375
for	O	-1	17931375
the	O	-1	17931375
study	O	-1	17931375
consist@@	O	-1	17931375
ed	O	-1	17931375
of	O	-1	17931375
50	O	-1	17931375
patients	O	-1	17931375
to	O	-1	17931375
whom	O	-1	17931375
sub@@	O	-1	17931375
c@@	O	-1	17931375
utaneous	O	-1	17931375
hepar@@	B-Chemical	D006493	17931375
in	I-Chemical	-1	17931375
was	O	-1	17931375
administ@@	O	-1	17931375
e@@	O	-1	17931375
red.	O	-1	17931375
He@@	B-Chemical	D006493	17931375
par@@	I-Chemical	-1	17931375
in	I-Chemical	-1	17931375
was	O	-1	17931375
injected	O	-1	17931375
over	O	-1	17931375
10	O	-1	17931375
secon@@	O	-1	17931375
ds	O	-1	17931375
on	O	-1	17931375
the	O	-1	17931375
right	O	-1	17931375
ab@@	O	-1	17931375
domin@@	O	-1	17931375
al	O	-1	17931375
sit@@	O	-1	17931375
e	O	-1	17931375
and	O	-1	17931375
30	O	-1	17931375
secon@@	O	-1	17931375
ds	O	-1	17931375
on	O	-1	17931375
the	O	-1	17931375
left	O	-1	17931375
ab@@	O	-1	17931375
domin@@	O	-1	17931375
al	O	-1	17931375
sit@@	O	-1	17931375
e.	O	-1	17931375
In@@	O	-1	17931375
j@@	O	-1	17931375
ec@@	O	-1	17931375
tions	O	-1	17931375
a@@	O	-1	17931375
reas	O	-1	17931375
were	O	-1	17931375
assessed	O	-1	17931375
for	O	-1	17931375
the	O	-1	17931375
presence	O	-1	17931375
of	O	-1	17931375
b@@	B-Disease	D003288	17931375
ru@@	I-Disease	-1	17931375
is@@	I-Disease	-1	17931375
ing	I-Disease	-1	17931375
at	O	-1	17931375
4@@	O	-1	17931375
8	O	-1	17931375
and	O	-1	17931375
7@@	O	-1	17931375
2	O	-1	17931375
hours	O	-1	17931375
after	O	-1	17931375
each	O	-1	17931375
injec@@	O	-1	17931375
tion.	O	-1	17931375
D@@	O	-1	17931375
imen@@	O	-1	17931375
sions	O	-1	17931375
of	O	-1	17931375
the	O	-1	17931375
b@@	B-Disease	D003288	17931375
ru@@	I-Disease	-1	17931375
is@@	I-Disease	-1	17931375
ing	I-Disease	-1	17931375
on	O	-1	17931375
the	O	-1	17931375
hepar@@	B-Chemical	D006493	17931375
in	I-Chemical	-1	17931375
ap@@	O	-1	17931375
pl@@	O	-1	17931375
ied	O	-1	17931375
a@@	O	-1	17931375
reas	O	-1	17931375
were	O	-1	17931375
measured	O	-1	17931375
using	O	-1	17931375
trans@@	O	-1	17931375
pa@@	O	-1	17931375
rent	O	-1	17931375
mil@@	O	-1	17931375
li@@	O	-1	17931375
me@@	O	-1	17931375
tri@@	O	-1	17931375
c	O	-1	17931375
meas@@	O	-1	17931375
uring	O	-1	17931375
pa@@	O	-1	17931375
per@@	O	-1	17931375
.	O	-1	17931375
The	O	-1	17931375
visual	O	-1	17931375
an@@	O	-1	17931375
alo@@	O	-1	17931375
g	O	-1	17931375
s@@	O	-1	17931375
cal@@	O	-1	17931375
e	O	-1	17931375
(V@@	O	-1	17931375
A@@	O	-1	17931375
S)	O	-1	17931375
was	O	-1	17931375
used	O	-1	17931375
to	O	-1	17931375
meas@@	O	-1	17931375
ure	O	-1	17931375
pain	B-Disease	D010146	17931375
int@@	O	-1	17931375
ensity	O	-1	17931375
and	O	-1	17931375
a	O	-1	17931375
sto@@	O	-1	17931375
p@@	O	-1	17931375
-@@	O	-1	17931375
w@@	O	-1	17931375
at@@	O	-1	17931375
ch	O	-1	17931375
was	O	-1	17931375
used	O	-1	17931375
to	O	-1	17931375
time	O	-1	17931375
the	O	-1	17931375
pain	B-Disease	D010146	17931375
perio@@	O	-1	17931375
d.	O	-1	17931375
D@@	O	-1	17931375
at@@	O	-1	17931375
a	O	-1	17931375
were	O	-1	17931375
an@@	O	-1	17931375
al@@	O	-1	17931375
ys@@	O	-1	17931375
ed	O	-1	17931375
using	O	-1	17931375
ch@@	O	-1	17931375
i@@	O	-1	17931375
-@@	O	-1	17931375
s@@	O	-1	17931375
qu@@	O	-1	17931375
are	O	-1	17931375
test@@	O	-1	17931375
,	O	-1	17931375
M@@	O	-1	17931375
an@@	O	-1	17931375
n@@	O	-1	17931375
-@@	O	-1	17931375
W@@	O	-1	17931375
h@@	O	-1	17931375
it@@	O	-1	17931375
ne@@	O	-1	17931375
y	O	-1	17931375
U@@	O	-1	17931375
,	O	-1	17931375
W@@	O	-1	17931375
il@@	O	-1	17931375
co@@	O	-1	17931375
x@@	O	-1	17931375
on	O	-1	17931375
signed	O	-1	17931375
ran@@	O	-1	17931375
k@@	O	-1	17931375
s	O	-1	17931375
tests	O	-1	17931375
and	O	-1	17931375
correl@@	O	-1	17931375
ation.	O	-1	17931375
RESULTS:	O	-1	17931375
The	O	-1	17931375
perc@@	O	-1	17931375
ent@@	O	-1	17931375
age	O	-1	17931375
of	O	-1	17931375
b@@	B-Disease	D003288	17931375
ru@@	I-Disease	-1	17931375
is@@	I-Disease	-1	17931375
ing	I-Disease	-1	17931375
occur@@	O	-1	17931375
rence	O	-1	17931375
was	O	-1	17931375
6@@	O	-1	17931375
4@@	O	-1	17931375
%	O	-1	17931375
with	O	-1	17931375
the	O	-1	17931375
injection	O	-1	17931375
of	O	-1	17931375
10	O	-1	17931375
secon@@	O	-1	17931375
ds	O	-1	17931375
duration	O	-1	17931375
and	O	-1	17931375
4@@	O	-1	17931375
2@@	O	-1	17931375
%	O	-1	17931375
in	O	-1	17931375
the	O	-1	17931375
3@@	O	-1	17931375
0-@@	O	-1	17931375
second	O	-1	17931375
injec@@	O	-1	17931375
tion.	O	-1	17931375
It	O	-1	17931375
was	O	-1	17931375
determined	O	-1	17931375
that	O	-1	17931375
the	O	-1	17931375
size	O	-1	17931375
of	O	-1	17931375
the	O	-1	17931375
b@@	B-Disease	D003288	17931375
ru@@	I-Disease	-1	17931375
is@@	I-Disease	-1	17931375
ing	I-Disease	-1	17931375
was	O	-1	17931375
sm@@	O	-1	17931375
all@@	O	-1	17931375
er	O	-1	17931375
in	O	-1	17931375
the	O	-1	17931375
3@@	O	-1	17931375
0-@@	O	-1	17931375
second	O	-1	17931375
injec@@	O	-1	17931375
tion.	O	-1	17931375
P@@	B-Disease	D010146	17931375
ain	I-Disease	-1	17931375
int@@	O	-1	17931375
ensity	O	-1	17931375
and	O	-1	17931375
pain	B-Disease	D010146	17931375
period	O	-1	17931375
were	O	-1	17931375
statis@@	O	-1	17931375
tically	O	-1	17931375
significantly	O	-1	17931375
lower	O	-1	17931375
for	O	-1	17931375
the	O	-1	17931375
3@@	O	-1	17931375
0-@@	O	-1	17931375
second	O	-1	17931375
injection	O	-1	17931375
than	O	-1	17931375
for	O	-1	17931375
the	O	-1	17931375
10-@@	O	-1	17931375
second	O	-1	17931375
injec@@	O	-1	17931375
tion.	O	-1	17931375
CONCLUSIONS:	O	-1	17931375
It	O	-1	17931375
was	O	-1	17931375
determined	O	-1	17931375
that	O	-1	17931375
injection	O	-1	17931375
duration	O	-1	17931375
had	O	-1	17931375
an	O	-1	17931375
effect	O	-1	17931375
on	O	-1	17931375
b@@	B-Disease	D003288	17931375
ru@@	I-Disease	-1	17931375
is@@	I-Disease	-1	17931375
ing	I-Disease	-1	17931375
and	O	-1	17931375
pain	B-Disease	D010146	17931375
following	O	-1	17931375
the	O	-1	17931375
sub@@	O	-1	17931375
c@@	O	-1	17931375
utaneous	O	-1	17931375
administration	O	-1	17931375
of	O	-1	17931375
hepar@@	B-Chemical	D006493	17931375
in	I-Chemical	-1	17931375
.	O	-1	17931375
This	O	-1	17931375
study	O	-1	17931375
should	O	-1	17931375
be	O	-1	17931375
repe@@	O	-1	17931375
ated	O	-1	17931375
on	O	-1	17931375
a	O	-1	17931375
larg@@	O	-1	17931375
er	O	-1	17931375
sam@@	O	-1	17931375
ple@@	O	-1	17931375
.	O	-1	17931375
R@@	O	-1	17931375
E@@	O	-1	17931375
L@@	O	-1	17931375
E@@	O	-1	17931375
V@@	O	-1	17931375
AN@@	O	-1	17931375
C@@	O	-1	17931375
E	O	-1	17931375
T@@	O	-1	17931375
O	O	-1	17931375
CL@@	O	-1	17931375
IN@@	O	-1	17931375
I@@	O	-1	17931375
CA@@	O	-1	17931375
L	O	-1	17931375
P@@	O	-1	17931375
R@@	O	-1	17931375
AC@@	O	-1	17931375
TI@@	O	-1	17931375
C@@	O	-1	17931375
E:	O	-1	17931375
Whe@@	O	-1	17931375
n	O	-1	17931375
administ@@	O	-1	17931375
ering	O	-1	17931375
sub@@	O	-1	17931375
c@@	O	-1	17931375
utaneous	O	-1	17931375
hepar@@	B-Chemical	D006493	17931375
in	I-Chemical	-1	17931375
injec@@	O	-1	17931375
tion@@	O	-1	17931375
s,	O	-1	17931375
it	O	-1	17931375
is	O	-1	17931375
important	O	-1	17931375
to	O	-1	17931375
exten@@	O	-1	17931375
d	O	-1	17931375
the	O	-1	17931375
duration	O	-1	17931375
of	O	-1	17931375
the	O	-1	17931375
injec@@	O	-1	17931375
tion.	O	-1	17931375

Ac@@	O	-1	15649445
ute	O	-1	15649445
res@@	B-Chemical	D012110	15649445
er@@	I-Chemical	-1	15649445
pine	I-Chemical	-1	15649445
and	O	-1	15649445
sub@@	O	-1	15649445
chronic	O	-1	15649445
haloperidol	B-Chemical	D006220	15649445
treat@@	O	-1	15649445
ments	O	-1	15649445
change	O	-1	15649445
syn@@	O	-1	15649445
ap@@	O	-1	15649445
t@@	O	-1	15649445
os@@	O	-1	15649445
om@@	O	-1	15649445
al	O	-1	15649445
brain	O	-1	15649445
glutamate	B-Chemical	D018698	15649445
u@@	O	-1	15649445
pt@@	O	-1	15649445
ake	O	-1	15649445
and	O	-1	15649445
el@@	O	-1	15649445
ic@@	O	-1	15649445
it	O	-1	15649445
o@@	B-Disease	D004409	15649445
ro@@	I-Disease	-1	15649445
fac@@	I-Disease	-1	15649445
ial	I-Disease	-1	15649445
dyskine@@	I-Disease	-1	15649445
sia	I-Disease	-1	15649445
in	O	-1	15649445
rats.	O	-1	15649445
R@@	B-Chemical	D012110	15649445
es@@	I-Chemical	-1	15649445
er@@	I-Chemical	-1	15649445
pine	I-Chemical	-1	15649445
-	O	-1	15649445
and	O	-1	15649445
haloperidol	B-Chemical	D006220	15649445
-induced	O	-1	15649445
o@@	B-Disease	D004409	15649445
ro@@	I-Disease	-1	15649445
fac@@	I-Disease	-1	15649445
ial	I-Disease	-1	15649445
dyskine@@	I-Disease	-1	15649445
sia	I-Disease	-1	15649445
are	O	-1	15649445
p@@	O	-1	15649445
ut@@	O	-1	15649445
ative	O	-1	15649445
anim@@	O	-1	15649445
al	O	-1	15649445
models	O	-1	15649445
of	O	-1	15649445
t@@	B-Disease	D004409	15649445
ardi@@	I-Disease	-1	15649445
ve	I-Disease	-1	15649445
dyskine@@	I-Disease	-1	15649445
sia	I-Disease	-1	15649445
(	O	-1	15649445
T@@	B-Disease	D004409	15649445
D	I-Disease	-1	15649445
)	O	-1	15649445
wh@@	O	-1	15649445
ose	O	-1	15649445
path@@	O	-1	15649445
oph@@	O	-1	15649445
ysi@@	O	-1	15649445
ology	O	-1	15649445
has	O	-1	15649445
been	O	-1	15649445
related	O	-1	15649445
to	O	-1	15649445
free	O	-1	15649445
ra@@	O	-1	15649445
d@@	O	-1	15649445
ical	O	-1	15649445
generation	O	-1	15649445
and	O	-1	15649445
oxid@@	O	-1	15649445
ative	O	-1	15649445
stres@@	O	-1	15649445
s.	O	-1	15649445
In	O	-1	15649445
the	O	-1	15649445
present	O	-1	15649445
study,	O	-1	15649445
the	O	-1	15649445
au@@	O	-1	15649445
th@@	O	-1	15649445
ors	O	-1	15649445
induced	O	-1	15649445
o@@	B-Disease	D004409	15649445
ro@@	I-Disease	-1	15649445
fac@@	I-Disease	-1	15649445
ial	I-Disease	-1	15649445
dyskine@@	I-Disease	-1	15649445
sia	I-Disease	-1	15649445
by	O	-1	15649445
acute	O	-1	15649445
res@@	B-Chemical	D012110	15649445
er@@	I-Chemical	-1	15649445
pine	I-Chemical	-1	15649445
and	O	-1	15649445
sub@@	O	-1	15649445
chronic	O	-1	15649445
haloperidol	B-Chemical	D006220	15649445
administration	O	-1	15649445
to	O	-1	15649445
rats.	O	-1	15649445
R@@	B-Chemical	D012110	15649445
es@@	I-Chemical	-1	15649445
er@@	I-Chemical	-1	15649445
pine	I-Chemical	-1	15649445
injection	O	-1	15649445
(@@	O	-1	15649445
one	O	-1	15649445
dose	O	-1	15649445
of	O	-1	15649445
1	O	-1	15649445
mg/kg	O	-1	15649445
s@@	O	-1	15649445
.@@	O	-1	15649445
c@@	O	-1	15649445
.)	O	-1	15649445
every	O	-1	15649445
other	O	-1	15649445
day	O	-1	15649445
for	O	-1	15649445
3	O	-1	15649445
days	O	-1	15649445
caused	O	-1	15649445
a	O	-1	15649445
significant	O	-1	15649445
increase	O	-1	15649445
in	O	-1	15649445
vac@@	O	-1	15649445
u@@	O	-1	15649445
ous	O	-1	15649445
ch@@	O	-1	15649445
e@@	O	-1	15649445
w@@	O	-1	15649445
ing,	O	-1	15649445
t@@	O	-1	15649445
on@@	O	-1	15649445
gu@@	O	-1	15649445
e	O	-1	15649445
prot@@	O	-1	15649445
ru@@	O	-1	15649445
sion	O	-1	15649445
and	O	-1	15649445
duration	O	-1	15649445
of	O	-1	15649445
fac@@	O	-1	15649445
ial	O	-1	15649445
t@@	O	-1	15649445
witch@@	O	-1	15649445
ing,	O	-1	15649445
compared	O	-1	15649445
to	O	-1	15649445
the	O	-1	15649445
control@@	O	-1	15649445
.	O	-1	15649445
H@@	B-Chemical	D006220	15649445
alo@@	I-Chemical	-1	15649445
perid@@	I-Chemical	-1	15649445
ol	I-Chemical	-1	15649445
administration	O	-1	15649445
(@@	O	-1	15649445
one	O	-1	15649445
dose	O	-1	15649445
of	O	-1	15649445
12	O	-1	15649445
mg/kg	O	-1	15649445
on@@	O	-1	15649445
ce	O	-1	15649445
a	O	-1	15649445
week	O	-1	15649445
s@@	O	-1	15649445
.@@	O	-1	15649445
c@@	O	-1	15649445
.)	O	-1	15649445
for	O	-1	15649445
4	O	-1	15649445
weeks	O	-1	15649445
caused	O	-1	15649445
an	O	-1	15649445
increase	O	-1	15649445
in	O	-1	15649445
vac@@	O	-1	15649445
u@@	O	-1	15649445
ous	O	-1	15649445
ch@@	O	-1	15649445
e@@	O	-1	15649445
w@@	O	-1	15649445
ing,	O	-1	15649445
t@@	O	-1	15649445
on@@	O	-1	15649445
gu@@	O	-1	15649445
e	O	-1	15649445
prot@@	O	-1	15649445
ru@@	O	-1	15649445
sion	O	-1	15649445
and	O	-1	15649445
duration	O	-1	15649445
of	O	-1	15649445
fac@@	O	-1	15649445
ial	O	-1	15649445
t@@	O	-1	15649445
witch@@	O	-1	15649445
ing	O	-1	15649445
observed	O	-1	15649445
in	O	-1	15649445
four	O	-1	15649445
week@@	O	-1	15649445
ly	O	-1	15649445
evalu@@	O	-1	15649445
ations.	O	-1	15649445
After	O	-1	15649445
the	O	-1	15649445
treat@@	O	-1	15649445
ments	O	-1	15649445
and	O	-1	15649445
behavioral	O	-1	15649445
observ@@	O	-1	15649445
ation,	O	-1	15649445
glutamate	B-Chemical	D018698	15649445
u@@	O	-1	15649445
pt@@	O	-1	15649445
ake	O	-1	15649445
by	O	-1	15649445
seg@@	O	-1	15649445
ments	O	-1	15649445
of	O	-1	15649445
the	O	-1	15649445
brain	O	-1	15649445
was	O	-1	15649445
analy@@	O	-1	15649445
z@@	O	-1	15649445
ed.	O	-1	15649445
A	O	-1	15649445
decreased	O	-1	15649445
glutamate	B-Chemical	D018698	15649445
u@@	O	-1	15649445
pt@@	O	-1	15649445
ake	O	-1	15649445
was	O	-1	15649445
observed	O	-1	15649445
in	O	-1	15649445
the	O	-1	15649445
sub@@	O	-1	15649445
cor@@	O	-1	15649445
tical	O	-1	15649445
par@@	O	-1	15649445
ts	O	-1	15649445
of	O	-1	15649445
animals	O	-1	15649445
treated	O	-1	15649445
with	O	-1	15649445
res@@	B-Chemical	D012110	15649445
er@@	I-Chemical	-1	15649445
pine	I-Chemical	-1	15649445
and	O	-1	15649445
haloperidol	B-Chemical	D006220	15649445
,	O	-1	15649445
compared	O	-1	15649445
to	O	-1	15649445
the	O	-1	15649445
control@@	O	-1	15649445
.	O	-1	15649445
Im@@	O	-1	15649445
port@@	O	-1	15649445
ant@@	O	-1	15649445
ly,	O	-1	15649445
a	O	-1	15649445
decrease	O	-1	15649445
in	O	-1	15649445
glutamate	B-Chemical	D018698	15649445
u@@	O	-1	15649445
pt@@	O	-1	15649445
ake	O	-1	15649445
correl@@	O	-1	15649445
ates	O	-1	15649445
neg@@	O	-1	15649445
atively	O	-1	15649445
with	O	-1	15649445
an	O	-1	15649445
increase	O	-1	15649445
in	O	-1	15649445
the	O	-1	15649445
incidence	O	-1	15649445
of	O	-1	15649445
o@@	B-Disease	D004409	15649445
ro@@	I-Disease	-1	15649445
fac@@	I-Disease	-1	15649445
ial	I-Disease	-1	15649445
dis@@	I-Disease	-1	15649445
kine@@	I-Disease	-1	15649445
sia	I-Disease	-1	15649445
.	O	-1	15649445
These	O	-1	15649445
results	O	-1	15649445
indicate	O	-1	15649445
that	O	-1	15649445
early	O	-1	15649445
changes	O	-1	15649445
in	O	-1	15649445
glutamate	B-Chemical	D018698	15649445
trans@@	O	-1	15649445
por@@	O	-1	15649445
t	O	-1	15649445
may	O	-1	15649445
be	O	-1	15649445
related	O	-1	15649445
to	O	-1	15649445
the	O	-1	15649445
development	O	-1	15649445
of	O	-1	15649445
vac@@	O	-1	15649445
u@@	O	-1	15649445
ous	O	-1	15649445
ch@@	O	-1	15649445
e@@	O	-1	15649445
w@@	O	-1	15649445
ing	O	-1	15649445
mo@@	O	-1	15649445
ve@@	O	-1	15649445
ments	O	-1	15649445
in	O	-1	15649445
rats.	O	-1	15649445

Ac@@	B-Disease	D011605	14698717
ute	I-Disease	-1	14698717
psycho@@	I-Disease	-1	14698717
sis	I-Disease	-1	14698717
due	O	-1	14698717
to	O	-1	14698717
treatment	O	-1	14698717
with	O	-1	14698717
pheny@@	B-Chemical	D010672	14698717
to@@	I-Chemical	-1	14698717
in	I-Chemical	-1	14698717
in	O	-1	14698717
a	O	-1	14698717
non@@	O	-1	14698717
epileptic	O	-1	14698717
patient@@	O	-1	14698717
.	O	-1	14698717
The	O	-1	14698717
development	O	-1	14698717
of	O	-1	14698717
psycho@@	B-Disease	D011605	14698717
sis	I-Disease	-1	14698717
related	O	-1	14698717
to	O	-1	14698717
anti@@	O	-1	14698717
epileptic	O	-1	14698717
drug	O	-1	14698717
treatment	O	-1	14698717
is	O	-1	14698717
us@@	O	-1	14698717
ually	O	-1	14698717
at@@	O	-1	14698717
tri@@	O	-1	14698717
but@@	O	-1	14698717
ed	O	-1	14698717
to	O	-1	14698717
the	O	-1	14698717
inter@@	O	-1	14698717
action	O	-1	14698717
between	O	-1	14698717
the	O	-1	14698717
epileptic	B-Disease	D004827	14698717
brain	O	-1	14698717
sub@@	O	-1	14698717
strat@@	O	-1	14698717
um	O	-1	14698717
and	O	-1	14698717
the	O	-1	14698717
anti@@	O	-1	14698717
epileptic	O	-1	14698717
drug@@	O	-1	14698717
s.	O	-1	14698717
The	O	-1	14698717
case	O	-1	14698717
of	O	-1	14698717
a	O	-1	14698717
non@@	O	-1	14698717
epileptic	O	-1	14698717
patient	O	-1	14698717
who	O	-1	14698717
developed	O	-1	14698717
psycho@@	B-Disease	D011605	14698717
sis	I-Disease	-1	14698717
following	O	-1	14698717
pheny@@	B-Chemical	D010672	14698717
to@@	I-Chemical	-1	14698717
in	I-Chemical	-1	14698717
treatment	O	-1	14698717
for	O	-1	14698717
tri@@	B-Disease	D014277	14698717
g@@	I-Disease	-1	14698717
em@@	I-Disease	-1	14698717
inal	I-Disease	-1	14698717
ne@@	I-Disease	-1	14698717
ur@@	I-Disease	-1	14698717
al@@	I-Disease	-1	14698717
g@@	I-Disease	-1	14698717
ia	I-Disease	-1	14698717
is	O	-1	14698717
descri@@	O	-1	14698717
be@@	O	-1	14698717
d.	O	-1	14698717
This	O	-1	14698717
case	O	-1	14698717
suggests	O	-1	14698717
that	O	-1	14698717
the	O	-1	14698717
psycho@@	B-Disease	D011605	14698717
tic	I-Disease	-1	14698717
symptoms	I-Disease	-1	14698717
that	O	-1	14698717
occ@@	O	-1	14698717
ur	O	-1	14698717
following	O	-1	14698717
pheny@@	B-Chemical	D010672	14698717
to@@	I-Chemical	-1	14698717
in	I-Chemical	-1	14698717
treatment	O	-1	14698717
in	O	-1	14698717
some	O	-1	14698717
epileptic	B-Disease	D004827	14698717
patients	O	-1	14698717
may	O	-1	14698717
be	O	-1	14698717
the	O	-1	14698717
direct	O	-1	14698717
result	O	-1	14698717
of	O	-1	14698717
medic@@	O	-1	14698717
ation,	O	-1	14698717
un@@	O	-1	14698717
related	O	-1	14698717
to	O	-1	14698717
seizures	B-Disease	D012640	14698717
.	O	-1	14698717

The	O	-1	12617329
effect	O	-1	12617329
of	O	-1	12617329
treatment	O	-1	12617329
with	O	-1	12617329
g@@	B-Chemical	D006170	12617329
um	I-Chemical	-1	12617329
A@@	I-Chemical	-1	12617329
ra@@	I-Chemical	-1	12617329
b@@	I-Chemical	-1	12617329
ic	I-Chemical	-1	12617329
on	O	-1	12617329
g@@	B-Chemical	D005839	12617329
ent@@	I-Chemical	-1	12617329
am@@	I-Chemical	-1	12617329
icin	I-Chemical	-1	12617329
nephro@@	B-Disease	D007674	12617329
toxicity	I-Disease	-1	12617329
in	O	-1	12617329
rat@@	O	-1	12617329
s:	O	-1	12617329
a	O	-1	12617329
pre@@	O	-1	12617329
lim@@	O	-1	12617329
inary	O	-1	12617329
study.	O	-1	12617329
In	O	-1	12617329
the	O	-1	12617329
present	O	-1	12617329
wor@@	O	-1	12617329
k	O	-1	12617329
we	O	-1	12617329
assessed	O	-1	12617329
the	O	-1	12617329
effect	O	-1	12617329
of	O	-1	12617329
treatment	O	-1	12617329
of	O	-1	12617329
rats	O	-1	12617329
with	O	-1	12617329
g@@	B-Chemical	D006170	12617329
um	I-Chemical	-1	12617329
A@@	I-Chemical	-1	12617329
ra@@	I-Chemical	-1	12617329
b@@	I-Chemical	-1	12617329
ic	I-Chemical	-1	12617329
on	O	-1	12617329
acute	B-Disease	D058186	12617329
renal	I-Disease	-1	12617329
failure	I-Disease	-1	12617329
induced	O	-1	12617329
by	O	-1	12617329
g@@	B-Chemical	D005839	12617329
ent@@	I-Chemical	-1	12617329
am@@	I-Chemical	-1	12617329
icin	I-Chemical	-1	12617329
(	O	-1	12617329
G@@	B-Chemical	D005839	12617329
M	I-Chemical	-1	12617329
)	O	-1	12617329
nephro@@	B-Disease	D007674	12617329
toxicity	I-Disease	-1	12617329
.	O	-1	12617329
R@@	O	-1	12617329
at@@	O	-1	12617329
s	O	-1	12617329
were	O	-1	12617329
treated	O	-1	12617329
with	O	-1	12617329
the	O	-1	12617329
ve@@	O	-1	12617329
h@@	O	-1	12617329
ic@@	O	-1	12617329
le	O	-1	12617329
(@@	O	-1	12617329
2	O	-1	12617329
m@@	O	-1	12617329
L@@	O	-1	12617329
/@@	O	-1	12617329
k@@	O	-1	12617329
g	O	-1	12617329
of	O	-1	12617329
dis@@	O	-1	12617329
ti@@	O	-1	12617329
lled	O	-1	12617329
w@@	O	-1	12617329
at@@	O	-1	12617329
er	O	-1	12617329
and	O	-1	12617329
5%	O	-1	12617329
w@@	O	-1	12617329
/@@	O	-1	12617329
v	O	-1	12617329
cell@@	O	-1	12617329
ulo@@	O	-1	12617329
se@@	O	-1	12617329
,	O	-1	12617329
10	O	-1	12617329
da@@	O	-1	12617329
ys@@	O	-1	12617329
),	O	-1	12617329
g@@	B-Chemical	D006170	12617329
um	I-Chemical	-1	12617329
A@@	I-Chemical	-1	12617329
ra@@	I-Chemical	-1	12617329
b@@	I-Chemical	-1	12617329
ic	I-Chemical	-1	12617329
(@@	O	-1	12617329
2	O	-1	12617329
m@@	O	-1	12617329
L@@	O	-1	12617329
/@@	O	-1	12617329
k@@	O	-1	12617329
g	O	-1	12617329
of	O	-1	12617329
a	O	-1	12617329
10@@	O	-1	12617329
%	O	-1	12617329
w@@	O	-1	12617329
/@@	O	-1	12617329
v	O	-1	12617329
a@@	O	-1	12617329
qu@@	O	-1	12617329
e@@	O	-1	12617329
ous	O	-1	12617329
sus@@	O	-1	12617329
pen@@	O	-1	12617329
sion	O	-1	12617329
of	O	-1	12617329
g@@	B-Chemical	D006170	12617329
um	I-Chemical	-1	12617329
A@@	I-Chemical	-1	12617329
ra@@	I-Chemical	-1	12617329
b@@	I-Chemical	-1	12617329
ic	I-Chemical	-1	12617329
po@@	O	-1	12617329
w@@	O	-1	12617329
der@@	O	-1	12617329
,	O	-1	12617329
or@@	O	-1	12617329
ally	O	-1	12617329
for	O	-1	12617329
10	O	-1	12617329
da@@	O	-1	12617329
ys@@	O	-1	12617329
),	O	-1	12617329
or	O	-1	12617329
g@@	B-Chemical	D006170	12617329
um	I-Chemical	-1	12617329
A@@	I-Chemical	-1	12617329
ra@@	I-Chemical	-1	12617329
b@@	I-Chemical	-1	12617329
ic	I-Chemical	-1	12617329
concomit@@	O	-1	12617329
ant@@	O	-1	12617329
ly	O	-1	12617329
with	O	-1	12617329
G@@	B-Chemical	D005839	12617329
M	I-Chemical	-1	12617329
(@@	O	-1	12617329
80@@	O	-1	12617329
mg/k@@	O	-1	12617329
g/@@	O	-1	12617329
day	O	-1	12617329
int@@	O	-1	12617329
ram@@	O	-1	12617329
us@@	O	-1	12617329
cul@@	O	-1	12617329
ar@@	O	-1	12617329
ly,	O	-1	12617329
during	O	-1	12617329
the	O	-1	12617329
las@@	O	-1	12617329
t	O	-1	12617329
six	O	-1	12617329
days	O	-1	12617329
of	O	-1	12617329
the	O	-1	12617329
treatment	O	-1	12617329
perio@@	O	-1	12617329
d@@	O	-1	12617329
).	O	-1	12617329
Ne@@	B-Disease	D007674	12617329
ph@@	I-Disease	-1	12617329
ro@@	I-Disease	-1	12617329
toxicity	I-Disease	-1	12617329
was	O	-1	12617329
assessed	O	-1	12617329
by	O	-1	12617329
meas@@	O	-1	12617329
uring	O	-1	12617329
the	O	-1	12617329
concentrations	O	-1	12617329
of	O	-1	12617329
creatinine	B-Chemical	D003404	12617329
and	O	-1	12617329
ure@@	B-Chemical	D014508	12617329
a	I-Chemical	-1	12617329
in	O	-1	12617329
the	O	-1	12617329
plasma	O	-1	12617329
and	O	-1	12617329
reduced	O	-1	12617329
glut@@	B-Chemical	D005978	12617329
athi@@	I-Chemical	-1	12617329
one	I-Chemical	-1	12617329
(	O	-1	12617329
G@@	B-Chemical	D005978	12617329
S@@	I-Chemical	-1	12617329
H	I-Chemical	-1	12617329
)	O	-1	12617329
in	O	-1	12617329
the	O	-1	12617329
kidney	O	-1	12617329
cor@@	O	-1	12617329
t@@	O	-1	12617329
ex@@	O	-1	12617329
,	O	-1	12617329
and	O	-1	12617329
by	O	-1	12617329
li@@	O	-1	12617329
ght	O	-1	12617329
micro@@	O	-1	12617329
sco@@	O	-1	12617329
p@@	O	-1	12617329
ic	O	-1	12617329
examin@@	O	-1	12617329
ation	O	-1	12617329
of	O	-1	12617329
kidney	O	-1	12617329
sec@@	O	-1	12617329
tions.	O	-1	12617329
The	O	-1	12617329
results	O	-1	12617329
indic@@	O	-1	12617329
ated	O	-1	12617329
that	O	-1	12617329
concomit@@	O	-1	12617329
ant	O	-1	12617329
treatment	O	-1	12617329
with	O	-1	12617329
g@@	B-Chemical	D006170	12617329
um	I-Chemical	-1	12617329
A@@	I-Chemical	-1	12617329
ra@@	I-Chemical	-1	12617329
b@@	I-Chemical	-1	12617329
ic	I-Chemical	-1	12617329
and	O	-1	12617329
G@@	B-Chemical	D005839	12617329
M	I-Chemical	-1	12617329
significantly	O	-1	12617329
increased	O	-1	12617329
creatinine	B-Chemical	D003404	12617329
and	O	-1	12617329
ure@@	B-Chemical	D014508	12617329
a	I-Chemical	-1	12617329
by	O	-1	12617329
about	O	-1	12617329
18@@	O	-1	12617329
3	O	-1	12617329
and	O	-1	12617329
2@@	O	-1	12617329
3@@	O	-1	12617329
9@@	O	-1	12617329
%,	O	-1	12617329
respecti@@	O	-1	12617329
vely	O	-1	12617329
(@@	O	-1	12617329
compared	O	-1	12617329
to	O	-1	12617329
4@@	O	-1	12617329
3@@	O	-1	12617329
2	O	-1	12617329
and	O	-1	12617329
34@@	O	-1	12617329
6@@	O	-1	12617329
%,	O	-1	12617329
respectivel@@	O	-1	12617329
y,	O	-1	12617329
in	O	-1	12617329
rats	O	-1	12617329
treated	O	-1	12617329
with	O	-1	12617329
cell@@	O	-1	12617329
ulo@@	O	-1	12617329
se	O	-1	12617329
and	O	-1	12617329
G@@	B-Chemical	D005839	12617329
M	I-Chemical	-1	12617329
),	O	-1	12617329
and	O	-1	12617329
decreased	O	-1	12617329
that	O	-1	12617329
of	O	-1	12617329
cor@@	O	-1	12617329
tical	O	-1	12617329
G@@	B-Chemical	D005978	12617329
S@@	I-Chemical	-1	12617329
H	I-Chemical	-1	12617329
by	O	-1	12617329
2@@	O	-1	12617329
1@@	O	-1	12617329
%	O	-1	12617329
(@@	O	-1	12617329
compared	O	-1	12617329
to	O	-1	12617329
27@@	O	-1	12617329
%	O	-1	12617329
in	O	-1	12617329
the	O	-1	12617329
cell@@	O	-1	12617329
ulo@@	O	-1	12617329
se	O	-1	12617329
plus	O	-1	12617329
G@@	B-Chemical	D005839	12617329
M	I-Chemical	-1	12617329
group@@	O	-1	12617329
)	O	-1	12617329
The	O	-1	12617329
G@@	B-Chemical	D005839	12617329
M	I-Chemical	-1	12617329
-induced	O	-1	12617329
pro@@	O	-1	12617329
xim@@	O	-1	12617329
al	O	-1	12617329
tub@@	B-Disease	D007683	12617329
ular	I-Disease	-1	12617329
necro@@	I-Disease	-1	12617329
sis	I-Disease	-1	12617329
appe@@	O	-1	12617329
a@@	O	-1	12617329
red	O	-1	12617329
to	O	-1	12617329
be	O	-1	12617329
s@@	O	-1	12617329
li@@	O	-1	12617329
gh@@	O	-1	12617329
tly	O	-1	12617329
less	O	-1	12617329
severe	O	-1	12617329
in	O	-1	12617329
rats	O	-1	12617329
given	O	-1	12617329
G@@	B-Chemical	D005839	12617329
M	I-Chemical	-1	12617329
to@@	O	-1	12617329
ge@@	O	-1	12617329
ther	O	-1	12617329
with	O	-1	12617329
g@@	B-Chemical	D006170	12617329
um	I-Chemical	-1	12617329
A@@	I-Chemical	-1	12617329
ra@@	I-Chemical	-1	12617329
b@@	I-Chemical	-1	12617329
ic	I-Chemical	-1	12617329
than	O	-1	12617329
in	O	-1	12617329
those	O	-1	12617329
given	O	-1	12617329
G@@	B-Chemical	D005839	12617329
M	I-Chemical	-1	12617329
and	O	-1	12617329
cell@@	O	-1	12617329
ulo@@	O	-1	12617329
se.	O	-1	12617329
It	O	-1	12617329
could	O	-1	12617329
be	O	-1	12617329
inf@@	O	-1	12617329
er@@	O	-1	12617329
red	O	-1	12617329
that	O	-1	12617329
g@@	B-Chemical	D006170	12617329
um	I-Chemical	-1	12617329
A@@	I-Chemical	-1	12617329
ra@@	I-Chemical	-1	12617329
b@@	I-Chemical	-1	12617329
ic	I-Chemical	-1	12617329
treatment	O	-1	12617329
has	O	-1	12617329
induced	O	-1	12617329
a	O	-1	12617329
mod@@	O	-1	12617329
est	O	-1	12617329
ame@@	O	-1	12617329
li@@	O	-1	12617329
or@@	O	-1	12617329
ation	O	-1	12617329
of	O	-1	12617329
some	O	-1	12617329
of	O	-1	12617329
the	O	-1	12617329
hist@@	O	-1	12617329
ological	O	-1	12617329
and	O	-1	12617329
bio@@	O	-1	12617329
chemical	O	-1	12617329
indic@@	O	-1	12617329
es	O	-1	12617329
of	O	-1	12617329
G@@	B-Chemical	D005839	12617329
M	I-Chemical	-1	12617329
nephro@@	B-Disease	D007674	12617329
toxicity	I-Disease	-1	12617329
.	O	-1	12617329
F@@	O	-1	12617329
urther	O	-1	12617329
wor@@	O	-1	12617329
k	O	-1	12617329
is	O	-1	12617329
war@@	O	-1	12617329
ran@@	O	-1	12617329
ted	O	-1	12617329
on	O	-1	12617329
the	O	-1	12617329
effect	O	-1	12617329
of	O	-1	12617329
the	O	-1	12617329
treat@@	O	-1	12617329
ments	O	-1	12617329
on	O	-1	12617329
renal	O	-1	12617329
functional	O	-1	12617329
as@@	O	-1	12617329
p@@	O	-1	12617329
ects	O	-1	12617329
in	O	-1	12617329
models	O	-1	12617329
of	O	-1	12617329
chronic	B-Disease	D007676	12617329
renal	I-Disease	-1	12617329
failure	I-Disease	-1	12617329
,	O	-1	12617329
and	O	-1	12617329
on	O	-1	12617329
the	O	-1	12617329
mechanis@@	O	-1	12617329
m@@	O	-1	12617329
(@@	O	-1	12617329
s)	O	-1	12617329
invol@@	O	-1	12617329
ved.	O	-1	12617329

V@@	B-Disease	D006212	12523465
i@@	I-Disease	-1	12523465
sual	I-Disease	-1	12523465
h@@	I-Disease	-1	12523465
all@@	I-Disease	-1	12523465
uc@@	I-Disease	-1	12523465
in@@	I-Disease	-1	12523465
ations	I-Disease	-1	12523465
associated	O	-1	12523465
with	O	-1	12523465
z@@	B-Chemical	C022189	12523465
on@@	I-Chemical	-1	12523465
is@@	I-Chemical	-1	12523465
amide	I-Chemical	-1	12523465
.	O	-1	12523465
Z@@	B-Chemical	C022189	12523465
on@@	I-Chemical	-1	12523465
is@@	I-Chemical	-1	12523465
amide	I-Chemical	-1	12523465
is	O	-1	12523465
a	O	-1	12523465
b@@	O	-1	12523465
ro@@	O	-1	12523465
ad@@	O	-1	12523465
-@@	O	-1	12523465
sp@@	O	-1	12523465
ect@@	O	-1	12523465
ru@@	O	-1	12523465
m	O	-1	12523465
anti@@	O	-1	12523465
epileptic	O	-1	12523465
drug	O	-1	12523465
used	O	-1	12523465
to	O	-1	12523465
tre@@	O	-1	12523465
at	O	-1	12523465
various	O	-1	12523465
typ@@	O	-1	12523465
es	O	-1	12523465
of	O	-1	12523465
seizures	B-Disease	D012640	12523465
.	O	-1	12523465
Although	O	-1	12523465
visual	B-Disease	D006212	12523465
h@@	I-Disease	-1	12523465
all@@	I-Disease	-1	12523465
uc@@	I-Disease	-1	12523465
in@@	I-Disease	-1	12523465
ations	I-Disease	-1	12523465
have	O	-1	12523465
not	O	-1	12523465
been	O	-1	12523465
reported	O	-1	12523465
as	O	-1	12523465
an	O	-1	12523465
adverse	O	-1	12523465
effect	O	-1	12523465
of	O	-1	12523465
this	O	-1	12523465
agent@@	O	-1	12523465
,	O	-1	12523465
we	O	-1	12523465
describe	O	-1	12523465
three	O	-1	12523465
patients	O	-1	12523465
who	O	-1	12523465
experienced	O	-1	12523465
comple@@	O	-1	12523465
x	O	-1	12523465
visual	B-Disease	D006212	12523465
h@@	I-Disease	-1	12523465
all@@	I-Disease	-1	12523465
uc@@	I-Disease	-1	12523465
in@@	I-Disease	-1	12523465
ations	I-Disease	-1	12523465
and	O	-1	12523465
al@@	O	-1	12523465
te@@	O	-1	12523465
red	O	-1	12523465
mental	O	-1	12523465
status	O	-1	12523465
after	O	-1	12523465
z@@	B-Chemical	C022189	12523465
on@@	I-Chemical	-1	12523465
is@@	I-Chemical	-1	12523465
amide	I-Chemical	-1	12523465
treatment	O	-1	12523465
was	O	-1	12523465
be@@	O	-1	12523465
gu@@	O	-1	12523465
n	O	-1	12523465
or	O	-1	12523465
its	O	-1	12523465
dos@@	O	-1	12523465
age	O	-1	12523465
increas@@	O	-1	12523465
ed.	O	-1	12523465
All	O	-1	12523465
three	O	-1	12523465
had	O	-1	12523465
been	O	-1	12523465
diagnos@@	O	-1	12523465
ed	O	-1	12523465
ear@@	O	-1	12523465
li@@	O	-1	12523465
er	O	-1	12523465
with	O	-1	12523465
epilep@@	B-Disease	D004827	12523465
sy	I-Disease	-1	12523465
,	O	-1	12523465
and	O	-1	12523465
their	O	-1	12523465
electro@@	O	-1	12523465
encephalo@@	O	-1	12523465
gra@@	O	-1	12523465
m	O	-1	12523465
(@@	O	-1	12523465
E@@	O	-1	12523465
E@@	O	-1	12523465
G@@	O	-1	12523465
)	O	-1	12523465
findings	O	-1	12523465
were	O	-1	12523465
abnormal@@	O	-1	12523465
.	O	-1	12523465
D@@	O	-1	12523465
uring	O	-1	12523465
monit@@	O	-1	12523465
or@@	O	-1	12523465
ing,	O	-1	12523465
visual	B-Disease	D006212	12523465
h@@	I-Disease	-1	12523465
all@@	I-Disease	-1	12523465
uc@@	I-Disease	-1	12523465
in@@	I-Disease	-1	12523465
ations	I-Disease	-1	12523465
did	O	-1	12523465
not	O	-1	12523465
correl@@	O	-1	12523465
ate	O	-1	12523465
with	O	-1	12523465
E@@	O	-1	12523465
E@@	O	-1	12523465
G	O	-1	12523465
re@@	O	-1	12523465
ad@@	O	-1	12523465
ing@@	O	-1	12523465
s,	O	-1	12523465
n@@	O	-1	12523465
or	O	-1	12523465
did	O	-1	12523465
vi@@	O	-1	12523465
de@@	O	-1	12523465
o	O	-1	12523465
recor@@	O	-1	12523465
ding	O	-1	12523465
cap@@	O	-1	12523465
t@@	O	-1	12523465
ure	O	-1	12523465
any	O	-1	12523465
of	O	-1	12523465
the	O	-1	12523465
descri@@	O	-1	12523465
bed	O	-1	12523465
event@@	O	-1	12523465
s.	O	-1	12523465
N@@	O	-1	12523465
one	O	-1	12523465
of	O	-1	12523465
the	O	-1	12523465
patients	O	-1	12523465
had	O	-1	12523465
experienced	O	-1	12523465
visual	B-Disease	D006212	12523465
h@@	I-Disease	-1	12523465
all@@	I-Disease	-1	12523465
uc@@	I-Disease	-1	12523465
in@@	I-Disease	-1	12523465
ations	I-Disease	-1	12523465
before	O	-1	12523465
this	O	-1	12523465
event@@	O	-1	12523465
.	O	-1	12523465
The	O	-1	12523465
only	O	-1	12523465
rec@@	O	-1	12523465
ent	O	-1	12523465
change	O	-1	12523465
in	O	-1	12523465
their	O	-1	12523465
treatment	O	-1	12523465
was	O	-1	12523465
the	O	-1	12523465
int@@	O	-1	12523465
ro@@	O	-1	12523465
duction	O	-1	12523465
or	O	-1	12523465
increased	O	-1	12523465
dos@@	O	-1	12523465
age	O	-1	12523465
of	O	-1	12523465
z@@	B-Chemical	C022189	12523465
on@@	I-Chemical	-1	12523465
is@@	I-Chemical	-1	12523465
amide	I-Chemical	-1	12523465
.	O	-1	12523465
W@@	O	-1	12523465
it@@	O	-1	12523465
h	O	-1	12523465
either	O	-1	12523465
discontinu@@	O	-1	12523465
ation	O	-1	12523465
or	O	-1	12523465
decreased	O	-1	12523465
dos@@	O	-1	12523465
age	O	-1	12523465
of	O	-1	12523465
the	O	-1	12523465
drug	O	-1	12523465
the	O	-1	12523465
symptoms	O	-1	12523465
dis@@	O	-1	12523465
appe@@	O	-1	12523465
a@@	O	-1	12523465
red	O	-1	12523465
and	O	-1	12523465
did	O	-1	12523465
not	O	-1	12523465
recur@@	O	-1	12523465
.	O	-1	12523465
F@@	O	-1	12523465
urther	O	-1	12523465
observ@@	O	-1	12523465
ations	O	-1	12523465
and	O	-1	12523465
reports	O	-1	12523465
wil@@	O	-1	12523465
l	O	-1	12523465
he@@	O	-1	12523465
l@@	O	-1	12523465
p	O	-1	12523465
cl@@	O	-1	12523465
ar@@	O	-1	12523465
if@@	O	-1	12523465
y	O	-1	12523465
this	O	-1	12523465
adverse	O	-1	12523465
effect@@	O	-1	12523465
.	O	-1	12523465
U@@	O	-1	12523465
n@@	O	-1	12523465
ti@@	O	-1	12523465
l	O	-1	12523465
th@@	O	-1	12523465
en@@	O	-1	12523465
,	O	-1	12523465
clin@@	O	-1	12523465
ici@@	O	-1	12523465
ans	O	-1	12523465
need	O	-1	12523465
to	O	-1	12523465
be	O	-1	12523465
aw@@	O	-1	12523465
are	O	-1	12523465
of	O	-1	12523465
this	O	-1	12523465
possible	O	-1	12523465
complication	O	-1	12523465
associated	O	-1	12523465
with	O	-1	12523465
z@@	B-Chemical	C022189	12523465
on@@	I-Chemical	-1	12523465
is@@	I-Chemical	-1	12523465
amide	I-Chemical	-1	12523465
.	O	-1	12523465

G@@	O	-1	11961407
L@@	O	-1	11961407
EP@@	O	-1	11961407
P@@	O	-1	11961407
1	O	-1	11961407
receptor	O	-1	11961407
ty@@	B-Chemical	D014443	11961407
ros@@	I-Chemical	-1	11961407
ine	I-Chemical	-1	11961407
phosph@@	O	-1	11961407
at@@	O	-1	11961407
ase	O	-1	11961407
(P@@	O	-1	11961407
t@@	O	-1	11961407
pro@@	O	-1	11961407
)	O	-1	11961407
in	O	-1	11961407
rat	O	-1	11961407
PA@@	B-Chemical	D011692	11961407
N	I-Chemical	-1	11961407
nephro@@	B-Disease	D009401	11961407
sis	I-Disease	-1	11961407
.	O	-1	11961407
A	O	-1	11961407
mark@@	O	-1	11961407
er	O	-1	11961407
of	O	-1	11961407
acute	O	-1	11961407
po@@	O	-1	11961407
d@@	O	-1	11961407
ocyte	O	-1	11961407
injur@@	O	-1	11961407
y.	O	-1	11961407
G@@	O	-1	11961407
lo@@	O	-1	11961407
mer@@	O	-1	11961407
ular	O	-1	11961407
epi@@	O	-1	11961407
thelial	O	-1	11961407
protein	O	-1	11961407
1	O	-1	11961407
(@@	O	-1	11961407
G@@	O	-1	11961407
L@@	O	-1	11961407
EP@@	O	-1	11961407
P@@	O	-1	11961407
1)	O	-1	11961407
is	O	-1	11961407
a	O	-1	11961407
po@@	O	-1	11961407
d@@	O	-1	11961407
ocyte	O	-1	11961407
receptor	O	-1	11961407
membran@@	O	-1	11961407
e	O	-1	11961407
protein	O	-1	11961407
ty@@	B-Chemical	D014443	11961407
ros@@	I-Chemical	-1	11961407
ine	I-Chemical	-1	11961407
phosph@@	O	-1	11961407
at@@	O	-1	11961407
ase	O	-1	11961407
loc@@	O	-1	11961407
ated	O	-1	11961407
on	O	-1	11961407
the	O	-1	11961407
ap@@	O	-1	11961407
ical	O	-1	11961407
cell	O	-1	11961407
membran@@	O	-1	11961407
e	O	-1	11961407
of	O	-1	11961407
v@@	O	-1	11961407
is@@	O	-1	11961407
c@@	O	-1	11961407
eral	O	-1	11961407
glomerular	O	-1	11961407
epi@@	O	-1	11961407
thelial	O	-1	11961407
cell	O	-1	11961407
and	O	-1	11961407
fo@@	O	-1	11961407
o@@	O	-1	11961407
t	O	-1	11961407
pro@@	O	-1	11961407
cess@@	O	-1	11961407
es.	O	-1	11961407
This	O	-1	11961407
receptor	O	-1	11961407
pl@@	O	-1	11961407
ays	O	-1	11961407
a	O	-1	11961407
role	O	-1	11961407
in	O	-1	11961407
reg@@	O	-1	11961407
ul@@	O	-1	11961407
ating	O	-1	11961407
the	O	-1	11961407
struct@@	O	-1	11961407
ure	O	-1	11961407
and	O	-1	11961407
function	O	-1	11961407
of	O	-1	11961407
po@@	O	-1	11961407
d@@	O	-1	11961407
ocyte	O	-1	11961407
fo@@	O	-1	11961407
o@@	O	-1	11961407
t	O	-1	11961407
pro@@	O	-1	11961407
ces@@	O	-1	11961407
s.	O	-1	11961407
To	O	-1	11961407
bet@@	O	-1	11961407
ter	O	-1	11961407
under@@	O	-1	11961407
st@@	O	-1	11961407
and	O	-1	11961407
the	O	-1	11961407
u@@	O	-1	11961407
til@@	O	-1	11961407
ity	O	-1	11961407
of	O	-1	11961407
G@@	O	-1	11961407
L@@	O	-1	11961407
EP@@	O	-1	11961407
P@@	O	-1	11961407
1	O	-1	11961407
as	O	-1	11961407
a	O	-1	11961407
mark@@	O	-1	11961407
er	O	-1	11961407
of	O	-1	11961407
glomerular	B-Disease	D007674	11961407
injury	I-Disease	-1	11961407
,	O	-1	11961407
the	O	-1	11961407
amoun@@	O	-1	11961407
t	O	-1	11961407
and	O	-1	11961407
di@@	O	-1	11961407
stri@@	O	-1	11961407
bu@@	O	-1	11961407
tion	O	-1	11961407
of	O	-1	11961407
G@@	O	-1	11961407
L@@	O	-1	11961407
EP@@	O	-1	11961407
P@@	O	-1	11961407
1	O	-1	11961407
protein	O	-1	11961407
and	O	-1	11961407
mRNA	O	-1	11961407
were	O	-1	11961407
examined	O	-1	11961407
by	O	-1	11961407
immuno@@	O	-1	11961407
histo@@	O	-1	11961407
chem@@	O	-1	11961407
ist@@	O	-1	11961407
r@@	O	-1	11961407
y,	O	-1	11961407
W@@	O	-1	11961407
est@@	O	-1	11961407
er@@	O	-1	11961407
n	O	-1	11961407
blo@@	O	-1	11961407
t	O	-1	11961407
and	O	-1	11961407
R@@	O	-1	11961407
N@@	O	-1	11961407
ase	O	-1	11961407
prot@@	O	-1	11961407
ection	O	-1	11961407
ass@@	O	-1	11961407
ay	O	-1	11961407
in	O	-1	11961407
a	O	-1	11961407
model	O	-1	11961407
of	O	-1	11961407
po@@	O	-1	11961407
d@@	O	-1	11961407
ocyte	O	-1	11961407
injury	O	-1	11961407
in	O	-1	11961407
the	O	-1	11961407
rat@@	O	-1	11961407
.	O	-1	11961407
P@@	B-Chemical	D011692	11961407
uro@@	I-Chemical	-1	11961407
m@@	I-Chemical	-1	11961407
ycin	I-Chemical	-1	11961407
amin@@	I-Chemical	-1	11961407
on@@	I-Chemical	-1	11961407
ucle@@	I-Chemical	-1	11961407
o@@	I-Chemical	-1	11961407
side	I-Chemical	-1	11961407
nephro@@	B-Disease	D009401	11961407
sis	I-Disease	-1	11961407
was	O	-1	11961407
induced	O	-1	11961407
by	O	-1	11961407
single	O	-1	11961407
intra@@	O	-1	11961407
per@@	O	-1	11961407
it@@	O	-1	11961407
one@@	O	-1	11961407
al	O	-1	11961407
injection	O	-1	11961407
of	O	-1	11961407
p@@	B-Chemical	D011692	11961407
uro@@	I-Chemical	-1	11961407
m@@	I-Chemical	-1	11961407
ycin	I-Chemical	-1	11961407
amin@@	I-Chemical	-1	11961407
on@@	I-Chemical	-1	11961407
ucle@@	I-Chemical	-1	11961407
o@@	I-Chemical	-1	11961407
side	I-Chemical	-1	11961407
(	O	-1	11961407
PA@@	B-Chemical	D011692	11961407
N	I-Chemical	-1	11961407
,	O	-1	11961407
20	O	-1	11961407
mg/@@	O	-1	11961407
10@@	O	-1	11961407
0@@	O	-1	11961407
g	O	-1	11961407
B@@	O	-1	11961407
W@@	O	-1	11961407
).	O	-1	11961407
T@@	O	-1	11961407
is@@	O	-1	11961407
su@@	O	-1	11961407
es	O	-1	11961407
were	O	-1	11961407
analy@@	O	-1	11961407
zed	O	-1	11961407
at	O	-1	11961407
0@@	O	-1	11961407
,	O	-1	11961407
5,	O	-1	11961407
7@@	O	-1	11961407
,	O	-1	11961407
1@@	O	-1	11961407
1,	O	-1	11961407
2@@	O	-1	11961407
1,	O	-1	11961407
4@@	O	-1	11961407
5,	O	-1	11961407
8@@	O	-1	11961407
0	O	-1	11961407
and	O	-1	11961407
12@@	O	-1	11961407
6	O	-1	11961407
days	O	-1	11961407
after	O	-1	11961407
PA@@	B-Chemical	D011692	11961407
N	I-Chemical	-1	11961407
injection	O	-1	11961407
so	O	-1	11961407
as	O	-1	11961407
to	O	-1	11961407
includ@@	O	-1	11961407
e	O	-1	11961407
both	O	-1	11961407
the	O	-1	11961407
acute	O	-1	11961407
phase	O	-1	11961407
of	O	-1	11961407
proteinuria	B-Disease	D011507	11961407
associated	O	-1	11961407
with	O	-1	11961407
fo@@	O	-1	11961407
o@@	O	-1	11961407
t	O	-1	11961407
pro@@	O	-1	11961407
cess	O	-1	11961407
eff@@	O	-1	11961407
ac@@	O	-1	11961407
ement	O	-1	11961407
(@@	O	-1	11961407
days	O	-1	11961407
5-@@	O	-1	11961407
1@@	O	-1	11961407
1)	O	-1	11961407
and	O	-1	11961407
the	O	-1	11961407
chronic	O	-1	11961407
phase	O	-1	11961407
of	O	-1	11961407
proteinuria	B-Disease	D011507	11961407
associated	O	-1	11961407
with	O	-1	11961407
glomer@@	B-Disease	D005921	11961407
u@@	I-Disease	-1	11961407
los@@	I-Disease	-1	11961407
clero@@	I-Disease	-1	11961407
sis	I-Disease	-1	11961407
(@@	O	-1	11961407
days	O	-1	11961407
4@@	O	-1	11961407
5-@@	O	-1	11961407
12@@	O	-1	11961407
6@@	O	-1	11961407
).	O	-1	11961407
A@@	O	-1	11961407
t	O	-1	11961407
day	O	-1	11961407
5,	O	-1	11961407
G@@	O	-1	11961407
L@@	O	-1	11961407
EP@@	O	-1	11961407
P@@	O	-1	11961407
1	O	-1	11961407
protein	O	-1	11961407
and	O	-1	11961407
mRNA	O	-1	11961407
were	O	-1	11961407
reduced	O	-1	11961407
from	O	-1	11961407
the	O	-1	11961407
normal	O	-1	11961407
range	O	-1	11961407
(2@@	O	-1	11961407
6@@	O	-1	11961407
5.@@	O	-1	11961407
2	O	-1	11961407
+/-	O	-1	11961407
7@@	O	-1	11961407
9.@@	O	-1	11961407
6	O	-1	11961407
x	O	-1	11961407
10@@	O	-1	11961407
(6@@	O	-1	11961407
)	O	-1	11961407
mol@@	O	-1	11961407
es@@	O	-1	11961407
/@@	O	-1	11961407
glomerul@@	O	-1	11961407
us	O	-1	11961407
and	O	-1	11961407
10@@	O	-1	11961407
0@@	O	-1	11961407
%)	O	-1	11961407
to	O	-1	11961407
1@@	O	-1	11961407
5%	O	-1	11961407
of	O	-1	11961407
normal	O	-1	11961407
(4@@	O	-1	11961407
1.@@	O	-1	11961407
8	O	-1	11961407
+/-	O	-1	11961407
4.@@	O	-1	11961407
8	O	-1	11961407
x	O	-1	11961407
10@@	O	-1	11961407
(6@@	O	-1	11961407
)	O	-1	11961407
mol@@	O	-1	11961407
es@@	O	-1	11961407
/@@	O	-1	11961407
glomerul@@	O	-1	11961407
us,	O	-1	11961407
p	O	-1	11961407
<	O	-1	11961407
0.00@@	O	-1	11961407
5@@	O	-1	11961407
).	O	-1	11961407
This	O	-1	11961407
occurred	O	-1	11961407
in	O	-1	11961407
association	O	-1	11961407
with	O	-1	11961407
an	O	-1	11961407
increase	O	-1	11961407
in	O	-1	11961407
urinary	O	-1	11961407
protein	O	-1	11961407
cont@@	O	-1	11961407
ent	O	-1	11961407
from	O	-1	11961407
1.@@	O	-1	11961407
8	O	-1	11961407
+/-	O	-1	11961407
1	O	-1	11961407
to	O	-1	11961407
9@@	O	-1	11961407
9.@@	O	-1	11961407
0	O	-1	11961407
+/-	O	-1	11961407
6@@	O	-1	11961407
1	O	-1	11961407
mg/@@	O	-1	11961407
day	O	-1	11961407
(p	O	-1	11961407
<	O	-1	11961407
0.00@@	O	-1	11961407
1).	O	-1	11961407
In	O	-1	11961407
contrast@@	O	-1	11961407
,	O	-1	11961407
po@@	O	-1	11961407
doc@@	O	-1	11961407
aly@@	O	-1	11961407
x@@	O	-1	11961407
in	O	-1	11961407
did	O	-1	11961407
not	O	-1	11961407
change	O	-1	11961407
significantly	O	-1	11961407
at	O	-1	11961407
this	O	-1	11961407
ti@@	O	-1	11961407
me.	O	-1	11961407
B@@	O	-1	11961407
y	O	-1	11961407
day	O	-1	11961407
1@@	O	-1	11961407
1,	O	-1	11961407
G@@	O	-1	11961407
L@@	O	-1	11961407
EP@@	O	-1	11961407
P@@	O	-1	11961407
1	O	-1	11961407
protein	O	-1	11961407
and	O	-1	11961407
mRNA	O	-1	11961407
had	O	-1	11961407
be@@	O	-1	11961407
gu@@	O	-1	11961407
n	O	-1	11961407
to	O	-1	11961407
retur@@	O	-1	11961407
n	O	-1	11961407
to@@	O	-1	11961407
war@@	O	-1	11961407
ds	O	-1	11961407
basel@@	O	-1	11961407
ine.	O	-1	11961407
B@@	O	-1	11961407
y	O	-1	11961407
day	O	-1	11961407
4@@	O	-1	11961407
5-@@	O	-1	11961407
12@@	O	-1	11961407
6,	O	-1	11961407
at	O	-1	11961407
a	O	-1	11961407
time	O	-1	11961407
when	O	-1	11961407
glomerular	O	-1	11961407
s@@	O	-1	11961407
car@@	O	-1	11961407
r@@	O	-1	11961407
ing	O	-1	11961407
was	O	-1	11961407
present@@	O	-1	11961407
,	O	-1	11961407
G@@	O	-1	11961407
L@@	O	-1	11961407
EP@@	O	-1	11961407
P@@	O	-1	11961407
1	O	-1	11961407
was	O	-1	11961407
abs@@	O	-1	11961407
ent	O	-1	11961407
from	O	-1	11961407
glomer@@	O	-1	11961407
u@@	O	-1	11961407
los@@	O	-1	11961407
clero@@	O	-1	11961407
tic	O	-1	11961407
a@@	O	-1	11961407
reas	O	-1	11961407
although	O	-1	11961407
the	O	-1	11961407
total	O	-1	11961407
glomerular	O	-1	11961407
cont@@	O	-1	11961407
ent	O	-1	11961407
of	O	-1	11961407
G@@	O	-1	11961407
L@@	O	-1	11961407
EP@@	O	-1	11961407
P@@	O	-1	11961407
1	O	-1	11961407
was	O	-1	11961407
not	O	-1	11961407
different	O	-1	11961407
from	O	-1	11961407
normal@@	O	-1	11961407
.	O	-1	11961407
We	O	-1	11961407
concl@@	O	-1	11961407
ude	O	-1	11961407
that	O	-1	11961407
G@@	O	-1	11961407
L@@	O	-1	11961407
EP@@	O	-1	11961407
P@@	O	-1	11961407
1	O	-1	11961407
ex@@	O	-1	11961407
pres@@	O	-1	11961407
sion,	O	-1	11961407
un@@	O	-1	11961407
like	O	-1	11961407
po@@	O	-1	11961407
doc@@	O	-1	11961407
aly@@	O	-1	11961407
x@@	O	-1	11961407
in,	O	-1	11961407
ref@@	O	-1	11961407
l@@	O	-1	11961407
ects	O	-1	11961407
po@@	O	-1	11961407
d@@	O	-1	11961407
ocyte	O	-1	11961407
injury	O	-1	11961407
induced	O	-1	11961407
by	O	-1	11961407
PA@@	B-Chemical	D011692	11961407
N	I-Chemical	-1	11961407
.	O	-1	11961407
G@@	O	-1	11961407
L@@	O	-1	11961407
EP@@	O	-1	11961407
P@@	O	-1	11961407
1	O	-1	11961407
expression	O	-1	11961407
may	O	-1	11961407
be	O	-1	11961407
a	O	-1	11961407
use@@	O	-1	11961407
ful	O	-1	11961407
mark@@	O	-1	11961407
er	O	-1	11961407
of	O	-1	11961407
po@@	O	-1	11961407
d@@	O	-1	11961407
ocyte	O	-1	11961407
injur@@	O	-1	11961407
y.	O	-1	11961407

T@@	B-Chemical	D013988	9401499
ic@@	I-Chemical	-1	9401499
lop@@	I-Chemical	-1	9401499
idine	I-Chemical	-1	9401499
-induced	O	-1	9401499
ap@@	B-Disease	D000741	9401499
las@@	I-Disease	-1	9401499
tic	I-Disease	-1	9401499
anemia	I-Disease	-1	9401499
:	O	-1	9401499
report	O	-1	9401499
of	O	-1	9401499
three	O	-1	9401499
Ch@@	O	-1	9401499
in@@	O	-1	9401499
ese	O	-1	9401499
patients	O	-1	9401499
and	O	-1	9401499
revie@@	O	-1	9401499
w	O	-1	9401499
of	O	-1	9401499
the	O	-1	9401499
literat@@	O	-1	9401499
ure.	O	-1	9401499
In	O	-1	9401499
this	O	-1	9401499
study,	O	-1	9401499
three	O	-1	9401499
Ch@@	O	-1	9401499
in@@	O	-1	9401499
ese	O	-1	9401499
patients	O	-1	9401499
with	O	-1	9401499
tic@@	B-Chemical	D013988	9401499
lop@@	I-Chemical	-1	9401499
idine	I-Chemical	-1	9401499
-induced	O	-1	9401499
ap@@	B-Disease	D000741	9401499
las@@	I-Disease	-1	9401499
tic	I-Disease	-1	9401499
anemia	I-Disease	-1	9401499
were	O	-1	9401499
reported	O	-1	9401499
and	O	-1	9401499
an@@	O	-1	9401499
other	O	-1	9401499
13	O	-1	9401499
patients	O	-1	9401499
in	O	-1	9401499
the	O	-1	9401499
E@@	O	-1	9401499
n@@	O	-1	9401499
gl@@	O	-1	9401499
is@@	O	-1	9401499
h	O	-1	9401499
literat@@	O	-1	9401499
ure	O	-1	9401499
were	O	-1	9401499
revie@@	O	-1	9401499
we@@	O	-1	9401499
d.	O	-1	9401499
We	O	-1	9401499
at@@	O	-1	9401499
tem@@	O	-1	9401499
pt@@	O	-1	9401499
ed	O	-1	9401499
to	O	-1	9401499
f@@	O	-1	9401499
ind	O	-1	9401499
underlying	O	-1	9401499
simil@@	O	-1	9401499
ar@@	O	-1	9401499
iti@@	O	-1	9401499
es,	O	-1	9401499
evalu@@	O	-1	9401499
ate	O	-1	9401499
the	O	-1	9401499
risk	O	-1	9401499
fact@@	O	-1	9401499
or@@	O	-1	9401499
s,	O	-1	9401499
and	O	-1	9401499
identi@@	O	-1	9401499
f@@	O	-1	9401499
y	O	-1	9401499
appro@@	O	-1	9401499
pri@@	O	-1	9401499
ate	O	-1	9401499
treatment	O	-1	9401499
for	O	-1	9401499
this	O	-1	9401499
complic@@	O	-1	9401499
ation.	O	-1	9401499
All	O	-1	9401499
but	O	-1	9401499
one	O	-1	9401499
of	O	-1	9401499
the	O	-1	9401499
patients	O	-1	9401499
were	O	-1	9401499
over	O	-1	9401499
60	O	-1	9401499
years	O	-1	9401499
ol@@	O	-1	9401499
d,	O	-1	9401499
and	O	-1	9401499
the	O	-1	9401499
6	O	-1	9401499
who	O	-1	9401499
di@@	O	-1	9401499
ed	O	-1	9401499
were	O	-1	9401499
all	O	-1	9401499
ol@@	O	-1	9401499
der	O	-1	9401499
than	O	-1	9401499
6@@	O	-1	9401499
5@@	O	-1	9401499
.	O	-1	9401499
The@@	O	-1	9401499
refore,	O	-1	9401499
old	O	-1	9401499
age	O	-1	9401499
may	O	-1	9401499
be	O	-1	9401499
a	O	-1	9401499
risk	O	-1	9401499
factor	O	-1	9401499
for	O	-1	9401499
develop@@	O	-1	9401499
ing	O	-1	9401499
this	O	-1	9401499
complic@@	O	-1	9401499
ation.	O	-1	9401499
A@@	B-Disease	D000380	9401499
gran@@	I-Disease	-1	9401499
ulo@@	I-Disease	-1	9401499
cyto@@	I-Disease	-1	9401499
sis	I-Disease	-1	9401499
occurred	O	-1	9401499
3-@@	O	-1	9401499
20	O	-1	9401499
weeks	O	-1	9401499
after	O	-1	9401499
initi@@	O	-1	9401499
ation	O	-1	9401499
of	O	-1	9401499
tic@@	B-Chemical	D013988	9401499
lop@@	I-Chemical	-1	9401499
idine	I-Chemical	-1	9401499
,	O	-1	9401499
so	O	-1	9401499
frequent	O	-1	9401499
examin@@	O	-1	9401499
ation	O	-1	9401499
of	O	-1	9401499
wh@@	O	-1	9401499
ite	O	-1	9401499
cell	O	-1	9401499
coun@@	O	-1	9401499
t	O	-1	9401499
during	O	-1	9401499
treatment	O	-1	9401499
is	O	-1	9401499
recomm@@	O	-1	9401499
en@@	O	-1	9401499
de@@	O	-1	9401499
d.	O	-1	9401499
There	O	-1	9401499
se@@	O	-1	9401499
em@@	O	-1	9401499
ed	O	-1	9401499
to	O	-1	9401499
be	O	-1	9401499
no	O	-1	9401499
direct	O	-1	9401499
correl@@	O	-1	9401499
ation	O	-1	9401499
between	O	-1	9401499
the	O	-1	9401499
dose	O	-1	9401499
or	O	-1	9401499
duration	O	-1	9401499
used	O	-1	9401499
and	O	-1	9401499
the	O	-1	9401499
severity	O	-1	9401499
of	O	-1	9401499
b@@	B-Disease	D001855	9401499
one	I-Disease	-1	9401499
m@@	I-Disease	-1	9401499
ar@@	I-Disease	-1	9401499
ro@@	I-Disease	-1	9401499
w	I-Disease	-1	9401499
sup@@	I-Disease	-1	9401499
pression	I-Disease	-1	9401499
.	O	-1	9401499
Treat@@	O	-1	9401499
ment	O	-1	9401499
for	O	-1	9401499
tic@@	B-Chemical	D013988	9401499
lop@@	I-Chemical	-1	9401499
idine	I-Chemical	-1	9401499
-induced	O	-1	9401499
ap@@	B-Disease	D000741	9401499
las@@	I-Disease	-1	9401499
tic	I-Disease	-1	9401499
anemia	I-Disease	-1	9401499
with	O	-1	9401499
co@@	O	-1	9401499
lon@@	O	-1	9401499
y-@@	O	-1	9401499
stimul@@	O	-1	9401499
ating	O	-1	9401499
factors	O	-1	9401499
se@@	O	-1	9401499
em@@	O	-1	9401499
ed	O	-1	9401499
to	O	-1	9401499
have	O	-1	9401499
lit@@	O	-1	9401499
t@@	O	-1	9401499
le	O	-1	9401499
effect@@	O	-1	9401499
.	O	-1	9401499
The	O	-1	9401499
fac@@	O	-1	9401499
t	O	-1	9401499
that	O	-1	9401499
5	O	-1	9401499
of	O	-1	9401499
the	O	-1	9401499
6	O	-1	9401499
patients	O	-1	9401499
who	O	-1	9401499
received	O	-1	9401499
con@@	O	-1	9401499
current	O	-1	9401499
calcium	B-Chemical	D002118	9401499
channel	O	-1	9401499
block@@	O	-1	9401499
ers	O	-1	9401499
di@@	O	-1	9401499
ed,	O	-1	9401499
should	O	-1	9401499
al@@	O	-1	9401499
er@@	O	-1	9401499
t	O	-1	9401499
clin@@	O	-1	9401499
ici@@	O	-1	9401499
ans	O	-1	9401499
to	O	-1	9401499
be	O	-1	9401499
more	O	-1	9401499
cau@@	O	-1	9401499
ti@@	O	-1	9401499
ous	O	-1	9401499
when	O	-1	9401499
using	O	-1	9401499
these	O	-1	9401499
two	O	-1	9401499
drugs	O	-1	9401499
sim@@	O	-1	9401499
ult@@	O	-1	9401499
ane@@	O	-1	9401499
ous@@	O	-1	9401499
ly.	O	-1	9401499

F@@	O	-1	2273650
ac@@	O	-1	2273650
il@@	O	-1	2273650
it@@	O	-1	2273650
ation	O	-1	2273650
of	O	-1	2273650
memory	O	-1	2273650
re@@	O	-1	2273650
tri@@	O	-1	2273650
ev@@	O	-1	2273650
al	O	-1	2273650
by	O	-1	2273650
pre-@@	O	-1	2273650
test	O	-1	2273650
morphine	B-Chemical	D009020	2273650
and	O	-1	2273650
its	O	-1	2273650
state	O	-1	2273650
depend@@	O	-1	2273650
ency	O	-1	2273650
in	O	-1	2273650
the	O	-1	2273650
st@@	O	-1	2273650
ep@@	O	-1	2273650
-@@	O	-1	2273650
through	O	-1	2273650
type	O	-1	2273650
p@@	O	-1	2273650
as@@	O	-1	2273650
sive	O	-1	2273650
avoid@@	O	-1	2273650
ance	O	-1	2273650
lear@@	O	-1	2273650
ning	O	-1	2273650
test	O	-1	2273650
in	O	-1	2273650
mice.	O	-1	2273650
A@@	B-Disease	D000647	2273650
m@@	I-Disease	-1	2273650
ne@@	I-Disease	-1	2273650
sia	I-Disease	-1	2273650
produced	O	-1	2273650
by	O	-1	2273650
scopol@@	B-Chemical	D012601	2273650
amine	I-Chemical	-1	2273650
and	O	-1	2273650
cyclo@@	B-Chemical	D003513	2273650
he@@	I-Chemical	-1	2273650
xim@@	I-Chemical	-1	2273650
ide	I-Chemical	-1	2273650
were	O	-1	2273650
reversed	O	-1	2273650
by	O	-1	2273650
morphine	B-Chemical	D009020	2273650
given	O	-1	2273650
30	O	-1	2273650
min	O	-1	2273650
before	O	-1	2273650
the	O	-1	2273650
test	O	-1	2273650
trial	O	-1	2273650
(@@	O	-1	2273650
pre-@@	O	-1	2273650
test@@	O	-1	2273650
),	O	-1	2273650
and	O	-1	2273650
pre-@@	O	-1	2273650
test	O	-1	2273650
morphine	B-Chemical	D009020	2273650
also	O	-1	2273650
fac@@	O	-1	2273650
il@@	O	-1	2273650
it@@	O	-1	2273650
ated	O	-1	2273650
the	O	-1	2273650
memory	O	-1	2273650
re@@	O	-1	2273650
tri@@	O	-1	2273650
ev@@	O	-1	2273650
al	O	-1	2273650
in	O	-1	2273650
the	O	-1	2273650
animals	O	-1	2273650
administered	O	-1	2273650
n@@	B-Chemical	D009270	2273650
al@@	I-Chemical	-1	2273650
ox@@	I-Chemical	-1	2273650
one	I-Chemical	-1	2273650
during	O	-1	2273650
the	O	-1	2273650
tra@@	O	-1	2273650
in@@	O	-1	2273650
ing	O	-1	2273650
tri@@	O	-1	2273650
al.	O	-1	2273650
S@@	O	-1	2273650
im@@	O	-1	2273650
il@@	O	-1	2273650
ar@@	O	-1	2273650
ly,	O	-1	2273650
pre-@@	O	-1	2273650
test	O	-1	2273650
scopol@@	B-Chemical	D012601	2273650
amine	I-Chemical	-1	2273650
par@@	O	-1	2273650
ti@@	O	-1	2273650
ally	O	-1	2273650
reversed	O	-1	2273650
the	O	-1	2273650
scopol@@	B-Chemical	D012601	2273650
amine	I-Chemical	-1	2273650
-induced	O	-1	2273650
am@@	B-Disease	D000647	2273650
ne@@	I-Disease	-1	2273650
sia	I-Disease	-1	2273650
,	O	-1	2273650
but	O	-1	2273650
not	O	-1	2273650
significant@@	O	-1	2273650
ly@@	O	-1	2273650
;	O	-1	2273650
and	O	-1	2273650
pre-@@	O	-1	2273650
test	O	-1	2273650
cyclo@@	B-Chemical	D003513	2273650
he@@	I-Chemical	-1	2273650
xim@@	I-Chemical	-1	2273650
ide	I-Chemical	-1	2273650
fail@@	O	-1	2273650
ed	O	-1	2273650
to	O	-1	2273650
re@@	O	-1	2273650
verse	O	-1	2273650
the	O	-1	2273650
cyclo@@	B-Chemical	D003513	2273650
he@@	I-Chemical	-1	2273650
xim@@	I-Chemical	-1	2273650
ide	I-Chemical	-1	2273650
-induced	O	-1	2273650
am@@	B-Disease	D000647	2273650
ne@@	I-Disease	-1	2273650
sia	I-Disease	-1	2273650
.	O	-1	2273650
These	O	-1	2273650
results	O	-1	2273650
suggest	O	-1	2273650
that	O	-1	2273650
the	O	-1	2273650
fac@@	O	-1	2273650
il@@	O	-1	2273650
it@@	O	-1	2273650
ation	O	-1	2273650
of	O	-1	2273650
memory	O	-1	2273650
re@@	O	-1	2273650
tri@@	O	-1	2273650
ev@@	O	-1	2273650
al	O	-1	2273650
by	O	-1	2273650
pre-@@	O	-1	2273650
test	O	-1	2273650
morphine	B-Chemical	D009020	2273650
might	O	-1	2273650
be	O	-1	2273650
the	O	-1	2273650
direct	O	-1	2273650
action	O	-1	2273650
of	O	-1	2273650
morphine	B-Chemical	D009020	2273650
ra@@	O	-1	2273650
ther	O	-1	2273650
than	O	-1	2273650
a	O	-1	2273650
state	O	-1	2273650
dependent	O	-1	2273650
effect@@	O	-1	2273650
.	O	-1	2273650

T@@	O	-1	10683478
est	O	-1	10683478
condi@@	O	-1	10683478
tions	O	-1	10683478
influence	O	-1	10683478
the	O	-1	10683478
response	O	-1	10683478
to	O	-1	10683478
a	O	-1	10683478
drug	O	-1	10683478
ch@@	O	-1	10683478
all@@	O	-1	10683478
enge	O	-1	10683478
in	O	-1	10683478
ro@@	O	-1	10683478
d@@	O	-1	10683478
ent@@	O	-1	10683478
s.	O	-1	10683478
These	O	-1	10683478
studies	O	-1	10683478
were	O	-1	10683478
con@@	O	-1	10683478
duc@@	O	-1	10683478
ted	O	-1	10683478
to	O	-1	10683478
ex@@	O	-1	10683478
amine	O	-1	10683478
the	O	-1	10683478
differen@@	O	-1	10683478
tial	O	-1	10683478
response	O	-1	10683478
to	O	-1	10683478
a	O	-1	10683478
drug	O	-1	10683478
ch@@	O	-1	10683478
all@@	O	-1	10683478
enge	O	-1	10683478
under	O	-1	10683478
vari@@	O	-1	10683478
ed	O	-1	10683478
experimental	O	-1	10683478
test	O	-1	10683478
condi@@	O	-1	10683478
tions	O	-1	10683478
ro@@	O	-1	10683478
ut@@	O	-1	10683478
ine@@	O	-1	10683478
ly	O	-1	10683478
em@@	O	-1	10683478
p@@	O	-1	10683478
lo@@	O	-1	10683478
y@@	O	-1	10683478
ed	O	-1	10683478
to	O	-1	10683478
study	O	-1	10683478
drug@@	O	-1	10683478
-induced	O	-1	10683478
behavioral	O	-1	10683478
and	O	-1	10683478
neuro@@	O	-1	10683478
physi@@	O	-1	10683478
ological	O	-1	10683478
responses	O	-1	10683478
in	O	-1	10683478
ro@@	O	-1	10683478
d@@	O	-1	10683478
ent@@	O	-1	10683478
s.	O	-1	10683478
A@@	B-Chemical	D001058	10683478
po@@	I-Chemical	-1	10683478
morphine	I-Chemical	-1	10683478
,	O	-1	10683478
a	O	-1	10683478
non@@	O	-1	10683478
selective	O	-1	10683478
dopamine	B-Chemical	D018491	10683478
agon@@	I-Chemical	-1	10683478
ist	I-Chemical	-1	10683478
,	O	-1	10683478
was	O	-1	10683478
sel@@	O	-1	10683478
ected	O	-1	10683478
due	O	-1	10683478
to	O	-1	10683478
its	O	-1	10683478
b@@	O	-1	10683478
i@@	O	-1	10683478
pha@@	O	-1	10683478
sic	O	-1	10683478
behavioral	O	-1	10683478
effect@@	O	-1	10683478
s,	O	-1	10683478
its	O	-1	10683478
ability	O	-1	10683478
to	O	-1	10683478
induce	O	-1	10683478
hypo@@	B-Disease	D007035	10683478
ther@@	I-Disease	-1	10683478
mia	I-Disease	-1	10683478
,	O	-1	10683478
and	O	-1	10683478
to	O	-1	10683478
produce	O	-1	10683478
dist@@	O	-1	10683478
inc@@	O	-1	10683478
t	O	-1	10683478
changes	O	-1	10683478
to	O	-1	10683478
dopamine	B-Chemical	D004298	10683478
t@@	O	-1	10683478
ur@@	O	-1	10683478
no@@	O	-1	10683478
ver	O	-1	10683478
in	O	-1	10683478
the	O	-1	10683478
ro@@	O	-1	10683478
d@@	O	-1	10683478
ent	O	-1	10683478
bra@@	O	-1	10683478
in.	O	-1	10683478
F@@	O	-1	10683478
rom	O	-1	10683478
such	O	-1	10683478
experim@@	O	-1	10683478
ents	O	-1	10683478
there	O	-1	10683478
is	O	-1	10683478
evidence	O	-1	10683478
that	O	-1	10683478
character@@	O	-1	10683478
ization	O	-1	10683478
and	O	-1	10683478
det@@	O	-1	10683478
ection	O	-1	10683478
of	O	-1	10683478
apo@@	B-Chemical	D001058	10683478
morphine	I-Chemical	-1	10683478
-induced	O	-1	10683478
activity	O	-1	10683478
in	O	-1	10683478
ro@@	O	-1	10683478
d@@	O	-1	10683478
ents	O	-1	10683478
cri@@	O	-1	10683478
tically	O	-1	10683478
depend@@	O	-1	10683478
s	O	-1	10683478
up@@	O	-1	10683478
on	O	-1	10683478
the	O	-1	10683478
test	O	-1	10683478
condi@@	O	-1	10683478
tions	O	-1	10683478
em@@	O	-1	10683478
p@@	O	-1	10683478
lo@@	O	-1	10683478
y@@	O	-1	10683478
ed.	O	-1	10683478
In	O	-1	10683478
rats,	O	-1	10683478
det@@	O	-1	10683478
ection	O	-1	10683478
of	O	-1	10683478
apo@@	B-Chemical	D001058	10683478
morphine	I-Chemical	-1	10683478
-induced	O	-1	10683478
hyperactivity	B-Disease	D006948	10683478
was	O	-1	10683478
fac@@	O	-1	10683478
il@@	O	-1	10683478
it@@	O	-1	10683478
ated	O	-1	10683478
by	O	-1	10683478
a	O	-1	10683478
period	O	-1	10683478
of	O	-1	10683478
ac@@	O	-1	10683478
cl@@	O	-1	10683478
im@@	O	-1	10683478
ati@@	O	-1	10683478
z@@	O	-1	10683478
ation	O	-1	10683478
to	O	-1	10683478
the	O	-1	10683478
test	O	-1	10683478
condi@@	O	-1	10683478
tions.	O	-1	10683478
M@@	O	-1	10683478
ore@@	O	-1	10683478
o@@	O	-1	10683478
ver,	O	-1	10683478
test	O	-1	10683478
condi@@	O	-1	10683478
tions	O	-1	10683478
can	O	-1	10683478
im@@	O	-1	10683478
pac@@	O	-1	10683478
t	O	-1	10683478
up@@	O	-1	10683478
on	O	-1	10683478
other	O	-1	10683478
physi@@	O	-1	10683478
ological	O	-1	10683478
responses	O	-1	10683478
to	O	-1	10683478
apo@@	B-Chemical	D001058	10683478
morphine	I-Chemical	-1	10683478
such	O	-1	10683478
as	O	-1	10683478
drug@@	O	-1	10683478
-induced	O	-1	10683478
hypo@@	B-Disease	D007035	10683478
ther@@	I-Disease	-1	10683478
mia	I-Disease	-1	10683478
.	O	-1	10683478
In	O	-1	10683478
mic@@	O	-1	10683478
e,	O	-1	10683478
apo@@	B-Chemical	D001058	10683478
morphine	I-Chemical	-1	10683478
produced	O	-1	10683478
qu@@	O	-1	10683478
al@@	O	-1	10683478
it@@	O	-1	10683478
atively	O	-1	10683478
different	O	-1	10683478
responses	O	-1	10683478
under	O	-1	10683478
novel	O	-1	10683478
condi@@	O	-1	10683478
tions	O	-1	10683478
when	O	-1	10683478
compared	O	-1	10683478
to	O	-1	10683478
those	O	-1	10683478
behavi@@	O	-1	10683478
ors	O	-1	10683478
el@@	O	-1	10683478
ic@@	O	-1	10683478
ited	O	-1	10683478
in	O	-1	10683478
the	O	-1	10683478
ho@@	O	-1	10683478
m@@	O	-1	10683478
e	O	-1	10683478
test	O	-1	10683478
c@@	O	-1	10683478
age.	O	-1	10683478
D@@	O	-1	10683478
ru@@	O	-1	10683478
g@@	O	-1	10683478
-induced	O	-1	10683478
g@@	O	-1	10683478
ros@@	O	-1	10683478
s	O	-1	10683478
activity	O	-1	10683478
coun@@	O	-1	10683478
ts	O	-1	10683478
were	O	-1	10683478
increased	O	-1	10683478
in	O	-1	10683478
the	O	-1	10683478
novel	O	-1	10683478
expl@@	O	-1	10683478
or@@	O	-1	10683478
atory	O	-1	10683478
bo@@	O	-1	10683478
x	O	-1	10683478
on@@	O	-1	10683478
ly,	O	-1	10683478
while	O	-1	10683478
meas@@	O	-1	10683478
ures	O	-1	10683478
of	O	-1	10683478
ste@@	O	-1	10683478
re@@	O	-1	10683478
ot@@	O	-1	10683478
yp@@	O	-1	10683478
ic	O	-1	10683478
behavi@@	O	-1	10683478
or	O	-1	10683478
were	O	-1	10683478
similar	O	-1	10683478
in	O	-1	10683478
bo@@	O	-1	10683478
th@@	O	-1	10683478
.	O	-1	10683478
B@@	O	-1	10683478
y	O	-1	10683478
contrast@@	O	-1	10683478
,	O	-1	10683478
apo@@	B-Chemical	D001058	10683478
morphine	I-Chemical	-1	10683478
-induced	O	-1	10683478
locom@@	O	-1	10683478
o@@	O	-1	10683478
tion	O	-1	10683478
was	O	-1	10683478
more	O	-1	10683478
pro@@	O	-1	10683478
min@@	O	-1	10683478
ent	O	-1	10683478
in	O	-1	10683478
the	O	-1	10683478
novel	O	-1	10683478
expl@@	O	-1	10683478
or@@	O	-1	10683478
atory	O	-1	10683478
b@@	O	-1	10683478
ox@@	O	-1	10683478
.	O	-1	10683478
D@@	B-Chemical	D004298	10683478
op@@	I-Chemical	-1	10683478
amine	I-Chemical	-1	10683478
t@@	O	-1	10683478
ur@@	O	-1	10683478
no@@	O	-1	10683478
ver	O	-1	10683478
rati@@	O	-1	10683478
o@@	O	-1	10683478
s	O	-1	10683478
(	O	-1	10683478
DO@@	B-Chemical	D015102	10683478
PA@@	I-Chemical	-1	10683478
C	I-Chemical	-1	10683478
:	O	-1	10683478
D@@	B-Chemical	D018491	10683478
A	I-Chemical	-1	10683478
and	O	-1	10683478
H@@	B-Chemical	D006719	10683478
V@@	I-Chemical	-1	10683478
A	I-Chemical	-1	10683478
:	O	-1	10683478
D@@	B-Chemical	D018491	10683478
A	I-Chemical	-1	10683478
)	O	-1	10683478
were	O	-1	10683478
found	O	-1	10683478
to	O	-1	10683478
be	O	-1	10683478
lower	O	-1	10683478
in	O	-1	10683478
those	O	-1	10683478
animals	O	-1	10683478
exposed	O	-1	10683478
to	O	-1	10683478
the	O	-1	10683478
expl@@	O	-1	10683478
or@@	O	-1	10683478
atory	O	-1	10683478
bo@@	O	-1	10683478
x	O	-1	10683478
when	O	-1	10683478
compared	O	-1	10683478
to	O	-1	10683478
their	O	-1	10683478
ho@@	O	-1	10683478
m@@	O	-1	10683478
e	O	-1	10683478
c@@	O	-1	10683478
age	O	-1	10683478
coun@@	O	-1	10683478
ter@@	O	-1	10683478
part@@	O	-1	10683478
s.	O	-1	10683478
However,	O	-1	10683478
apo@@	B-Chemical	D001058	10683478
morphine	I-Chemical	-1	10683478
-induced	O	-1	10683478
reduc@@	O	-1	10683478
tions	O	-1	10683478
in	O	-1	10683478
stri@@	O	-1	10683478
atal	O	-1	10683478
dopamine	B-Chemical	D004298	10683478
t@@	O	-1	10683478
ur@@	O	-1	10683478
no@@	O	-1	10683478
ver	O	-1	10683478
were	O	-1	10683478
det@@	O	-1	10683478
ected	O	-1	10683478
in	O	-1	10683478
both	O	-1	10683478
novel	O	-1	10683478
and	O	-1	10683478
ho@@	O	-1	10683478
m@@	O	-1	10683478
e	O	-1	10683478
c@@	O	-1	10683478
age	O	-1	10683478
en@@	O	-1	10683478
vi@@	O	-1	10683478
ron@@	O	-1	10683478
ment@@	O	-1	10683478
s.	O	-1	10683478
The	O	-1	10683478
implic@@	O	-1	10683478
ations	O	-1	10683478
of	O	-1	10683478
these	O	-1	10683478
findings	O	-1	10683478
are	O	-1	10683478
discus@@	O	-1	10683478
sed	O	-1	10683478
with	O	-1	10683478
partic@@	O	-1	10683478
ular	O	-1	10683478
em@@	O	-1	10683478
pha@@	O	-1	10683478
sis	O	-1	10683478
up@@	O	-1	10683478
on	O	-1	10683478
con@@	O	-1	10683478
duc@@	O	-1	10683478
ting	O	-1	10683478
psych@@	O	-1	10683478
oph@@	O	-1	10683478
armac@@	O	-1	10683478
ological	O	-1	10683478
ch@@	O	-1	10683478
all@@	O	-1	10683478
enge	O	-1	10683478
tests	O	-1	10683478
in	O	-1	10683478
ro@@	O	-1	10683478
d@@	O	-1	10683478
ent@@	O	-1	10683478
s.	O	-1	10683478

